{"meta":{"query_hash":"f6b61b014da0","filters":{"topic":"Lung Cancer Treatments and Mutations"},"cohort_total":2464,"direct_labels_cover":16,"predictions_cover":2464,"exported":2464,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f6b61b014da0","api":"https://metacan.xera.ac/api/v1/cohort?topic=Lung+Cancer+Treatments+and+Mutations"},"results":[{"id":"W140208436","doi":"10.2165/00002512-200724050-00005","title":"Docetaxel in Non-Small Cell Lung Cancer","year":2007,"lang":"en","type":"review","venue":"Drugs & Aging","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Lung cancer; Chemotherapy; Oncology; Internal medicine; Quality of life (healthcare); Cancer; Performance status; Disease; Intensive care medicine","score_opus":0.0277096246261844,"score_gpt":0.39929221516780933,"score_spread":0.3715825905416249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W140208436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014385112,0.96104974,0.00004662105,0.0000703916,0.00040424135,0.0012003933,0.00003132925,0.000043333763,0.037010122],"genre_scores_gemma":[0.00024938368,0.9902538,0.00036938966,0.00026814613,0.00042332293,0.0003184847,0.0001813537,0.00008081194,0.007855289],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984677,0.000026104213,0.00047302202,0.00042183432,0.00018803065,0.00042329798],"domain_scores_gemma":[0.9992202,0.00008256329,0.00019645995,0.000317873,0.000046303892,0.00013662568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001714603,0.00035654794,0.0011387876,0.00039302913,0.000056041892,0.000026196585,0.00011424959,0.00016587599,0.00012896888],"category_scores_gemma":[0.000005797911,0.00027819563,0.00030103032,0.00046545127,0.000020577923,0.00004557539,0.00004385675,0.00044535793,0.000055266974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002377865,0.000092927745,0.0006291506,0.020456979,0.0002103928,0.00017463883,0.0018416154,0.0000028424095,3.2235832e-7,0.000011829391,0.0011758624,0.97540104],"study_design_scores_gemma":[0.0009415239,0.000011699181,0.00012246934,0.028063728,0.0029290072,0.000016143933,0.00007759313,0.000022002381,0.0000030876442,0.0000025551783,0.9675512,0.00025899854],"about_ca_topic_score_codex":0.0016317561,"about_ca_topic_score_gemma":0.00015662627,"teacher_disagreement_score":0.97514206,"about_ca_system_score_codex":0.0009191315,"about_ca_system_score_gemma":0.0007691863,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W1458558311","doi":"10.14694/edbook_am.2015.35.e420","title":"Expectations in the Care of Lung Cancer","year":2015,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Metric (unit); Lung cancer; Clinical Practice; Medicine; Value (mathematics); Face (sociological concept); Population; Intensive care medicine; Actuarial science; Family medicine; Computer science; Operations management; Oncology; Sociology; Economics; Machine learning","score_opus":0.1420664096474788,"score_gpt":0.6069059533660344,"score_spread":0.46483954371855557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1458558311","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009400004,0.98090357,0.0000033240565,0.008685678,0.00026857137,0.0009989928,0.0001181612,0.0000047891513,0.008922938],"genre_scores_gemma":[0.0002807664,0.9910408,0.0024623128,0.0020536396,0.00050802005,0.0008562332,0.00039505283,0.00001953379,0.0023835874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766845,0.00031399954,0.0013146922,0.0002694231,0.00029194803,0.00014149943],"domain_scores_gemma":[0.99473506,0.0030440683,0.0013222203,0.00030049344,0.0004977764,0.000100408724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037081877,0.00017552507,0.0020390956,0.00005121593,0.000036471305,0.000002235073,0.00019528494,0.00019660722,0.00021321206],"category_scores_gemma":[0.00023161803,0.00011148924,0.0010192131,0.00038342457,0.0009666306,0.00003309144,0.000025646938,0.00043398846,0.000006377421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014165399,0.00090089155,0.0032693688,0.001824776,0.0008550142,7.9956965e-7,0.0071336813,0.0000014168322,1.9652372e-8,0.00031275,0.08136887,0.9043183],"study_design_scores_gemma":[0.00060000987,0.00043186083,0.003278195,0.0013089175,0.0029980121,0.000006285169,0.008332916,0.0000023450777,3.3739155e-8,0.000029206978,0.9829264,0.00008578399],"about_ca_topic_score_codex":0.00042678564,"about_ca_topic_score_gemma":0.000039209233,"teacher_disagreement_score":0.90423244,"about_ca_system_score_codex":0.00067174056,"about_ca_system_score_gemma":0.020813528,"threshold_uncertainty_score":0.9847376},"labels":[],"label_agreement":null},{"id":"W1459454467","doi":"10.3747/co.19.1012","title":"Corrigendum: Survival and Treatment Patterns in Elderly Patients with Advanced Non-Small-Cell Lung Cancer in Manitoba","year":2012,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Bioinformatics; Internal medicine; Gerontology; Intensive care medicine; Biology","score_opus":0.04451427469265426,"score_gpt":0.37159046427294484,"score_spread":0.3270761895802906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1459454467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93027025,0.019559111,0.000022790671,0.00017200391,0.03769869,0.0035706111,0.00061596325,0.000031740004,0.008058816],"genre_scores_gemma":[0.90962195,0.040732395,0.0002202636,0.00014228048,0.0029971001,0.005489266,0.009091088,0.00030921667,0.031396415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981072,0.000081049475,0.00042149177,0.00058602815,0.00020956401,0.00059466047],"domain_scores_gemma":[0.99906707,0.000042222833,0.00026760003,0.00028538477,0.00011794604,0.00021978303],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000056453286,0.000491713,0.00095649576,0.00032195594,0.0000494829,0.0000126932855,0.000085909465,0.00036040353,0.00013013654],"category_scores_gemma":[0.00000571205,0.00036627147,0.00006861036,0.00017573476,0.000052668136,0.00007569792,0.000047246074,0.00061481685,0.0000071036516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024342591,0.0027267658,0.81015533,0.00045260994,0.00015649112,0.00007145129,0.0012570596,0.0000033747856,9.315442e-7,0.000002169353,0.007113001,0.17781739],"study_design_scores_gemma":[0.015554604,0.0024896846,0.7922516,0.0011584173,0.0009460351,0.0000041489093,0.0005052522,0.00004096241,0.00000340744,0.0000016679176,0.1867015,0.000342754],"about_ca_topic_score_codex":0.0026288484,"about_ca_topic_score_gemma":0.06726991,"teacher_disagreement_score":0.1795885,"about_ca_system_score_codex":0.003400223,"about_ca_system_score_gemma":0.0012300216,"threshold_uncertainty_score":0.99987894},"labels":[],"label_agreement":null},{"id":"W146744671","doi":"10.69645/nwxf5510","title":"Early detection of lung cancer","year":2009,"lang":"en","type":"article","venue":"˜The œbiomedical & life sciences collection.","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lung cancer; Medicine; Lung; Cancer; Oncology; Internal medicine","score_opus":0.013577539808778837,"score_gpt":0.33635023613663334,"score_spread":0.3227726963278545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W146744671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94337636,0.0041281385,0.009004025,0.022071645,0.00248789,0.0013743715,0.000023627548,0.00018635423,0.017347567],"genre_scores_gemma":[0.9956212,0.00010450387,0.00019149637,0.0009571642,0.0002766354,0.00004833329,0.0000023574423,0.000004317121,0.002794014],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987399,0.00003404772,0.00024018357,0.00022104925,0.00055531424,0.00020952083],"domain_scores_gemma":[0.99942195,0.000063892534,0.000094992116,0.00013247103,0.00010685771,0.00017983082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023838395,0.00009126611,0.00016496886,0.0001809327,0.00051288056,0.000020336081,0.0001160063,0.00006191377,0.00019385581],"category_scores_gemma":[0.000060408885,0.00005439167,0.00008026524,0.0018857053,0.0004550872,0.00009349288,0.000013025754,0.000115623945,0.0000071427216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016929649,0.005298489,0.1366259,0.0003691748,0.0021067194,0.000066420944,0.015548281,0.0005536168,0.12557662,0.0028340076,0.22898722,0.4803406],"study_design_scores_gemma":[0.005599523,0.0059064953,0.88888085,0.00031344485,0.0011882199,0.00012248491,0.00090131117,0.02045469,0.004769335,0.0016067927,0.06982671,0.00043012152],"about_ca_topic_score_codex":0.00084362837,"about_ca_topic_score_gemma":0.000102534395,"teacher_disagreement_score":0.75225496,"about_ca_system_score_codex":0.0001576719,"about_ca_system_score_gemma":0.0007075762,"threshold_uncertainty_score":0.39447144},"labels":[],"label_agreement":null},{"id":"W1480640671","doi":"10.3747/co.22.2566","title":"Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review","year":2015,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Western University; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University; Cancer Care Ontario; Juravinski Cancer Centre","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Afatinib; Erlotinib; Medicine; Gefitinib; Oncology; Lung cancer; Epidermal growth factor receptor; Internal medicine; Erlotinib Hydrochloride; Progression-free survival; Chemotherapy; Clinical trial; Tyrosine kinase; Cancer; Receptor","score_opus":0.1600229524860078,"score_gpt":0.45815364937899683,"score_spread":0.298130696892989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1480640671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003261984,0.9783636,0.0000019043928,0.0003931662,0.001283247,0.015494734,0.000983666,0.000017642127,0.00020006273],"genre_scores_gemma":[0.00038010522,0.9945567,0.00011063634,0.00011724169,0.00026963503,0.004053819,0.0002800487,0.00007141318,0.0001603818],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944588,0.0014765864,0.0025021809,0.0006249367,0.0004683568,0.00046917028],"domain_scores_gemma":[0.9942654,0.0016878638,0.002547682,0.00090426987,0.0004011106,0.00019372132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006238398,0.0007682771,0.005577735,0.000243107,0.00008487072,0.000020081621,0.0003882383,0.00034972437,0.000052356303],"category_scores_gemma":[0.00045401606,0.00037009516,0.000906236,0.00069589436,0.00026376738,0.00007611068,0.00010171389,0.0005039513,0.000006139487],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029199839,0.0026904976,0.0026494649,0.8428801,0.000814611,0.000011074738,0.0031198047,3.0491307e-7,0.0000011865088,0.000028911458,0.0035461176,0.14422877],"study_design_scores_gemma":[0.00287078,0.0013534874,0.0002098903,0.46688583,0.02237909,0.00008666291,0.00025573402,0.000010979672,0.000010511141,0.0000025052639,0.5055879,0.00034664452],"about_ca_topic_score_codex":0.00022534856,"about_ca_topic_score_gemma":0.00008508395,"teacher_disagreement_score":0.50204176,"about_ca_system_score_codex":0.0011164572,"about_ca_system_score_gemma":0.002603776,"threshold_uncertainty_score":0.9998751},"labels":[],"label_agreement":null},{"id":"W1485401317","doi":"10.1038/bjc.2015.181","title":"Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel","year":2015,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Internal medicine; Carboplatin; Lung cancer; Quality of life (healthcare); Toxicity; Surgery; Paclitaxel; Gastroenterology; Oncology; Cancer; Chemotherapy; Cisplatin","score_opus":0.04050747418019523,"score_gpt":0.3860574733065346,"score_spread":0.3455499991263394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1485401317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98295313,0.013335463,0.00003615154,0.00038434027,0.0006476943,0.00069438183,0.00017707804,0.0000139369295,0.0017578043],"genre_scores_gemma":[0.9936019,0.0035493893,0.0004071848,0.00053873553,0.00031892597,0.00007070346,0.000022068909,0.00007280274,0.001418289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741393,0.00023472494,0.0010112034,0.00035905067,0.0005957792,0.0003852923],"domain_scores_gemma":[0.9976487,0.00015743951,0.0006370405,0.00017617195,0.0008808458,0.00049977115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067735696,0.00025955684,0.00086788833,0.0001383075,0.000071346425,0.00007830087,0.00011035259,0.00014521893,0.00019178558],"category_scores_gemma":[0.00011872027,0.0002232158,0.00012470718,0.0003024017,0.00015061964,0.00025242058,0.00002980939,0.00041854402,0.0000018375014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011090051,0.0010463747,0.9707671,0.00013297665,0.00053537544,0.00026322322,0.0006208295,0.00003558191,0.000036239653,0.000003827302,0.0013585672,0.024090916],"study_design_scores_gemma":[0.035587534,0.0008121222,0.95540404,0.0019565646,0.0007713551,0.00008216356,0.0008451673,0.00002831343,0.00013320855,0.000011756115,0.004079929,0.0002878527],"about_ca_topic_score_codex":0.011920453,"about_ca_topic_score_gemma":0.022300519,"teacher_disagreement_score":0.03447853,"about_ca_system_score_codex":0.0004940365,"about_ca_system_score_gemma":0.0010453567,"threshold_uncertainty_score":0.99553996},"labels":[],"label_agreement":null},{"id":"W1486211631","doi":"10.1111/ajco.12189","title":"Preparing for tomorrow: Molecular diagnostics and the changing nonsmall cell lung cancer landscape","year":2014,"lang":"en","type":"review","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Anaplastic lymphoma kinase; Medicine; Lung cancer; Targeted therapy; Cancer; Oncology; Identification (biology); Precision medicine; Chemotherapy; Internal medicine; Bioinformatics; Intensive care medicine; Cancer research; Pathology; Biology","score_opus":0.04746569454896561,"score_gpt":0.48354004033448117,"score_spread":0.43607434578551557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1486211631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000082193226,0.9844683,0.0018153876,0.0014607761,0.0017127474,0.0015014425,0.000026286187,0.000009373317,0.008923536],"genre_scores_gemma":[0.0017643927,0.9934374,0.001769611,0.0003212049,0.0017311606,0.00020229473,0.000023054841,0.00005574325,0.00069514016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966642,0.0004402558,0.0020318183,0.0002976176,0.0002150159,0.00035104805],"domain_scores_gemma":[0.9905104,0.006386185,0.002243477,0.00028354998,0.00030131626,0.00027507145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025086566,0.0003033292,0.0035520226,0.00019662411,0.00010720516,0.000028643866,0.00019899524,0.00049367285,0.000024990894],"category_scores_gemma":[0.0015548863,0.00016298948,0.0011865683,0.0001580559,0.00020333575,0.00004015834,0.000074758784,0.00085569895,0.0000032267449],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036986562,0.00029229073,0.0005204459,0.004737652,0.002031326,0.00014747873,0.0003043791,0.0000048085476,1.1955954e-7,0.0003973027,0.0074079256,0.9837864],"study_design_scores_gemma":[0.0066989744,0.0011819031,0.00001989251,0.0046772393,0.018714646,0.00045877634,0.00017697937,0.00011430141,7.3453714e-7,0.0000701759,0.9677385,0.00014788834],"about_ca_topic_score_codex":0.0000062912236,"about_ca_topic_score_gemma":0.000009366379,"teacher_disagreement_score":0.9836385,"about_ca_system_score_codex":0.00016939962,"about_ca_system_score_gemma":0.0021886306,"threshold_uncertainty_score":0.6646518},"labels":[],"label_agreement":null},{"id":"W1490955258","doi":"10.1002/cncr.29132","title":"Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Université de Montréal; Montreal General Hospital","funders":"National Cancer Institute","keywords":"Pemetrexed; Ramucirumab; Medicine; Carboplatin; Oncology; Internal medicine; Cisplatin; Lung cancer; Chemotherapy","score_opus":0.012195219696041053,"score_gpt":0.32965939991071064,"score_spread":0.3174641802146696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1490955258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919408,0.0006496251,0.0005627289,0.00021157486,0.000056821373,0.0062282863,0.000036861533,0.000010935232,0.0003023463],"genre_scores_gemma":[0.99621755,0.00019709222,0.0012037066,0.0001722587,0.000013677242,0.0017499742,0.00005499743,0.00004304458,0.0003476731],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986871,0.00007405809,0.00040564674,0.00037291646,0.00023656822,0.00022371089],"domain_scores_gemma":[0.99906164,0.00015224554,0.00028033054,0.0002353767,0.00018675427,0.000083646104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002032003,0.0002358849,0.00081325776,0.0002026755,0.000053608434,0.000020748912,0.000090340465,0.000034648485,0.00006810437],"category_scores_gemma":[0.000026770616,0.00016045968,0.000019322486,0.00042988994,0.000071306604,0.00016262176,0.000025923588,0.00012599312,3.3964398e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13128392,0.026108244,0.7939049,0.00072449836,0.00061566115,0.000014396682,0.009720028,0.0018220607,0.000095327596,0.000023527193,0.00009984983,0.035587586],"study_design_scores_gemma":[0.91364163,0.0049097002,0.07391907,0.0007794554,0.00064549287,5.943138e-7,0.00042862498,0.0050989315,0.00029356586,0.000018145514,0.000052443247,0.00021232502],"about_ca_topic_score_codex":0.0021078095,"about_ca_topic_score_gemma":0.010130697,"teacher_disagreement_score":0.7823577,"about_ca_system_score_codex":0.0002889375,"about_ca_system_score_gemma":0.00024231944,"threshold_uncertainty_score":0.6543356},"labels":[],"label_agreement":null},{"id":"W1491879437","doi":"10.1097/jto.0000000000000141","title":"Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Merck KGaA","keywords":"Cetuximab; T790M; Medicine; Vinorelbine; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Chemotherapy; Immunohistochemistry; Exon; Cisplatin; Cancer research; Cancer; Gefitinib; Colorectal cancer; Biology; Gene","score_opus":0.014516855675895071,"score_gpt":0.4043220095751472,"score_spread":0.38980515389925213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1491879437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964327,0.0004837771,0.00058477983,0.0009371424,0.00011646719,0.0010980604,0.0000057117504,0.000004833645,0.00033648417],"genre_scores_gemma":[0.9972276,0.000048684808,0.0023198728,0.00013602985,0.00010101278,0.000037989823,0.000010732817,0.000019142752,0.00009893869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861425,0.00027377883,0.0005532903,0.00014603011,0.00024529177,0.00016737301],"domain_scores_gemma":[0.9978778,0.00078345626,0.0007671939,0.00015638578,0.00030164805,0.00011351747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047935394,0.00013111324,0.000554454,0.00017457225,0.00007659818,0.000009083679,0.00007730943,0.00007690841,0.000017681858],"category_scores_gemma":[0.00018801616,0.00007396574,0.000051295076,0.00021019326,0.00008979738,0.00011959227,0.000018135337,0.00028029326,3.972258e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005261471,0.0009497796,0.94878495,0.00008011478,0.00014573958,0.000008161985,0.0091255475,0.0005730733,0.000048761172,0.000006969845,0.000048978218,0.03496644],"study_design_scores_gemma":[0.03639958,0.002777007,0.9576047,0.00021667291,0.0008563064,0.0000056628805,0.0013988529,0.000103050384,0.00026398667,0.0000636365,0.00023856615,0.000071992195],"about_ca_topic_score_codex":0.00008423995,"about_ca_topic_score_gemma":0.000069983646,"teacher_disagreement_score":0.034894448,"about_ca_system_score_codex":0.00046672006,"about_ca_system_score_gemma":0.00055736187,"threshold_uncertainty_score":0.30162355},"labels":[],"label_agreement":null},{"id":"W1497402064","doi":"10.1200/jco.2012.46.1764","title":"Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Lung cancer; Internal medicine; Quality of life (healthcare); Adenocarcinoma; Oncology; Cisplatin; Chemotherapy; Nausea; Cancer; Epidermal growth factor receptor; Gefitinib","score_opus":0.016549367195252213,"score_gpt":0.30265093653605807,"score_spread":0.2861015693408059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1497402064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923229,0.00025600012,0.000044115386,0.00008320432,0.000020583691,0.0070702103,0.00004271437,0.000014315955,0.0001459175],"genre_scores_gemma":[0.9957404,0.0000045147517,0.00025895532,0.00005781034,0.000008034538,0.0038004464,0.00004786612,0.000020057701,0.00006187292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839896,0.00009782896,0.00063436525,0.00028135063,0.00033616097,0.0002513155],"domain_scores_gemma":[0.9988046,0.00021399432,0.0003526474,0.00023696161,0.00024014054,0.00015163263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017347126,0.00017016078,0.0006221816,0.00025707253,0.000028528826,0.00000942866,0.000050519015,0.000039353617,0.000029997704],"category_scores_gemma":[0.00015988998,0.00010985248,0.000021194532,0.0005001837,0.00007211409,0.0002156336,0.000014765999,0.000095558426,2.4246918e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005459051,0.0034195993,0.9758687,0.00016469609,0.00035411748,0.0000055564337,0.002931639,0.00006628471,0.000009926765,0.00001068068,0.0000100142015,0.011699706],"study_design_scores_gemma":[0.119538166,0.0012563432,0.87568223,0.00008755347,0.00028042353,5.897745e-7,0.002796453,0.00023116716,0.000020055119,0.000002403084,6.356264e-7,0.00010396314],"about_ca_topic_score_codex":0.0018012429,"about_ca_topic_score_gemma":0.0011928447,"teacher_disagreement_score":0.11407912,"about_ca_system_score_codex":0.0001344415,"about_ca_system_score_gemma":0.00012945851,"threshold_uncertainty_score":0.4479654},"labels":[],"label_agreement":null},{"id":"W1502073970","doi":"10.1183/09031936.00077809","title":"EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration","year":2009,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universidad de Navarra; Queen's University; Vrije Universiteit Amsterdam; Institut National de la Santé et de la Recherche Médicale","keywords":"Lung cancer; Biobank; Carcinogenesis; Oncology; Medicine; Tissue microarray; Cancer; Internal medicine; Bioinformatics; Biology","score_opus":0.048377541021181296,"score_gpt":0.370490840010659,"score_spread":0.3221132989894777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1502073970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411225,0.0002200672,0.00088589895,0.0008537874,0.00017280673,0.0030531683,0.00004980174,0.000064582964,0.00058760715],"genre_scores_gemma":[0.9807161,0.000008488215,0.011711575,0.005220206,0.00041849507,0.000028578663,0.000006399693,0.0000595097,0.0018306287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840987,0.00023631834,0.0004198666,0.00035435383,0.0002640913,0.00031551954],"domain_scores_gemma":[0.9985895,0.000031088715,0.00015171227,0.00022463819,0.00044535295,0.0005577211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006452796,0.0002081194,0.00024465978,0.00036710565,0.0003496622,0.00036018877,0.00009668784,0.000021889799,0.000008079174],"category_scores_gemma":[0.0004366912,0.00017199853,0.000050907605,0.0004726852,0.00002138925,0.00027048698,0.000035313777,0.00017866699,0.00002588716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005189625,0.009522568,0.38084492,0.00019543717,0.0011500228,0.004231782,0.2101137,0.00052977534,0.08134101,0.0001944532,0.04710981,0.2595769],"study_design_scores_gemma":[0.023385957,0.013258536,0.75372916,0.0005291689,0.00048805925,0.00006938885,0.01004684,0.00010855575,0.0010899694,0.000006499142,0.19672734,0.00056053966],"about_ca_topic_score_codex":0.00002344898,"about_ca_topic_score_gemma":0.00010739624,"teacher_disagreement_score":0.37288424,"about_ca_system_score_codex":0.00017979105,"about_ca_system_score_gemma":0.00036637287,"threshold_uncertainty_score":0.7013897},"labels":[],"label_agreement":null},{"id":"W1512537193","doi":"10.1111/j.1759-7714.2011.00088.x","title":"Design and application of a self‐evaluation questionnaire for individuals at a high‐risk of lung cancer","year":2011,"lang":"en","type":"article","venue":"Thoracic Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sichuan University","keywords":"Medicine; Lung cancer; Internal medicine; Population; Depression (economics); Physical therapy; Reliability (semiconductor); Cancer; Oncology; Environmental health","score_opus":0.03342927822576069,"score_gpt":0.40035233006467463,"score_spread":0.36692305183891394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1512537193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9344505,0.008414667,0.053109877,0.00018909066,0.00010788834,0.0033416012,0.00020558805,0.000039799295,0.00014100777],"genre_scores_gemma":[0.98359907,0.0008818069,0.012621673,0.00003385329,0.00005259284,0.0026497107,0.000033590182,0.000017371165,0.00011035013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992381,0.00005614041,0.00022498395,0.00018630661,0.00019203432,0.000102472324],"domain_scores_gemma":[0.9991215,0.000043723077,0.00028278283,0.00016250733,0.00033814402,0.000051358023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033068852,0.00009464816,0.00021596906,0.00007475806,0.00006229909,0.0000023530338,0.00003174085,0.000059863833,0.00010377382],"category_scores_gemma":[0.000025912228,0.000078451245,0.000038295595,0.00013366793,0.000048514987,0.00006324059,0.000013924253,0.000035145502,5.832682e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001092767,0.0004194416,0.62660146,0.0013581512,0.0017185166,4.334431e-7,0.015033496,0.00065326795,0.004385227,0.00067526294,0.0007075921,0.34735435],"study_design_scores_gemma":[0.00551625,0.00069533236,0.8461053,0.000994019,0.014683826,0.0000075189037,0.00017093593,0.03282255,0.09558591,0.0025377192,0.00058191473,0.00029876552],"about_ca_topic_score_codex":0.0031412751,"about_ca_topic_score_gemma":0.00022965168,"teacher_disagreement_score":0.3470556,"about_ca_system_score_codex":0.00030413677,"about_ca_system_score_gemma":0.00030934683,"threshold_uncertainty_score":0.47486895},"labels":[],"label_agreement":null},{"id":"W1518589111","doi":"10.1002/cbf.3090","title":"Loss of EGF‐dependent cell proliferation ability on radioresistant cell HepG2‐8960‐R","year":2015,"lang":"en","type":"article","venue":"Cell Biochemistry and Function","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Radioresistance; Cetuximab; Cell growth; Cancer research; Epidermal growth factor receptor; Epidermal growth factor; Cell; Cell culture; Cancer; Biology; Chemistry; Colorectal cancer; Biochemistry; Genetics","score_opus":0.011151826050085597,"score_gpt":0.2528454531779308,"score_spread":0.24169362712784517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1518589111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689881,0.0007313462,0.00029377622,0.00013444353,0.00018042861,0.00029154538,0.000030166604,0.000027816866,0.029322341],"genre_scores_gemma":[0.9928237,0.000056468954,0.00016626214,0.000070068374,0.00014321881,0.000025256815,0.00019568599,0.0000101371115,0.0065092095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991807,0.000016851263,0.00020074823,0.0002769157,0.0002052986,0.00011949456],"domain_scores_gemma":[0.99934,0.000017812035,0.000100187084,0.0002383253,0.00014037198,0.00016327835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012248449,0.00013160407,0.00015998767,0.000028459795,0.000058977774,0.00001344818,0.000026596339,0.0001124088,0.000053049353],"category_scores_gemma":[0.0000168256,0.00010901302,0.00004944337,0.00007935359,0.00005313942,0.000043905206,0.0000120184695,0.00009889215,0.000011408482],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002460456,0.0020815458,0.019631019,0.0015221054,0.000064964835,0.000019120922,0.0007150281,0.00009289768,0.9671752,0.000022357179,0.0045703175,0.0016449974],"study_design_scores_gemma":[0.002883185,0.00075829466,0.002590633,0.000036087735,0.00026401758,0.0000075555354,0.00044645558,0.000080999605,0.990786,0.000071805625,0.0019654029,0.00010955144],"about_ca_topic_score_codex":0.000022745107,"about_ca_topic_score_gemma":9.3713504e-7,"teacher_disagreement_score":0.023835557,"about_ca_system_score_codex":0.00015487477,"about_ca_system_score_gemma":0.00017767501,"threshold_uncertainty_score":0.4445422},"labels":[],"label_agreement":null},{"id":"W1529488333","doi":"10.1016/j.lungcan.2013.11.006","title":"Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cetuximab; Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; Chemotherapy; Odds ratio; Meta-analysis; Randomized controlled trial; Proportional hazards model; Confidence interval; Cancer; Colorectal cancer","score_opus":0.10246975773111995,"score_gpt":0.409869584780272,"score_spread":0.3073998270491521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529488333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83837557,0.10589757,0.005433723,0.0030249343,0.00063004467,0.017817792,0.028104201,0.000055779205,0.00066041143],"genre_scores_gemma":[0.95995474,0.008043635,0.00903852,0.00090777,0.0002455622,0.0138132,0.0051886323,0.00009714288,0.002710782],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968321,0.00015461931,0.001523452,0.00069643214,0.00046112176,0.00033227788],"domain_scores_gemma":[0.9955372,0.0014210027,0.0013515601,0.0011013456,0.00042676815,0.00016212465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004827449,0.00042505295,0.0050933314,0.00026233672,0.00007551917,0.000026952186,0.00028917688,0.00012815771,0.005637684],"category_scores_gemma":[0.00012993759,0.00026482457,0.0019338372,0.00044065213,0.00008143257,0.00015773087,0.00006661679,0.00007470619,0.0000022567017],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030712496,0.001704845,0.0025495936,0.00047733923,0.92188865,0.000003817667,0.008188181,0.011166924,0.0018221275,0.000016567494,0.0059268405,0.015542592],"study_design_scores_gemma":[0.20834629,0.00044962112,0.0005645051,0.00008876685,0.7470544,2.3073554e-7,0.00022138035,0.021663094,0.019763075,0.000044279634,0.0015352682,0.00026908188],"about_ca_topic_score_codex":0.034257535,"about_ca_topic_score_gemma":0.003344045,"teacher_disagreement_score":0.17763379,"about_ca_system_score_codex":0.00056790083,"about_ca_system_score_gemma":0.0008248953,"threshold_uncertainty_score":0.9999804},"labels":[],"label_agreement":null},{"id":"W1532269447","doi":"10.1093/annonc/mdu349.91","title":"The Relationship Between Egfr and Kras Mutation Status and Overall Survival (Os) in the Ncic Ctg Br.26 Randomized Trial of Dacomitinib (D) Versus Placebo (P) in Patients with Previously Treated Non Small Cell Lung Cancer (Nsclc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; KRAS; Internal medicine; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology; Colorectal cancer; Alternative medicine","score_opus":0.04690554964151951,"score_gpt":0.37916275750292766,"score_spread":0.33225720786140817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1532269447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357724,0.0004138701,0.0000147984565,0.001080393,0.00008593922,0.0026922345,0.000019658912,0.000005900914,0.0021099465],"genre_scores_gemma":[0.99919105,0.00028743973,0.00005428627,0.0000833644,0.000043236625,0.00020789933,0.000065866996,0.000013548455,0.000053308544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983126,0.0006869065,0.0004516152,0.00017631087,0.00016096173,0.0002116008],"domain_scores_gemma":[0.9941821,0.0051524392,0.00033822143,0.00014729057,0.0001261177,0.00005383914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010564495,0.0001269209,0.0005618777,0.00010212183,0.000063186235,0.000009775778,0.00005297109,0.00009941149,0.0000040519917],"category_scores_gemma":[0.00051454693,0.000071299735,0.00004567472,0.00013915225,0.00016702608,0.00005717927,0.000015188412,0.00014742489,2.7196725e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35722542,0.00026530388,0.63514113,0.0000566894,0.00015090487,0.0000016655306,0.0028207945,0.000030929787,0.0000025041088,0.0001465006,0.00005131375,0.0041068196],"study_design_scores_gemma":[0.4757669,0.0024594755,0.5208524,0.00006764315,0.00036110953,2.370995e-7,0.00014653997,0.000070593465,0.000018997536,0.000087246604,0.00012203029,0.000046829657],"about_ca_topic_score_codex":0.0023081892,"about_ca_topic_score_gemma":0.0024310155,"teacher_disagreement_score":0.11854146,"about_ca_system_score_codex":0.000075480486,"about_ca_system_score_gemma":0.000259251,"threshold_uncertainty_score":0.3489307},"labels":[],"label_agreement":null},{"id":"W1539990701","doi":"10.1002/cncy.20150","title":"<i>EGFR</i> gene status in cytological samples of nonsmall cell lung carcinoma","year":2011,"lang":"en","type":"review","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Fluorescence in situ hybridization; Cancer; Carcinoma; Oncology; Polymerase chain reaction; Cancer research; Pathology; Internal medicine; Gene; Biology","score_opus":0.07489019474961393,"score_gpt":0.3811306723359568,"score_spread":0.3062404775863429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1539990701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025255943,0.99037284,0.00005911722,0.000027535829,0.00046296514,0.0012795246,0.000661532,0.000034261422,0.0045766113],"genre_scores_gemma":[0.0050216224,0.9914859,0.001199778,0.00014632558,0.00017595076,0.00081586343,0.0004160052,0.00006989024,0.00066866504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975846,0.00019757949,0.0008413631,0.0006649037,0.000114401606,0.0005971665],"domain_scores_gemma":[0.9985578,0.00012618657,0.00045066117,0.00055660756,0.00011822262,0.00019050675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012518383,0.00046617302,0.0025596211,0.0003487199,0.00003632784,0.0000053327894,0.00019483383,0.0005235182,0.0004033913],"category_scores_gemma":[0.000039463815,0.00030887875,0.00041268172,0.00034934175,0.00021637825,0.000036289348,0.000104641156,0.00045301116,0.000025362007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001920705,0.0010100814,0.11491833,0.03146883,0.0003709354,0.002652032,0.0014664652,0.000002171576,0.000089545574,0.00087364885,0.0010699347,0.84588593],"study_design_scores_gemma":[0.001903993,0.00044984667,0.00939069,0.0027872715,0.003937028,0.00048961135,0.000043706084,0.0000010292786,0.000079557314,0.000035641784,0.98049986,0.0003817753],"about_ca_topic_score_codex":0.00079046324,"about_ca_topic_score_gemma":0.00017230568,"teacher_disagreement_score":0.9794299,"about_ca_system_score_codex":0.0007402814,"about_ca_system_score_gemma":0.0018510148,"threshold_uncertainty_score":0.99993634},"labels":[],"label_agreement":null},{"id":"W1540531200","doi":"10.1002/cncr.29386","title":"Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?","year":2015,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Oncology; Internal medicine; Cancer; Intensive care medicine","score_opus":0.0342854516727444,"score_gpt":0.3519391858602297,"score_spread":0.3176537341874853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1540531200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98939484,0.0018096962,0.000035323275,0.0011546158,0.00038937086,0.0013426435,0.00024966183,0.00005426814,0.005569548],"genre_scores_gemma":[0.982552,0.0027489855,0.00019339276,0.00079186284,0.00014520856,0.0011746881,0.00016430432,0.00006330814,0.012166247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987446,0.000030267409,0.00027571226,0.00038200282,0.0002081392,0.00035927005],"domain_scores_gemma":[0.99910915,0.000023739905,0.00014615097,0.00029575513,0.00015131231,0.00027387566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000037603095,0.00027744958,0.00044018409,0.00017522073,0.00004493815,0.000021558479,0.00006712459,0.000047037123,0.00033265332],"category_scores_gemma":[0.0000036809467,0.00020929912,0.00009172715,0.00031505618,0.000024551742,0.000075820775,0.000013699354,0.00008914854,0.000015093709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016293618,0.000764935,0.9816993,0.00011940568,0.0003610651,0.000057797253,0.002400044,0.00026255977,0.000032614476,0.000004347073,0.0029975122,0.011137483],"study_design_scores_gemma":[0.02696892,0.00064178853,0.954023,0.0007087331,0.0014745927,0.0000018670088,0.00085760595,0.0008262203,0.003871419,0.000035731144,0.010167502,0.0004226239],"about_ca_topic_score_codex":0.031752408,"about_ca_topic_score_gemma":0.028070547,"teacher_disagreement_score":0.027676305,"about_ca_system_score_codex":0.0033783868,"about_ca_system_score_gemma":0.00074300636,"threshold_uncertainty_score":0.9896646},"labels":[],"label_agreement":null},{"id":"W1544082798","doi":"10.1002/cncy.21290","title":"Standardizing preanalytical variables for molecular cytopathology","year":2013,"lang":"en","type":"editorial","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Cytopathology; Medicine; Medical physics; Selection (genetic algorithm); Pathology; Cytology; Computer science; Artificial intelligence","score_opus":0.011530281030368331,"score_gpt":0.3709302139362861,"score_spread":0.35939993290591776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1544082798","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019573222,0.0111057935,0.024521407,0.0019128483,0.9434146,0.003647773,0.004875598,0.00029618916,0.008268462],"genre_scores_gemma":[0.005641339,0.0020191667,0.013642626,0.0013591518,0.94944495,0.0077636125,0.004735442,0.00044061113,0.014953131],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969545,0.00011323328,0.00061046774,0.0010714005,0.00045141522,0.0007990052],"domain_scores_gemma":[0.99717426,0.0005197488,0.00030026512,0.00073020376,0.000998545,0.00027696727],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00030317192,0.00056130876,0.0014619876,0.00026071302,0.000155244,0.000051307634,0.00023311573,0.0014410733,0.00042335744],"category_scores_gemma":[0.00086544006,0.00048736972,0.0003871048,0.00017426237,0.00027579183,0.000077122975,0.0001043583,0.0007361743,0.000050283958],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034113936,0.00014126641,0.0002731197,0.0005921938,0.00056896795,0.00066054857,0.0001734282,0.00002787788,0.0020963002,0.0012511038,0.98961455,0.0042595128],"study_design_scores_gemma":[0.0038828787,0.00092393206,0.00011998224,0.00030788523,0.0039562546,0.000124878,0.000042267784,0.000055659206,0.0006963983,0.0013838944,0.9880522,0.0004537779],"about_ca_topic_score_codex":0.00012088978,"about_ca_topic_score_gemma":0.000025193278,"teacher_disagreement_score":0.010878781,"about_ca_system_score_codex":0.0009847052,"about_ca_system_score_gemma":0.0026648229,"threshold_uncertainty_score":0.9998553},"labels":[],"label_agreement":null},{"id":"W1550870843","doi":"10.1002/cjp2.15","title":"<i><scp>R</scp>ead<scp>M</scp>ax</i>—a novel reading and scoring approach for <i><scp>EGFR</scp></i> gene copy number to predict therapeutic benefit of erlotinib treatment in <i><scp>EGFR</scp></i> wild‐type non‐small‐cell lung cancer","year":2015,"lang":"en","type":"article","venue":"The Journal of Pathology Clinical Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Erlotinib; Fluorescence in situ hybridization; Oncology; Hazard ratio; Population; Fish <Actinopterygii>; Internal medicine; Wild type; Copy-number variation; Medicine; Cancer research; Epidermal growth factor receptor; Cancer; Biology; Gene; Genetics; Mutant; Genome","score_opus":0.1525949567385149,"score_gpt":0.46388578960825555,"score_spread":0.3112908328697407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1550870843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755813,0.008745401,0.002557835,0.0005360257,0.0009469283,0.0037354378,0.00027025767,0.00004635186,0.0075804535],"genre_scores_gemma":[0.956042,0.011744654,0.01567318,0.001527008,0.0018933556,0.0006345361,0.00011414377,0.0002776809,0.012093437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991642,0.0010743454,0.0026162583,0.001096321,0.0015795802,0.0019914724],"domain_scores_gemma":[0.97520417,0.018770324,0.0011955753,0.001112787,0.002249828,0.0014673222],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010637873,0.00077179173,0.0021684375,0.00072013214,0.0004364761,0.00011209099,0.0009663549,0.00075284194,0.0000065110685],"category_scores_gemma":[0.008919615,0.00053815206,0.0005225082,0.001527491,0.00085012004,0.00031255605,0.0004334567,0.0021523961,0.00002718429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012594748,0.008387989,0.8673181,0.0009251373,0.0033347018,0.00077981,0.026953148,0.0044469535,0.035725318,0.0004088759,0.045188062,0.005272449],"study_design_scores_gemma":[0.1749369,0.07997187,0.31282175,0.006527666,0.019523421,0.007956147,0.082952656,0.014403535,0.12625036,0.004855193,0.16883756,0.0009629269],"about_ca_topic_score_codex":0.00045444843,"about_ca_topic_score_gemma":0.00018825551,"teacher_disagreement_score":0.55449635,"about_ca_system_score_codex":0.0010727119,"about_ca_system_score_gemma":0.0027866024,"threshold_uncertainty_score":0.999707},"labels":[],"label_agreement":null},{"id":"W1570155762","doi":"10.3747/co.22.2419","title":"Comparing Effectiveness with Efficacy: Outcomes of Palliative Chemotherapy for Non-Small-Cell Lung Cancer in Routine Practice","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"Health Research Board; Genomic Health","keywords":"Medicine; Lung cancer; Randomized controlled trial; Cohort; Quality of life (healthcare); Internal medicine; Cancer registry; Chemotherapy; Cancer; Performance status; Oncology","score_opus":0.09217220989090426,"score_gpt":0.48038120562149306,"score_spread":0.3882089957305888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1570155762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900099,0.0015924126,0.0033648822,0.0010131021,0.00043183373,0.00200403,0.000015700969,0.000016344715,0.0015518147],"genre_scores_gemma":[0.9975434,0.00011903723,0.0015598368,0.000089014626,0.00006315765,0.00052359386,0.000029901585,0.000018757442,0.000053306416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992415,0.00006612448,0.00020393997,0.0002047272,0.000101991856,0.00018172193],"domain_scores_gemma":[0.99876237,0.0005342582,0.0001948494,0.00012124991,0.00030188882,0.0000853578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022399862,0.00013208658,0.0005172851,0.00007523922,0.000021546779,0.0000036644385,0.000051521703,0.000052462736,0.0000062888953],"category_scores_gemma":[0.00009577463,0.00009270818,0.00004740624,0.00014619964,0.000044560977,0.000047634803,0.000015564501,0.00011964832,0.000001039075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024126708,0.0022534858,0.98177296,0.00036318626,0.00036101334,0.0000063624584,0.0042768554,0.00043406984,0.00008563031,0.00006828926,0.00013547839,0.0078300135],"study_design_scores_gemma":[0.04524996,0.0017867308,0.9398961,0.00043818387,0.00091055565,0.000003047851,0.0008697651,0.002488276,0.0012744342,0.000015161169,0.0069279936,0.00013980892],"about_ca_topic_score_codex":0.00021662521,"about_ca_topic_score_gemma":0.00019290083,"teacher_disagreement_score":0.042837292,"about_ca_system_score_codex":0.0007594946,"about_ca_system_score_gemma":0.0007295595,"threshold_uncertainty_score":0.37805298},"labels":[],"label_agreement":null},{"id":"W1572793643","doi":"10.1158/1538-7445.am2014-824","title":"Abstract 824: In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Delmar (Canada)","funders":"","keywords":"Medicine; Lung cancer; Gefitinib; Cisplatin; Oncology; Internal medicine; Brain metastasis; Clinical trial; Chemotherapy; Cancer; Metastasis; Cancer research; Epidermal growth factor receptor","score_opus":0.05436315843481817,"score_gpt":0.4469286762644234,"score_spread":0.39256551782960525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1572793643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986008,0.0032208061,0.0000053916547,0.0008139385,0.00007631927,0.0012132433,0.000042988515,0.000004537243,0.008614765],"genre_scores_gemma":[0.99540865,0.0024637969,0.000054420587,0.000040233623,0.00012578056,0.00064589287,0.0000074779177,0.000018653964,0.0012351156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861157,0.00009577277,0.00029597257,0.00024061928,0.00040686983,0.00034921517],"domain_scores_gemma":[0.99894696,0.0003789477,0.000068711124,0.00037518083,0.00015733384,0.00007288005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004273466,0.00011783228,0.00031003516,0.0002569182,0.00004074978,0.000008744186,0.00014813055,0.000062384985,0.00039192464],"category_scores_gemma":[0.000029070514,0.00007345858,0.00007998851,0.000514643,0.00011035927,0.00003163446,0.000016020675,0.00017614417,0.0000041711255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016418187,0.008494153,0.6873254,0.0021683231,0.0004774091,0.0001194418,0.050397534,0.0021004686,0.14559259,0.00025357283,0.006232019,0.09519729],"study_design_scores_gemma":[0.013705908,0.0013798884,0.8207611,0.0009801352,0.00018448268,0.0000015998731,0.0012389895,0.00041558422,0.1478082,0.00005583106,0.013311768,0.00015653014],"about_ca_topic_score_codex":0.022972062,"about_ca_topic_score_gemma":0.005342102,"teacher_disagreement_score":0.1334357,"about_ca_system_score_codex":0.000693972,"about_ca_system_score_gemma":0.00068255886,"threshold_uncertainty_score":0.98353404},"labels":[],"label_agreement":null},{"id":"W1572964200","doi":"10.1111/ajco.12190","title":"<scp>N</scp>ational <scp>W</scp>orking <scp>G</scp>roup <scp>M</scp>eeting on <scp>ALK</scp> diagnostics in lung cancer","year":2014,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Comprehensive Cancer Network; Royal College of Pathologists of Australasia; Pfizer","keywords":"Lung cancer; Medicine; Cancer research; Oncology","score_opus":0.04332227479013119,"score_gpt":0.4227194851432604,"score_spread":0.37939721035312923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1572964200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8147391,0.007605286,0.0016061991,0.0028496068,0.009557327,0.0019138305,0.00021877431,0.00021614823,0.1612937],"genre_scores_gemma":[0.94633156,0.010125963,0.0059053097,0.005176106,0.011695621,0.00034685386,0.0003134915,0.00043594206,0.019669177],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98394364,0.0021097185,0.00666403,0.0019026527,0.0025671357,0.0028128373],"domain_scores_gemma":[0.8962157,0.09295135,0.0056087626,0.0012377447,0.0018436211,0.0021428436],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.007262462,0.0015288016,0.004426342,0.0014823374,0.0007629774,0.00029261585,0.0013022827,0.0021777262,0.00006537328],"category_scores_gemma":[0.101479985,0.0013353411,0.001686401,0.0016940433,0.0010281716,0.00077489816,0.00040778017,0.005367385,0.00034092946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009856663,0.0066468073,0.5189273,0.00045712135,0.0036661706,0.0024684588,0.009510728,0.0028590653,0.0005157632,0.0032529784,0.41860765,0.032989394],"study_design_scores_gemma":[0.015432088,0.0060740625,0.19181027,0.0019147466,0.0027437091,0.0007662354,0.013701006,0.0017633261,0.0005425777,0.0017718063,0.76334345,0.00013669938],"about_ca_topic_score_codex":0.00025039547,"about_ca_topic_score_gemma":0.00056037324,"teacher_disagreement_score":0.3447358,"about_ca_system_score_codex":0.0022831562,"about_ca_system_score_gemma":0.004965052,"threshold_uncertainty_score":0.9997461},"labels":[],"label_agreement":null},{"id":"W1575098853","doi":"10.1016/j.jmoldx.2015.03.005","title":"Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non–Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue","year":2015,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stage (stratigraphy); Biology; Gene; RNA; Carcinoma; Lung; Cancer research; Cell; Computational biology; Molecular biology; Oncology; Genetics; Internal medicine; Medicine","score_opus":0.029585065658817484,"score_gpt":0.3267632172794425,"score_spread":0.29717815162062505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1575098853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96504015,0.0019966888,0.03144001,0.0001701487,0.00023852511,0.0008246268,0.000038443166,0.000006427486,0.00024500873],"genre_scores_gemma":[0.971049,0.00013030044,0.028379045,0.00009007144,0.0001489754,0.000015947617,0.00001632466,0.00004290123,0.0001274024],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983983,0.00005426996,0.0006461507,0.00016194508,0.0004582085,0.00028110822],"domain_scores_gemma":[0.9974734,0.0003471906,0.0004630902,0.00023612617,0.0011155613,0.0003646227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004196768,0.00019187325,0.0005360509,0.00019381016,0.000045791126,0.000024046605,0.00012307418,0.00010469471,0.000014061401],"category_scores_gemma":[0.0011456565,0.00015689421,0.00019820154,0.00022276067,0.00006416805,0.00008481535,0.000035836347,0.00019167947,0.0000019527245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012005322,0.0021649848,0.91866577,0.001340001,0.0011649027,0.0019480508,0.0018702961,0.009266811,0.05933814,0.000094176765,0.0011839991,0.0017623317],"study_design_scores_gemma":[0.034249026,0.0141663905,0.0966619,0.001715081,0.01736618,0.0008555808,0.000786358,0.11041825,0.72055763,0.00011905801,0.002275097,0.0008294082],"about_ca_topic_score_codex":0.000034412893,"about_ca_topic_score_gemma":0.0000022399672,"teacher_disagreement_score":0.82200384,"about_ca_system_score_codex":0.00025269893,"about_ca_system_score_gemma":0.0010403132,"threshold_uncertainty_score":0.639796},"labels":[],"label_agreement":null},{"id":"W1591182382","doi":"10.5737/1181912x18315","title":"ONLINE Special Article: Nursing care for patients with non-small cell lung cancer receiving adjuvant chemotherapy: Evidence–based implications for practice","year":2008,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Adjuvant chemotherapy; Lung cancer; Chemotherapy; Oncology; Adjuvant; Nursing practice; Evidence-based nursing; Nursing; Cancer; Family medicine; Internal medicine; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.15768508348346416,"score_gpt":0.5559520550814163,"score_spread":0.39826697159795216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1591182382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9386784,0.015683362,0.031998355,0.0037366254,0.00055979635,0.007838031,0.0009600956,0.000037157883,0.0005081621],"genre_scores_gemma":[0.949073,0.003957957,0.04206442,0.0014684737,0.0012407154,0.0015499435,0.0002882902,0.00012408082,0.00023312678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836344,0.000041361734,0.0005297977,0.00042840966,0.00028296132,0.00035402933],"domain_scores_gemma":[0.9960092,0.00083241856,0.0007169503,0.00033571923,0.0018850814,0.00022064995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020777984,0.00025276956,0.00055946474,0.0002442395,0.00054072344,0.0001840652,0.00041777178,0.000074140924,0.0003038807],"category_scores_gemma":[0.00030752906,0.00020506242,0.00017804574,0.00042455323,0.00006581289,0.001135315,0.00003274874,0.00014091756,4.0315786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036851508,0.0027864503,0.8716979,0.0006594239,0.0005557413,0.0000037620275,0.0029074112,0.0007529806,0.008325498,0.0000100008365,0.030077254,0.078538425],"study_design_scores_gemma":[0.008018756,0.00019672139,0.9699453,0.002912258,0.0017042815,0.0000059827935,0.00033009305,0.00069158064,0.008782794,0.00007851177,0.0070110145,0.0003227065],"about_ca_topic_score_codex":0.0003487163,"about_ca_topic_score_gemma":0.00011781234,"teacher_disagreement_score":0.098247394,"about_ca_system_score_codex":0.000623574,"about_ca_system_score_gemma":0.0010802231,"threshold_uncertainty_score":0.83622026},"labels":[],"label_agreement":null},{"id":"W1595203599","doi":"10.1002/cncy.21395","title":"Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites","year":2014,"lang":"en","type":"article","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fine-needle aspiration; Primary tumor; Biopsy; Cancer; Disease; Metastatic tumor; Metastasis; Tumor heterogeneity; Pathology; Cytopathology; Cytology; Radiology; Internal medicine","score_opus":0.030400682051549006,"score_gpt":0.38399352718334734,"score_spread":0.35359284513179834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1595203599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507475,0.00049307564,0.0021774159,0.0010289159,0.000102964914,0.000987246,0.000036544585,0.000030231864,0.00006888561],"genre_scores_gemma":[0.99494964,0.000011076891,0.002103497,0.001829856,0.00009156567,0.0008383701,0.000038680286,0.000017062568,0.00012027217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922216,0.0000576457,0.00016381797,0.00031034477,0.00007278902,0.00017323458],"domain_scores_gemma":[0.9994993,0.00006903754,0.000064975866,0.00018512533,0.00006490134,0.000116647505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016776963,0.000107857915,0.00026838714,0.000098913035,0.00013065766,0.000009067386,0.00003829352,0.000019992896,0.000031181764],"category_scores_gemma":[0.000085876316,0.00008887473,0.000039448045,0.00010891277,0.00003370559,0.000048666345,0.000037195598,0.000037681042,0.00000863151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022738402,0.000274261,0.9436702,0.00009620089,0.00025802347,0.000038823546,0.0025217305,0.000034004905,0.025710842,0.00018046297,0.00021347655,0.026774585],"study_design_scores_gemma":[0.0044901655,0.002097529,0.9749249,0.000029566005,0.0016414457,0.00013355912,0.00045399502,0.00026950365,0.012440003,0.00026888293,0.0030624312,0.0001879706],"about_ca_topic_score_codex":0.00003379654,"about_ca_topic_score_gemma":0.00021719141,"teacher_disagreement_score":0.031254742,"about_ca_system_score_codex":0.00014915752,"about_ca_system_score_gemma":0.00004235525,"threshold_uncertainty_score":0.36242062},"labels":[],"label_agreement":null},{"id":"W1604653849","doi":"10.1593/neo.08200","title":"Phosphorylated Epidermal Growth Factor Receptor on Tumor-Associated Endothelial Cells Is a Primary Target for Therapy with Tyrosine Kinase Inhibitors","year":2008,"lang":"en","type":"article","venue":"Neoplasia","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Cancer research; Epidermal growth factor receptor; TGF alpha; EGFR inhibitors; Small hairpin RNA; Biology; Tyrosine kinase; Protein kinase B; Epidermal growth factor; Phosphorylation; Cell culture; Medicine; Cancer; Internal medicine; Signal transduction; Cell biology; Gene knockdown","score_opus":0.013203883396432997,"score_gpt":0.25322931578264685,"score_spread":0.24002543238621385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1604653849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428284,0.00029898368,0.000037000747,0.0010831241,0.00038407466,0.0014785494,0.0010242414,0.00015993018,0.0012512706],"genre_scores_gemma":[0.9906816,0.00018901446,0.0017655436,0.002837832,0.00026395023,0.0002215567,0.0005012546,0.00009042547,0.0034488623],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985705,0.000032016596,0.00027682804,0.0003991491,0.00032617128,0.0003953099],"domain_scores_gemma":[0.99910724,0.0001238767,0.00016159215,0.0002115844,0.00019689334,0.0001988199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000457478,0.00030724544,0.0004294574,0.0001020123,0.0002311565,0.000016199108,0.0000650694,0.00010958713,0.00036142537],"category_scores_gemma":[0.00003254902,0.0002186542,0.00015008032,0.00022176979,0.00008170392,0.00009340362,0.00000903875,0.00017135042,0.00006584743],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025366807,0.010318094,0.17638329,0.00034153802,0.0038819544,0.0011382796,0.013353827,0.00006277661,0.35905528,0.00016543524,0.39809343,0.011839273],"study_design_scores_gemma":[0.024185304,0.006972205,0.03781901,0.0002226752,0.00019558737,0.000074603726,0.00007511398,0.00004433974,0.8737749,0.0000281194,0.056142237,0.00046594592],"about_ca_topic_score_codex":0.00014988844,"about_ca_topic_score_gemma":0.000007457754,"teacher_disagreement_score":0.51471955,"about_ca_system_score_codex":0.00037551156,"about_ca_system_score_gemma":0.00046689814,"threshold_uncertainty_score":0.8916459},"labels":[],"label_agreement":null},{"id":"W1630105108","doi":"10.1002/cncy.21595","title":"Preanalytic parameters in epidermal growth factor receptor mutation testing for non–small cell lung carcinoma: A review of cytologic series","year":2015,"lang":"en","type":"review","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Pathology; Lung cancer; Cytology; Lymph node; Biopsy; Cancer; Internal medicine","score_opus":0.09007052677116206,"score_gpt":0.38676263427054,"score_spread":0.2966921074993779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1630105108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001936068,0.991488,0.00011108408,0.00015687413,0.00040277123,0.004804213,0.0006442859,0.000035155037,0.00042159192],"genre_scores_gemma":[0.00088677177,0.9877908,0.0061916723,0.00023360258,0.00013973519,0.0035843435,0.0007652099,0.000080530655,0.0003273207],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973139,0.00024119428,0.0011733975,0.00066203607,0.00015651892,0.00045292696],"domain_scores_gemma":[0.9974924,0.00043309262,0.0009839449,0.0003873553,0.00055225834,0.00015099542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036845487,0.00050202885,0.0031025484,0.00032987865,0.000044295808,0.000008195151,0.00017312304,0.00033455333,0.00003276262],"category_scores_gemma":[0.00077316404,0.0003886923,0.00043292614,0.0005926839,0.0001268758,0.00008597982,0.000051801504,0.00031300331,0.000007337759],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009806717,0.00025215096,0.009112464,0.6026607,0.00029303497,0.00041882796,0.00065520935,0.000007362308,0.000017833394,0.00002848333,0.0015150888,0.3849408],"study_design_scores_gemma":[0.013394034,0.007546396,0.0049454886,0.5367376,0.057957225,0.0037581977,0.00058053236,0.00018154041,0.00040921522,0.00039761496,0.37086233,0.0032297983],"about_ca_topic_score_codex":0.0001955771,"about_ca_topic_score_gemma":0.000042928335,"teacher_disagreement_score":0.381711,"about_ca_system_score_codex":0.0010748127,"about_ca_system_score_gemma":0.0025340216,"threshold_uncertainty_score":0.9998565},"labels":[],"label_agreement":null},{"id":"W1635544046","doi":"","title":"Severe Intracranial Hypertension Associated with Tetracycline Use in Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"American journal of cancer case reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Rash; Lung cancer; Tetracycline; Lumbar puncture; Epidermal growth factor receptor; Cancer; Internal medicine; Surgery; Antibiotics; Cerebrospinal fluid","score_opus":0.017485594968634183,"score_gpt":0.31073317497445335,"score_spread":0.2932475800058192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1635544046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967455,0.0015068202,0.000087956,0.0006341012,0.00043305353,0.00032854135,0.000018625842,0.0000121652365,0.00023323],"genre_scores_gemma":[0.99718195,0.00034325494,0.001197984,0.0005465735,0.00028672453,0.000028594692,0.000008268747,0.000042936554,0.00036373167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998284,0.000052984502,0.0007031818,0.00023643047,0.00043525093,0.00028816526],"domain_scores_gemma":[0.997205,0.00008620891,0.0011992023,0.00020837283,0.0008859559,0.00041522415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000269801,0.00020901937,0.00066983036,0.000194542,0.00004564453,0.000028132861,0.000030486854,0.000053375123,0.00004947306],"category_scores_gemma":[0.00013432921,0.00014480235,0.000106040614,0.00047048694,0.00009848431,0.00023166998,0.000014513624,0.0003447709,4.6659895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000601021,0.00042124712,0.6310464,0.000023520297,0.00047064634,0.34527296,0.00084190886,0.0019265404,0.00024545167,1.3746994e-7,0.0011469913,0.018003173],"study_design_scores_gemma":[0.015328313,0.004030586,0.544722,0.002983312,0.0051634856,0.4195405,0.003323763,0.0013248277,0.0007309112,0.000012341133,0.0021058025,0.00073416857],"about_ca_topic_score_codex":0.01163549,"about_ca_topic_score_gemma":0.0048281113,"teacher_disagreement_score":0.0863244,"about_ca_system_score_codex":0.0010603453,"about_ca_system_score_gemma":0.0020947668,"threshold_uncertainty_score":0.9949461},"labels":[],"label_agreement":null},{"id":"W1654793955","doi":"10.3978/j.issn.2072-1439.2012.s012","title":"AB 12. Chronomodulated chemotherapy in chemo naïve NSCLC patients","year":2012,"lang":"en","type":"article","venue":"PubMed Central","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacogenomics; Chemotherapy; Lung cancer; Oncology; Internal medicine; Pharmacology","score_opus":0.010170323644032994,"score_gpt":0.25858514795065873,"score_spread":0.24841482430662573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1654793955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99024683,0.00038859635,0.000023859999,0.00054326706,0.00064980774,0.0008422744,0.000012164795,0.000048049842,0.0072451364],"genre_scores_gemma":[0.9974868,0.00004799082,0.00020219263,0.00075070414,0.00038090377,0.00017076888,0.0001658039,0.000024983528,0.0007698189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842197,0.00001289219,0.00017623747,0.00015954692,0.00015241138,0.0010769385],"domain_scores_gemma":[0.9993465,0.00000982338,0.000045956174,0.00016107621,0.000022040937,0.0004146383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007896842,0.00013224462,0.00018059992,0.000065252025,0.000031155414,0.000010772276,0.00004376339,0.00006734654,0.00023149377],"category_scores_gemma":[0.00002419272,0.000110052984,0.000061833525,0.00012176581,0.00002696993,0.00015440496,0.000010329481,0.0000961015,0.00002988248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105902895,0.0008840594,0.93623173,0.000016207861,0.000104302046,0.0000029110238,0.0014065289,0.0000031802117,0.00003907829,0.000045196637,0.0015332855,0.059627615],"study_design_scores_gemma":[0.0058859577,0.000040003062,0.9778887,0.000019793244,0.00006169104,0.0000031211998,0.000041449184,0.000025785896,0.0011170694,0.000008366787,0.014803428,0.000104620914],"about_ca_topic_score_codex":0.00010890318,"about_ca_topic_score_gemma":0.000018102206,"teacher_disagreement_score":0.059522994,"about_ca_system_score_codex":0.0009018905,"about_ca_system_score_gemma":0.0000945485,"threshold_uncertainty_score":0.44878304},"labels":[],"label_agreement":null},{"id":"W166317910","doi":"10.3978/j.issn.2218-6751.2014.06.09","title":"Prognostic markers in lung cancer: is it ready for prime time?","year":2014,"lang":"en","type":"review","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Lung cancer; Gene; microRNA; Microarray; Cancer; Medicine; Biology; Oncology; Cancer research; Gene expression; Bioinformatics; Mutation; Internal medicine; Genetics","score_opus":0.0515233082881312,"score_gpt":0.3884260500202136,"score_spread":0.33690274173208234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W166317910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003595001,0.97913826,0.000013883741,0.0007503933,0.00027931077,0.0120053105,0.0002887432,0.00003953607,0.00748099],"genre_scores_gemma":[0.000017151526,0.9103133,0.00011909892,0.00034517972,0.00030042938,0.05861358,0.00065891555,0.00007331733,0.029559046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845165,0.000045919987,0.0004615197,0.00041767763,0.00016502109,0.00045821918],"domain_scores_gemma":[0.998973,0.00024295226,0.00023015693,0.00031488255,0.000068992245,0.00017002334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002448869,0.00029962612,0.0012875077,0.00019247201,0.000038492202,0.00002242707,0.00010373215,0.00019647731,0.00011892292],"category_scores_gemma":[0.00017058515,0.00022082734,0.0002747008,0.00022314541,0.00002735145,0.000037671845,0.000022199669,0.00016064655,0.000037899925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020457988,0.000071387505,0.0002932812,0.015701514,0.0006617895,0.000007286905,0.000042024556,8.459803e-8,5.3309255e-9,0.000008349135,0.046718467,0.93647534],"study_design_scores_gemma":[0.0010390433,0.000035250036,0.0013664424,0.0058434554,0.0063049616,0.000011574539,0.000003099343,0.000022417507,2.2040295e-7,0.000004641991,0.9851698,0.00019905632],"about_ca_topic_score_codex":0.00013604896,"about_ca_topic_score_gemma":0.000028082626,"teacher_disagreement_score":0.93845135,"about_ca_system_score_codex":0.0008504409,"about_ca_system_score_gemma":0.00057028426,"threshold_uncertainty_score":0.90050775},"labels":[],"label_agreement":null},{"id":"W1668780299","doi":"10.1111/1759-7714.12102","title":"Tumor response and clinical toxicity associated with second‐line chemotherapy regimens for advanced non‐squamous non‐small cell lung cancer: A retrospective cohort study","year":2014,"lang":"en","type":"article","venue":"Thoracic Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; University of Toronto","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Docetaxel; Medicine; Oncology; Internal medicine; Lung cancer; Neutropenia; Chemotherapy; Retrospective cohort study; Febrile neutropenia; Cisplatin","score_opus":0.013299624342715503,"score_gpt":0.3795160286502666,"score_spread":0.36621640430755115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1668780299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991499,0.0004987255,0.0007469664,0.0007445154,0.00025934188,0.0052781655,0.00031916067,0.0001024153,0.0005517106],"genre_scores_gemma":[0.9879793,0.00013438199,0.00067707844,0.0011344369,0.00028920962,0.0018970373,0.00004317388,0.00009493741,0.0077504627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978169,0.00016853603,0.0004763847,0.0007948723,0.0002990497,0.0004442277],"domain_scores_gemma":[0.99798614,0.00044728853,0.00038800505,0.00046246705,0.0004551238,0.00026098793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010299742,0.00035396966,0.0009308267,0.000093524955,0.00022326448,0.00003300197,0.000096725096,0.00011772609,0.00017887985],"category_scores_gemma":[0.0001944268,0.00027555195,0.0001286994,0.0002943961,0.00012251544,0.00009087548,0.000029743298,0.0003036452,0.0000016990218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01552587,0.0015132756,0.9713211,0.00013097543,0.0013032659,0.000029358385,0.001872956,0.000058479134,0.0019915826,0.0000022294792,0.0012287401,0.0050221435],"study_design_scores_gemma":[0.016087621,0.005864803,0.9673879,0.00028382527,0.0023157625,0.000007098486,0.0003870509,0.0024734272,0.0040894663,0.000015413652,0.0007124376,0.00037520003],"about_ca_topic_score_codex":0.0006102375,"about_ca_topic_score_gemma":0.0052234754,"teacher_disagreement_score":0.007198752,"about_ca_system_score_codex":0.0010991608,"about_ca_system_score_gemma":0.00070760783,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W1701841458","doi":"10.1111/resp.12377","title":"Molecular alterations in non‐small‐cell lung cancer: Perspective for targeted therapy and specimen management for the bronchoscopist","year":2014,"lang":"en","type":"review","venue":"Respirology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Anaplastic lymphoma kinase; Epidermal growth factor receptor; ROS1; Cancer; Targeted therapy; Pathology; Oncology; Lung; Molecular pathology; Internal medicine; Adenocarcinoma; Gene","score_opus":0.02389548087400997,"score_gpt":0.3898513366537585,"score_spread":0.36595585577974854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1701841458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000075374795,0.9847189,0.0032879482,0.0014214541,0.00019129053,0.008784719,0.000117804986,0.000013408593,0.0013890968],"genre_scores_gemma":[0.00017472862,0.9864209,0.0011755766,0.00062202575,0.00024390624,0.009705119,0.00015425915,0.000054760676,0.0014486911],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988547,0.000065157314,0.0003101357,0.00043300475,0.00006426378,0.00027273997],"domain_scores_gemma":[0.999097,0.0003051362,0.00015741405,0.00030679334,0.00007810844,0.00005557424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014013945,0.00026022055,0.00083037576,0.00016241144,0.00012145189,0.000021432485,0.000107531,0.00015264479,0.00003134291],"category_scores_gemma":[0.000015281214,0.00016568512,0.000218693,0.00011616681,0.00005845744,0.000014469377,0.000027026774,0.00013806277,0.0000016717809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042592926,0.00037199896,0.000115967676,0.01616996,0.0044882433,0.000036707665,0.0012196276,0.00009034106,0.000017689754,0.014751553,0.0046957447,0.9576162],"study_design_scores_gemma":[0.0035048898,0.0004899739,0.00022667497,0.0009486199,0.0029062245,0.0000065513327,0.0000847563,0.00024156825,0.0000074186282,0.00015840918,0.9912648,0.00016008467],"about_ca_topic_score_codex":0.0002166151,"about_ca_topic_score_gemma":0.00015857255,"teacher_disagreement_score":0.9865691,"about_ca_system_score_codex":0.0004039594,"about_ca_system_score_gemma":0.00022316928,"threshold_uncertainty_score":0.67564434},"labels":[],"label_agreement":null},{"id":"W1713591079","doi":"10.3747/co.22.2296","title":"Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre","year":2015,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Docetaxel; Erlotinib; Gefitinib; Internal medicine; Oncology; Lung cancer; Progression-free survival; Retrospective cohort study; Erlotinib Hydrochloride; Cancer; Chemotherapy; Epidermal growth factor receptor","score_opus":0.09363111991465187,"score_gpt":0.47573335739767375,"score_spread":0.38210223748302186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1713591079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047931372,0.98403347,5.362716e-7,0.00045867974,0.0020306227,0.0067231045,0.0005877546,0.000042089916,0.005644462],"genre_scores_gemma":[0.00010920267,0.9913702,0.00021026241,0.00013060233,0.00061288394,0.0010620685,0.0019394058,0.00010197863,0.004463375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630827,0.00044390737,0.0014218994,0.000939823,0.00033413482,0.0005519459],"domain_scores_gemma":[0.9962322,0.0003053342,0.0015410034,0.00069851987,0.0008634467,0.0003595034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021344116,0.00079215073,0.0039332593,0.0004338544,0.000071002796,0.000010463402,0.00016707733,0.00033944618,0.00054815836],"category_scores_gemma":[0.00016414774,0.0005368589,0.00053958653,0.0010576232,0.00010585714,0.00010345164,0.00012721484,0.00047819986,0.000041378295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033972217,0.005706365,0.005587192,0.11174137,0.0010999407,0.0007571015,0.0026664303,9.823594e-7,0.000001957961,0.000003985385,0.020838033,0.8512569],"study_design_scores_gemma":[0.0045420183,0.0022873064,0.00009574976,0.06599466,0.018268846,0.00009398817,0.00023217507,0.000003018778,0.000014554175,8.4275194e-7,0.9080931,0.00037372202],"about_ca_topic_score_codex":0.00092987204,"about_ca_topic_score_gemma":0.008167349,"teacher_disagreement_score":0.8872551,"about_ca_system_score_codex":0.023602044,"about_ca_system_score_gemma":0.006746439,"threshold_uncertainty_score":0.9997083},"labels":[],"label_agreement":null},{"id":"W1763748567","doi":"10.1200/jco.2012.30.15_suppl.5504","title":"Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Panitumumab; Response Evaluation Criteria in Solid Tumors; Larynx; Head and neck squamous-cell carcinoma; Chemotherapy; Head and neck cancer; Phases of clinical research; Cetuximab; Cancer; Surgery","score_opus":0.057174723813613576,"score_gpt":0.46188841779417833,"score_spread":0.4047136939805648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1763748567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397385,0.0024337987,0.000026528247,0.0013715242,0.000383382,0.0005869149,0.00009650486,9.628476e-7,0.0011265196],"genre_scores_gemma":[0.99894726,0.0004158075,0.0003412426,0.00014914795,0.000113455884,0.0000024155288,0.0000024948747,0.0000057877296,0.000022392152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969312,0.00070051244,0.0017875363,0.00013415517,0.00025865593,0.00018792748],"domain_scores_gemma":[0.9947667,0.0026413484,0.002049022,0.00017089989,0.00017415758,0.00019788682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013575024,0.00013406384,0.0015549529,0.00011770414,0.000048332888,0.0000032876314,0.00008905502,0.00011232526,0.000030237628],"category_scores_gemma":[0.001456262,0.000070335314,0.0003603039,0.0005049244,0.0005468327,0.000090483016,0.00007557937,0.00035459743,1.0655977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085991286,0.0135856075,0.8255345,0.00010588496,0.0028185043,0.00002503278,0.003968649,0.000023992669,0.000058933187,0.0004681832,0.00007127617,0.067348115],"study_design_scores_gemma":[0.11491016,0.009411926,0.86695945,0.000074439275,0.0073123993,0.000043053173,0.00064331345,0.00009209266,0.00025437173,0.00010918491,0.00013789024,0.000051735256],"about_ca_topic_score_codex":0.00028502394,"about_ca_topic_score_gemma":0.00029412584,"teacher_disagreement_score":0.06729638,"about_ca_system_score_codex":0.00017282067,"about_ca_system_score_gemma":0.00064330956,"threshold_uncertainty_score":0.28681907},"labels":[],"label_agreement":null},{"id":"W1773700395","doi":"10.1016/j.semradonc.2015.05.006","title":"The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism−Based Models: A Step Toward Prevention","year":2015,"lang":"en","type":"review","venue":"Seminars in Radiation Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Radiogenomics; Concomitant; Radiation treatment planning; Toxicity; Oncology; Cancer; Adverse effect; Precision medicine; Bioinformatics; Intensive care medicine; Internal medicine; Pathology; Radiology; Biology","score_opus":0.09800846330238522,"score_gpt":0.42438786620750196,"score_spread":0.32637940290511674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1773700395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028982887,0.99257743,0.0030679072,0.00019805258,0.0007904901,0.0019833592,0.000111908324,0.000036375128,0.00094464957],"genre_scores_gemma":[0.00041258696,0.9943665,0.0039492548,0.000057590714,0.00027579028,0.00020774864,0.0003762921,0.000052778494,0.00030141967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978971,0.00040052854,0.000850265,0.00032282685,0.0002856246,0.00024364977],"domain_scores_gemma":[0.9983816,0.00025647116,0.0008059698,0.00033209508,0.00012739166,0.00009645176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005517526,0.00026211215,0.0011305606,0.00033560864,0.00008237238,0.000013896693,0.00012015599,0.00041261385,0.000020987462],"category_scores_gemma":[0.000065700624,0.00019492261,0.0002824524,0.00041981984,0.00011523108,0.0001125391,0.000017664808,0.0002517541,0.0000018906412],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009815676,0.0005373284,0.000043642285,0.0010601229,0.0002650074,0.000011495308,0.0004145997,0.00050405465,0.000015832353,0.0000662324,0.0008913417,0.9960922],"study_design_scores_gemma":[0.0024073683,0.0015434801,0.000015000082,0.004714718,0.0017740799,0.00007192126,0.00015534896,0.019135626,0.000011766852,0.00017376481,0.9698484,0.00014855298],"about_ca_topic_score_codex":0.00008680839,"about_ca_topic_score_gemma":0.000027200085,"teacher_disagreement_score":0.9959436,"about_ca_system_score_codex":0.0045955502,"about_ca_system_score_gemma":0.002777833,"threshold_uncertainty_score":0.9992256},"labels":[],"label_agreement":null},{"id":"W1788867760","doi":"10.1002/cncr.28723","title":"Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer","year":2014,"lang":"en","type":"review","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; Conquer Cancer Foundation","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Tyrosine kinase; Cancer; Acquired resistance; Clinical trial; Tyrosine-kinase inhibitor; Oncology; EGFR inhibitors; Cancer research; Internal medicine; Receptor","score_opus":0.012874157728887944,"score_gpt":0.3203719676223,"score_spread":0.3074978098934121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1788867760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009491708,0.98196274,0.000049371112,0.00010509875,0.0007359037,0.0054927687,0.00073812186,0.000034560522,0.0013897157],"genre_scores_gemma":[0.0049722986,0.98391116,0.0016257504,0.00016620712,0.00020357594,0.003951367,0.00030821786,0.000156087,0.0047053453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750304,0.00006143274,0.0007914745,0.00075669034,0.00039611166,0.00049123034],"domain_scores_gemma":[0.9983229,0.00004834234,0.00056076184,0.0005329045,0.00026521433,0.00026989044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000065491324,0.0005825468,0.0017872027,0.0002942982,0.000053568932,0.0000138520245,0.00020334459,0.00017790846,0.00022317964],"category_scores_gemma":[0.000010960542,0.00042716227,0.00024079162,0.00069087645,0.00005049304,0.00008628407,0.00007396556,0.00014460043,0.000013750752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006160655,0.00061324245,0.021815863,0.11368727,0.0014712393,0.000050907653,0.00064458227,0.000043535427,0.000005098373,0.000027329874,0.006346589,0.8546783],"study_design_scores_gemma":[0.005910215,0.00032927791,0.010935241,0.10984054,0.0037335085,2.5038113e-7,0.000042029584,0.0000013341655,0.00014832203,0.0000014264234,0.86831874,0.0007390971],"about_ca_topic_score_codex":0.00018822514,"about_ca_topic_score_gemma":0.00024031829,"teacher_disagreement_score":0.86197215,"about_ca_system_score_codex":0.0018098938,"about_ca_system_score_gemma":0.0006277642,"threshold_uncertainty_score":0.999818},"labels":[],"label_agreement":null},{"id":"W1797421894","doi":"10.1200/jco.2006.24.18_suppl.7008","title":"Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Internal medicine; Hazard ratio; Etoposide; Chemotherapy; Vinca; Cisplatin; Oncology; Lung cancer; Confidence interval; Stage (stratigraphy); Clinical trial; Randomized controlled trial; Pharmacology","score_opus":0.18839369014743626,"score_gpt":0.5980156452928224,"score_spread":0.40962195514538613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1797421894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98704106,0.0010405186,0.0026045984,0.0022507778,0.001627638,0.0013219482,0.000024959176,0.000007745372,0.004080783],"genre_scores_gemma":[0.9930432,0.00033272765,0.004861996,0.00048099994,0.00094598666,0.000023231652,0.00009322279,0.000013638774,0.00020499177],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9808538,0.007829917,0.009983098,0.00025578137,0.00088197103,0.00019543798],"domain_scores_gemma":[0.9596471,0.02770618,0.009863629,0.00023286465,0.0022854519,0.00026475565],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05594835,0.00017112363,0.0066505424,0.0004914447,0.000054419084,0.000009548607,0.00011813791,0.00043015776,0.00040235536],"category_scores_gemma":[0.06566642,0.00010546792,0.003256561,0.0005270112,0.00023245497,0.00011669727,0.000042183554,0.000572177,0.0000035506746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21947473,0.009548011,0.40304485,0.000046446967,0.048372094,0.00009885514,0.0003183748,0.01138909,0.000030319341,0.00019189034,0.0057861763,0.30169916],"study_design_scores_gemma":[0.42267323,0.0036654905,0.3558921,0.00013687783,0.14873901,0.000007046321,0.000094660456,0.067362964,0.000012798695,0.0004630037,0.0008456316,0.00010721651],"about_ca_topic_score_codex":0.0001248028,"about_ca_topic_score_gemma":0.000068788024,"teacher_disagreement_score":0.30159193,"about_ca_system_score_codex":0.00036124166,"about_ca_system_score_gemma":0.0022723305,"threshold_uncertainty_score":0.97209984},"labels":[],"label_agreement":null},{"id":"W1814699096","doi":"10.1016/j.ctrv.2004.08.002","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"letter","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Chemotherapy; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer; Cisplatin","score_opus":0.01463295194877606,"score_gpt":0.32321337576972325,"score_spread":0.3085804238209472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1814699096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8928692,0.042552575,0.00006519874,0.03167735,0.0007036021,0.028970672,0.0025730275,0.00010045723,0.00048796798],"genre_scores_gemma":[0.54010725,0.27169362,0.009373163,0.06727476,0.0019549385,0.08897269,0.01299256,0.0014749808,0.0061560413],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920209,0.0004654111,0.0023752977,0.0028310195,0.000821693,0.001485663],"domain_scores_gemma":[0.99501663,0.0005798415,0.0023882708,0.0011960436,0.00034529532,0.0004738976],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00054824055,0.0023990332,0.005096148,0.0007073262,0.00021618648,0.0002321655,0.00031410347,0.0008183024,0.00020684289],"category_scores_gemma":[0.00003022522,0.0015985701,0.00030043806,0.00096049934,0.0002409414,0.00068617135,0.000074577736,0.0021170403,0.0000019780973],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2660007,0.022349657,0.4287684,0.016693415,0.008818368,0.004553122,0.04191408,0.002387171,0.0076030996,0.000015506053,0.011037456,0.18985905],"study_design_scores_gemma":[0.8783428,0.016892921,0.026263006,0.025980389,0.0059937057,0.000025744936,0.0013696476,0.00091509067,0.0026640596,0.000017852439,0.03764297,0.0038918164],"about_ca_topic_score_codex":0.08312356,"about_ca_topic_score_gemma":0.15984346,"teacher_disagreement_score":0.6123421,"about_ca_system_score_codex":0.0063881557,"about_ca_system_score_gemma":0.004141427,"threshold_uncertainty_score":0.9988747},"labels":[],"label_agreement":null},{"id":"W1819148429","doi":"10.1200/jco.2012.30.15_suppl.lba7500","title":"LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Pemetrexed; Medicine; Afatinib; Oncology; Internal medicine; Cisplatin; Adenocarcinoma; Lung cancer; Erlotinib; Chemotherapy; Epidermal growth factor receptor; Cancer","score_opus":0.1257192747879889,"score_gpt":0.5202801478412544,"score_spread":0.39456087305326554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1819148429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417585,0.00077979325,0.00019478747,0.00045672586,0.0006232182,0.0034133017,0.00001744707,0.0000034982438,0.00033536422],"genre_scores_gemma":[0.99313563,0.00010779759,0.0062758066,0.00005503248,0.00017911958,0.0001560842,0.000009672982,0.000020640357,0.000060211296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971076,0.00029280307,0.0019289535,0.00017004556,0.00030283365,0.0001977235],"domain_scores_gemma":[0.9906925,0.0053310604,0.0029815405,0.00019772584,0.00059974415,0.00019743173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011709051,0.0001744088,0.0017281846,0.000098231365,0.00012962666,0.00000888671,0.00012357793,0.00009591366,0.000026518495],"category_scores_gemma":[0.0030843585,0.000092744616,0.00017985904,0.00018030233,0.00015221674,0.0002549251,0.000059281574,0.0002087004,1.5373313e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.510997,0.035624932,0.36433238,0.00009671506,0.00503364,0.000014275526,0.0048185177,0.00011415192,0.000042158,0.00009333482,0.000055284145,0.07877762],"study_design_scores_gemma":[0.844467,0.055713058,0.09202893,0.00023962828,0.0050472803,0.000010683287,0.0015600086,0.00046698368,0.00012465932,0.000016522199,0.00023687685,0.00008836195],"about_ca_topic_score_codex":0.000094164665,"about_ca_topic_score_gemma":0.000037038888,"teacher_disagreement_score":0.33347002,"about_ca_system_score_codex":0.00026201925,"about_ca_system_score_gemma":0.0006641988,"threshold_uncertainty_score":0.37820157},"labels":[],"label_agreement":null},{"id":"W1834243275","doi":"10.1200/jco.2010.28.15_suppl.e21092","title":"Estrogen receptor-beta (ER-beta) expression and non-small cell lung cancer (NSCLC) outcome.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Estrogen receptor; Cohort; Stage (stratigraphy); Cancer; Univariate analysis; Multivariate analysis; Breast cancer; Biology","score_opus":0.0652614506696828,"score_gpt":0.4781060407951108,"score_spread":0.412844590125428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834243275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789909,0.0012262616,0.00012891123,0.008134482,0.003182141,0.00026755058,0.00000931203,0.000009733039,0.008050694],"genre_scores_gemma":[0.9812064,0.0011228798,0.012413212,0.0016321217,0.0020035268,0.0000141134915,0.0000044746116,0.000024770734,0.0015784863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776405,0.000108220396,0.0014696345,0.000208229,0.00022558603,0.00022427955],"domain_scores_gemma":[0.9971368,0.000709565,0.0011201589,0.00020041999,0.00030695403,0.00052614044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009650493,0.00015074147,0.0010058413,0.000086352615,0.00006998933,0.000013695125,0.00012511415,0.00039808848,0.000443874],"category_scores_gemma":[0.0002878843,0.00009708031,0.0003230425,0.0000717117,0.00013075647,0.000102616745,0.000054896238,0.001141615,0.000013449915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000778384,0.0010874907,0.9214801,0.00006391869,0.00031508564,0.00013185026,0.00024090499,0.000005603369,0.013080258,0.00006191851,0.010574494,0.052179955],"study_design_scores_gemma":[0.022428911,0.0056977477,0.67980415,0.0002747381,0.0027650883,0.0002339417,0.0002370305,0.000069509966,0.006254903,0.00006549098,0.28191796,0.0002505738],"about_ca_topic_score_codex":0.000048473496,"about_ca_topic_score_gemma":0.000048896865,"teacher_disagreement_score":0.27134344,"about_ca_system_score_codex":0.000099806726,"about_ca_system_score_gemma":0.0015501241,"threshold_uncertainty_score":0.49598122},"labels":[],"label_agreement":null},{"id":"W1837617056","doi":"","title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Epidermal growth factor receptor; Cancer research; Autophosphorylation; Receptor tyrosine kinase; Tyrosine kinase; Epidermal growth factor; GRB2; Tropomyosin receptor kinase C; Growth factor receptor; Platelet-derived growth factor receptor; Gefitinib; ROR1; Biology; Signal transduction; Growth factor receptor inhibitor; Medicine; Cell biology; Internal medicine; Cancer; Receptor; Growth factor; Kinase; Protein kinase A","score_opus":0.02782150552786074,"score_gpt":0.3281403449556285,"score_spread":0.30031883942776777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1837617056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961824,0.0034814642,0.0000026376758,0.004570784,0.0004322174,0.00085776165,0.00007131463,0.000042379997,0.0009231869],"genre_scores_gemma":[0.9951027,0.0017066457,0.00023054164,0.00088892085,0.00020234882,0.0013254168,0.000054072985,0.000017911238,0.00047143997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926007,0.000019879573,0.00014598081,0.00021370056,0.00010217371,0.00025819617],"domain_scores_gemma":[0.99952644,0.00002185704,0.000039362065,0.0001491726,0.0000391744,0.0002239657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008054153,0.00010380256,0.00018437028,0.00007084217,0.000040401665,0.000021336828,0.000042448584,0.00006159746,0.00028938064],"category_scores_gemma":[0.000044826626,0.00008204578,0.00002648147,0.000114924675,0.000034544806,0.00018271286,0.000018050869,0.00015343979,0.000004336648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005661835,0.00018177708,0.76088774,0.00015767524,0.00010340666,0.000017882194,0.00045393838,3.110569e-7,0.0003390052,0.0010615183,0.0021724314,0.23456767],"study_design_scores_gemma":[0.0014650567,0.000016988502,0.98066956,0.000019011135,0.00008826517,0.000008731438,0.00002192269,0.000028291508,0.0005689087,0.00006429199,0.016955096,0.000093891686],"about_ca_topic_score_codex":0.0009345674,"about_ca_topic_score_gemma":0.0010417236,"teacher_disagreement_score":0.23447378,"about_ca_system_score_codex":0.00010066001,"about_ca_system_score_gemma":0.000071518014,"threshold_uncertainty_score":0.33457297},"labels":[],"label_agreement":null},{"id":"W1841324351","doi":"10.3978/j.issn.2072-1439.2015.01.41","title":"Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy?","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Bevacizumab; Nintedanib; Internal medicine; Oncology; Chemotherapy; Lung cancer; Placebo; Performance status; Lung; Surgery; Pathology; Idiopathic pulmonary fibrosis","score_opus":0.02586150697104927,"score_gpt":0.2778020549831973,"score_spread":0.25194054801214805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1841324351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97068816,0.02297373,0.000006672788,0.0005687431,0.00011122947,0.0020144796,0.000017231638,0.0000193392,0.0036004374],"genre_scores_gemma":[0.99638355,0.0010498927,0.0001407179,0.0002843268,0.000060503295,0.0014045964,0.00002313831,0.000032345015,0.00062091893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988759,0.000038367125,0.00030573717,0.00025827446,0.00017886277,0.0003428718],"domain_scores_gemma":[0.99933565,0.000027112272,0.00010143392,0.00029636666,0.0001026079,0.00013683911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017294694,0.00017038293,0.00035820116,0.00018882175,0.000014607606,0.0000089554915,0.00010155299,0.00007623149,0.000019760793],"category_scores_gemma":[0.000011806185,0.00012812477,0.00010951201,0.00035802482,0.000028587014,0.00007593032,0.000016781645,0.00009254585,0.000003544216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031958986,0.00061387353,0.93591356,0.000032230815,0.00009082915,0.00003979678,0.0045708544,0.000053523465,0.0017771691,0.0000067976157,0.00011837206,0.056463383],"study_design_scores_gemma":[0.010744341,0.0001637824,0.9609474,0.00003639402,0.000038656486,0.0000039662323,0.0007019308,0.000105878375,0.026029313,0.00006377581,0.0010390533,0.00012550974],"about_ca_topic_score_codex":0.0011550916,"about_ca_topic_score_gemma":0.00022410005,"teacher_disagreement_score":0.056337874,"about_ca_system_score_codex":0.00021750735,"about_ca_system_score_gemma":0.00025024774,"threshold_uncertainty_score":0.5224776},"labels":[],"label_agreement":null},{"id":"W1842992197","doi":"10.3978/j.issn.2218-6751.2014.11.06","title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.","year":2015,"lang":"en","type":"review","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"T790M; Medicine; Lung cancer; Epidermal growth factor receptor; Targeted therapy; Cancer; Acquired resistance; Exon; Mutation; Cancer research; Disease; EGFR inhibitors; Bioinformatics; Oncology; Gene; Internal medicine; Gefitinib; Biology; Genetics","score_opus":0.028129811661183318,"score_gpt":0.328210754018052,"score_spread":0.30008094235686866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1842992197","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049520473,0.9899663,0.000079058904,0.0003193796,0.00007462386,0.007647831,0.0003150558,0.000022646667,0.0015255932],"genre_scores_gemma":[0.0006691289,0.98726565,0.001678998,0.00022432998,0.000021927892,0.008010303,0.00070766394,0.000055145218,0.00136688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831164,0.00013049321,0.00055116095,0.0003877921,0.00034957976,0.0002693284],"domain_scores_gemma":[0.9986867,0.00009677074,0.00036108587,0.00027800188,0.00037312173,0.0002043438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002771967,0.00031642878,0.0014757913,0.00027014257,0.000033431745,0.000012018479,0.00008523301,0.00009429467,0.0000102214935],"category_scores_gemma":[0.00017305191,0.00020442,0.00009497445,0.0007043705,0.00006183462,0.00008344549,0.000028823608,0.00014550437,0.0000053723397],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007352063,0.00020495681,0.00015789668,0.015183075,0.0005316715,0.000011661205,0.00055509753,2.5099703e-7,2.2629333e-8,0.00023924377,0.0010358175,0.9820068],"study_design_scores_gemma":[0.0030906203,0.00027629748,0.014074597,0.03698818,0.0038104625,0.0000058960823,0.00015437842,1.570351e-7,0.0000024157105,0.00058453623,0.9405957,0.00041674773],"about_ca_topic_score_codex":0.000028175185,"about_ca_topic_score_gemma":0.0000524186,"teacher_disagreement_score":0.98159003,"about_ca_system_score_codex":0.00042329312,"about_ca_system_score_gemma":0.00034447046,"threshold_uncertainty_score":0.8336006},"labels":[],"label_agreement":null},{"id":"W1876898604","doi":"10.1183/13993003/erj.44.suppl_58.1929","title":"Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut)","year":2014,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Pemetrexed; Oncology; Gemcitabine; Lung cancer; Erlotinib; Progression-free survival; Cisplatin; Gastroenterology; Chemotherapy; Epidermal growth factor receptor; Cancer","score_opus":0.033152789031815205,"score_gpt":0.36442433782498534,"score_spread":0.3312715487931701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1876898604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947309,0.0017011722,0.00080310216,0.00007943042,0.00015833617,0.0011182319,0.000076426375,0.000026553746,0.0013058345],"genre_scores_gemma":[0.99785614,0.0002615696,0.0011062806,0.00036473625,0.00012127597,0.000054831497,0.000054778728,0.00010605144,0.000074318436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966157,0.00061197596,0.0010915074,0.00058975996,0.0005018502,0.00058920035],"domain_scores_gemma":[0.99778205,0.0001969256,0.0008825614,0.00036069288,0.00045107293,0.00032668273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009132964,0.0004779198,0.0012853665,0.0006926544,0.00034204804,0.0001266788,0.00028650646,0.00003112709,0.00007842967],"category_scores_gemma":[0.000063143496,0.00037029161,0.00009490986,0.0008239397,0.00011581465,0.0005925994,0.00012879344,0.0006017122,0.0000013856587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018153479,0.0016739237,0.9827177,0.00018650235,0.0020184596,0.00013495145,0.004566807,0.0029312675,0.0009866151,0.000023181396,0.000076879165,0.0028683548],"study_design_scores_gemma":[0.12232588,0.001404119,0.8617534,0.0017909311,0.0020605263,0.000007785937,0.0011840508,0.0075997403,0.0008270041,0.00000196286,0.00044358018,0.0006009877],"about_ca_topic_score_codex":0.00027423387,"about_ca_topic_score_gemma":0.0014034375,"teacher_disagreement_score":0.12096428,"about_ca_system_score_codex":0.0006402881,"about_ca_system_score_gemma":0.00028004622,"threshold_uncertainty_score":0.9998749},"labels":[],"label_agreement":null},{"id":"W1884843684","doi":"10.18632/oncotarget.3472","title":"Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Oncotarget","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Cetuximab; T790M; Epidermal growth factor receptor; Exon; Lung cancer; Medicine; KRAS; Cancer research; Cancer; Osimertinib; Oncology; Internal medicine; Biology; Erlotinib; Genetics; Gefitinib; Colorectal cancer; Gene","score_opus":0.020599895564908075,"score_gpt":0.31467356550185444,"score_spread":0.29407366993694634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1884843684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530375,0.0018658568,0.00035795014,0.00036252022,0.00027737202,0.00097298855,0.00042559367,0.000015712712,0.00041825772],"genre_scores_gemma":[0.9960765,0.00020888065,0.0027907393,0.00016099995,0.00009345958,0.000103140286,0.00006442993,0.000032857068,0.00046897546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989067,0.000051209,0.0002813098,0.00031315538,0.00016286629,0.00028478427],"domain_scores_gemma":[0.99920434,0.00008942517,0.00012988417,0.00017039402,0.00016504031,0.00024094552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016722459,0.00018296244,0.0004253545,0.00010160682,0.000035404668,0.000009594971,0.000038499187,0.000079566365,0.00002509935],"category_scores_gemma":[0.00004711617,0.00015849448,0.0000682335,0.00012596596,0.000046435616,0.0000866006,0.00002888534,0.00009031348,0.0000031352731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034240194,0.00034772768,0.94143486,0.00048535128,0.00007083648,0.00016188931,0.003403026,0.000036016347,0.047271844,0.000009966985,0.004884946,0.0015511361],"study_design_scores_gemma":[0.024052408,0.0008581403,0.50292766,0.0008884395,0.00057657,0.000053562242,0.0014054467,0.006141569,0.45123398,0.00012831303,0.010892832,0.0008410769],"about_ca_topic_score_codex":0.0010364655,"about_ca_topic_score_gemma":0.0005532704,"teacher_disagreement_score":0.4385072,"about_ca_system_score_codex":0.00030214773,"about_ca_system_score_gemma":0.00031442032,"threshold_uncertainty_score":0.6463217},"labels":[],"label_agreement":null},{"id":"W1900281415","doi":"10.1155/2013/618691","title":"Sex as an Independent Prognostic Factor in a Population-Based, Non-Small Cell Lung Cancer Cohort","year":2013,"lang":"en","type":"article","venue":"Canadian Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Adenocarcinoma; Histology; Internal medicine; Cancer registry; Proportional hazards model; Population; Cancer; Cohort; Oncology","score_opus":0.015443144418391914,"score_gpt":0.29834580709947917,"score_spread":0.28290266268108727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1900281415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960345,0.0006032824,0.000026317977,0.00038373886,0.00025117976,0.0011319171,0.000039117065,0.000013710099,0.0015162418],"genre_scores_gemma":[0.99527526,0.0000088482775,0.00010163253,0.0034440274,0.0002621605,0.00022420676,0.000028050179,0.00003757187,0.000618225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864924,0.000061977706,0.00033621854,0.0002461702,0.0002546138,0.00045180004],"domain_scores_gemma":[0.99811536,0.000027402952,0.00011594739,0.00020624424,0.0001941931,0.001340856],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001224129,0.00017928181,0.0002358106,0.0004826885,0.00019542339,0.00012045942,0.00010624356,0.00012268034,0.0022331765],"category_scores_gemma":[0.00003661278,0.00015712701,0.000067028515,0.00018985005,0.000017886883,0.00019461267,0.0000055158594,0.00039150042,0.00005089648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000073796987,0.0000653324,0.99561435,0.00003136616,0.00005745322,0.00034539323,0.00030247887,0.00023440378,0.00012943958,0.0000052679284,0.00078439,0.002422756],"study_design_scores_gemma":[0.0016884062,0.00019164216,0.9950438,0.0001423053,0.00012804377,0.000040772306,0.00015433226,0.0005350389,0.00012946583,0.000024737641,0.0017503452,0.0001711226],"about_ca_topic_score_codex":0.22907054,"about_ca_topic_score_gemma":0.28800383,"teacher_disagreement_score":0.058933295,"about_ca_system_score_codex":0.0022187526,"about_ca_system_score_gemma":0.0060606743,"threshold_uncertainty_score":0.99957407},"labels":[],"label_agreement":null},{"id":"W1920342986","doi":"10.1016/j.lungcan.2015.07.004","title":"Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Lung cancer; Relative survival; Population; Cancer; Demography; Oncology; Internal medicine; Cancer registry; Environmental health","score_opus":0.021763515646647368,"score_gpt":0.34458078962022687,"score_spread":0.3228172739735795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1920342986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994846,0.0022886212,0.000021664993,0.00088652916,0.00021232535,0.00075155863,0.00006797088,0.000005393136,0.0009199574],"genre_scores_gemma":[0.99894714,0.000016309199,0.00006266425,0.00017967462,0.000047778507,0.00032837124,0.000029264414,0.000014241417,0.0003745663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988824,0.00008983526,0.00028813013,0.00023247354,0.0003198255,0.00018731676],"domain_scores_gemma":[0.99942666,0.00009012679,0.00012548675,0.00018641938,0.0000895031,0.000081810314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020531371,0.00013878426,0.00029547297,0.00014124908,0.000033190787,0.000007935963,0.0000759553,0.00003623533,0.000048560658],"category_scores_gemma":[0.000017672803,0.0000976264,0.000024691268,0.00052166975,0.000017982595,0.000077827295,0.000017028351,0.00015836488,9.97312e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010588061,0.0001401984,0.9896511,0.00005448969,0.000059503054,0.000042825835,0.006299097,0.0024411804,0.0000072169446,0.0000084297135,0.0003407328,0.0008493564],"study_design_scores_gemma":[0.0038285458,0.00010609449,0.98624533,0.00017839117,0.0002624769,6.040879e-7,0.002646291,0.0065735015,0.000017106848,0.000006279315,0.00003632029,0.000099071316],"about_ca_topic_score_codex":0.9772679,"about_ca_topic_score_gemma":0.9930572,"teacher_disagreement_score":0.015789263,"about_ca_system_score_codex":0.001960125,"about_ca_system_score_gemma":0.0029055865,"threshold_uncertainty_score":0.51543856},"labels":[],"label_agreement":null},{"id":"W1924587196","doi":"10.1593/neo.101174","title":"Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide","year":2011,"lang":"en","type":"article","venue":"Neoplasia","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; European Society for Medical Oncology","keywords":"Cyclophosphamide; Maximum tolerated dose; Medicine; Pharmacology; Sensitivity (control systems); Internal medicine; Chemotherapy; Pharmacokinetics; Engineering","score_opus":0.01826625152620595,"score_gpt":0.273487508654924,"score_spread":0.255221257128718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924587196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96965814,0.0003501089,0.0004491964,0.0016592386,0.00046856617,0.001564666,0.000101240636,0.00025767012,0.025491195],"genre_scores_gemma":[0.98081964,0.00002867371,0.0072407415,0.0029491112,0.00012959636,0.00019694932,0.00007764451,0.00009212988,0.00846554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753207,0.000092181595,0.00044869632,0.0008221079,0.00037276206,0.00073219417],"domain_scores_gemma":[0.99798006,0.000097659096,0.00014260932,0.00083517184,0.0001755057,0.0007689847],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026808548,0.000453936,0.0006590037,0.00023337847,0.00021644369,0.000049116163,0.00015187243,0.00014253534,0.00038211775],"category_scores_gemma":[0.00013934933,0.00041515531,0.00017160358,0.0006965303,0.00007202487,0.00020744542,0.00010239353,0.00021761071,0.00080898503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025582617,0.0040307264,0.68329835,0.0008879808,0.0029632775,0.014149161,0.03541874,0.0009499983,0.04013094,0.0029783489,0.11324266,0.07636719],"study_design_scores_gemma":[0.0043221433,0.0005877981,0.91736233,0.00060710084,0.00045991206,0.0001296687,0.00097310107,0.00005846292,0.055237275,0.00041255204,0.019098196,0.0007514521],"about_ca_topic_score_codex":0.00085602136,"about_ca_topic_score_gemma":0.0014048187,"teacher_disagreement_score":0.23406398,"about_ca_system_score_codex":0.00078537175,"about_ca_system_score_gemma":0.0004311025,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W193216906","doi":"","title":"[Non-small-cell lung cancer (NSCLC) in an elderly patient--a case of squamous cell carcinoma successfully treated with chemotherapy using vinorelbine].","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Vinorelbine; Medicine; Lung cancer; Chemotherapy; Internal medicine; Regimen; Outpatient clinic; Oncology; Chemotherapy regimen; Squamous carcinoma; Carcinoma; Surgery; Cisplatin","score_opus":0.014734371987483298,"score_gpt":0.27069456639769335,"score_spread":0.25596019441021006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W193216906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444455,0.00094766263,0.000039609255,0.00009881692,0.00005707311,0.0020870795,0.00003149721,0.000034286666,0.0022594493],"genre_scores_gemma":[0.99802625,0.000036478832,0.00028896026,0.00014859812,0.00006275325,0.0009032946,0.00003894864,0.000058421767,0.0004362977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986529,0.00003060909,0.00032548682,0.00036224845,0.00016460534,0.00046415406],"domain_scores_gemma":[0.99908406,0.000023598317,0.00017463145,0.00032470594,0.00016215126,0.0002308787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005316284,0.00024251317,0.00036028828,0.00021558146,0.00006666028,0.00002214303,0.00007000926,0.00008999595,0.00006176957],"category_scores_gemma":[0.0000030904166,0.00018858381,0.00006048404,0.0004848321,0.00004842696,0.00014472549,0.000011739666,0.0001199185,4.891389e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074344565,0.0011336777,0.95688426,0.00017465398,0.000057543657,0.0023946085,0.0019909611,0.0003299019,0.0008437165,0.0000011507647,0.00003228015,0.035413805],"study_design_scores_gemma":[0.023341343,0.0014609831,0.9355283,0.00009174125,0.00108352,0.00060802477,0.0014002151,0.0029773526,0.032887142,0.0000027613469,0.00013332417,0.00048528987],"about_ca_topic_score_codex":0.018980194,"about_ca_topic_score_gemma":0.0037087714,"teacher_disagreement_score":0.034928516,"about_ca_system_score_codex":0.00041195843,"about_ca_system_score_gemma":0.0002419805,"threshold_uncertainty_score":0.9875525},"labels":[],"label_agreement":null},{"id":"W1934286911","doi":"10.1016/j.lungcan.2015.09.004","title":"Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Queen's University; Ottawa Hospital","funders":"Canadian Cancer Society Research Institute; Cancer Care Ontario; Cancer Research Institute","keywords":"Medicine; Internal medicine; Biomarker; Oncology; Proportional hazards model; Vascular endothelial growth factor; Gastroenterology; VEGF receptors","score_opus":0.07367530118651305,"score_gpt":0.4186572175267875,"score_spread":0.3449819163402744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934286911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961835,0.0008329162,0.00001652964,0.00085125066,0.00031478403,0.001361968,0.00020468565,0.0000068368727,0.00022752228],"genre_scores_gemma":[0.9988763,0.000025722404,0.00010048194,0.00010297255,0.000048813603,0.00008991053,0.000010011295,0.000013105953,0.0007327202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984815,0.00029321233,0.00056420837,0.00022314164,0.0002754853,0.00016242352],"domain_scores_gemma":[0.99887997,0.00030296887,0.00022800906,0.00031872932,0.00015146,0.00011886006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011115205,0.00013293597,0.00060174783,0.00027972335,0.000019859302,0.0000050176395,0.00010635892,0.000089585024,0.00017020444],"category_scores_gemma":[0.00040040212,0.00007784594,0.00024773757,0.00094047573,0.000096784875,0.00004794696,0.000029731778,0.00009395897,4.835846e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10364232,0.0006980331,0.8537857,0.00016127792,0.0072560385,0.000007449038,0.020966418,0.00020756798,0.004490941,0.000040051633,0.0025157772,0.0062284227],"study_design_scores_gemma":[0.03570247,0.004365156,0.9359218,0.00036346997,0.005212455,0.0000017812863,0.0066196523,0.0002488188,0.008633332,0.000052104122,0.0026610654,0.0002179065],"about_ca_topic_score_codex":0.001859849,"about_ca_topic_score_gemma":0.0008524902,"teacher_disagreement_score":0.08213609,"about_ca_system_score_codex":0.00015478628,"about_ca_system_score_gemma":0.00066266616,"threshold_uncertainty_score":0.31744656},"labels":[],"label_agreement":null},{"id":"W1963548021","doi":"10.1016/j.canep.2015.04.005","title":"ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Cardinal Health; National Comprehensive Cancer Network","keywords":"Medicine; Anaplastic lymphoma kinase; Lung cancer; Crizotinib; Internal medicine; Oncology; ALK inhibitor; Chemotherapy","score_opus":0.06686973675134084,"score_gpt":0.3767030155513632,"score_spread":0.30983327880002237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963548021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98596627,0.0040481715,0.001928724,0.0030613954,0.00044442015,0.0027406358,0.00055198884,0.000043441367,0.0012149725],"genre_scores_gemma":[0.98184896,0.0005955695,0.009100574,0.0021457344,0.000488157,0.0040016384,0.00032530507,0.000060718507,0.0014333698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986488,0.00006794772,0.00029886403,0.00047904457,0.000074871146,0.00043047784],"domain_scores_gemma":[0.998434,0.00052788,0.00020155724,0.00020228214,0.00033339468,0.0003008513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015872634,0.00025203283,0.0005614668,0.000059503076,0.00009881096,0.0000061094056,0.000044134777,0.00008879505,0.000024964034],"category_scores_gemma":[0.000113219765,0.00016793428,0.000055097556,0.00007390477,0.00006566804,0.000048031445,0.000024320327,0.00007344859,0.00000204972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036097365,0.00021261847,0.97266775,0.00011672832,0.00046816363,0.0000069492653,0.0009370817,0.0001922838,0.000033455875,0.000012276572,0.003056339,0.021935392],"study_design_scores_gemma":[0.017848082,0.0045249294,0.9601957,0.0005509137,0.0022806053,0.000005341731,0.000278937,0.0017249269,0.00031884917,0.00008602864,0.011834701,0.0003509664],"about_ca_topic_score_codex":0.006974664,"about_ca_topic_score_gemma":0.0010243771,"teacher_disagreement_score":0.021584427,"about_ca_system_score_codex":0.0009642997,"about_ca_system_score_gemma":0.00041513712,"threshold_uncertainty_score":0.99963796},"labels":[],"label_agreement":null},{"id":"W1965355592","doi":"10.1097/jto.0b013e31826910ff","title":"Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Battle; Biomarker; Internal medicine; Oncology; Clinical trial; Ancient history; Genetics","score_opus":0.0532146545083367,"score_gpt":0.49037195425966423,"score_spread":0.43715729975132755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965355592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945267,0.00077271956,0.000024603007,0.0017470444,0.0018633935,0.00032120856,0.000028648252,0.0000038298995,0.00071187975],"genre_scores_gemma":[0.99768937,0.000085886015,0.0015041817,0.00016059054,0.00038627873,0.000005879776,0.000012749456,0.000008482376,0.00014655878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878,0.00024091991,0.0006127591,0.000072599905,0.00016774381,0.00012596899],"domain_scores_gemma":[0.99773365,0.001254737,0.00057739613,0.00012261156,0.00018737702,0.00012424654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049703056,0.00008407936,0.00046409498,0.00005103862,0.000037623282,0.0000052307482,0.00006217489,0.00011846691,0.000110088054],"category_scores_gemma":[0.00068883586,0.000041370797,0.00015532543,0.00006666164,0.00011693239,0.00009599472,0.000023958644,0.0001651242,0.0000039083207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011968307,0.0011169205,0.78318614,0.000007901109,0.000719669,0.0000060066864,0.00038550064,4.982167e-8,0.00003150802,0.000004598351,0.0025173454,0.20005605],"study_design_scores_gemma":[0.017975848,0.0038391324,0.96814907,0.0000581109,0.0014018627,0.00002072132,0.0001959745,0.0000019652819,0.00008266859,0.000035431345,0.008200822,0.00003841329],"about_ca_topic_score_codex":0.000038849244,"about_ca_topic_score_gemma":0.0000064301635,"teacher_disagreement_score":0.20001763,"about_ca_system_score_codex":0.000070760136,"about_ca_system_score_gemma":0.00021406516,"threshold_uncertainty_score":0.16870521},"labels":[],"label_agreement":null},{"id":"W1965945689","doi":"10.1158/1538-7445.am2012-1232","title":"Abstract 1232: Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Lung cancer; Cancer research; Cancer; Medicine; Targeted therapy; Epidermal growth factor receptor; Receptor tyrosine kinase; Small hairpin RNA; Tyrosine kinase; EGFR inhibitors; Bioinformatics; Gene; Biology; Oncology; Internal medicine; Receptor; Genetics","score_opus":0.053612020385462054,"score_gpt":0.42470477319784306,"score_spread":0.371092752812381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965945689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96187276,0.025569772,0.000015448539,0.0035113106,0.000431742,0.0017029935,0.00007567928,0.00003210732,0.006788194],"genre_scores_gemma":[0.9830837,0.0024430847,0.00031572315,0.0006087619,0.001054928,0.001647557,0.000018494862,0.00006745154,0.01076029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975787,0.00006187947,0.00030650926,0.0004290286,0.000603696,0.001020234],"domain_scores_gemma":[0.99855727,0.00013612912,0.000053895492,0.00044420682,0.00030124246,0.0005072643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060423225,0.00021619612,0.00032023015,0.00037346545,0.00019213415,0.000053474014,0.00017049858,0.000111845155,0.00086542265],"category_scores_gemma":[0.000049587477,0.00018226376,0.000076190925,0.0008619561,0.00007284169,0.00020474753,0.000070072485,0.0005331295,0.000057955243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015561214,0.001331136,0.5314401,0.0009553083,0.00019080631,0.00012282001,0.009317547,0.000101464146,0.3391293,0.00012093143,0.094219714,0.02151479],"study_design_scores_gemma":[0.006961449,0.0002316215,0.6716078,0.001902773,0.000065758744,0.0000019642134,0.0006842263,0.000021410428,0.2007999,0.000025991303,0.11727338,0.00042376138],"about_ca_topic_score_codex":0.005347375,"about_ca_topic_score_gemma":0.003155945,"teacher_disagreement_score":0.1401677,"about_ca_system_score_codex":0.0021604092,"about_ca_system_score_gemma":0.00083084975,"threshold_uncertainty_score":0.9475771},"labels":[],"label_agreement":null},{"id":"W1966162777","doi":"10.1097/jto.0b013e3181f49c22","title":"Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Gemcitabine; Placebo; Clinical endpoint; Hazard ratio; Internal medicine; Lung cancer; Oncology; Phases of clinical research; Chemotherapy; Surgery; Gastroenterology; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.014081198314610735,"score_gpt":0.42025279930545734,"score_spread":0.4061716009908466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966162777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961955,0.000580608,0.000049171893,0.0006836304,0.0003009368,0.0020167243,0.000017287985,0.000003028911,0.00015310146],"genre_scores_gemma":[0.998489,0.0002159676,0.0009622349,0.00014976902,0.000058758775,0.00007235934,0.0000058341598,0.00001563253,0.000030423113],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859744,0.00016863135,0.0006181585,0.00016981587,0.00024983656,0.00019610126],"domain_scores_gemma":[0.99860835,0.00028979642,0.0005676858,0.0001957444,0.00024686265,0.000091552836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004738527,0.00016252385,0.00055704056,0.00022893275,0.000051558036,0.000008463531,0.00013201173,0.00008532453,0.00006355106],"category_scores_gemma":[0.000040610223,0.0000835495,0.000050465875,0.00028117915,0.0000724786,0.00007777233,0.000012284681,0.000547061,2.5923768e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07959852,0.018595088,0.18945009,0.00008964241,0.000202159,0.00031843415,0.01025279,0.0002129226,0.0009011179,9.141043e-7,0.00006856485,0.70030975],"study_design_scores_gemma":[0.16812222,0.07529889,0.74823135,0.0005028188,0.0010024569,0.00006487092,0.0032939361,0.00021084746,0.00078257045,0.000005544552,0.0022711493,0.00021333095],"about_ca_topic_score_codex":0.000111930036,"about_ca_topic_score_gemma":0.0024399967,"teacher_disagreement_score":0.7000964,"about_ca_system_score_codex":0.0002372814,"about_ca_system_score_gemma":0.0010341525,"threshold_uncertainty_score":0.34070498},"labels":[],"label_agreement":null},{"id":"W1966226479","doi":"10.1016/s0169-5002(00)80174-9","title":"Is there a role for maintenance chemotherapy in patients treated for non-small cell lung cancer (NSCLC) stage IIIB and IV?","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Chemotherapy; Internal medicine; non-small cell lung cancer (NSCLC); Lung cancer","score_opus":0.0073079127568988255,"score_gpt":0.29998126115390294,"score_spread":0.2926733483970041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966226479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839777,0.006140985,0.00011883795,0.001229142,0.00013021256,0.0040102806,0.0010310418,0.000039952993,0.0033218742],"genre_scores_gemma":[0.93448466,0.0026903627,0.00061525847,0.002497438,0.00018283202,0.003954125,0.00012395694,0.00009862374,0.05535277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987417,0.000009810455,0.00025042484,0.00044316414,0.00012067902,0.0004342463],"domain_scores_gemma":[0.99939543,0.00003918675,0.000090474125,0.00022246219,0.0001326554,0.00011976353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048735757,0.00024984434,0.00035879572,0.00006716278,0.00010107523,0.000025526422,0.00007152452,0.00010762954,0.0008603674],"category_scores_gemma":[0.0000037478985,0.00019929351,0.000106284744,0.00015576897,0.00003450743,0.00008695425,0.000008115983,0.00008746246,0.0000016193608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025547296,0.0005079526,0.9163458,0.0008550911,0.0005190563,0.0000041594,0.005010385,0.00008713795,0.00043223667,0.000019493376,0.01451565,0.059148323],"study_design_scores_gemma":[0.074948415,0.0011775602,0.73605096,0.0019419483,0.0015020177,0.0000013337037,0.0004038302,0.024460923,0.0074419384,0.000072586256,0.15111521,0.0008832875],"about_ca_topic_score_codex":0.0025838371,"about_ca_topic_score_gemma":0.0009301201,"teacher_disagreement_score":0.18029484,"about_ca_system_score_codex":0.00056481163,"about_ca_system_score_gemma":0.0002561484,"threshold_uncertainty_score":0.942042},"labels":[],"label_agreement":null},{"id":"W1967807600","doi":"10.4021/wjon441w","title":"Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC","year":2012,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Gefitinib; Adenocarcinoma; Radiology; Complete response; Computed tomography; Oncology; Nuclear medicine; Cancer; Internal medicine; Chemotherapy; Epidermal growth factor receptor","score_opus":0.013731049210706524,"score_gpt":0.332502105796113,"score_spread":0.3187710565854065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967807600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928648,0.0037478125,0.000020781777,0.0020042607,0.00009052944,0.00020169161,0.000027758675,0.0000026238706,0.001039758],"genre_scores_gemma":[0.99685246,0.0000702203,0.0023500123,0.00032316084,0.00002648323,0.00000736574,0.000005406988,0.000009678147,0.00035519985],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989846,0.00018088044,0.0004145804,0.000070622336,0.0001684185,0.00018092908],"domain_scores_gemma":[0.999083,0.00018094141,0.00037920434,0.00008423904,0.00010832233,0.00016428399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003969032,0.00009031654,0.00043245644,0.00030294296,0.000024330084,0.0000042544207,0.000027283566,0.0000071537374,0.00008761321],"category_scores_gemma":[0.000041413256,0.000060368962,0.00004277443,0.00021345953,0.00009174382,0.000114946255,0.000015224077,0.00015101166,0.0000014800994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1027815,0.012090302,0.6054517,0.00024104433,0.004829099,0.025510916,0.010342145,0.000053118867,0.08031593,0.0012300665,0.040613014,0.11654117],"study_design_scores_gemma":[0.028335122,0.01888833,0.41617227,0.0006141403,0.0015846912,0.023323273,0.0010711936,0.0000075468774,0.0018191597,0.000046402038,0.507926,0.00021191569],"about_ca_topic_score_codex":0.00021577638,"about_ca_topic_score_gemma":0.0001652463,"teacher_disagreement_score":0.46731293,"about_ca_system_score_codex":0.0002855239,"about_ca_system_score_gemma":0.0002653763,"threshold_uncertainty_score":0.24617748},"labels":[],"label_agreement":null},{"id":"W1969861768","doi":"10.1586/14737140.5.5.767","title":"Erlotinib in the treatment of non-small cell lung cancer","year":2005,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Carboplatin; Gemcitabine; Tyrosine kinase; Erlotinib Hydrochloride; Pharmacology; Oncology; Clinical trial; Paclitaxel; Internal medicine; Cancer; Cancer research; Cisplatin; Chemotherapy; Receptor","score_opus":0.04832690947366825,"score_gpt":0.4556003170371752,"score_spread":0.40727340756350694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969861768","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037140842,0.99135894,0.000007231752,0.0006003391,0.00022959968,0.0057764063,0.00008009062,0.00001022966,0.0019000474],"genre_scores_gemma":[0.000016080527,0.99466515,0.0005237876,0.0011689442,0.0005174851,0.0025017753,0.00009842376,0.00006587034,0.00044248815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976533,0.00016441039,0.001133877,0.00040773238,0.00034634647,0.00029430297],"domain_scores_gemma":[0.99815595,0.0001786248,0.0006654789,0.0008150131,0.00011565711,0.000069298934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019330693,0.00052521506,0.003105992,0.00014007225,0.00003419526,0.000007171817,0.00028070714,0.00013478761,0.0005837508],"category_scores_gemma":[0.000006170476,0.00025774894,0.0010537446,0.00053317245,0.00009391353,0.000034218705,0.000009515578,0.0001468014,0.0000063158113],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020684973,0.0012633229,0.00008042741,0.0413849,0.00060260494,0.000011060727,0.0013607913,1.68233e-7,0.0000032266782,0.000010119906,0.0018285892,0.9534341],"study_design_scores_gemma":[0.0014373176,0.00056503364,0.000052921023,0.11495531,0.0016938437,0.00001014965,0.000038919618,0.0000016731004,0.00003508952,5.7682655e-7,0.8810261,0.00018308034],"about_ca_topic_score_codex":0.00059260026,"about_ca_topic_score_gemma":0.000041439747,"teacher_disagreement_score":0.953251,"about_ca_system_score_codex":0.00044093275,"about_ca_system_score_gemma":0.0011557672,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W1970048391","doi":"10.1586/14737140.3.4.435","title":"Second-line chemotherapy for non-small cell lung cancer","year":2003,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Vinorelbine; Pemetrexed; Oncology; Internal medicine; Gefitinib; Gemcitabine; Lung cancer; Erlotinib; Chemotherapy; Febrile neutropenia; Irinotecan; Taxane; Neutropenia; Pharmacology; Cancer; Epidermal growth factor receptor; Breast cancer; Cisplatin","score_opus":0.039516222572945965,"score_gpt":0.43354636874922986,"score_spread":0.3940301461762839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970048391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003767697,0.98706084,0.00035767618,0.000533097,0.00075238605,0.008637145,0.00028012448,0.00003660927,0.002338336],"genre_scores_gemma":[7.425347e-7,0.97752976,0.0035513868,0.008316216,0.0007562247,0.004631586,0.00030393936,0.00021592996,0.004694233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971834,0.00008483355,0.0012297813,0.00071469916,0.00030917357,0.000478107],"domain_scores_gemma":[0.9975963,0.00015310058,0.0008400939,0.0008759323,0.00034379304,0.00019078166],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026874142,0.0007833542,0.0041037546,0.0001444568,0.00008430565,0.000016970216,0.00028126355,0.00026156456,0.0033698622],"category_scores_gemma":[0.000013233377,0.00051682006,0.0016744585,0.0004431501,0.00008837057,0.000056147237,0.000015408516,0.00025205108,0.00001002631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003716135,0.00033610826,0.000006816461,0.18300262,0.0013933225,0.0000037060129,0.00012328984,3.602635e-8,0.000017177577,0.000021669208,0.030797048,0.78426105],"study_design_scores_gemma":[0.0024183802,0.00034488356,0.000001932154,0.13890389,0.0018703066,0.000014115883,0.0000069979947,0.0000028623308,0.0002486209,0.0000042646893,0.85577726,0.00040648278],"about_ca_topic_score_codex":0.000043178516,"about_ca_topic_score_gemma":0.0000058575574,"teacher_disagreement_score":0.8249802,"about_ca_system_score_codex":0.0003965548,"about_ca_system_score_gemma":0.002035213,"threshold_uncertainty_score":0.9997283},"labels":[],"label_agreement":null},{"id":"W1970476748","doi":"10.1056/nejmoa050736","title":"Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Clinical trial; Erlotinib Hydrochloride; Placebo; Cancer; Pathology","score_opus":0.02248944063098263,"score_gpt":0.4079720786852618,"score_spread":0.3854826380542792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970476748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97549856,0.008429029,0.00015155897,0.014513582,0.00043470433,0.00016161372,0.0000027848037,0.0000039091437,0.00080424605],"genre_scores_gemma":[0.99499375,0.0013573634,0.000709283,0.0006073512,0.0020030525,0.0000012231336,0.000002137703,0.000010062951,0.0003157908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866533,0.00004595557,0.0008121125,0.00008952934,0.00027600743,0.000111085996],"domain_scores_gemma":[0.9991391,0.00013516264,0.00028595363,0.000088591594,0.000112298774,0.00023892456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053601817,0.000091165646,0.00051013,0.00015932547,0.000010437773,0.0000018483987,0.000045106404,0.00005227055,0.00013816339],"category_scores_gemma":[0.0002707614,0.00005503228,0.00006150176,0.000113883936,0.00008256218,0.000055317854,0.0000094185825,0.00023948458,2.807961e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003215131,0.00010796433,0.924545,0.000047067442,0.00027127843,0.00011983489,0.0007952291,0.000051028608,0.00026696865,0.000044272223,0.0015423034,0.07188755],"study_design_scores_gemma":[0.10451383,0.001996647,0.8653772,0.0011284897,0.0016911626,0.0004209162,0.00016827116,0.00019767301,0.00024807692,0.00006085693,0.024111591,0.00008528016],"about_ca_topic_score_codex":0.00023441749,"about_ca_topic_score_gemma":0.00015834207,"teacher_disagreement_score":0.10419232,"about_ca_system_score_codex":0.00006855273,"about_ca_system_score_gemma":0.00020425665,"threshold_uncertainty_score":0.22441512},"labels":[],"label_agreement":null},{"id":"W1970622265","doi":"10.4021//jmc.v3i2.513","title":"Long-Term Remission After Gefitinib Therapy in an Elderly Patient With Advanced Non-Small-Cell Lung Carcinoma","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gefitinib; Medicine; Oncology; Internal medicine; Epidermal growth factor receptor; Lung cancer; Adenocarcinoma; Performance status; Tyrosine-kinase inhibitor; Targeted therapy; Chemotherapy; Cancer","score_opus":0.017878359407430853,"score_gpt":0.33056448132673055,"score_spread":0.3126861219192997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970622265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247766,0.006057622,0.00007986304,0.00076206605,0.00019246407,0.00024452704,0.0000030633428,0.000005661229,0.00017707508],"genre_scores_gemma":[0.9979922,0.0003812699,0.00056514214,0.000608763,0.00036027498,0.000018476625,0.000008113885,0.000018684628,0.000047050493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857426,0.00004684388,0.00036209883,0.000104080194,0.0006694926,0.0002432203],"domain_scores_gemma":[0.9988557,0.000084300475,0.00018189225,0.00013395876,0.00012863417,0.00061551674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018615017,0.0001299656,0.00027248252,0.00010860114,0.00003208025,0.000012071953,0.00006658432,0.00008932036,0.00044868092],"category_scores_gemma":[0.00004992201,0.00007281317,0.000068503534,0.00009775266,0.00003545195,0.00020336013,0.000012251611,0.00028535764,0.0000018103782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015693695,0.0013831283,0.8629362,0.00007211363,0.00004606371,0.0072284173,0.0021101048,0.0000021180033,0.0003463916,7.851446e-7,0.00018219644,0.124123104],"study_design_scores_gemma":[0.009907898,0.009008213,0.9698962,0.0012526722,0.00021161177,0.004805298,0.0008404231,0.000020514555,0.0032238378,0.000001777788,0.0006872337,0.00014434905],"about_ca_topic_score_codex":0.000028261102,"about_ca_topic_score_gemma":0.000030328594,"teacher_disagreement_score":0.12397875,"about_ca_system_score_codex":0.00013526001,"about_ca_system_score_gemma":0.00038910066,"threshold_uncertainty_score":0.49127412},"labels":[],"label_agreement":null},{"id":"W1971546178","doi":"10.1038/sj.bjc.6601478","title":"Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib","year":2003,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital","funders":"","keywords":"Gefitinib; Medicine; Oncology; Radiation therapy; Chemotherapy; Quality of life (healthcare); Lung cancer; Internal medicine; Brain metastasis; Clinical trial; Epidermal growth factor receptor; Cancer; Metastasis","score_opus":0.08069286411793578,"score_gpt":0.42054096828390813,"score_spread":0.33984810416597233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971546178","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060739424,0.9370314,0.000049257313,0.0000382583,0.00005102466,0.001001645,0.0010581039,0.0000032638854,0.000027654149],"genre_scores_gemma":[0.016353622,0.98232883,0.0009821353,0.00004647654,0.00006225898,0.000067581255,0.00003150369,0.00004186723,0.000085712214],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9982863,0.00014084781,0.0007527218,0.00021091434,0.00043889228,0.00017028776],"domain_scores_gemma":[0.9963444,0.0004298896,0.001967601,0.00012750072,0.00096073805,0.00016987053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029542125,0.00024039169,0.0020608567,0.00013667237,0.000053236006,0.000023524088,0.00007237001,0.00008305043,0.000031306747],"category_scores_gemma":[0.00027769452,0.000167733,0.00025626688,0.00023564979,0.00011092274,0.00021247416,0.000009617792,0.00017852729,7.877211e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080371246,0.0004203179,0.011090438,0.017565124,0.0026109668,0.000030923853,0.000022070186,0.0000046315154,0.0000012223676,0.000015160129,0.00028217392,0.96715325],"study_design_scores_gemma":[0.024456108,0.009342033,0.085267015,0.5632754,0.030664109,0.001434369,0.000064049054,7.0669824e-7,0.00007614894,0.000009711559,0.28454837,0.0008620024],"about_ca_topic_score_codex":0.00065691967,"about_ca_topic_score_gemma":0.0004538362,"teacher_disagreement_score":0.96629125,"about_ca_system_score_codex":0.00013044871,"about_ca_system_score_gemma":0.0015956415,"threshold_uncertainty_score":0.68399537},"labels":[],"label_agreement":null},{"id":"W1971737397","doi":"10.1111/j.1582-4934.2009.00991.x","title":"Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis","year":2010,"lang":"en","type":"review","venue":"Journal of Cellular and Molecular Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Eisai; F. Hoffmann-La Roche; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Gefitinib; Erlotinib; Lung cancer; Oncology; Medicine; Internal medicine; Epidermal growth factor receptor; Chemotherapy; Cancer","score_opus":0.01356794701440404,"score_gpt":0.368742977523374,"score_spread":0.3551750305089699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971737397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02189361,0.97445285,0.00160914,0.00026780312,0.00036817655,0.0010568055,0.000024528903,0.000005914872,0.0003211444],"genre_scores_gemma":[0.010587248,0.98710114,0.0009142397,0.00044008816,0.00022625907,0.00004897247,0.00026655133,0.00006469117,0.00035083634],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970465,0.00014797658,0.001644506,0.00034322057,0.0005631854,0.0002546146],"domain_scores_gemma":[0.9973674,0.0001940325,0.0012982868,0.00032116257,0.00043800863,0.00038114795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004914161,0.0004378005,0.003396088,0.00096612383,0.00004731794,0.000017643106,0.00014482616,0.0003170274,0.00007442614],"category_scores_gemma":[0.00012144135,0.00024057025,0.0007823175,0.00078207225,0.00014189827,0.000058143964,0.00002800217,0.0010108482,0.000001110287],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022798916,0.002857913,0.38014287,0.011921793,0.03659566,0.0037784304,0.0008168728,0.000024561594,0.00008111,0.00001951586,0.00035397717,0.5631793],"study_design_scores_gemma":[0.028989078,0.0033806423,0.042687032,0.030074347,0.5105062,0.00014058831,0.00018675698,0.000060198403,0.000030346875,0.00002070859,0.38296458,0.00095952686],"about_ca_topic_score_codex":0.00009659803,"about_ca_topic_score_gemma":0.000057621433,"teacher_disagreement_score":0.5622198,"about_ca_system_score_codex":0.00014620986,"about_ca_system_score_gemma":0.00075750466,"threshold_uncertainty_score":0.981017},"labels":[],"label_agreement":null},{"id":"W1971745560","doi":"10.1093/annonc/mdr033","title":"Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials","year":2011,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Alberta; Princess Margaret Cancer Centre; Saint John Regional Hospital; Dalhousie University","funders":"National Cancer Institute; Alberta Cancer Foundation; GlaxoSmithKline; Ligue Contre le Cancer; U.S. Public Health Service; Les Laboratories Pierre Fabre; Sanofi","keywords":"Medicine; Vinorelbine; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Lung cancer; Cancer; Predictive marker; Clinical trial; Cisplatin; Confidence interval","score_opus":0.1547743045193898,"score_gpt":0.5033060809807542,"score_spread":0.34853177646136446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971745560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21240264,0.77019274,0.0001268198,0.00012052804,0.00022487403,0.013942716,0.0020837707,0.000011675479,0.00089422986],"genre_scores_gemma":[0.038972728,0.9545585,0.0002873494,0.000065162414,0.00011921633,0.004039064,0.0013827403,0.00005617092,0.0005190829],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99463785,0.0008810105,0.0033267415,0.0005931717,0.00027838236,0.00028285905],"domain_scores_gemma":[0.9899906,0.003834837,0.004322978,0.00053492753,0.0012174656,0.00009920892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029897909,0.00042940804,0.011971552,0.0010808989,0.000033907017,0.0000066777593,0.00023186256,0.0005620245,0.0005584721],"category_scores_gemma":[0.00062197493,0.0003042918,0.0020042367,0.00095423625,0.00013559124,0.000056369023,0.00004595398,0.00021961793,6.608164e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20788063,0.0077535636,0.004326599,0.0064174975,0.13489203,0.000022346718,0.0071632904,0.00020413147,0.00003709357,0.000025801284,0.0004605117,0.6308165],"study_design_scores_gemma":[0.59475434,0.015071909,0.010429508,0.008043436,0.3132027,0.0000028545678,0.00073918275,0.0009059613,0.00086690456,0.00016882858,0.05519996,0.0006144135],"about_ca_topic_score_codex":0.01035617,"about_ca_topic_score_gemma":0.0015983195,"teacher_disagreement_score":0.6302021,"about_ca_system_score_codex":0.00024992545,"about_ca_system_score_gemma":0.0017037445,"threshold_uncertainty_score":0.99994093},"labels":[],"label_agreement":null},{"id":"W1971811999","doi":"10.1097/jto.0000000000000356","title":"Forty Years of the International Association for Study of Lung Cancer Pathology Committee","year":2014,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Lung cancer; Multidisciplinary approach; Adenocarcinoma; Clinical Practice; Pathology; Cancer; Clinical Oncology; Family medicine; Oncology; Internal medicine","score_opus":0.04240405601126869,"score_gpt":0.5292521534044129,"score_spread":0.4868480973931442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971811999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016638951,0.97366387,0.00007511516,0.0010183626,0.0051848902,0.0022421535,0.00018307597,0.000004542791,0.000989022],"genre_scores_gemma":[0.015846543,0.97999173,0.00072859274,0.00018196808,0.0010511302,0.00017752392,0.000029112574,0.000043183954,0.0019501919],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998228,0.00025803907,0.0009988333,0.000106765954,0.00029739397,0.000110974644],"domain_scores_gemma":[0.9948898,0.00056572503,0.003731595,0.00017475401,0.00060004106,0.00003810787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008568418,0.00012131296,0.0015699336,0.00018451353,0.000026723732,0.0000036509098,0.00025446486,0.00023773924,0.00003503337],"category_scores_gemma":[0.00037140024,0.000074058706,0.00053574605,0.00012427678,0.000031811203,0.000030937572,0.00005225356,0.00031386648,4.2643518e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016648958,0.0010266887,0.008403119,0.0027692395,0.0037990487,0.000019541627,0.0006831936,0.000007527174,0.0000036036517,0.000015169275,0.007321502,0.9757849],"study_design_scores_gemma":[0.0015088989,0.0018518702,0.0059303734,0.002922469,0.015652612,0.0001563482,0.000177386,0.0000060202906,0.000003948079,0.000046532627,0.9716764,0.00006713417],"about_ca_topic_score_codex":0.00002845451,"about_ca_topic_score_gemma":0.000088982364,"teacher_disagreement_score":0.9757177,"about_ca_system_score_codex":0.0012896227,"about_ca_system_score_gemma":0.0012634302,"threshold_uncertainty_score":0.33723184},"labels":[],"label_agreement":null},{"id":"W1972429976","doi":"10.3747/co.19.1054","title":"Supportive Care Treatments for Toxicities of Anti-EGFR and Other Targeted Agents","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Crizotinib; Erlotinib; Gefitinib; Rash; Lung cancer; Oncology; Internal medicine; Epidermal growth factor receptor; Tyrosine-kinase inhibitor; Cancer","score_opus":0.1012468712766291,"score_gpt":0.47129243635249485,"score_spread":0.3700455650758657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972429976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850555,0.010036535,0.00008481415,0.000116539275,0.00073009596,0.0007732699,0.0003094871,0.000016861426,0.0028768666],"genre_scores_gemma":[0.9985637,0.00017964478,0.00041422382,0.00009209119,0.0001322784,0.00014429835,0.00017212782,0.000012968626,0.00028864056],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946994,0.000018693932,0.00015017459,0.000110201174,0.000059612237,0.00019137631],"domain_scores_gemma":[0.9996158,0.000037820944,0.00008635416,0.000081890896,0.00008303472,0.00009509963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029602186,0.00009340842,0.00024898077,0.00005654373,0.000040251507,0.0000018615353,0.00001985597,0.000051975756,0.00011066072],"category_scores_gemma":[0.00001829745,0.000070271584,0.000055347566,0.00003935723,0.00007002169,0.000043546617,0.000013428417,0.00003304447,0.000004465909],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016394428,0.001438657,0.8938737,0.00027600015,0.00068525446,0.0000026590499,0.01839046,5.541848e-7,0.0008254324,0.0005392745,0.003616473,0.08018758],"study_design_scores_gemma":[0.010428382,0.0026573555,0.4456291,0.00012249593,0.0020102311,0.00002579274,0.009016794,0.000021394972,0.009197005,0.00009180011,0.5206171,0.00018252947],"about_ca_topic_score_codex":0.000020200865,"about_ca_topic_score_gemma":0.000005568971,"teacher_disagreement_score":0.5170007,"about_ca_system_score_codex":0.00019249655,"about_ca_system_score_gemma":0.000104176375,"threshold_uncertainty_score":0.28655922},"labels":[],"label_agreement":null},{"id":"W1972663496","doi":"10.1517/14656566.6.10.1693","title":"Combination therapy versus single agent chemotherapy in non-small cell lung cancer","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Vinorelbine; Docetaxel; Gemcitabine; Oncology; Chemotherapy; Lung cancer; Internal medicine; Cisplatin; Combination chemotherapy; Quality of life (healthcare); Performance status; Intensive care medicine","score_opus":0.08944024370707172,"score_gpt":0.4632380360425038,"score_spread":0.3737977923354321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972663496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000155715,0.9884364,0.000034681678,0.0009792238,0.003306165,0.0039654328,0.000048782214,0.000115049384,0.0029585434],"genre_scores_gemma":[0.00007840492,0.99054813,0.00025273208,0.0029522441,0.0015710073,0.0022565152,0.0004259299,0.00024307931,0.0016719579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974557,0.0001425324,0.00071775785,0.00077537383,0.0004146634,0.000493972],"domain_scores_gemma":[0.998714,0.00013646904,0.00039000926,0.00046545485,0.000083491774,0.00021051994],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012943978,0.0007803703,0.0013994753,0.0005037379,0.00010631994,0.00005419396,0.00024299895,0.00032816976,0.0015531856],"category_scores_gemma":[0.000002751809,0.00061174197,0.00056080666,0.00049607904,0.000041103107,0.00010267361,0.0000138301975,0.00046530852,0.000057560006],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065110275,0.0027457662,0.000012519589,0.00068972347,0.0006519654,0.000012123839,0.00130272,0.000007692282,0.00016251356,0.000015784879,0.010762806,0.98298526],"study_design_scores_gemma":[0.023402955,0.0007888784,0.000013923548,0.0046304874,0.000086955784,0.0000046489863,0.000028498143,0.00009478447,0.0008592424,0.0000012066054,0.969557,0.00053140963],"about_ca_topic_score_codex":0.0001533472,"about_ca_topic_score_gemma":0.000007692273,"teacher_disagreement_score":0.9824539,"about_ca_system_score_codex":0.0020017168,"about_ca_system_score_gemma":0.000571798,"threshold_uncertainty_score":0.9996334},"labels":[],"label_agreement":null},{"id":"W1973414121","doi":"10.1097/pas.0b013e3181f7dae3","title":"Optimal Immunohistochemical Markers For Distinguishing Lung Adenocarcinomas From Squamous Cell Carcinomas in Small Tumor Samples","year":2010,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tissue microarray; Pathology; Adenocarcinoma; Medicine; Immunohistochemistry; Biopsy; Lung; Basal cell; Carcinoma; Anatomical pathology; Cancer; Internal medicine","score_opus":0.013213757573288501,"score_gpt":0.29016095920261537,"score_spread":0.27694720162932684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973414121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960552,0.0009713911,0.0003036534,0.0014910402,0.00030383834,0.00027397898,0.000042660195,0.000011212231,0.0005470219],"genre_scores_gemma":[0.98693216,0.000016675804,0.012224258,0.0002690025,0.00044067315,0.000022731208,0.000022676952,0.00002791821,0.000043934044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986572,0.00012113651,0.0005394982,0.00021372754,0.00013463476,0.00033376785],"domain_scores_gemma":[0.9977107,0.0012281579,0.00050662603,0.0002474006,0.00014163248,0.0001654624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042744743,0.00017364774,0.00063742895,0.00010660195,0.00008761625,0.000017133301,0.00022973758,0.00005044779,0.000055615765],"category_scores_gemma":[0.00025985754,0.0001123905,0.00024500993,0.00015357144,0.0005107763,0.000037398175,0.000047988313,0.00066344003,0.0000018371306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017675731,0.0015362679,0.7537221,0.00010734888,0.0003852713,0.014428075,0.0067605814,0.00023396478,0.18900533,0.00052878,0.0014605812,0.014156027],"study_design_scores_gemma":[0.020640621,0.0055597783,0.9350478,0.00015888046,0.0019907278,0.014388124,0.006651826,0.000805338,0.005111987,0.00083350623,0.008130763,0.00068066875],"about_ca_topic_score_codex":0.0004465104,"about_ca_topic_score_gemma":0.000026278296,"teacher_disagreement_score":0.18389334,"about_ca_system_score_codex":0.0001361999,"about_ca_system_score_gemma":0.0002222989,"threshold_uncertainty_score":0.45831516},"labels":[],"label_agreement":null},{"id":"W1973723712","doi":"10.3816/clc.2008.n.050","title":"Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Cetuximab; Lung cancer; Medicine; Bevacizumab; Oncology; Epidermal growth factor receptor; Internal medicine; Mesothelioma; Cancer; Targeted therapy; Chemotherapy; Pathology; Colorectal cancer","score_opus":0.10775675957468764,"score_gpt":0.5328252449507797,"score_spread":0.425068485376092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973723712","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001215742,0.9721345,0.000029044366,0.00075112,0.003440877,0.011455697,0.0015568051,0.00012846115,0.009287787],"genre_scores_gemma":[0.0007289666,0.9478148,0.00019136608,0.00084751705,0.0027175108,0.017377641,0.000481227,0.00040361853,0.029437343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900637,0.000898912,0.0029552504,0.0027438423,0.0013719953,0.0019662676],"domain_scores_gemma":[0.99348766,0.0020804408,0.000984678,0.0015818132,0.0008481118,0.0010173002],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0010965622,0.0014832265,0.0049981624,0.0008147875,0.0005618805,0.00009993226,0.00072500634,0.0014220896,0.002294418],"category_scores_gemma":[0.00031915284,0.0011360935,0.0014013791,0.0021400834,0.00060951395,0.0002496469,0.00033031098,0.004536112,0.000076488206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009232778,0.002371684,0.01851212,0.030266646,0.0040577264,0.0016425869,0.00078042404,0.0006300384,0.0000023853029,0.0001578145,0.13191275,0.8087425],"study_design_scores_gemma":[0.0075695845,0.0007904664,0.0013779319,0.06371486,0.0041756965,0.000019978512,0.00006039185,0.0007972227,0.000009992353,0.0000063160887,0.92019975,0.0012778002],"about_ca_topic_score_codex":0.006083619,"about_ca_topic_score_gemma":0.009802066,"teacher_disagreement_score":0.8074647,"about_ca_system_score_codex":0.007847756,"about_ca_system_score_gemma":0.010247075,"threshold_uncertainty_score":0.9998743},"labels":[],"label_agreement":null},{"id":"W1974784556","doi":"10.1038/bjc.2011.207","title":"Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer","year":2011,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Chemotherapy; Internal medicine; Disease; Targeted therapy; Cancer; Tyrosine kinase; Receptor","score_opus":0.057280688703651786,"score_gpt":0.4023850470155091,"score_spread":0.3451043583118573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974784556","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04952398,0.94519436,0.000026806596,0.00002369837,0.0012660245,0.002063619,0.001717406,0.0000052834957,0.00017880103],"genre_scores_gemma":[0.002765624,0.9949106,0.0009879288,0.00008229332,0.00048593397,0.00021395276,0.00012362254,0.000105166546,0.00032485952],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967639,0.00007677102,0.0020399445,0.00036544938,0.00037827884,0.0003756785],"domain_scores_gemma":[0.99598855,0.00013778127,0.002408938,0.0001750881,0.0009940492,0.0002955917],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026847306,0.000372971,0.002763537,0.00027261113,0.00005061234,0.000025746096,0.00023523712,0.000311813,0.00045036804],"category_scores_gemma":[0.00007622207,0.00029858042,0.0008729434,0.00028416366,0.00008488124,0.00015832938,0.000032379485,0.00047669027,0.0000012077297],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035391742,0.00075287564,0.23351012,0.010911698,0.0032440675,0.000055717974,0.00006458675,0.0000014222323,1.3383166e-7,9.141838e-7,0.0036262323,0.7474783],"study_design_scores_gemma":[0.019219015,0.0012693715,0.40844202,0.120818004,0.0123066185,0.00007378404,0.000019801828,0.000003583309,0.000010256869,0.0000032679684,0.4372662,0.0005680941],"about_ca_topic_score_codex":0.0017423315,"about_ca_topic_score_gemma":0.000599835,"teacher_disagreement_score":0.7469102,"about_ca_system_score_codex":0.00050037535,"about_ca_system_score_gemma":0.002241566,"threshold_uncertainty_score":0.99994665},"labels":[],"label_agreement":null},{"id":"W1974903221","doi":"10.1056/nejmoa1311107","title":"Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1475,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ceritinib; Crizotinib; Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Internal medicine; Lung cancer; Oncology; Gastroenterology","score_opus":0.012453423067173609,"score_gpt":0.3153880680622122,"score_spread":0.3029346449950386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974903221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9168141,0.007210538,0.001359348,0.02630239,0.0012211055,0.00037581872,0.0000041065355,0.000015452606,0.046697177],"genre_scores_gemma":[0.9898785,0.000950534,0.0007290269,0.0017601212,0.004506444,0.000006249545,0.000007320189,0.000021681375,0.0021401646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998837,0.00005451459,0.0004682445,0.00012261968,0.00031025856,0.00020734154],"domain_scores_gemma":[0.99903715,0.00013403682,0.00022109677,0.00013783843,0.00015593469,0.0003139557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004954408,0.00014096181,0.0004936549,0.00020410102,0.00003336269,0.0000065403674,0.000081363985,0.000057469708,0.00035485782],"category_scores_gemma":[0.00012536257,0.0000892185,0.000065648834,0.00019470272,0.000041367715,0.000059107522,0.000009226118,0.00031288966,0.0000032170667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017029552,0.0005236045,0.4114434,0.00048724705,0.00048929773,0.0008009748,0.010517345,0.0002536768,0.023102414,0.00011523994,0.07248624,0.4780776],"study_design_scores_gemma":[0.33735254,0.003963793,0.12946826,0.004574111,0.002522457,0.0012602665,0.00080512336,0.0007501801,0.0023744837,0.0003414989,0.51624876,0.00033853564],"about_ca_topic_score_codex":0.00083384255,"about_ca_topic_score_gemma":0.0003640348,"teacher_disagreement_score":0.47773907,"about_ca_system_score_codex":0.00012201634,"about_ca_system_score_gemma":0.00034304408,"threshold_uncertainty_score":0.38854444},"labels":[],"label_agreement":null},{"id":"W1975313529","doi":"10.1016/s1556-0864(15)31641-5","title":"Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline","year":2006,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Cancer Care Ontario; Juravinski Cancer Centre; Sudbury Regional Hospital","funders":"","keywords":"Docetaxel; Medicine; Internal medicine; Erlotinib; Pemetrexed; Oncology; Lung cancer; Gefitinib; Topotecan; Febrile neutropenia; Afatinib; Guideline; Regimen; Vinorelbine; Chemotherapy; Cancer; Neutropenia; Epidermal growth factor receptor; Pathology; Cisplatin","score_opus":0.07230581937056216,"score_gpt":0.5353964829965041,"score_spread":0.463090663625942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975313529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008691919,0.9814305,0.0003518629,0.0017824206,0.0009206916,0.015041496,0.00022997103,0.00001554891,0.00021887582],"genre_scores_gemma":[0.000003987959,0.98267263,0.008943558,0.0013873,0.0009018483,0.0027927202,0.00013281022,0.000094199364,0.0030709608],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99443895,0.0008489375,0.0036046451,0.0004089928,0.00031952752,0.0003789766],"domain_scores_gemma":[0.9880402,0.0015629163,0.0079310015,0.00039445877,0.001802269,0.00026915356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022292626,0.0006034217,0.0066122087,0.00031200718,0.000100673205,0.000041587173,0.00025559159,0.00039625424,0.00014510777],"category_scores_gemma":[0.00081764115,0.0002934233,0.0007236836,0.00034886936,0.00005458268,0.0001347419,0.000042034324,0.00061534287,0.000003131368],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012414299,0.00056379486,5.6559566e-7,0.7338839,0.0025303194,0.0008437986,0.000109849316,7.597903e-7,7.5965636e-7,0.0000011736323,0.017047979,0.24377565],"study_design_scores_gemma":[0.0012150727,0.0040644924,1.1619049e-7,0.39509773,0.065458104,0.016483705,0.000085136875,0.000009157357,0.0000013219103,0.0000011226745,0.5174077,0.0001763329],"about_ca_topic_score_codex":0.000012434657,"about_ca_topic_score_gemma":0.000041500432,"teacher_disagreement_score":0.5003597,"about_ca_system_score_codex":0.0022651134,"about_ca_system_score_gemma":0.008210871,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W1975807921","doi":"10.1097/jto.0b013e31827ce554","title":"A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"Universitair Ziekenhuis Gent; International Association for the Study of Lung Cancer; Amgen","keywords":"Medicine; Carboplatin; Neutropenia; Hazard ratio; Internal medicine; Lung cancer; Clinical endpoint; Confidence interval; Anemia; Paclitaxel; Placebo; Adverse effect; Performance status; Randomized controlled trial; Gastroenterology; Chemotherapy; Surgery; Cisplatin; Pathology","score_opus":0.025710527713149682,"score_gpt":0.45832775688968086,"score_spread":0.43261722917653117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975807921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915731,0.002439974,0.00056063954,0.00075775926,0.00014312302,0.0042999717,0.00002844217,0.000004224488,0.00019279627],"genre_scores_gemma":[0.9901414,0.00062514766,0.007658935,0.00004401118,0.00008901131,0.0005689587,0.0000050235612,0.00002160124,0.0008459259],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987014,0.00009569091,0.0007371833,0.00015134327,0.00015482023,0.00015957102],"domain_scores_gemma":[0.9974974,0.0005229542,0.001092448,0.00014149002,0.0006094135,0.00013629207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021701069,0.00017916186,0.0015622164,0.0001547348,0.000046123994,0.0000053848116,0.000047791695,0.00007167759,0.000072945935],"category_scores_gemma":[0.00006199999,0.00009273736,0.0001300365,0.00010629998,0.00009908178,0.00007896396,0.000009994154,0.00008289581,1.563743e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73945034,0.01982268,0.020563118,0.0010015514,0.006655908,0.00017969895,0.023232426,0.000557388,0.0037735004,0.000005267533,0.00017354047,0.1845846],"study_design_scores_gemma":[0.88360095,0.08563158,0.0016697708,0.0004738073,0.012822243,0.00022422375,0.0076704007,0.0030339968,0.0041263434,0.00003620854,0.0005539408,0.00015655473],"about_ca_topic_score_codex":0.0004115571,"about_ca_topic_score_gemma":0.00055260235,"teacher_disagreement_score":0.18442805,"about_ca_system_score_codex":0.00029545213,"about_ca_system_score_gemma":0.0007487634,"threshold_uncertainty_score":0.37817198},"labels":[],"label_agreement":null},{"id":"W1977749101","doi":"10.1016/j.lungcan.2004.07.040","title":"Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Lung cancer; Stage (stratigraphy); Univariate analysis; Carboplatin; Multivariate analysis; Performance status; Chemotherapy; Population; Histology; Cancer; Gastroenterology; Oncology; Cisplatin","score_opus":0.015688345930696318,"score_gpt":0.3198114188996633,"score_spread":0.304123072968967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977749101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845021,0.009451302,0.00090872555,0.0015430878,0.0003404039,0.0020332697,0.00032651407,0.00004947116,0.0008451316],"genre_scores_gemma":[0.9946329,0.0005345236,0.0002599327,0.0006874033,0.00017117942,0.00095328066,0.00008843612,0.00006844427,0.0026039039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988668,0.000016018097,0.00024101412,0.00030657748,0.0002027018,0.00036688245],"domain_scores_gemma":[0.99895084,0.00012780556,0.00026225825,0.00026334275,0.00029500682,0.00010071899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084217594,0.00025030205,0.00038897526,0.000058302805,0.00016090128,0.000017075985,0.000112921596,0.0000916123,0.00024206411],"category_scores_gemma":[0.000016094455,0.00014220287,0.00013622736,0.0002762539,0.000051730218,0.00008931672,0.000013817775,0.0001612312,2.9595472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002432196,0.0023938422,0.78322047,0.0021533452,0.011379005,0.00001867418,0.048721224,0.01885689,0.09145847,0.00011295574,0.010822608,0.028430339],"study_design_scores_gemma":[0.05589565,0.0027728034,0.6095937,0.004151645,0.00516372,0.000002256843,0.002773231,0.0014231114,0.30765727,0.0001307086,0.009280374,0.001155543],"about_ca_topic_score_codex":0.000650982,"about_ca_topic_score_gemma":0.0039502,"teacher_disagreement_score":0.21619882,"about_ca_system_score_codex":0.0007220696,"about_ca_system_score_gemma":0.0009308152,"threshold_uncertainty_score":0.57988644},"labels":[],"label_agreement":null},{"id":"W1978236936","doi":"10.1097/jto.0b013e318290868f","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Lung cancer; Tyrosine kinase; Oncology; Internal medicine; Cancer; Selection (genetic algorithm); Pathology; Receptor","score_opus":0.014683227863495754,"score_gpt":0.41812177314189347,"score_spread":0.40343854527839773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978236936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972452,0.0016146568,0.011540494,0.008826332,0.0005759196,0.0036443446,0.0013328211,0.000004647952,0.000008775725],"genre_scores_gemma":[0.97791916,0.00015768253,0.020193081,0.00044509166,0.00033166193,0.00078916486,0.000095083684,0.000023064847,0.00004599239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981847,0.00011695636,0.0011053482,0.00017751592,0.00024609096,0.00016938378],"domain_scores_gemma":[0.99088764,0.0016093815,0.0030492996,0.00008657191,0.004324454,0.00004263028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011015566,0.00013352587,0.0005602887,0.00010431618,0.00010150998,0.000008736016,0.00009426556,0.000113856564,0.0000036729036],"category_scores_gemma":[0.0029163975,0.000087523294,0.00012346593,0.00016331291,0.00005512157,0.00008579626,0.00003139375,0.00010293632,8.633668e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032963392,0.0021903547,0.7534816,0.00031214757,0.004239749,0.000003853183,0.0019461736,0.0019673328,0.07527795,0.00006530039,0.03613245,0.121086754],"study_design_scores_gemma":[0.06831558,0.051397335,0.5245193,0.0013550363,0.037798185,0.000063887775,0.010729671,0.2072919,0.065834895,0.0024158726,0.029385237,0.000893111],"about_ca_topic_score_codex":0.00094210665,"about_ca_topic_score_gemma":0.0002941427,"teacher_disagreement_score":0.2289623,"about_ca_system_score_codex":0.00087489554,"about_ca_system_score_gemma":0.00035081067,"threshold_uncertainty_score":0.35690963},"labels":[],"label_agreement":null},{"id":"W1978599343","doi":"10.1158/1538-7445.am2014-lb-77","title":"Abstract LB-77: The Met receptor tyrosine kinase drives signaling through EGFR and ErbB3 in Met-amplified non-small-cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"ERBB3; Receptor tyrosine kinase; Cancer research; Tyrosine kinase; ErbB; Epidermal growth factor receptor; Cyclin-dependent kinase 8; Proto-oncogene tyrosine-protein kinase Src; Signal transduction; Biology; ERBB4; ROR1; Autophosphorylation; Kinase; Cancer; Cell biology; Platelet-derived growth factor receptor; Receptor; Protein kinase A; Biochemistry; Notch signaling pathway; Growth factor","score_opus":0.06111581085428957,"score_gpt":0.42670170940010793,"score_spread":0.36558589854581836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978599343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764011,0.012596134,0.00013823618,0.0043252837,0.0002502751,0.0013579519,0.00006560184,0.00003187861,0.0048335707],"genre_scores_gemma":[0.9915979,0.002982995,0.0008329742,0.000457617,0.0005038523,0.0010558624,0.00003667018,0.000053575106,0.002478581],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978739,0.00015001102,0.0003074132,0.0005200248,0.00051549764,0.0006331778],"domain_scores_gemma":[0.99857813,0.00042894558,0.000079777215,0.00042913947,0.00029071627,0.00019331634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080826256,0.00021765898,0.00035840363,0.00016662688,0.00033276135,0.00009945824,0.0002049255,0.000109606335,0.0009005141],"category_scores_gemma":[0.000107014064,0.00014494984,0.00007065668,0.0005732593,0.00028860432,0.00014692964,0.00009977022,0.000612102,0.000022447626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00138677,0.001001738,0.12209412,0.0024024884,0.0010898911,0.00010419591,0.025589503,0.0010182057,0.7478201,0.0028531267,0.033574387,0.061065525],"study_design_scores_gemma":[0.02801998,0.0019171714,0.18678865,0.0056887,0.001324771,0.0000172934,0.011396109,0.0015334254,0.5687167,0.002213276,0.19080359,0.0015802953],"about_ca_topic_score_codex":0.01012727,"about_ca_topic_score_gemma":0.0014720071,"teacher_disagreement_score":0.17910331,"about_ca_system_score_codex":0.0006099069,"about_ca_system_score_gemma":0.00064596394,"threshold_uncertainty_score":0.9964644},"labels":[],"label_agreement":null},{"id":"W1979709562","doi":"10.3747/co.19.1149","title":"Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; London Health Sciences Centre","funders":"","keywords":"KRAS; Crizotinib; Medicine; Pemetrexed; Lung cancer; Epidermal growth factor receptor; Anaplastic lymphoma kinase; EGFR inhibitors; Oncology; Targeted therapy; Biomarker; Cancer research; Cetuximab; Internal medicine; Cancer; Chemotherapy; Colorectal cancer; Biology","score_opus":0.21885860831020587,"score_gpt":0.5815272708993818,"score_spread":0.36266866258917596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979709562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58255243,0.12125728,0.0019223174,0.015624553,0.056734785,0.0040881685,0.000110504756,0.00053251174,0.21717742],"genre_scores_gemma":[0.9909254,0.002431467,0.0031500356,0.0008332917,0.0018265174,0.00017836875,0.00021438288,0.000036848993,0.00040369428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981212,0.00034217254,0.00041175596,0.0003331142,0.00026945502,0.00052232674],"domain_scores_gemma":[0.99799484,0.0007888938,0.00026124858,0.00034550743,0.00013790933,0.0004716054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008177626,0.00021525599,0.00049071107,0.000121375735,0.00010628373,0.000013995045,0.000097410695,0.00018015325,0.00038142304],"category_scores_gemma":[0.00069310074,0.00016395033,0.0002481974,0.00019682232,0.00017459705,0.00028991848,0.00006996633,0.00039480362,0.0005043458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028825362,0.0040195454,0.38379854,0.000069590504,0.0008022534,0.000029268269,0.00050237007,1.4174817e-7,0.000026055151,0.0007429576,0.08078151,0.52893955],"study_design_scores_gemma":[0.0039323256,0.0010497107,0.09372846,0.00006581679,0.001898598,0.0001732269,0.00047888205,0.00001286588,0.000060235943,0.000029369947,0.898422,0.00014848138],"about_ca_topic_score_codex":0.000018956993,"about_ca_topic_score_gemma":0.0000057095576,"teacher_disagreement_score":0.8176405,"about_ca_system_score_codex":0.00051707885,"about_ca_system_score_gemma":0.00047565103,"threshold_uncertainty_score":0.66857004},"labels":[],"label_agreement":null},{"id":"W1979840121","doi":"10.1002/ijc.27339","title":"Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies","year":2011,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":503,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut National de la Recherche Scientifique; Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Lung cancer; Medicine; Cancer; Relative risk; Lung; Case-control study; Cigarette smoking; Environmental health; Oncology; Internal medicine; Pathology; Confidence interval","score_opus":0.03076127353565602,"score_gpt":0.39062671410878147,"score_spread":0.3598654405731255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979840121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61693335,0.36901236,0.009295183,0.0027196745,0.00081127795,0.0002782473,0.00084800355,0.000006206558,0.00009572392],"genre_scores_gemma":[0.9968842,0.0016881223,0.0009001346,0.00024025458,0.00018329298,0.000050771898,0.0000035620237,0.000006424212,0.000043210293],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99928844,0.000021977843,0.0003109068,0.00009601226,0.00020928998,0.00007338954],"domain_scores_gemma":[0.99797505,0.000623369,0.0005233372,0.00005522506,0.0007844776,0.00003853367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012974186,0.00008615231,0.000342667,0.00014294729,0.00006228522,0.000009098566,0.000076651224,0.000033046865,0.00022413731],"category_scores_gemma":[0.0001948327,0.0000475418,0.00017674427,0.00008916774,0.0000940705,0.000085990614,0.00001509711,0.00010289585,4.8983384e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012918947,0.00008395179,0.44561204,0.000014164991,0.52526724,0.00025303336,0.005588705,0.00080845883,0.00011312018,0.000418142,0.00037751577,0.020171722],"study_design_scores_gemma":[0.0056258114,0.00025942555,0.5444964,0.0003354521,0.43318585,0.00011975228,0.001037875,0.011919691,0.0006833876,0.0019673603,0.00025622032,0.00011277387],"about_ca_topic_score_codex":0.0018952228,"about_ca_topic_score_gemma":0.00091216294,"teacher_disagreement_score":0.37995088,"about_ca_system_score_codex":0.00025021625,"about_ca_system_score_gemma":0.0001127046,"threshold_uncertainty_score":0.28650224},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W1980062933","doi":"10.1002/widm.1047","title":"Machine learning methods for predicting tumor response in lung cancer","year":2012,"lang":"en","type":"article","venue":"Wiley Interdisciplinary Reviews Data Mining and Knowledge Discovery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Radiation therapy; Lung cancer; Medicine; Cancer; Personalization; Treatment of lung cancer; Radiation treatment planning; Intensive care medicine; Oncology; Bioinformatics; Internal medicine; Computer science; Biology","score_opus":0.07363155616305792,"score_gpt":0.4794801865354944,"score_spread":0.40584863037243646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980062933","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29801098,0.68728536,0.008228067,0.0006786979,0.0011389405,0.0021003173,0.00067024986,0.000075215015,0.0018121589],"genre_scores_gemma":[0.8917029,0.025158266,0.066582635,0.00032211648,0.0016717223,0.002290106,0.0032682724,0.0001764529,0.008827564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979325,0.00045820366,0.00059023325,0.00051077077,0.000070516886,0.00043776425],"domain_scores_gemma":[0.9983672,0.0006671356,0.00020202833,0.0005434819,0.00004053043,0.00017962398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027276024,0.0002761991,0.0006735657,0.00018085707,0.0002570645,0.000060082748,0.00018622479,0.000059863673,0.000034949557],"category_scores_gemma":[0.0007475543,0.00020526252,0.00011007964,0.0002464354,0.00006762057,0.0009861398,0.0008734477,0.00022593745,0.0000042735614],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029136378,0.0007381823,0.47444513,0.0029833121,0.00039656612,0.00001595493,0.024393044,0.0000054225784,0.00091362937,0.000033767403,0.009401577,0.48375976],"study_design_scores_gemma":[0.010965626,0.0022859976,0.09149513,0.03984348,0.0054039075,0.0005664996,0.011903323,0.1382879,0.00029395553,0.000053933596,0.697205,0.0016952404],"about_ca_topic_score_codex":0.000024688641,"about_ca_topic_score_gemma":0.00006068726,"teacher_disagreement_score":0.68780345,"about_ca_system_score_codex":0.00020324922,"about_ca_system_score_gemma":0.00018820121,"threshold_uncertainty_score":0.8370363},"labels":[],"label_agreement":null},{"id":"W1980094335","doi":"10.1371/journal.pone.0072966","title":"EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for Oil Sands Innovation, University of Alberta; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Universitätsspital Zürich; Centre Hospitalier Universitaire Vaudois","keywords":"Erlotinib; KRAS; Epidermal growth factor receptor; Lung cancer; Bevacizumab; Exon; Erlotinib Hydrochloride; Cancer research; Medicine; Gefitinib; Biomarker; EGFR inhibitors; Cancer; Biology; Oncology; Internal medicine; Gene; Colorectal cancer; Chemotherapy; Genetics","score_opus":0.0372568101852567,"score_gpt":0.294213648767592,"score_spread":0.2569568385823353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980094335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989449,0.0002405071,0.00001172582,0.006431089,0.00006420576,0.0018161964,0.000055161632,0.000015360152,0.0019167457],"genre_scores_gemma":[0.9879567,0.00003344811,0.0019441083,0.00054456963,0.00003802478,0.00053382857,0.0000049859455,0.000023410004,0.008920908],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99910027,0.000049060844,0.00022849535,0.00019442472,0.00021686063,0.00021089177],"domain_scores_gemma":[0.9992481,0.00009709987,0.00007116666,0.00034183537,0.00013147881,0.000110308094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011223416,0.00011429699,0.00022984306,0.00011110599,0.000040918236,0.000009109657,0.00010893333,0.000052106134,0.00033549257],"category_scores_gemma":[0.00008135662,0.000071177434,0.000054588912,0.00032479674,0.000032647757,0.00004478459,0.000046936348,0.00008892978,0.000045487333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015286361,0.0035986335,0.40654624,0.0006420834,0.0010785019,0.000016502083,0.0076272134,0.00005042234,0.5707564,0.000011647869,0.005098734,0.0030450195],"study_design_scores_gemma":[0.0035025128,0.00022882779,0.9048979,0.0010285863,0.0005363855,0.0000011624774,0.00043175265,0.00037403696,0.08868722,0.0000143793595,0.00016818201,0.00012904758],"about_ca_topic_score_codex":0.0031851605,"about_ca_topic_score_gemma":0.00047967676,"teacher_disagreement_score":0.4983517,"about_ca_system_score_codex":0.00028931838,"about_ca_system_score_gemma":0.00029444406,"threshold_uncertainty_score":0.48150313},"labels":[],"label_agreement":null},{"id":"W1980672928","doi":"10.1016/j.cllc.2012.01.003","title":"Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; KRAS; Erlotinib Hydrochloride; Placebo; Lung cancer; Clinical endpoint; non-small cell lung cancer (NSCLC); Phases of clinical research; Epidermal growth factor receptor; Population; Clinical trial; Pharmacology; Cancer; Pathology","score_opus":0.06581369968642774,"score_gpt":0.42345110690013255,"score_spread":0.3576374072137048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980672928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532639,0.0037712934,0.0015550615,0.00008819528,0.00048426495,0.04032757,0.00017398481,0.000038418526,0.00029730864],"genre_scores_gemma":[0.98590857,0.0009790069,0.003020543,0.00010912373,0.00013926512,0.008151788,0.0001566995,0.00009167226,0.0014433573],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99570125,0.0004695381,0.0019593346,0.0006916145,0.0005791004,0.00059918524],"domain_scores_gemma":[0.99504936,0.0023541884,0.0010977911,0.00047148095,0.0006141747,0.00041298423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011372056,0.0005093708,0.0022618244,0.00023141169,0.000098841374,0.000020856758,0.00016813952,0.00016469779,0.0003738902],"category_scores_gemma":[0.00028130168,0.00034072265,0.00018870183,0.00057078584,0.00032315022,0.0002782445,0.00007420247,0.00037603473,0.0000015689494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8745722,0.007682243,0.102906376,0.0005627602,0.0026823166,0.000023257615,0.0046856413,0.0038642697,0.000024932096,0.000009721338,0.00036764223,0.0026186397],"study_design_scores_gemma":[0.9717525,0.0045085456,0.006709479,0.0009271642,0.008166714,0.000002389211,0.0009304098,0.006331748,0.0002162838,0.000001033208,0.00006574797,0.00038797027],"about_ca_topic_score_codex":0.0012368596,"about_ca_topic_score_gemma":0.0016831245,"teacher_disagreement_score":0.097180314,"about_ca_system_score_codex":0.00047291094,"about_ca_system_score_gemma":0.0021747863,"threshold_uncertainty_score":0.99990445},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W1980810683","doi":"10.1007/s11523-007-0042-9","title":"Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study","year":2007,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ste. Anne's Hospital","funders":"National Cancer Institute; World Health Organization","keywords":"Docetaxel; Medicine; Gefitinib; Internal medicine; Lung cancer; Chemotherapy; Oncology; Combination therapy; Adverse effect; Rash; Cancer; Epidermal growth factor receptor","score_opus":0.013741353526704404,"score_gpt":0.3733654310320024,"score_spread":0.359624077505298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980810683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807699,0.0012485387,0.005572032,0.0006347677,0.00014783697,0.009187584,0.000039586357,0.000056022876,0.0023437608],"genre_scores_gemma":[0.9885989,0.00011787494,0.006316091,0.0006186607,0.00007964971,0.0026522952,0.00021239503,0.000043072905,0.0013610584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99861294,0.00007200992,0.0004309144,0.00036261295,0.00014119185,0.00038031756],"domain_scores_gemma":[0.9988188,0.0003398481,0.0002648326,0.00018521897,0.0002751122,0.000116147545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052916317,0.00023424745,0.00086431025,0.0002229526,0.00012955969,0.000006746282,0.00006536022,0.00009821825,0.00017274279],"category_scores_gemma":[0.000022232596,0.00015167047,0.00006875884,0.0003079906,0.00007640886,0.00007661715,0.000011138047,0.00017950682,9.733042e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8425724,0.034681898,0.019020805,0.00023018007,0.0020126023,0.00047414063,0.02389068,0.00048875547,0.010559075,0.00015692654,0.00038024178,0.0655323],"study_design_scores_gemma":[0.94866174,0.03443628,0.003401035,0.00007282327,0.000794697,0.000017864677,0.0018830769,0.0010678843,0.006155689,0.000042399326,0.003240324,0.00022617388],"about_ca_topic_score_codex":0.00021295175,"about_ca_topic_score_gemma":0.0027784505,"teacher_disagreement_score":0.10608935,"about_ca_system_score_codex":0.00046113948,"about_ca_system_score_gemma":0.00070008414,"threshold_uncertainty_score":0.61849415},"labels":[],"label_agreement":null},{"id":"W1981145667","doi":"10.1002/ijc.24150","title":"<i>MET</i> gene amplification or <i>EGFR</i> mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors","year":2008,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Ministry of Education, Culture, Sports, Science and Technology; National Cancer Institute; Genome Canada","keywords":"Gene knockdown; T790M; Cancer research; Molecular biology; Biology; Tyrosine kinase; Copy-number variation; Cell culture; Exon; Gene duplication; Mutation; C-Met; Epidermal growth factor receptor; Gene; Cancer; Signal transduction; KRAS; Receptor; Genetics; Hepatocyte growth factor","score_opus":0.016762229938837782,"score_gpt":0.3411604147815188,"score_spread":0.324398184842681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981145667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927897,0.0018480521,0.0010354074,0.0025788106,0.0008071803,0.0003412626,0.000072523064,0.000021156682,0.0005059267],"genre_scores_gemma":[0.994854,0.0014421863,0.0015863747,0.000756524,0.00056556397,0.000058672133,0.00007770059,0.00003168851,0.00062731805],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983658,0.000034935725,0.0005338079,0.00020026635,0.0006829477,0.00018224957],"domain_scores_gemma":[0.99823606,0.000058501915,0.0005185319,0.000117975826,0.00093368645,0.00013522178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010260599,0.00018179852,0.00030122386,0.00038932852,0.00006235341,0.000029384631,0.00013217806,0.00006168916,0.00020322778],"category_scores_gemma":[0.0000455584,0.00012451845,0.00008796673,0.0004042385,0.000079426136,0.00041683784,0.000013314248,0.00020238002,0.0000036811673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030251652,0.0019840964,0.6518902,0.00017093455,0.008616177,0.009855337,0.008671806,0.0386719,0.13892274,0.00042110131,0.0131974965,0.097346514],"study_design_scores_gemma":[0.06369646,0.003934676,0.41672257,0.003943502,0.0029207247,0.007151687,0.001612921,0.0013649976,0.45933002,0.00022324189,0.03798488,0.0011143289],"about_ca_topic_score_codex":0.0017033613,"about_ca_topic_score_gemma":0.0006225687,"teacher_disagreement_score":0.32040727,"about_ca_system_score_codex":0.0024545037,"about_ca_system_score_gemma":0.0013834117,"threshold_uncertainty_score":0.64184415},"labels":[],"label_agreement":null},{"id":"W1981508868","doi":"10.3747/co.20.1568","title":"Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology Clinical Practice Guidelines for Egfr and Alk Testing in Lung Cancer in Canada","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"National Comprehensive Cancer Network; AstraZeneca","keywords":"Lung cancer; Medicine; Pathology; Molecular pathology; Association (psychology); Clinical Practice; Family medicine; Oncology; Psychology; Biology","score_opus":0.09443315981957721,"score_gpt":0.535275867014201,"score_spread":0.4408427071946238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981508868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96805495,0.0028630123,0.0000780267,0.023264626,0.0006647502,0.0044134213,0.00063145836,0.0000017290208,0.00002800504],"genre_scores_gemma":[0.99648696,0.00062375865,0.00025843416,0.0003454196,0.000084656036,0.0021610854,0.000011151067,0.000006595254,0.000021941098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867994,0.00024286477,0.00061645015,0.00015277791,0.00016203862,0.00014590332],"domain_scores_gemma":[0.99018323,0.007106759,0.0011910206,0.000115272596,0.0013858043,0.000017919334],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0014984875,0.00008482347,0.00037358436,0.00003181488,0.00006324104,0.0000041800886,0.00011242755,0.000047519945,0.0000017887302],"category_scores_gemma":[0.011631707,0.000039248094,0.00006801029,0.00015696602,0.00009816372,0.000036267153,0.00004601226,0.00012842295,5.156707e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032162978,0.00029009668,0.96729565,0.000041789066,0.00044432163,4.9664857e-7,0.0009765268,0.0004100757,0.000053846823,0.00008753226,0.0041265925,0.025951466],"study_design_scores_gemma":[0.008515161,0.00058338017,0.96126586,0.00005932075,0.0009891782,0.0000029498697,0.003780221,0.02299152,0.0000100871885,0.00007600669,0.0016802569,0.00004605043],"about_ca_topic_score_codex":0.26615074,"about_ca_topic_score_gemma":0.34455043,"teacher_disagreement_score":0.07839968,"about_ca_system_score_codex":0.0016862635,"about_ca_system_score_gemma":0.0017003618,"threshold_uncertainty_score":0.99669373},"labels":[],"label_agreement":null},{"id":"W1981587467","doi":"10.3747/co.19.908","title":"Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Erlotinib; Adenocarcinoma; Epidermal growth factor receptor; Oncology; Neoadjuvant therapy; Internal medicine; EGFR inhibitors; Lung cancer; Stage (stratigraphy); Mutation; Surgical resection; Cancer research; Pathology; Cancer; Gene; Biology","score_opus":0.06219112607459917,"score_gpt":0.42773052754503743,"score_spread":0.3655394014704383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981587467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943079,0.003778207,0.0000644704,0.00019713087,0.0002969707,0.00045370715,0.000016192886,0.0000113281385,0.00087413285],"genre_scores_gemma":[0.9994201,0.00007702817,0.0002127976,0.000011462277,0.00013515695,0.000031205098,0.00003325152,0.000009927906,0.00006906023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992761,0.000107058266,0.00020292413,0.00012346028,0.00014197509,0.00014847204],"domain_scores_gemma":[0.9993748,0.00009488673,0.00020624006,0.00014097166,0.000104008264,0.00007911064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014911666,0.000082866296,0.00021273825,0.000054980115,0.000067764304,0.0000025261145,0.000031458876,0.00005647679,0.000032323274],"category_scores_gemma":[0.00003562683,0.000049471495,0.00003240186,0.00013594178,0.000113243535,0.000113557835,0.000026492267,0.00012751341,3.1091122e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080454664,0.000832987,0.9405281,0.000309573,0.00013534103,0.000009742989,0.0058091553,0.000015931311,0.0012126184,0.0007410886,0.00008285238,0.049518067],"study_design_scores_gemma":[0.0052194414,0.003131405,0.97896725,0.00024910487,0.00042960068,0.00024999038,0.0023909905,0.00049803633,0.0034215047,0.000024239256,0.0053264247,0.00009202133],"about_ca_topic_score_codex":0.00007384413,"about_ca_topic_score_gemma":0.000025133952,"teacher_disagreement_score":0.049426045,"about_ca_system_score_codex":0.00014215992,"about_ca_system_score_gemma":0.00017452156,"threshold_uncertainty_score":0.20173891},"labels":[],"label_agreement":null},{"id":"W1981670168","doi":"10.1097/cco.0000000000000163","title":"Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer","year":2015,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Memorial Sloan-Kettering Cancer Center; AstraZeneca","keywords":"Medicine; Oncology; Epidermal growth factor receptor; Internal medicine; Adjuvant; Adjuvant therapy; Lung cancer; Targeted therapy; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer; Receptor","score_opus":0.10477887583478196,"score_gpt":0.47276052158525356,"score_spread":0.3679816457504716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981670168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003173566,0.98043674,0.000008653414,0.00030492953,0.0145146055,0.0028102156,0.0006676349,0.000046645153,0.00089321827],"genre_scores_gemma":[0.00012929567,0.9944387,0.00012437977,0.000032706394,0.0015446113,0.0016279904,0.0014031908,0.00008527299,0.0006138238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996867,0.00035866807,0.001163381,0.000732499,0.00028586242,0.0005926001],"domain_scores_gemma":[0.9983779,0.00021414876,0.0005506013,0.00034279388,0.00017536664,0.0003391906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000257914,0.0005762253,0.002189324,0.00073289644,0.000044345117,0.000019076198,0.00019443574,0.0005794791,0.0003717591],"category_scores_gemma":[0.00010444044,0.000465339,0.00031412116,0.0006833681,0.00009950161,0.000115422336,0.00012810862,0.0010335252,0.0001045386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007727057,0.0016537955,0.015632847,0.033101752,0.0001328794,0.000044620494,0.0010414051,0.000003005656,9.54292e-7,0.00010252305,0.033265024,0.91494393],"study_design_scores_gemma":[0.003238391,0.0003716465,0.0006081181,0.017028583,0.00037743326,0.0000098394685,0.00003568822,0.000010332241,0.000002171593,0.000003745156,0.9779383,0.00037576575],"about_ca_topic_score_codex":0.00067346066,"about_ca_topic_score_gemma":0.0000892801,"teacher_disagreement_score":0.94467324,"about_ca_system_score_codex":0.0047117113,"about_ca_system_score_gemma":0.004221791,"threshold_uncertainty_score":0.9997798},"labels":[],"label_agreement":null},{"id":"W1982291583","doi":"10.1038/nrclinonc.2013.158","title":"Drug rechallenge and treatment beyond progression—implications for drug resistance","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine; Drug resistance; Disease; Drug; Intensive care medicine; Cancer; Chemotherapy; Pharmacotherapy; Oncology; Internal medicine; Pharmacology; Biology","score_opus":0.19520676732876532,"score_gpt":0.5925349983358467,"score_spread":0.39732823100708137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982291583","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.8100455e-7,0.9610145,0.000011245527,0.014841999,0.00078519655,0.014890016,0.0001840925,0.000063890584,0.008208148],"genre_scores_gemma":[6.21763e-7,0.93782055,0.023886375,0.00094282447,0.0010730551,0.01343084,0.0008859881,0.0000831114,0.021876615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952732,0.0007358662,0.0023156623,0.0011334546,0.0001309183,0.00041094015],"domain_scores_gemma":[0.9936004,0.003153679,0.0015348964,0.00097098364,0.0002643573,0.00047567455],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011637362,0.0006561058,0.0056759324,0.00013248989,0.00019968224,0.000024570438,0.00021410179,0.0016086547,0.000059929753],"category_scores_gemma":[0.0011144434,0.00036396112,0.0015052019,0.00026624658,0.00021846873,0.000063852785,0.000070411676,0.0012770649,0.00010479757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029480892,0.00079460535,0.00001727366,0.008180963,0.0005843521,0.0000071571403,0.000038403352,9.902925e-10,2.4016552e-8,0.0013769298,0.10063233,0.88833845],"study_design_scores_gemma":[0.0018617779,0.00068331434,0.000033680666,0.010931687,0.009799196,0.00004751674,0.000006761469,1.362426e-7,5.7466885e-8,0.00056748703,0.9757857,0.00028272677],"about_ca_topic_score_codex":0.000003004404,"about_ca_topic_score_gemma":0.00014561221,"teacher_disagreement_score":0.88805574,"about_ca_system_score_codex":0.0009146635,"about_ca_system_score_gemma":0.0017740715,"threshold_uncertainty_score":0.9998812},"labels":[],"label_agreement":null},{"id":"W1982375306","doi":"10.1097/01.jto.0000283409.92625.b0","title":"PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Juravinski Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Bevacizumab; Chemotherapy; Vascular endothelial growth factor; Lung cancer; Oncology; Angiogenesis; Lung; Cancer research; Internal medicine; Pathology; VEGF receptors","score_opus":0.06686320572958923,"score_gpt":0.5102595416486647,"score_spread":0.44339633591907546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982375306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898686,0.00025998888,0.0032756878,0.0021485612,0.00047779994,0.0024963073,0.0014489831,0.0000025083543,0.000021564281],"genre_scores_gemma":[0.99445456,0.00014786074,0.0046860497,0.00018298136,0.00013007871,0.00019643804,0.0001646126,0.000020206084,0.000017208149],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9915557,0.0027905898,0.004579386,0.00024448827,0.0006306793,0.00019918793],"domain_scores_gemma":[0.98037624,0.010327132,0.0073181367,0.00016371738,0.0017037807,0.00011100582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022510016,0.00020312374,0.0026921397,0.00090094353,0.000045361125,0.0000052682176,0.00015946705,0.00018921008,0.000052728887],"category_scores_gemma":[0.005377063,0.00013205664,0.0005015955,0.0009405465,0.00012407487,0.00014074052,0.000006781803,0.00027632824,1.3483941e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08238554,0.004771713,0.08973543,0.0003242954,0.0044205706,0.000004472451,0.0015897887,0.010869062,0.78265285,0.00009975796,0.00046921129,0.022677327],"study_design_scores_gemma":[0.05102656,0.00808685,0.68345827,0.00082747923,0.0064391885,0.0000023922237,0.0011816074,0.0011894442,0.24699071,0.00006453269,0.0005017947,0.00023115957],"about_ca_topic_score_codex":0.014700284,"about_ca_topic_score_gemma":0.064777955,"teacher_disagreement_score":0.5937229,"about_ca_system_score_codex":0.0019742413,"about_ca_system_score_gemma":0.009874929,"threshold_uncertainty_score":0.99573815},"labels":[],"label_agreement":null},{"id":"W1982550511","doi":"10.1007/s12672-015-0218-1","title":"Androgen Pathway Manipulation and Survival in Patients with Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Hormones and Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Cancer registry; Cancer; Proportional hazards model; Oncology; Retrospective cohort study; Epidemiology; Cohort; Population; Prostate cancer; Hazard ratio; Cohort study; Gynecology","score_opus":0.016868394556311034,"score_gpt":0.2968106626372282,"score_spread":0.27994226808091716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982550511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987784,0.010731659,0.000012484296,0.00029501025,0.00007824875,0.0003051391,0.000027683363,0.000011593305,0.0007541275],"genre_scores_gemma":[0.998751,0.00064304564,0.00004549385,0.000093362076,0.000054065433,0.000094191455,0.000030202506,0.000011465402,0.0002771847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952507,0.000007981299,0.00008247997,0.0001474806,0.00012713765,0.0001098328],"domain_scores_gemma":[0.9997363,0.0000047302874,0.000030334666,0.00006020778,0.00006803825,0.00010038715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003061897,0.000083455234,0.000132868,0.00003689312,0.00003145314,0.000013644169,0.000010602172,0.000030587777,0.000018073242],"category_scores_gemma":[0.0000021483484,0.000056867495,0.00000822194,0.00007885704,0.000022658875,0.00008706473,0.000010650318,0.000037564772,3.4101373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002346485,0.000046052166,0.97439975,0.00002694397,0.00006126103,0.0000041455405,0.0006113497,0.00002463608,0.000010204257,0.00007090198,0.00015729458,0.024352808],"study_design_scores_gemma":[0.0046031275,0.00017501798,0.99242353,0.00007204533,0.00013424884,0.0000012079921,0.00015227735,0.0002570085,0.00003095819,0.00002534767,0.0020398851,0.00008536664],"about_ca_topic_score_codex":0.0018887669,"about_ca_topic_score_gemma":0.000920856,"teacher_disagreement_score":0.024267443,"about_ca_system_score_codex":0.00010999792,"about_ca_system_score_gemma":0.00010202007,"threshold_uncertainty_score":0.2855263},"labels":[],"label_agreement":null},{"id":"W1983633702","doi":"10.1016/j.ijrobp.2014.08.231","title":"Economic Burden and Treatments of Progression to Metastatic Disease in ALK+ NSCLC Patients","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Comprehensive Cancer Network","keywords":"Medicine; Crizotinib; Anaplastic lymphoma kinase; Internal medicine; Lung cancer; Oncology; Metastasis; non-small cell lung cancer (NSCLC); Cancer","score_opus":0.012424456086481232,"score_gpt":0.3655351189743213,"score_spread":0.35311066288784004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983633702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506867,0.00018876932,0.0011143051,0.0021972738,0.00062373304,0.0003378984,0.000068813424,0.000006909133,0.00039361857],"genre_scores_gemma":[0.99632585,0.00013422551,0.002715632,0.00024662827,0.00041279968,0.00002046232,0.00010255219,0.000012770537,0.000029083354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990219,0.00009997766,0.00048316622,0.00014806939,0.0001340126,0.00011290712],"domain_scores_gemma":[0.998875,0.00015091033,0.00050102716,0.000084679596,0.00023311492,0.00015525802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016454654,0.00011510093,0.00032411542,0.00017562309,0.000023777511,0.00000886762,0.00010078953,0.00004193029,0.000021363605],"category_scores_gemma":[0.0001442172,0.00009068209,0.00008198112,0.000060234244,0.000059379698,0.00014259989,0.00003005369,0.000092547445,0.000010064264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048458544,0.00042219998,0.6801322,0.000009533254,0.00040452165,0.000011560045,0.00044898957,0.0006090927,0.0002126241,0.0014954465,0.00010950607,0.31565973],"study_design_scores_gemma":[0.024445344,0.004493316,0.94128096,0.00031831727,0.0007761769,0.00003250775,0.00008812283,0.003701163,0.0008256184,0.008521364,0.015304963,0.0002121179],"about_ca_topic_score_codex":0.00004261468,"about_ca_topic_score_gemma":0.0000064631586,"teacher_disagreement_score":0.31544763,"about_ca_system_score_codex":0.0005917913,"about_ca_system_score_gemma":0.0003024096,"threshold_uncertainty_score":0.36979085},"labels":[],"label_agreement":null},{"id":"W1983651288","doi":"10.3747/co.19.1132","title":"Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Oncology; Disease; Precision medicine; Personalized medicine; Internal medicine; Quality of life (healthcare); Cancer; Stage (stratigraphy); Targeted therapy; Chemotherapy; Intensive care medicine; Bioinformatics; Pathology","score_opus":0.26718611167136147,"score_gpt":0.5732445284416359,"score_spread":0.3060584167702744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983651288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67258763,0.3119674,0.00095943763,0.0033445368,0.006604449,0.0028308844,0.000037277176,0.000040413823,0.0016279448],"genre_scores_gemma":[0.9732968,0.021474063,0.0013649674,0.0003353814,0.0022241569,0.00076139043,0.00016351574,0.000042910808,0.00033676598],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738836,0.00063539,0.0010095151,0.0003426645,0.00017837723,0.00044567403],"domain_scores_gemma":[0.99825895,0.0007119464,0.00037429354,0.00016282845,0.0000988671,0.0003931364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026854717,0.00022427006,0.0012580006,0.00017794486,0.00006763735,0.000007028467,0.00006005393,0.00008714095,0.00032620796],"category_scores_gemma":[0.0006649113,0.0001547795,0.00013339221,0.0001771476,0.00019454054,0.000083565414,0.000045115386,0.000407844,0.0000089519635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004205049,0.0026592226,0.58332676,0.0008576868,0.0003168317,0.000020561634,0.0063924366,0.0000012949921,0.0002251467,0.00016554829,0.007385865,0.39822814],"study_design_scores_gemma":[0.06923844,0.0019009196,0.2287182,0.0021972272,0.009268338,0.00008767813,0.0019852764,0.0023200763,0.00015310907,0.00016742994,0.68338823,0.00057508517],"about_ca_topic_score_codex":0.00008058476,"about_ca_topic_score_gemma":0.000039324994,"teacher_disagreement_score":0.6760024,"about_ca_system_score_codex":0.0004673788,"about_ca_system_score_gemma":0.0006667677,"threshold_uncertainty_score":0.6311724},"labels":[],"label_agreement":null},{"id":"W1983913656","doi":"10.1016/j.lungcan.2005.02.011","title":"Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gefitinib; Medicine; Histology; Adenocarcinoma; Ethnic group; Internal medicine; Oncology; Carcinoma; Lung; Cancer; Epidermal growth factor receptor; Anthropology","score_opus":0.0075751153579548735,"score_gpt":0.28768857319094115,"score_spread":0.2801134578329863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983913656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932261,0.001202492,0.000034758945,0.002145271,0.0001106848,0.0026749293,0.00025528987,0.0000121493085,0.00033831905],"genre_scores_gemma":[0.9966706,0.000016515289,0.0006251612,0.0008905972,0.000041036434,0.0007480749,0.000030678788,0.000025979745,0.0009513339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998827,0.000067772766,0.0003347918,0.00034404112,0.000119744494,0.00030665254],"domain_scores_gemma":[0.99928874,0.00008918966,0.000112279326,0.00026051566,0.000117127456,0.00013214308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067148794,0.00016910832,0.00037904398,0.00017833796,0.00004444313,0.0000045243,0.00009675301,0.000065453736,0.000016455666],"category_scores_gemma":[0.00007426437,0.00013064746,0.000056529698,0.00039738812,0.000046856432,0.000045177552,0.000045573102,0.00010970599,7.52818e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034220836,0.00019521332,0.980652,0.000093342605,0.000030205416,0.0000046964988,0.0070013935,0.0002669588,0.00039728673,9.886672e-7,0.0010355256,0.006900306],"study_design_scores_gemma":[0.0066287005,0.0007220039,0.9884638,0.0001388882,0.00016178824,8.6319363e-7,0.00019477283,0.00029784284,0.0010825059,5.8487274e-7,0.0021890684,0.00011913853],"about_ca_topic_score_codex":0.0016564138,"about_ca_topic_score_gemma":0.010423052,"teacher_disagreement_score":0.008766638,"about_ca_system_score_codex":0.0007437204,"about_ca_system_score_gemma":0.0002226013,"threshold_uncertainty_score":0.58163077},"labels":[],"label_agreement":null},{"id":"W1984047229","doi":"10.3389/fonc.2014.00238","title":"Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; McGill University Health Centre; Royal Victoria Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Oncology; Erlotinib; Internal medicine; Cancer; Pharmacology; Cancer research; Epidermal growth factor receptor","score_opus":0.02081758059418618,"score_gpt":0.41189741689791476,"score_spread":0.39107983630372856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984047229","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000747678,0.9901916,0.0002746106,0.00044866148,0.00074563845,0.0024780184,0.00004970277,0.000020391388,0.0050437422],"genre_scores_gemma":[0.0008355396,0.9860701,0.009742023,0.0001562419,0.000021034337,0.001101329,0.000111007204,0.000054406886,0.0019083322],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982115,0.00022749545,0.0007213835,0.00035699658,0.00017342911,0.0003092031],"domain_scores_gemma":[0.9991438,0.000095414034,0.00032722284,0.0003199885,0.00004061619,0.00007300811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002302763,0.00032083425,0.0026386927,0.0006627041,0.00002654573,0.000006017207,0.00015532573,0.00018051888,0.000064204345],"category_scores_gemma":[0.000007730369,0.0002242264,0.00014034123,0.00061508064,0.00011936359,0.000035906764,0.00004557856,0.00028191684,0.0000033849794],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097270524,0.00035469176,0.0038383799,0.012585011,0.0033787137,0.00036571405,0.001962193,0.000062703526,8.343273e-8,0.00027581386,0.0050788536,0.9720006],"study_design_scores_gemma":[0.0029379537,0.0008157414,0.0010815732,0.026944412,0.005033972,0.000029057963,0.001624666,0.000031245134,7.721737e-7,0.000093141214,0.9611382,0.0002692911],"about_ca_topic_score_codex":0.0003423998,"about_ca_topic_score_gemma":0.00035155826,"teacher_disagreement_score":0.9717313,"about_ca_system_score_codex":0.001409479,"about_ca_system_score_gemma":0.00047031132,"threshold_uncertainty_score":0.91436875},"labels":[],"label_agreement":null},{"id":"W1984098997","doi":"10.3389/fonc.2014.00204","title":"Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto","funders":"","keywords":"KRAS; Lung cancer; Medicine; Malignancy; Adenocarcinoma; Oncology; Cancer; Targeted therapy; Radiation therapy; Internal medicine; Bioinformatics; Colorectal cancer; Biology","score_opus":0.05100543033185505,"score_gpt":0.5200063554822374,"score_spread":0.46900092515038233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984098997","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034293025,0.98301476,0.0002342316,0.0008451176,0.0062166904,0.0022828882,0.00004984736,0.000031354823,0.0072908313],"genre_scores_gemma":[0.000043433294,0.98849577,0.009044531,0.00055723224,0.0003926398,0.0007771227,0.00019467862,0.00006278846,0.00043178568],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964293,0.001124877,0.000979174,0.0007834789,0.00020858887,0.00047455836],"domain_scores_gemma":[0.99720097,0.0014498981,0.0006800566,0.0003869279,0.000054927797,0.000227231],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012655508,0.0004460846,0.0032430687,0.0005646877,0.000050760777,0.000020045214,0.00017055565,0.00080655445,0.000037432063],"category_scores_gemma":[0.0008464247,0.00035024754,0.00033917098,0.00043330982,0.00024708107,0.00012470418,0.00009285913,0.0009115812,0.000007787434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012998896,0.0003685146,0.026305255,0.004220395,0.0014776023,0.0002736682,0.00015900764,4.1109345e-7,1.26758435e-8,0.000021352767,0.075864635,0.89117914],"study_design_scores_gemma":[0.003761954,0.0006393657,0.0009010568,0.006217845,0.006821293,0.00013607023,0.00017757535,0.000048014994,5.8962137e-8,0.000018879879,0.9810003,0.00027758887],"about_ca_topic_score_codex":0.00048465945,"about_ca_topic_score_gemma":0.00033896987,"teacher_disagreement_score":0.9051357,"about_ca_system_score_codex":0.0022352338,"about_ca_system_score_gemma":0.0021169882,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W1984146948","doi":"10.1016/j.lungcan.2012.04.014","title":"National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; National Comprehensive Cancer Network","keywords":"Medicine; Docetaxel; Gefitinib; Erlotinib; Pemetrexed; Oncology; Internal medicine; Gemcitabine; Lung cancer; Guideline; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Pathology","score_opus":0.02256977514883364,"score_gpt":0.37233941694808714,"score_spread":0.3497696417992535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984146948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97523355,0.013251941,0.00016302847,0.0014868671,0.0013401327,0.0020194913,0.0010596705,0.000017293618,0.0054280018],"genre_scores_gemma":[0.9940268,0.00088685617,0.00015624786,0.00035167902,0.00032624317,0.0012354564,0.00011848535,0.000029698464,0.0028685625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864644,0.000050460934,0.00028052562,0.00020008521,0.00041374174,0.00040872747],"domain_scores_gemma":[0.99919206,0.00014407269,0.00012153691,0.0001830205,0.00017183577,0.0001875028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023846191,0.00016665758,0.0002879029,0.00006834161,0.0000637717,0.000006518632,0.00008675917,0.000096944204,0.0005002286],"category_scores_gemma":[0.00006914358,0.000103559614,0.00010857833,0.0002531196,0.000049623683,0.000064448235,0.000025756584,0.000102669444,0.0000013590547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015309517,0.0005121109,0.9887219,0.000188821,0.00031382163,0.0000012052996,0.0018747705,0.00014411073,0.00010259433,0.000068639616,0.0045730695,0.0033458497],"study_design_scores_gemma":[0.004872843,0.00007683302,0.98708904,0.0002782248,0.0003965781,0.0000018262369,0.00003722945,0.0025859335,0.0011972145,0.000007492998,0.003345149,0.00011162614],"about_ca_topic_score_codex":0.025586698,"about_ca_topic_score_gemma":0.01674967,"teacher_disagreement_score":0.018793197,"about_ca_system_score_codex":0.0015806688,"about_ca_system_score_gemma":0.002610499,"threshold_uncertainty_score":0.980902},"labels":[],"label_agreement":null},{"id":"W1984238071","doi":"10.1097/01.jto.0000283088.78970.9b","title":"PRS-03: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Gemcitabine; Tolerability; Internal medicine; Hazard ratio; Lung cancer; Clinical endpoint; Cisplatin; Oncology; Randomization; Performance status; Chemotherapy; Randomized controlled trial; Confidence interval; Adverse effect","score_opus":0.023517749746730113,"score_gpt":0.43480362599452227,"score_spread":0.41128587624779217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984238071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935104,0.00053868996,0.0017815075,0.00018441753,0.0005873206,0.0021769989,0.000028752318,0.000009991504,0.0011818842],"genre_scores_gemma":[0.9883548,0.000056294753,0.010738577,0.00012098309,0.00010786502,0.000063006424,0.000023807514,0.00004593891,0.00048871664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715704,0.00011975807,0.0013560334,0.00031407442,0.0005974911,0.00045560673],"domain_scores_gemma":[0.9965446,0.0005192467,0.0015563484,0.00025778072,0.0008421397,0.00027991054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064380077,0.0003266309,0.0013216186,0.00059279334,0.000072987335,0.000010236171,0.00018539952,0.000115367984,0.00018605568],"category_scores_gemma":[0.00014570364,0.00021862198,0.0001215542,0.00075513753,0.00008329116,0.00019842281,0.000052522624,0.000507241,0.0000022225554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5361421,0.030895572,0.08139877,0.0010993502,0.0046879533,0.0063361456,0.034141444,0.010464619,0.002686276,0.000005520121,0.0006752381,0.29146698],"study_design_scores_gemma":[0.6241478,0.13171944,0.1797606,0.0023069098,0.014872135,0.00022489783,0.035124213,0.0040472583,0.005821493,0.000013138156,0.0010261033,0.0009359967],"about_ca_topic_score_codex":0.00030714323,"about_ca_topic_score_gemma":0.0029737402,"teacher_disagreement_score":0.290531,"about_ca_system_score_codex":0.0021754545,"about_ca_system_score_gemma":0.002437041,"threshold_uncertainty_score":0.89151454},"labels":[],"label_agreement":null},{"id":"W1984408971","doi":"10.1097/jto.0000000000000037","title":"Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Placebo; Internal medicine; Lung cancer; Nausea; Cisplatin; Clinical endpoint; Randomization; Phases of clinical research; Performance status; Gastroenterology; Oncology; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.058801172210615704,"score_gpt":0.4491317996074688,"score_spread":0.3903306273968531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984408971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724293,0.0018866075,0.0008323154,0.008617159,0.0037640466,0.0056288727,0.000024397836,0.000029903953,0.0067874356],"genre_scores_gemma":[0.9909654,0.0006141544,0.001906443,0.0003103009,0.0020192123,0.0008620486,0.00006227268,0.00007032088,0.0031897984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958211,0.0004127854,0.0020470868,0.00042775253,0.0005757013,0.00071553857],"domain_scores_gemma":[0.9954586,0.0015206574,0.0016597011,0.00043986348,0.00053662725,0.00038453253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019251618,0.0005076421,0.0022788383,0.00050396647,0.00048652478,0.00010911278,0.00042750474,0.00036650064,0.0007250297],"category_scores_gemma":[0.00025976167,0.00032723337,0.0005545328,0.00053374056,0.00026473438,0.00037437686,0.00017645571,0.001295099,0.00004512936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9742282,0.0016732641,0.00028076416,0.00018919843,0.0011079442,0.00034029692,0.0032612479,0.0072295438,0.00039304545,0.000026441943,0.0036128198,0.0076572387],"study_design_scores_gemma":[0.95073026,0.004289713,0.000056769484,0.00038438436,0.0038889742,0.00022374693,0.00097339205,0.035339672,0.00046692597,0.000030160903,0.0033026424,0.0003133291],"about_ca_topic_score_codex":0.0015138119,"about_ca_topic_score_gemma":0.0016791109,"teacher_disagreement_score":0.028110126,"about_ca_system_score_codex":0.002536749,"about_ca_system_score_gemma":0.0023595518,"threshold_uncertainty_score":0.999918},"labels":[],"label_agreement":null},{"id":"W1985243683","doi":"10.3389/fphar.2013.00058","title":"Therapy’s Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université du Québec à Montréal","funders":"Social Sciences and Humanities Research Council of Canada; Canadian Institutes of Health Research","keywords":"Resistance (ecology); Drug resistance; Medicine; Clinical trial; Oncology; Cancer; Bioinformatics; Internal medicine; Biology; Genetics","score_opus":0.017644994274338292,"score_gpt":0.3371436227374273,"score_spread":0.319498628463089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985243683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767775,0.004184684,0.0000355324,0.0019965551,0.0020319233,0.002008954,0.0000056252916,0.000008498027,0.002050464],"genre_scores_gemma":[0.98914397,0.00034601637,0.00045673148,0.0020311428,0.000052014697,0.0006551237,8.596295e-7,0.000014034346,0.0073001324],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993139,0.000055173175,0.00021919407,0.00015747885,0.00012064896,0.00013359998],"domain_scores_gemma":[0.9996195,0.000014074343,0.00006442702,0.0001711769,0.0000863175,0.000044544664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005577308,0.00008654059,0.00027138984,0.000098852586,0.000014136898,7.728474e-7,0.00012469897,0.00003171467,0.0004126036],"category_scores_gemma":[0.0000040692844,0.00005881512,0.000044831686,0.00017389214,0.00007580901,0.00002984285,0.000016682154,0.00008568632,0.0000010039321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047211652,0.001152255,0.43086058,0.000026362535,0.0004737059,0.0000029646708,0.008333003,0.000037858586,0.0113686435,0.0000026802004,0.5276695,0.019600328],"study_design_scores_gemma":[0.007686927,0.00062215986,0.8628606,0.00004920058,0.00024575565,9.066732e-7,0.0013799293,0.000062777406,0.008285851,0.000055738004,0.11863308,0.000117070034],"about_ca_topic_score_codex":0.0007237568,"about_ca_topic_score_gemma":0.00020938508,"teacher_disagreement_score":0.432,"about_ca_system_score_codex":0.0006158687,"about_ca_system_score_gemma":0.0002577122,"threshold_uncertainty_score":0.451772},"labels":[],"label_agreement":null},{"id":"W1986187845","doi":"10.1016/j.lungcan.2012.10.006","title":"VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Universitair Medisch Centrum Groningen; Maastricht Universitair Medisch Centrum; Institute for Oil Sands Innovation, University of Alberta; Universiteit Maastricht; Inselspital, Universitätsspital Bern","keywords":"Erlotinib; Medicine; Bevacizumab; Internal medicine; Lung cancer; Oncology; Hazard ratio; Gefitinib; Confidence interval; Proportional hazards model; Chemotherapy; Log-rank test; Cancer; Epidermal growth factor receptor","score_opus":0.00779591278885484,"score_gpt":0.28823118241143075,"score_spread":0.2804352696225759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986187845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091846,0.005290324,0.00013688269,0.000368925,0.00004900786,0.0027636953,0.00030389658,0.000016177355,0.00015262913],"genre_scores_gemma":[0.99706894,0.00026978418,0.0005260419,0.00020131866,0.00005508257,0.0015525533,0.0001613855,0.00003417811,0.0001307003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886286,0.000022125727,0.00025412018,0.00031331117,0.00020594404,0.00034162082],"domain_scores_gemma":[0.99916553,0.0001344898,0.00018648611,0.00022575661,0.00017326254,0.00011448803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007214206,0.0002436874,0.00047554815,0.00014908002,0.00012986634,0.000027956388,0.000059816768,0.000064091066,0.000019301586],"category_scores_gemma":[0.000013985407,0.00014110401,0.00005732083,0.00062208774,0.00009368262,0.00012466505,0.000013964847,0.00009987672,9.312588e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011925129,0.00046599322,0.98841333,0.0005222335,0.0021165598,0.0000040596974,0.004287347,0.00074699725,0.000032408632,0.000009547536,0.00010289372,0.0021060854],"study_design_scores_gemma":[0.010907337,0.001001706,0.96445346,0.0005072144,0.01882435,0.0000021708697,0.0002838856,0.0032629617,0.00021172065,0.0000010714685,0.00034426153,0.00019988303],"about_ca_topic_score_codex":0.00199463,"about_ca_topic_score_gemma":0.0044482243,"teacher_disagreement_score":0.023959924,"about_ca_system_score_codex":0.00020721425,"about_ca_system_score_gemma":0.00023968838,"threshold_uncertainty_score":0.5754055},"labels":[],"label_agreement":null},{"id":"W1987622504","doi":"10.1016/j.lungcan.2011.05.027","title":"ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"Pfizer","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Internal medicine; Oncology; Chemotherapy; Fluorescence in situ hybridization; Adenocarcinoma; Tyrosine-kinase inhibitor; Fusion gene; Cancer; Cancer research; Gene; Biology","score_opus":0.02078302751036611,"score_gpt":0.3394637568106692,"score_spread":0.3186807293003031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987622504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922377,0.003703718,0.00020635399,0.00038790973,0.00017560954,0.0015396781,0.0006269487,0.00007503405,0.0010470428],"genre_scores_gemma":[0.99497026,0.0004451638,0.001069146,0.00035381777,0.00032933184,0.0010931788,0.00011266344,0.00005293255,0.0015734781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989651,0.00002293371,0.0001328842,0.00043109013,0.00015291016,0.00029512658],"domain_scores_gemma":[0.99921834,0.000040314513,0.000097373886,0.00021541094,0.00019934471,0.00022921788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039663366,0.00023577981,0.00030178967,0.00007790973,0.00020464328,0.000020977257,0.000037328242,0.00008575642,0.00018443969],"category_scores_gemma":[0.0000086128275,0.00016897447,0.00005173925,0.0001455939,0.00007617149,0.00023785881,0.00001978833,0.00008904327,5.5610406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024151955,0.0024193814,0.6932236,0.0012285688,0.0046929684,0.001091713,0.013033144,0.00005604789,0.08950775,0.00023188883,0.007465551,0.16289745],"study_design_scores_gemma":[0.022239823,0.006323893,0.54283214,0.0018360204,0.010708514,0.00026127324,0.00062096864,0.0051085637,0.40523183,0.000031554726,0.003626667,0.0011787546],"about_ca_topic_score_codex":0.014574489,"about_ca_topic_score_gemma":0.003972298,"teacher_disagreement_score":0.31572407,"about_ca_system_score_codex":0.00048494965,"about_ca_system_score_gemma":0.00032120914,"threshold_uncertainty_score":0.9919875},"labels":[],"label_agreement":null},{"id":"W1987756569","doi":"10.1016/s0169-5002(03)00148-x","title":"Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Observational study; Lung cancer; Population; General surgery; Demography; Intensive care medicine; Oncology; Internal medicine; Environmental health","score_opus":0.043261292114015505,"score_gpt":0.41295802667273485,"score_spread":0.3696967345587193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987756569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962249,0.0007523966,0.00011824423,0.00051830296,0.00016723346,0.0011764829,0.00014602041,0.0000062738704,0.0008901935],"genre_scores_gemma":[0.99887097,0.000050253577,0.00011987362,0.00017583626,0.000030242045,0.00047332956,0.0000590954,0.0000114116765,0.00020898001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890333,0.000065857836,0.00039321015,0.00015603293,0.000365998,0.00011555552],"domain_scores_gemma":[0.99933696,0.00006157413,0.0002072663,0.00023785817,0.00013238775,0.00002395737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016394074,0.00009592187,0.00023651026,0.00010269229,0.000026831025,0.000004007949,0.000071584946,0.000030312374,0.00043031957],"category_scores_gemma":[0.000013755591,0.0000677386,0.00006178719,0.0003204103,0.000014536275,0.00005191814,0.0000087164,0.00006390285,8.8146535e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081529965,0.0005821483,0.9932709,0.00047374898,0.00045301768,0.000007853026,0.0013609721,0.001535458,0.000015403562,0.0012534932,0.00014698866,0.0008184977],"study_design_scores_gemma":[0.0032813402,0.00010443197,0.99393296,0.00044381781,0.00067799905,5.35499e-7,0.0006327723,0.0005982493,0.00014361831,0.0000299889,0.000095861345,0.000058414516],"about_ca_topic_score_codex":0.007170387,"about_ca_topic_score_gemma":0.0017196923,"teacher_disagreement_score":0.005450695,"about_ca_system_score_codex":0.0002089518,"about_ca_system_score_gemma":0.00025540497,"threshold_uncertainty_score":0.99944097},"labels":[],"label_agreement":null},{"id":"W1987942363","doi":"10.3389/fonc.2014.00174","title":"A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Targeted therapy; Clinical trial; Anaplastic lymphoma kinase; Cancer research; Oncology; Oncogene; Acquired resistance; Cancer; Internal medicine; Bioinformatics; Biology; Cell cycle","score_opus":0.07222494324445801,"score_gpt":0.48774575845650153,"score_spread":0.41552081521204354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987942363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001206163,0.988151,0.0012732452,0.00021826803,0.0018466522,0.0047452897,0.00006339303,0.000012002065,0.0036780664],"genre_scores_gemma":[0.000024916328,0.9871387,0.0097932,0.0003834058,0.000199429,0.0013043982,0.00007738171,0.000051294057,0.0010272597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933816,0.0024811234,0.0030754514,0.000588848,0.00015812294,0.00031482134],"domain_scores_gemma":[0.99630207,0.0012586379,0.0018050428,0.00041084553,0.00008848596,0.00013491766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00654196,0.00035497034,0.0084145125,0.0003777792,0.000024704877,0.000005281539,0.00016528186,0.0006525822,0.000025726122],"category_scores_gemma":[0.001139985,0.00026766313,0.0005502309,0.00035814743,0.00008675504,0.00002493676,0.00004740688,0.00059252355,0.0000021214285],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009190485,0.00017672183,0.0008651992,0.35033727,0.000440087,0.00009539648,0.00016909708,3.7630036e-7,8.0094406e-7,0.000026265248,0.023700316,0.6240966],"study_design_scores_gemma":[0.0030314776,0.00021497002,0.000032123637,0.29027337,0.0056768595,0.000018763156,0.00005841134,0.000014077379,3.920653e-7,0.000025650917,0.70047957,0.00017432599],"about_ca_topic_score_codex":0.00011128578,"about_ca_topic_score_gemma":0.00031063388,"teacher_disagreement_score":0.67677927,"about_ca_system_score_codex":0.0012757989,"about_ca_system_score_gemma":0.0023574058,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W1988782368","doi":"10.1109/jbhi.2014.2377517","title":"A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"IEEE Journal of Biomedical and Health Informatics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Lung cancer; Medicine; Oncology; Epidermal growth factor receptor; Decision tree; Erlotinib; Targeted therapy; Internal medicine; Personalized medicine; non-small cell lung cancer (NSCLC); Clinical trial; Clinical decision support system; Cancer; Bioinformatics; Decision support system; Machine learning; Computer science; Artificial intelligence; Biology","score_opus":0.05089780953981815,"score_gpt":0.4030895795922225,"score_spread":0.3521917700524044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988782368","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0723357,0.0027025084,0.9143675,0.009084766,0.00038153632,0.0008058612,0.00006829447,0.000007974912,0.00024584407],"genre_scores_gemma":[0.97243893,0.0024008425,0.019739872,0.004542845,0.0002846557,0.00007321171,0.000014397375,0.000013319032,0.0004919244],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987097,0.00001422151,0.00082507834,0.000042746724,0.00022300347,0.00018526168],"domain_scores_gemma":[0.9990225,0.000054398184,0.0004214138,0.00005083923,0.00017618923,0.00027467211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006761911,0.00008450092,0.00033074708,0.0001862089,0.0000683895,0.000011514538,0.000045550194,0.00006024095,0.000010012425],"category_scores_gemma":[0.000019785477,0.000056089775,0.0001181896,0.00009240569,0.00006256053,0.000088684785,0.0000069914067,0.0001738232,3.5945683e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003140859,0.0060759913,0.038849067,0.059947006,0.002619679,0.000020341535,0.27501383,0.0067427624,0.00023828697,0.0020696118,0.06955,0.53573257],"study_design_scores_gemma":[0.010061804,0.0020665913,0.004302135,0.0021830539,0.0003739729,0.000045582154,0.0012489989,0.9739553,0.000013040412,0.0004004136,0.005266179,0.00008293654],"about_ca_topic_score_codex":0.000031392792,"about_ca_topic_score_gemma":0.00002638267,"teacher_disagreement_score":0.96721256,"about_ca_system_score_codex":0.00024217075,"about_ca_system_score_gemma":0.00075120304,"threshold_uncertainty_score":0.22872747},"labels":[],"label_agreement":null},{"id":"W1989170383","doi":"10.1002/cncy.20102","title":"Detection of <i>EGFR</i> and <i>KRAS</i> mutations in fine‐needle aspirates stored on Whatman FTA cards","year":2010,"lang":"en","type":"article","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Medicine; KRAS; Pathology; Internal medicine; Cancer; Colorectal cancer","score_opus":0.010689122066438742,"score_gpt":0.3124481267611393,"score_spread":0.30175900469470057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989170383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954125,0.0006111744,0.000030201887,0.00078332104,0.0005392572,0.00032087116,0.00006190029,0.000028483088,0.0022122618],"genre_scores_gemma":[0.99859554,0.0000823816,0.0001573728,0.00045896784,0.0001134439,0.00019076305,0.00004079329,0.000017521237,0.00034322953],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992836,0.000028010141,0.00019941208,0.00023956847,0.000085888016,0.00016352892],"domain_scores_gemma":[0.9995171,0.000045806475,0.00007926661,0.00019357385,0.000095474694,0.00006882384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007805571,0.00011768916,0.00025625993,0.00015120684,0.00005290108,0.0000069262533,0.00003696362,0.00010944096,0.000057054585],"category_scores_gemma":[0.00004769533,0.00010235388,0.000035516707,0.00018106894,0.00014222367,0.00006455336,0.000014250009,0.00020873464,0.0000056138315],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027355363,0.00046021517,0.16214994,0.00012395305,0.00008026099,0.00012649334,0.0024163267,0.000105144434,0.76783884,0.00066323834,0.00035525457,0.06540679],"study_design_scores_gemma":[0.010083255,0.0021450114,0.7454228,0.00019137344,0.00061049085,0.00038265783,0.0006380286,0.0001958479,0.22315387,0.00077086594,0.016027903,0.00037791292],"about_ca_topic_score_codex":0.0004805963,"about_ca_topic_score_gemma":0.0032087998,"teacher_disagreement_score":0.5832728,"about_ca_system_score_codex":0.00009065316,"about_ca_system_score_gemma":0.00013488583,"threshold_uncertainty_score":0.417387},"labels":[],"label_agreement":null},{"id":"W1990479271","doi":"10.4161/cc.9.19.13463","title":"The CINSARC signature: Prognostic and predictive of response to chemotherapy?","year":2010,"lang":"en","type":"letter","venue":"Cell Cycle","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Institute of Cancer Research; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale","keywords":"Biology; Chemotherapy; Signature (topology); Cancer research; Oncology; Computational biology; Genetics","score_opus":0.004754859271061607,"score_gpt":0.2633352078185665,"score_spread":0.2585803485475049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990479271","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15184145,0.0023208174,0.00006207766,0.8377088,0.00048423998,0.0023458602,0.00024397242,0.00004539885,0.0049474495],"genre_scores_gemma":[0.5763616,0.00023216868,0.0007730483,0.3874195,0.0016671704,0.00032189768,0.0002496297,0.00012402394,0.03285101],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999254,0.000041860756,0.00013508605,0.00021412407,0.00018592118,0.0001690357],"domain_scores_gemma":[0.99906516,0.0003875292,0.00007800849,0.0003128133,0.00009355216,0.0000629221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010004647,0.00014317677,0.00020052171,0.000055901804,0.000083433195,0.000015741898,0.0000771401,0.00039485798,0.000040741845],"category_scores_gemma":[0.00007968335,0.00008763948,0.00005491911,0.00008579085,0.00009729996,0.000014930742,0.000022801894,0.00087662844,0.000009950168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010512173,0.00008237538,0.0005500847,0.00015661742,0.00021455338,0.00008820049,0.0013621695,0.0000017563756,0.008515729,0.0000014579633,0.9846891,0.0032867459],"study_design_scores_gemma":[0.0013130483,0.00074733957,0.013970642,0.0001266507,0.0004319572,0.000014762659,0.000059895203,0.000017667195,0.0052935425,0.00011377227,0.9777966,0.000114084425],"about_ca_topic_score_codex":0.000014545521,"about_ca_topic_score_gemma":0.0000028943737,"teacher_disagreement_score":0.45028928,"about_ca_system_score_codex":0.00004432639,"about_ca_system_score_gemma":0.00014962131,"threshold_uncertainty_score":0.38085634},"labels":[],"label_agreement":null},{"id":"W1990609895","doi":"10.1378/chest.128.4_meetingabstracts.169s-c","title":"THE RELATIONSHIP BETWEEN LUNG FUNCTION AND NON- SMALL CELL LUNG CANCER IN MEN AND WOMEN","year":2005,"lang":"en","type":"article","venue":"CHEST Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Lung function; Lung","score_opus":0.019944545654088548,"score_gpt":0.309887219148426,"score_spread":0.28994267349433744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990609895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98924047,0.004800636,0.00018148459,0.002876126,0.00006154809,0.00017967337,0.000003058344,0.0000060363336,0.0026509883],"genre_scores_gemma":[0.99664843,0.0006257565,0.00017102328,0.00007946199,0.00042367,0.00003072888,0.0000024758078,0.00000957056,0.0020088546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949753,0.0000196463,0.00015509667,0.00008833574,0.000079293466,0.00016007491],"domain_scores_gemma":[0.9995808,0.00013674978,0.000065785905,0.00006031423,0.000029486502,0.00012683924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021349153,0.000070108064,0.000098897115,0.000056644847,0.0002510535,0.00005417391,0.000022750424,0.000041029605,0.000026436208],"category_scores_gemma":[0.00002397016,0.000045651435,0.000015330146,0.000075903714,0.000028937839,0.000098623794,0.00001109005,0.0002276818,0.0000013452925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003240255,0.00001768091,0.98906654,0.00003921323,0.00005063302,0.0000031999207,0.002607034,0.000014932366,0.00005831112,0.000014785959,0.00051482674,0.007580433],"study_design_scores_gemma":[0.0019987435,0.000052781685,0.994102,0.00007458509,0.00018123916,0.000021035381,0.0007575364,0.00027448413,0.000028060227,0.0001714059,0.0022895893,0.0000485185],"about_ca_topic_score_codex":0.000028792678,"about_ca_topic_score_gemma":0.000049342147,"teacher_disagreement_score":0.0075319144,"about_ca_system_score_codex":0.00036484242,"about_ca_system_score_gemma":0.00012792823,"threshold_uncertainty_score":0.1930926},"labels":[],"label_agreement":null},{"id":"W1990824482","doi":"10.1158/1538-7445.am2012-2879","title":"Abstract 2879: Pre-clinical characterization of Dacomitinib, an irreversible pan-HER inhibitor, combined with radiation therapy in head and neck cancer models","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cancer; Radiation therapy; Head and neck cancer; Cancer research; Oncology; Lung cancer; EGFR inhibitors; Clonogenic assay; Internal medicine; In vivo; Pathology; Epidermal growth factor receptor; Biology","score_opus":0.11863684387384996,"score_gpt":0.47501195519765516,"score_spread":0.35637511132380517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990824482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607646,0.0015127048,0.000011934427,0.00080032286,0.00012476872,0.0010222973,0.000056134963,0.000015294641,0.00038008002],"genre_scores_gemma":[0.99368864,0.0049191746,0.000071848655,0.00013010085,0.00028584682,0.0003340916,0.000130166,0.000027386974,0.0004127654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986868,0.00010841079,0.00028395993,0.00024081988,0.00035495457,0.0003250505],"domain_scores_gemma":[0.99920994,0.00007669401,0.00008908974,0.0002105776,0.00022137,0.00019233327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048471216,0.00011103427,0.00026314132,0.00016120411,0.00006854098,0.0000202548,0.000049341394,0.0000983544,0.00019118852],"category_scores_gemma":[0.000015739777,0.000084223924,0.000026901802,0.00032115343,0.00012397807,0.0005245603,0.000018006016,0.00026387602,0.000002090842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003448192,0.0014494235,0.885493,0.00015262263,0.00017770562,0.000004910462,0.0036379432,0.00004202055,0.027285961,0.00013792924,0.00025131696,0.077918984],"study_design_scores_gemma":[0.0064745536,0.0011560653,0.98492974,0.00027967666,0.000030536066,0.0000014313223,0.00010432107,0.00026344,0.005484101,0.00004419659,0.00113865,0.000093262184],"about_ca_topic_score_codex":0.0031364842,"about_ca_topic_score_gemma":0.00054330175,"teacher_disagreement_score":0.099436775,"about_ca_system_score_codex":0.00023982678,"about_ca_system_score_gemma":0.0005226935,"threshold_uncertainty_score":0.47414467},"labels":[],"label_agreement":null},{"id":"W1991781559","doi":"10.1016/j.lungcan.2011.05.004","title":"Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Nausea; Maintenance therapy; Chemotherapy; Adverse effect; Carboplatin; Phases of clinical research; Surgery; Cancer; Clinical trial; Cisplatin","score_opus":0.02031515920557238,"score_gpt":0.3429522428959205,"score_spread":0.32263708369034816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991781559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921337,0.0012473131,0.00010711275,0.000061139035,0.00021629347,0.003973906,0.00010412726,0.000031150874,0.002125273],"genre_scores_gemma":[0.9938412,0.00045207067,0.00076352805,0.00044359997,0.00003317869,0.0016146952,0.000030965697,0.00006553844,0.0027552696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983536,0.000045023386,0.00043221773,0.00043042187,0.0003331444,0.00040559474],"domain_scores_gemma":[0.9987828,0.00003480906,0.0002691799,0.00039077393,0.0003733603,0.00014906857],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007502304,0.00030310778,0.00055100536,0.00015569355,0.00009088431,0.000007825014,0.00014019103,0.000044183253,0.00093192334],"category_scores_gemma":[0.000011011335,0.00019394212,0.000057609643,0.00046908288,0.000061995575,0.00014944663,0.000033415818,0.00017598615,0.0000019049472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024322411,0.02982466,0.84290415,0.0006212129,0.0021908071,0.00023733193,0.04585049,0.00044626245,0.00037481575,0.000025201023,0.00075517374,0.05244747],"study_design_scores_gemma":[0.3425542,0.06918052,0.5601113,0.0034982879,0.0041265595,0.0000067031524,0.0092531415,0.0010467197,0.0076439297,0.000026384669,0.001339521,0.0012126977],"about_ca_topic_score_codex":0.006671943,"about_ca_topic_score_gemma":0.0049943295,"teacher_disagreement_score":0.31823182,"about_ca_system_score_codex":0.00039427902,"about_ca_system_score_gemma":0.0008284396,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W1992624894","doi":"10.1097/jto.0000000000000318","title":"Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Pemetrexed; Docetaxel; Lung cancer; Internal medicine; Quality of life (healthcare); Oncology; Performance status; ALK inhibitor; Chemotherapy; Physical therapy; Nursing","score_opus":0.015420929267800036,"score_gpt":0.4012637173132929,"score_spread":0.3858427880454929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992624894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532443,0.00022372008,0.00011151679,0.00034455612,0.00009250532,0.0033515762,0.000015838908,0.00000431503,0.0005315471],"genre_scores_gemma":[0.9965681,0.00007389647,0.0029629837,0.00014144515,0.000021693373,0.00013596074,0.00001888113,0.000019128856,0.00005792946],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973916,0.0005249351,0.0014350192,0.0001848785,0.0002782519,0.0001853563],"domain_scores_gemma":[0.99622834,0.00052336906,0.0024121983,0.00014752596,0.00056735607,0.00012119558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007099682,0.00019097983,0.0021112435,0.0002529893,0.00001924605,0.0000042104984,0.000053345433,0.000095231706,0.000022162536],"category_scores_gemma":[0.00024853298,0.000110875466,0.00011581923,0.00023371386,0.00013574102,0.000087846776,0.000012162902,0.00019199,6.5933726e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53983086,0.0020281372,0.4468692,0.00016061019,0.00061152823,0.000011441318,0.0026030804,0.00007579625,0.00015813131,0.0000011613117,0.000007126069,0.007642932],"study_design_scores_gemma":[0.6572297,0.007018707,0.33272207,0.0005827067,0.0008780273,0.000005594972,0.0003544817,0.00012622034,0.0009684865,0.0000045224056,0.00001421545,0.00009522573],"about_ca_topic_score_codex":0.0007054671,"about_ca_topic_score_gemma":0.000554603,"teacher_disagreement_score":0.117398895,"about_ca_system_score_codex":0.00027106405,"about_ca_system_score_gemma":0.00080682605,"threshold_uncertainty_score":0.45213702},"labels":[],"label_agreement":null},{"id":"W1992813866","doi":"10.3747/co.19.955","title":"egfr Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Cancer; Protein-Tyrosine Kinases; Quality of life (healthcare); Cancer research; Tyrosine-kinase inhibitor; Bioinformatics; Oncology; Internal medicine; Biology; Receptor","score_opus":0.058560057331227024,"score_gpt":0.455997478371914,"score_spread":0.39743742104068697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992813866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.901214,0.056233928,0.00010849434,0.00671063,0.01251747,0.0014157485,0.000113905924,0.00012895129,0.021556858],"genre_scores_gemma":[0.9942492,0.0015772978,0.0002879866,0.00027999107,0.0014592204,0.00045911927,0.00015389053,0.000021590202,0.0015116887],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907196,0.00004328979,0.00023638265,0.00017278356,0.000112516616,0.00036308673],"domain_scores_gemma":[0.99944746,0.000044103068,0.00007088877,0.00015794419,0.00008539387,0.00019420304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010119975,0.0001271696,0.0002528709,0.00014560972,0.00006026024,0.000005611146,0.00004180623,0.00009004967,0.00050652697],"category_scores_gemma":[0.000045641627,0.00009585107,0.00006357729,0.00020390931,0.000056957437,0.00008053246,0.000031812608,0.00021270044,0.0001321202],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000621544,0.0019678671,0.8063858,0.00013579907,0.00007243351,0.000016386839,0.00092024193,0.000007521532,0.00043381887,0.0004588324,0.024717687,0.16482143],"study_design_scores_gemma":[0.0028914972,0.00017593602,0.21906903,0.00017573762,0.00032973202,0.000016833545,0.00008618577,0.0001338169,0.00016301851,0.000012851734,0.77682865,0.000116706855],"about_ca_topic_score_codex":0.00015697844,"about_ca_topic_score_gemma":0.00022815926,"teacher_disagreement_score":0.75211096,"about_ca_system_score_codex":0.0012363695,"about_ca_system_score_gemma":0.00032063507,"threshold_uncertainty_score":0.5546115},"labels":[],"label_agreement":null},{"id":"W1992935310","doi":"10.1038/bjc.2013.506","title":"Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)","year":2013,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Toronto Public Health; Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Regione Lombardia; Fondazione Cariplo","keywords":"Medicine; Lung cancer; Odds ratio; Internal medicine; Confidence interval; Hormone replacement therapy (female-to-male); Oncology; Cancer; Adenocarcinoma; Gynecology; Epidemiology; Testosterone (patch)","score_opus":0.010477942706757021,"score_gpt":0.31886773180015293,"score_spread":0.3083897890933959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992935310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8537318,0.13829757,0.00087484287,0.004328821,0.00054547447,0.00057727605,0.0015715186,0.000010379803,0.000062278305],"genre_scores_gemma":[0.9073806,0.088015154,0.000824395,0.0012889627,0.0010288509,0.000440153,0.000043977205,0.000027508877,0.000950427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987035,0.00003865184,0.00046755298,0.00021141945,0.00036133223,0.00021755247],"domain_scores_gemma":[0.9980582,0.00022668892,0.00051712536,0.00012590899,0.00089399895,0.00017810262],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013741717,0.0001447448,0.0004278111,0.00010375123,0.00018316139,0.0002808001,0.00014185783,0.00006393639,0.0012001625],"category_scores_gemma":[0.00012388351,0.00011147747,0.00026527222,0.00022460773,0.000080964026,0.00041287762,0.000029488398,0.00023579928,4.6378443e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002533696,0.000082783015,0.84521383,0.000019245084,0.022473676,0.000042044132,0.00045151275,0.0006226704,0.0005031454,0.000008771964,0.062035754,0.068293184],"study_design_scores_gemma":[0.004694525,0.000058794336,0.95226765,0.00042007052,0.023580333,0.00006684786,0.00017687446,0.007848809,0.00012581504,0.00004587356,0.010568094,0.00014631503],"about_ca_topic_score_codex":0.111993045,"about_ca_topic_score_gemma":0.021492096,"teacher_disagreement_score":0.1070538,"about_ca_system_score_codex":0.00044032064,"about_ca_system_score_gemma":0.00046915817,"threshold_uncertainty_score":0.9997129},"labels":[],"label_agreement":null},{"id":"W1993061513","doi":"10.4021//jmc.v2i5.253","title":"Erlotinib May be More Effective for Central Nervous Metastasis of Lung Adenocarcinoma Than Gefitinib Because of the Difference in the Clinical Regimes","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Adenocarcinoma; Brain metastasis; Lung cancer; Adenocarcinoma of the lung; Lung; Central nervous system; Metastasis; Oncology; Epidermal growth factor receptor; Internal medicine; Cancer","score_opus":0.09005212488419989,"score_gpt":0.4111526048948469,"score_spread":0.321100480010647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993061513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904557,0.0016239904,0.000104990904,0.0066664494,0.0002964778,0.0006750607,0.00007270493,0.0000028433751,0.00010178749],"genre_scores_gemma":[0.9984433,0.00016864059,0.00041562074,0.0006536111,0.00023056702,0.000025198213,0.0000041390226,0.000011006044,0.000047922364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977703,0.00030430325,0.00079108425,0.00012098267,0.0008106182,0.00020267857],"domain_scores_gemma":[0.99680763,0.0019942613,0.0005874545,0.00023241714,0.00020025752,0.00017797736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001018211,0.0001248043,0.00054876646,0.000074266296,0.00004395481,0.000005026604,0.00030438695,0.00010742466,0.0000972338],"category_scores_gemma":[0.0026750483,0.000054660584,0.00042373847,0.00016240796,0.0003608836,0.000046995367,0.00004117346,0.00037304588,1.349295e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019557774,0.0020685361,0.9499032,0.00033294372,0.0011016629,0.0010276686,0.009160413,0.0000011167302,0.000034317884,0.00063051656,0.0043252404,0.029458627],"study_design_scores_gemma":[0.0038297852,0.0019232292,0.98642415,0.0006364966,0.0016263096,0.001185871,0.0024602665,0.000027881273,0.0015130092,0.00010202124,0.00021775012,0.000053237483],"about_ca_topic_score_codex":0.0003793164,"about_ca_topic_score_gemma":0.00011933605,"teacher_disagreement_score":0.036520965,"about_ca_system_score_codex":0.000047541704,"about_ca_system_score_gemma":0.0005076437,"threshold_uncertainty_score":0.3202476},"labels":[],"label_agreement":null},{"id":"W1993982225","doi":"10.1016/j.lungcan.2008.10.002","title":"Improved survival from lung cancer in British Columbia compared to Scotland—Are different treatment rates the whole story?","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Proportional hazards model; Multivariate analysis; Life expectancy; Surgery; Confidence interval; Population","score_opus":0.016353814824862152,"score_gpt":0.32141116587109064,"score_spread":0.3050573510462285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993982225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806263,0.012044088,0.000021159713,0.0029398787,0.0010074027,0.0017188699,0.0013545371,0.00006587826,0.00022189508],"genre_scores_gemma":[0.98424387,0.0012661207,0.000037906404,0.0006383941,0.0004661517,0.001840415,0.00017393786,0.00004918673,0.011284047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985206,0.00007564737,0.000265732,0.0004726444,0.00026107332,0.00040426213],"domain_scores_gemma":[0.999135,0.000089497604,0.00010229486,0.00035459382,0.000109779954,0.00020881175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039602477,0.00021792643,0.0005404275,0.000041766514,0.00032861414,0.000099674755,0.00012127262,0.00007453094,0.0007753937],"category_scores_gemma":[0.000013735172,0.00019765936,0.00011723076,0.0002284794,0.00007061529,0.00007189792,0.00003822141,0.00016544851,0.0000060439925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011609149,0.0002999989,0.966887,0.000035663103,0.0006915816,0.00009758797,0.002415334,0.00020629326,0.00081451354,5.6861273e-7,0.024771873,0.0036634726],"study_design_scores_gemma":[0.005384728,0.000110482884,0.9835404,0.00046818177,0.00053273205,0.0000069976504,0.00057412137,0.0016914683,0.000225393,0.000003465416,0.007227223,0.00023478575],"about_ca_topic_score_codex":0.36576128,"about_ca_topic_score_gemma":0.82215613,"teacher_disagreement_score":0.45639485,"about_ca_system_score_codex":0.002216137,"about_ca_system_score_gemma":0.00040478192,"threshold_uncertainty_score":0.8490017},"labels":[],"label_agreement":null},{"id":"W1994389066","doi":"10.3747/co.21.1740","title":"Managing Treatment–Related Adverse Events Associated with Alk Inhibitors","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Crizotinib; Anaplastic lymphoma kinase; Medicine; Adverse effect; ALK inhibitor; Oncology; Internal medicine; Bioinformatics; Lung cancer; Biology","score_opus":0.03546994488907047,"score_gpt":0.38978439833693834,"score_spread":0.3543144534478679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994389066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94912034,0.0005037553,0.00017484781,0.0017861378,0.0014163436,0.00076816045,0.0000143487005,0.00018505406,0.04603101],"genre_scores_gemma":[0.9971308,0.00011121751,0.00009547408,0.00009232957,0.000119818025,0.00009185295,0.00030649963,0.000023957351,0.002028017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990575,0.00007989647,0.00021055689,0.00025644846,0.00013316698,0.00026243852],"domain_scores_gemma":[0.9993978,0.000073495015,0.0001348926,0.00017071201,0.00007852155,0.00014454148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082083025,0.00016631631,0.00031043924,0.000109558365,0.000097565164,0.0000024595304,0.00003842283,0.00008673448,0.000110755136],"category_scores_gemma":[0.000047977293,0.00011547593,0.00008349532,0.00018956022,0.000054822267,0.00005330258,0.000015395259,0.000116559015,0.00008969332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002808371,0.0041321865,0.43737224,0.000050080453,0.0017145998,0.000114878,0.0023886005,0.00011323579,0.00009964833,0.0006222714,0.0022339383,0.5508775],"study_design_scores_gemma":[0.041629985,0.010122817,0.22756128,0.0007767215,0.0045986897,0.00012687343,0.0006867505,0.0022926205,0.0003180732,0.0011073673,0.71022904,0.00054980564],"about_ca_topic_score_codex":0.000027249453,"about_ca_topic_score_gemma":0.000054124233,"teacher_disagreement_score":0.70799506,"about_ca_system_score_codex":0.0010035918,"about_ca_system_score_gemma":0.0002094364,"threshold_uncertainty_score":0.47089717},"labels":[],"label_agreement":null},{"id":"W1994403941","doi":"10.3389/fonc.2014.00244","title":"Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Clinical trial; Epidermal growth factor receptor; Oncology; Lung cancer; Tyrosine kinase; Internal medicine; First line; Mutation; Cancer research; Cancer; Receptor; Biology","score_opus":0.14364252261538102,"score_gpt":0.5224782663723971,"score_spread":0.3788357437570161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994403941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010779141,0.98877144,0.0005918613,0.0003472583,0.0015463879,0.0029856695,0.00003771249,0.000014506027,0.0057040746],"genre_scores_gemma":[0.0000026745226,0.9833609,0.014584462,0.0006600106,0.0001419892,0.0006609623,0.0002447152,0.000047799727,0.00029647633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952447,0.0014794783,0.0023474053,0.00041779058,0.00018071596,0.00032991404],"domain_scores_gemma":[0.9969913,0.0011204636,0.0013254735,0.00039805207,0.000069627145,0.00009511162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003304563,0.00035399778,0.008283456,0.00084859016,0.000024656065,0.0000041938306,0.00018249424,0.00028414113,0.00011160346],"category_scores_gemma":[0.002835288,0.00026032713,0.00064707303,0.00071381783,0.00008682683,0.00004395819,0.00006951305,0.00045960973,0.000014317152],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019803963,0.00016864625,0.00007672458,0.12787148,0.0005785178,0.0000736932,0.00012093417,4.165586e-7,6.5675714e-8,0.000043666758,0.027015667,0.8440304],"study_design_scores_gemma":[0.0016406407,0.0002679558,0.0000055509,0.21250656,0.0051848497,0.000044109773,0.000052422143,0.0000044434855,2.0180714e-7,0.000079735146,0.78007734,0.00013620568],"about_ca_topic_score_codex":0.00009305565,"about_ca_topic_score_gemma":0.000050281997,"teacher_disagreement_score":0.8438942,"about_ca_system_score_codex":0.0018929759,"about_ca_system_score_gemma":0.002043137,"threshold_uncertainty_score":0.9999849},"labels":[],"label_agreement":null},{"id":"W1995170617","doi":"10.1007/s00280-014-2481-1","title":"Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carboplatin; Medicine; Neutropenia; Etoposide; Topotecan; Internal medicine; Leukopenia; Pharmacology; Lung cancer; Docetaxel; Chemotherapy; Febrile neutropenia; Oncology; Gastroenterology; Cisplatin","score_opus":0.00965616637976602,"score_gpt":0.37579528785663024,"score_spread":0.3661391214768642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995170617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962011,0.0010799661,0.000045096986,0.0010683194,0.00007269747,0.0013405198,0.00002679206,0.000015222085,0.00015026599],"genre_scores_gemma":[0.9967143,0.001348495,0.00013553856,0.00088009366,0.000044461307,0.00075535243,0.000011633282,0.00002314253,0.000086969085],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991527,0.000058238933,0.00022268691,0.00026126014,0.00012366532,0.00018144403],"domain_scores_gemma":[0.99955094,0.000052565887,0.00014263399,0.00008512608,0.00011347875,0.000055253444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000078827296,0.00015997305,0.0004214112,0.00012730589,0.000036620633,0.000004093669,0.000041959047,0.000038274113,0.00016863881],"category_scores_gemma":[0.0000019655124,0.000111571775,0.00001361901,0.00025649584,0.000103795035,0.00008022543,0.0000053747904,0.00012781167,1.1837972e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06494449,0.014380892,0.4093632,0.0005466541,0.0013183,0.00006889826,0.110760085,0.00131343,0.019089157,0.000087514934,0.00028075866,0.3778466],"study_design_scores_gemma":[0.69546574,0.05215355,0.1456111,0.0016147044,0.00057212776,0.000015719548,0.012208731,0.0019407826,0.086627,0.00017522593,0.0030016645,0.00061365706],"about_ca_topic_score_codex":0.00081065204,"about_ca_topic_score_gemma":0.002493313,"teacher_disagreement_score":0.63052124,"about_ca_system_score_codex":0.00015483686,"about_ca_system_score_gemma":0.00018646824,"threshold_uncertainty_score":0.4549765},"labels":[],"label_agreement":null},{"id":"W1995684830","doi":"10.1358/dot.2006.42.3.957358","title":"Clinical experience with erlotinib in non-small-cell lung cancer(NSCLC)","year":2006,"lang":"en","type":"review","venue":"Drugs of today","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Epidermal growth factor receptor; Erlotinib Hydrochloride; Oncology; Tyrosine kinase; EGFR inhibitors; Cancer research; Cancer; T790M; Tyrosine-kinase inhibitor; Clinical trial; Internal medicine; Pharmacology; Gefitinib; Receptor","score_opus":0.03141548310013683,"score_gpt":0.41588384948687834,"score_spread":0.38446836638674153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995684830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022324114,0.9795076,0.000019695935,0.00005463032,0.00029546797,0.00191151,0.00008108901,0.000025045192,0.01587254],"genre_scores_gemma":[0.0013748163,0.990953,0.00088375725,0.000076551376,0.00025040534,0.00070166413,0.00016973427,0.00006649225,0.0055235783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979218,0.00006403841,0.00095226755,0.00050535816,0.00025735784,0.0002991466],"domain_scores_gemma":[0.9986116,0.00017963152,0.0004965313,0.0004896022,0.000091719376,0.00013090315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017002078,0.00035950975,0.0018165105,0.0001733919,0.000032866155,0.000011276633,0.00019366886,0.00023727813,0.0000884835],"category_scores_gemma":[0.000016682927,0.00023851822,0.0003606473,0.00036098715,0.00011167513,0.000046647427,0.000043764223,0.00036865805,0.000011768781],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054535914,0.00092535315,0.01695101,0.019699464,0.00042027506,0.00012951126,0.0015733782,0.000007215901,4.3454455e-7,0.000022605125,0.0032740925,0.95694214],"study_design_scores_gemma":[0.0031964874,0.0002817439,0.00173219,0.03975999,0.0034135014,0.000015142785,0.00020516998,0.000013077509,0.000008889143,0.0000015459151,0.95098203,0.00039021063],"about_ca_topic_score_codex":0.0015076566,"about_ca_topic_score_gemma":0.00019998603,"teacher_disagreement_score":0.9565519,"about_ca_system_score_codex":0.00025324847,"about_ca_system_score_gemma":0.0013005951,"threshold_uncertainty_score":0.97264904},"labels":[],"label_agreement":null},{"id":"W1996111914","doi":"10.3747/co.19.1069","title":"The Importance of Multidisciplinary Team Management of Patients with Non-Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Multidisciplinary approach; Psychosocial; Medicine; Multidisciplinary team; Quality of life (healthcare); Palliative care; Lung cancer; Intensive care medicine; Psychosocial support; Nursing; Oncology; Psychiatry","score_opus":0.03233569068111263,"score_gpt":0.4022631286998378,"score_spread":0.3699274380187252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996111914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845986,0.0069522946,0.00008722796,0.00013316856,0.0006482531,0.000893489,0.000030614556,0.000007302983,0.0066490904],"genre_scores_gemma":[0.99791133,0.00075902126,0.0005964553,0.000013168734,0.000062382904,0.00022390166,0.000042187276,0.000011723742,0.0003798361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993013,0.000017075343,0.00022844449,0.000114362316,0.00013180096,0.00020697797],"domain_scores_gemma":[0.9993403,0.000038311646,0.00022114936,0.00020570325,0.00012172865,0.00007280792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007686396,0.00009483878,0.00020142335,0.000030133986,0.00006219559,0.0000012430722,0.00006750405,0.000031103624,0.000034029348],"category_scores_gemma":[0.000002298723,0.000053222717,0.000044462424,0.00010195692,0.00008583949,0.000035294004,0.000055801334,0.00007542995,0.0000019226015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017530177,0.001794312,0.97725195,0.00040070977,0.00023821068,0.0000011711896,0.0009795446,0.000006666774,0.000012291794,0.00010116468,0.0012171321,0.01782156],"study_design_scores_gemma":[0.003930617,0.00041520502,0.9804058,0.00017540337,0.0008617446,6.5135373e-7,0.00055700616,0.000055664368,0.00019668335,0.0000062177483,0.013332414,0.00006260368],"about_ca_topic_score_codex":0.000011672764,"about_ca_topic_score_gemma":0.000022778162,"teacher_disagreement_score":0.017758956,"about_ca_system_score_codex":0.00021120171,"about_ca_system_score_gemma":0.00012922288,"threshold_uncertainty_score":0.21703595},"labels":[],"label_agreement":null},{"id":"W1996141967","doi":"10.1002/1097-0142(20010801)92:3<595::aid-cncr1359>3.0.co;2-d","title":"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma","year":2001,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Cancer Care Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Eli Lilly Canada; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Antifolate; Performance status; Internal medicine; Phases of clinical research; Gastroenterology; Cisplatin; Neutropenia; Chemotherapy; Surgery; Urology; Oncology; Antimetabolite","score_opus":0.010902909804608847,"score_gpt":0.3144783918800072,"score_spread":0.30357548207539836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996141967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960708,0.0016462965,0.000010356394,0.00009220917,0.00006689296,0.0017816095,0.00004778761,0.000018061677,0.000265982],"genre_scores_gemma":[0.9987381,0.0003375507,0.00014505959,0.00008114507,0.00002117391,0.00019699067,0.00006016135,0.000027345124,0.00039246198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909157,0.000017616487,0.00023705814,0.00028581236,0.0001761397,0.00019182876],"domain_scores_gemma":[0.9994233,0.00002705291,0.000111392816,0.00020474715,0.0001420612,0.00009142964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030328536,0.00017282026,0.0003142297,0.00013022867,0.000084757055,0.0000057276566,0.000041579824,0.000037554553,0.00013261994],"category_scores_gemma":[0.000009189736,0.00012252008,0.000025975414,0.00033902418,0.00003147686,0.00009514621,0.00001969365,0.000085757376,7.8504604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003357086,0.00766968,0.96785295,0.000047470377,0.00014549021,0.00003502752,0.005132119,0.00010185294,0.00057160784,6.760089e-7,0.00004109304,0.0150449695],"study_design_scores_gemma":[0.09464965,0.014521592,0.8881086,0.0001255916,0.00024036357,0.000001244004,0.0006081306,0.00053869095,0.0006753464,0.0000017128623,0.00036830548,0.00016078127],"about_ca_topic_score_codex":0.0013035093,"about_ca_topic_score_gemma":0.0011248672,"teacher_disagreement_score":0.09129257,"about_ca_system_score_codex":0.00012292973,"about_ca_system_score_gemma":0.00009468628,"threshold_uncertainty_score":0.4996224},"labels":[],"label_agreement":null},{"id":"W1996192566","doi":"10.1097/jto.0b013e3181ffe909","title":"Pharmacogenetic and Germline Prognostic Markers of Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Toronto; Cancer Care Ontario","keywords":"Pharmacogenetics; Medicine; Lung cancer; Candidate gene; Oncology; Population; Bioinformatics; Internal medicine; Genotype; Genetics; Biology; Gene","score_opus":0.03054511726158285,"score_gpt":0.4697045928526449,"score_spread":0.43915947559106205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996192566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880493,0.007282738,0.000110151654,0.0010207753,0.0003848512,0.00020802021,0.000006857755,0.000003851451,0.0029334133],"genre_scores_gemma":[0.9934802,0.0010742954,0.004728803,0.00024201209,0.0001388685,0.000008872313,0.0000010086287,0.000009604336,0.00031633908],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993477,0.000047995043,0.00032456417,0.0000696957,0.00010408017,0.00010596531],"domain_scores_gemma":[0.9992138,0.000055772467,0.00034363312,0.000057634115,0.00021051939,0.00011863659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016964946,0.00007020799,0.00029755096,0.00011686852,0.000020229585,0.0000017308327,0.00004131671,0.000050626328,0.0003829028],"category_scores_gemma":[0.000038475875,0.0000494147,0.00006373461,0.00008408113,0.00007344704,0.00004528242,0.000014538964,0.00011543247,7.3598903e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050607715,0.001141219,0.47830698,0.00058123755,0.002228832,0.00076915155,0.002780275,0.000010637471,0.011620438,0.00002075432,0.003996105,0.4934836],"study_design_scores_gemma":[0.0057233176,0.00851926,0.9302594,0.00086807436,0.013587094,0.0035256871,0.0006642324,0.00045196412,0.017360112,0.00024732781,0.018577164,0.00021636291],"about_ca_topic_score_codex":0.000027346985,"about_ca_topic_score_gemma":0.000007576836,"teacher_disagreement_score":0.49326724,"about_ca_system_score_codex":0.00011772092,"about_ca_system_score_gemma":0.0004725414,"threshold_uncertainty_score":0.4192517},"labels":[],"label_agreement":null},{"id":"W1997170706","doi":"10.1097/01.jto.0000284095.28451.43","title":"P3-120: Response rates of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) in clinical practice","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Erlotinib; Gefitinib; Oncology; Internal medicine; Lung cancer; Chemotherapy; Erlotinib Hydrochloride; Progression-free survival; Cancer; Epidermal growth factor receptor","score_opus":0.0665285186272268,"score_gpt":0.555089055594481,"score_spread":0.48856053696725416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997170706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503155,0.0024768033,0.00029901986,0.0087726265,0.0007444861,0.0010456896,0.000012430394,0.0000072949665,0.001610075],"genre_scores_gemma":[0.9686876,0.0021203174,0.02514727,0.0028669038,0.0003148001,0.000037213602,0.0000049236614,0.000030745225,0.00079023716],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965133,0.0005794378,0.001945788,0.00026131605,0.0003112878,0.00038887895],"domain_scores_gemma":[0.994631,0.0027985717,0.0012975245,0.00023380117,0.0007322732,0.00030683872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004498798,0.00020762357,0.0010584608,0.0005277578,0.000033093424,0.000009809081,0.00018265039,0.00021038923,0.00015801715],"category_scores_gemma":[0.001270509,0.00014747729,0.00017400079,0.0006032555,0.00007536855,0.00016536507,0.000029001982,0.0006773714,0.0000070173714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51881355,0.009967258,0.16155216,0.00021918629,0.0006830278,0.0075724814,0.010425802,0.0018299826,0.028855471,0.000012931384,0.0012285665,0.2588396],"study_design_scores_gemma":[0.038153537,0.034875717,0.7900962,0.002090139,0.0010851069,0.0013986318,0.009535786,0.00031735055,0.034451503,0.000044514807,0.08748711,0.00046435912],"about_ca_topic_score_codex":0.00029310797,"about_ca_topic_score_gemma":0.0010902107,"teacher_disagreement_score":0.6285441,"about_ca_system_score_codex":0.00094911375,"about_ca_system_score_gemma":0.0036821414,"threshold_uncertainty_score":0.6531961},"labels":[],"label_agreement":null},{"id":"W1997664351","doi":"10.1620/tjem.214.359","title":"Successful Treatment of Carcinomatous Meningitis with Gefitinib in a Patient with Lung Adenocarcinoma Harboring a Mutated EGF Receptor Gene","year":2008,"lang":"en","type":"article","venue":"The Tohoku Journal of Experimental Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Gefitinib; Medicine; Lung cancer; Adenocarcinoma; Epidermal growth factor receptor; Meningeal carcinomatosis; Internal medicine; Brain metastasis; Lung; Meningitis; Cerebrospinal fluid; Cancer research; Gastroenterology; Oncology; Cancer; Pathology; Metastasis; Surgery","score_opus":0.017984231432048376,"score_gpt":0.29344944853350063,"score_spread":0.2754652171014523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997664351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97988063,0.017721832,0.000025678544,0.00083560846,0.00012332185,0.00070144446,0.00000932744,0.000013174939,0.00068898924],"genre_scores_gemma":[0.99801767,0.00036790586,0.0011440442,0.00007757891,0.0001868293,0.00006138431,0.000015753678,0.000039106595,0.000089738845],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818224,0.000066360284,0.0006779197,0.00019721918,0.0005946425,0.00028161533],"domain_scores_gemma":[0.99874914,0.00008309282,0.0005112172,0.00025305763,0.00019698036,0.00020651902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008905694,0.00027607256,0.0007381088,0.00024569855,0.00010849088,0.00000523031,0.00010437452,0.00004039288,0.00018843687],"category_scores_gemma":[0.000012850825,0.00013149604,0.0000816046,0.00035084962,0.0003186457,0.00011812224,0.000015956028,0.00013856312,0.0000013223556],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01430109,0.0045898575,0.5911395,0.00011363183,0.0030454362,0.018451912,0.15105087,0.00031567042,0.21341403,0.000058857215,0.00052144664,0.002997708],"study_design_scores_gemma":[0.042953175,0.05923317,0.097611666,0.0023765117,0.0014470775,0.03319753,0.02817014,0.00012847995,0.7342161,0.000004919903,0.0002958856,0.00036535092],"about_ca_topic_score_codex":0.00092216174,"about_ca_topic_score_gemma":0.00001802827,"teacher_disagreement_score":0.5208021,"about_ca_system_score_codex":0.00064205815,"about_ca_system_score_gemma":0.00030729297,"threshold_uncertainty_score":0.5362253},"labels":[],"label_agreement":null},{"id":"W1998082963","doi":"10.1158/1538-7445.am2014-1184","title":"Abstract 1184: Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patient-derived xenografts (PDX) of non-small cell lung cancer (NSCLC)","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Gefitinib; Epidermal growth factor receptor; Cetuximab; EGFR inhibitors; Lung cancer; Cancer research; Population; Oncology; Targeted therapy; Cancer; Erlotinib Hydrochloride; Internal medicine","score_opus":0.0393501112748828,"score_gpt":0.3739480744670184,"score_spread":0.3345979631921356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998082963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371285,0.0015158479,0.009131728,0.000870673,0.0002764685,0.0017342444,0.0007651925,0.000028398552,0.0019645975],"genre_scores_gemma":[0.9899211,0.00042583465,0.00837572,0.00009143728,0.0001225072,0.00060216925,0.000086690474,0.0000674715,0.0003070821],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707013,0.00012872764,0.0007814818,0.0005021363,0.0009161954,0.00060133246],"domain_scores_gemma":[0.9967334,0.0002657283,0.00030570794,0.0004894448,0.0019401618,0.0002655173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032400867,0.0002486589,0.00063455215,0.00033588882,0.00016609112,0.000014561537,0.00025210992,0.00013194609,0.00041550642],"category_scores_gemma":[0.00017404479,0.00022049512,0.0001748551,0.0008086265,0.00015999154,0.00016803078,0.000088402885,0.00032694623,0.0000066091843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072427175,0.0004247027,0.0012409074,0.0020353075,0.00038062394,0.0000035045873,0.017900571,0.0027607104,0.9704259,0.00034526575,0.0016260938,0.0021321424],"study_design_scores_gemma":[0.002649306,0.0004617313,0.0025007618,0.0015050898,0.00019316946,3.3011176e-7,0.0025456655,0.0012490157,0.9878498,0.0005357878,0.00026730183,0.00024208748],"about_ca_topic_score_codex":0.007189036,"about_ca_topic_score_gemma":0.00051132176,"teacher_disagreement_score":0.017423855,"about_ca_system_score_codex":0.0005088679,"about_ca_system_score_gemma":0.001197415,"threshold_uncertainty_score":0.9994222},"labels":[],"label_agreement":null},{"id":"W1999922074","doi":"10.1007/s10552-010-9537-2","title":"Family history and lung cancer risk: international multicentre case–control study in Eastern and Central Europe and meta-analyses","year":2010,"lang":"en","type":"review","venue":"Cancer Causes & Control","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Lung cancer; Medicine; Family history; Odds ratio; Internal medicine; Cancer; Case-control study; Oncology; Epidemiology","score_opus":0.09532231865154553,"score_gpt":0.4292152910073197,"score_spread":0.3338929723557742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999922074","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063693607,0.987048,0.000027286433,0.00018569913,0.0008020961,0.0035508994,0.0018671121,0.00003313593,0.00011646522],"genre_scores_gemma":[0.088797554,0.907751,0.000025198267,0.000431211,0.00037154625,0.0014104904,0.000025688658,0.000079882244,0.0011073875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737406,0.0003244642,0.0007332413,0.00085367664,0.00029397185,0.00042059817],"domain_scores_gemma":[0.99825144,0.00031518284,0.0005461556,0.0003442961,0.00021152876,0.0003313942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016708605,0.0006560861,0.0026827322,0.00030583984,0.00009903499,0.00007895985,0.00010914004,0.00019333317,0.00031630337],"category_scores_gemma":[0.00011027957,0.00045000282,0.00028677424,0.00012299269,0.00015329052,0.00016749308,0.000056786477,0.00065210456,0.0000017327617],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033960937,0.0005609475,0.15796453,0.003504356,0.08093623,0.0039370344,0.0024224138,0.000023357734,0.000012898848,0.000011586363,0.00063893176,0.7496481],"study_design_scores_gemma":[0.013195624,0.00015161943,0.028313184,0.00090976106,0.3674233,0.000337722,0.00024082439,0.0007148684,1.5255623e-7,7.688357e-7,0.5881681,0.00054406194],"about_ca_topic_score_codex":0.009577093,"about_ca_topic_score_gemma":0.012225515,"teacher_disagreement_score":0.749104,"about_ca_system_score_codex":0.0008553358,"about_ca_system_score_gemma":0.0008250043,"threshold_uncertainty_score":0.9997952},"labels":[],"label_agreement":null},{"id":"W2000208967","doi":"10.1007/s11033-013-2713-1","title":"Association between CYP1A1 polymorphisms and esophageal cancer: a meta-analysis","year":2013,"lang":"en","type":"review","venue":"Molecular Biology Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill Genome Centre; Royal Victoria Hospital","funders":"Canadian Institutes of Health Research; Xinxiang Medical University","keywords":"Meta-analysis; Esophageal cancer; Association (psychology); Genetics; Biology; Internal medicine; Medicine; Oncology; Computational biology; Cancer; Psychology","score_opus":0.05536345874273412,"score_gpt":0.41371194634701897,"score_spread":0.35834848760428484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000208967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015014576,0.9972769,0.00022747515,0.00050589227,0.000134567,0.0011637512,0.00017642081,0.000045046065,0.00031978678],"genre_scores_gemma":[0.0007250653,0.98575115,0.0005112504,0.00020130299,0.00012427641,0.0011517531,0.002494936,0.00004891579,0.008991355],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9978133,0.00020319544,0.000795798,0.0007090725,0.00018045242,0.00029817928],"domain_scores_gemma":[0.9979706,0.00008574188,0.0011157353,0.00052828353,0.00012724742,0.00017238782],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025528262,0.00041357044,0.003984118,0.00034964966,0.00007362025,0.000026964244,0.000051486713,0.00058019924,0.00045669673],"category_scores_gemma":[0.0000715519,0.0002709624,0.0020761807,0.00047861028,0.000050248702,0.000025894251,0.00005790044,0.00024355068,0.000014218125],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.593144e-7,0.000042962965,0.01217978,0.00069869845,0.83124,0.00096659217,0.000021090731,3.9584165e-7,0.000006899297,0.000019328607,0.00065100647,0.1541724],"study_design_scores_gemma":[0.000079066536,0.000045981298,0.00027232486,0.0000507882,0.6405125,0.00013178283,6.3504245e-7,1.8199215e-7,0.000007617854,0.000061847146,0.35869202,0.00014521374],"about_ca_topic_score_codex":0.0007149617,"about_ca_topic_score_gemma":0.000019208053,"teacher_disagreement_score":0.35804102,"about_ca_system_score_codex":0.00034089232,"about_ca_system_score_gemma":0.00037797078,"threshold_uncertainty_score":0.99997425},"labels":[],"label_agreement":null},{"id":"W2000440749","doi":"10.3892/or.18.2.313","title":"Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: Implications for optimal postoperative adjuvant chemotherapy","year":2007,"lang":"en","type":"article","venue":"Oncology Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Medicine; Dosing; Chemotherapy; Regimen; Stage (stratigraphy); Adjuvant; Cancer; Adjuvant therapy; Progressive disease; Maximum tolerated dose; Surgery; Urology; Internal medicine; Gastroenterology; Oncology; Biology","score_opus":0.014165222874588119,"score_gpt":0.3857481617942738,"score_spread":0.3715829389196857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000440749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989377,0.00043514802,0.0016796313,0.0018699295,0.0013774103,0.003206037,0.00006485308,0.00008164842,0.0019082971],"genre_scores_gemma":[0.99036574,0.000054511078,0.0075850096,0.00075678097,0.00019347553,0.00036682296,0.00019755258,0.00006291501,0.00041716886],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99796575,0.00003780719,0.000701874,0.00057812233,0.00020144154,0.00051501964],"domain_scores_gemma":[0.99759424,0.0007566056,0.00049121433,0.0005043281,0.000436836,0.00021675053],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034918627,0.00031792023,0.0007954776,0.00012269036,0.00019524958,0.000024600844,0.00007806689,0.00021594464,0.000064115564],"category_scores_gemma":[0.00022034092,0.0002686532,0.00017481759,0.0001963383,0.0002279661,0.000102877144,0.000016574386,0.00019794209,0.0000017696078],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11697858,0.010843912,0.04981284,0.00082928024,0.0061799577,0.0036897922,0.010481444,0.00014300016,0.5083415,0.0007612752,0.00951407,0.2824244],"study_design_scores_gemma":[0.11359359,0.04030214,0.5458289,0.0007918171,0.0018147943,0.00050049415,0.0009923805,0.000054351534,0.28704387,0.00012136917,0.008342247,0.00061405473],"about_ca_topic_score_codex":0.0000374166,"about_ca_topic_score_gemma":0.000068943285,"teacher_disagreement_score":0.49601606,"about_ca_system_score_codex":0.00079816725,"about_ca_system_score_gemma":0.0011958105,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W2000585758","doi":"10.1200/jco.2012.47.0583","title":"Reply to V. Lorusso et al","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Alberta Cancer Foundation","funders":"","keywords":"Medicine","score_opus":0.13822695942533522,"score_gpt":0.550176613336425,"score_spread":0.41194965391108973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000585758","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012684711,0.0006079691,0.0001039913,0.96928924,0.005896237,0.00025502508,0.000015956566,0.000010163727,0.022552948],"genre_scores_gemma":[0.0011955581,0.0004222064,0.005638256,0.97027934,0.014665601,0.000008138097,0.000033246448,0.000039778293,0.0077178925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963942,0.00036404608,0.0022377248,0.00021136105,0.00047726877,0.00031537877],"domain_scores_gemma":[0.9951852,0.0017235758,0.0018324367,0.00030539502,0.0004858914,0.0004675248],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021123714,0.0001915629,0.0018690398,0.00018111676,0.000026732674,0.000010045144,0.00016222037,0.0008161625,0.00052090816],"category_scores_gemma":[0.0022288219,0.00012293438,0.0007878382,0.000093965886,0.00008360844,0.000080449536,0.000050915816,0.0038197068,0.00026436622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005310942,0.00053764565,0.002800408,0.000019722174,0.00103247,0.003113934,0.00008561416,8.9149665e-7,0.0000021791502,0.000014901259,0.9538853,0.037975796],"study_design_scores_gemma":[0.0033890675,0.008433052,0.013996677,0.00015459949,0.0016703551,0.0010273446,0.00001345371,4.1020385e-7,0.0000019645342,0.000070855705,0.97113717,0.000105030624],"about_ca_topic_score_codex":0.000040502313,"about_ca_topic_score_gemma":0.0000048467964,"teacher_disagreement_score":0.037870765,"about_ca_system_score_codex":0.0003606804,"about_ca_system_score_gemma":0.003511317,"threshold_uncertainty_score":0.99847853},"labels":[],"label_agreement":null},{"id":"W2002606479","doi":"10.1007/s00280-012-2008-6","title":"Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Pemetrexed; Medicine; Sunitinib; Tolerability; Cisplatin; Lung cancer; Pharmacokinetics; Internal medicine; Mesothelioma; Oncology; Response Evaluation Criteria in Solid Tumors; Dosing; Pharmacology; Chemotherapy; Phases of clinical research; Cancer; Adverse effect; Pathology","score_opus":0.011945402496927991,"score_gpt":0.3474005889607801,"score_spread":0.3354551864638521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002606479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475807,0.0021393476,0.0000110521105,0.00012673788,0.000059070888,0.002737433,0.000081598984,0.0000127171825,0.00007397322],"genre_scores_gemma":[0.9971526,0.0015137666,0.00027339012,0.0003403189,0.000046451347,0.00053664343,0.00005079279,0.00003662674,0.000049364455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988368,0.000067574285,0.00028755766,0.00034577155,0.00013693262,0.0003253215],"domain_scores_gemma":[0.99933034,0.00006753194,0.00019277738,0.00009932302,0.000104231585,0.00020581325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015001485,0.0002612701,0.00049111753,0.00018602105,0.000060787126,0.000010124895,0.000031410615,0.000058308146,0.000036963866],"category_scores_gemma":[0.0000019146437,0.00018364082,0.000008739072,0.00029501322,0.0001521982,0.00021988743,0.0000139268095,0.00013389428,2.5159279e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028591279,0.0023682455,0.9383358,0.00022824803,0.0003508756,0.000009896334,0.009638016,0.00002850255,0.010027896,8.0352277e-7,0.000020465437,0.010399998],"study_design_scores_gemma":[0.14181995,0.0057389424,0.83607763,0.00018905681,0.0006761335,0.0000061642945,0.00064642663,0.0004902335,0.014094499,8.9990544e-7,0.00004418141,0.00021587129],"about_ca_topic_score_codex":0.0004186341,"about_ca_topic_score_gemma":0.00043504458,"teacher_disagreement_score":0.11322867,"about_ca_system_score_codex":0.00009134585,"about_ca_system_score_gemma":0.00011280746,"threshold_uncertainty_score":0.74886554},"labels":[],"label_agreement":null},{"id":"W2002716449","doi":"10.3389/fonc.2014.00157","title":"Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Lung cancer; Medicine; Oncology; Squamous cell cancer; Internal medicine; Lung; Cancer; Cancer research","score_opus":0.017310472600303706,"score_gpt":0.3581944367372233,"score_spread":0.34088396413691957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002716449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069985085,0.985394,0.0013963293,0.00018951835,0.0017758026,0.008437151,0.0012378152,0.000032443542,0.0008370949],"genre_scores_gemma":[0.00023873152,0.97426105,0.009587304,0.00017837058,0.00028257078,0.0105150165,0.0012880482,0.00013078304,0.0035181367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975692,0.00010707576,0.0007534205,0.0008060131,0.00015250372,0.00061180216],"domain_scores_gemma":[0.9982617,0.00034157786,0.0006328508,0.0003905855,0.00011444734,0.0002588316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010583769,0.0007006093,0.0033252295,0.00035643205,0.00014770796,0.00002141341,0.00014507421,0.00034468563,0.00006825059],"category_scores_gemma":[0.000021048652,0.0004702999,0.00028869294,0.00023635341,0.0001179133,0.00005664385,0.000034380126,0.00027788623,0.000001489926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052095397,0.0015902937,0.04279734,0.041485142,0.0037122762,0.00010385388,0.0011823785,0.00007099806,2.917569e-8,0.000014404747,0.030525057,0.8779973],"study_design_scores_gemma":[0.014579528,0.0037002242,0.00027451283,0.003191115,0.017645432,0.000018142297,0.000054795986,0.0009610759,6.185931e-7,0.000009366566,0.95913494,0.0004302258],"about_ca_topic_score_codex":0.00083022245,"about_ca_topic_score_gemma":0.0028229393,"teacher_disagreement_score":0.9286099,"about_ca_system_score_codex":0.004487148,"about_ca_system_score_gemma":0.0022983844,"threshold_uncertainty_score":0.9997749},"labels":[],"label_agreement":null},{"id":"W2002937040","doi":"10.1371/journal.pmed.0020073","title":"Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain","year":2005,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3526,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Washington University in St. Louis; Genentech; AstraZeneca; LUNGevity Foundation; Memorial Sloan-Kettering Cancer Center; CHEST Foundation; Canadian Institutes of Health Research; American Cancer Society","keywords":"Gefitinib; Erlotinib; T790M; Cancer research; Epidermal growth factor receptor; Lung cancer; Resistance mutation; Medicine; Mutation; Erlotinib Hydrochloride; Tyrosine kinase; Tyrosine-kinase inhibitor; Biology; Cancer; Oncology; Internal medicine; Genetics; Receptor","score_opus":0.023973084570948718,"score_gpt":0.3131054173142422,"score_spread":0.2891323327432935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002937040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678253,0.0007718156,0.000043531614,0.023616016,0.00003764166,0.0012619395,0.0000672887,0.000033256085,0.0063431887],"genre_scores_gemma":[0.99062604,0.000013034133,0.0009643787,0.004817464,0.0001957273,0.0001675889,0.00012943335,0.00002639205,0.0030599453],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9984471,0.000080837075,0.00042059078,0.00026887882,0.00052663055,0.0002559206],"domain_scores_gemma":[0.9988384,0.00038001972,0.00017428982,0.00031365838,0.00017370572,0.00011988816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002936707,0.00017541662,0.00042121342,0.00018095635,0.00006460841,0.000006603467,0.000109109074,0.000060919592,0.0008662339],"category_scores_gemma":[0.00037789645,0.000093428345,0.000034001772,0.0007014674,0.00010609336,0.00007956972,0.000011174329,0.00010390753,0.000009043301],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015793048,0.0072296425,0.15257272,0.0019418237,0.0037472364,0.004760139,0.60958636,0.00006204801,0.032327056,0.0037242558,0.15952575,0.0087299105],"study_design_scores_gemma":[0.047887154,0.004904659,0.88214165,0.008275422,0.0029273366,0.00019909913,0.024036177,0.00028300285,0.011182071,0.00047631742,0.017061267,0.0006258186],"about_ca_topic_score_codex":0.00006790461,"about_ca_topic_score_gemma":0.0026854067,"teacher_disagreement_score":0.72956896,"about_ca_system_score_codex":0.00027243854,"about_ca_system_score_gemma":0.0001865157,"threshold_uncertainty_score":0.94846535},"labels":[],"label_agreement":null},{"id":"W2003360283","doi":"10.1097/jto.0000000000000196","title":"Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Royal Columbian Hospital; University Health Network","funders":"Ontario Ministry of Health and Long-Term Care; AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Histology; Population; Pathology; Mutation; Lung cancer; Cytology; Internal medicine; Adenocarcinoma; Mutation testing; Epidermal growth factor receptor; Oncology; Cancer; Biology; Gene; Genetics","score_opus":0.02377364564514958,"score_gpt":0.4344116558714719,"score_spread":0.41063801022632235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003360283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947882,0.00008796632,0.0014715561,0.0024635019,0.00014960062,0.00014926295,0.000005517598,0.000011077377,0.0008732629],"genre_scores_gemma":[0.98847324,0.0000013394248,0.010836228,0.0004198916,0.000120002966,0.0000061645173,0.00006194016,0.00001166969,0.000069532965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991452,0.00015141086,0.00031402282,0.00008746678,0.00017031204,0.00013156043],"domain_scores_gemma":[0.9979776,0.0010731446,0.00047903095,0.000064713466,0.0003350149,0.00007045201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041800347,0.00008371741,0.00031141556,0.0002118748,0.000056121953,0.000014922139,0.000044202865,0.00008338514,0.000024003817],"category_scores_gemma":[0.0015791537,0.00005724302,0.00003959176,0.00029819275,0.000022595028,0.00009920104,0.0000041485214,0.00019455681,9.348158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005216623,0.00036078444,0.9322727,0.00003158501,0.000112188194,0.00013054846,0.00023006035,0.003848135,0.00016702827,0.00003570012,0.00011383336,0.06217581],"study_design_scores_gemma":[0.0018936485,0.0019292912,0.99244887,0.0002999318,0.00034336778,0.00014654214,0.00009991482,0.0017734801,0.0002861089,0.00045323154,0.00026237758,0.000063221465],"about_ca_topic_score_codex":0.00042173706,"about_ca_topic_score_gemma":0.00068037986,"teacher_disagreement_score":0.06211259,"about_ca_system_score_codex":0.000577702,"about_ca_system_score_gemma":0.00043320042,"threshold_uncertainty_score":0.23343027},"labels":[],"label_agreement":null},{"id":"W2003380267","doi":"10.3747/co.21.2023","title":"Optimism About Breakthroughs in the Age of Targeted Therapy: the Canadian Lung Cancer Conference 2014; Vancouver, British Columbia; February 7, 2014","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Optimism; Lung cancer; Family medicine; Gerontology; Library science; Oncology; Psychology","score_opus":0.0364124463938517,"score_gpt":0.37890342704815627,"score_spread":0.34249098065430456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003380267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8700147,0.06546106,0.00040162154,0.011616887,0.008852463,0.0047024363,0.00054126594,0.000078344434,0.03833118],"genre_scores_gemma":[0.9913504,0.0054018954,0.00009146981,0.0016851054,0.00026421619,0.00041999258,0.00015396127,0.000019363908,0.0006135819],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998602,0.00024288907,0.00031042862,0.0002681979,0.00020314417,0.0003733491],"domain_scores_gemma":[0.9990555,0.00016125586,0.00014154342,0.000344576,0.0001815227,0.0001155859],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033898855,0.0001303563,0.0003713279,0.000050725423,0.00022832342,0.00005929403,0.00025489015,0.00012699315,0.0010056803],"category_scores_gemma":[0.000042354142,0.00010555958,0.0000870728,0.00016326607,0.00028316575,0.000058665268,0.000023979313,0.00034121794,0.000008389773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003536163,0.000451457,0.18825628,0.00007045056,0.00017142738,0.00005618409,0.0034712926,0.00004667236,0.000043470016,0.00014903871,0.6700729,0.13717547],"study_design_scores_gemma":[0.0029935353,0.00025191723,0.54469985,0.00016300954,0.00018780463,0.000028071063,0.00034856342,0.00038506452,0.0000092814,0.00022309538,0.45058125,0.0001285241],"about_ca_topic_score_codex":0.83436936,"about_ca_topic_score_gemma":0.98967594,"teacher_disagreement_score":0.35644358,"about_ca_system_score_codex":0.0005457562,"about_ca_system_score_gemma":0.001746354,"threshold_uncertainty_score":0.99990755},"labels":[],"label_agreement":null},{"id":"W2004018927","doi":"10.1016/j.lungcan.2011.12.003","title":"Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ministry of Health; Canadian Centre for Applied Research in Cancer Control","funders":"BC Cancer Agency","keywords":"Erlotinib; Medicine; Lung cancer; Internal medicine; Oncology; Cost-effectiveness analysis; Cohort; Survival analysis; Erlotinib Hydrochloride; Cost effectiveness; Univariate analysis; Population; Cancer; Multivariate analysis; Epidermal growth factor receptor","score_opus":0.028621419008751803,"score_gpt":0.41023038328219824,"score_spread":0.3816089642734464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004018927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95399016,0.024640456,0.0014847962,0.00025617421,0.0010475033,0.010607048,0.0028568006,0.0000985001,0.0050185416],"genre_scores_gemma":[0.9699473,0.0036785698,0.0012663405,0.00009735775,0.0005033175,0.011756474,0.0006988927,0.000080519,0.011971223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980433,0.000054984685,0.00048608246,0.00051710044,0.00025673702,0.0006417683],"domain_scores_gemma":[0.9980386,0.00025710987,0.00036876733,0.00047448045,0.0005403764,0.00032070559],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000097527365,0.00041670335,0.0011044352,0.0003281207,0.00016545792,0.000014423687,0.00009406031,0.00011037847,0.0003276368],"category_scores_gemma":[0.0000151033255,0.00029830672,0.00048068466,0.0010052508,0.00006208136,0.00015656701,0.000024668763,0.000088585344,0.0000027803003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034844447,0.0019049436,0.9306322,0.0027660418,0.010604169,0.000021213045,0.014157476,0.004775846,0.0019126118,0.0000536911,0.000516811,0.02917059],"study_design_scores_gemma":[0.053938877,0.0061159665,0.5570798,0.0027819332,0.15638955,0.000009216252,0.00909798,0.0064530754,0.16984323,0.000009768819,0.036510468,0.0017701295],"about_ca_topic_score_codex":0.013091286,"about_ca_topic_score_gemma":0.020063587,"teacher_disagreement_score":0.37355235,"about_ca_system_score_codex":0.0029606353,"about_ca_system_score_gemma":0.0010590844,"threshold_uncertainty_score":0.9999469},"labels":[],"label_agreement":null},{"id":"W2004469331","doi":"10.1016/j.lungcan.2008.02.002","title":"Brief report: Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Docetaxel; Gefitinib; Oncology; Chemotherapy; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Epidermal growth factor receptor","score_opus":0.02022896833383872,"score_gpt":0.35836567103033284,"score_spread":0.3381367026964941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004469331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95946336,0.03343601,0.00019407172,0.0012665231,0.00025913253,0.004123937,0.00017782797,0.000038035923,0.0010411139],"genre_scores_gemma":[0.97975355,0.013630773,0.003191875,0.0014792999,0.00011747792,0.00071984925,0.00010849412,0.0000834381,0.00091526797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715203,0.000054359174,0.0012424081,0.00059172756,0.00056855974,0.00039090635],"domain_scores_gemma":[0.99759173,0.00013792179,0.00090190425,0.00064375415,0.0005540841,0.00017061908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002238905,0.00038250416,0.001474751,0.00019578192,0.000059737773,0.0000045518127,0.0001782266,0.00011430909,0.0005837996],"category_scores_gemma":[0.00009796244,0.00030209738,0.00038279465,0.00096241524,0.000084641564,0.00008458665,0.000019150038,0.0002252929,7.695438e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074659092,0.0029175475,0.8671415,0.012810647,0.0025128047,0.0007252159,0.013071477,0.004432695,0.077295355,0.000026243953,0.0041795755,0.0074210316],"study_design_scores_gemma":[0.06527852,0.0025284102,0.5637925,0.066835806,0.0018754955,0.000068822126,0.00035110948,0.000995108,0.29103455,0.000008280636,0.0061745183,0.0010568526],"about_ca_topic_score_codex":0.003573274,"about_ca_topic_score_gemma":0.0008409918,"teacher_disagreement_score":0.303349,"about_ca_system_score_codex":0.0007550097,"about_ca_system_score_gemma":0.0022549287,"threshold_uncertainty_score":0.99994314},"labels":[],"label_agreement":null},{"id":"W2004682614","doi":"10.3816/clc.2006.s.005","title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations","year":2006,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; T790M; Oncology; Internal medicine; Tyrosine kinase; Erlotinib Hydrochloride; Clinical trial; Cancer; Cancer research; Receptor","score_opus":0.05832898923244735,"score_gpt":0.4730369604921097,"score_spread":0.41470797125966236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004682614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024429231,0.98468304,0.000010313796,0.00026419436,0.0017871632,0.003520041,0.006006612,0.0000793771,0.0012063622],"genre_scores_gemma":[0.0009416236,0.9893218,0.0003139416,0.00022758146,0.0017795805,0.0015103257,0.0025714394,0.00017905852,0.0031546266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99465615,0.00033084425,0.0029432732,0.0009771462,0.00044158378,0.0006510146],"domain_scores_gemma":[0.9960984,0.0011970764,0.0013054572,0.00060346903,0.00035443596,0.0004411356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032245243,0.0008048758,0.0040829205,0.00046736887,0.0000986707,0.000032070446,0.00025246062,0.0007671128,0.0026565026],"category_scores_gemma":[0.00035727228,0.0005390261,0.0018567111,0.0010668098,0.00031281047,0.00021687576,0.00010358208,0.0012771547,0.000014295081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033469094,0.0011141842,0.07084663,0.033028986,0.003041939,0.00013833634,0.00010762268,0.000021695454,0.0000030213564,0.000011768603,0.076144606,0.8152065],"study_design_scores_gemma":[0.011302903,0.0013442895,0.09632686,0.08271405,0.020442763,0.000049422233,0.000020968693,0.00010077759,0.000014665918,0.00001690709,0.7859734,0.001692985],"about_ca_topic_score_codex":0.0044490662,"about_ca_topic_score_gemma":0.00079171197,"teacher_disagreement_score":0.8135135,"about_ca_system_score_codex":0.00429968,"about_ca_system_score_gemma":0.013140637,"threshold_uncertainty_score":0.99970615},"labels":[],"label_agreement":null},{"id":"W2004818337","doi":"10.3111/13696998.2012.703631","title":"A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies","year":2012,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Database; Retrospective cohort study; Cancer; MEDLINE; Family medicine; Internal medicine","score_opus":0.06342109857381367,"score_gpt":0.4330840846767386,"score_spread":0.3696629861029249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004818337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019207133,0.99101627,0.00000895326,0.00028177595,0.000884216,0.0030651628,0.0024535425,0.000003912584,0.00036542903],"genre_scores_gemma":[0.00013428865,0.9976841,0.00022333169,0.00038720173,0.000605017,0.0002650707,0.0004507312,0.000055717872,0.00019451212],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99612725,0.00015516378,0.0023643712,0.0005021616,0.0005266263,0.00032440742],"domain_scores_gemma":[0.99439937,0.00075230614,0.0032592127,0.0005954357,0.0006408587,0.00035279334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020163385,0.0004770026,0.0055353036,0.00027401076,0.00006546996,0.000021653663,0.00043499348,0.00026888776,0.0001822162],"category_scores_gemma":[0.0016080983,0.00031232397,0.00032029964,0.0003479911,0.00045340188,0.00028612575,0.00026562592,0.0010215619,0.0000010754449],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013307856,0.0039098524,0.07107618,0.45904598,0.023137761,0.00024611625,0.0017166528,0.000003497769,6.547534e-8,0.00014448247,0.03742046,0.3899911],"study_design_scores_gemma":[0.09886987,0.00046058276,0.0046826974,0.49329382,0.022442965,0.00007353402,0.00008843268,0.00006332948,0.0000012352136,0.000010936122,0.37950674,0.0005058671],"about_ca_topic_score_codex":0.0010354111,"about_ca_topic_score_gemma":0.0008015942,"teacher_disagreement_score":0.38948524,"about_ca_system_score_codex":0.0027221278,"about_ca_system_score_gemma":0.0067316093,"threshold_uncertainty_score":0.9999329},"labels":[],"label_agreement":null},{"id":"W2005151616","doi":"10.3747/co.v16i3.302","title":"Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed?","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Hormone replacement therapy (female-to-male); Performance status; Proportional hazards model; Univariate analysis; Oncology; Stage (stratigraphy); Cancer; Cohort; Survival analysis; Multivariate analysis; Gynecology","score_opus":0.04511739296843662,"score_gpt":0.41184438123779243,"score_spread":0.3667269882693558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005151616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98673296,0.0021631538,0.00011778739,0.008229709,0.0002666348,0.0015113926,0.00006642013,0.00003420035,0.00087777054],"genre_scores_gemma":[0.99268425,0.0022296354,0.00042209474,0.0016084677,0.00015535958,0.00093587214,0.00014221153,0.000016208776,0.001805926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915135,0.000025653488,0.00016985388,0.00025116903,0.000116217816,0.0002857551],"domain_scores_gemma":[0.99935603,0.000060435683,0.00015692726,0.00013746305,0.00013501343,0.00015411768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013523945,0.00014018307,0.0003257946,0.000055826815,0.00009797935,0.0000146282955,0.00003672554,0.00007192894,0.000027910159],"category_scores_gemma":[0.00001058998,0.00009945355,0.000026374028,0.00006109757,0.000020478577,0.00004093831,0.0000059492572,0.00009038815,3.4490958e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022798304,0.0024969457,0.7145469,0.00010501105,0.00070287375,0.000008067988,0.013753352,0.000009607657,0.0010464024,0.00012275386,0.0098438505,0.2550844],"study_design_scores_gemma":[0.033947982,0.015314453,0.74152696,0.000042336473,0.0006123598,0.0000067305014,0.0014856751,0.0003587663,0.0003476963,0.00007530066,0.20602648,0.00025524705],"about_ca_topic_score_codex":0.00008879066,"about_ca_topic_score_gemma":0.00020685545,"teacher_disagreement_score":0.25482917,"about_ca_system_score_codex":0.0014231452,"about_ca_system_score_gemma":0.0004604678,"threshold_uncertainty_score":0.4055598},"labels":[],"label_agreement":null},{"id":"W2005507799","doi":"10.3747/co.20.1226","title":"Overall Survival Should Be the Primary Endpoint in Clinical Trials for Advanced Non-Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Surrogate endpoint; Oncology; Pemetrexed; Internal medicine; Lung cancer; Clinical trial; Progression-free survival; Cancer; Crizotinib; Chemotherapy; Overall survival","score_opus":0.3022978229486874,"score_gpt":0.5550188770654189,"score_spread":0.25272105411673146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005507799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94687194,0.008050689,0.001406996,0.0221816,0.007450497,0.0075940774,0.00013080229,0.00004526499,0.006268145],"genre_scores_gemma":[0.954682,0.00933047,0.0033676792,0.0092291655,0.0037760446,0.014372595,0.00071993185,0.000114418486,0.004407678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979764,0.00032742953,0.0008783982,0.0003410743,0.00013771148,0.0003389774],"domain_scores_gemma":[0.9973709,0.0017811797,0.00028937432,0.00026648538,0.0001550716,0.00013701705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013523475,0.00017396454,0.0008186048,0.00006124317,0.000066488756,0.000013952769,0.000121431985,0.00015175166,0.00032837223],"category_scores_gemma":[0.00039997854,0.000105291845,0.00027450043,0.00008549034,0.000076121905,0.000064376574,0.00005413791,0.00034697948,0.0000122435085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015735414,0.0043492746,0.2334756,0.000684407,0.0005732694,0.000016721135,0.0020308534,0.00010321042,0.0012231417,0.0005808529,0.09475961,0.6606295],"study_design_scores_gemma":[0.034475103,0.0014674301,0.35691085,0.00020191699,0.0014361615,0.0000046378905,0.0004819443,0.0017762029,0.00023574676,0.000405968,0.6023018,0.0003022495],"about_ca_topic_score_codex":0.00017383443,"about_ca_topic_score_gemma":0.00025115962,"teacher_disagreement_score":0.66032726,"about_ca_system_score_codex":0.00060558616,"about_ca_system_score_gemma":0.0010189465,"threshold_uncertainty_score":0.4293677},"labels":[],"label_agreement":null},{"id":"W2005842252","doi":"10.1097/jto.0000000000000230","title":"Comparison of the Yield of Different Diagnostic Procedures for Cellular Differentiation and Genetic Profiling of Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Biopsy; Bronchoalveolar lavage; Pathology; Epidermal growth factor receptor; Carcinoma; Lung; Cancer; Oncology; Internal medicine","score_opus":0.022712014938560135,"score_gpt":0.4126552338120417,"score_spread":0.3899432188734816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005842252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975194,0.0021931098,0.006630083,0.00046179676,0.00028464172,0.0006011217,0.000009109562,0.0000013682386,0.00006681991],"genre_scores_gemma":[0.997308,0.00016512688,0.0023026685,0.00002772575,0.00010780069,0.000028113778,0.0000023436369,0.000009493704,0.000048699418],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909693,0.000053583895,0.00054052525,0.00007863851,0.00013607765,0.000094269344],"domain_scores_gemma":[0.9980814,0.0004976031,0.0009955156,0.000098956516,0.00027919246,0.00004736696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001042024,0.00008570921,0.000508796,0.0000769945,0.000031754735,0.000002481474,0.00007189058,0.00007413048,0.000009707774],"category_scores_gemma":[0.000273914,0.00004981128,0.00010996469,0.00005674353,0.000056422094,0.000018537858,0.00002238993,0.00010226224,2.9339864e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039710908,0.00087863166,0.7492717,0.0026345106,0.00030510957,0.0000012113983,0.0013881074,0.00034618773,0.22995216,0.000021430864,0.00012732972,0.014676546],"study_design_scores_gemma":[0.0013906092,0.0021826376,0.45698977,0.0008695865,0.003204248,0.000013883462,0.00033889513,0.004181681,0.530619,0.00011529354,0.00003959476,0.000054783104],"about_ca_topic_score_codex":0.000018548726,"about_ca_topic_score_gemma":0.000047372556,"teacher_disagreement_score":0.30066687,"about_ca_system_score_codex":0.000077644094,"about_ca_system_score_gemma":0.0002652814,"threshold_uncertainty_score":0.2031245},"labels":[],"label_agreement":null},{"id":"W2006472996","doi":"10.1016/j.lungcan.2010.01.012","title":"Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Medical prescription; Population; Cancer registry; Total cost; Average cost; Cancer; Emergency medicine; Medical record; Intensive care medicine; Internal medicine","score_opus":0.010535648217525272,"score_gpt":0.3217445640135893,"score_spread":0.311208915796064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006472996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476427,0.0010507595,0.0020557945,0.0002202071,0.00018676533,0.001038342,0.0003132682,0.00000890678,0.00036167543],"genre_scores_gemma":[0.9962553,0.000327955,0.0024117474,0.00018531893,0.000034096487,0.00033968597,0.00008095722,0.000024808292,0.00034015262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991757,0.000012310267,0.00029794374,0.0001874457,0.00019158765,0.0001350096],"domain_scores_gemma":[0.9993413,0.000026259668,0.00022152545,0.00021687224,0.00013426757,0.000059780978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005823231,0.00013457268,0.00033199528,0.00008867079,0.000023250908,0.000004696927,0.00004573158,0.000037625574,0.0004913525],"category_scores_gemma":[0.0000012823806,0.00011215404,0.00007016004,0.00011176792,0.000032765704,0.000036742385,0.000012332886,0.0000716526,1.752975e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018967858,0.00020184043,0.9893858,0.0028542269,0.0004911033,0.000003884755,0.00041957418,0.00029780326,0.0026199664,0.00005844173,0.000099414385,0.0033782574],"study_design_scores_gemma":[0.003802068,0.00006765847,0.9791389,0.0007158187,0.0015284405,6.2656164e-7,0.00005714393,0.0044466206,0.009950937,0.000009956069,0.00018037546,0.000101419355],"about_ca_topic_score_codex":0.0094134845,"about_ca_topic_score_gemma":0.0018445185,"teacher_disagreement_score":0.010246874,"about_ca_system_score_codex":0.0001080273,"about_ca_system_score_gemma":0.00010231606,"threshold_uncertainty_score":0.9971829},"labels":[],"label_agreement":null},{"id":"W2006489296","doi":"10.1097/jto.0000000000000239","title":"Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval; Pfizer (Canada); Centre Hospitalier de l’Université de Montréal; McGill University; London Health Sciences Centre; Princess Margaret Cancer Centre; Health Sciences North; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; University Health Network; University of Alberta; Dalhousie University; University of Ottawa; McGill University Health Centre; Jewish General Hospital; Health Sciences Centre; University of Calgary; Ottawa Hospital; McMaster University Medical Centre; University of Alberta Hospital; University of Toronto; University of British Columbia; Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Immunohistochemistry; Lung cancer; Intraclass correlation; Fluorescence in situ hybridization; Crizotinib; Oncology; Internal medicine; Pathology; Biology","score_opus":0.021496453022647334,"score_gpt":0.42448151199295237,"score_spread":0.402985058970305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006489296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8478002,0.00027148405,0.15004393,0.0008903488,0.0001762835,0.0005983475,0.000027328977,0.000003149996,0.00018894892],"genre_scores_gemma":[0.96619296,0.000023088358,0.033535782,0.00011249841,0.000060166043,0.000020723579,0.0000045335078,0.000010253987,0.000040006296],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999327,0.00005096727,0.00033011893,0.000083279745,0.00009236488,0.00011628865],"domain_scores_gemma":[0.9990304,0.00013483853,0.000269982,0.000051268515,0.00039870501,0.00011479774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002983346,0.00006550556,0.00027311125,0.00025838468,0.000041282376,0.00000673698,0.000027791055,0.000049959403,0.0000062588388],"category_scores_gemma":[0.0003456032,0.000053251806,0.000025469431,0.00012517009,0.00001749003,0.00008144066,0.000006563036,0.000045882585,3.2232812e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014180633,0.0004555681,0.12463656,0.00018262384,0.00018529934,0.000033493256,0.0025918195,0.7524829,0.00013178439,0.000010479109,0.00010235639,0.11776905],"study_design_scores_gemma":[0.0039717997,0.0015755778,0.020683423,0.00021721555,0.0007020857,0.000028690103,0.00042021493,0.97212774,0.00003854606,0.000022275275,0.00016528092,0.00004715058],"about_ca_topic_score_codex":0.0029874132,"about_ca_topic_score_gemma":0.029704435,"teacher_disagreement_score":0.21964484,"about_ca_system_score_codex":0.0009334648,"about_ca_system_score_gemma":0.0011789411,"threshold_uncertainty_score":0.9880009},"labels":[],"label_agreement":null},{"id":"W2006813505","doi":"10.1097/jto.0b013e3181cee24f","title":"Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Neutropenia; Internal medicine; Interim analysis; Lung cancer; Febrile neutropenia; Phases of clinical research; Discontinuation; Adverse effect; Leukopenia; Combination therapy; Oncology; Surgery; Chemotherapy; Randomized controlled trial","score_opus":0.019319522764414274,"score_gpt":0.43457780159295745,"score_spread":0.41525827882854316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006813505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476457,0.0004905823,0.000050892646,0.00032725272,0.000697673,0.002663407,0.00001245925,0.000006852598,0.0009863172],"genre_scores_gemma":[0.99702626,0.00011990981,0.0017552712,0.00016538882,0.00015143558,0.00012617107,0.000009563619,0.000029807568,0.00061621406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99814004,0.00014328699,0.0009228269,0.00021018213,0.0003379467,0.00024571584],"domain_scores_gemma":[0.9975639,0.00018170192,0.0011664736,0.00023661515,0.0006778568,0.00017347328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061187334,0.00022233759,0.0013402337,0.00045151912,0.00006399051,0.000008513489,0.00014842127,0.00013009801,0.00052964484],"category_scores_gemma":[0.00003974621,0.0001384559,0.0001542298,0.00031788545,0.000077227305,0.0001446125,0.00003120539,0.00060515077,9.257204e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8462779,0.028378123,0.031870503,0.00009575804,0.001318504,0.00021896878,0.0089878915,0.0003218963,0.0037045404,0.0000029788362,0.00009102639,0.078731924],"study_design_scores_gemma":[0.93642265,0.042618535,0.011713526,0.00014068093,0.0013610534,0.000033432225,0.0014183283,0.00009543911,0.005328716,0.000013605332,0.00069668976,0.00015733726],"about_ca_topic_score_codex":0.00018236546,"about_ca_topic_score_gemma":0.000984831,"teacher_disagreement_score":0.09014477,"about_ca_system_score_codex":0.00035649465,"about_ca_system_score_gemma":0.0014514124,"threshold_uncertainty_score":0.5799239},"labels":[],"label_agreement":null},{"id":"W2008582463","doi":"10.1097/01.cad.0000190282.05748.63","title":"Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors","year":2005,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Vomiting; Regimen; Nausea; Cisplatin; Doxorubicin; Internal medicine; Toxicity; Gastroenterology; Diarrhea; Chemotherapy; Phases of clinical research; Neutropenia","score_opus":0.008319956625518418,"score_gpt":0.3313097557740054,"score_spread":0.32298979914848697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008582463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628365,0.000287399,0.000013338075,0.00050710974,0.000083127255,0.0010070979,0.000059406953,0.000019852692,0.0017389917],"genre_scores_gemma":[0.99820817,0.00015654413,0.0007046519,0.00023133047,0.00009993461,0.000094668634,0.00005843188,0.00002375086,0.00042252953],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99892837,0.00001662238,0.0003362056,0.00025758552,0.00023909946,0.00022211175],"domain_scores_gemma":[0.99944556,0.000028928309,0.00015430062,0.00018718575,0.00009528702,0.00008874892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006210382,0.00015974266,0.00041455714,0.00012509419,0.00003951241,0.000007663895,0.00004223088,0.000038846545,0.00008052907],"category_scores_gemma":[0.0000134011325,0.00011858284,0.000038965558,0.00022591482,0.00007366627,0.00017421933,0.000016237476,0.00009547624,0.0000037201987],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0812384,0.0128958,0.34847018,0.0003764274,0.0007197035,0.000027575234,0.0076063187,0.00052254973,0.005880792,0.00036088767,0.0009576252,0.54094374],"study_design_scores_gemma":[0.7706677,0.006582714,0.1941483,0.00082122267,0.0005520883,0.0000026869536,0.00053279067,0.0003432971,0.022606276,0.00003588002,0.0032671788,0.0004398777],"about_ca_topic_score_codex":0.00019235004,"about_ca_topic_score_gemma":0.0000840501,"teacher_disagreement_score":0.6894293,"about_ca_system_score_codex":0.0001074349,"about_ca_system_score_gemma":0.00015377274,"threshold_uncertainty_score":0.48356676},"labels":[],"label_agreement":null},{"id":"W2008945954","doi":"10.1016/j.ijrobp.2013.06.1428","title":"Is There an Oligometastatic State in Non-Small Cell Lung Cancer (NSCLC)?: A Systematic Review of Outcomes and Prognostic Factors","year":2013,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Radiosurgery; SABR volatility model; non-small cell lung cancer (NSCLC); Oncology; Ablative case; Lung cancer; Radiation therapy; Internal medicine; Surgery","score_opus":0.035025610709751534,"score_gpt":0.4055954286741305,"score_spread":0.370569817964379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008945954","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009657453,0.9857265,0.00044914812,0.00023208624,0.00069528533,0.0028088237,0.00034383513,0.000010691354,0.000076230965],"genre_scores_gemma":[0.0058150133,0.9923196,0.0006327921,0.00040221636,0.0001770505,0.00028009148,0.00020748892,0.00005316775,0.00011260187],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99683183,0.0004266349,0.0019413359,0.00028783837,0.00029031257,0.0002220546],"domain_scores_gemma":[0.9946172,0.00069334824,0.003534659,0.00022180339,0.00077514123,0.00015780027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045801015,0.00042102332,0.0030641493,0.00035782543,0.000029814788,0.000025580159,0.00033380167,0.00021456016,0.000076653225],"category_scores_gemma":[0.00027000307,0.00026912597,0.0004925875,0.00024231664,0.0000932229,0.00021754178,0.00004757237,0.00046897112,0.0000069306443],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025978356,0.00116848,0.19813329,0.58233255,0.007427773,0.00007237929,0.0022105584,0.000018154367,0.0000052249065,0.00016561364,0.00029584926,0.20814413],"study_design_scores_gemma":[0.008795136,0.0023529818,0.014047814,0.9244616,0.03206263,0.00029356574,0.0003410023,0.00044243745,0.000026987515,0.0009909843,0.015296221,0.0008886458],"about_ca_topic_score_codex":0.00015011462,"about_ca_topic_score_gemma":0.00001545536,"teacher_disagreement_score":0.34212902,"about_ca_system_score_codex":0.0009789008,"about_ca_system_score_gemma":0.0015091855,"threshold_uncertainty_score":0.9999761},"labels":[],"label_agreement":null},{"id":"W2008960928","doi":"10.5858/arpa.2013-0232-cp","title":"Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non–Small Cell Carcinoma of the Lung","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; Cancer Care Ontario","funders":"","keywords":"Reimbursement; Biomarker; Scope (computer science); Test (biology); Medicine; Discretion; Medical physics; Template; Medical education; Computer science; Health care; Political science; Biology","score_opus":0.02052770657167475,"score_gpt":0.2804564880868605,"score_spread":0.2599287815151858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008960928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955456,0.00030449685,0.00017278027,0.00021001673,0.00011061809,0.0010197965,0.0004506192,0.0000064145725,0.00217965],"genre_scores_gemma":[0.9869665,0.0000044177727,0.012704543,0.0000548038,0.00004041424,0.0000342825,0.00010439776,0.000020278565,0.000070380636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812955,0.00006904371,0.0012063778,0.0002479877,0.00017709167,0.00016993638],"domain_scores_gemma":[0.9958265,0.000742749,0.002337854,0.00047883828,0.0005483615,0.00006569007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021827899,0.00014829171,0.00060571235,0.0001237701,0.000040630195,6.695178e-7,0.000109618486,0.000050425813,0.0000145202785],"category_scores_gemma":[0.0009437941,0.00008431373,0.000063330896,0.00025185934,0.0005954506,0.000032964937,0.000046244593,0.00008808373,2.0619471e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003132991,0.00021718761,0.72123635,0.00028853098,0.00012584054,0.000014082473,0.003078322,0.000005754672,0.27369544,0.000007474272,0.00025863934,0.0007590719],"study_design_scores_gemma":[0.006985172,0.0012555773,0.9166752,0.00070876186,0.0006150739,0.000003591934,0.00061378075,0.00008863288,0.07288907,0.0000728012,0.000032707903,0.000059652946],"about_ca_topic_score_codex":0.00052736496,"about_ca_topic_score_gemma":0.000022766715,"teacher_disagreement_score":0.20080638,"about_ca_system_score_codex":0.000015832647,"about_ca_system_score_gemma":0.00027073122,"threshold_uncertainty_score":0.34382144},"labels":[],"label_agreement":null},{"id":"W2009101885","doi":"10.1158/1538-7445.am2012-3667","title":"Abstract 3667: Inactivating BRAF mutations confer dasatinib sensitivity in lung cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Dasatinib; Cancer research; Mutation; Cancer; Lung cancer; Transfection; Kinase; Tyrosine kinase; Medicine; Biology; Gene; Internal medicine; Genetics; Receptor","score_opus":0.10635581743494316,"score_gpt":0.5078567328954511,"score_spread":0.4015009154605079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009101885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815264,0.0018804752,0.000032066768,0.0022935616,0.00022601809,0.0008687552,0.00007184299,0.000041967312,0.013058946],"genre_scores_gemma":[0.9967136,0.0002091099,0.00017152353,0.00021687,0.0005329265,0.0007738956,0.000053951248,0.00003726883,0.0012908506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981086,0.00010806154,0.00024278284,0.00028136894,0.00053198606,0.00072720327],"domain_scores_gemma":[0.99870634,0.00035694166,0.000057487603,0.00025158245,0.0003579932,0.00026964472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069992495,0.00014228105,0.00024671396,0.00028531047,0.00023114895,0.000038776663,0.00005472382,0.0000935314,0.0015623721],"category_scores_gemma":[0.00020448759,0.00012458726,0.000054161002,0.00064017944,0.00014123507,0.00033291866,0.000049986582,0.0006096803,0.00003558722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013675148,0.00045324097,0.9305909,0.00032797962,0.00022541084,0.000074450676,0.00542083,0.00013521229,0.039924584,0.00073343824,0.0036699683,0.018307216],"study_design_scores_gemma":[0.0020541616,0.00004322656,0.97448134,0.0005396845,0.0000766386,0.000014884016,0.0014588553,0.00027490803,0.016808521,0.00005475007,0.0040144413,0.00017856012],"about_ca_topic_score_codex":0.013795961,"about_ca_topic_score_gemma":0.0028619603,"teacher_disagreement_score":0.04389045,"about_ca_system_score_codex":0.0015316545,"about_ca_system_score_gemma":0.0011026285,"threshold_uncertainty_score":0.9993503},"labels":[],"label_agreement":null},{"id":"W2010130357","doi":"10.3389/fonc.2014.00386","title":"Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party","year":2015,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Vinorelbine; Oncology; Medicine; Internal medicine; Lung cancer; Cisplatin; Survival analysis; Chemotherapy","score_opus":0.018458141163870966,"score_gpt":0.33142481333797436,"score_spread":0.3129666721741034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010130357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99213797,0.0002551046,0.00111875,0.00077263097,0.00016632173,0.005349361,0.00012981468,0.000010537984,0.000059493115],"genre_scores_gemma":[0.99258566,0.000026002977,0.006438957,0.000134385,0.000032571115,0.0007202954,0.000040431456,0.000015476759,0.00000622259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986944,0.00039501803,0.00028169926,0.00035254646,0.00012374394,0.00015259988],"domain_scores_gemma":[0.9992827,0.00027188475,0.00013037451,0.000105250205,0.00015279287,0.00005695643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005700564,0.0001343778,0.00043617937,0.00012732623,0.000027992888,0.000005282874,0.000051338513,0.00006992462,0.000001248251],"category_scores_gemma":[0.00033494545,0.00008703479,0.000014115298,0.00031887635,0.000081601844,0.00005385448,0.000030368008,0.000111435045,2.0634241e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028434578,0.0007735428,0.9422793,0.0000085471665,0.00013941099,0.0000072371618,0.022800751,0.00033731095,0.0004703524,0.000009110988,0.0001052194,0.00463464],"study_design_scores_gemma":[0.02157562,0.0072306874,0.96405566,0.00012986429,0.00007674857,1.8040454e-7,0.006187882,0.00011949322,0.00018853114,0.00022760392,0.00013347052,0.000074249525],"about_ca_topic_score_codex":0.00036039326,"about_ca_topic_score_gemma":0.0014529993,"teacher_disagreement_score":0.021776369,"about_ca_system_score_codex":0.0006044878,"about_ca_system_score_gemma":0.00013906366,"threshold_uncertainty_score":0.3549176},"labels":[],"label_agreement":null},{"id":"W2010465480","doi":"10.1097/jto.0b013e31824fe9e6","title":"A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Credit Valley Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; KRAS; Hazard ratio; Internal medicine; Oncology; Chemotherapy; Lung cancer; Confounding; Cancer; Proportional hazards model; Confidence interval; Colorectal cancer","score_opus":0.012510923849754602,"score_gpt":0.37922587982214323,"score_spread":0.3667149559723886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010465480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973711,0.0008407747,0.00007772625,0.0007171247,0.00025492607,0.00038269488,0.00009732737,0.0000025987422,0.00025573635],"genre_scores_gemma":[0.99855065,0.000036676505,0.0009801369,0.00025496757,0.00008809308,0.000031005937,0.000006369105,0.000014846694,0.00003727593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874574,0.0002469956,0.00051678147,0.00011494199,0.00021696322,0.000158568],"domain_scores_gemma":[0.99722886,0.0014929986,0.0008485923,0.00015680252,0.00017173696,0.000101028534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043682178,0.00014391262,0.0008632175,0.00026898232,0.000037176145,0.0000035944854,0.00008146237,0.000079152334,0.000117062904],"category_scores_gemma":[0.00013906613,0.00008719379,0.00022203554,0.00049095356,0.00008499015,0.000068091635,0.000014192522,0.00022492601,3.5608653e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042695757,0.0009258257,0.9465492,0.0001477504,0.003462262,0.00003075104,0.007704873,0.005357081,0.021414764,0.00000328587,0.000036463964,0.010098206],"study_design_scores_gemma":[0.0058635334,0.0015140993,0.9048815,0.000325293,0.010115667,0.0000041932162,0.0008923549,0.0014760015,0.07479065,0.000017848077,0.00003390036,0.000084981024],"about_ca_topic_score_codex":0.00039068077,"about_ca_topic_score_gemma":0.0005259331,"teacher_disagreement_score":0.05337589,"about_ca_system_score_codex":0.0003930013,"about_ca_system_score_gemma":0.0004190122,"threshold_uncertainty_score":0.35556597},"labels":[],"label_agreement":null},{"id":"W2010596261","doi":"10.1002/cncr.11319","title":"Weekly paclitaxel and gemcitabine chemotherapy for metastatic non‐small cell lung carcinoma (NSCLC)","year":2003,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Montreal General Hospital; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"","keywords":"Gemcitabine; Medicine; Chemotherapy; Paclitaxel; Internal medicine; Lung cancer; Stage (stratigraphy); Carcinoma; Antimetabolite; Progressive disease; Toxicity; Gastroenterology; Oncology; Surgery","score_opus":0.018397693851931057,"score_gpt":0.31703637790143147,"score_spread":0.2986386840495004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010596261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664004,0.015461685,0.003880571,0.0021741958,0.00031654252,0.0017868073,0.00011945173,0.000037686037,0.009822703],"genre_scores_gemma":[0.9775613,0.0003603092,0.0062320996,0.0015089731,0.00010900536,0.0006095529,0.00002840336,0.00004392024,0.013546419],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992775,0.000012044245,0.00014842625,0.00024756216,0.00007903753,0.00023544616],"domain_scores_gemma":[0.99949694,0.000047609014,0.000054228713,0.00017532147,0.00009108677,0.00013483172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006499968,0.00014900163,0.00024327764,0.000049093574,0.00007982366,0.000016712047,0.00002924152,0.000035060584,0.00018468172],"category_scores_gemma":[0.000015343367,0.000117914366,0.000071767434,0.00009430013,0.000035976394,0.00004593406,0.000004741506,0.00005595334,0.0000035720982],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00179754,0.0026282838,0.6001239,0.0069643683,0.004691442,0.00018851893,0.021035915,0.00011154179,0.07450529,0.0069244727,0.16553399,0.11549475],"study_design_scores_gemma":[0.09472319,0.003017943,0.29564282,0.00070491154,0.008825358,0.0001294673,0.003842132,0.0025258465,0.098728485,0.0020578948,0.48811835,0.0016835765],"about_ca_topic_score_codex":0.000120473815,"about_ca_topic_score_gemma":0.000032511678,"teacher_disagreement_score":0.32258436,"about_ca_system_score_codex":0.00015716047,"about_ca_system_score_gemma":0.00027725197,"threshold_uncertainty_score":0.48084083},"labels":[],"label_agreement":null},{"id":"W2010840029","doi":"10.1097/jto.0b013e318220cb8e","title":"A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Oncology; Internal medicine; Randomized controlled trial; MEDLINE; non-small cell lung cancer (NSCLC); Pathology","score_opus":0.1074515341946355,"score_gpt":0.4733191048693627,"score_spread":0.3658675706747272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010840029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021642781,0.9918212,0.0000015299328,0.0036551799,0.0001871008,0.0033383274,0.00014906164,9.011298e-7,0.00063022214],"genre_scores_gemma":[0.00014030907,0.99847823,0.00040411705,0.00047107862,0.000032036,0.0002462774,0.000013113398,0.000016405169,0.00019842455],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976128,0.00078992674,0.0012307912,0.0001164084,0.00009809935,0.00015197859],"domain_scores_gemma":[0.99617136,0.0012989442,0.0019117031,0.00031277857,0.00019483444,0.000110400804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006401689,0.00021408056,0.0022787652,0.000342618,0.000046833193,0.000006638247,0.00013471708,0.00013666142,0.00006488068],"category_scores_gemma":[0.00013092482,0.000090369955,0.00035852563,0.00027968638,0.00008156058,0.000017688651,0.000007062318,0.00020658363,0.000001140564],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084232895,0.0010532343,0.00009502814,0.61883163,0.006768635,0.00024425532,0.0027150367,8.8572415e-7,4.2168463e-7,0.000034590394,0.009276576,0.36089545],"study_design_scores_gemma":[0.00045530693,0.0017883867,0.000045118974,0.34723058,0.05823923,0.0006687132,0.00036364837,0.0000038248436,0.0000012917255,0.0000033846661,0.591106,0.0000945274],"about_ca_topic_score_codex":0.008921047,"about_ca_topic_score_gemma":0.0134612825,"teacher_disagreement_score":0.5818294,"about_ca_system_score_codex":0.0011271264,"about_ca_system_score_gemma":0.0029826318,"threshold_uncertainty_score":0.99767864},"labels":[],"label_agreement":null},{"id":"W2011193838","doi":"10.1097/01.jto.0000284100.58945.65","title":"P3-125: Similar characteristics of responders treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) Gefitinib and Erlotinib for advanced non small cell lung cancer (NSCLC) in a single Canadian institution.","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Epidermal growth factor receptor; Internal medicine; Oncology; Lung cancer; Progressive disease; Erlotinib Hydrochloride; Tyrosine-kinase inhibitor; Performance status; Cancer; Disease","score_opus":0.018077672776778027,"score_gpt":0.3596085842959359,"score_spread":0.3415309115191579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011193838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177283,0.0008455711,0.00039688812,0.0052011637,0.00034039843,0.00088597235,0.00016603086,0.000006350769,0.00038479004],"genre_scores_gemma":[0.99535906,0.00016298982,0.0033859105,0.00056581566,0.00022942814,0.000028723096,0.000027728205,0.000027123475,0.00021319359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859685,0.00007681082,0.0006324816,0.0001799693,0.00015285012,0.00036104914],"domain_scores_gemma":[0.99810004,0.00030948408,0.00067024835,0.00011676712,0.00050892425,0.0002945557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045010843,0.00019430774,0.0005589995,0.00041063246,0.00011931678,0.00001271249,0.00008345743,0.00015876936,0.000027848366],"category_scores_gemma":[0.0001632065,0.00012644961,0.000086037915,0.0003056325,0.00015716387,0.0001319501,0.000012401648,0.00028530866,3.1749963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049429398,0.0030179133,0.4882808,0.0016052735,0.0012673137,0.0017087959,0.014634362,0.00026970005,0.18211892,0.00011508264,0.0035350313,0.2540174],"study_design_scores_gemma":[0.029356893,0.021625677,0.71692616,0.003367869,0.0040411633,0.0007141486,0.008041114,0.00030352053,0.16226247,0.0000345562,0.052419268,0.00090716995],"about_ca_topic_score_codex":0.0032870113,"about_ca_topic_score_gemma":0.021327807,"teacher_disagreement_score":0.25311023,"about_ca_system_score_codex":0.0013572464,"about_ca_system_score_gemma":0.0019328169,"threshold_uncertainty_score":0.9965304},"labels":[],"label_agreement":null},{"id":"W2012503365","doi":"10.1016/j.cllc.2011.11.010","title":"Delay Between the Initial Symptoms, the Diagnosis and the Onset of Specific Treatment in Elderly Patients With Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Medicine; Lung cancer; Cancer; Lung; Internal medicine; Surgery; Pediatrics","score_opus":0.0431387002219345,"score_gpt":0.421283475776395,"score_spread":0.3781447755544605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012503365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97400427,0.017140372,0.000008570565,0.0055527934,0.00041881084,0.002142666,0.0002466381,0.0000117574455,0.00047412846],"genre_scores_gemma":[0.99205077,0.004707104,0.000020408132,0.000709003,0.0006621883,0.0016461103,0.000036789505,0.000024876488,0.00014273674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843943,0.00023404561,0.0005130881,0.00023928878,0.00026598907,0.00030814015],"domain_scores_gemma":[0.99744207,0.0017307426,0.00021136743,0.00039268704,0.00009878975,0.00012437199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037637036,0.0001961314,0.00046110438,0.000032033033,0.00016190483,0.000019693554,0.00012311718,0.00008920436,0.00017799556],"category_scores_gemma":[0.000053232747,0.00007263411,0.00012813449,0.0002029599,0.0005769219,0.00008175128,0.000040303086,0.0002501072,0.0000018514147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005735347,0.00033845686,0.94983464,0.000022919341,0.00092618546,0.0000019797785,0.0014331914,0.000008972368,6.938596e-8,0.0000723011,0.002333269,0.044454448],"study_design_scores_gemma":[0.009213221,0.00043297635,0.978911,0.00023438872,0.0021449192,0.0000013837042,0.00010398737,0.000029522578,0.0000148498075,0.0000180276,0.008798534,0.00009719656],"about_ca_topic_score_codex":0.0017168333,"about_ca_topic_score_gemma":0.0009262611,"teacher_disagreement_score":0.04435725,"about_ca_system_score_codex":0.00029729347,"about_ca_system_score_gemma":0.00026437733,"threshold_uncertainty_score":0.2961933},"labels":[],"label_agreement":null},{"id":"W2012620812","doi":"10.1002/cyto.a.20101","title":"Nuclear morphometry as a biomarker for bronchial intraepithelial neoplasia: Correlation with genetic damage and cancer development","year":2004,"lang":"en","type":"article","venue":"Cytometry Part A","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Histopathology; Biomarker; Pathology; Intraepithelial neoplasia; Cancer; Loss of heterozygosity; Biology; Surrogate endpoint; Medicine; Allele; Internal medicine; Prostate cancer; Genetics; Gene","score_opus":0.013513375222547657,"score_gpt":0.3024415267820203,"score_spread":0.28892815155947266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012620812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394363,0.00049786665,0.0033536134,0.00054876186,0.00025253434,0.00075660594,0.000032866632,0.000054416672,0.00055967725],"genre_scores_gemma":[0.98487014,0.00007304011,0.013599356,0.00045358363,0.00016512444,0.00017311823,0.000065719556,0.000039157156,0.0005607473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991523,0.0000073643055,0.00017630006,0.00026868543,0.00017795488,0.00021738153],"domain_scores_gemma":[0.999565,0.000025851195,0.000049456634,0.00012949624,0.00007388404,0.00015629086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047666188,0.00015275806,0.0001996363,0.00020711383,0.00016438098,0.000032067,0.000034139353,0.00007521384,0.00017001723],"category_scores_gemma":[0.000024896433,0.00011757595,0.000033501212,0.00036874498,0.00007149213,0.00007418082,0.000018428562,0.00007320806,0.000032050193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006652198,0.0020793534,0.6462244,0.0009781971,0.004593828,0.00045020026,0.011069647,0.0006162777,0.016229123,0.0010526113,0.008796637,0.30125755],"study_design_scores_gemma":[0.015699651,0.0011978343,0.8880117,0.00037392977,0.0009054872,0.00029340762,0.00046033843,0.00037417913,0.0030874598,0.00008482479,0.08913041,0.0003807839],"about_ca_topic_score_codex":0.000082569844,"about_ca_topic_score_gemma":0.00003780825,"teacher_disagreement_score":0.30087677,"about_ca_system_score_codex":0.00027290615,"about_ca_system_score_gemma":0.00041485624,"threshold_uncertainty_score":0.47946084},"labels":[],"label_agreement":null},{"id":"W2013357857","doi":"10.1097/jto.0b013e318274a83e","title":"Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; BC Cancer Agency; Toronto General Hospital; University Health Network; University of British Columbia","funders":"","keywords":"Medicine; Immunohistochemistry; Antibody; Pathology; Identification (biology); Lung; Carcinoma; Cancer research; Immunology; Internal medicine; Biology","score_opus":0.020855329640578263,"score_gpt":0.42071270338615807,"score_spread":0.39985737374557984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013357857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909505,0.0038904073,0.002959847,0.0008835481,0.0002050028,0.00042666993,0.000014296255,0.000002295046,0.0006674013],"genre_scores_gemma":[0.9897503,0.0001875105,0.008551536,0.00014783522,0.00012601721,0.000023565424,0.0000128512975,0.000012109767,0.0011882522],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99898183,0.000019523688,0.0005729687,0.000106874875,0.00014223701,0.00017653998],"domain_scores_gemma":[0.9989547,0.000046685025,0.0005616212,0.00014261852,0.00021795541,0.00007637986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060138496,0.000090278,0.0003323024,0.00013556879,0.000043165397,0.0000076123783,0.000060438095,0.00009803952,0.000038684084],"category_scores_gemma":[0.000028551449,0.00007734833,0.000085620355,0.000083147,0.000027652053,0.00011504775,0.000023883755,0.0001348112,8.780026e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014391433,0.00095961493,0.3543754,0.00091073435,0.00032456647,0.000036951868,0.0052475645,0.0000121630555,0.6114092,0.0000052673704,0.0024903913,0.022789016],"study_design_scores_gemma":[0.008272803,0.0017528654,0.57495874,0.00065672083,0.0034734136,0.0007370162,0.00393752,0.0009000153,0.39780566,0.00006786938,0.0071723466,0.0002650277],"about_ca_topic_score_codex":0.00005194804,"about_ca_topic_score_gemma":0.0000012774808,"teacher_disagreement_score":0.22058335,"about_ca_system_score_codex":0.00033738377,"about_ca_system_score_gemma":0.0001959324,"threshold_uncertainty_score":0.31541735},"labels":[],"label_agreement":null},{"id":"W2013456934","doi":"10.3747/co.19.862","title":"EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; University of Calgary; BC Cancer Agency; Jewish General Hospital; University Health Network","funders":"","keywords":"Gefitinib; Erlotinib; Exon; Lung cancer; Medicine; Concordance; Mutation; Epidermal growth factor receptor; Tyrosine kinase; Cancer research; Oncology; Cancer; Internal medicine; Gene; Biology; Genetics; Receptor","score_opus":0.10068751439099467,"score_gpt":0.45132136549733787,"score_spread":0.3506338511063432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013456934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812296,0.013321601,0.00011636654,0.00062270765,0.00071955274,0.00082425267,0.00001675088,0.000011784875,0.003137359],"genre_scores_gemma":[0.9978012,0.00057275104,0.00059829786,0.00007415636,0.00032230472,0.0004236913,0.00006166637,0.000010084007,0.00013586595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932224,0.000048890586,0.00020917632,0.000117395306,0.00008475725,0.00021757191],"domain_scores_gemma":[0.9994611,0.00015749576,0.00011139772,0.00013462115,0.000075570875,0.000059798207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009184785,0.0001057897,0.00021203555,0.00007677758,0.0000423446,0.000003319969,0.000039440496,0.000045659228,0.000044396136],"category_scores_gemma":[0.000022314247,0.00005918983,0.00004709332,0.0002151341,0.000036125566,0.00004142308,0.000006704972,0.0000668222,0.0000062872728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053915846,0.0052201566,0.7136134,0.00015888923,0.000056197972,0.000019691424,0.011932256,0.00004630765,0.0011327215,0.00004172634,0.00048669212,0.26723808],"study_design_scores_gemma":[0.0121012535,0.0030609905,0.8966602,0.0002925888,0.0018491582,0.000053169093,0.0020725399,0.0020745692,0.004315413,0.000022903598,0.07730406,0.00019313705],"about_ca_topic_score_codex":0.0003587781,"about_ca_topic_score_gemma":0.00010630786,"teacher_disagreement_score":0.26704493,"about_ca_system_score_codex":0.00067806087,"about_ca_system_score_gemma":0.00025620827,"threshold_uncertainty_score":0.24136913},"labels":[],"label_agreement":null},{"id":"W2013601613","doi":"10.1371/journal.pone.0121211","title":"Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review","year":2015,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Eli Lilly Japan; Pfizer; Chugai Pharmaceutical; Taiho Pharmaceutical; AstraZeneca; Eli Lilly and Company","keywords":"Surrogate endpoint; Lung cancer; Medicine; Oncology; Clinical trial; Internal medicine; Intensive care medicine; Bioinformatics; Biology","score_opus":0.05132807077938279,"score_gpt":0.3827981638476881,"score_spread":0.3314700930683053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013601613","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05976035,0.92139083,0.0000056641597,0.000022941194,0.00008526337,0.018219074,0.0004109717,0.0000152028715,0.000089686044],"genre_scores_gemma":[0.007517648,0.9871998,0.0012141508,0.000028872402,0.000025277337,0.0029221862,0.00082550454,0.00011637178,0.00015020609],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99467415,0.0010289837,0.0022711034,0.0004782647,0.0011954334,0.00035204136],"domain_scores_gemma":[0.99490845,0.00019497715,0.0027598946,0.00083146273,0.0011667226,0.00013847784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011359109,0.0005212935,0.0059371633,0.00028324756,0.00003595594,0.000021643866,0.00036926626,0.00018641411,0.000044025037],"category_scores_gemma":[0.0012050148,0.0002952672,0.000341493,0.0013948932,0.00004411045,0.00011356933,0.000110387795,0.00036309063,0.0000013992958],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024310198,0.007164614,0.0036733705,0.97694635,0.0027575125,0.000052228184,0.00012311005,0.000005232751,0.00005408389,5.4408645e-7,0.000014868322,0.008964996],"study_design_scores_gemma":[0.013983523,0.0004618019,0.0010393696,0.9467,0.037309036,0.0000021766698,0.000018123008,0.000057596146,0.000104898354,0.000002625846,0.000034616005,0.0002862447],"about_ca_topic_score_codex":0.00020451163,"about_ca_topic_score_gemma":0.000095479205,"teacher_disagreement_score":0.06580894,"about_ca_system_score_codex":0.00059806457,"about_ca_system_score_gemma":0.002063437,"threshold_uncertainty_score":0.99994993},"labels":[],"label_agreement":null},{"id":"W2013678573","doi":"10.3389/fonc.2014.00213","title":"Maintenance Therapies for Non-Small Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Lung cancer; Maintenance therapy; Internal medicine; Toxicity; Intensive care medicine; Randomized controlled trial; Cancer; Targeted therapy; Chemotherapy","score_opus":0.02241255743552119,"score_gpt":0.39423145141561305,"score_spread":0.3718188939800919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013678573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003476032,0.9788819,0.00672753,0.0003645885,0.0034629905,0.0030866226,0.00010243639,0.000025004922,0.0073454683],"genre_scores_gemma":[0.0000062269705,0.96173954,0.019926913,0.00048538268,0.0005056106,0.0040027606,0.0001829292,0.00007366342,0.013076962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985559,0.000070466755,0.00046585,0.00042829878,0.00007108254,0.00040842258],"domain_scores_gemma":[0.99909043,0.00014139948,0.00031044905,0.0002902965,0.00007627598,0.000091158734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016543358,0.00032373998,0.002118793,0.00024264569,0.00005327581,0.000008477615,0.00016129829,0.00044725006,0.000042215335],"category_scores_gemma":[0.00002800064,0.00023294264,0.0003792134,0.00016459229,0.00007683749,0.000020797343,0.000024713696,0.0002884327,0.000006794503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034482557,0.00012239198,0.0004977988,0.01309322,0.00043433992,0.00002249564,0.0003331144,0.0000016160731,9.648961e-8,0.000028597648,0.18056169,0.8048701],"study_design_scores_gemma":[0.002250542,0.0003446849,0.000027814242,0.004185486,0.0031485907,0.000012921205,0.00009096067,0.000087369546,4.530675e-7,0.00006329999,0.9895814,0.00020649174],"about_ca_topic_score_codex":0.00007967491,"about_ca_topic_score_gemma":0.000080553415,"teacher_disagreement_score":0.8090197,"about_ca_system_score_codex":0.0018619936,"about_ca_system_score_gemma":0.0017899842,"threshold_uncertainty_score":0.9499125},"labels":[],"label_agreement":null},{"id":"W2014411355","doi":"10.1080/14926150802177878","title":"A New Era for<i>CJSMTE</i>/Une nouvelle ére pour la<i>RCESMT</i>","year":2008,"lang":"fr","type":"article","venue":"Canadian Journal of Science Mathematics and Technology Education","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy; Political science","score_opus":0.011378226423984951,"score_gpt":0.2921310415602229,"score_spread":0.28075281513623795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014411355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74399084,0.04363986,0.01408842,0.17978606,0.005138226,0.00088496495,0.000038533526,0.000022279532,0.012410803],"genre_scores_gemma":[0.810522,0.0010732474,0.16775678,0.00033411835,0.0005308415,0.000017421817,0.0000029198886,0.00002349514,0.019739171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891824,0.0000063553234,0.00036332832,0.00016918541,0.0001591867,0.00038370932],"domain_scores_gemma":[0.9980418,0.00007764263,0.0002964242,0.00018701288,0.00067975593,0.00071734295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033935238,0.00013710702,0.000262429,0.00089049357,0.00059412426,0.000052207426,0.00023012949,0.00016022522,0.00007624092],"category_scores_gemma":[0.0004064096,0.00012164858,0.00005229962,0.00108739,0.0015101806,0.0002341341,0.000012026481,0.00023162003,0.000012182352],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011779014,0.0006858362,0.012778365,0.000527263,0.00027755674,0.00017764104,0.039785914,0.000014477054,0.0036071062,0.32682493,0.110972114,0.504337],"study_design_scores_gemma":[0.005871431,0.0020156815,0.008624556,0.00528328,0.00219534,0.037329234,0.08602414,0.0014728495,0.007983115,0.31762612,0.5246488,0.0009254955],"about_ca_topic_score_codex":0.0021808464,"about_ca_topic_score_gemma":0.0017105396,"teacher_disagreement_score":0.50341153,"about_ca_system_score_codex":0.0004473588,"about_ca_system_score_gemma":0.036293082,"threshold_uncertainty_score":0.9691702},"labels":[],"label_agreement":null},{"id":"W2014633297","doi":"10.1016/s1470-2045(14)70203-7","title":"VeriStrat validated in patients with non-small-cell lung cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gefitinib; Medicine; Oncology; Internal medicine; Lung cancer; Clinical Oncology; Chemotherapy; Targeted therapy; Tyrosine-kinase inhibitor; Cancer; Epidermal growth factor receptor; Cancer research","score_opus":0.021411344125403336,"score_gpt":0.33752057463548435,"score_spread":0.316109230510081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014633297","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21997982,0.00046137685,0.000053339605,0.7286645,0.000937523,0.0024770147,0.0001920305,0.00008161154,0.047152735],"genre_scores_gemma":[0.083046585,0.00020901936,0.00049570506,0.89880615,0.005213735,0.00081307534,0.002170817,0.00011809856,0.0091268085],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986525,0.0001313797,0.0002378694,0.00033267873,0.00018995164,0.00045557742],"domain_scores_gemma":[0.9990264,0.000102104175,0.0002096291,0.00051146856,0.00010602763,0.000044344775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116387535,0.00026503115,0.0008001273,0.00007939981,0.0000592049,0.000014959076,0.00020637443,0.00043663481,0.00030451568],"category_scores_gemma":[0.000006852967,0.00014980257,0.000056164936,0.00015139427,0.00008842147,0.000021510963,0.00003351109,0.0010919234,0.000036273144],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038207162,0.0001701094,0.119373,0.00035619145,0.00033720644,0.0002533124,0.00042847154,0.000020562886,0.000005562265,0.000002775476,0.8778544,0.00081632845],"study_design_scores_gemma":[0.011612511,0.00086463627,0.07186407,0.00025865444,0.0011920275,0.00001069311,0.000015210839,0.000032950167,0.000018381012,0.000009889293,0.91391325,0.00020773111],"about_ca_topic_score_codex":0.00068009674,"about_ca_topic_score_gemma":0.000267116,"teacher_disagreement_score":0.17014161,"about_ca_system_score_codex":0.0007078972,"about_ca_system_score_gemma":0.00065869454,"threshold_uncertainty_score":0.61087716},"labels":[],"label_agreement":null},{"id":"W2014719020","doi":"10.1097/jto.0b013e3181f77b58","title":"Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Ministry of Health, Labour and Welfare; Ministry of Education, Culture, Sports, Science and Technology; Uehara Memorial Foundation","keywords":"Medicine; Mediastinal lymph node; Lung cancer; Carcinoembryonic antigen; Mediastinoscopy; Adenocarcinoma; Adenosquamous carcinoma; Gemcitabine; Pathology; Radiology; Cancer; Metastasis; Internal medicine","score_opus":0.01937904244433617,"score_gpt":0.41664265429161007,"score_spread":0.3972636118472739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014719020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949859,0.00038534723,0.0018862179,0.00029657813,0.0016337313,0.0005173427,0.000023274117,0.000013267419,0.00025835828],"genre_scores_gemma":[0.98654664,0.00007965185,0.011082084,0.00006616965,0.002084663,0.000036836063,0.000013866441,0.000028939423,0.00006115254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861836,0.00010484906,0.00058004906,0.00019017288,0.00029338658,0.00021320739],"domain_scores_gemma":[0.9986308,0.000052292995,0.0005733751,0.0001722105,0.00037389956,0.00019739823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015299694,0.00019865159,0.0005153662,0.00023163174,0.000111940266,0.000017045479,0.000052541825,0.00020080434,0.00015898312],"category_scores_gemma":[0.000019450856,0.00013420568,0.00016068212,0.00016837995,0.00009193909,0.0002901642,0.0000054064176,0.00023727895,6.505533e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008071309,0.0015500725,0.024060382,0.0000600822,0.0005121522,0.00016064067,0.0028660994,0.00040649148,0.8353621,0.0000029656944,0.000014773004,0.12693296],"study_design_scores_gemma":[0.016416244,0.04483467,0.12165745,0.00026610759,0.00937662,0.011137675,0.0008103069,0.0023514356,0.78771305,0.0000619844,0.004920008,0.00045444042],"about_ca_topic_score_codex":0.00052303285,"about_ca_topic_score_gemma":0.001643636,"teacher_disagreement_score":0.12647852,"about_ca_system_score_codex":0.00089841353,"about_ca_system_score_gemma":0.0010690289,"threshold_uncertainty_score":0.5472749},"labels":[],"label_agreement":null},{"id":"W2015319412","doi":"10.1097/jto.0b013e3181a9a03b","title":"Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Cancer; Targeted therapy; Oncology; Internal medicine","score_opus":0.01405356603031655,"score_gpt":0.43465061647998,"score_spread":0.42059705044966345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015319412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963106,0.00723062,0.00008024368,0.027610218,0.00036218687,0.00034623794,0.0000721222,0.0000073083543,0.0011851015],"genre_scores_gemma":[0.9954595,0.0018971673,0.00091070804,0.0009866249,0.00032769947,0.000010721999,0.000025774576,0.00000829923,0.00037351603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899477,0.00016658856,0.00043128317,0.000088403474,0.00018004616,0.00013893397],"domain_scores_gemma":[0.9988126,0.00020982556,0.00037486598,0.000113071495,0.0004241998,0.00006541076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001639064,0.0000880743,0.00034178558,0.000121432975,0.000042372936,0.0000053882395,0.00010554159,0.000083138766,0.000117181036],"category_scores_gemma":[0.000050234445,0.00005259756,0.00008319464,0.00036639845,0.000045076184,0.00011264489,0.0000074944933,0.0002534301,5.6957515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008063336,0.0037470337,0.56649643,0.000046190955,0.0024844746,0.00047809316,0.026049322,0.0013670722,0.074255556,0.00007528075,0.103833646,0.21310358],"study_design_scores_gemma":[0.0029417526,0.0022501978,0.9766435,0.00016565548,0.0006864162,0.00008094139,0.0012694289,0.00018591573,0.0046604527,0.00022863035,0.010809565,0.00007754636],"about_ca_topic_score_codex":0.0004220806,"about_ca_topic_score_gemma":0.00019255941,"teacher_disagreement_score":0.4101471,"about_ca_system_score_codex":0.0002574078,"about_ca_system_score_gemma":0.0010631459,"threshold_uncertainty_score":0.21448663},"labels":[],"label_agreement":null},{"id":"W2015378165","doi":"10.1097/01.jto.0000283154.03863.ae","title":"B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Regional Municipality of Durham; Ottawa Hospital","funders":"","keywords":"Medicine; Gefitinib; Chemotherapy; Lung cancer; Internal medicine; Oncology; Performance status; Placebo; Randomized controlled trial; Cancer; Epidermal growth factor receptor; Pathology","score_opus":0.021232777513109966,"score_gpt":0.41634247318091366,"score_spread":0.3951096956678037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015378165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913319,0.0021329902,0.0001114049,0.00012860371,0.0006348097,0.0047332775,0.00004126634,0.000009133399,0.0008766479],"genre_scores_gemma":[0.9960344,0.0011457151,0.0021540318,0.00009466882,0.00012794562,0.00019528398,0.00004788887,0.000046100064,0.00015396635],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973652,0.00012135551,0.0011705067,0.0003403669,0.00046698298,0.00053560437],"domain_scores_gemma":[0.99698824,0.00030647934,0.0014532284,0.00020486608,0.0007266511,0.00032055486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000533985,0.00035377764,0.0014673762,0.0004096249,0.00014031949,0.0000147693045,0.00013758152,0.00016402142,0.000043348293],"category_scores_gemma":[0.000039242033,0.0002517375,0.00013252768,0.00027177107,0.00016397613,0.00027601476,0.000059400332,0.0004950299,7.439644e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84991187,0.006290244,0.034369923,0.0003812425,0.0011336551,0.00027944002,0.031216132,0.0012373395,0.000077692945,5.135066e-7,0.0000205564,0.0750814],"study_design_scores_gemma":[0.9296368,0.029597668,0.009757265,0.00060922554,0.0026990592,0.000027367454,0.025835792,0.00052534224,0.0007998277,3.158418e-7,0.0002654146,0.0002459758],"about_ca_topic_score_codex":0.0005113757,"about_ca_topic_score_gemma":0.0016415108,"teacher_disagreement_score":0.07972489,"about_ca_system_score_codex":0.0017285581,"about_ca_system_score_gemma":0.0012163433,"threshold_uncertainty_score":0.9999935},"labels":[],"label_agreement":null},{"id":"W2015395716","doi":"10.1007/s10637-013-0024-y","title":"Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; University of California, Davis; Celgene; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Paclitaxel; Progressive disease; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Cisplatin","score_opus":0.01173629540340306,"score_gpt":0.31101612161331627,"score_spread":0.2992798262099132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015395716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393785,0.00010830779,0.000030855324,0.0018930527,0.0001944268,0.0022833652,0.000106682695,0.000023227107,0.0014222352],"genre_scores_gemma":[0.9925596,0.000009617072,0.003710683,0.0011644827,0.00014382915,0.0005422651,0.0002842053,0.000033382465,0.0015519343],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99852175,0.00002256387,0.00042135984,0.00032345494,0.0004665033,0.00024436842],"domain_scores_gemma":[0.9989093,0.000083494,0.00024491097,0.00021190722,0.00026835775,0.000282027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005029884,0.00021784488,0.00035972358,0.0002104747,0.000078402256,0.00001427651,0.000084069565,0.0000510788,0.00022925035],"category_scores_gemma":[0.0000671923,0.00016985304,0.00007297858,0.00036049503,0.000091807684,0.00018438818,0.000022612301,0.0001304519,0.000015850997],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15456094,0.08407237,0.37571278,0.0035686807,0.0044055087,0.00018993884,0.091647446,0.05145025,0.033849802,0.0038841139,0.0723802,0.124277964],"study_design_scores_gemma":[0.8576228,0.012604273,0.09753645,0.0020517437,0.00072879565,0.0000025259728,0.00064245355,0.001721243,0.023672957,0.001422346,0.001312381,0.0006820297],"about_ca_topic_score_codex":0.002747319,"about_ca_topic_score_gemma":0.00012028539,"teacher_disagreement_score":0.7030619,"about_ca_system_score_codex":0.0005517197,"about_ca_system_score_gemma":0.0021399516,"threshold_uncertainty_score":0.6926406},"labels":[],"label_agreement":null},{"id":"W2015739947","doi":"10.1016/j.lungcan.2013.07.012","title":"Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"National Cancer Institute; Eli Lilly and Company","keywords":"Vinorelbine; Gemcitabine; Medicine; Cisplatin; Oncology; Lung cancer; Internal medicine; Randomized controlled trial; Chemotherapy","score_opus":0.014542369910559483,"score_gpt":0.34099801955339265,"score_spread":0.3264556496428332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015739947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96381366,0.0034281786,0.0043704095,0.00073530216,0.0011756286,0.023343384,0.0022038806,0.0001086698,0.0008208982],"genre_scores_gemma":[0.9646069,0.0008383359,0.0037568107,0.00020063925,0.00069688854,0.016094118,0.001908709,0.00020217126,0.011695443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99401104,0.00017405378,0.0028743052,0.001241513,0.00070028764,0.0009987799],"domain_scores_gemma":[0.99404234,0.0009570157,0.002373141,0.0011852361,0.0009223842,0.0005198766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006351333,0.0010060414,0.005744218,0.0010050408,0.00022820073,0.00007339393,0.00043852726,0.00030646406,0.0037095102],"category_scores_gemma":[0.00015537231,0.00072194485,0.001329411,0.0014068185,0.00035401955,0.0004032539,0.000108994194,0.00033550052,0.000008584655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.924952,0.0010768786,0.00071468524,0.0013178021,0.018187666,0.000018844075,0.002178513,0.043623377,0.0034809709,0.00004696416,0.0029436052,0.0014587527],"study_design_scores_gemma":[0.72970575,0.0023063507,0.00022940108,0.00063246925,0.03402539,0.0000037264763,0.0003354164,0.2301152,0.0018327989,0.0000071126315,0.00020218054,0.00060421746],"about_ca_topic_score_codex":0.017769985,"about_ca_topic_score_gemma":0.009690159,"teacher_disagreement_score":0.1952462,"about_ca_system_score_codex":0.0031000015,"about_ca_system_score_gemma":0.0035759418,"threshold_uncertainty_score":0.99952316},"labels":[],"label_agreement":null},{"id":"W2016081804","doi":"10.1097/jto.0b013e318227816a","title":"Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Epidermal growth factor receptor; Oncology; Lung cancer; Internal medicine; T790M; Targeted therapy; Tyrosine-kinase inhibitor; Cancer; Gefitinib","score_opus":0.08567214479608881,"score_gpt":0.46499578844738887,"score_spread":0.37932364365130006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016081804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632085,0.000076253375,0.006183679,0.0005467235,0.000096923424,0.006279821,0.000053967826,0.000005417238,0.0004363585],"genre_scores_gemma":[0.92807025,0.0000141374885,0.07048291,0.00016755534,0.00006167846,0.0011565272,0.0000158257,0.000014509806,0.000016633272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783003,0.000350538,0.0012279085,0.0002280047,0.00016445386,0.00019907186],"domain_scores_gemma":[0.9971292,0.0006666654,0.0011766192,0.0001601211,0.00070203247,0.0001653742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009617759,0.00014485676,0.00094818196,0.00022297124,0.00006722141,0.000008554554,0.00013189873,0.00017111687,0.000021671125],"category_scores_gemma":[0.00060825725,0.00007997969,0.0002625101,0.0004862723,0.00024360478,0.000065247936,0.000033019907,0.00038328007,1.8121023e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002269805,0.0027479094,0.95222706,0.0001189545,0.0013235129,0.000036222602,0.0012167506,0.00003540231,0.000034470264,0.000009205969,0.000027528951,0.039953172],"study_design_scores_gemma":[0.0051102927,0.005867889,0.9811099,0.00013364959,0.005675821,0.000013393563,0.0005760415,0.0012973773,0.00005078898,0.000028131091,0.00005151141,0.0000851954],"about_ca_topic_score_codex":0.00003323827,"about_ca_topic_score_gemma":0.000028067185,"teacher_disagreement_score":0.06429923,"about_ca_system_score_codex":0.000099420846,"about_ca_system_score_gemma":0.0006076566,"threshold_uncertainty_score":0.3261477},"labels":[],"label_agreement":null},{"id":"W2016112560","doi":"10.3111/13696998.2014.1003644","title":"Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Anaplastic lymphoma kinase; Internal medicine; Medical diagnosis; Oncology; ALK inhibitor; Brain metastasis; Ceritinib; Cancer; Metastasis; Radiology","score_opus":0.018142104251795008,"score_gpt":0.33406712434552266,"score_spread":0.31592502009372764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016112560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992826,0.000574865,0.000051250307,0.005574908,0.00040221345,0.00029658285,0.0000655646,0.0000038709904,0.000204767],"genre_scores_gemma":[0.99592716,0.0021772562,0.00039321525,0.0007776463,0.00055187504,0.000013832445,0.000027649296,0.000023467077,0.00010789609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866563,0.000052530177,0.00074426446,0.00019148158,0.00015523718,0.00019085048],"domain_scores_gemma":[0.9985475,0.0001670647,0.00038226112,0.0001351686,0.00006280092,0.00070519804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052987464,0.00016139717,0.000616795,0.0001191054,0.00002066064,0.00002558808,0.00009926304,0.000115262046,0.000106885025],"category_scores_gemma":[0.00004730593,0.000107663654,0.00009783995,0.000025185513,0.000062756066,0.00011484141,0.000030440755,0.00021275508,0.0000037490847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003998786,0.00045553807,0.96685743,0.000027863503,0.0005515439,0.00007463369,0.00043466245,0.00031929964,7.785035e-8,0.000013390001,0.001305964,0.029559726],"study_design_scores_gemma":[0.072583996,0.006961822,0.8871367,0.0006170149,0.0017173572,0.00012229853,0.0007531381,0.004795046,0.000026837115,0.000036424597,0.02492338,0.00032598944],"about_ca_topic_score_codex":0.0012124159,"about_ca_topic_score_gemma":0.0011373623,"teacher_disagreement_score":0.07972073,"about_ca_system_score_codex":0.0008806575,"about_ca_system_score_gemma":0.0018904188,"threshold_uncertainty_score":0.43903962},"labels":[],"label_agreement":null},{"id":"W2016852257","doi":"10.3747/co.v18i3.877","title":"Managing Treatment-Related Adverse Events Associated with egfr Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Rash; Lung cancer; Epidermal growth factor receptor; Erlotinib; Adverse effect; Tyrosine kinase; EGFR inhibitors; Cancer; Tyrosine-kinase inhibitor; Afatinib; Oncology; Diarrhea; Internal medicine; Receptor","score_opus":0.04002080926772303,"score_gpt":0.37226841258662136,"score_spread":0.33224760331889835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016852257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859896,0.0033928356,0.000039437997,0.00025967028,0.0010514811,0.0013553298,0.000032336222,0.00007629607,0.0078030387],"genre_scores_gemma":[0.9964962,0.0009406355,0.0002493451,0.000063176085,0.00005556866,0.0005419314,0.00021555935,0.000042834472,0.0013947441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985978,0.00006364943,0.00036281938,0.00041110473,0.00012922578,0.00043541836],"domain_scores_gemma":[0.9992337,0.00004064944,0.0002285704,0.00021255921,0.000107998094,0.00017650254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000734193,0.0002765909,0.0004619477,0.00023041121,0.000080308215,0.0000023082116,0.00006905097,0.00012914765,0.00021341734],"category_scores_gemma":[0.000016639679,0.00021188849,0.000092253205,0.0004201023,0.000056167886,0.00010271409,0.000029844441,0.00021118582,0.00001988307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005172587,0.004925653,0.91839534,0.000100940364,0.0004938932,0.00036645276,0.0058174143,0.00015464799,0.00035299954,0.000021499498,0.00022926749,0.06862465],"study_design_scores_gemma":[0.07802353,0.005612208,0.8906396,0.0028490096,0.00436473,0.000032903517,0.0021909967,0.0025125442,0.0038778754,0.0001167633,0.008933088,0.00084671885],"about_ca_topic_score_codex":0.0005193369,"about_ca_topic_score_gemma":0.0011105954,"teacher_disagreement_score":0.077506274,"about_ca_system_score_codex":0.0026847413,"about_ca_system_score_gemma":0.00059557706,"threshold_uncertainty_score":0.86405617},"labels":[],"label_agreement":null},{"id":"W2017028093","doi":"10.1371/journal.pmed.1000315","title":"Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma","year":2010,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; University of British Columbia; Vancouver General Hospital; Canadian Centre for Applied Research in Cancer Control; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; Michael Smith Health Research BC; Natural Sciences and Engineering Research Council of Canada; U.S. Department of Defense","keywords":"Biology; Cancer research; Gene knockdown; Lung cancer; Adenocarcinoma; RNA interference; Ectopic expression; Cancer; Gene; RNA; Genetics; Pathology; Medicine","score_opus":0.04680042115390062,"score_gpt":0.3802007256445857,"score_spread":0.33340030449068503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017028093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97480315,0.0027392989,0.00019411813,0.0014104076,0.0005586745,0.0008189507,0.00002941168,0.00006175097,0.01938421],"genre_scores_gemma":[0.99292964,0.000109713226,0.00094715756,0.00058536767,0.0008569916,0.00010300764,0.00020603846,0.00005177699,0.004210326],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99816275,0.000033112403,0.0005439661,0.00049436657,0.00041246373,0.00035333185],"domain_scores_gemma":[0.9986038,0.00022028708,0.00016434191,0.00050024036,0.00022253269,0.0002887899],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016673931,0.0003126249,0.00063423155,0.00045766373,0.0000874345,0.000017035,0.00015717442,0.00013889765,0.0013013912],"category_scores_gemma":[0.00023815804,0.00021356586,0.00010800333,0.00052632164,0.0001827109,0.000091871145,0.000043693384,0.00058271893,0.00011726519],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019458741,0.0011493337,0.064631,0.000135006,0.00014246971,0.00039813897,0.0059492243,0.000008967103,0.9234556,0.00010216511,0.0032163754,0.00061715173],"study_design_scores_gemma":[0.03621536,0.0027994015,0.5810663,0.00073196203,0.0039256345,0.00039606527,0.008156583,0.002766799,0.34839523,0.00014925597,0.014492185,0.0009052244],"about_ca_topic_score_codex":0.0016773775,"about_ca_topic_score_gemma":0.0007692195,"teacher_disagreement_score":0.57506037,"about_ca_system_score_codex":0.00031327584,"about_ca_system_score_gemma":0.00031894303,"threshold_uncertainty_score":0.99961156},"labels":[],"label_agreement":null},{"id":"W2017192126","doi":"10.2147/lctt.s5909","title":"Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer","year":2010,"lang":"en","type":"review","venue":"Lung Cancer Targets and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Maintenance therapy; Intensive care medicine; Oncology; Internal medicine; Chemotherapy","score_opus":0.02265153622851954,"score_gpt":0.37220063618721083,"score_spread":0.34954909995869127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017192126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016154413,0.98713505,0.00012540606,0.0012660681,0.0012883403,0.0076280534,0.0003167867,0.000053565218,0.00057127385],"genre_scores_gemma":[0.0006375065,0.9840621,0.0004356668,0.0012999296,0.00086967635,0.010355896,0.0001485551,0.00019620388,0.0019944645],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732476,0.00007019275,0.00070609414,0.0008771858,0.00022880039,0.0007929824],"domain_scores_gemma":[0.99829847,0.00026878947,0.00052143895,0.0006059715,0.00012154994,0.00018376645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028076814,0.00078677956,0.0017572033,0.00016438535,0.00034352293,0.00009130022,0.00030789763,0.00038219252,0.00015088628],"category_scores_gemma":[0.000011454929,0.00044444212,0.00049840356,0.0003696183,0.00011249044,0.000115578616,0.00003455361,0.0007912936,0.000001355709],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019908437,0.00016570602,0.001778542,0.0040863324,0.00085225224,0.00001450127,0.0012176253,0.000010243053,0.000018207265,0.00014986996,0.0010872423,0.9904204],"study_design_scores_gemma":[0.0059343283,0.00022216159,0.0005141819,0.007213033,0.0008762984,0.000011031195,0.000047012425,0.00023828183,0.000028467726,0.00008808086,0.9842856,0.00054154015],"about_ca_topic_score_codex":0.001020939,"about_ca_topic_score_gemma":0.0006304656,"teacher_disagreement_score":0.98987883,"about_ca_system_score_codex":0.0004411638,"about_ca_system_score_gemma":0.0012696182,"threshold_uncertainty_score":0.99980074},"labels":[],"label_agreement":null},{"id":"W2017377922","doi":"10.1016/s1556-0864(15)31635-x","title":"A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Lung cancer; Internal medicine; Paclitaxel; Chemotherapy; Oncology; Cancer; Gastroenterology; Pharmacokinetics; Cisplatin","score_opus":0.012420980461030769,"score_gpt":0.416144619225652,"score_spread":0.4037236387646212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017377922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701625,0.0006423416,0.000121619305,0.00083810237,0.000059182803,0.0007908054,0.000008512617,0.0000023227344,0.00052086],"genre_scores_gemma":[0.9974606,0.00007719934,0.0022352657,0.000079449725,0.00002563614,0.000038076516,0.00002256221,0.000014139739,0.00004709009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989721,0.00007658948,0.0004092657,0.00012113237,0.00029522364,0.0001256623],"domain_scores_gemma":[0.9987781,0.000058639744,0.00053187046,0.0000754533,0.0005073228,0.000048613958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037384123,0.00011090533,0.00038838715,0.00024379943,0.000020854033,0.00000449641,0.000031579715,0.00006992149,0.000030459454],"category_scores_gemma":[0.000023563876,0.00007612064,0.000024384635,0.0002354623,0.000039651113,0.00011375569,0.0000052643613,0.00014914776,1.4268753e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010567054,0.0071252175,0.8102529,0.00016780104,0.00013653515,0.000049738817,0.0019133331,0.004373184,0.00060302013,0.0000059407016,0.000044717333,0.16476053],"study_design_scores_gemma":[0.09015505,0.018838497,0.8817428,0.0007143983,0.0010018011,0.000028924453,0.00038836064,0.0045418185,0.0020855726,0.00015534642,0.00021282774,0.0001346422],"about_ca_topic_score_codex":0.00045222588,"about_ca_topic_score_gemma":0.0020928106,"teacher_disagreement_score":0.1646259,"about_ca_system_score_codex":0.000724463,"about_ca_system_score_gemma":0.0006846552,"threshold_uncertainty_score":0.31041098},"labels":[],"label_agreement":null},{"id":"W2018449419","doi":"10.1016/j.ypmed.2007.06.020","title":"Environment and cancer—How can the ecological study help us?","year":2007,"lang":"en","type":"editorial","venue":"Preventive Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Adenosquamous carcinoma; Adenocarcinoma; Internal medicine; Epidermal growth factor receptor; Oncology; Lung cancer; Disease; Cancer; Histology; Stage (stratigraphy); Carcinoma; Pathology","score_opus":0.01638117315066745,"score_gpt":0.35080808417170023,"score_spread":0.3344269110210328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018449419","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.096013345,0.02208645,0.00013531955,0.018119358,0.8487854,0.010036112,0.0005084186,0.00012517032,0.0041904016],"genre_scores_gemma":[0.17410974,0.00658348,0.00006319955,0.0005705542,0.7781043,0.0012059014,0.0006961929,0.00008676004,0.038579866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973887,0.00015901616,0.00034530435,0.0006206535,0.0011212655,0.00036503602],"domain_scores_gemma":[0.9982399,0.00070759427,0.00025591068,0.00041854923,0.00015102499,0.00022701747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069776794,0.00041028502,0.00078980887,0.00011773096,0.00021216963,0.000019233783,0.00015053019,0.00027911915,0.0005396275],"category_scores_gemma":[0.0004292115,0.00021080588,0.00008942925,0.0001312862,0.00041858514,0.000027787095,0.00012799284,0.0008366385,0.000007686151],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001490138,0.0008592415,0.018416336,0.00012579751,0.0016655417,0.0002422045,0.0037606454,9.704459e-7,0.000015200282,0.000007657432,0.9599189,0.014838499],"study_design_scores_gemma":[0.005328438,0.0031438556,0.10197525,0.00039791985,0.0048699807,0.000008759524,0.0032898923,0.000002667496,0.000010044559,0.00005566309,0.8807104,0.00020713011],"about_ca_topic_score_codex":0.0016554878,"about_ca_topic_score_gemma":0.0007534928,"teacher_disagreement_score":0.08355891,"about_ca_system_score_codex":0.00064420805,"about_ca_system_score_gemma":0.00031593576,"threshold_uncertainty_score":0.85964143},"labels":[],"label_agreement":null},{"id":"W2018660330","doi":"10.1016/j.jval.2014.08.2321","title":"The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Canadian Centre for Applied Research in Cancer Control; St. Michael's Hospital","funders":"","keywords":"Crizotinib; Docetaxel; Medicine; Pemetrexed; Lung cancer; Oncology; Internal medicine; Cost effectiveness; Chemotherapy; Cisplatin","score_opus":0.02990311617713927,"score_gpt":0.373961673780633,"score_spread":0.34405855760349374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018660330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882808,0.0036316328,0.0002355756,0.0011490115,0.00040050893,0.0025971974,0.0000351143,0.000018047263,0.0036521116],"genre_scores_gemma":[0.9976267,0.0007380092,0.00038553588,0.00027502037,0.000066403336,0.00047617266,0.000019864738,0.00002483346,0.00038741456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854296,0.0003370138,0.0004140479,0.00023988081,0.00014261433,0.00032348072],"domain_scores_gemma":[0.9987393,0.000627472,0.0001635593,0.0002836036,0.00007902412,0.00010705509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010242874,0.00012789978,0.00038046064,0.00010265033,0.00007654506,0.0000059591744,0.00007918177,0.000054662036,0.00002772872],"category_scores_gemma":[0.000087939494,0.00009119117,0.00004953532,0.00028769177,0.000038043574,0.000038129205,0.000016901715,0.00020586152,0.0000023838486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030375693,0.001959578,0.75025785,0.0145807015,0.00022810992,0.00003721232,0.012180586,0.056881588,0.01067888,0.0016347785,0.00069986354,0.1478233],"study_design_scores_gemma":[0.022308797,0.0017161984,0.92301184,0.0049097645,0.0001173269,0.000007912979,0.0008253104,0.0210882,0.0093749445,0.00041481556,0.015911335,0.00031354843],"about_ca_topic_score_codex":0.008582105,"about_ca_topic_score_gemma":0.0033257308,"teacher_disagreement_score":0.172754,"about_ca_system_score_codex":0.00052955025,"about_ca_system_score_gemma":0.0006963439,"threshold_uncertainty_score":0.9980198},"labels":[],"label_agreement":null},{"id":"W2018738320","doi":"10.3747/co.19.1068","title":"Personalized Choice of Maintenance Therapies in Non-Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Context (archaeology); Lung cancer; Maintenance therapy; Intensive care medicine; Clinical trial; Personalized medicine; Cancer; Oncology; Chemotherapy; Bioinformatics; Internal medicine","score_opus":0.07075192905857029,"score_gpt":0.4458252665029909,"score_spread":0.3750733374444206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018738320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529697,0.038637172,0.00014055404,0.00087602244,0.001042352,0.00049788976,0.000017427483,0.000012651759,0.0058062808],"genre_scores_gemma":[0.9960552,0.0018668271,0.0003098393,0.0001616209,0.00023690781,0.00023307928,0.00001766724,0.0000121636385,0.0011067191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932635,0.000033383232,0.00018163526,0.0001222055,0.00007635233,0.00026006476],"domain_scores_gemma":[0.9995668,0.000071883675,0.00009658553,0.00011069328,0.0000736981,0.000080324106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008668976,0.00009701798,0.0002777897,0.000074791176,0.000021586253,0.0000016984382,0.000048611204,0.000056237124,0.00028404634],"category_scores_gemma":[0.00001930539,0.0000731158,0.000060589977,0.00012588144,0.00006973415,0.00004636067,0.000017590024,0.00012398786,0.0000072038297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008633744,0.001216744,0.9570536,0.00027264212,0.00009573733,0.0000030674564,0.0077170124,0.0000027197946,0.001170062,0.00022087518,0.0028463937,0.0293148],"study_design_scores_gemma":[0.008771247,0.00024268203,0.6830436,0.0003209948,0.0004228461,0.0000073856395,0.0010953812,0.00018164131,0.0006103949,0.00001827228,0.3051517,0.00013388607],"about_ca_topic_score_codex":0.00024216363,"about_ca_topic_score_gemma":0.00012367203,"teacher_disagreement_score":0.3023053,"about_ca_system_score_codex":0.0003950134,"about_ca_system_score_gemma":0.0002474951,"threshold_uncertainty_score":0.31101084},"labels":[],"label_agreement":null},{"id":"W2019527474","doi":"10.1097/jto.0b013e3181aba89f","title":"A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Erlotinib; Bortezomib; Lung cancer; Oncology; Internal medicine; Phases of clinical research; Cancer; Clinical trial; Multiple myeloma; Epidermal growth factor receptor","score_opus":0.013298029746935674,"score_gpt":0.42461881121354794,"score_spread":0.4113207814666123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019527474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493176,0.0016803299,0.00007165972,0.00077922636,0.000058761427,0.0020523479,0.0000020634886,0.000004061555,0.0004197958],"genre_scores_gemma":[0.99812204,0.00046764655,0.0010912085,0.00009068978,0.000023577652,0.000060980405,0.0000042090037,0.0000095679725,0.0001300849],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99867815,0.00021702936,0.00068166805,0.0001335795,0.00014027773,0.00014931976],"domain_scores_gemma":[0.9988218,0.00014435651,0.0006557745,0.00008900926,0.000205945,0.0000831009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053445966,0.00012540893,0.0010494707,0.00036208247,0.000018776236,0.0000049524983,0.000045612527,0.00006648338,0.000012236339],"category_scores_gemma":[0.0000465104,0.00008351321,0.000051235103,0.00028412632,0.000037562502,0.00010079387,0.0000063845696,0.00020651608,9.992179e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62696004,0.030215697,0.14407142,0.00025777487,0.0007131838,0.0017346032,0.02224892,0.0009903206,0.00435683,0.0000042069537,0.00006585457,0.16838117],"study_design_scores_gemma":[0.8576227,0.02298817,0.11071878,0.00073583843,0.0024923265,0.00018241836,0.0024182717,0.0010378705,0.0015948587,0.00003828612,0.000045111894,0.00012540577],"about_ca_topic_score_codex":0.00020914194,"about_ca_topic_score_gemma":0.0006892485,"teacher_disagreement_score":0.23066263,"about_ca_system_score_codex":0.00035596688,"about_ca_system_score_gemma":0.00043201013,"threshold_uncertainty_score":0.34055698},"labels":[],"label_agreement":null},{"id":"W2019875881","doi":"10.1016/j.cllc.2012.04.003","title":"A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Rash; Nausea; Neutropenia; Lung cancer; Adverse effect; Pharmacokinetics; Internal medicine; Phases of clinical research; Oncology; Response Evaluation Criteria in Solid Tumors; Pharmacology; Toxicity; Chemotherapy; Cisplatin","score_opus":0.04642812213176898,"score_gpt":0.4313785693585379,"score_spread":0.3849504472267689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019875881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896256,0.0017422152,0.000050840543,0.00011578663,0.0002732799,0.0069934176,0.00007530844,0.000034713346,0.001088862],"genre_scores_gemma":[0.9960698,0.00023662532,0.0004410938,0.00026283725,0.00019409327,0.0015420646,0.000096785625,0.00008110816,0.0010755967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975462,0.00015591495,0.00085354544,0.00055086514,0.00038213725,0.0005113221],"domain_scores_gemma":[0.9981916,0.00016109746,0.000466594,0.0004921324,0.00035688747,0.00033170325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033780382,0.00033816256,0.00087097444,0.00014869243,0.000080424026,0.000027298558,0.00019004005,0.00014890562,0.00029242187],"category_scores_gemma":[0.000037680176,0.00021987615,0.0000563363,0.0006831106,0.000095378804,0.0002579349,0.00007049303,0.00032508723,0.0000034349112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047518783,0.03877852,0.9285477,0.00019968038,0.0010732926,0.000014952597,0.004078472,0.00007312602,0.00003440313,0.0000021622507,0.0004354031,0.022010416],"study_design_scores_gemma":[0.11338644,0.0104019195,0.86929166,0.0009247245,0.0041277776,0.0000011196532,0.00044999397,0.00081648334,0.00010761036,9.894527e-7,0.00015613227,0.00033514964],"about_ca_topic_score_codex":0.00451694,"about_ca_topic_score_gemma":0.0045780223,"teacher_disagreement_score":0.10863456,"about_ca_system_score_codex":0.00056868244,"about_ca_system_score_gemma":0.00061401434,"threshold_uncertainty_score":0.8966289},"labels":[],"label_agreement":null},{"id":"W2019887136","doi":"10.1055/s-0029-1213984","title":"Bevacizumab in Kombination mit Cisplatin/Gemcitabin versus Cisplatin/Gemcitabin als Erstlinientherapie bei Patienten mit fortgeschrittenem nichtsquamösen nichtkleinzelligen Lungenkarzinom (NSCLC): eine randomisierte Phase III Studie (AVAiL)","year":2009,"lang":"de","type":"article","venue":"Pneumologie","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel; Gynecology; Oncology; Chemotherapy; Internal medicine","score_opus":0.03461760218847333,"score_gpt":0.3588650643113455,"score_spread":0.3242474621228722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019887136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7834138,0.18495949,0.0006005738,0.008647989,0.0064618043,0.008822049,0.0006518379,0.00047102565,0.005971423],"genre_scores_gemma":[0.9835634,0.009045811,0.00077201996,0.0010110082,0.0009486415,0.0006809919,0.0021220918,0.0002006408,0.0016553468],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989873,0.0006691547,0.0031811649,0.0023233793,0.0015573296,0.0023959673],"domain_scores_gemma":[0.9935645,0.0016748876,0.0013958619,0.0017636654,0.00080175436,0.0007993495],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014625756,0.0016937623,0.0027527541,0.0013053811,0.0007108493,0.00022272511,0.0008790914,0.0009106125,0.00046190157],"category_scores_gemma":[0.0013254439,0.0015665665,0.0008820308,0.0019713375,0.0003740611,0.00075490633,0.0002503779,0.0011854112,0.00067235675],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.099468164,0.03695252,0.02679976,0.0007227803,0.034472052,0.004859397,0.020375174,0.0012681757,0.0062753675,0.0021037064,0.014306663,0.7523962],"study_design_scores_gemma":[0.82257867,0.034574904,0.04202352,0.002667423,0.04137954,0.000057255817,0.0034735012,0.008485141,0.0053874566,0.0032142745,0.030945605,0.0052127037],"about_ca_topic_score_codex":0.000522407,"about_ca_topic_score_gemma":0.00032157017,"teacher_disagreement_score":0.74718356,"about_ca_system_score_codex":0.0023357219,"about_ca_system_score_gemma":0.000972175,"threshold_uncertainty_score":0.9995809},"labels":[],"label_agreement":null},{"id":"W2020555572","doi":"10.1007/s10637-013-0055-4","title":"Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"U.S. Food and Drug Administration; GlaxoSmithKline","keywords":"Lapatinib; Pharmacokinetics; Cmax; Medicine; Meal; Tolerability; Pharmacology; Internal medicine; Gastroenterology; Adverse effect; Cancer; Breast cancer; Trastuzumab","score_opus":0.0052637587914176305,"score_gpt":0.2631291230371833,"score_spread":0.25786536424576567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020555572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979241,0.00006894345,0.0000115395815,0.00065073074,0.00006108776,0.00093241327,0.000034864992,0.0000115650655,0.00030475928],"genre_scores_gemma":[0.99680156,0.000014879464,0.0021566907,0.00048905436,0.00003131623,0.00005656583,0.00010542317,0.000018210942,0.00032631285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990535,0.00002744965,0.00027306814,0.00017435268,0.00033867225,0.00013300077],"domain_scores_gemma":[0.9991973,0.00017154079,0.00017930462,0.00009740559,0.00019119921,0.0001632695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000025163976,0.00013433804,0.00025742725,0.00011377134,0.000019875648,0.0000057488774,0.000039557508,0.00002785,0.000037731217],"category_scores_gemma":[0.0000555253,0.00010203848,0.000021213877,0.00015966845,0.00012674276,0.000112909656,0.0000140123775,0.00007558187,0.000008064832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019667414,0.0031378046,0.83964086,0.0026223725,0.0008887839,0.000022832432,0.013345599,0.009634717,0.073339865,0.0039699636,0.0071566263,0.04427384],"study_design_scores_gemma":[0.013508864,0.00091433496,0.8480159,0.00092010846,0.0001324183,5.6549567e-7,0.00004953848,0.00013581636,0.1337522,0.0024107029,0.00003284818,0.00012673615],"about_ca_topic_score_codex":0.00026487018,"about_ca_topic_score_gemma":0.000007886572,"teacher_disagreement_score":0.060412325,"about_ca_system_score_codex":0.00005539643,"about_ca_system_score_gemma":0.00013611375,"threshold_uncertainty_score":0.41610086},"labels":[],"label_agreement":null},{"id":"W2020600748","doi":"10.1200/jco.2012.43.4522","title":"Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Epidermal growth factor receptor; Medicine; Epidermal growth factor; Growth factor receptor inhibitor; Cancer research; TGF alpha; Lung cancer; Receptor; Oncology; Internal medicine","score_opus":0.0918863305507524,"score_gpt":0.46809057986487623,"score_spread":0.37620424931412383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020600748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03745329,0.9509221,0.000013246533,0.0016237433,0.0060200514,0.0022842165,0.00022609744,0.00002113621,0.0014361533],"genre_scores_gemma":[0.0053624623,0.9858893,0.0027282757,0.00053956563,0.0040971534,0.000115972674,0.00008327663,0.00013972551,0.001044278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891431,0.0012510753,0.0075453557,0.00066009024,0.0006649664,0.0007354111],"domain_scores_gemma":[0.9857402,0.0037650778,0.0076766848,0.00041066797,0.0014482904,0.0009590739],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001365192,0.0007919932,0.008659048,0.00068449765,0.0000671419,0.000023193224,0.00052983954,0.0019260758,0.0020549083],"category_scores_gemma":[0.0032398407,0.0005307514,0.0023517276,0.00063850003,0.00028530692,0.00031845956,0.00015833486,0.0030743496,0.00011124392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072871835,0.003391323,0.041123703,0.008195232,0.00338405,0.0001889756,0.0004753939,0.0000025121071,0.00009682715,0.000021620614,0.02266726,0.9197244],"study_design_scores_gemma":[0.007825201,0.006388009,0.007677129,0.012234307,0.0062785638,0.00013111101,0.00014036977,0.000012448577,0.0001229612,0.000031771884,0.9585543,0.0006038063],"about_ca_topic_score_codex":0.0006709826,"about_ca_topic_score_gemma":0.00009259001,"teacher_disagreement_score":0.93588704,"about_ca_system_score_codex":0.0015557874,"about_ca_system_score_gemma":0.011749771,"threshold_uncertainty_score":0.9997144},"labels":[],"label_agreement":null},{"id":"W2020681158","doi":"10.1200/jco.2009.24.5217","title":"Reply to S.G. Williams et al","year":2009,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.10431215521935314,"score_gpt":0.5630857426648429,"score_spread":0.4587735874454898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020681158","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048000507,0.010426935,0.0008434286,0.8842186,0.014613663,0.00025432892,0.000010295549,0.000008878021,0.041623395],"genre_scores_gemma":[0.177807,0.0074037174,0.017899405,0.76820916,0.005248752,0.0000023972373,0.0000039276915,0.00002057678,0.02340508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959741,0.00049156253,0.0025860032,0.00021836977,0.00037057308,0.00035937535],"domain_scores_gemma":[0.99532866,0.0016083249,0.0012814495,0.00023527881,0.000534858,0.0010113961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035479346,0.00015910287,0.0013898752,0.000114484814,0.000043562577,0.000015447371,0.00015959976,0.00028591126,0.00055441546],"category_scores_gemma":[0.004650985,0.00011667694,0.00059477123,0.00019716345,0.00012844526,0.00017596703,0.00002498889,0.0010931917,0.00030778407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001131545,0.0025102426,0.00383192,0.0000058587298,0.00044508404,0.0015586566,0.00025181097,0.00006780705,0.00002575167,0.0014120105,0.46814197,0.5206173],"study_design_scores_gemma":[0.005948355,0.03968973,0.11981111,0.0003420317,0.0009750429,0.00061840186,0.00013213186,0.000019577063,0.000012986631,0.0009323921,0.83143187,0.000086385975],"about_ca_topic_score_codex":0.00006113961,"about_ca_topic_score_gemma":0.000018660241,"teacher_disagreement_score":0.52053094,"about_ca_system_score_codex":0.00048564686,"about_ca_system_score_gemma":0.004243673,"threshold_uncertainty_score":0.7528093},"labels":[],"label_agreement":null},{"id":"W2020779524","doi":"10.1358/dot.2004.40.10.863742","title":"Gefitinib: Current status in the treatment of non-small cell lungcancer","year":2004,"lang":"en","type":"review","venue":"Drugs of today","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gefitinib; Medicine; Lung cancer; Tolerability; Oncology; Epidermal growth factor receptor; Internal medicine; Chemotherapy; Tyrosine-kinase inhibitor; Cancer; Adverse effect","score_opus":0.03334470967723603,"score_gpt":0.38308849286908947,"score_spread":0.34974378319185345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020779524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006766252,0.9906311,0.000003994742,0.00004864819,0.00028410016,0.0021118552,0.00037627842,0.000008394004,0.0058589736],"genre_scores_gemma":[0.0010800307,0.9971522,0.00020378822,0.000015738558,0.00011565792,0.00046723947,0.00039420705,0.00003657075,0.00053457415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984857,0.000055414937,0.0006478372,0.00028283018,0.00025028083,0.00027797904],"domain_scores_gemma":[0.99878484,0.00014476293,0.0004278536,0.00049708673,0.00006901331,0.00007642859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085756204,0.0003341268,0.0013886892,0.00018408468,0.000023720166,0.0000064901424,0.00013726852,0.00010982539,0.00007013006],"category_scores_gemma":[0.0000064776154,0.00017972324,0.00054647395,0.00027286072,0.00005949388,0.000020932916,0.0000140242,0.00014456957,0.00001724284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015322761,0.0019097885,0.00014373744,0.018099274,0.00026744764,0.000015095274,0.004389139,0.0000053472613,3.9850497e-7,0.0000494127,0.00020757456,0.97489744],"study_design_scores_gemma":[0.0022972538,0.00060460967,0.00024945152,0.014651472,0.0033142192,0.0000044450585,0.00021458224,6.5006276e-7,0.00002644151,0.000015848476,0.97848153,0.00013951483],"about_ca_topic_score_codex":0.0010850321,"about_ca_topic_score_gemma":0.000063449275,"teacher_disagreement_score":0.9782739,"about_ca_system_score_codex":0.0007666033,"about_ca_system_score_gemma":0.0014510575,"threshold_uncertainty_score":0.73289007},"labels":[],"label_agreement":null},{"id":"W2021963511","doi":"10.1007/s11523-008-0093-6","title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies","year":2008,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Parks and Wilderness Society","funders":"","keywords":"Medicine; Cetuximab; Epidermal growth factor receptor; EGFR inhibitors; Tyrosine kinase; Lung cancer; Cancer; Colorectal cancer; Cancer research; Drug resistance; Gefitinib; Erlotinib; Signal transduction; Targeted therapy; Receptor tyrosine kinase; Bioinformatics; Oncology; Internal medicine; Receptor; Biology","score_opus":0.013520744220156556,"score_gpt":0.3217577086328896,"score_spread":0.30823696441273307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021963511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96678156,0.00051300204,0.020210128,0.009035636,0.00018351682,0.0016590435,0.00009145134,0.00006713155,0.0014585148],"genre_scores_gemma":[0.9845944,0.000031740285,0.014319806,0.00024425946,0.000025340129,0.000332282,0.00012131994,0.000010890075,0.00031996318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994351,0.000022684673,0.00020246935,0.00016352374,0.000059275797,0.00011689093],"domain_scores_gemma":[0.9994079,0.000059171325,0.00009747549,0.00008657415,0.000278791,0.00007009793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048147147,0.000076596625,0.00017755589,0.00010437945,0.00013162314,0.000003629713,0.000019817639,0.000054433167,0.0000101159385],"category_scores_gemma":[0.000040587092,0.000069882575,0.000028535982,0.00018940581,0.000036686863,0.00006556516,0.000009765346,0.00004068105,0.0000014071944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015838747,0.002939438,0.0053506987,0.00033008322,0.00035977532,0.000012545373,0.011949947,0.00020999716,0.70521665,0.2102399,0.040896647,0.020910427],"study_design_scores_gemma":[0.019954778,0.018471079,0.31821185,0.0002918692,0.0012570127,0.00019884671,0.007284769,0.00035186,0.44717315,0.10006853,0.085984565,0.0007517035],"about_ca_topic_score_codex":0.00006621027,"about_ca_topic_score_gemma":0.00019629113,"teacher_disagreement_score":0.31286114,"about_ca_system_score_codex":0.00023406702,"about_ca_system_score_gemma":0.00028900598,"threshold_uncertainty_score":0.28497285},"labels":[],"label_agreement":null},{"id":"W2022249592","doi":"10.1158/1535-7163.targ-09-b32","title":"Abstract B32: Retrospective correlative study between EGFRvIII, HPV, p16, c-MET and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Immunohistochemistry; Cancer; Univariate analysis; Head and neck squamous-cell carcinoma; Head and neck cancer; Epidermal growth factor receptor; Multivariate analysis","score_opus":0.018213220886722625,"score_gpt":0.31584793952418144,"score_spread":0.29763471863745883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022249592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596447,0.0010159507,0.00002442821,0.0004911858,0.000067896755,0.0022188604,0.00010396435,0.000010438262,0.000102836624],"genre_scores_gemma":[0.99915093,0.000013424118,0.00021660217,0.00043324803,0.000014442873,0.00008112625,0.0000082509105,0.000027869593,0.00005408765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860793,0.0001268985,0.0003062039,0.0003513372,0.00038057138,0.00022706424],"domain_scores_gemma":[0.99919015,0.00007766714,0.00015925655,0.0002972546,0.00016309165,0.00011258565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013792567,0.00024044098,0.00040261337,0.00013482208,0.00008550428,0.000018704022,0.00007289833,0.000047198875,0.000012276581],"category_scores_gemma":[0.000023435308,0.00014714364,0.000043225555,0.0004671513,0.00008273278,0.000054281474,0.000033103428,0.00021535442,4.814367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043474003,0.0010321283,0.9702943,0.000030024925,0.0002031714,0.000033589033,0.009902725,0.000040953077,0.0006379239,0.000004756544,0.000009897817,0.013463122],"study_design_scores_gemma":[0.00902409,0.008625773,0.97764355,0.000130164,0.0007708121,0.0000014050502,0.0010813136,0.0000069752195,0.0024505113,0.00003373519,0.00007043288,0.000161268],"about_ca_topic_score_codex":0.0003019631,"about_ca_topic_score_gemma":0.00023254949,"teacher_disagreement_score":0.013301854,"about_ca_system_score_codex":0.00041046223,"about_ca_system_score_gemma":0.00025363828,"threshold_uncertainty_score":0.60003436},"labels":[],"label_agreement":null},{"id":"W2024080866","doi":"10.1007/s10637-007-9045-8","title":"Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of California, Davis","keywords":"Vinorelbine; Erlotinib; Medicine; Internal medicine; Vinca alkaloid; Neutropenia; Febrile neutropenia; Oncology; Lung cancer; Mucositis; Epidermal growth factor receptor; Combination therapy; Pharmacology; Chemotherapy; Gastroenterology; Cancer; Vincristine; Cisplatin","score_opus":0.01803718802920216,"score_gpt":0.3682471109087651,"score_spread":0.35020992287956293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024080866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949812,0.00022987669,0.000081109596,0.0022218877,0.000067238885,0.0008385699,0.00001371624,0.00003988037,0.0015264824],"genre_scores_gemma":[0.99397874,0.0000060515968,0.0033596554,0.00097937,0.00014426826,0.00003847176,0.00007864486,0.000016639093,0.0013981339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989213,0.00001590869,0.00033817248,0.00026097996,0.00026192606,0.00020176035],"domain_scores_gemma":[0.9993567,0.00008539589,0.00007479016,0.00012810984,0.000063156476,0.0002918492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019431653,0.0001318896,0.00020777747,0.00016055326,0.000057348127,0.000014494992,0.000037600563,0.0000308122,0.000054838772],"category_scores_gemma":[0.0000884152,0.00011175622,0.000026001326,0.0002597463,0.000072920906,0.00011641736,0.000020216146,0.000099282275,0.000015405376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018168164,0.00793179,0.7901825,0.00017442196,0.0005842685,0.0016086777,0.045997497,0.00032977914,0.030541325,0.01276678,0.004001641,0.10406455],"study_design_scores_gemma":[0.042453885,0.0024197195,0.92896396,0.000511535,0.00027143804,0.00017126834,0.0066172895,0.00038030566,0.0071273344,0.007569523,0.003111666,0.0004020646],"about_ca_topic_score_codex":0.00033521044,"about_ca_topic_score_gemma":0.00013538281,"teacher_disagreement_score":0.13878152,"about_ca_system_score_codex":0.000117163545,"about_ca_system_score_gemma":0.000416456,"threshold_uncertainty_score":0.45572865},"labels":[],"label_agreement":null},{"id":"W2024360503","doi":"10.1097/jto.0b013e31827e2145","title":"Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Oncology; Clinical Practice; Internal medicine; Family medicine","score_opus":0.08774807205020181,"score_gpt":0.544413237073292,"score_spread":0.45666516502309024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024360503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98102415,0.0016426743,0.00082228816,0.012017515,0.001258674,0.0024488312,0.000024032626,0.000014116179,0.0007477216],"genre_scores_gemma":[0.98847526,0.00042435163,0.009039668,0.0011203254,0.0005850636,0.00016400435,0.000028598739,0.000034210934,0.00012850916],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99153984,0.0038748141,0.0033752215,0.00032221532,0.0004668228,0.0004210875],"domain_scores_gemma":[0.9836458,0.010300686,0.0047475644,0.0003468381,0.00071110897,0.00024799388],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009334325,0.0002694051,0.0025931806,0.00046006154,0.00009164491,0.00004582189,0.0002075068,0.0002589035,0.00021102115],"category_scores_gemma":[0.0144907795,0.00014744155,0.00037063594,0.0004834023,0.00009825878,0.00072466163,0.00003722379,0.0009439597,0.00001592987],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0326933,0.0036752378,0.007888819,0.000017973201,0.0006987625,0.00035098434,0.0019061266,0.00008994317,0.00027337568,0.000006534944,0.0005360381,0.95186293],"study_design_scores_gemma":[0.46560815,0.10882545,0.22793071,0.0067777946,0.011886786,0.00046071943,0.07935001,0.00042811857,0.0007764186,0.0022838525,0.094416365,0.0012556189],"about_ca_topic_score_codex":0.00012794392,"about_ca_topic_score_gemma":0.0001927016,"teacher_disagreement_score":0.9506073,"about_ca_system_score_codex":0.0006076769,"about_ca_system_score_gemma":0.00093002134,"threshold_uncertainty_score":0.9938106},"labels":[],"label_agreement":null},{"id":"W2024536871","doi":"10.1038/modpathol.2014.56","title":"Comment on ‘Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization'","year":2014,"lang":"en","type":"letter","venue":"Modern Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Immunohistochemistry; Fluorescence in situ hybridization; Adenocarcinoma; Pathology; In situ hybridization; Medicine; Lung; Biology; Internal medicine; Cancer; Gene expression","score_opus":0.0329553825973481,"score_gpt":0.3487590623084117,"score_spread":0.3158036797110636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024536871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59445804,0.0048030405,0.0053224824,0.3890831,0.00036872813,0.0045376034,0.00015689635,0.000047886522,0.0012222616],"genre_scores_gemma":[0.9205911,0.000014398303,0.0023999598,0.07533539,0.00015768838,0.00040692228,0.0009690063,0.000042352098,0.000083175975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985952,0.00006970985,0.00049990515,0.00042096063,0.00014489358,0.0002693624],"domain_scores_gemma":[0.9991806,0.00017570403,0.00022509287,0.00030476338,0.00008237622,0.00003143572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012923396,0.00022559639,0.0006211992,0.00018263122,0.0000333339,0.0000065424074,0.000068137466,0.0002601948,0.0000046767736],"category_scores_gemma":[0.00007348671,0.00021265018,0.000056195968,0.000055774824,0.000063457686,0.000014309553,0.000041298765,0.00043763765,9.366746e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011654919,0.002325992,0.5680147,0.007041532,0.0004105418,0.0013567111,0.009434364,0.00046518137,0.058912486,0.00003158956,0.34373412,0.0071073184],"study_design_scores_gemma":[0.13602923,0.010061204,0.46890745,0.018337416,0.0061603673,0.0006892349,0.0012576238,0.17138377,0.039415587,0.00093467114,0.14292666,0.0038968003],"about_ca_topic_score_codex":0.0000801077,"about_ca_topic_score_gemma":0.000014981494,"teacher_disagreement_score":0.3261331,"about_ca_system_score_codex":0.00043746142,"about_ca_system_score_gemma":0.00006251244,"threshold_uncertainty_score":0.8671623},"labels":[],"label_agreement":null},{"id":"W2025267040","doi":"10.1016/j.lungcan.2013.06.023","title":"What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Cancer; Disease; Internal medicine; Physical therapy","score_opus":0.020265612033253267,"score_gpt":0.37654256354529836,"score_spread":0.3562769515120451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025267040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460937,0.04176589,0.0000010463257,0.002256386,0.0008826443,0.0068615098,0.0012487416,0.000013432635,0.00087667105],"genre_scores_gemma":[0.96057004,0.03160091,0.000045457982,0.00035629654,0.00019207534,0.00584422,0.00018316365,0.000040871066,0.0011669665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977426,0.00015070623,0.000593037,0.00064896815,0.00034304213,0.0005216591],"domain_scores_gemma":[0.9978203,0.0006647094,0.00026347773,0.0006052438,0.0005082823,0.00013799295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014894365,0.00036719305,0.0006053384,0.00011740622,0.00028397574,0.00014048607,0.0002361252,0.00009784231,0.00020421135],"category_scores_gemma":[0.000027853006,0.00020467164,0.00011632285,0.00026637525,0.00023422718,0.00037470929,0.000067996276,0.00023855866,0.0000035426333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028523293,0.0010885176,0.88686967,0.00010476918,0.0008523849,0.0000101448095,0.09436808,0.000661207,0.000022456148,0.000009210494,0.0015438079,0.014184547],"study_design_scores_gemma":[0.017903402,0.0011519291,0.87694937,0.000748354,0.0020424216,5.337864e-7,0.09603917,0.0008031193,0.0007490499,0.000012657087,0.003261018,0.00033895037],"about_ca_topic_score_codex":0.09895635,"about_ca_topic_score_gemma":0.056073755,"teacher_disagreement_score":0.04288259,"about_ca_system_score_codex":0.001747376,"about_ca_system_score_gemma":0.0010266993,"threshold_uncertainty_score":0.96115047},"labels":[],"label_agreement":null},{"id":"W2025756290","doi":"10.1097/jto.0b013e318200f972","title":"Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Anaplastic lymphoma kinase; Lung cancer; Epidermal growth factor receptor; Medicine; Cancer research; Cancer; Receptor tyrosine kinase; Oncology; Targeted therapy; Tyrosine kinase; Mesothelioma; Bioinformatics; Internal medicine; Biology; Pathology; Receptor","score_opus":0.054740956245108996,"score_gpt":0.500218743728637,"score_spread":0.44547778748352795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025756290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98386216,0.0009713517,0.00004255614,0.01210448,0.000673277,0.00035697166,0.00015019465,0.0000034285786,0.0018355541],"genre_scores_gemma":[0.9929322,0.0005386922,0.00546309,0.0008070099,0.00013012502,0.000011682953,0.000003454836,0.000012004537,0.00010171961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785763,0.0006054524,0.0010808728,0.0001520611,0.00015132049,0.0001526386],"domain_scores_gemma":[0.9957569,0.001397081,0.002125648,0.0002092877,0.000401824,0.00010920909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009086896,0.000107700784,0.00080078846,0.00007555142,0.00006217977,0.0000012873385,0.00018380112,0.00011596367,0.000050870854],"category_scores_gemma":[0.00037849194,0.000056648445,0.0002824238,0.0002814484,0.000737856,0.000040880008,0.00008300306,0.00033839472,3.360713e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004700778,0.0010965595,0.80257064,0.000045954384,0.0037905546,0.000022322176,0.008988836,0.00002520099,0.0052559646,0.00010302139,0.020345645,0.15305452],"study_design_scores_gemma":[0.0019217505,0.0058447546,0.97553235,0.00027155163,0.0022320629,0.00006835903,0.0067289704,0.00008326443,0.002840188,0.0004732724,0.0039318707,0.00007160212],"about_ca_topic_score_codex":0.0028954337,"about_ca_topic_score_gemma":0.00032051135,"teacher_disagreement_score":0.17296171,"about_ca_system_score_codex":0.00014043058,"about_ca_system_score_gemma":0.0011605168,"threshold_uncertainty_score":0.4377049},"labels":[],"label_agreement":null},{"id":"W2025771461","doi":"10.1016/j.jval.2014.03.1100","title":"Evaluation of current data sources in Europe for the conduct of real-world studies on lung and renal cell carcinoma: A systematic literature review","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Renal cell carcinoma; Cancer; Real world data; Population; Kidney cancer; Clinical trial; MEDLINE; Cancer registry; Cohort; Oncology; Systematic review; Internal medicine; Intensive care medicine; Data science; Computer science; Environmental health","score_opus":0.2568931885691528,"score_gpt":0.47826495939832736,"score_spread":0.22137177082917459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025771461","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19417442,0.7998481,0.0000115729235,0.0015974059,0.00014675803,0.004046324,0.000069601534,0.000003412934,0.00010241166],"genre_scores_gemma":[0.95612466,0.043387864,0.00009540538,0.00012473314,0.00003645756,0.00013989303,0.000058654965,0.000007194886,0.000025112471],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9983743,0.00060040393,0.00051683636,0.0001616863,0.00026150228,0.00008529234],"domain_scores_gemma":[0.9984369,0.00057714275,0.0003160467,0.00035703593,0.00028682555,0.000026022379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004199725,0.000073975774,0.00042560734,0.00009638904,0.000029081975,0.0000034196103,0.00006248119,0.000010628759,7.8645263e-7],"category_scores_gemma":[0.0008441433,0.000040334973,0.000017151036,0.00030351276,0.000025813946,0.000031410906,0.000023828796,0.0000737481,1.4050492e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007949163,0.00042290072,0.017437255,0.9590682,0.00014201633,0.0000013660399,0.012717243,0.001132982,0.00003236396,0.001979218,0.0023348625,0.004652135],"study_design_scores_gemma":[0.010023641,0.001982354,0.064251475,0.8102097,0.004876838,0.000012240992,0.0014179879,0.105265416,0.00024021411,0.00040480163,0.0010851067,0.00023022405],"about_ca_topic_score_codex":0.00030290158,"about_ca_topic_score_gemma":0.00016948715,"teacher_disagreement_score":0.76195025,"about_ca_system_score_codex":0.00012276863,"about_ca_system_score_gemma":0.00031235404,"threshold_uncertainty_score":0.16448125},"labels":[],"label_agreement":null},{"id":"W2026319709","doi":"10.1016/s0169-5002(00)00135-5","title":"The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Cisplatin; Proportional hazards model; Lung cancer; Internal medicine; Oncology; Retrospective cohort study; Carboplatin; Logistic regression; Chemotherapy; Toxicity","score_opus":0.005698174636181947,"score_gpt":0.3125502786399122,"score_spread":0.30685210400373025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026319709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875303,0.00906335,0.0000031231752,0.0013038528,0.000093668634,0.0006527159,0.000048640675,0.000013654088,0.001290704],"genre_scores_gemma":[0.99151486,0.0038606315,0.00017226189,0.00026515208,0.000043096043,0.00026460717,0.000003778382,0.0000220534,0.0038535658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903953,0.00005075535,0.00023414553,0.00027266511,0.00016238338,0.00024049403],"domain_scores_gemma":[0.99931246,0.0002290388,0.00007468138,0.00022400903,0.00006730158,0.00009249348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017123947,0.00015585107,0.00024601916,0.00006335283,0.00010636707,0.000016022595,0.000057003457,0.000057734767,0.00011052353],"category_scores_gemma":[0.000030723175,0.000109090695,0.000027659868,0.00020365305,0.00009434863,0.00007732972,0.000019882034,0.0001517284,0.0000011735455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071617626,0.00019632338,0.9205688,0.0004792274,0.00023644381,0.000037999554,0.003719891,0.011451892,0.019014427,0.00010974991,0.00034915633,0.036674283],"study_design_scores_gemma":[0.0048518814,0.00022570443,0.9874357,0.0006598599,0.00021174592,0.000002876404,0.00015853172,0.0018433018,0.002468229,0.000014322516,0.0019823904,0.00014547106],"about_ca_topic_score_codex":0.0012405684,"about_ca_topic_score_gemma":0.0013000298,"teacher_disagreement_score":0.06686684,"about_ca_system_score_codex":0.00020654457,"about_ca_system_score_gemma":0.00027863067,"threshold_uncertainty_score":0.44485894},"labels":[],"label_agreement":null},{"id":"W2026635246","doi":"10.1097/jto.0b013e3181c6f035","title":"First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review","year":2010,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Sunnybrook Health Science Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Pemetrexed; Vinorelbine; Oncology; Bevacizumab; Carboplatin; Internal medicine; Docetaxel; Gemcitabine; Gefitinib; Irinotecan; Lung cancer; Chemotherapy; Randomized controlled trial; Cancer; Epidermal growth factor receptor; Cisplatin; Colorectal cancer","score_opus":0.028756584065757228,"score_gpt":0.4678776361280142,"score_spread":0.439121052062257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026635246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033990282,0.9912002,0.000028724111,0.0007814428,0.0006597432,0.006624772,0.000034393073,0.0000051969405,0.0003256166],"genre_scores_gemma":[0.0001638417,0.9970097,0.0006298131,0.0002689311,0.0003377585,0.0009907635,0.000018626197,0.00005002684,0.0005305704],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9964391,0.0004397565,0.0023422004,0.00022577186,0.0002989489,0.00025424745],"domain_scores_gemma":[0.99444264,0.0005970358,0.003981699,0.0005622697,0.0003027723,0.00011360466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083129783,0.00043871207,0.0061254916,0.0003102099,0.00004428278,0.000009004403,0.00034933886,0.0003543756,0.00004434566],"category_scores_gemma":[0.00006507886,0.0002082216,0.0010888703,0.0004271106,0.00004593933,0.00004368506,0.000010970253,0.00054654013,0.0000050235785],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006777446,0.0009992942,0.000013747398,0.6856844,0.0007794818,0.00025608108,0.0007765575,0.000005220661,0.0000017751596,0.0000011401582,0.00010687359,0.31130767],"study_design_scores_gemma":[0.0013651042,0.0025768757,0.000004659339,0.6512321,0.032296266,0.0025325124,0.00013434823,0.000006210575,0.000003812561,0.000002359271,0.30971676,0.00012896123],"about_ca_topic_score_codex":0.00003427316,"about_ca_topic_score_gemma":0.00008607267,"teacher_disagreement_score":0.3111787,"about_ca_system_score_codex":0.0019268594,"about_ca_system_score_gemma":0.0024736181,"threshold_uncertainty_score":0.84910303},"labels":[],"label_agreement":null},{"id":"W2026940417","doi":"10.1007/s10637-014-0139-9","title":"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Oncology; Maximum tolerated dose; Internal medicine; Pharmacology; Chemotherapy; Cisplatin; Cancer; Gefitinib","score_opus":0.008347684921314954,"score_gpt":0.287026971593901,"score_spread":0.27867928667258607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026940417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967986,0.000016724118,0.000108319146,0.00087711576,0.000052886633,0.0013086699,0.000023800556,0.000025643287,0.00078825495],"genre_scores_gemma":[0.99498236,0.0000018266035,0.0038495513,0.00026446997,0.00006324477,0.00007253327,0.0004912412,0.000021606169,0.00025318752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879026,0.000043803277,0.00035929636,0.0002501177,0.00040514919,0.00015134006],"domain_scores_gemma":[0.9990942,0.00012515877,0.00024296362,0.00015035862,0.00019405154,0.00019325627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010328247,0.00016294986,0.00035457735,0.00014797608,0.000045787932,0.000013051252,0.000038142414,0.00004148117,0.000024736219],"category_scores_gemma":[0.00013965224,0.00011854089,0.000026371332,0.00029414342,0.00015484157,0.00017725676,0.000010670977,0.000089609304,0.0000019914798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23266467,0.009815691,0.61908597,0.00032747112,0.0007427132,0.000017637278,0.007818139,0.001481861,0.0021206671,0.0062449137,0.000883728,0.11879651],"study_design_scores_gemma":[0.46235976,0.012823208,0.5202831,0.0004723674,0.00022144085,0.0000023255882,0.0001218243,0.0010464207,0.00097407727,0.0013182241,0.00017064725,0.00020659855],"about_ca_topic_score_codex":0.0001013081,"about_ca_topic_score_gemma":0.000039749593,"teacher_disagreement_score":0.22969508,"about_ca_system_score_codex":0.00006668798,"about_ca_system_score_gemma":0.0003916533,"threshold_uncertainty_score":0.48339573},"labels":[],"label_agreement":null},{"id":"W2027650328","doi":"10.1097/01.jto.0000283191.47168.f6","title":"C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Everolimus; Response Evaluation Criteria in Solid Tumors; Lung cancer; Internal medicine; Clinical endpoint; Oncology; Adverse effect; Progressive disease; Phases of clinical research; Pharmacodynamics; non-small cell lung cancer (NSCLC); Chemotherapy; Cancer; Urology; Pharmacokinetics; Clinical trial","score_opus":0.011632239800556256,"score_gpt":0.40016437341604594,"score_spread":0.38853213361548966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027650328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963412,0.0005883887,0.0005270136,0.00038996123,0.00023945047,0.0018049859,0.000010214353,0.000010754864,0.0000880064],"genre_scores_gemma":[0.9914892,0.00011992011,0.0076254914,0.00040941418,0.00014072807,0.000032918335,0.000004244494,0.0000483915,0.00012972909],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99803597,0.000079868325,0.00093167723,0.00027254096,0.0003436379,0.00033629645],"domain_scores_gemma":[0.9979777,0.00019904492,0.001065408,0.00019016006,0.00036572784,0.00020197482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047789278,0.0002668856,0.0008625577,0.00044308553,0.00010672882,0.000010289483,0.00010685243,0.00014522673,0.000063534215],"category_scores_gemma":[0.000029110724,0.00017806662,0.00008431613,0.00037818291,0.00006650751,0.0001603634,0.000019343022,0.00035800817,2.385207e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07305217,0.01580395,0.40256372,0.00023640603,0.0006147642,0.00031357427,0.016706767,0.0006312021,0.004030344,2.2495792e-7,0.00006319803,0.48598367],"study_design_scores_gemma":[0.29592305,0.13401136,0.52790904,0.0020930558,0.0022869904,0.000075803335,0.009507216,0.0008402653,0.02463003,0.0000070480155,0.0020538585,0.000662275],"about_ca_topic_score_codex":0.00011586435,"about_ca_topic_score_gemma":0.00055775174,"teacher_disagreement_score":0.4853214,"about_ca_system_score_codex":0.0008277712,"about_ca_system_score_gemma":0.0011266192,"threshold_uncertainty_score":0.7261346},"labels":[],"label_agreement":null},{"id":"W2028524821","doi":"10.1517/17425255.2013.832755","title":"The role of afatinib in the management of non-small cell lung carcinoma","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Drug Metabolism & Toxicology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Afatinib; T790M; Medicine; Resistance mutation; Lung cancer; Lapatinib; Tyrosine kinase; Tyrosine-kinase inhibitor; Drug resistance; Targeted therapy; Cancer research; Oncology; Pharmacology; Erlotinib; Epidermal growth factor receptor; Cancer; Internal medicine; Gefitinib; Biology; Receptor; Trastuzumab; Genetics","score_opus":0.02677984578039177,"score_gpt":0.36038117216467985,"score_spread":0.3336013263842881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028524821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004685194,0.9799756,0.000005571821,0.00037910108,0.0011320882,0.0035457993,0.00002784795,0.000010286478,0.01445521],"genre_scores_gemma":[0.001991575,0.99382657,0.0004996655,0.00019615669,0.00027960722,0.0021667846,0.00009659121,0.000047573933,0.0008954918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976283,0.00040343055,0.0009139059,0.00039576308,0.00030526228,0.00035336328],"domain_scores_gemma":[0.997993,0.0004013975,0.0005966292,0.0008581887,0.000080043945,0.00007075194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037243374,0.0003936022,0.001497895,0.00022215988,0.00009524998,0.000014160544,0.0005070046,0.00021119231,0.00008813726],"category_scores_gemma":[0.0000127638805,0.00019716618,0.00044200436,0.00034947696,0.00012762182,0.000030013349,0.00010916322,0.0003383336,0.000027254655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003606888,0.0008139869,0.000032186115,0.003083578,0.000638438,0.000011286801,0.0036481076,0.000002169837,0.000015853431,0.0056785126,0.0041902736,0.98184955],"study_design_scores_gemma":[0.0011982826,0.0001262229,0.00065751636,0.0017184477,0.0004987826,0.000010311493,0.0018791371,0.00001338025,0.00012328812,0.000043874144,0.99358046,0.00015032204],"about_ca_topic_score_codex":0.00017592238,"about_ca_topic_score_gemma":0.000008803549,"teacher_disagreement_score":0.98939013,"about_ca_system_score_codex":0.00011170262,"about_ca_system_score_gemma":0.0002847569,"threshold_uncertainty_score":0.80402035},"labels":[],"label_agreement":null},{"id":"W2028688785","doi":"10.1097/jto.0000000000000075","title":"Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Biomarker; Oncology; Lung cancer; Internal medicine; Drug development; Drug; Phases of clinical research; Targeted therapy; Cancer; Pharmacology","score_opus":0.032864315858611784,"score_gpt":0.4776749802075942,"score_spread":0.4448106643489824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028688785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888377,0.0035279884,0.00014624922,0.004010599,0.0018577193,0.0004321662,0.000006991257,0.000006351049,0.001174192],"genre_scores_gemma":[0.9861107,0.0037554665,0.007986802,0.00041562426,0.001128689,0.000024273637,0.0000036810204,0.000017910028,0.0005568505],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99839306,0.000441505,0.00070682773,0.00016022877,0.00012304909,0.00017531872],"domain_scores_gemma":[0.9985116,0.00039393667,0.00066501094,0.00011778369,0.00014455456,0.00016711724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014088649,0.00011529032,0.0005704988,0.00017744426,0.000050785828,0.000011458435,0.000072312665,0.0001837752,0.00012882293],"category_scores_gemma":[0.0002685003,0.000079719764,0.0001357086,0.00014006734,0.00009490453,0.00006530907,0.000019253388,0.00039756089,0.0000028552374],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072694525,0.0015722543,0.17358348,0.00010625151,0.0014199966,0.00009318129,0.0021080764,0.00001708817,0.0029381544,0.0000060610055,0.011714034,0.7337469],"study_design_scores_gemma":[0.22931042,0.030528624,0.47657362,0.00091869774,0.007508736,0.00035714864,0.0029723474,0.0015526527,0.0028713145,0.0003660405,0.24644473,0.00059566856],"about_ca_topic_score_codex":0.00012126056,"about_ca_topic_score_gemma":0.000082042956,"teacher_disagreement_score":0.73315126,"about_ca_system_score_codex":0.00024984512,"about_ca_system_score_gemma":0.0006206664,"threshold_uncertainty_score":0.32508776},"labels":[],"label_agreement":null},{"id":"W2028849325","doi":"10.1007/s00280-011-1755-0","title":"A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Medicine; Pemetrexed; Sunitinib; Neutropenia; Lung cancer; Internal medicine; Dosing; Pharmacokinetics; Adverse effect; Febrile neutropenia; Oncology; Cancer; Pharmacology; Chemotherapy; Cisplatin","score_opus":0.015190002316557639,"score_gpt":0.34029376063834094,"score_spread":0.3251037583217833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028849325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622023,0.00059478,0.000022158194,0.000037920083,0.000057536152,0.0029295438,0.000018555587,0.00001078981,0.00010849097],"genre_scores_gemma":[0.99766374,0.0007789098,0.00020113817,0.00026133205,0.000018240687,0.0009795344,0.00003930339,0.000030720457,0.000027093734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898493,0.00006636066,0.00026003292,0.0003178274,0.00012467298,0.00024618435],"domain_scores_gemma":[0.9995104,0.0000250657,0.00016206449,0.000087144144,0.00011755494,0.00009778462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008962817,0.00020535066,0.0003996191,0.00024203006,0.000030465038,0.0000042844713,0.000040534065,0.000050908522,0.00011037223],"category_scores_gemma":[8.097374e-7,0.00015238288,0.000008462026,0.00039339502,0.000080343714,0.00017788196,0.000007722773,0.00014145854,3.6108265e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013350127,0.00815731,0.9459618,0.00016444316,0.00019040852,0.000018562983,0.015441299,0.00010646142,0.0049114786,8.565023e-7,0.0000062372415,0.011691023],"study_design_scores_gemma":[0.13037066,0.0071716816,0.8446384,0.00017838925,0.0003331726,0.0000015699543,0.00089072704,0.0006483273,0.01558876,0.0000018691211,0.000008496211,0.00016794998],"about_ca_topic_score_codex":0.0013979945,"about_ca_topic_score_gemma":0.0020350623,"teacher_disagreement_score":0.11702053,"about_ca_system_score_codex":0.0001762983,"about_ca_system_score_gemma":0.00015546664,"threshold_uncertainty_score":0.6213994},"labels":[],"label_agreement":null},{"id":"W2028889234","doi":"10.1016/j.ejca.2014.05.024","title":"Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Clinical trial; Clinical endpoint; Context (archaeology); Progression-free survival; Medicine; Clinical Practice; Surrogate endpoint; Intensive care medicine; End point; Endpoint Determination; Clinical study design; Overall survival; Oncology; Medical physics; Internal medicine; Family medicine; Computer science","score_opus":0.17382677235232438,"score_gpt":0.59671152223017,"score_spread":0.42288474987784563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028889234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000482608,0.9881172,0.00004364187,0.0019350101,0.002178052,0.00078218075,0.000080627084,0.0000149860925,0.006365653],"genre_scores_gemma":[0.0006771612,0.9881034,0.0030914582,0.0003228169,0.0074440446,0.000012219039,0.000025556723,0.00010561396,0.00021771724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98243636,0.012088711,0.003963811,0.00054152205,0.00071207207,0.00025750158],"domain_scores_gemma":[0.98924977,0.00482982,0.0041941362,0.00053798116,0.00058312673,0.00060519425],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020094154,0.0003985784,0.004136391,0.00020855902,0.00006138258,0.00009381099,0.00034214577,0.00015413729,0.0003427107],"category_scores_gemma":[0.01900863,0.00024209048,0.0010106856,0.0001497281,0.00022712354,0.00026564134,0.0001150166,0.0015613383,0.00002663406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069141696,0.00075421383,0.0009838839,0.00033501693,0.0021699942,0.0014878534,0.0005356143,3.5143495e-7,1.3319617e-7,0.00004695923,0.00224783,0.99074674],"study_design_scores_gemma":[0.0068166624,0.0027932157,0.0064228303,0.018088507,0.01246243,0.00037098062,0.000898233,0.0000018476583,2.1051918e-7,0.000055724544,0.9518374,0.00025191923],"about_ca_topic_score_codex":0.00006981252,"about_ca_topic_score_gemma":0.00005234855,"teacher_disagreement_score":0.9904948,"about_ca_system_score_codex":0.00026240727,"about_ca_system_score_gemma":0.0021228073,"threshold_uncertainty_score":0.98925465},"labels":[],"label_agreement":null},{"id":"W2030193153","doi":"10.1097/jto.0b013e31822f657a","title":"Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canadian Centre for Applied Research in Cancer Control; University of British Columbia","funders":"","keywords":"Docetaxel; Erlotinib; Medicine; Oncology; Proportional hazards model; Internal medicine; Lung cancer; Hazard ratio; Population; Cost effectiveness; Survival analysis; Cancer; Epidermal growth factor receptor; Confidence interval","score_opus":0.06841015148918138,"score_gpt":0.4833870429544134,"score_spread":0.41497689146523203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030193153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98649305,0.0012333455,0.0037262726,0.00028800196,0.0005814041,0.0018937739,0.00017160056,0.000011324925,0.005601226],"genre_scores_gemma":[0.97986156,0.00075952004,0.01226973,0.00009251655,0.00030747522,0.00032926045,0.00002751115,0.000029161523,0.0063232803],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985526,0.00012849315,0.000717558,0.00020677893,0.00013770883,0.0002568438],"domain_scores_gemma":[0.9975902,0.000387913,0.0010050698,0.00022104521,0.00058822864,0.00020758857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036921276,0.0002046381,0.0012651981,0.0005909274,0.00006052769,0.000005730617,0.00010185666,0.000115042305,0.0006619479],"category_scores_gemma":[0.000025194742,0.00012891037,0.0005601968,0.0005679273,0.00005861648,0.00007516823,0.000013933987,0.000113033275,0.0000014245429],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06517847,0.018580755,0.39993963,0.002832448,0.04278303,0.0014555758,0.015042917,0.0011947852,0.011645142,0.00007475744,0.0015913195,0.43968117],"study_design_scores_gemma":[0.035023145,0.062944725,0.5109641,0.00083008443,0.14870317,0.00045197646,0.0019199231,0.0026948263,0.1905097,0.00020253747,0.045083947,0.00067184854],"about_ca_topic_score_codex":0.0008447842,"about_ca_topic_score_gemma":0.0037993435,"teacher_disagreement_score":0.4390093,"about_ca_system_score_codex":0.0012876075,"about_ca_system_score_gemma":0.0015017465,"threshold_uncertainty_score":0.7247865},"labels":[],"label_agreement":null},{"id":"W2030244887","doi":"10.1158/1078-0432.12aacriaslc-b34","title":"Abstract B34: Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Lung cancer; Cancer research; Targeted therapy; Medicine; Epidermal growth factor receptor; Receptor tyrosine kinase; Cancer; Small hairpin RNA; Tyrosine kinase; EGFR inhibitors; Bioinformatics; Biology; Gene; Oncology; Internal medicine; Receptor; Genetics","score_opus":0.1316648686409949,"score_gpt":0.519220940674001,"score_spread":0.3875560720330061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030244887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664665,0.019019833,0.000014650752,0.0057391273,0.0008130867,0.0017964195,0.00007072882,0.000034507528,0.006045144],"genre_scores_gemma":[0.98277426,0.005272925,0.00056143774,0.0013856925,0.0020902941,0.0011729603,0.000017427963,0.00006832302,0.0066567073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967198,0.00016713966,0.0007292232,0.0005963852,0.0007054077,0.0010820532],"domain_scores_gemma":[0.99745595,0.00069205114,0.00009809694,0.0005731595,0.00039180872,0.00078891113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001964869,0.00023541717,0.0005245284,0.00027070366,0.00018344715,0.000053045827,0.00022825916,0.00020995803,0.0008848081],"category_scores_gemma":[0.00027432723,0.00019098191,0.00016543096,0.0008306282,0.00015669179,0.00018165295,0.00011402525,0.0010392253,0.000090528236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024281438,0.001873334,0.9069664,0.00039708527,0.00013738587,0.00008845417,0.0016371978,0.000025736514,0.007950308,0.000055045697,0.044828035,0.03361287],"study_design_scores_gemma":[0.0067209215,0.00036568625,0.9024226,0.0011014981,0.00006224624,7.982559e-7,0.00024037843,0.000025771247,0.009792182,0.000028528684,0.078961626,0.00027775628],"about_ca_topic_score_codex":0.0037485228,"about_ca_topic_score_gemma":0.0030697177,"teacher_disagreement_score":0.034133594,"about_ca_system_score_codex":0.0013020637,"about_ca_system_score_gemma":0.0010960927,"threshold_uncertainty_score":0.9688028},"labels":[],"label_agreement":null},{"id":"W2030267719","doi":"10.3747/co.19.959","title":"Re. Karam I, Melosky B. Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Tyrosine kinase; Lung cancer; Gefitinib; Cancer research; Mutation; Second line; Statement (logic); Oncology; First line; Internal medicine; Cancer; Receptor; Genetics; Gene; Biology","score_opus":0.04993453140751817,"score_gpt":0.4229905339288198,"score_spread":0.3730560025213016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030267719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037653,0.00092937343,0.00023356559,0.0019677652,0.0013077364,0.0022032051,0.00018016643,0.000056025132,0.0027456058],"genre_scores_gemma":[0.9927909,0.000062847364,0.0032089134,0.0008485104,0.000337241,0.0016170137,0.00022142922,0.000042502306,0.00087067444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982287,0.00022695928,0.0004222355,0.00039847847,0.00020564126,0.0005179735],"domain_scores_gemma":[0.9984031,0.00028260553,0.00018871967,0.00031962796,0.00036065147,0.0004453435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025590177,0.00025569054,0.00042889928,0.00029649632,0.00012097447,0.000015791433,0.00009115951,0.00011867172,0.0007109299],"category_scores_gemma":[0.00009261796,0.00020774563,0.00005901627,0.00039451334,0.00006634199,0.00015480733,0.000043645676,0.0003144155,0.000106053754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01586212,0.019149873,0.6609253,0.0007642838,0.00074017636,0.00038988583,0.11638022,0.0023951952,0.0038175993,0.00014894671,0.01419427,0.16523209],"study_design_scores_gemma":[0.024660347,0.016046297,0.7104686,0.00095889095,0.0017441035,0.00010580012,0.0094587095,0.002415454,0.004303539,0.0000380676,0.22875534,0.0010448324],"about_ca_topic_score_codex":0.00015746456,"about_ca_topic_score_gemma":0.0047565824,"teacher_disagreement_score":0.21456107,"about_ca_system_score_codex":0.0014643605,"about_ca_system_score_gemma":0.0009927227,"threshold_uncertainty_score":0.8471621},"labels":[],"label_agreement":null},{"id":"W2030293545","doi":"10.3747/co.v16i1.393","title":"The Role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic, and Recurrent Non-Small-Cell Lung Cancer: A Canadian National Consensus Statement","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Royal Victoria Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Nova Scotia Cancer Centre; Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Oncology; Lung cancer; Internal medicine; Erlotinib; Clinical trial; Epidermal growth factor receptor; Targeted therapy; Chemotherapy; Tyrosine kinase; Cancer; Receptor","score_opus":0.032929288552221256,"score_gpt":0.39069927099007545,"score_spread":0.3577699824378542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030293545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9280831,0.045639385,0.000026625941,0.019274388,0.0017183127,0.0034873202,0.00092339254,0.000015013826,0.0008324483],"genre_scores_gemma":[0.9930141,0.0050101667,0.0005080089,0.0005029171,0.00016827052,0.00051977823,0.0000920736,0.00001654669,0.00016811962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988112,0.00007495691,0.0003725782,0.0002359884,0.0001893831,0.00031592022],"domain_scores_gemma":[0.9987508,0.00024337982,0.00023937986,0.00013363974,0.00043435607,0.00019842606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016425081,0.00017305734,0.00026863377,0.00007518619,0.00027805235,0.000013821085,0.00008788743,0.000043686698,0.000035841378],"category_scores_gemma":[0.000105861516,0.00010115606,0.000095265066,0.00012866648,0.00011826922,0.000029595669,0.000015965226,0.00014042264,0.0000012891043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001261089,0.0014956701,0.032291193,0.00018857345,0.0005293603,0.00000461039,0.0035930567,0.000041161453,0.0065804017,0.0029780606,0.026884124,0.9241527],"study_design_scores_gemma":[0.015623924,0.0034122746,0.030247953,0.00031281303,0.00060819107,0.00001985286,0.0014967219,0.0009628208,0.026305629,0.0021352633,0.918521,0.00035355386],"about_ca_topic_score_codex":0.0017992319,"about_ca_topic_score_gemma":0.004705414,"teacher_disagreement_score":0.92379916,"about_ca_system_score_codex":0.00083186134,"about_ca_system_score_gemma":0.0024600574,"threshold_uncertainty_score":0.4364036},"labels":[],"label_agreement":null},{"id":"W2030485399","doi":"10.3816/clc.2006.n.030","title":"K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review","year":2006,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Lung; Oncology; Internal medicine; Carcinoma; Small Cell Lung Carcinoma; Cancer research; Mutation; Small-cell carcinoma; Genetics; Gene; Biology","score_opus":0.0674510554685044,"score_gpt":0.47978170261092284,"score_spread":0.41233064714241846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030485399","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047221176,0.9809916,0.000030240399,0.0004576244,0.0010215896,0.00582698,0.0002742499,0.00006338546,0.011287123],"genre_scores_gemma":[0.000058162994,0.9833274,0.00035229855,0.0012527523,0.0009829235,0.003453611,0.0012248061,0.00013687156,0.009211196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556065,0.00024452386,0.0023542189,0.000989648,0.00030813587,0.0005428451],"domain_scores_gemma":[0.997268,0.0006374113,0.00073455676,0.00084153854,0.00019315715,0.00032532317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049148,0.0006378087,0.0035885598,0.00023592278,0.00008948099,0.00002828257,0.00025987823,0.00055223145,0.00047229006],"category_scores_gemma":[0.00015786482,0.00048489677,0.0014182483,0.0008749522,0.00012276525,0.00006467564,0.000085549545,0.0011198659,0.000121442165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012198752,0.0008024215,0.014515432,0.18170092,0.00062454597,0.0003326783,0.00003475775,0.0000031196394,2.7395211e-8,0.000016479,0.11981424,0.68214315],"study_design_scores_gemma":[0.0018626078,0.000093508614,0.002430471,0.11507256,0.021300193,0.000024849362,0.0000056386184,0.000045410805,7.8158095e-8,0.0000060314073,0.8587356,0.0004230519],"about_ca_topic_score_codex":0.0007662735,"about_ca_topic_score_gemma":0.00046145014,"teacher_disagreement_score":0.73892134,"about_ca_system_score_codex":0.0012780969,"about_ca_system_score_gemma":0.003565866,"threshold_uncertainty_score":0.99976027},"labels":[],"label_agreement":null},{"id":"W2030882637","doi":"10.1158/1078-0432.ccr-06-0261","title":"Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy","year":2006,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Epidermal growth factor receptor; Cancer research; Tyrosine kinase; Lung cancer; Tyrosine-kinase inhibitor; Epidermal growth factor; Cancer; Receptor tyrosine kinase; Receptor; Medicine; Biology; Oncology; Internal medicine","score_opus":0.25774027928360477,"score_gpt":0.5452083421699896,"score_spread":0.2874680628863848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030882637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004517688,0.9729114,0.00022374073,0.0007939396,0.0017015184,0.01623344,0.0033602407,0.000079188845,0.00017884746],"genre_scores_gemma":[0.00039553505,0.9640143,0.0014434241,0.00027727624,0.004193386,0.02494371,0.0015243769,0.0001815097,0.0030264612],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99461734,0.00059715955,0.0016528929,0.00140908,0.00056021713,0.0011633355],"domain_scores_gemma":[0.99379826,0.0032280488,0.0005116069,0.00042224422,0.0015182949,0.0005215661],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001221491,0.00063417363,0.0022845934,0.00033810118,0.0004325247,0.00008323548,0.0002850851,0.0009769764,0.0005123345],"category_scores_gemma":[0.00067302363,0.00042003422,0.0014970183,0.00070618995,0.00030935486,0.00007237446,0.00009731282,0.0012458498,0.000017103726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018656023,0.0011543832,0.0034873153,0.01156914,0.0008189878,0.000005621742,0.000040516446,0.0000010088521,0.000025184749,0.0000137128745,0.12615979,0.85485876],"study_design_scores_gemma":[0.004959114,0.0039973496,0.00040953822,0.0049595856,0.00090537284,0.0000024078965,0.000017376491,0.000064670785,0.00019065777,0.000019900475,0.98402077,0.00045323797],"about_ca_topic_score_codex":0.0012321428,"about_ca_topic_score_gemma":0.00018549654,"teacher_disagreement_score":0.857861,"about_ca_system_score_codex":0.0020060795,"about_ca_system_score_gemma":0.004393639,"threshold_uncertainty_score":0.9998251},"labels":[],"label_agreement":null},{"id":"W2030901022","doi":"10.1097/jto.0b013e3181729299","title":"A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Proportional hazards model; Erlotinib Hydrochloride; Lung cancer; Placebo; Oncology; Cancer; Epidermal growth factor receptor; Pathology","score_opus":0.13341071472068913,"score_gpt":0.5576453272849964,"score_spread":0.4242346125643073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030901022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958786,0.00011909396,0.00007149504,0.000804786,0.001051838,0.001770064,0.000056052733,0.0000037640693,0.00024430954],"genre_scores_gemma":[0.9974615,0.00008180519,0.0013346967,0.00029646544,0.00047688134,0.00010499726,0.000022145727,0.000014319924,0.00020720717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962853,0.0006088498,0.0022462208,0.00019155568,0.0004790822,0.00018899667],"domain_scores_gemma":[0.9953928,0.0015748802,0.0016080413,0.000095910735,0.001132152,0.00019620248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002693302,0.00013524157,0.0013244019,0.00018353866,0.00005960881,0.000003270359,0.00009515307,0.00013952768,0.000028152574],"category_scores_gemma":[0.0033282943,0.00008598931,0.00018585422,0.00024159178,0.00014017407,0.000102715334,0.00001543601,0.00033571813,2.6991214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010370325,0.0058743344,0.95066285,0.000033136035,0.0010644681,0.000293234,0.00021442767,0.000056505738,0.0000019150032,0.000004773096,0.0025659264,0.028858082],"study_design_scores_gemma":[0.017202891,0.01627116,0.9575813,0.00017599299,0.0010423046,0.00011066955,0.00016683222,0.00005682724,0.0000040662994,0.000018249571,0.007292854,0.000076880606],"about_ca_topic_score_codex":0.009727605,"about_ca_topic_score_gemma":0.12883975,"teacher_disagreement_score":0.11911214,"about_ca_system_score_codex":0.00076878647,"about_ca_system_score_gemma":0.010201621,"threshold_uncertainty_score":0.9968667},"labels":[],"label_agreement":null},{"id":"W2031379570","doi":"10.1081/cnv-67172","title":"State of the Art in Therapy for Non-Small Cell Lung Cancer","year":2005,"lang":"en","type":"review","venue":"Cancer Investigation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Disease; Chemotherapy; Radiation therapy; Intensive care medicine; Quality of life (healthcare); Oncology; Cancer; Adjuvant chemotherapy; Internal medicine; Surgery; Breast cancer; Nursing","score_opus":0.058486521006174144,"score_gpt":0.3933712949867484,"score_spread":0.33488477398057426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031379570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001486857,0.99255824,0.00003670676,0.00044793996,0.0004508198,0.004321335,0.00031594548,0.000013248996,0.00036890805],"genre_scores_gemma":[0.00012563662,0.9897543,0.00028260544,0.00044721534,0.0002970864,0.004233782,0.00020222427,0.000056763092,0.004600347],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881494,0.00004323152,0.0004990827,0.0002924902,0.00015296976,0.00019731508],"domain_scores_gemma":[0.99897647,0.00006455021,0.00046061963,0.00029660316,0.00012638152,0.000075389835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104527666,0.00025634692,0.000750536,0.000120015844,0.000047529516,0.000011275691,0.000121996425,0.000120845165,0.000048326136],"category_scores_gemma":[0.000010111015,0.00016041886,0.00026700005,0.00037303258,0.000076832,0.000052528565,0.0000115160665,0.00018570607,0.0000027110066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015173685,0.000054789172,0.001366726,0.010270826,0.00022959572,6.6705877e-7,0.0007618857,0.00016129551,0.000019305007,0.0000129848895,0.005703991,0.98140275],"study_design_scores_gemma":[0.0015279093,0.000053167736,0.0008247187,0.01574207,0.0013489821,0.0000013812642,0.0000076480455,0.00015555532,0.00034456878,0.00006800163,0.9797504,0.00017558462],"about_ca_topic_score_codex":0.00030576927,"about_ca_topic_score_gemma":0.0005838026,"teacher_disagreement_score":0.98122716,"about_ca_system_score_codex":0.00075945136,"about_ca_system_score_gemma":0.0025953741,"threshold_uncertainty_score":0.65416914},"labels":[],"label_agreement":null},{"id":"W2031398056","doi":"10.1158/1538-7445.am2012-lb-449","title":"Abstract LB-449: KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small-cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"KRAS; Antifolate; Pemetrexed; Cancer research; Biology; Cancer; Mutation; Molecular biology; Antimetabolite; Chemotherapy; Gene; Genetics; Cisplatin","score_opus":0.05520699532945354,"score_gpt":0.4316036562978303,"score_spread":0.37639666096837676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031398056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898062,0.005998653,0.00013378369,0.0012994324,0.0001684686,0.0014542466,0.000096808646,0.00002857866,0.0010138795],"genre_scores_gemma":[0.99605536,0.0020014201,0.00022631258,0.0001557296,0.00024398125,0.0006576593,0.000052228264,0.000032078628,0.0005752509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983748,0.00009123192,0.00019713814,0.00031782012,0.00037991337,0.0006390514],"domain_scores_gemma":[0.99893814,0.00015573426,0.000049766266,0.00022594693,0.00028660905,0.00034378824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006552053,0.00013811316,0.00019914341,0.00029212298,0.00015817548,0.000052285064,0.00004014521,0.00008061186,0.00013761836],"category_scores_gemma":[0.00005168973,0.000118748285,0.000026795438,0.0004698483,0.000070833674,0.00022685788,0.000039002913,0.00028779218,0.000020128537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036495898,0.00037638142,0.79088265,0.0005420379,0.00016778172,0.000047139147,0.019303532,0.00019089572,0.14282507,0.000054766424,0.0015625759,0.043682218],"study_design_scores_gemma":[0.0015105631,0.00007856563,0.98074776,0.00028088802,0.00006436293,0.000004759981,0.0009285921,0.00025526155,0.014235174,0.000019302279,0.0017526895,0.0001220735],"about_ca_topic_score_codex":0.011054266,"about_ca_topic_score_gemma":0.002424768,"teacher_disagreement_score":0.18986513,"about_ca_system_score_codex":0.0007824631,"about_ca_system_score_gemma":0.0004827382,"threshold_uncertainty_score":0.9955312},"labels":[],"label_agreement":null},{"id":"W2031403784","doi":"10.1097/jto.0b013e31815ba7d0","title":"Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of California, Davis","keywords":"Medicine; Pemetrexed; Internal medicine; Neutropenia; Tolerability; Lung cancer; Oncology; Progressive disease; Bortezomib; Toxicity; Gastroenterology; Surgery; Chemotherapy; Adverse effect; Multiple myeloma; Cisplatin","score_opus":0.01833055488774541,"score_gpt":0.4664682977449494,"score_spread":0.448137742857204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031403784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974478,0.0010824947,0.00025198612,0.00017136129,0.00015869876,0.0005428633,0.000008198367,0.000002791564,0.00033384134],"genre_scores_gemma":[0.997439,0.00018510729,0.0021594074,0.00005372423,0.00006466643,0.000013402647,0.000001784753,0.000015786658,0.000067118206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987173,0.00006176996,0.0006705068,0.00014448943,0.00022080715,0.00018512897],"domain_scores_gemma":[0.9985722,0.00014689604,0.00078281335,0.00013021573,0.00023538648,0.00013252777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031023758,0.00014688699,0.00078461034,0.0004247197,0.000025459158,0.0000027445471,0.0000659441,0.000049879007,0.00002249976],"category_scores_gemma":[0.000025468784,0.000094577204,0.00006012772,0.00021369896,0.000057636273,0.000054573116,0.000017772954,0.00021821538,1.0932292e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020619208,0.027037598,0.6371267,0.00041346913,0.000998387,0.00120729,0.007336375,0.0006861468,0.023707941,0.000009928621,0.000028683182,0.2808283],"study_design_scores_gemma":[0.06594608,0.07099912,0.74728197,0.0015342402,0.0034336636,0.00020705472,0.015843788,0.00027483096,0.09412642,0.000028488063,0.00009171684,0.0002326587],"about_ca_topic_score_codex":0.00012870709,"about_ca_topic_score_gemma":0.000996895,"teacher_disagreement_score":0.28059563,"about_ca_system_score_codex":0.00035991406,"about_ca_system_score_gemma":0.00036518925,"threshold_uncertainty_score":0.38567463},"labels":[],"label_agreement":null},{"id":"W2031514510","doi":"10.1177/1078155210381794","title":"Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents","year":2010,"lang":"en","type":"review","venue":"Journal of Oncology Pharmacy Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Pharmacology; Famotidine; Drug interaction; Drug; Ranitidine; Cimetidine; Context (archaeology); Pharmacokinetics; Epidermal growth factor receptor; Internal medicine; Cancer","score_opus":0.25394962200006704,"score_gpt":0.5227555704228933,"score_spread":0.2688059484228263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031514510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03773067,0.9301742,0.000037848586,0.02365828,0.0038807893,0.0029613804,0.00014545709,0.00002374073,0.001387655],"genre_scores_gemma":[0.025169872,0.96923333,0.0014353215,0.002021405,0.0014809285,0.00005631911,0.00003844184,0.00008493601,0.000479434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995231,0.0015574914,0.0018591245,0.00040947492,0.00057104975,0.0003718962],"domain_scores_gemma":[0.9861464,0.0072370893,0.005232715,0.00042658238,0.0006312002,0.0003260029],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028626746,0.0005224953,0.001985514,0.00030658318,0.0004331014,0.00014713006,0.00033465258,0.00026974283,0.00013149022],"category_scores_gemma":[0.003049695,0.00028204685,0.00044646405,0.00029920088,0.000348578,0.0012311582,0.00019386741,0.003517852,0.000005889798],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006187688,0.0006027467,0.00053189753,0.0016468439,0.0058169016,0.00034269446,0.0053691627,0.0000061913056,0.00027479156,0.000012991014,0.015130613,0.9696464],"study_design_scores_gemma":[0.0036584698,0.00049414684,0.00031047247,0.003162035,0.029636625,0.0070230504,0.0014226029,0.000029007075,0.00018917095,0.000005060448,0.9538662,0.00020317557],"about_ca_topic_score_codex":0.00033198035,"about_ca_topic_score_gemma":0.00002148515,"teacher_disagreement_score":0.9694432,"about_ca_system_score_codex":0.000558957,"about_ca_system_score_gemma":0.0017955232,"threshold_uncertainty_score":0.99996316},"labels":[],"label_agreement":null},{"id":"W2031570350","doi":"10.1097/jto.0b013e318283d958","title":"KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer","year":2013,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; KRAS; Lung cancer; Oncology; Internal medicine; Lung; Cancer; Cancer research; Pathology; Colorectal cancer","score_opus":0.026520790264676575,"score_gpt":0.464020375822829,"score_spread":0.43749958555815244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031570350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031029093,0.9896275,0.00007864499,0.00048251604,0.00062637014,0.002073016,0.000047886195,0.0000066515213,0.003954507],"genre_scores_gemma":[0.0008902767,0.9944238,0.001883811,0.000104760875,0.0003334584,0.00040735924,0.000041553598,0.00004362664,0.0018713293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982385,0.00022183101,0.0008736898,0.0002311783,0.00017971141,0.00025511443],"domain_scores_gemma":[0.9977897,0.00045720473,0.001087772,0.00013467307,0.00028651694,0.00024416702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028746563,0.00028475368,0.0016484542,0.0005346001,0.000052821106,0.000022255841,0.000108434884,0.00035293572,0.00020086067],"category_scores_gemma":[0.00011598389,0.00019576949,0.00026036607,0.00028954487,0.000090474714,0.00010779842,0.000031045558,0.0007450686,0.000014875881],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014794436,0.00038912764,0.0010515476,0.00893851,0.0010643628,0.0007578931,0.00069102313,0.000013455519,0.0000011669556,0.0000030761892,0.0015805719,0.98536134],"study_design_scores_gemma":[0.0020241768,0.0043088016,0.003474143,0.031448178,0.037633993,0.0035818282,0.0007673411,0.00013090632,0.0000029226649,0.00012524903,0.91614443,0.00035804493],"about_ca_topic_score_codex":0.0000984994,"about_ca_topic_score_gemma":0.00005370588,"teacher_disagreement_score":0.9850033,"about_ca_system_score_codex":0.0012591507,"about_ca_system_score_gemma":0.004292761,"threshold_uncertainty_score":0.7983248},"labels":[],"label_agreement":null},{"id":"W2031625514","doi":"10.1097/01.jto.0000269737.05962.a0","title":"Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Epidermal growth factor receptor; Gemcitabine; Internal medicine; ERCC1; Targeted therapy; Cancer research; KRAS; Tyrosine kinase; Cancer; Predictive marker; Chemotherapy; Erlotinib; Adjuvant therapy; DNA repair; Gene; Biology; Receptor","score_opus":0.052436483941243665,"score_gpt":0.5092956571945961,"score_spread":0.45685917325335246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031625514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055668666,0.98870623,0.0008276704,0.00012585621,0.0012286939,0.0025362417,0.00014294942,0.000006716363,0.0008587591],"genre_scores_gemma":[0.0004986199,0.9833153,0.014495483,0.00013087064,0.00056796684,0.00032142422,0.00012028981,0.00006862692,0.00048141772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978801,0.00011722786,0.0011545471,0.0002975044,0.00014328051,0.00040730985],"domain_scores_gemma":[0.99679977,0.0008978031,0.0014761576,0.00021271392,0.00038681936,0.00022673869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032810587,0.00038849603,0.0025222348,0.0007608512,0.000072684204,0.000010901541,0.00015500616,0.0003311373,0.000046388297],"category_scores_gemma":[0.000068506204,0.00021561125,0.0005167131,0.00031082454,0.000049165956,0.000054784603,0.00002587662,0.00041265687,0.0000034730867],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065515796,0.001570055,0.003995771,0.00190021,0.00090695015,0.00030400485,0.00021416252,0.0000055999503,3.875069e-7,0.0000039547876,0.0003192969,0.99012446],"study_design_scores_gemma":[0.004077719,0.0071562105,0.0005277505,0.010820568,0.010818346,0.00017619331,0.000055833214,0.000006904577,0.0000029119317,0.000015253177,0.9661451,0.0001972246],"about_ca_topic_score_codex":0.00006601129,"about_ca_topic_score_gemma":0.00019250812,"teacher_disagreement_score":0.98992723,"about_ca_system_score_codex":0.0039034968,"about_ca_system_score_gemma":0.0041724714,"threshold_uncertainty_score":0.99992037},"labels":[],"label_agreement":null},{"id":"W2032371685","doi":"10.1016/j.lungcan.2005.06.010","title":"Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline","year":2005,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Cancer Care Ontario","funders":"European Society for Medical Oncology","keywords":"Docetaxel; Taxane; Medicine; Oncology; Vinorelbine; Gemcitabine; Internal medicine; Lung cancer; Cisplatin; Paclitaxel; Guideline; Chemotherapy; Regimen; Cancer; Breast cancer; Pathology","score_opus":0.030239857460425346,"score_gpt":0.4431672683192456,"score_spread":0.41292741085882023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032371685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011313567,0.96914077,0.00032373195,0.0043715346,0.0005178992,0.023736943,0.00058894715,0.0000907888,0.0012282863],"genre_scores_gemma":[0.0000017212934,0.94927895,0.0032828078,0.0071141724,0.0008913506,0.02786761,0.000492415,0.00021018856,0.010860794],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964108,0.0001383833,0.0016514328,0.0009059788,0.00034992633,0.0005434741],"domain_scores_gemma":[0.9957992,0.00074339425,0.0016589444,0.0008209367,0.0006915444,0.00028600646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048383637,0.000887373,0.0043223435,0.00016052894,0.00021551832,0.000058824244,0.00023843975,0.00029514928,0.00032224527],"category_scores_gemma":[0.00037573156,0.0006012859,0.00063522154,0.00041965337,0.000045158195,0.00019583695,0.000052544787,0.00034722374,0.000012712227],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006679964,0.00016524791,0.000003986607,0.81157994,0.0025240614,0.000020787485,0.00016905708,0.000013576859,4.4085482e-7,0.000009849701,0.020680299,0.16476592],"study_design_scores_gemma":[0.0017163866,0.00015954045,2.6455274e-7,0.341141,0.05257552,0.00010231919,0.000021247377,0.00006857872,0.0000011303994,0.0000012456991,0.6038538,0.00035896563],"about_ca_topic_score_codex":0.00057040487,"about_ca_topic_score_gemma":0.00022904444,"teacher_disagreement_score":0.5831735,"about_ca_system_score_codex":0.0012945834,"about_ca_system_score_gemma":0.002085456,"threshold_uncertainty_score":0.99964386},"labels":[],"label_agreement":null},{"id":"W2032604714","doi":"10.1097/jto.0b013e3181eaf30f","title":"Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Gemcitabine; Cisplatin; Lung cancer; Oncology; Internal medicine; Phases of clinical research; Chemotherapy; Histology","score_opus":0.014013495300058607,"score_gpt":0.37180322837231183,"score_spread":0.3577897330722532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032604714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99090225,0.0024843344,0.0005310694,0.0009151082,0.0008429835,0.0030752714,0.00025862284,0.000010236236,0.0009801557],"genre_scores_gemma":[0.99639934,0.00052502076,0.0018992429,0.0001702719,0.00016779857,0.00014222936,0.0001783068,0.000047846985,0.00046991714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996931,0.0003490308,0.0014945501,0.00045047395,0.00040909435,0.00036581192],"domain_scores_gemma":[0.9951413,0.0014883919,0.0022205445,0.0003704079,0.00057319104,0.00020613821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008907812,0.00036684168,0.0016557397,0.00024990176,0.00016235794,0.000016167023,0.00023411661,0.00025592212,0.00008737202],"category_scores_gemma":[0.0002771495,0.00023651999,0.00012965222,0.00040921933,0.0001902859,0.00013605296,0.00007979578,0.00083653897,3.6603217e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8838141,0.0039301543,0.04083653,0.00020014374,0.0013362666,0.00014688463,0.029826146,0.0030548233,0.003961487,0.0000012761773,0.0022563345,0.030635865],"study_design_scores_gemma":[0.93441695,0.004898246,0.031459633,0.0004942966,0.00690885,0.000013115473,0.004763562,0.012667207,0.0018616444,0.0000036340878,0.0021461814,0.00036670692],"about_ca_topic_score_codex":0.002668731,"about_ca_topic_score_gemma":0.0064894403,"teacher_disagreement_score":0.050602835,"about_ca_system_score_codex":0.001168949,"about_ca_system_score_gemma":0.0012763843,"threshold_uncertainty_score":0.96450055},"labels":[],"label_agreement":null},{"id":"W2032713794","doi":"10.1097/01.jto.0000283530.57729.23","title":"P2-066: Analysis of EGFR gene copy number, EGFR mutations, KRAS mutations and EGFR expression in a cohort of non-small cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors at a North American institution.","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"KRAS; Erlotinib; CISH; Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; Chromogenic in situ hybridization; Cancer research; Population; Tyrosine kinase; Fluorescence in situ hybridization; Neuroblastoma RAS viral oncogene homolog; Gene duplication; EGFR inhibitors; Oncology; Cancer; Internal medicine; Gene; Biology; Gene expression; In situ hybridization; Genetics; Receptor","score_opus":0.009157552079469352,"score_gpt":0.3628220872885492,"score_spread":0.35366453520907987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032713794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728626,0.0004155757,0.0010080545,0.00016764329,0.00010829508,0.000600617,0.00020220251,0.000007867802,0.00020346825],"genre_scores_gemma":[0.9934862,0.00031817926,0.005730176,0.00008015175,0.000057635716,0.00003246969,0.00020958706,0.000021219284,0.000064339685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978954,0.00012664229,0.0010961308,0.00025343176,0.00035700752,0.00027135416],"domain_scores_gemma":[0.9969024,0.00022607052,0.0015742584,0.00015346907,0.00088898314,0.00025480104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022697277,0.00022904859,0.0010129089,0.00091931707,0.00010558596,0.0000074720133,0.000079774516,0.000103133614,0.00005158271],"category_scores_gemma":[0.000079609075,0.00017061968,0.00016274561,0.0016072588,0.00030727955,0.0001849969,0.000034491197,0.0002274764,6.532062e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017829163,0.001559227,0.9823024,0.00012795565,0.0012333508,0.00019797769,0.0019178408,0.0011290584,0.0051254476,0.0000012353273,0.00006792051,0.004554656],"study_design_scores_gemma":[0.0033030608,0.0014218944,0.9502577,0.0002083922,0.005598659,0.000048672457,0.00042400183,0.00023890902,0.038302176,0.0000013245548,0.000056534955,0.00013867546],"about_ca_topic_score_codex":0.002060781,"about_ca_topic_score_gemma":0.004547068,"teacher_disagreement_score":0.033176728,"about_ca_system_score_codex":0.0013356776,"about_ca_system_score_gemma":0.00070544495,"threshold_uncertainty_score":0.6957668},"labels":[],"label_agreement":null},{"id":"W2033266412","doi":"10.1136/jcp.2005.031351","title":"Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Immunohistochemistry; Pathology; Lung cancer; Lung; Medicine; Cancer; Biology; Internal medicine","score_opus":0.07916123705072226,"score_gpt":0.4964492865478379,"score_spread":0.4172880494971156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033266412","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078266626,0.9905841,0.0003120837,0.00035954974,0.00023851225,0.0071067256,0.00007467997,0.000002859042,0.00053884555],"genre_scores_gemma":[0.00016459463,0.96118397,0.036792528,0.00018394525,0.00020999867,0.0012223898,0.00008861444,0.00003755686,0.00011642534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956842,0.00048272524,0.0030039267,0.00036387777,0.00024697746,0.00021831527],"domain_scores_gemma":[0.99643797,0.0006110214,0.0019798763,0.0002018372,0.00059750344,0.00017182094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003429817,0.00027605172,0.0035176594,0.00024301003,0.00001978282,0.0000052198816,0.00013130813,0.0003998491,0.000015314235],"category_scores_gemma":[0.001083062,0.00018600258,0.0008196606,0.00023104715,0.00010052679,0.000034267854,0.00003969926,0.00057105965,4.684248e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006547232,0.002197535,0.0023915216,0.09579798,0.0006072647,0.00006547288,0.000053582204,0.000003338559,0.000006698386,0.000003895066,0.006264107,0.8919539],"study_design_scores_gemma":[0.039927267,0.01081209,0.00845309,0.23983267,0.17207544,0.0026620817,0.00007843126,0.00080679177,0.000008193972,0.00009686302,0.52401364,0.0012334475],"about_ca_topic_score_codex":0.000015650097,"about_ca_topic_score_gemma":0.0000045216734,"teacher_disagreement_score":0.8907204,"about_ca_system_score_codex":0.00029273075,"about_ca_system_score_gemma":0.0026312962,"threshold_uncertainty_score":0.75849646},"labels":[],"label_agreement":null},{"id":"W2033630804","doi":"10.1016/s1556-0864(15)31590-2","title":"Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montfort Hospital","funders":"Bristol-Myers Squibb","keywords":"Medicine; Carboplatin; Lung cancer; Neutropenia; Internal medicine; Confidence interval; Regimen; Performance status; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Febrile neutropenia; Surgery; Oncology; Progressive disease; Cisplatin","score_opus":0.007400073066617246,"score_gpt":0.3712792204894756,"score_spread":0.3638791474228584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033630804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547267,0.00039690794,0.0000678918,0.0007762383,0.00022404142,0.0016099622,0.00002962595,0.000011053515,0.0014116158],"genre_scores_gemma":[0.99484295,0.000012184988,0.0042210254,0.0001265093,0.000101075646,0.00009811961,0.000022898661,0.00003379274,0.0005414553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984285,0.00009992297,0.00062343664,0.00022866594,0.00031066115,0.00030877496],"domain_scores_gemma":[0.99845755,0.00007287667,0.00068442634,0.00018448666,0.00044961183,0.00015102615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016512071,0.00023032208,0.0006900217,0.0002553527,0.00009245464,0.000013402725,0.00009906395,0.00008289872,0.00003112625],"category_scores_gemma":[0.000012327805,0.00014653265,0.00006988294,0.00026101625,0.00004574915,0.00016279341,0.000023476981,0.00036097775,9.1234614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038958274,0.03131944,0.87277937,0.00013435722,0.00059053075,0.0014721544,0.004704362,0.0017647537,0.00042576715,0.0000011384074,0.00054288126,0.04730698],"study_design_scores_gemma":[0.11252378,0.20102093,0.675242,0.00073418487,0.0031303521,0.000037719834,0.004567396,0.0006251961,0.0005030371,0.000009583216,0.0012751278,0.00033068607],"about_ca_topic_score_codex":0.00061219407,"about_ca_topic_score_gemma":0.002870652,"teacher_disagreement_score":0.19753735,"about_ca_system_score_codex":0.0008016165,"about_ca_system_score_gemma":0.00072039943,"threshold_uncertainty_score":0.5975428},"labels":[],"label_agreement":null},{"id":"W2034309045","doi":"10.1016/s0169-5002(03)00161-2","title":"Ongoing and future trials of biologic therapies in lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Chemotherapy; Oncology; Clinical trial; Cancer; Intensive care medicine; Targeted therapy; Internal medicine; Lung","score_opus":0.05967837281913717,"score_gpt":0.4635147829541828,"score_spread":0.4038364101350456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034309045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025730662,0.99508834,0.0000033127164,0.00028957936,0.00092312135,0.0020866576,0.00034635034,0.000021890708,0.000983422],"genre_scores_gemma":[0.00006664925,0.9961336,0.00014816926,0.00017676615,0.00074782316,0.0013157495,0.000087032975,0.00004924977,0.0012749147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980665,0.00024126389,0.000857355,0.00041145436,0.0001560035,0.00026746182],"domain_scores_gemma":[0.99879915,0.00020189083,0.00059023383,0.0002603076,0.00006965641,0.00007877443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038125122,0.00038208754,0.0027164218,0.00024173198,0.00004686977,0.000015739746,0.00007616207,0.00032214404,0.0007235485],"category_scores_gemma":[0.00003743191,0.00023261945,0.00035678336,0.0003908289,0.00006381038,0.000049127062,0.000021323962,0.0002749896,8.606506e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030846488,0.00006225829,0.0061176056,0.023816884,0.0022330356,0.000015668891,0.0005641655,0.0000015926429,0.0000031209443,0.00018559449,0.001828975,0.9651402],"study_design_scores_gemma":[0.0013237316,0.00005167404,0.0005096048,0.018827721,0.0061019324,0.000011437876,0.00006453917,0.0000041635353,0.0000026472228,0.0000108287795,0.97286516,0.00022653755],"about_ca_topic_score_codex":0.00091987086,"about_ca_topic_score_gemma":0.00052642985,"teacher_disagreement_score":0.9710362,"about_ca_system_score_codex":0.00063296786,"about_ca_system_score_gemma":0.0010789151,"threshold_uncertainty_score":0.94859457},"labels":[],"label_agreement":null},{"id":"W2035196686","doi":"10.1097/jto.0000000000000314","title":"Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Steering committee; Medical physics; Oncology; Engineering management","score_opus":0.10711290547778558,"score_gpt":0.5311780178185476,"score_spread":0.424065112340762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035196686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9480658,0.0008999922,0.03726343,0.00594002,0.00050352054,0.007159129,0.000010416752,0.0000068731083,0.00015083165],"genre_scores_gemma":[0.9107126,0.000047203743,0.086631335,0.00019429198,0.00024242619,0.0019776616,0.0000034806947,0.0000248418,0.0001661843],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973189,0.00018560133,0.0018381112,0.00018958554,0.00025073043,0.00021705736],"domain_scores_gemma":[0.9963658,0.0007820064,0.0019132029,0.00018821035,0.0006625276,0.00008826152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002405615,0.00017875333,0.00092972594,0.00026105376,0.00007640672,0.000014658179,0.00013296101,0.00013824315,0.000014079419],"category_scores_gemma":[0.0005897294,0.000112215625,0.0002066628,0.00022337816,0.00011866797,0.000081430335,0.000036470476,0.00022589092,6.795327e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010291992,0.00060667744,0.08608917,0.0030475794,0.0021015743,0.00002385468,0.03903792,0.003671636,0.023601407,0.00016820974,0.0031774007,0.8281826],"study_design_scores_gemma":[0.029585242,0.02912818,0.36048326,0.112529196,0.008773548,0.0006724191,0.2025509,0.023709893,0.13868071,0.0029418047,0.08887785,0.0020670004],"about_ca_topic_score_codex":0.00016596414,"about_ca_topic_score_gemma":0.0019226111,"teacher_disagreement_score":0.82611555,"about_ca_system_score_codex":0.0006677389,"about_ca_system_score_gemma":0.0026829098,"threshold_uncertainty_score":0.47593668},"labels":[],"label_agreement":null},{"id":"W2036489555","doi":"10.1002/ssu.10016","title":"Prognostic factors in cancer","year":2003,"lang":"en","type":"review","venue":"Seminars in Surgical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":289,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Disease; Cancer; Affect (linguistics); Intensive care medicine; Clinical Practice; Relevance (law); Oncology; Internal medicine; Family medicine; Psychology","score_opus":0.062109771294127314,"score_gpt":0.46951062991220605,"score_spread":0.40740085861807873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036489555","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032482136,0.95712835,2.7091855e-7,0.000078848476,0.00054016145,0.0013729458,0.000034339908,0.000018908533,0.04050137],"genre_scores_gemma":[0.00010057017,0.9951202,0.00007799955,0.00005225829,0.00008210003,0.00084464747,0.0001892311,0.000041648476,0.0034912948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980945,0.00023568922,0.0006546592,0.0004481376,0.00015182876,0.00041520168],"domain_scores_gemma":[0.99877346,0.00067474466,0.00017410953,0.0002026576,0.00002885541,0.00014617013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017429751,0.00033533602,0.0021927482,0.00034668317,0.000020991843,0.00000518938,0.00008955269,0.0006387524,0.0004991665],"category_scores_gemma":[0.00006510932,0.00023031502,0.00027208286,0.00065030064,0.0000972035,0.000024759765,0.00003183121,0.00064734125,0.000036032085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017179382,0.00063080544,0.0056950618,0.0023676462,0.00011327961,0.003296903,0.0001568163,0.0000014360561,1.6458209e-8,0.000082686274,0.00038159412,0.9872566],"study_design_scores_gemma":[0.0010186972,0.00037985903,0.00013606768,0.012399559,0.00094362727,0.00028434835,0.000046106732,7.466639e-7,1.5051113e-7,0.000019879228,0.98458326,0.00018769148],"about_ca_topic_score_codex":0.00017268765,"about_ca_topic_score_gemma":0.00023224972,"teacher_disagreement_score":0.9870689,"about_ca_system_score_codex":0.0024079962,"about_ca_system_score_gemma":0.0019404773,"threshold_uncertainty_score":0.9391974},"labels":[],"label_agreement":null},{"id":"W2037177568","doi":"10.1097/jto.0b013e318275b327","title":"Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Regional Municipality of Durham; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Erlotinib; Quality of life (healthcare); Internal medicine; Gemcitabine; Lung cancer; Oncology; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.037281891279979544,"score_gpt":0.46244101102089336,"score_spread":0.4251591197409138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037177568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905233,0.0042621903,0.00126259,0.0011136129,0.0005581062,0.0012756576,0.00007411383,0.0000075623752,0.0009228895],"genre_scores_gemma":[0.98926306,0.00036751758,0.009050311,0.00030952596,0.00036742314,0.00007917777,0.000032758253,0.00002371635,0.00050649187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963925,0.00042147367,0.002328137,0.00018803177,0.00034109093,0.00032878213],"domain_scores_gemma":[0.9939023,0.0020045023,0.0030228796,0.00023197051,0.00058932824,0.00024902035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027837772,0.00023188874,0.0029854863,0.00053877407,0.000040273368,0.000004768516,0.00013811029,0.00019111203,0.000434134],"category_scores_gemma":[0.0014031604,0.00017046183,0.0006478801,0.0010297861,0.00009415568,0.00015308184,0.000025847203,0.0003278697,3.476128e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83002406,0.0045592403,0.10537179,0.00058370235,0.0072957305,0.000016198474,0.0034097608,0.0023012294,0.025305152,0.000006171037,0.0005598735,0.020567087],"study_design_scores_gemma":[0.9463391,0.0033915306,0.025697585,0.0003510341,0.012830207,0.000016662281,0.00052102795,0.003676062,0.0060531925,0.000020978272,0.0008365457,0.00026612266],"about_ca_topic_score_codex":0.0004990176,"about_ca_topic_score_gemma":0.00056778337,"teacher_disagreement_score":0.116314985,"about_ca_system_score_codex":0.00045587283,"about_ca_system_score_gemma":0.00094420544,"threshold_uncertainty_score":0.69512314},"labels":[],"label_agreement":null},{"id":"W2037559535","doi":"10.1097/cco.0b013e3282f335a3","title":"Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes","year":2008,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Exelixis","keywords":"Erlotinib; Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; Tyrosine kinase; Erlotinib Hydrochloride; Tyrosine-kinase inhibitor; Monoclonal antibody; Docetaxel; Cancer research; Bevacizumab; EGFR inhibitors; Clinical trial; Oncology; Pharmacology; Cancer; Internal medicine; Receptor; Antibody; Immunology; Chemotherapy","score_opus":0.13193670485339143,"score_gpt":0.5022138484156957,"score_spread":0.3702771435623043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037559535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035828786,0.99329364,0.000001386169,0.000836906,0.002773106,0.0022403884,0.0003091952,0.000010405076,0.00017666839],"genre_scores_gemma":[0.00012296188,0.9974471,0.000026164276,0.000017061759,0.00061997835,0.00122005,0.0005065388,0.000019552452,0.000020633797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980764,0.000389684,0.0007706592,0.0003729476,0.00015095221,0.0002393504],"domain_scores_gemma":[0.9988527,0.00042948336,0.00037159224,0.00021929313,0.000051595158,0.00007530606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009261941,0.00031248468,0.0015502033,0.0002700076,0.000044285975,0.000004958165,0.00008688935,0.00023723007,0.000039589777],"category_scores_gemma":[0.000046251826,0.00018177927,0.00022083675,0.00032675228,0.00014571323,0.00004006797,0.000022039641,0.0002499008,0.000002337091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028299353,0.0012033483,0.006707609,0.0068666534,0.00014273322,0.000006303138,0.002100474,2.4878688e-7,5.3548302e-8,0.000074091055,0.006588626,0.9762816],"study_design_scores_gemma":[0.0017566311,0.0007104466,0.0028206124,0.007167257,0.00030898544,0.00004647146,0.00004798878,0.0000024307528,5.2903374e-7,0.000006383593,0.98700297,0.00012928213],"about_ca_topic_score_codex":0.0009809543,"about_ca_topic_score_gemma":0.000087594126,"teacher_disagreement_score":0.98041433,"about_ca_system_score_codex":0.0016336034,"about_ca_system_score_gemma":0.0012470927,"threshold_uncertainty_score":0.74127436},"labels":[],"label_agreement":null},{"id":"W2038822008","doi":"10.1097/01.jto.0000284054.96114.bf","title":"P3-078: MO19390: an open-label safety study of bevacizumab in combination with chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Bevacizumab; Medicine; Carboplatin; Chemotherapy; Internal medicine; Oncology; Regimen; Chemotherapy regimen; Clinical endpoint; Lung cancer; Surgery; Clinical trial; Cisplatin","score_opus":0.023025813081603036,"score_gpt":0.4326784761061702,"score_spread":0.40965266302456715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038822008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995217,0.00033330184,0.0004545834,0.00036493764,0.00021085673,0.0029110066,0.000025423868,0.00000501874,0.00047784502],"genre_scores_gemma":[0.99389285,0.00043701872,0.005183056,0.00007250583,0.000053691198,0.00007151699,0.000032924698,0.00003837169,0.00021809257],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980681,0.00008647127,0.0009394672,0.0002621481,0.00037872748,0.0002650822],"domain_scores_gemma":[0.9973067,0.0001470155,0.0013328055,0.00026819855,0.0007680943,0.00017717048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032656698,0.0002585732,0.000988976,0.00031734622,0.00006989028,0.000008638644,0.00018302136,0.00010596732,0.000060734244],"category_scores_gemma":[0.000015516707,0.00015388112,0.000042464973,0.0004192951,0.000056473382,0.00021607798,0.000024566574,0.00018197995,4.3122483e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15887234,0.094226904,0.21709374,0.00024126041,0.00085052376,0.0003385466,0.014781334,0.0011248164,0.00028398097,0.00000202062,0.000025337195,0.5121592],"study_design_scores_gemma":[0.1504512,0.3837778,0.45359087,0.00082124746,0.0020702232,0.000065538465,0.0041258004,0.00043307382,0.0036264104,0.000010716966,0.0007509751,0.0002761682],"about_ca_topic_score_codex":0.0005792127,"about_ca_topic_score_gemma":0.0060428167,"teacher_disagreement_score":0.511883,"about_ca_system_score_codex":0.0018133011,"about_ca_system_score_gemma":0.0011874045,"threshold_uncertainty_score":0.627509},"labels":[],"label_agreement":null},{"id":"W2038934354","doi":"10.3747/co.19.1114","title":"Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pemetrexed; Erlotinib; Oncology; Internal medicine; Lung cancer; Crizotinib; Carboplatin; Docetaxel; Chemotherapy; Bevacizumab; Gefitinib; Cetuximab; Cancer; Epidermal growth factor receptor; Cisplatin","score_opus":0.05009744908512064,"score_gpt":0.3993068974870531,"score_spread":0.34920944840193247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038934354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98269373,0.011223889,0.0005407442,0.0005818559,0.0008985004,0.0025517752,0.00029267516,0.000029536845,0.0011873107],"genre_scores_gemma":[0.99351513,0.0009530673,0.0019805343,0.00012381814,0.0002676863,0.0018063064,0.0004515231,0.00003174876,0.00087021035],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990965,0.000019358991,0.00020186281,0.0002355728,0.00008246587,0.00036425644],"domain_scores_gemma":[0.99925864,0.00012816145,0.00012350254,0.00015452722,0.00009553261,0.00023963471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043461394,0.0002044108,0.00039631256,0.00006653365,0.00011985596,0.000008509975,0.00003385671,0.000047254263,0.00011753609],"category_scores_gemma":[0.000008004771,0.00013154998,0.000061361876,0.00007251296,0.000051521656,0.00007814993,0.000015353658,0.000070174916,0.000006018128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005180786,0.00531831,0.92770046,0.0006646916,0.0007549351,0.0000051407187,0.0036428333,0.000010865234,0.000011451788,0.00013625828,0.0030166314,0.05822037],"study_design_scores_gemma":[0.039242435,0.009170087,0.18645853,0.00017115657,0.006170656,0.000026070844,0.00028385708,0.00090407784,0.00030908157,0.000028736684,0.7568721,0.00036320896],"about_ca_topic_score_codex":0.000051590017,"about_ca_topic_score_gemma":0.00020364554,"teacher_disagreement_score":0.75385547,"about_ca_system_score_codex":0.0005982598,"about_ca_system_score_gemma":0.0002776249,"threshold_uncertainty_score":0.53644526},"labels":[],"label_agreement":null},{"id":"W2039529590","doi":"10.1097/jto.0b013e318168be93","title":"Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mutation; Exon; Adenocarcinoma; Mutation testing; Molecular biology; Medicine; Genetic heterogeneity; Tumor heterogeneity; Pathology; Cancer research; Gene; Genetics; Biology; Cancer; Phenotype","score_opus":0.03125366369807042,"score_gpt":0.4581790945065547,"score_spread":0.4269254308084843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039529590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942409,0.0023191294,0.00033041663,0.0013127939,0.00026355777,0.00015118654,0.0000031211864,0.0000035979635,0.0013752913],"genre_scores_gemma":[0.99559015,0.00014352301,0.0037718946,0.00013913798,0.00013087236,0.0000035407088,0.0000043180844,0.0000079051115,0.00020863315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911433,0.000081475046,0.00046076495,0.00007575453,0.0001576807,0.00011001384],"domain_scores_gemma":[0.99918574,0.00007998076,0.00037457855,0.00008976842,0.00019070612,0.0000792416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018826059,0.000068487534,0.00036892254,0.00022153236,0.000026670241,0.0000014635976,0.000051689443,0.000085314394,0.000060379607],"category_scores_gemma":[0.000077405464,0.000053770527,0.00007653623,0.00015777916,0.000059567952,0.00008761636,0.000011031715,0.0001539984,0.0000041389453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002238658,0.0017997568,0.8013106,0.00027975955,0.000543356,0.008234242,0.0057439697,0.00030285068,0.012760691,0.00005722802,0.0020898602,0.16463906],"study_design_scores_gemma":[0.002231532,0.0031962325,0.9494491,0.00013123683,0.0005082948,0.009283632,0.00037133484,0.00007276531,0.030983366,0.00008842758,0.0036128855,0.00007114584],"about_ca_topic_score_codex":0.00004532962,"about_ca_topic_score_gemma":0.000038376398,"teacher_disagreement_score":0.1645679,"about_ca_system_score_codex":0.00043422615,"about_ca_system_score_gemma":0.0005244629,"threshold_uncertainty_score":0.21926984},"labels":[],"label_agreement":null},{"id":"W2039675637","doi":"10.1371/journal.pone.0017479","title":"Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis","year":2011,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Toronto; University Health Network; Toronto Public Health; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Care Ontario","keywords":"Lung cancer; Medicine; Chronic bronchitis; Meta-analysis; COPD; Internal medicine; Relative risk; Bronchitis; Pneumonia; Confidence interval; Cancer; Lung; Case-control study; Tuberculosis; Pathology","score_opus":0.12196215655901245,"score_gpt":0.38253912197094364,"score_spread":0.2605769654119312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039675637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025564175,0.99121845,0.0000052653927,0.00008302685,0.00001056549,0.0074581727,0.0010335434,0.000044117507,0.00014427853],"genre_scores_gemma":[0.000012863238,0.9894429,0.00014148181,0.00018876525,0.000044894823,0.0063368413,0.00018564724,0.00005176819,0.003594841],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9979825,0.00027120227,0.0007695522,0.00052744994,0.00025039806,0.0001988707],"domain_scores_gemma":[0.9980526,0.00016584297,0.0007396976,0.00065254106,0.00013130096,0.00025800648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016475313,0.00045932134,0.009286504,0.00019653862,0.00009280102,0.000033517816,0.000082327904,0.000100767356,0.0005618031],"category_scores_gemma":[0.00014177721,0.00025861152,0.0012218981,0.00044745248,0.000046410492,0.000062060404,0.00005431765,0.00018147392,0.000008144392],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.2544614e-7,0.00020179687,0.00009482411,0.5770598,0.42201367,0.000007266369,0.00003487172,5.966199e-9,2.5993214e-9,0.0000051983225,0.00010003871,0.0004817198],"study_design_scores_gemma":[0.00012609492,0.000027529164,0.0000154348,0.17066966,0.8273349,0.000008354737,0.0000020966845,0.000007601771,3.0284017e-8,0.0000025111647,0.0016214397,0.0001843593],"about_ca_topic_score_codex":0.00022239961,"about_ca_topic_score_gemma":0.000030448373,"teacher_disagreement_score":0.40639013,"about_ca_system_score_codex":0.00015929449,"about_ca_system_score_gemma":0.00019542096,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W2040035091","doi":"10.3129/i09-158","title":"Trichomegaly secondary to erlotinib","year":2009,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Cancer","score_opus":0.023952566954921792,"score_gpt":0.31933202178582076,"score_spread":0.29537945483089895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040035091","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018551968,0.0025382577,0.000009124595,0.79338443,0.0022295604,0.00048130727,0.00017109505,0.000005441032,0.18262883],"genre_scores_gemma":[0.20227359,0.000009309041,0.0017598027,0.7074769,0.008428255,0.000017017377,0.00027235993,0.000111845504,0.079650916],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848926,0.00006431732,0.0005255977,0.000219937,0.00018022099,0.0005206625],"domain_scores_gemma":[0.99805874,0.0000684842,0.0002914836,0.00028097373,0.00036831718,0.00093198725],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012066871,0.00025334928,0.000757532,0.0011518986,0.00008453271,0.00003330481,0.00022699016,0.0005641801,0.0042406525],"category_scores_gemma":[0.00013106702,0.00021705597,0.0002757602,0.0002629533,0.0000636868,0.00005676708,0.000005781269,0.0016096339,0.00011800979],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022197537,0.0000112434,0.00093625067,0.000031800646,0.0002915685,0.25809833,0.00013053203,0.0000031528812,0.0000021261617,0.0000050064887,0.7390494,0.0014184016],"study_design_scores_gemma":[0.0007823235,0.0013951492,0.009193676,0.00012084084,0.00037980417,0.30664346,0.000017014105,1.1979897e-7,0.000006105854,0.00013485049,0.68119603,0.0001306265],"about_ca_topic_score_codex":0.002058493,"about_ca_topic_score_gemma":0.00009960729,"teacher_disagreement_score":0.18372162,"about_ca_system_score_codex":0.0007216539,"about_ca_system_score_gemma":0.008382616,"threshold_uncertainty_score":0.99723893},"labels":[],"label_agreement":null},{"id":"W2040376006","doi":"10.1097/jto.0b013e3181d1273d","title":"Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Sanofi","keywords":"Pemetrexed; Medicine; Gemcitabine; Cisplatin; Oncology; Internal medicine; Lung cancer; Subgroup analysis; Exploratory analysis; Chemotherapy; Confidence interval","score_opus":0.017154949277299467,"score_gpt":0.4004389938961633,"score_spread":0.3832840446188638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040376006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973613,0.0002021218,0.00007251627,0.000215156,0.0003734784,0.0011181883,0.00024452302,0.0000043133964,0.00040841632],"genre_scores_gemma":[0.99606013,0.00016671437,0.0034309716,0.000010717109,0.0000968088,0.000034015375,0.00014300722,0.000021443248,0.000036199544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976208,0.00012634708,0.0014266823,0.0002689043,0.0003381979,0.00021907645],"domain_scores_gemma":[0.9964543,0.0003137108,0.002091248,0.00032254163,0.0005810758,0.00023709735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042425215,0.0002432514,0.0014926034,0.0008253475,0.000048680504,0.0000045244524,0.00011089377,0.00015931744,0.00005706517],"category_scores_gemma":[0.00014207113,0.00017140068,0.00018776077,0.0008793267,0.00013166074,0.0001748299,0.000025494104,0.00026152193,1.4860916e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.796162,0.013756622,0.024922328,0.00016466322,0.0038950765,0.00012837144,0.00849437,0.0015878634,0.004119245,0.000004621026,0.000009153643,0.1467557],"study_design_scores_gemma":[0.7477819,0.098639496,0.122124664,0.0004621454,0.020653524,0.000014331264,0.0024789653,0.0015503989,0.005726426,0.000005179415,0.00030050075,0.00026251626],"about_ca_topic_score_codex":0.0002831185,"about_ca_topic_score_gemma":0.0051816427,"teacher_disagreement_score":0.14649317,"about_ca_system_score_codex":0.00039907693,"about_ca_system_score_gemma":0.0008887914,"threshold_uncertainty_score":0.69895166},"labels":[],"label_agreement":null},{"id":"W2041593349","doi":"10.3816/clc.2004.s.018","title":"Bronchoalveolar Carcinoma: Current Treatment and Future Trends","year":2004,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Carcinoma; Clinical trial; Cancer; Pathology; Oncology; Internal medicine","score_opus":0.07846136581312092,"score_gpt":0.5167491071157707,"score_spread":0.4382877413026498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041593349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002733665,0.99294025,0.0000028240274,0.0007062923,0.002972672,0.0012274644,0.0004069762,0.0000741962,0.0016420193],"genre_scores_gemma":[0.00003411281,0.98821443,0.00010556586,0.000100200545,0.0054093627,0.0008759023,0.000610846,0.00009271834,0.004556836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742067,0.00010568163,0.000995505,0.0008921893,0.00019739705,0.0003885494],"domain_scores_gemma":[0.9983267,0.00014458569,0.00036126864,0.0005863682,0.00007704847,0.0005039987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001099405,0.0006325094,0.0024951287,0.00018364648,0.00011946684,0.00003623025,0.00010341884,0.000480174,0.00047918333],"category_scores_gemma":[0.000015651487,0.00039701565,0.0011815302,0.00026210118,0.00014774733,0.000054814907,0.000050359886,0.0005923082,0.000028877876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025092566,0.0004526097,0.0021616668,0.008744757,0.0014367132,0.000045941386,0.00006650871,1.2858352e-7,3.667486e-9,0.00007524603,0.0035779981,0.98341334],"study_design_scores_gemma":[0.0031251258,0.00053593924,0.0024332572,0.009889867,0.022949902,0.000049141316,0.0000058748356,0.0000021076314,4.913906e-8,0.000008213608,0.96067077,0.00032975353],"about_ca_topic_score_codex":0.0001098238,"about_ca_topic_score_gemma":0.00004631609,"teacher_disagreement_score":0.9830836,"about_ca_system_score_codex":0.0019216184,"about_ca_system_score_gemma":0.0025065634,"threshold_uncertainty_score":0.9998482},"labels":[],"label_agreement":null},{"id":"W2041814933","doi":"10.1097/jto.0b013e3181a94b08","title":"Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Genentech; Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Erlotinib; Pharmacodynamics; Separation (statistics); Pharmacology; Oncology; Internal medicine; Pharmacokinetics; Cancer; Chemotherapy; Machine learning; Epidermal growth factor receptor; Cisplatin","score_opus":0.022437710646904255,"score_gpt":0.4925979184773803,"score_spread":0.4701602078304761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041814933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713998,0.00014430973,0.014395327,0.012224439,0.00025493256,0.00049501227,0.000002745928,0.000011353583,0.0010720827],"genre_scores_gemma":[0.9819745,0.000031259933,0.016579332,0.0010714468,0.00010589317,0.000010977002,0.000013964918,0.0000090369085,0.00020360714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901277,0.00011002332,0.00041326915,0.00011832,0.00019469015,0.00015094687],"domain_scores_gemma":[0.9991659,0.000053136544,0.0003103212,0.00008303514,0.00024598796,0.00014164406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032769926,0.000110691384,0.00034295363,0.00043903844,0.00003740672,0.000013433135,0.00006652451,0.0000600908,0.000039658495],"category_scores_gemma":[0.00004627574,0.00007920714,0.000060187667,0.00030686441,0.00002095869,0.0001752149,0.0000066933835,0.00020414038,0.00000846085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0144224465,0.005052467,0.0022132087,0.00002892227,0.00022317641,0.0007199576,0.0016772485,0.00062926905,0.026825428,0.00020794553,0.0005071173,0.94749284],"study_design_scores_gemma":[0.11405706,0.38634214,0.3874757,0.002856235,0.0072825346,0.006711388,0.007050634,0.014122368,0.041892856,0.0039825905,0.026944611,0.0012818945],"about_ca_topic_score_codex":0.0000059987487,"about_ca_topic_score_gemma":0.000027974456,"teacher_disagreement_score":0.9462109,"about_ca_system_score_codex":0.00071481924,"about_ca_system_score_gemma":0.0003941475,"threshold_uncertainty_score":0.32299733},"labels":[],"label_agreement":null},{"id":"W2042386784","doi":"10.1016/j.cell.2012.08.029","title":"Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing","year":2012,"lang":"en","type":"article","venue":"Cell","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1826,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Human Genome Research Institute; Canadian Institutes of Health Research; National Institute of General Medical Sciences; Broad Institute","keywords":"Biology; Adenocarcinoma; Exome sequencing; Genetics; Gene; Lung cancer; Mutation; Exome; Somatic cell; Context (archaeology); ARID1A; Germline mutation; Cancer research; Cancer; Pathology","score_opus":0.02714034130342818,"score_gpt":0.2718057737046342,"score_spread":0.24466543240120603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042386784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9201739,0.00526796,0.0018573039,0.0007893683,0.00010225121,0.00044607458,0.0000047277786,0.000023689314,0.07133472],"genre_scores_gemma":[0.99454886,0.000024831432,0.0020969035,0.00019356485,0.00009247556,0.000024088067,0.000010191187,0.000011812621,0.0029972799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995304,0.0000137623965,0.00010199327,0.00007791001,0.000109535016,0.00016644555],"domain_scores_gemma":[0.99962646,0.00003232661,0.00006759483,0.0001654682,0.0000424442,0.000065708366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006122566,0.00007147285,0.00011418493,0.000030997428,0.00005818109,0.0000046470172,0.000040753257,0.000025460227,0.000086536355],"category_scores_gemma":[0.000004871788,0.00003859123,0.000036022997,0.00008854128,0.000041222873,0.00005596477,0.000012956242,0.00006904012,0.000010751195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112430665,0.00021977191,0.9599537,0.00043756992,0.00042579958,0.00004495554,0.020226944,0.00010957584,0.012262522,0.00059528346,0.0045139887,0.0010974429],"study_design_scores_gemma":[0.0033094264,0.0002394236,0.9661696,0.00029245784,0.0007615807,0.00012156201,0.007959596,0.0004537544,0.012958441,0.000040635096,0.00749565,0.00019789439],"about_ca_topic_score_codex":0.00009091513,"about_ca_topic_score_gemma":0.000003512465,"teacher_disagreement_score":0.074374944,"about_ca_system_score_codex":0.00010423752,"about_ca_system_score_gemma":0.00011460692,"threshold_uncertainty_score":0.15737048},"labels":[],"label_agreement":null},{"id":"W2042581859","doi":"10.1016/s1556-0864(15)30414-7","title":"Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University","funders":"","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Immunohistochemistry; Chemotherapy; EGFR inhibitors; Clinical trial; Cancer; Pathology","score_opus":0.02562727282986741,"score_gpt":0.43916000619585455,"score_spread":0.4135327333659871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042581859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767,0.0003234906,0.009113697,0.00035827584,0.00036674246,0.0017851093,0.0001432646,0.000008880759,0.00023052828],"genre_scores_gemma":[0.90661615,0.00005198201,0.09241743,0.000058935635,0.00034567673,0.00015503191,0.00004394104,0.00002993255,0.00028093296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984648,0.00008125757,0.0007845662,0.00022943717,0.0001742273,0.00026571736],"domain_scores_gemma":[0.9969113,0.00054064,0.0012501077,0.00012449376,0.0010348078,0.00013865685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002331272,0.00018946297,0.00080343866,0.00009165117,0.00009554154,0.0000057684274,0.00006580239,0.00013089082,0.00003414634],"category_scores_gemma":[0.000062031264,0.00010818561,0.000209279,0.00009949928,0.000057326804,0.00010978526,0.000009375894,0.00012303589,1.8746387e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019973472,0.003586719,0.8690908,0.00044001828,0.00048235504,0.00000795412,0.00048389166,0.000071184324,0.0022564703,0.0000015041247,0.00088762154,0.102718],"study_design_scores_gemma":[0.050858397,0.081017494,0.7497107,0.0014858403,0.0055763363,0.000046685927,0.0006511818,0.00054084347,0.09381529,0.00004759697,0.015815116,0.00043456352],"about_ca_topic_score_codex":0.000055506072,"about_ca_topic_score_gemma":0.00008646329,"teacher_disagreement_score":0.11938015,"about_ca_system_score_codex":0.00044684275,"about_ca_system_score_gemma":0.0011045556,"threshold_uncertainty_score":0.4411681},"labels":[],"label_agreement":null},{"id":"W2042624738","doi":"10.3747/co.v17i2.549","title":"Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Royal Victoria Hospital","funders":"College of Engineering, Michigan State University; Michigan State University","keywords":"Medicine; Erlotinib; Bevacizumab; Targeted therapy; Lung cancer; Oncology; Maintenance therapy; Disease; Regimen; Chemotherapy; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.043687794541709325,"score_gpt":0.39082979912586496,"score_spread":0.3471420045841556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042624738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98488027,0.0077457028,0.0006438739,0.0018598975,0.00080415246,0.0015976203,0.000032846638,0.000030380621,0.002405278],"genre_scores_gemma":[0.99622786,0.0005435311,0.000862479,0.0002986304,0.00018670192,0.0015028683,0.00008964643,0.000023159053,0.00026512373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990288,0.0000906383,0.00022218128,0.00026280349,0.00017160995,0.00022395935],"domain_scores_gemma":[0.99932146,0.00015623856,0.00012066549,0.00023396476,0.00010596921,0.00006169231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016370835,0.00017723197,0.00030328636,0.00010942239,0.00011011001,0.000016651986,0.00010460972,0.000058579863,0.00016312025],"category_scores_gemma":[0.000011415361,0.000092467046,0.000056265377,0.00021358317,0.00010548079,0.000048440812,0.000012135552,0.00035844368,0.000008509355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002331176,0.0123343095,0.64454293,0.0017219395,0.004036166,0.000105762054,0.13131526,0.0017280312,0.01606706,0.0048722867,0.007495871,0.17344922],"study_design_scores_gemma":[0.083586656,0.007524014,0.49123707,0.0019150552,0.007523309,0.00075701426,0.04892135,0.025242519,0.0030696038,0.0004081684,0.32774934,0.0020658947],"about_ca_topic_score_codex":0.00010547403,"about_ca_topic_score_gemma":0.00033176504,"teacher_disagreement_score":0.3202535,"about_ca_system_score_codex":0.0002609964,"about_ca_system_score_gemma":0.0007704033,"threshold_uncertainty_score":0.37706965},"labels":[],"label_agreement":null},{"id":"W2042846576","doi":"10.1097/jto.0b013e318168c815","title":"Second-Line Treatment of Advanced Non-small Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Erlotinib; Gefitinib; Chemotherapy; Oncology; Lung cancer; Internal medicine; Performance status; Cancer; Intensive care medicine; Epidermal growth factor receptor; Cisplatin","score_opus":0.024784287049145974,"score_gpt":0.43600086396255666,"score_spread":0.4112165769134107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042846576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98390055,0.0063319406,0.00018930192,0.0012152635,0.0006367459,0.0003078806,0.000022088368,0.000006240485,0.0073899813],"genre_scores_gemma":[0.9804613,0.003091739,0.0080697285,0.00021754127,0.00039055463,0.0000232268,0.000006477821,0.000018381203,0.0077210437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990242,0.000039475846,0.00050854514,0.00011448137,0.00013846214,0.00017483695],"domain_scores_gemma":[0.9987217,0.000076215714,0.00058465864,0.00014428509,0.0003157338,0.00015738195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000758752,0.00013308981,0.00062550814,0.00015707072,0.000053448963,0.0000018129414,0.00006249623,0.0000953816,0.0004805805],"category_scores_gemma":[0.000011437938,0.00009089614,0.0002075205,0.00012874576,0.00005821501,0.00006608715,0.0000098004175,0.00011755486,0.00000416202],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009317824,0.013009887,0.1524763,0.0009929157,0.0041536167,0.006484267,0.020056393,0.002709481,0.106246226,0.000020287924,0.011372284,0.6731605],"study_design_scores_gemma":[0.03055368,0.05370718,0.19737364,0.00080780505,0.009640064,0.0072408346,0.0024895556,0.0005588374,0.32910523,0.000095104915,0.36785385,0.0005742321],"about_ca_topic_score_codex":0.000036841953,"about_ca_topic_score_gemma":0.00006218062,"teacher_disagreement_score":0.67258626,"about_ca_system_score_codex":0.0008292633,"about_ca_system_score_gemma":0.0014618859,"threshold_uncertainty_score":0.5262019},"labels":[],"label_agreement":null},{"id":"W2043014115","doi":"10.1097/01.jto.0000283353.30118.37","title":"PD2-1-7: Differences in the gene expression profiles of tumors from patients with and without COPD","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"COPD; Lung cancer; Medicine; Lung; Carcinogenesis; Inflammation; Confounding; Internal medicine; Cancer; Oncology; Immunology; Pathology","score_opus":0.018745053422091377,"score_gpt":0.3952673920409283,"score_spread":0.37652233861883694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043014115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982582,0.00040451504,0.00017925799,0.00042124806,0.000078075354,0.00019869336,0.000007941793,0.0000016315022,0.00045044435],"genre_scores_gemma":[0.9937654,0.00003052718,0.0059682513,0.000116209856,0.000075249925,0.0000030115784,0.0000056761537,0.0000047458643,0.000030903353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928164,0.00006916663,0.00029305575,0.00006893804,0.00019552711,0.0000916616],"domain_scores_gemma":[0.9992608,0.00013328835,0.0003605968,0.00007288827,0.00012090883,0.000051531748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024894872,0.000066734116,0.00029013326,0.00009220959,0.000027075923,0.0000041917465,0.000057149864,0.000046858902,0.000019063229],"category_scores_gemma":[0.000036380992,0.000030343992,0.000024250141,0.00007711519,0.00007842424,0.00005650019,0.000010960374,0.00013568412,3.1197433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016634463,0.0004698836,0.9764122,0.00001815118,0.00006517697,0.000054380474,0.0022148367,8.230366e-7,0.0023368888,0.0000043223317,0.000074879375,0.016685033],"study_design_scores_gemma":[0.0016561124,0.002076717,0.98798484,0.00025482642,0.00021583255,0.00006372106,0.0014157229,0.0000025478453,0.006005089,0.00009089372,0.00020073757,0.000032987497],"about_ca_topic_score_codex":0.000038941856,"about_ca_topic_score_gemma":0.00003938545,"teacher_disagreement_score":0.016652046,"about_ca_system_score_codex":0.00006647556,"about_ca_system_score_gemma":0.00014830627,"threshold_uncertainty_score":0.12373921},"labels":[],"label_agreement":null},{"id":"W2043150920","doi":"10.1097/01.jto.0000391377.17179.6b","title":"Targeting Vascular Endothelial Growth Factor in Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bevacizumab; Aflibercept; Lung cancer; Oncology; Internal medicine; Vascular endothelial growth factor; Erlotinib; Hazard ratio; Angiogenesis; Placental growth factor; Cancer; Chemotherapy; Epidermal growth factor receptor; Confidence interval; VEGF receptors","score_opus":0.013680175737415284,"score_gpt":0.42623934737230396,"score_spread":0.41255917163488864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043150920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922968,0.0010345207,0.00016054677,0.0031100996,0.0017177985,0.00017619504,0.000011208003,0.0000075247544,0.0014852823],"genre_scores_gemma":[0.9942883,0.0003019267,0.0038617984,0.00035434114,0.00092820975,0.000011026336,0.000002360163,0.000014589915,0.00023743713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991325,0.000054474764,0.00036672124,0.00009553992,0.00017144163,0.00017929009],"domain_scores_gemma":[0.9992256,0.000097843724,0.00026459707,0.000078023986,0.00021249225,0.00012144109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025278152,0.000089756344,0.00034733163,0.0001817505,0.00003654492,0.000008079131,0.00007497326,0.00011811249,0.0005154639],"category_scores_gemma":[0.0002265964,0.00006381258,0.00011965608,0.00011810192,0.000035376044,0.00010483866,0.000015158375,0.00052355044,0.0000040439863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011244282,0.0012024981,0.66538584,0.00026635116,0.0011011274,0.0016047433,0.0040834695,0.00009172345,0.18789144,0.00019513367,0.0036267114,0.13342653],"study_design_scores_gemma":[0.013408805,0.0032915324,0.6817824,0.0006680649,0.0036201992,0.001985744,0.0013837061,0.0010901743,0.027930109,0.00080721604,0.26343077,0.0006012418],"about_ca_topic_score_codex":0.00012391707,"about_ca_topic_score_gemma":0.000109996276,"teacher_disagreement_score":0.25980407,"about_ca_system_score_codex":0.00034625398,"about_ca_system_score_gemma":0.00078502,"threshold_uncertainty_score":0.5643968},"labels":[],"label_agreement":null},{"id":"W2043511551","doi":"10.1016/j.humimm.2011.07.253","title":"228-P Is C1q ready for prime time?","year":2011,"lang":"en","type":"article","venue":"Human Immunology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Prime (order theory); Prime time; Computer science; Mathematics; Combinatorics; Telecommunications","score_opus":0.06721406947930669,"score_gpt":0.36337599447478725,"score_spread":0.29616192499548055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043511551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73681045,0.0021259147,0.0003005536,0.0010809904,0.00046081038,0.0015446909,0.0000694976,0.00026358507,0.2573435],"genre_scores_gemma":[0.91122514,0.000031208885,0.0025728769,0.00092975993,0.00012112747,0.00022726614,0.00022948686,0.000038274637,0.08462488],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99948615,0.00001018025,0.0001317531,0.00015778096,0.00003606868,0.000178087],"domain_scores_gemma":[0.9995744,0.000015234455,0.000047957208,0.00026229772,0.000070252114,0.000029863351],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003190913,0.00008399126,0.00016954225,0.00006177565,0.00010553813,0.0000035385542,0.000055121254,0.0000764402,0.0025430548],"category_scores_gemma":[0.000009432141,0.00006971942,0.00005581539,0.00003411549,0.00007643958,0.000032172895,0.000017412065,0.000057950256,0.000583797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023493057,0.004769816,0.023337176,0.00024359558,0.009823642,0.000190266,0.04629104,1.6622079e-7,0.47254637,0.1320385,0.21927813,0.089132],"study_design_scores_gemma":[0.014510107,0.0070521217,0.27409115,0.00011114133,0.0018081218,0.00023232563,0.0005267204,0.000017481138,0.0891481,0.011600595,0.60037166,0.0005304621],"about_ca_topic_score_codex":0.00014459921,"about_ca_topic_score_gemma":0.0000063139937,"teacher_disagreement_score":0.38339826,"about_ca_system_score_codex":0.00006310793,"about_ca_system_score_gemma":0.000058289083,"threshold_uncertainty_score":0.99836874},"labels":[],"label_agreement":null},{"id":"W2043604340","doi":"10.1097/jto.0000000000000505","title":"Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Hazard ratio; Cohort; Internal medicine; Cluster (spacecraft); Proportional hazards model; Survival analysis; Stage (stratigraphy); Cancer; Oncology; Phenotype; Disease; Cohort study; Pathology; Confidence interval; Genetics; Biology; Gene","score_opus":0.02075688296798867,"score_gpt":0.41624481291248194,"score_spread":0.3954879299444933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043604340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130666,0.001006617,0.0039096223,0.00077956886,0.0003078661,0.0006708344,0.000009051777,0.0000065445784,0.0020032087],"genre_scores_gemma":[0.99397814,0.00006695716,0.004782892,0.00020160456,0.00016428699,0.00002544953,0.0000067927576,0.000016886348,0.00075696403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849004,0.00016257694,0.0005865219,0.00017990783,0.00038334273,0.00019760874],"domain_scores_gemma":[0.9977227,0.000045801742,0.00081072457,0.00024825882,0.00091918325,0.00025337358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065290945,0.00014903344,0.00090261915,0.00033130334,0.000047707083,0.000011769347,0.00012905867,0.000085341424,0.00007197454],"category_scores_gemma":[0.000022779092,0.000097464326,0.00020071257,0.0004933424,0.000051897514,0.00010330379,0.000034845445,0.00021635185,0.0000021859887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027185974,0.002155276,0.9714715,0.00007146621,0.008815334,0.0002644393,0.0012480471,0.006277456,0.0002772535,6.306932e-7,0.00078676344,0.005913243],"study_design_scores_gemma":[0.010369362,0.014998951,0.8653082,0.00014850248,0.09888993,0.0004066071,0.0029824425,0.0017508098,0.0027538938,0.000017748514,0.0021094093,0.00026411013],"about_ca_topic_score_codex":0.0004804042,"about_ca_topic_score_gemma":0.0009783721,"teacher_disagreement_score":0.10616326,"about_ca_system_score_codex":0.0006169674,"about_ca_system_score_gemma":0.0015810695,"threshold_uncertainty_score":0.39744797},"labels":[],"label_agreement":null},{"id":"W2045626426","doi":"10.1097/jto.0b013e31824166c1","title":"Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Pharmacogenetics; Odds ratio; Placebo; Epidermal growth factor receptor; Confidence interval; Gastroenterology; Genotype; Cancer; Pathology; Biology; Genetics","score_opus":0.03442907352970298,"score_gpt":0.5197147873300292,"score_spread":0.4852857138003262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045626426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849046,0.0052745542,0.0008415948,0.00046060182,0.0013702398,0.0024167267,0.000020365424,0.0000037999453,0.001121665],"genre_scores_gemma":[0.9940505,0.0016306889,0.0031043724,0.00017430584,0.0004919288,0.0001554875,0.000008716531,0.000017156703,0.00036683062],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956968,0.00089089014,0.0026704837,0.00016098809,0.00028609863,0.0002947707],"domain_scores_gemma":[0.9945978,0.0017160513,0.002843822,0.00018432939,0.00039757363,0.00026045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036214753,0.00018662693,0.003823628,0.00075400475,0.000023881968,0.0000033212832,0.00013154393,0.00017737075,0.0003447166],"category_scores_gemma":[0.0004409779,0.00012734509,0.0013163153,0.00058012304,0.00012738358,0.00009065287,0.000024568932,0.00035366265,7.9068866e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93711007,0.006345086,0.0094525665,0.00009459784,0.009521814,0.00004700425,0.0014040975,0.00087581825,0.0042619715,0.0000017013735,0.00014268626,0.030742574],"study_design_scores_gemma":[0.93496174,0.0027831045,0.0012770545,0.00012368822,0.054859564,0.000017307124,0.00027430846,0.0028649603,0.0023150092,0.00000491275,0.00042411682,0.000094210925],"about_ca_topic_score_codex":0.000060862283,"about_ca_topic_score_gemma":0.000051484676,"teacher_disagreement_score":0.04533775,"about_ca_system_score_codex":0.00029784534,"about_ca_system_score_gemma":0.0013287325,"threshold_uncertainty_score":0.5192982},"labels":[],"label_agreement":null},{"id":"W2047101113","doi":"10.1164/rccm.201002-0188oc","title":"EGFR Tyrosine Kinase Inhibition Worsens Acute Lung Injury in Mice with Repairing Airway Epithelium","year":2010,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Gefitinib; Medicine; Bronchoalveolar lavage; Lung; Respiratory epithelium; Epidermal growth factor receptor; Erlotinib; Pneumonia; Usual interstitial pneumonia; Pathology; Diffuse alveolar damage; Cancer research; Immunology; Internal medicine; Idiopathic pulmonary fibrosis; Cancer","score_opus":0.007696980937622981,"score_gpt":0.3234975536820561,"score_spread":0.31580057274443313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047101113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908913,0.0012795896,0.00019346992,0.0066542993,0.00020860418,0.00015067465,0.000011165199,0.000016418167,0.00059448765],"genre_scores_gemma":[0.99561363,0.000059816823,0.0010748551,0.0026708094,0.00052138814,0.000007900603,0.0000046928394,0.000021356076,0.000025566436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987261,0.000071010305,0.00043532898,0.00020012919,0.00033128605,0.0002361405],"domain_scores_gemma":[0.99870783,0.00015118196,0.00015168899,0.00015426408,0.00046557534,0.0003694818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027798917,0.00016952731,0.00049117405,0.00027595813,0.000080949816,0.000011599781,0.000042011066,0.000050033355,0.00005552247],"category_scores_gemma":[0.00029085725,0.00009985519,0.00005614894,0.0003622151,0.0008755857,0.00015009254,0.000015981172,0.0005930716,0.0000010541347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069545186,0.00084553123,0.3888193,0.0008320769,0.00065516296,0.012919724,0.011818675,0.00000771062,0.2676675,0.0023082471,0.0020248357,0.3051467],"study_design_scores_gemma":[0.04745109,0.14218064,0.52837384,0.01612308,0.013532661,0.013534486,0.083066285,0.00011303703,0.096702605,0.0005078597,0.05621233,0.0022021201],"about_ca_topic_score_codex":0.00005929487,"about_ca_topic_score_gemma":0.00005156095,"teacher_disagreement_score":0.3029446,"about_ca_system_score_codex":0.00010133884,"about_ca_system_score_gemma":0.00022081919,"threshold_uncertainty_score":0.40719765},"labels":[],"label_agreement":null},{"id":"W2047220014","doi":"10.1007/s11864-010-0137-x","title":"How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?","year":2011,"lang":"en","type":"review","venue":"Current Treatment Options in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Lung cancer; Oncology; Epidermal growth factor receptor; Chemotherapy; Vascular endothelial growth factor; Targeted therapy; Internal medicine; Quality of life (healthcare); Cancer; VEGF receptors; Cisplatin","score_opus":0.08467429622991147,"score_gpt":0.42896544193682934,"score_spread":0.3442911457069179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047220014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051565864,0.9909813,0.000030370145,0.00024217121,0.0014712439,0.0043396093,0.00031154623,0.00005941241,0.0020487083],"genre_scores_gemma":[0.00034169506,0.9837768,0.0008700821,0.000016260345,0.0002260308,0.009868492,0.0010327247,0.0000807485,0.003787162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977398,0.00018695644,0.00064124214,0.00072989,0.0001086151,0.000593482],"domain_scores_gemma":[0.99862957,0.00013310055,0.00046250067,0.0005291364,0.00008334908,0.00016235556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009212164,0.00069355045,0.002286935,0.0008541376,0.00010279299,0.000032293854,0.00017360048,0.0004435791,0.00019637772],"category_scores_gemma":[0.000012256762,0.00049636926,0.00048165384,0.0006769872,0.00009076946,0.000091937414,0.000051671832,0.0004651147,0.00003627382],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028176411,0.0046060844,0.004333225,0.0048646308,0.00065755716,0.00013515883,0.0012041739,0.000008481472,3.731573e-7,0.00013027205,0.0005944818,0.98343736],"study_design_scores_gemma":[0.0040083183,0.0007196867,0.00079271675,0.008321277,0.0039059464,0.000027978962,0.00036405562,0.00002232216,0.0000015595077,0.000023547678,0.9814497,0.00036288975],"about_ca_topic_score_codex":0.00042597536,"about_ca_topic_score_gemma":0.001806844,"teacher_disagreement_score":0.9830745,"about_ca_system_score_codex":0.0068048663,"about_ca_system_score_gemma":0.0021050018,"threshold_uncertainty_score":0.99974877},"labels":[],"label_agreement":null},{"id":"W2047301121","doi":"10.1667/rrxx33.1","title":"New Translational Possibilities for Microenvironmental Modulation of Radiosensitivity","year":2011,"lang":"en","type":"review","venue":"Radiation Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Radiation oncology; Medicine; Radiosensitivity; Library science; Oncology; Cancer; Gerontology; Internal medicine; Radiation therapy","score_opus":0.16259023138903886,"score_gpt":0.48611602765431156,"score_spread":0.32352579626527267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047301121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023523349,0.99453306,0.00091133884,0.00009060464,0.000093075665,0.0029471384,0.0004304018,0.000012124533,0.000747014],"genre_scores_gemma":[0.0011215837,0.98804253,0.0047092866,0.0000062392287,0.00030365912,0.00018168308,0.0012934634,0.000041626023,0.004299928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985822,0.00014561274,0.00041245276,0.00029593302,0.0003478521,0.00021598476],"domain_scores_gemma":[0.998916,0.00046032146,0.0001431113,0.00024224246,0.000115525734,0.00012284625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039928104,0.00015826926,0.00063412363,0.0003723028,0.00009529755,0.000012336008,0.00005816335,0.00017382478,0.00025773054],"category_scores_gemma":[0.00008045016,0.00013368724,0.00033718735,0.00022263992,0.00007914678,0.000062224324,0.00001097547,0.00018205361,0.000022861386],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004742899,0.00011096965,0.000064783424,0.0039201532,0.0003033979,0.0000010476009,0.0003878758,0.0000018922497,0.000014962813,0.0012487166,0.0010422596,0.9928565],"study_design_scores_gemma":[0.0014315638,0.00032762453,0.0026426665,0.0016010597,0.000890756,0.000023895023,0.00004114847,0.000103340426,0.000045301942,0.0010621877,0.99168205,0.00014838444],"about_ca_topic_score_codex":0.00017742212,"about_ca_topic_score_gemma":0.000007841354,"teacher_disagreement_score":0.99270815,"about_ca_system_score_codex":0.00038426276,"about_ca_system_score_gemma":0.0011558626,"threshold_uncertainty_score":0.5451607},"labels":[],"label_agreement":null},{"id":"W2047672685","doi":"10.1586/14737167.8.3.223","title":"Gefitinib: a consideration of cost","year":2008,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Gefitinib; Lung cancer; Medicine; Health care; Quality of life (healthcare); Oncology; Cost effectiveness; Cancer; Intensive care medicine; Internal medicine; Epidermal growth factor receptor; Economic growth; Risk analysis (engineering); Economics; Nursing","score_opus":0.09299769910041608,"score_gpt":0.5864324815195039,"score_spread":0.4934347824190878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047672685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4826758,0.38963336,0.00013323408,0.036964025,0.00078015303,0.008365274,0.00024142051,0.0000778937,0.08112884],"genre_scores_gemma":[0.54485846,0.4433566,0.003008609,0.0061854357,0.00015333838,0.00037730392,0.00010765745,0.000037373404,0.0019152171],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855375,0.00011125412,0.000623717,0.00020581845,0.00028010947,0.00022532609],"domain_scores_gemma":[0.99862,0.0003280157,0.00015196692,0.00030659197,0.00045463076,0.00013884674],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005468821,0.000117501244,0.00062386866,0.00016206686,0.00009277671,0.0000044793683,0.00010483874,0.00003480031,0.0017735218],"category_scores_gemma":[0.00021803941,0.00009192392,0.00020443673,0.00015231113,0.00020243833,0.00010049067,0.000050146227,0.00016643754,0.00006603828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055766694,0.0033531294,0.1432127,0.022063555,0.0036065225,0.00025474525,0.007408729,0.000017870541,0.030352026,0.0061986637,0.5710193,0.21195509],"study_design_scores_gemma":[0.012029381,0.0007866843,0.0324933,0.006643075,0.0004056219,0.0003538144,0.0005717585,0.00042999047,0.090114556,0.00014965657,0.8555125,0.0005096586],"about_ca_topic_score_codex":0.00016566724,"about_ca_topic_score_gemma":0.0000035589746,"teacher_disagreement_score":0.2844932,"about_ca_system_score_codex":0.00019094528,"about_ca_system_score_gemma":0.0006044481,"threshold_uncertainty_score":0.999139},"labels":[],"label_agreement":null},{"id":"W2048348290","doi":"10.3389/fonc.2014.00233","title":"Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Clinical trial; Targeted therapy; Epidermal growth factor receptor; Lung cancer; EGFR inhibitors; Crizotinib; Biomarker; Oncology; Pharmacology; Cancer; Internal medicine; Biology","score_opus":0.028390614323871858,"score_gpt":0.4102419312717828,"score_spread":0.38185131694791097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048348290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025995892,0.9790564,0.00026610654,0.01343883,0.0019010992,0.0028721555,0.0000959851,0.000027403456,0.0023160004],"genre_scores_gemma":[0.0000053097315,0.970392,0.016678505,0.0009839124,0.0022750904,0.00068525405,0.000101388,0.00004678476,0.00883179],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977897,0.00055695896,0.0006647873,0.00053847866,0.0001400322,0.00031006386],"domain_scores_gemma":[0.9987898,0.0003241988,0.00025371855,0.0003232631,0.000050663108,0.00025839786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006395615,0.00034603607,0.003118423,0.00040429382,0.00006673508,0.000023653238,0.00011135032,0.00032656675,0.000034748922],"category_scores_gemma":[0.00009789097,0.00024299332,0.00015196127,0.0002903543,0.0000729172,0.000037374408,0.0000682202,0.00025717154,0.0000067594483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014152771,0.00005086252,0.00017065821,0.0016777552,0.0004441977,0.00003142553,0.0011512408,1.09013506e-7,2.5221937e-7,0.000046285448,0.35916397,0.6371217],"study_design_scores_gemma":[0.0017139332,0.0002829405,0.0003046454,0.001702254,0.0012514417,0.000017618084,0.000293237,4.239064e-7,2.984081e-7,0.00016241135,0.99406385,0.00020693343],"about_ca_topic_score_codex":0.000035203855,"about_ca_topic_score_gemma":0.00007474071,"teacher_disagreement_score":0.6369148,"about_ca_system_score_codex":0.0005840001,"about_ca_system_score_gemma":0.00034728015,"threshold_uncertainty_score":0.990898},"labels":[],"label_agreement":null},{"id":"W2048530977","doi":"10.1155/2012/249082","title":"Ancillary Testing in Lung Cancer Diagnosis","year":2012,"lang":"en","type":"article","venue":"Pulmonary Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; Canada Research Chairs; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Lung; Pathology; Cancer; Immunohistochemistry; Radiology; Intensive care medicine; Internal medicine","score_opus":0.04119938171374238,"score_gpt":0.37282536411578404,"score_spread":0.33162598240204166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048530977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85418075,0.08106684,0.000029969064,0.011286039,0.00090561254,0.0007704269,0.00001998048,0.00010938835,0.051630978],"genre_scores_gemma":[0.9942006,0.0009134238,0.000476513,0.0014827348,0.0012459856,0.00069550116,0.000049465056,0.000025234627,0.0009105783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989379,0.000026063712,0.0002445092,0.00017554824,0.00023688747,0.00037907052],"domain_scores_gemma":[0.99926895,0.00019516952,0.000055782537,0.00017912361,0.00006309082,0.00023789928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021060836,0.00014303417,0.0002774994,0.00014640512,0.000056183282,0.0000020639814,0.000043302556,0.000052857915,0.00077878044],"category_scores_gemma":[0.00022986026,0.00010269032,0.000029042189,0.00046899158,0.000059254828,0.00013875689,0.00002236005,0.00014267366,0.000013445195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002714559,0.00024734403,0.95833415,0.0001343357,0.00004868176,0.00014792461,0.0006528588,0.000005799931,0.00040137512,0.000039801776,0.005189671,0.034770906],"study_design_scores_gemma":[0.0012567356,0.00010219976,0.9743819,0.00082343514,0.00034578267,0.00013565969,0.00024456455,0.0005086612,0.00011536026,0.00002654478,0.021945188,0.00011396959],"about_ca_topic_score_codex":0.001414718,"about_ca_topic_score_gemma":0.000029788427,"teacher_disagreement_score":0.1400198,"about_ca_system_score_codex":0.0003056634,"about_ca_system_score_gemma":0.000099193734,"threshold_uncertainty_score":0.85271},"labels":[],"label_agreement":null},{"id":"W2048594374","doi":"10.1097/01.jto.0000284084.26665.47","title":"P3-108: Correlative genomics in a phase II clinical trial of first-line therapy of erlotinib for clinically selected patients with advanced non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; Lung cancer; Adenocarcinoma; Population; KRAS; Cancer; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.03825366415585448,"score_gpt":0.5004756711090539,"score_spread":0.4622220069531994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048594374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912523,0.00038363587,0.0046259942,0.0003745783,0.0008068623,0.002274385,0.000044645032,0.0000040669274,0.00023351272],"genre_scores_gemma":[0.97652376,0.0008116992,0.02194017,0.00016444035,0.00034680395,0.000036422483,0.000026477876,0.000027886994,0.00012233855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970974,0.00011002884,0.0021510974,0.00019377319,0.00020143559,0.0002463041],"domain_scores_gemma":[0.99448097,0.0012066929,0.002595766,0.00015070352,0.0014072241,0.00015863393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012780157,0.00016562664,0.0011532755,0.00020928432,0.000045825498,0.0000020810232,0.00011891549,0.0002324009,0.000027141288],"category_scores_gemma":[0.00035934846,0.00011366357,0.00023917198,0.00030548667,0.000113669485,0.000068583635,0.000019747235,0.00041524885,1.5447644e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56615734,0.017846657,0.18422185,0.00009793993,0.0007959914,0.000036695037,0.0019510478,0.00031454893,0.00036716307,0.0000021973992,0.00012004289,0.22808851],"study_design_scores_gemma":[0.5707919,0.2869312,0.12943238,0.0006043926,0.0018899787,0.000018354625,0.00042228607,0.00090068276,0.0023809962,0.00004212355,0.006353205,0.00023252612],"about_ca_topic_score_codex":0.000018767092,"about_ca_topic_score_gemma":0.00020659162,"teacher_disagreement_score":0.2690845,"about_ca_system_score_codex":0.00040249934,"about_ca_system_score_gemma":0.0019087588,"threshold_uncertainty_score":0.46350658},"labels":[],"label_agreement":null},{"id":"W2048653810","doi":"10.1172/jci31809","title":"New molecularly targeted therapies for lung cancer","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Investigation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Gillson Longenbaugh Foundation","keywords":"Lung cancer; Medicine; Disease; Cancer; Targeted therapy; Bioinformatics; Intensive care medicine; Oncology; Pathology; Internal medicine; Biology","score_opus":0.18508919977471613,"score_gpt":0.547475026098917,"score_spread":0.3623858263242008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048653810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004701981,0.9820136,0.014644179,0.00090041646,0.001337279,0.0009298714,0.000022280716,0.000012017325,0.00009338078],"genre_scores_gemma":[0.0000066328516,0.9666369,0.028396782,0.00072901096,0.0028431779,0.000029774348,0.00008512088,0.00004663774,0.0012259512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997043,0.00011259478,0.002165653,0.00018374165,0.00033293487,0.00016208623],"domain_scores_gemma":[0.99607706,0.0006782886,0.0021402924,0.00016385905,0.0005220174,0.00041846826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093133247,0.000227979,0.0017602415,0.00020515546,0.00004583168,0.000032176693,0.00010854338,0.00038342475,0.00007396279],"category_scores_gemma":[0.0006268966,0.00014579289,0.0012242313,0.00023465547,0.00006555101,0.0001254449,0.0000068817785,0.0005266029,0.0000024878555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057278263,0.000054993205,0.00030178472,0.002887414,0.002181711,0.00001910035,0.00008746035,0.000001806909,0.0000017426256,0.00015369384,0.0150915235,0.9791615],"study_design_scores_gemma":[0.0018259715,0.00052171276,0.000254296,0.012769566,0.010313977,0.00004817088,0.000008034649,0.000024429464,0.0000070463425,0.0005824609,0.9735118,0.00013254226],"about_ca_topic_score_codex":0.000024015188,"about_ca_topic_score_gemma":0.0000057333214,"teacher_disagreement_score":0.97902894,"about_ca_system_score_codex":0.00018255126,"about_ca_system_score_gemma":0.003920597,"threshold_uncertainty_score":0.69549704},"labels":[],"label_agreement":null},{"id":"W2048790445","doi":"10.1002/humu.20512","title":"Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature","year":2007,"lang":"en","type":"article","venue":"Human Mutation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Biology; Indel; Genetics; INDEL Mutation; Somatic cell; Database; Computational biology; Gene; Genotype; Single-nucleotide polymorphism","score_opus":0.04011510838076978,"score_gpt":0.3883125630817358,"score_spread":0.348197454700966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048790445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547195,0.0001502203,0.0016515218,0.00006522403,0.000040818155,0.0004781137,0.000046606856,0.000046635272,0.002048923],"genre_scores_gemma":[0.9961766,0.00000437923,0.0018904431,0.0001010546,0.000040165738,0.000025790214,0.0013877964,0.00002298133,0.00035081155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988339,0.00003851278,0.0004102002,0.00020600413,0.00031761252,0.0001937843],"domain_scores_gemma":[0.9990961,0.00011745287,0.00026946294,0.00018111788,0.0002668897,0.00006899898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025723022,0.00013562701,0.00025179924,0.00040752193,0.0001084319,0.000014155772,0.000044697776,0.00008351521,0.00008484293],"category_scores_gemma":[0.00012557399,0.00011326847,0.000047400787,0.0005036895,0.000052489195,0.00017774187,0.000008651829,0.0001634276,0.0000064304018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010742915,0.0049700974,0.59274787,0.0019448794,0.003218691,0.0019106807,0.03340096,0.0115764495,0.33802485,0.0026976985,0.0007139098,0.0077196388],"study_design_scores_gemma":[0.0054874904,0.00045397316,0.9778501,0.001052903,0.0010475522,0.000024548353,0.002581946,0.0009847037,0.009889552,0.00041338903,0.000009742156,0.00020409685],"about_ca_topic_score_codex":0.0006539909,"about_ca_topic_score_gemma":0.0011220973,"teacher_disagreement_score":0.38510227,"about_ca_system_score_codex":0.0002912691,"about_ca_system_score_gemma":0.00014606953,"threshold_uncertainty_score":0.46189544},"labels":[],"label_agreement":null},{"id":"W2049086053","doi":"10.1093/annonc/mdv050.12","title":"Afatinib (A) Vs Erlotinib (E) as Second-Line Treatment of Patients (PTS) with Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (LL8), a Phase Iii Global Trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Clinical endpoint; Lung cancer; Erlotinib; Oncology; Progression-free survival; Chemotherapy regimen; Surrogate endpoint; Chemotherapy; Surgery; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.04037316368819774,"score_gpt":0.3937972074679882,"score_spread":0.3534240437797904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049086053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022496,0.0007305922,0.00006464435,0.0011776796,0.0003980774,0.0028267237,0.00033173565,0.000022176973,0.0042234194],"genre_scores_gemma":[0.99787945,0.000020567066,0.0006879029,0.0005104758,0.00010925913,0.0001658716,0.0002196499,0.000034776684,0.00037204448],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99796045,0.00010532192,0.0008138412,0.00035341617,0.00042047194,0.000346507],"domain_scores_gemma":[0.9977167,0.00021762,0.0008681559,0.00047500405,0.00051653385,0.0002059346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017107159,0.00032913033,0.0011009912,0.00008848985,0.00007246829,0.0000042563956,0.00014614321,0.00016185436,0.00011735172],"category_scores_gemma":[0.0000977642,0.00020289213,0.00037266943,0.0003261001,0.00014701734,0.00007866636,0.000026256042,0.00008580214,0.0000014939965],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57036465,0.07228645,0.23432536,0.0009601548,0.0033088806,0.000255604,0.015784925,0.0035898844,0.0015408675,0.00012137516,0.0052487166,0.092213124],"study_design_scores_gemma":[0.77045506,0.15132546,0.010822136,0.00018437633,0.0020257551,0.000009556445,0.00061772024,0.0011001815,0.053381328,0.000049531547,0.009701005,0.000327859],"about_ca_topic_score_codex":0.00044310954,"about_ca_topic_score_gemma":0.00028995378,"teacher_disagreement_score":0.22350323,"about_ca_system_score_codex":0.00039365608,"about_ca_system_score_gemma":0.0016386388,"threshold_uncertainty_score":0.8273701},"labels":[],"label_agreement":null},{"id":"W2050091722","doi":"10.2165/00151829-200605020-00006","title":"Pharmacoeconomics of Systemic Therapies for Lung Cancer","year":2006,"lang":"en","type":"review","venue":"Treatments in Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Pharmacoeconomics; Lung cancer; Docetaxel; Intensive care medicine; Oncology; Pharmacy; Chemotherapy; Cost effectiveness; Cancer; Population; Quality of life (healthcare); Internal medicine; Family medicine; Risk analysis (engineering)","score_opus":0.09016758498454981,"score_gpt":0.49929020798692997,"score_spread":0.40912262300238017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050091722","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058557774,0.9924207,0.00002381189,0.00005875716,0.0005628324,0.0048169573,0.00043924002,0.000036360456,0.0010557731],"genre_scores_gemma":[0.00026804153,0.9932501,0.00009078898,0.0001577881,0.0005574769,0.0034595707,0.00037812622,0.000107087566,0.0017310557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767584,0.000086392836,0.001238154,0.0004874303,0.00019431004,0.00031789893],"domain_scores_gemma":[0.9983949,0.0002640792,0.00069651933,0.00043075313,0.000103603925,0.00011016486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002006476,0.00054249674,0.0028428612,0.0005290405,0.00004822791,0.0000042286356,0.00013300923,0.00024028377,0.00015374817],"category_scores_gemma":[0.000023991865,0.0003487311,0.000376206,0.0002815483,0.00013083698,0.000059485556,0.000017323953,0.00016203959,0.0000032263795],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087486194,0.00047810905,0.0028797712,0.043821376,0.0047040824,0.000063099884,0.0004909677,0.000014697485,0.000010598466,0.000111328096,0.0070905522,0.94024795],"study_design_scores_gemma":[0.008862042,0.0005935414,0.00013752088,0.04937472,0.015729161,0.000022555316,0.00009150699,0.000012745851,0.000007345569,0.00000736335,0.924903,0.00025853803],"about_ca_topic_score_codex":0.0003501651,"about_ca_topic_score_gemma":0.000048371137,"teacher_disagreement_score":0.9399894,"about_ca_system_score_codex":0.0015342793,"about_ca_system_score_gemma":0.0009850574,"threshold_uncertainty_score":0.99989647},"labels":[],"label_agreement":null},{"id":"W2050271614","doi":"10.1097/jto.0b013e31829f6a43","title":"Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; William Osler Health System; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Gefitinib; Epidermal growth factor receptor; Internal medicine; Adenocarcinoma; Oncology; Lung cancer; Turnaround time; Clinical trial; Cancer","score_opus":0.08133866460632966,"score_gpt":0.4917260507136124,"score_spread":0.41038738610728276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050271614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881868,0.0018547821,0.0003261745,0.007043556,0.0003428435,0.0017084089,0.00007530196,0.000011043481,0.0004510893],"genre_scores_gemma":[0.98477656,0.000090274014,0.014360778,0.00021978389,0.00027650283,0.00020831496,0.000016326188,0.000021009111,0.000030433828],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984869,0.00014113949,0.00075667066,0.00017613565,0.00015086537,0.0002882871],"domain_scores_gemma":[0.99777603,0.00015177258,0.00077846786,0.00010682351,0.0009273446,0.00025956475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034022986,0.00012874622,0.0005628796,0.0002937608,0.00005439334,0.00001656107,0.00009321448,0.00008478835,0.00005836532],"category_scores_gemma":[0.000048666,0.000101564874,0.00007499249,0.00017268972,0.000012607617,0.00023602536,0.000016160173,0.00014397319,0.0000011979455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049581815,0.0004782962,0.053822305,0.003823337,0.00029161526,0.000024485722,0.017154852,0.00017115672,0.00390822,0.00005689298,0.00072782306,0.9190452],"study_design_scores_gemma":[0.01116036,0.03128369,0.6762389,0.0020315319,0.0009818247,0.00033259243,0.26346576,0.0010903222,0.011696612,0.000049781054,0.0012291295,0.00043950425],"about_ca_topic_score_codex":0.003622016,"about_ca_topic_score_gemma":0.0054375185,"teacher_disagreement_score":0.9186057,"about_ca_system_score_codex":0.0017308044,"about_ca_system_score_gemma":0.0017011779,"threshold_uncertainty_score":0.54754287},"labels":[],"label_agreement":null},{"id":"W2051096017","doi":"10.1097/jto.0b013e31826c1155","title":"Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Lung cancer; Internal medicine; Clinical trial; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology; Alternative medicine; Epidermal growth factor receptor","score_opus":0.031063588858787277,"score_gpt":0.44058916429867845,"score_spread":0.40952557543989115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051096017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955895,0.00041702436,0.000010347466,0.00033275672,0.0002586691,0.0030877837,0.000041021052,0.000003009274,0.000259918],"genre_scores_gemma":[0.998831,0.000091626964,0.00051226176,0.000083535684,0.00023812159,0.00016059812,0.000007611096,0.000016715114,0.00005857575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975062,0.0008423096,0.0009841463,0.0001499618,0.00027502817,0.00024235243],"domain_scores_gemma":[0.9960364,0.00231625,0.0012051002,0.00015207955,0.00017416239,0.00011599984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018192265,0.00016768418,0.00086111185,0.00010632933,0.00004798723,0.0000094305915,0.00012048691,0.00014030424,0.000018389874],"category_scores_gemma":[0.0008479134,0.0000670549,0.000088680914,0.00029903487,0.00014458805,0.00013579376,0.000020375732,0.000465305,2.4653934e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18294461,0.003275987,0.798827,0.000049441183,0.00024397759,0.000029135528,0.0016738222,0.000049288894,0.00004633163,7.1956754e-7,0.00004329353,0.012816386],"study_design_scores_gemma":[0.085026324,0.022605581,0.88710916,0.00053126394,0.0024435748,0.0000742858,0.0016759046,0.00011500127,0.00013534454,0.0000028728264,0.00020164289,0.00007906491],"about_ca_topic_score_codex":0.000044345103,"about_ca_topic_score_gemma":0.00040406315,"teacher_disagreement_score":0.09791828,"about_ca_system_score_codex":0.00028296083,"about_ca_system_score_gemma":0.0009422334,"threshold_uncertainty_score":0.27344194},"labels":[],"label_agreement":null},{"id":"W2051780629","doi":"10.1097/01.jto.0000268668.64625.f2","title":"Should Mutational Analyses of Tumor Samples Bypass Histopathology?","year":2007,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Histopathology; Pathology","score_opus":0.11166283347676562,"score_gpt":0.5254802178010496,"score_spread":0.41381738432428394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051780629","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05004582,0.008709155,0.0034817087,0.9180235,0.0040340223,0.00066429237,0.00032186566,0.000034335233,0.014685256],"genre_scores_gemma":[0.06992231,0.00029809045,0.07002492,0.8371755,0.013028224,0.000029850544,0.00077410415,0.00015418876,0.008592818],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997429,0.00021191583,0.0012281061,0.00022386729,0.0006051951,0.00030187896],"domain_scores_gemma":[0.99598217,0.0006109105,0.0020928816,0.00024262747,0.0009526489,0.000118754295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056178204,0.0002694849,0.001394986,0.000938817,0.000055557874,0.000007719886,0.0001978929,0.00065220275,0.0004879969],"category_scores_gemma":[0.00029904532,0.00019789446,0.0005374849,0.00024502573,0.00027460617,0.000079143945,0.000031408767,0.0016039145,0.000012134276],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009587043,0.0005085364,0.0017057514,0.0004566289,0.001580329,0.025011735,0.00039581727,0.000039245293,0.0018723017,0.000017417764,0.94784456,0.019608991],"study_design_scores_gemma":[0.0011248962,0.002620178,0.009696593,0.0003073045,0.0070103756,0.014253923,0.0001881273,0.0000049876085,0.0012615249,0.00041295466,0.96293986,0.00017930359],"about_ca_topic_score_codex":0.000053008476,"about_ca_topic_score_gemma":0.0000123091595,"teacher_disagreement_score":0.08084805,"about_ca_system_score_codex":0.0010292459,"about_ca_system_score_gemma":0.002188295,"threshold_uncertainty_score":0.8069902},"labels":[],"label_agreement":null},{"id":"W2052175813","doi":"10.1158/1538-7445.am10-1751","title":"Abstract 1751: The influence of sex on prognostic markers for non-small cell lung cancer","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Oncology; Lung cancer; Proportional hazards model; Medicine; Internal medicine; Transcriptome; Etiology; Disease; Survival analysis; Univariate analysis; Microarray; Hazard ratio; Bioinformatics; Biology; Gene; Multivariate analysis; Gene expression; Confidence interval; Genetics","score_opus":0.03670504911382957,"score_gpt":0.42789456925241237,"score_spread":0.3911895201385828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052175813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904384,0.0004350994,0.000005117802,0.0018310193,0.00017486731,0.0023868738,0.00011367348,0.000014251548,0.0046007154],"genre_scores_gemma":[0.9932991,0.00021561982,0.00012404266,0.00019234298,0.00023630084,0.002534739,0.000012139415,0.000030041496,0.003355644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871796,0.00002267201,0.00018681282,0.0002658908,0.0004111563,0.00039552056],"domain_scores_gemma":[0.9983721,0.00054559135,0.000065329186,0.00037708442,0.0005027736,0.00013716191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004568652,0.000113583264,0.00017792192,0.00010405184,0.00018773024,0.000024166377,0.00019483866,0.00007766336,0.00030580777],"category_scores_gemma":[0.0001616537,0.00007074969,0.0000737345,0.0002547629,0.00019406731,0.000045910394,0.000033398763,0.00050730933,0.000009412465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002198761,0.0010978576,0.4575392,0.00414722,0.0009726692,0.000046758123,0.0061715944,0.002119755,0.42481855,0.0004426406,0.046019047,0.054425932],"study_design_scores_gemma":[0.0039629326,0.0007411734,0.8936447,0.000867071,0.0003235468,0.0000027393296,0.0006861025,0.0004468776,0.07997367,0.0001301991,0.019007795,0.00021321588],"about_ca_topic_score_codex":0.0027669065,"about_ca_topic_score_gemma":0.0008304504,"teacher_disagreement_score":0.43610546,"about_ca_system_score_codex":0.0002014229,"about_ca_system_score_gemma":0.0014154689,"threshold_uncertainty_score":0.41827533},"labels":[],"label_agreement":null},{"id":"W2053199152","doi":"10.3390/cancers3033506","title":"An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)","year":2011,"lang":"en","type":"article","venue":"Cancers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; ERCC1; Epidermal growth factor receptor; Randomized controlled trial; Erlotinib; Clinical trial; Biomarker; Cancer; Biology","score_opus":0.08881224349185424,"score_gpt":0.3338571486428721,"score_spread":0.24504490515101784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053199152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878807,0.0029856602,0.0020750735,0.0003123605,0.0001711723,0.002944248,0.00015540973,0.00001303141,0.002554961],"genre_scores_gemma":[0.996167,0.00048880954,0.0017872915,0.00038267177,0.00004795832,0.0010107832,0.00001620804,0.000015404918,0.00008388374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991445,0.000070324866,0.00020972325,0.00022833048,0.00017124249,0.0001759116],"domain_scores_gemma":[0.9991473,0.00010455907,0.00011107743,0.00045657356,0.00009989702,0.00008060683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009441154,0.00013859091,0.00021991295,0.000094194336,0.00004343762,0.0000068137474,0.0001411213,0.000041661962,0.000029433091],"category_scores_gemma":[0.000011912211,0.00007113946,0.00008951169,0.00035952605,0.00010075341,0.000083267485,0.000005260319,0.000045461227,5.751476e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006404663,0.0035771527,0.6296918,0.0007262158,0.0025216052,0.000031857537,0.23674716,0.07316918,0.004522401,0.000071664675,0.0061551426,0.03638117],"study_design_scores_gemma":[0.013505709,0.0122292815,0.80961454,0.0023820053,0.0059074466,0.0000056693348,0.020055547,0.074229896,0.05465921,0.000010708568,0.006835257,0.00056474836],"about_ca_topic_score_codex":0.024083037,"about_ca_topic_score_gemma":0.0009433727,"teacher_disagreement_score":0.21669161,"about_ca_system_score_codex":0.0012028397,"about_ca_system_score_gemma":0.0012504722,"threshold_uncertainty_score":0.9824157},"labels":[],"label_agreement":null},{"id":"W2053394601","doi":"10.1097/jto.0b013e31822ae061","title":"Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Docetaxel; Febrile neutropenia; Rash; Neutropenia; Internal medicine; Oncology; Mucositis; Chemotherapy; Pharmacodynamics; Epidermal growth factor receptor; Pharmacology; Surgery; Pharmacokinetics; Cancer","score_opus":0.06447132353536798,"score_gpt":0.5097804440297722,"score_spread":0.4453091204944042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053394601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98764324,0.00019925648,0.004476517,0.0022670934,0.0010300368,0.0006858624,0.000027116213,0.000016137588,0.0036547526],"genre_scores_gemma":[0.96600723,0.000034312183,0.03283564,0.00031020312,0.0003502478,0.000013192515,0.000013928314,0.00001680721,0.00041842947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982107,0.00020325676,0.0010195681,0.00015927415,0.00021515244,0.00019204234],"domain_scores_gemma":[0.9981795,0.00011164494,0.0008578963,0.00015563561,0.00046542505,0.00022987646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006705151,0.00014757054,0.00061242335,0.00033978742,0.00008140588,0.0000073529554,0.0001248213,0.00011992977,0.0001454977],"category_scores_gemma":[0.00022695334,0.00011038344,0.00019033306,0.00028119062,0.000067405264,0.0001651566,0.000035760822,0.0002555287,0.000009997902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6597646,0.008497758,0.000059609203,0.00006759615,0.0014524626,0.00049185095,0.010330667,0.00007046885,0.07996083,0.00008339574,0.0016517877,0.237569],"study_design_scores_gemma":[0.4961859,0.32221487,0.0017109758,0.0015447375,0.01127509,0.0028252297,0.003379798,0.0023244836,0.1348216,0.0009534958,0.022103557,0.0006602603],"about_ca_topic_score_codex":0.000025575711,"about_ca_topic_score_gemma":0.000013235532,"teacher_disagreement_score":0.31371713,"about_ca_system_score_codex":0.00033077315,"about_ca_system_score_gemma":0.0007854382,"threshold_uncertainty_score":0.45013058},"labels":[],"label_agreement":null},{"id":"W2053652371","doi":"10.1053/j.seminoncol.2013.12.008","title":"Genes and Pathology of Non-Small Cell Lung Carcinoma","year":2013,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Lung cancer; Adenocarcinoma; Context (archaeology); Histopathology; Pathology; Molecular pathology; Carcinoma; Lung; Pathological; Oncology; Cancer; Internal medicine; Bioinformatics; Gene; Biology; Genetics","score_opus":0.027016335082217544,"score_gpt":0.38322859187598013,"score_spread":0.35621225679376256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053652371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0072928313,0.9812167,0.0000066151133,0.000046081976,0.00030030985,0.0013587336,0.000029040282,0.000008103607,0.009741527],"genre_scores_gemma":[0.0002805126,0.9939222,0.002773828,0.00005598661,0.00009199613,0.00041318478,0.00011028084,0.000036031604,0.0023159902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987423,0.00010590896,0.00050386996,0.00034566235,0.00005833317,0.0002439167],"domain_scores_gemma":[0.99905235,0.00024077311,0.00029230458,0.00027461772,0.000053969772,0.00008599315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012228865,0.00025233542,0.0017437066,0.00027633065,0.000022312352,0.0000027465842,0.00008825538,0.0005214108,0.00007893079],"category_scores_gemma":[0.000021103631,0.00019132618,0.00014215075,0.0001539368,0.00014023135,0.00001620964,0.00008459468,0.0002600145,0.000016267051],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000073336128,0.00019913269,0.0027009856,0.011688291,0.00008274519,0.00055242947,0.00053570315,1.2641515e-7,0.000021151915,0.000014894752,0.0012034306,0.9829938],"study_design_scores_gemma":[0.0011481855,0.000962037,0.0005118963,0.004140984,0.0024551253,0.00079010765,0.00018556709,0.000007375249,0.00001914106,0.000015878382,0.9895988,0.00016491264],"about_ca_topic_score_codex":0.0001116376,"about_ca_topic_score_gemma":0.000029250015,"teacher_disagreement_score":0.98839533,"about_ca_system_score_codex":0.0003700152,"about_ca_system_score_gemma":0.00090643455,"threshold_uncertainty_score":0.78020555},"labels":[],"label_agreement":null},{"id":"W2054045151","doi":"10.1177/1087057109350919","title":"Identification and Preliminary Characterization of Novel Small Molecules That Inhibit Growth of Human Lung Adenocarcinoma Cells","year":2009,"lang":"en","type":"article","venue":"SLAS DISCOVERY","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; Commonwealth Foundation","keywords":"KRAS; Adenocarcinoma; Tyrosine kinase; Epidermal growth factor receptor; Cancer research; Mutant; Lung cancer; Biology; Epidermal growth factor; Receptor tyrosine kinase; Lung; Small molecule; Targeted therapy; Identification (biology); Cell culture; Cancer; Signal transduction; Mutation; Medicine; Internal medicine; Cell biology; Gene; Biochemistry; Genetics","score_opus":0.015816205702262408,"score_gpt":0.2747062191042196,"score_spread":0.2588900134019572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054045151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948636,0.0002998627,0.0038164763,0.00024186655,0.0000481441,0.0003642064,0.0000763366,0.000012340229,0.00027712891],"genre_scores_gemma":[0.998791,0.00006145309,0.00017678482,0.000070236674,0.000031787167,0.000010270096,0.00026705363,0.000010331868,0.0005811266],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993915,0.000010519363,0.00022315558,0.00016723706,0.00012295066,0.000084615516],"domain_scores_gemma":[0.99955106,0.000011757303,0.00018370111,0.00015234396,0.00006731375,0.000033845037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039149676,0.00009210344,0.0001715539,0.00009753501,0.000036512116,0.000016835933,0.000035361543,0.000044296954,0.000004965216],"category_scores_gemma":[0.0000071890067,0.00008104836,0.00004753286,0.00008843041,0.00004807034,0.00022532982,0.000014928689,0.000038325572,5.2825965e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008037892,0.00039291638,0.030243266,0.00019438348,0.000059630427,0.0000030287931,0.000689067,0.0000019891356,0.9657345,0.0022856535,0.000027491973,0.00028769023],"study_design_scores_gemma":[0.0007735275,0.0002983275,0.57366043,0.00013447115,0.00022258313,0.000004702213,0.00007371112,0.00010979333,0.42457128,0.00010120316,0.0000014911748,0.000048493715],"about_ca_topic_score_codex":0.00003375343,"about_ca_topic_score_gemma":0.0000022622396,"teacher_disagreement_score":0.54341716,"about_ca_system_score_codex":0.000034532506,"about_ca_system_score_gemma":0.000043936714,"threshold_uncertainty_score":0.33050564},"labels":[],"label_agreement":null},{"id":"W2054266161","doi":"10.1097/jto.0b013e3182370e02","title":"Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Bevacizumab; Internal medicine; Lung cancer; Adverse effect; Surgery; Clinical endpoint; Chemotherapy; Proteinuria; Oncology; Randomized controlled trial","score_opus":0.017857850082036206,"score_gpt":0.37348717613681515,"score_spread":0.3556293260547789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054266161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954147,0.0012980727,0.00041450295,0.00033937863,0.00039379296,0.0015984912,0.000039163355,0.0000040701325,0.00049784296],"genre_scores_gemma":[0.9927973,0.0018990015,0.0050208666,0.000042213636,0.00008530901,0.000026943891,0.0000114123295,0.000025850937,0.000091089074],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99797565,0.00011385776,0.0012104247,0.00021310875,0.00023518718,0.00025176187],"domain_scores_gemma":[0.9979133,0.0002712979,0.0011881635,0.00017452949,0.00031779447,0.00013494176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037602716,0.0002076903,0.0010705448,0.0003273789,0.000034648736,0.0000027274605,0.000117578165,0.00014817975,0.0001181855],"category_scores_gemma":[0.00008630545,0.0001396884,0.000099802055,0.00031900435,0.000089628404,0.00009984572,0.00002684594,0.00034911121,2.2190169e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6015515,0.0046102437,0.089129694,0.00057997974,0.00031349238,0.00014162716,0.0076816212,0.0005460498,0.00007244798,0.0000020582072,0.00004212504,0.29532918],"study_design_scores_gemma":[0.44752795,0.055984013,0.48583588,0.003227203,0.0017677847,0.0000969849,0.00081555103,0.0009894441,0.00186036,0.00001531587,0.0015098149,0.00036972328],"about_ca_topic_score_codex":0.00023120698,"about_ca_topic_score_gemma":0.0015125755,"teacher_disagreement_score":0.39670616,"about_ca_system_score_codex":0.00096785795,"about_ca_system_score_gemma":0.0012426579,"threshold_uncertainty_score":0.56963277},"labels":[],"label_agreement":null},{"id":"W2054340543","doi":"10.1016/s1470-2045(13)70473-x","title":"Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Docetaxel; Cetuximab; Medicine; Oncology; Internal medicine; Open label; Lung cancer; Chemotherapy; Clinical trial; Cancer; Colorectal cancer; Cisplatin","score_opus":0.07556084289108853,"score_gpt":0.44264760369058054,"score_spread":0.367086760799492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054340543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97214395,0.0014181511,0.00009620254,0.0062558744,0.00038517956,0.017467808,0.00007489869,0.000058866222,0.0020990563],"genre_scores_gemma":[0.95419127,0.0004388857,0.0051228143,0.004153549,0.0007752236,0.030710207,0.00007308811,0.000074556265,0.0044604302],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788576,0.0003215053,0.00049197656,0.00047880987,0.00023258464,0.00058933743],"domain_scores_gemma":[0.9982651,0.00048614116,0.00038290196,0.000515249,0.00019269744,0.0001579121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039371985,0.00035797368,0.0013200234,0.000119107804,0.00012334909,0.00008472712,0.0003466245,0.00014435558,0.003165899],"category_scores_gemma":[0.00007888036,0.00014529786,0.00005502197,0.00044992566,0.00016033441,0.00013249868,0.00006412282,0.0003648055,0.00002288339],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9417759,0.006504459,0.003113013,0.00015726968,0.0005726591,0.00043777973,0.0029080142,0.000010155856,0.00027989055,0.0000021857227,0.00484413,0.039394516],"study_design_scores_gemma":[0.9664498,0.018939095,0.0007865006,0.00046605198,0.0008165133,0.000042164575,0.00035245522,0.0026863096,0.0005147098,0.000007788388,0.0086596245,0.00027901272],"about_ca_topic_score_codex":0.0007219877,"about_ca_topic_score_gemma":0.002830722,"teacher_disagreement_score":0.039115503,"about_ca_system_score_codex":0.00052559294,"about_ca_system_score_gemma":0.0031686504,"threshold_uncertainty_score":0.99774534},"labels":[],"label_agreement":null},{"id":"W2054571776","doi":"10.1053/sonc.2002.37470","title":"Pemetrexed in the treatment of non[ndash ]small cell lung cancer","year":2002,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pemetrexed; Medicine; Docetaxel; Oncology; Internal medicine; Lung cancer; Chemotherapy; Carboplatin; Regimen; Rash; Cisplatin","score_opus":0.04361158469312567,"score_gpt":0.4382746969562653,"score_spread":0.39466311226313966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054571776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089410844,0.9741263,0.0000011587975,0.00018503684,0.00035400444,0.0024390228,0.00006897546,0.000007881031,0.021923538],"genre_scores_gemma":[0.000119024975,0.9914784,0.0003444608,0.00009475236,0.00015468914,0.0017625869,0.0001254586,0.0000369577,0.0058837086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833435,0.00018820593,0.00064839213,0.00036556367,0.00013991022,0.0003235718],"domain_scores_gemma":[0.9987047,0.00046050086,0.00032609946,0.00041682943,0.00003628891,0.000055636156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015069901,0.00034126977,0.0018589484,0.00038536923,0.000025903593,0.0000039149104,0.00017381359,0.00037686198,0.00029864238],"category_scores_gemma":[0.000016093492,0.00020170126,0.00032591654,0.0005913766,0.00007956641,0.0000148331255,0.00001922703,0.00025840817,0.000014232138],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018422641,0.0021599745,0.0013524384,0.0038455694,0.00021023759,0.0005001206,0.003853195,0.0000028927063,5.925864e-7,0.000005749959,0.0024044144,0.98564637],"study_design_scores_gemma":[0.0022918517,0.0017258793,0.00028112732,0.007052137,0.003325061,0.00006763281,0.0002821504,0.000017955357,0.0000031693,0.0000034025247,0.9848056,0.00014405309],"about_ca_topic_score_codex":0.00075540505,"about_ca_topic_score_gemma":0.0011012058,"teacher_disagreement_score":0.98550236,"about_ca_system_score_codex":0.0028658132,"about_ca_system_score_gemma":0.0010018261,"threshold_uncertainty_score":0.8225139},"labels":[],"label_agreement":null},{"id":"W2054754015","doi":"10.3389/fonc.2014.00182","title":"Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Biomarker; Medicine; Lung cancer; Pathology; Lung; Sampling (signal processing); Cancer; Radiology; Internal medicine; Biology; Computer science","score_opus":0.050192247161782146,"score_gpt":0.38595319671637895,"score_spread":0.3357609495545968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054754015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041349038,0.9211972,0.00080416515,0.00037346146,0.0019670923,0.0022163107,0.000031761643,0.00003844756,0.07333021],"genre_scores_gemma":[0.00036341374,0.9843149,0.010094762,0.00039699086,0.00041196097,0.0009185208,0.00012778354,0.00008575044,0.0032859119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979436,0.00029711903,0.00054911553,0.0006277764,0.0001248438,0.00045758113],"domain_scores_gemma":[0.9983612,0.00037577434,0.00041181862,0.0005817444,0.00015359066,0.000115915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038067118,0.00043224794,0.0019796358,0.00033533887,0.0001215421,0.000016747941,0.00029443458,0.0005756579,0.000025675618],"category_scores_gemma":[0.00022738261,0.00026033356,0.000372667,0.00051049923,0.00027103594,0.000020969484,0.00010105733,0.0006707263,0.000035153687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037316604,0.00040193106,0.011688891,0.004563692,0.00047513665,0.0008155302,0.0012705667,0.0000011316957,5.7432334e-7,0.00006540762,0.07864693,0.9020329],"study_design_scores_gemma":[0.0013614353,0.00053226145,0.0019920089,0.0014075761,0.003961627,0.00025166833,0.00096565945,0.0001024376,2.9801453e-7,0.000091420516,0.9890833,0.00025030764],"about_ca_topic_score_codex":0.000268906,"about_ca_topic_score_gemma":0.000027964183,"teacher_disagreement_score":0.9104364,"about_ca_system_score_codex":0.0031791187,"about_ca_system_score_gemma":0.0021587235,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W2055491409","doi":"10.3389/fonc.2014.00329","title":"Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Cancer research; Epidermal growth factor receptor; Anaplastic lymphoma kinase; Crizotinib; Targeted therapy; Medicine; PTEN; Adenocarcinoma; Wnt signaling pathway; Lung cancer; Receptor tyrosine kinase; Trk receptor; Tyrosine kinase; PI3K/AKT/mTOR pathway; Protein kinase B; Epithelial–mesenchymal transition; Erlotinib; Signal transduction; Cancer; Oncology; Biology; Metastasis; Internal medicine; Receptor; Neurotrophin","score_opus":0.1576575008798927,"score_gpt":0.5599445184976513,"score_spread":0.40228701761775854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055491409","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021751544,0.9891597,0.0019576394,0.00017328405,0.0042226976,0.0033614282,0.000027493565,0.000014671027,0.0010613058],"genre_scores_gemma":[0.000052179254,0.98688823,0.011570396,0.000102575475,0.0003781647,0.0005656046,0.0001883733,0.00004276087,0.00021171547],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944681,0.0022132678,0.0022825524,0.00055956887,0.00012948524,0.00034705206],"domain_scores_gemma":[0.997217,0.0014825622,0.00081985025,0.00026751138,0.000036066274,0.00017702185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046808277,0.00034002253,0.0064199287,0.0005443082,0.000031204083,0.000013073,0.00010112944,0.00037756003,0.000021267382],"category_scores_gemma":[0.0026928352,0.00024152973,0.00044686277,0.00024149263,0.00014393398,0.000036428224,0.000051004412,0.00076913787,0.0000118711305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007907997,0.0004823171,0.0012050675,0.0056974054,0.00033107816,0.00014009383,0.00016608581,3.6653321e-7,1.44240255e-8,0.000014079181,0.010096712,0.9817877],"study_design_scores_gemma":[0.005296702,0.0006926399,0.00021811717,0.005960194,0.0039909263,0.000051851704,0.000054799406,0.000066078304,3.4347785e-8,0.0001698542,0.9833126,0.00018618483],"about_ca_topic_score_codex":0.00002693866,"about_ca_topic_score_gemma":0.000040501764,"teacher_disagreement_score":0.98160154,"about_ca_system_score_codex":0.00094610534,"about_ca_system_score_gemma":0.0018296728,"threshold_uncertainty_score":0.9849297},"labels":[],"label_agreement":null},{"id":"W2055718473","doi":"10.1002/path.1612","title":"Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers","year":2004,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"World Health Organization","keywords":"Chromogranin A; Adenocarcinoma; Tissue microarray; Cytokeratin; Immunohistochemistry; Synaptophysin; Pathology; Lung cancer; Internal medicine; Carcinoma; Small Cell Lung Carcinoma; Biology; Oncology; Cancer; Small-cell carcinoma; Medicine","score_opus":0.01885201599082935,"score_gpt":0.3497826194916076,"score_spread":0.33093060350077824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055718473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944958,0.004410777,0.00022380103,0.00021708447,0.00005246989,0.00047271402,0.000011942444,0.0000014355808,0.0001139929],"genre_scores_gemma":[0.9992239,0.00024176647,0.00043437435,0.00003350068,0.000017828175,0.000015049859,0.0000043509367,0.000008630733,0.000020619043],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99870867,0.00030939752,0.00049506844,0.00010369942,0.00026418976,0.000118982316],"domain_scores_gemma":[0.9991517,0.00013158812,0.0003009117,0.0001468432,0.00021900905,0.00004991145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011378671,0.000097785276,0.00041954214,0.00022951857,0.000029263281,0.0000025898435,0.000079296915,0.0000553605,0.000055125503],"category_scores_gemma":[0.000076677265,0.00006626311,0.00006320723,0.00025123422,0.00010077293,0.000027380293,0.000026560514,0.00017946106,9.008181e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003134003,0.0018677668,0.096412994,0.00017130579,0.0026485585,0.0003436572,0.023727546,0.007221012,0.85959035,6.8620665e-7,0.00011959782,0.00476253],"study_design_scores_gemma":[0.05375788,0.008240563,0.808128,0.00073886,0.05756987,0.0020099373,0.028173072,0.0036598276,0.037291408,0.000070428636,0.000016929811,0.00034324266],"about_ca_topic_score_codex":0.0009043846,"about_ca_topic_score_gemma":0.0004244984,"teacher_disagreement_score":0.82229894,"about_ca_system_score_codex":0.00027231962,"about_ca_system_score_gemma":0.00025969805,"threshold_uncertainty_score":0.2702131},"labels":[],"label_agreement":null},{"id":"W2055763096","doi":"10.1002/1097-0142(20000801)89:3<543::aid-cncr9>3.0.co;2-v","title":"A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma","year":2000,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Eli Lilly and Company","keywords":"Medicine; Gemcitabine; Internal medicine; Regimen; Neutropenia; Gastroenterology; Etoposide; Chemotherapy; Lung cancer; Phases of clinical research; Surgery","score_opus":0.01211772588647223,"score_gpt":0.3239034912944637,"score_spread":0.31178576540799147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055763096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955193,0.0011437207,0.000001817678,0.00007973189,0.000035245575,0.0018080465,0.00008188895,0.000006522409,0.001323722],"genre_scores_gemma":[0.9984201,0.00010402472,0.000085435706,0.000060733608,0.000019990954,0.00042245767,0.000042150354,0.000014104797,0.0008309669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992615,0.00002679309,0.00021182907,0.000172456,0.00018368114,0.00014376944],"domain_scores_gemma":[0.9995273,0.000020446701,0.00007730811,0.00025539863,0.00007747849,0.000042096173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000021118602,0.00012942987,0.0002908987,0.000054253782,0.000043985372,0.0000024332667,0.00005204039,0.000021100657,0.00026140848],"category_scores_gemma":[0.000001279969,0.00007060037,0.000040031948,0.00020668453,0.00003476433,0.000043981912,0.0000044849176,0.000038398255,8.3911783e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00574099,0.044926845,0.7931124,0.00011972474,0.00043109237,0.00006833451,0.061071113,0.0010978288,0.00024724362,0.0000069106195,0.0001664708,0.09301102],"study_design_scores_gemma":[0.14841491,0.05630248,0.7840862,0.00013468122,0.0018833255,0.0000018109602,0.0034631833,0.00022316254,0.0019381804,0.000003422315,0.003355503,0.00019308354],"about_ca_topic_score_codex":0.0014819783,"about_ca_topic_score_gemma":0.0009488916,"teacher_disagreement_score":0.14267392,"about_ca_system_score_codex":0.0003208233,"about_ca_system_score_gemma":0.00017957916,"threshold_uncertainty_score":0.28789994},"labels":[],"label_agreement":null},{"id":"W2056180028","doi":"10.1016/j.lungcan.2011.10.020","title":"Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gefitinib; Adenocarcinoma; Erlotinib; Immunohistochemistry; Lung cancer; Epidermal growth factor receptor; Pathology; Adenosquamous carcinoma; Stage (stratigraphy); Oncology; Cancer; Cancer research; Internal medicine; Biology","score_opus":0.027699810195255678,"score_gpt":0.3586723438470089,"score_spread":0.3309725336517532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056180028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894805,0.007002144,0.000038834238,0.0007392961,0.00025537264,0.0012626541,0.00010525409,0.00006278851,0.001585596],"genre_scores_gemma":[0.9894175,0.0008737362,0.0007551266,0.001549698,0.00010327206,0.0007304753,0.000019959922,0.000049933104,0.0065002944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824995,0.00013937087,0.0003896732,0.0005691194,0.00022100765,0.000430858],"domain_scores_gemma":[0.9989868,0.00016095296,0.00014415562,0.00030868917,0.00013456927,0.0002648678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003468436,0.00027696704,0.0005288285,0.0001137515,0.0000863202,0.000020638638,0.000115325514,0.00022887635,0.00024855378],"category_scores_gemma":[0.000073239484,0.00019546243,0.00009099893,0.00024282168,0.00013413302,0.00006300427,0.00004618451,0.0004532007,0.0000025022348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011420159,0.0006557799,0.9638451,0.000047390615,0.0002675484,0.00048365092,0.008951757,0.000012072939,0.0090899505,0.000013491701,0.0021778992,0.0030352469],"study_design_scores_gemma":[0.006928773,0.0011822515,0.9881346,0.00040772246,0.00028591527,0.0000091647635,0.00012313272,0.000052784115,0.0013542101,0.000003827394,0.001248032,0.00026959347],"about_ca_topic_score_codex":0.003313867,"about_ca_topic_score_gemma":0.0007088424,"teacher_disagreement_score":0.024289541,"about_ca_system_score_codex":0.00081798004,"about_ca_system_score_gemma":0.00054634025,"threshold_uncertainty_score":0.7970727},"labels":[],"label_agreement":null},{"id":"W2057039211","doi":"10.3747/co.22.2430","title":"Management of egfr tki—Induced Dermatologic Adverse Events","year":2015,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lakeridge Health; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Johnson and Johnson; Janssen Biotech; Astellas Pharma; AstraZeneca; Celgene; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Paronychia; Adverse effect; Dermatology; Gefitinib; Rash; Erlotinib; Epidermal growth factor receptor; EGFR inhibitors; Lung cancer; Clinical trial; Chemotherapy; Cancer; Oncology; Internal medicine","score_opus":0.26541752241258504,"score_gpt":0.5492822625137567,"score_spread":0.28386474010117163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057039211","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000591574,0.97799426,0.000014252308,0.00007603498,0.0020300036,0.0018331265,0.000052476753,0.000040253813,0.017900461],"genre_scores_gemma":[0.00009434589,0.99770385,0.000356748,0.000022306212,0.000112279326,0.00043759824,0.00059281476,0.000030567815,0.00064946426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837106,0.00013227713,0.0006431608,0.00035423215,0.00023077715,0.00026847486],"domain_scores_gemma":[0.99874425,0.00004256146,0.00049455574,0.00039888103,0.00014101756,0.00017875942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013555962,0.00031827088,0.0018475881,0.00020005254,0.000031880154,0.000001114297,0.00016167955,0.00026099404,0.000120134064],"category_scores_gemma":[0.000013808051,0.00022516283,0.00040191275,0.0002519972,0.000047798803,0.000028615224,0.0001155361,0.0002730344,0.00024950897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013643902,0.00084556965,0.000083997395,0.020236244,0.0009667141,0.00018114089,0.000062953215,1.1448352e-7,1.8720394e-8,0.00039024636,0.003538126,0.9736812],"study_design_scores_gemma":[0.0017200649,0.00034834494,0.000049140537,0.0087632025,0.009061677,0.00016978303,0.00008538108,0.0000010368105,2.4301949e-7,0.00008656287,0.97956127,0.00015327633],"about_ca_topic_score_codex":0.000004369834,"about_ca_topic_score_gemma":0.0000013995682,"teacher_disagreement_score":0.97602314,"about_ca_system_score_codex":0.0011297324,"about_ca_system_score_gemma":0.0010049865,"threshold_uncertainty_score":0.9181874},"labels":[],"label_agreement":null},{"id":"W2057099389","doi":"10.1016/j.cllc.2016.04.002","title":"Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Internal medicine; Hazard ratio; Carboplatin; Lung cancer; Neutropenia; Gastroenterology; Paclitaxel; Oncology; Anemia; Urology; Chemotherapy; Confidence interval; Cisplatin","score_opus":0.008273552640896074,"score_gpt":0.3253109315871075,"score_spread":0.3170373789462114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057099389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590164,0.0008095664,0.00002947283,0.0006449914,0.00007175459,0.0022417998,0.00014906745,0.000015590698,0.00013612525],"genre_scores_gemma":[0.99800116,0.0009312228,0.00020011024,0.00020902428,0.000020914253,0.00030742338,0.00013709001,0.000042322397,0.00015070889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977329,0.000091380876,0.0008278023,0.0006093713,0.00037579917,0.00036275564],"domain_scores_gemma":[0.9982713,0.00048786952,0.0004226255,0.0003486102,0.00031491622,0.00015469515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021695861,0.00029765468,0.0009746452,0.00037119136,0.000043828008,0.000010200723,0.000093149,0.00013208482,0.00006460855],"category_scores_gemma":[0.00007055441,0.00016950467,0.00007505378,0.0011434903,0.0001615809,0.00016876639,0.000027972803,0.00022239963,4.0984375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067698793,0.0026933635,0.961466,0.000103068065,0.0010172348,0.0000039801043,0.00046058596,0.0012010545,0.0000054867196,0.000005036628,0.0000111025465,0.026263203],"study_design_scores_gemma":[0.06513301,0.003843944,0.92722005,0.0015150158,0.0011466418,2.4225326e-8,0.000029128449,0.00079834077,0.00004183669,0.000003440972,0.00003699732,0.00023157144],"about_ca_topic_score_codex":0.0010099051,"about_ca_topic_score_gemma":0.0076160347,"teacher_disagreement_score":0.058363136,"about_ca_system_score_codex":0.0006031999,"about_ca_system_score_gemma":0.0003747021,"threshold_uncertainty_score":0.69122},"labels":[],"label_agreement":null},{"id":"W2057313386","doi":"10.1186/1471-2407-14-940","title":"Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study","year":2014,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Docetaxel; Pemetrexed; Internal medicine; Gemcitabine; Oncology; Discontinuation; Vinorelbine; Lung cancer; Retrospective cohort study; Chemotherapy; Surgery","score_opus":0.01186398028525617,"score_gpt":0.36839360871647436,"score_spread":0.3565296284312182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057313386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991984,0.00011880917,0.0009717765,0.00013536488,0.00030710083,0.008226201,0.00013095727,0.000027555809,0.00016241884],"genre_scores_gemma":[0.9951104,0.000025158897,0.0002515992,0.0004678674,0.00020010833,0.0038076348,0.00006053814,0.00004793696,0.00002873955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753356,0.00032205303,0.00072146615,0.00072934467,0.00031758062,0.0003759718],"domain_scores_gemma":[0.9964631,0.0024338844,0.00037101188,0.0003241481,0.00030278633,0.00010502555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018425923,0.00031152446,0.0008919104,0.000092491224,0.00014630472,0.000027643648,0.00011665298,0.00015678431,0.000010881684],"category_scores_gemma":[0.0007240823,0.00019520518,0.00013070127,0.0004267733,0.00008624421,0.00008554798,0.00003424152,0.00041913328,3.828306e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023308506,0.0029637811,0.98939323,0.00019151923,0.0001993223,0.000007197261,0.00078275026,0.0023189909,0.000003959226,7.8014654e-7,0.00003249002,0.0017751533],"study_design_scores_gemma":[0.048663344,0.0027209779,0.93382686,0.0006199409,0.00062338705,2.991514e-7,0.00010856043,0.013177721,0.000015040398,0.000008798866,0.000012498692,0.00022258647],"about_ca_topic_score_codex":0.0017688915,"about_ca_topic_score_gemma":0.070449196,"teacher_disagreement_score":0.06868031,"about_ca_system_score_codex":0.00086377206,"about_ca_system_score_gemma":0.00047479247,"threshold_uncertainty_score":0.9465127},"labels":[],"label_agreement":null},{"id":"W2057618618","doi":"10.1097/jto.0b013e318199e03a","title":"BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Lung cancer; Biomarker; Internal medicine; Tissue microarray; Immunohistochemistry; Chromogranin A; Multivariate analysis; Univariate analysis; Cancer; Population; Pathology; Biology","score_opus":0.019581209392830187,"score_gpt":0.43774782563849296,"score_spread":0.41816661624566276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057618618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771606,0.002655789,0.002505989,0.0130422,0.0010885044,0.001125642,0.000021081878,0.00000992938,0.0023902783],"genre_scores_gemma":[0.98654205,0.00029963715,0.010142465,0.0010967845,0.00048906973,0.000046220055,0.000006125729,0.000015051491,0.001362626],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906045,0.000044570945,0.000433195,0.00013561726,0.00010091762,0.00022523313],"domain_scores_gemma":[0.9990284,0.000130383,0.00037045474,0.0001018589,0.00023923321,0.00012971407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027081274,0.00011578382,0.0004406098,0.00016297355,0.000042720094,0.000009510162,0.00008055295,0.00012965886,0.00005386827],"category_scores_gemma":[0.00005714706,0.00008194163,0.0001309649,0.00011919988,0.00001620302,0.00008019036,0.000010623721,0.00021952408,0.0000012342042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007814307,0.00466428,0.083197124,0.0007427247,0.00041738327,0.0005481217,0.0066124643,0.00016946338,0.21576889,0.000014922431,0.023164062,0.6568863],"study_design_scores_gemma":[0.044114653,0.03687595,0.623853,0.0047386494,0.008636854,0.00087337074,0.0036461481,0.0088936845,0.13851693,0.0016915802,0.12703554,0.0011236122],"about_ca_topic_score_codex":0.000023806151,"about_ca_topic_score_gemma":0.00003677154,"teacher_disagreement_score":0.6557627,"about_ca_system_score_codex":0.0005026173,"about_ca_system_score_gemma":0.0007721002,"threshold_uncertainty_score":0.3341483},"labels":[],"label_agreement":null},{"id":"W2057886846","doi":"10.1097/01.jto.0000283106.85632.e3","title":"A3-03: Pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC): Results from a randomized phase III dose finding trial in patients who progressed following platinum-containing chemotherapy","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Docetaxel; Chemotherapy; Oncology; Interim analysis; Performance status; Phases of clinical research; Toxicity; Randomized controlled trial; Gastroenterology; Surgery; Cisplatin","score_opus":0.02359953387203726,"score_gpt":0.44636421540173876,"score_spread":0.4227646815297015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057886846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891998,0.0024323594,0.0012122556,0.00059138564,0.0011920647,0.0049953666,0.000057764224,0.0000075394832,0.0003114315],"genre_scores_gemma":[0.990348,0.00039953305,0.0081114285,0.000109816596,0.0004824271,0.00025517025,0.0000472545,0.000032784224,0.00021360767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974891,0.00014050372,0.0015087625,0.00023797361,0.00027643115,0.00034722523],"domain_scores_gemma":[0.9950688,0.0026150655,0.0017466685,0.00019302072,0.0002517268,0.00012470118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013908179,0.00024140374,0.0015576365,0.00029408143,0.00010929356,0.000015125317,0.00012248335,0.00015309431,0.000020937412],"category_scores_gemma":[0.00027560885,0.00014453393,0.0005965357,0.00024793655,0.00005329909,0.0001063818,0.000010369908,0.00018402025,2.2646084e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.707431,0.0028511991,0.0025156692,0.000023926457,0.001352871,0.00006726915,0.01118576,0.00009978716,0.00068946654,6.6394836e-7,0.000044732355,0.27373764],"study_design_scores_gemma":[0.9702351,0.01317801,0.0035659387,0.00056117825,0.0030509557,0.0000028873505,0.0013659013,0.0009117837,0.0060180645,0.000020497424,0.00096049503,0.0001291632],"about_ca_topic_score_codex":0.00019782418,"about_ca_topic_score_gemma":0.0001721499,"teacher_disagreement_score":0.27360848,"about_ca_system_score_codex":0.001203315,"about_ca_system_score_gemma":0.00077455427,"threshold_uncertainty_score":0.58939224},"labels":[],"label_agreement":null},{"id":"W2057935373","doi":"10.1016/j.ijrobp.2003.09.091","title":"Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies","year":2004,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; EGFR inhibitors; Epidermal growth factor receptor; Drug; Drug resistance; Chemotherapy; Lung cancer; Pharmacology; Combination therapy; Oncology; Cancer; Internal medicine","score_opus":0.0301652909814909,"score_gpt":0.4060449897394728,"score_spread":0.3758796987579819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057935373","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021860369,0.9643018,0.027902504,0.001686977,0.0032544348,0.0011060061,0.00016195595,0.000051523588,0.001316149],"genre_scores_gemma":[0.0033817922,0.9778397,0.015014051,0.0003161977,0.0024810052,0.00008335215,0.0003822862,0.000062163905,0.00043945605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794614,0.00017999414,0.0010472779,0.00032378818,0.00029451068,0.00020828491],"domain_scores_gemma":[0.99734885,0.00019111356,0.001503755,0.00016372235,0.00060691644,0.000185671],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003250737,0.00033506798,0.0011811231,0.00030524042,0.00007839314,0.00006794972,0.000249153,0.0003939489,0.000035895067],"category_scores_gemma":[0.00013417826,0.0002694011,0.00042384202,0.00021990667,0.00009781494,0.0003178565,0.000059907772,0.00032157195,0.000027663871],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012935509,0.00030854705,0.000079451616,0.00067064515,0.0019381309,0.00007381715,0.00037060893,0.000043795302,0.000044090946,0.048183553,0.00078649656,0.9473715],"study_design_scores_gemma":[0.0033162555,0.0013984048,0.000089014575,0.0072078356,0.0020288073,0.0003295045,0.00012443226,0.0000043525065,0.00004547378,0.04065198,0.9445356,0.00026831715],"about_ca_topic_score_codex":0.000010427188,"about_ca_topic_score_gemma":0.000011020345,"teacher_disagreement_score":0.9471032,"about_ca_system_score_codex":0.0016990649,"about_ca_system_score_gemma":0.0033562076,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W2059479059","doi":"10.1016/s0169-5002(00)80204-4","title":"Phase I/II study of biweekly paclitaxel and cisplatin in nonsmall cell lung cancer (NSCLC). Final result with QOL data","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cisplatin; Paclitaxel; Oncology; Internal medicine; Lung cancer; non-small cell lung cancer (NSCLC); Chemotherapy; A549 cell","score_opus":0.03128569605859117,"score_gpt":0.39326052230896336,"score_spread":0.3619748262503722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059479059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846221,0.007552459,0.000014112005,0.0006993613,0.000087570486,0.0015627746,0.0006740545,0.000027430202,0.004760132],"genre_scores_gemma":[0.99122024,0.00085928565,0.00035281607,0.00021274811,0.00012694814,0.00034491174,0.00012723269,0.00003749632,0.0067183413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983957,0.000042583335,0.00037985216,0.00056184176,0.0003109633,0.00030906545],"domain_scores_gemma":[0.9989401,0.00005089244,0.00012796493,0.0006586916,0.00008467874,0.00013764268],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012049907,0.0002312506,0.00041748813,0.00012359326,0.00011338865,0.000017995451,0.00015032521,0.000064609034,0.00096930435],"category_scores_gemma":[0.000009270364,0.0001737469,0.000024706964,0.00036853694,0.00006901421,0.00019377994,0.00006577034,0.00019882381,0.0000014978759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009852224,0.019866485,0.7685075,0.0012441275,0.0019288856,0.00053039874,0.030217389,0.0011627732,0.0018171121,0.00003207842,0.02529011,0.13955091],"study_design_scores_gemma":[0.35378832,0.033707686,0.48504284,0.007781614,0.016402006,0.00010559042,0.009279173,0.046646614,0.0022260821,0.000032308766,0.04250514,0.0024826233],"about_ca_topic_score_codex":0.012978423,"about_ca_topic_score_gemma":0.010169155,"teacher_disagreement_score":0.3439361,"about_ca_system_score_codex":0.00023670387,"about_ca_system_score_gemma":0.0005618117,"threshold_uncertainty_score":0.999944},"labels":[],"label_agreement":null},{"id":"W2059645245","doi":"10.1016/s0169-5002(02)00167-8","title":"Second line chemotherapy for NSCLC: establishing a gold standard","year":2002,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Vinorelbine; Oncology; Lung cancer; Internal medicine; Paclitaxel; Ifosfamide; Chemotherapy; Population; Surgery; Etoposide; Cisplatin","score_opus":0.03752359896036843,"score_gpt":0.41298845336235307,"score_spread":0.3754648544019846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059645245","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025312236,0.98434675,0.00035940687,0.0004139588,0.00084318896,0.003389253,0.001796319,0.000101494,0.0087471],"genre_scores_gemma":[0.0000029821676,0.9380054,0.0011161625,0.0006783788,0.0015080977,0.0022621737,0.00048223688,0.0001644532,0.05578012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982827,0.000022672199,0.00049311307,0.000537686,0.00025392915,0.0004099456],"domain_scores_gemma":[0.99878454,0.00013608174,0.00029290162,0.00044037995,0.00016686512,0.00017924415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000102786216,0.00045845078,0.0016653937,0.00016254699,0.00008706515,0.00008789518,0.00013899866,0.00029241052,0.0027336648],"category_scores_gemma":[0.000031734395,0.00033946734,0.00061431294,0.00029998773,0.000034338955,0.000117672986,0.000020351028,0.00030749626,0.000012119625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004405346,0.000054821692,0.000007487476,0.020034438,0.0014916898,0.0000119495835,0.00018032957,8.291126e-7,3.3705857e-7,0.00006020216,0.10436472,0.87374914],"study_design_scores_gemma":[0.0024012711,0.00018319987,0.0000017656889,0.017319761,0.0057915864,0.000023344668,0.0000095930445,0.000038344217,0.0000034663333,0.000013343676,0.97390336,0.0003109365],"about_ca_topic_score_codex":0.00005435461,"about_ca_topic_score_gemma":0.00009810832,"teacher_disagreement_score":0.8734382,"about_ca_system_score_codex":0.0014025804,"about_ca_system_score_gemma":0.0009671226,"threshold_uncertainty_score":0.9999057},"labels":[],"label_agreement":null},{"id":"W2061415759","doi":"10.1093/annonc/mdt459.53","title":"Phase III Study of Crizotinib vs. Chemotherapy in Advanced ALK+ NSCLC: Patient-Reported Symptoms and Quality of Life","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Crizotinib; Docetaxel; Internal medicine; Lung cancer; Quality of life (healthcare); Pemetrexed; Chemotherapy; ALK inhibitor; Phases of clinical research; Randomization; Performance status; Oncology; non-small cell lung cancer (NSCLC); Clinical trial; Cisplatin","score_opus":0.0706192058174058,"score_gpt":0.46268956407546463,"score_spread":0.3920703582580588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061415759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955098,0.00034014662,0.000005444833,0.0011975117,0.000054000597,0.0011150739,0.000010085952,0.000007790055,0.001760135],"genre_scores_gemma":[0.99886495,0.00014087032,0.00013930432,0.0006822319,0.000011094314,0.00008306907,0.000013088153,0.000009033802,0.000056330693],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987005,0.00008154988,0.0007727283,0.00017187165,0.00014049606,0.00013287154],"domain_scores_gemma":[0.99871165,0.0001216598,0.00053716404,0.00021313323,0.00033208137,0.00008430409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001659044,0.000095664334,0.00066526385,0.000109309425,0.000013322261,0.0000012109399,0.000038586695,0.0000662325,0.000107613174],"category_scores_gemma":[0.00013557162,0.000076959695,0.000048119975,0.00014383609,0.000096971235,0.00006625591,0.000017964567,0.000059213195,6.711972e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069953064,0.038630784,0.3472819,0.00022574737,0.0015618827,0.000017930102,0.020174937,0.000014627563,0.025517413,0.00013262143,0.0009251838,0.5585217],"study_design_scores_gemma":[0.095616885,0.053101264,0.82972175,0.00011342586,0.0001990849,0.0000056851313,0.0074460814,0.000030479687,0.011535833,0.00015936086,0.0019177594,0.0001524051],"about_ca_topic_score_codex":0.0020104803,"about_ca_topic_score_gemma":0.00012868924,"teacher_disagreement_score":0.5583693,"about_ca_system_score_codex":0.000020393281,"about_ca_system_score_gemma":0.00020153043,"threshold_uncertainty_score":0.31383252},"labels":[],"label_agreement":null},{"id":"W2061481386","doi":"10.1007/s12672-012-0105-y","title":"Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Hormones and Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; CancerCare Manitoba; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Estrogen receptor; Univariate analysis; Cohort; Immunohistochemistry; Multivariate analysis; Cancer; Stage (stratigraphy); Estrogen; Breast cancer; Pathology; Biology","score_opus":0.013763272116483975,"score_gpt":0.30095409300934683,"score_spread":0.28719082089286285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061481386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518372,0.04647814,0.000016315582,0.00010215984,0.0003493097,0.0003399264,0.00008461751,0.000008358917,0.0007840066],"genre_scores_gemma":[0.9954813,0.0034172884,0.00020911124,0.000025361052,0.00020444907,0.00024538356,0.000021818785,0.000018845498,0.00037643913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993161,0.000012235194,0.0001692742,0.00014082648,0.00011591539,0.0002456643],"domain_scores_gemma":[0.9996346,0.000019947556,0.000071738315,0.000109091656,0.0000385154,0.00012609758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002621449,0.00012611512,0.0002525963,0.000058782694,0.000033435783,0.000008434034,0.00003456443,0.000038706454,0.00024201967],"category_scores_gemma":[0.0000016140868,0.00009769919,0.00005568935,0.000103621096,0.000030796335,0.00008210665,0.000021538042,0.00007149682,0.0000023686678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001000341,0.00046868486,0.9287653,0.00030716255,0.00068865094,0.0000030425133,0.00643843,0.000015828518,0.027493497,0.00019432738,0.0006429966,0.033981744],"study_design_scores_gemma":[0.013754955,0.0007028748,0.93029344,0.00030858003,0.003520277,0.000002404779,0.0017698228,0.00037678142,0.040739063,0.000018523911,0.008113245,0.00040001812],"about_ca_topic_score_codex":0.005166944,"about_ca_topic_score_gemma":0.00021332127,"teacher_disagreement_score":0.043644138,"about_ca_system_score_codex":0.00010633089,"about_ca_system_score_gemma":0.00011060346,"threshold_uncertainty_score":0.78109086},"labels":[],"label_agreement":null},{"id":"W2062054551","doi":"10.1016/j.radonc.2014.07.014","title":"Cisplatin vs. carboplatin-based chemoradiotherapy in patients &gt;65years of age with stage III non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Office of Research and Development; Sanofi","keywords":"Carboplatin; Medicine; Internal medicine; Cisplatin; Hazard ratio; Lung cancer; Oncology; Chemoradiotherapy; Confidence interval; Neutropenia; Chemotherapy; Odds ratio; Surgery","score_opus":0.006591472663945682,"score_gpt":0.2962721719393989,"score_spread":0.28968069927545326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062054551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943619,0.0009071252,0.0010045992,0.0003205072,0.00009905412,0.00080212025,0.000019567084,0.000017447053,0.0024676907],"genre_scores_gemma":[0.9924989,0.00033336543,0.0048677134,0.0012809797,0.000077006924,0.000098515564,0.000033249846,0.000038945465,0.00077133114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990335,0.000056223587,0.00026772136,0.0002735699,0.00012925893,0.00023972095],"domain_scores_gemma":[0.99937606,0.0000994605,0.0001692298,0.00019690131,0.000054890304,0.00010344934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116296666,0.00018384376,0.000594227,0.00014112989,0.000042700973,0.0000070973692,0.00005615706,0.000135911,0.00013550873],"category_scores_gemma":[0.0000038762732,0.00014090209,0.00004713387,0.00016930432,0.00010663036,0.000031710395,0.000004595867,0.00013219213,3.4827573e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034734174,0.0010546735,0.94222593,0.00033301066,0.00027195353,0.000047716847,0.00471198,0.0009590669,0.0056542493,0.000057307185,0.00026883703,0.040941827],"study_design_scores_gemma":[0.07436736,0.00800816,0.87783676,0.00027669346,0.000292644,0.000005019712,0.00010667961,0.012195245,0.0053692497,0.0000073593565,0.021153897,0.000380921],"about_ca_topic_score_codex":0.0007534823,"about_ca_topic_score_gemma":0.0007505252,"teacher_disagreement_score":0.07089394,"about_ca_system_score_codex":0.0005356331,"about_ca_system_score_gemma":0.0003670642,"threshold_uncertainty_score":0.57458204},"labels":[],"label_agreement":null},{"id":"W2062547449","doi":"10.1016/j.lungcan.2013.11.010","title":"KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"","keywords":"KRAS; Colorectal cancer; Medicine; Lung cancer; Carcinogenesis; Oncology; Internal medicine; Cancer research; Genotype; Cancer; Biology; Genetics; Gene","score_opus":0.010244901197998242,"score_gpt":0.32954041298713815,"score_spread":0.3192955117891399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062547449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9478176,0.03118894,0.000460788,0.014251266,0.00040164945,0.0041480823,0.00058811076,0.000080841484,0.0010627025],"genre_scores_gemma":[0.96805453,0.004583617,0.0012506687,0.00093461,0.0002616719,0.021862091,0.00016195717,0.000063430845,0.002827426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987026,0.000017734712,0.0003128578,0.0004341679,0.000110026915,0.0004226444],"domain_scores_gemma":[0.9990919,0.00011722203,0.00012859597,0.00020530734,0.00028290387,0.00017403258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050540813,0.00024777884,0.0003458577,0.0001596424,0.00023211379,0.000058060017,0.000090165,0.00011375175,0.00049760845],"category_scores_gemma":[0.0000109332805,0.00021239088,0.000088224515,0.00035283214,0.00008273892,0.00018597364,0.00002056396,0.00014839065,0.000003910828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010348202,0.00029044325,0.9239288,0.0005711662,0.00090295053,0.000002502221,0.0075431797,0.000574183,0.024446027,0.00044722186,0.015788805,0.025401222],"study_design_scores_gemma":[0.0058182683,0.00013171135,0.97662765,0.0003573157,0.0012652291,0.000005023513,0.0006232204,0.0070600603,0.0034393098,0.00045093516,0.0038245225,0.00039678416],"about_ca_topic_score_codex":0.015609285,"about_ca_topic_score_gemma":0.009901478,"teacher_disagreement_score":0.0526988,"about_ca_system_score_codex":0.0007586382,"about_ca_system_score_gemma":0.00075925706,"threshold_uncertainty_score":0.9909459},"labels":[],"label_agreement":null},{"id":"W2062656631","doi":"10.1016/j.jval.2012.03.1227","title":"PCN110 Health-Related Quality of Life in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Adverse effect; Lung cancer; Disease; Palliative care; Performance status; Stage (stratigraphy); Health care; Cancer; Internal medicine; Physical therapy","score_opus":0.04398484578602466,"score_gpt":0.3838714521447991,"score_spread":0.33988660635877443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062656631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825692,0.012742982,0.000026198408,0.0017665743,0.00051223167,0.0015571774,0.000063096595,0.000020868118,0.0007416786],"genre_scores_gemma":[0.9965652,0.0009446923,0.00089938013,0.0011648928,0.000047458005,0.00011971123,0.00006893243,0.00002555435,0.0001641523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763215,0.00024560484,0.0011148067,0.00022972077,0.00023310217,0.00054462586],"domain_scores_gemma":[0.99869156,0.00011603203,0.0004833183,0.0002525772,0.00007244958,0.00038403925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007139522,0.00014888446,0.0006123797,0.00017991419,0.000050048922,0.0000024681683,0.00005808912,0.00007834869,0.000049795257],"category_scores_gemma":[0.000085708234,0.00013331046,0.000058722868,0.0004187102,0.00002368747,0.00009442135,0.000020993102,0.000226374,0.000006309459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013738927,0.0011195735,0.9830074,0.0015738967,0.000026131951,6.264541e-7,0.008803884,0.0012102905,0.000019443169,0.00008529773,0.00023396136,0.0037821492],"study_design_scores_gemma":[0.007035706,0.00030726707,0.9903675,0.0009089938,0.000016102573,3.2156214e-7,0.00042321527,0.00052139576,0.000046854668,0.000020938556,0.0002450767,0.00010668383],"about_ca_topic_score_codex":0.10514345,"about_ca_topic_score_gemma":0.0011622928,"teacher_disagreement_score":0.10398115,"about_ca_system_score_codex":0.0012198308,"about_ca_system_score_gemma":0.0017650966,"threshold_uncertainty_score":0.9008155},"labels":[],"label_agreement":null},{"id":"W2063065521","doi":"10.1111/his.12331","title":"Epidermal growth factor receptor mutation‐specific immunohistochemical antibodies in lung adenocarcinoma","year":2013,"lang":"en","type":"article","venue":"Histopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Immunohistochemistry; Epidermal growth factor receptor; Adenocarcinoma; Gefitinib; Antibody; Biology; Lung cancer; Molecular biology; Pathology; Cancer research; Mutation; Exon; Cancer; Medicine; Gene; Immunology; Genetics","score_opus":0.01396605578519249,"score_gpt":0.29031997020580363,"score_spread":0.27635391442061114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063065521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838625,0.0062162937,0.000193806,0.0025456732,0.000477162,0.0005880419,0.000018682575,0.00007638714,0.0060214223],"genre_scores_gemma":[0.9944661,0.000100271,0.0026473661,0.00032575807,0.000112530026,0.00019867315,0.00014616361,0.000026192482,0.0019769443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988726,0.00005597583,0.000330075,0.00032914127,0.000115563475,0.0002966497],"domain_scores_gemma":[0.9994056,0.00006110796,0.000079428646,0.00023446401,0.00012509614,0.00009427348],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000037742913,0.0001662792,0.00033340175,0.00019795675,0.00007682353,0.000010193077,0.00007379888,0.00012453357,0.0012352905],"category_scores_gemma":[0.000067316774,0.00014845144,0.00008101522,0.0001415694,0.00015652626,0.0001244355,0.00002816148,0.000192598,0.00046620806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016062132,0.0005480107,0.7224906,0.00017572843,0.000035765253,0.0009655544,0.0065968265,0.0000017858108,0.23506054,0.0032494494,0.027638886,0.0030762507],"study_design_scores_gemma":[0.0017774975,0.00015350089,0.9922131,0.000030757234,0.000048947448,0.0005058794,0.000185145,0.000035559868,0.0014523681,0.00026515726,0.0031702626,0.00016187537],"about_ca_topic_score_codex":0.00019779667,"about_ca_topic_score_gemma":0.000004503167,"teacher_disagreement_score":0.26972246,"about_ca_system_score_codex":0.000559295,"about_ca_system_score_gemma":0.00009674036,"threshold_uncertainty_score":0.9996777},"labels":[],"label_agreement":null},{"id":"W2065028684","doi":"10.1097/jto.0b013e3181fd83a4","title":"Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Vinorelbine; Epidermal growth factor receptor; Oncology; Hazard ratio; Internal medicine; Chemotherapy; Lung cancer; Fluorescence in situ hybridization; Copy-number variation; Mutation; Cancer research; Cisplatin; Cancer; Confidence interval; Gene; Biology; Genetics","score_opus":0.00959289005364907,"score_gpt":0.3787633561425244,"score_spread":0.3691704660888753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065028684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946255,0.0010017956,0.0016977435,0.0012093639,0.00039970403,0.0008354753,0.00016443181,0.0000037283398,0.00006227341],"genre_scores_gemma":[0.96901834,0.00062240404,0.02985252,0.00015200122,0.00021515832,0.000057561243,0.000023694449,0.000020605527,0.00003769076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990468,0.000059962997,0.00043132156,0.00014992547,0.00011373494,0.00019825027],"domain_scores_gemma":[0.99867266,0.0003053431,0.0004635435,0.0000638076,0.00033293728,0.00016172037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022800009,0.00012939108,0.00046600975,0.00012715207,0.000037830345,0.000007828039,0.00003524123,0.00013336199,0.00005328535],"category_scores_gemma":[0.000112829075,0.000098185745,0.000055645854,0.00009630713,0.00009250352,0.00010402585,0.000011918704,0.00023268993,2.433143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057059648,0.0010341281,0.85375893,0.0006243038,0.0003663673,0.00009799662,0.008862526,0.000035350462,0.089715905,0.000039516173,0.0003434125,0.039415598],"study_design_scores_gemma":[0.010298823,0.003019719,0.9236854,0.0003047974,0.0009483221,0.0002725908,0.000762968,0.00074227614,0.05875707,0.00042607283,0.00063064665,0.00015135772],"about_ca_topic_score_codex":0.000100398596,"about_ca_topic_score_gemma":0.000081822,"teacher_disagreement_score":0.06992642,"about_ca_system_score_codex":0.00022580885,"about_ca_system_score_gemma":0.0005493242,"threshold_uncertainty_score":0.40038985},"labels":[],"label_agreement":null},{"id":"W2066047258","doi":"10.1016/j.critrevonc.2012.02.004","title":"Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions","year":2012,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Sunitinib; Axitinib; Bevacizumab; Medicine; Angiogenesis; Vascular endothelial growth factor; Sorafenib; Fibroblast growth factor; Lung cancer; Cancer research; Oncology; Platelet-derived growth factor receptor; Growth factor; Pharmacology; Internal medicine; Chemotherapy; Cancer; VEGF receptors; Receptor; Hepatocellular carcinoma","score_opus":0.12314918485587871,"score_gpt":0.5226966903665233,"score_spread":0.3995475055106446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066047258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046298046,0.99214983,0.00002102356,0.0025594246,0.0018174584,0.002249624,0.000058341524,0.00004995635,0.0010480732],"genre_scores_gemma":[0.00007886884,0.9937591,0.0031905195,0.0011273607,0.0007284948,0.00074948184,0.00021849843,0.0000612662,0.00008639556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952987,0.0011884008,0.0018952386,0.0008374068,0.00011705614,0.0006632306],"domain_scores_gemma":[0.9970131,0.0015173747,0.00030527933,0.0005035447,0.00009511692,0.0005655863],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009397522,0.0005681438,0.0053524366,0.0003017171,0.00013755987,0.000015955937,0.00013144778,0.0013120286,0.00035283156],"category_scores_gemma":[0.0013953792,0.0004020015,0.00062463613,0.00038404236,0.0007034647,0.000092151065,0.00016868873,0.001011902,0.0002758432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010771108,0.0006554184,0.0015587274,0.008490537,0.0003574903,0.00025433305,0.00004778708,6.093277e-10,3.486893e-8,0.0074669337,0.0022458315,0.9789121],"study_design_scores_gemma":[0.0010624531,0.00022923957,0.00071163336,0.0065512923,0.007623776,0.0030835574,0.000024648052,0.0000020286736,6.127492e-8,0.0001284954,0.98028463,0.00029818417],"about_ca_topic_score_codex":0.00000808203,"about_ca_topic_score_gemma":0.000029263201,"teacher_disagreement_score":0.978614,"about_ca_system_score_codex":0.00025545352,"about_ca_system_score_gemma":0.0004554056,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W2066584196","doi":"10.3389/fonc.2014.00190","title":"Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Anaplastic lymphoma kinase; Targeted therapy; Lung cancer; Epidermal growth factor receptor; Medicine; Cancer research; Drug resistance; Tyrosine kinase; Crizotinib; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Oncology; Cancer; Internal medicine; Biology; Receptor; Genetics","score_opus":0.03153233252284752,"score_gpt":0.40333582528187667,"score_spread":0.37180349275902913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066584196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009848629,0.98957205,0.0007957805,0.0011131659,0.00083120633,0.0057250517,0.00014170767,0.000014318256,0.00082183455],"genre_scores_gemma":[0.0002468053,0.9714183,0.01778304,0.00046524435,0.00007397054,0.006367934,0.00013117482,0.000050787097,0.0034627032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982273,0.00015630599,0.00055150467,0.0005915262,0.00009594111,0.00037744656],"domain_scores_gemma":[0.9989843,0.00031282415,0.00020943394,0.00024938575,0.00007457974,0.00016947092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018013212,0.0003713138,0.002017425,0.0004604789,0.000059002177,0.000011739697,0.00012945714,0.0002903426,0.000013133119],"category_scores_gemma":[0.00006929282,0.000272876,0.00018881027,0.0003346557,0.0000628235,0.000022503664,0.000020959724,0.00013281553,0.0000022146617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003047403,0.00042619073,0.0006383771,0.002343147,0.0005844601,0.00024496962,0.001375874,0.000021444162,0.000013203935,0.00007148287,0.024612773,0.96936333],"study_design_scores_gemma":[0.0040723314,0.00045650668,0.000050854727,0.0035429406,0.001004127,0.000006864656,0.00008981023,0.00004446655,0.000035874644,0.00008882299,0.9903699,0.0002375005],"about_ca_topic_score_codex":0.00017801048,"about_ca_topic_score_gemma":0.0012544353,"teacher_disagreement_score":0.9691258,"about_ca_system_score_codex":0.0023045144,"about_ca_system_score_gemma":0.0018782851,"threshold_uncertainty_score":0.99997234},"labels":[],"label_agreement":null},{"id":"W2066898096","doi":"10.1097/jto.0b013e3181d86e8b","title":"Maintenance Therapy in Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; Maintenance therapy; Internal medicine; Intensive care medicine; Chemotherapy","score_opus":0.030570816910562584,"score_gpt":0.4891913458128282,"score_spread":0.4586205289022656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066898096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001989733,0.99004364,0.0000528425,0.0005559737,0.0020389524,0.0010539958,0.0000211728,0.0000072018242,0.0042364975],"genre_scores_gemma":[0.00017688477,0.99172807,0.0038675747,0.00031079684,0.0006939612,0.00014401993,0.000012750386,0.00005978993,0.00300618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980436,0.00013735707,0.0010454167,0.00024616133,0.00018508732,0.00034238608],"domain_scores_gemma":[0.9975209,0.0001820051,0.0015428617,0.00027114578,0.00029257356,0.00019046728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040451455,0.00033710126,0.0024087927,0.00043210844,0.00003826639,0.000011953927,0.00024004486,0.00053435226,0.0001732449],"category_scores_gemma":[0.000044260625,0.00021148639,0.0005705528,0.00031694066,0.00005441024,0.00007822704,0.000028822084,0.0015476975,0.000010588426],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021930491,0.00042906508,0.00022727535,0.0034019384,0.0002964785,0.0008122552,0.0002424453,0.0000045493703,0.000017798664,0.0000024679214,0.001125584,0.99322087],"study_design_scores_gemma":[0.0016405489,0.0010780992,0.00020478957,0.011751931,0.00222712,0.00082839787,0.00005741419,0.000004341672,0.000014807449,0.0000140913,0.9820073,0.00017115718],"about_ca_topic_score_codex":0.00003363077,"about_ca_topic_score_gemma":0.00010602135,"teacher_disagreement_score":0.9930497,"about_ca_system_score_codex":0.0014323593,"about_ca_system_score_gemma":0.0049719056,"threshold_uncertainty_score":0.8819947},"labels":[],"label_agreement":null},{"id":"W2067215627","doi":"10.1016/j.ijrobp.2009.07.379","title":"Dosimetric and Clinical Parameters Contributing to Esophagitis and Radiation Pneumonitis following Treatment for Small-cell Lung Carcinoma","year":2009,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Esophagitis; Radiation Pneumonitis; Lung; Carcinoma; Pneumonitis; Radiology; Internal medicine; Oncology; Disease","score_opus":0.026767943745435716,"score_gpt":0.38622669190446196,"score_spread":0.35945874815902623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067215627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793714,0.0025979988,0.011742062,0.004170657,0.0012133267,0.00067577016,0.00008382385,0.000020146252,0.00012481574],"genre_scores_gemma":[0.9894469,0.0009722327,0.007149978,0.001317935,0.00092195434,0.000022521454,0.00011419311,0.000016135262,0.000038151466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985951,0.000106340754,0.00067232375,0.0002526615,0.00012815888,0.00024539646],"domain_scores_gemma":[0.9979824,0.00081872684,0.000559782,0.00008434941,0.00033588882,0.00021889838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040431775,0.00017681107,0.00049400865,0.00022059836,0.00012610576,0.000045637433,0.00008725805,0.00015530619,0.0000031200777],"category_scores_gemma":[0.00035873498,0.00015219176,0.00024287561,0.00014395802,0.000044246193,0.00015489994,0.000019827174,0.00014954184,0.0000017394373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002229249,0.00030300388,0.56305915,0.000003933937,0.00059470336,0.00003933508,0.00030455948,0.000047911995,0.00038311418,0.00044580712,0.00010846014,0.43448707],"study_design_scores_gemma":[0.033474997,0.013079182,0.933615,0.00009341625,0.002237862,0.00029642743,0.00018531021,0.0047819703,0.0029797684,0.0027153052,0.006227006,0.00031373056],"about_ca_topic_score_codex":0.000035095498,"about_ca_topic_score_gemma":0.0000031510053,"teacher_disagreement_score":0.43417335,"about_ca_system_score_codex":0.0008904774,"about_ca_system_score_gemma":0.00034286533,"threshold_uncertainty_score":0.62061995},"labels":[],"label_agreement":null},{"id":"W2068132555","doi":"10.1016/j.lungcan.2009.09.007","title":"The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University","funders":"","keywords":"Medicine; Taxane; Lung cancer; Oncology; Regimen; Internal medicine; Cancer; Disease; Chemotherapy; Bioinformatics; Breast cancer; Biology","score_opus":0.010544525231161473,"score_gpt":0.34552796477521425,"score_spread":0.3349834395440528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068132555","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083719974,0.9879409,0.0000040353902,0.00016220972,0.00036421753,0.0024990092,0.00013997644,0.000025998424,0.008026466],"genre_scores_gemma":[0.0029298803,0.99167347,0.00009850422,0.00009018617,0.0003792209,0.0019013701,0.00007075959,0.00007980719,0.0027767958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997563,0.00007061363,0.00095364754,0.0005492194,0.00031815088,0.0005453728],"domain_scores_gemma":[0.99853855,0.00018260327,0.00054436346,0.0005214933,0.00010209837,0.00011088384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023065899,0.00046098966,0.0015284612,0.0002125138,0.00008769826,0.000025369998,0.00027491702,0.00028251088,0.00006902819],"category_scores_gemma":[0.000028954433,0.000315805,0.00031232825,0.00072542793,0.00006071476,0.000059213475,0.00005015644,0.00063370744,0.0000023751272],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092068374,0.00025542456,0.039110757,0.022443857,0.0005503648,0.00006215897,0.0014464658,0.000097789445,0.00001604165,0.000040270705,0.0017437264,0.9341411],"study_design_scores_gemma":[0.0030044946,0.000085420805,0.0058564814,0.079063214,0.0048677754,0.000008629903,0.00026948904,0.0012261198,0.00010858573,0.000027097718,0.90489864,0.0005840363],"about_ca_topic_score_codex":0.004385485,"about_ca_topic_score_gemma":0.0073970533,"teacher_disagreement_score":0.93355703,"about_ca_system_score_codex":0.0021188408,"about_ca_system_score_gemma":0.0019830638,"threshold_uncertainty_score":0.9999294},"labels":[],"label_agreement":null},{"id":"W2068632645","doi":"10.3389/fonc.2014.00173","title":"Is the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Disease; Quality of life (healthcare); Regimen; Oncology; Intensive care medicine; Clinical trial; Lung cancer; Stage (stratigraphy); Internal medicine","score_opus":0.2532619430195417,"score_gpt":0.5413465065444971,"score_spread":0.28808456352495543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068632645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046102007,0.98185885,0.00005161225,0.008103724,0.001324627,0.00492464,0.00040280988,0.0000050941103,0.002867595],"genre_scores_gemma":[0.0016612328,0.99491537,0.0005434253,0.0013320278,0.00021765045,0.0008444871,0.00019695597,0.000024356716,0.00026448368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927048,0.003643286,0.0026869923,0.00031397678,0.000467243,0.00018370169],"domain_scores_gemma":[0.995002,0.001593441,0.0024237102,0.0006671333,0.00025206667,0.000061698636],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013848641,0.00020691549,0.0034450067,0.000284411,0.00002894821,0.0000035831554,0.00023227537,0.00035202055,0.000039019087],"category_scores_gemma":[0.009517002,0.000101925456,0.00039224574,0.00052749534,0.00012768156,0.000017521896,0.000040342282,0.0002865453,0.0000017948041],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005775296,0.00025880584,0.0020129057,0.0020543134,0.0007875034,0.000002493179,0.002628384,0.000010714388,2.3818187e-7,0.0000833846,0.06801183,0.9235719],"study_design_scores_gemma":[0.0052824887,0.0003920435,0.0031894455,0.0028326965,0.0038676118,0.0000027139504,0.0019148915,0.00003230104,0.0000011375312,0.00024087873,0.9821423,0.00010149003],"about_ca_topic_score_codex":0.000580627,"about_ca_topic_score_gemma":0.0007843299,"teacher_disagreement_score":0.92347044,"about_ca_system_score_codex":0.00092965004,"about_ca_system_score_gemma":0.0028322802,"threshold_uncertainty_score":0.99882627},"labels":[],"label_agreement":null},{"id":"W2068722130","doi":"10.1038/ncponc0909","title":"Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?","year":2007,"lang":"en","type":"letter","venue":"Nature Clinical Practice Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"ERCC1; Messenger RNA; Cancer; Lung cancer; Biology; Cancer research; Medicine; Computational biology; Oncology; Gene; Genetics; DNA repair","score_opus":0.08356583590998254,"score_gpt":0.5005505703121375,"score_spread":0.4169847344021549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068722130","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022482783,0.033455413,0.000072817085,0.91632205,0.0013866205,0.004241572,0.000096427044,0.000031785974,0.021910554],"genre_scores_gemma":[0.17808317,0.003831916,0.010374049,0.79846996,0.0048323693,0.0005438798,0.000091652466,0.00011148995,0.0036615203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963566,0.0008815193,0.0010896043,0.0007730846,0.00047394127,0.0004252348],"domain_scores_gemma":[0.99010396,0.007615214,0.0011701236,0.00049142836,0.0004733723,0.00014592132],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0025877957,0.0003807962,0.0012039795,0.0001685215,0.000111591,0.000021316384,0.00021032506,0.005272074,0.000057547655],"category_scores_gemma":[0.004798995,0.00023561643,0.0001487828,0.0002394781,0.0005018,0.00013538437,0.00016528042,0.010717836,0.0000021630467],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031194324,0.0019686678,0.010617189,0.0017936414,0.0009818624,0.0048546507,0.0011315438,0.0000027971337,0.0015362161,0.000036760273,0.8605212,0.113436066],"study_design_scores_gemma":[0.0064613316,0.0018570806,0.02301634,0.001034509,0.0023640029,0.00019322576,0.0003108757,0.000020318515,0.00024211519,0.000058625254,0.9641721,0.00026944152],"about_ca_topic_score_codex":0.00035337242,"about_ca_topic_score_gemma":0.0004459026,"teacher_disagreement_score":0.15560038,"about_ca_system_score_codex":0.000536016,"about_ca_system_score_gemma":0.0019199922,"threshold_uncertainty_score":0.9960193},"labels":[],"label_agreement":null},{"id":"W2069422280","doi":"10.1097/jto.0b013e318189f551","title":"The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review","year":2008,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Histology; Lung cancer; Internal medicine; Oncology; Clinical trial; Pathology","score_opus":0.012812267287756213,"score_gpt":0.43091978674002324,"score_spread":0.41810751945226704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069422280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003045026,0.99608064,0.0000077189,0.00054088933,0.00040230234,0.0017290855,0.00004807829,0.0000030845558,0.0008836766],"genre_scores_gemma":[0.00011166822,0.9982937,0.000679864,0.00012067861,0.00017270964,0.00021977813,0.000023471015,0.000027137416,0.00035099845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794585,0.00033456137,0.0011303406,0.00020576023,0.00015637222,0.00022714908],"domain_scores_gemma":[0.9968317,0.0005630208,0.0018958914,0.00020150497,0.00038587872,0.00012199338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029341812,0.00026888636,0.0024523747,0.00024385542,0.000060724735,0.000005270577,0.00016728361,0.0003124121,0.000008185671],"category_scores_gemma":[0.00019234112,0.00014798225,0.00035091653,0.0003735138,0.00012940899,0.00005598978,0.00004411413,0.00088125735,6.011592e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020368087,0.00023578135,0.00050993555,0.03751618,0.00048952276,0.00065136125,0.00059982063,0.0000018072022,0.0000014758283,0.0000029544183,0.0012092602,0.9585782],"study_design_scores_gemma":[0.0005810568,0.0014784773,0.00031319488,0.13097857,0.006778922,0.004722219,0.000064823245,0.00000673391,0.0000012275062,0.000014963331,0.85496503,0.00009475967],"about_ca_topic_score_codex":0.0000071404866,"about_ca_topic_score_gemma":0.00002655222,"teacher_disagreement_score":0.95848346,"about_ca_system_score_codex":0.00085156,"about_ca_system_score_gemma":0.0030632338,"threshold_uncertainty_score":0.6034541},"labels":[],"label_agreement":null},{"id":"W2069425136","doi":"10.3816/clc.2009.s.004","title":"Extending Outcomes: Epidermal Growth Factor Receptor–Targeted Monoclonal Antibodies in Non–Small-Cell Lung Cancer","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cetuximab; Epidermal growth factor receptor; Medicine; Monoclonal antibody; Lung cancer; Tyrosine kinase; Cancer research; Targeted therapy; Oncology; Epidermal growth factor; Antibody; Cancer; Internal medicine; Immunology; Receptor","score_opus":0.07954086513988046,"score_gpt":0.4812353200448106,"score_spread":0.40169445490493016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069425136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023276294,0.98722124,0.000032666772,0.0007342859,0.0032435767,0.003925256,0.00094607874,0.00014187634,0.0014273826],"genre_scores_gemma":[0.0006083347,0.9872359,0.00097466615,0.0011601232,0.0016374041,0.0014140519,0.00060938473,0.00019449375,0.006165627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377906,0.00033417964,0.002768036,0.0015193938,0.0005232305,0.0010761012],"domain_scores_gemma":[0.99624664,0.0010813146,0.001072117,0.00073171174,0.0002686332,0.00059960654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046014128,0.0011564536,0.0050397697,0.00045941139,0.00018095478,0.00007203683,0.00042849183,0.0009990953,0.0014627445],"category_scores_gemma":[0.00033694127,0.0008455261,0.0018297064,0.0006907925,0.00017132779,0.00018890864,0.00014318428,0.0017652675,0.00006074892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010724907,0.00091373647,0.30426034,0.020519327,0.0032500455,0.00023893158,0.00024243773,0.000009200224,0.0000018387283,0.000026729209,0.019112552,0.6513176],"study_design_scores_gemma":[0.008235872,0.00043751308,0.1278554,0.06793795,0.02073635,0.000025470803,0.000057330424,0.00031941754,0.000008612682,0.000023592489,0.77208376,0.0022787468],"about_ca_topic_score_codex":0.00085860555,"about_ca_topic_score_gemma":0.0003523396,"teacher_disagreement_score":0.7529712,"about_ca_system_score_codex":0.0023109927,"about_ca_system_score_gemma":0.0030023833,"threshold_uncertainty_score":0.99945},"labels":[],"label_agreement":null},{"id":"W2070030853","doi":"10.1007/s10637-012-9856-0","title":"A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Neutropenia; Paclitaxel; Lung cancer; Adverse effect; Internal medicine; Toxicity; Population; Oncology; Pharmacology; Chemotherapy; Gastroenterology","score_opus":0.011286878644105476,"score_gpt":0.31518292024716726,"score_spread":0.3038960416030618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070030853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973052,0.0002272522,0.000057201585,0.00023771686,0.00006198202,0.0015843482,0.000020008289,0.000013940381,0.00049236085],"genre_scores_gemma":[0.9968289,0.0000041283547,0.0023754044,0.0001722476,0.000038149126,0.00022653029,0.00012924413,0.000026001393,0.00019940687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988596,0.000037323553,0.0003007757,0.00020478347,0.0003764385,0.00022110136],"domain_scores_gemma":[0.9993297,0.00005004687,0.00018345773,0.00012781202,0.00013849052,0.00017050463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006968257,0.0001626227,0.00023714165,0.00020672647,0.000037129677,0.000009515885,0.000050533676,0.00003148723,0.00003381235],"category_scores_gemma":[0.000010712184,0.00012583229,0.000016562764,0.00040859738,0.000047961777,0.00029113732,0.000014332305,0.00012753576,0.0000013185345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006120937,0.006741124,0.97341895,0.00012428909,0.000077584235,0.000004323585,0.014030566,0.0016700404,0.00080473645,0.000028103725,0.000103087106,0.002385108],"study_design_scores_gemma":[0.07865162,0.0013437372,0.91429144,0.00071204704,0.00029051583,0.000001011106,0.0012174651,0.00082474394,0.002394967,0.000042301534,0.000051048817,0.00017912524],"about_ca_topic_score_codex":0.0009283752,"about_ca_topic_score_gemma":0.00011873498,"teacher_disagreement_score":0.07803953,"about_ca_system_score_codex":0.00035349632,"about_ca_system_score_gemma":0.0004942712,"threshold_uncertainty_score":0.5131292},"labels":[],"label_agreement":null},{"id":"W2070367561","doi":"10.1097/00001622-200207000-00001","title":"Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer","year":2002,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Vinorelbine; Docetaxel; Oncology; Lung cancer; Gemcitabine; Internal medicine; Chemotherapy; Cisplatin; Carboplatin; Cancer; Paclitaxel; Cost effectiveness; Intensive care medicine","score_opus":0.181850235748183,"score_gpt":0.5464531142649413,"score_spread":0.36460287851675827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070367561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000043523187,0.98562056,0.0003578763,0.000064522086,0.005688332,0.0072289915,0.0002649611,0.00001657697,0.0007538362],"genre_scores_gemma":[0.000008592887,0.99048114,0.00017811799,0.000012542199,0.00045444333,0.00801982,0.00064259686,0.00004891937,0.0001538194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998549,0.00016944332,0.0005515903,0.00037463,0.00010312359,0.00025225582],"domain_scores_gemma":[0.9985963,0.00058934797,0.0003831308,0.0002304273,0.00012145862,0.000079301266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020043737,0.00028603844,0.0017631062,0.00025914988,0.00002806034,0.0000037134673,0.00010805822,0.0003003456,0.00017122107],"category_scores_gemma":[0.000026746637,0.0002231266,0.0003770675,0.00026272878,0.000058410405,0.00002479397,0.000022665748,0.00025736899,0.0000062927334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070903465,0.0009922389,0.00021853742,0.09942534,0.00023842887,7.779214e-7,0.000114598566,0.0000023579023,3.9623953e-7,0.00009960209,0.0037718653,0.89506495],"study_design_scores_gemma":[0.0048792143,0.00041958853,0.000072036884,0.030192997,0.0010153659,0.000010096842,0.000008084705,0.000042978685,0.0000025219922,0.000008957532,0.96318686,0.00016127418],"about_ca_topic_score_codex":0.000024235012,"about_ca_topic_score_gemma":0.0000029014464,"teacher_disagreement_score":0.959415,"about_ca_system_score_codex":0.0015618969,"about_ca_system_score_gemma":0.0013415016,"threshold_uncertainty_score":0.90988386},"labels":[],"label_agreement":null},{"id":"W2070763870","doi":"10.1093/annonc/mdv048.21","title":"Role of Treatment in International Differences in One-Year Mortality From Early Stage Non-Small Cell Lung Cancer: a Tentative Answer From the International Cancer Benchmarking Partnership Study","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Benchmarking; Lung cancer; Stage (stratigraphy); Oncology; General partnership; Cancer; Internal medicine","score_opus":0.15202475012584318,"score_gpt":0.4490947623995554,"score_spread":0.2970700122737122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070763870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925291,0.0006640057,0.0000042605316,0.0012899657,0.00029172108,0.0006980715,0.00051961304,0.0000045639667,0.0039987257],"genre_scores_gemma":[0.9983644,0.0004990534,0.00012755998,0.00019722301,0.0001770853,0.0003456081,0.000109694025,0.000008569107,0.00017078902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988201,0.00011672789,0.0003939029,0.00026218352,0.00025364343,0.00015343312],"domain_scores_gemma":[0.9990876,0.00021775183,0.00026484468,0.00015389398,0.0002095285,0.00006643665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001798847,0.00013071799,0.00039956585,0.000100069745,0.000015783378,0.000010007609,0.00018291743,0.000063828025,0.00029209795],"category_scores_gemma":[0.000027363425,0.00009174931,0.00006292001,0.00011338158,0.000069915426,0.00007987038,0.00005328386,0.000110749264,0.0000011143577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048806285,0.0019924536,0.9476661,0.0000041774033,0.00096846075,0.000017054841,0.04390903,0.00010860761,0.00034984463,0.00001860294,0.00009984597,0.004377773],"study_design_scores_gemma":[0.0050912085,0.00137126,0.97380894,0.00009913366,0.00020790123,9.0297114e-8,0.01711453,0.0004935541,0.0011394438,0.00015852774,0.00044376444,0.000071665854],"about_ca_topic_score_codex":0.29715413,"about_ca_topic_score_gemma":0.11761516,"teacher_disagreement_score":0.17953897,"about_ca_system_score_codex":0.0005336241,"about_ca_system_score_gemma":0.0008467442,"threshold_uncertainty_score":0.8984861},"labels":[],"label_agreement":null},{"id":"W2071188109","doi":"10.1177/1078155212464087","title":"Efficacy vs. effectiveness: Erlotinib in previously treated non-small-cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Internal medicine; Oncology; Regimen; Erlotinib Hydrochloride; Chemotherapy; Cancer; Randomized controlled trial; Surgery; Epidermal growth factor receptor","score_opus":0.0349619244226064,"score_gpt":0.4534841221746531,"score_spread":0.4185221977520467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071188109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97406584,0.008537378,0.000091390015,0.0037940915,0.001031716,0.0012104308,0.00000381673,0.000015893154,0.011249466],"genre_scores_gemma":[0.992214,0.003432546,0.0016077949,0.0015426843,0.0007329609,0.00009332025,0.0000050381386,0.00003455253,0.00033709063],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980705,0.0005510007,0.0005854562,0.000155539,0.00022298207,0.0004145289],"domain_scores_gemma":[0.99660397,0.0017036869,0.0008388385,0.00013412374,0.00038855377,0.00033082397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013929696,0.00019646097,0.000589184,0.00024281983,0.000068902154,0.000015156427,0.0001088651,0.000090777576,0.00022636581],"category_scores_gemma":[0.00045956657,0.00015024682,0.00015095172,0.00033099603,0.000040583145,0.0007938764,0.000028240293,0.00069778814,0.000024732488],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017959312,0.012397188,0.90239465,0.00044885627,0.002262711,0.0015867378,0.0060572186,0.00030803858,0.012997341,0.000013620523,0.0063686715,0.037205633],"study_design_scores_gemma":[0.08919303,0.0031854827,0.4342318,0.0007827722,0.013289954,0.004018052,0.0006525189,0.00024722095,0.017274547,0.0000032273815,0.43677136,0.0003500241],"about_ca_topic_score_codex":0.00035345284,"about_ca_topic_score_gemma":0.000013713473,"teacher_disagreement_score":0.46816286,"about_ca_system_score_codex":0.0013628853,"about_ca_system_score_gemma":0.0013522339,"threshold_uncertainty_score":0.6126888},"labels":[],"label_agreement":null},{"id":"W2071539936","doi":"10.1097/jto.0b013e3182773fce","title":"Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Afatinib; Lung cancer; Placebo; Internal medicine; Gefitinib; Erlotinib; Adverse effect; Quality of life (healthcare); Randomized controlled trial; Chest pain; Gastroenterology; Cancer; Pathology; Epidermal growth factor receptor","score_opus":0.02487591600355954,"score_gpt":0.4309749554100554,"score_spread":0.4060990394064959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071539936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993539,0.001240774,0.000047071284,0.0003093805,0.0001805775,0.003945069,0.000108877684,0.000006429278,0.00062286644],"genre_scores_gemma":[0.9958334,0.0006886799,0.0026675,0.00006925342,0.000090186855,0.0002022363,0.000032181375,0.000026140593,0.00039044232],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99592835,0.00043862336,0.002741538,0.0002452894,0.00037937262,0.00026682884],"domain_scores_gemma":[0.99293745,0.0011974587,0.004200728,0.00022287526,0.0012070151,0.00023446292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012250392,0.00024684,0.0026447992,0.00033523087,0.000032327753,0.0000071075083,0.00011969425,0.00017717641,0.0001075445],"category_scores_gemma":[0.0008524854,0.00014922257,0.00024055952,0.0003284842,0.00018931294,0.00017416247,0.000032805805,0.00025345926,2.5739385e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93821925,0.004813289,0.030189184,0.0008515783,0.0013104291,0.000020307656,0.0042662555,0.00014590287,0.001930093,0.000005453517,0.00012623363,0.01812201],"study_design_scores_gemma":[0.95566875,0.01345652,0.020898674,0.0015985362,0.003155379,0.000015586023,0.00081877987,0.00036202837,0.003808229,0.000011194121,0.000044162618,0.0001621645],"about_ca_topic_score_codex":0.0014708621,"about_ca_topic_score_gemma":0.00037880402,"teacher_disagreement_score":0.017959846,"about_ca_system_score_codex":0.0002638459,"about_ca_system_score_gemma":0.0013499433,"threshold_uncertainty_score":0.608512},"labels":[],"label_agreement":null},{"id":"W2073188790","doi":"10.1159/000225033","title":"Clinical Evaluation of Two Weekly Dose Schedules of ‘IC-140’","year":2009,"lang":"en","type":"article","venue":"Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Leukopenia; Medicine; Toxicity; Gastroenterology; Internal medicine; Surgery","score_opus":0.09143190221976283,"score_gpt":0.543773560856015,"score_spread":0.4523416586362522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073188790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587771,0.00050735334,0.00010361214,0.0028505684,0.00025447572,0.00032564267,0.000005565272,0.000010208074,0.037165448],"genre_scores_gemma":[0.9938841,0.000061363105,0.0052976757,0.00032330386,0.0001104338,0.000010906089,0.000025537176,0.0000036364986,0.0002830433],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992142,0.00010776551,0.00031969993,0.00010950701,0.00017095059,0.00007789068],"domain_scores_gemma":[0.9992807,0.000086446955,0.00015107819,0.00015387706,0.0002806189,0.000047299658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051912206,0.000048616224,0.00026972315,0.000050872983,0.00001385641,7.6701093e-7,0.00003182899,0.00007440734,0.00022181905],"category_scores_gemma":[0.00016444726,0.00003792549,0.000071540046,0.00007944654,0.00007284003,0.000023652281,0.000006425225,0.00006357765,0.000013733327],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003005459,0.003117298,0.04907621,0.000023759223,0.00026466645,0.000010621498,0.00037267583,0.000043622986,0.0051344833,0.0075836377,0.001617325,0.9324551],"study_design_scores_gemma":[0.025244104,0.013243184,0.92631555,0.0001157756,0.0033627362,0.00003328544,0.00036527604,0.0011200265,0.003676955,0.010701819,0.015708603,0.00011271549],"about_ca_topic_score_codex":0.000036760564,"about_ca_topic_score_gemma":0.000027920549,"teacher_disagreement_score":0.9323424,"about_ca_system_score_codex":0.00011544848,"about_ca_system_score_gemma":0.0006862033,"threshold_uncertainty_score":0.2428763},"labels":[],"label_agreement":null},{"id":"W2073397984","doi":"10.1016/s0169-5002(00)80192-0","title":"Integrated analysis for two randomized phase III studies comparing Taxotere at 75 mg/m2 and 100 mg/m2 to control regimens in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based chemotherapy","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Randomized controlled trial","score_opus":0.013373242699183347,"score_gpt":0.33694084528434476,"score_spread":0.32356760258516143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073397984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833923,0.0057599237,0.0015234195,0.0005028049,0.00006741722,0.00806235,0.00027373945,0.00007363541,0.00034443027],"genre_scores_gemma":[0.9878162,0.00057624903,0.0007561769,0.001227109,0.00007628227,0.0059320065,0.00029903732,0.00007384941,0.0032430645],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772084,0.000102546706,0.00064335327,0.00071993744,0.00025817615,0.0005551251],"domain_scores_gemma":[0.9985107,0.00025003657,0.00028800825,0.0003437036,0.00035934988,0.00024818158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019141872,0.00049628486,0.0018884242,0.0003435194,0.0001948812,0.000044837485,0.0000936004,0.000089761474,0.00030070732],"category_scores_gemma":[0.000019960087,0.00035179098,0.0002458377,0.00082616054,0.000107605745,0.000089982386,0.000014385129,0.0001526354,0.0000013370711],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2277668,0.001095183,0.71665573,0.0005608055,0.015598631,0.000033953464,0.010087946,0.01680343,0.00072811864,0.0000017893228,0.0018313065,0.008836332],"study_design_scores_gemma":[0.8322114,0.0007357791,0.01928915,0.0017223591,0.01685592,0.0000013776908,0.00024661818,0.12643215,0.0014367277,0.0000015097747,0.00048597995,0.0005810449],"about_ca_topic_score_codex":0.009506693,"about_ca_topic_score_gemma":0.015403579,"teacher_disagreement_score":0.69736654,"about_ca_system_score_codex":0.0016073677,"about_ca_system_score_gemma":0.00030309267,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W2073442590","doi":"10.2482/haigan.49.37","title":"Review of the 23rd Seminar for Lung Cancer Mass Screening","year":2009,"lang":"en","type":"article","venue":"Haigan","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lung cancer; Medicine; Oncology; Internal medicine","score_opus":0.018398024318207508,"score_gpt":0.3819969402199114,"score_spread":0.36359891590170385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073442590","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046291903,0.7548961,0.0152935535,0.13487749,0.0010765222,0.008737739,0.00032372208,0.00017729156,0.038325652],"genre_scores_gemma":[0.8919281,0.030129435,0.01849081,0.03864643,0.0006390348,0.000416491,0.000094729265,0.0000488478,0.01960612],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996408,0.00000627605,0.0001101453,0.00007901696,0.000077165794,0.00008658207],"domain_scores_gemma":[0.99967444,0.000015161344,0.000056469446,0.00015673872,0.0000660392,0.000031125157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051026334,0.00005227984,0.00013277074,0.000011694983,0.0000469592,0.0000023021787,0.00004054877,0.000017214872,0.000051615792],"category_scores_gemma":[0.000027766686,0.000030897765,0.00008477353,0.00008944275,0.0000128796555,0.000020980955,0.0000040474856,0.00003343497,4.2717647e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019414573,0.00036021328,0.04369466,0.017315282,0.00094360596,0.000012660934,0.0018049745,0.00006513966,0.019554274,0.003325394,0.51743144,0.39529818],"study_design_scores_gemma":[0.006914771,0.0008599629,0.09940302,0.10573502,0.006570201,0.00003956958,0.00028855927,0.0017410766,0.044979382,0.00052944274,0.732468,0.00047097093],"about_ca_topic_score_codex":0.00002752304,"about_ca_topic_score_gemma":0.0000047026156,"teacher_disagreement_score":0.8456362,"about_ca_system_score_codex":0.00003961802,"about_ca_system_score_gemma":0.000075249096,"threshold_uncertainty_score":0.12599742},"labels":[],"label_agreement":null},{"id":"W2073990067","doi":"10.1038/sj.tpj.6500444","title":"Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib","year":2007,"lang":"en","type":"article","venue":"The Pharmacogenomics Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute of Environmental Health Sciences; Dana-Farber/Harvard Cancer Center; National Cancer Institute; Massachusetts General Hospital; AstraZeneca","keywords":"Gefitinib; Lung cancer; Internal medicine; Epidermal growth factor receptor; Hazard ratio; Genotype; Oncology; Allele; Medicine; Biology; Gastroenterology; Tyrosine-kinase inhibitor; Rash; Confidence interval; Cancer; Genetics; Gene","score_opus":0.025547497360492406,"score_gpt":0.3590342355438876,"score_spread":0.3334867381833952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073990067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966833,0.0005855582,0.00012315257,0.0011778222,0.00032370485,0.00061491755,0.000083238374,0.000013560785,0.00039474753],"genre_scores_gemma":[0.99604267,0.0015510955,0.00040617786,0.0011535597,0.00032480765,0.000013401451,0.000017030276,0.000039831928,0.00045140344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986135,0.00006385369,0.0005528526,0.00020500185,0.00017826978,0.00038651857],"domain_scores_gemma":[0.99896467,0.00020174794,0.00026333498,0.000105153435,0.000138701,0.000326414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036717087,0.00021320347,0.00035644625,0.00012561423,0.00018168025,0.000035833185,0.00010909682,0.000061298604,0.0001720602],"category_scores_gemma":[0.000018006733,0.00012062926,0.00011184595,0.00012675794,0.00008477396,0.00009102973,0.000032875152,0.0004781627,0.000006563462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007164206,0.0005108812,0.98989874,0.00001348592,0.00059264584,0.000079811216,0.0006478701,0.000006548554,0.0012231895,0.0000024942462,0.00024572192,0.006062183],"study_design_scores_gemma":[0.014996903,0.00034057358,0.9802446,0.000065810804,0.0009533034,0.00010005518,0.00009554981,0.00014478686,0.002567338,0.000005213978,0.00030597928,0.00017988321],"about_ca_topic_score_codex":0.0002923761,"about_ca_topic_score_gemma":0.00008073072,"teacher_disagreement_score":0.014280483,"about_ca_system_score_codex":0.00034652316,"about_ca_system_score_gemma":0.00019608984,"threshold_uncertainty_score":0.49191183},"labels":[],"label_agreement":null},{"id":"W2074269068","doi":"10.1016/j.cllc.2013.08.001","title":"A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium","year":2013,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; University of Toronto; University of Ottawa; McGill University; Ottawa Hospital","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Internal medicine; Proto-oncogene tyrosine-protein kinase Src; Oncology; Chemotherapy; Cancer; Kinase; Population; Receptor","score_opus":0.02339027935434116,"score_gpt":0.41810573937268414,"score_spread":0.39471546001834296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074269068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984096,0.0043504303,0.000019093672,0.0014869821,0.0011266038,0.0078368,0.00035284372,0.000050404782,0.0006808487],"genre_scores_gemma":[0.99248457,0.001916663,0.00029244556,0.0004695772,0.0006286303,0.0028999,0.00017356781,0.000062007166,0.0010726184],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99629676,0.00020236026,0.0018441353,0.00072233,0.00040600367,0.00052841153],"domain_scores_gemma":[0.9968902,0.00037915853,0.0010154359,0.0008260576,0.0005295773,0.00035959648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045407529,0.00039224626,0.0012097401,0.00011792184,0.00017446316,0.000020177475,0.00032841362,0.0002554953,0.00052787294],"category_scores_gemma":[0.00025738438,0.0002707911,0.0003334868,0.00048624535,0.00040617952,0.0002609597,0.00014639294,0.00048575178,0.000002413402],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08350331,0.14327239,0.37323827,0.0030252852,0.0035980355,0.0001398418,0.009950231,0.00034050463,0.010995537,0.00013389868,0.024221493,0.34758124],"study_design_scores_gemma":[0.83332485,0.07787762,0.03360411,0.0043798853,0.0073709125,0.0000061733163,0.0011843286,0.008644429,0.024871299,0.00006690912,0.007353482,0.0013159736],"about_ca_topic_score_codex":0.0027055868,"about_ca_topic_score_gemma":0.0005779318,"teacher_disagreement_score":0.74982154,"about_ca_system_score_codex":0.00037044592,"about_ca_system_score_gemma":0.0015836046,"threshold_uncertainty_score":0.9999744},"labels":[],"label_agreement":null},{"id":"W2074855273","doi":"10.3747/co.v18i5.780","title":"Survival and Treatment Patterns in Elderly Patients with Advanced Non-Small-Cell Lung Cancer in Manitoba","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Lung cancer; Carboplatin; Cohort; Chemotherapy; Internal medicine; Cancer; Stage (stratigraphy); Oncology; Cancer registry; Surgery; Cisplatin","score_opus":0.0491990397046019,"score_gpt":0.36853175012707445,"score_spread":0.3193327104224726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074855273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544555,0.0009375355,0.000031434578,0.00006226026,0.0004788706,0.0010406966,0.000040633204,0.000012101108,0.0019509193],"genre_scores_gemma":[0.99826914,0.00089925446,0.00016922178,0.000021549828,0.000038752274,0.00046950867,0.000058815567,0.000016631271,0.000057140747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918896,0.000032622014,0.00018835884,0.00027282277,0.00007390435,0.00024336125],"domain_scores_gemma":[0.99963915,0.00002597423,0.000069484,0.00012404131,0.000049872033,0.00009144705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002879822,0.00015754884,0.00030047089,0.00012221531,0.000023831053,0.0000035931234,0.000034725577,0.00005630372,0.00007092863],"category_scores_gemma":[0.000002640995,0.000113123715,0.000022545784,0.00010010292,0.000028447841,0.000051258092,0.00001758433,0.000104501036,0.00000275891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024935525,0.0018761337,0.81256604,0.00005903053,0.000040783092,0.000041173695,0.0024870995,0.0000033617932,0.000005855888,0.000006281262,0.0000087222015,0.18265618],"study_design_scores_gemma":[0.014888403,0.002499893,0.98010486,0.0001871886,0.00018392978,0.000001671563,0.0007381795,0.00004382683,0.000062490115,0.0000052852306,0.001171657,0.00011262031],"about_ca_topic_score_codex":0.0021451032,"about_ca_topic_score_gemma":0.034237664,"teacher_disagreement_score":0.18254356,"about_ca_system_score_codex":0.000833766,"about_ca_system_score_gemma":0.00023314213,"threshold_uncertainty_score":0.98338497},"labels":[],"label_agreement":null},{"id":"W2074958345","doi":"10.2217/lmt.12.2","title":"Angiogenesis Inhibitors in Lung Cancer: Beyond VEGF?","year":2012,"lang":"en","type":"article","venue":"Lung Cancer Management","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Lung cancer; Oncology; Internal medicine; Cisplatin; Carboplatin; Gemcitabine; Cancer; Chemotherapy","score_opus":0.008807989497668254,"score_gpt":0.33172476882490604,"score_spread":0.3229167793272378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074958345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70921236,0.16579044,0.0002894341,0.008644666,0.0049943146,0.00435794,0.0001260169,0.0002885674,0.10629626],"genre_scores_gemma":[0.98305076,0.0040711784,0.0005157688,0.0013687173,0.0006930688,0.0017155521,0.00004934638,0.000052867057,0.008482741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984548,0.000024294808,0.00029054575,0.00032729085,0.00032978953,0.0005732628],"domain_scores_gemma":[0.99933314,0.000014223722,0.000085005944,0.000322707,0.000040778916,0.00020414796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012028532,0.00022986195,0.00028560965,0.00026867192,0.000090570305,0.0000228412,0.00009267618,0.000063115,0.00061242987],"category_scores_gemma":[0.0000027555552,0.00020499474,0.00011799035,0.0005206915,0.000031305237,0.00020138333,0.000082025384,0.0000942374,0.000017350423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008236735,0.0003836212,0.8944261,0.0008480956,0.0012181812,0.0000576303,0.0016948425,0.00026988992,0.000114851486,0.0012662703,0.050661325,0.048976816],"study_design_scores_gemma":[0.005878855,0.00008148123,0.79981744,0.0012386495,0.004049846,0.0000071762556,0.0008465916,0.0008719871,0.0013288545,0.00004627731,0.1852089,0.00062391645],"about_ca_topic_score_codex":0.0019310175,"about_ca_topic_score_gemma":0.00039726065,"teacher_disagreement_score":0.2738384,"about_ca_system_score_codex":0.0016145782,"about_ca_system_score_gemma":0.00009685726,"threshold_uncertainty_score":0.8359443},"labels":[],"label_agreement":null},{"id":"W2075000534","doi":"10.1016/j.clinthera.2013.08.007","title":"Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline","year":2013,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Medicine; KRAS; Epidermal growth factor receptor; EGFR inhibitors; T790M; Cetuximab; Colorectal cancer; Erlotinib; Oncology; Lung cancer; Panitumumab; Cancer; Cancer research; Internal medicine","score_opus":0.21777312751887434,"score_gpt":0.4774846052985893,"score_spread":0.259711477779715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075000534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037467787,0.9954804,0.000101479185,0.000759176,0.0007820016,0.0015291196,0.00020568259,0.00010090266,0.0010037296],"genre_scores_gemma":[0.000026823483,0.99015003,0.0017848811,0.0018130357,0.0010605153,0.00013676035,0.00033776028,0.000115898045,0.004574293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997323,0.00028960075,0.00126339,0.0005657397,0.00022128983,0.0003370172],"domain_scores_gemma":[0.99749875,0.0010603358,0.00042950964,0.00053195364,0.00017064305,0.00030878859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024959282,0.00051284157,0.0022209089,0.00008364414,0.00009280314,0.000053052383,0.0001513976,0.0006596077,0.00050532474],"category_scores_gemma":[0.0001022027,0.00031538808,0.0007060639,0.00015795052,0.00024212681,0.00006153077,0.000068748435,0.0007619894,0.00027972454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011794344,0.0002903646,0.00023523896,0.0020002348,0.001434389,0.000008663102,0.00006577908,2.8784186e-9,3.622341e-7,0.0001768603,0.002054774,0.99372154],"study_design_scores_gemma":[0.0010333739,0.0003971887,0.00008402427,0.0023322664,0.0029417325,0.000038315153,0.000017230088,0.0000052513715,8.939384e-7,0.00014609627,0.99270344,0.0003001688],"about_ca_topic_score_codex":0.000013936483,"about_ca_topic_score_gemma":0.0000014395487,"teacher_disagreement_score":0.9934214,"about_ca_system_score_codex":0.00010650476,"about_ca_system_score_gemma":0.0005767542,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W2075202876","doi":"10.1016/j.lungcan.2014.12.014","title":"Maintenance chemotherapy in advanced NSCLC: A population-based assessment of eligibility","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Maintenance therapy; Chemotherapy; Internal medicine; Population; Performance status; Oncology; Cancer","score_opus":0.01605880244225595,"score_gpt":0.4216548494356635,"score_spread":0.40559604699340757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075202876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890113,0.0009541929,0.0010442829,0.0023140823,0.000235925,0.0008419147,0.000033712742,0.000036145113,0.005528444],"genre_scores_gemma":[0.9946937,0.00003758113,0.0038468572,0.0006627271,0.000040010993,0.00020779537,0.000042670446,0.000015723033,0.00045292487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914473,0.000020351128,0.00024193227,0.00021336507,0.00021929396,0.00016033101],"domain_scores_gemma":[0.9993839,0.000026904598,0.000098048265,0.00024926654,0.00015085374,0.00009098733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011622935,0.00010269109,0.00025389247,0.00006851102,0.000015355063,0.0000043637438,0.00004319959,0.00004184763,0.000094176576],"category_scores_gemma":[0.00002920836,0.00008314808,0.000054670927,0.00023147096,0.000022509257,0.00006071877,0.000006145999,0.000075078635,7.669996e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023033388,0.00023035458,0.9879604,0.00009706123,0.00005911499,0.000004487148,0.00021719915,0.002769923,0.0002957289,0.00023591987,0.00054263417,0.0073568528],"study_design_scores_gemma":[0.0074057784,0.00013015055,0.98169154,0.00032987248,0.00008078518,8.7881693e-7,0.00007042308,0.008518908,0.0004347696,0.00017056092,0.0010708792,0.00009543818],"about_ca_topic_score_codex":0.0023504149,"about_ca_topic_score_gemma":0.0005983834,"teacher_disagreement_score":0.0072614145,"about_ca_system_score_codex":0.0010977439,"about_ca_system_score_gemma":0.0007920616,"threshold_uncertainty_score":0.355314},"labels":[],"label_agreement":null},{"id":"W2075483442","doi":"10.3747/co.19.1113","title":"Drug Resistance and Its Significance for Treatment Decisions in Non-Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Drug; Drug resistance; Cancer drugs; Intensive care medicine; Bioinformatics; Pharmacology; Oncology; Biology; Genetics","score_opus":0.0833563062212418,"score_gpt":0.4511235880960217,"score_spread":0.3677672818747799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075483442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9124037,0.079056546,0.00042602338,0.0019180372,0.0012267466,0.0022706387,0.000098330216,0.000023209208,0.0025767458],"genre_scores_gemma":[0.98394483,0.0074313344,0.0011567398,0.00010249197,0.00030208597,0.002359435,0.000049686787,0.000020690522,0.0046327007],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990909,0.000028750557,0.00021775489,0.00024606936,0.0000681497,0.00034835728],"domain_scores_gemma":[0.9992623,0.00025909493,0.00008051007,0.00013495485,0.000076082,0.00018708468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097887125,0.00014734798,0.00031794456,0.00008908277,0.0000812376,0.0000057498582,0.000041109022,0.000059081638,0.000034048237],"category_scores_gemma":[0.000034488934,0.00011455008,0.000055180655,0.0001205712,0.000028673949,0.00006165276,0.000016908662,0.00006413847,0.0000062744843],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012242706,0.008710581,0.6468045,0.00081601355,0.0003896004,0.000034115437,0.019567804,0.000034309738,0.0031094367,0.0016965962,0.03433115,0.28328162],"study_design_scores_gemma":[0.015848184,0.0004590194,0.11087152,0.00046550247,0.001160609,0.000008152436,0.0006115209,0.0006666756,0.0028352013,0.00009839962,0.866663,0.0003122298],"about_ca_topic_score_codex":0.000042496667,"about_ca_topic_score_gemma":0.00076285366,"teacher_disagreement_score":0.83233184,"about_ca_system_score_codex":0.0009812413,"about_ca_system_score_gemma":0.00037625185,"threshold_uncertainty_score":0.46712166},"labels":[],"label_agreement":null},{"id":"W2076210163","doi":"10.1158/1538-7445.am2014-5340","title":"Abstract 5340: Bioinformatic analyses approaches for personalized oncogenomics","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Transcriptome; Genome; Biology; Computational biology; Genetics; Cancer genome sequencing; Genomics; Whole genome sequencing; DNA sequencing; Gene; Gene expression","score_opus":0.36297669028808754,"score_gpt":0.529471534395429,"score_spread":0.1664948441073415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076210163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94371724,0.0031465762,0.0030065004,0.0046673287,0.00018167011,0.0022932745,0.00012195393,0.00007959517,0.04278586],"genre_scores_gemma":[0.9918082,0.00020283752,0.0022517014,0.0001973628,0.00033545858,0.0008251366,0.00010085745,0.000026575859,0.0042519164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989371,0.000026513784,0.0001794705,0.00018980165,0.00031994664,0.0003472127],"domain_scores_gemma":[0.99912876,0.00020397516,0.000042313666,0.00023643867,0.00022471233,0.00016378479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004651546,0.000096980904,0.00021708639,0.00017663176,0.00020489047,0.00004718221,0.0000934883,0.000054035238,0.00025045947],"category_scores_gemma":[0.00013171913,0.00007142005,0.00011476703,0.00022569057,0.00011097726,0.00008033931,0.0000220651,0.00014801222,0.00005255309],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032660118,0.001401513,0.010744773,0.006139877,0.0046064113,0.000022784605,0.015412063,0.0009283124,0.062348958,0.034961328,0.06250822,0.79765975],"study_design_scores_gemma":[0.021079702,0.0018782618,0.0347918,0.00079341064,0.001369814,0.00003334003,0.007885679,0.01519608,0.039823007,0.0046591796,0.8716927,0.0007969834],"about_ca_topic_score_codex":0.00029201186,"about_ca_topic_score_gemma":0.000046029316,"teacher_disagreement_score":0.80918455,"about_ca_system_score_codex":0.00039072757,"about_ca_system_score_gemma":0.0005063305,"threshold_uncertainty_score":0.2912425},"labels":[],"label_agreement":null},{"id":"W2076372717","doi":"10.1378/chest.128.2.947","title":"Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer","year":2005,"lang":"en","type":"review","venue":"CHEST Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Vinorelbine; Gemcitabine; Docetaxel; Oncology; Lung cancer; Chemotherapy; Tolerability; Internal medicine; Population; Cisplatin; Adverse effect","score_opus":0.022762226387545346,"score_gpt":0.3597748668325382,"score_spread":0.33701264044499285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076372717","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021722927,0.99572676,0.000541857,0.00015524226,0.00032511508,0.001870588,0.00008622626,0.000015187429,0.0010617727],"genre_scores_gemma":[0.000022889919,0.98928607,0.0041535445,0.00019664355,0.0014919662,0.00034489113,0.00015823236,0.000114050046,0.004231691],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988299,0.000013522814,0.0003967498,0.00024438166,0.00019841059,0.00031703373],"domain_scores_gemma":[0.998823,0.0000423203,0.00045821338,0.00019320639,0.00024443143,0.000238846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006580537,0.00035731657,0.0009855931,0.00012544816,0.00015004518,0.000059438804,0.000116255986,0.00016983904,0.00022401488],"category_scores_gemma":[0.00000500146,0.00021214143,0.00039404086,0.00012299487,0.000023525297,0.000063060455,0.000007117974,0.0003919356,0.000008259142],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039488816,0.00029619757,0.0009070908,0.008973697,0.0008702867,0.000011107706,0.0001847699,0.0000011646262,9.426731e-8,6.602352e-7,0.0054701697,0.98324525],"study_design_scores_gemma":[0.005145563,0.00049405557,0.00044565837,0.010886503,0.005877155,0.000057437916,0.000010850581,0.0000029866521,0.0000018852475,0.0000013622922,0.97684914,0.00022741257],"about_ca_topic_score_codex":0.000008641089,"about_ca_topic_score_gemma":0.000009568718,"teacher_disagreement_score":0.98301786,"about_ca_system_score_codex":0.00070946995,"about_ca_system_score_gemma":0.0015922367,"threshold_uncertainty_score":0.8650877},"labels":[],"label_agreement":null},{"id":"W2077860295","doi":"10.4161/cbt.29687","title":"Impact of<i>ERBB2</i>mutations on in vitro sensitivity of bladder cancer to lapatinib","year":2014,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Lapatinib; Cancer research; Biology; Gene; Mutation; Tyrosine-kinase inhibitor; Cell growth; Cancer; Cell culture; Tyrosine kinase; Receptor tyrosine kinase; Signal transduction; Genetics; Breast cancer; Trastuzumab","score_opus":0.02429787946999678,"score_gpt":0.40558478127511466,"score_spread":0.3812869018051179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077860295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962423,0.0005985182,0.00016528553,0.0012638934,0.00018606427,0.00045529637,0.00031970796,0.0000150728965,0.0007538517],"genre_scores_gemma":[0.99784005,0.0004080542,0.00025830994,0.0010313549,0.0001225092,0.00018580852,0.00006186579,0.000016500555,0.00007553399],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991918,0.000112321206,0.00021913392,0.0002186511,0.00006774965,0.00019033252],"domain_scores_gemma":[0.999301,0.0001609672,0.000107734224,0.00021682783,0.00013686041,0.00007657459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012753876,0.0001359165,0.00038528713,0.00014293013,0.00002595247,0.0000018248144,0.00003982093,0.00008018721,0.00027814903],"category_scores_gemma":[0.000031472857,0.00009563181,0.00011661312,0.00024495833,0.000095847616,0.00002189644,0.000007847923,0.000086104366,0.0000054561874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013870002,0.00037628398,0.23160672,0.000013550366,0.0006448895,0.0000020906905,0.0013656465,0.0008245568,0.63593566,0.0001855732,0.00037442413,0.12728357],"study_design_scores_gemma":[0.0042056823,0.0016906467,0.8556863,0.00009888291,0.00010107302,0.0000026098253,0.00005141537,0.00013776106,0.13592295,0.0002601046,0.001696209,0.0001463491],"about_ca_topic_score_codex":0.007893587,"about_ca_topic_score_gemma":0.00077642716,"teacher_disagreement_score":0.6240796,"about_ca_system_score_codex":0.00019716185,"about_ca_system_score_gemma":0.00031000937,"threshold_uncertainty_score":0.99871296},"labels":[],"label_agreement":null},{"id":"W2078664639","doi":"10.14740/wjon845w","title":"Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review","year":2014,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pemetrexed; Interstitial pneumonitis; Hypersensitivity pneumonitis; Pneumonitis; Intensive care medicine; Medical physics; Internal medicine; Lung; Chemotherapy; Respiratory disease","score_opus":0.021487311161303372,"score_gpt":0.4005299984067537,"score_spread":0.3790426872454503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078664639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460249,0.034805983,0.000044063112,0.009362991,0.00076888787,0.00055772514,0.0000032113746,0.000012183364,0.008420035],"genre_scores_gemma":[0.9942408,0.0026902729,0.00042009138,0.001852797,0.000357757,0.000008442449,0.0000014897789,0.000008882488,0.00041942205],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9992213,0.00013410508,0.00033502546,0.00009751575,0.0001080939,0.00010393447],"domain_scores_gemma":[0.999237,0.00009895204,0.00021980154,0.000098309705,0.00020399588,0.00014193926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003013708,0.00009155543,0.00042403096,0.00021424911,0.00005248741,0.000014647995,0.000036426973,0.00003049288,0.00005527461],"category_scores_gemma":[0.00010545043,0.00006232278,0.000071917544,0.00021224306,0.000024028383,0.00007105122,0.00001936572,0.00027260307,0.0000027394422],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003089228,0.002293002,0.019576777,0.0008262864,0.0012448727,0.15893036,0.0070662377,5.297618e-7,0.00051019806,0.00016719189,0.013289232,0.7957864],"study_design_scores_gemma":[0.018922277,0.03470724,0.015503437,0.010749733,0.006405362,0.5883723,0.0044201515,0.00002576309,0.000046769816,0.00012695271,0.32043305,0.0002869699],"about_ca_topic_score_codex":0.000022436616,"about_ca_topic_score_gemma":0.00020678724,"teacher_disagreement_score":0.79549944,"about_ca_system_score_codex":0.00013586319,"about_ca_system_score_gemma":0.00014727807,"threshold_uncertainty_score":0.2541449},"labels":[],"label_agreement":null},{"id":"W2078793063","doi":"10.2174/138945010790030947","title":"Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer","year":2009,"lang":"en","type":"review","venue":"Current Drug Targets","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Pemetrexed; Medicine; Adjuvant; Lung cancer; Chemotherapy; Oncology; Adjuvant chemotherapy; Cancer research; Cancer; Internal medicine; Cisplatin","score_opus":0.01835616421936436,"score_gpt":0.36728973704898915,"score_spread":0.3489335728296248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078793063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029834392,0.99531233,0.000025832847,0.00017554437,0.00071359944,0.0022124345,0.00015730661,0.000017814771,0.0010867688],"genre_scores_gemma":[0.0012087384,0.996802,0.00011565964,0.000074745534,0.00043685496,0.0003568905,0.00047793015,0.000047797268,0.0004794249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998211,0.00008979903,0.0006103797,0.00040752997,0.00033115488,0.00035012056],"domain_scores_gemma":[0.9989337,0.00004740769,0.0003940555,0.00045078684,0.00008250026,0.00009159246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017093425,0.00042863982,0.0013885865,0.00024027815,0.00005446778,0.000016827518,0.00027981383,0.000117596755,0.00015667503],"category_scores_gemma":[0.000007514398,0.0002550337,0.00056274456,0.00038532834,0.000036468296,0.00003808599,0.00002665064,0.00045040462,0.000013292818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011671799,0.000751885,0.0002811534,0.009362928,0.00018888639,0.00001571659,0.0011369096,0.000005549607,0.0000019905758,0.0000045409843,0.0080125835,0.98022616],"study_design_scores_gemma":[0.0017638196,0.00006392843,0.00086889014,0.011990062,0.0033177445,0.000009536613,0.00010173989,0.00007310434,0.000018939994,0.00001591729,0.98150903,0.0002673121],"about_ca_topic_score_codex":0.00017716161,"about_ca_topic_score_gemma":0.000039587914,"teacher_disagreement_score":0.9799589,"about_ca_system_score_codex":0.0002932885,"about_ca_system_score_gemma":0.00075908407,"threshold_uncertainty_score":0.99999017},"labels":[],"label_agreement":null},{"id":"W2078797757","doi":"10.1016/j.ejca.2008.10.022","title":"A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of Ottawa; Queen's University; Ottawa Hospital","funders":"AstraZeneca","keywords":"Gemcitabine; Medicine; Pharmacokinetics; Cisplatin; Internal medicine; Nausea; Tolerability; Pharmacology; Phases of clinical research; Oncology; Chemotherapy; Gastroenterology; Adverse effect","score_opus":0.032184655486617995,"score_gpt":0.35429100915301104,"score_spread":0.32210635366639306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078797757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969829,0.0008884158,0.000010896332,0.000039094448,0.00021340053,0.0016110546,0.0002319794,0.0000014111328,0.000020890628],"genre_scores_gemma":[0.99938923,0.0003321622,0.00010613725,0.000030279489,0.000075632626,0.000026326808,0.0000060893944,0.000024113278,0.000010056998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971962,0.000497318,0.0012597222,0.00020057798,0.00071758445,0.00012857927],"domain_scores_gemma":[0.99753666,0.00009094368,0.0013572824,0.00010582269,0.0008059446,0.000103319515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066836266,0.00017923735,0.00082645105,0.000184302,0.00003966088,0.000003990526,0.00010139978,0.000017856428,0.000013529741],"category_scores_gemma":[0.00010609177,0.00010942083,0.000044872995,0.00033573297,0.00011561647,0.00017508194,0.000027211929,0.00019791425,4.2641757e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006079781,0.008198417,0.97422564,0.0001687156,0.00046830624,0.00004242838,0.0042088125,0.0012472102,0.0020593887,9.617116e-7,0.000028344411,0.003271968],"study_design_scores_gemma":[0.11881725,0.009853045,0.8683151,0.0005870589,0.00068591605,0.0000028208121,0.00047912865,0.00011888313,0.0010224569,3.5686182e-7,0.000026487634,0.00009148823],"about_ca_topic_score_codex":0.030908106,"about_ca_topic_score_gemma":0.08593115,"teacher_disagreement_score":0.11273747,"about_ca_system_score_codex":0.00020458217,"about_ca_system_score_gemma":0.0012153996,"threshold_uncertainty_score":0.97554517},"labels":[],"label_agreement":null},{"id":"W2079094353","doi":"10.1097/01.coc.0000256103.21797.e5","title":"Oral Versus Intravenous Administration of Vinorelbine as a Single Agent for the First-Line Treatment of Metastatic Nonsmall Cell Lung Carcinoma (NSCLC)","year":2007,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"","keywords":"Vinorelbine; Medicine; Internal medicine; Chemotherapy; Gastroenterology; Carcinoma; Surgery","score_opus":0.10356668326748363,"score_gpt":0.4792282221413577,"score_spread":0.37566153887387405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079094353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868992,0.00080711435,0.0062466287,0.0036644973,0.00065928017,0.0006275061,0.00002235337,0.000003864284,0.0010695616],"genre_scores_gemma":[0.98877513,0.0003515561,0.010102249,0.00033659674,0.00029529593,0.000012700829,0.000011797031,0.00001564665,0.000099014214],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9977369,0.00009632499,0.0016089395,0.00014066312,0.00021183958,0.00020536465],"domain_scores_gemma":[0.9937338,0.0035723583,0.001909634,0.00018881839,0.00042244003,0.00017295415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007412189,0.00013963302,0.0010710487,0.000094016075,0.00004615141,0.0000033491508,0.00009840872,0.000056446643,0.00004254343],"category_scores_gemma":[0.000354141,0.000082251114,0.00046515043,0.00017143608,0.0004196287,0.00003132702,0.000010836617,0.00013003293,0.0000015142267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047075525,0.013795392,0.016162185,0.000081435275,0.002740336,0.0004949728,0.0016350432,0.00010220404,0.0004749179,0.000110814326,0.00026622188,0.917061],"study_design_scores_gemma":[0.06046395,0.7333446,0.1133016,0.00013243669,0.015773647,0.00067275594,0.004813445,0.00056739943,0.007294333,0.000093445204,0.063303635,0.00023872049],"about_ca_topic_score_codex":0.00024954372,"about_ca_topic_score_gemma":0.00031638145,"teacher_disagreement_score":0.91682225,"about_ca_system_score_codex":0.00032421746,"about_ca_system_score_gemma":0.001497104,"threshold_uncertainty_score":0.3354103},"labels":[],"label_agreement":null},{"id":"W2079997250","doi":"10.1097/jto.0b013e31827ce38e","title":"Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Research Resources","keywords":"Medicine; Lung cancer; Trastuzumab; Lapatinib; Cancer research; Pemetrexed; T790M; Oncology; Erlotinib; Bevacizumab; Internal medicine; Afatinib; Carboplatin; Crizotinib; Tyrosine-kinase inhibitor; Cancer; Epidermal growth factor receptor; Gefitinib; Breast cancer; Chemotherapy; Cisplatin","score_opus":0.01443599740957417,"score_gpt":0.3844427298241555,"score_spread":0.3700067324145813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079997250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895674,0.0009967983,0.00043096114,0.006687006,0.00017618993,0.00073983095,0.0000054024126,0.000013519997,0.0013828903],"genre_scores_gemma":[0.9936994,0.00042331073,0.0036490313,0.0002456763,0.0002065575,0.00009161776,0.0000314534,0.000023762339,0.0016292364],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99902195,0.00006901547,0.00032909916,0.00017789053,0.00022502219,0.00017701906],"domain_scores_gemma":[0.9986675,0.00005164165,0.0005462266,0.00010642042,0.00045616587,0.00017209201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010815405,0.00018241556,0.00042589384,0.00017294541,0.00011986693,0.000033110595,0.000024975749,0.000112651695,0.00013120913],"category_scores_gemma":[0.000005251553,0.000101716294,0.000048523718,0.0001604549,0.00007341944,0.00028427556,0.000010432769,0.00016847251,0.0000033833003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0091977995,0.011133892,0.37736598,0.0014278372,0.0036594416,0.007783586,0.019687869,0.0014926826,0.033885933,0.000070836606,0.011538606,0.5227555],"study_design_scores_gemma":[0.06876984,0.09919054,0.64960384,0.007709047,0.017633948,0.025294116,0.01608625,0.0064449604,0.09432682,0.00036673763,0.013206536,0.0013673645],"about_ca_topic_score_codex":0.00025656074,"about_ca_topic_score_gemma":0.00020758614,"teacher_disagreement_score":0.5213882,"about_ca_system_score_codex":0.0007660054,"about_ca_system_score_gemma":0.00065477076,"threshold_uncertainty_score":0.41478702},"labels":[],"label_agreement":null},{"id":"W2080178255","doi":"10.1186/1471-2164-8-297","title":"Effect of active smoking on the human bronchial epithelium transcriptome","year":2007,"lang":"en","type":"article","venue":"BMC Genomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"National Institute of Dental and Craniofacial Research; Canadian Institutes of Health Research; Genome British Columbia; Michael Smith Health Research BC; Genome Canada","keywords":"Transcriptome; Lung cancer; Gene expression; Smoking cessation; Biology; Tobacco smoke; Gene; Serial analysis of gene expression; Cancer; Lung; Gene expression profiling; Microarray; Internal medicine; Physiology; Medicine; Bioinformatics; Genetics; Pathology","score_opus":0.01872524056088154,"score_gpt":0.3260203081060879,"score_spread":0.30729506754520636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080178255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98948926,0.00008157439,0.00032889325,0.00010759966,0.00015643377,0.00047939728,0.000018317014,0.0000151502545,0.009323397],"genre_scores_gemma":[0.9992507,0.000004262546,0.0000918527,0.00013853614,0.00013050972,0.0000122434285,0.000015005771,0.000015840846,0.0003410137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994904,0.000030068028,0.00013253247,0.000107946296,0.00010332437,0.00013574216],"domain_scores_gemma":[0.99953,0.0001861453,0.000054525022,0.00017335152,0.000021773292,0.000034188786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002358232,0.00008782955,0.00014640686,0.000046328052,0.00008624356,0.000004682591,0.00005137689,0.000039141858,0.000042751766],"category_scores_gemma":[0.000017956321,0.000052541225,0.000097167685,0.00005747405,0.000042265314,0.0000146053835,0.0000062395334,0.00008928528,0.0000075329367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004947295,0.0009092821,0.07109424,0.00056894077,0.0017437446,0.000044512086,0.02249822,0.0002527889,0.7433507,0.011766216,0.0006726093,0.14215147],"study_design_scores_gemma":[0.006352811,0.0028951752,0.2486082,0.000111121015,0.001093732,0.000016069269,0.00073711085,0.000025621086,0.73267716,0.00022018359,0.0070887236,0.00017409761],"about_ca_topic_score_codex":0.00008044617,"about_ca_topic_score_gemma":0.000048154652,"teacher_disagreement_score":0.17751396,"about_ca_system_score_codex":0.00017183201,"about_ca_system_score_gemma":0.00005620611,"threshold_uncertainty_score":0.2142569},"labels":[],"label_agreement":null},{"id":"W2080555188","doi":"10.1016/j.lungcan.2015.02.018","title":"Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Taiwan University Hospital; Ministry of Health, British Columbia; Ministry of Science and Technology, Taiwan; Ministry of Health and Welfare","keywords":"Medicine; Malignant pleural effusion; Pleural effusion; Adenocarcinoma; Metastatic adenocarcinoma; Lung; Oncology; Internal medicine; Pathology; Radiology; Cancer","score_opus":0.033619703688109695,"score_gpt":0.3827414251283273,"score_spread":0.34912172144021764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080555188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951411,0.002180662,0.000059811977,0.0006332231,0.000108483626,0.0012840655,0.00007737697,0.000015763724,0.0004995055],"genre_scores_gemma":[0.99808335,0.000090739486,0.0010500225,0.0001548297,0.00003235317,0.00024836542,0.000097326665,0.000018945248,0.00022406882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898046,0.00004797121,0.00033552025,0.00025363953,0.00021114126,0.00017123781],"domain_scores_gemma":[0.9992703,0.0000488992,0.00012377856,0.00020697583,0.00019284434,0.0001571974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001237002,0.00011570645,0.00028066634,0.000084163425,0.000030414893,0.00000802046,0.000044281085,0.00003413761,0.000030832794],"category_scores_gemma":[0.00005478476,0.00007990422,0.000030642077,0.00020760504,0.00008045919,0.00008174185,0.000031169988,0.00008633136,0.0000012216217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025768988,0.0002780942,0.99499923,0.00013508325,0.00019619004,0.000008106224,0.00059263146,0.000009809544,0.000015524867,0.000058091806,0.0010791773,0.002370379],"study_design_scores_gemma":[0.006432017,0.00041114463,0.99119,0.00039697118,0.0008479476,0.0000039618135,0.00009574588,0.000319317,0.000016820279,0.000042057294,0.00015953467,0.00008448771],"about_ca_topic_score_codex":0.000461641,"about_ca_topic_score_gemma":0.00023609937,"teacher_disagreement_score":0.006174327,"about_ca_system_score_codex":0.00015373333,"about_ca_system_score_gemma":0.0002662148,"threshold_uncertainty_score":0.32583994},"labels":[],"label_agreement":null},{"id":"W2080647562","doi":"10.1097/jto.0000000000000288","title":"Practice Makes Perfect Protocols: The Canadian Anaplastic Lymphoma Kinase Study","year":2014,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Lymphoma; Anaplastic large-cell lymphoma; Cancer research; Oncology; Internal medicine","score_opus":0.0381527367887229,"score_gpt":0.4712579935456024,"score_spread":0.4331052567568795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080647562","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032830543,0.00037404962,0.000025055075,0.96674985,0.0012786416,0.0122019155,0.000020088579,0.000015139267,0.016052224],"genre_scores_gemma":[0.10299602,0.000026304378,0.0014007982,0.874111,0.012486677,0.0033737943,0.00004826314,0.00012119479,0.0054359464],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689984,0.0010682119,0.0007278184,0.00025510462,0.0006132485,0.0004357689],"domain_scores_gemma":[0.99602115,0.0010897489,0.0012816058,0.0004716482,0.0008636339,0.00027219558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012515907,0.0003146271,0.00091238675,0.00045471813,0.00033343438,0.0000942356,0.0003344168,0.0005598354,0.00017056543],"category_scores_gemma":[0.0010973982,0.00017896741,0.0002588545,0.00022375735,0.00013063276,0.00012231478,0.000028908851,0.0016718362,0.00006712816],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011347112,0.00079635385,0.00068819494,0.0001849632,0.0018550705,0.026214661,0.0012622603,0.000010111229,0.000002363896,0.000003939004,0.90140176,0.06644564],"study_design_scores_gemma":[0.0018146047,0.012797422,0.0021711092,0.00029918234,0.005605272,0.0112645,0.00096464175,0.000010242641,0.000004399692,0.000026358057,0.9648911,0.00015118653],"about_ca_topic_score_codex":0.010137205,"about_ca_topic_score_gemma":0.035368983,"teacher_disagreement_score":0.09971297,"about_ca_system_score_codex":0.0032071655,"about_ca_system_score_gemma":0.00871308,"threshold_uncertainty_score":0.9969066},"labels":[],"label_agreement":null},{"id":"W2080972533","doi":"10.3389/fonc.2014.00320","title":"Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Lung cancer; Medicine; Clinical trial; Adenocarcinoma; Oncology; Cancer; Lung; Internal medicine; Cancer research","score_opus":0.12489638375425767,"score_gpt":0.5554608499413399,"score_spread":0.4305644661870823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080972533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003853404,0.990073,0.0005932517,0.0001564051,0.0047763693,0.003390203,0.000052073538,0.000015463413,0.0009046547],"genre_scores_gemma":[0.00008551915,0.99227846,0.00559247,0.00010485943,0.00039907434,0.0009994836,0.00013816901,0.000046239125,0.00035572058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99459463,0.0022637951,0.0020842259,0.0005668931,0.00013002672,0.00036045187],"domain_scores_gemma":[0.997476,0.0011975003,0.0008830549,0.00023181402,0.000038529535,0.00017314267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034052979,0.0003428985,0.005678443,0.0004681242,0.000035970115,0.000012828639,0.00009748333,0.00035367403,0.000044855144],"category_scores_gemma":[0.0011859051,0.00024641302,0.0004000215,0.00023320419,0.00012344969,0.000035955327,0.000045944325,0.0007640441,0.0000037696623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063649924,0.00048280193,0.0045799,0.013808669,0.00022166155,0.00010217069,0.00021011039,0.0000021625194,2.4273557e-8,0.000007684543,0.01878216,0.961739],"study_design_scores_gemma":[0.004999626,0.0003509825,0.00014739163,0.00428701,0.006521265,0.00001876381,0.0000415815,0.00018610059,9.9380635e-8,0.000057880185,0.98319095,0.00019836875],"about_ca_topic_score_codex":0.00007885543,"about_ca_topic_score_gemma":0.0000884634,"teacher_disagreement_score":0.96440876,"about_ca_system_score_codex":0.0014908644,"about_ca_system_score_gemma":0.002490901,"threshold_uncertainty_score":0.9999988},"labels":[],"label_agreement":null},{"id":"W2081213854","doi":"10.1097/01.jto.0000283780.87833.c2","title":"P3-023: Preliminary results of an escalating dose phase I /II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Newfoundland and Labrador Centre for Applied Health Research; University of Calgary","funders":"","keywords":"Nimotuzumab; Medicine; Radiation therapy; Oncology; Internal medicine; Toxicity; Phases of clinical research; Epidermal growth factor receptor; Chemotherapy; Progressive disease; Lung cancer; Clinical trial; Gastroenterology; Cancer; Surgery","score_opus":0.041263050625945694,"score_gpt":0.4926962457130592,"score_spread":0.4514331950871135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081213854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950679,0.00016763115,0.0017698277,0.00049692276,0.00033329977,0.002059524,0.00003078826,0.0000048252746,0.00006925919],"genre_scores_gemma":[0.98785096,0.0001483081,0.011518887,0.00011631614,0.00020222989,0.000018092494,0.000030137668,0.000026557107,0.00008850359],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694735,0.00036566737,0.0016812206,0.00023442999,0.0004840371,0.00028727925],"domain_scores_gemma":[0.996598,0.00094058056,0.0017430336,0.00021456035,0.0003669984,0.00013680711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024468647,0.00018538118,0.00092174084,0.000308543,0.00008066281,0.000008323723,0.00017843327,0.00019671248,0.000014659079],"category_scores_gemma":[0.00025904956,0.00009954503,0.00014996581,0.0003785613,0.00023662727,0.00023469543,0.000019944137,0.00042353873,5.1811e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6924311,0.022337534,0.05502298,0.000039388142,0.00025315315,0.00021257834,0.0016254857,0.00016443254,0.0007772152,0.000009769239,0.000024605622,0.22710174],"study_design_scores_gemma":[0.43120444,0.22545819,0.33937514,0.0006076667,0.00022239673,0.00007605061,0.0004998411,0.0009365713,0.0011630504,0.000023267377,0.00032695994,0.000106432904],"about_ca_topic_score_codex":0.00011250805,"about_ca_topic_score_gemma":0.0001417875,"teacher_disagreement_score":0.28435215,"about_ca_system_score_codex":0.0004403337,"about_ca_system_score_gemma":0.0012750186,"threshold_uncertainty_score":0.40593284},"labels":[],"label_agreement":null},{"id":"W2083299269","doi":"10.1002/cncr.25214","title":"Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer","year":2010,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Denaturing high performance liquid chromatography; Epidermal growth factor receptor; Medicine; Exon; Lung cancer; Mutation; Cancer research; Somatic cell; Tyrosine kinase; Tyrosine-kinase inhibitor; Internal medicine; Epidermal growth factor; Oncology; Cancer; Biology; Receptor; Gene; Genetics","score_opus":0.0062658726697495054,"score_gpt":0.2771239543859354,"score_spread":0.2708580817161859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083299269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933813,0.0029775691,0.000043697288,0.00082791626,0.000949016,0.00069800165,0.00032626165,0.00011918127,0.00067704177],"genre_scores_gemma":[0.995954,0.0009647582,0.00069957663,0.00038652052,0.00027819132,0.0009357858,0.000133054,0.000056904806,0.0005912124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986143,0.000021566775,0.000314991,0.00039190636,0.00021390151,0.0004433233],"domain_scores_gemma":[0.9991989,0.000054274817,0.00012196995,0.000243728,0.00016926546,0.00021182433],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000043577536,0.00025109306,0.00029516136,0.00023120346,0.00015161838,0.000026132553,0.00011736062,0.00016862832,0.001295734],"category_scores_gemma":[0.0000224792,0.00021957763,0.00008681787,0.0005114894,0.00008618031,0.00023846331,0.000026649108,0.00047694755,0.000019115618],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025769076,0.0003221515,0.47529048,0.0004745944,0.00031144323,0.000020093132,0.0013641744,0.000083292754,0.51439863,0.000034411052,0.004056663,0.0033864116],"study_design_scores_gemma":[0.0048361127,0.00022623617,0.46100146,0.00040531362,0.00041155622,0.0000103924,0.00007261003,0.00066360284,0.52603954,0.000006774243,0.0058176247,0.0005087919],"about_ca_topic_score_codex":0.0025940223,"about_ca_topic_score_gemma":0.0014863771,"teacher_disagreement_score":0.014289012,"about_ca_system_score_codex":0.00031881765,"about_ca_system_score_gemma":0.00043561799,"threshold_uncertainty_score":0.9996172},"labels":[],"label_agreement":null},{"id":"W2083528984","doi":"10.1016/s0169-5002(00)80809-0","title":"An evaluation of screening for lung cancer in Niigata prefecture, Japan. A population-based case control study","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.028015871405128834,"score_gpt":0.4197786026991805,"score_spread":0.39176273129405165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083528984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950744,0.0029880893,0.00082739233,0.0002448083,0.00014107549,0.0054772887,0.0006294631,0.000035649133,0.00014880048],"genre_scores_gemma":[0.99560463,0.000012121578,0.00036565046,0.00025626476,0.00017941449,0.003276389,0.00012585109,0.00003546932,0.00014419333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985553,0.000123546,0.00035198338,0.00034903435,0.00039271993,0.00022740674],"domain_scores_gemma":[0.999085,0.0000887812,0.000123729,0.0003111561,0.0002958368,0.0000954824],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004015575,0.00016993507,0.00034034398,0.00013699474,0.00010065751,0.000016737213,0.0000549683,0.00006911278,0.001634544],"category_scores_gemma":[0.000035953133,0.00014532136,0.00007690818,0.00025435825,0.000016598935,0.00014157259,0.0000030718727,0.0000933947,2.5225782e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006455598,0.00042811257,0.7401504,0.00013732462,0.00044902097,0.00001635756,0.0013118421,0.16751443,0.00009303035,0.000005334327,0.000099181336,0.08914941],"study_design_scores_gemma":[0.014485839,0.00028579019,0.5208445,0.00026090603,0.0035010346,0.000006660529,0.00019603508,0.4601581,0.000092801376,0.0000090763115,0.00003081209,0.00012841503],"about_ca_topic_score_codex":0.019676637,"about_ca_topic_score_gemma":0.018648801,"teacher_disagreement_score":0.2926437,"about_ca_system_score_codex":0.00069825543,"about_ca_system_score_gemma":0.00054123695,"threshold_uncertainty_score":0.99927807},"labels":[],"label_agreement":null},{"id":"W2083547960","doi":"10.1097/01.jto.0000283087.71346.19","title":"PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Docetaxel; Gefitinib; Lung cancer; Internal medicine; Oncology; Tolerability; Hazard ratio; Population; Clinical endpoint; Randomized controlled trial; Performance status; Chemotherapy; Cancer; Epidermal growth factor receptor; Adverse effect; Confidence interval","score_opus":0.033084413309192914,"score_gpt":0.45279197386248055,"score_spread":0.4197075605532876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083547960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892774,0.00028763965,0.0027551015,0.00040816827,0.00021493227,0.0063336487,0.000025391675,0.000017173059,0.00068052835],"genre_scores_gemma":[0.9843129,0.00003779197,0.014088084,0.00044933675,0.00006994978,0.00030156152,0.0000280416,0.00006555468,0.0006467641],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99728876,0.00027099886,0.0011564712,0.0003691488,0.0004440911,0.00047054514],"domain_scores_gemma":[0.9965464,0.0007078135,0.001453449,0.0002839726,0.0007116934,0.00029670433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010500733,0.00039350186,0.001753666,0.00038879918,0.000097528835,0.000046794874,0.00027832392,0.00010078085,0.00016723921],"category_scores_gemma":[0.00009353247,0.00021850287,0.00009145599,0.00053316547,0.00013943162,0.00026990726,0.000039307088,0.00047234155,0.0000013660068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.894408,0.021498602,0.02477028,0.00015275921,0.0027338895,0.0017651668,0.0020041105,0.0005131624,0.00013256042,0.0000010059472,0.000097000855,0.05192347],"study_design_scores_gemma":[0.93453854,0.046023972,0.009231718,0.001103358,0.0053473767,0.00006102274,0.0013310909,0.00079622935,0.0011081055,0.0000024615251,0.0001735318,0.00028257357],"about_ca_topic_score_codex":0.00028126375,"about_ca_topic_score_gemma":0.002623875,"teacher_disagreement_score":0.051640894,"about_ca_system_score_codex":0.001111801,"about_ca_system_score_gemma":0.0022724818,"threshold_uncertainty_score":0.8910288},"labels":[],"label_agreement":null},{"id":"W2083631366","doi":"10.1159/000134238","title":"Hormone Replacement Therapy as a Risk Factor for Non-Small Cell Lung Cancer: Results of a Case-Control Study","year":2007,"lang":"en","type":"article","venue":"Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Odds ratio; Lung cancer; Internal medicine; Hormone replacement therapy (female-to-male); Risk factor; Confidence interval; Cancer; Epidemiology; Case-control study; Body mass index; Oncology; Gynecology","score_opus":0.019779813993806638,"score_gpt":0.3844022115952827,"score_spread":0.3646223976014761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083631366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753923,0.0015992172,0.0013329854,0.00037045588,0.00023513094,0.0043996284,0.0006948965,0.00002266895,0.003805807],"genre_scores_gemma":[0.99600434,0.00036159088,0.0009798734,0.00028199737,0.00015978531,0.00047138982,0.000012276116,0.000020912994,0.0017078064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989074,0.000047861886,0.00040075302,0.00027842628,0.0001053443,0.00026020585],"domain_scores_gemma":[0.9987941,0.00037249568,0.0002873142,0.00026303483,0.00017255606,0.00011049542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039843703,0.00013528716,0.0003959159,0.00009134532,0.00008661323,0.0000036970673,0.00004670818,0.00009467444,0.00007424957],"category_scores_gemma":[0.000051424893,0.00010101462,0.00009156555,0.000096210926,0.000027849359,0.000019464756,0.000010557704,0.00010208507,0.0000027715835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.113839865,0.022679683,0.24988808,0.00021992576,0.0083695045,0.0039277324,0.083878875,0.00011300758,0.021323616,0.000037847534,0.010582114,0.48513976],"study_design_scores_gemma":[0.37281924,0.13113599,0.3977256,0.00007076389,0.0062583126,0.00041416098,0.015281348,0.00077150285,0.010672658,0.000045788376,0.06428914,0.00051549106],"about_ca_topic_score_codex":0.0033603883,"about_ca_topic_score_gemma":0.0023433056,"teacher_disagreement_score":0.48462427,"about_ca_system_score_codex":0.0004752648,"about_ca_system_score_gemma":0.00049809105,"threshold_uncertainty_score":0.50799245},"labels":[],"label_agreement":null},{"id":"W2083744249","doi":"10.1016/j.lungcan.2005.08.005","title":"A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Willingness to pay; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Marital status; Population; Environmental health","score_opus":0.011568644818447691,"score_gpt":0.33183083068366953,"score_spread":0.3202621858652218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083744249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905214,0.004028313,0.000119725024,0.0014208092,0.00065501966,0.0025296984,0.00013142526,0.000054190583,0.0005394632],"genre_scores_gemma":[0.99475324,0.00026352672,0.0008755545,0.00061561365,0.0003856901,0.001059548,0.000021864103,0.00007249594,0.0019524663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794865,0.00004156942,0.0005881702,0.00055573694,0.0003528347,0.00051306305],"domain_scores_gemma":[0.99890256,0.000046788187,0.00019901012,0.00034428018,0.0002447287,0.00026265328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008367711,0.00034623075,0.0006350183,0.00023368851,0.00008349454,0.000018052295,0.0001344549,0.00009784762,0.0003788615],"category_scores_gemma":[0.000024899042,0.00026609216,0.00010762409,0.0006648385,0.000035161753,0.00020352042,0.00006003832,0.00025869915,0.000005659143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037713334,0.0015193503,0.9623059,0.00040692362,0.000251368,0.000052614523,0.008785146,0.005221891,0.006288513,0.00000610944,0.0012264216,0.013558637],"study_design_scores_gemma":[0.017835874,0.00091371435,0.9376315,0.0012581946,0.0012428347,0.000003672344,0.0011843056,0.0029837736,0.033006504,0.000003553158,0.003303189,0.0006329194],"about_ca_topic_score_codex":0.009435058,"about_ca_topic_score_gemma":0.009730399,"teacher_disagreement_score":0.02671799,"about_ca_system_score_codex":0.0010648033,"about_ca_system_score_gemma":0.000549723,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W2084182647","doi":"10.3816/clc.2002.n.021","title":"Promising Developments in Targeted Therapies for non–small-Cell Lung Cancer","year":2002,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Targeted therapy; Cancer; Treatment of lung cancer; Radiation therapy; Oncology; Chemotherapy; Angiogenesis; Receptor tyrosine kinase; Bioinformatics; Cancer research; Internal medicine; Receptor; Biology","score_opus":0.053392158803135914,"score_gpt":0.4216195487616121,"score_spread":0.3682273899584762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084182647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9515878,0.031371884,0.00033922642,0.004260522,0.0018897085,0.0044927816,0.00012030896,0.00010761241,0.005830134],"genre_scores_gemma":[0.9707042,0.0038958364,0.0051136795,0.0026460506,0.0006352824,0.0025349734,0.0000664499,0.00006142564,0.0143421255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981593,0.000039504794,0.0006758286,0.00050279545,0.00017792267,0.00044463383],"domain_scores_gemma":[0.9990136,0.00021465243,0.00017077665,0.00024954244,0.00016238696,0.00018901356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002145491,0.00023213401,0.00050636457,0.000092820505,0.00011964105,0.000029003966,0.000114342874,0.00017655907,0.00060677435],"category_scores_gemma":[0.00007715344,0.00018650418,0.0001780825,0.00025547403,0.00006604065,0.00008988166,0.000031850264,0.0002512602,0.00000443365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000273722,0.000783571,0.92261326,0.0005146326,0.0008510476,0.000023648807,0.0023103675,0.000059473623,0.0004248338,0.000020619118,0.027785895,0.044338897],"study_design_scores_gemma":[0.03973868,0.0006822814,0.8204488,0.0030887679,0.003135343,0.0000066100606,0.00046044588,0.031926386,0.00247898,0.0000851315,0.0967133,0.0012352451],"about_ca_topic_score_codex":0.0002109056,"about_ca_topic_score_gemma":0.00037905868,"teacher_disagreement_score":0.10216446,"about_ca_system_score_codex":0.0005861658,"about_ca_system_score_gemma":0.00047973677,"threshold_uncertainty_score":0.760542},"labels":[],"label_agreement":null},{"id":"W2084290454","doi":"10.3747/co.21.1997","title":"Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Celgene","keywords":"Taxane; Medicine; Paclitaxel; Tolerability; Carboplatin; Oncology; Lung cancer; Internal medicine; Clinical trial; non-small cell lung cancer (NSCLC); Cancer; Chemotherapy; Adverse effect; Breast cancer","score_opus":0.09854761769337628,"score_gpt":0.4897928811606104,"score_spread":0.39124526346723415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084290454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007514004,0.9921737,0.0000151324,0.0005413473,0.0012964144,0.0030269674,0.00013205987,0.000014290844,0.0020486936],"genre_scores_gemma":[0.00040782493,0.99538857,0.000054197924,0.00012578692,0.0004394047,0.0027282392,0.0005039881,0.00003800998,0.00031398033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984064,0.00012465968,0.0006235342,0.00040779126,0.00014710845,0.0002905248],"domain_scores_gemma":[0.9985678,0.00028653946,0.0005285357,0.00047730937,0.00006888039,0.00007093373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010484618,0.00040900052,0.0019067753,0.00020469204,0.0000526578,0.000005462823,0.00017204726,0.00020107317,0.00009199281],"category_scores_gemma":[0.000015625046,0.0002177428,0.00038487272,0.00025403048,0.00006060368,0.000015664957,0.000022475579,0.00023860937,0.000034832792],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044126537,0.002313516,0.00038807964,0.010372289,0.00024508694,0.000032283308,0.00052315637,0.000024357725,9.3858176e-8,0.000038267946,0.0012457129,0.98477304],"study_design_scores_gemma":[0.0034579108,0.0018766085,0.000115019946,0.007109654,0.004368563,0.000016470638,0.000033646662,0.000022193073,0.000002462461,0.0000056570475,0.9828342,0.00015762204],"about_ca_topic_score_codex":0.000076458404,"about_ca_topic_score_gemma":0.0003461511,"teacher_disagreement_score":0.9846154,"about_ca_system_score_codex":0.0012507418,"about_ca_system_score_gemma":0.00091925124,"threshold_uncertainty_score":0.8879294},"labels":[],"label_agreement":null},{"id":"W2084340355","doi":"10.1016/j.lungcan.2013.06.008","title":"An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Erlotinib; Medicine; Rash; Internal medicine; Adverse effect; Bioavailability; Gastroenterology; Tyrosine-kinase inhibitor; Diarrhea; Erlotinib Hydrochloride; Drug; Pharmacology; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.017004457116695577,"score_gpt":0.36295304428943587,"score_spread":0.3459485871727403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084340355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127996,0.0030545508,0.00011092071,0.0033699141,0.0003683397,0.0010983914,0.000012734354,0.000009719449,0.0006954683],"genre_scores_gemma":[0.9991116,0.000071706985,0.00015483545,0.00012167205,0.00013206198,0.0002458673,0.000021055757,0.000008910955,0.00013231763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99916506,0.00010200099,0.00020483216,0.00011741316,0.00033172127,0.00007896583],"domain_scores_gemma":[0.9991542,0.00004081062,0.00020628532,0.00022637051,0.00033472842,0.000037571142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024636177,0.00006929369,0.00012957038,0.000046409037,0.00007645247,0.000015501582,0.00004991168,0.00003320876,0.00025148256],"category_scores_gemma":[0.00007080205,0.000035762965,0.000036735604,0.0001665121,0.00012469919,0.00019050401,0.000015139972,0.00007137809,7.212586e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083460106,0.0007353945,0.22109978,0.00065711583,0.00081618206,5.4106494e-7,0.015126889,0.0011182942,0.43146342,0.00071793067,0.00812965,0.3193002],"study_design_scores_gemma":[0.01155206,0.00022317217,0.7124754,0.0011073835,0.0035261633,0.000018062756,0.0015256407,0.070019454,0.19874233,0.0004006567,0.00028546428,0.00012418763],"about_ca_topic_score_codex":0.0011095951,"about_ca_topic_score_gemma":0.00008293373,"teacher_disagreement_score":0.49137565,"about_ca_system_score_codex":0.00015964496,"about_ca_system_score_gemma":0.00022013125,"threshold_uncertainty_score":0.2753558},"labels":[],"label_agreement":null},{"id":"W2084415993","doi":"10.1097/jto.0b013e318220c93e","title":"Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Adverse effect; Lung cancer; Progression-free survival; Clinical endpoint; Internal medicine; Nausea; Surgery; Phases of clinical research; Urology; Gastroenterology; Oncology; Clinical trial; Chemotherapy","score_opus":0.022733172148207265,"score_gpt":0.434747771304466,"score_spread":0.41201459915625877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084415993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400395,0.00033780432,0.00013247824,0.00015855693,0.0006919655,0.0006870578,0.000014012977,0.0000037106627,0.003970449],"genre_scores_gemma":[0.99102557,0.00012667793,0.008275488,0.000119158045,0.00015791475,0.00002574094,0.000005787812,0.00001769503,0.00024597405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99887806,0.000060115653,0.000585905,0.000118475495,0.00018231763,0.00017515168],"domain_scores_gemma":[0.9985585,0.00005183725,0.0007666201,0.0001322569,0.00036521206,0.00012554771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019476585,0.00011880823,0.00055646163,0.0002112814,0.000021029762,0.000002307007,0.00008709533,0.0000988319,0.00015121339],"category_scores_gemma":[0.000029963383,0.0000794456,0.00009464939,0.00017111999,0.000045465935,0.00010426973,0.000014458619,0.00023941648,0.0000015271586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4537165,0.029779183,0.19641133,0.00036807993,0.0008807276,0.0005294904,0.008499881,0.000082730534,0.001060867,0.0000101420355,0.00060976396,0.30805132],"study_design_scores_gemma":[0.63457304,0.1254346,0.21515343,0.0011807986,0.004519114,0.00006428395,0.001188278,0.00008200039,0.011689822,0.00007321598,0.005685679,0.0003557474],"about_ca_topic_score_codex":0.00006925489,"about_ca_topic_score_gemma":0.00007301908,"teacher_disagreement_score":0.30769557,"about_ca_system_score_codex":0.00035170093,"about_ca_system_score_gemma":0.0010269858,"threshold_uncertainty_score":0.32396975},"labels":[],"label_agreement":null},{"id":"W2084437976","doi":"10.1016/s1556-0864(15)31597-5","title":"Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review","year":2006,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Lung cancer; Oncology; Internal medicine; Epidermal growth factor receptor; Erlotinib Hydrochloride; Placebo; Chemotherapy; Cancer; Pathology","score_opus":0.05388417740941101,"score_gpt":0.4443536176957201,"score_spread":0.39046944028630914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084437976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004984137,0.9887902,0.000003254473,0.0007377385,0.00047351207,0.004729391,0.00016462913,0.0000025235363,0.00011460272],"genre_scores_gemma":[0.0006360602,0.9979334,0.0003951135,0.00015470298,0.00023619198,0.00027283927,0.000016447852,0.0000329683,0.00032228796],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99582815,0.0010816082,0.0023528223,0.00019651839,0.00031877196,0.0002221286],"domain_scores_gemma":[0.99383783,0.0011731051,0.0042502806,0.00035750042,0.00029551095,0.00008576523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058409193,0.00037329234,0.0043178014,0.00023375422,0.00004721096,0.000011552402,0.00022430762,0.00024423096,0.000022748578],"category_scores_gemma":[0.00018179655,0.000157003,0.0009252366,0.0003983935,0.000109038636,0.000067119065,0.00002797431,0.0003735915,8.5049254e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006699878,0.0013360912,0.0011035978,0.85898197,0.0012016913,0.00009022637,0.0011845496,0.0000014931018,0.000004879119,0.0000040691093,0.0019607185,0.1340637],"study_design_scores_gemma":[0.0012053964,0.0026132588,0.00054889196,0.712906,0.0479866,0.0009229283,0.0001870146,0.0000032898,0.000041823478,0.0000031493007,0.23336768,0.0002139612],"about_ca_topic_score_codex":0.0002650874,"about_ca_topic_score_gemma":0.00008711922,"teacher_disagreement_score":0.23140696,"about_ca_system_score_codex":0.0009623329,"about_ca_system_score_gemma":0.0017443254,"threshold_uncertainty_score":0.64023966},"labels":[],"label_agreement":null},{"id":"W2084469406","doi":"10.1159/000381209","title":"Aspergillosis Superinfection as a Cause of Death of Crizotinib-Induced Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy","year":2015,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Crizotinib; Lung cancer; Aspergillosis; Superinfection; Adverse effect; Interstitial lung disease; Corticosteroid; Surgery; Lung; Internal medicine; Immunology","score_opus":0.03922760119402731,"score_gpt":0.3804825623964624,"score_spread":0.3412549612024351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084469406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699897,0.00024434994,0.00003193234,0.00016175093,0.00028912243,0.0008010103,0.000014546654,0.00003238785,0.0014259067],"genre_scores_gemma":[0.9994027,0.00006583414,0.00009087206,0.00007248091,0.000052841697,0.0001352747,0.00006509029,0.000025930358,0.0000889777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986944,0.00008148366,0.00056801585,0.00029514733,0.0001794806,0.0001814415],"domain_scores_gemma":[0.99866307,0.0000628785,0.00033596283,0.0003354525,0.00034549137,0.00025715778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013659848,0.00016726635,0.0004988577,0.00021253039,0.000027604001,0.0000055249234,0.000021721853,0.00010065072,0.00007872711],"category_scores_gemma":[0.00016749026,0.00012360209,0.00006710811,0.0002107536,0.00009875935,0.00009881877,0.000021102785,0.00010735637,8.867698e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046261786,0.0016885108,0.76135427,0.000093009156,0.00057934015,0.22180222,0.0016574649,0.0001030315,0.0032013254,0.00009248487,0.00003661859,0.004765581],"study_design_scores_gemma":[0.046603207,0.037909,0.5934934,0.0010573418,0.0054520364,0.24756198,0.003932217,0.000545006,0.060829762,0.0002805527,0.0014853812,0.0008501359],"about_ca_topic_score_codex":0.0062376535,"about_ca_topic_score_gemma":0.00052491174,"teacher_disagreement_score":0.16786085,"about_ca_system_score_codex":0.0006350605,"about_ca_system_score_gemma":0.0012313048,"threshold_uncertainty_score":0.9429508},"labels":[],"label_agreement":null},{"id":"W2084920067","doi":"10.1097/01.jto.0000284067.45483.01","title":"P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Tolerability; Regimen; Lung cancer; Oncology; Internal medicine; Pharmacology; Combination therapy; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.013891774908671052,"score_gpt":0.39219524273297685,"score_spread":0.3783034678243058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084920067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550223,0.0007934819,0.00012360669,0.00029156427,0.000113077316,0.0026746981,0.000019522904,0.0000092914825,0.00047250287],"genre_scores_gemma":[0.99774855,0.00004755578,0.0010423451,0.000100952144,0.00010795667,0.000106619504,0.000011602919,0.00004181695,0.00079261145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982632,0.00016343774,0.00060555566,0.00023842456,0.00037145457,0.00035795502],"domain_scores_gemma":[0.9979525,0.00012778281,0.00092163635,0.00024484898,0.0005650456,0.00018813822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003903191,0.00028779602,0.0009085832,0.00040711532,0.000069279144,0.000012493562,0.00010712847,0.000089221794,0.000050253882],"category_scores_gemma":[0.000009927669,0.00012873892,0.00009197793,0.00070187787,0.00009485229,0.00009951516,0.000014532389,0.00023738862,5.509253e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04650705,0.024745127,0.83078265,0.000074805874,0.0017897565,0.0018142166,0.012496766,0.000096223004,0.00034953872,2.474718e-7,0.0003079687,0.08103566],"study_design_scores_gemma":[0.16778478,0.35060114,0.4364209,0.001004398,0.014616759,0.00028405513,0.018353181,0.00008472283,0.0070424653,0.0000011532479,0.0033351514,0.000471291],"about_ca_topic_score_codex":0.001276453,"about_ca_topic_score_gemma":0.0073517733,"teacher_disagreement_score":0.39436173,"about_ca_system_score_codex":0.0009838204,"about_ca_system_score_gemma":0.00084822933,"threshold_uncertainty_score":0.5249821},"labels":[],"label_agreement":null},{"id":"W2085286841","doi":"10.1016/j.lungcan.2013.10.007","title":"A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Chemotherapy; Oncology; Disease; Mutation; Internal medicine; Tyrosine-kinase inhibitor; Population; Cancer research; Cancer; Gene; Genetics; Receptor","score_opus":0.010582962090107244,"score_gpt":0.33281845815150135,"score_spread":0.3222354960613941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085286841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07786177,0.90825534,0.000092662856,0.00027202565,0.00017444702,0.011846354,0.0014264514,0.000018417351,0.00005252791],"genre_scores_gemma":[0.2905539,0.6966635,0.00035492232,0.0008503522,0.00005309623,0.006929775,0.0043631573,0.00012240339,0.00010891685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760073,0.00017946091,0.0009342601,0.0005276638,0.0005171914,0.00024068731],"domain_scores_gemma":[0.9972263,0.00011517975,0.0012962098,0.0005116062,0.00073271943,0.00011801439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011664752,0.0004712598,0.0013095092,0.00019849512,0.00005652727,0.000011696284,0.00008463306,0.00014674576,0.00023522346],"category_scores_gemma":[0.000043185268,0.00030626642,0.00035902485,0.00078772614,0.00007102947,0.00014064235,0.000016917409,0.00023463836,6.848005e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00114152,0.0030047921,0.4642983,0.41854483,0.0004644678,0.000013381352,0.00029171625,0.0007950587,0.000012610874,0.000012012728,0.00023473742,0.11118655],"study_design_scores_gemma":[0.012633046,0.00038654995,0.48991156,0.48679426,0.007838693,4.5139913e-7,0.000008033453,0.0010556348,0.00020625316,0.000008443771,0.0005958512,0.0005612018],"about_ca_topic_score_codex":0.0014044751,"about_ca_topic_score_gemma":0.00034893755,"teacher_disagreement_score":0.21269213,"about_ca_system_score_codex":0.0022820435,"about_ca_system_score_gemma":0.0018496398,"threshold_uncertainty_score":0.99993896},"labels":[],"label_agreement":null},{"id":"W2085526020","doi":"10.1055/s-2004-829641","title":"Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Therapy","year":2004,"lang":"en","type":"article","venue":"Seminars in Respiratory and Critical Care Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Targeted therapy; Cancer; Toxicity; EGFR inhibitors; Cancer therapy; Oncology; Internal medicine","score_opus":0.022460906820646,"score_gpt":0.37519699608764917,"score_spread":0.35273608926700317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085526020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9046836,0.08468894,0.000013920016,0.007936516,0.00040778823,0.0004894458,0.000025998706,0.00003227582,0.0017215227],"genre_scores_gemma":[0.9935337,0.0017512792,0.00010196083,0.003983497,0.00039316533,0.00015316816,0.00001584541,0.000024239613,0.000043191347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857795,0.00006213012,0.00037528027,0.00036516052,0.00027935553,0.00034014235],"domain_scores_gemma":[0.99927354,0.00016764046,0.000028820046,0.00015480471,0.00013325785,0.0002419248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014117101,0.0002083688,0.00040173694,0.00022677184,0.00006968412,0.00000814821,0.00005233649,0.00014196758,0.0002216319],"category_scores_gemma":[0.00037925728,0.00015461614,0.000042564057,0.0003292413,0.0003460377,0.0001092802,0.000020740179,0.00032509025,0.0000022375675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040946133,0.00035623982,0.9059947,0.0009558151,0.000054797318,0.00080154656,0.014832435,0.000008249929,0.0051608467,0.0026293383,0.0014355382,0.06736104],"study_design_scores_gemma":[0.05563486,0.009198001,0.78772855,0.021420779,0.0005845439,0.00010323573,0.037929326,0.000024202422,0.038473833,0.0023678949,0.04497247,0.0015623325],"about_ca_topic_score_codex":0.00043167823,"about_ca_topic_score_gemma":0.00015527986,"teacher_disagreement_score":0.118266165,"about_ca_system_score_codex":0.00045610007,"about_ca_system_score_gemma":0.0002583798,"threshold_uncertainty_score":0.6305063},"labels":[],"label_agreement":null},{"id":"W2085851845","doi":"10.1016/j.lungcan.2003.10.009","title":"Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Ottawa","funders":"","keywords":"Vinorelbine; Medicine; Gemcitabine; Cisplatin; Regimen; Etoposide; Lung cancer; Paclitaxel; Chemotherapy; Internal medicine; Oncology; Pharmacology; Cancer; Drug resistance; Biology","score_opus":0.01439211725772029,"score_gpt":0.38193406914075567,"score_spread":0.3675419518830354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085851845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861541,0.005083195,0.00086344586,0.00030994098,0.00061727583,0.0032887566,0.0001020625,0.00004318618,0.0035380593],"genre_scores_gemma":[0.985721,0.0004451169,0.0021524306,0.00047155452,0.00020490012,0.002025023,0.000020420299,0.000071434064,0.00888815],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867684,0.00002040123,0.00034723151,0.0004017461,0.00021159959,0.00034221477],"domain_scores_gemma":[0.99901617,0.0000473042,0.0002507279,0.00033823538,0.00022635896,0.00012120348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009119937,0.00023251482,0.00042295133,0.000085521926,0.0001794663,0.000010691118,0.00008850191,0.00005733453,0.00025651237],"category_scores_gemma":[0.000014982425,0.00019874376,0.00011535734,0.00020653941,0.000023138104,0.00007772391,0.0000152019,0.00010720574,5.0446414e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057064937,0.04278496,0.3952089,0.0057948767,0.012045552,0.00011656921,0.118692234,0.011366238,0.22800782,0.00060866313,0.042325635,0.13734205],"study_design_scores_gemma":[0.39317545,0.022480031,0.00753335,0.003147516,0.01237112,0.000019652993,0.012057901,0.020407878,0.45208162,0.00011797732,0.074472114,0.0021353867],"about_ca_topic_score_codex":0.0009888127,"about_ca_topic_score_gemma":0.0003842668,"teacher_disagreement_score":0.38767555,"about_ca_system_score_codex":0.00046538527,"about_ca_system_score_gemma":0.00043003488,"threshold_uncertainty_score":0.81045353},"labels":[],"label_agreement":null},{"id":"W2086962483","doi":"10.1016/s0169-5002(00)80188-9","title":"Phase II trial of alternating 4 chemotherapy regimens in non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Oncology; Internal medicine","score_opus":0.01205030497229059,"score_gpt":0.36270405458209004,"score_spread":0.35065374960979945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086962483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97906524,0.0039128116,0.000027737318,0.0010932275,0.00043126073,0.0014104445,0.00006427056,0.000031354873,0.0139636705],"genre_scores_gemma":[0.9760094,0.0025340093,0.00040750852,0.0007365404,0.0006164176,0.0006048957,0.000025659574,0.00004826807,0.019017255],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99876636,0.000019821347,0.00037161406,0.00031615832,0.00021717344,0.00030887613],"domain_scores_gemma":[0.99939,0.000027452732,0.00014402767,0.00027143958,0.00006516105,0.00010189589],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000084586296,0.00019001351,0.0003881847,0.000100734964,0.00007294473,0.000009880762,0.00009205528,0.000080541875,0.0025563443],"category_scores_gemma":[0.00000435883,0.00016405291,0.00011260009,0.00025246321,0.00003443356,0.00007322533,0.000013393798,0.00015512935,0.0000027222407],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07841952,0.020225007,0.14673822,0.0027091692,0.0037852493,0.00032053448,0.04996464,0.005932286,0.048318285,0.000116446805,0.044055834,0.5994148],"study_design_scores_gemma":[0.85939485,0.0048325625,0.009562896,0.0030800127,0.002467958,0.000011112419,0.0003571347,0.02147016,0.060293034,0.000039035516,0.03754179,0.0009494302],"about_ca_topic_score_codex":0.0054635517,"about_ca_topic_score_gemma":0.0005345896,"teacher_disagreement_score":0.78097534,"about_ca_system_score_codex":0.0005386741,"about_ca_system_score_gemma":0.0004190527,"threshold_uncertainty_score":0.99835545},"labels":[],"label_agreement":null},{"id":"W2087310881","doi":"10.1016/j.cct.2008.01.004","title":"Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21","year":2008,"lang":"en","type":"article","venue":"Contemporary Clinical Trials","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Medicine; Erlotinib; Adverse effect; Rash; Oncology; Drug; Pharmacology; Internal medicine; Intensive care medicine; Epidermal growth factor receptor; Cancer","score_opus":0.36207271461006674,"score_gpt":0.5042172067643471,"score_spread":0.14214449215428038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087310881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912123,0.0008001833,0.0000045744073,0.00006125658,0.000440746,0.0063193506,0.00021515955,0.000034767258,0.0009116492],"genre_scores_gemma":[0.99829274,0.00043366558,0.00008081014,0.000015320773,0.0002618027,0.00029543255,0.000119124255,0.00003026214,0.00047083257],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99478537,0.001256239,0.0030090723,0.00047662278,0.00031089887,0.00016179978],"domain_scores_gemma":[0.99365646,0.003608983,0.0015205138,0.00072011055,0.00025366255,0.00024029691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015764241,0.00032009234,0.0025763293,0.00019750696,0.0000677953,0.0000033003478,0.00007333045,0.00018586795,0.00012020298],"category_scores_gemma":[0.0011050142,0.00020654322,0.0008240888,0.00027202288,0.00013840802,0.00010302398,0.00002445057,0.000086904096,0.000010128755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020532837,0.033644315,0.87852645,0.00023693952,0.0114198765,0.004729936,0.0104768565,0.000034796878,0.007014321,0.000046029636,0.0004474726,0.032890167],"study_design_scores_gemma":[0.30287588,0.44576535,0.13397817,0.0009363536,0.011111504,0.0010086872,0.006783682,0.000043189008,0.094444126,0.00011997391,0.0022966191,0.00063646253],"about_ca_topic_score_codex":0.0028656544,"about_ca_topic_score_gemma":0.000026688736,"teacher_disagreement_score":0.74454826,"about_ca_system_score_codex":0.00033155532,"about_ca_system_score_gemma":0.0011421066,"threshold_uncertainty_score":0.8422588},"labels":[],"label_agreement":null},{"id":"W2087764235","doi":"10.1186/1471-2407-7-128","title":"Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients","year":2007,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Baker Hughes (Canada); Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"BC Cancer Agency; University of British Columbia; Michael Smith Health Research BC; Genome British Columbia; Canada's Michael Smith Genome Sciences Centre; Genome Canada","keywords":"Gefitinib; Exon; Epidermal growth factor receptor; Lung cancer; Cancer research; Gene duplication; Point mutation; Tyrosine kinase; Tyrosine-kinase inhibitor; Adenocarcinoma; Biology; Copy-number variation; Medicine; Oncology; Molecular biology; Mutation; Cancer; Gene; Internal medicine; Genetics; Receptor; Genome","score_opus":0.010093036546359211,"score_gpt":0.36946631779564115,"score_spread":0.3593732812492819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087764235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755234,0.0005730875,0.00013501153,0.00012830415,0.000037482445,0.00057921855,0.00046558343,0.0000069350644,0.00052205665],"genre_scores_gemma":[0.9987482,0.000110613226,0.0005640785,0.000103219085,0.000014895019,0.00015450692,0.00004806916,0.000011439664,0.0002450131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990376,0.00004716059,0.00036580127,0.00022421566,0.00017304198,0.00015214738],"domain_scores_gemma":[0.99914825,0.00029441965,0.00013101046,0.00011899044,0.00020920974,0.000098127755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019100046,0.00010360542,0.00036187912,0.00051114394,0.000033373195,0.000005109107,0.000023793318,0.000053968477,0.00019006163],"category_scores_gemma":[0.00020939841,0.000096593336,0.000046951456,0.0014645007,0.00007426978,0.000073519834,0.000020220494,0.00007050641,4.1673778e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012752884,0.00027087503,0.9938728,0.000042889944,0.00034352284,0.0000037242305,0.0028686002,0.00056036277,0.00011405635,0.000106342486,0.00007412385,0.00046741188],"study_design_scores_gemma":[0.0026474951,0.00012217014,0.9945176,0.00024278938,0.0011429775,8.5390684e-7,0.0005024283,0.0005034416,0.00016899797,0.00002179808,0.000046304238,0.00008314847],"about_ca_topic_score_codex":0.025825953,"about_ca_topic_score_gemma":0.061207008,"teacher_disagreement_score":0.035381053,"about_ca_system_score_codex":0.00059051946,"about_ca_system_score_gemma":0.0002778512,"threshold_uncertainty_score":0.98066115},"labels":[],"label_agreement":null},{"id":"W2088357532","doi":"10.1016/s1556-0864(15)31605-1","title":"Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation","funders":"","keywords":"Vinorelbine; Medicine; Gefitinib; Oncology; Lung cancer; Cisplatin; Chemotherapy; Vinblastine; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.012515906492385633,"score_gpt":0.39447117709965124,"score_spread":0.3819552706072656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088357532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989565,0.00065876264,0.0017999407,0.0028501714,0.0005344747,0.0011181228,0.00007860408,0.000016266542,0.0033786467],"genre_scores_gemma":[0.97360176,0.00015954861,0.018671699,0.0010494983,0.001080357,0.0001301047,0.000062572806,0.00005608021,0.005188376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984994,0.000040577273,0.0006285295,0.00021954621,0.00026369232,0.00034824098],"domain_scores_gemma":[0.9978151,0.00018966079,0.0008855515,0.00015733947,0.00078380713,0.00016856825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017157517,0.00023933248,0.0006637122,0.00019107189,0.00011224099,0.000019338759,0.000124619,0.00016430207,0.00021989665],"category_scores_gemma":[0.000027508035,0.00014499649,0.00016956328,0.00020217635,0.000069173766,0.00010938249,0.000017454811,0.00025324308,0.0000029544099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04568083,0.01004504,0.5963774,0.0016669403,0.0025944072,0.0009815472,0.0037668657,0.0012569312,0.0058033466,0.00005737905,0.10222052,0.2295488],"study_design_scores_gemma":[0.071028925,0.0516562,0.6353717,0.0022770306,0.012356667,0.0011489663,0.0010275332,0.002052679,0.031799473,0.00031747867,0.18977492,0.0011884288],"about_ca_topic_score_codex":0.0001985278,"about_ca_topic_score_gemma":0.000258963,"teacher_disagreement_score":0.22836037,"about_ca_system_score_codex":0.00074111833,"about_ca_system_score_gemma":0.0012076675,"threshold_uncertainty_score":0.5912785},"labels":[],"label_agreement":null},{"id":"W2088500044","doi":"10.1016/j.critrevonc.2012.07.006","title":"Treatment of metastatic cervical cancer: Future directions involving targeted agents","year":2012,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cervical cancer; Clinical trial; Disease; Oncology; Targeted therapy; Chemotherapy; Cancer; Radiation therapy; Internal medicine; Intensive care medicine","score_opus":0.13359325886132045,"score_gpt":0.5007791000466785,"score_spread":0.367185841185358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088500044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010283648,0.9918747,0.000018500401,0.0012569006,0.0019185365,0.0031631724,0.00015217387,0.000044730397,0.0015610316],"genre_scores_gemma":[0.00007924489,0.99135786,0.002643693,0.00022759866,0.0004740405,0.0045421086,0.00033751864,0.000075348325,0.00026259382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951636,0.0010791699,0.0021142673,0.00067869143,0.00019608703,0.00076816697],"domain_scores_gemma":[0.9968289,0.0014368687,0.0005083465,0.00063821924,0.00016059571,0.00042702822],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029701306,0.0007035907,0.007258649,0.00044811136,0.0001005467,0.000007621445,0.00018676,0.0007341097,0.0013939077],"category_scores_gemma":[0.00065769575,0.0004672997,0.0010703651,0.00075580995,0.00037632856,0.00007764136,0.00006941371,0.0005299101,0.00018789167],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019921456,0.002608208,0.00034538013,0.026913479,0.0007666945,0.0003136079,0.00033257634,2.7850566e-8,2.817577e-7,0.007656937,0.00077625504,0.96026665],"study_design_scores_gemma":[0.0010859759,0.0007058558,0.000054174187,0.012139895,0.014409612,0.0011904495,0.00007967103,0.0000037923176,0.0000017769115,0.000119645876,0.96992517,0.0002839922],"about_ca_topic_score_codex":0.00011957263,"about_ca_topic_score_gemma":0.00025993894,"teacher_disagreement_score":0.96914893,"about_ca_system_score_codex":0.002141775,"about_ca_system_score_gemma":0.0014687179,"threshold_uncertainty_score":0.99977785},"labels":[],"label_agreement":null},{"id":"W2088955344","doi":"10.1016/j.ctrv.2011.05.009","title":"Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)","year":2011,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Merck KGaA; Pfizer","keywords":"Medicine; Epidermal growth factor receptor; Targeted therapy; Growth factor receptor; Lung cancer; Growth factor; Platelet-derived growth factor receptor; Oncology; Growth factor receptor inhibitor; Insulin-like growth factor 1 receptor; Cancer research; Receptor; Cancer; Internal medicine","score_opus":0.2202845222937452,"score_gpt":0.47681434557765334,"score_spread":0.25652982328390816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088955344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001283583,0.9815449,0.00002351397,0.00007725552,0.00093458884,0.015521499,0.00031206806,0.000027992937,0.001429786],"genre_scores_gemma":[0.0000045150423,0.96307725,0.0025450261,0.00033178367,0.0002771095,0.027960485,0.0015040722,0.0001112706,0.0041885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627364,0.00020270528,0.001841635,0.0010232767,0.00014390565,0.0005148326],"domain_scores_gemma":[0.9979848,0.00016994357,0.0009172816,0.00045831833,0.00013589757,0.0003337443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003603544,0.00083453394,0.003534736,0.0002234141,0.00014061313,0.00003427715,0.00014506737,0.00033398834,0.00040559913],"category_scores_gemma":[0.000038437916,0.0005642425,0.0006674126,0.00036032326,0.000055425593,0.000081312915,0.000053808806,0.00024570455,0.000032942025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041362535,0.0006381977,0.005697898,0.0138717,0.0010814359,0.000016085674,0.00043672556,2.5025608e-7,1.0535901e-7,0.0000064397323,0.004960518,0.97324926],"study_design_scores_gemma":[0.005269689,0.00029084407,0.0008751611,0.030941585,0.008496984,0.0000066992734,0.000014453014,0.000010405026,0.0000021140424,0.0000051345296,0.95364845,0.00043849382],"about_ca_topic_score_codex":0.0002816204,"about_ca_topic_score_gemma":0.00037547434,"teacher_disagreement_score":0.9728108,"about_ca_system_score_codex":0.0024223318,"about_ca_system_score_gemma":0.0026759629,"threshold_uncertainty_score":0.9996809},"labels":[],"label_agreement":null},{"id":"W2089290845","doi":"10.1158/0008-5472.can-07-5428","title":"Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institute on Aging","keywords":"T790M; Cancer research; Gefitinib; Protein kinase B; Epidermal growth factor receptor; EGFR inhibitors; Erlotinib; PI3K/AKT/mTOR pathway; Kinase; Tyrosine kinase; Phosphorylation; Tyrosine-kinase inhibitor; Chemistry; Biology; Signal transduction; Pharmacology; Cancer; Cell biology; Medicine; Receptor; Internal medicine; Biochemistry","score_opus":0.0647584607196473,"score_gpt":0.4074752702221794,"score_spread":0.3427168095025321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089290845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985048,0.00847513,0.000023096844,0.0028818634,0.00011113595,0.00059870095,0.00008929304,0.00005627227,0.002716493],"genre_scores_gemma":[0.9908367,0.0028120074,0.00030216572,0.00018628109,0.00038318994,0.00029399578,0.000043060514,0.000032818323,0.0051098084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982678,0.0000820476,0.00020701076,0.00039190977,0.0006240143,0.0004271886],"domain_scores_gemma":[0.99892163,0.00016509074,0.000038620074,0.00025847479,0.00037722374,0.00023893337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002215841,0.00014060845,0.00023065179,0.00021249813,0.0004741949,0.00004205674,0.000052289437,0.00007658486,0.00034460772],"category_scores_gemma":[0.00012691048,0.000116994066,0.000049426657,0.00042714292,0.00033303403,0.00018293693,0.0000602553,0.00030845831,0.000022186952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019936296,0.00077851856,0.048332047,0.0014476391,0.00047043242,0.0029510574,0.0076252394,0.000031551142,0.8699865,0.0025921487,0.05756386,0.006227402],"study_design_scores_gemma":[0.007039463,0.0006077769,0.029426023,0.0018443698,0.00018016997,0.00016490066,0.0013439,0.000022058422,0.8677768,0.0014027952,0.08975022,0.00044150546],"about_ca_topic_score_codex":0.0004651425,"about_ca_topic_score_gemma":0.00017772612,"teacher_disagreement_score":0.032186367,"about_ca_system_score_codex":0.00047907472,"about_ca_system_score_gemma":0.0006018035,"threshold_uncertainty_score":0.47708797},"labels":[],"label_agreement":null},{"id":"W2089545132","doi":"10.1002/cncr.22331","title":"Evaluation of denaturing high‐performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall‐cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Epidermal growth factor receptor; Lung cancer; Epidermal growth factor; Medicine; Identification (biology); Cancer; Chromatography; Cancer research; Receptor; Pathology; Internal medicine; Biology; Chemistry","score_opus":0.018015491295921556,"score_gpt":0.3565531800593447,"score_spread":0.33853768876342316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089545132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98569804,0.0041805524,0.0074424637,0.00017516034,0.00037018795,0.0017015691,0.00018733721,0.000026351545,0.00021835575],"genre_scores_gemma":[0.9949204,0.00036766083,0.0022007858,0.000027811748,0.0001378362,0.0021122694,0.00011865995,0.000028584229,0.00008601763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984691,0.000087383734,0.00056844,0.00027844886,0.00040735287,0.0001892825],"domain_scores_gemma":[0.9983346,0.00009211611,0.0004135777,0.00017091264,0.00094578834,0.00004300889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004483788,0.00014690797,0.00028521035,0.0003663595,0.00007682543,0.0000083909545,0.000058295824,0.00010021093,0.0001617001],"category_scores_gemma":[0.00006735642,0.00013864771,0.000111857946,0.0005197412,0.000043307777,0.00021513853,0.000008852354,0.00008715992,0.0000011694009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006670837,0.00049072533,0.03662555,0.0015723446,0.0004904936,5.7855874e-7,0.0013559951,0.012792696,0.89661384,0.00014626134,0.0001541379,0.049090292],"study_design_scores_gemma":[0.0031772235,0.00019911167,0.15862423,0.0002704583,0.0011956043,0.000001703023,0.00007991714,0.020168828,0.8160065,0.0000875944,0.00006507396,0.0001237505],"about_ca_topic_score_codex":0.003915825,"about_ca_topic_score_gemma":0.0007265913,"teacher_disagreement_score":0.12199869,"about_ca_system_score_codex":0.0006018129,"about_ca_system_score_gemma":0.00055898743,"threshold_uncertainty_score":0.5919582},"labels":[],"label_agreement":null},{"id":"W2089664277","doi":"10.3816/clc.2008.n.037","title":"An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial","year":2008,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Gemcitabine; Medicine; Oncology; Internal medicine; Cisplatin; Erlotinib Hydrochloride; Clinical endpoint; Chemotherapy; Progression-free survival; Randomized controlled trial; Epidermal growth factor receptor; Cancer","score_opus":0.035958572531297826,"score_gpt":0.4227494391711765,"score_spread":0.3867908666398787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089664277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8898669,0.00088849827,0.00025685795,0.0011141393,0.0019069589,0.1028988,0.002767869,0.00006297727,0.00023700102],"genre_scores_gemma":[0.9187296,0.0011766739,0.0005744428,0.00020721984,0.00058551255,0.07217179,0.0016057616,0.00013402152,0.004814947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99283046,0.00045111522,0.0038551057,0.0013525995,0.00086645305,0.0006442476],"domain_scores_gemma":[0.99358565,0.0021775954,0.0019970275,0.00104358,0.0007597099,0.00043643836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009786066,0.0008764988,0.002820198,0.00024446938,0.00033553044,0.000039090024,0.00051767135,0.0003355536,0.0013291987],"category_scores_gemma":[0.0006455062,0.0006416494,0.00068429677,0.0006458473,0.00042030524,0.000385058,0.00016581434,0.00061033183,0.0000012895811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8368415,0.03589637,0.10657898,0.0007270726,0.0043713115,0.000060332837,0.0032451225,0.0038618094,0.0011544791,0.000012826736,0.0032338644,0.0040162858],"study_design_scores_gemma":[0.8818885,0.010282704,0.0022044193,0.0005409341,0.0026474714,0.000004777851,0.00030495948,0.09807473,0.0010989727,0.0000057447655,0.0024084921,0.0005382663],"about_ca_topic_score_codex":0.0017519693,"about_ca_topic_score_gemma":0.024007149,"teacher_disagreement_score":0.104374565,"about_ca_system_score_codex":0.0011127407,"about_ca_system_score_gemma":0.000996462,"threshold_uncertainty_score":0.99960345},"labels":[],"label_agreement":null},{"id":"W2089716357","doi":"10.1038/onc.2009.197","title":"Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors","year":2009,"lang":"en","type":"review","venue":"Oncogene","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Erlotinib; Gefitinib; KRAS; Biology; Lung cancer; Epidermal growth factor receptor; Cancer research; Tyrosine kinase; Targeted therapy; Precision medicine; Personalized medicine; EGFR inhibitors; Biomarker; Oncology; Gene; Mutation; Cancer; Bioinformatics; Medicine; Signal transduction; Genetics","score_opus":0.03950159899510071,"score_gpt":0.37938764396242636,"score_spread":0.33988604496732566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089716357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058916476,0.93505126,0.0009126923,0.000050841576,0.000040104842,0.003864527,0.0011101897,0.000006820577,0.000047072677],"genre_scores_gemma":[0.043973166,0.92064875,0.03163103,0.000091820555,0.00014209012,0.0025620353,0.000592541,0.0001150622,0.00024350782],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837565,0.00013115701,0.00078541593,0.00030963184,0.0002530774,0.00014505959],"domain_scores_gemma":[0.9984679,0.0002843604,0.00065986486,0.0002828382,0.00022983174,0.000075197066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004055487,0.0002388808,0.0010476661,0.0003390225,0.000036550773,0.000005087091,0.00008145834,0.00013338258,0.000018689701],"category_scores_gemma":[0.0001251074,0.00016438872,0.00028132726,0.0011611622,0.000045323053,0.000023364311,0.0000293266,0.000072641764,1.8248599e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017028131,0.001071518,0.007505142,0.036105197,0.004511707,0.000031318108,0.00065543706,0.00076735544,0.3255379,0.000008237025,0.00023423172,0.62186915],"study_design_scores_gemma":[0.018720595,0.0033828726,0.0067261215,0.1860639,0.088509925,0.00006704358,0.0002872207,0.002363182,0.5887556,0.00003512292,0.1038743,0.0012140798],"about_ca_topic_score_codex":0.00058151176,"about_ca_topic_score_gemma":0.000032953707,"teacher_disagreement_score":0.62065506,"about_ca_system_score_codex":0.00023863184,"about_ca_system_score_gemma":0.0006696374,"threshold_uncertainty_score":0.67035776},"labels":[],"label_agreement":null},{"id":"W2090288228","doi":"10.1007/s00408-004-2539-7","title":"Phase II Study of Troxacitabine (BCH-4556) in Patients with Advanced Non-Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Lung","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Business Development Bank of Canada; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Performance status; Gastroenterology; Cancer; Anemia; Rash; Phases of clinical research; Surgery; Clinical trial","score_opus":0.006232495591213058,"score_gpt":0.31363198704698375,"score_spread":0.30739949145577067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090288228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958393,0.0005015012,0.00006351579,0.00014104114,0.00008111456,0.001746948,0.00003293632,0.00002217218,0.001571472],"genre_scores_gemma":[0.99753755,0.00002094684,0.0007121919,0.00009985825,0.0000587332,0.00024291447,0.000050204886,0.000027268836,0.0012503488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903077,0.00001367239,0.0002699298,0.00024945632,0.00021572354,0.00022045782],"domain_scores_gemma":[0.99942774,0.000015629425,0.00011036178,0.00024233774,0.00011494693,0.0000889987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034799043,0.000158104,0.00030305408,0.00011784622,0.00006159383,0.0000046503405,0.00005736639,0.00003336081,0.00011478838],"category_scores_gemma":[0.000005838529,0.00011810114,0.000032070962,0.0002595875,0.000017314987,0.000110303736,0.000024671794,0.00010290105,0.0000017443787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010955171,0.017418971,0.9503486,0.00014312935,0.00027234416,0.00001643573,0.0074471817,0.0011440312,0.00045637356,0.0000047382773,0.0003101353,0.021342518],"study_design_scores_gemma":[0.19191034,0.015675986,0.78074706,0.00063650706,0.001889903,0.0000013546531,0.00174555,0.0036033762,0.0023596282,0.0000017229179,0.0010132835,0.00041526445],"about_ca_topic_score_codex":0.00033627902,"about_ca_topic_score_gemma":0.0007774792,"teacher_disagreement_score":0.19081482,"about_ca_system_score_codex":0.0002780978,"about_ca_system_score_gemma":0.00012875385,"threshold_uncertainty_score":0.48160246},"labels":[],"label_agreement":null},{"id":"W2090299129","doi":"10.2165/00151829-200504020-00001","title":"Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer","year":2005,"lang":"en","type":"review","venue":"Treatments in Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Toxicity; Lung cancer; Chemotherapy; Oncology; Pharmacy; Internal medicine; Pharmacology; Intensive care medicine; Family medicine","score_opus":0.036541587243973966,"score_gpt":0.3929872630475807,"score_spread":0.35644567580360675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090299129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033051174,0.9608358,0.000016505366,0.00011983861,0.0002055409,0.0035329761,0.000032236756,0.00004374085,0.0021621627],"genre_scores_gemma":[0.0017249956,0.99437207,0.0005348527,0.0002696596,0.00041465164,0.001227144,0.000078063,0.00014759394,0.0012309713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997131,0.00012015255,0.0009002118,0.0009492614,0.0003454135,0.00055394694],"domain_scores_gemma":[0.99851227,0.00016212025,0.0004586892,0.00054713606,0.00006211989,0.00025764588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028177587,0.0007912374,0.0025192066,0.0006155018,0.0000768565,0.000013049856,0.00012572022,0.0002933522,0.00012050459],"category_scores_gemma":[0.000029286537,0.0005022768,0.000114213326,0.00065307884,0.00013524551,0.000106888256,0.000036927657,0.00051205483,0.0000029809773],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014143017,0.00049922895,0.012251429,0.0071765985,0.00044913025,0.00037988857,0.0007650251,0.000018868299,0.000029474302,0.0000026841594,0.000053337728,0.9782329],"study_design_scores_gemma":[0.08627224,0.0060440013,0.023521544,0.19860275,0.014728617,0.00011907131,0.0012898521,0.00017920088,0.00014959577,0.000003938568,0.6668129,0.0022763102],"about_ca_topic_score_codex":0.0011616795,"about_ca_topic_score_gemma":0.0009972485,"teacher_disagreement_score":0.9759566,"about_ca_system_score_codex":0.0021264567,"about_ca_system_score_gemma":0.0011687194,"threshold_uncertainty_score":0.99974287},"labels":[],"label_agreement":null},{"id":"W2090635330","doi":"10.1111/j.1525-1438.2005.00431.x","title":"Trial design for testing new therapies in ovarian cancer","year":2005,"lang":"en","type":"review","venue":"International Journal of Gynecological Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Cancer; Gynecology; Internal medicine","score_opus":0.25186206854200555,"score_gpt":0.5056156728524875,"score_spread":0.253753604310482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090635330","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041532803,0.99184734,0.001296887,0.0021833824,0.0026312713,0.0016023066,0.000064805994,0.000010121337,0.00032233453],"genre_scores_gemma":[0.0001748526,0.9816007,0.010676342,0.0005005948,0.0052027577,0.0005360709,0.000016866989,0.000034272904,0.0012575502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801064,0.00008880384,0.0010327124,0.00022954804,0.00041117988,0.00022709821],"domain_scores_gemma":[0.9969012,0.001350589,0.00094873086,0.00008506257,0.0005659682,0.00014843243],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003465813,0.00027294917,0.0012553333,0.00030908568,0.000034935547,0.000051697047,0.0003116952,0.00024932355,0.00119345],"category_scores_gemma":[0.0008073748,0.00016828722,0.0005307827,0.00019000152,0.000036321635,0.00011182617,0.000028689186,0.00040999017,0.000004164531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034322236,0.00027188743,0.00010601533,0.00018338273,0.0015737924,0.00010697959,0.00006607026,0.00015960285,0.0000011074112,0.00006341129,0.002722897,0.9913126],"study_design_scores_gemma":[0.024953313,0.0012575195,0.0002862705,0.0053461897,0.0017457269,0.00010633979,0.000011434349,0.000017177666,0.0000012881544,0.00031924463,0.96578497,0.0001705209],"about_ca_topic_score_codex":0.0001519743,"about_ca_topic_score_gemma":0.00010591944,"teacher_disagreement_score":0.9911421,"about_ca_system_score_codex":0.002014921,"about_ca_system_score_gemma":0.0042042877,"threshold_uncertainty_score":0.9997196},"labels":[],"label_agreement":null},{"id":"W2091070104","doi":"10.1155/2015/621324","title":"Preclinical Murine Models for Lung Cancer: Clinical Trial Applications","year":2015,"lang":"en","type":"review","venue":"BioMed Research International","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Clinical trial; Lung cancer; Medicine; Cancer; Intensive care medicine; Preclinical testing; Medical physics; Bioinformatics; Oncology; Pathology; Internal medicine; Biology","score_opus":0.6492250830308651,"score_gpt":0.7138985774200368,"score_spread":0.06467349438917169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091070104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017347991,0.9727932,0.0024613738,0.001715831,0.0032846,0.012243928,0.0022670901,0.00007143949,0.005160811],"genre_scores_gemma":[0.000005138254,0.9407798,0.00280881,0.000048249356,0.009712911,0.025729075,0.0046092295,0.000078937475,0.016227836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956745,0.00030104406,0.0014045677,0.00083940197,0.0012979555,0.00048252952],"domain_scores_gemma":[0.99527246,0.0013873272,0.00033463794,0.0005847565,0.0018586785,0.0005621293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028865593,0.0002960696,0.0013207,0.00067661825,0.00015638645,0.000089501824,0.0005980112,0.0004999185,0.00026838633],"category_scores_gemma":[0.0006737672,0.00021537057,0.0009111993,0.00049030577,0.0003062366,0.00010674958,0.00022556356,0.00081001985,0.00006188479],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002555937,0.0011511582,0.000008950352,0.0027434814,0.002344736,0.000008354061,0.000015863297,0.0000016918855,4.675295e-8,0.0017430765,0.12354019,0.8658865],"study_design_scores_gemma":[0.02396744,0.0005965588,0.000001530021,0.0024417085,0.0013670948,0.000015266467,0.000008456587,0.0013285759,1.14945685e-7,0.0006229653,0.9694776,0.00017266712],"about_ca_topic_score_codex":0.00006840028,"about_ca_topic_score_gemma":0.0000123752625,"teacher_disagreement_score":0.86571383,"about_ca_system_score_codex":0.0014594969,"about_ca_system_score_gemma":0.0062099025,"threshold_uncertainty_score":0.999424},"labels":[],"label_agreement":null},{"id":"W2091130375","doi":"10.1517/13543780903066772","title":"EGFR-directed therapies to treat non-small-cell lung cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lung cancer; Medicine; Tyrosine kinase; Cancer research; Cancer; Angiogenesis; Epidermal growth factor receptor; Monoclonal antibody; Disease; Drug development; Targeted therapy; Drug; Oncology; Immunology; Pharmacology; Internal medicine; Receptor; Antibody","score_opus":0.04626132764116791,"score_gpt":0.3999452614262695,"score_spread":0.3536839337851016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091130375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023891042,0.9829099,0.000031500946,0.0046904013,0.0008840896,0.0024066395,0.00021494376,0.00021553766,0.008623056],"genre_scores_gemma":[0.000012588203,0.9753057,0.002475037,0.0051903785,0.0014968888,0.0022521482,0.0022719968,0.000108521475,0.010886775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759674,0.000109186425,0.0006266418,0.0007444241,0.0005555288,0.00036745906],"domain_scores_gemma":[0.9983598,0.00020531147,0.00026205223,0.00047346752,0.00019993055,0.0004994112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008600707,0.00066042633,0.0012403086,0.00042999056,0.00021810865,0.000062679654,0.00019978423,0.000298427,0.00038614596],"category_scores_gemma":[0.00004181173,0.00044118523,0.00043137372,0.00059447484,0.00007426549,0.00007684004,0.000033247776,0.00032649277,0.00019929853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003095024,0.0003182446,0.000019519284,0.0022925169,0.00042911488,0.00000811338,0.0032250204,0.000014127093,0.000008240037,0.00065267744,0.14637809,0.8466234],"study_design_scores_gemma":[0.0010352042,0.00022106641,0.000080768536,0.017016105,0.00027017356,0.000011064241,0.00006804941,0.0000343987,0.00004234562,0.00006197489,0.9807011,0.00045778957],"about_ca_topic_score_codex":0.00030326625,"about_ca_topic_score_gemma":0.000004283825,"teacher_disagreement_score":0.8461656,"about_ca_system_score_codex":0.0011227847,"about_ca_system_score_gemma":0.0023225395,"threshold_uncertainty_score":0.999804},"labels":[],"label_agreement":null},{"id":"W2091189556","doi":"10.1158/1538-7445.am2012-4819","title":"Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC)","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Sorafenib; KRAS; Gene signature; Lung cancer; Medicine; Cancer; Adenocarcinoma; Internal medicine; Cancer research; Oncology; Hepatocellular carcinoma; Gene expression; Biology; Gene; Colorectal cancer","score_opus":0.05708683597365023,"score_gpt":0.43128345273831864,"score_spread":0.3741966167646684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091189556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746672,0.015517776,0.000014142737,0.00080925046,0.0005778472,0.0020747418,0.00008061648,0.000059366612,0.0061990665],"genre_scores_gemma":[0.98970735,0.0028044947,0.00038741858,0.00009934287,0.0011369227,0.0011766155,0.00010022359,0.00007915001,0.0045084944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971843,0.00009837824,0.00035701322,0.0005001326,0.0007496638,0.0011105387],"domain_scores_gemma":[0.99836147,0.00016442471,0.000086502325,0.0005120009,0.00036624717,0.0005093826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055532134,0.00025430875,0.00036175718,0.0003585217,0.00022645084,0.00004728228,0.00023016047,0.0001906023,0.001197837],"category_scores_gemma":[0.00006332422,0.00020007214,0.0000932457,0.0007288429,0.00013166832,0.00024280137,0.00011885405,0.0007470263,0.000095087606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009182255,0.00176541,0.62339956,0.00097423955,0.00020982043,0.000087905704,0.005117784,0.00022412787,0.32690585,0.000018987741,0.029508084,0.010870021],"study_design_scores_gemma":[0.0066556907,0.00024179484,0.6193579,0.001821937,0.00019738887,0.000008199575,0.000536004,0.00010738488,0.36049622,0.0000110571245,0.010206225,0.0003602262],"about_ca_topic_score_codex":0.0033475016,"about_ca_topic_score_gemma":0.00022694244,"teacher_disagreement_score":0.033590373,"about_ca_system_score_codex":0.0013167491,"about_ca_system_score_gemma":0.0018027382,"threshold_uncertainty_score":0.9997152},"labels":[],"label_agreement":null},{"id":"W2092137529","doi":"10.1097/jto.0b013e3181d40a1b","title":"The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Lung cancer; Cancer; Adverse effect; Confidence interval; Clinical trial; Chemotherapy; Oncology","score_opus":0.08061870314447525,"score_gpt":0.5216139087608775,"score_spread":0.44099520561640226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092137529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962169,0.00087492756,0.000007865936,0.001132185,0.0007879426,0.00070385245,0.0001413166,9.299407e-7,0.00013408042],"genre_scores_gemma":[0.99560225,0.0032969501,0.000552049,0.00018546672,0.00022002478,0.000026857913,0.0000035462951,0.000008079013,0.00010477801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960063,0.00076585653,0.0026133172,0.00013477544,0.00034722683,0.00013248762],"domain_scores_gemma":[0.992224,0.00332477,0.003597047,0.0001510226,0.0005756646,0.00012752543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005787267,0.0001343657,0.0016452182,0.00012562018,0.000034086213,0.0000012380167,0.0001171284,0.00014979093,0.00003642633],"category_scores_gemma":[0.001610912,0.0000786562,0.00025983062,0.00013533734,0.00018089176,0.000057808265,0.000016169397,0.00024479756,4.157682e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036892723,0.0045711375,0.73703533,0.0007007952,0.0048154704,0.000028357883,0.0024346223,0.0071064974,0.056521807,0.000110110035,0.0009431286,0.14884003],"study_design_scores_gemma":[0.020345304,0.0033871937,0.9583279,0.00047277563,0.0012241419,0.000009742382,0.00040751984,0.000109730754,0.0111819,0.000059173875,0.0043602968,0.00011430998],"about_ca_topic_score_codex":0.07211282,"about_ca_topic_score_gemma":0.15932341,"teacher_disagreement_score":0.22129259,"about_ca_system_score_codex":0.00064900547,"about_ca_system_score_gemma":0.0114496425,"threshold_uncertainty_score":0.9941545},"labels":[],"label_agreement":null},{"id":"W2092652143","doi":"10.1007/s10637-013-0010-4","title":"Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hôpital Notre-Dame","funders":"Pfizer","keywords":"Medicine; Carboplatin; Pemetrexed; Neutropenia; Sunitinib; Rash; Leukopenia; Internal medicine; Adverse effect; Pharmacokinetics; Dosing; Oncology; Gastroenterology; Pharmacology; Toxicity; Chemotherapy; Cancer; Cisplatin","score_opus":0.010599644717435757,"score_gpt":0.2852261942459808,"score_spread":0.27462654952854504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092652143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671,0.000016028413,0.000013064422,0.0007334137,0.000022866727,0.0018268237,0.000053434564,0.000022008511,0.0006023597],"genre_scores_gemma":[0.9960212,0.0000011176966,0.0029402887,0.0001484177,0.000018854937,0.00011473432,0.00046724375,0.000017560022,0.00027057185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998863,0.0000322828,0.00033937226,0.00023810244,0.000385893,0.00014137386],"domain_scores_gemma":[0.9990866,0.00009318389,0.00018746433,0.00014932793,0.00031095347,0.00017245034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059954273,0.00015238363,0.0002555408,0.00014663956,0.000046454512,0.000016335247,0.000034132852,0.0000309685,0.000029760318],"category_scores_gemma":[0.00006909965,0.00010835463,0.000014738506,0.0003550652,0.00010666165,0.00022860625,0.000013103408,0.000076124554,0.0000031350514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039727185,0.0037998764,0.9689534,0.000073294555,0.00033734602,0.000011247584,0.010754667,0.00052327954,0.0012743226,0.00033578937,0.0004177804,0.009546287],"study_design_scores_gemma":[0.05846329,0.0043535843,0.9345387,0.00021052553,0.00013458703,0.0000013264627,0.000988509,0.00033055147,0.00058000674,0.00025746034,0.00001898901,0.00012245563],"about_ca_topic_score_codex":0.0008592852,"about_ca_topic_score_gemma":0.00016152607,"teacher_disagreement_score":0.054490574,"about_ca_system_score_codex":0.00007070277,"about_ca_system_score_gemma":0.00035966965,"threshold_uncertainty_score":0.44185737},"labels":[],"label_agreement":null},{"id":"W2093441915","doi":"10.1155/2010/524629","title":"Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?","year":2010,"lang":"en","type":"article","venue":"Chemotherapy Research and Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"Eli Lilly and Company","keywords":"Gemcitabine; Carboplatin; Medicine; Histology; Internal medicine; Lung cancer; Cancer; Pemetrexed; Cisplatin; Chemotherapy; Oncology","score_opus":0.026594891847981243,"score_gpt":0.38960052209256224,"score_spread":0.363005630244581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093441915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922611,0.0002686174,0.00003547296,0.0019830423,0.000081705315,0.0013039756,0.00007444318,0.000026820619,0.003964815],"genre_scores_gemma":[0.9917663,0.0011356724,0.0010169384,0.00021789824,0.000114331946,0.00009716697,0.00008927541,0.000072311515,0.0054901144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983817,0.00008637113,0.00021313697,0.00040915573,0.0004464102,0.00046323036],"domain_scores_gemma":[0.99728715,0.0006824958,0.00021457071,0.00041644866,0.0011166717,0.00028265835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000406904,0.00024683686,0.0004081787,0.00016084664,0.00018575026,0.000045211065,0.00011442852,0.00010584796,0.0007589391],"category_scores_gemma":[0.00010644918,0.00012357286,0.00004030869,0.00045852727,0.000385156,0.000255975,0.000019783754,0.00053038955,0.0000027568597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023993926,0.0016296451,0.9640715,0.00032820564,0.0009154316,0.00005810393,0.0014429354,0.000008076249,0.0051310775,0.000006813397,0.0008852277,0.0015290629],"study_design_scores_gemma":[0.042420268,0.012323708,0.880258,0.00031393472,0.00057440717,0.000034204928,0.0007430786,0.00022449926,0.026610501,0.000014480467,0.03595895,0.0005239722],"about_ca_topic_score_codex":0.0058065336,"about_ca_topic_score_gemma":0.002664313,"teacher_disagreement_score":0.083813496,"about_ca_system_score_codex":0.00015564544,"about_ca_system_score_gemma":0.00071243016,"threshold_uncertainty_score":0.87777805},"labels":[],"label_agreement":null},{"id":"W2093849386","doi":"10.1002/1097-0142(20010815)92:4<830::aid-cncr1389>3.0.co;2-c","title":"Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma","year":2001,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Eli Lilly (Canada); Hôpital Notre-Dame; Royal Victoria Hospital","funders":"","keywords":"Vinorelbine; Gemcitabine; Medicine; Regimen; Internal medicine; Chemotherapy; Gastroenterology; Phases of clinical research; Antimetabolite; Survival rate; Surgery; Oncology; Cisplatin","score_opus":0.016346892051935284,"score_gpt":0.31970922922137857,"score_spread":0.3033623371694433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093849386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97086513,0.010446461,0.0037837431,0.005025575,0.00010138005,0.001599955,0.000058775993,0.00006951558,0.008049463],"genre_scores_gemma":[0.9631419,0.0007341575,0.0053610187,0.0014073988,0.00016605789,0.0006281248,0.000053672265,0.00004817462,0.028459473],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993348,0.00000571703,0.00011246172,0.00023583684,0.00009508217,0.00021610569],"domain_scores_gemma":[0.9995291,0.000028814098,0.000052939184,0.00017510474,0.000095084586,0.00011895178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003483675,0.00014007482,0.00022389955,0.00005512009,0.00007502618,0.000015205099,0.00003197758,0.000025380436,0.00023585613],"category_scores_gemma":[0.0000031062477,0.00009677625,0.00003721111,0.0001330742,0.000045272343,0.000062822066,0.0000068754,0.000048678303,0.0000026446498],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007165548,0.0014554133,0.809782,0.0024042323,0.0031293195,0.00030281095,0.006699912,0.00022919955,0.018334303,0.0014805633,0.07087742,0.07813927],"study_design_scores_gemma":[0.091046885,0.0052971873,0.30380303,0.0007178336,0.007974548,0.00046044734,0.0013811996,0.004698532,0.045761857,0.00051131577,0.5370211,0.0013260673],"about_ca_topic_score_codex":0.0002333355,"about_ca_topic_score_gemma":0.0000662027,"teacher_disagreement_score":0.505979,"about_ca_system_score_codex":0.00015493581,"about_ca_system_score_gemma":0.00019409637,"threshold_uncertainty_score":0.3946421},"labels":[],"label_agreement":null},{"id":"W2097042869","doi":"10.1016/j.lungcan.2004.02.002","title":"Response to ‘is “no treatment” better than radiotherapy and chemotherapy? by L. Debevec’","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Lung cancer; Oncology; Surgery; Internal medicine; Carcinoma","score_opus":0.006875953594191144,"score_gpt":0.3305384188192248,"score_spread":0.32366246522503367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097042869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9269582,0.0059909336,0.00027778622,0.064658575,0.00019457255,0.0008410077,0.00011486627,0.000070375645,0.00089364924],"genre_scores_gemma":[0.8547398,0.004190402,0.0059567117,0.07648018,0.00061981316,0.00094867096,0.000055116187,0.00014538724,0.05686395],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999155,0.000018653482,0.00012730656,0.00031567574,0.00013931777,0.00024404666],"domain_scores_gemma":[0.9994576,0.000025425485,0.000032851738,0.00023783329,0.000046444005,0.0001998662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040346185,0.00019161077,0.00023557611,0.00006455068,0.000087817876,0.00002764378,0.000039103998,0.00006444036,0.0005642673],"category_scores_gemma":[0.0000050420026,0.00014161093,0.00006461994,0.00013211988,0.000035005116,0.000063519925,0.000006262179,0.00004816079,0.000023718605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014310237,0.0013103975,0.26871005,0.00014902596,0.005314992,0.00014548321,0.029870547,0.00005662302,0.17735265,0.00008236198,0.32586294,0.17683469],"study_design_scores_gemma":[0.016993692,0.0016907878,0.06922648,0.00021943699,0.00046654546,0.00003234368,0.00006807224,0.000036581172,0.023382412,0.000054436412,0.8874748,0.00035444478],"about_ca_topic_score_codex":0.0012017696,"about_ca_topic_score_gemma":0.000079523095,"teacher_disagreement_score":0.56161183,"about_ca_system_score_codex":0.0010899199,"about_ca_system_score_gemma":0.00021358386,"threshold_uncertainty_score":0.6178331},"labels":[],"label_agreement":null},{"id":"W2098115324","doi":"10.1158/0008-5472.46.65.1","title":"A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of General Medical Sciences","keywords":"Biology; Molecular biology; Promoter; Allele; Transfection; Genotype; Haplotype; Transcription factor; Gene; Epidermal growth factor receptor; Cell culture; Sp1 transcription factor; Electrophoretic mobility shift assay; Epidermal growth factor; Gene expression; Genetics; Receptor","score_opus":0.09712728811643104,"score_gpt":0.40229234579723866,"score_spread":0.3051650576808076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098115324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435384,0.0006705623,0.000008789165,0.013190131,0.000120080236,0.0007076064,0.00018226053,0.000011475644,0.00075527525],"genre_scores_gemma":[0.9963235,0.00014687516,0.00020965717,0.00029374004,0.0003663275,0.00029537606,0.00007560486,0.000017286093,0.002271613],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987575,0.00012204684,0.00020568848,0.00019877825,0.0004506225,0.0002653634],"domain_scores_gemma":[0.9993525,0.00007280235,0.000045973087,0.00018903805,0.00025644485,0.000083253566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020806788,0.00008228405,0.00015559052,0.00016539638,0.000092772534,0.000010409225,0.00006234433,0.00006121612,0.0017928969],"category_scores_gemma":[0.00006274726,0.00005511648,0.00006694368,0.0004160278,0.00011945761,0.00009668963,0.000045280492,0.00029945595,0.000086160006],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015899873,0.0013476735,0.39669403,0.00031637214,0.0003579751,0.000021788022,0.005129992,0.00002490346,0.42532223,0.00015555734,0.020893252,0.14814623],"study_design_scores_gemma":[0.0038652532,0.0002582225,0.75606185,0.000403373,0.000058312686,0.00002036098,0.00009982218,0.0000640002,0.23146841,0.00030727158,0.007267358,0.00012578384],"about_ca_topic_score_codex":0.0017567943,"about_ca_topic_score_gemma":0.00072918803,"teacher_disagreement_score":0.3593678,"about_ca_system_score_codex":0.00059337786,"about_ca_system_score_gemma":0.00045118784,"threshold_uncertainty_score":0.9991196},"labels":[],"label_agreement":null},{"id":"W2098158939","doi":"10.1093/annonc/mdi126","title":"Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montfort Hospital","funders":"Centre hospitalier régional universitaire de Lille; Centre Hospitalier Universitaire de Nice; Eli Lilly and Company","keywords":"Medicine; Vinorelbine; Docetaxel; Gemcitabine; Internal medicine; Neutropenia; Hazard ratio; Lung cancer; Febrile neutropenia; Phases of clinical research; Chemotherapy; Gastroenterology; Progression-free survival; Cisplatin; Oncology; Confidence interval; Surgery","score_opus":0.15369913740941848,"score_gpt":0.5084618124912188,"score_spread":0.3547626750818003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098158939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744994,0.0021084577,0.00029450338,0.004394644,0.00025478416,0.0036539577,0.0001261889,0.000021153537,0.0016963419],"genre_scores_gemma":[0.9924773,0.00022848032,0.0041186437,0.00076304626,0.00015925957,0.0013052294,0.000045060347,0.000035339162,0.00086763146],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99828535,0.00009377971,0.0006851978,0.00035643042,0.00014788774,0.00043136938],"domain_scores_gemma":[0.99804217,0.0008269189,0.00038620393,0.00033644127,0.00028174312,0.00012652937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041185273,0.0002428732,0.00072102033,0.00018456038,0.00016314146,0.00001280656,0.00012471735,0.000072766336,0.00017818254],"category_scores_gemma":[0.0001709119,0.00015802521,0.00012870948,0.0003548787,0.00008176386,0.00013044012,0.00004633508,0.00019442271,0.0000027228994],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041608732,0.019501306,0.004529182,0.00081963406,0.0028684055,0.005013819,0.025096927,0.0054375683,0.0027889197,0.00011583978,0.009290506,0.88292915],"study_design_scores_gemma":[0.71150386,0.08463067,0.0063897213,0.0010343256,0.013243958,0.0013265194,0.04665241,0.07602853,0.010477176,0.000097572905,0.047248438,0.0013667896],"about_ca_topic_score_codex":0.0008639726,"about_ca_topic_score_gemma":0.0076829214,"teacher_disagreement_score":0.88156235,"about_ca_system_score_codex":0.00020747932,"about_ca_system_score_gemma":0.00082261674,"threshold_uncertainty_score":0.6444081},"labels":[],"label_agreement":null},{"id":"W2098549466","doi":"10.1136/jclinpath-2012-201240","title":"Comparison of molecular testing methods for the detection of <i>EGFR</i> mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Sanger sequencing; Concordance; Molecular biology; Mutation; Lung cancer; Biology; Pyrosequencing; Pathology; Medicine; Gene; Genetics","score_opus":0.07957595431632936,"score_gpt":0.5144353866920599,"score_spread":0.43485943237573055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098549466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82822275,0.0015725553,0.16843653,0.00048334402,0.0003801939,0.0006917834,0.000008996255,0.00000267637,0.00020115585],"genre_scores_gemma":[0.86723787,0.00006871947,0.13242507,0.000096689604,0.00008731746,0.000041713785,0.0000022702354,0.000012054184,0.000028298613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99749607,0.00020826748,0.0019048703,0.0001163107,0.00012298436,0.00015150203],"domain_scores_gemma":[0.99443305,0.0027837395,0.0017835923,0.00016907913,0.00075938087,0.000071157076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011605171,0.00010228747,0.0008655031,0.00012544531,0.000029611476,0.0000030714366,0.00010542294,0.00013499658,0.000022989412],"category_scores_gemma":[0.0010991953,0.00006765178,0.00023072642,0.00021085434,0.000135781,0.000055333498,0.000021730697,0.0002905811,4.7511253e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035214817,0.001097902,0.08212355,0.00028886422,0.00031483988,0.000016803162,0.0014749459,0.004533757,0.8106468,0.00003505598,0.00007002511,0.09904531],"study_design_scores_gemma":[0.009122521,0.0045242994,0.29443595,0.00035750115,0.00238289,0.00007240697,0.0011893474,0.02117182,0.6657305,0.0006578368,0.00022570459,0.00012922945],"about_ca_topic_score_codex":0.00011494793,"about_ca_topic_score_gemma":0.000045801447,"teacher_disagreement_score":0.21231242,"about_ca_system_score_codex":0.000042529744,"about_ca_system_score_gemma":0.00028558477,"threshold_uncertainty_score":0.27587596},"labels":[],"label_agreement":null},{"id":"W2098934955","doi":"10.3747/co.19.1042","title":"Making a Difference with Teamwork","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Teamwork; Lung cancer; Cancer; Intensive care medicine; Oncology; Internal medicine; Management","score_opus":0.14625418518343652,"score_gpt":0.4931591497776985,"score_spread":0.34690496459426196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098934955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9412784,0.00628352,0.0019628378,0.0010951916,0.001387423,0.0004552181,0.0000054757234,0.0000908134,0.047441106],"genre_scores_gemma":[0.99750453,0.00003667127,0.0012522998,0.00016968993,0.00035324367,0.00007233191,0.000014614308,0.000008666289,0.0005879503],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99953085,0.000015165922,0.00007644424,0.00009346592,0.000073471594,0.00021057509],"domain_scores_gemma":[0.99970007,0.000027020911,0.000038921098,0.00010826174,0.000033608638,0.000092131915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034207806,0.00007123712,0.00014118485,0.000034496854,0.000046484558,0.0000034205407,0.000025828078,0.0000321124,0.000119360055],"category_scores_gemma":[0.000012699836,0.000045107114,0.000023255794,0.000079533485,0.00004108524,0.000031688774,0.0000145945305,0.000101344056,0.000056503526],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008633291,0.00082653074,0.6796993,0.000039807688,0.000076708144,0.000008648199,0.0021108733,4.4343668e-7,0.000045939967,0.0015280386,0.0011353015,0.31444204],"study_design_scores_gemma":[0.0016458438,0.00054435723,0.3979299,0.000137162,0.00035453573,0.00012447358,0.00020130609,0.0000123453865,0.00004093719,0.000055992707,0.5988706,0.0000825517],"about_ca_topic_score_codex":0.0000036882705,"about_ca_topic_score_gemma":0.00000569651,"teacher_disagreement_score":0.5977353,"about_ca_system_score_codex":0.00031815283,"about_ca_system_score_gemma":0.00023100807,"threshold_uncertainty_score":0.18394148},"labels":[],"label_agreement":null},{"id":"W2100143077","doi":"10.1053/j.seminoncol.2005.02.013","title":"Redefining Bronchioloalveolar Carcinoma","year":2005,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Histopathology; Adenocarcinoma; Lung cancer; Pathology; Carcinoma; Cancer; Natural history; Lung; Internal medicine","score_opus":0.04757776916274788,"score_gpt":0.44223082909283284,"score_spread":0.394653059930085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100143077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044898803,0.9180972,0.0000016886195,0.00018430107,0.00042506462,0.0007649224,0.000025506304,0.00003825782,0.080418155],"genre_scores_gemma":[0.000053785858,0.9910973,0.0026174162,0.00024255496,0.00044523418,0.0003234574,0.0003604371,0.0000589558,0.004800875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983191,0.00012809299,0.0006001708,0.00045491647,0.00012039886,0.00037731772],"domain_scores_gemma":[0.9989629,0.00026815102,0.00024120662,0.00037840233,0.000030046533,0.00011932246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019702823,0.00032844374,0.0018936355,0.00034976858,0.000051825293,0.0000065234904,0.00012997241,0.0006246105,0.00027254922],"category_scores_gemma":[0.0000868605,0.0002628554,0.00032809665,0.00030494152,0.000086134074,0.000029635357,0.00006796867,0.00061995053,0.0001934778],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012307277,0.00017865216,0.00024601456,0.0016661668,0.00014116138,0.0006255435,0.0002953526,4.294674e-7,1.1976614e-7,0.00012329775,0.0039865137,0.9927244],"study_design_scores_gemma":[0.00085081294,0.00061439,0.00007155326,0.00897438,0.0019517688,0.0010046829,0.00008180929,0.0000020234547,1.7400441e-7,0.000017878921,0.98623836,0.00019217],"about_ca_topic_score_codex":0.00005064555,"about_ca_topic_score_gemma":0.000049329818,"teacher_disagreement_score":0.99253225,"about_ca_system_score_codex":0.0022554772,"about_ca_system_score_gemma":0.0019861,"threshold_uncertainty_score":0.99998236},"labels":[],"label_agreement":null},{"id":"W2100524303","doi":"10.1183/09031936.00097214","title":"BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers","year":2015,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Roche; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Epidemiology; Lung cancer; Internal medicine; Population; Pathological; Observational study; Cancer; Molecular epidemiology; Oncology; Environmental health; Genotype; Genetics","score_opus":0.0410217605262048,"score_gpt":0.36974467377872167,"score_spread":0.32872291325251685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100524303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97355014,0.014774739,0.00009255072,0.0013624616,0.00018314789,0.00017319874,0.000009861017,0.000014500335,0.009839375],"genre_scores_gemma":[0.9963471,0.00021111392,0.00042260098,0.0025812373,0.00018556218,0.0000034030268,0.0000016517222,0.000023020759,0.00022426149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987474,0.0003689882,0.0003371878,0.00016730893,0.0001896527,0.00018943675],"domain_scores_gemma":[0.9992726,0.000036192927,0.00015241883,0.00012919225,0.00011433689,0.00029527379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000730274,0.00012648798,0.00026849203,0.00013996908,0.000042990785,0.000016195592,0.000068292065,0.00003882625,0.000050496994],"category_scores_gemma":[0.00022282654,0.000086933585,0.00006746037,0.00013511749,0.00009060423,0.00009274163,0.000037854003,0.0003042677,0.000003717491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000610789,0.00028577555,0.90869427,0.000086833104,0.00049130677,0.0047406256,0.001513157,0.0005936238,0.010388605,0.00056607206,0.03871911,0.033309862],"study_design_scores_gemma":[0.005398156,0.0007479178,0.9552503,0.00038342905,0.00024954564,0.0003660586,0.00032136202,0.00003220953,0.0011419045,0.00007520692,0.035853717,0.00018017125],"about_ca_topic_score_codex":0.000032585995,"about_ca_topic_score_gemma":0.0000037888224,"teacher_disagreement_score":0.04655608,"about_ca_system_score_codex":0.00014144121,"about_ca_system_score_gemma":0.00022526026,"threshold_uncertainty_score":0.35450488},"labels":[],"label_agreement":null},{"id":"W2100754752","doi":"10.1200/jco.2011.35.3979","title":"Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With<i>EGFR</i>-Activating Mutations","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"Academia Sinica; National Science Council","keywords":"Epidermal growth factor receptor; Cancer research; Mutation; Adenocarcinoma; Medicine; Chromosome; Targeted therapy; Comparative genomic hybridization; Lung cancer; Biology; Oncology; Cancer; Gene; Internal medicine; Genetics","score_opus":0.1195927804389629,"score_gpt":0.45732585793151553,"score_spread":0.33773307749255266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100754752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588454,0.0006098582,0.00013299068,0.0018823086,0.00018493999,0.00035712344,0.00001831977,0.0000063791776,0.0009235403],"genre_scores_gemma":[0.98864967,0.00021886283,0.010442167,0.00029901948,0.00009191586,0.000020217967,0.000008540686,0.000015327123,0.00025426436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977576,0.0002566836,0.0015357775,0.00015626659,0.00013865712,0.00015502378],"domain_scores_gemma":[0.9971716,0.0012019255,0.001087892,0.0001359127,0.00021667234,0.00018603541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004589994,0.00013372004,0.0009851252,0.00022207788,0.00005491136,0.0000059238096,0.0000542601,0.00011586565,0.00007064396],"category_scores_gemma":[0.0005442885,0.00008405752,0.00016177038,0.00013109439,0.00017569282,0.00014703027,0.000018228142,0.00023601617,0.0000012559038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004068826,0.0018206245,0.9763078,0.000024735653,0.0010799275,0.00047443586,0.004512169,0.000030484929,0.00073690974,0.00007144888,0.000029061275,0.010843548],"study_design_scores_gemma":[0.012033721,0.010720738,0.97448367,0.00009586121,0.00073703233,0.00024601005,0.00070040463,0.00014543047,0.00035003154,0.00010501541,0.00031061383,0.000071455324],"about_ca_topic_score_codex":0.00020959372,"about_ca_topic_score_gemma":0.00020651009,"teacher_disagreement_score":0.010772092,"about_ca_system_score_codex":0.00030103856,"about_ca_system_score_gemma":0.0014336018,"threshold_uncertainty_score":0.34277663},"labels":[],"label_agreement":null},{"id":"W2100917720","doi":"10.1097/jto.0b013e31825cca1c","title":"Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Erlotinib; Medicine; Sunitinib; Internal medicine; Adverse effect; Lung cancer; Rash; Pharmacokinetics; Oncology; Pharmacology; Cmax; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.0495951457264359,"score_gpt":0.4846970472410096,"score_spread":0.4351019015145737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100917720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825653,0.011562173,0.00047308358,0.001471054,0.0008736537,0.0023582615,0.000025883248,0.0000047602266,0.0006658657],"genre_scores_gemma":[0.991742,0.0012265356,0.0047852006,0.00013068103,0.00036439736,0.00033861093,0.0000039722154,0.00002345213,0.001385145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986813,0.00011472167,0.0006286584,0.00010765725,0.00016513583,0.00030250443],"domain_scores_gemma":[0.99820894,0.0006187427,0.00062831165,0.00018085702,0.0002389354,0.00012421705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045487258,0.00015773471,0.00070102455,0.00017878869,0.00006828435,0.000005499658,0.0001018699,0.0000490771,0.00005514073],"category_scores_gemma":[0.0000451915,0.000090237234,0.00019815545,0.00018624833,0.000048724578,0.000093735616,0.000011330644,0.0001348166,0.0000016090135],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009750026,0.025542151,0.1767325,0.0006029936,0.0034149978,0.0003164474,0.05747361,0.0024995178,0.0018205228,0.000026145335,0.0012389631,0.7205821],"study_design_scores_gemma":[0.10508416,0.12864353,0.3805861,0.0013427988,0.050084945,0.0015370041,0.16389798,0.0033665835,0.014605731,0.00014234443,0.1498417,0.0008671628],"about_ca_topic_score_codex":0.00012820092,"about_ca_topic_score_gemma":0.00028752442,"teacher_disagreement_score":0.71971494,"about_ca_system_score_codex":0.0010540393,"about_ca_system_score_gemma":0.0009457974,"threshold_uncertainty_score":0.36797678},"labels":[],"label_agreement":null},{"id":"W2101035251","doi":"10.3816/clc.2006.n.022","title":"Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2006,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Epidermal growth factor receptor; Clinical trial; Oncology; Internal medicine; Cancer; Erlotinib Hydrochloride","score_opus":0.05956746420320729,"score_gpt":0.40224162754214093,"score_spread":0.34267416333893364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101035251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682797,0.0027764188,0.00003798172,0.0003892063,0.0035916085,0.0037146965,0.0024009002,0.000013284705,0.00024790716],"genre_scores_gemma":[0.99587876,0.00039966853,0.0002159465,0.00041451197,0.0013369016,0.0010949073,0.00023627501,0.000044025517,0.00037903653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956407,0.00041170148,0.0021204497,0.00066291733,0.00083192106,0.00033229348],"domain_scores_gemma":[0.9948868,0.0028619329,0.0011801077,0.00025120427,0.0006370614,0.00018287155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015202852,0.00031297738,0.0013049104,0.000086844026,0.00010385062,0.000011871885,0.00020642311,0.00020760132,0.00026306894],"category_scores_gemma":[0.0007881542,0.00020212325,0.00022246591,0.00016896617,0.00021469026,0.00014978641,0.000055459703,0.0003770262,9.396616e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021148873,0.0017037414,0.9826997,0.0001991479,0.0007707365,0.0000031457905,0.0005617815,0.0001534733,0.000053299766,0.00002048473,0.010575544,0.001144092],"study_design_scores_gemma":[0.017522853,0.0007245467,0.9758659,0.0006931812,0.0015185676,1.4034477e-7,0.00014728466,0.00020619262,0.000077657955,0.000016787397,0.003010705,0.0002161592],"about_ca_topic_score_codex":0.30543196,"about_ca_topic_score_gemma":0.33038798,"teacher_disagreement_score":0.024956014,"about_ca_system_score_codex":0.001187712,"about_ca_system_score_gemma":0.0035963673,"threshold_uncertainty_score":0.82423466},"labels":[],"label_agreement":null},{"id":"W2101080120","doi":"10.1016/j.jval.2013.03.696","title":"Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Toronto Public Health; Ontario Institute for Cancer Research; University Health Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Internal medicine; Cost effectiveness","score_opus":0.03934213499226,"score_gpt":0.33639221429708416,"score_spread":0.2970500793048242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101080120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911258,0.00014543759,0.00022005773,0.0000705647,0.00006703499,0.008170547,0.000010632709,0.000010655569,0.0001792252],"genre_scores_gemma":[0.9924931,0.000027112634,0.004816468,0.00003326786,0.000006650365,0.002482599,0.00005760115,0.000024819326,0.000058366524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888134,0.00009173922,0.0003358133,0.0002702012,0.00013736486,0.00028355335],"domain_scores_gemma":[0.9989302,0.00048978947,0.00019938794,0.00012892082,0.0001752,0.00007649521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020017342,0.00015471419,0.00037093466,0.00019993847,0.000046621823,0.0000069057387,0.000031397114,0.000040823845,0.000008979455],"category_scores_gemma":[0.000037109214,0.00011169933,0.00001924677,0.00029690482,0.000014908124,0.00011064053,0.00000949166,0.00010025025,3.6325417e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003568476,0.0017509667,0.9668255,0.0008719413,0.000017194921,0.000002261536,0.004760839,0.014374871,0.00005908132,0.0000070225574,0.0000012172915,0.010972284],"study_design_scores_gemma":[0.014929366,0.0045877425,0.9675075,0.0060874615,0.000037049158,5.8819705e-7,0.0002846972,0.0062678484,0.00017485069,0.0000143018615,0.000010004167,0.00009858124],"about_ca_topic_score_codex":0.4801404,"about_ca_topic_score_gemma":0.14711456,"teacher_disagreement_score":0.33302584,"about_ca_system_score_codex":0.0035433103,"about_ca_system_score_gemma":0.0013183092,"threshold_uncertainty_score":0.9265633},"labels":[],"label_agreement":null},{"id":"W2101440707","doi":"10.1016/j.cllc.2015.05.010","title":"A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Regional Municipality of Durham; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; McGill University Health Centre; Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Adverse effect; Hazard ratio; Chemotherapy; Randomized controlled trial; Confidence interval; Cisplatin","score_opus":0.08825096488267198,"score_gpt":0.4698113163662173,"score_spread":0.38156035148354533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101440707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787045,0.004274023,0.00052566343,0.0013659047,0.00030097095,0.014221906,0.000279909,0.000024823736,0.00030227043],"genre_scores_gemma":[0.9850707,0.002303106,0.0027922662,0.0005311354,0.00015312707,0.00653485,0.0001636237,0.00008372777,0.0023674378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972593,0.00021859238,0.0011708931,0.00067342125,0.00031706408,0.00036068526],"domain_scores_gemma":[0.9976923,0.00063787034,0.0005683383,0.00037283349,0.00042720808,0.00030143504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095137843,0.00040409382,0.0019887858,0.00025147712,0.00008101853,0.000046784724,0.00014781853,0.00015552167,0.00012899112],"category_scores_gemma":[0.00009110441,0.0002640594,0.00012486715,0.00046652235,0.00020168695,0.00018806856,0.00003196999,0.00019721105,3.0677884e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9455742,0.011340507,0.025462702,0.00015439338,0.0014637868,0.000020637446,0.0026544088,0.00019872753,0.00011834163,0.000021403217,0.00052621786,0.012464663],"study_design_scores_gemma":[0.9473722,0.026370184,0.0007229449,0.0006465221,0.0014669122,0.000001836864,0.0002948113,0.020924488,0.0009861811,0.00006112944,0.00085447874,0.00029831112],"about_ca_topic_score_codex":0.0035480238,"about_ca_topic_score_gemma":0.012677851,"teacher_disagreement_score":0.024739757,"about_ca_system_score_codex":0.0011856154,"about_ca_system_score_gemma":0.0023277514,"threshold_uncertainty_score":0.99998116},"labels":[],"label_agreement":null},{"id":"W2102524820","doi":"10.1200/jco.2013.54.6002","title":"Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase–Positive, Non–Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Lymphoma; Cancer research; Anaplastic large-cell lymphoma; Internal medicine","score_opus":0.076843681284141,"score_gpt":0.47441961923952775,"score_spread":0.39757593795538676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102524820","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18341762,0.0033258884,0.013443631,0.7715974,0.010573186,0.009693329,0.0009733418,0.00002269853,0.0069529177],"genre_scores_gemma":[0.09476267,0.0016672184,0.0026760867,0.8735749,0.017273696,0.00086133165,0.00024221856,0.0002333776,0.008708488],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955356,0.0007950853,0.002298541,0.00044065982,0.00045975068,0.00047034616],"domain_scores_gemma":[0.97650474,0.018623317,0.0028381024,0.00037900393,0.0013196858,0.0003351759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023971633,0.00037690715,0.0029126701,0.00022217003,0.00014428057,0.000020421527,0.00035236226,0.0010866739,0.00011354096],"category_scores_gemma":[0.0016511211,0.00023277465,0.0011303576,0.00020071292,0.00023901399,0.000052446612,0.00010548378,0.0012479101,0.000020161557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009470657,0.00078949885,0.011252665,0.0015581949,0.002947057,0.0006564335,0.00024959905,0.00016003725,0.000098203804,0.0000060941466,0.9086634,0.06414818],"study_design_scores_gemma":[0.02190727,0.01579066,0.029605284,0.0031547297,0.008610655,0.000204187,0.00002703592,0.00030546566,0.0007459354,0.000025867239,0.9193712,0.00025171097],"about_ca_topic_score_codex":0.00009531212,"about_ca_topic_score_gemma":0.000109017274,"teacher_disagreement_score":0.10197752,"about_ca_system_score_codex":0.0015100088,"about_ca_system_score_gemma":0.0040512127,"threshold_uncertainty_score":0.9492275},"labels":[],"label_agreement":null},{"id":"W2102625113","doi":"10.1200/jco.2013.51.1816","title":"Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":364,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; EMD Serono; Varian Medical Systems; F. Hoffmann-La Roche; Genentech; AstraZeneca; Celgene; Quest Diagnostics","keywords":"Medicine; Gefitinib; Internal medicine; Hazard ratio; Placebo; Lung cancer; Chemotherapy; Oncology; Cancer; Gastroenterology; Surgery; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.1397857239891092,"score_gpt":0.5090334062363405,"score_spread":0.3692476822472313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102625113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98095375,0.00032245816,0.00000526888,0.0068275835,0.0017298767,0.0011915666,0.000014463539,0.0000046253854,0.008950402],"genre_scores_gemma":[0.9975169,0.00020118267,0.00046830793,0.000519191,0.00046813412,0.000035889454,0.000002447949,0.000013802022,0.0007741644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645114,0.0005117533,0.0022845888,0.00018338456,0.00034305686,0.00022606262],"domain_scores_gemma":[0.9943362,0.0028795602,0.0017042189,0.00027996599,0.0006007387,0.00019931412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014960807,0.0001262325,0.0010622226,0.00010969678,0.000045836183,0.0000075217818,0.00023791124,0.00019325873,0.0001434554],"category_scores_gemma":[0.0019482198,0.00007270769,0.00028154344,0.0002680788,0.00013193513,0.00006717138,0.000072561816,0.0008490974,0.0000089543655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054783624,0.014333377,0.83345914,0.00012935264,0.0023225788,0.0005423058,0.0040790057,0.00047853394,0.00081257307,0.000026228989,0.03550726,0.053526007],"study_design_scores_gemma":[0.08298543,0.013248016,0.8957963,0.00017815706,0.0009809091,0.00002326939,0.0012855395,0.00029747875,0.00008288669,0.00002727567,0.0050206757,0.0000740454],"about_ca_topic_score_codex":0.0019677004,"about_ca_topic_score_gemma":0.0025764757,"teacher_disagreement_score":0.06233716,"about_ca_system_score_codex":0.00035269637,"about_ca_system_score_gemma":0.0025041676,"threshold_uncertainty_score":0.44422856},"labels":[],"label_agreement":null},{"id":"W2103498729","doi":"10.1016/j.ijrobp.2010.07.1180","title":"Outcomes of Bimodality and Trimodality Therapy in Patients with Stage III Non-small Cell Lung Cancer (NSCLC)","year":2010,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Radiation therapy; Stage (stratigraphy); Univariate analysis; Chemotherapy; Lung cancer; Oncology; Multivariate analysis; Survival analysis; Retrospective cohort study; Subgroup analysis; Gastroenterology; Surgery; Confidence interval","score_opus":0.012026938151247772,"score_gpt":0.34278933933767497,"score_spread":0.3307624011864272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103498729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613947,0.00014426358,0.0011403374,0.0008699268,0.0008170205,0.00040187547,0.0001262321,0.000007695742,0.0003531584],"genre_scores_gemma":[0.9978625,0.00026097574,0.0010929325,0.00039210395,0.0002485216,0.000018142146,0.000054589458,0.000015307325,0.00005489103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888194,0.000071070186,0.0005363757,0.00016999287,0.00020005277,0.0001405436],"domain_scores_gemma":[0.9981153,0.00017405988,0.0008278883,0.00012280012,0.0006709306,0.00008902538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026629175,0.00015176935,0.00045541493,0.00013220625,0.000034129655,0.000010443122,0.00014405837,0.0001405235,0.00004471037],"category_scores_gemma":[0.00004403936,0.000106405016,0.00009546925,0.00010878522,0.00013300363,0.00016595105,0.000023651915,0.00035167497,6.662316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073841045,0.0009724731,0.9684312,0.000010309605,0.00054397556,0.0000050523695,0.0006991513,0.00007180926,0.0011801433,0.00074374507,0.000033442488,0.026570292],"study_design_scores_gemma":[0.019949913,0.00087427493,0.97606146,0.000031021573,0.00012692064,0.0000029674632,0.00004794064,0.00023245388,0.0016028297,0.0003718996,0.0006044848,0.0000938513],"about_ca_topic_score_codex":0.00033550916,"about_ca_topic_score_gemma":0.00008692907,"teacher_disagreement_score":0.026476441,"about_ca_system_score_codex":0.00031088994,"about_ca_system_score_gemma":0.00082578463,"threshold_uncertainty_score":0.43390706},"labels":[],"label_agreement":null},{"id":"W2104258423","doi":"10.1016/j.lungcan.2012.10.007","title":"Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer","year":2012,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"European Society for Medical Oncology","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Cancer; Overall survival; Progression-free survival","score_opus":0.055567186221244326,"score_gpt":0.4467526399012807,"score_spread":0.3911854536800364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104258423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014787668,0.9750661,0.000041283427,0.000088626715,0.0016087659,0.0062917504,0.00093808427,0.00003149384,0.001146189],"genre_scores_gemma":[0.006177458,0.9879559,0.00042965144,0.00006157907,0.00032578618,0.0035142426,0.0005528565,0.00015328333,0.0008292233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954943,0.00045868466,0.0018909752,0.0008002466,0.0006160614,0.000739709],"domain_scores_gemma":[0.9972773,0.00031462286,0.0012168738,0.0007246021,0.00015180634,0.00031477615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009837737,0.00076389866,0.004390813,0.00049623934,0.00005210018,0.000025451794,0.00028505732,0.00044314182,0.00046711654],"category_scores_gemma":[0.00013566163,0.00058378954,0.00050473434,0.00065266946,0.00007279629,0.00015473817,0.00017245642,0.00055778713,0.0000014415725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011133556,0.0020683233,0.021554431,0.057911098,0.0029483652,0.0002846614,0.0012512954,0.00007083147,0.00026346318,0.000059335696,0.00083197915,0.91164285],"study_design_scores_gemma":[0.1973803,0.0009717964,0.009540208,0.21718617,0.054503627,0.000030467894,0.00032326978,0.00083941745,0.00092373847,0.00006182448,0.5142243,0.004014894],"about_ca_topic_score_codex":0.0028632767,"about_ca_topic_score_gemma":0.0014887626,"teacher_disagreement_score":0.90762794,"about_ca_system_score_codex":0.0013320977,"about_ca_system_score_gemma":0.0019525781,"threshold_uncertainty_score":0.9996613},"labels":[],"label_agreement":null},{"id":"W2104748005","doi":"10.1200/jco.2009.24.3030","title":"Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Oncology; Internal medicine; Biomarker; Hazard ratio; Epidermal growth factor receptor; KRAS; Cancer; Confidence interval; Biology; Colorectal cancer","score_opus":0.12122439436534593,"score_gpt":0.490069456183446,"score_spread":0.36884506181810006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104748005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81279683,0.005029476,0.00011056207,0.17714004,0.0010080634,0.0030650578,0.000292911,0.000007282604,0.0005498023],"genre_scores_gemma":[0.6755992,0.014041041,0.0021429576,0.2910148,0.014183404,0.00021293339,0.0015624062,0.00014645128,0.0010967684],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99362993,0.0010904528,0.0041783825,0.0004306356,0.00038528323,0.00028528637],"domain_scores_gemma":[0.9891506,0.0052449717,0.0044774604,0.0006299021,0.00029973814,0.00019734915],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024969308,0.00035221598,0.004883724,0.00016136357,0.00002962682,0.000020101652,0.0005057906,0.0008673124,0.00008355481],"category_scores_gemma":[0.0015459047,0.0001725228,0.00054125057,0.00014022653,0.0004005752,0.0000910666,0.00009693721,0.0027376944,6.2514374e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8106689,0.0031454663,0.019508561,0.00015206989,0.0071682786,0.0055068927,0.00038561376,0.0000120139275,0.000011817388,0.0000014233051,0.14404379,0.009395188],"study_design_scores_gemma":[0.91934365,0.010500534,0.0017220643,0.0010022788,0.020149916,0.00008685639,0.000045277775,0.00019603879,0.000010080022,0.000019256966,0.0467663,0.00015776789],"about_ca_topic_score_codex":0.0010429894,"about_ca_topic_score_gemma":0.00051152374,"teacher_disagreement_score":0.13719755,"about_ca_system_score_codex":0.00020052852,"about_ca_system_score_gemma":0.0025259387,"threshold_uncertainty_score":0.99956304},"labels":[],"label_agreement":null},{"id":"W2104963800","doi":"10.1016/s0169-5002(00)00116-1","title":"Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Autocrine signalling; Epidermal growth factor receptor; TGF alpha; Cancer research; Epidermal growth factor; Adenocarcinoma; Transforming growth factor; Signal transduction; Medicine; Biology; Receptor; Internal medicine; Cancer; Cell biology","score_opus":0.013661247539169781,"score_gpt":0.3215154356152042,"score_spread":0.3078541880760344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104963800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99273354,0.003836663,0.00009649895,0.00054370175,0.00009022484,0.00074719614,0.00052443997,0.00002107713,0.0014066898],"genre_scores_gemma":[0.9977569,0.0010151161,0.000251698,0.00013342801,0.000058051148,0.000101952115,0.00006533025,0.000028105569,0.00058940676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986851,0.00003756031,0.00044679732,0.00028741956,0.00030184473,0.00024126878],"domain_scores_gemma":[0.99941677,0.00007496043,0.00012280283,0.0001477975,0.00011018641,0.00012750778],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004635032,0.00018652914,0.00040424478,0.00017800106,0.00006387787,0.000008439626,0.00006482637,0.000115252325,0.0026162372],"category_scores_gemma":[0.00001566184,0.00015620976,0.00009172868,0.00021601285,0.000082048886,0.00021997545,0.000007704024,0.00015872823,0.0000022919646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028159152,0.00020528726,0.9451855,0.00079852197,0.00022357721,0.000011564914,0.014140037,0.000016495123,0.033011053,0.000066976565,0.0005581494,0.0055012773],"study_design_scores_gemma":[0.0045250407,0.0001657599,0.7503831,0.0008129383,0.0003437298,0.000009931118,0.00044142015,0.00019041085,0.24262828,0.000046997695,0.00024956113,0.00020283484],"about_ca_topic_score_codex":0.0019931926,"about_ca_topic_score_gemma":0.000106371306,"teacher_disagreement_score":0.20961723,"about_ca_system_score_codex":0.00026650282,"about_ca_system_score_gemma":0.00024615272,"threshold_uncertainty_score":0.9982955},"labels":[],"label_agreement":null},{"id":"W2105026490","doi":"10.1200/jco.2007.14.8924","title":"Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":665,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Erlotinib; KRAS; Medicine; Epidermal growth factor receptor; Hazard ratio; Fluorescence in situ hybridization; EGFR inhibitors; Internal medicine; Oncology; Erlotinib Hydrochloride; Cancer research; Cancer; Biology; Gene; Colorectal cancer; Genetics; Confidence interval","score_opus":0.1692448192514435,"score_gpt":0.5560504929225468,"score_spread":0.3868056736711033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105026490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919086,0.000641709,0.0000055974456,0.004614903,0.001031743,0.0006178043,0.000053431377,0.00000164819,0.0011245639],"genre_scores_gemma":[0.9965467,0.00058845023,0.0010721035,0.0013167827,0.00030123498,0.000012963007,0.0000022979618,0.000009676074,0.00014978797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923346,0.001571964,0.0050948523,0.00019845704,0.0006419923,0.00015812744],"domain_scores_gemma":[0.9893016,0.0066954037,0.0027122828,0.00013787576,0.00080314314,0.00034968258],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012268959,0.000121128614,0.0022598053,0.00020821992,0.000028778271,0.0000014692143,0.00012576177,0.00019340047,0.000054287848],"category_scores_gemma":[0.019187357,0.0000869868,0.00029688797,0.0002891482,0.00031346182,0.000083289524,0.00004473938,0.00036684232,4.0137502e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06258963,0.006076464,0.89022267,0.000038271053,0.0023679321,0.00034293983,0.0008674911,0.00008974974,0.0024017163,0.00006733015,0.009072067,0.025863726],"study_design_scores_gemma":[0.023683967,0.016456995,0.9189883,0.00016765705,0.0006069365,0.00009771717,0.0007349998,0.000009943181,0.00019982592,0.0000938048,0.038885757,0.000074114505],"about_ca_topic_score_codex":0.035384122,"about_ca_topic_score_gemma":0.097252354,"teacher_disagreement_score":0.061868228,"about_ca_system_score_codex":0.0002974233,"about_ca_system_score_gemma":0.016725805,"threshold_uncertainty_score":0.98907447},"labels":[],"label_agreement":null},{"id":"W2105660133","doi":"10.1093/annonc/mdv208","title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Oncology; Lung cancer; Internal medicine; Cancer","score_opus":0.05669316549900459,"score_gpt":0.41655574449152644,"score_spread":0.35986257899252183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105660133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883034,0.0005223457,0.00001290939,0.0010268375,0.000033964086,0.00059767766,0.00001844974,0.000008765121,0.009475608],"genre_scores_gemma":[0.99261147,0.000040671282,0.0061983545,0.00049542496,0.000012988849,0.000091336085,0.000013866097,0.000011962844,0.0005239493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941105,0.000018577051,0.0001572684,0.00016686675,0.000096889875,0.0001493235],"domain_scores_gemma":[0.99932456,0.00011637475,0.00006744252,0.00010209699,0.00023869667,0.00015081593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006393471,0.00009101462,0.00024622577,0.00010777447,0.000016974935,0.0000026036553,0.000022470758,0.000042280168,0.00003568549],"category_scores_gemma":[0.00006812653,0.00006091162,0.000014503648,0.00017663515,0.000024109782,0.000044745473,0.000018430666,0.000025058278,0.000009845245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014318576,0.00091988733,0.5012333,0.000013557964,0.00008585349,0.000021930991,0.0005352626,0.0001177842,0.00022684083,0.0000015821638,0.0011334333,0.49427876],"study_design_scores_gemma":[0.017360108,0.01694502,0.9460138,0.00025267643,0.000212403,0.000005116744,0.00007963646,0.00032643502,0.00060803443,0.000027425343,0.018035816,0.00013354473],"about_ca_topic_score_codex":0.0003021957,"about_ca_topic_score_gemma":0.00008698539,"teacher_disagreement_score":0.4941452,"about_ca_system_score_codex":0.00018672502,"about_ca_system_score_gemma":0.0003501284,"threshold_uncertainty_score":0.24839038},"labels":[],"label_agreement":null},{"id":"W2105738161","doi":"10.1177/1758834010374727","title":"Highlights of the 2nd European Lung Cancer Conference","year":2010,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine","score_opus":0.015730350520810843,"score_gpt":0.41357133399359536,"score_spread":0.3978409834727845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105738161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68012226,0.018897275,0.0014582255,0.06461581,0.0052772965,0.001303406,0.000018489825,0.00007816899,0.22822908],"genre_scores_gemma":[0.9938077,0.00264184,0.00034220546,0.002406601,0.00019011114,0.000042332405,0.0000028339934,0.000012373207,0.00055404415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895614,0.0001223522,0.00027426257,0.00016884875,0.00029104052,0.00018734687],"domain_scores_gemma":[0.9993184,0.00015835877,0.0001127131,0.00023524842,0.000068550326,0.000106686515],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000246713,0.00009821521,0.0002704939,0.000038651906,0.000044580047,0.0000021665453,0.0002097915,0.00009941253,0.0016035985],"category_scores_gemma":[0.00007086072,0.000053873526,0.00005027414,0.00015923027,0.00048122247,0.000050838196,0.000044451448,0.00041434952,0.0000051638463],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001850354,0.0006290051,0.043428726,0.00009829992,0.00015915117,0.000104290695,0.0018760035,0.000010771383,0.0037960391,0.029298503,0.00016681655,0.9202474],"study_design_scores_gemma":[0.0047841268,0.00037102908,0.092026696,0.00029189064,0.00032151482,0.000090162255,0.0001881184,0.0006066809,0.0015005053,0.002416082,0.89726305,0.00014013246],"about_ca_topic_score_codex":0.000061080755,"about_ca_topic_score_gemma":0.0010242391,"teacher_disagreement_score":0.92010725,"about_ca_system_score_codex":0.00009049444,"about_ca_system_score_gemma":0.0006660393,"threshold_uncertainty_score":0.99930906},"labels":[],"label_agreement":null},{"id":"W2106275780","doi":"10.1200/jco.2009.22.3370","title":"Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Gefitinib; KRAS; Epidermal growth factor receptor; Internal medicine; Oncology; Lung cancer; Rash; Response Evaluation Criteria in Solid Tumors; Regimen; Stage (stratigraphy); Progressive disease; Cancer; Clinical trial; Phases of clinical research; Chemotherapy; Colorectal cancer","score_opus":0.11865377465017504,"score_gpt":0.572227637953893,"score_spread":0.45357386330371796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106275780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896127,0.000592726,0.000049548526,0.0028993515,0.0008200534,0.0008407116,0.000012488242,0.000004852669,0.0051675895],"genre_scores_gemma":[0.99418014,0.00072133564,0.0011652807,0.0017823608,0.0007577107,0.0000137238,0.0000026333512,0.000011375877,0.001365411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950146,0.0004827532,0.003767366,0.00023780017,0.00028322884,0.00021426036],"domain_scores_gemma":[0.99598235,0.0010650856,0.0019071589,0.00020404933,0.0005197617,0.00032160294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024200606,0.00015092494,0.0017997735,0.00014251668,0.000045984234,0.0000050477015,0.0001461963,0.00027379324,0.00021432039],"category_scores_gemma":[0.0008595006,0.000101759084,0.0003791685,0.00019123612,0.00009868479,0.00010171051,0.000037267906,0.0010284997,0.0000021299525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009752083,0.14669526,0.6223377,0.00004788273,0.001191096,0.0016741968,0.0047869068,0.00021548569,0.00016034207,0.000035654863,0.0029762553,0.21012713],"study_design_scores_gemma":[0.109049916,0.23641284,0.6434891,0.00020033821,0.0019203603,0.00002846646,0.002257097,0.00039253788,0.00008591738,0.000025975703,0.006014386,0.0001230152],"about_ca_topic_score_codex":0.00010799614,"about_ca_topic_score_gemma":0.00031401863,"teacher_disagreement_score":0.21000412,"about_ca_system_score_codex":0.00020405973,"about_ca_system_score_gemma":0.0030897772,"threshold_uncertainty_score":0.5481132},"labels":[],"label_agreement":null},{"id":"W2107113060","doi":"10.3747/co.21.2148","title":"Relationship of Thyroid Transcription Factor 1 to EGFR Status in Non-Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"University of British Columbia","keywords":"Medicine; Epidermal growth factor receptor; Immunohistochemistry; Lung cancer; Thyroid Transcription Factor 1; Internal medicine; Oncology; Thyroid; Lung; Pathology; Cancer; Adenocarcinoma","score_opus":0.07227713090769651,"score_gpt":0.4248366959866894,"score_spread":0.3525595650789929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107113060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893926,0.0017040535,0.00232673,0.00083525735,0.0008491309,0.0007098079,0.000046609188,0.000017210457,0.0041185953],"genre_scores_gemma":[0.99859124,0.00016425844,0.00045742348,0.00010875967,0.000106235406,0.0001884003,0.000059506216,0.000012205852,0.00031199591],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992062,0.000054258137,0.00025287792,0.00018346887,0.00009163397,0.00021154915],"domain_scores_gemma":[0.99949265,0.00008640342,0.000074442105,0.00013583618,0.00008336544,0.00012731619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007341832,0.00009676849,0.00024462614,0.00016414563,0.000028525066,0.0000030880801,0.00004099234,0.00007495756,0.00011577022],"category_scores_gemma":[0.000042587817,0.00008368302,0.0000512186,0.00019068526,0.00002329252,0.000037821068,0.0000094045745,0.00014709658,0.0000146632865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012728554,0.0007002509,0.9395353,0.0002620729,0.000027655047,0.0000018709055,0.005899353,0.0001394096,0.0061517754,0.0002759226,0.0013976902,0.045481417],"study_design_scores_gemma":[0.0045175552,0.000721831,0.94212216,0.0001334114,0.00023787374,0.0000014135709,0.00021667413,0.0005557101,0.0009790572,0.000057366324,0.050355725,0.000101249025],"about_ca_topic_score_codex":0.00025354748,"about_ca_topic_score_gemma":0.00062886043,"teacher_disagreement_score":0.048958033,"about_ca_system_score_codex":0.0006073102,"about_ca_system_score_gemma":0.00030708272,"threshold_uncertainty_score":0.34124947},"labels":[],"label_agreement":null},{"id":"W2107468161","doi":"10.3389/fonc.2015.00020","title":"The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine","year":2015,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Oncology; Personalized medicine; Internal medicine; Cancer; Precision medicine; Bioinformatics; Pathology; Biology","score_opus":0.02680968617823263,"score_gpt":0.3754791561056938,"score_spread":0.3486694699274612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107468161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83166873,0.12958708,0.0028057056,0.015512375,0.0026668059,0.0027073706,0.000040912677,0.000014988576,0.014996049],"genre_scores_gemma":[0.9201394,0.0233887,0.036648043,0.000537139,0.0003182565,0.0005678095,0.000056719346,0.000052899428,0.01829104],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991121,0.000073919386,0.00035674137,0.00014770174,0.00012545445,0.00018406237],"domain_scores_gemma":[0.99938947,0.00011183108,0.00015823392,0.00016010639,0.000072303395,0.00010806091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015539573,0.00011252866,0.0005886829,0.000120569166,0.000015253176,0.0000011259231,0.000065302556,0.000053545795,0.000046569345],"category_scores_gemma":[0.00003728526,0.00006626756,0.00005566735,0.00023688147,0.00016585801,0.00001857897,0.000007773009,0.00008089693,5.664169e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029205878,0.0024386763,0.5939481,0.0002073327,0.0011563841,0.00021724803,0.09373249,0.0004145857,0.00044102102,0.00019894514,0.07106268,0.23326196],"study_design_scores_gemma":[0.20490178,0.028638579,0.11508607,0.0012781019,0.006786551,0.000052914012,0.070514776,0.011297038,0.0031216156,0.0024513465,0.5553231,0.00054812356],"about_ca_topic_score_codex":0.005871556,"about_ca_topic_score_gemma":0.0024495863,"teacher_disagreement_score":0.4842604,"about_ca_system_score_codex":0.0012141163,"about_ca_system_score_gemma":0.0020432018,"threshold_uncertainty_score":0.88760746},"labels":[],"label_agreement":null},{"id":"W2108457914","doi":"10.1158/1055-9965.epi-07-0470","title":"A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies","year":2008,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Massachusetts General Hospital","keywords":"Observational study; Medicine; Data quality; Quality assurance; Exact test; Clinical trial; Data collection; Intensive care medicine; Oncology; Internal medicine; Statistics; Pathology","score_opus":0.26249248259935504,"score_gpt":0.4849340158107057,"score_spread":0.22244153321135068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108457914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9310423,0.054970425,0.00024429517,0.011875029,0.00050777505,0.001195273,0.00007583165,0.000040925803,0.000048145575],"genre_scores_gemma":[0.9923295,0.0036965278,0.0018321967,0.000918976,0.00006537109,0.00073064526,0.00011818814,0.000013553729,0.00029506473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781376,0.00061772176,0.0008313502,0.00035667125,0.00016402843,0.00021645632],"domain_scores_gemma":[0.99686086,0.0021311778,0.0005258406,0.0002464827,0.0001579996,0.00007764507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009018955,0.0002036672,0.0007805466,0.000055267737,0.00019220701,0.0000022761412,0.00007466225,0.00008261959,0.000037726684],"category_scores_gemma":[0.00068499683,0.000119424985,0.00022396406,0.000097797296,0.0004055134,0.00006190478,0.00004863756,0.00008098978,0.0000021944688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017358953,0.00010882976,0.97870606,0.0002083465,0.005276975,0.000002705629,0.0004307462,0.000005900901,0.0009423092,0.0002132681,0.0010464184,0.012884859],"study_design_scores_gemma":[0.0021556688,0.00014021194,0.9942308,0.00019618485,0.0012935833,0.0000069469406,0.0006180736,0.0001224851,0.00017977854,0.0006457996,0.00030669518,0.00010375949],"about_ca_topic_score_codex":0.00058715715,"about_ca_topic_score_gemma":0.0000717665,"teacher_disagreement_score":0.061287176,"about_ca_system_score_codex":0.000257437,"about_ca_system_score_gemma":0.00019614348,"threshold_uncertainty_score":0.48700094},"labels":[],"label_agreement":null},{"id":"W2108598528","doi":"10.1016/j.currproblcancer.2009.10.002","title":"Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions","year":2009,"lang":"en","type":"review","venue":"Current Problems in Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Gefitinib; In vivo; Epidermal growth factor receptor; Medicine; Apoptosis; Pharmacology; Lapatinib; IC50; In vitro; Epidermal growth factor; Prodrug; Growth inhibition; Receptor; Cancer research; Biochemistry; Cancer; Internal medicine; Chemistry; Biology; Trastuzumab; Breast cancer","score_opus":0.05871859868774859,"score_gpt":0.41055215005244916,"score_spread":0.35183355136470057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108598528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029880957,0.9899466,0.000005108813,0.00034261987,0.005853697,0.0027035384,0.0007391651,0.00009768778,0.0002816738],"genre_scores_gemma":[0.0000142339995,0.99390954,0.00006886526,0.000025480322,0.0032347238,0.0017848985,0.00071969785,0.00007374851,0.0001688279],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997321,0.00010787295,0.0008502758,0.0007900858,0.00031971885,0.0006110615],"domain_scores_gemma":[0.99872905,0.0000674408,0.00038700862,0.0003153609,0.00014674416,0.0003544205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008623236,0.00064506015,0.0015535237,0.00045387607,0.00012488062,0.000060853177,0.00009760802,0.00025814906,0.0002759462],"category_scores_gemma":[0.000030475681,0.00047686393,0.00034295337,0.0006819577,0.00008067344,0.00018907567,0.000057560006,0.001033939,0.000026695381],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004876148,0.00040048402,0.00084526767,0.015832797,0.00017886655,0.0000019090396,0.00041743775,3.3244848e-7,1.5157978e-7,0.000067424495,0.004783707,0.97746676],"study_design_scores_gemma":[0.00092637376,0.00010701092,0.00054543366,0.035112765,0.0013144485,0.000011183543,0.000014179115,8.720379e-7,5.727559e-7,0.00005688081,0.9614911,0.00041914583],"about_ca_topic_score_codex":0.00014145234,"about_ca_topic_score_gemma":0.00009572206,"teacher_disagreement_score":0.9770476,"about_ca_system_score_codex":0.0016423812,"about_ca_system_score_gemma":0.001401074,"threshold_uncertainty_score":0.9997683},"labels":[],"label_agreement":null},{"id":"W2108603842","doi":"10.3747/co.19.1058","title":"The Role of Molecular Pathology in Non-Small-Cell Lung Carcinoma—Now and in the Future","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"AstraZeneca; Pfizer; Amgen","keywords":"Anaplastic lymphoma kinase; Cancer research; Medicine; Epidermal growth factor receptor; Tyrosine kinase; Fusion gene; Lung cancer; Carcinoma; Receptor tyrosine kinase; Targeted therapy; Pathology; Gene; Bioinformatics; Oncology; Biology; Internal medicine; Cancer; Receptor; Genetics","score_opus":0.017205219934748252,"score_gpt":0.35671406677642836,"score_spread":0.3395088468416801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108603842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93603545,0.05894435,0.00001090395,0.001260415,0.00039329458,0.00041555756,0.0000034295629,0.0000025970792,0.0029339811],"genre_scores_gemma":[0.9986943,0.0008583872,0.000055355744,0.00011527781,0.00013280315,0.000106069965,0.000011629015,0.0000057375732,0.000020467802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937934,0.00011244724,0.00015121269,0.00009805433,0.000055166052,0.00020375637],"domain_scores_gemma":[0.9996373,0.00009168407,0.000055056214,0.00015345858,0.000024485511,0.000038028666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021259423,0.00007349731,0.00016102158,0.000052016076,0.000032453787,0.0000026005155,0.000065448236,0.000068235,0.000006017976],"category_scores_gemma":[0.000010577677,0.00003999211,0.000028342054,0.00010494556,0.000067889414,0.000019057368,0.000028955548,0.00018011921,0.0000024507117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004877111,0.0005453817,0.951733,0.000045028493,0.000012970977,0.000030836993,0.005142127,0.0000013892128,0.0013436081,0.0005294343,0.000244246,0.040323194],"study_design_scores_gemma":[0.002475041,0.0002497907,0.91115075,0.000022563156,0.00015963556,0.000074411684,0.0050706333,0.0000922693,0.00067467714,0.00020125396,0.079769805,0.000059186375],"about_ca_topic_score_codex":0.000014912346,"about_ca_topic_score_gemma":0.00018029015,"teacher_disagreement_score":0.07952556,"about_ca_system_score_codex":0.00008956112,"about_ca_system_score_gemma":0.000097379285,"threshold_uncertainty_score":0.16308308},"labels":[],"label_agreement":null},{"id":"W2109142777","doi":"10.1158/1078-0432.ccr-05-1798","title":"Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Tolerability; Adverse effect; Medicine; Internal medicine; Toxicity; Clinical trial; Oncology; Database","score_opus":0.34036259393371626,"score_gpt":0.621832050974023,"score_spread":0.2814694570403068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109142777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974011,0.00087837345,0.000008668448,0.0001876609,0.000096878444,0.0012755855,0.000021751413,0.000004203153,0.00012575963],"genre_scores_gemma":[0.9981939,0.0001355112,0.000112066686,0.000030547853,0.000016582397,0.0013133925,0.00006514421,0.000011057202,0.000121770536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964489,0.0007230566,0.0009047092,0.00026347025,0.0014152821,0.0002446294],"domain_scores_gemma":[0.99768597,0.0003396526,0.0001868006,0.0001706616,0.0015615444,0.000055363238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029838963,0.000082390165,0.0003618813,0.00019170542,0.000034654033,0.0000014193698,0.00006974609,0.00007150659,0.00016934298],"category_scores_gemma":[0.0024750065,0.00006450201,0.000052094125,0.0006797822,0.00016483136,0.00009533529,0.000045826437,0.00017791719,0.0000018641124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005234124,0.003179293,0.9829623,0.00009808761,0.0001086449,0.000004829018,0.0019454483,0.00019225216,0.0006253165,0.000008861353,0.0005377135,0.009813835],"study_design_scores_gemma":[0.014855194,0.0008232179,0.97648484,0.0004837974,0.000108223445,6.233642e-8,0.0011713577,0.0018110629,0.0039299815,0.000247392,0.000024735062,0.00006013814],"about_ca_topic_score_codex":0.0023178759,"about_ca_topic_score_gemma":0.0010047534,"teacher_disagreement_score":0.014331781,"about_ca_system_score_codex":0.00056640885,"about_ca_system_score_gemma":0.0005139453,"threshold_uncertainty_score":0.35039505},"labels":[],"label_agreement":null},{"id":"W2109240520","doi":"10.1200/jco.2009.22.9427","title":"Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Queen's University","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Placebo; Clinical trial; Lung cancer; Randomized controlled trial; Oncology; Internal medicine; Clinical endpoint; Double blind; Cancer; Chemotherapy; Cisplatin; Pathology","score_opus":0.20092922610680142,"score_gpt":0.563303123281749,"score_spread":0.3623738971749476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109240520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877349,0.0013326264,0.00015602836,0.0019478195,0.0013477039,0.006096399,0.000008835885,0.00000887192,0.001366812],"genre_scores_gemma":[0.99187875,0.001854395,0.0036764836,0.000676999,0.0012537419,0.000119619,0.0000040795157,0.000028387412,0.00050754653],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.988547,0.0031372078,0.007060495,0.00041954505,0.00051053724,0.00032521124],"domain_scores_gemma":[0.9847415,0.0094756475,0.004628488,0.0002792859,0.00041446797,0.00046062606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023106284,0.0003049809,0.006421109,0.0002481029,0.000044984445,0.000017377795,0.00016639323,0.00047201372,0.00009549483],"category_scores_gemma":[0.004644452,0.00016243942,0.00072090665,0.00029504922,0.00027706253,0.00015385232,0.000031448362,0.0011694635,9.837158e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8863081,0.009931212,0.036069352,0.000040862404,0.0013757406,0.0005214801,0.0006799328,0.000059142414,0.000025148038,0.000013187483,0.00020388268,0.064771995],"study_design_scores_gemma":[0.8935656,0.066981405,0.031385235,0.00027497002,0.0059857867,0.000054100256,0.00085453567,0.0001489636,0.000009559163,0.000044654535,0.0005429805,0.00015218939],"about_ca_topic_score_codex":0.00024577053,"about_ca_topic_score_gemma":0.0013180905,"teacher_disagreement_score":0.06461981,"about_ca_system_score_codex":0.00019408109,"about_ca_system_score_gemma":0.003427204,"threshold_uncertainty_score":0.8008223},"labels":[],"label_agreement":null},{"id":"W2109743880","doi":"10.1158/1078-0432.14aacriaslc-ia10","title":"Abstract IA10: Molecular testing to personalized EGFR and ALK inhibitor therapies in lung cancer.","year":2014,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Anaplastic lymphoma kinase; Lung cancer; Cancer research; Adenocarcinoma; Crizotinib; Targeted therapy; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer; Medicine; Fusion gene; Tyrosine kinase; Fluorescence in situ hybridization; Biology; Pathology; Internal medicine; Gene; Genetics; Chromosome","score_opus":0.1627069123620948,"score_gpt":0.5623998535843598,"score_spread":0.39969294122226506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109743880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97706044,0.006633724,0.000025839468,0.011271182,0.00016652088,0.0008248182,0.000017582712,0.00003108275,0.003968783],"genre_scores_gemma":[0.99501187,0.0007785879,0.0010008245,0.0013067515,0.0005730517,0.0005315931,0.000005838158,0.00003357381,0.0007578953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794346,0.00018648832,0.00040254334,0.00048490686,0.00050497364,0.00047765137],"domain_scores_gemma":[0.9979775,0.0010296819,0.000048653426,0.00024831758,0.00033093977,0.00036490857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015328057,0.00013455162,0.000365265,0.0001595137,0.00013726224,0.000051449322,0.000104092986,0.00010862846,0.00027838035],"category_scores_gemma":[0.0013016458,0.00010604056,0.000068101945,0.00048635033,0.0002473874,0.000059982805,0.000081441365,0.0005620575,0.000014522562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084480434,0.00039765952,0.70512414,0.00038977113,0.00028204685,0.00011167385,0.0016744783,0.000039164228,0.0101126265,0.0005891956,0.004410719,0.27602372],"study_design_scores_gemma":[0.008387451,0.0010015164,0.9420485,0.001571989,0.00013094749,0.0000058092232,0.0005824768,0.00093452015,0.0012626731,0.00063241384,0.043136224,0.0003054658],"about_ca_topic_score_codex":0.0035598462,"about_ca_topic_score_gemma":0.000536131,"teacher_disagreement_score":0.27571827,"about_ca_system_score_codex":0.000338694,"about_ca_system_score_gemma":0.0006074837,"threshold_uncertainty_score":0.53814465},"labels":[],"label_agreement":null},{"id":"W211008619","doi":"10.3978/j.issn.2072-1439.2015.01.53","title":"Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Clovis Oncology","keywords":"Gefitinib; Medicine; Erlotinib; Lung cancer; Epidermal growth factor receptor; Tyrosine kinase; Targeted therapy; Oncology; Cancer research; Internal medicine; Tyrosine-kinase inhibitor; Cancer; Receptor","score_opus":0.016100695681610374,"score_gpt":0.2766067075592,"score_spread":0.26050601187758965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W211008619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371744,0.010928705,0.0000076688575,0.0024899542,0.00045420753,0.0017369485,0.000073253745,0.000026134765,0.00056567456],"genre_scores_gemma":[0.9963801,0.00035272024,0.0005260497,0.000129571,0.00039101893,0.0017855932,0.00003145856,0.000024939265,0.00037855253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989722,0.000028745859,0.00026152443,0.00024461804,0.0001745081,0.00031841802],"domain_scores_gemma":[0.999268,0.00002275558,0.000112987356,0.0001351054,0.00013537322,0.00032575705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011381096,0.00015424509,0.00029699336,0.00014208724,0.000024021214,0.000014450934,0.00005178352,0.00008480921,0.000010883946],"category_scores_gemma":[0.000039230188,0.000120817815,0.000042771346,0.0002473742,0.00006521258,0.000103394515,0.000035882917,0.00011557954,0.0000011326409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020925625,0.00034890353,0.9143506,0.000354765,0.00007984575,0.000030549647,0.0018203995,0.0000021628375,0.00014673756,0.000015906358,0.003412275,0.07922859],"study_design_scores_gemma":[0.0059391186,0.00010984544,0.97213936,0.000112719375,0.00020012206,0.0000063412194,0.0003416824,0.000042116677,0.017397488,0.000008618829,0.0035413401,0.0001612203],"about_ca_topic_score_codex":0.0005592486,"about_ca_topic_score_gemma":0.00016175609,"teacher_disagreement_score":0.079067364,"about_ca_system_score_codex":0.00025206135,"about_ca_system_score_gemma":0.00018062846,"threshold_uncertainty_score":0.49268076},"labels":[],"label_agreement":null},{"id":"W2110202780","doi":"10.1634/theoncologist.2015-0058","title":"Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Body mass index; Lean body mass; Toxicity; Body surface area; Afatinib; Lung cancer; Body surface; Internal medicine; Cancer; Oncology; Gastroenterology; Body weight; Gefitinib","score_opus":0.013567195967992085,"score_gpt":0.29274849743977227,"score_spread":0.27918130147178016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110202780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960229,0.00012217974,0.000037899637,0.0012199002,0.00009246683,0.0013861768,0.00020620535,0.000034331402,0.0008779536],"genre_scores_gemma":[0.99765974,0.000028268272,0.0010494913,0.00015193874,0.000039589144,0.00009579401,0.00022090909,0.000024115065,0.000730133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987655,0.00006840195,0.0002492982,0.0003461445,0.0002517601,0.0003188637],"domain_scores_gemma":[0.9991223,0.00005345519,0.00017364726,0.00017319445,0.00021119272,0.0002661859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001717016,0.0002088956,0.00028278562,0.00006567929,0.00012176056,0.000033221862,0.00006057414,0.00008558928,0.000029507157],"category_scores_gemma":[0.0000453335,0.00014433812,0.00001914682,0.00023878698,0.00012396074,0.00010339526,0.000038380324,0.000299583,0.0000021966996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014580076,0.00064933917,0.9884712,0.0000650006,0.00006197859,0.00002198642,0.0004465843,0.00030070913,0.0055189123,0.000007489024,0.002870218,0.00012856022],"study_design_scores_gemma":[0.012472127,0.0020970416,0.98233455,0.00035193327,0.00018268345,0.000029197688,0.0011737081,0.0005188851,0.00047368638,0.00006698548,0.00010068407,0.00019852415],"about_ca_topic_score_codex":0.0011706772,"about_ca_topic_score_gemma":0.00023958764,"teacher_disagreement_score":0.01101412,"about_ca_system_score_codex":0.0007852288,"about_ca_system_score_gemma":0.00042595775,"threshold_uncertainty_score":0.5885938},"labels":[],"label_agreement":null},{"id":"W2110554273","doi":"10.1186/1476-4598-11-70","title":"Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"Amgen","keywords":"Cisplatin; Docetaxel; Cancer research; Lung cancer; Pharmacology; Biology; Chemotherapy; Oncology; Medicine; Internal medicine","score_opus":0.021690013502050676,"score_gpt":0.31985397601207954,"score_spread":0.29816396251002886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110554273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393696,0.0025993627,0.0018312449,0.00016877362,0.00004024463,0.0009429433,0.0000271676,0.000011855536,0.00044144367],"genre_scores_gemma":[0.99821067,0.0001648779,0.0009043828,0.000098111166,0.000018502833,0.00032091376,0.000019395775,0.000029659752,0.0002334998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991256,0.000029732075,0.0001862306,0.00021862314,0.00017569071,0.00026413795],"domain_scores_gemma":[0.99955004,0.000019734942,0.000108365515,0.00016458124,0.00006706675,0.00009021906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008231053,0.00015967703,0.0003192694,0.00016086383,0.000039889073,0.00000889853,0.000039328243,0.00006186568,0.000045456978],"category_scores_gemma":[0.0000063682046,0.00012403778,0.00003014688,0.00029766734,0.00005015681,0.00019079325,0.000024019797,0.00012970196,3.3380263e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065955234,0.0014163314,0.79576975,0.0006036395,0.00019075835,0.000084189036,0.0025016677,0.003935168,0.19176343,0.000058396563,0.00003959594,0.002977517],"study_design_scores_gemma":[0.021745702,0.0003864072,0.7385138,0.00096303294,0.00064649445,0.000011428358,0.00017717932,0.031866618,0.20522355,0.0000376828,0.000057892932,0.0003701984],"about_ca_topic_score_codex":0.008460261,"about_ca_topic_score_gemma":0.006075532,"teacher_disagreement_score":0.057255942,"about_ca_system_score_codex":0.00027660344,"about_ca_system_score_gemma":0.00019138903,"threshold_uncertainty_score":0.9981425},"labels":[],"label_agreement":null},{"id":"W2110655770","doi":"10.1002/prot.21111","title":"Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations","year":2006,"lang":"en","type":"article","venue":"Proteins Structure Function and Bioinformatics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"T790M; Gefitinib; Mutation; Mutant; Point mutation; Mutagenesis; Molecular dynamics; Computational biology; Biology; Chemistry; Genetics; Epidermal growth factor receptor; Gene; Cancer; Computational chemistry","score_opus":0.018016083637224053,"score_gpt":0.3289903166708865,"score_spread":0.31097423303366245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110655770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830351,0.00004365832,0.0143351145,0.00037700133,0.000039908653,0.00088263844,0.0007803603,0.000025219062,0.00048100727],"genre_scores_gemma":[0.9928367,9.437616e-7,0.0062032836,0.00023494124,0.00003567763,0.000009345804,0.00065868546,0.0000071017903,0.000013301339],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99929166,0.00003403662,0.00027378544,0.00011932671,0.00017714311,0.00010406141],"domain_scores_gemma":[0.9993374,0.000109627304,0.00014784111,0.00016230739,0.0001708498,0.00007201861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000020416292,0.00016878276,0.00023181742,0.00012870312,0.00020329618,0.000047595022,0.000019038634,0.000059135065,0.000032852033],"category_scores_gemma":[0.000033687043,0.000093883726,0.00006471377,0.00023466436,0.000087904125,0.00012507939,0.000019575133,0.00011255355,0.0000012462801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034511576,0.0008799404,0.12883298,0.0006935105,0.008503116,0.000043246786,0.04518431,0.24948081,0.42980903,0.0983387,0.00084351737,0.033939667],"study_design_scores_gemma":[0.0020379685,0.0012021085,0.672985,0.0001075025,0.0008419714,0.000032226482,0.0019610457,0.29828304,0.011493461,0.010740755,0.000040169027,0.00027470835],"about_ca_topic_score_codex":0.00078110513,"about_ca_topic_score_gemma":0.00057584123,"teacher_disagreement_score":0.5441521,"about_ca_system_score_codex":0.00013071846,"about_ca_system_score_gemma":0.00008441931,"threshold_uncertainty_score":0.3828467},"labels":[],"label_agreement":null},{"id":"W2111003603","doi":"10.1016/j.ctrv.2006.12.002","title":"Chemotherapy dose–response relationships in non-small cell lung cancer and implied resistance mechanisms","year":2007,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Canadian Agency for Drugs and Technologies in Health; Élisabeth Bruyère Hospital","funders":"","keywords":"Medicine; Lung cancer; Chemotherapy; Drug resistance; Oncology; Cell; Internal medicine; Cancer research; Biology","score_opus":0.08004728811877747,"score_gpt":0.4160621748165402,"score_spread":0.3360148866977627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111003603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018367867,0.9873037,0.00012041212,0.00031321082,0.0002961966,0.009488107,0.00022636453,0.000054720713,0.0020136386],"genre_scores_gemma":[0.000034830286,0.9701826,0.0023231131,0.00028936123,0.00020650339,0.009913744,0.0002474312,0.00016130644,0.016641142],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637574,0.00033357486,0.001351395,0.0010860307,0.00022474151,0.00062849285],"domain_scores_gemma":[0.99761534,0.0003505071,0.0007701337,0.0008501514,0.000069885034,0.0003439853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006800596,0.001047552,0.0034446367,0.0004628221,0.00019853507,0.000051631174,0.00015351544,0.00045505332,0.00023252754],"category_scores_gemma":[0.00002564774,0.0007106308,0.0006534727,0.0008150166,0.00006569666,0.00008594156,0.000031912834,0.00046959092,0.00003951874],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031903642,0.000363999,0.000581493,0.018404486,0.0006395915,0.0001024246,0.00074996566,7.8813997e-7,0.000007248003,0.00006318715,0.001418811,0.977349],"study_design_scores_gemma":[0.0039561363,0.00017531685,0.00084589055,0.03149529,0.0061431252,0.000018551664,0.00003290909,0.0000026667656,0.000016414604,0.000023643,0.95675474,0.0005352902],"about_ca_topic_score_codex":0.0004093363,"about_ca_topic_score_gemma":0.0016236119,"teacher_disagreement_score":0.9768137,"about_ca_system_score_codex":0.004882587,"about_ca_system_score_gemma":0.001640795,"threshold_uncertainty_score":0.9995345},"labels":[],"label_agreement":null},{"id":"W2111479968","doi":"10.1200/jco.2006.06.7835","title":"Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Docetaxel; Pemetrexed; Medicine; Tolerability; Internal medicine; Neutropenia; Chemotherapy; Lung cancer; Oncology; Febrile neutropenia; Population; Toxicity; Surgery; Adverse effect; Cisplatin","score_opus":0.02282379912447964,"score_gpt":0.3976881623197988,"score_spread":0.3748643631953192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111479968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616426,0.00035444184,0.00016192003,0.00015276395,0.00014344431,0.002585906,0.00022621473,0.0000058784944,0.00020516902],"genre_scores_gemma":[0.9967644,0.00018113175,0.0021783393,0.00016473362,0.00011299072,0.000084946194,0.0003509684,0.000027675176,0.00013481874],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948571,0.00030925806,0.0037606747,0.00030901047,0.0005084256,0.0002555523],"domain_scores_gemma":[0.99190867,0.0012534916,0.0051780907,0.00026555167,0.0011927212,0.00020148598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008026998,0.0002771832,0.0052162507,0.000520002,0.000025534058,0.000006584008,0.00014304095,0.00021808204,0.00029372805],"category_scores_gemma":[0.00018783445,0.0001641064,0.00077725935,0.0008398654,0.00018071289,0.00011142829,0.000013500156,0.00036041415,2.2462116e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61613554,0.01597285,0.35380986,0.00003440249,0.0074693775,0.000022999628,0.00027135797,0.0008314141,0.00005889134,6.3487965e-7,0.00004512113,0.0053475373],"study_design_scores_gemma":[0.7034489,0.023169447,0.25612038,0.00022533625,0.015870728,4.8809335e-7,0.000035658562,0.00073377887,0.00023198604,0.00000747131,0.000044887103,0.00011095526],"about_ca_topic_score_codex":0.001526933,"about_ca_topic_score_gemma":0.004590672,"teacher_disagreement_score":0.097689465,"about_ca_system_score_codex":0.00029588628,"about_ca_system_score_gemma":0.0010966753,"threshold_uncertainty_score":0.6692065},"labels":[],"label_agreement":null},{"id":"W2111592390","doi":"10.1158/1535-7163.mct-09-0868","title":"Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Sorafenib; Erlotinib; Medicine; Pharmacodynamics; Pharmacokinetics; Pharmacology; Dosing; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer; Hepatocellular carcinoma","score_opus":0.023696432221420247,"score_gpt":0.4094501007553262,"score_spread":0.3857536685339059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111592390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938723,0.003312395,0.00036576958,0.00072385784,0.00017663374,0.0013153242,0.00008406061,0.000022759677,0.00012694095],"genre_scores_gemma":[0.9956509,0.0027382153,0.000322983,0.00077732414,0.0000447672,0.00013541135,0.00028375429,0.00003402894,0.000012607412],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988399,0.00009286441,0.00030426512,0.000297659,0.0003138139,0.00015145859],"domain_scores_gemma":[0.999363,0.00002815689,0.00013098486,0.0001949949,0.00019355144,0.00008929358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022673012,0.00017107998,0.00027959526,0.00011957276,0.00005023632,0.000016748585,0.000051506737,0.000074283176,0.000123454],"category_scores_gemma":[0.0000053945732,0.00015364989,0.000032605756,0.00014289153,0.00009724358,0.000108403125,0.000014817117,0.00017926832,4.3519202e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043183865,0.0007228833,0.013543039,0.000013500738,0.00021113583,0.000007552357,0.0009449175,0.00004542004,0.6785026,0.000040579405,0.0000016156049,0.3055349],"study_design_scores_gemma":[0.059182446,0.0017804956,0.22385775,0.00018110189,0.0018953059,0.00001981419,0.0002224738,0.114124246,0.59601355,0.0014840658,0.0008272413,0.00041154254],"about_ca_topic_score_codex":0.0005594201,"about_ca_topic_score_gemma":0.00013124006,"teacher_disagreement_score":0.30512336,"about_ca_system_score_codex":0.00007745311,"about_ca_system_score_gemma":0.00018913657,"threshold_uncertainty_score":0.62656605},"labels":[],"label_agreement":null},{"id":"W2111645707","doi":"10.7554/elife.06907","title":"Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma","year":2015,"lang":"en","type":"article","venue":"eLife","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health","keywords":"KRAS; Biology; Oncogene; Cancer research; Phenotype; Adenocarcinoma; Mutation; MAPK/ERK pathway; Mutant; Gene; Synthetic lethality; Cancer; Signal transduction; Genetics; Cell cycle","score_opus":0.10769307058316803,"score_gpt":0.3766289958914241,"score_spread":0.2689359253082561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111645707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98326844,0.010753324,0.00022059018,0.0042901644,0.000092247996,0.000395868,0.000013138466,0.000018167744,0.0009480527],"genre_scores_gemma":[0.9989156,0.00019278916,0.00021762491,0.0002706481,0.000042549564,0.000039430655,0.0000073832007,0.000009042714,0.00030489464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991385,0.0000905565,0.00017645452,0.00017060277,0.00029093717,0.00013295942],"domain_scores_gemma":[0.9991626,0.0003060817,0.000090812006,0.0002462928,0.00009564458,0.00009853691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000332381,0.00009286338,0.00018711522,0.00005546517,0.000064993845,0.00001285075,0.00006246811,0.000041108666,0.000023967108],"category_scores_gemma":[0.00042532856,0.00006175342,0.000041321684,0.00014898754,0.00018730944,0.00011366418,0.000048743674,0.00010123459,0.000008187883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011950243,0.00021769643,0.97724676,0.00013669791,0.0001657421,0.000041379168,0.015799388,0.0000784472,0.00041801974,0.001027814,0.0008779664,0.0038705904],"study_design_scores_gemma":[0.0015150632,0.00020524909,0.988189,0.00034263215,0.0004614508,0.000081034814,0.005388544,0.0005195327,0.0022534584,0.0004669793,0.00046973664,0.0001073221],"about_ca_topic_score_codex":0.000813562,"about_ca_topic_score_gemma":0.00043281418,"teacher_disagreement_score":0.015647192,"about_ca_system_score_codex":0.0001921631,"about_ca_system_score_gemma":0.00037409304,"threshold_uncertainty_score":0.25182313},"labels":[],"label_agreement":null},{"id":"W2112321541","doi":"10.1016/j.juro.2008.05.001","title":"Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?","year":2008,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; AstraZeneca","keywords":"Gefitinib; Vascular endothelial growth factor; Medicine; Epidermal growth factor receptor; Angiogenesis; Epidermal growth factor; Cancer research; Endothelial stem cell; Endocrinology; Vascular endothelial growth factor A; Growth factor receptor inhibitor; Internal medicine; Growth factor; Cell growth; Cancer; Biology; Receptor; In vitro; Biochemistry","score_opus":0.031484937160070205,"score_gpt":0.31838193665180364,"score_spread":0.2868969994917334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112321541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346197,0.0014157185,0.0010814669,0.0032535847,0.00024500603,0.00040129537,0.00007719331,0.0000030041429,0.00006078797],"genre_scores_gemma":[0.9985116,0.0005569888,0.0000755416,0.00053413317,0.00021685398,0.0000070548517,0.0000012864547,0.000011578259,0.000084949585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925303,0.00007636999,0.0003192832,0.000054452168,0.00019227513,0.00010460332],"domain_scores_gemma":[0.9988525,0.00028198236,0.0004026608,0.00015355514,0.00027824243,0.000031070016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011460811,0.000074988675,0.00024600592,0.000049528735,0.00006327762,9.1809903e-7,0.00011452856,0.000050369945,0.00008736383],"category_scores_gemma":[0.00007472854,0.00003540941,0.00021012149,0.000076223405,0.00014018049,0.000030438716,0.000010869362,0.00010395409,3.6492372e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020065915,0.0042677643,0.45039073,0.00055459596,0.028336756,0.000027835373,0.08990689,0.0064022015,0.35290918,0.0024306036,0.0056631947,0.039044347],"study_design_scores_gemma":[0.010826391,0.0022875047,0.96232903,0.000043888456,0.0029749728,0.0002667671,0.00009773672,0.00084784883,0.016523894,0.0010008101,0.002732018,0.00006911847],"about_ca_topic_score_codex":0.00006289332,"about_ca_topic_score_gemma":0.00000480189,"teacher_disagreement_score":0.51193833,"about_ca_system_score_codex":0.000034080185,"about_ca_system_score_gemma":0.00025555157,"threshold_uncertainty_score":0.1443954},"labels":[],"label_agreement":null},{"id":"W2112524831","doi":"10.1200/jco.2011.39.2993","title":"Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Erlotinib; Medicine; Sunitinib; Internal medicine; Lung cancer; Rash; Oncology; Erlotinib Hydrochloride; Hazard ratio; Clinical endpoint; Epidermal growth factor receptor; Phases of clinical research; Gastroenterology; Cancer; Chemotherapy; Clinical trial; Confidence interval","score_opus":0.07140800855381599,"score_gpt":0.47321302083902184,"score_spread":0.4018050122852058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112524831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869837,0.000827484,0.000053823765,0.00063045055,0.0031315314,0.0036555745,0.000027880444,0.000023552298,0.004665958],"genre_scores_gemma":[0.9945612,0.00045651878,0.0016944627,0.0005437299,0.0015985644,0.00019373612,0.000057224093,0.00005664497,0.0008379395],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954207,0.00042338733,0.0026578212,0.00031573515,0.0004943082,0.00068805745],"domain_scores_gemma":[0.9940659,0.0017976075,0.002389334,0.00028771738,0.0005985912,0.00086085347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001479458,0.00034056389,0.0022137545,0.00024739627,0.000084991094,0.000014899673,0.00019833681,0.00041380676,0.00026588602],"category_scores_gemma":[0.00092208566,0.00023168331,0.00040718957,0.00034920668,0.0001542648,0.00030669867,0.000046240642,0.0010817259,0.000010821277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8080894,0.012425644,0.12155983,0.000078818484,0.0012573416,0.00026196404,0.0016631957,0.00022499081,0.00000933465,0.000011315884,0.0012023927,0.053215828],"study_design_scores_gemma":[0.88469106,0.051063705,0.047557294,0.00035859097,0.0034351465,0.00002423629,0.00043531726,0.00015543612,0.00003851036,0.0000019884762,0.011987436,0.00025126903],"about_ca_topic_score_codex":0.00019629742,"about_ca_topic_score_gemma":0.00033730746,"teacher_disagreement_score":0.07660172,"about_ca_system_score_codex":0.0014381612,"about_ca_system_score_gemma":0.0055029187,"threshold_uncertainty_score":0.97619414},"labels":[],"label_agreement":null},{"id":"W2113898985","doi":"10.1093/annonc/mdu326.1","title":"Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"","keywords":"Medicine; Oncology; Biomarker; Internal medicine; Adjuvant; Lung cancer; ERCC1","score_opus":0.027900055226187572,"score_gpt":0.38879716577754386,"score_spread":0.3608971105513563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113898985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820801,0.0017348748,0.00038441847,0.0063218144,0.00013181411,0.0017192011,0.00006969991,0.00001719531,0.007540891],"genre_scores_gemma":[0.9967453,0.0007449938,0.00073971757,0.00089367176,0.000083277155,0.00038200442,0.00004719338,0.00002064269,0.0003432107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991688,0.00005382241,0.00022538684,0.00023818233,0.000069505215,0.0002443147],"domain_scores_gemma":[0.9991529,0.00031084544,0.0001293161,0.00012721577,0.00018819617,0.00009155472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022835303,0.00011922375,0.00035783803,0.0001350494,0.000038507955,0.0000039853508,0.000048113812,0.00012171931,0.000024889867],"category_scores_gemma":[0.000112569425,0.000095934585,0.00005502701,0.00014143821,0.0000847619,0.000037086946,0.000016023598,0.00008726131,6.7165627e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006571253,0.0021426207,0.72714466,0.0011845573,0.0015342206,0.000031873835,0.007262459,0.000057202156,0.016709749,0.00008124816,0.02323842,0.21404177],"study_design_scores_gemma":[0.018435368,0.010071127,0.9170347,0.0005201407,0.00072938745,0.0000112489915,0.00037490876,0.005668697,0.019074459,0.00023923568,0.027615571,0.00022519544],"about_ca_topic_score_codex":0.00030428352,"about_ca_topic_score_gemma":0.00028414186,"teacher_disagreement_score":0.21381657,"about_ca_system_score_codex":0.00008497327,"about_ca_system_score_gemma":0.00040104263,"threshold_uncertainty_score":0.3912099},"labels":[],"label_agreement":null},{"id":"W2114223339","doi":"10.3389/fonc.2014.00256","title":"Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Squamous cell cancer; Oncology; Lung cancer; Internal medicine; Lung; Cancer; Basal cell; Algorithm; Computer science","score_opus":0.023126436994403858,"score_gpt":0.38408062101800017,"score_spread":0.3609541840235963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114223339","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000060481474,0.976842,0.009652197,0.00008172721,0.0023513965,0.00883475,0.0004767167,0.000028793876,0.001671962],"genre_scores_gemma":[0.000055303444,0.92623055,0.057176054,0.0001365236,0.00030535666,0.010343023,0.0016944379,0.00014772729,0.0039110146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978299,0.0000952714,0.00066391326,0.0006824608,0.00016270719,0.00056575827],"domain_scores_gemma":[0.99852085,0.00022119573,0.00050471694,0.00040969896,0.00014064573,0.00020287203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009027193,0.00061366183,0.003165391,0.0004026633,0.00009000989,0.000014246986,0.00015187071,0.00032511438,0.000030106155],"category_scores_gemma":[0.000019446405,0.00039435824,0.00039945295,0.00026367835,0.000083627136,0.000038961552,0.00002447343,0.00022806879,0.000007830641],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015768592,0.0015131444,0.0033540605,0.010149418,0.0014629163,0.00007448602,0.00040699425,0.000015710562,1.2645713e-8,0.000002082377,0.014333246,0.96853024],"study_design_scores_gemma":[0.012691074,0.0053964877,0.00013543233,0.0019381517,0.01635557,0.0000118791095,0.00005881694,0.00040478213,4.6294156e-7,0.0000065600734,0.9626373,0.00036349002],"about_ca_topic_score_codex":0.00031562356,"about_ca_topic_score_gemma":0.00013608403,"teacher_disagreement_score":0.96816677,"about_ca_system_score_codex":0.004885121,"about_ca_system_score_gemma":0.0025935904,"threshold_uncertainty_score":0.9998508},"labels":[],"label_agreement":null},{"id":"W2114292376","doi":"10.6058/jlc.2009.8.2.61","title":"Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Gefitinib; Docetaxel; Medicine; Oncology; Lung cancer; Internal medicine; Epidermal growth factor receptor; Population; Clinical trial; Cancer","score_opus":0.013719161576767482,"score_gpt":0.35969464480183744,"score_spread":0.34597548322506994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114292376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085754,0.005451849,0.00004829311,0.00041717466,0.0003740403,0.00059424026,0.000043211014,0.000008847404,0.0022047777],"genre_scores_gemma":[0.9984238,0.00034356237,0.0004720806,0.00013678629,0.00017907894,0.000021605576,0.0000141448745,0.00002312243,0.0003857927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984498,0.000026296342,0.0006379643,0.00017605866,0.00043537337,0.0002745105],"domain_scores_gemma":[0.99839985,0.000045425142,0.0007012418,0.00017103514,0.00052009703,0.00016234274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007994277,0.00020706157,0.00063895556,0.00021946314,0.000043169195,0.000015075822,0.00010921354,0.00008340808,0.00015249183],"category_scores_gemma":[0.000011800787,0.00014388113,0.00012000818,0.0003331067,0.000033471337,0.00015533251,0.0000104743895,0.00028649802,6.032372e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043849824,0.0010942984,0.98302716,0.00016194492,0.0005267181,0.000025684696,0.0015940991,0.0017471118,0.00030365016,0.0000032887408,0.0026271616,0.004503921],"study_design_scores_gemma":[0.023942653,0.002086632,0.9665853,0.0016076588,0.0018493928,0.0000027449703,0.00012390688,0.00052208756,0.0027231248,0.0000018699717,0.0003930309,0.00016162489],"about_ca_topic_score_codex":0.0005825395,"about_ca_topic_score_gemma":0.0002927616,"teacher_disagreement_score":0.019557672,"about_ca_system_score_codex":0.0007939213,"about_ca_system_score_gemma":0.0007030512,"threshold_uncertainty_score":0.58673024},"labels":[],"label_agreement":null},{"id":"W2114446999","doi":"10.1200/jco.2012.48.1390","title":"Pooled Analysis of the Prognostic and Predictive Effects of <i>KRAS</i> Mutation Status and <i>KRAS</i> Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Institut National Du Cancer; National Cancer Institute; Ligue Contre le Cancer; Sanofi","keywords":"KRAS; Medicine; Hazard ratio; Internal medicine; Mutation; Oncology; Proportional hazards model; Cancer; Lung cancer; Stage (stratigraphy); Gastroenterology; Genetics; Colorectal cancer; Gene; Biology; Confidence interval","score_opus":0.032671352513065584,"score_gpt":0.42311563614531184,"score_spread":0.39044428363224626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114446999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958665,0.0016760958,0.0001307923,0.0006228924,0.00018460628,0.0014041887,0.00003591963,0.0000017957406,0.00007725392],"genre_scores_gemma":[0.9974291,0.0018481147,0.00041421695,0.00015315755,0.00005249162,0.0000435758,0.000007013716,0.000010966895,0.00004141293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963161,0.00080763025,0.002296756,0.00016560151,0.0002583298,0.00015562525],"domain_scores_gemma":[0.991764,0.004480101,0.002936597,0.00011927867,0.00058210065,0.00011791952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017743506,0.000121414145,0.001778747,0.00035408823,0.000015481903,0.000005124569,0.000063294196,0.0002050935,0.000026417605],"category_scores_gemma":[0.0033226546,0.00007405725,0.0002421637,0.0006462637,0.00016230746,0.000109977715,0.00002101182,0.00032497628,8.244468e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024829477,0.00096173584,0.97005093,0.00030761198,0.002443863,0.00004163783,0.002505168,0.0008150961,0.006454626,0.0000038671715,0.00003181598,0.013900722],"study_design_scores_gemma":[0.01676302,0.004291983,0.96537095,0.0004018675,0.0064448966,0.0000045528195,0.00027276305,0.0031129003,0.0032019096,0.00007050286,0.000012791168,0.000051879084],"about_ca_topic_score_codex":0.0015697984,"about_ca_topic_score_gemma":0.001048824,"teacher_disagreement_score":0.014280072,"about_ca_system_score_codex":0.00013986573,"about_ca_system_score_gemma":0.0010428361,"threshold_uncertainty_score":0.39777678},"labels":[],"label_agreement":null},{"id":"W2114553251","doi":"10.1158/1078-0432.ccr-07-0547","title":"Relationship of<i>EGFR</i>Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Erlotinib; Epidermal growth factor receptor; Biology; EGFR inhibitors; Cancer research; Tyrosine kinase; Molecular biology; Gene; Lung cancer; Cancer; Genetics; Receptor; Medicine; Internal medicine","score_opus":0.1712660412785758,"score_gpt":0.5120324427055788,"score_spread":0.340766401427003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114553251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98021936,0.0016469379,0.00035816885,0.015304364,0.00020857998,0.0011787328,0.00005732502,0.000018961817,0.001007591],"genre_scores_gemma":[0.9962845,0.00026406057,0.0013382826,0.00062786555,0.0004524207,0.0002198142,0.000047698817,0.000020838936,0.00074455404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974399,0.00036402076,0.0008331235,0.0003859037,0.00062273967,0.00035428285],"domain_scores_gemma":[0.995142,0.0035079562,0.000120401484,0.00035568688,0.00060033565,0.00027361023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002746799,0.000119706136,0.00026441357,0.00031000786,0.00020828022,0.000028019658,0.00016597225,0.0001402074,0.00010955759],"category_scores_gemma":[0.0023819185,0.00008017542,0.00007730904,0.0009653197,0.0003021381,0.00010522688,0.000058848433,0.000552306,0.00003269309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003912537,0.00046851367,0.9734902,0.000085566266,0.000019602538,0.0000089245705,0.0028448324,0.000005022127,0.0034155657,0.0006779167,0.011389804,0.0072028446],"study_design_scores_gemma":[0.001512946,0.00034366577,0.9772239,0.000164191,0.000036730897,0.0000027599374,0.0013336197,0.0000050919016,0.0102019925,0.0005897403,0.008485396,0.00010001968],"about_ca_topic_score_codex":0.0006729902,"about_ca_topic_score_gemma":0.00018909019,"teacher_disagreement_score":0.016065126,"about_ca_system_score_codex":0.00016022428,"about_ca_system_score_gemma":0.00047311472,"threshold_uncertainty_score":0.3269459},"labels":[],"label_agreement":null},{"id":"W2115098410","doi":"10.3747/co.v16i4.465","title":"Optimizing the Management of Advanced Non-small-Cell Lung Cancer: A Personal View","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Pace; Scope (computer science); Personalized medicine; Intensive care medicine; Bioinformatics; Computer science","score_opus":0.041244839867292764,"score_gpt":0.41902115998469674,"score_spread":0.377776320117404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115098410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7954021,0.12598471,0.0022550218,0.010814982,0.002212222,0.0032115697,0.00003694572,0.000073945426,0.060008474],"genre_scores_gemma":[0.9811817,0.012263621,0.00455456,0.00054680026,0.00017171913,0.00028141873,0.000033558055,0.00001347054,0.0009531541],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993094,0.000019893969,0.00019004197,0.00017820166,0.00011046125,0.00019200573],"domain_scores_gemma":[0.99959016,0.000022681088,0.000106774205,0.00014845157,0.000069083835,0.00006285441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006612823,0.000109373905,0.0002402921,0.000039426704,0.00007258047,0.0000040146138,0.0000801201,0.000033456283,0.00010750411],"category_scores_gemma":[0.0000015938163,0.00007166572,0.00008876762,0.00013425505,0.000037151847,0.00002594979,0.000024186338,0.00012042422,0.0000052647893],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013426377,0.0011233012,0.0027521432,0.00069049705,0.0003518695,0.000038201022,0.0049706525,0.00018707498,0.0004287648,0.00040666966,0.0023642967,0.98655224],"study_design_scores_gemma":[0.026231373,0.0037759156,0.09240524,0.0036096876,0.009015951,0.00007339794,0.008326729,0.007701535,0.0018026443,0.00017897996,0.846262,0.0006165738],"about_ca_topic_score_codex":0.0000089183595,"about_ca_topic_score_gemma":0.0000053738486,"teacher_disagreement_score":0.9859357,"about_ca_system_score_codex":0.0003059908,"about_ca_system_score_gemma":0.00019471567,"threshold_uncertainty_score":0.29224434},"labels":[],"label_agreement":null},{"id":"W2115330744","doi":"10.1093/annonc/mdq020","title":"Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Gemcitabine; Hazard ratio; Clinical endpoint; Internal medicine; Placebo; Lung cancer; Oncology; Cisplatin; Progression-free survival; Chemotherapy; Confidence interval; Surgery; Urology; Gastroenterology; Clinical trial; Pathology","score_opus":0.0480325960961244,"score_gpt":0.4125897085681237,"score_spread":0.3645571124719993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115330744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837746,0.0005276717,0.00026215566,0.0058971574,0.0005610621,0.005474567,0.00081192283,0.000031315438,0.0026595655],"genre_scores_gemma":[0.9903521,0.0017921394,0.0021885308,0.00089668564,0.00068736845,0.0011104688,0.00047851662,0.000047617912,0.0024465702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983355,0.00005714193,0.0006184321,0.0004583981,0.00018526736,0.00034528604],"domain_scores_gemma":[0.9971866,0.0014557982,0.00044180933,0.0003345599,0.00036198605,0.00021922038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003924069,0.0002756609,0.00095165195,0.000105086525,0.00014077892,0.000016474665,0.000102727114,0.0002283768,0.00027032956],"category_scores_gemma":[0.00022459947,0.00018023927,0.00013741733,0.00010894031,0.00013360719,0.00007596688,0.000024347159,0.00022066827,0.0000020526454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95913005,0.0024178214,0.00017051194,0.000062634106,0.00097444246,0.00007885626,0.002021065,0.000022083752,0.0037487862,0.000027113618,0.0036907892,0.027655832],"study_design_scores_gemma":[0.9376195,0.027388342,0.00030356093,0.00007558196,0.00082783523,0.00001952854,0.00011499417,0.00090201996,0.005866012,0.00007637573,0.026592184,0.00021405594],"about_ca_topic_score_codex":0.0027624066,"about_ca_topic_score_gemma":0.0046266946,"teacher_disagreement_score":0.027441775,"about_ca_system_score_codex":0.000050919152,"about_ca_system_score_gemma":0.0012678847,"threshold_uncertainty_score":0.73499435},"labels":[],"label_agreement":null},{"id":"W2115684400","doi":"10.1093/annonc/mdg455","title":"Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montfort Hospital","funders":"","keywords":"Vinorelbine; Medicine; Lung cancer; Regimen; Internal medicine; Neutropenia; Cisplatin; Chemotherapy; Oncology; Gastroenterology; Surgery","score_opus":0.03387055618300612,"score_gpt":0.39976659891928085,"score_spread":0.36589604273627474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115684400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97076344,0.00032287173,0.00014621689,0.0021326412,0.00006377378,0.0007152672,0.000011465325,0.0000069383664,0.025837371],"genre_scores_gemma":[0.99609697,0.00018918219,0.0021797884,0.00059329864,0.000009182531,0.00020484051,0.000025547768,0.000013803225,0.0006873964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925256,0.000034670455,0.00022338648,0.00019199966,0.000092195674,0.00020518308],"domain_scores_gemma":[0.99944705,0.00006651824,0.00015185185,0.00011813597,0.00016363732,0.0000528254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110869936,0.0001076578,0.00033853587,0.00017502515,0.00001780421,0.0000019281565,0.000036885922,0.00008589897,0.00005165264],"category_scores_gemma":[0.00003079537,0.00008801202,0.000027528546,0.00031880147,0.000041200063,0.00008108992,0.000009016536,0.00012917547,0.0000013296834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065608867,0.015448495,0.791313,0.00058085,0.00079568045,0.00044926672,0.01751126,0.0041459925,0.027304828,0.0043162815,0.0020993047,0.12947415],"study_design_scores_gemma":[0.07666401,0.013523374,0.8322332,0.00085521006,0.00042398914,0.00005487892,0.0029037353,0.0014851453,0.055626273,0.00039884148,0.015373292,0.0004580497],"about_ca_topic_score_codex":0.0008393121,"about_ca_topic_score_gemma":0.002239831,"teacher_disagreement_score":0.12901609,"about_ca_system_score_codex":0.00024186382,"about_ca_system_score_gemma":0.0006564732,"threshold_uncertainty_score":0.3589026},"labels":[],"label_agreement":null},{"id":"W2116036495","doi":"10.1093/annonc/mdi013","title":"Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Vinorelbine; Docetaxel; Medicine; Cisplatin; Internal medicine; Lung cancer; Chemotherapy; Oncology; Gastroenterology","score_opus":0.1282926510778313,"score_gpt":0.49958957761632844,"score_spread":0.3712969265384971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116036495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583126,0.0008592934,0.00047113936,0.001459113,0.0005983452,0.0071815113,0.0022756648,0.000043955388,0.0012796982],"genre_scores_gemma":[0.9896959,0.00010860841,0.0022361293,0.00030413238,0.00026016872,0.0011503836,0.00069478044,0.00006635071,0.005483512],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99626386,0.000114783696,0.0015819625,0.00080067513,0.0005295888,0.00070915284],"domain_scores_gemma":[0.9967968,0.00039262025,0.0010752403,0.0005407203,0.000781401,0.00041326013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061988406,0.0005073089,0.0013997703,0.00023540131,0.00028572395,0.000026941982,0.0002533413,0.00023321476,0.0003850309],"category_scores_gemma":[0.0002692656,0.00038506548,0.00036974618,0.0004464257,0.00017743428,0.00013908406,0.00016627558,0.00021527847,0.0000043151445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75145096,0.03749681,0.0024906262,0.0008076594,0.0032957285,0.0006224576,0.0058957515,0.011441957,0.1444044,0.000033947672,0.018699253,0.023360476],"study_design_scores_gemma":[0.7307933,0.13707829,0.0007761601,0.0003795909,0.0024143625,0.000017830998,0.00046822985,0.0009488141,0.11848548,0.000011394913,0.008134666,0.0004918648],"about_ca_topic_score_codex":0.0012048209,"about_ca_topic_score_gemma":0.001907651,"teacher_disagreement_score":0.09958148,"about_ca_system_score_codex":0.00060638273,"about_ca_system_score_gemma":0.0016870663,"threshold_uncertainty_score":0.9998601},"labels":[],"label_agreement":null},{"id":"W2116142233","doi":"10.3747/co.19.891","title":"Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Credit Valley Hospital","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Chemotherapy; Histology; Randomized controlled trial; Placebo; Confidence interval; Pathology; Cisplatin","score_opus":0.07980002636897117,"score_gpt":0.43877515206088674,"score_spread":0.3589751256919156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116142233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72740763,0.2607932,0.003706084,0.00047413932,0.00040255114,0.004567926,0.00015202975,0.000020161313,0.0024762615],"genre_scores_gemma":[0.9947295,0.0018264578,0.0009665651,0.0000414522,0.00005165405,0.0019377121,0.00020836918,0.000014857039,0.00022342251],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99588144,0.0012666303,0.0019166024,0.0003213003,0.00026059386,0.00035343098],"domain_scores_gemma":[0.99472004,0.0024265395,0.0019628294,0.00037062183,0.0003753169,0.00014467174],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002788139,0.0002792033,0.015377521,0.0018530118,0.000026770202,0.0000025562113,0.00010693754,0.00013453313,0.0010193419],"category_scores_gemma":[0.0004985913,0.00015841446,0.0041592936,0.002104362,0.00017358332,0.000055763052,0.000025119673,0.00016831447,9.451997e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08467708,0.0032320102,0.16407077,0.00014151656,0.7401467,0.000004197211,0.0025120943,0.0016812277,0.001068097,0.0002258398,0.00006980643,0.002170664],"study_design_scores_gemma":[0.22397034,0.00020325204,0.008539731,0.000008461091,0.7622349,8.058513e-7,0.0002624196,0.0039291726,0.00034416092,0.000008127962,0.000395673,0.000102958475],"about_ca_topic_score_codex":0.0012440219,"about_ca_topic_score_gemma":0.0024771325,"teacher_disagreement_score":0.26732185,"about_ca_system_score_codex":0.00043258135,"about_ca_system_score_gemma":0.00045168807,"threshold_uncertainty_score":0.99989384},"labels":[],"label_agreement":null},{"id":"W2116385092","doi":"10.1200/jco.2007.13.0856","title":"Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital","funders":"Eli Lilly Canada; American Society of Clinical Oncology; Merck KGaA; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Carboplatin; Cetuximab; Lung cancer; Internal medicine; Chemotherapy; Clinical endpoint; Cisplatin; Pleural effusion; Phases of clinical research; Progression-free survival; Surgery; Gastroenterology; Oncology; Urology; Randomized controlled trial; Cancer; Colorectal cancer","score_opus":0.07258268299772243,"score_gpt":0.5066041090782099,"score_spread":0.43402142608048744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116385092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98798585,0.00037152076,0.0038419822,0.00055974553,0.00043677268,0.0065050316,0.00003268299,0.0000117169275,0.00025471728],"genre_scores_gemma":[0.9720887,0.0005449428,0.024384249,0.00070772425,0.00030788008,0.0002831998,0.000017153408,0.000060813756,0.0016053373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955436,0.00022169344,0.002972486,0.0003384809,0.0005554313,0.00036832588],"domain_scores_gemma":[0.98902947,0.0052775485,0.0035031834,0.0002683764,0.0015302267,0.00039120746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002096075,0.00033934953,0.0036912116,0.00019873968,0.00013135627,0.00000860997,0.00015608632,0.00014800286,0.00027604267],"category_scores_gemma":[0.0015075947,0.00014141838,0.0003016736,0.00033778636,0.00019454953,0.00014109642,0.000027959391,0.00045409973,5.0887866e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8915915,0.027364135,0.023377378,0.00014630874,0.004556477,0.00042850967,0.002175474,0.00044098124,0.000014545564,0.000001807692,0.0001189083,0.04978398],"study_design_scores_gemma":[0.7251917,0.26132658,0.0037365085,0.0003069936,0.006316616,0.000052745225,0.00092698593,0.00087145856,0.00007250049,0.00000620202,0.0010366045,0.00015506556],"about_ca_topic_score_codex":0.00019984024,"about_ca_topic_score_gemma":0.003724732,"teacher_disagreement_score":0.23396246,"about_ca_system_score_codex":0.00030774597,"about_ca_system_score_gemma":0.004353341,"threshold_uncertainty_score":0.77226406},"labels":[],"label_agreement":null},{"id":"W2116569903","doi":"10.1053/j.seminoncol.2005.04.014","title":"Introduction: Non-Small Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine","score_opus":0.008520434493519578,"score_gpt":0.3504902629080791,"score_spread":0.34196982841455953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116569903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8344625,0.008252068,0.00010438703,0.051257893,0.0013548589,0.00068694475,0.000008905983,0.00005008434,0.103822336],"genre_scores_gemma":[0.9145354,0.003488568,0.013281445,0.0030975507,0.004836134,0.00046895436,0.00005562439,0.00003686158,0.060199443],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931276,0.000018114344,0.00017264036,0.0002237488,0.00006477642,0.00020797494],"domain_scores_gemma":[0.99963844,0.00003342551,0.000049507777,0.0001640692,0.00004488954,0.00006965741],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008014727,0.00009221535,0.00020532843,0.000098327575,0.00003821117,0.000003614765,0.000045398334,0.00010478468,0.0010362549],"category_scores_gemma":[0.000012996582,0.00008167248,0.000037259695,0.00016289891,0.000040346396,0.00004004751,0.000020143525,0.00015960934,0.000059660986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002735084,0.001511891,0.13850082,0.00015281777,0.00015965186,0.00026609516,0.007227777,0.0010575829,0.0052156392,0.00019415417,0.43047944,0.41496062],"study_design_scores_gemma":[0.0028721858,0.00043637585,0.01170445,0.00007620088,0.00024947317,0.00009090165,0.00047788292,0.00055002817,0.0039667455,0.000019569106,0.9794437,0.000112483205],"about_ca_topic_score_codex":0.0001267053,"about_ca_topic_score_gemma":0.0003953656,"teacher_disagreement_score":0.54896426,"about_ca_system_score_codex":0.0011002778,"about_ca_system_score_gemma":0.00042072908,"threshold_uncertainty_score":0.9998769},"labels":[],"label_agreement":null},{"id":"W2116720928","doi":"10.1016/j.lungcan.2013.07.025","title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; Canadian Institutes of Health Research; Canary Foundation; U.S. Department of Defense","keywords":"Lung cancer; Medicine; Disease; Cancer; Adenocarcinoma; Oncology; Bioinformatics; Cancer research; Internal medicine; Biology","score_opus":0.037756950148784545,"score_gpt":0.39314686098660384,"score_spread":0.3553899108378193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116720928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037808757,0.9948393,0.0004592128,0.00054143835,0.00019885764,0.001643605,0.00020872527,0.00006576196,0.0020053082],"genre_scores_gemma":[0.0003383415,0.9936609,0.00068847457,0.0003466969,0.00023245109,0.0031862976,0.0002228842,0.00007157964,0.0012523357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895674,0.000032818203,0.00032265994,0.00038147173,0.00007555393,0.00023075454],"domain_scores_gemma":[0.9991341,0.00009010689,0.00015949055,0.0003980347,0.000088778674,0.00012944294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000026926302,0.00032179005,0.00074841233,0.00012380214,0.00019204628,0.000069755675,0.00007815085,0.00014506072,0.00019660738],"category_scores_gemma":[0.0000071491204,0.0002077387,0.00018814385,0.0002136631,0.000055136024,0.000059176433,0.00002922625,0.00019115083,0.000047207774],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001181537,0.000035356057,0.00029621107,0.002134889,0.0010067263,0.0000012149113,0.00024398127,0.0000023566724,0.0000024127735,0.0010406686,0.0011032971,0.9941317],"study_design_scores_gemma":[0.00039884352,0.000044742927,0.001127463,0.0044342694,0.005339234,0.00008411378,0.000024176188,0.000020375574,0.0000011983196,0.00018493338,0.9880963,0.0002443616],"about_ca_topic_score_codex":0.00022586626,"about_ca_topic_score_gemma":0.00007755151,"teacher_disagreement_score":0.99388736,"about_ca_system_score_codex":0.0002912852,"about_ca_system_score_gemma":0.00070260715,"threshold_uncertainty_score":0.8471339},"labels":[],"label_agreement":null},{"id":"W2117203654","doi":"10.4161/cc.27201","title":"Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)","year":2013,"lang":"en","type":"article","venue":"Cell Cycle","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Breast Cancer Campaign; GlaxoSmithKline","keywords":"Lapatinib; Ductal carcinoma; Matrigel; Cancer research; Cancer stem cell; Breast cancer; Biology; Cancer; Population; Oncology; Progenitor cell; Stem cell; Internal medicine; Pathology; Medicine; Angiogenesis; Trastuzumab; Cell biology","score_opus":0.0268258790524767,"score_gpt":0.30940226786976305,"score_spread":0.28257638881728636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117203654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944006,0.00025335094,0.000008927008,0.00022414536,0.00006534029,0.0011212148,0.0000072280004,0.000010906108,0.003908289],"genre_scores_gemma":[0.9989638,0.00000985645,0.00042003742,0.000057622157,0.000050186805,0.00024612003,0.000042121475,0.000014438801,0.00019582364],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990212,0.000045061817,0.0004197422,0.00021066952,0.00013211982,0.00017121155],"domain_scores_gemma":[0.9996116,0.000043663516,0.00006871773,0.00015666525,0.000055823395,0.00006350726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009491882,0.00009518899,0.0002448483,0.00013193503,0.000011657394,0.000008674243,0.00004028055,0.000084601015,0.000029981722],"category_scores_gemma":[0.00001586526,0.000084150815,0.00003904373,0.00018945662,0.000023565453,0.0001951398,0.000021310872,0.00012877071,0.000022064583],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061256177,0.0031901216,0.64282197,0.00035638237,0.00002982475,0.00009005549,0.008184664,0.0019775927,0.33535448,0.000075509735,0.00017524401,0.0071316087],"study_design_scores_gemma":[0.010868954,0.00042988933,0.360927,0.00017399702,0.000058266207,0.000012113396,0.0009650184,0.026019786,0.59954655,0.0007707847,0.000014067503,0.00021357357],"about_ca_topic_score_codex":0.00071994175,"about_ca_topic_score_gemma":0.00033097545,"teacher_disagreement_score":0.28189498,"about_ca_system_score_codex":0.00013311967,"about_ca_system_score_gemma":0.00015023527,"threshold_uncertainty_score":0.34315705},"labels":[],"label_agreement":null},{"id":"W2117890976","doi":"10.3747/co.19.1018","title":"A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; University of British Columbia; University of Calgary; McGill University; Dalhousie University; Royal Victoria Hospital; Ottawa Hospital; BC Cancer Agency; Montreal General Hospital; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Tyrosine kinase; Targeted therapy; Cancer; Oncology; Erlotinib; Personalized medicine; Companion diagnostic; Disease; Internal medicine; Gefitinib; Cancer research; Bioinformatics; Receptor; Biology","score_opus":0.0849552293686681,"score_gpt":0.3993099554364875,"score_spread":0.3143547260678194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117890976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718811,0.02258636,0.00027069566,0.0005284038,0.000929689,0.0030971486,0.0004098681,0.000005560852,0.00029117783],"genre_scores_gemma":[0.9942719,0.0018514245,0.000811766,0.000057990328,0.00021282636,0.0021654079,0.000098305856,0.000020783664,0.00050961645],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990554,0.00003498829,0.0003057472,0.00018572228,0.00010717277,0.00031095766],"domain_scores_gemma":[0.99919075,0.00021729905,0.00013937727,0.00020004738,0.00009792348,0.00015457845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004590008,0.00017917415,0.0004783349,0.00008978492,0.000042256877,0.0000026762234,0.000046054833,0.000046746663,0.00003146333],"category_scores_gemma":[0.000013187161,0.00010729341,0.00011849078,0.00018896356,0.000046478515,0.000035117322,0.000010526456,0.000038731196,4.511936e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012459239,0.014413364,0.71344745,0.00053122203,0.0008490245,0.0000060472285,0.021090839,0.0005890085,0.0015052359,0.00014116967,0.0034695796,0.24271111],"study_design_scores_gemma":[0.03793085,0.0058436296,0.15235348,0.0003364681,0.0056599868,0.00001376906,0.004266551,0.0049861385,0.01604593,0.0000027303547,0.77215636,0.0004040933],"about_ca_topic_score_codex":0.38306063,"about_ca_topic_score_gemma":0.23434108,"teacher_disagreement_score":0.7686868,"about_ca_system_score_codex":0.0043166676,"about_ca_system_score_gemma":0.002111644,"threshold_uncertainty_score":0.9995056},"labels":[],"label_agreement":null},{"id":"W2118345793","doi":"10.3390/jpm2030077","title":"Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System","year":2012,"lang":"en","type":"review","venue":"Journal of Personalized Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Manitoba","funders":"","keywords":"Personalized medicine; Subtyping; Medicine; Biomarker; Companion diagnostic; Precision medicine; Erlotinib; Lung cancer; Health care; Oncology; Epidermal growth factor receptor; Targeted therapy; Workload; Cancer; Internal medicine; Bioinformatics; Pathology; Computer science; Biology","score_opus":0.2423020025635594,"score_gpt":0.5165354182033168,"score_spread":0.27423341563975745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118345793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013713365,0.98080254,0.000116788964,0.013060366,0.0017708867,0.0025165416,0.00015007825,0.000030518284,0.0015385702],"genre_scores_gemma":[0.00035003785,0.98857045,0.0010149735,0.00044159338,0.0074522737,0.00062978273,0.00027454185,0.00013797819,0.0011283916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938057,0.00032853527,0.002853215,0.00051383284,0.0017363909,0.0007623314],"domain_scores_gemma":[0.99372846,0.0007500302,0.0031567651,0.00025391168,0.0014923644,0.0006184784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00408508,0.00073880726,0.0049070716,0.001321809,0.00017220949,0.0000112141915,0.0002624881,0.00037670456,0.0004759012],"category_scores_gemma":[0.00052602484,0.0004479174,0.00080127176,0.0005708944,0.000254548,0.0001749196,0.000037648068,0.0008679353,0.0000018764738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000871163,0.00039973794,0.00040743055,0.24223556,0.007339647,0.00033325306,0.022726906,0.0000017311327,0.0000096726035,0.015901467,0.010992259,0.6987812],"study_design_scores_gemma":[0.013368155,0.00077607285,0.000038545302,0.15060917,0.013990073,0.0020773355,0.006784234,0.000052440995,2.596871e-7,0.000029168792,0.8119838,0.00029071057],"about_ca_topic_score_codex":0.0002748023,"about_ca_topic_score_gemma":0.0001833086,"teacher_disagreement_score":0.8009916,"about_ca_system_score_codex":0.0039592385,"about_ca_system_score_gemma":0.0034771494,"threshold_uncertainty_score":0.9998644},"labels":[],"label_agreement":null},{"id":"W2119038990","doi":"10.1093/annonc/mds461","title":"Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Hazard ratio; Gastroenterology; Lung cancer; Anemia; Carboplatin; Clinical endpoint; Adverse effect; Surgery; Chemotherapy; Randomized controlled trial; Confidence interval","score_opus":0.019705394086644214,"score_gpt":0.3615424749756235,"score_spread":0.34183708088897924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119038990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938371,0.0015745441,0.000021529051,0.0014687384,0.00004381278,0.0009731898,0.000017779648,0.000005102231,0.002058206],"genre_scores_gemma":[0.99780256,0.0013190899,0.0003989614,0.00022842313,0.000014359776,0.00007431521,0.000045760968,0.000015443235,0.000101092024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991868,0.000038611273,0.0002920776,0.00015067866,0.00012171264,0.00021013305],"domain_scores_gemma":[0.9992509,0.00014112523,0.00021744243,0.000121178884,0.00019860138,0.000070742295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012093326,0.00012196818,0.0003884188,0.00013704337,0.00002201496,0.0000015053059,0.000034748864,0.00007921984,0.000021391781],"category_scores_gemma":[0.000020880689,0.000086406966,0.000020888816,0.00021412582,0.000066889486,0.000099240926,0.000010493135,0.0000991789,3.767851e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040377434,0.0032464275,0.904748,0.000105673105,0.00013359614,0.0000057559664,0.004410376,0.00023372484,0.0001479269,0.000049964892,0.000030041254,0.08285073],"study_design_scores_gemma":[0.029705547,0.013390546,0.95409065,0.0002640786,0.00007588578,0.0000018153988,0.00024764842,0.00005333423,0.0012265065,0.000013925252,0.0008384616,0.000091567475],"about_ca_topic_score_codex":0.001406335,"about_ca_topic_score_gemma":0.0012601583,"teacher_disagreement_score":0.082759164,"about_ca_system_score_codex":0.000094688156,"about_ca_system_score_gemma":0.00025276668,"threshold_uncertainty_score":0.3523574},"labels":[],"label_agreement":null},{"id":"W2119100187","doi":"10.1200/jco.2005.03.6491","title":"Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Topotecan; Medicine; Neutropenia; Internal medicine; Lung cancer; Regimen; Chemotherapy; Febrile neutropenia; Gastroenterology; Phases of clinical research; Oncology; Surgery","score_opus":0.04141248829153858,"score_gpt":0.4636003644563013,"score_spread":0.4221878761647627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119100187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953216,0.00015520182,0.00020491975,0.0004930455,0.00043877497,0.0012524843,0.0000058835594,0.000009276892,0.002118836],"genre_scores_gemma":[0.9966058,0.000019226229,0.0023134102,0.00040769254,0.0002537168,0.000034042252,0.000008547829,0.000020227713,0.00033734617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975107,0.00013193667,0.0015599955,0.00022855643,0.00027552195,0.00029330776],"domain_scores_gemma":[0.99808955,0.00019133875,0.0008290035,0.00015832196,0.0004304691,0.00030132133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005233244,0.00016376715,0.0013068077,0.0001744675,0.000046239566,0.00001077788,0.00011086599,0.00012057582,0.000049362247],"category_scores_gemma":[0.00010694729,0.00011056151,0.00011782534,0.00027093175,0.00004576035,0.000088425055,0.0000298725,0.00052455463,0.0000024461842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010662884,0.026910942,0.8984251,0.000019682087,0.00039141055,0.00043492607,0.0005590374,0.0015540584,0.000025020645,0.0000021486449,0.00032082957,0.060693942],"study_design_scores_gemma":[0.12427209,0.040808175,0.83209896,0.00015252517,0.001116403,0.000010019998,0.00023706829,0.00019005369,0.000041217394,0.000007805129,0.00095319847,0.0001124999],"about_ca_topic_score_codex":0.00090160494,"about_ca_topic_score_gemma":0.0032533316,"teacher_disagreement_score":0.11360921,"about_ca_system_score_codex":0.00067289395,"about_ca_system_score_gemma":0.0014307735,"threshold_uncertainty_score":0.45085675},"labels":[],"label_agreement":null},{"id":"W2119391913","doi":"10.1200/jco.2011.37.8349","title":"Maintenance Therapy Comes of Age for Non–Small-Cell Lung Cancer, but at What Cost?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.13290531571665418,"score_gpt":0.4857187324848399,"score_spread":0.3528134167681857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119391913","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.081991956,0.032353424,0.0006815865,0.854436,0.018265879,0.0041936296,0.00027357065,0.000020545052,0.0077834073],"genre_scores_gemma":[0.0072712423,0.13255805,0.0063780276,0.79433537,0.013695879,0.00025655323,0.00013761046,0.00014121099,0.045226045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623686,0.00019496327,0.0025605983,0.0002960242,0.00032412063,0.00038745263],"domain_scores_gemma":[0.99168146,0.0025857857,0.0041937125,0.00033188664,0.00097530487,0.00023182938],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010003458,0.0002960322,0.0028207628,0.00015478101,0.000052371794,0.00001559266,0.00031394407,0.0013156177,0.00034270118],"category_scores_gemma":[0.00036154359,0.00018802259,0.0012758425,0.00007514357,0.00027991927,0.00013001668,0.000050205377,0.001802418,0.000005657943],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003394239,0.00095252023,0.00687637,0.00039773932,0.002522434,0.0017882953,0.00029259373,0.000002399246,0.00005259499,0.000005820097,0.9100674,0.07364764],"study_design_scores_gemma":[0.018880513,0.008397811,0.005834085,0.0009722009,0.0026855087,0.00015057203,0.000087785535,0.000013655371,0.00017768465,0.00013209325,0.96250015,0.00016796334],"about_ca_topic_score_codex":0.00010274555,"about_ca_topic_score_gemma":0.00007788009,"teacher_disagreement_score":0.10020463,"about_ca_system_score_codex":0.00066552573,"about_ca_system_score_gemma":0.003428981,"threshold_uncertainty_score":0.99998087},"labels":[],"label_agreement":null},{"id":"W2119768199","doi":"10.1016/j.lungcan.2014.09.017","title":"Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab–carboplatin–paclitaxel and carboplatin–paclitaxel: A retrospective cohort study","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Cancer Institute; National Institute on Aging","keywords":"Medicine; Carboplatin; Hazard ratio; Bevacizumab; Internal medicine; Proportional hazards model; Cohort; Retrospective cohort study; Paclitaxel; Oncology; Lung cancer; Surgery; Cancer; Chemotherapy; Confidence interval","score_opus":0.00681406673692153,"score_gpt":0.33009641403799533,"score_spread":0.3232823473010738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119768199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945705,0.0008200238,0.00021638791,0.00010288673,0.000070407295,0.0025393742,0.00017319382,0.00006571667,0.0014415114],"genre_scores_gemma":[0.99885446,0.00004071487,0.00026665936,0.000019352105,0.000070205264,0.00028074975,0.00030605835,0.000055984252,0.000105795254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980671,0.00009347336,0.00039195782,0.0005646507,0.00061474915,0.00026810495],"domain_scores_gemma":[0.9985188,0.00012318845,0.00033707067,0.00030702667,0.0005176331,0.00019623416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013474979,0.000326331,0.00092230755,0.00011437432,0.00015312336,0.000027059572,0.000053158426,0.00009020807,0.00002444495],"category_scores_gemma":[0.00007187738,0.0002248563,0.00003098044,0.0003551524,0.00018908353,0.00016448823,0.000032421114,0.00015813929,2.6070245e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005561986,0.00030291683,0.9909443,0.00012885615,0.0012568167,0.0000024423011,0.0032910246,0.000029183626,0.000019308214,0.00004499669,0.000034802146,0.003389137],"study_design_scores_gemma":[0.010956707,0.0040525384,0.97960216,0.00043661724,0.0025270872,8.6996624e-7,0.0015433951,0.0004351281,0.00015743404,0.000010971504,0.000024979137,0.00025209523],"about_ca_topic_score_codex":0.0015152557,"about_ca_topic_score_gemma":0.0009398412,"teacher_disagreement_score":0.01134214,"about_ca_system_score_codex":0.00031350812,"about_ca_system_score_gemma":0.000121328645,"threshold_uncertainty_score":0.91693735},"labels":[],"label_agreement":null},{"id":"W2120326191","doi":"10.1097/jto.0000000000000115","title":"An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Anaplastic lymphoma kinase; Immunohistochemistry; Medicine; Concordance; Fluorescence in situ hybridization; Crizotinib; Lung cancer; Fish <Actinopterygii>; Pathology; Companion diagnostic; Cancer; Oncology; Internal medicine; Biology; Gene","score_opus":0.022543182242455412,"score_gpt":0.4662150926820093,"score_spread":0.4436719104395539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120326191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085003,0.000098549914,0.0063893083,0.0017336621,0.00032079875,0.00039908115,0.000018837698,0.00001031413,0.00017943178],"genre_scores_gemma":[0.9973381,0.000066356595,0.0017126271,0.0002488621,0.00058760785,0.0000046189,0.000014521819,0.000014960984,0.000012327385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851084,0.00044795912,0.00044582842,0.00021623012,0.00023813339,0.00014100465],"domain_scores_gemma":[0.9984347,0.00045252807,0.00051186455,0.00010791234,0.00034809954,0.00014486017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092110294,0.00015273363,0.0004481084,0.00017430611,0.0001795176,0.00006606301,0.00006542813,0.00009900881,0.0000046772325],"category_scores_gemma":[0.0001552813,0.0001060165,0.00004065774,0.00010266551,0.00018330352,0.0003611511,0.00003812412,0.00028062452,3.5094746e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006670067,0.00019022322,0.5694793,0.000028412403,0.0011023415,0.000057669648,0.003889807,0.000035671972,0.006709842,0.0000128318425,0.00001659256,0.41781035],"study_design_scores_gemma":[0.0024407334,0.0057660104,0.97645706,0.00015568896,0.0029541224,0.0008536696,0.0045463974,0.0037407621,0.0019012188,0.00037256855,0.0006745546,0.00013720519],"about_ca_topic_score_codex":0.00016342232,"about_ca_topic_score_gemma":0.00012690134,"teacher_disagreement_score":0.41767314,"about_ca_system_score_codex":0.00022418109,"about_ca_system_score_gemma":0.00018479677,"threshold_uncertainty_score":0.43232277},"labels":[],"label_agreement":null},{"id":"W2120645476","doi":"10.1016/j.jval.2014.03.523","title":"The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Ontario Institute for Cancer Research; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Crizotinib; Docetaxel; Medicine; Pemetrexed; Lung cancer; Oncology; Internal medicine; Chemotherapy; Cisplatin","score_opus":0.047150660884849434,"score_gpt":0.37851540281673596,"score_spread":0.33136474193188653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120645476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170786,0.00076395745,0.00008169723,0.0016199226,0.00023501285,0.0019447356,0.0000055310084,0.0000124434255,0.0036288318],"genre_scores_gemma":[0.99886477,0.00014585644,0.00036483005,0.00016663127,0.000023532559,0.00018775245,0.000024384299,0.000013947018,0.00020829009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857813,0.00039736528,0.0004121664,0.00019689376,0.00015072385,0.00026469366],"domain_scores_gemma":[0.99889725,0.0006340279,0.00010539972,0.0002447666,0.00004407809,0.000074481104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012949097,0.00009872857,0.00034353393,0.00012966983,0.00004377745,0.0000044389303,0.000059179718,0.00004807299,0.0000112998905],"category_scores_gemma":[0.00023216572,0.00007070173,0.00003350067,0.00027439796,0.000038544018,0.00004088414,0.000013213311,0.0002510466,0.0000023467273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028113073,0.0012830081,0.832865,0.001037986,0.00005568166,0.000031153526,0.010021757,0.015166667,0.00065771106,0.0033197075,0.000057777776,0.13269226],"study_design_scores_gemma":[0.008698074,0.00090087776,0.97703564,0.0017732402,0.000013558783,0.0000046277914,0.00027544846,0.0010524897,0.0002667907,0.00077185954,0.0091286125,0.00007876377],"about_ca_topic_score_codex":0.2589223,"about_ca_topic_score_gemma":0.2988329,"teacher_disagreement_score":0.14417067,"about_ca_system_score_codex":0.0010405685,"about_ca_system_score_gemma":0.0008034752,"threshold_uncertainty_score":0.74601257},"labels":[],"label_agreement":null},{"id":"W2121182949","doi":"10.3747/co.v15i6.382","title":"Retrospective Practice Review of Treatment of Metastatic Non-Small-Cell Lung Cancer with Second-Line Erlotinib","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Moncton Hospital; Jewish General Hospital; BC Cancer Agency","funders":"Jewish General Hospital","keywords":"Erlotinib; Medicine; Docetaxel; Oncology; Lung cancer; Internal medicine; Pemetrexed; Chemotherapy; Erlotinib Hydrochloride; Retrospective cohort study; Performance status; Progression-free survival; Cancer; Epidermal growth factor receptor; Cisplatin","score_opus":0.07730207527553745,"score_gpt":0.4541147123436647,"score_spread":0.37681263706812723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121182949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57754326,0.38694316,0.00055840967,0.0025590209,0.00092007313,0.004987523,0.0003660179,0.000041049723,0.02608148],"genre_scores_gemma":[0.7098101,0.27895245,0.0068095685,0.0005381741,0.00021832409,0.0009886558,0.00022384814,0.000050350838,0.0024085708],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989364,0.00007495433,0.0004114706,0.00024832276,0.0001527808,0.00017604772],"domain_scores_gemma":[0.9984576,0.00012296674,0.00051288726,0.00024829234,0.0005610446,0.0000971909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008716941,0.00017369894,0.0007920452,0.00007467927,0.000041875654,9.661356e-7,0.00004629563,0.0000346179,0.0005066903],"category_scores_gemma":[0.000054609452,0.00011444666,0.00011168966,0.00024380386,0.000117525706,0.0000571431,0.0000120161785,0.0000967764,0.0000046228233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005975722,0.0661433,0.570084,0.08419378,0.0168164,0.0014043453,0.04063594,0.00014426539,0.0038220698,0.0008245931,0.040594447,0.16936119],"study_design_scores_gemma":[0.05268762,0.05905643,0.082372315,0.017748648,0.039934814,0.0014885663,0.0017592921,0.00042148822,0.015711486,0.000029445851,0.72796386,0.00082601],"about_ca_topic_score_codex":0.00016246787,"about_ca_topic_score_gemma":0.0000865578,"teacher_disagreement_score":0.68736947,"about_ca_system_score_codex":0.00095287175,"about_ca_system_score_gemma":0.0017415726,"threshold_uncertainty_score":0.5547904},"labels":[],"label_agreement":null},{"id":"W2121252421","doi":"10.7150/ijms.4609","title":"EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation","year":2013,"lang":"en","type":"review","venue":"International Journal of Medical Sciences","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Università degli Studi di Milano","keywords":"Erlotinib; Epidermal growth factor receptor; Targeted therapy; KRAS; Medicine; Oncology; Lung cancer; Cancer research; Subtyping; Adenocarcinoma; Gefitinib; Internal medicine; Cancer; Colorectal cancer","score_opus":0.05750503526344831,"score_gpt":0.44902980577728213,"score_spread":0.39152477051383383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121252421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008236116,0.9836708,0.0008280485,0.0092736455,0.003338425,0.001141893,0.000064225795,0.000011878241,0.00084751326],"genre_scores_gemma":[0.0013727493,0.99416184,0.0010744602,0.0005493108,0.0020259235,0.00019649295,0.00004366293,0.000023984338,0.0005515681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624765,0.00006941489,0.00090325833,0.0002955578,0.002227834,0.0002563011],"domain_scores_gemma":[0.99746114,0.000551083,0.0010284999,0.00009924732,0.000515487,0.00034456194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008285826,0.00026817902,0.00085099787,0.00042683256,0.00011305204,0.00010821831,0.00084917265,0.00023913677,0.0008869378],"category_scores_gemma":[0.00022550934,0.0001377866,0.00063265243,0.00025106696,0.00015970516,0.00014549124,0.000034618428,0.00040669675,0.000019226123],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036577414,0.00028300073,0.000061315,0.00040749102,0.00078256207,0.00011117934,0.0001374203,0.00000786209,0.0000026457506,0.00012264567,0.0052901907,0.9927571],"study_design_scores_gemma":[0.004224471,0.0017946473,0.00007561515,0.015276932,0.0013097652,0.00049105316,0.00009616261,0.00048343826,0.00010070375,0.0003689356,0.97551894,0.00025930515],"about_ca_topic_score_codex":0.00022107366,"about_ca_topic_score_gemma":0.000020469684,"teacher_disagreement_score":0.9924978,"about_ca_system_score_codex":0.00073194044,"about_ca_system_score_gemma":0.004513608,"threshold_uncertainty_score":0.97113466},"labels":[],"label_agreement":null},{"id":"W2121828831","doi":"10.5858/2007-131-1014-rdilcs","title":"Resolving Dilemmas in Lung Cancer Staging and Histologic Typing","year":2007,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Pathology; Medicine; Typing; Biology; Genetics","score_opus":0.013177951748565635,"score_gpt":0.34293673350345444,"score_spread":0.3297587817548888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121828831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711857,0.021775924,0.0007208836,0.0018973909,0.00019511831,0.0002633533,0.0000135074915,0.000028809494,0.003919316],"genre_scores_gemma":[0.99586385,0.0009821242,0.0021557272,0.0007073315,0.0001104778,0.000018599358,0.000014727105,0.000014938198,0.00013223676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990026,0.000060165836,0.00033884324,0.00025224627,0.000089562986,0.0002565895],"domain_scores_gemma":[0.99923885,0.00031069346,0.0001227233,0.00017562247,0.000047746445,0.000104395425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003383615,0.00012540266,0.00037088915,0.00034075795,0.000054962424,0.00000120994,0.000049246602,0.000053623222,0.00005004878],"category_scores_gemma":[0.00019014106,0.000096856355,0.000020167978,0.0002392895,0.0004891557,0.000045262703,0.000034132303,0.00019114715,4.0182638e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017967998,0.0000737095,0.91002494,0.0002366356,0.00007153146,0.0010005141,0.009046035,0.0000056868557,0.0645638,0.0012383156,0.0001510815,0.013408079],"study_design_scores_gemma":[0.0034001707,0.00033108503,0.98886436,0.00093183626,0.0002695143,0.00006113957,0.0017289917,0.00012831898,0.0012747481,0.00025753365,0.0026358874,0.0001164159],"about_ca_topic_score_codex":0.00016738182,"about_ca_topic_score_gemma":0.00021606545,"teacher_disagreement_score":0.078839436,"about_ca_system_score_codex":0.0000787757,"about_ca_system_score_gemma":0.00016546318,"threshold_uncertainty_score":0.39496875},"labels":[],"label_agreement":null},{"id":"W2122190388","doi":"10.1097/jto.0000000000000667","title":"The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials","year":2015,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Oncology; Lung cancer; Clinical trial; Internal medicine; Chemotherapy; Performance status; Overall survival; Cisplatin","score_opus":0.09060818567827861,"score_gpt":0.5530540261727904,"score_spread":0.4624458404945118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122190388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0750095,0.91986173,0.000059587426,0.00083796895,0.0019489765,0.0018916948,0.000042844098,0.0000031978232,0.00034451068],"genre_scores_gemma":[0.018294469,0.98024726,0.00032259506,0.00006564575,0.0005820952,0.00006460397,0.0000030979884,0.000035304936,0.0003849115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944754,0.0015486006,0.0031339042,0.00021059714,0.0004041502,0.00022733286],"domain_scores_gemma":[0.9896361,0.0027432689,0.0063588326,0.0004212306,0.0007232115,0.000117326665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076286034,0.0002676385,0.0033679802,0.00019520757,0.00006314388,0.000006978665,0.00040581182,0.00040781233,0.000009976246],"category_scores_gemma":[0.0016156975,0.00012380882,0.00089533394,0.00039887134,0.00016309197,0.000060468068,0.000054739336,0.00095902133,8.057354e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014663052,0.0006026217,0.002631014,0.0035882113,0.0006790421,0.000016368816,0.00020857622,0.00050360645,0.000018030465,0.0000071383542,0.00016096854,0.99011815],"study_design_scores_gemma":[0.013171445,0.009185555,0.013273549,0.048360206,0.017898615,0.00017625009,0.0007383993,0.00020191178,0.00006764485,0.00013231022,0.89637303,0.0004210937],"about_ca_topic_score_codex":0.00018353738,"about_ca_topic_score_gemma":0.00037365913,"teacher_disagreement_score":0.98969704,"about_ca_system_score_codex":0.0022905068,"about_ca_system_score_gemma":0.0075665032,"threshold_uncertainty_score":0.9980597},"labels":[],"label_agreement":null},{"id":"W2122327814","doi":"10.1158/1078-0432.ccr-12-1818","title":"Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial","year":2013,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Sorafenib; Battle; Biomarker; Medicine; Oncology; Internal medicine; Clinical trial; Hepatocellular carcinoma; History; Biology; Archaeology","score_opus":0.4025781398296305,"score_gpt":0.5987744791664563,"score_spread":0.19619633933682584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122327814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819846,0.00072494027,0.000005510662,0.008547596,0.00011591764,0.0010732572,0.000037522816,0.0000052587156,0.0012915642],"genre_scores_gemma":[0.9983472,0.0005371539,0.00010397337,0.00016581581,0.00015435136,0.00021185339,0.000033107255,0.000006586786,0.00043993362],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979873,0.0004908456,0.00054074975,0.0002922952,0.00045456315,0.00023427658],"domain_scores_gemma":[0.9942072,0.0048934487,0.00007427868,0.00035873477,0.00035606435,0.00011024882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011919637,0.0000753225,0.00037054354,0.00023250749,0.00006685286,0.000026415066,0.00012074466,0.0000808239,0.000293834],"category_scores_gemma":[0.0011098668,0.00004333864,0.00014826324,0.0010044138,0.00045327816,0.00004237901,0.00005625732,0.00035508536,0.000022447757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15838906,0.007080824,0.34329337,0.00030188236,0.006307766,0.00014227557,0.003997171,0.00003737698,0.00081570965,0.00028191277,0.102380425,0.37697223],"study_design_scores_gemma":[0.054745115,0.0010037958,0.9335244,0.000044704604,0.000389131,0.0000010465576,0.00037772287,0.00020002939,0.000043885393,0.00009797277,0.009522232,0.00004992191],"about_ca_topic_score_codex":0.0053451387,"about_ca_topic_score_gemma":0.00041970512,"teacher_disagreement_score":0.59023106,"about_ca_system_score_codex":0.000054420783,"about_ca_system_score_gemma":0.00028417932,"threshold_uncertainty_score":0.80802864},"labels":[],"label_agreement":null},{"id":"W2122343496","doi":"10.1093/annonc/mdl042","title":"A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Paclitaxel; Pharmacokinetics; Neutropenia; Tolerability; Lung cancer; Epidermal growth factor receptor; Pharmacology; Rash; Internal medicine; Toxicity; Adverse effect; Gastroenterology; Chemotherapy; Oncology; Cancer","score_opus":0.016704306551795816,"score_gpt":0.36909628742680917,"score_spread":0.35239198087501333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122343496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549943,0.0001575897,0.000023680916,0.00058428117,0.00008430204,0.002616545,0.00015036328,0.000010464762,0.0008733362],"genre_scores_gemma":[0.99907416,0.000040376992,0.00023715805,0.00018135663,0.000022005705,0.00016413117,0.00015918208,0.000028281249,0.00009334673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839413,0.00015863568,0.00053506845,0.00032342252,0.00028863753,0.0003001226],"domain_scores_gemma":[0.9986037,0.000111170615,0.00048262722,0.00020795708,0.0005404045,0.000054126012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001093585,0.00022486226,0.00066218677,0.00022482534,0.00006515397,0.0000058449004,0.000111520916,0.000095501404,0.00003813549],"category_scores_gemma":[0.000019025605,0.00014659541,0.000057379024,0.00045448673,0.00011106273,0.00015351434,0.000031649703,0.00019668684,7.2453525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039874106,0.025464142,0.9605815,0.000104604136,0.0002746796,0.00003447618,0.0045739873,0.00016117466,0.0025672934,0.00003755612,0.00013614961,0.0020770398],"study_design_scores_gemma":[0.062372442,0.014662844,0.91553104,0.00033044297,0.00020199297,0.0000017323604,0.00085571717,0.00007892969,0.0057706865,0.00001224641,0.000033237524,0.00014867182],"about_ca_topic_score_codex":0.0039751595,"about_ca_topic_score_gemma":0.0018116502,"teacher_disagreement_score":0.058385033,"about_ca_system_score_codex":0.00030638586,"about_ca_system_score_gemma":0.00057574443,"threshold_uncertainty_score":0.6009278},"labels":[],"label_agreement":null},{"id":"W2122397603","doi":"10.1007/978-1-60761-524-8_10","title":"Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"book-chapter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Erlotinib; Gefitinib; Cetuximab; Medicine; Epidermal growth factor receptor; Docetaxel; Lung cancer; Oncology; Bevacizumab; Erlotinib Hydrochloride; Internal medicine; Chemotherapy; Clinical trial; EGFR inhibitors; Monoclonal antibody; Tyrosine kinase; Pharmacology; Cancer research; Cancer; Immunology; Receptor; Antibody","score_opus":0.014440951987985687,"score_gpt":0.30870348784135115,"score_spread":0.2942625358533655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122397603","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26835072,0.13056256,0.0000678889,0.008197107,0.010359427,0.015479058,0.0058047012,0.00019599502,0.5609825],"genre_scores_gemma":[0.25884986,0.04850296,0.000849482,0.0016007337,0.005381537,0.0037506903,0.00078127166,0.000468521,0.67981493],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979428,0.000024946245,0.0006071378,0.0005831835,0.0004163131,0.00042560836],"domain_scores_gemma":[0.99852276,0.00012775512,0.00041978963,0.00056465,0.00020286987,0.00016218724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006232126,0.0006053624,0.00088205794,0.00023418093,0.00010066168,0.000023267325,0.00018698623,0.00049175014,0.0024818494],"category_scores_gemma":[0.0000063383304,0.0003904519,0.00040444068,0.00009753129,0.00012842916,0.000065568616,0.00002478071,0.0005033016,0.000016652815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025301727,0.0062889676,0.54108727,0.012832098,0.01559454,0.0010339186,0.107400864,0.00018254336,0.024610158,0.005048384,0.13579094,0.14760013],"study_design_scores_gemma":[0.016420297,0.001971197,0.029480556,0.0056537003,0.01150438,0.000025317291,0.00035637213,0.00019318085,0.03047373,0.00022416351,0.90173054,0.0019665519],"about_ca_topic_score_codex":0.0055820243,"about_ca_topic_score_gemma":0.0035808678,"teacher_disagreement_score":0.7659396,"about_ca_system_score_codex":0.0015111322,"about_ca_system_score_gemma":0.0011067977,"threshold_uncertainty_score":0.99985474},"labels":[],"label_agreement":null},{"id":"W2122553809","doi":"10.1016/s0140-6736(08)61758-4","title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University Health Centre","funders":"AstraZeneca","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Internal medicine; Regimen; Hazard ratio; Population; Oncology; Chemotherapy; Performance status; Cancer; Epidermal growth factor receptor; Confidence interval","score_opus":0.06467038308692118,"score_gpt":0.372727022308989,"score_spread":0.30805663922206783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122553809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813842,0.0016428451,0.000020943146,0.0015352634,0.00038030732,0.0030149324,0.00004888175,0.00006507992,0.011907545],"genre_scores_gemma":[0.9922267,0.0012610349,0.000088339,0.00045446603,0.0010419489,0.00089779485,0.00007321842,0.00002690569,0.003929591],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988611,0.00006963344,0.0003206289,0.00024388751,0.00013600534,0.00036879574],"domain_scores_gemma":[0.99916303,0.00015533148,0.00011898856,0.00041541818,0.000048628033,0.000098614466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016476789,0.0001886662,0.00064966455,0.0000636446,0.0001131731,0.000016011452,0.00014997226,0.00006312109,0.000291964],"category_scores_gemma":[0.000042876327,0.000115551025,0.000134579,0.00020611068,0.00006444277,0.000048274735,0.000022594413,0.00019895924,0.000020865324],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94156677,0.0017504898,0.0050486815,0.00016253162,0.0009113163,0.00046145968,0.0074785925,0.00005993482,0.0014578184,0.000034418943,0.037557475,0.0035104973],"study_design_scores_gemma":[0.9908744,0.00077340356,0.0013219309,0.00018328328,0.0008298834,0.000019798585,0.000099983066,0.0005732393,0.0013595363,0.000006228552,0.003811683,0.0001466404],"about_ca_topic_score_codex":0.0011605461,"about_ca_topic_score_gemma":0.000486877,"teacher_disagreement_score":0.049307603,"about_ca_system_score_codex":0.00020271399,"about_ca_system_score_gemma":0.00028466835,"threshold_uncertainty_score":0.47120342},"labels":[],"label_agreement":null},{"id":"W2122566405","doi":"10.1200/jco.2013.53.3448","title":"Reality Check for Pemetrexed and Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Pemetrexed; Medicine; Lung cancer; Maintenance therapy; Oncology; Cancer; Internal medicine; Chemotherapy; Cisplatin","score_opus":0.10795916909754573,"score_gpt":0.5124767683272579,"score_spread":0.40451759922971214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122566405","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0974703,0.004396404,0.00071469054,0.8903273,0.0024255512,0.0015393054,0.000047144276,0.00000898889,0.0030703184],"genre_scores_gemma":[0.05214809,0.023170296,0.010257844,0.89539874,0.011361383,0.0002506525,0.000070146285,0.00009872176,0.0072441576],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967919,0.00023368471,0.0020612665,0.0003414657,0.00022472847,0.000346983],"domain_scores_gemma":[0.99466807,0.0020719187,0.0022799722,0.0002349967,0.00055825175,0.00018678966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016658991,0.00025007047,0.0022397127,0.00016024186,0.000035372883,0.00001014436,0.00015274165,0.0010444763,0.00005305683],"category_scores_gemma":[0.0008040796,0.0001649909,0.0005080113,0.000101372556,0.0001307483,0.000056203033,0.000023153974,0.0020777138,0.000001092331],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031963997,0.0006710521,0.036367867,0.0004500084,0.0008227143,0.0006710909,0.00015715533,0.000014162239,0.000035999383,0.0000053975227,0.8232513,0.13435686],"study_design_scores_gemma":[0.02599844,0.007315753,0.049817313,0.0005138649,0.00094419805,0.00008141991,0.000033485994,0.00014097209,0.00001712237,0.00017903802,0.9147978,0.00016058036],"about_ca_topic_score_codex":0.00014352643,"about_ca_topic_score_gemma":0.00015222224,"teacher_disagreement_score":0.13419627,"about_ca_system_score_codex":0.00047311262,"about_ca_system_score_gemma":0.0026648343,"threshold_uncertainty_score":0.9026748},"labels":[],"label_agreement":null},{"id":"W2123027432","doi":"10.1158/1535-7163.mct-07-0138","title":"Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; University of Pittsburgh; AstraZeneca","keywords":"Gefitinib; Erlotinib; Head and neck squamous-cell carcinoma; Cancer research; Epithelial–mesenchymal transition; Epidermal growth factor receptor; Biology; Vimentin; Squamous carcinoma; Medicine; Pathology; Oncology; Carcinoma; Internal medicine; Cancer; Head and neck cancer; Immunohistochemistry; Metastasis","score_opus":0.014017879677184339,"score_gpt":0.2841128916032479,"score_spread":0.27009501192606356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123027432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98039055,0.013831526,0.002188665,0.0006061532,0.000110721776,0.0009802534,0.000121321944,0.000018207475,0.0017525755],"genre_scores_gemma":[0.9954073,0.00021970473,0.0026416234,0.0011235046,0.000091184476,0.000055800887,0.000028721912,0.000049793463,0.00038240777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99856806,0.000036570025,0.00038112904,0.00039848467,0.0002390729,0.0003766639],"domain_scores_gemma":[0.9992692,0.000046527406,0.00010135826,0.0002542706,0.00013440695,0.00019425254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013138904,0.00025344847,0.0003561654,0.00017683387,0.000062869636,0.000016463791,0.00006765174,0.0001355799,0.000009034587],"category_scores_gemma":[0.0000030128683,0.00023975805,0.00006840125,0.00026384392,0.00007099979,0.000043304743,0.000023176945,0.00016337547,7.3198845e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002098185,0.0008241453,0.20004654,0.002004507,0.00008689675,0.00058655895,0.021495353,0.00030903213,0.7690243,0.00004855417,0.00005405588,0.0034218382],"study_design_scores_gemma":[0.010090646,0.0009292426,0.33606493,0.00018503908,0.00079481205,0.0000124322505,0.0006166143,0.0005605457,0.64915377,0.000050037434,0.0011980627,0.00034388347],"about_ca_topic_score_codex":0.0008749553,"about_ca_topic_score_gemma":0.0012210009,"teacher_disagreement_score":0.1360184,"about_ca_system_score_codex":0.00015957668,"about_ca_system_score_gemma":0.00022244603,"threshold_uncertainty_score":0.977705},"labels":[],"label_agreement":null},{"id":"W2123604427","doi":"10.6000/1929-2279.2012.01.01.15","title":"EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence","year":2012,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Tyrosine kinase; Carcinoma; Gefitinib; Chemotherapy; Cancer; Receptor","score_opus":0.023462319002535967,"score_gpt":0.3835249603084931,"score_spread":0.3600626413059571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123604427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867831,0.008851245,0.000007967878,0.0023725799,0.00052970275,0.00090626354,0.0000670163,0.000010362271,0.00047180292],"genre_scores_gemma":[0.99663234,0.0018699745,0.00022429056,0.000105593455,0.00057767564,0.00012506131,0.000044701683,0.00004440337,0.00037598665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969088,0.00019387476,0.0005812119,0.0002539794,0.0012260617,0.00083611323],"domain_scores_gemma":[0.99741846,0.00016194463,0.00030328037,0.00019828713,0.0013758587,0.0005421771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008871232,0.00023879291,0.00050067116,0.000483975,0.00013088615,0.000065430875,0.00018836517,0.00010517625,0.00032122098],"category_scores_gemma":[0.000099406665,0.00014426404,0.000099058074,0.0007544558,0.00014993097,0.0005433534,0.00007436611,0.0009146484,0.000006659662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00230305,0.0014457671,0.9868236,0.00021063325,0.00026254822,0.00014391165,0.0011218531,0.00011557869,0.0011265134,0.000014175684,0.0028628483,0.0035695173],"study_design_scores_gemma":[0.014526689,0.0015966234,0.9639189,0.0021784604,0.00034422975,0.000022633669,0.0002845289,0.00013657303,0.010876003,0.000018357672,0.0058021867,0.00029481575],"about_ca_topic_score_codex":0.0020281204,"about_ca_topic_score_gemma":0.0005638727,"teacher_disagreement_score":0.022904705,"about_ca_system_score_codex":0.0014158557,"about_ca_system_score_gemma":0.001386503,"threshold_uncertainty_score":0.58829165},"labels":[],"label_agreement":null},{"id":"W2123611729","doi":"10.1158/0008-5472.can-08-2223","title":"Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"U.S. Public Health Service; Chung Shan Medical University; National Cancer Institute; National Institutes of Health; Chiba University; Samuel Waxman Cancer Research Foundation","keywords":"KRAS; Cancer research; MAPK/ERK pathway; Lung cancer; Epidermal growth factor receptor; Kinase; MEK inhibitor; V600E; Tyrosine kinase; Biology; Receptor tyrosine kinase; Protein kinase domain; Cancer; Mutant; Medicine; Signal transduction; Internal medicine; Colorectal cancer; Cell biology; Genetics; Gene","score_opus":0.053975531625271134,"score_gpt":0.4196293516469179,"score_spread":0.36565382002164676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123611729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984579,0.010095501,0.000035446043,0.00028315574,0.00015992214,0.0008882418,0.00004192157,0.000013973449,0.003902806],"genre_scores_gemma":[0.9880795,0.005689839,0.00029778824,0.000053895714,0.00017028973,0.00073259836,0.0000060392913,0.000026829373,0.0049432204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983979,0.000058107224,0.00024303804,0.00030919866,0.0005563225,0.00043545003],"domain_scores_gemma":[0.9990882,0.00007850932,0.000045565554,0.0002912067,0.0003189988,0.00017748734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016608252,0.0001102323,0.00023938375,0.0002754237,0.00009451492,0.000006004379,0.00014971044,0.00007415433,0.00055026216],"category_scores_gemma":[0.000031713185,0.000092802504,0.00005279601,0.0006245208,0.00018044512,0.000050930696,0.000055723154,0.00031123558,0.000010389839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013384038,0.00021264314,0.97423685,0.0003900567,0.00009882981,0.0002206822,0.003142509,0.00041154047,0.015482149,0.000007704755,0.0036817514,0.0019814624],"study_design_scores_gemma":[0.0032685325,0.00028250585,0.9506505,0.00050050404,0.000120042976,0.000018511599,0.00033288667,0.00048637384,0.042115808,0.000022797414,0.0020597135,0.0001418273],"about_ca_topic_score_codex":0.012051392,"about_ca_topic_score_gemma":0.0029082801,"teacher_disagreement_score":0.026633658,"about_ca_system_score_codex":0.00065166294,"about_ca_system_score_gemma":0.0018193513,"threshold_uncertainty_score":0.99452746},"labels":[],"label_agreement":null},{"id":"W2123683855","doi":"10.1093/jnci/djp518","title":"Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Hamilton Health Sciences; University Health Network; University of Toronto; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Placebo; Randomized controlled trial; Internal medicine; Oncology; Erlotinib Hydrochloride; Clinical trial; Cancer; Pathology; Alternative medicine","score_opus":0.027905751893824212,"score_gpt":0.41188930207637414,"score_spread":0.3839835501825499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123683855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863531,0.00060989364,0.000100872014,0.0018128676,0.006541863,0.0019849534,0.00007013575,0.000004422818,0.002521869],"genre_scores_gemma":[0.99539536,0.00057064625,0.0009607089,0.00036459332,0.0015998821,0.00027929342,0.0000067971455,0.000013379635,0.0008093199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973434,0.00013870884,0.0016708305,0.00018949433,0.0004923072,0.00016524103],"domain_scores_gemma":[0.9969616,0.0005038342,0.0016567003,0.00016331952,0.00059742585,0.000117110634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018508428,0.00017163416,0.0014275309,0.00039074168,0.00006747747,0.000017576043,0.0002521556,0.00012416975,0.00020036845],"category_scores_gemma":[0.000602501,0.000103253486,0.001201153,0.00033664316,0.00016648877,0.00020025039,0.000029022589,0.0005618488,0.0000014473728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8786133,0.00073113927,0.039629567,0.000056329125,0.0068695014,0.000009090945,0.00038931647,0.070116535,0.00078943896,0.0003461822,0.00087437313,0.0015752144],"study_design_scores_gemma":[0.96937156,0.0001604133,0.016346304,0.00015210807,0.0065930793,0.000008479206,0.000023955214,0.0050569763,0.00057721185,0.00013856389,0.0014540545,0.00011729594],"about_ca_topic_score_codex":0.0004928923,"about_ca_topic_score_gemma":0.0038684853,"teacher_disagreement_score":0.09075825,"about_ca_system_score_codex":0.00054047373,"about_ca_system_score_gemma":0.004289759,"threshold_uncertainty_score":0.76098484},"labels":[],"label_agreement":null},{"id":"W2124214040","doi":"10.1158/1078-0432.ccr-06-0099","title":"<i>Epidermal Growth Factor Receptor</i>Mutation Testing in the Care of Lung Cancer Patients","year":2006,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Erlotinib; Gefitinib; Epidermal growth factor receptor; Medicine; Lung cancer; Oncology; Mutation; Clinical trial; Internal medicine; Cancer; Tyrosine kinase; Targeted therapy; T790M; Companion diagnostic; Cancer research; Biology; Genetics; Gene; Receptor","score_opus":0.3017331670672577,"score_gpt":0.6000678028015249,"score_spread":0.2983346357342672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124214040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041803974,0.9885276,0.0000012031911,0.00025547718,0.0004712752,0.0033780825,0.0007978835,0.000019334719,0.0023687468],"genre_scores_gemma":[0.007276263,0.98847395,0.00010044619,0.00010342275,0.0008770822,0.0020209583,0.0007531644,0.00007371622,0.00032100728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950116,0.0011332404,0.0015137716,0.0006381226,0.0011451968,0.0005580246],"domain_scores_gemma":[0.9940895,0.0033426073,0.00046536248,0.0004405876,0.0015181251,0.00014383964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010072938,0.00031480586,0.0014909527,0.00031645657,0.0001540553,0.000037699825,0.00037603042,0.00037467844,0.00015674377],"category_scores_gemma":[0.0016777267,0.00019107337,0.00044570238,0.001453547,0.0002904842,0.000083385334,0.00010083119,0.0015603348,0.000014619171],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004836037,0.00045159744,0.09213295,0.01687115,0.00024385269,0.00002391362,0.00046442825,0.0000017697954,1.2860475e-7,0.000022539884,0.0068293936,0.8829099],"study_design_scores_gemma":[0.004128216,0.0011394704,0.063794196,0.041546542,0.002308556,0.0000047806298,0.00024153234,0.000017358876,0.0000043060218,0.000040847503,0.88628864,0.00048557427],"about_ca_topic_score_codex":0.0067637973,"about_ca_topic_score_gemma":0.00064465817,"teacher_disagreement_score":0.88242435,"about_ca_system_score_codex":0.0012609741,"about_ca_system_score_gemma":0.0035335147,"threshold_uncertainty_score":0.9998503},"labels":[],"label_agreement":null},{"id":"W2125665528","doi":"10.1200/jco.2015.62.1342","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":851,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Pemetrexed; Oncology; Gefitinib; Erlotinib; Internal medicine; Crizotinib; Docetaxel; Lung cancer; Carboplatin; Afatinib; Chemotherapy; Bevacizumab; Cancer; Epidermal growth factor receptor; Malignant pleural effusion; Cisplatin","score_opus":0.19771397044676403,"score_gpt":0.6016853804165807,"score_spread":0.4039714099698167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125665528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8612616,0.008705594,0.015797526,0.093678646,0.011019387,0.0028364349,0.00015594838,0.00004611282,0.006498754],"genre_scores_gemma":[0.49780864,0.067894705,0.34764895,0.06964326,0.014050971,0.00014209638,0.00006962448,0.00014005552,0.002601716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98576486,0.0017264127,0.010863142,0.00053971977,0.00061979296,0.0004860496],"domain_scores_gemma":[0.96962273,0.01120643,0.0127598625,0.0005171089,0.004650167,0.0012436867],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022424819,0.0003216325,0.00475002,0.00008456826,0.000072049406,0.000013439947,0.0004190161,0.0009345522,0.000076491226],"category_scores_gemma":[0.009520001,0.00021982896,0.0022808968,0.00027973286,0.0007520261,0.0002129917,0.00010190406,0.0018667615,0.000011571618],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023709623,0.010999243,0.16160806,0.00014928517,0.005429714,0.00028174557,0.00046545436,0.00018553714,0.000055849818,0.000060664635,0.3294579,0.46759692],"study_design_scores_gemma":[0.049319033,0.045946084,0.01439176,0.00015141824,0.0039245775,0.00022778111,0.002395834,0.0024352307,0.00002214343,0.00004171534,0.8809467,0.00019775484],"about_ca_topic_score_codex":0.0003609189,"about_ca_topic_score_gemma":0.00008066391,"teacher_disagreement_score":0.55148876,"about_ca_system_score_codex":0.0006707331,"about_ca_system_score_gemma":0.02385866,"threshold_uncertainty_score":0.9988232},"labels":[],"label_agreement":null},{"id":"W2125702644","doi":"10.1158/1078-0432.ccr-14-1749","title":"Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Institutes of Health Research; Ontario Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center","keywords":"Lung cancer; Adenocarcinoma; Oncology; Medicine; Internal medicine; Mutation; Cancer research; Cancer; Gene; Biology; Genetics","score_opus":0.256740816745565,"score_gpt":0.5908408432994869,"score_spread":0.33410002655392196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125702644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96722233,0.016806003,0.00024994806,0.007576874,0.0008082386,0.0033651995,0.00006500345,0.0000323657,0.0038740216],"genre_scores_gemma":[0.99582326,0.00012177341,0.0013885672,0.00018935133,0.00043599054,0.0005519256,0.000017743418,0.000022819202,0.0014485825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998125,0.00023101777,0.00042103708,0.00027919494,0.0005773455,0.00036638213],"domain_scores_gemma":[0.9967029,0.001437562,0.000091967624,0.00034157335,0.0011365715,0.00028943646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013805241,0.00009264345,0.0002769904,0.000069470385,0.0001359191,0.000020427295,0.0001776287,0.00011077058,0.00004700374],"category_scores_gemma":[0.005710944,0.000051891217,0.00015793799,0.00037400756,0.0003921934,0.000045539076,0.000112017566,0.00055765675,0.000003969853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010057406,0.00039034017,0.907077,0.0003472657,0.00032184066,0.0000073247693,0.001968865,0.00002537847,0.0002628977,0.0024415797,0.05937792,0.026773859],"study_design_scores_gemma":[0.018560603,0.0060063545,0.8419644,0.0019220524,0.0011890092,0.000006761457,0.008217955,0.0036785337,0.0041625085,0.012858448,0.10104779,0.0003855814],"about_ca_topic_score_codex":0.0012259579,"about_ca_topic_score_gemma":0.00033453017,"teacher_disagreement_score":0.06511258,"about_ca_system_score_codex":0.00036507248,"about_ca_system_score_gemma":0.002780177,"threshold_uncertainty_score":0.6836946},"labels":[],"label_agreement":null},{"id":"W2126013413","doi":"10.1016/j.lungcan.2004.03.007","title":"Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"","keywords":"Docetaxel; Medicine; Gemcitabine; Internal medicine; Regimen; Toxicity; Oncology; Phases of clinical research; Chemotherapy; Progressive disease; Performance status; Gastroenterology; Surgery","score_opus":0.02758055674964294,"score_gpt":0.3685417805657494,"score_spread":0.34096122381610644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126013413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885514,0.003710206,0.0008084058,0.001550566,0.00045513702,0.0036210713,0.0003451742,0.000032214943,0.0009258287],"genre_scores_gemma":[0.9927494,0.00014137127,0.002599891,0.00090816646,0.00029193584,0.0010543307,0.00009488411,0.00004501531,0.0021150236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998833,0.00001480251,0.00027521458,0.00042221483,0.00014342472,0.0003113211],"domain_scores_gemma":[0.9992956,0.000067572786,0.00010989099,0.00022329827,0.00007823647,0.00022542017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007386928,0.0002447227,0.00038798866,0.00009698355,0.00019418569,0.000037634094,0.000045513,0.000053660446,0.00005760077],"category_scores_gemma":[0.000023167302,0.00019175843,0.00009172176,0.000084106876,0.000053888823,0.00008403713,0.00003255457,0.00010264633,0.0000014735418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53871065,0.043681357,0.059369355,0.022502916,0.014460224,0.0016497936,0.10284748,0.0006210275,0.053899366,0.00311916,0.03762536,0.121513315],"study_design_scores_gemma":[0.94480914,0.013835861,0.0071196505,0.0010208314,0.008997319,0.00004123597,0.00063912274,0.0052952818,0.008717283,0.000102836115,0.008715867,0.0007055739],"about_ca_topic_score_codex":0.00029062064,"about_ca_topic_score_gemma":0.00013211265,"teacher_disagreement_score":0.40609848,"about_ca_system_score_codex":0.00026512516,"about_ca_system_score_gemma":0.00030307315,"threshold_uncertainty_score":0.7819682},"labels":[],"label_agreement":null},{"id":"W2126151458","doi":"10.3816/clc.2009.n.075","title":"Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress","year":2009,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Mesothelioma; Clinical trial; Cancer; Oncology; Vascular endothelial growth factor; Epidermal growth factor receptor; Internal medicine; VEGF receptors; Pathology","score_opus":0.13413378968187842,"score_gpt":0.5875380266209496,"score_spread":0.45340423693907117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126151458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057937974,0.9819644,0.0000072330895,0.004325073,0.0027640553,0.0056415508,0.003428299,0.000048472866,0.0017629919],"genre_scores_gemma":[0.000044553723,0.9818386,0.00007806245,0.003844972,0.0025287643,0.004073741,0.001260847,0.00008653916,0.0062439493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99395037,0.0011996499,0.0019690972,0.0011867139,0.0010092144,0.000684965],"domain_scores_gemma":[0.9951223,0.0021862302,0.00061598216,0.00085261685,0.0009243984,0.00029847087],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020643284,0.0006207341,0.0028458084,0.00018643391,0.00022175164,0.00009480943,0.0006930004,0.00051391695,0.0020249253],"category_scores_gemma":[0.0009040374,0.0003617287,0.0007793186,0.0009954685,0.00046007746,0.00019752089,0.00021870085,0.0021036346,0.000044291006],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012871066,0.00033913637,0.0034581006,0.008178711,0.001891024,0.00020109561,0.00016989194,0.0000025696822,4.9431055e-8,0.00012358114,0.25221124,0.73329586],"study_design_scores_gemma":[0.00086923107,0.00012546495,0.002150752,0.19220752,0.0035873884,0.000011824616,0.0000319895,0.000038768605,1.3610182e-7,0.000015815027,0.8006617,0.00029944637],"about_ca_topic_score_codex":0.0017151298,"about_ca_topic_score_gemma":0.0026380038,"teacher_disagreement_score":0.73299646,"about_ca_system_score_codex":0.0017211677,"about_ca_system_score_gemma":0.003421418,"threshold_uncertainty_score":0.9998835},"labels":[],"label_agreement":null},{"id":"W2126156851","doi":"10.1016/j.jval.2013.08.503","title":"Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Ontario Institute for Cancer Research; University of Toronto; Toronto Public Health; St. Michael's Hospital","funders":"","keywords":"Crizotinib; Medicine; Oncology; Population; Lung cancer; Internal medicine; Cost effectiveness; ALK inhibitor; Environmental health","score_opus":0.030345237848856524,"score_gpt":0.3114200689726865,"score_spread":0.28107483112382997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126156851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892714,0.00043895,0.00014348386,0.0002734611,0.000119805336,0.00927982,0.00018896862,0.00001347135,0.00027063277],"genre_scores_gemma":[0.9954661,0.000036421425,0.0019486264,0.00006128735,0.00001760683,0.0022885278,0.000097275864,0.000027095282,0.000057031164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986249,0.00008665361,0.00039438414,0.00035091885,0.00018163641,0.0003614601],"domain_scores_gemma":[0.99857646,0.0005546766,0.00023255205,0.00015518648,0.00029794578,0.00018318911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016326366,0.0001989797,0.00049469725,0.00012704347,0.00010466114,0.000011661612,0.000036172656,0.000047830465,0.000006546002],"category_scores_gemma":[0.000039320916,0.00014845455,0.000024160734,0.00024415323,0.000018198978,0.00008891974,0.000015621921,0.00008503925,1.1886311e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058321527,0.00056734204,0.9791559,0.0026695991,0.00006539463,0.000007891727,0.0016557414,0.006093507,0.000031598618,0.000013194739,0.000010949407,0.009145657],"study_design_scores_gemma":[0.015852636,0.0032507624,0.96488965,0.004497353,0.00009864839,0.000003164496,0.00047918336,0.010483086,0.00025564042,0.000005851386,0.000044850807,0.00013917526],"about_ca_topic_score_codex":0.9873343,"about_ca_topic_score_gemma":0.93775636,"teacher_disagreement_score":0.049577985,"about_ca_system_score_codex":0.0057364726,"about_ca_system_score_gemma":0.0024497455,"threshold_uncertainty_score":0.9980803},"labels":[],"label_agreement":null},{"id":"W2126270742","doi":"10.1016/j.lungcan.2009.11.018","title":"Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pemetrexed; Medicine; Erlotinib; Gefitinib; Oncology; Cetuximab; Bevacizumab; Internal medicine; Lung cancer; Adenocarcinoma; Clinical trial; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Colorectal cancer","score_opus":0.04081135753217011,"score_gpt":0.44960652796712375,"score_spread":0.4087951704349536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126270742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01063804,0.9820114,0.000002224985,0.0011213901,0.00079976325,0.0022235813,0.0010234391,0.000010464285,0.0021697166],"genre_scores_gemma":[0.006168726,0.9900777,0.00049162126,0.00003426832,0.00024008079,0.00051932305,0.0003745883,0.000037975926,0.002055721],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974024,0.00016278058,0.0013884166,0.00039680436,0.00041430173,0.00023526335],"domain_scores_gemma":[0.99643075,0.00019898402,0.0023932073,0.00044991,0.00046434908,0.000062802676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023548641,0.00033420126,0.001801007,0.00021364428,0.00003311336,0.0000040733153,0.00023086976,0.00028043386,0.00006389949],"category_scores_gemma":[0.00008977702,0.00022510764,0.00035480165,0.00044061377,0.000046150693,0.00007543611,0.00003612487,0.00014777773,2.0840062e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040416574,0.0013919699,0.0036413795,0.005659519,0.0013059766,0.0000065020604,0.004334113,0.00076737895,0.00008415378,0.0000042393535,0.0003381485,0.98206246],"study_design_scores_gemma":[0.007236693,0.0015518675,0.00298668,0.052082423,0.006808992,0.000004630886,0.00044537566,0.000503578,0.0047394596,0.000008087071,0.92325836,0.00037384548],"about_ca_topic_score_codex":0.0058399634,"about_ca_topic_score_gemma":0.0059090606,"teacher_disagreement_score":0.9816886,"about_ca_system_score_codex":0.004538605,"about_ca_system_score_gemma":0.0014303855,"threshold_uncertainty_score":0.9992828},"labels":[],"label_agreement":null},{"id":"W2126372889","doi":"10.1158/1078-0432.ccr-06-2610","title":"Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rash; Erlotinib; Internal medicine; Medicine; Gefitinib; Gemcitabine; Epidermal growth factor receptor; Erlotinib Hydrochloride; Hazard ratio; Gastroenterology; Oncology; Cancer; Confidence interval","score_opus":0.1488288453879716,"score_gpt":0.5328739408514896,"score_spread":0.38404509546351806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126372889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970117,0.0006252473,0.000024561903,0.00068733445,0.00006389796,0.0014691171,0.00004980177,0.00001071404,0.00005759998],"genre_scores_gemma":[0.99911946,0.00015483872,0.00017519771,0.000053816595,0.00013458321,0.000096669384,0.00009649489,0.000018307925,0.0001506115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977868,0.00022543476,0.00076769973,0.00033153422,0.0004912722,0.00039724892],"domain_scores_gemma":[0.99751955,0.001537474,0.00013327615,0.0001561693,0.0004968311,0.00015671542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018970611,0.00013579444,0.00046116635,0.0002186812,0.00012724928,0.000009495476,0.000060459413,0.00006917046,0.00003913179],"category_scores_gemma":[0.00064467115,0.00008062915,0.000035411893,0.0006426091,0.00029560173,0.000076154574,0.00007525795,0.0004719409,0.000003872217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026993982,0.0016495036,0.96338654,0.00005602279,0.00016456618,0.000010626625,0.0023804714,0.0000013391377,0.000036558384,0.000013135626,0.00025853282,0.02934329],"study_design_scores_gemma":[0.038544625,0.0009327852,0.9577301,0.00038846102,0.00005393369,1.7562726e-7,0.0004832623,0.000010398765,0.0011467432,0.0000038189264,0.0006235939,0.00008208451],"about_ca_topic_score_codex":0.0003520887,"about_ca_topic_score_gemma":0.0016220358,"teacher_disagreement_score":0.035845228,"about_ca_system_score_codex":0.00040238624,"about_ca_system_score_gemma":0.00039530112,"threshold_uncertainty_score":0.32879615},"labels":[],"label_agreement":null},{"id":"W2126491616","doi":"10.1183/09031936.00010111","title":"Nomogram to predict the presence of<i>EGFR</i>activating mutation in lung adenocarcinoma","year":2011,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"National Taiwan University; National Taiwan University Hospital; Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Nomogram; Adenocarcinoma; Lung; Mutation; Oncology; Adenocarcinoma of the lung; Lung cancer; Internal medicine; Cancer research; Genetics; Cancer; Gene","score_opus":0.0384611590508813,"score_gpt":0.3070397475274314,"score_spread":0.2685785884765501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126491616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695251,0.000816311,0.00075522857,0.00016560616,0.0001827361,0.00039719485,0.0000037603395,0.00001961259,0.028134475],"genre_scores_gemma":[0.9980639,0.000007988576,0.00095148105,0.00057561084,0.00021658285,0.000008526664,0.0000011443082,0.000025368223,0.00014937394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987642,0.00027279207,0.00038674148,0.00014715994,0.00024414892,0.00018496941],"domain_scores_gemma":[0.9992694,0.000057041503,0.00018429635,0.00021660155,0.00012947005,0.00014318213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000647325,0.000102730504,0.00013834385,0.000161435,0.0001242776,0.000023463173,0.0001476318,0.000017794178,0.00009031664],"category_scores_gemma":[0.00020232871,0.00006726707,0.00006591527,0.00026947324,0.00004763528,0.0001361011,0.000039330214,0.0002741946,0.000019334435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003820378,0.00035825177,0.911351,0.000068248475,0.00021617905,0.0015025253,0.023348883,0.00022499042,0.004506098,0.00015184432,0.0029530819,0.054936808],"study_design_scores_gemma":[0.0012549432,0.0005995394,0.99116784,0.00027128385,0.00007812632,0.00021272017,0.000974597,0.000060966904,0.0016462813,0.000018157007,0.0036393574,0.000076163036],"about_ca_topic_score_codex":0.000024600646,"about_ca_topic_score_gemma":0.000006889743,"teacher_disagreement_score":0.07981681,"about_ca_system_score_codex":0.00010360899,"about_ca_system_score_gemma":0.00015085314,"threshold_uncertainty_score":0.27430716},"labels":[],"label_agreement":null},{"id":"W2126925889","doi":"10.1126/scitranslmed.3007013","title":"A Blood-Based Proteomic Classifier for the Molecular Characterization of Pulmonary Nodules","year":2013,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Caprion (Canada)","funders":"National Cancer Institute","keywords":"Lung cancer; Medicine; Lung; Classifier (UML); Biopsy; Pathology; Radiology; Internal medicine; Artificial intelligence; Computer science","score_opus":0.017592182115474173,"score_gpt":0.31082429323749433,"score_spread":0.29323211112202013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126925889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92173165,0.00016395826,0.03848183,0.035989385,0.00015078938,0.0025229848,0.000028968205,0.000021573704,0.0009088552],"genre_scores_gemma":[0.9965033,0.0000062740055,0.0022117659,0.00054010877,0.00008757144,0.00038927575,0.000095963864,0.000007923672,0.00015784531],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99903363,0.000008677326,0.0002079638,0.00018223065,0.00042942946,0.0001380439],"domain_scores_gemma":[0.9992628,0.000086131964,0.000075380674,0.00016176772,0.00034439203,0.00006949063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019754125,0.00008003126,0.00012848836,0.000119371194,0.00014057527,0.000007673118,0.000098125114,0.000020413701,0.0002082078],"category_scores_gemma":[0.000061983956,0.000044384975,0.000043910375,0.00038504854,0.00059054577,0.00013602675,0.0000030535423,0.000044511402,0.0000036910972],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035549343,0.00011340779,0.004378006,0.000055314693,0.000031778425,9.831394e-7,0.00018193842,0.00004437484,0.9829484,0.0025366503,0.000010647153,0.009662949],"study_design_scores_gemma":[0.0035653936,0.00047184632,0.8372066,0.00029692746,0.0006367256,0.000022800386,0.00009380324,0.046657942,0.10876302,0.0016329484,0.0005323591,0.000119613345],"about_ca_topic_score_codex":0.000045395576,"about_ca_topic_score_gemma":9.1678703e-7,"teacher_disagreement_score":0.8741854,"about_ca_system_score_codex":0.000019389847,"about_ca_system_score_gemma":0.00028435138,"threshold_uncertainty_score":0.22797294},"labels":[],"label_agreement":null},{"id":"W2127342594","doi":"10.1056/nejmoa043623","title":"Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1832,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Vinorelbine; Internal medicine; Neutropenia; Lung cancer; Gastroenterology; Surgery; Hazard ratio; Chemotherapy; Regimen; Cisplatin; Confidence interval","score_opus":0.021427260195029142,"score_gpt":0.3306539613456979,"score_spread":0.30922670115066875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127342594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612037,0.00474124,0.0006139488,0.03032029,0.00045643005,0.0003295017,0.000003183138,0.000011542555,0.0023201767],"genre_scores_gemma":[0.98615086,0.0012456423,0.0023409445,0.0013905205,0.0048418795,0.000008192221,0.00002613112,0.000022220192,0.003973604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985894,0.000040921954,0.00063041685,0.00013557781,0.00039232898,0.00021134682],"domain_scores_gemma":[0.9988947,0.00012132589,0.00031480516,0.00014090292,0.00026739936,0.00026087635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038125654,0.00015382224,0.00047637903,0.00029688902,0.00003872287,0.0000072724984,0.00008377633,0.000073233765,0.00050647074],"category_scores_gemma":[0.00015335881,0.0001000935,0.000054346405,0.00035974404,0.00003148737,0.0001248325,0.0000113804845,0.0003639155,0.0000032170956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052090846,0.0005504707,0.5744138,0.00038661592,0.00056571735,0.00093418156,0.015277223,0.0058393897,0.025847374,0.000082776576,0.07931929,0.29157412],"study_design_scores_gemma":[0.29105437,0.0031685452,0.59797573,0.003498012,0.0018501963,0.00064548803,0.00045245315,0.009289528,0.0029643402,0.0000960818,0.08872175,0.00028348368],"about_ca_topic_score_codex":0.0012681973,"about_ca_topic_score_gemma":0.0013893305,"teacher_disagreement_score":0.29129064,"about_ca_system_score_codex":0.0005057794,"about_ca_system_score_gemma":0.00072796346,"threshold_uncertainty_score":0.55454993},"labels":[],"label_agreement":null},{"id":"W2127685474","doi":"10.1200/jco.2007.15.2280","title":"Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"American Society of Clinical Oncology; AstraZeneca","keywords":"Medicine; Erlotinib; Lung cancer; Internal medicine; Placebo; Hazard ratio; Cancer; Clinical trial; Chemotherapy; Quality of life (healthcare); Surgery; Gastroenterology; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.22132737951902,"score_gpt":0.5780171170297974,"score_spread":0.35668973751077737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127685474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093944,0.0005188325,0.00011431837,0.004548507,0.0020439394,0.001348279,0.000118496784,0.0000015641826,0.00036662017],"genre_scores_gemma":[0.9958321,0.00066548,0.00071008655,0.0016500935,0.00079874555,0.000104453735,0.0000071552067,0.000010553221,0.00022132986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99336493,0.0012628249,0.004306651,0.00022463966,0.0006468765,0.00019410088],"domain_scores_gemma":[0.9894953,0.0054014022,0.0036848707,0.00022619778,0.0010251665,0.00016709065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008849779,0.00014056478,0.0023028515,0.00015481118,0.00009366184,0.0000035727298,0.00033726165,0.00018357277,0.00007382779],"category_scores_gemma":[0.0046785795,0.000071400056,0.000896175,0.00056530454,0.00020963716,0.00010050549,0.000027981936,0.000562319,5.7111386e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036425106,0.006827572,0.9471015,0.000040162828,0.0059373914,0.000055696662,0.0011194169,0.0073094866,0.00006371794,0.000043140855,0.0030341712,0.024825243],"study_design_scores_gemma":[0.01953246,0.0069418293,0.9536471,0.000072150266,0.009021735,0.000011276996,0.0009083639,0.0011479515,0.00001970044,0.00002742875,0.008593212,0.000076823206],"about_ca_topic_score_codex":0.03208002,"about_ca_topic_score_gemma":0.5316696,"teacher_disagreement_score":0.4995896,"about_ca_system_score_codex":0.00043977392,"about_ca_system_score_gemma":0.015517228,"threshold_uncertainty_score":0.9900639},"labels":[],"label_agreement":null},{"id":"W2127766722","doi":"10.1158/1541-7786.mcr-06-0095","title":"Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Gefitinib; Lung cancer; Cancer research; Epidermal growth factor receptor; Microarray; Biology; Gene expression profiling; Gene expression; Gene; Microarray analysis techniques; Cancer; Oncology; Medicine; Genetics","score_opus":0.025920322826489327,"score_gpt":0.3855937390332659,"score_spread":0.35967341620677656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127766722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98081887,0.0071367435,0.0027496659,0.0021138175,0.0001571975,0.0019136106,0.00020753738,0.00004892397,0.004853637],"genre_scores_gemma":[0.9895782,0.00054487353,0.002738294,0.00054681394,0.00048451894,0.0012118089,0.00015246554,0.000074339114,0.004668691],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971796,0.00025628545,0.00033122188,0.00067035755,0.000792495,0.0007700104],"domain_scores_gemma":[0.99854314,0.0001054743,0.00005359065,0.00048263773,0.0005049265,0.00031022902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067419116,0.00024057688,0.0003388889,0.0002936625,0.00014559446,0.00004598378,0.000115723145,0.00013611754,0.0002537459],"category_scores_gemma":[0.00004821358,0.00021123288,0.00009619988,0.00069530605,0.0000550512,0.000074381904,0.00014595724,0.00039466246,0.000022439595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027165373,0.0005740009,0.02626738,0.00034470594,0.00003245357,0.0010822845,0.00040989288,0.005410364,0.95471394,0.000005823775,0.00869999,0.0021874963],"study_design_scores_gemma":[0.0032451882,0.00017392279,0.018582633,0.0005421003,0.00010638132,0.000006852117,0.00010627856,0.0036048866,0.9696297,0.00001531822,0.0037510365,0.00023568857],"about_ca_topic_score_codex":0.040949225,"about_ca_topic_score_gemma":0.008015593,"teacher_disagreement_score":0.032933634,"about_ca_system_score_codex":0.0010178039,"about_ca_system_score_gemma":0.00085150445,"threshold_uncertainty_score":0.9654372},"labels":[],"label_agreement":null},{"id":"W2128316782","doi":"10.1016/j.ijrobp.2007.07.1698","title":"Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study","year":2007,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Eli Lilly (Canada); Sunnybrook Hospital; Ottawa Regional Cancer Foundation; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pemetrexed; Carboplatin; Regimen; Internal medicine; Cisplatin; Lung cancer; Phases of clinical research; Chemotherapy; Premedication; Oncology; Urology; Gastroenterology; Surgery","score_opus":0.025730527926234696,"score_gpt":0.41701540497284445,"score_spread":0.39128487704660975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128316782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9081578,0.0014432826,0.08242625,0.0009603209,0.004221392,0.0015577291,0.00036543666,0.000038106205,0.00082964497],"genre_scores_gemma":[0.9932636,0.00042239568,0.0018256434,0.00048855256,0.0029039136,0.00010793059,0.0003338185,0.000043252494,0.0006108651],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978387,0.00009260397,0.00102161,0.0003262049,0.0003495969,0.00037133633],"domain_scores_gemma":[0.99638397,0.0005186476,0.0014162795,0.00016663401,0.0012879438,0.00022650842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084876997,0.00027185702,0.00057914964,0.00033121536,0.00021869403,0.000036663903,0.0002813913,0.00018482252,0.00012479376],"category_scores_gemma":[0.00018234768,0.00023878543,0.00027936028,0.00026665328,0.00007298048,0.0002864033,0.00005386113,0.00038151312,0.0000057834472],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015036225,0.008095368,0.4711079,0.00006470884,0.002683848,0.00008971038,0.004857384,0.0015948183,0.005425397,0.0019326289,0.003946175,0.49869844],"study_design_scores_gemma":[0.3208423,0.0710807,0.14984562,0.0005521923,0.00835644,0.00025834786,0.005486257,0.059612643,0.041532896,0.0022370156,0.338331,0.0018645971],"about_ca_topic_score_codex":0.00014248716,"about_ca_topic_score_gemma":0.0000689892,"teacher_disagreement_score":0.49683383,"about_ca_system_score_codex":0.0019385726,"about_ca_system_score_gemma":0.0013569234,"threshold_uncertainty_score":0.9737388},"labels":[],"label_agreement":null},{"id":"W2128496826","doi":"10.1172/jci46088","title":"Growing a tumor stroma: a role for granulin and the bone marrow","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Investigation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre","funders":"Astellas Foundation for Research on Metabolic Disorders; Japan Society for the Promotion of Science; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Astellas Pharma; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Uehara Memorial Foundation; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Suzuken Memorial Foundation","keywords":"Stromal cell; Bone marrow; Stroma; Cancer research; Haematopoiesis; Carcinogenesis; Tumor progression; Biology; Progenitor cell; Stem cell; Cancer; Immunology; Pathology; Medicine; Cell biology; Genetics; Immunohistochemistry","score_opus":0.06277724694104093,"score_gpt":0.3767053342269013,"score_spread":0.31392808728586036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128496826","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08029457,0.002410317,0.0003980668,0.9141546,0.0010734423,0.0010486232,0.000032166998,0.000014706124,0.0005735372],"genre_scores_gemma":[0.044995543,0.00045294064,0.014788793,0.9211544,0.016082976,0.00010120607,0.00015611618,0.00008181335,0.0021862164],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978399,0.00019185884,0.0013525276,0.00016919765,0.00029663058,0.00014987773],"domain_scores_gemma":[0.99679977,0.0011310445,0.0014158814,0.00016461148,0.00034510213,0.00014357937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013760941,0.00016348787,0.00082475046,0.00009463714,0.0000848732,0.000036183912,0.00008340157,0.00028439282,0.00001916987],"category_scores_gemma":[0.0011998463,0.000090575406,0.00047576413,0.0000646828,0.0003628397,0.00016437664,0.000012552984,0.0011900625,0.000002932354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017935752,0.00012783073,0.0057640327,0.00045079718,0.0015356577,0.00036658047,0.0008458937,0.0000017137874,0.00008874638,0.0011645643,0.980159,0.007701601],"study_design_scores_gemma":[0.040009372,0.0035830936,0.015318721,0.0023274242,0.012056952,0.001476375,0.00025380062,0.00047100306,0.00015422158,0.15393206,0.7700284,0.0003885371],"about_ca_topic_score_codex":0.000028725724,"about_ca_topic_score_gemma":0.0000030105466,"teacher_disagreement_score":0.21013057,"about_ca_system_score_codex":0.0000392046,"about_ca_system_score_gemma":0.00044252613,"threshold_uncertainty_score":0.5170295},"labels":[],"label_agreement":null},{"id":"W2130603905","doi":"10.1200/jco.2014.56.2157","title":"Targeted Therapies in Non–Small-Cell Lung Cancer Management: No Cost-Effective Strategies?","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.05229756594478189,"score_gpt":0.47000264755812027,"score_spread":0.41770508161333836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130603905","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028138753,0.008797962,0.0010010101,0.7902801,0.011495626,0.007816302,0.000055411387,0.000039063747,0.1523758],"genre_scores_gemma":[0.052788004,0.01006263,0.0040657525,0.8992564,0.02005828,0.0008791864,0.00012158403,0.00014416942,0.012623975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622995,0.0005717176,0.0020767078,0.00034571998,0.0003722152,0.00040371958],"domain_scores_gemma":[0.99512917,0.0015872563,0.00228312,0.00026879882,0.00055185327,0.00017977705],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012448969,0.00033247075,0.0022590465,0.00032566648,0.000041376432,0.000028393675,0.00024997987,0.0012768578,0.0004485107],"category_scores_gemma":[0.00016901363,0.00022750981,0.00064258615,0.00016791528,0.00014948868,0.00010817782,0.00004518465,0.003648844,0.00004150413],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014218568,0.0011148852,0.011873719,0.0007962982,0.0046075163,0.007888245,0.00034654516,0.000075076685,0.000010916687,0.000021225906,0.8953525,0.076491244],"study_design_scores_gemma":[0.013759449,0.004436771,0.036913272,0.00069557526,0.003269052,0.00006647198,0.00014064414,0.00009573141,0.0000040153327,0.00013798618,0.9402812,0.00019979487],"about_ca_topic_score_codex":0.0001357939,"about_ca_topic_score_gemma":0.0000900281,"teacher_disagreement_score":0.13975182,"about_ca_system_score_codex":0.0008096364,"about_ca_system_score_gemma":0.0020382535,"threshold_uncertainty_score":0.9986498},"labels":[],"label_agreement":null},{"id":"W2130986264","doi":"10.1016/s0093-7754(01)90297-0","title":"Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Vinorelbine; Ifosfamide; Lung cancer; Chemotherapy; Internal medicine; Oncology; Phases of clinical research; Cancer; Surgery; Cisplatin","score_opus":0.1612092728561817,"score_gpt":0.5138659854352491,"score_spread":0.3526567125790674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130986264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010652273,0.97962844,0.000005617977,0.00020931839,0.00028900598,0.005311103,0.0009977575,0.000004670133,0.0029018326],"genre_scores_gemma":[0.00040286416,0.99660677,0.00037465224,0.00017460808,0.00015517756,0.0011256166,0.00035497954,0.00003448572,0.0007708335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945167,0.0013650437,0.003100985,0.00046494912,0.00024123001,0.00031113473],"domain_scores_gemma":[0.99435663,0.002521326,0.0023279113,0.0005515564,0.00013368935,0.000108885586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026288503,0.00047258558,0.0074435687,0.00032979302,0.000024465156,0.0000032114376,0.00020468666,0.0003143983,0.0003556702],"category_scores_gemma":[0.0002620548,0.00028656458,0.00059399207,0.00059226155,0.00014414875,0.000028265898,0.000045620516,0.00025495,6.6565167e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003097288,0.002887952,0.0005823531,0.098383754,0.0006909946,0.00006356101,0.0010651674,0.000002067482,0.000010982287,0.000063963314,0.0002477603,0.8956917],"study_design_scores_gemma":[0.03336781,0.004263818,0.000050570652,0.13039687,0.010068374,0.00006500216,0.00037946342,0.000007892775,0.000053040956,0.000012820432,0.8210079,0.00032641328],"about_ca_topic_score_codex":0.0018330938,"about_ca_topic_score_gemma":0.0038940478,"teacher_disagreement_score":0.8953653,"about_ca_system_score_codex":0.0007367112,"about_ca_system_score_gemma":0.0023822207,"threshold_uncertainty_score":0.99995863},"labels":[],"label_agreement":null},{"id":"W2131592861","doi":"10.1007/s40259-015-0130-9","title":"Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Boehringer Ingelheim","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Oncology; Cetuximab; Internal medicine; EGFR inhibitors; Cancer research; Tyrosine kinase; Pharmacology; Cancer; Receptor","score_opus":0.1326961338418439,"score_gpt":0.3950047831603708,"score_spread":0.26230864931852693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131592861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010379641,0.98845106,0.000002810821,0.00033047548,0.00087408145,0.0017088782,0.00011358042,0.00004946275,0.008365826],"genre_scores_gemma":[0.00046539117,0.99386895,0.00022292088,0.00012195064,0.00078819186,0.00030517997,0.0011533104,0.00005321548,0.0030208859],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984021,0.000091721675,0.00048233624,0.00043961938,0.0003366822,0.00024754184],"domain_scores_gemma":[0.9990993,0.00004366313,0.0002047447,0.00038197552,0.00008352136,0.00018676766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018899232,0.0003551209,0.0009612228,0.0003661665,0.00005247038,0.000037932998,0.00008031391,0.00025042117,0.00009735123],"category_scores_gemma":[0.000046659123,0.000263131,0.00026863845,0.0004294085,0.00003237079,0.000078463745,0.000029916793,0.00024600432,0.00046528404],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015344078,0.0002928608,0.000014797441,0.0016902041,0.00012221588,0.00007306559,0.0001826577,9.716535e-7,0.000002955832,0.00012924908,0.029394025,0.96808165],"study_design_scores_gemma":[0.0014031157,0.0002746443,0.00000997191,0.0076948022,0.0010725143,0.000016601829,0.000051562743,0.000006790677,0.000025839792,0.000015730693,0.9891906,0.00023783647],"about_ca_topic_score_codex":0.00025145515,"about_ca_topic_score_gemma":0.000049084152,"teacher_disagreement_score":0.96784383,"about_ca_system_score_codex":0.0011358173,"about_ca_system_score_gemma":0.001111391,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W2132037522","doi":"10.1016/j.lungcan.2004.11.029","title":"Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"GlaxoSmithKline","keywords":"Vinorelbine; Gemcitabine; Medicine; Internal medicine; Lung cancer; Performance status; Population; Chemotherapy; Progressive disease; Oncology; Phases of clinical research; Antimetabolite; Gastroenterology; Surgery","score_opus":0.011925274054068338,"score_gpt":0.3126804444621362,"score_spread":0.3007551704080679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132037522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062026,0.0022854835,0.0002709088,0.00042663678,0.00031386895,0.0049984646,0.0005402888,0.00007162586,0.00047247557],"genre_scores_gemma":[0.98925275,0.0009282757,0.0013747032,0.00070817274,0.00027398046,0.002159004,0.00059894565,0.00013402732,0.004570127],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973253,0.000054947963,0.00049674994,0.0006526001,0.0006402393,0.00083014654],"domain_scores_gemma":[0.9986459,0.00004255884,0.00031874285,0.00041560733,0.00028106038,0.0002961568],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008342087,0.00056856475,0.00071510504,0.00018876027,0.00022921126,0.000057801095,0.00013989143,0.00008222607,0.0010664902],"category_scores_gemma":[0.0000038465746,0.00033174676,0.00007747527,0.0004605467,0.00011697313,0.00041715382,0.0000274259,0.00033991528,0.0000028843872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5602076,0.01014423,0.3861542,0.00063130783,0.0029482043,0.000104948005,0.0053406004,0.001797813,0.0005319462,0.0000027136514,0.0077657886,0.02437061],"study_design_scores_gemma":[0.9117421,0.03695508,0.022479821,0.0015933241,0.0034093107,0.000006209549,0.0002559691,0.006046393,0.0036831426,1.9077481e-7,0.012838585,0.0009898982],"about_ca_topic_score_codex":0.003455975,"about_ca_topic_score_gemma":0.005843234,"teacher_disagreement_score":0.3636744,"about_ca_system_score_codex":0.0012563884,"about_ca_system_score_gemma":0.0014834645,"threshold_uncertainty_score":0.99991345},"labels":[],"label_agreement":null},{"id":"W2132165198","doi":"10.1038/nm.1790","title":"Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study","year":2008,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Queen's University; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; U.S. Public Health Service","keywords":"Lung cancer; Adenocarcinoma; Oncology; Stage (stratigraphy); Internal medicine; Covariate; Microarray analysis techniques; Survival analysis; Microarray; Medicine; Cancer; Bioinformatics; Gene expression; Gene; Biology; Computer science; Machine learning; Genetics","score_opus":0.036264107200383,"score_gpt":0.36208443921334094,"score_spread":0.32582033201295796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132165198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919159,0.0023871872,0.000996537,0.0012884829,0.0008249139,0.0017253343,0.00002701176,0.00012761062,0.00070705096],"genre_scores_gemma":[0.9958125,0.000030258927,0.0014898607,0.00039102,0.0005611708,0.00015561118,0.0005282003,0.000033349144,0.0009980623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980437,0.00011567331,0.0004259813,0.00046281342,0.00070017896,0.00025164633],"domain_scores_gemma":[0.99899256,0.00009914668,0.0001186956,0.00040022988,0.00021732316,0.00017205224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002954101,0.00023374897,0.00043784935,0.00043604051,0.00014839185,0.000005059271,0.00007812752,0.0002650568,0.00020995675],"category_scores_gemma":[0.00026701204,0.00016592818,0.000057718553,0.0006531604,0.00007467265,0.00011110979,0.00002091861,0.0006338199,0.000011993408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040790578,0.001549152,0.9821187,0.0000539239,0.00008962901,0.00048242114,0.0029779153,0.000080182515,0.009920326,0.0000035772428,0.0020670858,0.0002491456],"study_design_scores_gemma":[0.025790144,0.00082751876,0.962884,0.00023581224,0.00041216,0.00006172496,0.00058334327,0.0014086036,0.0074402294,0.0000040322675,0.0002245541,0.00012785525],"about_ca_topic_score_codex":0.00020872054,"about_ca_topic_score_gemma":0.00008173749,"teacher_disagreement_score":0.025382238,"about_ca_system_score_codex":0.00031931605,"about_ca_system_score_gemma":0.00023258157,"threshold_uncertainty_score":0.6766355},"labels":[],"label_agreement":null},{"id":"W2132870547","doi":"10.1016/s1470-2045(14)71173-8","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Pemetrexed; Lung cancer; Internal medicine; Adenocarcinoma; Lung; Gemcitabine; Chemotherapy; Population; Gastroenterology; Oncology; Cisplatin; Surgery; Gefitinib; Epidermal growth factor receptor; Cancer","score_opus":0.17100506631650386,"score_gpt":0.4951860196022361,"score_spread":0.32418095328573227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132870547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9628026,0.004286501,0.015245482,0.0063499417,0.00082092703,0.0036389676,0.0044686613,0.000058399357,0.002328557],"genre_scores_gemma":[0.9868315,0.00010659501,0.0047779633,0.00082980306,0.00088065316,0.00021072917,0.0062123933,0.000032644304,0.000117742136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997747,0.0005902059,0.0006582255,0.0004483922,0.0002613775,0.00029480283],"domain_scores_gemma":[0.9928087,0.0054675075,0.0005859752,0.0007228797,0.00026358626,0.00015133004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019404739,0.0002310315,0.0017194519,0.00015674949,0.00010913282,0.000026355588,0.00024782043,0.000114329756,0.00019219457],"category_scores_gemma":[0.0009088597,0.0001580474,0.00020674226,0.00029645988,0.00014978842,0.000103850914,0.000048327933,0.00013611017,0.0000018832362],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6963817,0.002798289,0.11018233,0.0003810475,0.08172291,0.00022535921,0.019564223,0.005411376,0.00422535,0.0021610167,0.041376535,0.035569873],"study_design_scores_gemma":[0.66074675,0.001862386,0.023279697,0.00007401693,0.03959235,0.000006313746,0.0008956725,0.26969802,0.00096621393,0.00026454806,0.0023190489,0.00029497573],"about_ca_topic_score_codex":0.00096315285,"about_ca_topic_score_gemma":0.0003780268,"teacher_disagreement_score":0.26428664,"about_ca_system_score_codex":0.0003370136,"about_ca_system_score_gemma":0.00069110113,"threshold_uncertainty_score":0.6444986},"labels":[],"label_agreement":null},{"id":"W2133134511","doi":"10.1093/aje/kwr332","title":"Female Reproductive Factors, Gene Polymorphisms in the Estrogen Metabolism Pathway, and Risk of Lung Cancer in Chinese Women","year":2012,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Changi General Hospital; DNA Genotek","keywords":"Lung cancer; Estrogen; Medicine; Gene; Cancer; Genetics; Internal medicine; Physiology; Biology; Oncology; Bioinformatics","score_opus":0.02011930608470826,"score_gpt":0.36167074066709637,"score_spread":0.3415514345823881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133134511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97700113,0.021461206,0.00004578609,0.0011169037,0.00014367071,0.00015833779,0.000034115383,0.000001740017,0.000037081933],"genre_scores_gemma":[0.9950291,0.0031550773,0.0011947117,0.000306435,0.0002654245,0.00002217342,0.0000030314159,0.000009367417,0.000014703965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816614,0.00073588727,0.00057228294,0.00013808507,0.000082586186,0.00030503483],"domain_scores_gemma":[0.99802405,0.00080336217,0.00080345204,0.00018962366,0.000058591846,0.00012094844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002025483,0.000119726756,0.0008156047,0.00016901462,0.00002390869,0.0000011269418,0.000077384146,0.000032353157,0.000029117851],"category_scores_gemma":[0.0012978651,0.000062364226,0.00007990284,0.00028762675,0.000265382,0.00009172323,0.000018510447,0.00025228958,1.8808025e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016466384,0.0001373134,0.9758437,0.000004431447,0.00034865225,0.000008831529,0.015870413,0.00006223295,0.00035883056,0.00010498462,0.000017600047,0.0070783007],"study_design_scores_gemma":[0.00080462254,0.00031975014,0.99516207,0.00002335859,0.00019781232,0.00012788986,0.0027252776,0.000011439938,0.00011594194,0.00022476375,0.00023585456,0.00005124803],"about_ca_topic_score_codex":0.004972968,"about_ca_topic_score_gemma":0.00006781443,"teacher_disagreement_score":0.019318296,"about_ca_system_score_codex":0.00014512423,"about_ca_system_score_gemma":0.00013766224,"threshold_uncertainty_score":0.7517673},"labels":[],"label_agreement":null},{"id":"W2133353215","doi":"10.1517/14656566.7.2.177","title":"A review of erlotinib and its clinical use","year":2006,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Rash; Epidermal growth factor receptor; Gemcitabine; Clinical trial; Oncology; Erlotinib Hydrochloride; Internal medicine; Gefitinib; Lung cancer; Tyrosine-kinase inhibitor; Pancreatic cancer; Pharmacology; Cancer","score_opus":0.22250994714479316,"score_gpt":0.5773877545529791,"score_spread":0.3548778074081859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133353215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012676735,0.99559927,0.0000044511003,0.00040168737,0.000872801,0.0023064592,0.00012381394,0.00004664994,0.0006436288],"genre_scores_gemma":[3.2778019e-7,0.99091595,0.00022009826,0.0064449143,0.00076735753,0.0003017855,0.00039061264,0.00008100948,0.00087792316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792224,0.00022086994,0.0010115218,0.0004429122,0.00022655836,0.00017592314],"domain_scores_gemma":[0.9986756,0.0002892086,0.00046755586,0.000304149,0.000101893434,0.0001616157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021215569,0.00037632202,0.0018990122,0.00012947235,0.000039298615,0.000011330132,0.00008864129,0.00016688474,0.00036359832],"category_scores_gemma":[0.00003935507,0.00025047173,0.0006012141,0.00019522678,0.00004738265,0.000063690124,0.000015037787,0.0002655719,0.0000305483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037134418,0.00044280573,0.000005377713,0.028100017,0.00052977726,0.0000058067913,0.000022464419,1.0721176e-8,0.0000015032239,0.00007791656,0.11157573,0.85920143],"study_design_scores_gemma":[0.001654351,0.00033433453,0.0000053958224,0.1354438,0.0002605537,0.000035082125,9.410353e-7,0.0000016953398,0.0000081863445,0.0000011045471,0.8620838,0.00017074237],"about_ca_topic_score_codex":0.00001853291,"about_ca_topic_score_gemma":1.5470862e-7,"teacher_disagreement_score":0.8590307,"about_ca_system_score_codex":0.00007599964,"about_ca_system_score_gemma":0.0003351844,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W2134029343","doi":"10.1158/0008-5472.can-12-4136","title":"Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"National Cancer Institute","keywords":"Gefitinib; Cancer research; Cancer stem cell; Stem cell; Biology; T790M; Downregulation and upregulation; Population; Cancer; Epidermal growth factor receptor; Medicine; Cell biology; Genetics","score_opus":0.060552013784821807,"score_gpt":0.3762643656085135,"score_spread":0.31571235182369173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134029343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916427,0.0017073819,0.0000034252323,0.0028325266,0.00008758616,0.0018761454,0.000056883655,0.000021891407,0.0017714292],"genre_scores_gemma":[0.9679845,0.0002736203,0.00006990002,0.0002475444,0.000048969756,0.00204254,0.000009306223,0.000035188496,0.02928842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981925,0.00009446584,0.0002695939,0.0003302755,0.0006873431,0.00042585586],"domain_scores_gemma":[0.998625,0.000059234673,0.00007906327,0.00024707153,0.0008262402,0.00016342808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021155275,0.00013293495,0.00026593136,0.00027733453,0.00008746984,0.00003317611,0.00010339627,0.00006915616,0.00032553973],"category_scores_gemma":[0.0000117383,0.0000960026,0.00003214689,0.0009022759,0.00011548406,0.0001544415,0.000035958386,0.00014657913,0.000031212658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019861849,0.001556296,0.07633768,0.0019129736,0.00060422684,0.00012329574,0.04820098,0.00047859698,0.7499489,0.000057414232,0.10119912,0.017594308],"study_design_scores_gemma":[0.0052587753,0.00097312196,0.08076063,0.0042864415,0.00013076243,0.0000011782449,0.006150911,0.00009618848,0.89662945,0.000050051305,0.005318618,0.00034385786],"about_ca_topic_score_codex":0.008590577,"about_ca_topic_score_gemma":0.005171582,"teacher_disagreement_score":0.14668055,"about_ca_system_score_codex":0.0013325219,"about_ca_system_score_gemma":0.00093151873,"threshold_uncertainty_score":0.9980113},"labels":[],"label_agreement":null},{"id":"W2134330266","doi":"10.3389/fonc.2014.00258","title":"Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Personalized medicine; Intensive care medicine; Precision medicine; Drug; Disease; Lung cancer; Adverse effect; Oncology; Internal medicine; Bioinformatics; Pathology; Pharmacology","score_opus":0.04944504546472784,"score_gpt":0.45484710417006086,"score_spread":0.405402058705333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134330266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030113368,0.9931139,0.0000465459,0.000086297405,0.00019322071,0.0013317638,0.00008128623,0.0000025540924,0.002133128],"genre_scores_gemma":[0.004203531,0.9885693,0.006780311,0.000022978598,0.000050024253,0.00013678746,0.00010066161,0.0000234073,0.00011296974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984651,0.0002965065,0.0008004248,0.00020005337,0.00008752443,0.00015038648],"domain_scores_gemma":[0.99824816,0.0007623426,0.0007017787,0.0002126893,0.000034161065,0.0000408919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004012861,0.00021279434,0.0027913821,0.00030620737,0.000011302231,9.718171e-7,0.000102175174,0.00012225004,0.000046167643],"category_scores_gemma":[0.00022174323,0.00011615899,0.00014941396,0.00020557997,0.00031496573,0.000020112584,0.00001657042,0.00018006982,6.0861896e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000721469,0.00020170657,0.006875874,0.004730135,0.0012989778,0.000030226021,0.0017255641,0.0000056006947,0.0000019426768,0.00003284667,0.0009919932,0.984033],"study_design_scores_gemma":[0.05135019,0.035963167,0.029924747,0.06723512,0.053290576,0.0010955875,0.004516062,0.00048682428,0.000008076765,0.001636647,0.75364774,0.0008452619],"about_ca_topic_score_codex":0.0020124146,"about_ca_topic_score_gemma":0.00006699222,"teacher_disagreement_score":0.98318774,"about_ca_system_score_codex":0.0009094314,"about_ca_system_score_gemma":0.0011615094,"threshold_uncertainty_score":0.4736826},"labels":[],"label_agreement":null},{"id":"W2134667653","doi":"10.1200/jco.2004.08.163","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2433,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Lung cancer; Febrile neutropenia; Chemotherapy; Regimen; Dexamethasone; Chemotherapy regimen; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cisplatin","score_opus":0.04615425508884495,"score_gpt":0.4591494644487017,"score_spread":0.41299520935985673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134667653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441224,0.00032962157,0.00016438459,0.0012749071,0.00040331783,0.0020576632,0.0000055493642,0.000005462451,0.0013468437],"genre_scores_gemma":[0.9959084,0.00078666775,0.0023927519,0.0003744359,0.00028272456,0.000056517347,0.00001018772,0.000023232025,0.00016512744],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971646,0.00020848235,0.0018921841,0.00018511592,0.0003387604,0.00021084558],"domain_scores_gemma":[0.99612427,0.00084663375,0.0021092144,0.00015926769,0.0005312697,0.00022931822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010514946,0.00017942865,0.0024215388,0.00016968531,0.000022848244,0.0000051589236,0.00009388992,0.00018971063,0.0000915265],"category_scores_gemma":[0.00034268646,0.00009518034,0.0003518582,0.00025829606,0.00019095783,0.00008287624,0.000008470229,0.00041339535,6.777243e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94633883,0.012823638,0.025257964,0.00003585609,0.0021707984,0.000119915276,0.00039568037,0.00014738104,0.000008424442,0.0000051693232,0.00008796329,0.012608364],"study_design_scores_gemma":[0.9316074,0.053101726,0.010592678,0.00029246448,0.003769055,0.0000057012776,0.000053058397,0.000027603512,0.000118354685,0.0000075799767,0.00033418243,0.00009020005],"about_ca_topic_score_codex":0.00038064,"about_ca_topic_score_gemma":0.0002439179,"teacher_disagreement_score":0.04027809,"about_ca_system_score_codex":0.0004222906,"about_ca_system_score_gemma":0.003233135,"threshold_uncertainty_score":0.57354426},"labels":[],"label_agreement":null},{"id":"W2134897113","doi":"10.1200/jco.2010.33.3757","title":"Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; Internal medicine; Oncology; Mutation; Cancer research; Wild type; Cancer; Biology; Gene; Genetics; Mutant","score_opus":0.10864596059875335,"score_gpt":0.4753398324394152,"score_spread":0.3666938718406618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134897113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785003,0.0027562068,0.0031018467,0.0015915872,0.0013861912,0.0010217153,0.0003088244,0.000011490383,0.011321814],"genre_scores_gemma":[0.94029856,0.001912939,0.05436187,0.00065312744,0.00065742957,0.00014757947,0.00003895329,0.000029739951,0.0018998068],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975006,0.00006795668,0.0018150271,0.00022659778,0.00017815278,0.00021168444],"domain_scores_gemma":[0.99497634,0.0016805531,0.0020955736,0.00018838831,0.00076292915,0.00029621954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034067116,0.00017027363,0.0012262434,0.00008384183,0.000062535604,0.0000032383728,0.00011006349,0.00024483458,0.00019332305],"category_scores_gemma":[0.00037801312,0.00011848777,0.0005521575,0.000106213265,0.00014097113,0.00015287563,0.000016877035,0.0002742895,0.0000034000616],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024060812,0.02036679,0.43012112,0.00029043993,0.011989856,0.00050193834,0.017902367,0.00094448705,0.0021541873,0.001263487,0.0037449955,0.48665953],"study_design_scores_gemma":[0.1254218,0.07953912,0.6848562,0.0014596697,0.022743542,0.00008518334,0.0020005256,0.0011466857,0.011972159,0.007093317,0.063169435,0.0005123948],"about_ca_topic_score_codex":0.0002874319,"about_ca_topic_score_gemma":0.00028605296,"teacher_disagreement_score":0.4861471,"about_ca_system_score_codex":0.00042477163,"about_ca_system_score_gemma":0.0023031444,"threshold_uncertainty_score":0.4831791},"labels":[],"label_agreement":null},{"id":"W2136715524","doi":"10.1158/0008-5472.can-09-3421","title":"Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; Howard Hughes Medical Institute","keywords":"Gefitinib; Epidermal growth factor receptor; Cancer research; Lung cancer; Extracellular; Epidermal growth factor; Kinase; Cancer; Signal transduction; Biology; Receptor; Medicine; Internal medicine; Cell biology","score_opus":0.032393143749651854,"score_gpt":0.37646347192751584,"score_spread":0.344070328177864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136715524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101806,0.00029966971,0.001094273,0.004288466,0.00018876494,0.0021563426,0.00076462986,0.00008483341,0.00010495245],"genre_scores_gemma":[0.99724364,0.000051757874,0.0006303127,0.000109503315,0.00023783291,0.00074187585,0.0003505177,0.0000658985,0.00056863856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973388,0.00027306683,0.00041425016,0.0005333027,0.00077137735,0.000669244],"domain_scores_gemma":[0.9957318,0.0011300592,0.00018958843,0.00034231995,0.002221915,0.00038434612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065896113,0.0002588083,0.0004657213,0.0004535976,0.0003582857,0.000053757165,0.000101774946,0.00017762388,0.00090488256],"category_scores_gemma":[0.0005652724,0.0002098086,0.0000868056,0.0013772681,0.00027132503,0.00025993443,0.000052656815,0.0007147028,0.000014119258],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007014063,0.00027109563,0.024831036,0.00020980887,0.00047518234,0.00003120216,0.0011900316,0.0003132436,0.9665714,0.00008031938,0.0013156282,0.0040096594],"study_design_scores_gemma":[0.0027121522,0.00024529026,0.06108764,0.0005834906,0.00013038993,0.000003986556,0.00032046696,0.001572171,0.9322783,0.000018608416,0.00083259324,0.00021494964],"about_ca_topic_score_codex":0.007863824,"about_ca_topic_score_gemma":0.00090526365,"teacher_disagreement_score":0.036256604,"about_ca_system_score_codex":0.0007203757,"about_ca_system_score_gemma":0.0016114603,"threshold_uncertainty_score":0.9987429},"labels":[],"label_agreement":null},{"id":"W2136969752","doi":"10.1093/annonc/mdv045.12","title":"Development of Resistance Models to Tyrosine Kinase Inhibitors (TKIS) in Patient-Derived Xenograft Models (PDXS) of Lung Adenocarcinoma with Epidermal Growth Factor Receptor (EGFR) Mutations","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Crizotinib; Erlotinib; Medicine; Gefitinib; Epidermal growth factor receptor; Cancer research; Adenocarcinoma; Erlotinib Hydrochloride; Lung cancer; Afatinib; Osimertinib; Resistance mutation; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Cancer; Internal medicine; Biology; Receptor; Gene","score_opus":0.08761446753943258,"score_gpt":0.36196760566391345,"score_spread":0.27435313812448087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136969752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276614,0.0009637677,0.0016430379,0.0019061465,0.0000756617,0.0008404502,0.000120763485,0.000015737243,0.0016683175],"genre_scores_gemma":[0.9675197,0.00003970029,0.031861283,0.00024104673,0.000019865805,0.00012933402,0.000091556336,0.000024553645,0.00007297255],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982312,0.00007544682,0.00080512266,0.00027809085,0.00032393984,0.00028621804],"domain_scores_gemma":[0.9981196,0.000082478866,0.0003898714,0.0002201685,0.0009452526,0.00024265703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001519269,0.00018681922,0.00063024246,0.00035261596,0.0000353167,0.000002973115,0.000092148795,0.00011045509,0.000019437644],"category_scores_gemma":[0.00007180568,0.00015546624,0.00006574924,0.00045242198,0.00012980055,0.0002109554,0.00004750837,0.0000966841,0.0000019111724],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023446793,0.017498178,0.09827997,0.0029094392,0.0038567558,0.0005018611,0.5619204,0.037406545,0.14158182,0.007858247,0.02456644,0.08017357],"study_design_scores_gemma":[0.026267363,0.016986063,0.0545187,0.0027419513,0.000773156,0.000044526663,0.026648443,0.0031642718,0.8590137,0.0028537842,0.005767048,0.0012210158],"about_ca_topic_score_codex":0.00029946124,"about_ca_topic_score_gemma":0.00046186108,"teacher_disagreement_score":0.71743184,"about_ca_system_score_codex":0.00023524837,"about_ca_system_score_gemma":0.0013467585,"threshold_uncertainty_score":0.633973},"labels":[],"label_agreement":null},{"id":"W2137043950","doi":"10.1016/s1470-2045(15)00006-6","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Erlotinib; Medicine; Clinical endpoint; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Oncology; Population; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.06509205628352367,"score_gpt":0.4127227631918144,"score_spread":0.34763070690829073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137043950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760129,0.0005500681,0.0000098057935,0.0006435172,0.000720855,0.009161214,0.00017534928,0.000018669305,0.012707621],"genre_scores_gemma":[0.99702364,0.000015350204,0.0004210868,0.00021808733,0.00026442218,0.00085159024,0.0001679471,0.000029429024,0.0010084292],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982089,0.0004341275,0.0005355892,0.0002670282,0.0002638419,0.0002905076],"domain_scores_gemma":[0.9976114,0.0005994525,0.00065058115,0.0006642896,0.00032781824,0.00014644189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034927475,0.00023353388,0.0013501475,0.00004453721,0.00009729912,0.000010380627,0.00030463273,0.0000904564,0.00013342766],"category_scores_gemma":[0.00017415136,0.000107524225,0.000092284514,0.00015912385,0.00017262342,0.000088045075,0.00005223423,0.00010903666,0.0000028926638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9791286,0.010686673,0.0021620921,0.00003937075,0.00050561136,0.000014867433,0.0032920113,0.000071345385,0.0003634615,0.00009852868,0.00069817627,0.0029392883],"study_design_scores_gemma":[0.93078166,0.06107069,0.0011517083,0.00001570981,0.0020654022,0.0000034833947,0.0005008799,0.00036744424,0.0017602202,0.000021142945,0.0021581713,0.00010349958],"about_ca_topic_score_codex":0.00018776795,"about_ca_topic_score_gemma":0.00016859252,"teacher_disagreement_score":0.05038402,"about_ca_system_score_codex":0.00042059415,"about_ca_system_score_gemma":0.0011898157,"threshold_uncertainty_score":0.43847105},"labels":[],"label_agreement":null},{"id":"W2137488285","doi":"10.1200/jco.2008.16.2545","title":"Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Angiogenesis; Lung cancer; Cancer research; Cancer; Oncology; Clinical trial; Internal medicine","score_opus":0.15655623511511305,"score_gpt":0.5619253721958037,"score_spread":0.40536913708069067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137488285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948757,0.0014382956,0.000009123764,0.0017420923,0.00066251383,0.0007454227,0.000014739736,0.0000018751482,0.0005101801],"genre_scores_gemma":[0.9981288,0.0004281685,0.0005337677,0.00036516268,0.00040971392,0.00004297613,0.0000036242798,0.000011383535,0.00007641626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99461555,0.0019813017,0.0027275223,0.00015200026,0.00037677295,0.00014682469],"domain_scores_gemma":[0.99171966,0.0053421496,0.0020727713,0.000109729765,0.0006099678,0.00014570284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010131494,0.000116274714,0.0014903243,0.0004755802,0.000021683656,0.0000020540672,0.00005663746,0.0001799861,0.000115936426],"category_scores_gemma":[0.007831185,0.00007633319,0.0005292348,0.0003686381,0.00007205556,0.00007900826,0.000009468838,0.0003305524,0.0000019845488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057170942,0.00428515,0.879879,0.000040933013,0.00069722114,0.0009420976,0.0033632421,0.0059497184,0.0028115357,0.0000024314727,0.0019260822,0.042931672],"study_design_scores_gemma":[0.021877924,0.009315553,0.9653507,0.00031184577,0.00083420984,0.00006607665,0.00034819264,0.0003594357,0.0012979516,0.00002993546,0.00014669528,0.00006148735],"about_ca_topic_score_codex":0.00046475645,"about_ca_topic_score_gemma":0.00029097844,"teacher_disagreement_score":0.08547172,"about_ca_system_score_codex":0.0014053995,"about_ca_system_score_gemma":0.007863837,"threshold_uncertainty_score":0.99776065},"labels":[],"label_agreement":null},{"id":"W2137578149","doi":"10.1093/ije/30.4.809","title":"Socioeconomic status and lung cancer risk in Canada","year":2001,"lang":"en","type":"article","venue":"International Journal of Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Socioeconomic status; Lung cancer; Medicine; Demography; Social class; Odds ratio; Epidemiology; Population; Risk factor; Logistic regression; Gerontology; Environmental health; Internal medicine","score_opus":0.020031456000127373,"score_gpt":0.39140522931225546,"score_spread":0.37137377331212806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137578149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817759,0.0062037497,0.00011741945,0.010624558,0.0007598665,0.00004916786,0.000025095916,0.0000012752286,0.00044299767],"genre_scores_gemma":[0.9855975,0.011412469,0.00046305495,0.0021768895,0.00023456829,0.000003921277,0.0000061106625,0.0000045741435,0.00010094144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992391,0.000072054696,0.00041180692,0.00007737041,0.0000622758,0.00013742637],"domain_scores_gemma":[0.99900186,0.0004385061,0.00030632582,0.000037959413,0.000117331925,0.000098002805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027550373,0.0000547131,0.00024279383,0.00009558489,0.0000130790295,0.0000021457852,0.00004980065,0.000026835794,0.0003162775],"category_scores_gemma":[0.00033581056,0.00004219092,0.000037372793,0.000018493229,0.000028192275,0.000055479148,0.000012161472,0.00015251036,9.3460443e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011993166,0.000017484957,0.97780496,0.0000023382906,0.00037869083,0.00011721305,0.00008158299,0.00058485044,0.0000086185355,0.00019055657,0.0025755342,0.018118212],"study_design_scores_gemma":[0.0016033076,0.00004327115,0.9821001,0.00004304348,0.00008590588,0.0002693955,0.000106996755,0.0007812983,0.0000048748793,0.0008467685,0.014079764,0.000035238558],"about_ca_topic_score_codex":0.7266497,"about_ca_topic_score_gemma":0.65477544,"teacher_disagreement_score":0.07187422,"about_ca_system_score_codex":0.0015294551,"about_ca_system_score_gemma":0.0013249645,"threshold_uncertainty_score":0.3999472},"labels":[],"label_agreement":null},{"id":"W2137654068","doi":"10.1038/onc.2014.280","title":"CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis","year":2014,"lang":"en","type":"article","venue":"Oncogene","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Institute","keywords":"Biology; Metastasis; Cancer research; Adenocarcinoma; Epidermal growth factor receptor; Oncogene; Gene silencing; Lung cancer; Cancer; Cell; Pathology; Cell cycle; Medicine; Gene","score_opus":0.014761988664262147,"score_gpt":0.29146694965265735,"score_spread":0.2767049609883952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137654068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075115,0.0015081213,0.00014148973,0.003069505,0.000031788302,0.00054588076,0.00004656165,0.00006678325,0.0038387256],"genre_scores_gemma":[0.995304,0.000027824924,0.0021453318,0.00064623484,0.000059171518,0.00009801689,0.00006959399,0.00002562776,0.001624207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999271,0.000028655315,0.000115594914,0.00023411526,0.0001718722,0.00017879349],"domain_scores_gemma":[0.99954516,0.000039959694,0.000064914464,0.00012363854,0.00009770883,0.00012860024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008835722,0.00012695606,0.00023548187,0.000054057888,0.00009245048,0.000022902694,0.00002942639,0.00004659634,0.000106294436],"category_scores_gemma":[0.000047418653,0.00008623994,0.000039369595,0.00015896097,0.000042660846,0.000052530588,0.000016071368,0.000053837157,0.000009060602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015891108,0.0008103903,0.92834973,0.00016149058,0.0033201312,0.00009018422,0.002021823,9.496632e-7,0.0068023806,0.0002178793,0.005930601,0.052135505],"study_design_scores_gemma":[0.020345883,0.0068632914,0.7557298,0.0010317093,0.015828352,0.0003957654,0.00048665586,0.002749528,0.17151406,0.00030775656,0.023738,0.0010092105],"about_ca_topic_score_codex":0.00007708295,"about_ca_topic_score_gemma":0.00003548697,"teacher_disagreement_score":0.17261997,"about_ca_system_score_codex":0.000086341344,"about_ca_system_score_gemma":0.000085167834,"threshold_uncertainty_score":0.35167626},"labels":[],"label_agreement":null},{"id":"W2138004837","doi":"10.1002/jcp.22980","title":"Mitochondrial DNA mutations in respiratory complex‐I in never‐smoker lung cancer patients contribute to lung cancer progression and associated with <i>EGFR</i> gene mutation","year":2011,"lang":"en","type":"article","venue":"Journal of Cellular Physiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute; University of British Columbia","keywords":"Mitochondrial DNA; Lung cancer; Mutation; KRAS; Biology; Exon; Cancer research; Cancer; Gene mutation; Epidermal growth factor receptor; Gene; Molecular biology; Medicine; Genetics; Pathology","score_opus":0.01780356406610301,"score_gpt":0.31776328049300917,"score_spread":0.29995971642690616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138004837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723977,0.0011694162,0.00012654431,0.00028093715,0.00030747225,0.00077110535,0.0000517688,0.000007287957,0.000045681816],"genre_scores_gemma":[0.998567,0.000053891075,0.00039213928,0.00060031994,0.00013909551,0.000112792026,0.000083541796,0.00002205177,0.000029212448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986785,0.00014483467,0.00049825193,0.00020423847,0.00022076203,0.0002534225],"domain_scores_gemma":[0.9988765,0.0000555211,0.0004239958,0.00009091937,0.00041148945,0.00014153527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113308604,0.00015884655,0.00044226163,0.00026172734,0.000061153296,0.00000849405,0.000058536283,0.0001016673,0.00006750916],"category_scores_gemma":[0.00006378356,0.00011786567,0.000051421415,0.0003244321,0.0000603468,0.00019598896,0.000021097603,0.00021267493,5.619385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030121678,0.0015849835,0.57289845,0.00011003389,0.000801719,0.00033802338,0.005716603,0.0008208729,0.41163278,0.000033130167,0.0012086937,0.0018425414],"study_design_scores_gemma":[0.011914537,0.0010745696,0.9719418,0.0005965462,0.00044731572,0.0000065307254,0.00008723804,0.00045674047,0.013049423,0.00005138508,0.00021905376,0.00015480227],"about_ca_topic_score_codex":0.0002646251,"about_ca_topic_score_gemma":0.0004286943,"teacher_disagreement_score":0.3990434,"about_ca_system_score_codex":0.00055333006,"about_ca_system_score_gemma":0.00037642792,"threshold_uncertainty_score":0.48064226},"labels":[],"label_agreement":null},{"id":"W2138047541","doi":"10.1158/1078-0432.ccr-04-1169","title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institutes of Health; National Cancer Institute; Samuel Waxman Cancer Research Foundation","keywords":"Erlotinib; Cyclin D1; Epidermal growth factor receptor; Cancer research; Cell cycle; Epidermal growth factor; Tyrosine kinase; Biology; Erlotinib Hydrochloride; Lung cancer; Cell growth; Cancer; Medicine; Internal medicine; Receptor","score_opus":0.16625342764581966,"score_gpt":0.5242624049371198,"score_spread":0.3580089772913002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138047541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781169,0.0020725378,0.000025263173,0.01610394,0.00058581226,0.001232713,0.00021265841,0.00006650484,0.0015836523],"genre_scores_gemma":[0.9920052,0.0042554033,0.00044511777,0.00077088084,0.00079178205,0.00056596106,0.00012129212,0.000046594047,0.0009977653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665916,0.00032672155,0.00080682634,0.0007901365,0.00072754524,0.0006895954],"domain_scores_gemma":[0.99747247,0.00081732107,0.00012589975,0.00040890675,0.0006135976,0.00056178065],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010266898,0.0002148411,0.0005399397,0.000278764,0.00017892479,0.000045905985,0.0001262474,0.00023929562,0.0009816585],"category_scores_gemma":[0.0029004114,0.00017763581,0.0001799174,0.00083944906,0.0005088328,0.00025081265,0.00007544283,0.0011845148,0.00013259624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005707243,0.005253138,0.89866436,0.00056655286,0.00046616,0.0014254341,0.0029479766,0.0005705326,0.0074742,0.0012494506,0.018813325,0.05686162],"study_design_scores_gemma":[0.0151700135,0.002169418,0.9487103,0.0016422244,0.0001264703,0.000017492888,0.00051407365,0.000018127355,0.022334615,0.0016536724,0.0072550494,0.00038850395],"about_ca_topic_score_codex":0.017046943,"about_ca_topic_score_gemma":0.0025157914,"teacher_disagreement_score":0.056473114,"about_ca_system_score_codex":0.0023842265,"about_ca_system_score_gemma":0.0033289294,"threshold_uncertainty_score":0.9999316},"labels":[],"label_agreement":null},{"id":"W2138200001","doi":"10.1016/j.jmoldx.2013.03.001","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors","year":2013,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":461,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Guideline; Anaplastic lymphoma kinase; Medicine; Lung cancer; Family medicine; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer; Pathology","score_opus":0.009204737053342864,"score_gpt":0.3159489873506346,"score_spread":0.30674425029729174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138200001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552337,0.0041973544,0.037731275,0.001131109,0.00027190516,0.001321508,0.000059060752,0.000007338757,0.000046786452],"genre_scores_gemma":[0.95073926,0.00021474874,0.048147906,0.0005504326,0.00016359694,0.00010163178,0.000034370187,0.000034453024,0.0000135752325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989568,0.000013988861,0.00055846066,0.000111848705,0.00020358153,0.00015530619],"domain_scores_gemma":[0.99702585,0.00023467014,0.0004436417,0.000069056914,0.0021010435,0.00012574725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001073892,0.00012229697,0.000270797,0.00011865222,0.000048940747,0.000017190025,0.000036859885,0.000060433318,0.0000072891776],"category_scores_gemma":[0.0018114523,0.00010009968,0.00010904634,0.000138186,0.000026672402,0.00007912699,0.000013644512,0.000073760595,1.3921616e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004175264,0.0022273571,0.40581882,0.001520204,0.0020880725,0.00005753263,0.00041920136,0.0049948147,0.40887415,0.0003586584,0.088533245,0.08469041],"study_design_scores_gemma":[0.029097615,0.009824278,0.05430645,0.0032367674,0.009125453,0.00012170268,0.00015000599,0.02475515,0.85518944,0.0014664517,0.012079398,0.0006473116],"about_ca_topic_score_codex":0.00007514211,"about_ca_topic_score_gemma":0.0000032838896,"teacher_disagreement_score":0.44631526,"about_ca_system_score_codex":0.00012605023,"about_ca_system_score_gemma":0.00019264173,"threshold_uncertainty_score":0.40819463},"labels":[],"label_agreement":null},{"id":"W2138297714","doi":"10.1056/nejmoa050753","title":"Erlotinib in Previously Treated Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5451,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Hotel Dieu Shaver Health and Rehabilitation Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McGill University","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Lung cancer; Hazard ratio; Internal medicine; Erlotinib Hydrochloride; Chemotherapy; Randomization; Placebo; Performance status; Oncology; Surgery; Epidermal growth factor receptor; Gastroenterology; Cancer; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.014324095017099497,"score_gpt":0.32927200354779684,"score_spread":0.3149479085306973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138297714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609581,0.012982613,0.0001676345,0.017588459,0.0003386611,0.0004407687,0.000002341187,0.000012414771,0.0075089745],"genre_scores_gemma":[0.9853162,0.0024103767,0.00089312735,0.0010421881,0.0043671895,0.000008697659,0.00000843373,0.00002227689,0.0059315213],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987895,0.000035929566,0.00054324046,0.000124608,0.00027897424,0.00022778739],"domain_scores_gemma":[0.9990606,0.00008234906,0.0002481028,0.00012745812,0.00015481208,0.0003266916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032051993,0.00015286497,0.0004871678,0.00024944104,0.000028325157,0.0000058242704,0.00007685786,0.00005766295,0.00061125896],"category_scores_gemma":[0.000067468136,0.00009287093,0.0000672551,0.00023411443,0.0000326378,0.00008057413,0.000007932216,0.00028458994,0.0000046488844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013135312,0.0005644912,0.5322969,0.00019701014,0.00047780699,0.00087182195,0.011052915,0.0006414033,0.0044747787,0.000021205546,0.039780773,0.40830734],"study_design_scores_gemma":[0.45227262,0.005619603,0.23796919,0.006142143,0.0051249876,0.0023442174,0.00085283373,0.0013217333,0.004309927,0.00007606537,0.2835312,0.00043550073],"about_ca_topic_score_codex":0.0008503137,"about_ca_topic_score_gemma":0.00073731696,"teacher_disagreement_score":0.4509591,"about_ca_system_score_codex":0.00027425934,"about_ca_system_score_gemma":0.000509307,"threshold_uncertainty_score":0.66928566},"labels":[],"label_agreement":null},{"id":"W2139142789","doi":"10.1093/annonc/mdm592","title":"A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Alberta Cancer Foundation","funders":"U.S. Food and Drug Administration","keywords":"Pemetrexed; Medicine; Hazard ratio; Lung cancer; Internal medicine; Interim analysis; Confidence interval; Oncology; Chemotherapy; Toxicity; Randomized controlled trial; Surgery; Cisplatin","score_opus":0.05161190808332462,"score_gpt":0.4126153450498675,"score_spread":0.3610034369665429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139142789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293727,0.0009203717,0.00016202613,0.00045216398,0.00012361478,0.0044277967,0.000084183965,0.000015171447,0.0008773751],"genre_scores_gemma":[0.9948964,0.0011449909,0.0017405095,0.00036007655,0.00003615744,0.00075454544,0.00011998515,0.000023977414,0.0009233577],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984839,0.00013030971,0.0006013859,0.0003083361,0.00019139725,0.00028465284],"domain_scores_gemma":[0.998746,0.00030886155,0.00034243945,0.00017398453,0.0002658016,0.00016296074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019035419,0.00023948519,0.0016196179,0.00020488718,0.000068582616,0.000005163818,0.0000461784,0.00005984229,0.0002491487],"category_scores_gemma":[0.000056823148,0.00014709779,0.000097907854,0.00020695436,0.00016674907,0.000082573446,0.000020260908,0.00009503452,0.0000011715999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9650739,0.004691476,0.004678301,0.0000977956,0.0013026485,0.0002097532,0.002089356,0.00017892169,0.000045065917,0.000010372189,0.0001492771,0.021473132],"study_design_scores_gemma":[0.9622555,0.031823914,0.0019563758,0.00012858525,0.0011567828,0.000010913568,0.00015527653,0.00033794093,0.0012599728,0.000013597431,0.00075974036,0.0001414055],"about_ca_topic_score_codex":0.0011802546,"about_ca_topic_score_gemma":0.0018060064,"teacher_disagreement_score":0.027132437,"about_ca_system_score_codex":0.00024438355,"about_ca_system_score_gemma":0.0014029355,"threshold_uncertainty_score":0.5998474},"labels":[],"label_agreement":null},{"id":"W2139939379","doi":"10.1634/theoncologist.2008-0232","title":"The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":692,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Docetaxel; Gemcitabine; Oncology; Internal medicine; Histology; Hazard ratio; Lung cancer; Proportional hazards model; Chemotherapy; Cisplatin; Confidence interval","score_opus":0.13005089114996987,"score_gpt":0.5312090846097777,"score_spread":0.4011581934598078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139939379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048244226,0.9918813,0.000028822333,0.0023140938,0.00042432974,0.0030508095,0.000039890565,0.000024520607,0.002187969],"genre_scores_gemma":[0.0005840316,0.99723613,0.000105319465,0.00032259975,0.00019930532,0.00030141618,0.00006199741,0.000021867354,0.001167357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979765,0.00029380576,0.0009788941,0.00026837373,0.00024267318,0.00023977231],"domain_scores_gemma":[0.9967241,0.0013604834,0.00092455756,0.0007104091,0.0002133877,0.000067018045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043846876,0.000319641,0.0028347464,0.00009321517,0.00019697845,0.0000062761032,0.00037238843,0.0000825932,0.00004308552],"category_scores_gemma":[0.0009386429,0.00013271965,0.00064448337,0.0004353654,0.00039954652,0.000013878963,0.00012709846,0.0002515511,0.000008685005],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001169376,0.00045158205,0.000001191399,0.014968085,0.0014519069,0.000016309745,0.00013366864,1.00254624e-7,0.0000018522758,0.0003201208,0.00931328,0.97322494],"study_design_scores_gemma":[0.0033865098,0.0011549103,0.000008244431,0.06865012,0.01647945,0.00005038065,0.00014018235,3.2998352e-7,0.0000023239222,0.000026378353,0.9099799,0.00012128362],"about_ca_topic_score_codex":0.000072859875,"about_ca_topic_score_gemma":0.000033639237,"teacher_disagreement_score":0.9731037,"about_ca_system_score_codex":0.0005451803,"about_ca_system_score_gemma":0.0006003399,"threshold_uncertainty_score":0.54121506},"labels":[],"label_agreement":null},{"id":"W2139940827","doi":"10.3892/ol.2015.3414","title":"Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma","year":2015,"lang":"en","type":"article","venue":"Oncology Letters","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"National Cancer Institute; Chiba University","keywords":"KRAS; Oncogene; Molecular medicine; Adenocarcinoma; Ethnic group; Cell cycle; Gene; Oncology; Cancer research; Medicine; Lung cancer; Internal medicine; Cancer; Biology; Genetics; Colorectal cancer; Political science","score_opus":0.030516689195534602,"score_gpt":0.3607207047021883,"score_spread":0.3302040155066537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139940827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756438,0.0008239201,0.00044280142,0.019749047,0.0002074255,0.0002847009,0.000008897547,0.000020805142,0.0028185747],"genre_scores_gemma":[0.9922379,0.000019748235,0.002677514,0.0046727555,0.00012044972,0.00003172344,0.000032826272,0.000008763465,0.00019829403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950725,0.000048702495,0.000106747146,0.00013687996,0.00008279057,0.000117638534],"domain_scores_gemma":[0.9995932,0.000060936454,0.00005541506,0.0001253537,0.00004523861,0.00011986335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000829115,0.00007205487,0.00018946044,0.00006166238,0.000038485763,0.000003788462,0.000026293981,0.000056325258,0.000019939529],"category_scores_gemma":[0.000032125932,0.000060183425,0.000029459909,0.00007232373,0.00010512455,0.000046329103,0.00001903068,0.00007902008,0.0000061020196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003330457,0.0006804306,0.63232857,0.00015539181,0.0009608755,0.0005855537,0.009530485,0.00013387355,0.19987166,0.0012057482,0.1474587,0.0067556603],"study_design_scores_gemma":[0.013493352,0.0026134735,0.93297577,0.0000897728,0.0016593338,0.00065623206,0.00050751196,0.00062443916,0.021612763,0.00011975934,0.025345603,0.0003019907],"about_ca_topic_score_codex":0.00011947853,"about_ca_topic_score_gemma":0.000043604778,"teacher_disagreement_score":0.3006472,"about_ca_system_score_codex":0.00022371567,"about_ca_system_score_gemma":0.00018401779,"threshold_uncertainty_score":0.24542089},"labels":[],"label_agreement":null},{"id":"W2140508852","doi":"10.1097/jto.0000000000000225","title":"Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Pemetrexed; Medicine; Docetaxel; Erlotinib; Lung cancer; Internal medicine; Chemotherapy; Oncology; Population; Retrospective cohort study; Cancer; Erlotinib Hydrochloride; Performance status; Surgery; Epidermal growth factor receptor; Cisplatin","score_opus":0.014809590185107559,"score_gpt":0.4152750910974777,"score_spread":0.4004655009123701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140508852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540443,0.00830596,0.0002646541,0.0043475092,0.00022978189,0.00067778816,0.000013428974,0.000006543172,0.0007499183],"genre_scores_gemma":[0.9800171,0.0077194492,0.010157013,0.0014523694,0.00019731456,0.00003198915,0.00001328332,0.000032396718,0.00037905734],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99844825,0.00008804146,0.0009024032,0.00016988147,0.00021605044,0.00017536551],"domain_scores_gemma":[0.9977997,0.00010237642,0.0013042524,0.00021049881,0.0004952638,0.00008791723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005030432,0.0001648041,0.0010414782,0.00020086413,0.000019282455,0.0000031394318,0.00012487061,0.00012398891,0.00009582283],"category_scores_gemma":[0.00009768616,0.00012561984,0.00021409805,0.00027654663,0.000041700565,0.00007057044,0.000008400244,0.0002017822,8.041347e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068675634,0.0033400827,0.21698122,0.0067438595,0.0011114542,0.000040717165,0.0015347892,0.00065415393,0.09471821,0.000048114252,0.0017410215,0.6662188],"study_design_scores_gemma":[0.021907568,0.010161903,0.8806522,0.010683144,0.0026258007,0.000068994734,0.00074089406,0.0019050795,0.05816352,0.0002761503,0.012369177,0.00044556064],"about_ca_topic_score_codex":0.00019221327,"about_ca_topic_score_gemma":0.00014777198,"teacher_disagreement_score":0.6657733,"about_ca_system_score_codex":0.00058977783,"about_ca_system_score_gemma":0.00068720896,"threshold_uncertainty_score":0.5122628},"labels":[],"label_agreement":null},{"id":"W2140832617","doi":"10.1200/jco.2014.57.3055","title":"Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Guideline; Anaplastic lymphoma kinase; Lung cancer; Oncology; Epidermal growth factor receptor; Internal medicine; Cancer; Family medicine; Pathology","score_opus":0.03833756373049924,"score_gpt":0.4406086431182212,"score_spread":0.40227107938772194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140832617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809075,0.00012826218,0.010575802,0.0034818375,0.00083556975,0.0027992872,0.001262083,0.0000037067744,0.000005953695],"genre_scores_gemma":[0.9811685,0.00011946459,0.017497899,0.0004152975,0.0003750844,0.00034617606,0.00003521311,0.00002582218,0.000016552276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508923,0.00055097754,0.00338401,0.00027844828,0.000458265,0.00023904466],"domain_scores_gemma":[0.97225595,0.010031066,0.012195023,0.00013648428,0.005288399,0.000093085495],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003315947,0.00018258601,0.0018365066,0.000092677816,0.00007726572,0.0000026110595,0.00016301195,0.00021623455,0.0000033683325],"category_scores_gemma":[0.015259832,0.0001138831,0.00059550593,0.00027064353,0.00032816196,0.00005789033,0.000047554495,0.00018859639,6.3628587e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078051924,0.0045519965,0.9325947,0.0002529024,0.003116772,0.0000010485151,0.00031103834,0.00080994744,0.0040024435,0.000058702728,0.0016613802,0.04483386],"study_design_scores_gemma":[0.045105122,0.07324171,0.85099566,0.00025098372,0.006529385,0.0000035271894,0.0009285247,0.015458695,0.0052972343,0.00006292257,0.0019622077,0.0001640441],"about_ca_topic_score_codex":0.00042114066,"about_ca_topic_score_gemma":0.00034089028,"teacher_disagreement_score":0.08159907,"about_ca_system_score_codex":0.00090907275,"about_ca_system_score_gemma":0.0017562691,"threshold_uncertainty_score":0.9930351},"labels":[],"label_agreement":null},{"id":"W2140920559","doi":"10.1016/j.jval.2014.03.428","title":"Treatment and Survival Patterns Among Alk+ Nsclc Patients Following Crizotinib Discontinuation","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Crizotinib; Medicine; Discontinuation; Regimen; Internal medicine; Lung cancer; Oncology; Chemotherapy; Surgery","score_opus":0.024100602778406022,"score_gpt":0.333350544246424,"score_spread":0.309249941468018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140920559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996594,0.00012418332,0.00029872745,0.00096932705,0.00034298145,0.0006851219,0.00001448833,0.000028227809,0.00094292086],"genre_scores_gemma":[0.9990395,0.0000762632,0.00028523983,0.00012043962,0.00007890791,0.000055986235,0.00012561258,0.00001691543,0.00020116131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903226,0.00011957075,0.0002666888,0.00022479924,0.00013857303,0.00021808695],"domain_scores_gemma":[0.9995246,0.000088833454,0.00008322684,0.0001450693,0.000020323878,0.00013797257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016851947,0.0001145854,0.0002496844,0.00008005491,0.00008206846,0.000016096517,0.000019916268,0.000033620596,0.000007497106],"category_scores_gemma":[0.00004935893,0.00008837088,0.00004927666,0.00007552971,0.000013605448,0.00007867696,0.0000098910095,0.000050825645,0.0000040473856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017907021,0.00028720262,0.95941514,0.000041130137,0.00003665141,0.0000024832887,0.001564102,0.000034764173,0.0000035087357,0.0001597184,0.000010044032,0.03842738],"study_design_scores_gemma":[0.0047877086,0.0011047487,0.9916941,0.00025804737,0.000058162914,8.819259e-7,0.00020694516,0.0011833279,0.000019711655,0.000054586628,0.0005574603,0.000074304786],"about_ca_topic_score_codex":0.011947041,"about_ca_topic_score_gemma":0.0005405648,"teacher_disagreement_score":0.038353074,"about_ca_system_score_codex":0.00032666916,"about_ca_system_score_gemma":0.00009571806,"threshold_uncertainty_score":0.9946325},"labels":[],"label_agreement":null},{"id":"W2141303400","doi":"10.1093/annonc/mdu517","title":"Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Erlotinib Hydrochloride; Internal medicine; Lung cancer; Hazard ratio; Clinical endpoint; Oncology; Regimen; Randomized controlled trial; Adverse effect; Phases of clinical research; Gastroenterology; Clinical trial; Epidermal growth factor receptor; Cancer; Confidence interval","score_opus":0.033394814567876636,"score_gpt":0.38624635300747656,"score_spread":0.35285153843959993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141303400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987836,0.00018663655,0.000057957768,0.0009797136,0.00019142289,0.0028407203,0.000027731736,0.000009025134,0.0058284304],"genre_scores_gemma":[0.99882114,0.0000677794,0.00027231427,0.00017375914,0.00003993821,0.00034189265,0.00013657984,0.00002003916,0.0001265789],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99849045,0.00018718428,0.0005783366,0.00024408706,0.00025818672,0.00024175431],"domain_scores_gemma":[0.99851304,0.00042495303,0.0004577349,0.0001966811,0.00032945676,0.00007810874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039259947,0.00016525247,0.0010159818,0.00027087826,0.000020028381,0.000003416374,0.000074801595,0.00010797945,0.00006175006],"category_scores_gemma":[0.000095673175,0.00011766803,0.00007343576,0.0002779637,0.00016626283,0.00008991148,0.000016903266,0.00013740387,0.0000011547445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9526064,0.0071235704,0.029000064,0.00010176009,0.00031993404,0.000014614001,0.0014412173,0.00009124186,0.000018002467,0.00019049502,0.00018915249,0.008903541],"study_design_scores_gemma":[0.9604019,0.0211486,0.016412968,0.00017493084,0.00043797973,0.0000010808819,0.00009840282,0.00033993338,0.00049877877,0.000019797439,0.00035510625,0.00011050653],"about_ca_topic_score_codex":0.0015365044,"about_ca_topic_score_gemma":0.0012436346,"teacher_disagreement_score":0.01402503,"about_ca_system_score_codex":0.00012630117,"about_ca_system_score_gemma":0.0005864966,"threshold_uncertainty_score":0.47983631},"labels":[],"label_agreement":null},{"id":"W2141381346","doi":"10.1200/jco.2005.04.4420","title":"Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor Therapy","year":2006,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Erlotinib; Epidermal growth factor receptor; Gefitinib; Internal medicine; Oncology; Exon; Lung cancer; Clinical trial; Retrospective cohort study; Predictive marker; Cancer; Gene; Genetics; Biology","score_opus":0.09442976966772315,"score_gpt":0.4454575769674457,"score_spread":0.35102780729972255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141381346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73113465,0.0017080486,0.0000723363,0.2641816,0.0015806869,0.0007183587,0.000091797716,0.0000051618595,0.000507352],"genre_scores_gemma":[0.8911889,0.002050608,0.0006299347,0.10001383,0.005489838,0.000019661633,0.000088082386,0.000050926315,0.00046821963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996333,0.0005783619,0.0023034518,0.00020248986,0.00036035725,0.00022234273],"domain_scores_gemma":[0.99079645,0.0062410305,0.0023028243,0.00013869858,0.0004234174,0.000097600976],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00081809645,0.00021671096,0.0017269609,0.00018982058,0.000031565334,0.000008461283,0.00013624637,0.0009035034,0.000059581307],"category_scores_gemma":[0.0016051867,0.000109125154,0.0004188097,0.00010888821,0.00025902162,0.00007391997,0.000026789778,0.0024958705,0.0000013953511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011754726,0.0009744003,0.7952894,0.00016733969,0.0018260948,0.0007227849,0.00092072104,0.000008555449,0.000027502658,0.0000049920036,0.18437707,0.014505652],"study_design_scores_gemma":[0.0068522943,0.010112025,0.82349384,0.0005515424,0.0008932497,0.000105160594,0.00016868113,0.00001342826,0.00004197336,0.00020902057,0.15743642,0.00012237982],"about_ca_topic_score_codex":0.000082388804,"about_ca_topic_score_gemma":0.0000127181975,"teacher_disagreement_score":0.16416779,"about_ca_system_score_codex":0.00019503241,"about_ca_system_score_gemma":0.001641901,"threshold_uncertainty_score":0.9998054},"labels":[],"label_agreement":null},{"id":"W2142148449","doi":"10.1016/s1470-2045(09)70155-x","title":"Molecular predictive and prognostic markers in non-small-cell lung cancer","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oncology; Targeted therapy; Internal medicine; Adjuvant; Chemotherapy; Cancer; Adjuvant chemotherapy; Intensive care medicine","score_opus":0.028587391361870357,"score_gpt":0.3983639984049767,"score_spread":0.36977660704310633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142148449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066571485,0.97790766,0.000025967081,0.00097445014,0.00016239937,0.0029021031,0.00005410183,0.000026354168,0.017281277],"genre_scores_gemma":[0.00056698534,0.996451,0.00021713215,0.0007041726,0.0003019003,0.001189587,0.000078048295,0.00003249126,0.0004586387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987754,0.00019062022,0.00029069962,0.00032100175,0.00009218574,0.0003300528],"domain_scores_gemma":[0.9992015,0.00021564799,0.0001855909,0.00028240195,0.0000370724,0.00007778051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021277563,0.00026113234,0.0014972005,0.000102820726,0.000042819494,0.0000099205645,0.00012877055,0.0002452461,0.000028977314],"category_scores_gemma":[0.00003242771,0.0001548057,0.00011359587,0.00021305172,0.00008208529,0.000016988228,0.000046713907,0.0004610373,0.000006174241],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011174269,0.00020786752,0.0011524003,0.008703496,0.0006916821,0.0004731892,0.00050871633,0.0000101844025,0.00000108859,0.000049054168,0.002601026,0.98548955],"study_design_scores_gemma":[0.0031296103,0.0007631234,0.003167872,0.00897887,0.008492436,0.00015026912,0.000060657014,0.000106150896,7.8416605e-7,0.000043823908,0.9748993,0.00020712194],"about_ca_topic_score_codex":0.00013268528,"about_ca_topic_score_gemma":0.00008567468,"teacher_disagreement_score":0.9852824,"about_ca_system_score_codex":0.0006691587,"about_ca_system_score_gemma":0.0010661663,"threshold_uncertainty_score":0.63127935},"labels":[],"label_agreement":null},{"id":"W2142455578","doi":"10.17140/prrmoj-1-104","title":"Microarray Analysis Identifies Pathways In Progression of Early Stage Lung Adenocarcinoma: The Importance of Focal Adhesion and ECM-Receptor Interactions","year":2014,"lang":"en","type":"article","venue":"Pulmonary Research and Respiratory Medicine - Open Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; National Research Council Canada","funders":"Dalhousie University","keywords":"Focal adhesion; Cancer research; Adenocarcinoma; Biology; Microarray analysis techniques; Microarray; Signal transduction; Receptor; Pathology; Medicine; Cell biology; Cancer; Gene; Genetics; Gene expression","score_opus":0.0771321017521195,"score_gpt":0.4299170359411204,"score_spread":0.3527849341890009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142455578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858504,0.010235653,0.00003887768,0.0020222873,0.000080042584,0.0006505229,0.0000147905785,0.0000033463793,0.0011041029],"genre_scores_gemma":[0.99844,0.0006125837,0.000113968876,0.00007145921,0.00016746596,0.000041656258,0.000012827247,0.000012947121,0.0005270444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977654,0.00045121432,0.00062791584,0.0002678016,0.000613467,0.00027417616],"domain_scores_gemma":[0.998404,0.00035788934,0.0002805697,0.00028242415,0.00040623936,0.00026885245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028412414,0.00013257364,0.00048288348,0.0006435549,0.00033408188,0.000050663257,0.00022630236,0.000057059395,0.00020189442],"category_scores_gemma":[0.00029355782,0.00007156885,0.00006463651,0.0007597688,0.0006576097,0.00029079718,0.0001783908,0.000592962,8.262633e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095795013,0.00028074573,0.9533961,0.00017299312,0.00033839192,0.00010237805,0.0018237841,0.0000028389825,0.034020666,0.000110392335,0.0009821077,0.0078116595],"study_design_scores_gemma":[0.0025025632,0.0029382084,0.98165107,0.0010983347,0.00040167186,0.00011513509,0.005384896,0.00031600925,0.002425102,0.0002520636,0.002818469,0.00009647564],"about_ca_topic_score_codex":0.00028387769,"about_ca_topic_score_gemma":0.00017570036,"teacher_disagreement_score":0.03159556,"about_ca_system_score_codex":0.00008005827,"about_ca_system_score_gemma":0.00025650207,"threshold_uncertainty_score":0.29184932},"labels":[],"label_agreement":null},{"id":"W2143814205","doi":"10.1158/1535-7163.mct-13-0649","title":"KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"London Health Sciences Centre","keywords":"KRAS; Pemetrexed; Antifolate; Cancer research; Gene knockdown; Biology; Mutant; Cancer; Cell culture; Antimetabolite; Gene; Genetics; Colorectal cancer; Chemotherapy","score_opus":0.012331464038611479,"score_gpt":0.2861007131037423,"score_spread":0.27376924906513084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143814205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828174,0.0040294137,0.008696242,0.00037867643,0.0003126558,0.0011050577,0.000115199175,0.000066871544,0.0024784438],"genre_scores_gemma":[0.99225813,0.0013552648,0.0004933738,0.004696837,0.00006360912,0.00045447593,0.0000755107,0.000098954646,0.000503836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810976,0.00009720494,0.00031511253,0.00049378653,0.00042637307,0.0005577706],"domain_scores_gemma":[0.99899304,0.00005151194,0.00021693291,0.00036275,0.00021799661,0.0001577594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001079616,0.0003489985,0.00044496442,0.00016557734,0.000093465555,0.000039815703,0.00010279716,0.00016294833,0.00011108385],"category_scores_gemma":[0.000005319915,0.00028626245,0.00011101625,0.00041483753,0.000037921105,0.000067724104,0.000013618894,0.0002927811,0.000009819782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000927508,0.0014995623,0.012811509,0.0003127901,0.003123268,0.00032201532,0.01814542,0.00977967,0.8639886,0.00043953126,0.000101836384,0.088548325],"study_design_scores_gemma":[0.011812667,0.0008030677,0.020037308,0.0005850672,0.002854038,0.0000027563212,0.00020358231,0.0077639385,0.9531239,0.0004992613,0.0016789929,0.0006353802],"about_ca_topic_score_codex":0.0011321292,"about_ca_topic_score_gemma":0.0011093523,"teacher_disagreement_score":0.08913538,"about_ca_system_score_codex":0.00063016504,"about_ca_system_score_gemma":0.00056183164,"threshold_uncertainty_score":0.99995893},"labels":[],"label_agreement":null},{"id":"W2144900656","doi":"10.1158/1535-7163.mct-08-1068","title":"Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"U.S. Department of Veterans Affairs","keywords":"KRAS; Lung cancer; Medicine; Epidermal growth factor receptor; Immunohistochemistry; Paclitaxel; Internal medicine; Fluorescence in situ hybridization; Targeted therapy; Cancer; Oncology; Cancer research; Biology; Colorectal cancer; Gene","score_opus":0.008356432669197871,"score_gpt":0.31058050054610215,"score_spread":0.30222406787690426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144900656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921764,0.0010981829,0.006106386,0.0007008767,0.00005494036,0.0026370396,0.000088432265,0.000018912582,0.00007761213],"genre_scores_gemma":[0.99209034,0.00006620821,0.0053367857,0.0017083053,0.0000073408655,0.0006097488,0.000031505744,0.000055043387,0.00009470681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874115,0.000039050134,0.00027190536,0.00033564126,0.0002903619,0.0003218642],"domain_scores_gemma":[0.9990142,0.000030644795,0.00015686497,0.0003237467,0.00037073053,0.00010382431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007278349,0.0002411278,0.00036365146,0.00017579505,0.00004366055,0.00001309798,0.000095635136,0.00007448532,0.0000056475196],"category_scores_gemma":[0.000006482394,0.00018803928,0.000062951294,0.00037311733,0.000029526722,0.000056729725,0.000010297782,0.00008918548,3.9529093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044247568,0.0043102847,0.5691112,0.0008213983,0.00090156414,0.00021035684,0.0061851502,0.011561044,0.22860456,0.00010284065,0.000038131624,0.13390589],"study_design_scores_gemma":[0.040696174,0.012636832,0.6149472,0.0016915702,0.0016888208,0.0000037939437,0.0002458454,0.0020208918,0.3241217,0.000100026635,0.0011496521,0.0006974728],"about_ca_topic_score_codex":0.00011582888,"about_ca_topic_score_gemma":0.000118013966,"teacher_disagreement_score":0.13320842,"about_ca_system_score_codex":0.00046462042,"about_ca_system_score_gemma":0.00047396417,"threshold_uncertainty_score":0.7668019},"labels":[],"label_agreement":null},{"id":"W2145099193","doi":"10.1200/jco.2013.53.1186","title":"Cost Effectiveness of <i>EML4-ALK</i> Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced <i>ALK</i>-Positive Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Home and Community Care Support Services","funders":"Canadian Centre for Applied Research in Cancer Control; Cancer Care Ontario","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Population; Internal medicine; ALK inhibitor; Cost effectiveness; Environmental health","score_opus":0.055664576065031,"score_gpt":0.45262045482489144,"score_spread":0.39695587875986044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145099193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926348,0.00037247312,0.0029084443,0.00054445764,0.0005014418,0.001729141,0.00005579138,0.000006787795,0.0012466928],"genre_scores_gemma":[0.98662394,0.0004270066,0.0120618045,0.00035055232,0.00031510828,0.00010710965,0.000020312084,0.000026810168,0.00006734971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810684,0.00019938497,0.001061983,0.00023983444,0.0001818628,0.00021011966],"domain_scores_gemma":[0.9903983,0.006738959,0.001378691,0.00012714256,0.0010969545,0.00025997235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007922361,0.00018993794,0.0012650769,0.00007226359,0.00009187258,0.0000059940157,0.00005937832,0.00016298583,0.00000719723],"category_scores_gemma":[0.0010807683,0.00011481555,0.00019337397,0.00011351841,0.000116334806,0.00008319107,0.000024836283,0.00021260287,3.9554746e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014607049,0.0047524357,0.6368268,0.00039775623,0.0007343163,0.00002613412,0.00023279618,0.0005859544,0.00043401576,0.000009297824,0.00006865631,0.34132478],"study_design_scores_gemma":[0.090396464,0.109815024,0.7842705,0.0018744888,0.0043626647,0.00003148142,0.00006003622,0.0011147063,0.0018354758,0.00006551593,0.005979819,0.00019382377],"about_ca_topic_score_codex":0.000085893764,"about_ca_topic_score_gemma":0.00008381766,"teacher_disagreement_score":0.34113094,"about_ca_system_score_codex":0.0003139423,"about_ca_system_score_gemma":0.00085056864,"threshold_uncertainty_score":0.46820423},"labels":[],"label_agreement":null},{"id":"W2145173412","doi":"10.3747/co.21.2241","title":"Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Erlotinib; Gefitinib; Afatinib; Epidermal growth factor receptor; Rash; Diarrhea; Tyrosine kinase; ErbB; Adverse effect; ERBB3; Epidermal growth factor; Tyrosine-kinase inhibitor; Pharmacology; Oncology; Internal medicine; Cancer; Receptor","score_opus":0.045192743627074934,"score_gpt":0.389355629741363,"score_spread":0.3441628861142881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145173412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98776925,0.0014067568,0.0004134309,0.0024800827,0.0021519712,0.0006330205,0.00007203086,0.00005340731,0.0050200494],"genre_scores_gemma":[0.9983285,0.00028472918,0.00045886388,0.00011067861,0.00022485411,0.00009138165,0.00020668707,0.000018081313,0.000276221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900645,0.00006847217,0.0003075394,0.00023944055,0.0001537947,0.00022432038],"domain_scores_gemma":[0.9993574,0.000061635765,0.00014034624,0.0001837074,0.000102687874,0.00015424096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008694508,0.0001438141,0.00033311144,0.00008288578,0.000046113357,0.0000041106964,0.000063663174,0.000082600694,0.0002135579],"category_scores_gemma":[0.00004156833,0.00011638404,0.00008120613,0.0001429796,0.000063357926,0.000047783164,0.000044109183,0.00013057567,0.000051531122],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028452947,0.0040002195,0.05073357,0.0009638622,0.0005843136,0.000019791021,0.0009866949,9.136467e-7,0.01877771,0.0042573567,0.0646486,0.85474247],"study_design_scores_gemma":[0.012038606,0.003356085,0.070718534,0.0005602404,0.0009773995,0.000011473317,0.00028681327,0.00006798982,0.056390543,0.00024369598,0.8549436,0.00040507218],"about_ca_topic_score_codex":0.000027849714,"about_ca_topic_score_gemma":0.0000023448474,"teacher_disagreement_score":0.8543374,"about_ca_system_score_codex":0.00026431793,"about_ca_system_score_gemma":0.000075633696,"threshold_uncertainty_score":0.47460037},"labels":[],"label_agreement":null},{"id":"W2145355142","doi":"10.1371/journal.pone.0033003","title":"Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; BC Cancer Agency","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; National Human Genome Research Institute; Canadian Institutes of Health Research; Alvin J. Siteman Cancer Center; Canary Foundation","keywords":"KRAS; Genome instability; Adenocarcinoma; Lung cancer; Lung; Copy-number variation; Biology; Genome; Cancer research; Comparative genomic hybridization; Genetics; Gene; Bioinformatics; Pathology; Medicine; Internal medicine; Cancer; Mutation; DNA; DNA damage","score_opus":0.044690415740239,"score_gpt":0.2721401976219872,"score_spread":0.22744978188174822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145355142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966907,0.0021707292,0.0002526717,0.00016815928,0.000030113106,0.00054350955,0.000092964605,0.0000073919996,0.000043740565],"genre_scores_gemma":[0.9988425,0.0001502223,0.00084831245,0.000020328696,0.000041853018,0.000023287519,0.00001702162,0.000013397999,0.000043084856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919045,0.00003448984,0.0003129446,0.00015303591,0.00017139448,0.00013771147],"domain_scores_gemma":[0.9994029,0.000046538436,0.0001498003,0.0002084812,0.00008140873,0.00011089674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038524908,0.00011327478,0.00035583912,0.00007664278,0.00003203246,0.0000036922095,0.000026939982,0.000050997678,0.00007958856],"category_scores_gemma":[0.000022911756,0.000092388516,0.000043190394,0.00004690491,0.00014072542,0.000089962974,0.000033629352,0.00005608889,2.5396906e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011243914,0.0012263852,0.8146847,0.0006276839,0.000598374,5.4049656e-7,0.0013859313,0.0000010492284,0.18083362,0.00024127061,0.0000070394276,0.00028097795],"study_design_scores_gemma":[0.0016905912,0.00023437216,0.94746214,0.00015815994,0.0014693011,0.0000019687147,0.00009412026,0.0002978131,0.048485752,0.000038508664,0.0000012985179,0.000065993314],"about_ca_topic_score_codex":0.00012083419,"about_ca_topic_score_gemma":0.000009727972,"teacher_disagreement_score":0.13277744,"about_ca_system_score_codex":0.00006851235,"about_ca_system_score_gemma":0.000049962367,"threshold_uncertainty_score":0.37674943},"labels":[],"label_agreement":null},{"id":"W2145591421","doi":"10.3389/fonc.2014.00192","title":"Collaborative Care in NSCLC; the Role of Early Palliative Care","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Surgical oncology; Multidisciplinary approach; Palliative care; Radiation oncology; Lung cancer; Personalized medicine; Subtyping; Multidisciplinary team; Oncology; Precision medicine; Disease; Intensive care medicine; Internal medicine; Radiation therapy; Medical physics; Pathology; Nursing; Bioinformatics","score_opus":0.013200908568100174,"score_gpt":0.3935730754276424,"score_spread":0.3803721668595422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145591421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005334365,0.97379184,0.000021038755,0.00006704659,0.00068027095,0.002029592,0.00016735106,0.000007686598,0.023181854],"genre_scores_gemma":[0.0012684219,0.9957756,0.0015375598,0.000056216424,0.000113932285,0.00072819274,0.00028683693,0.00003252906,0.00020072445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850166,0.00035187823,0.0004943039,0.0002969984,0.00013183005,0.00022330583],"domain_scores_gemma":[0.9989308,0.00016358437,0.0003534004,0.0002880082,0.00021464021,0.00004955422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008678618,0.0002462423,0.0018674814,0.000280745,0.00003529262,0.000004785473,0.00016610783,0.00039376254,0.000014329259],"category_scores_gemma":[0.000070730355,0.0001551791,0.00017755665,0.0005750425,0.00016188661,0.000021718588,0.00003993014,0.00041065415,0.0000068370596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068764006,0.00006706622,0.008214623,0.002446513,0.00032763855,0.000031997,0.025450865,0.0000020165721,2.9533894e-8,0.0001312352,0.0010545872,0.9622047],"study_design_scores_gemma":[0.0012640053,0.0008827039,0.0008955684,0.00403904,0.0010785343,0.000001797838,0.026770456,0.0000015077319,8.476306e-7,0.00007408373,0.9648753,0.000116196046],"about_ca_topic_score_codex":0.0002410501,"about_ca_topic_score_gemma":0.00079743005,"teacher_disagreement_score":0.9638207,"about_ca_system_score_codex":0.002253188,"about_ca_system_score_gemma":0.0027033102,"threshold_uncertainty_score":0.632802},"labels":[],"label_agreement":null},{"id":"W2145708032","doi":"10.1023/a:1012208711013","title":"Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Vindesine; Gemcitabine; Internal medicine; Lung cancer; Nausea; Leukopenia; Performance status; Phases of clinical research; Clinical endpoint; Neutropenia; Chemotherapy; Gastroenterology; Surgery; Clinical trial; Oncology; Vincristine; Cyclophosphamide","score_opus":0.0746373964756905,"score_gpt":0.4710071340295249,"score_spread":0.39636973755383437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145708032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911168,0.0009444288,0.000040807485,0.00081139756,0.00033955617,0.0039800913,0.0000272196,0.00001783942,0.0027218326],"genre_scores_gemma":[0.99738085,0.0007478721,0.00050893775,0.00019388348,0.00006815621,0.0003687329,0.000019125328,0.000024922352,0.00068750867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978303,0.0002059073,0.0010347305,0.00040181298,0.00019798666,0.00032929497],"domain_scores_gemma":[0.997449,0.0009705568,0.0005866011,0.0003351076,0.000502347,0.00015641315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006064213,0.00020801004,0.0010415972,0.00021798939,0.00004682712,0.0000034547716,0.000101314756,0.00013217956,0.00014548011],"category_scores_gemma":[0.0003702007,0.00017848481,0.00016078055,0.00040338453,0.00008375748,0.00006983764,0.000045779427,0.00017785301,0.0000023767045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7321852,0.04738107,0.13516048,0.00011835208,0.001388267,0.00057427015,0.01136618,0.0013297274,0.010911563,0.000005692069,0.0002698478,0.05930936],"study_design_scores_gemma":[0.7609506,0.05334926,0.1722619,0.00025977945,0.0013494103,0.0000075625876,0.0051186634,0.0010267969,0.004110827,0.000010297229,0.001330724,0.00022416325],"about_ca_topic_score_codex":0.00056495046,"about_ca_topic_score_gemma":0.001260751,"teacher_disagreement_score":0.059085198,"about_ca_system_score_codex":0.00029911034,"about_ca_system_score_gemma":0.00055981585,"threshold_uncertainty_score":0.72783995},"labels":[],"label_agreement":null},{"id":"W2148407853","doi":"10.1093/annonc/mdq682","title":"An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Medicine; Gefitinib; Docetaxel; Oncology; Lung cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.1087354976583922,"score_gpt":0.450226711195727,"score_spread":0.3414912135373348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148407853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873452,0.0007031327,0.0000068869826,0.0004806041,0.00062749966,0.0021955087,0.000088641704,0.0000057715697,0.008546707],"genre_scores_gemma":[0.9970821,0.0017933734,0.00016421401,0.00029099794,0.00008155774,0.00033139516,0.000028087568,0.000013804999,0.00021447813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99834687,0.00026214018,0.0008983681,0.00023322308,0.00008032676,0.00017905339],"domain_scores_gemma":[0.99808353,0.00043934234,0.0008454949,0.00039524774,0.00017088909,0.000065514454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060270715,0.00015081573,0.0015002841,0.00030408436,0.0000203719,0.0000022724003,0.00018259823,0.00013287627,0.0008898839],"category_scores_gemma":[0.00009090101,0.00009891334,0.00053249917,0.00027277117,0.00018124987,0.0000657129,0.000024854207,0.000118461336,0.0000012423625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9818797,0.002017505,0.0008218373,0.000032624463,0.004062944,0.000004020231,0.002937946,0.0001780534,0.001193394,0.00013575093,0.00008471421,0.0066514774],"study_design_scores_gemma":[0.9665066,0.010960674,0.0018018371,0.000041599204,0.002615633,5.3453846e-7,0.0003959542,0.00043728502,0.01670366,0.00007891126,0.00037347473,0.00008385917],"about_ca_topic_score_codex":0.002804496,"about_ca_topic_score_gemma":0.0045283935,"teacher_disagreement_score":0.015510267,"about_ca_system_score_codex":0.00008754669,"about_ca_system_score_gemma":0.0009370679,"threshold_uncertainty_score":0.97436047},"labels":[],"label_agreement":null},{"id":"W2149095868","doi":"10.1200/jco.2008.18.4408","title":"Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute","keywords":"Gefitinib; Medicine; Placebo; Internal medicine; Lung cancer; Hazard ratio; Performance status; Clinical endpoint; Chemotherapy; Population; Adverse effect; Oncology; Gastroenterology; Cancer; Randomized controlled trial; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.031070941737457582,"score_gpt":0.4432891018328478,"score_spread":0.41221816009539025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149095868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963565,0.00036868072,0.0000312209,0.00068366865,0.00011146742,0.0017826108,0.000007120671,0.000003876411,0.00065485627],"genre_scores_gemma":[0.9963315,0.00076711236,0.0020134808,0.0006730714,0.000073771334,0.000032607793,0.000004915867,0.000012444779,0.00009108449],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978361,0.00015684582,0.0013663331,0.00017666748,0.000258571,0.00020545429],"domain_scores_gemma":[0.9971585,0.000573584,0.0015014807,0.00010738597,0.00044546093,0.00021355611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064357487,0.00015722746,0.0018214273,0.00011834378,0.00004422091,0.000004102969,0.00006033603,0.000087086366,0.00002922175],"category_scores_gemma":[0.000115885116,0.000087246786,0.00008882543,0.00014053058,0.00012400947,0.00010830263,0.000011200419,0.00038289613,1.4620741e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5406404,0.016434407,0.37240905,0.000036304664,0.00070917787,0.00006545591,0.00280591,0.0003453835,0.000017961864,9.167978e-7,0.000057145735,0.06647788],"study_design_scores_gemma":[0.6344917,0.06243427,0.3005382,0.00021688297,0.0009896151,0.000007893718,0.00058590993,0.00044695052,0.0000329112,0.000002133239,0.00018258578,0.00007093917],"about_ca_topic_score_codex":0.00005819415,"about_ca_topic_score_gemma":0.00010674156,"teacher_disagreement_score":0.09385128,"about_ca_system_score_codex":0.00015079773,"about_ca_system_score_gemma":0.0010898223,"threshold_uncertainty_score":0.35578206},"labels":[],"label_agreement":null},{"id":"W2149270596","doi":"10.2147/pgpm.s55339","title":"Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer","year":2014,"lang":"en","type":"review","venue":"Pharmacogenomics and Personalized Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Academy of Medical Sciences; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Afatinib; Medicine; Epidermal growth factor receptor; T790M; Lung cancer; Adenocarcinoma; EGFR inhibitors; Precision medicine; Drug resistance; Oncology; Targeted therapy; Osimertinib; Cancer research; Gefitinib; Cancer; Erlotinib; Internal medicine; Pathology; Biology","score_opus":0.09332858321314516,"score_gpt":0.4054736549770533,"score_spread":0.31214507176390816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149270596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019731119,0.990154,0.00023746437,0.0017786806,0.00078472344,0.0030862207,0.00006203818,0.000034139517,0.0018896102],"genre_scores_gemma":[0.0016407308,0.9899992,0.00030620987,0.001078929,0.0034464835,0.0006886195,0.0010398065,0.00014032175,0.0016597394],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970759,0.00013182845,0.001005405,0.00087541377,0.00045201083,0.00045942192],"domain_scores_gemma":[0.99830467,0.00021470386,0.00052848563,0.00029709763,0.00016745177,0.0004876225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005608544,0.0007819833,0.0027353168,0.0005639833,0.00013203597,0.000025397145,0.00014710853,0.00026509239,0.00064550893],"category_scores_gemma":[0.000034253455,0.0004700743,0.0001828276,0.00049171364,0.00026000492,0.00008463065,0.00005080537,0.0005769214,0.0000067342717],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029411758,0.00020214988,0.00042095085,0.029220682,0.0011442367,0.00019336522,0.0052544083,0.000009559293,0.00086376304,0.000044988003,0.010467356,0.95188445],"study_design_scores_gemma":[0.013597429,0.00062133605,0.000015706046,0.030546317,0.012613906,0.00019093364,0.00022925285,0.0013182521,0.000025505802,0.000005465076,0.94033784,0.0004980691],"about_ca_topic_score_codex":0.0010430089,"about_ca_topic_score_gemma":0.000094160176,"teacher_disagreement_score":0.95138633,"about_ca_system_score_codex":0.0007088275,"about_ca_system_score_gemma":0.0007426176,"threshold_uncertainty_score":0.9997751},"labels":[],"label_agreement":null},{"id":"W2149564448","doi":"10.1093/annonc/mdt235","title":"Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Carboplatin; Paclitaxel; Oncology; Nab-paclitaxel; Internal medicine; Lung cancer; Chemotherapy; Cisplatin","score_opus":0.012136169378837273,"score_gpt":0.33752077610764764,"score_spread":0.32538460672881037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149564448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938241,0.0011676579,0.000053692227,0.0027830522,0.00002064875,0.0010104849,0.000026098183,0.000004828457,0.0011093876],"genre_scores_gemma":[0.997824,0.0010697033,0.00034007092,0.00032214326,0.0000041193243,0.00011894862,0.0001231071,0.000012457204,0.00018545164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906474,0.000052041978,0.00036222272,0.00022507751,0.00011494335,0.00018097545],"domain_scores_gemma":[0.9990598,0.00013535081,0.0002906437,0.00014980228,0.00030390648,0.000060472325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008162257,0.00013162733,0.00060574623,0.000275005,0.000022240913,0.000001859787,0.000045494453,0.0000961207,0.000071057046],"category_scores_gemma":[0.000018445675,0.00009469242,0.000035030833,0.00045981884,0.00010099473,0.00006963471,0.000011721884,0.000097131,5.0029166e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024001459,0.002528705,0.9572202,0.00006335568,0.0006353729,0.0000058508535,0.0018378586,0.00079417287,0.00019446513,0.000017764838,0.00015284533,0.03414925],"study_design_scores_gemma":[0.023033367,0.010225027,0.964661,0.00007719854,0.00032073256,7.24329e-7,0.00015411062,0.00037812037,0.0005157976,0.000016758348,0.00052199134,0.00009514075],"about_ca_topic_score_codex":0.00576087,"about_ca_topic_score_gemma":0.0029819591,"teacher_disagreement_score":0.034054108,"about_ca_system_score_codex":0.00013616016,"about_ca_system_score_gemma":0.00021880884,"threshold_uncertainty_score":0.87087506},"labels":[],"label_agreement":null},{"id":"W2149654081","doi":"10.1016/s1470-2045(14)70472-3","title":"Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; University of Ottawa; Jewish General Hospital; Regional Municipality of Durham; Princess Margaret Cancer Centre; BC Cancer Agency; Queen's University; Juravinski Cancer Centre","funders":"Cancer Care Ontario; Cancer Research Institute","keywords":"Medicine; Internal medicine; Erlotinib; Gefitinib; Placebo; Lung cancer; Population; Performance status; Oncology; Cancer; Adverse effect; Clinical trial; Surgery; Epidermal growth factor receptor; Pathology","score_opus":0.044423323650779334,"score_gpt":0.3947671100906369,"score_spread":0.3503437864398576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149654081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98401546,0.00016149983,0.00045019793,0.00114628,0.00022898028,0.008974734,0.000059929705,0.00008597804,0.0048769084],"genre_scores_gemma":[0.9921492,0.00006737306,0.0017843074,0.0008938534,0.00025654145,0.003746466,0.00019914811,0.000065264154,0.00083784515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980379,0.00030313153,0.00045599492,0.0004197973,0.00025172866,0.00053147215],"domain_scores_gemma":[0.998246,0.000586128,0.0003636096,0.0004747957,0.00017447084,0.00015500927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040641552,0.00032433769,0.0012399488,0.00012668104,0.00012602108,0.000023236322,0.00019341041,0.00008343421,0.00019574405],"category_scores_gemma":[0.000044659526,0.00016062846,0.00006475082,0.00040234395,0.00014125857,0.00008595685,0.000030510439,0.00031885452,0.000012386349],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790225,0.0024276634,0.0111183785,0.00016935267,0.00072190637,0.00006273805,0.0018647835,0.00089167926,0.00006739775,0.000014385419,0.00072255597,0.0029166585],"study_design_scores_gemma":[0.9813638,0.008394375,0.0022673006,0.00025844618,0.002108727,0.000016911046,0.00023220162,0.001737246,0.0002669911,0.000006758544,0.0031174668,0.00022982151],"about_ca_topic_score_codex":0.00037986448,"about_ca_topic_score_gemma":0.0025910952,"teacher_disagreement_score":0.008851077,"about_ca_system_score_codex":0.0004641504,"about_ca_system_score_gemma":0.00091011875,"threshold_uncertainty_score":0.6550239},"labels":[],"label_agreement":null},{"id":"W2150358925","doi":"10.1200/jco.2005.03.045","title":"Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Meta-analysis; Chemotherapy; Lung cancer; Oncology; Platinum; Internal medicine; Platinum compounds; Cisplatin","score_opus":0.12789743782114668,"score_gpt":0.5192591901018222,"score_spread":0.3913617522806755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150358925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013089707,0.9893638,0.000112417285,0.004162874,0.001423325,0.001712352,0.00021536244,0.00000831854,0.001692592],"genre_scores_gemma":[0.004079608,0.98286045,0.00804326,0.0027111997,0.0009488706,0.00023858361,0.00017464963,0.00009405794,0.0008493058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922595,0.00078016776,0.005368066,0.00053675077,0.000668169,0.00038736576],"domain_scores_gemma":[0.9848885,0.0048738755,0.008236869,0.0007973324,0.0008729164,0.00033053313],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023230368,0.0005894454,0.011768058,0.0009018185,0.000054717286,0.000037479767,0.0006132148,0.0012059397,0.0008200602],"category_scores_gemma":[0.001071344,0.00030597835,0.009738038,0.002372407,0.00015042194,0.00013758636,0.00004182385,0.0024652912,0.0000019412034],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035556701,0.004140803,0.0018374104,0.003661356,0.21137683,0.00028779026,0.00027785898,0.0039491556,0.0000021994622,0.0000057760158,0.0025394422,0.76836574],"study_design_scores_gemma":[0.021498106,0.0022036165,0.0012128698,0.002265183,0.48368323,0.000009275382,0.000018880737,0.0008953847,0.0000045407605,0.0000026714933,0.4879714,0.00023486816],"about_ca_topic_score_codex":0.00006601089,"about_ca_topic_score_gemma":0.00053146924,"teacher_disagreement_score":0.76813084,"about_ca_system_score_codex":0.0010405022,"about_ca_system_score_gemma":0.013734577,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W2151843619","doi":"10.1158/1541-7786.mcr-13-0003-t","title":"Fer Protein-Tyrosine Kinase Promotes Lung Adenocarcinoma Cell Invasion and Tumor Metastasis","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; Magyar Tudományos Akadémia","keywords":"Cancer research; Tyrosine kinase; Metastasis; Adenocarcinoma; Biology; Receptor tyrosine kinase; Epidermal growth factor receptor; Gefitinib; Cancer; Kinase; Signal transduction; Medicine; Internal medicine; Cell biology","score_opus":0.03692200303844042,"score_gpt":0.3701378296369269,"score_spread":0.3332158265984865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151843619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97286665,0.016789325,0.00008816952,0.005063917,0.00003047441,0.0031161467,0.000021322192,0.000039011426,0.0019849562],"genre_scores_gemma":[0.993052,0.00010739046,0.0014409409,0.00027562334,0.00005999063,0.0020319587,0.000030964606,0.00005150003,0.0029496162],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980406,0.00013947772,0.00018772745,0.00046903462,0.0006574434,0.000505707],"domain_scores_gemma":[0.99877375,0.000029151492,0.00003890938,0.00039304412,0.00044355818,0.00032156723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023874089,0.00017647646,0.00024257612,0.00023688766,0.00020562639,0.00011368385,0.00010131043,0.000055242905,0.0007596474],"category_scores_gemma":[0.0000679235,0.00013568405,0.0000658033,0.00044275363,0.00014734152,0.00013425497,0.00013357299,0.00031546483,0.000074566524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001320731,0.00041905648,0.01895934,0.0007361692,0.00025274654,0.00063405244,0.0005558682,0.0000031571822,0.9631574,0.00031319642,0.004291018,0.0105459355],"study_design_scores_gemma":[0.0030638722,0.0007306849,0.035465453,0.00038820002,0.00026388283,0.000041281324,0.00021827237,0.00031596504,0.9562733,0.00049020373,0.0025033907,0.00024550344],"about_ca_topic_score_codex":0.0037924827,"about_ca_topic_score_gemma":0.000038928403,"teacher_disagreement_score":0.020185336,"about_ca_system_score_codex":0.00030507238,"about_ca_system_score_gemma":0.00042836566,"threshold_uncertainty_score":0.83176064},"labels":[],"label_agreement":null},{"id":"W2152357395","doi":"10.25011/cim.v35i4.17146","title":"BAP1 is a good prognostic factor in advanced non-small cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China","keywords":"BAP1; Medicine; Oncology; Lung cancer; Internal medicine; Cancer research; Cancer; Western blot; Survival analysis; Biology; Gene","score_opus":0.10263060761440136,"score_gpt":0.40747244673546024,"score_spread":0.3048418391210589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152357395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792046,0.0053424137,0.000049528757,0.010964673,0.00051298423,0.00089678104,0.000024001713,0.000025766372,0.0029792413],"genre_scores_gemma":[0.9907095,0.0005449591,0.00092400203,0.00493872,0.00062522775,0.00017779884,0.000029791354,0.000021598134,0.002028447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856913,0.000060866398,0.0005346105,0.00032644917,0.00016637276,0.0003425413],"domain_scores_gemma":[0.9987342,0.00023305659,0.00013467706,0.00017144962,0.00009681563,0.00062981586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020948371,0.00020956575,0.00055556226,0.00007797097,0.000054997814,0.0000044202325,0.00005195274,0.00010920016,0.00031161626],"category_scores_gemma":[0.00047057678,0.00013289101,0.000059044454,0.00024303848,0.0010967815,0.00013926715,0.00003654312,0.00033662864,0.000013445395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019305891,0.0002821849,0.9889783,0.00018154406,0.00008573381,0.000009957456,0.0036793076,3.5568308e-7,0.0005903184,0.00015095255,0.0016370023,0.004384993],"study_design_scores_gemma":[0.0054356437,0.00076445536,0.9856227,0.00096409576,0.00041928457,0.000004145289,0.00050779973,0.00012586219,0.0007696785,0.0003846859,0.004856123,0.0001455417],"about_ca_topic_score_codex":0.00021570019,"about_ca_topic_score_gemma":0.00004424674,"teacher_disagreement_score":0.011504847,"about_ca_system_score_codex":0.0000658092,"about_ca_system_score_gemma":0.00021290717,"threshold_uncertainty_score":0.54191387},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2152452482","doi":"10.1158/1078-0432.795.11.2","title":"The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Cetuximab; Epidermal growth factor receptor; Lung cancer; Cancer research; Medicine; Cancer; Cell cycle; EGFR inhibitors; In vivo; Oncology; Internal medicine; Biology; Colorectal cancer","score_opus":0.049015660487748455,"score_gpt":0.5172781675729077,"score_spread":0.4682625070851592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152452482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97496086,0.011933723,0.000005148666,0.011997215,0.000043113632,0.0009249459,0.000002607901,0.0000046364207,0.00012775119],"genre_scores_gemma":[0.9680521,0.030733926,0.000074337826,0.00020359177,0.00008477294,0.00035289762,0.000002303564,0.000010483694,0.00048560504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901575,0.00013374262,0.00024216309,0.00018559545,0.00024226398,0.00018045842],"domain_scores_gemma":[0.9985697,0.0010955958,0.000047431175,0.00011594151,0.0001040564,0.000067253015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006793214,0.00006008002,0.00020157649,0.00009306251,0.000057627487,0.0000137685065,0.000038911858,0.000056825324,0.000019847641],"category_scores_gemma":[0.00021420358,0.00003384824,0.000014407256,0.00031000745,0.0002191426,0.000064188505,0.0000167173,0.00025824472,3.3955288e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024464421,0.0003871197,0.6149348,0.00021068021,0.00007093622,0.000008191284,0.00061529886,0.0000067926417,0.00010980854,0.00009393715,0.00039727733,0.3807187],"study_design_scores_gemma":[0.015966123,0.00086243893,0.9779535,0.00042608913,0.00003334536,0.000001224223,0.000072645584,0.0014649064,0.0006488875,0.00006517658,0.0024585354,0.00004711942],"about_ca_topic_score_codex":0.0017097417,"about_ca_topic_score_gemma":0.0071977945,"teacher_disagreement_score":0.3806716,"about_ca_system_score_codex":0.00025117895,"about_ca_system_score_gemma":0.00037299906,"threshold_uncertainty_score":0.40165383},"labels":[],"label_agreement":null},{"id":"W2152816062","doi":"10.1200/jco.2009.26.3996","title":"Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma","year":2010,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Cancer research; Receptor; Cancer; Pathology; Human Epidermal Growth Factor Receptor 2; Internal medicine; Oncology; Breast cancer","score_opus":0.04852154863458824,"score_gpt":0.4610932813893908,"score_spread":0.4125717327548026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152816062","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4586406,0.0013889942,0.00001861899,0.0027298476,0.53492737,0.000925588,0.00015817901,0.000013593555,0.0011972119],"genre_scores_gemma":[0.18050778,0.008846953,0.00549429,0.0014066664,0.8022387,0.00017934317,0.00025490904,0.00018244327,0.0008888955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925841,0.0008737086,0.004605573,0.00060173793,0.0007368321,0.0005980265],"domain_scores_gemma":[0.9893009,0.0050333478,0.0035840615,0.00037777016,0.00090313336,0.0008007731],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0027684467,0.00048605487,0.0035854762,0.0008222636,0.000047713962,0.000030739993,0.00043005781,0.0033551895,0.00026556544],"category_scores_gemma":[0.0057502,0.00037125472,0.00075271947,0.0003712969,0.00021226708,0.00025027388,0.00008916289,0.005626162,0.000011907047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011972926,0.0069772317,0.18661866,0.0006606172,0.0021669716,0.0040275436,0.0014889626,0.000009437595,0.00042655447,0.0000029711161,0.73802906,0.047619052],"study_design_scores_gemma":[0.049464222,0.01277929,0.090269245,0.0016221886,0.0019611237,0.00008445737,0.00029718224,0.00013546739,0.000075041105,0.000051672167,0.84266573,0.0005943582],"about_ca_topic_score_codex":0.0025006018,"about_ca_topic_score_gemma":0.010053934,"teacher_disagreement_score":0.27813283,"about_ca_system_score_codex":0.0015390811,"about_ca_system_score_gemma":0.01684635,"threshold_uncertainty_score":0.99987394},"labels":[],"label_agreement":null},{"id":"W2152905269","doi":"10.1016/s1470-2045(12)70087-6","title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Gefitinib; Internal medicine; Clinical endpoint; Hazard ratio; Placebo; Lung cancer; Oncology; Performance status; Chemotherapy; Adenocarcinoma; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.03765453655497886,"score_gpt":0.40357536614862405,"score_spread":0.3659208295936452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152905269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956275,0.0009952454,0.00049139163,0.0009808997,0.00036985302,0.006951853,0.00033945526,0.000020487658,0.00028807606],"genre_scores_gemma":[0.9720966,0.0004026507,0.022351637,0.0004536573,0.0006859982,0.0033412394,0.00008571102,0.000055205695,0.0005272701],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99861413,0.000110561494,0.00047165106,0.00022929635,0.00017360687,0.0004007506],"domain_scores_gemma":[0.99777454,0.0011445216,0.00048644486,0.00028309555,0.00019580862,0.00011559615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003379942,0.00023912193,0.0010875778,0.00006591623,0.00006344567,0.000006362424,0.00009950212,0.000072479605,0.00026782634],"category_scores_gemma":[0.00011299625,0.00012423753,0.000094268966,0.0001504936,0.00015494805,0.00009107152,0.000022673212,0.00012304173,5.7337013e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97559595,0.0027116633,0.0045613186,0.0007667326,0.0014805763,0.0000043938267,0.004030999,0.00001836582,0.0006087182,0.000020931071,0.00068814226,0.009512194],"study_design_scores_gemma":[0.97853273,0.00999559,0.0013524304,0.00025391477,0.003679655,0.0000052191713,0.0005117324,0.00022120975,0.0018394139,0.000008430234,0.0034202894,0.00017938075],"about_ca_topic_score_codex":0.000051199077,"about_ca_topic_score_gemma":0.00026886273,"teacher_disagreement_score":0.021860246,"about_ca_system_score_codex":0.00011396554,"about_ca_system_score_gemma":0.00056178897,"threshold_uncertainty_score":0.50662595},"labels":[],"label_agreement":null},{"id":"W2153655235","doi":"10.1183/09031936.00197013","title":"Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?","year":2014,"lang":"en","type":"review","venue":"European Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Sampling (signal processing); Lung cancer; Medicine; Lung; Cancer therapy; Cancer; Pathology; Oncology; Medical physics; Intensive care medicine; Internal medicine; Computer science","score_opus":0.09638963706361418,"score_gpt":0.4296163460091597,"score_spread":0.3332267089455455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153655235","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017028795,0.99319744,0.001700768,0.0003047393,0.00028964598,0.0031340546,0.000075632306,0.000011993243,0.0011154191],"genre_scores_gemma":[0.00012482605,0.9911941,0.0041534114,0.0028019827,0.00093491515,0.00041507016,0.00003162027,0.00015766978,0.00018635628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978409,0.00039077425,0.00078602537,0.000335153,0.00032741332,0.00031975025],"domain_scores_gemma":[0.99835426,0.00028263073,0.0007107406,0.00032080992,0.00023124983,0.00010028538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013144703,0.0003540441,0.0009149199,0.00017332107,0.00019397757,0.00015596612,0.0003299354,0.000059870952,0.000040212846],"category_scores_gemma":[0.000059029415,0.00021731472,0.00048012787,0.00023087245,0.000035696037,0.00009623081,0.000027688417,0.00043668094,0.0000024969381],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041835196,0.00011371609,0.000020355797,0.006404398,0.00092347886,0.00011283941,0.00073942274,0.00001463469,0.000028869921,0.0000797024,0.0013771676,0.9901436],"study_design_scores_gemma":[0.0025697693,0.00049405225,0.00007390821,0.01928144,0.0023861993,0.00008047841,0.00020284545,0.00001062786,0.00001574898,0.000011605407,0.9746739,0.00019942095],"about_ca_topic_score_codex":0.0000044731833,"about_ca_topic_score_gemma":0.0000010147485,"teacher_disagreement_score":0.98994416,"about_ca_system_score_codex":0.00023494208,"about_ca_system_score_gemma":0.00039238107,"threshold_uncertainty_score":0.8861837},"labels":[],"label_agreement":null},{"id":"W2153732710","doi":"10.1158/1078-0432.ccr-03-0470","title":"<b> <i>Skp2</i> </b> Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with <b> <i>ras</i> </b> Mutation Is a Poor Prognostic Marker","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; Cancer research; SKP2; Mutation; Cell cycle; Adenocarcinoma; Gene; Lung cancer; Copy-number variation; Gene mutation; Gene dosage; Gene expression; Cancer; Molecular biology; Pathology; Genetics; Medicine; Ubiquitin","score_opus":0.05996688744326527,"score_gpt":0.44183755208976144,"score_spread":0.38187066464649616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153732710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112934,0.0011176051,0.000027206737,0.003159154,0.000057918925,0.0023460286,0.0000824004,0.000024187195,0.002056177],"genre_scores_gemma":[0.99619955,0.0004382246,0.00048197905,0.0008382087,0.00013341125,0.000995089,0.000076938544,0.0000531652,0.00078346074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972848,0.0002251037,0.00066037144,0.0006795323,0.0005814232,0.0005687396],"domain_scores_gemma":[0.99838537,0.00047545985,0.00014281819,0.00030765502,0.00035154613,0.0003371371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007021191,0.00022687651,0.0004943213,0.00021015611,0.0001678572,0.000056156034,0.00012307764,0.00018934376,0.00014772889],"category_scores_gemma":[0.00015521166,0.00017891887,0.00006740373,0.0007946921,0.00018093096,0.0001788558,0.00009357753,0.00089886953,0.00003245292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009636707,0.0009659935,0.99326956,0.00038218775,0.000029803969,0.0004741313,0.0011265468,0.0001400163,0.0010052734,0.000022186465,0.0012078604,0.0004127605],"study_design_scores_gemma":[0.014088229,0.000665973,0.97178364,0.0026735005,0.000109432905,0.000040765757,0.00066943595,0.0007807702,0.008546052,0.00020716382,0.00018379583,0.00025124138],"about_ca_topic_score_codex":0.0035574571,"about_ca_topic_score_gemma":0.0033696075,"teacher_disagreement_score":0.021485928,"about_ca_system_score_codex":0.0006097663,"about_ca_system_score_gemma":0.0011816525,"threshold_uncertainty_score":0.72960997},"labels":[],"label_agreement":null},{"id":"W2153865661","doi":"10.1200/jco.2007.14.4824","title":"Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":573,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; AstraZeneca","keywords":"Medicine; Gefitinib; Docetaxel; Internal medicine; Performance status; Lung cancer; Interim analysis; Placebo; Chemoradiotherapy; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology","score_opus":0.08398044194763006,"score_gpt":0.4845825549230046,"score_spread":0.40060211297537457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153865661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932073,0.0016221028,0.0003108735,0.0017676705,0.0009521753,0.00095195486,0.000030245887,0.0000046228697,0.0011530906],"genre_scores_gemma":[0.9819543,0.012620065,0.0010099318,0.0010910253,0.00061172975,0.00006880928,0.0000060044213,0.000016248949,0.0026218856],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971541,0.00016774787,0.002037222,0.00020570266,0.00020715935,0.00022807757],"domain_scores_gemma":[0.9971268,0.0007732587,0.0013995349,0.00013131066,0.0003219937,0.00024708794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010032034,0.00015619295,0.0015409532,0.00012594702,0.000039573566,0.0000063521115,0.00008021138,0.00022095951,0.00040860902],"category_scores_gemma":[0.00033492595,0.00010258904,0.00019341627,0.00013747666,0.00024543217,0.000120985154,0.000019907453,0.00051655015,0.0000011032946],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77789944,0.021290556,0.06148108,0.00039560205,0.0015086216,0.003328592,0.004371811,0.00010884271,0.0015085334,0.00006294561,0.008458226,0.11958572],"study_design_scores_gemma":[0.9239024,0.024809206,0.010209826,0.00043750135,0.0008062646,0.00029657927,0.0003865482,0.0009541483,0.0009024261,0.000009952805,0.037099432,0.00018569913],"about_ca_topic_score_codex":0.00017407222,"about_ca_topic_score_gemma":0.00015517029,"teacher_disagreement_score":0.14600295,"about_ca_system_score_codex":0.00028528617,"about_ca_system_score_gemma":0.0032393443,"threshold_uncertainty_score":0.57464576},"labels":[],"label_agreement":null},{"id":"W2153964141","doi":"10.1093/annonc/mdi312","title":"Smoking and lung cancer in Harbin, northeast China","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Lung cancer; Odds ratio; Confidence interval; Internal medicine; Lung; Case-control study; Cancer; Incidence (geometry)","score_opus":0.03279184355381752,"score_gpt":0.43606015689424726,"score_spread":0.40326831334042973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153964141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508145,0.005226794,0.0000062104286,0.023441171,0.00006356772,0.0001585848,0.0000126149525,0.000008076593,0.020268502],"genre_scores_gemma":[0.99700093,0.0009781051,0.00015636806,0.0013006809,0.00009328246,0.000027622167,0.0000049390983,0.000006046408,0.00043203574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995743,0.000013649796,0.00013809057,0.00009970347,0.00005217198,0.00012208635],"domain_scores_gemma":[0.9997743,0.000018968614,0.000050386487,0.00006644467,0.00004136519,0.000048537986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067883666,0.00005267256,0.00018051281,0.00007192465,0.000019531688,0.0000017714625,0.000019625124,0.000048886795,0.00014193197],"category_scores_gemma":[0.000011807763,0.00004327396,0.000023201577,0.00007238407,0.000038686365,0.000045438366,0.000012338534,0.00006716988,0.0000011130528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011597368,0.0003438135,0.55291873,0.000057240915,0.00020389182,0.00003345865,0.0021292788,0.00008736605,0.00030352632,0.0004042413,0.0025388997,0.44086358],"study_design_scores_gemma":[0.0022498295,0.00049025624,0.9318586,0.00010540798,0.00013373973,0.000025145995,0.000081904465,0.00040988566,0.00063482986,0.00006153,0.063888416,0.000060445593],"about_ca_topic_score_codex":0.0005790781,"about_ca_topic_score_gemma":0.0011748427,"teacher_disagreement_score":0.44080314,"about_ca_system_score_codex":0.00006053536,"about_ca_system_score_gemma":0.00016593574,"threshold_uncertainty_score":0.17646609},"labels":[],"label_agreement":null},{"id":"W2154210596","doi":"10.3816/clc.2008.s.010","title":"Emerging Safety Data for Bevacizumab in Advanced Non–Small-Cell Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Bevacizumab; Medicine; Internal medicine; Oncology; Adverse effect; Lung cancer; Clinical trial; Chemotherapy; Surgery","score_opus":0.10299938257047753,"score_gpt":0.523098341916035,"score_spread":0.42009895934555747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154210596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006262935,0.983171,0.00030763604,0.00047283113,0.002863341,0.007631918,0.0036785337,0.00008470341,0.0017274417],"genre_scores_gemma":[0.00002270204,0.98066413,0.0019380762,0.00057980855,0.0019146766,0.004391017,0.0036335865,0.00022989188,0.0066260933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437934,0.00014757112,0.0024510017,0.0018203877,0.00035844487,0.0008432763],"domain_scores_gemma":[0.99540555,0.0010454571,0.00091062876,0.0019913863,0.00023012952,0.0004168257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045188342,0.0008076758,0.0037142348,0.00024042359,0.00021045469,0.000029101657,0.00077631406,0.0006971532,0.00040189884],"category_scores_gemma":[0.000306487,0.0006416485,0.0009937971,0.00061802246,0.0001296289,0.00018993372,0.0003506432,0.001100068,0.000016820577],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002601313,0.0004267998,0.0028224522,0.021778256,0.0016039378,0.00008147403,0.000099003904,0.0000435824,1.5190734e-7,0.000008799098,0.035420436,0.937455],"study_design_scores_gemma":[0.006669411,0.00014551607,0.00037966238,0.027928252,0.009801282,0.000017408523,0.000023107354,0.0013319353,3.8130804e-7,0.0000033997435,0.95307237,0.00062730204],"about_ca_topic_score_codex":0.0004216387,"about_ca_topic_score_gemma":0.0010815724,"teacher_disagreement_score":0.93682766,"about_ca_system_score_codex":0.0019521138,"about_ca_system_score_gemma":0.006250614,"threshold_uncertainty_score":0.99960345},"labels":[],"label_agreement":null},{"id":"W2154302986","doi":"10.5430/jst.v2n5p1","title":"The place of TKI in the treatment of EGFR mutation-positive lung cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gefitinib; Erlotinib; Lung cancer; Medicine; Carboplatin; Oncology; Epidermal growth factor receptor; Internal medicine; Chemotherapy; Paclitaxel; Cancer research; Exon; Cancer; Biology; Gene; Cisplatin","score_opus":0.012241682821333952,"score_gpt":0.3636789278659512,"score_spread":0.3514372450446172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154302986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889257,0.0075891265,0.000021054057,0.0018953498,0.00019543368,0.00027747883,0.000024287889,0.0000011638266,0.0010704246],"genre_scores_gemma":[0.9985345,0.00084540516,0.000091134185,0.0000718862,0.00018042844,0.000017552378,0.0000020890736,0.000006732896,0.00025030013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991931,0.000050558116,0.00036213183,0.000037446487,0.00022747347,0.00012931686],"domain_scores_gemma":[0.9990831,0.00023286458,0.00039061828,0.00009189369,0.00015141693,0.00005010567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001956062,0.000073034054,0.00022281303,0.00006498985,0.00005056388,0.0000041384424,0.00005764802,0.000018033274,0.000022505692],"category_scores_gemma":[0.00002687393,0.000032714834,0.00010583835,0.00013381064,0.000057606045,0.000083743216,0.000003193389,0.00006688725,5.938953e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022932459,0.0065539056,0.7328177,0.0002396986,0.004002929,0.00041632832,0.20697415,0.0032714263,0.0025596982,0.0027298522,0.0055677653,0.03257326],"study_design_scores_gemma":[0.0071535464,0.0027936916,0.9427739,0.000790037,0.0019167295,0.00062333007,0.017263932,0.00026848697,0.02322302,0.00016950245,0.0029065423,0.00011731232],"about_ca_topic_score_codex":0.00023762691,"about_ca_topic_score_gemma":0.00006457413,"teacher_disagreement_score":0.20995612,"about_ca_system_score_codex":0.00029387238,"about_ca_system_score_gemma":0.00023621612,"threshold_uncertainty_score":0.13340722},"labels":[],"label_agreement":null},{"id":"W2154320833","doi":"10.1093/annonc/mdq067","title":"The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Histology; Pooled analysis; Oncology; Randomized controlled trial; Internal medicine; Meta-analysis","score_opus":0.03235035266287021,"score_gpt":0.42815541762568093,"score_spread":0.3958050649628107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154320833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285454,0.0008701674,0.000010174827,0.004113432,0.00008713903,0.00074382895,0.000038114867,0.0000027390117,0.0012798967],"genre_scores_gemma":[0.9975222,0.0013325311,0.00019185647,0.000471507,0.000010817931,0.00013080891,0.0000068805152,0.000004976439,0.00032844575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985726,0.0002964574,0.00076118286,0.00014513881,0.000091082045,0.00013355081],"domain_scores_gemma":[0.9949993,0.0038451955,0.0006757513,0.00020816326,0.00022766746,0.000043936067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013678051,0.00009723364,0.0019680732,0.00029490623,0.00002490068,0.0000014402799,0.00007696216,0.000118259806,0.00003563803],"category_scores_gemma":[0.0011785704,0.00005592826,0.00026210165,0.0002452747,0.00029964303,0.00001755115,0.000021166983,0.000121311285,1.8523896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11824677,0.0040166173,0.6880525,0.00053399015,0.047365785,0.00007295004,0.022127118,0.019720074,0.040818397,0.0017927767,0.0010747934,0.056178242],"study_design_scores_gemma":[0.331168,0.0036733677,0.6060726,0.0001568028,0.03515987,0.000006928122,0.001221271,0.0056932573,0.014583888,0.00048055773,0.0015132722,0.00027017097],"about_ca_topic_score_codex":0.0030894817,"about_ca_topic_score_gemma":0.0022420725,"teacher_disagreement_score":0.21292123,"about_ca_system_score_codex":0.000027437722,"about_ca_system_score_gemma":0.0003214942,"threshold_uncertainty_score":0.4670393},"labels":[],"label_agreement":null},{"id":"W2154581953","doi":"10.1016/s1470-2045(10)70151-0","title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Adverse effect; Lung cancer; Clinical endpoint; Population; Chemotherapy; Surgery; Oncology; Phases of clinical research; Incidence (geometry); Clinical trial","score_opus":0.022379649479756486,"score_gpt":0.3924690575272414,"score_spread":0.3700894080474849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154581953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111545,0.0007613528,0.00013797566,0.0036608637,0.00029367185,0.0025734184,0.000053435106,0.000029846487,0.0013740073],"genre_scores_gemma":[0.99720526,0.00063274556,0.0005705137,0.000688128,0.00025353912,0.00037873726,0.00002913686,0.000029336588,0.00021262521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987611,0.00008208621,0.00038034952,0.00031357343,0.00013424107,0.0003286471],"domain_scores_gemma":[0.9986758,0.00043734198,0.00019686882,0.0004992162,0.00009948945,0.00009127738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003614156,0.00020604808,0.00073238835,0.00009667119,0.00010756224,0.000006873547,0.00016507384,0.00011309777,0.00013195134],"category_scores_gemma":[0.000048836893,0.0001327551,0.000060126025,0.00023754878,0.00012709571,0.000036724174,0.000038407503,0.00039114154,0.000002562978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03870433,0.024494503,0.6029387,0.000491334,0.0008135745,0.0003462706,0.025808662,0.0029456164,0.030601796,0.0000550244,0.0007306563,0.2720695],"study_design_scores_gemma":[0.3912926,0.01866634,0.54466856,0.0001936552,0.0012285932,0.00003419171,0.0014338228,0.010875456,0.0067988206,0.00004460792,0.024267353,0.0004960247],"about_ca_topic_score_codex":0.0009979252,"about_ca_topic_score_gemma":0.005359361,"teacher_disagreement_score":0.35258827,"about_ca_system_score_codex":0.00017839132,"about_ca_system_score_gemma":0.00044845877,"threshold_uncertainty_score":0.5413596},"labels":[],"label_agreement":null},{"id":"W2154662831","doi":"10.1200/jco.2011.36.8456","title":"First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":735,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Cisplatin; Internal medicine; Adenocarcinoma; Lung cancer; Chemotherapy; Lung; Cancer","score_opus":0.13184785630743598,"score_gpt":0.4544081414491074,"score_spread":0.32256028514167145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154662831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860841,0.0022600668,0.00006485897,0.008937546,0.0012828631,0.00045281465,0.0000036649483,0.0000033832018,0.0009107091],"genre_scores_gemma":[0.9973752,0.00023096762,0.00091932947,0.00043031716,0.00087097724,0.000007946593,0.0000016215406,0.000013879521,0.00014975379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978109,0.00018811847,0.001355249,0.00012091652,0.00030673936,0.00021805742],"domain_scores_gemma":[0.9963461,0.001955316,0.0011276263,0.00015883545,0.00016594416,0.00024616873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011324952,0.0001242383,0.00086899096,0.0000857998,0.00004878544,0.000004700831,0.00009673184,0.00020474492,0.00008877162],"category_scores_gemma":[0.0010150899,0.00006643039,0.00020929142,0.00016460552,0.00021401158,0.00015342022,0.00004498988,0.0005127918,0.000001102197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14444748,0.0041270605,0.83191586,0.00008146858,0.0010015037,0.00015859051,0.0008542404,0.00023280377,0.000014709575,0.00012574879,0.0025645313,0.014476014],"study_design_scores_gemma":[0.17770204,0.022010269,0.78033406,0.0002598517,0.001713976,0.00014097615,0.00024147796,0.00017275281,0.000036245736,0.000034171146,0.01726624,0.0000879452],"about_ca_topic_score_codex":0.00006605978,"about_ca_topic_score_gemma":0.00021213164,"teacher_disagreement_score":0.051581793,"about_ca_system_score_codex":0.000259805,"about_ca_system_score_gemma":0.0006019919,"threshold_uncertainty_score":0.27089527},"labels":[],"label_agreement":null},{"id":"W2154734647","doi":"10.1111/jcmm.12278","title":"Pooled analysis of clinical outcome for <scp>EGFR TKI</scp>‐treated patients with <i><scp>EGFR</scp></i> mutation‐positive <scp>NSCLC</scp>","year":2014,"lang":"en","type":"article","venue":"Journal of Cellular and Molecular Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"F. Hoffmann-La Roche","keywords":"Erlotinib; Gefitinib; Medicine; Oncology; Internal medicine; Afatinib; Lung cancer; Chemotherapy; Epidermal growth factor receptor; Cancer","score_opus":0.012117651339938402,"score_gpt":0.3210887572776774,"score_spread":0.30897110593773897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154734647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9397851,0.002403552,0.05293286,0.00040879188,0.0003325628,0.00093823497,0.00007963321,0.000024454797,0.003094805],"genre_scores_gemma":[0.9938129,0.00013039078,0.002296477,0.0015721602,0.0003399739,0.000024166124,0.0006142975,0.00007487792,0.0011347627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569094,0.00026589746,0.001951872,0.0004890572,0.0011103033,0.0004919136],"domain_scores_gemma":[0.9935352,0.0017565829,0.0017258808,0.000444202,0.0018342213,0.00070390815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012271539,0.00047061083,0.0020881335,0.00083656434,0.00014751795,0.000029964485,0.00019528727,0.0002590011,0.0000106112875],"category_scores_gemma":[0.003324744,0.00031189868,0.00069707644,0.00097013183,0.00032447756,0.00016520893,0.000040008785,0.00044291638,0.0000029987634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062922225,0.0047743767,0.85148656,0.00092923024,0.060735453,0.0015708363,0.0079130195,0.0010005587,0.04509025,0.0015973932,0.011147462,0.013125643],"study_design_scores_gemma":[0.08721392,0.026427165,0.6369774,0.0020453057,0.15741909,0.00027012924,0.0048853788,0.0036554835,0.05116947,0.0007302289,0.028944187,0.00026224303],"about_ca_topic_score_codex":0.00007588483,"about_ca_topic_score_gemma":0.000015129494,"teacher_disagreement_score":0.21450916,"about_ca_system_score_codex":0.0001230585,"about_ca_system_score_gemma":0.0002573962,"threshold_uncertainty_score":0.9999333},"labels":[],"label_agreement":null},{"id":"W2154793156","doi":"10.6000/1929-2279.2013.02.04.5","title":"Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma","year":2013,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Drug; Drug resistance; Resistance (ecology); Lung cancer; Medicine; Pharmacology; Biology; Internal medicine; Microbiology; Ecology","score_opus":0.021520124594103955,"score_gpt":0.37135931892003415,"score_spread":0.3498391943259302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154793156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97417724,0.008733544,0.00010786135,0.010310822,0.00018728155,0.0006753751,0.0000082932875,0.000006399273,0.005793196],"genre_scores_gemma":[0.9847764,0.0010888635,0.0025559324,0.00019939884,0.00020253396,0.00011490289,0.0000040076548,0.000026056292,0.011031899],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982169,0.00009339805,0.00041662948,0.0001710239,0.00066828233,0.0004337292],"domain_scores_gemma":[0.99836874,0.000120000164,0.00015613392,0.00020943637,0.0008846709,0.0002609983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063228805,0.000119397104,0.00030953786,0.00044867763,0.00009071908,0.00006953291,0.00019945628,0.00005091014,0.00071226904],"category_scores_gemma":[0.00005171146,0.00008614194,0.00009363696,0.0004445757,0.00006107344,0.00024800896,0.000045781082,0.00055543345,0.000037015074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014920738,0.001561583,0.37349454,0.0016103921,0.0006951501,0.0017472768,0.008506121,0.00014873577,0.13753827,0.0014310128,0.46180287,0.00997198],"study_design_scores_gemma":[0.02126478,0.0011888071,0.6115034,0.0035510685,0.00056693197,0.00011476983,0.007483769,0.00075411104,0.2892069,0.015987543,0.047686912,0.00069098524],"about_ca_topic_score_codex":0.0017461542,"about_ca_topic_score_gemma":0.001052588,"teacher_disagreement_score":0.41411597,"about_ca_system_score_codex":0.0007098861,"about_ca_system_score_gemma":0.00090651074,"threshold_uncertainty_score":0.7798847},"labels":[],"label_agreement":null},{"id":"W2154943084","doi":"10.1200/jco.2014.60.1492","title":"Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i>-Mutant Lung Adenocarcinoma","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Epidermal growth factor receptor; Cancer research; Lung cancer; Adenocarcinoma; Targeted therapy; Cetuximab; Cancer; Pathology; Internal medicine","score_opus":0.12799527912535108,"score_gpt":0.4583505217761397,"score_spread":0.33035524265078864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154943084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928137,0.0021095974,0.00004736105,0.0030803464,0.0007859349,0.00051872304,0.00002281501,0.0000047196977,0.00061681814],"genre_scores_gemma":[0.989244,0.00026405216,0.009754434,0.0005205745,0.00017633435,0.000010093045,0.000003027869,0.000012547005,0.0000149533935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950421,0.0005087133,0.003619916,0.00025122284,0.00036474838,0.00021331251],"domain_scores_gemma":[0.99524665,0.0013519421,0.0018640565,0.0002220642,0.000701921,0.00061338657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027866587,0.00014218272,0.0016392842,0.00017196155,0.0000166151,0.0000037447992,0.00012202511,0.00027869703,0.000018080635],"category_scores_gemma":[0.0034288252,0.00010161306,0.000319815,0.0002291181,0.0003474889,0.00008862828,0.00007729634,0.00038656313,0.0000010744683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008821121,0.0026056704,0.91902375,0.00012346866,0.00049749285,0.00040828087,0.0007425661,0.0000011285985,0.0004914674,0.000012996951,0.002206405,0.06506564],"study_design_scores_gemma":[0.012625811,0.01579769,0.96130866,0.00047829334,0.0007348066,0.000063181804,0.0007669505,0.00006891928,0.00088827003,0.00018518462,0.006982151,0.00010009501],"about_ca_topic_score_codex":0.000044167962,"about_ca_topic_score_gemma":0.00018807873,"teacher_disagreement_score":0.06496554,"about_ca_system_score_codex":0.00012941533,"about_ca_system_score_gemma":0.0017824525,"threshold_uncertainty_score":0.41436607},"labels":[],"label_agreement":null},{"id":"W2154948351","doi":"10.1200/jco.2003.06.099","title":"Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vinorelbine; Medicine; Gemcitabine; Internal medicine; Lung cancer; Cisplatin; Hazard ratio; Oncology; Chemotherapy; Cancer; Ototoxicity; Confidence interval","score_opus":0.13445089668490903,"score_gpt":0.4988893839233714,"score_spread":0.3644384872384624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154948351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979955,0.0012238241,0.0006266955,0.0085923225,0.0039755977,0.0044982666,0.00042017878,0.000007723353,0.0007003593],"genre_scores_gemma":[0.9879938,0.0009658096,0.005588133,0.0019456282,0.0014162933,0.00037831947,0.00004237795,0.000049763963,0.0016199114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904595,0.0012539995,0.0064387955,0.00045173016,0.0009573686,0.00043859117],"domain_scores_gemma":[0.9819936,0.008372605,0.0071638785,0.00035072642,0.0015216639,0.0005975136],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008695245,0.00041561358,0.0044325786,0.0001483532,0.00021757623,0.0000169745,0.00037048073,0.0003645746,0.0001445388],"category_scores_gemma":[0.013186333,0.00019996225,0.0007563995,0.0004998442,0.0012216162,0.00017612749,0.00007759123,0.0009439896,2.0691397e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91587603,0.0047756764,0.014443163,0.00077817787,0.008402985,0.00016914771,0.0011905843,0.010012126,0.0006961839,0.0017471488,0.027060553,0.01484823],"study_design_scores_gemma":[0.93217695,0.01555582,0.004896937,0.00088256126,0.007670435,0.00012915811,0.00052406586,0.008075931,0.0003279492,0.00015794889,0.029250577,0.00035163897],"about_ca_topic_score_codex":0.013296367,"about_ca_topic_score_gemma":0.11462382,"teacher_disagreement_score":0.10132745,"about_ca_system_score_codex":0.0012872192,"about_ca_system_score_gemma":0.038524438,"threshold_uncertainty_score":0.995126},"labels":[],"label_agreement":null},{"id":"W2154969724","doi":"10.1146/annurev-pathol-011110-130206","title":"EGFR Mutations and Lung Cancer","year":2011,"lang":"en","type":"review","venue":"Annual Review of Pathology Mechanisms of Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":970,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epidermal growth factor receptor; Tyrosine kinase; Protein kinase domain; Cancer research; Lung cancer; Mutation; Medicine; Receptor tyrosine kinase; Kinase; Targeted therapy; Mutant; EGFR inhibitors; Cancer; Biology; Oncology; Internal medicine; Gene; Receptor; Cell biology; Genetics","score_opus":0.025287382431191753,"score_gpt":0.40575061926058964,"score_spread":0.38046323682939787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154969724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000032360679,0.99443144,0.00022950926,0.00015632904,0.00016542326,0.0019084291,0.002682738,0.000018471881,0.00040440957],"genre_scores_gemma":[0.000026944886,0.99681497,0.0010303566,0.0003805415,0.000037173846,0.00068652956,0.0005440799,0.000043256423,0.00043613606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983466,0.00014826961,0.00078031176,0.0003784348,0.00015567862,0.00019067278],"domain_scores_gemma":[0.99822277,0.00007498695,0.0006748079,0.000445388,0.00030590486,0.0002761152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018367724,0.00032657644,0.0020776317,0.00016717463,0.00004026933,0.0000017570915,0.00011794795,0.00014212246,0.00036554888],"category_scores_gemma":[0.00018844916,0.00021043225,0.0005321194,0.00021012165,0.00014915182,0.000063782376,0.000070718444,0.00014773062,0.0000080350055],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014428082,0.00023560246,0.000009521675,0.3854398,0.00061698013,0.00014694374,0.00011418388,1.6722492e-8,8.217445e-7,0.007850523,0.0006641869,0.604907],"study_design_scores_gemma":[0.00081292656,0.00047257994,0.000098766126,0.40369448,0.07349412,0.00015408058,0.00006728699,8.2603947e-7,0.0000067400615,0.0016600931,0.5191399,0.00039824873],"about_ca_topic_score_codex":0.000022619373,"about_ca_topic_score_gemma":0.0000020207292,"teacher_disagreement_score":0.60450876,"about_ca_system_score_codex":0.00005913049,"about_ca_system_score_gemma":0.0010258943,"threshold_uncertainty_score":0.8581178},"labels":[],"label_agreement":null},{"id":"W2155440695","doi":"10.1016/s1470-2045(05)70255-2","title":"Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Vinorelbine; Medicine; Gemcitabine; Neutropenia; Internal medicine; Chemotherapy; Hazard ratio; Lung cancer; Clinical endpoint; Surgery; Oncology; Clinical trial; Cisplatin; Confidence interval","score_opus":0.09235030140493503,"score_gpt":0.4565041393492671,"score_spread":0.3641538379443321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155440695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035699338,0.95397747,0.000011015162,0.0010193167,0.00014335841,0.007273162,0.00011392177,0.000025609539,0.001736823],"genre_scores_gemma":[0.0038353594,0.99231845,0.00037005986,0.00024501196,0.000459324,0.002171921,0.0001749179,0.000053073298,0.0003718976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997067,0.0006291593,0.0012571159,0.0005082919,0.00013761145,0.00040082444],"domain_scores_gemma":[0.99648964,0.0015429525,0.0011280067,0.000667331,0.00006530301,0.000106769534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091825303,0.0004999825,0.008717425,0.00044543092,0.000060162256,0.000013246969,0.00021608363,0.00031611032,0.00016705366],"category_scores_gemma":[0.000069980175,0.00026492262,0.00093804824,0.0008701772,0.00006852667,0.000026111014,0.000037413392,0.0002804632,0.0000032756022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033330005,0.00074293924,0.00031033973,0.0011175318,0.015984511,0.000028582355,0.00076639606,0.00005874024,0.00005544381,0.0000090263275,0.00006201592,0.9775315],"study_design_scores_gemma":[0.19180217,0.0014901613,0.00393477,0.0029610975,0.22159737,0.000019186415,0.000057234243,0.0002891054,0.000041542735,0.0000040650784,0.57737684,0.00042642673],"about_ca_topic_score_codex":0.00064813806,"about_ca_topic_score_gemma":0.0026062606,"teacher_disagreement_score":0.977105,"about_ca_system_score_codex":0.001230114,"about_ca_system_score_gemma":0.0014425342,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W2155762971","doi":"10.1093/jnci/92.16.1321","title":"Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer","year":2000,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa; Statistics Canada","funders":"","keywords":"Vinorelbine; Vindesine; Medicine; Gemcitabine; Oncology; Cisplatin; Regimen; Vinblastine; Population; Cost effectiveness; Internal medicine; Lung cancer; Chemotherapy; Quality of life (healthcare)","score_opus":0.0767527267921201,"score_gpt":0.45110217147367393,"score_spread":0.37434944468155384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155762971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53344685,0.023763074,0.39298007,0.028322354,0.011491778,0.006029169,0.0016184554,0.0000382705,0.0023099934],"genre_scores_gemma":[0.85351557,0.0020709555,0.12435648,0.006385481,0.0028580087,0.0010797366,0.00003252323,0.00006788495,0.00963339],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987893,0.000012546741,0.0004908458,0.0001365023,0.00040535204,0.00016545504],"domain_scores_gemma":[0.99843425,0.00021094109,0.0003425923,0.00010226594,0.0008231047,0.000086861786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000236439,0.00013499074,0.0002803286,0.00011616607,0.0002287323,0.00003350522,0.00018649787,0.000055264965,0.00043819577],"category_scores_gemma":[0.00012424961,0.0000865153,0.0006019814,0.00022068489,0.00004854503,0.00018120729,0.000010646616,0.00017160982,0.0000020888988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009370658,0.004790367,0.012942304,0.005655626,0.015105494,0.000018124072,0.004734314,0.1316964,0.0044257706,0.013419431,0.17029922,0.6275423],"study_design_scores_gemma":[0.051371407,0.0019444332,0.041542925,0.020919524,0.021043472,0.00038710266,0.00027264093,0.019150492,0.017932195,0.08804898,0.7362856,0.0011012268],"about_ca_topic_score_codex":0.000042550044,"about_ca_topic_score_gemma":0.000115367795,"teacher_disagreement_score":0.62644106,"about_ca_system_score_codex":0.0007652658,"about_ca_system_score_gemma":0.0012534697,"threshold_uncertainty_score":0.47979364},"labels":[],"label_agreement":null},{"id":"W2156364905","doi":"10.1016/j.cllc.2011.09.001","title":"Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Tyrosine kinase; Erlotinib Hydrochloride; Cancer research; Pharmacology; Epidermal growth factor; Oncology; Cancer; Internal medicine; Receptor","score_opus":0.0489669299611967,"score_gpt":0.3717236146720273,"score_spread":0.32275668471083063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156364905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737176,0.0022631339,0.01361353,0.0039327,0.0023359046,0.0015706398,0.00024771952,0.000093399525,0.0022253757],"genre_scores_gemma":[0.9854384,0.00015825954,0.011218752,0.001471695,0.0003951747,0.00016571059,0.00004068321,0.000038841183,0.0010724493],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983759,0.000058838625,0.000669686,0.00040905908,0.00024837282,0.00023817125],"domain_scores_gemma":[0.99885947,0.00008796236,0.00019723072,0.00031614836,0.00026404022,0.00027517413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017426746,0.00017861486,0.00041961402,0.0000757198,0.00007751701,0.0000089806945,0.00008667011,0.00013679941,0.00061302603],"category_scores_gemma":[0.00032937768,0.00015192536,0.00019586728,0.00022098611,0.00006129294,0.000096770455,0.00004118303,0.00014917519,0.000016384198],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005148459,0.0055010887,0.4204836,0.0020784677,0.0038089415,0.00032049915,0.006830343,0.00012801075,0.32081845,0.03364188,0.17858925,0.022651033],"study_design_scores_gemma":[0.0074265734,0.0016090035,0.11987379,0.001772418,0.0017843441,0.000003989485,0.00012532833,0.00038011797,0.85439515,0.00095057517,0.010889869,0.00078882097],"about_ca_topic_score_codex":0.00020832846,"about_ca_topic_score_gemma":0.00021062237,"teacher_disagreement_score":0.5335767,"about_ca_system_score_codex":0.00023923304,"about_ca_system_score_gemma":0.00021650495,"threshold_uncertainty_score":0.67122054},"labels":[],"label_agreement":null},{"id":"W2156455627","doi":"10.2217/17455057.3.1.1","title":"Non-Small Cell Lung Cancer: Does Estrogen Affect Outcome?","year":2006,"lang":"en","type":"article","venue":"Women s Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Affect (linguistics); Estrogen; Lung cancer; Oncology; Outcome (game theory); Medicine; Cancer; Internal medicine; Psychology; Communication; Economics","score_opus":0.010242273135022337,"score_gpt":0.34302137258944754,"score_spread":0.3327790994544252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156455627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500973,0.0020933745,0.000096082505,0.0034992907,0.00033689753,0.0009795121,0.00006908868,0.00009190527,0.00782413],"genre_scores_gemma":[0.984389,0.00019971593,0.0007701029,0.0018584132,0.00034769444,0.00036784777,0.000064833104,0.000031938933,0.011970433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878657,0.000021393818,0.0002787171,0.00025327122,0.00015580683,0.00050422613],"domain_scores_gemma":[0.9993316,0.000024432082,0.000115194125,0.00024005614,0.000036224967,0.0002524942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013532088,0.00015284681,0.00033650827,0.00007751266,0.00014813805,0.00001658501,0.00005339256,0.000044190954,0.00019935945],"category_scores_gemma":[0.0000024532976,0.00010247655,0.00006698404,0.00015123074,0.00002007501,0.00003516501,0.000015473943,0.00010774592,0.0000315203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004383977,0.0003094779,0.98652834,0.00072135153,0.000086861364,0.000026260193,0.0017377012,0.000035710218,0.00014466271,0.00018076823,0.006846187,0.0033388203],"study_design_scores_gemma":[0.012643064,0.0015588868,0.85657203,0.0003712356,0.0004719955,0.000029879498,0.0019451894,0.00041663685,0.0023077524,0.00026168016,0.1228062,0.0006154702],"about_ca_topic_score_codex":0.006983476,"about_ca_topic_score_gemma":0.0006190984,"teacher_disagreement_score":0.12995635,"about_ca_system_score_codex":0.0013175147,"about_ca_system_score_gemma":0.00077360234,"threshold_uncertainty_score":0.9996291},"labels":[],"label_agreement":null},{"id":"W2156728903","doi":"10.1097/jto.0b013e3181f7c6d4","title":"Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Pemetrexed; Medicine; Histology; Gemcitabine; Internal medicine; Lung cancer; Oncology; Docetaxel; Chemotherapy; Hazard ratio; Proportional hazards model; Cisplatin; Confidence interval","score_opus":0.0683959621102853,"score_gpt":0.5275235590163642,"score_spread":0.45912759690607885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156728903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926476,0.0025486199,0.0003214367,0.0015775394,0.0013287471,0.0006062406,0.000040015013,0.0000050652097,0.0009247318],"genre_scores_gemma":[0.9970431,0.0005713814,0.0017352311,0.00007665789,0.00023333795,0.000053451415,0.000018778393,0.000016319795,0.00025173964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978505,0.00027242748,0.001287214,0.000199734,0.00014843685,0.00024169189],"domain_scores_gemma":[0.9978722,0.0005081821,0.0010647983,0.00018607493,0.00023152312,0.0001372265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066662556,0.00019442322,0.0015685734,0.0007345411,0.000032977452,0.0000071126137,0.00010720049,0.00024683593,0.00039011711],"category_scores_gemma":[0.00022765047,0.00013968119,0.00028454076,0.00034631634,0.00008559942,0.00014248087,0.00001726668,0.0005084901,0.000001464319],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01419927,0.009389041,0.20492463,0.00016853574,0.001000504,0.0010984418,0.003787937,0.00013684442,0.5287613,0.000006509619,0.00076100294,0.23576598],"study_design_scores_gemma":[0.2182502,0.049915664,0.26143888,0.0011273652,0.028206913,0.003729186,0.010094949,0.008759389,0.38501233,0.0003327249,0.03182441,0.0013079806],"about_ca_topic_score_codex":0.0034765068,"about_ca_topic_score_gemma":0.023345979,"teacher_disagreement_score":0.234458,"about_ca_system_score_codex":0.0012768331,"about_ca_system_score_gemma":0.0013051754,"threshold_uncertainty_score":0.9944754},"labels":[],"label_agreement":null},{"id":"W2156921701","doi":"10.3389/fphar.2013.00057","title":"Systemic cancer therapy: achievements and challenges that lie ahead","year":2013,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Cancer; Medicine; Systemic therapy; Intensive care medicine; Internal medicine; Breast cancer","score_opus":0.03944102994547627,"score_gpt":0.34354972724435545,"score_spread":0.3041086972988792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156921701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8347214,0.14933863,0.000055657336,0.010153524,0.002402539,0.0011987432,0.000008975188,0.000039922947,0.0020806328],"genre_scores_gemma":[0.89793235,0.097804725,0.00048274908,0.0016660205,0.00014146675,0.0007888146,0.000008071496,0.000017209713,0.0011586155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930614,0.000047281865,0.00012487127,0.00021642463,0.00007999334,0.00022526343],"domain_scores_gemma":[0.9997333,0.000017168717,0.000046702782,0.00008213255,0.000029969158,0.00009069016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051194183,0.000116926254,0.00024308391,0.00011880288,0.000040870127,0.0000071131185,0.000049125618,0.000069442656,0.00031565438],"category_scores_gemma":[0.0000017813129,0.00009178235,0.0000250504,0.000059239173,0.00006022697,0.000087976056,0.000019441257,0.000106325846,0.000013334859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022482454,0.00039234848,0.5072507,0.00025559438,0.0011640065,0.00005122102,0.0028941398,0.000007917562,0.005533164,0.00004617712,0.117491126,0.36468875],"study_design_scores_gemma":[0.033651333,0.001089461,0.6814349,0.00039158587,0.0009757094,0.00012624757,0.005563672,0.0009115215,0.007124384,0.0010934807,0.26700673,0.0006309731],"about_ca_topic_score_codex":0.0002104409,"about_ca_topic_score_gemma":0.000010910351,"teacher_disagreement_score":0.3640578,"about_ca_system_score_codex":0.00018319485,"about_ca_system_score_gemma":0.00007021033,"threshold_uncertainty_score":0.37427756},"labels":[],"label_agreement":null},{"id":"W2156990656","doi":"","title":"Intérêt de la thérapie ciblée pour le cancer du poumon non à petites cellules de stade avancé","year":2014,"lang":"fr","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"","keywords":"Medicine; Gynecology","score_opus":0.006345767561173124,"score_gpt":0.3010592579561528,"score_spread":0.2947134903949797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156990656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.619949,0.027779497,0.038035963,0.03563835,0.001713488,0.0006648483,0.00011157488,0.00017876668,0.27592853],"genre_scores_gemma":[0.91048604,0.0048423675,0.0075682644,0.0016857915,0.0019122319,0.00010756931,0.00003537228,0.00006257987,0.07329976],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839264,0.00016863686,0.0002609649,0.0003408224,0.0001838467,0.00065305835],"domain_scores_gemma":[0.9987655,0.00038616144,0.00009814705,0.0002943192,0.000105907086,0.0003499642],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036948203,0.00027410738,0.0003247462,0.000110099485,0.0001825695,0.00007577452,0.00012709982,0.0001939601,0.0023363293],"category_scores_gemma":[0.000097346434,0.0002358925,0.00013022119,0.00015420846,0.00018950652,0.00013622576,0.000042657677,0.00023876275,0.00024405704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021988068,0.003470669,0.49424705,0.0011798308,0.001763322,0.00029865841,0.011212787,0.0038392209,0.056806702,0.08095853,0.1957395,0.15026386],"study_design_scores_gemma":[0.010753207,0.00063403934,0.20285912,0.0016048792,0.002083438,0.00014163961,0.0034244107,0.040322814,0.049318958,0.005790474,0.6823135,0.00075350155],"about_ca_topic_score_codex":0.020572897,"about_ca_topic_score_gemma":0.0013883455,"teacher_disagreement_score":0.48657402,"about_ca_system_score_codex":0.0007033354,"about_ca_system_score_gemma":0.0015098429,"threshold_uncertainty_score":0.9985757},"labels":[],"label_agreement":null},{"id":"W2157181501","doi":"10.1503/cmaj.1040795","title":"A man whose scapula was spared a drug-associated rash","year":2005,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vinorelbine; Rash; Gemcitabine; Medicine; Cisplatin; Chemotherapy; Scapula; Carcinoma; Surgery; Oncology; Internal medicine","score_opus":0.006164854297506183,"score_gpt":0.2750691110026428,"score_spread":0.2689042567051366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157181501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7242149,0.0007992054,0.000036894275,0.24639226,0.001014573,0.0004030886,0.000086039545,0.00008396879,0.026969051],"genre_scores_gemma":[0.9609113,0.00016116908,0.0002640108,0.023089161,0.002076017,0.000017366843,0.00008338992,0.00003065529,0.013366951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973749,0.00011310424,0.00044613166,0.00018229421,0.0012881162,0.0005954911],"domain_scores_gemma":[0.9967419,0.00008826274,0.0002238015,0.00012043679,0.00043812895,0.002387508],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081124087,0.00015351755,0.00030275655,0.0002324965,0.00036450377,0.0000933743,0.00012344343,0.00028654395,0.006774654],"category_scores_gemma":[0.0012133135,0.00013486434,0.00016249914,0.0003028517,0.000030919076,0.00015343592,0.000010296452,0.0007041841,0.0004695965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016257123,0.00023016526,0.1582966,0.000008539523,0.0008309202,0.00085283734,0.0015818652,0.000010408513,0.000017694614,0.00013648342,0.77661556,0.06140266],"study_design_scores_gemma":[0.0050787283,0.00006714313,0.15294166,0.00020782897,0.00032594227,0.0004922133,0.00057760195,0.00043777598,0.000027004044,0.00009028096,0.8395526,0.00020123366],"about_ca_topic_score_codex":0.003189134,"about_ca_topic_score_gemma":0.09005555,"teacher_disagreement_score":0.23669636,"about_ca_system_score_codex":0.004874768,"about_ca_system_score_gemma":0.004752104,"threshold_uncertainty_score":0.99894536},"labels":[],"label_agreement":null},{"id":"W2157334646","doi":"10.1016/j.ejca.2012.01.038","title":"Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Massachusetts General Hospital","keywords":"Lung cancer; Medicine; Family history; Odds ratio; Internal medicine; Confounding; Family aggregation; Cancer; Confidence interval; Relative risk; Oncology; Disease","score_opus":0.010665304344032381,"score_gpt":0.2941586248469896,"score_spread":0.2834933205029572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157334646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.904706,0.09084564,0.000066463814,0.0015153703,0.000646321,0.00025726753,0.00075571594,0.000003888028,0.0012033514],"genre_scores_gemma":[0.99581796,0.0023573893,0.000083530555,0.00067125325,0.00041816634,0.000026029691,0.00000910549,0.00002594929,0.0005906192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998125,0.00035969063,0.00057360437,0.00012887947,0.0006392313,0.00017355644],"domain_scores_gemma":[0.9979107,0.00013068336,0.0011585047,0.00026417064,0.00038085453,0.00015511001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000537305,0.00015008061,0.00039735145,0.00017419047,0.000037216523,0.00000896254,0.0002880458,0.000017479955,0.0007829875],"category_scores_gemma":[0.00009347669,0.00007660949,0.00025130797,0.00037429124,0.00015426941,0.00013922514,0.000047483813,0.0002601464,3.6857287e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004481188,0.00016176568,0.9756214,0.000024301331,0.009875779,0.000014655159,0.0034262633,0.0015667665,0.0004666009,0.000008497358,0.006146896,0.0022389495],"study_design_scores_gemma":[0.0029521657,0.000031916825,0.9695449,0.00067404733,0.017384594,0.0000018916714,0.00021524378,0.00033751572,0.00009032451,0.0000016067403,0.008684649,0.00008116139],"about_ca_topic_score_codex":0.006335754,"about_ca_topic_score_gemma":0.0011062957,"teacher_disagreement_score":0.09111197,"about_ca_system_score_codex":0.0010034019,"about_ca_system_score_gemma":0.0014745832,"threshold_uncertainty_score":0.95778066},"labels":[],"label_agreement":null},{"id":"W2157709503","doi":"10.1158/1078-0432.ccr-06-1593","title":"Genetic Deletions in Sputum as Diagnostic Markers for Early Detection of Stage I Non–Small Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"FHIT; Sputum; Lung cancer; Biology; Cancer; Stage (stratigraphy); Pathology; Loss of heterozygosity; Lung; Cancer research; Medicine; Internal medicine; Gene; Carcinogenesis; Tumor suppressor gene; Genetics; Tuberculosis","score_opus":0.09187760573161653,"score_gpt":0.5262772465952479,"score_spread":0.43439964086363136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157709503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902692,0.0028581694,0.0020669168,0.0005192067,0.0004113417,0.002422401,0.000081454644,0.000016177188,0.0013551307],"genre_scores_gemma":[0.99187875,0.0021825957,0.00064082217,0.00013438096,0.00039117844,0.0011318142,0.000010515936,0.00003873054,0.0035912085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779695,0.000113780174,0.00068033044,0.00042407843,0.00041267334,0.00057219923],"domain_scores_gemma":[0.9960887,0.0026560558,0.000110655135,0.00030747306,0.0005496374,0.0002875059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015675995,0.00012716443,0.0003383789,0.00029653177,0.00011461008,0.000016379294,0.000118343756,0.00017106738,0.00026976605],"category_scores_gemma":[0.00096849335,0.000113510556,0.00016402615,0.00059640995,0.00020857019,0.000044867178,0.000049292838,0.00050874165,0.000012122585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019293838,0.00079108763,0.91845685,0.00068872934,0.000203281,0.000081272774,0.00045414944,0.00014778505,0.0026651025,0.000025112597,0.0008712746,0.073685974],"study_design_scores_gemma":[0.0048869587,0.001571935,0.98282164,0.00034822704,0.0002251428,0.0000013804612,0.0002966412,0.0005523005,0.0054243184,0.00007953927,0.0036655192,0.00012640648],"about_ca_topic_score_codex":0.01432575,"about_ca_topic_score_gemma":0.012107586,"teacher_disagreement_score":0.07355957,"about_ca_system_score_codex":0.00062843616,"about_ca_system_score_gemma":0.0012166562,"threshold_uncertainty_score":0.9922379},"labels":[],"label_agreement":null},{"id":"W2157800450","doi":"10.3389/fonc.2014.00177","title":"Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; McGill University Health Centre; Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Pemetrexed; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Paclitaxel; Population; non-small cell lung cancer (NSCLC); Cisplatin","score_opus":0.03719669395776834,"score_gpt":0.4282887704478306,"score_spread":0.3910920764900623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157800450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000055359683,0.9805845,0.0015958695,0.0010747655,0.0017610037,0.0020219565,0.000021011903,0.000039565388,0.012895771],"genre_scores_gemma":[0.0000041374956,0.95030063,0.037640598,0.0008237636,0.0002913441,0.000359979,0.00024592047,0.00009186023,0.01024175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974114,0.00033127892,0.0009153485,0.00061885186,0.00019542672,0.00052772387],"domain_scores_gemma":[0.99857265,0.00022499706,0.00040957888,0.0005404646,0.00003249736,0.0002198411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039677927,0.00047684694,0.0035823463,0.0009907375,0.000034154134,0.000012217811,0.00021421342,0.00045695316,0.00018858394],"category_scores_gemma":[0.00015261427,0.00037866924,0.0004057758,0.00078257883,0.00011683149,0.00005139269,0.00003552139,0.0006165454,0.00006569502],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065013846,0.0002940323,0.00027897078,0.002272905,0.0006360035,0.00022323804,0.00036065653,8.4648127e-7,4.932463e-8,0.00010110996,0.11410838,0.8816588],"study_design_scores_gemma":[0.005260756,0.0006840872,0.00004321709,0.004332091,0.0018401654,0.000107168176,0.00017710961,0.000010953314,1.8655798e-7,0.00052004,0.98675084,0.00027341346],"about_ca_topic_score_codex":0.00035036405,"about_ca_topic_score_gemma":0.00017969996,"teacher_disagreement_score":0.8813854,"about_ca_system_score_codex":0.0029469559,"about_ca_system_score_gemma":0.0028489658,"threshold_uncertainty_score":0.99986655},"labels":[],"label_agreement":null},{"id":"W2158664495","doi":"10.1200/jco.2004.00.6650","title":"Side Effects Related to Cancer Treatment","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","score_opus":0.07315946024600528,"score_gpt":0.5540068520501057,"score_spread":0.4808473918041004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158664495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9140566,0.0015832025,0.000040548828,0.060411993,0.001454517,0.00032568828,0.0000024745711,0.000012230907,0.022112766],"genre_scores_gemma":[0.97980213,0.0010700632,0.00559269,0.0065138964,0.001254686,0.000019044885,0.0000014420608,0.000013408865,0.0057326085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983564,0.000113538605,0.0011072519,0.000115834526,0.00015645694,0.00015051881],"domain_scores_gemma":[0.9979511,0.0008107908,0.0004958171,0.00011155216,0.00019523929,0.00043553897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041300134,0.00009253297,0.00083020364,0.000080420534,0.000028289993,0.0000037407208,0.00004912735,0.00016955515,0.00015481462],"category_scores_gemma":[0.0006481226,0.00005499584,0.00032563607,0.00010111334,0.000038117923,0.000055267006,0.000010714338,0.00024320045,0.0001021231],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009987323,0.0019510423,0.024191102,0.000008026124,0.001149928,0.00050173263,0.00033429143,0.00020643896,0.00018741128,0.00009717245,0.0056558126,0.9647183],"study_design_scores_gemma":[0.012858614,0.021404395,0.2637152,0.00010813801,0.001523656,0.00022248378,0.000036216094,0.000033551383,0.00040598793,0.00012245914,0.6995048,0.000064510736],"about_ca_topic_score_codex":0.00004917512,"about_ca_topic_score_gemma":0.00010459135,"teacher_disagreement_score":0.9646538,"about_ca_system_score_codex":0.0007361392,"about_ca_system_score_gemma":0.00165336,"threshold_uncertainty_score":0.29329896},"labels":[],"label_agreement":null},{"id":"W2159023504","doi":"10.1016/j.lungcan.2014.03.008","title":"A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC)","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; Lung cancer; Hazard ratio; Internal medicine; Proportional hazards model; Stage (stratigraphy); Cancer; Biology; Confidence interval","score_opus":0.01713595473144952,"score_gpt":0.3254411212676625,"score_spread":0.308305166536213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159023504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921268,0.0028684796,0.0015188843,0.00054843276,0.00022672274,0.0015453555,0.0003057859,0.00004205138,0.0008174541],"genre_scores_gemma":[0.9948381,0.00043874438,0.0016310812,0.0006783463,0.000051434105,0.00041760036,0.000046667257,0.00006456256,0.0018334405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756354,0.00013162316,0.0006296796,0.00070105575,0.0004354135,0.00053868146],"domain_scores_gemma":[0.9984598,0.000184588,0.00034923537,0.00049354474,0.00028171713,0.00023111177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029517178,0.000384058,0.00086958834,0.000121652,0.00010018983,0.000021765813,0.00013681313,0.000109570115,0.00031749957],"category_scores_gemma":[0.00006351859,0.0002985261,0.00010016194,0.00042995243,0.00017631565,0.00011149283,0.000073424104,0.0002257199,0.0000024438916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004806644,0.00029435343,0.9856133,0.0009779572,0.0007075947,0.00008354115,0.0023903623,0.0015092168,0.0053412174,0.000017180717,0.00016586421,0.0024187607],"study_design_scores_gemma":[0.015626164,0.00066680106,0.9486163,0.0015711667,0.002988525,0.000020390053,0.00024754708,0.02696884,0.0024065713,0.000040435647,0.0002324545,0.0006147725],"about_ca_topic_score_codex":0.0068910345,"about_ca_topic_score_gemma":0.018828603,"teacher_disagreement_score":0.036996957,"about_ca_system_score_codex":0.001475377,"about_ca_system_score_gemma":0.0007196969,"threshold_uncertainty_score":0.9999467},"labels":[],"label_agreement":null},{"id":"W2159478595","doi":"10.3978/j.issn.2218-6751.2015.07.17","title":"Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Hazard ratio; Proportional hazards model; Wild type; non-small cell lung cancer (NSCLC); Clinical trial; Cancer; Biology; Confidence interval","score_opus":0.041167845288394976,"score_gpt":0.29540997102641686,"score_spread":0.2542421257380219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159478595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495685,0.00080022,0.0000030917554,0.00027480273,0.00020617871,0.0028563521,0.0004184502,0.00000867638,0.00047536945],"genre_scores_gemma":[0.99843043,0.00014415225,0.00008824643,0.00024711413,0.00003449044,0.0007560136,0.00013704754,0.00002198749,0.00014054484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984187,0.0001362046,0.00058303605,0.00025889944,0.0003607459,0.00024241758],"domain_scores_gemma":[0.99861395,0.00012341197,0.00046707134,0.00033052795,0.00034166666,0.00012337005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035784772,0.00018685703,0.00067209895,0.00022904293,0.000027156822,0.000013886618,0.00008566959,0.00008229648,0.000012346648],"category_scores_gemma":[0.00007988123,0.00010377725,0.00010955174,0.0008654748,0.00007631147,0.00006722995,0.000026479422,0.00011749571,1.4144784e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02875326,0.0008358811,0.93284595,0.000029334116,0.0017728294,0.0000027498172,0.0059218006,0.00008396128,0.00001764949,0.0000019475142,0.00028189245,0.029452773],"study_design_scores_gemma":[0.039966565,0.00078700826,0.9566768,0.000058117694,0.0009945019,2.0264787e-7,0.00012598318,0.000053451855,0.0010373379,0.0000067964497,0.0001847202,0.00010853601],"about_ca_topic_score_codex":0.0016968248,"about_ca_topic_score_gemma":0.0008268579,"teacher_disagreement_score":0.029344236,"about_ca_system_score_codex":0.00013196006,"about_ca_system_score_gemma":0.00026535738,"threshold_uncertainty_score":0.42319134},"labels":[],"label_agreement":null},{"id":"W2159491273","doi":"10.1111/j.1365-2753.2005.00546.x","title":"The impact of practice guidelines and funding policies on the use of new drugs in advanced non‐small cell lung cancer*","year":2005,"lang":"en","type":"article","venue":"Journal of Evaluation in Clinical Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Cancer Care Ontario","funders":"","keywords":"Medicine; Cancer; Lung cancer; Intensive care medicine; Family medicine; Business; Oncology; Internal medicine","score_opus":0.2491545421103633,"score_gpt":0.6001829499100136,"score_spread":0.35102840779965033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159491273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92379916,0.003027005,0.00008060697,0.071293466,0.00019471861,0.0005813682,0.000003473251,0.0000014805845,0.0010187144],"genre_scores_gemma":[0.9787857,0.008288044,0.01051175,0.0017950692,0.0003805423,0.000011311885,9.708981e-7,0.000011786237,0.00021484989],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99690104,0.00059496233,0.0016801078,0.00011211102,0.0005807231,0.00013108503],"domain_scores_gemma":[0.97651315,0.018695863,0.002429076,0.00020231876,0.0020691976,0.00009039135],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007572407,0.000100945166,0.00031761415,0.00011859228,0.000054754953,0.00003083284,0.00007769452,0.00006449911,0.00003117889],"category_scores_gemma":[0.064001806,0.00005198031,0.00013379933,0.00028184516,0.000057883364,0.0006970273,0.00002196259,0.0004558336,7.575995e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013033497,0.0038258182,0.25785023,0.000105388506,0.0017326542,0.000022341137,0.018114975,0.27735892,0.0011269803,0.00040738788,0.042582225,0.38383958],"study_design_scores_gemma":[0.021363446,0.004176948,0.83757806,0.0021794185,0.004674904,0.00015059709,0.01479276,0.062357258,0.0004903698,0.00035301343,0.051641323,0.0002419327],"about_ca_topic_score_codex":0.0016705402,"about_ca_topic_score_gemma":0.00021218658,"teacher_disagreement_score":0.57972777,"about_ca_system_score_codex":0.00035784792,"about_ca_system_score_gemma":0.001647345,"threshold_uncertainty_score":0.9438825},"labels":[],"label_agreement":null},{"id":"W2160028603","doi":"10.1200/jco.2015.62.5715","title":"Reply to J.J. Beitler et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.17197422739283363,"score_gpt":0.5675292840060916,"score_spread":0.39555505661325796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160028603","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027401312,0.0034010825,0.00025767932,0.91045463,0.026873099,0.00041146344,0.000050456045,0.000009211627,0.055802226],"genre_scores_gemma":[0.0013982183,0.0014589927,0.008572338,0.93063635,0.022128649,0.000011903011,0.000042247888,0.00006253439,0.035688758],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99251324,0.0012319055,0.0043679303,0.00041689648,0.00091674575,0.000553282],"domain_scores_gemma":[0.9894114,0.0038408514,0.0031510289,0.0004613204,0.0018054507,0.0013299425],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006577298,0.0003548053,0.0031532876,0.00026025466,0.000047605154,0.000025281392,0.00035517945,0.00122615,0.0016254626],"category_scores_gemma":[0.009239821,0.0002477347,0.0010974259,0.00020000398,0.00026361988,0.0001448816,0.00011651444,0.0048980955,0.0014567885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012119821,0.001312507,0.0035662462,0.000036265563,0.002218865,0.0077429735,0.00034804427,0.00003267794,0.0000039793044,0.00010248751,0.8732368,0.110187195],"study_design_scores_gemma":[0.008479346,0.025355237,0.011731726,0.00063641614,0.0033122823,0.0012178998,0.00011011929,0.00000738332,0.000002110117,0.00039487638,0.94854987,0.00020272515],"about_ca_topic_score_codex":0.00016931405,"about_ca_topic_score_gemma":0.000038682134,"teacher_disagreement_score":0.109984465,"about_ca_system_score_codex":0.0013266434,"about_ca_system_score_gemma":0.015112439,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W2160500377","doi":"10.1183/09031936.00050706","title":"Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study","year":2006,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Hazard ratio; Lung cancer; Odds ratio; Adenocarcinoma; Oncology; Performance status; Univariate analysis; Confidence interval; Epidermal growth factor receptor; Cancer; Multivariate analysis; Gastroenterology","score_opus":0.024084188909772417,"score_gpt":0.3843779527395927,"score_spread":0.36029376382982026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160500377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914636,0.0014479804,0.00013631347,0.000121349956,0.00014447418,0.00070553913,0.0000307083,0.000035908866,0.005914103],"genre_scores_gemma":[0.99793947,0.000056564862,0.00012850665,0.0010339211,0.00028773482,0.00003281688,0.000016960004,0.000051565577,0.0004524488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801975,0.00079622655,0.0005010976,0.00015901538,0.0002308654,0.00029303614],"domain_scores_gemma":[0.9992718,0.00003298059,0.00023450646,0.00024734356,0.0001024178,0.000110937624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007965697,0.00016860857,0.00021853927,0.00018450458,0.0003576439,0.00006677673,0.0001246932,0.000018948047,0.00020975956],"category_scores_gemma":[0.000005306975,0.00014381128,0.00007147187,0.00017103888,0.000016747865,0.000168095,0.00003324828,0.0005173769,0.000017507982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017329244,0.0014616917,0.9823547,0.000021403319,0.00007357367,0.00042425198,0.0033961462,0.0001189365,0.002262461,0.0000048348666,0.00093735557,0.008771366],"study_design_scores_gemma":[0.01741869,0.00085910864,0.9549209,0.00008461822,0.00013038023,0.000026934367,0.0038578538,0.000009310399,0.00029866246,0.000004652942,0.022245731,0.00014317263],"about_ca_topic_score_codex":0.0003261551,"about_ca_topic_score_gemma":0.002304135,"teacher_disagreement_score":0.027433801,"about_ca_system_score_codex":0.0003437014,"about_ca_system_score_gemma":0.00019514683,"threshold_uncertainty_score":0.58644533},"labels":[],"label_agreement":null},{"id":"W2161676909","doi":"10.3747/co.19.949","title":"Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; EGFR inhibitors; Mutation; Tyrosine-kinase inhibitor; Internal medicine; Cancer research; Erlotinib Hydrochloride; Biomarker; Tyrosine kinase; Gefitinib; Cancer; Gene; Receptor; Biology; Genetics","score_opus":0.04870029174905834,"score_gpt":0.4237004489221756,"score_spread":0.3750001571731173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161676909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921683,0.0007503018,0.0002551009,0.0012836831,0.0011424853,0.0018033527,0.0001547492,0.000042185206,0.0023998367],"genre_scores_gemma":[0.99370474,0.000042482294,0.002883936,0.00064462196,0.00027040206,0.0013636227,0.00017355259,0.00003379,0.0008828704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855924,0.00018142573,0.00033681933,0.00032102654,0.00016276077,0.00043875078],"domain_scores_gemma":[0.9987152,0.00021087195,0.0001443542,0.00024875428,0.00029541916,0.00038536236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020145903,0.00020747072,0.00034587382,0.0002513318,0.000097500706,0.000012150099,0.00007019129,0.000090978065,0.00059352064],"category_scores_gemma":[0.000066039174,0.00016689082,0.00004665012,0.0003228258,0.000052751944,0.00012631761,0.00003361208,0.00024833094,0.0000998197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009903726,0.012802889,0.7634504,0.00042134043,0.00040247958,0.0002346749,0.07523788,0.0014474232,0.0034982965,0.00010787575,0.006460525,0.12603249],"study_design_scores_gemma":[0.01798689,0.010923077,0.77358836,0.00056777464,0.001017846,0.00011418441,0.0044031437,0.0015434645,0.0024272918,0.000018034685,0.18675996,0.0006499486],"about_ca_topic_score_codex":0.00012536437,"about_ca_topic_score_gemma":0.0024819397,"teacher_disagreement_score":0.18029943,"about_ca_system_score_codex":0.0012404931,"about_ca_system_score_gemma":0.0008829994,"threshold_uncertainty_score":0.68056107},"labels":[],"label_agreement":null},{"id":"W2162881491","doi":"10.14740/wjon894w","title":"Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chemotherapy; Radiation therapy; Lung cancer; Internal medicine; Metastasis; Medical record; Performance status; Surgery; Stage (stratigraphy); Cancer; Life expectancy; Population","score_opus":0.03938883680365671,"score_gpt":0.3380277956748512,"score_spread":0.2986389588711945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162881491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97043663,0.0015033145,0.00006583891,0.0019228545,0.0002990651,0.00042774493,0.000005055243,0.0000043080904,0.025335185],"genre_scores_gemma":[0.9936923,0.000080337,0.0028455646,0.00015438211,0.00016486038,0.00004162249,0.000007651531,0.000015459382,0.0029978575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992322,0.00003743,0.00029033303,0.000110855886,0.00014837162,0.0001808226],"domain_scores_gemma":[0.9992501,0.00003614304,0.00025140497,0.00009313708,0.00017314494,0.000196039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079202626,0.0001199955,0.00037646794,0.00023632737,0.000022322352,0.000006879251,0.000050645427,0.000044286582,0.000042546977],"category_scores_gemma":[0.0000060761054,0.00007250237,0.00005644207,0.0001891996,0.000032303316,0.00006346483,0.000008438957,0.00013962934,0.000003266245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009800759,0.0022291008,0.9273204,0.00002482084,0.00030918876,0.00031878866,0.0030756965,0.00045159116,0.000009476269,0.000014966242,0.0017346168,0.06353123],"study_design_scores_gemma":[0.086045556,0.030034037,0.7296182,0.00035990684,0.0026077253,0.00019751955,0.0017161946,0.000271323,0.00037542646,0.00005479941,0.14841074,0.00030859368],"about_ca_topic_score_codex":0.00022557024,"about_ca_topic_score_gemma":0.0016309645,"teacher_disagreement_score":0.19770226,"about_ca_system_score_codex":0.0016646379,"about_ca_system_score_gemma":0.0014192032,"threshold_uncertainty_score":0.43529704},"labels":[],"label_agreement":null},{"id":"W2163254508","doi":"10.1586/14737140.6.10.1411","title":"A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy","year":2006,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Carcinoma; Tyrosine kinase; Cancer research; Oncology; Targeted therapy; Lung; Epidermal growth factor; Internal medicine; Receptor tyrosine kinase; Cancer; Pathology; Receptor","score_opus":0.038230925156746504,"score_gpt":0.4177292789177271,"score_spread":0.3794983537609806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163254508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043050386,0.99332106,0.00011629905,0.0006112316,0.00034741277,0.0053000418,0.0001317384,0.000011761085,0.000117375006],"genre_scores_gemma":[0.000012109156,0.9970344,0.0013144686,0.0005466885,0.00016242317,0.00061608636,0.00017159633,0.00004092734,0.00010135003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977505,0.00018461932,0.0010941114,0.0004537114,0.00024328653,0.00027373878],"domain_scores_gemma":[0.9983796,0.00016313052,0.0007257585,0.000483095,0.00016931715,0.00007911261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002418797,0.00044429596,0.0024734281,0.00009194838,0.000041789044,0.000006793888,0.00021574735,0.000081215505,0.000084039675],"category_scores_gemma":[0.00004201344,0.00021356667,0.0006283366,0.0004288979,0.00014403298,0.000058797665,0.000027310334,0.0002216589,9.709552e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008248729,0.00022036188,0.00017051351,0.01577035,0.00018520525,7.92541e-7,0.00006833658,1.2182697e-7,0.000010814044,0.000025900235,0.0028906297,0.9805745],"study_design_scores_gemma":[0.0017104563,0.0005139057,0.0007637933,0.051615197,0.00022140617,0.0000061188935,0.0000022400486,5.598923e-7,0.00005064954,0.00009268451,0.9448302,0.00019280067],"about_ca_topic_score_codex":0.00004698983,"about_ca_topic_score_gemma":0.000015921523,"teacher_disagreement_score":0.98038167,"about_ca_system_score_codex":0.00013901712,"about_ca_system_score_gemma":0.0010416863,"threshold_uncertainty_score":0.8708996},"labels":[],"label_agreement":null},{"id":"W2163274852","doi":"10.1093/annonc/mdt258","title":"Concern on quality-of-life analysis in the OPTIMAL study","year":2013,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Carboplatin; Erlotinib; Lung cancer; Quality of life (healthcare); Oncology; Gemcitabine; Internal medicine; Gefitinib; Scopus; Chemotherapy; Cancer; MEDLINE; Epidermal growth factor receptor","score_opus":0.22547308270688926,"score_gpt":0.5238021405454498,"score_spread":0.29832905783856056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163274852","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3913518,0.00034083438,0.0000063484586,0.59179497,0.000116831776,0.0010076999,0.00007483327,0.0000068401114,0.015299846],"genre_scores_gemma":[0.5834092,0.00008154243,0.00005403312,0.41463795,0.00037875987,0.00014504929,0.0002241617,0.000012861513,0.0010564832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809456,0.00048813768,0.00062835205,0.00024712627,0.00034276006,0.00019904945],"domain_scores_gemma":[0.9980799,0.00071147125,0.00047709706,0.00047185112,0.0002255804,0.000034131113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046799483,0.00016304354,0.0011179856,0.00036252785,0.000022529448,0.0000046349955,0.00018483416,0.0003114981,0.00034059276],"category_scores_gemma":[0.00014111977,0.00009893651,0.0002864794,0.00040119077,0.00012259596,0.000021643802,0.000024000778,0.0005405002,0.000023877534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023720514,0.0023962953,0.04887392,0.00011642071,0.008117323,0.00024513665,0.005374858,0.00011599588,0.000004307691,0.00008698231,0.9299566,0.004474933],"study_design_scores_gemma":[0.0043732617,0.013282786,0.22945336,0.00006236626,0.004938357,0.0000042407696,0.0036710114,0.00001861396,0.000015286296,0.00006779452,0.74390906,0.00020385341],"about_ca_topic_score_codex":0.0028849489,"about_ca_topic_score_gemma":0.00020761513,"teacher_disagreement_score":0.19205737,"about_ca_system_score_codex":0.00005456607,"about_ca_system_score_gemma":0.0004262793,"threshold_uncertainty_score":0.43611988},"labels":[],"label_agreement":null},{"id":"W2163933632","doi":"10.1016/j.humpath.2015.02.001","title":"Accuracy of classifying poorly differentiated non–small cell lung carcinoma biopsies with commonly used lung carcinoma markers","year":2015,"lang":"en","type":"article","venue":"Human Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Adenocarcinoma; Adenosquamous carcinoma; Immunohistochemistry; Pathology; Biopsy; Carcinoma; Medicine; Tissue microarray; Lung; Lung cancer; Cancer; Internal medicine","score_opus":0.03822147948428445,"score_gpt":0.30970320364329845,"score_spread":0.271481724159014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163933632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905293,0.0008721331,0.00018251233,0.00021962967,0.00016594818,0.0007675543,0.000045009136,0.00007307161,0.007144835],"genre_scores_gemma":[0.99756616,0.0000075498315,0.00061492884,0.00015770177,0.00006960855,0.00007661336,0.00029736478,0.000057051726,0.001153042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844474,0.00012057005,0.00040251328,0.00040483996,0.00021496192,0.000412367],"domain_scores_gemma":[0.9986149,0.000085333995,0.00030025246,0.0005220535,0.00024645496,0.0002310179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012511662,0.00029310375,0.0005903908,0.00025271229,0.00014394952,0.000022383758,0.00015046421,0.00015366102,0.00007999654],"category_scores_gemma":[0.000027194315,0.00022655158,0.00010545813,0.0002012862,0.00022362258,0.00009063674,0.00007508156,0.00023017911,0.000009455149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003167258,0.00035084676,0.9751293,0.00030375467,0.00016571124,0.00065362075,0.005457202,0.0000063766934,0.015907295,0.00008964196,0.0013721607,0.00024733157],"study_design_scores_gemma":[0.00931797,0.0012777532,0.98015255,0.00012752888,0.0012025208,0.00023969752,0.0022760464,0.0004911922,0.0044842996,0.000024521261,0.0001452209,0.00026070664],"about_ca_topic_score_codex":0.00049279764,"about_ca_topic_score_gemma":0.00027222425,"teacher_disagreement_score":0.0114229955,"about_ca_system_score_codex":0.00022734024,"about_ca_system_score_gemma":0.00035658263,"threshold_uncertainty_score":0.92385054},"labels":[],"label_agreement":null},{"id":"W2164811818","doi":"10.1093/annonc/mdu349.56","title":"Prophylactic Treatment for Rash Induced By Egfr Inhibitor Improves Rash Without Compromising on Efficacy the Pancanadian Rash Trial: a Randomized Phase III Trial in Nsclc","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Mount Sinai Hospital; Burnaby Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Randomized controlled trial; Dermatology; Oncology; Internal medicine","score_opus":0.0762739308251862,"score_gpt":0.44747249216685153,"score_spread":0.37119856134166535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164811818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973912,0.00017455935,0.00006581375,0.010260897,0.0007408107,0.013379494,0.00003510829,0.000028725217,0.0014025773],"genre_scores_gemma":[0.9954856,0.000045521574,0.00015574302,0.0013664695,0.0006416665,0.0016911458,0.000105197876,0.000038783397,0.0004698537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99761677,0.0005459972,0.00082571135,0.00039721586,0.00018991808,0.0004243857],"domain_scores_gemma":[0.99695885,0.0018056657,0.00051942,0.00036227098,0.00015820209,0.00019559462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010578316,0.00028678577,0.001537718,0.00019373912,0.0001394291,0.000024642646,0.00010980345,0.00020063957,0.000020750453],"category_scores_gemma":[0.0009795243,0.00017179493,0.00036376575,0.00017212951,0.0001828449,0.00006313993,0.0000147189485,0.00016936073,0.000004534102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86206305,0.0048933458,0.000011399373,0.00003224766,0.00054020947,0.000005713648,0.0012251554,0.0000027144324,0.0071134926,0.00014968065,0.0010317954,0.122931175],"study_design_scores_gemma":[0.95012134,0.027471555,0.00006487938,0.00007548007,0.0007834243,0.0000033771882,0.00013440901,0.0001839333,0.0065729525,0.00016809328,0.014270335,0.00015019388],"about_ca_topic_score_codex":0.0015255124,"about_ca_topic_score_gemma":0.0005843115,"teacher_disagreement_score":0.12278098,"about_ca_system_score_codex":0.0003399106,"about_ca_system_score_gemma":0.0010265535,"threshold_uncertainty_score":0.70055944},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2165109429","doi":"10.1093/annonc/mdt536","title":"Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Erlotinib; Medicine; Everolimus; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Phases of clinical research; Erlotinib Hydrochloride; Progressive disease; Cancer; Chemotherapy; Gastroenterology; Randomized controlled trial; Epidermal growth factor receptor","score_opus":0.027617763052634362,"score_gpt":0.40064832894675095,"score_spread":0.3730305658941166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165109429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352324,0.00034422826,0.0000025379313,0.00031927347,0.000053749598,0.0032260267,0.000021941858,0.0000116346055,0.002497354],"genre_scores_gemma":[0.99829704,0.000142458,0.00015784251,0.00027699393,0.000016217151,0.00060550874,0.00003730962,0.000019389841,0.00044726135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989481,0.000047896378,0.0003973251,0.00022469334,0.00013837297,0.00024361283],"domain_scores_gemma":[0.9988958,0.000048142432,0.00028046768,0.00021666205,0.0004642889,0.00009460056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006044167,0.00014448239,0.0005301784,0.00014280461,0.000032730084,0.0000018678421,0.000070426824,0.000068278394,0.00016570778],"category_scores_gemma":[0.000015894377,0.00010380891,0.00004243268,0.00024088351,0.000042451316,0.0000879897,0.0000286107,0.00008673194,0.000002693346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016718906,0.044012304,0.8501588,0.00017199089,0.00055673334,0.000024627485,0.010680236,0.00016865892,0.0008788812,0.0000020148993,0.0013304069,0.09034345],"study_design_scores_gemma":[0.09770053,0.13344151,0.7609322,0.00031579286,0.0008076819,0.0000018102334,0.0017471893,0.00013794913,0.0036593652,0.000007942926,0.0010445126,0.00020352949],"about_ca_topic_score_codex":0.0027839805,"about_ca_topic_score_gemma":0.00085564423,"teacher_disagreement_score":0.09602864,"about_ca_system_score_codex":0.00008501884,"about_ca_system_score_gemma":0.00031428653,"threshold_uncertainty_score":0.42332044},"labels":[],"label_agreement":null},{"id":"W2166070477","doi":"10.1097/jto.0b013e31827ed0ff","title":"Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012","year":2013,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cetuximab; Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Chemotherapy; Cancer; Internal medicine; Targeted therapy; Tyrosine kinase; Cancer research; Receptor; Colorectal cancer","score_opus":0.04816229289077918,"score_gpt":0.4939762288443586,"score_spread":0.44581393595357943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166070477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010750702,0.9938644,0.00003766349,0.0011647359,0.0017725581,0.0010267813,0.00012900266,0.000011368962,0.0009184268],"genre_scores_gemma":[0.00016787167,0.9954448,0.0015564893,0.00018151643,0.0010274439,0.00014344382,0.00009550943,0.000052170628,0.0013307641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734354,0.00038310105,0.0013468128,0.00022499064,0.00027786713,0.00042366696],"domain_scores_gemma":[0.9971871,0.00025348781,0.0016913773,0.00015841346,0.00037934812,0.0003303107],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002858787,0.0003361088,0.0024289833,0.00066983927,0.00004454043,0.00001947355,0.000080840015,0.0005003737,0.0016899946],"category_scores_gemma":[0.00013639267,0.00022562906,0.0005114521,0.00033094385,0.00005946382,0.0003236521,0.000037286634,0.0009845785,0.0000612232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009895425,0.00034102818,0.00032594064,0.007558758,0.00069396436,0.00037956,0.00022618964,8.8092736e-7,0.000005725283,0.000011307403,0.01893767,0.97142005],"study_design_scores_gemma":[0.00079495553,0.0007032085,0.00033461608,0.0129251825,0.0037714317,0.0009147392,0.00005310065,0.0000021190742,0.0000095625355,0.00002156673,0.9802884,0.00018115607],"about_ca_topic_score_codex":0.00017007916,"about_ca_topic_score_gemma":0.000051733296,"teacher_disagreement_score":0.97123885,"about_ca_system_score_codex":0.004016426,"about_ca_system_score_gemma":0.004107997,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W2166720958","doi":"10.1177/1758834011399306","title":"Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Lung cancer; Regimen; Oncology; Maintenance therapy; Intensive care medicine; Chemotherapy; Immunotherapy; Disease; Internal medicine; Clinical trial; Cancer; Adverse effect","score_opus":0.018753666172804957,"score_gpt":0.3790955163536733,"score_spread":0.36034185018086834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166720958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93918973,0.041086216,0.002474214,0.0030665898,0.0005660006,0.001276862,0.0000064904716,0.000048757916,0.012285124],"genre_scores_gemma":[0.9688655,0.025221707,0.002273026,0.0028602947,0.00004714405,0.00048662673,0.000004570964,0.00002163887,0.00021947414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820334,0.0001213979,0.00053052424,0.00044992534,0.00024074076,0.00045407997],"domain_scores_gemma":[0.9990858,0.00024336876,0.00013273036,0.00025939714,0.00007331492,0.00020543428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004014038,0.00022538131,0.00068755477,0.00012859325,0.000050169263,0.0000028438822,0.0001513951,0.0002103821,0.00043213982],"category_scores_gemma":[0.00006707959,0.00016143854,0.000059395676,0.000272733,0.00034154844,0.0001695422,0.0000385928,0.00040791545,0.000003668282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045918176,0.0007867748,0.66592306,0.000065077,0.00004151719,0.0000872191,0.0021514434,0.000012426952,0.000046193763,0.00054016686,0.0000068758973,0.32988006],"study_design_scores_gemma":[0.01459488,0.0013119807,0.960745,0.00023985749,0.00008734517,0.00003313498,0.0010856995,0.0007739674,0.00014262361,0.004340821,0.016394632,0.00025005528],"about_ca_topic_score_codex":0.00047669705,"about_ca_topic_score_gemma":0.0016313792,"teacher_disagreement_score":0.32963002,"about_ca_system_score_codex":0.00075115386,"about_ca_system_score_gemma":0.0007881748,"threshold_uncertainty_score":0.6583273},"labels":[],"label_agreement":null},{"id":"W2167332374","doi":"10.1586/14737140.2014.881719","title":"<i>nab</i>-paclitaxel for the management of patients with advanced non-small-cell lung cancer","year":2014,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre; Montreal General Hospital","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Regimen; Neutropenia; Lung cancer; Oncology; Internal medicine; Nab-paclitaxel; Clinical endpoint; Chemotherapy; Clinical trial; Cisplatin","score_opus":0.01929512401140155,"score_gpt":0.39704526007426705,"score_spread":0.3777501360628655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167332374","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000144812975,0.9865417,0.00086374686,0.00026288634,0.00034077337,0.01110746,0.00019603819,0.000015361382,0.0006575766],"genre_scores_gemma":[0.00001866809,0.98860013,0.0038932904,0.001172162,0.00016581868,0.0053865854,0.00020492211,0.00011198056,0.00044641277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775124,0.000057055167,0.0009538622,0.00048255673,0.00043343686,0.00032188089],"domain_scores_gemma":[0.99734795,0.00018686401,0.0010206331,0.00095045415,0.00040501342,0.00008911084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021025077,0.0005389012,0.0026773287,0.000070693844,0.00008291531,0.000008309226,0.00034256536,0.00009228534,0.00017032766],"category_scores_gemma":[0.0000054237953,0.00025887328,0.0008063099,0.00035784813,0.00011789921,0.000045002238,0.000035726236,0.00014057333,0.000002006298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000936986,0.0003093478,0.00006438679,0.20976926,0.002745614,8.680884e-7,0.00008573833,4.70117e-7,4.557012e-7,0.000042461,0.0023952303,0.78449243],"study_design_scores_gemma":[0.002716438,0.00045577387,0.00008654324,0.19686763,0.004941127,6.5786713e-7,0.00001840371,0.000002587089,0.000014765108,0.0000014874606,0.7946729,0.00022167826],"about_ca_topic_score_codex":0.000053254287,"about_ca_topic_score_gemma":0.0000027827657,"teacher_disagreement_score":0.7922777,"about_ca_system_score_codex":0.0001890955,"about_ca_system_score_gemma":0.00044289712,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W2167634945","doi":"10.1634/theoncologist.2011-0079","title":"Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Oncology; Stage (stratigraphy); Cancer research; Internal medicine; Pharmacology","score_opus":0.06412952942016496,"score_gpt":0.38629462010173876,"score_spread":0.3221650906815738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167634945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98172563,0.00044566987,0.000016991651,0.0001979023,0.00009111477,0.00048484185,0.000022007547,0.000011092012,0.017004771],"genre_scores_gemma":[0.99420613,0.00023040986,0.00012896604,0.0001911636,0.00003781844,0.000022100816,0.0000068852646,0.000012771728,0.0051637455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995001,0.000022410411,0.00012972832,0.00012405585,0.000073996904,0.00014971757],"domain_scores_gemma":[0.9996318,0.000034397726,0.0000798378,0.00016667259,0.000022106173,0.000065164764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008639865,0.00010065278,0.00020037557,0.00003988616,0.000028343138,0.0000037635975,0.000061865845,0.000046224897,0.00052404904],"category_scores_gemma":[0.0000065220893,0.000056656878,0.000048634072,0.00010146825,0.000063817024,0.000018103596,0.000016280092,0.0000895472,0.0000027889992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066081743,0.000652879,0.98323303,0.00006495728,0.0002936153,0.000022209046,0.0069740713,0.000066924644,0.0019798316,0.000030438168,0.0010894536,0.0049317926],"study_design_scores_gemma":[0.003284685,0.0008248491,0.9932617,0.000045330933,0.00018055864,9.842355e-7,0.00022786371,0.00021761631,0.0016561652,0.000024042434,0.0002155189,0.000060660932],"about_ca_topic_score_codex":0.01618761,"about_ca_topic_score_gemma":0.0009992163,"teacher_disagreement_score":0.015188393,"about_ca_system_score_codex":0.00028036436,"about_ca_system_score_gemma":0.0003444445,"threshold_uncertainty_score":0.99036366},"labels":[],"label_agreement":null},{"id":"W2167921436","doi":"10.1093/annonc/mdp392","title":"Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Gemcitabine; Internal medicine; Oncology; Lung cancer; Population; Cisplatin; Performance status; Predictive marker; Hazard ratio; Chemotherapy; Cancer; Confidence interval","score_opus":0.05359093777156162,"score_gpt":0.43231529474374103,"score_spread":0.37872435697217943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167921436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890953,0.0013737916,0.00010371682,0.00063457136,0.0002827275,0.0034224845,0.000028095763,0.00001702512,0.0050423457],"genre_scores_gemma":[0.9983941,0.0005311293,0.00035849548,0.0001335838,0.00006244005,0.00034523974,0.00009348269,0.000013277501,0.000068270056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99836797,0.00012695634,0.00070464134,0.00032039412,0.00014915956,0.00033086896],"domain_scores_gemma":[0.99835026,0.0009260555,0.0003287916,0.00013834074,0.00013234073,0.0001241931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035919982,0.00021439717,0.0013789898,0.0003558156,0.000037690035,0.0000065752765,0.00006137989,0.00013436782,0.000037388127],"category_scores_gemma":[0.00034270718,0.00017425188,0.000116504925,0.0003554654,0.00009383707,0.00010387872,0.000023979415,0.0002139666,4.298189e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9277024,0.0029948964,0.0440722,0.00009811151,0.00042054692,0.00009338477,0.004716252,0.00065544667,0.0009167041,0.000052445357,0.00012324647,0.018154325],"study_design_scores_gemma":[0.941119,0.0077829557,0.040874314,0.00027443774,0.0006521536,0.0000021285414,0.00061493553,0.0074638515,0.00094744907,0.000048383838,0.000076733195,0.00014362783],"about_ca_topic_score_codex":0.00052844663,"about_ca_topic_score_gemma":0.0005601645,"teacher_disagreement_score":0.018010698,"about_ca_system_score_codex":0.0001667341,"about_ca_system_score_gemma":0.00049059815,"threshold_uncertainty_score":0.71057856},"labels":[],"label_agreement":null},{"id":"W2168654307","doi":"10.1186/gm385","title":"Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies","year":2012,"lang":"en","type":"article","venue":"Genome Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Institutes of Health; Center for Translational Molecular Medicine; Government of Ontario; Ontario Institute for Cancer Research","keywords":"Biomarker; Medicine; Hazard ratio; Confidence interval; Biomarker discovery; Oncology; Personalized medicine; Bioinformatics; Internal medicine; Computer science; Proteomics; Biology","score_opus":0.146234176021666,"score_gpt":0.41281456280813345,"score_spread":0.26658038678646745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168654307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8490038,0.02676477,0.10201021,0.0115926545,0.00026007695,0.0010680695,0.00011821856,0.00012587414,0.00905633],"genre_scores_gemma":[0.9710551,0.0001247311,0.027746012,0.00023728027,0.0002974493,0.000021030764,0.00027946182,0.000014219662,0.00022474548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989691,0.00007118616,0.00025442935,0.00020631574,0.00025486015,0.00024414144],"domain_scores_gemma":[0.9984683,0.000369359,0.00017543696,0.00080697075,0.000083804494,0.00009614445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009558059,0.00012325081,0.00039250535,0.00018847806,0.00009376602,0.000003924555,0.00018351532,0.000028937291,0.00015399088],"category_scores_gemma":[0.00025904813,0.000056399087,0.000044711862,0.00071362825,0.0002132241,0.0001357797,0.00009296031,0.00007305618,0.000002449782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065994036,0.00030364012,0.57333237,0.00064370414,0.027969413,0.000046910518,0.020789081,0.00011149887,0.17177676,0.00066385424,0.0010367581,0.20266607],"study_design_scores_gemma":[0.0044316836,0.000983169,0.8970074,0.00023118308,0.042169705,0.00012209025,0.039845247,0.0004167033,0.0036850297,0.0000656406,0.010733028,0.00030914156],"about_ca_topic_score_codex":0.00074057706,"about_ca_topic_score_gemma":0.000043028194,"teacher_disagreement_score":0.323675,"about_ca_system_score_codex":0.00004735334,"about_ca_system_score_gemma":0.000066676155,"threshold_uncertainty_score":0.2299888},"labels":[],"label_agreement":null},{"id":"W2168841302","doi":"10.1158/1078-0432.ccr-06-0462","title":"Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":584,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Gefitinib; Erlotinib; Epidermal growth factor receptor; Lung cancer; Medicine; Exon; Erlotinib Hydrochloride; Internal medicine; Oncology; Mutation; Point mutation; Cancer research; Cancer; Biology; Genetics; Gene","score_opus":0.09555870628366898,"score_gpt":0.44217766275407155,"score_spread":0.3466189564704026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168841302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428266,0.0002213896,0.000019209607,0.00094712485,0.00010687072,0.0029218108,0.00074025535,0.00004927252,0.00071141403],"genre_scores_gemma":[0.9948967,0.00019183019,0.00019793805,0.000079234,0.0001903405,0.0014010714,0.0007243604,0.000070515336,0.002248019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631584,0.00055854867,0.0008835108,0.0006603707,0.00090320554,0.0006785153],"domain_scores_gemma":[0.99599904,0.0011902719,0.0004280214,0.00027516467,0.0018250649,0.00028243195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007054659,0.00027004906,0.000741532,0.00029448283,0.00017686583,0.000030737407,0.00015063967,0.00023937965,0.0004187336],"category_scores_gemma":[0.0006262294,0.00017552631,0.000106054904,0.0012598835,0.00035487907,0.00012747139,0.000041375566,0.00073229754,0.0000061782116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043380377,0.0025573536,0.9901222,0.00025737085,0.0002617722,0.000054667755,0.00032053885,0.000079796446,0.00011421998,0.000007793925,0.0009974502,0.0008888219],"study_design_scores_gemma":[0.0153547,0.0024405306,0.9791524,0.0009285022,0.0002869193,8.026468e-7,0.0002195647,0.0001865279,0.0010788998,0.000007956555,0.00013149648,0.00021171973],"about_ca_topic_score_codex":0.015361608,"about_ca_topic_score_gemma":0.03673966,"teacher_disagreement_score":0.021378051,"about_ca_system_score_codex":0.0009557963,"about_ca_system_score_gemma":0.0017446859,"threshold_uncertainty_score":0.9911952},"labels":[],"label_agreement":null},{"id":"W2169331014","doi":"10.1200/jco.2006.05.8073","title":"Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Quality of life (healthcare); Internal medicine; Clinical trial; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.14253774717634815,"score_gpt":0.5537721827973425,"score_spread":0.4112344356209944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169331014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637693,0.00021840476,0.000010576268,0.0012435209,0.00082241005,0.0008197322,0.0002010047,0.0000015797804,0.0003058639],"genre_scores_gemma":[0.9987954,0.00011553101,0.000103135164,0.0005216958,0.0003009438,0.000033253775,0.000014962229,0.0000086964765,0.000106398256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904421,0.0012828021,0.0069155577,0.00021122985,0.000986626,0.00016167913],"domain_scores_gemma":[0.988065,0.0026898049,0.007290568,0.0001696327,0.0016198246,0.00016515527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067304373,0.0001444575,0.0030737598,0.00019767767,0.00003150133,0.0000026235004,0.00016732058,0.00016325638,0.00009020392],"category_scores_gemma":[0.0042031533,0.00007717467,0.0006343728,0.00071686564,0.00022299206,0.00007296077,0.00003544106,0.0003843391,3.2227522e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004355916,0.008839361,0.9705483,0.000045154575,0.009505124,0.000006469825,0.00009394702,0.0019059558,0.000033730088,0.000037476242,0.0009166035,0.0037119635],"study_design_scores_gemma":[0.022092713,0.0045556556,0.9653901,0.00011607865,0.006992354,3.5451893e-7,0.00011437024,0.00015871854,0.00002572333,0.0000096216445,0.00048080002,0.0000635504],"about_ca_topic_score_codex":0.3290504,"about_ca_topic_score_gemma":0.70178264,"teacher_disagreement_score":0.37273222,"about_ca_system_score_codex":0.0007936584,"about_ca_system_score_gemma":0.01227504,"threshold_uncertainty_score":0.99332446},"labels":[],"label_agreement":null},{"id":"W2169647448","doi":"10.1038/sj.bjc.6603289","title":"Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)","year":2006,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Epirubicin; Radiation therapy; Chemotherapy; Internal medicine; Surgery; Cisplatin; Induction chemotherapy; Phases of clinical research; Gastroenterology; Oncology; Cyclophosphamide","score_opus":0.01137640728690949,"score_gpt":0.29716569295313766,"score_spread":0.2857892856662282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169647448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002355,0.0075626015,0.0001572677,0.00019200485,0.00025177567,0.0011501147,0.0006383813,0.0000073872766,0.000016940048],"genre_scores_gemma":[0.9956105,0.0023639635,0.0006699174,0.00027739196,0.00023561902,0.00013411857,0.00013901948,0.00005209792,0.00051739113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805117,0.000058887075,0.0007653767,0.0002586893,0.00055103906,0.00031483063],"domain_scores_gemma":[0.9984374,0.00009244678,0.00070310954,0.00011588406,0.00040594803,0.00024519308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016339807,0.00024262081,0.00069667585,0.00018013512,0.00009158286,0.0000426624,0.00007067082,0.0000575221,0.00031189312],"category_scores_gemma":[0.000017359367,0.00018185536,0.00008379675,0.00026682112,0.00008279326,0.00021720085,0.000014490125,0.00015768896,7.988842e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1935814,0.006122854,0.77478355,0.0003942373,0.00081101165,0.0009477176,0.00029321958,0.00049481425,0.0009140759,3.1895544e-7,0.0039882925,0.017668493],"study_design_scores_gemma":[0.4048068,0.002737532,0.5852214,0.0038459438,0.0011373253,0.000015581301,0.00006748247,0.000264394,0.0011556062,7.013343e-7,0.00047072387,0.00027650507],"about_ca_topic_score_codex":0.0075837607,"about_ca_topic_score_gemma":0.0038792507,"teacher_disagreement_score":0.21122539,"about_ca_system_score_codex":0.0005143517,"about_ca_system_score_gemma":0.0015117772,"threshold_uncertainty_score":0.9990248},"labels":[],"label_agreement":null},{"id":"W2169947883","doi":"10.1200/jco.2006.07.6554","title":"Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Epidermal growth factor receptor; Head and neck squamous-cell carcinoma; Cancer research; EGFR inhibitors; Internal medicine; Oncology; Pathology; Head and neck cancer; Cancer","score_opus":0.09179712853265751,"score_gpt":0.47614567131897656,"score_spread":0.384348542786319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169947883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997461,0.00162651,0.000017484772,0.00020204685,0.00008399499,0.00049102586,0.000033902328,0.0000012346047,0.000082753504],"genre_scores_gemma":[0.9983022,0.00023075267,0.0013274839,0.000076817174,0.000022474542,0.0000039692095,0.000002263055,0.000008172653,0.00002587024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854046,0.00015338323,0.00090336875,0.00012401916,0.0001673657,0.00011138204],"domain_scores_gemma":[0.99722004,0.0013809146,0.00092801126,0.00006320807,0.00029709286,0.00011072172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005365342,0.000106338426,0.0008136249,0.00009509695,0.000025200556,0.0000016734647,0.00003220952,0.00003871343,0.000005281925],"category_scores_gemma":[0.00030514778,0.000046027784,0.000036332098,0.00013672563,0.00048435005,0.00004831559,0.000025057205,0.00017918738,3.03885e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01689358,0.0017979353,0.9470022,0.00016580505,0.00043387944,0.00013951748,0.0010350414,0.0000035355874,0.000036374146,0.000002235859,0.000029872012,0.03246006],"study_design_scores_gemma":[0.023384944,0.02824064,0.9452848,0.00021309721,0.001382011,0.00010093311,0.00096379203,0.000030644147,0.00018908884,0.000011671315,0.00015567362,0.000042708885],"about_ca_topic_score_codex":0.00008353699,"about_ca_topic_score_gemma":0.00055633,"teacher_disagreement_score":0.03241735,"about_ca_system_score_codex":0.00006804018,"about_ca_system_score_gemma":0.00035017077,"threshold_uncertainty_score":0.18769586},"labels":[],"label_agreement":null},{"id":"W2169983495","doi":"10.1158/1078-0432.ccr-06-1005","title":"Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Epidermal growth factor receptor; Statement (logic); Lung cancer; Medicine; Cancer; Epidermal growth factor; Cancer research; Receptor; Oncology; Internal medicine; Political science","score_opus":0.1906762735697729,"score_gpt":0.5538509507929525,"score_spread":0.36317467722317964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169983495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96765417,0.023071444,0.000008738289,0.0044394815,0.00038713447,0.0021153907,0.00054168777,0.00001647424,0.0017654602],"genre_scores_gemma":[0.944114,0.052428134,0.00012660847,0.00023735936,0.0003715166,0.0012029994,0.00019475789,0.000030682895,0.001293919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964317,0.00043878934,0.0010820804,0.0005285229,0.00086262316,0.00065629004],"domain_scores_gemma":[0.99822444,0.0008180745,0.00017351712,0.00036682494,0.0002721143,0.00014504406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088582764,0.00021279955,0.0005697136,0.00027644148,0.00010531419,0.000022191418,0.00023519617,0.00012258404,0.000651807],"category_scores_gemma":[0.00014418966,0.0001376098,0.00017491452,0.0008611414,0.00027059665,0.00018440884,0.00004112826,0.00039427506,0.0000093031385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082778063,0.0040904065,0.9629512,0.00019425203,0.00016617338,0.00006099204,0.0008830589,0.00010462475,0.00013062521,0.0001201796,0.007472641,0.02299811],"study_design_scores_gemma":[0.009886021,0.0010894358,0.90019566,0.00041194243,0.00009172528,8.632988e-7,0.0002983311,0.00030650612,0.0006453751,0.00011534612,0.08680712,0.00015166646],"about_ca_topic_score_codex":0.020934261,"about_ca_topic_score_gemma":0.007976624,"teacher_disagreement_score":0.079334475,"about_ca_system_score_codex":0.0014103773,"about_ca_system_score_gemma":0.00082145684,"threshold_uncertainty_score":0.98558545},"labels":[],"label_agreement":null},{"id":"W2171902402","doi":"10.1158/1055-9965.epi-07-0251","title":"Factors Associated with Human Small Aggressive Non–Small Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Lung cancer; Family history; Internal medicine; Oncology; Odds ratio; Confidence interval; Cancer","score_opus":0.07157887094691168,"score_gpt":0.4053220619999182,"score_spread":0.33374319105300654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171902402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796212,0.010824126,0.0044181505,0.00088223006,0.0006498361,0.0014206184,0.00006120245,0.00012698029,0.001995661],"genre_scores_gemma":[0.99140614,0.0004074995,0.0007409677,0.00065790286,0.00022879217,0.0004072933,0.00079291686,0.00006511011,0.0052933767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975463,0.00024393857,0.00067323056,0.0006581448,0.00013351587,0.0007448544],"domain_scores_gemma":[0.9976418,0.0004623691,0.001026107,0.0003287093,0.00023686446,0.0003041428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009649803,0.00038852965,0.00073351193,0.00021970598,0.00028806375,0.00000896506,0.000128492,0.00035703162,0.00043015808],"category_scores_gemma":[0.00019769253,0.00028510953,0.00026728972,0.00033512892,0.0002094718,0.000088414046,0.00003713199,0.0002773568,0.0000037788827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022869786,0.0002763648,0.9839908,0.00012014296,0.0025712356,0.000035057008,0.00041600646,0.000043364806,0.0016276161,0.000038458646,0.0037562808,0.0068959673],"study_design_scores_gemma":[0.00393854,0.00045179416,0.9873443,0.0010625707,0.0026503503,0.000003642925,0.00027155803,0.00011416377,0.0029334628,0.00024249284,0.00065319496,0.0003338962],"about_ca_topic_score_codex":0.0016580117,"about_ca_topic_score_gemma":0.0070872186,"teacher_disagreement_score":0.011784946,"about_ca_system_score_codex":0.0012825519,"about_ca_system_score_gemma":0.00044904888,"threshold_uncertainty_score":0.9999601},"labels":[],"label_agreement":null},{"id":"W2172101615","doi":"10.1158/1078-0432.ccr-07-4150","title":"Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Kinase; Adenocarcinoma; Medicine; MAPK/ERK pathway; Lung cancer; p38 mitogen-activated protein kinases; Protein kinase A; Internal medicine; Cisplatin; Lung; Cancer; Biology; Chemotherapy; Biochemistry","score_opus":0.35111240558703977,"score_gpt":0.5603538008838003,"score_spread":0.2092413952967605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172101615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935617,0.0006225031,0.000008578805,0.0017229259,0.000080820355,0.0035565053,0.000018321254,0.000032457407,0.000396222],"genre_scores_gemma":[0.99712044,0.00008409459,0.00007620188,0.00011417463,0.00024214906,0.00086332846,0.000035632984,0.000027740676,0.0014362368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970479,0.000587624,0.0005583961,0.0006388679,0.0007021451,0.00046506448],"domain_scores_gemma":[0.99829423,0.0005784652,0.00009330453,0.0003353517,0.0003734144,0.00032524683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083339517,0.00018825218,0.00055478717,0.00028590995,0.0002645212,0.000023897817,0.0001123026,0.00015129932,0.00014302426],"category_scores_gemma":[0.00030309113,0.00015395899,0.0000765259,0.00084072904,0.00045818323,0.00026923607,0.00010086163,0.00095140515,0.000013292543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014136774,0.0008616963,0.9893796,0.000052480358,0.00041165686,0.000096465694,0.0037118138,0.0000035069013,0.00074441876,0.000011354559,0.0018273059,0.0014860603],"study_design_scores_gemma":[0.008972064,0.0012793074,0.98391134,0.00017701168,0.00010189544,0.000002090484,0.0020794154,0.00004586344,0.0024420798,0.000034423465,0.00080484897,0.00014967438],"about_ca_topic_score_codex":0.005305179,"about_ca_topic_score_gemma":0.00023775737,"teacher_disagreement_score":0.007558386,"about_ca_system_score_codex":0.00072527333,"about_ca_system_score_gemma":0.0009842933,"threshold_uncertainty_score":0.8019879},"labels":[],"label_agreement":null},{"id":"W2172909145","doi":"10.1200/jco.2015.62.3918","title":"Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Induced Skin Toxicities in Patients With Metastatic Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Randomized controlled trial; Regimen; Tyrosine-kinase inhibitor; Internal medicine; Epidermal growth factor receptor; Pharmacology; Oncology; Dermatology; Cancer","score_opus":0.14144659934668885,"score_gpt":0.5190120435884947,"score_spread":0.3775654442418059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172909145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910117,0.00029272473,0.000006017386,0.0020749941,0.0010583934,0.005319082,0.000057212685,0.0000051879506,0.00017470813],"genre_scores_gemma":[0.9980574,0.000056538192,0.00033549592,0.00028293167,0.0008422773,0.00027196744,0.00002363981,0.000031662647,0.00009805976],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935182,0.0024175001,0.0027709913,0.00025862767,0.0006558696,0.00037883827],"domain_scores_gemma":[0.9921718,0.0032615338,0.002844218,0.00023621992,0.00084117556,0.00064503175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003586109,0.00030857924,0.0029022004,0.00034503508,0.00007155827,0.000021391259,0.00012360715,0.00017947609,0.0001172818],"category_scores_gemma":[0.0060875504,0.00014179978,0.00073354837,0.00028646152,0.00020635466,0.0001684059,0.000014557279,0.000532826,0.0000014698521],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94809806,0.0072068986,0.003996161,0.00001789323,0.0026569096,0.00008224183,0.0021620577,0.00007926491,0.000020645253,0.0000076259194,0.00042188293,0.035250355],"study_design_scores_gemma":[0.83646774,0.15284598,0.0072794887,0.00019690036,0.0024124186,0.000007844013,0.00028476238,0.00019574494,0.00011728125,0.000031307387,0.00004463931,0.00011586064],"about_ca_topic_score_codex":0.04639325,"about_ca_topic_score_gemma":0.008089385,"teacher_disagreement_score":0.14563908,"about_ca_system_score_codex":0.0033405344,"about_ca_system_score_gemma":0.016956924,"threshold_uncertainty_score":0.988616},"labels":[],"label_agreement":null},{"id":"W2174829579","doi":"10.1002/jmrs.144","title":"Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion‐positive lung cancer patient","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Radiation Sciences","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Island Health; BC Cancer Agency","funders":"U.S. Public Health Service; National Cancer Institute; Kræftens Bekæmpelse","keywords":"Ablative case; Medicine; Radiofrequency ablation; Anaplastic lymphoma kinase; Radiation therapy; Lung cancer; Radiology; Radiosurgery; Ablation; Stereotactic radiotherapy; Oncology; Internal medicine","score_opus":0.022561824216805044,"score_gpt":0.37007881588214914,"score_spread":0.3475169916653441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174829579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644924,0.011105547,0.00051565183,0.0013845154,0.00015939157,0.0003146456,0.000017297823,0.0000038985936,0.000049839637],"genre_scores_gemma":[0.99596953,0.0029530837,0.0008586064,0.00010286152,0.00008227214,0.00001582805,0.000006128175,0.00000637007,0.0000053211406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979141,0.00015300029,0.00047715663,0.00016513154,0.0011441219,0.0001465107],"domain_scores_gemma":[0.998471,0.00030302882,0.00050275004,0.00007091571,0.0002664608,0.00038581406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041676487,0.00012429919,0.00036376622,0.00039986,0.000066867375,0.000033091103,0.00006856443,0.00004879067,0.00006923479],"category_scores_gemma":[0.00021618712,0.0000724234,0.00003663432,0.00054231094,0.00024047654,0.0005498905,0.0000047471126,0.00005129641,1.4542944e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009700525,0.0012383952,0.7384591,0.000034468558,0.00036066573,0.00025819626,0.016877525,0.0018610229,0.00013951708,0.0001517173,0.000037233254,0.23961207],"study_design_scores_gemma":[0.026178222,0.03826548,0.8608845,0.0013985839,0.0010850623,0.0006340279,0.009382709,0.059398163,0.0018141511,0.00017037799,0.00047740433,0.00031134806],"about_ca_topic_score_codex":0.00082180975,"about_ca_topic_score_gemma":0.00029217513,"teacher_disagreement_score":0.23930073,"about_ca_system_score_codex":0.0007311139,"about_ca_system_score_gemma":0.0018241167,"threshold_uncertainty_score":0.3235905},"labels":[],"label_agreement":null},{"id":"W2177996735","doi":"10.1016/j.cllc.2015.09.008","title":"A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; Hamilton Health Sciences; University of Toronto; Juravinski Hospital; McMaster University; Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Hamilton Health Sciences; Roche","keywords":"Medicine; Erlotinib; Lung cancer; Oncology; Internal medicine; Cancer; Radiation therapy; Epidermal growth factor receptor","score_opus":0.06595579759172852,"score_gpt":0.48889927542257866,"score_spread":0.4229434778308501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2177996735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879514,0.003645355,0.0006485632,0.00054705585,0.0012890103,0.0050490918,0.0005222465,0.000023920202,0.00032337167],"genre_scores_gemma":[0.9952449,0.00072306517,0.00059381704,0.00029750727,0.0006389595,0.0015255301,0.00021199536,0.000035078865,0.0007291474],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984852,0.000054872908,0.0005926471,0.00038936487,0.00024994323,0.00022794043],"domain_scores_gemma":[0.9982661,0.00025728415,0.00043206185,0.00018765927,0.00054753124,0.0003093891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002456803,0.00019294657,0.00055001763,0.000052454594,0.00008355538,0.000012498358,0.00005817514,0.000116371346,0.000042602405],"category_scores_gemma":[0.00016136092,0.00013626165,0.00012002871,0.00014028496,0.00011434353,0.0000842263,0.000030020812,0.00015042302,5.8528633e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0844521,0.011763461,0.6784089,0.0009653799,0.0019845658,0.0000041012036,0.0035999974,0.000071533614,0.000018275598,0.00006412259,0.017449686,0.20121783],"study_design_scores_gemma":[0.8574388,0.0395612,0.064758256,0.0014142744,0.010467334,4.7141975e-7,0.00027715103,0.010926524,0.00045372482,0.000042650616,0.014066682,0.0005929586],"about_ca_topic_score_codex":0.0001277638,"about_ca_topic_score_gemma":0.000094802635,"teacher_disagreement_score":0.77298665,"about_ca_system_score_codex":0.00027923222,"about_ca_system_score_gemma":0.0011203948,"threshold_uncertainty_score":0.5556589},"labels":[],"label_agreement":null},{"id":"W2179281780","doi":"10.5114/wo.2015.52660","title":"Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations","year":2015,"lang":"en","type":"letter","venue":"Współczesna Onkologia","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Afatinib; Oncology; Medicine; Internal medicine; Epidermal growth factor receptor; Cancer research; Cancer; Gefitinib","score_opus":0.028996389092277697,"score_gpt":0.2922094534749163,"score_spread":0.2632130643826386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179281780","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59299386,0.00073120947,0.0005099676,0.3933015,0.0036536108,0.0051522497,0.0015027496,0.00020296361,0.0019519243],"genre_scores_gemma":[0.39283136,0.0001613892,0.008701685,0.54448646,0.032592278,0.0008667364,0.013593449,0.00040644925,0.006360231],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764806,0.00012935672,0.00037551828,0.0006397549,0.0007591081,0.00044822268],"domain_scores_gemma":[0.99792117,0.00023891251,0.00035760354,0.0006826108,0.0006249157,0.00017481214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017781826,0.00049166684,0.00070913084,0.00016466304,0.00022512444,0.000056998833,0.00023602693,0.00037341006,0.00012799243],"category_scores_gemma":[0.000051642633,0.00026999816,0.000074517884,0.00024925015,0.00024298146,0.0001678276,0.000057739977,0.0007487131,0.000015990308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091768644,0.00033406564,0.064019606,0.00011433319,0.0010492585,0.00010847901,0.0019263988,0.00022249247,0.000016588237,0.000011830204,0.9299473,0.0013319626],"study_design_scores_gemma":[0.011314116,0.0071115317,0.07873508,0.00039763088,0.0010397821,0.000021881015,0.0001563028,0.000027394399,0.000060022274,0.000040945302,0.9004725,0.0006227863],"about_ca_topic_score_codex":0.0008081008,"about_ca_topic_score_gemma":0.00027802514,"teacher_disagreement_score":0.2001625,"about_ca_system_score_codex":0.00024959946,"about_ca_system_score_gemma":0.0003591286,"threshold_uncertainty_score":0.9999752},"labels":[],"label_agreement":null},{"id":"W2180481128","doi":"10.1038/nature13385","title":"Comprehensive molecular profiling of lung adenocarcinoma","year":2014,"lang":"en","type":"article","venue":"Nature","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5830,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Human Genome Research Institute; Howard Hughes Medical Institute","keywords":"Biology; Exon; Adenocarcinoma; Somatic cell; Alternative splicing; Lung cancer; KRAS; RNA splicing; Cancer research; Germline mutation; Messenger RNA; Genetics; Gene; Oncogene; Mutation; Molecular biology; Cancer; RNA; Medicine; Pathology; Cell cycle","score_opus":0.006625504655281512,"score_gpt":0.3152565461208155,"score_spread":0.308631041465534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180481128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98155105,0.00647372,0.0003928403,0.00093816774,0.00014865625,0.00029989483,0.000009047898,0.00002941023,0.010157209],"genre_scores_gemma":[0.99530053,0.000005332212,0.003365563,0.0010024608,0.000057573,0.000007593585,0.000042219897,0.000009546882,0.00020916524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996077,0.000011542895,0.000076177435,0.00010392621,0.00012260981,0.00007805738],"domain_scores_gemma":[0.9996315,0.000019867352,0.000033603814,0.00014495802,0.00012959479,0.000040427083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000017346221,0.000058802252,0.0001268731,0.00003752791,0.000019299265,0.0000025787494,0.000029488288,0.0002319233,0.000020826199],"category_scores_gemma":[0.0000243228,0.000044792116,0.000048823033,0.000083081926,0.000018081631,0.000017118398,0.000010144767,0.00036356546,0.000003921993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034721554,0.00052619947,0.588376,0.0018739545,0.0014951307,0.000197146,0.0016920976,0.00020091455,0.32454166,0.059509467,0.009115962,0.0121242795],"study_design_scores_gemma":[0.007229827,0.0007467841,0.5377171,0.00044891375,0.0015100999,0.00012276215,0.00028910517,0.0028492606,0.4136966,0.0012154278,0.033841264,0.0003328544],"about_ca_topic_score_codex":0.000006908698,"about_ca_topic_score_gemma":3.4885974e-7,"teacher_disagreement_score":0.08915495,"about_ca_system_score_codex":0.000028461993,"about_ca_system_score_gemma":0.000041667707,"threshold_uncertainty_score":0.18265694},"labels":[],"label_agreement":null},{"id":"W2186391570","doi":"10.1016/j.jval.2015.09.1142","title":"Economic Burden of Patients with Alk+ Mutation non-Small Cell Lung Cancer After Treatment with Crizotinib: a Canadian Retrospective Observational Study","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Novartis (Canada)","funders":"","keywords":"Crizotinib; Ceritinib; Anaplastic lymphoma kinase; Medicine; Lung cancer; ALK inhibitor; Internal medicine; Oncology; Targeted therapy; Cancer","score_opus":0.03972989836728169,"score_gpt":0.32777090872210174,"score_spread":0.28804101035482005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2186391570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957325,0.00022540858,0.000012921871,0.0006887862,0.0000939599,0.0025338542,0.00024006987,0.000009581628,0.00046294509],"genre_scores_gemma":[0.9980544,0.000016105576,0.0008187456,0.00012761077,0.00006502428,0.0005333674,0.00014161122,0.000026007876,0.00021717187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989761,0.000048605518,0.00028455295,0.00027030075,0.00018046226,0.00023997486],"domain_scores_gemma":[0.99916506,0.000022490814,0.00016091739,0.00017185247,0.00018858368,0.00029111098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010130147,0.00014782556,0.00029834695,0.00016515118,0.000044379307,0.000008869041,0.000030290481,0.00003081796,0.000033120952],"category_scores_gemma":[0.000004530445,0.00010573618,0.000020830552,0.00015119067,0.000021658798,0.00007558637,0.0000048911243,0.00006307195,0.000003199716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00041286094,0.0004564122,0.9724449,0.000061458435,0.0001380123,0.000021636492,0.014913278,0.011211374,1.8827222e-7,0.0000090795265,0.000054653985,0.00027617958],"study_design_scores_gemma":[0.009372768,0.0052956506,0.9808981,0.0001741189,0.00016377853,0.0000013503901,0.0017291171,0.0021270642,0.000008134546,0.000010032743,0.00012274174,0.00009716212],"about_ca_topic_score_codex":0.7932094,"about_ca_topic_score_gemma":0.41642776,"teacher_disagreement_score":0.37678158,"about_ca_system_score_codex":0.005641518,"about_ca_system_score_gemma":0.0060250936,"threshold_uncertainty_score":0.9996098},"labels":[],"label_agreement":null},{"id":"W2187920436","doi":"","title":"Where next for gefi tinib in patients with lung cancer","year":2006,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Clinical trial; Oncology; Internal medicine; Placebo; Cancer; Intensive care medicine; Alternative medicine; Epidermal growth factor receptor; Pathology","score_opus":0.007475610093341798,"score_gpt":0.30660205590010137,"score_spread":0.29912644580675957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187920436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708744,0.0007561384,0.00029368134,0.0011465797,0.00008054699,0.0011845971,0.000035738212,0.0000347439,0.025593564],"genre_scores_gemma":[0.9843093,0.000011372248,0.0016707766,0.0002792484,0.00006890623,0.00024960795,0.00009954368,0.000014240404,0.01329701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996117,0.0000022785446,0.000084432184,0.0001085419,0.0000753521,0.0001177107],"domain_scores_gemma":[0.99980474,0.000011615918,0.000021104448,0.00007418354,0.000061239196,0.000027125612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00001105246,0.000060225404,0.00009336531,0.000031577896,0.000024557532,0.000008205705,0.000014372547,0.00002159017,0.00026918243],"category_scores_gemma":[0.0000017726207,0.000037877817,0.000018446772,0.000069982234,0.000008933978,0.000057208403,0.0000031430015,0.00002410414,0.0000030734534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013819,0.00023021392,0.9808135,0.00005809686,0.000049842187,0.0000015548684,0.00006854037,0.000038910104,0.00000851513,0.00035734498,0.014639706,0.0035955932],"study_design_scores_gemma":[0.00904688,0.00023391286,0.97174793,0.00013052851,0.00018237799,3.4578608e-7,0.000046617217,0.00020647864,0.00007189399,0.000032561653,0.018220939,0.000079551995],"about_ca_topic_score_codex":0.0019410851,"about_ca_topic_score_gemma":0.0032350672,"teacher_disagreement_score":0.013434883,"about_ca_system_score_codex":0.00012620768,"about_ca_system_score_gemma":0.00008211865,"threshold_uncertainty_score":0.2947359},"labels":[],"label_agreement":null},{"id":"W2193195635","doi":"10.3390/molecules201219816","title":"Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging","year":2015,"lang":"en","type":"review","venue":"Molecules","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Kinome; Positron emission tomography; Medicine; Kinase; Preclinical imaging; Molecular imaging; Cancer research; Pet imaging; In vivo; Pharmacology; Chemistry; Nuclear medicine; Biology; Biochemistry","score_opus":0.02369168937597631,"score_gpt":0.3787045067628682,"score_spread":0.3550128173868919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2193195635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004436276,0.99731284,0.0005085779,0.000114644,0.000034144174,0.001616756,0.000018796194,0.000006556574,0.0003432944],"genre_scores_gemma":[0.00009277378,0.994753,0.0037226633,0.00003456962,0.000031895117,0.0010090582,0.0003221202,0.000014894494,0.000019009232],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933547,0.000030480758,0.00027745444,0.00016186008,0.00010726617,0.00008747848],"domain_scores_gemma":[0.9995836,0.000051509858,0.00014296432,0.00012619764,0.00006575085,0.000029959177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016252045,0.00012588427,0.0004185099,0.00008005604,0.000028014285,0.000006803826,0.000046915804,0.000023056245,7.1886376e-7],"category_scores_gemma":[0.000029525903,0.00007369423,0.000044767068,0.0001278523,0.000026271378,0.000025511245,0.000011449568,0.000051990668,7.932578e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000058857568,0.000051047715,0.000033248867,0.0028951357,0.00003236674,0.0000041934727,0.00027381929,3.6571103e-7,0.0000010899686,0.00009261183,0.000112403795,0.9964978],"study_design_scores_gemma":[0.0004953108,0.000028705888,0.00001309274,0.0018531181,0.00042318026,0.00002232272,0.00011498603,0.000011076108,0.000014193025,0.000059665137,0.9968966,0.00006771409],"about_ca_topic_score_codex":0.0000044273716,"about_ca_topic_score_gemma":0.000016812271,"teacher_disagreement_score":0.9967842,"about_ca_system_score_codex":0.00013005872,"about_ca_system_score_gemma":0.00029138394,"threshold_uncertainty_score":0.30051637},"labels":[],"label_agreement":null},{"id":"W2196580706","doi":"10.1200/jco.2010.28.18_suppl.lba7005","title":"A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Placebo; Lung cancer; Rash; Gastroenterology; Hazard ratio; Epidermal growth factor receptor; Surgery; Cancer; Oncology; Pathology; Confidence interval","score_opus":0.08185732026370005,"score_gpt":0.4656413726622132,"score_spread":0.3837840523985132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196580706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791389,0.00033899114,0.00011464264,0.0058799153,0.006153411,0.006600056,0.00007337106,0.00001209869,0.0016886168],"genre_scores_gemma":[0.9932891,0.0003654821,0.00094813114,0.00091716147,0.0030427238,0.00036611396,0.000012781382,0.000039567432,0.0010189384],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921389,0.0013599338,0.005062396,0.0003515222,0.0006207322,0.00046649465],"domain_scores_gemma":[0.98600125,0.0076379715,0.004528978,0.00035298645,0.00093564996,0.0005431314],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0050072423,0.0003280309,0.0043405048,0.00024545324,0.00011324487,0.00002175134,0.000366362,0.000635457,0.00080830685],"category_scores_gemma":[0.005140983,0.00018368849,0.0015688743,0.00032834642,0.0004926254,0.00014698062,0.000092051305,0.0025541522,0.0000053298454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98039925,0.0067294217,0.002954127,0.00008255801,0.0012943731,0.00010744569,0.0007466001,0.000016399274,0.0035166962,0.000048448976,0.0017193314,0.0023853602],"study_design_scores_gemma":[0.98506004,0.0068465914,0.0011650583,0.0002121033,0.0020036045,0.000029270079,0.00012334296,0.00035819938,0.0010302262,0.00003223841,0.0029748287,0.00016449158],"about_ca_topic_score_codex":0.00085439393,"about_ca_topic_score_gemma":0.0012905326,"teacher_disagreement_score":0.014150202,"about_ca_system_score_codex":0.00035493128,"about_ca_system_score_gemma":0.006604158,"threshold_uncertainty_score":0.999747},"labels":[],"label_agreement":null},{"id":"W2198210452","doi":"10.1007/978-3-319-24223-1_5","title":"Anti-angiogenesis in Personalized Therapy of Lung Cancer","year":2015,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Ontario Clinical Oncology Group; Juravinski Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Lung cancer; Oncology; Sunitinib; Docetaxel; Carboplatin; Internal medicine; Pemetrexed; Nintedanib; Chemotherapy; Maintenance therapy; Combination therapy; Erlotinib; Angiogenesis; Cancer; Epidermal growth factor receptor; Lung; Cisplatin","score_opus":0.09203948023216074,"score_gpt":0.5227360185476067,"score_spread":0.4306965383154459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198210452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026228228,0.9952611,0.0000012439383,0.00011006951,0.00029491817,0.0008274965,0.000027594355,0.000007765248,0.000847036],"genre_scores_gemma":[0.0037377607,0.99525785,0.00008292458,0.00015114901,0.00015119115,0.00038398695,0.00015618773,0.000020059711,0.000058876372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988392,0.000083535546,0.00047632345,0.00032662027,0.00008294,0.00019136499],"domain_scores_gemma":[0.9994966,0.00008255456,0.00018430728,0.0001327248,0.00003178235,0.00007207265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109768014,0.0002607295,0.0017909122,0.00029748183,0.000014026137,9.954288e-7,0.000065440065,0.00015810238,0.00012726194],"category_scores_gemma":[0.000015659876,0.00015319043,0.00009602629,0.00029326507,0.0003418197,0.000049095754,0.00002636727,0.00010592987,5.4632005e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090819274,0.00025581283,0.009427306,0.0016248807,0.00024608534,0.000029875031,0.0012749766,1.9417713e-7,0.00017804542,0.00020966033,0.00011953521,0.9865428],"study_design_scores_gemma":[0.0037962263,0.00067427417,0.00007841632,0.007341334,0.00021266476,0.000038413396,0.0006221788,0.0000020262707,0.00006743989,0.00002359551,0.9869945,0.00014892784],"about_ca_topic_score_codex":0.00044716528,"about_ca_topic_score_gemma":0.000032184722,"teacher_disagreement_score":0.98687494,"about_ca_system_score_codex":0.00021048522,"about_ca_system_score_gemma":0.00020834763,"threshold_uncertainty_score":0.62469244},"labels":[],"label_agreement":null},{"id":"W2217745328","doi":"10.1097/jto.0b013e31824c98b9","title":"KRAS Mutation Spectrum Notably Diverges between Non-small Cell Lung and Colorectal Carcinomas: In Response","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"KRAS; Colorectal cancer; Medicine; Oncology; Lung cancer; Biomarker; Context (archaeology); Epidermal growth factor receptor; Cetuximab; Internal medicine; Cancer research; Cancer; Mutation; Biology; Gene; Genetics","score_opus":0.01722374543797107,"score_gpt":0.3880828342954637,"score_spread":0.37085908885749264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2217745328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937201,0.001677838,0.0001803373,0.0027084178,0.0004027155,0.0002554355,0.000008918266,0.0000058995365,0.001040297],"genre_scores_gemma":[0.9967317,0.00009480639,0.0022727572,0.00011242572,0.0004368686,0.000006980334,0.000006086529,0.000013954663,0.0003244291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989201,0.0001951599,0.00038772356,0.00010153215,0.00013762106,0.00025790348],"domain_scores_gemma":[0.9989819,0.00034362983,0.00031328484,0.00007360651,0.000082753686,0.00020483976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007424815,0.000114102884,0.00040745593,0.00030304134,0.00005441886,0.0000097995835,0.000050997696,0.00012502483,0.000038401457],"category_scores_gemma":[0.000074317446,0.000089911344,0.000068532245,0.00015730724,0.000049650003,0.00017548644,0.000023520879,0.00026767072,0.0000066377625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034599379,0.0004036201,0.97234446,0.00007558032,0.00014929584,0.0005054868,0.0071245837,0.000011638412,0.0044033336,0.000007375122,0.00032872346,0.0111859515],"study_design_scores_gemma":[0.0018733788,0.0021365737,0.9865539,0.00007124569,0.0007753457,0.00065568695,0.0010083632,0.000027987591,0.004962958,0.000063547086,0.0017872681,0.00008372594],"about_ca_topic_score_codex":0.000056552348,"about_ca_topic_score_gemma":0.000045358294,"teacher_disagreement_score":0.0142094465,"about_ca_system_score_codex":0.0005912952,"about_ca_system_score_gemma":0.000504174,"threshold_uncertainty_score":0.3666478},"labels":[],"label_agreement":null},{"id":"W2222860631","doi":"10.1016/j.jtho.2015.09.006","title":"Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Cancer; Internal medicine; Biopsy; Informed consent; Oncology; Pathology; Alternative medicine","score_opus":0.10706431643290101,"score_gpt":0.5944875724242861,"score_spread":0.48742325599138503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222860631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908027,0.00032221517,0.00029296553,0.0067894207,0.0005109469,0.00081149355,0.000021260405,0.0000048364354,0.0004441359],"genre_scores_gemma":[0.99585307,0.0002240981,0.0025066717,0.0003163826,0.00031614146,0.00010667436,0.0000020051089,0.000016607466,0.0006583822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735904,0.000814612,0.0010107268,0.00018834599,0.00033062266,0.00029664286],"domain_scores_gemma":[0.996857,0.0010692886,0.00065778085,0.00016305057,0.00093703426,0.00031588387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032906102,0.00010558549,0.00072726206,0.00035993697,0.00005444594,0.0000104358105,0.0000931414,0.0001264501,0.00010890118],"category_scores_gemma":[0.0017409857,0.00005416744,0.00010945873,0.00031415277,0.00007354797,0.00012827326,0.000030833355,0.00030582014,0.000010103056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069180666,0.00096138543,0.69429713,0.00004700086,0.00014418736,0.00011322321,0.00074173283,0.00004444341,0.000648164,0.0000019052792,0.0013375849,0.29474518],"study_design_scores_gemma":[0.0091489265,0.0073836325,0.9657853,0.0010822687,0.00060124556,0.0000103099665,0.0005740267,0.000022905086,0.001463817,0.00003243884,0.013792856,0.000102246915],"about_ca_topic_score_codex":0.000028222885,"about_ca_topic_score_gemma":0.00030227532,"teacher_disagreement_score":0.29464293,"about_ca_system_score_codex":0.000859803,"about_ca_system_score_gemma":0.0012535747,"threshold_uncertainty_score":0.2248355},"labels":[],"label_agreement":null},{"id":"W2222964070","doi":"10.1200/jco.2009.27.15_suppl.8098","title":"Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Erlotinib; Medicine; Rash; Internal medicine; KRAS; Lung cancer; Oncology; T790M; EGFR inhibitors; Epidermal growth factor receptor; Cancer; Gastroenterology; Colorectal cancer","score_opus":0.03416316718002527,"score_gpt":0.44370908392750447,"score_spread":0.4095459167474792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222964070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997635,0.0005018213,0.000045018194,0.0072821067,0.000352668,0.0004994832,0.0000066413995,0.0000054989505,0.0013304095],"genre_scores_gemma":[0.9963918,0.00042948854,0.00043070212,0.0020854783,0.00029887928,0.000009274325,0.000011268607,0.0000133435005,0.00032978266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797773,0.00027134572,0.0011274861,0.00019185773,0.00024852515,0.0001830351],"domain_scores_gemma":[0.9976299,0.0005510701,0.0011794426,0.00011847662,0.0003251765,0.0001959794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080259,0.00015259319,0.00069115584,0.00012565285,0.00005985325,0.000013225209,0.000079005666,0.00013541682,0.000048109297],"category_scores_gemma":[0.00015746262,0.00007314773,0.0001325273,0.00019365485,0.00008323318,0.00011736249,0.000016245449,0.00046507685,0.0000019459085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005233576,0.0024802042,0.8096323,0.00003678814,0.00024960077,0.00034987574,0.00039783103,0.000031082433,0.0012023471,0.0000021127244,0.0056788125,0.17470549],"study_design_scores_gemma":[0.020721024,0.005394959,0.9676145,0.00040631663,0.00096514175,0.000049320734,0.000094124305,0.0009659965,0.00045027264,0.00001075758,0.0032333715,0.00009423464],"about_ca_topic_score_codex":0.00006206595,"about_ca_topic_score_gemma":0.000053251148,"teacher_disagreement_score":0.17461126,"about_ca_system_score_codex":0.00028397547,"about_ca_system_score_gemma":0.000739973,"threshold_uncertainty_score":0.29828778},"labels":[],"label_agreement":null},{"id":"W2223712877","doi":"10.1200/jco.2007.25.18_suppl.7527","title":"A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Clinical endpoint; Vinorelbine; Concomitant; Internal medicine; Randomization; Placebo; non-small cell lung cancer (NSCLC); Chemoradiotherapy; Chemotherapy; Cisplatin; Performance status; Lung cancer; Randomized controlled trial; Urology; Pathology","score_opus":0.0719299591436853,"score_gpt":0.48674956615895193,"score_spread":0.41481960701526666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223712877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892338,0.0011854443,0.004506822,0.0016960179,0.000762423,0.0018580946,0.000018570987,0.000011502288,0.00072731485],"genre_scores_gemma":[0.99028534,0.0013835242,0.004515079,0.0014718253,0.0011832076,0.000050853483,0.000005196871,0.00004848983,0.0010564865],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968524,0.0000978535,0.0020829635,0.00031843965,0.00032350028,0.00032485145],"domain_scores_gemma":[0.9957276,0.00076173403,0.0022152737,0.00023070983,0.00067021215,0.0003944919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018984921,0.00025302466,0.0018457201,0.00017694534,0.00009059788,0.00001254181,0.00012551752,0.000307965,0.00010474916],"category_scores_gemma":[0.00010116809,0.00016810492,0.00026048403,0.00020007759,0.00019882561,0.000121223995,0.00001537905,0.0005769896,2.9549227e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1687811,0.066059366,0.26613462,0.0005656694,0.010358254,0.0010112327,0.020449892,0.00011353167,0.022637727,0.000057153953,0.0073931767,0.43643826],"study_design_scores_gemma":[0.6463841,0.18237294,0.10606399,0.00051468884,0.0054990863,0.00033077013,0.010983159,0.0006296856,0.010783465,0.000045952675,0.035832897,0.00055927207],"about_ca_topic_score_codex":0.00039840388,"about_ca_topic_score_gemma":0.000620185,"teacher_disagreement_score":0.477603,"about_ca_system_score_codex":0.00046259203,"about_ca_system_score_gemma":0.0021164222,"threshold_uncertainty_score":0.685512},"labels":[],"label_agreement":null},{"id":"W2228560864","doi":"10.1200/jco.2007.25.18_suppl.6555","title":"Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Guideline; Randomized controlled trial; Gemcitabine; Lung cancer; Clinical endpoint; Internal medicine; Oncology; Cancer; Family medicine; Chemotherapy; Pathology","score_opus":0.37975122270478584,"score_gpt":0.5914904204564964,"score_spread":0.21173919775171052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228560864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97155654,0.008611141,0.011189504,0.0057829097,0.00023058578,0.000743477,0.000007275169,0.0000021155843,0.0018764253],"genre_scores_gemma":[0.99113595,0.0011039212,0.0045709186,0.002780407,0.0002612847,0.000036560796,0.0000010143654,0.000010243452,0.00009972017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969888,0.00027516388,0.0021531826,0.00017601321,0.00019615961,0.00021072254],"domain_scores_gemma":[0.991339,0.007361511,0.0007017853,0.00015739453,0.000333856,0.00010643002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044465438,0.0001285192,0.0019665654,0.00019205837,0.000025151805,0.000004462388,0.00016553457,0.00019321723,0.00010175506],"category_scores_gemma":[0.0007329548,0.00006565712,0.0013764421,0.00049071264,0.000093886214,0.00011549333,0.0000084748335,0.0004287814,4.8751957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015382197,0.012761891,0.6399545,0.00055930385,0.14195639,0.0004915202,0.07553447,0.0075948806,0.0005807435,0.0001762661,0.00088182575,0.104125984],"study_design_scores_gemma":[0.024253385,0.007242297,0.74498,0.00025324532,0.2111018,0.000017947841,0.0024379203,0.003488771,0.0007826124,0.00027873993,0.0049550342,0.00020826184],"about_ca_topic_score_codex":0.0001903126,"about_ca_topic_score_gemma":0.002254116,"teacher_disagreement_score":0.10502546,"about_ca_system_score_codex":0.00016426407,"about_ca_system_score_gemma":0.0013862078,"threshold_uncertainty_score":0.26774195},"labels":[],"label_agreement":null},{"id":"W2232493204","doi":"10.1136/jclinpath-2015-203437","title":"A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Immunohistochemistry; Pathology; Epidermal growth factor receptor; Cell; Medicine; Biology; Receptor; Internal medicine","score_opus":0.02824896006905444,"score_gpt":0.39551765773397674,"score_spread":0.3672686976649223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232493204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86921746,0.000051146337,0.12883833,0.0005342386,0.00008645853,0.0010331989,0.00011799668,0.0000011837778,0.00012002316],"genre_scores_gemma":[0.9678264,0.0000036814195,0.031772327,0.000022846234,0.00007702637,0.00011838404,0.000039789677,0.000008853732,0.00013066144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986868,0.000077380515,0.00077650126,0.00016155635,0.00020476004,0.000092993476],"domain_scores_gemma":[0.99634635,0.0013376438,0.0010279783,0.0001353104,0.0011067799,0.000045942823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010215292,0.00008894888,0.0004646859,0.00006876557,0.00004642874,0.0000033185072,0.000048911188,0.00012394969,0.000016142265],"category_scores_gemma":[0.00027809336,0.00004650941,0.00020169899,0.0001200712,0.00010636734,0.000041846706,0.000008910445,0.000119474644,2.6504585e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027964804,0.0009180246,0.96117145,0.00013508259,0.0006725456,0.0000043988844,0.00039367733,0.0007818277,0.03227578,0.000032737902,0.000042195108,0.0007758047],"study_design_scores_gemma":[0.024319805,0.0023493695,0.93577904,0.00018885129,0.0116166165,0.000043309294,0.00033936652,0.013988508,0.009846514,0.0014332735,0.00000676666,0.000088590816],"about_ca_topic_score_codex":0.000035545265,"about_ca_topic_score_gemma":0.000079818485,"teacher_disagreement_score":0.098609,"about_ca_system_score_codex":0.00012838868,"about_ca_system_score_gemma":0.0013105819,"threshold_uncertainty_score":0.2324916},"labels":[],"label_agreement":null},{"id":"W2234005477","doi":"10.1634/theoncologist.2015-0209","title":"Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Erlotinib; Medicine; Oncology; Erlotinib Hydrochloride; Epidermal growth factor receptor; Internal medicine; Lung cancer; Chemotherapy; EGFR inhibitors; Gefitinib; Cancer","score_opus":0.04183407779112243,"score_gpt":0.362706235453725,"score_spread":0.3208721576626026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234005477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027914655,0.97118574,0.000012604347,0.0014533949,0.00032301477,0.0033893508,0.00024959104,0.000010660732,0.020584151],"genre_scores_gemma":[0.22212507,0.7753933,0.000050792496,0.00012165592,0.0001166145,0.00034408137,0.000053055453,0.00002308275,0.0017723588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985512,0.0003318079,0.0005103659,0.00018367736,0.00024875093,0.00017420709],"domain_scores_gemma":[0.9985174,0.0003586311,0.00052523066,0.0005230246,0.000052919753,0.00002277306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000298201,0.0002059294,0.00068456266,0.000056039677,0.00007237735,0.0000056588215,0.00024597833,0.0001171593,0.00012936418],"category_scores_gemma":[0.000026301423,0.00006897824,0.00032980886,0.00025036404,0.00023209189,0.000022917959,0.00009529133,0.00020260234,0.000012228347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017196128,0.0023513625,0.0018716363,0.076770484,0.0009789016,0.00017885833,0.003303512,0.0000020279672,0.00002581064,0.006487714,0.033067256,0.8747905],"study_design_scores_gemma":[0.0038624518,0.000822461,0.013173656,0.016229382,0.0075009917,0.000064392276,0.0009419698,0.0000015097602,0.00021886683,0.00019757649,0.9566548,0.0003319645],"about_ca_topic_score_codex":0.00016601651,"about_ca_topic_score_gemma":0.000016182406,"teacher_disagreement_score":0.9235875,"about_ca_system_score_codex":0.00045724315,"about_ca_system_score_gemma":0.00024558077,"threshold_uncertainty_score":0.28128508},"labels":[],"label_agreement":null},{"id":"W2240322070","doi":"10.1158/1538-8514.pi3k14-a46","title":"Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN)","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Oncology; Internal medicine; Epidermal growth factor receptor; EGFR inhibitors; Cancer; Cancer research; Colorectal cancer","score_opus":0.02081037150155034,"score_gpt":0.29531306301326465,"score_spread":0.2745026915117143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240322070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924992,0.0034506244,0.00006282435,0.0017247333,0.000048835635,0.00053339516,0.000067778834,0.0000072346147,0.0016053948],"genre_scores_gemma":[0.9983254,0.000029690267,0.00035351448,0.000983456,0.000014349117,0.000059659134,0.0000075422386,0.000025868347,0.00020049744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913687,0.000025052019,0.00021421375,0.0001831852,0.00027799603,0.00016269053],"domain_scores_gemma":[0.9993472,0.000013579615,0.00011198582,0.00029583796,0.00014649854,0.000084873376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005699503,0.00013292283,0.00023587364,0.00006859586,0.000023595385,0.0000066703983,0.000056616806,0.000051852923,0.000006367551],"category_scores_gemma":[0.00000463587,0.000091752576,0.00004027587,0.00028825522,0.00007299226,0.000028731543,0.000021405505,0.0001010151,3.4476156e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033091593,0.0017284325,0.6453277,0.0011951722,0.00032333154,0.00022452317,0.018790947,0.0018690233,0.32064164,0.0006173013,0.0003858715,0.0055869427],"study_design_scores_gemma":[0.010781318,0.0010242522,0.55927634,0.0005023853,0.0004472653,0.000010152513,0.0007639425,0.00003292406,0.42374983,0.0002576035,0.0029116275,0.00024236146],"about_ca_topic_score_codex":0.0016493172,"about_ca_topic_score_gemma":0.003180767,"teacher_disagreement_score":0.103108205,"about_ca_system_score_codex":0.0002501888,"about_ca_system_score_gemma":0.0004075122,"threshold_uncertainty_score":0.37415615},"labels":[],"label_agreement":null},{"id":"W2241018235","doi":"10.1200/jco.2007.25.18_suppl.7589","title":"A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Everolimus; Internal medicine; Lung cancer; Clinical endpoint; Adverse effect; Response Evaluation Criteria in Solid Tumors; Progressive disease; Phases of clinical research; Oncology; Chemotherapy; Cancer; non-small cell lung cancer (NSCLC); Pharmacodynamics; Urology; Surgery; Pharmacokinetics; Clinical trial","score_opus":0.03359885154060354,"score_gpt":0.44575969787648095,"score_spread":0.4121608463358774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241018235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966334,0.00035397135,0.00032880637,0.0005702848,0.00035993927,0.0016050391,0.0000064562405,0.000008599539,0.00013352143],"genre_scores_gemma":[0.99210787,0.00033231292,0.0060448498,0.0010700419,0.00027188216,0.000024651412,0.0000026723633,0.00004153296,0.0001041696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99665654,0.00012740126,0.002217562,0.00030762758,0.00037787153,0.00031301717],"domain_scores_gemma":[0.99617076,0.0009371405,0.0019546205,0.00019078286,0.0004338071,0.0003128623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011884772,0.00024453772,0.0014436747,0.00026443708,0.00007747024,0.0000072203648,0.00011305536,0.00023674074,0.000059512102],"category_scores_gemma":[0.0001918738,0.00015377373,0.00016156709,0.00029405215,0.000109285524,0.00013056885,0.00002101984,0.0005843173,3.0468902e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06126902,0.02978878,0.53037596,0.000077350735,0.0005252919,0.00021143716,0.0040702336,0.00022035364,0.0003911558,3.4148042e-7,0.00006483176,0.37300524],"study_design_scores_gemma":[0.39193174,0.16903654,0.43182948,0.0006660981,0.00088295504,0.000013315859,0.001851359,0.0004571559,0.0013834226,0.0000035711864,0.0017091882,0.00023519041],"about_ca_topic_score_codex":0.00013812304,"about_ca_topic_score_gemma":0.00079759635,"teacher_disagreement_score":0.37277004,"about_ca_system_score_codex":0.00045657775,"about_ca_system_score_gemma":0.0021282334,"threshold_uncertainty_score":0.6270711},"labels":[],"label_agreement":null},{"id":"W2242180794","doi":"10.1200/jco.2006.24.18_suppl.20078","title":"Homocysteine (HC) level as possible predictor of pemetrexed efficacy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Oncology; Breast cancer; Lung cancer; Thymidylate synthase; Clinical trial; Clinical endpoint; Cancer; non-small cell lung cancer (NSCLC); Chemotherapy; Cisplatin","score_opus":0.1174673415127637,"score_gpt":0.5064209303012609,"score_spread":0.3889535887884972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242180794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963348,0.0009569682,0.00020039028,0.006004923,0.0010449379,0.00021204309,0.000016985909,0.0000099537965,0.028205814],"genre_scores_gemma":[0.986903,0.00014302168,0.005598279,0.000580109,0.0014371595,0.0000024957233,0.000009345059,0.000014311689,0.0053122807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971533,0.0001330273,0.0020640306,0.00012853966,0.0003547751,0.00016632737],"domain_scores_gemma":[0.99642426,0.001146296,0.0014538724,0.00017214831,0.0005780766,0.0002253558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009273285,0.00010607821,0.0011459098,0.00015183892,0.000030184035,0.0000046592645,0.000109747896,0.00023036626,0.00030536114],"category_scores_gemma":[0.001631783,0.00006955132,0.00047650476,0.00018475314,0.000158299,0.00007437115,0.00002417082,0.00039126692,0.000025187597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013220066,0.02968225,0.5512913,0.00022258134,0.0042309132,0.0029610381,0.00042549227,0.00021989265,0.0029358563,0.0036166965,0.10288427,0.28830963],"study_design_scores_gemma":[0.024075018,0.019978445,0.8755248,0.0001620812,0.0015437828,0.0004987278,0.000075141266,0.000027779633,0.0005888529,0.0008116418,0.07663653,0.00007716336],"about_ca_topic_score_codex":0.00018648706,"about_ca_topic_score_gemma":0.00004144849,"teacher_disagreement_score":0.32423353,"about_ca_system_score_codex":0.00014477682,"about_ca_system_score_gemma":0.002257071,"threshold_uncertainty_score":0.40039468},"labels":[],"label_agreement":null},{"id":"W2243951255","doi":"10.1200/jco.2005.23.16_suppl.8134","title":"A prospective comparison of Karnofsky (KPS) with ECOG performance status in patients with non-small cell lung cancer (NSCLC): A COMET group study investigating sensitivity and specificity issues important in clinical decision making","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Performance status; Lung cancer; Docetaxel; Chemotherapy; Oncology; Prospective cohort study; Cancer; Stage (stratigraphy)","score_opus":0.048724069456037626,"score_gpt":0.47034381034725353,"score_spread":0.4216197408912159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243951255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978933,0.0004351684,0.000077204335,0.00018136446,0.00014986371,0.0010936585,0.000007760562,0.000004393881,0.00015730297],"genre_scores_gemma":[0.9825458,0.00028627328,0.016776979,0.00015481138,0.00019708216,0.000013106325,0.000002040079,0.000018114037,0.000005771814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956085,0.00040687062,0.0029605927,0.00032658377,0.00042025198,0.00027716343],"domain_scores_gemma":[0.9950966,0.0016495077,0.0024269745,0.0001580281,0.00043254395,0.00023630443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028829747,0.00019272129,0.0018192934,0.0001996789,0.00004613819,0.000011510855,0.00006262589,0.00016914649,0.000009432286],"category_scores_gemma":[0.00051050907,0.000121149205,0.00009246669,0.00029610767,0.0002225883,0.00019528014,0.000054042484,0.0010595748,3.34106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00837882,0.009428395,0.92494214,0.000055221888,0.00024714853,0.00013350065,0.0023566817,0.00047792663,0.0000047044714,0.0000018832485,0.000021536795,0.05395205],"study_design_scores_gemma":[0.027675457,0.02333356,0.94290733,0.0010955071,0.00046474184,0.000010792431,0.0011943633,0.0031315342,0.0000151031045,0.000006275197,0.000047683603,0.000117618656],"about_ca_topic_score_codex":0.0002703942,"about_ca_topic_score_gemma":0.007906584,"teacher_disagreement_score":0.05383443,"about_ca_system_score_codex":0.0004630772,"about_ca_system_score_gemma":0.0011483885,"threshold_uncertainty_score":0.4940321},"labels":[],"label_agreement":null},{"id":"W2244426249","doi":"10.1200/jco.2008.26.15_suppl.8054","title":"The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vinorelbine; Gemcitabine; Internal medicine; Carboplatin; Lung cancer; Pemetrexed; Oncology; Chemotherapy; Toxicity; Cisplatin","score_opus":0.16680126201493473,"score_gpt":0.5176512512286201,"score_spread":0.3508499892136854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244426249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367064,0.0019029556,0.000010481333,0.0022845806,0.00091190496,0.00078089256,0.00007067167,0.0000015677261,0.00036632657],"genre_scores_gemma":[0.97498393,0.022982096,0.00034833295,0.0009068276,0.00056637934,0.000029059533,0.000002523271,0.0000105975905,0.00017025924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927262,0.0011715645,0.0052615013,0.00020418846,0.00045001548,0.00018650427],"domain_scores_gemma":[0.9813773,0.013112253,0.0044878176,0.00015773223,0.00064217823,0.00022269793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008360242,0.00017060318,0.0029117744,0.00010438491,0.000059132013,0.0000025554523,0.00014133163,0.0002632413,0.00003163354],"category_scores_gemma":[0.0048011434,0.000094926,0.00052790105,0.00015553558,0.00040870623,0.00006260665,0.000020184842,0.0003942078,1.148527e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032089036,0.008734538,0.7683935,0.00017534765,0.005095934,0.00020111722,0.0012173505,0.006289782,0.0026659914,0.00007734268,0.004479353,0.17058071],"study_design_scores_gemma":[0.04826359,0.010706121,0.9262703,0.0004587404,0.0011178519,0.00002565259,0.0000965323,0.00020818473,0.002114412,0.000039233153,0.01058694,0.000112435264],"about_ca_topic_score_codex":0.04673337,"about_ca_topic_score_gemma":0.079658434,"teacher_disagreement_score":0.17046827,"about_ca_system_score_codex":0.0009097512,"about_ca_system_score_gemma":0.023060815,"threshold_uncertainty_score":0.98247755},"labels":[],"label_agreement":null},{"id":"W2245804800","doi":"10.1200/jco.2006.24.18_suppl.7211","title":"Prognostic significance of immunohistochemical markers in non-small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Tissue microarray; Immunohistochemistry; Oncology; Adenocarcinoma; Internal medicine; Cancer; Carcinoma; Pathology; Biomarker; Small-cell carcinoma; Population; Biology","score_opus":0.03203882266499846,"score_gpt":0.4396795485552337,"score_spread":0.40764072589023526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245804800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98034745,0.002239558,0.00014032396,0.0016721019,0.000614251,0.0003899172,0.0000053183057,0.000003405704,0.014587686],"genre_scores_gemma":[0.9940771,0.00030701596,0.0042363843,0.000288321,0.00042601573,0.000023074013,0.0000033444742,0.000012250509,0.0006265027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976074,0.00010376161,0.0017942904,0.00013410588,0.00018466431,0.00017577635],"domain_scores_gemma":[0.9973404,0.0009838833,0.0011746027,0.000113790404,0.0002642738,0.00012306377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000748149,0.00009882601,0.0009194597,0.000099528406,0.000013690945,0.000002464124,0.00010038739,0.00021280962,0.00009681332],"category_scores_gemma":[0.00042125254,0.00007263016,0.00028075447,0.0001484233,0.0001412638,0.00003651872,0.000017107848,0.0005051485,0.0000020003245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002529783,0.0035156922,0.9607712,0.00018466797,0.00027721786,0.0004590528,0.00011933166,0.00018841354,0.008295196,0.000035983623,0.0073205167,0.016302926],"study_design_scores_gemma":[0.011271609,0.0037213385,0.97497654,0.00035920317,0.0010578509,0.000050578215,0.000115714814,0.00020719127,0.0012210273,0.00011681062,0.0068051117,0.00009699897],"about_ca_topic_score_codex":0.00043767353,"about_ca_topic_score_gemma":0.00008858562,"teacher_disagreement_score":0.016205927,"about_ca_system_score_codex":0.00038224485,"about_ca_system_score_gemma":0.0024143993,"threshold_uncertainty_score":0.42830405},"labels":[],"label_agreement":null},{"id":"W2249358575","doi":"10.1200/jco.2006.24.18_suppl.5566","title":"A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Oncology; Chemotherapy; Adverse effect; Gastroenterology; Cancer; Breast cancer; Trastuzumab","score_opus":0.09390375300937577,"score_gpt":0.4973413336384716,"score_spread":0.40343758062909585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249358575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975406,0.00066923624,0.00003371259,0.0007573344,0.00030380228,0.00049228355,0.000014751737,0.0000020988593,0.00018619365],"genre_scores_gemma":[0.9977794,0.00014391833,0.0016341931,0.000142268,0.00015488984,0.000012608655,0.0000020610828,0.000010728416,0.000119901066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970014,0.0003701441,0.0020789173,0.00015236872,0.00025328933,0.00014387653],"domain_scores_gemma":[0.99654347,0.0014784493,0.0015580999,0.00014414552,0.00015610366,0.000119757504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011488138,0.00012300919,0.0012121189,0.00011783058,0.00005033374,0.0000054518696,0.00008968434,0.000074771175,0.000039592695],"category_scores_gemma":[0.0010824625,0.000058279453,0.00012071606,0.00017135758,0.00016689781,0.00007244722,0.00007181589,0.00033528794,1.6093493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06890755,0.1195146,0.46844885,0.000922488,0.0022880554,0.004833681,0.013433961,0.00016137931,0.0038957945,0.000067900655,0.0022374077,0.31528834],"study_design_scores_gemma":[0.11253824,0.1824012,0.6894363,0.0021079283,0.0039115064,0.0009995629,0.0057562394,0.0004898086,0.0003968576,0.00029493272,0.0014896939,0.00017771944],"about_ca_topic_score_codex":0.00016866696,"about_ca_topic_score_gemma":0.00036052355,"teacher_disagreement_score":0.31511062,"about_ca_system_score_codex":0.00007352005,"about_ca_system_score_gemma":0.0010056703,"threshold_uncertainty_score":0.23765671},"labels":[],"label_agreement":null},{"id":"W2249501726","doi":"10.1200/jco.2009.27.15_suppl.e22066","title":"Molecular changes in epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) biopsies at time of progression compared to initial biopsy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Lung cancer; Exon; Medicine; Epidermal growth factor receptor; Missense mutation; Biopsy; Liquid biopsy; Oncology; T790M; Mutation; Pathology; Cancer research; Internal medicine; Cancer; Gene; Gefitinib; Biology; Genetics","score_opus":0.05801625254943917,"score_gpt":0.4727867438395973,"score_spread":0.41477049129015814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249501726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842948,0.0008535064,0.000027851785,0.01297196,0.00045540827,0.00051499606,0.000022246062,0.000005569855,0.0008536621],"genre_scores_gemma":[0.9946885,0.00033572922,0.0028711576,0.0016183942,0.00033213518,0.000016725371,0.000009454698,0.00001347223,0.00011441215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759924,0.00022651741,0.0014899021,0.00017749156,0.00024350926,0.0002633496],"domain_scores_gemma":[0.9979798,0.00042101575,0.0009131401,0.0001143683,0.00028381412,0.0002878617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057220424,0.00015452276,0.0012467455,0.00030885797,0.000020329135,0.000004517388,0.00012457793,0.00026344176,0.00019519351],"category_scores_gemma":[0.00042919966,0.0001106609,0.00019448188,0.0002655125,0.000077372126,0.000059537895,0.00004209294,0.00040153856,0.0000086004175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012334021,0.0074068177,0.77131075,0.0002645882,0.00041960212,0.0023815767,0.0041635972,0.00020378186,0.11365461,0.000014221842,0.0034359975,0.084410414],"study_design_scores_gemma":[0.016987715,0.0105769755,0.941622,0.0014389796,0.0003652397,0.000092399074,0.00021030291,0.00024511665,0.026588598,0.000022562941,0.0016486183,0.00020144862],"about_ca_topic_score_codex":0.000078459656,"about_ca_topic_score_gemma":0.00014948731,"teacher_disagreement_score":0.17031127,"about_ca_system_score_codex":0.0004851387,"about_ca_system_score_gemma":0.00092650007,"threshold_uncertainty_score":0.45126203},"labels":[],"label_agreement":null},{"id":"W2249979977","doi":"10.1093/annonc/mdu438.51","title":"Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Cancer research; PD-L1; Internal medicine; Immunotherapy; Cancer","score_opus":0.016153954546913596,"score_gpt":0.3261462411814098,"score_spread":0.3099922866344962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249979977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963701,0.00014880554,0.0009797032,0.000099845754,0.000021346093,0.000860333,0.00002653934,0.000008060152,0.0014853127],"genre_scores_gemma":[0.997981,0.0000489005,0.0016967686,0.000046783076,0.000008125706,0.00006586635,0.000089924055,0.000015508338,0.00004710076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988765,0.000086843196,0.00034820286,0.0002852791,0.00019340958,0.00020974655],"domain_scores_gemma":[0.99859136,0.00013060597,0.0005549179,0.00023583167,0.00039232618,0.000094937706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013929134,0.00016383943,0.0007910483,0.000378622,0.00003202795,0.0000033291492,0.000052793508,0.00010174849,0.000006716599],"category_scores_gemma":[0.0000409047,0.00011499597,0.00007254162,0.0004894365,0.00010146577,0.00010575857,0.000026709617,0.00010042034,1.7931012e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062896316,0.0021050866,0.9549244,0.0003043817,0.00058273243,0.000011238975,0.0014252579,0.00056080846,0.010073649,0.000013016759,0.000013347566,0.02369642],"study_design_scores_gemma":[0.012532021,0.00857184,0.9357005,0.0002260984,0.0022770339,0.0000028399504,0.00014675775,0.0027372227,0.03762515,0.000006389171,0.00006773293,0.00010646959],"about_ca_topic_score_codex":0.00036078037,"about_ca_topic_score_gemma":0.00038680172,"teacher_disagreement_score":0.027551498,"about_ca_system_score_codex":0.000059540343,"about_ca_system_score_gemma":0.00027046778,"threshold_uncertainty_score":0.46893996},"labels":[],"label_agreement":null},{"id":"W2250123711","doi":"10.1200/jco.2006.24.18_suppl.7223","title":"Factors impacting survival of patients with post-surgical disease recurrence in non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Asymptomatic; Surgery; Pneumonectomy; Adenocarcinoma; Stage (stratigraphy); Lung cancer; Wedge resection; Population; Cancer; Medical record; Disease; Internal medicine; Resection","score_opus":0.048830304523288834,"score_gpt":0.44922290567546,"score_spread":0.4003926011521712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250123711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628216,0.0004419862,0.00003170387,0.0007176876,0.00066993036,0.00025916743,0.000041500516,0.000003068314,0.0015527763],"genre_scores_gemma":[0.9990239,0.000098978395,0.00031603043,0.00009101713,0.00033311735,0.000004004684,0.000017302056,0.000012580329,0.00010306885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782306,0.00015195852,0.0013719165,0.00015057375,0.00029710005,0.00020541815],"domain_scores_gemma":[0.996728,0.0010377566,0.0012789557,0.00010752,0.0005324694,0.00031526882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005058416,0.00012951653,0.0009083548,0.000106282416,0.00002442932,0.0000046381247,0.000084469386,0.00013090915,0.000078607125],"category_scores_gemma":[0.00038714483,0.00007528868,0.00024415785,0.00015056382,0.00009288692,0.000093435774,0.000020208714,0.00048000077,6.580123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003236611,0.0029434,0.9856952,0.000056083303,0.00012229085,0.00022838109,0.00012253193,0.00013734473,0.0000057632533,0.000007737469,0.000114442526,0.007330229],"study_design_scores_gemma":[0.011482416,0.00349156,0.9830242,0.0002621002,0.00059024227,0.0000027342478,0.00010013382,0.000043615935,0.000014945305,0.000012103874,0.0009020164,0.00007396311],"about_ca_topic_score_codex":0.00037989218,"about_ca_topic_score_gemma":0.00026901677,"teacher_disagreement_score":0.008245804,"about_ca_system_score_codex":0.00025147543,"about_ca_system_score_gemma":0.002390736,"threshold_uncertainty_score":0.4241063},"labels":[],"label_agreement":null},{"id":"W2253719211","doi":"10.1200/jco.2007.25.18_suppl.18010","title":"Treatment patterns and clinical outcomes in lung cancer patients with brain metastasis","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Brain metastasis; Radiosurgery; Lung cancer; Univariate analysis; Cancer; Multivariate analysis; Internal medicine; Odds ratio; Oncology; Metastasis; Radiation therapy; Surgery","score_opus":0.07409255344312178,"score_gpt":0.538988027168225,"score_spread":0.46489547372510326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253719211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904455,0.0002421319,0.00014582626,0.0077824118,0.0006027305,0.00031744098,0.00001711914,0.000004261393,0.0004425953],"genre_scores_gemma":[0.9948099,0.00077474606,0.0016814156,0.0021550078,0.0002960784,0.000005848201,0.000005026152,0.000013268782,0.00025867324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973379,0.00017597077,0.0018748996,0.00017802279,0.00022834653,0.00020489043],"domain_scores_gemma":[0.9958953,0.0025226471,0.0009001055,0.00010927252,0.00021647036,0.0003561892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013335061,0.00013247265,0.0012959263,0.00012632589,0.000024710145,0.0000058434616,0.00004836266,0.0001811264,0.00007071763],"category_scores_gemma":[0.0006889077,0.00006984884,0.00027769065,0.00008474909,0.00010479889,0.00008346643,0.00001691672,0.00036479137,0.0000012121741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016987814,0.0034933873,0.7816967,0.000008934388,0.0014030599,0.00039029345,0.000100987476,0.000001618333,1.8642416e-7,0.000011699633,0.00016137313,0.21103302],"study_design_scores_gemma":[0.024868064,0.016241135,0.94888335,0.00006424939,0.0014835079,0.000028688213,0.00008799698,0.000008983172,0.000002256477,0.000012207123,0.0082559325,0.000063629595],"about_ca_topic_score_codex":0.00036053063,"about_ca_topic_score_gemma":0.0025798585,"teacher_disagreement_score":0.21096939,"about_ca_system_score_codex":0.00038979997,"about_ca_system_score_gemma":0.00089989137,"threshold_uncertainty_score":0.2848353},"labels":[],"label_agreement":null},{"id":"W2255227919","doi":"10.1200/jco.2013.31.15_suppl.8027","title":"Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for <i>KRAS</i>-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Trametinib; KRAS; Internal medicine; Lung cancer; Tolerability; Oncology; Response Evaluation Criteria in Solid Tumors; MEK inhibitor; Adverse effect; Cancer; Phases of clinical research; Chemotherapy; Gastroenterology; Colorectal cancer; Cisplatin; Kinase; MAPK/ERK pathway","score_opus":0.05341897179698591,"score_gpt":0.47188179646885986,"score_spread":0.41846282467187396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255227919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876654,0.0009221398,0.00048410837,0.0063791024,0.0015090107,0.002495528,0.000012634368,0.000009764959,0.00052229746],"genre_scores_gemma":[0.9845537,0.0009323355,0.011802641,0.0013614517,0.00062716013,0.00020752329,0.00001632183,0.000033775803,0.00046512522],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99721307,0.00019661839,0.0017433187,0.00028971513,0.0002602401,0.00029702904],"domain_scores_gemma":[0.9959612,0.0014062615,0.0013432786,0.00014779287,0.00077812927,0.0003633633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011849971,0.00020715338,0.0014062554,0.00019160598,0.000057488876,0.000024686267,0.00009371799,0.00027183417,0.00010406035],"category_scores_gemma":[0.00092131144,0.00013549229,0.00022193963,0.00028272436,0.0001198244,0.0002363555,0.000021175165,0.0005469988,0.000002224213],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25946203,0.029273856,0.05855913,0.00048667475,0.0019304254,0.00051539904,0.0017807306,0.00013363738,0.0083856005,0.0000806984,0.011856322,0.62753546],"study_design_scores_gemma":[0.8078932,0.113139935,0.030028302,0.0007724127,0.0033475435,0.000084726686,0.00092233834,0.0019327247,0.0014499907,0.0002587118,0.039796166,0.00037390296],"about_ca_topic_score_codex":0.00013215543,"about_ca_topic_score_gemma":0.00024693864,"teacher_disagreement_score":0.62716156,"about_ca_system_score_codex":0.0003224486,"about_ca_system_score_gemma":0.0023606494,"threshold_uncertainty_score":0.5525215},"labels":[],"label_agreement":null},{"id":"W2255387339","doi":"10.1200/jco.2012.30.15_suppl.7511","title":"A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC):  NCIC Clinical Trials Group study BR29.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université Laval; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; Juravinski Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Clinical endpoint; Placebo; Progression-free survival; Interim analysis; Toxicity; Randomized controlled trial; Urology; Surgery; Chemotherapy; Confidence interval; Pathology","score_opus":0.11957790843673835,"score_gpt":0.4782846970651768,"score_spread":0.3587067886284384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255387339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98596346,0.00042999798,0.00011759313,0.00010950711,0.0020741336,0.0110006025,0.00008757576,0.00001596813,0.00020114846],"genre_scores_gemma":[0.9940466,0.0008118658,0.0029197983,0.000118882985,0.0015366821,0.0003275977,0.000045345707,0.00008335939,0.000109831715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9839493,0.0057046935,0.008136025,0.000557121,0.0010426841,0.0006101554],"domain_scores_gemma":[0.9818214,0.00853391,0.0073181908,0.0004526226,0.0010274961,0.00084633555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0134463925,0.00054545625,0.00820332,0.00037780683,0.000059797494,0.000017372231,0.00028984694,0.0006560523,0.00022621774],"category_scores_gemma":[0.0052137375,0.0002914649,0.0010762524,0.0004693614,0.00041278958,0.0004359267,0.000051837345,0.0012233147,0.0000015014598],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72536844,0.019816373,0.24069123,0.00012303445,0.0026874645,0.00006074015,0.0019591774,0.000054789965,0.000032842272,0.0000025650222,0.0000660015,0.009137349],"study_design_scores_gemma":[0.8540016,0.09223245,0.043710545,0.0005818217,0.00819582,0.000008860887,0.00062836445,0.000044510478,0.00010147059,0.0000026927733,0.00022503673,0.00026682916],"about_ca_topic_score_codex":0.0009506859,"about_ca_topic_score_gemma":0.0015525526,"teacher_disagreement_score":0.19698068,"about_ca_system_score_codex":0.0005387549,"about_ca_system_score_gemma":0.0049940078,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W2257288783","doi":"10.1200/jco.2009.27.15_suppl.e13509","title":"Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Regimen; Chemotherapy; Lung cancer; Ovarian cancer; Oncology; Endometrial cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Adenocarcinoma; Progressive disease; Gastroenterology","score_opus":0.04456309385165381,"score_gpt":0.511309083828003,"score_spread":0.4667459899763492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257288783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971012,0.000039527167,0.000026707263,0.001212423,0.00021133093,0.0004366153,0.0000016623385,0.0000032117098,0.00096731924],"genre_scores_gemma":[0.9987322,0.000018966413,0.00072296005,0.0004021251,0.00006935969,0.0000027108836,0.0000052120627,0.0000056757676,0.000040807143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978706,0.000121681536,0.001527775,0.000100533005,0.0002743547,0.000105010964],"domain_scores_gemma":[0.997782,0.00024500504,0.0012372922,0.00010367385,0.0005055497,0.00012651375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005501068,0.000077667566,0.00093427696,0.0001408677,0.000015485082,0.0000018920041,0.00005732477,0.000071644135,0.000021907916],"category_scores_gemma":[0.000573299,0.000048805417,0.00008522082,0.0001695669,0.000041499392,0.000112287824,0.0000067187775,0.00029380407,0.0000010690843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013702704,0.11017899,0.5594785,0.000009478378,0.00027858096,0.0002274254,0.0006313071,0.00011446788,0.00002560003,0.000046981495,0.0001415185,0.3151644],"study_design_scores_gemma":[0.096022375,0.18585709,0.7170678,0.00007057603,0.0002676115,0.0000071705585,0.00028818997,0.000019617019,0.000014082508,0.000099114164,0.0002531378,0.000033260556],"about_ca_topic_score_codex":0.0000064805076,"about_ca_topic_score_gemma":0.00001563193,"teacher_disagreement_score":0.31513113,"about_ca_system_score_codex":0.00013747462,"about_ca_system_score_gemma":0.0005216608,"threshold_uncertainty_score":0.19902273},"labels":[],"label_agreement":null},{"id":"W2259127335","doi":"10.1158/1078-0432.ccr-15-2218","title":"Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute; Universitat de Girona; Astellas Pharma US","keywords":"Medicine; Erlotinib; Internal medicine; Pharmacodynamics; Adverse effect; Nausea; Epidermal growth factor receptor; Oncology; Insulin-like growth factor 1 receptor; Cohort; Vomiting; Cancer; Pharmacology; Pharmacokinetics; Gastroenterology; Receptor","score_opus":0.11269773919679285,"score_gpt":0.5568681410234685,"score_spread":0.44417040182667566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259127335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687624,0.000109214365,0.000009964662,0.0006673242,0.00006463721,0.001873147,0.000037878806,0.00001503116,0.00034654266],"genre_scores_gemma":[0.9990876,0.00012999536,0.00009194514,0.00004955346,0.00008758249,0.00022431108,0.000013286218,0.000022797218,0.00029295142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790806,0.00021727277,0.0005797739,0.00041640032,0.0005798752,0.00029863088],"domain_scores_gemma":[0.9982997,0.00057051703,0.00011777039,0.00029745317,0.0005079349,0.0002065891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007206132,0.00011135023,0.00040690327,0.00016855155,0.00006707672,0.000009523602,0.00007130003,0.00006297772,0.000097108794],"category_scores_gemma":[0.0004178386,0.000063823,0.000034818302,0.00036242398,0.00025472732,0.00011847615,0.000057201312,0.0002619917,0.0000066649523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055046845,0.0068810787,0.80467755,0.000036904272,0.0000932175,0.000015511336,0.00051712606,0.0000026420582,0.000106587795,0.00001600797,0.00007822144,0.18207046],"study_design_scores_gemma":[0.05747981,0.015840078,0.925254,0.00045231485,0.00006323127,4.148794e-7,0.00039743353,0.000016377424,0.00016110583,0.000040539515,0.0002148843,0.00007984562],"about_ca_topic_score_codex":0.00021848828,"about_ca_topic_score_gemma":0.00037507678,"teacher_disagreement_score":0.18199062,"about_ca_system_score_codex":0.00015433003,"about_ca_system_score_gemma":0.0003711381,"threshold_uncertainty_score":0.26026264},"labels":[],"label_agreement":null},{"id":"W2259127997","doi":"10.1016/j.cllc.2016.01.002","title":"Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Cetuximab; T790M; Epidermal growth factor receptor; Amphiregulin; Medicine; Erlotinib; Cancer research; Lung cancer; Gefitinib; Tyrosine kinase; Pharmacology; Internal medicine; Cancer; Receptor; Colorectal cancer","score_opus":0.028141009738623202,"score_gpt":0.3555576282809079,"score_spread":0.3274166185422847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259127997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97992134,0.0030867145,0.0005032387,0.011776711,0.00070376624,0.0021370156,0.0014169199,0.00018612052,0.00026819386],"genre_scores_gemma":[0.9890493,0.0006851928,0.0019554417,0.0034538785,0.00052856334,0.00083647313,0.000115167495,0.000116128926,0.00325986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602795,0.00017148636,0.0013869493,0.0010625654,0.0005235184,0.00082753925],"domain_scores_gemma":[0.9972815,0.0004972501,0.00030647384,0.00062196894,0.00044709299,0.0008457447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022378576,0.00047210619,0.0009330134,0.0002608291,0.00012454232,0.000036517016,0.00019440083,0.0003319023,0.0003621686],"category_scores_gemma":[0.0011443406,0.00033497022,0.00029592108,0.0005658604,0.00019500585,0.00031403027,0.00014391332,0.0004029409,0.000092666945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060785143,0.0024295843,0.78718036,0.0005845594,0.0007195442,0.00014927535,0.0021536003,0.000060586044,0.099716544,0.00014288267,0.09051852,0.010266042],"study_design_scores_gemma":[0.0968106,0.0045502377,0.5877466,0.012028889,0.002530837,0.000016368494,0.0004369566,0.004936689,0.27017033,0.00026226896,0.0161389,0.0043712975],"about_ca_topic_score_codex":0.00014780686,"about_ca_topic_score_gemma":0.00055500475,"teacher_disagreement_score":0.19943373,"about_ca_system_score_codex":0.0012601243,"about_ca_system_score_gemma":0.0009806266,"threshold_uncertainty_score":0.99991024},"labels":[],"label_agreement":null},{"id":"W2262699108","doi":"10.1200/jco.2007.25.18_suppl.7649","title":"IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Gemcitabine; Toxicity; Adverse effect; Internal medicine; Pharmacokinetics; Dosing; Gastroenterology; Urology; Chemotherapy; Pharmacology","score_opus":0.06008348037096114,"score_gpt":0.46732605000908123,"score_spread":0.4072425696381201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262699108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952094,0.00014391172,0.00009956182,0.00014636466,0.00066202803,0.00367713,0.000028351204,0.0000035403966,0.000029694122],"genre_scores_gemma":[0.9985855,0.000113683884,0.00090627314,0.000101156045,0.0001999969,0.00004780236,0.0000051414977,0.000027856542,0.000012580294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925494,0.0016000457,0.0045618373,0.0003454176,0.0006858353,0.00025742227],"domain_scores_gemma":[0.9923689,0.002702745,0.0037686871,0.00024023667,0.0006975744,0.00022187123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064040096,0.00024306038,0.0025209633,0.00024212414,0.00004084135,0.0000071335426,0.00016574938,0.00024297436,0.000023943867],"category_scores_gemma":[0.0022296987,0.00013103106,0.0002267976,0.00046597028,0.00016448332,0.00016889811,0.000055541477,0.00095728564,1.8430103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032843027,0.059939653,0.87608486,0.00006592434,0.00068728195,0.000054709766,0.0037722874,0.000025989319,0.00010124315,0.0000017736405,0.00001624775,0.026406994],"study_design_scores_gemma":[0.20080517,0.089796506,0.7053638,0.00027508475,0.0011139454,0.0000019437564,0.0024274443,0.000024247558,0.00005429648,0.0000043082346,0.000043006123,0.000090263224],"about_ca_topic_score_codex":0.00034190348,"about_ca_topic_score_gemma":0.00360162,"teacher_disagreement_score":0.17072108,"about_ca_system_score_codex":0.00028803584,"about_ca_system_score_gemma":0.0009968886,"threshold_uncertainty_score":0.5343292},"labels":[],"label_agreement":null},{"id":"W2263836274","doi":"10.1093/annonc/mdu349.29","title":"Epidermal Growth Factor Receptor (Egfr) and Abcg2 Polymorphisms and Treatment Outcome in the Randomized Phase III Torch Trial in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ontario Institute for Cancer Research; Lakeridge Health; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; Lung cancer; Docetaxel; Epidermal growth factor receptor; Pharmacology; Gastroenterology; Cancer","score_opus":0.04311287922148474,"score_gpt":0.40817573337076535,"score_spread":0.36506285414928064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263836274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99088633,0.00094908936,0.00002412296,0.003700626,0.00026402902,0.0027623859,0.00005250586,0.000006779797,0.001354111],"genre_scores_gemma":[0.99627316,0.0014090958,0.00020485705,0.0011231191,0.00009994617,0.000635922,0.00004602753,0.0000143307225,0.00019351557],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984391,0.0003041271,0.00059092656,0.00027354405,0.00011985213,0.00027248228],"domain_scores_gemma":[0.9987098,0.00070878473,0.0002451377,0.00015063146,0.00008533706,0.000100298996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003731679,0.000194962,0.0009764127,0.0001519364,0.000045136276,0.0000073755896,0.000060306695,0.000114027665,0.000051704195],"category_scores_gemma":[0.00013978979,0.00011832054,0.00010273149,0.00010817684,0.00011517568,0.0000715955,0.000021125334,0.000106549516,9.913445e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53970474,0.006895635,0.25024116,0.0001415753,0.00049851293,0.000036334324,0.017530989,0.0000096240465,0.0010176866,0.00017142699,0.0005497629,0.18320253],"study_design_scores_gemma":[0.95418984,0.006380541,0.035601377,0.00006557894,0.00028818386,0.000002072312,0.00020849219,0.00013084704,0.0010029733,0.000037471673,0.0019582969,0.00013429842],"about_ca_topic_score_codex":0.0019356245,"about_ca_topic_score_gemma":0.0003851061,"teacher_disagreement_score":0.41448513,"about_ca_system_score_codex":0.00014251012,"about_ca_system_score_gemma":0.00019378688,"threshold_uncertainty_score":0.48249716},"labels":[],"label_agreement":null},{"id":"W2264190290","doi":"","title":"Pharmacokinetics of ARRY-543 from a Phase 1 study in cancer patients","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pharmacokinetics; Dosing; Medicine; Pharmacology; Animal science; Chemistry; Internal medicine; Biology","score_opus":0.032733211282353625,"score_gpt":0.412456535462635,"score_spread":0.3797233241802814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264190290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932149,0.00403981,0.0006433199,0.0002233949,0.0003019819,0.0010004583,0.00017080871,0.000020760292,0.00038456384],"genre_scores_gemma":[0.9977089,0.00035806984,0.0002297567,0.0013526205,0.00006892904,0.000106222404,0.000055871824,0.000040097446,0.000079523044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987268,0.0000319656,0.00037458714,0.00025835124,0.0003496098,0.00025867886],"domain_scores_gemma":[0.99933785,0.000027344688,0.00012720044,0.00024317372,0.00017238733,0.00009202986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008115506,0.00017940364,0.0003003139,0.00013134954,0.000026598133,0.0000072327816,0.000088660796,0.000059318074,0.00019802642],"category_scores_gemma":[0.000003984046,0.00015783634,0.00007498646,0.0003393838,0.000043751952,0.000031762138,0.000022224729,0.00014170249,0.0000021790654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093962904,0.008130692,0.78807306,0.000040443905,0.0015282212,0.00014200117,0.005229324,0.0001236751,0.07236354,0.00001333273,0.00004468781,0.12337141],"study_design_scores_gemma":[0.057826135,0.002720356,0.5933349,0.0002864378,0.003913835,0.0000012454556,0.0011346198,0.00036463846,0.3248311,0.00014464908,0.014929721,0.0005123337],"about_ca_topic_score_codex":0.0024158033,"about_ca_topic_score_gemma":0.0006578224,"teacher_disagreement_score":0.25246754,"about_ca_system_score_codex":0.00030741064,"about_ca_system_score_gemma":0.0001859094,"threshold_uncertainty_score":0.6436379},"labels":[],"label_agreement":null},{"id":"W2264286082","doi":"10.1200/jco.2006.24.18_suppl.7154","title":"Compliance of adjuvant chemotherapy in non-small cell lung cancer (NSCLC); No longer an issue","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Carboplatin; Vinorelbine; Chemotherapy; Internal medicine; Febrile neutropenia; Neutropenia; Lung cancer; Oncology; Surgery; Cisplatin","score_opus":0.06479395018166687,"score_gpt":0.4942472899670299,"score_spread":0.42945333978536304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264286082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776303,0.0022053989,0.0001971935,0.003806388,0.0010686495,0.0002984931,0.000008646482,0.0000045695183,0.014780338],"genre_scores_gemma":[0.9867919,0.0010769292,0.006109514,0.002162494,0.001608877,0.000008698242,0.000004941398,0.000019632762,0.0022170087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775994,0.00010545828,0.0016093081,0.00015587344,0.00018304195,0.00018635431],"domain_scores_gemma":[0.99779266,0.00033415406,0.0011070743,0.00015997469,0.0004383379,0.00016778022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066465815,0.00011539746,0.0011065159,0.000090681155,0.000017338712,0.0000037463224,0.00011792759,0.00021104624,0.00042529125],"category_scores_gemma":[0.00008409267,0.000081844686,0.00022970288,0.00011867902,0.000103056314,0.00007944824,0.000012033029,0.0004322378,0.0000116813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035341606,0.008706448,0.838797,0.0002142379,0.0003652111,0.00057268684,0.0005621533,0.00038672335,0.0024261898,0.000029024884,0.018853905,0.12555225],"study_design_scores_gemma":[0.01835197,0.005744454,0.9225043,0.00039514675,0.00042684228,0.00004110352,0.00009191717,0.00074772374,0.00058924046,0.00007059382,0.05093079,0.000105903615],"about_ca_topic_score_codex":0.0005270506,"about_ca_topic_score_gemma":0.0003843045,"teacher_disagreement_score":0.12544635,"about_ca_system_score_codex":0.00021898844,"about_ca_system_score_gemma":0.0013548348,"threshold_uncertainty_score":0.4656641},"labels":[],"label_agreement":null},{"id":"W2265262314","doi":"10.1200/jco.2007.25.18_suppl.7678","title":"Cost-effectiveness analysis (CEA) of third-line erlotinib therapy compared to best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Oncology; Lung cancer; Internal medicine; Cost effectiveness; Docetaxel; Clinical endpoint; Cost-effectiveness analysis; Cancer; Surgery; Epidermal growth factor receptor; Randomized controlled trial","score_opus":0.08738385517410992,"score_gpt":0.5118081672593614,"score_spread":0.4244243120852515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265262314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989819,0.0015542414,0.004422558,0.00035385293,0.00070768205,0.0022879196,0.00012901083,0.0000058677,0.0007198902],"genre_scores_gemma":[0.99242425,0.0007699563,0.0053962055,0.0006191663,0.0003194305,0.00011767807,0.000039242124,0.000024654808,0.00028940695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968118,0.00018754962,0.0021376847,0.00028595983,0.0002509517,0.0003260669],"domain_scores_gemma":[0.99418765,0.0022681141,0.0014337626,0.00016965656,0.0015731597,0.00036762768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017955675,0.00013506819,0.0021332204,0.00020769506,0.00005460324,0.000015564761,0.00014492405,0.0002554415,0.0000975602],"category_scores_gemma":[0.0004985158,0.0001438831,0.00071629987,0.00057856017,0.00009602451,0.000073846684,0.000024296098,0.0004066262,9.425645e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00585629,0.0028115485,0.83197725,0.00014793962,0.0019326059,0.0002632109,0.001060944,0.0021133758,0.00033434623,8.0285446e-7,0.00036199688,0.15313968],"study_design_scores_gemma":[0.028867394,0.011145282,0.9472187,0.00045651945,0.0030881402,0.000016678781,0.0023656054,0.00017157556,0.00071469916,0.000012803959,0.00580122,0.00014137637],"about_ca_topic_score_codex":0.008797059,"about_ca_topic_score_gemma":0.18080623,"teacher_disagreement_score":0.17200917,"about_ca_system_score_codex":0.0006312995,"about_ca_system_score_gemma":0.0022151645,"threshold_uncertainty_score":0.99780345},"labels":[],"label_agreement":null},{"id":"W2268267848","doi":"10.1016/j.jtho.2015.11.014","title":"First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":356,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Lung cancer; Oncology; Internal medicine; Pemetrexed; Epidermal growth factor receptor; Adenocarcinoma; Chemotherapy; Hazard ratio; Cisplatin; Erlotinib; Cancer; Confidence interval","score_opus":0.01940608127207443,"score_gpt":0.3866569509001219,"score_spread":0.3672508696280475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268267848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675233,0.00067198096,0.00029144363,0.011522865,0.00020454924,0.0003649797,0.00010591247,0.0000050597178,0.000080905396],"genre_scores_gemma":[0.99268925,0.0005505451,0.006026604,0.00040218938,0.00011665595,0.000021198915,0.000014128308,0.000019472549,0.0001599553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914455,0.00007332077,0.0003433982,0.00014257221,0.00012740854,0.00016875521],"domain_scores_gemma":[0.998802,0.00042368393,0.0003510541,0.00007710081,0.00019424487,0.00015188102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013567701,0.00013598424,0.00041669444,0.00015985713,0.000059521473,0.000009526331,0.00004250028,0.00007208869,0.00010459694],"category_scores_gemma":[0.00006364108,0.00007819427,0.000039461578,0.00010593667,0.00008267796,0.00013732085,0.000015452764,0.00012382417,7.7836876e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007654377,0.0009353783,0.85719454,0.00013856296,0.0005987595,0.00007847694,0.0016013248,0.000021096053,0.0011671478,0.000005875288,0.00066710176,0.12993734],"study_design_scores_gemma":[0.029308137,0.006627078,0.95410967,0.00037301859,0.0009390177,0.000052679115,0.00019084454,0.000041523697,0.0048733214,0.000034261833,0.0032677108,0.00018276715],"about_ca_topic_score_codex":0.00010279066,"about_ca_topic_score_gemma":0.0003862753,"teacher_disagreement_score":0.12975456,"about_ca_system_score_codex":0.0003243034,"about_ca_system_score_gemma":0.0002858175,"threshold_uncertainty_score":0.318867},"labels":[],"label_agreement":null},{"id":"W2269217367","doi":"10.1200/jco.2006.24.18_suppl.7507","title":"Recommendations for revised response criteria for malignant lymphoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Mantle cell lymphoma; Follicular lymphoma; Internal medicine; Oncology; Clinical endpoint; Clinical trial; Non-Hodgkin's lymphoma; PET-CT; Nuclear medicine; Positron emission tomography","score_opus":0.17071722134882844,"score_gpt":0.5605959368862315,"score_spread":0.3898787155374031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269217367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6065307,0.0011666092,0.027498715,0.35085154,0.0061424375,0.0024701522,0.00023703474,0.000033303942,0.005069462],"genre_scores_gemma":[0.8022125,0.00023904993,0.17949128,0.0074366517,0.0038771413,0.00013704952,0.00007670374,0.000036424528,0.0064932522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778056,0.00025142287,0.0016046112,0.00011902866,0.00009297626,0.00015142621],"domain_scores_gemma":[0.9937888,0.0043897945,0.0009369627,0.00011511733,0.00062534073,0.00014400882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003042526,0.0000790572,0.0007225033,0.00008678462,0.000081250735,0.000009535622,0.00006274411,0.0001624138,0.000092155286],"category_scores_gemma":[0.0036789335,0.0000543786,0.00049611006,0.00006105659,0.000058326354,0.000067328685,0.000008427922,0.000099188415,0.0000040659615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049392886,0.00418645,0.0032668307,0.00008110505,0.00070399715,0.00010955088,0.00010789896,0.000005410155,0.0013293491,0.0024803118,0.58792233,0.35041386],"study_design_scores_gemma":[0.019098105,0.011344182,0.04618002,0.00009804962,0.0008871921,0.00014255696,0.0000731011,0.000075193406,0.00013295164,0.0029295348,0.9189832,0.000055875782],"about_ca_topic_score_codex":0.000009709366,"about_ca_topic_score_gemma":0.000008252932,"teacher_disagreement_score":0.35035798,"about_ca_system_score_codex":0.0002130841,"about_ca_system_score_gemma":0.0017351034,"threshold_uncertainty_score":0.44042927},"labels":[],"label_agreement":null},{"id":"W2270007049","doi":"10.1200/jco.2006.24.18_suppl.7051","title":"Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study JBR.10","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Vinorelbine; Medicine; Chemotherapy; Oncology; Internal medicine; Regimen; Cisplatin; Lung cancer; Chemotherapy regimen; Paclitaxel; Cancer","score_opus":0.07838231343958373,"score_gpt":0.47967867436520883,"score_spread":0.4012963609256251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270007049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927764,0.00208955,0.00004195116,0.002550362,0.0011328774,0.0006827137,0.0001619091,0.0000020360992,0.0005622106],"genre_scores_gemma":[0.99562794,0.001317585,0.00076248863,0.0007714898,0.00078325794,0.00003071811,0.00002294632,0.000014070595,0.00066951703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99361336,0.0005040677,0.0047515947,0.0003078842,0.0006230033,0.00020006679],"domain_scores_gemma":[0.99271214,0.0027792894,0.0034563416,0.000206116,0.00065649854,0.00018962873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042822766,0.00018960111,0.0029757938,0.0001902351,0.00006382919,0.0000073045035,0.00022039135,0.00028066587,0.0003818155],"category_scores_gemma":[0.0006823177,0.000111736575,0.0005510406,0.00046145383,0.00015678222,0.00009231708,0.000059590646,0.00060699653,1.15943735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035783702,0.0036656163,0.9659996,0.000029168024,0.0031885288,0.000039365415,0.00022355706,0.0069320314,0.00086317165,0.000012180687,0.003937605,0.011530819],"study_design_scores_gemma":[0.026433256,0.0016521297,0.9578468,0.00023325763,0.0057668905,0.000002224585,0.00015705214,0.003191604,0.00031796205,0.00004362649,0.0042547975,0.000100352554],"about_ca_topic_score_codex":0.21805777,"about_ca_topic_score_gemma":0.558818,"teacher_disagreement_score":0.34076023,"about_ca_system_score_codex":0.0005613783,"about_ca_system_score_gemma":0.005694687,"threshold_uncertainty_score":0.9999421},"labels":[],"label_agreement":null},{"id":"W2271051170","doi":"10.1016/j.jtho.2015.11.010","title":"Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Queen's University; University of Ottawa; Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Epidermal growth factor receptor; Placebo; Transversion; Cancer research; Cancer; Mutation; Confidence interval; Pathology; Biology; Genetics; Colorectal cancer","score_opus":0.009590676305780855,"score_gpt":0.329713282366593,"score_spread":0.3201226060608121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271051170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983259,0.0005014361,0.0001348078,0.00022192445,0.00006877883,0.00062550296,0.00008392003,0.0000025944787,0.00003513088],"genre_scores_gemma":[0.9989492,0.000038785944,0.0008703335,0.000026669448,0.000024194758,0.000015449274,0.00004411593,0.000012033988,0.000019199135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891084,0.0001604598,0.00042261108,0.00013201953,0.00024284908,0.00013120212],"domain_scores_gemma":[0.9979382,0.0001274595,0.00086377416,0.000072328796,0.00086801685,0.00013018264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015142573,0.00012267132,0.0004946887,0.0003573153,0.000026877453,0.000005849427,0.000031392647,0.00007421874,0.0000066056273],"category_scores_gemma":[0.000121572186,0.00006810601,0.000042752148,0.00062834873,0.0001122242,0.0001328334,0.000013387188,0.00013697158,4.637426e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043521193,0.0005584096,0.9848468,0.00011679534,0.0013356955,0.000023957573,0.0039809905,0.001643635,0.0003383185,0.0000013361735,0.000013498214,0.0027884583],"study_design_scores_gemma":[0.0048498223,0.005195856,0.97378224,0.00026962959,0.010033601,0.000011106059,0.0007884811,0.0011356774,0.0038622417,0.0000058495502,0.0000034348338,0.00006204909],"about_ca_topic_score_codex":0.00048654238,"about_ca_topic_score_gemma":0.00026426802,"teacher_disagreement_score":0.011064534,"about_ca_system_score_codex":0.0004037242,"about_ca_system_score_gemma":0.0007252447,"threshold_uncertainty_score":0.27772826},"labels":[],"label_agreement":null},{"id":"W2273754125","doi":"10.1200/jop.2015.008813","title":"Implementation of a Lung Cancer Nurse Navigator Enhances Patient Care and Delivery of Systemic Therapy at the British Columbia Cancer Agency, Vancouver","year":2016,"lang":"en","type":"article","venue":"Journal of Oncology Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Medicine; Cancer; Agency (philosophy); Lung cancer; Nursing; Family medicine; Intensive care medicine; Oncology; Internal medicine","score_opus":0.01082037320235006,"score_gpt":0.38737490530446067,"score_spread":0.3765545321021106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273754125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95997393,0.037569303,0.00000997244,0.00087986153,0.0007438785,0.00044749814,0.00009189254,0.0000023605858,0.00028128017],"genre_scores_gemma":[0.9660445,0.032966513,0.00019688955,0.00030796966,0.000105456595,0.00005820794,0.00000131653,0.000009872354,0.0003092787],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99890834,0.00015493498,0.00047769994,0.0001037251,0.00024413635,0.000111172645],"domain_scores_gemma":[0.9971277,0.0003841649,0.0013660656,0.000090580834,0.0009688067,0.00006264126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018632427,0.00006767063,0.00029873202,0.00002448811,0.00012781365,0.000016027723,0.000051394294,0.000057635258,0.00040167494],"category_scores_gemma":[0.000056532008,0.00004724733,0.000074404365,0.000076962606,0.00010565834,0.00028024515,0.000015387552,0.00009145528,2.6515687e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008278516,0.00024608054,0.23494306,0.00016666991,0.0014712356,0.000097780285,0.011491789,0.0000046918126,0.030159207,0.0000012180665,0.028026558,0.69256383],"study_design_scores_gemma":[0.04301468,0.022870367,0.45205128,0.008245815,0.012680046,0.004769107,0.15603355,0.000008687098,0.04599518,0.000035742054,0.25377303,0.0005225175],"about_ca_topic_score_codex":0.027891831,"about_ca_topic_score_gemma":0.070711374,"teacher_disagreement_score":0.69204134,"about_ca_system_score_codex":0.00082095084,"about_ca_system_score_gemma":0.0014203668,"threshold_uncertainty_score":0.97858155},"labels":[],"label_agreement":null},{"id":"W2273853937","doi":"10.1016/j.lungcan.2016.02.013","title":"ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Cetuximab; In vivo; Monoclonal antibody; A549 cell; Epidermal growth factor receptor; Chemistry; Cancer research; Apoptosis; Pharmacology; Receptor; Medicine; Biology; Antibody; Immunology; Biochemistry","score_opus":0.0188192176814274,"score_gpt":0.35069398863298906,"score_spread":0.33187477095156165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273853937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858063,0.0021374475,0.0028087208,0.0016461915,0.00044232534,0.0012893878,0.00036579813,0.000083263425,0.005420579],"genre_scores_gemma":[0.991749,0.0004423235,0.0004025897,0.00059746904,0.00041837397,0.0007034887,0.000031008058,0.000079746605,0.005576032],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979622,0.00002652112,0.00035706363,0.00067949196,0.00033750702,0.0006372358],"domain_scores_gemma":[0.9989568,0.000050418083,0.00019150016,0.00041482234,0.00015037345,0.00023611348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011129805,0.0003697995,0.00055474014,0.0002136228,0.00015342132,0.00003373976,0.00014705818,0.00012814104,0.00045682862],"category_scores_gemma":[0.0000072575885,0.00026425192,0.0001580681,0.0003356902,0.00008251202,0.0003548334,0.00007926124,0.00025017315,0.000009579949],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002328236,0.0010585408,0.44502974,0.0005991514,0.0004528946,0.00013416115,0.0013212829,0.0014225787,0.54385227,0.00023303802,0.002830837,0.0028326858],"study_design_scores_gemma":[0.03270685,0.0004055232,0.7994503,0.005872838,0.0023738162,0.000042852003,0.00016453602,0.0290117,0.12509976,0.00025285833,0.002955091,0.0016639156],"about_ca_topic_score_codex":0.009842866,"about_ca_topic_score_gemma":0.0026407759,"teacher_disagreement_score":0.41875252,"about_ca_system_score_codex":0.0016253953,"about_ca_system_score_gemma":0.00080509245,"threshold_uncertainty_score":0.999981},"labels":[],"label_agreement":null},{"id":"W2274356777","doi":"10.1200/jco.2005.23.16_suppl.7033","title":"Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Lung cancer; Hazard ratio; Regimen; Univariate analysis; Placebo; Performance status; Proportional hazards model; Multivariate analysis; Cancer; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.04783894533645828,"score_gpt":0.41836067420291057,"score_spread":0.3705217288664523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274356777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252033,0.0013229963,0.0007891143,0.0013735921,0.001410977,0.00054421014,0.00013517207,0.0000062783333,0.0018972995],"genre_scores_gemma":[0.98848325,0.0002689,0.00825387,0.00093418086,0.0013420548,0.000029797706,0.000026069205,0.000028844186,0.0006330422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793506,0.00006188473,0.0012651044,0.00021222443,0.00033734072,0.00018839112],"domain_scores_gemma":[0.996017,0.000969414,0.001825263,0.00016011528,0.0007822817,0.0002459522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003806692,0.00014803515,0.0010180154,0.000079466896,0.00003820088,0.0000026273312,0.0001194661,0.00025214275,0.00019470128],"category_scores_gemma":[0.00017271987,0.00009588299,0.00032032264,0.00004625439,0.000103525395,0.00011443573,0.000027853597,0.00038999197,6.3679596e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008081551,0.003060949,0.9464616,0.00006285203,0.00094829866,0.000016750977,0.0027537602,0.00019976932,0.00012041231,0.000004097223,0.0074430783,0.030846864],"study_design_scores_gemma":[0.029283766,0.00985712,0.91879725,0.0007032587,0.0027152675,0.0000023755028,0.00032889156,0.0004158558,0.00057631434,0.000023444605,0.037172418,0.00012401446],"about_ca_topic_score_codex":0.00018132257,"about_ca_topic_score_gemma":0.00011446628,"teacher_disagreement_score":0.030722851,"about_ca_system_score_codex":0.00083437166,"about_ca_system_score_gemma":0.0018253656,"threshold_uncertainty_score":0.3909995},"labels":[],"label_agreement":null},{"id":"W2274765772","doi":"10.1093/annonc/mdu347.5","title":"Egfr Del19/L858R Activating Mutation (M+) Subgroup in Radiant: Baseline Characteristics, Prognostic Role, and Disease-Free Survival (Dfs) By Stage","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Distributed File System; Stage (stratigraphy); Oncology; Internal medicine; Disease; Baseline (sea); Subgroup analysis; Mutation; Survival analysis; Overall survival; Meta-analysis; Genetics","score_opus":0.027277831118630698,"score_gpt":0.3616885405395957,"score_spread":0.334410709420965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274765772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657864,0.0005604738,0.0005053774,0.009614331,0.00015479745,0.00049891113,0.00025585576,0.000026106263,0.00180552],"genre_scores_gemma":[0.99742854,0.00022134352,0.00036916047,0.0009907259,0.00014403218,0.00005106941,0.00045380564,0.00002002098,0.00032128548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988949,0.00014288217,0.00034692805,0.00023781054,0.00014355358,0.00023394426],"domain_scores_gemma":[0.99874544,0.00047741484,0.00019652289,0.0001984638,0.00015585341,0.00022631812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039927708,0.00013071336,0.00036790431,0.000116641706,0.00004865475,0.00001003187,0.00006161701,0.0000781023,0.00004253643],"category_scores_gemma":[0.0018757763,0.00010747516,0.000039587067,0.00012165322,0.00008577111,0.00010885561,0.000031803655,0.00011373684,0.0000037100826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010609153,0.0016887832,0.5536021,0.00041136204,0.00024422523,0.00018966253,0.0014684988,0.000019834459,0.0027698358,0.0012801748,0.003213253,0.43405136],"study_design_scores_gemma":[0.0064408127,0.002423984,0.93317205,0.00020923073,0.00023621191,0.000017405297,0.00057279575,0.0039086468,0.00064531725,0.0009596898,0.051177844,0.00023602966],"about_ca_topic_score_codex":0.00032256873,"about_ca_topic_score_gemma":0.00014647728,"teacher_disagreement_score":0.43381533,"about_ca_system_score_codex":0.000060280756,"about_ca_system_score_gemma":0.00023278249,"threshold_uncertainty_score":0.43827102},"labels":[],"label_agreement":null},{"id":"W2275071246","doi":"10.1093/annonc/mdu349.85","title":"Effective Knowledge Dissemination Improves Histological Classification of Non Small Cell Lung Cancer: Reducing the Rates of Nsclc – not Otherwise Specified (Nos)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; non-small cell lung cancer (NSCLC); Lung cancer; Oncology; Internal medicine; Pathology","score_opus":0.048154059760466536,"score_gpt":0.4275572446699737,"score_spread":0.37940318490950714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275071246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969372,0.0014426596,0.00046794506,0.0021090144,0.00018368813,0.0007899212,0.000015186394,0.000009100843,0.025610525],"genre_scores_gemma":[0.99864113,0.00027576782,0.0002558007,0.0000777813,0.000096745986,0.0001381342,0.000016864835,0.000010542837,0.0004872482],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99913996,0.00013690897,0.0003355865,0.00018114073,0.00008064129,0.0001257661],"domain_scores_gemma":[0.9982631,0.00064910867,0.0004588796,0.0002030782,0.00038626316,0.00003952271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032740217,0.000100525205,0.0003803035,0.000081116246,0.000042275627,0.0000018730192,0.00008535811,0.00011272836,0.000028284201],"category_scores_gemma":[0.0001479294,0.00006483426,0.00009493366,0.00014245458,0.00017773536,0.000030974585,0.000019204579,0.000090071866,0.0000016372734],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009259775,0.0012266607,0.0071113487,0.00040200638,0.00023531896,0.0000011442287,0.005257714,0.000025591342,0.6216783,0.001184824,0.0024995701,0.35945153],"study_design_scores_gemma":[0.0015899575,0.0032394396,0.51955295,0.00021701073,0.00047064284,0.0000025861725,0.0005638406,0.0027093184,0.46877798,0.00008887194,0.0027031866,0.0000841827],"about_ca_topic_score_codex":0.00025460013,"about_ca_topic_score_gemma":0.00008483566,"teacher_disagreement_score":0.51244164,"about_ca_system_score_codex":0.000106857246,"about_ca_system_score_gemma":0.00021104219,"threshold_uncertainty_score":0.26438645},"labels":[],"label_agreement":null},{"id":"W2276317671","doi":"10.1021/acs.jmedchem.5b00840","title":"Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Science Foundation of Liaoning Province; National Natural Science Foundation of China","keywords":"T790M; Osimertinib; Epidermal growth factor receptor; Chemistry; EGFR inhibitors; Small molecule; Mutant; Cancer research; Tyrosine kinase; Pharmacology; Lung cancer; Kinase; Drug resistance; Mutation; Receptor; Gefitinib; Biochemistry; Erlotinib; Medicine; Biology; Internal medicine; Genetics; Gene","score_opus":0.019665695048410207,"score_gpt":0.2858173852410763,"score_spread":0.2661516901926661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2276317671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95415103,0.02707495,0.00001917448,0.00795598,0.000060037466,0.00014445743,0.000003867851,0.0000037117795,0.010586782],"genre_scores_gemma":[0.9918443,0.006879513,0.00035651642,0.00009467609,0.0002029768,0.000016811337,0.0000010864865,0.00001377141,0.00059032236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891114,0.000020639858,0.0004316008,0.00015779502,0.0003192877,0.00015951427],"domain_scores_gemma":[0.99899906,0.00019567815,0.00034047267,0.00012628955,0.00020829074,0.00013023154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032508778,0.00014123667,0.00029799866,0.00006383525,0.00003912068,0.0000035625735,0.00009029437,0.000071694376,0.00003306896],"category_scores_gemma":[0.00016659508,0.00007175931,0.000054428358,0.0000871466,0.00010252278,0.00002936545,0.00001877571,0.0002181348,4.5887683e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018528505,0.0012486835,0.021656016,0.0024871533,0.0012069141,0.0005288952,0.07010148,0.0000046460113,0.8625704,0.00004816165,0.00178234,0.036512442],"study_design_scores_gemma":[0.015953893,0.00048442773,0.12050682,0.020115487,0.0006307037,0.00007905093,0.042571828,0.000014573419,0.797002,0.00004035096,0.0022087677,0.0003920889],"about_ca_topic_score_codex":0.0000053918,"about_ca_topic_score_gemma":0.000059563547,"teacher_disagreement_score":0.09885081,"about_ca_system_score_codex":0.00040354033,"about_ca_system_score_gemma":0.0005858846,"threshold_uncertainty_score":0.29262596},"labels":[],"label_agreement":null},{"id":"W2277339257","doi":"10.1200/jco.2009.27.15_suppl.7501","title":"Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinorelbine; Internal medicine; Hazard ratio; Log-rank test; Randomization; Cisplatin; Randomized controlled trial; Lung cancer; Oncology; Stage (stratigraphy); Chemotherapy; Survival analysis; Adjuvant therapy; Surgery; Confidence interval","score_opus":0.13055816293999017,"score_gpt":0.5077501815159932,"score_spread":0.377192018576003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277339257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528354,0.0003389656,0.00028672683,0.0013783517,0.0005737355,0.000845049,0.000049004844,0.000004288777,0.0012403328],"genre_scores_gemma":[0.99696624,0.00061476295,0.001590364,0.0001623029,0.00021674948,0.000010375826,0.00008252372,0.000008732099,0.00034792835],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99528134,0.0006465141,0.0033573036,0.00019630509,0.00034038245,0.00017812975],"domain_scores_gemma":[0.9928418,0.0030418239,0.0030230505,0.00017066783,0.0007360634,0.00018662047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028988945,0.00015289534,0.003286666,0.00046298536,0.00003596165,0.0000049253476,0.000102077174,0.00025696552,0.00030147133],"category_scores_gemma":[0.0018390827,0.00010897697,0.00060238707,0.0007505036,0.00015447906,0.00008684616,0.000025048887,0.00041991513,2.0278597e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9716196,0.004715554,0.0074002785,0.000031158288,0.0040849065,0.000085948246,0.00050529116,0.00052357087,0.0013271192,0.000044398887,0.00034611727,0.009316032],"study_design_scores_gemma":[0.8905328,0.018473316,0.068365425,0.000087914115,0.0113026295,0.0000014277168,0.000115223826,0.010389953,0.00013986934,0.000017048855,0.0004919538,0.00008244548],"about_ca_topic_score_codex":0.0006832875,"about_ca_topic_score_gemma":0.00079198886,"teacher_disagreement_score":0.08108683,"about_ca_system_score_codex":0.00018694522,"about_ca_system_score_gemma":0.0015508009,"threshold_uncertainty_score":0.44439518},"labels":[],"label_agreement":null},{"id":"W2278057905","doi":"10.1200/jco.2004.22.90140.7022","title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Erlotinib Hydrochloride; Regimen; Chemotherapy; Pemetrexed; Oncology; Carboplatin; Chemotherapy regimen; Placebo; Randomized controlled trial; Gastroenterology; Epidermal growth factor receptor; Cancer; Cisplatin; Pathology","score_opus":0.0520902160985434,"score_gpt":0.4512543726723138,"score_spread":0.39916415657377036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278057905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838412,0.00062289083,0.00038221007,0.0030237855,0.002516264,0.009243582,0.00015756475,0.000008217088,0.00020429921],"genre_scores_gemma":[0.98917866,0.0007391328,0.005961256,0.0008584893,0.0023913484,0.00052405015,0.000048729453,0.000057456837,0.000240867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98441225,0.0018985777,0.011313321,0.00050311023,0.0013955138,0.00047724225],"domain_scores_gemma":[0.9779771,0.010378094,0.009172579,0.0003022794,0.0016901628,0.0004797676],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013263103,0.00047327485,0.00976462,0.00037981503,0.000064212196,0.000009384715,0.00033355007,0.00067011465,0.00020640588],"category_scores_gemma":[0.01694616,0.00028304636,0.002164645,0.0005172906,0.00035768843,0.00023383838,0.000043651595,0.0011681177,2.8714894e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94185287,0.009386052,0.0054785777,0.00015338098,0.0059142946,0.00009509577,0.0005438735,0.02916705,0.00001501774,0.000015084484,0.00039538692,0.0069832886],"study_design_scores_gemma":[0.9635171,0.025429364,0.0013542911,0.0012232303,0.0049834717,0.000005418561,0.00014106379,0.0016688167,0.000046356283,0.000046523783,0.001354061,0.00023030085],"about_ca_topic_score_codex":0.0104246745,"about_ca_topic_score_gemma":0.044781245,"teacher_disagreement_score":0.04032827,"about_ca_system_score_codex":0.0011164735,"about_ca_system_score_gemma":0.041444745,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W2278983443","doi":"10.1038/bjc.2016.22","title":"Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients","year":2016,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; Juravinski Cancer Centre; Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Credit Valley Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; Toronto General Hospital; Toronto East General Hospital; York Central Hospital; University Health Network","funders":"University of Toronto; University Health Network","keywords":"Hazard ratio; Medicine; Internal medicine; Odds ratio; Oncology; Epidermal growth factor receptor; Mutation; Cohort; Population; Proportional hazards model; Confidence interval; Cancer; Biology; Genetics; Gene","score_opus":0.015872836115168393,"score_gpt":0.385789185036649,"score_spread":0.3699163489214806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278983443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700856,0.00082831905,0.0007887645,0.00033293967,0.0003999743,0.00025098165,0.00020507502,0.000004816375,0.00018058844],"genre_scores_gemma":[0.9981801,0.001012716,0.00035438285,0.000075292635,0.0002603243,0.000009169477,0.000025205083,0.000015333895,0.00006749522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986295,0.00010356262,0.00071993563,0.000120530196,0.00029085574,0.00013558743],"domain_scores_gemma":[0.9981275,0.00016291936,0.00066123286,0.00004826383,0.00088197243,0.00011808834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016135632,0.000088865076,0.00033362227,0.00013672773,0.000028291248,0.000012463183,0.00003747674,0.00008084541,0.00037090408],"category_scores_gemma":[0.00038346785,0.00006685529,0.00022479634,0.00013619015,0.000049358732,0.0004648363,0.0000057924813,0.00014629713,0.0000042724414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005656714,0.00036340655,0.52338916,0.000012397753,0.0002890608,0.00008463775,0.0001376853,0.000008132346,0.0005444391,0.0000028751394,0.00054100994,0.47406152],"study_design_scores_gemma":[0.0072211092,0.0011202241,0.9883332,0.0013154683,0.00016814494,0.00014945448,0.000038687904,0.000006805096,0.0014145817,0.00010134395,0.000060886654,0.000070093716],"about_ca_topic_score_codex":0.0014607416,"about_ca_topic_score_gemma":0.00020343892,"teacher_disagreement_score":0.47399142,"about_ca_system_score_codex":0.0007276168,"about_ca_system_score_gemma":0.00046013907,"threshold_uncertainty_score":0.40611395},"labels":[],"label_agreement":null},{"id":"W2280859858","doi":"10.1200/jco.2007.25.18_suppl.3513","title":"A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Breast cancer; Clinical endpoint; Internal medicine; Pneumonitis; Oncology; Phases of clinical research; Metastatic breast cancer; Cancer; Gastroenterology; Clinical trial; Lung","score_opus":0.07323034241048873,"score_gpt":0.527863117070832,"score_spread":0.45463277466034324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280859858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975676,0.00026831872,0.00013342903,0.00047930476,0.00053217524,0.00088215136,0.000018961804,0.000001970314,0.00011607495],"genre_scores_gemma":[0.9985923,0.00011987406,0.0010253801,0.00009310397,0.00011722841,0.000011923761,0.0000041320723,0.0000100630095,0.00002597284],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996243,0.0004070223,0.002666025,0.00012710283,0.0004009082,0.00015595605],"domain_scores_gemma":[0.9953609,0.0014075297,0.0023217492,0.00012522022,0.00059715885,0.00018743811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019808062,0.00012484804,0.00228704,0.00021718872,0.00001991487,0.0000015728626,0.00007815858,0.00006135277,0.00009706268],"category_scores_gemma":[0.00060032576,0.00006592379,0.00025627387,0.00017348323,0.00018413755,0.000060292714,0.000024723591,0.00036672596,2.8767943e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36758283,0.057023864,0.4499117,0.000037000802,0.0017873037,0.000074827614,0.0006810778,0.000018035958,0.0000073442984,0.00003466288,0.000025640285,0.12281569],"study_design_scores_gemma":[0.55996376,0.034131043,0.40322825,0.00022959635,0.001945117,0.000010292665,0.00032928886,0.000019125924,0.000010357859,0.000054418284,0.00003893019,0.000039810562],"about_ca_topic_score_codex":0.00013567592,"about_ca_topic_score_gemma":0.0004575952,"teacher_disagreement_score":0.19238093,"about_ca_system_score_codex":0.00016244249,"about_ca_system_score_gemma":0.0007258959,"threshold_uncertainty_score":0.2688294},"labels":[],"label_agreement":null},{"id":"W2281688700","doi":"10.1039/c6mb00038j","title":"Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Molecular BioSystems","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of Northwest Territories","funders":"","keywords":"Afatinib; Lung cancer; Cancer research; Epidermal growth factor receptor; Biology; Oncology; Internal medicine; Computational biology; Genetics; Medicine; Erlotinib; Cancer","score_opus":0.009134115434847162,"score_gpt":0.30610422288215444,"score_spread":0.2969701074473073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281688700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764075,0.0009281666,0.016584989,0.0005576789,0.00025867592,0.0025583268,0.00028235075,0.0000518927,0.0023703882],"genre_scores_gemma":[0.9958188,0.000016788239,0.0009650606,0.00006724716,0.0000715219,0.00072915806,0.00004066622,0.000037768717,0.0022530048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990681,0.00003178646,0.00024513074,0.0002706965,0.00015293629,0.00023134326],"domain_scores_gemma":[0.99920225,0.000043493084,0.00014820864,0.00025108218,0.00026183395,0.00009311748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010018178,0.00014659292,0.000299945,0.00007555095,0.00004605322,0.000007690644,0.000059092396,0.00008121578,0.000054277247],"category_scores_gemma":[0.000028579243,0.00009396149,0.00012757802,0.00018051089,0.000025095245,0.00003060543,0.000014943853,0.000034855155,0.000007116424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009797598,0.00018819269,0.012690958,0.000808536,0.00037063126,0.000013458247,0.00021964443,0.000003997873,0.98231214,0.00006550228,0.0015664856,0.0016624989],"study_design_scores_gemma":[0.004901218,0.00036119935,0.0023629614,0.000617222,0.00052311784,0.000009233043,0.00005189906,0.0006181307,0.9889934,0.0000097929205,0.0014015462,0.00015028042],"about_ca_topic_score_codex":0.00034023286,"about_ca_topic_score_gemma":0.000039968505,"teacher_disagreement_score":0.019411253,"about_ca_system_score_codex":0.00020075178,"about_ca_system_score_gemma":0.0003302375,"threshold_uncertainty_score":0.38316384},"labels":[],"label_agreement":null},{"id":"W2281806191","doi":"10.1200/jco.2009.27.15_suppl.8074","title":"ABT-869 in non-small cell lung cancer (NSCLC): Interim results","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Interim analysis; Clinical endpoint; Internal medicine; Population; Toxicity; Progression-free survival; Surgery; Phases of clinical research; Lung cancer; Gastroenterology; Oncology; Urology; Clinical trial; Overall survival","score_opus":0.07936534600916437,"score_gpt":0.5235844798026544,"score_spread":0.4442191337934901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281806191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91999805,0.0014439088,0.00017705273,0.026083436,0.0017270487,0.00028932787,0.000008405575,0.00000778224,0.050264984],"genre_scores_gemma":[0.98767567,0.001398478,0.0027509273,0.005394221,0.0011192281,0.000004578167,0.0000033100923,0.000009530609,0.0016440836],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99740016,0.0001237145,0.0019298369,0.00016656736,0.00016979572,0.00020991918],"domain_scores_gemma":[0.9977827,0.0005369785,0.0010078872,0.00014769683,0.0002482727,0.00027646538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011381055,0.00011201669,0.0009290105,0.00013614207,0.000021537751,0.0000071093223,0.00011688318,0.00025191353,0.00008347078],"category_scores_gemma":[0.0006116635,0.00007663676,0.00029253014,0.00013808037,0.00005209248,0.000076047385,0.000017236849,0.0007455701,0.000010778011],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016134238,0.009440715,0.15558228,0.00008517888,0.00069055095,0.0044896756,0.002405133,0.00022946202,0.0010589323,0.00008937818,0.06749642,0.74229807],"study_design_scores_gemma":[0.033539638,0.015848998,0.86525714,0.0005773833,0.00085566565,0.00014790922,0.00022871517,0.00028871722,0.00022573315,0.00021426042,0.08267899,0.00013683946],"about_ca_topic_score_codex":0.00009776046,"about_ca_topic_score_gemma":0.00016621634,"teacher_disagreement_score":0.7421612,"about_ca_system_score_codex":0.00038531213,"about_ca_system_score_gemma":0.002037486,"threshold_uncertainty_score":0.36144128},"labels":[],"label_agreement":null},{"id":"W2284382116","doi":"10.1097/jto.0000000000000403","title":"Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Asymptomatic; Adenocarcinoma; Radiology; Brain metastasis; Magnetic resonance imaging; Radiation therapy; Alectinib; Brain tumor; Pathology; Cancer; Internal medicine; Metastasis","score_opus":0.038139767453974266,"score_gpt":0.45984445410499986,"score_spread":0.42170468665102556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284382116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846261,0.00034472518,0.00006173319,0.0103791235,0.00052455324,0.00023611895,0.000017331233,0.000008068022,0.0038022597],"genre_scores_gemma":[0.9932731,0.0000170426,0.0033848982,0.0028907396,0.00019280538,0.0000064960313,0.00002402275,0.000014107865,0.00019682612],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99870855,0.00030275132,0.00041937648,0.00013174624,0.0002663894,0.00017120237],"domain_scores_gemma":[0.99878776,0.00016413284,0.00032980164,0.00013412676,0.00028858645,0.00029557763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039263477,0.00011775991,0.00041304316,0.0002838978,0.000032420478,0.00001101227,0.0000642058,0.00008028686,0.000054658416],"category_scores_gemma":[0.0002448143,0.00008025044,0.000085832085,0.00015597936,0.000040167222,0.00014632731,0.00002199706,0.0002588837,0.000015022084],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0119113475,0.011978581,0.009163547,0.000044429453,0.0003479064,0.00863423,0.011825733,0.00031342093,0.004447831,0.00018390376,0.012268352,0.9288807],"study_design_scores_gemma":[0.063514754,0.36302054,0.21487871,0.0024538874,0.006493202,0.019888617,0.04911417,0.0014214676,0.039764978,0.0052569443,0.2327436,0.001449111],"about_ca_topic_score_codex":0.000038080383,"about_ca_topic_score_gemma":0.000062589,"teacher_disagreement_score":0.9274316,"about_ca_system_score_codex":0.00071849365,"about_ca_system_score_gemma":0.00059543725,"threshold_uncertainty_score":0.3272518},"labels":[],"label_agreement":null},{"id":"W2285582134","doi":"10.1200/jco.2006.24.18_suppl.7005","title":"An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Placebo; Erlotinib Hydrochloride; Cancer; Gastroenterology; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.11025402821699447,"score_gpt":0.5157098089888925,"score_spread":0.40545578077189803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285582134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621564,0.0007617159,0.000017991972,0.0005654433,0.00047934114,0.0015577418,0.00020674366,5.5028886e-7,0.0001948545],"genre_scores_gemma":[0.99887186,0.00060685986,0.00015000047,0.00008432778,0.00017782376,0.00007849132,0.000015730207,0.0000057704865,0.000009142146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936763,0.0015648038,0.0038208447,0.00017591917,0.0006215957,0.00014055043],"domain_scores_gemma":[0.9870601,0.007548816,0.004531719,0.00017486421,0.00062064367,0.000063848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047104387,0.00012555016,0.0016852737,0.00016741345,0.000027177028,0.0000024858834,0.0001668968,0.00012649554,0.000014254435],"category_scores_gemma":[0.0017019506,0.000060248927,0.0003147763,0.0005626794,0.00027171097,0.00006558745,0.000011719398,0.00025694157,6.579362e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074415654,0.009162172,0.96079504,0.000044429395,0.0023566694,0.000025764264,0.0032410861,0.014536311,0.00003552256,0.000023653973,0.000086903936,0.002250858],"study_design_scores_gemma":[0.024316082,0.012771655,0.94967586,0.000085874635,0.007559978,0.0000022303172,0.0035163786,0.0018827464,0.000034675006,0.000022145077,0.00009259361,0.000039755483],"about_ca_topic_score_codex":0.10721837,"about_ca_topic_score_gemma":0.6863764,"teacher_disagreement_score":0.57915807,"about_ca_system_score_codex":0.00043306383,"about_ca_system_score_gemma":0.0057648052,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W2285955673","doi":"10.1200/jco.2007.25.18_suppl.2511","title":"Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"ERCC1; Nucleotide excision repair; Single-nucleotide polymorphism; XRCC1; Base excision repair; Hazard ratio; DNA repair; Medicine; Internal medicine; Genotype; Cisplatin; Cancer research; Esophageal cancer; SNP; Oncology; Xeroderma pigmentosum; Proportional hazards model; Cancer; Confidence interval; Biology; Genetics; Gene; Chemotherapy","score_opus":0.06661110890946402,"score_gpt":0.4668430125661221,"score_spread":0.40023190365665806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285955673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281794,0.002387663,0.0001426414,0.0030245848,0.0006483251,0.00032011027,0.000006205787,0.000010401576,0.0006421372],"genre_scores_gemma":[0.9880846,0.0012377313,0.0088603,0.0010434675,0.00058548746,0.0000039493393,0.000001966621,0.000018973735,0.00016351897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703014,0.00016999329,0.0020281237,0.00021903715,0.00033334002,0.00021935167],"domain_scores_gemma":[0.99639106,0.0016817476,0.0011333898,0.0001621321,0.00029209052,0.00033955282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024694637,0.00012514445,0.0009839007,0.00020436198,0.000034559635,0.0000039373876,0.00008137114,0.0002659578,0.00014344574],"category_scores_gemma":[0.0016283612,0.00008778534,0.00025627165,0.00020633863,0.00020771727,0.000105523315,0.00003764209,0.0004732121,0.000003667454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010177369,0.0039300323,0.6217596,0.0000730458,0.00046291458,0.0038303598,0.0007441401,0.00006512042,0.007150976,0.00018743177,0.0023768134,0.3492422],"study_design_scores_gemma":[0.0075398516,0.007737255,0.97579813,0.00027027327,0.00047154454,0.00023152745,0.00011931726,0.000119755576,0.00044414736,0.00019236133,0.00699733,0.00007849777],"about_ca_topic_score_codex":0.00013286313,"about_ca_topic_score_gemma":0.000094949704,"teacher_disagreement_score":0.35403854,"about_ca_system_score_codex":0.00022952928,"about_ca_system_score_gemma":0.0010341458,"threshold_uncertainty_score":0.35797822},"labels":[],"label_agreement":null},{"id":"W2286173468","doi":"10.1200/jco.2015.63.8049","title":"Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition","year":2016,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology; AstraZeneca Canada; American Society of Clinical Oncology","keywords":"Medicine; Cancer; Cancer research; Oncology; Internal medicine","score_opus":0.06750101670510644,"score_gpt":0.5144393905794349,"score_spread":0.44693837387432844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286173468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040505645,0.98770165,0.000091488444,0.0037508963,0.0013956198,0.0012183897,0.000027102778,0.0000060010852,0.0017583014],"genre_scores_gemma":[0.0044532055,0.9919846,0.0011066783,0.0005710863,0.0011123728,0.00009824242,0.000012029008,0.000035453846,0.0006263554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946053,0.00044060944,0.00418172,0.0002544612,0.00025871696,0.0002591815],"domain_scores_gemma":[0.99097383,0.0028467705,0.005120401,0.00028082723,0.00058549317,0.00019267008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001973834,0.00027513478,0.0036925033,0.00023976021,0.000033376462,0.0000073990864,0.000197831,0.00062572584,0.00052925345],"category_scores_gemma":[0.0010515595,0.00013351737,0.0012228705,0.00025228033,0.00014890617,0.00009755189,0.00006775235,0.0014094881,0.0000050250233],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046609904,0.00093682023,0.0011414444,0.004422588,0.0007742358,0.0002525806,0.00010813834,0.0000010557919,0.0000044405415,0.000008171875,0.0014374319,0.990447],"study_design_scores_gemma":[0.014213359,0.0091076,0.0017887454,0.06020055,0.0060777115,0.00032031068,0.00011022861,0.00003360483,0.000071272654,0.0000664951,0.9077687,0.00024140676],"about_ca_topic_score_codex":0.00001806362,"about_ca_topic_score_gemma":0.00012298724,"teacher_disagreement_score":0.9902056,"about_ca_system_score_codex":0.0005856696,"about_ca_system_score_gemma":0.0060256035,"threshold_uncertainty_score":0.9996093},"labels":[],"label_agreement":null},{"id":"W2286863291","doi":"10.1097/jto.0000000000000624","title":"PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Erlotinib; Hazard ratio; Oncology; Internal medicine; Lung cancer; Anaplastic lymphoma kinase; Predictive marker; Confidence interval; Proportional hazards model; Cancer; Epidermal growth factor receptor","score_opus":0.021082067881831982,"score_gpt":0.42347044043921617,"score_spread":0.4023883725573842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286863291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832196,0.0016836955,0.0027092458,0.002264787,0.0005995607,0.0015510299,0.00002497558,0.000010169381,0.0028345985],"genre_scores_gemma":[0.98653716,0.00016370129,0.010484458,0.00019028598,0.000481471,0.000323753,0.000014000435,0.000028330885,0.0017768668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989164,0.00006316279,0.0003848769,0.00017882006,0.00020832173,0.0002484376],"domain_scores_gemma":[0.99864984,0.000106178755,0.00040859316,0.00011104894,0.00045289632,0.0002714186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024335479,0.00016641074,0.0005045118,0.00018979779,0.00004518492,0.000012250945,0.00006634507,0.0001273468,0.000047200585],"category_scores_gemma":[0.000045789646,0.00010071285,0.00011083202,0.00012346826,0.000042274925,0.00010482458,0.000017098966,0.00013506204,0.0000025107267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.111976534,0.012863611,0.55630845,0.00063658814,0.0031920245,0.007072377,0.021601167,0.00405199,0.014346483,0.000012718784,0.01301587,0.25492218],"study_design_scores_gemma":[0.16609214,0.26363268,0.32277718,0.007354413,0.032813806,0.009609132,0.031111473,0.01445226,0.05640706,0.0007702869,0.093419105,0.0015604295],"about_ca_topic_score_codex":0.000120131066,"about_ca_topic_score_gemma":0.00009701368,"teacher_disagreement_score":0.25336176,"about_ca_system_score_codex":0.0014001335,"about_ca_system_score_gemma":0.0024740037,"threshold_uncertainty_score":0.43887764},"labels":[],"label_agreement":null},{"id":"W2287184838","doi":"10.1200/jco.2007.25.18_suppl.7539","title":"Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada); Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Gemcitabine; Cetuximab; Carboplatin; Internal medicine; Regimen; Lung cancer; Clinical endpoint; Chemotherapy; Pleural effusion; Oncology; Chemotherapy regimen; Progression-free survival; Phases of clinical research; Gastroenterology; Cisplatin; Urology; Cancer; Randomized controlled trial; Colorectal cancer","score_opus":0.060468335524432794,"score_gpt":0.48103428015090904,"score_spread":0.42056594462647623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287184838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818638,0.00075803493,0.0051719123,0.006677626,0.0007759677,0.0013149215,0.000012324168,0.000010234749,0.0034152074],"genre_scores_gemma":[0.97514844,0.0010776317,0.019203333,0.0011650681,0.0006147082,0.00008665776,0.000018867544,0.00003118,0.0026541103],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751896,0.00005159403,0.0016839824,0.00022480088,0.00021578108,0.00030490162],"domain_scores_gemma":[0.9958834,0.0019659642,0.0012248277,0.00014385293,0.0005035744,0.0002783699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010019849,0.00018420827,0.0011894099,0.00017377034,0.00005762938,0.000006948334,0.00007729462,0.0002300282,0.00008884764],"category_scores_gemma":[0.00044493837,0.00010725618,0.00023657299,0.00019880947,0.000064436,0.00011000494,0.000012078528,0.00031009706,0.000003274744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08039589,0.023672735,0.36336616,0.00028401194,0.0016897592,0.0025483859,0.0016328152,0.0014556155,0.0003323059,0.000106822474,0.0015760163,0.5229395],"study_design_scores_gemma":[0.34287998,0.18211587,0.38051093,0.0011241527,0.0042950846,0.00043249287,0.00094360067,0.0016226653,0.0021989858,0.0002752055,0.08317705,0.000423969],"about_ca_topic_score_codex":0.00022748872,"about_ca_topic_score_gemma":0.005620761,"teacher_disagreement_score":0.52251554,"about_ca_system_score_codex":0.0010848921,"about_ca_system_score_gemma":0.0028348956,"threshold_uncertainty_score":0.50289834},"labels":[],"label_agreement":null},{"id":"W2287692022","doi":"10.1200/jco.2007.25.18_suppl.lba7514","title":"Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Carboplatin; Bevacizumab; Clinical endpoint; Placebo; Oncology; Cisplatin; Chemotherapy; Lung cancer; Progression-free survival; Neutropenia; Surgery; Randomized controlled trial; Pathology","score_opus":0.03669029450550364,"score_gpt":0.44934336801465313,"score_spread":0.4126530735091495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287692022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995102,0.0002965372,0.00020109925,0.00031068738,0.0002673432,0.0034916436,0.0000050008957,0.0000032939074,0.00032239273],"genre_scores_gemma":[0.99795,0.00029055835,0.0013781787,0.00014422946,0.000082748615,0.0000547036,0.000011098752,0.000023667255,0.00006481787],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697095,0.00011060075,0.002038619,0.00026300075,0.00035774976,0.00025904956],"domain_scores_gemma":[0.99631983,0.0009718197,0.0017686711,0.00014292638,0.0005668871,0.0002298658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011327979,0.00020783437,0.001399698,0.0002853929,0.000032686436,0.000006488763,0.00008343526,0.00016595724,0.000031328098],"category_scores_gemma":[0.00013673208,0.00012271368,0.00008182452,0.00032612338,0.000081750186,0.00013696266,0.000019056006,0.0005627473,2.2680472e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5068745,0.0256417,0.3734148,0.00007803748,0.0002794692,0.00024851094,0.0032256222,0.00014897337,0.000024943742,6.928568e-7,0.000018105704,0.09004462],"study_design_scores_gemma":[0.6400554,0.036057197,0.32109496,0.0003513751,0.0006345056,0.000009338645,0.0012597808,0.0002958951,0.00008003884,0.0000014726216,0.00006343899,0.000096566044],"about_ca_topic_score_codex":0.00021931362,"about_ca_topic_score_gemma":0.0046747425,"teacher_disagreement_score":0.13318092,"about_ca_system_score_codex":0.00042050733,"about_ca_system_score_gemma":0.0012423685,"threshold_uncertainty_score":0.50041187},"labels":[],"label_agreement":null},{"id":"W2288248616","doi":"10.1155/2013/506383","title":"Tailored Therapy in Lung Cancer","year":2013,"lang":"en","type":"review","venue":"Canadian Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Lung cancer; Pharmacogenetics; Tyrosine kinase; Disease; Cancer; Bioinformatics; Cancer research; Oncology; Internal medicine; Gene; Genotype; Receptor; Biology; Genetics","score_opus":0.0662191805795366,"score_gpt":0.40108012580552344,"score_spread":0.33486094522598686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288248616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014624657,0.995549,0.0000011881317,0.00016891533,0.0006172969,0.0011790032,0.00005661044,0.000010062437,0.0022716331],"genre_scores_gemma":[0.000027583503,0.9955315,0.000026811073,0.0016307867,0.00082505355,0.0003771071,0.000024493178,0.0000786094,0.0014780513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833536,0.00011910593,0.00057692465,0.00025527808,0.00019861844,0.00051470497],"domain_scores_gemma":[0.9981897,0.000027999775,0.0002521697,0.00027096196,0.00014190438,0.0011172555],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015919899,0.00033734355,0.0010674535,0.0009747504,0.0001550874,0.00009789435,0.00016680373,0.0002910326,0.0027977617],"category_scores_gemma":[0.000025995361,0.00023959365,0.0003429652,0.00038450508,0.00004270293,0.00010508615,0.0000070548326,0.00085353805,0.00008327191],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000040763484,0.000018810724,0.0008398993,0.0009603312,0.0004558725,0.000766729,0.0000747379,9.1026646e-7,2.3288514e-7,0.000017296119,0.026971111,0.96989],"study_design_scores_gemma":[0.00091963535,0.000088019595,0.00038038017,0.007795141,0.00056447886,0.00023666964,0.000019772186,0.0000012924523,2.1678602e-7,0.0000063126326,0.98977566,0.00021239388],"about_ca_topic_score_codex":0.020085849,"about_ca_topic_score_gemma":0.048094865,"teacher_disagreement_score":0.9696776,"about_ca_system_score_codex":0.0039727637,"about_ca_system_score_gemma":0.017471358,"threshold_uncertainty_score":0.9998508},"labels":[],"label_agreement":null},{"id":"W2290578604","doi":"10.1007/s11060-016-2057-5","title":"Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Lung cancer; Internal medicine; Brain metastasis; Lesion; Oncology; Lung; Multivariate analysis; Cancer; Gastroenterology; Metastasis; Pathology","score_opus":0.010725364498258824,"score_gpt":0.29469522462007497,"score_spread":0.28396986012181613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290578604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742436,0.00071112765,0.000026502505,0.0014172668,0.00013650936,0.00020067874,0.00004120462,0.0000018666084,0.000040451083],"genre_scores_gemma":[0.99787796,0.0016813132,0.00014136155,0.00023271472,0.000029059303,0.0000031431728,0.0000013865143,0.00001196596,0.000021075737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993312,0.0000783201,0.0002494428,0.00011795844,0.00010140386,0.000121692035],"domain_scores_gemma":[0.99921626,0.00022360327,0.00025346063,0.000058198915,0.00013858498,0.00010991227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011336448,0.00009519122,0.00034841287,0.0001910288,0.000019711773,0.0000056608405,0.000026327203,0.000043251926,0.000011758236],"category_scores_gemma":[0.000032168617,0.00005302467,0.000022079641,0.00011865018,0.000075401855,0.00007944172,0.000018110986,0.000105585495,6.061721e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007864658,0.00018945613,0.9783811,0.000061943945,0.00015149315,0.00020804317,0.00056438526,0.0000023220323,0.012460941,0.0000024555038,0.00003468693,0.00715669],"study_design_scores_gemma":[0.009013065,0.004393481,0.984265,0.00017664592,0.00045105894,0.00007155688,0.000051014093,0.0000091907095,0.00047051467,0.000008011383,0.001033982,0.00005647127],"about_ca_topic_score_codex":0.00018277093,"about_ca_topic_score_gemma":0.00035996904,"teacher_disagreement_score":0.011990427,"about_ca_system_score_codex":0.0000545227,"about_ca_system_score_gemma":0.00017012017,"threshold_uncertainty_score":0.21622832},"labels":[],"label_agreement":null},{"id":"W2295354328","doi":"10.1016/s1470-2045(15)00614-2","title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ignyta; National Institutes of Health; University of Washington; Astex Pharmaceuticals; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Ariad Pharmaceuticals; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Servier; Universität Heidelberg","keywords":"Ceritinib; Crizotinib; Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Tyrosine-kinase inhibitor; Clinical trial; Cancer","score_opus":0.04046967010096525,"score_gpt":0.3862219429664884,"score_spread":0.3457522728655231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295354328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305506,0.00013232476,0.000020019652,0.009349887,0.0001864919,0.002628687,0.0012266496,0.000012432124,0.0033884726],"genre_scores_gemma":[0.99806935,0.00033719838,0.00028474999,0.00054506684,0.00020394831,0.00015435954,0.00012121413,0.000015937563,0.0002681925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988525,0.00023918136,0.00026723318,0.00026780125,0.00012356453,0.00024972428],"domain_scores_gemma":[0.9986581,0.0005590025,0.00024583173,0.0003847432,0.00009096927,0.00006132015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047984,0.00013821808,0.0005039352,0.000023117755,0.000087709974,0.0000104296305,0.00019493952,0.000080041566,0.00008471293],"category_scores_gemma":[0.000066880035,0.000058256595,0.000017878949,0.0001232845,0.00014519379,0.00007634992,0.00008798479,0.00015023045,0.0000024059811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78882253,0.006001228,0.09214197,0.00003862979,0.00080992223,0.000027690068,0.004775498,0.000003923829,0.0051531484,0.000023640887,0.0060761306,0.09612568],"study_design_scores_gemma":[0.74846417,0.002224434,0.23609027,0.00022494828,0.0005978648,9.2322415e-7,0.00013595629,0.000073960335,0.0010075009,0.000008897867,0.011059755,0.00011132406],"about_ca_topic_score_codex":0.004069437,"about_ca_topic_score_gemma":0.0037489969,"teacher_disagreement_score":0.1439483,"about_ca_system_score_codex":0.00022599295,"about_ca_system_score_gemma":0.00034422954,"threshold_uncertainty_score":0.61517984},"labels":[],"label_agreement":null},{"id":"W2296687919","doi":"10.1371/journal.pone.0150567","title":"Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Lung Cancer Research Foundation","keywords":"Erlotinib; EGFR inhibitors; Cancer research; Epidermal growth factor receptor; A549 cell; Erlotinib Hydrochloride; Viability assay; Pharmacology; Protein kinase B; Tyrosine kinase; Medicine; Tyrosine-kinase inhibitor; Lung cancer; Apoptosis; Chemistry; Cancer; Receptor; Oncology; Internal medicine; Biochemistry","score_opus":0.01684690545262213,"score_gpt":0.2694724055276227,"score_spread":0.25262550007500056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296687919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703217,0.00011245844,0.00017310453,0.0008011105,0.00005107043,0.001125862,0.000015452999,0.000032503405,0.0006562944],"genre_scores_gemma":[0.99863935,0.00009907941,0.00043858352,0.000061228995,0.000054305456,0.0003070286,0.000009336626,0.00002469844,0.00036642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904084,0.00003708692,0.00018631227,0.00028878357,0.0002040484,0.0002429468],"domain_scores_gemma":[0.9995151,0.000060546707,0.00009929147,0.0001536772,0.0000798016,0.00009154527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008056358,0.0001479298,0.00028478255,0.00014963711,0.00003668598,0.000009436101,0.000038874186,0.000057924608,0.000037367092],"category_scores_gemma":[0.0000205179,0.00009894367,0.000026102429,0.00025629756,0.000039252896,0.00015607917,0.0000151693985,0.00012434788,0.000009157555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034346388,0.0043026195,0.3709156,0.00023088059,0.00006980019,0.00007142793,0.00038273024,0.000011887064,0.61876875,0.00000674185,0.000018921533,0.004877173],"study_design_scores_gemma":[0.007666126,0.00045379822,0.29954746,0.0022316184,0.00018974232,8.859094e-7,0.000052305928,0.0005317003,0.6891848,0.000011700243,0.0000024835917,0.0001273906],"about_ca_topic_score_codex":0.00062722474,"about_ca_topic_score_gemma":0.0014450393,"teacher_disagreement_score":0.07136812,"about_ca_system_score_codex":0.00042809008,"about_ca_system_score_gemma":0.00026453374,"threshold_uncertainty_score":0.4034806},"labels":[],"label_agreement":null},{"id":"W2302018332","doi":"10.1159/000415103","title":"Therapeutic Ratio and Fractionation in Cancer of the Lung","year":2015,"lang":"en","type":"review","venue":"Frontiers of radiation therapy and oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Fractionation; Oncology; Internal medicine; Chromatography","score_opus":0.046599290387837236,"score_gpt":0.41867506016310013,"score_spread":0.3720757697752629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302018332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038032484,0.9975079,0.00007549084,0.00047615834,0.00043749352,0.0008615864,0.000028040582,0.000003455032,0.00022950095],"genre_scores_gemma":[0.0015290853,0.9977866,0.00011121689,0.000106482905,0.00005964894,0.000121870034,0.000040253493,0.0000106807565,0.00023416299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992939,0.00012331334,0.00029540635,0.00012622424,0.000096319585,0.00006483848],"domain_scores_gemma":[0.999366,0.00005572446,0.00038618126,0.000096615106,0.00006622342,0.000029271683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001489959,0.00010741797,0.0006509438,0.0001459594,0.000028244496,0.000002959703,0.000034820157,0.00017649785,0.000012201448],"category_scores_gemma":[0.000013214429,0.000066694425,0.00006888807,0.00016083008,0.00008436004,0.00005254091,0.0000066309685,0.00011300483,1.0154547e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043131324,0.00007159707,0.004115726,0.00045288174,0.00031573142,3.307284e-7,0.0006439814,0.0000033389908,0.0000010183488,0.00014763362,0.0022219757,0.99198264],"study_design_scores_gemma":[0.0015672635,0.00020506624,0.0073879375,0.00033941827,0.0006708807,0.000007576794,0.00008857701,0.000081393926,0.0000052080222,0.00013543025,0.989454,0.000057274672],"about_ca_topic_score_codex":0.00010218547,"about_ca_topic_score_gemma":0.000021739745,"teacher_disagreement_score":0.99192536,"about_ca_system_score_codex":0.00036065336,"about_ca_system_score_gemma":0.0008610392,"threshold_uncertainty_score":0.27197197},"labels":[],"label_agreement":null},{"id":"W2304288722","doi":"10.1016/j.jtho.2016.03.007","title":"The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Windsor Regional Hospital","funders":"Cancer Care Ontario; Ontario Ministry of Health and Long-Term Care; Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Internal medicine; Oncology; Docetaxel; Hazard ratio; Maintenance therapy; Lung cancer; Randomized controlled trial; Chemotherapy; Gemcitabine; Confidence interval; Cisplatin","score_opus":0.0387747819572843,"score_gpt":0.4359392451606983,"score_spread":0.39716446320341403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304288722","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042739947,0.9931328,0.000030074396,0.0003138262,0.00025194706,0.0056442176,0.00009389294,0.0000018077168,0.00010401309],"genre_scores_gemma":[0.0006817456,0.9977611,0.00017690951,0.00009067335,0.00006483972,0.00055132125,0.0000084240855,0.000029136081,0.0006358674],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99631894,0.000890953,0.0020488668,0.00015914152,0.0003539182,0.00022820181],"domain_scores_gemma":[0.992265,0.0012668236,0.0052749403,0.0005270362,0.00059538387,0.0000708132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080589904,0.00031301254,0.003941465,0.00016628613,0.000044560114,0.000009201145,0.0003176935,0.00014216885,0.000008626531],"category_scores_gemma":[0.00015796197,0.00009682086,0.0005738438,0.00029789316,0.0000932372,0.000056333552,0.000022511194,0.00025489577,0.0000019042617],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020348854,0.0006085061,0.00038008468,0.7949,0.0018544212,0.0001270374,0.0004710537,0.000001923077,2.2699892e-7,0.000006186849,0.00066236116,0.2007847],"study_design_scores_gemma":[0.0010515562,0.0020017584,0.0000617612,0.8422822,0.031250585,0.00047697782,0.00012047353,0.0000012798184,6.1535764e-7,0.0000011443284,0.122661896,0.00008977714],"about_ca_topic_score_codex":0.00005693577,"about_ca_topic_score_gemma":0.000061524996,"teacher_disagreement_score":0.20069493,"about_ca_system_score_codex":0.0018314238,"about_ca_system_score_gemma":0.0028441383,"threshold_uncertainty_score":0.50453794},"labels":[],"label_agreement":null},{"id":"W2304373741","doi":"10.1097/jto.0000000000000693","title":"Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Hazard ratio; Placebo; Lung cancer; Gastroenterology; Clinical endpoint; Oncology; Progression-free survival; Confidence interval; Randomized controlled trial; Hepatocellular carcinoma; Chemotherapy; Pathology","score_opus":0.02768786980656785,"score_gpt":0.4436823993396465,"score_spread":0.41599452953307864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304373741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961455,0.00032003142,0.00019925568,0.0010817365,0.00044436584,0.0005062238,0.0000052688233,0.0000026119415,0.0012950114],"genre_scores_gemma":[0.99629766,0.00004136895,0.0028812746,0.00012890289,0.00019534558,0.000010439724,0.000006938835,0.000011686958,0.0004264073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990809,0.000068214686,0.000445427,0.00008530686,0.00020985029,0.00011033301],"domain_scores_gemma":[0.9987568,0.00003666882,0.00058392884,0.00008844231,0.00038922936,0.00014492338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022705359,0.000087329965,0.0003822892,0.00015166975,0.000015072469,0.0000046380787,0.00005501093,0.000090118,0.00005033309],"category_scores_gemma":[0.000026256179,0.000056244404,0.000057482044,0.00013341292,0.000026856827,0.00008730152,0.0000060639936,0.00015502852,8.296863e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48146716,0.007507493,0.39459252,0.00018445686,0.0005484626,0.00029998913,0.0047489093,0.00060301693,0.00059300155,0.000008625774,0.00309119,0.10635516],"study_design_scores_gemma":[0.4659157,0.10359108,0.3869406,0.0012132043,0.0036689304,0.0001486514,0.0020495155,0.0004692186,0.012542907,0.00018273851,0.022824936,0.00045249885],"about_ca_topic_score_codex":0.000041866348,"about_ca_topic_score_gemma":0.00005471852,"teacher_disagreement_score":0.10590266,"about_ca_system_score_codex":0.00047309033,"about_ca_system_score_gemma":0.0024487055,"threshold_uncertainty_score":0.43438983},"labels":[],"label_agreement":null},{"id":"W2309537020","doi":"10.1200/jco.2004.22.90140.7018","title":"A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Febrile neutropenia; Lung cancer; Vinorelbine; Regimen; Nausea; Surgery; Chemotherapy; Gastroenterology; Oncology; Cisplatin","score_opus":0.05815052593919202,"score_gpt":0.4588959697301544,"score_spread":0.4007454437909624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309537020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334645,0.0010795044,0.00016985288,0.0018215048,0.00047349298,0.0013125096,0.00002075429,0.0000047123767,0.0017712327],"genre_scores_gemma":[0.99603724,0.001005863,0.0017747232,0.00026202743,0.0003703144,0.00003640759,0.0000045066004,0.000016031447,0.00049286307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972136,0.00020277356,0.0019529598,0.00022598935,0.00020854,0.00019612155],"domain_scores_gemma":[0.99684024,0.0011007008,0.0013616821,0.00011911233,0.00033584403,0.00024244706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012106617,0.00015752162,0.0016166356,0.00017866214,0.000045230114,0.0000072728703,0.00007465685,0.0002301119,0.00010129344],"category_scores_gemma":[0.0010626479,0.000107447944,0.00020513611,0.00014757446,0.00020519282,0.00008270228,0.00006309081,0.00062323327,5.100889e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88753074,0.008023661,0.06471552,0.00025714317,0.0011726052,0.0007856088,0.0034993626,0.000108480504,0.0032815584,0.000099672354,0.00050104095,0.030024601],"study_design_scores_gemma":[0.7518973,0.042219553,0.20217645,0.00053334696,0.000964164,0.000055130724,0.00024889444,0.0002884321,0.00038969063,0.0001802914,0.0009357546,0.000110999434],"about_ca_topic_score_codex":0.00044603398,"about_ca_topic_score_gemma":0.0011552607,"teacher_disagreement_score":0.13746093,"about_ca_system_score_codex":0.00035003686,"about_ca_system_score_gemma":0.0016837567,"threshold_uncertainty_score":0.43816},"labels":[],"label_agreement":null},{"id":"W2311987714","doi":"10.1200/jco.2010.28.15_suppl.e18081","title":"Asian ethnicity and survival outcomes in advanced non-small cell lung cancer (NSCLC) patients receiving systemic therapy: A regional Canadian experience.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Cancer registry; Population; Oncology; Systemic therapy; Stage (stratigraphy); Cancer; Breast cancer","score_opus":0.0570699073644474,"score_gpt":0.45676593031620727,"score_spread":0.3996960229517599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311987714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901807,0.00046526897,0.000010010172,0.003960103,0.002283636,0.0003695663,0.000006597041,0.000004122716,0.0027200035],"genre_scores_gemma":[0.99618167,0.00097236765,0.0008722267,0.0014213728,0.0002955334,0.000025885543,0.0000026340476,0.000015430003,0.00021291111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800086,0.00015289271,0.0011702566,0.00020112947,0.00021091591,0.00026395483],"domain_scores_gemma":[0.9977151,0.0005588457,0.00072451186,0.00013974906,0.00032381038,0.0005379607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077349175,0.00013755406,0.0009431026,0.00015981581,0.000060465307,0.000009571015,0.000114434115,0.000289458,0.00006688922],"category_scores_gemma":[0.0005516889,0.00009433704,0.00016916427,0.00011180266,0.000105340754,0.000110801,0.0000176118,0.00088535715,0.0000012347873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035194054,0.00046693208,0.93115276,0.00001855535,0.0001107426,0.000097261014,0.0018210824,0.0000049489718,0.00014744246,0.0000071455124,0.00013719402,0.065683976],"study_design_scores_gemma":[0.010193216,0.0012743828,0.983292,0.00015977351,0.000104565624,0.000034658846,0.0006844012,0.000035046447,0.000013486881,0.000014532905,0.0041041123,0.00008984954],"about_ca_topic_score_codex":0.011897677,"about_ca_topic_score_gemma":0.13555105,"teacher_disagreement_score":0.12365338,"about_ca_system_score_codex":0.00036524015,"about_ca_system_score_gemma":0.0036665865,"threshold_uncertainty_score":0.9946822},"labels":[],"label_agreement":null},{"id":"W2313559881","doi":"10.1093/annonc/mdv532.29","title":"445P Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Afatinib; Pemetrexed; Subgroup analysis; Gemcitabine; Lung cancer; Oncology; Gastroenterology; Chemotherapy; Cancer; Gefitinib; Cisplatin; Epidermal growth factor receptor; Confidence interval","score_opus":0.05072019802966627,"score_gpt":0.4117482572379524,"score_spread":0.3610280592082861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313559881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911376,0.0009904265,0.000115755654,0.0027553774,0.00008175879,0.0007749099,0.00004363697,0.00002643212,0.004074073],"genre_scores_gemma":[0.99755824,0.00024904095,0.0008761778,0.0006442956,0.00004299914,0.0001044697,0.00019282098,0.000040203424,0.00029174678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982861,0.00013076,0.0004507892,0.00040511737,0.00033437365,0.00039284176],"domain_scores_gemma":[0.9988309,0.00016969458,0.00022239641,0.0002463137,0.00032015334,0.00021051978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028898148,0.0002546699,0.000701956,0.00028827,0.00005212799,0.000017373615,0.000089659385,0.0000944595,0.000048400863],"category_scores_gemma":[0.00007610567,0.00019735916,0.000046914472,0.0004425834,0.00016079767,0.0002720039,0.000027371281,0.00020744863,0.000002405414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027048264,0.001859976,0.98176914,0.00008555552,0.0005326633,0.00011938396,0.0031080174,0.00047783437,0.00027054493,0.00014893578,0.0026374734,0.006285639],"study_design_scores_gemma":[0.03960642,0.0073572267,0.94066554,0.00040842924,0.00045434872,0.000028979463,0.001500924,0.00082338264,0.0015382044,0.00008647658,0.0071006883,0.00042939617],"about_ca_topic_score_codex":0.0019196367,"about_ca_topic_score_gemma":0.0014270135,"teacher_disagreement_score":0.041103624,"about_ca_system_score_codex":0.00029017832,"about_ca_system_score_gemma":0.0005101245,"threshold_uncertainty_score":0.8048073},"labels":[],"label_agreement":null},{"id":"W2313812295","doi":"10.1093/annonc/mdv048.07","title":"Prognostic Classification of Lung Adenocarcinoma by Integrated Mirna-Mrna Expression Profiles","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"microRNA; Medicine; Adenocarcinoma; Oncology; Lung cancer; Internal medicine; Gene expression profiling; Gene expression; Cancer; Gene; Biology; Genetics","score_opus":0.10538770042695247,"score_gpt":0.4342140308115797,"score_spread":0.3288263303846273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313812295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804022,0.0027400132,0.00014775113,0.0041705025,0.00013309158,0.00063044234,0.0000559627,0.000026085581,0.011693958],"genre_scores_gemma":[0.9977967,0.00008208631,0.0008482492,0.00016138295,0.000034778583,0.000079093064,0.00023984721,0.000010694369,0.0007471725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992178,0.00006458965,0.00029591686,0.00014693911,0.00014669597,0.00012807261],"domain_scores_gemma":[0.9989051,0.0000674368,0.00023621376,0.00016067407,0.00051893183,0.00011159608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013458842,0.00008496579,0.00027600594,0.00008487471,0.000018253346,0.0000022401846,0.0000583219,0.000108417764,0.000057751786],"category_scores_gemma":[0.00019192217,0.00006220543,0.000048205682,0.00014300065,0.00009450429,0.000060575643,0.000016482201,0.00007469007,0.0000066499592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092093856,0.0022609867,0.51634675,0.00024105911,0.00033008304,0.000027453005,0.0026787054,0.0000044362005,0.121509105,0.00049280026,0.3120064,0.043181274],"study_design_scores_gemma":[0.007065594,0.011324039,0.57586735,0.0006605864,0.0007680237,0.00007209669,0.003321517,0.0007392054,0.30506077,0.0005684887,0.094298914,0.00025340795],"about_ca_topic_score_codex":0.000098381635,"about_ca_topic_score_gemma":0.0000048988263,"teacher_disagreement_score":0.21770751,"about_ca_system_score_codex":0.00006740626,"about_ca_system_score_gemma":0.000531462,"threshold_uncertainty_score":0.25366637},"labels":[],"label_agreement":null},{"id":"W2315566794","doi":"10.1200/jco.2015.33.15_suppl.8100","title":"Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Afatinib; Lung cancer; Erlotinib; Chemotherapy; Gastroenterology; Surgery; Cancer","score_opus":0.12256242700886709,"score_gpt":0.46623995907749505,"score_spread":0.34367753206862794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315566794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151593,0.00080284703,0.00015830428,0.0022510977,0.0017691491,0.0023442626,0.00046282864,0.000011936743,0.00068363966],"genre_scores_gemma":[0.99615294,0.000029385606,0.0018622814,0.0010741135,0.00042508772,0.00003165864,0.00026436916,0.00003622435,0.00012394605],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99415493,0.00041324136,0.0038606406,0.00041615628,0.00085456466,0.00030044708],"domain_scores_gemma":[0.9900979,0.0022226493,0.0055115977,0.0010440386,0.00075618137,0.00036763737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010234895,0.00035671794,0.002161074,0.00006377445,0.000101326594,0.000011296466,0.00045158877,0.00025970268,0.00014294653],"category_scores_gemma":[0.001768261,0.00016505415,0.0006977147,0.0003329474,0.00020711056,0.00016496723,0.000084422405,0.00037735727,0.0000015860014],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18451405,0.022453304,0.755447,0.000048809878,0.0019676082,0.0002672419,0.0011468601,0.00047491494,0.000024824423,0.000003578235,0.0017522102,0.031899616],"study_design_scores_gemma":[0.7445276,0.107762516,0.12283439,0.00018863236,0.0071950266,0.00002595062,0.0006367508,0.0018709904,0.00067858555,0.000040513703,0.013987409,0.00025164997],"about_ca_topic_score_codex":0.00036215724,"about_ca_topic_score_gemma":0.0003619479,"teacher_disagreement_score":0.6326126,"about_ca_system_score_codex":0.0006249154,"about_ca_system_score_gemma":0.0036830057,"threshold_uncertainty_score":0.67307127},"labels":[],"label_agreement":null},{"id":"W2315607170","doi":"10.1158/1538-7445.am2011-2530","title":"Abstract 2530: The anticancer kinase inhibitor dovitinib (TKI258/CHIR258) may have multiple modes of action because it also binds DNA and inhibits topoisomerase I and topoisomerase IIα","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Topoisomerase; Tyrosine kinase; Biology; Biochemistry; Kinase; Molecular biology; Tyrosine-kinase inhibitor; Fibroblast growth factor receptor; DNA; Receptor; Fibroblast growth factor; Chemistry; Cancer","score_opus":0.1557381596321504,"score_gpt":0.44102447292447355,"score_spread":0.2852863132923231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315607170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913959,0.0023339207,0.0000056875333,0.002963499,0.0001269119,0.0010918992,0.00020229502,0.000029082028,0.0018508382],"genre_scores_gemma":[0.9951496,0.0026094583,0.000118298536,0.00024080276,0.00028857513,0.00037760753,0.00003208903,0.000043153963,0.0011403947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793226,0.000105251595,0.00037705962,0.0004980125,0.000582589,0.0005048509],"domain_scores_gemma":[0.99841374,0.00030611196,0.00011610551,0.0004401444,0.00040368817,0.00032019962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049883325,0.0002344634,0.0003521927,0.00027509747,0.00036854844,0.00005989291,0.00011162896,0.00012754569,0.0004619126],"category_scores_gemma":[0.00018297065,0.00016035842,0.00007309097,0.00032880413,0.0006859362,0.00028522505,0.00011818495,0.00045977897,0.000009718395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037194774,0.0016030509,0.18638204,0.0014794325,0.0009967762,0.00023800331,0.02030551,0.000016638667,0.6765704,0.00086905377,0.0067230626,0.10109653],"study_design_scores_gemma":[0.007085554,0.00081420114,0.14136851,0.000769355,0.00031690716,0.000041312203,0.007993183,0.00023359316,0.8343968,0.00036204734,0.0062522143,0.00036634784],"about_ca_topic_score_codex":0.007727906,"about_ca_topic_score_gemma":0.0025494548,"teacher_disagreement_score":0.15782636,"about_ca_system_score_codex":0.0002284986,"about_ca_system_score_gemma":0.00043625166,"threshold_uncertainty_score":0.99887973},"labels":[],"label_agreement":null},{"id":"W2316810850","doi":"10.1158/1535-7163.targ-09-a105","title":"Abstract A105: Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: Associations of response by CT or DCE-MRI with patient outcome","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Oncology; Internal medicine; Hepatocellular carcinoma; Progression-free survival; Cancer; Clinical trial; Lung cancer; Phases of clinical research; Sorafenib; Interim analysis; Nuclear medicine; Urology; Overall survival; Confidence interval","score_opus":0.03472244194285886,"score_gpt":0.3741749619326415,"score_spread":0.33945251998978265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316810850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843575,0.011207364,0.00074921356,0.00089957996,0.00008113099,0.001663762,0.0008335457,0.000019725654,0.00018821316],"genre_scores_gemma":[0.99489105,0.0017805848,0.0018629028,0.0009004301,0.000017835291,0.00016423654,0.00009414875,0.000045998037,0.00024280683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775827,0.00015840048,0.001022629,0.0003638561,0.00037638773,0.00032044112],"domain_scores_gemma":[0.9982819,0.00020980244,0.0008126704,0.00034253954,0.00022120163,0.0001318843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041510304,0.00030382804,0.00090819463,0.00017144308,0.000056746147,0.000015503507,0.0000981653,0.0001003355,0.000059046815],"category_scores_gemma":[0.000032427346,0.00022758715,0.00015870317,0.00036956108,0.00006043189,0.00006336944,0.000014627922,0.00021292934,3.887308e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099012675,0.0028179013,0.070721716,0.00030698424,0.000822171,0.0002348281,0.0030794134,0.0017339719,0.8875824,0.0000071713825,0.00013471006,0.022657467],"study_design_scores_gemma":[0.032592665,0.0042018592,0.033259656,0.0006349202,0.0025013639,0.0000062395516,0.000418839,0.00089179876,0.9214692,0.0000270102,0.0035055792,0.00049083156],"about_ca_topic_score_codex":0.00069373456,"about_ca_topic_score_gemma":0.00018924296,"teacher_disagreement_score":0.037462056,"about_ca_system_score_codex":0.00038215285,"about_ca_system_score_gemma":0.0008163193,"threshold_uncertainty_score":0.92807347},"labels":[],"label_agreement":null},{"id":"W2317450955","doi":"10.1177/155989771306025","title":"State of the Art Treatment for Lung Cancer","year":2013,"lang":"en","type":"article","venue":"MD Conference Express","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Medicine; Oncology; Chemotherapy; Quality of life (healthcare); Internal medicine; Disease; Overall survival; Toxicity; Cancer; Intensive care medicine","score_opus":0.028043387059790596,"score_gpt":0.3466454228764108,"score_spread":0.3186020358166202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317450955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97377133,0.0011554018,0.0035090747,0.0045797518,0.00046285696,0.0037501522,0.0003009852,0.00004381741,0.0124266455],"genre_scores_gemma":[0.9760328,0.00015709182,0.0004954132,0.00014023036,0.000039999064,0.0015416049,0.000016444337,0.000009867743,0.02156655],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99952745,0.00000985046,0.00011911424,0.00012274571,0.00009005666,0.00013076291],"domain_scores_gemma":[0.99947137,0.000030029396,0.000060293827,0.00022280347,0.00016529854,0.00005020144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000013109844,0.00008564425,0.00014926176,0.000016862059,0.000048591006,0.000014642341,0.000059583275,0.00001852296,0.00044404794],"category_scores_gemma":[0.000006860008,0.0000465082,0.00007012287,0.00004009976,0.000041416202,0.00005149985,0.000013348247,0.000024441319,0.0000071729],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042125682,0.0017625412,0.15128762,0.0007392236,0.0029921168,0.0000064123965,0.017586213,0.00056167715,0.16259733,0.0047074747,0.20622529,0.45111287],"study_design_scores_gemma":[0.01939201,0.0017383937,0.1755077,0.0016087517,0.0027233793,0.000012250953,0.0012089867,0.014358213,0.48626673,0.0030107494,0.29344603,0.0007268289],"about_ca_topic_score_codex":0.000756821,"about_ca_topic_score_gemma":0.00007972916,"teacher_disagreement_score":0.45038602,"about_ca_system_score_codex":0.00009335637,"about_ca_system_score_gemma":0.0002192164,"threshold_uncertainty_score":0.48620135},"labels":[],"label_agreement":null},{"id":"W2319518956","doi":"10.1007/s00330-016-4252-3","title":"Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics","year":2016,"lang":"en","type":"article","venue":"European Radiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint Mary's University; Dalhousie University","funders":"Pfizer Canada; Dalhousie Medical Research Foundation","keywords":"Medicine; Neuroradiology; Lung cancer; Interventional radiology; Radiology; Ultrasound; Mutation; Medical physics; Oncology; Internal medicine; Genetics; Biology; Neurology","score_opus":0.016094266955431393,"score_gpt":0.31694242674841333,"score_spread":0.30084815979298196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319518956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696507,0.0010117559,0.027906,0.00045996153,0.0001873197,0.00043122942,0.00005945911,0.000044489814,0.00024910274],"genre_scores_gemma":[0.9921401,0.00033037658,0.007053245,0.00012681072,0.00019476877,0.000028501454,0.000024368577,0.000036570615,0.00006523167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991326,0.000065805325,0.00022586135,0.0002500272,0.000045180244,0.00028055784],"domain_scores_gemma":[0.9996076,0.0000718576,0.000095287,0.00009259483,0.000052353764,0.000080262886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016485591,0.00010758581,0.00018405105,0.00015104245,0.000085369036,0.000010984338,0.000027715983,0.000020706198,0.0000033943288],"category_scores_gemma":[0.00008290407,0.00007964355,0.000029579276,0.000075618256,0.00006805258,0.0000973088,0.000020912914,0.00006138123,4.511419e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118760596,0.000025450605,0.9510673,0.000090180874,0.000078382014,0.00008052969,0.0009048488,0.00034187082,0.013755203,0.00022810273,0.00002894569,0.03328042],"study_design_scores_gemma":[0.00655926,0.00017154966,0.6261987,0.0007896588,0.0004639347,0.00030018762,0.0001729483,0.36449572,0.0001519095,0.0003353071,0.00013400099,0.00022679538],"about_ca_topic_score_codex":0.000075419906,"about_ca_topic_score_gemma":0.000021715397,"teacher_disagreement_score":0.36415386,"about_ca_system_score_codex":0.00018993487,"about_ca_system_score_gemma":0.0001969013,"threshold_uncertainty_score":0.32477698},"labels":[],"label_agreement":null},{"id":"W2320121320","doi":"10.1093/annonc/mdw163","title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute","keywords":"Medicine; KRAS; Pemetrexed; Discontinuation; ROS1; Internal medicine; Lung cancer; Oncology; Crizotinib; Retrospective cohort study; Anaplastic lymphoma kinase; Lung; Gene rearrangement; Gastroenterology; Adenocarcinoma; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.07948592838997814,"score_gpt":0.47377688865988016,"score_spread":0.394290960269902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320121320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756621,0.00097551465,0.00008630321,0.01802866,0.00019333321,0.000419312,0.00002157538,0.000024653218,0.004588508],"genre_scores_gemma":[0.9967038,0.00052708766,0.0003758606,0.0016852103,0.00004796541,0.000068612295,0.0000059339577,0.000013615868,0.000571903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903244,0.00010829561,0.00035688627,0.00018672433,0.00012656898,0.00018907875],"domain_scores_gemma":[0.99897325,0.00042660802,0.0001646569,0.00021013476,0.00015054831,0.00007478057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029754872,0.000101518526,0.00051455136,0.0001203796,0.000019503848,0.0000018222324,0.00005708221,0.000099313154,0.00009881606],"category_scores_gemma":[0.00009933384,0.00005159087,0.000097540884,0.00012973598,0.0001508202,0.000047885256,0.000007187657,0.00007303341,0.0000070374244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007340125,0.00024799886,0.9484602,0.000052720065,0.0004519001,0.00006287077,0.00036948954,0.0000058172773,0.00026872012,0.0001099454,0.0015727635,0.04766355],"study_design_scores_gemma":[0.013123582,0.00477398,0.9621949,0.0006790804,0.00025821556,0.000016632503,0.0004795841,0.000016246053,0.00038167927,0.000047625228,0.017898044,0.00013042803],"about_ca_topic_score_codex":0.0005223591,"about_ca_topic_score_gemma":0.00078742893,"teacher_disagreement_score":0.047533125,"about_ca_system_score_codex":0.00018223227,"about_ca_system_score_gemma":0.00086907565,"threshold_uncertainty_score":0.21038146},"labels":[],"label_agreement":null},{"id":"W2320169864","doi":"10.1097/01.cot.0000455783.87798.a3","title":"Stage IV Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Oncology Times","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Stage (stratigraphy); Medicine; Oncology; Geology","score_opus":0.012244046888259676,"score_gpt":0.381749766265429,"score_spread":0.3695057193771693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320169864","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14869249,0.0013857966,0.00037617199,0.01229166,0.00054103695,0.00036190863,0.000019858599,0.000109244844,0.8362218],"genre_scores_gemma":[0.72778034,0.00010311827,0.0013606306,0.0026194665,0.0002983655,0.000121220044,0.000029375418,0.00001526804,0.26767224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958444,0.000022831291,0.00008223458,0.00012240354,0.00005825111,0.0001298528],"domain_scores_gemma":[0.999686,0.000051036317,0.000035169094,0.00012054281,0.000037513688,0.00006976164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000052023188,0.00006243681,0.0001563758,0.000024658528,0.000053710584,0.00000382729,0.000028381595,0.00006065605,0.003111211],"category_scores_gemma":[0.000019707582,0.000046630117,0.000034343,0.00004952396,0.00004076535,0.0000274713,0.000011944624,0.00006293978,0.00009978295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020476284,0.00064034224,0.31064516,0.0001415898,0.0009849591,0.00009806941,0.001734219,0.00008517234,0.0019398977,0.013138816,0.49027368,0.18011335],"study_design_scores_gemma":[0.0019262736,0.00034068213,0.03982689,0.000024366607,0.00035313438,0.000010761214,0.00005986112,0.0008713,0.00034546969,0.00007738838,0.9560997,0.00006419155],"about_ca_topic_score_codex":0.00016817752,"about_ca_topic_score_gemma":0.000069806905,"teacher_disagreement_score":0.57908785,"about_ca_system_score_codex":0.00020170698,"about_ca_system_score_gemma":0.00023320319,"threshold_uncertainty_score":0.99780005},"labels":[],"label_agreement":null},{"id":"W2322672763","doi":"10.1093/annonc/mdt459.52","title":"PH 1 Study of PI3KMTOR Inhibitors PF-04691502 or PF-05212384 + MEK Inhibitor PD-0325901 or Irinotecan in Advanced Cancer","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Nausea; Gastroenterology; Internal medicine; Irinotecan; Vomiting; Mucositis; Diarrhea; Cancer; Colorectal cancer; Toxicity","score_opus":0.07367149013791352,"score_gpt":0.4553707728587884,"score_spread":0.3816992827208749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322672763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904046,0.00057368824,0.0000027550939,0.004079657,0.0005733599,0.0020475436,0.0000658445,0.000033736058,0.0022188006],"genre_scores_gemma":[0.99439186,0.0004760452,0.00028957755,0.00089065824,0.0002633785,0.00067444536,0.000026771871,0.000039535775,0.0029477044],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99787176,0.00011491768,0.000855191,0.00040759513,0.0003101924,0.0004403517],"domain_scores_gemma":[0.99824905,0.00023980347,0.0004138239,0.00037813128,0.0005197626,0.00019942876],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017777743,0.0002593124,0.0009288761,0.00027026734,0.00005110381,0.00000685634,0.00014516425,0.00018239624,0.0013109385],"category_scores_gemma":[0.00021670133,0.00017639091,0.00010630916,0.0005441596,0.00014642005,0.00019715069,0.00007794451,0.00021556714,0.00002902004],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008302885,0.025941,0.12444909,0.0006987783,0.0018396152,0.00055251486,0.02240026,0.00039354104,0.016452143,0.000078013836,0.073183134,0.725709],"study_design_scores_gemma":[0.0632657,0.12548126,0.46344995,0.0016047661,0.0014055698,0.00009941709,0.037040778,0.00014612706,0.09558078,0.00028206673,0.21042046,0.0012230894],"about_ca_topic_score_codex":0.006078972,"about_ca_topic_score_gemma":0.006910591,"teacher_disagreement_score":0.72448593,"about_ca_system_score_codex":0.00023623959,"about_ca_system_score_gemma":0.001087177,"threshold_uncertainty_score":0.999602},"labels":[],"label_agreement":null},{"id":"W2322844138","doi":"10.1155/2003/729635","title":"The Descriptive Epidemiology of Primary Lung Cancer in an Alberta Cohort with a Mutivariate Analysis of Survival to Two Years","year":2003,"lang":"en","type":"article","venue":"Canadian Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Epidemiology; Lung cancer; Cohort; Cancer survival; Cohort study; Survival analysis; Oncology; Environmental health; Internal medicine; Cancer","score_opus":0.03176328187881397,"score_gpt":0.350292949493084,"score_spread":0.31852966761427004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322844138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955498,0.0013074165,0.000101463396,0.00025634904,0.0001188838,0.0002850126,0.000048719474,0.0000014057442,0.002330939],"genre_scores_gemma":[0.9985744,0.000031077852,0.00022463202,0.00092053553,0.000032042302,0.000026514716,0.000004567362,0.000013239526,0.00017300705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986754,0.00034354982,0.00039199626,0.00015688976,0.00013252265,0.00029965705],"domain_scores_gemma":[0.9986624,0.00018816898,0.0001857679,0.00022251665,0.00021900955,0.0005221161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008212878,0.00009769229,0.0004813011,0.00051540806,0.00008777,0.000006072204,0.000089970556,0.00004399239,0.00012013779],"category_scores_gemma":[0.00021409272,0.000065571636,0.000081115955,0.0007531712,0.00009325323,0.000056926434,0.0000044502563,0.0001746933,4.7378495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010520911,0.000025439775,0.99277765,0.000004762197,0.0016457484,0.00006822925,0.0009250466,0.0019895162,0.00009623151,0.0008839464,0.00010830761,0.001369943],"study_design_scores_gemma":[0.0009767959,0.00022288224,0.9942099,0.00005941647,0.0013636918,0.000012122487,0.00034328652,0.00006629965,0.000024903728,0.000026096095,0.0026263057,0.00006830777],"about_ca_topic_score_codex":0.13586347,"about_ca_topic_score_gemma":0.8140219,"teacher_disagreement_score":0.67815846,"about_ca_system_score_codex":0.0010665584,"about_ca_system_score_gemma":0.0037142101,"threshold_uncertainty_score":0.86989087},"labels":[],"label_agreement":null},{"id":"W2325094700","doi":"10.2165/00024669-200504040-00006","title":"Erlotinib","year":2005,"lang":"de","type":"article","venue":"American Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Erlotinib; Pharmacology; Internal medicine; Cancer","score_opus":0.00928745523564239,"score_gpt":0.3634912078921711,"score_spread":0.3542037526565287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325094700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52543664,0.41054368,0.00037538385,0.049628485,0.0053110616,0.0004049063,0.0001003934,0.000024396704,0.008175066],"genre_scores_gemma":[0.9650058,0.019287165,0.0017636251,0.0033833121,0.008116985,0.000009159214,0.0000029189205,0.000040187475,0.002390856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843365,0.000056391702,0.0006034116,0.00014526784,0.00043982556,0.0003214776],"domain_scores_gemma":[0.9980382,0.000074535346,0.00094821793,0.0001854277,0.0003925026,0.00036113412],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001511106,0.00019213416,0.00058598944,0.00016343694,0.000069940186,0.00002783585,0.00014126401,0.000034208144,0.0014779875],"category_scores_gemma":[0.00003461158,0.00014578317,0.0002547263,0.0003386668,0.00027304448,0.00015992884,0.000015460566,0.00031677485,0.00019142931],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040474278,0.00029733437,0.048731185,0.00001785085,0.0035032593,0.00008991643,0.0027866815,0.00037855818,0.00011116097,0.00008461004,0.01983779,0.9237569],"study_design_scores_gemma":[0.003205973,0.0021675855,0.02947013,0.0006301231,0.0055711567,0.000058873688,0.0010907489,0.00007029078,0.00059452205,0.000020042504,0.9569237,0.00019684777],"about_ca_topic_score_codex":0.00033864746,"about_ca_topic_score_gemma":0.000056721285,"teacher_disagreement_score":0.9370859,"about_ca_system_score_codex":0.0006325289,"about_ca_system_score_gemma":0.0013317358,"threshold_uncertainty_score":0.99943477},"labels":[],"label_agreement":null},{"id":"W2325642881","doi":"10.1016/j.lungcan.2016.04.004","title":"EGFR mutation status on brain metastases from non-small cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Incidence (geometry); Clinical endpoint; Brain metastasis; Cumulative incidence; Epidermal growth factor receptor; Multivariate analysis; Population; Cancer; Metastasis; Cohort; Clinical trial","score_opus":0.011819419277273258,"score_gpt":0.3313313429954913,"score_spread":0.319511923718218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325642881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94824785,0.012525218,0.0036752252,0.018293342,0.0019660247,0.0019503535,0.0033365595,0.00020842737,0.009796978],"genre_scores_gemma":[0.9684246,0.0014668398,0.0010922286,0.0047544907,0.00081663294,0.001059842,0.00027778736,0.00009084172,0.02201673],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998412,0.000046424484,0.00027232638,0.00049939315,0.00030900844,0.00046083768],"domain_scores_gemma":[0.99880505,0.00029166517,0.0001506145,0.0003614755,0.00013854158,0.0002526441],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006217025,0.0002715071,0.00033602453,0.00011631555,0.000117441596,0.000031017513,0.00008119498,0.00008962547,0.0026519906],"category_scores_gemma":[0.00004214821,0.00015931591,0.0001257808,0.00018822061,0.00004754058,0.0001436618,0.000024436291,0.00011713539,0.000056212408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014163445,0.0009947759,0.33420098,0.0006727481,0.004027733,0.00037405858,0.0066274153,0.0012469548,0.049218312,0.00039442355,0.38163635,0.2191899],"study_design_scores_gemma":[0.045951452,0.0013902191,0.38146245,0.0058880975,0.012188421,0.00001472735,0.0010505702,0.0043641794,0.17919326,0.0004512571,0.36593196,0.002113392],"about_ca_topic_score_codex":0.010234592,"about_ca_topic_score_gemma":0.0020117774,"teacher_disagreement_score":0.21707651,"about_ca_system_score_codex":0.0013533668,"about_ca_system_score_gemma":0.0007136854,"threshold_uncertainty_score":0.9982597},"labels":[],"label_agreement":null},{"id":"W2326174046","doi":"10.1097/cad.0000000000000212","title":"Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals","year":2015,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Medical Research Group","funders":"Genentech","keywords":"Erlotinib; Ranitidine; Pharmacology; Cmax; Pharmacokinetics; Medicine; Omeprazole; Erlotinib Hydrochloride; Tolerability; Proton-pump inhibitor; Gastroenterology; Internal medicine; Epidermal growth factor receptor; Adverse effect; Cancer","score_opus":0.023990155459102155,"score_gpt":0.39359497066074256,"score_spread":0.3696048152016404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326174046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075,0.0012740595,0.0000070608835,0.0013504139,0.00034026796,0.0007233305,0.00005935462,0.000029619729,0.0054658935],"genre_scores_gemma":[0.99771804,0.00053746573,0.000100037134,0.0008980071,0.0001567742,0.00010296863,0.00004051892,0.000023280581,0.0004229138],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886733,0.00008144862,0.00026521602,0.00021871344,0.00031855295,0.00024872992],"domain_scores_gemma":[0.9993569,0.00010577888,0.000116843265,0.00018549623,0.0000714157,0.00016352815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002835515,0.0001506256,0.00037419325,0.00019975778,0.000022484295,0.0000063934735,0.00006834394,0.000048867205,0.00007636345],"category_scores_gemma":[0.00003572667,0.00011490241,0.00006108616,0.00040940495,0.000042804193,0.000048911024,0.00001967249,0.00014266913,0.000034780485],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021258937,0.001315087,0.8336638,0.0006828684,0.0004878767,0.000040041014,0.004802644,0.00062856294,0.002264169,0.00013307342,0.018603377,0.1352526],"study_design_scores_gemma":[0.15262397,0.033485297,0.33474475,0.0026750276,0.0033681856,0.000054399043,0.001316635,0.00073825486,0.36735076,0.00015479483,0.10226686,0.0012210582],"about_ca_topic_score_codex":0.00046770312,"about_ca_topic_score_gemma":0.000009453898,"teacher_disagreement_score":0.49891904,"about_ca_system_score_codex":0.0001975721,"about_ca_system_score_gemma":0.0003059739,"threshold_uncertainty_score":0.46855843},"labels":[],"label_agreement":null},{"id":"W2326186476","doi":"10.5114/kitp.2012.30845","title":"TORAKOCHIRURGIA DNA ploidy as an independent prognostic factor: 10-year results in a group of patients surgically treated for squamous cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Polish Journal of Cardio-Thoracic Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Medicine; Cardiothoracic surgery; Cancer; Squamous cell cancer; Internal medicine; Oncology; Surgery","score_opus":0.023175950625438833,"score_gpt":0.34160518309271704,"score_spread":0.3184292324672782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326186476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944589,0.0023240552,0.000023155213,0.0000692752,0.0007380029,0.0008091654,0.0005620836,0.000019816136,0.0009955545],"genre_scores_gemma":[0.9985111,0.0001954396,0.00013010601,0.000048471404,0.00057587435,0.00007151098,0.00021450833,0.000058448797,0.00019456059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691224,0.000286217,0.001193305,0.00024417226,0.00075477985,0.0006093025],"domain_scores_gemma":[0.99681574,0.0007264982,0.0008419315,0.00026626582,0.0007888048,0.0005607676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011149136,0.00028163975,0.0010173724,0.00054265995,0.000060414666,0.00003338274,0.000111318375,0.00017633935,0.00008091108],"category_scores_gemma":[0.0006801686,0.00022400233,0.0005464013,0.00035853888,0.000048318274,0.0005321661,0.000025225783,0.00023592783,0.0000020842638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046814494,0.0017140327,0.9818064,0.0002884727,0.00043207858,0.00008427324,0.0013711858,0.000031888776,0.0001916032,0.0000054943544,0.0020173097,0.007375827],"study_design_scores_gemma":[0.005856896,0.00082419475,0.98278177,0.00053309434,0.0016008364,0.000082147504,0.00043388066,0.000019200717,0.0037175976,0.000015512505,0.0038002662,0.0003346192],"about_ca_topic_score_codex":0.00042051662,"about_ca_topic_score_gemma":0.000038134895,"teacher_disagreement_score":0.007041208,"about_ca_system_score_codex":0.0005762939,"about_ca_system_score_gemma":0.0006361935,"threshold_uncertainty_score":0.91345495},"labels":[],"label_agreement":null},{"id":"W23274571","doi":"10.1200/jco.2009.27.15_suppl.3527","title":"Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Placebo; Proportional hazards model; Adverse effect; Confidence interval","score_opus":0.10256373920177174,"score_gpt":0.46136241685791207,"score_spread":0.3587986776561403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23274571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353284,0.00026148025,0.000020204872,0.00031546358,0.0012551903,0.0044175526,0.00012600873,0.000002962749,0.000068292786],"genre_scores_gemma":[0.9971623,0.00052509794,0.001420703,0.00022932935,0.00049433345,0.00008628861,0.00002051377,0.000024640758,0.000036829057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921999,0.0013737004,0.0049106814,0.00038315263,0.0008748394,0.00025773325],"domain_scores_gemma":[0.9923708,0.0024997399,0.003643613,0.00017414468,0.0009867316,0.00032500434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050921193,0.0002936318,0.004420123,0.00028149557,0.00004108325,0.0000055927717,0.00013338617,0.0002951396,0.000073712115],"category_scores_gemma":[0.0025226707,0.0001637301,0.00030286633,0.00030618662,0.00025309063,0.00025054105,0.000023498853,0.00064731407,3.42861e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8678154,0.01634005,0.099014156,0.000057721576,0.000990592,0.00007433253,0.00070078525,0.00020690082,0.00011687381,0.0000032897954,0.000089740526,0.014590164],"study_design_scores_gemma":[0.8646563,0.07092003,0.061485104,0.00045972262,0.0016855648,0.000004232065,0.00023742273,0.000106138374,0.000093128896,0.0000068335803,0.00019138608,0.00015412718],"about_ca_topic_score_codex":0.027000632,"about_ca_topic_score_gemma":0.1598694,"teacher_disagreement_score":0.13286877,"about_ca_system_score_codex":0.00038436928,"about_ca_system_score_gemma":0.009273638,"threshold_uncertainty_score":0.99634284},"labels":[],"label_agreement":null},{"id":"W2328211964","doi":"10.1097/mlr.0000000000000484","title":"Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer","year":2016,"lang":"en","type":"article","venue":"Medical Care","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"National Institute of Environmental Health Sciences","keywords":"Medicine; Colorectal cancer; Lung cancer; Cancer; Internal medicine; Current Procedural Terminology; Oncology; KRAS; Mutation; Algorithm; Surgery; Gene; Biology; Computer science; Genetics","score_opus":0.016750334174951087,"score_gpt":0.3658302841016981,"score_spread":0.349079949926747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328211964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913276,0.0014580998,0.004474755,0.0022619658,0.000050634208,0.00031828348,0.00006596737,0.0000035626133,0.00003913337],"genre_scores_gemma":[0.99944293,0.00003732609,0.00025150832,0.00005691513,0.00001918545,0.00013816448,0.00003111438,0.000003604518,0.00001922497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954224,0.000018047302,0.0001741406,0.00007483753,0.00014396512,0.00004677695],"domain_scores_gemma":[0.9993363,0.00032628232,0.00007520244,0.000051906572,0.00018854495,0.000021738928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012990163,0.000030084506,0.00008370464,0.000029001603,0.000017856273,0.0000011893065,0.000021913775,0.000035044806,0.00002198835],"category_scores_gemma":[0.00070223643,0.000016381351,0.000014859602,0.00006261552,0.00007534541,0.000016361873,0.0000067865885,0.00001993095,1.0169466e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001526836,0.00011799173,0.49489227,0.0008847007,0.0001419619,0.000026229389,0.0054797507,0.00010210553,0.27881047,0.0016938674,0.00013077752,0.21756718],"study_design_scores_gemma":[0.005857328,0.00032158263,0.726563,0.00083135185,0.0005964809,0.000028954077,0.0016177177,0.0020045175,0.2611466,0.00077799754,0.00016397814,0.00009050361],"about_ca_topic_score_codex":0.00007628915,"about_ca_topic_score_gemma":0.000038975963,"teacher_disagreement_score":0.23167072,"about_ca_system_score_codex":0.00004747157,"about_ca_system_score_gemma":0.00015479849,"threshold_uncertainty_score":0.084069334},"labels":[],"label_agreement":null},{"id":"W2328702979","doi":"10.1093/annonc/mdv532.27","title":"443P Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Gefitinib; Progression-free survival; Randomized controlled trial; Gastroenterology; Cancer; Epidermal growth factor receptor; Chemotherapy","score_opus":0.04387169014604697,"score_gpt":0.39460912769524864,"score_spread":0.35073743754920167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328702979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043155,0.00023523753,0.000022203973,0.0012468955,0.00021984936,0.0012056516,0.00006215056,0.000005285533,0.006571156],"genre_scores_gemma":[0.9993025,0.000008565055,0.00015980321,0.00019994056,0.000022123082,0.000049164566,0.000042344516,0.000014161815,0.00020141937],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987405,0.00014220538,0.0005050674,0.00017413913,0.00026548278,0.0001726],"domain_scores_gemma":[0.99871635,0.00015014764,0.00038907854,0.00026229816,0.00038567293,0.000096450334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023317085,0.00013830485,0.0006152413,0.000112100905,0.00002868377,0.0000026818002,0.00008413634,0.000092411334,0.000016531667],"category_scores_gemma":[0.00013574389,0.000085225925,0.000087749155,0.00019441958,0.00016650601,0.000055859975,0.000039845243,0.00009907992,3.514175e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028722404,0.008974785,0.9470567,0.0002027371,0.0003382136,0.000030537212,0.008497552,0.0001453128,0.00055657397,0.0005785527,0.002336807,0.0025598248],"study_design_scores_gemma":[0.5014703,0.033213787,0.44955763,0.000092819435,0.0012777792,0.0000056322597,0.001996025,0.00022869513,0.010441078,0.00010331118,0.0013665718,0.00024634323],"about_ca_topic_score_codex":0.0007153392,"about_ca_topic_score_gemma":0.0002005549,"teacher_disagreement_score":0.49749908,"about_ca_system_score_codex":0.00006002403,"about_ca_system_score_gemma":0.00061392726,"threshold_uncertainty_score":0.34754124},"labels":[],"label_agreement":null},{"id":"W2331253186","doi":"10.1016/j.ypat.2012.11.048","title":"Comprehensive genomic characterization of squamous cell lung cancers","year":2013,"lang":"en","type":"article","venue":"Yearbook of Pathology and Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Human Genome Research Institute; BC Cancer Agency","keywords":"Medicine; Oncology; Lung cancer; Squamous cell cancer; Internal medicine; Cancer research; Pathology; Cancer","score_opus":0.008202313703053505,"score_gpt":0.2715481435712307,"score_spread":0.2633458298681772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331253186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953782,0.0021986535,0.000047619727,0.00035059341,0.00013248737,0.00037002505,0.000032508215,0.000012106522,0.0014778023],"genre_scores_gemma":[0.9986166,0.0002412522,0.0001342867,0.0004948342,0.00008267084,0.000026096259,0.00005407674,0.000010537294,0.00033968606],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99944913,0.000034657034,0.00021629817,0.00012936768,0.00007585581,0.00009470108],"domain_scores_gemma":[0.9993953,0.000035598954,0.00014036278,0.00013347101,0.00022845223,0.000066809494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043311935,0.00008601471,0.00029166165,0.00008926867,0.000024286628,8.469298e-7,0.000025991747,0.00006856004,0.0003404241],"category_scores_gemma":[0.000013933886,0.000065749395,0.000016152113,0.00009396709,0.00026350404,0.00004060559,0.000011446005,0.000068536,0.0000058118285],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003914654,0.000048498947,0.02828276,0.00029158374,0.000040849645,0.000044393124,0.0016899861,0.0000013238579,0.9682871,0.00011265855,0.0004567681,0.00070492644],"study_design_scores_gemma":[0.004705341,0.0011383148,0.9580152,0.00016652326,0.00053726404,0.000037009762,0.0008599259,0.000077781246,0.030294893,0.000041263436,0.004006318,0.00012016279],"about_ca_topic_score_codex":0.00009275658,"about_ca_topic_score_gemma":0.0000021114843,"teacher_disagreement_score":0.9379922,"about_ca_system_score_codex":0.000038937633,"about_ca_system_score_gemma":0.00015133047,"threshold_uncertainty_score":0.3727405},"labels":[],"label_agreement":null},{"id":"W2332752715","doi":"10.18632/oncotarget.8350","title":"A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Stage (stratigraphy); Oncology; Window of opportunity; Internal medicine; Biomarker; Erlotinib Hydrochloride; Cancer; Epidermal growth factor receptor; Biology","score_opus":0.01557352490979636,"score_gpt":0.31768214220873175,"score_spread":0.3021086172989354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332752715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974983,0.000107019376,0.00004630713,0.00026812378,0.000077297846,0.0015011159,0.00020264827,0.000005344762,0.00029386138],"genre_scores_gemma":[0.99705714,0.000017770177,0.0005129953,0.000033935867,0.000012535181,0.00009142123,0.0000037030507,0.000014804082,0.0022556717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902266,0.00010443353,0.00034033,0.00020479177,0.00017453606,0.00015324292],"domain_scores_gemma":[0.99924576,0.00007888425,0.0001644212,0.00020034627,0.00016760359,0.00014299496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026579987,0.00011520039,0.00035998016,0.00016753073,0.000022946993,0.0000031778698,0.00005631913,0.000030838397,0.000116241696],"category_scores_gemma":[0.000060706076,0.00007846706,0.000038082042,0.00017659696,0.000054949644,0.000067698624,0.00004615393,0.000044977594,5.5918713e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004253352,0.0012138344,0.79726535,0.00011977641,0.00022500288,0.0000440126,0.010505448,0.000021602611,0.18602146,0.0000017752415,0.00019887683,0.00012953031],"study_design_scores_gemma":[0.009110673,0.0030127636,0.9527638,0.00027441225,0.00022276636,0.0000012039869,0.0027580855,0.000029480603,0.031683434,0.0000019450404,0.00005652256,0.000084889085],"about_ca_topic_score_codex":0.0056962785,"about_ca_topic_score_gemma":0.0008586515,"teacher_disagreement_score":0.15549849,"about_ca_system_score_codex":0.00010393038,"about_ca_system_score_gemma":0.00061913364,"threshold_uncertainty_score":0.8611107},"labels":[],"label_agreement":null},{"id":"W2332945822","doi":"10.1093/annonc/mdt460.85","title":"Potential Predictive Markers of Efficacy of Dacomitinib in Patients with Recurrent/Metastatic Scchn from a Phase 2 Trial","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; PTEN; Oncology; Internal medicine; Immunohistochemistry; Clinical endpoint; Predictive marker; Clinical trial; Cancer research; Pathology; Cancer; PI3K/AKT/mTOR pathway; Apoptosis; Biology","score_opus":0.03272214602876293,"score_gpt":0.39986339364829837,"score_spread":0.3671412476195354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332945822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637145,0.00008923637,0.000041385865,0.00041765915,0.00014293032,0.001437325,0.00030873754,0.000004691855,0.0011865842],"genre_scores_gemma":[0.99870497,0.000027655351,0.0007870616,0.000083517945,0.00003130962,0.00006583327,0.0002692631,0.000009110799,0.000021275284],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9989822,0.00008165813,0.00046180148,0.00015393834,0.00018179118,0.00013861773],"domain_scores_gemma":[0.9989168,0.00016622418,0.00037760785,0.00015257197,0.0003190199,0.00006778479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008987841,0.00009472204,0.000505212,0.00014134722,0.000010288182,0.0000014274207,0.000056068166,0.000053499974,0.00032334574],"category_scores_gemma":[0.000114994895,0.00006998088,0.000078303325,0.00014355443,0.0001451982,0.00006897403,0.000017886083,0.00007782616,0.0000027504614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5704465,0.0465351,0.06683323,0.00019785091,0.003539796,0.000037422706,0.0028845093,0.00008362542,0.0007832462,0.0000567128,0.00648086,0.30212116],"study_design_scores_gemma":[0.37176448,0.09206504,0.5325138,0.00029793766,0.0008401308,0.0000011457049,0.000459596,0.0001432676,0.0011178618,0.00020898704,0.00048755552,0.00010020185],"about_ca_topic_score_codex":0.000666921,"about_ca_topic_score_gemma":0.000019904328,"teacher_disagreement_score":0.46568057,"about_ca_system_score_codex":0.000033877594,"about_ca_system_score_gemma":0.0003028583,"threshold_uncertainty_score":0.3540409},"labels":[],"label_agreement":null},{"id":"W2334423299","doi":"10.1093/neuonc/nou240.32","title":"BM-32 * CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL","year":2014,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ceritinib; Medicine; Internal medicine; non-small cell lung cancer (NSCLC); Lung cancer; Cohort; Anaplastic lymphoma kinase; ALK inhibitor; Gastroenterology; Oncology","score_opus":0.020618376259350306,"score_gpt":0.34023702853253257,"score_spread":0.31961865227318226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334423299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778623,0.00038836757,0.000111591406,0.0033157659,0.00031867294,0.0041749286,0.00027448506,0.00001700269,0.0036129758],"genre_scores_gemma":[0.995723,0.0001343526,0.00059113605,0.0015719302,0.00024239752,0.0014117763,0.00017058438,0.0000363748,0.00011842905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864244,0.00023028879,0.00032474907,0.00035084636,0.00015768278,0.00029397817],"domain_scores_gemma":[0.9984115,0.00093992555,0.00019335214,0.0002577746,0.0001011183,0.00009636909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001648156,0.00021769614,0.0005807335,0.00010335238,0.00008493386,0.000011925434,0.00007667328,0.000091881986,0.00003878483],"category_scores_gemma":[0.00007622659,0.00013006941,0.00009556206,0.00012987731,0.00009892914,0.000043201755,0.000014879073,0.00007790024,0.0000011469486],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15738587,0.025089396,0.30169544,0.0012424979,0.0022735924,0.00025579624,0.03668634,0.00016583805,0.033129998,0.0004742904,0.022907129,0.4186938],"study_design_scores_gemma":[0.43297184,0.050903134,0.050048083,0.00012816873,0.003737147,0.000022968607,0.0010289365,0.0002999309,0.008216529,0.000034345576,0.45222118,0.0003877462],"about_ca_topic_score_codex":0.0005373616,"about_ca_topic_score_gemma":0.00086095184,"teacher_disagreement_score":0.42931405,"about_ca_system_score_codex":0.00020263997,"about_ca_system_score_gemma":0.00037180932,"threshold_uncertainty_score":0.53040767},"labels":[],"label_agreement":null},{"id":"W2335841583","doi":"10.1080/15384047.2016.1139241","title":"Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells","year":2016,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Radioresistance; Cancer research; Clonogenic assay; Biology; A549 cell; SABR volatility model; Cell growth; Lung cancer; Radiosensitivity; Radiation therapy; Apoptosis; Cell culture; Pathology; Medicine; Internal medicine; Genetics","score_opus":0.015211981628090846,"score_gpt":0.3345106327677507,"score_spread":0.3192986511396599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335841583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887183,0.0026398262,0.0030728986,0.0037257972,0.0005845191,0.0009258742,0.00013450696,0.000028929122,0.00016940579],"genre_scores_gemma":[0.993848,0.0029025378,0.0002830122,0.0008441742,0.00031642604,0.0006768099,0.000018572791,0.000029213712,0.0010812161],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99883884,0.00012011155,0.00023821085,0.00039715387,0.000070288384,0.00033540212],"domain_scores_gemma":[0.9993186,0.00016531599,0.00008003899,0.00020827565,0.00008498215,0.0001427781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008491789,0.00019129235,0.00028490147,0.00013656831,0.000069343616,0.000009452125,0.00008777827,0.0001234291,0.00073058973],"category_scores_gemma":[0.000013514176,0.00011907385,0.00006835137,0.00017495044,0.00007721232,0.000030894487,0.000020547024,0.00008650487,0.000017441418],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025480182,0.00011515718,0.175245,0.000010176423,0.00015977168,0.0000074112227,0.0013590934,0.000019766543,0.73721796,0.000014928857,0.00032816053,0.08297455],"study_design_scores_gemma":[0.008895169,0.0007901125,0.7675624,0.000217693,0.00013363229,0.0000013242692,0.000050629344,0.000092654416,0.21266177,0.00006772717,0.009253039,0.00027388395],"about_ca_topic_score_codex":0.0004895435,"about_ca_topic_score_gemma":0.00023657893,"teacher_disagreement_score":0.59231734,"about_ca_system_score_codex":0.00062333565,"about_ca_system_score_gemma":0.00043066422,"threshold_uncertainty_score":0.7999445},"labels":[],"label_agreement":null},{"id":"W2336132735","doi":"10.3747/co.23.2849","title":"Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Lung cancer; Oncology; Wild type; Tyrosine kinase; Cancer research; Internal medicine; Cancer; Biology; Receptor; Genetics","score_opus":0.058213744531025666,"score_gpt":0.4033101495230818,"score_spread":0.3450964049920561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336132735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9426129,0.043623485,0.0005251991,0.0039900895,0.001287053,0.0017590026,0.000141495,0.000027574524,0.0060332124],"genre_scores_gemma":[0.95017326,0.03982718,0.0007636156,0.00039351397,0.0004507349,0.0006327843,0.00011024285,0.00004652825,0.0076021664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99896145,0.00003911331,0.0002393692,0.00030838998,0.0001339542,0.00031770638],"domain_scores_gemma":[0.9990419,0.00009778787,0.00017200402,0.00034920935,0.00019825628,0.00014081532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004442642,0.00020464767,0.00039933037,0.0000652254,0.0000733577,0.000011309879,0.000075778495,0.000075176315,0.0005095114],"category_scores_gemma":[0.000004065229,0.0000880372,0.00008369212,0.00015835137,0.00015782744,0.000094859126,0.000022336928,0.00007424534,0.000020840851],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092492596,0.0068356176,0.1763917,0.0004100591,0.0014315185,0.00002497121,0.010184584,0.000023019733,0.0017602129,0.00008912993,0.0057170973,0.7962072],"study_design_scores_gemma":[0.025243359,0.012496662,0.014419506,0.0008281735,0.004893023,0.00005175586,0.004239455,0.000395701,0.009593466,0.000026002717,0.927434,0.00037886348],"about_ca_topic_score_codex":0.00013729083,"about_ca_topic_score_gemma":0.00019574906,"teacher_disagreement_score":0.9217169,"about_ca_system_score_codex":0.00084630627,"about_ca_system_score_gemma":0.0009911878,"threshold_uncertainty_score":0.55787927},"labels":[],"label_agreement":null},{"id":"W2336729059","doi":"10.1016/s1556-0864(16)30288-x","title":"178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; EMD Serono; Pfizer; Daiichi-Sankyo; Novartis Pharma; Ariad Pharmaceuticals; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Ceritinib; Medicine; Internal medicine; Crizotinib; Oncology; Hazard ratio; Confidence interval; Lung cancer","score_opus":0.017134398721657618,"score_gpt":0.43364449810355965,"score_spread":0.41651009938190203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336729059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98334974,0.000662317,0.00009756456,0.013605633,0.00027794935,0.0005911477,0.000045472112,0.000012859371,0.0013573099],"genre_scores_gemma":[0.9981169,0.00007047028,0.0010968811,0.00015795197,0.00012290697,0.000027460324,0.000026399408,0.000019953255,0.00036108997],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983056,0.00026461523,0.0006008444,0.00016680971,0.00044481634,0.00021730067],"domain_scores_gemma":[0.9975809,0.00020817724,0.001022772,0.00014172056,0.00084544683,0.00020097186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061735464,0.00014073106,0.00054854125,0.00023226648,0.000045024506,0.0000075972384,0.000080830374,0.00013976522,0.000105375766],"category_scores_gemma":[0.00049785123,0.0000740521,0.00010491705,0.00021720423,0.00012306728,0.00020141569,0.000023764882,0.00018204696,0.0000029057535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018314904,0.003111941,0.2339559,0.00010135192,0.0004556962,0.0009729318,0.0013826075,0.0000024449694,0.013051588,0.00002963137,0.0006039481,0.72801703],"study_design_scores_gemma":[0.01698147,0.017157877,0.94322217,0.0065687117,0.0018548279,0.00026350282,0.0008923395,0.000049995666,0.008294142,0.00040842663,0.0040472643,0.00025926044],"about_ca_topic_score_codex":0.000006849511,"about_ca_topic_score_gemma":0.000047195772,"teacher_disagreement_score":0.7277578,"about_ca_system_score_codex":0.0004310522,"about_ca_system_score_gemma":0.0009952115,"threshold_uncertainty_score":0.3019757},"labels":[],"label_agreement":null},{"id":"W2336940083","doi":"10.1021/acs.analchem.6b00707","title":"Initial Diagnosis of <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Based on Analysis of <i>ALK</i> Status Utilizing Droplet Digital PCR","year":2016,"lang":"en","type":"article","venue":"Analytical Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Genome British Columbia","keywords":"Anaplastic lymphoma kinase; Chemistry; Digital polymerase chain reaction; Fusion gene; Molecular biology; Fluorescence in situ hybridization; Cancer research; Crizotinib; Lung cancer; Chromosomal translocation; ALK inhibitor; Gene; Polymerase chain reaction; Chromosome; Biology; Pathology; Biochemistry","score_opus":0.012469087834498904,"score_gpt":0.31523884649443007,"score_spread":0.30276975865993117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336940083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93639857,0.00018899936,0.00068946776,0.0005807018,0.00003346194,0.0002293288,0.0019677016,0.000025216632,0.05988655],"genre_scores_gemma":[0.99834096,0.00010328232,0.00008190887,0.00026444357,0.000075055745,0.000062169114,0.00028154266,0.000025368989,0.00076528394],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840367,0.000012622492,0.00045333445,0.00039552443,0.0003865832,0.00034826936],"domain_scores_gemma":[0.99842453,0.00045578647,0.00019182805,0.00038618242,0.00026306632,0.00027862852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005497913,0.0002309594,0.00064085255,0.00012739384,0.00004005098,0.000016082815,0.00009593662,0.00012588064,0.0008043354],"category_scores_gemma":[0.00011864116,0.00016276138,0.0004265594,0.00066527585,0.00017512677,0.000071948925,0.00003782489,0.00012006107,0.0000037554303],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007153867,0.0024055343,0.9522882,0.00073294673,0.0067401356,0.00013115068,0.00031747675,0.00032739618,0.028114079,0.000037523947,0.0018816039,0.0063085407],"study_design_scores_gemma":[0.009064663,0.0005372564,0.05247003,0.0015484763,0.029497901,0.0000031310526,0.0003810606,0.018504018,0.88608617,0.000018597415,0.0012714611,0.0006172667],"about_ca_topic_score_codex":0.00023676548,"about_ca_topic_score_gemma":0.0000144313835,"teacher_disagreement_score":0.8998182,"about_ca_system_score_codex":0.00028034742,"about_ca_system_score_gemma":0.0004136222,"threshold_uncertainty_score":0.8806909},"labels":[],"label_agreement":null},{"id":"W2337140923","doi":"10.3747/co.23.2955","title":"Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Oncology; Cancer research; Wild type; Internal medicine; Bioinformatics; Biology; Genetics; Gene","score_opus":0.05547052393832417,"score_gpt":0.41040982093982603,"score_spread":0.35493929700150184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337140923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730304,0.014142667,0.00041149653,0.008429707,0.00087301485,0.0016256202,0.00013164512,0.000020549835,0.0013349009],"genre_scores_gemma":[0.97355294,0.011955243,0.001199113,0.00085532153,0.00030207392,0.0008632288,0.000060541115,0.000051373223,0.011160166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988208,0.000092078924,0.00025250664,0.00034305145,0.0001499951,0.00034160548],"domain_scores_gemma":[0.9988026,0.00021698808,0.00014301209,0.0004100603,0.0002251076,0.00020221806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010222407,0.00021147315,0.0004033561,0.00009829821,0.00007727097,0.000012760535,0.00008652279,0.0000739955,0.0003711877],"category_scores_gemma":[0.0000139199,0.00009473296,0.00007820277,0.00022146506,0.00012216397,0.00008209007,0.000029241603,0.00007083216,0.00003183924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013923208,0.008974257,0.12612772,0.00034538435,0.0016212178,0.000056065473,0.025622454,0.00006148295,0.011985089,0.000048544134,0.013409484,0.7978251],"study_design_scores_gemma":[0.016701387,0.015205528,0.016641693,0.0006231415,0.0021758708,0.00003446729,0.003423365,0.00013110336,0.009784675,0.000008478109,0.9349987,0.00027161874],"about_ca_topic_score_codex":0.00012019402,"about_ca_topic_score_gemma":0.00017527275,"teacher_disagreement_score":0.9215892,"about_ca_system_score_codex":0.0011115551,"about_ca_system_score_gemma":0.0013164195,"threshold_uncertainty_score":0.4064245},"labels":[],"label_agreement":null},{"id":"W2337227118","doi":"10.1016/s1556-0864(16)30250-7","title":"140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Gefitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Erlotinib; Adverse effect; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.03421572737096714,"score_gpt":0.4650041278192836,"score_spread":0.43078840044831646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337227118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98465234,0.0004617484,0.0042851996,0.0024422817,0.00073860475,0.005310241,0.00030096192,0.000016072743,0.0017925429],"genre_scores_gemma":[0.97654057,0.0005067028,0.020508727,0.00016566571,0.00049194286,0.0009842148,0.00004515057,0.000052486437,0.0007045544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975719,0.0001238376,0.0012030517,0.00034934925,0.000324258,0.00042764415],"domain_scores_gemma":[0.99553436,0.00083727424,0.00214055,0.00026222694,0.00092006475,0.00030554723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003799158,0.00034280858,0.0012229328,0.00018028784,0.00024503615,0.000033712127,0.00022840156,0.0001517855,0.00011564572],"category_scores_gemma":[0.00034818795,0.00020385135,0.00023201427,0.000245093,0.000086427404,0.00037789711,0.00005382135,0.00014891376,0.0000018947633],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57449734,0.015753685,0.0040407637,0.00036584574,0.0021833153,0.00012320968,0.0014732402,0.0002985719,0.0027886312,0.000018425757,0.00041621,0.39804074],"study_design_scores_gemma":[0.9206968,0.055147454,0.0006299465,0.0021743097,0.004793668,0.00008264826,0.00040526918,0.00046208492,0.010029478,0.000069062204,0.0052058357,0.00030345004],"about_ca_topic_score_codex":0.00013725559,"about_ca_topic_score_gemma":0.0001296738,"teacher_disagreement_score":0.3977373,"about_ca_system_score_codex":0.0023655503,"about_ca_system_score_gemma":0.0025453349,"threshold_uncertainty_score":0.83128166},"labels":[],"label_agreement":null},{"id":"W2338387150","doi":"10.1200/jco.2009.27.15_suppl.8009","title":"Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Vandetanib; Medicine; Erlotinib; Internal medicine; Oncology; Lung cancer; Gastroenterology; Cancer; Epidermal growth factor receptor; Sorafenib","score_opus":0.04300033028782617,"score_gpt":0.43502298832109537,"score_spread":0.3920226580332692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338387150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252933,0.00051847793,0.00009754177,0.0018872123,0.0007827755,0.003298375,0.000011988403,0.000005967826,0.00086835586],"genre_scores_gemma":[0.9952002,0.00040265868,0.0027472412,0.0006792875,0.0005863569,0.00010034693,0.000014359649,0.000026250724,0.00024330804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99631417,0.00020966791,0.0024507488,0.0002849483,0.00043634413,0.0003041129],"domain_scores_gemma":[0.9958616,0.0008540002,0.0022389514,0.00021902683,0.0005012482,0.0003252044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001022039,0.000248571,0.002633755,0.00018513855,0.00003760979,0.000008226235,0.00013007165,0.00032524142,0.0003640171],"category_scores_gemma":[0.0002067077,0.00015999663,0.0005554034,0.00021523041,0.00016297514,0.00014531978,0.00001958004,0.0006284663,0.0000021695066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.950812,0.010905972,0.014897884,0.000037559963,0.0009946054,0.000103736624,0.0005570777,0.000051603754,0.00009795053,0.0000027080375,0.00010869289,0.021430245],"study_design_scores_gemma":[0.93892,0.034413736,0.02280854,0.00035125983,0.0022703959,0.0000061320366,0.000059735103,0.000028552524,0.00025671374,0.0000072123044,0.0007347578,0.00014294505],"about_ca_topic_score_codex":0.000024955234,"about_ca_topic_score_gemma":0.00026593942,"teacher_disagreement_score":0.023507766,"about_ca_system_score_codex":0.0005218173,"about_ca_system_score_gemma":0.0022089023,"threshold_uncertainty_score":0.65244734},"labels":[],"label_agreement":null},{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","score_opus":0.04042620639566981,"score_gpt":0.40655069506489666,"score_spread":0.36612448866922687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339311613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650932,0.0005435644,0.00024605944,0.00524533,0.00069729635,0.014685846,0.00041830647,0.000035044162,0.013035372],"genre_scores_gemma":[0.9889732,0.0005944843,0.0005554717,0.00046228236,0.00062506594,0.006309278,0.0002389847,0.000043205167,0.002198035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982007,0.00023140771,0.00055297033,0.0003777637,0.000232213,0.0004049102],"domain_scores_gemma":[0.99680245,0.001705522,0.0005971078,0.00040592597,0.0003468392,0.00014214564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023528114,0.0003075065,0.0014247695,0.00007388002,0.00019339132,0.00002012219,0.00020236282,0.00011795278,0.00049346604],"category_scores_gemma":[0.00012265531,0.00014154638,0.00011598271,0.00016150187,0.00015847546,0.000087053966,0.0000411895,0.00008712494,0.000015821272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9712113,0.007917766,0.0012832746,0.000046386616,0.003003733,0.000073044335,0.0023946518,0.000027923425,0.00023791914,0.000111848705,0.00084760843,0.01284453],"study_design_scores_gemma":[0.9616703,0.028687034,0.0007298147,0.00016028043,0.0045104614,0.000004461681,0.00011722901,0.00024945792,0.0010163462,0.000019480985,0.0026634878,0.00017164451],"about_ca_topic_score_codex":0.000580292,"about_ca_topic_score_gemma":0.0004465189,"teacher_disagreement_score":0.02388001,"about_ca_system_score_codex":0.0009452555,"about_ca_system_score_gemma":0.0011203759,"threshold_uncertainty_score":0.57720935},"labels":[],"label_agreement":null},{"id":"W2339638771","doi":"10.1016/j.jtho.2016.02.002","title":"Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"World Health Organization","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Confidence interval; Adjuvant therapy; Randomized controlled trial; Adjuvant; Proportional hazards model; Clinical trial; Cancer","score_opus":0.012577229196344153,"score_gpt":0.3953484298414588,"score_spread":0.38277120064511466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339638771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904407,0.0017300716,0.0048571504,0.0006815625,0.0001261161,0.0019328578,0.00014992342,0.000004898766,0.00007667826],"genre_scores_gemma":[0.99769545,0.00018986945,0.0017226548,0.000062908846,0.0000667581,0.00016955228,0.000035228877,0.000015337811,0.00004226976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974164,0.0011146086,0.00088994077,0.00018197286,0.00024090086,0.00015621915],"domain_scores_gemma":[0.99336874,0.004613707,0.0013684524,0.00012429597,0.0004031099,0.000121698235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013039211,0.00017750698,0.002066076,0.0004950334,0.00003354358,0.000007776814,0.00005948322,0.00011089151,0.00010344911],"category_scores_gemma":[0.00068747177,0.00008136713,0.0003050735,0.0003659427,0.00011995269,0.00008475482,0.000009643356,0.00014396028,3.7255927e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23367389,0.00079145376,0.68743485,0.00006553471,0.0075182104,0.000048643422,0.0011062464,0.0004339313,0.00065630703,3.3859405e-7,0.0000286266,0.06824195],"study_design_scores_gemma":[0.317693,0.007751678,0.5918048,0.0008202236,0.07674114,0.000003659338,0.000097795084,0.0020700372,0.0028447101,0.000029206627,0.000022223614,0.000121504825],"about_ca_topic_score_codex":0.00014341313,"about_ca_topic_score_gemma":0.00011271193,"teacher_disagreement_score":0.095630035,"about_ca_system_score_codex":0.00033680734,"about_ca_system_score_gemma":0.0006912313,"threshold_uncertainty_score":0.33180553},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2339800992","doi":"10.1200/jco.2006.24.18_suppl.3054","title":"Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Mucositis; Tolerability; Neutropenia; Internal medicine; Gastroenterology; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Carboplatin; Toxicity; Phases of clinical research; Surgery; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.07360003561611962,"score_gpt":0.4515215525426398,"score_spread":0.3779215169265202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339800992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621683,0.00009148216,0.000012608265,0.00011783294,0.0008482601,0.0023387456,0.00030474775,0.000001620252,0.00006789589],"genre_scores_gemma":[0.99917233,0.000043369844,0.00047612019,0.000038582282,0.00015827634,0.000055594086,0.000018361749,0.000019432377,0.000017950522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909957,0.0014989396,0.0057959105,0.00031364363,0.0011890972,0.0002067336],"domain_scores_gemma":[0.9893478,0.0016026015,0.006876031,0.00021994357,0.0018172106,0.00013642243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036558514,0.00022758255,0.0026042268,0.00027225097,0.000029903273,0.000002618106,0.00021728767,0.00018635324,0.000013286173],"category_scores_gemma":[0.0023164714,0.00013548422,0.00023760094,0.0005282436,0.00023471641,0.00018387582,0.000038265738,0.0005654777,1.535443e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037468437,0.052085374,0.90148246,0.0001225319,0.0007593458,0.000019930092,0.0017757398,0.0018716693,0.0002394861,0.0000056309127,0.00008199836,0.00408742],"study_design_scores_gemma":[0.1736455,0.049761154,0.77352434,0.00050511013,0.0009319992,8.5016836e-7,0.0011011711,0.0001115858,0.00027345325,0.0000088030865,0.000041484807,0.00009454529],"about_ca_topic_score_codex":0.1312,"about_ca_topic_score_gemma":0.4975339,"teacher_disagreement_score":0.3663339,"about_ca_system_score_codex":0.0006373166,"about_ca_system_score_gemma":0.008868809,"threshold_uncertainty_score":0.99675},"labels":[],"label_agreement":null},{"id":"W2340263198","doi":"10.5858/arpa.2016-0091-sa","title":"Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society","year":2016,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytopathology; Lung cancer; Medicine; Pathology; Lung; Cytology; Biomarker; Carcinoma; Cancer; Intensive care medicine; Internal medicine; Biology","score_opus":0.018075318295825843,"score_gpt":0.30432648076941204,"score_spread":0.2862511624735862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340263198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983212,0.0035396859,0.0001236143,0.0061951256,0.00028242348,0.00045112916,0.00021009559,0.000021982392,0.0059639527],"genre_scores_gemma":[0.9969739,0.00014046126,0.0020173334,0.00055773556,0.00011624515,0.00004128516,0.000016202184,0.000024200286,0.0001126885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982071,0.00033935803,0.00052611734,0.00045395514,0.00017095472,0.00030253947],"domain_scores_gemma":[0.9976127,0.001251483,0.00033062388,0.0005266993,0.00019325172,0.00008520259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002295147,0.00021263248,0.00065719057,0.00017257442,0.000058293597,6.5466423e-7,0.00017510295,0.00012937174,0.00012157977],"category_scores_gemma":[0.0006947359,0.00011470931,0.00011949531,0.0004471999,0.0021787474,0.000048810514,0.000107127766,0.00019740874,0.0000017358664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017255012,0.00017283588,0.52880496,0.000042139978,0.00015929331,0.00062716025,0.0068414332,8.5968304e-7,0.4608179,0.00065976905,0.00017685184,0.0015242286],"study_design_scores_gemma":[0.0040310216,0.0004151209,0.9821495,0.0005066502,0.00043102464,0.00020250163,0.0045724483,0.000075551834,0.005484767,0.0018718072,0.00015300975,0.0001066439],"about_ca_topic_score_codex":0.0003901756,"about_ca_topic_score_gemma":0.000102627266,"teacher_disagreement_score":0.45533314,"about_ca_system_score_codex":0.0001406363,"about_ca_system_score_gemma":0.0004529822,"threshold_uncertainty_score":0.8027685},"labels":[],"label_agreement":null},{"id":"W2340723773","doi":"10.1016/s1556-0864(16)30286-6","title":"176P: ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Chemotherapy; Incidence (geometry); Retrospective cohort study; Cohort; Medical record; Population; Cancer; Stage (stratigraphy); Oncology; Disease; Anaplastic lymphoma kinase","score_opus":0.014809282303309438,"score_gpt":0.3853893853732345,"score_spread":0.3705801030699251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340723773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877564,0.001097634,0.00027470556,0.006766502,0.00050788414,0.00030490258,0.000063398555,0.000010164855,0.0032184368],"genre_scores_gemma":[0.99509436,0.0004886434,0.0010608179,0.00073733676,0.00025364966,0.000014917913,0.000004216852,0.000029055554,0.0023170207],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99883807,0.000119761404,0.00045643278,0.00014523264,0.0001892797,0.0002512152],"domain_scores_gemma":[0.99798316,0.00019448077,0.00089923036,0.00016218264,0.0006016264,0.00015932419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032508344,0.0001527478,0.0008413093,0.0001567567,0.00005478823,0.0000059544127,0.000107232445,0.00015224038,0.00032414417],"category_scores_gemma":[0.000054840722,0.00008283023,0.00013432557,0.00018316876,0.000091253874,0.000091594025,0.000018508481,0.00019783854,0.000005576629],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013922676,0.013070239,0.11618319,0.0009648192,0.019724853,0.005314123,0.025904972,0.00015817859,0.37846556,0.00009309665,0.0637525,0.3624458],"study_design_scores_gemma":[0.035542272,0.0271152,0.7179687,0.006456987,0.024034638,0.0012274929,0.0012359364,0.000082535415,0.15512708,0.00073356536,0.029675443,0.0008001771],"about_ca_topic_score_codex":0.00023858827,"about_ca_topic_score_gemma":0.0001322435,"teacher_disagreement_score":0.6017855,"about_ca_system_score_codex":0.00071788504,"about_ca_system_score_gemma":0.0014730504,"threshold_uncertainty_score":0.35491514},"labels":[],"label_agreement":null},{"id":"W2341741235","doi":"10.1016/s1556-0864(16)30248-9","title":"138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Tolerability; Lung cancer; Internal medicine; Adverse effect; Pharmacokinetics; Oncology; Urology; Incidence (geometry); Pharmacology; Gastroenterology; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.012401138771057037,"score_gpt":0.41622696611177845,"score_spread":0.4038258273407214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341741235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950089,0.0025267112,0.00016559052,0.0006847998,0.00011058668,0.00088635937,0.00015382613,0.0000026664163,0.0004606008],"genre_scores_gemma":[0.9977585,0.0010170933,0.0009668302,0.00008968992,0.000048092024,0.00001641942,0.000012580028,0.000020235431,0.00007057316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982949,0.00019672514,0.0008045387,0.00020013099,0.00029090032,0.00021282655],"domain_scores_gemma":[0.9968172,0.00077419146,0.0013863619,0.00018302744,0.0007034607,0.0001358023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029768373,0.00021548201,0.0007930037,0.00029866587,0.00004883906,0.0000045492616,0.000090614034,0.00009737586,0.000067137735],"category_scores_gemma":[0.00010929503,0.0001055799,0.00014404197,0.0002415902,0.00017292019,0.00014304662,0.000034083037,0.00018372448,2.3653377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080456175,0.0056697424,0.50481427,0.00090139534,0.005288552,0.00017484048,0.014967546,0.0037563846,0.035371788,0.00004467444,0.00029235147,0.3482623],"study_design_scores_gemma":[0.014290294,0.013507677,0.9576671,0.001977651,0.0022966517,0.00003667995,0.000907953,0.00023812825,0.008926313,0.000008630956,0.000017098126,0.00012583735],"about_ca_topic_score_codex":0.00021849567,"about_ca_topic_score_gemma":0.000085043735,"teacher_disagreement_score":0.45285285,"about_ca_system_score_codex":0.00076998665,"about_ca_system_score_gemma":0.0008429845,"threshold_uncertainty_score":0.43054232},"labels":[],"label_agreement":null},{"id":"W2342231480","doi":"10.1200/jco.2005.23.16_suppl.7218","title":"Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Carboplatin; Medicine; Cisplatin; Internal medicine; Oncology; Lung cancer; Chemotherapy; Confidence interval; Meta-analysis; Relative risk; Survival analysis; Survival rate","score_opus":0.1327738122868268,"score_gpt":0.5022415155505532,"score_spread":0.36946770326372635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342231480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831371,0.004735957,0.0006227238,0.00840005,0.00013287537,0.00023673924,0.000003588008,0.000004476679,0.0027265232],"genre_scores_gemma":[0.9781294,0.00038327192,0.01791363,0.0029566132,0.00023540539,0.000015794441,0.0000028891914,0.000011999402,0.00035102543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783355,0.00012299039,0.0015189602,0.00018103742,0.00017683496,0.00016660607],"domain_scores_gemma":[0.9973961,0.0010401225,0.0010412422,0.00013180023,0.00017612487,0.00021459787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009509459,0.00013033171,0.0021992205,0.00022070699,0.00002648795,0.000007307438,0.0000672984,0.00015620817,0.00026548948],"category_scores_gemma":[0.00012863078,0.00008707758,0.0007983547,0.00026220884,0.000052770014,0.00006077981,0.000011266354,0.00045941467,0.0000011122786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015791871,0.0016642526,0.86025256,0.00004325871,0.053854268,0.00015516017,0.00055622123,0.029730357,0.00021719237,0.000008045998,0.00026373073,0.051675767],"study_design_scores_gemma":[0.025075419,0.002176127,0.7061726,0.000040705083,0.21996053,0.000016203745,0.0001188973,0.040367737,0.0003786206,0.00001639299,0.0055160015,0.00016081144],"about_ca_topic_score_codex":0.00013511392,"about_ca_topic_score_gemma":0.0012330139,"teacher_disagreement_score":0.16610625,"about_ca_system_score_codex":0.00022486338,"about_ca_system_score_gemma":0.0009793931,"threshold_uncertainty_score":0.35509205},"labels":[],"label_agreement":null},{"id":"W2342494804","doi":"10.1056/nejm-jw.na34145","title":"EML4-ALK Testing in Advanced NSCLC","year":2014,"lang":"en","type":"article","venue":"Journal watch","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crizotinib; Medicine; Oncology; Lung cancer; ALK inhibitor; Pemetrexed; Internal medicine; Chemotherapy; Cisplatin","score_opus":0.016564740233328046,"score_gpt":0.3380741687171631,"score_spread":0.32150942848383507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342494804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447848,0.000201684,0.0004976518,0.014760521,0.0003191545,0.00014288943,8.936948e-7,0.00002559361,0.03926681],"genre_scores_gemma":[0.9892256,0.000048824502,0.0070031066,0.00048166892,0.00029363506,0.0000059788845,0.0000021999806,0.000011909832,0.0029270793],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99942523,0.000019493875,0.00017766882,0.00008367191,0.0001341072,0.00015984333],"domain_scores_gemma":[0.9996003,0.00006534347,0.00006267743,0.000086605774,0.000079912126,0.00010516386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001473963,0.00006510504,0.0001365225,0.000047703514,0.00007704193,0.000019208677,0.000034191,0.000027554333,0.00005729068],"category_scores_gemma":[0.00021237571,0.000046161615,0.000037216432,0.00014818444,0.000009506055,0.00008238512,0.000008228193,0.000193469,0.00003174983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018066006,0.00040221933,0.33413038,0.00005254376,0.000110563305,0.00032950472,0.0018057919,0.00045524765,0.008849424,0.0001768494,0.007633571,0.64587325],"study_design_scores_gemma":[0.016285157,0.0015769876,0.7533774,0.0013874039,0.00036414195,0.0024128633,0.00087119313,0.0020851318,0.0018789093,0.0054196697,0.21396093,0.00038021838],"about_ca_topic_score_codex":0.00002925583,"about_ca_topic_score_gemma":0.00001885566,"teacher_disagreement_score":0.64549303,"about_ca_system_score_codex":0.0001777075,"about_ca_system_score_gemma":0.00008212619,"threshold_uncertainty_score":0.1882416},"labels":[],"label_agreement":null},{"id":"W2343357842","doi":"10.1200/jco.2006.24.18_suppl.6102","title":"Delays in diagnosis and initiating treatment for patients with lung cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Referral; Cancer; Stage (stratigraphy); Cohort; Prospective cohort study; Radiation therapy; Surgery; Internal medicine; Family medicine","score_opus":0.07356683456888244,"score_gpt":0.5099142626954823,"score_spread":0.4363474281265999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343357842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506193,0.0009082823,0.000068423105,0.00257166,0.00020419326,0.00037871092,0.000013575825,0.0000022955821,0.00079093326],"genre_scores_gemma":[0.9941288,0.00061421917,0.00424242,0.00047526296,0.00037689344,0.00008575766,0.000007166986,0.0000085906695,0.000060868424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891555,0.000042624015,0.00075424905,0.00009038778,0.000087845154,0.00010935192],"domain_scores_gemma":[0.99818325,0.0009799923,0.00051285286,0.000040560753,0.00019442002,0.00008893907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021854376,0.00006889493,0.0005363947,0.000060510967,0.000026132027,0.0000041544636,0.000018310286,0.00008670415,0.00001818111],"category_scores_gemma":[0.00020957435,0.0000396266,0.0000890324,0.000051400693,0.000039742932,0.00006048336,0.0000049971095,0.00010648198,1.7778764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009711905,0.0018620077,0.88692015,0.000014061249,0.00021797334,0.000047474958,0.00007370017,0.000039806662,4.93556e-7,0.000033943685,0.00046172852,0.10935744],"study_design_scores_gemma":[0.022114536,0.013359155,0.9527793,0.00013072528,0.00081118656,0.000010082868,0.000036152825,0.000101645004,0.0000068141485,0.00008924473,0.010518802,0.00004234304],"about_ca_topic_score_codex":0.00023735214,"about_ca_topic_score_gemma":0.0006190947,"teacher_disagreement_score":0.10931509,"about_ca_system_score_codex":0.00031850042,"about_ca_system_score_gemma":0.0006672974,"threshold_uncertainty_score":0.16159259},"labels":[],"label_agreement":null},{"id":"W2344399638","doi":"10.1200/jco.2007.25.18_suppl.7585","title":"Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): Final analysis of JBR.10 randomized trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Vinorelbine; Nausea; Quality of life (healthcare); Internal medicine; Clinical endpoint; Randomized controlled trial; Chemotherapy; Stage (stratigraphy); Cancer; Oncology; Surgery; Physical therapy; Cisplatin","score_opus":0.1197165307642956,"score_gpt":0.5607811755889253,"score_spread":0.44106464482462965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344399638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897978,0.00085735804,0.006287058,0.0004650901,0.00046624002,0.0011380195,0.0001279605,0.0000026404107,0.0008578846],"genre_scores_gemma":[0.99405175,0.0006986825,0.0037348352,0.00023829132,0.00055884116,0.000015525045,0.000011575359,0.000016016547,0.0006744709],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937839,0.00041071794,0.005012743,0.00017511094,0.00038487726,0.00023267315],"domain_scores_gemma":[0.9845491,0.007163504,0.006522834,0.00022650776,0.0012130686,0.00032500582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008451729,0.00016712943,0.0050229556,0.00034308154,0.00002137115,0.0000030226388,0.00014840816,0.0003162727,0.00056685193],"category_scores_gemma":[0.0028894162,0.00010314867,0.0036790941,0.0003574647,0.00024639023,0.000057432007,0.000014944892,0.00032400966,2.8354765e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8587385,0.003578349,0.10865118,0.00012858858,0.016183328,0.000011229452,0.0005387858,0.00027754952,0.00058616814,0.000014293303,0.0005103332,0.010781696],"study_design_scores_gemma":[0.65838367,0.011813851,0.3188324,0.000061319115,0.009662769,8.8181025e-7,0.00008552002,0.00039878718,0.0003795948,0.00002315887,0.0002875567,0.00007052416],"about_ca_topic_score_codex":0.0014489705,"about_ca_topic_score_gemma":0.00027572917,"teacher_disagreement_score":0.2101812,"about_ca_system_score_codex":0.00024758434,"about_ca_system_score_gemma":0.0047463384,"threshold_uncertainty_score":0.84198},"labels":[],"label_agreement":null},{"id":"W2345013950","doi":"10.1093/annonc/mdv532.30","title":"446P Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Pemetrexed; Gemcitabine; Afatinib; Lung cancer; Oncology; Gastroenterology; Chemotherapy; Stage (stratigraphy); Cisplatin; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.10346504082146057,"score_gpt":0.4721182781609065,"score_spread":0.36865323733944594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345013950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919328,0.0014816481,0.0002909488,0.0010665464,0.0002992497,0.00099339,0.00017646782,0.000021219392,0.0037377414],"genre_scores_gemma":[0.9966577,0.0002003059,0.0017691017,0.0005284624,0.000098913995,0.00009066541,0.00036934446,0.000027597564,0.00025787446],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99876285,0.0000794742,0.0004209084,0.00026892897,0.00022487347,0.00024298379],"domain_scores_gemma":[0.9982504,0.00037107515,0.00036355446,0.00019179608,0.0006602894,0.00016285351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021750933,0.00016638095,0.00054931565,0.00017322767,0.000048235135,0.000007857511,0.00007356036,0.00009753617,0.000053773143],"category_scores_gemma":[0.00024135991,0.00014897432,0.00013425323,0.0001990521,0.00015635519,0.00012876718,0.000023615232,0.00008249781,0.0000028487757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032188334,0.0119139645,0.27510628,0.0012500028,0.015063179,0.0003162141,0.04389422,0.0004348657,0.009666351,0.0026024505,0.12155813,0.48600602],"study_design_scores_gemma":[0.12039746,0.036566522,0.7640633,0.0005714733,0.0048059514,0.00004477359,0.0059022335,0.0016335245,0.040146388,0.0011141592,0.023922002,0.0008322023],"about_ca_topic_score_codex":0.00037676722,"about_ca_topic_score_gemma":0.00006949927,"teacher_disagreement_score":0.48895705,"about_ca_system_score_codex":0.00013706587,"about_ca_system_score_gemma":0.00036872944,"threshold_uncertainty_score":0.60749966},"labels":[],"label_agreement":null},{"id":"W2346194474","doi":"10.1200/jco.2007.25.18_suppl.7513","title":"Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gefitinib; Docetaxel; Internal medicine; Hazard ratio; Interim analysis; Regimen; Randomization; Lung cancer; Surgery; Clinical endpoint; Randomized controlled trial; Chemotherapy; Cancer; Confidence interval; Epidermal growth factor receptor","score_opus":0.02211199768896288,"score_gpt":0.4177544959195442,"score_spread":0.39564249823058134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346194474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933582,0.00026769438,0.0025886921,0.00022745797,0.000593751,0.0017118325,0.00013026947,0.000004077351,0.001118026],"genre_scores_gemma":[0.99680966,0.00033055025,0.0020380886,0.0002883082,0.0001010452,0.0000651567,0.000110403234,0.000018478186,0.00023829514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954281,0.00028120793,0.0032853533,0.00025415653,0.00044238393,0.00030882587],"domain_scores_gemma":[0.991981,0.0024547454,0.004096697,0.00017573292,0.0010350022,0.00025677567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002493039,0.00020762814,0.0031577074,0.00040125806,0.00002104927,0.0000042073652,0.00010523631,0.00027741087,0.00016051944],"category_scores_gemma":[0.0010458234,0.0001387921,0.0006981139,0.00065351574,0.00021603443,0.00012489542,0.000019850626,0.00046873075,4.5329827e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9529507,0.005988196,0.028841786,0.00003123184,0.0054779667,0.00011176354,0.00044424535,0.00037854747,0.000056538865,0.000005873015,0.0001923283,0.005520779],"study_design_scores_gemma":[0.94603735,0.013351998,0.02702634,0.0001587598,0.011921967,6.2982804e-7,0.00021672025,0.00067670195,0.00020698083,0.0000027408157,0.00027680496,0.00012299242],"about_ca_topic_score_codex":0.00020352838,"about_ca_topic_score_gemma":0.0006069446,"teacher_disagreement_score":0.007363802,"about_ca_system_score_codex":0.0004696637,"about_ca_system_score_gemma":0.001741514,"threshold_uncertainty_score":0.56597775},"labels":[],"label_agreement":null},{"id":"W2346455687","doi":"10.6000/1927-7229.2015.04.03.1","title":"Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors","year":2015,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; Lung cancer; Epidermal growth factor receptor; Progression-free survival; Performance status; Erlotinib Hydrochloride; Cancer; Chemotherapy","score_opus":0.020525075217112748,"score_gpt":0.3760198581670536,"score_spread":0.35549478294994086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346455687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310595,0.0009936414,0.00017576232,0.0025476287,0.00024122323,0.0005192224,0.000010434778,0.0000052098253,0.0024009056],"genre_scores_gemma":[0.99202925,0.00027237085,0.003964962,0.0015861071,0.0002687298,0.000016203388,0.000012842526,0.000023477309,0.0018260569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910116,0.000020461504,0.00035806195,0.00014321585,0.00017736589,0.0001997565],"domain_scores_gemma":[0.99830127,0.00012851575,0.00028367972,0.000087699664,0.00083454367,0.0003642797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014765392,0.0001303883,0.0004984328,0.000103334016,0.000039079983,0.000010093741,0.000054549597,0.00007903874,0.00009831106],"category_scores_gemma":[0.000077807636,0.00007925033,0.00007481186,0.00013289433,0.00006695503,0.000087344975,0.0000113901215,0.00017593401,0.0000018886558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042199485,0.007518915,0.8310601,0.0003075367,0.0043435954,0.00060352654,0.0036448268,0.00069884834,0.0005100296,0.00042065486,0.02544717,0.08324532],"study_design_scores_gemma":[0.19140716,0.20132099,0.30672503,0.00072582375,0.007240774,0.0006062781,0.0021643362,0.005051215,0.0013340401,0.0007577088,0.2818554,0.0008112526],"about_ca_topic_score_codex":0.000017155955,"about_ca_topic_score_gemma":0.000027890952,"teacher_disagreement_score":0.5243351,"about_ca_system_score_codex":0.00034746996,"about_ca_system_score_gemma":0.0014848841,"threshold_uncertainty_score":0.32317343},"labels":[],"label_agreement":null},{"id":"W2354104805","doi":"","title":"The evaluations of advanced non-small cell lung cancer patients treated with erlotnib","year":2007,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Rash; Erlotinib; Tolerability; Oncology; Univariate analysis; Progressive disease; Statistical significance; Gastroenterology; Toxicity; Log-rank test; Multivariate analysis; Adverse effect; Disease; Survival analysis; Cancer; Epidermal growth factor receptor","score_opus":0.009504661274028018,"score_gpt":0.33327126571845134,"score_spread":0.32376660444442334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2354104805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567235,0.0003310747,0.0005362841,0.00017632073,0.00006400741,0.0009918548,0.00001623573,0.000024436013,0.041136272],"genre_scores_gemma":[0.98760086,0.000069908725,0.0010235903,0.00010532389,0.00002320844,0.000101409234,0.0000447448,0.000015514663,0.011015439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993046,0.000008225321,0.00018541676,0.00012933214,0.00019819019,0.00017422783],"domain_scores_gemma":[0.9992103,0.00007844648,0.000087905595,0.0001833838,0.00036600447,0.00007399018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007796322,0.00009415155,0.00012319948,0.00004358572,0.0001219851,0.0000059831814,0.000041874253,0.000026560989,0.00010053273],"category_scores_gemma":[0.0000105961635,0.000047654717,0.000037193488,0.00020953202,0.000038958275,0.0000379024,0.000007603516,0.000047293568,0.0000038657404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038643496,0.00061947934,0.9704034,0.000056111265,0.00032841443,0.0000036755919,0.0010573157,0.00018786083,0.0018061759,0.00010447997,0.0010485257,0.023998164],"study_design_scores_gemma":[0.007663107,0.0007893526,0.95934415,0.00012091163,0.0010215666,0.0000010686556,0.0006400757,0.000330798,0.028061962,0.0000072526527,0.0019068845,0.00011287544],"about_ca_topic_score_codex":0.00053657417,"about_ca_topic_score_gemma":0.0011855417,"teacher_disagreement_score":0.030877348,"about_ca_system_score_codex":0.00014683636,"about_ca_system_score_gemma":0.00020529854,"threshold_uncertainty_score":0.1943303},"labels":[],"label_agreement":null},{"id":"W2358862840","doi":"10.1093/annonc/mdu349.74","title":"Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Ceritinib; Anaplastic lymphoma kinase; Medicine; Crizotinib; Lung cancer; ALK inhibitor; Alectinib; Anaplastic large-cell lymphoma; Cancer research; Lymphoma; Oncology; Internal medicine","score_opus":0.014815493515201703,"score_gpt":0.34389950172465844,"score_spread":0.3290840082094567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2358862840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402696,0.00043428154,0.000056845878,0.00035044222,0.00007730278,0.00068092626,0.000113124646,0.000008758017,0.0042513707],"genre_scores_gemma":[0.9980893,0.00051805144,0.00088702474,0.00027895384,0.000027620626,0.00004423221,0.0000967561,0.000023303004,0.000034744466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987859,0.00008824128,0.00045328707,0.00027172195,0.00015112394,0.0002496855],"domain_scores_gemma":[0.9988147,0.00014114857,0.00034849317,0.00024520807,0.00031051337,0.0001399416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014465247,0.00016618942,0.0006388399,0.00015934103,0.000030266767,0.0000021481635,0.00007810072,0.00010196637,0.000043153643],"category_scores_gemma":[0.00004830502,0.00013473998,0.000045771154,0.00018776773,0.000156803,0.000085686894,0.000027537108,0.00006999911,7.9533453e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021354314,0.0074979584,0.3912747,0.0011980446,0.0005325365,0.00003773792,0.0035143518,0.0006431457,0.006015308,0.0001669713,0.00035487735,0.56741005],"study_design_scores_gemma":[0.043849453,0.015724478,0.9238765,0.00066178676,0.0004221434,0.0000039775596,0.00021685782,0.00027844918,0.010374294,0.000014395496,0.0043908567,0.0001867887],"about_ca_topic_score_codex":0.0005401487,"about_ca_topic_score_gemma":0.00068968395,"teacher_disagreement_score":0.56722325,"about_ca_system_score_codex":0.000071688664,"about_ca_system_score_gemma":0.0003526366,"threshold_uncertainty_score":0.54945374},"labels":[],"label_agreement":null},{"id":"W2362271377","doi":"","title":"Influence of different dose-intensity navelbine plus cisplatin as the first-line treatment in patients with advanced non-small cell lung cancer","year":2008,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Internal medicine; Cisplatin; Oncology; Lung cancer; Univariate analysis; Stage (stratigraphy); Chemotherapy; Log-rank test; Cancer; Survival analysis; Multivariate analysis","score_opus":0.008688789253041937,"score_gpt":0.27237065460667453,"score_spread":0.2636818653536326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2362271377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963673,0.0001585459,0.0000293743,0.0004953045,0.0000434368,0.0016837684,0.000024390129,0.000020906078,0.0011770268],"genre_scores_gemma":[0.9970988,0.00024517445,0.00019782817,0.00040433567,0.000019330875,0.00024061848,0.00004618252,0.000019672689,0.0017280732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898225,0.000010200573,0.0002850711,0.00026303268,0.00023148117,0.0002279456],"domain_scores_gemma":[0.9991892,0.00005060401,0.00012754965,0.00032207376,0.00022172695,0.00008883443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000018574105,0.00022699089,0.0004015844,0.000065178654,0.00010146096,0.0000036948675,0.000067132794,0.000043860047,0.00006666537],"category_scores_gemma":[0.000009010507,0.00010991954,0.00005975951,0.0001890538,0.00007317518,0.000056686247,0.000026993921,0.000090597125,0.000004473332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001160218,0.0011085727,0.98441637,0.000065240674,0.00017982087,0.000032184962,0.0028020146,0.009236027,0.00009526876,0.000008096048,0.000040850915,0.0008553427],"study_design_scores_gemma":[0.01455214,0.001721337,0.9777556,0.00020491132,0.00029271506,0.000004751435,0.00008430801,0.0006868888,0.0044810697,0.0000042908623,0.000090498586,0.00012149749],"about_ca_topic_score_codex":0.0043889233,"about_ca_topic_score_gemma":0.002509954,"teacher_disagreement_score":0.013391921,"about_ca_system_score_codex":0.000604707,"about_ca_system_score_gemma":0.00027460622,"threshold_uncertainty_score":0.6634768},"labels":[],"label_agreement":null},{"id":"W2373606074","doi":"10.1016/j.ejca.2016.03.081","title":"RECIST 1.1—Update and clarification: From the RECIST committee","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1894,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Cancer Society Research Institute; National Cancer Institute; National Cancer Research Institute","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Medical physics; Radiology; Disease; Progressive disease; Internal medicine","score_opus":0.022424082969743978,"score_gpt":0.3170312627307039,"score_spread":0.29460717976095996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2373606074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46964106,0.065458275,0.0067907134,0.3917363,0.0023289786,0.00048429833,0.00024920213,0.000043511576,0.06326764],"genre_scores_gemma":[0.98482955,0.0055079428,0.0011244792,0.002432642,0.0011566348,0.000002280925,0.0000034021002,0.00002285207,0.004920198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993033,0.0001283246,0.0002438411,0.00008520279,0.00016220518,0.000077127166],"domain_scores_gemma":[0.99925476,0.000093611394,0.00020493809,0.00018119448,0.00017686305,0.00008861797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002968982,0.00006933054,0.00012453677,0.000021383237,0.00008296892,0.000026572814,0.00009291719,0.000010706583,0.0003734255],"category_scores_gemma":[0.000057735597,0.000030433763,0.00004933706,0.00005344315,0.00008391327,0.00007962236,0.000016165926,0.00010875717,0.000037613394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022025037,0.000038926806,0.022916727,0.0000036638503,0.00036034794,0.00011292534,0.00044940325,7.601432e-7,0.002245894,0.00031923284,0.08184233,0.8914895],"study_design_scores_gemma":[0.0017851156,0.00010212297,0.24901196,0.00022074091,0.0002612474,0.00005147165,0.000060751056,6.0674273e-7,0.0002797748,0.00015061279,0.74803454,0.00004103059],"about_ca_topic_score_codex":0.000037781338,"about_ca_topic_score_gemma":0.000020802841,"teacher_disagreement_score":0.8914485,"about_ca_system_score_codex":0.00007267913,"about_ca_system_score_gemma":0.00008565142,"threshold_uncertainty_score":0.4088747},"labels":[],"label_agreement":null},{"id":"W2395110963","doi":"10.1158/1557-3265.pmsclingen15-02","title":"Abstract 02: Pan-cancer analysis of hotspot mutations in genes encoding the members of mitogen activated protein kinase (MAPK) and phosphoinosidtide-3 kinase (PI3K) pathways among smokers and non-smokers","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; PTEN; Neuroblastoma RAS viral oncogene homolog; Medicine; Lung cancer; Cancer research; Oncology; CDKN2A; STK11; Internal medicine; Amplicon; PI3K/AKT/mTOR pathway; Cancer; Gene; Biology; Genetics; Colorectal cancer; Signal transduction","score_opus":0.11947682819167309,"score_gpt":0.46531219065385726,"score_spread":0.34583536246218416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395110963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350125,0.0030075687,0.0000066579646,0.0016018299,0.000080086305,0.0012794544,0.0002450227,0.000011945409,0.00026618422],"genre_scores_gemma":[0.9949832,0.0039977874,0.00006190072,0.00004185689,0.00005006324,0.0006033243,0.000017175716,0.000025663732,0.00021903252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974379,0.00021450692,0.00080253946,0.00053428876,0.00059575133,0.00041501442],"domain_scores_gemma":[0.9970912,0.0015318367,0.00027748835,0.00042760314,0.00045593592,0.00021593749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013499677,0.0001875575,0.00064688775,0.00047075562,0.00015250378,0.00002390774,0.00015853293,0.00015701813,0.00030787097],"category_scores_gemma":[0.00062386337,0.000110861365,0.00019410726,0.001384425,0.0012545048,0.00015988424,0.00010079125,0.00037729475,0.0000010468351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097346265,0.0003092186,0.7972529,0.00020953442,0.0020206284,0.00003833977,0.0015164288,0.000053157015,0.12043288,0.000044353867,0.0001102015,0.077038884],"study_design_scores_gemma":[0.0032072251,0.00027081254,0.89372283,0.0007040354,0.0008378502,4.3789532e-7,0.001261084,0.00013227774,0.09950402,0.00008302377,0.00015046171,0.00012597232],"about_ca_topic_score_codex":0.01865416,"about_ca_topic_score_gemma":0.004158077,"teacher_disagreement_score":0.0964699,"about_ca_system_score_codex":0.00027105582,"about_ca_system_score_gemma":0.00072099763,"threshold_uncertainty_score":0.9878807},"labels":[],"label_agreement":null},{"id":"W2398991740","doi":"10.1016/j.jtcvs.2016.05.028","title":"Narcissus, the beam and lung cancer: What is the message?","year":2016,"lang":"en","type":"letter","venue":"Journal of Thoracic and Cardiovascular Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; General surgery; Surgery; Pathology","score_opus":0.014323451959942432,"score_gpt":0.3141893539292564,"score_spread":0.29986590196931395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398991740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004542171,0.5397704,0.0000906707,0.4541353,0.001069009,0.00026061895,0.000022348286,0.000006173502,0.00010325842],"genre_scores_gemma":[0.021254638,0.64212996,0.000035995323,0.31806517,0.013286849,0.00008077721,0.00001862863,0.00010842685,0.0050195362],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979359,0.00024120546,0.00044695815,0.0002498291,0.00083555933,0.0002905818],"domain_scores_gemma":[0.9981212,0.0005788731,0.0003488521,0.0005687671,0.00028016567,0.0001021157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014769515,0.00028653213,0.0010451704,0.00014113421,0.00026596372,0.00020272055,0.00012839914,0.0002661056,0.000050488725],"category_scores_gemma":[0.00004418665,0.0001168459,0.0015880398,0.00012706379,0.00020843832,0.0002771692,0.000055944907,0.0008845048,0.000001093794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047171514,0.0000069002917,0.0014817601,0.00032208246,0.0125447465,0.0008651224,0.00037346486,0.0000013923604,0.0000027863805,5.450296e-7,0.6810076,0.3033464],"study_design_scores_gemma":[0.0002757561,0.00002710152,0.0014118687,0.002235982,0.012578333,0.0027381757,0.00029877608,0.0000021331966,0.00008078379,0.000042101878,0.98014885,0.00016016349],"about_ca_topic_score_codex":0.000056538527,"about_ca_topic_score_gemma":0.0000010530673,"teacher_disagreement_score":0.30318624,"about_ca_system_score_codex":0.00009955472,"about_ca_system_score_gemma":0.0004096637,"threshold_uncertainty_score":0.47648376},"labels":[],"label_agreement":null},{"id":"W2399551246","doi":"10.1200/jco.2005.23.16_suppl.7233","title":"Bimodality versus trimodality therapy for locally advanced non-small cell lung cancer (NSCLC) at the British Columbia Cancer Agency: Favorable outcomes and low treatment-related mortality with multidisciplinary patient selection","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Radiation therapy; Surgery; Cancer; Retrospective cohort study; Lung cancer; Induction chemotherapy; Stage (stratigraphy); Performance status; Chemotherapy; Internal medicine","score_opus":0.04526821462993005,"score_gpt":0.43913695265222485,"score_spread":0.39386873802229483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399551246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078685,0.0030197292,0.00015381513,0.0028705113,0.00084446743,0.0018185407,0.00010060144,0.000016421076,0.00038905462],"genre_scores_gemma":[0.99045193,0.0052901395,0.0011233628,0.00052527746,0.0002751305,0.00029646413,0.000017162758,0.000029131315,0.0019913714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974531,0.00023255557,0.0013860012,0.00035984753,0.00025526911,0.00031320838],"domain_scores_gemma":[0.9967375,0.0009022377,0.001335041,0.00019106503,0.00054386014,0.00029030576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068818335,0.00019694943,0.001113219,0.000025300767,0.000465904,0.000057674817,0.00008373025,0.00025609654,0.00017597825],"category_scores_gemma":[0.00011381058,0.00013701705,0.00038867816,0.0001449847,0.00020845467,0.00015380254,0.000028696846,0.0003507846,6.920027e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006141912,0.002617555,0.7421035,0.000033941564,0.0019703726,0.00003862015,0.0004508202,0.0010197234,0.00009924768,7.340596e-7,0.000670078,0.24485347],"study_design_scores_gemma":[0.051419,0.014272184,0.9263963,0.00014381699,0.002005964,0.000034240744,0.00017376084,0.0015142944,0.0001854259,0.000030012417,0.0036621357,0.00016284733],"about_ca_topic_score_codex":0.015686003,"about_ca_topic_score_gemma":0.14213511,"teacher_disagreement_score":0.24469063,"about_ca_system_score_codex":0.0014331666,"about_ca_system_score_gemma":0.0057971803,"threshold_uncertainty_score":0.999839},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":true,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2402016156","doi":"10.1158/1535-7163.targ-15-b194","title":"Abstract B194: Tivantinib in combination with erlotinib vs erlotinib alone for EGFR mutant NSCLC: Subgroup results from the phase 3 MARQUEE study","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Cancer; Medicine; Oncology; Pharmacology; Internal medicine; Epidermal growth factor receptor","score_opus":0.04897850486155135,"score_gpt":0.3676255073323042,"score_spread":0.31864700247075284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402016156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842637,0.0012951668,0.001618559,0.0064398036,0.00034092128,0.004727358,0.00052150217,0.00007664242,0.00071634486],"genre_scores_gemma":[0.9956507,0.00006652554,0.0007831444,0.0019810325,0.0001352446,0.0006346029,0.0004838177,0.000083075734,0.00018186419],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980027,0.00009705311,0.0004949968,0.0005068568,0.0005221346,0.00037627592],"domain_scores_gemma":[0.9984978,0.00020307556,0.000241893,0.000585317,0.00032977498,0.00014216654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040078175,0.00031114556,0.00042935333,0.000085965185,0.00011552505,0.000064532294,0.00018618301,0.00009674064,0.000021034097],"category_scores_gemma":[0.000043915476,0.00020502754,0.00009179253,0.00034671722,0.00008746585,0.00009311345,0.000026160067,0.00024746745,0.0000073569586],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14835003,0.056814726,0.18825287,0.00031558357,0.01631612,0.0027756016,0.1359509,0.0027630453,0.09458607,0.0017521166,0.0044134436,0.3477095],"study_design_scores_gemma":[0.50028527,0.021848878,0.28084508,0.0013899195,0.0079578785,0.00005753606,0.02038158,0.0038364062,0.057263415,0.0016991277,0.10239849,0.0020364486],"about_ca_topic_score_codex":0.0024704624,"about_ca_topic_score_gemma":0.0016374817,"teacher_disagreement_score":0.3519352,"about_ca_system_score_codex":0.00035717656,"about_ca_system_score_gemma":0.0005531373,"threshold_uncertainty_score":0.83607805},"labels":[],"label_agreement":null},{"id":"W2402920640","doi":"","title":"Downregulating activated epidermal growth factor receptor has no effect on RBM5 expression.","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Epidermal growth factor receptor; Cancer research; Lung cancer; Adenocarcinoma; KRAS; Epidermal growth factor; Cell growth; Biology; Small interfering RNA; Gene expression; Medicine; Pathology; Cancer; Cell culture; Receptor; Internal medicine; Gene; Transfection; Colorectal cancer","score_opus":0.02954303446121928,"score_gpt":0.28825249969319283,"score_spread":0.2587094652319736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402920640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98455906,0.00014207429,0.000021274838,0.00087216386,0.0007467546,0.0014090234,0.00002690263,0.0001572274,0.012065525],"genre_scores_gemma":[0.9944558,0.000003933266,0.00031399232,0.0003121106,0.0006993439,0.0015265491,0.00007767331,0.00003302576,0.002577538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988181,0.00007679661,0.00017194799,0.000204055,0.00022914345,0.0004999425],"domain_scores_gemma":[0.9990817,0.00022316111,0.00008511893,0.0002096227,0.00006053233,0.0003398745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013574974,0.00017733712,0.00024422735,0.00007831035,0.00015479409,0.000026193915,0.00004712148,0.000084384716,0.00032349728],"category_scores_gemma":[0.00040662216,0.000118083364,0.0000927483,0.00012281399,0.00003542762,0.00021186777,0.000023500266,0.00014042524,0.00018614672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017697879,0.0015140526,0.39310563,0.00038569793,0.0009566558,0.00002129965,0.0020451606,0.000006243171,0.15035005,0.00018082294,0.044532306,0.4051323],"study_design_scores_gemma":[0.0022249497,0.0001531036,0.73301744,0.00007146682,0.00011479152,0.0000067932456,0.000017345117,0.000003067046,0.25159425,0.0000044901817,0.01265088,0.00014144753],"about_ca_topic_score_codex":0.00003550614,"about_ca_topic_score_gemma":3.7236427e-7,"teacher_disagreement_score":0.40499085,"about_ca_system_score_codex":0.00022895791,"about_ca_system_score_gemma":0.000029370098,"threshold_uncertainty_score":0.48152998},"labels":[],"label_agreement":null},{"id":"W2403654892","doi":"10.1016/j.jtho.2016.05.008","title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Pfizer Canada; Chugai Pharmaceutical; Eisai; National Comprehensive Cancer Network; Ariad Pharmaceuticals; Genentech; AstraZeneca Canada; EMD Serono; International Association for the Study of Lung Cancer; Gilead Sciences; GlaxoSmithKline; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Osimertinib; Epidermal growth factor receptor; Oncology; Internal medicine; Erlotinib; Targeted therapy; Tyrosine kinase; Cancer; Receptor","score_opus":0.03320840595427421,"score_gpt":0.4896282325833793,"score_spread":0.4564198266291051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403654892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003583349,0.9835849,0.00028207563,0.0029303632,0.0024990735,0.005433189,0.00046922223,0.0000038747876,0.0012139828],"genre_scores_gemma":[0.0041208426,0.99143296,0.000686978,0.00005471497,0.00023122448,0.000739895,0.000019787529,0.0000326213,0.00268098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997203,0.00029422145,0.0015243673,0.00020624841,0.0004942234,0.00027797688],"domain_scores_gemma":[0.9927451,0.0020453902,0.004118617,0.00018659452,0.00083788147,0.00006640367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013028738,0.00023979931,0.0011395379,0.00027639538,0.000109915956,0.000018487219,0.00025293906,0.00013018491,0.000032417083],"category_scores_gemma":[0.00006837044,0.00011891222,0.00031280288,0.00017822994,0.000044348322,0.000042229,0.000060265746,0.00031272802,6.0148733e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012945391,0.0012547084,0.00095267396,0.003704236,0.011309783,0.00010735767,0.002123248,0.0009761073,0.000003164729,0.00003476341,0.0047902823,0.9734491],"study_design_scores_gemma":[0.015524501,0.006369264,0.0036848458,0.058912415,0.048909117,0.000052502615,0.011488894,0.00073178316,0.0000905084,0.000046812005,0.8537201,0.00046920902],"about_ca_topic_score_codex":0.00032225158,"about_ca_topic_score_gemma":0.0003509795,"teacher_disagreement_score":0.9729799,"about_ca_system_score_codex":0.007290891,"about_ca_system_score_gemma":0.0024491304,"threshold_uncertainty_score":0.9965199},"labels":[],"label_agreement":null},{"id":"W2406780605","doi":"10.1200/jco.2009.27.15_suppl.8039","title":"Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Neutropenia; Placebo; Internal medicine; Gemcitabine; Bevacizumab; Adverse effect; Clinical endpoint; Gastroenterology; Phases of clinical research; Surgery; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.04465509602666898,"score_gpt":0.4493318156673473,"score_spread":0.4046767196406783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406780605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445045,0.00074514287,0.0001996731,0.0011187211,0.00037664623,0.002457285,0.00006300661,0.0000048003576,0.00058428023],"genre_scores_gemma":[0.99516314,0.0016973855,0.002572419,0.00017164307,0.00015127077,0.000035231024,0.00001879211,0.000016499676,0.00017362522],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943867,0.00036941317,0.004231182,0.0003192367,0.0004344848,0.00025901903],"domain_scores_gemma":[0.99300164,0.002081286,0.0035437667,0.00024315422,0.0008497305,0.0002804506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017880986,0.0002527954,0.0031208515,0.00023253063,0.000049771246,0.0000044937287,0.0001279972,0.00019237153,0.000045559853],"category_scores_gemma":[0.0015099006,0.00014768331,0.00025692905,0.00030251849,0.00016724937,0.00011352248,0.000034987606,0.00061184424,3.2972554e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76651096,0.026564274,0.029584544,0.000095832766,0.00057410385,0.00021945177,0.0017460494,0.00039979536,0.000013638331,0.00000146949,0.00017854168,0.17411135],"study_design_scores_gemma":[0.7887407,0.10757202,0.0987974,0.0007479306,0.0023480076,0.000022229468,0.00032567873,0.0008667269,0.000034726407,0.000012440742,0.00040550975,0.00012663857],"about_ca_topic_score_codex":0.0001930574,"about_ca_topic_score_gemma":0.001459864,"teacher_disagreement_score":0.1739847,"about_ca_system_score_codex":0.0002857793,"about_ca_system_score_gemma":0.0014220135,"threshold_uncertainty_score":0.6022351},"labels":[],"label_agreement":null},{"id":"W2409115721","doi":"10.1016/j.jval.2015.09.1199","title":"Cost-Effectiveness Of Ceritinib In Previously Treated Patients With Crizotinib In Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In Canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Medicine; Ceritinib; Pemetrexed; Internal medicine; Oncology; Lung cancer; Population; Anaplastic large-cell lymphoma; Lymphoma; Chemotherapy","score_opus":0.025349565040491275,"score_gpt":0.3133472650491722,"score_spread":0.2879977000086809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409115721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457824,0.000847182,0.000009781404,0.00009808014,0.00012714302,0.0037581392,0.00019856688,0.0000071954128,0.00037569847],"genre_scores_gemma":[0.9989734,0.0000845011,0.000102159094,0.00010157054,0.000012150176,0.0005481829,0.00013136906,0.000029833076,0.00001678291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980732,0.00035539144,0.0005203887,0.00034108447,0.00025289663,0.00045699393],"domain_scores_gemma":[0.9990202,0.00028442396,0.00017130845,0.00016830985,0.00013644416,0.0002192971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003192262,0.00019823745,0.0005832086,0.0003081016,0.000018579181,0.00000469868,0.00006376645,0.000056493995,0.0000062497993],"category_scores_gemma":[0.00005813436,0.00017075807,0.000019700561,0.0007605898,0.000027708931,0.00006544953,0.000016288219,0.0001386099,4.7905735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001346937,0.0008256498,0.9726627,0.001081521,0.000023047422,0.00014447395,0.0025832083,0.018870434,0.0000057632024,0.0000060322063,0.000020285474,0.0024299738],"study_design_scores_gemma":[0.020428855,0.0011042369,0.9688767,0.0050526178,0.00003637261,0.0000022002178,0.0005743737,0.0035165527,0.00025165477,0.000004687735,0.000014062577,0.00013766081],"about_ca_topic_score_codex":0.9817974,"about_ca_topic_score_gemma":0.94123477,"teacher_disagreement_score":0.040562622,"about_ca_system_score_codex":0.00903594,"about_ca_system_score_gemma":0.009641924,"threshold_uncertainty_score":0.9959725},"labels":[],"label_agreement":null},{"id":"W2410584117","doi":"10.1016/j.cllc.2016.05.012","title":"Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non–small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McMaster University; CancerCare Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Lung cancer; Internal medicine; Referral; Chemotherapy; Cancer; Population; Comorbidity; Cohort; Retrospective cohort study; Malignancy; Oncology; Family medicine","score_opus":0.03130862013876824,"score_gpt":0.4316367468939699,"score_spread":0.4003281267552017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410584117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247414,0.0006238114,0.0013913374,0.0018270153,0.0003315081,0.0023079778,0.00050748466,0.000024232799,0.000512484],"genre_scores_gemma":[0.9907318,0.002409681,0.0014305124,0.00061475066,0.00026511043,0.0012755204,0.000047477082,0.00004929858,0.0031758787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986134,0.000025988842,0.00046103302,0.00044884364,0.00017732807,0.00027341265],"domain_scores_gemma":[0.9988143,0.00020958,0.00024229,0.00029658747,0.00023852597,0.00019874123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008604662,0.00022667383,0.00053288584,0.00004356982,0.000061325445,0.000010922812,0.000059434988,0.0001103563,0.00024908988],"category_scores_gemma":[0.00000926836,0.00011936615,0.000146867,0.00006228871,0.00008429245,0.000064244225,0.000015619702,0.00006954647,4.209339e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004991374,0.0008017036,0.9197968,0.00022099145,0.00094287546,0.0000018196191,0.000121339064,0.000002778555,0.00006897247,0.000015014002,0.0010926817,0.076435864],"study_design_scores_gemma":[0.025850167,0.0034237115,0.96450996,0.00071329984,0.0017520847,4.2976723e-7,0.000023148315,0.00020175453,0.00033588754,0.000007312726,0.003006168,0.0001760577],"about_ca_topic_score_codex":0.00041102522,"about_ca_topic_score_gemma":0.00046458535,"teacher_disagreement_score":0.07625981,"about_ca_system_score_codex":0.0005073068,"about_ca_system_score_gemma":0.0005954219,"threshold_uncertainty_score":0.48676103},"labels":[],"label_agreement":null},{"id":"W2415409512","doi":"10.1016/j.jtho.2016.05.029","title":"Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma; PharmaMar; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer; Eli Lilly and Company","keywords":"Crizotinib; Medicine; Ceritinib; Oncology; Alectinib; ALK inhibitor; Internal medicine; Targeted therapy; Lung cancer; Cancer","score_opus":0.03761913424189329,"score_gpt":0.46634445798500007,"score_spread":0.4287253237431068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415409512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946908,0.002127876,0.00026298905,0.0010616991,0.00009822232,0.00062753505,0.000015876289,0.0000128427655,0.0011021626],"genre_scores_gemma":[0.99594975,0.00015277983,0.0035261451,0.00012860715,0.000109419234,0.000019040577,0.0000073180977,0.000016865044,0.00009009784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983066,0.00033273958,0.00073879585,0.00017910782,0.0002174868,0.00022532506],"domain_scores_gemma":[0.9980362,0.00043379143,0.00080019725,0.00013376477,0.00040801862,0.00018801096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024984006,0.00018486749,0.0010976786,0.00022779123,0.000040714534,0.000009944689,0.00008607163,0.00010574497,0.00009850662],"category_scores_gemma":[0.000086927044,0.0001023535,0.000074698975,0.00015265918,0.0002299418,0.00024014078,0.000013286816,0.00020693387,0.0000018686862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09656645,0.0051137195,0.11340683,0.00010673229,0.0016665464,0.0009303276,0.016680509,0.00006903925,0.12703906,0.00012186397,0.00008961281,0.6382093],"study_design_scores_gemma":[0.05622262,0.054980118,0.83230186,0.0025754063,0.0018917181,0.0020698209,0.0062661357,0.00008353543,0.040813666,0.00019054505,0.002283904,0.00032065512],"about_ca_topic_score_codex":0.00005585101,"about_ca_topic_score_gemma":0.00013649832,"teacher_disagreement_score":0.718895,"about_ca_system_score_codex":0.00020462205,"about_ca_system_score_gemma":0.000491214,"threshold_uncertainty_score":0.41738546},"labels":[],"label_agreement":null},{"id":"W2416222571","doi":"10.1016/j.ejmech.2016.01.045","title":"Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines","year":2016,"lang":"en","type":"article","venue":"European Journal of Medicinal Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Science Foundation of Liaoning Province; National Natural Science Foundation of China","keywords":"Gefitinib; Chemistry; Epidermal growth factor receptor; Moiety; Quinazoline; EGFR inhibitors; Potency; Cell culture; Structure–activity relationship; IC50; Stereochemistry; Mutant; Pharmacology; In vitro; Receptor; Biochemistry; Biology","score_opus":0.0110967368950739,"score_gpt":0.2702799521043617,"score_spread":0.2591832152092878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416222571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801372,0.00038294893,0.0063888677,0.0018131459,0.00015002243,0.00012651047,0.000010085237,0.0000319477,0.01095927],"genre_scores_gemma":[0.9940171,0.0002180918,0.0024134193,0.00021451092,0.0015820147,0.000001892793,0.000009214595,0.000055585053,0.0014881382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983504,0.00006051528,0.00044629193,0.00028245672,0.0005787033,0.0002816329],"domain_scores_gemma":[0.99816257,0.0000667594,0.00054391805,0.0002709492,0.0004821533,0.0004736484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003700649,0.00028254098,0.00040782508,0.000058629037,0.00010496817,0.000019378362,0.00017111817,0.000046671143,0.00006450301],"category_scores_gemma":[0.00014828019,0.00015413192,0.00011769972,0.00015165388,0.00016482337,0.00023151691,0.00003850456,0.00037614832,0.000007457518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001285209,0.0005826947,0.0004900971,0.000121773846,0.00020066206,0.000757075,0.0006265225,0.000018671248,0.9659225,5.214839e-7,0.00014501953,0.029849274],"study_design_scores_gemma":[0.009027323,0.0018078161,0.010999803,0.0019908098,0.00037871316,0.0010455507,0.0009459241,0.0000066516795,0.9728081,0.0000017771987,0.0007788319,0.00020866592],"about_ca_topic_score_codex":0.000005693487,"about_ca_topic_score_gemma":0.0000011281636,"teacher_disagreement_score":0.029640608,"about_ca_system_score_codex":0.00022794218,"about_ca_system_score_gemma":0.00040470247,"threshold_uncertainty_score":0.6285317},"labels":[],"label_agreement":null},{"id":"W2417711898","doi":"10.7326/acpjc-2007-146-2-031","title":"Adjuvant vinorelbine plus cisplatin extended survival longer than observation in resected non–small-cell lung cancer at median 76 months","year":2007,"lang":"en","type":"article","venue":"ACP Journal Club","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Vinorelbine; Medicine; Adjuvant; Lung cancer; Cisplatin; Oncology; Internal medicine; Stage (stratigraphy); Adjuvant chemotherapy; Cancer; Chemotherapy; Breast cancer","score_opus":0.02466879799243627,"score_gpt":0.3407390746741528,"score_spread":0.31607027668171656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417711898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030274,0.0026775997,0.00053180184,0.001803247,0.0009903391,0.00066710456,0.000021886106,0.000033745142,0.0029715174],"genre_scores_gemma":[0.99147207,0.00077193347,0.0011676031,0.0003893817,0.0007415743,0.00003912005,0.00011159124,0.000052438947,0.005254281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786764,0.000064739215,0.00064683217,0.0003041639,0.00055224175,0.0005643625],"domain_scores_gemma":[0.9985645,0.0001609909,0.00029367706,0.00026834433,0.0003191797,0.00039333882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062039145,0.0002533888,0.00043180087,0.000301856,0.00021751023,0.000038666916,0.0001374831,0.00016262813,0.00047847437],"category_scores_gemma":[0.00010876903,0.00019888485,0.00012671044,0.00049397687,0.00004149861,0.00019790682,0.000054469823,0.00053920393,0.000018369996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024797842,0.00062076707,0.9290746,0.00018044864,0.00051542325,0.002679917,0.008160699,0.0005702022,0.026186217,0.000029118997,0.005575992,0.023926875],"study_design_scores_gemma":[0.009439821,0.00033875104,0.9800663,0.0004116953,0.00044203212,0.00015304581,0.0007210466,0.002627076,0.0043451595,0.000058515277,0.0011523666,0.00024417936],"about_ca_topic_score_codex":0.0018909588,"about_ca_topic_score_gemma":0.02349283,"teacher_disagreement_score":0.050991755,"about_ca_system_score_codex":0.0018244718,"about_ca_system_score_gemma":0.0005706488,"threshold_uncertainty_score":0.9943259},"labels":[],"label_agreement":null},{"id":"W2418487199","doi":"10.1093/annonc/mdv586.02","title":"LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Gefitinib; Clinical endpoint; Lung cancer; Oncology; Randomized controlled trial; Adverse effect; Progression-free survival; Gastroenterology; Cancer; Epidermal growth factor receptor; Overall survival","score_opus":0.09753371172681696,"score_gpt":0.4686301177362061,"score_spread":0.37109640600938915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418487199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711879,0.00092348724,0.00031066325,0.004003521,0.0006368014,0.011437343,0.00086767774,0.000026779879,0.010605865],"genre_scores_gemma":[0.98897356,0.0005638134,0.005177861,0.0005094776,0.00021730679,0.0035362777,0.00032856103,0.000043776578,0.0006493605],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975372,0.00018633342,0.0010510131,0.0004803814,0.00032653275,0.0004185723],"domain_scores_gemma":[0.9958293,0.0009296235,0.0013770194,0.0004421562,0.0012054648,0.00021645532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054629357,0.00033544053,0.0012688919,0.000086813394,0.00020257152,0.000023939323,0.000255158,0.00014778566,0.000020172227],"category_scores_gemma":[0.0009951113,0.00021120324,0.0001916713,0.0003418159,0.00017564752,0.00022513841,0.000093996256,0.000115741495,0.0000013499788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9139771,0.012286393,0.0021377977,0.00024968624,0.0017922125,0.000014901526,0.0037420928,0.0012638747,0.00014075833,0.00016212753,0.0017552138,0.062477842],"study_design_scores_gemma":[0.95161724,0.028316597,0.00017740928,0.0006565516,0.0016805968,0.000004060647,0.00047751796,0.0012202454,0.0062812143,0.0001066037,0.009248257,0.00021369845],"about_ca_topic_score_codex":0.0014847592,"about_ca_topic_score_gemma":0.00038953315,"teacher_disagreement_score":0.062264144,"about_ca_system_score_codex":0.00066642504,"about_ca_system_score_gemma":0.0023851232,"threshold_uncertainty_score":0.8612618},"labels":[],"label_agreement":null},{"id":"W2419311181","doi":"10.1097/pai.0000000000000267","title":"Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non–Small Cell Lung Cancer in Canada","year":2015,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia; University Health Network; McMaster University; University of Toronto","funders":"","keywords":"Immunohistochemistry; Crizotinib; Lung cancer; Fluorescence in situ hybridization; Medicine; Fish <Actinopterygii>; In situ hybridization; Oncology; Internal medicine; Pathology; Biology; Gene; Gene expression","score_opus":0.012210182259088598,"score_gpt":0.2944110282533495,"score_spread":0.28220084599426093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419311181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886124,0.00384483,0.0019172825,0.00024270022,0.00010973331,0.0011478914,0.000022740282,0.000021994296,0.0040804264],"genre_scores_gemma":[0.99136025,0.000019924011,0.0066101365,0.0003512875,0.000025243487,0.0011852836,0.00023219886,0.000045080764,0.00017058525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983781,0.000011710971,0.0004634465,0.00053655857,0.00015716521,0.0004530139],"domain_scores_gemma":[0.99916977,0.000051680563,0.00017885686,0.00030977896,0.0001707222,0.00011918594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001301665,0.00027501638,0.0004022864,0.00007721062,0.00006830106,0.000012304186,0.00013285724,0.00013082307,0.000006828368],"category_scores_gemma":[0.00009131231,0.00030863588,0.00003275812,0.00032393352,0.0000691678,0.000028063874,0.00007040964,0.00023417683,5.433702e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012574447,0.000065554326,0.009657446,0.00033203818,0.000036616388,0.00015283749,0.00023856018,0.0002925237,0.9882472,0.00001550335,0.00012223989,0.0007137484],"study_design_scores_gemma":[0.0065701515,0.000060823117,0.009908217,0.00024972623,0.00021682591,0.00017579133,0.000850646,0.0005968041,0.9807379,0.00006996577,0.000060772,0.0005023618],"about_ca_topic_score_codex":0.12015438,"about_ca_topic_score_gemma":0.0021321098,"teacher_disagreement_score":0.11802227,"about_ca_system_score_codex":0.003874583,"about_ca_system_score_gemma":0.005552119,"threshold_uncertainty_score":0.9999494},"labels":[],"label_agreement":null},{"id":"W2420177892","doi":"10.3747/co.23.3193","title":"The Canadian Lung Cancer Conference 2016","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Session (web analytics); Alternative medicine; Family medicine; Medical education; Oncology; Pathology; World Wide Web","score_opus":0.07958154591534164,"score_gpt":0.4707863788551745,"score_spread":0.3912048329398329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2420177892","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18408345,0.07799165,0.0010175938,0.44333854,0.021176338,0.0031950567,0.00045700383,0.00020753797,0.26853284],"genre_scores_gemma":[0.9882851,0.003455995,0.000025248553,0.00027875157,0.00032419222,0.00024434263,0.000009356963,0.000008948113,0.0073680193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994189,0.000024821968,0.000103356964,0.00012889075,0.00007288535,0.0002511352],"domain_scores_gemma":[0.9993827,0.00007759772,0.000038938695,0.00014919744,0.00014249774,0.00020911635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006011818,0.00006881839,0.00010843257,0.000035916717,0.00022329578,0.000010865538,0.00006482188,0.0000472243,0.0005350783],"category_scores_gemma":[0.00003954169,0.000030414321,0.000033043885,0.00004957413,0.00011965541,0.000029265964,0.000012328753,0.00006951549,0.00008926619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027424883,0.000055012908,0.06135815,0.000011601568,0.00010815754,0.000012801484,0.00025769838,1.1521664e-7,0.00011530037,0.005479994,0.10351658,0.82905716],"study_design_scores_gemma":[0.001131508,0.00006682297,0.02699104,0.0001052886,0.00013905202,0.0000093593635,0.00002860424,0.00002262907,0.000050449977,0.00019150104,0.9712144,0.00004933246],"about_ca_topic_score_codex":0.015954854,"about_ca_topic_score_gemma":0.3060733,"teacher_disagreement_score":0.86769783,"about_ca_system_score_codex":0.0012964824,"about_ca_system_score_gemma":0.0036800478,"threshold_uncertainty_score":0.99059796},"labels":[],"label_agreement":null},{"id":"W2425777806","doi":"10.3747/co.23.3120","title":"Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Saint-Luc; Queen Elizabeth II Health Sciences Centre; University of Alberta; Occupational Cancer Research Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; McGill University; BC Cancer Agency; Hôpital Notre-Dame; Nova Scotia Health Authority; Royal Victoria Hospital; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Jewish General Hospital; Juravinski Cancer Centre; University of Manitoba","funders":"Pfizer Canada; U.S. Food and Drug Administration; AstraZeneca","keywords":"Crizotinib; Anaplastic lymphoma kinase; Ceritinib; Medicine; Alectinib; Lung cancer; ALK inhibitor; Internal medicine; Oncology; Cancer research; ROS1; Targeted therapy; Population; Cancer; Adenocarcinoma","score_opus":0.028011698753604736,"score_gpt":0.3924874001777501,"score_spread":0.3644757014241453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2425777806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984857,0.0019850929,0.000056935016,0.0041535166,0.00063488074,0.00067625614,0.000185847,0.000010148375,0.0074403114],"genre_scores_gemma":[0.99860394,0.00041825356,0.00015176648,0.00014697437,0.00007064982,0.00016191101,0.00004582578,0.000012294842,0.0003883943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921656,0.00003664262,0.00022396275,0.00019954651,0.00006722982,0.000256065],"domain_scores_gemma":[0.9993852,0.00008082672,0.00010255653,0.000107014705,0.00015072078,0.0001737179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057291178,0.000105653584,0.0002575788,0.0001941921,0.000029860783,0.0000016411443,0.000029227356,0.0000718198,0.00012561459],"category_scores_gemma":[0.000025618796,0.00007690581,0.000044916273,0.0001363706,0.00006595742,0.000027790224,0.000011664258,0.00009062663,0.000010204965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025796102,0.0008354514,0.8253855,0.00022452942,0.000102675425,0.00018965418,0.0028916502,0.00002352239,0.019504076,0.00023756736,0.0054468126,0.1449006],"study_design_scores_gemma":[0.036635943,0.0020455448,0.85013837,0.0043309233,0.0012072336,0.000069218455,0.0018479516,0.00024635144,0.053353906,0.00026877216,0.04927078,0.00058498356],"about_ca_topic_score_codex":0.016003227,"about_ca_topic_score_gemma":0.11158012,"teacher_disagreement_score":0.14431562,"about_ca_system_score_codex":0.0020091047,"about_ca_system_score_gemma":0.002094948,"threshold_uncertainty_score":0.99054927},"labels":[],"label_agreement":null},{"id":"W2427086075","doi":"","title":"[A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy].","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Esophagus; Dacarbazine; Radiation therapy; Melanoma; Regimen; Surgery; Oncology; Internal medicine; Chemotherapy","score_opus":0.02432076204266727,"score_gpt":0.28486969842131243,"score_spread":0.2605489363786452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2427086075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98588604,0.004776795,0.000048126392,0.0044956156,0.00015350751,0.0011225808,0.00013459638,0.000029095021,0.0033536348],"genre_scores_gemma":[0.9934544,0.000015925172,0.00026594423,0.00051558675,0.00021531625,0.00078483735,0.000027721891,0.000015521478,0.0047047627],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992839,0.000035820234,0.00018502044,0.00016345452,0.0001271415,0.00020462407],"domain_scores_gemma":[0.99939203,0.00014245338,0.000057111418,0.00027883134,0.000047278016,0.00008229549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013892744,0.00009104063,0.00015658708,0.00009342772,0.00007323656,0.000015146193,0.000055898276,0.000032397864,0.000046189776],"category_scores_gemma":[0.000039930117,0.00005235688,0.00006692189,0.000284963,0.000028096405,0.000033762382,0.000016458163,0.0000455073,0.000009815916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016278287,0.0009509128,0.46287847,0.000031285035,0.0011189051,0.005748629,0.004363398,0.00003485976,0.0014313293,0.007283011,0.032279614,0.48225176],"study_design_scores_gemma":[0.0019073408,0.00010634259,0.9839286,0.000019092391,0.0001791779,0.00023407862,0.0003700785,0.0000046993696,0.0052240575,0.0005415324,0.00740564,0.00007932135],"about_ca_topic_score_codex":0.003348183,"about_ca_topic_score_gemma":0.00016330676,"teacher_disagreement_score":0.52105016,"about_ca_system_score_codex":0.00008431405,"about_ca_system_score_gemma":0.000042754113,"threshold_uncertainty_score":0.5061473},"labels":[],"label_agreement":null},{"id":"W2427710323","doi":"10.3747/co.23.2920","title":"Astragalus-Containing Traditional Chinese Medicine, with and without Prescription Based on Syndrome Differentiation, Combined with Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systemic Review and Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fok Ying Tong Education Foundation; Science and Technology Commission of Shanghai Municipality","keywords":"Medicine; Lung cancer; Internal medicine; Hazard ratio; Meta-analysis; Oncology; Traditional Chinese medicine; Medical prescription; Adverse effect; Chemotherapy; Traditional medicine; Cancer; Confidence interval; Alternative medicine; Pharmacology; Pathology","score_opus":0.0823462388698185,"score_gpt":0.42333019106495123,"score_spread":0.3409839521951327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2427710323","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004941616,0.98483056,0.0057592466,0.00090522325,0.00013926582,0.0072824094,0.000458738,0.00003798685,0.000092437935],"genre_scores_gemma":[0.0071684974,0.9815752,0.000491003,0.00030224095,0.00010011015,0.008510691,0.0015609028,0.000074311945,0.00021705459],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9978403,0.00016009132,0.000691533,0.00076418364,0.00026832175,0.000275574],"domain_scores_gemma":[0.99791867,0.0003453709,0.00091620133,0.00034135245,0.0002760714,0.00020231417],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022720551,0.0006550037,0.0050351913,0.00036947185,0.00012680386,0.000015992739,0.000090632595,0.00015634489,0.000157715],"category_scores_gemma":[0.000024214354,0.00030670466,0.0004496662,0.00038255347,0.00012410988,0.0000722878,0.000009733366,0.00023782706,6.095613e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024884616,0.0021437274,0.01072676,0.39180645,0.2912691,0.00004436972,0.0006210639,0.00004821118,0.00000313284,0.00013842685,0.0008934965,0.29981682],"study_design_scores_gemma":[0.01400142,0.0062906323,0.0013807602,0.028584821,0.91359985,0.00022612627,0.000018578956,0.00041688545,1.8239177e-7,0.000007813158,0.03500169,0.00047122518],"about_ca_topic_score_codex":0.000011080646,"about_ca_topic_score_gemma":0.000039873696,"teacher_disagreement_score":0.6223308,"about_ca_system_score_codex":0.00052688847,"about_ca_system_score_gemma":0.0008064846,"threshold_uncertainty_score":0.9999385},"labels":[],"label_agreement":null},{"id":"W2428372814","doi":"10.3747/co.23.3019","title":"Approach to Biomarker Testing: Perspectives from Various Specialties","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Specialty; Biomarker; Population; Cancer; Test (biology); Family medicine; Intensive care medicine; Oncology; Medical physics; Internal medicine; Environmental health","score_opus":0.14812294865082462,"score_gpt":0.4398298745682899,"score_spread":0.2917069259174653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2428372814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6405295,0.0069297533,0.012612791,0.010666938,0.0034626669,0.0016422307,0.0002014291,0.00030727798,0.3236474],"genre_scores_gemma":[0.9894722,0.000080704536,0.0076369857,0.00015031254,0.00089272636,0.00014738577,0.000030495505,0.000019718549,0.001569474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921954,0.00003461935,0.00014139952,0.00030437816,0.00010501085,0.00019507385],"domain_scores_gemma":[0.99931747,0.00016441947,0.000047146248,0.0001849176,0.00013553584,0.00015050563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047311605,0.00011260497,0.00022514812,0.00009084294,0.000060191123,0.000007848928,0.000059583082,0.000054190197,0.0002019041],"category_scores_gemma":[0.00022066598,0.000067369285,0.000048556692,0.00014361524,0.00008593269,0.00003743369,0.000039496186,0.000058903246,0.00017741515],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025800162,0.0027473075,0.065781385,0.000025068723,0.00034947548,0.000024801255,0.009978126,8.259065e-7,0.0041021677,0.0027419755,0.030581169,0.8834097],"study_design_scores_gemma":[0.0037126811,0.0007482165,0.30677286,0.00010727842,0.00037174887,0.000034281187,0.0017859285,0.000026532327,0.00015112985,0.0009748564,0.6851325,0.00018200833],"about_ca_topic_score_codex":0.00007607051,"about_ca_topic_score_gemma":0.00001296672,"teacher_disagreement_score":0.8832277,"about_ca_system_score_codex":0.00056227425,"about_ca_system_score_gemma":0.00029188805,"threshold_uncertainty_score":0.27472398},"labels":[],"label_agreement":null},{"id":"W2430525989","doi":"10.1016/j.ijrobp.2016.06.006","title":"The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases","year":2016,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Internal medicine; Hazard ratio; KRAS; Lung cancer; Adenocarcinoma; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Cause of death; Anaplastic lymphoma kinase; Gastroenterology; Cancer; Disease; Confidence interval; Receptor","score_opus":0.010160089030063267,"score_gpt":0.31099238678540253,"score_spread":0.30083229775533926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2430525989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682564,0.0005313618,0.0003092732,0.0017530087,0.00016192332,0.00025273173,0.00014281238,0.0000015816182,0.000021644642],"genre_scores_gemma":[0.99948084,0.00018074155,0.00016274971,0.000056289104,0.00007775206,0.000006453949,0.000020973575,0.0000064876986,0.000007687946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991748,0.00019559373,0.00033207526,0.0000894019,0.00014355057,0.00006458236],"domain_scores_gemma":[0.9983023,0.00079284015,0.0005270662,0.00007352656,0.00027127308,0.000032995606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026291257,0.000084626045,0.0002380427,0.00007660318,0.000041072126,0.000005146655,0.00004701721,0.000043015632,0.0000021436103],"category_scores_gemma":[0.00020494073,0.000039230777,0.000037835813,0.000066720815,0.00020794377,0.000096532385,0.000019965675,0.00007531106,6.403086e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007902494,0.00014445628,0.9801524,0.000011807377,0.00035145195,0.0000025308555,0.00017539166,0.000034904908,0.0033077172,0.0032366747,0.000037728194,0.011754644],"study_design_scores_gemma":[0.00951858,0.0029792618,0.97022456,0.0001557047,0.00024663864,0.00001894919,0.000021070264,0.00006333705,0.016268793,0.00041056928,0.000053640444,0.000038888473],"about_ca_topic_score_codex":0.000025276446,"about_ca_topic_score_gemma":0.000016735043,"teacher_disagreement_score":0.012961077,"about_ca_system_score_codex":0.000122036545,"about_ca_system_score_gemma":0.0001121107,"threshold_uncertainty_score":0.15997846},"labels":[],"label_agreement":null},{"id":"W2460081483","doi":"","title":"Predictive biomarkers for EGFR therapy.","year":2009,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; KRAS; Lung cancer; Clinical trial; Randomized controlled trial; Afatinib; Epidermal growth factor receptor; Placebo; Cancer; Pathology","score_opus":0.02343977583092558,"score_gpt":0.30336982083833025,"score_spread":0.27993004500740465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460081483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50686735,0.009253781,0.006953728,0.059397884,0.0014363296,0.021396978,0.00032647236,0.00077961804,0.39358786],"genre_scores_gemma":[0.99432534,0.000065198896,0.0004144688,0.0013114826,0.0001260449,0.0015547725,0.000046811074,0.000007782854,0.0021480815],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995957,0.0000042873335,0.000067079534,0.00011035243,0.00006499528,0.00015759835],"domain_scores_gemma":[0.99974424,0.000018794291,0.000021290813,0.00009412293,0.00003932514,0.000082207385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004461277,0.000055607314,0.00008270011,0.000037548303,0.00004312272,0.00000814252,0.000022622426,0.0000262473,0.000012786055],"category_scores_gemma":[0.000021808502,0.000040073377,0.000056339013,0.00006682516,0.000014446954,0.00003875071,0.0000017132802,0.00001985017,0.0000023042212],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000455864,0.0001854372,0.0022291054,0.0000050117824,0.00032476557,0.0000034363568,0.0001651637,0.0000010094626,0.000055431905,0.00021773252,0.011440688,0.9849163],"study_design_scores_gemma":[0.0038476924,0.0003047899,0.9151808,0.0000055771725,0.0001465783,0.0000069849307,0.00005200379,0.000032056556,0.0010284053,0.0008516404,0.07848704,0.000056435223],"about_ca_topic_score_codex":0.000007819603,"about_ca_topic_score_gemma":8.264919e-7,"teacher_disagreement_score":0.98485994,"about_ca_system_score_codex":0.00008497257,"about_ca_system_score_gemma":0.000029581091,"threshold_uncertainty_score":0.1634145},"labels":[],"label_agreement":null},{"id":"W2461111129","doi":"10.1200/jco.2010.28.18_suppl.lba7511","title":"Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Paclitaxel; Carboplatin; Internal medicine; Gemcitabine; Clinical endpoint; Nab-paclitaxel; Urology; Oncology; Gastroenterology; Randomized controlled trial; Chemotherapy; Cisplatin","score_opus":0.04164344622846952,"score_gpt":0.4491886765088216,"score_spread":0.40754523028035206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461111129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991183,0.0020580087,0.00011095908,0.0025455062,0.0005960911,0.0020495632,0.00006625868,0.00000567557,0.0013849797],"genre_scores_gemma":[0.9911676,0.002434626,0.0054920395,0.00032164875,0.00035427778,0.0000665119,0.000013035622,0.000027313756,0.00012293042],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952058,0.00039285,0.0034447873,0.00032846048,0.0003675122,0.00026056843],"domain_scores_gemma":[0.99029326,0.00508244,0.0033544928,0.0002734885,0.00063314475,0.00036314034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030087798,0.00027111833,0.0033893706,0.00024376523,0.000045420056,0.000008667738,0.00011215088,0.0003569181,0.00003717699],"category_scores_gemma":[0.0020324534,0.00017197523,0.000359401,0.00020846074,0.00054282567,0.00008687323,0.000025228397,0.0008891783,1.7859341e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9538452,0.0045427997,0.011458334,0.00012640696,0.00077480107,0.00018086885,0.0014266616,0.00024243158,0.0026294836,0.000011699992,0.00009152826,0.024669785],"study_design_scores_gemma":[0.9558122,0.02845747,0.008982451,0.00048384833,0.0012999488,0.00003924143,0.00029987292,0.0025429765,0.0010917889,0.00007731453,0.00075534364,0.00015749873],"about_ca_topic_score_codex":0.0014072962,"about_ca_topic_score_gemma":0.0019865492,"teacher_disagreement_score":0.024512285,"about_ca_system_score_codex":0.00009656026,"about_ca_system_score_gemma":0.0028536909,"threshold_uncertainty_score":0.7012946},"labels":[],"label_agreement":null},{"id":"W2461766591","doi":"10.1016/j.cllc.2016.06.007","title":"Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe","year":2016,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Globe; Lung cancer; Oncology; Clinical Oncology; Internal medicine; Medical physics; Cancer; Ophthalmology","score_opus":0.29665332049895055,"score_gpt":0.6364577698399324,"score_spread":0.33980444934098186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461766591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029832976,0.9888542,0.000024261259,0.0017557673,0.001644941,0.0036684268,0.00043075788,0.00001736675,0.0035744286],"genre_scores_gemma":[0.00007671779,0.99333733,0.00004841517,0.000760522,0.0017510212,0.0013288979,0.00008430455,0.000046854744,0.0025659117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934606,0.0024585433,0.0029933914,0.00054423127,0.00024924017,0.00029397092],"domain_scores_gemma":[0.98980623,0.0077598533,0.0014734803,0.0006179892,0.00019776977,0.00014465812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036909368,0.0003786033,0.0057101464,0.00010192444,0.0000544083,0.000014387233,0.00025031716,0.00056570687,0.00083706895],"category_scores_gemma":[0.001984872,0.0001634887,0.0013577109,0.00043589086,0.00033665242,0.00005311433,0.00008980723,0.00062698324,0.000049036018],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016123021,0.00031453793,0.00037669484,0.0072274953,0.0019849997,0.00003095907,0.0000540862,3.848505e-7,7.525241e-8,0.0005114629,0.009415378,0.9799227],"study_design_scores_gemma":[0.0013979091,0.0003963082,0.00022008331,0.044466075,0.009158397,0.000013933667,0.000022157508,0.0000028024858,3.5412754e-7,0.000084578016,0.9440744,0.00016301985],"about_ca_topic_score_codex":0.00010506666,"about_ca_topic_score_gemma":0.00024649737,"teacher_disagreement_score":0.9797597,"about_ca_system_score_codex":0.001109216,"about_ca_system_score_gemma":0.004315387,"threshold_uncertainty_score":0.91653174},"labels":[],"label_agreement":null},{"id":"W2461969175","doi":"","title":"First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases","year":2016,"lang":"en","type":"article","venue":"QUT ePrints (Queensland University of Technology)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Chugai Pharmaceutical; Genentech; Astellas Pharma; Ono Pharmaceutical; Eisai; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Vertex Pharmaceuticals; Clovis Oncology; Boehringer Ingelheim; Amgen; Ariad Pharmaceuticals; Sanofi; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Medicine; Lung cancer; Oncology; Internal medicine; Pemetrexed; Epidermal growth factor receptor; Adenocarcinoma; Chemotherapy; Hazard ratio; Brain metastasis; Cisplatin; Cancer; Erlotinib; Metastasis; Confidence interval","score_opus":0.008287370395692415,"score_gpt":0.24428567230611792,"score_spread":0.2359983019104255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461969175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251586,0.00010573722,0.00035624587,0.0061308234,0.00002715133,0.00047417427,0.00023019665,0.00003782117,0.00012198065],"genre_scores_gemma":[0.99531287,0.00040595458,0.0039547454,0.000034846416,0.0000063276616,0.0000035281462,0.000028355242,0.000011341616,0.0002420237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993845,0.000012983267,0.00011311122,0.00025551187,0.00007793386,0.00015591826],"domain_scores_gemma":[0.9994912,0.00008397094,0.00010408359,0.00015920117,0.00009420702,0.0000672999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003208651,0.00013222887,0.00026413216,0.00023569303,0.000084989624,0.000003375989,0.00006523688,0.00010195579,0.000090323425],"category_scores_gemma":[0.000020713933,0.00009827153,0.000024842631,0.00016945924,0.00020404882,0.00007583793,0.000050304156,0.00008410019,0.0000017318266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068646664,0.00020683878,0.9879027,0.000060027254,0.00019755303,0.000012169253,0.00033123416,0.0000024805856,0.00039944117,0.000050357467,0.00009140403,0.0100593185],"study_design_scores_gemma":[0.020611756,0.00049102464,0.97240984,0.00017618209,0.00020273658,0.0000014334935,0.00019974045,0.000021430771,0.004889699,0.00004314524,0.00081588345,0.0001370942],"about_ca_topic_score_codex":0.00084668957,"about_ca_topic_score_gemma":0.0010834882,"teacher_disagreement_score":0.019925289,"about_ca_system_score_codex":0.0001069472,"about_ca_system_score_gemma":0.00006607712,"threshold_uncertainty_score":0.40073967},"labels":[],"label_agreement":null},{"id":"W2468165760","doi":"10.1007/s12253-015-9970-3","title":"Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma","year":2015,"lang":"en","type":"article","venue":"Pathology & Oncology Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"","keywords":"Head and neck squamous-cell carcinoma; Medicine; Mutation; Oncology; Clinical trial; Internal medicine; Druggability; Head and neck cancer; Cancer research; Bioinformatics; Cancer; Biology; Genetics; Gene","score_opus":0.1360215535244707,"score_gpt":0.48215960525096047,"score_spread":0.34613805172648976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468165760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97610825,0.0017004377,0.000012396591,0.0021074247,0.00008446236,0.00071302016,0.000016920234,0.000014786258,0.019242303],"genre_scores_gemma":[0.99654937,0.000020407524,0.0026224446,0.00008650952,0.000044847122,0.00012258501,0.000049659026,0.00001290137,0.0004912931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813884,0.0005843146,0.00031858069,0.00034704115,0.00021080098,0.0004004251],"domain_scores_gemma":[0.99854046,0.00049972435,0.00006109936,0.00023861261,0.00045272766,0.00020735509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015341713,0.00009468479,0.00035755176,0.0003157721,0.00008994219,0.0000043983114,0.000073770236,0.00019308194,0.000040567935],"category_scores_gemma":[0.000835521,0.00008246812,0.00003407282,0.00037355334,0.00058088766,0.00005001155,0.000098549535,0.0004522518,0.000022458542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003490844,0.000987951,0.98567927,0.00007242763,0.000008090445,0.0008057399,0.005910125,0.000008706064,0.0036367797,0.00014239123,0.00062530144,0.0017741574],"study_design_scores_gemma":[0.010374611,0.004460454,0.97460145,0.000016560678,0.00007600034,0.00028160945,0.005595989,0.00015538,0.0013399454,0.0018777092,0.0011271645,0.00009315148],"about_ca_topic_score_codex":0.00064105255,"about_ca_topic_score_gemma":0.0005071722,"teacher_disagreement_score":0.020441104,"about_ca_system_score_codex":0.0004811802,"about_ca_system_score_gemma":0.0012484757,"threshold_uncertainty_score":0.33629522},"labels":[],"label_agreement":null},{"id":"W2472856960","doi":"","title":"[Tumoral urinary cytology: comparison with histologic lesions according to the 1998 ISUP/OMS classification].","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Cytology; Pathology; Medicine; Urinary system; Anatomy","score_opus":0.05849291548939121,"score_gpt":0.32205118664489263,"score_spread":0.2635582711555014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472856960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456157,0.00049685733,0.00017214964,0.024478253,0.00014691199,0.0016223952,0.0000118594735,0.00012886542,0.027327016],"genre_scores_gemma":[0.98930883,0.000024298428,0.000446637,0.0013629977,0.00011312227,0.002531193,0.000053452124,0.000015291691,0.0061441693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909693,0.000036887082,0.00017577512,0.00024353202,0.0001443419,0.00030252145],"domain_scores_gemma":[0.99938756,0.000053854637,0.00005026288,0.00032179442,0.000030037785,0.00015651407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008499435,0.00011956765,0.00021060137,0.00006108976,0.00025483043,0.000020575286,0.00011126518,0.000044161727,0.00008873864],"category_scores_gemma":[0.000020899995,0.000066094486,0.00004498803,0.00025291403,0.00008077368,0.00005627613,0.000016778089,0.00013498028,0.00017453091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004483034,0.0008642472,0.5102202,0.000019749514,0.00024446583,0.000103984705,0.00112228,0.00017253187,0.000022264685,0.00065428385,0.023027772,0.46309987],"study_design_scores_gemma":[0.00076978176,0.00018270138,0.84766185,0.000011654235,0.0002310586,0.00014579263,0.0006743771,0.00009853139,0.000023274179,0.000026607264,0.15008858,0.000085803906],"about_ca_topic_score_codex":0.00007414934,"about_ca_topic_score_gemma":0.000043852153,"teacher_disagreement_score":0.46301407,"about_ca_system_score_codex":0.00021799654,"about_ca_system_score_gemma":0.000066501176,"threshold_uncertainty_score":0.2695255},"labels":[],"label_agreement":null},{"id":"W2473303007","doi":"10.1007/s10654-016-0180-4","title":"Bridging the etiologic and prognostic outlooks in individualized assessment of absolute risk of an illness: application in lung cancer","year":2016,"lang":"en","type":"article","venue":"European Journal of Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Western University","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Lung cancer; Bridging (networking); Intensive care medicine; Epidemiology; Public health; Risk assessment; Absolute risk reduction; Internal medicine; Oncology; Pathology","score_opus":0.032349781241539255,"score_gpt":0.3970341760759944,"score_spread":0.36468439483445514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473303007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881873,0.0015226614,0.0075903255,0.0019470858,0.00006403095,0.00028222532,0.00001596987,0.0000027029057,0.00038769818],"genre_scores_gemma":[0.995511,0.0014415589,0.0028086524,0.00013352894,0.000068186964,0.000012081611,0.000003109708,0.000008877843,0.000013017909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997191,0.0016473976,0.00083746697,0.00012298758,0.00006628867,0.00013484374],"domain_scores_gemma":[0.99783176,0.0009199534,0.00097312196,0.00013546788,0.00008872621,0.000050977404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004144913,0.00007783885,0.00042460288,0.00013632163,0.000022219961,0.0000011677467,0.00008712743,0.000025111769,0.000011413545],"category_scores_gemma":[0.0011960678,0.000037471724,0.000046976584,0.00008687361,0.00014142013,0.000050854494,0.000026109972,0.00015635416,2.3048212e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007442672,0.00008274422,0.94295245,0.00003096801,0.00011234092,0.00001633006,0.0004974189,0.00024372808,0.0008977874,0.00026035358,0.000039803752,0.054791637],"study_design_scores_gemma":[0.0024381701,0.00038203446,0.99485344,0.0003464492,0.00019787783,0.00003957472,0.000121916164,0.0010805819,0.000020229436,0.00025967043,0.00021942864,0.000040646635],"about_ca_topic_score_codex":0.00016508691,"about_ca_topic_score_gemma":0.00006981202,"teacher_disagreement_score":0.05475099,"about_ca_system_score_codex":0.000073563744,"about_ca_system_score_gemma":0.0000994403,"threshold_uncertainty_score":0.15280525},"labels":[],"label_agreement":null},{"id":"W2473581189","doi":"10.1093/annonc/mdv532.60","title":"476TiP Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; T790M; Epidermal growth factor receptor; Tyrosine kinase; Tyrosine-kinase inhibitor; Lung cancer; Internal medicine; Oncology; Cancer research; Phases of clinical research; Cancer; Receptor; Chemotherapy; Gefitinib","score_opus":0.039078873484982665,"score_gpt":0.3792393443305347,"score_spread":0.340160470845552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473581189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953721,0.00044953992,0.000010144311,0.0006895092,0.00012382252,0.0022451254,0.00040156933,0.000015991,0.0006922056],"genre_scores_gemma":[0.99793077,0.00008877667,0.0005450881,0.00036974877,0.00011205437,0.00057301717,0.0001653993,0.000043931585,0.00017121373],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.998269,0.0001422339,0.0004858627,0.0004425416,0.00028803467,0.000372325],"domain_scores_gemma":[0.9981238,0.000057365858,0.00035243036,0.00029109238,0.0008428802,0.00033240253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009647575,0.00032357415,0.00079526094,0.00024699696,0.00005087487,0.000006210916,0.000074572396,0.00011938944,0.000060906495],"category_scores_gemma":[0.000014615652,0.00021285229,0.00006149699,0.0003047458,0.00011820736,0.00019294476,0.000039251812,0.000121577854,0.0000024617211],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024801956,0.07611723,0.8406388,0.00010993332,0.0009748752,0.0002718947,0.032828454,0.000032239812,0.0008303823,0.000003202206,0.0007940095,0.022596998],"study_design_scores_gemma":[0.12920181,0.48722082,0.32942593,0.00055449636,0.0011847803,0.0000073814995,0.0039708167,0.000037081845,0.04706959,0.0000055928963,0.0008549437,0.00046674153],"about_ca_topic_score_codex":0.004604133,"about_ca_topic_score_gemma":0.0024305033,"teacher_disagreement_score":0.5112129,"about_ca_system_score_codex":0.0005185036,"about_ca_system_score_gemma":0.001019946,"threshold_uncertainty_score":0.86798644},"labels":[],"label_agreement":null},{"id":"W2474212125","doi":"10.1200/jco.2015.33.15_suppl.8002","title":"Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Clinical endpoint; Erlotinib; Lung cancer; Oncology; Progression-free survival; Gefitinib; Chemotherapy; Gastroenterology; Cancer; Randomized controlled trial; Epidermal growth factor receptor","score_opus":0.050945110925988676,"score_gpt":0.436446730433968,"score_spread":0.3855016195079793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474212125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317163,0.00063849165,0.0002765706,0.0017870574,0.0014539964,0.0011417491,0.0001453846,0.000008319051,0.0013768104],"genre_scores_gemma":[0.99647087,0.00003379379,0.0011481177,0.0015743732,0.00057413883,0.0000142796525,0.000059953374,0.000027703658,0.00009677657],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99517167,0.0007513079,0.0025530448,0.00030438296,0.00094136386,0.0002782422],"domain_scores_gemma":[0.9920838,0.002552447,0.0037288822,0.00050176337,0.00081442564,0.00031870298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016493412,0.00029424965,0.0022179426,0.00008304887,0.00008188636,0.000012880906,0.00037640415,0.00027142774,0.00025248452],"category_scores_gemma":[0.00089033676,0.00014042953,0.0013872387,0.0005059499,0.0002151705,0.00012389595,0.000038635662,0.00055055175,9.4104445e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28395495,0.008935303,0.6878032,0.000019015404,0.0046264026,0.000069803464,0.0010988195,0.0010819703,0.000072429706,0.000019829304,0.00085758214,0.011460702],"study_design_scores_gemma":[0.6274205,0.03802318,0.32142884,0.000073251256,0.0066114087,0.000003942116,0.00046591164,0.0013045068,0.0006266571,0.00008319119,0.0037651767,0.00019342721],"about_ca_topic_score_codex":0.0003385132,"about_ca_topic_score_gemma":0.00025734247,"teacher_disagreement_score":0.36637437,"about_ca_system_score_codex":0.00038328863,"about_ca_system_score_gemma":0.0036104096,"threshold_uncertainty_score":0.64047116},"labels":[],"label_agreement":null},{"id":"W2474293588","doi":"","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"QUT ePrints (Queensland University of Technology)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Lung cancer; Internal medicine; Adenocarcinoma; Gemcitabine; Lung; Chemotherapy; Population; Oncology; Gastroenterology; Cisplatin; Surgery; Gefitinib; Epidermal growth factor receptor; Cancer","score_opus":0.05997448800695917,"score_gpt":0.37807466310289883,"score_spread":0.3181001750959397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474293588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735571,0.0007513582,0.019941056,0.0012826171,0.00012793428,0.0014970349,0.002248036,0.00007373149,0.00052110455],"genre_scores_gemma":[0.98694783,0.00007587207,0.010709338,0.000028125802,0.000037151425,0.000005081733,0.0020344798,0.000017799419,0.00014433316],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99847436,0.00010201164,0.00042679973,0.00054287346,0.00024346108,0.00021048954],"domain_scores_gemma":[0.99747366,0.0007831503,0.0005336024,0.0007048216,0.0003686953,0.00013606739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049734255,0.00022243518,0.0011268742,0.00064005813,0.00011033812,0.000011053079,0.00028199877,0.00020045527,0.00016771484],"category_scores_gemma":[0.000448023,0.00021414013,0.00022800946,0.0004961614,0.00024275228,0.00013297072,0.000102100814,0.0001366159,0.0000015235006],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17414397,0.0023630883,0.71598434,0.00040374402,0.058389083,0.0003436387,0.005026892,0.0014172151,0.004653922,0.0022031532,0.005057107,0.030013833],"study_design_scores_gemma":[0.65732855,0.001355001,0.11672633,0.000317099,0.04708392,0.000005654569,0.004844623,0.1619713,0.007954757,0.0005384767,0.0012059617,0.0006683444],"about_ca_topic_score_codex":0.0016022759,"about_ca_topic_score_gemma":0.00029748026,"teacher_disagreement_score":0.599258,"about_ca_system_score_codex":0.0001988306,"about_ca_system_score_gemma":0.00033416593,"threshold_uncertainty_score":0.87323815},"labels":[],"label_agreement":null},{"id":"W2474670944","doi":"10.1097/01.jto.0000283407.07873.7c","title":"PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Gefitinib; Medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Internal medicine; Epidermal growth factor receptor; Clinical endpoint; Adenocarcinoma; Cancer; Progressive disease; Chemotherapy; Clinical trial","score_opus":0.050427726566217516,"score_gpt":0.5477697998901098,"score_spread":0.49734207332389224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474670944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562201,0.0005724154,0.00080013415,0.003228283,0.0008152148,0.00023553922,0.0000048565507,0.000007134787,0.038116332],"genre_scores_gemma":[0.98676354,0.00013476955,0.00821653,0.0011742216,0.0006071707,0.0000027055992,0.0000034821917,0.000011223394,0.0030863355],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843556,0.00014797559,0.0009183633,0.00011645403,0.00017616215,0.00020550172],"domain_scores_gemma":[0.99863917,0.00039563558,0.00041805295,0.00011067971,0.00024815366,0.00018831357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018512034,0.000090846,0.00048545667,0.00020432488,0.00003137449,0.0000067839514,0.00007042219,0.00015541991,0.00023200596],"category_scores_gemma":[0.00028137316,0.00006369534,0.00014884886,0.00016638768,0.00008244827,0.00010444155,0.000019111805,0.0005055435,0.000020861038],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00623457,0.0029015495,0.29626358,0.00006017822,0.00056040304,0.0063933157,0.0031604436,0.000032776843,0.0005907255,0.0004635045,0.0032691122,0.68006986],"study_design_scores_gemma":[0.0051975357,0.008113564,0.82789946,0.00024963703,0.0005789991,0.0013044922,0.0032129514,0.000026469535,0.0009983514,0.00017104422,0.15211785,0.00012962313],"about_ca_topic_score_codex":0.000016386992,"about_ca_topic_score_gemma":0.00013145599,"teacher_disagreement_score":0.6799402,"about_ca_system_score_codex":0.00044115848,"about_ca_system_score_gemma":0.00086671254,"threshold_uncertainty_score":0.25974205},"labels":[],"label_agreement":null},{"id":"W2482156283","doi":"10.1158/1538-7445.am2016-4666","title":"Abstract 4666: Phosphatidylinositol 3-kinase (PI3K) and mTOR inhibitors demonstrate broad efficacy and synergy in head and neck cancer cell lines and patient-derived xenografts","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Science Centre; University of Saskatchewan; Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research; Western University","funders":"","keywords":"Everolimus; PI3K/AKT/mTOR pathway; Cancer research; Medicine; Cancer; Kinase; Pharmacology; Biology; Oncology; Internal medicine; Signal transduction; Genetics","score_opus":0.031893132370459314,"score_gpt":0.3788481480947124,"score_spread":0.3469550157242531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482156283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9477993,0.04858069,7.1024493e-7,0.002269861,0.00012102018,0.000809313,0.00008758745,0.00002252415,0.00030896952],"genre_scores_gemma":[0.9686844,0.030342352,0.00009074202,0.000101596066,0.0001630445,0.00028910005,0.0000066543303,0.00003217838,0.00028992962],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99835557,0.000056829413,0.00028016279,0.0005261553,0.00029911197,0.0004821584],"domain_scores_gemma":[0.9989475,0.0002201047,0.00006524225,0.00018508373,0.00017692643,0.00040512465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013132037,0.00021307691,0.00031124198,0.00016145909,0.00019598471,0.00007724958,0.00004679187,0.00011526328,0.00011065963],"category_scores_gemma":[0.00005702452,0.00014510863,0.00002184262,0.00021051208,0.00040953213,0.0002251338,0.00009113951,0.00020331572,0.0000018617895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011126691,0.00037978336,0.22746865,0.00060619233,0.00015626315,0.00017860704,0.0027190703,0.0000029150945,0.25366014,0.000032614265,0.0014965861,0.5121865],"study_design_scores_gemma":[0.0147541845,0.001184516,0.78036714,0.0028355853,0.00012838491,0.000024062845,0.0009529759,0.000028730552,0.19184957,0.00006975293,0.007405385,0.00039973157],"about_ca_topic_score_codex":0.008951198,"about_ca_topic_score_gemma":0.0033933623,"teacher_disagreement_score":0.55289847,"about_ca_system_score_codex":0.00023220266,"about_ca_system_score_gemma":0.00035015703,"threshold_uncertainty_score":0.9976483},"labels":[],"label_agreement":null},{"id":"W2489765770","doi":"10.1200/jco.2013.31.15_suppl.8034","title":"Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Clinical endpoint; Lung cancer; Placebo; Population; non-small cell lung cancer (NSCLC); Bevacizumab; Intention-to-treat analysis; Phases of clinical research; Hazard ratio; Surgery; Gastroenterology; Adverse effect; Oncology; Randomized controlled trial; Chemotherapy; Confidence interval; Pathology","score_opus":0.034398276347925506,"score_gpt":0.4187136529175101,"score_spread":0.3843153765695846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489765770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894295,0.0010806483,0.00038085843,0.0006990236,0.00091569766,0.0071696835,0.000021830285,0.000010189404,0.00029261984],"genre_scores_gemma":[0.99557954,0.00048671194,0.0026795007,0.00022825139,0.00022050698,0.00051321875,0.000017764887,0.00005776148,0.00021673898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99450195,0.0003711838,0.0036328256,0.00041868043,0.0006578291,0.00041755787],"domain_scores_gemma":[0.9920316,0.002092368,0.0035065392,0.00038876472,0.001588208,0.0003925331],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011675743,0.00040213656,0.003655201,0.00047211078,0.000044836826,0.000012175705,0.00026198593,0.00032173184,0.0005111856],"category_scores_gemma":[0.00051121326,0.0002623138,0.00058404973,0.00045987306,0.000241309,0.00024191641,0.00006948055,0.00085727876,0.0000028213233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8444742,0.019470917,0.11876278,0.00019328333,0.002745209,0.00011191828,0.003227934,0.0009099035,0.000025270823,4.3304513e-7,0.00026044587,0.0098177325],"study_design_scores_gemma":[0.9350902,0.024537375,0.030296843,0.000579378,0.0039537502,0.000004409144,0.001698816,0.003359121,0.00011080293,0.0000011018161,0.00015366894,0.0002145438],"about_ca_topic_score_codex":0.0013406598,"about_ca_topic_score_gemma":0.003400065,"teacher_disagreement_score":0.09061602,"about_ca_system_score_codex":0.0008114474,"about_ca_system_score_gemma":0.0016688497,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W2494947788","doi":"10.1200/jco.2016.34.15_suppl.9007","title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; ALK inhibitor; Internal medicine; Refractory (planetary science); Lung cancer; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Ceritinib; Gastroenterology; Randomized controlled trial; Phases of clinical research; Clinical trial; Surgery; Oncology; Malignant pleural effusion","score_opus":0.03449083937050493,"score_gpt":0.4326835096161204,"score_spread":0.39819267024561544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494947788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215627,0.00049340044,0.00028984982,0.002123949,0.0012845325,0.0016896056,0.00007185891,0.0000069452394,0.0018836053],"genre_scores_gemma":[0.9957739,0.0010255842,0.0015999734,0.0003256923,0.00088070973,0.000041418298,0.00002049846,0.000029406583,0.0003027763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99484736,0.00044573145,0.003684429,0.0003450892,0.00041642805,0.00026099087],"domain_scores_gemma":[0.9892729,0.0057114274,0.0037966585,0.0002557476,0.0005450705,0.00041820863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019432354,0.00023323183,0.0027203271,0.00013904201,0.000047470006,0.000007493285,0.00011763089,0.0003132405,0.0002659579],"category_scores_gemma":[0.0032003238,0.00012297918,0.00042148578,0.00011697531,0.00037756108,0.00014441053,0.000041748543,0.0005257368,0.0000021612198],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8363082,0.009817798,0.104209885,0.00004650271,0.0012622293,0.0007389787,0.00046858334,0.0000051451093,0.00008740229,0.0000040221657,0.0007545349,0.04629673],"study_design_scores_gemma":[0.8462183,0.016296087,0.12802298,0.0008591945,0.0022644515,0.00004066063,0.00003708186,0.000023970877,0.000068507485,0.000019669811,0.0060209227,0.00012819978],"about_ca_topic_score_codex":0.00051354995,"about_ca_topic_score_gemma":0.00031436552,"teacher_disagreement_score":0.046168532,"about_ca_system_score_codex":0.0003012441,"about_ca_system_score_gemma":0.0029477396,"threshold_uncertainty_score":0.5229164},"labels":[],"label_agreement":null},{"id":"W2498107952","doi":"10.1080/03007995.2016.1220934","title":"Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ceritinib; Hazard ratio; Internal medicine; Proportional hazards model; Confidence interval; Lung cancer; Anaplastic lymphoma kinase; Oncology; Gastroenterology; Surgery","score_opus":0.027203361286943395,"score_gpt":0.4169194016918633,"score_spread":0.3897160404049199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498107952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99073964,0.0017044593,0.00013895573,0.004825648,0.00014396299,0.0016463794,0.00018450934,0.000027778744,0.0005886491],"genre_scores_gemma":[0.99431497,0.00351946,0.00009561984,0.00003902023,0.00033967415,0.00039183747,0.00045847613,0.000026113134,0.0008148543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976846,0.00011853788,0.00019767525,0.0003867635,0.0011678307,0.00044457908],"domain_scores_gemma":[0.99811655,0.0003807922,0.00006662478,0.000114324066,0.0005382591,0.0007834257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043883183,0.00014487011,0.0002529594,0.00012553617,0.00017487255,0.000029522686,0.000060521015,0.000102891696,0.00018730182],"category_scores_gemma":[0.0003251039,0.00008091237,0.0000209172,0.00023890565,0.00010337435,0.00010287496,0.00009765794,0.00023398243,0.000019857694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034200767,0.00026609702,0.64905894,0.00012634996,0.00009700782,0.0000034647692,0.00015287404,3.6424375e-8,0.00013145673,0.000005101174,0.0015228757,0.34829378],"study_design_scores_gemma":[0.009341068,0.002277558,0.96976185,0.0050171507,0.000105326224,6.5690915e-7,0.000027301396,0.000038526534,0.0010557172,0.000014653616,0.012187272,0.00017290097],"about_ca_topic_score_codex":0.00006217027,"about_ca_topic_score_gemma":0.000016694443,"teacher_disagreement_score":0.34812087,"about_ca_system_score_codex":0.0005127004,"about_ca_system_score_gemma":0.0003909134,"threshold_uncertainty_score":0.32995105},"labels":[],"label_agreement":null},{"id":"W2501562494","doi":"10.1093/annonc/mdv343.14","title":"Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Rash; Internal medicine; Tolerability; Adverse effect; Lung cancer; Pharmacokinetics; Gastroenterology; Oncology; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.02164130412154888,"score_gpt":0.3719260686575253,"score_spread":0.35028476453597646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501562494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282587,0.00056072266,0.000013963283,0.00064773485,0.000053047148,0.0010482743,0.000066046836,0.000006850358,0.0047775162],"genre_scores_gemma":[0.99812204,0.00034034092,0.0005504566,0.00071778515,0.0000185823,0.00007902979,0.00005739017,0.000013908881,0.000100446894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900806,0.000052102474,0.00034175828,0.00023240007,0.00017794778,0.00018775041],"domain_scores_gemma":[0.9987794,0.0001485613,0.00027886755,0.00014993218,0.0005103366,0.00013290491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010202388,0.00014111912,0.0004005959,0.00012393006,0.000022723641,0.0000018408513,0.000048647344,0.00007459467,0.000008906318],"category_scores_gemma":[0.000053826716,0.00010784048,0.000029882476,0.00017756234,0.000096172924,0.00007845391,0.000022711161,0.00009766444,0.0000018331116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027795974,0.013326389,0.5418858,0.00061468955,0.0009923775,0.00014492961,0.034808755,0.080305174,0.0010339771,0.00032658572,0.0007523523,0.29801297],"study_design_scores_gemma":[0.021441834,0.01247333,0.9599775,0.0004964004,0.00019792406,0.0000023819168,0.00038951,0.000094701696,0.0043803654,0.000012170397,0.00042250552,0.00011137521],"about_ca_topic_score_codex":0.00050896563,"about_ca_topic_score_gemma":0.00016186558,"teacher_disagreement_score":0.41809168,"about_ca_system_score_codex":0.00020464853,"about_ca_system_score_gemma":0.00061821885,"threshold_uncertainty_score":0.4397607},"labels":[],"label_agreement":null},{"id":"W2506500153","doi":"10.1158/1538-7445.am2016-ct079","title":"Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; T790M; Internal medicine; Tolerability; Oncology; Progressive disease; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Lung cancer; Clinical trial; Epidermal growth factor receptor; Chemotherapy; Cancer; Adverse effect; Gefitinib","score_opus":0.026487983187163024,"score_gpt":0.3484391199797316,"score_spread":0.3219511367925686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2506500153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941213,0.0003041245,0.0000073956803,0.0004136815,0.00008540858,0.0038656334,0.0005511208,0.000029112705,0.0006221976],"genre_scores_gemma":[0.99636513,0.0001431697,0.00016972673,0.00004152987,0.0001941324,0.0018005257,0.000085379805,0.000094039955,0.0011063527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690586,0.00016628944,0.00045095818,0.0008063706,0.00089138956,0.00077913847],"domain_scores_gemma":[0.9977445,0.00014962,0.00015639822,0.00056468084,0.00093426113,0.0004505115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019159858,0.00040351506,0.0005824946,0.00047929265,0.00019207591,0.00003488511,0.00015090493,0.00011225462,0.000360797],"category_scores_gemma":[0.000022773744,0.00022088246,0.00006811678,0.00063143985,0.00021599226,0.00034628433,0.000080118865,0.00028366657,0.000021372793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011669451,0.013807172,0.9371259,0.00021669256,0.00050540786,0.00023350002,0.009621003,0.000004764786,0.013746662,0.0000029654266,0.00030978257,0.012756693],"study_design_scores_gemma":[0.03479932,0.031131253,0.84649134,0.0013747512,0.00022710668,0.000001730661,0.0014161335,0.0000026981056,0.084086135,0.0000035069572,0.00013489957,0.00033110764],"about_ca_topic_score_codex":0.0060575665,"about_ca_topic_score_gemma":0.0025969497,"teacher_disagreement_score":0.09063454,"about_ca_system_score_codex":0.0022249494,"about_ca_system_score_gemma":0.0011593006,"threshold_uncertainty_score":0.9157269},"labels":[],"label_agreement":null},{"id":"W2508060336","doi":"10.1007/s40265-016-0628-6","title":"Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations","year":2016,"lang":"en","type":"review","venue":"Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer research; Oncology; Mutation; Cell culture; Pharmacotherapy; Cancer; Internal medicine; Gene; Biology; Genetics","score_opus":0.031521627619089235,"score_gpt":0.3615598605783705,"score_spread":0.33003823295928125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508060336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008111242,0.99028945,0.0004682903,0.00011640805,0.00058777,0.00397443,0.0017552597,0.00004529092,0.0019520033],"genre_scores_gemma":[0.00044193663,0.9325159,0.005604106,0.00005440066,0.0004585237,0.0016912255,0.0013431463,0.00012444827,0.05776628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980272,0.000024734369,0.00075314,0.0005353817,0.00020503877,0.00045452386],"domain_scores_gemma":[0.9984608,0.00016720966,0.0005562882,0.0003637898,0.00016736485,0.00028454047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006430837,0.0005274036,0.0016746214,0.00026889195,0.00013361308,0.000019720885,0.00013884762,0.00018395347,0.000514608],"category_scores_gemma":[0.000009841346,0.00036215901,0.00068013335,0.00021090398,0.00003340798,0.00007703868,0.000030109915,0.00009030637,0.0000502668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049168884,0.00057090266,0.00030289186,0.0149037205,0.0031674092,0.000023006949,0.0020933186,0.000009124905,0.00006305949,0.000023315491,0.0030502693,0.97574383],"study_design_scores_gemma":[0.0049907626,0.0002484941,0.00009481622,0.008574128,0.008756067,0.000008075368,0.00003905206,0.00001350003,0.0018182008,0.000009062899,0.97507775,0.00037010587],"about_ca_topic_score_codex":0.00029795,"about_ca_topic_score_gemma":0.00007379198,"teacher_disagreement_score":0.9753737,"about_ca_system_score_codex":0.0016592151,"about_ca_system_score_gemma":0.0050178985,"threshold_uncertainty_score":0.99988306},"labels":[],"label_agreement":null},{"id":"W2510390818","doi":"10.1007/s00428-016-2005-y","title":"ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization","year":2016,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"AstraZeneca; Pfizer","keywords":"Immunohistochemistry; Adenocarcinoma; Fluorescence in situ hybridization; Lung cancer; Medicine; Lung; Pathology; Adenocarcinoma of the lung; Anaplastic lymphoma kinase; In situ hybridization; Oncology; Internal medicine; Cancer; Biology; Gene expression; Gene; Genetics","score_opus":0.012732016193236677,"score_gpt":0.3459870751279423,"score_spread":0.33325505893470564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510390818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97721106,0.019796252,0.00069937494,0.00088325306,0.000095872005,0.0007989987,0.000039353094,0.00006676301,0.00040909884],"genre_scores_gemma":[0.9886007,0.01008307,0.0005269419,0.0003391336,0.000065271015,0.00009054237,0.00008425474,0.000032016866,0.00017810697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757993,0.00020359612,0.0005417771,0.0009269407,0.00023279634,0.0005149529],"domain_scores_gemma":[0.998595,0.000496025,0.0002031489,0.00043031143,0.00005346945,0.00022205504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041096163,0.0003972661,0.00055777497,0.00022743303,0.0001250519,0.000026747706,0.00014966569,0.00022719539,0.00001549588],"category_scores_gemma":[0.0004800804,0.00027756137,0.00005530922,0.00025743767,0.00097422686,0.0003381414,0.00017948372,0.00043417636,0.000003106314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038791544,0.00015692042,0.532655,0.00033460755,0.000100427205,0.00017765394,0.00061508926,0.0000015254972,0.43749943,0.000048537306,0.00008256709,0.027940348],"study_design_scores_gemma":[0.005262129,0.0005712326,0.9619662,0.0008446675,0.00035354827,0.00008488268,0.00025374597,0.00018966255,0.029664004,0.00040413122,0.000048137124,0.00035766853],"about_ca_topic_score_codex":0.00016403217,"about_ca_topic_score_gemma":0.00003808487,"teacher_disagreement_score":0.42931122,"about_ca_system_score_codex":0.00017305116,"about_ca_system_score_gemma":0.00014072425,"threshold_uncertainty_score":0.99996763},"labels":[],"label_agreement":null},{"id":"W2512042252","doi":"10.1016/j.jtho.2016.08.139","title":"An Anaplastic Lymphoma Kinase Immunohistochemistry–Negative but Fluorescence In Situ Hybridization–Positive Lung Adenocarcinoma Is Resistant to Crizotinib","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Canadian Cancer Society Research Institute","keywords":"Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Fluorescence in situ hybridization; Cancer research; Lung cancer; Immunohistochemistry; Fusion gene; Medicine; Adenocarcinoma; Tyrosine-kinase inhibitor; Molecular biology; In situ hybridization; Cancer; Biology; Pathology; Gene expression; Gene; Internal medicine","score_opus":0.01211312311629011,"score_gpt":0.39674905284954265,"score_spread":0.38463592973325256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512042252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022466,0.00052137347,0.0018111952,0.00545128,0.00027681657,0.00033423692,0.00006245251,0.000012297161,0.0013056975],"genre_scores_gemma":[0.9922651,0.000051378196,0.006279159,0.00053566037,0.0002109571,0.000019811909,0.000007671845,0.000022619506,0.0006076213],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984073,0.0001496164,0.0006112246,0.0002680243,0.00028168893,0.00028211382],"domain_scores_gemma":[0.99813616,0.00027560457,0.00042215397,0.00024628677,0.00059867854,0.000321116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026219327,0.0001821471,0.00048642748,0.0002882275,0.00008474078,0.000016969661,0.00016585129,0.000110828194,0.00011177018],"category_scores_gemma":[0.00043903495,0.0001257485,0.000102049264,0.00030167546,0.00010806711,0.00021516327,0.00003234393,0.00013079305,0.000016204389],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0116109755,0.00128625,0.00972642,0.00008979217,0.00035830023,0.0035746729,0.004350069,0.000014561401,0.86370915,0.00006331765,0.0020502375,0.10316627],"study_design_scores_gemma":[0.007528913,0.010274504,0.4472361,0.002081059,0.0012614358,0.0020176254,0.002547554,0.0000877218,0.52517545,0.00028314794,0.0010878227,0.00041869795],"about_ca_topic_score_codex":0.000055975826,"about_ca_topic_score_gemma":0.00003128809,"teacher_disagreement_score":0.43750966,"about_ca_system_score_codex":0.0024032453,"about_ca_system_score_gemma":0.0012871758,"threshold_uncertainty_score":0.6284403},"labels":[],"label_agreement":null},{"id":"W2512074876","doi":"10.1503/cmaj.1040806","title":"From bench to bedside and back again?","year":2004,"lang":"en","type":"editorial","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bench to bedside; Computer science; Data science; Medicine; World Wide Web; Medical physics","score_opus":0.004428764391674849,"score_gpt":0.28374963637789097,"score_spread":0.27932087198621613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512074876","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044507515,0.0014922757,0.00005625438,0.08803909,0.894166,0.0005328523,0.0014785901,0.000026999624,0.009757178],"genre_scores_gemma":[0.0009616082,0.0005835954,0.0005807381,0.01002261,0.97920835,0.000017437107,0.00088176964,0.000053068867,0.0076908474],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996621,0.00006437586,0.0004579205,0.00030205047,0.0020685857,0.00048603266],"domain_scores_gemma":[0.99476486,0.00036872955,0.0002207531,0.00014220564,0.000642438,0.0038610292],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004890399,0.00022723382,0.00048270426,0.00025860747,0.00021622104,0.00014645809,0.00013298626,0.0013307659,0.00588376],"category_scores_gemma":[0.003603822,0.00020125284,0.00011782181,0.00017202752,0.000026130307,0.00007025745,0.000019176996,0.0017111133,0.0006049098],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000009599525,0.00002602276,0.0014175657,0.000013170801,0.00049742765,0.00067676866,0.00047974315,0.000001195695,6.8692015e-7,0.000004448982,0.9878451,0.009028225],"study_design_scores_gemma":[0.002221345,0.00013678486,0.003288809,0.0005275532,0.00037979468,0.000051727784,0.00014309505,0.0000028222937,0.0000013270951,0.00017780362,0.9928915,0.00017743724],"about_ca_topic_score_codex":0.03831256,"about_ca_topic_score_gemma":0.069021456,"teacher_disagreement_score":0.08504232,"about_ca_system_score_codex":0.005804319,"about_ca_system_score_gemma":0.020904807,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W2512922897","doi":"10.1093/annonc/mdw322","title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Lung cancer; Adenocarcinoma; Adverse effect; Pharmacokinetics; Oncology; Gastroenterology; Post-hoc analysis; Incidence (geometry); Chemotherapy; Urology; Pharmacology; Surgery; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.061415987782471974,"score_gpt":0.4621472999199842,"score_spread":0.40073131213751223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512922897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98339224,0.0051935776,0.000111540554,0.006746369,0.000088843386,0.0035229854,0.0003300499,0.0000032330404,0.0006111419],"genre_scores_gemma":[0.99863964,0.00079419353,0.00009374536,0.00020603745,0.000038570233,0.000118097625,0.000019212368,0.000008760902,0.00008174866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99794227,0.00096259156,0.0006836076,0.0001549035,0.00014302747,0.000113591435],"domain_scores_gemma":[0.98183477,0.016793689,0.000807221,0.00018982409,0.00033433197,0.000040181454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017753374,0.00012702437,0.0012274684,0.00008579455,0.000049146453,0.0000015807624,0.00005924454,0.00007309479,0.000029264276],"category_scores_gemma":[0.0028955722,0.000049456703,0.00029776862,0.000094694486,0.00040595085,0.000030079975,0.000027911072,0.0000394204,1.3933182e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7281753,0.0015063022,0.0070345737,0.0011561196,0.011730692,0.000007768,0.0065717855,0.00005242995,0.052258633,0.0064088516,0.0013852008,0.1837124],"study_design_scores_gemma":[0.44087407,0.021447407,0.20076245,0.0010554333,0.0105033945,0.00001890079,0.00046434844,0.00015543142,0.3241898,0.00025453776,0.00014418761,0.0001300365],"about_ca_topic_score_codex":0.00010732123,"about_ca_topic_score_gemma":0.000008079627,"teacher_disagreement_score":0.28730118,"about_ca_system_score_codex":0.000038020284,"about_ca_system_score_gemma":0.00018762096,"threshold_uncertainty_score":0.34664795},"labels":[],"label_agreement":null},{"id":"W2513734563","doi":"10.1016/j.cllc.2016.07.007","title":"Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Astellas Foundation for Research on Metabolic Disorders","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Oncology; Placebo; Adverse effect; Pharmacology; Clinical endpoint; Cancer; Randomized controlled trial; Pathology","score_opus":0.026824492551650855,"score_gpt":0.3907059977854347,"score_spread":0.3638815052337838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513734563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446595,0.00012644164,0.00013960876,0.0009092889,0.00014566748,0.0038986593,0.00015733972,0.000026830354,0.00013021554],"genre_scores_gemma":[0.9975555,0.00019216149,0.00052771467,0.00025312728,0.000092517344,0.00087459054,0.00004174056,0.000055798995,0.0004068799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979304,0.00012842637,0.0007849442,0.00055335835,0.00029206206,0.00031078205],"domain_scores_gemma":[0.9979573,0.00083540863,0.00046598795,0.00021397183,0.00035756416,0.00016975743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019985963,0.0002711832,0.00063966785,0.00017694615,0.00007443549,0.000015592095,0.00007868922,0.00011965424,0.0001905864],"category_scores_gemma":[0.00016522004,0.00015671793,0.000046636764,0.0004101931,0.0001328229,0.000226323,0.0000279004,0.0002606211,8.201686e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068125995,0.006754655,0.9596654,0.00018808283,0.00038053817,0.0000134316715,0.0041124914,0.000020667778,0.00014805587,0.0000039949564,0.00010545687,0.021794615],"study_design_scores_gemma":[0.13317783,0.0049979715,0.85712117,0.0016967386,0.00042719726,8.816765e-7,0.0009629839,0.00045300377,0.0008512052,0.0000033587762,0.000038808248,0.00026886744],"about_ca_topic_score_codex":0.00089904474,"about_ca_topic_score_gemma":0.0018661055,"teacher_disagreement_score":0.12636523,"about_ca_system_score_codex":0.00043882374,"about_ca_system_score_gemma":0.00066241,"threshold_uncertainty_score":0.6390771},"labels":[],"label_agreement":null},{"id":"W2514360855","doi":"10.5858/arpa.2012-0720-oa","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Medicine; Anaplastic lymphoma kinase; Lung cancer; Family medicine; Oncology; Internal medicine; Pathology","score_opus":0.009531255861994709,"score_gpt":0.3332404848885003,"score_spread":0.32370922902650556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514360855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733121,0.0030588065,0.008236839,0.0051817065,0.00033122604,0.004923491,0.004933245,0.000011616331,0.000010999124],"genre_scores_gemma":[0.98556983,0.00023579253,0.010800324,0.00060970045,0.00021692304,0.0020222354,0.00048808256,0.00003152059,0.000025610676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980889,0.00014092265,0.0009967413,0.00032814368,0.00023569119,0.00020960682],"domain_scores_gemma":[0.99329644,0.0024804783,0.0016694367,0.00017534595,0.0023309125,0.000047377507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071974826,0.00018718516,0.00063427095,0.00012790151,0.0001087022,0.0000028989678,0.000110530964,0.00008846525,0.000003597686],"category_scores_gemma":[0.0038534307,0.0001247443,0.000074690004,0.00021397787,0.00029916424,0.000056334142,0.000044126587,0.00008956058,8.728303e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006885352,0.0006553223,0.71769756,0.00027260647,0.0013042592,0.0000022836875,0.00356822,0.00022472606,0.2600905,0.00022791688,0.006589467,0.008678587],"study_design_scores_gemma":[0.054756112,0.016354183,0.7937823,0.0011181099,0.012499559,0.000006626931,0.00804056,0.04971661,0.057799403,0.001862633,0.0035242627,0.00053966866],"about_ca_topic_score_codex":0.0010572701,"about_ca_topic_score_gemma":0.0002618843,"teacher_disagreement_score":0.20229109,"about_ca_system_score_codex":0.00016361778,"about_ca_system_score_gemma":0.0002251016,"threshold_uncertainty_score":0.5086925},"labels":[],"label_agreement":null},{"id":"W2514523591","doi":"10.1007/s10637-016-0383-2","title":"Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Nivolumab; Pembrolizumab; Medicine; Lung cancer; Tyrosine kinase; Erlotinib; EGFR inhibitors; Cancer research; Oncology; Anaplastic lymphoma kinase; Internal medicine; Immunotherapy; Cancer; Epidermal growth factor receptor; Receptor","score_opus":0.01607847236170796,"score_gpt":0.2932689510862317,"score_spread":0.27719047872452374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514523591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615828,0.0026234582,0.000717504,0.03009374,0.0005693976,0.0013367244,0.000055933335,0.00011074836,0.0029097248],"genre_scores_gemma":[0.98291725,0.000077879085,0.0062250113,0.0023421813,0.0013540288,0.00015158603,0.00008336317,0.00006416434,0.006784523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798703,0.00003723732,0.0005928629,0.00051360123,0.00041165936,0.00045759926],"domain_scores_gemma":[0.9986173,0.00013252322,0.00017740345,0.0002099745,0.00013099538,0.00073179585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016982734,0.000312859,0.0003232629,0.00028400304,0.00011175174,0.00005095402,0.00011554285,0.00011527617,0.00026879183],"category_scores_gemma":[0.00008534069,0.00023409989,0.00011409102,0.0005810012,0.00006809304,0.00022864409,0.00005137249,0.00018251548,0.000065535154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026738897,0.00044732526,0.17937346,0.0003281287,0.00034029144,0.000110575944,0.01196271,0.003112093,0.6177031,0.0017622167,0.08862023,0.09597253],"study_design_scores_gemma":[0.030313907,0.0010552048,0.123549074,0.009854873,0.0010828434,0.000039638653,0.002580576,0.0017829828,0.760756,0.0077687106,0.058947988,0.0022681674],"about_ca_topic_score_codex":0.004400869,"about_ca_topic_score_gemma":0.0003256305,"teacher_disagreement_score":0.14305298,"about_ca_system_score_codex":0.0009343074,"about_ca_system_score_gemma":0.0025248795,"threshold_uncertainty_score":0.9546316},"labels":[],"label_agreement":null},{"id":"W2514694404","doi":"10.1188/16.onf.544-547","title":"The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Oncology nursing forum","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Context (archaeology); Lung cancer; Lung; Constitutional symptoms; Pericardial fluid; Past medical history; Emergency department; Surgery; Pathology; Internal medicine; Disease; Pericardium","score_opus":0.016115427815850864,"score_gpt":0.3547330741332659,"score_spread":0.33861764631741503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514694404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.879642,0.013623727,0.0036391516,0.0709009,0.0018504934,0.0025808113,0.00007096303,0.000049814775,0.027642101],"genre_scores_gemma":[0.9947545,0.00032642385,0.0013001995,0.00030624215,0.000030769992,0.00021562085,0.000008514936,0.000016763504,0.0030409624],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991154,0.000053195425,0.00027163932,0.00016683096,0.00010827423,0.0002846382],"domain_scores_gemma":[0.9992278,0.00027985778,0.0001441496,0.00017329551,0.00011814802,0.000056752633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014500001,0.00010064154,0.0002347339,0.0000878869,0.00012919663,0.000006774362,0.00006479262,0.000047574293,0.00008476804],"category_scores_gemma":[0.000041490322,0.000056931724,0.000061929815,0.00012663542,0.00018602365,0.00006287889,0.000012373462,0.00007294412,0.000007754905],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056094147,0.0017660185,0.2320872,0.00016659363,0.00074063503,0.00009315553,0.019504946,0.00006691853,0.044578988,0.001819648,0.042065844,0.6565491],"study_design_scores_gemma":[0.0760617,0.0063253315,0.58259064,0.0127183,0.008400219,0.00013324968,0.076454274,0.006165155,0.05855988,0.0059455335,0.1654294,0.0012162895],"about_ca_topic_score_codex":0.00030548527,"about_ca_topic_score_gemma":0.0010357705,"teacher_disagreement_score":0.6553328,"about_ca_system_score_codex":0.0012964316,"about_ca_system_score_gemma":0.0005685116,"threshold_uncertainty_score":0.33901235},"labels":[],"label_agreement":null},{"id":"W2515313589","doi":"10.1002/hep.28215","title":"Poster Session 1: Practice Issues; Signal Transduction and Nuclear Receptors","year":2015,"lang":"en","type":"article","venue":"Hepatology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Vancouver General Hospital; London Health Sciences Centre; Capital District Health Authority; University Health Network","funders":"","keywords":"Session (web analytics); Signal transduction; Receptor; Transduction (biophysics); SIGNAL (programming language); Cell biology; Neuroscience; Computational biology; Medicine; Psychology; Biology; Computer science; Internal medicine; Biophysics; World Wide Web","score_opus":0.027777884725032783,"score_gpt":0.35591886027277936,"score_spread":0.32814097554774657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515313589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9507661,0.0011000494,0.000070459726,0.033291217,0.0005524928,0.0002479476,0.00000286111,0.00007162067,0.013897263],"genre_scores_gemma":[0.99520063,0.00014023934,0.0017631671,0.0015010968,0.00010913387,0.000007822827,0.000021959502,0.000013109391,0.0012428429],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995389,0.000053078533,0.00009310981,0.00013849822,0.000078663805,0.00009776359],"domain_scores_gemma":[0.9996641,0.000023711737,0.00003330481,0.000077665085,0.000091888476,0.000109326145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006341922,0.00006231442,0.00012279097,0.000041054984,0.0000418947,0.000006999134,0.000013243786,0.00007169115,0.00031751028],"category_scores_gemma":[0.000040664,0.000048249363,0.000017185805,0.00005307508,0.000043048356,0.00012771353,0.000007706274,0.00007289232,0.00007677611],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006648767,0.0022983362,0.484223,0.00028220244,0.0012968677,0.0010759683,0.061219495,0.000003449071,0.014760074,0.00861918,0.23756376,0.18200888],"study_design_scores_gemma":[0.0027342704,0.0010002224,0.002653538,0.000030000054,0.00044628888,0.0018030579,0.0023990383,0.00011883456,0.0009248616,0.00017037011,0.987615,0.000104550156],"about_ca_topic_score_codex":0.00021895676,"about_ca_topic_score_gemma":0.000009023984,"teacher_disagreement_score":0.7500512,"about_ca_system_score_codex":0.00005895514,"about_ca_system_score_gemma":0.000070545095,"threshold_uncertainty_score":0.34765148},"labels":[],"label_agreement":null},{"id":"W2516744702","doi":"10.5858/arpa.2015-0316-oa","title":"Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens","year":2016,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Adenocarcinoma; Pathology; Cytopathology; Large cell; Carcinoma; Small Cell Lung Carcinoma; Anaplastic lymphoma kinase; Lung; Lymph node; Papanicolaou stain; Not Otherwise Specified; Anaplastic carcinoma; Squamous-cell carcinoma of the lung; Epidermal growth factor receptor; Stage (stratigraphy); Cytology; Cancer; Small-cell carcinoma; Internal medicine; Cervical cancer; Biology","score_opus":0.011432390283194996,"score_gpt":0.2782713141924371,"score_spread":0.26683892390924213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516744702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876477,0.0061516073,0.00018084426,0.0020467283,0.0002578436,0.00053101615,0.00015050605,0.000033985238,0.0029997495],"genre_scores_gemma":[0.99752307,0.00018897242,0.0010677865,0.0006961316,0.00017170915,0.00006989706,0.00013880318,0.000032954722,0.000110652516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767226,0.0003434678,0.0007494594,0.00058899896,0.00018289976,0.00046294014],"domain_scores_gemma":[0.99730223,0.0016660313,0.00030468745,0.00052389316,0.00005618231,0.0001469738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017316917,0.00028809026,0.0008854663,0.00054025743,0.000040164527,0.0000017851162,0.0001871931,0.0001521191,0.00030975472],"category_scores_gemma":[0.0004313789,0.00018666762,0.00006661321,0.00031910816,0.00065479917,0.00008584982,0.000102611535,0.0002932031,0.000011500216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024710115,0.0003132173,0.7076931,0.00007684093,0.000021270353,0.0027190521,0.0028636975,0.0000014482727,0.28459823,0.00010572189,0.00010494773,0.0012553887],"study_design_scores_gemma":[0.011361217,0.00080826605,0.9780341,0.0002620348,0.00021020306,0.000064566055,0.00064615294,0.00002328064,0.007820727,0.0005470734,0.000064563676,0.00015785338],"about_ca_topic_score_codex":0.0002737582,"about_ca_topic_score_gemma":0.00018218467,"teacher_disagreement_score":0.2767775,"about_ca_system_score_codex":0.00018291097,"about_ca_system_score_gemma":0.00033001552,"threshold_uncertainty_score":0.7612085},"labels":[],"label_agreement":null},{"id":"W2519194501","doi":"10.1097/01.jto.0000283823.54863.21","title":"P2-165: A phase I/II study of concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Ottawa; Eli Lilly (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pemetrexed; Carboplatin; Regimen; Internal medicine; Lung cancer; Cisplatin; Premedication; Oncology; Phases of clinical research; Chemotherapy; Urology; Gastroenterology; Surgery","score_opus":0.027489787078774534,"score_gpt":0.4922198396536212,"score_spread":0.4647300525748467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519194501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935021,0.0019067149,0.0008466917,0.00033710082,0.0009188607,0.000770452,0.000020499585,0.000005606138,0.0016920031],"genre_scores_gemma":[0.9978661,0.00019011827,0.00073242944,0.000114043054,0.00028160974,0.000017433742,0.000007853886,0.000017225717,0.00077317335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982335,0.00009573647,0.00096121366,0.00016188441,0.00029387965,0.00025380292],"domain_scores_gemma":[0.9981703,0.00016708838,0.0010247282,0.00014229026,0.00032167914,0.00017391058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083248084,0.00015243357,0.00063646113,0.0005329284,0.00006065604,0.000005987987,0.00009850265,0.000110543755,0.00018962429],"category_scores_gemma":[0.000059024605,0.00012049127,0.00011160323,0.0003827378,0.000036223253,0.00010710244,0.000032479467,0.0003633236,0.0000013785639],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041367793,0.024629131,0.24860989,0.000433262,0.0008314442,0.0015790127,0.028112836,0.0007612776,0.0070397407,0.000017830438,0.0013834317,0.6824654],"study_design_scores_gemma":[0.11205768,0.12335424,0.6494945,0.0014197459,0.010026874,0.0004683703,0.03894923,0.0039150845,0.02459724,0.000048124235,0.03486727,0.00080159033],"about_ca_topic_score_codex":0.000309422,"about_ca_topic_score_gemma":0.00084481563,"teacher_disagreement_score":0.68166375,"about_ca_system_score_codex":0.0010489041,"about_ca_system_score_gemma":0.0009243994,"threshold_uncertainty_score":0.49134913},"labels":[],"label_agreement":null},{"id":"W2519959729","doi":"10.1097/01.jto.0000283821.09121.0c","title":"P2-163: Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC): A Single Institution Canadian Experience","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Carboplatin; Regimen; Radiation therapy; Lung cancer; Stage (stratigraphy); Etoposide; Chemotherapy; Adenocarcinoma; Surgery; Cisplatin; Nuclear medicine; Oncology; Internal medicine; Cancer","score_opus":0.028421123536006804,"score_gpt":0.4409167984616368,"score_spread":0.41249567492563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519959729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96601915,0.0018372998,0.01893832,0.0016303397,0.0023406057,0.00078389345,0.0000392219,0.000010017926,0.008401175],"genre_scores_gemma":[0.99390405,0.00009916246,0.0030158663,0.00064178865,0.00058130315,0.000041675972,0.000019095423,0.000014160803,0.0016829119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989039,0.000020486985,0.0004641876,0.00014302887,0.00015032195,0.00031813292],"domain_scores_gemma":[0.9985942,0.00006915588,0.0004605359,0.00009950793,0.00039687072,0.00037972693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035052697,0.00012390841,0.00033317643,0.00026682453,0.0001368958,0.000016304275,0.00008175651,0.00013316864,0.00013690321],"category_scores_gemma":[0.000051470994,0.00010378067,0.000117052645,0.00016705143,0.000057655176,0.00014800264,0.000008803048,0.00017821841,0.000002823208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038351351,0.002498175,0.045993872,0.00088740163,0.0008296499,0.001244039,0.03420136,0.0005914937,0.05126237,0.00022281698,0.014732147,0.84370154],"study_design_scores_gemma":[0.020099362,0.008673585,0.06632033,0.0011770262,0.0040326444,0.0008181365,0.016346427,0.0022959176,0.12886646,0.000045679804,0.75052464,0.00079976895],"about_ca_topic_score_codex":0.005200145,"about_ca_topic_score_gemma":0.021601902,"teacher_disagreement_score":0.84290177,"about_ca_system_score_codex":0.0032816045,"about_ca_system_score_gemma":0.0032529496,"threshold_uncertainty_score":0.9962513},"labels":[],"label_agreement":null},{"id":"W2520064697","doi":"10.18632/oncotarget.12065","title":"Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vertex Pharmaceuticals (Canada)","funders":"","keywords":"Erlotinib; Triple-negative breast cancer; Crizotinib; Medicine; Cancer research; EGFR inhibitors; Gefitinib; Lapatinib; Receptor tyrosine kinase; Epidermal growth factor receptor; Crosstalk; Targeted therapy; Tyrosine kinase; Breast cancer; Lung cancer; Oncology; Cancer; Internal medicine; Receptor; Trastuzumab","score_opus":0.010325613670637484,"score_gpt":0.3110296367389623,"score_spread":0.3007040230683248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520064697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930549,0.0008051857,0.00027370025,0.0021204662,0.00017077744,0.0004027582,0.00013647054,0.000042210388,0.002993528],"genre_scores_gemma":[0.9945933,0.00011735048,0.0027326192,0.00026648003,0.00012632944,0.0000509935,0.000019979505,0.000019968635,0.0020729448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913675,0.000028630893,0.00019945418,0.00025084475,0.00013584078,0.0002484633],"domain_scores_gemma":[0.999543,0.000106248815,0.00006646572,0.000101278725,0.00006120702,0.00012179597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012656042,0.00012921309,0.00023188883,0.000084629384,0.00007704445,0.00001660017,0.000032425847,0.000048641243,0.0003151444],"category_scores_gemma":[0.00007913161,0.000082092825,0.00003881145,0.00015239071,0.00007698267,0.00014579188,0.00001991613,0.00007265832,0.000016051386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071128056,0.00023538248,0.85635716,0.000103600374,0.00043706878,0.00024606002,0.005356973,0.00007835119,0.10706356,0.0006120541,0.0052792197,0.023519281],"study_design_scores_gemma":[0.078156896,0.0024431166,0.7919399,0.0036355348,0.001187419,0.00046808049,0.009246305,0.000770311,0.047688887,0.0059205433,0.056609698,0.0019332704],"about_ca_topic_score_codex":0.001175023,"about_ca_topic_score_gemma":0.00015817929,"teacher_disagreement_score":0.07744561,"about_ca_system_score_codex":0.0005551057,"about_ca_system_score_gemma":0.00024976264,"threshold_uncertainty_score":0.34506103},"labels":[],"label_agreement":null},{"id":"W2520501086","doi":"10.1016/j.cpet.2016.08.008","title":"Molecular Imaging and Precision Medicine in Lung Cancer","year":2016,"lang":"en","type":"review","venue":"PET Clinics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Precision medicine; Lung cancer; Biomarker; Disease; Cancer; Lung; Oncology; Internal medicine; Pathology","score_opus":0.03263889956480497,"score_gpt":0.4809749719053772,"score_spread":0.4483360723405722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520501086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043857533,0.9955233,0.00006341217,0.001010096,0.00043333982,0.0008260878,0.000049727627,0.000023216224,0.0020269924],"genre_scores_gemma":[0.000046466255,0.99813634,0.00015507157,0.00030029236,0.00026337343,0.00017751046,0.00007801973,0.00004883185,0.00079408597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859357,0.000059862956,0.0005925218,0.00038298935,0.00018195731,0.00018908427],"domain_scores_gemma":[0.99897426,0.00032885463,0.00022060279,0.00029958988,0.00006001223,0.000116677285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002359016,0.00024503568,0.0011794689,0.00018897996,0.000026600823,0.000008159227,0.00006690602,0.00008272079,0.0001706678],"category_scores_gemma":[0.00020868082,0.00014028016,0.00013119227,0.00016315733,0.00006851497,0.000038784125,0.000050179777,0.0002249708,0.000011149924],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000068256154,0.000030072955,0.00072286534,0.004757459,0.00015325255,0.00024571683,0.000059436104,1.207373e-7,2.0632046e-7,0.000052512234,0.0011794881,0.99279207],"study_design_scores_gemma":[0.0013676882,0.00004308181,0.000109532426,0.065781556,0.002381816,0.000085687665,0.000009710197,0.00004801496,1.237553e-7,0.00008849982,0.9299443,0.00014000061],"about_ca_topic_score_codex":0.00008473502,"about_ca_topic_score_gemma":0.000017651088,"teacher_disagreement_score":0.99265206,"about_ca_system_score_codex":0.0002628112,"about_ca_system_score_gemma":0.00044471078,"threshold_uncertainty_score":0.57204586},"labels":[],"label_agreement":null},{"id":"W2521916949","doi":"10.1016/j.jtho.2016.08.056","title":"P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Oncology; Adverse effect; Adenocarcinoma; Randomized controlled trial; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.014894614685271545,"score_gpt":0.39925166213243707,"score_spread":0.38435704744716553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521916949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696454,0.00065101776,0.00709421,0.016453281,0.001622601,0.0028625412,0.00020262368,0.000015501757,0.0014528566],"genre_scores_gemma":[0.9915508,0.00026468432,0.003915262,0.00085266464,0.0014317915,0.00031156966,0.000039006773,0.00004356404,0.0015906673],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983857,0.000105756306,0.000664514,0.0002169903,0.00030704925,0.00031998917],"domain_scores_gemma":[0.99668956,0.0009802452,0.00102916,0.0001913189,0.00092951,0.00018020121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037357718,0.00021416474,0.0005772602,0.00013983356,0.00023886365,0.000022385007,0.00015838422,0.00013835652,0.00013811693],"category_scores_gemma":[0.00015284843,0.00010088,0.0002120778,0.00016013678,0.00010043982,0.00016450735,0.000025857378,0.00021748325,0.0000044723297],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38977855,0.007914764,0.09209402,0.00080316176,0.006132156,0.00056430866,0.008917222,0.0005211851,0.00047423394,0.00014954494,0.038333498,0.45431733],"study_design_scores_gemma":[0.58261764,0.109609365,0.14474577,0.005013545,0.029764064,0.00078109524,0.0024235973,0.0014664311,0.007046106,0.00058669207,0.11461832,0.0013273724],"about_ca_topic_score_codex":0.000049454404,"about_ca_topic_score_gemma":0.00013227703,"teacher_disagreement_score":0.45298997,"about_ca_system_score_codex":0.0010322172,"about_ca_system_score_gemma":0.0012779882,"threshold_uncertainty_score":0.4113767},"labels":[],"label_agreement":null},{"id":"W2522029373","doi":"10.1038/srep33710","title":"The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Crizotinib; Cancer research; Gene knockdown; Chemistry; Molecular biology; Biology; Cell culture; Medicine; Genetics; Oncology; Lung cancer","score_opus":0.04282249358754165,"score_gpt":0.33869125947209827,"score_spread":0.29586876588455663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522029373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497604,0.00018851028,0.0001336022,0.0007117049,0.0013415238,0.0008821944,0.0000048557026,0.000023272842,0.0017383085],"genre_scores_gemma":[0.9896452,0.0000011763751,0.00033371424,0.000028476832,0.000038097616,0.000073722105,0.0000054985894,0.000015635685,0.009858503],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981674,0.00008767123,0.00049399293,0.0004856675,0.0004979022,0.0002673473],"domain_scores_gemma":[0.99852055,0.000097283984,0.00023270736,0.00090845855,0.00013302351,0.00010797513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010254552,0.00011124231,0.00019394179,0.000114359915,0.00040499365,0.00011316653,0.000087243985,0.000027472215,0.000056864515],"category_scores_gemma":[0.00021858102,0.000059061065,0.00005789338,0.00033529082,0.00019910412,0.00014615835,0.000046949182,0.000055037093,0.0000040117507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017353597,0.0008074792,0.3955013,0.00004272964,0.00023230973,0.0016726042,0.013141681,0.00008952442,0.5619556,0.00020154548,0.013267119,0.01291463],"study_design_scores_gemma":[0.003415313,0.0004565857,0.625436,0.0013217066,0.00042665954,0.000023160992,0.0017718741,0.000008914277,0.16197686,0.0017247221,0.20296356,0.0004746298],"about_ca_topic_score_codex":0.00037552966,"about_ca_topic_score_gemma":0.0018721455,"teacher_disagreement_score":0.3999787,"about_ca_system_score_codex":0.00023532358,"about_ca_system_score_gemma":0.0002908775,"threshold_uncertainty_score":0.31149247},"labels":[],"label_agreement":null},{"id":"W2522615762","doi":"10.1016/j.jtho.2016.08.027","title":"P1.05: An International Epidemiological Analysis of Young Patients Diagnosed With NSCLC (ADUJOV-CLICaP)","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Adenocarcinoma; Lung cancer; Population; Stage (stratigraphy); Retrospective cohort study; Cancer; Cancer registry; Oncology","score_opus":0.029275830899180573,"score_gpt":0.46054303011625375,"score_spread":0.4312671992170732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522615762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925512,0.0000695456,0.001558264,0.0028585773,0.00039434555,0.00013887078,0.000032179836,0.000007819887,0.0023891828],"genre_scores_gemma":[0.9942092,0.00015359664,0.0048094844,0.00035527372,0.00018151644,0.0000085010915,0.00002181636,0.000008984997,0.00025165832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855286,0.00018508498,0.0006532976,0.00015973735,0.0002893917,0.00015962878],"domain_scores_gemma":[0.99779344,0.00040345913,0.0008400037,0.00017601332,0.0006035254,0.00018357212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045717804,0.00011585378,0.000740281,0.00041408904,0.000031240237,0.0000047085437,0.0001510949,0.000113569615,0.0003508292],"category_scores_gemma":[0.00046479554,0.000054555207,0.00023640391,0.0002818191,0.00012288257,0.00019923039,0.000023431943,0.00013046824,0.000003713375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017454799,0.0013363467,0.84780663,0.0000064394517,0.0034046804,0.00019171633,0.0003132041,0.000029416613,0.0004364927,0.00007994218,0.0005066321,0.14414302],"study_design_scores_gemma":[0.0024573773,0.0053864922,0.9810065,0.000099086355,0.0046023624,0.000097068056,0.0001634077,0.000036046407,0.0001687641,0.00007923034,0.0058380235,0.00006564683],"about_ca_topic_score_codex":0.000033201424,"about_ca_topic_score_gemma":0.000057936828,"teacher_disagreement_score":0.14407736,"about_ca_system_score_codex":0.00038655518,"about_ca_system_score_gemma":0.0002400004,"threshold_uncertainty_score":0.3841334},"labels":[],"label_agreement":null},{"id":"W2523018303","doi":"10.1016/j.jtho.2016.08.130","title":"Response to Yamamoto et al.","year":2016,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Mutation; Cancer research; Lung cancer; Tyrosine kinase; Oncology; Phenotype; Cancer; Internal medicine; Gene; Biology; Genetics; Colorectal cancer; Receptor","score_opus":0.027093633624768382,"score_gpt":0.48318756875809393,"score_spread":0.4560939351333255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523018303","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042818687,0.00038190986,0.00027801102,0.98569536,0.0019916487,0.00035255976,0.00004987593,0.000014576439,0.0069541777],"genre_scores_gemma":[0.0007620417,0.00012782046,0.0041984417,0.9576855,0.003016724,0.000020675983,0.000015480557,0.000051281266,0.034122057],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979555,0.00050441996,0.00059644715,0.00020827596,0.00042587167,0.00030950934],"domain_scores_gemma":[0.99774855,0.0006043267,0.0006351212,0.00030984732,0.0004895715,0.0002126022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010550782,0.00021787021,0.00081631663,0.000559857,0.000041209,0.000017880202,0.00019384419,0.00047439782,0.0004930597],"category_scores_gemma":[0.00039558593,0.00013263896,0.00029633366,0.00013285092,0.000051702584,0.0000816984,0.000048523674,0.0012545292,0.00023156543],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047188145,0.0000806041,0.000044211345,0.000032057615,0.00051152334,0.008947855,0.00023758248,6.8038054e-7,0.0011566442,0.0000017720018,0.9280064,0.056261823],"study_design_scores_gemma":[0.0010068188,0.0046221116,0.00059657195,0.00055942254,0.000871869,0.0039353017,0.000032346445,1.777488e-7,0.00016545935,0.00008660326,0.98799896,0.00012435783],"about_ca_topic_score_codex":0.0000058357386,"about_ca_topic_score_gemma":0.0000027280014,"teacher_disagreement_score":0.05999253,"about_ca_system_score_codex":0.0012671134,"about_ca_system_score_gemma":0.0025081476,"threshold_uncertainty_score":0.5450375},"labels":[],"label_agreement":null},{"id":"W2524433904","doi":"10.1016/j.jtho.2016.08.055","title":"P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Pemetrexed; Gemcitabine; Chemotherapy; Oncology; Lung cancer; Cisplatin; Adenocarcinoma; Gefitinib; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.018030987761416553,"score_gpt":0.4345742131105186,"score_spread":0.41654322534910204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524433904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197525,0.00018615558,0.0044574235,0.0014337703,0.00061110704,0.0004252844,0.00013525764,0.000007895344,0.00076783384],"genre_scores_gemma":[0.99344033,0.00007850968,0.0055508884,0.00023630293,0.00019096148,0.000019495896,0.000055090895,0.000019160369,0.00040923845],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987554,0.000094382674,0.0005723642,0.0001469475,0.00025154516,0.00017938075],"domain_scores_gemma":[0.997711,0.00060807937,0.000837621,0.00014482124,0.00057889405,0.00011958598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029120885,0.000120659526,0.0006244558,0.0004300425,0.000045108816,0.000006928205,0.00009028937,0.00011559283,0.00019200794],"category_scores_gemma":[0.00019649122,0.00007988401,0.0003751447,0.00037170868,0.00007423431,0.0001369371,0.000010936946,0.00009393337,0.0000030057042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028285298,0.003019108,0.08412419,0.00011727425,0.025228715,0.0001807988,0.007307309,0.00008041764,0.006703153,0.00015199994,0.004878888,0.83992285],"study_design_scores_gemma":[0.026654935,0.01120891,0.9280864,0.00033177817,0.020803869,0.000036493468,0.0008909829,0.00015646513,0.005647918,0.00018468942,0.0057739746,0.00022359345],"about_ca_topic_score_codex":0.000017886434,"about_ca_topic_score_gemma":0.000032982032,"teacher_disagreement_score":0.8439622,"about_ca_system_score_codex":0.0006454206,"about_ca_system_score_gemma":0.00036188812,"threshold_uncertainty_score":0.32575753},"labels":[],"label_agreement":null},{"id":"W2525323356","doi":"10.1200/jco.2007.25.18_suppl.7594","title":"Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene mutations detected by denaturing high-performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Gefitinib; Denaturing high performance liquid chromatography; Medicine; Exon; Lung cancer; Epidermal growth factor receptor; Erlotinib; Point mutation; ROS1; Mutation; Internal medicine; Oncology; Gene mutation; Cancer research; Adenocarcinoma; Cancer; Gene; Biology; Genetics","score_opus":0.028761481619544903,"score_gpt":0.4024679377034675,"score_spread":0.3737064560839226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525323356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927945,0.0036077336,0.0005265151,0.0016554042,0.00049944955,0.0006158445,0.000056699057,0.0000156207,0.0002282048],"genre_scores_gemma":[0.9863364,0.0034686625,0.009278583,0.0004948872,0.00030200958,0.000038333554,0.00002381927,0.00002352556,0.0000337413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968535,0.00016272292,0.0021835677,0.0002734438,0.00019313472,0.0003336344],"domain_scores_gemma":[0.99538696,0.0019610012,0.0016185216,0.00016121687,0.0005532489,0.0003190567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010722226,0.00019418482,0.0010182391,0.0003391378,0.00008194143,0.000008461615,0.00014723922,0.0004144739,0.000033845336],"category_scores_gemma":[0.0009226641,0.00014544866,0.00022584057,0.00040211377,0.00022932902,0.00014003518,0.00004108892,0.0008358746,0.0000012878338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013890853,0.0015797287,0.95456195,0.00017440089,0.00030045438,0.000083305335,0.00037698093,0.000030945197,0.02454053,0.0000120431,0.00043360118,0.016516984],"study_design_scores_gemma":[0.0059491815,0.005040994,0.97253865,0.00023422448,0.00064082356,0.00014831696,0.00008333274,0.000025858406,0.015041131,0.000025700123,0.00014518262,0.00012661002],"about_ca_topic_score_codex":0.000109315544,"about_ca_topic_score_gemma":0.00015172384,"teacher_disagreement_score":0.017976705,"about_ca_system_score_codex":0.00019501781,"about_ca_system_score_gemma":0.000984809,"threshold_uncertainty_score":0.5931224},"labels":[],"label_agreement":null},{"id":"W2526148797","doi":"10.1200/jco.2014.32.15_suppl.7501","title":"A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Rash; Erlotinib; Clinical endpoint; Chemotherapy; Oncology; Surgery; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.07699324678474728,"score_gpt":0.457988531164614,"score_spread":0.38099528437986674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526148797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894414,0.00010559755,0.00060476037,0.0013094757,0.0015385911,0.0047668843,0.00008203182,0.000011151572,0.0021401118],"genre_scores_gemma":[0.9953142,0.00020530679,0.0025063038,0.00061540416,0.0007356622,0.00014743321,0.00005103994,0.000059224643,0.00036544242],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99456406,0.0008432676,0.0030267795,0.00045364647,0.00068236346,0.0004298733],"domain_scores_gemma":[0.99194396,0.003064612,0.003553878,0.0002996294,0.00069130334,0.0004466377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003518157,0.00035454126,0.0035051613,0.00032328945,0.00009064153,0.000021736407,0.00018296311,0.00024756257,0.00004523801],"category_scores_gemma":[0.0008012451,0.00019964973,0.0005448634,0.00033016907,0.0002913903,0.0001918234,0.000028413757,0.00091760623,0.0000017167679],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97189426,0.0059893914,0.008774203,0.00007796742,0.0021286097,0.00032923667,0.0014135097,0.00020889787,0.000030355674,0.000005235836,0.00023795862,0.008910375],"study_design_scores_gemma":[0.9014938,0.08521643,0.0059884815,0.0009905865,0.0027980392,0.000023375704,0.0003094211,0.0012876539,0.00019290546,0.0000025047593,0.001484555,0.00021227554],"about_ca_topic_score_codex":0.00085173483,"about_ca_topic_score_gemma":0.0023392201,"teacher_disagreement_score":0.079227045,"about_ca_system_score_codex":0.00068535923,"about_ca_system_score_gemma":0.0035917433,"threshold_uncertainty_score":0.81414795},"labels":[],"label_agreement":null},{"id":"W2526843003","doi":"10.1164/rccm.201602-0300oc","title":"Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors","year":2016,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health; Institute of Cancer Research","funders":"National Research Program for Biopharmaceuticals; National Health Research Institutes; National Science Council","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Single-nucleotide polymorphism; Hazard ratio; Epidermal growth factor receptor; Adenocarcinoma; Progression-free survival; Cohort; Tyrosine kinase; Gefitinib; Cancer research; Cancer; Chemotherapy; Gene; Genotype; Receptor; Biology; Genetics; Confidence interval","score_opus":0.012921268423083762,"score_gpt":0.31002963790073634,"score_spread":0.29710836947765257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526843003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119,0.0060254205,0.00021046918,0.002112649,0.00010848753,0.00022278399,0.00002145314,0.00000795373,0.0001007953],"genre_scores_gemma":[0.9990231,0.000105184256,0.00028628233,0.0003348231,0.00020840528,0.000010277139,0.0000029682358,0.000022848884,0.000006141977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827844,0.00010341503,0.0005944112,0.0002087818,0.00057007617,0.00024485588],"domain_scores_gemma":[0.998174,0.00035288194,0.00025150098,0.00021549458,0.00065804605,0.00034804174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016242941,0.00019303945,0.000625226,0.00027232894,0.000058639213,0.0000049260675,0.00008919929,0.00004773729,0.000031582502],"category_scores_gemma":[0.0006667682,0.00009932935,0.00005960389,0.00035944287,0.00096491084,0.00013072099,0.000027926599,0.0001645694,1.5981351e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010533785,0.00018651616,0.9341341,0.0001747835,0.00008369956,0.00038028564,0.00054751686,0.0000026843275,0.00030420054,0.000042702133,0.00009473114,0.062995374],"study_design_scores_gemma":[0.01344981,0.021896666,0.9557817,0.0042510526,0.0008378954,0.000069115595,0.002183796,0.0000046344057,0.0009841325,0.000029149152,0.00034987353,0.00016218035],"about_ca_topic_score_codex":0.00008095899,"about_ca_topic_score_gemma":0.000028225077,"teacher_disagreement_score":0.0628332,"about_ca_system_score_codex":0.00017421831,"about_ca_system_score_gemma":0.00020862388,"threshold_uncertainty_score":0.40505335},"labels":[],"label_agreement":null},{"id":"W2530471001","doi":"10.1097/pai.0000000000000440","title":"Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology","year":2016,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Immunohistochemistry; KRAS; Adenocarcinoma; Pathology; Colorectal cancer; Lung cancer; Metastasis; Biology; Medicine; Cancer; Internal medicine","score_opus":0.004604516844985595,"score_gpt":0.2548708930398291,"score_spread":0.25026637619484354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530471001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97724664,0.0063366657,0.0048998767,0.0013330973,0.00010528145,0.0006459225,0.000038979004,0.0001444442,0.009249077],"genre_scores_gemma":[0.99461335,0.000116424926,0.0017652978,0.0008442854,0.00005347592,0.00058675656,0.00032226235,0.000107976564,0.0015901953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975224,0.000033977172,0.000488409,0.0010245473,0.00030724274,0.00062338944],"domain_scores_gemma":[0.9981689,0.000049135902,0.00026352305,0.0011192369,0.00014662331,0.00025257753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007079965,0.0005593574,0.00065644924,0.00010931919,0.00016954515,0.000023037046,0.00024837535,0.00035022086,0.0005135958],"category_scores_gemma":[0.000025915795,0.00042674394,0.00015528717,0.00021543444,0.0006836401,0.00005770138,0.00017061955,0.00030255486,0.00004986773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006507702,0.00027690158,0.0017722899,0.00010870985,0.0005788123,0.0021772939,0.00006969158,0.0000010369195,0.99167925,0.00038093876,0.00020636128,0.0020979696],"study_design_scores_gemma":[0.00579354,0.0003898657,0.012303211,0.00014297581,0.0010405314,0.01133999,0.00012443625,0.000004061576,0.9676309,0.00032448187,0.00024352146,0.0006624547],"about_ca_topic_score_codex":0.00003463093,"about_ca_topic_score_gemma":2.4424834e-8,"teacher_disagreement_score":0.024048295,"about_ca_system_score_codex":0.000469552,"about_ca_system_score_gemma":0.00022463979,"threshold_uncertainty_score":0.99981844},"labels":[],"label_agreement":null},{"id":"W2530924785","doi":"10.1016/b978-0-12-800886-7.00023-6","title":"Molecular Testing in Lung Cancer","year":2016,"lang":"en","type":"book-chapter","venue":"Diagnostic Molecular Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Anaplastic lymphoma kinase; Lung cancer; Medicine; Epidermal growth factor receptor; Personalized medicine; Molecular diagnostics; Tyrosine kinase; Cancer; Epitome; Companion diagnostic; Precision medicine; Pathology; Bioinformatics; Cancer research; Biology; Internal medicine; Receptor; Computer science","score_opus":0.01303027373549892,"score_gpt":0.3128051678135373,"score_spread":0.29977489407803837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530924785","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023976559,0.033938523,0.002888245,0.0026974028,0.00077181164,0.0024153478,0.00031126302,0.00015644933,0.9328444],"genre_scores_gemma":[0.7275445,0.0049232407,0.005739748,0.012209541,0.00091932254,0.0029482476,0.0008595892,0.001016744,0.24383909],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821883,0.00003754849,0.00041701508,0.00066317985,0.0002418408,0.00042157463],"domain_scores_gemma":[0.99848145,0.00049333693,0.00018371445,0.00051258027,0.0001664312,0.00016247192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000084166946,0.0004198279,0.00065848255,0.00030603673,0.000037173988,0.000010452902,0.00011201473,0.00043918216,0.00045261363],"category_scores_gemma":[0.0007956256,0.00035336285,0.00016918175,0.000066460845,0.00012966244,0.000024339615,0.00007926939,0.00035290868,0.00009986229],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015844994,0.0005987901,0.06461163,0.0015318053,0.0026123845,0.38321134,0.00069512666,0.00039234804,0.030263102,0.32451105,0.0030028406,0.18841113],"study_design_scores_gemma":[0.08181504,0.008740613,0.14518279,0.09151011,0.051049333,0.018133497,0.00012754083,0.001156837,0.0270658,0.22771102,0.3309921,0.016515316],"about_ca_topic_score_codex":0.000045356974,"about_ca_topic_score_gemma":0.000025347232,"teacher_disagreement_score":0.7035679,"about_ca_system_score_codex":0.00039917819,"about_ca_system_score_gemma":0.0004756007,"threshold_uncertainty_score":0.9998918},"labels":[],"label_agreement":null},{"id":"W2532258671","doi":"10.1200/jco.2016.34.15_suppl.e20527","title":"Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre Integre de Sante et de Services Sociaux de Laval; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Brain metastasis; Oncology; Neurocognitive; Lung cancer; Stage (stratigraphy); Systemic therapy; Performance status; Cancer; Breast cancer; Metastasis; Cognition","score_opus":0.0489489259364999,"score_gpt":0.47480463435842896,"score_spread":0.42585570842192905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532258671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239,0.002282757,0.00012729804,0.0024653361,0.00077319756,0.0004538715,0.000051776864,0.0000034812085,0.0014523168],"genre_scores_gemma":[0.9962136,0.0023820528,0.00034016278,0.00011186764,0.00038340414,0.000016130984,0.000001870574,0.000014623625,0.0005362808],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975646,0.00055809814,0.0013593908,0.00016064172,0.00020597351,0.00015125729],"domain_scores_gemma":[0.9920847,0.0058816816,0.0014328127,0.00015882084,0.00022061913,0.00022135413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010751596,0.00015106314,0.0016960265,0.00010981152,0.000023339393,0.0000026721318,0.00006589395,0.00016099717,0.000060054233],"category_scores_gemma":[0.0004957638,0.000070698035,0.00040517873,0.000063393534,0.00016517614,0.00003988105,0.000015696496,0.000120090466,0.0000021898882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011802705,0.0037224484,0.5065621,0.00066264725,0.00401971,0.00044704156,0.00046059338,0.00004975955,0.012797416,0.00008193067,0.0017837875,0.4576099],"study_design_scores_gemma":[0.17762476,0.3986034,0.32407224,0.0057017,0.021194443,0.0005049675,0.00038530145,0.0001481626,0.04478097,0.000045382407,0.026528342,0.00041032402],"about_ca_topic_score_codex":0.00013045885,"about_ca_topic_score_gemma":0.000055788965,"teacher_disagreement_score":0.45719954,"about_ca_system_score_codex":0.00031724284,"about_ca_system_score_gemma":0.0013105273,"threshold_uncertainty_score":0.28829822},"labels":[],"label_agreement":null},{"id":"W2536396512","doi":"10.1016/s1470-2045(16)30508-3","title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; AstraZeneca","keywords":"Osimertinib; Lung cancer; Medicine; Open label; Cancer; Oncology; Internal medicine; Adenocarcinoma; Clinical trial","score_opus":0.06472232217388303,"score_gpt":0.4461270129553907,"score_spread":0.3814046907815077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536396512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96515226,0.0013761533,0.0011288644,0.0089955395,0.00065656455,0.01068486,0.00046547787,0.00011416468,0.011426136],"genre_scores_gemma":[0.9860511,0.00024408822,0.0026331726,0.0025221768,0.0004469859,0.0033260793,0.000063111,0.000064668704,0.004648625],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810594,0.00018712594,0.0003962126,0.00053746667,0.00014954469,0.00062368193],"domain_scores_gemma":[0.9979934,0.0006895262,0.0002975699,0.00055756944,0.00029924727,0.0001626951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028999447,0.00030042842,0.0008288603,0.00006545162,0.00026206867,0.00003291011,0.00038040295,0.00011315439,0.00022090919],"category_scores_gemma":[0.000104654995,0.00015909206,0.00006806381,0.00022388605,0.00011406251,0.00014927128,0.0001416532,0.00015175412,0.000026811816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049166318,0.08704337,0.05548121,0.00043431288,0.007315743,0.0004341015,0.025355719,0.000054386805,0.18039238,0.00034903156,0.024906602,0.5690668],"study_design_scores_gemma":[0.7143987,0.06837609,0.01912476,0.0012998723,0.013269087,0.00007615656,0.0053220964,0.0023349102,0.06395339,0.00021068526,0.1103705,0.0012637479],"about_ca_topic_score_codex":0.00037573287,"about_ca_topic_score_gemma":0.00043423683,"teacher_disagreement_score":0.66523236,"about_ca_system_score_codex":0.00090732233,"about_ca_system_score_gemma":0.0005248894,"threshold_uncertainty_score":0.6487586},"labels":[],"label_agreement":null},{"id":"W2538621833","doi":"10.1200/jco.2007.25.18_suppl.17041","title":"20-year epidemiology and treatment experience with lung cancer in Manitoba, Canada","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Radiation therapy; Epidemiology; Chemotherapy; Cancer registry; Cancer; Proportional hazards model; Surveillance, Epidemiology, and End Results; Oncology; Surgery","score_opus":0.11716392257767029,"score_gpt":0.5240651159084065,"score_spread":0.40690119333073627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538621833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98766524,0.0018708176,0.00008145532,0.0072797188,0.000528543,0.00017039903,0.000004064033,0.0000020791758,0.0023976865],"genre_scores_gemma":[0.9935629,0.0013888685,0.0022084424,0.0021027927,0.00044521454,0.000008871301,0.0000010999678,0.0000069940015,0.00027482017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983293,0.000113639886,0.0010989682,0.00013323722,0.00010924272,0.00021560992],"domain_scores_gemma":[0.99736494,0.0015672958,0.00055982766,0.00008204912,0.0001229858,0.00030289864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009378006,0.00008882431,0.0008576406,0.000059967933,0.000025292902,0.0000014028112,0.000039434824,0.00011834076,0.00006567146],"category_scores_gemma":[0.00047249708,0.000050576913,0.000062592706,0.00007569538,0.00012252778,0.00004238087,0.0000090000985,0.00024915626,3.5788472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014712261,0.0003065153,0.9053778,0.0000057069105,0.00023241455,0.001207766,0.00022264764,0.000030463634,0.0000059801177,0.000053735745,0.0006624655,0.09042329],"study_design_scores_gemma":[0.007013219,0.0047112224,0.94759893,0.00007018491,0.0002830035,0.00027968877,0.0008857874,0.000034203647,0.000014512922,0.000026626574,0.039031908,0.000050708284],"about_ca_topic_score_codex":0.14845768,"about_ca_topic_score_gemma":0.8497873,"teacher_disagreement_score":0.70132965,"about_ca_system_score_codex":0.0010805867,"about_ca_system_score_gemma":0.0037570884,"threshold_uncertainty_score":0.85721284},"labels":[],"label_agreement":null},{"id":"W2544190873","doi":"10.1016/j.jval.2016.08.471","title":"Mapping of Existing Data Sources for the Conduct of Real-World Studies on Lung Cancer in China","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cornerstone; MEDLINE; Medicine; China; Inclusion (mineral); Lung cancer; Family medicine; Clinical trial; Data science; Computer science; Internal medicine; Psychology; Geography; Political science","score_opus":0.29867573564660616,"score_gpt":0.5047160025495164,"score_spread":0.20604026690291027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544190873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752295,0.010058202,0.00006341149,0.01254044,0.000260391,0.0011264312,0.00025052336,0.000009031312,0.00046207756],"genre_scores_gemma":[0.9962223,0.002703099,0.0004455724,0.00010966615,0.00007350791,0.00006890548,0.0000073137653,0.0000087195585,0.00036090336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992089,0.00004920707,0.00035953597,0.00014910263,0.00009760988,0.00013563749],"domain_scores_gemma":[0.99876875,0.000698381,0.00020574007,0.00026858863,0.00003560347,0.000022969287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005902462,0.000060560094,0.00025919284,0.00011386944,0.000043447217,0.0000012260722,0.00007860569,0.000012229084,0.000005923617],"category_scores_gemma":[0.00023502772,0.000030361043,0.000018245537,0.00018222757,0.000050747833,0.0000332462,0.00003104157,0.000044176944,1.189404e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036254257,0.0003883758,0.86431515,0.0058915447,0.00069433154,0.0000053461813,0.04419783,0.0051461984,0.001021616,0.008674316,0.0020086726,0.067294054],"study_design_scores_gemma":[0.009945757,0.00083511847,0.931128,0.027040733,0.00022585255,0.0000029483517,0.011023725,0.011088631,0.002095558,0.0013788539,0.0050094198,0.0002254045],"about_ca_topic_score_codex":0.022838388,"about_ca_topic_score_gemma":0.0031750482,"teacher_disagreement_score":0.06706865,"about_ca_system_score_codex":0.00026384447,"about_ca_system_score_gemma":0.00034419406,"threshold_uncertainty_score":0.9836686},"labels":[],"label_agreement":null},{"id":"W2544627141","doi":"10.1016/j.lungcan.2016.10.011","title":"Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Boehringer Ingelheim (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Nintedanib; Internal medicine; Lung cancer; Hazard ratio; Placebo; Clinical endpoint; Oncology; Bevacizumab; Gastroenterology; Chemotherapy; Surgery; Randomized controlled trial; Confidence interval; Lung; Idiopathic pulmonary fibrosis; Pathology","score_opus":0.02024304551739279,"score_gpt":0.34881623179503624,"score_spread":0.3285731862776434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544627141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683908,0.0045611425,0.001155256,0.0006685322,0.0038338283,0.017350316,0.0003219633,0.00020810119,0.003510011],"genre_scores_gemma":[0.96745664,0.0013466033,0.00067294284,0.0002536439,0.00070325227,0.009671536,0.0002835212,0.00022988356,0.019381968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99514693,0.0002023445,0.0012283842,0.0012932541,0.0009987602,0.0011303277],"domain_scores_gemma":[0.99639565,0.0007477094,0.00083947816,0.0008968005,0.00058322493,0.00053713296],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043506426,0.0008850746,0.0020497579,0.00063663354,0.00023786406,0.00006972992,0.00033645358,0.00033695923,0.0019561488],"category_scores_gemma":[0.00018621141,0.0005321265,0.0003985378,0.0010814356,0.00021347616,0.0005106374,0.00009992493,0.00054235704,0.000017219118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9787383,0.0012673303,0.005004304,0.000347928,0.0021613047,0.00010342097,0.0020361084,0.0003321663,0.00021465051,0.000014268265,0.0035923566,0.006187828],"study_design_scores_gemma":[0.9845324,0.0022914584,0.0005540967,0.0019507712,0.0049039153,0.000001971387,0.00026829855,0.0021731737,0.0007990851,0.0000015529333,0.001730748,0.00079249835],"about_ca_topic_score_codex":0.004556204,"about_ca_topic_score_gemma":0.0058196187,"teacher_disagreement_score":0.015871957,"about_ca_system_score_codex":0.006582998,"about_ca_system_score_gemma":0.0035166962,"threshold_uncertainty_score":0.999713},"labels":[],"label_agreement":null},{"id":"W2549137967","doi":"10.1002/ijc.30533","title":"Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non‐small cell lung cancer","year":2016,"lang":"en","type":"review","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Clinical trial; Tyrosine-kinase inhibitor; Oncology; Internal medicine; Anaplastic lymphoma kinase; Drug development; Tyrosine kinase; Targeted therapy; ALK inhibitor; Cancer; Drug; Pharmacology; Receptor","score_opus":0.03647996718676179,"score_gpt":0.4127008107511185,"score_spread":0.3762208435643567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549137967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002939357,0.989725,0.005075114,0.0004720508,0.002459542,0.0011064165,0.00061973993,0.0000070100336,0.00024121549],"genre_scores_gemma":[0.00035439522,0.9797815,0.014756375,0.00015696659,0.0022981744,0.0005922084,0.00010564834,0.000070351794,0.0018843476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974313,0.000028124441,0.0014563281,0.00023193323,0.00065478496,0.00019757255],"domain_scores_gemma":[0.9954612,0.00018537314,0.0018123403,0.00012516488,0.0022618633,0.00015404857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002271603,0.0003215069,0.0011059652,0.00041568466,0.000051577907,0.000030862935,0.00030026567,0.00015152253,0.00041780557],"category_scores_gemma":[0.000063969936,0.00020859258,0.00060712063,0.0001152233,0.000040143215,0.00012086169,0.00004012431,0.00016800399,0.0000039550278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000407488,0.00035602355,0.00012491523,0.0052145123,0.0049771536,0.000034878474,0.00035973595,0.000013518406,0.00047809424,0.00009743692,0.005568072,0.9823682],"study_design_scores_gemma":[0.004204067,0.00014648486,0.00008621783,0.044043984,0.0036229675,0.00004338408,0.000015823927,0.000007570947,0.0019615353,0.000012178922,0.9456345,0.00022132386],"about_ca_topic_score_codex":0.000017642453,"about_ca_topic_score_gemma":0.000047558467,"teacher_disagreement_score":0.98214686,"about_ca_system_score_codex":0.0015293554,"about_ca_system_score_gemma":0.008738735,"threshold_uncertainty_score":0.99688077},"labels":[],"label_agreement":null},{"id":"W2550461848","doi":"10.1183/13993003.congress-2016.oa3342","title":"Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with<i>EGFR</i>mutation-positive (<i>EGFR</i>m+) NSCLC: LUX-Lung 7","year":2016,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Afatinib; Discontinuation; Gefitinib; Rash; Lung cancer; Clinical endpoint; Gastroenterology; Adverse effect; Oncology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.010426986937050839,"score_gpt":0.30572591582662006,"score_spread":0.2952989288895692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550461848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8822567,0.00039281085,0.016853847,0.021400856,0.0007652753,0.010694432,0.0017543905,0.000584411,0.065297276],"genre_scores_gemma":[0.9638221,0.00015726454,0.0048468867,0.0016681888,0.00031252974,0.0016298342,0.0009561305,0.000106350635,0.02650068],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976889,0.00003498505,0.00051732955,0.0007190441,0.00045157224,0.00058818783],"domain_scores_gemma":[0.9977213,0.00054842624,0.00023451252,0.0004714397,0.00065819244,0.00036614292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007590999,0.0004914726,0.0005499335,0.00016008005,0.00035206391,0.00005003055,0.00010221161,0.00012719558,0.00078307913],"category_scores_gemma":[0.00011463555,0.0002676642,0.00023843038,0.00022748394,0.00011647583,0.00030830633,0.000027021764,0.00006564718,0.00022800305],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02393725,0.022793965,0.31453624,0.0007650302,0.012094839,0.0005695526,0.011169744,0.00016140286,0.0016068186,0.018156605,0.044985875,0.54922265],"study_design_scores_gemma":[0.33309656,0.1113353,0.23362896,0.0049620057,0.015116471,0.0004473943,0.0022045914,0.00103427,0.06009165,0.0029567927,0.23088188,0.0042441203],"about_ca_topic_score_codex":0.0003968612,"about_ca_topic_score_gemma":0.0003131703,"teacher_disagreement_score":0.54497856,"about_ca_system_score_codex":0.0010668288,"about_ca_system_score_gemma":0.00041082187,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W2551446562","doi":"10.1016/j.jtho.2016.08.067","title":"P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Tolerability; Internal medicine; Lung cancer; Adverse effect; Post-hoc analysis; Incidence (geometry); Oncology; Pharmacokinetics; Erlotinib; Cancer; Epidermal growth factor receptor","score_opus":0.026308255957970872,"score_gpt":0.49145907067676575,"score_spread":0.4651508147187949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551446562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946989,0.001410648,0.00015239947,0.0018823876,0.00014744618,0.00033052635,0.00007228588,0.0000034020316,0.0013020204],"genre_scores_gemma":[0.9979613,0.00049646903,0.0011808845,0.000105636886,0.00009587401,0.000003577658,0.000010091145,0.000011880468,0.00013432],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854875,0.00018993343,0.00074528746,0.00013308293,0.00022371268,0.00015923628],"domain_scores_gemma":[0.99780685,0.00067850674,0.0008415704,0.00013134746,0.0004027405,0.00013896415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033163797,0.0001388972,0.000672259,0.0004078249,0.000026075515,0.0000029771227,0.00006082742,0.00010092134,0.00014034816],"category_scores_gemma":[0.00022803368,0.00007680614,0.00020685514,0.00019999893,0.000108581364,0.000116789095,0.000019131321,0.00014187468,0.0000019721497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043941304,0.004452445,0.017191384,0.00015351309,0.0033487373,0.00063815666,0.0051487326,0.0007391122,0.06118518,0.000138377,0.00039231122,0.8626707],"study_design_scores_gemma":[0.00958803,0.022421304,0.9558233,0.0011073677,0.0016400298,0.00044121605,0.00071586366,0.000052492764,0.007937462,0.000065479355,0.00010443373,0.00010304724],"about_ca_topic_score_codex":0.00011007497,"about_ca_topic_score_gemma":0.000027865366,"teacher_disagreement_score":0.9386319,"about_ca_system_score_codex":0.00089207856,"about_ca_system_score_gemma":0.00077075016,"threshold_uncertainty_score":0.31320634},"labels":[],"label_agreement":null},{"id":"W2552295594","doi":"10.5530/ijmedph.2016.4.11","title":"Lung Cancer in India: A Scientometric Study of Publications during 2005–14","year":2016,"lang":"en","type":"article","venue":"International Journal of Medicine and Public Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Scopus; China; Demography; Traditional medicine; Library science; Internal medicine; Geography; MEDLINE; Political science","score_opus":0.046951733982646876,"score_gpt":0.4539470321677788,"score_spread":0.4069952981851319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552295594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8453296,0.0026499901,0.00013307927,0.15070131,0.00042990816,0.00024438553,0.0000150134365,0.000004864021,0.00049183803],"genre_scores_gemma":[0.99624515,0.0023933153,0.000055835833,0.0006000148,0.00033517418,0.000014354958,0.000002518158,0.0000064162923,0.0003472239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830234,0.000057100166,0.0006468038,0.00011659685,0.0006926032,0.00018456376],"domain_scores_gemma":[0.9982699,0.00012020853,0.0004669523,0.00009038626,0.0007536966,0.00029884258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086914806,0.000073576906,0.00028565532,0.0025589336,0.000037791444,0.000012483094,0.0001305816,0.000025899502,0.0002629598],"category_scores_gemma":[0.00053743063,0.00004133159,0.000029048868,0.00082849927,0.00007349136,0.00026197592,0.000026462367,0.00011562773,3.5182862e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073453506,0.0009965423,0.91743386,0.000049361337,0.00041529225,0.00003321147,0.0040790034,0.0000015330018,0.00017181973,0.000400713,0.0034040087,0.07294123],"study_design_scores_gemma":[0.011594558,0.00067154394,0.978875,0.0005948064,0.000048614504,0.00016709937,0.0025991949,0.000011510734,0.000009229051,0.00003272379,0.0053560934,0.00003964142],"about_ca_topic_score_codex":0.00051492994,"about_ca_topic_score_gemma":0.00017051242,"teacher_disagreement_score":0.15091555,"about_ca_system_score_codex":0.00054198375,"about_ca_system_score_gemma":0.0011739151,"threshold_uncertainty_score":0.28792253},"labels":[],"label_agreement":null},{"id":"W2556521065","doi":"10.1016/j.jtho.2016.11.2218","title":"A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Pemetrexed; Medicine; KRAS; Docetaxel; Internal medicine; Oncology; Lung cancer; Tolerability; Rash; MEK inhibitor; Chemotherapy; Cancer; Adverse effect; Colorectal cancer; MAPK/ERK pathway; Cisplatin; Biology","score_opus":0.034283906387632686,"score_gpt":0.49569798246561175,"score_spread":0.4614140760779791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556521065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962198,0.000470425,0.0003134494,0.00073317834,0.00037721207,0.0013829191,0.000017747758,0.000009126132,0.00047615706],"genre_scores_gemma":[0.99141294,0.00006818547,0.0070965,0.00017784475,0.00014265622,0.00009792258,0.0000028342763,0.000029321141,0.0009717892],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981958,0.0001923521,0.0006844558,0.00023316823,0.000393275,0.00030092348],"domain_scores_gemma":[0.9980473,0.00026244408,0.0007766707,0.00018550639,0.0005406047,0.00018745594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000552664,0.00019291576,0.0007140245,0.00031579915,0.000055751985,0.000009654863,0.000118662014,0.00008021169,0.0002421599],"category_scores_gemma":[0.00019233856,0.00009500319,0.00008669524,0.0003357819,0.000041277664,0.00016926891,0.000025358006,0.00024942032,0.0000033661083],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029237827,0.018407568,0.21380389,0.00011903951,0.00062028,0.0005839381,0.0044226474,0.000120942204,0.0013166249,3.8061415e-7,0.00021301222,0.73115385],"study_design_scores_gemma":[0.34467804,0.16647306,0.46845448,0.0022637865,0.007533922,0.00016146616,0.006295744,0.00046331732,0.001593128,0.000017538598,0.0015387435,0.0005267926],"about_ca_topic_score_codex":0.000041211897,"about_ca_topic_score_gemma":0.00023207665,"teacher_disagreement_score":0.73062706,"about_ca_system_score_codex":0.0014597487,"about_ca_system_score_gemma":0.0020048155,"threshold_uncertainty_score":0.38741177},"labels":[],"label_agreement":null},{"id":"W2556818341","doi":"10.1016/j.jtho.2016.08.069","title":"P1.47: ABOUND.sqm QoL by Response: Interim Analysis of Squamous NSCLC Pts Treated With nab-Paclitaxel/Carboplatin Induction Therapy","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Clinical endpoint; Interim analysis; Induction chemotherapy; non-small cell lung cancer (NSCLC); Oncology; Paclitaxel; Lung cancer; Quality of life (healthcare); Maintenance therapy; Response Evaluation Criteria in Solid Tumors; Interim; Randomized controlled trial; Progressive disease; Chemotherapy","score_opus":0.024417823025486642,"score_gpt":0.4399750097691598,"score_spread":0.4155571867436732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556818341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924047,0.00096383196,0.0005717321,0.0048731402,0.00020057378,0.0002435324,0.00004403992,0.000015865635,0.0006825593],"genre_scores_gemma":[0.99649954,0.00018595929,0.00089210976,0.00020615247,0.00012458902,0.0000138680225,0.000013789704,0.000023082375,0.0020408838],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99824214,0.0003786743,0.0006696227,0.00019129612,0.00030906603,0.00020920149],"domain_scores_gemma":[0.9977821,0.00038421026,0.00094822113,0.00024900114,0.00047503444,0.00016143199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005645602,0.00018083538,0.00082765805,0.00069824565,0.00005330214,0.000011579139,0.00010403543,0.00017732612,0.0003210472],"category_scores_gemma":[0.00015461001,0.0000956244,0.00024183972,0.0007300412,0.00016464393,0.0001717066,0.000012595102,0.00019521904,0.0000041927824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05991302,0.0019447423,0.03164313,0.00002918412,0.009816018,0.00037473708,0.0022467065,0.000029130699,0.36222196,0.000014019995,0.0033264237,0.52844095],"study_design_scores_gemma":[0.025263356,0.07608886,0.62947124,0.0010023727,0.028318465,0.002343496,0.0039734375,0.000071056034,0.14786011,0.00018807694,0.08471372,0.0007058022],"about_ca_topic_score_codex":0.00009028447,"about_ca_topic_score_gemma":0.000045686793,"teacher_disagreement_score":0.5978281,"about_ca_system_score_codex":0.0007960511,"about_ca_system_score_gemma":0.00063881744,"threshold_uncertainty_score":0.38994497},"labels":[],"label_agreement":null},{"id":"W2559063525","doi":"10.1371/journal.pone.0167460","title":"Human Lung Tissue Transcriptome: Influence of Sex and Age","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; St. Paul's Hospital; University of British Columbia; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Associazione Italiana per la Ricerca sul Cancro","keywords":"Transcriptome; Lung; Gene; Biology; Gene expression; Adenocarcinoma; Lung cancer; Adenocarcinoma of the lung; Genetics; Pathology; Internal medicine; Medicine; Cancer","score_opus":0.024994185255447336,"score_gpt":0.30893878528104673,"score_spread":0.2839446000255994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559063525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680203,0.00028017064,0.00001560875,0.00059027126,0.0000043319424,0.00021053177,0.000016504284,0.00002121893,0.0020593395],"genre_scores_gemma":[0.9934596,0.000056643545,0.0003483131,0.00008353868,0.000023551522,0.00001914676,0.0000037619955,0.0000076804845,0.0059977686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996339,0.0000061132287,0.00009190081,0.00009209516,0.00010226626,0.00007373217],"domain_scores_gemma":[0.9997675,0.000012766834,0.000022127098,0.000110203415,0.00003490603,0.000052523294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000021562097,0.000048163238,0.00014028997,0.000030935727,0.000025454874,0.0000026477594,0.000019821517,0.000022398242,0.00008566006],"category_scores_gemma":[0.00001063801,0.000030785715,0.000010933164,0.00003871488,0.000052170977,0.000048551432,0.0000050938816,0.000021894144,0.0000054489724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009308024,0.00041968474,0.031771388,0.00017764531,0.00025633178,0.000016189128,0.0008954923,1.5274557e-7,0.9647204,0.0002096938,0.00006355317,0.0014601625],"study_design_scores_gemma":[0.004503886,0.0007072755,0.48739165,0.0014001539,0.001400527,0.0000067423603,0.00007405333,0.000004896108,0.50335526,0.00037850096,0.0006386613,0.00013842128],"about_ca_topic_score_codex":0.00004467946,"about_ca_topic_score_gemma":0.000007671477,"teacher_disagreement_score":0.46136516,"about_ca_system_score_codex":0.000025108617,"about_ca_system_score_gemma":0.000017302931,"threshold_uncertainty_score":0.12554051},"labels":[],"label_agreement":null},{"id":"W2559883227","doi":"10.1155/2016/3562820","title":"Severe Erosive Pill Esophagitis Induced by Crizotinib Therapy: A Case Report and Literature Review","year":2016,"lang":"en","type":"article","venue":"Case Reports in Gastrointestinal Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Crizotinib; Medicine; Esophagitis; Pill; Adverse effect; Tolerability; Anaplastic lymphoma kinase; Internal medicine; Lung cancer; Oncology; Dermatology; Pharmacology; Disease","score_opus":0.01922035012967255,"score_gpt":0.32865329578236563,"score_spread":0.3094329456526931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559883227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90880364,0.07310582,0.00016026011,0.013960108,0.00024670537,0.0019162616,0.000056217385,0.00011404887,0.0016369678],"genre_scores_gemma":[0.989204,0.005421427,0.0013212648,0.0018420304,0.00030058855,0.00018949786,0.0001166776,0.000052713727,0.0015518051],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9975589,0.00007035688,0.0009792462,0.00069735275,0.00032155632,0.00037258927],"domain_scores_gemma":[0.9978293,0.00021785272,0.00048635184,0.00061663706,0.0004249632,0.00042488688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005085446,0.00035928393,0.0007051993,0.00015851064,0.000095407595,0.00001455553,0.000026253745,0.00006732296,0.00020718854],"category_scores_gemma":[0.0021869394,0.00020323189,0.0000740602,0.0003771553,0.00020282606,0.00015613007,0.00003633129,0.00029658267,0.0000020342663],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006586095,0.00012666028,0.017447015,0.0004809712,0.000049946142,0.9568881,0.00023513474,2.7362404e-8,0.002750217,0.000008320083,0.008003221,0.013944545],"study_design_scores_gemma":[0.0027844459,0.0015233972,0.0016990905,0.045317996,0.00024279152,0.94644326,0.00019334164,0.0000011316695,0.00013540605,0.00006852437,0.0014163946,0.00017420901],"about_ca_topic_score_codex":0.00032178545,"about_ca_topic_score_gemma":0.000038433525,"teacher_disagreement_score":0.08040038,"about_ca_system_score_codex":0.00020592519,"about_ca_system_score_gemma":0.0002203208,"threshold_uncertainty_score":0.82875556},"labels":[],"label_agreement":null},{"id":"W2560331278","doi":"10.1158/1078-0432.ccr-16-1968","title":"Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients","year":2016,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Nintedanib; Vandetanib; Ramucirumab; Sunitinib; Bevacizumab; Erlotinib; Lung cancer; Oncology; Aflibercept; Sorafenib; Internal medicine; Vascular endothelial growth factor; Population; Cancer; Cancer research; Epidermal growth factor receptor; Hepatocellular carcinoma; Idiopathic pulmonary fibrosis; Lung; Chemotherapy; VEGF receptors","score_opus":0.42812998280999054,"score_gpt":0.5598813256620567,"score_spread":0.1317513428520662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560331278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020108176,0.96769327,0.00001559435,0.00027724195,0.00077061343,0.008734515,0.0022104967,0.000018702172,0.00017138732],"genre_scores_gemma":[0.0022510707,0.9767144,0.000020369496,0.000033021628,0.00078634184,0.014841669,0.00017676137,0.00012550502,0.005050905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963324,0.00038825517,0.0010246132,0.00071270874,0.00079296774,0.0007490545],"domain_scores_gemma":[0.99164367,0.005559261,0.0006768696,0.00088892673,0.0009883677,0.00024292046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010888265,0.00042776964,0.0016093623,0.00015554033,0.00049707235,0.000039133218,0.00046402126,0.00021718012,0.00015637033],"category_scores_gemma":[0.00029470408,0.00016163402,0.0011739214,0.00064485177,0.00036725122,0.000056633515,0.00008778115,0.00049790053,0.000014111282],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025859015,0.0012640075,0.018070059,0.0019966878,0.0057966304,0.000005517118,0.00031734654,0.0000041442254,8.033345e-8,0.0000037387856,0.001551317,0.97073185],"study_design_scores_gemma":[0.0068957363,0.0033569532,0.01882003,0.017148562,0.014465984,5.15743e-7,0.00006124981,0.000038731505,0.000010460565,0.0000071865975,0.93892795,0.00026661344],"about_ca_topic_score_codex":0.0015731003,"about_ca_topic_score_gemma":0.00091350765,"teacher_disagreement_score":0.97046524,"about_ca_system_score_codex":0.0016502612,"about_ca_system_score_gemma":0.002321612,"threshold_uncertainty_score":0.6591244},"labels":[],"label_agreement":null},{"id":"W2560717039","doi":"10.1056/nejmoa1612674","title":"Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3329,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Osimertinib; T790M; Pemetrexed; Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Cancer research; Chemotherapy; Cancer; Receptor; Erlotinib; Gefitinib; Cisplatin","score_opus":0.018132957900684584,"score_gpt":0.35575247863132764,"score_spread":0.33761952073064305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560717039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8968509,0.012573903,0.0018710376,0.0798701,0.0015974182,0.0006332621,0.000034395725,0.000028416755,0.0065405904],"genre_scores_gemma":[0.9883536,0.0018837398,0.00047043755,0.0013875217,0.0031953962,0.0000074912064,0.0000051712354,0.000023343666,0.004673317],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998571,0.0000569812,0.00057879195,0.0001448008,0.0004164285,0.00023203298],"domain_scores_gemma":[0.9986253,0.0004138005,0.00030504772,0.00012789197,0.00021019546,0.00031778528],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034586946,0.00016256161,0.0005271108,0.00026954553,0.00003208683,0.000004120427,0.000079804784,0.000058273094,0.001373556],"category_scores_gemma":[0.0004015765,0.00007047223,0.00006545382,0.00029031152,0.00007155308,0.00013127754,0.000012222947,0.0001957193,0.0000042898873],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052717216,0.00028664985,0.25779346,0.000069864276,0.0008130163,0.0016252277,0.0042516342,0.00001495733,0.014555589,0.00009059196,0.04160612,0.6736212],"study_design_scores_gemma":[0.49289635,0.006750896,0.3969957,0.014326555,0.0028984698,0.0027005884,0.0006952258,0.00007177802,0.008737289,0.00044853715,0.073063925,0.0004146806],"about_ca_topic_score_codex":0.0005510485,"about_ca_topic_score_gemma":0.00033524062,"teacher_disagreement_score":0.6732065,"about_ca_system_score_codex":0.00031434983,"about_ca_system_score_gemma":0.0006058455,"threshold_uncertainty_score":0.9995393},"labels":[],"label_agreement":null},{"id":"W2562488255","doi":"10.3747/co.23.3273","title":"Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Lakeridge Health; Novartis (Canada); University of British Columbia; Princess Margaret Cancer Centre; Ottawa Hospital; Jewish General Hospital; University of Ottawa; Vancouver Coastal Health","funders":"Novartis Pharmaceuticals Canada","keywords":"Crizotinib; Ceritinib; Medicine; Anaplastic lymphoma kinase; Internal medicine; Lung cancer; Oncology; ALK inhibitor; Retrospective cohort study; Discontinuation; Medical record","score_opus":0.020709577490459822,"score_gpt":0.3579219315229582,"score_spread":0.3372123540324984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562488255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494106,0.0002351173,0.00002115453,0.00060115126,0.00040433506,0.0019635141,0.00029501817,0.000011205014,0.001527458],"genre_scores_gemma":[0.99895,0.00019463325,0.000015200962,0.000031485895,0.000071409944,0.0004526137,0.000047933416,0.000017934912,0.00021875495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990152,0.000056695764,0.00015604937,0.00035951345,0.00010656561,0.00030596208],"domain_scores_gemma":[0.99937975,0.000036231755,0.00006811137,0.0001451102,0.00012870214,0.00024208636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000036616166,0.0001785552,0.00034803044,0.00015136503,0.00006818085,0.0000072879675,0.000035020043,0.000050530554,0.000054412507],"category_scores_gemma":[0.000005972938,0.00010323851,0.000025408699,0.000105134066,0.000040717397,0.000044884197,0.00001696091,0.000078939855,0.000003704697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021163917,0.0020756242,0.9577403,0.000014741767,0.00022067646,0.000070633534,0.0038435427,3.5729124e-7,0.0000024543149,0.0000073259166,0.00004295965,0.035769735],"study_design_scores_gemma":[0.01976684,0.005466528,0.9725718,0.0001295716,0.00048519656,0.000002020532,0.0005637053,0.000007694749,0.000014611203,0.0000024933752,0.00087041885,0.0001191423],"about_ca_topic_score_codex":0.080514066,"about_ca_topic_score_gemma":0.4686327,"teacher_disagreement_score":0.38811862,"about_ca_system_score_codex":0.004319678,"about_ca_system_score_gemma":0.000887486,"threshold_uncertainty_score":0.99950254},"labels":[],"label_agreement":null},{"id":"W2562879586","doi":"10.3233/cbm-161680","title":"ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes","year":2016,"lang":"en","type":"article","venue":"Cancer Biomarkers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Locus (genetics); Gene duplication; Biology; Copy-number variation; Gene dosage; Gene; Molecular biology; Fluorescence in situ hybridization; Genetics; Gene expression; Chromosome; Genome","score_opus":0.030344621135806406,"score_gpt":0.3643718565068905,"score_spread":0.33402723537108414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562879586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93148685,0.022685818,0.00028111547,0.010487078,0.0031541025,0.0017384285,0.0003074352,0.00020327239,0.029655907],"genre_scores_gemma":[0.97931665,0.011430056,0.00057994464,0.00021363179,0.00048673287,0.0008449599,0.00012054857,0.00007149343,0.0069360025],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815285,0.000029696717,0.00037879957,0.00062717614,0.0003248905,0.00048659288],"domain_scores_gemma":[0.99887073,0.00009195086,0.00014649334,0.0005001821,0.00015066651,0.00024000539],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000106063766,0.00028135465,0.00033163,0.00019503191,0.00011758979,0.000043551194,0.0001457957,0.00012941807,0.0033089104],"category_scores_gemma":[0.000011546457,0.00020874508,0.00011974078,0.000630658,0.00015150654,0.00021228277,0.000028896702,0.000086493106,0.00023080599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01140096,0.0005203879,0.63255405,0.00020053041,0.0020769397,0.00012448205,0.0009789314,0.000019816924,0.12669629,0.0015167083,0.12693883,0.09697205],"study_design_scores_gemma":[0.058570743,0.00040526592,0.2406678,0.0015653579,0.0010599822,0.000043280023,0.00083673093,0.000061570805,0.17692353,0.00020765634,0.51846135,0.0011967192],"about_ca_topic_score_codex":0.0035030704,"about_ca_topic_score_gemma":0.00066444784,"teacher_disagreement_score":0.39188626,"about_ca_system_score_codex":0.0020987655,"about_ca_system_score_gemma":0.00061636284,"threshold_uncertainty_score":0.9976022},"labels":[],"label_agreement":null},{"id":"W2563380092","doi":"10.1183/13993003.congress-2015.oa265","title":"Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial","year":2015,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Rash; Clinical endpoint; Discontinuation; Lung cancer; Erlotinib; Incidence (geometry); Randomized controlled trial; Cancer","score_opus":0.019978679444304422,"score_gpt":0.3264943260710871,"score_spread":0.30651564662678266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563380092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97463644,0.0004201756,0.00004766681,0.00018674166,0.00035544048,0.0038870783,0.00018223764,0.000035579535,0.020248618],"genre_scores_gemma":[0.98715055,0.000008963041,0.00058696326,0.00011897262,0.000104951716,0.00023691652,0.00021627476,0.000041627525,0.011534771],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982066,0.00006165743,0.0005974172,0.00035259462,0.000495615,0.00028607494],"domain_scores_gemma":[0.9981881,0.00009370001,0.000426096,0.00059759343,0.0004340739,0.0002604717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007458353,0.0003206652,0.0006829724,0.00009525859,0.00006955747,0.000008346828,0.00011242012,0.00008109641,0.00045553394],"category_scores_gemma":[0.00004398954,0.000162888,0.00020654382,0.00026706926,0.00010702067,0.000100492965,0.000030655185,0.00007643579,0.000006361443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60252976,0.09183608,0.20970191,0.0012032402,0.002639308,0.00017449827,0.04348178,0.0006433831,0.003756955,0.0007554532,0.014635389,0.028642219],"study_design_scores_gemma":[0.84424156,0.056291237,0.0072407196,0.000091108515,0.002892311,0.000011287767,0.0017447799,0.000494119,0.0808754,0.00002002863,0.005763262,0.0003341719],"about_ca_topic_score_codex":0.0005255625,"about_ca_topic_score_gemma":0.0001557885,"teacher_disagreement_score":0.2417118,"about_ca_system_score_codex":0.00038194115,"about_ca_system_score_gemma":0.00087948405,"threshold_uncertainty_score":0.66423804},"labels":[],"label_agreement":null},{"id":"W2564762951","doi":"10.1158/1538-7445.am2015-763","title":"Abstract 763: Implications of resistance patterns with NSCLC targeted agents","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Population; Tumor progression; T790M; Cancer research; Cancer; Mutation; Discontinuation; Oncology; Internal medicine; ROS1; Biology; Adenocarcinoma; Gene; Genetics","score_opus":0.1377646992956434,"score_gpt":0.48178957406990697,"score_spread":0.3440248747742636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564762951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96875566,0.0014923374,0.00009796708,0.004982696,0.000055857137,0.0007164097,0.00022799247,0.000030418923,0.02364066],"genre_scores_gemma":[0.9940295,0.000152553,0.0002611355,0.00008883656,0.00008632058,0.00036398062,0.00007465077,0.000022671724,0.0049203015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987906,0.00002963823,0.00016017244,0.000226227,0.0005116183,0.00028174042],"domain_scores_gemma":[0.99842364,0.000046227724,0.000052593503,0.00039106893,0.00083469664,0.0002517849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021076977,0.00008170045,0.00015863053,0.00012976471,0.00008102316,0.000014451446,0.00011092549,0.00003981353,0.0003149228],"category_scores_gemma":[0.00005009089,0.00005960871,0.000031913798,0.00041502234,0.00011662367,0.00007162181,0.000025544234,0.00017427938,0.00002609801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002554115,0.0014035545,0.7526609,0.0009526581,0.0012878329,0.00015361233,0.006633669,0.00009848592,0.025819056,0.0023165338,0.18554829,0.02057132],"study_design_scores_gemma":[0.0034168612,0.000306239,0.95319873,0.00049303053,0.00009816131,0.0000053182516,0.001034731,0.0000034547666,0.010309454,0.00036507958,0.030648705,0.000120241115],"about_ca_topic_score_codex":0.0011602406,"about_ca_topic_score_gemma":0.00090704043,"teacher_disagreement_score":0.20053786,"about_ca_system_score_codex":0.00042852655,"about_ca_system_score_gemma":0.0011225687,"threshold_uncertainty_score":0.34481838},"labels":[],"label_agreement":null},{"id":"W2564916912","doi":"10.1093/neuonc/now212.106","title":"BMET-06. IMPROVED SURVIVAL AND PROGNOSTIC ABILITY IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: AN UPDATE OF THE GRADED PROGNOSTIC ASSESSMENT FOR LUNG CANCER USING MOLECULAR MARKERS (LUNG-molGPA)","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Adenocarcinoma; Hazard ratio; Performance status; Lung; Brain metastasis; Cancer; Metastasis; Confidence interval","score_opus":0.013344724573392022,"score_gpt":0.36020624101857973,"score_spread":0.3468615164451877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564916912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98970395,0.00035863323,0.0010259149,0.002683699,0.00034425984,0.005448716,0.00038420726,0.00002314441,0.000027444506],"genre_scores_gemma":[0.9961613,0.000037485643,0.0017431524,0.0005057932,0.000039216924,0.0013999052,0.00005413095,0.00004967846,0.000009363789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787635,0.00042401208,0.000434118,0.00057415897,0.00026380332,0.00042758437],"domain_scores_gemma":[0.99822915,0.00066412316,0.0003223337,0.00034347354,0.0002815322,0.00015936285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032245985,0.0002662031,0.0005474468,0.00010701734,0.00010026678,0.000015172081,0.00012284039,0.000102065795,0.000030933672],"category_scores_gemma":[0.00036766325,0.00015118564,0.00008280153,0.00027463213,0.00022839774,0.00015347113,0.000073482544,0.00015789129,5.5352153e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007192446,0.00079111214,0.9281714,0.00037746903,0.000491077,0.000018299408,0.00023784835,0.00010628074,0.06384414,0.000072171475,0.00007903014,0.005091914],"study_design_scores_gemma":[0.023598796,0.0030073281,0.9489917,0.00055716,0.004599952,0.000013958401,0.00019430691,0.013944239,0.004046074,0.00006177616,0.00058758515,0.00039710023],"about_ca_topic_score_codex":0.00067669776,"about_ca_topic_score_gemma":0.0009758676,"teacher_disagreement_score":0.05979806,"about_ca_system_score_codex":0.0009345377,"about_ca_system_score_gemma":0.00156147,"threshold_uncertainty_score":0.6165171},"labels":[],"label_agreement":null},{"id":"W2565052207","doi":"10.1097/cco.0000000000000353","title":"Concurrent driver mutations/rearrangements in non-small-cell lung cancer","year":2016,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Lung cancer; Cancer research; Clinical trial; Tyrosine kinase; Targeted therapy; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Cancer; Mutation; Epidermal growth factor receptor; Bioinformatics; Oncology; Gene; Internal medicine; Biology; Genetics; Receptor","score_opus":0.09186391266753373,"score_gpt":0.4942987861066422,"score_spread":0.40243487343910844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565052207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004908466,0.9805293,0.00010555925,0.00020453389,0.0133192055,0.0035222059,0.00022553797,0.000028450426,0.0020160936],"genre_scores_gemma":[0.00007212434,0.9937386,0.000057215548,0.000028378952,0.0007431914,0.0037942026,0.00095466804,0.000057836096,0.0005538067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744743,0.00020206331,0.0009865619,0.000665358,0.00020576044,0.00049284945],"domain_scores_gemma":[0.9987141,0.00022826476,0.00046106597,0.00031572804,0.00010653189,0.00017433429],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017654442,0.00046394704,0.0016497232,0.0007173108,0.000050113602,0.0000138338355,0.00018959482,0.0003608064,0.0005878104],"category_scores_gemma":[0.00003269651,0.0003412636,0.00029537108,0.00048100788,0.00009232932,0.000070229624,0.00009855516,0.0005681231,0.0001845954],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008388989,0.0008620179,0.0032738575,0.017197233,0.00015938286,0.000015389598,0.00043539668,0.0000017606532,2.4810944e-7,0.00005627145,0.0074013495,0.9705887],"study_design_scores_gemma":[0.004792206,0.00016404495,0.00080983754,0.04575702,0.0006969873,0.000012998299,0.000035332236,0.000023079105,2.6635425e-7,0.000009919682,0.94740397,0.00029434048],"about_ca_topic_score_codex":0.00008657518,"about_ca_topic_score_gemma":0.000054599313,"teacher_disagreement_score":0.97029436,"about_ca_system_score_codex":0.0035251777,"about_ca_system_score_gemma":0.0025565422,"threshold_uncertainty_score":0.9999039},"labels":[],"label_agreement":null},{"id":"W2565711919","doi":"10.1038/bjc.2016.420","title":"EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6","year":2016,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Lung cancer; Adenocarcinoma; Internal medicine; Epidermal growth factor receptor; Oncology; Liquid biopsy; Lung; Mutation; Pathology; Cancer; Biology; Gefitinib; Gene","score_opus":0.005319400910376899,"score_gpt":0.276573494396567,"score_spread":0.27125409348619006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565711919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223787,0.006574191,0.0006688259,0.00008767437,0.000097131015,0.00013987979,0.000051398038,0.0000024883934,0.00014055643],"genre_scores_gemma":[0.9989604,0.00073095947,0.00017270356,0.000021721444,0.0000486321,0.000006814727,0.0000043678,0.00000961584,0.000044806227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901366,0.000033745462,0.00050382584,0.000100059486,0.00025102132,0.00009765754],"domain_scores_gemma":[0.9989046,0.0000543454,0.00051138253,0.00007997927,0.00039166227,0.000058041158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121298486,0.00006498784,0.00032360852,0.00031895473,0.000026278776,0.0000081694425,0.00004050231,0.000042789703,0.00007223367],"category_scores_gemma":[0.00009789735,0.00005121472,0.00011027352,0.0003760792,0.00003725415,0.00018185384,0.000011946769,0.0000643172,6.150226e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009895827,0.000121920326,0.83874255,0.0001242702,0.00082962203,0.000055591066,0.00043524118,0.00013891958,0.0058081457,0.0000022698157,0.000044948123,0.15359758],"study_design_scores_gemma":[0.0046274518,0.00015795446,0.9853911,0.0008502986,0.002602706,0.00005991863,0.00012748914,0.00038830782,0.005691605,0.000029440678,0.000018852286,0.000054898792],"about_ca_topic_score_codex":0.0011592902,"about_ca_topic_score_gemma":0.0012845952,"teacher_disagreement_score":0.15354268,"about_ca_system_score_codex":0.00028955447,"about_ca_system_score_gemma":0.000108265325,"threshold_uncertainty_score":0.20884757},"labels":[],"label_agreement":null},{"id":"W2566055673","doi":"10.1093/annonc/mdv343.02","title":"Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Erlotinib; Clinical endpoint; Lung cancer; Oncology; Gefitinib; Progression-free survival; Chemotherapy; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.042023443954744014,"score_gpt":0.41986721954357664,"score_spread":0.37784377558883264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566055673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928443,0.0007035201,0.00014360831,0.002373215,0.00024824814,0.0016633762,0.00039434142,0.000014202902,0.0016151816],"genre_scores_gemma":[0.9970205,0.000030592997,0.00059854204,0.0018535247,0.00008834356,0.00006931904,0.00025707696,0.000018574212,0.0000635631],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982384,0.00018143906,0.00064823846,0.0002630759,0.0004473045,0.0002215332],"domain_scores_gemma":[0.99772215,0.00034519046,0.0008241996,0.00050266035,0.0005013631,0.000104417966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031971256,0.00021345803,0.0009252829,0.00007182637,0.00006663894,0.000005413336,0.00021409552,0.0001166069,0.00027964453],"category_scores_gemma":[0.00014136542,0.00010883769,0.00043257297,0.00067493715,0.00016822289,0.000075245574,0.000024649098,0.000113671515,6.953501e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33120328,0.011169014,0.5402516,0.00005890414,0.024758974,0.000019545143,0.008018093,0.001764131,0.00081076904,0.00015595576,0.003962306,0.0778274],"study_design_scores_gemma":[0.75802964,0.03276998,0.16963394,0.00025634858,0.0061943056,0.0000012821822,0.0013434486,0.0016260357,0.017086433,0.00028314878,0.012397861,0.0003775913],"about_ca_topic_score_codex":0.00043976752,"about_ca_topic_score_gemma":0.00020114293,"teacher_disagreement_score":0.42682636,"about_ca_system_score_codex":0.00010623166,"about_ca_system_score_gemma":0.0010244278,"threshold_uncertainty_score":0.4438272},"labels":[],"label_agreement":null},{"id":"W2566465788","doi":"10.1200/jop.2016.014019","title":"Impact of Reflex <i>EGFR</i>/<i>ALK</i> Testing on Time to Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Oncology Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; North York General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Interquartile range; Internal medicine; Lung cancer; Cancer; Performance status; Systemic therapy; Retrospective cohort study; Quality of life (healthcare); Oncology; Breast cancer","score_opus":0.025967482052240295,"score_gpt":0.4251943302299555,"score_spread":0.3992268481777152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566465788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691992,0.00022315241,0.000027365802,0.0015365966,0.00015449185,0.0007299948,0.00004601135,0.0000047915983,0.028078426],"genre_scores_gemma":[0.9830458,0.00012437018,0.015548271,0.0002773166,0.00012994929,0.00002511743,0.0000050335834,0.000027582526,0.00081653014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877423,0.00007101115,0.00049985974,0.00016326115,0.00028209126,0.00020954116],"domain_scores_gemma":[0.99508214,0.00064979936,0.0024239908,0.00035833984,0.0012769436,0.00020876728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019197044,0.00018475391,0.0006479767,0.00014106125,0.0001336053,0.000013083357,0.00013080677,0.000081042825,0.00007008432],"category_scores_gemma":[0.00063340896,0.00011419432,0.00014135754,0.00011056932,0.00006111149,0.00031580366,0.00002270757,0.00017071624,0.000009498124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038578212,0.021499509,0.5548584,0.00016886012,0.004582213,0.00079004996,0.003083542,0.0039574867,0.016870465,0.0000034772336,0.0028308975,0.35277689],"study_design_scores_gemma":[0.03299431,0.122335106,0.8155311,0.0005958921,0.0057053016,0.00022936781,0.00020780423,0.00007976322,0.0032241321,0.0000027965818,0.018869428,0.0002250561],"about_ca_topic_score_codex":0.00034947222,"about_ca_topic_score_gemma":0.000028536975,"teacher_disagreement_score":0.35255182,"about_ca_system_score_codex":0.0013603123,"about_ca_system_score_gemma":0.001532925,"threshold_uncertainty_score":0.4656709},"labels":[],"label_agreement":null},{"id":"W2566737927","doi":"10.1158/1538-7445.am2015-4891","title":"Abstract 4891: Comprehensive genetic profiling of chromosomal translocations in lung cancer tumors: development and validation of a next-generation sequencing panel in an international multicenter study","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Crizotinib; ROS1; Fluorescence in situ hybridization; Fusion gene; Lung cancer; Cancer research; Biology; Immunohistochemistry; Cancer; Anaplastic lymphoma kinase; Gene duplication; Targeted therapy; Pathology; Gene; Adenocarcinoma; Medicine; Genetics; Immunology","score_opus":0.3260875125507967,"score_gpt":0.4778528570219041,"score_spread":0.1517653444711074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566737927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975136,0.00084024196,0.00003529604,0.00012225799,0.000069667105,0.001350805,0.000020537755,0.000005378191,0.0000422288],"genre_scores_gemma":[0.99768376,0.00009196285,0.001423528,0.000009542074,0.00006748676,0.0006239081,0.0000737988,0.00001270722,0.000013323139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986708,0.00008828052,0.00039781677,0.00024155204,0.00043547768,0.00016605928],"domain_scores_gemma":[0.9990177,0.000037912363,0.00007470735,0.00012055355,0.0006632934,0.00008583544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000277393,0.00008555883,0.00018479595,0.00034583075,0.000036350593,0.000020371956,0.00007049755,0.0000352051,0.000027497657],"category_scores_gemma":[0.00003520436,0.00007923839,0.000013064947,0.00029083897,0.00005742352,0.00023341451,0.000021772235,0.00014631383,3.6060476e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018638541,0.000558823,0.76431423,0.00022144291,0.00009366779,0.00002137892,0.029651932,0.0063567483,0.19325522,0.000010410778,0.0000036862605,0.0053260582],"study_design_scores_gemma":[0.0045571784,0.00021715756,0.8201943,0.000568635,0.00004137438,0.000002008846,0.012019171,0.0119806705,0.15030952,0.0000063558928,0.000009623938,0.000094011906],"about_ca_topic_score_codex":0.0047578816,"about_ca_topic_score_gemma":0.0035248548,"teacher_disagreement_score":0.055880032,"about_ca_system_score_codex":0.0010007018,"about_ca_system_score_gemma":0.0014599833,"threshold_uncertainty_score":0.7192526},"labels":[],"label_agreement":null},{"id":"W2566738039","doi":"10.1016/j.lungcan.2016.12.014","title":"Oligometastatic non-small cell lung cancer: Where do we go next?","year":2016,"lang":"de","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Disease; Cancer","score_opus":0.008859829446741413,"score_gpt":0.3254124924975059,"score_spread":0.3165526630507645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566738039","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006117128,0.51151204,0.00026985104,0.0035550757,0.47048712,0.00298711,0.0047857505,0.00014604034,0.005645331],"genre_scores_gemma":[0.0017610764,0.41748288,0.00031150857,0.00026462376,0.46952084,0.0037196146,0.0005077688,0.0004724796,0.10595921],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99212617,0.00021099088,0.0015124595,0.002230088,0.0017767028,0.0021436012],"domain_scores_gemma":[0.9939834,0.0008529044,0.001293384,0.0017233719,0.001044872,0.0011020831],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00032377196,0.0018513419,0.0024115664,0.00054838735,0.00058232126,0.00045645318,0.000890738,0.001418633,0.010219685],"category_scores_gemma":[0.00008247982,0.0014350632,0.00083745207,0.000822653,0.00028060857,0.0004961793,0.0002680171,0.0016748107,0.001054103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00046228917,0.00039996704,0.0075830603,0.009622802,0.0074628247,0.00028936312,0.0036290581,0.00012564124,0.00024884625,0.000029839099,0.9415153,0.02863097],"study_design_scores_gemma":[0.011111848,0.00034719778,0.00022905452,0.019542662,0.026144274,0.0000034122968,0.00032175583,0.00042315276,0.00026796391,0.00004015473,0.9400237,0.0015447923],"about_ca_topic_score_codex":0.006822259,"about_ca_topic_score_gemma":0.0021533414,"teacher_disagreement_score":0.10031388,"about_ca_system_score_codex":0.007634582,"about_ca_system_score_gemma":0.009913978,"threshold_uncertainty_score":0.99987775},"labels":[],"label_agreement":null},{"id":"W2567735230","doi":"10.1016/j.jcjo.2016.11.018","title":"Corneal edema with a systemic epidermal growth factor receptor inhibitor","year":2017,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Erlotinib; Gefitinib; Medicine; Epidermal growth factor receptor; Rash; Lung cancer; EGFR inhibitors; Erlotinib Hydrochloride; Adverse effect; Oncology; Nausea; Internal medicine; Cancer; Cancer research","score_opus":0.02870735442658865,"score_gpt":0.30080270257085545,"score_spread":0.2720953481442668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567735230","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45122677,0.0041066995,0.000021512522,0.51318914,0.0073837363,0.0012122227,0.0011112905,0.00001558293,0.021733051],"genre_scores_gemma":[0.95701927,0.0000111609,0.0004362328,0.022269912,0.008660254,0.00002634894,0.00022489179,0.00011890056,0.01123305],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99805456,0.00011983589,0.0005987224,0.00030762126,0.00027452182,0.00064472004],"domain_scores_gemma":[0.99690115,0.00011193711,0.0010257759,0.00043184834,0.00070916204,0.0008201434],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011253383,0.00038627087,0.0010864373,0.0004073042,0.00024320067,0.00007384409,0.00033219502,0.00077959377,0.001707078],"category_scores_gemma":[0.00019243568,0.00027934325,0.00025708685,0.00007782722,0.00030681727,0.00013431649,0.00001149923,0.001711893,0.000073925105],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092139424,0.000016123266,0.03234409,0.00029992487,0.0009846417,0.3652916,0.00025142528,7.1613294e-7,0.000015659763,0.000006358803,0.60058916,0.000108146596],"study_design_scores_gemma":[0.0023213713,0.0020872673,0.007727811,0.0015721597,0.0008436269,0.86412704,0.00006031825,5.589857e-7,0.000048093778,0.000025022231,0.12087443,0.00031231673],"about_ca_topic_score_codex":0.0053094,"about_ca_topic_score_gemma":0.00013088714,"teacher_disagreement_score":0.5057925,"about_ca_system_score_codex":0.0010134933,"about_ca_system_score_gemma":0.008291055,"threshold_uncertainty_score":0.99996585},"labels":[],"label_agreement":null},{"id":"W2567850999","doi":"10.1016/j.jtho.2016.11.1666","title":"P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Ceritinib; Medicine; Crizotinib; Anaplastic lymphoma kinase; Pharmacokinetics; Internal medicine; ALK inhibitor; non-small cell lung cancer (NSCLC); Clinical endpoint; Gastroenterology; Oncology; Lung cancer; Randomized controlled trial","score_opus":0.06544336920317444,"score_gpt":0.515530127097982,"score_spread":0.4500867578948075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567850999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508905,0.00018791943,0.000076113225,0.0013305248,0.00051453756,0.0009333719,0.00003536059,0.000007948324,0.0018251896],"genre_scores_gemma":[0.9966663,0.00008233944,0.0024410835,0.00009381163,0.00012234416,0.00004434194,0.000010378799,0.000031475574,0.00050793163],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976323,0.0003186746,0.001002616,0.00024566293,0.00043325574,0.0003674805],"domain_scores_gemma":[0.9974126,0.00032003783,0.0013183295,0.00039289152,0.0003366882,0.00021943571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066324463,0.00023582905,0.0011587341,0.000477683,0.000100318925,0.000032610114,0.00025701986,0.000082402614,0.00015435796],"category_scores_gemma":[0.00034060172,0.00015399823,0.00009999791,0.00025689704,0.00015385401,0.00031220462,0.000056925597,0.00047562656,0.0000058109413],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3255551,0.044131324,0.04800464,0.00070163916,0.006071458,0.043017626,0.04313437,0.00070825586,0.006411243,0.00002279555,0.0011619382,0.4810796],"study_design_scores_gemma":[0.43522698,0.23813905,0.22152059,0.003919047,0.010912477,0.0034662485,0.07295062,0.0010571212,0.0021137712,0.0003406305,0.009296681,0.0010567774],"about_ca_topic_score_codex":0.0006527132,"about_ca_topic_score_gemma":0.0081065865,"teacher_disagreement_score":0.48002285,"about_ca_system_score_codex":0.0006703431,"about_ca_system_score_gemma":0.001142608,"threshold_uncertainty_score":0.62798655},"labels":[],"label_agreement":null},{"id":"W2567996140","doi":"10.1016/j.jtho.2016.11.1279","title":"P2.03a-069 Effectiveness of Adjuvant Carboplatin-Based Chemotherapy Compared to Cisplatin in Resected Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Carboplatin; Vinorelbine; Medicine; Cisplatin; Regimen; Lung cancer; Internal medicine; Oncology; Chemotherapy; Adjuvant","score_opus":0.021799149197732324,"score_gpt":0.4554990417687556,"score_spread":0.43369989257102326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567996140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939732,0.0004210617,0.0005148179,0.0014028737,0.00056078675,0.0007427483,0.000019974188,0.0000056167905,0.002358947],"genre_scores_gemma":[0.99628526,0.00003778383,0.0030842952,0.0002043824,0.00015211447,0.000042887605,0.0000061736428,0.000024810095,0.000162275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986082,0.0001964332,0.0005613471,0.0001780042,0.0002210457,0.00023496897],"domain_scores_gemma":[0.9978774,0.0003281911,0.00085059326,0.0003279267,0.0004385753,0.00017730397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006543786,0.00016292914,0.00088956946,0.0002982034,0.00008574173,0.000014925658,0.00021576359,0.00013859323,0.000074168485],"category_scores_gemma":[0.00012965804,0.00012635624,0.00013860482,0.00015352771,0.000066367385,0.00006581476,0.000028313216,0.00030194176,0.0000017798301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015437326,0.0018196801,0.7435649,0.0012686253,0.0006156211,0.0008094576,0.003371765,0.005142504,0.18369804,0.000005072577,0.00069223763,0.043574788],"study_design_scores_gemma":[0.008407048,0.0019404312,0.91392,0.0015591802,0.0005493684,0.000040179984,0.00019693092,0.0018609178,0.07090598,0.00002076785,0.00047282322,0.00012637519],"about_ca_topic_score_codex":0.0007977785,"about_ca_topic_score_gemma":0.0006614582,"teacher_disagreement_score":0.17035511,"about_ca_system_score_codex":0.0008699268,"about_ca_system_score_gemma":0.0014754899,"threshold_uncertainty_score":0.5152658},"labels":[],"label_agreement":null},{"id":"W2568379852","doi":"10.1016/j.jtho.2016.11.258","title":"OA06.03 Transcriptome Analysis of ATM-Deficient NSCLC","year":2017,"lang":"fr","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge; University of Calgary","funders":"","keywords":"Synthetic lethality; Medicine; Transcriptome; Cancer research; Lung cancer; Cancer; Targeted therapy; Epigenetics; Oncology; Bioinformatics; DNA repair; Internal medicine; Biology; Gene; Gene expression; Genetics","score_opus":0.03592268970109802,"score_gpt":0.4830086538398027,"score_spread":0.44708596413870466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568379852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8589834,0.048740733,0.0019320922,0.03487551,0.011823101,0.00035597023,0.00019004148,0.000008144804,0.043091025],"genre_scores_gemma":[0.98476917,0.0020454673,0.002361378,0.000295506,0.00085068715,0.0000042845577,0.000010242299,0.00002101428,0.009642275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99758494,0.00022879291,0.0011218395,0.00020725415,0.00044846398,0.00040868687],"domain_scores_gemma":[0.9959875,0.00019735048,0.0021851433,0.0005885969,0.0007006946,0.00034072867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010259354,0.00021551897,0.0014708969,0.00067700446,0.00024855338,0.000041575728,0.0004019671,0.0002910021,0.0013658382],"category_scores_gemma":[0.00027241497,0.00017062576,0.0009613842,0.00039444037,0.00046309317,0.00026898738,0.000042221887,0.0004391561,0.00004623772],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026805107,0.005119565,0.04310106,0.00052520557,0.036115244,0.0025646375,0.00861557,0.0015042006,0.008981148,0.0014855141,0.0060343225,0.883273],"study_design_scores_gemma":[0.005200489,0.009333003,0.42017418,0.0014496499,0.17275056,0.0010961425,0.0037688934,0.0014234141,0.0026410993,0.0004837256,0.38130197,0.00037688098],"about_ca_topic_score_codex":0.00025939115,"about_ca_topic_score_gemma":0.0001617918,"teacher_disagreement_score":0.8828961,"about_ca_system_score_codex":0.0010070283,"about_ca_system_score_gemma":0.001395097,"threshold_uncertainty_score":0.99954706},"labels":[],"label_agreement":null},{"id":"W2569046072","doi":"10.1016/j.jtho.2016.11.362","title":"OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Erlotinib; Lung cancer; Oncology; Adenocarcinoma; Post-hoc analysis; Gastroenterology; Lung; Refractory (planetary science); Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.04173091787525284,"score_gpt":0.4870332160086389,"score_spread":0.44530229813338607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569046072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927368,0.00078673556,0.00029047803,0.0024813192,0.0007318385,0.0013108948,0.00008297106,0.0000024511364,0.001576501],"genre_scores_gemma":[0.99793226,0.000025770792,0.0006667678,0.00020435645,0.00026027573,0.000045862016,0.000021676939,0.000016411179,0.0008266031],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978076,0.0003090458,0.0011308489,0.00018159444,0.00033539083,0.00023551036],"domain_scores_gemma":[0.9954242,0.000783746,0.00265792,0.00064375176,0.00040210845,0.000088287845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012552927,0.00017126345,0.0010289267,0.00039567013,0.00017965806,0.000017390263,0.0004879376,0.00014807018,0.00015436434],"category_scores_gemma":[0.0005442197,0.00009554078,0.00064579677,0.00033023438,0.00019563005,0.00014293386,0.000047564572,0.00032438088,3.239147e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6140586,0.016903715,0.1921354,0.001593848,0.00784268,0.0009076803,0.029053863,0.0020083797,0.0275221,0.00017840425,0.00561116,0.10218413],"study_design_scores_gemma":[0.37543702,0.028617637,0.5038912,0.00039806648,0.047077384,0.0002731885,0.0061690654,0.0029644205,0.03188825,0.00021354813,0.0026261618,0.00044402262],"about_ca_topic_score_codex":0.000031877764,"about_ca_topic_score_gemma":0.000302823,"teacher_disagreement_score":0.31175584,"about_ca_system_score_codex":0.00030137377,"about_ca_system_score_gemma":0.00095089833,"threshold_uncertainty_score":0.389604},"labels":[],"label_agreement":null},{"id":"W2569092380","doi":"10.1016/j.jtho.2016.11.1643","title":"P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Internal medicine; Nausea; Adverse effect; Refractory (planetary science); Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Randomized controlled trial; Gastroenterology; Clinical trial; Lung cancer","score_opus":0.03058263829566181,"score_gpt":0.507547969852704,"score_spread":0.4769653315570422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569092380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850425,0.0009108894,0.00026111357,0.0066416985,0.002208729,0.00095332635,0.000036446836,0.0000095774685,0.0039357343],"genre_scores_gemma":[0.99126315,0.00042843077,0.0064566378,0.00037327473,0.0011060148,0.000035644094,0.00003632694,0.000020366688,0.00028012847],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978215,0.00039954053,0.0009485284,0.00022577643,0.00029362887,0.00031101823],"domain_scores_gemma":[0.9973173,0.00059861806,0.0013396567,0.00027576042,0.00016517038,0.0003034658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097346894,0.00020120553,0.0013366073,0.00017267841,0.00017378807,0.00008475221,0.00016820787,0.00017647712,0.00034359726],"category_scores_gemma":[0.0005178881,0.00014197158,0.00026060586,0.000042651805,0.0002748327,0.00032464103,0.000055409233,0.00052855775,0.000004855345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73726636,0.0039217537,0.0044329776,0.000036983958,0.0013971409,0.0015050789,0.0016862542,0.000004215516,0.0017386253,0.00008970605,0.0017011345,0.24621975],"study_design_scores_gemma":[0.94898504,0.006071749,0.026586695,0.00032557678,0.0024603384,0.00032539514,0.0006043371,0.000375105,0.00034310785,0.0009968509,0.012737978,0.00018781508],"about_ca_topic_score_codex":0.00040761984,"about_ca_topic_score_gemma":0.00011738625,"teacher_disagreement_score":0.24603194,"about_ca_system_score_codex":0.0004839529,"about_ca_system_score_gemma":0.001385702,"threshold_uncertainty_score":0.5789433},"labels":[],"label_agreement":null},{"id":"W2569188319","doi":"10.1016/j.jtho.2016.11.363","title":"OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"","keywords":"Afatinib; Medicine; Gefitinib; Internal medicine; Clinical endpoint; Rash; Lung cancer; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.039474801036027844,"score_gpt":0.48193392923488265,"score_spread":0.4424591281988548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569188319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98200494,0.00048224189,0.0002007458,0.005294404,0.0014561755,0.00024565074,0.00004893469,0.000009513821,0.010257398],"genre_scores_gemma":[0.99574625,0.00035899965,0.0027816924,0.00012658667,0.00023122402,0.0000076997585,0.00006368859,0.000018349343,0.00066547806],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99817723,0.00011680912,0.0009008288,0.00020077397,0.00033326136,0.00027111985],"domain_scores_gemma":[0.99707824,0.00028856323,0.0015579986,0.000443056,0.00045832162,0.00017383571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000571688,0.00017720326,0.0011504061,0.0005773844,0.00012761613,0.000020682022,0.00025328397,0.00016982004,0.0003939943],"category_scores_gemma":[0.00048772196,0.00014011978,0.00035789574,0.00032238598,0.00011902635,0.0002492418,0.00006204209,0.00034844206,0.0000045123306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07455573,0.006811038,0.35054612,0.00043263094,0.03129372,0.005100636,0.004903699,0.015827846,0.005398794,0.00070939894,0.0050424,0.499378],"study_design_scores_gemma":[0.02631385,0.006558881,0.9077413,0.00046907229,0.019748498,0.0001550692,0.00085199747,0.00319818,0.0012041205,0.00018707984,0.03321952,0.00035243103],"about_ca_topic_score_codex":0.00016960567,"about_ca_topic_score_gemma":0.0011004293,"teacher_disagreement_score":0.5571952,"about_ca_system_score_codex":0.00056998595,"about_ca_system_score_gemma":0.00055726146,"threshold_uncertainty_score":0.5713919},"labels":[],"label_agreement":null},{"id":"W2569251433","doi":"10.1016/j.jtho.2016.11.415","title":"MA06.01 Overall Survival Characterization of Incidental N2 Non-Small Cell Lung Cancer over 14 Years at a Single Canadian Institution","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Oncology; Institution; Internal medicine","score_opus":0.02048787871871421,"score_gpt":0.391425412883193,"score_spread":0.3709375341644788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569251433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178207,0.00013935207,0.000089256595,0.0010735393,0.0020205823,0.00023016974,0.00006232775,0.0000036767142,0.0045990436],"genre_scores_gemma":[0.99705434,0.0001563811,0.00030805005,0.00024275444,0.00041981708,0.000006184225,0.00003278619,0.000015286061,0.001764428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990896,0.000043118333,0.00036819762,0.000116283045,0.00018961683,0.00019315816],"domain_scores_gemma":[0.9985359,0.000018509212,0.0008272706,0.00018632534,0.00020782738,0.00022419842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019223156,0.00010550292,0.0003656435,0.00019150267,0.00015559327,0.000024213354,0.0001275151,0.00014204616,0.00024501764],"category_scores_gemma":[0.000041246574,0.00009278435,0.00011129224,0.00004796673,0.00007659969,0.00023397809,0.000040424315,0.00016753959,0.00000469569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015369474,0.00077706965,0.68880546,0.00025549385,0.0005963615,0.0011590245,0.002583849,0.00007344097,0.2709107,0.00003562378,0.0015712037,0.031694826],"study_design_scores_gemma":[0.002048491,0.0006803348,0.9747613,0.00024110051,0.00076050457,0.00017878167,0.000057215002,0.00012784498,0.0065012784,0.000010468077,0.014532913,0.00009977016],"about_ca_topic_score_codex":0.017035937,"about_ca_topic_score_gemma":0.047985334,"teacher_disagreement_score":0.28595585,"about_ca_system_score_codex":0.002598071,"about_ca_system_score_gemma":0.0017648604,"threshold_uncertainty_score":0.9895097},"labels":[],"label_agreement":null},{"id":"W2569605734","doi":"10.1186/s12880-016-0175-3","title":"CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"BMC Medical Imaging","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Natural Science Foundation of China","keywords":"Epidermal growth factor receptor; Meta-analysis; Lung cancer; Medicine; Confidence interval; Odds ratio; Publication bias; Oncology; Radiology; Internal medicine; Cancer","score_opus":0.07217960541611954,"score_gpt":0.4073036938472972,"score_spread":0.3351240884311777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569605734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000053451954,0.9932868,0.0022618354,0.0003640737,0.000072589246,0.0033322463,0.00042291742,0.00002382655,0.0002303846],"genre_scores_gemma":[0.00017018766,0.9948398,0.0014168482,0.00042691568,0.00009485461,0.0014181522,0.00042845696,0.00006229941,0.0011425081],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967619,0.00028678813,0.0014271786,0.00055177376,0.00068370195,0.00028862167],"domain_scores_gemma":[0.99605703,0.000600578,0.00189433,0.0007027199,0.0003242945,0.00042103312],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005122918,0.00054182525,0.0088658715,0.00024734906,0.00011401609,0.000052527037,0.0002473326,0.000086168475,0.0010515486],"category_scores_gemma":[0.00073689444,0.00029301902,0.0014207605,0.0003256271,0.00015740871,0.000097295306,0.00006810076,0.00033614447,0.000009152277],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023226426,0.000062294595,0.0003974025,0.9219669,0.07130602,0.00014509737,0.000062326624,2.659774e-8,2.6863352e-8,0.000003116054,0.0001656655,0.00588882],"study_design_scores_gemma":[0.00037066164,0.000019099005,0.000070669055,0.14849281,0.84733963,0.0001714207,0.000012928782,0.00006364295,4.6969862e-7,3.1546577e-7,0.003218902,0.00023946655],"about_ca_topic_score_codex":0.00022252025,"about_ca_topic_score_gemma":0.000038854338,"teacher_disagreement_score":0.7760336,"about_ca_system_score_codex":0.00016191062,"about_ca_system_score_gemma":0.0019235458,"threshold_uncertainty_score":0.9999522},"labels":[],"label_agreement":null},{"id":"W2569660087","doi":"10.1016/j.jtho.2016.11.1670","title":"P3.02b-003 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Lung cancer; Internal medicine; Oncology; Immunohistochemistry; Lung; Adenocarcinoma; Carcinoma; Epidermal growth factor receptor; Cancer","score_opus":0.017297589953040496,"score_gpt":0.393243893855291,"score_spread":0.37594630390225053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569660087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629366,0.00045067523,0.000062967345,0.0006281375,0.00047764208,0.0005554331,0.00019226882,0.0000024556368,0.0013367329],"genre_scores_gemma":[0.9974321,0.000008193124,0.0021327857,0.000063998305,0.0000735225,0.000010024301,0.000014399991,0.000017041779,0.00024795122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987606,0.00008010631,0.0005776496,0.00015584826,0.00024018543,0.00018564449],"domain_scores_gemma":[0.99677306,0.00029659586,0.0019251347,0.00035787935,0.000526455,0.000120852346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003157787,0.0001468303,0.00072985963,0.00024697764,0.00016636077,0.000012921319,0.0001883943,0.000081320126,0.00007868991],"category_scores_gemma":[0.00018759466,0.00008667277,0.0002616423,0.00018928084,0.00019857816,0.000113778064,0.000050691167,0.00014301825,1.4601721e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012055562,0.0010632743,0.9717925,0.00047136808,0.003923374,0.000041111947,0.0009784553,0.00007507677,0.0004782824,0.000012939355,0.00096641015,0.008141652],"study_design_scores_gemma":[0.011227564,0.006814596,0.95888275,0.000087383894,0.017873824,0.000028025828,0.00064817275,0.0008907056,0.0027777364,0.00001161503,0.00065441127,0.00010319988],"about_ca_topic_score_codex":0.00004375707,"about_ca_topic_score_gemma":0.00013392139,"teacher_disagreement_score":0.0139504485,"about_ca_system_score_codex":0.00020288325,"about_ca_system_score_gemma":0.00051298254,"threshold_uncertainty_score":0.3534413},"labels":[],"label_agreement":null},{"id":"W2570114477","doi":"10.1016/j.jtho.2016.11.1785","title":"P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; T790M; non-small cell lung cancer (NSCLC); Internal medicine; Oncology; Osimertinib; Lung cancer; Erlotinib; EGFR inhibitors; Acquired resistance; Phases of clinical research; Resistance mutation; Cancer; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Gefitinib; Clinical trial; A549 cell","score_opus":0.02240743886775497,"score_gpt":0.4393268700468884,"score_spread":0.41691943117913344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570114477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946009,0.00024137188,0.000045246023,0.0007808891,0.0005416485,0.0010134178,0.00017562907,0.0000056270337,0.0025952586],"genre_scores_gemma":[0.99749863,0.000057289224,0.0017595382,0.00010448291,0.00023215004,0.000030355774,0.000020745214,0.000027793229,0.0002690065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793166,0.00013587113,0.0009952324,0.00026418845,0.0004014676,0.00027158568],"domain_scores_gemma":[0.99645036,0.00014899249,0.002147524,0.00051436323,0.00053537125,0.00020336416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040235117,0.00021451159,0.0008744185,0.0002325072,0.00014570823,0.00002783531,0.00028417874,0.00013025657,0.000069826536],"category_scores_gemma":[0.00013316153,0.00014379286,0.00009922935,0.00010950096,0.00008439871,0.00019718103,0.00006607702,0.00040513984,0.0000029764785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045350887,0.025730435,0.80658334,0.00019273518,0.0017440809,0.0017601167,0.026339946,0.0002624432,0.0018406115,0.0000015544517,0.0011598736,0.08903395],"study_design_scores_gemma":[0.09801031,0.026720114,0.8616194,0.001469776,0.0037077002,0.000037291164,0.004253164,0.00042431167,0.0022949865,0.000027034237,0.0011506312,0.00028528256],"about_ca_topic_score_codex":0.0021097523,"about_ca_topic_score_gemma":0.0018331067,"teacher_disagreement_score":0.08874866,"about_ca_system_score_codex":0.0007158697,"about_ca_system_score_gemma":0.0012534065,"threshold_uncertainty_score":0.5863703},"labels":[],"label_agreement":null},{"id":"W2570151487","doi":"10.1016/j.jtho.2016.11.045","title":"ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; ROS1; Lung cancer; Oncogene; Liquid biopsy; Personalized medicine; Cancer research; Crizotinib; Cancer; Fusion gene; Targeted therapy; Tyrosine kinase; KRAS; Mutation; Precision medicine; Gene; Oncology; Bioinformatics; Internal medicine; Adenocarcinoma; Pathology; Biology; Genetics; Cell cycle","score_opus":0.036203383191534697,"score_gpt":0.49293769551190125,"score_spread":0.45673431232036654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570151487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708937,0.0038112458,0.002069523,0.010536946,0.0025667623,0.00094759045,0.000027393306,0.000018546345,0.009128288],"genre_scores_gemma":[0.9854453,0.000817617,0.0105552,0.0004764731,0.00089584483,0.00004062309,0.000006031506,0.000023444425,0.0017394607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907726,0.000046504625,0.00040499296,0.00012548178,0.00015413288,0.0001916212],"domain_scores_gemma":[0.99812305,0.00010845347,0.00092607253,0.0003084161,0.0003848176,0.00014918909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002693845,0.00011665412,0.0005183028,0.00010037697,0.00023351135,0.000026235313,0.00019989604,0.00011914559,0.000056794248],"category_scores_gemma":[0.00014368785,0.00007988923,0.00023262823,0.000029712539,0.00006723315,0.00016256254,0.000019502506,0.00015517467,0.000009715974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005218315,0.00054179376,0.0049401964,0.000104572144,0.00089586317,0.00029805646,0.00064258964,0.00005606527,0.029859524,0.000087715685,0.0040094717,0.95334584],"study_design_scores_gemma":[0.03276442,0.027152648,0.043711327,0.0018840147,0.0036907685,0.0102399625,0.0024361694,0.00026663265,0.023686346,0.001427225,0.8522087,0.0005318264],"about_ca_topic_score_codex":0.000006894759,"about_ca_topic_score_gemma":0.0000111145155,"teacher_disagreement_score":0.952814,"about_ca_system_score_codex":0.00044728644,"about_ca_system_score_gemma":0.00084661733,"threshold_uncertainty_score":0.3257788},"labels":[],"label_agreement":null},{"id":"W2570179707","doi":"10.1016/j.jtho.2016.11.1695","title":"P3.02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Erlotinib; Cancer research; Epigenomics; Epidermal growth factor receptor; Biology; Population; Medicine; Cancer; Internal medicine; DNA methylation; Genetics; Gene expression; Gene","score_opus":0.04549280924966785,"score_gpt":0.4478053006809738,"score_spread":0.40231249143130593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570179707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98733765,0.00036378414,0.00017149237,0.008752044,0.0013613194,0.0003928816,0.000012702494,0.000021039272,0.0015870703],"genre_scores_gemma":[0.99299157,0.00006981965,0.004385354,0.001031441,0.0012718946,0.0000066295197,0.00003676378,0.000033040058,0.00017349812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982887,0.00019892026,0.00068818446,0.00018333858,0.00033924473,0.00030160448],"domain_scores_gemma":[0.9974541,0.000112986425,0.0015398388,0.00038591953,0.0003457984,0.00016132474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062932004,0.0001910527,0.0005961703,0.0001759321,0.00067421707,0.0001340027,0.00024298693,0.0001612286,0.000044180575],"category_scores_gemma":[0.00016995786,0.0001224073,0.00018093962,0.00009264946,0.00014462056,0.00042182434,0.00007488681,0.00044674912,0.000009386624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009362077,0.0018325954,0.16263731,0.0003470504,0.0029041045,0.0033882966,0.008776649,0.00033396823,0.30648622,0.00006145286,0.0018959582,0.50197434],"study_design_scores_gemma":[0.0027724726,0.0013281264,0.9812991,0.0005892614,0.0017873546,0.0027055456,0.0006233225,0.00020100894,0.0020369808,0.000094009105,0.006388082,0.00017473933],"about_ca_topic_score_codex":0.00011139968,"about_ca_topic_score_gemma":0.000040874096,"teacher_disagreement_score":0.8186618,"about_ca_system_score_codex":0.0007122805,"about_ca_system_score_gemma":0.0006756492,"threshold_uncertainty_score":0.5185601},"labels":[],"label_agreement":null},{"id":"W2570225271","doi":"10.1016/j.jtho.2016.11.1690","title":"P3.02b-023 Physician Patterns of Care in Patients with EGFR Mutation+ NSCLC: An International Survey into Testing and Treatment Choice","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; China; Family medicine; Internal medicine","score_opus":0.03218217973167105,"score_gpt":0.4488049454194688,"score_spread":0.41662276568779777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570225271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982389,0.000058955015,0.000030420002,0.00034499107,0.00021017909,0.00021026404,0.000042184136,0.000003128407,0.00086097966],"genre_scores_gemma":[0.9970542,0.000017017452,0.0025983849,0.000071931,0.00014238668,0.0000066862444,0.000054996326,0.000012092813,0.0000422562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991827,0.00008741397,0.00031492184,0.00012630055,0.00018421984,0.00010446921],"domain_scores_gemma":[0.9982587,0.0001597416,0.0006981114,0.00016568702,0.0006278369,0.00008992851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014565616,0.000105469764,0.00034443277,0.00014568456,0.00008871884,0.000023727822,0.00010399519,0.000052881565,0.0000081808885],"category_scores_gemma":[0.00020310875,0.00007292426,0.00003397913,0.000047324713,0.0000557854,0.00030020668,0.000022021326,0.00010220838,5.948402e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008582819,0.0005129939,0.69898045,0.00002167862,0.00015817185,0.00005212087,0.0014317076,0.000026531647,0.000024197647,0.0000018935377,0.0000024843948,0.29792947],"study_design_scores_gemma":[0.0039774384,0.008552818,0.9859351,0.0002448196,0.00024561523,0.000024818677,0.0005769006,0.000037002144,0.00011539481,0.000020762856,0.00021000992,0.000059357928],"about_ca_topic_score_codex":0.0016840209,"about_ca_topic_score_gemma":0.0040238067,"teacher_disagreement_score":0.29787013,"about_ca_system_score_codex":0.00060536305,"about_ca_system_score_gemma":0.00033719005,"threshold_uncertainty_score":0.2973765},"labels":[],"label_agreement":null},{"id":"W2570273251","doi":"10.1016/j.jtho.2016.11.436","title":"MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Osimertinib; Internal medicine; T790M; Oncology; Hazard ratio; Population; Carboplatin; Gastroenterology; Chemotherapy; Cisplatin; Confidence interval; Cancer; Gefitinib; Epidermal growth factor receptor; Erlotinib","score_opus":0.022921898595448742,"score_gpt":0.4647339912339375,"score_spread":0.44181209263848875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570273251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97201896,0.00030202235,0.0066899173,0.010472251,0.0012384048,0.0007792074,0.00011409472,0.000021789836,0.008363329],"genre_scores_gemma":[0.9697655,0.00004458944,0.027096912,0.00037529718,0.00037636323,0.000037577258,0.000081906794,0.000025179943,0.002196679],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984423,0.000088628265,0.0006819439,0.0002297853,0.00027857372,0.00027876472],"domain_scores_gemma":[0.99675184,0.00039576594,0.0015925253,0.00032781274,0.0007189911,0.00021304266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042390698,0.00018966626,0.0008473347,0.0004569258,0.0003768783,0.00005511549,0.00019451893,0.00015034105,0.00013547942],"category_scores_gemma":[0.0006417709,0.0001466146,0.00048449414,0.00022051127,0.00010177698,0.00035498367,0.00003154949,0.00024366395,0.000019335963],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018220086,0.0011638382,0.019837357,0.00011635335,0.011137792,0.00085274706,0.002222885,0.0011123432,0.0054414007,0.00016756335,0.0034770898,0.93625057],"study_design_scores_gemma":[0.02566758,0.021821002,0.80499476,0.0007119502,0.05439338,0.001890296,0.0027854934,0.0069051892,0.03430331,0.0018036838,0.043932125,0.00079120405],"about_ca_topic_score_codex":0.00003170824,"about_ca_topic_score_gemma":0.000094179246,"teacher_disagreement_score":0.9354593,"about_ca_system_score_codex":0.0005778864,"about_ca_system_score_gemma":0.00054289366,"threshold_uncertainty_score":0.597877},"labels":[],"label_agreement":null},{"id":"W2570652997","doi":"10.1016/j.jtho.2016.11.886","title":"P1.06-022 Clinical Characteristics of Survival Outliers in Stage IV Adenocarcinoma Lung Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adenocarcinoma; Lung cancer; Internal medicine; Stage (stratigraphy); Survival analysis; Survival rate; Overdiagnosis; Cancer; Oncology; Disease; Carcinoma","score_opus":0.048994167802714636,"score_gpt":0.5144322426180289,"score_spread":0.46543807481531424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570652997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368405,0.0003870927,0.000030669926,0.0015984064,0.0022634864,0.00024484296,0.00006332311,0.0000032997275,0.0017247999],"genre_scores_gemma":[0.99708575,0.0004178021,0.00055281783,0.00017352888,0.00044028184,0.0000068247914,0.000013285838,0.000017159944,0.0012925446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982045,0.00016223323,0.0010105468,0.00014444238,0.0002722013,0.00020606222],"domain_scores_gemma":[0.9972772,0.00014838249,0.0017367224,0.00027309934,0.00038424338,0.00018034111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006969685,0.000121562036,0.00084360107,0.00015006882,0.000083160885,0.000014785745,0.00020881376,0.0001666675,0.00011817157],"category_scores_gemma":[0.00046781776,0.00009340068,0.00018056176,0.000052849307,0.00016335827,0.00014248614,0.00006158083,0.00042539847,0.0000027982792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011717529,0.0009576406,0.9379323,0.00009521519,0.00032706966,0.00028153587,0.00053977745,0.0000027931505,0.00003672544,0.00001698874,0.0005792614,0.058058936],"study_design_scores_gemma":[0.003076521,0.0015379523,0.9864159,0.00019304571,0.0007013167,0.000018849289,0.00020465012,0.000060851387,0.00003885755,0.00001489263,0.0076645156,0.00007262482],"about_ca_topic_score_codex":0.000109897075,"about_ca_topic_score_gemma":0.00010612514,"teacher_disagreement_score":0.05798631,"about_ca_system_score_codex":0.00054551626,"about_ca_system_score_gemma":0.0010237665,"threshold_uncertainty_score":0.3808769},"labels":[],"label_agreement":null},{"id":"W2570785609","doi":"10.1016/j.jtho.2016.11.006","title":"PL03.03: Randomized Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Pemetrexed; Medicine; T790M; Internal medicine; Oncology; Carboplatin; Erlotinib; Chemotherapy; Cisplatin; Epidermal growth factor receptor; Gefitinib; Cancer","score_opus":0.029999989005579823,"score_gpt":0.4933886263280734,"score_spread":0.4633886373224936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570785609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876845,0.00057808764,0.0018799008,0.0021169821,0.0009706836,0.0027141252,0.00004405407,0.000011919548,0.003999739],"genre_scores_gemma":[0.99143326,0.00007375437,0.0068165096,0.00017925719,0.00034151736,0.000116227784,0.000015811962,0.000028008923,0.0009956763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978847,0.00019251934,0.0011438356,0.00021103933,0.00031033478,0.00025758863],"domain_scores_gemma":[0.9950496,0.00093334354,0.0026293187,0.00037633235,0.000817871,0.00019356649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010505283,0.0002113068,0.0018155251,0.000247087,0.00028123704,0.000022417938,0.00023688666,0.00012923259,0.000094390954],"category_scores_gemma":[0.0012411398,0.00014567353,0.00042193398,0.000087203254,0.0001890947,0.00023943643,0.000047584155,0.00026584254,0.0000038489147],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71741366,0.009915855,0.0013078171,0.0001025065,0.004622793,0.00039388385,0.006906625,0.000057378587,0.0054373224,0.00007631085,0.0012827528,0.2524831],"study_design_scores_gemma":[0.9342951,0.029905919,0.004333382,0.00051513733,0.009234229,0.00033036742,0.0048507815,0.00031467056,0.011131761,0.00048495448,0.0043639694,0.000239686],"about_ca_topic_score_codex":0.000056086392,"about_ca_topic_score_gemma":0.000041210027,"teacher_disagreement_score":0.25224343,"about_ca_system_score_codex":0.00032113437,"about_ca_system_score_gemma":0.0005968966,"threshold_uncertainty_score":0.59403944},"labels":[],"label_agreement":null},{"id":"W2570847733","doi":"10.1016/j.jtho.2016.11.619","title":"P1.02-036 An EGFR Tyrosine Kinase Inhibitor Sensitive Patient-Derived Lung Cancer Xenograft Model without Classical Sensitizing Mutations","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; T790M; Cancer research; Exon; Medicine; Lung cancer; Tyrosine kinase; Molecular biology; Erlotinib Hydrochloride; Point mutation; Tyrosine-kinase inhibitor; Wild type; Osimertinib; Protein kinase domain; Gefitinib; Mutant; Epidermal growth factor receptor; Cancer; Oncology; Biology; Gene; Internal medicine; Genetics; Receptor","score_opus":0.029850153302110067,"score_gpt":0.4542525652315685,"score_spread":0.42440241192945843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570847733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831302,0.00034577667,0.0017061492,0.012007145,0.00095359486,0.00040915585,0.00007129047,0.000028608985,0.0013480646],"genre_scores_gemma":[0.9825724,0.00008611781,0.015111922,0.0008783002,0.00087572454,0.000020540461,0.000033924134,0.000041620762,0.0003794892],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982925,0.00015661902,0.0005994762,0.0002622531,0.0003434385,0.00034571768],"domain_scores_gemma":[0.9972649,0.00008457067,0.0010099167,0.00036352518,0.00084054173,0.00043651005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023563842,0.00023334601,0.0006832044,0.00021523099,0.00056557363,0.000082605184,0.00011438477,0.00020219687,0.000030606505],"category_scores_gemma":[0.00018183867,0.00018286439,0.00020407086,0.00008339573,0.00027024595,0.0005260676,0.000063493724,0.00050084625,0.0000048675324],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008354775,0.0042932644,0.020075219,0.00030124237,0.00322806,0.009196325,0.023425464,0.008062514,0.40068537,0.00028487644,0.006832033,0.5152609],"study_design_scores_gemma":[0.03344087,0.025262058,0.21613686,0.0054632286,0.031619336,0.017197674,0.021026358,0.37383252,0.25114763,0.0015225186,0.020589959,0.0027609554],"about_ca_topic_score_codex":0.000118371,"about_ca_topic_score_gemma":0.00025316575,"teacher_disagreement_score":0.5124999,"about_ca_system_score_codex":0.0010273636,"about_ca_system_score_gemma":0.0013219606,"threshold_uncertainty_score":0.74569935},"labels":[],"label_agreement":null},{"id":"W2570860829","doi":"10.1016/j.jtho.2016.11.1289","title":"P2.03b-008 The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Cohort; Internal medicine; Brain metastasis; Disease; Quality of life (healthcare); Cancer; Stage (stratigraphy); Metastasis","score_opus":0.034841824826755526,"score_gpt":0.5079073517794082,"score_spread":0.47306552695265264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570860829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114615,0.002807983,0.000015245838,0.0051914398,0.00011312494,0.000393255,0.0001371594,0.0000013126039,0.00019434752],"genre_scores_gemma":[0.9990772,0.00057736074,0.00012615012,0.00014773493,0.000029314711,0.000009586301,0.000006425944,0.000007908477,0.000018334722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895567,0.00023840633,0.00043359536,0.0001006597,0.00013058778,0.00014106419],"domain_scores_gemma":[0.9983236,0.00018559616,0.0009976557,0.00023904334,0.00015415669,0.00009990296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041814323,0.00012081306,0.00060600834,0.00011651403,0.000077624274,0.0000071085105,0.000094742085,0.000045726836,0.00002411331],"category_scores_gemma":[0.00015412373,0.000056689496,0.00016569809,0.00005211831,0.0001481459,0.00006465882,0.000022338849,0.00011513003,1.1664999e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028456468,0.0028656337,0.6601196,0.00012275943,0.0015801986,0.00007182161,0.004150922,0.00010943508,0.000884524,0.000025517145,0.0010112914,0.32621264],"study_design_scores_gemma":[0.0029203235,0.0083600925,0.9833046,0.00031822946,0.00031987278,0.000036775567,0.0001775979,0.00008718794,0.0039944565,0.00018494851,0.0002513851,0.00004452218],"about_ca_topic_score_codex":0.002608082,"about_ca_topic_score_gemma":0.0005608027,"teacher_disagreement_score":0.32616812,"about_ca_system_score_codex":0.0006265863,"about_ca_system_score_gemma":0.0010318799,"threshold_uncertainty_score":0.39426574},"labels":[],"label_agreement":null},{"id":"W2570957508","doi":"10.1016/j.jtho.2016.11.1868","title":"P3.02c-073 Evidence Suggesting a Dichotomous “Present vs absent” Determinant of PDL1 Inhibitor Efficacy in Non-Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Cancer","score_opus":0.03564783153842322,"score_gpt":0.4638598057751654,"score_spread":0.4282119742367422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570957508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990091,0.00348141,0.00008892759,0.0034096038,0.00106614,0.0005913284,0.000007692011,0.000006698209,0.001257185],"genre_scores_gemma":[0.9949533,0.0008818589,0.0024928947,0.00012816874,0.0007247355,0.000031910684,0.0000012023863,0.000025738076,0.0007602089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809253,0.00011456886,0.0008848643,0.00023170943,0.00032563254,0.00035071617],"domain_scores_gemma":[0.9969013,0.0004296383,0.0016383526,0.000406912,0.00039156762,0.00023228159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006360991,0.00019726543,0.0008114318,0.00026553601,0.00013073266,0.000033653527,0.0003240056,0.0001660199,0.00006300948],"category_scores_gemma":[0.00046796165,0.00014710524,0.00021031516,0.000113759,0.00013905445,0.00023206793,0.00011599459,0.00047571294,0.000004488677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067597465,0.0037111451,0.4605598,0.0017239618,0.0005689251,0.0075242915,0.008668416,0.0006213302,0.057448953,0.0000035460464,0.0025407975,0.4498691],"study_design_scores_gemma":[0.009896319,0.0067404527,0.9040656,0.012920679,0.0032786096,0.0015028734,0.00079038506,0.0022548637,0.052060757,0.000031135296,0.0060175974,0.00044069096],"about_ca_topic_score_codex":0.0008528662,"about_ca_topic_score_gemma":0.0003747158,"teacher_disagreement_score":0.4494284,"about_ca_system_score_codex":0.00081287674,"about_ca_system_score_gemma":0.0014924266,"threshold_uncertainty_score":0.5998777},"labels":[],"label_agreement":null},{"id":"W2571097605","doi":"10.1016/j.jtho.2016.11.514","title":"MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; T790M; Clinical trial; Population; Target lesion; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.05776611874330057,"score_gpt":0.5222276652436241,"score_spread":0.4644615465003235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571097605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98687124,0.00016864476,0.00028734846,0.010234066,0.00056960917,0.0008197533,0.0005043456,0.000007602154,0.00053738675],"genre_scores_gemma":[0.98909205,0.000015757272,0.009276417,0.0007103119,0.00031631606,0.000014242209,0.00014382135,0.000024347963,0.0004067155],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977234,0.0005652809,0.00084100245,0.00029323343,0.00032236663,0.00025470916],"domain_scores_gemma":[0.99653035,0.0006465358,0.0013538044,0.00080230494,0.00037848947,0.00028850176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015780613,0.00018365543,0.0010335719,0.0002510878,0.00022100066,0.000035827674,0.00042776385,0.000096308635,0.00015238998],"category_scores_gemma":[0.0025956386,0.00012183708,0.00009441668,0.00010450324,0.000075931835,0.00043923143,0.00017880012,0.00027206537,0.000015381947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3685036,0.0068544983,0.053621016,0.000014721155,0.001651141,0.0015350438,0.0026831925,0.000049515504,0.006279214,0.000006224175,0.002716638,0.5560852],"study_design_scores_gemma":[0.107977234,0.037601672,0.8071068,0.0012730706,0.004706888,0.00009568881,0.0006557446,0.0000560562,0.0037523198,0.00014497762,0.036292467,0.0003370735],"about_ca_topic_score_codex":0.00013336824,"about_ca_topic_score_gemma":0.00024152105,"teacher_disagreement_score":0.7534858,"about_ca_system_score_codex":0.00050729024,"about_ca_system_score_gemma":0.0010188252,"threshold_uncertainty_score":0.4968372},"labels":[{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"grok","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"opus","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2571125375","doi":"10.1016/j.jtho.2016.11.146","title":"MTE12.01 Clinically Relevant Signal Transduction Pathways","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"DNA damage; DNA repair; Cancer research; Autocrine signalling; Cell cycle; Cancer; Cancer cell; Cell cycle checkpoint; Medicine; Signal transduction; Lung cancer; Cell growth; Biology; Cell biology; DNA; Pathology; Cell culture; Genetics; Internal medicine","score_opus":0.051937804890367874,"score_gpt":0.4824144023932271,"score_spread":0.4304765975028592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571125375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392686,0.00056130276,0.0026893553,0.02808927,0.0026338005,0.0002849917,0.000011276619,0.000021137443,0.026440263],"genre_scores_gemma":[0.9884411,0.00033941338,0.008640549,0.0004459064,0.0011433322,0.0000041741014,0.0000032781145,0.0000140773045,0.0009681767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881166,0.00007953324,0.0006120674,0.00012094694,0.00021370998,0.00016210912],"domain_scores_gemma":[0.9983109,0.00010061131,0.00087998837,0.0002507111,0.00027115727,0.00018663528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063466525,0.00009696317,0.00043579523,0.00009095889,0.00021115228,0.000027904734,0.00014692095,0.00014895869,0.00039193442],"category_scores_gemma":[0.00021156209,0.000067634566,0.00023358133,0.000031472733,0.00012196287,0.00018623621,0.000016639202,0.00036289336,0.000027743648],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041589714,0.0011999409,0.008747465,0.00006941758,0.0006702589,0.0017014855,0.0011491189,0.000020563513,0.012780242,0.0001515188,0.0043757283,0.9649753],"study_design_scores_gemma":[0.013281146,0.037166588,0.33176455,0.0009740482,0.007962397,0.014441703,0.0019571928,0.00026850763,0.011271357,0.008507528,0.571893,0.0005120143],"about_ca_topic_score_codex":0.000011156326,"about_ca_topic_score_gemma":0.000009953657,"teacher_disagreement_score":0.9644633,"about_ca_system_score_codex":0.00027439705,"about_ca_system_score_gemma":0.00084602274,"threshold_uncertainty_score":0.4291407},"labels":[],"label_agreement":null},{"id":"W2571237858","doi":"10.1016/j.jtho.2016.11.1687","title":"P3.02b-020 Gender and Ethnicity Influence on Outcome in EGFRmut+ NSCLC Patients Treated at a Single Canadian Institution","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Red Cross Society; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Ethnic group; Demography; Cohort; Statistical significance; Oncology; Retrospective cohort study; Adenocarcinoma; Cancer","score_opus":0.05802074750904134,"score_gpt":0.45492069164079807,"score_spread":0.3968999441317567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571237858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98725075,0.00009703949,0.0000043202854,0.0016491467,0.00029663317,0.00020841295,0.000013104137,0.0000041399944,0.010476478],"genre_scores_gemma":[0.99856967,0.00003304687,0.00023211657,0.0008257461,0.00007069828,0.00000441306,0.0000063400466,0.00000804423,0.000249953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991015,0.000063502084,0.00036014497,0.0001298584,0.00014927234,0.00019570584],"domain_scores_gemma":[0.9989176,0.00004176787,0.00040109418,0.00017773549,0.0001878119,0.00027400962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019346629,0.00010776514,0.00033220058,0.00024697784,0.0002127044,0.00002088964,0.000085947635,0.00014061312,0.000039582177],"category_scores_gemma":[0.0003331937,0.000080378486,0.000052330543,0.00005862,0.00010981131,0.00017709877,0.00002703278,0.00023756755,0.000013226272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082052447,0.000406506,0.95944357,0.000025650048,0.00008734292,0.00052033924,0.00064015476,0.000036741396,0.0004258809,0.000032201777,0.00019479982,0.037366316],"study_design_scores_gemma":[0.0021476166,0.0017786378,0.9906671,0.00010980895,0.00021266895,0.00015354832,0.000051386694,0.00001615845,0.00022069704,0.00005463835,0.0045180772,0.000069655376],"about_ca_topic_score_codex":0.009473124,"about_ca_topic_score_gemma":0.028936082,"teacher_disagreement_score":0.03729666,"about_ca_system_score_codex":0.002832914,"about_ca_system_score_gemma":0.0005387514,"threshold_uncertainty_score":0.9971229},"labels":[],"label_agreement":null},{"id":"W2571282285","doi":"10.1016/j.jtho.2016.11.1802","title":"P3.02c-007 Assessment of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Delmar (Canada)","funders":"","keywords":"Cisplatin; Medicine; Propidium iodide; Carboplatin; Oxaliplatin; Cytotoxicity; Cancer research; Lung cancer; Oncology; MTT assay; Context (archaeology); Chemotherapy; Cancer; Pharmacology; Apoptosis; Internal medicine; In vitro; Programmed cell death; Chemistry; Colorectal cancer; Biology; Biochemistry","score_opus":0.03400603725908536,"score_gpt":0.4911374968613661,"score_spread":0.45713145960228074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571282285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98328245,0.0011001108,0.000078328136,0.0027459972,0.00073014403,0.0005303356,0.000016780592,0.0000022203108,0.011513639],"genre_scores_gemma":[0.99304014,0.0029201526,0.002593005,0.0001001225,0.00026555939,0.00004098019,0.000003011382,0.000014105175,0.0010229084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870235,0.00013155663,0.0006227218,0.00012211896,0.00024527783,0.00017599195],"domain_scores_gemma":[0.9975325,0.00025639893,0.001505115,0.00040419897,0.00021330273,0.00008852678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039586824,0.00013835145,0.0006652207,0.00018619695,0.000086789485,0.00001092437,0.00021551731,0.0001283334,0.00013457272],"category_scores_gemma":[0.000043117798,0.000073149706,0.00019181284,0.00008469416,0.000100044075,0.000112413196,0.00001665734,0.00022524192,9.233421e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006139655,0.015648095,0.64980674,0.00076339615,0.002009971,0.0025468136,0.014466418,0.0002663861,0.011145484,0.000033326956,0.002740024,0.29443368],"study_design_scores_gemma":[0.012497415,0.027017953,0.8840544,0.00085294043,0.00497962,0.00033847534,0.0033392424,0.00051661883,0.009090002,0.000039688948,0.0570777,0.0001959389],"about_ca_topic_score_codex":0.0006895914,"about_ca_topic_score_gemma":0.0007152502,"teacher_disagreement_score":0.29423776,"about_ca_system_score_codex":0.00109836,"about_ca_system_score_gemma":0.0019655193,"threshold_uncertainty_score":0.34867468},"labels":[],"label_agreement":null},{"id":"W2571417207","doi":"10.1016/j.jtho.2016.11.245","title":"OA04.02 Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Smoking cessation; Lung cancer screening; Internal medicine; Stage (stratigraphy); Cancer; Clinical endpoint; Clinical trial; Pathology","score_opus":0.02356426324017958,"score_gpt":0.4274010001882532,"score_spread":0.40383673694807365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571417207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948934,0.0001798142,0.000051662955,0.00051054655,0.0015593402,0.0008466198,0.000045670276,0.0000070724786,0.0019059068],"genre_scores_gemma":[0.99589384,0.00004827518,0.002037449,0.00009062516,0.00054296287,0.000068448375,0.000019563158,0.000029453366,0.0012693652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984409,0.00006572712,0.00069078954,0.00022797362,0.0003098225,0.00026474532],"domain_scores_gemma":[0.99744874,0.00005877388,0.0016187441,0.00039336953,0.00029308157,0.00018730389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030692888,0.00017165231,0.00065122946,0.0001785352,0.00014481602,0.00005428536,0.00019423808,0.00015706384,0.00017079852],"category_scores_gemma":[0.00007089525,0.00012414876,0.00013044344,0.000060765466,0.00006146528,0.00023562575,0.000051468156,0.00045254818,0.0000021946366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021175643,0.0013367464,0.94425935,0.00003199214,0.00026752512,0.0046646046,0.0008398328,0.000013559456,0.00008526104,3.8902542e-7,0.0002574448,0.027067674],"study_design_scores_gemma":[0.03851936,0.0041468055,0.95172864,0.0002542707,0.0018532679,0.00006333529,0.00015029436,0.000010336001,0.00033355493,0.000005581201,0.0028078612,0.00012666582],"about_ca_topic_score_codex":0.0026014156,"about_ca_topic_score_gemma":0.0010670733,"teacher_disagreement_score":0.026941009,"about_ca_system_score_codex":0.0009579619,"about_ca_system_score_gemma":0.0013166469,"threshold_uncertainty_score":0.5062639},"labels":[],"label_agreement":null},{"id":"W2573011907","doi":"10.1200/jco.2006.24.18_suppl.10068","title":"Use of denaturing high performance liquid chromatography (dHPLC) for detection of EGFR mutations in patients with NSCLC","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Denaturing high performance liquid chromatography; Exon; genomic DNA; Epidermal growth factor receptor; Missense mutation; Molecular biology; DNA sequencing; Gene; Mutation; Lung cancer; Biology; Genetics; Cancer research; Medicine; Cancer; Pathology","score_opus":0.037885809764650766,"score_gpt":0.39847104845873427,"score_spread":0.3605852386940835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573011907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99857765,0.00006511408,0.0005070537,0.00020582607,0.00024279534,0.0002876834,0.000009159203,0.000003042055,0.00010169592],"genre_scores_gemma":[0.9937634,0.000040307557,0.005968129,0.000063714004,0.00011997397,0.000008375907,0.000009751817,0.00000916,0.00001720189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983662,0.00005008283,0.0012303289,0.00008204497,0.00017066362,0.00010067541],"domain_scores_gemma":[0.9975569,0.0005784079,0.0011795639,0.00007937381,0.0005487407,0.000056972593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030538495,0.00006798846,0.0005783782,0.00021839859,0.00002262242,0.0000020990558,0.00003857703,0.00012793406,0.0000056074273],"category_scores_gemma":[0.0002587197,0.00004603487,0.00015972038,0.00018340092,0.00010018164,0.00015462785,0.0000067165392,0.0001939252,2.4255206e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011369059,0.0036736415,0.94615674,0.00011775556,0.00043772455,0.000012368794,0.00008986373,0.0011694112,0.0007298555,0.00007136495,0.000059448033,0.036112785],"study_design_scores_gemma":[0.010613018,0.020259708,0.96451104,0.00019095346,0.00046166603,0.000010355566,0.000021469958,0.00007638496,0.0029593897,0.000043897573,0.00081143196,0.000040688516],"about_ca_topic_score_codex":0.00011365123,"about_ca_topic_score_gemma":0.00013444513,"teacher_disagreement_score":0.036072098,"about_ca_system_score_codex":0.00009171564,"about_ca_system_score_gemma":0.00040395514,"threshold_uncertainty_score":0.18772475},"labels":[],"label_agreement":null},{"id":"W2576796004","doi":"10.1136/esmoopen-2016-000118","title":"Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Samsung; Genentech; Eisai; Amgen; Ariad Pharmaceuticals; Boehringer Ingelheim; Helsinn; Clovis Oncology; Sanofi; Helsinn Therapeutics; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Atezolizumab; Medicine; Ramucirumab; Nivolumab; Oncology; Internal medicine; Chemotherapy; Lung cancer; Immunotherapy; Nintedanib; Cancer; Lung","score_opus":0.015096098638421188,"score_gpt":0.3330041230318293,"score_spread":0.3179080243934081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576796004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900569,0.000009931013,0.00057332206,0.0021585005,0.000049028735,0.0029790523,0.00014076581,0.000024174995,0.0040083323],"genre_scores_gemma":[0.9912311,0.000011153227,0.0027448544,0.00057651417,0.000025712314,0.00082323555,0.00011727617,0.000039706174,0.0044304808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907774,0.000012780598,0.00017039041,0.00031938168,0.00020344707,0.0002162731],"domain_scores_gemma":[0.9993609,0.00002717112,0.00009498088,0.00026382506,0.00015227175,0.000100835765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003181135,0.00016946015,0.00025130555,0.00007565716,0.000067176734,0.000029453888,0.00011547144,0.00004824859,0.0004577495],"category_scores_gemma":[0.00001806855,0.00009817385,0.00003236573,0.0001340331,0.00006965934,0.00039922888,0.000044507153,0.000063740765,0.00002674562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030348287,0.0012579247,0.949778,0.000012248985,0.00022635334,0.000015144035,0.0016899866,0.000010611852,0.000020021873,0.000013558949,0.00020869827,0.043732625],"study_design_scores_gemma":[0.027799701,0.00058554846,0.9658656,0.00054568273,0.00009456699,0.0000014048161,0.000058460293,0.000017601704,0.00063168694,0.000028062786,0.004222942,0.0001487437],"about_ca_topic_score_codex":0.00022554457,"about_ca_topic_score_gemma":0.0012774522,"teacher_disagreement_score":0.04358388,"about_ca_system_score_codex":0.00025323709,"about_ca_system_score_gemma":0.00012978482,"threshold_uncertainty_score":0.5012036},"labels":[],"label_agreement":null},{"id":"W2576814507","doi":"10.1016/j.ctrv.2017.01.003","title":"Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head &amp; neck","year":2017,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Ottawa; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; EGFR inhibitors; Head and neck cancer; Biomarker; Oncology; Head and neck squamous-cell carcinoma; Cancer research; Targeted therapy; Cancer; Clinical trial; Squamous carcinoma; Internal medicine; Carcinoma; Biology","score_opus":0.10154198292516915,"score_gpt":0.46727080123517467,"score_spread":0.36572881831000553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576814507","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015002334,0.97938174,0.0000036514484,0.00022852868,0.00016663106,0.004384953,0.00058432383,0.000005405667,0.00024241084],"genre_scores_gemma":[0.004290854,0.9924207,0.00009196205,0.0000719994,0.000059647202,0.0016127863,0.000101125515,0.00003198575,0.0013189836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981712,0.00030331718,0.0007650866,0.00045541726,0.00008907127,0.00021589604],"domain_scores_gemma":[0.9982325,0.00012398431,0.00075668853,0.0007204069,0.000044834676,0.00012162483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020214645,0.00040362356,0.002297182,0.0001698815,0.000068500514,0.000010084094,0.00007593243,0.00015477845,0.000042684012],"category_scores_gemma":[0.000056233563,0.00021720654,0.0003255781,0.00015480867,0.000093185205,0.00003443808,0.00005806912,0.00011086097,0.0000028907937],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013684474,0.00015216062,0.011324817,0.020157378,0.00018214101,0.000008981176,0.00060468464,7.904859e-7,0.000021767737,0.000008964168,0.00040998115,0.9669915],"study_design_scores_gemma":[0.001798652,0.00043570914,0.0024438745,0.029286912,0.0030290019,0.000020029409,0.000010784431,3.639539e-7,0.000025182855,0.0000034797092,0.9627915,0.00015452948],"about_ca_topic_score_codex":0.0045612673,"about_ca_topic_score_gemma":0.002990175,"teacher_disagreement_score":0.966837,"about_ca_system_score_codex":0.0013970018,"about_ca_system_score_gemma":0.00084382115,"threshold_uncertainty_score":0.8857426},"labels":[],"label_agreement":null},{"id":"W2577702683","doi":"10.1016/j.cllc.2017.01.004","title":"Antiangiogenic Therapy in Advanced Non–small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials","year":2017,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Confidence interval; Hazard ratio; Lung cancer; Odds ratio; Meta-analysis; Randomized controlled trial; Population; Relative risk; Cochrane Library; Oncology; Gastroenterology","score_opus":0.3277469335734769,"score_gpt":0.5966271301539737,"score_spread":0.26888019658049683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577702683","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004240623,0.98308986,0.00013407657,0.00025733165,0.0010667681,0.012626995,0.0015895623,0.000037328966,0.0007740206],"genre_scores_gemma":[0.00069469895,0.9824112,0.00034118007,0.00030234235,0.00052255875,0.010154172,0.00063705957,0.00012532799,0.0048114653],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9891289,0.002015778,0.006398956,0.0013464348,0.000524467,0.0005854663],"domain_scores_gemma":[0.9860362,0.005365551,0.0059942235,0.001827044,0.0004079449,0.00036907897],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.005962613,0.00097593106,0.03568802,0.0009075775,0.00012443251,0.000053476968,0.0005941925,0.0007565282,0.0029096175],"category_scores_gemma":[0.0012152338,0.00058091775,0.025967972,0.0011694571,0.00032457133,0.000109098124,0.00009123266,0.0007422607,0.0000055283235],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01197281,0.0010394929,0.00017533373,0.003963762,0.5216553,0.000045350127,0.00011448515,0.000033570155,0.0000011387328,0.000006139333,0.0010065767,0.459986],"study_design_scores_gemma":[0.17312315,0.00015372834,0.000014409295,0.0023031274,0.6657277,0.0000010694276,0.000005707808,0.0003182592,0.0000036531367,0.0000035240494,0.15798482,0.00036086887],"about_ca_topic_score_codex":0.0015789525,"about_ca_topic_score_gemma":0.0006633847,"teacher_disagreement_score":0.45962512,"about_ca_system_score_codex":0.0005490164,"about_ca_system_score_gemma":0.0042112665,"threshold_uncertainty_score":0.99966425},"labels":[],"label_agreement":null},{"id":"W2581697909","doi":"10.17140/prrmoj-4-132","title":"An Unbalanced Exon-Expression qPCR-based Assay for Detection of ALK Translocation (Fusion) in Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Pulmonary Research and Respiratory Medicine - Open Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"University of Toronto; Pfizer","keywords":"Chromosomal translocation; Lung cancer; Exon; Cancer research; Fusion gene; Molecular biology; Fusion; Biology; Medicine; Pathology; Gene; Genetics; Philosophy","score_opus":0.11236295800835251,"score_gpt":0.495412398560616,"score_spread":0.3830494405522635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581697909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97493905,0.008639605,0.0026507396,0.008000459,0.00041503768,0.0029627017,0.000033074033,0.000012535074,0.0023468195],"genre_scores_gemma":[0.9977303,0.0007819125,0.0002615029,0.0001546241,0.00050191244,0.00030607398,0.000020274681,0.000023036975,0.00022037065],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980799,0.00025710952,0.0004456624,0.0003038681,0.00057627045,0.0003372166],"domain_scores_gemma":[0.99815995,0.0001693563,0.0002513019,0.0004012426,0.00063006434,0.00038811812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029452292,0.0001384137,0.0003778156,0.00039181265,0.000981925,0.000087952896,0.00033347175,0.000103418424,0.00012150789],"category_scores_gemma":[0.00034700774,0.00009211131,0.000042009142,0.00016660515,0.00033275204,0.00053758646,0.000043029366,0.0004506771,3.978543e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005022948,0.0007019452,0.10221558,0.000407364,0.00007825861,0.00016197757,0.0005849784,0.00005943827,0.66447836,0.000024492427,0.0008181806,0.22544645],"study_design_scores_gemma":[0.037143588,0.01207918,0.75145775,0.010055226,0.00031053412,0.0001962912,0.0026835662,0.019084075,0.14409168,0.0011370626,0.021297846,0.0004632152],"about_ca_topic_score_codex":0.0006113184,"about_ca_topic_score_gemma":0.00028319564,"teacher_disagreement_score":0.64924216,"about_ca_system_score_codex":0.00020201823,"about_ca_system_score_gemma":0.0008096773,"threshold_uncertainty_score":0.75522727},"labels":[],"label_agreement":null},{"id":"W2581835979","doi":"10.1200/jco.2009.27.15_suppl.8011","title":"Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Gefitinib; Internal medicine; Tolerability; Oncology; Lung cancer; Randomized controlled trial; Population; Meta-analysis; Chemotherapy; Cancer; Adverse effect; Epidermal growth factor receptor","score_opus":0.2585591461781658,"score_gpt":0.5740744277265593,"score_spread":0.3155152815483935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581835979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279404,0.0033396445,0.00036157682,0.0018400749,0.00024340101,0.0006497504,0.00007006931,0.0000046469545,0.00069677195],"genre_scores_gemma":[0.98833877,0.0005859569,0.009904192,0.0008070195,0.00020206247,0.000011232002,0.000023696435,0.000011919504,0.000115140945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925948,0.0011548211,0.0053522564,0.00032003463,0.0003719016,0.00020618924],"domain_scores_gemma":[0.98912513,0.004579929,0.0050114365,0.00023909037,0.00067660154,0.00036781703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037791007,0.00020957194,0.006847561,0.00023992422,0.00002656946,0.000008956475,0.0001196498,0.00035747906,0.00021090994],"category_scores_gemma":[0.0019329811,0.00011789903,0.0015577395,0.00036640317,0.00011330022,0.00010399053,0.000019881893,0.00073915755,8.510452e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007507989,0.004606745,0.90082425,0.000014487964,0.048398882,0.000054146625,0.00018339611,0.0003325037,0.0000107794585,0.0000022538375,0.00027951266,0.03778507],"study_design_scores_gemma":[0.02678448,0.010054034,0.76350313,0.000046251505,0.19874474,0.0000011897781,0.00006608591,0.00030272052,0.000037099293,0.000027234395,0.00034805032,0.00008495554],"about_ca_topic_score_codex":0.0001459853,"about_ca_topic_score_gemma":0.0002914782,"teacher_disagreement_score":0.15034586,"about_ca_system_score_codex":0.00011336745,"about_ca_system_score_gemma":0.0011120678,"threshold_uncertainty_score":0.48077828},"labels":[],"label_agreement":null},{"id":"W2582067464","doi":"10.1371/journal.pone.0236580","title":"Molecular profiling of non-small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Pfizer Canada; Boehringer Ingelheim Canada; Pfizer; Roche Canada","keywords":"Profiling (computer programming); Lung cancer; Medicine; Computer science; Pathology","score_opus":0.03017478577138593,"score_gpt":0.2920056904559487,"score_spread":0.26183090468456277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582067464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025947,0.0013540514,0.0003417453,0.0016661781,0.000013365959,0.0004977773,0.000020921983,0.000025003674,0.0058214725],"genre_scores_gemma":[0.99124175,0.00008064249,0.0075595244,0.0006896471,0.00006976244,0.00007157988,0.000020261212,0.00001606425,0.00025078343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995522,0.000004970908,0.00010657978,0.00012118576,0.0001231011,0.00009198484],"domain_scores_gemma":[0.99969304,0.000007628547,0.00004160644,0.00009395587,0.00007721352,0.00008658216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000012198711,0.000060376082,0.00016549068,0.000017491333,0.000015247006,0.00000285346,0.000030475734,0.00002455265,0.000086457556],"category_scores_gemma":[0.000012225475,0.000052114923,0.000035895242,0.00009641853,0.000010604258,0.000016498636,0.000013477976,0.000057633802,0.000008189836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043319735,0.0007566172,0.06392231,0.0012984477,0.0006138273,0.000029855959,0.0010424225,0.00007821901,0.9318558,0.00003917756,0.000108954446,0.00021106162],"study_design_scores_gemma":[0.0012220847,0.00016880094,0.001788927,0.00025104563,0.0014107199,2.2508362e-7,0.00007293798,0.004593456,0.9904057,0.0000045909787,0.00002405029,0.000057458517],"about_ca_topic_score_codex":0.00006313618,"about_ca_topic_score_gemma":0.0000019760162,"teacher_disagreement_score":0.06213338,"about_ca_system_score_codex":0.000037565784,"about_ca_system_score_gemma":0.00013941462,"threshold_uncertainty_score":0.2125185},"labels":[],"label_agreement":null},{"id":"W2583817758","doi":"","title":"Lung Cancer Associations Are Enriched For Regulatory Variants In Non-Tumor Lung Tissue","year":2016,"lang":"en","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université Laval; University of British Columbia","funders":"","keywords":"Medicine; Lung; Lung cancer; Cancer; Pathology; Oncology; Internal medicine","score_opus":0.013906129563886992,"score_gpt":0.33060387017623943,"score_spread":0.31669774061235245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583817758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561454,0.0021348451,0.0047997446,0.0018602139,0.00039621894,0.0012059878,0.0031651398,0.000084579384,0.0007387203],"genre_scores_gemma":[0.99533135,0.00036545965,0.0011322665,0.00041487484,0.00041709814,0.0002001009,0.0012002903,0.00003633372,0.0009022534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987127,0.00004762507,0.0002704702,0.00046353228,0.00014883632,0.00035682786],"domain_scores_gemma":[0.99880356,0.0002860798,0.00016848286,0.00056035357,0.000044780812,0.00013675612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024554887,0.00017766883,0.00031225177,0.000090413574,0.00021484852,0.000034326684,0.00024444688,0.00005136548,0.000022379787],"category_scores_gemma":[0.00002274977,0.00012419606,0.000030137558,0.0001718804,0.00003332465,0.000269068,0.00014782046,0.00008617828,0.0000020785565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020178786,0.00022260581,0.9567199,0.00078928546,0.00065482926,0.000041578693,0.0042890324,0.00014416389,0.0060042455,0.00015014566,0.006072963,0.024709495],"study_design_scores_gemma":[0.0025809628,0.000037941947,0.9528568,0.0012021405,0.00046255084,0.000006721059,0.00025805604,0.040078454,0.000030449652,0.00012465552,0.0021786846,0.00018259836],"about_ca_topic_score_codex":0.0010962982,"about_ca_topic_score_gemma":0.00528599,"teacher_disagreement_score":0.03993429,"about_ca_system_score_codex":0.00017096417,"about_ca_system_score_gemma":0.00011131585,"threshold_uncertainty_score":0.5064568},"labels":[],"label_agreement":null},{"id":"W2585800361","doi":"10.1002/mc.22622","title":"Pathway‐analysis of published genome‐wide association studies of lung cancer: A potential role for the <i>CYP4F3</i> locus","year":2017,"lang":"en","type":"review","venue":"Molecular Carcinogenesis","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Duke Cancer Institute; National Cancer Institute; National Institutes of Health; Cancer Research UK; Wellcome Trust; National Human Genome Research Institute; World Health Organization","keywords":"Biology; Locus (genetics); Lung cancer; Genome-wide association study; Genetics; Genetic association; Genome; Computational biology; Evolutionary biology; Single-nucleotide polymorphism; Gene; Genotype; Oncology","score_opus":0.03801559440434384,"score_gpt":0.3836329988174015,"score_spread":0.34561740441305766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585800361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040247658,0.9943562,0.00073937693,0.0004500241,0.0002534599,0.0021826907,0.0014754732,0.000015904063,0.00012436946],"genre_scores_gemma":[0.007850342,0.98890847,0.00012416736,0.00010364943,0.000117457166,0.0014499604,0.00068990386,0.00006968809,0.0006863432],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976511,0.0001279909,0.00085600885,0.00048199488,0.0005695847,0.00031329278],"domain_scores_gemma":[0.9956229,0.00050647353,0.0017495389,0.0010226982,0.0010172644,0.00008116563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004614847,0.00038740126,0.002909721,0.0004596407,0.000211072,0.000042477746,0.00034414366,0.00024635092,0.000024159994],"category_scores_gemma":[0.00075972336,0.00025185477,0.0025755865,0.0006548345,0.00007768291,0.000057154193,0.000104947656,0.000118081494,5.733938e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010175368,0.000388739,0.012877592,0.032441083,0.3747673,0.000069056376,0.00090029405,0.0006437335,0.0005343037,0.000079162666,0.0017207139,0.5754763],"study_design_scores_gemma":[0.0013893768,0.00014244519,0.0026692736,0.002330988,0.5398039,0.000003879313,0.00014816379,0.00013880823,0.0005978749,0.000023156212,0.45234138,0.00041076753],"about_ca_topic_score_codex":0.0007090458,"about_ca_topic_score_gemma":0.0001527979,"teacher_disagreement_score":0.5750655,"about_ca_system_score_codex":0.0008244025,"about_ca_system_score_gemma":0.0011763418,"threshold_uncertainty_score":0.9999934},"labels":[],"label_agreement":null},{"id":"W2586322118","doi":"10.1093/annonc/mdw435.42","title":"Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Vancouver General Hospital; BC Cancer Agency; Ottawa Hospital; University of British Columbia; McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Gefitinib; Clinical endpoint; Discontinuation; Lung cancer; T790M; Gastroenterology; Oncology; Cancer; Clinical trial; Epidermal growth factor receptor","score_opus":0.06096577234198846,"score_gpt":0.4218890440377996,"score_spread":0.3609232716958111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586322118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98042995,0.00045938132,0.0002748873,0.007907005,0.0006170006,0.002243559,0.0027815863,0.00002234472,0.0052642715],"genre_scores_gemma":[0.99442977,0.00038983265,0.00033119836,0.0019698795,0.00047360617,0.00026502192,0.0015160689,0.000043131226,0.00058148976],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977687,0.00023580692,0.0006098478,0.00058315217,0.00036990762,0.00043256214],"domain_scores_gemma":[0.99721056,0.0010329188,0.0004827933,0.0006865909,0.00043392638,0.00015320457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035866088,0.00027629393,0.0006595509,0.000102787395,0.00010658357,0.000017683777,0.0003454221,0.00016574652,0.00048612358],"category_scores_gemma":[0.0001628143,0.00015702136,0.00009198386,0.0001974093,0.00016684516,0.00026447317,0.00012696681,0.00019574216,0.000017232129],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22985798,0.021000786,0.4694072,0.00024379043,0.0054595447,0.00056897773,0.012693519,0.00009880967,0.0017495023,0.00042855096,0.0889017,0.16958964],"study_design_scores_gemma":[0.5913413,0.018538553,0.36269745,0.0014002825,0.0025217913,0.000007662478,0.00074994523,0.00072203693,0.0031540836,0.00014257258,0.018039575,0.0006847094],"about_ca_topic_score_codex":0.0036486469,"about_ca_topic_score_gemma":0.0020841274,"teacher_disagreement_score":0.36148337,"about_ca_system_score_codex":0.00024481575,"about_ca_system_score_gemma":0.0012940179,"threshold_uncertainty_score":0.6403145},"labels":[],"label_agreement":null},{"id":"W2586406195","doi":"10.1016/s0923-7534(21)00604-9","title":"446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Afatinib; Erlotinib; Medicine; Lung cancer; Internal medicine; Oncology; Immunohistochemistry; Predictive marker; Adenocarcinoma; Carcinoma; KRAS; Epidermal growth factor receptor; Cancer","score_opus":0.020458390560395893,"score_gpt":0.3443730455752647,"score_spread":0.3239146550148688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586406195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996162,0.00025980017,0.00002522445,0.0011695937,0.000057403595,0.00075223565,0.00046932828,0.000003216608,0.0011012015],"genre_scores_gemma":[0.99920326,0.000012945609,0.00024282899,0.00020383539,0.000011015698,0.00004528949,0.00002916783,0.000011703155,0.00023992127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990619,0.00005447194,0.00040488126,0.0001839843,0.000119781515,0.00017500178],"domain_scores_gemma":[0.99872726,0.00028749456,0.00040497392,0.00021762608,0.0003076402,0.00005499421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015516671,0.000107856205,0.0005309334,0.00023635842,0.00002320431,0.0000011631379,0.0000696601,0.00005903171,0.00008580999],"category_scores_gemma":[0.00006987737,0.000057397552,0.00012042123,0.0003678068,0.00015314721,0.000042874177,0.000028713383,0.00003534143,1.4042057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001179618,0.0007390302,0.9925627,0.00022196907,0.0007022514,0.0000032359949,0.0006516471,0.000010490993,0.00073420774,0.000031183015,0.0007246279,0.002439007],"study_design_scores_gemma":[0.0077852537,0.0036568756,0.977794,0.000059871556,0.0015538903,0.0000015051398,0.00018458409,0.00019767953,0.008331121,0.000014461784,0.00035654535,0.000064231455],"about_ca_topic_score_codex":0.00017527443,"about_ca_topic_score_gemma":0.0005751175,"teacher_disagreement_score":0.014768751,"about_ca_system_score_codex":0.000046068293,"about_ca_system_score_gemma":0.00023016908,"threshold_uncertainty_score":0.23406042},"labels":[],"label_agreement":null},{"id":"W2586451500","doi":"10.1182/blood.v106.11.2451.2451","title":"Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rituximab; Adverse effect; Cohort; Anesthesia; Internal medicine; Lymphoma","score_opus":0.018739291878907587,"score_gpt":0.32345383506984593,"score_spread":0.3047145431909383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586451500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150336,0.00015647472,0.0003125872,0.003891301,0.00013773543,0.0015269767,0.000014720504,0.000062666935,0.0023941768],"genre_scores_gemma":[0.9928587,0.000033122276,0.004286968,0.000475721,0.0007095432,0.000107329666,0.00011155376,0.00001975999,0.0013972681],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989052,0.000031949752,0.0003139827,0.00025380254,0.00030812487,0.00018696452],"domain_scores_gemma":[0.99941146,0.000028461944,0.00007864545,0.00024565263,0.00007634815,0.00015942426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012944237,0.00012245496,0.00023693645,0.00017344345,0.000053726555,0.000018953937,0.000057263274,0.000083608626,0.00014799036],"category_scores_gemma":[0.000089495916,0.00010741363,0.00004549308,0.00022819267,0.000020443653,0.0001288469,0.000026928104,0.00011622781,0.00016030899],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0712612,0.091455765,0.29890752,0.00035671997,0.0017027913,0.000120954,0.038148526,0.00059667823,0.06399889,0.0005957406,0.007467485,0.4253877],"study_design_scores_gemma":[0.4667076,0.003531522,0.51181465,0.0004420034,0.0011475328,0.000041462332,0.00026257767,0.0005626454,0.004873992,0.00007859559,0.0101969,0.00034055675],"about_ca_topic_score_codex":0.00014666724,"about_ca_topic_score_gemma":0.00028439576,"teacher_disagreement_score":0.42504716,"about_ca_system_score_codex":0.00015236254,"about_ca_system_score_gemma":0.00016420527,"threshold_uncertainty_score":0.43802005},"labels":[],"label_agreement":null},{"id":"W2586598566","doi":"","title":"Comparing Tyrosine Phosphorylation Changes after Erlotinib Treatment betweem Drug Sensitive and Drug Resistant Non-small Cell Lung Cancer Lines by Mass Spectrometry","year":2010,"lang":"en","type":"dissertation","venue":"TSpace (University of Toronto)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Erlotinib; Drug; Lung cancer; Mass spectrometry; Pharmacology; Cancer research; Chemistry; Cancer; Medicine; Oncology; Internal medicine; Chromatography; Epidermal growth factor receptor","score_opus":0.008124479511050244,"score_gpt":0.26395056979350623,"score_spread":0.255826090282456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586598566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97736347,0.010911429,0.000051308947,0.0007605305,0.0003033542,0.0009613171,0.0002907091,0.000046094374,0.009311777],"genre_scores_gemma":[0.91811275,0.003916777,0.0020292276,0.000015983496,0.00012668267,0.000009076493,0.0013200701,0.000042504955,0.07442694],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99888176,0.000030042042,0.00013369255,0.0004739778,0.00022299058,0.00025753112],"domain_scores_gemma":[0.99898666,0.00004499954,0.0003311959,0.00024911258,0.00021567072,0.0001723539],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000059654714,0.0003569868,0.00065821654,0.00010012073,0.00019119821,0.000020918278,0.00006934682,0.00019649377,0.0008446865],"category_scores_gemma":[0.0000033331812,0.0003721025,0.00012621596,0.00007882207,0.000050848415,0.00013537765,0.000022610233,0.00018416217,0.0000027157146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012251197,0.0021753667,0.13813598,0.005759062,0.0068436894,0.00045335302,0.40927622,0.00002268489,0.38138413,0.000042137966,0.011729702,0.031926453],"study_design_scores_gemma":[0.0054903277,0.00046410316,0.89383113,0.001056534,0.0058619147,0.0000022419201,0.05240763,0.0003781443,0.038866103,0.000001976319,0.0010382609,0.0006016385],"about_ca_topic_score_codex":0.20297696,"about_ca_topic_score_gemma":0.49883312,"teacher_disagreement_score":0.75569516,"about_ca_system_score_codex":0.0011324952,"about_ca_system_score_gemma":0.00023255016,"threshold_uncertainty_score":0.9998731},"labels":[],"label_agreement":null},{"id":"W2586817040","doi":"10.1016/s0923-7534(21)00602-5","title":"444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ceritinib; Medicine; ALK inhibitor; Anaplastic lymphoma kinase; Lung cancer; Pemetrexed; Internal medicine; Docetaxel; Oncology; non-small cell lung cancer (NSCLC); Crizotinib; Chemotherapy","score_opus":0.021495627258612666,"score_gpt":0.36108279209954686,"score_spread":0.3395871648409342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586817040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420047,0.00020047177,0.0000072388243,0.000597805,0.000035076173,0.004398156,0.000044150172,0.000025620902,0.0004910339],"genre_scores_gemma":[0.99870783,0.00023638588,0.00018477572,0.00021072976,0.0000071274094,0.00050684606,0.00003904723,0.000040066927,0.00006717655],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99770397,0.00026005929,0.0009209869,0.00046208248,0.00029407235,0.00035883355],"domain_scores_gemma":[0.99810976,0.00040368704,0.0006682551,0.0003342394,0.00034138578,0.00014267738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025388546,0.0003062629,0.001602634,0.00034342852,0.000033192748,0.0000048683646,0.00006780683,0.0000473886,0.000045782243],"category_scores_gemma":[0.00027664923,0.00017058372,0.000079449725,0.00036645666,0.00024244681,0.00014107418,0.00001988627,0.00007335957,7.593944e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27909186,0.014964544,0.50030303,0.00007191021,0.00087488483,0.0005820733,0.0019192154,0.0000050485783,0.00017466067,0.00000532325,0.000030409241,0.20197703],"study_design_scores_gemma":[0.6468585,0.052454673,0.29739434,0.0005650485,0.0004213802,0.00004655,0.00075714634,0.000007376036,0.0010705156,0.000009863412,0.00023688744,0.00017769012],"about_ca_topic_score_codex":0.00090356334,"about_ca_topic_score_gemma":0.0010806937,"teacher_disagreement_score":0.36776668,"about_ca_system_score_codex":0.00013423954,"about_ca_system_score_gemma":0.00030898512,"threshold_uncertainty_score":0.69562024},"labels":[],"label_agreement":null},{"id":"W2586895513","doi":"10.5072/prism/28522","title":"Treatment at Disease-progression in EGFR-mutated NSCLC Patients: Results from a single Canadian Institution","year":2016,"lang":"en","type":"dissertation","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Institution; Internal medicine; Disease; Political science","score_opus":0.013408722322907612,"score_gpt":0.3108038023623191,"score_spread":0.29739508003941145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586895513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.898884,0.00052156654,0.0000018810654,0.00095269864,0.0010288735,0.0016831445,0.0028270425,0.000088251465,0.094012536],"genre_scores_gemma":[0.88266236,0.00013754633,0.00010583507,0.00009731775,0.00010672139,0.0002365636,0.08448254,0.000042245036,0.03212889],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982935,0.00003438286,0.00045053865,0.0005888306,0.00028897848,0.00034377587],"domain_scores_gemma":[0.9986874,0.000043399858,0.00017555339,0.0003656576,0.00017228974,0.0005557107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000022194245,0.00035063195,0.00036265873,0.00037531587,0.00017253206,0.000026223655,0.000054756594,0.00024120983,0.00033262934],"category_scores_gemma":[0.00009459797,0.00022544441,0.000117876356,0.00017985834,0.000027717871,0.00011099686,0.000007572674,0.00008059893,0.00020603837],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025410851,0.0066499044,0.28702882,0.00023483433,0.0016933891,0.001998418,0.008802372,0.000014811788,0.0017325404,0.00018154223,0.008589954,0.6576626],"study_design_scores_gemma":[0.03449702,0.001423268,0.91819364,0.004431991,0.0015993579,0.0000023720065,0.00041212415,0.000054518787,0.0020831134,0.00013519502,0.036457337,0.00071007165],"about_ca_topic_score_codex":0.23065299,"about_ca_topic_score_gemma":0.6169854,"teacher_disagreement_score":0.6569525,"about_ca_system_score_codex":0.008085032,"about_ca_system_score_gemma":0.001581212,"threshold_uncertainty_score":0.9957228},"labels":[],"label_agreement":null},{"id":"W2586921579","doi":"10.1093/annonc/mdw383.30","title":"Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Clinical endpoint; Gefitinib; Lung cancer; Tolerability; Population; Oncology; Randomized controlled trial; Gastroenterology; Cancer; Adverse effect; Epidermal growth factor receptor","score_opus":0.01587110195835063,"score_gpt":0.36530185834130474,"score_spread":0.3494307563829541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586921579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97714007,0.00028446323,0.00060907955,0.009780707,0.00015814931,0.008288373,0.00037565205,0.000045030574,0.003318505],"genre_scores_gemma":[0.9892698,0.00037867756,0.002385894,0.0010301069,0.00019622434,0.0031574809,0.00038973405,0.00007747392,0.0031146049],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99743223,0.00020239552,0.0008033872,0.00063971244,0.00035408343,0.00056817627],"domain_scores_gemma":[0.99701166,0.0009237264,0.0006219611,0.00035990702,0.0007779037,0.00030481108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025347163,0.00046355303,0.0015497181,0.000315316,0.000115139526,0.000012795934,0.00012147414,0.00018273667,0.000555911],"category_scores_gemma":[0.00014046313,0.0002629271,0.00019897452,0.0003816993,0.00021661277,0.00018895895,0.0000330209,0.00012925161,0.000038983217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9189696,0.008793841,0.004907424,0.00014886743,0.002272485,0.0002465192,0.0054912646,0.0008106018,0.00033641022,0.000020453974,0.002003135,0.055999413],"study_design_scores_gemma":[0.94753695,0.03903473,0.001835867,0.001223618,0.001658856,0.000010324149,0.00020740692,0.00025167386,0.004527563,0.000010478218,0.0033339097,0.0003686306],"about_ca_topic_score_codex":0.00043172378,"about_ca_topic_score_gemma":0.0014825326,"teacher_disagreement_score":0.05563078,"about_ca_system_score_codex":0.0006476472,"about_ca_system_score_gemma":0.0014083055,"threshold_uncertainty_score":0.9999823},"labels":[],"label_agreement":null},{"id":"W2587089540","doi":"10.1016/s0923-7534(21)00598-6","title":"440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Eisai; Ariad Pharmaceuticals; Gilead Sciences; Chugai Pharmaceutical; Amgen; Pfizer; Genentech; AstraZeneca; Allergan; Eli Lilly and Company","keywords":"Medicine; Afatinib; Gefitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Gastroenterology; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.03230020250565641,"score_gpt":0.3771746745983067,"score_spread":0.3448744720926503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587089540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713058,0.00014693502,0.000174265,0.0073614186,0.00026564414,0.0007267898,0.000855754,0.00003038704,0.01913299],"genre_scores_gemma":[0.9959074,0.000119333745,0.00078167353,0.0015064919,0.0001328395,0.000078656994,0.0007917455,0.000031817493,0.0006500077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983003,0.00013443126,0.0004657727,0.0004187981,0.00031908683,0.00036160267],"domain_scores_gemma":[0.9982456,0.0005221719,0.000299866,0.00033672815,0.00044209947,0.0001535278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016701706,0.00021477429,0.0005710639,0.00015588591,0.000054419615,0.000008928476,0.00012625272,0.0001539708,0.00046389218],"category_scores_gemma":[0.00016517517,0.00014256506,0.00008076085,0.00016275438,0.00014688571,0.00023895144,0.000053105454,0.00012531727,0.00005242038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077156373,0.004606398,0.77943224,0.00008091196,0.0017768516,0.000430491,0.003969221,0.00002414092,0.0008665811,0.0023027323,0.014532841,0.18426193],"study_design_scores_gemma":[0.020620896,0.0060334615,0.9602947,0.0004865411,0.00031636373,0.000008404262,0.00023660682,0.000022903334,0.0017918953,0.00048835063,0.009457861,0.00024199011],"about_ca_topic_score_codex":0.0013213224,"about_ca_topic_score_gemma":0.00065251294,"teacher_disagreement_score":0.18401994,"about_ca_system_score_codex":0.00021903418,"about_ca_system_score_gemma":0.00048441466,"threshold_uncertainty_score":0.58136344},"labels":[],"label_agreement":null},{"id":"W2587099123","doi":"10.1093/annonc/mdw435.41","title":"Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ceritinib; Medicine; Crizotinib; Anaplastic lymphoma kinase; Internal medicine; ALK inhibitor; non-small cell lung cancer (NSCLC); Lung cancer; Gastroenterology; Oncology","score_opus":0.02151021713983857,"score_gpt":0.34944480111477094,"score_spread":0.32793458397493236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587099123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231315,0.0008450646,0.000011008931,0.0016745132,0.000071767834,0.0029008086,0.0005443681,0.00003491938,0.0016043957],"genre_scores_gemma":[0.9974869,0.00077642326,0.0001187209,0.00083256623,0.000054951208,0.0003761418,0.00010570785,0.00005366428,0.00019492663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805444,0.00017995296,0.0005331277,0.00055951666,0.00024499913,0.00042796796],"domain_scores_gemma":[0.99819213,0.00045567247,0.0004132329,0.0004347204,0.00031191003,0.00019231427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017795093,0.0003366818,0.0007359193,0.00011183609,0.00009878013,0.000012845958,0.00013555073,0.000051822222,0.00007564439],"category_scores_gemma":[0.00005630695,0.00017778747,0.000055722343,0.00022336945,0.00022722787,0.00012544825,0.000025967822,0.000109165325,0.0000030381882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06539376,0.0128545305,0.6278999,0.00012437599,0.0014077867,0.0008096793,0.0069750533,0.000018053519,0.0011497333,0.0000037223624,0.0022846733,0.28107876],"study_design_scores_gemma":[0.2529891,0.03891126,0.686983,0.001292716,0.00095087424,0.00002769997,0.0015999487,0.000041405357,0.0053256936,0.0000036928723,0.011469429,0.000405211],"about_ca_topic_score_codex":0.002950405,"about_ca_topic_score_gemma":0.0031364819,"teacher_disagreement_score":0.28067356,"about_ca_system_score_codex":0.00019442373,"about_ca_system_score_gemma":0.0006539436,"threshold_uncertainty_score":0.72499627},"labels":[],"label_agreement":null},{"id":"W2587420003","doi":"10.1093/annonc/mdw611","title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Chugai Pharmaceutical; Genentech; Ono Pharmaceutical; Astellas Pharma; Chinese University of Hong Kong; GlaxoSmithKline; AstraZeneca Korea; Clovis Oncology; Vertex Pharmaceuticals; International Association for the Study of Lung Cancer; Amgen; ACEA Biosciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Gefitinib; Afatinib; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Epidermal growth factor receptor; T790M; Proportional hazards model; Gastroenterology; Confidence interval; Cancer","score_opus":0.08223081129384406,"score_gpt":0.4570319687057121,"score_spread":0.37480115741186804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587420003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98536754,0.00037978555,0.00004137723,0.0030956154,0.0009961897,0.0018509192,0.0018154548,0.000011937738,0.006441195],"genre_scores_gemma":[0.9958762,0.0002306448,0.00048651788,0.0005101748,0.00030186147,0.000166329,0.0022301245,0.00002617568,0.00017199013],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985179,0.000103652674,0.0003949507,0.00042588197,0.0002565163,0.00030111134],"domain_scores_gemma":[0.99750996,0.0005897768,0.00058476196,0.00088638684,0.00032643744,0.00010266271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021109775,0.00019800794,0.00051348325,0.00005275829,0.00021849229,0.000028456192,0.00041001232,0.00010947762,0.00013105174],"category_scores_gemma":[0.00021395019,0.00013740858,0.0000628543,0.000069753056,0.00014539,0.00028416663,0.00013672494,0.0001991474,0.0000045296215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43746075,0.012344293,0.37311152,0.00015667733,0.004163429,0.00038283356,0.009790896,0.00039111063,0.00025323243,0.00020164969,0.0150372,0.1467064],"study_design_scores_gemma":[0.5263442,0.011044046,0.45454535,0.000318082,0.0013191412,9.300358e-7,0.0006896824,0.0009254987,0.0006052862,0.00003582943,0.0038857814,0.00028622494],"about_ca_topic_score_codex":0.0048604123,"about_ca_topic_score_gemma":0.0032561102,"teacher_disagreement_score":0.14642017,"about_ca_system_score_codex":0.00015195076,"about_ca_system_score_gemma":0.0009045755,"threshold_uncertainty_score":0.7347522},"labels":[],"label_agreement":null},{"id":"W2588062955","doi":"10.1093/annonc/mdw383.52","title":"Addressing disease progression in EGFRmut+ NSCLC patients","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Progression-free survival; Lung cancer; Discontinuation; Log-rank test; Adenocarcinoma; Progressive disease; Chemotherapy; Survival analysis; Cancer","score_opus":0.1087581454542716,"score_gpt":0.49244884498441693,"score_spread":0.38369069953014534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588062955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97500855,0.00046063008,0.00001852799,0.010764488,0.00012616563,0.00033555427,0.000021732887,0.000014702943,0.01324963],"genre_scores_gemma":[0.99862343,0.00011628894,0.00018847304,0.0006334664,0.000039679555,0.000040419978,0.000018233537,0.0000074338404,0.00033258394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994172,0.00003391171,0.0001738582,0.00012458423,0.00010344845,0.00014699419],"domain_scores_gemma":[0.99951464,0.000052944437,0.00008570668,0.00011627754,0.000120043675,0.000110376764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006259587,0.00005922148,0.00016604147,0.000083604995,0.000019394409,0.0000015395885,0.00003129723,0.000046059948,0.00008622722],"category_scores_gemma":[0.00011940499,0.00003395994,0.00004164454,0.000073152696,0.000060635022,0.00006359586,0.000019709407,0.00003146353,0.000015507514],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045335817,0.0010106306,0.34390298,0.000027923026,0.000029661942,0.000044105127,0.0001560035,2.817361e-7,0.00036571568,0.0001317506,0.0022685782,0.651609],"study_design_scores_gemma":[0.0054309745,0.0017726296,0.9464365,0.000783849,0.000064324515,0.0000016247066,0.00002732468,0.000003991803,0.0014369299,0.00046014434,0.04351625,0.000065427965],"about_ca_topic_score_codex":0.000014458378,"about_ca_topic_score_gemma":0.000008778719,"teacher_disagreement_score":0.65154356,"about_ca_system_score_codex":0.000064416934,"about_ca_system_score_gemma":0.000246407,"threshold_uncertainty_score":0.13848461},"labels":[],"label_agreement":null},{"id":"W2588078738","doi":"10.1093/annonc/mdw383.27","title":"Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Adverse effect; Cohort; Internal medicine; Lung cancer; Cancer; Health care; Population; Disease; Emergency medicine; Environmental health","score_opus":0.02375497880615168,"score_gpt":0.3987762668068963,"score_spread":0.37502128800074463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588078738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996883,0.00034117117,0.0000020885716,0.00078778417,0.00007884249,0.0008605497,0.00025563128,0.000007675362,0.00078325416],"genre_scores_gemma":[0.99827063,0.00082877075,0.000078641046,0.00032425503,0.000026026692,0.00007232342,0.000029917815,0.00002168195,0.0003477465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990495,0.00004403236,0.0002962716,0.00021444443,0.00013504206,0.00026070763],"domain_scores_gemma":[0.99905807,0.00006038181,0.00026686638,0.00020492951,0.00029896223,0.000110821486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005381065,0.00015042051,0.0004178304,0.00013642933,0.000022833945,4.1038518e-7,0.000060287064,0.00008874022,0.0001968222],"category_scores_gemma":[0.00000983372,0.0000872007,0.000091896145,0.0001311626,0.000033239146,0.000072914874,0.000012861683,0.00008388686,0.000002269775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056631626,0.0014136686,0.9549325,0.00013243192,0.0002801708,0.000012527269,0.0007305709,0.00015059105,0.0014432926,0.0000022514475,0.00009883628,0.035140004],"study_design_scores_gemma":[0.019553257,0.011368728,0.9632443,0.0006101613,0.000035312867,0.0000012978292,0.000039602084,0.0000022501724,0.004916918,0.00000554976,0.0001340721,0.00008855461],"about_ca_topic_score_codex":0.0006242721,"about_ca_topic_score_gemma":0.0006059171,"teacher_disagreement_score":0.03505145,"about_ca_system_score_codex":0.00045682353,"about_ca_system_score_gemma":0.00064115744,"threshold_uncertainty_score":0.35559413},"labels":[],"label_agreement":null},{"id":"W2588216634","doi":"10.1093/annonc/mdw383.96","title":"A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Pemetrexed; Internal medicine; Oncology; Metastatic breast cancer; Taxane; Clinical endpoint; Phases of clinical research; Cancer; Chemotherapy; Breast cancer; Randomized controlled trial","score_opus":0.034498615738255564,"score_gpt":0.3920148553917564,"score_spread":0.3575162396535008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588216634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994241,0.00022038659,0.0001946623,0.00077468,0.00011413285,0.003807775,0.00020344499,0.00001827382,0.00042562105],"genre_scores_gemma":[0.9965958,0.00020398694,0.0015660402,0.00017302785,0.000015399144,0.00053936895,0.00008036223,0.000051079453,0.00077494705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974977,0.00021397788,0.000812597,0.0005452283,0.00045075372,0.0004797898],"domain_scores_gemma":[0.99731797,0.0005208822,0.0007148687,0.0003555099,0.00092974363,0.00016104849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002479674,0.000371834,0.0012311838,0.0005524049,0.000050224284,0.000007613713,0.00016067528,0.00009856573,0.00022173596],"category_scores_gemma":[0.00014916652,0.00019322043,0.00006301845,0.0011145597,0.00015897842,0.00026478886,0.000048073885,0.00016518057,0.0000025626757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.550191,0.107858084,0.15342087,0.00086829194,0.003487645,0.001523249,0.012122042,0.00032523283,0.0014080121,0.000020622409,0.00041477784,0.16836022],"study_design_scores_gemma":[0.5168155,0.23688926,0.23005249,0.0018663233,0.0018711874,0.000013846443,0.005304809,0.00021787632,0.0062896595,0.000010254757,0.00017862885,0.0004902044],"about_ca_topic_score_codex":0.0015933602,"about_ca_topic_score_gemma":0.01962021,"teacher_disagreement_score":0.16787001,"about_ca_system_score_codex":0.0004645898,"about_ca_system_score_gemma":0.0017998905,"threshold_uncertainty_score":0.99826914},"labels":[],"label_agreement":null},{"id":"W2588381983","doi":"10.1093/annonc/mdw383.38","title":"Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Erlotinib; Gastroenterology; Population; Lung cancer; Oncology; Epidermal growth factor receptor; Cancer","score_opus":0.1378102222120783,"score_gpt":0.4826661338630271,"score_spread":0.34485591165094875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588381983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807869,0.0013252912,0.000022464017,0.002665115,0.00024332567,0.012874388,0.00051689165,0.000002206444,0.00156337],"genre_scores_gemma":[0.9975995,0.00011999927,0.00021027344,0.00004719576,0.000058563146,0.0016908058,0.000018159615,0.000013101913,0.00024239568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99785614,0.00054363767,0.0009128002,0.00018465423,0.00033118928,0.00017160323],"domain_scores_gemma":[0.99450654,0.0031627151,0.0011552853,0.0004579353,0.0006898252,0.000027680191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019587209,0.0001519099,0.00089422095,0.00006747969,0.00004234978,0.000002260373,0.0002483626,0.000086930595,0.00008850931],"category_scores_gemma":[0.00096137804,0.00006406916,0.00021081808,0.00016940435,0.00029039377,0.00006150368,0.00003114276,0.000048878654,2.0102898e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85989153,0.01613027,0.0009870194,0.0003792858,0.0009349297,0.0000028817299,0.005126714,0.00011802877,0.038713492,0.00021336717,0.00079168566,0.07671079],"study_design_scores_gemma":[0.82699203,0.02882641,0.0011603492,0.00008290046,0.002251141,0.000002548026,0.0005916222,0.000757863,0.13883641,0.00013909875,0.00030378046,0.000055825425],"about_ca_topic_score_codex":0.00020988863,"about_ca_topic_score_gemma":0.00021306452,"teacher_disagreement_score":0.10012291,"about_ca_system_score_codex":0.00013231546,"about_ca_system_score_gemma":0.0014428599,"threshold_uncertainty_score":0.26126644},"labels":[],"label_agreement":null},{"id":"W2588521106","doi":"10.1093/annonc/mdw332.04","title":"Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Internal medicine; ALK inhibitor; Adverse effect; Phases of clinical research; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Lung cancer; Randomized controlled trial; Oncology; Refractory (planetary science); Gastroenterology; Surgery; Clinical trial","score_opus":0.0444454593184638,"score_gpt":0.4245253480343797,"score_spread":0.3800798887159159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588521106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733848,0.0020160207,0.00009175384,0.007664622,0.00054909923,0.0026388175,0.00070118083,0.000026652044,0.012927033],"genre_scores_gemma":[0.9936623,0.0028529093,0.00044978448,0.0009586973,0.0004359626,0.00024291786,0.0001341711,0.000029371107,0.0012339015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99768007,0.00029731638,0.0009992676,0.000477633,0.00017980908,0.00036589956],"domain_scores_gemma":[0.9964878,0.002298317,0.00050691195,0.00029946823,0.00018795556,0.00021956056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006409144,0.00023918533,0.001231543,0.0001571587,0.000055076292,0.0000076562665,0.00009575033,0.0002244518,0.00026534527],"category_scores_gemma":[0.0006968916,0.00015626325,0.00018767844,0.00012733336,0.00026963954,0.00009482873,0.00004749633,0.00017996045,0.000009647405],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8619995,0.0029807633,0.00032299783,0.000042616113,0.0006072974,0.000113055794,0.002771485,0.000003380887,0.0067629674,0.000031197364,0.0041389675,0.12022578],"study_design_scores_gemma":[0.96755844,0.003935066,0.0027839192,0.00041891594,0.00068755785,0.0000049470596,0.000095100724,0.00006609304,0.0037355707,0.00007629563,0.02046055,0.00017754153],"about_ca_topic_score_codex":0.0030766511,"about_ca_topic_score_gemma":0.0005310491,"teacher_disagreement_score":0.12004824,"about_ca_system_score_codex":0.0001287839,"about_ca_system_score_gemma":0.001025672,"threshold_uncertainty_score":0.63722306},"labels":[],"label_agreement":null},{"id":"W2588842038","doi":"10.1093/annonc/mdw382.14","title":"The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Population; Positron emission tomography; Hazard ratio; Regimen; Oncology; Internal medicine; Subgroup analysis; Progression-free survival; Nuclear medicine; Stage (stratigraphy); Lung cancer; Randomized controlled trial; Pemetrexed; Carboplatin; Etoposide; Cisplatin; Chemotherapy; Confidence interval","score_opus":0.038459242891521826,"score_gpt":0.46535531133918057,"score_spread":0.42689606844765876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588842038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894007,0.00049289415,0.000005794425,0.0066672144,0.0000689689,0.0010222067,0.000053903546,0.000009307714,0.00227903],"genre_scores_gemma":[0.9993124,0.00031080097,0.000014231021,0.00010095633,0.000038398593,0.00006547936,0.000010890852,0.000010714556,0.00013613656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986754,0.00027413078,0.0003205675,0.00019834531,0.00029398125,0.00023759306],"domain_scores_gemma":[0.9986292,0.00061554596,0.00021182119,0.00033779058,0.0001297761,0.000075841504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879606,0.00013744955,0.00034840163,0.00009484883,0.000101891,0.000009380374,0.00016310834,0.00004537709,0.000016942831],"category_scores_gemma":[0.00012692214,0.000053472108,0.00009629204,0.00015497365,0.00014086434,0.00006791618,0.00005135851,0.00010639785,3.7751255e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011482168,0.0150969755,0.6421963,0.000057937294,0.0012197779,0.0001280213,0.0066902065,0.0000028245267,0.02067642,0.00041502365,0.023131242,0.27890313],"study_design_scores_gemma":[0.070194274,0.08630769,0.81988215,0.0007176687,0.00048633618,0.000033580553,0.0056365575,0.00003969918,0.00662542,0.0018052089,0.007940109,0.00033132182],"about_ca_topic_score_codex":0.00044111555,"about_ca_topic_score_gemma":0.00006616356,"teacher_disagreement_score":0.2785718,"about_ca_system_score_codex":0.00005496213,"about_ca_system_score_gemma":0.00021683742,"threshold_uncertainty_score":0.21805292},"labels":[],"label_agreement":null},{"id":"W2588936898","doi":"10.1200/jco.2005.23.16_suppl.7018","title":"Symptom response in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib: Quality of life analysis of the NCIC CTG BR.21 trial","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Clinical endpoint; Quality of life (healthcare); Internal medicine; Placebo; Lung cancer; Palliative care; Discontinuation; Randomized controlled trial; Cancer; Pathology; Epidermal growth factor receptor","score_opus":0.06928640520948959,"score_gpt":0.48546743199420195,"score_spread":0.41618102678471236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588936898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958153,0.000250148,0.000025802605,0.0023319896,0.0003080755,0.0005964656,0.000038418973,0.000003077371,0.0006307739],"genre_scores_gemma":[0.9979992,0.00015712497,0.00048251223,0.0007312063,0.00026116075,0.000014776298,0.000005395071,0.0000134543825,0.0003351949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948866,0.0011874068,0.0031020981,0.00019062836,0.00044327634,0.00019000101],"domain_scores_gemma":[0.99256873,0.0027991855,0.0034127196,0.000290118,0.0006987471,0.00023049329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028132095,0.0001456053,0.0019587125,0.0002967824,0.000029346902,0.0000035888547,0.00017867617,0.00025221522,0.00012941023],"category_scores_gemma":[0.0021128252,0.00007875239,0.0007189239,0.0007605391,0.00017192162,0.000064266,0.00003087473,0.0004820164,9.1477096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19506054,0.005036831,0.79019326,0.00002918657,0.0027578874,0.000010581693,0.0005592102,0.0009802028,0.00008255773,0.0000028115926,0.0002479892,0.005038943],"study_design_scores_gemma":[0.10000849,0.008718612,0.8838888,0.00012968731,0.0060471045,0.0000012183467,0.000119933735,0.0002737255,0.00010042145,0.0000017449076,0.0006442952,0.00006599592],"about_ca_topic_score_codex":0.0006355946,"about_ca_topic_score_gemma":0.0015441782,"teacher_disagreement_score":0.09505205,"about_ca_system_score_codex":0.00043098387,"about_ca_system_score_gemma":0.0038169562,"threshold_uncertainty_score":0.6771116},"labels":[],"label_agreement":null},{"id":"W2589784053","doi":"10.1200/jco.2005.23.16_suppl.7007","title":"Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Immunohistochemistry; Epidermal growth factor receptor; Gefitinib; Erlotinib Hydrochloride; KRAS; Internal medicine; Cancer; Oncology; Polysomy; Copy-number variation; Exon; Fluorescence in situ hybridization; EGFR inhibitors; Chromogenic in situ hybridization; Cancer research; Pathology; Gene expression; In situ hybridization; Gene; Biology; Genetics","score_opus":0.09834642691559599,"score_gpt":0.4801009994690773,"score_spread":0.38175457255348133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589784053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958847,0.00017126527,0.000021470703,0.0023870035,0.00041140718,0.00095649064,0.00007957079,0.0000014389517,0.000086643835],"genre_scores_gemma":[0.99777645,0.00012069166,0.0012696971,0.0004303231,0.00030225102,0.0000311259,0.0000181477,0.000009312454,0.000041976582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99363375,0.0014174065,0.0039600893,0.00021087434,0.00061453023,0.00016335798],"domain_scores_gemma":[0.9946349,0.0013820888,0.0030722246,0.00012345806,0.0005945806,0.00019269742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033786602,0.00013875015,0.0020992511,0.0002471518,0.000024683848,0.0000033333974,0.00011703743,0.0002468017,0.00007160039],"category_scores_gemma":[0.0068349284,0.000075384996,0.00038880832,0.00049586257,0.00018397612,0.00011527351,0.00003049349,0.000480832,9.51108e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056395944,0.0029902477,0.92260325,0.000023534385,0.002229581,0.000033457283,0.00010010967,0.00048219683,0.00079650834,0.000024044364,0.00032939514,0.0139917545],"study_design_scores_gemma":[0.090809755,0.0045463135,0.9001417,0.00021332987,0.0014360298,0.000002489397,0.00001947223,0.000112189584,0.001229522,0.000012045386,0.0014017847,0.00007533787],"about_ca_topic_score_codex":0.009749236,"about_ca_topic_score_gemma":0.06844038,"teacher_disagreement_score":0.058691144,"about_ca_system_score_codex":0.0005340078,"about_ca_system_score_gemma":0.0055960375,"threshold_uncertainty_score":0.99684495},"labels":[],"label_agreement":null},{"id":"W2590117034","doi":"10.1200/jco.2013.31.4_suppl.395","title":"Association of tissue factor pathway inhibitor gene polymorphism -33T→C with disease-free survival in colorectal cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Genotype; Tissue factor pathway inhibitor; Colorectal cancer; Internal medicine; Single-nucleotide polymorphism; Gastroenterology; Proportional hazards model; Hazard ratio; Factor V; Factor V Leiden; Oncology; Cancer; Tissue factor; Gene; Biology; Thrombosis; Venous thrombosis; Genetics; Coagulation","score_opus":0.04433500510912326,"score_gpt":0.42100574124322204,"score_spread":0.3766707361340988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590117034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98323053,0.00047032032,0.000023531375,0.014049292,0.001088751,0.00035993863,0.000059909107,0.000005619636,0.0007121227],"genre_scores_gemma":[0.9967058,0.0002738486,0.0009417727,0.00036068875,0.00093033037,0.000023496812,0.000006942576,0.000015111858,0.0007420607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772006,0.00021436336,0.0013182962,0.00013541606,0.0004230469,0.00018881015],"domain_scores_gemma":[0.99656785,0.0009153921,0.0015249786,0.000115754505,0.0005392736,0.0003367646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056197966,0.00011119655,0.00096060097,0.000102153645,0.000021174043,0.000006379649,0.00010393096,0.00021216231,0.0003789734],"category_scores_gemma":[0.001471975,0.00007178854,0.00016705166,0.00014106336,0.00007869954,0.00013778337,0.000026987816,0.00039705445,0.00000885015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022952026,0.0018202387,0.944074,0.000028794237,0.00071496965,0.0002591459,0.00022107083,0.000019707524,0.0037852726,0.000029967767,0.002764018,0.043987628],"study_design_scores_gemma":[0.011274854,0.0062522255,0.9746183,0.00009907159,0.00035820535,0.000017529062,0.000073649855,0.000018084786,0.0015984268,0.00013748529,0.005478455,0.00007370888],"about_ca_topic_score_codex":0.00052223995,"about_ca_topic_score_gemma":0.0006832043,"teacher_disagreement_score":0.04391392,"about_ca_system_score_codex":0.00063891284,"about_ca_system_score_gemma":0.0028687739,"threshold_uncertainty_score":0.50890815},"labels":[],"label_agreement":null},{"id":"W2591951146","doi":"10.1200/jco.2012.30.15_suppl.2572","title":"Does the addition of molecular targeted therapy to standard treatments lead to better or worse outcomes overall? A systematic review of EGFR-targeted therapies used in combination with standard treatments.","year":2012,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Statistics Canada; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Erlotinib; Cetuximab; Targeted therapy; Progression-free survival; Rash; Lapatinib; Combination therapy; Pemetrexed; Gefitinib; Cancer; Trastuzumab; Breast cancer; Chemotherapy; Colorectal cancer; Epidermal growth factor receptor","score_opus":0.0988626422243408,"score_gpt":0.4955390530168683,"score_spread":0.39667641079252747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591951146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009196218,0.9765166,0.00015963247,0.004973074,0.00049754564,0.008136562,0.00044791208,0.000010528242,0.00006192392],"genre_scores_gemma":[0.0031630597,0.9909362,0.0025215214,0.002287817,0.000094648036,0.0004858624,0.00013428151,0.00006256407,0.00031404747],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9922574,0.0016696573,0.004606214,0.00028143806,0.00089738466,0.00028790813],"domain_scores_gemma":[0.9916087,0.0020921007,0.0047351923,0.00050691253,0.00080702227,0.0002501202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021527747,0.00048887444,0.008381665,0.00038327716,0.00004131222,0.000011804018,0.0002498828,0.00033647596,0.00023930472],"category_scores_gemma":[0.0010610998,0.00016481815,0.0011782103,0.0004980519,0.00011149049,0.00012777049,0.000028855657,0.0004593126,0.0000055776513],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009955746,0.0059693987,0.0045029577,0.16990477,0.029550612,0.00040851417,0.0016929888,0.0000029329913,0.0000066309963,0.00004610754,0.0006945937,0.7772648],"study_design_scores_gemma":[0.033355407,0.0643721,0.0071167448,0.5836351,0.051093623,0.00013798427,0.00037897745,5.635379e-7,0.00004358012,0.000105699255,0.25924402,0.00051619124],"about_ca_topic_score_codex":0.000032308286,"about_ca_topic_score_gemma":0.00005021916,"teacher_disagreement_score":0.77674854,"about_ca_system_score_codex":0.0013610673,"about_ca_system_score_gemma":0.0022469568,"threshold_uncertainty_score":0.6721089},"labels":[],"label_agreement":null},{"id":"W2592854110","doi":"10.1200/jco.2013.31.15_suppl.8108","title":"Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced <i>ALK</i>+ non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Docetaxel; Pemetrexed; ALK inhibitor; Internal medicine; Clinical endpoint; Chemotherapy; Oncology; Quality of life (healthcare); Performance status; Randomization; Clinical trial; Cisplatin","score_opus":0.08649349253772255,"score_gpt":0.49274907376296934,"score_spread":0.4062555812252468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592854110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974827,0.00034262252,0.00003590694,0.00026089585,0.00017458171,0.0012742798,0.000012574187,0.00000320129,0.00041322256],"genre_scores_gemma":[0.99887437,0.00016365445,0.00056570675,0.00026467518,0.000063036896,0.000026274252,0.0000032020257,0.000017031414,0.000022037828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957769,0.00026572373,0.0032410307,0.0002013101,0.0003383867,0.00017665503],"domain_scores_gemma":[0.99341816,0.00084316154,0.0044652433,0.00022484161,0.000758149,0.00029047253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006482615,0.00017367455,0.0021094834,0.0001460417,0.000016772121,0.0000033003869,0.00008128971,0.00012615752,0.0000879202],"category_scores_gemma":[0.00031415923,0.00010599412,0.00024633374,0.00018196131,0.00014534242,0.000078670826,0.000018967565,0.00032867532,1.7907666e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02919088,0.04327815,0.8739445,0.00012257473,0.0022352783,0.000043597858,0.0040210453,0.00061545015,0.006361507,9.972218e-7,0.00014843246,0.040037546],"study_design_scores_gemma":[0.11649499,0.0855348,0.79443944,0.00035239026,0.00068602816,0.000008702907,0.0015195842,0.0001397305,0.0006863129,0.0000038074004,0.00004252645,0.00009171518],"about_ca_topic_score_codex":0.0017152282,"about_ca_topic_score_gemma":0.00029851386,"teacher_disagreement_score":0.08730411,"about_ca_system_score_codex":0.00022140745,"about_ca_system_score_gemma":0.0017023549,"threshold_uncertainty_score":0.4322315},"labels":[],"label_agreement":null},{"id":"W2593722736","doi":"10.3747/co.24.3266","title":"Rate of Egfr Mutation Testing for Patients with Nonsquamous Non-Small-Cell Lung Cancer with Implementation of Reflex Testing by Pathologists","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Institute of Health Services and Policy Research; Thunder Bay Regional Health Sciences Centre; Institute for Work & Health; Southlake Regional Health Center; Health Sciences North; University of Toronto; Toronto East General Hospital; Royal Victoria Regional Health Centre; North York General Hospital; Sunnybrook Health Science Centre","funders":"AstraZeneca Canada","keywords":"Medicine; Reflex; Internal medicine; Oncology; Lung cancer; Cancer; Epidermal growth factor receptor; Database","score_opus":0.07684679117836438,"score_gpt":0.46125812271747724,"score_spread":0.3844113315391129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593722736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952583,0.00021981019,0.0015943133,0.000118059186,0.00019670969,0.0017403814,0.00023352889,0.00001600527,0.0006229224],"genre_scores_gemma":[0.9890213,0.000011394765,0.010072404,0.00002357338,0.00004851249,0.00047070015,0.00029344406,0.000021854676,0.000036830224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909776,0.00002877429,0.0003184642,0.00024490416,0.00010356891,0.00020650061],"domain_scores_gemma":[0.9977996,0.00019811605,0.00091721915,0.00021287208,0.00081297976,0.000059222646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013047078,0.00014168193,0.0003168971,0.00006164538,0.00017543371,0.000010224332,0.000079249214,0.00004978593,0.000010043584],"category_scores_gemma":[0.0001321853,0.00010179265,0.000028355134,0.00008977998,0.00011411758,0.00009154002,0.000024163422,0.00007742886,3.6560525e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027597038,0.0005912139,0.8633379,0.00052049157,0.000078571094,0.000004708246,0.0007021457,0.000032312055,0.0024350989,0.000006264221,0.00024116575,0.13177417],"study_design_scores_gemma":[0.018865215,0.008531282,0.9609913,0.0005464138,0.0014744331,0.0000068751465,0.00056144135,0.00070859346,0.007679175,0.000021330186,0.00042200752,0.00019193953],"about_ca_topic_score_codex":0.0005961174,"about_ca_topic_score_gemma":0.0002453178,"teacher_disagreement_score":0.13158223,"about_ca_system_score_codex":0.0002604483,"about_ca_system_score_gemma":0.0005879441,"threshold_uncertainty_score":0.41509837},"labels":[],"label_agreement":null},{"id":"W2594051854","doi":"10.1016/j.ctarc.2017.02.005","title":"Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC","year":2017,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; BC Research (Canada); BC Cancer Agency","funders":"Boehringer Ingelheim; AstraZeneca","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Erlotinib Hydrochloride; Oncology; EGFR inhibitors; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Receptor","score_opus":0.16822991829360176,"score_gpt":0.49793433245532476,"score_spread":0.329704414161723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594051854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8528196,0.03947805,0.0000027697595,0.095616736,0.00013832976,0.0012329428,0.00009085634,0.00003905555,0.01058166],"genre_scores_gemma":[0.9533739,0.043812215,0.00019237502,0.00009507071,0.00017504892,0.00066117547,0.00016206157,0.000021068034,0.0015070502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890167,0.00012235115,0.00017636946,0.00027727443,0.00020932582,0.00031298568],"domain_scores_gemma":[0.99692416,0.00026491785,0.00006378553,0.0024253735,0.00014544024,0.00017632481],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00022619759,0.000143176,0.00021267017,0.00011985709,0.0020581174,0.0001811593,0.00049704785,0.00007035794,0.0000657687],"category_scores_gemma":[0.000048621077,0.0000894626,0.000047546713,0.0001491607,0.00050411525,0.00023044538,0.00021873621,0.00028699942,0.000016476673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005209004,0.0032352917,0.5022776,0.000043965032,0.0014918095,0.000050014107,0.025603862,0.00004698091,0.0011060213,0.02390814,0.0012542957,0.4404611],"study_design_scores_gemma":[0.0067548114,0.0010626053,0.8590473,0.00062729197,0.00042843804,0.0000085858555,0.0036853098,0.0016597481,0.00046762067,0.004979526,0.121007845,0.00027090675],"about_ca_topic_score_codex":0.021279413,"about_ca_topic_score_gemma":0.01554828,"teacher_disagreement_score":0.4401902,"about_ca_system_score_codex":0.0006419011,"about_ca_system_score_gemma":0.00038071518,"threshold_uncertainty_score":0.99924105},"labels":[],"label_agreement":null},{"id":"W2594551140","doi":"10.1002/cncy.21813","title":"The squamous situation: Ancillary testing in pulmonary squamous cell carcinoma and implications for cytology laboratories","year":2017,"lang":"en","type":"article","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Children's Hospital of Pittsburgh","keywords":"Medicine; Cytology; Basal cell; Oncology; Internal medicine; Pathology","score_opus":0.0336303632612142,"score_gpt":0.34587204289515183,"score_spread":0.3122416796339376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594551140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97341835,0.009374543,0.00014314518,0.012530197,0.00038165456,0.0008224423,0.00013341464,0.000033208464,0.0031630336],"genre_scores_gemma":[0.9970598,0.00014449176,0.00070443,0.0004026527,0.0002467792,0.0010217926,0.000030375428,0.00002091535,0.00036875985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990885,0.000033845874,0.00021928665,0.00031686338,0.00004857817,0.0002929241],"domain_scores_gemma":[0.99862635,0.00038737673,0.00016702994,0.00048640513,0.00025833937,0.000074490454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001438277,0.00013285129,0.00023297462,0.00004966237,0.0008864338,0.000041781714,0.0001249328,0.00010446379,0.0000037599661],"category_scores_gemma":[0.00047421924,0.000101311016,0.000029891715,0.0000911332,0.00029260208,0.00009029199,0.00005796486,0.000113934315,0.0000017204554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009495548,0.00006426692,0.97427636,0.00006755065,0.000005909766,0.00007676252,0.00046413546,0.000008252751,0.0054048174,0.0015115179,0.0003003628,0.017725095],"study_design_scores_gemma":[0.0015919501,0.00025098462,0.9895044,0.000010348775,0.00012925621,0.0002402662,0.00022027876,0.000108715176,0.00060008164,0.0016580555,0.005578698,0.000106962034],"about_ca_topic_score_codex":0.00022719639,"about_ca_topic_score_gemma":0.00070508476,"teacher_disagreement_score":0.023641443,"about_ca_system_score_codex":0.00016591116,"about_ca_system_score_gemma":0.00046773427,"threshold_uncertainty_score":0.6817822},"labels":[],"label_agreement":null},{"id":"W2596260927","doi":"10.1200/jco.2004.22.90140.3104","title":"The BC Cancer Agency experience with gefitinib in advanced non-small cell lung cancer (NSCLC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Lung cancer; Adenocarcinoma; Oncology; Population; Cancer; Gastroenterology; Pathology; Epidermal growth factor receptor","score_opus":0.053792637891429566,"score_gpt":0.4935900234301468,"score_spread":0.4397973855387172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596260927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864854,0.00453986,0.00021891609,0.009076192,0.0011737437,0.00038080002,0.00000353441,0.000005777221,0.0059526362],"genre_scores_gemma":[0.9861612,0.0078853145,0.002481149,0.0018468321,0.00060355186,0.000107522916,7.7709495e-7,0.000017739412,0.0008959457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997953,0.00007802843,0.0012479752,0.00018794132,0.00024601995,0.0002870129],"domain_scores_gemma":[0.9977627,0.00055449083,0.0009432343,0.00017209939,0.00031737852,0.00025009437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005390274,0.00013468096,0.00070045097,0.000056746154,0.0000896185,0.000010390274,0.00016355001,0.00014923624,0.00009825763],"category_scores_gemma":[0.00022969849,0.000070003516,0.00018265645,0.00018896304,0.00017560727,0.00010949605,0.000023352974,0.0006410636,0.0000037175573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049515194,0.0023355873,0.68592703,0.00006736479,0.0005251642,0.0016255305,0.0061735883,0.0036426946,0.00046560337,0.0001312249,0.00075279275,0.29340187],"study_design_scores_gemma":[0.03234413,0.0074889227,0.904401,0.00087519124,0.00079784537,0.00013146142,0.0017218133,0.00007222527,0.00061981566,0.00019503575,0.05115122,0.00020134862],"about_ca_topic_score_codex":0.0006678367,"about_ca_topic_score_gemma":0.0023887255,"teacher_disagreement_score":0.29320052,"about_ca_system_score_codex":0.0005908823,"about_ca_system_score_gemma":0.0057338667,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W2596356909","doi":"10.1200/jco.2014.32.15_suppl.8013","title":"Pan-Canadian rash trial with EGFR inhibitors.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbott (Canada); Princess Margaret Cancer Centre; Baker Hughes (Canada); Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Erlotinib; Rash; Medicine; Erlotinib Hydrochloride; Internal medicine; Minocycline; Dermatology; Surgery; Cancer; Epidermal growth factor receptor; Antibiotics","score_opus":0.07618340137758299,"score_gpt":0.49099512744974955,"score_spread":0.41481172607216654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596356909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90740335,0.00017769614,0.00020348837,0.030801713,0.0030812114,0.000361439,0.0000025653178,0.000008784777,0.057959743],"genre_scores_gemma":[0.9869762,0.00006864803,0.0025603091,0.0055189533,0.0040143398,0.000004095229,0.000002683614,0.000012009933,0.0008427809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982399,0.00017925477,0.0010894176,0.000107216736,0.00020840137,0.00017580738],"domain_scores_gemma":[0.99753207,0.00074904907,0.0006944536,0.00012524595,0.0002867535,0.0006124024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013497905,0.00008207769,0.00080178643,0.00011030365,0.00004425689,0.000008253988,0.000068610716,0.00021257329,0.00016267768],"category_scores_gemma":[0.0014577657,0.000047368358,0.00023696787,0.00008783885,0.00011118922,0.00006592859,0.000007534705,0.0004728954,0.000040476607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048074547,0.0025118336,0.09539311,0.0000197339,0.0013945109,0.00093323266,0.00022123252,0.000012265795,0.000020630781,0.0009430489,0.0707654,0.7797105],"study_design_scores_gemma":[0.10502363,0.029567933,0.070667885,0.000059845817,0.00079434033,0.00023087922,0.000058694175,0.000011916076,0.0000126680325,0.00025154828,0.79325974,0.0000609121],"about_ca_topic_score_codex":0.0012525212,"about_ca_topic_score_gemma":0.007142025,"teacher_disagreement_score":0.77964956,"about_ca_system_score_codex":0.00024552067,"about_ca_system_score_gemma":0.0046534957,"threshold_uncertainty_score":0.8255102},"labels":[],"label_agreement":null},{"id":"W2596957725","doi":"10.1200/jco.2012.30.15_suppl.7592","title":"Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Internal medicine; Histology; Paclitaxel; Carboplatin; Gastroenterology; Lung cancer; Neutropenia; Clinical endpoint; Cancer; Randomized controlled trial; Urology; Oncology; Chemotherapy; Cisplatin","score_opus":0.02133934613977678,"score_gpt":0.405305727424815,"score_spread":0.38396638128503824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596957725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944072,0.0020682449,0.00023007863,0.0018858291,0.00015975919,0.00047875888,0.000010288271,0.0000025817092,0.0007572757],"genre_scores_gemma":[0.9961466,0.0019694066,0.001277896,0.00037479386,0.000053602274,0.000014214898,0.000020675181,0.000014606525,0.00012816516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783236,0.00019135777,0.0013632991,0.00017393233,0.00021740643,0.00022166864],"domain_scores_gemma":[0.9970984,0.0008657031,0.0013822503,0.00012820694,0.00032676186,0.00019870374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070848776,0.00014744475,0.0013181142,0.0002735433,0.00002595205,0.0000023379614,0.000065731685,0.00019813511,0.000042310705],"category_scores_gemma":[0.0001965055,0.00009335314,0.000117784766,0.00040575428,0.00012888253,0.00011908865,0.000013810067,0.0004251783,3.9290694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011676762,0.0058568856,0.936419,0.000029679706,0.0008319057,0.000023933397,0.00093798304,0.0004442055,0.000022460748,0.000009639313,0.000067751345,0.043679796],"study_design_scores_gemma":[0.05380377,0.019465055,0.9232196,0.00012690984,0.0012702013,0.0000071900877,0.000128633,0.00017795856,0.000040598206,0.00000655628,0.0016648768,0.000088652894],"about_ca_topic_score_codex":0.00049774017,"about_ca_topic_score_gemma":0.0011486857,"teacher_disagreement_score":0.043591145,"about_ca_system_score_codex":0.00042385815,"about_ca_system_score_gemma":0.000719521,"threshold_uncertainty_score":0.38068306},"labels":[],"label_agreement":null},{"id":"W2597369096","doi":"10.1200/jco.2007.25.18_suppl.4076","title":"Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients &gt;65 years compared with those ≤65: The BICC-C study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; FOLFIRI; Irinotecan; Bevacizumab; Internal medicine; Regimen; Placebo; Surgery; Gastroenterology; Colorectal cancer; Chemotherapy; Cancer","score_opus":0.07233552466216654,"score_gpt":0.4737691966828702,"score_spread":0.4014336720207037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597369096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467933,0.000194114,0.00012976048,0.0028575286,0.00028578067,0.00062009116,0.0000071840627,0.000004447353,0.0012217861],"genre_scores_gemma":[0.99857086,0.00023511543,0.00066532684,0.0002837656,0.00012605725,0.0000030049189,0.0000057752172,0.00001096626,0.000099106845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975731,0.00018415008,0.0016346704,0.0001335326,0.0003183854,0.00015616055],"domain_scores_gemma":[0.9959436,0.0023225439,0.0009667449,0.00017149486,0.0004242794,0.00017131455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018519082,0.00010353725,0.00085052714,0.00014609286,0.000055179706,0.00000456485,0.00010392602,0.0001037402,0.000034188724],"category_scores_gemma":[0.001007625,0.000057655434,0.00011005251,0.00025942113,0.00021703403,0.00005784971,0.00003970568,0.0004557029,0.000001534882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007091207,0.021008477,0.87441194,0.000012856006,0.00054116984,0.00021584032,0.0013146643,0.0001225435,0.0000033486212,0.0000927587,0.00023743384,0.09494775],"study_design_scores_gemma":[0.039594393,0.020505385,0.93001974,0.00009655506,0.0005828698,0.000028509518,0.0004929129,0.000045672805,0.000004540748,0.00004538643,0.008533091,0.000050959843],"about_ca_topic_score_codex":0.00009589669,"about_ca_topic_score_gemma":0.0011299079,"teacher_disagreement_score":0.094896786,"about_ca_system_score_codex":0.00015652488,"about_ca_system_score_gemma":0.00042831947,"threshold_uncertainty_score":0.23511203},"labels":[],"label_agreement":null},{"id":"W2597532593","doi":"10.1200/jco.2013.31.15_suppl.e19077","title":"Clinical impact of <i>EGFR</i> mutation fraction and tumor cellularity in <i>EGFR</i> mutation positive NSCLC.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Grand River Hospital; Trillium Health Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; York Central Hospital; Toronto East General Hospital; University of Toronto; Ottawa Hospital; Health Sciences Centre; University Health Network; Royal Columbian Hospital; Princess Margaret Cancer Centre; Mount Sinai Hospital; Credit Valley Hospital","funders":"","keywords":"Medicine; Mutation; Internal medicine; Exon; Oncology; Biopsy; Pathology; Gastroenterology; Gene; Genetics; Biology","score_opus":0.053940914662725235,"score_gpt":0.5001591688104652,"score_spread":0.44621825414773997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597532593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932238,0.0003678745,0.0006677969,0.0024558145,0.00057548215,0.00048672946,0.000009565982,0.0000067188726,0.0022062398],"genre_scores_gemma":[0.9944884,0.00029021397,0.0035849775,0.0010496777,0.00047908386,0.000008828517,0.00002011658,0.000014512909,0.0000641658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960138,0.00056794094,0.002741008,0.00021227874,0.00028002137,0.0001849559],"domain_scores_gemma":[0.9942415,0.0022699048,0.0022403004,0.00013114332,0.0007921664,0.00032500664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020491509,0.00014491905,0.0012624665,0.00017931148,0.000035412286,0.000013320512,0.000063814296,0.00031578258,0.00012462545],"category_scores_gemma":[0.0021112696,0.0001026098,0.0004902786,0.00018660983,0.00022094167,0.00040258295,0.000022454173,0.0008304702,0.000015853546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030863308,0.004415954,0.7059333,0.00004653351,0.0008618102,0.0007637523,0.00038960253,0.00008648393,0.000888335,0.000076852775,0.0018374817,0.2816136],"study_design_scores_gemma":[0.011124812,0.014140982,0.97062606,0.00014689214,0.0006293602,0.0005264447,0.0003158046,0.0006030215,0.00014861743,0.0012065179,0.0004450565,0.00008644161],"about_ca_topic_score_codex":0.0008364603,"about_ca_topic_score_gemma":0.00006870473,"teacher_disagreement_score":0.28152716,"about_ca_system_score_codex":0.00040063693,"about_ca_system_score_gemma":0.0016071236,"threshold_uncertainty_score":0.41843066},"labels":[],"label_agreement":null},{"id":"W2597637166","doi":"10.1200/jco.2012.30.15_suppl.e13011","title":"Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Internal medicine; Cohort; Maximum tolerated dose; Toxicity; Gastroenterology; Cancer; Oncology; Surgery; Epidermal growth factor receptor","score_opus":0.07679519443808776,"score_gpt":0.5008483345529107,"score_spread":0.4240531401148229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597637166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512273,0.000095062234,0.00014509355,0.0013269557,0.0007353374,0.0009102325,0.000005298298,0.000011803348,0.0016475017],"genre_scores_gemma":[0.9909395,0.00004407361,0.0075855167,0.00068840326,0.0005070005,0.00003082073,0.000027499284,0.000024241488,0.00015296221],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99693716,0.00030989255,0.0018053254,0.0001732239,0.000455411,0.0003189995],"domain_scores_gemma":[0.9964801,0.00059639366,0.0017956209,0.00017475663,0.0005031329,0.00044998404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012625267,0.0001782423,0.0013936501,0.00017765137,0.000040495685,0.000008387209,0.000084552055,0.0001725169,0.00009761697],"category_scores_gemma":[0.0011306012,0.00010290948,0.00017291884,0.0003059099,0.0001347015,0.00039607682,0.000016807488,0.00057713006,0.000009726998],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40440413,0.027738359,0.33525008,0.000021317148,0.0004307488,0.00016136348,0.00050274865,0.000050945342,0.000017146367,0.00004204952,0.00046612666,0.23091497],"study_design_scores_gemma":[0.414696,0.13077569,0.4501362,0.00019623045,0.0006365911,0.000026702917,0.00017335551,0.000046025398,0.000021356098,0.00002582171,0.0031619049,0.00010408303],"about_ca_topic_score_codex":0.000015732006,"about_ca_topic_score_gemma":0.00005870737,"teacher_disagreement_score":0.23081088,"about_ca_system_score_codex":0.00036246088,"about_ca_system_score_gemma":0.0013674143,"threshold_uncertainty_score":0.41965267},"labels":[],"label_agreement":null},{"id":"W2597980213","doi":"10.1200/jco.2014.32.15_suppl.e19080","title":"Population-based evaluation of second-line palliative chemotherapy (SCT) versus erlotinib (E) in advanced non-small cell lung cancer (NSCLC) patients (pts).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Erlotinib; Internal medicine; Vinorelbine; Lung cancer; Pemetrexed; Oncology; Population; Cancer; Performance status; Proportional hazards model; Hazard ratio; Chemotherapy; Epidermal growth factor receptor; Confidence interval; Cisplatin","score_opus":0.07575034353656812,"score_gpt":0.5097801773952608,"score_spread":0.4340298338586927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597980213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427986,0.0002676506,0.0002632338,0.001074637,0.0013961119,0.0006987343,0.000012660137,0.000004201566,0.0020029142],"genre_scores_gemma":[0.9952328,0.000121987396,0.0032076961,0.00090456236,0.00036518127,0.00003006264,0.000036196405,0.000019383962,0.00008209247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698246,0.0003757537,0.0018142184,0.00018995652,0.00046666517,0.00017096073],"domain_scores_gemma":[0.99486005,0.0014621454,0.0021044991,0.00015591687,0.0012530504,0.00016434139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019825846,0.00013994557,0.0009950328,0.00015081375,0.000026198399,0.0000035009466,0.00009281823,0.00022345659,0.0003934293],"category_scores_gemma":[0.0013338958,0.00010551879,0.0002623612,0.00016946202,0.000044271725,0.00008291135,0.000009674107,0.0003817315,0.0000022385946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058081974,0.0023827928,0.8269405,0.00006936824,0.0002618456,0.0000037170735,0.00031344948,0.0045248982,0.000081626895,0.000008672646,0.00017903066,0.15942591],"study_design_scores_gemma":[0.074161045,0.008009183,0.9063409,0.00023330619,0.00083237316,3.511107e-7,0.00006120192,0.0087790545,0.00029162338,0.00006484741,0.0011387101,0.00008739299],"about_ca_topic_score_codex":0.00012531834,"about_ca_topic_score_gemma":0.00080602133,"teacher_disagreement_score":0.15933852,"about_ca_system_score_codex":0.0007091126,"about_ca_system_score_gemma":0.0025348242,"threshold_uncertainty_score":0.44966692},"labels":[],"label_agreement":null},{"id":"W2598236349","doi":"10.1200/jco.2015.33.15_suppl.7540","title":"Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA <i>EGFR</i> positive (IHC/FISH) non-small cell lung cancer (NSCLC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Clinical endpoint; Placebo; Oncology; Subgroup analysis; Randomized controlled trial; Adjuvant; Surgery; Gastroenterology; Confidence interval; Cancer; Epidermal growth factor receptor; Pathology","score_opus":0.12479863557113825,"score_gpt":0.4557257503106037,"score_spread":0.33092711473946546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598236349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868686,0.00022511982,0.00013720944,0.001002595,0.0051293196,0.0032862958,0.000346732,0.000009288586,0.0029948074],"genre_scores_gemma":[0.9964031,0.000109816996,0.0014809706,0.00037016242,0.0009400599,0.00009024165,0.00017205857,0.00003887449,0.00039469352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941704,0.0008754147,0.00341397,0.00042370238,0.00072828116,0.0003882135],"domain_scores_gemma":[0.9910213,0.0039020104,0.0033737826,0.0002661865,0.0008495213,0.00058723026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034357135,0.00030039056,0.0029780562,0.00028533567,0.0000737272,0.000021953534,0.00018733305,0.00028684048,0.00003288513],"category_scores_gemma":[0.0021103064,0.0002081661,0.0007723195,0.000302932,0.00018972844,0.0002345735,0.000048806767,0.0009421645,0.0000038815697],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98104274,0.0053240517,0.004728412,0.000026164342,0.0017619347,0.0006859954,0.0022055495,0.00023628847,0.000039184342,0.0000026164496,0.0015479882,0.002399089],"study_design_scores_gemma":[0.9470094,0.04228211,0.003149129,0.0006080474,0.0038510005,0.000007617658,0.0005270714,0.0006625275,0.00017458716,0.000010344139,0.0015314366,0.00018673792],"about_ca_topic_score_codex":0.0027078104,"about_ca_topic_score_gemma":0.0026392885,"teacher_disagreement_score":0.036958057,"about_ca_system_score_codex":0.00091297185,"about_ca_system_score_gemma":0.0051015057,"threshold_uncertainty_score":0.90498525},"labels":[],"label_agreement":null},{"id":"W2599058564","doi":"10.1200/jco.2013.31.15_suppl.7516","title":"Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Adenocarcinoma; Histology; Internal medicine; Oncology; Cancer; Progressive disease; Epidermal growth factor receptor; Pathology; Chemotherapy","score_opus":0.07637053929550952,"score_gpt":0.46607542450189837,"score_spread":0.38970488520638885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599058564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901366,0.00039742887,0.0012117667,0.0027059212,0.00089614885,0.0023142465,0.000009152367,0.000008387178,0.0023203539],"genre_scores_gemma":[0.9923805,0.0001070577,0.0029403141,0.0008842818,0.0005315101,0.00031189085,0.0000036852107,0.000028035412,0.0028127292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763906,0.00023802373,0.0014271138,0.00022380601,0.00021414379,0.0002578688],"domain_scores_gemma":[0.9933301,0.0035117802,0.0013090565,0.0001290668,0.0013937177,0.00032627632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009725281,0.00017051486,0.0012933256,0.00012084781,0.00007847653,0.000019506453,0.00007958993,0.00018740748,0.00024902856],"category_scores_gemma":[0.00058782636,0.00009747428,0.0003457417,0.00017577082,0.00010885423,0.0001743845,0.000017802671,0.00046844722,0.000011264286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035898692,0.003736759,0.9510497,0.00003984839,0.0024218273,0.00014875851,0.002198151,0.000021977196,0.000033381846,0.0000039205083,0.016362466,0.020393375],"study_design_scores_gemma":[0.0133440355,0.02007312,0.96010303,0.00015622811,0.002359895,0.00004868706,0.0009645979,0.0003941254,0.00004713194,0.000020419488,0.002369648,0.000119081655],"about_ca_topic_score_codex":0.00036035295,"about_ca_topic_score_gemma":0.00023169302,"teacher_disagreement_score":0.020274295,"about_ca_system_score_codex":0.0002345851,"about_ca_system_score_gemma":0.004102089,"threshold_uncertainty_score":0.727693},"labels":[],"label_agreement":null},{"id":"W2599537025","doi":"10.3389/fonc.2017.00050","title":"Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epidermal growth factor receptor; Epithelial–mesenchymal transition; Medicine; Lung cancer; Cancer research; Discoidin domain; Personalized medicine; Tyrosine kinase; Oncology; Targeted therapy; Precision medicine; Lung; Cancer; Receptor tyrosine kinase; Internal medicine; Bioinformatics; Pathology; Receptor; Biology; Metastasis","score_opus":0.06153199649100901,"score_gpt":0.43311072863085076,"score_spread":0.37157873213984177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599537025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021774776,0.98988867,0.00008919639,0.0014475209,0.0011545704,0.0028576981,0.00011933473,0.0000053898457,0.004219892],"genre_scores_gemma":[0.00017796516,0.9932927,0.0016286148,0.000129744,0.0001544135,0.0005496335,0.00012399581,0.00004279331,0.003900144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981027,0.00022218704,0.0008366128,0.00036920718,0.0001818552,0.00028741444],"domain_scores_gemma":[0.99805117,0.00033959874,0.00089520565,0.0005585452,0.000054240914,0.000101268306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021808445,0.00038389376,0.0033898926,0.0003571606,0.000041631385,0.0000029947566,0.00023466781,0.00021632643,0.00029829255],"category_scores_gemma":[0.00006511589,0.00020785403,0.00033579156,0.00022220508,0.00028662148,0.000019206342,0.000018891891,0.00031067152,0.0000030590018],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021832091,0.0010072552,0.0010607691,0.0045598825,0.0011148286,0.00018913145,0.003578797,0.00000908837,5.5214883e-7,0.000068724425,0.01441759,0.9737751],"study_design_scores_gemma":[0.007977417,0.002374376,0.00015060164,0.007879982,0.0074505573,0.000011366416,0.00037823088,0.000051853367,0.000004350063,0.00004674065,0.9735315,0.00014306603],"about_ca_topic_score_codex":0.002862125,"about_ca_topic_score_gemma":0.00084737845,"teacher_disagreement_score":0.973632,"about_ca_system_score_codex":0.0020943573,"about_ca_system_score_gemma":0.0038592343,"threshold_uncertainty_score":0.84760416},"labels":[],"label_agreement":null},{"id":"W2599986538","doi":"10.1200/jco.2013.31.15_suppl.2523","title":"A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Afatinib; Internal medicine; Maximum tolerated dose; Gastroenterology; Pharmacology; Urology; Nuclear medicine; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.04642476607821685,"score_gpt":0.45680400366740986,"score_spread":0.41037923758919304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599986538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972144,0.00004894658,0.0001334598,0.000961449,0.00015172514,0.0009485597,0.000006383664,0.000004812247,0.00053029193],"genre_scores_gemma":[0.9962892,0.00004761991,0.003161721,0.00022177788,0.00012506115,0.000028382283,0.000026906133,0.000012153221,0.00008717311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971249,0.00022672852,0.0019063804,0.00019510179,0.00036588454,0.00018100112],"domain_scores_gemma":[0.99601775,0.0007319836,0.0021037296,0.00015103033,0.0007485726,0.00024695808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069549633,0.0001482856,0.0018249925,0.000304501,0.000025819834,0.000009409887,0.00006510372,0.00013576225,0.00009049457],"category_scores_gemma":[0.00082619936,0.00008702495,0.00019548464,0.00044920974,0.00018008058,0.00020855988,0.000015187608,0.00037113501,0.0000015425908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3240968,0.021535708,0.41126487,0.000031116124,0.0023845364,0.00014100659,0.0003060272,0.00017484082,0.00005268886,0.00001562717,0.00013454481,0.23986225],"study_design_scores_gemma":[0.32974175,0.12874092,0.5388779,0.000096620046,0.0018537156,0.0000098184,0.000117513104,0.0003453063,0.000015582415,0.00003713746,0.00010109286,0.00006265477],"about_ca_topic_score_codex":0.00006146733,"about_ca_topic_score_gemma":0.00012226944,"teacher_disagreement_score":0.2397996,"about_ca_system_score_codex":0.00011360001,"about_ca_system_score_gemma":0.00077715743,"threshold_uncertainty_score":0.35487744},"labels":[],"label_agreement":null},{"id":"W2600031158","doi":"10.1200/jco.2012.30.15_suppl.7007","title":"Prognostic and predictive effects of<i> KRAS</i> mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; Hazard ratio; Colorectal cancer; Oncology; Internal medicine; Mutation; Cancer; Chemotherapy; Lung cancer; Cancer research; Genetics; Gene; Confidence interval; Biology","score_opus":0.05092843085666312,"score_gpt":0.45615974207965954,"score_spread":0.40523131122299644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600031158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375796,0.0027963382,0.0001690015,0.00050571485,0.00083789654,0.0011659582,0.0000064335377,0.000004862826,0.0007558597],"genre_scores_gemma":[0.99812996,0.00034440306,0.00070131477,0.00024088225,0.00045053643,0.000043487453,0.0000043610985,0.0000141064265,0.000070950635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781543,0.0004577581,0.001165605,0.00013659468,0.00021305002,0.00021156452],"domain_scores_gemma":[0.995286,0.0029996512,0.0009941785,0.00009462648,0.00037118146,0.0002543485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012090489,0.00011636602,0.00091328536,0.00014531854,0.00003190254,0.000004327938,0.000058943057,0.00017182411,0.000015378746],"category_scores_gemma":[0.0015584152,0.000082033264,0.00011663565,0.00019680834,0.00009621083,0.000109899906,0.000029953235,0.0005653848,0.0000014076322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002437732,0.004723178,0.9791923,0.0002136178,0.0005216302,0.00026728993,0.0030536696,0.00002368151,0.00032599168,0.000004123432,0.00043749818,0.0087993],"study_design_scores_gemma":[0.015217519,0.015411139,0.9654683,0.00033774745,0.002147411,0.000053937943,0.00049916893,0.0002322088,0.00019345192,0.000016556021,0.0003593458,0.000063237916],"about_ca_topic_score_codex":0.00015159344,"about_ca_topic_score_gemma":0.00018986507,"teacher_disagreement_score":0.013724011,"about_ca_system_score_codex":0.00020827547,"about_ca_system_score_gemma":0.0011754523,"threshold_uncertainty_score":0.33452195},"labels":[],"label_agreement":null},{"id":"W2600193304","doi":"10.1200/jco.2007.25.18_suppl.7611","title":"A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T790M; Internal medicine; Lapatinib; Clinical endpoint; KRAS; Population; Lung cancer; non-small cell lung cancer (NSCLC); Gastroenterology; Phases of clinical research; Oncology; Cancer; Chemotherapy; Surgery; Clinical trial; Breast cancer; Trastuzumab; Colorectal cancer","score_opus":0.0857046195069171,"score_gpt":0.4627108171647395,"score_spread":0.3770061976578224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600193304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945841,0.0013894615,0.0006535863,0.00025616187,0.0009221522,0.0012909467,0.000010645531,0.000009276084,0.00088366494],"genre_scores_gemma":[0.97404313,0.00029723305,0.022744494,0.0009987775,0.0005780091,0.000051530264,0.0000058401915,0.000054662567,0.0012263075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965266,0.00020050455,0.0022328007,0.00032311064,0.00032866868,0.0003883455],"domain_scores_gemma":[0.99466616,0.0019183692,0.0023482079,0.00023017601,0.00050313404,0.00033397757],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013596872,0.00029508866,0.0019735922,0.00024964398,0.000067175715,0.0000065686104,0.00016428383,0.00016481213,0.0009819276],"category_scores_gemma":[0.0004270447,0.00015263827,0.00023024227,0.00019962237,0.0002031918,0.000170916,0.000029659343,0.0008106529,0.0000015051015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8253336,0.013235308,0.13250303,0.0003316793,0.0017541286,0.0023593185,0.0030860384,0.00046759393,0.0004091225,0.0000038352355,0.00015350475,0.020362837],"study_design_scores_gemma":[0.7557422,0.19109416,0.028666519,0.0015869156,0.0027040432,0.00018149425,0.0009651353,0.0016536217,0.0011618146,0.0000025852135,0.015918605,0.00032291707],"about_ca_topic_score_codex":0.00043835145,"about_ca_topic_score_gemma":0.021103894,"teacher_disagreement_score":0.17785886,"about_ca_system_score_codex":0.0008842991,"about_ca_system_score_gemma":0.0053130197,"threshold_uncertainty_score":0.99993134},"labels":[],"label_agreement":null},{"id":"W2600507120","doi":"10.1200/jco.2009.27.15_suppl.11023","title":"TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Erlotinib; Amphiregulin; Gastroenterology; Hazard ratio; Lung cancer; Placebo; Biomarker; non-small cell lung cancer (NSCLC); Oncology; Cancer; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.1284308504461082,"score_gpt":0.49728029437540094,"score_spread":0.36884944392929275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600507120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884463,0.00070985116,0.000024679428,0.0074551604,0.00077852793,0.0009871464,0.00005969064,0.0000027430588,0.0015359042],"genre_scores_gemma":[0.99314564,0.00090707705,0.00062053656,0.0043654377,0.0006759522,0.00003934492,0.000011309576,0.000012770604,0.00022190504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99428254,0.00097491295,0.0036001287,0.00027763293,0.0005834834,0.00028130334],"domain_scores_gemma":[0.99349576,0.003144129,0.002346223,0.00012654121,0.00062074966,0.00026656708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060139755,0.00020485937,0.0018801716,0.00016694116,0.00004837332,0.000010360236,0.0001774418,0.00030064612,0.000061388026],"category_scores_gemma":[0.0023804063,0.00011568429,0.00022622959,0.0003173796,0.00018722928,0.00013399155,0.000018048275,0.00082596374,3.3972066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076069273,0.0033470578,0.9204471,0.0000457269,0.0005348141,0.0002287597,0.00044184033,0.00038721488,0.00002740535,0.000039043407,0.005572381,0.06132173],"study_design_scores_gemma":[0.03927158,0.0047320863,0.9480906,0.00042622027,0.0007910062,0.000023180934,0.000112502436,0.00021573913,0.000017302737,0.00004269626,0.0061636763,0.00011336856],"about_ca_topic_score_codex":0.02725459,"about_ca_topic_score_gemma":0.26872334,"teacher_disagreement_score":0.24146874,"about_ca_system_score_codex":0.0007747434,"about_ca_system_score_gemma":0.010527758,"threshold_uncertainty_score":0.9950816},"labels":[],"label_agreement":null},{"id":"W2600523014","doi":"10.3389/fonc.2017.00052","title":"Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; Nintedanib; Lung cancer; Context (archaeology); Oncology; Immunotherapy; Personalized medicine; Ramucirumab; Nivolumab; Angiogenesis; Internal medicine; Cancer; Chemotherapy; Overall survival; Bioinformatics; Lung; Epidermal growth factor receptor","score_opus":0.037382824971240965,"score_gpt":0.43647212859862405,"score_spread":0.3990893036273831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600523014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019835593,0.99313855,0.0004911182,0.0009290948,0.00090837455,0.0032777789,0.00009933687,0.000004700595,0.00095269916],"genre_scores_gemma":[0.00006721705,0.9924048,0.00458428,0.00021939365,0.00015330806,0.0017048663,0.00010015702,0.000039660103,0.00072630774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870443,0.00011435035,0.0005117958,0.00032174579,0.00010144412,0.00024620723],"domain_scores_gemma":[0.99884754,0.00022132676,0.0004804404,0.00035096816,0.000059526832,0.000040216684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003405808,0.00026515595,0.0021140068,0.00024145553,0.00006878595,0.00000479617,0.00021980032,0.00028228172,0.000032039727],"category_scores_gemma":[0.000041890507,0.000159981,0.00022764486,0.00015589937,0.00023698139,0.000028594905,0.000018317816,0.00023193227,1.9806079e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017701309,0.0001417208,0.0020169634,0.0060070455,0.0005392076,0.00003210526,0.0024519505,7.959056e-7,0.000004480804,0.000011490154,0.004025355,0.9845919],"study_design_scores_gemma":[0.008307975,0.0005440933,0.0005056447,0.009015354,0.002537393,0.00002185826,0.0006264698,0.000030235009,0.0000014875217,0.000026743715,0.97823995,0.00014280798],"about_ca_topic_score_codex":0.00035522075,"about_ca_topic_score_gemma":0.0001577448,"teacher_disagreement_score":0.9844491,"about_ca_system_score_codex":0.00048972043,"about_ca_system_score_gemma":0.0011041793,"threshold_uncertainty_score":0.6523836},"labels":[],"label_agreement":null},{"id":"W2600540592","doi":"10.1016/j.radonc.2017.03.007","title":"Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer","year":2017,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Whole brain radiotherapy; Oncology; Lung cancer; Brain metastasis; Radiation therapy; Radiosurgery; Retrospective cohort study; Cancer; Metastasis","score_opus":0.018358128448878033,"score_gpt":0.38890226392480465,"score_spread":0.37054413547592663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600540592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724194,0.005742857,0.0018944653,0.016028404,0.00031210535,0.0017769039,0.00100162,0.000034880566,0.00078939286],"genre_scores_gemma":[0.9557549,0.0049081272,0.031296667,0.002105991,0.0005982522,0.0015097627,0.0006070842,0.000053328382,0.0031659163],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946827,0.000021935262,0.000098188946,0.00021112328,0.000053463664,0.00014704236],"domain_scores_gemma":[0.9994212,0.00011682761,0.000099899364,0.00021824383,0.0000514146,0.00009243791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000019098592,0.00012080721,0.00028856442,0.00003326848,0.00034368105,0.000026262564,0.000041971558,0.000058199137,0.00014737612],"category_scores_gemma":[0.000009559792,0.000076898636,0.00005218924,0.000015549875,0.00009661049,0.00007745967,0.0000052254754,0.000030509067,5.679061e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00215526,0.0016996884,0.6424435,0.000033128814,0.004470431,0.00003436708,0.0024221428,0.000054041204,0.00049148675,0.0009787735,0.00479434,0.34042287],"study_design_scores_gemma":[0.034780048,0.0073221745,0.39498132,0.00005844187,0.0016637896,0.000009546113,0.00008422298,0.0009292323,0.00013392093,0.00007656613,0.55977523,0.00018550223],"about_ca_topic_score_codex":0.0010579337,"about_ca_topic_score_gemma":0.001079788,"teacher_disagreement_score":0.5549809,"about_ca_system_score_codex":0.0006573835,"about_ca_system_score_gemma":0.0002197872,"threshold_uncertainty_score":0.31358352},"labels":[],"label_agreement":null},{"id":"W2600627787","doi":"10.1200/jco.2013.31.15_suppl.e19131","title":"Less toxic chemotherapy on the uptake of all lines of chemotherapy in advanced non-small cell lung cancer: A 10-year retrospective population-based review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Erlotinib; Docetaxel; Lung cancer; Chemotherapy; Internal medicine; Retrospective cohort study; Population; Oncology; Cancer; Surgery; Cisplatin; Epidermal growth factor receptor","score_opus":0.0500419783845666,"score_gpt":0.45640071460609166,"score_spread":0.4063587362215251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600627787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752673,0.0021424885,0.000029754463,0.019984152,0.00026843883,0.00088794203,0.000008660296,0.0000034122531,0.0014078651],"genre_scores_gemma":[0.97913855,0.010541373,0.0025579755,0.007083736,0.00027224934,0.000043438722,0.0000052713704,0.000022002425,0.0003353792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974592,0.00013518325,0.0018479939,0.00015721931,0.0002518058,0.00014864994],"domain_scores_gemma":[0.9963332,0.0007744879,0.001969158,0.00022547353,0.000593198,0.00010447393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094913214,0.00013610591,0.0012753446,0.00008897072,0.000017068984,0.0000027557278,0.00014610431,0.0001669617,0.00037787654],"category_scores_gemma":[0.0005106591,0.00007876426,0.0003699046,0.00019894358,0.00006985486,0.000050344664,0.0000075533185,0.00038795103,0.000003694665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044074855,0.005501923,0.82632023,0.00073596317,0.0009848943,0.000027043021,0.00050896214,0.0005043578,0.0024329035,0.00012219402,0.010665527,0.14778852],"study_design_scores_gemma":[0.013190784,0.0055392412,0.9734098,0.0017295533,0.00035307088,0.000003488435,0.0001835173,0.0003395397,0.0012960094,0.00014366045,0.003726034,0.000085318134],"about_ca_topic_score_codex":0.00033562555,"about_ca_topic_score_gemma":0.00011832153,"teacher_disagreement_score":0.14770322,"about_ca_system_score_codex":0.0002986128,"about_ca_system_score_gemma":0.0010802557,"threshold_uncertainty_score":0.4137483},"labels":[],"label_agreement":null},{"id":"W2600997638","doi":"10.1200/jco.2013.31.15_suppl.8096","title":"Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for <i>ALK</i> gene rearrangements.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Health Sciences North; University of British Columbia; Ottawa Hospital; University Health Network; McMaster University Medical Centre; Health Sciences Centre; University of Ottawa; McGill University; McGill University Health Centre; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; University of Toronto; Dalhousie University; Jewish General Hospital","funders":"","keywords":"Immunohistochemistry; Fluorescence in situ hybridization; Medicine; Fish <Actinopterygii>; Context (archaeology); Crizotinib; Lung cancer; Pathology; Oncology; Internal medicine; Biology; Gene; Genetics; Fishery","score_opus":0.03625839351098122,"score_gpt":0.4253426449634531,"score_spread":0.3890842514524719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600997638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98296964,0.00033102054,0.00012016458,0.012947281,0.00037731155,0.0015596177,0.000052190306,0.000003988817,0.0016387693],"genre_scores_gemma":[0.986353,0.00029720296,0.009061569,0.0037012426,0.000212054,0.000062887,0.000016841415,0.000018374754,0.00027685487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980887,0.000102817576,0.001073792,0.00024600976,0.0001760465,0.00031261408],"domain_scores_gemma":[0.9977368,0.0003094768,0.00032867547,0.00015589622,0.00045526845,0.0010138722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009092591,0.00013982119,0.0007188304,0.00018405741,0.000088029075,0.000033943277,0.000090472575,0.0001381078,0.00006220706],"category_scores_gemma":[0.001046192,0.00011382766,0.00009273613,0.00010300107,0.000073678224,0.00013226316,0.000025910076,0.00029099023,0.0000034641798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047570285,0.0038446093,0.5832662,0.00014839803,0.0020348933,0.001436139,0.0048078545,0.000071472015,0.010503778,0.0000132697605,0.044420406,0.34469593],"study_design_scores_gemma":[0.038503405,0.010710405,0.8560151,0.00026702706,0.0012140296,0.00017421144,0.0026698215,0.00024501755,0.000379155,0.00006521892,0.08942218,0.00033444838],"about_ca_topic_score_codex":0.12983796,"about_ca_topic_score_gemma":0.30682585,"teacher_disagreement_score":0.34436148,"about_ca_system_score_codex":0.00096684054,"about_ca_system_score_gemma":0.0025389076,"threshold_uncertainty_score":0.87595654},"labels":[],"label_agreement":null},{"id":"W2601373489","doi":"10.1200/jco.2012.30.15_suppl.7607","title":"Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Lung cancer; Quality of life (healthcare); Hazard ratio; Oncology; Proportional hazards model; Randomized controlled trial; Statistical significance; Cancer; Confidence interval","score_opus":0.24414952474483395,"score_gpt":0.5801434326413669,"score_spread":0.33599390789653294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601373489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838372,0.0045319283,0.000024283909,0.009456731,0.0014603299,0.00028608012,0.00005438045,0.0000040659347,0.00034500938],"genre_scores_gemma":[0.99553275,0.0025690317,0.00033659648,0.0009248187,0.00050241844,0.00001268417,0.000009178286,0.0000090990825,0.00010341164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944243,0.00081233465,0.004039749,0.00012144478,0.00036871186,0.00023346132],"domain_scores_gemma":[0.99319255,0.0018174035,0.0039770473,0.000178183,0.00040256573,0.00043223344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005340792,0.00010375094,0.002609941,0.00035119188,0.000018019775,0.0000013503992,0.000092898656,0.00024927914,0.0004135861],"category_scores_gemma":[0.0026152672,0.00005631198,0.0006052858,0.0006329196,0.00014595762,0.00012422842,0.000027127751,0.00044857472,5.5960066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016247517,0.0021663425,0.97593063,0.00018702255,0.0051323557,0.000009521777,0.0014012167,0.000055303055,0.0000115097555,0.00009325282,0.00020119615,0.013186905],"study_design_scores_gemma":[0.0058932826,0.0016470706,0.9876966,0.00021938894,0.0030352317,0.0000023648022,0.00021390639,0.00024131635,0.000006234309,0.000029275841,0.00096714083,0.00004819676],"about_ca_topic_score_codex":0.0066431086,"about_ca_topic_score_gemma":0.0035685203,"teacher_disagreement_score":0.013138708,"about_ca_system_score_codex":0.00031935802,"about_ca_system_score_gemma":0.0020518121,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W2601526318","doi":"10.1200/jco.2006.24.18_suppl.10082","title":"Competing risk events determining probability of cause-specific failure in nasopharyngeal carcinoma","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Cumulative incidence; Nasopharyngeal carcinoma; Incidence (geometry); Survival analysis; Cohort; Distant metastasis; Internal medicine; Statistics; Oncology; Metastasis; Cancer; Radiation therapy","score_opus":0.08881425952069948,"score_gpt":0.4466953554891056,"score_spread":0.3578810959684061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601526318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644506,0.00038489964,0.0000645803,0.0010914879,0.00045984992,0.00021608088,0.000006584587,0.000004426224,0.0013270297],"genre_scores_gemma":[0.9893814,0.00008095129,0.009806794,0.000092383125,0.00058351795,0.0000036247982,0.0000038630155,0.00001014303,0.00003735504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968091,0.00036997822,0.002253934,0.00015604784,0.00023731614,0.00017360186],"domain_scores_gemma":[0.99652535,0.0011857252,0.0017280406,0.00014415577,0.0002861978,0.0001305333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001779284,0.00010098662,0.0010517357,0.00011165329,0.000030540697,0.000002774066,0.000090350564,0.00019309939,0.000052352654],"category_scores_gemma":[0.0005977281,0.00007319716,0.000298834,0.00013486385,0.00011230302,0.000077898774,0.000028397715,0.00062433485,0.0000030797682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000710153,0.0014487054,0.9709967,0.000031136584,0.00011076888,0.0003838068,0.00018427087,0.00008779656,0.00008886636,0.00005447803,0.00026522073,0.02563811],"study_design_scores_gemma":[0.008513627,0.003500104,0.97976804,0.00012007892,0.00031472923,0.00015464025,0.00017996528,0.00005134318,0.000058373058,0.0006659694,0.006619712,0.000053403666],"about_ca_topic_score_codex":0.00010162608,"about_ca_topic_score_gemma":0.00035882942,"teacher_disagreement_score":0.025584705,"about_ca_system_score_codex":0.00026794747,"about_ca_system_score_gemma":0.000993095,"threshold_uncertainty_score":0.29848936},"labels":[],"label_agreement":null},{"id":"W2603579700","doi":"10.1200/jco.2009.27.15_suppl.8045","title":"Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): Subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Internal medicine; Pemetrexed; Oncology; Hazard ratio; Gemcitabine; Population; Subgroup analysis; Chemotherapy; Cisplatin; Confidence interval","score_opus":0.07379111199909638,"score_gpt":0.47491572716304753,"score_spread":0.40112461516395115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603579700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965036,0.0005058372,0.00009330613,0.00040119328,0.00037964145,0.0011706052,0.000034524182,0.000003929968,0.0009073957],"genre_scores_gemma":[0.9981898,0.0003262287,0.0012176397,0.000041398347,0.000108662665,0.000022804696,0.000036769874,0.000016922699,0.00003977605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434525,0.00025460773,0.0042962735,0.00033349276,0.00046311622,0.00030724652],"domain_scores_gemma":[0.9942784,0.0012415727,0.0034040804,0.000319221,0.0005027981,0.0002539534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008209526,0.00027791128,0.0034515443,0.0009515437,0.000030215266,0.000003945485,0.0001766242,0.00020226231,0.00008007406],"category_scores_gemma":[0.00052735227,0.0002107825,0.00069284503,0.001256452,0.00008952643,0.00011067063,0.00003143003,0.000386363,5.206866e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035001744,0.060371947,0.7784003,0.00005510558,0.0027230685,0.00015854074,0.0041951123,0.010153219,0.00013217394,0.0000035000785,0.00001640477,0.10878888],"study_design_scores_gemma":[0.19172376,0.04567747,0.74964905,0.00027497404,0.007093459,0.0000013122456,0.000996068,0.0043100016,0.000105502266,0.0000030365268,0.000053846034,0.0001115077],"about_ca_topic_score_codex":0.0008867978,"about_ca_topic_score_gemma":0.007848891,"teacher_disagreement_score":0.15672202,"about_ca_system_score_codex":0.0008175915,"about_ca_system_score_gemma":0.0008949195,"threshold_uncertainty_score":0.85954607},"labels":[],"label_agreement":null},{"id":"W2603873395","doi":"10.1200/jco.2013.31.15_suppl.e22042","title":"ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Immunohistochemistry; Internal medicine; Fish <Actinopterygii>; Lung cancer; Oncology; Pathology; Biology","score_opus":0.03635374449625242,"score_gpt":0.4636437514692342,"score_spread":0.4272900069729818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603873395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842316,0.00014032074,0.00048767112,0.0015681628,0.0006359199,0.0005540502,0.0000061660135,0.0000068810705,0.012369248],"genre_scores_gemma":[0.99458325,0.00005627386,0.0040509393,0.00037384624,0.0004352997,0.000014733468,0.000023433882,0.000017554605,0.00044464413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778825,0.00015388476,0.0013793366,0.00020058519,0.0003114735,0.00016647782],"domain_scores_gemma":[0.9974476,0.00034835673,0.0009529644,0.00019700381,0.00082046335,0.00023361944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079519727,0.0001331072,0.00074056187,0.00012321863,0.00003833377,0.000020544121,0.00014424215,0.00017460075,0.00018645194],"category_scores_gemma":[0.0002960043,0.00009237916,0.00012976867,0.00011190455,0.00010465541,0.00012945865,0.000026944757,0.00053312426,0.000007161334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018798969,0.004648842,0.9776565,0.000025646219,0.00041888174,0.0009505773,0.0007728331,0.000119996104,0.0023816393,0.000006400053,0.00093433814,0.010204453],"study_design_scores_gemma":[0.020761725,0.010315723,0.963507,0.00010017748,0.0005378441,0.00025674084,0.0018142681,0.00044801628,0.00014479522,0.000021009819,0.0019832072,0.00010947222],"about_ca_topic_score_codex":0.00023482715,"about_ca_topic_score_gemma":0.000050484035,"teacher_disagreement_score":0.018881828,"about_ca_system_score_codex":0.00044748522,"about_ca_system_score_gemma":0.0020478505,"threshold_uncertainty_score":0.37671128},"labels":[],"label_agreement":null},{"id":"W2604289439","doi":"10.1200/jco.2014.32.15_suppl.e17700","title":"Population-based analysis of time to palliative chemotherapy (TPC) and survival in advanced non-small cell lung cancer (NSCLC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Proportional hazards model; Chemotherapy; Population; Cancer; Cancer registry; Stage (stratigraphy)","score_opus":0.034304220876474854,"score_gpt":0.4681306263126796,"score_spread":0.43382640543620477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604289439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933979,0.00017325662,0.001314252,0.0034572852,0.0001729739,0.00021763465,0.000009710312,0.0000025633592,0.0012544484],"genre_scores_gemma":[0.9925012,0.00016945458,0.0051803226,0.0016857524,0.00015354408,0.000007836346,0.000008257972,0.00001015065,0.00028347556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982457,0.00016134963,0.0011549059,0.00014797706,0.00016694442,0.00012308269],"domain_scores_gemma":[0.9971967,0.0013436778,0.0008809885,0.000109078755,0.00027568525,0.000193894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091575587,0.00009427746,0.0012795393,0.00026506302,0.000016198117,0.0000031286343,0.000059539238,0.00013277703,0.00021468184],"category_scores_gemma":[0.00042500484,0.00006841695,0.00024810724,0.00036231338,0.00003190618,0.00003478776,0.0000093485105,0.00020950704,0.000001923155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013775874,0.0006743811,0.95089823,0.000026442689,0.0009357547,0.000010195165,0.00030646683,0.0048814546,0.00022950256,0.0000051772427,0.00009116587,0.040563647],"study_design_scores_gemma":[0.008821495,0.0024407385,0.97710204,0.000096608404,0.0019323551,4.360667e-7,0.000044791133,0.0080223335,0.000086313536,0.000018241257,0.0013732004,0.00006142403],"about_ca_topic_score_codex":0.00031471136,"about_ca_topic_score_gemma":0.00058091653,"teacher_disagreement_score":0.04050222,"about_ca_system_score_codex":0.00018930636,"about_ca_system_score_gemma":0.00071211916,"threshold_uncertainty_score":0.2789962},"labels":[],"label_agreement":null},{"id":"W2604441806","doi":"10.1200/jco.2012.30.15_suppl.7541","title":"A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Phases of clinical research; Nausea; Adverse effect; Chemotherapy; Pemetrexed; Gastroenterology; Aflibercept; Oncology; Chemotherapy regimen; Surgery; Cisplatin; Bevacizumab","score_opus":0.03250744216774533,"score_gpt":0.43348421097930134,"score_spread":0.40097676881155603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604441806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725485,0.00046435444,0.000065075685,0.00018328564,0.00014886215,0.0016933379,0.0000074587665,0.000003334727,0.00017943453],"genre_scores_gemma":[0.99641085,0.00011553618,0.0031415317,0.00013515817,0.00003628339,0.000048576127,0.000008811679,0.000020701744,0.00008252941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764085,0.0002545938,0.0014120928,0.00017472911,0.00026887673,0.00024886432],"domain_scores_gemma":[0.9974845,0.00049848674,0.0012950004,0.00012522425,0.00036915948,0.0002276487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006705423,0.0001666484,0.0010867565,0.00026651687,0.000029762228,0.0000036769325,0.000059183923,0.00008808911,0.000036862],"category_scores_gemma":[0.00017723338,0.00010274505,0.00005958456,0.00028806378,0.00007590018,0.00020847001,0.000026503123,0.00040692015,4.551382e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012173499,0.057780456,0.8700212,0.00008267132,0.0003030233,0.00008058462,0.005585327,0.0001013772,0.000014240614,7.821455e-7,0.000024703893,0.053832084],"study_design_scores_gemma":[0.1689622,0.06683154,0.76111984,0.00037129322,0.0012219988,0.0000062061085,0.0010719361,0.0002674474,0.000015088895,0.0000014447915,0.000048414167,0.000082588274],"about_ca_topic_score_codex":0.00023188714,"about_ca_topic_score_gemma":0.0012060676,"teacher_disagreement_score":0.15678869,"about_ca_system_score_codex":0.0002816106,"about_ca_system_score_gemma":0.0005394351,"threshold_uncertainty_score":0.41898215},"labels":[],"label_agreement":null},{"id":"W2604835886","doi":"10.3389/fonc.2017.00033","title":"The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Immunotherapy; Medicine; Lung cancer; Targeted therapy; Cancer; Oncology; Lung; Cancer research; Internal medicine","score_opus":0.02760174251381286,"score_gpt":0.4003973173196842,"score_spread":0.37279557480587133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604835886","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010199063,0.9938887,0.00002296042,0.0003847347,0.00035058337,0.0021901042,0.000037735626,0.0000023995092,0.0021029084],"genre_scores_gemma":[0.0007213683,0.9965571,0.0013805146,0.00008761267,0.000026593987,0.00084437797,0.000035634566,0.000023556297,0.00032323648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858606,0.0002891306,0.00056236796,0.00022522628,0.000110664776,0.00022656024],"domain_scores_gemma":[0.99890006,0.00017421524,0.00048594424,0.00039653876,0.000024253322,0.000018974864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006556784,0.00020926475,0.0012082855,0.0002551841,0.000056627854,0.00000823143,0.00029280793,0.00013611544,0.00001147088],"category_scores_gemma":[0.000008348396,0.00011384958,0.00013747919,0.00021195045,0.0001383392,0.000026067019,0.000035390665,0.0002498227,1.3639303e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009655401,0.0002245178,0.0032380933,0.002011892,0.00073328643,0.000039370578,0.002358041,0.000006375476,0.0000023101127,0.00004309572,0.001347786,0.9898987],"study_design_scores_gemma":[0.0031406523,0.00021609056,0.0036229983,0.0025990382,0.000586079,0.0000037813309,0.0021394175,0.00003951106,0.00000523317,0.00008245349,0.9874611,0.00010364816],"about_ca_topic_score_codex":0.00093476404,"about_ca_topic_score_gemma":0.00044632837,"teacher_disagreement_score":0.989795,"about_ca_system_score_codex":0.00035400767,"about_ca_system_score_gemma":0.00037429045,"threshold_uncertainty_score":0.4642651},"labels":[],"label_agreement":null},{"id":"W2606398220","doi":"10.1016/j.ijrobp.2017.01.163","title":"Attrition in the Treatment of Metastatic Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Systemic therapy; Cancer; Retrospective cohort study; Performance status; Medical record; Attrition; Confounding; Cohort; Radiation therapy; Oncology","score_opus":0.036550172860902314,"score_gpt":0.4019950326550569,"score_spread":0.36544485979415464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606398220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873767,0.0016960489,0.0021423977,0.0054244855,0.0013403418,0.00046610014,0.00009895854,0.0000055003957,0.0014494589],"genre_scores_gemma":[0.99414885,0.0029524928,0.0014606008,0.00034765806,0.00086434884,0.000051945477,0.000058249923,0.000012013696,0.0001038235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989866,0.00009973982,0.00048709393,0.00012565643,0.0001717874,0.00012911738],"domain_scores_gemma":[0.9980817,0.00021456639,0.0010633334,0.00018657629,0.00040459723,0.000049271657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022282662,0.00012696449,0.0003617853,0.00011117706,0.00008983954,0.000025263776,0.0002727487,0.00007481265,0.000040372626],"category_scores_gemma":[0.000058562553,0.000083427396,0.00019188649,0.00005825913,0.00010945162,0.00016126425,0.0000128512365,0.00013721893,0.0000038458297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037368154,0.0027854764,0.8398083,0.000029553132,0.0012538448,0.00010815639,0.0039882683,0.00063155935,0.0028228627,0.0017152538,0.00067107956,0.14581198],"study_design_scores_gemma":[0.046901137,0.0076324157,0.86545587,0.00037427878,0.0033054976,0.00026252808,0.0010364678,0.005841023,0.014733042,0.0070218453,0.047073968,0.00036196123],"about_ca_topic_score_codex":0.00027743157,"about_ca_topic_score_gemma":0.000066935834,"teacher_disagreement_score":0.14545001,"about_ca_system_score_codex":0.00082294963,"about_ca_system_score_gemma":0.00057672133,"threshold_uncertainty_score":0.34020704},"labels":[],"label_agreement":null},{"id":"W2606483628","doi":"10.1016/j.bmcl.2017.04.064","title":"Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development","year":2017,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Foundation for Innovation; Cancer Research Society","keywords":"Chemistry; Scaffold; Quinazoline; Trk receptor; Radiosynthesis; Chemical synthesis; Combinatorial chemistry; Stereochemistry; In vitro; Biochemistry; Receptor; Positron emission tomography; Biomedical engineering; Neuroscience","score_opus":0.019138494958294543,"score_gpt":0.29709861881089605,"score_spread":0.2779601238526015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606483628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98820055,0.0003380989,0.00086750457,0.009666483,0.00013353977,0.00057834655,0.000011529606,0.00003926865,0.00016467932],"genre_scores_gemma":[0.9906177,0.000017651839,0.008172922,0.0004968815,0.00023254506,0.000096168085,0.000034811637,0.000034067267,0.00029725608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988763,0.000011626085,0.0002886364,0.0003188284,0.0002560765,0.00024858135],"domain_scores_gemma":[0.99897736,0.00012097709,0.00021794054,0.00036706723,0.00012746315,0.0001891652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019308012,0.00021453526,0.00037307388,0.000041951633,0.00030095904,0.000019577114,0.00013229066,0.00007507693,0.00013351474],"category_scores_gemma":[0.0003922634,0.00017424666,0.0000564956,0.00006637865,0.0001865089,0.000046516077,0.00003193231,0.000085227955,0.0000035219873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006465387,0.00023071254,0.00070824014,0.00057995477,0.0003197904,0.00009011794,0.00030244252,0.0000014811739,0.99176866,0.0000019757076,0.0021165325,0.003233571],"study_design_scores_gemma":[0.0041898587,0.00020556794,0.002542002,0.0005909476,0.0006709617,0.00013232228,0.000097984426,0.00010006417,0.9887842,0.000002869848,0.0025049031,0.0001783485],"about_ca_topic_score_codex":0.000035700195,"about_ca_topic_score_gemma":8.4748314e-7,"teacher_disagreement_score":0.009169601,"about_ca_system_score_codex":0.00021039939,"about_ca_system_score_gemma":0.00060150307,"threshold_uncertainty_score":0.7105573},"labels":[],"label_agreement":null},{"id":"W2607454228","doi":"10.1016/j.jtho.2017.04.003","title":"Plasma ctDNA Analysis for Detection of the EGFR  T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Chugai Pharmaceutical; Pfizer; AstraZeneca; Ono Pharmaceutical; Bristol-Myers Squibb; Eli Lilly and Company; Astellas Pharma","keywords":"T790M; Osimertinib; Medicine; Lung cancer; Internal medicine; Oncology; Mutation; Cancer; Pathology; Adenocarcinoma; Biology; Gene; ROS1; Genetics","score_opus":0.011154955999801906,"score_gpt":0.40021180272298307,"score_spread":0.38905684672318114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607454228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611926,0.000088950816,0.001979987,0.00057352957,0.00039833807,0.0005122651,0.000016153766,0.0000017460354,0.0003097738],"genre_scores_gemma":[0.9974263,0.000021900547,0.0021751218,0.000047666847,0.00006243046,0.00003562615,0.0000045690017,0.0000093710005,0.00021703918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927425,0.000037926915,0.00033052824,0.0000973606,0.00014610839,0.00011382836],"domain_scores_gemma":[0.9981572,0.000062714695,0.0011303807,0.00018227437,0.00041999394,0.00004744554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015955832,0.00008080254,0.00035870296,0.00019032204,0.00011511453,0.000009202663,0.000104818486,0.00007083864,0.000012151292],"category_scores_gemma":[0.00006892292,0.000047611342,0.00014440423,0.00015901659,0.000043197444,0.00012241385,0.0000143161715,0.00013101682,2.0842155e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033760273,0.0005352523,0.8443789,0.00012977695,0.0010192133,0.000012507516,0.0009411701,0.004755001,0.0015742774,0.0000014268453,0.000023454255,0.14325298],"study_design_scores_gemma":[0.0047525708,0.0018039753,0.9759082,0.00013266332,0.004494605,0.0000072253074,0.00019522167,0.0012944704,0.011054495,0.0000171947,0.00028654616,0.00005279549],"about_ca_topic_score_codex":0.0001037835,"about_ca_topic_score_gemma":0.0012215992,"teacher_disagreement_score":0.14320019,"about_ca_system_score_codex":0.0005216429,"about_ca_system_score_gemma":0.0003911453,"threshold_uncertainty_score":0.19415341},"labels":[],"label_agreement":null},{"id":"W2609015711","doi":"10.1200/jco.2016.71.2893","title":"Pooled Analysis of the Prognostic and Predictive Effects of <i>TP53</i> Comutation Status Combined With <i>KRAS</i> or <i>EGFR</i> Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; World Health Organization","keywords":"KRAS; Medicine; Hazard ratio; Internal medicine; Oncology; Adenocarcinoma; Proportional hazards model; Lung cancer; Stage (stratigraphy); Chemotherapy; Cancer; Colorectal cancer; Confidence interval; Biology","score_opus":0.045219409724995316,"score_gpt":0.44734358681033815,"score_spread":0.4021241770853428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609015711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657893,0.00042303817,0.00024580926,0.0008498027,0.00020878502,0.0014851878,0.00007020258,0.0000019162962,0.00013631175],"genre_scores_gemma":[0.9980853,0.00096439617,0.00061128807,0.00016292316,0.000047256402,0.000040329764,0.000007939821,0.000013672771,0.00006689905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961943,0.00076030404,0.002365938,0.0001750389,0.00033725626,0.0001671661],"domain_scores_gemma":[0.9888952,0.0045351437,0.0055813813,0.0002376936,0.0006355104,0.000115079565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021655618,0.0001433542,0.0023452502,0.0002875323,0.000037651178,0.00000801659,0.00013644162,0.00018952331,0.000013090834],"category_scores_gemma":[0.004192783,0.00007500886,0.00028734142,0.00044564728,0.0002646049,0.00011966261,0.000027676686,0.0003710145,3.645558e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023206806,0.0017278378,0.9559821,0.00035142706,0.0037770316,0.00013887172,0.0020047089,0.0013374006,0.002384371,0.00000427292,0.000026703909,0.00905851],"study_design_scores_gemma":[0.039905287,0.01202793,0.9300635,0.0008342614,0.010647284,0.000005020785,0.00019113942,0.002771686,0.0034516721,0.000024696596,0.000017589819,0.000059927348],"about_ca_topic_score_codex":0.0009718792,"about_ca_topic_score_gemma":0.003385086,"teacher_disagreement_score":0.025918555,"about_ca_system_score_codex":0.000176745,"about_ca_system_score_gemma":0.0019676567,"threshold_uncertainty_score":0.50194556},"labels":[],"label_agreement":null},{"id":"W2609723037","doi":"10.1016/j.lungcan.2017.04.016","title":"Uncommon EGFR mutations in advanced non-small cell lung cancer","year":2017,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Exon; Epidermal growth factor receptor; Point mutation; Lung cancer; Medicine; Cancer research; Mutation; Tyrosine kinase; Gefitinib; Gene; Genetics; Biology; Cancer; Oncology; Internal medicine; Receptor","score_opus":0.040083472598513976,"score_gpt":0.4348004016307965,"score_spread":0.3947169290322825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609723037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021206836,0.973859,0.000037412883,0.00028005906,0.0017607623,0.0038268566,0.0005942669,0.00007860945,0.019350974],"genre_scores_gemma":[0.0004060653,0.96718097,0.00039286798,0.0001842868,0.000628839,0.006762262,0.0006497035,0.0001803052,0.023614718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972989,0.00006721431,0.0008049636,0.00085167727,0.00032320892,0.00065404706],"domain_scores_gemma":[0.9976869,0.00011865831,0.00071518205,0.0010391742,0.000169802,0.00027024577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011479076,0.0007156984,0.002163444,0.00039613937,0.000267305,0.00008232752,0.00037252915,0.0004101035,0.0005570449],"category_scores_gemma":[0.000028886883,0.0005823736,0.0005646922,0.00042245572,0.00007975487,0.00017993752,0.00009365442,0.00073256856,0.000037252932],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029773393,0.0002484394,0.00604914,0.035462182,0.0011143825,0.00019218051,0.00075384084,0.00018529904,0.0000022976958,0.000027826984,0.006268657,0.94966596],"study_design_scores_gemma":[0.0024942553,0.000057602945,0.00086877024,0.04244018,0.009350734,0.000013675683,0.00004551241,0.00019107803,0.000006591406,0.000008592909,0.9439292,0.00059382746],"about_ca_topic_score_codex":0.0045008026,"about_ca_topic_score_gemma":0.0058072386,"teacher_disagreement_score":0.9490722,"about_ca_system_score_codex":0.0034549441,"about_ca_system_score_gemma":0.004058841,"threshold_uncertainty_score":0.99966276},"labels":[],"label_agreement":null},{"id":"W2609778940","doi":"10.1200/jco.2012.30.15_suppl.7586","title":"Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Single-nucleotide polymorphism; Medicine; Oncology; Internal medicine; Lung cancer; Hazard ratio; Genotype; Biology; Genetics; Gene; Confidence interval","score_opus":0.05036446819673839,"score_gpt":0.38306842211244996,"score_spread":0.33270395391571156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609778940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952135,0.0007299173,0.000023817915,0.00041080246,0.00095491164,0.00037044488,0.00006553452,0.0000039587585,0.002227077],"genre_scores_gemma":[0.9980378,0.00022823551,0.00064261485,0.00027871903,0.00038442525,0.00000566741,0.0000057816997,0.00002160752,0.00039514125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771315,0.00025096475,0.0013002119,0.000121115976,0.00038429158,0.00023026754],"domain_scores_gemma":[0.99533975,0.0009103911,0.0029013203,0.00012646736,0.0005083072,0.00021376275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079981674,0.00014085189,0.0008616423,0.00006421063,0.000046096193,0.000004358184,0.00009057942,0.00018679565,0.00008638451],"category_scores_gemma":[0.00027823236,0.00008215225,0.00019613365,0.00014444834,0.00010880498,0.00009487116,0.000037629554,0.00035896944,7.8899967e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010545846,0.0021650696,0.9800563,0.000062555475,0.0007155539,0.000008807176,0.00086173025,0.000031831707,0.0063342866,0.0000041833528,0.000344727,0.008360395],"study_design_scores_gemma":[0.013896872,0.0040426203,0.9692092,0.00021628951,0.0021916565,0.000006186398,0.0001952708,0.000080690086,0.008329429,0.000004395606,0.0017385798,0.00008879592],"about_ca_topic_score_codex":0.00015932893,"about_ca_topic_score_gemma":0.000080112724,"teacher_disagreement_score":0.012842287,"about_ca_system_score_codex":0.00032124444,"about_ca_system_score_gemma":0.0008995818,"threshold_uncertainty_score":0.33500713},"labels":[],"label_agreement":null},{"id":"W2609863464","doi":"10.1002/ijc.30750","title":"Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium","year":2017,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Centre Hospitalier de l’Université de Montréal","funders":"National Center for Research Resources; National Institute of Environmental Health Sciences; Canadian Cancer Society Research Institute; National Cancer Institute; Fondazione Cariplo; National Institutes of Health; Regione Lombardia; Università degli Studi di Genova; Cancer Care Ontario","keywords":"Medicine; Lung cancer; Menarche; Menopause; Risk factor; Breast cancer; Gynecology; Internal medicine; Cancer; Oncology; Physiology; Obstetrics","score_opus":0.013699700734757621,"score_gpt":0.38295216186355546,"score_spread":0.36925246112879784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609863464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95874375,0.017789494,0.00015474168,0.019389845,0.002493898,0.00018806793,0.0009020318,0.0000073491888,0.00033082717],"genre_scores_gemma":[0.98777485,0.009405032,0.00014462299,0.00045842392,0.0016667806,0.000040061434,0.000021144973,0.000015661168,0.00047343675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849313,0.000035179,0.0004019071,0.00029690037,0.0006322315,0.00014064809],"domain_scores_gemma":[0.9975587,0.00014114792,0.0009925605,0.00024218865,0.00093777786,0.00012762027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018261916,0.00017778217,0.00035865983,0.00016522048,0.0002475681,0.0002370938,0.00033477446,0.00005609233,0.0007524525],"category_scores_gemma":[0.00024226743,0.000109298606,0.00017515208,0.00006925525,0.0002037934,0.00037460506,0.00011081963,0.000272583,2.882703e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038544787,0.000045732613,0.95275074,0.0000049816085,0.032401804,0.000034710443,0.001792666,0.00019223969,0.00047582563,0.000063111926,0.0022437098,0.009609014],"study_design_scores_gemma":[0.0026146374,0.000030450623,0.9788516,0.00021590569,0.011891863,0.00001996485,0.00039035952,0.00155473,0.0010447337,0.00012229517,0.0031451401,0.000118306045],"about_ca_topic_score_codex":0.019849338,"about_ca_topic_score_gemma":0.0047683767,"teacher_disagreement_score":0.029031092,"about_ca_system_score_codex":0.00052578194,"about_ca_system_score_gemma":0.00043653048,"threshold_uncertainty_score":0.9866776},"labels":[],"label_agreement":null},{"id":"W2610105293","doi":"10.1177/1758834017704329","title":"Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Practice; Affect (linguistics); Lung cancer; Medical physics; Oncology; Intensive care medicine; Family medicine; Psychology","score_opus":0.31719594479789304,"score_gpt":0.5822947835792166,"score_spread":0.26509883878132356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610105293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000109721455,0.9923521,0.00041448761,0.0009995875,0.00024947166,0.0055158352,0.000046078047,0.000004320347,0.00030836085],"genre_scores_gemma":[0.00014508322,0.98440075,0.013844258,0.0008429075,0.000049687445,0.0006328195,0.000020132433,0.000026487407,0.000037889713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691874,0.00068386085,0.0014922288,0.00038595806,0.00030056495,0.00021864646],"domain_scores_gemma":[0.9888418,0.008171008,0.0020915768,0.0005594831,0.00021691894,0.00011924681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282215,0.00025596388,0.0026136613,0.00007176803,0.000029894552,0.0000030371846,0.00028692835,0.00034232592,0.00002185922],"category_scores_gemma":[0.0067777224,0.00015372114,0.00032644268,0.00028151344,0.0005500702,0.00011006113,0.00009847686,0.00052517763,1.3518577e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004064393,0.0004403649,0.0040198844,0.14587545,0.00019376786,0.000010007616,0.000085430096,0.000004348942,2.82273e-7,0.00007086736,0.00002161973,0.8492373],"study_design_scores_gemma":[0.0019679207,0.0006562028,0.0007076293,0.20157343,0.005921803,0.00003743577,0.000014997073,0.00006481096,0.000002897317,0.00024435442,0.78868735,0.000121158824],"about_ca_topic_score_codex":0.00019446334,"about_ca_topic_score_gemma":0.00019660234,"teacher_disagreement_score":0.84911615,"about_ca_system_score_codex":0.00024850166,"about_ca_system_score_gemma":0.00472752,"threshold_uncertainty_score":0.83864176},"labels":[],"label_agreement":null},{"id":"W2610324036","doi":"10.14740/wjon1017w","title":"What Can We Save for the First-Line Treatment of NSCLC in 2016?","year":2017,"lang":"en","type":"editorial","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.030797708253453387,"score_gpt":0.4082315311385027,"score_spread":0.3774338228850493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610324036","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014747896,0.04060796,0.00003149559,0.051094774,0.9047098,0.001195437,0.00015529328,0.000004079947,0.0020536536],"genre_scores_gemma":[0.0064546755,0.14906682,0.00055506924,0.00019764314,0.80719614,0.00018333254,0.00012154911,0.000065514105,0.03615923],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985976,0.000039183393,0.0006958313,0.00015724111,0.00028590657,0.0002242341],"domain_scores_gemma":[0.9961049,0.0016309157,0.001357421,0.00033226731,0.00047925333,0.00009526736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027545262,0.00021909969,0.0010718092,0.0003248507,0.000104863284,0.000026757632,0.00020665115,0.00027877485,0.00005782078],"category_scores_gemma":[0.00022670624,0.00011975448,0.00036078983,0.000073404495,0.00013131057,0.00008222664,0.000019149862,0.00034174387,0.0000020390075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013818904,0.00075183116,0.0001356476,0.00007584669,0.0011412491,0.00020584548,0.0011847197,0.00002383644,0.0000037822151,0.000013471841,0.7893374,0.2057445],"study_design_scores_gemma":[0.012428483,0.00715791,0.0002975313,0.0011622166,0.0022677523,0.000048483922,0.00020712538,0.000005751554,0.000027612374,0.00019234794,0.9761232,0.00008156864],"about_ca_topic_score_codex":0.00023147458,"about_ca_topic_score_gemma":0.016858816,"teacher_disagreement_score":0.20566294,"about_ca_system_score_codex":0.0017258198,"about_ca_system_score_gemma":0.0039328863,"threshold_uncertainty_score":0.94076145},"labels":[],"label_agreement":null},{"id":"W2610580219","doi":"10.3747/co.24.3524","title":"Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective","year":2017,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; T790M; Lung cancer; Clinical trial; Oncology; Targeted therapy; Liquid biopsy; Internal medicine; Epidermal growth factor receptor; Osimertinib; Pathology; Bioinformatics; Cancer; Erlotinib; Gefitinib; Biology","score_opus":0.2692291929302765,"score_gpt":0.6097416592307872,"score_spread":0.3405124663005107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610580219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003464053,0.9873743,0.00026377474,0.0009940763,0.0012683691,0.0025774941,0.0005164156,0.000026955653,0.006632207],"genre_scores_gemma":[0.00027577538,0.99553096,0.0017976265,0.000029959545,0.00033940026,0.001211798,0.0004931753,0.00004059197,0.00028069597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977555,0.00023351815,0.00086315547,0.0007619741,0.00010413025,0.00028169717],"domain_scores_gemma":[0.99742067,0.0004062389,0.000994942,0.000678334,0.00028044547,0.00021938361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021004947,0.00034281172,0.0021488047,0.00014077626,0.00012464992,0.000014631972,0.00017181352,0.00042539663,0.00008552466],"category_scores_gemma":[0.00007550031,0.00026647173,0.0003807917,0.00010979677,0.00039319595,0.000039915638,0.00020962252,0.0006518326,0.000020943038],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046208777,0.0015813111,0.0033969118,0.005971551,0.0021422182,0.00025422507,0.00037171738,5.1586188e-8,2.0103192e-7,0.0008985265,0.0020634811,0.9832736],"study_design_scores_gemma":[0.0029298146,0.0004465435,0.0057067145,0.004866506,0.023123303,0.00015077312,0.00024049892,0.000012554355,2.1430255e-7,0.00021136508,0.9620949,0.00021679148],"about_ca_topic_score_codex":0.00012253791,"about_ca_topic_score_gemma":0.000037167367,"teacher_disagreement_score":0.9830568,"about_ca_system_score_codex":0.0007558452,"about_ca_system_score_gemma":0.0020656164,"threshold_uncertainty_score":0.9999787},"labels":[],"label_agreement":null},{"id":"W2610732323","doi":"10.1002/cncy.21868","title":"Consistency and reproducibility of next‐generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens","year":2017,"lang":"en","type":"article","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Public Health Agency","keywords":"Medicine; Reproducibility; Computational biology; Consistency (knowledge bases); DNA sequencing; Medical physics; Molecular diagnostics; Bioinformatics; Oncology; Genetics; Biology; DNA; Chromatography; Artificial intelligence","score_opus":0.2648634268306701,"score_gpt":0.4402387328564022,"score_spread":0.1753753060257321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610732323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961643,0.00066930254,0.00017711811,0.00041271184,0.00022113882,0.0010157977,0.000046110243,0.000015118838,0.0012784089],"genre_scores_gemma":[0.99767077,0.00003078635,0.001734972,0.00019039013,0.00008918064,0.00017510475,0.00001104291,0.000010752626,0.00008700754],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99849695,0.00015910174,0.00030600192,0.00076540484,0.00013478828,0.00013774159],"domain_scores_gemma":[0.99876624,0.00010039734,0.00025229104,0.0006629627,0.00015377335,0.00006432083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005165991,0.00013639843,0.0003723027,0.00006636053,0.0002165756,0.000026802029,0.000052265143,0.00006730703,0.000029426143],"category_scores_gemma":[0.0009334816,0.00010892273,0.000032758173,0.000039048264,0.00031625206,0.000073557894,0.000045615372,0.00012300193,0.0000012325312],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009321061,0.0010481607,0.42665613,0.000087179345,0.00042974306,0.00072032824,0.008137329,0.00012600652,0.5309732,0.014309922,0.000018903986,0.00817207],"study_design_scores_gemma":[0.031046988,0.005183021,0.94136584,0.00011840154,0.0005911963,0.0001173337,0.0021560653,0.0004925454,0.01777742,0.000835242,0.000079034486,0.0002369378],"about_ca_topic_score_codex":0.00041512813,"about_ca_topic_score_gemma":0.00037363885,"teacher_disagreement_score":0.5147097,"about_ca_system_score_codex":0.00014093851,"about_ca_system_score_gemma":0.00020760871,"threshold_uncertainty_score":0.444174},"labels":[],"label_agreement":null},{"id":"W2611044189","doi":"10.1016/j.jmb.2017.04.018","title":"Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer","year":2017,"lang":"en","type":"review","venue":"Journal of Molecular Biology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Cancer Research UK","keywords":"Synthetic lethality; Lethality; Context (archaeology); Epidermal growth factor receptor; Computational biology; Biology; Acquired resistance; Cancer; Neuroscience; Cancer research; Genetics; DNA repair","score_opus":0.047350952743329094,"score_gpt":0.45301065935330126,"score_spread":0.4056597066099722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611044189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001878749,0.9953877,0.00045525367,0.00074301386,0.0006209802,0.0005210775,0.00003956439,0.000004839793,0.00034884535],"genre_scores_gemma":[0.0038357205,0.9933311,0.0017248507,0.00027377892,0.0006021736,0.000066201545,0.000019424408,0.000033677865,0.000113114336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818873,0.00030670347,0.0007908185,0.0003068116,0.00008128508,0.00032567664],"domain_scores_gemma":[0.9983935,0.0001478174,0.0008678606,0.00030369544,0.00011892918,0.00016820562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048670618,0.00026916826,0.0018404521,0.00023492353,0.00007188206,0.000017567038,0.00016524426,0.00032770017,0.00001784279],"category_scores_gemma":[0.00030639203,0.00018937422,0.00028434707,0.00012847711,0.00010214574,0.000031623684,0.000084220366,0.00045693398,0.0000015834277],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024094051,0.00018942972,0.005702278,0.01033803,0.0027173124,0.0015276829,0.00032836644,0.000010397009,0.00045900428,0.0026043588,0.0011819699,0.9747002],"study_design_scores_gemma":[0.0009523921,0.0003024643,0.00035428276,0.024462892,0.0018995752,0.00031813356,0.000010237448,6.5175055e-7,0.000010685106,0.00076839974,0.97068346,0.00023682264],"about_ca_topic_score_codex":0.00008378745,"about_ca_topic_score_gemma":0.00009315134,"teacher_disagreement_score":0.9744634,"about_ca_system_score_codex":0.0004239208,"about_ca_system_score_gemma":0.0005997644,"threshold_uncertainty_score":0.77224565},"labels":[],"label_agreement":null},{"id":"W2611207416","doi":"10.3747/co.24.3495","title":"Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Mount Sinai Hospital; Trillium Health Centre; University of Toronto; University Health Network; University of Ottawa; Princess Margaret Cancer Centre; Cancer Care Ontario; Barrie Urology Group; Women's College Hospital; McMaster University","funders":"Government of Ontario; Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Medicine; Lung cancer; Context (archaeology); Medical physics; Personalized medicine; Cancer; Specialty; Pathology; Intensive care medicine; Bioinformatics; Internal medicine","score_opus":0.06377226674774933,"score_gpt":0.42121386995421906,"score_spread":0.3574416032064697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611207416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858929,0.0047336505,0.00007872831,0.0011259683,0.00050099875,0.00055038463,0.0000025237239,0.000009287684,0.007105563],"genre_scores_gemma":[0.99849206,0.00012958555,0.0006505594,0.00011048566,0.00008499434,0.00015858407,0.000008189118,0.000012380004,0.000353154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992032,0.000021957743,0.00020755995,0.0002619304,0.000079319165,0.00022599939],"domain_scores_gemma":[0.99946344,0.00006770153,0.00014154665,0.00017851724,0.000057460973,0.000091332025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014024889,0.000120791105,0.00032587355,0.000083145096,0.00008593397,0.000011276224,0.00006983233,0.000067541056,0.000091486116],"category_scores_gemma":[0.00015276547,0.000099036544,0.000021341626,0.000051645424,0.000112159214,0.00004931322,0.000057421406,0.00027744926,0.0000011029629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004641086,0.00018018171,0.90600187,0.0001539776,0.000021814614,0.00018101923,0.0031866145,0.000005686469,0.0031651696,0.000019665298,0.000047975554,0.086989634],"study_design_scores_gemma":[0.01338105,0.00037868787,0.9785712,0.0008156098,0.0003321228,0.000024855639,0.0003167029,0.00307223,0.00012951334,0.000046851153,0.0027945808,0.00013660839],"about_ca_topic_score_codex":0.12547372,"about_ca_topic_score_gemma":0.1606139,"teacher_disagreement_score":0.08685303,"about_ca_system_score_codex":0.0010412658,"about_ca_system_score_gemma":0.0006492814,"threshold_uncertainty_score":0.8803498},"labels":[],"label_agreement":null},{"id":"W2611252707","doi":"10.1200/jco.2007.25.18_suppl.7571","title":"Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (<i>EGFR</i>) gene and codons 12 and 13 of the <i>KRAS</i> gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Exon; Gefitinib; Epidermal growth factor receptor; Erlotinib; Polysomy; Molecular biology; Medicine; Copy-number variation; Gene; EGFR inhibitors; Point mutation; Cancer research; Cancer; Biology; Mutation; Internal medicine; Genetics; Fluorescence in situ hybridization; Genome","score_opus":0.05193385057218633,"score_gpt":0.43144863797094735,"score_spread":0.379514787398761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611252707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559885,0.0023469091,0.000026199568,0.0009212412,0.00021744345,0.0004904665,0.00024287657,0.0000010968148,0.00015489952],"genre_scores_gemma":[0.99626637,0.002526478,0.00065317634,0.00043080054,0.000055921893,0.000012603431,0.000007309386,0.00001197839,0.000035359306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976464,0.00017509915,0.0015225153,0.00017552148,0.00031777425,0.00016272094],"domain_scores_gemma":[0.9969124,0.0004185949,0.0017498448,0.0001091797,0.0006740232,0.00013592542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051867595,0.00014694186,0.0009619083,0.00016096196,0.00002920896,0.000002265168,0.00010416268,0.00016534446,0.000024566094],"category_scores_gemma":[0.00027615545,0.000079635865,0.0001241169,0.0003463612,0.00048244387,0.00007762388,0.00005284905,0.00031152027,1.595561e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014797306,0.0007298666,0.9736865,0.00010823337,0.0006176366,0.000010922723,0.00045017948,0.0003591375,0.020769872,0.000007214434,0.000104103885,0.0016766042],"study_design_scores_gemma":[0.011217111,0.0009352697,0.9506713,0.00035528492,0.00078366796,0.000007686395,0.000066045075,0.00006228767,0.035654284,0.000008528001,0.00017051623,0.000068014066],"about_ca_topic_score_codex":0.0062759095,"about_ca_topic_score_gemma":0.010927005,"teacher_disagreement_score":0.023015194,"about_ca_system_score_codex":0.00020018022,"about_ca_system_score_gemma":0.0019681023,"threshold_uncertainty_score":0.948734},"labels":[],"label_agreement":null},{"id":"W2612006186","doi":"10.2147/ott.s104177","title":"New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib","year":2017,"lang":"en","type":"review","venue":"OncoTargets and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Afatinib; Medicine; Nivolumab; Lung cancer; Pembrolizumab; Ramucirumab; Oncology; Docetaxel; Context (archaeology); Squamous-cell carcinoma of the lung; Internal medicine; Chemotherapy; Cancer; Intensive care medicine; Immunotherapy; Epidermal growth factor receptor; Erlotinib","score_opus":0.05241281530813648,"score_gpt":0.4199899764586437,"score_spread":0.36757716115050726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612006186","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006498618,0.9890403,0.000001460703,0.000155832,0.00022221294,0.0021120731,0.00006182765,0.000009681598,0.0077467514],"genre_scores_gemma":[0.0016595959,0.9945685,0.00033149103,0.00006104127,0.00015116588,0.00048749807,0.000082223465,0.000039377173,0.002619077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885386,0.000051767063,0.0003664908,0.00032130623,0.00018913997,0.0002174575],"domain_scores_gemma":[0.9990187,0.000112448695,0.00034579006,0.00040742353,0.000027888706,0.000087697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059946953,0.00036634965,0.0011750371,0.000106927095,0.00011561805,0.00002364983,0.00012640946,0.00012111632,0.000053016232],"category_scores_gemma":[0.000003960512,0.00018221143,0.00021504928,0.000086704196,0.000028342309,0.00003374887,0.000006804004,0.00010786488,0.0000034414309],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077558136,0.00055479206,0.00040605987,0.0007144097,0.00026042433,0.00003388868,0.0014539531,4.978373e-7,5.6297733e-7,0.000042562802,0.00026300765,0.9961923],"study_design_scores_gemma":[0.0048226854,0.001321047,0.000698233,0.0025509337,0.00056547625,0.000006986198,0.000031220796,5.3940306e-7,0.000019485142,0.000030864256,0.98978734,0.00016516855],"about_ca_topic_score_codex":0.0007188202,"about_ca_topic_score_gemma":0.000119862285,"teacher_disagreement_score":0.9960271,"about_ca_system_score_codex":0.0002866948,"about_ca_system_score_gemma":0.0008675091,"threshold_uncertainty_score":0.7430366},"labels":[],"label_agreement":null},{"id":"W2612399534","doi":"10.1016/j.lungcan.2017.05.010","title":"Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Afatinib; Erlotinib; Medicine; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Population; Gastroenterology; Adenocarcinoma; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.01816073625509867,"score_gpt":0.3500462134743749,"score_spread":0.33188547721927625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612399534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887367,0.00029945903,0.0000015419068,0.00023656039,0.00008437251,0.0094346665,0.00019865,0.000007709033,0.0010003694],"genre_scores_gemma":[0.99794537,0.0000019058024,0.000020824411,0.00004828848,0.000031868047,0.0012769278,0.000021635098,0.000030474952,0.0006226797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799174,0.00020062807,0.0004130229,0.00031368763,0.00084413897,0.00023675681],"domain_scores_gemma":[0.9979091,0.000070186215,0.0006004771,0.00095049076,0.00043096635,0.00003876948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003949301,0.00023255147,0.00035840395,0.000056917037,0.00021341945,0.000023960527,0.0003138923,0.000051542753,0.00013330978],"category_scores_gemma":[0.00010396028,0.00009647708,0.000051933403,0.00035079115,0.000131807,0.00014962353,0.000042697593,0.00021474891,1.8379964e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019330312,0.0026148097,0.9876743,0.00017641862,0.000107324486,0.0000072132934,0.005012426,0.0005075082,0.00035000057,0.0000018284364,0.000058830647,0.0015562845],"study_design_scores_gemma":[0.048888233,0.0019870051,0.93838876,0.00047333725,0.0013814787,0.0000013353407,0.0013704589,0.0017948403,0.005581689,0.0000016291181,0.000010194003,0.00012104666],"about_ca_topic_score_codex":0.001973308,"about_ca_topic_score_gemma":0.01466972,"teacher_disagreement_score":0.049285572,"about_ca_system_score_codex":0.00046558422,"about_ca_system_score_gemma":0.0009583559,"threshold_uncertainty_score":0.81860477},"labels":[],"label_agreement":null},{"id":"W2612481440","doi":"10.1093/annonc/mdx091.031","title":"Pharmacist led proactive follow-up algorithm for advanced EGFR positive NSCLC patients on afatinib","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York Central Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Afatinib; Rash; Nausea; Internal medicine; Diarrhea; Adverse effect; Stomatitis; Anorexia; Algorithm; Gastroenterology; Surgery; Erlotinib; Cancer","score_opus":0.07598121900764358,"score_gpt":0.47676101371144064,"score_spread":0.40077979470379704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612481440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8549226,0.0001464696,0.0011401471,0.010511538,0.0020380663,0.0046192817,0.001119042,0.000048436745,0.12545444],"genre_scores_gemma":[0.991591,0.000066428605,0.003724554,0.0014913937,0.00013787232,0.0003732436,0.00023756064,0.000022260961,0.0023557192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991582,0.000028983763,0.00021084378,0.00024307118,0.00013184105,0.00022706293],"domain_scores_gemma":[0.9985913,0.0001337756,0.00033335507,0.00024935434,0.0005902935,0.000101912156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008382585,0.00013477699,0.00037270976,0.0000619661,0.00022602729,0.000009128406,0.000098625256,0.000081243255,0.0000300651],"category_scores_gemma":[0.00018507647,0.00010961103,0.00014310435,0.000030320345,0.000109211505,0.00012452292,0.00002634443,0.00008271867,0.000015434189],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002566695,0.0015674992,0.0018888537,0.000021500764,0.0008048023,0.000016532278,0.00091901596,0.0000012545752,0.00038350315,0.00020277375,0.004136151,0.9874914],"study_design_scores_gemma":[0.16086015,0.08180841,0.31049055,0.000574525,0.002489139,0.000025780206,0.0010146698,0.0008128695,0.24012092,0.0020196869,0.1989398,0.0008435051],"about_ca_topic_score_codex":0.00004349812,"about_ca_topic_score_gemma":0.000011835099,"teacher_disagreement_score":0.9866479,"about_ca_system_score_codex":0.000108885775,"about_ca_system_score_gemma":0.00024272544,"threshold_uncertainty_score":0.4469808},"labels":[],"label_agreement":null},{"id":"W2612571093","doi":"10.1093/annonc/mdx091.039","title":"A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Pemetrexed; Ramucirumab; Internal medicine; Oncology; Cisplatin; non-small cell lung cancer (NSCLC); Chemotherapy; Phases of clinical research; Lung cancer","score_opus":0.08800601839666418,"score_gpt":0.4505259432474428,"score_spread":0.3625199248507786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612571093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020785,0.0003207373,0.00006638874,0.0015198549,0.0002242213,0.006011179,0.0004953623,0.0000124461285,0.001141957],"genre_scores_gemma":[0.996532,0.00025230047,0.0013613577,0.0004408489,0.000053677955,0.00075440505,0.00024591564,0.000037246,0.00032221887],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772936,0.0001494673,0.0009607294,0.00053291314,0.00028783345,0.0003397156],"domain_scores_gemma":[0.99665487,0.0005874239,0.0013954767,0.00071025983,0.0005119208,0.00014005597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039431808,0.00030256814,0.0016160726,0.00015010539,0.00014520019,0.000021173739,0.00037318136,0.00013636285,0.00009611449],"category_scores_gemma":[0.00034466045,0.00020623158,0.00008244567,0.00014024404,0.0001603965,0.0001318688,0.00008115349,0.00020170577,0.0000014870681],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8204702,0.054118156,0.0068326867,0.00014334814,0.00067977956,0.000117336625,0.0070816856,0.0006963016,0.00008998959,0.0000012972727,0.0008916586,0.10887756],"study_design_scores_gemma":[0.94295025,0.04008703,0.009844365,0.00065936946,0.0006144149,7.379826e-7,0.00028164397,0.0033100822,0.0014207858,0.000010996663,0.0006116145,0.00020869612],"about_ca_topic_score_codex":0.006825402,"about_ca_topic_score_gemma":0.010246394,"teacher_disagreement_score":0.122480065,"about_ca_system_score_codex":0.0002521338,"about_ca_system_score_gemma":0.0014781691,"threshold_uncertainty_score":0.9997882},"labels":[],"label_agreement":null},{"id":"W2612623181","doi":"10.1093/annonc/mdx091.061","title":"ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Internal medicine; Oncology; Ceritinib; Lung cancer; Hazard ratio; Clinical trial; Cancer; Crizotinib; Gefitinib; Epidermal growth factor receptor; Confidence interval; Erlotinib","score_opus":0.06719118390064971,"score_gpt":0.4620846983699624,"score_spread":0.3948935144693127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612623181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689459,0.00047580898,0.0000040113655,0.0013765305,0.00016954866,0.0014710878,0.00007385319,0.000007775336,0.027475486],"genre_scores_gemma":[0.996981,0.0007684046,0.00020210273,0.00016508557,0.00007160281,0.0002632018,0.000018793415,0.000017280243,0.0015125282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884236,0.00007001909,0.00043277777,0.00027109584,0.00012072161,0.00026303745],"domain_scores_gemma":[0.99870026,0.00010406657,0.0004769177,0.00039980878,0.00021578767,0.00010313179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011060683,0.00016737962,0.0006167949,0.00018478316,0.00008025282,0.000006969833,0.00012572171,0.00007328164,0.000056811274],"category_scores_gemma":[0.000023371147,0.00013251921,0.000104161714,0.00008896882,0.00008236383,0.000065461696,0.000051695442,0.00009348813,0.0000032890152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001616901,0.015954666,0.9206266,0.0000790661,0.0010302209,0.00022911181,0.013376974,0.000043152126,0.001120344,0.000010576777,0.0006402439,0.04527218],"study_design_scores_gemma":[0.02164516,0.010512212,0.95038104,0.00028695594,0.0008528551,0.0000018537081,0.0019802367,0.00013806338,0.013175876,0.000005218862,0.00090971444,0.00011083513],"about_ca_topic_score_codex":0.03824922,"about_ca_topic_score_gemma":0.022793978,"teacher_disagreement_score":0.045161344,"about_ca_system_score_codex":0.00027065128,"about_ca_system_score_gemma":0.0005335789,"threshold_uncertainty_score":0.9950375},"labels":[],"label_agreement":null},{"id":"W2612729833","doi":"10.1093/annonc/mdx195.002","title":"Establishment of a diagnostic algorithm for ROS1 testing in Canada","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Institut universitaire de cardiologie et de pneumologie de Québec; Capital District Health Authority; University Health Network; CancerCare Manitoba; Health Sciences Centre; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; University of Alberta; William Osler Health System; Princess Margaret Cancer Centre","funders":"","keywords":"ROS1; Crizotinib; Medicine; Immunohistochemistry; Lung cancer; Fluorescence in situ hybridization; Adenocarcinoma; Oncology; Fish <Actinopterygii>; Pathology; Internal medicine; Cancer; Algorithm; Biology; Gene; Computer science; Genetics","score_opus":0.08863118656972734,"score_gpt":0.43400513045276834,"score_spread":0.345373943883041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612729833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696834,0.00074138405,0.00031754264,0.01025755,0.00041754733,0.0010363008,0.00021959288,0.0000058213673,0.017320849],"genre_scores_gemma":[0.99294007,0.000062085346,0.0064089587,0.00035020133,0.00003751933,0.00007367053,0.000013021171,0.00000524484,0.00010922631],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995255,0.000008367051,0.00018882893,0.00008408018,0.000066018896,0.00012720161],"domain_scores_gemma":[0.99877757,0.0006450929,0.00018861334,0.00015670471,0.00018771423,0.00004432197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009403702,0.000045743396,0.00023451116,0.000034256787,0.000035945166,0.0000022549727,0.000058776273,0.000026329419,0.000010103881],"category_scores_gemma":[0.0013970515,0.000039053702,0.000024539519,0.000030196721,0.000037182115,0.000032808653,0.000018726882,0.000030947496,2.2868981e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029847683,0.0002685078,0.12662135,0.00006690107,0.0000854198,0.00006178168,0.0001628413,0.000024671554,0.00012068439,0.000066678775,0.0036042659,0.86888707],"study_design_scores_gemma":[0.005906361,0.004037764,0.93805486,0.0003388862,0.00021656633,0.000021540247,0.0004617058,0.0014820491,0.0068978188,0.0006383906,0.041832764,0.00011127944],"about_ca_topic_score_codex":0.7142676,"about_ca_topic_score_gemma":0.5420548,"teacher_disagreement_score":0.8687758,"about_ca_system_score_codex":0.00013805958,"about_ca_system_score_gemma":0.0022594775,"threshold_uncertainty_score":0.4663015},"labels":[],"label_agreement":null},{"id":"W2612777803","doi":"10.1093/annonc/mdx091.013","title":"Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Gefitinib; Discontinuation; Clinical endpoint; Lung cancer; Gastroenterology; Oncology; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.08899710198320918,"score_gpt":0.4670936908508817,"score_spread":0.3780965888676725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612777803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976984,0.00012029637,0.000045729877,0.010762886,0.00033624406,0.001744619,0.0019039839,0.000017822995,0.008084365],"genre_scores_gemma":[0.99109066,0.00003894215,0.00038889644,0.0016977089,0.00024154992,0.000084171545,0.0062620817,0.00002182237,0.00017416556],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99850965,0.00013889636,0.00043198065,0.00038929092,0.00026606864,0.0002641058],"domain_scores_gemma":[0.9976142,0.00034687872,0.0005515182,0.0010338,0.00035465418,0.00009894938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026829593,0.00017444904,0.00048243807,0.000068465735,0.0002317624,0.0000340633,0.00041462702,0.00012343818,0.00029906374],"category_scores_gemma":[0.00038270134,0.00011197033,0.000054698565,0.00009516789,0.00023979678,0.00031540668,0.00012712445,0.00018948571,0.00002095598],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2947929,0.02019582,0.2696606,0.00006364217,0.0052248463,0.0007200779,0.009382182,0.00003482296,0.00018444446,0.000787515,0.13511607,0.2638371],"study_design_scores_gemma":[0.30150798,0.013386795,0.6599296,0.00026882679,0.0010874623,0.0000063363577,0.0004966021,0.00034811767,0.000555358,0.0002030589,0.021954903,0.00025496545],"about_ca_topic_score_codex":0.0016094137,"about_ca_topic_score_gemma":0.00069000374,"teacher_disagreement_score":0.39026898,"about_ca_system_score_codex":0.00007263614,"about_ca_system_score_gemma":0.0005975329,"threshold_uncertainty_score":0.45660174},"labels":[],"label_agreement":null},{"id":"W2612955291","doi":"10.3389/fonc.2017.00097","title":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Medicine; Lung cancer; Oncology; Cancer research; Internal medicine; Cetuximab; Tyrosine kinase; EGFR inhibitors; Cancer; Receptor","score_opus":0.04784615567394414,"score_gpt":0.39475463412912754,"score_spread":0.3469084784551834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612955291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011550031,0.98991066,0.000090221656,0.00028791858,0.0015428,0.004230075,0.00048589017,0.000017016613,0.0022803922],"genre_scores_gemma":[0.0010690121,0.9866154,0.008205639,0.000035230456,0.00021105989,0.0022385244,0.00029510897,0.00009312552,0.0012368708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753845,0.00023445724,0.00091014575,0.00063755055,0.00019262871,0.00048674498],"domain_scores_gemma":[0.99804306,0.00020962062,0.0009739761,0.000506741,0.00008542929,0.00018115938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001140611,0.00061400025,0.0036494397,0.00075893744,0.000060623588,0.000011630064,0.0001778087,0.00033848596,0.00006157041],"category_scores_gemma":[0.000057191126,0.0004090949,0.00033337655,0.00030516853,0.00016371769,0.000057941572,0.000028992392,0.00033419125,0.0000057971984],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004297216,0.0024019552,0.010843595,0.007479453,0.0010614125,0.00064310106,0.0012268639,0.0000065384766,0.0000016172384,0.000008761725,0.0037840488,0.97211295],"study_design_scores_gemma":[0.017090945,0.009636522,0.00087393983,0.020932686,0.007205925,0.00003712454,0.00027281887,0.000033303368,0.00018670865,0.000019050121,0.94306445,0.0006465361],"about_ca_topic_score_codex":0.0020815348,"about_ca_topic_score_gemma":0.00092916435,"teacher_disagreement_score":0.9714664,"about_ca_system_score_codex":0.0045733512,"about_ca_system_score_gemma":0.003263451,"threshold_uncertainty_score":0.9998361},"labels":[],"label_agreement":null},{"id":"W2613561165","doi":"10.1093/annonc/mdx091.022","title":"LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Afatinib; Medicine; Oncology; Squamous-cell carcinoma of the lung; Lung; Internal medicine; Carcinoma; Basal cell; Cancer; Gefitinib","score_opus":0.03757846680497356,"score_gpt":0.4270860889978361,"score_spread":0.38950762219286256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613561165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961897,0.00016992679,0.000016711729,0.0008605589,0.000121728175,0.0013025256,0.00016498782,0.0000040263735,0.0011698059],"genre_scores_gemma":[0.9989921,0.000008218846,0.000118851545,0.00023385692,0.000018837338,0.00005810046,0.00005241039,0.000013672573,0.000503951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986608,0.00014053442,0.0005675924,0.0002257517,0.00020844614,0.00019689118],"domain_scores_gemma":[0.99776375,0.00023074335,0.0007980501,0.00071603246,0.00040116656,0.00009026472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031355408,0.00014071882,0.00082133507,0.0003175344,0.00006400663,0.0000037858563,0.00020217967,0.00008402156,0.00012287122],"category_scores_gemma":[0.00025579278,0.000088331006,0.00018334427,0.0003325551,0.00013541937,0.00007321258,0.00006395685,0.00009002088,4.945322e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18317398,0.0046466165,0.79742634,0.00013142922,0.000843843,0.00003934547,0.0025095248,0.00024416388,0.0018760512,0.000007197857,0.00031640375,0.008785111],"study_design_scores_gemma":[0.09738126,0.011349479,0.87918204,0.000054310716,0.0016082737,4.3802015e-7,0.000082171464,0.00005199521,0.010081152,0.0000018336294,0.00013257345,0.00007445414],"about_ca_topic_score_codex":0.00019571347,"about_ca_topic_score_gemma":0.0005785144,"teacher_disagreement_score":0.08579273,"about_ca_system_score_codex":0.00008529024,"about_ca_system_score_gemma":0.0004219597,"threshold_uncertainty_score":0.3602034},"labels":[],"label_agreement":null},{"id":"W2613587169","doi":"10.1016/j.jtho.2016.11.540","title":"P1.01-016 An International Epidemiological Analysis of Young Patients Diagnosed with NSCLC (AduJov - CLICaP)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Stage (stratigraphy); Adenocarcinoma; Population; Lung cancer; Retrospective cohort study; Cancer","score_opus":0.03913262411329611,"score_gpt":0.489806248689828,"score_spread":0.45067362457653193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613587169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897133,0.00006251632,0.0004593122,0.0020755935,0.00049410196,0.0001519439,0.000034757213,0.000006222316,0.00700224],"genre_scores_gemma":[0.99378014,0.00014271941,0.0052469857,0.00031720137,0.00024230938,0.000007734766,0.00005491754,0.00000931652,0.00019865533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986041,0.00014987774,0.0006183829,0.0001678382,0.00029684947,0.00016290566],"domain_scores_gemma":[0.9972335,0.0002146548,0.0014889505,0.00033815068,0.0005338474,0.00019090109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005298338,0.00012289658,0.00080518215,0.00031318312,0.00011364795,0.000018966515,0.0002882511,0.00012865891,0.00025306904],"category_scores_gemma":[0.00066672504,0.00007181987,0.00025332114,0.00011836684,0.00017990089,0.0002820057,0.000043011856,0.0002224898,0.000003252743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017155273,0.0014029028,0.91927457,0.000008899409,0.0037276556,0.00025489889,0.00039464404,0.000077420846,0.000087584835,0.00007678688,0.0004068869,0.072572224],"study_design_scores_gemma":[0.0020020718,0.003798274,0.98452055,0.00006749532,0.0052662236,0.00006550278,0.00019325347,0.0001996566,0.000058911453,0.00006900412,0.003694703,0.00006436438],"about_ca_topic_score_codex":0.0001129656,"about_ca_topic_score_gemma":0.0001621587,"teacher_disagreement_score":0.07250786,"about_ca_system_score_codex":0.00029467937,"about_ca_system_score_gemma":0.0002541003,"threshold_uncertainty_score":0.29287294},"labels":[],"label_agreement":null},{"id":"W2613815573","doi":"10.1093/annonc/mdx091.040","title":"Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ramucirumab; Docetaxel; Medicine; Internal medicine; Oncology; Adverse effect; Adenocarcinoma; Neutropenia; Chemotherapy; Phases of clinical research; Surgery; Cancer; Gastroenterology","score_opus":0.06405871301770999,"score_gpt":0.4300355723682339,"score_spread":0.36597685935052393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613815573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033767,0.0008184051,0.00053723744,0.0005066807,0.00008075046,0.0056483825,0.0017967798,0.0000072499006,0.00026685826],"genre_scores_gemma":[0.9955435,0.00060278,0.0009765847,0.0001708151,0.00005322825,0.00080599333,0.0002618273,0.000035241203,0.0015500241],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979506,0.00009815438,0.0010370333,0.0004207516,0.00023942105,0.00025402417],"domain_scores_gemma":[0.99586695,0.0005519447,0.0018276541,0.00076492975,0.00083953637,0.00014900704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028043025,0.00028703647,0.0027060108,0.00035203565,0.00008448141,0.0000054730262,0.00018993033,0.00012280206,0.00042283267],"category_scores_gemma":[0.00009166707,0.00018484608,0.00037837602,0.00022335569,0.00014686173,0.00007114218,0.000030874508,0.000057914007,2.6648937e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75583804,0.04025606,0.12602079,0.00048531705,0.032384593,0.000036137975,0.022225816,0.00038843893,0.0019991738,0.0000033115787,0.0004700155,0.019892316],"study_design_scores_gemma":[0.82902044,0.06272741,0.064671814,0.00019837018,0.01781508,4.516132e-7,0.0010589006,0.0009023524,0.02224771,0.000005310112,0.0011372901,0.00021488777],"about_ca_topic_score_codex":0.008429721,"about_ca_topic_score_gemma":0.012255232,"teacher_disagreement_score":0.073182404,"about_ca_system_score_codex":0.00017427791,"about_ca_system_score_gemma":0.0005970282,"threshold_uncertainty_score":0.99817324},"labels":[],"label_agreement":null},{"id":"W2614025577","doi":"10.1093/annonc/mdx091.020","title":"Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Afatinib; Gefitinib; Internal medicine; Clinical endpoint; Post-hoc analysis; Log-rank test; Gastroenterology; Clinical trial; Oncology; Survival analysis; Cancer","score_opus":0.04144403855572252,"score_gpt":0.43218556591083973,"score_spread":0.3907415273551172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614025577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916772,0.00022736259,0.000024119176,0.0012498343,0.000030071678,0.0020660036,0.0015846451,0.00001119846,0.0031295156],"genre_scores_gemma":[0.99596053,0.00016786964,0.0020268527,0.00009809508,0.000047021826,0.00029802756,0.000556382,0.000026304486,0.0008189153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985294,0.000046554283,0.00053533266,0.00037086775,0.00019858291,0.00031930182],"domain_scores_gemma":[0.9975057,0.00022552212,0.00080942264,0.00061857863,0.0006036348,0.000237125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010079944,0.00029679947,0.0013912604,0.00035992925,0.00011394585,0.00001026617,0.00010515476,0.00012664127,0.00027026676],"category_scores_gemma":[0.000089040535,0.00018729048,0.0004379986,0.00019675252,0.00017238449,0.00010265123,0.000035221365,0.000029050741,0.000003950806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011346783,0.009991124,0.6589935,0.00017938844,0.04254138,0.000025122896,0.004565093,0.00046234997,0.0012634624,0.00013639603,0.0027215858,0.2677738],"study_design_scores_gemma":[0.017798454,0.06689463,0.8979975,0.00012588361,0.011273472,0.0000034441323,0.00019512833,0.000207249,0.0022048801,0.000017692111,0.0030990494,0.00018262852],"about_ca_topic_score_codex":0.0012545616,"about_ca_topic_score_gemma":0.00036459975,"teacher_disagreement_score":0.26759118,"about_ca_system_score_codex":0.00027973615,"about_ca_system_score_gemma":0.00047951122,"threshold_uncertainty_score":0.7637484},"labels":[],"label_agreement":null},{"id":"W2614942658","doi":"10.1016/j.jtho.2017.05.002","title":"EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; T790M; Afatinib; Gefitinib; Internal medicine; Oncology; Erlotinib; Sanger sequencing; Mutation; Genotyping; Cancer; Epidermal growth factor receptor; Genetics; Genotype; Gene; Biology","score_opus":0.052111973696244984,"score_gpt":0.5453192214811934,"score_spread":0.4932072477849484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614942658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937218,0.00029587984,0.0025515838,0.0022815203,0.00025938818,0.0004615687,0.000007904226,0.0000032679236,0.00041712646],"genre_scores_gemma":[0.99430114,0.000049007333,0.005244841,0.00003412664,0.000111325964,0.000036966383,0.0000078129915,0.0000051755865,0.00020958224],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991066,0.000050474784,0.0005222988,0.000100340585,0.00013264142,0.00008767072],"domain_scores_gemma":[0.9975925,0.00008095228,0.0014306919,0.00008810758,0.0007698384,0.000037909795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035265306,0.000069981856,0.0004470589,0.00029393972,0.00016414688,0.000007945892,0.000041097148,0.000040542338,0.000008604972],"category_scores_gemma":[0.00046619598,0.000048115377,0.00014577358,0.00016157792,0.000064037544,0.00017638344,0.000010405779,0.00009201469,2.1633798e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016552802,0.007564685,0.19386819,0.00027025808,0.012170352,0.00018533466,0.022987094,0.0043747267,0.017684832,0.0003099202,0.0009935078,0.7230383],"study_design_scores_gemma":[0.0451173,0.11451587,0.64378124,0.000833822,0.04198221,0.0007250519,0.016719686,0.009667905,0.1120221,0.0075152777,0.006653167,0.00046635003],"about_ca_topic_score_codex":0.000062456435,"about_ca_topic_score_gemma":0.00043573958,"teacher_disagreement_score":0.72257197,"about_ca_system_score_codex":0.00060338574,"about_ca_system_score_gemma":0.00032347778,"threshold_uncertainty_score":0.1962088},"labels":[],"label_agreement":null},{"id":"W2615007775","doi":"10.1080/0284186x.2017.1328128","title":"Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study","year":2017,"lang":"en","type":"article","venue":"Acta Oncologica","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Brain metastasis; Oncology; Lung; Internal medicine; Clinical endpoint; Incidence (geometry); Pathology; Cancer; Metastasis; Clinical trial","score_opus":0.03032337385515657,"score_gpt":0.34277627382795944,"score_spread":0.3124528999728029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615007775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941935,0.00010226868,0.000015882611,0.0023253176,0.00013598117,0.0019338093,0.00038264005,0.00006558668,0.0008450209],"genre_scores_gemma":[0.9971175,0.000016583886,0.0007971879,0.00036609525,0.000058723344,0.000742076,0.00040802246,0.000026017904,0.00046779754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986642,0.00012165487,0.00030234395,0.00038293214,0.0002290719,0.00029982463],"domain_scores_gemma":[0.99851,0.0003357951,0.0004596831,0.00036535083,0.00019104173,0.00013813566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012934333,0.0002284881,0.00048505783,0.00012406315,0.00047962146,0.00005855459,0.00016382236,0.0000998734,0.00028906978],"category_scores_gemma":[0.00042279693,0.00015968889,0.00007966191,0.00016241941,0.00004373132,0.00016651153,0.000033510107,0.00019585546,0.000005302295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013959028,0.0022536186,0.99531305,0.000035260495,0.00027250228,0.00015529846,0.00056875875,0.00009361246,0.00015592425,0.0000017171621,0.00058740564,0.0004232445],"study_design_scores_gemma":[0.006124943,0.00091399014,0.99063045,0.00016787776,0.0007768823,9.83684e-7,0.0006379551,0.0002706812,0.00019566427,0.000007813536,0.00008782317,0.0001849594],"about_ca_topic_score_codex":0.0048842924,"about_ca_topic_score_gemma":0.009832168,"teacher_disagreement_score":0.0059853527,"about_ca_system_score_codex":0.00080332265,"about_ca_system_score_gemma":0.00047342834,"threshold_uncertainty_score":0.73836213},"labels":[],"label_agreement":null},{"id":"W2616373451","doi":"10.1200/jco.2014.32.15_suppl.e19056","title":"Referral to a cancer center (CC), medical oncologist (MO), and use of systemic treatment (ST) in stage IV non-small cell lung cancer (NSCLC) patients: Comparison of years 2003-2006 and 2010 cohorts in a single Canadian institution.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Referral; Internal medicine; Cohort; Stage (stratigraphy); Lung cancer; Cancer registry; Cancer; Surgery; Family medicine","score_opus":0.08267592595053168,"score_gpt":0.4478556017995932,"score_spread":0.3651796758490615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616373451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620545,0.000926095,0.000026045536,0.00100552,0.0008623329,0.00059531565,0.00011423093,0.0000018471617,0.00026314973],"genre_scores_gemma":[0.9972372,0.0011571319,0.0005408277,0.0007040246,0.00011493608,0.000030723444,0.000010024732,0.000010592661,0.00019453155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746364,0.00021767573,0.0016470405,0.00020235592,0.00023371844,0.00023555387],"domain_scores_gemma":[0.9978826,0.00035040718,0.00079958135,0.00010766538,0.0003155442,0.0005441795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059807586,0.00013543047,0.001296644,0.00027764318,0.00002091474,0.0000064574515,0.0000668532,0.00030404332,0.00003435716],"category_scores_gemma":[0.00057842967,0.0000997929,0.00007519826,0.00018434576,0.00018600545,0.00007831886,0.000028508934,0.00034127498,4.1422192e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082571537,0.003766519,0.9669267,0.000089205736,0.00014728625,0.000099717654,0.00089466537,0.00016107655,0.000020633835,0.000007797699,0.0021859715,0.02487471],"study_design_scores_gemma":[0.022048889,0.0065144086,0.9484571,0.0010936763,0.00033436585,0.000017747123,0.00020602546,0.0005700287,0.000014176977,0.000001478634,0.020652736,0.000089319314],"about_ca_topic_score_codex":0.14061476,"about_ca_topic_score_gemma":0.5291575,"teacher_disagreement_score":0.38854274,"about_ca_system_score_codex":0.0016266908,"about_ca_system_score_gemma":0.00432122,"threshold_uncertainty_score":0.86510795},"labels":[],"label_agreement":null},{"id":"W2618442076","doi":"10.3389/fonc.2017.00113","title":"Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"","keywords":"T790M; Osimertinib; Epidermal growth factor receptor; Cancer research; Lung cancer; Medicine; Tyrosine kinase; Targeted therapy; Cancer; Epidermal growth factor; Oncology; Erlotinib; Gefitinib; Internal medicine; Receptor","score_opus":0.04093652492455219,"score_gpt":0.38581914730338623,"score_spread":0.34488262237883405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618442076","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007055152,0.9868363,0.0003970771,0.00050499535,0.006410053,0.0027414106,0.00027204503,0.000037898357,0.0020946849],"genre_scores_gemma":[0.000749922,0.98064166,0.011109171,0.00014627693,0.0013914212,0.0017525563,0.0020252722,0.00009943826,0.0020842564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972651,0.0002648573,0.0010647223,0.0006880403,0.0001764386,0.0005408146],"domain_scores_gemma":[0.99840623,0.00011618627,0.00079601596,0.0003549339,0.00014611457,0.00018053543],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027588283,0.0005013618,0.0021020975,0.0007478332,0.00020129491,0.0000401367,0.00021353224,0.00073576986,0.000095543044],"category_scores_gemma":[0.00024907166,0.0004350134,0.00031701848,0.00034305043,0.00011737576,0.00016265809,0.000065714565,0.00077174976,0.000018423241],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044428678,0.0007117761,0.01915115,0.009081492,0.0003864076,0.0003452799,0.0020417473,0.000056911074,0.00003995576,0.000013567533,0.13582668,0.8323006],"study_design_scores_gemma":[0.0028159355,0.00024013499,0.0004831934,0.0045768404,0.001741864,0.000012290284,0.0001682993,0.0004165808,0.000061873165,0.000010725678,0.98898476,0.00048748567],"about_ca_topic_score_codex":0.001076717,"about_ca_topic_score_gemma":0.00060483825,"teacher_disagreement_score":0.8531581,"about_ca_system_score_codex":0.004039896,"about_ca_system_score_gemma":0.002825022,"threshold_uncertainty_score":0.99981016},"labels":[],"label_agreement":null},{"id":"W2620097568","doi":"10.1016/j.jtho.2017.05.019","title":"Scientific Advances in Thoracic Oncology 2016","year":2017,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Foundation Medicine; Loxo Oncology; Pharmacyclics; Chugai Pharmaceutical; EMD Serono; Genentech; Medela; Astellas Pharma; Daiichi-Sankyo; Taiho Pharmaceutical; National Institutes of Health; Regeneron Pharmaceuticals; Meiji Seika Pharma; American Cancer Society; Shionogi; Helsinn; Mirati Therapeutics; Clovis Oncology; Varian Medical Systems; Ariad Pharmaceuticals; Cancer Research UK; Array BioPharma; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; G1 Therapeutics; Celgene; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer","keywords":"Medicine; Lung cancer; Targeted therapy; Immunotherapy; Oncology; Radiation therapy; Internal medicine; Radiation oncology; Medical physics; Cancer; Intensive care medicine","score_opus":0.09726148855054398,"score_gpt":0.5912693878452375,"score_spread":0.4940078992946936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620097568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004618203,0.9706821,0.000033983702,0.0011585277,0.0055169677,0.00078118395,0.000036017795,0.0000125214665,0.02173253],"genre_scores_gemma":[0.00007789357,0.9855449,0.002556884,0.00009569005,0.0010601156,0.00006053309,0.000052614072,0.00005116522,0.0105002085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639624,0.0005754029,0.0017016127,0.0004405417,0.00040466306,0.00048151604],"domain_scores_gemma":[0.99449295,0.00044802425,0.0035879111,0.00063798827,0.00051443494,0.0003186642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019147306,0.000419483,0.003994627,0.0012933355,0.0002313369,0.00008167926,0.0005589751,0.0007366934,0.00022057489],"category_scores_gemma":[0.00048836553,0.00027204453,0.0008467315,0.000374101,0.0004395757,0.00046038162,0.00010798177,0.0013009381,0.00016035301],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002648219,0.00066624983,0.00003127014,0.0047401185,0.00039394328,0.00267764,0.00017280239,0.0000012359145,0.0000010592909,0.00002059106,0.0047185495,0.98631173],"study_design_scores_gemma":[0.00062142033,0.0019500148,0.00003614861,0.016661948,0.005202749,0.0052143238,0.00009200566,0.000001062578,0.0000019470797,0.00022606648,0.9697905,0.00020180835],"about_ca_topic_score_codex":0.0000092871,"about_ca_topic_score_gemma":0.00011476572,"teacher_disagreement_score":0.9861099,"about_ca_system_score_codex":0.0029916274,"about_ca_system_score_gemma":0.012674849,"threshold_uncertainty_score":0.9999732},"labels":[],"label_agreement":null},{"id":"W2620604883","doi":"10.1016/j.ctarc.2017.06.002","title":"The influence of season and distance to a cancer centre on lung cancer treatment rates","year":2017,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Lung cancer; Cancer; Medicine; Oncology; Internal medicine; Demography; Sociology","score_opus":0.08108672179372736,"score_gpt":0.5047361230608941,"score_spread":0.42364940126716677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620604883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8793865,0.051923797,0.0000014294252,0.06484764,0.000057408597,0.0016997395,0.00037549628,0.000018365194,0.0016896562],"genre_scores_gemma":[0.81019133,0.18030408,0.00008280606,0.00006765434,0.000051607713,0.002391984,0.000018190498,0.00001791869,0.0068744346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874836,0.00011754598,0.00019691348,0.00032111106,0.00025072362,0.00036536183],"domain_scores_gemma":[0.9971281,0.0004187511,0.000116809286,0.0016550327,0.00040462447,0.00027662574],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00014405974,0.00019879067,0.00028314107,0.00008482124,0.002488215,0.00015501937,0.00033485878,0.000050867977,0.000026449781],"category_scores_gemma":[0.00007836861,0.00011336607,0.000059214064,0.000156242,0.0007430632,0.000112527436,0.00017924339,0.0001345183,0.0000026789403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065947516,0.0008854299,0.7579848,0.000111277004,0.0016685675,0.0000075463313,0.0073539643,0.00016865753,0.0011791288,0.0044970573,0.0017035467,0.22378054],"study_design_scores_gemma":[0.004362545,0.001056023,0.8355269,0.0013726436,0.0007127333,0.0000026128448,0.0010655607,0.00059710315,0.002606182,0.00015672135,0.1523188,0.00022221093],"about_ca_topic_score_codex":0.019084105,"about_ca_topic_score_gemma":0.022928009,"teacher_disagreement_score":0.22355832,"about_ca_system_score_codex":0.0011355997,"about_ca_system_score_gemma":0.00065861543,"threshold_uncertainty_score":0.9988104},"labels":[],"label_agreement":null},{"id":"W2623169983","doi":"10.15173/m.v1i22.815","title":"Tumour Heterogeneity and Treatment: One Step Forward or Two Steps Back?","year":2013,"lang":"en","type":"article","venue":"The Meducator","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.03499126999483528,"score_gpt":0.3427584110849058,"score_spread":0.30776714109007053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623169983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98821664,0.0007770303,0.000019617823,0.0065775583,0.00017830172,0.0010729723,0.00001917545,0.000033966615,0.0031047475],"genre_scores_gemma":[0.9870657,0.0001608348,0.0013463482,0.0007234285,0.0002672584,0.0003137064,0.000021856866,0.000024787225,0.010076096],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999285,0.00003639855,0.00014224729,0.00019541015,0.00012058186,0.00022038294],"domain_scores_gemma":[0.99931014,0.00007340781,0.000047970014,0.0003100991,0.00004878242,0.00020961437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000048817972,0.00014892644,0.00022534016,0.00003680103,0.00012630755,0.00003693441,0.000057587007,0.0000268715,0.0010839484],"category_scores_gemma":[0.000017623792,0.00007299923,0.000059280854,0.000088211826,0.00007529481,0.00007265273,0.000022737475,0.00005324291,0.0005788284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017280461,0.009567667,0.29860038,0.0005650333,0.009707669,0.000104732535,0.027808703,0.0000068028676,0.042163447,0.002478331,0.071378775,0.5358904],"study_design_scores_gemma":[0.02545954,0.0050545894,0.7593032,0.00037822916,0.005321566,0.00065616047,0.007846044,0.00024991992,0.050048385,0.0007713016,0.14401062,0.0009004623],"about_ca_topic_score_codex":0.0011916354,"about_ca_topic_score_gemma":0.00034236626,"teacher_disagreement_score":0.53498995,"about_ca_system_score_codex":0.00016858822,"about_ca_system_score_gemma":0.00021871056,"threshold_uncertainty_score":0.9998292},"labels":[],"label_agreement":null},{"id":"W2623725180","doi":"10.1016/s1470-2045(17)30339-x","title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Shionogi; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Eli Lilly and Company","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; ALK inhibitor; Internal medicine; Chemotherapy; Oncology; Docetaxel; Pemetrexed; Gastroenterology; Cisplatin","score_opus":0.04534884463340635,"score_gpt":0.4133336191056075,"score_spread":0.3679847744722012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623725180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619135,0.0006901593,0.00001527056,0.008796905,0.00056432246,0.010969549,0.00006133995,0.00002805908,0.01696088],"genre_scores_gemma":[0.9910239,0.0015949364,0.0006561208,0.0022036333,0.0007178829,0.002614627,0.000047007634,0.000060473434,0.0010814274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983894,0.00017737865,0.0003723526,0.00041064373,0.00017518444,0.0004750034],"domain_scores_gemma":[0.998349,0.00028177028,0.00045639838,0.00065190945,0.00012567459,0.00013523168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005353074,0.000284415,0.0013572027,0.000054018423,0.00033214624,0.00010762573,0.00042195566,0.00013901903,0.00018174261],"category_scores_gemma":[0.00007924026,0.00016961434,0.00006359263,0.00006837053,0.0002177148,0.00013298875,0.00006758898,0.00027477866,0.0000033230394],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9393207,0.0030424315,0.020210078,0.000073836294,0.0009590885,0.00003108732,0.0022506223,0.0000014481452,0.00014881854,0.000012333374,0.0041224957,0.02982705],"study_design_scores_gemma":[0.9631067,0.006986218,0.013187671,0.00013864863,0.0006674747,0.000002782725,0.00010263124,0.0000950685,0.00009492955,0.000010903215,0.015415606,0.00019140082],"about_ca_topic_score_codex":0.00085769984,"about_ca_topic_score_gemma":0.0011331049,"teacher_disagreement_score":0.02963565,"about_ca_system_score_codex":0.0002794537,"about_ca_system_score_gemma":0.0005413057,"threshold_uncertainty_score":0.6916672},"labels":[],"label_agreement":null},{"id":"W2624631663","doi":"10.1016/j.cllc.2017.05.019","title":"An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research","keywords":"Medicine; Epidermal growth factor receptor; Gefitinib; Oncology; Lung cancer; Targeted therapy; Mutation; Internal medicine; non-small cell lung cancer (NSCLC); Erlotinib; Cancer; Gene","score_opus":0.06694516579670678,"score_gpt":0.47560684700353717,"score_spread":0.4086616812068304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624631663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98316467,0.0029470432,0.001913809,0.0026386168,0.00032055288,0.0014296889,0.000094097166,0.00005846832,0.007433054],"genre_scores_gemma":[0.98764646,0.00024013399,0.010348181,0.0008041852,0.00027913292,0.00024557742,0.000034485252,0.000021300371,0.00038051512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988101,0.00006852514,0.0003012625,0.0004452481,0.00014726099,0.0002276122],"domain_scores_gemma":[0.9990352,0.00011708318,0.00011632201,0.0003495701,0.00016081608,0.00022102559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026053604,0.00014457901,0.0003136694,0.00005821902,0.00022472058,0.00013726289,0.00011682185,0.000096142685,0.000046822734],"category_scores_gemma":[0.00009094485,0.00011543312,0.000053262633,0.00009171492,0.00014432,0.00026508776,0.000026247695,0.00021115954,0.0000034848545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037505222,0.0009234591,0.62239796,0.00013538255,0.0008211541,0.00021470981,0.0058444925,0.0001480177,0.00057531154,0.00096424395,0.0005053051,0.3670949],"study_design_scores_gemma":[0.0035794973,0.00084222585,0.95554066,0.00042142518,0.00038023753,0.000026242666,0.00082410354,0.037284605,0.00007383505,0.0006645265,0.00009919753,0.00026343955],"about_ca_topic_score_codex":0.0011227386,"about_ca_topic_score_gemma":0.00039835845,"teacher_disagreement_score":0.36683148,"about_ca_system_score_codex":0.00022260418,"about_ca_system_score_gemma":0.0004169056,"threshold_uncertainty_score":0.47072262},"labels":[],"label_agreement":null},{"id":"W2625444591","doi":"10.1200/jco.2013.31.15_suppl.11085","title":"The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Guideline; Medicine; Lung cancer; Family medicine; Test (biology); Oncology; Internal medicine; Pathology","score_opus":0.06652384845840413,"score_gpt":0.49076404251944145,"score_spread":0.4242401940610373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625444591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561719,0.0045601795,0.004883235,0.030378588,0.0017143342,0.0019933395,0.000022490958,0.00000683048,0.00026912798],"genre_scores_gemma":[0.9816418,0.0004661581,0.014284569,0.0021455032,0.0010632736,0.00014715099,0.0000068109644,0.000018459377,0.00022622151],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819416,0.00006614039,0.0013520264,0.000098414464,0.00014659243,0.00014266017],"domain_scores_gemma":[0.99364376,0.0031478398,0.0011640402,0.000080273945,0.0018562501,0.00010783747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010341957,0.00008095768,0.00043053477,0.000031438783,0.0001308321,0.000011239251,0.00006170933,0.00010815247,0.000013255661],"category_scores_gemma":[0.0048630587,0.00003858023,0.00017770525,0.00008622797,0.000107955806,0.000060270624,0.000017954118,0.0001870424,2.8288525e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016267297,0.0012267192,0.18741605,0.00010511328,0.0013633844,0.0000029945345,0.00017748038,0.0002247496,0.0027785134,0.00014012892,0.1377155,0.6672226],"study_design_scores_gemma":[0.03520299,0.02313309,0.28597835,0.00043144016,0.0057632914,0.00007015857,0.00025589505,0.015848612,0.0021806578,0.0013108125,0.62960297,0.00022170835],"about_ca_topic_score_codex":0.0002210064,"about_ca_topic_score_gemma":0.00009599143,"teacher_disagreement_score":0.66700095,"about_ca_system_score_codex":0.0001226462,"about_ca_system_score_gemma":0.00071655243,"threshold_uncertainty_score":0.58218867},"labels":[],"label_agreement":null},{"id":"W2626656823","doi":"10.1200/jco.2014.32.15_suppl.tps11136","title":"A prospective study to compare qPCR to IHC and FISH for the detection of anaplastic lymphoma kinase (ALK) fusions in FFPE specimens from NSCLC patients (<i>PCRTALK</i>).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Foundation; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Medicine; Lung cancer; Oncology; ALK inhibitor; Internal medicine; Ceritinib; Cancer; ROS1; Alectinib; Clinical trial; Pathology; Adenocarcinoma","score_opus":0.04696207987794973,"score_gpt":0.4361324568823926,"score_spread":0.3891703770044429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626656823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947712,0.00004059182,0.0008364258,0.001946894,0.0007083456,0.0013251164,0.000037461592,0.0000034523653,0.0003305036],"genre_scores_gemma":[0.9977842,0.000014251585,0.0007802296,0.00097326277,0.00035571223,0.000043838932,0.0000025954475,0.000010161532,0.000035768626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998275,0.00016458085,0.0010505458,0.0001779497,0.00019808013,0.0001338776],"domain_scores_gemma":[0.9958907,0.002831482,0.0004905687,0.00013995732,0.00041036517,0.00023697046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062884414,0.00009967119,0.0007474354,0.000115816074,0.000064135005,0.0000071074837,0.00007929198,0.00005545873,0.000017229682],"category_scores_gemma":[0.0027807045,0.00006081572,0.00012564135,0.00016678555,0.000054054144,0.000043748856,0.000045979035,0.00016019848,0.0000025416157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008567039,0.006408554,0.8198121,0.000010326954,0.0004966924,0.000025465526,0.0024707809,0.00006986472,0.00014014401,0.000020871345,0.00057725335,0.16140088],"study_design_scores_gemma":[0.016611423,0.029611152,0.94586736,0.00008257361,0.0006400879,0.000005593319,0.0012019948,0.000120321696,0.000041067975,0.00013672582,0.0056284657,0.000053254178],"about_ca_topic_score_codex":0.00027557934,"about_ca_topic_score_gemma":0.008284317,"teacher_disagreement_score":0.16134763,"about_ca_system_score_codex":0.0002133532,"about_ca_system_score_gemma":0.0002795494,"threshold_uncertainty_score":0.46228433},"labels":[],"label_agreement":null},{"id":"W2627006580","doi":"10.3389/fphar.2017.00385","title":"Trends and Patterns of Disparities in Oral Cavity and Pharyngeal Cancer in Serbia: Prevalence and Economic Consequences in a Transitional Country","year":2017,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oral cavity; Cancer; Medicine; Front (military); Geography; Internal medicine; Dentistry","score_opus":0.013234173025146082,"score_gpt":0.3512431011172832,"score_spread":0.3380089280921371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2627006580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932357,0.0037406837,0.0000036824706,0.0020765555,0.0003013785,0.00018615018,0.00036097906,0.0000021739625,0.0000926711],"genre_scores_gemma":[0.9936665,0.0058841896,0.00009868464,0.00015272299,0.0000211302,0.00008989351,0.000010964784,0.0000041866238,0.00007169862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941987,0.00004399215,0.00017352127,0.00018691077,0.00003524399,0.00014044264],"domain_scores_gemma":[0.99982285,0.000027807151,0.000056950616,0.00004537952,0.0000068280424,0.00004018982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009955829,0.000081840466,0.00027660467,0.00018684797,0.000028928225,0.00000824644,0.000037037214,0.000055278924,0.00005699362],"category_scores_gemma":[0.0000036263823,0.00007968374,0.000008549941,0.000027655371,0.00035485832,0.00015721866,0.000017416933,0.00011758226,3.3560497e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030120712,0.000075092874,0.9927958,0.00020177434,0.00003906944,0.00008692153,0.00079184584,0.000028741615,0.00023027396,0.00002726992,0.00019215395,0.005229844],"study_design_scores_gemma":[0.005864528,0.000066829314,0.9921423,0.00012956867,0.000077063705,0.00001743862,0.00013118623,0.001116073,0.00016204256,0.00016835169,0.00005980118,0.0000647883],"about_ca_topic_score_codex":0.010672911,"about_ca_topic_score_gemma":0.024046449,"teacher_disagreement_score":0.013373538,"about_ca_system_score_codex":0.00016738391,"about_ca_system_score_gemma":0.00013116848,"threshold_uncertainty_score":0.9959151},"labels":[],"label_agreement":null},{"id":"W2643935873","doi":"10.1200/jco.2017.35.15_suppl.2502","title":"Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Ceritinib; Anaplastic lymphoma kinase; Maculopapular rash; Gastroenterology; Rash; Nivolumab; Lung cancer; Oncology; Cancer; Immunotherapy","score_opus":0.027392140811896774,"score_gpt":0.42423401251126663,"score_spread":0.39684187169936985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2643935873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845832,0.00038325146,0.00012685337,0.0016700039,0.0012630705,0.0005416496,0.000032557964,0.0000065241434,0.011392881],"genre_scores_gemma":[0.99513674,0.00038490744,0.0023531686,0.0009006749,0.0005011751,0.000026534832,0.000010138979,0.000031169588,0.00065551297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758416,0.00012702684,0.001343153,0.00028903954,0.0003142934,0.0003423368],"domain_scores_gemma":[0.9959953,0.0005736854,0.002041089,0.00031407052,0.0006609173,0.0004149605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042160612,0.00020907471,0.0012694455,0.00013369933,0.00015701297,0.000027415814,0.0002334592,0.00025642494,0.00007750528],"category_scores_gemma":[0.0006551793,0.00014702795,0.0002469898,0.00008203192,0.00021401144,0.00025310935,0.000061013292,0.0004844449,0.00000825675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01899625,0.004496125,0.7297627,0.00009121026,0.0006210558,0.0021852572,0.00056888023,0.00020795682,0.000031059335,0.000017241184,0.0009156813,0.2421066],"study_design_scores_gemma":[0.07440897,0.017161733,0.903014,0.0007851394,0.0009682703,0.000044605207,0.00018897891,0.0002669863,0.00007316298,0.000015990656,0.0029158387,0.00015633737],"about_ca_topic_score_codex":0.00037825885,"about_ca_topic_score_gemma":0.001041614,"teacher_disagreement_score":0.24195026,"about_ca_system_score_codex":0.0011161634,"about_ca_system_score_gemma":0.004505341,"threshold_uncertainty_score":0.79922813},"labels":[],"label_agreement":null},{"id":"W2654683002","doi":"10.1200/jco.2016.34.15_suppl.e20510","title":"Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Afatinib; Erlotinib; Gastroenterology; Population; Lung cancer; Clinical trial; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.17038854741746326,"score_gpt":0.5311208798933007,"score_spread":0.36073233247583747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2654683002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98453456,0.001096457,0.00006726407,0.003886398,0.001002534,0.008412193,0.00017259187,0.0000014346866,0.00082656386],"genre_scores_gemma":[0.99805844,0.00019658309,0.0007233213,0.000071896124,0.00031553302,0.0003682344,0.000004218675,0.000014927184,0.00024686463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99445575,0.0014651116,0.003121031,0.00017908288,0.00060302985,0.00017596234],"domain_scores_gemma":[0.97789544,0.015954204,0.004561943,0.0004240276,0.0010916017,0.00007277306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007971409,0.00017805764,0.0019218598,0.00007404013,0.000047013542,0.000004249784,0.00037347866,0.00017384464,0.00011425414],"category_scores_gemma":[0.0071854936,0.000064276595,0.0006135087,0.00016634117,0.00041524752,0.000093046656,0.000036336853,0.0001950369,2.8160855e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89650047,0.01847649,0.0024719446,0.00012360205,0.0009974127,0.000008875096,0.0011106528,0.00008308278,0.003412651,0.000059817972,0.00041080534,0.07634417],"study_design_scores_gemma":[0.9153643,0.06293303,0.0050073634,0.00012845403,0.006550462,0.000011928127,0.0004213022,0.0009531076,0.007824227,0.00016875195,0.00057786424,0.000059192702],"about_ca_topic_score_codex":0.00005666981,"about_ca_topic_score_gemma":0.00014556188,"teacher_disagreement_score":0.076284975,"about_ca_system_score_codex":0.0003143561,"about_ca_system_score_gemma":0.0042943307,"threshold_uncertainty_score":0.8602226},"labels":[],"label_agreement":null},{"id":"W2655216406","doi":"10.1016/j.lungcan.2017.06.014","title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Institut universitaire de cardiologie et de pneumologie de Québec; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Lung cancer; T790M; Internal medicine; Missense mutation; Oncology; Epidermal growth factor receptor; Sanger sequencing; Mutation; Cancer; Gefitinib; Gene; Biology","score_opus":0.004125159358973921,"score_gpt":0.2923107701616074,"score_spread":0.2881856108026335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2655216406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931352,0.0019422019,0.00018373542,0.00014881328,0.00024969046,0.0027071515,0.00014072953,0.000022664364,0.0014698029],"genre_scores_gemma":[0.9981935,0.00018387884,0.00015546253,0.00008295144,0.00006481873,0.0008190715,0.000104466926,0.000038358256,0.00035751663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891675,0.000024424246,0.00021797663,0.0003396672,0.00023969881,0.00026147356],"domain_scores_gemma":[0.99902594,0.00007221336,0.0002808459,0.00027739414,0.0002249838,0.00011863216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043601154,0.00020583466,0.0003413852,0.00010771769,0.0001435348,0.00003216537,0.000078475015,0.00008225939,0.000028766377],"category_scores_gemma":[0.00003866337,0.00015797002,0.000034572593,0.00010605933,0.00010841814,0.00018636641,0.00002659791,0.00013776522,9.2610605e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058079796,0.00028256152,0.991522,0.0012815914,0.00038565454,0.000035111127,0.0024164286,0.00021264104,0.00024738736,0.0000040299583,0.00027713203,0.0027546221],"study_design_scores_gemma":[0.010959287,0.0006027328,0.97880137,0.0021232218,0.0015360874,0.0000010692262,0.00005454873,0.002428324,0.0033022426,0.0000057472166,0.000025283698,0.00016011104],"about_ca_topic_score_codex":0.0021608907,"about_ca_topic_score_gemma":0.0005446101,"teacher_disagreement_score":0.012720698,"about_ca_system_score_codex":0.00042755075,"about_ca_system_score_gemma":0.00042246588,"threshold_uncertainty_score":0.64418304},"labels":[],"label_agreement":null},{"id":"W2658185239","doi":"10.1016/j.cllc.2017.06.002","title":"Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Royal Victoria Hospital; Kingston General Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Afatinib; Medicine; Erlotinib; Lung cancer; Internal medicine; Discontinuation; Adverse effect; Oncology; Quality of life (healthcare); Cancer; Epidermal growth factor receptor","score_opus":0.05280740285528082,"score_gpt":0.43782188862627236,"score_spread":0.3850144857709915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2658185239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408954,0.00041073532,0.000007482569,0.00016805665,0.0002840313,0.0046159523,0.0002995995,0.000006630718,0.00011797915],"genre_scores_gemma":[0.99893695,0.000021419195,0.000181871,0.00022852642,0.00005164882,0.000421403,0.00003972342,0.000037747977,0.00008067995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972423,0.00013389671,0.0014633372,0.0005350282,0.00037411583,0.00025136943],"domain_scores_gemma":[0.9969298,0.00037947058,0.0012467479,0.0009983312,0.00028192293,0.00016369161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005143135,0.00026312348,0.0010088513,0.00007113344,0.00008801442,0.00001818713,0.00033741127,0.000113902315,0.00011323983],"category_scores_gemma":[0.00019909053,0.00017877808,0.00006488663,0.00015159226,0.0002288584,0.00018595942,0.00013817815,0.00025821698,8.080414e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037168127,0.015214565,0.94193727,0.00049615686,0.00016608542,0.0000027096119,0.0012564093,0.00014953697,0.00011050143,0.0000027407955,0.000024027058,0.0034718784],"study_design_scores_gemma":[0.22847022,0.008853774,0.7597796,0.00026861147,0.00030155794,2.4325052e-8,0.00022727053,0.0014168465,0.0005307451,0.0000014837818,0.000006194282,0.00014371125],"about_ca_topic_score_codex":0.0018698741,"about_ca_topic_score_gemma":0.011204849,"teacher_disagreement_score":0.19130209,"about_ca_system_score_codex":0.00019683247,"about_ca_system_score_gemma":0.0005488868,"threshold_uncertainty_score":0.72903585},"labels":[],"label_agreement":null},{"id":"W2693468451","doi":"10.1016/s0923-7534(20)33072-6","title":"Lux-Lung 8: A Randomized, Open-Label, Phase III Trial of Afatinib vs. Erlotinib in Patients with Advanced Squamous Cell Carcinoma of the Lung as Second-Line Therapy Following First-Line Platinum-Based Chemotherapy","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Oncology; Internal medicine; Squamous-cell carcinoma of the lung; Lung; Basal cell; Platinum; Lung cancer; Gefitinib; Carcinoma; Open label; Randomized controlled trial; Epidermal growth factor receptor; Cancer","score_opus":0.03861108824468808,"score_gpt":0.3984599953154056,"score_spread":0.35984890707071754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2693468451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893243,0.0011569905,0.00004324371,0.0010169554,0.0003256941,0.0060839336,0.00007051752,0.0000095200485,0.0023607176],"genre_scores_gemma":[0.99727607,0.000064087755,0.0007268748,0.0011743086,0.00007389935,0.00034453778,0.00010121708,0.0000417182,0.00019727577],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99781513,0.00024990065,0.0009973265,0.0002574976,0.00031855813,0.00036160508],"domain_scores_gemma":[0.997461,0.0007176275,0.0010021123,0.00042221262,0.0002853971,0.000111617665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071689667,0.0002627411,0.0015054432,0.00014853227,0.000065247805,0.000004883941,0.00023427718,0.00014913772,0.00022900605],"category_scores_gemma":[0.00015246426,0.00016334257,0.000226203,0.00033011,0.00016600505,0.00016327015,0.00004101501,0.00017099861,6.7755155e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9237254,0.01937143,0.03980543,0.00015847087,0.0005021881,0.0000069596804,0.003447507,0.00011124899,0.0006862529,0.000035227902,0.00039150857,0.011758339],"study_design_scores_gemma":[0.9487826,0.019002788,0.005758795,0.0001403717,0.00034042774,0.0000012041215,0.00010168803,0.0002477426,0.024586024,0.000017081402,0.0008728894,0.00014834174],"about_ca_topic_score_codex":0.00026450827,"about_ca_topic_score_gemma":0.00006149585,"teacher_disagreement_score":0.03404664,"about_ca_system_score_codex":0.000086682434,"about_ca_system_score_gemma":0.0006626036,"threshold_uncertainty_score":0.6660916},"labels":[],"label_agreement":null},{"id":"W2725557045","doi":"10.1200/jco.2017.73.8567","title":"Reply to T.J. Powles et al","year":2017,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.15364047627747526,"score_gpt":0.5749700092059125,"score_spread":0.4213295329284372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725557045","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043442575,0.003353121,0.0002044923,0.9106248,0.029826561,0.0003956613,0.0000561304,0.000008163717,0.051186826],"genre_scores_gemma":[0.003984579,0.0031698777,0.0072266096,0.92034686,0.026207766,0.000011764538,0.00003065252,0.0000594581,0.03896242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931129,0.0010151858,0.0041546226,0.000454255,0.00069080305,0.0005722109],"domain_scores_gemma":[0.9867835,0.0049698763,0.0054466305,0.00073898537,0.0010970468,0.0009639647],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005058819,0.00037381062,0.003431501,0.00024200437,0.00015093312,0.00005705991,0.00060365244,0.0012410256,0.0011391612],"category_scores_gemma":[0.013257519,0.00026242618,0.0014647227,0.000076528784,0.0004395784,0.00019844284,0.00014715362,0.0048731286,0.00085336086],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010503961,0.0011281479,0.0064826263,0.000050712373,0.0023944315,0.014067183,0.00022640082,0.0000105342315,0.000007069754,0.00014296612,0.81297666,0.16146286],"study_design_scores_gemma":[0.006988491,0.020414516,0.048415884,0.0012082238,0.0032151144,0.0016873297,0.00006444956,0.000004807638,0.0000037775558,0.00031805548,0.91747445,0.00020489868],"about_ca_topic_score_codex":0.00023677095,"about_ca_topic_score_gemma":0.000058294947,"teacher_disagreement_score":0.16125795,"about_ca_system_score_codex":0.00084094517,"about_ca_system_score_gemma":0.011034919,"threshold_uncertainty_score":0.9999828},"labels":[],"label_agreement":null},{"id":"W2727630783","doi":"10.1093/jjco/hyx094","title":"Sex differences in lung cancer survival: long-term trends using population-based cancer registry data in Osaka, Japan","year":2017,"lang":"en","type":"article","venue":"Japanese Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Japan Agency for Medical Research and Development","keywords":"Medicine; Relative survival; Lung cancer; Cancer registry; Cancer; Hazard ratio; Population; Confounding; Proportional hazards model; Adenocarcinoma; Internal medicine; Survival analysis; Oncology; Demography; Environmental health; Confidence interval","score_opus":0.25870595467761626,"score_gpt":0.5692948609833443,"score_spread":0.310588906305728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727630783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917682,0.00048722286,0.000018053266,0.005925505,0.0011577482,0.00014930566,0.000025141186,0.0000061885435,0.0004626581],"genre_scores_gemma":[0.99780875,0.0003402119,0.0003737848,0.00036083066,0.0007438209,0.00001321735,0.000029020897,0.000016103133,0.00031428318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973118,0.000264857,0.0015059877,0.0003168994,0.00032716297,0.0002733428],"domain_scores_gemma":[0.996611,0.0007565736,0.0015620178,0.0006797581,0.00015439493,0.00023625436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013447282,0.00016121769,0.0011684191,0.00022488748,0.000118238255,0.000035940244,0.00049184414,0.00022914352,0.00023652775],"category_scores_gemma":[0.0010977642,0.00011440727,0.00014824387,0.00015123175,0.00016348422,0.00033313132,0.00008412606,0.000553947,6.7111296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068474386,0.0007090779,0.94891644,0.00004109728,0.00017978942,0.00030037295,0.00025259767,0.0001972888,0.00004516714,0.000004020002,0.000030896037,0.04863851],"study_design_scores_gemma":[0.008411683,0.00037791693,0.9853744,0.00039845516,0.00039246565,0.000031600583,0.00014155047,0.004647453,0.0000052174455,0.000013335801,0.00009601622,0.0001099383],"about_ca_topic_score_codex":0.012409023,"about_ca_topic_score_gemma":0.029932242,"teacher_disagreement_score":0.048528574,"about_ca_system_score_codex":0.00054896355,"about_ca_system_score_gemma":0.0016308108,"threshold_uncertainty_score":0.99416745},"labels":[],"label_agreement":null},{"id":"W2730563863","doi":"10.3747/co.24.3486","title":"Efficacy of Metronomic Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer and Poor Performance Status","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institute on Aging","keywords":"Vinorelbine; Medicine; Internal medicine; Lung cancer; Chemotherapy; Oncology; Performance status; Progressive disease; Cancer; Surgery; Cisplatin","score_opus":0.02148979335003335,"score_gpt":0.37633965766756255,"score_spread":0.3548498643175292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730563863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957068,0.0020145413,0.000016348085,0.00012449194,0.0003543509,0.0007767953,0.000029240857,0.0000069033013,0.0009705112],"genre_scores_gemma":[0.99818134,0.0010776387,0.00042547885,0.00001630361,0.00003761128,0.000115868446,0.00004687149,0.000013536757,0.000085335734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926776,0.000010593476,0.00019537055,0.0002174635,0.000074457945,0.00023433931],"domain_scores_gemma":[0.99933124,0.000033704433,0.00022491335,0.00022283942,0.000090357455,0.00009696527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000036721376,0.00012342563,0.00031789314,0.00009206817,0.000080121674,0.0000072955195,0.00006906562,0.00004402686,0.000026919979],"category_scores_gemma":[0.000017227903,0.00009203562,0.000024140143,0.000044661767,0.00009531512,0.000093709474,0.000039927334,0.00012523239,0.0000017014492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047424773,0.0006857425,0.7725928,0.00016517009,0.00005174053,0.0000017208249,0.00039094244,0.00003262151,0.00006466384,0.0000032374787,0.00004551517,0.22549164],"study_design_scores_gemma":[0.02112363,0.0017831412,0.9723092,0.00023267769,0.00028455033,6.5777544e-7,0.000049364353,0.00038996246,0.00033145357,9.1550123e-7,0.0034038713,0.00009063233],"about_ca_topic_score_codex":0.00018609977,"about_ca_topic_score_gemma":0.00024636876,"teacher_disagreement_score":0.22540101,"about_ca_system_score_codex":0.00036316086,"about_ca_system_score_gemma":0.00038853232,"threshold_uncertainty_score":0.37531036},"labels":[],"label_agreement":null},{"id":"W2734805455","doi":"10.1016/j.jtho.2017.07.005","title":"ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Merck Sharp and Dohme; Yuhan; Novartis Pharmaceuticals Corporation; AstraZeneca; Celgene; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ceritinib; Medicine; Crizotinib; Anaplastic lymphoma kinase; Gastroenterology; Tolerability; Pharmacokinetics; Internal medicine; Meal; Vomiting; Nausea; ALK inhibitor; Pharmacology; Adverse effect; Lung cancer","score_opus":0.02337236563680686,"score_gpt":0.4175437570014449,"score_spread":0.3941713913646381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734805455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548066,0.00024328308,0.00016194217,0.00022234945,0.00044808091,0.0028956116,0.0000852573,0.00000857362,0.00045426894],"genre_scores_gemma":[0.9977485,0.000075490585,0.0015779658,0.000055577293,0.00007411207,0.00021026375,0.000019711257,0.000052570354,0.00018581691],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99685824,0.0005713094,0.0011792919,0.0003481839,0.0005696551,0.00047334481],"domain_scores_gemma":[0.9961678,0.00059669936,0.0019618876,0.00040130314,0.00058300456,0.00028931908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007074098,0.00037156555,0.002052448,0.0005875684,0.00012770342,0.000042944157,0.00025992616,0.00009321922,0.00010847319],"category_scores_gemma":[0.00032206508,0.00022464822,0.00014204452,0.0003316752,0.00021168962,0.0002871018,0.000049874885,0.0003530442,0.0000015389128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8906046,0.015155401,0.047456004,0.00041044966,0.0024170782,0.004248999,0.009301348,0.0005119638,0.00027675543,4.8642937e-7,0.000056760455,0.02956015],"study_design_scores_gemma":[0.86091757,0.03574622,0.089706525,0.001671454,0.006316467,0.00007385867,0.0039731003,0.0009510965,0.00028790307,0.000004422656,0.000059568658,0.00029180848],"about_ca_topic_score_codex":0.0019262338,"about_ca_topic_score_gemma":0.0137277115,"teacher_disagreement_score":0.042250525,"about_ca_system_score_codex":0.001071289,"about_ca_system_score_gemma":0.0020478552,"threshold_uncertainty_score":0.9160888},"labels":[],"label_agreement":null},{"id":"W2735375447","doi":"10.1016/j.lungcan.2017.07.012","title":"Lack of response to nivolumab in a patient with EGFR -mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Niilo Helanderin Säätiö; Institute of Cancer Research","keywords":"Nivolumab; Medicine; Lung cancer; Adenocarcinoma; Oncology; Cancer research; Mutant; Cell; Internal medicine; Cancer; Immunotherapy; Gene; Biology","score_opus":0.017948375462460104,"score_gpt":0.3245573099012019,"score_spread":0.3066089344387418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735375447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97982424,0.008527286,0.00016788697,0.0036219163,0.000852942,0.004343375,0.00044883805,0.000050325598,0.0021631862],"genre_scores_gemma":[0.99040556,0.0009063665,0.0005977517,0.001318835,0.00021861916,0.0022080475,0.000024736259,0.00014382567,0.0041762665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996834,0.00008069353,0.00068092055,0.00092226715,0.00054056104,0.000941571],"domain_scores_gemma":[0.99740255,0.00008458775,0.0003659935,0.0010590496,0.00049042644,0.00059739145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000205515,0.00055996433,0.00090079836,0.00036263897,0.00028141902,0.00007583466,0.00040715197,0.00020012674,0.00036464827],"category_scores_gemma":[0.000034563578,0.00046273007,0.00016415959,0.00054578006,0.00009437976,0.00017573549,0.00009932717,0.00035959884,0.0000097511975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018608345,0.0007567865,0.8635374,0.0023751373,0.0007886019,0.0005783956,0.030676756,0.004773674,0.06664368,0.000008012214,0.0065742745,0.004678956],"study_design_scores_gemma":[0.021165976,0.0030774872,0.76407075,0.006347331,0.0037231029,0.000027268283,0.0013530527,0.0032382598,0.18877774,0.000004568934,0.006744184,0.0014702999],"about_ca_topic_score_codex":0.03686217,"about_ca_topic_score_gemma":0.05584424,"teacher_disagreement_score":0.12213406,"about_ca_system_score_codex":0.0030108837,"about_ca_system_score_gemma":0.0032697725,"threshold_uncertainty_score":0.99978244},"labels":[],"label_agreement":null},{"id":"W2736524699","doi":"10.1200/jco.2016.34.15_suppl.2566","title":"Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Mucositis; Docetaxel; Internal medicine; Lung cancer; Oncology; Cancer; Nausea; Neutropenia; Rash; Adverse effect; Cisplatin; Chemotherapy; Pharmacology","score_opus":0.07143554523852524,"score_gpt":0.49383403129225345,"score_spread":0.4223984860537282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736524699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913106,0.00010261194,0.000030193558,0.007025578,0.00040160265,0.00043213094,0.0000053767235,0.0000026648552,0.0006892691],"genre_scores_gemma":[0.9988686,0.00008246173,0.00029682383,0.00034872163,0.00021387596,0.0000064822557,5.794979e-7,0.000008615618,0.00017387094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791425,0.00028920305,0.0012974663,0.00012470492,0.00026677156,0.00010760996],"domain_scores_gemma":[0.9969793,0.0012628076,0.0011753498,0.00014978866,0.0003057366,0.00012700666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010669307,0.00008773125,0.00073835993,0.00008878773,0.000032100736,0.0000044008357,0.00007928821,0.00011163992,0.00003434773],"category_scores_gemma":[0.0011557358,0.000036544483,0.00008959222,0.00012700909,0.00016369375,0.00011785466,0.000031576987,0.00029258276,0.0000011600279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006760967,0.026242265,0.7600851,0.000028726396,0.0006078184,0.00025934007,0.0010826341,0.0000025850502,0.0005133286,0.00022594817,0.0014427861,0.20274848],"study_design_scores_gemma":[0.15192395,0.07669035,0.76106554,0.00043047438,0.0010198769,0.0002350728,0.0011496607,0.000021057127,0.00030266575,0.00028937648,0.006788153,0.000083796374],"about_ca_topic_score_codex":0.000023780274,"about_ca_topic_score_gemma":0.0001302077,"teacher_disagreement_score":0.20266467,"about_ca_system_score_codex":0.00010156378,"about_ca_system_score_gemma":0.0007219111,"threshold_uncertainty_score":0.14902408},"labels":[],"label_agreement":null},{"id":"W2736712994","doi":"10.1016/s0923-7534(20)33023-4","title":"A Phase I Study of Daily Afatinib, an Irreversible Erbb Family Blocker, Combined With Weekly Paclitaxel and 2-Weekly Bevacizumab in Patients with Advanced Solid Tumours","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Bevacizumab; Afatinib; Paclitaxel; ErbB; Oncology; Internal medicine; Pharmacology; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.038400199057915245,"score_gpt":0.40077139395288713,"score_spread":0.3623711948949719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736712994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709713,0.00025084798,0.0000045304705,0.0004041854,0.0000563341,0.0012595996,0.00005114725,0.00001540565,0.0008608152],"genre_scores_gemma":[0.9985933,0.000032649838,0.00085544644,0.00023647184,0.000018809213,0.00005780316,0.00008795354,0.000023533252,0.00009405763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987073,0.00009678081,0.00037197434,0.00024779123,0.00024337668,0.00033276647],"domain_scores_gemma":[0.99884564,0.00007889874,0.00029852957,0.0002715144,0.0003042756,0.00020112171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016862967,0.00018738878,0.00066074997,0.00019451576,0.00004836227,0.0000036544875,0.00006983307,0.00006985115,0.000013954118],"category_scores_gemma":[0.000029676718,0.00013487539,0.00002842943,0.00026047774,0.0001185287,0.00026230936,0.00002925992,0.0001198711,0.0000011031386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01402897,0.04582809,0.90734357,0.0000807473,0.0004978125,0.00003058447,0.009534629,0.000015338766,0.00021877636,0.000035132914,0.0003355453,0.02205079],"study_design_scores_gemma":[0.06020462,0.14960214,0.7798662,0.000098555836,0.00037069406,0.000005812765,0.009239277,0.000009109339,0.00023912775,0.00001635114,0.00021691684,0.00013118681],"about_ca_topic_score_codex":0.0004066713,"about_ca_topic_score_gemma":0.00027339382,"teacher_disagreement_score":0.1274774,"about_ca_system_score_codex":0.000060867544,"about_ca_system_score_gemma":0.00021527491,"threshold_uncertainty_score":0.55000585},"labels":[],"label_agreement":null},{"id":"W2740133950","doi":"10.1158/1538-7445.am2017-lb-274","title":"Abstract LB-274: Whole-exome sequencing reveals tyrosine kinase-resistant mutations in pretreatment EGFR-mutant lung adenocarcinomas","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Providence Health Care","funders":"","keywords":"Cancer research; KRAS; Exome sequencing; Lung cancer; Epidermal growth factor receptor; Mutation; Gene; Medicine; Malignancy; Cancer; Tyrosine kinase; Exome; T790M; Biology; Oncology; Internal medicine; Genetics; Receptor","score_opus":0.10090290041638919,"score_gpt":0.45124048624093493,"score_spread":0.35033758582454577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740133950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97571105,0.0063210735,0.000012612912,0.0067673833,0.00021972969,0.0018408432,0.00029919323,0.00005445103,0.008773668],"genre_scores_gemma":[0.9914374,0.0005170463,0.00028109885,0.00008864021,0.00027944107,0.0011128689,0.00013035093,0.000064202206,0.0060889875],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99697196,0.00009390415,0.0004834736,0.0006733299,0.0008993344,0.00087799557],"domain_scores_gemma":[0.99767256,0.00016019288,0.00017388425,0.001144047,0.00046789245,0.00038142654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006713143,0.0002712965,0.0004568585,0.0004435152,0.0009614751,0.00025071503,0.00033945128,0.00013512844,0.0005110337],"category_scores_gemma":[0.00031674892,0.00022437121,0.00012433428,0.00037987292,0.00034397017,0.0003445603,0.00012981064,0.0005604004,0.00009808339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010293667,0.0008453299,0.27443787,0.0011103913,0.00077297987,0.0040488304,0.0053871037,0.0002099381,0.69611204,0.0018867402,0.0048002107,0.009359205],"study_design_scores_gemma":[0.005391925,0.0004494132,0.9543288,0.0019455095,0.00026378894,0.00003119477,0.0012032476,0.00015632332,0.031965956,0.0007638681,0.0031715685,0.000328402],"about_ca_topic_score_codex":0.011132718,"about_ca_topic_score_gemma":0.0023868184,"teacher_disagreement_score":0.67989093,"about_ca_system_score_codex":0.005165558,"about_ca_system_score_gemma":0.001841476,"threshold_uncertainty_score":0.9986534},"labels":[],"label_agreement":null},{"id":"W2740653063","doi":"10.1158/1538-7445.am2017-1774","title":"Abstract 1774: Progression-free survival curves suggest a dichotomous determinant of PD-L1 inhibitor efficacy","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Ottawa","funders":"","keywords":"Internal medicine; Medicine; Oncology; Population; Lung cancer; Progression-free survival; Epidermal growth factor receptor; Area under the curve; Receiver operating characteristic; Tyrosine-kinase inhibitor; Proportional hazards model; Cancer; Chemotherapy","score_opus":0.09293664651431557,"score_gpt":0.5037445147351651,"score_spread":0.4108078682208496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740653063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800784,0.005283667,0.0000015853495,0.0040755495,0.00041737038,0.0013533203,0.00015502438,0.000034630502,0.008600429],"genre_scores_gemma":[0.99434084,0.0021013778,0.00010811875,0.000037876565,0.00044245203,0.00043764466,0.000029170675,0.00003899805,0.0024635536],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976696,0.00006022423,0.00029835975,0.0003786437,0.0010843156,0.0005088533],"domain_scores_gemma":[0.9974218,0.00022755751,0.00017142121,0.0013170487,0.00057645974,0.0002857385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063885347,0.00015928803,0.00037219422,0.00014783563,0.0004995886,0.00007440856,0.0004940575,0.000092004564,0.0004026968],"category_scores_gemma":[0.00092663243,0.000113892915,0.00011428437,0.00014740734,0.00054323033,0.00015591554,0.00024556273,0.00039467876,0.00003430023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052944054,0.0048429496,0.33637282,0.007847979,0.0012579451,0.0019690858,0.0027940513,0.000003793553,0.1111457,0.00043185055,0.08654964,0.44148976],"study_design_scores_gemma":[0.0063619255,0.00093775615,0.9108248,0.006008517,0.00017635779,0.000018721263,0.00014963072,0.0000086938835,0.05929219,0.00012234396,0.015878595,0.00022047975],"about_ca_topic_score_codex":0.0021184117,"about_ca_topic_score_gemma":0.00050291547,"teacher_disagreement_score":0.574452,"about_ca_system_score_codex":0.0002544451,"about_ca_system_score_gemma":0.0010606967,"threshold_uncertainty_score":0.4644418},"labels":[],"label_agreement":null},{"id":"W2740681758","doi":"10.1158/1538-7445.am2017-536","title":"Abstract 536: Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Biology; Carcinogenesis; Cancer research; STAT1; Transcriptome; Transcription factor; Signal transduction; Cell biology; Cancer; Gene expression; Genetics; Gene","score_opus":0.14900902949361608,"score_gpt":0.529443425600651,"score_spread":0.380434396107035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740681758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944284,0.00039002925,0.000014474323,0.0011951813,0.00032764755,0.0007069604,0.00018434679,0.0000103818165,0.0027426055],"genre_scores_gemma":[0.99759734,0.00027457744,0.00006468296,0.000014043895,0.00030173032,0.00031924585,0.000020573343,0.000022546652,0.0013852827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982842,0.00002452229,0.00036548963,0.0002612234,0.0007766507,0.00028789343],"domain_scores_gemma":[0.99796003,0.00009294029,0.00027322603,0.00067176024,0.00083760923,0.00016440799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059415615,0.00009230149,0.00026574603,0.00019110097,0.00024345335,0.000037775724,0.00025868742,0.00007110543,0.00032044802],"category_scores_gemma":[0.00055422226,0.00007807089,0.0000791384,0.00015304983,0.00022825705,0.00014479294,0.000060560316,0.0001722131,0.000027513845],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003917144,0.00040994395,0.012167391,0.00036656906,0.00026899518,0.000017092123,0.0015624472,0.0000034395796,0.95702916,0.00060590863,0.0005707977,0.026606545],"study_design_scores_gemma":[0.0016099446,0.00014381408,0.45465082,0.00014133193,0.000089261106,0.0000019558333,0.00034039424,0.000007332548,0.5420014,0.00017321577,0.00077958306,0.000060926246],"about_ca_topic_score_codex":0.0056717386,"about_ca_topic_score_gemma":0.0002991108,"teacher_disagreement_score":0.44248343,"about_ca_system_score_codex":0.00036650882,"about_ca_system_score_gemma":0.002172576,"threshold_uncertainty_score":0.85740095},"labels":[],"label_agreement":null},{"id":"W2741797682","doi":"10.3390/cancers9080099","title":"Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Cancers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency","keywords":"Anaplastic lymphoma kinase; Lung cancer; Immunohistochemistry; Fluorescence in situ hybridization; Molecular biology; Crizotinib; Real-time polymerase chain reaction; Biology; Cancer research; Fish <Actinopterygii>; Pathology; Medicine; Gene; Genetics","score_opus":0.014420300801480384,"score_gpt":0.33024242818124383,"score_spread":0.31582212737976345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741797682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966026,0.0011613552,0.00015015359,0.00024677187,0.00013723616,0.0006376707,0.00002695422,0.0000024270767,0.0010348134],"genre_scores_gemma":[0.9988425,0.00027650135,0.00012379498,0.00006175513,0.000029290692,0.00034964606,0.0000033460035,0.000007933145,0.0003052533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995446,0.0000041738385,0.00016767746,0.00011654172,0.000059955255,0.00010704866],"domain_scores_gemma":[0.99953187,0.000039357248,0.00013477018,0.00020872451,0.000055813576,0.00002944866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009119375,0.00006749397,0.00018582362,0.000038207352,0.00006507654,0.0000057499046,0.00007253589,0.000037874866,0.000006068156],"category_scores_gemma":[0.000024257735,0.000052811058,0.000027168875,0.000052918873,0.00005257301,0.000035811667,0.000016901582,0.000067268935,7.866311e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095618627,0.00007143933,0.70056164,0.0015639242,0.00014297027,0.0000015634432,0.006099939,0.0055001285,0.24237251,0.0000015385747,0.00077208114,0.041956097],"study_design_scores_gemma":[0.0049379296,0.0003003435,0.67626035,0.0008702674,0.00027423122,0.0000012872205,0.0010451116,0.035739888,0.27929237,0.0000017029961,0.0011496573,0.00012684976],"about_ca_topic_score_codex":0.0059191776,"about_ca_topic_score_gemma":0.0029732331,"teacher_disagreement_score":0.041829247,"about_ca_system_score_codex":0.00072256115,"about_ca_system_score_gemma":0.00028584036,"threshold_uncertainty_score":0.8948065},"labels":[],"label_agreement":null},{"id":"W2742146827","doi":"10.1158/1538-7445.am2017-3149","title":"Abstract 3149: Identification of genes associated with the cisplatin resistance in cervical cancer cells expressing E545K mutation","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cisplatin; Cervical cancer; Medicine; Mutation; Cancer research; Cancer; PI3K/AKT/mTOR pathway; Gene; Phenotype; Molecular biology; Pathology; Internal medicine; Biology; Chemotherapy; Genetics; Signal transduction","score_opus":0.07989371942787618,"score_gpt":0.4571750191036448,"score_spread":0.3772812996757686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742146827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909548,0.0023177532,0.00002741557,0.003905779,0.00009002797,0.0006496245,0.00007329278,0.000011842665,0.0019694485],"genre_scores_gemma":[0.9967866,0.00033335557,0.000056200843,0.00002963548,0.00009294276,0.00046070854,0.000023953166,0.000021939604,0.0021946535],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99847674,0.00008336501,0.0002628751,0.00027052275,0.0006245214,0.0002819476],"domain_scores_gemma":[0.9984695,0.00018966204,0.0002638574,0.00048823407,0.00052323367,0.0000655584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064061506,0.00009733316,0.00018880093,0.000113249174,0.00045971212,0.000107715394,0.00021717284,0.0000703624,0.00013095025],"category_scores_gemma":[0.00013703115,0.00006409493,0.00003539565,0.00023435795,0.00030440738,0.00018767982,0.000035718407,0.00027208903,0.0000048617744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001456787,0.0006034939,0.13468345,0.00072979904,0.0005527569,0.00015283354,0.008847559,0.0009228485,0.81054074,0.00044703836,0.004811923,0.03625076],"study_design_scores_gemma":[0.0016491312,0.00004316976,0.85417634,0.00087515207,0.00007602306,5.560204e-7,0.00050645595,0.00011388689,0.14173526,0.00015538845,0.00058462116,0.0000840222],"about_ca_topic_score_codex":0.003533179,"about_ca_topic_score_gemma":0.014401918,"teacher_disagreement_score":0.7194929,"about_ca_system_score_codex":0.00053748995,"about_ca_system_score_gemma":0.0006227821,"threshold_uncertainty_score":0.8036608},"labels":[],"label_agreement":null},{"id":"W2744441485","doi":"10.1016/j.lungcan.2017.07.038","title":"Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; Docetaxel; Refractory (planetary science); Population; Placebo; Lung cancer; Clinical endpoint; Surgery; Randomized controlled trial; Oncology; Cancer; Pathology","score_opus":0.02050992220569165,"score_gpt":0.37174037695729134,"score_spread":0.3512304547515997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744441485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815339,0.0018012426,0.00014581128,0.000150627,0.00021483653,0.012464286,0.0035779814,0.00001978319,0.000091521586],"genre_scores_gemma":[0.9821231,0.00032765325,0.00041957016,0.000074120166,0.00008260897,0.0062112384,0.00022218384,0.00007717976,0.010462393],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99793255,0.00007287477,0.00067778834,0.00058050593,0.0003896697,0.00034662636],"domain_scores_gemma":[0.9966918,0.000327425,0.0015253999,0.00084974593,0.0003713855,0.00023422622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009708165,0.00044729255,0.0017417499,0.00014999985,0.00016295549,0.000028450113,0.00017179232,0.00007210808,0.0006119526],"category_scores_gemma":[0.000079242396,0.00022718041,0.00015809028,0.00010865149,0.00014076947,0.00018931254,0.000034599343,0.000099999044,2.9985682e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49213836,0.0086084595,0.4871347,0.0005513274,0.0042592767,0.00011889787,0.005361603,0.00015907765,0.000024690733,9.1188133e-7,0.00013640027,0.001506305],"study_design_scores_gemma":[0.83621013,0.0050864466,0.14656511,0.0015054699,0.0081120385,2.742602e-7,0.0007168817,0.00086565776,0.00050427846,0.0000017693541,0.00012343233,0.00030854432],"about_ca_topic_score_codex":0.0107741095,"about_ca_topic_score_gemma":0.023496168,"teacher_disagreement_score":0.34407175,"about_ca_system_score_codex":0.0007995626,"about_ca_system_score_gemma":0.0015888587,"threshold_uncertainty_score":0.99581325},"labels":[],"label_agreement":null},{"id":"W2744614251","doi":"10.1371/journal.pone.0181867","title":"Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"European Society for Medical Oncology; International Association for the Study of Lung Cancer; AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Internal medicine; Cohort; Lung cancer; Oncology; Proportional hazards model; Retrospective cohort study","score_opus":0.04012288366534214,"score_gpt":0.37592129608054675,"score_spread":0.3357984124152046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744614251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951475,0.00016453936,0.0000010883355,0.001177499,0.00010902796,0.00079977914,0.000092972296,0.000024127792,0.0024834345],"genre_scores_gemma":[0.9978551,0.000060756105,0.00059212395,0.00021850098,0.000058816582,0.00018270712,0.000116392104,0.00002044351,0.00089511875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877983,0.000033496795,0.0003999919,0.00025507304,0.00035738703,0.00017424671],"domain_scores_gemma":[0.9988152,0.000060149527,0.00019067588,0.0005804589,0.00015194452,0.00020156361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009798717,0.00012413031,0.00044097402,0.000060579547,0.000069502945,0.000017399696,0.00009975061,0.000067061104,0.00017427845],"category_scores_gemma":[0.00037516747,0.00009073124,0.00011086045,0.000048077898,0.00013471182,0.00010079719,0.000060698476,0.000117874006,0.000040618434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005004453,0.0069230287,0.9883293,0.000094001436,0.00065236015,0.00009406555,0.00013606723,1.1679578e-7,0.00001081189,0.000011181163,0.00011777409,0.0031308797],"study_design_scores_gemma":[0.004835788,0.00027187614,0.9927991,0.00067466527,0.0010551105,2.0506684e-7,0.0000126468085,0.00003250161,0.000080121485,0.000109443026,0.00004082013,0.000087703076],"about_ca_topic_score_codex":0.0000833898,"about_ca_topic_score_gemma":0.000044388908,"teacher_disagreement_score":0.006651153,"about_ca_system_score_codex":0.00007716885,"about_ca_system_score_gemma":0.00011513506,"threshold_uncertainty_score":0.36999127},"labels":[],"label_agreement":null},{"id":"W2745692610","doi":"10.1002/bies.201700059","title":"Cancer: Towards a general theory of the target","year":2017,"lang":"en","type":"review","venue":"BioEssays","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Cancer; Computational biology; Biology; Genetics","score_opus":0.10701537012802162,"score_gpt":0.4443113420477046,"score_spread":0.33729597191968297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745692610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002813384,0.97135574,0.000011215508,0.00017138441,0.000776604,0.000775545,0.00048853905,0.000016038699,0.02640211],"genre_scores_gemma":[0.00003808842,0.9779056,0.00021357804,0.00006586605,0.00043529406,0.00024199163,0.00007970529,0.000033474953,0.020986404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991241,0.00007310262,0.0002656555,0.00020570292,0.00018074944,0.00015069272],"domain_scores_gemma":[0.9987452,0.000024055495,0.00037452346,0.00073153834,0.00006554881,0.000059104266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012229712,0.00021312163,0.0009538909,0.00004951366,0.00011611483,0.000013350511,0.0002599249,0.0001556134,0.00027044077],"category_scores_gemma":[0.000045947094,0.00010053572,0.0005493997,0.00007724792,0.00013685168,0.00002155884,0.00007552025,0.00014911497,0.000013326388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004970351,0.00005302378,0.00005788675,0.004866656,0.0007329004,0.0000067705273,0.000060568233,1.1736663e-7,4.1507445e-7,0.00210546,0.0033483494,0.98876286],"study_design_scores_gemma":[0.000282663,0.000032224496,0.0001345856,0.007035483,0.003573844,0.00001762442,0.0000055653486,5.7339287e-7,0.000008435859,0.000240001,0.98857224,0.00009678188],"about_ca_topic_score_codex":0.00024593985,"about_ca_topic_score_gemma":0.000009418611,"teacher_disagreement_score":0.9886661,"about_ca_system_score_codex":0.00017556085,"about_ca_system_score_gemma":0.0016894874,"threshold_uncertainty_score":0.4099728},"labels":[],"label_agreement":null},{"id":"W2746282229","doi":"10.1200/jco.2017.35.15_suppl.e20503","title":"Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Adverse effect; Crizotinib; Refractory (planetary science); Nausea; Lung cancer; Ceritinib; Vomiting; Phases of clinical research; Surgery; Randomized controlled trial; Clinical trial","score_opus":0.07764790315109184,"score_gpt":0.5180193048804581,"score_spread":0.4403714017293663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746282229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705661,0.0024288758,0.00016931779,0.007305462,0.0049095764,0.0014731088,0.00006031184,0.00001149241,0.0130757885],"genre_scores_gemma":[0.9875019,0.0026371353,0.002986763,0.002029046,0.0035192056,0.0000946972,0.00002731786,0.000038574086,0.0011653149],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948175,0.0006321423,0.0034507895,0.00036192354,0.0003704342,0.000367216],"domain_scores_gemma":[0.99002653,0.004055348,0.004473773,0.00047917644,0.00042318855,0.00054198736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030878666,0.00027180332,0.0033209075,0.00015598017,0.0001505656,0.00005549134,0.00037810643,0.00048038812,0.0008225396],"category_scores_gemma":[0.004812016,0.00018427825,0.0010350638,0.00006494342,0.00040916284,0.00026598445,0.00007956238,0.00126783,0.000023243465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8610249,0.011794686,0.024827622,0.00005636996,0.0023452798,0.001712531,0.00088905665,0.000014183948,0.00048726838,0.000028100754,0.009548207,0.087271765],"study_design_scores_gemma":[0.94398475,0.0064875493,0.020303199,0.0004218809,0.0032899552,0.000024651967,0.0001357332,0.00046694418,0.00021858238,0.00025285973,0.024228793,0.00018513155],"about_ca_topic_score_codex":0.0018125053,"about_ca_topic_score_gemma":0.0006336769,"teacher_disagreement_score":0.08708663,"about_ca_system_score_codex":0.0003160879,"about_ca_system_score_gemma":0.0047546895,"threshold_uncertainty_score":0.9006232},"labels":[],"label_agreement":null},{"id":"W2748599797","doi":"10.1136/esmoopen-2017-000219","title":"Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Cancer Research UK; Pfizer","keywords":"Crizotinib; Medicine; Internal medicine; Lung cancer; Tolerability; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; ALK inhibitor; Oncology; Adverse effect; Population; Clinical trial; Phases of clinical research","score_opus":0.016457186674279232,"score_gpt":0.34050324695636136,"score_spread":0.3240460602820821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748599797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867952,0.000047452566,0.00001468599,0.00030684072,0.00006675284,0.005646082,0.0007844584,0.0000034042725,0.0063351295],"genre_scores_gemma":[0.99545383,0.000026440272,0.0017454281,0.000031394942,0.00001725955,0.00028251662,0.00022112663,0.000014818696,0.0022071896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899554,0.000056822635,0.00034308492,0.00024933746,0.00019496716,0.00016023705],"domain_scores_gemma":[0.9988567,0.00010205406,0.0004463456,0.0003239846,0.00021878874,0.00005209096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016617104,0.00012896671,0.0003312218,0.00004000974,0.00016908027,0.000022140037,0.00019456337,0.00003208886,0.000045691933],"category_scores_gemma":[0.000112609865,0.00007848868,0.000036851645,0.00008593842,0.00009218676,0.00015680809,0.00012681447,0.00009209178,6.441049e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12523136,0.005287411,0.8436404,0.0003507055,0.0005701707,0.000014059176,0.0091736,0.00025222523,0.00011285646,0.000036729703,0.0006200942,0.014710402],"study_design_scores_gemma":[0.17418775,0.0009157588,0.82150817,0.0007864808,0.00033761555,6.313075e-7,0.000092724455,0.00026038225,0.0016977171,0.0000030375336,0.00013446753,0.000075289405],"about_ca_topic_score_codex":0.002087255,"about_ca_topic_score_gemma":0.0016826664,"teacher_disagreement_score":0.04895639,"about_ca_system_score_codex":0.000090462505,"about_ca_system_score_gemma":0.0003439458,"threshold_uncertainty_score":0.32006752},"labels":[],"label_agreement":null},{"id":"W2748693890","doi":"10.1200/jco.2012.30.15_suppl.3007","title":"First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Crizotinib; Oncology; Gastroenterology; Lung cancer","score_opus":0.08638177473718214,"score_gpt":0.544109239422946,"score_spread":0.45772746468576386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748693890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393,0.00027263185,0.0000034879354,0.0025069553,0.0011261259,0.00039963677,0.0000015161484,0.0000021147744,0.0017575563],"genre_scores_gemma":[0.99839985,0.000043640757,0.00021101217,0.0004935699,0.00068869063,0.000010113074,5.23463e-7,0.000008814242,0.0001437999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732655,0.00023192119,0.0019381634,0.00009057033,0.0002266495,0.00018611918],"domain_scores_gemma":[0.99784935,0.0005805384,0.0011110675,0.00016392197,0.00012973786,0.00016540212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013688946,0.000084281404,0.0009668085,0.00010452494,0.000030161378,0.000001814872,0.00010751315,0.00010874391,0.000060736944],"category_scores_gemma":[0.0010148751,0.000047707174,0.00019155946,0.00016545005,0.0000825,0.00011143708,0.00003753756,0.0005473569,0.0000023936727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018790605,0.03888129,0.9282836,0.000025208996,0.00023252086,0.00024774863,0.0027551258,0.000118445896,0.0002713152,0.00006016468,0.0008342485,0.026411291],"study_design_scores_gemma":[0.043365195,0.019195192,0.92057544,0.00017500589,0.00033048034,0.000067221285,0.0015917211,0.000013662635,0.00015141949,0.00010894174,0.014370189,0.000055533004],"about_ca_topic_score_codex":0.000052431453,"about_ca_topic_score_gemma":0.0004305721,"teacher_disagreement_score":0.041486133,"about_ca_system_score_codex":0.00023129156,"about_ca_system_score_gemma":0.00054869126,"threshold_uncertainty_score":0.23780239},"labels":[],"label_agreement":null},{"id":"W2750645423","doi":"10.3747/co.24.3561","title":"Oral Chinese Herbal Medicine as Maintenance Treatment after Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis","year":2017,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Hazard ratio; Cochrane Library; Lung cancer; Internal medicine; Confidence interval; Placebo; Relative risk; Quality of life (healthcare); Randomized controlled trial; Systematic review; Cancer; MEDLINE; Oncology; Alternative medicine; Pathology","score_opus":0.14327103032900035,"score_gpt":0.5303172860375038,"score_spread":0.3870462557085035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750645423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000058911523,0.98058957,0.00019376235,0.00177792,0.0004212253,0.016141256,0.00043436608,0.000032160442,0.0004038529],"genre_scores_gemma":[0.000024462213,0.9531146,0.00030652693,0.000628667,0.0001875998,0.037836213,0.0005240155,0.000080493606,0.0072974083],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996856,0.00020302256,0.0013386619,0.00092469587,0.00020556874,0.00047206617],"domain_scores_gemma":[0.9964279,0.000283877,0.001610601,0.0010811518,0.00029560982,0.0003008864],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0003677401,0.00096087495,0.014916367,0.00027084298,0.00014741001,0.000023119477,0.00024150913,0.0002500523,0.00046683953],"category_scores_gemma":[0.00012488868,0.0004709453,0.0028330183,0.00033878622,0.00014699297,0.00005959036,0.000046341298,0.0002297401,0.000012510961],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055248292,0.00046054443,0.000036710662,0.736877,0.16109255,0.00004405812,0.00024710287,2.559361e-7,3.641506e-8,0.000005701529,0.00082911586,0.10035163],"study_design_scores_gemma":[0.0023009966,0.0006133512,0.0000040826817,0.03300114,0.562317,0.000045461748,0.000009369951,0.000010231278,4.1163972e-8,0.0000051636866,0.40148008,0.00021304649],"about_ca_topic_score_codex":0.00011600319,"about_ca_topic_score_gemma":0.00023287097,"teacher_disagreement_score":0.7038759,"about_ca_system_score_codex":0.0014899347,"about_ca_system_score_gemma":0.0011327153,"threshold_uncertainty_score":0.9997742},"labels":[],"label_agreement":null},{"id":"W2750974247","doi":"10.3747/co.24.3496","title":"Patterns of Spread and Prognostic Implications of Lung Cancer Metastasis in an Era of Driver Mutations","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; BC Cancer Agency","funders":"Varian Medical Systems; Pfizer","keywords":"Medicine; Internal medicine; Cohort; Oncology; Brain metastasis; Lung cancer; Hazard ratio; Incidence (geometry); Cumulative incidence; Metastasis; Bone metastasis; Cancer; Confidence interval","score_opus":0.08158171228416032,"score_gpt":0.4875882708283341,"score_spread":0.4060065585441738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750974247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996706,0.0011421569,0.0001567525,0.0008564249,0.00012703249,0.00047751243,0.00031745058,0.0000038306293,0.00021281221],"genre_scores_gemma":[0.99898124,0.00041242366,0.00033441102,0.000008772712,0.000020033192,0.0001574715,0.00006875768,0.000005811904,0.000011102812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994555,0.0000269878,0.00024465125,0.00012765569,0.000058648246,0.000086528715],"domain_scores_gemma":[0.9991947,0.00006504485,0.00027026978,0.00024025331,0.00017863189,0.000051090086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048338323,0.000062377105,0.00026736822,0.000077145516,0.000042001415,0.000002826929,0.00006517061,0.000034503177,0.000054714197],"category_scores_gemma":[0.00006001208,0.000052746585,0.000033639277,0.00004702385,0.00011480574,0.00007741139,0.000028361139,0.0000726997,2.0332034e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018733412,0.0006658031,0.9115264,0.00019885808,0.00009795046,0.000001170596,0.0013813006,0.000007274907,0.000867531,0.0005122756,0.000026774249,0.08469593],"study_design_scores_gemma":[0.0015055323,0.00028227194,0.99589294,0.00020802674,0.00069134793,0.0000032913504,0.0001458353,0.00011915601,0.000680769,0.00011824477,0.000315163,0.000037439113],"about_ca_topic_score_codex":0.00056974235,"about_ca_topic_score_gemma":0.0012835314,"teacher_disagreement_score":0.08465849,"about_ca_system_score_codex":0.000075384945,"about_ca_system_score_gemma":0.00026255945,"threshold_uncertainty_score":0.21509434},"labels":[],"label_agreement":null},{"id":"W2752145111","doi":"10.1007/s40273-017-0563-8","title":"Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Precision medicine; Erlotinib; Cancer; Population; Epidermal growth factor receptor; Intensive care medicine; Oncology; Internal medicine; Pathology; Environmental health","score_opus":0.23812144414758424,"score_gpt":0.5266995212851098,"score_spread":0.28857807713752553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752145111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014344309,0.98879164,0.00002471773,0.0006540719,0.0006231191,0.0039006781,0.005930982,0.000005926459,0.000054514145],"genre_scores_gemma":[0.000021514452,0.9963095,0.00056250073,0.0005068187,0.00022182986,0.0013520259,0.0009303669,0.00003513189,0.00006027664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858624,0.00005358689,0.0009099305,0.00025568166,0.00004565591,0.00014891187],"domain_scores_gemma":[0.9978802,0.0004567447,0.0010633724,0.0004485749,0.0001077509,0.00004331267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022460097,0.0002741115,0.0015653665,0.00013563814,0.00006939767,0.000043836204,0.00016407834,0.000078901714,0.0001022294],"category_scores_gemma":[0.000060945444,0.00018213106,0.00054712966,0.00004215995,0.00006641329,0.00016436746,0.000022348584,0.0002182816,9.656019e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020267216,0.00033493352,0.000075207005,0.2440255,0.002085795,0.0000018861757,0.0006460496,0.000046866233,0.000002008763,0.0014917975,0.039436016,0.71183366],"study_design_scores_gemma":[0.0010844313,0.00002217737,0.0000054765997,0.07090438,0.004308555,0.000014527325,0.000003614808,0.00019745427,0.000003907662,0.000010828482,0.9233145,0.00013011853],"about_ca_topic_score_codex":0.00005831851,"about_ca_topic_score_gemma":0.000034181776,"teacher_disagreement_score":0.8838785,"about_ca_system_score_codex":0.00030284404,"about_ca_system_score_gemma":0.001440036,"threshold_uncertainty_score":0.74270886},"labels":[],"label_agreement":null},{"id":"W2753944011","doi":"10.1093/annonc/mdx523","title":"Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Vancouver General Hospital; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Afatinib; Medicine; Lung cancer; Fusion gene; Cancer research; Adenocarcinoma; Cancer; Transcriptome; Epigenetics; Bioinformatics; Oncology; Internal medicine; Gene; Epidermal growth factor receptor; Biology; Gefitinib; Genetics; Gene expression","score_opus":0.16885170927104307,"score_gpt":0.4920367757455327,"score_spread":0.32318506647448964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753944011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977953,0.001550021,0.000101930855,0.012216374,0.0002600298,0.0009824791,0.00045180623,0.000008041058,0.0064762766],"genre_scores_gemma":[0.99784386,0.00031468537,0.0006539881,0.00024061011,0.00006368223,0.00020617191,0.000022085698,0.000010435987,0.00064450747],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993349,0.000019138515,0.00024944343,0.00013168773,0.000086538,0.00017832642],"domain_scores_gemma":[0.99888194,0.0001142793,0.0005018099,0.00024685933,0.00020769266,0.000047417063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013021364,0.00009307057,0.00034971503,0.000035109944,0.0001664552,0.0000066117545,0.00012698937,0.000045755245,0.000056307777],"category_scores_gemma":[0.00011003422,0.000052655305,0.00013899214,0.000034083463,0.00016422984,0.000053467775,0.00002749499,0.000036352038,8.557445e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012036709,0.0070295287,0.15716736,0.00079065014,0.006830895,0.000028688108,0.0056111705,0.00057478494,0.06875176,0.00943268,0.0063400916,0.7362387],"study_design_scores_gemma":[0.01970807,0.014699614,0.25816512,0.00035432712,0.0028390537,0.000023179484,0.0024205407,0.00035276797,0.54488164,0.0026546111,0.15359437,0.00030667544],"about_ca_topic_score_codex":0.0016716314,"about_ca_topic_score_gemma":0.000378627,"teacher_disagreement_score":0.73593205,"about_ca_system_score_codex":0.00006111639,"about_ca_system_score_gemma":0.0007809701,"threshold_uncertainty_score":0.25270176},"labels":[],"label_agreement":null},{"id":"W2754952150","doi":"10.1016/j.lungcan.2017.08.022","title":"An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Adenocarcinoma; Population; Lung cancer; Metastasis; Stage (stratigraphy); Oncology; Bone metastasis; Cancer; Environmental health","score_opus":0.015829704587617663,"score_gpt":0.37095163349537746,"score_spread":0.3551219289077598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754952150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878033,0.0005115575,0.0006179765,0.00060896616,0.00051738846,0.000564909,0.0004095717,0.00002851325,0.00893782],"genre_scores_gemma":[0.99612904,0.0003751565,0.0009344915,0.0003664004,0.00021820607,0.0002948091,0.00029354575,0.000024564319,0.0013637724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862623,0.000029691235,0.00032671302,0.0004416055,0.00030276534,0.00027297426],"domain_scores_gemma":[0.998308,0.000041228253,0.00042490105,0.0006713176,0.00037555574,0.00017902152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001051428,0.00020846746,0.00055347866,0.00016435918,0.00019360679,0.000040751165,0.00029842526,0.00009973555,0.00090793404],"category_scores_gemma":[0.000036213474,0.00013963901,0.0001789005,0.00017307802,0.00011145341,0.00022091264,0.00004949491,0.00014337801,0.0000019024903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019525859,0.0003396378,0.9916198,0.00006059812,0.003546284,0.000008040922,0.00047841287,0.0011034341,0.000155694,0.0000454254,0.00073145167,0.0017159303],"study_design_scores_gemma":[0.0025321608,0.00014904763,0.9771278,0.00014090988,0.0070855985,3.4014005e-7,0.000035438537,0.012000327,0.0002495494,0.0000039867377,0.0005248248,0.00015002604],"about_ca_topic_score_codex":0.006185226,"about_ca_topic_score_gemma":0.0020870417,"teacher_disagreement_score":0.014492042,"about_ca_system_score_codex":0.0004167064,"about_ca_system_score_gemma":0.00022351359,"threshold_uncertainty_score":0.9941241},"labels":[],"label_agreement":null},{"id":"W2755843609","doi":"10.1200/jco.2017.35.15_suppl.9071","title":"Afatinib in patients with metastatic <i>HER2</i>-mutant lung cancers: An international multicenter study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Lung cancer; Clinical endpoint; T790M; Trastuzumab; KRAS; Exon; Point mutation; Cancer; Epidermal growth factor receptor; Gefitinib; Mutant; Clinical trial; Breast cancer; Biology; Genetics","score_opus":0.08792403434115671,"score_gpt":0.5279885917996495,"score_spread":0.4400645574584928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755843609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944618,0.000022088561,0.000041404062,0.001685924,0.0013523333,0.00045578773,0.000009380108,0.0000034984869,0.0019678178],"genre_scores_gemma":[0.9960438,0.00004041428,0.002753102,0.00067839166,0.00036102193,0.000010877866,0.0000065878653,0.000013040534,0.000092776194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791485,0.00017147981,0.0012145956,0.00017049142,0.00038033194,0.00014826616],"domain_scores_gemma":[0.9971518,0.00025851652,0.0015992388,0.0002698672,0.00049274374,0.00022786003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009117737,0.000107809305,0.00075067853,0.0000942425,0.00006681223,0.000031769483,0.00023520294,0.00006650766,0.00013518613],"category_scores_gemma":[0.0010110908,0.000064819935,0.00011866211,0.000034483888,0.00010778944,0.00043219284,0.00003818462,0.00041828142,0.000003902756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004576693,0.006734605,0.9532032,0.000006900903,0.00096272014,0.00050859054,0.00063376484,0.0000304016,0.0000016373649,0.000007886992,0.00011024254,0.033223342],"study_design_scores_gemma":[0.036644217,0.013085609,0.9456977,0.00010350109,0.00072515564,0.000010767664,0.00048174418,0.00020574903,0.0000025669303,0.000014350063,0.0029668906,0.00006170399],"about_ca_topic_score_codex":0.00024514282,"about_ca_topic_score_gemma":0.000883612,"teacher_disagreement_score":0.03316164,"about_ca_system_score_codex":0.00043923926,"about_ca_system_score_gemma":0.0011921834,"threshold_uncertainty_score":0.26432803},"labels":[],"label_agreement":null},{"id":"W2755938503","doi":"10.3389/fonc.2017.00222","title":"Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Lung cancer; Chromosomal translocation; Cancer research; Epidermal growth factor receptor; Medicine; Targeted therapy; Mutation; Lymphoma; Cancer; Gene; Oncology; Biology; Bioinformatics; Internal medicine; Genetics","score_opus":0.03799832351981941,"score_gpt":0.40347100201715325,"score_spread":0.36547267849733384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755938503","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020330085,0.989284,0.0013210048,0.000255033,0.0013258476,0.0024833232,0.0002708809,0.000022374057,0.0030045775],"genre_scores_gemma":[0.002169661,0.97975355,0.014035672,0.00007119346,0.00015879306,0.001835873,0.000676892,0.00006501262,0.0012333256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982431,0.00008340074,0.00065486267,0.00052454404,0.00010357709,0.0003905162],"domain_scores_gemma":[0.99895895,0.00012134599,0.00040537128,0.00031973966,0.00006649313,0.00012813127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013294304,0.0003587426,0.0017892821,0.00044852516,0.00018482136,0.000021275508,0.00018897848,0.0004540294,0.000018362982],"category_scores_gemma":[0.000032427084,0.00032916572,0.00015184844,0.00021987388,0.00017984751,0.00010651452,0.00004164083,0.00059113494,0.0000021585188],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002945524,0.0005974144,0.011331251,0.007235289,0.000298697,0.00017771476,0.00254286,0.00021854872,0.00000996873,0.00001773559,0.0011507618,0.9763903],"study_design_scores_gemma":[0.006535535,0.00023388743,0.0033937264,0.0077780555,0.0036374545,0.000053425232,0.0011591567,0.0012348376,0.0000036393646,0.000018883768,0.97544265,0.0005087695],"about_ca_topic_score_codex":0.00076364854,"about_ca_topic_score_gemma":0.0015333537,"teacher_disagreement_score":0.9758815,"about_ca_system_score_codex":0.0016549159,"about_ca_system_score_gemma":0.0020752132,"threshold_uncertainty_score":0.999916},"labels":[],"label_agreement":null},{"id":"W2756225528","doi":"10.1200/jco.2013.31.15_suppl.e19518","title":"Lack of effect of bendamustine on Fridericia corrected QT interval (QTcF) in a phase III study of bendamustine-rituximab in advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Bendamustine; Medicine; QT interval; Rituximab; Internal medicine; Mantle cell lymphoma; Cardiology; Lymphoma","score_opus":0.06540326270168666,"score_gpt":0.4896914087772768,"score_spread":0.4242881460755901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756225528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637115,0.00016437208,0.000022792094,0.00034454936,0.0009071386,0.0014642242,0.000020016345,0.0000068943364,0.00069886027],"genre_scores_gemma":[0.9985186,0.00013064005,0.0007211786,0.00023724604,0.00013908325,0.000051927833,0.000009904663,0.000031736196,0.00015970296],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939089,0.00062589865,0.00433906,0.00031761467,0.00048613062,0.0003224042],"domain_scores_gemma":[0.9926959,0.0029384252,0.0032630225,0.00031975145,0.00056472165,0.00021815771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014725727,0.0002939088,0.003351497,0.0005347177,0.000020795804,0.000004369912,0.00024183946,0.00029507012,0.0002501294],"category_scores_gemma":[0.001852098,0.00019297216,0.0003852079,0.00051479856,0.00017229236,0.00013317441,0.00009253913,0.00042800623,0.000008036899],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09741665,0.14840542,0.11005087,0.0005844257,0.0010476124,0.0018940095,0.0041274657,0.00039955036,0.0032481954,0.0000044369353,0.0009807298,0.63184065],"study_design_scores_gemma":[0.3983972,0.19156814,0.39657694,0.0013972013,0.0011482406,0.00016871023,0.0030442937,0.0011011974,0.0058860844,0.000017657676,0.0004922743,0.00020205011],"about_ca_topic_score_codex":0.0010186688,"about_ca_topic_score_gemma":0.0007580087,"teacher_disagreement_score":0.6316386,"about_ca_system_score_codex":0.00045619567,"about_ca_system_score_gemma":0.0013829118,"threshold_uncertainty_score":0.7869176},"labels":[],"label_agreement":null},{"id":"W2756994529","doi":"10.1200/jco.2017.35.15_suppl.11506","title":"Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"T790M; Medicine; Osimertinib; Lung cancer; Cancer research; Tumor progression; Oncology; Internal medicine; Tolerability; Cancer; Gefitinib; Epidermal growth factor receptor; Erlotinib; Adverse effect","score_opus":0.061520828854786255,"score_gpt":0.46344675650710715,"score_spread":0.4019259276523209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756994529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322104,0.0016088877,0.00013106051,0.0016572463,0.0014082064,0.00085239054,0.000018404364,0.000007102796,0.0010956583],"genre_scores_gemma":[0.98508275,0.000367465,0.012967965,0.00035369763,0.0010481073,0.000055272165,0.000008196798,0.000028935454,0.000087594766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969507,0.0001973134,0.0019436954,0.00031224752,0.00031536657,0.00028068622],"domain_scores_gemma":[0.99574524,0.00050778023,0.0027216736,0.0002982269,0.0005004775,0.00022661228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001288839,0.00019669073,0.0012553076,0.00017652544,0.00019186674,0.000023625564,0.0001863199,0.0002074426,0.000014238378],"category_scores_gemma":[0.0017171539,0.00013831283,0.00038619596,0.000103156955,0.00011212899,0.00016580496,0.00005387668,0.0006558738,0.0000015255335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0108116185,0.0037309793,0.60532624,0.00022880135,0.0006147261,0.0014261461,0.0010348345,0.0005181803,0.33754298,0.00009355369,0.0005172084,0.03815476],"study_design_scores_gemma":[0.043264553,0.020704955,0.75263095,0.0033517554,0.0019108662,0.000054608474,0.00055937335,0.0015649803,0.17302813,0.00018273138,0.0023675465,0.0003795651],"about_ca_topic_score_codex":0.00012977034,"about_ca_topic_score_gemma":0.00045988106,"teacher_disagreement_score":0.16451484,"about_ca_system_score_codex":0.00075780536,"about_ca_system_score_gemma":0.0037186844,"threshold_uncertainty_score":0.6596787},"labels":[],"label_agreement":null},{"id":"W2757470630","doi":"10.1136/esmoopen-2017-000225","title":"Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Hospital for Sick Children; Public Health Ontario; University of Toronto; SickKids Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Subgroup analysis; Systemic therapy; Clinical trial; Randomized controlled trial; Clinical endpoint; Cancer; Oncology; Systematic review; MEDLINE; Breast cancer","score_opus":0.25827546618447417,"score_gpt":0.4876232192284989,"score_spread":0.22934775304402472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757470630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018940808,0.98309964,0.0000049835407,0.00027582096,0.00009854727,0.0147795975,0.001343935,0.000013670718,0.00019437261],"genre_scores_gemma":[0.00067354925,0.9863908,0.00020916846,0.0005620159,0.000050236118,0.007032379,0.00061114045,0.00006614958,0.0044045374],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99669397,0.00029967443,0.0014666589,0.0007861924,0.00044880278,0.00030471024],"domain_scores_gemma":[0.9949191,0.0004132071,0.002223575,0.0019284489,0.00031109195,0.0002045774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006504327,0.0006051597,0.009197087,0.00008654795,0.00032808838,0.0002752534,0.00071142573,0.00016201609,0.00076068944],"category_scores_gemma":[0.00011481412,0.00022332858,0.0011004546,0.00029512492,0.00011133267,0.00017044791,0.00024467317,0.0003399098,0.000027964912],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007526022,0.00025599622,0.0006141809,0.40289137,0.5708858,0.000009073033,0.00049614446,9.4477593e-7,2.540372e-9,0.0000070587644,0.00023000741,0.024534186],"study_design_scores_gemma":[0.0010108912,0.00018593147,0.0009226559,0.121171646,0.8233215,0.000012162211,0.000052773037,0.000001897484,1.7411166e-8,7.2955163e-7,0.053063918,0.00025587925],"about_ca_topic_score_codex":0.00366582,"about_ca_topic_score_gemma":0.0007836034,"teacher_disagreement_score":0.2817197,"about_ca_system_score_codex":0.00030284928,"about_ca_system_score_gemma":0.0009169775,"threshold_uncertainty_score":0.91070753},"labels":[],"label_agreement":null},{"id":"W2759185183","doi":"10.1200/jco.2013.31.15_suppl.e19147","title":"Phase I/II trial of combination nab-paclitaxel and pemetrexed in advanced solid tumor patients (pts) with emphasis on non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Neutropenia; Internal medicine; Oncology; Lung cancer; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Toxicity; Progressive disease; Clinical endpoint; Chemotherapy; Gastroenterology; Surgery; Clinical trial; Cisplatin","score_opus":0.03792672054753038,"score_gpt":0.4652624784664411,"score_spread":0.4273357579189107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759185183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520624,0.00023376042,0.000039721614,0.0016432443,0.0006266931,0.0010743798,0.00001059612,0.000003401536,0.001161937],"genre_scores_gemma":[0.99716294,0.00035811632,0.0014493337,0.0006211411,0.00017002462,0.000057938472,0.000006953153,0.00001563864,0.00015789144],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977835,0.00012789025,0.0014620487,0.00017846521,0.0002727976,0.00017529],"domain_scores_gemma":[0.9969727,0.0005748232,0.0015140823,0.00011917107,0.0005935338,0.00022573395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050596765,0.00013671324,0.0010347392,0.00019542094,0.00003758987,0.000005453663,0.00006892824,0.00013235258,0.00007317],"category_scores_gemma":[0.0005635746,0.0000888782,0.00014957257,0.00015462427,0.000099156714,0.00014555853,0.000021829293,0.00037131624,0.0000017487064],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14141214,0.08460484,0.17414019,0.00022143923,0.0008684133,0.00017924931,0.0015005438,0.00011666675,0.00058365957,0.000043083026,0.0012280607,0.5951017],"study_design_scores_gemma":[0.5898577,0.17372735,0.23322518,0.0005253804,0.0007797294,0.000009527041,0.00024184931,0.00019289817,0.00045998368,0.00009584661,0.0007710559,0.00011352848],"about_ca_topic_score_codex":0.00017199,"about_ca_topic_score_gemma":0.00009063615,"teacher_disagreement_score":0.59498817,"about_ca_system_score_codex":0.0003433108,"about_ca_system_score_gemma":0.0014306876,"threshold_uncertainty_score":0.36243477},"labels":[],"label_agreement":null},{"id":"W2759808499","doi":"10.1200/jco.2017.35.15_suppl.9036","title":"ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; T790M; Internal medicine; Discontinuation; Lung cancer; Oncology; Interstitial lung disease; Interim analysis; Chemotherapy; Cancer; Surgery; Gastroenterology; Clinical trial; Lung; Erlotinib; Adenocarcinoma; Epidermal growth factor receptor; ROS1","score_opus":0.06083654637233833,"score_gpt":0.4858123714878276,"score_spread":0.42497582511548926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759808499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886728,0.00011568,0.000010405689,0.00092437,0.00047331006,0.000958344,0.000017723129,0.0000030837202,0.008824291],"genre_scores_gemma":[0.99771047,0.00029519785,0.0006916875,0.00017138029,0.00031989152,0.000039301318,0.0000043018404,0.000019175774,0.0007485977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747276,0.00019054777,0.001591902,0.00022749009,0.00029270662,0.00022459032],"domain_scores_gemma":[0.99578595,0.000486071,0.0026461463,0.00030938882,0.00050879177,0.00026366772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049379683,0.00017801824,0.0013904341,0.00016969105,0.00008400484,0.000012346788,0.00016562393,0.00013338515,0.00004870727],"category_scores_gemma":[0.00016794704,0.00010692335,0.00021723552,0.00009611209,0.00011505098,0.00011315063,0.000040395837,0.00040208924,0.0000022626623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071287546,0.021952305,0.92005605,0.00001768468,0.0012327683,0.00039402873,0.0015577468,0.000039635106,0.0000061980036,0.000002093596,0.00025034903,0.047362365],"study_design_scores_gemma":[0.05881358,0.053207017,0.884386,0.0003217332,0.0021709763,0.0000047366098,0.0004899306,0.00002773446,0.00007531951,0.000004030933,0.00041933378,0.00007963102],"about_ca_topic_score_codex":0.0037367104,"about_ca_topic_score_gemma":0.007455198,"teacher_disagreement_score":0.051684827,"about_ca_system_score_codex":0.0007459045,"about_ca_system_score_gemma":0.0023008278,"threshold_uncertainty_score":0.5648813},"labels":[],"label_agreement":null},{"id":"W2760959429","doi":"10.1093/annonc/mdx363.043","title":"EGFR copy number aberrations detected in cfDNA from advanced NSCLC patients","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"T790M; Medicine; KRAS; Neuroblastoma RAS viral oncogene homolog; Epidermal growth factor receptor; Liquid biopsy; Exon; Cancer research; Mutation; Deep sequencing; Osimertinib; Resistance mutation; Oncology; Gefitinib; Internal medicine; Cancer; Gene; Polymerase chain reaction; Biology; Erlotinib; Genetics; Genome","score_opus":0.04919668819991271,"score_gpt":0.4522982180161306,"score_spread":0.40310152981621794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760959429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401473,0.00005745096,0.000017989225,0.0045634992,0.00026057725,0.00031264103,0.00007890208,0.000014129469,0.05454756],"genre_scores_gemma":[0.997254,0.00008728393,0.0010713945,0.000623994,0.000047559322,0.00005469194,0.00014092613,0.000010080073,0.0007100762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999333,0.000027432558,0.00023129657,0.00015974932,0.00009321805,0.00015526556],"domain_scores_gemma":[0.99912554,0.000058025693,0.0001983736,0.00032175818,0.0002257287,0.000070565446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004223438,0.00008168648,0.00026131386,0.000045593704,0.00009677087,0.00000716302,0.00008649195,0.00009554624,0.00029252065],"category_scores_gemma":[0.00021533713,0.00006429866,0.00004660489,0.000050817518,0.00008419744,0.000119291326,0.000028193215,0.00008490493,0.00005535123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044604996,0.0013056864,0.80161303,0.0000120420455,0.00020733454,0.000034096032,0.0010766513,0.0000072833514,0.00078970444,0.0001799372,0.0055686473,0.18875952],"study_design_scores_gemma":[0.0052681346,0.0008097476,0.9518162,0.00005991011,0.00007530277,0.000001400279,0.000081646416,0.000015886817,0.0023067298,0.0006300615,0.038866486,0.00006850359],"about_ca_topic_score_codex":0.0008942058,"about_ca_topic_score_gemma":0.0010826926,"teacher_disagreement_score":0.188691,"about_ca_system_score_codex":0.000065761735,"about_ca_system_score_gemma":0.0002290371,"threshold_uncertainty_score":0.32028958},"labels":[],"label_agreement":null},{"id":"W2761062133","doi":"10.2196/resprot.7750","title":"Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol","year":2017,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Protocol (science); Medicine; Lung cancer; Cancer; Family medicine; Gerontology; Oncology; Demography; Alternative medicine; Internal medicine; Pathology; Sociology","score_opus":0.12453978852808203,"score_gpt":0.5490535235379241,"score_spread":0.42451373500984213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761062133","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.420927,3.7076236e-7,3.84473e-7,0.00025831338,0.0000019069116,0.5770458,0.000017874047,0.000014157257,0.0017341825],"genre_scores_gemma":[0.17869928,0.0000016415295,0.000043525306,0.000034204993,0.000030130828,0.8187074,0.00002506718,0.000027323085,0.0024314008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758834,0.00031383746,0.00029447573,0.0004703076,0.0007929389,0.0005401187],"domain_scores_gemma":[0.99821234,0.00018159063,0.0001797198,0.0009032032,0.00034741647,0.00017574214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005342368,0.00026047698,0.0003461656,0.00035395147,0.0007732531,0.00040157256,0.00034428202,0.000048625978,0.00005122498],"category_scores_gemma":[0.000027051901,0.00012461847,0.00003931846,0.00038201606,0.0003208501,0.00020992375,0.000108260894,0.00032771638,0.0000036819013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008233017,0.0038491907,0.9860792,0.00034965918,0.00013616237,0.00010571577,0.0073542176,0.000010471824,0.0000033576066,0.000006834502,0.00038572255,0.0008961432],"study_design_scores_gemma":[0.019888336,0.005125539,0.96461815,0.0010495626,0.000038443253,3.7916178e-7,0.0016915731,0.00007908142,0.000049019418,0.000020135383,0.007303966,0.00013583901],"about_ca_topic_score_codex":0.038106095,"about_ca_topic_score_gemma":0.027092868,"teacher_disagreement_score":0.2422277,"about_ca_system_score_codex":0.0005935879,"about_ca_system_score_gemma":0.0005177235,"threshold_uncertainty_score":0.99066013},"labels":[],"label_agreement":null},{"id":"W2761725905","doi":"10.1093/annonc/mdx380.051","title":"Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Afatinib; Medicine; Osimertinib; Internal medicine; Oncology; Lung cancer; Erlotinib; Clinical trial; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.028470831148526596,"score_gpt":0.3871186485849103,"score_spread":0.3586478174363837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761725905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824626,0.00041660498,0.000012201186,0.0047697057,0.00007712347,0.0005938782,0.000045042467,0.000010059104,0.011612774],"genre_scores_gemma":[0.9983416,0.00018867086,0.00029925167,0.000732987,0.000030561954,0.000065565684,0.000090994945,0.000014566144,0.00023577953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999192,0.000049027873,0.00022585501,0.00020642798,0.00013553283,0.00019114478],"domain_scores_gemma":[0.99893874,0.00009202201,0.00027445072,0.00021849218,0.000392887,0.00008340729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108216074,0.00012460319,0.00031596786,0.00010570162,0.00013348677,0.000018751862,0.00006931329,0.00008399684,0.000037535865],"category_scores_gemma":[0.000083991625,0.000091159796,0.00003797304,0.000048183767,0.0002805135,0.00019693171,0.000027996257,0.00009395333,0.0000030616243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007753693,0.0008981378,0.90443015,0.00005445274,0.000491122,0.0001642635,0.0077434373,0.000007315369,0.00019106035,0.0005968819,0.0003215494,0.084326245],"study_design_scores_gemma":[0.005094002,0.003648838,0.9885793,0.00018027908,0.00012904975,0.000012285593,0.00074496295,0.00003011238,0.00087521406,0.000138255,0.00047584355,0.00009191207],"about_ca_topic_score_codex":0.0014204192,"about_ca_topic_score_gemma":0.0011857216,"teacher_disagreement_score":0.08423433,"about_ca_system_score_codex":0.00008145989,"about_ca_system_score_gemma":0.000221458,"threshold_uncertainty_score":0.37173885},"labels":[],"label_agreement":null},{"id":"W2763325663","doi":"10.1093/annonc/mdx380.049","title":"Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Internal medicine; Lung cancer; Progressive disease; Oncology; Anaplastic lymphoma kinase; Crizotinib; Progression-free survival; Disease; Chemotherapy","score_opus":0.05513182186318976,"score_gpt":0.46955359442437333,"score_spread":0.41442177256118357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763325663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7164014,0.0029926267,0.0000024009375,0.03776736,0.000405499,0.0010940703,0.000043472573,0.000029765386,0.24126343],"genre_scores_gemma":[0.99693024,0.0006767026,0.00042188732,0.00033476172,0.00012996102,0.00021856595,0.00005023365,0.000014764623,0.0012228717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991134,0.00003651396,0.00024912838,0.00023407716,0.00013317306,0.00023370495],"domain_scores_gemma":[0.9989936,0.00004314114,0.00021214431,0.00043641575,0.000107134205,0.00020756127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006884627,0.0001347361,0.0003728256,0.000091495946,0.00012287781,0.00000933188,0.000083227256,0.00008010243,0.000055154476],"category_scores_gemma":[0.0001063931,0.00009736217,0.00011070983,0.000049759747,0.00015403295,0.00011536913,0.000032478438,0.00006479408,0.000016158638],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012922728,0.0021615378,0.048728842,0.00003547552,0.00016317397,0.0005570002,0.0007411221,0.0000054186544,0.00073122117,0.00020088229,0.0015766425,0.9438064],"study_design_scores_gemma":[0.01643908,0.009651254,0.26535013,0.00038471306,0.00036599644,0.000024647263,0.00035313418,0.000029543722,0.0051927464,0.00082876015,0.7011714,0.00020860317],"about_ca_topic_score_codex":0.00014566208,"about_ca_topic_score_gemma":0.00014871528,"teacher_disagreement_score":0.9435978,"about_ca_system_score_codex":0.0001236068,"about_ca_system_score_gemma":0.0004882099,"threshold_uncertainty_score":0.39703143},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2763765527","doi":"10.1093/annonc/mdx380.047","title":"Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiosurgery; Crizotinib; Brain metastasis; Anaplastic lymphoma kinase; Internal medicine; Lung cancer; Asymptomatic; Chemotherapy; Oncology; Cancer; Gastroenterology; Radiation therapy; Surgery; Metastasis","score_opus":0.023965181839550615,"score_gpt":0.36322897004167853,"score_spread":0.33926378820212794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763765527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948792,0.0005830894,0.00006572089,0.0006466769,0.00015513928,0.00078313745,0.0004939185,0.000008571747,0.0023845567],"genre_scores_gemma":[0.99828035,0.0003237061,0.00071561727,0.00031484352,0.00008664001,0.000054724365,0.000117535834,0.000026384247,0.00008020086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986425,0.00009434893,0.00045200496,0.00033324963,0.00018350992,0.00029436927],"domain_scores_gemma":[0.99811655,0.0003820263,0.0005748359,0.00032457086,0.00043398244,0.00016801056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001805401,0.00021800258,0.0006755522,0.0001607941,0.00010866722,0.000011602472,0.00011988713,0.00011421951,0.00007228477],"category_scores_gemma":[0.00023051404,0.0001709045,0.000074262825,0.00009191297,0.00030604104,0.00013689607,0.000058880465,0.0001155557,0.0000017553682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01153195,0.011413104,0.6024373,0.0006643933,0.0012829794,0.00042302982,0.0036151572,0.00013130363,0.002098347,0.00005431087,0.001281173,0.36506695],"study_design_scores_gemma":[0.025254615,0.009613956,0.95494205,0.0005861549,0.0009336649,0.000009500538,0.00018212723,0.00027145675,0.0070759137,0.000008334412,0.0009372364,0.00018496868],"about_ca_topic_score_codex":0.0027564089,"about_ca_topic_score_gemma":0.0016995687,"teacher_disagreement_score":0.364882,"about_ca_system_score_codex":0.00010129411,"about_ca_system_score_gemma":0.00077929185,"threshold_uncertainty_score":0.6969284},"labels":[],"label_agreement":null},{"id":"W2764070276","doi":"10.1200/jco.2017.35.15_suppl.e20502","title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Internal medicine; Brain metastasis; Nausea; Lung cancer; Refractory (planetary science); ALK inhibitor; Adverse effect; Vomiting; Gastroenterology; Oncology; Surgery; Cancer; Metastasis","score_opus":0.06366795087877529,"score_gpt":0.4881444277727967,"score_spread":0.4244764768940214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764070276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857901,0.0007303498,0.000039893705,0.007379037,0.00079344236,0.0017611608,0.000026725822,0.000003080152,0.0034762453],"genre_scores_gemma":[0.9951673,0.0006161098,0.00079774775,0.0025343013,0.00055320445,0.00008329823,0.000010887286,0.000019353622,0.00021780531],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99614614,0.0010124135,0.001987817,0.0002483732,0.00034349549,0.0002617476],"domain_scores_gemma":[0.99217165,0.0045323865,0.0025029602,0.00030722324,0.00025182546,0.00023394408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00447913,0.00019897436,0.0019726541,0.00013669905,0.00011273041,0.000044514265,0.00024057367,0.00019399436,0.000076545235],"category_scores_gemma":[0.003984575,0.00010228398,0.000313487,0.00007650611,0.0003980376,0.0002072433,0.000043537326,0.00086716417,0.0000015097636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77355087,0.014227316,0.12566595,0.00007358951,0.0010106595,0.0007875059,0.0015991611,0.000012368341,0.000021138138,0.00003075133,0.0036235882,0.07939711],"study_design_scores_gemma":[0.867694,0.01377625,0.10965161,0.00028706793,0.0015792997,0.000023749833,0.00021655452,0.0000911355,0.000014552187,0.000044304303,0.0065123853,0.00010907719],"about_ca_topic_score_codex":0.0006078143,"about_ca_topic_score_gemma":0.0009504657,"teacher_disagreement_score":0.09414315,"about_ca_system_score_codex":0.00014850027,"about_ca_system_score_gemma":0.0020175027,"threshold_uncertainty_score":0.47701964},"labels":[],"label_agreement":null},{"id":"W2764209889","doi":"10.24870/cjb.2017-a63","title":"Elucidating the mechanisms of resistance to tyrosine kinase inhibitors in lung cancer patients","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Biotechnology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lung cancer; Tyrosine kinase; Cancer research; Medicine; Acquired resistance; Cancer; Chemistry; Internal medicine; Receptor","score_opus":0.008519025885344362,"score_gpt":0.29050692049863064,"score_spread":0.28198789461328627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764209889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95956016,0.0013848243,0.00033469958,0.037385985,0.0005363142,0.00031759526,0.000047933743,0.0000040511795,0.00042842777],"genre_scores_gemma":[0.9988209,0.00003833946,0.0006547067,0.00027577643,0.00004249094,0.000007844825,0.0000014378079,0.000009519133,0.00014896337],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993357,0.000011520747,0.00027992026,0.000090779635,0.000092234135,0.00018986],"domain_scores_gemma":[0.9990864,0.000013206264,0.00031657566,0.0002730352,0.00015010008,0.00016072321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011711075,0.00007326112,0.00020047631,0.00031260474,0.00016152425,0.000015029072,0.00021744218,0.00010686311,0.000026962596],"category_scores_gemma":[0.00032644538,0.000051328603,0.000042220363,0.00014567061,0.00011665878,0.000055916014,0.000017681114,0.00019578893,8.3984963e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044938645,0.00034655453,0.7057593,0.00034499317,0.00082799146,0.0012723557,0.0047528795,0.00013428231,0.070457235,0.0205957,0.022196045,0.17286329],"study_design_scores_gemma":[0.0065083555,0.001234027,0.43954864,0.003142084,0.0005052684,0.000060025606,0.0013212102,0.00005316606,0.52241886,0.0022504434,0.022627223,0.00033072845],"about_ca_topic_score_codex":0.0086131105,"about_ca_topic_score_gemma":0.12283534,"teacher_disagreement_score":0.4519616,"about_ca_system_score_codex":0.0003679131,"about_ca_system_score_gemma":0.0007768031,"threshold_uncertainty_score":0.99798864},"labels":[],"label_agreement":null},{"id":"W2765592067","doi":"10.1016/j.lungcan.2017.10.011","title":"GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Medicine; Crizotinib; Adenocarcinoma; Internal medicine; Lung; Oncology; Lung cancer; Cancer","score_opus":0.030852924415628154,"score_gpt":0.42492225879756107,"score_spread":0.3940693343819329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765592067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97545576,0.011567009,0.000005592535,0.004203369,0.00078951486,0.000802334,0.000024342395,0.000036599726,0.0071154563],"genre_scores_gemma":[0.988536,0.00080512324,0.00020644147,0.0007213849,0.0004971443,0.0002054782,0.0000072771672,0.00003052167,0.0089906175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986262,0.000048878348,0.00033108026,0.00044261728,0.00021918913,0.00033203867],"domain_scores_gemma":[0.9990614,0.00007891972,0.00011952769,0.00039128956,0.00007647182,0.00027239916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002465971,0.00016888094,0.00033360475,0.00013784604,0.00029800925,0.0000706608,0.000108405686,0.00011191363,0.00019345926],"category_scores_gemma":[0.0003152804,0.00014340604,0.000067869354,0.00009855599,0.000046553265,0.00021880808,0.00013898437,0.00020200337,0.000020312003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000710664,0.00010855782,0.98585,0.0001446143,0.00013441042,0.000201253,0.001269585,0.000014197451,0.0015309822,0.00012437675,0.003561413,0.006349973],"study_design_scores_gemma":[0.0034018215,0.00022097093,0.977771,0.00077704166,0.0003081444,0.000023341487,0.00012732203,0.00056387164,0.0025882781,0.000027540893,0.013996624,0.00019407186],"about_ca_topic_score_codex":0.0021584055,"about_ca_topic_score_gemma":0.00070244644,"teacher_disagreement_score":0.013080229,"about_ca_system_score_codex":0.00031963977,"about_ca_system_score_gemma":0.0003777091,"threshold_uncertainty_score":0.58479285},"labels":[],"label_agreement":null},{"id":"W2766164907","doi":"10.1016/j.jtho.2016.11.1329","title":"P2.03b-048 Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Biomarker; Lung cancer; Internal medicine; Oncology; Cancer; Adenocarcinoma","score_opus":0.03329229529869292,"score_gpt":0.4661179616146297,"score_spread":0.4328256663159368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766164907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98889744,0.00018637667,0.00019020849,0.0024003452,0.00059744145,0.0005264542,0.000008395513,0.000005830651,0.0071874955],"genre_scores_gemma":[0.98918194,0.000019635278,0.009707549,0.0005436019,0.00014103738,0.000032871932,0.0000027326548,0.000022507213,0.0003481555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900097,0.000035006862,0.00037123146,0.00016584902,0.00018849951,0.00023843805],"domain_scores_gemma":[0.9982784,0.00008021121,0.00071157375,0.00024557541,0.00048366326,0.00020060556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019359672,0.00013587192,0.00042662487,0.00021658228,0.00013404933,0.000049828086,0.0002491548,0.00007916524,0.000038574908],"category_scores_gemma":[0.00015903714,0.00009233518,0.00005134003,0.00014816519,0.000038569637,0.00030731925,0.00007740554,0.00022045361,0.0000032297094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014469051,0.00046827135,0.8190751,0.00007853946,0.00011788077,0.00021067534,0.000349002,0.00016624318,0.00039032503,4.6189874e-7,0.00056501705,0.1771316],"study_design_scores_gemma":[0.003868348,0.0017881817,0.9901946,0.0006382409,0.00045667906,0.00002742725,0.000067153764,0.00008485111,0.0004487483,0.000011370913,0.0023103433,0.000104008715],"about_ca_topic_score_codex":0.00015751811,"about_ca_topic_score_gemma":0.00027464252,"teacher_disagreement_score":0.17702758,"about_ca_system_score_codex":0.00068887597,"about_ca_system_score_gemma":0.0008666284,"threshold_uncertainty_score":0.37653196},"labels":[],"label_agreement":null},{"id":"W2766257935","doi":"10.1200/jco.2017.35.15_suppl.11583","title":"Role of ERBB signaling in RET-rearranged lung cancer and contribution of EGFR amplification to cabozantinib resistance.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cabozantinib; Cancer research; Vandetanib; Erlotinib; Crizotinib; Medicine; Afatinib; Gefitinib; Lung cancer; EGFR inhibitors; Tyrosine-kinase inhibitor; Cancer; Epidermal growth factor receptor; Tyrosine kinase; Internal medicine; Receptor","score_opus":0.06657449776878374,"score_gpt":0.5173603709212642,"score_spread":0.4507858731524804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766257935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98910904,0.0018884292,0.000107855005,0.006991197,0.00025385624,0.00024831717,0.000013186021,0.0000016132573,0.0013865039],"genre_scores_gemma":[0.9972958,0.0006996024,0.0014852618,0.000161881,0.00021914062,0.00000512184,0.0000025003915,0.0000055937417,0.0001251095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828136,0.000092992195,0.0012545732,0.00010579883,0.00016367805,0.000101612575],"domain_scores_gemma":[0.99689186,0.00045186363,0.0017912111,0.00015854977,0.00057934254,0.00012719717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013747575,0.000059956856,0.00077629875,0.000085879015,0.000044195862,0.0000054787993,0.00007984292,0.00014492714,0.0000235983],"category_scores_gemma":[0.0024671764,0.00004533088,0.0001064467,0.000055816123,0.00011509278,0.000084825966,0.000017707733,0.00021794025,3.534914e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006786053,0.0008832036,0.87356895,0.00009765817,0.0004912422,0.000041556257,0.0009582078,0.00004256172,0.04850583,0.0011607213,0.00069156295,0.06677246],"study_design_scores_gemma":[0.007747395,0.001295534,0.97628236,0.0005560084,0.00048966333,0.000008273032,0.00020934631,0.000047466383,0.0031698423,0.00038727073,0.009760802,0.000046056764],"about_ca_topic_score_codex":0.00022723386,"about_ca_topic_score_gemma":0.00067712006,"teacher_disagreement_score":0.1027134,"about_ca_system_score_codex":0.00012214041,"about_ca_system_score_gemma":0.0007656292,"threshold_uncertainty_score":0.29536188},"labels":[],"label_agreement":null},{"id":"W2766497866","doi":"10.1016/j.jval.2017.08.012","title":"Utilization and Treatment Patterns Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Predictive Molecular Biomarker (BMX) Tests","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Internal medicine; Lung cancer; Medicine; Oncology; Stage (stratigraphy); Biology","score_opus":0.024863729510475538,"score_gpt":0.3383560817909946,"score_spread":0.313492352280519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766497866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590766,0.0008507751,0.0005009836,0.00028099673,0.00012612819,0.0018421862,0.00009058214,0.000022294875,0.00037839822],"genre_scores_gemma":[0.99757576,0.0011859882,0.00063309434,0.000083400395,0.000021075019,0.000270527,0.00008522018,0.0000309974,0.000113932365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898535,0.000044722514,0.00021584971,0.00033895136,0.0001506712,0.00026445356],"domain_scores_gemma":[0.9991583,0.000032475447,0.00023803789,0.00031803595,0.00008309287,0.00017004802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006803161,0.00017036244,0.00024702545,0.000091214126,0.00021920059,0.000030890063,0.00004609034,0.00004908416,0.000009623751],"category_scores_gemma":[0.000021238151,0.00012738236,0.000024449277,0.000069043905,0.000040765965,0.00013437397,0.000021459424,0.000064884,4.8271016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010686434,0.00029094738,0.9683869,0.00022314844,0.0000779672,0.000016669468,0.0016167735,0.00068100425,0.000016985061,0.0000027082592,0.000008162648,0.028571907],"study_design_scores_gemma":[0.005342974,0.00084272394,0.98446554,0.0012532333,0.0001231194,9.2637197e-7,0.000103185266,0.007493947,0.00022186132,0.000005305694,0.00004308116,0.00010410079],"about_ca_topic_score_codex":0.01613544,"about_ca_topic_score_gemma":0.0013182623,"teacher_disagreement_score":0.028467806,"about_ca_system_score_codex":0.00074928114,"about_ca_system_score_gemma":0.00035657207,"threshold_uncertainty_score":0.9904162},"labels":[],"label_agreement":null},{"id":"W2767332835","doi":"10.1093/annonc/mdx426.009","title":"Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"PDGFRA; Medicine; Cancer research; Transcriptome; Oncology; Biology; Genetics; Gene; Stromal cell","score_opus":0.038125030446366254,"score_gpt":0.39023209872016196,"score_spread":0.3521070682737957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767332835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949917,0.0006743828,0.00007591745,0.00062439236,0.000099575496,0.00065727584,0.00017795146,0.000016074608,0.002682736],"genre_scores_gemma":[0.9963513,0.00008700709,0.0021341585,0.00009993023,0.000027380187,0.00004278232,0.00032372394,0.000017851997,0.0009158662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845475,0.00006950611,0.0006147977,0.00037855408,0.0001725043,0.00030989214],"domain_scores_gemma":[0.9982358,0.000107046835,0.00056576234,0.0005172765,0.00039480315,0.00017930083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004027332,0.00018885244,0.0007587295,0.00046026893,0.00011174837,0.000017756012,0.00015599844,0.00019976654,0.000057758607],"category_scores_gemma":[0.00042450792,0.000145404,0.0001471727,0.00032212352,0.00021606895,0.00020152015,0.00006218443,0.00013378919,0.0000026519156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055989656,0.005260795,0.9497264,0.0004134939,0.0018370281,0.0009729797,0.005060596,0.00018294966,0.010671143,0.000034646273,0.001810206,0.018430801],"study_design_scores_gemma":[0.011457152,0.0038742821,0.96780455,0.000057376154,0.0016101366,0.000029215413,0.0007865251,0.008074145,0.0050258357,0.00008319307,0.0010238781,0.00017373847],"about_ca_topic_score_codex":0.0087992335,"about_ca_topic_score_gemma":0.0011304383,"teacher_disagreement_score":0.018257063,"about_ca_system_score_codex":0.000083077925,"about_ca_system_score_gemma":0.00046562543,"threshold_uncertainty_score":0.99780124},"labels":[],"label_agreement":null},{"id":"W2767515241","doi":"10.1016/j.jtho.2017.09.748","title":"P1.02-016 Establishment of Lung Adenocarcinoma Organoid Cultures","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Organoid; Medicine; Adenocarcinoma; Lung; Pathology; Internal medicine; Cell biology; Cancer; Biology","score_opus":0.02089828376509513,"score_gpt":0.4626878867959317,"score_spread":0.4417896030308366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767515241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566175,0.004061028,0.00018642726,0.013128247,0.0013913475,0.00029617455,0.000015720016,0.000009730654,0.024293842],"genre_scores_gemma":[0.9931086,0.00024022274,0.003564752,0.0002517033,0.00047506453,0.0000040070786,0.000003944464,0.000012945798,0.0023387843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989709,0.000051944615,0.0004557329,0.00010854973,0.0002478595,0.00016498624],"domain_scores_gemma":[0.99808335,0.000050748302,0.001014204,0.00031266606,0.00038173422,0.00015729398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000275957,0.00010875613,0.0004927771,0.00012495808,0.00015117713,0.000026699323,0.00021280398,0.00011491408,0.00025469376],"category_scores_gemma":[0.00016245784,0.00007144662,0.00015515361,0.000049716782,0.00011997906,0.00019712096,0.000054116692,0.0002182727,0.0000070221026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049063833,0.0036362384,0.4958784,0.0007787576,0.004052385,0.0039471723,0.008130226,0.000039730505,0.033368163,0.0009116676,0.11657125,0.32777962],"study_design_scores_gemma":[0.004964467,0.0055713304,0.82504195,0.0005722466,0.0044520344,0.0033216714,0.0016573147,0.00003364778,0.029130725,0.0006276056,0.12440724,0.00021976704],"about_ca_topic_score_codex":0.000045330442,"about_ca_topic_score_gemma":0.00001666427,"teacher_disagreement_score":0.32916355,"about_ca_system_score_codex":0.00039685713,"about_ca_system_score_gemma":0.0006990172,"threshold_uncertainty_score":0.29135087},"labels":[],"label_agreement":null},{"id":"W2767533365","doi":"10.1016/j.jtho.2016.11.1711","title":"P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Subgroup analysis; Adverse effect; Oncology; Randomized controlled trial; Population; Gastroenterology; Confidence interval; Epidermal growth factor receptor; Cancer","score_opus":0.037671125392540354,"score_gpt":0.4715929215892605,"score_spread":0.43392179619672017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767533365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335927,0.0003075122,0.00061592436,0.0012561785,0.00083626574,0.00073215726,0.00027501388,0.0000092455875,0.0026084317],"genre_scores_gemma":[0.9944566,0.00014418007,0.003970794,0.00011444322,0.00030813192,0.00005266569,0.00029384726,0.000024234489,0.00063508464],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983745,0.00009189417,0.0007514654,0.00022230828,0.00031122827,0.00024856508],"domain_scores_gemma":[0.9964232,0.0005826514,0.0017181142,0.00034768935,0.0007350641,0.00019330354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002918056,0.00019843827,0.00094173977,0.00042303928,0.00024853996,0.000033128657,0.00016974409,0.00015716071,0.00017089967],"category_scores_gemma":[0.00047297432,0.00015449757,0.0005746478,0.00019713491,0.000117926036,0.00020415026,0.000030044856,0.00014408755,0.0000068127824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054903433,0.0110944165,0.17723365,0.00029344845,0.056470595,0.0014698479,0.015101679,0.0014966864,0.0005541727,0.00027777016,0.00246042,0.6786439],"study_design_scores_gemma":[0.030560542,0.03446758,0.87400675,0.00035794426,0.05022367,0.00008302068,0.0012164024,0.0009935311,0.001970416,0.00022154301,0.0055966307,0.0003019518],"about_ca_topic_score_codex":0.00019261244,"about_ca_topic_score_gemma":0.00031434384,"teacher_disagreement_score":0.6967731,"about_ca_system_score_codex":0.00107351,"about_ca_system_score_gemma":0.00048683045,"threshold_uncertainty_score":0.63002276},"labels":[],"label_agreement":null},{"id":"W2767552869","doi":"10.1016/j.jtho.2017.09.1471","title":"P3.01-030 CNS Metastases in EGFR Mutation Positive (EGFRm) NSCLC Patients: The Prognostic Relevance of Presenting Symptoms","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Relevance (law); Oncology; Internal medicine; Clinical significance","score_opus":0.01999370768669994,"score_gpt":0.4286620453183036,"score_spread":0.40866833763160365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767552869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165237,0.00067261606,0.00020482799,0.0034284864,0.00045424738,0.0005256891,0.000023819633,0.000004626321,0.0030333125],"genre_scores_gemma":[0.997486,0.0000800863,0.0018696211,0.00017014578,0.00015249508,0.000017357923,0.000013586962,0.0000130427925,0.00019766019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986536,0.00019700278,0.00057149946,0.00012297153,0.0002730874,0.00018185821],"domain_scores_gemma":[0.9973719,0.00054332305,0.0012750279,0.00023212277,0.00050805305,0.00006954728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004711863,0.000111272275,0.00042632385,0.00014421153,0.00016386413,0.000025562653,0.00018049114,0.00007082627,0.000023787548],"category_scores_gemma":[0.0015728081,0.00006894749,0.00012704064,0.00009747928,0.00016415874,0.00028513567,0.000047766716,0.00025678903,0.0000034233851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026385963,0.002906074,0.5046997,0.00022389021,0.0013896467,0.0009150049,0.0057816436,0.00031398376,0.0009375321,0.00025108672,0.0010343796,0.47890848],"study_design_scores_gemma":[0.0030507282,0.0035118598,0.9842641,0.00077672064,0.0018358727,0.00034780326,0.00097613194,0.00020722674,0.0020834426,0.0006849043,0.0021588898,0.00010232427],"about_ca_topic_score_codex":0.00009257465,"about_ca_topic_score_gemma":0.00008613115,"teacher_disagreement_score":0.47956443,"about_ca_system_score_codex":0.00029719318,"about_ca_system_score_gemma":0.00038133748,"threshold_uncertainty_score":0.28115973},"labels":[],"label_agreement":null},{"id":"W2768069700","doi":"10.1016/j.jtho.2017.09.1456","title":"P3.01-015 Differential Outcomes between First and Second Generation TKIs in Patients with Activating EGFR Mutations in NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Differential (mechanical device); Oncology; Internal medicine","score_opus":0.028821338462236397,"score_gpt":0.42280130659606613,"score_spread":0.39397996813382974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768069700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621916,0.000034630164,0.0001526351,0.002668317,0.00018126382,0.00023063652,0.00001174961,0.0000027481192,0.0004988641],"genre_scores_gemma":[0.99790365,0.000005949052,0.0016826421,0.00006706716,0.00016543822,0.000008315623,0.000024307687,0.000010424026,0.00013224078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919647,0.000051491643,0.0003651358,0.000110685614,0.00014548999,0.00013070893],"domain_scores_gemma":[0.99908066,0.00010241078,0.00051033415,0.00011572071,0.00011100886,0.00007987492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013824357,0.00009769368,0.00038467287,0.0002063006,0.00015258713,0.000036559988,0.00006239993,0.00008374164,0.000055980683],"category_scores_gemma":[0.00012154122,0.00006769079,0.000036052705,0.00004914694,0.00005712968,0.00028187133,0.00002399595,0.0002213402,8.915257e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026634373,0.00027115535,0.9295073,0.000022119859,0.00014599627,0.0000405541,0.00093112746,0.000016667425,0.000062043146,0.0000057026655,0.000050173883,0.0686808],"study_design_scores_gemma":[0.0041542994,0.0010693715,0.9935928,0.000111008565,0.00023417077,0.000015194445,0.00016096041,0.000059663565,0.00010417763,0.0000364543,0.00039973177,0.0000621767],"about_ca_topic_score_codex":0.00006213154,"about_ca_topic_score_gemma":0.0014856255,"teacher_disagreement_score":0.068618625,"about_ca_system_score_codex":0.00032695231,"about_ca_system_score_gemma":0.00019761606,"threshold_uncertainty_score":0.276035},"labels":[],"label_agreement":null},{"id":"W2768085936","doi":"10.1016/j.jtho.2017.09.1148","title":"P2.01-046 Clinical Characteristics of Survival with De Novo Versus Relapsed Metastatic Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Histology; Performance status; Cancer; Proportional hazards model; Log-rank test; Stage (stratigraphy); Multivariate analysis; Retrospective cohort study; Survival analysis","score_opus":0.05919334601014433,"score_gpt":0.4998981719931777,"score_spread":0.4407048259830334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768085936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896947,0.00032864208,0.0010426828,0.0021438003,0.0021211717,0.00024583648,0.00003302851,0.0000051192064,0.004385013],"genre_scores_gemma":[0.9842302,0.00055876595,0.013488892,0.00015321755,0.0005683937,0.000009661806,0.0000062294757,0.00002541141,0.00095920265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998511,0.00014253307,0.0007413647,0.0001440426,0.0002250065,0.00023605293],"domain_scores_gemma":[0.99685204,0.0003733996,0.001765355,0.00032647347,0.00044533762,0.00023741889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079590775,0.00014459238,0.00089006877,0.00009621963,0.000116149255,0.000019650653,0.0002090117,0.00012180423,0.000102704726],"category_scores_gemma":[0.00027240659,0.00009860718,0.00018781036,0.00005418506,0.00018139614,0.00009775654,0.000038797458,0.00043437234,0.0000034944708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033216536,0.003280111,0.81911814,0.00083105895,0.0048976345,0.0046208673,0.0021102547,0.000059523896,0.002112166,0.000049870767,0.0020250923,0.12767877],"study_design_scores_gemma":[0.0214826,0.013124468,0.93262297,0.00077348854,0.014948061,0.0006756055,0.0008629479,0.00034361906,0.0015335116,0.00003737315,0.013330846,0.00026448307],"about_ca_topic_score_codex":0.00010006032,"about_ca_topic_score_gemma":0.00018330697,"teacher_disagreement_score":0.12741427,"about_ca_system_score_codex":0.0004063652,"about_ca_system_score_gemma":0.0025250486,"threshold_uncertainty_score":0.44793278},"labels":[],"label_agreement":null},{"id":"W2768204041","doi":"10.1016/j.jtho.2016.11.1585","title":"P3.01-019 Desmoplasia is Associated with Poor Prognosis and Carcinoma-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Desmoplasia; Medicine; Adenocarcinoma; Lung cancer; Pathology; Oncology; Internal medicine; Cancer; Carcinoma; Stroma; Immunohistochemistry","score_opus":0.020913697856810916,"score_gpt":0.3924394119058729,"score_spread":0.371525714049062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768204041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396497,0.00067697023,0.000018633596,0.0035153877,0.0001820846,0.00046624203,0.000040248557,0.000008683304,0.0011267806],"genre_scores_gemma":[0.99801487,0.0001335744,0.0007013922,0.0003931181,0.000094196184,0.000035118872,0.000009332133,0.000028229431,0.00059016043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869174,0.00010944878,0.00043954822,0.00021944303,0.00020987801,0.00032993426],"domain_scores_gemma":[0.998101,0.00010302929,0.0010976664,0.00016796353,0.00031961768,0.00021072241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035199118,0.00019756304,0.0006923087,0.00016731131,0.00021270638,0.000051998155,0.00014536618,0.00022998349,0.000042014217],"category_scores_gemma":[0.00010193084,0.00014394538,0.00010971663,0.000111240326,0.000107716536,0.00017631373,0.00005188941,0.00037248648,0.0000014059266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086951314,0.0007885321,0.98827124,0.00009971049,0.00074318465,0.00079780887,0.0011745386,0.000017784612,0.0013394085,5.137431e-7,0.0012568755,0.0046408796],"study_design_scores_gemma":[0.0049545467,0.0025108603,0.9828863,0.00079598074,0.0017373238,0.00022664046,0.00021275828,0.00042904622,0.0058524166,0.000010034257,0.00023152775,0.00015256039],"about_ca_topic_score_codex":0.00049925334,"about_ca_topic_score_gemma":0.0034028755,"teacher_disagreement_score":0.005384946,"about_ca_system_score_codex":0.0009561201,"about_ca_system_score_gemma":0.00091292034,"threshold_uncertainty_score":0.5869922},"labels":[],"label_agreement":null},{"id":"W2768218337","doi":"10.1016/j.jtho.2017.11.046","title":"P2.05-019 Overall Survival (OS) of Pathological T1N0 Non-Small Cell Lung Cancer (NSCLC) After Resection","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval","funders":"","keywords":"Medicine; Pathological; Lung cancer; Oncology; Resection; Internal medicine; Radiology; Surgery","score_opus":0.028320343359701267,"score_gpt":0.44581546228381236,"score_spread":0.41749511892411106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768218337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798725,0.0012343089,0.00046474108,0.0031993398,0.0021956016,0.0002826624,0.000025922614,0.000006767914,0.0127181355],"genre_scores_gemma":[0.99350023,0.0005886742,0.002116638,0.0002826192,0.0008199296,0.000024300656,0.0000040722744,0.000019083647,0.0026444308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986424,0.00012672902,0.0005396792,0.00018193337,0.00026322133,0.00024605112],"domain_scores_gemma":[0.9979924,0.00009560701,0.0009842115,0.0003268762,0.00042916875,0.00017176713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051396847,0.00015382528,0.00062669173,0.00014422665,0.00013491088,0.000024722052,0.0001863066,0.00023133683,0.00033019474],"category_scores_gemma":[0.00010887657,0.00010708835,0.0002443705,0.00005153294,0.000121003424,0.00016218568,0.00007009092,0.00041657937,0.0000067762658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019161364,0.003230587,0.825914,0.0008805618,0.001419072,0.005681579,0.0034875656,0.0002301566,0.023286961,0.00006210999,0.013200895,0.10344511],"study_design_scores_gemma":[0.004572226,0.004505956,0.9697054,0.0005053527,0.00209898,0.0006601944,0.00028698274,0.0001488448,0.005089451,0.00018672255,0.01205636,0.0001835123],"about_ca_topic_score_codex":0.00019619173,"about_ca_topic_score_gemma":0.0001974728,"teacher_disagreement_score":0.14379138,"about_ca_system_score_codex":0.00042729414,"about_ca_system_score_gemma":0.00078805804,"threshold_uncertainty_score":0.4366936},"labels":[],"label_agreement":null},{"id":"W2768399638","doi":"10.1016/j.jtho.2017.07.033","title":"A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Adenocarcinoma; KRAS; ROS1; Lung cancer; Oncology; Cancer; Cancer research; Internal medicine; Colorectal cancer","score_opus":0.025807942625664194,"score_gpt":0.3868548193563452,"score_spread":0.361046876730681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768399638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75237346,0.0028229528,0.00011665202,0.23575075,0.0004800108,0.0025415097,0.0001426306,0.000025098296,0.005746925],"genre_scores_gemma":[0.9495079,0.00009927533,0.0150326295,0.025685139,0.0033296559,0.00014232787,0.00017929934,0.0001452374,0.005878547],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977102,0.00024736213,0.0007893835,0.00035267966,0.0005183995,0.00038194572],"domain_scores_gemma":[0.9946803,0.0001833444,0.0032319173,0.00060454634,0.0011029891,0.0001969037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028082525,0.00041474332,0.0015169681,0.0005113119,0.0001806545,0.000023585719,0.00025081536,0.00070063956,0.00016122728],"category_scores_gemma":[0.00013529032,0.00024512157,0.00023457265,0.00016034553,0.00031415923,0.00016821758,0.00005916579,0.0018822612,0.000006149396],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084985,0.0009200196,0.0030088166,0.0017800091,0.002668875,0.8793583,0.0017422779,0.0000096331505,0.0017153549,0.0000019608885,0.075561464,0.024734795],"study_design_scores_gemma":[0.0063113794,0.042476617,0.004833222,0.0064532445,0.011126722,0.7983918,0.0012398689,0.000016059847,0.0034526077,0.00011100595,0.12497682,0.0006106285],"about_ca_topic_score_codex":0.0002750843,"about_ca_topic_score_gemma":0.0001444481,"teacher_disagreement_score":0.2100656,"about_ca_system_score_codex":0.00066470075,"about_ca_system_score_gemma":0.0046731555,"threshold_uncertainty_score":0.99957675},"labels":[],"label_agreement":null},{"id":"W2768571810","doi":"10.1016/j.jtho.2017.11.023","title":"P2.04-010 Afatinib in Combination with Pembrolizumab in Patients with Stage IIIB/IV Squamous Cell Carcinoma (SCC) of the Lung","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Pembrolizumab; Stage (stratigraphy); Squamous-cell carcinoma of the lung; Basal cell; Oncology; Internal medicine; Lung; Cancer; Immunotherapy; Gefitinib","score_opus":0.011921780221711545,"score_gpt":0.37027959043291175,"score_spread":0.3583578102112002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768571810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936497,0.00010483463,0.000022680584,0.0011501919,0.00021711481,0.0005034894,0.000009278597,0.0000023433975,0.0043403357],"genre_scores_gemma":[0.9987165,0.0000052608525,0.00051373604,0.00007595478,0.000036589525,0.00000953692,0.000005018723,0.000015984979,0.0006214273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886113,0.00011295734,0.00042448158,0.000118572774,0.00031064684,0.000172192],"domain_scores_gemma":[0.9981641,0.00007573269,0.0010855887,0.00030068282,0.00030556475,0.000068313864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024215411,0.0001252445,0.00043761602,0.0001863761,0.00009067408,0.000013686129,0.00018747177,0.00009036743,0.000029124987],"category_scores_gemma":[0.00007716984,0.000065539316,0.000058607166,0.000118888296,0.00012223625,0.00017831178,0.0000363349,0.00033516495,8.4213565e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041770786,0.0016446655,0.986955,0.00011425045,0.000043229677,0.000157217,0.0015434265,0.00010860177,0.00006057524,0.000023978528,0.00010068728,0.005071281],"study_design_scores_gemma":[0.014745094,0.004834849,0.97849286,0.00017173187,0.00029297726,0.000036124708,0.00039002582,0.000084856336,0.0005295623,0.000027510221,0.00032772063,0.00006672049],"about_ca_topic_score_codex":0.0002091919,"about_ca_topic_score_gemma":0.00052560493,"teacher_disagreement_score":0.010568015,"about_ca_system_score_codex":0.0005975782,"about_ca_system_score_gemma":0.0007587492,"threshold_uncertainty_score":0.26726156},"labels":[],"label_agreement":null},{"id":"W2768643568","doi":"10.3390/metabo7040060","title":"Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach","year":2017,"lang":"en","type":"review","venue":"Metabolites","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Metabolome; Metabolomics; Biomarker; Medicine; Bioinformatics; Computational biology; Biology; Pharmacology","score_opus":0.06776925511652118,"score_gpt":0.4244907328393876,"score_spread":0.35672147772286644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768643568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003720464,0.9949067,0.00051564403,0.00011890569,0.0006995381,0.002780067,0.0003392711,0.000026563419,0.00024124113],"genre_scores_gemma":[0.0011155719,0.98648393,0.0071571157,0.00001365146,0.0007900537,0.0012659965,0.00008630683,0.000070763395,0.0030165825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998422,0.00015493245,0.00052449014,0.0003711655,0.00024144925,0.0002859327],"domain_scores_gemma":[0.99800503,0.00048557285,0.0004170286,0.0008100871,0.00016951023,0.000112741225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059763796,0.00033760007,0.0018803149,0.00024729018,0.00018687529,0.000055261815,0.00030512532,0.00012413818,0.000008034999],"category_scores_gemma":[0.0007366417,0.00018220281,0.00076852867,0.00018286998,0.00007161997,0.0000489669,0.00007306033,0.0001540956,0.000015719763],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042846415,0.00016510654,0.000016786043,0.007929049,0.002132551,0.0000039691936,0.00050601765,0.0000038029818,0.00012409088,0.00010704497,0.00014620945,0.9884369],"study_design_scores_gemma":[0.00076855713,0.000089780624,0.00039681318,0.0028646903,0.016912892,0.000030643725,0.00013208968,0.0000060434627,0.00009414584,0.00001480689,0.9785303,0.0001592564],"about_ca_topic_score_codex":0.000023657421,"about_ca_topic_score_gemma":1.5822341e-7,"teacher_disagreement_score":0.9882777,"about_ca_system_score_codex":0.000050832397,"about_ca_system_score_gemma":0.0006010373,"threshold_uncertainty_score":0.7430015},"labels":[],"label_agreement":null},{"id":"W2768856356","doi":"10.1007/s40271-017-0287-z","title":"Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)","year":2017,"lang":"en","type":"article","venue":"Patient","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Afatinib; Medicine; Lung cancer; Internal medicine; Oncology; Chemotherapy; Epidermal growth factor receptor; Cancer; Quality of life (healthcare); Gefitinib","score_opus":0.010292376920464705,"score_gpt":0.35255061810851746,"score_spread":0.34225824118805276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768856356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650466,0.00047407867,0.00027128638,0.00009192403,0.00014284649,0.002180934,0.0001185841,0.000029779123,0.00018592135],"genre_scores_gemma":[0.99774045,0.0001029577,0.001271957,0.00013434794,0.000010835652,0.00031362224,0.000342661,0.00003779269,0.00004540347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978973,0.000044102257,0.00069402927,0.0005469549,0.000474365,0.00034319298],"domain_scores_gemma":[0.9970923,0.00010717171,0.0011862906,0.0004743821,0.001008243,0.00013160174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008335366,0.0003636917,0.0009230464,0.00034926346,0.0003371627,0.000052165975,0.00009167286,0.00005124953,0.000016796246],"category_scores_gemma":[0.000064432345,0.0002236992,0.000078486315,0.00047515024,0.00013793436,0.00040257387,0.00005542604,0.00013868918,3.5132328e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016153776,0.0013200121,0.96016777,0.00019022303,0.004767048,0.000048122558,0.019783089,0.008091146,0.00010368505,0.000007769823,0.0000063747034,0.003899371],"study_design_scores_gemma":[0.03047619,0.0014389496,0.946549,0.0007071279,0.0044911047,0.0000011437363,0.0026542947,0.010988616,0.0023668846,0.0000049626733,0.0000050132526,0.0003167401],"about_ca_topic_score_codex":0.0014108681,"about_ca_topic_score_gemma":0.0018888566,"teacher_disagreement_score":0.028860811,"about_ca_system_score_codex":0.00044447646,"about_ca_system_score_gemma":0.00018449716,"threshold_uncertainty_score":0.91221887},"labels":[],"label_agreement":null},{"id":"W2769322745","doi":"10.1016/j.cels.2017.10.014","title":"Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Cell Systems","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Human Genome Research Institute; Harvard Forest, Harvard University; Defense Advanced Research Projects Agency; National Cancer Institute; National Institutes of Health; Microsoft; Amazon Web Services; Howard Hughes Medical Institute; M.S.I. Foundation; Nvidia","keywords":"Histopathology; Biology; Adenocarcinoma; Association (psychology); Lung; Omics; Computational biology; Pathology; Bioinformatics; Medicine; Genetics; Internal medicine; Cancer; Psychology","score_opus":0.008224462173081456,"score_gpt":0.2737384225970617,"score_spread":0.26551396042398023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769322745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882947,0.001193623,0.000057760128,0.0002757446,0.0003312168,0.0003592603,0.000021501563,0.000009508323,0.009456687],"genre_scores_gemma":[0.9894117,0.000026549038,0.00003356883,0.00001795681,0.00007326973,0.00003167158,0.000024694738,0.0000099645695,0.010370589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952936,0.000022523349,0.00012984371,0.00011360508,0.00010091603,0.00010375594],"domain_scores_gemma":[0.99939084,0.000019114335,0.0002473017,0.00025658132,0.00005588137,0.00003030647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008229977,0.00006185313,0.00019992901,0.000046657213,0.000051664712,0.000015218123,0.000053774504,0.00006718751,0.000005136552],"category_scores_gemma":[0.000016214113,0.00004638795,0.000023815173,0.000018758428,0.000014594225,0.000039672163,0.000010379684,0.0000643041,0.0000028548668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029230032,0.00005768965,0.9974284,0.00023842238,0.000029435489,0.000054535903,0.0007062939,0.000015608279,0.000634573,0.000046912093,0.0006892301,0.00006968076],"study_design_scores_gemma":[0.0017452078,0.000111950176,0.9964565,0.00013612132,0.00016155656,0.00002237311,0.0002541453,0.00006448903,0.000559409,0.0000022457375,0.0004398046,0.000046194342],"about_ca_topic_score_codex":0.001600661,"about_ca_topic_score_gemma":0.0002948908,"teacher_disagreement_score":0.0017159778,"about_ca_system_score_codex":0.00036204007,"about_ca_system_score_gemma":0.00006545896,"threshold_uncertainty_score":0.24197313},"labels":[],"label_agreement":null},{"id":"W2769658312","doi":"10.21037/tlcr.2017.10.14","title":"The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated non-small cell lung cancer","year":2017,"lang":"en","type":"letter","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Regional Municipality of Ottawa","funders":"","keywords":"Epidermal growth factor receptor; Medicine; Lung cancer; Lung; Cancer; Cell; Cancer research; Receptor; Epidermal growth factor; Bioinformatics; Oncology; Pathology; Internal medicine; Biology; Genetics","score_opus":0.0379390279010288,"score_gpt":0.379747758848595,"score_spread":0.3418087309475662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769658312","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08797709,0.05381127,0.0007922503,0.7696761,0.0015782005,0.019153923,0.06501293,0.00017080583,0.0018274593],"genre_scores_gemma":[0.49409664,0.017568469,0.0128249815,0.07089215,0.037941605,0.07992846,0.16841279,0.0026267583,0.11570814],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953697,0.00029624027,0.00056459394,0.001061062,0.0015502267,0.0011582323],"domain_scores_gemma":[0.9942111,0.0027733434,0.00033668705,0.00071518426,0.0017059604,0.00025772292],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031368807,0.00067268807,0.00082050305,0.00031553983,0.0016082227,0.00033571702,0.00045880087,0.00041809728,0.0013183603],"category_scores_gemma":[0.000085356914,0.00041248923,0.00037559797,0.00025483736,0.00026593806,0.00025008403,0.000033808723,0.0011298655,0.000012056984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002161254,0.00038919583,0.119587995,0.0011367978,0.0058891107,0.00007687981,0.0016814012,0.000075579366,0.000105396735,0.000009851506,0.86291677,0.0059697507],"study_design_scores_gemma":[0.036356777,0.002133052,0.11570625,0.0030392304,0.0060709813,0.0000039094202,0.00012190209,0.0038218156,0.0013823893,0.00011917104,0.82972544,0.0015190756],"about_ca_topic_score_codex":0.008082328,"about_ca_topic_score_gemma":0.0018765954,"teacher_disagreement_score":0.69878393,"about_ca_system_score_codex":0.0013361598,"about_ca_system_score_gemma":0.0038916147,"threshold_uncertainty_score":0.9998327},"labels":[],"label_agreement":null},{"id":"W2769765347","doi":"10.1093/annonc/mdx729.007","title":"CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Oncology; Internal medicine; Gefitinib; Erlotinib; Lung cancer; non-small cell lung cancer (NSCLC); Cancer; Epidermal growth factor receptor","score_opus":0.04141203295170755,"score_gpt":0.42077395280170077,"score_spread":0.37936191984999323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769765347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878963,0.0007910493,0.000056632623,0.006343778,0.00020379,0.002680203,0.0014067781,0.000012428906,0.00060903816],"genre_scores_gemma":[0.9973908,0.0003705581,0.00049430394,0.0010426191,0.00008225468,0.00011554464,0.00039559588,0.000038954753,0.000069352325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809974,0.00024704638,0.0004983937,0.0005048352,0.00034698244,0.00030302446],"domain_scores_gemma":[0.9967496,0.0005232402,0.0006118117,0.0010541215,0.0009475255,0.00011371825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037052468,0.0002416977,0.0006884172,0.000117818185,0.00026341257,0.00002498747,0.00035169718,0.0001042162,0.000035677036],"category_scores_gemma":[0.00024998354,0.00017055449,0.000060702503,0.00016270851,0.0001372951,0.00020237363,0.00014979651,0.0001872581,0.0000033363965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.111844555,0.0031489348,0.6205359,0.00010988107,0.0014529341,0.00038883163,0.090890676,0.0011415557,0.0018747842,0.000004770157,0.0014755245,0.16713166],"study_design_scores_gemma":[0.02309813,0.033123847,0.9208191,0.00085310393,0.00055010634,0.0000030449737,0.008063364,0.00009076811,0.0110968305,0.000016812517,0.002054401,0.0002305178],"about_ca_topic_score_codex":0.006290781,"about_ca_topic_score_gemma":0.010996811,"teacher_disagreement_score":0.30028316,"about_ca_system_score_codex":0.00029610164,"about_ca_system_score_gemma":0.0009769024,"threshold_uncertainty_score":0.95098203},"labels":[],"label_agreement":null},{"id":"W2771972433","doi":"10.24870/cjb.2017-a231","title":"Comparing genomic landscape of early stage, treatment naïve and late stage, drug resistant EGFR-mutant lung adenocarcinomas","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Biotechnology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Stage (stratigraphy); Mutant; Adenocarcinoma; Oncology; Drug; Lung; Cancer research; Internal medicine; Biology; Medicine; Pharmacology; Gene; Cancer; Genetics","score_opus":0.020722398738893023,"score_gpt":0.28655351728518286,"score_spread":0.2658311185462898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771972433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907513,0.004540685,0.000016088232,0.0030985193,0.0001683313,0.00022129736,0.000094146235,0.00000946668,0.0011001253],"genre_scores_gemma":[0.9977082,0.00044254865,0.0003450829,0.000031383388,0.00004684277,0.0000030004321,0.000004761338,0.000019343772,0.0013988112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990681,0.00001806431,0.00036614688,0.00016681182,0.00008957361,0.0002912924],"domain_scores_gemma":[0.99863094,0.00001925626,0.00047579512,0.0004133552,0.000096251155,0.00036438258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106907326,0.00015242891,0.00048136475,0.0004515827,0.00026923206,0.00004742686,0.0001842243,0.00014519086,0.000052559128],"category_scores_gemma":[0.000039973762,0.00012053647,0.00008465798,0.00006590195,0.00028553355,0.000083623796,0.000024488965,0.0002100258,0.000002261421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039352433,0.00008090945,0.9622632,0.00012209722,0.0013650527,0.0030611348,0.0021912616,0.000048588234,0.020616971,0.0023438076,0.00026574678,0.007247659],"study_design_scores_gemma":[0.005506841,0.0016344169,0.9595876,0.00026686626,0.000730238,0.0002738283,0.0010468886,0.00019961572,0.019341972,0.00011215578,0.01110584,0.00019375164],"about_ca_topic_score_codex":0.021809729,"about_ca_topic_score_gemma":0.044790354,"teacher_disagreement_score":0.022980627,"about_ca_system_score_codex":0.0004851078,"about_ca_system_score_gemma":0.0012129967,"threshold_uncertainty_score":0.98470414},"labels":[],"label_agreement":null},{"id":"W2771999728","doi":"10.1080/17476348.2018.1411805","title":"Personalized medicine for non-small cell lung cancer: where are we now and where can we go?","year":2017,"lang":"en","type":"editorial","venue":"Expert Review of Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Personalized medicine; Cancer; Precision medicine; Intensive care medicine; Oncology; Internal medicine; Bioinformatics; Pathology","score_opus":0.029427068233113283,"score_gpt":0.3957935245207308,"score_spread":0.3663664562876175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771999728","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015425649,0.7791302,0.00004542084,0.057006463,0.15785463,0.0037232414,0.00054294674,0.00004941607,0.001632237],"genre_scores_gemma":[0.0000071046775,0.67980146,0.00022449624,0.0019640892,0.30341148,0.0013510991,0.0003551228,0.00014689022,0.012738261],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99513,0.00016086556,0.0014921643,0.0011949819,0.0013905133,0.00063149584],"domain_scores_gemma":[0.99334747,0.0007927702,0.002161636,0.0015011783,0.0015167872,0.0006801844],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093828264,0.0010746646,0.0042033824,0.0002912446,0.00034093723,0.000018256438,0.00054082804,0.0007646656,0.000978584],"category_scores_gemma":[0.00081581407,0.0007001064,0.00042608287,0.00021279739,0.00086149375,0.00009511752,0.000103923674,0.0008182404,0.000004426521],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019033396,0.00009284292,0.0004924402,0.112253204,0.0006788593,0.000084935986,0.0013482153,5.253996e-8,0.00022061003,0.0000038064502,0.8750264,0.009608278],"study_design_scores_gemma":[0.009194491,0.001256668,0.000028780003,0.2566497,0.003731852,0.000007344445,0.00045679943,0.000004987313,0.00003588797,0.0000043573605,0.7282243,0.00040485038],"about_ca_topic_score_codex":0.00067658175,"about_ca_topic_score_gemma":0.0014267823,"teacher_disagreement_score":0.14680214,"about_ca_system_score_codex":0.0006303776,"about_ca_system_score_gemma":0.0024808408,"threshold_uncertainty_score":0.9999347},"labels":[],"label_agreement":null},{"id":"W2774813249","doi":"10.3389/fonc.2017.00311","title":"Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine","year":2017,"lang":"en","type":"editorial","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Oncology; Precision medicine; Internal medicine; Cancer research; Pathology","score_opus":0.015701957438355563,"score_gpt":0.3623719395358817,"score_spread":0.34666998209752614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774813249","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015894697,0.009254722,0.000068188485,0.003364431,0.9800438,0.0018756202,0.00033666554,0.00000885586,0.0034581951],"genre_scores_gemma":[0.0009700047,0.019484704,0.001834581,0.0001235163,0.9715861,0.00050040236,0.0005789383,0.0000790901,0.004842651],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767536,0.0001761768,0.0007453816,0.00047475245,0.00056154234,0.0003668142],"domain_scores_gemma":[0.9973755,0.00074625335,0.00088073633,0.00063801126,0.00022796076,0.00013156208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003412863,0.00041649508,0.0018778319,0.00033782137,0.000055296092,0.0000063647003,0.00031914294,0.00059124525,0.00015557333],"category_scores_gemma":[0.00030229086,0.00025839347,0.00020142042,0.00018020405,0.00029081077,0.000036093905,0.000024915036,0.0006509183,0.000002122173],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014509687,0.0009774937,0.0020915722,0.00027192055,0.0008761094,0.00007450844,0.005556928,0.000027667096,0.000025181445,0.000008953259,0.9797878,0.008850873],"study_design_scores_gemma":[0.018232957,0.0040243836,0.00032750372,0.0012251483,0.0024807332,6.311012e-7,0.0007071272,0.000075448974,0.00010463723,0.00008901917,0.9725603,0.00017214933],"about_ca_topic_score_codex":0.011133797,"about_ca_topic_score_gemma":0.0023548778,"teacher_disagreement_score":0.016781988,"about_ca_system_score_codex":0.0026109163,"about_ca_system_score_gemma":0.007310862,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W2776194348","doi":"10.1093/annonc/mdx820","title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":251,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; T790M; Oncology; Ceritinib; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Clinical trial; Lung cancer; Cancer; Epidermal growth factor receptor; Erlotinib; Crizotinib; Gefitinib","score_opus":0.12983846215596354,"score_gpt":0.5199645404744228,"score_spread":0.39012607831845925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776194348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827991,0.00013198593,0.000042100528,0.011973504,0.00015089533,0.0011517524,0.0016255341,0.000011977964,0.0021131444],"genre_scores_gemma":[0.9957092,0.000025099014,0.0014343653,0.0016383034,0.000078799734,0.000055148612,0.00076662516,0.000017408594,0.0002750438],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99847686,0.00026763554,0.0004661482,0.00037650336,0.00017661318,0.00023622006],"domain_scores_gemma":[0.99756306,0.00053854554,0.00045723002,0.0010113308,0.0002698036,0.00016000697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006900486,0.00014401201,0.00075016863,0.00012697361,0.00014449225,0.000011320795,0.00028343222,0.000072610856,0.00012259427],"category_scores_gemma":[0.0021539086,0.00010583727,0.000052183346,0.00007849943,0.00009452758,0.00021815105,0.00018024455,0.00009716569,0.000019903899],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26340935,0.011292102,0.057158098,0.000015738922,0.002045411,0.00026664056,0.004187874,0.000027184637,0.008670388,0.000046205703,0.008079071,0.644802],"study_design_scores_gemma":[0.118371,0.03809195,0.7965129,0.0004189682,0.0008957221,0.0000021224537,0.00022832662,0.000027551905,0.008930996,0.00014625282,0.03613888,0.0002353523],"about_ca_topic_score_codex":0.00066370686,"about_ca_topic_score_gemma":0.00034801554,"teacher_disagreement_score":0.7393548,"about_ca_system_score_codex":0.000070752634,"about_ca_system_score_gemma":0.0005191211,"threshold_uncertainty_score":0.43159187},"labels":[],"label_agreement":null},{"id":"W2780291350","doi":"10.3747/co.24.3691","title":"Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003–2006 with 2010–2011","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health; University of Calgary; Alberta Health Services; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Systemic therapy; Lung cancer; Referral; Stage (stratigraphy); Oncology; Internal medicine; Cancer; Intensive care medicine; Family medicine; Breast cancer","score_opus":0.17610596340571621,"score_gpt":0.5139131830637007,"score_spread":0.3378072196579845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780291350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793302,0.0047614733,0.0028531647,0.004550859,0.001725321,0.005022445,0.00037114916,0.000016108284,0.0013692952],"genre_scores_gemma":[0.99251133,0.0009554951,0.002369984,0.00017254954,0.00024406282,0.0021109905,0.00013695445,0.000034880526,0.0014637333],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857336,0.00005544434,0.00054128485,0.00031511948,0.00017615876,0.00033860034],"domain_scores_gemma":[0.9980924,0.00018810737,0.0005672403,0.0004056968,0.00051915203,0.00022739384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032284632,0.00017583794,0.00095397927,0.00013426202,0.000089953355,0.0000047870567,0.00023940999,0.00022272643,0.00010779507],"category_scores_gemma":[0.00013978741,0.00012967974,0.00008059001,0.00007812991,0.00015641966,0.00003936305,0.000036321526,0.00018261322,0.0000022281508],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00587748,0.004969522,0.81513876,0.0021819146,0.00048564462,0.000020652245,0.0048347223,0.000088160865,0.0012210505,0.0004315369,0.08804079,0.076709785],"study_design_scores_gemma":[0.10148304,0.038470075,0.21257246,0.0037973302,0.0021475253,0.00007399434,0.0035760647,0.008511075,0.005459608,0.00004108527,0.62311375,0.00075401907],"about_ca_topic_score_codex":0.0012742191,"about_ca_topic_score_gemma":0.004669296,"teacher_disagreement_score":0.6025663,"about_ca_system_score_codex":0.0005973824,"about_ca_system_score_gemma":0.0030591341,"threshold_uncertainty_score":0.5426772},"labels":[],"label_agreement":null},{"id":"W2781517286","doi":"10.15406/jcpcr.2017.08.00275","title":"ALK Inhibitors in NSCLC- Crizotinib and Beyond","year":2017,"lang":"en","type":"article","venue":"Journal of Cancer Prevention & Current Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Crizotinib; Medicine; Clinical Oncology; Surgical oncology; Oncology; Internal medicine; Cancer imaging; ALK inhibitor; Lung cancer; Cancer research; Cancer","score_opus":0.10560698792565754,"score_gpt":0.5415047981555298,"score_spread":0.43589781022987223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781517286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587214,0.025736177,0.000051131527,0.007393577,0.0010222836,0.00053734705,0.000008025666,0.0000045759125,0.006525499],"genre_scores_gemma":[0.9922723,0.005802572,0.00015172886,0.00001483989,0.00052590715,0.000031524054,0.000002714676,0.00001050012,0.0011879157],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851024,0.00009943558,0.00037046825,0.00013986164,0.0006535753,0.00022639918],"domain_scores_gemma":[0.9988175,0.000046422334,0.00027256747,0.00019701578,0.0004943277,0.00017218335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010352657,0.000080628175,0.00022533932,0.00034812625,0.00022213427,0.00010494517,0.00012369565,0.000042352054,0.0001562261],"category_scores_gemma":[0.0001984404,0.000061153456,0.00009422055,0.00011440869,0.00012750502,0.00034373454,0.00006726204,0.0005124518,0.000004049464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000285907,0.00048738898,0.20401362,0.00016581384,0.00012769572,0.000049013164,0.0005952484,0.0000029194557,0.0006913852,0.0003673054,0.005913783,0.78729993],"study_design_scores_gemma":[0.00990217,0.0011438696,0.85204977,0.0032563868,0.00023498671,0.00007960704,0.00052934786,0.000053255404,0.00173343,0.004769057,0.1261014,0.0001467088],"about_ca_topic_score_codex":0.00012614984,"about_ca_topic_score_gemma":0.00021752185,"teacher_disagreement_score":0.78715324,"about_ca_system_score_codex":0.00028403517,"about_ca_system_score_gemma":0.0007119045,"threshold_uncertainty_score":0.24937657},"labels":[],"label_agreement":null},{"id":"W2782376830","doi":"","title":"Abstract #3559: A quantitative survey of tyrosine phosphorylation changes with erlotinib treatment in EGFR mutant and wildtype NSCLC cell lines","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Epidermal growth factor receptor; Cancer research; T790M; Erlotinib Hydrochloride; Tyrosine kinase; EGFR inhibitors; Lung cancer; Wild type; Gefitinib; Cancer; Biology; Chemistry; Oncology; Medicine; Mutant; Internal medicine; Receptor; Gene; Genetics","score_opus":0.11233706393893941,"score_gpt":0.4535162266702026,"score_spread":0.34117916273126314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782376830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003154,0.0063506323,0.000005615959,0.0016795294,0.000024825844,0.0008930698,0.00009026765,0.000011452155,0.00091308664],"genre_scores_gemma":[0.9963931,0.0024943158,0.00024869526,0.00003656616,0.000031251435,0.00011123062,0.000074871125,0.0000149912075,0.0005950057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989819,0.00006690888,0.00014824426,0.0002581355,0.00029277342,0.00025204313],"domain_scores_gemma":[0.99907804,0.00020202766,0.00006268531,0.00015970293,0.0004003987,0.00009717316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031904058,0.000121589765,0.00026458272,0.0002037741,0.00006186638,0.000015242553,0.000037741753,0.000048980233,0.000059308753],"category_scores_gemma":[0.000053227373,0.00008209476,0.00001686565,0.0005233509,0.00011192497,0.000059210994,0.000008651499,0.00012104911,0.000003434973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01482804,0.003886979,0.55018306,0.0006010695,0.0005274492,0.00030240152,0.01746031,0.00026453123,0.26022166,0.0005857565,0.0007656079,0.15037312],"study_design_scores_gemma":[0.0036028177,0.0034862154,0.93798804,0.00034332217,0.000046445013,0.0000029656771,0.0004239758,0.000066781984,0.05365488,0.000029001683,0.00026897748,0.00008654447],"about_ca_topic_score_codex":0.01487551,"about_ca_topic_score_gemma":0.018335085,"teacher_disagreement_score":0.38780499,"about_ca_system_score_codex":0.00037366824,"about_ca_system_score_gemma":0.0005808612,"threshold_uncertainty_score":0.99957776},"labels":[],"label_agreement":null},{"id":"W2782956976","doi":"10.1093/jnci/djx260","title":"Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)","year":2017,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation","keywords":"Estrogen receptor; Internal medicine; Hazard ratio; Medicine; Lung cancer; Estrogen; Quartile; Hormone receptor; Sex hormone receptor; Immunohistochemistry; Oncology; Receptor; Proportional hazards model; Endocrinology; Cancer; Steroid hormone receptor; Progesterone receptor; Sex hormone-binding globulin; Confidence interval; Hormone; Breast cancer; Androgen","score_opus":0.02693754542768846,"score_gpt":0.3577633970894001,"score_spread":0.33082585166171163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782956976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825226,0.0051387763,0.00003258303,0.005107266,0.0027388562,0.00038698106,0.0000624497,0.000005124316,0.004005385],"genre_scores_gemma":[0.99313116,0.0014164282,0.00036991248,0.00082679116,0.0010662411,0.000040914987,0.00000313864,0.000016010512,0.0031294127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987754,0.000021515909,0.00036725475,0.00015215529,0.0005151792,0.00016846681],"domain_scores_gemma":[0.9987602,0.000025561554,0.00059275556,0.00015352061,0.00035125745,0.00011667353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002644527,0.00014302191,0.00027967972,0.00013641451,0.00031668888,0.00007307861,0.00024690572,0.0000542039,0.000048682985],"category_scores_gemma":[0.000097986405,0.000096033444,0.00007713267,0.00009408541,0.000118439246,0.00036332296,0.00006716535,0.00031123927,9.4687647e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007131793,0.0004831389,0.9058933,0.00035035727,0.0010009921,0.00021156436,0.0033903394,0.003835676,0.011750168,0.00022590137,0.04375001,0.028395373],"study_design_scores_gemma":[0.012047599,0.0003211053,0.79639626,0.0013147331,0.00093348214,0.0002868981,0.00013728999,0.0004378668,0.015960963,0.00029185318,0.17154625,0.00032571293],"about_ca_topic_score_codex":0.0011830461,"about_ca_topic_score_gemma":0.0009586901,"teacher_disagreement_score":0.12779625,"about_ca_system_score_codex":0.001001178,"about_ca_system_score_gemma":0.0012670069,"threshold_uncertainty_score":0.391613},"labels":[],"label_agreement":null},{"id":"W2783868265","doi":"10.5539/cco.v7n1p22","title":"Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique","year":2018,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"CISH; Anaplastic lymphoma kinase; KRAS; Chromogenic in situ hybridization; Lung cancer; Medicine; Crizotinib; Internal medicine; non-small cell lung cancer (NSCLC); Oncology; Cancer research; Pathology; Cancer; Biology; Gene; In situ hybridization; Gene expression","score_opus":0.020405075162081808,"score_gpt":0.4049459563881973,"score_spread":0.3845408812261155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783868265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977023,0.0034789287,0.001676561,0.0004298242,0.00070332957,0.00071724923,0.000072318464,0.000020408886,0.0031311442],"genre_scores_gemma":[0.9941858,0.0032836657,0.00042072346,0.00076777773,0.0003805434,0.0004393013,0.0000145294325,0.000018549275,0.00048907934],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99880105,0.000055327655,0.00051146623,0.00033518337,0.00007781623,0.00021915544],"domain_scores_gemma":[0.9991525,0.00020133455,0.00018577886,0.00015699357,0.00013976995,0.00016366088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001949984,0.00013149703,0.00048250993,0.00007603437,0.00004834575,0.0000040554437,0.000056252113,0.00027545379,0.00013600668],"category_scores_gemma":[0.00005827473,0.000110145025,0.000079374964,0.00019634153,0.00025306255,0.000035686593,0.00003215097,0.00014437974,0.000002659316],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001847286,0.0015431023,0.21375522,0.00023668207,0.00030643097,0.00006655842,0.00041474748,0.000004371691,0.046679236,0.000009507346,0.0029761232,0.73216075],"study_design_scores_gemma":[0.040078647,0.017877938,0.655072,0.00081852847,0.0030688322,0.000056592376,0.0003777559,0.0019787557,0.20177428,0.00014117039,0.07808127,0.0006742354],"about_ca_topic_score_codex":0.0022548058,"about_ca_topic_score_gemma":0.0042855386,"teacher_disagreement_score":0.7314865,"about_ca_system_score_codex":0.00046170803,"about_ca_system_score_gemma":0.0008031512,"threshold_uncertainty_score":0.44915837},"labels":[],"label_agreement":null},{"id":"W2784100755","doi":"10.1038/modpathol.2017.191","title":"Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases","year":2018,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Fusion gene; Immunohistochemistry; Pathology; ETV6; Biology; Medicine; Gene; Chromosomal translocation","score_opus":0.0172236995393507,"score_gpt":0.33157842855234476,"score_spread":0.31435472901299405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784100755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929951,0.000120999335,0.00507369,0.00035092278,0.000106687956,0.00023513281,0.000029336657,0.000025785925,0.0010623864],"genre_scores_gemma":[0.99849004,0.000031122065,0.0005171239,0.0002817337,0.00004777141,0.000032545948,0.00019922263,0.000014534935,0.00038593533],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993681,0.00004035699,0.00018286484,0.0001897478,0.00008029874,0.00013867287],"domain_scores_gemma":[0.9996081,0.000014737131,0.000072459625,0.0001866273,0.000079148245,0.000038943774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044326553,0.000083426334,0.00019071517,0.00012155484,0.000027731943,0.0000023252803,0.000030241423,0.0000752163,0.000046789508],"category_scores_gemma":[0.00003609939,0.00007253558,0.00003348538,0.000105844396,0.00009296403,0.000035485806,0.00001985822,0.00004409849,0.000023144756],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018790469,0.00022304726,0.01655805,0.000039257404,0.000024513205,0.0010603792,0.0016314755,0.000008698067,0.9664307,0.00019793182,0.000028172546,0.013609874],"study_design_scores_gemma":[0.009054887,0.0045250896,0.51608247,0.00033288196,0.00055862905,0.0028623445,0.00017755857,0.005920097,0.45437852,0.0019765175,0.0036598798,0.00047112795],"about_ca_topic_score_codex":0.00004468426,"about_ca_topic_score_gemma":0.000034550103,"teacher_disagreement_score":0.5120522,"about_ca_system_score_codex":0.000072960705,"about_ca_system_score_gemma":0.00007292982,"threshold_uncertainty_score":0.2957915},"labels":[],"label_agreement":null},{"id":"W2784164991","doi":"10.21037/jtd.2017.12.119","title":"Ablative therapy in oligometastatic non-small cell lung cancer—an editorial on recent evidence","year":2018,"lang":"en","type":"letter","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Ablative case; Lung cancer; Oncology; Internal medicine; Radiation therapy","score_opus":0.03932311681334757,"score_gpt":0.414331995628809,"score_spread":0.37500887881546147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784164991","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25246578,0.027575506,0.00022020948,0.6050881,0.10738758,0.0047399895,0.0007962052,0.000057147,0.0016694199],"genre_scores_gemma":[0.047047533,0.035594523,0.0019062934,0.38847095,0.51802886,0.00042639318,0.00035040014,0.00036337215,0.007811688],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973619,0.00024385517,0.0006866466,0.0003554936,0.000989297,0.00036280608],"domain_scores_gemma":[0.9972257,0.00025072374,0.00088535564,0.00041338868,0.0007821278,0.00044271557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038372044,0.00038054722,0.00070532784,0.0005008494,0.00006987983,0.000074285934,0.00026714182,0.00023337902,0.0003948881],"category_scores_gemma":[0.00018965855,0.00026770218,0.00027961464,0.00031021482,0.000067198845,0.00028148867,0.00002133861,0.001290058,0.000017333106],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037937653,0.0007386096,0.0031943212,0.0010176656,0.0005641716,0.002509176,0.0009881135,0.000095652766,0.000029650802,2.770265e-7,0.9784073,0.00866126],"study_design_scores_gemma":[0.0071057924,0.0072365487,0.016729023,0.027121918,0.0069957124,0.000040084462,0.00023713392,0.00021438149,0.00056550326,0.00028493762,0.9324769,0.0009920878],"about_ca_topic_score_codex":0.00009625836,"about_ca_topic_score_gemma":0.000013338577,"teacher_disagreement_score":0.41064128,"about_ca_system_score_codex":0.0011002594,"about_ca_system_score_gemma":0.0029214586,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W2784623697","doi":"10.1016/j.jtho.2017.12.001","title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Guideline; Medicine; KRAS; ROS1; Lung cancer; Context (archaeology); Targeted therapy; Companion diagnostic; Pathology; Oncology; Internal medicine; Medical physics; Adenocarcinoma; Cancer; Family medicine; Intensive care medicine","score_opus":0.019680333514212882,"score_gpt":0.43259753655044925,"score_spread":0.41291720303623636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784623697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775223,0.0011348887,0.014739835,0.0039425856,0.0006854003,0.0017281133,0.00008019186,0.000012953448,0.00015374241],"genre_scores_gemma":[0.9600015,0.00002485233,0.038787887,0.0003336147,0.0005338405,0.000107999,0.000043717962,0.000022877139,0.00014371198],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909264,0.000031157244,0.0004885342,0.00010594868,0.00012849597,0.00015322209],"domain_scores_gemma":[0.99687034,0.0001347073,0.0006693891,0.00007745054,0.0021812196,0.0000669185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018737884,0.00011179587,0.0003264164,0.000101958576,0.000110862675,0.000005605483,0.00004421736,0.00006190335,0.000024957953],"category_scores_gemma":[0.00012682739,0.000058577258,0.00009450291,0.00022366206,0.00006279778,0.000053864165,0.0000065638624,0.000047752226,1.7212233e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023118163,0.004399671,0.100331925,0.00029171468,0.006001273,0.000033912824,0.0015574052,0.0015791833,0.10888719,0.00003495806,0.050085407,0.7036792],"study_design_scores_gemma":[0.030751392,0.14127117,0.019880168,0.0008877107,0.021749875,0.00030497153,0.00056250737,0.026962467,0.51483744,0.00012810394,0.24225347,0.00041073552],"about_ca_topic_score_codex":0.000095147305,"about_ca_topic_score_gemma":0.000071069226,"teacher_disagreement_score":0.70326847,"about_ca_system_score_codex":0.00064728473,"about_ca_system_score_gemma":0.0007642954,"threshold_uncertainty_score":0.23887113},"labels":[],"label_agreement":null},{"id":"W2785259638","doi":"10.1016/j.jmoldx.2017.11.004","title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":352,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Guideline; Medicine; KRAS; Context (archaeology); ROS1; Lung cancer; Targeted therapy; Companion diagnostic; Pathology; Medical physics; Oncology; Internal medicine; Adenocarcinoma; Family medicine; Cancer; Biology","score_opus":0.010938892321164472,"score_gpt":0.3211284489140964,"score_spread":0.31018955659293196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785259638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88094896,0.0040200036,0.110544585,0.0015315304,0.00045098274,0.0022543562,0.00019257079,0.000015240447,0.000041764426],"genre_scores_gemma":[0.96395415,0.00015255091,0.034897164,0.00042347072,0.0003020354,0.00011280006,0.00009261388,0.000043018325,0.000022219683],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989111,0.000019419902,0.0005162842,0.00012547387,0.00024823932,0.00017948718],"domain_scores_gemma":[0.9961146,0.00024202319,0.0005371976,0.00011704914,0.002897367,0.000091775095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011321635,0.00015744133,0.0002862493,0.00009935951,0.00010664046,0.000013988116,0.000056109035,0.00005125774,0.000010437221],"category_scores_gemma":[0.00061337795,0.000091113005,0.00013092344,0.00026718582,0.000057784287,0.00004498782,0.0000086251985,0.000048735877,1.5736111e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068836645,0.007860558,0.38461363,0.0006233751,0.014091606,0.00019633357,0.0014970233,0.017220307,0.37133798,0.00032279716,0.096481875,0.09887085],"study_design_scores_gemma":[0.021425545,0.024627462,0.008902929,0.0009046787,0.011417187,0.00005782853,0.00009101209,0.013611508,0.8989627,0.00008423864,0.019625949,0.0002889927],"about_ca_topic_score_codex":0.00007719957,"about_ca_topic_score_gemma":0.00002159071,"teacher_disagreement_score":0.52762467,"about_ca_system_score_codex":0.00027300723,"about_ca_system_score_gemma":0.00043412595,"threshold_uncertainty_score":0.37154806},"labels":[],"label_agreement":null},{"id":"W2785714424","doi":"10.1200/jco.2013.31.15_suppl.8052","title":"Molecular marker assessments for epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) and histoscore (H-score) in the phase III SELECT trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Immunohistochemistry; Internal medicine; Oncology; Lung cancer; Population; Biomarker; Progression-free survival; Cetuximab; Phases of clinical research; Clinical trial; Gastroenterology; Cancer; Pathology; Chemotherapy; Colorectal cancer","score_opus":0.06635778604162187,"score_gpt":0.4973250380851857,"score_spread":0.4309672520435638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785714424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040854,0.0010889543,0.0007282101,0.0051525543,0.00056197855,0.0010839043,0.000016520351,0.0000047944527,0.00095454697],"genre_scores_gemma":[0.9934952,0.00034060862,0.0030965926,0.0020939147,0.0003521843,0.00014123727,0.00003442673,0.000017711434,0.00042812235],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975936,0.00029633116,0.0014673002,0.00019209566,0.0002449992,0.00020570529],"domain_scores_gemma":[0.9969012,0.0014472123,0.0010193805,0.00015121112,0.00028419506,0.00019680317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010224321,0.0001453658,0.00085418375,0.000053424774,0.0000591136,0.000016759663,0.00013776064,0.00026167062,0.00020640634],"category_scores_gemma":[0.0013443471,0.00008446272,0.00026924652,0.000071315124,0.00011245927,0.00013998109,0.000022405075,0.0005450006,0.0000022450818],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1115563,0.015979478,0.015320494,0.00020734762,0.0014897891,0.0003424178,0.0008161017,0.0000015384978,0.34366748,0.000058335892,0.31261817,0.19794254],"study_design_scores_gemma":[0.72751635,0.057492524,0.02860768,0.0005508683,0.0020150729,0.00042276387,0.000812699,0.00019713187,0.0137872705,0.0008727078,0.16721727,0.0005076855],"about_ca_topic_score_codex":0.000041144005,"about_ca_topic_score_gemma":8.7331546e-7,"teacher_disagreement_score":0.61596,"about_ca_system_score_codex":0.00028237837,"about_ca_system_score_gemma":0.0008532211,"threshold_uncertainty_score":0.344429},"labels":[],"label_agreement":null},{"id":"W2787639107","doi":"10.1177/1758834017753338","title":"Turning <i>EGFR</i> mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors","year":2018,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Osimertinib; Afatinib; Erlotinib; T790M; Gefitinib; Medicine; Lung cancer; Tolerability; Oncology; Epidermal growth factor receptor; Resistance mutation; Erlotinib Hydrochloride; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Adverse effect; Biology; Receptor","score_opus":0.018763228355649305,"score_gpt":0.4154327985471971,"score_spread":0.3966695701915478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787639107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047978314,0.990311,0.0030115563,0.00085373956,0.0011172176,0.0031267742,0.000058732596,0.00008082088,0.0009603242],"genre_scores_gemma":[0.0016503732,0.9901529,0.0012753842,0.001326833,0.0020520824,0.0023716923,0.00058194343,0.00015982552,0.00042895955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959675,0.00041489178,0.0010355159,0.0010164514,0.00078080414,0.0007848272],"domain_scores_gemma":[0.997436,0.00056613825,0.0006824233,0.00045828844,0.00022148885,0.0006356897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039212094,0.00082202203,0.0022336852,0.00033186466,0.00021129537,0.000029511828,0.00037350552,0.00060698745,0.00074504875],"category_scores_gemma":[0.0000447819,0.0005453292,0.00035453352,0.00073641,0.0008890207,0.00020571436,0.000095029194,0.0011587486,0.000027888264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007131051,0.000882659,0.00012475868,0.0057703736,0.0009787729,0.001742103,0.0010866256,0.00009645279,0.00000548786,0.000043901317,0.00011241551,0.9884433],"study_design_scores_gemma":[0.008598335,0.0032202962,0.000035999063,0.02319677,0.004572718,0.0002084699,0.00013881136,0.0005323614,0.000035582532,0.000058409147,0.9587455,0.0006567627],"about_ca_topic_score_codex":0.00018117414,"about_ca_topic_score_gemma":0.00039147827,"teacher_disagreement_score":0.9877866,"about_ca_system_score_codex":0.004168615,"about_ca_system_score_gemma":0.011225608,"threshold_uncertainty_score":0.99969983},"labels":[],"label_agreement":null},{"id":"W2789873517","doi":"10.1158/1535-7163.mct-17-0552","title":"Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of California, San Francisco; National Institutes of Health; Sunnybrook Research Institute","keywords":"Pharmacodynamics; Pharmacology; Biomarker; Medicine; Pharmacokinetics; Drug; Biology","score_opus":0.019470182303289663,"score_gpt":0.3456646254658927,"score_spread":0.32619444316260304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789873517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97151375,0.00234782,0.022202339,0.0008647431,0.00025815386,0.0017912969,0.000030069685,0.0000816559,0.0009101507],"genre_scores_gemma":[0.97742987,0.000076970544,0.017222926,0.0044675297,0.00010055863,0.00055018585,0.000050893268,0.00005912208,0.000041974417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831796,0.00006405344,0.0004308518,0.00047270156,0.00033510922,0.00037933196],"domain_scores_gemma":[0.9990089,0.000035006055,0.00015729303,0.00033807973,0.00025846018,0.00020224518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001654315,0.00032227606,0.0004524179,0.00017060066,0.000112503294,0.00002142472,0.00015015584,0.00009657796,0.00004826169],"category_scores_gemma":[0.000013656395,0.00026168386,0.00012898872,0.0005304308,0.00014934094,0.000028650747,0.00007265313,0.00014623675,0.00002403102],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004482328,0.00036224356,0.001161175,0.00009330433,0.001685856,0.00005814956,0.0022111551,0.001104417,0.9497164,0.001146307,0.00003305004,0.041979734],"study_design_scores_gemma":[0.0031115788,0.00045546363,0.001413839,0.00020209933,0.0008658517,0.000007361842,0.0001241771,0.00033649028,0.98431164,0.00022984951,0.008620222,0.00032145213],"about_ca_topic_score_codex":0.00007719007,"about_ca_topic_score_gemma":0.000017398588,"teacher_disagreement_score":0.041658282,"about_ca_system_score_codex":0.00044905173,"about_ca_system_score_gemma":0.00040076888,"threshold_uncertainty_score":0.99998355},"labels":[],"label_agreement":null},{"id":"W2789883645","doi":"10.1038/s41388-018-0185-4","title":"The multiple paths towards MET receptor addiction in cancer","year":2018,"lang":"en","type":"review","venue":"Oncogene","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Addiction; Oncogene; Biology; Cancer; Receptor tyrosine kinase; Lung cancer; Mechanism (biology); Carcinogenesis; Population; Cancer research; Targeted therapy; Bioinformatics; Oncology; Kinase; Medicine; Genetics; Neuroscience; Cell cycle; Environmental health","score_opus":0.0645783213865305,"score_gpt":0.4285196051196201,"score_spread":0.36394128373308965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789883645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024289671,0.9940797,0.0000055360842,0.0001354485,0.0012015399,0.0010635582,0.0003424232,0.00003294461,0.0031145758],"genre_scores_gemma":[0.00002163651,0.9904343,0.00030573527,0.00006190401,0.0009572815,0.001220782,0.0005002631,0.00004868168,0.006449417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988453,0.00007627607,0.00036649354,0.00029512163,0.00019222926,0.000224575],"domain_scores_gemma":[0.99924016,0.00009046124,0.00017862336,0.00031781246,0.00008604223,0.000086888576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016133212,0.00023343613,0.00069404824,0.000087096494,0.00011699354,0.000020243528,0.000098433215,0.000177618,0.0003508127],"category_scores_gemma":[0.00007803484,0.00012769837,0.00025607465,0.00030029973,0.000049354476,0.000029043416,0.000031134496,0.00017655667,0.00018709766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013537521,0.00006945009,0.000021309712,0.00061013835,0.00042016298,0.0000072824496,0.00007108726,1.2174335e-7,0.0000023383125,0.000005774554,0.015178267,0.98360056],"study_design_scores_gemma":[0.0006091906,0.00015495723,0.000020071408,0.0051204157,0.0016749629,0.000011833561,0.000017659104,0.0000029418043,0.000016166012,0.0000031934865,0.9922492,0.00011941692],"about_ca_topic_score_codex":0.0007071075,"about_ca_topic_score_gemma":0.00082321296,"teacher_disagreement_score":0.9834811,"about_ca_system_score_codex":0.0009778029,"about_ca_system_score_gemma":0.0011544173,"threshold_uncertainty_score":0.52073884},"labels":[],"label_agreement":null},{"id":"W2789986687","doi":"10.3747/co.25.3867","title":"Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Ottawa; Juravinski Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Centre Hospitalier de l’Université de Montréal; Université Laval; William Osler Health System; Ottawa Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; KRAS; Lung cancer; Oncology; Neuroblastoma RAS viral oncogene homolog; ROS1; Biomarker; Context (archaeology); Internal medicine; Anaplastic lymphoma kinase; Cancer; Epidermal growth factor receptor; Adenocarcinoma","score_opus":0.07204960100922177,"score_gpt":0.45917952221591524,"score_spread":0.3871299212066935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789986687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98056966,0.0019270356,0.0012021062,0.0011060586,0.002312515,0.0020829893,0.00044834602,0.00006385254,0.01028746],"genre_scores_gemma":[0.99493927,0.000014414943,0.003845719,0.00024835908,0.0002776309,0.00039572414,0.00014664643,0.000024408131,0.00010784675],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925095,0.00001131969,0.00012792475,0.00021046991,0.000090021385,0.0003093286],"domain_scores_gemma":[0.99896085,0.00005721989,0.000068332185,0.000110059445,0.0005955522,0.00020800352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048861526,0.00010448521,0.00018213417,0.00009601519,0.00020970553,0.0000080668915,0.000035730256,0.000042543084,0.000086379536],"category_scores_gemma":[0.00008711956,0.00007714659,0.000027249302,0.00016315815,0.00007628051,0.00005386754,0.000009067583,0.000058140507,0.000003463874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019031238,0.000112063855,0.58022684,0.000057547222,0.00012449261,0.000002602252,0.0003130849,0.000001998667,0.000033206823,0.000029664037,0.004352839,0.41455537],"study_design_scores_gemma":[0.007890409,0.0019473099,0.3983274,0.00032165533,0.0005722472,0.0000038575945,0.00008517747,0.0005207568,0.000065651664,0.000019600344,0.5900889,0.00015700757],"about_ca_topic_score_codex":0.002461707,"about_ca_topic_score_gemma":0.02479494,"teacher_disagreement_score":0.5857361,"about_ca_system_score_codex":0.0012878667,"about_ca_system_score_gemma":0.0016523126,"threshold_uncertainty_score":0.99300003},"labels":[],"label_agreement":null},{"id":"W2790018618","doi":"10.1016/j.ctarc.2018.02.002","title":"Benefit of crizotinib in a lung cancer patient with discordant ALK testing results","year":2018,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Anaplastic lymphoma kinase; Oncology; Pleural effusion; Internal medicine; Radiology; Pathology; Malignant pleural effusion","score_opus":0.12461204940114946,"score_gpt":0.47865714152750405,"score_spread":0.3540450921263546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790018618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521034,0.013450066,0.0000062365134,0.008276833,0.000038783317,0.0014651744,0.0002728275,0.000026439146,0.024360277],"genre_scores_gemma":[0.9885799,0.006559814,0.0025024342,0.00003400962,0.000047923,0.0012884911,0.000065816945,0.00001897275,0.0009026035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988454,0.00007981517,0.00028342538,0.00026019942,0.00023493827,0.00029619652],"domain_scores_gemma":[0.99802536,0.00032999553,0.00008951586,0.00082359806,0.00059911073,0.00013242313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014837291,0.00013168252,0.00023886244,0.0002200338,0.00035483495,0.00002239265,0.0001415845,0.00002669987,0.000024921159],"category_scores_gemma":[0.000063372914,0.00008393833,0.000029501605,0.00069850317,0.00058241416,0.000080167745,0.00012292663,0.00015243441,0.0000014615352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026861853,0.0039434014,0.55408823,0.0002919459,0.0015449214,0.00006856331,0.026015123,0.00008870682,0.0035157157,0.0023046662,0.00090746966,0.4045451],"study_design_scores_gemma":[0.040608846,0.021440513,0.8120049,0.011228658,0.002189529,0.00015341504,0.012500719,0.010911151,0.019662451,0.0007988914,0.06748567,0.0010152486],"about_ca_topic_score_codex":0.016436633,"about_ca_topic_score_gemma":0.0145460535,"teacher_disagreement_score":0.40352982,"about_ca_system_score_codex":0.00059993885,"about_ca_system_score_gemma":0.00068443565,"threshold_uncertainty_score":0.990113},"labels":[],"label_agreement":null},{"id":"W2790034830","doi":"10.1093/jncics/pkx010","title":"Factors Associated With Small Aggressive Non–Small Cell Lung Cancers in the National Lung Screening Trial: A Validation Study","year":2018,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Brock University; Alberta Health Services","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Odds ratio; Oncology; National Lung Screening Trial; Logistic regression; Confidence interval; Family history; Univariate analysis; Lung; Cohort; Cancer; Lung cancer screening; Multivariate analysis","score_opus":0.06144544541069428,"score_gpt":0.3578060002387793,"score_spread":0.296360554828085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790034830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991026,0.00021432017,0.00030513562,0.00093575247,0.0003886059,0.0029360477,0.0000647752,0.000054798904,0.004074605],"genre_scores_gemma":[0.997185,0.000018294557,0.000077126686,0.00047163918,0.00062796456,0.0006694897,0.00010538694,0.000041194977,0.0008038956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981483,0.000113523995,0.00032325697,0.0004225234,0.00060112233,0.00039125],"domain_scores_gemma":[0.9989009,0.00014966624,0.0004148546,0.00021157385,0.00023308488,0.00008992166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032246154,0.00026704805,0.00034100589,0.00019737048,0.00026056328,0.00007546224,0.00016493784,0.000078460216,0.00017845922],"category_scores_gemma":[0.00009092074,0.00016672359,0.0000820479,0.0006908152,0.00006970923,0.00011664219,0.000025625255,0.0002573101,0.0000026967666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040520276,0.001205963,0.96234274,0.00004733376,0.0013412422,0.00007133256,0.0265687,0.00071241386,0.00009507795,0.0000400072,0.002953229,0.0005699208],"study_design_scores_gemma":[0.06496849,0.0030205764,0.91865295,0.00056970876,0.0015718725,0.0000040895006,0.0060912645,0.0018626739,0.0023844857,0.000043564636,0.0003933588,0.0004369336],"about_ca_topic_score_codex":0.005373549,"about_ca_topic_score_gemma":0.018381404,"teacher_disagreement_score":0.060916465,"about_ca_system_score_codex":0.0020641794,"about_ca_system_score_gemma":0.0011586748,"threshold_uncertainty_score":0.99953055},"labels":[],"label_agreement":null},{"id":"W2790791873","doi":"10.3747/co.25.3723","title":"Real-World Outcomes in Patients with Alk-Positive Non-Small Cell Lung Cancer Treated with Crizotinib","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Internal medicine; Oncology; Anaplastic lymphoma kinase; Medical record; ALK inhibitor; Clinical trial; Retrospective cohort study","score_opus":0.0275592958335146,"score_gpt":0.3951885060309335,"score_spread":0.3676292101974189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790791873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421783,0.000113122835,0.000037369275,0.00037192673,0.000360684,0.0012597387,0.0000711863,0.00003890035,0.023529239],"genre_scores_gemma":[0.99677575,0.00005409753,0.00039901515,0.00017072045,0.00013187517,0.00030494126,0.0002071468,0.000032997414,0.0019234703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888974,0.000042223717,0.00022437044,0.00035522578,0.00014932541,0.00033910866],"domain_scores_gemma":[0.99916136,0.000057649082,0.00013825693,0.00020172009,0.0003025355,0.00013846064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003778634,0.00021935625,0.00044696275,0.00019334225,0.000074736396,0.000008664429,0.00006286357,0.000060948063,0.00014597455],"category_scores_gemma":[0.000005624226,0.00013581825,0.000037928236,0.0003200635,0.00013765154,0.000059037386,0.000023869668,0.00017115609,0.000018381188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083391153,0.0018282208,0.9869903,0.000053840984,0.00020875038,0.000026993632,0.0013708773,0.0000034947532,0.000010048186,0.0000178075,0.0009502034,0.007705603],"study_design_scores_gemma":[0.013550426,0.0033932407,0.9767819,0.0002698094,0.0007386748,0.0000013598874,0.00009467659,0.000055632612,0.0003125534,0.0000022481508,0.004634409,0.00016507265],"about_ca_topic_score_codex":0.0013564902,"about_ca_topic_score_gemma":0.006220706,"teacher_disagreement_score":0.022557903,"about_ca_system_score_codex":0.00089097803,"about_ca_system_score_gemma":0.0005369118,"threshold_uncertainty_score":0.55385077},"labels":[],"label_agreement":null},{"id":"W2791818089","doi":"10.1200/jco.2018.36.5_suppl.172","title":"Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; KRAS; Nivolumab; Internal medicine; Atezolizumab; Oncology; ROS1; Lung cancer; Adenocarcinoma; Cancer; Immunotherapy; Population; Microsatellite instability; Colorectal cancer","score_opus":0.04160812740707414,"score_gpt":0.44612770733337315,"score_spread":0.404519579926299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791818089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938418,0.00039913246,0.00034498048,0.00089136086,0.001225978,0.0003595293,0.0000026252878,0.0000041802277,0.0029303778],"genre_scores_gemma":[0.99483,0.0001311628,0.003889955,0.00034057946,0.0007125357,0.000010948778,0.000003215924,0.000018537408,0.00006303755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968208,0.0001443056,0.002438909,0.00016323094,0.0002360568,0.00019669392],"domain_scores_gemma":[0.9966583,0.00057443226,0.0018114311,0.00015376342,0.00063584134,0.0001661827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008887994,0.0001239549,0.00084256293,0.00017311017,0.000041698077,0.000006918219,0.00009946561,0.00018602722,0.00006019974],"category_scores_gemma":[0.0011640767,0.000094324656,0.00034172574,0.00019795734,0.00010633027,0.00010546479,0.000044085813,0.00052375864,0.0000028124682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027568853,0.0070002903,0.83263946,0.00016945109,0.0008583673,0.00019373688,0.0028568532,0.00038609368,0.028160807,0.00003251199,0.00042208107,0.12452348],"study_design_scores_gemma":[0.02599319,0.007387595,0.9157593,0.0010868723,0.000683766,0.000009493401,0.00021432438,0.00056470075,0.04624667,0.000029634417,0.0018796471,0.00014475298],"about_ca_topic_score_codex":0.00019322697,"about_ca_topic_score_gemma":0.00003581912,"teacher_disagreement_score":0.12437873,"about_ca_system_score_codex":0.0003530094,"about_ca_system_score_gemma":0.001494794,"threshold_uncertainty_score":0.38464478},"labels":[],"label_agreement":null},{"id":"W2791989359","doi":"10.1016/j.jtho.2018.03.005","title":"Translation of Knowledge to Practice—Improving Awareness in NSCLC Molecular Testing","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University Health Network; Princess Margaret Cancer Centre; Ottawa Hospital; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Specialty; Intervention (counseling); Lung cancer; Medical physics; Knowledge translation; Lung cancer screening; Family medicine; Oncology; Nursing","score_opus":0.04596574257182692,"score_gpt":0.5004211194500483,"score_spread":0.45445537687822135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791989359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96256715,0.00089474453,0.014208517,0.0039831153,0.0006268316,0.00029417267,0.0000019603094,0.000007232715,0.017416246],"genre_scores_gemma":[0.92880857,0.0000046293944,0.0706939,0.00021640596,0.00020564179,0.0000040907416,9.094728e-7,0.000009609044,0.000056265046],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991288,0.00010755412,0.00043410913,0.00008752036,0.00012305086,0.00011896382],"domain_scores_gemma":[0.9984788,0.00026723332,0.00036215488,0.00008745465,0.0007173457,0.00008705423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053491944,0.00006724507,0.00029830413,0.00026550208,0.000028040606,0.0000043986615,0.000055424654,0.00007099739,0.00001637615],"category_scores_gemma":[0.00079939107,0.000054317512,0.0000499754,0.00036008446,0.000036967347,0.00013035077,0.000012084372,0.00013826325,0.0000054884226],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010266721,0.0006253485,0.0054228767,0.00008930274,0.00010543305,0.00022764041,0.0036246746,0.00007345699,0.06911832,0.000022542567,0.0000767369,0.919587],"study_design_scores_gemma":[0.024758069,0.08240451,0.24286485,0.007297871,0.010974545,0.011866334,0.01460816,0.0071830107,0.35077253,0.0017341895,0.24436368,0.0011722561],"about_ca_topic_score_codex":0.000064988715,"about_ca_topic_score_gemma":0.00007264938,"teacher_disagreement_score":0.9184147,"about_ca_system_score_codex":0.00028761738,"about_ca_system_score_gemma":0.0010439613,"threshold_uncertainty_score":0.22150038},"labels":[],"label_agreement":null},{"id":"W2793051369","doi":"10.1016/j.lungcan.2018.02.011","title":"Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Lung cancer; Adverse effect; Oncology; Internal medicine; Overall survival; Intensive care medicine; Lung","score_opus":0.007534355708445017,"score_gpt":0.3166972310667556,"score_spread":0.3091628753583106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793051369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234694,0.0017089354,0.0000241596,0.00017057007,0.0005119825,0.0016815605,0.00027165498,0.00003482497,0.0032493414],"genre_scores_gemma":[0.9956705,0.0007671514,0.0001594713,0.00067477254,0.00023429652,0.0003255563,0.000107409265,0.000066992514,0.0019938431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847215,0.00003586998,0.00024700921,0.00049797434,0.00029868112,0.00044829384],"domain_scores_gemma":[0.9990759,0.000043419495,0.00014856944,0.00030127622,0.00021569271,0.00021516747],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000056500518,0.00034446566,0.000401401,0.00012480027,0.00010376398,0.0000119919805,0.0000810538,0.000101505546,0.00096042006],"category_scores_gemma":[0.0000051432985,0.00024214172,0.00007136214,0.00021766365,0.000051022434,0.00018725515,0.00002290503,0.00020852327,0.000005499916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028643422,0.00045634568,0.9767081,0.00011250969,0.00044746805,0.000016430462,0.001355855,0.00037991107,0.00024352873,0.0000046495825,0.0006480895,0.016762735],"study_design_scores_gemma":[0.024046347,0.002349382,0.969908,0.00081015925,0.00023964398,0.000001816187,0.00008958799,0.00075120793,0.0005736983,0.0000053560066,0.0008654909,0.00035929854],"about_ca_topic_score_codex":0.0022639032,"about_ca_topic_score_gemma":0.0061252583,"teacher_disagreement_score":0.021182004,"about_ca_system_score_codex":0.0012527658,"about_ca_system_score_gemma":0.00046294628,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W2793187279","doi":"10.2147/ott.s148363","title":"Response to crizotinib in a non-small-cell lung cancer patient harboring an &lt;em&gt;EML4-ALK&lt;/em&gt; fusion with an atypical &lt;em&gt;LTBP1&lt;/em&gt; insertion","year":2018,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Lung cancer; Fusion gene; Cancer research; KRAS; Medicine; Cancer; Biology; Oncology; Internal medicine; Gene; Genetics","score_opus":0.01388789291140281,"score_gpt":0.2961615911127861,"score_spread":0.2822736982013833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793187279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904993,0.0041075144,0.00030248964,0.001087141,0.0007227076,0.0023024506,0.00009874561,0.00016301619,0.00071661104],"genre_scores_gemma":[0.9900305,0.00198826,0.0032776447,0.002117916,0.00075363606,0.00055357313,0.00016351383,0.000173956,0.0009409489],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99581146,0.00032812782,0.0007920145,0.001263941,0.0008126782,0.0009917947],"domain_scores_gemma":[0.99732655,0.000114400296,0.00030294224,0.00088734605,0.00052214466,0.0008466295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064556487,0.00074534654,0.00086259167,0.00047868522,0.0005596593,0.00020305016,0.00025452577,0.0003258828,0.00046059623],"category_scores_gemma":[0.000047855374,0.00056355883,0.00014881798,0.0006950607,0.00012933262,0.00051257154,0.000094507144,0.00038261493,0.000034010096],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079131745,0.007657273,0.06758908,0.00030141443,0.00095003255,0.0006230438,0.08637751,0.00024093334,0.48374245,0.00034419366,0.003137091,0.26990524],"study_design_scores_gemma":[0.035442356,0.033623308,0.6997761,0.002215298,0.00071327516,0.000091228234,0.002848588,0.005376751,0.021719238,0.00018552151,0.19574647,0.0022618426],"about_ca_topic_score_codex":0.00049839634,"about_ca_topic_score_gemma":0.007962495,"teacher_disagreement_score":0.63218707,"about_ca_system_score_codex":0.00067556807,"about_ca_system_score_gemma":0.00062276045,"threshold_uncertainty_score":0.9996816},"labels":[],"label_agreement":null},{"id":"W2794061572","doi":"10.1016/j.cllc.2018.03.009","title":"Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Genentech; Ariad Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Medicine; Lung cancer; Lung; Internal medicine; Oncology; Squamous-cell carcinoma of the lung; Erlotinib; Epidermal growth factor receptor; Cancer","score_opus":0.0457708610967405,"score_gpt":0.4460203423078012,"score_spread":0.4002494812110607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794061572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768361,0.012646886,0.00051242416,0.0010218129,0.0012585281,0.005307553,0.0009424391,0.00005074289,0.0014235267],"genre_scores_gemma":[0.9911213,0.003628108,0.00059434,0.0005462612,0.0009561,0.00087094,0.00027352676,0.0001057326,0.0019037233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99512315,0.00039080018,0.0021317832,0.0010195028,0.00073071016,0.0006040696],"domain_scores_gemma":[0.9941978,0.0016241608,0.0017228666,0.00086277723,0.0011862713,0.0004061098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005684334,0.0006623168,0.0020035566,0.00019552521,0.00037737572,0.000049202747,0.0002541055,0.00032587777,0.0007198806],"category_scores_gemma":[0.00033118812,0.00040242999,0.0006409596,0.0006770638,0.00068299385,0.0002105765,0.0001057207,0.00029347104,0.000004173538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024666456,0.0025143623,0.9734918,0.0008384589,0.0062861606,0.000023160206,0.0033145298,0.0003886212,0.00021383054,0.00003245663,0.0039862613,0.0064437166],"study_design_scores_gemma":[0.039647713,0.004235163,0.9013645,0.0035940348,0.02820925,0.000007891779,0.00042071153,0.010152768,0.010882813,0.000027045495,0.00071591325,0.0007422218],"about_ca_topic_score_codex":0.0045259376,"about_ca_topic_score_gemma":0.0017106838,"teacher_disagreement_score":0.07212732,"about_ca_system_score_codex":0.00096033054,"about_ca_system_score_gemma":0.0013400742,"threshold_uncertainty_score":0.99984276},"labels":[],"label_agreement":null},{"id":"W2794723335","doi":"10.1158/2159-8290.cd-17-1004","title":"Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i> -Rearranged Cancers","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; GlaxoSmithKline","keywords":"Afatinib; ERBB3; Medicine; Cancer research; ErbB; Oncology; Cancer; Internal medicine; Erlotinib; Epidermal growth factor receptor","score_opus":0.017207825056623476,"score_gpt":0.3378055771221455,"score_spread":0.320597752065522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794723335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868492,0.0021830925,0.00005526241,0.0051400578,0.0007382003,0.0008729468,0.00014079089,0.00012577575,0.003894668],"genre_scores_gemma":[0.9856066,0.00042569247,0.00025878157,0.0058956756,0.0003742644,0.0005135041,0.000036709473,0.000044649147,0.006844133],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987091,0.00007865372,0.00022298818,0.0003939533,0.00022678613,0.00036851174],"domain_scores_gemma":[0.9992284,0.00005933969,0.000052697163,0.00035031917,0.00013190397,0.00017732837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014062156,0.00019444988,0.00029791013,0.00019519805,0.000087325614,0.000039761326,0.00009166095,0.00007170542,0.000421873],"category_scores_gemma":[0.00006142972,0.00015766734,0.00007772993,0.0007180217,0.00009611307,0.00020667528,0.000020933949,0.00011510083,0.000059488637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059075706,0.00080919074,0.22741476,0.00009282739,0.0013269685,0.0002735512,0.020029001,0.00037226456,0.4485559,0.000108164175,0.17248043,0.06946124],"study_design_scores_gemma":[0.011216506,0.0019423902,0.7097153,0.0005729189,0.00015320828,0.000011040468,0.0006617872,0.00008599021,0.062082145,0.00007814767,0.21296555,0.0005149989],"about_ca_topic_score_codex":0.004350551,"about_ca_topic_score_gemma":0.0030337165,"teacher_disagreement_score":0.48230055,"about_ca_system_score_codex":0.0012842558,"about_ca_system_score_gemma":0.0012559837,"threshold_uncertainty_score":0.65767604},"labels":[],"label_agreement":null},{"id":"W2794844459","doi":"10.1186/s12943-018-0810-4","title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"review","venue":"Molecular Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Ceritinib; Alectinib; Lung cancer; Cancer research; ALK inhibitor; Targeted therapy; ROS1; Gefitinib; Medicine; Biology; Cancer; Oncology; Internal medicine; Epidermal growth factor receptor; Adenocarcinoma","score_opus":0.014403252018254601,"score_gpt":0.3215182845415255,"score_spread":0.3071150325232709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794844459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023814763,0.9947293,0.00030522989,0.000059373684,0.0004903545,0.0013561022,0.000049094433,0.0000139088115,0.0006151735],"genre_scores_gemma":[0.014018731,0.9840607,0.0000635769,0.00014534162,0.00017264421,0.00097087177,0.000046695972,0.000076847864,0.00044455752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998546,0.00008455857,0.0004520504,0.00040703826,0.00019968911,0.0003106688],"domain_scores_gemma":[0.99909085,0.00008900226,0.0003138857,0.00030398875,0.00011386967,0.00008838274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013014929,0.0003387454,0.0007801673,0.00013667153,0.00010772679,0.000025929932,0.000100058794,0.00017201422,0.000053477637],"category_scores_gemma":[0.00001587793,0.00021678163,0.00021708362,0.00035075113,0.00009928513,0.000024241124,0.00004334894,0.00015124769,0.0000033248814],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102178106,0.00012079258,0.00068793487,0.012996449,0.0011534496,0.000054197393,0.0002536474,0.000019530595,0.00018469199,0.000033184035,0.00050947914,0.98388445],"study_design_scores_gemma":[0.0038354278,0.0004470516,0.0012283872,0.025320107,0.013921473,0.000014533652,0.00011914016,0.0003542223,0.00029832218,0.000037258134,0.95386016,0.0005639233],"about_ca_topic_score_codex":0.0008493428,"about_ca_topic_score_gemma":0.00037562315,"teacher_disagreement_score":0.98332053,"about_ca_system_score_codex":0.0005886123,"about_ca_system_score_gemma":0.0011205174,"threshold_uncertainty_score":0.88400984},"labels":[],"label_agreement":null},{"id":"W2794945244","doi":"10.1016/j.lungcan.2018.03.025","title":"Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Oncology; Docetaxel; Internal medicine; Bevacizumab; Ramucirumab; Lung cancer; Nintedanib; Refractory (planetary science); Chemotherapy; Lung; Idiopathic pulmonary fibrosis","score_opus":0.018027658250240105,"score_gpt":0.3736487933526319,"score_spread":0.3556211351023918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794945244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005497033,0.9825032,0.000038851504,0.00010584909,0.0007888542,0.0088733,0.0017420511,0.000037442325,0.00041345737],"genre_scores_gemma":[0.00071989145,0.9825436,0.0005388483,0.0007381599,0.0009886442,0.008498965,0.0007707047,0.0001954842,0.005005716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975472,0.000093622875,0.0006339252,0.0007778582,0.00033246801,0.0006149172],"domain_scores_gemma":[0.99753314,0.00029911104,0.001075383,0.0006353323,0.00033683653,0.0001201919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014987917,0.00066838285,0.0013631938,0.00020398473,0.00019881863,0.000045145694,0.00031339453,0.00027363258,0.0006444003],"category_scores_gemma":[0.000023757431,0.0003382952,0.0004202219,0.00051863043,0.00007297489,0.00012269345,0.0000343807,0.00039530065,0.0000043483774],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010556072,0.0007565594,0.0073289964,0.03196022,0.0032142873,0.000080667225,0.0028601633,0.000017235769,0.0000029235548,0.0000020016653,0.014290103,0.93843126],"study_design_scores_gemma":[0.008081618,0.0009968415,0.0010350966,0.03415545,0.0050245635,0.000008878369,0.00009311466,0.0000577164,0.00001541933,0.0000015610477,0.94994485,0.0005849144],"about_ca_topic_score_codex":0.00017178046,"about_ca_topic_score_gemma":0.0014296834,"teacher_disagreement_score":0.9378463,"about_ca_system_score_codex":0.0010873041,"about_ca_system_score_gemma":0.0025582968,"threshold_uncertainty_score":0.9999069},"labels":[],"label_agreement":null},{"id":"W2795421086","doi":"10.1111/cyt.12534","title":"Cytological preparations for molecular analysis: A review of technical procedures, advantages and limitations for referring samples for testing","year":2018,"lang":"en","type":"review","venue":"Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Medical physics; Data science; Computational biology; Computer science; Biology","score_opus":0.18589211871342876,"score_gpt":0.48262973641555146,"score_spread":0.2967376177021227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795421086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015162061,0.94863856,0.043372642,0.00017540906,0.000036974332,0.006707643,0.0007857961,0.000049260652,0.00021856159],"genre_scores_gemma":[0.000115505805,0.83479446,0.1523903,0.00015376476,0.000082896,0.010524862,0.0018263698,0.000032877382,0.000078974015],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833685,0.00005866458,0.0007655727,0.00053375703,0.00007032112,0.00023482296],"domain_scores_gemma":[0.9967008,0.001915381,0.00047292563,0.00032239972,0.00051440444,0.00007405059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032870186,0.0002576126,0.0018762005,0.0002466306,0.00013354074,0.000008683791,0.000093255396,0.00024154491,0.0000023183122],"category_scores_gemma":[0.0070451284,0.00018871333,0.00061934744,0.00038394515,0.0001478684,0.000030106405,0.00003669674,0.00008437506,4.5761382e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014105873,0.0006087431,0.00022555805,0.5900073,0.0038649363,0.000023787206,0.00012598284,0.0000039381785,0.00026573933,0.010899079,0.0026676364,0.39116624],"study_design_scores_gemma":[0.0009851613,0.002180873,0.00014562122,0.041389942,0.07560575,0.0004766111,0.000026617145,0.000026445136,0.000017138209,0.0008548964,0.877984,0.00030696008],"about_ca_topic_score_codex":0.0000011145419,"about_ca_topic_score_gemma":0.000022629027,"teacher_disagreement_score":0.8753163,"about_ca_system_score_codex":0.00008426389,"about_ca_system_score_gemma":0.0005508206,"threshold_uncertainty_score":0.8434186},"labels":[],"label_agreement":null},{"id":"W2796418582","doi":"10.1200/po.17.00125","title":"Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to <i>EGFR</i> Mutation Detection in Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Genotyping; T790M; KRAS; Liquid biopsy; Lung cancer; Epidermal growth factor receptor; Biomarker; Medicine; Oncology; Cancer; Biology; Cancer research; Internal medicine; Genotype; Gene; Genetics","score_opus":0.03265072183519806,"score_gpt":0.4358843568916937,"score_spread":0.4032336350564956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796418582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06815306,0.90951914,0.0048914347,0.00029976244,0.0011818605,0.012237835,0.000110029214,0.000041091454,0.003565768],"genre_scores_gemma":[0.07927402,0.91047657,0.0018702723,0.00041936187,0.00048853393,0.006730639,0.00036938427,0.00008431729,0.0002868843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772644,0.00027291902,0.0009463942,0.0005397274,0.00024211397,0.00027238243],"domain_scores_gemma":[0.9984252,0.00041975707,0.0005626933,0.0003789699,0.00013538724,0.000078029705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051320763,0.0002936881,0.0010637341,0.0005272734,0.000069050315,0.0000131719735,0.00021190057,0.00043366622,0.000049317783],"category_scores_gemma":[0.00005959829,0.00020736751,0.00018278955,0.0008623157,0.00006509551,0.0000604349,0.000067588604,0.0003314207,0.000049452912],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029643116,0.00044040204,0.00006900024,0.0020017487,0.00008072353,0.000023097708,0.0023148963,0.000038838578,0.00039911133,0.000009024277,0.00014851587,0.99417824],"study_design_scores_gemma":[0.0033952405,0.0023936606,0.000495147,0.006085671,0.0016207072,0.00016528166,0.0006073366,0.0005991459,0.00065434957,0.000014972913,0.98364466,0.0003238226],"about_ca_topic_score_codex":0.00081371446,"about_ca_topic_score_gemma":0.0020283302,"teacher_disagreement_score":0.9938544,"about_ca_system_score_codex":0.0022351514,"about_ca_system_score_gemma":0.0008176902,"threshold_uncertainty_score":0.84562016},"labels":[],"label_agreement":null},{"id":"W2797366988","doi":"10.1016/s1556-0864(18)30402-7","title":"128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Gefitinib; Internal medicine; Erlotinib; Oncology; Discontinuation; Hazard ratio; Erlotinib Hydrochloride; Lung cancer; T790M; Progression-free survival; Ceritinib; Cancer; Chemotherapy; Epidermal growth factor receptor; Crizotinib; Confidence interval","score_opus":0.011624847890201916,"score_gpt":0.42550727448115244,"score_spread":0.41388242659095054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797366988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924203,0.0010160932,0.000024573177,0.004158194,0.0004390303,0.00064651325,0.00004256547,0.000015564256,0.0012371585],"genre_scores_gemma":[0.9960836,0.00030902907,0.0026875227,0.000547187,0.00013282617,0.000015154241,0.00004654327,0.000032999396,0.00014514096],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982125,0.00011426579,0.00073750346,0.00020355583,0.00045641093,0.00027573376],"domain_scores_gemma":[0.9967836,0.00012562274,0.00089143094,0.00023588489,0.0017949422,0.00016849834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018491404,0.0002263614,0.00090489833,0.00030256677,0.00009190217,0.000009678918,0.00013131017,0.00016315076,0.00019935695],"category_scores_gemma":[0.00014582378,0.00013346733,0.00014187623,0.0003060916,0.00016645745,0.00016708876,0.000027985,0.00027037185,0.000007953513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064378396,0.0013412039,0.4036213,0.00009073578,0.00055627775,0.00020162472,0.0044269944,0.000026861519,0.00029192946,0.000008214843,0.0002132627,0.5248432],"study_design_scores_gemma":[0.042325202,0.22362375,0.68485373,0.0021604397,0.0011872194,0.00018923687,0.0033982752,0.000014318082,0.01574912,0.00011358849,0.026031848,0.0003532608],"about_ca_topic_score_codex":0.000051743256,"about_ca_topic_score_gemma":0.00024761274,"teacher_disagreement_score":0.52448994,"about_ca_system_score_codex":0.0007765729,"about_ca_system_score_gemma":0.0007842722,"threshold_uncertainty_score":0.54426396},"labels":[],"label_agreement":null},{"id":"W2797413838","doi":"10.1016/s1556-0864(18)30413-1","title":"139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Lung cancer; Quality of life (healthcare); Internal medicine; Clinical trial; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.013171972127239433,"score_gpt":0.365184037464687,"score_spread":0.35201206533744756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797413838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395555,0.0010564455,0.000062686435,0.0008955765,0.002242861,0.00096907286,0.00044619,0.000019786808,0.0003518462],"genre_scores_gemma":[0.993962,0.000085152584,0.005210307,0.00019223137,0.0002687104,0.000036249745,0.0001392938,0.00005825314,0.000047825826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717087,0.00016462358,0.0013182263,0.0003586894,0.0005546992,0.00043291494],"domain_scores_gemma":[0.9952447,0.00023370082,0.0018129998,0.00028174632,0.0021209614,0.00030590483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012386794,0.00036291248,0.0012696985,0.00034029307,0.00009582874,0.000014766801,0.00015011452,0.00022744942,0.00032434307],"category_scores_gemma":[0.00021917575,0.00025652672,0.00020571862,0.00039197487,0.00016434872,0.0002629687,0.00005651976,0.00043233478,0.0000041202356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067970835,0.0014224066,0.8593962,0.00024453524,0.0013492599,0.00029799182,0.008166465,0.000044470187,0.004670435,8.4484736e-7,0.0011751695,0.055261377],"study_design_scores_gemma":[0.05360169,0.039720904,0.78354865,0.0018077632,0.003404713,0.0000146801585,0.0038675568,0.00002731086,0.11078897,0.000008503259,0.0026439826,0.0005652457],"about_ca_topic_score_codex":0.00033603594,"about_ca_topic_score_gemma":0.0005049807,"teacher_disagreement_score":0.10611854,"about_ca_system_score_codex":0.0019736676,"about_ca_system_score_gemma":0.0016494031,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W2797717415","doi":"10.1016/s1556-0864(18)30462-3","title":"188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Pemetrexed; Lung cancer; Chemotherapy; Oncology; Internal medicine; Chemotherapy regimen; Surgery; Cancer; Immunotherapy; Cisplatin","score_opus":0.017137625849516266,"score_gpt":0.3920154032273718,"score_spread":0.3748777773778555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797717415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935293,0.0005375385,0.00018089428,0.0016011598,0.0011378286,0.0008148328,0.000014330149,0.000012313717,0.0021717767],"genre_scores_gemma":[0.99619126,0.0005984206,0.0020212438,0.00027236232,0.00041800077,0.000046683854,0.00001778019,0.000047924445,0.0003863033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822986,0.00009715804,0.0006593809,0.00029498362,0.0002963443,0.0004222645],"domain_scores_gemma":[0.99847203,0.00015048504,0.00057928666,0.00023764755,0.00036608387,0.00019445481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018520193,0.00029954486,0.0008357989,0.0003673991,0.00007201212,0.000014672653,0.00013260494,0.00017463099,0.00017508572],"category_scores_gemma":[0.000027262691,0.00020788494,0.00012698521,0.00031341118,0.000056166868,0.00016631317,0.000022443004,0.00033443636,0.000005915648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1394933,0.0070198723,0.6435942,0.00019155837,0.0010217442,0.00060620747,0.007103313,0.001712518,0.00043661642,0.000006424934,0.00025172008,0.1985625],"study_design_scores_gemma":[0.10913671,0.029786544,0.8508243,0.00077051116,0.0010481909,0.0000368748,0.00034838036,0.0007295459,0.0012991491,0.00002162105,0.00566051,0.0003376618],"about_ca_topic_score_codex":0.0005919073,"about_ca_topic_score_gemma":0.004588551,"teacher_disagreement_score":0.20723008,"about_ca_system_score_codex":0.0033866393,"about_ca_system_score_gemma":0.001286482,"threshold_uncertainty_score":0.88559437},"labels":[],"label_agreement":null},{"id":"W2797855100","doi":"10.1016/s1556-0864(18)30408-8","title":"133PD Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for non-small cell lung cancer (NSCLC): A systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Hazard ratio; Subgroup analysis; Lung cancer; Odds ratio; Epidermal growth factor receptor; Randomized controlled trial; Adjuvant; Confidence interval; Cancer","score_opus":0.06433220985350852,"score_gpt":0.46556820384650194,"score_spread":0.4012359939929934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797855100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019966776,0.9902835,0.00042366123,0.0018577623,0.0006521894,0.0059030494,0.00072619657,0.0000142605095,0.00011944164],"genre_scores_gemma":[0.000056277528,0.9901267,0.004181847,0.0009906152,0.0007167288,0.0011934856,0.00011755169,0.00009741944,0.0025193412],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99469554,0.000758116,0.003119746,0.0005576053,0.00039384168,0.00047515004],"domain_scores_gemma":[0.9916451,0.0008152924,0.0052519073,0.0005080328,0.0012763893,0.00050325965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014278875,0.00077126874,0.014599546,0.0008189163,0.0001431024,0.000044466247,0.00030099874,0.00049439125,0.0005019412],"category_scores_gemma":[0.00044535415,0.0004329212,0.005019945,0.0008010416,0.00011163522,0.00015371363,0.000081254824,0.00060252444,0.000014273332],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083789746,0.00034312188,0.000008377404,0.8057314,0.17113613,0.0001157604,0.00017350868,3.134489e-7,0.0000020354921,0.0000024629883,0.010577807,0.0118252905],"study_design_scores_gemma":[0.0005092565,0.0010872044,0.0000023469222,0.06259121,0.8017324,0.00034337206,0.000031087315,0.000005127668,0.000012635851,0.000002752739,0.13339293,0.00028964653],"about_ca_topic_score_codex":0.00004618888,"about_ca_topic_score_gemma":0.00004138528,"teacher_disagreement_score":0.7431402,"about_ca_system_score_codex":0.0014568797,"about_ca_system_score_gemma":0.0024433997,"threshold_uncertainty_score":0.99981225},"labels":[],"label_agreement":null},{"id":"W2798175078","doi":"10.1016/s1556-0864(18)30417-9","title":"143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Beijing Municipal Administration of Hospitals","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Gefitinib; Lung cancer; Brain metastasis; Chemotherapy; Lung; Metastasis; Cancer; Epidermal growth factor receptor","score_opus":0.011749373589137637,"score_gpt":0.4082338298060519,"score_spread":0.39648445621691425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798175078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994355,0.00027047136,0.003516604,0.00030895468,0.00028734162,0.00084490044,0.000017444168,0.000012413652,0.00038682108],"genre_scores_gemma":[0.9871398,0.000009557257,0.012430902,0.0000476091,0.00024152406,0.000031488584,0.000031469324,0.000016391332,0.000051263665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986163,0.00017155669,0.0005804439,0.0001763824,0.00021300827,0.00024235512],"domain_scores_gemma":[0.9979794,0.00030635003,0.0008131251,0.00008824863,0.0006746091,0.0001382544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038553562,0.0001323444,0.00059813104,0.00036475164,0.00013226757,0.000025216423,0.000053305845,0.000092422764,0.0000127513],"category_scores_gemma":[0.00012970694,0.00008086189,0.000083117746,0.0004230659,0.0000665391,0.00014141842,0.000016172358,0.00014133817,6.016207e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090249255,0.00063579617,0.8807804,0.0007379806,0.0022397023,0.0004013287,0.0065895338,0.00025306296,0.0001230263,0.00002561965,0.00007526234,0.09911338],"study_design_scores_gemma":[0.006884404,0.009771381,0.9548962,0.005230475,0.0072852746,0.0012377977,0.00850368,0.0056961067,0.00018999387,0.000005876508,0.00011314343,0.00018566813],"about_ca_topic_score_codex":0.00002479765,"about_ca_topic_score_gemma":0.00009746306,"teacher_disagreement_score":0.098927714,"about_ca_system_score_codex":0.0009826404,"about_ca_system_score_gemma":0.0004188634,"threshold_uncertainty_score":0.32974523},"labels":[],"label_agreement":null},{"id":"W2799769189","doi":"10.1016/j.cllc.2018.04.023","title":"Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non–Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Lung cancer; Paclitaxel; Clinical endpoint; Gastroenterology; Oncology; Cancer; Chemotherapy; Surgery; Randomized controlled trial; Cisplatin","score_opus":0.037175147913758796,"score_gpt":0.4235430040380626,"score_spread":0.3863678561243038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799769189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882997,0.001567246,0.00017032186,0.003167452,0.0012230854,0.0036010027,0.0006950867,0.00016728882,0.0011087671],"genre_scores_gemma":[0.9849749,0.00044002527,0.0019312892,0.0021344577,0.00044214743,0.0011405018,0.00024201407,0.00016138602,0.008533237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99411285,0.0005285372,0.002154446,0.0013991012,0.0007968841,0.0010081579],"domain_scores_gemma":[0.99445605,0.0022633255,0.00087494816,0.0010831874,0.000714743,0.0006077281],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012106787,0.0007505388,0.0016170499,0.00022542216,0.00030808084,0.000076772725,0.00031483884,0.0004815598,0.0010433438],"category_scores_gemma":[0.0013349805,0.0005317819,0.00029746047,0.00091979734,0.00036843683,0.00030979546,0.00011806617,0.00086840906,0.000019064431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022011232,0.0016072802,0.959945,0.0004165802,0.0008284638,0.0000369924,0.001244007,0.00014913917,0.00024145549,0.0000075750354,0.004838886,0.008673359],"study_design_scores_gemma":[0.03068243,0.0032431458,0.9590839,0.0015803365,0.0010635651,0.0000011670086,0.0003136477,0.0011983007,0.00028564266,0.000011248949,0.0017798563,0.0007567389],"about_ca_topic_score_codex":0.001831467,"about_ca_topic_score_gemma":0.00983206,"teacher_disagreement_score":0.008671197,"about_ca_system_score_codex":0.0012927806,"about_ca_system_score_gemma":0.0017067932,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2799848443","doi":"10.1016/s1470-2045(18)30096-2","title":"Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Radiation oncology; Guideline; Radiation therapy; Medicine; Precision oncology; Medical physics; Oncology; Internal medicine; Cancer; Pathology","score_opus":0.047103449275449474,"score_gpt":0.4542423468226427,"score_spread":0.40713889754719323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799848443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005135635,0.98765707,0.0037701614,0.0047961245,0.0002053973,0.0025352044,0.000081197395,0.000041902793,0.00039937856],"genre_scores_gemma":[0.000079778736,0.97977996,0.011985862,0.0057178787,0.0008189806,0.00076027086,0.0005915629,0.00006910395,0.00019658118],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983053,0.00035580664,0.0005016454,0.000365206,0.00013967726,0.00033234555],"domain_scores_gemma":[0.9978944,0.0006569583,0.0008386221,0.0004219043,0.00012860111,0.000059478225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010769765,0.00028910392,0.0016541688,0.00003644226,0.0002780499,0.000021588236,0.00020740664,0.00016944895,0.000016875678],"category_scores_gemma":[0.00006319069,0.0001355018,0.00028255588,0.00019187228,0.00043779894,0.000029977838,0.000044704655,0.00031328475,0.0000026464734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023243629,0.00009081671,0.000010446588,0.00045217067,0.001795945,0.000005081887,0.0007126683,0.0000033537435,0.000026102814,0.000054569045,0.12527126,0.87134516],"study_design_scores_gemma":[0.0032296567,0.0029101942,0.000014500746,0.0005166915,0.0026001905,0.0001412621,0.00019832402,0.00025331663,0.000002353692,0.00003559818,0.98995525,0.00014268412],"about_ca_topic_score_codex":0.00007351188,"about_ca_topic_score_gemma":0.00000635379,"teacher_disagreement_score":0.87120247,"about_ca_system_score_codex":0.00087407103,"about_ca_system_score_gemma":0.0008073478,"threshold_uncertainty_score":0.5525603},"labels":[],"label_agreement":null},{"id":"W2800017367","doi":"10.1016/j.jtho.2018.03.007","title":"Anticipating the Next Step in the Management of ALK-Positive NSCLC","year":2018,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.04491257495077399,"score_gpt":0.4625493609170052,"score_spread":0.4176367859662312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800017367","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027366534,0.0015292588,0.00027067878,0.9242097,0.0012298515,0.0009142376,0.000018127694,0.0000042578827,0.044457365],"genre_scores_gemma":[0.26349917,0.00097222126,0.011247178,0.7105251,0.009182809,0.00008595048,0.00006964655,0.000079386446,0.004338511],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819076,0.00038737277,0.00065785786,0.00012771857,0.0004103397,0.00022596409],"domain_scores_gemma":[0.9979982,0.00039749034,0.0010439978,0.0002717762,0.00026115627,0.000027384713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084458885,0.0001612692,0.0005639069,0.00017816607,0.00007141362,0.000018232253,0.0003018343,0.00024940065,0.000078881174],"category_scores_gemma":[0.000023451026,0.00007593536,0.0002052275,0.00020409081,0.00016515875,0.000060824972,0.000049519924,0.0011244467,0.000009042648],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055573304,0.0004247558,0.0004265207,0.0005088536,0.002712084,0.007318657,0.0056308415,0.0000051601373,0.000029985024,0.000036379326,0.75219554,0.23015548],"study_design_scores_gemma":[0.001450909,0.0033985872,0.009878552,0.0022965518,0.006263416,0.0017714388,0.0051414706,0.000031338375,0.00006019401,0.00022415548,0.9693567,0.00012665038],"about_ca_topic_score_codex":0.000037483424,"about_ca_topic_score_gemma":0.000014685933,"teacher_disagreement_score":0.23613265,"about_ca_system_score_codex":0.0003663853,"about_ca_system_score_gemma":0.00031870062,"threshold_uncertainty_score":0.4885224},"labels":[],"label_agreement":null},{"id":"W2800450935","doi":"10.14740/wjon1090e","title":"Synchronous Presence of <i>EGFR</i>, <i>ALK</i> Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature","year":2018,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Adenocarcinoma; Mutation; Cancer research; Stage (stratigraphy); Cancer; Immune system; Oncology; Gene; Internal medicine; Immunology; Genetics; Biology","score_opus":0.008800247604499642,"score_gpt":0.3356210569189912,"score_spread":0.32682080931449153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800450935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732192,0.022511484,0.000091031834,0.0006165491,0.00010003027,0.00063757534,0.00004129483,0.0000039283136,0.002778888],"genre_scores_gemma":[0.9900937,0.004698014,0.0038612888,0.00021651063,0.00010793778,0.000025952828,0.000010462713,0.000015428273,0.00097069226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986147,0.00010512494,0.000725492,0.00017829574,0.000207245,0.00016911743],"domain_scores_gemma":[0.9976261,0.000160948,0.0010294691,0.00021047598,0.00084288913,0.00013006893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028271117,0.00013280539,0.000586969,0.00027896967,0.000049968236,0.0000075818625,0.000068193396,0.00006759551,0.00007326692],"category_scores_gemma":[0.000084013736,0.00009132726,0.00006581041,0.0005487494,0.00017752979,0.00014924334,0.000033138553,0.00030261197,2.0157066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058591184,0.003373699,0.53928727,0.022904325,0.0015216159,0.30947,0.03678783,0.00016801312,0.05168332,0.00007546677,0.014211786,0.014657551],"study_design_scores_gemma":[0.043201048,0.024639424,0.35958174,0.30407804,0.006202262,0.19140142,0.0018427584,0.00042436362,0.030648869,0.00007713397,0.03701443,0.0008884983],"about_ca_topic_score_codex":0.00092389056,"about_ca_topic_score_gemma":0.0019309121,"teacher_disagreement_score":0.2811737,"about_ca_system_score_codex":0.0002636186,"about_ca_system_score_gemma":0.0012748507,"threshold_uncertainty_score":0.37242174},"labels":[],"label_agreement":null},{"id":"W2800655067","doi":"10.1016/j.jtho.2018.04.020","title":"Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Osimertinib; Afatinib; Medicine; T790M; Oncology; Internal medicine; Epidermal growth factor receptor; Erlotinib; Receptor; Gefitinib","score_opus":0.027782159604277618,"score_gpt":0.4703620014734104,"score_spread":0.4425798418691328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800655067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96410745,0.0008267161,0.00023036789,0.008574284,0.0010470984,0.00030434868,0.000008964986,0.000020956639,0.024879793],"genre_scores_gemma":[0.9916669,0.000063286745,0.0052525997,0.0010599059,0.0006754479,0.0000101216665,0.000008087218,0.000023326776,0.0012402855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983334,0.00015533883,0.00078038906,0.00016915066,0.00026237598,0.00029937818],"domain_scores_gemma":[0.998451,0.00014914795,0.00053869036,0.00018949597,0.0004626909,0.0002089966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052148214,0.00015231535,0.00056673255,0.0003512822,0.000071494265,0.000014042436,0.00012522566,0.00015815646,0.000602556],"category_scores_gemma":[0.00023917288,0.00011133013,0.0001397837,0.00037862823,0.00015772779,0.00012932149,0.000028743394,0.00034147303,0.00007769934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028302548,0.005905294,0.04373429,0.00027428655,0.0021672654,0.009311046,0.013419757,0.00006307712,0.059260376,0.00037314912,0.037885386,0.79930353],"study_design_scores_gemma":[0.021918101,0.039609123,0.46404475,0.0021621247,0.004202012,0.006712233,0.0061510545,0.0005892826,0.035365175,0.0024921533,0.41592866,0.0008253377],"about_ca_topic_score_codex":0.00007250452,"about_ca_topic_score_gemma":0.00014985207,"teacher_disagreement_score":0.7984782,"about_ca_system_score_codex":0.0006766883,"about_ca_system_score_gemma":0.0010624044,"threshold_uncertainty_score":0.65975654},"labels":[],"label_agreement":null},{"id":"W2802092885","doi":"10.4067/s0034-98872018000200266","title":"Interpretando un caso atípico: el tiempo de evolución determina el diagnóstico e impacta en el pronóstico de los linfomas no Hodgkin","year":2018,"lang":"es","type":"letter","venue":"Revista médica de Chile","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Humanities; Philosophy","score_opus":0.007306574311739134,"score_gpt":0.33562750242936706,"score_spread":0.3283209281176279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802092885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65147036,0.09705681,0.019510074,0.093106546,0.0068138405,0.021839345,0.014356519,0.0019864293,0.09386005],"genre_scores_gemma":[0.8827496,0.009269813,0.0049849288,0.062898204,0.021931177,0.0014455365,0.0028215467,0.00089207094,0.013007132],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932717,0.00075003516,0.001421585,0.0014269282,0.00088959065,0.0022401363],"domain_scores_gemma":[0.994252,0.0011964747,0.00092234265,0.0019929076,0.0004417152,0.0011945254],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00084190955,0.0014484675,0.0020368511,0.0004676609,0.00052179187,0.0005248489,0.0010010331,0.0014524803,0.002560574],"category_scores_gemma":[0.0025993704,0.0012498674,0.0008718463,0.00042606276,0.000642008,0.00025706465,0.00035516612,0.0021828576,0.0011266137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009051111,0.0019373869,0.14824471,0.008835859,0.0062964563,0.0066689267,0.00800435,0.0000053407275,0.0023234817,0.00060000725,0.7825354,0.03364302],"study_design_scores_gemma":[0.00593394,0.0023128174,0.037368596,0.01173344,0.010264092,0.0019229478,0.00014349754,0.001581593,0.00058974104,0.00034750925,0.9259415,0.0018603017],"about_ca_topic_score_codex":0.0006846144,"about_ca_topic_score_gemma":0.000025702187,"teacher_disagreement_score":0.23127921,"about_ca_system_score_codex":0.004242896,"about_ca_system_score_gemma":0.004046398,"threshold_uncertainty_score":0.99984384},"labels":[],"label_agreement":null},{"id":"W2802172791","doi":"10.1200/jco.2017.77.2293","title":"Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Quality of life (healthcare); Internal medicine; Odds ratio; Hazard ratio; Cancer; Clinical trial; Performance status; Confidence interval; Chemotherapy; Oncology","score_opus":0.05406334905879762,"score_gpt":0.4881889375538155,"score_spread":0.43412558849501787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802172791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556524,0.0006382439,0.000013449304,0.001263839,0.00068434374,0.00076798326,0.00000420891,0.0000032034097,0.0010595056],"genre_scores_gemma":[0.9974751,0.001151276,0.00053631986,0.00023029567,0.00047183788,0.000027777869,0.0000016794312,0.000013632875,0.00009206794],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99814814,0.00011404333,0.0012742304,0.00014728171,0.00014913313,0.00016716952],"domain_scores_gemma":[0.9970727,0.0007654733,0.0015437532,0.00016297931,0.0002881421,0.0001669538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038202864,0.00013476166,0.00091502664,0.00006974386,0.00003461828,0.0000045748784,0.0000535362,0.00013028279,0.00007611978],"category_scores_gemma":[0.00015408082,0.00006114637,0.0002509691,0.00013798359,0.00020821011,0.000052784402,0.000010208394,0.00021634686,4.6873208e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32188272,0.0031988325,0.29822743,0.000012823135,0.0031810305,0.00012973403,0.0016334096,0.00006401155,0.00028623288,0.0000022865945,0.00024189024,0.3711396],"study_design_scores_gemma":[0.42848986,0.29489827,0.2677865,0.00016605188,0.0023818132,0.00007531689,0.00034215333,0.00029568127,0.00046033424,0.00001069447,0.004990033,0.00010326698],"about_ca_topic_score_codex":0.00040637146,"about_ca_topic_score_gemma":0.00025617413,"teacher_disagreement_score":0.37103632,"about_ca_system_score_codex":0.00053209736,"about_ca_system_score_gemma":0.003334991,"threshold_uncertainty_score":0.59161305},"labels":[],"label_agreement":null},{"id":"W2802528661","doi":"10.4212/cjhp.v51i2.1922","title":"Vinorelbine in advanced non-small-cell lung cancer: Has a survival benefit been achieved in clinical practice?","year":2018,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vinorelbine; Medicine; Gynecology; Cisplatin; Lung cancer; Regimen; Oncology; Cancer; Internal medicine; Chemotherapy; Surgery","score_opus":0.028784378919448666,"score_gpt":0.38706058870283594,"score_spread":0.35827620978338726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802528661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641921,0.0027165345,0.000011230581,0.027726226,0.001593602,0.0005912276,0.000028806438,0.0000045411502,0.0031357226],"genre_scores_gemma":[0.9964872,0.0004263763,0.0005182057,0.0012868362,0.0008731205,0.000018921502,0.0000066432167,0.000030820618,0.00035189057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998341,0.00008332943,0.000737058,0.00018603963,0.00022871455,0.00042384936],"domain_scores_gemma":[0.99824935,0.00017496296,0.0003789254,0.00020220006,0.00040240708,0.0005921819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007089047,0.00017645983,0.0004017318,0.00022577842,0.00016555595,0.000057595124,0.00025557983,0.000052474657,0.00018052234],"category_scores_gemma":[0.00021102147,0.00012723864,0.00013811245,0.00036571722,0.00019079483,0.00029347165,0.000020342117,0.0006509339,0.0000132252635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007239051,0.0005116713,0.96919245,0.000035815432,0.00039270037,0.001348784,0.005391916,0.00016259709,0.00011017473,0.00005484174,0.0029512427,0.019123934],"study_design_scores_gemma":[0.023736509,0.0024266962,0.9268503,0.0005529699,0.0010729512,0.00013830968,0.0013428113,0.00065373123,0.0005046865,0.00014589504,0.04222118,0.00035392935],"about_ca_topic_score_codex":0.072673626,"about_ca_topic_score_gemma":0.25234696,"teacher_disagreement_score":0.17967333,"about_ca_system_score_codex":0.00079995143,"about_ca_system_score_gemma":0.0043088333,"threshold_uncertainty_score":0.93350154},"labels":[],"label_agreement":null},{"id":"W2803026631","doi":"10.3747/co.25.4044","title":"Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Canada's Michael Smith Genome Sciences Centre; McGill University Health Centre; BC Cancer Foundation; University Health Network; Toronto General Hospital; University of Toronto; William Osler Health System; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital","funders":"Universitair Medisch Centrum Groningen; Université de Montréal; University of Alberta; AstraZeneca Canada; McGill University Health Centre; McGill University; Alberta Health Services; AstraZeneca","keywords":"Medicine; Osimertinib; T790M; Lung cancer; Oncology; Epidermal growth factor receptor; Internal medicine; Genetic testing; Cancer; Personalized medicine; Intensive care medicine; Bioinformatics; Erlotinib; Gefitinib","score_opus":0.31245684941358626,"score_gpt":0.5412194137319866,"score_spread":0.2287625643184003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803026631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650863,0.016757904,0.0001329256,0.011034427,0.0026402157,0.0015883541,0.000055726807,0.000018000566,0.0026861657],"genre_scores_gemma":[0.9972232,0.00021772385,0.00085600227,0.0004474701,0.0004219669,0.00066669995,0.000017030176,0.000011506906,0.00013842892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914354,0.000043658405,0.00022910898,0.000223281,0.000103274506,0.0002571108],"domain_scores_gemma":[0.99863493,0.00077486224,0.00020717633,0.00010897684,0.00019913455,0.00007489817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014647294,0.000092821785,0.00021771745,0.00009443912,0.00004737397,0.000006120107,0.000056577133,0.000041200972,0.00011290783],"category_scores_gemma":[0.0011262809,0.000079260135,0.000019042822,0.00025522237,0.000042278,0.00009698537,0.000013460697,0.00012883844,0.0000028442125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014325841,0.00025453203,0.77717906,0.00020477819,0.000021453514,0.000024704224,0.00024724027,0.000063263076,0.00009621397,0.00001616325,0.002345373,0.21940397],"study_design_scores_gemma":[0.013764835,0.002776956,0.5462589,0.0070345537,0.0009656128,0.000025311658,0.0013824712,0.050435044,0.0007551544,0.00006440282,0.37609404,0.00044270544],"about_ca_topic_score_codex":0.7604033,"about_ca_topic_score_gemma":0.9727554,"teacher_disagreement_score":0.37374866,"about_ca_system_score_codex":0.004047492,"about_ca_system_score_gemma":0.01114717,"threshold_uncertainty_score":0.99977577},"labels":[],"label_agreement":null},{"id":"W2803149877","doi":"10.6004/jnccn.2018.0046","title":"Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"Ariad Pharmaceuticals","keywords":"Medicine; Alectinib; Osimertinib; ROS1; Targeted therapy; Lung cancer; Oncology; Anaplastic lymphoma kinase; Erlotinib; Ceritinib; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer research; Cancer; Epidermal growth factor receptor; Adenocarcinoma; Receptor","score_opus":0.02476331531661414,"score_gpt":0.3389768553128095,"score_spread":0.3142135399961954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803149877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97725946,0.012417741,0.0013082671,0.003474671,0.0026327912,0.0021424235,0.00017795901,0.000012683421,0.0005740236],"genre_scores_gemma":[0.98588526,0.00039586314,0.0048638317,0.0054690177,0.002530725,0.00013469314,0.000017389742,0.000036662692,0.00066655065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879754,0.000038813152,0.00031333955,0.0001381478,0.00050159515,0.00021055472],"domain_scores_gemma":[0.9944966,0.00016559972,0.0005269432,0.00009240612,0.0046259128,0.00009256302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006772033,0.00015900501,0.0002973032,0.000064079584,0.00023187952,0.000020837258,0.00013880103,0.000033038898,0.00011661269],"category_scores_gemma":[0.000020221474,0.00008650443,0.00017287735,0.000291925,0.00007909519,0.00008378065,0.00001792252,0.00014947992,0.0000010137206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009398272,0.0012992563,0.4596473,0.00028470054,0.008186454,0.000007090228,0.002007841,0.050492764,0.0010829332,0.00017236319,0.4596155,0.0078055165],"study_design_scores_gemma":[0.025895322,0.002665597,0.8487164,0.0010276882,0.0022749137,0.00002018915,0.00011838796,0.0026258398,0.0014255864,0.0007602162,0.114122055,0.0003478474],"about_ca_topic_score_codex":0.000028478307,"about_ca_topic_score_gemma":0.00003139872,"teacher_disagreement_score":0.38906905,"about_ca_system_score_codex":0.00043366363,"about_ca_system_score_gemma":0.00091385667,"threshold_uncertainty_score":0.3527548},"labels":[],"label_agreement":null},{"id":"W2803880880","doi":"10.1016/j.jtho.2018.02.013","title":"Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Inclusion and exclusion criteria; Medical physics; Intensive care medicine; Standard of care; Inclusion (mineral); Outcome (game theory); Clinical Practice; Family medicine; Alternative medicine; Oncology; Surgery; Internal medicine; Pathology","score_opus":0.21930128236929497,"score_gpt":0.709621805487233,"score_spread":0.490320523117938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803880880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7856091,0.002688938,0.030174457,0.1621221,0.013350193,0.002095666,0.00020039458,0.000043286713,0.0037158453],"genre_scores_gemma":[0.95002836,0.000331392,0.040860087,0.0030743708,0.005184877,0.00006659699,0.000016457963,0.000021091035,0.00041675312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975222,0.0005157318,0.0014387562,0.0001810788,0.00014142148,0.00020084211],"domain_scores_gemma":[0.99631196,0.0012926995,0.0012271067,0.00016616801,0.00085080037,0.00015123707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048454464,0.00011479633,0.00090125564,0.00016233369,0.00021475961,0.000021822254,0.00010112003,0.00016478455,0.00061114907],"category_scores_gemma":[0.0026885576,0.000081375314,0.00036164073,0.0001341574,0.00012860761,0.00014907565,0.000047935184,0.00023991418,0.000002422576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061869496,0.00093575346,0.026336705,0.00018312337,0.001742456,0.000059264523,0.0034890645,0.0000035242033,0.0017781224,0.0000953214,0.15188628,0.8073034],"study_design_scores_gemma":[0.01189186,0.009541788,0.040707536,0.0019224967,0.01201712,0.0008584617,0.0042680087,0.0018144706,0.0030996995,0.0032740005,0.9102039,0.0004006804],"about_ca_topic_score_codex":0.000014696256,"about_ca_topic_score_gemma":0.00003204765,"teacher_disagreement_score":0.80690277,"about_ca_system_score_codex":0.00087545783,"about_ca_system_score_gemma":0.0012727171,"threshold_uncertainty_score":0.6691654},"labels":[],"label_agreement":null},{"id":"W2804624504","doi":"10.1097/sla.0000000000002829","title":"Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations","year":2018,"lang":"en","type":"article","venue":"Annals of Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; KRAS; Metastasectomy; Hazard ratio; Colorectal cancer; Internal medicine; Confidence interval; Wedge resection; Gastroenterology; Oncology; Lung; Metastasis; Multivariate analysis; Cancer; Surgery; Resection","score_opus":0.12127788373507084,"score_gpt":0.42412916764023395,"score_spread":0.30285128390516314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804624504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504304,0.00071425666,0.000098135475,0.00074089324,0.0013100419,0.00023830832,0.00021101815,0.00003422054,0.0016100892],"genre_scores_gemma":[0.9990692,0.00010445818,0.00023797569,0.0000787135,0.00021905215,0.000071290284,0.000056709927,0.000022408742,0.00014020175],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988304,0.000045296845,0.00040561458,0.00020661158,0.00026607173,0.000246026],"domain_scores_gemma":[0.9987388,0.00037097855,0.00016944794,0.000170851,0.0004318963,0.00011797349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030489964,0.00012116066,0.00043724294,0.00025291517,0.000111337235,0.000008827211,0.00004311155,0.000057480407,0.00013099788],"category_scores_gemma":[0.00022144735,0.000107884516,0.0003426573,0.0004754767,0.00014221412,0.0001528853,0.000022810573,0.00008839715,0.0000025300535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007996004,0.0011435836,0.8268687,0.00040700397,0.006811697,0.000093376286,0.001791423,0.000036788224,0.13938016,0.0010739146,0.011958392,0.009635366],"study_design_scores_gemma":[0.001616518,0.0003329348,0.4262669,0.0005531735,0.0015906239,0.0000070465853,0.0006999651,0.00054176105,0.564476,0.00024200701,0.003350665,0.00032238266],"about_ca_topic_score_codex":0.0015580864,"about_ca_topic_score_gemma":0.00019808798,"teacher_disagreement_score":0.4250959,"about_ca_system_score_codex":0.0000507948,"about_ca_system_score_gemma":0.0004956218,"threshold_uncertainty_score":0.4399403},"labels":[],"label_agreement":null},{"id":"W2807507270","doi":"10.21873/anticanres.12647","title":"Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Anticancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Vinorelbine; Medicine; Chemotherapy; Lung cancer; Oncology; Internal medicine; Cancer; Lung; Cisplatin","score_opus":0.03602313023833626,"score_gpt":0.4468200532946564,"score_spread":0.41079692305632015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807507270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215496,0.00053681445,0.00023698829,0.0013041665,0.00022051565,0.0023024448,0.000052666473,0.000021046953,0.0031704088],"genre_scores_gemma":[0.99301106,0.0004046639,0.0021664791,0.00037669757,0.000286979,0.0009521416,0.000051677813,0.000045937475,0.0027043703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982739,0.0000352099,0.00025259255,0.00044730763,0.00031708795,0.00067387737],"domain_scores_gemma":[0.99877715,0.00010833395,0.000049565864,0.00030686872,0.00060525857,0.00015282606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002954916,0.00015794365,0.00030728738,0.00028931338,0.00015263907,0.000029706896,0.00015014134,0.00007266947,0.0004007605],"category_scores_gemma":[0.000044206685,0.00013174566,0.00007637859,0.0005318861,0.00016919555,0.00010382617,0.000044450295,0.00020615695,0.000034864766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018276533,0.0012418587,0.9139265,0.00034559832,0.0002584429,0.0000061759665,0.0015665469,0.000018163708,0.005167505,0.00016028866,0.007937815,0.06754345],"study_design_scores_gemma":[0.037736084,0.0043447665,0.8430263,0.0005869959,0.00025116213,9.625313e-7,0.00046355557,0.0058416505,0.062392134,0.00036399608,0.0444858,0.00050662685],"about_ca_topic_score_codex":0.002228631,"about_ca_topic_score_gemma":0.0012762144,"teacher_disagreement_score":0.07090024,"about_ca_system_score_codex":0.0009420382,"about_ca_system_score_gemma":0.000710993,"threshold_uncertainty_score":0.53724325},"labels":[],"label_agreement":null},{"id":"W2807807160","doi":"10.3747/co.25.3839","title":"Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Crizotinib; Medicine; ROS1; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; T790M; Osimertinib; Alectinib; Cancer research; Cancer; Algorithm; Adenocarcinoma; Computer science","score_opus":0.17969691010666217,"score_gpt":0.511181054286443,"score_spread":0.33148414417978084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807807160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018612045,0.9823872,0.0029491603,0.00011027193,0.0045520407,0.008166466,0.0007580683,0.000070170805,0.0009880271],"genre_scores_gemma":[0.0000039440806,0.97527224,0.0034665717,0.000061527164,0.001965994,0.013603539,0.0016419108,0.00012786446,0.0038563923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749047,0.000105707455,0.00072155724,0.0007715576,0.0001536095,0.0007571153],"domain_scores_gemma":[0.9981663,0.00031131366,0.000556336,0.0004562698,0.00022872249,0.0002810077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018513447,0.00068958994,0.0026121181,0.00050565624,0.00021406251,0.000023408342,0.0001604579,0.0002505604,0.00019710565],"category_scores_gemma":[0.000023426615,0.0004760113,0.0009458502,0.0003706158,0.00008949253,0.000037462425,0.00005843038,0.00022900348,0.000083211286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025612848,0.0013133811,0.000015670787,0.020966182,0.00171787,0.00004129897,0.0007969639,6.1345816e-7,2.4096192e-7,0.000012667829,0.0057817143,0.9693278],"study_design_scores_gemma":[0.0046198275,0.0019274252,0.000001407472,0.0062142485,0.033543926,0.00007803019,0.00009350253,0.00033277477,0.0000047540084,0.000005949629,0.9528166,0.00036153733],"about_ca_topic_score_codex":0.000051342227,"about_ca_topic_score_gemma":0.000051034956,"teacher_disagreement_score":0.96896625,"about_ca_system_score_codex":0.0035085764,"about_ca_system_score_gemma":0.0037017984,"threshold_uncertainty_score":0.99976915},"labels":[],"label_agreement":null},{"id":"W2807828246","doi":"10.3747/co.25.3732","title":"Irreversible Tyrosine Kinase Inhibition of Epidermal Growth Factor Receptor with Afatinib in Egfr Activating Mutation–Positive Advanced Non-Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Epidermal growth factor receptor; Lung cancer; Tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Oncology; Erlotinib; Cancer; T790M; Internal medicine; Gefitinib; Receptor","score_opus":0.06858136331976289,"score_gpt":0.4347578323860398,"score_spread":0.36617646906627693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807828246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026654122,0.96621865,0.0003888868,0.00013240437,0.0010253964,0.0036996054,0.0006304394,0.000036505593,0.0012140003],"genre_scores_gemma":[0.0051921876,0.98753756,0.0028305145,0.000044644577,0.00046424964,0.0013802497,0.0022213813,0.000091783884,0.00023742783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783486,0.00018312939,0.0007941094,0.00059098884,0.00021031858,0.0003866148],"domain_scores_gemma":[0.99775565,0.0003292617,0.0010546606,0.0002218206,0.0004906248,0.00014801185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011375315,0.0004625798,0.0016599027,0.0004104369,0.0000872836,0.00000969358,0.00008968,0.00028049154,0.00022147434],"category_scores_gemma":[0.0000912085,0.0003562668,0.00021745339,0.00065224635,0.00013872216,0.00016265313,0.000055297474,0.0004947669,0.000014564658],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030984572,0.0018314266,0.0025931865,0.034649115,0.00054897176,0.000083172265,0.002565999,0.000008184463,0.00011934412,0.000029882915,0.0011539216,0.95610696],"study_design_scores_gemma":[0.02925412,0.0071411366,0.0038717464,0.21331716,0.011035312,0.00015044876,0.0013703266,0.0001563368,0.005855534,0.000023748487,0.72581375,0.0020103892],"about_ca_topic_score_codex":0.00014389622,"about_ca_topic_score_gemma":0.00011077764,"teacher_disagreement_score":0.95409656,"about_ca_system_score_codex":0.0022318533,"about_ca_system_score_gemma":0.0024686344,"threshold_uncertainty_score":0.99988896},"labels":[],"label_agreement":null},{"id":"W2808031111","doi":"10.3747/co.25.3792","title":"Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Ramucirumab; Lung cancer; Immunotherapy; Chemotherapy; Oncology; Targeted therapy; Internal medicine; Population; Cancer","score_opus":0.2665329888410611,"score_gpt":0.5374016390633534,"score_spread":0.2708686502222923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808031111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027474614,0.9832682,0.0033026221,0.00011759258,0.0023005141,0.010154117,0.000763879,0.00003256168,0.00003304987],"genre_scores_gemma":[0.0000044426965,0.97848034,0.007663695,0.00006852962,0.0006680716,0.011934271,0.00056216295,0.00007976686,0.00053870975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766016,0.0002078663,0.00086535036,0.00063030276,0.00020746286,0.0004288751],"domain_scores_gemma":[0.9959909,0.0018460421,0.000863495,0.00073329906,0.0003653361,0.00020093884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020618334,0.0005781354,0.0025385574,0.00017028426,0.0001653284,0.000014290994,0.00026217612,0.00017120241,0.00023463932],"category_scores_gemma":[0.000060802424,0.00028796835,0.0008176724,0.00034091083,0.00016446527,0.00006836915,0.000023661172,0.00015292827,0.000010720392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121683996,0.0027132938,0.000010773997,0.026308501,0.0008769498,0.000016639184,0.0003461733,0.0000061671626,2.2643583e-7,0.0000037320187,0.0007300241,0.9688658],"study_design_scores_gemma":[0.0049144,0.0105624655,0.0000068686104,0.014584158,0.038389105,0.00002103679,0.00008709085,0.0014335976,0.000009577336,0.000004093926,0.9297446,0.00024303235],"about_ca_topic_score_codex":0.0001044871,"about_ca_topic_score_gemma":0.0002166614,"teacher_disagreement_score":0.9686228,"about_ca_system_score_codex":0.00208047,"about_ca_system_score_gemma":0.006307721,"threshold_uncertainty_score":0.99995726},"labels":[],"label_agreement":null},{"id":"W2808333976","doi":"10.1001/jamaoncol.2018.0775","title":"Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Oncology; Internal medicine; Lung cancer; Gefitinib; Basal cell; Carcinoma; ErbB; Epidermal growth factor receptor; Cancer","score_opus":0.015937738691310308,"score_gpt":0.3583568929958549,"score_spread":0.34241915430454456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808333976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722863,0.000015306787,0.00005997767,0.000864293,0.00015616007,0.00086802343,0.000119839024,0.000030148272,0.010657592],"genre_scores_gemma":[0.99317497,0.000003102651,0.003302239,0.00044292214,0.00009352096,0.0000439254,0.00020806675,0.00002664396,0.0027045927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985223,0.0001295501,0.0005896013,0.00024880876,0.00029123123,0.00021855095],"domain_scores_gemma":[0.9971304,0.0007498606,0.0007366261,0.00024534707,0.0010305145,0.00010728734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017894969,0.00015529181,0.00061097683,0.00010455301,0.00006716441,0.000005461965,0.00006761937,0.0002000631,0.00018793624],"category_scores_gemma":[0.00029294577,0.00009214702,0.00008414437,0.00029517457,0.00020078699,0.00008317002,0.000019985759,0.0001443469,0.000011190565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018286767,0.0021262502,0.98992604,0.000061371946,0.000395127,0.0000175142,0.001246719,0.000004064389,0.000032473843,0.000020947535,0.0024102498,0.0019305603],"study_design_scores_gemma":[0.018597769,0.011923151,0.9645764,0.000029023166,0.0016983756,0.0000047748854,0.00035050846,0.00003526133,0.0008175279,0.000005263507,0.0018652932,0.00009664866],"about_ca_topic_score_codex":0.0003720424,"about_ca_topic_score_gemma":0.0007850256,"teacher_disagreement_score":0.025349641,"about_ca_system_score_codex":0.00032250426,"about_ca_system_score_gemma":0.0007398013,"threshold_uncertainty_score":0.37576464},"labels":[],"label_agreement":null},{"id":"W2808336072","doi":"10.3747/co.25.4099","title":"The Changing Landscape of Thoracic Malignancies","year":2018,"lang":"en","type":"editorial","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Bioinformatics; Cancer","score_opus":0.04235476898283684,"score_gpt":0.4586933964364802,"score_spread":0.41633862745364336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808336072","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013443645,0.018547408,0.000036205485,0.00034134128,0.9724643,0.00041480002,0.00013998096,0.000032170487,0.0066793896],"genre_scores_gemma":[0.0023886715,0.00514268,0.00008913386,0.000016739978,0.9863104,0.00018707276,0.00078906305,0.000037837308,0.005038352],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988911,0.000053850472,0.00026915708,0.00021438384,0.00029326294,0.00027822846],"domain_scores_gemma":[0.99842346,0.00049027224,0.0002683768,0.00029217772,0.00046532394,0.00006041192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002495179,0.00016187978,0.00041774905,0.00012659546,0.00015322604,0.000010689834,0.00012773124,0.00029956974,0.00007482687],"category_scores_gemma":[0.00034503415,0.000095358504,0.00012346152,0.00016007521,0.00018049753,0.000018729688,0.00006878143,0.00030838887,0.000044268283],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010846768,0.000133576,0.00022318176,0.00025736785,0.00018032215,0.0000069830744,0.0007477918,8.5760014e-8,0.0000051967377,0.000040259703,0.93407243,0.06422431],"study_design_scores_gemma":[0.00054258894,0.00063526304,0.00007744781,0.00039961986,0.0007704904,0.0000048392067,0.0003239332,0.00000815283,0.00005334281,0.00006240287,0.9970433,0.000078588855],"about_ca_topic_score_codex":0.0000058026226,"about_ca_topic_score_gemma":0.000022284605,"teacher_disagreement_score":0.06414572,"about_ca_system_score_codex":0.00021838045,"about_ca_system_score_gemma":0.0011914382,"threshold_uncertainty_score":0.3888607},"labels":[],"label_agreement":null},{"id":"W2808406755","doi":"10.1021/acs.molpharmaceut.8b00307","title":"Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"University at Buffalo; State University of New York; Roswell Park Alliance Foundation, Roswell Park Cancer Institute","keywords":"Afatinib; Erlotinib; Epidermal growth factor receptor; Cancer research; Gefitinib; EGFR inhibitors; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Targeted therapy; Pharmacology; Cancer; Lung cancer; Internal medicine; Receptor","score_opus":0.02031108426234213,"score_gpt":0.3625750264718094,"score_spread":0.34226394220946726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808406755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98023933,0.013746466,0.0012922944,0.0023340432,0.00031262933,0.0016887947,0.00028732428,0.000046640325,0.000052454692],"genre_scores_gemma":[0.9961236,0.00023102348,0.001305975,0.0013405805,0.00017147405,0.00048827127,0.000052532672,0.000044162345,0.00024239258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988576,0.000042800326,0.0002827011,0.0002568841,0.00024619664,0.00031382896],"domain_scores_gemma":[0.999005,0.000089911824,0.00011624508,0.00031709624,0.0003284383,0.00014329253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007685692,0.00021910999,0.0002579191,0.00006576407,0.00017778308,0.000018726007,0.00007837617,0.000033277163,0.00009449158],"category_scores_gemma":[0.000019142804,0.00014233432,0.00018014348,0.00022879615,0.00018184085,0.00003105665,0.000013348791,0.000048761452,0.0000044658286],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011554249,0.0012560207,0.002341609,0.00017023763,0.00089729397,0.000085878426,0.0010699772,0.000302955,0.9782181,0.00008009036,0.0015242352,0.012898198],"study_design_scores_gemma":[0.0074487003,0.0006172811,0.0010669593,0.000096861055,0.0027834976,0.000002921382,0.00009979758,0.0176583,0.93581456,0.000008093316,0.03425907,0.0001439633],"about_ca_topic_score_codex":0.0002729529,"about_ca_topic_score_gemma":0.00008467014,"teacher_disagreement_score":0.042403527,"about_ca_system_score_codex":0.00038636004,"about_ca_system_score_gemma":0.00026097885,"threshold_uncertainty_score":0.5804225},"labels":[],"label_agreement":null},{"id":"W2808479470","doi":"10.3747/co.25.3747","title":"Antiangiogenic Therapies in Non-Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Peking University; Peking University People's Hospital; National Natural Science Foundation of China","keywords":"Medicine; Pemetrexed; Docetaxel; Carboplatin; Bevacizumab; Nintedanib; Oncology; Lung cancer; Ramucirumab; Internal medicine; Chemotherapy; Paclitaxel; Erlotinib; Cancer; Epidermal growth factor receptor; Lung; Cisplatin","score_opus":0.11728053000617543,"score_gpt":0.4964554070194235,"score_spread":0.37917487701324804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808479470","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029318867,0.99181247,0.000019092802,0.00010145915,0.002630233,0.0017840662,0.00007293922,0.000029780116,0.003256769],"genre_scores_gemma":[0.00004930651,0.99640214,0.00011548409,0.000053481945,0.00090890186,0.001081323,0.00028470403,0.000053954613,0.0010506837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998531,0.00009569171,0.00047518182,0.00043983365,0.00010200938,0.00035627504],"domain_scores_gemma":[0.9991478,0.00008150196,0.0002639993,0.00031310413,0.000083898485,0.000109702465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105036954,0.0003433637,0.0014744158,0.00030397857,0.000047560014,0.000010091962,0.00014526791,0.00030510515,0.00042018405],"category_scores_gemma":[0.000009822029,0.00024458757,0.00042536185,0.00033519062,0.00008201702,0.000025118405,0.00005581322,0.0003396698,0.00012755801],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009331662,0.0005667031,0.0016476575,0.013206968,0.00051634596,0.000045426823,0.00060677214,8.3671274e-8,2.9869125e-7,0.000008844799,0.010237139,0.9731544],"study_design_scores_gemma":[0.0013682266,0.00021921255,0.0002177763,0.010126803,0.00456218,0.00003012295,0.00003251658,0.000007460101,6.46923e-7,0.0000050109015,0.98322994,0.00020010308],"about_ca_topic_score_codex":0.000074900665,"about_ca_topic_score_gemma":0.00017319756,"teacher_disagreement_score":0.9729928,"about_ca_system_score_codex":0.0011940222,"about_ca_system_score_gemma":0.002118237,"threshold_uncertainty_score":0.99739915},"labels":[],"label_agreement":null},{"id":"W2808586822","doi":"10.3747/co.25.3796","title":"Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Peking University; Peking University People's Hospital; National Natural Science Foundation of China","keywords":"T790M; Medicine; Tyrosine kinase; Epidermal growth factor receptor; Cancer research; Clinical trial; Pharmacology; Receptor; Bioinformatics; Oncology; Internal medicine; Biology; Gefitinib","score_opus":0.3280255419870526,"score_gpt":0.5794213739787181,"score_spread":0.2513958319916655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808586822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009573534,0.9870334,0.000045103236,0.0012220145,0.0071024355,0.0029783172,0.00073411025,0.000064566964,0.00072428],"genre_scores_gemma":[0.000018881377,0.9911249,0.0009766343,0.00019203345,0.0051199957,0.00042128167,0.00072786666,0.00006377785,0.0013546267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951072,0.0013386497,0.0020662867,0.0008576532,0.00021801771,0.00041221216],"domain_scores_gemma":[0.996009,0.001758604,0.00088318094,0.0004311878,0.00028745463,0.0006305699],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014519378,0.0004953334,0.004110663,0.0002455195,0.00011195699,0.000027808594,0.00014124198,0.00056920014,0.00031360026],"category_scores_gemma":[0.004309931,0.0003385936,0.00072206836,0.0002985034,0.00023559254,0.000053937994,0.00013000508,0.0005631857,0.00033323516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012631761,0.0005344852,0.00027636412,0.0050418936,0.00042838912,0.000025049318,0.00006591874,8.803019e-10,3.4524808e-7,0.00009635814,0.17507783,0.81832707],"study_design_scores_gemma":[0.0020674996,0.0011514904,0.000160678,0.010425434,0.0042809844,0.000026316144,0.000009853651,1.3556996e-7,0.0000025247232,0.000020282252,0.9815762,0.00027859656],"about_ca_topic_score_codex":0.000007975982,"about_ca_topic_score_gemma":0.00003291601,"teacher_disagreement_score":0.8180485,"about_ca_system_score_codex":0.00087192806,"about_ca_system_score_gemma":0.0016082869,"threshold_uncertainty_score":0.9999066},"labels":[],"label_agreement":null},{"id":"W2808690324","doi":"10.3747/co.25.3760","title":"ALK Inhibitors, Resistance Development, Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Regional Municipality of Durham; Queen's University","funders":"","keywords":"Medicine; Clinical trial; Bench to bedside; Personalized medicine; Precision medicine; Clinical Practice; Disease; Lung cancer; Intensive care medicine; Bioinformatics; Oncology; Internal medicine; Pathology; Medical physics; Family medicine","score_opus":0.5634958788641582,"score_gpt":0.6555574870456409,"score_spread":0.09206160818148268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808690324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026403973,0.9755061,0.000053267802,0.00014268621,0.008591096,0.0019963118,0.00006075666,0.00007281417,0.013574294],"genre_scores_gemma":[7.7169096e-7,0.98733157,0.0014692176,0.000069676826,0.004323155,0.0005839174,0.0009938788,0.000052491065,0.0051753474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949387,0.0012045202,0.0026118783,0.0006722502,0.00022027286,0.0003524077],"domain_scores_gemma":[0.9965097,0.0012125778,0.0013191772,0.00045861205,0.00020260189,0.00029733343],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027522936,0.00041267267,0.0042150794,0.00019554984,0.00011563687,0.000016630958,0.00016600935,0.00060783135,0.00027109912],"category_scores_gemma":[0.0016930106,0.00027462075,0.00092588394,0.00025058287,0.00020098983,0.00003294438,0.00008824883,0.0006169922,0.00081671943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003307862,0.0005228084,0.0000474994,0.005381716,0.0006914814,0.000027916098,0.000059919235,6.0456135e-10,7.701057e-9,0.000055145145,0.18743311,0.80574733],"study_design_scores_gemma":[0.0016885496,0.00026936756,0.000018480587,0.014255129,0.0057423813,0.00003380056,0.000008627192,6.8725576e-8,3.034959e-7,0.00002381533,0.9777345,0.00022498044],"about_ca_topic_score_codex":9.756363e-7,"about_ca_topic_score_gemma":0.000024695479,"teacher_disagreement_score":0.8055223,"about_ca_system_score_codex":0.001077786,"about_ca_system_score_gemma":0.006592581,"threshold_uncertainty_score":0.9999706},"labels":[],"label_agreement":null},{"id":"W2808971718","doi":"10.1016/j.lungcan.2018.06.023","title":"The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; KRAS; Lung cancer; Internal medicine; Oncology; Univariate analysis; Adenocarcinoma; Stage (stratigraphy); Somatic cell; Mutation; Cancer; Multivariate analysis; Gene; Genetics; Biology; Colorectal cancer","score_opus":0.008431921663189132,"score_gpt":0.3190394140510542,"score_spread":0.31060749238786506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808971718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98017263,0.014885978,0.00002349784,0.00079679623,0.0005276052,0.0023731622,0.00006683143,0.00006092505,0.0010925514],"genre_scores_gemma":[0.99641645,0.00069575955,0.0001218346,0.00006464336,0.00014391827,0.0012882348,0.000025731331,0.000044146665,0.0011993117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986199,0.00008828675,0.00038720854,0.00032094948,0.0002135975,0.00037004534],"domain_scores_gemma":[0.99869317,0.00053840125,0.00019191974,0.0002693438,0.00019365968,0.00011349093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014522362,0.0002195083,0.00035898224,0.00012379372,0.00023876883,0.00003081026,0.00009548523,0.00010102024,0.00012839661],"category_scores_gemma":[0.000110560555,0.00014623077,0.000064806234,0.00050014944,0.00018137475,0.00008106345,0.000037976206,0.00017047592,0.0000029983548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024174564,0.00021539214,0.96772325,0.0011098975,0.00069574383,0.000014151392,0.005558541,0.00029615668,0.018537907,0.000009930826,0.0009610831,0.004636181],"study_design_scores_gemma":[0.018207485,0.0014949229,0.81849194,0.0043286155,0.0054121236,0.000014953446,0.0004524187,0.08669588,0.06344803,0.000050793653,0.00087348354,0.00052935723],"about_ca_topic_score_codex":0.0072044716,"about_ca_topic_score_gemma":0.011822085,"teacher_disagreement_score":0.14923133,"about_ca_system_score_codex":0.0006237705,"about_ca_system_score_gemma":0.00052057503,"threshold_uncertainty_score":0.99940664},"labels":[],"label_agreement":null},{"id":"W2808999647","doi":"10.1126/scitranslmed.aao2301","title":"Afatinib restrains K-RAS–driven lung tumorigenesis","year":2018,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Austrian Science Fund","keywords":"Carcinogenesis; Afatinib; Cancer research; Lung; ErbB; Lung cancer; Signal transduction; Medicine; Biology; Chemistry; Receptor; Internal medicine; Epidermal growth factor receptor; Cell biology; Cancer; Gefitinib","score_opus":0.029341126729886084,"score_gpt":0.3984481030535986,"score_spread":0.36910697632371253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808999647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81557816,0.00068185653,0.006968506,0.044949424,0.0014317043,0.0010167481,0.00003839936,0.00018657254,0.1291486],"genre_scores_gemma":[0.9921202,0.000022555796,0.0050653927,0.00083632,0.0009898781,0.000024561443,0.000031879274,0.000011718284,0.00089749234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982093,0.000013527178,0.00025790892,0.000361028,0.0008624258,0.00029579867],"domain_scores_gemma":[0.9989869,0.00006837797,0.00005593171,0.00023309237,0.00039099282,0.00026470138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030013794,0.00012770691,0.00019009256,0.0002588969,0.00039784328,0.000012665793,0.00014043588,0.000026090318,0.0012641858],"category_scores_gemma":[0.00012705362,0.00008986619,0.000041488267,0.0009869993,0.0017466721,0.00020608725,0.000008341507,0.000079732126,0.00006160402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054194947,0.0007784987,0.5951692,0.00022921237,0.00041752486,0.00016827774,0.026894154,0.00017752471,0.22771652,0.06018673,0.009156606,0.07856385],"study_design_scores_gemma":[0.0034055824,0.0007719812,0.9802418,0.00037121878,0.00033882572,0.00008008696,0.00043695598,0.00364743,0.002806729,0.001629974,0.0060820766,0.0001873676],"about_ca_topic_score_codex":0.00008399634,"about_ca_topic_score_gemma":0.000047405003,"teacher_disagreement_score":0.38507262,"about_ca_system_score_codex":0.00010218125,"about_ca_system_score_gemma":0.00081150065,"threshold_uncertainty_score":0.9996488},"labels":[],"label_agreement":null},{"id":"W2809569991","doi":"10.1007/s12672-018-0336-7","title":"Androgen Receptor and Ki67 Expression and Survival Outcomes in Non-small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Hormones and Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Lung cancer; Medicine; Androgen receptor; Internal medicine; Oncology; Hazard ratio; Adenocarcinoma; Estrogen receptor; Cancer; Prostate cancer; Proportional hazards model; Breast cancer; Confidence interval","score_opus":0.012110471826498506,"score_gpt":0.3119544523035704,"score_spread":0.2998439804770719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809569991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726214,0.024962313,0.000014321848,0.0006903847,0.00019895186,0.0003341772,0.00004650449,0.000013820665,0.0011181377],"genre_scores_gemma":[0.9843021,0.013045285,0.0002166499,0.00023227124,0.00017329324,0.0001554432,0.000008104148,0.000017600467,0.0018492234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993422,0.000011753977,0.00012814037,0.00025323182,0.00008672406,0.00017791986],"domain_scores_gemma":[0.9996758,0.000020427547,0.000042036656,0.00009540765,0.00004418131,0.00012212855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045811725,0.00013539252,0.00024690098,0.00005117671,0.00009311387,0.000023651412,0.000021415153,0.0000629568,0.00011481751],"category_scores_gemma":[0.0000033973017,0.00009503555,0.000019330728,0.00006785171,0.000075014155,0.00007061345,0.000038351118,0.00006241003,0.0000011066184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012585809,0.000057768775,0.9638656,0.00012451799,0.000066642635,0.000005828168,0.0020740926,5.882497e-7,0.012513531,0.000011989447,0.0013217169,0.019831859],"study_design_scores_gemma":[0.005169318,0.00027386824,0.9726741,0.00029955438,0.00031042245,0.0000047008416,0.0007940297,0.00021733891,0.008715709,0.000026821495,0.01127165,0.00024249114],"about_ca_topic_score_codex":0.0022922973,"about_ca_topic_score_gemma":0.0010052405,"teacher_disagreement_score":0.019589368,"about_ca_system_score_codex":0.000056895056,"about_ca_system_score_gemma":0.00006570249,"threshold_uncertainty_score":0.38754374},"labels":[],"label_agreement":null},{"id":"W2809721683","doi":"10.1016/j.jtho.2018.06.016","title":"Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre","funders":"National Institute for Occupational Safety and Health; National Institute of General Medical Sciences; National Institute of Environmental Health Sciences; Canadian Cancer Society Research Institute; National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; Princess Margaret Hospital Foundation; National Human Genome Research Institute; World Health Organization","keywords":"Exome; Allele; Genetics; Medicine; Lung cancer; Genome-wide association study; Gene; Exome sequencing; Single-nucleotide polymorphism; Bioinformatics; Genotype; Biology; Oncology; Mutation","score_opus":0.014577304658999247,"score_gpt":0.43538794440216555,"score_spread":0.4208106397431663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809721683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465007,0.0012171338,0.0007251751,0.0023470053,0.00032169232,0.00027026772,0.000047661953,0.0000029945493,0.00041801165],"genre_scores_gemma":[0.9983962,0.0002573479,0.0007826979,0.00019310552,0.00027260167,0.000006001163,0.0000027951464,0.0000053869057,0.00008384042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917597,0.00014038972,0.00036801005,0.000102317994,0.0000830023,0.00013032749],"domain_scores_gemma":[0.9988481,0.00010229288,0.0003296672,0.00009993604,0.00050695176,0.00011306659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054802094,0.00007467492,0.00039734572,0.00013372373,0.000037532114,0.0000037580203,0.000043537544,0.00008782263,0.00014948193],"category_scores_gemma":[0.00025969007,0.00004862226,0.000052713287,0.00016478499,0.0000839353,0.000067867535,0.000022181428,0.00015662723,0.0000013759053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039259903,0.0006701083,0.7846884,0.00009865215,0.0005279921,0.00007177498,0.004567322,0.000024638486,0.00830017,0.000053193435,0.0021538695,0.19491786],"study_design_scores_gemma":[0.002500595,0.003633783,0.97810626,0.00028369416,0.0006906883,0.00017813384,0.0004991464,0.00023133989,0.005063112,0.0003833998,0.008357764,0.00007210398],"about_ca_topic_score_codex":0.00019569685,"about_ca_topic_score_gemma":0.00086609955,"teacher_disagreement_score":0.19484575,"about_ca_system_score_codex":0.00054193067,"about_ca_system_score_gemma":0.0005045698,"threshold_uncertainty_score":0.19827582},"labels":[],"label_agreement":null},{"id":"W2810356983","doi":"10.1016/j.jval.2018.04.286","title":"Clinical Characteristics, Treatment Patterns, And Health Care Resource Utilization In Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: A Medical Record Review Study In The United States And Canada","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Carboplatin; Lung cancer; Medical record; Internal medicine; Etoposide; Stage (stratigraphy); Cisplatin; Cancer; Retrospective cohort study; Oncology; Chemotherapy","score_opus":0.05425463639825754,"score_gpt":0.41486277107407804,"score_spread":0.3606081346758205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810356983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643235,0.023421967,0.000034257933,0.0082529755,0.00012585182,0.0036672067,0.00013694166,0.00000940078,0.000027854696],"genre_scores_gemma":[0.78881574,0.20154051,0.000080303944,0.008793606,0.00008244717,0.00024668206,0.0003664162,0.000020726415,0.000053554966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972468,0.00069242495,0.0009576723,0.00041746098,0.00030651892,0.00037914055],"domain_scores_gemma":[0.99886274,0.0002625022,0.00025035182,0.0002673171,0.00007804641,0.000279031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011865392,0.00018854378,0.00063497014,0.00013452383,0.000108937435,0.000012832894,0.000079556,0.00005372255,0.000020469311],"category_scores_gemma":[0.0000754249,0.00013098586,0.000017244705,0.0003705638,0.00005009096,0.000030176596,0.00003223866,0.00026104192,1.649044e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001420259,0.00043765275,0.93062603,0.002534293,0.000021577544,0.00009244554,0.008201315,0.000028275434,2.1370907e-8,0.000002691679,0.00041464105,0.05749901],"study_design_scores_gemma":[0.008859384,0.003990578,0.9421738,0.0090949815,0.00006501864,0.000007306011,0.01217136,0.0047988263,5.101007e-7,0.0000012053212,0.018687172,0.0001498857],"about_ca_topic_score_codex":0.96795917,"about_ca_topic_score_gemma":0.9734972,"teacher_disagreement_score":0.17811856,"about_ca_system_score_codex":0.0016732287,"about_ca_system_score_gemma":0.0045338487,"threshold_uncertainty_score":0.8042853},"labels":[],"label_agreement":null},{"id":"W2849436258","doi":"10.1055/s-0038-1641965","title":"Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation","year":2018,"lang":"de","type":"article","venue":"Diabetologie und Stoffwechsel","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Dapagliflozin; TIMI; Medicine; Gynecology; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Myocardial infarction","score_opus":0.035759632289994014,"score_gpt":0.37965419133511685,"score_spread":0.34389455904512284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2849436258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71490633,0.2068616,0.006200684,0.01081762,0.021174915,0.0042581977,0.00089018734,0.0012236518,0.033666823],"genre_scores_gemma":[0.98544395,0.0014068652,0.003182827,0.0021351115,0.0027556678,0.00017060072,0.0007480582,0.00010515945,0.004051755],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653006,0.00016104087,0.00074161537,0.0009562874,0.00050624885,0.0011047745],"domain_scores_gemma":[0.9975649,0.00021659864,0.00034763722,0.00092337094,0.0005596379,0.00038786154],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029679877,0.00061842456,0.00089546695,0.0003011345,0.00074037065,0.00011609118,0.00030692178,0.00048614797,0.0009146835],"category_scores_gemma":[0.00048335447,0.00053386245,0.00025610873,0.0006336004,0.0005926577,0.00024748777,0.00018291728,0.00039953328,0.0038675086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007665812,0.0030984636,0.5917657,0.0006319021,0.01734549,0.0005823757,0.0074838507,0.000034950248,0.0014858778,0.00784468,0.16153796,0.20742218],"study_design_scores_gemma":[0.007907289,0.003433209,0.32977256,0.0007520061,0.019856416,0.000015401734,0.00087474246,0.0014858708,0.0049043833,0.002978603,0.6264309,0.0015885797],"about_ca_topic_score_codex":0.0002815261,"about_ca_topic_score_gemma":0.00010516207,"teacher_disagreement_score":0.46489295,"about_ca_system_score_codex":0.00065283047,"about_ca_system_score_gemma":0.00047019377,"threshold_uncertainty_score":0.9999986},"labels":[],"label_agreement":null},{"id":"W2851615044","doi":"10.1136/esmoopen-2018-000364","title":"Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Crizotinib; Lung cancer; Tolerability; Internal medicine; Quality of life (healthcare); ALK inhibitor; Performance status; Clinical endpoint; Oncology; Cancer; Adverse effect; Clinical trial","score_opus":0.013236844071678787,"score_gpt":0.34607403689540206,"score_spread":0.33283719282372326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2851615044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206936,0.000009144578,0.0000039880574,0.000079467056,0.000081147205,0.00407896,0.00008172254,0.000011566473,0.0035846673],"genre_scores_gemma":[0.99846154,0.000002786895,0.00029764464,0.00019643137,0.000014827807,0.00042744764,0.00009034442,0.000031954096,0.00047700643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848574,0.000055329892,0.00051180046,0.00040868967,0.00025992343,0.00027850442],"domain_scores_gemma":[0.99887395,0.00003869171,0.00037837823,0.00035411303,0.00025000755,0.00010488711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006687829,0.00021086627,0.00059088017,0.00019807032,0.00009577119,0.000019962456,0.00014313492,0.000023532779,0.00008336623],"category_scores_gemma":[0.000024026886,0.00015496455,0.00003333172,0.00070689246,0.00008308491,0.00013037489,0.00012223562,0.00012277691,0.0000015368558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023156514,0.012345509,0.96853393,0.000019323508,0.0003716646,0.00007056115,0.012808482,0.0000107077785,0.000014420793,3.5972306e-7,0.00015921048,0.0033501734],"study_design_scores_gemma":[0.028784798,0.013253344,0.95533586,0.00014027536,0.0003567815,4.7536176e-7,0.0014920299,0.000022406648,0.00035941316,3.832943e-7,0.000091569455,0.00016264398],"about_ca_topic_score_codex":0.07551273,"about_ca_topic_score_gemma":0.1560146,"teacher_disagreement_score":0.08050188,"about_ca_system_score_codex":0.00022693358,"about_ca_system_score_gemma":0.0003409649,"threshold_uncertainty_score":0.9306435},"labels":[],"label_agreement":null},{"id":"W2861076589","doi":"10.1111/1759-7714.12791","title":"Heterogeneous responses and resistant mechanisms to crizotinib in <i>ALK</i>‐positive advanced non‐small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Thoracic Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"National Key Research and Development Program of China","keywords":"Crizotinib; Medicine; Lung cancer; KRAS; Anaplastic lymphoma kinase; ALK inhibitor; Cancer research; Fluorescence in situ hybridization; Mutation; ROS1; Oncology; Targeted therapy; Internal medicine; Cancer; Gene; Genetics; Adenocarcinoma; Biology","score_opus":0.014273537824221968,"score_gpt":0.37253799177836183,"score_spread":0.35826445395413986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2861076589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987703,0.0044198586,0.00080220494,0.0016624002,0.00037951922,0.0013844873,0.00028001683,0.000058569312,0.0033099002],"genre_scores_gemma":[0.98715633,0.0005334426,0.0037416061,0.002118573,0.00020326636,0.00075668877,0.000014191964,0.00005576572,0.005420117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985192,0.000057407196,0.0002752178,0.0005243139,0.00020421765,0.0004196655],"domain_scores_gemma":[0.99910945,0.00006488742,0.00008641978,0.00029363143,0.00019459148,0.00025104795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012861856,0.00024604073,0.000362819,0.00018748271,0.00014219989,0.000030755702,0.00007797836,0.00008332322,0.0002533918],"category_scores_gemma":[0.000024519413,0.00021413372,0.000054905388,0.0003519062,0.000072829986,0.00007422167,0.00006292025,0.0001285449,0.000016598879],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022233253,0.00067299,0.016610637,0.00085023063,0.00065158017,0.0007664568,0.023169722,0.0003986219,0.7817501,0.000224903,0.002258258,0.15041326],"study_design_scores_gemma":[0.0060223476,0.0028481388,0.06085008,0.0027244838,0.0014284635,0.00006668163,0.0012284657,0.00051475636,0.9104205,0.0003189115,0.012625848,0.00095136266],"about_ca_topic_score_codex":0.0024124943,"about_ca_topic_score_gemma":0.0065987757,"teacher_disagreement_score":0.1494619,"about_ca_system_score_codex":0.00056766503,"about_ca_system_score_gemma":0.0004772346,"threshold_uncertainty_score":0.873212},"labels":[],"label_agreement":null},{"id":"W2884617673","doi":"10.1016/j.jtho.2018.07.008","title":"CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non–Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Natural Science Foundation of China","keywords":"Crizotinib; Anaplastic lymphoma kinase; Cancer research; ALK inhibitor; Fusion gene; Molecular biology; Receptor tyrosine kinase; Biology; Lung cancer; Medicine; Signal transduction; Gene; Cell biology; Genetics; Oncology","score_opus":0.038738264174478565,"score_gpt":0.47200986640491716,"score_spread":0.4332716022304386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884617673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96284163,0.00073038327,0.00095946004,0.014463,0.0013648288,0.00055414625,0.000013361045,0.0000100299285,0.019063149],"genre_scores_gemma":[0.977396,0.00015076561,0.012797775,0.002720422,0.0010027557,0.000051255854,0.0000032087805,0.000029260147,0.0058485703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986139,0.00007723713,0.0005042339,0.0002062619,0.0002671287,0.00033125555],"domain_scores_gemma":[0.9987044,0.000090439295,0.00036071436,0.00020986325,0.00036519766,0.00026940912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060544617,0.00015954915,0.0005106724,0.00044957318,0.00007027329,0.000016436758,0.00015321355,0.00013429797,0.00044787873],"category_scores_gemma":[0.00006852047,0.00012079698,0.000120596094,0.00032754484,0.000054830412,0.00009303377,0.00005473499,0.00030254034,0.000023574798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023969645,0.0066711293,0.14564718,0.0006525305,0.0014749714,0.0030673887,0.06293182,0.0002943739,0.19452871,0.00007014945,0.12126422,0.43942788],"study_design_scores_gemma":[0.012597043,0.013761924,0.25863215,0.0016299196,0.0028395907,0.0009698927,0.006487792,0.00036713033,0.02348582,0.000078398654,0.6786642,0.0004861422],"about_ca_topic_score_codex":0.0002457948,"about_ca_topic_score_gemma":0.00075134,"teacher_disagreement_score":0.5574,"about_ca_system_score_codex":0.0011958199,"about_ca_system_score_gemma":0.001041185,"threshold_uncertainty_score":0.4925958},"labels":[],"label_agreement":null},{"id":"W2884869701","doi":"10.3747/co.25.3733","title":"Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Tyrosine kinase; Chemotherapy; Oncology; Central nervous system; Tyrosine-kinase inhibitor; Disease; Radiation therapy; Anaplastic lymphoma kinase; Internal medicine; Cancer; Cancer research; Receptor","score_opus":0.06503716703729023,"score_gpt":0.4306379998897843,"score_spread":0.36560083285249406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884869701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020222615,0.9906405,0.0000213228,0.00068848586,0.0027797457,0.0029066126,0.00044272825,0.000052704003,0.0004456158],"genre_scores_gemma":[0.00013092686,0.99468446,0.00039192662,0.00010727363,0.0012565495,0.0017015546,0.0008534406,0.00008692101,0.00078697107],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971418,0.00022958714,0.00102826,0.0008454014,0.0001991445,0.00055585004],"domain_scores_gemma":[0.9981286,0.00022187139,0.00071298267,0.00041935936,0.00018711253,0.00033007824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003796036,0.00063953846,0.0022674438,0.00062393874,0.00013808713,0.000038160262,0.00013487534,0.00041003065,0.00016069112],"category_scores_gemma":[0.00010110497,0.0005037785,0.00037758573,0.0006558486,0.00021793881,0.00009586449,0.00017360601,0.00065836177,0.00005096687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052964933,0.0024712204,0.00377839,0.04198922,0.00059888687,0.00022420324,0.00046559633,0.0000037134175,0.000010406276,0.000025911753,0.09044338,0.8599361],"study_design_scores_gemma":[0.0028585477,0.0004883579,0.00013506603,0.022107001,0.0043245964,0.0000694336,0.00010918396,0.000031312204,0.000037401685,0.000007618811,0.9694282,0.0004032859],"about_ca_topic_score_codex":0.00021980098,"about_ca_topic_score_gemma":0.0007060574,"teacher_disagreement_score":0.8789848,"about_ca_system_score_codex":0.0020203607,"about_ca_system_score_gemma":0.001806977,"threshold_uncertainty_score":0.9997414},"labels":[],"label_agreement":null},{"id":"W2885167354","doi":"10.1007/s00520-018-4392-x","title":"Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib","year":2018,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"BC Cancer Agency","keywords":"Medicine; Afatinib; Discontinuation; Algorithm; Polypharmacy; Adverse effect; Rash; Pharmacist; Diarrhea; Pharmacy; Internal medicine; Emergency medicine; Cancer; Erlotinib; Epidermal growth factor receptor; Family medicine","score_opus":0.020550771235656948,"score_gpt":0.3733345746989304,"score_spread":0.3527838034632734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885167354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98098326,0.00090887013,0.0042188726,0.00039805914,0.0016158108,0.0065401904,0.0015118608,0.000104886116,0.0037181717],"genre_scores_gemma":[0.9632869,0.00003620173,0.03187037,0.00019050615,0.0002374243,0.0025911082,0.00054164574,0.00006260534,0.0011832877],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986624,0.000019624726,0.00025205914,0.00048084895,0.00021943136,0.00036565156],"domain_scores_gemma":[0.9983368,0.000054559678,0.00015304382,0.00020608233,0.0011311289,0.00011837207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043815755,0.00021936899,0.0003088187,0.00010975615,0.00014117689,0.00001181713,0.000060652084,0.00007432304,0.00014996772],"category_scores_gemma":[0.000054919707,0.00016539083,0.000080571335,0.0002557987,0.00012310596,0.00023440288,0.000031320313,0.00011535404,0.0000063110615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002297564,0.0006008986,0.33235332,0.00014128603,0.00053126505,0.000021232492,0.023466956,0.0000065842723,0.000097183234,0.00000518863,0.00065806543,0.63982046],"study_design_scores_gemma":[0.03501599,0.0075778007,0.9314138,0.0013171743,0.0007212442,0.0000031595966,0.014249787,0.00038602753,0.003777495,0.000033942764,0.0049459096,0.0005576645],"about_ca_topic_score_codex":0.00012709276,"about_ca_topic_score_gemma":0.0010620516,"teacher_disagreement_score":0.6392628,"about_ca_system_score_codex":0.0009562444,"about_ca_system_score_gemma":0.0006490611,"threshold_uncertainty_score":0.6744442},"labels":[],"label_agreement":null},{"id":"W2885210084","doi":"10.1016/j.cllc.2018.07.008","title":"Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; Clovis Oncology","keywords":"T790M; Liquid biopsy; Lung cancer; Medicine; Cancer research; KRAS; Cell-free fetal DNA; DNA sequencing; Resistance mutation; Oncology; Gene; Osimertinib; Exon; EGFR inhibitors; Internal medicine; Epidermal growth factor receptor; Gefitinib; Cancer; Polymerase chain reaction; Erlotinib; Biology; Genetics; Reverse transcriptase; Colorectal cancer","score_opus":0.0895180354257775,"score_gpt":0.3965163339387146,"score_spread":0.3069982985129371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885210084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041945,0.001514757,0.0009049629,0.0035407506,0.0012803592,0.0007433933,0.00012517562,0.000050552033,0.0014206115],"genre_scores_gemma":[0.98789614,0.00025279296,0.004038038,0.0012354405,0.0029707113,0.00012500223,0.000049582024,0.000023907856,0.0034083559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846977,0.00013537328,0.00058270904,0.0004015937,0.00024284708,0.0001676899],"domain_scores_gemma":[0.9987464,0.00013610742,0.00016368095,0.00039950284,0.0003656624,0.00018864872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057537144,0.00013199169,0.00027079228,0.000081979255,0.00014672466,0.000028577455,0.00006114053,0.00013935956,0.00006641916],"category_scores_gemma":[0.0005130312,0.0001135725,0.00007018286,0.00021038986,0.00013105264,0.00016315217,0.00004024666,0.000120638404,0.0000066768253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031710025,0.00022843492,0.043667927,0.00017990274,0.0002352866,0.000009746641,0.0018568244,0.000039323804,0.6805011,0.0002502719,0.26609653,0.0037636503],"study_design_scores_gemma":[0.022035379,0.008432309,0.36434627,0.0022249182,0.0037568603,0.000020883635,0.0007037878,0.024016466,0.50493324,0.0003925288,0.06815369,0.0009836985],"about_ca_topic_score_codex":0.0000722589,"about_ca_topic_score_gemma":0.0005024044,"teacher_disagreement_score":0.32067832,"about_ca_system_score_codex":0.00042901767,"about_ca_system_score_gemma":0.0005553008,"threshold_uncertainty_score":0.46313524},"labels":[],"label_agreement":null},{"id":"W2885340034","doi":"10.1158/1538-7445.am2018-4026","title":"Abstract 4026: Mechanism of cisplatin resistance and enhanced cell migration in cervical cancer cells expressing <i>PIK3CA</i>-E545K mutation","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cisplatin; PI3K/AKT/mTOR pathway; Cervical cancer; Medicine; Cancer research; Cancer; Radiation therapy; Mutation; Chemotherapy; Oncology; Internal medicine; Gene; Biology; Genetics; Signal transduction","score_opus":0.04044493040350706,"score_gpt":0.41346176074547075,"score_spread":0.3730168303419637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885340034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905102,0.0020507765,0.0003352155,0.0008300533,0.00015689843,0.00071544,0.000056174104,0.000019798475,0.0053254343],"genre_scores_gemma":[0.9960654,0.0009092802,0.00094638264,0.00008260192,0.00021663832,0.00032604704,0.000021575719,0.000029697858,0.0014024057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998242,0.00007937869,0.00034890135,0.00040881927,0.00054279057,0.00037807223],"domain_scores_gemma":[0.9988634,0.0001396734,0.00011504761,0.00024447739,0.000499467,0.00013791509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036476017,0.00014106931,0.00026160254,0.00025167008,0.00015244239,0.000036413425,0.000085530744,0.00011607107,0.00042849683],"category_scores_gemma":[0.000037988855,0.00012614754,0.000037511574,0.00048878527,0.00021815521,0.0001757479,0.0000388668,0.00027452112,0.000011414274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004961615,0.00015341236,0.0009834402,0.0004911078,0.000034083634,0.000019846246,0.0042039044,0.00002096307,0.98716044,0.00024183934,0.0009274351,0.005267334],"study_design_scores_gemma":[0.0021494182,0.00018783647,0.01751111,0.0008085573,0.00004624619,0.0000010321182,0.00063968595,0.00018089321,0.97696906,0.00069688464,0.00068624766,0.00012300111],"about_ca_topic_score_codex":0.003275906,"about_ca_topic_score_gemma":0.008032645,"teacher_disagreement_score":0.016527671,"about_ca_system_score_codex":0.00040980446,"about_ca_system_score_gemma":0.0005408764,"threshold_uncertainty_score":0.5144147},"labels":[],"label_agreement":null},{"id":"W2885455637","doi":"","title":"Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial","year":2017,"lang":"en","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Refractory (planetary science); Randomized controlled trial; Oncology; Internal medicine; Lung cancer","score_opus":0.027372411114877766,"score_gpt":0.38391361452475453,"score_spread":0.3565412034098768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885455637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327344,0.0009507443,0.00038621834,0.0005034147,0.0004415992,0.0012432353,0.0010623041,0.00004677475,0.0020922911],"genre_scores_gemma":[0.9899513,0.0009633681,0.0019859013,0.00024462538,0.000658085,0.00007880271,0.005999926,0.000029869007,0.00008808768],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99802524,0.00021351466,0.00046769853,0.000643784,0.00023177943,0.00041797684],"domain_scores_gemma":[0.9978678,0.00054407143,0.00030003165,0.0009960441,0.000020678697,0.00027135023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048048244,0.00027992326,0.0007780572,0.00006779867,0.000451964,0.00027825052,0.00041516294,0.000069057285,0.0000413201],"category_scores_gemma":[0.000044856686,0.00021189489,0.000066354856,0.000045661,0.00022950886,0.00047314196,0.00040917078,0.00027912078,0.0000021714527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6534776,0.003089547,0.108282626,0.00068896887,0.0035753248,0.00059769704,0.026887752,0.00011237447,0.0015699351,0.0004267581,0.0011348223,0.20015661],"study_design_scores_gemma":[0.75454724,0.0003624755,0.121329434,0.0009791558,0.0011093194,0.00001687694,0.00084870605,0.117921956,0.000016637547,0.00038162828,0.002166093,0.0003204973],"about_ca_topic_score_codex":0.0085659325,"about_ca_topic_score_gemma":0.0034035116,"teacher_disagreement_score":0.19983612,"about_ca_system_score_codex":0.000058729944,"about_ca_system_score_gemma":0.00019703389,"threshold_uncertainty_score":0.9980361},"labels":[],"label_agreement":null},{"id":"W2886137239","doi":"","title":"Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer","year":2017,"lang":"en","type":"article","venue":"University of Southern Denmark Research Portal (University of Southern Denmark)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Lung cancer; Medicine; Concordance; Twin study; Genetic predisposition; Heritability; Cancer; Internal medicine; Dizygotic twin; Demography; Oncology; Genetics; Biology","score_opus":0.02827937686718148,"score_gpt":0.33170495276107814,"score_spread":0.3034255758938967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886137239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921809,0.0011326186,0.00003832609,0.00052467897,0.000049399692,0.0010803638,0.0008583064,0.000012761674,0.0041226726],"genre_scores_gemma":[0.9917864,0.00056467974,0.00010024192,0.00000636191,0.00004303064,9.4397734e-7,0.000013250016,0.000022675968,0.0074624238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796534,0.00018298185,0.0001921085,0.00042452145,0.00088541233,0.0003496391],"domain_scores_gemma":[0.9978365,0.00010643603,0.00047961602,0.000743709,0.000627536,0.00020623927],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004591781,0.00019063699,0.00044940438,0.00029215292,0.0012113026,0.000025464122,0.0006513337,0.00013746743,0.0023844973],"category_scores_gemma":[0.0000393189,0.00018275475,0.00016604945,0.00025940136,0.0012550644,0.00013901544,0.00042701155,0.00034593846,0.000018411216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011014673,0.0006529912,0.93995124,0.00029316728,0.0016922666,0.00026084922,0.04674831,0.000050261722,0.00067813095,0.000019559933,0.0007692047,0.0077825626],"study_design_scores_gemma":[0.006122499,0.0005886416,0.5650221,0.0005168837,0.0018469074,0.000010026142,0.4245963,0.00056540384,0.000057147685,0.000050484232,0.00041783229,0.00020577625],"about_ca_topic_score_codex":0.07485822,"about_ca_topic_score_gemma":0.024385836,"teacher_disagreement_score":0.377848,"about_ca_system_score_codex":0.00013069801,"about_ca_system_score_gemma":0.00043691028,"threshold_uncertainty_score":0.99852747},"labels":[],"label_agreement":null},{"id":"W2886226874","doi":"10.1158/1538-7445.am2018-1817","title":"Abstract 1817: Establishment and characterization of non-small cell lung cancer cell line variants selected for resistance to osimertinib","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Osimertinib; T790M; Cancer research; Lung cancer; Epidermal growth factor receptor; Cell culture; Medicine; Biology; Cancer; Oncology; Gefitinib; Internal medicine; Erlotinib; Genetics","score_opus":0.036383641769147504,"score_gpt":0.40245924002207756,"score_spread":0.36607559825293007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886226874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915341,0.0012500323,0.0006841899,0.0011449351,0.00020048926,0.0023923246,0.00044381488,0.000021904401,0.0023281777],"genre_scores_gemma":[0.98580694,0.0009790653,0.0010830952,0.00018788052,0.0004698638,0.0012050528,0.00012430298,0.00004445756,0.010099325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984722,0.000029502482,0.0002929719,0.00041683775,0.0003394469,0.00044902437],"domain_scores_gemma":[0.9977587,0.000088574234,0.0001018397,0.00027207463,0.0015389234,0.00023989468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029927705,0.0001428037,0.0002602278,0.00014994467,0.00018706442,0.00004021173,0.00010777061,0.00008035925,0.00035694987],"category_scores_gemma":[0.0000500507,0.00012482122,0.00003302936,0.00057978684,0.000084776984,0.00011290848,0.0000467605,0.00013586569,0.000004985148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011056912,0.000280788,0.007088058,0.001137246,0.00011022649,0.0000039523943,0.0018835939,0.000004144812,0.98010176,0.000014309945,0.0049658157,0.0033044214],"study_design_scores_gemma":[0.0036080005,0.0007125117,0.20820731,0.00072668405,0.00019684531,5.539087e-7,0.00012884526,0.00029827838,0.77040046,0.000010516102,0.015528332,0.00018166992],"about_ca_topic_score_codex":0.0014540706,"about_ca_topic_score_gemma":0.0012010636,"teacher_disagreement_score":0.2097013,"about_ca_system_score_codex":0.00047168075,"about_ca_system_score_gemma":0.0010384587,"threshold_uncertainty_score":0.50900614},"labels":[],"label_agreement":null},{"id":"W2886894848","doi":"10.1186/s12885-018-4736-4","title":"Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study","year":2018,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Regional Development Fund; Fundação para a Ciência e a Tecnologia; Associazione Italiana per la Ricerca sul Cancro; Queen's University","keywords":"ROS1; Fusion gene; Concordance; Adenocarcinoma; Multiplex; Lung cancer; Lung; Cancer research; Medicine; Oncology; Computational biology; Biology; Pathology; Internal medicine; Cancer; Bioinformatics; Gene; Genetics","score_opus":0.3156760810898595,"score_gpt":0.4549812695320846,"score_spread":0.13930518844222511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886894848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9100616,0.00035093003,0.0871733,0.000024553741,0.00029456848,0.0018032002,0.000046314173,0.000047861962,0.00019767012],"genre_scores_gemma":[0.98607653,0.000007768348,0.012524521,0.000053449585,0.00067506765,0.00033715312,0.000045333418,0.00002492912,0.0002552734],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984126,0.00012988063,0.0002959467,0.00038190908,0.00051422784,0.00026544352],"domain_scores_gemma":[0.99851507,0.00010992992,0.00009882397,0.00029015343,0.0008725169,0.000113503665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002790211,0.00015314564,0.00022489013,0.00026780172,0.0005578272,0.000029543944,0.000063708045,0.00008349087,0.00010816623],"category_scores_gemma":[0.00026285864,0.0001225478,0.00008094122,0.0005509767,0.00021768281,0.00011008585,0.00003102623,0.00016150458,0.0000066402135],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073961983,0.0023817427,0.044553116,0.000251114,0.0004061235,0.000033667653,0.005588418,0.14718574,0.79021966,0.00003002698,0.0000869694,0.008523769],"study_design_scores_gemma":[0.0042430772,0.00048205734,0.0064402237,0.00010611463,0.00033912706,0.000015700862,0.0011523253,0.97216755,0.01471502,0.0000015808694,0.00021443528,0.00012276664],"about_ca_topic_score_codex":0.008719116,"about_ca_topic_score_gemma":0.011128599,"teacher_disagreement_score":0.8249818,"about_ca_system_score_codex":0.0015524579,"about_ca_system_score_gemma":0.0021644616,"threshold_uncertainty_score":0.9978819},"labels":[],"label_agreement":null},{"id":"W2887042787","doi":"10.1158/1538-7445.am2018-1642","title":"Abstract 1642: Alectinib in treatment-naïve anaplastic lymphoma kinase-positive (<i>ALK</i>+) metastatic non-small-cell lung cancer (mNSCLC): Systematic literature review (SLR) and network meta-analysis (NMA)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Alectinib; Medicine; Crizotinib; Ceritinib; Internal medicine; Oncology; Anaplastic lymphoma kinase; Lung cancer; Pemetrexed; Chemotherapy","score_opus":0.07856360242995693,"score_gpt":0.43501263597532397,"score_spread":0.35644903354536706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887042787","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11034522,0.8783718,0.00007173409,0.0015354342,0.00019780349,0.0063610836,0.0005698852,0.00004699945,0.0025000917],"genre_scores_gemma":[0.85170346,0.13368885,0.0005890116,0.0008542,0.00045956371,0.007829964,0.00023750566,0.00010593109,0.0045315404],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99598324,0.00055557676,0.00078842766,0.000953205,0.0007635375,0.00095600286],"domain_scores_gemma":[0.9968163,0.0008634948,0.0002715196,0.0007398026,0.0008846457,0.00042423554],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010696931,0.00050787453,0.0023571684,0.00067686103,0.00037099048,0.00017531845,0.00019989593,0.0001256782,0.00083262497],"category_scores_gemma":[0.00013170217,0.0003393124,0.0006469937,0.0038441734,0.0002252513,0.00018586169,0.000071608745,0.00034429756,0.000028195669],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021252045,0.003498144,0.019459786,0.33196935,0.58036953,0.0045306464,0.016604751,0.00095710915,0.0020628136,0.00022264369,0.029153695,0.009046321],"study_design_scores_gemma":[0.013508313,0.0029708159,0.034118127,0.104240924,0.83430016,0.00014960769,0.001125915,0.0026146444,0.003265452,0.0001260164,0.0020620602,0.0015179482],"about_ca_topic_score_codex":0.0032874823,"about_ca_topic_score_gemma":0.00783017,"teacher_disagreement_score":0.7446829,"about_ca_system_score_codex":0.0015701352,"about_ca_system_score_gemma":0.0011277992,"threshold_uncertainty_score":0.9999059},"labels":[],"label_agreement":null},{"id":"W2887314183","doi":"10.1038/s41388-018-0454-2","title":"Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI","year":2018,"lang":"en","type":"article","venue":"Oncogene","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Hakai Institute; National Taiwan University; National Health Research Institutes; National Institute for Health and Care Research","keywords":"Gefitinib; Gene knockdown; Vimentin; Downregulation and upregulation; Cancer research; Epithelial–mesenchymal transition; Biology; Epidermal growth factor receptor; Cancer; Cell culture; Immunology; Genetics; Gene; Immunohistochemistry","score_opus":0.020682308916906575,"score_gpt":0.34507196935255047,"score_spread":0.3243896604356439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887314183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8888924,0.0003563345,0.043128084,0.041849103,0.00087097596,0.0032971324,0.0021334135,0.00020838797,0.019264176],"genre_scores_gemma":[0.95877105,0.000020349107,0.020922069,0.006690115,0.000634578,0.00047206657,0.0003859572,0.000050658415,0.012053149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878466,0.000027103923,0.00027666954,0.00037510696,0.00022955696,0.00030690109],"domain_scores_gemma":[0.9989254,0.000054945678,0.00007014939,0.00034302316,0.00038670684,0.0002197748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102286656,0.0001881564,0.00028111323,0.000114413386,0.0003234738,0.000028964441,0.00007679379,0.00009906326,0.00046150156],"category_scores_gemma":[0.000029294428,0.00016938601,0.0001421557,0.00022567507,0.000068808215,0.00010620909,0.000013102058,0.000042532098,0.00020346533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024109466,0.001366549,0.00018681643,0.0003205966,0.0011492023,0.00008903988,0.052068245,0.00002997399,0.84953415,0.024647858,0.04736748,0.020829147],"study_design_scores_gemma":[0.01356433,0.0039581894,0.0015748158,0.00041187278,0.0027766698,0.00009103858,0.0026429496,0.000862227,0.75133294,0.033609513,0.18832226,0.00085317256],"about_ca_topic_score_codex":0.00013854595,"about_ca_topic_score_gemma":0.0009257809,"teacher_disagreement_score":0.14095478,"about_ca_system_score_codex":0.00031502993,"about_ca_system_score_gemma":0.00022679911,"threshold_uncertainty_score":0.6907361},"labels":[],"label_agreement":null},{"id":"W2887639123","doi":"10.1158/1538-7445.am2018-2894","title":"Abstract 2894: Neratinib effects significant changes in human brain endothelial cells, demonstrating that it may have a therapeutic use in cancers with brain metastasis","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neratinib; Brain metastasis; Medicine; Tyrosine-kinase inhibitor; Cancer research; Breast cancer; Cancer; Internal medicine; Metastasis; Oncology; Trastuzumab","score_opus":0.12807098152279556,"score_gpt":0.4465441814490924,"score_spread":0.31847319992629686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887639123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98700094,0.00046323208,0.000035774756,0.008658791,0.000108046115,0.0020895554,0.00011451453,0.00003399856,0.0014951538],"genre_scores_gemma":[0.9948562,0.00012186898,0.00029065055,0.001217073,0.00031443036,0.0012130933,0.000031299704,0.00006588585,0.001889506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99711466,0.00039385265,0.00027404274,0.00062333775,0.00072534813,0.0008687587],"domain_scores_gemma":[0.9982403,0.00086245587,0.00009073755,0.0003928393,0.0001922219,0.0002214611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010836959,0.00027303016,0.00042670046,0.0005243289,0.00023313359,0.00014070031,0.00017072305,0.000109448534,0.00039637001],"category_scores_gemma":[0.00010456133,0.00020480582,0.00005579834,0.000609846,0.0004554487,0.00018623065,0.00004126317,0.0006310722,0.000012380156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001014478,0.0004645335,0.0967314,0.00054763054,0.0005515972,0.00088481494,0.012351055,0.00013154668,0.83909875,0.00026524754,0.0038564235,0.044102542],"study_design_scores_gemma":[0.015216522,0.004179637,0.14920023,0.0031200098,0.00021574054,0.000024635123,0.007090268,0.00031496727,0.8074523,0.0001506451,0.012288256,0.0007467867],"about_ca_topic_score_codex":0.032832157,"about_ca_topic_score_gemma":0.17424987,"teacher_disagreement_score":0.14141771,"about_ca_system_score_codex":0.0013948303,"about_ca_system_score_gemma":0.0013017558,"threshold_uncertainty_score":0.9736083},"labels":[],"label_agreement":null},{"id":"W2888017273","doi":"10.1634/theoncologist.2018-0089","title":"Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Placebo; Lung cancer; Confidence interval; Gastroenterology; Population; Oncology; Cancer; Pathology","score_opus":0.015630401558201345,"score_gpt":0.35533037232813364,"score_spread":0.3396999707699323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888017273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779929,0.000042980293,0.000059044683,0.00011861792,0.00006944951,0.01585702,0.00007187894,0.00005626534,0.0057318415],"genre_scores_gemma":[0.9958356,0.000014560131,0.0008836068,0.00005184488,0.000054596916,0.0024222275,0.0000385252,0.00005405495,0.0006449927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780935,0.00014554599,0.0006010133,0.0005791697,0.00035926804,0.0005056361],"domain_scores_gemma":[0.99838036,0.00013995971,0.00056410447,0.0004815638,0.00032651497,0.00010751183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035979899,0.00037476697,0.0009863687,0.00017607049,0.00014994724,0.00002429875,0.00021099589,0.00007765336,0.000058546484],"category_scores_gemma":[0.000046091012,0.00021883464,0.0000468463,0.00070407725,0.00030019606,0.00010974321,0.00008259565,0.0003881909,0.0000015725801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075966753,0.005925601,0.9748159,0.00011456247,0.00024547806,0.00006600258,0.009743454,0.00080057397,0.00016900898,0.0000044393255,0.00002868814,0.00048959034],"study_design_scores_gemma":[0.11266833,0.015747584,0.86380446,0.0008426683,0.0005881744,0.000003851657,0.0021762843,0.0034332003,0.0004898127,0.0000014808733,0.0000120965715,0.00023207293],"about_ca_topic_score_codex":0.0047945473,"about_ca_topic_score_gemma":0.022108084,"teacher_disagreement_score":0.11101148,"about_ca_system_score_codex":0.0028093169,"about_ca_system_score_gemma":0.0015695269,"threshold_uncertainty_score":0.9957359},"labels":[],"label_agreement":null},{"id":"W2888297491","doi":"10.3747/co.25.3978","title":"Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real-World Population of Advanced Non-Small-Cell Lung Cancer Patients?","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Population; Clinical trial; Internal medicine; Cancer; Cohort; Systemic therapy; Performance status; Malignancy; Oncology","score_opus":0.16776025737185646,"score_gpt":0.5818256828358195,"score_spread":0.414065425463963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888297491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314386,0.00013041853,0.00006507076,0.00007736782,0.0041085845,0.0013194793,0.00006656588,0.00002305238,0.0010656189],"genre_scores_gemma":[0.9982208,0.00020674337,0.00040588278,0.0000404299,0.00068087346,0.00013115242,0.00021371209,0.0000138161195,0.00008659386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838245,0.00017488343,0.00080698676,0.0003372216,0.00013296552,0.00016547772],"domain_scores_gemma":[0.9979682,0.000081180784,0.0009309437,0.00028231103,0.00063094177,0.00010642126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025480078,0.00012629767,0.00053282443,0.00011869183,0.00005519525,0.0000036961376,0.00006195906,0.00010993789,0.00012013244],"category_scores_gemma":[0.00014807536,0.000105724175,0.000113413065,0.00023315557,0.00010396854,0.00010309465,0.000027855009,0.0001335106,0.0000020392613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015815713,0.004410761,0.93094367,0.00025550128,0.00008462351,8.4203646e-7,0.0005969358,0.0000047099156,0.00047121767,0.000015317297,0.0008600255,0.046540692],"study_design_scores_gemma":[0.039182607,0.005647808,0.9499345,0.00018242611,0.0006283135,3.2963416e-7,0.00007907474,0.00044540068,0.00077919866,0.000063252046,0.0029584465,0.00009866757],"about_ca_topic_score_codex":0.0005270647,"about_ca_topic_score_gemma":0.00250359,"teacher_disagreement_score":0.046442028,"about_ca_system_score_codex":0.00043334285,"about_ca_system_score_gemma":0.00033595876,"threshold_uncertainty_score":0.43113068},"labels":[],"label_agreement":null},{"id":"W2888952267","doi":"10.1016/j.lungcan.2018.08.024","title":"Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Alberta Cancer Foundation; University of Calgary; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Innovative Research Group Project of the National Natural Science Foundation of China","keywords":"Osimertinib; Medicine; Lung cancer; Afatinib; Cost effectiveness; Oncology; Quality-adjusted life year; Confidence interval; Internal medicine; Adenocarcinoma; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.005681807896931517,"score_gpt":0.30050355462623246,"score_spread":0.29482174672930095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888952267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027383,0.004973591,0.000018680374,0.00036837533,0.0003915182,0.0009791986,0.000305411,0.00001534773,0.002674035],"genre_scores_gemma":[0.9970434,0.0010112727,0.00009758571,0.0003381971,0.00009225059,0.00041985777,0.000063817875,0.00003564181,0.0008979819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828273,0.000032125903,0.00058746163,0.0004671299,0.00016205433,0.0004685011],"domain_scores_gemma":[0.9990737,0.000052101735,0.0002418245,0.0003716207,0.0001102729,0.00015050864],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007592326,0.00024545373,0.0007332078,0.0003817679,0.00004017174,0.00000866332,0.00012511604,0.00007246119,0.0013918781],"category_scores_gemma":[0.0000083267005,0.00021906575,0.00011112153,0.00096134207,0.000047161717,0.0000813552,0.000030024212,0.00013805469,0.0000025814136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024637714,0.00008915685,0.9697231,0.00018535058,0.001436014,0.0000367191,0.0016768248,0.020856367,0.0017240831,0.0000059557274,0.00051633315,0.003503692],"study_design_scores_gemma":[0.0069147493,0.0001559653,0.8770173,0.000824737,0.006317189,0.0000015032942,0.0004535562,0.0912798,0.015633881,0.0000032493144,0.0009914933,0.00040657286],"about_ca_topic_score_codex":0.9534879,"about_ca_topic_score_gemma":0.99411106,"teacher_disagreement_score":0.092705816,"about_ca_system_score_codex":0.0064379876,"about_ca_system_score_gemma":0.005111837,"threshold_uncertainty_score":0.99952096},"labels":[],"label_agreement":null},{"id":"W2888966082","doi":"10.1371/journal.pone.0202865","title":"Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study","year":2018,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck","keywords":"Observational study; Lung cancer; Medicine; Oncology; Internal medicine; Cancer; Bioinformatics; Biology","score_opus":0.05449292962866757,"score_gpt":0.3066587333379423,"score_spread":0.2521658037092747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888966082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965025,0.00007001985,0.00015993844,0.000104692415,0.000022480172,0.002816514,0.00012957978,0.000027632192,0.00016663081],"genre_scores_gemma":[0.98813933,0.000009141644,0.010251937,0.00010845216,0.00008988777,0.0010638525,0.00009981869,0.000027535294,0.0002100584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928707,0.000007294829,0.00012574796,0.00025242686,0.00016632822,0.00016114938],"domain_scores_gemma":[0.9993207,0.000057135054,0.00006835048,0.0001345328,0.0003363095,0.000082971805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000017799952,0.00013460431,0.0001999649,0.000032237782,0.00011343164,0.000013687515,0.000024520068,0.000019998732,0.000013322077],"category_scores_gemma":[0.000020058565,0.0000987441,0.000018200215,0.000076714445,0.000018855399,0.000051527073,0.000012585976,0.000027730699,9.817053e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016994798,0.007494543,0.9874892,0.00009965652,0.0006741305,0.0000054011725,0.00077875046,0.000010160112,0.0012568041,0.0000018125819,0.0000044595054,0.0020150824],"study_design_scores_gemma":[0.01121729,0.010736639,0.96918386,0.00031145435,0.0019461198,3.3142172e-7,0.00014410594,0.0013167479,0.0050051315,0.0000041164117,0.0000072086723,0.0001269863],"about_ca_topic_score_codex":0.00025711395,"about_ca_topic_score_gemma":0.00015088679,"teacher_disagreement_score":0.018305382,"about_ca_system_score_codex":0.00017568431,"about_ca_system_score_gemma":0.00012535087,"threshold_uncertainty_score":0.40266675},"labels":[],"label_agreement":null},{"id":"W2889005127","doi":"10.1200/jco.2013.31.15_suppl.8104","title":"A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Clinical endpoint; Internal medicine; Lung cancer; Oncology; KRAS; Phases of clinical research; Chemotherapy; Cancer; Gastroenterology; Clinical trial; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.050834212854776045,"score_gpt":0.4696614283411989,"score_spread":0.4188272154864229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889005127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98837966,0.00070347957,0.00015663568,0.004155018,0.001641225,0.0014367931,0.000008892,0.000011792894,0.0035064959],"genre_scores_gemma":[0.9901163,0.00029707613,0.0053930725,0.0016821774,0.0014390332,0.00014538848,0.000009921846,0.00003311308,0.0008839208],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99672216,0.00021129705,0.0021460277,0.00026512318,0.00030285967,0.00035254736],"domain_scores_gemma":[0.9962885,0.0008787779,0.0016307503,0.00019523015,0.00047928432,0.0005274725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009521473,0.0002102422,0.0014936842,0.00017680679,0.000071370676,0.000016162663,0.00013041733,0.00028204964,0.00040158906],"category_scores_gemma":[0.00049678906,0.00013636771,0.000313945,0.00021860923,0.00011682328,0.00022734163,0.000041849264,0.0010097733,0.000012365455],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29704797,0.060230967,0.10611868,0.00028350006,0.002206654,0.0038529031,0.0041184104,0.00051722466,0.0030558822,0.000049353843,0.01868023,0.50383824],"study_design_scores_gemma":[0.81468844,0.13964525,0.018217402,0.0009184052,0.0018541507,0.0001533532,0.0008698867,0.0009808933,0.00050335116,0.00006160022,0.021814428,0.0002928188],"about_ca_topic_score_codex":0.0001866449,"about_ca_topic_score_gemma":0.00020247763,"teacher_disagreement_score":0.5176405,"about_ca_system_score_codex":0.00034602496,"about_ca_system_score_gemma":0.0041986196,"threshold_uncertainty_score":0.74481714},"labels":[],"label_agreement":null},{"id":"W2889732036","doi":"10.4103/jco.jco_3_18","title":"Response to osimertinib in EGF816-resistant T790M-mutated lung cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; T790M; Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Adenocarcinoma; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Cancer research; Gefitinib; Cancer; Receptor; Erlotinib","score_opus":0.04712176482318364,"score_gpt":0.4887936186369286,"score_spread":0.44167185381374496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889732036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98036784,0.0033582903,0.00019550904,0.012923704,0.0019287581,0.0003205145,0.000012844987,0.000009244787,0.0008832967],"genre_scores_gemma":[0.9975371,0.00014378228,0.0005207177,0.00086880487,0.0005272424,0.000025222887,0.0000024427745,0.000014202768,0.0003605289],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987155,0.0001549428,0.0005417544,0.00012925225,0.00022155777,0.00023699547],"domain_scores_gemma":[0.9988113,0.0001361785,0.00027291174,0.00011317395,0.00043936,0.00022704671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004779293,0.00010880538,0.00038078154,0.0003560232,0.00004431422,0.000008608272,0.00008432219,0.00006448849,0.00039995546],"category_scores_gemma":[0.0002677617,0.00007943235,0.000085956715,0.00033759282,0.000058687332,0.00006827412,0.000023361281,0.00023686432,0.000022230452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10909883,0.0057716793,0.17289284,0.00023783669,0.0015317472,0.0022278149,0.022617456,0.00023011443,0.11186705,0.00027265973,0.19471923,0.37853277],"study_design_scores_gemma":[0.011563844,0.008221367,0.2340379,0.0009434379,0.0007006123,0.00025819388,0.00038938146,0.00016185718,0.0051020803,0.00007853755,0.7383663,0.00017648011],"about_ca_topic_score_codex":0.000036645248,"about_ca_topic_score_gemma":0.000133021,"teacher_disagreement_score":0.5436471,"about_ca_system_score_codex":0.0011210381,"about_ca_system_score_gemma":0.0016796419,"threshold_uncertainty_score":0.4379232},"labels":[],"label_agreement":null},{"id":"W2889756721","doi":"10.1016/j.joim.2018.09.001","title":"The use of a standardized Chinese herbal formula in patients with advanced lung cancer: a feasibility study","year":2018,"lang":"en","type":"article","venue":"Journal of Integrative Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Quality of life (healthcare); Adverse effect; Stage (stratigraphy); Cancer; Internal medicine; Oncology","score_opus":0.019777295493679518,"score_gpt":0.39201788242725494,"score_spread":0.3722405869335754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889756721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629813,0.0006290754,0.00046332052,0.0009859658,0.0002436451,0.0012119141,0.000021481423,0.0000039229176,0.00014256846],"genre_scores_gemma":[0.9988396,0.000078135905,0.0006737522,0.00009407337,0.00013432818,0.000021300357,0.0000034355862,0.000012039223,0.00014332707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833757,0.00010996207,0.0006703765,0.00013029057,0.0005994507,0.00015235912],"domain_scores_gemma":[0.9967504,0.00025951915,0.0005764684,0.00020907515,0.0021000365,0.000104473154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004042394,0.0001831226,0.0006734325,0.00013581837,0.00008113285,0.0000079088995,0.00008827436,0.000025051915,0.00005791203],"category_scores_gemma":[0.0009423666,0.00006156578,0.00007439915,0.00043581333,0.00030890145,0.00020029629,0.000014913516,0.0002469377,1.3726792e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011385187,0.0009975471,0.9681503,0.000020482437,0.0006597559,0.000020150761,0.009970568,0.000009861753,0.00013131565,0.000012141598,0.0005752292,0.008067441],"study_design_scores_gemma":[0.026774602,0.017602382,0.94937664,0.0011849101,0.0004777533,0.000008054822,0.0038474675,0.00006826772,0.00009213817,0.000034664332,0.00047226457,0.000060829036],"about_ca_topic_score_codex":0.00034210747,"about_ca_topic_score_gemma":0.0023115631,"teacher_disagreement_score":0.018773653,"about_ca_system_score_codex":0.00054785935,"about_ca_system_score_gemma":0.000409779,"threshold_uncertainty_score":0.25105795},"labels":[],"label_agreement":null},{"id":"W2890046006","doi":"10.1200/jco.2018.36.15_suppl.2515","title":"A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vomiting; Nausea; Internal medicine; Tolerability; Pharmacodynamics; Hypokalemia; Gastroenterology; Pharmacokinetics; Adverse effect","score_opus":0.07626437236207907,"score_gpt":0.5230527555881498,"score_spread":0.44678838322607073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890046006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974968,0.000041416453,0.00011652656,0.00047081028,0.00046094254,0.0007681598,0.0000052896753,0.000004642781,0.0006354225],"genre_scores_gemma":[0.9958872,0.000027010297,0.0030719491,0.0005137254,0.00028474216,0.000016985263,0.0000027709325,0.000016679034,0.00017894678],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9963957,0.0002760478,0.0025346645,0.00018723276,0.00040914732,0.00019722042],"domain_scores_gemma":[0.9961545,0.0006582225,0.0018315109,0.0001831422,0.00094153965,0.00023112084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095445436,0.00013805932,0.0015441856,0.00016518694,0.000028258326,0.0000035995374,0.000102428494,0.00008316995,0.000108961205],"category_scores_gemma":[0.0015046439,0.00007541024,0.00013589636,0.00028054626,0.00020689867,0.00012950612,0.000029184303,0.00039563517,0.0000065074164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10733074,0.17334358,0.31571513,0.00008908957,0.0023848435,0.0016970843,0.003920006,0.000038520426,0.00011724322,0.0000121495505,0.0013500825,0.3940015],"study_design_scores_gemma":[0.19299203,0.54622084,0.25264025,0.00044534105,0.0015800549,0.00007723392,0.0022262922,0.000061528684,0.00014954263,0.00006200299,0.0034271204,0.00011775443],"about_ca_topic_score_codex":0.000049121096,"about_ca_topic_score_gemma":0.0005505081,"teacher_disagreement_score":0.39388376,"about_ca_system_score_codex":0.00019237067,"about_ca_system_score_gemma":0.0026649435,"threshold_uncertainty_score":0.4727495},"labels":[],"label_agreement":null},{"id":"W2890074783","doi":"10.1200/jco.2016.34.15_suppl.e23134","title":"Clinico-pathologic and molecular characteristics of patients with resected lung adenocarcinoma.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"KRAS; Medicine; Adenocarcinoma; Malignancy; Stage (stratigraphy); Internal medicine; Lung cancer; Molecular pathology; Lung; Oncology; Adjuvant therapy; Pathology; Cancer; Gastroenterology; Colorectal cancer; Gene; Biology","score_opus":0.046947412984324234,"score_gpt":0.4493518904111951,"score_spread":0.40240447742687085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890074783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605054,0.00032195536,0.0003273912,0.0023149678,0.00028810458,0.00017108329,0.000018051027,0.000004079254,0.0005038142],"genre_scores_gemma":[0.99625903,0.0003232054,0.0025418364,0.0006080836,0.00015766938,0.000002131296,0.0000039845486,0.00001028589,0.00009375718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805343,0.00017589545,0.00131195,0.00012803412,0.00020939893,0.000121311554],"domain_scores_gemma":[0.9967274,0.0008749647,0.0013913022,0.00013781585,0.00066408684,0.00020441141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006381723,0.000085977284,0.0008755854,0.00007492745,0.000017424343,0.0000024464498,0.000060884682,0.00018093412,0.00005417081],"category_scores_gemma":[0.001941792,0.000040319625,0.00013377887,0.000067243105,0.00022997387,0.00005988315,0.000026175217,0.00023208343,0.000001989126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030730036,0.0009461264,0.9306418,0.000022115722,0.0003614921,0.0006184048,0.0000414221,7.008392e-8,0.00017271776,0.00006357021,0.00024279921,0.06381648],"study_design_scores_gemma":[0.01169675,0.014900726,0.96986264,0.00014026056,0.0008800692,0.00009156921,0.000015899122,0.0000020453897,0.00005865765,0.00009705579,0.0022070627,0.00004725937],"about_ca_topic_score_codex":0.0000021165522,"about_ca_topic_score_gemma":0.0000013885999,"teacher_disagreement_score":0.06376922,"about_ca_system_score_codex":0.000067569745,"about_ca_system_score_gemma":0.0006801464,"threshold_uncertainty_score":0.23246467},"labels":[],"label_agreement":null},{"id":"W2890307745","doi":"10.1158/1557-3265.aacriaslc18-b21","title":"Abstract B21: Investigating targeted driver mutations and PD-L1 expression for improved therapy of non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"KRAS; Lung cancer; Medicine; ROS1; Targeted therapy; Immunotherapy; Cancer research; Immunohistochemistry; Oncology; Cancer; Adenocarcinoma; Internal medicine; Pathology; Colorectal cancer","score_opus":0.15439677921671938,"score_gpt":0.5357251731605476,"score_spread":0.3813283939438282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890307745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920668,0.0030263967,0.00018706809,0.001539574,0.0002702972,0.0018720856,0.00015717301,0.000023440867,0.0008571766],"genre_scores_gemma":[0.990139,0.0021757567,0.004645854,0.00035083364,0.0007438566,0.0009044382,0.000052323292,0.000041131923,0.0009467954],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982656,0.00008212004,0.00053547823,0.00045325965,0.00027012383,0.00039338655],"domain_scores_gemma":[0.9973507,0.000847538,0.000173234,0.00029102596,0.0010304645,0.0003070617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075976073,0.00014188969,0.00035290944,0.00011786276,0.00029108534,0.000028188675,0.00012066229,0.00015842346,0.00035941598],"category_scores_gemma":[0.0003455944,0.00010618151,0.000115732946,0.0002715537,0.0006608447,0.00009037056,0.0000626273,0.00038039678,0.0000033682127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018854204,0.00094859954,0.28028983,0.0008515051,0.0005470881,0.0000060296034,0.004248607,0.0000172377,0.5940271,0.00003501375,0.017551081,0.09959249],"study_design_scores_gemma":[0.016255775,0.0026227825,0.7029414,0.0012378359,0.0002466189,0.000001178611,0.0007477226,0.0056509264,0.25788155,0.00061878125,0.011459359,0.0003360208],"about_ca_topic_score_codex":0.0015374108,"about_ca_topic_score_gemma":0.00028435737,"teacher_disagreement_score":0.42265162,"about_ca_system_score_codex":0.00013975342,"about_ca_system_score_gemma":0.0012508793,"threshold_uncertainty_score":0.43299565},"labels":[],"label_agreement":null},{"id":"W2890366457","doi":"10.1200/jco.2018.36.15_suppl.e21060","title":"Real-world dose adjustment study of first-line afatinib in pts with <i>EGFR</i> mutation-positive (<i>EGFR</i>m+) advanced NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Afatinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Incidence (geometry); Medical record; Oncology; Gefitinib; Cancer; Epidermal growth factor receptor","score_opus":0.061094580241303154,"score_gpt":0.48453997645575086,"score_spread":0.4234453962144477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890366457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98125464,0.00020141553,0.00009631468,0.0031844077,0.00089085085,0.0010059315,0.000010370313,0.000010365789,0.013345716],"genre_scores_gemma":[0.99259025,0.00032223985,0.0047390135,0.0009369268,0.0008198356,0.00003162615,0.000009133958,0.000024715475,0.00052623096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627525,0.0003052898,0.002423615,0.00027522637,0.000473437,0.00024718576],"domain_scores_gemma":[0.9946511,0.0016810183,0.0020404842,0.0002556477,0.0010845673,0.00028721636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010693978,0.00019570884,0.0014577158,0.00026965878,0.000058668218,0.0000053562308,0.00013383223,0.00013954313,0.0001116541],"category_scores_gemma":[0.00066257926,0.00012682221,0.00019120195,0.00047398455,0.00025040662,0.00016773572,0.000036924535,0.0005164215,0.000009131846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054066535,0.053007144,0.5104913,0.00011145677,0.0036741449,0.0034899707,0.009918648,0.0009202014,0.00015299908,0.00038913536,0.0023661181,0.36141232],"study_design_scores_gemma":[0.056667406,0.10972188,0.82378304,0.00053570245,0.0014698376,0.00013258652,0.0025507114,0.00008655616,0.0002148666,0.00015769996,0.004534178,0.00014555892],"about_ca_topic_score_codex":0.00042458958,"about_ca_topic_score_gemma":0.00978998,"teacher_disagreement_score":0.36126676,"about_ca_system_score_codex":0.00047160036,"about_ca_system_score_gemma":0.0014459232,"threshold_uncertainty_score":0.54630387},"labels":[],"label_agreement":null},{"id":"W2890374573","doi":"10.1200/jco.2017.35.15_suppl.9018","title":"Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; T790M; Medicine; Internal medicine; Genotyping; Gastroenterology; Oncology; Aura; Progression-free survival; Epidermal growth factor receptor; Chemotherapy; Genotype; Cancer; Gefitinib; Erlotinib; Genetics","score_opus":0.23769348002614202,"score_gpt":0.5610531228271586,"score_spread":0.3233596428010166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890374573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97157484,0.0000520875,0.000014449025,0.01578551,0.00090847904,0.00041528553,0.000021101036,0.0000020382156,0.011226213],"genre_scores_gemma":[0.99769676,0.00007407502,0.0006219183,0.0009870033,0.0003682521,0.000008949289,0.0000024605692,0.0000070977962,0.00023351064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706775,0.00026482306,0.002136787,0.00009885909,0.00031981265,0.000111981775],"domain_scores_gemma":[0.99398464,0.0024955228,0.0028557496,0.00031180677,0.00025630122,0.0000959959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282593,0.00007958613,0.0010178977,0.00008387345,0.00006186178,0.0000064954907,0.00026275753,0.0001433422,0.00006838289],"category_scores_gemma":[0.006420544,0.00004428518,0.00035693694,0.000057451205,0.00032604387,0.00007191861,0.000019791474,0.0004772723,0.000010003411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24423315,0.020739574,0.5747485,0.00019189395,0.0026600533,0.0009878186,0.004033236,0.00033166193,0.00036492103,0.0077013117,0.0052325362,0.13877536],"study_design_scores_gemma":[0.093629,0.02609702,0.85621977,0.0001943217,0.0006809544,0.000064008724,0.0002947026,0.000104855586,0.000039186405,0.00073953543,0.02189073,0.00004593395],"about_ca_topic_score_codex":0.00008331226,"about_ca_topic_score_gemma":0.00005837267,"teacher_disagreement_score":0.28147125,"about_ca_system_score_codex":0.000064722146,"about_ca_system_score_gemma":0.00080570666,"threshold_uncertainty_score":0.76864547},"labels":[],"label_agreement":null},{"id":"W2890521724","doi":"10.1016/j.jtho.2018.07.026","title":"PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pemetrexed; Pembrolizumab; Medicine; Placebo; Internal medicine; Carboplatin; Quality of life (healthcare); Oncology; Cisplatin; Chemotherapy; Cancer; Pathology","score_opus":0.04196411465326621,"score_gpt":0.4600915825657306,"score_spread":0.41812746791246436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890521724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864447,0.0005396798,0.0004551616,0.005973244,0.00048308054,0.00056767283,0.000016477808,0.000015129909,0.0055048126],"genre_scores_gemma":[0.9934265,0.000054321874,0.004412727,0.0006740341,0.00027581496,0.000011659945,0.000009934263,0.000028995364,0.0011060218],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970514,0.0003826503,0.0015461346,0.00021134394,0.00045107276,0.00035738086],"domain_scores_gemma":[0.9966098,0.0004780969,0.0017719186,0.0002604116,0.0005428685,0.000336911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012743375,0.00020172352,0.0012811053,0.00043875197,0.00008283435,0.00000839013,0.00014296696,0.00022515109,0.00048288284],"category_scores_gemma":[0.0006138537,0.00012834184,0.00013476884,0.00057063,0.0002243726,0.00013378529,0.00003155434,0.0005207038,0.000015930134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44925126,0.010189507,0.1635728,0.0018395387,0.0037275644,0.0024304134,0.032332264,0.00048544517,0.003782687,0.00021689906,0.01889388,0.31327772],"study_design_scores_gemma":[0.07903693,0.08347231,0.8081982,0.0020016881,0.0016606367,0.004321737,0.007914078,0.0006372409,0.0018261789,0.00039392873,0.00988427,0.00065280683],"about_ca_topic_score_codex":0.00074093044,"about_ca_topic_score_gemma":0.001884301,"teacher_disagreement_score":0.64462537,"about_ca_system_score_codex":0.0009356904,"about_ca_system_score_gemma":0.0040535647,"threshold_uncertainty_score":0.719085},"labels":[],"label_agreement":null},{"id":"W2890614044","doi":"10.1016/j.tranon.2018.08.010","title":"Short-Term Responders of Non–Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms","year":2018,"lang":"en","type":"article","venue":"Translational Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"HRAS; PTEN; Medicine; Lung cancer; Adenocarcinoma; Internal medicine; Exon; Cancer research; Oncology; Tyrosine kinase; Cancer; Gene; KRAS; Biology; Receptor; PI3K/AKT/mTOR pathway; Signal transduction; Genetics; Colorectal cancer","score_opus":0.010999450330161161,"score_gpt":0.32247162102257154,"score_spread":0.3114721706924104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890614044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99186116,0.0004792265,0.0035418114,0.0011436258,0.00021133013,0.0009481714,0.0004913754,0.000012336255,0.0013109685],"genre_scores_gemma":[0.9881174,0.00004893186,0.010595568,0.00019107264,0.00006285735,0.000106542015,0.00015393959,0.000017636312,0.000706082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989225,0.000039184117,0.00038927392,0.00026185004,0.0002303175,0.00015684415],"domain_scores_gemma":[0.9991474,0.00013181086,0.00012422903,0.00013328774,0.00034935807,0.00011392022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008791918,0.00013040625,0.00028157982,0.00014945156,0.00007439519,0.0000030951971,0.000058103546,0.00009146092,0.000093089184],"category_scores_gemma":[0.000013529932,0.00011763892,0.000049573704,0.0002094804,0.00017021866,0.00007580021,0.000013916522,0.000067932335,0.0000015842998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068477388,0.0038038236,0.5857398,0.004470215,0.00072563236,0.000038231487,0.018803457,0.0003621229,0.35167778,0.00704166,0.0015546682,0.018934883],"study_design_scores_gemma":[0.0032264795,0.0012320908,0.9725957,0.00030613504,0.00080948614,0.0000015130319,0.00004545852,0.00006403098,0.020894092,0.0003326959,0.00036297177,0.00012934043],"about_ca_topic_score_codex":0.000057910944,"about_ca_topic_score_gemma":0.0002907984,"teacher_disagreement_score":0.3868559,"about_ca_system_score_codex":0.00018625746,"about_ca_system_score_gemma":0.00047345998,"threshold_uncertainty_score":0.47971758},"labels":[],"label_agreement":null},{"id":"W2890739427","doi":"10.1200/jco.2018.36.15_suppl.9027","title":"Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; T790M; Medicine; Internal medicine; Oncology; Lung cancer; Clinical trial; Acquired resistance; Gastroenterology; Cancer; Epidermal growth factor receptor; Gefitinib; Erlotinib","score_opus":0.09850696491913635,"score_gpt":0.5246477761164255,"score_spread":0.4261408111972892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890739427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811382,0.000059949958,0.00004060485,0.014719725,0.00067990413,0.00048819225,0.000009216587,0.000002681976,0.0028614865],"genre_scores_gemma":[0.9958647,0.000031358348,0.0018974742,0.0012728041,0.0005442043,0.000012910489,7.16539e-7,0.00000782068,0.0003680474],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99687666,0.00066424045,0.0019127653,0.000104775354,0.0003163939,0.00012514392],"domain_scores_gemma":[0.99422735,0.003786571,0.0011441559,0.00018614244,0.0005095179,0.00014623521],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00310485,0.000072139046,0.0007605774,0.0001515087,0.000026259462,0.0000033413307,0.0001599775,0.0001512154,0.00010038979],"category_scores_gemma":[0.008988893,0.000042214662,0.0002470527,0.00027841105,0.00028061692,0.000061385355,0.000016998492,0.0003222936,0.000020625414],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87728226,0.0074304147,0.035266116,0.00003514464,0.0009553453,0.00031033647,0.01166147,0.000045382614,0.0016175861,0.0005082349,0.00613541,0.05875231],"study_design_scores_gemma":[0.0857962,0.09951436,0.7605327,0.00022249494,0.0006505623,0.00009986519,0.00081897277,0.000032592903,0.0004110106,0.00046477726,0.0514017,0.00005476503],"about_ca_topic_score_codex":0.00006558539,"about_ca_topic_score_gemma":0.000047166355,"teacher_disagreement_score":0.791486,"about_ca_system_score_codex":0.00007800159,"about_ca_system_score_gemma":0.0020287423,"threshold_uncertainty_score":0.99935883},"labels":[],"label_agreement":null},{"id":"W2890760483","doi":"10.1200/jco.2016.34.15_suppl.11585","title":"Prognostic and predictive effects of <i>TP53</i> mutation in patients with <i>EGFR</i>-mutated non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Stage (stratigraphy); Oncology; Demographics; Cancer; Biology","score_opus":0.013517193474923658,"score_gpt":0.3810150777036595,"score_spread":0.36749788422873586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890760483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641466,0.00044192476,0.00060188153,0.0008564486,0.00038270134,0.00075940765,0.000013015136,0.0000039390657,0.00052599586],"genre_scores_gemma":[0.998262,0.0003158393,0.00085596286,0.00032595225,0.00012715028,0.000026647676,0.0000042233637,0.000014359513,0.00006789082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998323,0.0001473089,0.0010071278,0.00015601587,0.00021129509,0.00015520427],"domain_scores_gemma":[0.9964562,0.0016998624,0.0010906042,0.00008057992,0.00048311087,0.00018964492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036293626,0.00011362274,0.0007642362,0.00011139899,0.000017173401,0.0000028457266,0.000048713522,0.00015515635,0.000011340254],"category_scores_gemma":[0.00063540536,0.0000587378,0.00008882833,0.00012768141,0.00012984902,0.000099683486,0.000016890297,0.00023711582,8.084788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003943021,0.0018572821,0.9514748,0.0001651823,0.0003791395,0.000192212,0.00037278325,0.000021366784,0.0001884949,0.0000026106911,0.00021875254,0.04118435],"study_design_scores_gemma":[0.0330012,0.018310515,0.94520146,0.0011604253,0.00147491,0.0000141583705,0.00003528478,0.00005227732,0.00047109713,0.000029092133,0.0001861711,0.00006343526],"about_ca_topic_score_codex":0.000033351393,"about_ca_topic_score_gemma":0.0000389874,"teacher_disagreement_score":0.041120917,"about_ca_system_score_codex":0.00020166763,"about_ca_system_score_gemma":0.0012727753,"threshold_uncertainty_score":0.23952581},"labels":[],"label_agreement":null},{"id":"W2891282311","doi":"10.1200/jco.2017.35.15_suppl.e20588","title":"A phase IV study using multi-omics to identify mechanisms of response and resistance to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients with distinct progression free survival outcomes.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Hôpital Notre-Dame; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; ALK inhibitor; Progression-free survival; Adenocarcinoma; Cancer; Chemotherapy; Progressive disease","score_opus":0.09242738899590684,"score_gpt":0.5440280215783889,"score_spread":0.45160063258248206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891282311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937985,0.00006786983,0.0021937112,0.0014768544,0.0007684589,0.0015749185,0.00004704413,0.0000037737796,0.0000688589],"genre_scores_gemma":[0.9577324,0.000014072372,0.041792702,0.00021957202,0.000064560125,0.000032492906,0.00000148534,0.000024403584,0.00011835471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728566,0.00030773372,0.0014875962,0.00029775905,0.0003901665,0.00023108345],"domain_scores_gemma":[0.9960607,0.0007414172,0.0017902253,0.0004270853,0.00058955397,0.0003909893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019578577,0.00017780115,0.0012954033,0.00016276541,0.00011804324,0.000021953758,0.0002518715,0.000127112,0.0000068469794],"category_scores_gemma":[0.003168253,0.000117076714,0.0001186662,0.000100476354,0.000080741345,0.0001362776,0.00015344449,0.00035296663,4.1055924e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04555809,0.009814774,0.9316971,0.00005474422,0.00024271739,0.00032774167,0.0010301406,0.00002304111,0.0009750995,0.0000029314888,0.000030091573,0.010243549],"study_design_scores_gemma":[0.06988272,0.014727992,0.91326296,0.00058870926,0.0006434454,0.0000024656445,0.00041382216,0.00005382601,0.00015973518,0.000020427047,0.00013353025,0.00011037233],"about_ca_topic_score_codex":0.000130156,"about_ca_topic_score_gemma":0.0023761261,"teacher_disagreement_score":0.03959899,"about_ca_system_score_codex":0.00031939798,"about_ca_system_score_gemma":0.0012277236,"threshold_uncertainty_score":0.47742498},"labels":[],"label_agreement":null},{"id":"W2891331437","doi":"10.1200/jco.2018.36.15_suppl.2062","title":"Neurological death in patients with EGFR-mutant non-small cell lung cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Radiosurgery; Incidence (geometry); Exact test; Cause of death; Internal medicine; Cancer; Mortality rate; Surgery; Disease; Radiation therapy","score_opus":0.05322073428816949,"score_gpt":0.4530012459895872,"score_spread":0.3997805117014177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891331437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903734,0.00012961517,0.00010368685,0.0028459204,0.0008595027,0.0002934268,0.000004296477,0.0000053352,0.005384863],"genre_scores_gemma":[0.99296296,0.00014294355,0.00241866,0.0034536715,0.00084041717,0.000007611075,0.0000022485897,0.000013306742,0.00015816305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980821,0.00013412807,0.0011449124,0.00018330112,0.00022641887,0.00022913655],"domain_scores_gemma":[0.99791735,0.0004102008,0.0007912417,0.00013044356,0.0004652939,0.00028548768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005471753,0.00011806615,0.0008423538,0.00008949341,0.000035745656,0.0000057960774,0.00010824822,0.00021945659,0.00016825812],"category_scores_gemma":[0.00028587706,0.00006613697,0.00015428843,0.00013163671,0.00013198605,0.0000614333,0.000029387358,0.0006024439,0.000009405423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041462225,0.0024471804,0.9767867,0.000013480423,0.00015963962,0.00040478402,0.00010958721,0.000014109849,0.000008314105,0.000012506411,0.00075028726,0.015147203],"study_design_scores_gemma":[0.016601099,0.031855177,0.9416972,0.00007652722,0.0005552341,0.000027733773,0.000016039729,0.00014002786,0.000021613465,0.000030542695,0.008913334,0.000065495],"about_ca_topic_score_codex":0.00005301072,"about_ca_topic_score_gemma":0.00012055918,"teacher_disagreement_score":0.035089508,"about_ca_system_score_codex":0.00019497554,"about_ca_system_score_gemma":0.0016985339,"threshold_uncertainty_score":0.30131263},"labels":[],"label_agreement":null},{"id":"W2891394568","doi":"10.1200/jco.2018.36.15_suppl.e21072","title":"Detection of <i>EGFR</i> mutations in cfDNA and development of resistance.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; T790M; Oncology; Lung cancer; Cohort; Cancer; Adenocarcinoma","score_opus":0.08581517410043638,"score_gpt":0.4951139988762518,"score_spread":0.4092988247758154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891394568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408406,0.0003100307,0.00079616293,0.00089580053,0.0003128795,0.00009249185,0.0000013870194,0.0000014689605,0.0035057254],"genre_scores_gemma":[0.9842715,0.000101715916,0.015203049,0.00014552122,0.00014152407,0.0000018871194,7.6205487e-7,0.000003641317,0.00013037816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983615,0.00006840252,0.0013247371,0.000062944375,0.00012010242,0.00006228792],"domain_scores_gemma":[0.9982677,0.0004034683,0.00084090146,0.00005433162,0.00035715682,0.00007643831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007786956,0.000041472747,0.00048497476,0.00010476524,0.000019425273,9.3923245e-7,0.000028134978,0.000095291165,0.00002291527],"category_scores_gemma":[0.0006416614,0.00002994782,0.000060938448,0.00010134715,0.00017991629,0.000043296302,0.000009679759,0.00014472993,0.0000012588902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051879506,0.0030650797,0.15334803,0.00016017191,0.00082175795,0.00009483257,0.0049382653,0.0000056329445,0.010523089,0.00021179605,0.0005653677,0.821078],"study_design_scores_gemma":[0.0090890005,0.0058493977,0.91539764,0.0002290687,0.00032573484,0.000054750926,0.0008289378,0.000011904566,0.009242093,0.00053358095,0.058388148,0.00004974563],"about_ca_topic_score_codex":0.000010037541,"about_ca_topic_score_gemma":0.0005637527,"teacher_disagreement_score":0.8210283,"about_ca_system_score_codex":0.000093183044,"about_ca_system_score_gemma":0.0012386371,"threshold_uncertainty_score":0.2197289},"labels":[],"label_agreement":null},{"id":"W2891448801","doi":"10.1200/jco.2016.34.15_suppl.tps9110","title":"A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Internal medicine; Oncology; Regimen; Hazard ratio; Clinical endpoint; Phases of clinical research; Taxane; Progression-free survival; Chemotherapy; Cancer; Randomized controlled trial; Confidence interval; Breast cancer","score_opus":0.04533389530143748,"score_gpt":0.44474085606756897,"score_spread":0.39940696076613147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891448801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521446,0.00017843783,0.00049499254,0.0010212027,0.00042462136,0.0024077033,0.000058761005,0.0000090687845,0.0001907258],"genre_scores_gemma":[0.9937646,0.00027706244,0.004856932,0.00021925748,0.000078284604,0.00011394545,0.000015044475,0.000047972997,0.00062693947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953635,0.0005303749,0.0025390445,0.0004477181,0.00069929444,0.00042011077],"domain_scores_gemma":[0.9930168,0.0025016048,0.0025853373,0.00028796552,0.0012674198,0.00034088065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010080937,0.00035806626,0.002300221,0.00050120277,0.000049182407,0.000011913678,0.000211232,0.00017003935,0.00025062336],"category_scores_gemma":[0.0010557207,0.00016233577,0.00015845214,0.0009027657,0.00019042456,0.00035111356,0.000047517842,0.00055462384,0.0000025745794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54845065,0.0820131,0.24229139,0.00019567498,0.002469951,0.0027734286,0.0018799156,0.00017614945,0.000103084814,0.0000041713433,0.00015401938,0.11948847],"study_design_scores_gemma":[0.44866163,0.21403778,0.33095637,0.0013201095,0.002508835,0.000031560066,0.0018187867,0.00014785689,0.00017062592,0.000006051921,0.000121064324,0.00021932978],"about_ca_topic_score_codex":0.0003581369,"about_ca_topic_score_gemma":0.010072211,"teacher_disagreement_score":0.13202468,"about_ca_system_score_codex":0.00097042747,"about_ca_system_score_gemma":0.0048921406,"threshold_uncertainty_score":0.8678447},"labels":[],"label_agreement":null},{"id":"W2891578028","doi":"10.1200/jco.2016.34.15_suppl.e20640","title":"Effect of molecular profile in non-small cell lung carcinoma on the development of brain metastases.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto Western Hospital; Princess Margaret Cancer Centre; Centre Integre de Sante et de Services Sociaux de Laval","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; KRAS; Univariate analysis; Adenocarcinoma; Histology; Stage (stratigraphy); Performance status; Gastroenterology; Cancer; Multivariate analysis","score_opus":0.04085546704490309,"score_gpt":0.4418191791213141,"score_spread":0.400963712076411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891578028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991922,0.00017635219,0.00029340637,0.003796805,0.0001985989,0.0003878155,0.0000048901466,0.0000011407618,0.0032189449],"genre_scores_gemma":[0.99665654,0.00001720367,0.0026554542,0.00039777128,0.00006197052,0.000013202422,0.0000011137494,0.000008279862,0.00018845765],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99770755,0.0004785023,0.0013974473,0.00009727543,0.00019932576,0.000119908436],"domain_scores_gemma":[0.9945673,0.0040616775,0.0009791394,0.0001381653,0.00015397665,0.00009975034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031373834,0.000087517496,0.0008231567,0.00009437301,0.000012540915,9.988429e-7,0.00010111805,0.00010739676,0.00008759941],"category_scores_gemma":[0.0013923586,0.000036377347,0.00024402344,0.00008854641,0.00008424191,0.000020815476,0.000025063311,0.0002202988,0.0000048648812],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081744585,0.004780386,0.42729968,0.00045362316,0.0015007938,0.000838252,0.0012292665,0.000020246516,0.049266286,0.000249518,0.0045402143,0.5016473],"study_design_scores_gemma":[0.036262065,0.042694937,0.5320211,0.00092577375,0.0014569942,0.000054021628,0.00017340155,0.000041800962,0.37760767,0.000082143604,0.008541003,0.00013905877],"about_ca_topic_score_codex":0.000008831006,"about_ca_topic_score_gemma":0.000012301963,"teacher_disagreement_score":0.50150824,"about_ca_system_score_codex":0.0001535331,"about_ca_system_score_gemma":0.001503327,"threshold_uncertainty_score":0.26668376},"labels":[],"label_agreement":null},{"id":"W2892143167","doi":"10.1200/jco.2016.34.15_suppl.e20534","title":"Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Gemcitabine; Lung cancer; Chemotherapy; Carboplatin; Proportional hazards model; Relative risk; Cisplatin; Confidence interval","score_opus":0.09988383138418304,"score_gpt":0.494027381386435,"score_spread":0.39414355000225193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892143167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873347,0.0018361527,0.004800672,0.0042747343,0.0005868946,0.0004962371,0.0002832248,0.0000031592851,0.00038418607],"genre_scores_gemma":[0.9885434,0.00418139,0.0053237025,0.0007906866,0.00067182473,0.0000151563945,0.0000066420084,0.000018795132,0.00044839608],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99651235,0.00023769196,0.0026919085,0.000187481,0.00020564791,0.00016491144],"domain_scores_gemma":[0.9906381,0.00487678,0.0035414596,0.00019097766,0.00055010995,0.00020259383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021696645,0.00013421466,0.003585473,0.00020627723,0.000024801335,0.0000039323963,0.00010883639,0.00025937418,0.00036210465],"category_scores_gemma":[0.0011638062,0.000073884294,0.0009734608,0.00015830806,0.00012727057,0.00005986872,0.000017644954,0.0001605989,3.9445388e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018738696,0.0070712366,0.2845664,0.00027331384,0.07181194,0.0001109329,0.0023511143,0.000100747166,0.0339964,0.000110967914,0.0039282944,0.57693994],"study_design_scores_gemma":[0.06503318,0.010489352,0.850317,0.00040873737,0.05733746,0.0000061014143,0.00024451906,0.00042882859,0.003844131,0.00045211124,0.01128084,0.0001577296],"about_ca_topic_score_codex":0.00030748927,"about_ca_topic_score_gemma":0.00015703608,"teacher_disagreement_score":0.5767822,"about_ca_system_score_codex":0.00014074828,"about_ca_system_score_gemma":0.0017494981,"threshold_uncertainty_score":0.3964792},"labels":[],"label_agreement":null},{"id":"W2892376413","doi":"10.1200/jco.2018.36.15_suppl.8533","title":"The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Demographics; Exon; Oncology; Stage (stratigraphy); Smoking history; Epidermal growth factor receptor; Exome; Exome sequencing; Mutation; Cancer; Gene; Genetics; Biology; Demography","score_opus":0.038393804658525356,"score_gpt":0.4377770137652252,"score_spread":0.39938320910669983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892376413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97877043,0.0030767045,0.000084931446,0.0034592508,0.0018428733,0.0005606639,0.000004577825,0.0000032883681,0.012197266],"genre_scores_gemma":[0.9971764,0.00040541188,0.0002634194,0.000931956,0.0006346794,0.00002286354,5.8758843e-7,0.000016960023,0.0005477114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769634,0.00041545733,0.001275093,0.00012769287,0.0003088461,0.00017657295],"domain_scores_gemma":[0.9943215,0.0030736409,0.0017935712,0.00026187746,0.00042814913,0.00012124874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022789626,0.00011932775,0.0008113878,0.00005386006,0.000067119196,0.0000028021557,0.00020213675,0.00017078125,0.00018454445],"category_scores_gemma":[0.0010912889,0.00005240379,0.00042223933,0.000080325626,0.00041077897,0.00002445148,0.0000353584,0.00053062564,0.000003420877],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029530123,0.00515308,0.29406744,0.00097249355,0.009055129,0.0010535151,0.005022171,0.00012866418,0.057505433,0.0014145715,0.06106559,0.5350318],"study_design_scores_gemma":[0.040136855,0.13823764,0.24904047,0.0025638014,0.011997127,0.00017174859,0.00054275064,0.0010158088,0.17011552,0.0001624064,0.38564122,0.00037464447],"about_ca_topic_score_codex":0.00007304931,"about_ca_topic_score_gemma":0.000028808166,"teacher_disagreement_score":0.5346572,"about_ca_system_score_codex":0.0004950797,"about_ca_system_score_gemma":0.0022350505,"threshold_uncertainty_score":0.39648837},"labels":[],"label_agreement":null},{"id":"W2893040167","doi":"10.1634/theoncologist.2018-0150","title":"Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; St. Joseph’s Healthcare Hamilton","funders":"Canadian Institutes of Health Research","keywords":"Osimertinib; Medicine; Cost effectiveness; Lung cancer; Quality-adjusted life year; Oncology; Epidermal growth factor receptor; Internal medicine; Erlotinib; Cancer; Risk analysis (engineering)","score_opus":0.02511183467803173,"score_gpt":0.38573719465674927,"score_spread":0.36062535997871753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893040167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791571,0.00069249654,0.0014525835,0.00034461418,0.00022634545,0.0023442935,0.00004859994,0.000027312548,0.01570668],"genre_scores_gemma":[0.9970995,0.00007939826,0.000969098,0.00022656664,0.00009725004,0.00097285915,0.00004140933,0.000020776513,0.00049311947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901503,0.00014181553,0.00025740665,0.00023576364,0.00011923071,0.00023075717],"domain_scores_gemma":[0.9983171,0.0010285497,0.00018594084,0.00020991394,0.00020136643,0.000057101337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025617421,0.00014990207,0.0003229522,0.000066916495,0.00012607135,0.000009649208,0.000097573524,0.00006602218,0.000092589806],"category_scores_gemma":[0.0001269869,0.00009927531,0.00006632087,0.00030764885,0.00022771556,0.00006373535,0.000031929594,0.00012187071,0.0000077612285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071097524,0.0040132036,0.6638082,0.0012014585,0.0011351561,0.00052262045,0.033775028,0.01130671,0.05392562,0.0009961592,0.0013996687,0.22080638],"study_design_scores_gemma":[0.021154016,0.0029335185,0.86293334,0.0015518029,0.0011608702,0.000017815624,0.0030803073,0.002775932,0.10341302,0.00027925917,0.0003803883,0.00031972068],"about_ca_topic_score_codex":0.00405714,"about_ca_topic_score_gemma":0.0016730224,"teacher_disagreement_score":0.22048666,"about_ca_system_score_codex":0.0006860003,"about_ca_system_score_gemma":0.00041382792,"threshold_uncertainty_score":0.6133209},"labels":[],"label_agreement":null},{"id":"W2894446537","doi":"10.1002/ijc.31895","title":"Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC","year":2018,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Gene duplication; Medicine; Protein kinase domain; Oncology; Kinase; Cancer research; Epidermal growth factor receptor; Internal medicine; Biology; Cancer; Genetics; Gene","score_opus":0.023778689625598814,"score_gpt":0.4506324583486082,"score_spread":0.4268537687230094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894446537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850643,0.0007060951,0.0011368224,0.011060656,0.001146272,0.0001303185,0.000023159157,0.000003991664,0.00072836026],"genre_scores_gemma":[0.99485767,0.00017374095,0.0028942744,0.0013112772,0.0005908898,0.000010614167,0.0000041097633,0.000007948534,0.00014948111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989691,0.000024948085,0.00052100624,0.000082967825,0.00032985696,0.000072117815],"domain_scores_gemma":[0.99869704,0.00008161893,0.00026606844,0.00008393258,0.00080068025,0.00007068184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020100115,0.00006380328,0.00021751162,0.0002029667,0.000011257275,0.000008291201,0.00012392351,0.000034710796,0.00031272793],"category_scores_gemma":[0.00011222829,0.00004512866,0.0001131354,0.00010607791,0.000057312962,0.000083142724,0.000015328069,0.000082818915,0.000008084459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009189188,0.0003731377,0.9192734,0.0000043300674,0.0010649842,0.000028502269,0.0017908192,0.000018339602,0.0032370617,0.00084877113,0.0014623916,0.07097939],"study_design_scores_gemma":[0.0029559908,0.0002817536,0.9781775,0.0001673755,0.00008110639,0.000011355134,0.00018425641,0.000007895665,0.001346487,0.00092667283,0.01581559,0.000044010812],"about_ca_topic_score_codex":0.00019267078,"about_ca_topic_score_gemma":0.0002946233,"teacher_disagreement_score":0.070935376,"about_ca_system_score_codex":0.00021597483,"about_ca_system_score_gemma":0.00024901825,"threshold_uncertainty_score":0.34241518},"labels":[],"label_agreement":null},{"id":"W2895007836","doi":"10.1136/bmjopen-2018-021611","title":"Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"BMJ Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"Medical Research Council; University of Bristol; Cancer Research UK","keywords":"Medicine; Meta-analysis; Lung cancer; Relative risk; Confidence interval; Cohort study; Cohort; Internal medicine; Publication bias; Cancer; Demography","score_opus":0.16752829501052885,"score_gpt":0.5339712530658876,"score_spread":0.3664429580553587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895007836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017212234,0.94944024,0.000010157682,0.0001995697,0.000015854797,0.048727114,0.0011461814,0.000006960726,0.0004521801],"genre_scores_gemma":[0.000009136936,0.9212561,0.00016460818,0.00040923172,0.00002528416,0.07383716,0.000043127435,0.000033314576,0.0042220326],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99804556,0.00025421346,0.0008427737,0.00047427946,0.0001703113,0.00021287384],"domain_scores_gemma":[0.9982605,0.00022560338,0.0007871746,0.0005096933,0.00008516756,0.0001318517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010071322,0.00033166335,0.007270603,0.00019897844,0.000075107906,0.000106600346,0.0001567246,0.000099888,0.00071909366],"category_scores_gemma":[0.0002551803,0.00018299815,0.00061381195,0.000432766,0.000024095716,0.0000926634,0.0001405565,0.00010365966,0.0000026422902],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007795155,0.000018032591,0.000019135205,0.7723415,0.22145101,0.0000061377214,0.00052655925,4.766175e-8,1.2024157e-9,0.0000058619576,0.00033461073,0.005289313],"study_design_scores_gemma":[0.00046441786,0.00006653019,0.000012305129,0.10628465,0.8591742,0.000018158411,0.000046991507,0.000010075051,1.0997656e-8,0.000010080954,0.03373009,0.00018252307],"about_ca_topic_score_codex":0.0007019585,"about_ca_topic_score_gemma":0.00024573132,"teacher_disagreement_score":0.6660569,"about_ca_system_score_codex":0.00042700703,"about_ca_system_score_gemma":0.000488686,"threshold_uncertainty_score":0.78735715},"labels":[],"label_agreement":null},{"id":"W2896248377","doi":"10.2217/fon-2018-0711","title":"Sequential treatment with afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: an observational study","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Afatinib; Medicine; T790M; Observational study; Internal medicine; Lung cancer; Oncology; Clinical trial; Chemotherapy; Retrospective cohort study; Cancer; Epidermal growth factor receptor; Erlotinib; Gefitinib","score_opus":0.024571066342871796,"score_gpt":0.35720369986363815,"score_spread":0.33263263352076633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896248377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946372,0.00011251927,0.000051784227,0.00078156195,0.00020608272,0.002279411,0.000077984485,0.000024427516,0.0018290381],"genre_scores_gemma":[0.995282,0.000015542442,0.002231317,0.00061993627,0.0005138072,0.00056132994,0.00045588365,0.0000292882,0.00029091066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988894,0.00007379366,0.00021921885,0.00040695918,0.0001781917,0.00023247248],"domain_scores_gemma":[0.9992224,0.000041226787,0.00013933638,0.00016747857,0.00029581873,0.00013373485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005086075,0.00021661783,0.00033113887,0.0000935446,0.0001466334,0.0000169894,0.000042730324,0.00008863971,0.000090785325],"category_scores_gemma":[0.000002286654,0.00014095174,0.000019492752,0.00021344509,0.00009452903,0.00012685049,0.000014199289,0.00009981366,0.00000303652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023943228,0.0037697023,0.9725625,0.000019500423,0.00044296795,0.00010241894,0.012288313,0.000020037229,0.000053980923,0.000022551783,0.00011702633,0.0082066795],"study_design_scores_gemma":[0.025982874,0.031095536,0.9378313,0.00005448252,0.000955864,0.0000128645825,0.0023189287,0.00013015624,0.00022274256,0.000003319398,0.0012273274,0.00016463579],"about_ca_topic_score_codex":0.001125043,"about_ca_topic_score_gemma":0.0075276955,"teacher_disagreement_score":0.034731228,"about_ca_system_score_codex":0.0006624966,"about_ca_system_score_gemma":0.0008531549,"threshold_uncertainty_score":0.5747845},"labels":[],"label_agreement":null},{"id":"W2896825577","doi":"10.1007/s10637-018-0680-z","title":"Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; University of Toronto; Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Selumetinib; Medicine; Carboplatin; Pemetrexed; Cohort; Internal medicine; Adverse effect; Chemotherapy; Tolerability; Neutropenia; Oncology; Cisplatin; Cancer; Gastroenterology; KRAS","score_opus":0.03154237553643747,"score_gpt":0.3657243787929642,"score_spread":0.33418200325652675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896825577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944368,0.00009012626,0.00002668777,0.0021469402,0.00009821291,0.0025259524,0.0004403805,0.000028232067,0.00020664137],"genre_scores_gemma":[0.99356955,0.000017408365,0.003926186,0.00092700776,0.000112583744,0.00021366423,0.00024855576,0.000046132456,0.00093889545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979449,0.00017653167,0.0006392166,0.0003859962,0.0005569088,0.00029643075],"domain_scores_gemma":[0.9981416,0.0002008292,0.00047842078,0.00025088323,0.0004940277,0.00043425255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033884723,0.00025050572,0.0007614408,0.00035374393,0.000118859345,0.000024838128,0.00008811368,0.000051501724,0.00047287537],"category_scores_gemma":[0.00034620633,0.00017603142,0.000047455494,0.00083457556,0.00012784761,0.00018686896,0.000009955462,0.00011967566,0.0000038730327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016407669,0.0032873214,0.8655604,0.00014892813,0.003198312,0.000069807116,0.04379717,0.00025228853,0.00033197596,0.00015713272,0.0072775776,0.059511416],"study_design_scores_gemma":[0.2033064,0.013249183,0.7624226,0.0034269395,0.0017607866,0.0000060807947,0.0063878316,0.00017710568,0.0024876918,0.00067639526,0.0053966204,0.00070234307],"about_ca_topic_score_codex":0.056197073,"about_ca_topic_score_gemma":0.21428213,"teacher_disagreement_score":0.18689874,"about_ca_system_score_codex":0.0008296452,"about_ca_system_score_gemma":0.0030861918,"threshold_uncertainty_score":0.9500878},"labels":[],"label_agreement":null},{"id":"W2897029126","doi":"10.1016/j.jtho.2018.08.1906","title":"P3.15-30 Treatment Patterns and Survival of Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Era of Novel Therapies","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Targeted therapy; Lung cancer; Chemotherapy; Radiation therapy; Immunotherapy; Population; Palliative care; Cancer","score_opus":0.02091967962354643,"score_gpt":0.39365789217145725,"score_spread":0.37273821254791084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897029126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709696,0.0005394371,0.0003154396,0.00078025024,0.00019457533,0.0003890707,0.00007984049,0.0000015340087,0.000602881],"genre_scores_gemma":[0.9981166,0.00033873838,0.0011049579,0.00014296615,0.00012659848,0.000014356921,0.000005018874,0.000012123306,0.00013864176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991131,0.00007953136,0.0003756308,0.00010189621,0.00019079303,0.0001390798],"domain_scores_gemma":[0.99885637,0.00012392936,0.00053212966,0.00013428362,0.0002992996,0.00005399657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002050038,0.000121317076,0.00044292695,0.00009344157,0.00003441138,0.00000530123,0.0000787583,0.000060711813,0.00009681243],"category_scores_gemma":[0.0000069905327,0.000061076265,0.000059490318,0.00009717611,0.0001110427,0.000054943837,0.000013791874,0.00013846824,3.187161e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002154581,0.0025083576,0.9472017,0.00014002115,0.00055664434,0.000035222005,0.014064303,0.000018972481,0.0006259763,0.0000056353865,0.000047327805,0.03264123],"study_design_scores_gemma":[0.0071660485,0.010746269,0.97545147,0.00030874313,0.0008711932,0.00001609687,0.002732463,0.000059661106,0.0014114205,0.00000456532,0.0011612757,0.000070809896],"about_ca_topic_score_codex":0.00059236994,"about_ca_topic_score_gemma":0.0011019665,"teacher_disagreement_score":0.032570418,"about_ca_system_score_codex":0.00023401785,"about_ca_system_score_gemma":0.0004819926,"threshold_uncertainty_score":0.2490618},"labels":[],"label_agreement":null},{"id":"W2897073503","doi":"10.1158/1078-0432.ccr-18-1640","title":"Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"KRAS; Cancer research; Lung cancer; Crizotinib; Medicine; Targeted therapy; Exon; Mutation; Cancer; Biology; Oncology; Internal medicine; Colorectal cancer; Gene; Genetics","score_opus":0.14412588355530465,"score_gpt":0.5362777339219142,"score_spread":0.3921518503666096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897073503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883282,0.0024701266,0.000058683094,0.004237653,0.00037177085,0.0016611991,0.000075592405,0.000022546259,0.0027742302],"genre_scores_gemma":[0.9900613,0.003609316,0.00078900624,0.0006393205,0.00073170435,0.0008305097,0.00002291902,0.00004048173,0.0032754827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727494,0.00026018565,0.0006936356,0.0005565837,0.0006901918,0.00052446],"domain_scores_gemma":[0.9972807,0.00070570316,0.00013667814,0.00046074638,0.0011170858,0.0002990822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001473824,0.00016336465,0.00049377367,0.0003039525,0.00010914699,0.000019816585,0.00022075207,0.00017103471,0.00081663165],"category_scores_gemma":[0.00055140874,0.00012582235,0.00010526691,0.0011296228,0.0002935575,0.00008638478,0.000072872,0.0005105789,0.00002333783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009783451,0.0020118996,0.79023844,0.0005772836,0.00057148095,0.000046671714,0.0065794303,0.000045916662,0.11463139,0.00013380636,0.027067514,0.048312724],"study_design_scores_gemma":[0.010862186,0.0033142616,0.536241,0.0014292758,0.00012148857,4.6843246e-7,0.00067394477,0.0002532746,0.4152236,0.00034921285,0.031190729,0.000340566],"about_ca_topic_score_codex":0.0034884196,"about_ca_topic_score_gemma":0.00492706,"teacher_disagreement_score":0.3005922,"about_ca_system_score_codex":0.000601604,"about_ca_system_score_gemma":0.0016689801,"threshold_uncertainty_score":0.89415437},"labels":[],"label_agreement":null},{"id":"W2897305886","doi":"10.1016/j.cllc.2018.10.001","title":"LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University","funders":"Canadian Cancer Society Research Institute; National Institutes of Health; Institut National Du Cancer; Sanofi; Texas Medical Board; Ligue Contre le Cancer; Foundation for the National Institutes of Health","keywords":"Immunohistochemistry; Medicine; Lung cancer; Oncology; Pathology; Internal medicine","score_opus":0.023872109312829584,"score_gpt":0.40891452944386075,"score_spread":0.3850424201310312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897305886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98998594,0.0040703793,0.0002481911,0.0006210556,0.00042337726,0.0017274745,0.00019194793,0.000053701042,0.0026779163],"genre_scores_gemma":[0.9956914,0.00035591572,0.00072975556,0.00020621734,0.0003361177,0.00088716915,0.00014592789,0.00004131332,0.0016061922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979935,0.00006161787,0.00078290154,0.0005915211,0.00024980385,0.0003205995],"domain_scores_gemma":[0.99820745,0.0003555003,0.00035954296,0.00040157005,0.00046816154,0.00020775721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002785195,0.00024864916,0.0005179183,0.00009155565,0.00008865705,0.000014637851,0.00012546913,0.00026814587,0.00047519928],"category_scores_gemma":[0.00041212162,0.00020494149,0.00013037036,0.0004321267,0.00047027436,0.000058072423,0.000048612044,0.00027724786,0.0000018495062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004976081,0.0009025004,0.9313981,0.0018236764,0.0010459595,0.000030426803,0.0005718237,0.000052750675,0.0492919,0.0000017335416,0.0077324356,0.0021726203],"study_design_scores_gemma":[0.038723156,0.0030671367,0.58378273,0.0085669365,0.008421621,0.000014396542,0.00046090275,0.03760144,0.31688482,0.000027142101,0.0013417216,0.001107996],"about_ca_topic_score_codex":0.00079939165,"about_ca_topic_score_gemma":0.00014565025,"teacher_disagreement_score":0.34761536,"about_ca_system_score_codex":0.00077553943,"about_ca_system_score_gemma":0.0019430862,"threshold_uncertainty_score":0.83572716},"labels":[],"label_agreement":null},{"id":"W2897963283","doi":"10.1093/annonc/mdy292.082","title":"Biopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; AstraZeneca (Canada); University of Alberta","funders":"","keywords":"Medicine; Osimertinib; T790M; Lung cancer; Biopsy; Internal medicine; Cancer; Oncology; Erlotinib; ROS1; Adenocarcinoma; Epidermal growth factor receptor","score_opus":0.024889791945023658,"score_gpt":0.41918213251374986,"score_spread":0.3942923405687262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897963283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97791237,0.00024563895,0.00001448454,0.0016467809,0.00030260117,0.0008928475,0.000064299355,0.000010488721,0.01891048],"genre_scores_gemma":[0.99699295,0.0000914676,0.00059312064,0.0016059416,0.00007304085,0.00027649247,0.00008809861,0.000016163678,0.0002627039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896294,0.00004135198,0.0002578983,0.00027746495,0.0001340196,0.0003263394],"domain_scores_gemma":[0.99904424,0.000041288225,0.00015844847,0.00015117002,0.00041234313,0.00019249662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062745494,0.00013405204,0.0002537815,0.00023954948,0.000079059784,0.0000048195448,0.00006853653,0.00011783452,0.00009833689],"category_scores_gemma":[0.000035132776,0.00011320124,0.000045295863,0.00025503073,0.00010860115,0.00008631505,0.000013978839,0.000095663185,0.000012957557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019641176,0.0031248578,0.4826283,0.00017155563,0.0001842935,0.0003404306,0.049611695,0.000086475535,0.0060660196,0.00012194297,0.0028945387,0.4528058],"study_design_scores_gemma":[0.008342677,0.012884992,0.9049848,0.000953908,0.00013186931,0.000010951452,0.0015871512,0.0003690355,0.06255961,0.000047158377,0.007848019,0.0002798537],"about_ca_topic_score_codex":0.031220725,"about_ca_topic_score_gemma":0.03706949,"teacher_disagreement_score":0.4525259,"about_ca_system_score_codex":0.0004694166,"about_ca_system_score_gemma":0.0009407145,"threshold_uncertainty_score":0.9805015},"labels":[],"label_agreement":null},{"id":"W2898173281","doi":"10.1016/j.jtho.2018.08.538","title":"MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Crizotinib; Alectinib; Medicine; Lung cancer; Ceritinib; Cohort; Anaplastic lymphoma kinase; Concomitant; Internal medicine; Oncology; ALK inhibitor; Tyrosine-kinase inhibitor; Cancer research; Cancer","score_opus":0.052950821730096645,"score_gpt":0.47823845112969793,"score_spread":0.4252876293996013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898173281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858499,0.0004973453,0.00017482489,0.004472489,0.0002648152,0.0004684484,0.000027749438,0.0000029212517,0.008241511],"genre_scores_gemma":[0.99582505,0.000058083053,0.0034820633,0.00020194483,0.00011105022,0.000013786413,0.00002295199,0.000009804108,0.00027526572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983591,0.00033807685,0.0007847776,0.00011587112,0.00025385368,0.00014831255],"domain_scores_gemma":[0.9982661,0.00035644256,0.0007969875,0.00015386943,0.00037689274,0.000049710543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056572625,0.000108981876,0.00046888707,0.00029859488,0.000043099877,0.000005667197,0.00011185864,0.0000888825,0.000040725987],"category_scores_gemma":[0.00012711766,0.00007299237,0.000111417765,0.00036490613,0.00020434092,0.00014650177,0.00001505202,0.00018011841,0.00000262232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049860273,0.019784693,0.41402957,0.0007452632,0.006168733,0.0041331793,0.26027715,0.0007211912,0.09919666,0.0062476615,0.010062164,0.12877348],"study_design_scores_gemma":[0.020219209,0.007130138,0.8911164,0.002139522,0.0036536867,0.00036814046,0.017301893,0.000351747,0.039678685,0.009546592,0.008183594,0.0003104302],"about_ca_topic_score_codex":0.00024508196,"about_ca_topic_score_gemma":0.0030795408,"teacher_disagreement_score":0.4770868,"about_ca_system_score_codex":0.00063661434,"about_ca_system_score_gemma":0.00069428893,"threshold_uncertainty_score":0.29765424},"labels":[],"label_agreement":null},{"id":"W2898201615","doi":"10.1016/j.jtho.2018.08.1077","title":"P2.01-23 Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Internal medicine; Oncology; Anaplastic lymphoma kinase; Lung cancer; Targeted therapy; Crizotinib; Cancer; Cancer research","score_opus":0.017870239617701726,"score_gpt":0.42931481677263383,"score_spread":0.4114445771549321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898201615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853325,0.0014729785,0.001047831,0.006629297,0.0016075388,0.0007306873,0.000055106466,0.000021220236,0.003102875],"genre_scores_gemma":[0.98250836,0.000504948,0.0114063965,0.0013919694,0.0010227775,0.00006948593,0.00001744556,0.000048197802,0.0030303989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997882,0.00024243048,0.0008164042,0.00030857263,0.00029601608,0.00045458757],"domain_scores_gemma":[0.9979634,0.0003534878,0.0005385334,0.00028063392,0.0004499713,0.00041394559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007873947,0.00024937704,0.00069061434,0.0006363868,0.000093644696,0.000018248063,0.0002090105,0.00019599753,0.0003117857],"category_scores_gemma":[0.0002548502,0.00019494718,0.00017208191,0.00046506902,0.000114436945,0.00015977383,0.00006310497,0.00034435463,0.00003263776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03844213,0.0019664546,0.4993802,0.0004144617,0.0013230115,0.0033292333,0.004198846,0.0002253092,0.04287342,0.000002321211,0.023962267,0.38388234],"study_design_scores_gemma":[0.016613236,0.017233683,0.8596615,0.0031924956,0.003649827,0.0014272063,0.0013769342,0.0013466866,0.033361595,0.000022458938,0.061466876,0.00064751116],"about_ca_topic_score_codex":0.000087843786,"about_ca_topic_score_gemma":0.000894459,"teacher_disagreement_score":0.38323483,"about_ca_system_score_codex":0.0013380485,"about_ca_system_score_gemma":0.0019468517,"threshold_uncertainty_score":0.7949715},"labels":[],"label_agreement":null},{"id":"W2898210229","doi":"10.1016/j.jtho.2018.08.868","title":"P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Gefitinib; Osimertinib; Internal medicine; Observational study; Toxicity; Oncology; Dermatology; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.017464433877562375,"score_gpt":0.45503046161288235,"score_spread":0.43756602773532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898210229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748434,0.00008115896,0.0002569327,0.0024548422,0.00046117025,0.00052744633,0.000009799538,0.000014147481,0.021351133],"genre_scores_gemma":[0.9779778,0.000031154013,0.019627925,0.000443271,0.00027791463,0.000044690467,0.000020158897,0.000020014646,0.0015570681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865645,0.00010565152,0.000534177,0.00015425368,0.00031515263,0.00023433802],"domain_scores_gemma":[0.998563,0.000111908215,0.0005035342,0.00014590031,0.0005422074,0.0001334721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024226043,0.00014113181,0.0004475181,0.00042096776,0.00008203315,0.00001562475,0.000082952145,0.00006856231,0.00014734216],"category_scores_gemma":[0.000050886803,0.00009594252,0.000067787914,0.0003632237,0.00014658443,0.00024679664,0.000020253077,0.00024102612,0.000007021431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004742823,0.0031579405,0.7201737,0.00010547357,0.0005230711,0.00047588462,0.003978647,0.0001053077,0.00027605312,0.00040473256,0.0014194591,0.26463687],"study_design_scores_gemma":[0.006764118,0.009997664,0.9607386,0.00061703427,0.0006428038,0.00012594284,0.0019555783,0.000051013638,0.000374734,0.00051676447,0.018057294,0.00015846167],"about_ca_topic_score_codex":0.00008049586,"about_ca_topic_score_gemma":0.0021897834,"teacher_disagreement_score":0.2644784,"about_ca_system_score_codex":0.0012440472,"about_ca_system_score_gemma":0.0012161143,"threshold_uncertainty_score":0.39124227},"labels":[],"label_agreement":null},{"id":"W2898220308","doi":"10.1093/annonc/mdy292.064","title":"Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Oncology; Internal medicine; Squamous-cell carcinoma of the lung; Lung; Phases of clinical research; Basal cell; Clinical trial; Epidermal growth factor receptor; Cancer","score_opus":0.053951533739119546,"score_gpt":0.4301635303496723,"score_spread":0.37621199661055277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898220308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841271,0.00037874185,0.000015905067,0.0003607157,0.00037997877,0.0013403236,0.00058165623,0.000010498329,0.012805051],"genre_scores_gemma":[0.99867606,0.000030072179,0.00024232501,0.00014184417,0.000110379675,0.00007642507,0.00024443533,0.000014408992,0.00046401966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983049,0.00010819469,0.00066884176,0.00032060788,0.00030962046,0.00028783214],"domain_scores_gemma":[0.9977697,0.00018774788,0.0007845023,0.00046188955,0.00067058374,0.00012553368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009623334,0.00022833953,0.00095401803,0.00015289489,0.0000790588,0.0000030892993,0.00013106476,0.0001208689,0.00056578196],"category_scores_gemma":[0.000065828295,0.00014337193,0.00036228623,0.0007002001,0.00030625897,0.000060045666,0.00003359319,0.00005967412,0.0000024383382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67551064,0.04289925,0.17086506,0.000292085,0.012412947,0.00009041202,0.007316844,0.0004856058,0.0009008278,0.00048100203,0.0019178032,0.0868275],"study_design_scores_gemma":[0.602694,0.24460223,0.09049005,0.00004952312,0.019451324,0.0000054421057,0.0008619063,0.0006671835,0.030312475,0.000024284247,0.01055045,0.0002911327],"about_ca_topic_score_codex":0.00051337865,"about_ca_topic_score_gemma":0.0008540663,"teacher_disagreement_score":0.20170298,"about_ca_system_score_codex":0.00029139017,"about_ca_system_score_gemma":0.00083370256,"threshold_uncertainty_score":0.6194916},"labels":[],"label_agreement":null},{"id":"W2898224495","doi":"10.1016/j.jtho.2018.08.438","title":"MA14.11 Factors Associated with Early Mortality in Non-Small Cell Lung Cancer Patients Following Systemic Anti-Cancer Treatment","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Population; Regimen; Cancer; Logistic regression; Disease; Performance status; Univariate analysis; Multivariate analysis","score_opus":0.02800090055143276,"score_gpt":0.4166349053164878,"score_spread":0.388634004765055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898224495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701697,0.00055223296,0.00003213512,0.00015456222,0.0010236404,0.0006131747,0.000043673805,0.000012146264,0.0005514904],"genre_scores_gemma":[0.9987748,0.000112112735,0.0001080324,0.00009235951,0.00022055519,0.00004809112,0.000016479948,0.000030131867,0.0005973945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984704,0.00012832295,0.0005750096,0.0002112751,0.00028373266,0.0003312508],"domain_scores_gemma":[0.99847835,0.00007917573,0.00074171205,0.00014481749,0.00037752165,0.000178432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020709287,0.00022241929,0.000791793,0.00021623047,0.00008697164,0.000017394776,0.00009370495,0.0001666516,0.000066044784],"category_scores_gemma":[0.000026767877,0.00014080555,0.00018775683,0.0002726282,0.00005225048,0.00014419573,0.000016828448,0.0001890114,0.0000020718485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023278872,0.0012553893,0.9907536,0.00005889372,0.0012379101,0.00017447949,0.003113504,0.00004264534,0.0008967106,3.8286998e-7,0.00009614968,0.002137554],"study_design_scores_gemma":[0.004917631,0.003707448,0.9836381,0.00088465813,0.0028970486,0.000009772208,0.00047056787,0.000052825835,0.0030963286,0.0000020791597,0.00018397941,0.00013956112],"about_ca_topic_score_codex":0.0015753536,"about_ca_topic_score_gemma":0.0025152431,"teacher_disagreement_score":0.0071154917,"about_ca_system_score_codex":0.003645415,"about_ca_system_score_gemma":0.0010756948,"threshold_uncertainty_score":0.95326334},"labels":[],"label_agreement":null},{"id":"W2898226771","doi":"10.1093/annonc/mdy287.027","title":"Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Regimen; Internal medicine; Phases of clinical research; Clinical endpoint; Toxicity; Neutropenia; Gastroenterology; Pharmacokinetics; Surgery; Oncology; Urology; Clinical trial","score_opus":0.06985598141590381,"score_gpt":0.45456290614222555,"score_spread":0.38470692472632173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898226771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408746,0.00031526358,0.0000054530847,0.000725627,0.000081272665,0.0015056003,0.00013060335,0.000014010107,0.0031347277],"genre_scores_gemma":[0.9982079,0.00015304945,0.00033885683,0.00042993273,0.00004213783,0.00018478998,0.000086545624,0.000018192355,0.00053854473],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99849874,0.00009239234,0.00058799784,0.00030728226,0.0002328735,0.00028068724],"domain_scores_gemma":[0.9985055,0.00007643904,0.00037457707,0.00025360548,0.00068214204,0.0001077336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015018303,0.00016891897,0.00061484735,0.0001831538,0.000055200784,0.0000020545947,0.000086588654,0.000054188455,0.00004673611],"category_scores_gemma":[0.00007817194,0.00012224432,0.0000454995,0.0003654381,0.00017862697,0.00009395311,0.00003340553,0.000099212164,0.000003844576],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048148554,0.23407395,0.05888352,0.00022709281,0.0016357898,0.0003625316,0.01872879,0.00008306371,0.00030926333,0.000030167355,0.004920082,0.6325972],"study_design_scores_gemma":[0.3642744,0.53639036,0.0846273,0.00066299,0.0010365763,0.000016364122,0.0014917208,0.000110868496,0.0029428713,0.000054959368,0.008138268,0.00025329096],"about_ca_topic_score_codex":0.0013640296,"about_ca_topic_score_gemma":0.0030729661,"teacher_disagreement_score":0.6323439,"about_ca_system_score_codex":0.00013468676,"about_ca_system_score_gemma":0.00056825636,"threshold_uncertainty_score":0.4984979},"labels":[],"label_agreement":null},{"id":"W2898234690","doi":"10.1016/j.jtho.2018.12.006","title":"EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Germline; Lung cancer; Germline mutation; Medicine; T790M; Epidermal growth factor receptor; Cancer research; Cancer; Mutation; Oncology; Genetics; Internal medicine; Biology; Gene; Gefitinib","score_opus":0.008632132505897637,"score_gpt":0.42818809126769625,"score_spread":0.41955595876179863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898234690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917206,0.0030562046,0.000014780663,0.0042981207,0.00026701248,0.00048730455,0.000026269361,0.0000029629557,0.0001267192],"genre_scores_gemma":[0.99804795,0.000529117,0.0006596318,0.00046889854,0.00008803378,0.00003226404,0.0000041781022,0.000010568259,0.00015936367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991222,0.00007646146,0.00039452995,0.00015816106,0.0000939402,0.00015470585],"domain_scores_gemma":[0.9993627,0.0000981114,0.00017417224,0.0000812716,0.00015495275,0.00012877809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017782007,0.00011189004,0.0004059789,0.0002448103,0.000022998747,0.000008498679,0.000042201238,0.000073594,0.00009430406],"category_scores_gemma":[0.00005864283,0.000067777546,0.000035221892,0.00021047075,0.000037121717,0.000089032525,0.000029641076,0.00018606726,0.0000010426699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004123623,0.00032591075,0.90272456,0.000072946925,0.00006783442,0.000023255101,0.0033477535,0.00044260456,0.0009470507,0.000001187493,0.00005431875,0.09158024],"study_design_scores_gemma":[0.0020622043,0.00072835776,0.9952618,0.00018801453,0.0001161614,0.00003531703,0.0003711334,0.0004685192,0.000072779694,0.000109864384,0.000518192,0.00006765273],"about_ca_topic_score_codex":0.0005069904,"about_ca_topic_score_gemma":0.0075923395,"teacher_disagreement_score":0.09253727,"about_ca_system_score_codex":0.0006111309,"about_ca_system_score_gemma":0.0003890602,"threshold_uncertainty_score":0.42367035},"labels":[],"label_agreement":null},{"id":"W2898236034","doi":"10.1093/annonc/mdy292.130","title":"Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Osimertinib; Medicine; Gefitinib; T790M; Oncology; Internal medicine; Erlotinib; Randomized controlled trial; Progression-free survival; Lung cancer; Epidermal growth factor receptor; Chemotherapy; Cancer","score_opus":0.07165732510328492,"score_gpt":0.4499715277299406,"score_spread":0.37831420262665566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898236034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663276,0.00008094877,0.0060686814,0.0011122865,0.00012651738,0.0049549104,0.00010346711,0.000016814696,0.0009036383],"genre_scores_gemma":[0.99521554,0.0000817432,0.0031248594,0.0006515061,0.00008041914,0.00046264674,0.00018315975,0.000024207195,0.00017593076],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986537,0.00013466028,0.0005562063,0.00021891911,0.0002233594,0.00021314132],"domain_scores_gemma":[0.9976816,0.0004009175,0.00057958876,0.00020428427,0.0010395708,0.00009401353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003457864,0.0001692196,0.001084498,0.000114735296,0.000082683735,0.0000035668388,0.000056639896,0.00006053839,0.0001461704],"category_scores_gemma":[0.00015184742,0.000087568405,0.00011428983,0.00015731102,0.00063453865,0.00008062546,0.000009884898,0.000051836538,0.0000015476242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92077017,0.0060179397,0.00030235449,0.00003874577,0.001963616,0.0000045533975,0.001468148,0.0000034531904,0.00011155621,0.000108755055,0.00033916425,0.06887153],"study_design_scores_gemma":[0.83173203,0.1520905,0.000065137545,0.00008600367,0.0011599505,0.0000064634887,0.00020285613,0.00018482044,0.006998474,0.00007771889,0.0073016407,0.000094391435],"about_ca_topic_score_codex":0.00010244497,"about_ca_topic_score_gemma":0.000091228445,"teacher_disagreement_score":0.14607257,"about_ca_system_score_codex":0.00003593613,"about_ca_system_score_gemma":0.00097633916,"threshold_uncertainty_score":0.35709357},"labels":[],"label_agreement":null},{"id":"W2898240093","doi":"10.1016/j.jtho.2018.08.580","title":"P1.01-24 Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Lung cancer; Exact test; Proportional hazards model; Univariate analysis; Oncology; Nivolumab; Pneumonitis; Cancer; Immunotherapy; Multivariate analysis; Lung","score_opus":0.024906584256811845,"score_gpt":0.45849635894258267,"score_spread":0.4335897746857708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898240093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954145,0.002021406,0.00034874567,0.0005707732,0.00047191148,0.0006361054,0.0000100723355,0.000005990444,0.00052047527],"genre_scores_gemma":[0.9850019,0.0012781897,0.012451059,0.00047799543,0.00029266457,0.000015326843,0.0000061910123,0.000035686648,0.00044097772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982166,0.0002145334,0.00095667917,0.00017208078,0.00021323534,0.0002268195],"domain_scores_gemma":[0.9980643,0.00024782293,0.00096548354,0.00018423896,0.00040630353,0.00013189705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042835067,0.00016830747,0.0008882333,0.00025775688,0.000038628456,0.0000070079727,0.00012443183,0.00010911228,0.00020912262],"category_scores_gemma":[0.000033956174,0.00010578369,0.00017508649,0.00028786602,0.00016725108,0.00007728983,0.000009706413,0.00029520658,0.0000020968812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016332293,0.005938195,0.7746663,0.0001127557,0.0018168911,0.00018018532,0.002621625,0.000035657453,0.0021779723,0.0000015878759,0.001043589,0.19507295],"study_design_scores_gemma":[0.033279117,0.028731044,0.9212241,0.00076821545,0.0021596139,0.00011066309,0.00022608753,0.00024288165,0.0044210344,0.00000817219,0.008638804,0.00019024627],"about_ca_topic_score_codex":0.0001361199,"about_ca_topic_score_gemma":0.000109961926,"teacher_disagreement_score":0.1948827,"about_ca_system_score_codex":0.0005615574,"about_ca_system_score_gemma":0.0011968241,"threshold_uncertainty_score":0.43137336},"labels":[],"label_agreement":null},{"id":"W2898256364","doi":"10.1016/j.jtho.2018.08.1082","title":"P2.01-28 Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010 – 2014 Diagnoses","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Lung cancer; Regimen; Systemic therapy; Oncology; Confidence interval; non-small cell lung cancer (NSCLC); Overall survival; Statistical significance; Cancer; Breast cancer","score_opus":0.044355790065831624,"score_gpt":0.4331714993479645,"score_spread":0.3888157092821329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898256364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919557,0.0017892151,0.00008960467,0.0027238105,0.0009370584,0.0003598066,0.00004988125,0.0000064843944,0.0020884206],"genre_scores_gemma":[0.9959764,0.0018956282,0.00016170218,0.0004701631,0.00059161044,0.000011283345,0.0000047751814,0.000016727387,0.00087174424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881095,0.00020284945,0.00042833333,0.00013005297,0.00023157321,0.00019624086],"domain_scores_gemma":[0.9984339,0.00043533064,0.0005574941,0.00021681222,0.00020713064,0.00014931803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037972105,0.00015506531,0.0005097358,0.00012045801,0.00007529735,0.000013551563,0.00007868156,0.00009866218,0.00029588293],"category_scores_gemma":[0.00008387138,0.00007929062,0.00012505891,0.000048500475,0.00011223828,0.00007675328,0.000021616821,0.0001482152,0.0000145904805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014786549,0.007351813,0.6860914,0.0011875336,0.010380587,0.002333167,0.01960523,0.00006819862,0.021613281,0.0016575607,0.054747723,0.18017694],"study_design_scores_gemma":[0.008018434,0.0350764,0.91091645,0.0012158699,0.003387991,0.0020605389,0.0051422603,0.000051773022,0.0070914584,0.000240997,0.026528893,0.00026892332],"about_ca_topic_score_codex":0.00014995679,"about_ca_topic_score_gemma":0.000084143954,"teacher_disagreement_score":0.22482505,"about_ca_system_score_codex":0.00048678927,"about_ca_system_score_gemma":0.00043839967,"threshold_uncertainty_score":0.32397103},"labels":[],"label_agreement":null},{"id":"W2898275110","doi":"10.1016/j.jtho.2018.08.466","title":"MA18.02 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Crizotinib; Ceritinib; Oncology; Progression-free survival; Internal medicine; Overall survival; Lung cancer","score_opus":0.03575520757573197,"score_gpt":0.46958224673083526,"score_spread":0.4338270391551033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898275110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955616,0.00037292336,0.001437799,0.0009215161,0.000093242685,0.00019431608,0.000002542099,0.000002677376,0.0014133627],"genre_scores_gemma":[0.9949781,0.00006365848,0.004565423,0.000030282381,0.0001041964,0.0000069250377,0.000003391134,0.0000059266963,0.0002421483],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993271,0.00006111304,0.00034361842,0.000068937945,0.00009640519,0.00010282957],"domain_scores_gemma":[0.99932593,0.000048317375,0.00029233485,0.00008016779,0.00019530879,0.000057928948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002717945,0.00007674789,0.00024716984,0.00015365156,0.00004530196,0.00000467261,0.000034335742,0.000058594585,0.000024388077],"category_scores_gemma":[0.000030335203,0.000039633287,0.000065982174,0.00011379553,0.00006906685,0.00008226975,0.000010569767,0.000070467395,0.0000023679388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004994476,0.0022970599,0.13924457,0.00006020497,0.0016173745,0.00009908756,0.021194736,0.004114019,0.010156502,0.0002733834,0.0008179386,0.81513065],"study_design_scores_gemma":[0.007111618,0.024924412,0.9329866,0.00043539813,0.0016104167,0.0016298234,0.0019553474,0.010478856,0.012836858,0.0024581149,0.00336783,0.00020471647],"about_ca_topic_score_codex":0.00008796985,"about_ca_topic_score_gemma":0.00005238763,"teacher_disagreement_score":0.8149259,"about_ca_system_score_codex":0.0019055392,"about_ca_system_score_gemma":0.0013222275,"threshold_uncertainty_score":0.49829188},"labels":[],"label_agreement":null},{"id":"W2898310631","doi":"10.1016/j.jtho.2018.08.784","title":"P1.09-08 Integrating NGS Information for Staging Multiple Lung Adenocarcinoma: A McGill University Health Centre Retrospective Study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Adenocarcinoma; KRAS; Stage (stratigraphy); Neuroblastoma RAS viral oncogene homolog; Lung cancer; Internal medicine; Oncology; Lung; PDGFRA; Pathology; Cancer; Pathological; Stromal cell; Colorectal cancer; GiST","score_opus":0.019190825211845883,"score_gpt":0.4146866018561452,"score_spread":0.3954957766442993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898310631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837687,0.00014142686,0.005600997,0.007031185,0.00076000654,0.0013141816,0.0001419222,0.000028344675,0.0012132507],"genre_scores_gemma":[0.9890168,0.0000149255875,0.009988652,0.00037536025,0.0002476629,0.0000022024,0.000013735787,0.000008706686,0.00033196755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989832,0.00011199933,0.00041228675,0.00010953747,0.00017278262,0.00021021454],"domain_scores_gemma":[0.99815744,0.00009090619,0.00073044706,0.00010494964,0.0007672841,0.00014894555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005012988,0.00010612026,0.0003993249,0.0002403471,0.00031157536,0.000009227347,0.00007775712,0.000060533912,0.000026511498],"category_scores_gemma":[0.000209115,0.00008496021,0.00010264849,0.00019663242,0.000040367624,0.00041010522,0.000031111762,0.00022693141,0.000004635459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061689247,0.001953272,0.6696877,0.0002881424,0.0015801155,0.00019010725,0.05839017,0.000023142986,0.00014608732,0.00030633694,0.01392145,0.24734458],"study_design_scores_gemma":[0.019806357,0.03207184,0.60681975,0.00065252493,0.0028042493,0.00064072653,0.21125136,0.0038116712,0.00039189545,0.00023707717,0.12113889,0.00037362784],"about_ca_topic_score_codex":0.00024595557,"about_ca_topic_score_gemma":0.00038505063,"teacher_disagreement_score":0.24697095,"about_ca_system_score_codex":0.0034209504,"about_ca_system_score_gemma":0.00068679877,"threshold_uncertainty_score":0.89456666},"labels":[],"label_agreement":null},{"id":"W2898315580","doi":"10.1016/j.jtho.2018.08.647","title":"P1.01-91 A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Ifosfamide; Vinorelbine; Medicine; Chemotherapy; Lung cancer; Internal medicine; Oncology; Cohort; Surgery; Urology; Etoposide; Cisplatin","score_opus":0.02175414671195695,"score_gpt":0.45420331419668747,"score_spread":0.4324491674847305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898315580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963941,0.0014481265,0.00014514719,0.00054828834,0.00029661265,0.0006012873,0.000013250194,0.0000045425627,0.0005486757],"genre_scores_gemma":[0.9953477,0.0003387663,0.0038120106,0.00008108448,0.00022400443,0.000020843958,0.0000026716114,0.000017917222,0.00015503004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984683,0.00008894929,0.000891507,0.00016792312,0.00018940672,0.00019395347],"domain_scores_gemma":[0.9981809,0.00022487881,0.0009459675,0.00015999548,0.0003625863,0.00012566484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003595462,0.00015128437,0.00078808615,0.00029771018,0.000049900304,0.000004319753,0.00008832413,0.000093831884,0.00007895543],"category_scores_gemma":[0.00011661586,0.00011221399,0.00007653326,0.00028525572,0.00010082457,0.000100195124,0.00004878498,0.00023450721,4.4106383e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015936151,0.018638741,0.5516802,0.0012269275,0.0011362121,0.0007857413,0.029463965,0.0011570166,0.07707309,0.000004628677,0.00041027347,0.30248708],"study_design_scores_gemma":[0.11094521,0.10387266,0.6737652,0.004057068,0.007893682,0.00058635074,0.020325238,0.007117749,0.06829626,0.00014181201,0.00239046,0.00060830335],"about_ca_topic_score_codex":0.0003471344,"about_ca_topic_score_gemma":0.0014379743,"teacher_disagreement_score":0.30187875,"about_ca_system_score_codex":0.0002898805,"about_ca_system_score_gemma":0.00047795134,"threshold_uncertainty_score":0.45759538},"labels":[],"label_agreement":null},{"id":"W2898333243","doi":"10.1016/j.jtho.2018.08.1441","title":"P2.13-46 Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Lung cancer; Medicine; Mutation; Cancer research; Adenocarcinoma; Afatinib; Epidermal growth factor receptor; Protein kinase domain; Cancer; Pleural effusion; Oncology; Lung; Internal medicine; Tyrosine kinase; Pathology; Gene; Receptor; Gefitinib; Biology; Genetics","score_opus":0.01718842428348755,"score_gpt":0.4322136961175025,"score_spread":0.41502527183401494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898333243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306333,0.0006135534,0.00020549988,0.0033890144,0.00079134473,0.00046625396,0.000038240378,0.0000084281555,0.0014243359],"genre_scores_gemma":[0.9951482,0.000121127305,0.003561596,0.0005647357,0.00034862943,0.000024740932,0.0000376777,0.000019847508,0.00017344387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836415,0.00018186083,0.00080373936,0.00015426672,0.0002940889,0.00020192009],"domain_scores_gemma":[0.9980522,0.00016377734,0.00068243337,0.00013142596,0.00080384256,0.00016631848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020729376,0.00015900876,0.00059579057,0.00039540307,0.0000718921,0.0000072544017,0.00009894953,0.00014124245,0.00018025584],"category_scores_gemma":[0.00007158758,0.0001187876,0.00013415156,0.00039893587,0.00024599285,0.00020002575,0.000015081213,0.0002664428,0.000004205266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032957525,0.0017127212,0.8861451,0.0005699513,0.001130619,0.00021273672,0.026623437,0.00051838433,0.022908222,0.00006444561,0.001819949,0.054998696],"study_design_scores_gemma":[0.006148946,0.0032552045,0.9813575,0.00056617544,0.0009556222,0.00014232064,0.00082246517,0.00031790257,0.0023676453,0.0010554931,0.0028594644,0.00015127168],"about_ca_topic_score_codex":0.00021499873,"about_ca_topic_score_gemma":0.0007621482,"teacher_disagreement_score":0.0952124,"about_ca_system_score_codex":0.0005971339,"about_ca_system_score_gemma":0.00089699274,"threshold_uncertainty_score":0.48440176},"labels":[],"label_agreement":null},{"id":"W2898363961","doi":"10.1016/j.jtho.2018.08.598","title":"P1.01-42 Real-World Evaluation of Tolerability in Older Adult Patients (≥75 years old) with EGFR-mutated NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Afatinib; Gefitinib; Internal medicine; Tolerability; Observational study; Quality of life (healthcare); Oncology; Adverse effect; Epidermal growth factor receptor; Cancer","score_opus":0.02458887489881074,"score_gpt":0.45411237828709883,"score_spread":0.4295235033882881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898363961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157655,0.000050163646,0.000032409727,0.00079782575,0.00036778738,0.0005210086,0.0000080885775,0.0000067377478,0.006639456],"genre_scores_gemma":[0.99735296,0.000021847081,0.0019522,0.00023668412,0.00016244022,0.000013951656,0.000017128037,0.0000147421915,0.00022802466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982052,0.00027151685,0.0006521433,0.00015775955,0.00053719856,0.00017617989],"domain_scores_gemma":[0.9971815,0.000084614905,0.0006529394,0.00018937029,0.0017807138,0.00011088015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085259345,0.0001123146,0.00047641792,0.00030789126,0.000029745539,0.0000056547437,0.00007637513,0.000093488066,0.00029995586],"category_scores_gemma":[0.00018062623,0.00008029284,0.00007368962,0.00040859435,0.00013851558,0.0001346347,0.000016403092,0.00020691202,0.000007808123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004724321,0.002820264,0.7064773,0.000078433004,0.00039280558,0.00007665141,0.004196662,0.00008831845,0.00034242452,0.00002636287,0.0011989881,0.27957746],"study_design_scores_gemma":[0.0063080657,0.0042642658,0.986013,0.00034991268,0.0009903173,0.00004460605,0.00038174004,0.00022243355,0.00066161284,0.00020158065,0.00048744545,0.00007501182],"about_ca_topic_score_codex":0.0003227859,"about_ca_topic_score_gemma":0.0013416405,"teacher_disagreement_score":0.2795357,"about_ca_system_score_codex":0.0011004555,"about_ca_system_score_gemma":0.00095715316,"threshold_uncertainty_score":0.32843062},"labels":[],"label_agreement":null},{"id":"W2898381418","doi":"10.1016/j.jtho.2018.08.872","title":"P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; T790M; Lung cancer; Oncology; Gastroenterology; Cancer; Adenocarcinoma","score_opus":0.023622924812197785,"score_gpt":0.4398612666076692,"score_spread":0.4162383417954714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898381418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944614,0.0006014052,0.0015190303,0.0005810634,0.00019335707,0.00011126992,0.0000022808892,0.0000022130769,0.0025279736],"genre_scores_gemma":[0.98141515,0.00003889692,0.018167727,0.00004163104,0.00006941425,0.0000035940893,0.0000012969895,0.0000049438027,0.0002573695],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992237,0.000045805507,0.00047591556,0.00006303313,0.000114940514,0.000076609605],"domain_scores_gemma":[0.99911785,0.00006811767,0.00042306172,0.000060057664,0.00028078957,0.00005012506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027070055,0.000051823154,0.0002657141,0.00021529762,0.000033579807,0.0000017466613,0.000030790947,0.000058975354,0.000028654145],"category_scores_gemma":[0.000080757425,0.000040893257,0.000028718157,0.00015179106,0.000105621264,0.00006008889,0.000010060178,0.00008996567,0.0000012684241],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037225015,0.0012614554,0.025526436,0.00042825117,0.00060409156,0.00013189107,0.020780498,0.000019752635,0.10918705,0.00008911561,0.00033964386,0.83790934],"study_design_scores_gemma":[0.004696132,0.00472737,0.7133103,0.0008867717,0.00081746967,0.00056321616,0.0059356866,0.000055123215,0.22148542,0.0010078526,0.046358503,0.00015613307],"about_ca_topic_score_codex":0.000014037165,"about_ca_topic_score_gemma":0.0009005655,"teacher_disagreement_score":0.8377532,"about_ca_system_score_codex":0.00025840293,"about_ca_system_score_gemma":0.0005989659,"threshold_uncertainty_score":0.16675787},"labels":[],"label_agreement":null},{"id":"W2898391067","doi":"10.1016/j.jtho.2018.08.967","title":"P1.15-34 Treatment Patterns and Outcomes of Stage III Non-Small Cell Lung Cancer (NSCLC): Real World Evidence of How our Patients Fare","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Lung cancer; Cancer registry; Perioperative; Cancer; Population; Medical record; Chemotherapy; Oncology; Cohort; Surgery","score_opus":0.03304343641617705,"score_gpt":0.4459690156488541,"score_spread":0.41292557923267703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898391067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947311,0.0008973669,0.00011575969,0.0022890824,0.000611521,0.00045701928,0.000079991296,0.000004836584,0.0008132649],"genre_scores_gemma":[0.9929926,0.001209806,0.0011141903,0.00014439797,0.00022247569,0.000017865805,0.0000052601954,0.000018815803,0.0042746365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870354,0.00008853605,0.0005648612,0.00017485513,0.00025226903,0.00021590976],"domain_scores_gemma":[0.9978563,0.00012407423,0.0010775069,0.00020328216,0.00056428014,0.00017453618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017978545,0.0001866824,0.00081511773,0.00025373552,0.00005478969,0.00000914878,0.00010411424,0.000091982445,0.00007923487],"category_scores_gemma":[0.000032259635,0.00012261429,0.00016549176,0.000135599,0.00007024718,0.00013660631,0.000043193373,0.00013667725,7.9085635e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011730096,0.0008886684,0.94910717,0.00033527473,0.00068234955,0.000073423886,0.0024235127,0.0000052417563,0.0009302632,0.0000027029798,0.00059099594,0.043787416],"study_design_scores_gemma":[0.004874776,0.009418873,0.9687481,0.0011410399,0.0026184565,0.00001956598,0.002033078,0.000045736822,0.009677018,0.0000055999344,0.0012857558,0.0001320216],"about_ca_topic_score_codex":0.001377052,"about_ca_topic_score_gemma":0.0025308642,"teacher_disagreement_score":0.043655396,"about_ca_system_score_codex":0.00080578506,"about_ca_system_score_gemma":0.00073315325,"threshold_uncertainty_score":0.50000656},"labels":[],"label_agreement":null},{"id":"W2898410765","doi":"10.1093/annonc/mdy287.064","title":"Can concomitant diseases predict the compliance with cisplatin plus RT in patients with LA SCCHN? An exploratory endpoint analysis of the COMPLY trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for Oil Sands Innovation, University of Alberta","keywords":"Medicine; Internal medicine; Concomitant; Odds ratio; Univariate analysis; Cumulative dose; Cisplatin; Logistic regression; Oncology; Surgery; Multivariate analysis; Chemotherapy","score_opus":0.06533599826466881,"score_gpt":0.3947368519462247,"score_spread":0.3294008536815559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898410765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960052,0.000044423432,0.00001649497,0.0014755783,0.0000612378,0.00080561027,0.00033045022,0.000007936466,0.0012530849],"genre_scores_gemma":[0.9991555,0.000009073002,0.00007181264,0.00053163926,0.000040856383,0.00007002392,0.00008356229,0.000009626743,0.000027902905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892586,0.00021480628,0.00029511258,0.00017522386,0.00023873846,0.00015027315],"domain_scores_gemma":[0.99877435,0.00018063824,0.00029577283,0.00037303419,0.0003035356,0.00007264451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015547546,0.00010963417,0.00048583982,0.00010084648,0.00006886391,0.0000044927465,0.00013420187,0.00004274227,0.000038653856],"category_scores_gemma":[0.000042850326,0.00005077443,0.00007345869,0.0004797818,0.0006495712,0.00005027225,0.000029919413,0.00008649103,4.949118e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043506164,0.0024331836,0.94131017,0.0000333295,0.0027928578,0.000016654096,0.0055932864,0.0003783248,0.000025272919,0.00029230653,0.00064267166,0.0029757603],"study_design_scores_gemma":[0.029190037,0.011292596,0.95523876,0.00009880134,0.001893046,0.0000012078406,0.0010741688,0.0002807738,0.00018141352,0.00002547445,0.0006543725,0.0000693515],"about_ca_topic_score_codex":0.00027149045,"about_ca_topic_score_gemma":0.002488467,"teacher_disagreement_score":0.014316129,"about_ca_system_score_codex":0.000078857374,"about_ca_system_score_gemma":0.0006662475,"threshold_uncertainty_score":0.2393372},"labels":[],"label_agreement":null},{"id":"W2898445532","doi":"10.1016/j.jtho.2018.08.1410","title":"P2.13-15 Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Medicine; HRAS; PTEN; Internal medicine; Oncology; Lung cancer; Adenocarcinoma; Exon; Cancer research; Cancer; Afatinib; KRAS; Gefitinib; Gene; Epidermal growth factor receptor; PI3K/AKT/mTOR pathway; Genetics; Signal transduction; Colorectal cancer; Biology","score_opus":0.017331345528136075,"score_gpt":0.41609928299778154,"score_spread":0.39876793746964545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898445532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742634,0.0008160641,0.0048990683,0.0036896206,0.00043032717,0.00037508702,0.00006440304,0.0000075225166,0.002291576],"genre_scores_gemma":[0.97286767,0.00016105417,0.024830973,0.00029566328,0.00014079182,0.000010013288,0.0000054926177,0.000015635715,0.0016727338],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99861693,0.000118539916,0.0006264002,0.00016899199,0.00030017734,0.00016896804],"domain_scores_gemma":[0.9983392,0.00021515928,0.00048354513,0.00021637329,0.0005674559,0.00017826288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004410619,0.00012154423,0.0005054394,0.0002744951,0.00006828672,0.0000060194816,0.00012312655,0.00010508899,0.000100553385],"category_scores_gemma":[0.00016257454,0.000094893716,0.00009077393,0.00023504626,0.00022558804,0.00013110744,0.0000412818,0.00014724575,0.0000028544448],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033467583,0.00388049,0.035482567,0.004957854,0.0032791873,0.0012219897,0.023568038,0.00007396234,0.65439016,0.0067990157,0.012078622,0.2208005],"study_design_scores_gemma":[0.0042460696,0.019814702,0.8804129,0.003054998,0.0060890084,0.0011610693,0.002096189,0.000026128311,0.06739631,0.007358669,0.00794462,0.0003993868],"about_ca_topic_score_codex":0.000013937553,"about_ca_topic_score_gemma":0.00008527596,"teacher_disagreement_score":0.8449303,"about_ca_system_score_codex":0.00031328012,"about_ca_system_score_gemma":0.0006468007,"threshold_uncertainty_score":0.38696533},"labels":[],"label_agreement":null},{"id":"W2898483684","doi":"10.1016/j.jtho.2018.08.961","title":"P1.15-28 Real World Treatment Patterns and Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Erlotinib; Afatinib; Oncology; Stage (stratigraphy); Lung cancer; Cancer registry; Cohort; Population; Radiation therapy; Cancer; Epidermal growth factor receptor","score_opus":0.021860780063442664,"score_gpt":0.39339348510295974,"score_spread":0.3715327050395171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898483684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882614,0.0003209745,0.00003300369,0.00097105314,0.00086295087,0.00027763957,0.000042566575,0.0000025402003,0.009227856],"genre_scores_gemma":[0.9899659,0.00031591524,0.00056384533,0.00017819216,0.0002727116,0.000013213895,0.0000072919324,0.000015595666,0.008667327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883556,0.00007560959,0.0005103821,0.00015325464,0.00018710547,0.00023805536],"domain_scores_gemma":[0.99893904,0.00009882405,0.00044999388,0.00013862153,0.0001867046,0.00018680863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001857258,0.0001525215,0.0006002046,0.00019379077,0.00004250102,0.0000064907895,0.00006922045,0.00007155654,0.00052903197],"category_scores_gemma":[0.0000067238807,0.000111402995,0.000068801484,0.000117301686,0.000057013902,0.000055272278,0.000023658049,0.00020893765,4.7093346e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001067718,0.00048609547,0.9741907,0.000096089294,0.00036977232,0.0007062608,0.0028009543,0.000022409278,0.00041691607,0.0000060345915,0.0009870048,0.01885004],"study_design_scores_gemma":[0.003628382,0.0028923084,0.97280097,0.00029320538,0.0009127808,0.000060674345,0.0009016158,0.00005599612,0.0021768343,0.000007703954,0.016157057,0.000112464055],"about_ca_topic_score_codex":0.95347005,"about_ca_topic_score_gemma":0.99902934,"teacher_disagreement_score":0.045559276,"about_ca_system_score_codex":0.004083456,"about_ca_system_score_gemma":0.00684224,"threshold_uncertainty_score":0.9997397},"labels":[],"label_agreement":null},{"id":"W2898490299","doi":"10.1093/annonc/mdy424.065","title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"KU Leuven; Genentech; AstraZeneca; Celgene; Novartis Pharma; Astellas Pharma; Clovis Oncology; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Atezolizumab; Pemetrexed; Oncology; Population; Carboplatin; Docetaxel; Progression-free survival; Adverse effect; Paclitaxel; Clinical endpoint; Chemotherapy; Randomized controlled trial; Cancer; Cisplatin; Nivolumab; Immunotherapy","score_opus":0.036991900916455926,"score_gpt":0.43898577525450966,"score_spread":0.4019938743380537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898490299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937338,0.00063701073,0.00010580116,0.0008506495,0.00008728645,0.0028162168,0.0001293478,0.000024033901,0.0016158193],"genre_scores_gemma":[0.9979145,0.00052315375,0.00077179866,0.00016941271,0.00007757251,0.00026297642,0.00010277302,0.00003191198,0.00014592435],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99775547,0.00018850596,0.000845835,0.0005036711,0.00037642385,0.00033009233],"domain_scores_gemma":[0.99759805,0.00053824694,0.00057069445,0.0006042663,0.0005146927,0.00017402197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042770934,0.00029591686,0.0016458939,0.00034015262,0.00010385436,0.000007988491,0.00015651096,0.00015172892,0.00022469182],"category_scores_gemma":[0.00021182826,0.0001846727,0.00012668553,0.0007606557,0.0002972809,0.00010365252,0.000064342836,0.00015238844,0.0000013480856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59769326,0.01785969,0.18251976,0.00007428123,0.008523898,0.0003867766,0.03265039,0.00013451374,0.002106766,0.000011724082,0.00012471786,0.15791424],"study_design_scores_gemma":[0.74234086,0.13447154,0.10496654,0.00030287026,0.003195018,0.000023604462,0.0078766495,0.0012142645,0.0038608036,0.00013126456,0.0012007128,0.0004158544],"about_ca_topic_score_codex":0.006179543,"about_ca_topic_score_gemma":0.020678109,"teacher_disagreement_score":0.15749837,"about_ca_system_score_codex":0.0000824409,"about_ca_system_score_gemma":0.00055096834,"threshold_uncertainty_score":0.99719197},"labels":[],"label_agreement":null},{"id":"W2898505405","doi":"10.1017/s1460396918000547","title":"A review of radiation genomics: integrating patient radiation response with genomics for personalised and targeted radiation therapy","year":2018,"lang":"en","type":"review","venue":"Journal of Radiotherapy in Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University; University of Guelph; Grand River Hospital; Western University","funders":"","keywords":"Radiation therapy; Radiosensitivity; Medicine; Adverse effect; Genomics; Oncology; Cancer; Radiogenomics; Medical physics; Bioinformatics; Internal medicine; Genetics; Biology; Radiology; Genome; Gene","score_opus":0.024888906890823796,"score_gpt":0.3889343501656641,"score_spread":0.3640454432748403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898505405","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011673742,0.99396497,0.0007247503,0.0009692799,0.00022944425,0.002849886,0.000062799656,0.0000061505016,0.000025352885],"genre_scores_gemma":[0.000036230278,0.98083466,0.01720354,0.001199222,0.000419442,0.00011492405,0.00009809948,0.00007583489,0.000018020459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997141,0.0007502059,0.0013856855,0.00025307963,0.0002930219,0.0001769911],"domain_scores_gemma":[0.9931796,0.0016840931,0.004231221,0.00022844385,0.00056828535,0.00010830863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020215025,0.00032897407,0.0015319039,0.00048842997,0.000069246045,0.000039317267,0.000095745694,0.00018192637,0.00002193828],"category_scores_gemma":[0.0011988792,0.00022475544,0.00032139505,0.00037857683,0.00005592683,0.00044404043,0.0000047016047,0.0003474539,3.9605587e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006067037,0.00024728084,0.000023176102,0.008660455,0.0018645093,0.000014527353,0.0033524,0.0000046419345,0.00006389943,0.000011231044,0.0011504921,0.97854036],"study_design_scores_gemma":[0.004824938,0.0044287858,0.00005169538,0.028047223,0.0026278878,0.0008166453,0.0002910195,0.000074306074,0.00003638158,0.000003975347,0.9586058,0.00019133548],"about_ca_topic_score_codex":0.000020913943,"about_ca_topic_score_gemma":0.0000019567785,"teacher_disagreement_score":0.97834903,"about_ca_system_score_codex":0.0017713939,"about_ca_system_score_gemma":0.0024280946,"threshold_uncertainty_score":0.916526},"labels":[],"label_agreement":null},{"id":"W2898540761","doi":"10.1016/j.jtho.2018.08.1698","title":"P3.03-21 CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage Non-Small Cell Lung Cancer Patients","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; CXCR4; Stage (stratigraphy); Oncology; Internal medicine; Tissue microarray; Immunohistochemistry; Proportional hazards model; Cancer; Survival analysis; Pathology; Receptor; Biology","score_opus":0.020166396533744767,"score_gpt":0.41012878725678936,"score_spread":0.3899623907230446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898540761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955427,0.0002044568,0.000064742424,0.00068522687,0.0008421886,0.0003666734,0.00007436864,0.0000071852414,0.0022124348],"genre_scores_gemma":[0.99541664,0.000042481344,0.00085586554,0.0006559177,0.00023750047,0.000026599297,0.000009129589,0.000024778603,0.0027311116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998418,0.0001408812,0.0005744738,0.00020662784,0.00034881287,0.00031124355],"domain_scores_gemma":[0.99825287,0.00010200255,0.00071071554,0.00014386383,0.0006077835,0.00018275552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031796022,0.00018020147,0.0005547168,0.00020119292,0.00005932182,0.000018287585,0.00011700938,0.00017395396,0.00036922554],"category_scores_gemma":[0.00007376728,0.00012035249,0.00009503152,0.00024328046,0.00007494503,0.00017908507,0.000042108284,0.00040543778,0.0000126451905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028980728,0.0010384802,0.98690134,0.00007603272,0.00017592982,0.0002525088,0.0028034095,0.0000049962223,0.00032835614,4.78819e-7,0.00096010364,0.004560309],"study_design_scores_gemma":[0.0048081344,0.0052919583,0.98359126,0.0010187489,0.000615429,0.000013336848,0.00021675011,0.00009506757,0.0015818716,0.000008386995,0.0025918642,0.00016719468],"about_ca_topic_score_codex":0.00028534964,"about_ca_topic_score_gemma":0.00048787412,"teacher_disagreement_score":0.0043931147,"about_ca_system_score_codex":0.0010942611,"about_ca_system_score_gemma":0.00071746565,"threshold_uncertainty_score":0.4907832},"labels":[],"label_agreement":null},{"id":"W2898574100","doi":"10.1016/j.jtho.2018.08.1408","title":"P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Osimertinib; Afatinib; Internal medicine; T790M; Oncology; Gefitinib; Lung cancer; Erlotinib; Radiation therapy; Cancer; Epidermal growth factor receptor","score_opus":0.01795045282709801,"score_gpt":0.43276516897080336,"score_spread":0.41481471614370535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898574100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837912,0.00036843747,0.00005639292,0.0011979933,0.0005330884,0.00078398216,0.000036393143,0.000007740079,0.013224772],"genre_scores_gemma":[0.9961206,0.00016927092,0.0006001978,0.00029702112,0.00033249633,0.000039312294,0.000018340326,0.000027283237,0.0023955123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976562,0.00022654365,0.001101138,0.00027395593,0.0003179431,0.0004241906],"domain_scores_gemma":[0.99741435,0.00012540261,0.0009208148,0.0003056939,0.0007791647,0.00045457142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068270235,0.00021586152,0.0011454944,0.0017889747,0.00009610444,0.0000140728025,0.00019906492,0.00014972338,0.00065695745],"category_scores_gemma":[0.000050013725,0.0001732803,0.00022220095,0.0018806104,0.00009440223,0.00009705677,0.000030967574,0.00040987038,0.000007432411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008365842,0.0013826961,0.9737945,0.000047960362,0.003913402,0.0006993246,0.004785279,0.0006485859,0.00030281063,8.922081e-7,0.0024556413,0.011132288],"study_design_scores_gemma":[0.003460314,0.003645259,0.97184324,0.00016592306,0.014297137,0.00004040187,0.002412797,0.00092050177,0.001050751,0.000008055858,0.001993766,0.00016186753],"about_ca_topic_score_codex":0.31617677,"about_ca_topic_score_gemma":0.80645525,"teacher_disagreement_score":0.49027848,"about_ca_system_score_codex":0.0022847196,"about_ca_system_score_gemma":0.0037270144,"threshold_uncertainty_score":0.7193224},"labels":[],"label_agreement":null},{"id":"W2898633288","doi":"10.3747/co.25.4379","title":"Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre; Royal Victoria Hospital; University of Alberta; Princess Margaret Cancer Centre; University of Calgary; Mount Sinai Hospital; Royal Victoria Regional Health Centre; Baker Hughes (Canada); Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; McGill University; Jewish General Hospital; William Osler Health System; BC Cancer Foundation; Spinal Cord Injury BC; Western University; Island Health; University of Toronto; BC Cancer Agency","funders":"Pfizer","keywords":"Crizotinib; Ceritinib; Alectinib; Medicine; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Oncology; Internal medicine; Clinical trial; Targeted therapy; Cancer; Malignant pleural effusion","score_opus":0.04875350955883927,"score_gpt":0.4505188471758009,"score_spread":0.4017653376169616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898633288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002930188,0.9831953,0.000008977552,0.0002741048,0.001073012,0.0023644315,0.00057818706,0.000013149787,0.009562656],"genre_scores_gemma":[0.0026793745,0.99488956,0.000084859865,0.00007472559,0.00032356833,0.00079926505,0.0008443173,0.000048751597,0.00025555372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998332,0.000121245386,0.0004945093,0.00053299754,0.00012612407,0.00039310806],"domain_scores_gemma":[0.9987846,0.00008000372,0.00039290875,0.00025055802,0.0002473981,0.0002445373],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010375684,0.00035539406,0.0013756132,0.00064041064,0.000057633748,0.00000572992,0.00008943883,0.00026431575,0.00016547945],"category_scores_gemma":[0.000027283953,0.0002943303,0.0002501832,0.00038518422,0.00009796249,0.000041759366,0.000026734044,0.00047010256,0.000043172706],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009300065,0.0014768218,0.001081991,0.011340682,0.00043856926,0.00018007663,0.0045466996,0.000006159951,0.0000019721717,0.00023470364,0.0057238284,0.9748755],"study_design_scores_gemma":[0.0027779005,0.0010053045,0.0005688469,0.031223735,0.003192781,0.000021486674,0.0007436291,0.000012820505,0.000017531163,0.000013742892,0.9601015,0.00032075788],"about_ca_topic_score_codex":0.0091403825,"about_ca_topic_score_gemma":0.05045167,"teacher_disagreement_score":0.9745547,"about_ca_system_score_codex":0.007921353,"about_ca_system_score_gemma":0.0065797404,"threshold_uncertainty_score":0.9999509},"labels":[],"label_agreement":null},{"id":"W2898760538","doi":"10.3747/co.25.3914","title":"Afatinib in Advanced Pretreated Non-Small-Cell Lung Cancer—A Canadian Experience","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Calgary; BC Cancer Foundation; BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; Spinal Cord Injury BC; University of Toronto; University Health Network","funders":"National Cancer Institute; Princess Margaret Cancer Foundation","keywords":"Afatinib; Medicine; Internal medicine; Lung cancer; Population; Oncology; Chemotherapy; Erlotinib; Cancer; Surgery; Epidermal growth factor receptor","score_opus":0.047285308264753675,"score_gpt":0.44549805351692867,"score_spread":0.398212745252175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898760538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705562,0.0022688685,0.00004446498,0.0007209028,0.0013201424,0.00081286265,0.0000238903,0.000029882569,0.024222797],"genre_scores_gemma":[0.99736786,0.00032399083,0.00036306205,0.00033758246,0.00022428937,0.0005509018,0.000056762125,0.000016975884,0.0007585717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989668,0.0000270036,0.00021700673,0.0003080834,0.0000794768,0.0004016326],"domain_scores_gemma":[0.9992697,0.000027303637,0.0000685714,0.00020224453,0.00014307995,0.0002890662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043274544,0.00014015127,0.0002506509,0.00018184121,0.00008931317,0.000007168505,0.000086464024,0.000088809145,0.00053385145],"category_scores_gemma":[0.000027395008,0.00012341724,0.0000362868,0.00031700358,0.00009978149,0.00005525938,0.000018266692,0.00014936138,0.00003981652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013153184,0.0005352281,0.8703677,0.00010745719,0.000050858132,0.00008989615,0.015230017,0.000013502868,0.0009896335,0.00004091256,0.004288169,0.1081551],"study_design_scores_gemma":[0.013240304,0.001952011,0.4867146,0.00067883416,0.0004035244,0.00003429367,0.0025163263,0.0030257828,0.006035811,0.000027321874,0.4848931,0.0004780969],"about_ca_topic_score_codex":0.026399117,"about_ca_topic_score_gemma":0.19107053,"teacher_disagreement_score":0.48060495,"about_ca_system_score_codex":0.0015269533,"about_ca_system_score_gemma":0.0018603031,"threshold_uncertainty_score":0.9800842},"labels":[],"label_agreement":null},{"id":"W2898875469","doi":"10.7759/cureus.3533","title":"Adenocarcinoma of the Lung with Miliary Metastases and Primary Resistance Exon 20 Mutations","year":2018,"lang":"en","type":"article","venue":"Cureus","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic","funders":"","keywords":"Exon; Medicine; Epidermal growth factor receptor; Adenocarcinoma; Lung; Lung cancer; Mutation; Adenocarcinoma of the lung; Cancer research; Tyrosine kinase; Presentation (obstetrics); Pathology; Internal medicine; Cancer; Gene; Receptor; Genetics; Radiology; Biology","score_opus":0.010011716488400964,"score_gpt":0.2810952800971138,"score_spread":0.27108356360871283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898875469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598413,0.017777987,0.0001462443,0.0017570129,0.0001116188,0.0005621751,0.0001190925,0.00002536314,0.019659221],"genre_scores_gemma":[0.9944809,0.000046834684,0.002059939,0.00023971159,0.00006344967,0.000025903902,0.000029299648,0.000009727003,0.0030441978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995686,0.000017903902,0.000094332965,0.0001206614,0.000116400275,0.000082129685],"domain_scores_gemma":[0.99955386,0.000032843152,0.00005248405,0.00022472024,0.0000945244,0.000041571297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003141893,0.000066985405,0.00011222924,0.000018553805,0.00009965258,0.000004765214,0.000038899394,0.000018819845,0.000046934143],"category_scores_gemma":[0.000017359229,0.0000376342,0.000024516523,0.000115079565,0.00021060194,0.00005743952,0.000017611534,0.000037628433,0.0000015981988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009139583,0.00077115,0.8934336,0.00081547134,0.001995277,0.00008734896,0.009187225,0.0000060714306,0.010964605,0.004935331,0.07454635,0.0023436374],"study_design_scores_gemma":[0.0018322709,0.00033958993,0.97948366,0.00025054417,0.0013907106,0.000049944272,0.00051370193,0.000016646349,0.0051190946,0.00027473897,0.010632679,0.00009644294],"about_ca_topic_score_codex":0.00006506316,"about_ca_topic_score_gemma":0.0003200804,"teacher_disagreement_score":0.08605006,"about_ca_system_score_codex":0.000053719552,"about_ca_system_score_gemma":0.00015895042,"threshold_uncertainty_score":0.15346782},"labels":[],"label_agreement":null},{"id":"W2899242749","doi":"10.1002/cncr.31779","title":"ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Celgene","keywords":"Medicine; Paclitaxel; Hazard ratio; Clinical endpoint; Internal medicine; Lung cancer; Randomized controlled trial; Oncology; Confidence interval; Progression-free survival; Gastroenterology; Surgery; Chemotherapy","score_opus":0.022656368416163333,"score_gpt":0.39025854811389876,"score_spread":0.36760217969773545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899242749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840129,0.0028743665,0.0005800189,0.00036649714,0.0004158756,0.0103350775,0.0003110219,0.00006596415,0.0010382879],"genre_scores_gemma":[0.96858996,0.0002156678,0.0010905657,0.0005174487,0.00039948983,0.010342151,0.00003957635,0.00009850638,0.018706651],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978381,0.00007064971,0.00061817886,0.0006505349,0.00028462557,0.0005379287],"domain_scores_gemma":[0.99794614,0.00021009348,0.00039265765,0.00055954535,0.00059746084,0.00029412218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014669348,0.00045371446,0.0012951316,0.00012235937,0.00025871265,0.000039512306,0.00011429102,0.00008426586,0.00091317395],"category_scores_gemma":[0.000039102913,0.00027552687,0.00019791507,0.00032412866,0.00029786644,0.0001463409,0.000023248385,0.00008959781,0.000010611258],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78612304,0.04306824,0.02058995,0.0012942186,0.00948092,0.00016407756,0.061393354,0.00020591065,0.04835684,0.00005210962,0.0022735428,0.02699778],"study_design_scores_gemma":[0.8633069,0.020453477,0.00031941096,0.00044454544,0.0073928526,0.000016695363,0.0035970102,0.001872599,0.098057605,0.000020843876,0.00407537,0.00044272095],"about_ca_topic_score_codex":0.0023623891,"about_ca_topic_score_gemma":0.0132859,"teacher_disagreement_score":0.077183805,"about_ca_system_score_codex":0.00073952414,"about_ca_system_score_gemma":0.0017643155,"threshold_uncertainty_score":0.9999697},"labels":[],"label_agreement":null},{"id":"W2899287048","doi":"10.3747/co.25.3945","title":"Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Adenocarcinoma; Clinical trial; Confidence interval; Stage (stratigraphy); V600E; Retrospective cohort study; Mutation; Cancer; Gene","score_opus":0.11725046317483108,"score_gpt":0.4506200761683101,"score_spread":0.33336961299347906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899287048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952096,0.00017791548,0.00009125231,0.00027058405,0.001428863,0.0023345158,0.00002151773,0.000052650394,0.0004131188],"genre_scores_gemma":[0.9973958,0.00046896253,0.0004463376,0.00014559235,0.00033013377,0.00095230044,0.00006456205,0.00003657083,0.00015970746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981922,0.00010063891,0.0005925782,0.0005412826,0.00020271649,0.0003706013],"domain_scores_gemma":[0.9989157,0.00012320705,0.00027176848,0.000250883,0.00020398287,0.00023448386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018802282,0.0002479398,0.0005654171,0.00018078188,0.00012852979,0.000027981809,0.000082853745,0.00006524967,0.000044682776],"category_scores_gemma":[0.00006464471,0.00019482613,0.000050530907,0.00016643135,0.00009511055,0.00013952884,0.000115720126,0.00024835576,0.000009703579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038194758,0.0038155918,0.94443357,0.0002682277,0.00037811958,0.00011952617,0.010941313,0.000001791427,7.5539214e-7,0.000004569797,0.00011218635,0.039542377],"study_design_scores_gemma":[0.019285567,0.0014076714,0.9723802,0.00036140377,0.0009971777,0.0000016643177,0.0037285534,0.00044444276,0.0000040092964,0.0000016891232,0.0012004431,0.00018715623],"about_ca_topic_score_codex":0.0000914688,"about_ca_topic_score_gemma":0.00033610608,"teacher_disagreement_score":0.039355222,"about_ca_system_score_codex":0.00035751794,"about_ca_system_score_gemma":0.00021520302,"threshold_uncertainty_score":0.7944779},"labels":[],"label_agreement":null},{"id":"W2899436946","doi":"10.1016/j.lungcan.2018.10.028","title":"Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Tolerability; Adverse effect; Internal medicine; Incidence (geometry); Medical record; Observational study; Oncology; Surgery; Epidermal growth factor receptor; Cancer; Gefitinib","score_opus":0.008844275390835923,"score_gpt":0.37523411298275683,"score_spread":0.3663898375919209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899436946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301815,0.00006236674,0.00006731748,0.000052571955,0.00008624323,0.0022928924,0.0012733646,0.000022696415,0.0031244105],"genre_scores_gemma":[0.9990681,0.000019652744,0.00018509467,0.000023906869,0.00005157669,0.00016808299,0.00042620327,0.000017461769,0.00003993775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987802,0.00009995216,0.00029317534,0.00040637763,0.0002537702,0.00016652117],"domain_scores_gemma":[0.9989839,0.00015948691,0.00020340522,0.00026108653,0.00030709346,0.000084988824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009017377,0.00018134843,0.00032383858,0.00009352794,0.00006949076,0.000010259951,0.000040959454,0.0000390572,0.000018362742],"category_scores_gemma":[0.000039037,0.00012957239,0.0000364548,0.00043815226,0.000072651135,0.0001230575,0.000013848232,0.00007256298,0.0000015373715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033036325,0.0011212722,0.9429465,0.000024146097,0.0006015926,0.000007096549,0.0033424282,0.00071347546,0.00004779363,0.000045519715,0.000018088915,0.01809575],"study_design_scores_gemma":[0.026152615,0.0034417987,0.96869457,0.00062280236,0.00037221302,2.586779e-7,0.00014026262,0.0002998455,0.00012788776,0.000027278162,0.000002974268,0.00011747547],"about_ca_topic_score_codex":0.024115253,"about_ca_topic_score_gemma":0.00612697,"teacher_disagreement_score":0.025748078,"about_ca_system_score_codex":0.0014418811,"about_ca_system_score_gemma":0.0002532165,"threshold_uncertainty_score":0.98238325},"labels":[],"label_agreement":null},{"id":"W2899795104","doi":"10.1002/ijc.31980","title":"New use for old drugs: The protective effect of atypical antipsychotics on hepatocellular carcinoma","year":2018,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Chiayi Chang Gung Memorial Hospital; Allergan; Chang Gung Medical Foundation; Sunovion; H. Lundbeck A/S; Stanley Medical Research Institute; Shire; Purdue University; Pfizer","keywords":"Quetiapine; Risperidone; Medicine; Antipsychotic; Internal medicine; Clozapine; Oncology; Odds ratio; Hepatocellular carcinoma; Population; Atypical antipsychotic; Schizophrenia (object-oriented programming); Logistic regression; Psychiatry; Pharmacology; Environmental health","score_opus":0.0188973259433909,"score_gpt":0.37632749557365475,"score_spread":0.35743016963026386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899795104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868604,0.00032611252,0.007188854,0.003531045,0.0013677044,0.0005507596,0.000032315485,0.0000035650914,0.00013927254],"genre_scores_gemma":[0.9970457,0.000037549984,0.00059866434,0.00040354682,0.0014538288,0.000020973312,0.0000024483647,0.000011753487,0.0004255439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992303,0.000024652063,0.00023093677,0.00007844947,0.00035709285,0.000078525714],"domain_scores_gemma":[0.9987003,0.00018520287,0.00023634885,0.00008946648,0.0007281875,0.000060498467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103088634,0.000079709775,0.00016735107,0.00007902262,0.000030320532,0.000017705022,0.000120692646,0.000033550994,0.000082139806],"category_scores_gemma":[0.000099134675,0.000043506283,0.00015414918,0.000055146207,0.00005534269,0.000072027186,0.000009090567,0.000103585655,0.0000025420352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11894076,0.0005749469,0.64920694,0.00011348946,0.008442396,0.00010096455,0.004183589,0.00021813968,0.010375454,0.0044105113,0.033014357,0.17041846],"study_design_scores_gemma":[0.031747073,0.016464267,0.6014015,0.0019704995,0.0028813498,0.00024355669,0.00024816717,0.0013037068,0.23418917,0.003268124,0.10599678,0.00028577266],"about_ca_topic_score_codex":0.00013541782,"about_ca_topic_score_gemma":0.000017893277,"teacher_disagreement_score":0.22381371,"about_ca_system_score_codex":0.0001997917,"about_ca_system_score_gemma":0.00024769624,"threshold_uncertainty_score":0.17741346},"labels":[],"label_agreement":null},{"id":"W2900619334","doi":"10.1002/ijc.32009","title":"A controlled trial of HNSCC patient‐derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth","year":2018,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network; Western University","funders":"Canadian Institutes of Health Research","keywords":"PI3K/AKT/mTOR pathway; Clinical trial; Medicine; Head and neck squamous-cell carcinoma; Targeted therapy; Cancer research; Oncology; Bioinformatics; Internal medicine; Biology; Radiation therapy; Cancer; Head and neck cancer; Signal transduction","score_opus":0.012145303034589439,"score_gpt":0.3507978994094582,"score_spread":0.3386525963748688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900619334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508464,0.0007825416,0.0002137923,0.0009197203,0.0013811934,0.0007169065,0.00003333893,0.000003901689,0.000863941],"genre_scores_gemma":[0.9982919,0.00015649313,0.0002712053,0.00027868382,0.0009089225,0.00003750871,0.000005923806,0.000011557372,0.000037767826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998121,0.00005857577,0.0010203328,0.00010133568,0.0005866905,0.00011203828],"domain_scores_gemma":[0.9967456,0.00015873619,0.001116166,0.000071454,0.0018432355,0.00006480385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021110638,0.000106008374,0.0005646563,0.0003596121,0.000016743687,0.000010273702,0.00007471777,0.000039841543,0.00016560167],"category_scores_gemma":[0.00033950823,0.00007923187,0.00023969512,0.00013844718,0.00009346588,0.00013575597,0.000014553541,0.00011261343,0.0000013134974],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7300486,0.0031854631,0.011951571,0.00007713601,0.004706716,0.00025744663,0.0036040824,0.00026621317,0.23268035,0.00062692066,0.00084961124,0.011745869],"study_design_scores_gemma":[0.8946418,0.004813008,0.018765077,0.0023047964,0.00093726814,0.000092131515,0.00023552842,0.00016487701,0.07664766,0.0007710533,0.0004813616,0.00014539616],"about_ca_topic_score_codex":0.00019382918,"about_ca_topic_score_gemma":0.00004160709,"teacher_disagreement_score":0.16459322,"about_ca_system_score_codex":0.00024926223,"about_ca_system_score_gemma":0.00039682802,"threshold_uncertainty_score":0.32309818},"labels":[],"label_agreement":null},{"id":"W2900632426","doi":"10.1016/j.phrs.2018.11.026","title":"Understanding antidepressant tachyphylaxis","year":2018,"lang":"en","type":"letter","venue":"Pharmacological Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; St Joseph's Health Care; Parkwood Institute","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Statin; Confidence interval; Proportional hazards model; Subgroup analysis; Meta-analysis; Oncology; Cancer","score_opus":0.5150994968715334,"score_gpt":0.5427440215124751,"score_spread":0.027644524640941692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900632426","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023642639,0.0008856927,0.00023533273,0.86712116,0.0007036404,0.0018383726,0.00011247153,0.00017739306,0.12656166],"genre_scores_gemma":[0.22925647,0.0015433807,0.00058005244,0.7002782,0.01861928,0.000686595,0.00080596097,0.00014283585,0.048087195],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99621284,0.00036149463,0.0002744819,0.0006981846,0.0014429119,0.0010100596],"domain_scores_gemma":[0.9980819,0.0008842285,0.00006041936,0.0003169652,0.00041044827,0.00024598956],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006850835,0.00026258198,0.00045273828,0.00040233173,0.00042288707,0.00009214402,0.00027779926,0.0006224826,0.007058374],"category_scores_gemma":[0.00028765848,0.00017797893,0.00019064688,0.000531688,0.00064535224,0.000058741334,0.0002216944,0.0035818159,0.0008987316],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011866272,0.00015819269,0.0004721055,0.00015409377,0.0005553543,0.0038737992,0.000049322392,1.9296317e-7,0.00063772936,0.00007905779,0.9934269,0.00047454055],"study_design_scores_gemma":[0.0014119536,0.0010086298,0.0004466713,0.0001118811,0.00038137144,0.000059339996,0.000044515797,0.00005815322,0.0007422329,0.0020335987,0.9935104,0.00019122373],"about_ca_topic_score_codex":0.000058937858,"about_ca_topic_score_gemma":0.0000014566323,"teacher_disagreement_score":0.2268922,"about_ca_system_score_codex":0.0014720001,"about_ca_system_score_gemma":0.000500555,"threshold_uncertainty_score":0.9998792},"labels":[],"label_agreement":null},{"id":"W2900778417","doi":"10.1093/annonc/mdy425","title":"Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Gefitinib; Erlotinib; Oncology; Discontinuation; Hazard ratio; Lung cancer; Progression-free survival; Erlotinib Hydrochloride; Ceritinib; T790M; Chemotherapy; Cancer; Epidermal growth factor receptor; Confidence interval; Crizotinib","score_opus":0.02403826421624572,"score_gpt":0.4144345232529033,"score_spread":0.3903962590366576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900778417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959947,0.0007560948,0.0000037707384,0.004961954,0.00013348534,0.00089227577,0.0001184664,0.000025635114,0.0035088353],"genre_scores_gemma":[0.99739313,0.00045714708,0.000485258,0.0011999954,0.00003626872,0.000053506883,0.00022061882,0.000026466962,0.00012763079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870133,0.000054776887,0.00043799332,0.0002600113,0.00027611226,0.00026974326],"domain_scores_gemma":[0.9977774,0.00009462308,0.00033065956,0.0002826797,0.001415712,0.000098904275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007946302,0.00019250248,0.0006889252,0.0001678008,0.00006126104,0.00000326774,0.00008885639,0.00013557459,0.00018621588],"category_scores_gemma":[0.00009869106,0.00012373402,0.00008754985,0.00025456963,0.00021209831,0.00008543917,0.000027177666,0.00009867238,0.000009257844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02666808,0.0015407983,0.55748224,0.000087104214,0.0004431831,0.000033225835,0.0050419597,0.000011270194,0.00023239237,0.00004861365,0.00045833437,0.40795282],"study_design_scores_gemma":[0.03896366,0.1842601,0.71707046,0.0007172898,0.0002240905,0.0000060303564,0.0013241498,0.0000061614155,0.03121362,0.0000931146,0.025884612,0.00023668987],"about_ca_topic_score_codex":0.00029785384,"about_ca_topic_score_gemma":0.00057838904,"teacher_disagreement_score":0.40771613,"about_ca_system_score_codex":0.00013565968,"about_ca_system_score_gemma":0.00041126073,"threshold_uncertainty_score":0.5045727},"labels":[],"label_agreement":null},{"id":"W2900911329","doi":"10.1016/j.lungcan.2018.11.016","title":"Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Internazionale di Ricerca in Medicina Onlus","keywords":"Medicine; Osimertinib; Gefitinib; Lung cancer; Oncology; Adenocarcinoma; Internal medicine; Cancer research; Histology; Cancer; Epidermal growth factor receptor","score_opus":0.016816815831995433,"score_gpt":0.3249436643751616,"score_spread":0.30812684854316613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900911329","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064304836,0.90633327,0.00006835423,0.00005988972,0.00023746281,0.004493591,0.024190607,0.00008518895,0.00022683396],"genre_scores_gemma":[0.9449653,0.022401277,0.0018323147,0.0005226339,0.0011491509,0.0057672677,0.021709675,0.0003908672,0.0012615264],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99686587,0.00011815925,0.0008316664,0.0009841019,0.0006761432,0.00052405015],"domain_scores_gemma":[0.99701595,0.000081245824,0.0006141883,0.0008685826,0.0008857998,0.00053423503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007323344,0.00078929926,0.0021918425,0.00086707366,0.00012868627,0.0000405776,0.00015104402,0.00025081538,0.0034022068],"category_scores_gemma":[0.000019807556,0.0005126771,0.00043910422,0.0020562138,0.0001315679,0.00014633629,0.00005996418,0.00028566914,0.000028331826],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014544795,0.010050841,0.67755574,0.081611075,0.04257308,0.016745169,0.007025,0.0001250942,0.0000029099706,0.000015985323,0.023827387,0.1259229],"study_design_scores_gemma":[0.028871248,0.017469862,0.1591412,0.02842512,0.5743391,0.0005941806,0.00038869953,0.00018471417,0.00004601779,0.0000028568347,0.18589668,0.0046403417],"about_ca_topic_score_codex":0.0020698863,"about_ca_topic_score_gemma":0.0030939488,"teacher_disagreement_score":0.88393193,"about_ca_system_score_codex":0.0012233551,"about_ca_system_score_gemma":0.00095200905,"threshold_uncertainty_score":0.9997325},"labels":[],"label_agreement":null},{"id":"W2901186138","doi":"10.1093/annonc/mdy446.007","title":"ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Internal medicine; Lung cancer; Oncology; Cancer; Gastroenterology; Adenocarcinoma","score_opus":0.07305210233867651,"score_gpt":0.4704252483093927,"score_spread":0.39737314597071616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901186138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882876,0.00010839284,0.000018831759,0.0002676346,0.00010819098,0.000814354,0.000041386775,0.0000090834255,0.010344484],"genre_scores_gemma":[0.99915195,0.000042641663,0.00023488476,0.00016987244,0.0000726241,0.0000578072,0.000048954185,0.000011145201,0.00021009866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988568,0.00006829436,0.00043122732,0.00023494271,0.00019644466,0.00021231662],"domain_scores_gemma":[0.99884534,0.00003735003,0.00034995133,0.00020363452,0.00048739932,0.00007635028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009867067,0.00013112144,0.00045890285,0.00017745973,0.00003457075,0.0000029707649,0.00006990083,0.00006448129,0.00008538868],"category_scores_gemma":[0.000015228926,0.00010008072,0.00004934705,0.000569319,0.00007542021,0.000060801747,0.000026718855,0.000067145775,0.0000024012493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012514495,0.0036178813,0.9785023,0.00004296692,0.00034697176,0.000009202375,0.001595468,0.000117721545,0.000072143455,0.0000052752257,0.0010777179,0.013360921],"study_design_scores_gemma":[0.0077387434,0.010694109,0.9787685,0.00010399777,0.0005612097,4.1888688e-7,0.00046268298,0.00010226199,0.001196469,0.000007981469,0.00028409346,0.000079503705],"about_ca_topic_score_codex":0.021407949,"about_ca_topic_score_gemma":0.03547636,"teacher_disagreement_score":0.0140684135,"about_ca_system_score_codex":0.0002063083,"about_ca_system_score_gemma":0.00040118344,"threshold_uncertainty_score":0.98510855},"labels":[],"label_agreement":null},{"id":"W2901517592","doi":"10.1016/j.ijrobp.2018.08.050","title":"Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; London Health Sciences Centre","funders":"","keywords":"Medicine; Clinical endpoint; Oncology; Lung cancer; Internal medicine; Overall survival; Randomized controlled trial; non-small cell lung cancer (NSCLC); Progression-free survival; Radiation therapy","score_opus":0.03389389002061656,"score_gpt":0.3895709411566672,"score_spread":0.35567705113605064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901517592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95727074,0.00068804034,0.033311874,0.002129143,0.0026445983,0.0032722973,0.00024251748,0.000014847444,0.00042597056],"genre_scores_gemma":[0.99275255,0.0014843105,0.0028041883,0.0011952291,0.0011858825,0.00026706987,0.00015227192,0.000028149738,0.00013033154],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966537,0.00060614,0.0017832496,0.00031775096,0.00034859357,0.00029056714],"domain_scores_gemma":[0.9941492,0.001426942,0.0022053393,0.00016927808,0.0019057936,0.00014342873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012899382,0.00029715075,0.0016707053,0.00031929265,0.000059429985,0.000027885202,0.0002866058,0.00014962009,0.00004819735],"category_scores_gemma":[0.00054827426,0.00021406218,0.00043560765,0.00023360213,0.0003439556,0.0002239302,0.00003144466,0.00030796413,0.000004930977],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.928062,0.0031979522,0.0059094056,0.000014221104,0.002715851,0.00002394738,0.0043395385,0.0008211479,0.009708869,0.00046358304,0.00058711757,0.04415632],"study_design_scores_gemma":[0.9599865,0.0041450807,0.0033745705,0.00020435051,0.0003749393,0.000008489286,0.00026083764,0.023089454,0.006504102,0.00049478194,0.0013749838,0.00018190316],"about_ca_topic_score_codex":0.00045596337,"about_ca_topic_score_gemma":0.00008210127,"teacher_disagreement_score":0.04397442,"about_ca_system_score_codex":0.00088268047,"about_ca_system_score_gemma":0.0014396894,"threshold_uncertainty_score":0.8729202},"labels":[],"label_agreement":null},{"id":"W2901521863","doi":"10.14740/wjon1167","title":"<i>EGFR</i> Mutation Detection and Its Association With Clinicopathological Characters of Lung Cancer Patients","year":2018,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Mutation; Oncology; Internal medicine; Dermatology; Gene; Genetics","score_opus":0.013359320722201017,"score_gpt":0.36500920619224136,"score_spread":0.35164988547004034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901521863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707896,0.00020232682,0.000061020608,0.0012066101,0.000449135,0.00017419706,0.000005040636,0.000004491918,0.00081822305],"genre_scores_gemma":[0.9986461,0.00015161914,0.00021963993,0.00038504123,0.00025173373,0.0000072307557,0.0000031517113,0.0000062304157,0.0003292758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992894,0.00006005082,0.0003175647,0.000078154815,0.00016156757,0.00009329512],"domain_scores_gemma":[0.99841744,0.000086978565,0.0007393687,0.000031902768,0.0006628388,0.000061461076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021543317,0.00006105556,0.0002476651,0.0001341454,0.000045183388,0.0000039941197,0.00002112443,0.00005960084,0.00004111132],"category_scores_gemma":[0.000090319525,0.000037334798,0.000036487436,0.00014596546,0.000038141607,0.000101305115,0.0000065935606,0.00013076041,0.0000011971719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001504326,0.00054869836,0.91861004,0.00004005985,0.0002993055,0.000042915883,0.0010760992,0.0000050339577,0.0039344938,0.000021042999,0.00030862825,0.073609374],"study_design_scores_gemma":[0.005307675,0.0065829717,0.9789119,0.00012220805,0.0008265498,0.000091388785,0.000053319764,0.000072692405,0.0037703777,0.000017544467,0.0041921604,0.000051259558],"about_ca_topic_score_codex":0.000009898545,"about_ca_topic_score_gemma":0.00012163858,"teacher_disagreement_score":0.073558114,"about_ca_system_score_codex":0.0005225223,"about_ca_system_score_gemma":0.00018504207,"threshold_uncertainty_score":0.15224688},"labels":[],"label_agreement":null},{"id":"W2901525385","doi":"10.1016/j.lungcan.2018.11.024","title":"Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Crizotinib; Medicine; Lung cancer; Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; ALK inhibitor; Internal medicine; Concomitant; Oncology; Cancer; Tyrosine-kinase inhibitor; Receptor","score_opus":0.008287191718323293,"score_gpt":0.3050793065326908,"score_spread":0.29679211481436746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901525385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9397941,0.015146625,0.004356134,0.0071672993,0.0033049067,0.0050964216,0.0008346083,0.00017848122,0.02412141],"genre_scores_gemma":[0.9808839,0.00025812356,0.0031539567,0.0026833478,0.0007077355,0.0012288038,0.000044520937,0.00007879481,0.010960844],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980613,0.000037499118,0.0003963921,0.0006347316,0.00029568226,0.0005744044],"domain_scores_gemma":[0.99877447,0.000072135925,0.00013429817,0.00039007855,0.00031371682,0.00031530982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000112221955,0.00032805873,0.00045383422,0.00019161416,0.00016845262,0.000036588146,0.00013092459,0.00013249443,0.00032052607],"category_scores_gemma":[0.000032038548,0.0002895059,0.00010066472,0.00057809177,0.00007762679,0.000115387535,0.000067017434,0.00020748441,0.000026990727],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004673711,0.0016571052,0.3911313,0.0017229728,0.0014536644,0.0008615384,0.032890797,0.0007326637,0.38293216,0.0013439141,0.17029203,0.010308122],"study_design_scores_gemma":[0.024834717,0.0011933696,0.16143984,0.008209374,0.0024782966,0.00001125349,0.0014548211,0.0062750573,0.74512243,0.0001817758,0.047026515,0.001772555],"about_ca_topic_score_codex":0.0062224325,"about_ca_topic_score_gemma":0.027810723,"teacher_disagreement_score":0.36219028,"about_ca_system_score_codex":0.0019160816,"about_ca_system_score_gemma":0.0006505924,"threshold_uncertainty_score":0.9999557},"labels":[],"label_agreement":null},{"id":"W2901630115","doi":"10.1093/annonc/mdy483.006","title":"Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Afatinib; Osimertinib; Medicine; T790M; Discontinuation; Internal medicine; Oncology; Erlotinib; Epidermal growth factor receptor; Cancer; Gefitinib","score_opus":0.023552021184561282,"score_gpt":0.4114248194822116,"score_spread":0.3878727982976503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901630115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96902126,0.000055279386,0.000016676313,0.0014655832,0.00011253572,0.0014588156,0.000049418388,0.000022982535,0.02779743],"genre_scores_gemma":[0.99716556,0.0000142464205,0.000541802,0.00097283314,0.000042511358,0.0001517335,0.00015275978,0.000022481858,0.0009360451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873865,0.0000950393,0.00038774524,0.00029768114,0.00022067687,0.00026023414],"domain_scores_gemma":[0.99878025,0.00013687107,0.0002447838,0.00021461776,0.00052314537,0.00010030671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012615719,0.00015508701,0.00044199667,0.00018132747,0.000062200554,0.000004665893,0.00006648645,0.000058145564,0.0001011164],"category_scores_gemma":[0.00006564245,0.00012055864,0.000048250018,0.00042179695,0.0001319348,0.000105821484,0.000021649614,0.00009555186,0.000017868957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063625304,0.009668534,0.8936452,0.000021232867,0.0008267,0.000084699306,0.008958322,0.000008656936,0.00027721273,0.000095147036,0.007514671,0.072537094],"study_design_scores_gemma":[0.018744223,0.033124764,0.9405908,0.00011070626,0.00025876547,0.0000016819349,0.0010265874,0.000009137437,0.0017929917,0.000042898486,0.004151142,0.00014630688],"about_ca_topic_score_codex":0.0007372292,"about_ca_topic_score_gemma":0.001640773,"teacher_disagreement_score":0.07239079,"about_ca_system_score_codex":0.00012236554,"about_ca_system_score_gemma":0.00028922653,"threshold_uncertainty_score":0.49162385},"labels":[],"label_agreement":null},{"id":"W2902378590","doi":"10.1002/cncr.31891","title":"Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"Ignyta; Chugai Pharmaceutical; Novartis Pharma; Genentech; Ono Pharmaceutical; Loxo Oncology; Astellas Pharma; Yuhan; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Clovis Oncology; Ariad Pharmaceuticals; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; T790M; Osimertinib; Internal medicine; Discontinuation; Lung cancer; Clinical endpoint; Hazard ratio; Confidence interval; Gastroenterology; Surgery; Oncology; Cancer; Clinical trial; Epidermal growth factor receptor; Gefitinib; Erlotinib","score_opus":0.01175999927836135,"score_gpt":0.3536241179805094,"score_spread":0.34186411870214806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902378590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177873,0.0055718366,0.00025811564,0.0001159154,0.00028867632,0.0009559641,0.00074298313,0.000021542573,0.00026622633],"genre_scores_gemma":[0.9973067,0.00026547114,0.00036605424,0.00029953246,0.00008994747,0.00046237555,0.00047644132,0.000030119834,0.00070337247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986863,0.000027892764,0.00036820152,0.0004111446,0.00024867913,0.00025774472],"domain_scores_gemma":[0.9986383,0.00006318843,0.00027288322,0.00027947064,0.0006377691,0.000108440465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003523792,0.00022580344,0.0006545492,0.0002857906,0.00007833898,0.000009617545,0.000076546596,0.000053452175,0.00034550138],"category_scores_gemma":[0.00001826706,0.00017177366,0.00012131558,0.00093867787,0.00011873691,0.00012337453,0.000025601603,0.0000841336,0.0000029404748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018818458,0.0006904053,0.9605845,0.00009405107,0.010698722,0.000021788326,0.008111274,0.0003332412,0.0007668479,0.0000011430934,0.0001915805,0.016624609],"study_design_scores_gemma":[0.025005925,0.00080392783,0.94195616,0.0006215024,0.01986984,1.2044445e-7,0.00037718166,0.00060380955,0.010518063,0.0000034970842,0.000030042716,0.00020991446],"about_ca_topic_score_codex":0.0019304319,"about_ca_topic_score_gemma":0.005674732,"teacher_disagreement_score":0.02312408,"about_ca_system_score_codex":0.0005386579,"about_ca_system_score_gemma":0.00033549534,"threshold_uncertainty_score":0.70047265},"labels":[],"label_agreement":null},{"id":"W2902576964","doi":"10.1002/cncy.22085","title":"The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective","year":2018,"lang":"en","type":"article","venue":"Cancer Cytopathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cytology; Lung cancer; Personalized medicine; Perspective (graphical); Precision medicine; Cancer; Molecular diagnostics; Medical physics; Intensive care medicine; Pathology; Internal medicine; Bioinformatics; Artificial intelligence","score_opus":0.023247364205856665,"score_gpt":0.42397179838495264,"score_spread":0.400724434179096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902576964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520551,0.037145216,0.00003666024,0.005310398,0.00022823617,0.00042546575,0.000009986123,0.000012586354,0.004776364],"genre_scores_gemma":[0.99701256,0.0015058066,0.00039922242,0.0005651429,0.00020440608,0.00020706268,0.000001569144,0.000014016359,0.000090213354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881417,0.00015672314,0.0003728836,0.0003192102,0.000088089284,0.00024892137],"domain_scores_gemma":[0.99905914,0.000344635,0.00012980732,0.00016905415,0.00023335438,0.00006399824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033803633,0.00011583111,0.0004485921,0.0001134358,0.00005657007,0.0000024209285,0.00006838636,0.000102427555,0.00005003092],"category_scores_gemma":[0.00059345906,0.00007820689,0.00003380515,0.0003022603,0.0011606583,0.00002345844,0.000038906568,0.000203429,6.64112e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035131676,0.0000643687,0.9686565,0.000023123745,0.00006421768,0.00015159155,0.0043001645,0.0000028470388,0.0072600413,0.004645513,0.00004265331,0.014437664],"study_design_scores_gemma":[0.008948621,0.001384816,0.9730709,0.00046781366,0.00041183262,0.00023611388,0.006009642,0.0013299495,0.0011601552,0.0051299203,0.0016901339,0.00016005829],"about_ca_topic_score_codex":0.004510004,"about_ca_topic_score_gemma":0.0028529202,"teacher_disagreement_score":0.04495747,"about_ca_system_score_codex":0.00028944548,"about_ca_system_score_gemma":0.00041699765,"threshold_uncertainty_score":0.6817807},"labels":[],"label_agreement":null},{"id":"W2903702568","doi":"10.1016/j.jtho.2018.12.004","title":"Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; BC Cancer Foundation; Terry Fox Research Institute","keywords":"Medicine; Carcinogenesis; Lung; Computational biology; Cancer research; Bioinformatics; Oncology; Internal medicine; Cancer; Biology","score_opus":0.03143621481148893,"score_gpt":0.4931988677928231,"score_spread":0.4617626529813342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903702568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020934,0.0012745125,0.00060427067,0.0013089561,0.00068260386,0.00022982707,0.000021570955,0.000009007288,0.0056599085],"genre_scores_gemma":[0.99460465,0.0002752446,0.0019077117,0.00032876618,0.00043547354,0.000007648847,0.000013276493,0.00001535992,0.0024118603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986536,0.00018536227,0.00062470563,0.00014585206,0.00022213453,0.00016835106],"domain_scores_gemma":[0.99729824,0.00022168389,0.0007269393,0.00014340514,0.00146834,0.0001414182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002646956,0.0001528091,0.0007068518,0.0003540843,0.00009009549,0.000013025728,0.00011872128,0.00010234483,0.0006806427],"category_scores_gemma":[0.00031451642,0.00009768775,0.0001961353,0.00033763406,0.0003546318,0.00015877468,0.000033697976,0.00019732067,0.00005016863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010995747,0.0032310772,0.05010859,0.00028026296,0.015055901,0.0023838591,0.048296742,0.00012289066,0.7868026,0.00037150166,0.036321655,0.0460292],"study_design_scores_gemma":[0.008791301,0.031672914,0.303245,0.0014210417,0.017417036,0.0038513814,0.036018707,0.00072796695,0.5597265,0.0010245367,0.03541936,0.0006842723],"about_ca_topic_score_codex":0.000121775105,"about_ca_topic_score_gemma":0.00012535826,"teacher_disagreement_score":0.25313643,"about_ca_system_score_codex":0.0006349985,"about_ca_system_score_gemma":0.0014454793,"threshold_uncertainty_score":0.74525607},"labels":[],"label_agreement":null},{"id":"W2903904475","doi":"10.1093/annonc/mdy415","title":"Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck; AstraZeneca","keywords":"Alectinib; Medicine; Crizotinib; Oncology; First line therapy; Internal medicine; Lung cancer","score_opus":0.1069926659110964,"score_gpt":0.4628576205310257,"score_spread":0.3558649546199293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903904475","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001909573,0.0015256944,0.000060652783,0.90323836,0.0010140126,0.0018660914,0.0002517115,0.000058339145,0.09007559],"genre_scores_gemma":[0.003065764,0.0020219462,0.0011588787,0.94162387,0.010502372,0.0007404416,0.0017128439,0.00011203336,0.039061856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983536,0.00006579085,0.00045448728,0.00044375152,0.0002231077,0.00045923947],"domain_scores_gemma":[0.9975839,0.00051856035,0.000377544,0.0004497086,0.0009777918,0.00009249542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020500986,0.00031627505,0.000932725,0.00020793645,0.00010370798,0.000008872029,0.00016073148,0.0008692334,0.0009048264],"category_scores_gemma":[0.0002700249,0.00024398866,0.00040429938,0.00013598251,0.00019541776,0.00003946235,0.000023621782,0.00044506404,0.00017849212],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010783372,0.0004094927,0.000046219186,0.0001815542,0.0014152649,0.0001401816,0.00044175907,2.935771e-7,0.00010865293,0.000015732172,0.9505599,0.045602594],"study_design_scores_gemma":[0.005939327,0.01895491,0.00013066827,0.00016191025,0.00037502908,0.00007696539,0.000015104619,0.0000060825923,0.0005507408,0.00054625276,0.97305167,0.0001913667],"about_ca_topic_score_codex":0.00023839765,"about_ca_topic_score_gemma":0.000058397232,"teacher_disagreement_score":0.051013734,"about_ca_system_score_codex":0.0000887157,"about_ca_system_score_gemma":0.00090824685,"threshold_uncertainty_score":0.99495685},"labels":[],"label_agreement":null},{"id":"W2904270864","doi":"10.1016/j.cllc.2018.12.009","title":"Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Chemotherapy; Clinical endpoint; Confidence interval; Cancer; Gastroenterology; Clinical trial; Colorectal cancer","score_opus":0.019217476370916184,"score_gpt":0.4167759382705536,"score_spread":0.3975584618996374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904270864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954271,0.00061097235,0.000106165666,0.0002611568,0.0001865304,0.0023911186,0.0001074812,0.000024288562,0.0008852017],"genre_scores_gemma":[0.99701995,0.00017474983,0.00057096,0.00036503267,0.00024656852,0.00075452967,0.00006719705,0.000041895295,0.0007591229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987715,0.000050594284,0.00045174864,0.0003623955,0.00012533186,0.00023845793],"domain_scores_gemma":[0.99870795,0.0004950185,0.00020997004,0.00018217914,0.00027696055,0.000127903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002119004,0.0001831315,0.00049883116,0.000071462266,0.000082035585,0.0000109156035,0.000051139836,0.00011010541,0.00008229316],"category_scores_gemma":[0.0000844924,0.00012723746,0.00008426636,0.00021939797,0.0001952207,0.00005044412,0.0000136660365,0.00012085482,7.995172e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018402785,0.00029097038,0.97762793,0.00048266782,0.0003697479,0.0000019790705,0.00040564424,0.00001106863,0.000073504685,0.000004067687,0.00079534535,0.018096805],"study_design_scores_gemma":[0.03568011,0.0060919835,0.94417304,0.0013196861,0.0025841093,9.0520274e-7,0.000035327885,0.005156931,0.0041556563,0.0000058177266,0.0005515757,0.00024484508],"about_ca_topic_score_codex":0.0006079496,"about_ca_topic_score_gemma":0.0005213689,"teacher_disagreement_score":0.033839833,"about_ca_system_score_codex":0.00020290469,"about_ca_system_score_gemma":0.00027251925,"threshold_uncertainty_score":0.5188593},"labels":[],"label_agreement":null},{"id":"W2906428870","doi":"10.21037/apm.2018.12.03","title":"Economic burden of brain metastases in patients with non-small cell lung cancer: costs and implications","year":2019,"lang":"en","type":"letter","venue":"Annals of Palliative Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lung cancer; Intensive care medicine; Cancer; Lung; Oncology; Internal medicine","score_opus":0.028596713938405228,"score_gpt":0.3577096342365872,"score_spread":0.32911292029818195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906428870","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44144094,0.0048290347,0.000046213667,0.5470132,0.00013858482,0.00248505,0.001896529,0.000009995012,0.0021404664],"genre_scores_gemma":[0.77856123,0.00434182,0.00049881346,0.20567852,0.0012505708,0.00047784377,0.0054563354,0.00014962688,0.0035852133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852246,0.000054056298,0.00054629653,0.00039675654,0.00022310899,0.0002573057],"domain_scores_gemma":[0.9981236,0.00040584273,0.0006533645,0.0003715232,0.0003740871,0.00007159658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012636311,0.0003076493,0.0010448525,0.00034447224,0.000023381843,0.000003425336,0.00011205137,0.00016349822,0.00013984388],"category_scores_gemma":[0.00004534285,0.00021219469,0.00006950738,0.00016223833,0.00020474766,0.000049546605,0.000032382723,0.00034597944,0.0000025805055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012938977,0.00010765419,0.5623816,0.0012283295,0.0008849891,0.000009955761,0.0013207067,0.000034313187,0.00004545277,0.00001850238,0.4328288,0.0010102399],"study_design_scores_gemma":[0.012627571,0.0027805488,0.9212184,0.005266579,0.0020163073,7.9639733e-7,0.00029962955,0.00004892333,0.00050779595,0.00003944541,0.054833088,0.00036094378],"about_ca_topic_score_codex":0.0046922895,"about_ca_topic_score_gemma":0.00026303093,"teacher_disagreement_score":0.37799573,"about_ca_system_score_codex":0.00017551,"about_ca_system_score_gemma":0.00041423022,"threshold_uncertainty_score":0.8653048},"labels":[],"label_agreement":null},{"id":"W2907212631","doi":"10.1016/j.cllc.2018.12.022","title":"Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genentech; Takeda Pharmaceutical Company; AbbVie; Celgene; Medtronic; Novartis; Sanofi; Merck; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Afatinib; Pembrolizumab; Squamous-cell carcinoma of the lung; Lung; Lung cancer; Oncology; Internal medicine; Basal cell; Cancer; Immunotherapy; Gefitinib; Epidermal growth factor receptor","score_opus":0.019693372578323994,"score_gpt":0.39662562323210593,"score_spread":0.37693225065378194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907212631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83660203,0.00026911835,0.00012202784,0.0001981955,0.00020330014,0.16177714,0.00018022166,0.000017048847,0.0006309197],"genre_scores_gemma":[0.91773516,0.0000059232966,0.00039111346,0.00014451962,0.00007493017,0.079836406,0.000024226634,0.000060671424,0.0017270667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975958,0.00014297607,0.00085712713,0.0005258062,0.00053637876,0.0003419477],"domain_scores_gemma":[0.997102,0.00056816585,0.0007196841,0.0009334812,0.0005460144,0.00013060478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001646551,0.00033846195,0.00082507305,0.000044209046,0.00013010469,0.000014286286,0.00022250041,0.00006606639,0.00011644674],"category_scores_gemma":[0.000046852547,0.00014387678,0.00026630049,0.0002753767,0.00024228211,0.00008206015,0.000044063898,0.00013734082,0.000001900333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011017633,0.0054312646,0.97628826,0.00080908416,0.00072592485,0.0000042499173,0.0011359396,0.0008202141,0.0000076171086,0.000017808356,0.00051955186,0.0032224257],"study_design_scores_gemma":[0.08088655,0.024427345,0.8857549,0.00037066918,0.0043990747,0.0000017835524,0.0005644635,0.0014676165,0.00034484486,0.000010728529,0.0015300572,0.00024196974],"about_ca_topic_score_codex":0.00015235289,"about_ca_topic_score_gemma":0.00015315611,"teacher_disagreement_score":0.09053339,"about_ca_system_score_codex":0.00037528836,"about_ca_system_score_gemma":0.0011559618,"threshold_uncertainty_score":0.5867125},"labels":[],"label_agreement":null},{"id":"W290753819","doi":"10.1016/j.ijrobp.2006.07.1348","title":"49","year":2006,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Carboplatin; Lung cancer; Nuclear medicine; Radiation therapy; Log-rank test; Vinblastine; Chemotherapy; Internal medicine; Stage (stratigraphy); Cisplatin; Survival analysis; Urology; Oncology","score_opus":0.01500292772141125,"score_gpt":0.3600377663989842,"score_spread":0.34503483867757295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W290753819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8946903,0.0022252994,0.024279336,0.019005341,0.0077163577,0.0004993196,0.000140118,0.00011578009,0.05132816],"genre_scores_gemma":[0.9909246,0.00020025742,0.0031456149,0.00110856,0.0039402656,0.000008414652,0.00015384698,0.000019468549,0.0004989504],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892503,0.00006200825,0.000513954,0.00013675737,0.00021002846,0.0001522485],"domain_scores_gemma":[0.99843156,0.00014066426,0.00059127307,0.00009962477,0.00065666495,0.00008021083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017547343,0.00012603066,0.00029249542,0.00012707584,0.0000550155,0.000019383831,0.00016277589,0.000132591,0.00010970693],"category_scores_gemma":[0.00007803355,0.00010273146,0.00019444218,0.000114582974,0.00009420267,0.00018482166,0.000021645357,0.00022784121,0.000070213486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043320624,0.0014927591,0.6864513,0.000009788981,0.0015152448,0.00018367554,0.00036943116,0.0009869147,0.008598101,0.06266725,0.018706525,0.21858579],"study_design_scores_gemma":[0.017929662,0.0023107252,0.21139744,0.000094831346,0.0008239129,0.0009887462,0.000128127,0.0009065756,0.0073531447,0.05395523,0.703785,0.00032660618],"about_ca_topic_score_codex":0.000051207528,"about_ca_topic_score_gemma":0.000005909972,"teacher_disagreement_score":0.68507844,"about_ca_system_score_codex":0.0007520242,"about_ca_system_score_gemma":0.00056800677,"threshold_uncertainty_score":0.41892672},"labels":[],"label_agreement":null},{"id":"W2907628865","doi":"10.1016/j.cllc.2018.12.017","title":"Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non–small-cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase B; Tropomyosin receptor kinase A; Tropomyosin receptor kinase C; Receptor tyrosine kinase; Crizotinib; Cancer research; Tyrosine kinase; Neurotrophin; Lung cancer; Medicine; Low-affinity nerve growth factor receptor; Kinase; Internal medicine; Receptor; Biology; Cell biology; Platelet-derived growth factor receptor; Neurotrophic factors; Growth factor","score_opus":0.04866820201861862,"score_gpt":0.48360318254583984,"score_spread":0.43493498052722124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907628865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665751,0.00266409,0.00020089651,0.015734103,0.0044350983,0.002486891,0.00012877186,0.00012704071,0.0076480205],"genre_scores_gemma":[0.95441186,0.0015623856,0.0018873083,0.014044264,0.003654195,0.0010556026,0.000025887026,0.000117019554,0.0232415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953869,0.00041607267,0.001775141,0.0011713636,0.0003985718,0.0008519695],"domain_scores_gemma":[0.9961657,0.001237106,0.00029835931,0.00091289333,0.00048368797,0.0009022772],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019527475,0.00039923884,0.0010805795,0.00020511531,0.00018398109,0.00005378302,0.0003171386,0.00044222688,0.0023105117],"category_scores_gemma":[0.0010980741,0.00033289517,0.00041526277,0.00073018414,0.00032440238,0.00012783225,0.00016433242,0.0007917586,0.00028229403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00712733,0.0011012532,0.8440122,0.0001618853,0.00045163365,0.0001356759,0.00069134985,0.000045892157,0.00045897206,0.000018947616,0.13706093,0.008733945],"study_design_scores_gemma":[0.013073086,0.0018498648,0.88507736,0.0012271465,0.0014908836,0.00000766048,0.00016059066,0.0023243842,0.0005045184,0.000025968224,0.09370905,0.00054951885],"about_ca_topic_score_codex":0.0013298151,"about_ca_topic_score_gemma":0.0028617708,"teacher_disagreement_score":0.04335188,"about_ca_system_score_codex":0.0007962957,"about_ca_system_score_gemma":0.0025642188,"threshold_uncertainty_score":0.9999123},"labels":[],"label_agreement":null},{"id":"W2909427482","doi":"10.1093/annonc/mdy553","title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","year":2019,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Francis Crick Institute","keywords":"Durvalumab; Medicine; Lung cancer; Stage (stratigraphy); Chemoradiotherapy; Oncology; Cancer; Internal medicine; Position paper; Intensive care medicine; Immunotherapy; Pathology; Nivolumab","score_opus":0.09409710497506642,"score_gpt":0.4474031423284522,"score_spread":0.3533060373533858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909427482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7130521,0.005645072,0.0036479735,0.012187659,0.2122434,0.027315892,0.025458662,0.000020200161,0.00042903353],"genre_scores_gemma":[0.7941886,0.0061163455,0.0053544557,0.0022031863,0.14734273,0.018162008,0.011930737,0.00038547136,0.014316463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997722,0.000091967835,0.0009455319,0.0004214259,0.0005372136,0.0002818021],"domain_scores_gemma":[0.99186623,0.004178536,0.0013481934,0.0004490184,0.0021156562,0.00004237795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007075996,0.0002791103,0.0010038564,0.00021591145,0.00007736919,0.000009671523,0.00032324952,0.0004153417,0.000028434972],"category_scores_gemma":[0.00075136585,0.00017393322,0.0002715097,0.00012412731,0.00019097315,0.00010107193,0.000058798,0.00022725743,5.8367874e-8],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008352252,0.0013935802,0.0008929062,0.0016499648,0.0011947463,0.000001550118,0.002582029,0.00015289219,0.006344638,0.00015759213,0.9714643,0.0058135595],"study_design_scores_gemma":[0.042092834,0.015349585,0.0017695837,0.0060715824,0.0035722526,0.0000031246332,0.0015199672,0.0035167283,0.039770868,0.0001366001,0.8856708,0.00052612403],"about_ca_topic_score_codex":0.0059981155,"about_ca_topic_score_gemma":0.0011938575,"teacher_disagreement_score":0.08579354,"about_ca_system_score_codex":0.0003876973,"about_ca_system_score_gemma":0.0018111215,"threshold_uncertainty_score":0.9067396},"labels":[],"label_agreement":null},{"id":"W2910133491","doi":"10.1097/coc.0000000000000513","title":"Survival Implications of De Novo Versus Recurrent Metastatic Non–Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cohort; Internal medicine; Oncology; Retrospective cohort study; Lung cancer; Cancer; Performance status; Multivariate analysis; Stage (stratigraphy); Radiation therapy; Disease","score_opus":0.08079565904110957,"score_gpt":0.517913950960586,"score_spread":0.43711829191947643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910133491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984638,0.0005032209,0.00082577043,0.004754134,0.0014805791,0.00027924465,0.000023723349,0.0000047639983,0.0074906023],"genre_scores_gemma":[0.98752004,0.001064333,0.010267649,0.0005922586,0.00027561703,0.000014907041,0.0000043361115,0.00001613257,0.000244723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981089,0.00021060594,0.0011526257,0.00015359865,0.00016255348,0.00021171653],"domain_scores_gemma":[0.9959775,0.0016142494,0.0014853579,0.00020943533,0.0004256283,0.0002878099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068789814,0.000108064654,0.0010561671,0.000092655064,0.000021902677,0.0000033609203,0.00014049803,0.00005184116,0.00023669578],"category_scores_gemma":[0.00026925767,0.00007991533,0.0003426112,0.00022586464,0.00021359799,0.000039673738,0.0000257059,0.0003702421,0.000011040091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042028893,0.0023904082,0.6326207,0.00008893335,0.0020053969,0.00006515775,0.0006490397,0.00019165622,0.0006824925,0.00019217053,0.0011517215,0.35575947],"study_design_scores_gemma":[0.02748046,0.03743086,0.88213503,0.00022973176,0.0067358543,0.00016905779,0.00214504,0.00025534647,0.0002195136,0.00011224756,0.042854622,0.00023225452],"about_ca_topic_score_codex":0.0001716358,"about_ca_topic_score_gemma":0.00008284945,"teacher_disagreement_score":0.3555272,"about_ca_system_score_codex":0.00029487343,"about_ca_system_score_gemma":0.0033256735,"threshold_uncertainty_score":0.5899602},"labels":[],"label_agreement":null},{"id":"W2910259404","doi":"10.1016/j.canlet.2019.01.009","title":"Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma","year":2019,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Irish Cancer Society; Enterprise Ireland; Health Research Board","keywords":"Pyrazine; Radiosensitivity; Small molecule; Cancer research; Chemistry; Adenocarcinoma; Molecule; Stereochemistry; Biology; Medicine; Biochemistry; Cancer; Internal medicine; Organic chemistry; Radiation therapy","score_opus":0.012783513836368589,"score_gpt":0.28842914645382633,"score_spread":0.2756456326174577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910259404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794676,0.0034918238,0.00016671004,0.01052796,0.00086258847,0.0012405447,0.0000691093,0.00012231625,0.0040513854],"genre_scores_gemma":[0.9875301,0.00015015338,0.00052296056,0.009324589,0.00041949278,0.0002037527,0.00011059488,0.00007675099,0.0016615646],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99764884,0.000069332236,0.00044606373,0.0007787449,0.00036706534,0.00068993063],"domain_scores_gemma":[0.9988184,0.00010295231,0.0001651495,0.0005814743,0.000086744425,0.00024525504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001488545,0.00041390746,0.00070466555,0.0002650168,0.00009643973,0.00005653838,0.00017827604,0.00012807596,0.0004817477],"category_scores_gemma":[0.000018473873,0.000382246,0.0001945317,0.0004717934,0.00018692258,0.00019576433,0.00006271607,0.00039929902,0.00030124595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011757761,0.00083550735,0.4491539,0.0006696253,0.001115441,0.002827678,0.003974634,0.0005429064,0.5150963,0.0002679392,0.013467738,0.010872549],"study_design_scores_gemma":[0.02012885,0.0010217776,0.8792435,0.0011252491,0.0009633186,0.00032900562,0.0005999625,0.0012976011,0.08266097,0.00007884148,0.011151882,0.0013990764],"about_ca_topic_score_codex":0.00096746336,"about_ca_topic_score_gemma":0.0005550238,"teacher_disagreement_score":0.43243533,"about_ca_system_score_codex":0.0008726453,"about_ca_system_score_gemma":0.00035080744,"threshold_uncertainty_score":0.99986297},"labels":[],"label_agreement":null},{"id":"W2911174524","doi":"10.1158/1078-0432.ccr-18-3325","title":"Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Gefitinib; Internal medicine; Erlotinib; T790M; Hazard ratio; Lung cancer; Oncology; Erlotinib Hydrochloride; Tyrosine-kinase inhibitor; Performance status; Epidermal growth factor receptor; Confidence interval; Cancer","score_opus":0.0551726375942707,"score_gpt":0.5012714979434845,"score_spread":0.44609886034921375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911174524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882358,0.0027395901,0.0000073824044,0.00064080267,0.00052098127,0.00670318,0.0003999114,0.000039458493,0.0007129362],"genre_scores_gemma":[0.9958505,0.00056033075,0.0007250443,0.00009478209,0.000071583614,0.0012789182,0.0003348346,0.00008302377,0.0010009762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667144,0.00017302658,0.0008036978,0.0007548008,0.0008283732,0.0007686403],"domain_scores_gemma":[0.9961764,0.00090792705,0.00025657887,0.0005654616,0.001779818,0.00031376453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005137073,0.00028192977,0.00092986546,0.00023080423,0.00011512441,0.000026738553,0.00022649136,0.0002105204,0.0003092714],"category_scores_gemma":[0.0002686874,0.00019128811,0.00019709747,0.00065982813,0.00018748481,0.00011873177,0.00009805129,0.0005674524,0.000012364152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05153014,0.00064176286,0.91694653,0.00093790976,0.0003573116,0.000010156693,0.0007340385,0.00012948351,0.00003964879,0.0000070425704,0.000324972,0.028340977],"study_design_scores_gemma":[0.10408544,0.020800985,0.8652087,0.0028908679,0.00066616706,1.7259394e-7,0.0008433943,0.00024385477,0.0020684479,0.000011807637,0.0028046668,0.0003755092],"about_ca_topic_score_codex":0.0007480595,"about_ca_topic_score_gemma":0.0010976826,"teacher_disagreement_score":0.0525553,"about_ca_system_score_codex":0.0011778381,"about_ca_system_score_gemma":0.0020918911,"threshold_uncertainty_score":0.7800503},"labels":[],"label_agreement":null},{"id":"W2911915950","doi":"10.1101/545525","title":"Design and evaluation of novel 4-anilinoquinolines and quinazolines EGFR inhibitors in lung cancer and chordoma","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharma; University of North Carolina at Chapel Hill; Ministero dello Sviluppo Economico; Fundação de Amparo à Pesquisa do Estado de São Paulo; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Ontario Ministry of Economic Development and Innovation; China Scholarship Council; Genome Canada; Pfizer","keywords":"Chordoma; Epidermal growth factor receptor; EGFR inhibitors; Lung cancer; Cancer research; Chemistry; Medicine; Computational biology; Oncology; Receptor; Internal medicine; Biology; Pathology","score_opus":0.030316428751581682,"score_gpt":0.3196127884623592,"score_spread":0.2892963597107775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911915950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746581,0.021861881,0.00045957754,0.00034555083,0.0004067246,0.0021379746,0.000087064196,0.000039122995,0.000004003685],"genre_scores_gemma":[0.99258584,0.0025447288,0.00420321,0.00006224748,0.00019289255,0.000351011,6.9483605e-7,0.000054952998,0.000004431695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998287,0.000067132874,0.0004353533,0.00063340476,0.00034756446,0.0002295291],"domain_scores_gemma":[0.99850774,0.00007600713,0.00028420903,0.00037205484,0.0006248457,0.00013511932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006001508,0.00033216382,0.000578291,0.0003096771,0.000048558573,0.00004662337,0.000059035072,0.00029457966,0.000007597374],"category_scores_gemma":[0.00012256978,0.00030720758,0.00003636448,0.00022310668,0.000115354174,0.00011297541,0.00013948245,0.0002478655,3.7266565e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002705898,0.0005203742,0.5811524,0.0038174933,0.0007718706,0.000014892847,0.00026703617,0.0021006453,0.41065234,0.00016234627,0.00011860457,0.00015143151],"study_design_scores_gemma":[0.007646205,0.00015205583,0.8848871,0.0028749146,0.0022130264,1.4629467e-7,0.000020510108,0.045936864,0.05565426,0.0000029640282,0.000110474946,0.0005015065],"about_ca_topic_score_codex":0.0004424763,"about_ca_topic_score_gemma":0.000020648911,"teacher_disagreement_score":0.35499805,"about_ca_system_score_codex":0.00030311142,"about_ca_system_score_gemma":0.0010138656,"threshold_uncertainty_score":0.999938},"labels":[],"label_agreement":null},{"id":"W2912107322","doi":"10.1016/j.jtho.2019.02.001","title":"Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Company; Astellas Pharma Canada; Meso Scale Diagnostics; AbbVie; Takeda Pharmaceuticals North America; EMD Serono; Novartis; Bayer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer","keywords":"Osimertinib; Medicine; Durvalumab; T790M; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer; Gefitinib; Erlotinib; Nivolumab","score_opus":0.027435261544773444,"score_gpt":0.4405778436775608,"score_spread":0.4131425821327874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912107322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774047,0.0047394964,0.00010163118,0.0050151753,0.002750525,0.0010412165,0.0000065250456,0.00003055469,0.008910152],"genre_scores_gemma":[0.99444216,0.0004985453,0.0015469294,0.001117875,0.00045837773,0.000034711135,0.000026887175,0.000060672686,0.0018138533],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971683,0.0002976987,0.0012071885,0.00036886896,0.0004891412,0.00046881635],"domain_scores_gemma":[0.9976627,0.00038028555,0.0010470306,0.00038545058,0.00029080498,0.00023369632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084729097,0.00030738587,0.0011399084,0.00033319223,0.000089864596,0.000031036132,0.00019598025,0.0002680008,0.00026874684],"category_scores_gemma":[0.00016596458,0.00023849668,0.0005130347,0.0003550413,0.00007096183,0.00030822709,0.000035124594,0.0006147041,0.000039253653],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088563345,0.004952964,0.1575893,0.0001688629,0.009899967,0.030049326,0.022544036,0.00083990337,0.016518444,0.00011546683,0.0033256456,0.66543275],"study_design_scores_gemma":[0.18975453,0.056635782,0.45671234,0.003496486,0.0069236485,0.020326454,0.007931989,0.0010424474,0.019903064,0.000706819,0.23443536,0.0021310668],"about_ca_topic_score_codex":0.0002858063,"about_ca_topic_score_gemma":0.00005694566,"teacher_disagreement_score":0.66330165,"about_ca_system_score_codex":0.0019475485,"about_ca_system_score_gemma":0.0019174638,"threshold_uncertainty_score":0.97256124},"labels":[],"label_agreement":null},{"id":"W2912424284","doi":"10.1093/ajcp/142.suppl1.212","title":"The Accuracy of Subclassifying Poorly Differentiated Non-Small Cell Lung Carcinoma Biopsies With Commonly Used Lung Carcinoma Markers","year":2014,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Carcinoma; Lung; Small Cell Lung Carcinoma; Pathology; Medicine; Lung cancer; Small-cell carcinoma; Internal medicine","score_opus":0.023941593812380597,"score_gpt":0.35039997526164185,"score_spread":0.32645838144926126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912424284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943038,0.00039273853,0.001540812,0.0021110524,0.0003916218,0.0002876046,0.000010157931,0.000011671329,0.0009505182],"genre_scores_gemma":[0.9972736,0.0001345979,0.0017135148,0.00050083554,0.00020595599,0.000008276095,0.000009841354,0.000037157486,0.000116180185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970168,0.00063836045,0.0014215974,0.00025626077,0.00029420576,0.00037279417],"domain_scores_gemma":[0.9936882,0.0030019607,0.0021315282,0.00044439087,0.0004434204,0.00029045538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095358706,0.00023752463,0.0012041549,0.00013984097,0.000152748,0.000023101902,0.0002856761,0.00009532641,0.000017295153],"category_scores_gemma":[0.0005959719,0.00013280706,0.00037299262,0.00027706334,0.0010488268,0.000073264426,0.00005562085,0.00061066763,0.0000022962067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016879179,0.0003269238,0.98027277,0.00005459095,0.00035704093,0.00021923364,0.00058756204,0.000009712573,0.00080889795,0.000022870796,0.00032502683,0.015327475],"study_design_scores_gemma":[0.005933105,0.0060677915,0.98298615,0.00013158488,0.0013261153,0.00039781377,0.0016212132,0.0006847274,0.00033136088,0.00001859118,0.00036051686,0.00014103667],"about_ca_topic_score_codex":0.00015432827,"about_ca_topic_score_gemma":0.00005727665,"teacher_disagreement_score":0.015186438,"about_ca_system_score_codex":0.00007060177,"about_ca_system_score_gemma":0.0005322262,"threshold_uncertainty_score":0.5415715},"labels":[],"label_agreement":null},{"id":"W2912617737","doi":"10.1016/j.jtho.2019.01.015","title":"Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Natural Science Foundation of China","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Acquired resistance; Adenocarcinoma; Pharmacology; Cancer research; Cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Gefitinib","score_opus":0.020512832974411158,"score_gpt":0.4515014186261033,"score_spread":0.4309885856516922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912617737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98328584,0.0016577072,0.0003546058,0.010189513,0.0009454022,0.0005345458,0.00001281251,0.000020821073,0.0029987348],"genre_scores_gemma":[0.9927667,0.00027434665,0.0033576386,0.000809265,0.0002380269,0.000013378698,0.000029427898,0.000028010067,0.0024832494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985366,0.00015338449,0.0005602215,0.00021423229,0.00029438417,0.00024119121],"domain_scores_gemma":[0.99852675,0.00019773903,0.00042955016,0.0001970254,0.0004155813,0.00023335837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000516338,0.00016269136,0.0005490692,0.0004615401,0.00012103682,0.000040400577,0.000106172214,0.00013093051,0.0001686502],"category_scores_gemma":[0.00010894082,0.00013074762,0.00011686824,0.0003734398,0.000051027637,0.0002644777,0.000030403078,0.00029891054,0.00002601017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049770786,0.002001982,0.61681783,0.00025582116,0.0014483513,0.0008152307,0.009311835,0.00021063848,0.11880101,0.0013230147,0.0035277167,0.2405095],"study_design_scores_gemma":[0.007309364,0.005848635,0.9438875,0.0003297636,0.0007187916,0.0012681278,0.0012538695,0.0004746193,0.0050245374,0.00030096204,0.03335538,0.0002284752],"about_ca_topic_score_codex":0.000033153567,"about_ca_topic_score_gemma":0.0000052093214,"teacher_disagreement_score":0.32706967,"about_ca_system_score_codex":0.00046880072,"about_ca_system_score_gemma":0.00059816195,"threshold_uncertainty_score":0.5331733},"labels":[],"label_agreement":null},{"id":"W2913258427","doi":"10.1016/j.ejca.2018.11.030","title":"Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Comprehensive Cancer Center, City of Hope; National Institutes of Health; University of South Alabama; Memorial Sloan-Kettering Cancer Center","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Progressive disease; Trastuzumab; Adenocarcinoma; Lung; Cancer; Gastroenterology; Disease; Breast cancer; Epidermal growth factor receptor; Gefitinib","score_opus":0.01237785248314384,"score_gpt":0.3307583307436871,"score_spread":0.3183804782605433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913258427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491674,0.0003972717,0.000024257544,0.00034537542,0.0008485729,0.0008652026,0.00003334042,0.000007080312,0.002562184],"genre_scores_gemma":[0.9984147,0.000079760655,0.00043478925,0.00013140206,0.00014411828,0.000009754293,0.000006396981,0.000032390722,0.0007466997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985311,0.00013533115,0.00043171344,0.00018238429,0.0005581124,0.00016133746],"domain_scores_gemma":[0.9988128,0.000026298256,0.0004100848,0.00013446486,0.00050891883,0.00010743882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022655749,0.0001459853,0.00031523322,0.00015698095,0.000024591513,0.00002735177,0.000111820955,0.0000072166877,0.0009025175],"category_scores_gemma":[0.000052693413,0.00008655911,0.000057627876,0.00020550388,0.00001996575,0.00017312923,0.000023061633,0.00022696788,0.000013736446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039981804,0.0010003533,0.9764345,0.000026875503,0.0011880624,0.00039420807,0.0053124973,0.0003197675,0.000013315695,0.0000032528585,0.0003271688,0.010981762],"study_design_scores_gemma":[0.021999981,0.0034749294,0.9689205,0.00076386466,0.0005249402,0.000012695068,0.0020133762,0.00010211905,0.000019155714,0.0000010859412,0.0020587342,0.000108562024],"about_ca_topic_score_codex":0.00008033322,"about_ca_topic_score_gemma":0.00031759337,"teacher_disagreement_score":0.0180018,"about_ca_system_score_codex":0.001294987,"about_ca_system_score_gemma":0.00040008617,"threshold_uncertainty_score":0.9881934},"labels":[],"label_agreement":null},{"id":"W2914469496","doi":"","title":"Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epidermal growth factor receptor; Tyrosine-kinase inhibitor; Cancer research; Lung cancer; Tyrosine kinase; Medicine; Gefitinib; Oncology; Cancer; Receptor; Internal medicine","score_opus":0.015403474532567865,"score_gpt":0.2745426734582585,"score_spread":0.25913919892569065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914469496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933322,0.000086044296,0.00082489115,0.0005381291,0.0002672497,0.0044076126,0.0004643894,0.00006148692,0.000017970044],"genre_scores_gemma":[0.9815847,0.0000026622304,0.012962452,0.00013885809,0.00014048279,0.004599327,0.00047596183,0.00004420634,0.00005129865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806386,0.00009479292,0.0005568588,0.0005025198,0.00034871345,0.00043328138],"domain_scores_gemma":[0.99770933,0.00053638296,0.0003580941,0.0002646297,0.0008298078,0.0003017499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005357192,0.00023662821,0.00042921983,0.00055834826,0.00011622885,0.00002864154,0.00008848909,0.000095684554,0.000014701109],"category_scores_gemma":[0.0014553905,0.00019891786,0.0000924634,0.0012089696,0.00003649777,0.00043493294,0.000016982043,0.0001703927,5.181593e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005577973,0.0005825433,0.95486355,0.0002709582,0.00016795937,0.0000021395604,0.0010155259,0.0015741839,0.018614067,0.00000121924,0.00004659864,0.017283268],"study_design_scores_gemma":[0.007370182,0.00082277064,0.9499329,0.00024467392,0.0008939815,1.6919992e-7,0.0001264858,0.002608716,0.037806075,0.0000016786815,0.000019511575,0.00017288046],"about_ca_topic_score_codex":0.0004898228,"about_ca_topic_score_gemma":0.00019612072,"teacher_disagreement_score":0.019192008,"about_ca_system_score_codex":0.000515148,"about_ca_system_score_gemma":0.00035983554,"threshold_uncertainty_score":0.8111634},"labels":[],"label_agreement":null},{"id":"W2914684938","doi":"10.1016/j.jaci.2018.12.573","title":"Effect of Azithromycin on EGFR Expression in Human Bronchial Epithelial Cells","year":2019,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Christie (Canada)","funders":"","keywords":"TLR2; Proinflammatory cytokine; Azithromycin; CD14; Immunology; Innate immune system; Transactivation; Biology; Medicine; Inflammation; Immune system; Microbiology; Antibiotics; Gene expression","score_opus":0.011536178245679877,"score_gpt":0.3681710614037886,"score_spread":0.3566348831581087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914684938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744666,0.00046711392,0.0000064923834,0.0002577019,0.0006630515,0.00013038295,0.000001711881,0.0000023558598,0.0010245271],"genre_scores_gemma":[0.9984927,0.0008147359,0.00008201368,0.000088682114,0.00013541475,0.0000011748239,0.0000022831819,0.000007221058,0.0003757653],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988794,0.00020719777,0.00060246297,0.000107645945,0.00009645292,0.000106843574],"domain_scores_gemma":[0.99905086,0.0004238273,0.00030931272,0.00012004915,0.000046366422,0.00004960591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037009755,0.00008621689,0.0005083567,0.00009145884,0.000020706882,0.0000026699906,0.000058582977,0.0001601492,0.0001903956],"category_scores_gemma":[0.00006255592,0.00005378359,0.00014839214,0.000040230683,0.00009739926,0.000040823194,0.000023602523,0.0003549476,0.0000100454],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023642434,0.0035313135,0.09010463,0.00011773235,0.0038212168,0.00027483833,0.0006864406,0.00008964554,0.81448764,0.0008297355,0.00082358293,0.061590776],"study_design_scores_gemma":[0.047091167,0.08368912,0.6635879,0.0010703244,0.00042642662,0.00014397253,0.00018403934,0.000017833865,0.19494563,0.00036394264,0.008297288,0.00018231956],"about_ca_topic_score_codex":0.00002057776,"about_ca_topic_score_gemma":0.000011339671,"teacher_disagreement_score":0.619542,"about_ca_system_score_codex":0.000033318527,"about_ca_system_score_gemma":0.00006524872,"threshold_uncertainty_score":0.21932313},"labels":[],"label_agreement":null},{"id":"W2915296465","doi":"10.3747/co.26.4809","title":"Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib","year":2019,"lang":"en","type":"letter","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; William Osler Health System; BC Cancer Foundation; Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Internal medicine; Oncology; ALK inhibitor","score_opus":0.05450463231190626,"score_gpt":0.412521131429233,"score_spread":0.35801649911732675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915296465","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5961162,0.004540198,0.00082591915,0.25740218,0.007536171,0.09985682,0.030116888,0.00042150015,0.0031841262],"genre_scores_gemma":[0.05508704,0.009980358,0.0066991937,0.5415322,0.015351241,0.18159294,0.036659308,0.0023243357,0.15077336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99611247,0.00013912612,0.0007127286,0.0016055171,0.00044685265,0.000983285],"domain_scores_gemma":[0.9965436,0.0005874388,0.001095926,0.0007357523,0.00079610996,0.00024118142],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004308701,0.0012220752,0.0021736838,0.00035855608,0.0002332793,0.00006605122,0.0001960237,0.0006977669,0.00027243688],"category_scores_gemma":[0.000041581196,0.0007163285,0.0003750842,0.00024756766,0.000106860025,0.000104058505,0.000041187504,0.0005126067,0.000044356853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01872401,0.011977055,0.077552974,0.0023859153,0.0039459933,0.001021518,0.012738875,0.00012167809,0.00001666388,0.0000015228579,0.6229303,0.24858353],"study_design_scores_gemma":[0.05318861,0.054399848,0.013577789,0.008803345,0.0054547563,0.000014055728,0.000638923,0.00037154357,0.0011006321,0.0000017307143,0.86143535,0.0010133907],"about_ca_topic_score_codex":0.0002486091,"about_ca_topic_score_gemma":0.0012998733,"teacher_disagreement_score":0.54102916,"about_ca_system_score_codex":0.006022867,"about_ca_system_score_gemma":0.0017425268,"threshold_uncertainty_score":0.99952877},"labels":[],"label_agreement":null},{"id":"W2915431268","doi":"10.1007/s00432-019-02862-x","title":"First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression","year":2019,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University Health Centre","funders":"Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Hazard ratio; Tolerability; Oncology; Adverse effect; Gastroenterology; Epidermal growth factor receptor; Surgery; Confidence interval; Cancer","score_opus":0.04627148785334907,"score_gpt":0.5548936099905363,"score_spread":0.5086221221371872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915431268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940477,0.0008086866,0.0000929467,0.00038915183,0.000107514,0.003453458,0.001005287,0.0000022695733,0.000092997434],"genre_scores_gemma":[0.9958617,0.0010634196,0.0023319968,0.000022149721,0.000113971895,0.00024085678,0.00029713174,0.000019812818,0.000048940674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972712,0.00018711253,0.0013474624,0.00028575576,0.0006046344,0.00030383104],"domain_scores_gemma":[0.9925861,0.0021111076,0.001603366,0.00015584366,0.0032531752,0.00029045512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005831705,0.00018630816,0.0014106623,0.00038996257,0.00007909541,0.000009693427,0.00007699398,0.00017388129,0.000043787393],"category_scores_gemma":[0.00039244417,0.000106657346,0.00037952486,0.00033489073,0.00033599764,0.00013663521,0.00003771089,0.00019466133,8.4708056e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063342825,0.007498009,0.74565977,0.00030837228,0.0067912885,0.0000065099953,0.0009976138,0.000112936286,0.000049696515,0.000031257357,0.00012047323,0.17508124],"study_design_scores_gemma":[0.048482712,0.167905,0.77618474,0.00097535626,0.003889973,0.0000021284154,0.0001641257,0.0016100989,0.00047821554,0.00009153982,0.000123785,0.00009234595],"about_ca_topic_score_codex":0.00017028759,"about_ca_topic_score_gemma":0.00017015841,"teacher_disagreement_score":0.17498888,"about_ca_system_score_codex":0.00044154658,"about_ca_system_score_gemma":0.0012779274,"threshold_uncertainty_score":0.43493602},"labels":[],"label_agreement":null},{"id":"W2915544780","doi":"10.3747/co.26.4116","title":"Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; Centre Hospitalier de l’Université de Montréal; Alberta Cancer Foundation; McGill University Health Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Manitoba; CancerCare Manitoba; University of Ottawa","funders":"Pfizer Canada; Bristol-Myers Squibb Canada; EMD Serono; Siemens Healthineers; AstraZeneca Canada; Varian Medical Systems; Sanofi; Amgen; Pfizer; Celgene; Health Research; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Merck Canada; Accuray","keywords":"Medicine; Clinical trial; Clinical Practice; Best practice; Medical physics; MEDLINE; Intensive care medicine; Consensus conference; Lung cancer; Quality of life (healthcare); Family medicine; Oncology; Pathology; Nursing; Internal medicine","score_opus":0.0325985276429622,"score_gpt":0.40318564352660696,"score_spread":0.3705871158836448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915544780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96531826,0.019079242,0.00001025949,0.0026316345,0.0013848745,0.0013976764,0.00009535972,0.000034625184,0.010048084],"genre_scores_gemma":[0.99515516,0.0011435502,0.0008224877,0.00055630674,0.00015274482,0.00034904492,0.00008710584,0.000033346936,0.0017002611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873286,0.00003969743,0.00024350523,0.00038728528,0.00012109936,0.00047557396],"domain_scores_gemma":[0.9988719,0.000073024225,0.00013665274,0.00023357147,0.00018022842,0.00050462614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068142006,0.00021066792,0.0004228562,0.00022481749,0.00010317569,0.000022149698,0.00007103828,0.000106292464,0.00039035603],"category_scores_gemma":[0.00001369214,0.00017377152,0.00006341987,0.00019322656,0.00010144232,0.000033575274,0.000036342986,0.0002293282,0.00008556863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076987446,0.000450522,0.89947265,0.0006505264,0.00042683352,0.00019225586,0.0013665183,0.000020972002,0.00027584546,0.00021415204,0.008104224,0.08874853],"study_design_scores_gemma":[0.032433063,0.0028671687,0.5025558,0.0019559374,0.0059131384,0.0007995397,0.0035926714,0.0062950943,0.0015909396,0.00025894248,0.4403713,0.0013663956],"about_ca_topic_score_codex":0.008142763,"about_ca_topic_score_gemma":0.010181191,"teacher_disagreement_score":0.4322671,"about_ca_system_score_codex":0.00080030167,"about_ca_system_score_gemma":0.0022205333,"threshold_uncertainty_score":0.9984621},"labels":[],"label_agreement":null},{"id":"W2915600464","doi":"10.1016/j.trsl.2019.02.011","title":"Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?","year":2019,"lang":"en","type":"article","venue":"Translational research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Sunnybrook Hospital","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Genentech; Hawaii Academy of Science; University of Minnesota; Merck","keywords":"Medicine; Internal medicine; Cohort; Oncology; Cancer; Retrospective cohort study; Performance status; Primary tumor; Survival analysis; Stage (stratigraphy); Proportional hazards model; Metastasis","score_opus":0.043942856433309065,"score_gpt":0.38333496908024456,"score_spread":0.3393921126469355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915600464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527645,0.00028638277,0.000021791764,0.0023882834,0.000010025409,0.001194271,0.00008531329,0.000009315004,0.00072817283],"genre_scores_gemma":[0.99801767,0.0000089257355,0.0013664227,0.000011517363,0.000012309123,0.00005155647,0.00017677664,0.000014102031,0.00034070437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987073,0.00007480592,0.000119392476,0.00024512442,0.0005973783,0.00025600547],"domain_scores_gemma":[0.9992197,0.00039431345,0.000018897788,0.00007848228,0.0001595857,0.00012902214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022268952,0.00009801285,0.00014889575,0.00017811538,0.00006040962,0.000028060726,0.00002863586,0.000020989488,0.00009894114],"category_scores_gemma":[0.00005018941,0.00006867434,0.000014202899,0.0001788676,0.0001728446,0.00010682685,0.000009777743,0.00018998646,0.0000036066908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047781612,0.00012017089,0.9961321,0.00010095321,0.00005000954,0.000009032611,0.0005292217,0.000014231348,0.00003068916,0.00043787924,0.000022755348,0.002075167],"study_design_scores_gemma":[0.0041732616,0.0009794742,0.99359614,0.00026136514,0.00003148699,0.000006671757,0.00039548104,0.00014095496,0.0000141570645,0.00016590228,0.00017181112,0.000063288586],"about_ca_topic_score_codex":0.00024010625,"about_ca_topic_score_gemma":0.00030330548,"teacher_disagreement_score":0.0036954454,"about_ca_system_score_codex":0.000092977236,"about_ca_system_score_gemma":0.00038548902,"threshold_uncertainty_score":0.28004584},"labels":[],"label_agreement":null},{"id":"W2915945704","doi":"10.1200/jgo.18.00057","title":"Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns","year":2019,"lang":"en","type":"article","venue":"Journal of Global Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Lung cancer; China; Performance status; Cancer; Internal medicine; Family medicine","score_opus":0.03266711388787702,"score_gpt":0.4065773539355205,"score_spread":0.3739102400476435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915945704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832445,0.0001574913,0.00003785768,0.00023332535,0.00045773634,0.00019891911,0.000505653,0.0000015577665,0.00008298105],"genre_scores_gemma":[0.9982054,0.00012281066,0.0013765363,0.00020362016,0.000038996528,0.000001888993,0.000025115238,0.0000060333728,0.00001957003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893236,0.000099807796,0.00058222155,0.000106495805,0.00017370319,0.00010539583],"domain_scores_gemma":[0.9980566,0.00032446935,0.00078437716,0.00005573119,0.0007182522,0.00006059598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013532817,0.0000811171,0.00047372153,0.000038418857,0.0000072483945,0.0000032761577,0.00005439597,0.000061275234,0.000034751887],"category_scores_gemma":[0.00030956487,0.000057967984,0.00004224503,0.000116592426,0.000049871807,0.00017588785,0.000020805815,0.0001266035,2.661421e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013259763,0.00068081316,0.97185826,0.00003252202,0.0003164049,0.000005008728,0.0000449516,0.000034946486,0.00009819129,0.00000294813,0.00036203288,0.025237933],"study_design_scores_gemma":[0.007004551,0.0026178325,0.98952806,0.00034585042,0.00010096982,0.0000060432426,0.00002180134,0.000048706617,0.00002659012,0.000002118813,0.00025121073,0.00004627115],"about_ca_topic_score_codex":0.0011523344,"about_ca_topic_score_gemma":0.0003455411,"teacher_disagreement_score":0.025191663,"about_ca_system_score_codex":0.0003787268,"about_ca_system_score_gemma":0.00033823593,"threshold_uncertainty_score":0.23638657},"labels":[],"label_agreement":null},{"id":"W2916036960","doi":"10.3390/cancers11030275","title":"Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides","year":2019,"lang":"en","type":"review","venue":"Cancers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Université Toulouse III - Paul Sabatier; Fondation de France; Institut National de la Santé et de la Recherche Médicale","keywords":"Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; Lung cancer; Receptor tyrosine kinase; Crizotinib; Cancer; Medicine; Targeted therapy; Kinase; Biology; Receptor; Oncology; Internal medicine; Cell biology","score_opus":0.051253372833637026,"score_gpt":0.3985680472300643,"score_spread":0.34731467439642727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916036960","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000097221615,0.996047,0.000014047235,0.00003152324,0.0006047795,0.0017386017,0.00007223374,0.000020332373,0.0013742505],"genre_scores_gemma":[0.002304115,0.9954068,0.00012698722,0.000059209902,0.00019822082,0.00043350042,0.00015268433,0.00006148891,0.0012569815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863875,0.00004536389,0.0005007873,0.00034109934,0.00020025096,0.00027373937],"domain_scores_gemma":[0.99923724,0.000038954444,0.00033189653,0.00025772568,0.00006731403,0.00006685385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076663346,0.00028248207,0.0014040244,0.00020130433,0.00002558243,0.000008600308,0.00010836455,0.0001573148,0.00017438162],"category_scores_gemma":[0.000012820753,0.00020977808,0.0003163911,0.00032575263,0.000060070168,0.00004479829,0.000021812342,0.00024737054,0.00002063204],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024248546,0.00003826807,0.0001550802,0.031326395,0.00093430665,0.000021301827,0.00021798504,0.0005641028,0.000013543104,0.000030582138,0.00051122473,0.966163],"study_design_scores_gemma":[0.0013324083,0.00021028654,0.00005606641,0.030468859,0.006098323,0.000016283702,0.00016162502,0.00009746742,0.000009016945,0.000013026887,0.9612328,0.00030387595],"about_ca_topic_score_codex":0.0011298844,"about_ca_topic_score_gemma":0.000038333535,"teacher_disagreement_score":0.96585906,"about_ca_system_score_codex":0.0030767738,"about_ca_system_score_gemma":0.0048504923,"threshold_uncertainty_score":0.8604565},"labels":[],"label_agreement":null},{"id":"W2916233810","doi":"10.1016/j.lungcan.2019.02.015","title":"A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Immunohistochemistry; Concordance; Lung cancer; Crizotinib; Fluorescence in situ hybridization; Internal medicine; Adenocarcinoma; Carcinoma; Oncology; Fish <Actinopterygii>; Pathology; Cancer; Biology; Gene","score_opus":0.04933984428612437,"score_gpt":0.4332631489433579,"score_spread":0.3839233046572335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916233810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894491,0.0025983327,0.00009477926,0.00043330988,0.0008425413,0.0023629586,0.00012115251,0.000043081363,0.0040547554],"genre_scores_gemma":[0.9962238,0.000042875443,0.0013369302,0.0004579358,0.0002505509,0.00021530352,0.000040499042,0.00003062949,0.0014014811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985033,0.00017799581,0.000401447,0.0004601325,0.00023755388,0.00021952609],"domain_scores_gemma":[0.99651134,0.0026450218,0.00012614578,0.00044166727,0.00013062551,0.00014521225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015354344,0.00017704924,0.0005507686,0.000076014105,0.000039465423,0.000008811068,0.00011326002,0.000082769984,0.00027877517],"category_scores_gemma":[0.00031239618,0.00013735042,0.00012645105,0.00019987841,0.000035437337,0.000050188093,0.00008539675,0.00016895085,0.000049470473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005925185,0.0016737077,0.98356146,0.00006281437,0.000343191,0.00013679407,0.0043091523,0.00024197072,0.0006405146,0.0000084695175,0.0015821654,0.006847253],"study_design_scores_gemma":[0.005532343,0.0018573082,0.98700815,0.00009878853,0.0016602605,0.0000026842954,0.002020673,0.00005280295,0.001243822,0.000019485175,0.00035534936,0.00014834429],"about_ca_topic_score_codex":0.004689018,"about_ca_topic_score_gemma":0.00016625956,"teacher_disagreement_score":0.006774706,"about_ca_system_score_codex":0.00019762742,"about_ca_system_score_gemma":0.0002274056,"threshold_uncertainty_score":0.70884234},"labels":[],"label_agreement":null},{"id":"W2917387482","doi":"10.1007/s11864-019-0617-6","title":"The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"review","venue":"Current Treatment Options in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Medicine; Bevacizumab; Oncology; Lung cancer; Atezolizumab; Anaplastic lymphoma kinase; Internal medicine; Population; Combination therapy; Targeted therapy; Chemotherapy; Maintenance therapy; Epidermal growth factor receptor; Immunotherapy; Cancer; Pembrolizumab; Cancer research","score_opus":0.04126358621587533,"score_gpt":0.4020381611712739,"score_spread":0.36077457495539855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917387482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.055025384,0.9394503,0.0000012264549,0.00015358155,0.0004857712,0.0045643137,0.0001326007,0.0000056777585,0.0001810975],"genre_scores_gemma":[0.025133014,0.97102284,0.00014016323,0.000005616907,0.000056622182,0.0033345402,0.00022675168,0.000034415803,0.00004603015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739504,0.00041963102,0.0013097922,0.0003889578,0.00016431775,0.00032227015],"domain_scores_gemma":[0.9981953,0.0005947313,0.0006393686,0.00045260543,0.00007196019,0.00004605585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003951602,0.00041929263,0.0016728893,0.0004527212,0.00006190272,0.000010542351,0.00016522706,0.00017330603,0.000018160255],"category_scores_gemma":[0.000020885043,0.00021924957,0.00046291752,0.00081406574,0.0001611007,0.00004094899,0.000045460714,0.0003385908,0.0000022874133],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057898767,0.0028391008,0.008881113,0.0017858457,0.0005516176,0.000011660552,0.0030798619,0.0000503267,0.000031650776,0.000048384278,0.000019206002,0.9826433],"study_design_scores_gemma":[0.0183342,0.0045640003,0.018084373,0.02105617,0.010188546,0.000055274475,0.0050167474,0.00026167725,0.0005791487,0.00010778585,0.92099166,0.0007603897],"about_ca_topic_score_codex":0.0014780076,"about_ca_topic_score_gemma":0.0009065959,"teacher_disagreement_score":0.9818829,"about_ca_system_score_codex":0.0014761762,"about_ca_system_score_gemma":0.0016049927,"threshold_uncertainty_score":0.8940738},"labels":[],"label_agreement":null},{"id":"W2918613436","doi":"10.2139/ssrn.3377373","title":"EML4-ALK V3 Drives Cell Migration Through NEK9 and NEK7 Kinases in Non-Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Cancer research; Cell; Cell biology; Microtubule; Kinase; Cell migration; Biology; Cytoplasm; Lung cancer; Medicine; Internal medicine; Genetics","score_opus":0.005009872254279862,"score_gpt":0.28144962678574215,"score_spread":0.2764397545314623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918613436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97185344,0.022256091,0.00045478903,0.0013716553,0.00019323757,0.00047755655,0.0000041861126,0.000021059619,0.003367973],"genre_scores_gemma":[0.9757232,0.01816906,0.00021740272,0.00024416554,0.00019732554,0.000028972609,0.000013471939,0.000034290377,0.0053721033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839646,0.00003178969,0.00023604855,0.00022631415,0.00016249156,0.00094688806],"domain_scores_gemma":[0.9995668,0.000031809257,0.00012795786,0.00013217582,0.00006525142,0.00007600182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016691683,0.00016768448,0.00023629944,0.000101979014,0.000098398334,0.00003954666,0.00006451982,0.00007323998,0.00005197184],"category_scores_gemma":[0.000005724017,0.00013317312,0.000070605594,0.0001598572,0.000022766759,0.0002184877,0.000016528038,0.0007018009,0.000015074855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034519428,0.00078461785,0.95358485,0.00030197616,0.0005452527,0.00005462652,0.008215618,0.0005916717,0.018795062,0.0035621466,0.0011404736,0.012078522],"study_design_scores_gemma":[0.09777939,0.01282775,0.6469363,0.003518281,0.007010757,0.0025796304,0.06504608,0.008287081,0.050711274,0.066817604,0.03496827,0.0035175567],"about_ca_topic_score_codex":0.0017065359,"about_ca_topic_score_gemma":0.0061642937,"teacher_disagreement_score":0.30664852,"about_ca_system_score_codex":0.0009991992,"about_ca_system_score_gemma":0.0018305667,"threshold_uncertainty_score":0.54306424},"labels":[],"label_agreement":null},{"id":"W2920366275","doi":"10.1007/s00432-019-02875-6","title":"Disparity in age at lung cancer diagnosis between current and former smokers","year":2019,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health","funders":"V Foundation for Cancer Research","keywords":"Medicine; Lung cancer; Smoking cessation; Cancer; Internal medicine; Cancer registry; Pathology","score_opus":0.16523920859484842,"score_gpt":0.6101757624703432,"score_spread":0.4449365538754948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920366275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620866,0.02564084,0.0000020945197,0.010711154,0.00041488875,0.00040688567,0.000026423706,0.000002118777,0.00070896355],"genre_scores_gemma":[0.90466917,0.09403747,0.000048170914,0.00021767346,0.00046866012,0.00008914836,0.00000356079,0.000009252471,0.00045691323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983085,0.00017717009,0.0006260834,0.00020209978,0.00035929497,0.00032685322],"domain_scores_gemma":[0.99784636,0.0011963345,0.00020164375,0.00009845516,0.00023888786,0.0004183235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012294112,0.000089750334,0.00062290725,0.00015985461,0.000062878185,0.000015391512,0.00007148421,0.00013698621,0.0003785998],"category_scores_gemma":[0.00020501854,0.000060182552,0.00009397786,0.00016697306,0.00027418634,0.00010518411,0.00009514805,0.00088411866,0.0000029217751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075237657,0.000311122,0.82874197,0.00009815381,0.0002870131,0.0000732832,0.00014488758,9.034361e-7,0.00000909486,0.000021652462,0.0052535813,0.164306],"study_design_scores_gemma":[0.005971794,0.0025480546,0.8714054,0.00034663788,0.0002409756,0.000009103291,0.000073404204,0.000014790827,0.000020105805,0.000194353,0.11912157,0.000053765707],"about_ca_topic_score_codex":0.00096087035,"about_ca_topic_score_gemma":0.0030163603,"teacher_disagreement_score":0.16425222,"about_ca_system_score_codex":0.0009074826,"about_ca_system_score_gemma":0.0010387338,"threshold_uncertainty_score":0.41454023},"labels":[],"label_agreement":null},{"id":"W2920658753","doi":"10.1016/j.jtho.2019.03.002","title":"Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Merck Sharp and Dohme; Boehringer Ingelheim; Novartis Pharmaceuticals Corporation; Celgene; Roche; AbbVie; Merck; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ceritinib; Internal medicine; Gastroenterology; Tolerability; Confidence interval; Adverse effect; Anaplastic lymphoma kinase; Pleural effusion","score_opus":0.016746586295062347,"score_gpt":0.3646053398538381,"score_spread":0.3478587535587757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920658753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937608,0.00028436107,0.000012655345,0.0017096747,0.00043194293,0.002079474,0.00029801423,0.000011723383,0.0014113393],"genre_scores_gemma":[0.99729764,0.0000669312,0.0018845161,0.00019348618,0.00017146188,0.000013809431,0.00015559723,0.00003848928,0.00017804565],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975434,0.00040146586,0.00087652623,0.00035737627,0.00052708626,0.00029413338],"domain_scores_gemma":[0.9964439,0.0014865896,0.000987818,0.00036942158,0.00052731525,0.00018491059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044466608,0.00028291973,0.00095374294,0.00017704304,0.00009228419,0.000020249525,0.00017390687,0.00013603664,0.00007651107],"category_scores_gemma":[0.00026835728,0.00014882073,0.00007588794,0.00040838504,0.00016741994,0.00018199305,0.00006968768,0.0005119755,0.0000056506233],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74626786,0.012367333,0.12226704,0.00007781536,0.003356487,0.0003566248,0.010942483,0.000101910315,0.00077614613,0.000007656111,0.000553922,0.102924764],"study_design_scores_gemma":[0.100645915,0.06203966,0.8297837,0.00093634357,0.0015163758,0.00004488331,0.0028582576,0.000005643272,0.00021721797,0.0000014572885,0.0017869951,0.00016357155],"about_ca_topic_score_codex":0.00012019401,"about_ca_topic_score_gemma":0.00023737189,"teacher_disagreement_score":0.7075167,"about_ca_system_score_codex":0.0006485767,"about_ca_system_score_gemma":0.0009343367,"threshold_uncertainty_score":0.60687333},"labels":[],"label_agreement":null},{"id":"W2921353678","doi":"10.1136/ejhpharm-2019-eahpconf.269","title":"4CPS-120 Erlotinib in non-small-cell lung cancer without epidermal growth factor receptor activating mutations","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Epidermal growth factor receptor; Oncology; Lung cancer; Chemotherapy; Taxane; Erlotinib Hydrochloride; Adverse effect; Cancer; Breast cancer","score_opus":0.038105665510673306,"score_gpt":0.4265117572884367,"score_spread":0.3884060917777634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921353678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895211,0.00028071512,0.000058203415,0.002047624,0.0026699377,0.0016140594,0.00006625272,0.00014377665,0.0035983347],"genre_scores_gemma":[0.9931111,0.00037396137,0.00078576023,0.0023668648,0.0010649477,0.00022341598,0.00015840757,0.00005948894,0.0018560826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976998,0.00014731692,0.0008718575,0.00061559916,0.00027407813,0.00039136427],"domain_scores_gemma":[0.99844116,0.00039895883,0.0003895369,0.0002448043,0.00026077352,0.0002647936],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002788546,0.0002792147,0.00051382417,0.00017732942,0.00014656325,0.000050912065,0.00013862106,0.0001314009,0.001843556],"category_scores_gemma":[0.00004717434,0.00024355641,0.000202727,0.00047523197,0.00003618236,0.00045555114,0.000052934327,0.0006335304,0.00015833146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033608318,0.0006065827,0.9859198,0.0006930245,0.0002709917,0.0000059529416,0.0016713,0.00020873538,0.0052274275,0.0000048302622,0.00025629904,0.0047990223],"study_design_scores_gemma":[0.021121748,0.00037915973,0.9316035,0.00083395594,0.00064498815,0.000011342507,0.0016994323,0.017291816,0.010740623,0.000033959477,0.015040328,0.00059913576],"about_ca_topic_score_codex":0.0041204467,"about_ca_topic_score_gemma":0.00068292697,"teacher_disagreement_score":0.054316238,"about_ca_system_score_codex":0.0002675132,"about_ca_system_score_gemma":0.00034859497,"threshold_uncertainty_score":0.9990689},"labels":[],"label_agreement":null},{"id":"W2923788634","doi":"10.1016/j.lungcan.2019.03.019","title":"The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"T790M; Medicine; Osimertinib; KRAS; Lung cancer; Internal medicine; Oncology; Allele; Mutation; Gene; Cancer; Genetics; Biology","score_opus":0.008538635240453023,"score_gpt":0.3203514058084362,"score_spread":0.3118127705679832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923788634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110943,0.0059157163,0.00024986657,0.00065855513,0.000060816903,0.0004258321,0.000008822214,0.0000044961816,0.0015664531],"genre_scores_gemma":[0.9965678,0.00050355226,0.0016102734,0.000024915871,0.0000093034705,0.00006371875,0.0000057150087,0.0000047857206,0.0012099767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995714,0.000011117453,0.0001513326,0.000100511155,0.000095388736,0.00007025642],"domain_scores_gemma":[0.9996842,0.00007643008,0.00007264497,0.00009129967,0.000052664767,0.00002272528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000680332,0.000045043103,0.00010713121,0.000029218289,0.000042587337,0.0000044996364,0.000019642272,0.000020824367,0.000027476615],"category_scores_gemma":[0.000016299711,0.000031021867,0.000007939467,0.000075766606,0.000040006802,0.000050028364,0.000011317191,0.000040484996,4.2012678e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070697116,0.00027402726,0.9001276,0.0014172111,0.000746882,0.000009850357,0.024759762,0.00023822917,0.012981814,0.0044840924,0.001603842,0.05264972],"study_design_scores_gemma":[0.001988069,0.00005028417,0.97651345,0.000440482,0.00012212092,0.0000033693943,0.0019284516,0.00060582056,0.0028837794,0.00022588135,0.015159465,0.00007880455],"about_ca_topic_score_codex":0.00031378402,"about_ca_topic_score_gemma":0.0011164113,"teacher_disagreement_score":0.07638588,"about_ca_system_score_codex":0.00008762631,"about_ca_system_score_gemma":0.00020328256,"threshold_uncertainty_score":0.1265035},"labels":[],"label_agreement":null},{"id":"W2923839935","doi":"10.1016/j.ctarc.2019.100130","title":"Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes","year":2019,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Lung cancer; Medicine; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.051103386016498616,"score_gpt":0.42214878576659487,"score_spread":0.37104539975009626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923839935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98446727,0.0068661436,0.0000039977717,0.0020847302,0.00013696533,0.0019616934,0.00018706419,0.00002860753,0.0042635123],"genre_scores_gemma":[0.9663943,0.026404712,0.00082619686,0.00006038579,0.000022324946,0.0014795866,0.00022158577,0.00003128954,0.004559625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884856,0.00006618109,0.00019079846,0.0003212206,0.00023734193,0.00033588763],"domain_scores_gemma":[0.9982514,0.00023777325,0.000083676045,0.0008715814,0.00032649792,0.00022907465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007158137,0.0002008376,0.0003252793,0.00015749448,0.00042742092,0.000053566597,0.00015600848,0.00006041757,0.000057897345],"category_scores_gemma":[0.0000125809665,0.0001341889,0.000040242783,0.00023738397,0.00020694776,0.00011613545,0.00016475565,0.00020250867,0.000010178579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043469112,0.00057824614,0.9582343,0.00012155368,0.000504003,0.000002645635,0.0024912197,0.0000037886036,0.00015947672,0.00006556133,0.00007530445,0.037329182],"study_design_scores_gemma":[0.023124967,0.0034973999,0.9520183,0.000596086,0.00092258764,0.0000025390286,0.0016138545,0.0007903683,0.00045361422,0.000012030253,0.01665037,0.00031787637],"about_ca_topic_score_codex":0.0013232002,"about_ca_topic_score_gemma":0.0005640536,"teacher_disagreement_score":0.037011303,"about_ca_system_score_codex":0.0006145209,"about_ca_system_score_gemma":0.0004811981,"threshold_uncertainty_score":0.54720646},"labels":[],"label_agreement":null},{"id":"W2923871137","doi":"10.6004/jnccn.2018.7184","title":"CLO19-033: Afatinib Followed by Osimertinib in EGFR Mutation-Positive (EGFRm+) Advanced NSCLC: Subgroup Analyses of the GioTag Study by ECOG PS, Age, and Ethnicity","year":2019,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Afatinib; Medicine; Osimertinib; T790M; Discontinuation; Internal medicine; Oncology; Clinical trial; Erlotinib; Cancer; Epidermal growth factor receptor; Gefitinib","score_opus":0.03281158859745364,"score_gpt":0.3887960014115104,"score_spread":0.35598441281405674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923871137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854713,0.009972793,0.000030885873,0.002084817,0.00073936325,0.001146144,0.00010370434,0.0000052801056,0.0004457189],"genre_scores_gemma":[0.9971284,0.00028479937,0.00017080507,0.0016301752,0.00019658927,0.000029849956,0.000018335853,0.00002107062,0.0005199351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776775,0.00028772574,0.0006973693,0.00022673763,0.0008131153,0.00020731434],"domain_scores_gemma":[0.99708885,0.00060196425,0.00093022076,0.00016617274,0.0011313512,0.00008145536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020038382,0.00020923479,0.00054070534,0.00008646638,0.00014780997,0.000021638567,0.00021556001,0.00006989429,0.000053097017],"category_scores_gemma":[0.00012091862,0.00012481066,0.00022845664,0.00064665766,0.0001122682,0.0001549065,0.0000726876,0.0003969788,0.0000010963923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051249233,0.0028569915,0.6336245,0.00018911867,0.007518213,0.000060582395,0.007023864,0.13569182,0.058326934,0.00020074741,0.14185241,0.007529923],"study_design_scores_gemma":[0.011034834,0.0008209223,0.97801083,0.0008059623,0.001021309,0.000039045244,0.00127921,0.00050281,0.0029453088,0.00045386047,0.002863372,0.00022256195],"about_ca_topic_score_codex":0.00025903116,"about_ca_topic_score_gemma":0.00017618947,"teacher_disagreement_score":0.34438634,"about_ca_system_score_codex":0.00044338556,"about_ca_system_score_gemma":0.0003490703,"threshold_uncertainty_score":0.5089631},"labels":[],"label_agreement":null},{"id":"W2925139051","doi":"10.1016/j.jtho.2019.03.007","title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":491,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme; Genentech; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Roche; Novartis; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer; AbbVie; Merck","keywords":"Alectinib; Medicine; Lung cancer; Crizotinib; Oncology; Internal medicine; Cancer research","score_opus":0.017898352291574746,"score_gpt":0.4489390676521736,"score_spread":0.43104071536059885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925139051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941905,0.00061233697,0.00001043805,0.0018672638,0.00015193608,0.00198448,0.00016464149,0.000002114677,0.0010163045],"genre_scores_gemma":[0.9994185,0.00025705513,0.00006387488,0.00014357205,0.000039872128,0.0000072125317,0.00001840373,0.000009440504,0.000042089294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982459,0.00053530664,0.00059957866,0.00021549029,0.00021913675,0.00018457827],"domain_scores_gemma":[0.99801016,0.00067913317,0.00068009086,0.00042165894,0.00014668926,0.00006224732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085017533,0.00016745894,0.00057980313,0.00010102243,0.00006758477,0.000009902717,0.00028214694,0.00008271818,0.00005833247],"category_scores_gemma":[0.00011180607,0.00007306245,0.00006835082,0.00047482346,0.000089264264,0.00008248332,0.00012016394,0.00035980841,3.340352e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07940067,0.023536874,0.6442787,0.00016321633,0.003032545,0.00072330754,0.03783946,0.004763978,0.014546775,0.000038044738,0.00069111004,0.1909853],"study_design_scores_gemma":[0.030204805,0.007596022,0.9545509,0.0004934862,0.0013734747,0.00021669992,0.003645932,0.0013176049,0.00035268432,0.000010544515,0.00015154561,0.000086267144],"about_ca_topic_score_codex":0.00081482594,"about_ca_topic_score_gemma":0.0006822101,"teacher_disagreement_score":0.31027222,"about_ca_system_score_codex":0.00046709453,"about_ca_system_score_gemma":0.00072905986,"threshold_uncertainty_score":0.29794002},"labels":[],"label_agreement":null},{"id":"W2925781938","doi":"10.1016/j.lungcan.2019.02.021","title":"Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"MSD K.K.; Chugai Pharmaceutical; Novartis Pharmaceuticals Canada; Kyowa Hakko Kirin; Eli Lilly Japan; Boehringer Ingelheim","keywords":"Osimertinib; Medicine; T790M; Lung cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer; Erlotinib; Gefitinib","score_opus":0.013287339905226491,"score_gpt":0.33521453676778146,"score_spread":0.32192719686255494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925781938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714847,0.007641975,0.000052362026,0.001867445,0.0007124938,0.0018182148,0.00011190217,0.00004702782,0.01626387],"genre_scores_gemma":[0.9893658,0.00046735437,0.00032825588,0.0005398823,0.00015861972,0.0005399804,0.0000698486,0.00005242065,0.008477834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982244,0.00003697637,0.00058509957,0.00045867258,0.00031421357,0.0003806433],"domain_scores_gemma":[0.9989253,0.000050337785,0.0002838991,0.00044913797,0.00015836643,0.000132946],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001273676,0.00024705034,0.0004908442,0.00015326474,0.000050359482,0.000018511764,0.000116111565,0.00013741002,0.0014833668],"category_scores_gemma":[0.000014954024,0.00021716724,0.00012635987,0.00041529784,0.00004607827,0.000122021855,0.00003072878,0.00013186017,0.000013485114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032784333,0.0008472487,0.8418149,0.002636032,0.00078672596,0.000080248974,0.0057806135,0.0008834287,0.1309322,0.000119756354,0.009706986,0.0031334434],"study_design_scores_gemma":[0.026298799,0.0017870782,0.6551053,0.006323521,0.0041513606,0.000009092444,0.0026037656,0.019549126,0.2667192,0.000047467256,0.016025176,0.0013801593],"about_ca_topic_score_codex":0.0031824848,"about_ca_topic_score_gemma":0.002416157,"teacher_disagreement_score":0.18670963,"about_ca_system_score_codex":0.00061351777,"about_ca_system_score_gemma":0.0011533654,"threshold_uncertainty_score":0.9994294},"labels":[],"label_agreement":null},{"id":"W2928679018","doi":"10.1158/1078-0432.ccr-18-2683","title":"Ultra-sensitive <i>EGFR</i> T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i> del19 Mutations and Treated with First-generation TKIs","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T790M; Lung cancer; Mutation; Medicine; Digital polymerase chain reaction; Internal medicine; Oncology; Cancer; Incidence (geometry); Clinical significance; Tyrosine kinase; Cancer research; Epidermal growth factor receptor; Biology; Gene; Polymerase chain reaction; Gefitinib; Genetics","score_opus":0.06552080965534572,"score_gpt":0.4572230571841265,"score_spread":0.39170224752878074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928679018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928944,0.0003760919,0.00026976966,0.0008398395,0.00031328487,0.0044971933,0.0002060425,0.00006086635,0.00054248155],"genre_scores_gemma":[0.99412733,0.00062654377,0.00022624654,0.00033467603,0.0004396644,0.0026087903,0.000355497,0.00006970676,0.0012115578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725246,0.0002196146,0.0004926735,0.0008278847,0.00068439153,0.0005229601],"domain_scores_gemma":[0.9968645,0.0008274253,0.00014216178,0.00030026273,0.0014709643,0.00039468426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006406319,0.00023444546,0.00039234952,0.00018555697,0.0004507811,0.00011204604,0.00008106965,0.0001903486,0.00013074325],"category_scores_gemma":[0.0003910658,0.00018293233,0.00009273639,0.00044064273,0.00018707808,0.00032681733,0.000030250152,0.00046763528,0.000012783633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00253646,0.0008110918,0.9759237,0.00028882484,0.0005988481,0.000016312033,0.0006355761,0.00024813035,0.001581379,0.000044470835,0.00043815046,0.01687701],"study_design_scores_gemma":[0.019312402,0.008297063,0.9358913,0.0009446575,0.0014182616,0.00001619386,0.0006252087,0.015357412,0.014929166,0.000044782595,0.0026008803,0.00056272425],"about_ca_topic_score_codex":0.002916731,"about_ca_topic_score_gemma":0.006436573,"teacher_disagreement_score":0.0400325,"about_ca_system_score_codex":0.0007646872,"about_ca_system_score_gemma":0.0008347569,"threshold_uncertainty_score":0.7459764},"labels":[],"label_agreement":null},{"id":"W2929106448","doi":"10.1097/coc.0000000000000533","title":"Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non–Small Cell Lung Cancer (NSCLC)","year":2019,"lang":"en","type":"review","venue":"American Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Odds ratio; Lung cancer; Epidermal growth factor receptor; Adjuvant; Randomized controlled trial; Subgroup analysis; Confidence interval; Cancer","score_opus":0.08513669810114843,"score_gpt":0.49292264131819974,"score_spread":0.4077859432170513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929106448","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013935727,0.97724766,0.000038379738,0.0016870354,0.0038929381,0.0016094263,0.00016456268,0.000018635623,0.0014056473],"genre_scores_gemma":[0.004490713,0.9890706,0.0018678334,0.0009698196,0.0025052354,0.00008839885,0.00007549229,0.00011984809,0.0008120686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922821,0.0012606294,0.0047348235,0.00062756956,0.0004510918,0.00064377947],"domain_scores_gemma":[0.9892835,0.0031075,0.0057546534,0.00043122954,0.0006655296,0.000757559],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011298127,0.0006124049,0.008080258,0.0006351655,0.00004791856,0.000018105684,0.00039277584,0.0006301291,0.00042007744],"category_scores_gemma":[0.0011116958,0.00041186475,0.0017501025,0.00089923956,0.00046667384,0.00011713027,0.00011161684,0.0026760974,0.000068179936],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006912355,0.0014188554,0.010245682,0.0027202163,0.0011324885,0.00077099353,0.00017487777,0.0000020978596,0.0000058719584,0.0000029637417,0.0053739324,0.9774608],"study_design_scores_gemma":[0.007519595,0.011016592,0.004416091,0.015645547,0.0070661246,0.00021883754,0.0001417538,0.000010961862,0.000008512161,0.000002598302,0.9534971,0.00045625825],"about_ca_topic_score_codex":0.0006262595,"about_ca_topic_score_gemma":0.00010280683,"teacher_disagreement_score":0.9770045,"about_ca_system_score_codex":0.001569636,"about_ca_system_score_gemma":0.012536577,"threshold_uncertainty_score":0.99983335},"labels":[],"label_agreement":null},{"id":"W2935807963","doi":"10.1634/theoncologist.2018-0695","title":"Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Lung cancer; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Population; ERBB3; Cancer; Confidence interval","score_opus":0.011574831623580938,"score_gpt":0.32075461059253885,"score_spread":0.30917977896895793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935807963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903402,0.00007800538,0.00001442367,0.00047179984,0.00019922334,0.0052372436,0.000011451512,0.00001141812,0.003636254],"genre_scores_gemma":[0.99823713,0.00003701756,0.00013765902,0.000099535086,0.000022470354,0.00026169408,0.0000745957,0.000015017001,0.0011148829],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991131,0.00010311627,0.00028349028,0.00016753541,0.0001774209,0.00015537185],"domain_scores_gemma":[0.9992712,0.00014269508,0.00023063534,0.00020184912,0.00012277572,0.00003085003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029435873,0.00012441374,0.0005319866,0.000081997074,0.000037899285,0.0000058022783,0.00007384952,0.000052633124,0.00007579957],"category_scores_gemma":[0.000028824026,0.000063068306,0.000037226884,0.000280626,0.000109384404,0.00005272959,0.000019422174,0.00012830879,0.0000018772067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87583256,0.005738535,0.114378504,0.000083344385,0.0001586174,0.000007837846,0.0020921608,0.00036062268,0.000055595483,0.00006156745,0.000105464,0.0011251827],"study_design_scores_gemma":[0.96112263,0.010308517,0.026895465,0.00020979949,0.00040533056,4.8693926e-7,0.00017522597,0.00049134245,0.00019332953,0.000013270597,0.0000990982,0.0000855199],"about_ca_topic_score_codex":0.0016380319,"about_ca_topic_score_gemma":0.0008304395,"teacher_disagreement_score":0.08748303,"about_ca_system_score_codex":0.00032892273,"about_ca_system_score_gemma":0.00044763065,"threshold_uncertainty_score":0.2571851},"labels":[],"label_agreement":null},{"id":"W2935839383","doi":"","title":"Does Glypican 3 expression in non-small cell lung cancer suggest an oncogenic function?","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Glypican 3; Immunohistochemistry; Stain; Tissue microarray; Adenocarcinoma; Medicine; Pathology; Lung cancer; Carcinoma; Hepatocellular carcinoma; Cancer; Staining; Internal medicine","score_opus":0.0364320093701061,"score_gpt":0.4387566909922535,"score_spread":0.4023246816221474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935839383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902144,0.0025820096,0.00017315004,0.0008778426,0.00052056945,0.0011080779,0.000039550356,0.000043031432,0.0044413526],"genre_scores_gemma":[0.98729706,0.000890902,0.000247921,0.00021434389,0.0007457402,0.0006931493,0.000047976526,0.000047556845,0.009815377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978679,0.000076843404,0.0002746171,0.0005073767,0.00055300444,0.00072028406],"domain_scores_gemma":[0.99868554,0.00010991292,0.000049782655,0.000432738,0.00033388007,0.00038816335],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065609283,0.00016305133,0.00023882512,0.00039252944,0.00021413984,0.000039226183,0.00015500959,0.00012607884,0.0011261238],"category_scores_gemma":[0.000022816297,0.00010303598,0.00006217969,0.0006952281,0.00010445358,0.00014721489,0.00006433312,0.0005291328,0.000021995127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001850686,0.0009921566,0.6216936,0.00049406354,0.00013477249,0.00024051729,0.0038978318,0.000113918104,0.323548,0.000048847935,0.0057281125,0.041257475],"study_design_scores_gemma":[0.008144983,0.00093459146,0.7067013,0.0009956025,0.00023180096,0.000005272824,0.0036554243,0.00019588764,0.24078913,0.00013198395,0.03780052,0.00041350626],"about_ca_topic_score_codex":0.008233449,"about_ca_topic_score_gemma":0.013134176,"teacher_disagreement_score":0.08500767,"about_ca_system_score_codex":0.001475001,"about_ca_system_score_gemma":0.0010573261,"threshold_uncertainty_score":0.999787},"labels":[],"label_agreement":null},{"id":"W2936115947","doi":"10.1016/j.lungcan.2019.04.014","title":"Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Boehringer Ingelheim","keywords":"Afatinib; Osimertinib; Medicine; Discontinuation; Internal medicine; Oncology; Lung cancer; Retrospective cohort study; Progression-free survival; Epidermal growth factor receptor; Chemotherapy; Cancer; Erlotinib","score_opus":0.007479056460664642,"score_gpt":0.29370941121208277,"score_spread":0.2862303547514181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936115947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917832,0.0025682019,0.00016912047,0.00024126159,0.00040643694,0.0020892348,0.00009256521,0.000024785537,0.0026251862],"genre_scores_gemma":[0.99708736,0.00020132403,0.00054788345,0.000382921,0.00008013779,0.00039934984,0.00011470779,0.000052686835,0.0011336119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868995,0.000021917136,0.00032116318,0.000357081,0.00030895864,0.00030091952],"domain_scores_gemma":[0.9991933,0.00007050773,0.00020096233,0.0002405014,0.00021025755,0.000084447136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064207285,0.00022659265,0.00040648432,0.00013777596,0.00006211215,0.000013969557,0.000075932076,0.000077238685,0.00028418988],"category_scores_gemma":[0.0000057869943,0.00017361053,0.000100364756,0.00036405664,0.000022935728,0.00015791599,0.000016690126,0.00015232724,0.0000035229755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003921593,0.00020092004,0.98447704,0.00029991163,0.0005300558,0.000018322906,0.0055581513,0.005979452,0.0005719525,0.000008063538,0.00009993591,0.0018640066],"study_design_scores_gemma":[0.022221658,0.0007683925,0.9578106,0.002828597,0.0008067353,0.0000010451029,0.00046360018,0.0045627505,0.009996241,0.000008754381,0.00014756108,0.00038405595],"about_ca_topic_score_codex":0.0055357227,"about_ca_topic_score_gemma":0.0014515996,"teacher_disagreement_score":0.02666646,"about_ca_system_score_codex":0.001152131,"about_ca_system_score_gemma":0.00067743164,"threshold_uncertainty_score":0.8368394},"labels":[],"label_agreement":null},{"id":"W2937060873","doi":"10.5858/arpa.2018-0396-cp","title":"Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee","year":2019,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"KRAS; Context (archaeology); Reimbursement; Medicine; Internal medicine; Oncology; Medical physics; Computational biology; Cancer; Biology","score_opus":0.03457619121714096,"score_gpt":0.41954845578471145,"score_spread":0.3849722645675705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937060873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671143,0.0005643591,0.00018809197,0.0004465992,0.000049658953,0.001720014,0.000056857232,0.0000032782843,0.00025970253],"genre_scores_gemma":[0.99469876,0.000021134514,0.0050540334,0.000082859384,0.0000064095434,0.00011489625,0.000008145569,0.000008332903,0.0000054328166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981317,0.0006987268,0.0006750283,0.00020318672,0.00014727481,0.0001440711],"domain_scores_gemma":[0.9971905,0.0017462396,0.0005625328,0.00034883656,0.00012619921,0.000025712417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005788531,0.00012282869,0.00080718595,0.00024873315,0.000031958378,3.852148e-7,0.000164863,0.00003455137,0.000001978455],"category_scores_gemma":[0.0004680722,0.00006713196,0.00003545901,0.0006836,0.0011175782,0.000017431414,0.000048821832,0.00015383078,3.56603e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012255814,0.0013265929,0.8547788,0.0002481247,0.000054276403,0.000016287959,0.023204071,0.00012951836,0.113528706,0.00018497654,0.0000020590821,0.0064039915],"study_design_scores_gemma":[0.0039802417,0.009045733,0.94397944,0.00022633208,0.0003657656,0.0000148095205,0.036279652,0.0018609171,0.0040730694,0.00011993199,0.0000064059436,0.000047711674],"about_ca_topic_score_codex":0.00010734638,"about_ca_topic_score_gemma":0.00019637105,"teacher_disagreement_score":0.10945564,"about_ca_system_score_codex":0.000029912591,"about_ca_system_score_gemma":0.00022026474,"threshold_uncertainty_score":0.41177633},"labels":[],"label_agreement":null},{"id":"W2937568210","doi":"10.21037/tlcr.2019.03.11","title":"Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort","year":2019,"lang":"en","type":"article","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Tissue microarray; KRAS; Immunohistochemistry; Polysomy; Pathology; Lung cancer; Medicine; Cancer research; Mesenchyme; Stage (stratigraphy); Molecular biology; Gene expression; Cancer; Biology; Oncology; Gene; Internal medicine; Colorectal cancer; Epithelium; Genetics; In situ hybridization","score_opus":0.03908537596756536,"score_gpt":0.46115396701745104,"score_spread":0.4220685910498857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937568210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854377,0.0011478232,0.00050057034,0.0052700723,0.00018202334,0.0049279914,0.00051037193,0.000031267165,0.0019921768],"genre_scores_gemma":[0.9926903,0.00034258314,0.0012249624,0.00021903864,0.00038529694,0.0015743135,0.00017483282,0.000051179515,0.0033374806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967132,0.00025257695,0.0006651134,0.000728942,0.000994509,0.0006456196],"domain_scores_gemma":[0.99867064,0.00024303288,0.000055961536,0.00027659137,0.000354121,0.00039964283],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012287449,0.00023278088,0.00051661854,0.00023654816,0.00016851524,0.00004196378,0.00012344177,0.00021595266,0.0024806892],"category_scores_gemma":[0.00001626452,0.00019544264,0.00014403314,0.0005253037,0.00008743517,0.00015327772,0.00003247286,0.00067605556,0.000057640875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014479625,0.0004589014,0.98716766,0.00040365313,0.00016300002,0.000069157766,0.0013432329,0.00023129693,0.0076766578,0.00014126659,0.00041051809,0.00048667967],"study_design_scores_gemma":[0.018748665,0.00033016357,0.9584419,0.0010828166,0.00032026105,0.000020019812,0.00013253535,0.00658838,0.008812706,0.00009911363,0.0049574873,0.00046593507],"about_ca_topic_score_codex":0.0019719868,"about_ca_topic_score_gemma":0.0006979852,"teacher_disagreement_score":0.028725758,"about_ca_system_score_codex":0.00040597733,"about_ca_system_score_gemma":0.0010828467,"threshold_uncertainty_score":0.9984312},"labels":[],"label_agreement":null},{"id":"W2937704370","doi":"10.1016/j.lungcan.2019.04.006","title":"First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Afatinib; Medicine; Term (time); Oncology; Internal medicine; Gefitinib; Cancer; Astronomy","score_opus":0.03130357438398415,"score_gpt":0.4238187698056362,"score_spread":0.39251519542165203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937704370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865708,0.007272365,0.0005200356,0.002087789,0.00021637611,0.0023699855,0.00019872292,0.000014285069,0.00074967725],"genre_scores_gemma":[0.99607474,0.0008201147,0.0002649596,0.00045708244,0.00007954302,0.00048364795,0.00013376668,0.000017352706,0.0016688049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988598,0.00006816713,0.0004202929,0.00026651713,0.00019399481,0.00019123494],"domain_scores_gemma":[0.9986984,0.0006378219,0.00021241815,0.00031278774,0.000090558475,0.00004799844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047616728,0.00013726256,0.0006442468,0.0002470009,0.000047936315,0.0000143522275,0.00007668053,0.000061630024,0.0002680413],"category_scores_gemma":[0.00013545706,0.00008697412,0.00020154206,0.0005898029,0.000037301576,0.0000784144,0.000013800334,0.000075144206,7.775542e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028182643,0.00022778417,0.9633772,0.0007583712,0.005072991,0.000011670383,0.004794656,0.0036067644,0.001173692,0.00034304618,0.0009011936,0.016914405],"study_design_scores_gemma":[0.016837578,0.00045213258,0.9553209,0.0006704951,0.0152600845,0.0000032341743,0.00063136156,0.007828711,0.00073924643,0.000051857005,0.0019660636,0.00023832839],"about_ca_topic_score_codex":0.00024823233,"about_ca_topic_score_gemma":0.0014388663,"teacher_disagreement_score":0.016676076,"about_ca_system_score_codex":0.00017708544,"about_ca_system_score_gemma":0.00015417919,"threshold_uncertainty_score":0.35467017},"labels":[],"label_agreement":null},{"id":"W2937974648","doi":"10.1200/jco.2015.33.15_suppl.e19065","title":"Early and late brain metastases in EGFR wild type and EGFR mutation positive non small cell lung cancer: Implications for survival.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Retrospective cohort study; Cohort; Radiation therapy; Gastroenterology; Pathology; Cancer","score_opus":0.10206436964531386,"score_gpt":0.5015900971370302,"score_spread":0.39952572749171633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937974648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974922,0.0019273919,0.0005687542,0.020899298,0.0003864676,0.00043353066,0.000039473758,0.000003640334,0.00081944227],"genre_scores_gemma":[0.9928038,0.0007064654,0.004485042,0.0013299002,0.00026049497,0.00002138159,0.000017712619,0.000011992698,0.00036322046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988148,0.00014036628,0.00071314664,0.00013541471,0.00007426387,0.00012199502],"domain_scores_gemma":[0.9971827,0.0014328769,0.0005143091,0.00006466649,0.00055602216,0.0002494092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067229,0.00008117379,0.00055749697,0.000090566355,0.000032095046,0.000011006489,0.000036022466,0.00012316501,0.000004253254],"category_scores_gemma":[0.0009229377,0.00006057675,0.000066652734,0.00011931483,0.00007009198,0.000099215606,0.000016260994,0.00021152242,5.904511e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043721246,0.0015702349,0.8230553,0.000106811814,0.00092445326,0.00015336454,0.0024255286,0.00015753586,0.00068382605,0.0005503885,0.0050051184,0.1609953],"study_design_scores_gemma":[0.012443074,0.0067670704,0.9711188,0.00008088321,0.0010407333,0.000057467896,0.00022965527,0.00024106223,0.000045188626,0.00074493716,0.0071596974,0.00007144326],"about_ca_topic_score_codex":0.00035501414,"about_ca_topic_score_gemma":0.00048815823,"teacher_disagreement_score":0.16092387,"about_ca_system_score_codex":0.00017771889,"about_ca_system_score_gemma":0.0013542383,"threshold_uncertainty_score":0.2470248},"labels":[],"label_agreement":null},{"id":"W2943658884","doi":"10.1111/cas.14032","title":"Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition","year":2019,"lang":"en","type":"article","venue":"Cancer Science","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Engineering Link (Canada)","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"ERCC1; Lung cancer; Cancer research; Thymidylate synthase; Epidermal growth factor receptor; Gemcitabine; Crizotinib; Biology; Medicine; Oncology; Cancer; Internal medicine; Gene; DNA repair; Fluorouracil; Nucleotide excision repair","score_opus":0.013444765309549855,"score_gpt":0.32656434733114914,"score_spread":0.3131195820215993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943658884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180514,0.00030719396,0.0019484742,0.0018567283,0.00026554253,0.0029025036,0.0002295678,0.000039860428,0.0006450223],"genre_scores_gemma":[0.9919266,0.00023256447,0.001577239,0.00040525588,0.00015763425,0.0012014429,0.000066830806,0.000017894386,0.0044145104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987255,0.000011734281,0.00017663618,0.00043847732,0.00029397,0.00035369454],"domain_scores_gemma":[0.9990526,0.00011164165,0.00016436286,0.00014117481,0.0003634805,0.00016676394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022225521,0.0001443772,0.00021209667,0.00012039639,0.00024993482,0.000074805896,0.00006796389,0.000074741714,0.000074767944],"category_scores_gemma":[0.00004035036,0.00011294594,0.000047992988,0.0004647502,0.00010595865,0.0002889435,0.000019371435,0.0000858893,0.000001992127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026187024,0.00008062253,0.97255033,0.00021709633,0.00023525995,0.0000016370755,0.0029593487,0.00011687343,0.0078139845,0.000016343323,0.00090085185,0.014845778],"study_design_scores_gemma":[0.00895426,0.0009519041,0.93364906,0.00045930932,0.0013243527,0.0000025992651,0.00080389006,0.010174838,0.039327417,0.00010832259,0.0039082,0.00033585867],"about_ca_topic_score_codex":0.00040468204,"about_ca_topic_score_gemma":0.00015254394,"teacher_disagreement_score":0.038901284,"about_ca_system_score_codex":0.0013099476,"about_ca_system_score_gemma":0.0011663584,"threshold_uncertainty_score":0.4605802},"labels":[],"label_agreement":null},{"id":"W2943711511","doi":"10.1016/j.lungcan.2019.04.027","title":"Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; Juravinski Cancer Centre; Lakeridge Health; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Hôpital Notre-Dame; Hamilton Health Sciences; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Pemetrexed; Selumetinib; Chemotherapy; Internal medicine; Hazard ratio; Tolerability; Carboplatin; Oncology; Lung cancer; Surgery; Adverse effect; Gastroenterology; KRAS; Cancer; Cisplatin; Confidence interval; Colorectal cancer","score_opus":0.016899006242002086,"score_gpt":0.3665936275924145,"score_spread":0.3496946213504124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943711511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667688,0.003600554,0.000486848,0.0006242168,0.0014055797,0.025324488,0.0015867947,0.000059105347,0.0001436278],"genre_scores_gemma":[0.9815077,0.0011064145,0.0032713031,0.001272556,0.00019536894,0.009638309,0.0002657203,0.00018512546,0.0025574889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957635,0.00032483213,0.0013520707,0.0010502898,0.00053173123,0.0009775839],"domain_scores_gemma":[0.9964609,0.0012464536,0.0007962549,0.0005018186,0.00045956098,0.0005349869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012237754,0.00072166475,0.0025788087,0.00058193173,0.00031745786,0.00009113301,0.00020790454,0.00016654974,0.0011429106],"category_scores_gemma":[0.00044473395,0.00051004224,0.00029212135,0.000747404,0.000078657526,0.00024592478,0.00004127877,0.00033387347,0.0000017054653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5156343,0.0039896443,0.32418525,0.0029421854,0.003963154,0.00007006091,0.014037302,0.0015443115,0.0008027546,0.0000028749887,0.0031089222,0.12971923],"study_design_scores_gemma":[0.9478691,0.006537994,0.009054765,0.0021647946,0.005447234,0.0000011822268,0.0010916934,0.021152852,0.0013108832,0.0000033320632,0.0044483948,0.00091773324],"about_ca_topic_score_codex":0.093407124,"about_ca_topic_score_gemma":0.4388573,"teacher_disagreement_score":0.43223482,"about_ca_system_score_codex":0.0028308723,"about_ca_system_score_gemma":0.0037006442,"threshold_uncertainty_score":0.99977016},"labels":[],"label_agreement":null},{"id":"W2943846365","doi":"10.1016/j.cllc.2019.05.003","title":"Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer Canada; Boehringer Ingelheim; British Microcirculation Society; Bayer; Boehringer Ingelheim España; AstraZeneca Canada; Roche; Genzyme; Eisai; Merck; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Hazard ratio; Oncology; Internal medicine; Lung cancer; Propensity score matching; Discontinuation; Cohort; Population; Proportional hazards model; Epidermal growth factor receptor; Cancer; Confidence interval","score_opus":0.030615193183594274,"score_gpt":0.4080269110230662,"score_spread":0.3774117178394719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943846365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955235,0.0006991855,0.000021575039,0.001207293,0.0005887704,0.001493785,0.00009673671,0.000038096365,0.00033103945],"genre_scores_gemma":[0.9976158,0.00007316931,0.00014345872,0.0006933156,0.00023076068,0.00024168537,0.00036533925,0.000024397255,0.0006120625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980728,0.00008240734,0.00086906645,0.0004946988,0.00020107492,0.00027994806],"domain_scores_gemma":[0.9990573,0.00034963223,0.00016371033,0.00022461807,0.000062005296,0.00014276344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033019343,0.00018915467,0.00061575504,0.00015110585,0.00005386894,0.000022292405,0.000054982356,0.00018626239,0.00044092693],"category_scores_gemma":[0.00013693994,0.0001557031,0.00009014998,0.0002823123,0.000035903657,0.00013671808,0.000023398798,0.00029362724,0.000010770321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009608671,0.00015985279,0.99642384,0.0001016469,0.00008305651,0.000007948068,0.00010773954,0.00014462843,0.000027254364,0.000020912335,0.00010931756,0.0027177029],"study_design_scores_gemma":[0.0070586735,0.0001830259,0.98725253,0.00031720218,0.0001687236,4.1391732e-7,0.000034136996,0.0044197245,0.000023379182,0.000022911441,0.0003476312,0.00017161788],"about_ca_topic_score_codex":0.00085743517,"about_ca_topic_score_gemma":0.010908372,"teacher_disagreement_score":0.010050937,"about_ca_system_score_codex":0.00046467377,"about_ca_system_score_gemma":0.00021082988,"threshold_uncertainty_score":0.63493884},"labels":[],"label_agreement":null},{"id":"W2944167983","doi":"10.1093/annonc/mdz128","title":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma; Novartis; Genentech; Merck","keywords":"Erlotinib; Gefitinib; Medicine; Tolerability; T790M; Internal medicine; Lung cancer; Hazard ratio; Erlotinib Hydrochloride; Oncology; Epidermal growth factor receptor; Cancer; Adverse effect; Confidence interval","score_opus":0.0629895344694283,"score_gpt":0.4538235096787264,"score_spread":0.39083397520929813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944167983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817042,0.0002719866,0.00000768448,0.00024051443,0.00029147358,0.0079023745,0.000103853155,0.00001065509,0.00946726],"genre_scores_gemma":[0.99566257,0.00018588192,0.0004878115,0.00034168403,0.00002206145,0.00073204713,0.000067490335,0.00003116954,0.002469265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982458,0.00013339157,0.0006914742,0.00037144223,0.00024073083,0.00031719077],"domain_scores_gemma":[0.9980837,0.0003973185,0.00060097425,0.0003601167,0.00044531503,0.000112542715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003378784,0.00021787488,0.00143097,0.00017390527,0.000033615655,0.000006904772,0.0001955102,0.00009538084,0.00042104025],"category_scores_gemma":[0.000068177644,0.00014583312,0.000057548055,0.00029600118,0.00008288613,0.00014667396,0.00009474603,0.00015507409,0.000004382828],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8626268,0.05398091,0.051092472,0.00026350343,0.0017186725,0.00007498244,0.0065750135,0.00019206601,0.00022298764,0.000030352481,0.0005302393,0.022691999],"study_design_scores_gemma":[0.9430498,0.04687564,0.005133218,0.00021312357,0.00069765653,5.927845e-7,0.0022093921,0.0001505456,0.00048152983,0.000002174099,0.0010295865,0.0001567515],"about_ca_topic_score_codex":0.0017165138,"about_ca_topic_score_gemma":0.0013939957,"teacher_disagreement_score":0.08042299,"about_ca_system_score_codex":0.00011949681,"about_ca_system_score_gemma":0.0009564895,"threshold_uncertainty_score":0.59469026},"labels":[],"label_agreement":null},{"id":"W2944541359","doi":"10.1200/jgo.18.00216","title":"Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival","year":2019,"lang":"en","type":"article","venue":"Journal of Global Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Lung cancer; Anaplastic lymphoma kinase; Oncology; Internal medicine; Adenocarcinoma; Radiation therapy; Cancer; Epidermal growth factor receptor; Population; Chemotherapy; Stage (stratigraphy); Targeted therapy","score_opus":0.01017900334021477,"score_gpt":0.35145891440919297,"score_spread":0.3412799110689782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944541359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891087,0.0004041518,0.000018472812,0.005236842,0.0009580842,0.00023930309,0.00005660131,0.0000024075814,0.003975437],"genre_scores_gemma":[0.99807316,0.00007986214,0.0002731303,0.0010431231,0.00009179413,0.0000054781517,0.000008981367,0.0000060235043,0.00041844865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917805,0.00007458893,0.0003879705,0.00009576157,0.00013021557,0.00013343226],"domain_scores_gemma":[0.9992122,0.00007064862,0.00032214253,0.00006521524,0.0002526707,0.000077118086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014346006,0.000083504965,0.0003434048,0.00006980022,0.000016642256,0.0000051782886,0.000042891854,0.00007020799,0.00025051797],"category_scores_gemma":[0.000025297653,0.00006358714,0.000058072364,0.00014100496,0.000051891086,0.00012432747,0.000021588708,0.00011003625,0.0000026757684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001974898,0.0003136861,0.99365556,0.00003750384,0.00030164715,0.000036095415,0.00029773082,0.000039073155,0.00066349347,0.00028246755,0.002385601,0.0017896432],"study_design_scores_gemma":[0.0075820764,0.0008903494,0.98669046,0.000100577134,0.0002893467,0.000015574553,0.00018547602,0.000028585246,0.000034860688,0.00019543168,0.0039374754,0.000049779886],"about_ca_topic_score_codex":0.0005841336,"about_ca_topic_score_gemma":0.0007392132,"teacher_disagreement_score":0.0089644585,"about_ca_system_score_codex":0.0008084077,"about_ca_system_score_gemma":0.00037683971,"threshold_uncertainty_score":0.2742996},"labels":[],"label_agreement":null},{"id":"W2944756121","doi":"10.1007/s40265-019-01115-y","title":"Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer","year":2019,"lang":"en","type":"review","venue":"Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Erlotinib; Medicine; Gefitinib; Lung cancer; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Oncology; Pharmacology; Cancer; Erlotinib Hydrochloride; EGFR inhibitors; Internal medicine","score_opus":0.026113738060411805,"score_gpt":0.38656500292374024,"score_spread":0.36045126486332846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944756121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018592787,0.94257504,0.0000050343824,0.000096140364,0.0002337361,0.0028022982,0.00007073616,0.000008114307,0.05402298],"genre_scores_gemma":[0.00021077521,0.99087894,0.00029962405,0.00014447847,0.000061440915,0.00089484284,0.00018407496,0.000033253495,0.0072925626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900025,0.000034859768,0.00035870867,0.00024798684,0.00017963884,0.00017854462],"domain_scores_gemma":[0.99920523,0.00006667808,0.00021302194,0.0004562582,0.000028148415,0.000030680018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108277694,0.00021529956,0.0008364461,0.00009801787,0.000020758587,0.000007301421,0.00017843614,0.000079000325,0.000085856285],"category_scores_gemma":[0.0000010875376,0.00012528773,0.00024161389,0.00026284007,0.000016403968,0.000021172676,0.000039948656,0.00018101414,0.000031311585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000754277,0.00018801489,0.00006695051,0.07255857,0.00062308967,0.000034511406,0.001168355,0.0000066991274,1.7572529e-7,0.00014541592,0.0013117628,0.9238889],"study_design_scores_gemma":[0.0014784288,0.000036945476,0.0001273226,0.025619363,0.005977525,0.0000032241255,0.00061851286,0.0000054921375,0.0000015547372,0.000003513591,0.96600133,0.00012679945],"about_ca_topic_score_codex":0.00009169438,"about_ca_topic_score_gemma":0.000007658942,"teacher_disagreement_score":0.96468955,"about_ca_system_score_codex":0.0002117567,"about_ca_system_score_gemma":0.0002652498,"threshold_uncertainty_score":0.51090854},"labels":[],"label_agreement":null},{"id":"W2944851422","doi":"10.1200/po.18.00356","title":"Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"KRAS; Medicine; Oncology; ROS1; Internal medicine; Personalized medicine; Genetic testing; Medicaid; Bevacizumab; Bioinformatics; Cancer; Adenocarcinoma; Chemotherapy; Biology; Health care","score_opus":0.14300265678417756,"score_gpt":0.42021702317582477,"score_spread":0.2772143663916472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944851422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711343,0.0003166871,0.026078228,0.00003826155,0.0004162901,0.0014294672,0.00004682028,0.000016911807,0.0005230066],"genre_scores_gemma":[0.8853,0.000028304272,0.114286214,0.000066938774,0.00008647615,0.00007778882,0.000035217065,0.0000349708,0.000084092644],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982669,0.0000754534,0.0007161863,0.00047573834,0.00014660353,0.00031913578],"domain_scores_gemma":[0.9984858,0.00053214177,0.00028982176,0.0003555405,0.00017441144,0.00016230793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031381487,0.00022413164,0.00059736206,0.00057317223,0.000080850405,0.000037082627,0.000106819054,0.00010968192,0.00012797676],"category_scores_gemma":[0.00015665936,0.00019566115,0.00015145795,0.00036525683,0.000017793378,0.00020423574,0.00007004299,0.00014507731,0.000024870198],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034979108,0.000054752276,0.0029148413,0.00001621869,0.00008864448,0.0000074474306,0.00051805953,0.5464681,0.43559837,0.0000012098745,0.000020418365,0.013962161],"study_design_scores_gemma":[0.0047198706,0.0016454924,0.0026672957,0.00017760294,0.00057328556,0.000024179564,0.00010499562,0.97566944,0.014195243,0.000044703764,0.00000845269,0.00016942687],"about_ca_topic_score_codex":0.0027963244,"about_ca_topic_score_gemma":0.0022136003,"teacher_disagreement_score":0.4292014,"about_ca_system_score_codex":0.009728696,"about_ca_system_score_gemma":0.003690916,"threshold_uncertainty_score":0.9940728},"labels":[],"label_agreement":null},{"id":"W2945103009","doi":"10.1186/s12885-019-5507-6","title":"Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials","year":2019,"lang":"en","type":"review","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Medicine; Anaplastic lymphoma kinase; Erlotinib; Oncology; Internal medicine; Atezolizumab; Lung cancer; Epidermal growth factor receptor; Pembrolizumab; Cancer; Immunotherapy","score_opus":0.11267037461875244,"score_gpt":0.43128079901432714,"score_spread":0.3186104243955747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945103009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004305732,0.9454897,0.00014955249,0.000016264472,0.00034495682,0.018632041,0.030998977,0.000017937098,0.000044827386],"genre_scores_gemma":[0.0007889833,0.98641163,0.0014944709,0.00006952577,0.00007106748,0.007069269,0.0012854398,0.00008938424,0.0027201988],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947313,0.0005967398,0.0029171337,0.0009507729,0.00036646918,0.0004375906],"domain_scores_gemma":[0.9888264,0.005407093,0.004216291,0.0005342714,0.00071622594,0.00029974655],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00049640134,0.0010093164,0.015515202,0.0006232765,0.00009757579,0.000030695373,0.00017698231,0.00018824746,0.0008306617],"category_scores_gemma":[0.0005545673,0.00058786024,0.0012388788,0.0011867394,0.00012837898,0.00017217068,0.000065834094,0.00016679661,0.0000019543882],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013723904,0.00043258388,0.00013956969,0.9398265,0.041770812,0.000010710066,0.0010117763,0.00001388131,0.000007875726,0.000006659134,0.00019684776,0.015210391],"study_design_scores_gemma":[0.016922534,0.0021143057,0.00037969038,0.36736834,0.60883325,0.00002064225,0.000438949,0.00043841702,0.00016113602,0.000002539563,0.0024911996,0.0008289604],"about_ca_topic_score_codex":0.00061512535,"about_ca_topic_score_gemma":0.0041243117,"teacher_disagreement_score":0.57245815,"about_ca_system_score_codex":0.00083674095,"about_ca_system_score_gemma":0.0034292329,"threshold_uncertainty_score":0.9996573},"labels":[],"label_agreement":null},{"id":"W2945470322","doi":"10.1200/edbk_239397","title":"A Career in Lung Cancer: Pushing Beyond Chemotherapy","year":2019,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Immunotherapy; Lung cancer; Medicine; Targeted therapy; Disease; Acquired resistance; Immune checkpoint; Chemotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.11820955466647794,"score_gpt":0.5606485425989242,"score_spread":0.44243898793244624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945470322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012167289,0.9693302,0.0000068141117,0.020544978,0.00067850127,0.0013452574,0.000073483876,0.0000132181185,0.00788591],"genre_scores_gemma":[0.000031863565,0.965513,0.0037450686,0.012369566,0.00086267,0.00054277584,0.0003033373,0.000050856437,0.016580846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715436,0.00018876154,0.0015626256,0.00054029416,0.00027831094,0.00027565932],"domain_scores_gemma":[0.994972,0.0028226404,0.0014463672,0.0003616294,0.00021447601,0.00018291759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047721944,0.00029852128,0.0034370052,0.00007651331,0.0000392343,0.0000059247304,0.00019353301,0.00039358638,0.0008875778],"category_scores_gemma":[0.00014660899,0.00023873904,0.0015606644,0.00035615772,0.00066894677,0.00006519545,0.000040920902,0.0007735265,0.000027224629],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027456153,0.0008789539,0.008226103,0.0030121952,0.0016607661,0.0000013621418,0.0005658762,0.000001568696,1.08891676e-7,0.00011992916,0.07010594,0.91539973],"study_design_scores_gemma":[0.0013135966,0.00041707998,0.005892315,0.0026638908,0.0025501654,0.000009510887,0.00021510253,0.0000112293665,7.206952e-8,0.000027001079,0.9867151,0.00018494626],"about_ca_topic_score_codex":0.0007902903,"about_ca_topic_score_gemma":0.00003928013,"teacher_disagreement_score":0.91660917,"about_ca_system_score_codex":0.0014033194,"about_ca_system_score_gemma":0.019531533,"threshold_uncertainty_score":0.9860268},"labels":[],"label_agreement":null},{"id":"W2945662040","doi":"","title":"Commentary on Abstracts #2 and #1968","year":2000,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vinorelbine; Docetaxel; Carboplatin; Gemcitabine; Regimen; Medicine; Cisplatin; Oncology; Internal medicine; Paclitaxel; Randomized controlled trial; Lung cancer; Chemotherapy","score_opus":0.010078747765214096,"score_gpt":0.31740324780281426,"score_spread":0.30732450003760015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945662040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6348162,0.00005295841,0.0000010009658,0.019945566,0.000016627966,0.00008902184,0.0000030601639,0.0000209727,0.34505457],"genre_scores_gemma":[0.9574668,0.000060503942,0.0002538308,0.024799645,0.000043752385,0.0000047022563,0.000019000974,0.000003499301,0.0173483],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998127,0.0000018493246,0.000041931016,0.00005695196,0.00003901535,0.000047524547],"domain_scores_gemma":[0.9998778,0.000010583796,0.00000412736,0.00005569777,0.0000041992785,0.000047565107],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000009356605,0.000032000455,0.00004225679,0.000011374473,0.000025683308,0.0000042193647,0.000005912913,0.000010207196,0.0028398475],"category_scores_gemma":[8.271026e-7,0.000021212245,0.000009577921,0.0000151517825,0.000010650997,0.00001737833,0.0000013877282,0.00002366504,0.00010980693],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020021193,0.0006609885,0.016700294,0.000024232899,0.0002173108,0.00010070833,0.0005965783,0.000019470994,0.00018723604,0.00044634938,0.49471673,0.4861299],"study_design_scores_gemma":[0.0029198632,0.00058399246,0.31746012,0.00004958118,0.0001424662,0.00003568513,0.0001199719,0.000029159914,0.0013079166,0.0001553954,0.6771211,0.00007474542],"about_ca_topic_score_codex":0.00018408133,"about_ca_topic_score_gemma":0.000013903795,"teacher_disagreement_score":0.48605517,"about_ca_system_score_codex":0.000017815177,"about_ca_system_score_gemma":0.0000065406243,"threshold_uncertainty_score":0.9980717},"labels":[],"label_agreement":null},{"id":"W2946907024","doi":"10.1200/jco.2019.37.15_suppl.3110","title":"Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in <i>EGFR</i>-mutated lung adenocarcinoma (LUAD).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adenocarcinoma; Biopsy; Pathological; Lung; Pathology; Lung cancer; Oncology; Internal medicine; Cancer","score_opus":0.04465612019417261,"score_gpt":0.44195616162485457,"score_spread":0.397300041430682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946907024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993146,0.0027883376,0.000025093703,0.0014275825,0.0012995878,0.00066114153,0.000009138663,0.000010089561,0.0006329984],"genre_scores_gemma":[0.99249965,0.0022177922,0.0038332334,0.0010784917,0.00028770493,0.000010026685,0.0000074960008,0.000018227824,0.000047400477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947799,0.0006601648,0.0036163758,0.00031603206,0.00035247652,0.00027506644],"domain_scores_gemma":[0.99558985,0.0016095173,0.0018089215,0.00023907813,0.00033257186,0.0004200361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012380802,0.00018725039,0.0018076889,0.000175315,0.000024651938,0.0000072889825,0.00012357079,0.00046698883,0.00013894588],"category_scores_gemma":[0.0010897757,0.00012382664,0.00044583657,0.00017568158,0.0003292817,0.00008499125,0.0000793009,0.0008269649,0.000009124858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018280591,0.0025903662,0.9518989,0.00004981678,0.00056134147,0.001048013,0.00040508318,0.000028823859,0.00047496855,0.000012436426,0.00044230395,0.04065991],"study_design_scores_gemma":[0.014419802,0.026674017,0.9523945,0.0001647972,0.00084928103,0.00034388644,0.00035854484,0.00011690702,0.0000874687,0.00009145594,0.0043969974,0.00010234497],"about_ca_topic_score_codex":0.000022283566,"about_ca_topic_score_gemma":0.000013176345,"teacher_disagreement_score":0.040557563,"about_ca_system_score_codex":0.00015916592,"about_ca_system_score_gemma":0.0010780663,"threshold_uncertainty_score":0.5049504},"labels":[],"label_agreement":null},{"id":"W2946942811","doi":"10.1200/jco.2019.37.15_suppl.tps10066","title":"A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with <i>RET</i>-altered cancers.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Medullary thyroid cancer; Oncology; Internal medicine; Cancer; Thyroid cancer","score_opus":0.03912156607813211,"score_gpt":0.4619869757031472,"score_spread":0.42286540962501507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946942811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962899,0.00013224235,0.0000044605836,0.0004553261,0.00094413967,0.0008430783,0.0000098177225,0.000004379316,0.0013166328],"genre_scores_gemma":[0.9983246,0.000092501796,0.0004618508,0.0003970088,0.0005828424,0.0000113712995,0.0000048501524,0.00001588868,0.00010909849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972702,0.00025952002,0.0016714851,0.00020697745,0.0004043461,0.00018746643],"domain_scores_gemma":[0.99666387,0.0006141693,0.0016731808,0.00016305615,0.0006820649,0.00020363984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067811593,0.00013084803,0.0012675938,0.00022562577,0.000017374292,0.0000037416014,0.00008963818,0.00015741984,0.00003859045],"category_scores_gemma":[0.00042743658,0.00008324077,0.0001481555,0.0003774779,0.000051565163,0.00012433068,0.000023629515,0.0006263472,0.0000058878327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012469145,0.031417932,0.94362557,0.0000326472,0.0005929765,0.00015470259,0.0013247225,0.00002735727,0.000010882358,0.0000040553036,0.0013610154,0.008978989],"study_design_scores_gemma":[0.13578427,0.15020911,0.71056145,0.00007256194,0.0011852981,0.000013729664,0.00049258675,0.000014344712,0.000015658668,0.000025271911,0.001543857,0.00008185131],"about_ca_topic_score_codex":0.00016467471,"about_ca_topic_score_gemma":0.0003014962,"teacher_disagreement_score":0.23306412,"about_ca_system_score_codex":0.00052128755,"about_ca_system_score_gemma":0.0033886477,"threshold_uncertainty_score":0.60113156},"labels":[],"label_agreement":null},{"id":"W2946997709","doi":"10.1200/jco.2019.37.15_suppl.9048","title":"Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Repeated measures design; Quality of life (healthcare); Tremelimumab; Chemotherapy; Population; Oncology; Nuclear medicine; Gastroenterology; Surgery; Cancer; Immunotherapy; Ipilimumab","score_opus":0.08890860114174669,"score_gpt":0.4595490581262037,"score_spread":0.370640456984457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946997709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846277,0.00027896222,0.00006244418,0.009847711,0.0014887799,0.00058174564,0.000027145687,0.000013604115,0.003071875],"genre_scores_gemma":[0.9922462,0.0003003708,0.0055005383,0.0012174967,0.00020948879,0.000009551404,0.000038159356,0.000028480516,0.000449698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596965,0.00018922273,0.0028097166,0.00030169758,0.00048110416,0.00024860929],"domain_scores_gemma":[0.9927909,0.004046307,0.0021884416,0.00034715148,0.00035916828,0.00026805612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089902314,0.00020368448,0.001711704,0.00014994253,0.0000298983,0.000010619549,0.00010521329,0.00012001698,0.0002988464],"category_scores_gemma":[0.0027753897,0.000120971505,0.0003356893,0.00019836043,0.000094868505,0.00013073142,0.000020374131,0.00058202335,0.00003876259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17875266,0.011538331,0.5137828,0.00006093323,0.008995,0.0069782347,0.0015639842,0.0011512346,0.00005409894,0.00005595833,0.0026480341,0.27441877],"study_design_scores_gemma":[0.23501888,0.037926815,0.6887835,0.00036541463,0.0021888302,0.00021961555,0.0006055096,0.0002947622,0.000046897618,0.0002240351,0.03411691,0.00020881004],"about_ca_topic_score_codex":0.00038114958,"about_ca_topic_score_gemma":0.00078525435,"teacher_disagreement_score":0.27420995,"about_ca_system_score_codex":0.00040220853,"about_ca_system_score_gemma":0.0020142614,"threshold_uncertainty_score":0.49330747},"labels":[],"label_agreement":null},{"id":"W2947085892","doi":"10.1200/jco.2019.37.15_suppl.e20574","title":"Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; Lung cancer; DNA methylation; Medicine; Brain metastasis; Oncology; Lung; Metastasis; Pathology; Adenocarcinoma; Cancer research; Internal medicine; Cancer; Biology; Gene expression; Gene; Genetics","score_opus":0.06494350395087325,"score_gpt":0.4981648071657933,"score_spread":0.43322130321492003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947085892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865873,0.0027679857,0.001290993,0.0066759717,0.00035907843,0.00044514274,0.000010812886,0.0000041888006,0.0018585663],"genre_scores_gemma":[0.97392124,0.0005376978,0.023761066,0.0013752162,0.00014727916,0.0000074025625,0.0000053960584,0.000013633523,0.00023105979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809426,0.00021003168,0.0011879611,0.00013042617,0.00026149163,0.00011582428],"domain_scores_gemma":[0.9967076,0.0013223839,0.0013503592,0.00010346595,0.00036398318,0.00015220937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015390196,0.000092881666,0.0011154322,0.000101988335,0.000017773791,0.0000041455096,0.000044023436,0.00007908216,0.000100688994],"category_scores_gemma":[0.00045401836,0.000053524724,0.00015330252,0.00012102112,0.00009397084,0.00012867848,0.000016671886,0.00031206108,0.0000011309111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00879415,0.0023792358,0.5273414,0.0010314456,0.009823055,0.00044669866,0.0009328778,0.00055014814,0.01417031,0.0014392385,0.0008166265,0.43227476],"study_design_scores_gemma":[0.067095086,0.052148815,0.81045055,0.0014734226,0.023251249,0.001358605,0.0015448837,0.0032741278,0.007709132,0.00089778117,0.030350298,0.00044606533],"about_ca_topic_score_codex":0.00003434419,"about_ca_topic_score_gemma":0.000018017368,"teacher_disagreement_score":0.4318287,"about_ca_system_score_codex":0.00015595218,"about_ca_system_score_gemma":0.0019898824,"threshold_uncertainty_score":0.3529966},"labels":[],"label_agreement":null},{"id":"W2947538095","doi":"10.1186/s13045-019-0731-8","title":"Emerging therapies for non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Natural Science Foundation of China","keywords":"Medicine; Hematology; Internal medicine; Lung cancer; Oncology; Intensive care medicine; Cancer; Medical physics","score_opus":0.04225786029802803,"score_gpt":0.44959770447566233,"score_spread":0.4073398441776343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947538095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013154671,0.99243027,0.00041775903,0.0012089578,0.0024089038,0.0015355994,0.000030070172,0.000009762507,0.0018271403],"genre_scores_gemma":[0.00004489826,0.99303377,0.0034378183,0.00039718472,0.0006020865,0.0002584988,0.000027133505,0.00007041693,0.0021282195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980208,0.000108203516,0.0011349383,0.000249718,0.00011956502,0.00036676158],"domain_scores_gemma":[0.9968074,0.00063730567,0.0018350456,0.00023122014,0.0003577997,0.00013124084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027617192,0.00034790704,0.003864545,0.00040507052,0.00007583675,0.000008444747,0.00020025762,0.0005845211,0.00018649001],"category_scores_gemma":[0.000040844887,0.00022563455,0.0010546211,0.00013603135,0.00006627101,0.000047798592,0.000033748667,0.00056407636,0.00001669767],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016337875,0.0006011992,0.0006521095,0.04738953,0.0071421755,0.00061540154,0.0011622842,0.0000034137897,0.00000726392,0.00035452447,0.0294102,0.91249853],"study_design_scores_gemma":[0.0026570717,0.0011313428,0.000008674425,0.006460416,0.017837182,0.0039001866,0.00017238877,0.0000068411746,0.000007953824,0.00002911285,0.9676272,0.00016160733],"about_ca_topic_score_codex":0.000012086474,"about_ca_topic_score_gemma":0.00001632908,"teacher_disagreement_score":0.93821704,"about_ca_system_score_codex":0.0007179265,"about_ca_system_score_gemma":0.0046355347,"threshold_uncertainty_score":0.920111},"labels":[],"label_agreement":null},{"id":"W2947681396","doi":"10.1200/jco.2019.37.15_suppl.e20505","title":"Model-driven metronomic vinorelbine in heavily pre-treated metastatic NSCLC and PM patients: Results of a phase I/II study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Vinorelbine; Neutropenia; Response Evaluation Criteria in Solid Tumors; non-small cell lung cancer (NSCLC); Phases of clinical research; Toxicity; Dosing; Internal medicine; Lung cancer; Pemetrexed; Population; Oncology; Surgery; Nuclear medicine; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.07419922990392695,"score_gpt":0.4936330278500683,"score_spread":0.41943379794614133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947681396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732643,0.0001489443,0.000038119033,0.00078592007,0.00021011586,0.00074428227,0.000034839082,0.00000373145,0.00070764235],"genre_scores_gemma":[0.99672616,0.0001080094,0.0025878812,0.00020635438,0.00005816188,0.0000073321653,0.000014315959,0.000011674871,0.00028011456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693567,0.00024749126,0.0022647793,0.00019233213,0.00021106172,0.00014865588],"domain_scores_gemma":[0.9972347,0.0007125593,0.0013645029,0.00017143636,0.00032497876,0.00019183499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010153258,0.00012138879,0.0013714981,0.00020956893,0.000018736999,0.0000033371512,0.00007796392,0.000099750105,0.000036970974],"category_scores_gemma":[0.00077950367,0.00008022279,0.00017897329,0.00014055493,0.00007649256,0.00012124879,0.00004539507,0.00034988107,0.0000031970196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043041196,0.0602833,0.7663585,0.00006733176,0.002681774,0.00019429496,0.0025147286,0.0019332884,0.0003437837,0.00003689357,0.0009098314,0.121635064],"study_design_scores_gemma":[0.20498803,0.16988729,0.61232847,0.00021176673,0.0024683424,0.000025683628,0.0005148716,0.007923455,0.000039463826,0.00010371615,0.001386873,0.00012200374],"about_ca_topic_score_codex":0.00013866853,"about_ca_topic_score_gemma":0.000118972224,"teacher_disagreement_score":0.16194683,"about_ca_system_score_codex":0.00020936222,"about_ca_system_score_gemma":0.0008170068,"threshold_uncertainty_score":0.32713902},"labels":[],"label_agreement":null},{"id":"W2947888157","doi":"10.1200/jco.2019.37.15_suppl.6065","title":"Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Contraindication; Durvalumab; Internal medicine; Common Terminology Criteria for Adverse Events; Cancer; Head and neck cancer; Adverse effect; Head and neck squamous-cell carcinoma; Tolerability; Oncology; Clinical endpoint; Surgery; Clinical trial; Pathology","score_opus":0.02629450861956823,"score_gpt":0.4376512528046826,"score_spread":0.41135674418511436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947888157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935248,0.0009204324,0.00027097776,0.004152024,0.000116800686,0.0007341377,0.000014500904,0.0000026932516,0.00026366234],"genre_scores_gemma":[0.99310917,0.00084891694,0.0046332646,0.0012264219,0.000073296076,0.000017475773,0.000008305653,0.000014835366,0.0000683233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839485,0.000071588314,0.00087192905,0.00019219969,0.0003265348,0.00014292377],"domain_scores_gemma":[0.99784005,0.00042316638,0.0009753785,0.000102160324,0.00040272,0.00025652375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035497345,0.00012726507,0.0010130488,0.00010135171,0.000019137662,0.0000037265615,0.000046686873,0.00009511664,0.000052606778],"category_scores_gemma":[0.00008721087,0.00006828255,0.000039909148,0.00011915118,0.00018261107,0.00010046547,0.000009089913,0.0002664976,3.3981777e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023667997,0.00074538426,0.77653867,0.00003827549,0.00042462055,0.000023615921,0.00041690393,0.00016489309,0.000018366909,0.00006224043,0.000038064572,0.19786097],"study_design_scores_gemma":[0.060337182,0.033173814,0.896549,0.00088934595,0.00026858697,0.000043482025,0.00008768593,0.000057760975,0.000004850695,0.000008467097,0.008500862,0.00007900651],"about_ca_topic_score_codex":0.00005701726,"about_ca_topic_score_gemma":0.000503715,"teacher_disagreement_score":0.19778197,"about_ca_system_score_codex":0.00019231677,"about_ca_system_score_gemma":0.0014293918,"threshold_uncertainty_score":0.27844816},"labels":[],"label_agreement":null},{"id":"W2948008600","doi":"10.1200/jco.2019.37.15_suppl.9036","title":"SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Interim analysis; Paclitaxel; Phases of clinical research; Adverse effect; Adenocarcinoma; Cancer; Chemotherapy; Randomized controlled trial","score_opus":0.028746556915911256,"score_gpt":0.4411868270330542,"score_spread":0.4124402701171429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948008600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396485,0.0004119441,0.0000537358,0.0004994508,0.0006495259,0.001751538,0.000028263476,0.000005763039,0.0026349323],"genre_scores_gemma":[0.996938,0.000107955166,0.0018851516,0.00030477415,0.00018479805,0.000036426034,0.0000114243585,0.0000355923,0.0004958767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969072,0.00025142467,0.001673431,0.0003418673,0.0005120467,0.00031407434],"domain_scores_gemma":[0.9957367,0.00084459374,0.0019419726,0.00028067417,0.000883104,0.0003129606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005894404,0.00025416442,0.0018758175,0.00018023193,0.000037894024,0.000008015893,0.00016326063,0.00019717276,0.00012913231],"category_scores_gemma":[0.0001361797,0.00015627196,0.00018671261,0.00030433654,0.00011438701,0.00019102692,0.00003781626,0.00084973016,0.00000561907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13416576,0.029026203,0.80482185,0.00010946,0.0022243941,0.00059391896,0.0028565729,0.0015713358,0.000045885517,0.0000031663608,0.00018502206,0.024396423],"study_design_scores_gemma":[0.31208804,0.12118536,0.56114733,0.0005164739,0.0022364443,0.000013323522,0.0020669755,0.00016213869,0.00006860064,0.0000023894172,0.00034517393,0.0001677464],"about_ca_topic_score_codex":0.00032108522,"about_ca_topic_score_gemma":0.0008523793,"teacher_disagreement_score":0.24367452,"about_ca_system_score_codex":0.00061254343,"about_ca_system_score_gemma":0.0030789452,"threshold_uncertainty_score":0.6372585},"labels":[],"label_agreement":null},{"id":"W2949974727","doi":"10.1200/jco.2012.30.15_suppl.6058","title":"Treatment and treatment outcomes of advanced NSCLC patients in routine clinical care: Results of the retrospective LUCEOR study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Erlotinib; Pemetrexed; Docetaxel; Gemcitabine; Lung cancer; Internal medicine; Adenocarcinoma; Stage (stratigraphy); KRAS; Cancer; Performance status; Oncology; Chemotherapy; Epidermal growth factor receptor","score_opus":0.07741247070655305,"score_gpt":0.5155121252538329,"score_spread":0.4380996545472799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949974727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947255,0.00040695365,8.5868004e-7,0.0014751981,0.0011126786,0.0008481773,0.000036379784,0.0000024263368,0.0013918102],"genre_scores_gemma":[0.99835163,0.00054167316,0.0005290546,0.00010619445,0.00022374371,0.000012790949,0.0000039224856,0.000010392347,0.00022059723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960458,0.0005329743,0.0028183374,0.00017084458,0.00025127365,0.00018072332],"domain_scores_gemma":[0.9952351,0.0017733412,0.0021301156,0.000261789,0.00039126465,0.00020838504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009905332,0.00015501081,0.0017851102,0.00007789621,0.000028170123,0.0000017098089,0.00007635693,0.00016923659,0.000006563231],"category_scores_gemma":[0.0026764793,0.00007341309,0.00047451234,0.00012861592,0.00019588818,0.00007912771,0.00003894547,0.00024744868,8.1915437e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050656823,0.01686609,0.8754475,0.000005449293,0.00084694894,0.000014433579,0.0024193805,0.0000029068253,0.0000020823234,0.000021729446,0.000030614927,0.09927718],"study_design_scores_gemma":[0.060253263,0.053497884,0.8817838,0.000044771114,0.0012423231,0.000007729845,0.0014321627,9.617617e-7,0.000028335768,0.00001660467,0.0016465113,0.00004566837],"about_ca_topic_score_codex":0.00022204779,"about_ca_topic_score_gemma":0.00035706625,"teacher_disagreement_score":0.09923151,"about_ca_system_score_codex":0.0007242908,"about_ca_system_score_gemma":0.0007509209,"threshold_uncertainty_score":0.3204189},"labels":[],"label_agreement":null},{"id":"W2950153856","doi":"10.1016/j.lungcan.2019.06.003","title":"Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Logistic regression; Population; Regimen; Cancer; Multivariate analysis; Mortality rate","score_opus":0.01801350174991846,"score_gpt":0.3217315413157189,"score_spread":0.30371803956580046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950153856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935681,0.0011161988,0.0000065914596,0.000031218522,0.0006779012,0.0040189456,0.00021314679,0.00007864338,0.000289218],"genre_scores_gemma":[0.9965429,0.000031456417,0.000006140803,0.00012953032,0.00006961022,0.0010085797,0.00022298354,0.00008833595,0.0019005089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979147,0.000085619,0.00041575017,0.0005782833,0.00055594055,0.00044973902],"domain_scores_gemma":[0.99895126,0.000063634805,0.00028783432,0.000368964,0.00019713787,0.00013116414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000119701996,0.00036441852,0.0006622542,0.00017095168,0.00010291752,0.000048945873,0.0001228767,0.00012953758,0.000501312],"category_scores_gemma":[0.000010862369,0.00026717386,0.00015288102,0.000524034,0.00001172661,0.00016735005,0.000019275043,0.00021898784,0.000004583252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109898596,0.0008283152,0.9929177,0.0001755136,0.0012482578,0.00000726657,0.00235556,0.0019860726,0.00021428584,5.0087596e-7,0.000076959135,0.00007966398],"study_design_scores_gemma":[0.01177147,0.00030281793,0.9840308,0.0011247274,0.0009876671,2.3524212e-8,0.00033606598,0.00088522135,0.0002369235,3.5319184e-7,0.000010435481,0.00031352276],"about_ca_topic_score_codex":0.026414393,"about_ca_topic_score_gemma":0.0064037265,"teacher_disagreement_score":0.020010665,"about_ca_system_score_codex":0.0020635305,"about_ca_system_score_gemma":0.0006138018,"threshold_uncertainty_score":0.99997807},"labels":[],"label_agreement":null},{"id":"W2953411656","doi":"10.1158/1538-7445.am2019-ct139","title":"Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Concomitant; Cancer; Gastroenterology; Gefitinib; Epidermal growth factor receptor","score_opus":0.06733122609892622,"score_gpt":0.47997346237144645,"score_spread":0.4126422362725202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953411656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948807,0.00016798203,0.00004589218,0.00024815282,0.000035572702,0.003711821,0.000079146295,0.000017470426,0.0008133013],"genre_scores_gemma":[0.99796164,0.000023155948,0.00021921498,0.000043602446,0.00003538959,0.00118392,0.00013900806,0.00004106706,0.00035300638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979569,0.00006671855,0.0003619991,0.000433056,0.00079573685,0.0003856414],"domain_scores_gemma":[0.9981672,0.0002762347,0.00015287506,0.00043660527,0.00084413885,0.00012294234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034665508,0.00016507844,0.00042751772,0.0005403295,0.00016936086,0.000030090914,0.00013734684,0.00005727249,0.00042229434],"category_scores_gemma":[0.00009582982,0.00012667241,0.00009612852,0.0014514436,0.00005832932,0.00016637976,0.000032432654,0.0002672904,0.0000044110884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003448226,0.018244265,0.87631017,0.00028153308,0.005128458,0.000021004173,0.014684635,0.004911642,0.015871417,0.000050599774,0.00008502072,0.06096304],"study_design_scores_gemma":[0.06941134,0.022801457,0.8713878,0.00040221369,0.0007563313,5.316092e-7,0.0101332525,0.0005264602,0.02300861,0.00006242558,0.0011337195,0.00037585423],"about_ca_topic_score_codex":0.0047939816,"about_ca_topic_score_gemma":0.0010438486,"teacher_disagreement_score":0.06596311,"about_ca_system_score_codex":0.00042055195,"about_ca_system_score_gemma":0.00044231847,"threshold_uncertainty_score":0.7247098},"labels":[],"label_agreement":null},{"id":"W2953564944","doi":"10.3747/co.26.4485","title":"Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Celgene; AstraZeneca","keywords":"Medicine; Carboplatin; Internal medicine; Hazard ratio; Gemcitabine; Proportional hazards model; Lung cancer; Oncology; Paclitaxel; Discontinuation; Progression-free survival; Cancer; Chemotherapy; Gastroenterology; Surgery; Confidence interval; Cisplatin","score_opus":0.04481276761613097,"score_gpt":0.4294808623479265,"score_spread":0.38466809473179553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953564944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98896,0.0054026516,0.00014084912,0.000101650694,0.0009874722,0.001846527,0.000047078818,0.000014661833,0.002499104],"genre_scores_gemma":[0.9983071,0.00050537055,0.00013498715,0.000018014654,0.000035920944,0.0005128987,0.000100570534,0.000019806663,0.00036531987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990136,0.00009121292,0.00027608825,0.000275402,0.00010925397,0.00023441261],"domain_scores_gemma":[0.99920315,0.00029049013,0.00012840475,0.00020549705,0.000091966926,0.00008047529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013079068,0.00016372718,0.0005521559,0.00015243089,0.000024663985,0.0000027104973,0.00006108026,0.000058856378,0.0002152761],"category_scores_gemma":[0.000019965782,0.00012728691,0.00009325356,0.00021170427,0.000037250593,0.00003875052,0.000029109697,0.0001253569,0.000029347448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047641987,0.0038984132,0.97550553,0.0027024602,0.00030226886,0.000044146684,0.0009244017,0.0004570094,0.0011017579,0.000031309708,0.00009650434,0.014459792],"study_design_scores_gemma":[0.051886152,0.0047194753,0.9167266,0.0016863829,0.0036755404,0.000026747353,0.00031515345,0.0042538065,0.008399298,0.00011080419,0.007848338,0.0003517355],"about_ca_topic_score_codex":0.00043026506,"about_ca_topic_score_gemma":0.00022190622,"teacher_disagreement_score":0.058778953,"about_ca_system_score_codex":0.0008657395,"about_ca_system_score_gemma":0.00042443446,"threshold_uncertainty_score":0.51906097},"labels":[],"label_agreement":null},{"id":"W2953576895","doi":"10.1016/j.jtho.2019.06.015","title":"A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Science Foundation of Sri Lanka; Roche; AstraZeneca Canada; Novartis; Pfizer Canada; Merck; U.S. Department of Energy; American Lung Association; AstraZeneca; Eli Lilly and Company; National Institutes of Health; National Science Foundation","keywords":"Osimertinib; Medicine; Neratinib; Exon; Cancer research; Adenocarcinoma; Mutation; Lung cancer; Oncology; Internal medicine; Genetics; Gene; Cancer; Biology; Trastuzumab","score_opus":0.017619743583859447,"score_gpt":0.3968537430336336,"score_spread":0.37923399944977415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953576895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793308,0.0011303949,0.00033466695,0.016185652,0.0005059258,0.00061968,0.00003324047,0.000010279691,0.0018493937],"genre_scores_gemma":[0.98563784,0.00007080052,0.009441217,0.002431593,0.00027585737,0.000013464653,0.00001542002,0.000022981398,0.0020908103],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99848145,0.000112092865,0.00063422613,0.0002513547,0.00026452666,0.00025636045],"domain_scores_gemma":[0.99853355,0.0002907658,0.00046132368,0.00014957809,0.0003458236,0.00021897144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042362412,0.00017088295,0.0006000661,0.0003269204,0.000051353218,0.000022290576,0.0000674665,0.00015290378,0.000085569845],"category_scores_gemma":[0.00018987655,0.0001387998,0.000083018545,0.0002705873,0.00005119591,0.00019487087,0.000032690365,0.00021191326,0.000020070836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030111693,0.0032194771,0.31722268,0.0013692739,0.0023374616,0.005890148,0.082681924,0.0005481659,0.44238925,0.00038993184,0.021727161,0.092112824],"study_design_scores_gemma":[0.016690288,0.008592741,0.8930704,0.002156907,0.0021415784,0.0044629094,0.014166837,0.0017222218,0.04378631,0.00019880585,0.012338071,0.00067294564],"about_ca_topic_score_codex":0.000039786493,"about_ca_topic_score_gemma":0.00016080058,"teacher_disagreement_score":0.5758477,"about_ca_system_score_codex":0.000537653,"about_ca_system_score_gemma":0.00056572206,"threshold_uncertainty_score":0.56600916},"labels":[],"label_agreement":null},{"id":"W2953753155","doi":"10.1158/1535-7163.mct-19-0105","title":"Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal; McGill University; Institut universitaire de cardiologie et de pneumologie de Québec; IGNIS Innovation (Canada); Jewish General Hospital","funders":"Pfizer Canada; Astex Pharmaceuticals","keywords":"Crizotinib; Anaplastic lymphoma kinase; Fusion gene; Oncology; KRAS; Exome sequencing; Lung cancer; Cancer research; Mutation; Internal medicine; Exome; Biology; Medicine; Gene; Genetics","score_opus":0.024932329947555787,"score_gpt":0.34800049562069807,"score_spread":0.3230681656731423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953753155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764836,0.0002713866,0.0001350822,0.00050650886,0.00018225546,0.0004783645,0.00008449804,0.000010314079,0.0006832058],"genre_scores_gemma":[0.9978873,0.00004326223,0.000045016946,0.0012634436,0.0000062372296,0.000034649867,0.00008980159,0.00001798944,0.000612274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990638,0.00004630412,0.00031657703,0.00018772917,0.00024892192,0.00013670327],"domain_scores_gemma":[0.9992436,0.00005931463,0.00017914968,0.0003381004,0.0001494478,0.000030383777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008656538,0.00011341515,0.00036282893,0.00012307099,0.00003289948,0.0000122214,0.00009392369,0.00006777222,0.00006311245],"category_scores_gemma":[0.000014346454,0.00006877781,0.0002192612,0.0006532806,0.000049945473,0.000030055528,0.000022413271,0.00011425575,0.0000023891992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040919032,0.0004246286,0.9898317,0.00000591101,0.00626192,0.000001004879,0.00041517318,0.0012925162,0.0011238554,0.00003536672,0.000008521464,0.0005585232],"study_design_scores_gemma":[0.0030927942,0.00008534301,0.99052644,0.00004739309,0.0048055034,1.2449215e-7,0.00008491584,0.0008359774,0.00021854827,0.0000088850675,0.00021549579,0.000078587254],"about_ca_topic_score_codex":0.00021217525,"about_ca_topic_score_gemma":0.0014205512,"teacher_disagreement_score":0.0030518752,"about_ca_system_score_codex":0.00012406448,"about_ca_system_score_gemma":0.00019728545,"threshold_uncertainty_score":0.28046775},"labels":[],"label_agreement":null},{"id":"W2954420975","doi":"10.1007/s12253-019-00685-2","title":"Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer","year":2019,"lang":"en","type":"review","venue":"Pathology & Oncology Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Health Services Authority; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Bayer HealthCare","keywords":"Trk receptor; Tropomyosin; Fusion gene; Fusion protein; Targeted therapy; Tropomyosin receptor kinase C; Cancer research; Gene; Kinase; Cancer; Biology; Receptor; Medicine; Internal medicine; Recombinant DNA; Biochemistry; Neurotrophin","score_opus":0.29579313961504594,"score_gpt":0.6368734818066709,"score_spread":0.341080342191625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954420975","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038369084,0.98683137,0.0006681931,0.00051742594,0.0012162671,0.008403262,0.00035000534,0.000056896977,0.0015728823],"genre_scores_gemma":[0.000008481443,0.94078934,0.04140673,0.00013917164,0.00038130776,0.007602779,0.0017154301,0.00015713813,0.0077996296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99436057,0.0023098846,0.00070402864,0.0011713431,0.00041423226,0.0010399678],"domain_scores_gemma":[0.9952376,0.0021410373,0.00039060434,0.0007849584,0.0011678737,0.000277964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021634013,0.000485881,0.0026545331,0.00087763765,0.00042547344,0.000030945073,0.00033173565,0.0010383977,0.0006249517],"category_scores_gemma":[0.0005260059,0.00032147227,0.00043368863,0.00074384926,0.00042016167,0.00008041765,0.00024218252,0.0014018781,0.00026695384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004004764,0.00074006437,0.0006640479,0.008928513,0.00074149587,0.00009508979,0.00030277245,1.1977978e-7,0.000025897352,0.00011525987,0.0037245015,0.98426175],"study_design_scores_gemma":[0.004106565,0.0037844323,0.00028762096,0.004656979,0.0036326426,0.00007069562,0.00009148796,0.0000026865657,0.000011053167,0.00005041281,0.98303264,0.00027275796],"about_ca_topic_score_codex":0.00009861494,"about_ca_topic_score_gemma":0.000059337046,"teacher_disagreement_score":0.983989,"about_ca_system_score_codex":0.0024477176,"about_ca_system_score_gemma":0.0042631477,"threshold_uncertainty_score":0.9999237},"labels":[],"label_agreement":null},{"id":"W2954921349","doi":"10.1200/jco.2019.37.15_suppl.9075","title":"Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Internal medicine; Lung cancer; Interim analysis; Clinical endpoint; Gastroenterology; Pneumonitis; Surgery; Lung; Clinical trial","score_opus":0.02964891069922355,"score_gpt":0.4736541712863544,"score_spread":0.44400526058713086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954921349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944256,0.0004743388,0.000008193877,0.00038160686,0.001397565,0.0025751584,0.0000741975,0.000008640316,0.00065468834],"genre_scores_gemma":[0.9987117,0.000038738646,0.000089149566,0.00034128176,0.00024526665,0.000052815,0.000019820034,0.000034722412,0.00046651438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560046,0.0004139724,0.002442936,0.00040981782,0.0007753316,0.0003574625],"domain_scores_gemma":[0.9951585,0.0006766077,0.0023814372,0.00029839287,0.0011292044,0.00035589305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053615,0.00029068408,0.0019593737,0.00028424675,0.00009581911,0.00000863477,0.00021851766,0.00020099705,0.00028306927],"category_scores_gemma":[0.00022620933,0.00018943117,0.00022825821,0.00033844647,0.000095247015,0.00021317603,0.00009824007,0.00096051674,0.0000051494967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01826845,0.1415849,0.8206567,0.000111952475,0.0009924481,0.00026688798,0.006633372,0.0002560643,0.000016910351,0.0000025167885,0.0005934014,0.010616352],"study_design_scores_gemma":[0.133861,0.2968972,0.5622137,0.00017304,0.0022793734,0.0000043363134,0.0034907148,0.00008518565,0.00005204255,0.0000043197374,0.0007658914,0.00017318112],"about_ca_topic_score_codex":0.0002461526,"about_ca_topic_score_gemma":0.00048976776,"teacher_disagreement_score":0.25844306,"about_ca_system_score_codex":0.0006242558,"about_ca_system_score_gemma":0.0021168366,"threshold_uncertainty_score":0.77247787},"labels":[],"label_agreement":null},{"id":"W2955159702","doi":"10.14740/wjon1204","title":"Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study","year":2019,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Mutation; Concordance; Lung cancer; Pathology; Immunohistochemistry; Adenocarcinoma; Biopsy; Cancer; Carcinoma; Pleural effusion; Oncology; Internal medicine; Cancer research; Gene; Biology","score_opus":0.01551812168118639,"score_gpt":0.3129236229980662,"score_spread":0.2974055013168798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955159702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953278,0.002933276,0.000007127058,0.0005457293,0.00011745773,0.0005390339,0.0000033788415,0.0000032236103,0.00052303233],"genre_scores_gemma":[0.9992364,0.000079290825,0.00045929343,0.00012432072,0.000029768711,0.000020402735,0.0000043953705,0.000008869207,0.000037253645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999012,0.00011142396,0.0004326635,0.00015630314,0.00011851751,0.00016909288],"domain_scores_gemma":[0.99912554,0.00046140287,0.00017807823,0.000059792117,0.00008572779,0.00008944212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015774538,0.0001115916,0.00040811603,0.000274108,0.000020919602,0.000005914992,0.000046257523,0.000066297674,0.000074823554],"category_scores_gemma":[0.00023363026,0.00008718904,0.00003119651,0.00016412175,0.00003900448,0.00009778049,0.00002229334,0.000311852,0.000004057475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030097432,0.00083827466,0.98112106,0.00007007026,0.000021580274,0.0009046458,0.0025447132,0.000017189343,0.012645022,0.000043450487,0.000010790946,0.0014822261],"study_design_scores_gemma":[0.008941102,0.0049009277,0.98313016,0.00005887943,0.00010426338,0.00048863376,0.00071935006,0.00005685101,0.0013786909,0.000059454203,0.000070502494,0.00009118401],"about_ca_topic_score_codex":0.00007871381,"about_ca_topic_score_gemma":0.00005152884,"teacher_disagreement_score":0.011266331,"about_ca_system_score_codex":0.0004134145,"about_ca_system_score_gemma":0.00021372049,"threshold_uncertainty_score":0.35554656},"labels":[],"label_agreement":null},{"id":"W2955414460","doi":"10.1158/1538-7445.am2019-1169","title":"Abstract 1169: Characterization of a small molecule inhibitor for GD3 synthase (ST8SIA1), a novel target in breast cancer stem-like cells","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"PI3K/AKT/mTOR pathway; Virtual screening; Cancer research; Protein kinase B; Metastasis; Chemistry; Protein Data Bank (RCSB PDB); Structural similarity; Small molecule; Cancer stem cell; Biology; Cancer; Stem cell; Computational biology; Cell biology; Biochemistry; Drug discovery; Signal transduction; Genetics","score_opus":0.044431328704136366,"score_gpt":0.384192596263569,"score_spread":0.33976126755943264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955414460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926958,0.00037534695,0.00013768325,0.0018954229,0.00033470476,0.0023704772,0.0018320904,0.000018415863,0.0003400263],"genre_scores_gemma":[0.9941784,0.00028397594,0.0002250954,0.00015021964,0.00020857126,0.0013860104,0.00017179304,0.00005293603,0.0033429884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983559,0.000029843919,0.00034023527,0.00039971256,0.00040872468,0.000465571],"domain_scores_gemma":[0.9988753,0.00008073902,0.000107077096,0.00030280405,0.0004747799,0.00015928553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003061583,0.00015394147,0.00033899987,0.0003031608,0.0000564976,0.000025919218,0.0001205967,0.000105874446,0.0005943649],"category_scores_gemma":[0.000011148215,0.00013163172,0.00008702973,0.00045350948,0.00008580847,0.00012088933,0.0000422628,0.00023782613,0.000022901355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008649474,0.0005476392,0.012312524,0.00094269123,0.0001243632,0.000009493112,0.0006181321,0.00007386516,0.9814128,0.00005641941,0.00039775652,0.0026393333],"study_design_scores_gemma":[0.01340234,0.00059035234,0.17225023,0.002632308,0.00015401533,0.000010884704,0.0006200568,0.0012407596,0.79630655,0.000029360337,0.012334797,0.0004283308],"about_ca_topic_score_codex":0.0021483516,"about_ca_topic_score_gemma":0.0002315102,"teacher_disagreement_score":0.18510626,"about_ca_system_score_codex":0.00066386303,"about_ca_system_score_gemma":0.0010900418,"threshold_uncertainty_score":0.6507879},"labels":[],"label_agreement":null},{"id":"W2955519268","doi":"10.2139/ssrn.3294079","title":"Identification and Verification of a Biomarker Panel for Early Diagnosis of Lung Cancer Patients","year":2018,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Lung cancer; Biomarker; Identification (biology); Medicine; Oncology; Internal medicine; Biology","score_opus":0.01417054437757194,"score_gpt":0.327747914319949,"score_spread":0.31357736994237706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955519268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995097,0.0017600082,0.002300915,0.00029663416,0.00010218505,0.0003693216,0.000027431559,0.0000040149534,0.000042507814],"genre_scores_gemma":[0.9973343,0.0021685115,0.000061226114,0.000013412112,0.00006595856,0.000077619756,0.00001531531,0.00000999896,0.00025364844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992422,0.00001579675,0.0002325025,0.0000968982,0.00011427924,0.00029835012],"domain_scores_gemma":[0.99923414,0.000027866208,0.00023256078,0.00007954195,0.0003920729,0.000033815173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002496937,0.000056646288,0.000117083844,0.00008082686,0.000066487155,0.0000066969064,0.00003402994,0.000032119056,0.000012283679],"category_scores_gemma":[0.000049949467,0.000045826095,0.000045814104,0.00009891222,0.000053595686,0.000083742336,0.0000046478517,0.0000831764,4.5086497e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035511414,0.00035459106,0.9039508,0.00009498131,0.0007993382,8.050759e-8,0.0010003682,3.8042762e-7,0.0065073557,0.0029175505,0.0002302993,0.08378913],"study_design_scores_gemma":[0.0030684334,0.001079831,0.9799916,0.00012468496,0.0008620016,0.000008184677,0.00023328209,0.00020358339,0.010587034,0.003510308,0.00025943868,0.000071599025],"about_ca_topic_score_codex":0.00015751249,"about_ca_topic_score_gemma":0.00011026384,"teacher_disagreement_score":0.08371753,"about_ca_system_score_codex":0.0002880676,"about_ca_system_score_gemma":0.0005302458,"threshold_uncertainty_score":0.18687339},"labels":[],"label_agreement":null},{"id":"W2957487981","doi":"10.1016/s2213-2600(19)30188-2","title":"Germline variants invited to lung cancer screening","year":2019,"lang":"en","type":"letter","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"","keywords":"Lung cancer; Genome-wide association study; Medicine; Context (archaeology); Genetic association; Population; Lung cancer susceptibility; Cancer; Oncology; Bioinformatics; Internal medicine; Genetics; Single-nucleotide polymorphism; Genotype; Biology; Environmental health; Gene","score_opus":0.07625950212863655,"score_gpt":0.40340418806451767,"score_spread":0.3271446859358811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957487981","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023541423,0.008172328,0.00036131457,0.9785392,0.0016205977,0.0021892444,0.0002218849,0.00018321512,0.00635804],"genre_scores_gemma":[0.0009551191,0.00021457014,0.00021598757,0.9435832,0.043958973,0.00039108534,0.00043677518,0.00014435513,0.010099961],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967608,0.00019260378,0.00060829666,0.0007041501,0.00093552866,0.0007986301],"domain_scores_gemma":[0.99730444,0.0003424297,0.00031944347,0.0015640352,0.0002883444,0.00018132896],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005885274,0.000560826,0.0014935484,0.00035016148,0.00018529718,0.000027158949,0.0004776414,0.00047629722,0.0011753497],"category_scores_gemma":[0.00027174037,0.0003154976,0.00014677222,0.0006287608,0.00016535749,0.00006520131,0.000118921875,0.0019565383,0.00012331866],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017939902,0.000020287795,0.0050237607,0.0005027797,0.0009478371,0.0005100387,0.0005171857,0.000031109706,0.00036797184,0.000011262882,0.9892279,0.00266048],"study_design_scores_gemma":[0.0043879296,0.00041534496,0.014024035,0.0027801604,0.0020335165,0.000038326805,0.000035622394,0.000083836225,0.00003204831,0.00001099847,0.97583693,0.00032123172],"about_ca_topic_score_codex":0.0005494552,"about_ca_topic_score_gemma":0.000044054403,"teacher_disagreement_score":0.042338375,"about_ca_system_score_codex":0.0003962738,"about_ca_system_score_gemma":0.0003705244,"threshold_uncertainty_score":0.9999297},"labels":[],"label_agreement":null},{"id":"W2961016476","doi":"10.21037/tlcr.2019.06.01","title":"Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Afatinib; Osimertinib; Erlotinib; T790M; Gefitinib; Medicine; Epidermal growth factor receptor; Lung cancer; Cancer research; Tyrosine kinase; Pharmacology; Oncology; Cancer; Internal medicine; Receptor","score_opus":0.13364455038556797,"score_gpt":0.4659004434974272,"score_spread":0.3322558931118592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961016476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005834629,0.9799628,0.0004950705,0.0016063473,0.00097102625,0.011264923,0.004777463,0.000028310704,0.00031056124],"genre_scores_gemma":[0.0012638147,0.9789167,0.00057528104,0.000036701025,0.0022538851,0.008659318,0.002294667,0.00014407717,0.0058555324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965019,0.00020947756,0.00090381067,0.0007621153,0.0009806717,0.00064198114],"domain_scores_gemma":[0.996822,0.0011421606,0.0003219683,0.0005042029,0.0010049058,0.00020473343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036053534,0.0005565716,0.0014134176,0.00042629056,0.0003984282,0.000060665247,0.0002419602,0.00034961058,0.00061111065],"category_scores_gemma":[0.000024444535,0.00034515248,0.000883996,0.0006861891,0.00015476691,0.0001225373,0.000018504932,0.0004242059,0.000015697211],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006249561,0.0015569075,0.0026926876,0.0652273,0.005608779,0.000009015857,0.0031352614,0.00043107543,0.0007486887,0.00044476014,0.023871176,0.8956494],"study_design_scores_gemma":[0.004945089,0.00087866245,0.00039013915,0.007796778,0.007987566,0.0000037205582,0.000037728874,0.0029409707,0.0016391162,0.000008925827,0.9728655,0.0005058099],"about_ca_topic_score_codex":0.002409445,"about_ca_topic_score_gemma":0.0004886081,"teacher_disagreement_score":0.94899434,"about_ca_system_score_codex":0.0018166924,"about_ca_system_score_gemma":0.005397109,"threshold_uncertainty_score":0.99990004},"labels":[],"label_agreement":null},{"id":"W2962334030","doi":"10.1007/s11523-019-00652-6","title":"Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Oncology; Epidermal growth factor receptor; Adenocarcinoma; Internal medicine; Resistance mutation; Cancer; Cancer research; Gefitinib; Erlotinib; Gene; Biology; Genetics; Polymerase chain reaction","score_opus":0.011041153909476078,"score_gpt":0.32929065762955295,"score_spread":0.3182495037200769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962334030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705588,0.0011621637,0.00069183484,0.0069001243,0.0008060782,0.005061537,0.00008569136,0.00004878507,0.0146849705],"genre_scores_gemma":[0.9859747,0.000065539905,0.0035899535,0.0032850625,0.000073457144,0.0021479256,0.0001044904,0.000034898072,0.0047239363],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987284,0.0000806543,0.00034577277,0.0003522198,0.00014897155,0.00034397244],"domain_scores_gemma":[0.9988894,0.00031630837,0.00022934847,0.00023960382,0.00024727828,0.00007805484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012421164,0.00017716375,0.00034732508,0.000099781755,0.000104575345,0.000009926953,0.0000919244,0.00015380637,0.00031451363],"category_scores_gemma":[0.00008661456,0.00012641618,0.00008854656,0.0002441171,0.000043036063,0.0000642972,0.00002592602,0.00012207753,0.000048457652],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028714271,0.009482682,0.04687369,0.0035306674,0.005708647,0.0010660755,0.450745,0.003300224,0.2826968,0.058563072,0.05412516,0.055193733],"study_design_scores_gemma":[0.14823115,0.024698447,0.102213666,0.002330136,0.0074096676,0.00011118287,0.044168416,0.037432175,0.44590774,0.061244868,0.123247825,0.0030047398],"about_ca_topic_score_codex":0.0007800438,"about_ca_topic_score_gemma":0.0015226854,"teacher_disagreement_score":0.40657657,"about_ca_system_score_codex":0.00093734707,"about_ca_system_score_gemma":0.000866871,"threshold_uncertainty_score":0.5155102},"labels":[],"label_agreement":null},{"id":"W2962768820","doi":"10.1016/j.lungcan.2019.07.021","title":"The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"AstraZeneca","keywords":"Medicine; Erlotinib; Afatinib; Adverse effect; Internal medicine; Gefitinib; Lung cancer; Population; Epidermal growth factor receptor; Rate ratio; Cancer; Oncology; Confidence interval","score_opus":0.011533414860820022,"score_gpt":0.2730662465461996,"score_spread":0.26153283168537955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962768820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394447,0.0024817977,0.000006798449,0.00022108656,0.00019686848,0.0018205424,0.001290911,0.000012068118,0.000025469904],"genre_scores_gemma":[0.9978523,0.00084955414,0.00007790743,0.00011589664,0.00004096756,0.00021348304,0.00026431188,0.000027196576,0.000558336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987626,0.00009227438,0.0003724737,0.0003352257,0.00019146857,0.00024596593],"domain_scores_gemma":[0.99872553,0.00015757508,0.0003860745,0.00020446851,0.00036774867,0.00015860463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008003813,0.00023022543,0.00037479613,0.00009037938,0.00013712185,0.000011267665,0.00004872407,0.000058315414,0.0000643676],"category_scores_gemma":[0.000027370725,0.00014894317,0.000047245463,0.00022478389,0.000095927164,0.00021854532,0.00002974137,0.00011772705,4.3452414e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037847273,0.00011188799,0.99422204,0.00086446333,0.00029374464,0.0000019023659,0.0012045391,0.000075607306,0.0012168624,0.000005127367,0.0012056547,0.00041970744],"study_design_scores_gemma":[0.0068509886,0.0006264142,0.9708676,0.0015870434,0.0008576281,9.941838e-7,0.00021471719,0.0013411039,0.017114127,5.494438e-7,0.00031382847,0.00022501635],"about_ca_topic_score_codex":0.005536805,"about_ca_topic_score_gemma":0.005807912,"teacher_disagreement_score":0.023354443,"about_ca_system_score_codex":0.00031267552,"about_ca_system_score_gemma":0.0002618861,"threshold_uncertainty_score":0.837003},"labels":[],"label_agreement":null},{"id":"W2962962686","doi":"10.1200/jco.2013.31.15_suppl.e19031","title":"Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Oncology; Internal medicine; Lung cancer; Chemotherapy; Cost effectiveness; Epidermal growth factor receptor; Cancer","score_opus":0.07104813067741954,"score_gpt":0.4856174590540123,"score_spread":0.41456932837659277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962962686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985934,0.0019530577,0.0003325616,0.0046610893,0.00097410387,0.00068251544,0.000031573047,0.000004120541,0.0015016461],"genre_scores_gemma":[0.98685354,0.005630351,0.005479875,0.0006733981,0.000555776,0.00006444829,0.000012491282,0.000017919063,0.00071218185],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99797785,0.00005472471,0.0014961624,0.00018878655,0.00010431203,0.00017814619],"domain_scores_gemma":[0.9955352,0.0022659407,0.001407271,0.00015276892,0.000388017,0.00025083346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000545532,0.00013308167,0.0013597414,0.00018113782,0.000041412983,0.0000075001494,0.000090031084,0.00018477044,0.0006388787],"category_scores_gemma":[0.00030741363,0.0000924694,0.000507056,0.00012412103,0.00008686135,0.0001012231,0.00001888974,0.00022786277,0.0000037482328],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028959457,0.003343104,0.42177704,0.00021541856,0.021691922,0.000049251586,0.0013031093,0.0063954922,0.0010805026,0.0001313612,0.005091932,0.5099614],"study_design_scores_gemma":[0.11079071,0.04276206,0.7667498,0.00016731358,0.01654989,0.000016972543,0.00046772358,0.013998399,0.0007335028,0.00020207679,0.047265593,0.00029596357],"about_ca_topic_score_codex":0.00030471568,"about_ca_topic_score_gemma":0.00043533568,"teacher_disagreement_score":0.5096654,"about_ca_system_score_codex":0.00019455607,"about_ca_system_score_gemma":0.0012017048,"threshold_uncertainty_score":0.6995273},"labels":[],"label_agreement":null},{"id":"W2964501256","doi":"10.1200/jco.2012.30.15_suppl.9591","title":"Bleomycin-associated lung toxicity in childhood cancer survivors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Medicine; DLCO; Pulmonary function testing; Pulmonary toxicity; Spirometry; Bleomycin; Internal medicine; Lung cancer; Diffusing capacity; Univariate analysis; Lung; Asymptomatic; Gastroenterology; Lung volumes; Surgery; Chemotherapy; Asthma","score_opus":0.07018806024973309,"score_gpt":0.5064385911034055,"score_spread":0.4362505308536724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964501256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98107636,0.0023381843,0.000024812283,0.0071997927,0.0020905943,0.00017031496,0.000006057671,0.0000074699083,0.00708642],"genre_scores_gemma":[0.9938614,0.0009706631,0.0004137442,0.003059314,0.0012568308,0.000006478596,0.0000032224857,0.000011866634,0.00041648917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773777,0.00026110708,0.0014031557,0.000094118375,0.00022537408,0.00027846222],"domain_scores_gemma":[0.99754685,0.0007703149,0.0009396498,0.0000952587,0.00028554883,0.00036240567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020223258,0.00009649625,0.0010015757,0.00010273938,0.000028152424,0.0000037307648,0.00007289038,0.00027397522,0.00032098332],"category_scores_gemma":[0.002174872,0.00006596659,0.00027857345,0.00018253172,0.00005719207,0.00019135384,0.000021317506,0.0006678541,0.000010040739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029192507,0.004638258,0.9537001,0.000009007455,0.00055668724,0.00008290812,0.0005124697,0.000013125535,0.000027922075,0.000061386054,0.002680535,0.037425637],"study_design_scores_gemma":[0.0070068515,0.001523999,0.9698221,0.00010200044,0.0005937233,0.000055468707,0.0001179998,0.000020961896,0.000037020734,0.000076246535,0.020581847,0.00006175568],"about_ca_topic_score_codex":0.00039645983,"about_ca_topic_score_gemma":0.0011412245,"teacher_disagreement_score":0.03736388,"about_ca_system_score_codex":0.0005533505,"about_ca_system_score_gemma":0.0016461082,"threshold_uncertainty_score":0.35145423},"labels":[],"label_agreement":null},{"id":"W2964621144","doi":"10.1016/j.euroneuro.2018.07.088","title":"GENETIC TESTING TO PREDICT ONSET AND TREATMENT OF PSYCHIATRIC DISORDERS—2018 UPDATE","year":2019,"lang":"en","type":"article","venue":"European Neuropsychopharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Protein kinase B; AKT1; Genotype; Lung cancer; Single-nucleotide polymorphism; Medicine; Internal medicine; Oncology; Metastasis; Cancer research; Cancer; Phosphorylation; Gene; Biology; Genetics","score_opus":0.01361929803750315,"score_gpt":0.31094940608494814,"score_spread":0.297330108047445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964621144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826785,0.00047026773,0.000022499478,0.0011177586,0.0008724097,0.0010170506,0.0000311565,0.00010625581,0.013684148],"genre_scores_gemma":[0.9944625,0.00053310115,0.0024272357,0.0014934931,0.00018195254,0.000022773522,0.000008900185,0.00007648028,0.00079359114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988271,0.00014607115,0.00028130843,0.0004084235,0.000099442346,0.00023763017],"domain_scores_gemma":[0.99931705,0.00007228052,0.00009621619,0.0002688437,0.000044086646,0.00020151986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045783712,0.00018542084,0.00025892488,0.00017532967,0.000043283217,0.000008270604,0.00007318819,0.000020905592,0.00013815644],"category_scores_gemma":[0.000015201558,0.00015191591,0.000056435347,0.00031206335,0.00004998073,0.00002748845,0.00003438651,0.00006551122,0.00025472036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091871753,0.001370078,0.810584,0.00009523342,0.00037315168,0.00018423669,0.00059105403,0.00017700464,0.050303392,0.000012987833,0.006961693,0.12842843],"study_design_scores_gemma":[0.0057587894,0.005005184,0.93232,0.00001514717,0.0004113432,0.000118610784,0.000016278236,0.00011454359,0.000053523214,0.000010304941,0.05605688,0.00011939407],"about_ca_topic_score_codex":0.000018939754,"about_ca_topic_score_gemma":0.0000032762591,"teacher_disagreement_score":0.12830904,"about_ca_system_score_codex":0.00003925859,"about_ca_system_score_gemma":0.00005320109,"threshold_uncertainty_score":0.6194951},"labels":[],"label_agreement":null},{"id":"W2964960971","doi":"10.1177/1078155219862040","title":"Comparison between two premedication regimens of dexamethasone before a pemetrexed-based chemotherapy: A single-center experience study","year":2019,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Dexamethasone; Pemetrexed; Regimen; Premedication; Chemotherapy; Internal medicine; Chemotherapy regimen; Single Center; Surgery; Anesthesia; Oncology; Cisplatin","score_opus":0.08138048394853586,"score_gpt":0.5062292627131044,"score_spread":0.42484877876456856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964960971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98816824,0.00028447347,0.0006663723,0.007104746,0.00036684072,0.0009909075,0.0000045652423,0.0000122974725,0.0024015745],"genre_scores_gemma":[0.9897888,0.000025032117,0.0086280145,0.001106025,0.00024580417,0.000021320757,0.000008315719,0.000020658088,0.0001560874],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797994,0.00032903106,0.0008011635,0.00018386787,0.0005256718,0.00018030504],"domain_scores_gemma":[0.9962444,0.00080054795,0.0018693261,0.00023031644,0.00069147325,0.00016398102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087790337,0.00014547442,0.00063873985,0.0002187328,0.000045675202,0.000011550188,0.00014905416,0.000046808815,0.00028712276],"category_scores_gemma":[0.00042477867,0.000112808506,0.00011820605,0.00029698526,0.000077241326,0.00044367817,0.000021334368,0.0004005208,0.000011971205],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032116259,0.012250032,0.91738504,0.000049492708,0.0014093552,0.000080985956,0.012015473,0.000034494202,0.009473513,0.0000036581712,0.0009371727,0.04314915],"study_design_scores_gemma":[0.18639211,0.050468672,0.20915341,0.0005459652,0.011237001,0.0013857601,0.027219046,0.0012099233,0.035371136,0.000023341032,0.47656643,0.00042718774],"about_ca_topic_score_codex":0.00005671542,"about_ca_topic_score_gemma":0.0000071052773,"teacher_disagreement_score":0.7082316,"about_ca_system_score_codex":0.00054969033,"about_ca_system_score_gemma":0.00078891905,"threshold_uncertainty_score":0.4600197},"labels":[],"label_agreement":null},{"id":"W2964966490","doi":"10.1200/jco.2013.31.15_suppl.9550","title":"Local tumor control and survival outcomes of percutaneous radiofrequency ablation plus post-ablation chemotherapy for lung tumors in nonsurgical patients: A meta-analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Radiofrequency ablation; Ablation; Chemotherapy; Brachytherapy; Percutaneous; Surgery; Lung; Radiology; Radiation therapy; Internal medicine","score_opus":0.05191714346333999,"score_gpt":0.4331676939418489,"score_spread":0.3812505504785089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964966490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848446,0.00068532384,0.0038453722,0.008888693,0.00022083303,0.0010518658,0.000034012042,0.0000053732992,0.0004239051],"genre_scores_gemma":[0.9957443,0.000067858186,0.0025773433,0.0013791841,0.00007693266,0.00002241438,0.000019117833,0.000012665335,0.00010021957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693143,0.00019664422,0.0022246204,0.00018283552,0.00029539887,0.00016905906],"domain_scores_gemma":[0.9945373,0.0027598483,0.0014285247,0.00012200913,0.00095521985,0.000197085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012376041,0.00014626209,0.0028907766,0.00024606354,0.000026424521,0.0000094521665,0.000064869695,0.00016844145,0.00027010706],"category_scores_gemma":[0.0012617749,0.000089791494,0.0011088168,0.00017930244,0.00014649707,0.00016662334,0.000007461262,0.0002863417,0.0000012497642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055543566,0.0034147394,0.8595972,0.00007490861,0.08765188,0.00019843693,0.00058821077,0.0015431137,0.0000749366,0.0003368401,0.00025529345,0.04071006],"study_design_scores_gemma":[0.019016054,0.005601413,0.90826374,0.000009855201,0.057735037,0.000093597846,0.00015491125,0.008428406,0.000003876534,0.00021983901,0.00037732563,0.000095941934],"about_ca_topic_score_codex":0.00027294442,"about_ca_topic_score_gemma":0.000090649024,"teacher_disagreement_score":0.048666522,"about_ca_system_score_codex":0.0002598291,"about_ca_system_score_gemma":0.0007443494,"threshold_uncertainty_score":0.36615908},"labels":[],"label_agreement":null},{"id":"W2965135759","doi":"10.1200/jco.2013.31.15_suppl.e20619","title":"Tumor-related symptoms (TRS) assessment in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with gefitinib or erlotinib: Preliminary results of an observational study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gefitinib; Erlotinib; Internal medicine; Lung cancer; Proportional hazards model; Oncology; Performance status; McNemar's test; Cancer; Epidermal growth factor receptor","score_opus":0.06981059494776864,"score_gpt":0.45693360202099204,"score_spread":0.3871230070732234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965135759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954018,0.000053024214,0.000014162666,0.00081081537,0.00022484448,0.0020672693,0.000032232558,0.000012247081,0.0013836337],"genre_scores_gemma":[0.9930462,0.00004288794,0.005637163,0.00039965662,0.00011534466,0.000143313,0.000060225528,0.00003642454,0.0005187806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581593,0.000328352,0.002685298,0.00034923226,0.0005349677,0.00028622098],"domain_scores_gemma":[0.9943623,0.000974186,0.0026720155,0.00026458828,0.0013831991,0.0003437031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007903194,0.0002455023,0.00137907,0.00018218608,0.000048414073,0.000010992679,0.00016673096,0.00018086635,0.00014901145],"category_scores_gemma":[0.00025623335,0.00013559386,0.0001297858,0.0003634166,0.00012544956,0.00032443213,0.000032315187,0.00072658877,0.0000023239384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032312535,0.017507954,0.9202297,0.000052369425,0.00087362685,0.00040069997,0.0006024022,0.0011716164,0.000024925306,0.0000035275098,0.000231557,0.026589138],"study_design_scores_gemma":[0.07066052,0.12291108,0.80328053,0.00049347675,0.0010281065,0.000028895254,0.00066119526,0.00065027253,0.000024681454,0.0000050537933,0.0001305608,0.00012561512],"about_ca_topic_score_codex":0.0005214346,"about_ca_topic_score_gemma":0.00040598345,"teacher_disagreement_score":0.11694911,"about_ca_system_score_codex":0.00046253417,"about_ca_system_score_gemma":0.0043151113,"threshold_uncertainty_score":0.7654822},"labels":[],"label_agreement":null},{"id":"W2965233712","doi":"10.1200/jco.2009.27.15_suppl.e19058","title":"Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Brain metastasis; Lung cancer; Oncology; Internal medicine; Cancer; Brain tumor; Metastasis; Pathology","score_opus":0.0587584564734445,"score_gpt":0.4711835553795538,"score_spread":0.4124250989061093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965233712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923368,0.0010430954,0.00014575025,0.004880802,0.0002446389,0.00027232736,0.00006693205,0.0000029447617,0.0010067137],"genre_scores_gemma":[0.9914321,0.00038512386,0.0060270666,0.00162015,0.00023054333,0.0000040891086,0.00001330161,0.000008249994,0.00027941522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984072,0.00009517884,0.0010990406,0.00013198522,0.00014641958,0.00012021893],"domain_scores_gemma":[0.99761933,0.0007717516,0.0010226072,0.000111163135,0.00024587451,0.00022924358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022245651,0.000117795134,0.0010548278,0.00006218026,0.000022787708,0.000004077336,0.000046351783,0.00010659451,0.00007889075],"category_scores_gemma":[0.00015600299,0.00006354389,0.00019084361,0.00005696531,0.00006652016,0.000056325804,0.000008431621,0.00017400041,8.3845447e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020431185,0.0030384834,0.90006715,0.0000127890735,0.0007985495,0.000100074794,0.00022121746,0.000017166964,0.000032588792,0.00000780474,0.0006470904,0.09301396],"study_design_scores_gemma":[0.023146974,0.022494271,0.9433479,0.000072486866,0.0028942178,0.00000740538,0.00006546896,0.00002431378,0.00010867484,0.00003407221,0.007743588,0.000060667535],"about_ca_topic_score_codex":0.00020881396,"about_ca_topic_score_gemma":0.000095982636,"teacher_disagreement_score":0.09295329,"about_ca_system_score_codex":0.00016844514,"about_ca_system_score_gemma":0.00082355307,"threshold_uncertainty_score":0.2591245},"labels":[],"label_agreement":null},{"id":"W2965372017","doi":"10.1200/jco.2013.31.15_suppl.6041","title":"Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); University Health Network; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Hôpital Notre-Dame; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre","funders":"","keywords":"Medicine; PTEN; Oncology; Internal medicine; Clinical endpoint; Immunohistochemistry; Clinical trial; PI3K/AKT/mTOR pathway; Apoptosis; Biology","score_opus":0.09366372852937581,"score_gpt":0.5018475318425942,"score_spread":0.4081838033132184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965372017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967452,0.00014971374,0.000113986396,0.00045488193,0.0005865079,0.0013069862,0.000060696155,0.0000015962422,0.00058039493],"genre_scores_gemma":[0.99724424,0.000061933744,0.0024252753,0.00005400531,0.00013753775,0.000019712083,0.000036235047,0.000009064441,0.0000119772085],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99571985,0.00068987336,0.0025213908,0.00013952113,0.0008166159,0.00011272602],"domain_scores_gemma":[0.9933444,0.0011238661,0.0032765924,0.00014939487,0.0019645256,0.00014117738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025219298,0.00010217567,0.0012427042,0.00018153567,0.000014684171,0.0000017953179,0.00008826363,0.00011909563,0.00040565204],"category_scores_gemma":[0.0035925356,0.000066341454,0.00025916935,0.00016445483,0.00019486807,0.00012456984,0.000023863005,0.00029887102,0.0000012150872],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31902772,0.058531605,0.034894764,0.000052171585,0.0036029047,0.000019512161,0.00070726254,0.000326422,0.00015757786,0.0000080259915,0.0011362799,0.58153576],"study_design_scores_gemma":[0.41225258,0.15909514,0.42097065,0.0004111979,0.0052646077,0.0000034383195,0.0002793859,0.0012199527,0.00007879737,0.00026971838,0.0001053461,0.000049200677],"about_ca_topic_score_codex":0.0001501417,"about_ca_topic_score_gemma":0.000021277223,"teacher_disagreement_score":0.5814865,"about_ca_system_score_codex":0.00018552496,"about_ca_system_score_gemma":0.0022792008,"threshold_uncertainty_score":0.44416055},"labels":[],"label_agreement":null},{"id":"W2965677886","doi":"10.1200/jco.2006.24.18_suppl.7161","title":"Identifying patients with non-small cell lung cancer (NSCLC) unlikely to benefit from erlotinib: An exploratory analysis of National Cancer of Institute of Canada Clinical Trials Group BR.21","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Lung cancer; Oncology; Proportional hazards model; Anemia; Weight loss; Erlotinib Hydrochloride; Placebo; Cancer; Clinical trial; Post-hoc analysis; Performance status; Epidermal growth factor receptor; Obesity; Pathology","score_opus":0.13256866154944452,"score_gpt":0.4964888718721104,"score_spread":0.36392021032266586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965677886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950487,0.000591042,0.0006190227,0.00053296454,0.0017368194,0.00045179803,0.00059499516,0.000002863698,0.0004218127],"genre_scores_gemma":[0.9937677,0.00022658583,0.0042521125,0.0006800106,0.0008253335,0.000024252095,0.00009861417,0.000020233958,0.00010519722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928397,0.00044964714,0.0052976958,0.00030540823,0.0008932803,0.00021425054],"domain_scores_gemma":[0.9893279,0.002049919,0.005641481,0.00022486769,0.0023607854,0.00039503945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032912793,0.00018932574,0.0030488789,0.0003478236,0.000043476553,0.0000061394176,0.00021711075,0.00025287722,0.00019967902],"category_scores_gemma":[0.0010292202,0.00013345215,0.0006573314,0.0005926769,0.00014182045,0.00019563093,0.000041090512,0.00040247047,2.8153846e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040121432,0.0032562646,0.9696851,0.00006288195,0.006286368,0.0000334751,0.00028892158,0.00578706,0.00018577723,0.000044457454,0.002108792,0.008248772],"study_design_scores_gemma":[0.013045475,0.0030621407,0.97103006,0.0003306223,0.009915379,7.1508674e-7,0.00017180851,0.00023813215,0.00018769862,0.0000477252,0.0018493421,0.00012088845],"about_ca_topic_score_codex":0.12689085,"about_ca_topic_score_gemma":0.53329504,"teacher_disagreement_score":0.4064042,"about_ca_system_score_codex":0.0005827439,"about_ca_system_score_gemma":0.011450684,"threshold_uncertainty_score":0.9941535},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2966105499","doi":"10.1200/jco.2013.31.15_suppl.e22159","title":"NSCLC driver mutations in the Quebec population: Epidemiologic and clinical evaluation.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; KRAS; Lung cancer; Oncology; Population; Internal medicine; Cohort; Cancer; Disease; Pathology; Colorectal cancer; Environmental health","score_opus":0.20462822897206867,"score_gpt":0.5768968645618086,"score_spread":0.3722686355897399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966105499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94961375,0.00058927614,0.00020578338,0.043968253,0.00072812673,0.00058297365,0.000001114415,0.0000043942077,0.004306335],"genre_scores_gemma":[0.9877098,0.00030402603,0.005825195,0.005190952,0.0007162754,0.000024521445,0.0000104252495,0.000005152214,0.00021361452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957166,0.0015333137,0.0022084892,0.00014292097,0.00027192227,0.00012676364],"domain_scores_gemma":[0.9917587,0.006412865,0.0010210639,0.00014853964,0.0004920911,0.00016673401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071377116,0.00008156176,0.00075329526,0.00007989719,0.000053752938,0.000012978169,0.000089688416,0.00024218664,0.00040609576],"category_scores_gemma":[0.008268736,0.0000422509,0.0002577267,0.00012743892,0.00017224491,0.00016968838,0.00001720135,0.00061100075,0.000031860138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008729155,0.0005482164,0.5902105,0.0000030688957,0.00015381209,0.00003553326,0.0001404573,0.000022239292,6.9184466e-7,0.0005027652,0.004448766,0.40384665],"study_design_scores_gemma":[0.005026556,0.0021673434,0.97777873,0.000032774667,0.00072162575,0.00013680969,0.00038538603,0.0007233485,9.259504e-8,0.0052111014,0.0077754674,0.00004074746],"about_ca_topic_score_codex":0.0010648916,"about_ca_topic_score_gemma":0.0011713746,"teacher_disagreement_score":0.4038059,"about_ca_system_score_codex":0.00015542987,"about_ca_system_score_gemma":0.0010778822,"threshold_uncertainty_score":0.98990464},"labels":[],"label_agreement":null},{"id":"W2966347344","doi":"10.1002/cncr.32422","title":"Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population‐based reflex testing","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Southlake Regional Health Center; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McGill University","funders":"Princess Margaret Cancer Foundation","keywords":"Anaplastic lymphoma kinase; Medicine; Immunohistochemistry; Lung cancer; Crizotinib; Fluorescence in situ hybridization; Population; Oncology; Pathology; Internal medicine; Biology","score_opus":0.024295351346164316,"score_gpt":0.3461724267988076,"score_spread":0.32187707545264327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966347344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845207,0.0017799315,0.0000017273093,0.00055626524,0.00025734078,0.00081143714,0.00032623167,0.00005076066,0.011695642],"genre_scores_gemma":[0.9973341,0.000028225657,0.00038075267,0.0006308143,0.00009247638,0.00052091124,0.0003455957,0.000039813433,0.00062728126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982076,0.000044688677,0.00046793866,0.00051910634,0.00022754453,0.00053312234],"domain_scores_gemma":[0.9983048,0.00070531666,0.0001748583,0.0003688514,0.00017813047,0.0002680469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015023262,0.00024368243,0.00033921353,0.00029313992,0.00009335007,0.00003206749,0.00011877489,0.0001264922,0.00016972669],"category_scores_gemma":[0.0021805342,0.00024205164,0.00003687125,0.00088549487,0.000027644759,0.000108184555,0.000022512744,0.00021402292,0.000018669045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019459405,0.00010590612,0.9797767,0.0002609874,0.00003861969,0.00026552868,0.00023593777,0.0026757496,0.0019861776,0.000009004818,0.0002455429,0.014205265],"study_design_scores_gemma":[0.007206359,0.00013800025,0.9777024,0.0055138147,0.00011259446,0.000016429516,0.00008198209,0.008007426,0.0002711701,0.000018106326,0.000628359,0.0003033891],"about_ca_topic_score_codex":0.6220404,"about_ca_topic_score_gemma":0.24227461,"teacher_disagreement_score":0.37976578,"about_ca_system_score_codex":0.0063263266,"about_ca_system_score_gemma":0.0035882285,"threshold_uncertainty_score":0.9974882},"labels":[],"label_agreement":null},{"id":"W2966390396","doi":"10.1200/jco.2007.25.18_suppl.6601","title":"Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Ottawa Hospital; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Nomogram; Internal medicine; Odds ratio; Clinical trial; Confidence interval; Statistical significance; Bootstrapping (finance); Surgery; Oncology","score_opus":0.11376492601828507,"score_gpt":0.5547181847297264,"score_spread":0.44095325871144136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966390396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942973,0.00012008783,0.0003946345,0.0010447621,0.0020693857,0.0014476199,0.000030264282,0.0000071363697,0.00058877165],"genre_scores_gemma":[0.99375916,0.00016078756,0.0036210294,0.001846738,0.000416934,0.000013534138,0.000031687392,0.000023685869,0.00012644396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9877996,0.0015122471,0.009350153,0.0003180728,0.0006237332,0.00039620223],"domain_scores_gemma":[0.99252987,0.0023450728,0.0035295873,0.00027100998,0.00056629337,0.0007581422],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01829783,0.00021202819,0.0032823354,0.0005194266,0.00003088663,0.0000024368007,0.00021867028,0.0005541899,0.00015896231],"category_scores_gemma":[0.01908824,0.00015565722,0.001010679,0.00050456414,0.00010254669,0.00012869878,0.00008414841,0.000924441,0.0000121933135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030184157,0.02984079,0.6984451,0.000020333853,0.0008547301,0.00097036257,0.00035566321,0.00006167251,0.000062235704,0.0000053913463,0.0007735767,0.23842598],"study_design_scores_gemma":[0.13629805,0.052615482,0.7990373,0.00023766184,0.0007080534,0.000015221885,0.00011690526,0.000059534876,0.00004201404,0.00006522963,0.010694418,0.000110151654],"about_ca_topic_score_codex":0.000074285475,"about_ca_topic_score_gemma":0.0001636362,"teacher_disagreement_score":0.23831584,"about_ca_system_score_codex":0.00042419764,"about_ca_system_score_gemma":0.0015860788,"threshold_uncertainty_score":0.98917437},"labels":[],"label_agreement":null},{"id":"W2966880369","doi":"10.1093/noajnl/vdz014.046","title":"THER-03. USING SUCCESSIVE EGF RECEPTOR ANTAGONISTS TO TREAT A PATIENT WITH EXTENSIVE METASTATIC DISEASE: CASE REPORT AND REVIEW OF THE LITERATURE","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Lesion; Pathology; Biopsy; Progressive disease; Adenocarcinoma; Radiology; Oncology; Internal medicine; Cancer; Disease","score_opus":0.010495578003000184,"score_gpt":0.34199001570576193,"score_spread":0.33149443770276177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966880369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934721,0.058177218,0.000013771975,0.004074163,0.0003146666,0.0021219898,0.000112363676,0.000014771624,0.00045007502],"genre_scores_gemma":[0.9824608,0.0069044214,0.0026811915,0.007242917,0.000055606146,0.00018618362,0.00005045394,0.000033149554,0.00038528934],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989809,0.00011881222,0.00025679416,0.00033483567,0.00016094615,0.00014772476],"domain_scores_gemma":[0.99873894,0.00020035477,0.00029329318,0.0003425785,0.00029441412,0.00013040885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048229736,0.00016081713,0.00040517477,0.000043303506,0.00009230398,0.000008836317,0.00004214369,0.000021940761,0.00004880421],"category_scores_gemma":[0.00023685528,0.00008300708,0.00005832359,0.00023298789,0.00010524795,0.0001259443,0.000036849968,0.000110578825,0.000002766311],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006979506,0.002764766,0.11658243,0.03109903,0.0015566024,0.643034,0.016863396,0.00058371044,0.051200107,0.00037786923,0.0046091084,0.124349505],"study_design_scores_gemma":[0.014602899,0.017433664,0.011742407,0.054003786,0.013324381,0.5269163,0.00596348,0.00011720408,0.02295515,0.00026538255,0.33130088,0.0013744244],"about_ca_topic_score_codex":0.000020111904,"about_ca_topic_score_gemma":0.00001988281,"teacher_disagreement_score":0.32669178,"about_ca_system_score_codex":0.0000961977,"about_ca_system_score_gemma":0.00032951473,"threshold_uncertainty_score":0.33849305},"labels":[],"label_agreement":null},{"id":"W2966944913","doi":"10.1200/jco.2009.27.15_suppl.3552","title":"Dual epidermal growth factor receptor (EGFR) inhibition: Phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cetuximab; Medicine; Erlotinib; Rash; Mucositis; Epidermal growth factor receptor; Internal medicine; Neutropenia; Toxicity; Pharmacology; Oncology; Cancer; Colorectal cancer","score_opus":0.08132331328723262,"score_gpt":0.5071893561485397,"score_spread":0.425866042861307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966944913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880813,0.00026306586,0.000033575117,0.009391489,0.00062825787,0.0005103028,0.000008952521,0.000014244397,0.0010688225],"genre_scores_gemma":[0.99495995,0.00017288307,0.0018783798,0.002237043,0.00063344033,0.0000073832175,0.000007866047,0.000013600278,0.000089471876],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965565,0.00033931786,0.002320485,0.0002394509,0.00028336686,0.00026083706],"domain_scores_gemma":[0.9971513,0.0008965556,0.0011492305,0.00011521355,0.0003019346,0.0003857266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011437841,0.00016928515,0.0014992993,0.00018279393,0.00006469963,0.0000134108905,0.000054615735,0.0001760695,0.00011227776],"category_scores_gemma":[0.0017836494,0.00012552446,0.00019503267,0.00017159845,0.000109682725,0.00024914663,0.000024686446,0.0008222177,0.000007471571],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018155443,0.059008066,0.33285135,0.00005800837,0.00095768395,0.009061008,0.0062111267,0.00002994562,0.002015153,0.00036569446,0.0029407989,0.5683457],"study_design_scores_gemma":[0.12252947,0.112868086,0.755841,0.0003256389,0.0005714085,0.0008258312,0.0027867458,0.000051160274,0.00034296417,0.00061904953,0.0030149461,0.0002236755],"about_ca_topic_score_codex":0.000011428926,"about_ca_topic_score_gemma":0.00001672838,"teacher_disagreement_score":0.568122,"about_ca_system_score_codex":0.0002140583,"about_ca_system_score_gemma":0.0009513605,"threshold_uncertainty_score":0.5118739},"labels":[],"label_agreement":null},{"id":"W2967034948","doi":"10.1200/jco.2007.25.18_suppl.3594","title":"A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Rash; Pharmacokinetics; Erlotinib; Pharmacodynamics; Toxicity; Internal medicine; Adverse effect; Gastroenterology; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.07361737481403348,"score_gpt":0.5449734878466853,"score_spread":0.47135611303265185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967034948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959854,0.00082568644,0.00016680273,0.0011719752,0.00044543284,0.0006750577,0.000008358573,0.000006892477,0.0007144198],"genre_scores_gemma":[0.99713606,0.0007441246,0.0011952047,0.00042045748,0.00020501498,0.0000067667957,0.0000028004645,0.00001475695,0.00027480486],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99711186,0.00020096207,0.0020160696,0.0002006677,0.0002608209,0.00020959525],"domain_scores_gemma":[0.997001,0.0011000383,0.001245609,0.000096238284,0.00028019267,0.00027691695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019615788,0.00014263252,0.0010117576,0.00023810823,0.000033942677,0.000005947528,0.00006368443,0.00012220259,0.000042359217],"category_scores_gemma":[0.00048182125,0.000107758875,0.0000997719,0.00019306253,0.00014760025,0.00016727082,0.00003423651,0.00046592555,8.62442e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026019663,0.029265344,0.22654215,0.00017372373,0.0009775651,0.0019638638,0.0038260831,0.00018082974,0.029818766,0.000038609516,0.0001580595,0.68103534],"study_design_scores_gemma":[0.11310177,0.05170869,0.8246305,0.00016631659,0.0014034994,0.00021831281,0.0036964444,0.0009347645,0.00034901415,0.00006145201,0.0035988968,0.0001303532],"about_ca_topic_score_codex":0.000046100435,"about_ca_topic_score_gemma":0.00013720745,"teacher_disagreement_score":0.680905,"about_ca_system_score_codex":0.000113461436,"about_ca_system_score_gemma":0.00043704905,"threshold_uncertainty_score":0.4394279},"labels":[],"label_agreement":null},{"id":"W2967188221","doi":"10.1117/12.2526056","title":"Modelling novel PDT approaches to target peripheral lung cancers (Conference Presentation)","year":2019,"lang":"en","type":"article","venue":"17th International Photodynamic Association World Congress","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Presentation (obstetrics); Computer science; Peripheral; Lung; Medicine; Radiology; Internal medicine","score_opus":0.0384193122603583,"score_gpt":0.30373675849782056,"score_spread":0.26531744623746223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967188221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74556977,0.00010853256,0.04561026,0.011740275,0.0058194655,0.0029681714,0.00061661156,0.00024663555,0.18732026],"genre_scores_gemma":[0.86916894,0.000009745811,0.0047755465,0.00069719943,0.00019749094,0.00023565379,0.0006680582,0.000032010747,0.12421535],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99813753,0.000027277316,0.00037460792,0.00044915636,0.0007079461,0.0003034569],"domain_scores_gemma":[0.99886525,0.000084411105,0.00028609115,0.00021281664,0.0004000861,0.00015134431],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015671182,0.0002126649,0.00028059084,0.0002619634,0.00009804183,0.00013328303,0.00019963794,0.00007467655,0.0011201648],"category_scores_gemma":[0.000036206035,0.00021145437,0.00012369179,0.00030195274,0.000017344302,0.00033601196,0.000055162058,0.00019808862,0.00010466756],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040212038,0.00042062075,0.30511338,0.000108300956,0.0024331259,0.000015850823,0.00217826,0.6605158,0.0014260797,0.021631869,0.004826365,0.0009282508],"study_design_scores_gemma":[0.0026434015,0.000048307833,0.013195025,0.00016726794,0.00014596256,0.000006606175,0.00027874514,0.97037405,0.0003715261,0.0002791783,0.012213651,0.00027630434],"about_ca_topic_score_codex":0.0007384811,"about_ca_topic_score_gemma":0.00038591074,"teacher_disagreement_score":0.30985823,"about_ca_system_score_codex":0.0041191014,"about_ca_system_score_gemma":0.00038727943,"threshold_uncertainty_score":0.99979293},"labels":[],"label_agreement":null},{"id":"W2967470466","doi":"10.1093/noajnl/vdz014.063","title":"MLTI-04. EVOLUTION OF TREATMENT PARADIGMS FOR PATIENTS WITH ≥1 BRAIN METASTASES FROM PRIMARY NON-SMALL-CELL LUNG CANCER – A SYSTEMATIC REVIEW","year":2019,"lang":"en","type":"review","venue":"Neuro-Oncology Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Randomized controlled trial; Temozolomide; non-small cell lung cancer (NSCLC); Adverse effect; Meta-analysis; Incidence (geometry); Progression-free survival; Clinical trial; Overall survival; Radiation therapy","score_opus":0.022577595142530504,"score_gpt":0.3658963861898324,"score_spread":0.3433187910473019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967470466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000077592966,0.9755879,0.00023100052,0.0001041756,0.00054352684,0.020421268,0.0026925907,0.00003444121,0.00030749742],"genre_scores_gemma":[0.000028025393,0.98441434,0.0013618194,0.00047821377,0.00010387849,0.010580414,0.0025531512,0.00009293385,0.000387226],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713075,0.00034164995,0.001149595,0.0007678592,0.00024627347,0.0003638956],"domain_scores_gemma":[0.99529254,0.0018681214,0.0017977819,0.0006689542,0.00023998151,0.00013264266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012392178,0.00067179726,0.0053752107,0.00017314185,0.000086088905,0.000008556447,0.00018769132,0.00020495677,0.000044281467],"category_scores_gemma":[0.00012514723,0.0003946604,0.00063944457,0.00024307166,0.000089114284,0.00013783485,0.000032850323,0.00017339406,0.000011308408],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013378258,0.0010404512,0.00055029895,0.93162155,0.0025477314,0.000018611092,0.00007609979,0.000011195424,0.0000029751382,0.000012919315,0.0008776642,0.0631067],"study_design_scores_gemma":[0.0047019385,0.004477854,0.00003996145,0.31348342,0.08174236,0.000016747908,0.0000165726,0.000008131164,0.000004118676,0.0000054937136,0.5951663,0.0003370726],"about_ca_topic_score_codex":0.00013081146,"about_ca_topic_score_gemma":0.000099191384,"teacher_disagreement_score":0.61813813,"about_ca_system_score_codex":0.0024891766,"about_ca_system_score_gemma":0.0028450526,"threshold_uncertainty_score":0.9998505},"labels":[],"label_agreement":null},{"id":"W2968378128","doi":"10.1002/ijc.32617","title":"Osimertinib confers potent binding affinity to EGFR kinase domain duplication","year":2019,"lang":"en","type":"letter","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"National Natural Science Foundation of China","keywords":"Osimertinib; Afatinib; Gefitinib; Erlotinib; Epidermal growth factor receptor; Tyrosine kinase; Cancer research; Medicine; Protein kinase domain; Kinase; Exon; Lung cancer; Gene duplication; Cancer; Pharmacology; Oncology; Internal medicine; Biology; Receptor; Genetics; Mutant; Gene","score_opus":0.021819753276462697,"score_gpt":0.3740240243295644,"score_spread":0.3522042710531017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968378128","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04867807,0.0010143166,0.00092050724,0.9400785,0.006132475,0.00053263165,0.00037362744,0.000018968316,0.0022509089],"genre_scores_gemma":[0.22488168,0.00058757165,0.0018481299,0.75148654,0.015644431,0.0001023668,0.0005593802,0.000110264285,0.004779653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979003,0.00003655669,0.00059482525,0.00023393014,0.0010234498,0.00021095894],"domain_scores_gemma":[0.99763817,0.00011803734,0.00069252093,0.0002009698,0.0012347461,0.0001155571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014451245,0.00022669394,0.00042032107,0.000507078,0.00003759986,0.00007170176,0.00031823188,0.0002237317,0.0006398474],"category_scores_gemma":[0.00006807431,0.0001823622,0.0002936728,0.00011675483,0.000031364885,0.00012746453,0.00004406489,0.00074695866,0.00013411374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004819806,0.00012384754,0.0025732606,0.000060697745,0.003011487,0.000875739,0.000463239,0.00020067739,0.0018322851,0.000115429604,0.9757315,0.01452988],"study_design_scores_gemma":[0.0026013658,0.0001995637,0.004855403,0.001004474,0.0007395316,0.00019766734,0.00008593094,0.0000065798517,0.0013327338,0.00012226366,0.98866487,0.00018961488],"about_ca_topic_score_codex":0.00022587007,"about_ca_topic_score_gemma":0.000017201763,"teacher_disagreement_score":0.18859197,"about_ca_system_score_codex":0.002224243,"about_ca_system_score_gemma":0.0009555937,"threshold_uncertainty_score":0.7436515},"labels":[],"label_agreement":null},{"id":"W2968495081","doi":"10.1634/theoncologist.2019-0297","title":"Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with<i>RAS/RAF</i>Alterations","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; Array BioPharma","keywords":"KRAS; Medicine; Neuroblastoma RAS viral oncogene homolog; MEK inhibitor; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Toxicity; Phases of clinical research; Pharmacology; Colorectal cancer; MAPK/ERK pathway; Kinase","score_opus":0.009872657720289805,"score_gpt":0.3163407426654571,"score_spread":0.3064680849451673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968495081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946492,0.00011134847,0.000015332902,0.00036727334,0.00007727388,0.0043044523,0.00003705981,0.000034673867,0.00040343578],"genre_scores_gemma":[0.9987894,0.000019421706,0.0003474029,0.00015490972,0.000029900682,0.00032844907,0.00011308124,0.000030187506,0.00018723466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986803,0.000094668496,0.0003451528,0.00032434895,0.0003517685,0.00020376487],"domain_scores_gemma":[0.9988884,0.00013364942,0.00029020492,0.00033530686,0.00027432264,0.00007815511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014024532,0.00022641553,0.0004390922,0.0001128471,0.00013461348,0.000031164567,0.000078693796,0.00004226327,0.000025999578],"category_scores_gemma":[0.000019582885,0.00011673631,0.000019700556,0.00041357824,0.00018773178,0.0002029881,0.000022542867,0.00016072713,0.0000024630694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016312726,0.028998153,0.9314007,0.00006812712,0.00040560975,0.00003829009,0.008857426,0.0003489198,0.0011861258,0.00013950451,0.000110016364,0.012134411],"study_design_scores_gemma":[0.16218482,0.113033034,0.70665556,0.00045297583,0.0004194385,0.000010266822,0.0058632893,0.00013482837,0.010597373,0.00001837958,0.00029267275,0.00033733808],"about_ca_topic_score_codex":0.00018565745,"about_ca_topic_score_gemma":0.00028523643,"teacher_disagreement_score":0.22474511,"about_ca_system_score_codex":0.00014733104,"about_ca_system_score_gemma":0.00023188627,"threshold_uncertainty_score":0.47603685},"labels":[],"label_agreement":null},{"id":"W2970542184","doi":"10.3747/co.26.5137","title":"Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; University of Ottawa; Calgary Laboratory Services; Saskatchewan Health; Saskatchewan Health Authority; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Institut universitaire de cardiologie et de pneumologie de Québec; University of Manitoba; St. Joseph’s Healthcare Hamilton; University of Calgary; Princess Margaret Cancer Centre; Alberta Cancer Foundation; Jewish General Hospital; University of Alberta; University of Saskatchewan; Université de Montréal; Dalhousie University; Canadian Red Cross Society","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Oncology; Adenocarcinoma; Cancer research; Internal medicine; Clinical trial; Targeted therapy; Cancer; Tyrosine kinase; Tyrosine-kinase inhibitor","score_opus":0.020749372668726094,"score_gpt":0.39353896156635976,"score_spread":0.37278958889763364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970542184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722249,0.0027242799,0.00002274735,0.0013042436,0.00081839634,0.0012912154,0.0001260915,0.000011772427,0.021476349],"genre_scores_gemma":[0.99885464,0.00025969892,0.00013966372,0.00013483822,0.0000732696,0.00018253372,0.00009781362,0.000016298067,0.00024124056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909526,0.000038209124,0.00021439593,0.00027860794,0.000088856796,0.0002846867],"domain_scores_gemma":[0.9992867,0.000046540576,0.00011761673,0.00012963776,0.00025530445,0.00016421152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006053243,0.00012965655,0.00034121383,0.000259751,0.000032331933,0.0000035710439,0.000041185256,0.00008112585,0.00016436288],"category_scores_gemma":[0.000019627003,0.0001221446,0.000066171364,0.00023712391,0.000044013694,0.000060940685,0.000016291577,0.00021053254,0.000018313749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039005248,0.0014591796,0.9525291,0.00034508845,0.00014242911,0.00010613464,0.020590218,0.00027578976,0.0062054796,0.0013612764,0.0011767951,0.015418463],"study_design_scores_gemma":[0.024894783,0.0033903243,0.9248186,0.0018808756,0.0010008897,0.000038542526,0.02075645,0.0014035845,0.01409303,0.00030516955,0.0068940255,0.0005237364],"about_ca_topic_score_codex":0.04772615,"about_ca_topic_score_gemma":0.08619702,"teacher_disagreement_score":0.038470864,"about_ca_system_score_codex":0.0031252087,"about_ca_system_score_gemma":0.002380309,"threshold_uncertainty_score":0.9586151},"labels":[],"label_agreement":null},{"id":"W2971565273","doi":"10.1093/neuonc/noz126.346","title":"P14.111 Successful treatment of extensive metastatic disease with successive use of two different EGF receptor antagonists: case report and review of the literature","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Lesion; Progressive disease; Adenocarcinoma; Biopsy; Pathology; Radiology; Oncology; Internal medicine; Cancer; Disease","score_opus":0.019081788891445513,"score_gpt":0.3480427698820698,"score_spread":0.32896098099062426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971565273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98336375,0.011730088,0.0000056953468,0.0023530442,0.0002172585,0.0018712322,0.0003518225,0.0000079636775,0.00009912991],"genre_scores_gemma":[0.99024457,0.008263867,0.000309593,0.000684712,0.000028048658,0.000107145104,0.00012426944,0.000021982287,0.00021583657],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9986616,0.00019194075,0.0004873548,0.00031874867,0.00019691026,0.00014347608],"domain_scores_gemma":[0.99776804,0.0004036861,0.0006801049,0.000557498,0.00045332103,0.00013734573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045249548,0.00020385042,0.0008217362,0.00006473091,0.000037739388,0.000006628522,0.00004960513,0.000031600524,0.000085031694],"category_scores_gemma":[0.00017289273,0.00010107279,0.00013499636,0.00020962994,0.00020030835,0.000080997845,0.00003528681,0.00008842063,8.018536e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00818899,0.010620672,0.6748782,0.029383082,0.00476591,0.16164802,0.008829176,0.00004645057,0.07251142,0.0011049829,0.0025727162,0.02545039],"study_design_scores_gemma":[0.0934143,0.091674395,0.19293138,0.05934383,0.06653708,0.21042587,0.0042646783,0.0002690426,0.14168046,0.00034926343,0.1371538,0.0019558868],"about_ca_topic_score_codex":0.00020685211,"about_ca_topic_score_gemma":0.00005990834,"teacher_disagreement_score":0.48194683,"about_ca_system_score_codex":0.00016469383,"about_ca_system_score_gemma":0.0005007691,"threshold_uncertainty_score":0.41216287},"labels":[],"label_agreement":null},{"id":"W2971814790","doi":"10.1111/ajco.13234","title":"Impact of Asian ethnicity on outcome in metastatic EGFR‐mutant non–small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Brain metastasis; Lung cancer; Oncology; Univariate analysis; Cohort; Proportional hazards model; Cancer; Population; Metastasis; Multivariate analysis; Confidence interval","score_opus":0.07858565461785147,"score_gpt":0.5110388023357402,"score_spread":0.4324531477178887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971814790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96407217,0.00040899497,0.000072196555,0.0028540033,0.0011716463,0.0006142909,0.000029670568,0.0000057349175,0.030771287],"genre_scores_gemma":[0.996763,0.00039017704,0.0012160081,0.00027913088,0.00020841211,0.000009681345,0.0000051754614,0.000027171167,0.0011012801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622154,0.00034757578,0.0024681285,0.00026606992,0.00034275008,0.00035391847],"domain_scores_gemma":[0.9963011,0.0010361945,0.0016669392,0.0003211036,0.00032228162,0.00035237859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015702315,0.0002250798,0.0019010768,0.00030115008,0.000021491489,0.0000068340687,0.00018289158,0.0002442438,0.00057550595],"category_scores_gemma":[0.00042686114,0.00014410308,0.00082419906,0.00029364362,0.00011484413,0.00009108687,0.000029511411,0.0010598864,0.000035274792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021875785,0.0031185674,0.9655446,0.00011201233,0.0010297742,0.0005112118,0.00075440656,0.00034817966,0.00067349686,0.00004062708,0.0007195495,0.02496],"study_design_scores_gemma":[0.015049743,0.014767703,0.96426505,0.0003185837,0.00133685,0.00014403558,0.0011093059,0.0002414199,0.00021746133,0.00009386558,0.0023034855,0.00015249105],"about_ca_topic_score_codex":0.00030589759,"about_ca_topic_score_gemma":0.00012663541,"teacher_disagreement_score":0.03269079,"about_ca_system_score_codex":0.0008389156,"about_ca_system_score_gemma":0.0031519758,"threshold_uncertainty_score":0.6301387},"labels":[],"label_agreement":null},{"id":"W2973064182","doi":"10.21037/tlcr.2019.09.04","title":"PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oceanography; Oncology; Intensive care medicine; Geology","score_opus":0.10090366445901688,"score_gpt":0.4873284687816115,"score_spread":0.38642480432259463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973064182","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009899496,0.98334444,0.00005181866,0.0006536172,0.00020504232,0.0068715,0.00064666726,0.000018186578,0.007218793],"genre_scores_gemma":[0.004287786,0.9866992,0.0003498178,0.000025214385,0.00033719954,0.0044018384,0.0005261902,0.000098856355,0.0032738799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962873,0.0003235151,0.0008588211,0.0007019224,0.0011481373,0.0006803],"domain_scores_gemma":[0.9976721,0.0009989402,0.000235498,0.0005800617,0.00038280824,0.00013060181],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005631948,0.00048118684,0.0014566506,0.00055868004,0.00017330128,0.000045196157,0.00033570753,0.00026125906,0.0003896431],"category_scores_gemma":[0.000011677243,0.00030022208,0.0005407033,0.0011630822,0.00013992576,0.0000977717,0.000016795171,0.0006381513,0.000017489027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026956803,0.0010327337,0.0073390524,0.042813703,0.001326137,0.000059654398,0.006597208,0.00059394265,0.000016395785,0.00023689936,0.0005189213,0.9391958],"study_design_scores_gemma":[0.0056489496,0.00078221346,0.001991928,0.03237949,0.0047013275,0.000012611911,0.0005081522,0.0008589782,0.000042884556,0.00003855084,0.95249057,0.000544367],"about_ca_topic_score_codex":0.0020842191,"about_ca_topic_score_gemma":0.0009770314,"teacher_disagreement_score":0.95197165,"about_ca_system_score_codex":0.0015198585,"about_ca_system_score_gemma":0.005646978,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W2977494420","doi":"10.1093/annonc/mdz260.104","title":"Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Ottawa Hospital; BC Cancer Agency; Saskatchewan Cancer Agency; Mount Sinai Hospital; University of Alberta; William Osler Health System; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Oncology","score_opus":0.054708360670253926,"score_gpt":0.4109913126050792,"score_spread":0.3562829519348253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977494420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98501515,0.000421311,0.00004505895,0.011106976,0.000023583343,0.00027309812,0.000012838381,0.0000013755496,0.00310061],"genre_scores_gemma":[0.99894273,0.000040373245,0.00026848156,0.000513401,0.000013274393,0.00000644231,0.0000033563879,0.000004582028,0.00020735052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996479,0.000024424087,0.00009740124,0.00006008648,0.000074850854,0.00009533127],"domain_scores_gemma":[0.99958503,0.00014235887,0.00007854352,0.00010939856,0.00005615677,0.000028490822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010017343,0.000050605468,0.0001817368,0.000016940834,0.00001678928,0.0000017693528,0.00004116524,0.000017092023,0.000021037038],"category_scores_gemma":[0.000011853376,0.000021139056,0.000019829331,0.00006385813,0.000045987414,0.000022922713,0.0000093068165,0.00005393929,2.1228831e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067476236,0.00014363714,0.81450945,0.000050917595,0.0008859988,0.00001283638,0.011810117,0.05519514,0.00062639185,0.00036943378,0.006055571,0.10966574],"study_design_scores_gemma":[0.0032234467,0.0023009637,0.9620497,0.00008145829,0.00012649166,0.000023033359,0.002878607,0.02763116,0.00013240574,0.00030671724,0.0011757803,0.00007021877],"about_ca_topic_score_codex":0.6472733,"about_ca_topic_score_gemma":0.53688896,"teacher_disagreement_score":0.14754026,"about_ca_system_score_codex":0.00006832528,"about_ca_system_score_gemma":0.0024318993,"threshold_uncertainty_score":0.4715616},"labels":[],"label_agreement":null},{"id":"W2977714774","doi":"10.14309/00000434-201610001-01639","title":"Severe Erosive Esophagitis Induced by Crizotinib Therapy: A Case Report and Review of the Literature","year":2016,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Crizotinib; Medicine; Odynophagia; Esophagitis; Nausea; Anaplastic lymphoma kinase; Vomiting; Adverse effect; Internal medicine; Lung cancer; Surgery; Dermatology; Esophagus","score_opus":0.009353558057199368,"score_gpt":0.30032937192424136,"score_spread":0.29097581386704197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977714774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96058947,0.00887988,0.000038685048,0.030130109,0.00009601811,0.00020119714,0.000034328583,0.000002585399,0.000027722204],"genre_scores_gemma":[0.9843696,0.008787457,0.00012335849,0.0065323147,0.00007076323,0.000006514832,0.0000014307502,0.000010032343,0.00009857762],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9990696,0.00020587613,0.000363351,0.0000949534,0.0001310127,0.00013525064],"domain_scores_gemma":[0.998476,0.000073820294,0.00089408935,0.0002453307,0.00023766924,0.00007306114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021498457,0.00010065785,0.00043644523,0.00003359864,0.000046609952,0.000004848897,0.00009425732,0.000015399373,0.000025719355],"category_scores_gemma":[0.00008792582,0.00003708422,0.0001253898,0.00010964272,0.00030099403,0.00004759068,0.000028145327,0.00015044416,3.1818914e-7],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024890129,0.0015010564,0.45831412,0.001134115,0.008535462,0.058939856,0.009110046,8.273995e-7,0.06723365,0.00006892792,0.06452817,0.30574363],"study_design_scores_gemma":[0.0052142707,0.01794613,0.052653767,0.006340971,0.00086062873,0.9132276,0.00047460583,2.0770956e-7,0.00090351654,0.000087689434,0.002214692,0.00007587667],"about_ca_topic_score_codex":0.000025486366,"about_ca_topic_score_gemma":0.0000042814786,"teacher_disagreement_score":0.8542878,"about_ca_system_score_codex":0.000038180646,"about_ca_system_score_gemma":0.00007860857,"threshold_uncertainty_score":0.15122508},"labels":[],"label_agreement":null},{"id":"W2978209786","doi":"10.1093/annonc/mdz260.108","title":"Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Ceritinib; Alectinib; Anaplastic lymphoma kinase; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; ALK inhibitor; Surrogate endpoint; Lung cancer; Tolerability; Clinical trial; Adverse effect; Chemotherapy","score_opus":0.025899461003756574,"score_gpt":0.3862981845905549,"score_spread":0.36039872358679836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978209786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98815525,0.00022822645,0.000007722279,0.00030246744,0.0002766365,0.0045281705,0.00013586547,0.000024275665,0.006341407],"genre_scores_gemma":[0.9981478,0.00007394788,0.00019620145,0.0005724033,0.000038393056,0.0004629839,0.00012276963,0.000051620063,0.00033386637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977592,0.00014172289,0.0006240809,0.00058831036,0.00039530415,0.000491353],"domain_scores_gemma":[0.99785656,0.00029698524,0.00069328205,0.00040589555,0.0005669945,0.00018030267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014888767,0.0003446934,0.0010346164,0.00031010475,0.0000625292,0.00000784545,0.00015189414,0.00014212182,0.00011491441],"category_scores_gemma":[0.000044092278,0.00027211805,0.00010342163,0.00044760297,0.00011265203,0.00013553383,0.000047635713,0.00017696182,0.000007777892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06169685,0.093074046,0.63236386,0.00070313487,0.0018089622,0.00034934844,0.018438237,0.0008078594,0.0018469207,0.00002885922,0.0008404281,0.18804151],"study_design_scores_gemma":[0.22512068,0.23634753,0.49119994,0.001622842,0.0012124274,0.000008387963,0.004055684,0.0003458881,0.038500957,0.000008426325,0.0010723418,0.0005049126],"about_ca_topic_score_codex":0.00095739606,"about_ca_topic_score_gemma":0.0009669933,"teacher_disagreement_score":0.1875366,"about_ca_system_score_codex":0.00025319742,"about_ca_system_score_gemma":0.00088854734,"threshold_uncertainty_score":0.9999731},"labels":[],"label_agreement":null},{"id":"W2978821371","doi":"10.1093/annonc/mdz260.065","title":"Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Crizotinib; Refractory (planetary science); Gastroenterology; Stock options; Randomized controlled trial; Surgery; Lung cancer","score_opus":0.038170941786937855,"score_gpt":0.41940971598255955,"score_spread":0.3812387741956217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978821371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90697455,0.000051704792,0.00000253072,0.008382759,0.00029175548,0.0018296079,0.00003241755,0.000009833079,0.082424834],"genre_scores_gemma":[0.99590534,0.000032672386,0.00012459458,0.0030000948,0.00012488135,0.00013405007,0.000148567,0.000021270216,0.00050855684],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984555,0.00014880615,0.00048909144,0.00029703256,0.00026900155,0.00034053597],"domain_scores_gemma":[0.999011,0.0001320923,0.00026079692,0.00036044963,0.00014240784,0.00009325371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031904058,0.00017592977,0.00054700446,0.00019286302,0.00004929328,0.0000071136415,0.00016073219,0.00015076243,0.00020488448],"category_scores_gemma":[0.000088266956,0.00011313265,0.000086228174,0.0002959082,0.00010307378,0.00012077315,0.000031946365,0.00027611424,0.000032232725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10639944,0.047346905,0.11889959,0.00021197193,0.0007181551,0.00042214274,0.041168198,0.00001881774,0.00050608115,0.0007564528,0.017305737,0.66624653],"study_design_scores_gemma":[0.3956721,0.14012238,0.23477077,0.0004240126,0.00027375174,0.000027024216,0.0037212705,0.00003475667,0.00043761847,0.000215684,0.22396535,0.00033528137],"about_ca_topic_score_codex":0.00047444893,"about_ca_topic_score_gemma":0.00083158875,"teacher_disagreement_score":0.6659112,"about_ca_system_score_codex":0.00009675503,"about_ca_system_score_gemma":0.00063333794,"threshold_uncertainty_score":0.46134156},"labels":[],"label_agreement":null},{"id":"W2978886033","doi":"10.1093/annonc/mdz407","title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Fondation ARC pour la Recherche sur le Cancer; CNIB","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; ROS1; Oncology; Internal medicine; Lung cancer; Clinical trial; Cancer; Adenocarcinoma","score_opus":0.08230904271557742,"score_gpt":0.4842450247288527,"score_spread":0.4019359820132753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978886033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95596236,0.000099950645,0.0000014647188,0.007948956,0.0004126566,0.0009973538,0.00013993327,0.000005660567,0.034431655],"genre_scores_gemma":[0.99465084,0.000053426134,0.00011136876,0.0009599491,0.00008393044,0.000027577624,0.00003068358,0.000007661952,0.0040745568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99909514,0.00009082762,0.00038521504,0.00015329954,0.00012492004,0.00015061119],"domain_scores_gemma":[0.9990828,0.00023715853,0.00023630222,0.00023816443,0.00016451647,0.000041079194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024021712,0.00007912649,0.0003843752,0.00007826866,0.000026249654,0.0000013842705,0.00008304712,0.00009544168,0.00012896828],"category_scores_gemma":[0.00028876937,0.00004537218,0.000102096325,0.00020175724,0.00008277542,0.000041938503,0.00004451527,0.00010126863,0.000009067102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5459845,0.022512054,0.0030332261,0.00015195792,0.0012560886,0.00014072593,0.016500896,0.000043415363,0.025465097,0.0021258383,0.034853335,0.34793285],"study_design_scores_gemma":[0.6096282,0.1547295,0.022254609,0.00048714346,0.0005298649,0.000039137307,0.0016848742,0.000036527592,0.07123021,0.00038149866,0.138799,0.00019945229],"about_ca_topic_score_codex":0.00023499828,"about_ca_topic_score_gemma":0.00011766948,"teacher_disagreement_score":0.34773338,"about_ca_system_score_codex":0.000044442106,"about_ca_system_score_gemma":0.0006244196,"threshold_uncertainty_score":0.18502238},"labels":[],"label_agreement":null},{"id":"W2979041297","doi":"10.1016/j.cllc.2019.09.007","title":"Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; Les Laboratories Pierre Fabre; Takeda Pharmaceutical Company; AbbVie; Roche; Novartis; Meso Scale Diagnostics; Sanofi; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Canadian Asian Studies Association; AstraZeneca; Bristol-Myers Squibb; Bayer","keywords":"Medicine; Osimertinib; Lung cancer; Liquid biopsy; Biopsy; Acquired resistance; Cancer; Pathology; Oncology; Cancer research; Internal medicine; Adenocarcinoma; ROS1","score_opus":0.023275238700409616,"score_gpt":0.4492838678513752,"score_spread":0.4260086291509656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979041297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881952,0.0024062574,0.000010467226,0.00085495284,0.0005273883,0.0077620815,0.0000671251,0.000029756215,0.00014680868],"genre_scores_gemma":[0.99752575,0.00015434848,0.00026958977,0.00037549913,0.00009620873,0.0011079548,0.000026431271,0.000039743307,0.00040448306],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732953,0.00035911374,0.00083513703,0.0006880189,0.00046135078,0.00032681972],"domain_scores_gemma":[0.99789584,0.000667361,0.0005725688,0.00049233343,0.00024902337,0.00012287691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009426523,0.0003002478,0.00073416595,0.00006837536,0.00026358047,0.000024950896,0.00014706695,0.000100141784,0.00010114139],"category_scores_gemma":[0.00032387231,0.00014696084,0.0000608445,0.00044249455,0.00021750308,0.00010480453,0.00009276499,0.0003952189,6.2379615e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38966945,0.008160853,0.53509986,0.0004324331,0.002000804,0.000055354998,0.006008149,0.0003140439,0.0032163763,0.000049331575,0.00035712944,0.054636195],"study_design_scores_gemma":[0.44327086,0.13008718,0.4077735,0.0049035503,0.0041339057,0.000005079855,0.0017881102,0.0048130597,0.0023292117,0.00007100473,0.00009661159,0.0007279441],"about_ca_topic_score_codex":0.00009013418,"about_ca_topic_score_gemma":0.00012890798,"teacher_disagreement_score":0.12732638,"about_ca_system_score_codex":0.00020844617,"about_ca_system_score_gemma":0.00035300825,"threshold_uncertainty_score":0.59928894},"labels":[],"label_agreement":null},{"id":"W2979419766","doi":"","title":"Prospective Randomized Phase II Parallel Study of Vinorelbine Maintenance Therapy versus Best Supportive Care in Advanced Non-Small Cell Lung Cancer.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton University","funders":"","keywords":"Vinorelbine; Gemcitabine; Carboplatin; Medicine; Hazard ratio; Internal medicine; Maintenance therapy; Lung cancer; Oncology; Chemotherapy; Randomized controlled trial; Performance status; Progression-free survival; Surgery; Confidence interval","score_opus":0.018719123923207258,"score_gpt":0.3393573836113696,"score_spread":0.32063825968816234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979419766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763834,0.0021260988,0.000019414992,0.00023985184,0.00041412443,0.012455962,0.000064273445,0.000020290936,0.008276603],"genre_scores_gemma":[0.97730494,0.00080636615,0.00013608228,0.000028521328,0.00007014168,0.019830553,0.000028654806,0.000029645187,0.0017651272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985442,0.00004785813,0.00039693757,0.0004068698,0.00020948683,0.00039460816],"domain_scores_gemma":[0.9985455,0.000075661,0.0004316232,0.000519734,0.0002944342,0.00013304695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017035031,0.00023183986,0.0008073103,0.00009715025,0.00021259816,0.000019869141,0.00017034421,0.000055251883,0.000023265928],"category_scores_gemma":[0.00012521067,0.00016936118,0.00013298422,0.00010298406,0.00012334027,0.00013777599,0.00005637624,0.00015050705,8.731592e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5360266,0.012246976,0.27176896,0.0002334505,0.0020097517,0.00023697986,0.05562676,0.00023026428,0.00014231825,0.000037992842,0.00012581273,0.12131416],"study_design_scores_gemma":[0.7238022,0.0020380733,0.2666773,0.00007666924,0.00060906087,7.9430447e-7,0.0053439643,0.000061708146,0.0011335307,0.000009946127,0.000085143256,0.0001615994],"about_ca_topic_score_codex":0.002489405,"about_ca_topic_score_gemma":0.0022600777,"teacher_disagreement_score":0.18777564,"about_ca_system_score_codex":0.0004839651,"about_ca_system_score_gemma":0.00022661738,"threshold_uncertainty_score":0.6906349},"labels":[],"label_agreement":null},{"id":"W2979480540","doi":"10.1016/j.clinthera.2019.09.008","title":"Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China","year":2019,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"China Medical Board","keywords":"Medicine; Osimertinib; Docetaxel; T790M; Oncology; Pemetrexed; Lung cancer; Internal medicine; Epidermal growth factor receptor; Cost effectiveness; Gemcitabine; Cancer; Chemotherapy; Erlotinib; Gefitinib; Cisplatin","score_opus":0.03739784824940182,"score_gpt":0.4140337343373992,"score_spread":0.37663588608799736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979480540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442744,0.00045896543,0.000033133656,0.00007925722,0.00021388243,0.003763388,0.00006414419,0.000016886268,0.0009428902],"genre_scores_gemma":[0.99827147,0.00026719412,0.00021853481,0.0002681043,0.000020402087,0.00027353037,0.00009725339,0.00003973383,0.00054375327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984812,0.00015003941,0.00058268395,0.00037257484,0.00015120495,0.00026230898],"domain_scores_gemma":[0.9988884,0.00036776494,0.0002032072,0.00032526755,0.00011799372,0.00009738986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019789638,0.00022409766,0.0006839286,0.00009494471,0.000016821623,0.000005572321,0.00007246608,0.00013206905,0.00018048527],"category_scores_gemma":[0.000012483007,0.0001529944,0.00010928351,0.00030231828,0.000059129507,0.000053278156,0.000017828204,0.00021212592,0.000010374416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004437836,0.0036116235,0.9649978,0.00018132036,0.00039832163,0.000012047164,0.0005806823,0.0012242154,0.00036981687,0.000005430781,8.42132e-7,0.02418004],"study_design_scores_gemma":[0.03767772,0.0050822934,0.95104045,0.0005489073,0.00041974016,5.1305346e-7,0.00006871814,0.0011091976,0.0035497076,0.000021778254,0.00031822769,0.00016276605],"about_ca_topic_score_codex":0.00022546679,"about_ca_topic_score_gemma":0.00022941545,"teacher_disagreement_score":0.033239882,"about_ca_system_score_codex":0.00040931033,"about_ca_system_score_gemma":0.0004509883,"threshold_uncertainty_score":0.623893},"labels":[],"label_agreement":null},{"id":"W2979635381","doi":"10.1016/s0140-6736(19)31264-4","title":"p16 status and choice of chemotherapy in the KEYNOTE-040 study – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute for Health and Care Research","keywords":"Medicine; Chemotherapy; Oncology; Internal medicine","score_opus":0.03634250563655816,"score_gpt":0.3650113062198207,"score_spread":0.32866880058326253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979635381","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20507668,0.0010068992,0.0000023301513,0.7870738,0.00022641657,0.0018371454,0.00009055813,0.000021567312,0.0046646185],"genre_scores_gemma":[0.20149054,0.00044587272,0.00007724411,0.78662044,0.0036710973,0.00012964851,0.00014322111,0.000048193237,0.0073737637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988722,0.00014821991,0.00020894941,0.0002326802,0.00028059143,0.0002573659],"domain_scores_gemma":[0.9985587,0.00033676665,0.00014095557,0.000911613,0.000036507743,0.000015483596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029756807,0.00016945427,0.00055703445,0.000054545057,0.00004029415,0.000023421404,0.00020434553,0.00011080728,0.00005219443],"category_scores_gemma":[0.00005116217,0.000079128025,0.000049651935,0.00013690848,0.00006468644,0.000024071704,0.000024329933,0.0007078192,0.000009861404],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013542658,0.00014007685,0.084296405,0.00015954325,0.00033524423,0.000040803756,0.008064172,0.00000102299,0.000012650455,0.000012078799,0.90548867,0.0013138925],"study_design_scores_gemma":[0.004038433,0.0003559702,0.25496936,0.00010656876,0.00028804975,0.0000073393967,0.00041189496,0.0000041626677,0.0000063392235,0.00008530817,0.73964953,0.0000770608],"about_ca_topic_score_codex":0.00133278,"about_ca_topic_score_gemma":0.00007360485,"teacher_disagreement_score":0.17067295,"about_ca_system_score_codex":0.000058977887,"about_ca_system_score_gemma":0.00010013317,"threshold_uncertainty_score":0.32267472},"labels":[],"label_agreement":null},{"id":"W2980670340","doi":"10.1016/j.jtho.2019.10.006","title":"Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Ignyta; EMD Serono; Eisai; Natera; Ariad Pharmaceuticals; Genentech; Bristol-Myers Squibb; AstraZeneca; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Daiichi-Sankyo","keywords":"Ceritinib; Medicine; Nivolumab; Cohort; Internal medicine; Lung cancer; Gastroenterology; Cancer; Anaplastic lymphoma kinase; Oncology; Immunotherapy; Malignant pleural effusion","score_opus":0.021819599369042156,"score_gpt":0.45051293979249973,"score_spread":0.4286933404234576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980670340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941588,0.00029336556,0.000014544764,0.0002710179,0.00048915594,0.0025596605,0.00008230403,0.000006318377,0.0021248376],"genre_scores_gemma":[0.9941646,0.00005586172,0.004946329,0.00013312289,0.000069029935,0.00004487151,0.000036362067,0.000031836513,0.00051799836],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810517,0.00019759385,0.000844107,0.00027605667,0.00030914714,0.0002679146],"domain_scores_gemma":[0.99781805,0.00008527048,0.0010241186,0.00031661958,0.00056215003,0.00019380533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040609558,0.00018859451,0.00088103855,0.00023626641,0.000044231107,0.000017169994,0.0002749824,0.00009387586,0.000051591018],"category_scores_gemma":[0.00004150105,0.00013859732,0.000041104136,0.00024385499,0.000040543797,0.00033294727,0.000066431545,0.00033534144,0.000002810621],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26687175,0.115042366,0.26696122,0.00048861216,0.0012267529,0.00091061497,0.013330856,0.0006071832,0.0050672274,9.2334096e-7,0.000464154,0.32902834],"study_design_scores_gemma":[0.58298165,0.1716865,0.22789939,0.001408561,0.002563105,0.000051178824,0.007218678,0.0009351566,0.0018572471,0.000004132759,0.0030208852,0.0003735367],"about_ca_topic_score_codex":0.0004825233,"about_ca_topic_score_gemma":0.0008199815,"teacher_disagreement_score":0.32865483,"about_ca_system_score_codex":0.0008715061,"about_ca_system_score_gemma":0.0010967185,"threshold_uncertainty_score":0.56518346},"labels":[],"label_agreement":null},{"id":"W2980696228","doi":"10.1200/jco.2019.37.27_suppl.102","title":"Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Exon; Lung cancer; Oncology; Mutation; Proportional hazards model; Retrospective cohort study; Confidence interval; Genetics; Gene; Biology","score_opus":0.0670128601008478,"score_gpt":0.47414937560977394,"score_spread":0.40713651550892616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980696228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940311,0.000964634,0.0001636241,0.003495553,0.00011987232,0.0008821817,0.000020599264,0.000008311807,0.00031413007],"genre_scores_gemma":[0.9946035,0.0004086636,0.0040171593,0.00071177824,0.00003943772,0.000030769734,0.000046262732,0.000015685078,0.00012674641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820155,0.00018575603,0.0009064697,0.0002404905,0.00027345738,0.00019230643],"domain_scores_gemma":[0.9978207,0.00054012606,0.00091976515,0.000120484234,0.00029443917,0.00030451437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042590618,0.00015897883,0.0010330772,0.00014512152,0.00008307982,0.000015346426,0.000038161583,0.00009246851,0.000026633455],"category_scores_gemma":[0.00011002898,0.00008714697,0.000050712257,0.00015402111,0.0001639731,0.00021706843,0.000014855569,0.00034674376,6.8131686e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002621252,0.0014320825,0.97512585,0.000078889185,0.0006097347,0.000059180562,0.00079740916,0.00017420587,4.933771e-7,0.000028108303,0.000058064907,0.019014735],"study_design_scores_gemma":[0.02557282,0.009516478,0.9624366,0.0004351906,0.00070837204,0.00006478999,0.00045361917,0.00034117032,0.0000010179265,0.000034407592,0.00034993712,0.00008556112],"about_ca_topic_score_codex":0.000755291,"about_ca_topic_score_gemma":0.0025908314,"teacher_disagreement_score":0.022951568,"about_ca_system_score_codex":0.00043758377,"about_ca_system_score_gemma":0.0018571017,"threshold_uncertainty_score":0.35537502},"labels":[],"label_agreement":null},{"id":"W2981461253","doi":"10.1016/j.jtho.2019.02.016","title":"Lung Cancer in the Middle East and North Africa Region","year":2019,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Les Laboratories Pierre Fabre; Sanofi; Roche; Novartis; Pfizer; Eli Lilly and Company","keywords":"Middle East; Medicine; Incidence (geometry); Population; Lung cancer; Tobacco control; Socioeconomics; Environmental health; Geography; Public health; Pathology","score_opus":0.04774636572610958,"score_gpt":0.4225679717225573,"score_spread":0.3748216059964477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981461253","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042161856,0.030573543,0.000028266915,0.0099090235,0.90852,0.00087872735,0.00009527903,0.000008381204,0.00782497],"genre_scores_gemma":[0.08527349,0.008643122,0.00035491915,0.00038762297,0.89830184,0.000060881022,0.000059180238,0.00005692689,0.006862003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998672,0.0001619713,0.00042987234,0.00015325382,0.00039358588,0.00018928373],"domain_scores_gemma":[0.99834454,0.00043460377,0.00065775187,0.00017314228,0.00030980594,0.00008017245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033035874,0.00016035819,0.0006287843,0.00017293969,0.000045125606,0.000019386745,0.0001483113,0.00038707,0.000027988242],"category_scores_gemma":[0.00018760152,0.00009162638,0.00011620925,0.0001630473,0.00005828104,0.00007302282,0.0000265884,0.0010005,0.0000027471415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086152076,0.00022222001,0.0021877943,0.00029236596,0.00035247373,0.0008104303,0.007672595,0.000014014162,0.0000025033946,0.0000027233857,0.96343285,0.024148505],"study_design_scores_gemma":[0.0012341432,0.0011637177,0.0023325325,0.00064744265,0.0018414775,0.00034407966,0.00116961,0.00001647065,4.1851246e-7,0.00001943929,0.9911455,0.00008516933],"about_ca_topic_score_codex":0.00006883569,"about_ca_topic_score_gemma":0.00035637134,"teacher_disagreement_score":0.043111637,"about_ca_system_score_codex":0.0008462286,"about_ca_system_score_gemma":0.0022674093,"threshold_uncertainty_score":0.43467307},"labels":[],"label_agreement":null},{"id":"W2981476678","doi":"10.1016/j.jtho.2019.08.286","title":"PC01.02 Real World Research Groups — ROS1ders","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Disease; Cancer; Family medicine; Oncology; Internal medicine; Adenocarcinoma","score_opus":0.06200485756519249,"score_gpt":0.5431354208941708,"score_spread":0.4811305633289783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981476678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8623365,0.00046133573,0.000031783427,0.011368887,0.001142815,0.0002986599,0.0000027003273,0.0000118654025,0.12434541],"genre_scores_gemma":[0.9738535,0.00023753433,0.0025889694,0.00044004145,0.00062316214,0.00000608501,0.000004776353,0.000018741319,0.022227183],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856335,0.00019553084,0.00039125618,0.00013481769,0.0004271433,0.00028791587],"domain_scores_gemma":[0.99860793,0.00026185956,0.0002370949,0.00020099433,0.000488603,0.00020349996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010454138,0.000088272034,0.0004057884,0.00048464132,0.0000702889,0.000015826456,0.00012100762,0.000099321,0.0007369215],"category_scores_gemma":[0.00006551423,0.0000627058,0.00013515215,0.0003965676,0.00008745905,0.0001258144,0.00003678205,0.00060520304,0.0002250802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0096529955,0.00328252,0.27233052,0.00044536788,0.0022576358,0.0039990502,0.0059612365,0.000120128134,0.012808281,0.005410195,0.14751965,0.53621244],"study_design_scores_gemma":[0.006000452,0.01394184,0.2904588,0.00056077284,0.0012391313,0.0023005991,0.00528689,0.00007730486,0.0020758891,0.0051530064,0.67264086,0.00026445842],"about_ca_topic_score_codex":0.000068961584,"about_ca_topic_score_gemma":0.00009475075,"teacher_disagreement_score":0.535948,"about_ca_system_score_codex":0.0009366895,"about_ca_system_score_gemma":0.0010260729,"threshold_uncertainty_score":0.8068774},"labels":[],"label_agreement":null},{"id":"W2981582597","doi":"10.3747/co.26.5399","title":"Panitumumab-Induced Pulmonary Toxicity","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Juravinski Cancer Centre","funders":"","keywords":"Panitumumab; Medicine; Epidermal growth factor receptor; Toxicity; Colorectal cancer; Cetuximab; Oncology; Head and neck cancer; Internal medicine; Antibody; EGFR inhibitors; Cancer; Immunology","score_opus":0.08620132065275363,"score_gpt":0.4490772864621713,"score_spread":0.3628759658094177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981582597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92205036,0.0007056763,0.000023462373,0.0009814777,0.0018415685,0.00048086108,0.00000730195,0.00005938458,0.07384994],"genre_scores_gemma":[0.9977575,0.000067759844,0.00008997438,0.00025085438,0.0002221797,0.00004747841,0.00006479844,0.000011333079,0.0014881402],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993447,0.000027455233,0.0001400068,0.00020172469,0.000101043675,0.00018508379],"domain_scores_gemma":[0.99954706,0.0000382376,0.000050183524,0.0001981731,0.000064145635,0.000102210055],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000049843664,0.00009324603,0.00022131253,0.000057624944,0.000037047754,0.0000044022945,0.000047146226,0.00006921764,0.00073546177],"category_scores_gemma":[0.000017614891,0.00007376954,0.00006749423,0.00009392712,0.000020782683,0.000044258297,0.000028800694,0.00015223748,0.0008276696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024999666,0.0031724623,0.36139983,0.00020169232,0.00022523821,0.0001287333,0.0007905218,0.0000024160247,0.021290477,0.0019211541,0.007399989,0.6032175],"study_design_scores_gemma":[0.0037266058,0.0016308085,0.19373155,0.00009584724,0.0003512437,0.00019400545,0.0003315231,0.00027166057,0.0020618334,0.0003846406,0.79702693,0.00019333116],"about_ca_topic_score_codex":0.0000105604,"about_ca_topic_score_gemma":0.0000052379505,"teacher_disagreement_score":0.78962696,"about_ca_system_score_codex":0.00033582578,"about_ca_system_score_gemma":0.00028620468,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W2981593005","doi":"10.1016/j.jtho.2019.08.2115","title":"EP1.03-34 Single Center Epidemiological Prevalence Study of Molecular Mutation in Bangladeshi Patients with Advanced Stage Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Science North","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Internal medicine; T790M; Cancer; Biopsy; Outpatient clinic; Single Center; Oncology; Gastroenterology; Pathology; Adenocarcinoma; ROS1","score_opus":0.015590104630153387,"score_gpt":0.3989717494112591,"score_spread":0.38338164478110576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981593005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967363,0.00044335658,0.00018548245,0.0002911437,0.00025653534,0.0011945319,0.0000170447,0.00000474024,0.00087088614],"genre_scores_gemma":[0.9967462,0.000050968363,0.0026321413,0.00021767602,0.000030832874,0.00003121673,0.000009917758,0.000015838717,0.00026523462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984667,0.00023933916,0.0006319655,0.00020633792,0.00024451094,0.00021119091],"domain_scores_gemma":[0.99839646,0.00015670226,0.00082232244,0.00016442788,0.00034283212,0.000117273055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032467907,0.00014759901,0.0006140249,0.00017964929,0.000020250991,0.0000045447887,0.000105661136,0.000098625074,0.00014680198],"category_scores_gemma":[0.000082653394,0.00009645931,0.00007652359,0.00018674537,0.000035075707,0.00012987567,0.000028093662,0.0002726127,0.0000027113363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024420829,0.0056370157,0.97265273,0.0003994005,0.00019677136,0.00031252968,0.001925924,0.0038194268,0.0039586374,0.0000019504314,0.000026537024,0.008626971],"study_design_scores_gemma":[0.014396902,0.025495969,0.95224655,0.00072587916,0.00094651524,0.00005355139,0.0026236703,0.00021772069,0.0028040244,0.000016721027,0.00029657385,0.00017590124],"about_ca_topic_score_codex":0.000046525463,"about_ca_topic_score_gemma":0.000060379036,"teacher_disagreement_score":0.020406181,"about_ca_system_score_codex":0.00077040895,"about_ca_system_score_gemma":0.00034803062,"threshold_uncertainty_score":0.39334965},"labels":[],"label_agreement":null},{"id":"W2981599940","doi":"10.1016/j.jtho.2019.08.1813","title":"P2.14-28 Real-World Management and Outcomes of Uncommon EGFR Mutation-Positive NSCLC Patients at Two Tertiary Canadian Cancer Centres","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gefitinib; Lung cancer; Internal medicine; Cohort; Oncology; Cancer; Population; Mutation; Epidermal growth factor receptor","score_opus":0.00936022518894539,"score_gpt":0.3967298458148208,"score_spread":0.3873696206258754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981599940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775387,0.00046583876,0.000005264011,0.0042775366,0.00073290244,0.00046381203,0.00006409428,0.0000045249362,0.016447319],"genre_scores_gemma":[0.992672,0.0002260447,0.0009146924,0.0008912505,0.000060375904,0.000010146447,0.000033190558,0.000015347416,0.005176904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890935,0.0000792889,0.0004402001,0.00013774422,0.00022299887,0.00021042905],"domain_scores_gemma":[0.99880105,0.00010391016,0.00045899968,0.00012777084,0.0002675867,0.00024067362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012467854,0.00012984195,0.00045413352,0.00037109357,0.00006333893,0.00000780665,0.00006948164,0.00005408077,0.00024088452],"category_scores_gemma":[0.000012994556,0.000095394564,0.000092383794,0.00013400221,0.000050121518,0.00010790248,0.000034939036,0.00013009849,0.000009601597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004218883,0.00022906612,0.91432714,0.00007713309,0.000912929,0.0002154225,0.0008735957,0.00005425922,0.00003244533,0.000078320816,0.0021372463,0.08064055],"study_design_scores_gemma":[0.00283087,0.00065906515,0.98761594,0.00023131518,0.0010904754,0.000040064977,0.00039517114,0.000021065991,0.00028901032,0.000094924726,0.006648459,0.000083640974],"about_ca_topic_score_codex":0.022336323,"about_ca_topic_score_gemma":0.09506993,"teacher_disagreement_score":0.08055691,"about_ca_system_score_codex":0.0017692515,"about_ca_system_score_gemma":0.00042500306,"threshold_uncertainty_score":0.984174},"labels":[],"label_agreement":null},{"id":"W2981621614","doi":"10.1016/j.jtho.2019.08.060","title":"PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Lung; Internal medicine","score_opus":0.023956229797011504,"score_gpt":0.4722920417351263,"score_spread":0.4483358119381148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981621614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833166,0.0013038921,0.00008021347,0.003840728,0.004398956,0.0018738458,0.0002437034,0.000015486248,0.00492655],"genre_scores_gemma":[0.98934066,0.00035139633,0.003518862,0.00039239542,0.0029475319,0.000075423435,0.00014510147,0.000041137337,0.0031874813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972474,0.00019066129,0.0013029769,0.0003826222,0.0005213413,0.00035499636],"domain_scores_gemma":[0.9974023,0.0004634504,0.0011595965,0.00025886222,0.0004402742,0.0002755039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008363887,0.0002535979,0.00091350323,0.0003925142,0.00012368475,0.000026652502,0.00022252806,0.0002989407,0.0004293952],"category_scores_gemma":[0.00019421666,0.00020583578,0.00025845427,0.00028128983,0.000041208797,0.00029701018,0.000051333947,0.000600112,0.000017393717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9495823,0.0072097313,0.0011952881,0.000110374654,0.0005364775,0.0004400887,0.0035457017,0.0022293588,0.002868915,0.000012523256,0.006127322,0.026141962],"study_design_scores_gemma":[0.9241597,0.026955727,0.0017956429,0.00064167456,0.0015708607,0.00008963101,0.00061673264,0.0038383848,0.0011508362,0.000112529284,0.038729787,0.00033849987],"about_ca_topic_score_codex":0.00033988917,"about_ca_topic_score_gemma":0.0004636056,"teacher_disagreement_score":0.032602463,"about_ca_system_score_codex":0.0018560926,"about_ca_system_score_gemma":0.0034631717,"threshold_uncertainty_score":0.83937395},"labels":[],"label_agreement":null},{"id":"W2981948498","doi":"10.1097/md.0000000000017559","title":"Expression of estrogen receptor beta and overall survival in non-small cell lung cancer patients","year":2019,"lang":"en","type":"article","venue":"Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Lung cancer; Oncology; Estrogen receptor; BETA (programming language); Estrogen receptor beta; Estrogen; Internal medicine; Cancer; Cancer research; Breast cancer","score_opus":0.008571873843136275,"score_gpt":0.2894615324121597,"score_spread":0.2808896585690234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981948498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352974,0.0013859334,0.000009632221,0.0005829896,0.00044361135,0.00061333907,0.000018972594,0.000008058028,0.0034077286],"genre_scores_gemma":[0.9978113,0.00028729133,0.00019007879,0.00013637087,0.00010997377,0.00002986875,0.00008566253,0.000014997998,0.0013344336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992502,0.000017240805,0.0002169828,0.00018777445,0.000188277,0.00013954194],"domain_scores_gemma":[0.9995671,0.00004054811,0.00008484537,0.00015075644,0.0000680256,0.00008873044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072054456,0.00010631655,0.00030828308,0.00008688464,0.000013949611,0.0000015756788,0.00003703253,0.000048581263,0.00044281714],"category_scores_gemma":[0.000012380494,0.0000720539,0.000022438551,0.000089537905,0.000031591364,0.000037352584,0.000025026895,0.00008027732,0.000004661337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009469785,0.00016352035,0.97187525,0.00026827757,0.000026690333,0.0000023473453,0.0013545891,0.0000049269775,0.023795392,0.000011550321,0.0014926263,0.0009101507],"study_design_scores_gemma":[0.0141821895,0.000794115,0.96721387,0.0014358833,0.00022909201,6.3885335e-7,0.0002738785,0.00011231949,0.012998124,0.000008107056,0.0026411829,0.00011058428],"about_ca_topic_score_codex":0.0009520849,"about_ca_topic_score_gemma":0.000027555612,"teacher_disagreement_score":0.014087492,"about_ca_system_score_codex":0.000083952466,"about_ca_system_score_gemma":0.00006342703,"threshold_uncertainty_score":0.4848537},"labels":[],"label_agreement":null},{"id":"W2982012895","doi":"10.4095/297368","title":"Introduction to the HALIP Activity","year":2015,"lang":"en","type":"report","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Natural Resources Canada","funders":"","keywords":"Computer science","score_opus":0.05162224092797484,"score_gpt":0.40543031438724975,"score_spread":0.3538080734592749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982012895","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00127705,0.00046254887,0.00042377753,0.105595015,0.0040404894,0.0011114255,0.000039653245,0.000098518234,0.8869515],"genre_scores_gemma":[0.05550554,0.00025719262,0.00041620017,0.00066643,0.018402452,0.0002081683,0.00023381332,0.000040706243,0.9242695],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988561,0.000014673288,0.00009968544,0.00023033384,0.0006914152,0.000107736785],"domain_scores_gemma":[0.9985937,0.000010608958,0.000055293593,0.00043655076,0.0007950071,0.00010884007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033763875,0.00011556462,0.0002084766,0.000056986235,0.000051038118,0.000016432012,0.00003809606,0.00008802458,0.0006309487],"category_scores_gemma":[0.00027351145,0.00005825939,0.00006695923,0.00012011882,0.000013515044,0.00002604404,0.000024579993,0.0001527247,0.00035044333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020723253,0.000056602246,0.000074383264,0.000026988304,0.00020528522,0.000005570127,0.000091394904,0.000003779904,0.000015269412,0.00001917858,0.95502776,0.044453047],"study_design_scores_gemma":[0.00019187668,0.00012965256,0.0026114008,0.00002298243,0.00058016373,0.000117330776,0.00004218877,0.0000019827055,0.00011216319,0.000012709399,0.9961163,0.00006126425],"about_ca_topic_score_codex":0.0022968946,"about_ca_topic_score_gemma":0.0005328465,"teacher_disagreement_score":0.10492858,"about_ca_system_score_codex":0.0014233858,"about_ca_system_score_gemma":0.0024148668,"threshold_uncertainty_score":0.6908446},"labels":[],"label_agreement":null},{"id":"W2982060206","doi":"10.1016/j.jtho.2019.08.634","title":"MA16.09 Clinical Practice and Outcomes in Patients with Stage III Unresectable Non-Small-Cell Lung Canceran Academic Centre, Canada","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Radiation therapy; Proportional hazards model; Lung cancer; Multivariate analysis; Retrospective cohort study; Cohort; Oncology; Surgery","score_opus":0.013554247824153636,"score_gpt":0.42283534156579977,"score_spread":0.4092810937416461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982060206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905924,0.0004922063,0.000018678884,0.0036323667,0.00070857647,0.00055027433,0.000016525195,0.0000031350132,0.0039858185],"genre_scores_gemma":[0.99262506,0.0002507144,0.0016648537,0.0014492659,0.00010058301,0.000003872388,0.0000075228018,0.000017727538,0.0038804205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984468,0.00014398742,0.000655282,0.00017979355,0.00030730182,0.0002668349],"domain_scores_gemma":[0.9981532,0.00047987513,0.00068844954,0.00014166323,0.0003057751,0.00023104915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047812192,0.00013852917,0.0006447796,0.00011173881,0.000037096448,0.000009012697,0.00009005574,0.00014429071,0.000083976985],"category_scores_gemma":[0.00013308108,0.00009230122,0.000047362035,0.00013276824,0.000033037424,0.00023036337,0.00003306225,0.0007498116,0.0000029764776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029764394,0.0005053582,0.98475474,0.00008749717,0.0003044994,0.00028786054,0.00038271432,0.00006322842,0.000010010731,0.0000044479275,0.0013868677,0.009236351],"study_design_scores_gemma":[0.011880804,0.002297885,0.9459927,0.00019897452,0.0008246332,0.000060222974,0.0014881623,0.00005772374,0.00003721589,0.0000047072826,0.037031777,0.00012518991],"about_ca_topic_score_codex":0.028974485,"about_ca_topic_score_gemma":0.07173048,"teacher_disagreement_score":0.042755995,"about_ca_system_score_codex":0.0011308299,"about_ca_system_score_gemma":0.0037020787,"threshold_uncertainty_score":0.9774917},"labels":[],"label_agreement":null},{"id":"W2982063399","doi":"10.1016/j.jtho.2019.08.527","title":"MA04.10 Development and Validation of a Gene Expression-Based Prognostic Signature in Early-Stage Squamous Cell Carcinoma of the Lung","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Stage (stratigraphy); Gene signature; Oncology; Basal cell; Lung; Signature (topology); Squamous-cell carcinoma of the lung; Gene expression; Internal medicine; Gene; Cancer research; Pathology; Genetics; Biology","score_opus":0.012718554698975771,"score_gpt":0.3540706444717813,"score_spread":0.34135208977280557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982063399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779665,0.00076410954,0.00009095897,0.0003098372,0.00015385637,0.00040983007,0.0000054020506,0.000001556638,0.0004678188],"genre_scores_gemma":[0.99489146,0.0000028930338,0.0044798427,0.000048393296,0.000024997435,0.000006765534,0.0000042174925,0.000008131974,0.0005333168],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991226,0.0000998273,0.00040442287,0.00008532649,0.00019213246,0.00009569452],"domain_scores_gemma":[0.99895704,0.0001666688,0.0005354318,0.00010883869,0.00018287021,0.00004914867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002324137,0.00007731511,0.00029348937,0.00013804004,0.000020121548,0.0000029967348,0.00006761569,0.000099584104,0.000070734925],"category_scores_gemma":[0.00006168209,0.000046707297,0.00005518499,0.00012451963,0.000032042535,0.000044272765,0.000018495064,0.00017162239,8.5634304e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011434434,0.00078101695,0.8849915,0.00062241155,0.000048285936,0.000086943925,0.0038627696,0.0006961261,0.10394158,0.0000037394432,0.00017002868,0.0036521405],"study_design_scores_gemma":[0.0023965538,0.0011758484,0.45917842,0.00026183735,0.0002604568,0.000037318365,0.00043409455,0.00011335829,0.5354779,0.000009484617,0.0005989271,0.00005583906],"about_ca_topic_score_codex":0.000013172243,"about_ca_topic_score_gemma":0.0000041275657,"teacher_disagreement_score":0.43153626,"about_ca_system_score_codex":0.00020260784,"about_ca_system_score_gemma":0.0008791185,"threshold_uncertainty_score":0.19046684},"labels":[],"label_agreement":null},{"id":"W2982150584","doi":"10.1002/cam4.2603","title":"Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Institut universitaire de cardiologie et de pneumologie de Québec; AstraZeneca (Canada); Université Laval; Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Cancer Society Research Institute; University Health Network; University of Toronto; AstraZeneca Canada; AstraZeneca","keywords":"Gefitinib; Medicine; Internal medicine; Osimertinib; Lung cancer; Epidermal growth factor receptor; Oncology; Rash; Chemotherapy; Cohort; Tyrosine-kinase inhibitor; Performance status; Erlotinib; Cancer","score_opus":0.01690395679656957,"score_gpt":0.3392901433306463,"score_spread":0.3223861865340767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982150584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96236247,0.01617358,0.000029824256,0.01587632,0.0012388901,0.0024751653,0.00024327477,0.00008441171,0.0015160451],"genre_scores_gemma":[0.9843772,0.0057935403,0.00042950088,0.003883189,0.00048204893,0.00047589547,0.00013598932,0.00006255967,0.0043600975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762577,0.00006676874,0.0006539973,0.0006914258,0.00033952424,0.0006225455],"domain_scores_gemma":[0.9985011,0.00012872182,0.00021371387,0.00034907085,0.00021292915,0.0005944299],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001912357,0.00038756366,0.00092096854,0.00041516565,0.00009872214,0.000013312516,0.00009851511,0.000082711624,0.0011474617],"category_scores_gemma":[0.000069014764,0.0002988953,0.000057844434,0.00076934707,0.0001404091,0.00014764872,0.000056420493,0.0002977172,0.000010462894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006822912,0.00020056946,0.9245496,0.0017775699,0.00012754535,0.000034700857,0.009551358,0.00007138583,0.01952614,0.00003583522,0.013230084,0.03021292],"study_design_scores_gemma":[0.014844284,0.0015155257,0.9361641,0.0065194312,0.0002729233,0.000005352533,0.0020274068,0.00044205456,0.02870945,0.00002664622,0.008910194,0.0005626464],"about_ca_topic_score_codex":0.024195714,"about_ca_topic_score_gemma":0.008699297,"teacher_disagreement_score":0.029650273,"about_ca_system_score_codex":0.0011900403,"about_ca_system_score_gemma":0.0009283625,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W2983439350","doi":"10.1093/neuonc/noz175.231","title":"CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"DNA methylation; Adenocarcinoma; Methylation; Biology; Cancer research; Lung cancer; Epigenetics; Metastasis; Lung; Brain metastasis; Pathology; Gene; Medicine; Cancer; Genetics; Internal medicine; Gene expression","score_opus":0.01898871956096887,"score_gpt":0.3415605696622252,"score_spread":0.32257185010125633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983439350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893088,0.0022363677,0.00010000159,0.003699536,0.00020714283,0.0007564104,0.000104791114,0.000039045677,0.0035479378],"genre_scores_gemma":[0.9935544,0.00020527754,0.001459353,0.004362769,0.000039229435,0.000043672804,0.0001364742,0.000028655499,0.00017014303],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984148,0.00020812271,0.00043585795,0.0004487334,0.00022636012,0.0002661365],"domain_scores_gemma":[0.9981966,0.00082333706,0.00024081721,0.00040520602,0.0001722874,0.00016175507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013725308,0.00020363044,0.0011731291,0.00047770012,0.000045302208,0.000009095882,0.000086244,0.0001285035,0.0006156744],"category_scores_gemma":[0.000060509203,0.00016701179,0.00022210425,0.00069575704,0.00011752679,0.0000658822,0.00009060877,0.00018720904,0.000028313701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005049673,0.00049648236,0.12871952,0.00032070477,0.010033061,0.0003750552,0.0026903078,0.00011769548,0.8391788,0.00044231402,0.0016654363,0.015455648],"study_design_scores_gemma":[0.011149828,0.004551035,0.8622939,0.00004793789,0.03803926,0.00031863843,0.0023166863,0.0018465591,0.022227667,0.000121235564,0.056643587,0.0004436752],"about_ca_topic_score_codex":0.00015466264,"about_ca_topic_score_gemma":0.000020163052,"teacher_disagreement_score":0.81695116,"about_ca_system_score_codex":0.0003098628,"about_ca_system_score_gemma":0.0003219914,"threshold_uncertainty_score":0.6810543},"labels":[],"label_agreement":null},{"id":"W2983767894","doi":"10.1016/s0167-8140(19)33197-4","title":"143 A Comparison of the Tumour Response in Esophageal Cancer Patients Treated with Tri-Modality Approach Using Either Cisplatin/5-FU or Carboplatin/Paclitaxel and Concomitant Radiation Therapy","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Concomitant; Carboplatin; Cisplatin; Medicine; Paclitaxel; Radiation therapy; Esophageal cancer; Oncology; Internal medicine; Chemotherapy; Radiology; Cancer","score_opus":0.027096162108765958,"score_gpt":0.36825563317758175,"score_spread":0.3411594710688158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983767894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424267,0.003730338,0.00004492298,0.00030529985,0.000058429905,0.0013971612,0.00003354461,0.000010387578,0.00017725813],"genre_scores_gemma":[0.99837774,0.00043061213,0.0006407918,0.0002669258,0.000030674466,0.000056289187,0.000010148663,0.000021853133,0.00016498554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876803,0.0003631343,0.00030412205,0.0002558691,0.00013706114,0.00017180889],"domain_scores_gemma":[0.9992448,0.00025397283,0.00023067511,0.00015454464,0.000056023073,0.00005994924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002513554,0.00016441663,0.0005365318,0.00008746994,0.00006794523,0.0000092475,0.000043041593,0.00012789635,0.000044673645],"category_scores_gemma":[0.000016904769,0.0000891147,0.000036541493,0.00022216263,0.00013135436,0.00006158612,0.000007966376,0.00013754128,1.2393177e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017889788,0.00062997494,0.9502294,0.000043951746,0.00023770663,0.0000057628613,0.0060905237,0.00016091725,0.0044950135,0.000034540033,0.000010042087,0.02017239],"study_design_scores_gemma":[0.020789007,0.0038272147,0.9612072,0.000068171525,0.00012172475,0.000026040572,0.00032139302,0.0122259045,0.00087935274,0.00000598618,0.0004161606,0.00011182096],"about_ca_topic_score_codex":0.0010455911,"about_ca_topic_score_gemma":0.00019050922,"teacher_disagreement_score":0.020060569,"about_ca_system_score_codex":0.00056068855,"about_ca_system_score_gemma":0.00040529494,"threshold_uncertainty_score":0.3633992},"labels":[],"label_agreement":null},{"id":"W2983824567","doi":"10.1182/blood-2019-125648","title":"The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Romidepsin; Anaplastic large-cell lymphoma; Cancer research; Context (archaeology); Brentuximab vedotin; Medicine; ALK inhibitor; Mitoxantrone; Panobinostat; Crizotinib; Lymphoma; Biology; Oncology; Internal medicine; Chemotherapy; Lung cancer; CD30","score_opus":0.02101724006020656,"score_gpt":0.3118811343708165,"score_spread":0.29086389431060994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983824567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504215,0.0016950761,0.0010692328,0.0008813576,0.00009778737,0.0007254993,0.000023644387,0.000015469033,0.00044977514],"genre_scores_gemma":[0.99720025,0.00011019596,0.00119912,0.000043935455,0.000021856371,0.000113892245,0.000015643102,0.000006376762,0.0012887033],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9995787,0.000006047029,0.00016374269,0.00009124981,0.0000786626,0.00008160615],"domain_scores_gemma":[0.9995644,0.00009069185,0.000079163634,0.00016784125,0.000081492486,0.000016384107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058549995,0.0000472076,0.000108531225,0.000014860738,0.00005558401,0.000009194273,0.00004717006,0.000026503849,0.000010388566],"category_scores_gemma":[0.000030468133,0.000026127775,0.000056465215,0.00004145339,0.000040638908,0.000016539234,0.000007345857,0.000017550186,0.0000089346195],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016576903,0.0027947552,0.16304533,0.00038406564,0.0015987906,0.0000034689442,0.0029015017,0.000055861216,0.78681886,0.035891082,0.0005930285,0.0057474845],"study_design_scores_gemma":[0.019107105,0.0015918962,0.5375322,0.00023975989,0.0023547236,0.000098606935,0.0024172622,0.00076897955,0.40502647,0.002500892,0.028083779,0.00027830456],"about_ca_topic_score_codex":0.0000058845376,"about_ca_topic_score_gemma":0.000004276572,"teacher_disagreement_score":0.3817924,"about_ca_system_score_codex":0.000007371646,"about_ca_system_score_gemma":0.000040456503,"threshold_uncertainty_score":0.10654597},"labels":[],"label_agreement":null},{"id":"W2989489239","doi":"10.25251/skin.3.supp.17","title":"Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Phase (matter); Medicine; Physics","score_opus":0.012942369372670017,"score_gpt":0.31888104224857944,"score_spread":0.3059386728759094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989489239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898077,0.0007022126,0.00005659308,0.007062837,0.00053308456,0.001054104,0.0001451601,0.0000055898718,0.0006327235],"genre_scores_gemma":[0.9944867,0.00026411877,0.00018109626,0.00035090663,0.00037164075,0.000003960178,0.000011314547,0.000022328444,0.004307965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981141,0.0002156545,0.0007842529,0.00013027704,0.0005760882,0.00017959875],"domain_scores_gemma":[0.9961297,0.0020117238,0.00084555586,0.00053446565,0.00035332362,0.00012523534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007553619,0.00016019397,0.0007059192,0.000103808365,0.00003718889,0.0000041798585,0.00021649717,0.000045980683,0.00013956825],"category_scores_gemma":[0.0008157492,0.00006499343,0.00011783931,0.00024195667,0.00019963535,0.00003206071,0.000015743062,0.00016316344,0.00000852434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9307609,0.00058844336,0.0002081722,0.000014874403,0.0015061038,0.00083525816,0.029539412,0.00012909403,0.013802449,0.000023472328,0.007817005,0.014774779],"study_design_scores_gemma":[0.6775671,0.17453691,0.0059005083,0.0046121744,0.0082312375,0.008448963,0.021379618,0.000058396374,0.014036639,0.00021751657,0.08470988,0.00030104868],"about_ca_topic_score_codex":0.00051819114,"about_ca_topic_score_gemma":0.000054683846,"teacher_disagreement_score":0.25319383,"about_ca_system_score_codex":0.00015614236,"about_ca_system_score_gemma":0.00039448767,"threshold_uncertainty_score":0.2650355},"labels":[],"label_agreement":null},{"id":"W2989867317","doi":"10.1016/j.jtho.2019.09.007","title":"Old Soldiers Never Die: Is There Still a Role for Immunohistochemistry in the Era of Next-Generation Sequencing Panel Testing?","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Guideline; Lung cancer; Targeted therapy; Internal medicine; Oncology; ROS1; Cancer; Crizotinib; Biomarker; Tyrosine kinase; Family medicine; Pathology; Adenocarcinoma; Receptor","score_opus":0.07770742997883114,"score_gpt":0.41005362564790665,"score_spread":0.33234619566907553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989867317","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47387424,0.009847497,0.00023414147,0.5096189,0.0015829535,0.001663358,0.0001516857,0.000012349373,0.003014905],"genre_scores_gemma":[0.41565973,0.00049726386,0.014596874,0.5508825,0.009388369,0.00017579213,0.00032391283,0.00013912842,0.0083364565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843603,0.00011816022,0.0007177943,0.00018783979,0.00029522134,0.00024496764],"domain_scores_gemma":[0.99747026,0.00052718486,0.0012059902,0.0002896359,0.00047516535,0.000031779833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048863684,0.00021432793,0.0007190463,0.00012098348,0.000050634982,0.00001997787,0.0002208869,0.0005424093,0.00004763313],"category_scores_gemma":[0.0002455544,0.00013688844,0.0002578531,0.000117362775,0.00006948206,0.00013058337,0.000019592804,0.0014467499,0.0000024119654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010260742,0.00045825,0.0016024272,0.0018496902,0.0017222496,0.0014706928,0.01194647,0.0002533892,0.1552218,0.000004523805,0.72549385,0.09895058],"study_design_scores_gemma":[0.0054142233,0.006938172,0.0021674794,0.0032051732,0.0070981453,0.0036746948,0.0051499396,0.0017427092,0.009685087,0.00059431075,0.95370334,0.0006267306],"about_ca_topic_score_codex":0.00016424425,"about_ca_topic_score_gemma":0.000006005277,"teacher_disagreement_score":0.22820948,"about_ca_system_score_codex":0.0012843618,"about_ca_system_score_gemma":0.0018959357,"threshold_uncertainty_score":0.62854886},"labels":[],"label_agreement":null},{"id":"W2990041408","doi":"10.1056/nejmoa1913662","title":"Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2816,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"AstraZeneca","keywords":"Osimertinib; T790M; Medicine; Oncology; Epidermal growth factor receptor; Lung cancer; Gefitinib; Internal medicine; Hazard ratio; Progression-free survival; Tyrosine kinase; Cancer research; Overall survival; Cancer; Erlotinib; Receptor; Confidence interval","score_opus":0.008928424385361516,"score_gpt":0.29171112979970326,"score_spread":0.28278270541434175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990041408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760741,0.001337043,0.000120876364,0.0081105465,0.000532159,0.00033652232,0.0000025787417,0.000015907497,0.013470257],"genre_scores_gemma":[0.9952014,0.00027423698,0.00049975794,0.0007687793,0.000705462,0.0000018971065,0.000022013248,0.000024769575,0.0025016721],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986443,0.000051260737,0.0004713932,0.00015270954,0.0004547254,0.00022559288],"domain_scores_gemma":[0.9989546,0.00014686042,0.0002605847,0.00016662113,0.00019880196,0.0002725426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027826612,0.00017452001,0.000596835,0.00021681628,0.000020228405,0.0000061273286,0.00007214168,0.00004936562,0.00046227846],"category_scores_gemma":[0.00007622492,0.00009605549,0.000049278005,0.0002711653,0.00004506487,0.00013126178,0.000007844204,0.00029865652,0.000015281586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026090974,0.00074021454,0.6838128,0.00018008891,0.0014379843,0.0037801466,0.0060855416,0.0019899432,0.022813672,0.00042913223,0.0056037293,0.24703579],"study_design_scores_gemma":[0.64681345,0.016035968,0.23599036,0.004459331,0.0014232182,0.0034300007,0.0012743449,0.00014842833,0.00161172,0.00038275679,0.08805318,0.0003772296],"about_ca_topic_score_codex":0.00035081996,"about_ca_topic_score_gemma":0.00012357574,"teacher_disagreement_score":0.6207225,"about_ca_system_score_codex":0.00014495106,"about_ca_system_score_gemma":0.0003888112,"threshold_uncertainty_score":0.5061625},"labels":[],"label_agreement":null},{"id":"W2990452764","doi":"10.1017/s1460396919000876","title":"A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy","year":2019,"lang":"en","type":"review","venue":"Journal of Radiotherapy in Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of Guelph; Grand River Hospital; McMaster University; University of Waterloo","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Cancer; Disease; Intensive care medicine; Oncology; Biomarker; Targeted therapy; Internal medicine; Precision medicine; Pathology","score_opus":0.030818410593622027,"score_gpt":0.4097702745365959,"score_spread":0.3789518639429739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990452764","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026526957,0.9918808,0.00012373083,0.0014650777,0.00041686077,0.0055200593,0.00023323439,0.0000052886744,0.00008971542],"genre_scores_gemma":[0.000027017213,0.9946571,0.0031521325,0.001013208,0.00027465876,0.00067892217,0.000023813449,0.00008157959,0.000091564216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783975,0.00026733332,0.0010311691,0.0003169632,0.0003030234,0.00024176593],"domain_scores_gemma":[0.993846,0.0030161664,0.0022187904,0.00019523011,0.0005616503,0.00016217363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008112895,0.00040337257,0.0022898165,0.00032188816,0.00004302702,0.000028638258,0.0001258827,0.0001947306,0.0000565987],"category_scores_gemma":[0.0008731741,0.0002721728,0.00038072612,0.00037518152,0.000075975266,0.00026611704,0.000011859626,0.00042055207,1.0205996e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000956947,0.00054475124,0.0023290573,0.19774161,0.008463907,0.00006524176,0.0010692843,0.0000025463355,0.0000159362,0.000002167944,0.0044535436,0.784355],"study_design_scores_gemma":[0.006875113,0.0016999845,0.00049270364,0.21473835,0.017530428,0.00050868344,0.000120110286,0.00008893116,0.000004232343,0.0000012171812,0.7576961,0.00024414953],"about_ca_topic_score_codex":0.00023098978,"about_ca_topic_score_gemma":0.0000071939185,"teacher_disagreement_score":0.78411084,"about_ca_system_score_codex":0.000589361,"about_ca_system_score_gemma":0.0032188958,"threshold_uncertainty_score":0.99997306},"labels":[],"label_agreement":null},{"id":"W2990814876","doi":"10.1200/jco.19.01348","title":"Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Lung cancer; Paclitaxel; Placebo; Internal medicine; Quality of life (healthcare); Oncology; Cancer; Chemotherapy; Pathology; Immunotherapy; Cisplatin; Nursing","score_opus":0.07244520924970478,"score_gpt":0.46937271443790735,"score_spread":0.3969275051882026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990814876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386823,0.00060320925,0.000103164006,0.0020828152,0.00032027287,0.0017823435,0.00004208752,0.00001165478,0.001186234],"genre_scores_gemma":[0.99060017,0.000115668125,0.0065358058,0.00128393,0.00008984759,0.000039794268,0.000015460404,0.00005664402,0.001262683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99418676,0.0006444821,0.0035595987,0.00039339793,0.00075518206,0.00046055857],"domain_scores_gemma":[0.9914666,0.0018172386,0.0047217333,0.00038161574,0.00097201904,0.0006408389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017143512,0.0003328776,0.0035230655,0.00023577159,0.00005310301,0.0000104957835,0.00017194422,0.00022600945,0.00026731673],"category_scores_gemma":[0.00072560995,0.0001571799,0.00020490242,0.0004937727,0.00024807852,0.00018373817,0.000031690965,0.0009949019,0.0000045557545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09400023,0.0045431196,0.8940866,0.00066573225,0.0015762872,0.0001680119,0.0012255048,0.0005034114,0.0000044647036,0.000014417098,0.00018008573,0.0030321428],"study_design_scores_gemma":[0.10707459,0.071689144,0.81702834,0.0009049514,0.0015449479,0.00008108446,0.00093814003,0.00026244513,0.0000060384423,0.000008654587,0.0002450892,0.00021660072],"about_ca_topic_score_codex":0.002733272,"about_ca_topic_score_gemma":0.006912347,"teacher_disagreement_score":0.07705828,"about_ca_system_score_codex":0.00068558595,"about_ca_system_score_gemma":0.015074904,"threshold_uncertainty_score":0.99050874},"labels":[],"label_agreement":null},{"id":"W2990936758","doi":"10.1093/annonc/mdz437.001","title":"Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Osimertinib; Internal medicine; T790M; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Phases of clinical research; Platinum; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Gefitinib; Erlotinib","score_opus":0.022808302268853824,"score_gpt":0.38039218338195413,"score_spread":0.3575838811131003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990936758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914966,0.0008271871,0.0000047707667,0.001892338,0.00034888426,0.0040317327,0.00016120396,0.000026265734,0.0012109985],"genre_scores_gemma":[0.99758095,0.0001764204,0.00029617077,0.0009851254,0.00011672199,0.00034526302,0.00016518812,0.00004724149,0.00028689997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786663,0.00016061957,0.0005647588,0.00059348886,0.000394301,0.00042019362],"domain_scores_gemma":[0.9982864,0.00035408704,0.000469456,0.0004366446,0.00028805685,0.0001653421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002367972,0.00033475907,0.00080294796,0.00014185716,0.00010361818,0.00001835281,0.00013912871,0.00014347672,0.00013805086],"category_scores_gemma":[0.000055304998,0.0002085533,0.00007492086,0.00026859593,0.00009017262,0.00013760047,0.00008737078,0.00029620377,0.0000070373585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021904089,0.011276175,0.84633577,0.00012037614,0.00043778642,0.00008104628,0.0057651745,0.00008663477,0.0027051275,0.00001076985,0.0015019106,0.10977512],"study_design_scores_gemma":[0.15068175,0.041581348,0.78839743,0.0014751088,0.0006496151,0.0000020062382,0.0014646474,0.0003751116,0.009787291,0.00001544575,0.005133687,0.0004365271],"about_ca_topic_score_codex":0.001409158,"about_ca_topic_score_gemma":0.000962139,"teacher_disagreement_score":0.12877767,"about_ca_system_score_codex":0.00021989197,"about_ca_system_score_gemma":0.0004863032,"threshold_uncertainty_score":0.8504557},"labels":[],"label_agreement":null},{"id":"W2991043538","doi":"10.1002/cam4.2670","title":"A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses","year":2019,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"National Cancer Institute; Novartis Pharma; National Institutes of Health; Moffitt Cancer Center","keywords":"Lung cancer; Anaplastic lymphoma kinase; Targeted therapy; Medicine; Cancer; Pathology; Adenocarcinoma; Cancer research; Oncology; Internal medicine; Malignant pleural effusion","score_opus":0.08363129157394206,"score_gpt":0.4858314458265126,"score_spread":0.40220015425257055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991043538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5130715,0.004033482,0.0019229495,0.05400189,0.0013512267,0.4186033,0.0010584146,0.00041647593,0.0055407514],"genre_scores_gemma":[0.65116334,0.000042290067,0.0012851644,0.0027424288,0.0009650207,0.33476388,0.0005695218,0.00008490488,0.008383462],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793535,0.00018316331,0.0006237492,0.0004230836,0.00045099904,0.00038362385],"domain_scores_gemma":[0.99806464,0.00019298382,0.00038979805,0.00064014544,0.0005050537,0.00020738924],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005217568,0.00032654093,0.00074144313,0.00021724624,0.0002613617,0.000020870322,0.00016755596,0.00008866331,0.0023385854],"category_scores_gemma":[0.00009305551,0.0002302093,0.00011140313,0.000363408,0.00015913937,0.00011972657,0.000028554326,0.00026664376,0.00000992211],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009290854,0.001608842,0.03925982,0.018378532,0.003044678,0.000024493542,0.0067122183,0.0010123831,0.797823,0.0010351156,0.0729904,0.048819628],"study_design_scores_gemma":[0.066379294,0.0046749273,0.1386866,0.00633845,0.0049704644,0.000007453699,0.001932271,0.0019597,0.19530532,0.000449603,0.57813925,0.0011567136],"about_ca_topic_score_codex":0.010017755,"about_ca_topic_score_gemma":0.0011637622,"teacher_disagreement_score":0.6025177,"about_ca_system_score_codex":0.0013241839,"about_ca_system_score_gemma":0.0010947007,"threshold_uncertainty_score":0.9985734},"labels":[],"label_agreement":null},{"id":"W2991273563","doi":"10.1002/cncr.32503","title":"Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; AstraZeneca","keywords":"T790M; Osimertinib; Medicine; Pemetrexed; Lung cancer; Internal medicine; Liquid biopsy; Epidermal growth factor receptor; Oncology; Resistance mutation; Digital polymerase chain reaction; Cancer; Chemotherapy; Polymerase chain reaction; Biology; Erlotinib; Gefitinib; Reverse transcriptase; Gene; Genetics","score_opus":0.017886191487955706,"score_gpt":0.3392736489653498,"score_spread":0.32138745747739406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991273563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98947734,0.0021835733,0.0006185972,0.0012718773,0.0009789065,0.0036408002,0.0014018149,0.000034102923,0.00039300972],"genre_scores_gemma":[0.9935563,0.00021720325,0.0015959492,0.0003121132,0.0002823273,0.0017048639,0.00089310337,0.00004508228,0.0013930328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984803,0.00006410739,0.00041329418,0.00052094116,0.00021059651,0.00031071255],"domain_scores_gemma":[0.99817526,0.0009816341,0.00027804633,0.0002247687,0.00022317402,0.00011710482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008657653,0.0002592168,0.0005212074,0.00016792906,0.00012165841,0.00004173519,0.000087258355,0.00011617167,0.0008205069],"category_scores_gemma":[0.000112677575,0.00019477106,0.00013965368,0.00058743276,0.00004354898,0.00019364903,0.00002196942,0.00015237137,0.000013773933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13445786,0.0011174846,0.5287664,0.0009154521,0.017676031,0.00007934243,0.059220806,0.020191286,0.033451,0.00016346596,0.0067266454,0.19723424],"study_design_scores_gemma":[0.32736135,0.0024628842,0.502497,0.00074938894,0.016342355,0.0000022872644,0.005275792,0.036765,0.10307885,0.00009855517,0.0041204193,0.0012461216],"about_ca_topic_score_codex":0.0042789853,"about_ca_topic_score_gemma":0.002893549,"teacher_disagreement_score":0.19598813,"about_ca_system_score_codex":0.00057367404,"about_ca_system_score_gemma":0.00035802377,"threshold_uncertainty_score":0.8983975},"labels":[],"label_agreement":null},{"id":"W2991620783","doi":"10.1093/annonc/mdz437.015","title":"Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Afatinib; Osimertinib; Internal medicine; Medical record; Observational study; Oncology; Pediatrics; Cancer; Erlotinib","score_opus":0.03242906789578016,"score_gpt":0.3811680364881982,"score_spread":0.34873896859241804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991620783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961875,0.000032636282,0.0000017430581,0.00056567276,0.00008857843,0.00063247746,0.000024022362,0.0000047042063,0.002462669],"genre_scores_gemma":[0.999511,0.000009964822,0.000042370022,0.00020102524,0.000008393984,0.000009342278,0.000042425912,0.000007799914,0.0001676972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909586,0.00012721063,0.0002923268,0.00017396397,0.00018119556,0.00012945198],"domain_scores_gemma":[0.9992558,0.00007668045,0.00022218804,0.00022006778,0.00018989945,0.000035405614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018386103,0.000085458225,0.0004659715,0.00015947822,0.000020172189,0.0000028612285,0.000057754594,0.000050015387,0.00012355334],"category_scores_gemma":[0.00003374042,0.00005241826,0.00006298461,0.00043792324,0.000057255147,0.000045282388,0.000040254967,0.00007680564,0.0000011010767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006162331,0.001275905,0.99147457,0.0000114865725,0.0020167627,0.000002454884,0.0014846893,0.00010283531,0.00012386029,0.000026375203,0.000069158006,0.0027956418],"study_design_scores_gemma":[0.005222181,0.003080804,0.98961663,0.000029844496,0.001199962,2.9848852e-7,0.00033427277,0.000057239264,0.00013465137,0.000007655556,0.00026820428,0.00004823978],"about_ca_topic_score_codex":0.0007356547,"about_ca_topic_score_gemma":0.00061438564,"teacher_disagreement_score":0.004605948,"about_ca_system_score_codex":0.000032620654,"about_ca_system_score_gemma":0.00014598777,"threshold_uncertainty_score":0.21375547},"labels":[],"label_agreement":null},{"id":"W2991627091","doi":"10.1016/j.jtho.2019.11.004","title":"Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Servier; Berlin Mathematical School; Exelixis; Meso Scale Diagnostics; Takeda Pharmaceutical Company; AbbVie; Gilead Sciences; Takeda Oncology; University of Colorado; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Novartis; GlaxoSmithKline; Sanofi-Aventis Deutschland; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Refractory (planetary science); Oncology; Internal medicine; Lung cancer","score_opus":0.025982608381588577,"score_gpt":0.4525316280524112,"score_spread":0.42654901967082265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991627091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901568,0.00025013523,0.000006885005,0.0038874643,0.0017905161,0.0008873419,0.000009154449,0.000005081704,0.0030065984],"genre_scores_gemma":[0.99803776,0.00007240269,0.00022127508,0.00085257646,0.00038963766,0.000017409786,0.0000047557696,0.000014063957,0.00039010833],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998344,0.00033822737,0.0006856916,0.00015372108,0.0002784058,0.00019993965],"domain_scores_gemma":[0.99863887,0.00059217017,0.00042865716,0.00017577916,0.00007878835,0.00008575377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009856882,0.00013897613,0.0006792931,0.00025770735,0.000030940926,0.000018234805,0.00012347108,0.00014566725,0.00008373351],"category_scores_gemma":[0.00026529178,0.00008109232,0.00012283065,0.00014680176,0.000045335764,0.00011388366,0.000015698384,0.0005427277,0.000021996211],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32843962,0.011643711,0.13962333,0.00041750507,0.0011606616,0.004392328,0.019041086,0.0000415223,0.0050634295,0.00065906666,0.0027382616,0.48677948],"study_design_scores_gemma":[0.7019049,0.07812248,0.15848754,0.0022150862,0.002196669,0.005336233,0.01739861,0.00015481598,0.00028286062,0.0007919473,0.032548044,0.00056082534],"about_ca_topic_score_codex":0.000050818748,"about_ca_topic_score_gemma":0.00007528784,"teacher_disagreement_score":0.48621866,"about_ca_system_score_codex":0.00034623663,"about_ca_system_score_gemma":0.0005349457,"threshold_uncertainty_score":0.3306849},"labels":[],"label_agreement":null},{"id":"W2993751725","doi":"10.1016/j.jtho.2019.11.023","title":"Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; EMD Serono; Daiichi-Sankyo; Clovis Oncology; Sanofi; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; Seattle Genetics; Merck KGaA; Regeneron Pharmaceuticals; Institute of Cancer Research; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Roche; Celgene; Novartis; Amgen; Boehringer Ingelheim; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Bayer; Illumina; Merck; Eli Lilly and Company; Samsung; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Clinical trial; DNA; Oncology; Genetics; Internal medicine","score_opus":0.03973765988084979,"score_gpt":0.5141260334831764,"score_spread":0.47438837360232666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993751725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996129,0.0002773673,0.000042541076,0.001483887,0.00030091015,0.0003829303,0.0000040428195,0.000001405975,0.0013779517],"genre_scores_gemma":[0.99896723,0.000030737378,0.00070964696,0.00006536967,0.0001890099,0.0000034580173,0.0000027871854,0.0000044568956,0.000027275211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998774,0.00026427442,0.0006544912,0.00007303182,0.00013629337,0.000097916185],"domain_scores_gemma":[0.99878156,0.0005314825,0.0004300329,0.00011986241,0.00009433652,0.000042743315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011399823,0.00005644202,0.00036149262,0.00018750028,0.00001739462,0.0000045100264,0.000067372086,0.00009563039,0.00003355568],"category_scores_gemma":[0.00046993405,0.0000334839,0.0001375454,0.000185687,0.00005164877,0.00008551213,0.000014159912,0.0002825542,0.0000016027192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012744619,0.0018722167,0.92684984,0.000046447956,0.00031121922,0.00018628106,0.0030799408,0.0004920498,0.00074581243,0.0001837914,0.00025187136,0.053235915],"study_design_scores_gemma":[0.022252927,0.0063804793,0.9676522,0.00011855057,0.00031803412,0.0003705752,0.0011798043,0.0003419183,0.000006212829,0.0012384166,0.000107241984,0.000033627814],"about_ca_topic_score_codex":0.00015882475,"about_ca_topic_score_gemma":0.00015119673,"teacher_disagreement_score":0.053202286,"about_ca_system_score_codex":0.00044557347,"about_ca_system_score_gemma":0.00073987857,"threshold_uncertainty_score":0.13654338},"labels":[],"label_agreement":null},{"id":"W2994716574","doi":"10.1016/j.lungcan.2019.12.005","title":"Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Company; Allergan Foundation; Sanofi; AstraZeneca; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Internal medicine; Cohort; Microsatellite instability; Clinical trial; Lung cancer; Targeted therapy; Cancer; Gene; Genetics","score_opus":0.027241171574302885,"score_gpt":0.3084478449207322,"score_spread":0.2812066733464293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994716574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703244,0.025930537,0.00003702014,0.0003749006,0.0004689805,0.0009367122,0.000014527916,0.00004599856,0.0018669543],"genre_scores_gemma":[0.9956915,0.0007580369,0.000072195304,0.00051312865,0.00013779024,0.0004239163,0.000083244675,0.000026269801,0.0022939402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906677,0.000018889385,0.00022953379,0.00026880487,0.00017449427,0.00024151223],"domain_scores_gemma":[0.99954766,0.000042417778,0.00007599019,0.00018897468,0.00006992378,0.00007505607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004784544,0.00015995147,0.00022950652,0.00013844768,0.000071701026,0.0000606828,0.00004138695,0.00007706621,0.00034965406],"category_scores_gemma":[0.000009378258,0.00012920005,0.000044765864,0.00021378607,0.000024677627,0.00030633764,0.000020955216,0.00011997328,0.000009201175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046573816,0.00006804452,0.93942726,0.00044514937,0.00012020613,0.000025053894,0.007942177,0.0005154961,0.047708757,0.000087420165,0.0010841414,0.0025297257],"study_design_scores_gemma":[0.012973481,0.00049713196,0.77851,0.0006531006,0.0017971405,0.00003257341,0.0047542127,0.07082287,0.12495109,0.0001330341,0.0038543437,0.0010210521],"about_ca_topic_score_codex":0.00280063,"about_ca_topic_score_gemma":0.0014800869,"teacher_disagreement_score":0.16091728,"about_ca_system_score_codex":0.0007862253,"about_ca_system_score_gemma":0.00025767097,"threshold_uncertainty_score":0.5268625},"labels":[],"label_agreement":null},{"id":"W2996433778","doi":"10.1016/j.ejca.2019.11.006","title":"Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Osimertinib; Gefitinib; Medicine; Erlotinib; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Post-hoc analysis; Oncology; Discontinuation; Clinical endpoint; Performance status; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.012771670707341618,"score_gpt":0.29648738081276316,"score_spread":0.2837157101054215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996433778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110097,0.0014303828,0.00002063723,0.00043525448,0.0016325332,0.001021266,0.00009309446,0.000026893998,0.0042389953],"genre_scores_gemma":[0.9967675,0.0001985489,0.0008403907,0.0005325807,0.00015469568,0.000027752936,0.000054443943,0.00010921611,0.0013148353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975134,0.00012454779,0.0010010501,0.00036174885,0.0005957892,0.00040346518],"domain_scores_gemma":[0.9975275,0.0001194973,0.0011072197,0.00033086637,0.00064385275,0.00027109374],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014811257,0.00035071728,0.000693494,0.00020671793,0.000059416532,0.000036172998,0.00015887847,0.000042554635,0.0013816894],"category_scores_gemma":[0.00005768518,0.00022026249,0.00015637437,0.00035602765,0.000039282622,0.00025725013,0.0000415237,0.00040003358,0.000029482533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011724161,0.0005248149,0.9504127,0.000060240898,0.0014748349,0.0005630903,0.0020026104,0.0013176509,0.00047741397,4.5574166e-7,0.000755529,0.030686514],"study_design_scores_gemma":[0.058237694,0.0023511162,0.93146974,0.0011134933,0.0012256977,0.000005614242,0.00051918067,0.000056917765,0.00090028497,5.371486e-7,0.0038118616,0.00030787534],"about_ca_topic_score_codex":0.0002853855,"about_ca_topic_score_gemma":0.00019392245,"teacher_disagreement_score":0.046513535,"about_ca_system_score_codex":0.0005033337,"about_ca_system_score_gemma":0.0007340283,"threshold_uncertainty_score":0.9995312},"labels":[],"label_agreement":null},{"id":"W2996463763","doi":"10.1093/annonc/mdz453.002","title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; KRAS; Chemotherapy; Placebo; Cancer; Immunotherapy; Pathology; Alternative medicine; Colorectal cancer","score_opus":0.042502437932729425,"score_gpt":0.40823391892670496,"score_spread":0.36573148099397557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996463763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816711,0.0016052005,0.00024294025,0.009147835,0.00018965665,0.003077556,0.00008646309,0.000033846474,0.003945378],"genre_scores_gemma":[0.9902116,0.0017959198,0.0017664485,0.004015585,0.00010558404,0.00033398264,0.00028259656,0.000061156694,0.0014271248],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980583,0.00005709702,0.0005856074,0.00048804138,0.0002704793,0.0005404795],"domain_scores_gemma":[0.99792063,0.0009686046,0.00030012886,0.0003036382,0.0003078516,0.00019916994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028616117,0.00031287092,0.0009609829,0.00025780062,0.000073803276,0.000015702806,0.000113052745,0.00018160968,0.00038386413],"category_scores_gemma":[0.0001447429,0.0002664691,0.00017438582,0.0002428188,0.00014913963,0.00012224716,0.00002354977,0.00018820672,0.000033574],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24830797,0.017195644,0.019032687,0.002755683,0.0065627536,0.0004710802,0.049102306,0.008945302,0.010256687,0.0051571294,0.012750816,0.61946195],"study_design_scores_gemma":[0.5428581,0.050246403,0.20042664,0.0005297078,0.0009195018,0.000463179,0.0018619888,0.011584029,0.028291702,0.005810839,0.15559581,0.0014121109],"about_ca_topic_score_codex":0.0005050968,"about_ca_topic_score_gemma":0.00015107098,"teacher_disagreement_score":0.61804986,"about_ca_system_score_codex":0.00032647865,"about_ca_system_score_gemma":0.0017242591,"threshold_uncertainty_score":0.9999788},"labels":[],"label_agreement":null},{"id":"W2997252595","doi":"10.1002/9780471420194.tnmm05","title":"Assessment of Treatment Outcome","year":2017,"lang":"en","type":"other","venue":"TNM Online","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Proportional hazards model; Outcome (game theory); Medicine; Oncology; Hazard ratio; Cancer; Clinical trial; Regression; Internal medicine; Survival analysis; Event (particle physics); Statistics; Confidence interval; Mathematics","score_opus":0.05118033448380055,"score_gpt":0.47340448709185434,"score_spread":0.4222241526080538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997252595","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002406591,0.0007021212,0.000033962064,0.0003393455,0.00028317358,0.0006048805,0.00612453,0.000083496816,0.9915878],"genre_scores_gemma":[0.0033223676,0.00046633204,0.0067194984,0.00006950372,0.0004022869,0.000044591783,0.0039675236,0.00017295101,0.98483497],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994078,0.000007343832,0.00016341599,0.0001828493,0.0001260191,0.0001125389],"domain_scores_gemma":[0.99903244,0.000012210191,0.00026443583,0.0005884001,0.000029061457,0.00007347046],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000015160931,0.00018488352,0.00051985047,0.00011686448,0.000023189688,0.0000045887587,0.00006187816,0.00011445774,0.0067305136],"category_scores_gemma":[0.000010625112,0.00012325039,0.00013946598,0.000023331011,0.000043994733,0.000008558269,0.000015676234,0.000060862105,0.000031290583],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021136848,0.0026983556,0.05440228,0.0004797337,0.0031850636,0.00014615296,0.00006632816,0.0000010503425,0.000056066994,0.00033375405,0.88435656,0.054253526],"study_design_scores_gemma":[0.0018893284,0.00056772167,0.030020202,0.00039145516,0.0010431098,0.0000070851206,0.000008825476,0.000014035629,0.000006273878,0.000005098784,0.96595573,0.00009111465],"about_ca_topic_score_codex":0.0011263603,"about_ca_topic_score_gemma":0.00065699057,"teacher_disagreement_score":0.0815992,"about_ca_system_score_codex":0.00029578776,"about_ca_system_score_gemma":0.00041336718,"threshold_uncertainty_score":0.99417746},"labels":[],"label_agreement":null},{"id":"W2998884390","doi":"10.1016/s0923-7534(20)34338-6","title":"Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Crizotinib; Medicine; Pemetrexed; Docetaxel; Oncology; Lung cancer; Chemotherapy; Internal medicine; non-small cell lung cancer (NSCLC); Cisplatin","score_opus":0.039196196959662574,"score_gpt":0.42555613764309647,"score_spread":0.3863599406834339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998884390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005145,0.00049114175,0.000015347283,0.0002469971,0.0002356924,0.0020002984,0.000085026004,0.00001078915,0.0068632513],"genre_scores_gemma":[0.9981342,0.00014791869,0.0006093729,0.00032372386,0.00005971049,0.00024331501,0.00006443251,0.000028042316,0.00038929092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877036,0.000057311387,0.0003929001,0.0002332292,0.00019656867,0.00034962222],"domain_scores_gemma":[0.99877936,0.00013458844,0.00034716135,0.00022161925,0.00038858736,0.00012868464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011947381,0.00018672047,0.00062423456,0.00016940174,0.000036719393,0.0000021436697,0.000080445374,0.00008282149,0.00029933563],"category_scores_gemma":[0.000022269242,0.00013170409,0.000057340483,0.00031580604,0.000062264764,0.000121925674,0.000023638766,0.00011741637,0.0000022401055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1124784,0.09464073,0.57957166,0.00028395082,0.002459187,0.000046423404,0.035221744,0.000050986815,0.0019072657,0.000014186656,0.0024617084,0.17086378],"study_design_scores_gemma":[0.3448729,0.09766409,0.5228305,0.00027553792,0.0011333497,0.0000016077599,0.006042017,0.00004338523,0.024781402,0.0000014934948,0.002034394,0.00031934664],"about_ca_topic_score_codex":0.0006962904,"about_ca_topic_score_gemma":0.00035563894,"teacher_disagreement_score":0.2323945,"about_ca_system_score_codex":0.00014310323,"about_ca_system_score_gemma":0.0004282408,"threshold_uncertainty_score":0.5370737},"labels":[],"label_agreement":null},{"id":"W2998933016","doi":"10.1016/s0923-7534(20)32761-7","title":"Prognostic and Predictive Values of KRAS in EGFR-Based Subgroups and Combined With p53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): A Lace-Bio Study","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; KRAS; Oncology; Internal medicine; Lung cancer; non-small cell lung cancer (NSCLC); Cancer; Colorectal cancer","score_opus":0.04513412016362859,"score_gpt":0.3880614483762426,"score_spread":0.342927328212614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998933016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489707,0.0016851154,0.000016199645,0.00063873065,0.000035513433,0.0018392643,0.00004142234,0.0000068342747,0.00083987345],"genre_scores_gemma":[0.9992022,0.000104816056,0.00021669253,0.0001492752,0.000019949575,0.00023773454,0.000021596437,0.000013916731,0.00003380349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990119,0.00015083795,0.00028793718,0.00018900236,0.000115881325,0.00024449578],"domain_scores_gemma":[0.999106,0.0003370035,0.00015919334,0.000118734104,0.00018155364,0.00009750608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028070924,0.00012890121,0.0004957016,0.00020827157,0.00002629653,0.0000028306952,0.000038888465,0.00007365778,0.000011447542],"category_scores_gemma":[0.000053558335,0.0000979032,0.000018919136,0.0002467761,0.00015428655,0.000049136434,0.000026529102,0.00013689249,1.7996477e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002806889,0.0035689818,0.9819309,0.0002448157,0.00019182595,0.000033829507,0.009703724,0.000037799626,0.00069264544,0.000010558844,0.00010945299,0.0006685584],"study_design_scores_gemma":[0.012387818,0.0150858825,0.9680028,0.0002963622,0.00037531488,0.000004259007,0.0020476733,0.0005540445,0.001108372,0.000014050715,0.000042822037,0.00008062879],"about_ca_topic_score_codex":0.0017310374,"about_ca_topic_score_gemma":0.002709803,"teacher_disagreement_score":0.013928147,"about_ca_system_score_codex":0.00007764347,"about_ca_system_score_gemma":0.00036829532,"threshold_uncertainty_score":0.39923766},"labels":[],"label_agreement":null},{"id":"W2999193669","doi":"10.1016/s0923-7534(20)33813-8","title":"Metastatic Nsclc Outcomes at a Single Canadian Institution Over a Decade","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; Internal medicine; Expanded access","score_opus":0.1073378157124141,"score_gpt":0.44809259043218,"score_spread":0.3407547747197659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999193669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9281721,0.0009102886,0.000023748853,0.008977739,0.00032680016,0.00024894066,0.000036686764,0.000013118414,0.06129057],"genre_scores_gemma":[0.99344665,0.000036700563,0.0005329673,0.004504648,0.000048144444,0.000024362505,0.00003590874,0.0000071450595,0.0013634728],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993953,0.000025630807,0.00015666157,0.000079530095,0.000082370796,0.0002605124],"domain_scores_gemma":[0.9994437,0.00004880624,0.000066972854,0.00011352745,0.00006996228,0.0002570103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009458873,0.00007211088,0.0002321249,0.00012691563,0.000062841296,0.000001919897,0.00002765458,0.000053398624,0.00030846687],"category_scores_gemma":[0.00008386553,0.000055475557,0.000069135,0.000090653906,0.00006119992,0.00008909607,0.000012113818,0.00004388874,0.000060575723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024922518,0.0024064167,0.82026845,0.000103958104,0.0016964347,0.00014313565,0.0057342444,0.000014387371,0.00384506,0.009993105,0.04412611,0.111419454],"study_design_scores_gemma":[0.0018349866,0.0009900654,0.43268514,0.000026448664,0.00040378512,0.00007523541,0.00013950691,0.0000056702875,0.0021561128,0.00011865308,0.5614808,0.000083550505],"about_ca_topic_score_codex":0.023713242,"about_ca_topic_score_gemma":0.038198646,"teacher_disagreement_score":0.5173547,"about_ca_system_score_codex":0.00035618592,"about_ca_system_score_gemma":0.0005008366,"threshold_uncertainty_score":0.9827879},"labels":[],"label_agreement":null},{"id":"W2999203985","doi":"10.1016/s2213-2600(19)30267-x","title":"Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study","year":2020,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Medical Research Council; Novartis Institutes for BioMedical Research; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Oncology; Open label; Internal medicine; Lung; Phases of clinical research; Small Cell Lung Carcinoma; Carcinoma; Mutant; Small-cell carcinoma; Clinical trial; Genetics","score_opus":0.05330810440844667,"score_gpt":0.3645879452239147,"score_spread":0.311279840815468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999203985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861437,0.002201222,0.000035991132,0.005457447,0.00005211156,0.0037954545,0.000030358671,0.000029504998,0.0022541732],"genre_scores_gemma":[0.99633235,0.00008989293,0.00012509427,0.0028959797,0.00036657572,0.000089800276,0.00001892951,0.000031916654,0.000049482278],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982296,0.00014605993,0.000553721,0.00042981404,0.00031650648,0.00032426056],"domain_scores_gemma":[0.9986779,0.0002174986,0.00023408099,0.000501066,0.00011962665,0.0002498449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046147406,0.00025128073,0.0008934004,0.00007368978,0.00009676923,0.000011504373,0.00026443833,0.000045713517,0.00006390632],"category_scores_gemma":[0.0001603011,0.0001360603,0.000018772067,0.00047647287,0.00017847396,0.00007312903,0.00012210563,0.00029133502,0.0000043059463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06833729,0.010011563,0.7668893,0.0018071696,0.00086388085,0.0017153475,0.12018086,0.000052197625,0.014417344,0.00009673339,0.0033230311,0.012305333],"study_design_scores_gemma":[0.54926115,0.024044195,0.3955855,0.0020573882,0.002131712,0.000027945396,0.016809814,0.002135734,0.0021940742,0.000003325369,0.005354325,0.0003948522],"about_ca_topic_score_codex":0.0004030464,"about_ca_topic_score_gemma":0.00021900129,"teacher_disagreement_score":0.48092383,"about_ca_system_score_codex":0.00008956592,"about_ca_system_score_gemma":0.00025897066,"threshold_uncertainty_score":0.5548378},"labels":[],"label_agreement":null},{"id":"W2999298181","doi":"10.1016/s0923-7534(20)33848-5","title":"Population Based Evaluation of Chemotherapy Use After First Line Gefitinib in Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gefitinib; Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Chemotherapy; Mutation; Epidermal growth factor; Population; Internal medicine; non-small cell lung cancer (NSCLC); Cancer research; Cancer; Receptor; Gene; Genetics; Biology","score_opus":0.05289967424600631,"score_gpt":0.4266385546678521,"score_spread":0.3737388804218458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999298181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945495,0.0008420296,0.0003196966,0.0022991807,0.00020347192,0.001204057,0.00016803751,0.000010341331,0.0004036434],"genre_scores_gemma":[0.99606246,0.00023907289,0.0017640588,0.0010172531,0.000115813134,0.00031209568,0.0004130215,0.000023725615,0.00005249497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987356,0.00013493856,0.0004553025,0.00018908277,0.00023910479,0.00024593718],"domain_scores_gemma":[0.99846476,0.0002210313,0.00036894061,0.00013131993,0.0007261813,0.00008774999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003194986,0.00014798593,0.00038631493,0.00019505093,0.000027737316,0.0000033959886,0.00003508881,0.00014466427,0.00036085857],"category_scores_gemma":[0.00012372473,0.0001337057,0.00009249861,0.00019456937,0.000030338508,0.0002817269,0.00000834725,0.00009031106,0.0000026862667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017870938,0.0015709954,0.9300008,0.00023355197,0.00014419592,0.0000037825055,0.0041039367,0.0012255979,0.0048368634,0.000014686901,0.00016967858,0.05590886],"study_design_scores_gemma":[0.0065288926,0.000872359,0.94925296,0.00023921266,0.000266677,0.0000015221498,0.00008269569,0.0020034944,0.040423013,0.0000168656,0.00019988722,0.00011244251],"about_ca_topic_score_codex":0.0013041954,"about_ca_topic_score_gemma":0.00053302787,"teacher_disagreement_score":0.055796415,"about_ca_system_score_codex":0.00036501148,"about_ca_system_score_gemma":0.0003940236,"threshold_uncertainty_score":0.54523605},"labels":[],"label_agreement":null},{"id":"W2999480386","doi":"10.1016/s0923-7534(20)33857-6","title":"Impact of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer research; Tyrosine kinase; Lung cancer; Oncology; Growth factor receptor inhibitor; Growth factor receptor; Internal medicine; Receptor; Cancer","score_opus":0.08292570209141926,"score_gpt":0.44010391423321615,"score_spread":0.3571782121417969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999480386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98443854,0.012230256,0.000033444714,0.0011794226,0.0001043903,0.0007474387,0.00038630568,0.000015894799,0.00086431147],"genre_scores_gemma":[0.9964929,0.0014350837,0.0010266618,0.00018114537,0.00009209799,0.00027843183,0.00009851454,0.000027108834,0.00036802236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984576,0.00011239896,0.0005982507,0.00025277855,0.00014659786,0.0004323897],"domain_scores_gemma":[0.99859977,0.00017448948,0.0004193423,0.0002825594,0.00028699823,0.0002368533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014913178,0.00025411838,0.0016705685,0.00040777627,0.000023252302,0.0000026115588,0.000066849076,0.000134309,0.000628362],"category_scores_gemma":[0.000040298775,0.00016962922,0.0012312918,0.00058282755,0.0000624129,0.00013331015,0.000024458051,0.00008968898,0.0000036337424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008347469,0.006591348,0.8681519,0.00016640684,0.088776745,0.000027961263,0.0040737465,0.00049299205,0.019804886,0.000023169434,0.0011577698,0.009898303],"study_design_scores_gemma":[0.008617006,0.009714669,0.6947242,0.00003727937,0.1367761,0.0000061277115,0.0002849299,0.00010400015,0.1466439,0.0000114540535,0.0027383224,0.00034197007],"about_ca_topic_score_codex":0.0061512757,"about_ca_topic_score_gemma":0.0004942195,"teacher_disagreement_score":0.1734277,"about_ca_system_score_codex":0.00048369064,"about_ca_system_score_gemma":0.0006322178,"threshold_uncertainty_score":0.92989296},"labels":[],"label_agreement":null},{"id":"W2999534522","doi":"10.1016/s0923-7534(20)33860-6","title":"Lux-Lung 3: Symptom and Health-Related Quality of Life Results from a Randomized Phase III Study in 1st-Line Advanced NSCLC Patients Harbouring EGFR Mutations","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Quality of life (healthcare); Lung cancer; Internal medicine; Lung; Nursing","score_opus":0.09859896412834444,"score_gpt":0.4854044553841062,"score_spread":0.38680549125576175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999534522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914308,0.0023136325,0.00003582485,0.0028855118,0.00017907341,0.002073696,0.00020719228,0.000018140887,0.0008561007],"genre_scores_gemma":[0.998389,0.0002163117,0.00040675112,0.00041509548,0.000036163474,0.00012054978,0.0003527141,0.000013109181,0.000050312083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973361,0.00046824513,0.0015197662,0.0002269082,0.00018476736,0.00026420195],"domain_scores_gemma":[0.9976186,0.00083652267,0.0008723746,0.00021286264,0.00024755448,0.00021205601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013428952,0.00014078354,0.0013068685,0.0001833162,0.000054005086,0.0000026333603,0.00004680462,0.00008777696,0.00002913937],"category_scores_gemma":[0.0009942556,0.000116712334,0.000093991075,0.00020407891,0.000118732976,0.00013765266,0.000033723918,0.000130948,0.0000014204215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38824677,0.049984146,0.36088935,0.00029564067,0.004670386,0.000027764303,0.0998266,0.00028065208,0.0005523052,0.0005276006,0.0006898647,0.09400892],"study_design_scores_gemma":[0.65203685,0.0026504095,0.3423933,0.00015334495,0.00031902743,9.431906e-7,0.0017821667,0.00017380678,0.00016329918,0.000119425364,0.00010395971,0.00010343021],"about_ca_topic_score_codex":0.0052946815,"about_ca_topic_score_gemma":0.00038013057,"teacher_disagreement_score":0.2637901,"about_ca_system_score_codex":0.00010055561,"about_ca_system_score_gemma":0.0003549984,"threshold_uncertainty_score":0.80040103},"labels":[],"label_agreement":null},{"id":"W2999685386","doi":"10.1016/s0923-7534(20)33845-x","title":"Activity of Afatinib in Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations in Lux-Lung 3, A Phase III Trial of Afatinib or Cisplatin/Pemetrexed in EGFR Mutation-Positive Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; T790M; Pemetrexed; Lung cancer; Internal medicine; Epidermal growth factor receptor; Population; Oncology; Cisplatin; Phases of clinical research; Gastroenterology; Erlotinib; Cancer; Chemotherapy; Gefitinib","score_opus":0.08199493858895551,"score_gpt":0.47671318873482305,"score_spread":0.39471825014586753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999685386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934102,0.00048223019,0.000082166254,0.0016056612,0.0003377148,0.0018906251,0.00046889886,0.00001089883,0.0017115853],"genre_scores_gemma":[0.99799144,0.00020833325,0.00079009635,0.00014774699,0.00011067415,0.00043894222,0.0001961972,0.000024791836,0.00009177085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974542,0.00040873376,0.0011484727,0.00027816728,0.00028097487,0.0004294226],"domain_scores_gemma":[0.9970679,0.0013975018,0.0008483773,0.00019722327,0.00035167506,0.00013731002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054571085,0.0002315875,0.0011047788,0.0007163105,0.000032650027,0.000003078586,0.00009826508,0.00022672993,0.00045136124],"category_scores_gemma":[0.0006988492,0.00020080013,0.000142473,0.00097596075,0.00016134598,0.00036506096,0.000037286518,0.00027621185,0.0000013429734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16885321,0.03699758,0.5044758,0.0013183278,0.0018534194,0.00018980076,0.06485227,0.00062797894,0.034713835,0.0010013208,0.001698743,0.18341775],"study_design_scores_gemma":[0.275602,0.009588451,0.60228914,0.0011595408,0.0006580328,0.000017245311,0.0035593237,0.0018179618,0.1045297,0.00012081156,0.0001912719,0.00046650498],"about_ca_topic_score_codex":0.007010652,"about_ca_topic_score_gemma":0.0047213254,"teacher_disagreement_score":0.18295124,"about_ca_system_score_codex":0.0004688001,"about_ca_system_score_gemma":0.0011365719,"threshold_uncertainty_score":0.9996017},"labels":[],"label_agreement":null},{"id":"W2999692341","doi":"10.1016/s0923-7534(20)33839-4","title":"A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Ramucirumab; Chemotherapy; Oncology; Internal medicine; Lung cancer; Cancer","score_opus":0.04621980569752529,"score_gpt":0.4137215862708068,"score_spread":0.36750178057328153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999692341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98955894,0.00031931477,0.00012995662,0.0005050524,0.00017318015,0.008184463,0.00016538416,0.00001330617,0.0009504096],"genre_scores_gemma":[0.99582446,0.000114526796,0.0018879387,0.0004476047,0.000030701205,0.0011852096,0.00035509685,0.000047168935,0.000107284766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974328,0.00029071316,0.0010231525,0.00046577698,0.00034700462,0.00044049753],"domain_scores_gemma":[0.9973254,0.000641383,0.0009825929,0.0004007273,0.0004943427,0.0001555355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006271392,0.0003310718,0.001528197,0.00031439192,0.00004761021,0.00001053009,0.00020011816,0.00014633182,0.000057353078],"category_scores_gemma":[0.00012669162,0.0002216881,0.000053207077,0.0005209909,0.00011036465,0.0002244038,0.000041743107,0.0002326882,0.000001401966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71667093,0.1237006,0.06893208,0.00015999808,0.0005599988,0.000040605395,0.017655365,0.00044048543,0.00026341667,0.0000029761288,0.0003936428,0.07117988],"study_design_scores_gemma":[0.9188989,0.037659474,0.03650961,0.0006954883,0.00045159564,6.675829e-7,0.0011651483,0.0016948853,0.002508108,0.0000064054384,0.00016618322,0.00024354024],"about_ca_topic_score_codex":0.0043285177,"about_ca_topic_score_gemma":0.005354306,"teacher_disagreement_score":0.20222794,"about_ca_system_score_codex":0.0003548483,"about_ca_system_score_gemma":0.0010631259,"threshold_uncertainty_score":0.9040178},"labels":[],"label_agreement":null},{"id":"W3000047582","doi":"10.1016/s0923-7534(20)34342-8","title":"Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Internal medicine; Placebo; Discontinuation; Lung cancer; Randomized controlled trial; Progression-free survival; Oncology; Surgery; Chemotherapy; Gastroenterology; Pathology; Hepatocellular carcinoma","score_opus":0.04848366754662953,"score_gpt":0.42563248272010473,"score_spread":0.3771488151734752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000047582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885413,0.0008214564,0.00013654509,0.0007777129,0.0002390359,0.0060940315,0.000016781369,0.0000075912535,0.003365557],"genre_scores_gemma":[0.99804604,0.00029099517,0.00027864598,0.00019459456,0.00013369512,0.0005813648,0.00008775096,0.000015923515,0.00037096982],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986618,0.000117890406,0.0006600976,0.00015577814,0.00016983048,0.00023459342],"domain_scores_gemma":[0.9986896,0.00020240224,0.0005942098,0.0001522152,0.00023878065,0.0001227935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047261044,0.00015285746,0.0011367977,0.00017007496,0.000028504111,0.0000032716341,0.000051758514,0.00013983231,0.00013070156],"category_scores_gemma":[0.00002438168,0.00010115441,0.0001541365,0.00012871639,0.000069325,0.0000969674,0.000007265076,0.000095455354,8.926221e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9803579,0.0065790727,0.0051823375,0.000056941248,0.00051293056,0.0000036025676,0.0015054401,0.00003658856,0.00023139201,0.000022769244,0.00030834545,0.005202705],"study_design_scores_gemma":[0.9837394,0.0074236207,0.00040760162,0.00008423389,0.00070679426,7.979518e-7,0.00008370602,0.00012299912,0.006782235,0.0000067225365,0.0005549344,0.00008695221],"about_ca_topic_score_codex":0.00031011656,"about_ca_topic_score_gemma":0.000065189684,"teacher_disagreement_score":0.009504771,"about_ca_system_score_codex":0.000078536534,"about_ca_system_score_gemma":0.00076204,"threshold_uncertainty_score":0.4124957},"labels":[],"label_agreement":null},{"id":"W3000072015","doi":"10.1093/aje/161.supplement_1.s67","title":"265-S: Methodological Differences Influencing Treatment Effect","year":2005,"lang":"en","type":"article","venue":"American Journal of Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Parkwood Institute","funders":"","keywords":"Medicine","score_opus":0.11522757685083267,"score_gpt":0.46891819723419426,"score_spread":0.3536906203833616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000072015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98633343,0.001953867,0.0033557974,0.0072883926,0.00012929364,0.00013067354,0.0000022811223,0.000014900519,0.00079134526],"genre_scores_gemma":[0.94394195,0.0006266181,0.052608557,0.0022306948,0.00046117642,0.000011308753,0.0000024897072,0.000008393478,0.000108810935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997646,0.0011981156,0.0006353953,0.00016109891,0.00008396851,0.00027547215],"domain_scores_gemma":[0.9937486,0.0051665283,0.0006269252,0.0001464781,0.00008309248,0.00022838755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013469921,0.00016243453,0.0012491748,0.00012373868,0.000050469633,0.0000027558617,0.00007332027,0.00004845225,0.00012777136],"category_scores_gemma":[0.0023467185,0.00008074479,0.00028577694,0.00012854587,0.00029203316,0.00005460325,0.000011565,0.00016803203,0.00001669123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036983233,0.00012939164,0.51420593,0.0000050119625,0.00062650547,0.00004961212,0.00032884363,0.00013341766,0.0004092986,0.00021244978,0.0002535119,0.4832762],"study_design_scores_gemma":[0.0043569803,0.04159185,0.91340446,0.00014885655,0.0018792697,0.0026453296,0.0006029381,0.00019297858,0.0008466831,0.0008776016,0.033230886,0.0002221587],"about_ca_topic_score_codex":0.00017848844,"about_ca_topic_score_gemma":0.000010330368,"teacher_disagreement_score":0.48305404,"about_ca_system_score_codex":0.00033492106,"about_ca_system_score_gemma":0.00013967346,"threshold_uncertainty_score":0.32926768},"labels":[],"label_agreement":null},{"id":"W3000084601","doi":"10.1016/s0923-7534(20)33847-3","title":"Pooled Analysis of Clinical Outcomes for Patients with EGFR Mutations in Non-Small-Cell Lung Cancer: An Update","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Erlotinib; Oncology; Gefitinib; Internal medicine; Lung cancer; Clinical trial; Chemotherapy regimen; Chemotherapy; Hazard ratio; Progression-free survival; Confidence interval; Cancer; Epidermal growth factor receptor","score_opus":0.06164023516607116,"score_gpt":0.4809542764778358,"score_spread":0.41931404131176464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000084601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680644,0.00015765232,0.00018231,0.0011140598,0.000114981056,0.00062297,0.00018981818,0.000005771881,0.0008059963],"genre_scores_gemma":[0.99601895,0.00009912481,0.0024036327,0.0007936971,0.00003405759,0.00014042876,0.0003927367,0.000011061202,0.0001063373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989509,0.000054258897,0.00054013333,0.00014889623,0.000097187454,0.00020863836],"domain_scores_gemma":[0.99876213,0.00023566252,0.00033802868,0.00018218604,0.00035816885,0.00012384247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025325423,0.0000924425,0.00071052235,0.00026023816,0.000023138262,0.0000015675936,0.00005625456,0.00009111544,0.00006301989],"category_scores_gemma":[0.000060142316,0.0000664927,0.00017621568,0.0003466349,0.00006134735,0.00009024722,0.000012051712,0.00006300047,8.655272e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032137605,0.003340843,0.9791554,0.000044935874,0.002983766,0.000001191811,0.00080566964,0.00018471344,0.000007802046,0.00006214777,0.00023774794,0.012854356],"study_design_scores_gemma":[0.0051107123,0.0018178726,0.98471546,0.00001778847,0.0065561715,1.3615335e-7,0.00017916522,0.0003992979,0.000090177324,0.0000117988275,0.0010386802,0.00006273362],"about_ca_topic_score_codex":0.0005990545,"about_ca_topic_score_gemma":0.0011833739,"teacher_disagreement_score":0.012791622,"about_ca_system_score_codex":0.00004449162,"about_ca_system_score_gemma":0.00029756373,"threshold_uncertainty_score":0.27114937},"labels":[],"label_agreement":null},{"id":"W3000276501","doi":"10.1007/s10147-020-01615-y","title":"Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis","year":2020,"lang":"en","type":"article","venue":"International Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Lung cancer; Proportional hazards model; Incidence (geometry); Oncology; Body mass index; Hormone replacement therapy (female-to-male); Cancer; Post-hoc analysis; Prostate cancer; Multivariate analysis; Gynecology; Confidence interval; Testosterone (patch)","score_opus":0.20062674201088657,"score_gpt":0.5646668424454658,"score_spread":0.36404010043457924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000276501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97218263,0.00024342415,0.0001178056,0.026774913,0.00020705181,0.00038283857,0.000009639247,0.000003080949,0.0000786078],"genre_scores_gemma":[0.99153477,0.00048381626,0.0003596708,0.007118706,0.00031293897,0.00016247614,0.000004837072,0.0000050435383,0.000017715869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763316,0.00038817053,0.0013014827,0.00016663631,0.0003837464,0.00012681264],"domain_scores_gemma":[0.997123,0.0017375947,0.00057591184,0.00009175903,0.000298985,0.00017274669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020037969,0.000077833094,0.0004938544,0.00018078006,0.00002256194,0.00003131743,0.00014408208,0.00007558488,0.00007711937],"category_scores_gemma":[0.0031863363,0.0000504218,0.00012930707,0.00037274367,0.000058753125,0.00017399505,0.00003488729,0.00036900336,8.1037285e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026616877,0.00044200648,0.9583363,0.0000021672352,0.0011275028,0.00019880365,0.0069369827,0.0006847878,0.000009335628,0.000047004713,0.00014202393,0.0054561943],"study_design_scores_gemma":[0.02482628,0.0036305145,0.9682826,0.000034719433,0.00034642816,0.0000060664474,0.0007075812,0.0011579683,0.0000013629792,0.00005258271,0.00090951216,0.00004439478],"about_ca_topic_score_codex":0.0006557925,"about_ca_topic_score_gemma":0.001323977,"teacher_disagreement_score":0.019656207,"about_ca_system_score_codex":0.00037569075,"about_ca_system_score_gemma":0.0004884322,"threshold_uncertainty_score":0.3814572},"labels":[],"label_agreement":null},{"id":"W3000729903","doi":"10.1016/s0923-7534(20)31932-3","title":"Lux-Lung 3: Afatinib Versus Cisplatin and Pemetrexed in Japanese Patients with Adenocarcinoma of the Lung Harboring an EGFR Mutation","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Cisplatin; Oncology; Adenocarcinoma; Internal medicine; Lung cancer; Lung; Chemotherapy; Cancer research; Erlotinib; Epidermal growth factor receptor; Cancer","score_opus":0.04714006362605189,"score_gpt":0.3980594596395092,"score_spread":0.35091939601345734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000729903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962152,0.0008683453,0.0000023837893,0.0003610786,0.00014964375,0.0004095839,0.000012577311,0.00000561195,0.0019755682],"genre_scores_gemma":[0.9994337,0.000022724415,0.0003069682,0.000093572635,0.000038551632,0.000026114703,0.000030671697,0.000010660902,0.00003705097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992767,0.00006647247,0.00022296494,0.00011526082,0.00014441514,0.00017421332],"domain_scores_gemma":[0.99932843,0.00011715102,0.00018443118,0.00015364427,0.00014425375,0.000072068804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013842424,0.00008642688,0.00023101328,0.0000961746,0.00003172758,0.0000021070719,0.00004348419,0.000061320425,0.00002711823],"category_scores_gemma":[0.00008127135,0.000057172656,0.000027420396,0.00018434419,0.00007855606,0.00015689526,0.000022274951,0.00007633813,4.8976807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007658537,0.00054936635,0.9835843,0.00007015956,0.000117532734,0.0000035166647,0.0065834564,0.000015997563,0.0001317779,0.0001106193,0.000081376325,0.00798605],"study_design_scores_gemma":[0.005580985,0.0017112335,0.99053156,0.00006901863,0.00020539411,0.0000038304393,0.00094651175,0.0001203125,0.0006909513,0.0000060213006,0.00008148744,0.000052689637],"about_ca_topic_score_codex":0.0003120431,"about_ca_topic_score_gemma":0.00010259073,"teacher_disagreement_score":0.0079333605,"about_ca_system_score_codex":0.000064933694,"about_ca_system_score_gemma":0.000102541046,"threshold_uncertainty_score":0.23314333},"labels":[],"label_agreement":null},{"id":"W3001249325","doi":"10.1177/1758835919895756","title":"Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; ROS1; Epidermal growth factor receptor; Medicine; Mutation; Lung cancer; Anaplastic large-cell lymphoma; PI3K/AKT/mTOR pathway; ERBB3; Fusion gene; Protein kinase domain; Cancer; Lymphoma; Biology; Gene; Oncology; Signal transduction; Adenocarcinoma; Genetics; Immunology; Internal medicine","score_opus":0.01754185532272969,"score_gpt":0.38092515561861406,"score_spread":0.3633833002958844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001249325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009568461,0.99112487,0.0037830186,0.0007532045,0.0008549815,0.0017994721,0.00005899177,0.000060177288,0.0006084636],"genre_scores_gemma":[0.005955652,0.9899852,0.0012930114,0.0011517449,0.00050044415,0.0005395826,0.00043518326,0.00007784426,0.00006128781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693435,0.0003506556,0.0009862294,0.0007368574,0.0005004109,0.00049146434],"domain_scores_gemma":[0.9975937,0.0011302744,0.00057938905,0.00015876199,0.00010998387,0.0004278847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023352163,0.0005333476,0.001991994,0.00027023343,0.00013591805,0.00001613246,0.00017399946,0.00061492884,0.00034105737],"category_scores_gemma":[0.00022108686,0.00040676497,0.00018181774,0.00045529468,0.0002533121,0.00017385188,0.00008754366,0.0005856515,0.000016862883],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011694284,0.0002662014,0.00023682941,0.007146043,0.00022082076,0.002088942,0.0010903376,0.00001240888,0.0000032306546,0.00007794573,0.000032886015,0.9887074],"study_design_scores_gemma":[0.0072484165,0.0015646714,0.00033548527,0.0067930543,0.0042642304,0.0004991841,0.0003843027,0.0038251241,0.000009400781,0.00027735365,0.9741959,0.0006028795],"about_ca_topic_score_codex":0.000079232486,"about_ca_topic_score_gemma":0.00009050827,"teacher_disagreement_score":0.9881045,"about_ca_system_score_codex":0.0013057769,"about_ca_system_score_gemma":0.0024724677,"threshold_uncertainty_score":0.9998384},"labels":[],"label_agreement":null},{"id":"W3001536410","doi":"10.1016/s0923-7534(20)33874-6","title":"Cumulative Exposure (EXP) to Bevacizumab (BV) Maintenance after Induction Therapy and Survival in Advanced Non-Small Cell Lung Cancer (NSCLC): A Time-Dependent Analysis from the Sail (MO19390) Study","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Oncology; Lung cancer; Internal medicine; Maintenance therapy; Chemotherapy","score_opus":0.039496959540608716,"score_gpt":0.39129361905550136,"score_spread":0.35179665951489264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001536410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917978,0.0034796773,0.00008366441,0.0022839042,0.00020942936,0.0012588054,0.00007553752,0.000010672403,0.0008004868],"genre_scores_gemma":[0.99700826,0.0005481889,0.00024137252,0.000962062,0.00014386486,0.0004960132,0.000022931297,0.000018275789,0.00055904774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866384,0.00019450622,0.000338615,0.0003054544,0.0001866827,0.00031090374],"domain_scores_gemma":[0.9990448,0.00018212295,0.00016706275,0.0002802662,0.00020223073,0.00012351261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000332479,0.00017960154,0.00053864444,0.0001572184,0.00005442187,0.000008532284,0.00008018504,0.000095125,0.00019158162],"category_scores_gemma":[0.000026723128,0.00011889068,0.00009381831,0.00042196817,0.0000439025,0.00012128998,0.000047656526,0.00016081975,0.0000067445403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020226294,0.0015516747,0.90381646,0.0000091847105,0.0017350094,0.000021312386,0.032011256,0.0003739365,0.0010000695,0.0000029568585,0.00023757268,0.057217922],"study_design_scores_gemma":[0.004846238,0.0016869216,0.9862117,0.0000407437,0.0007901671,0.0000014600699,0.004242089,0.00007560339,0.00068625814,0.000015253139,0.0012771279,0.000126433],"about_ca_topic_score_codex":0.003905541,"about_ca_topic_score_gemma":0.0040826946,"teacher_disagreement_score":0.082395226,"about_ca_system_score_codex":0.00018274905,"about_ca_system_score_gemma":0.00017203967,"threshold_uncertainty_score":0.59040356},"labels":[],"label_agreement":null},{"id":"W3003068047","doi":"10.1007/s00401-020-02124-y","title":"An update on the CNS manifestations of brain tumor polyposis syndromes","year":2020,"lang":"en","type":"review","venue":"Acta Neuropathologica","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children","keywords":"Medicine; Lynch syndrome; Cancer; Family history; Familial adenomatous polyposis; Colorectal cancer; Pathology; Internal medicine; Oncology; DNA mismatch repair","score_opus":0.06139626706916241,"score_gpt":0.3773987262014339,"score_spread":0.3160024591322715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003068047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023326927,0.9713338,0.000009994646,0.015462552,0.00028718376,0.0027302254,0.0010134215,0.00021796938,0.0066121793],"genre_scores_gemma":[0.024351718,0.97104055,0.00017900881,0.003501598,0.00009152045,0.00022674189,0.00032726783,0.000066416986,0.0002151941],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982878,0.00040326224,0.00043399745,0.00045907474,0.00021407551,0.0002018024],"domain_scores_gemma":[0.99831253,0.00047324723,0.00035739352,0.000680114,0.000048442453,0.00012829437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010883133,0.00033573306,0.000989262,0.000112741865,0.00013401688,0.00002730948,0.0002907154,0.00008260509,0.0002643288],"category_scores_gemma":[0.00030820366,0.00017400552,0.0003438857,0.00034752674,0.00010633728,0.000045864424,0.000053307864,0.00036571035,0.0001287194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071072485,0.0016720612,0.000083393905,0.006436518,0.0008264371,0.021864109,0.00065267424,0.0000013415757,0.0002720967,0.0041766255,0.015986495,0.94795716],"study_design_scores_gemma":[0.00020606388,0.0015095564,0.000907129,0.0016211198,0.0025536013,0.0026908077,0.00004777086,0.0000028568402,0.000006829331,0.000034473982,0.99023944,0.0001803768],"about_ca_topic_score_codex":0.0000050582125,"about_ca_topic_score_gemma":6.7969626e-7,"teacher_disagreement_score":0.97425294,"about_ca_system_score_codex":0.00005336968,"about_ca_system_score_gemma":0.00024723314,"threshold_uncertainty_score":0.70957386},"labels":[],"label_agreement":null},{"id":"W3003566688","doi":"10.1177/0846537119888387","title":"Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective","year":2020,"lang":"en","type":"article","venue":"Canadian Association of Radiologists Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Montreal General Hospital; Jewish General Hospital; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Adenocarcinoma; Population; Mutation; Lung; Logistic regression; Internal medicine; Receiver operating characteristic; Oncology; Univariate analysis; Pathology; Multivariate analysis; Radiology; Cancer; Genetics; Biology","score_opus":0.011904191055721535,"score_gpt":0.27749406109215613,"score_spread":0.2655898700364346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003566688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90578765,0.00361683,0.0052602882,0.08049301,0.0005570277,0.0009608212,0.0006858443,0.000036309477,0.0026022282],"genre_scores_gemma":[0.99832356,0.000021665333,0.00054431264,0.00089021487,0.0000992061,0.000006160464,0.0000566395,0.0000136334265,0.000044603174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987346,0.00017876209,0.00042326454,0.00016602271,0.00022602166,0.00027133085],"domain_scores_gemma":[0.9983148,0.00015539049,0.00049858104,0.000057869835,0.0005775911,0.0003957898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027776294,0.00012005998,0.00035218388,0.0002874315,0.00006094315,0.000012598483,0.000072989395,0.00009392596,0.00016847716],"category_scores_gemma":[0.0012202456,0.00011377507,0.00013769657,0.0003035352,0.00008151282,0.00011581369,0.0000039004512,0.00026697485,0.0000034620045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020987404,0.00004207976,0.9887634,0.000051968513,0.00025946385,0.00016345619,0.0019054108,0.0004697174,0.0001604913,0.00021874953,0.0071053677,0.0006500463],"study_design_scores_gemma":[0.004434734,0.00035704044,0.9873177,0.000086381406,0.00017788043,0.00005372848,0.0023902166,0.004371125,0.0004065713,0.00009541545,0.00018337781,0.00012582657],"about_ca_topic_score_codex":0.0130875725,"about_ca_topic_score_gemma":0.0062901704,"teacher_disagreement_score":0.09253593,"about_ca_system_score_codex":0.005173153,"about_ca_system_score_gemma":0.0022241331,"threshold_uncertainty_score":0.9986458},"labels":[],"label_agreement":null},{"id":"W3004077651","doi":"10.1200/jco.2006.24.18_suppl.7117","title":"Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized national cancer institute of Canada Clinical Trials Group (NCIC CTG) trials","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Performance status; Lung cancer; Cancer; Randomized controlled trial; Chemotherapy; Proportional hazards model; Clinical trial; Surgery; Confidence interval","score_opus":0.4992730892395016,"score_gpt":0.6213426952230742,"score_spread":0.12206960598357258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004077651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049991324,0.9845887,0.00001993541,0.00080139545,0.0015344479,0.007282254,0.0005497761,0.0000018267347,0.000222529],"genre_scores_gemma":[0.005212396,0.99315023,0.00036232834,0.00025908084,0.00054185576,0.00032390715,0.00007633174,0.000018789979,0.000055057906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9657149,0.014769026,0.017813928,0.00033715676,0.0011503974,0.0002146168],"domain_scores_gemma":[0.9116919,0.054822292,0.031977568,0.00023516601,0.0010153098,0.00025776925],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04232055,0.00039631285,0.02436603,0.00023685813,0.000032117667,0.000005861332,0.00021370569,0.00038404367,0.000056274275],"category_scores_gemma":[0.09866479,0.00017528901,0.0035153064,0.0003275494,0.0005516524,0.00006450201,0.00002330006,0.000752214,1.4376309e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031896073,0.019663863,0.012294922,0.056066472,0.030753102,0.0015144607,0.0002631199,0.000008575106,3.0613927e-7,0.00037832934,0.006440533,0.84072024],"study_design_scores_gemma":[0.20288421,0.008244891,0.0354688,0.073924534,0.07870396,0.0001676277,0.00008071931,0.000002642253,6.8357906e-7,0.0003384753,0.5999475,0.00023594181],"about_ca_topic_score_codex":0.019206226,"about_ca_topic_score_gemma":0.05668503,"teacher_disagreement_score":0.8404843,"about_ca_system_score_codex":0.0010632436,"about_ca_system_score_gemma":0.026068715,"threshold_uncertainty_score":0.99011827},"labels":[],"label_agreement":null},{"id":"W3004211670","doi":"10.1016/s1470-2045(19)30859-9","title":"Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca Schweiz; Takeda Pharmaceutical Company; Roche; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Afatinib; Osimertinib; Medicine; Gefitinib; Erlotinib; Lung cancer; T790M; Cancer research; Tyrosine kinase; Oncology; Resistance mutation; Internal medicine; Cancer; Epidermal growth factor receptor; Biology; Receptor; Genetics","score_opus":0.046250517288371484,"score_gpt":0.4013117916393306,"score_spread":0.35506127435095913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004211670","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010054996,0.0068016984,0.00014614334,0.95857203,0.0007507233,0.002713398,0.00028721394,0.000047538964,0.029675731],"genre_scores_gemma":[0.004842239,0.002380749,0.014058216,0.95798504,0.008576565,0.0033786495,0.0012465745,0.00012157572,0.007410371],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779737,0.00029101476,0.0005196907,0.00053987984,0.0001895134,0.00066251645],"domain_scores_gemma":[0.99765253,0.001300362,0.00044732267,0.00041414896,0.00013035489,0.000055295095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005140225,0.00031277112,0.0011607053,0.00012854736,0.00008636248,0.000022061324,0.00031373106,0.00045700645,0.000054169555],"category_scores_gemma":[0.0003228958,0.0002281967,0.00009287258,0.00030062246,0.00007345362,0.0000680057,0.0000651785,0.0016887109,0.000016968557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009185551,0.0001307678,0.0017497276,0.0012282977,0.00027986304,0.0015322162,0.003318891,0.000043606662,0.00016725814,0.000081374965,0.98999494,0.00055448967],"study_design_scores_gemma":[0.0071231825,0.00033323295,0.0004919089,0.00034642866,0.000978975,0.000013385694,0.00043008354,0.0001811488,0.000028066193,0.0001869386,0.9896671,0.00021950714],"about_ca_topic_score_codex":0.001199476,"about_ca_topic_score_gemma":0.0024169586,"teacher_disagreement_score":0.02226536,"about_ca_system_score_codex":0.0016332068,"about_ca_system_score_gemma":0.0012330482,"threshold_uncertainty_score":0.93055916},"labels":[],"label_agreement":null},{"id":"W3007156832","doi":"10.1371/journal.pone.0229179","title":"ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis","year":2020,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Ceritinib; Alectinib; Crizotinib; Anaplastic lymphoma kinase; Medicine; Internal medicine; Lung cancer; ALK inhibitor; Oncology; Hazard ratio; Odds ratio; Confidence interval","score_opus":0.1275881206820086,"score_gpt":0.3608455787062775,"score_spread":0.2332574580242689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007156832","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.1088712e-7,0.9842338,0.000072468734,0.0005944223,0.00003009265,0.014365469,0.00037660287,0.000040351344,0.00028655934],"genre_scores_gemma":[0.0000025494678,0.9796389,0.0018407638,0.00076210994,0.00027851004,0.013948355,0.00047933502,0.00007972067,0.0029697886],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977073,0.00012419665,0.0010554751,0.0005697025,0.00026546928,0.00027784499],"domain_scores_gemma":[0.997999,0.00028768415,0.0007830718,0.0005214905,0.0001676748,0.00024105464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024702615,0.0004968195,0.012187071,0.00012369448,0.0000889917,0.000033947457,0.00011524227,0.00014432405,0.00012213526],"category_scores_gemma":[0.000080148406,0.00030834854,0.0025590218,0.00087302603,0.00001802734,0.000030327592,0.000046545083,0.00020150232,0.000013890473],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000011115009,0.00013673221,0.0000028399063,0.64540684,0.35277677,0.0000073343613,0.000028989225,4.3859689e-7,3.3649492e-8,0.0000031334603,0.0011591039,0.0004766862],"study_design_scores_gemma":[0.00019068897,0.0000632033,8.0775415e-8,0.22085397,0.74537504,0.0000023354028,0.00000320431,0.00004754782,4.881636e-7,0.0000013996482,0.033279173,0.0001828863],"about_ca_topic_score_codex":0.000046206675,"about_ca_topic_score_gemma":0.000031342133,"teacher_disagreement_score":0.42455286,"about_ca_system_score_codex":0.00023697388,"about_ca_system_score_gemma":0.00042001967,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W3008940037","doi":"10.1093/annonc/mdy446","title":"ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; T790M; Internal medicine; Oncology; Asymptomatic; Interim analysis; Cancer; Clinical trial; Epidermal growth factor receptor; Erlotinib; Gefitinib","score_opus":0.04379992899427044,"score_gpt":0.43117338852474313,"score_spread":0.3873734595304727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008940037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906441,0.000028553824,0.0000062596446,0.0006812142,0.000049813552,0.00079412555,0.000088298475,0.000014980853,0.007692682],"genre_scores_gemma":[0.9975688,0.000029050503,0.00024971156,0.00020052449,0.000048042635,0.000050321174,0.000117910975,0.000017562692,0.0017181155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985365,0.0000849976,0.0005451891,0.0003079128,0.00026351144,0.00026186483],"domain_scores_gemma":[0.9984494,0.00032648476,0.0003554722,0.00032250583,0.00042912384,0.000117001764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014660884,0.0001629357,0.0007485438,0.00045733806,0.00004317616,0.0000040488994,0.00010885053,0.00008028572,0.00036888156],"category_scores_gemma":[0.00014450417,0.00011200976,0.00006145492,0.0013394956,0.00015619697,0.00005844939,0.00003574645,0.00010370965,0.000015096927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029443547,0.015658459,0.90353775,0.000020477912,0.0019931514,0.00003423605,0.0029827533,0.000021194957,0.00010424679,0.000004427663,0.007822489,0.06487648],"study_design_scores_gemma":[0.015140864,0.05720281,0.91234714,0.00006664873,0.0019972313,0.0000015274318,0.00072779186,0.000030952062,0.0027758968,0.0000025134743,0.009581511,0.00012510415],"about_ca_topic_score_codex":0.0028539365,"about_ca_topic_score_gemma":0.00960872,"teacher_disagreement_score":0.06475138,"about_ca_system_score_codex":0.00009265958,"about_ca_system_score_gemma":0.00027527843,"threshold_uncertainty_score":0.53618914},"labels":[],"label_agreement":null},{"id":"W3009161381","doi":"10.1200/jco.2007.25.18_suppl.7680","title":"Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Erlotinib; Lung cancer; Interim analysis; Internal medicine; Toxicity; Adverse effect; Bortezomib; Oncology; Phases of clinical research; Surgery; Cancer; Clinical trial; Multiple myeloma; Epidermal growth factor receptor","score_opus":0.039429499872711354,"score_gpt":0.47383255368477173,"score_spread":0.43440305381206035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009161381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952501,0.001051103,0.00013019175,0.0005693971,0.00017403469,0.0020161225,0.0000017544554,0.000003733695,0.00080358575],"genre_scores_gemma":[0.9976506,0.0008269053,0.0010628483,0.00017202825,0.000070200374,0.000039701034,0.0000035342944,0.000013520968,0.00016064597],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99692565,0.00029901296,0.0022188353,0.00017346433,0.00019686559,0.00018615041],"domain_scores_gemma":[0.99644834,0.0014222917,0.0015307441,0.00010333624,0.00032251378,0.00017278589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030806668,0.00013074139,0.0019234394,0.0002655787,0.000024421617,0.0000028688,0.000056420857,0.00014613614,0.000018368539],"category_scores_gemma":[0.0004685091,0.00008309854,0.00011785594,0.0002524776,0.00010437292,0.000088621855,0.000017718758,0.0004306069,1.419233e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42817947,0.032222595,0.46485195,0.00007324495,0.0006449846,0.0008396881,0.0039984053,0.0001384032,0.00023000811,0.000004679867,0.000040559564,0.06877603],"study_design_scores_gemma":[0.73336077,0.033558186,0.2300253,0.00030928708,0.0012990354,0.000028539613,0.00083814986,0.00026302855,0.00014488162,0.000012247279,0.00009346513,0.0000671138],"about_ca_topic_score_codex":0.0004303766,"about_ca_topic_score_gemma":0.0032363208,"teacher_disagreement_score":0.3051813,"about_ca_system_score_codex":0.00022065725,"about_ca_system_score_gemma":0.0009436784,"threshold_uncertainty_score":0.33886603},"labels":[],"label_agreement":null},{"id":"W3009747441","doi":"10.3747/co.27.5347","title":"Biopsy on Progression in Patients with EGFR Mutation–Positive Advanced Non-Small-Cell Lung Cancer—A Canadian Experience","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); BC Cancer Foundation; BC Cancer Agency; Spinal Cord Injury BC; Alberta Health Services","funders":"","keywords":"Medicine; T790M; Osimertinib; Lung cancer; Erlotinib; Internal medicine; Oncology; Biopsy; Retrospective cohort study; Cancer; Mutation; Epidermal growth factor receptor; Pathology; Gefitinib","score_opus":0.02544159754967788,"score_gpt":0.398278013277729,"score_spread":0.3728364157280511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009747441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931573,0.0005343274,0.000064667416,0.0019039864,0.00038729623,0.0013885102,0.000060195347,0.000022190294,0.0024814815],"genre_scores_gemma":[0.99802136,0.000036035577,0.00044166428,0.00062566646,0.00006882354,0.00052581914,0.00023216369,0.000017477138,0.00003097439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904436,0.000028448128,0.00017365781,0.00033259162,0.00013979798,0.00028116605],"domain_scores_gemma":[0.999306,0.000025521045,0.00009197597,0.00010254224,0.00013741804,0.00033653903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000018115681,0.00014902887,0.00022390035,0.00010944273,0.000081734426,0.000007921838,0.00006152084,0.00006072966,0.000068238776],"category_scores_gemma":[0.000018614166,0.00011352693,0.000025709076,0.0002863194,0.00004859292,0.0000652972,0.000013892175,0.00017539367,0.000012721615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006504068,0.0008382374,0.8721522,0.000101840385,0.00004132952,0.00014132683,0.0138475485,0.00015731806,0.00005857173,0.00002383295,0.0003600665,0.111627325],"study_design_scores_gemma":[0.015228241,0.004407583,0.96521217,0.0008219322,0.00022009098,0.0000049220757,0.0015210639,0.001053045,0.000978444,0.000003381445,0.010251689,0.00029743585],"about_ca_topic_score_codex":0.0020946884,"about_ca_topic_score_gemma":0.0049794638,"teacher_disagreement_score":0.11132989,"about_ca_system_score_codex":0.0012156569,"about_ca_system_score_gemma":0.0010905002,"threshold_uncertainty_score":0.4629494},"labels":[],"label_agreement":null},{"id":"W3010385770","doi":"10.5430/jst.v10n1p19","title":"Detecting EGFR mutations (L858R, T790M) using allele specific multiplex sequencing: A comparison with Pyrosequencing and TruSeq","year":2020,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"T790M; Pyrosequencing; Concordance; Multiplex; Molecular biology; Medicine; Multiplex polymerase chain reaction; Mutation; Polymerase chain reaction; Biology; Genetics; Gene; Internal medicine","score_opus":0.07471580483948895,"score_gpt":0.3471576297941418,"score_spread":0.27244182495465286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010385770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929167,0.00078314176,0.0049538356,0.0008479772,0.00006085572,0.00023042173,0.000008141947,0.000026432186,0.00017249503],"genre_scores_gemma":[0.97590125,0.00003768243,0.023432307,0.00026439995,0.00031055187,0.0000026332457,0.0000043325185,0.00003312531,0.000013728527],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871826,0.00003142696,0.00055102987,0.00017451897,0.00030424737,0.00022049686],"domain_scores_gemma":[0.99878496,0.00006888278,0.00049994944,0.00009061941,0.00023781402,0.00031776275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012236652,0.0001653259,0.00046785272,0.00013616981,0.00019946831,0.00004839924,0.000058043865,0.000038568323,0.000031830856],"category_scores_gemma":[0.00009581833,0.00012430357,0.00008555088,0.00026859145,0.00008064895,0.0002335534,0.000017828093,0.00032333043,0.0000025792035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020018425,0.0005340607,0.2559131,0.00067873363,0.0023106989,0.0063847145,0.069272056,0.08256198,0.56198627,0.00021033017,0.0006038698,0.017542334],"study_design_scores_gemma":[0.044280633,0.015293722,0.1464779,0.0058281217,0.0067862896,0.035315216,0.16799559,0.24841483,0.32143673,0.0005759656,0.005268223,0.0023267935],"about_ca_topic_score_codex":0.00006373389,"about_ca_topic_score_gemma":0.000023006454,"teacher_disagreement_score":0.24054953,"about_ca_system_score_codex":0.0004047988,"about_ca_system_score_gemma":0.00045578874,"threshold_uncertainty_score":0.50689524},"labels":[],"label_agreement":null},{"id":"W3010851249","doi":"10.1200/jco.2012.30.15_suppl.e18061","title":"Utility of nonsurgical diagnostic specimens in cellular differentiation and molecular profiling (EGFR mutation and EML4-ALK detection) of NSCLC.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Surgical pathology; Pathology; Fine-needle aspiration; Immunohistochemistry; Cytology; Biopsy","score_opus":0.05134337012688837,"score_gpt":0.43488942561501526,"score_spread":0.38354605548812687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010851249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952159,0.001494052,0.0020563882,0.00038686275,0.00027840395,0.00020660671,0.0000029004402,0.0000018690243,0.00035701905],"genre_scores_gemma":[0.99796873,0.00029555944,0.001544258,0.00004665297,0.00012628993,0.00000273447,0.0000034867583,0.000005372179,0.0000069038915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982883,0.0002177256,0.0011422522,0.00008789276,0.00016013456,0.000103743536],"domain_scores_gemma":[0.99733144,0.0015049865,0.0007654994,0.000067136505,0.00018582575,0.0001450868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009162419,0.00006825835,0.00060907006,0.0001016623,0.000014759856,0.0000020359903,0.000021428883,0.00015053758,0.000022479295],"category_scores_gemma":[0.0020000297,0.00005056181,0.00010207618,0.00008492899,0.00012355206,0.00009176981,0.00001660084,0.00023878804,4.334544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010572928,0.002279085,0.89070857,0.00012376504,0.0002965019,0.00016081223,0.00040150736,0.000008381,0.016338121,0.00023500666,0.000005850586,0.0883851],"study_design_scores_gemma":[0.005210462,0.002031541,0.97728515,0.000092822636,0.0006096132,0.00012886542,0.00016504311,0.0003467351,0.013637772,0.00027066603,0.00018043786,0.000040885294],"about_ca_topic_score_codex":0.000019004225,"about_ca_topic_score_gemma":0.000014185553,"teacher_disagreement_score":0.08834422,"about_ca_system_score_codex":0.000041945023,"about_ca_system_score_gemma":0.00019525635,"threshold_uncertainty_score":0.23943669},"labels":[],"label_agreement":null},{"id":"W3010938670","doi":"10.1186/s12014-020-9269-6","title":"Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition","year":2020,"lang":"en","type":"article","venue":"Clinical Proteomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Espace pour la vie; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal; McGill University; Institut universitaire de cardiologie et de pneumologie de Québec; IGNIS Innovation (Canada); Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Pfizer Canada; Astex Pharmaceuticals; Pfizer","keywords":"Crizotinib; Medicine; Oncology; Internal medicine; Targeted therapy; Tyrosine kinase; Anaplastic lymphoma kinase; Lung cancer; Cancer; Receptor","score_opus":0.03186463685941213,"score_gpt":0.3505426487374659,"score_spread":0.3186780118780538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010938670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753203,0.000033358407,0.005032217,0.016120786,0.000025230895,0.003049569,0.00028733583,0.000055747143,0.000075487944],"genre_scores_gemma":[0.9863487,0.0000013909204,0.009639347,0.0031869584,0.000083007886,0.00023421788,0.00020987175,0.00003134619,0.0002651432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985737,0.00020698794,0.0004751825,0.00034389613,0.00023589015,0.0001643355],"domain_scores_gemma":[0.9987906,0.00031499116,0.00024427008,0.0001805235,0.00025344957,0.00021614754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034871043,0.00015701198,0.00042034077,0.00004903834,0.0000450295,0.000018130631,0.000049066253,0.00015423287,0.000009741323],"category_scores_gemma":[0.003122877,0.00011392454,0.00012442772,0.0003949269,0.0001312041,0.00009027753,0.000026933743,0.00031856645,0.0000074548116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08392868,0.0059212074,0.015304573,0.00037312182,0.0013769264,0.0006988083,0.0017721027,0.00086008594,0.88736933,0.0002586663,0.0009136919,0.0012228283],"study_design_scores_gemma":[0.03337716,0.030646343,0.059900627,0.0019362418,0.0017772567,0.000005228129,0.00025194403,0.0012047186,0.869758,0.00030736814,0.00033546405,0.0004996343],"about_ca_topic_score_codex":0.000011948701,"about_ca_topic_score_gemma":0.0000049883092,"teacher_disagreement_score":0.050551523,"about_ca_system_score_codex":0.000085794556,"about_ca_system_score_gemma":0.00066537585,"threshold_uncertainty_score":0.4645708},"labels":[],"label_agreement":null},{"id":"W3010996890","doi":"10.1158/0008-5472.can-19-3819","title":"Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance <i>EGFR</i> Mutations","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Michael Smith Health Research BC; National Center for Advancing Translational Sciences; Lung Cancer Research Foundation; AstraZeneca","keywords":"Osimertinib; Afatinib; Erlotinib; Lung cancer; Cancer research; Drug resistance; Context (archaeology); Medicine; Mutation; Tyrosine-kinase inhibitor; Biology; Epidermal growth factor receptor; Pharmacology; Cancer; Oncology; Genetics; Internal medicine; Gene","score_opus":0.07865828639649587,"score_gpt":0.4131990002546753,"score_spread":0.33454071385817946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010996890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428284,0.0032622323,0.00023120901,0.046707027,0.00004381738,0.0007529141,0.00021646424,0.00004234854,0.0059155435],"genre_scores_gemma":[0.9959111,0.00091507635,0.00044318783,0.00032820203,0.00019192063,0.00007910394,0.00004275219,0.000019652472,0.0020689548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987229,0.00009488842,0.00020074668,0.00031020748,0.0004182196,0.0002530313],"domain_scores_gemma":[0.9988507,0.00024222564,0.000048707967,0.00019756498,0.0004191065,0.00024172071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028146073,0.000095940144,0.00023887532,0.00006644861,0.00018791159,0.000017045424,0.000048768416,0.000036368925,0.00019720486],"category_scores_gemma":[0.00019383284,0.00008344092,0.00004663448,0.00045981957,0.0002609459,0.00006998151,0.000055003213,0.00024493088,0.00001350523],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008040698,0.0024233616,0.280025,0.006247611,0.0023421866,0.0011582368,0.050232857,0.0009943872,0.24266867,0.0073962267,0.36079624,0.037674513],"study_design_scores_gemma":[0.0132349515,0.0011075413,0.12485351,0.0010477513,0.0006837047,0.000027338792,0.004981233,0.002190047,0.31352827,0.0013403201,0.5362866,0.0007187511],"about_ca_topic_score_codex":0.0007003761,"about_ca_topic_score_gemma":0.0019974068,"teacher_disagreement_score":0.17549035,"about_ca_system_score_codex":0.00014131832,"about_ca_system_score_gemma":0.00027496766,"threshold_uncertainty_score":0.3402622},"labels":[],"label_agreement":null},{"id":"W3011011573","doi":"10.1200/jco.2013.31.15_suppl.e19032","title":"Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Histology; Lung cancer; Population; Pathology; Cytology; Epidermal growth factor receptor; Internal medicine; Oncology; Cancer","score_opus":0.06873290670080613,"score_gpt":0.46435098595053964,"score_spread":0.3956180792497335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011011573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065465,0.0003289219,0.0007372132,0.0032050945,0.0009339356,0.00046701284,0.0000019042831,0.000008242392,0.0036630344],"genre_scores_gemma":[0.9741189,0.000034087236,0.023392092,0.0014751294,0.00080220605,0.00003363406,0.000010244198,0.000014937327,0.000118808304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997662,0.00014103325,0.0016477222,0.00015332885,0.00019659926,0.00019931045],"domain_scores_gemma":[0.99595785,0.0019800232,0.0012676326,0.000100914214,0.00047874852,0.00021481821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008293932,0.0001099302,0.00070321304,0.00017564387,0.00004915329,0.000013792155,0.000073029536,0.00020686768,0.00020775976],"category_scores_gemma":[0.001097928,0.00008329576,0.00018205454,0.00022820351,0.00003185705,0.0001238669,0.000012170451,0.00051547075,0.000008773886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012936123,0.0006825622,0.86377335,0.000054452143,0.00006459211,0.00020449475,0.00012020463,0.0038607123,0.0000971342,0.000004034307,0.0004945464,0.13051453],"study_design_scores_gemma":[0.0070960363,0.0024780673,0.96217096,0.00026533948,0.00040930024,0.000040097097,0.00009177508,0.02686586,0.000032791682,0.000085732994,0.0003841622,0.000079879035],"about_ca_topic_score_codex":0.0026316668,"about_ca_topic_score_gemma":0.0004820153,"teacher_disagreement_score":0.13043466,"about_ca_system_score_codex":0.0005851999,"about_ca_system_score_gemma":0.0023760125,"threshold_uncertainty_score":0.42149442},"labels":[],"label_agreement":null},{"id":"W3011197425","doi":"10.1200/jco.2013.31.15_suppl.7517","title":"Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Gene; Gene expression profiling; Microarray; Vinorelbine; Lung cancer; Oncology; Gene signature; Microarray analysis techniques; Cisplatin; Cancer research; ERCC1; Biology; Medicine; Gene expression; Internal medicine; Genetics; Chemotherapy","score_opus":0.024706717994601172,"score_gpt":0.3968956272237569,"score_spread":0.3721889092291557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011197425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484146,0.0009150928,0.0016862403,0.0007752028,0.0003249761,0.0011691109,0.00000507822,0.0000028532452,0.00028001427],"genre_scores_gemma":[0.99538636,0.000035950197,0.0038738407,0.00024049709,0.0002817485,0.00006810083,0.000008952476,0.000010550206,0.00009400614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986166,0.0001440057,0.0008470634,0.00012878381,0.00014298227,0.0001205596],"domain_scores_gemma":[0.9953742,0.0032110896,0.0008292079,0.00007434314,0.00036247118,0.00014870822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037788687,0.00008708408,0.00062628125,0.000098381344,0.000021173237,0.000003880613,0.00003961781,0.00026720227,0.000014645154],"category_scores_gemma":[0.0021053217,0.000056324512,0.00013034613,0.00006619478,0.00006013632,0.0001243234,0.0000142624995,0.00033595887,4.801579e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007038527,0.0073559494,0.69713205,0.0014872747,0.000291365,0.00020435124,0.002381103,0.00012494803,0.19983476,0.000026635857,0.0050951685,0.07902784],"study_design_scores_gemma":[0.018932339,0.021103732,0.90484154,0.00030221647,0.00055803097,0.000027359949,0.00021265213,0.0005399866,0.05267908,0.00032140472,0.00041114408,0.000070542694],"about_ca_topic_score_codex":0.000019183186,"about_ca_topic_score_gemma":0.0000034800503,"teacher_disagreement_score":0.20770943,"about_ca_system_score_codex":0.00012224991,"about_ca_system_score_gemma":0.00070576626,"threshold_uncertainty_score":0.25204188},"labels":[],"label_agreement":null},{"id":"W3011331060","doi":"10.1242/jcs.241505","title":"EML4–ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7","year":2020,"lang":"en","type":"article","venue":"Journal of Cell Science","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Korea Health Industry Development Institute; Worldwide Cancer Research; Medical Research Council Canada; Cancer Research UK; Wellcome Trust","keywords":"Biology; Microtubule; Cancer research; Cell biology; Cell; Cytoplasm; Genetics","score_opus":0.02653835530962023,"score_gpt":0.317118158293938,"score_spread":0.2905798029843178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011331060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916457,0.00074240705,0.001660516,0.005003776,0.000060559014,0.00044025632,0.0000022470101,0.0000122965785,0.00043222835],"genre_scores_gemma":[0.99134225,0.00041874358,0.007719303,0.0003539227,0.000080793354,0.0000030645974,0.0000021007334,0.0000075648477,0.00007225899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991884,0.000017493332,0.00023145687,0.00015619655,0.0002896068,0.00011682845],"domain_scores_gemma":[0.999275,0.000011041743,0.00019965932,0.000060334805,0.00028765315,0.00016630562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016850015,0.000076517186,0.000139374,0.0000537514,0.00016685388,0.000078249,0.000055784196,0.000028909271,0.000019681867],"category_scores_gemma":[0.000069512535,0.00005314896,0.000023853963,0.0004116371,0.000121192614,0.000551706,0.000026942125,0.000093837974,0.0000015643064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008139534,0.00009023267,0.0029523647,0.000058844296,0.000010067177,0.000014625896,0.0047234255,0.000023221875,0.9880257,0.000018433851,0.00016267446,0.0038390073],"study_design_scores_gemma":[0.0045631733,0.003563077,0.030458406,0.00024942687,0.0003237006,0.0002852552,0.0012203674,0.0036465765,0.9423142,0.0003571687,0.012820385,0.00019827785],"about_ca_topic_score_codex":0.00003060829,"about_ca_topic_score_gemma":0.000011938448,"teacher_disagreement_score":0.04571152,"about_ca_system_score_codex":0.0000773381,"about_ca_system_score_gemma":0.00041732076,"threshold_uncertainty_score":0.21673517},"labels":[],"label_agreement":null},{"id":"W3011665030","doi":"10.1200/jco.2012.30.15_suppl.e17521","title":"The utility of DR-70, a novel blood biomarker, in the early detection of lung cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EcoMetrix","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Adenocarcinoma; Cancer; Biomarker; Oncology; Lung; Gastroenterology; Pathology","score_opus":0.12354865599208495,"score_gpt":0.5256315099176719,"score_spread":0.40208285392558696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011665030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035966,0.0029004705,0.00012895165,0.004081207,0.0009181825,0.00020433914,0.0000058058195,0.0000014335556,0.0013999535],"genre_scores_gemma":[0.99853504,0.00073943735,0.00015767422,0.0002158206,0.00028950072,0.000007903226,3.2752732e-7,0.000004455796,0.0000498388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800205,0.00026376816,0.0013102281,0.000059029928,0.00022467024,0.00014023004],"domain_scores_gemma":[0.9962714,0.002058438,0.0011846024,0.0001454875,0.00025421655,0.00008587234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032373557,0.00005823317,0.00050559564,0.00004830897,0.00003733125,0.0000024808708,0.00011161293,0.0001364204,0.000025519825],"category_scores_gemma":[0.0011263863,0.00002771438,0.00024721803,0.00016428398,0.00019419192,0.00007112711,0.000016226944,0.00036296103,3.87553e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027361163,0.004653445,0.76841545,0.000046988007,0.00117913,0.000015943684,0.0011616916,0.0000013484805,0.002950069,0.000115261246,0.00057090307,0.21815364],"study_design_scores_gemma":[0.0048164134,0.0022237916,0.9841406,0.00005846092,0.0010686268,0.00007131261,0.00023187159,0.00008780595,0.000360892,0.00006382734,0.006852966,0.000023482644],"about_ca_topic_score_codex":0.00036287066,"about_ca_topic_score_gemma":0.0003228289,"teacher_disagreement_score":0.21813016,"about_ca_system_score_codex":0.00005914311,"about_ca_system_score_gemma":0.0007228013,"threshold_uncertainty_score":0.15769053},"labels":[],"label_agreement":null},{"id":"W3011939837","doi":"10.2217/fon-2019-0796","title":"Quality of Life with Second or Third Line <i>Nab</i> -Paclitaxel-Based Regimens in Advanced Non-Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Durvalumab; Quality of life (healthcare); Lung cancer; Paclitaxel; Internal medicine; Oncology; Nab-paclitaxel; Cancer; Physical therapy; Nursing; Immunotherapy","score_opus":0.022359610082821304,"score_gpt":0.36557717145172036,"score_spread":0.3432175613688991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011939837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9535688,0.0026691998,0.0005051317,0.028475141,0.00035860276,0.0013358311,0.00017023656,0.000054011245,0.012863037],"genre_scores_gemma":[0.97517824,0.00013421752,0.0068794135,0.015080751,0.00062297226,0.0002692991,0.0001019408,0.000036799116,0.0016963701],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987229,0.0000976188,0.00041965686,0.00035572323,0.00014555022,0.00025854493],"domain_scores_gemma":[0.99892676,0.00016422545,0.00026904562,0.00024511162,0.00015364877,0.00024118139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013243867,0.00019290119,0.0006897111,0.000064080734,0.00003685069,0.000003652604,0.00008702176,0.00017966192,0.0005553398],"category_scores_gemma":[0.000055438173,0.00012895186,0.00007246634,0.00035787534,0.00006654707,0.000045433117,0.000021648633,0.00028368126,0.0000054135367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06130116,0.0072506475,0.71631,0.011446071,0.0024403627,0.0031832242,0.03544961,0.004478276,0.05492184,0.0006561246,0.082560845,0.02000183],"study_design_scores_gemma":[0.14531735,0.02451228,0.2506939,0.0009691589,0.002114287,0.00006379229,0.013278371,0.0019029321,0.02704068,0.000030944888,0.53270423,0.001372083],"about_ca_topic_score_codex":0.00021605761,"about_ca_topic_score_gemma":0.0045875297,"teacher_disagreement_score":0.46561614,"about_ca_system_score_codex":0.00029818047,"about_ca_system_score_gemma":0.0026197154,"threshold_uncertainty_score":0.60805815},"labels":[],"label_agreement":null},{"id":"W3012305156","doi":"10.1002/cbin.11340","title":"Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies","year":2020,"lang":"en","type":"review","venue":"Cell Biology International","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cetuximab; Epidermal growth factor receptor; Panitumumab; Cancer research; Gefitinib; Growth factor receptor; Receptor tyrosine kinase; KRAS; Colorectal cancer; Biology; Cancer; EGFR inhibitors; Lung cancer; Signal transduction; Tyrosine kinase; Medicine; Internal medicine; Cell biology","score_opus":0.04392795639133396,"score_gpt":0.3861711967582503,"score_spread":0.34224324036691633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012305156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014309413,0.9934815,0.00004138108,0.0007431775,0.0016134378,0.0009670355,0.0012328986,0.000032975884,0.00045666067],"genre_scores_gemma":[0.0034051538,0.99132717,0.00016028942,0.0003264289,0.0003232235,0.0002629773,0.0040046233,0.000036137142,0.00015402141],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851316,0.000109983725,0.0005333328,0.0004898949,0.00012805681,0.0002255965],"domain_scores_gemma":[0.99924016,0.00013088569,0.00029316856,0.000120274046,0.00011115628,0.0001043694],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000060857234,0.00036043237,0.00092519633,0.0002634583,0.000045022636,0.000018126793,0.00017266627,0.00019349057,0.0005090805],"category_scores_gemma":[0.00004542105,0.0002730304,0.00021956842,0.00012278253,0.00008870623,0.000047518515,0.000060321687,0.00033360123,0.00006792063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001632752,0.00046169432,0.0026297204,0.0072184727,0.002005972,0.00005807203,0.0008158755,0.0000019114111,0.003611346,0.0006464512,0.00046020397,0.981927],"study_design_scores_gemma":[0.0018327635,0.00018473998,0.00019779916,0.0028270101,0.00032196133,0.0000053128133,0.000026167145,0.00003905138,0.00041028386,0.000019861911,0.9938858,0.00024925874],"about_ca_topic_score_codex":0.00013109378,"about_ca_topic_score_gemma":0.000018671737,"teacher_disagreement_score":0.9934256,"about_ca_system_score_codex":0.000867171,"about_ca_system_score_gemma":0.0009060904,"threshold_uncertainty_score":0.99997216},"labels":[],"label_agreement":null},{"id":"W3012372684","doi":"10.1016/j.clon.2020.02.031","title":"Local Treatment of ‘Oligometastases’: Wishful Thinking is Not Supported by Available Evidence – Authors' Reply","year":2020,"lang":"en","type":"letter","venue":"Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"SABR volatility model; Medicine; Wishful thinking; Ablative case; Stereotactic radiotherapy; Observational study; Radiation therapy; Medical physics; Psychotherapist; Radiosurgery; Internal medicine; Psychology","score_opus":0.14896975380013927,"score_gpt":0.46612305755299765,"score_spread":0.3171533037528584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012372684","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013280413,0.0035031587,0.00030240134,0.98666936,0.0017136876,0.0014362476,0.0007842942,0.00013138572,0.0041314033],"genre_scores_gemma":[0.0057018013,0.0032540264,0.0024197237,0.9434587,0.0028982756,0.00019588711,0.0021063555,0.00010343831,0.039861802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951686,0.0004717968,0.0020122528,0.0012146329,0.0005752716,0.00055743346],"domain_scores_gemma":[0.99448246,0.0028037592,0.0010889277,0.0009312827,0.0003022481,0.0003913037],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00044050073,0.0005053836,0.002572336,0.00013092453,0.00010335592,0.000020044874,0.00027918047,0.001317999,0.0037067577],"category_scores_gemma":[0.00087920943,0.00038443122,0.0008383684,0.0002916073,0.00069359667,0.000088414,0.00010016188,0.0014147963,0.00079961633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006301076,0.0011196631,0.0016864485,0.0002183331,0.0019741294,0.003739517,0.0003610918,3.5144427e-7,0.000041355725,0.000005645721,0.96578735,0.024436012],"study_design_scores_gemma":[0.004062588,0.01637816,0.00031210828,0.00032449316,0.005340094,0.00009441197,0.00004695369,0.000043770666,0.0006283193,0.00008828062,0.9724088,0.00027207172],"about_ca_topic_score_codex":0.0005794645,"about_ca_topic_score_gemma":0.000011889442,"teacher_disagreement_score":0.043210693,"about_ca_system_score_codex":0.0009872542,"about_ca_system_score_gemma":0.0031961529,"threshold_uncertainty_score":0.9999785},"labels":[],"label_agreement":null},{"id":"W3012425929","doi":"10.1200/jco.2006.24.18_suppl.7163","title":"Previously documented mutations in the epidermal growth factor receptor (EGFR) gene in a non-small cell lung cancer (NSCLC) population treated with gefitinib are not associated with response","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; Microdissection; Cancer research; Exon; Population; Adenocarcinoma; Laser capture microdissection; EGFR inhibitors; Oncology; Cancer; Internal medicine; Gene; Biology; Genetics; Gene expression","score_opus":0.04277994712074242,"score_gpt":0.41590917339034617,"score_spread":0.37312922626960376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012425929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905684,0.00020734982,0.00006547544,0.007784156,0.00011813828,0.00091075886,0.000045082437,0.000011481504,0.0002891868],"genre_scores_gemma":[0.99696714,0.000107044274,0.0010100694,0.0011329972,0.00023233455,0.00008845223,0.00008506356,0.000026454505,0.00035046454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963976,0.0010454744,0.001660724,0.0002353579,0.00035252256,0.00030832316],"domain_scores_gemma":[0.99501365,0.0024163902,0.0018187722,0.00014279663,0.00046998516,0.00013842748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015568851,0.00019769787,0.0009792331,0.00024546505,0.00006846646,0.000020402984,0.00011616198,0.00025037935,0.000062088315],"category_scores_gemma":[0.00089732656,0.000108822256,0.00016339737,0.00050407497,0.00008753565,0.00015886933,0.000010716425,0.0006888744,0.0000019684114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011564653,0.0024879992,0.9818886,0.0000228018,0.00028571527,0.0007085815,0.000703841,0.00057377736,0.00023043863,0.000005844968,0.0004359175,0.0010918516],"study_design_scores_gemma":[0.02011524,0.0045852647,0.97297597,0.0004944135,0.0007880812,0.00006742224,0.00029718192,0.00017849845,0.00013651157,0.000012914212,0.0002284566,0.00012005574],"about_ca_topic_score_codex":0.0021458715,"about_ca_topic_score_gemma":0.006673837,"teacher_disagreement_score":0.008912618,"about_ca_system_score_codex":0.0009825233,"about_ca_system_score_gemma":0.001500933,"threshold_uncertainty_score":0.4437643},"labels":[],"label_agreement":null},{"id":"W3012479383","doi":"10.1016/j.lungcan.2020.03.014","title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Chemotherapy; Epidermal growth factor receptor; Brain metastasis; Metastasis; Medical record; Exon; Cancer; Gene","score_opus":0.014483637179825948,"score_gpt":0.34744462399859594,"score_spread":0.33296098681877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012479383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924636,0.0016474338,0.00013859318,0.0016378253,0.0002841679,0.0028925247,0.0003620486,0.00007153875,0.0005022607],"genre_scores_gemma":[0.9953809,0.0004448974,0.00039422925,0.00089761935,0.00012761111,0.0018865627,0.00044390117,0.000054511867,0.0003697653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982665,0.00006342721,0.0004919141,0.00062029826,0.00027227122,0.00028557816],"domain_scores_gemma":[0.99912405,0.00005505908,0.00018213637,0.0002462212,0.00015038867,0.0002421675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00003689431,0.00033830942,0.00048095052,0.00015709092,0.00012081583,0.000036255868,0.00007266398,0.00006453888,0.00009134375],"category_scores_gemma":[0.000023211958,0.00025626167,0.000095534,0.0005168731,0.000026207306,0.00019102039,0.00004039646,0.00014099127,0.0000036586944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022317586,0.0009046911,0.98606086,0.00009045121,0.0004016286,0.000041609885,0.0050957478,0.0028046397,0.001855621,0.0000024297635,0.000048639802,0.0024705261],"study_design_scores_gemma":[0.011212731,0.0004324331,0.97992766,0.00011175289,0.0010775703,2.2264021e-7,0.00029004287,0.004967694,0.001493357,0.000008272013,0.00021785937,0.00026040128],"about_ca_topic_score_codex":0.018049331,"about_ca_topic_score_gemma":0.05911162,"teacher_disagreement_score":0.041062288,"about_ca_system_score_codex":0.0013889669,"about_ca_system_score_gemma":0.00026098793,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W3012568955","doi":"10.1097/ppo.0000000000000436","title":"Radiation in the Treatment of Oligometastatic and Oligoprogressive Disease","year":2020,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"SABR volatility model; Ablative case; Medicine; Disease; Radiation therapy; Randomized controlled trial; Intensive care medicine; Oncology; Internal medicine","score_opus":0.05109240320173766,"score_gpt":0.4357262261729195,"score_spread":0.38463382297118187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012568955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031107743,0.99661916,0.000003957382,0.0018922536,0.00010672435,0.00093279063,0.00007539015,0.0000029053333,0.000055717017],"genre_scores_gemma":[0.0008689915,0.99823004,0.00002083942,0.000123078,0.00038285542,0.00027629387,0.000027627071,0.000016447178,0.000053799962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991042,0.00015613057,0.0003221897,0.00012020807,0.00018122756,0.0001160692],"domain_scores_gemma":[0.9992378,0.00012078925,0.00033474073,0.000165024,0.000031838594,0.00010980898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009579386,0.00017052988,0.00064490316,0.00007853525,0.000080475445,0.00002880768,0.0000928273,0.000027458367,0.000041255804],"category_scores_gemma":[0.000019574134,0.00006619127,0.00020465131,0.00022498005,0.00006918402,0.00003004875,0.000006430528,0.00016055582,0.000002227546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030104302,0.000110479144,0.00018564753,0.001064185,0.00065451703,0.0001409664,0.001959523,0.0000025326085,3.3254302e-8,0.000045397246,0.00018194492,0.99562466],"study_design_scores_gemma":[0.0012261049,0.0003755104,0.0012284226,0.0037506153,0.009914436,0.00025354477,0.00019520514,0.000008278556,3.9663627e-7,0.00020095185,0.9827724,0.00007409385],"about_ca_topic_score_codex":0.00003825276,"about_ca_topic_score_gemma":0.000007167236,"teacher_disagreement_score":0.9955506,"about_ca_system_score_codex":0.00037427942,"about_ca_system_score_gemma":0.0008232699,"threshold_uncertainty_score":0.26992017},"labels":[],"label_agreement":null},{"id":"W3013118819","doi":"10.1001/jamanetworkopen.2020.1617","title":"Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease","year":2020,"lang":"en","type":"review","venue":"JAMA Network Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"University of Toronto","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Lung cancer; Meta-analysis; Disease; Data extraction; MEDLINE; Epidermal growth factor receptor; Intensive care medicine; Cancer; Erlotinib","score_opus":0.023560556669425067,"score_gpt":0.39120757651008214,"score_spread":0.36764701984065706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013118819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032705106,0.9824274,0.0011609806,0.00007018786,0.00012313006,0.014297104,0.0011683068,0.000008513067,0.00041728772],"genre_scores_gemma":[0.006784669,0.9808631,0.008834803,0.000049969527,0.00014328622,0.0013808799,0.0018469107,0.000066300716,0.000030064706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987436,0.00018409138,0.00046833552,0.0002903533,0.00017354947,0.00014006118],"domain_scores_gemma":[0.9984163,0.0005754668,0.0004912965,0.00021328096,0.00014610535,0.00015753816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023972432,0.00022861894,0.0017300537,0.000031081116,0.00004755588,0.00002289123,0.00012538498,0.000041079085,0.000020027108],"category_scores_gemma":[0.000050485993,0.00014141978,0.00015603927,0.00019888362,0.00004890716,0.00007609429,0.00010148313,0.00010362909,3.845065e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017935586,0.00044206198,0.010238431,0.038966723,0.0032489204,0.000016432403,0.00002510819,0.000019997318,1.4447223e-8,0.00035158385,0.00010371076,0.94479346],"study_design_scores_gemma":[0.017479137,0.003137401,0.2213085,0.08368706,0.03754504,0.0000055914425,0.000011421256,0.00013999107,1.3786388e-7,0.0001089647,0.6362209,0.00035588467],"about_ca_topic_score_codex":0.000021750537,"about_ca_topic_score_gemma":0.0000023710563,"teacher_disagreement_score":0.94443756,"about_ca_system_score_codex":0.00009603677,"about_ca_system_score_gemma":0.0008172645,"threshold_uncertainty_score":0.5766931},"labels":[],"label_agreement":null},{"id":"W3013446577","doi":"10.1016/s0140-6736(20)30164-1","title":"Small molecules, big impact: 20 years of targeted therapy in oncology","year":2020,"lang":"en","type":"review","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":602,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Drug development; Drug; Precision medicine; Targeted therapy; Oncology; Bioinformatics; Cancer; Pharmacology; Internal medicine; Pathology; Biology","score_opus":0.10722822152408364,"score_gpt":0.4180433705636626,"score_spread":0.31081514903957896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013446577","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014522923,0.99499965,0.0000045620427,0.0009755275,0.000108869936,0.0007915614,0.00019992936,0.0000194192,0.002755252],"genre_scores_gemma":[0.00014056436,0.9982083,0.00022410935,0.00039216597,0.0004693636,0.0000884577,0.00026986114,0.00002970063,0.000177476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920815,0.00011063313,0.00026879204,0.00015477395,0.000084789215,0.00017287751],"domain_scores_gemma":[0.9993056,0.000105022795,0.00016957977,0.00034618797,0.000022251535,0.00005134897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010020509,0.00015745104,0.0015911735,0.00006848076,0.0000105825275,0.000004498781,0.00017364409,0.00012033528,0.00006800454],"category_scores_gemma":[0.000033518652,0.00008607719,0.00022752407,0.00028968276,0.000042656502,0.0000061124206,0.00002516812,0.0002707825,0.000029938916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060474038,0.00007556736,0.000047789374,0.00070572866,0.0005738928,0.00009006889,0.00034773597,0.0000011056294,0.0000037625484,0.000040161158,0.0033010892,0.99475265],"study_design_scores_gemma":[0.0015062592,0.00040541554,0.00064783596,0.0012302134,0.0005225079,0.000026847885,0.000013199704,0.0000024614312,0.0000018184724,0.000040021358,0.99553174,0.00007170928],"about_ca_topic_score_codex":0.00022280934,"about_ca_topic_score_gemma":0.00006204906,"teacher_disagreement_score":0.99468094,"about_ca_system_score_codex":0.00021876402,"about_ca_system_score_gemma":0.0008471593,"threshold_uncertainty_score":0.3510126},"labels":[],"label_agreement":null},{"id":"W3014650073","doi":"10.1016/j.lungcan.2020.03.021","title":"Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Health Canada","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.025668098241412522,"score_gpt":0.33683787634941825,"score_spread":0.3111697781080057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014650073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71638155,0.03196811,0.0024967836,0.22841029,0.0012925718,0.007672481,0.009236659,0.00013388299,0.0024076875],"genre_scores_gemma":[0.9150326,0.0059488434,0.0017964717,0.04961908,0.002659721,0.0026778625,0.0060185688,0.0002224222,0.016024414],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99792457,0.00007404061,0.00064891425,0.00068126275,0.0003112114,0.00036002064],"domain_scores_gemma":[0.99862444,0.00020659252,0.00049363996,0.0004220281,0.00015514625,0.00009816956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008512879,0.0004454492,0.0006020001,0.00013914262,0.00010956767,0.00003653086,0.00014359118,0.00031943954,0.0001130327],"category_scores_gemma":[0.00003251829,0.0002907933,0.00015577444,0.00032010663,0.00006162218,0.00011128731,0.000050298375,0.0005212066,0.000003689008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015857242,0.00016845422,0.14726903,0.00055490836,0.001958047,0.0001221921,0.018429136,0.02110512,0.0013223349,0.0000015584003,0.8048347,0.0026487987],"study_design_scores_gemma":[0.043909416,0.0015919312,0.40756086,0.012657531,0.01461082,0.00001891906,0.00067265995,0.45732614,0.0049736407,0.00023699887,0.053613346,0.0028277359],"about_ca_topic_score_codex":0.037369635,"about_ca_topic_score_gemma":0.0019397101,"teacher_disagreement_score":0.75122136,"about_ca_system_score_codex":0.005548197,"about_ca_system_score_gemma":0.003623563,"threshold_uncertainty_score":0.9999544},"labels":[],"label_agreement":null},{"id":"W3015653861","doi":"10.1016/j.cllc.2020.03.009","title":"Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Geneseeq Technology","keywords":"Osimertinib; Medicine; Adenocarcinoma; Lung cancer; Mutant; Oncology; Profiling (computer programming); Acquired resistance; Internal medicine; Lung; Cancer research; Cancer; Gene; Genetics; Biology; ROS1","score_opus":0.019017340067786454,"score_gpt":0.3274518005291633,"score_spread":0.30843446046137685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015653861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249816,0.0021840478,0.002395814,0.0007609378,0.00007281295,0.0016703404,0.00010647994,0.00007076732,0.00024065886],"genre_scores_gemma":[0.9971444,0.000078468904,0.0015917149,0.0005106807,0.00006495646,0.00038628635,0.000038262548,0.000050026665,0.00013520384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810493,0.000077641766,0.0006662345,0.0005490317,0.0003184833,0.00028365236],"domain_scores_gemma":[0.99889237,0.00014351195,0.00030470535,0.00024242718,0.0001770679,0.00023989982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094551484,0.0002231901,0.00054315844,0.000052774965,0.000059418613,0.0000126651175,0.00007171389,0.000120926314,0.000036798516],"category_scores_gemma":[0.00008937303,0.00015338142,0.00008912061,0.00046801654,0.000095522715,0.0000941968,0.00002084712,0.00029392447,0.0000018415247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011806263,0.00056954386,0.95485663,0.00040529072,0.00079850724,0.00021738393,0.0011670868,0.00011954015,0.025411977,0.00003064018,0.0002599249,0.004357217],"study_design_scores_gemma":[0.046003155,0.01493481,0.5662722,0.0039787586,0.004572373,0.000032096956,0.0012325317,0.024122864,0.33666638,0.00003121032,0.0009980274,0.001155617],"about_ca_topic_score_codex":0.00044687284,"about_ca_topic_score_gemma":0.00045291046,"teacher_disagreement_score":0.38858443,"about_ca_system_score_codex":0.0002891571,"about_ca_system_score_gemma":0.00029982856,"threshold_uncertainty_score":0.62547123},"labels":[],"label_agreement":null},{"id":"W3016429630","doi":"10.1016/j.cllc.2020.04.009","title":"Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Hazard ratio; Chronic bronchitis; Confidence interval; Incidence (geometry); Internal medicine; Lung cancer screening; Proportional hazards model","score_opus":0.08453461208895334,"score_gpt":0.45741601521522296,"score_spread":0.3728814031262696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016429630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98659694,0.0020531085,0.000039944338,0.008940413,0.0005639261,0.0013550981,0.00016077425,0.0000207777,0.00026899675],"genre_scores_gemma":[0.99391264,0.00025416238,0.0000678339,0.0047676293,0.00051306613,0.0002756763,0.000023093697,0.00001944519,0.00016648433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982882,0.00010768381,0.00069556,0.0004445151,0.00026194923,0.00020208581],"domain_scores_gemma":[0.99827355,0.0009618934,0.0001716061,0.00025178265,0.00008400152,0.00025716424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036240128,0.00015340486,0.00046280443,0.00003422671,0.00008112769,0.000023867276,0.0001213258,0.00015085282,0.0003974936],"category_scores_gemma":[0.00089519034,0.00010944742,0.00011911576,0.00034145656,0.00018081392,0.00016606697,0.000076065335,0.00041072455,0.0000012890484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022477263,0.000055171084,0.98984516,0.00005284536,0.00034610348,0.000009079016,0.0020794752,0.00009528363,0.0000137779125,0.00005718749,0.00457798,0.0006202259],"study_design_scores_gemma":[0.014068053,0.00016329096,0.9825511,0.0003755252,0.00091882143,2.1406996e-7,0.00012023211,0.00092585024,0.000039768885,0.00005503226,0.0006650197,0.00011712037],"about_ca_topic_score_codex":0.005854398,"about_ca_topic_score_gemma":0.0030552596,"teacher_disagreement_score":0.011820327,"about_ca_system_score_codex":0.00021861395,"about_ca_system_score_gemma":0.00048030002,"threshold_uncertainty_score":0.88501376},"labels":[],"label_agreement":null},{"id":"W3016888440","doi":"10.1016/j.thorsurg.2020.01.008","title":"Epidermal Growth Factor Receptor Mutations","year":2020,"lang":"en","type":"review","venue":"Thoracic surgery clinics/Thorac. surg. clin.","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Helsinn Therapeutics; Takeda Pharmaceuticals U.S.A.; Helsinn; Merck","keywords":"Medicine; Epidermal growth factor receptor; Cancer research; Receptor; Genetics; Internal medicine; Biology","score_opus":0.14638390979000107,"score_gpt":0.4701615939741244,"score_spread":0.32377768418412334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016888440","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029096234,0.98324215,0.0001916929,0.0014991827,0.0051510246,0.0032392845,0.0025451367,0.0009050726,0.002935461],"genre_scores_gemma":[0.00039353324,0.9801199,0.0018074596,0.0008830663,0.0033398198,0.00082606176,0.008166958,0.00058808335,0.0038751343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98881304,0.0017409329,0.004859738,0.002139633,0.0011015068,0.0013451742],"domain_scores_gemma":[0.9799829,0.013546769,0.0026038035,0.0015822006,0.0008064104,0.0014779283],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.002000048,0.00177056,0.008282972,0.001069862,0.0004934005,0.00020522541,0.00049417105,0.0014520838,0.0024124328],"category_scores_gemma":[0.0052985204,0.0014828756,0.0048166756,0.0023565819,0.0003753366,0.00044964385,0.0002331668,0.002203573,0.0050398433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001905425,0.0006538938,0.0016213455,0.012024294,0.0025233754,0.0008034127,0.00018197854,5.4834226e-7,4.392496e-7,0.00004727649,0.018140977,0.96381193],"study_design_scores_gemma":[0.0003623012,0.00019267817,0.00013116101,0.011724295,0.009329235,0.00020960765,0.00009719317,0.000012819067,0.000011549444,0.00010583013,0.97654,0.0012833301],"about_ca_topic_score_codex":0.00007870961,"about_ca_topic_score_gemma":0.000011217392,"teacher_disagreement_score":0.9625286,"about_ca_system_score_codex":0.00079844234,"about_ca_system_score_gemma":0.0061784685,"threshold_uncertainty_score":0.99984425},"labels":[],"label_agreement":null},{"id":"W3017107411","doi":"10.1016/j.lungcan.2020.04.011","title":"Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Hazard ratio; Oncology; Anaplastic lymphoma kinase; Cochrane Library; Lung cancer; ALK inhibitor; Randomized controlled trial; Subgroup analysis; Confidence interval","score_opus":0.032884582674672175,"score_gpt":0.37616885597003563,"score_spread":0.3432842732953635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017107411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007846873,0.9884874,0.000015418782,0.0006652352,0.00007888154,0.009294534,0.00056166784,0.00002445439,0.00086455233],"genre_scores_gemma":[0.00024760887,0.993938,0.00011986439,0.00042722662,0.000073447976,0.003812482,0.00014678639,0.00007875532,0.0011557936],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967038,0.0002696762,0.0015800638,0.0007848479,0.00034277697,0.00031885583],"domain_scores_gemma":[0.99776036,0.00025908902,0.0010109522,0.00057793624,0.00013141346,0.00026026162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032980938,0.0006682434,0.010299036,0.00036161684,0.000062131294,0.000026533566,0.00014805145,0.00021943015,0.00025683304],"category_scores_gemma":[0.000059732076,0.00043458992,0.0013591545,0.0014499881,0.0000654629,0.000060506867,0.000084566855,0.00038570588,0.0000020302637],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016705304,0.000065316,0.00012058628,0.8598888,0.13291107,0.000033922617,0.00045571238,0.000005248698,4.885686e-7,0.0000035037983,0.00063229754,0.0058663497],"study_design_scores_gemma":[0.0010595876,0.000041022395,0.000025301539,0.12495365,0.82167125,0.000009109618,0.000019385043,0.000037138365,0.0000011630235,3.0027803e-7,0.051888473,0.0002936342],"about_ca_topic_score_codex":0.0019243642,"about_ca_topic_score_gemma":0.00080814806,"teacher_disagreement_score":0.73493516,"about_ca_system_score_codex":0.0006363451,"about_ca_system_score_gemma":0.0008404131,"threshold_uncertainty_score":0.9998106},"labels":[],"label_agreement":null},{"id":"W3017413818","doi":"10.1016/j.xcrm.2020.100007","title":"Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"U.S. Food and Drug Administration; Clovis Oncology; Exelixis; National Cancer Institute; AbbVie; Takeda Pharmaceuticals U.S.A.; Spectrum Pharmaceuticals; Novartis; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Gilead Sciences; National Institutes of Health; Medtronic","keywords":"Osimertinib; KRAS; Cancer research; Lung cancer; Adenocarcinoma; Biology; Somatic evolution in cancer; Acquired resistance; Mutation; Gene duplication; Medicine; Cancer; Gene; Genetics; Pathology","score_opus":0.016383452536505205,"score_gpt":0.31259315467042953,"score_spread":0.29620970213392434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017413818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727982,0.01461638,0.0021436573,0.006588321,0.0003109806,0.00074631115,0.000013068829,0.000040121788,0.00274292],"genre_scores_gemma":[0.99801654,0.00031762305,0.00044428217,0.00060898426,0.00012587104,0.000047561964,0.00003470852,0.000017893324,0.00038651327],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985721,0.000024332856,0.00055372453,0.000353653,0.00031709418,0.00017905867],"domain_scores_gemma":[0.9991806,0.000030265717,0.00028225084,0.00019901396,0.00010227932,0.00020559136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016290053,0.00014355156,0.00041475825,0.00007150098,0.000037932234,0.0000024162948,0.000029428578,0.000063646585,0.00014869148],"category_scores_gemma":[0.00010716908,0.00010935246,0.000040835774,0.00024971538,0.00010582266,0.00004930336,0.000023491662,0.00007454295,4.3811755e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008282181,0.00034018973,0.2642905,0.0017119948,0.00030085878,0.0026859182,0.0049440265,0.000075968484,0.7191469,0.00051176216,0.0036478224,0.0015158291],"study_design_scores_gemma":[0.017903153,0.0019772314,0.5085255,0.004153575,0.0034854887,0.00050354586,0.0022703372,0.0035124284,0.4450446,0.0017494011,0.010106118,0.00076865026],"about_ca_topic_score_codex":0.00036687512,"about_ca_topic_score_gemma":0.00012629796,"teacher_disagreement_score":0.27410227,"about_ca_system_score_codex":0.00018678223,"about_ca_system_score_gemma":0.0002301323,"threshold_uncertainty_score":0.4459264},"labels":[],"label_agreement":null},{"id":"W3018308921","doi":"10.1186/s12885-020-06826-0","title":"EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors","year":2020,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Center for Advancing Translational Sciences; AstraZeneca; AstraZeneca United States","keywords":"Medicine; Osimertinib; T790M; Oncology; Internal medicine; Epidermal growth factor receptor; Surgical oncology; Lung cancer; Resistance mutation; Targeted therapy; Cancer; Erlotinib; Gefitinib","score_opus":0.0778234020272974,"score_gpt":0.339499494972079,"score_spread":0.26167609294478156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018308921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682933,0.00030028276,0.00004007103,0.0013645168,0.00020444262,0.0009870783,0.00012652553,0.000045124576,0.00010260423],"genre_scores_gemma":[0.994985,0.000062619736,0.0035063124,0.00041269604,0.00038265946,0.00030170314,0.00015924164,0.000027653743,0.00016215305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989964,0.00003139605,0.00027773378,0.0003379101,0.00017695231,0.00017962957],"domain_scores_gemma":[0.999357,0.0001679145,0.00010975391,0.00008604407,0.000113992704,0.00016529318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000025540117,0.0001763446,0.00021668444,0.00008655215,0.00016498084,0.000041390867,0.000021147674,0.000057326128,0.00018566844],"category_scores_gemma":[0.00040865486,0.000114216,0.000035991336,0.0002777378,0.000026206917,0.00015109283,0.000013526109,0.00006784035,0.000008917731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006847082,0.0005087097,0.8051505,0.000074099975,0.00006755257,0.000024007684,0.00233846,0.00025207302,0.0012689036,0.000007840507,0.0010793516,0.18854378],"study_design_scores_gemma":[0.011959862,0.003245709,0.9636484,0.00074730115,0.00020722841,0.0000041296516,0.0001564753,0.003347076,0.013421199,0.0000064550486,0.00296004,0.00029615447],"about_ca_topic_score_codex":0.00030656726,"about_ca_topic_score_gemma":0.0018792761,"teacher_disagreement_score":0.18824764,"about_ca_system_score_codex":0.0006451721,"about_ca_system_score_gemma":0.0002365456,"threshold_uncertainty_score":0.46575937},"labels":[],"label_agreement":null},{"id":"W3018637389","doi":"10.1096/fasebj.2020.34.s1.00612","title":"Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance <i>EGFR</i> Mutations","year":2020,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Afatinib; Erlotinib; Lung cancer; Context (archaeology); Medicine; Drug resistance; Cancer research; Mutation; Cancer; Oncology; Epidermal growth factor receptor; Biology; Genetics; Internal medicine; Gene","score_opus":0.02124294871469279,"score_gpt":0.2845204444820401,"score_spread":0.2632774957673473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018637389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483293,0.0011594156,0.0019719186,0.045642953,0.0000666312,0.00023315316,0.00006530577,0.000021904187,0.002509375],"genre_scores_gemma":[0.9973061,0.00029374473,0.00072716986,0.00090405665,0.00021934588,0.0000027987253,0.000012890294,0.0000106393,0.0005232482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992802,0.00006807774,0.00022936253,0.000108966626,0.00019171773,0.00012168628],"domain_scores_gemma":[0.99930197,0.00014882075,0.00014521809,0.000114586255,0.00013062227,0.00015877475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019510124,0.00008942513,0.00018810798,0.00002382415,0.00025449807,0.000019949486,0.000039781287,0.000019972886,0.00007357405],"category_scores_gemma":[0.000094674644,0.000056812143,0.00006973936,0.000132304,0.00011208654,0.00006559738,0.000019044399,0.00020334538,0.0000058342475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072707273,0.0025771207,0.22740869,0.0011171645,0.005248143,0.0026207953,0.10136863,0.0039956626,0.46098062,0.0044350387,0.15555003,0.027427372],"study_design_scores_gemma":[0.032555744,0.0021906444,0.29119682,0.0014258112,0.0072794887,0.003299998,0.01768784,0.009358039,0.5077664,0.004318111,0.12160163,0.0013194846],"about_ca_topic_score_codex":0.000028176015,"about_ca_topic_score_gemma":0.00015496592,"teacher_disagreement_score":0.083680786,"about_ca_system_score_codex":0.0000396656,"about_ca_system_score_gemma":0.000086004424,"threshold_uncertainty_score":0.2316732},"labels":[],"label_agreement":null},{"id":"W3020988432","doi":"10.1021/acsmedchemlett.9b00599","title":"Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors","year":2020,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hunter Family Foundation; National Cancer Institute; Uncle Kory Foundation; Ziering Family Foundation; National Brain Tumor Society","keywords":"Penetrant (biochemical); Tyrosine-kinase inhibitor; Protein-Tyrosine Kinases; Cancer research; Tyrosine kinase; Medicine; Pharmacology; Chemistry; Internal medicine; Receptor; Cancer","score_opus":0.01519337616604374,"score_gpt":0.2690824842700128,"score_spread":0.2538891081039691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020988432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.893818,0.00032622687,0.00032497096,0.10418381,0.00007692363,0.00032088926,0.000022781143,0.000057205318,0.00086917356],"genre_scores_gemma":[0.96595544,0.000011341365,0.002326231,0.030782638,0.00041841544,0.000040934403,0.00027066373,0.000036449183,0.00015788103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998078,0.000015343876,0.00056225987,0.0004136565,0.0005801405,0.00035062886],"domain_scores_gemma":[0.99899167,0.00006188246,0.00017932677,0.000242702,0.00008242638,0.00044197426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013073705,0.0002778859,0.00044604664,0.00003926777,0.00008564337,0.000010335099,0.0001373204,0.000068396446,0.00008408422],"category_scores_gemma":[0.00014212853,0.00022449538,0.000104354935,0.0002468677,0.00014102625,0.00004758848,0.00004997501,0.00022369559,0.0000146435505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020341555,0.0001551722,0.00068186386,0.0006872324,0.00022177518,0.0007542588,0.0028911114,0.000015422034,0.9741538,0.0000041290837,0.01417412,0.006057685],"study_design_scores_gemma":[0.0042512366,0.00013594082,0.00261529,0.0009287746,0.00023139098,0.000097293494,0.0012333897,0.000040704133,0.9733755,0.0000017085009,0.016820136,0.00026862806],"about_ca_topic_score_codex":0.000021775671,"about_ca_topic_score_gemma":0.0000016562761,"teacher_disagreement_score":0.07340117,"about_ca_system_score_codex":0.0002647581,"about_ca_system_score_gemma":0.00044778842,"threshold_uncertainty_score":0.91546553},"labels":[],"label_agreement":null},{"id":"W3021093616","doi":"10.5195/ijms.2020.446","title":"Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies","year":2020,"lang":"en","type":"article","venue":"International Journal of Medical Students","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Lung cancer; Medicine; Immune system; Cancer; Targeted therapy; Epidermal growth factor receptor; Clinical trial; Immunotherapy; Cancer research; Tumor microenvironment; Oncology; Immunology; Internal medicine","score_opus":0.02760353868349943,"score_gpt":0.3747933217210906,"score_spread":0.3471897830375912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021093616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736004,0.011079204,0.0005695079,0.013874071,0.0006089188,0.0001684306,0.000010210073,0.000004581277,0.0000846686],"genre_scores_gemma":[0.9868577,0.009169077,0.00053826283,0.0027327447,0.0005955466,0.0000090967005,0.000011777603,0.0000109346065,0.00007486965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771225,0.000023982733,0.000394576,0.000100573074,0.0016871379,0.00008150144],"domain_scores_gemma":[0.9990812,0.000034120847,0.00026578875,0.00004372516,0.00039467923,0.00018050372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018105404,0.00009131107,0.00022347877,0.00006001743,0.00002621263,0.000042687716,0.0003441927,0.000054818534,0.0004241263],"category_scores_gemma":[0.00006127304,0.00006457086,0.000078705685,0.00006171933,0.00003854155,0.00010878413,0.000050368366,0.0001592252,0.0000011551687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015705952,0.0016865707,0.56553614,0.000121538025,0.006051169,0.00040587678,0.016798314,0.00017126539,0.19300091,0.000046972604,0.0068396977,0.20777094],"study_design_scores_gemma":[0.08110054,0.0043252604,0.776932,0.0022345814,0.0013219493,0.0002746823,0.0049333125,0.010140948,0.066384085,0.000066293214,0.051669315,0.0006170603],"about_ca_topic_score_codex":0.00006931766,"about_ca_topic_score_gemma":0.0000070199826,"teacher_disagreement_score":0.21139583,"about_ca_system_score_codex":0.00008199127,"about_ca_system_score_gemma":0.0002553997,"threshold_uncertainty_score":0.46438858},"labels":[],"label_agreement":null},{"id":"W3024486891","doi":"10.21037/jtd-19-4119","title":"Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Réseau de cancérologie Rossy","keywords":"Medicine; Lung cancer; Bronchoscopy; Pathology; Biopsy; Stage (stratigraphy); Molecular diagnostics; Companion diagnostic; Radiology; Cancer; Oncology; Bioinformatics; Internal medicine","score_opus":0.07903476962610688,"score_gpt":0.4631170803398016,"score_spread":0.3840823107136947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024486891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021376442,0.9941106,0.0013519833,0.0024245903,0.0003930829,0.001291822,0.00014859553,0.000027252456,0.00023068643],"genre_scores_gemma":[0.00023933587,0.98507214,0.012521292,0.00032178656,0.0008771484,0.00011069455,0.00005695865,0.00009986963,0.0007007631],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982891,0.000054162425,0.00079227344,0.00027331442,0.00034474253,0.00024640912],"domain_scores_gemma":[0.99709374,0.00030255492,0.0013308325,0.0002646226,0.00032048352,0.00068777363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011225476,0.0003475615,0.0015279347,0.00016896953,0.000082387225,0.00004730101,0.00018257936,0.00010358443,0.000040484923],"category_scores_gemma":[0.0014958527,0.00025224488,0.00066794147,0.00028496826,0.000025073035,0.00010974059,0.000036415535,0.00036125004,0.000013365872],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010170282,0.00016743226,0.000019364363,0.04143173,0.0006212289,0.001722917,0.000037731465,0.000012089414,0.000008526265,0.000009376261,0.0013784709,0.9544894],"study_design_scores_gemma":[0.0004326373,0.00043201522,0.000010562398,0.08267442,0.013280876,0.00014277172,0.00004309728,0.000005997811,0.000017111444,0.00007398091,0.9026847,0.00020184375],"about_ca_topic_score_codex":0.0000010223305,"about_ca_topic_score_gemma":1.9346807e-7,"teacher_disagreement_score":0.9542876,"about_ca_system_score_codex":0.0003037491,"about_ca_system_score_gemma":0.0016615525,"threshold_uncertainty_score":0.99999297},"labels":[],"label_agreement":null},{"id":"W3024577926","doi":"10.1200/po.19.00335","title":"Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Mount Sinai Hospital; McGill University Health Centre; Lakeridge Health; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T790M; Osimertinib; Concordance; Medicine; Epidermal growth factor receptor; Liquid biopsy; Internal medicine; Biopsy; Oncology; Cancer; Gefitinib","score_opus":0.10926900412114984,"score_gpt":0.47808154929876795,"score_spread":0.3688125451776181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024577926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783576,0.000016079819,0.00023037562,0.008711963,0.0006278202,0.0018951114,0.00006342753,0.000062647574,0.00055681355],"genre_scores_gemma":[0.98657036,0.000009778035,0.010694676,0.0020506452,0.0003659797,0.00016098871,0.00005445113,0.000021122323,0.00007198666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978962,0.00031628102,0.0008318381,0.00045864607,0.00024610237,0.0002509202],"domain_scores_gemma":[0.99807405,0.00097600726,0.00016070293,0.0001708766,0.00031826273,0.000300068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039984798,0.00015547698,0.0004616049,0.00009876331,0.00006960161,0.000021732638,0.00009332328,0.00009179253,0.0003839692],"category_scores_gemma":[0.003482084,0.00012388028,0.000054113287,0.0004349681,0.000018912644,0.000112923946,0.00012656364,0.00022421688,0.00020840646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095643505,0.001958433,0.906101,0.000018120305,0.000102456,0.00007365191,0.006903477,0.000019080784,0.00079454697,0.000021257729,0.004634223,0.07841734],"study_design_scores_gemma":[0.012943046,0.012997227,0.91439736,0.000072079296,0.00019500327,0.0000052632404,0.004102066,0.00037257635,0.0022304822,0.00001815294,0.052450012,0.00021674],"about_ca_topic_score_codex":0.00010654738,"about_ca_topic_score_gemma":0.0001112634,"teacher_disagreement_score":0.0782006,"about_ca_system_score_codex":0.00037403064,"about_ca_system_score_gemma":0.00039282313,"threshold_uncertainty_score":0.50516915},"labels":[],"label_agreement":null},{"id":"W3025802953","doi":"10.1016/j.lungcan.2020.03.022","title":"EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Ontario Institute for Cancer Research; Canadian Cancer Society","keywords":"Medicine; Oncology; Cancer research; Lung; Internal medicine; EGFR inhibitors; Epidermal growth factor receptor; Cancer","score_opus":0.0160674318140488,"score_gpt":0.3089211713185431,"score_spread":0.2928537395044943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025802953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828613,0.0049116146,0.00006542499,0.007625521,0.0005431417,0.0024327626,0.00041272037,0.00017500734,0.0009725127],"genre_scores_gemma":[0.9942033,0.00021757852,0.00029781566,0.0027855444,0.000400681,0.00083048124,0.00079788215,0.000085373795,0.00038128937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976916,0.00006845617,0.00046856093,0.00072753715,0.0005387898,0.00050505524],"domain_scores_gemma":[0.9989448,0.000063886466,0.00015978214,0.00031538503,0.00016003828,0.000356082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000043511976,0.00040149878,0.0005583026,0.00014240277,0.00011219828,0.00006066813,0.00013651597,0.00014575754,0.0003247933],"category_scores_gemma":[0.000023738032,0.00030229992,0.00013505183,0.000498246,0.000056910507,0.00021905851,0.000054634314,0.00030409117,0.000021288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019281302,0.0014731826,0.92866766,0.00042871555,0.0017522477,0.00028076262,0.011765603,0.0069130077,0.0007190946,0.00028427213,0.03419347,0.011593873],"study_design_scores_gemma":[0.047674995,0.0031366,0.7686769,0.0039093127,0.0037567422,0.0000025472248,0.00102084,0.12063887,0.038953833,0.0005512912,0.009753826,0.0019242633],"about_ca_topic_score_codex":0.0024504603,"about_ca_topic_score_gemma":0.00022903127,"teacher_disagreement_score":0.15999076,"about_ca_system_score_codex":0.0011963756,"about_ca_system_score_gemma":0.00031909428,"threshold_uncertainty_score":0.9999429},"labels":[],"label_agreement":null},{"id":"W3027850675","doi":"10.1016/j.cllc.2020.05.015","title":"Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Genentech; Meso Scale Diagnostics; Clovis Oncology; Chugai Pharmaceutical; Roche; Novartis; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AstraZeneca France; Takeda Pharmaceutical Company","keywords":"Crizotinib; Osimertinib; Medicine; Epidermal growth factor receptor; Lung cancer; Adenocarcinoma; Cancer research; Gefitinib; Tyrosine kinase; Oncology; Acquired resistance; Internal medicine; Erlotinib; Receptor; Cancer","score_opus":0.05111740777455702,"score_gpt":0.4146171040608322,"score_spread":0.36349969628627515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027850675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983928,0.0032360412,0.00072400266,0.008574137,0.00025633458,0.0011691716,0.00003846183,0.0001468356,0.0019270042],"genre_scores_gemma":[0.9943612,0.00023723785,0.0017216323,0.0025795696,0.00036230337,0.00028293955,0.00018125417,0.000048233556,0.00022563651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773765,0.000088492605,0.00086830923,0.00072840624,0.00028293388,0.00029419916],"domain_scores_gemma":[0.9986412,0.00021170171,0.00029774857,0.0003001594,0.00018278863,0.00036642252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033821553,0.00022623317,0.00058749254,0.00007881758,0.00010299301,0.000051801635,0.00005862125,0.00013350001,0.00012728547],"category_scores_gemma":[0.0002928743,0.00018787292,0.000089980225,0.00048189546,0.00014665807,0.00019039073,0.000050159248,0.0004258116,0.000004440396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006494393,0.00018854023,0.99114376,0.00023766022,0.00044162112,0.00083190884,0.0010262469,0.00005038691,0.00037143292,0.00045602824,0.0015733079,0.0030296787],"study_design_scores_gemma":[0.011629828,0.0011156453,0.97660536,0.0010499394,0.0017770426,0.0001823674,0.0005035157,0.0028884166,0.00055937306,0.000049033322,0.003260822,0.0003786591],"about_ca_topic_score_codex":0.00029457273,"about_ca_topic_score_gemma":0.00007603401,"teacher_disagreement_score":0.0145383915,"about_ca_system_score_codex":0.00027638944,"about_ca_system_score_gemma":0.0004897175,"threshold_uncertainty_score":0.76612353},"labels":[],"label_agreement":null},{"id":"W3027882342","doi":"10.1016/j.lungcan.2020.05.018","title":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canadian Cancer Society; Princess Margaret Cancer Foundation","keywords":"Alectinib; Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Medicine; Cancer research; Lung cancer; Exome sequencing; Adenocarcinoma; Oncology; Mutation; Internal medicine; Cancer; Biology; Gene","score_opus":0.01857981633021402,"score_gpt":0.31091791521905204,"score_spread":0.29233809888883805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027882342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711914,0.0070694964,0.0001692817,0.0030842111,0.0004440353,0.00097234483,0.00019801292,0.000033050568,0.0009104464],"genre_scores_gemma":[0.99668854,0.0002580691,0.00018677804,0.0011161475,0.00035194703,0.00043417807,0.000072168405,0.000027819578,0.00086434855],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998812,0.00006019586,0.00033814268,0.00036368993,0.0002481176,0.00017785485],"domain_scores_gemma":[0.99929726,0.000057692,0.00020899376,0.000191379,0.0001410884,0.000103596845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069789334,0.00016313021,0.00024271011,0.0000711459,0.00011536937,0.000026566408,0.00006195886,0.00007943317,0.00020789598],"category_scores_gemma":[0.000087704386,0.00012896236,0.000054698106,0.00048825913,0.000058601407,0.00016291127,0.000021895798,0.0000947653,0.0000014683426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029113465,0.0007684922,0.29410625,0.005489859,0.0015641099,0.00013508201,0.04510734,0.0036922977,0.55414623,0.006339655,0.034967553,0.05077181],"study_design_scores_gemma":[0.020025473,0.0007490523,0.62675744,0.0023857348,0.0024932066,0.000036008496,0.0016883371,0.032007053,0.29430595,0.00034924885,0.018245729,0.00095677556],"about_ca_topic_score_codex":0.0006659251,"about_ca_topic_score_gemma":0.007624599,"teacher_disagreement_score":0.33265117,"about_ca_system_score_codex":0.0005341046,"about_ca_system_score_gemma":0.00059056736,"threshold_uncertainty_score":0.5258933},"labels":[],"label_agreement":null},{"id":"W3028614809","doi":"10.1200/jco.2020.38.15_suppl.9502","title":"CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Humber River Regional Hospital; University of Saskatchewan; University of Alberta; Centre Hospitalier de l’Université de Montréal; Windsor Regional Hospital; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute","keywords":"Pemetrexed; Medicine; Durvalumab; Internal medicine; Gemcitabine; Lung cancer; Oncology; Chemotherapy; Tremelimumab; Clinical endpoint; Cancer; Randomized controlled trial; Pembrolizumab; Cisplatin; Immunotherapy; Ipilimumab","score_opus":0.04899802443508074,"score_gpt":0.4194738323229189,"score_spread":0.3704758078878382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028614809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174863,0.00038654899,0.00075540494,0.0037761398,0.0003316276,0.0024886962,0.00003288587,0.00000785731,0.00047222053],"genre_scores_gemma":[0.990921,0.00024338778,0.0058440096,0.0024649769,0.0002672651,0.00006133581,0.000009533962,0.00003666535,0.00015182445],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958972,0.0005605059,0.002599552,0.00027210516,0.00042576835,0.00024491525],"domain_scores_gemma":[0.9933722,0.003350265,0.0023503432,0.00015478417,0.00039789054,0.00037448845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013841406,0.00023887734,0.0029877375,0.00015266301,0.000033147062,0.000009976072,0.00011593142,0.00018818471,0.00023854345],"category_scores_gemma":[0.0015263604,0.0001368983,0.00041193477,0.00024144999,0.00022456392,0.000080366284,0.00001849196,0.0005646468,0.0000011136829],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94483083,0.0048154634,0.034694426,0.00022732155,0.0008273321,0.00023705307,0.0009368381,0.00025048965,0.00002487694,0.000003578062,0.0002430967,0.012908677],"study_design_scores_gemma":[0.94081986,0.03202183,0.020675968,0.00018284525,0.002490963,0.0000062153267,0.00015869767,0.0028853456,0.00007069782,0.00000696137,0.0005459107,0.00013472863],"about_ca_topic_score_codex":0.00017843586,"about_ca_topic_score_gemma":0.00016634609,"teacher_disagreement_score":0.027206367,"about_ca_system_score_codex":0.00022613471,"about_ca_system_score_gemma":0.0041403794,"threshold_uncertainty_score":0.73448557},"labels":[],"label_agreement":null},{"id":"W3028754062","doi":"10.1200/jco.2020.38.15_suppl.9582","title":"Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Pemetrexed; Lung cancer; Placebo; Internal medicine; Clinical endpoint; Oncology; Carboplatin; Cisplatin; Randomization; Progression-free survival; Chemotherapy; Clinical trial","score_opus":0.05799861924725461,"score_gpt":0.4282136198917117,"score_spread":0.3702150006444571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028754062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948741,0.00033987407,0.0010212365,0.0016348659,0.000096716256,0.0009906823,0.000036263544,0.000012332394,0.0009938895],"genre_scores_gemma":[0.98729295,0.00035276855,0.009864335,0.0018233744,0.00014247888,0.00003370098,0.00003256139,0.000049119662,0.00040869406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606377,0.00027177314,0.0023003004,0.00040859476,0.0005756468,0.0003798959],"domain_scores_gemma":[0.9949539,0.00077806634,0.0026246724,0.0002618498,0.0008800245,0.0005014987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005623461,0.0003382543,0.0030832896,0.00040613642,0.000042283737,0.000013535564,0.0002090176,0.0002039556,0.00045650735],"category_scores_gemma":[0.0003447726,0.00019012872,0.0004455823,0.0014614392,0.00017600023,0.0001297251,0.000028090715,0.0007169088,0.0000027177612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055065054,0.0039580013,0.90699476,0.00023179929,0.0075632078,0.00040133184,0.0018583984,0.0016643999,0.00005282844,0.0000013635554,0.00034713733,0.021861706],"study_design_scores_gemma":[0.11762588,0.047332242,0.7947602,0.0005207431,0.029799454,0.000047399037,0.00041613367,0.008065905,0.0003043997,0.0000027774888,0.0008052744,0.00031958186],"about_ca_topic_score_codex":0.00050156185,"about_ca_topic_score_gemma":0.0014251195,"teacher_disagreement_score":0.11223456,"about_ca_system_score_codex":0.0004452568,"about_ca_system_score_gemma":0.004271509,"threshold_uncertainty_score":0.7753224},"labels":[],"label_agreement":null},{"id":"W3030431591","doi":"10.1200/jco.2020.38.15_suppl.1512","title":"Smoking cessation (SC) and lung cancer (LC) outcomes: A survival benefit for recent-quitters? A pooled analysis of 34,649 International Lung Cancer Consortium (ILCCO) patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Lung cancer; Proportional hazards model; Internal medicine; Oncology; Survival analysis; Smoking cessation; Lung; Pooled analysis; Pathology; Confidence interval","score_opus":0.09175959229041371,"score_gpt":0.5037262991453846,"score_spread":0.4119667068549709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030431591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605271,0.0011361022,0.0010290287,0.03413354,0.0020465788,0.00043912354,0.00022344939,0.0000083757795,0.0004566934],"genre_scores_gemma":[0.9917948,0.0021053231,0.0006993616,0.004643565,0.0005375226,0.000039551618,0.00006726916,0.000016716704,0.00009588602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971607,0.00010195554,0.0018957858,0.0002450002,0.00041653338,0.00018008132],"domain_scores_gemma":[0.9951951,0.0010688036,0.0021017836,0.00009661697,0.001256569,0.0002811587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064888987,0.00014898561,0.0014410677,0.00022766583,0.000049072212,0.00001553505,0.00012367275,0.00019055851,0.0004049992],"category_scores_gemma":[0.0014780676,0.0001089607,0.0005088561,0.00032392822,0.00009164324,0.00016310594,0.000044763157,0.00030312082,1.689758e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018122153,0.0005206281,0.93240434,0.000065168526,0.018114734,0.000012766127,0.0006510166,0.00040708997,0.0000323511,0.00009654807,0.0009720696,0.044911075],"study_design_scores_gemma":[0.013870406,0.0013728628,0.94417965,0.00011010593,0.025267469,0.0000018567423,0.00023625049,0.0067266114,0.0000222335,0.000028129838,0.008079206,0.000105242405],"about_ca_topic_score_codex":0.000242513,"about_ca_topic_score_gemma":0.00040643493,"teacher_disagreement_score":0.044805832,"about_ca_system_score_codex":0.0004771578,"about_ca_system_score_gemma":0.0009428684,"threshold_uncertainty_score":0.44432887},"labels":[],"label_agreement":null},{"id":"W3030545184","doi":"10.1200/jco.2020.38.15_suppl.3605","title":"Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i>-fusion positive (<i>NTRK</i>-fp) solid tumors: An updated integrated analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Clinical trial; Trk receptor; Population; Clinical endpoint; Phases of clinical research; Progression-free survival; Overall survival; Receptor; Neurotrophin","score_opus":0.03283258638986669,"score_gpt":0.4283467893388865,"score_spread":0.3955142029490198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030545184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463713,0.00008244946,0.00021830357,0.0037231492,0.00012186619,0.00039147152,0.000033431472,0.000009188887,0.0007830181],"genre_scores_gemma":[0.995759,0.00013080834,0.0016676207,0.0021107784,0.00015473127,0.0000018249383,0.00013933668,0.00001468613,0.000021231666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671865,0.00044818266,0.002060539,0.00026851473,0.00031099346,0.00019314467],"domain_scores_gemma":[0.9965253,0.0005780072,0.0015602566,0.00013380223,0.0007117486,0.0004909244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006800695,0.00017143298,0.0018447144,0.00021916644,0.00003689387,0.000008743928,0.00010021494,0.0001979581,0.00014049585],"category_scores_gemma":[0.00078019104,0.00010707296,0.00021652078,0.00074827054,0.000178218,0.00015910773,0.00003658642,0.00064913626,0.0000023248338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046251524,0.0075698905,0.8537114,0.00002134085,0.0041732015,0.00050204,0.0021163416,0.00039365262,0.0001852972,0.000031413307,0.00065634813,0.084387526],"study_design_scores_gemma":[0.034538712,0.03601202,0.9212783,0.00015053527,0.0038841378,0.000029322362,0.00047883394,0.00049522106,0.00016513595,0.000014518048,0.0028424582,0.000110824076],"about_ca_topic_score_codex":0.000108549895,"about_ca_topic_score_gemma":0.00014699067,"teacher_disagreement_score":0.0842767,"about_ca_system_score_codex":0.00015336766,"about_ca_system_score_gemma":0.0010344521,"threshold_uncertainty_score":0.43663087},"labels":[],"label_agreement":null},{"id":"W3030829389","doi":"10.1200/jco.2020.38.15_suppl.e21558","title":"Does CNS metastases reduce systemic therapy lines for NSCLC patients with EGFR mutation?","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Osimertinib; Medicine; T790M; Oncology; Internal medicine; Brain metastasis; Clinical endpoint; Epidermal growth factor receptor; Lung cancer; Metastasis; Cancer; Erlotinib; Gefitinib; Clinical trial","score_opus":0.09906560483173175,"score_gpt":0.49189326110002424,"score_spread":0.39282765626829247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030829389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96476924,0.0006145817,0.0011935972,0.031242417,0.00094145763,0.0007784986,0.000051675102,0.000014979846,0.0003935459],"genre_scores_gemma":[0.98642486,0.00027547445,0.007479062,0.004431751,0.001186787,0.000022713126,0.00002664936,0.000017801549,0.00013490366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981955,0.00013288262,0.0011819347,0.00014758394,0.00021835655,0.00012371222],"domain_scores_gemma":[0.99656564,0.001115463,0.0010995562,0.000087108165,0.00085685967,0.00027536086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041785132,0.00010620263,0.000859584,0.000044921617,0.000045560482,0.0000092201135,0.000076370416,0.00010747818,0.00004769284],"category_scores_gemma":[0.0012798798,0.00004552564,0.00027114828,0.00009634233,0.00007478875,0.00010405938,0.000007995929,0.00021689797,0.000004665569],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043671776,0.0075054877,0.3237961,0.0002849859,0.00779865,0.0005133567,0.0018750571,0.00023255571,0.0002933734,0.0003506811,0.018402137,0.5952758],"study_design_scores_gemma":[0.12299671,0.12974396,0.33637437,0.0006263272,0.0061175176,0.00027823015,0.0019851713,0.00015767345,0.0007019699,0.00048468285,0.4001649,0.00036847926],"about_ca_topic_score_codex":0.0000061382466,"about_ca_topic_score_gemma":0.0000049268815,"teacher_disagreement_score":0.59490734,"about_ca_system_score_codex":0.00007964471,"about_ca_system_score_gemma":0.0012715948,"threshold_uncertainty_score":0.22557545},"labels":[],"label_agreement":null},{"id":"W3030899765","doi":"10.1200/jco.2020.38.15_suppl.e21080","title":"Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Internal medicine; Adenocarcinoma; Oncology; Concomitant; Lung cancer; Proportional hazards model; Stage (stratigraphy); Clinical endpoint; Survival analysis; Cancer; Colorectal cancer; Clinical trial; Biology","score_opus":0.02409773401546675,"score_gpt":0.41632360671051555,"score_spread":0.3922258726950488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030899765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707437,0.000665132,0.00016322495,0.0005794382,0.0002329142,0.00065145374,0.000053435466,0.0000031171303,0.00057693577],"genre_scores_gemma":[0.99744403,0.0010104611,0.0008030302,0.0005046329,0.00016590321,0.000018101964,0.000010418614,0.000012434588,0.00003099175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983502,0.00020768962,0.0009634873,0.00015914507,0.00017086175,0.00014862814],"domain_scores_gemma":[0.9974277,0.0011652613,0.00080330396,0.0000483346,0.00024728553,0.00030810825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004071521,0.0001075142,0.0007944253,0.000044592187,0.000018422488,0.0000057115067,0.000032732652,0.00014728175,0.00002419503],"category_scores_gemma":[0.0007164221,0.00007456734,0.0000875985,0.00010271694,0.000101362835,0.00009136533,0.00002524039,0.00036239804,8.8438094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003563944,0.0004780863,0.9810295,0.00020354126,0.00025700525,0.00015013822,0.0015669288,0.000047104528,0.00009308098,0.000001417008,0.00019863495,0.012410609],"study_design_scores_gemma":[0.01955059,0.019803796,0.95770556,0.00014999192,0.0010310924,0.000009097335,0.00008334613,0.00043279523,0.00053997384,0.0000063014686,0.0006302093,0.000057228997],"about_ca_topic_score_codex":0.00014243586,"about_ca_topic_score_gemma":0.000028979974,"teacher_disagreement_score":0.023323935,"about_ca_system_score_codex":0.00011089192,"about_ca_system_score_gemma":0.0007566815,"threshold_uncertainty_score":0.3040768},"labels":[],"label_agreement":null},{"id":"W3031120637","doi":"10.3747/co.27.6007","title":"Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"William Osler Health System; University of Toronto; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; BC Cancer Agency; University of Manitoba; BC Cancer Foundation; McMaster University; Spinal Cord Injury BC; CancerCare Manitoba","funders":"Pfizer Canada; Takeda Canada; AstraZeneca Canada; Merck Canada; F. Hoffmann-La Roche; AstraZeneca; Pfizer","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Clinical trial; Internal medicine; Erlotinib; Targeted therapy; Chemotherapy; Metastasis; T790M; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.060899684191336186,"score_gpt":0.4153526833248746,"score_spread":0.35445299913353845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031120637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7533276,0.10244325,0.02492091,0.07093199,0.011033134,0.024009496,0.003754437,0.0005918429,0.008987328],"genre_scores_gemma":[0.9552714,0.004220926,0.019689444,0.004143538,0.0027994043,0.0047490993,0.0019488723,0.00020264722,0.0069746296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865884,0.000030531886,0.0003182149,0.0004312701,0.00008427224,0.00047687703],"domain_scores_gemma":[0.9985241,0.000081751656,0.00012938397,0.00016682541,0.00017744124,0.00092049607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000031043102,0.0002529084,0.00053134153,0.00010019072,0.000119418495,0.0000125054685,0.00007340474,0.00011749075,0.00013382084],"category_scores_gemma":[0.00002105164,0.00021026249,0.00014190219,0.00019241542,0.000030592644,0.000023085806,0.000012932187,0.00011705601,0.000035288114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00029061537,0.00054535904,0.01206499,0.0005766271,0.00087784353,0.00023046248,0.006490586,0.00019644923,0.001269338,0.000028091692,0.04515273,0.9322769],"study_design_scores_gemma":[0.044781078,0.0051060603,0.00095841807,0.0005818244,0.0047472063,0.00016009195,0.0022366869,0.053368002,0.0019701326,0.000021979537,0.8854534,0.00061511114],"about_ca_topic_score_codex":0.02143768,"about_ca_topic_score_gemma":0.019428026,"teacher_disagreement_score":0.9316618,"about_ca_system_score_codex":0.004115284,"about_ca_system_score_gemma":0.0076821274,"threshold_uncertainty_score":0.99970776},"labels":[],"label_agreement":null},{"id":"W3031163605","doi":"10.1200/jco.2020.38.15_suppl.e21040","title":"Liquid chromatography coupled to multiple reaction monitoring (LC-MRM) for quantification of PD-L1 and PD1-signaling proteins in non-small cell lung carcinoma (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Genome Canada","keywords":"Immunohistochemistry; Selected reaction monitoring; PD-L1; Medicine; Cancer research; Fixation (population genetics); Immunotherapy; Molecular biology; Pathology; Chemistry; Mass spectrometry; Tandem mass spectrometry; Immune system; Biology; Immunology; Chromatography; Population","score_opus":0.09661896366092472,"score_gpt":0.43607204090373164,"score_spread":0.33945307724280693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031163605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895663,0.00039896558,0.0057325023,0.0027647791,0.0004165133,0.0010147963,0.000005439986,0.000006600852,0.00009409323],"genre_scores_gemma":[0.98440427,0.00012322857,0.014551696,0.00022082779,0.00061732874,0.000047342033,0.0000050555896,0.000016316968,0.000013939848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979971,0.00008044231,0.0014321326,0.00019110793,0.00015214158,0.00014705575],"domain_scores_gemma":[0.99752986,0.0007595178,0.00096931297,0.00009644276,0.0003704331,0.0002744422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008260607,0.00010439169,0.00076824235,0.00015611417,0.00003752897,0.0000065768522,0.000066718465,0.00017904729,0.000003738296],"category_scores_gemma":[0.0009079955,0.00008509906,0.00021802865,0.00020088622,0.00003969747,0.00008274116,0.000017964876,0.0002951785,0.0000011912683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012963554,0.0016232152,0.54086775,0.00052347285,0.0003279266,0.000075781674,0.0021572497,0.00026140068,0.42973384,0.00001545164,0.0001964037,0.011253941],"study_design_scores_gemma":[0.022273285,0.022648057,0.89534837,0.0005928106,0.0011667985,0.000032734697,0.0012989463,0.0055195736,0.04771578,0.000021142805,0.0031965268,0.00018596787],"about_ca_topic_score_codex":0.000108855485,"about_ca_topic_score_gemma":0.000025783223,"teacher_disagreement_score":0.38201806,"about_ca_system_score_codex":0.000105715066,"about_ca_system_score_gemma":0.0005965475,"threshold_uncertainty_score":0.3470239},"labels":[],"label_agreement":null},{"id":"W3031446019","doi":"10.1200/jco.2020.38.15_suppl.3511","title":"CodeBreak 100: Phase I study of AMG 510, a novel KRAS<sup>G12C</sup> inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Amgen","keywords":"KRAS; Medicine; Colorectal cancer; Cancer; Tolerability; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Lung cancer; Oncology; Phases of clinical research; Gastroenterology; Clinical trial; Adverse effect","score_opus":0.04131832107028971,"score_gpt":0.4393586368519075,"score_spread":0.3980403157816178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031446019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594724,0.00062677823,0.00004519498,0.0013260219,0.0003043407,0.001270184,0.00006957308,0.000008543597,0.00040210236],"genre_scores_gemma":[0.99689037,0.00033789955,0.0006100147,0.0015110445,0.00046547857,0.00007607957,0.000004998552,0.000044198907,0.000059948485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968601,0.00016222516,0.0019054401,0.0003651526,0.00039857265,0.00030850703],"domain_scores_gemma":[0.9968978,0.00037064287,0.0015901662,0.00013278215,0.0005141679,0.0004944249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041109565,0.00026770486,0.0017943176,0.00013571628,0.000047396188,0.000008933329,0.00013879176,0.00019610429,0.00008426948],"category_scores_gemma":[0.0002420985,0.00017883194,0.00017804548,0.00028472382,0.00015979694,0.00014579101,0.00005926369,0.0007114841,0.0000012984947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021069389,0.02035051,0.9189163,0.00015602881,0.0011026994,0.0002544056,0.00826841,0.0013890286,0.0007848548,0.0000017330273,0.00058153196,0.027125113],"study_design_scores_gemma":[0.18046986,0.10598107,0.7008085,0.00093030295,0.0024350763,0.000029201303,0.0035273258,0.0025465176,0.0007050465,0.0000035330156,0.0022379677,0.00032560766],"about_ca_topic_score_codex":0.0009235454,"about_ca_topic_score_gemma":0.0016297522,"teacher_disagreement_score":0.2181078,"about_ca_system_score_codex":0.00035030275,"about_ca_system_score_gemma":0.0025957564,"threshold_uncertainty_score":0.72925544},"labels":[],"label_agreement":null},{"id":"W3031536151","doi":"10.1002/ijc.33121","title":"Molecular characterisation of <scp><i>TP53</i></scp> mutated squamous cell carcinomas of the lung to identify putative targets for therapy","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Helse Sør-Øst RHF; Kreftforeningen","keywords":"Lung; Cancer research; Basal cell; Cell; Medicine; Pathology; Biology; Internal medicine; Genetics","score_opus":0.01772446886216508,"score_gpt":0.36191043749277896,"score_spread":0.3441859686306139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031536151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871674,0.0023752225,0.003985959,0.0049488028,0.00062460604,0.0004892531,0.00019358825,0.000004057987,0.00021108642],"genre_scores_gemma":[0.9977004,0.00009592011,0.0003677543,0.0014672292,0.00022448834,0.00003009741,0.0000191062,0.000017331178,0.00007769622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988777,0.000029468394,0.0004311839,0.000102328915,0.0004680751,0.000091234186],"domain_scores_gemma":[0.99782974,0.00009469652,0.0006075557,0.00006723721,0.0013144058,0.000086397486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008046713,0.00009691762,0.00023010327,0.00009185569,0.000020833386,0.00001232356,0.00018119699,0.000033156975,0.00003259688],"category_scores_gemma":[0.00013898396,0.00006644453,0.00020634988,0.00013166758,0.000031000633,0.0000987898,0.000021132195,0.0000880532,7.0693443e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094481336,0.00034789034,0.038326442,0.00013185936,0.0019121554,0.00004785908,0.017158885,0.0044560162,0.9275039,0.00013410549,0.003959713,0.005076404],"study_design_scores_gemma":[0.0052014687,0.0006085931,0.15285133,0.0001320806,0.0004316627,0.000016081314,0.0005359337,0.0005315985,0.83487487,0.00016399367,0.0046077045,0.00004470881],"about_ca_topic_score_codex":0.00007216298,"about_ca_topic_score_gemma":0.0000034961117,"teacher_disagreement_score":0.114524886,"about_ca_system_score_codex":0.00016857393,"about_ca_system_score_gemma":0.00034807756,"threshold_uncertainty_score":0.27095294},"labels":[],"label_agreement":null},{"id":"W3031830911","doi":"10.1200/jco.2020.38.29_suppl.281","title":"Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Proportional hazards model; Chemotherapy; Epidermal growth factor receptor; Cancer","score_opus":0.03915315525862403,"score_gpt":0.395961877732396,"score_spread":0.356808722473772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031830911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98457295,0.00013817028,0.00004111082,0.013270632,0.00054139755,0.0009757788,0.00005504541,0.000031843687,0.00037305406],"genre_scores_gemma":[0.99231493,0.0012024622,0.0025174387,0.002826572,0.0005554735,0.000042801734,0.000050599374,0.000086028274,0.00040368282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965834,0.00020505922,0.0020022143,0.00039169905,0.00040370863,0.0004139258],"domain_scores_gemma":[0.9955313,0.0012217168,0.0018839703,0.0001862728,0.0006451163,0.00053162745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033249106,0.00038849958,0.0018310852,0.00020976306,0.00007876621,0.000020361302,0.00016628826,0.000271976,0.000438272],"category_scores_gemma":[0.0003241952,0.00021348534,0.00028475613,0.0006087031,0.0001919008,0.00020531366,0.000023201392,0.0008611662,0.000004129874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05283383,0.0025326596,0.9303497,0.000080980746,0.0013484143,0.0004581294,0.00086713827,0.000135558,0.00006489715,7.505033e-7,0.0013268463,0.010001101],"study_design_scores_gemma":[0.094036855,0.020715067,0.8807225,0.00035469854,0.0006594433,0.0000037601044,0.000112907685,0.0001765513,0.0006282323,8.0376833e-7,0.0023502442,0.00023889059],"about_ca_topic_score_codex":0.0015525785,"about_ca_topic_score_gemma":0.002645698,"teacher_disagreement_score":0.049627148,"about_ca_system_score_codex":0.0008234399,"about_ca_system_score_gemma":0.0018106899,"threshold_uncertainty_score":0.870568},"labels":[],"label_agreement":null},{"id":"W3032325473","doi":"10.1200/jco.2020.38.15_suppl.3571","title":"Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Exome sequencing; Oncology; ROS1; Cohort; Adenocarcinoma; Internal medicine; Cancer; Bioinformatics; Genetics; Mutation; Gene; Biology","score_opus":0.07473910902682052,"score_gpt":0.47507493574155163,"score_spread":0.4003358267147311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032325473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801193,0.0006398037,0.00017477338,0.015410757,0.00018095788,0.00014213753,0.000009135776,0.000003622809,0.0033195058],"genre_scores_gemma":[0.99353254,0.00027167506,0.0024532045,0.0033391747,0.00029256404,0.0000018107861,0.000004017383,0.000008713257,0.00009627222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975813,0.0002977452,0.0016384001,0.00015062139,0.00020747005,0.00012447871],"domain_scores_gemma":[0.9966757,0.0015338109,0.0011619625,0.00010169248,0.00023361164,0.0002932137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007057549,0.000091715825,0.001485697,0.00023815404,0.000013432662,0.0000032576563,0.00010621631,0.00020310719,0.00030386698],"category_scores_gemma":[0.0014660811,0.00006703761,0.00061410974,0.0005169734,0.00014671471,0.00009254571,0.0000346669,0.0005181707,0.000006528188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017436012,0.0007185218,0.9794028,0.000018346538,0.0061223824,0.00067876285,0.0013217375,0.00044409206,0.0001341884,0.00009409508,0.001588931,0.007732589],"study_design_scores_gemma":[0.0067303334,0.003462842,0.97516996,0.0000302409,0.007698201,0.000020370218,0.0003058398,0.0015859334,0.000027699032,0.00005417141,0.0048625525,0.000051873616],"about_ca_topic_score_codex":0.000059089518,"about_ca_topic_score_gemma":0.000027639402,"teacher_disagreement_score":0.013413262,"about_ca_system_score_codex":0.00021355893,"about_ca_system_score_gemma":0.0014760082,"threshold_uncertainty_score":0.33271304},"labels":[],"label_agreement":null},{"id":"W3032353482","doi":"10.1200/jco.2020.38.15_suppl.9517","title":"Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Crizotinib; Medicine; Internal medicine; Lung cancer; ALK inhibitor; Fusion gene; ROS1; Anaplastic lymphoma kinase; Population; Oncology; Cancer; Cancer research; Adenocarcinoma; Gene; Biology; Genetics","score_opus":0.06326360016946156,"score_gpt":0.4715406169423998,"score_spread":0.40827701677293826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032353482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746041,0.00053425645,0.0050022565,0.017836036,0.0004088729,0.00025890826,0.000004194478,0.0000053240888,0.0013460129],"genre_scores_gemma":[0.98288476,0.00035032147,0.013375073,0.0027429531,0.00060133205,0.0000013343224,0.000005471053,0.000010730534,0.000028022609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971969,0.00033746925,0.0020028395,0.00015449995,0.00020572572,0.00010252887],"domain_scores_gemma":[0.99610615,0.002145214,0.0010716537,0.00008414042,0.00028169653,0.0003111512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016537353,0.0000869801,0.0010336606,0.00006156498,0.00001231787,0.0000032485827,0.0000488008,0.00022058334,0.000045803252],"category_scores_gemma":[0.0043078642,0.000055896286,0.00016571041,0.0001551773,0.00015575968,0.000066657645,0.000022188384,0.00057015865,0.000002459347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015457457,0.0073968847,0.72364086,0.00010304062,0.0015082716,0.0018806343,0.00046068875,0.0011847349,0.0003794396,0.0005538217,0.0031470794,0.24428712],"study_design_scores_gemma":[0.07108703,0.06332155,0.8064809,0.0005947616,0.0034407147,0.00033198067,0.00033286368,0.0061268215,0.00019578406,0.00022315865,0.047669146,0.00019532381],"about_ca_topic_score_codex":0.000016098244,"about_ca_topic_score_gemma":0.000014107722,"teacher_disagreement_score":0.2440918,"about_ca_system_score_codex":0.00004416137,"about_ca_system_score_gemma":0.0011215087,"threshold_uncertainty_score":0.51572275},"labels":[],"label_agreement":null},{"id":"W3032407878","doi":"10.1136/jclinpath-2020-206668","title":"Clinical implementation of circulating tumour DNA testing for <i>EGFR</i> T790M for detection of treatment resistance in non-small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Princess Margaret Cancer Foundation; AstraZeneca","keywords":"T790M; Osimertinib; Medicine; Liquid biopsy; Lung cancer; Digital polymerase chain reaction; Oncology; Internal medicine; Epidermal growth factor receptor; Biopsy; Cancer; Pathology; Biology; Gefitinib; Polymerase chain reaction; Gene; Erlotinib; Genetics","score_opus":0.10378860132425648,"score_gpt":0.4813024040996998,"score_spread":0.37751380277544333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032407878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757887,0.0004603994,0.009551908,0.00095141045,0.00038012888,0.0009309453,0.00006429818,0.0000044650924,0.0000775935],"genre_scores_gemma":[0.97547215,0.00011728229,0.023414405,0.00031044084,0.00057683256,0.00006228571,0.000008331123,0.000018587427,0.000019679825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969564,0.00012903333,0.0024286746,0.00021272378,0.000103487415,0.00016965829],"domain_scores_gemma":[0.99560845,0.0017254307,0.0019501166,0.00009244307,0.00050008646,0.000123483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010061603,0.000114935036,0.0008977539,0.0000716826,0.000032982498,0.000003176553,0.0000608396,0.00012703633,0.0000065242953],"category_scores_gemma":[0.001116568,0.00009109434,0.0004150629,0.00014490905,0.000053792937,0.00005225455,0.000011828628,0.0001718532,1.4783528e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019103753,0.00059672416,0.88095045,0.00064198347,0.0002585244,0.000051340743,0.0010167203,0.000161508,0.06085281,0.00001283949,0.0001096581,0.05343707],"study_design_scores_gemma":[0.033339817,0.016760565,0.923195,0.00051318214,0.002225325,0.000031835174,0.0010658829,0.0018729136,0.020103455,0.00026256003,0.00047339543,0.00015603758],"about_ca_topic_score_codex":0.000044834436,"about_ca_topic_score_gemma":0.00026278748,"teacher_disagreement_score":0.05328103,"about_ca_system_score_codex":0.00014917298,"about_ca_system_score_gemma":0.00066230376,"threshold_uncertainty_score":0.37147194},"labels":[],"label_agreement":null},{"id":"W3032812050","doi":"10.1200/jco.2020.38.15_suppl.9574","title":"Nazartinib (EGF816) in patients with treatment-naïve <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC): Updated phase II results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Internal medicine; Clinical endpoint; Phases of clinical research; non-small cell lung cancer (NSCLC); Gastroenterology; Lung cancer; Progression-free survival; Progressive disease; Brain metastasis; Adverse effect; Surgery; Oncology; Cancer; Metastasis; Toxicity; Overall survival; Clinical trial; Disease","score_opus":0.05481077897376951,"score_gpt":0.45096508008845376,"score_spread":0.39615430111468425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032812050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789743,0.00032805046,0.0000621666,0.0155599965,0.0004804541,0.00075825356,0.00011826273,0.000015160629,0.003703368],"genre_scores_gemma":[0.99174297,0.0004005912,0.0018911876,0.0048268265,0.00067391107,0.000022846516,0.00007462213,0.000032035896,0.00033499053],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965322,0.00017802273,0.0022880288,0.00034243887,0.00031856276,0.0003407623],"domain_scores_gemma":[0.9966363,0.00037858705,0.0016432034,0.00018560898,0.00048920914,0.0006671313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004507661,0.00024361376,0.0014525127,0.00010738585,0.00007168134,0.0000108693275,0.00013415508,0.0002536581,0.0001582114],"category_scores_gemma":[0.00029167134,0.00014774842,0.0003016398,0.0003194643,0.00010144967,0.00013193063,0.000039290375,0.0006187281,0.000011259407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09779196,0.03769835,0.6535768,0.000087301145,0.0028862692,0.003078038,0.0047818385,0.0004018314,0.00047940016,0.0000123429345,0.01932296,0.1798829],"study_design_scores_gemma":[0.37331212,0.19176638,0.2501447,0.0004406284,0.0046819677,0.000036261696,0.0004270256,0.0009610071,0.0010014704,0.00001236155,0.17681955,0.00039652112],"about_ca_topic_score_codex":0.00012667257,"about_ca_topic_score_gemma":0.00014034484,"teacher_disagreement_score":0.4034321,"about_ca_system_score_codex":0.00059577246,"about_ca_system_score_gemma":0.0034996397,"threshold_uncertainty_score":0.62082106},"labels":[],"label_agreement":null},{"id":"W3033478224","doi":"10.3389/fonc.2020.00800","title":"Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China","year":2020,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec; Université Laval","funders":"Nanjing University","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Oncology; Palliative chemotherapy; Lung cancer; Internal medicine; Cancer; Lung; Pathology; Biology","score_opus":0.014360646676298564,"score_gpt":0.36066581624720007,"score_spread":0.3463051695709015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033478224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481297,0.00034250616,0.00022333866,0.0007461788,0.00013557507,0.002116776,0.000049836268,0.000009464619,0.0015633525],"genre_scores_gemma":[0.9922904,0.00018388945,0.0065076756,0.0005573842,0.000023628345,0.00027282408,0.000057053683,0.000026404374,0.00008074967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860567,0.00016945176,0.0004203629,0.00035501525,0.00022096281,0.00022854372],"domain_scores_gemma":[0.99936706,0.000038837894,0.00024915516,0.00012922652,0.00012736981,0.00008837103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024311221,0.00016420787,0.0005875949,0.00014794445,0.000014101279,0.0000023023683,0.00006665379,0.000098466175,0.00008522412],"category_scores_gemma":[0.000032976284,0.00012265303,0.000035167825,0.00046391506,0.000085837004,0.00006439809,0.000011473037,0.00023912734,4.45462e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005639633,0.00085580675,0.94581157,0.000086713146,0.0001510476,0.00003199688,0.002629647,0.0021703457,0.000004742823,5.78989e-7,0.0003098995,0.04230801],"study_design_scores_gemma":[0.04194005,0.0034643405,0.94164586,0.00020907748,0.0002263054,1.5155176e-7,0.0008927697,0.01114614,0.00008355932,0.000003839911,0.00027269832,0.00011520527],"about_ca_topic_score_codex":0.00032532663,"about_ca_topic_score_gemma":0.00095102214,"teacher_disagreement_score":0.042192806,"about_ca_system_score_codex":0.0012303224,"about_ca_system_score_gemma":0.0009970663,"threshold_uncertainty_score":0.50016457},"labels":[],"label_agreement":null},{"id":"W3033954784","doi":"10.21037/jtd-2020-51","title":"One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer","year":2020,"lang":"en","type":"letter","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Lung cancer; Consensus conference; Mutant; Translational medicine; Bioinformatics; Pathology; Internal medicine; Gene; Genetics","score_opus":0.025050093181072267,"score_gpt":0.3779574411250777,"score_spread":0.3529073479440054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033954784","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011871414,0.00982549,0.00036382538,0.9848755,0.0005441785,0.0016418967,0.00071928604,0.000006289142,0.00083639775],"genre_scores_gemma":[0.057838704,0.0043098233,0.0017792132,0.9235136,0.0057893973,0.00039773202,0.0006358428,0.00009448755,0.005641215],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802715,0.00014013803,0.0006151857,0.00020433638,0.0008382386,0.00017498364],"domain_scores_gemma":[0.9984698,0.0003784031,0.0005166796,0.00021837447,0.00031812518,0.00009856921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029234483,0.00022824068,0.0005129194,0.000087388165,0.00013936087,0.00001908881,0.00018411942,0.000088166744,0.0001428395],"category_scores_gemma":[0.000029009414,0.0001130899,0.00060137105,0.00022648787,0.0001527124,0.0000446858,0.000010868381,0.0006753119,0.0000010638738],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017916978,0.00028710635,0.00013507273,0.0012678003,0.0039459215,0.00069225184,0.0016756257,0.00016815988,0.00001760386,0.00020541399,0.9829409,0.006872458],"study_design_scores_gemma":[0.007398298,0.0014287528,0.01458431,0.007827773,0.02865641,0.000093591945,0.0020413646,0.0009406964,0.00005329744,0.0006524513,0.93592554,0.00039752544],"about_ca_topic_score_codex":0.000032485445,"about_ca_topic_score_gemma":0.0000064419205,"teacher_disagreement_score":0.06136191,"about_ca_system_score_codex":0.000281402,"about_ca_system_score_gemma":0.0005107543,"threshold_uncertainty_score":0.46116725},"labels":[],"label_agreement":null},{"id":"W3036426983","doi":"10.1016/j.cllc.2020.06.015","title":"Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Guardant Health; Loxo Oncology; Bristol-Myers Squibb Canada; Genentech; Daiichi-Sankyo; LAM Therapeutics; National Institutes of Health; Seattle Genetics; Boehringer Ingelheim; NRG Oncology; F. Hoffmann-La Roche; International Studies Association; Novartis; National Cancer Institute; AbbVie; Merck; GlaxoSmithKline; Canadian Asian Studies Association; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Pfizer","keywords":"Medicine; Lung cancer; Circulating tumor DNA; Oncology; Internal medicine; Cancer; Targeted therapy; Cancer research","score_opus":0.017585960567135774,"score_gpt":0.3654505714863328,"score_spread":0.347864610919197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036426983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946602,0.002179891,0.00046665652,0.0006857272,0.00018576074,0.0014151236,0.00016242635,0.000034798275,0.00020939604],"genre_scores_gemma":[0.9970536,0.00033458465,0.00037686832,0.0013070905,0.00011249768,0.00029923389,0.00032502163,0.0000380166,0.00015308861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978817,0.00007211059,0.00091838103,0.0005412801,0.0003264021,0.0002600998],"domain_scores_gemma":[0.99860996,0.00011224115,0.0005084152,0.00025989107,0.00030416978,0.0002053133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013115455,0.00021718029,0.0007204362,0.000099112876,0.000058515132,0.00001762986,0.00010096478,0.00009095136,0.0003506188],"category_scores_gemma":[0.00007548557,0.00016798693,0.00021690883,0.0010099609,0.00006048198,0.00013292099,0.000022794615,0.00023165243,0.0000015242695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088708114,0.0004559088,0.98836774,0.00016009658,0.0016870844,0.000007440142,0.0006843218,0.0015907659,0.0017156244,0.0000014988209,0.0007720003,0.003670459],"study_design_scores_gemma":[0.011594728,0.00050312735,0.97067416,0.00021271726,0.0027118423,8.2866585e-8,0.00008889653,0.012077386,0.0018136929,0.0000017674428,0.00010616671,0.0002154068],"about_ca_topic_score_codex":0.00046084073,"about_ca_topic_score_gemma":0.0002707301,"teacher_disagreement_score":0.017693533,"about_ca_system_score_codex":0.0002554892,"about_ca_system_score_gemma":0.00042220688,"threshold_uncertainty_score":0.6850308},"labels":[],"label_agreement":null},{"id":"W3037379129","doi":"10.1080/13696998.2020.1789152","title":"Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; Roche (Canada); William Osler Health System; Vancouver Coastal Health","funders":"","keywords":"Medicine; Profiling (computer programming); Activity-based costing; Lung cancer; Operations management; Oncology; Business; Accounting; Computer science","score_opus":0.04434937502367767,"score_gpt":0.3662375444127789,"score_spread":0.32188816938910125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037379129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912022,0.0016747656,0.0009577889,0.005179161,0.00011737612,0.00066545716,0.00009659391,0.0000026187693,0.000104073544],"genre_scores_gemma":[0.99482894,0.001355349,0.00317737,0.0003297821,0.00023128021,0.000045788194,0.0000074510567,0.000020347166,0.0000036941724],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989511,0.000018287097,0.000723819,0.0001327021,0.00006888666,0.00010524894],"domain_scores_gemma":[0.9988499,0.00018238545,0.0005087298,0.0000982837,0.00011710456,0.00024356252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052286655,0.00008254098,0.00039699374,0.00008581056,0.00002374001,0.0000066970942,0.000079843216,0.00007719278,0.00006935077],"category_scores_gemma":[0.00008046981,0.0000736928,0.00009102468,0.000033435183,0.000047429203,0.00006412435,0.00002448339,0.000119468925,4.6760888e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022010207,0.0014441742,0.740292,0.003194611,0.002708615,0.000190938,0.013990259,0.024576623,0.008645581,0.003867787,0.003432231,0.19545612],"study_design_scores_gemma":[0.090271756,0.00418758,0.15955001,0.0017713527,0.007623654,0.0031537076,0.0054757376,0.70842856,0.013595795,0.0009713797,0.0041416413,0.0008288433],"about_ca_topic_score_codex":0.000320116,"about_ca_topic_score_gemma":0.0002750681,"teacher_disagreement_score":0.6838519,"about_ca_system_score_codex":0.0004250572,"about_ca_system_score_gemma":0.0021870674,"threshold_uncertainty_score":0.38797635},"labels":[],"label_agreement":null},{"id":"W3039432873","doi":"10.1016/j.lungcan.2020.06.032","title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Ignyta; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; MacroGenics; Juno Therapeutics; Pfizer; Incyte; Kite Pharma; Spectrum Pharmaceuticals; Yuhan; Merck KGaA; Regeneron Pharmaceuticals; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Tolerability; Oncology; Cohort; Clinical endpoint; Adverse effect; Cancer; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.033566138407838154,"score_gpt":0.387555711866924,"score_spread":0.3539895734590858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039432873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796407,0.0011110501,0.00030991473,0.015549217,0.00027252905,0.002548205,0.00014457901,0.000047408565,0.00037639562],"genre_scores_gemma":[0.995663,0.00038087292,0.00020265557,0.0015051427,0.00024696204,0.00039261955,0.00007371939,0.000026721424,0.0015083031],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99899054,0.00003654865,0.0002579062,0.00031510825,0.00016617919,0.00023373366],"domain_scores_gemma":[0.99952286,0.00007886281,0.00006890373,0.00016969779,0.000058291855,0.00010138155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010532106,0.00016441493,0.0003172321,0.000028289862,0.00017056808,0.000019602388,0.000070948234,0.0000353928,0.00016512493],"category_scores_gemma":[0.000044254524,0.0000968263,0.000050223112,0.00015321832,0.000033309185,0.0000901847,0.000048905502,0.00012899766,0.0000020799475],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16800062,0.013963667,0.4067583,0.0027583162,0.0076552494,0.0011528645,0.077351905,0.0050578928,0.004841517,0.0025766871,0.030430336,0.27945262],"study_design_scores_gemma":[0.4014795,0.02742528,0.25344998,0.0013264917,0.007390874,0.000060894163,0.0057605924,0.05202652,0.0008261818,0.0002973502,0.24837634,0.0015799707],"about_ca_topic_score_codex":0.0004374394,"about_ca_topic_score_gemma":0.0016734747,"teacher_disagreement_score":0.27787265,"about_ca_system_score_codex":0.00014730768,"about_ca_system_score_gemma":0.00022377155,"threshold_uncertainty_score":0.39484617},"labels":[],"label_agreement":null},{"id":"W3040832841","doi":"10.1016/j.annonc.2020.04.467","title":"PD-11 Impact of baseline symptom burden as assessed by patient-reported outcomes on overall survival of patients with metastatic gastrointestinal cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Interquartile range; Internal medicine; Cancer; Patient-reported outcome; Nausea; Psychosocial; Depression (economics); Anxiety; Colorectal cancer; Confounding; Pancreatic cancer; Gastrointestinal cancer; Proportional hazards model; Quality of life (healthcare)","score_opus":0.0518601967394296,"score_gpt":0.4208504308919753,"score_spread":0.3689902341525457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040832841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994975,0.00005938304,0.00007654089,0.0031173283,0.000045447494,0.0004877099,0.00058795494,0.000012929104,0.0006377563],"genre_scores_gemma":[0.99822253,0.000020672722,0.00055723975,0.000757511,0.000019842171,0.000024973695,0.0003138214,0.000020871466,0.00006253985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985415,0.000095724085,0.00057417504,0.00021956794,0.00035980667,0.00020924721],"domain_scores_gemma":[0.99790853,0.0002767875,0.00071165984,0.0001818733,0.00074444915,0.00017672108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000939028,0.0001840935,0.00079401553,0.000078909776,0.00001752934,0.0000022575673,0.00006550199,0.00003498566,0.00037531092],"category_scores_gemma":[0.00035586394,0.0001203832,0.00016736155,0.0001634846,0.00009166291,0.00005774957,0.000020894458,0.000087336426,0.0000019638428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029276253,0.0022825282,0.98136175,0.00012724957,0.0018914224,0.00005500222,0.0006130009,0.00062136864,0.0016742852,0.0000324339,0.0042081075,0.0042052455],"study_design_scores_gemma":[0.012247807,0.045700837,0.9360279,0.00026022503,0.0011745781,0.000010935931,0.0002355306,0.00017954939,0.0027791474,0.000027090764,0.0011912725,0.00016514398],"about_ca_topic_score_codex":0.0033343495,"about_ca_topic_score_gemma":0.000054481126,"teacher_disagreement_score":0.045333847,"about_ca_system_score_codex":0.00008245689,"about_ca_system_score_gemma":0.000879635,"threshold_uncertainty_score":0.5040561},"labels":[],"label_agreement":null},{"id":"W3041795233","doi":"10.21037/tlcr-19-581","title":"EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes","year":2020,"lang":"en","type":"article","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"BC Cancer Foundation; Genome British Columbia","keywords":"Medicine; T790M; Osimertinib; Digital polymerase chain reaction; Circulating tumor DNA; Internal medicine; Oncology; Lung cancer; Cancer; Epidermal growth factor receptor; Polymerase chain reaction; Erlotinib; Biology; Gene; Genetics","score_opus":0.12722794862402823,"score_gpt":0.4578815254063591,"score_spread":0.33065357678233087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041795233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747036,0.000647212,0.010885506,0.010990893,0.000079646205,0.0016751394,0.000535426,0.000038225313,0.00044435423],"genre_scores_gemma":[0.99861354,0.00002494197,0.0007771792,0.000020846728,0.00010916808,0.00029099706,0.00007944284,0.000019239045,0.00006463236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987693,0.000045682376,0.00040687178,0.00024279329,0.00037690447,0.00015848712],"domain_scores_gemma":[0.9983812,0.00051931455,0.000120849225,0.00011023481,0.0007642148,0.00010416991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033033182,0.00008431258,0.00021659817,0.00013199313,0.00015115476,0.000011857118,0.000059090933,0.000047958452,0.000017740058],"category_scores_gemma":[0.00028580808,0.00007056558,0.000067390916,0.00047087626,0.000106338506,0.00009807598,0.000010024713,0.000107423504,3.5863144e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015222032,0.000078644785,0.63589305,0.0006767155,0.00027010153,2.168717e-7,0.0010507124,0.0003115674,0.3509861,0.0013610115,0.000028615048,0.0091910735],"study_design_scores_gemma":[0.0014511531,0.00015775741,0.9743037,0.000068087764,0.0002472716,0.000001627482,0.00010961584,0.00672597,0.016271591,0.00048975734,0.000110632434,0.000062817664],"about_ca_topic_score_codex":0.00021441463,"about_ca_topic_score_gemma":0.00004805747,"teacher_disagreement_score":0.3384107,"about_ca_system_score_codex":0.000084207895,"about_ca_system_score_gemma":0.0003749891,"threshold_uncertainty_score":0.28775808},"labels":[],"label_agreement":null},{"id":"W3043250176","doi":"10.1016/j.lungcan.2020.07.014","title":"Mechanisms of osimertinib resistance and emerging treatment options","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Osimertinib; Medicine; Acquired resistance; Cancer research; Epidermal growth factor receptor; Internal medicine; Receptor; Cancer","score_opus":0.03198790611506145,"score_gpt":0.4082846209134547,"score_spread":0.3762967147983932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043250176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017996069,0.9953352,0.00022450357,0.0005078306,0.0002176418,0.001254893,0.00034468033,0.000043432945,0.0020699967],"genre_scores_gemma":[0.00004399309,0.9916248,0.001415305,0.000064272994,0.000117938944,0.0008255472,0.00013005851,0.000055921544,0.005722219],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988546,0.000033586275,0.00040196883,0.00037663305,0.00015523052,0.00017801179],"domain_scores_gemma":[0.99923986,0.00004714012,0.00025860503,0.00025719934,0.000053045453,0.0001441301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028133718,0.00030377024,0.0012792777,0.000097382486,0.000073387586,0.000010935652,0.000052115014,0.000112885384,0.00019812176],"category_scores_gemma":[0.0000108101,0.00021705644,0.00028064242,0.00025669392,0.00003879811,0.00003429082,0.000024602912,0.00010756675,0.0000052655687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029533134,0.00010415215,0.0000151191125,0.017201854,0.003039409,0.00004876733,0.0004215337,0.0000012985107,0.000008280057,0.00339503,0.0015679273,0.9741671],"study_design_scores_gemma":[0.0006934862,0.00011609337,0.000011707825,0.011549693,0.012462086,0.000011596377,0.00002816939,0.000012783827,0.000014462085,0.00006557743,0.97487193,0.00016238914],"about_ca_topic_score_codex":0.00011622116,"about_ca_topic_score_gemma":0.00006401341,"teacher_disagreement_score":0.9740047,"about_ca_system_score_codex":0.00057078956,"about_ca_system_score_gemma":0.00071034644,"threshold_uncertainty_score":0.88513047},"labels":[],"label_agreement":null},{"id":"W3044963562","doi":"10.1634/theoncologist.2020-0502","title":"Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an <i>HLA-DRB1-MET</i> Gene Fusion","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EMD Serono","keywords":"Crizotinib; Cabozantinib; Fusion gene; ROS1; Medicine; Lung cancer; Cancer research; KRAS; Erlotinib; Clinical trial; Oncology; Tyrosine kinase; Gene; Cancer; Internal medicine; Bioinformatics; Biology; Genetics; Receptor; Colorectal cancer; Epidermal growth factor receptor; Adenocarcinoma","score_opus":0.023497750649620886,"score_gpt":0.3182121643940267,"score_spread":0.2947144137444058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044963562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734045,0.0004735555,0.00033814486,0.0074029877,0.000058989383,0.0013800686,0.000035998673,0.00006523081,0.0029045935],"genre_scores_gemma":[0.991755,0.0000737904,0.0042538764,0.0032632218,0.00010769795,0.00029212295,0.000041363102,0.000037584763,0.00017531496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988171,0.00007849651,0.00022404805,0.00036510557,0.00022205847,0.00029319085],"domain_scores_gemma":[0.9992103,0.000100963414,0.00014469739,0.000290482,0.000069757334,0.00018382365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012331073,0.00020998133,0.0003401124,0.000046535017,0.00013781428,0.000029068406,0.00012663529,0.000047411133,0.00007609417],"category_scores_gemma":[0.000023018303,0.000109566936,0.000044830696,0.0004038574,0.00009589178,0.00006628906,0.00005164873,0.00021700157,0.000004738053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018326418,0.0136686,0.3513143,0.0013333716,0.0030888151,0.008065194,0.11266504,0.05555966,0.15673007,0.00026380256,0.010272603,0.26871213],"study_design_scores_gemma":[0.10885399,0.07275223,0.53044385,0.0024893864,0.013327765,0.00050383876,0.0231802,0.013470683,0.16995616,0.000022116164,0.061911676,0.0030880948],"about_ca_topic_score_codex":0.001723035,"about_ca_topic_score_gemma":0.0013084764,"teacher_disagreement_score":0.26562402,"about_ca_system_score_codex":0.0003218341,"about_ca_system_score_gemma":0.0004680253,"threshold_uncertainty_score":0.44680098},"labels":[],"label_agreement":null},{"id":"W3045943244","doi":"10.1073/pnas.2007474117","title":"An ErbB2 splice variant lacking exon 16 drives lung carcinoma","year":2020,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Institute for Research in Immunology and Cancer; McGill University; Université de Montréal; McGill University Health Centre","funders":"Institute of Cancer Research; Canada Research Chairs; Government of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"splice; Exon; Lung; Carcinoma; Alternative splicing; Biology; Genetics; Medicine; Internal medicine; Gene","score_opus":0.04596271819449623,"score_gpt":0.35759985644472614,"score_spread":0.31163713825022993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045943244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686116,0.00024070949,0.00000691431,0.015146516,0.000015593598,0.00025009396,0.000013418166,0.000017773049,0.015697388],"genre_scores_gemma":[0.9966638,0.000015906904,0.0018103652,0.0012717036,0.00014960847,0.000009022425,4.4673536e-7,0.0000041917187,0.0000749578],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99878407,0.0000033086853,0.00019661503,0.00021090829,0.00069664436,0.00010845439],"domain_scores_gemma":[0.9994762,0.00003762052,0.0002042176,0.000006679142,0.00020290779,0.0000723756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026324362,0.00007227535,0.00013245484,0.00006805623,0.00015555906,0.000014456195,0.00028243658,0.000041843432,0.000027172931],"category_scores_gemma":[0.00016275268,0.00004513435,0.000053983287,0.000505268,0.00027086705,0.00036574074,0.000046646826,0.00009786424,0.0000010668575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010778469,0.00026469133,0.26321855,0.0004479514,0.00014839423,1.8187511e-7,0.0069251237,0.00016099685,0.6245841,0.09872316,0.0036318828,0.0017871934],"study_design_scores_gemma":[0.0012648017,0.00043623862,0.7054751,0.00027281346,0.00028247372,0.000044539516,0.002519731,0.010555977,0.26879004,0.009155041,0.0010267829,0.00017646964],"about_ca_topic_score_codex":0.000018040135,"about_ca_topic_score_gemma":7.152477e-8,"teacher_disagreement_score":0.44225654,"about_ca_system_score_codex":0.000060150913,"about_ca_system_score_gemma":0.000075383716,"threshold_uncertainty_score":0.18405254},"labels":[],"label_agreement":null},{"id":"W3046741455","doi":"10.1200/jco.2020.38.15_suppl.e21684","title":"Efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with different metastatic sites: A systematic review and meta-analysis.","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; Meta-analysis; Subgroup analysis; Confidence interval","score_opus":0.12092407219383365,"score_gpt":0.48668873935238266,"score_spread":0.365764667158549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046741455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008587277,0.9943581,0.000022321025,0.00056620216,0.000099902456,0.0039750733,0.000053829594,0.0000028489324,0.00006294808],"genre_scores_gemma":[0.0025405374,0.99611664,0.0004979013,0.0003864374,0.000061242186,0.00022435315,0.00004292613,0.000036734356,0.0000932559],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98954856,0.0011279316,0.008336718,0.0003463965,0.00043849807,0.00020190865],"domain_scores_gemma":[0.9857752,0.0024911596,0.010600336,0.0003221061,0.0004632239,0.0003480067],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016966703,0.000463034,0.026841711,0.00037067788,0.000018612227,0.000008931661,0.00019016425,0.0002338971,0.00011170747],"category_scores_gemma":[0.0013074784,0.00020989576,0.0050378703,0.0006883014,0.000096479605,0.000049275695,0.00006898128,0.0010028634,0.0000016889194],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014917683,0.0029192488,0.0009604172,0.6773513,0.31188715,0.00019208377,0.00013406274,0.000003019883,5.289956e-8,0.0000012830334,0.000059691178,0.006342522],"study_design_scores_gemma":[0.004441971,0.003089121,0.001395652,0.061159577,0.9257948,0.000020994523,0.000016518416,0.000005343604,2.3114623e-7,0.0000010167553,0.0039247633,0.00015005875],"about_ca_topic_score_codex":0.000039291626,"about_ca_topic_score_gemma":0.000057989855,"teacher_disagreement_score":0.61619174,"about_ca_system_score_codex":0.00039150834,"about_ca_system_score_gemma":0.0019054142,"threshold_uncertainty_score":0.98760587},"labels":[],"label_agreement":null},{"id":"W3046932783","doi":"10.1093/noajnl/vdaa073.000","title":"04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2020,"lang":"en","type":"review","venue":"Neuro-Oncology Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; Meta-analysis; Lung cancer; Cancer; Epidermal growth factor receptor","score_opus":0.039024495037057606,"score_gpt":0.4208557410485946,"score_spread":0.38183124601153695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046932783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005474079,0.98927045,0.00033682282,0.0003312419,0.000028257657,0.00894042,0.001050867,0.000010431869,0.000026046691],"genre_scores_gemma":[0.00022007294,0.99362123,0.003880746,0.00027681945,0.000009213006,0.0016296109,0.0003168904,0.000029095798,0.000016298409],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975587,0.00038617905,0.0012025052,0.00046870098,0.00023914632,0.00014476452],"domain_scores_gemma":[0.9959774,0.0018220365,0.0015243967,0.00030574884,0.00020469954,0.00016573486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018108918,0.0003633381,0.008361778,0.00014523607,0.00005000202,0.000005030651,0.000085316744,0.00004458216,0.000036561076],"category_scores_gemma":[0.00044742954,0.00019629985,0.00072468474,0.00036401057,0.00015477878,0.00007040308,0.000035857,0.00013400915,2.8020077e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013268225,0.00043743927,0.00007688206,0.849302,0.13365108,0.000024630806,0.000026739717,0.0000025443665,9.336492e-8,0.000049230035,0.000011272455,0.016285388],"study_design_scores_gemma":[0.0015931708,0.0015640007,0.00011704976,0.012191753,0.9315131,0.000013151532,0.000006806941,0.0000075015005,7.876162e-8,0.0000057185775,0.052862696,0.00012498847],"about_ca_topic_score_codex":0.0000015028075,"about_ca_topic_score_gemma":0.0000045621473,"teacher_disagreement_score":0.8371103,"about_ca_system_score_codex":0.00006039879,"about_ca_system_score_gemma":0.0004562329,"threshold_uncertainty_score":0.8004876},"labels":[],"label_agreement":null},{"id":"W3047241006","doi":"10.1093/noajnl/vdaa073.058","title":"71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; Oncology; DNA methylation; Lung cancer; Adenocarcinoma; Biomarker; Medicine; Internal medicine; Proportional hazards model; CpG site; Cancer; Stage (stratigraphy); Cancer research; Biology; Gene; Genetics; Gene expression","score_opus":0.02438382448437263,"score_gpt":0.3437997888631176,"score_spread":0.3194159643787449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047241006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91680443,0.006460128,0.0012249313,0.07009256,0.00022498338,0.002680802,0.00008094542,0.00015906851,0.0022721486],"genre_scores_gemma":[0.9884442,0.000105333755,0.0027169392,0.008231748,0.00007046473,0.00028369803,0.00006197007,0.00003294761,0.000052696145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985174,0.00016442059,0.00030570474,0.0005110654,0.0002033338,0.000298056],"domain_scores_gemma":[0.9990251,0.000414825,0.00014437213,0.0001668192,0.000086895874,0.00016198082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009512708,0.00021907773,0.0004135804,0.00013105395,0.000074607815,0.00001636364,0.00007583295,0.00007851976,0.0001723884],"category_scores_gemma":[0.00031793345,0.00015694374,0.000059931066,0.00040953435,0.0001251833,0.0002963271,0.000031387048,0.00020352771,0.000021752561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002919371,0.0010693093,0.79616934,0.00052651984,0.0006701172,0.0040023015,0.0074816197,0.00014978003,0.10747974,0.00019254861,0.0030592987,0.07628003],"study_design_scores_gemma":[0.023031462,0.014741146,0.64395916,0.00038544915,0.002975067,0.0010554877,0.0018138901,0.0055406597,0.044647295,0.00047998477,0.26046357,0.00090684363],"about_ca_topic_score_codex":0.000023358847,"about_ca_topic_score_gemma":0.00012155741,"teacher_disagreement_score":0.25740427,"about_ca_system_score_codex":0.00014790839,"about_ca_system_score_gemma":0.0003074226,"threshold_uncertainty_score":0.639998},"labels":[],"label_agreement":null},{"id":"W3047425187","doi":"10.1093/noajnl/vdaa073.048","title":"60. IDEAL TREATMENT REGIMEN FOR PATIENTS WITH ≥1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","year":2020,"lang":"en","type":"review","venue":"Neuro-Oncology Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Lung cancer; Oncology; Randomized controlled trial; Brain metastasis; non-small cell lung cancer (NSCLC); Regimen; Cancer; Metastasis","score_opus":0.03903867881018443,"score_gpt":0.37570984179519107,"score_spread":0.33667116298500666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047425187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033303047,0.980741,0.00028485485,0.0012215907,0.00014237108,0.015624485,0.0017462415,0.00005067683,0.00018544834],"genre_scores_gemma":[0.0000035101766,0.9698621,0.0046709375,0.0038412763,0.00015096334,0.018599026,0.0023702842,0.0001020933,0.00039978692],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962474,0.0005825156,0.0012282492,0.0012062176,0.00027974343,0.0004558453],"domain_scores_gemma":[0.9947956,0.00241142,0.0016543275,0.0006574314,0.00018835753,0.0002928582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018468486,0.00091453845,0.012989677,0.00016626994,0.00018598553,0.000030160185,0.00019594294,0.00020249725,0.00008494531],"category_scores_gemma":[0.00009536534,0.0005041331,0.00199664,0.0006702446,0.000084928135,0.00011927284,0.00006643693,0.0002442853,0.0000062066865],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001080539,0.00044358667,0.00015167886,0.5757875,0.3816395,0.00014957583,0.00014212985,0.00002646583,1.17286305e-7,0.0000050407416,0.0023930804,0.039153263],"study_design_scores_gemma":[0.0012222837,0.0010553838,0.0000070805677,0.00972667,0.5978297,0.0000078126495,0.000006782143,0.000005556244,1.538053e-7,0.0000040733607,0.38990492,0.00022958129],"about_ca_topic_score_codex":0.00007916235,"about_ca_topic_score_gemma":0.0002444425,"teacher_disagreement_score":0.56606084,"about_ca_system_score_codex":0.00078272884,"about_ca_system_score_gemma":0.0010202581,"threshold_uncertainty_score":0.999741},"labels":[],"label_agreement":null},{"id":"W3047471655","doi":"10.21037/tlcr-19-346","title":"Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion","year":2020,"lang":"en","type":"article","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Seoul National University; National Natural Science Foundation of China","keywords":"Crizotinib; Medicine; Brain metastasis; Anaplastic lymphoma kinase; Internal medicine; Oncology; ALK inhibitor; Chemotherapy; Lung cancer; Sanger sequencing; Gastroenterology; Metastasis; Cancer; Mutation; Gene; Biology; Genetics","score_opus":0.04920964493460971,"score_gpt":0.4434830573297769,"score_spread":0.39427341239516717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047471655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986908,0.0009078001,0.0000394264,0.009768031,0.000012992304,0.0013848707,0.0004643901,0.00001288676,0.0005015945],"genre_scores_gemma":[0.9988032,0.00016539091,0.0003869322,0.00012610166,0.000029961753,0.00017987033,0.00016636432,0.00002652954,0.00011565332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821293,0.00020917799,0.00023622661,0.00036053933,0.0007040688,0.00027702755],"domain_scores_gemma":[0.9988076,0.0005303256,0.000047080262,0.0001532557,0.00024777674,0.00021397753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022962142,0.00016206663,0.00029441502,0.00025254113,0.00009136747,0.00001190013,0.000052677147,0.00004897911,0.00030382894],"category_scores_gemma":[0.0000763007,0.00010965934,0.00008006394,0.0005911764,0.000083541,0.00011188864,0.000010271413,0.00016199355,0.0000030154201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13971692,0.0018300177,0.72621,0.00015071129,0.0016800158,0.00007282438,0.0066430727,0.0033329888,0.011156998,0.00026033103,0.00041577147,0.10853034],"study_design_scores_gemma":[0.016851217,0.0076751034,0.97254395,0.00024984448,0.00015801881,0.0000016266342,0.000052298587,0.001150415,0.000499846,0.000030379504,0.0006722881,0.000115016555],"about_ca_topic_score_codex":0.0010143854,"about_ca_topic_score_gemma":0.00021743095,"teacher_disagreement_score":0.24633396,"about_ca_system_score_codex":0.000538768,"about_ca_system_score_gemma":0.0013189216,"threshold_uncertainty_score":0.4471778},"labels":[],"label_agreement":null},{"id":"W3047693464","doi":"10.1002/cnr2.1262","title":"High frequency of exon 20 <scp> S768I <i>EGFR</i> </scp> mutation detected in malignant pleural effusions: A poor prognosticator of <scp>NSCLC</scp>","year":2020,"lang":"en","type":"article","venue":"Cancer Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centre Technologique des Résidus Industriels","keywords":"Exon; Mutation; Adenocarcinoma; Lung cancer; Epidermal growth factor receptor; Pleural effusion; Malignant pleural effusion; Medicine; Cancer research; Cancer; Gene mutation; Targeted therapy; Pathology; Gene; Internal medicine; Biology; Genetics","score_opus":0.01669296787830679,"score_gpt":0.28771989957886657,"score_spread":0.2710269317005598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047693464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924929,0.0032951487,0.00014409088,0.0006338541,0.00039290814,0.0017460755,0.00014398672,0.00009841925,0.0010526221],"genre_scores_gemma":[0.996704,0.00017671393,0.0013825841,0.0004083113,0.00016376944,0.00054927694,0.00025241537,0.000056209505,0.00030674995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973526,0.000058386577,0.0011160976,0.0005730739,0.0005122299,0.00038763596],"domain_scores_gemma":[0.997836,0.00023906861,0.0008386871,0.0003829439,0.00040921944,0.00029409296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014187343,0.00028808462,0.0006691478,0.00018770932,0.000056546494,0.000013327973,0.000092466355,0.00014841197,0.000052910975],"category_scores_gemma":[0.001486369,0.00024407583,0.00014683533,0.0008556287,0.00012076963,0.0001501963,0.00004747334,0.00020229135,0.0000053513786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070339775,0.00097313983,0.603593,0.0013732185,0.0007970556,0.005150088,0.009202517,0.00034750358,0.36468765,0.00022785034,0.006649048,0.006928586],"study_design_scores_gemma":[0.007071153,0.0016325094,0.4983252,0.0024848725,0.0020835488,0.0006645701,0.002512545,0.00037824668,0.47978675,0.00061712874,0.004250109,0.00019335219],"about_ca_topic_score_codex":0.0018591678,"about_ca_topic_score_gemma":0.00029718006,"teacher_disagreement_score":0.11509911,"about_ca_system_score_codex":0.00027366282,"about_ca_system_score_gemma":0.0010775826,"threshold_uncertainty_score":0.9953123},"labels":[],"label_agreement":null},{"id":"W3064306546","doi":"10.1158/1078-0432.ccr-20-2081","title":"Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"Key Technology Research and Development Program of Shandong; Shandong Academy of Medical Sciences; Shandong First Medical University; AstraZeneca","keywords":"Osimertinib; T790M; Medicine; Internal medicine; Lung cancer; Oncology; Adverse effect; Cancer; Erlotinib; Epidermal growth factor receptor; Adenocarcinoma; ROS1","score_opus":0.07101337098720283,"score_gpt":0.45536085617458893,"score_spread":0.3843474851873861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3064306546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991721,0.0016063678,0.000008812111,0.0023699645,0.00010916213,0.0036415618,0.00031991847,0.00001709376,0.00020615477],"genre_scores_gemma":[0.99877495,0.00015846096,0.000054986212,0.00025704666,0.000113286434,0.00047711428,0.000021424354,0.000038105412,0.00010463058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963357,0.0011577602,0.0006691444,0.00058788445,0.0007369895,0.0005125119],"domain_scores_gemma":[0.99727356,0.0012805007,0.00018582176,0.00037490804,0.00046751922,0.00041765696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013210188,0.00019667168,0.0005720665,0.00012198434,0.00015388943,0.000033893426,0.00020170523,0.000086359294,0.000052307685],"category_scores_gemma":[0.00033131952,0.00011603452,0.00009282482,0.0007338417,0.000367177,0.000072113406,0.00013690487,0.00061794784,0.0000028156946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03268033,0.0016185527,0.9551606,0.00033438596,0.0009503577,0.00009546704,0.004278827,0.000027123426,0.00010369625,0.000002931348,0.0007999802,0.003947757],"study_design_scores_gemma":[0.013505136,0.0062889513,0.9726901,0.00045357202,0.00065767544,5.5249393e-7,0.005431059,0.00025605748,0.0002828713,4.920199e-7,0.00030969846,0.00012384767],"about_ca_topic_score_codex":0.0051858258,"about_ca_topic_score_gemma":0.00055357005,"teacher_disagreement_score":0.019175194,"about_ca_system_score_codex":0.00052699534,"about_ca_system_score_gemma":0.0014062969,"threshold_uncertainty_score":0.78394514},"labels":[],"label_agreement":null},{"id":"W3081040693","doi":"10.1200/jco.2009.27.15_suppl.8102","title":"Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; KRAS; Internal medicine; Oncology; Lung cancer; T790M; Adenocarcinoma; Population; Cancer; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.04097041188195424,"score_gpt":0.4639908822884745,"score_spread":0.4230204704065203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081040693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281263,0.00009097544,0.0009624155,0.001679401,0.0012405125,0.0030154595,0.000055479966,0.0000068707823,0.00013626799],"genre_scores_gemma":[0.9929832,0.00046597823,0.004821623,0.0010576774,0.00040747796,0.00006794211,0.00009150675,0.000026709122,0.00007785309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925676,0.00031334563,0.005993579,0.00037655,0.0004013492,0.00034756257],"domain_scores_gemma":[0.99218905,0.002774674,0.0032849668,0.00019775846,0.0012617783,0.00029178703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019242215,0.00023882405,0.0022641711,0.0002610294,0.000044907018,0.000007935098,0.00016452186,0.0004364989,0.000015797923],"category_scores_gemma":[0.00390897,0.00016707004,0.0005338785,0.00043730627,0.0001132889,0.00028877886,0.000014914063,0.00085187005,3.518075e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2728707,0.042477638,0.60766965,0.00005102022,0.00022819467,0.000035101642,0.00030643705,0.00025774172,0.0000056106037,0.0000021103176,0.00017813327,0.07591766],"study_design_scores_gemma":[0.3578277,0.14819467,0.49221316,0.00028339753,0.0006409159,7.174687e-7,0.000025887117,0.00019308434,0.000013362915,0.000029376508,0.00048466105,0.00009307251],"about_ca_topic_score_codex":0.000036965965,"about_ca_topic_score_gemma":0.0004778662,"teacher_disagreement_score":0.115456484,"about_ca_system_score_codex":0.0003277688,"about_ca_system_score_gemma":0.0028347524,"threshold_uncertainty_score":0.6812919},"labels":[],"label_agreement":null},{"id":"W3082062836","doi":"10.1016/j.annonc.2020.08.2100","title":"Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Pemetrexed; T790M; Tyrosine-kinase inhibitor; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Tyrosine kinase; Cancer research; Chemotherapy; Epidermal growth factor receptor; Erlotinib; Cisplatin; Gefitinib; Lung cancer; Cancer; Receptor","score_opus":0.049211310333982565,"score_gpt":0.40766079895236074,"score_spread":0.35844948861837816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082062836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028575,0.00032084816,0.00007218865,0.006922503,0.000143615,0.0012061622,0.00013864932,0.000053587784,0.00085666386],"genre_scores_gemma":[0.9955388,0.00007055714,0.0028948435,0.0008449403,0.00009363999,0.000116934316,0.0003658444,0.00003108887,0.000043363398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987289,0.000047074438,0.00033198728,0.0003833298,0.0002534022,0.00025534918],"domain_scores_gemma":[0.99871165,0.00027508783,0.00028411715,0.00017546605,0.00033743336,0.00021623439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008202674,0.00019298929,0.0006132529,0.00014392896,0.00007322018,0.000008596059,0.000052627955,0.000101779064,0.000028832492],"category_scores_gemma":[0.00024384524,0.00013826112,0.00012944956,0.00036869713,0.00008257346,0.00008899846,0.000031994507,0.000096770535,0.0000019040548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105359524,0.0052084145,0.22276692,0.0003754691,0.0061111017,0.00006380734,0.0027665594,0.0002368325,0.0021149088,0.00038939208,0.0041917847,0.6504153],"study_design_scores_gemma":[0.14201818,0.17470963,0.56019795,0.0005761547,0.008761317,0.0000025461145,0.0007434119,0.0011814631,0.015248313,0.00007254427,0.09567597,0.0008125419],"about_ca_topic_score_codex":0.000026868594,"about_ca_topic_score_gemma":0.00003629485,"teacher_disagreement_score":0.6496027,"about_ca_system_score_codex":0.00007263691,"about_ca_system_score_gemma":0.00018024625,"threshold_uncertainty_score":0.5638125},"labels":[],"label_agreement":null},{"id":"W3082658746","doi":"10.2217/fon-2020-0740","title":"Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Boehringer Ingelheim","keywords":"Afatinib; Osimertinib; Medicine; Lung cancer; Internal medicine; Oncology; T790M; Clinical trial; Cancer; Adenocarcinoma; Erlotinib; Epidermal growth factor receptor","score_opus":0.010261673574810951,"score_gpt":0.31282478021966725,"score_spread":0.3025631066448563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082658746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946353,0.0001987892,0.000038929673,0.00269572,0.00012891345,0.0012513576,0.00009448544,0.000007863936,0.0009486511],"genre_scores_gemma":[0.9982992,0.000012996862,0.00023574554,0.0010711293,0.00011420023,0.00010401304,0.000086953245,0.00001156784,0.000064183725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991128,0.00008571818,0.00024350677,0.00025883978,0.00016032674,0.00013884374],"domain_scores_gemma":[0.9994278,0.000049856175,0.00018474553,0.00012537502,0.00013574606,0.000076468954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044870958,0.0001274778,0.00040241514,0.00009041099,0.00006410906,0.0000060235684,0.00006270648,0.000066962035,0.000066900626],"category_scores_gemma":[0.000009559428,0.000079485406,0.00006339502,0.00072181475,0.00005332015,0.00003367054,0.00003582297,0.00015361219,5.761471e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007811188,0.0008855312,0.97960246,0.00004058264,0.0017208873,0.000032279237,0.014379471,0.00035443643,0.00008736172,0.000008081589,0.00022756416,0.001880239],"study_design_scores_gemma":[0.009511874,0.0021292865,0.9781771,0.000027200274,0.0068608867,0.0000010507896,0.002196195,0.00051873643,0.00019185331,7.467892e-7,0.00030473623,0.000080373575],"about_ca_topic_score_codex":0.00052284275,"about_ca_topic_score_gemma":0.0015318693,"teacher_disagreement_score":0.012183276,"about_ca_system_score_codex":0.00016819924,"about_ca_system_score_gemma":0.00037940778,"threshold_uncertainty_score":0.32413208},"labels":[],"label_agreement":null},{"id":"W3083034293","doi":"10.1158/1538-7445.am2020-741","title":"Abstract 741: Molecular and clinicopathological characteristics of Chinese non-small cell lung cancers with <i>ROS1</i> gene fusions identified by next-generation sequencing","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"ROS1; Crizotinib; Lung cancer; Medicine; Adenocarcinoma; Cancer research; Exon; Oncology; Fusion gene; Internal medicine; Targeted therapy; Cancer; Gene; Biology; Genetics","score_opus":0.09718839445636361,"score_gpt":0.39495905719508195,"score_spread":0.29777066273871833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083034293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435323,0.0026413056,0.00049064145,0.0010278422,0.00007301654,0.0007425848,0.00020956076,0.000021461241,0.0004403631],"genre_scores_gemma":[0.9968496,0.0012772558,0.0005708636,0.0004862539,0.00020964243,0.00018410716,0.00020863235,0.000032019867,0.00018162811],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984923,0.000056362143,0.00031010038,0.00042223642,0.00040836766,0.00031062643],"domain_scores_gemma":[0.9989637,0.00006562959,0.0001091031,0.00021492824,0.00034141456,0.0003052149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023566128,0.00015815905,0.00032641218,0.00006934712,0.00017969192,0.000055457527,0.00009710685,0.00009035629,0.000112352136],"category_scores_gemma":[0.0000754116,0.0001152571,0.00004952287,0.0003588092,0.00016171813,0.000087520326,0.000062326486,0.0003632383,0.0000043135947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020152782,0.00006134281,0.048911165,0.00029151866,0.000048566417,0.0001620511,0.001338617,0.0000499155,0.9467012,0.0000049401006,0.00078060105,0.0014485328],"study_design_scores_gemma":[0.009351706,0.0023836072,0.18853767,0.0006290601,0.00067006145,0.000046220506,0.001507503,0.006053114,0.78903633,0.000033900924,0.0010419412,0.00070885755],"about_ca_topic_score_codex":0.0007826547,"about_ca_topic_score_gemma":0.00008393758,"teacher_disagreement_score":0.15766487,"about_ca_system_score_codex":0.0003487665,"about_ca_system_score_gemma":0.0010236283,"threshold_uncertainty_score":0.4700048},"labels":[],"label_agreement":null},{"id":"W3083042226","doi":"10.1158/1538-7445.am2020-1324","title":"Abstract 1324: Genomic and clinical characteristics of MET exon14 alterations in 26,391 Chinese cancer patients","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Cancer; KRAS; Lung cancer; Medicine; Internal medicine; CDKN2A; Crizotinib; STK11; Oncology; Exon; ROS1; Population; Carcinogenesis; Cancer research; Gene; Genetics; Biology; Adenocarcinoma; Colorectal cancer","score_opus":0.10764201669093068,"score_gpt":0.5053879675990613,"score_spread":0.3977459509081307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083042226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995241,0.0008441579,0.0000038854228,0.0024089154,0.00013904469,0.00064000953,0.00028288472,0.000014199627,0.0004259216],"genre_scores_gemma":[0.99678105,0.0020840364,0.00009238993,0.0003176369,0.00031360163,0.00017602304,0.00006427532,0.000026858392,0.00014410407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865264,0.00006600879,0.00043163108,0.00029582463,0.00030800886,0.00024587533],"domain_scores_gemma":[0.99906033,0.00015429452,0.00007943828,0.00015691579,0.00030514627,0.00024386658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023332192,0.000105898,0.00033098343,0.00011195019,0.00006877012,0.000021711368,0.00008119965,0.00006701478,0.00037779985],"category_scores_gemma":[0.0002444329,0.00008344529,0.000052613377,0.0003299934,0.0001445285,0.00007682965,0.00006309743,0.00035904066,0.00001558912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000333461,0.0003007422,0.9748725,0.0001794663,0.00013931164,0.00001623672,0.0011440766,0.000005456715,0.0027856326,0.00002632625,0.00070895394,0.01948782],"study_design_scores_gemma":[0.002333464,0.00034057812,0.99511486,0.00012240153,0.000054927503,4.1852857e-7,0.000073541036,0.000105230945,0.00017539848,0.00002563687,0.0015838825,0.000069649024],"about_ca_topic_score_codex":0.0015012084,"about_ca_topic_score_gemma":0.00043678668,"teacher_disagreement_score":0.020242356,"about_ca_system_score_codex":0.00022027038,"about_ca_system_score_gemma":0.0006131907,"threshold_uncertainty_score":0.41366434},"labels":[],"label_agreement":null},{"id":"W3083419119","doi":"10.1158/1538-7445.am2020-1869","title":"Abstract 1869: Methylation signatures associated with T790M status in progressive NSCLC","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"T790M; Medicine; DNA methylation; Oncology; Methylation; Internal medicine; Bioinformatics; Cancer; Biology; Genetics; DNA; Adenocarcinoma; Gene; Gene expression","score_opus":0.07790474931393125,"score_gpt":0.4618267536533595,"score_spread":0.38392200433942825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083419119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98034877,0.0051273284,0.000011859982,0.0067478223,0.000038291233,0.0012569333,0.00007448126,0.000058229314,0.006336304],"genre_scores_gemma":[0.9985059,0.00014384865,0.000073649986,0.00029427718,0.00012030347,0.0003874636,0.00013214041,0.000026875341,0.00031552647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842983,0.00007738935,0.00014717971,0.00029409918,0.00061665283,0.00043484799],"domain_scores_gemma":[0.9990539,0.00015332388,0.000052336196,0.0001219439,0.0003777057,0.00024079875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019818058,0.00010370535,0.0001908926,0.0001396312,0.00009105213,0.000037371105,0.0000641735,0.00008205572,0.00053667167],"category_scores_gemma":[0.0003119053,0.00007469842,0.00002985315,0.00081673526,0.00009902114,0.000108346365,0.000023358489,0.0005207699,0.000019620418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009115902,0.0024045126,0.5459195,0.0011247509,0.0033234525,0.0036153411,0.03873403,0.0028298276,0.09580019,0.001325087,0.034665357,0.2611421],"study_design_scores_gemma":[0.008340369,0.0013330483,0.9669453,0.0010051326,0.00013607749,0.0000018043835,0.0015021465,0.00037412887,0.013479373,0.00019449623,0.0064342055,0.0002539419],"about_ca_topic_score_codex":0.0006999506,"about_ca_topic_score_gemma":0.00038140462,"teacher_disagreement_score":0.4210258,"about_ca_system_score_codex":0.0006688055,"about_ca_system_score_gemma":0.0011001629,"threshold_uncertainty_score":0.5876178},"labels":[],"label_agreement":null},{"id":"W3083451341","doi":"10.1158/1538-7445.am2020-5895","title":"Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of Toronto","funders":"","keywords":"KRAS; Biology; Cancer research; Oncogene; Transcriptome; Receptor tyrosine kinase; MAPK/ERK pathway; Gene; Genetics; Mutation; Kinase; Cell cycle; Gene expression","score_opus":0.09326818636019134,"score_gpt":0.4143546089192447,"score_spread":0.32108642255905334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083451341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879007,0.0009830269,0.00011067202,0.007586643,0.00008014423,0.00089956535,0.00030696302,0.000031177722,0.0021011147],"genre_scores_gemma":[0.9976145,0.00019920872,0.000060064984,0.00029384278,0.0003323745,0.0002591656,0.00047872524,0.000032334116,0.0007297969],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99845916,0.00006482952,0.00033963393,0.00032794298,0.00046299238,0.00034541302],"domain_scores_gemma":[0.9991328,0.000058671125,0.00007481187,0.0002198576,0.00031521925,0.00019862318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022211713,0.000119466364,0.00025467182,0.00023768976,0.000114427596,0.00004018468,0.000116419666,0.000072419694,0.00053366914],"category_scores_gemma":[0.00007987889,0.00010961452,0.000057769637,0.00074152905,0.00008084649,0.00019456029,0.000051189516,0.0003514496,0.000042639975],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019565939,0.00014998733,0.029338578,0.0004141871,0.000090228285,0.00006855316,0.005719029,0.00006940367,0.9607156,0.000328201,0.00017273382,0.0027378495],"study_design_scores_gemma":[0.0031041203,0.0003584634,0.925704,0.0005077445,0.00007249298,0.0000047516137,0.00067446416,0.0007022216,0.05338284,0.000051581635,0.015223881,0.00021345295],"about_ca_topic_score_codex":0.00043977177,"about_ca_topic_score_gemma":0.000096160074,"teacher_disagreement_score":0.9073327,"about_ca_system_score_codex":0.00042141665,"about_ca_system_score_gemma":0.00078506605,"threshold_uncertainty_score":0.5843303},"labels":[],"label_agreement":null},{"id":"W3083454034","doi":"10.1093/ajhp/zxaa197","title":"Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness","year":2020,"lang":"en","type":"review","venue":"American Journal of Health-System Pharmacy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Osimertinib; Medicine; Lung cancer; Erlotinib; Cost effectiveness; Oncology; Clinical trial; Epidermal growth factor receptor; Intensive care medicine; Cancer; Internal medicine; Risk analysis (engineering)","score_opus":0.1028731177825195,"score_gpt":0.48780156611554376,"score_spread":0.38492844833302425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083454034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017953202,0.97650903,0.00021801119,0.0008583006,0.00030320988,0.0038393228,0.00021117888,0.000009141652,0.00009860389],"genre_scores_gemma":[0.09676837,0.90190506,0.00047870728,0.00011583043,0.00031933625,0.00033193562,0.000033912336,0.00004336359,0.0000034741402],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953632,0.0016499343,0.0020061193,0.00033779925,0.00032664387,0.00031632744],"domain_scores_gemma":[0.99499774,0.0011991553,0.0030749652,0.00017384804,0.00026676978,0.00028751214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009391976,0.00041883925,0.0034316264,0.0002427139,0.00011437584,0.000039057413,0.00016185986,0.00005246087,0.0000039362153],"category_scores_gemma":[0.00001466566,0.00025106687,0.00051907694,0.0005210911,0.0001540347,0.00011790334,0.000014649479,0.00044134937,0.0000010275648],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023705485,0.00032884968,0.0012457089,0.012166611,0.0012034074,0.0004907517,0.0041475953,0.00029699143,6.866824e-7,0.000015911428,0.000019280767,0.97984713],"study_design_scores_gemma":[0.03588972,0.036758747,0.005475617,0.18776035,0.0388005,0.010054662,0.054106154,0.0014288573,0.000059351398,0.00000247684,0.62830895,0.0013546429],"about_ca_topic_score_codex":0.0030680806,"about_ca_topic_score_gemma":0.000040664872,"teacher_disagreement_score":0.9784925,"about_ca_system_score_codex":0.0026018103,"about_ca_system_score_gemma":0.0077891047,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W3084000608","doi":"10.1016/j.annonc.2020.08.2335","title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); William Osler Health System; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute; Boehringer Ingelheim","keywords":"Afatinib; Neuregulin 1; Cancer research; ErbB; Medicine; Fusion gene; Adenocarcinoma; Neuregulin; Lung cancer; Targeted therapy; Cancer; Epidermal growth factor receptor; Gene; Gefitinib; Oncology; Biology; Internal medicine; Receptor; Genetics","score_opus":0.09157322375780692,"score_gpt":0.45679954810592427,"score_spread":0.36522632434811736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084000608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000609321,0.99486184,0.000010272699,0.0009681898,0.00007239414,0.000875973,0.0000616016,0.000010919753,0.0025294998],"genre_scores_gemma":[0.018006017,0.98081523,0.00011754048,0.0007762,0.00011815393,0.00007066077,0.000023895562,0.000024207697,0.00004808773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988269,0.0002539311,0.00048398232,0.00022812409,0.000067243775,0.00013981014],"domain_scores_gemma":[0.9987964,0.00036601638,0.0005288034,0.00014371162,0.000100740246,0.00006432424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022622875,0.00018258224,0.00130488,0.000082782855,0.000061816325,0.0000038048606,0.00007318592,0.0001870181,0.000059252387],"category_scores_gemma":[0.0001092768,0.00010153265,0.00017068625,0.0001330863,0.00036180287,0.000016544434,0.0000652176,0.00017063638,0.0000031903044],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008030993,0.00007706424,0.00020418866,0.0013315902,0.0009067049,0.000003950211,0.00090822496,1.1576837e-7,0.000035877234,0.00033465412,0.00011887144,0.99599844],"study_design_scores_gemma":[0.0012526874,0.0010426496,0.0001320492,0.0010651811,0.0014348321,0.000054374243,0.00027987917,0.000017490482,0.00002600195,0.00049820443,0.9941196,0.00007708698],"about_ca_topic_score_codex":0.00014715864,"about_ca_topic_score_gemma":0.000015161916,"teacher_disagreement_score":0.9959214,"about_ca_system_score_codex":0.00002200977,"about_ca_system_score_gemma":0.00026352698,"threshold_uncertainty_score":0.41403812},"labels":[],"label_agreement":null},{"id":"W3084842279","doi":"10.21037/apm-20-605","title":"Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review","year":2020,"lang":"en","type":"review","venue":"Annals of Palliative Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; T790M; Epidermal growth factor receptor; Meta-analysis; Erlotinib; Cancer; Gefitinib","score_opus":0.18111024720617708,"score_gpt":0.4810402637746745,"score_spread":0.29993001656849744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084842279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.2093117e-7,0.9810655,0.0017133973,0.0038609072,0.000057024907,0.011285291,0.001893219,0.000041516043,0.000082612176],"genre_scores_gemma":[0.00012327616,0.99165267,0.00037036647,0.0013858576,0.00014098677,0.0051792404,0.00080185867,0.00007918262,0.00026657694],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99563956,0.00040951752,0.0020342653,0.00076217315,0.0007122519,0.00044221786],"domain_scores_gemma":[0.9949661,0.0007670702,0.0024118726,0.0006072164,0.0007966002,0.00045117983],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0006579655,0.00083189656,0.016443526,0.00036853863,0.00008616217,0.000012398995,0.00018697006,0.00011715059,0.00016236224],"category_scores_gemma":[0.00044925642,0.00038674727,0.0024759178,0.0015598891,0.00017155021,0.00005740204,0.000035408742,0.0002237088,0.0000018601766],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029709217,0.00004331507,0.000010613604,0.6301616,0.3661606,0.00006091211,0.00024045627,8.4610093e-7,1.3787322e-7,0.00014248399,0.0007207638,0.0024285598],"study_design_scores_gemma":[0.00056453684,0.00053147494,0.0000065552163,0.3268625,0.64140034,0.000015651996,0.0001504611,0.00004249469,0.0000025494096,0.0000012298402,0.030220933,0.00020127765],"about_ca_topic_score_codex":0.0004071239,"about_ca_topic_score_gemma":0.000060889808,"teacher_disagreement_score":0.3032991,"about_ca_system_score_codex":0.0001979153,"about_ca_system_score_gemma":0.0006345507,"threshold_uncertainty_score":0.99985844},"labels":[],"label_agreement":null},{"id":"W3085632552","doi":"10.3747/co.27.6049","title":"Real-World Treatment Patterns and Survival in Stage IV Non-Small-Cell Lung Cancer in Canada","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; McMaster University Medical Centre; AstraZeneca (Canada); Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Government of Ontario","keywords":"Medicine; Internal medicine; Carboplatin; Gefitinib; Lung cancer; Gemcitabine; Oncology; Histology; Chemotherapy; Stage (stratigraphy); Radiation therapy; Population; Cohort; Cancer; Cisplatin","score_opus":0.05876590559073092,"score_gpt":0.4026141718584998,"score_spread":0.3438482662677689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085632552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913946,0.0011064201,0.000012053472,0.0030466162,0.0005945344,0.00066386355,0.00017069456,0.000010016131,0.0030012045],"genre_scores_gemma":[0.9959922,0.0029284575,0.000025610756,0.00021822954,0.00012736372,0.00021906472,0.0000700613,0.000014724261,0.00040428247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909323,0.000045785386,0.00023393754,0.00028381633,0.00008743986,0.00025577273],"domain_scores_gemma":[0.99956864,0.00006152756,0.00006172999,0.000097840144,0.000023444474,0.00018679575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003271126,0.00014627364,0.0003691648,0.00007569835,0.00002211592,0.0000047276308,0.00003908062,0.00003319,0.00019644349],"category_scores_gemma":[0.000005166799,0.000121469064,0.000024538582,0.0001684114,0.000015476664,0.000023713292,0.000027639155,0.00013867122,0.0000016294745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007983714,0.0002709335,0.972921,0.00017564667,0.000044831424,0.00025188737,0.0018071291,0.000070978575,0.00003244181,0.000014314816,0.00035650283,0.023974506],"study_design_scores_gemma":[0.0071897996,0.000349208,0.9597992,0.00010140212,0.00016641754,0.0000013099296,0.0008792183,0.0022418895,0.00010594547,0.000001356668,0.02904001,0.0001242734],"about_ca_topic_score_codex":0.9041851,"about_ca_topic_score_gemma":0.994334,"teacher_disagreement_score":0.09014887,"about_ca_system_score_codex":0.003842852,"about_ca_system_score_gemma":0.0031064092,"threshold_uncertainty_score":0.9999812},"labels":[],"label_agreement":null},{"id":"W3087210493","doi":"10.1056/nejmoa2027071","title":"Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1756,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ono Pharmaceutical; Shionogi; Loxo Oncology; Astellas Pharma; Mirati Therapeutics; Daiichi Sankyo Europe; Sanofi; Halozyme; F. Hoffmann-La Roche; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Spectrum Pharmaceuticals; Amgen; Kyorin Pharmaceutical; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Medicine; Cancer research; Oncology; Internal medicine; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.021157826512823007,"score_gpt":0.3285523371855753,"score_spread":0.3073945106727523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087210493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92044157,0.0078103114,0.0004856003,0.06614082,0.0005192994,0.00040139956,0.000005905919,0.000020688318,0.004174431],"genre_scores_gemma":[0.9901901,0.0010230709,0.00042983436,0.004566629,0.0030593227,0.0000055065943,0.000015441427,0.000026150357,0.00068394747],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985901,0.000054630847,0.0006080365,0.0001580137,0.00036294397,0.00022626598],"domain_scores_gemma":[0.9987491,0.00011213428,0.00027729734,0.00010746887,0.00022636745,0.0005276645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023163858,0.0001627476,0.0005433959,0.00017199841,0.0000321662,0.00000678835,0.00010125281,0.000061862425,0.00053487683],"category_scores_gemma":[0.00021233459,0.00010382491,0.00006682524,0.00049117533,0.000040657644,0.00007047797,0.000014993108,0.00043843978,0.000004377656],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0088633215,0.0006726448,0.44276297,0.00079548213,0.0014510822,0.0064157266,0.040815055,0.0013634795,0.15714513,0.000028685163,0.20650992,0.13317649],"study_design_scores_gemma":[0.63663876,0.011039911,0.15596713,0.005800881,0.005756808,0.0013273833,0.0025711542,0.005066777,0.021861117,0.00013537289,0.15318622,0.0006484483],"about_ca_topic_score_codex":0.00079264276,"about_ca_topic_score_gemma":0.0001283836,"teacher_disagreement_score":0.6277755,"about_ca_system_score_codex":0.00014601205,"about_ca_system_score_gemma":0.00069568265,"threshold_uncertainty_score":0.5856526},"labels":[],"label_agreement":null},{"id":"W3087777340","doi":"10.1016/j.annonc.2020.08.089","title":"1195P The value of detecting resistance through liquid biopsy","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Niagara; Juravinski Cancer Centre; McGill University; University of Calgary; Jewish General Hospital; University Health Network; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Liquid biopsy; Biopsy; T790M; Targeted therapy; Oncology; Lung cancer; Internal medicine; Cohort; Cancer; Clinical trial; Adenocarcinoma; Pathology; Bioinformatics; ROS1","score_opus":0.09487938942729415,"score_gpt":0.43981916246007013,"score_spread":0.344939773032776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087777340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.820565,0.0025985925,0.00039392247,0.10284862,0.00012640649,0.0003278446,0.000021660662,0.000024578036,0.07309339],"genre_scores_gemma":[0.99330264,0.0002018012,0.0015666935,0.0045835795,0.00009848946,0.000012467754,0.0000035220255,0.000007739786,0.00022305814],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942684,0.000042898682,0.00021754268,0.00010975198,0.00009136811,0.000111625144],"domain_scores_gemma":[0.9993828,0.00014403052,0.00015643935,0.00013790966,0.00013978417,0.000039039423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009399957,0.000057927533,0.00023009979,0.000014198141,0.00004061988,0.0000012145396,0.000067922476,0.00004911651,0.000044498658],"category_scores_gemma":[0.00019509735,0.00003722892,0.000074906435,0.00015941657,0.00010679916,0.000031371175,0.000023443314,0.000074494215,0.000005787097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022335026,0.0040481267,0.015256208,0.0030105915,0.007525787,0.0009072064,0.1625418,0.0006223517,0.38807476,0.13039787,0.109057434,0.15622284],"study_design_scores_gemma":[0.0038305249,0.013362593,0.010799027,0.00023153104,0.0006886261,0.00006658911,0.004172696,0.00006967184,0.3302859,0.0021432866,0.63416916,0.00018038765],"about_ca_topic_score_codex":0.00008260453,"about_ca_topic_score_gemma":0.000016960492,"teacher_disagreement_score":0.52511173,"about_ca_system_score_codex":0.000016361788,"about_ca_system_score_gemma":0.00019625376,"threshold_uncertainty_score":0.15181515},"labels":[],"label_agreement":null},{"id":"W3087846510","doi":"10.1016/j.annonc.2020.08.1697","title":"1383P Lung cancer in adolescents and young adults (AYA) in Asia: Tumour characteristics and molecular profiles","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; KRAS; Internal medicine; Cohort; Cancer; Anaplastic lymphoma kinase; Oncogene; Lung cancer; Adenocarcinoma; Oncology; Stage (stratigraphy); Gastroenterology; Colorectal cancer; Cell cycle","score_opus":0.02435319907027539,"score_gpt":0.3794287028919217,"score_spread":0.3550755038216463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087846510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858832,0.0025007408,0.0000055959335,0.010582425,0.000051948216,0.00039256143,0.000040035786,0.0000064434375,0.00053709635],"genre_scores_gemma":[0.99710345,0.0013223955,0.000080948266,0.0013711337,0.000037755202,0.000047045825,0.000013790774,0.0000094390025,0.000014057286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999375,0.000031275682,0.0002070697,0.00017494269,0.000067194516,0.00014452932],"domain_scores_gemma":[0.9997106,0.000010008986,0.0000776838,0.000049142105,0.00006159643,0.00009094004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004866862,0.00008347983,0.00029366932,0.000066133,0.000011432926,0.0000033980386,0.000025483392,0.00007039309,0.000010793174],"category_scores_gemma":[0.000053057203,0.00007539547,0.00001742365,0.00010317038,0.00004921019,0.000039232906,0.000028637029,0.00010597592,5.8006793e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044180773,0.00023410354,0.9649383,0.0004772973,0.000057440666,0.0003675957,0.0023418986,0.0000016924338,0.0037530921,0.00006801426,0.00024583237,0.027072923],"study_design_scores_gemma":[0.0028989408,0.0007048056,0.99279654,0.0005192972,0.00006728673,0.000016554726,0.0003230695,0.00047380084,0.0016716032,0.00001575413,0.0004438726,0.000068489135],"about_ca_topic_score_codex":0.00034751097,"about_ca_topic_score_gemma":0.00020861426,"teacher_disagreement_score":0.027858226,"about_ca_system_score_codex":0.00003687096,"about_ca_system_score_gemma":0.00015160744,"threshold_uncertainty_score":0.3074538},"labels":[],"label_agreement":null},{"id":"W3088110133","doi":"10.1016/j.annonc.2020.08.1601","title":"1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Oncology; Internal medicine; Cancer research; Cancer; Adenocarcinoma","score_opus":0.03654913715870304,"score_gpt":0.40692508686977535,"score_spread":0.3703759497110723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088110133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909941,0.00041192706,0.0007493572,0.005386045,0.000030832693,0.0005008923,0.00011683547,0.000026454269,0.0017835383],"genre_scores_gemma":[0.9961836,0.0003152077,0.0017145909,0.0012881206,0.000011610819,0.000010153163,0.00042750564,0.000012286356,0.00003695697],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99890906,0.00013352116,0.00044256123,0.00024822503,0.00010873235,0.0001579273],"domain_scores_gemma":[0.9990732,0.00015127822,0.00020227647,0.00012797362,0.00028979394,0.0001554876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012526663,0.0001201035,0.0006560195,0.00020996736,0.000020380552,0.0000027687895,0.000052714196,0.00006328085,0.0001557972],"category_scores_gemma":[0.0001337519,0.00009656534,0.000079023754,0.00091493904,0.00011016873,0.00007340646,0.000026641514,0.00011643109,0.0000018910731],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018685428,0.005534834,0.05058206,0.00015180389,0.00782588,0.00043990812,0.018879313,0.0037176842,0.02493575,0.00056510215,0.0012306501,0.8674516],"study_design_scores_gemma":[0.040618863,0.041699536,0.8403704,0.00042738643,0.008343043,0.00005012227,0.009480115,0.009131174,0.03216332,0.0002976185,0.01685549,0.0005629093],"about_ca_topic_score_codex":0.000280174,"about_ca_topic_score_gemma":0.00026924605,"teacher_disagreement_score":0.8668887,"about_ca_system_score_codex":0.000040751842,"about_ca_system_score_gemma":0.00029735453,"threshold_uncertainty_score":0.39378202},"labels":[],"label_agreement":null},{"id":"W3088144056","doi":"10.1016/j.annonc.2020.08.2282","title":"LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Internal medicine; Interim analysis; Lung cancer; Clinical endpoint; ALK inhibitor; Oncology; Discontinuation; Adverse effect; Progression-free survival; Randomized controlled trial; Overall survival","score_opus":0.04310889108180626,"score_gpt":0.4027122095319315,"score_spread":0.3596033184501252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088144056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839956,0.00035867223,0.000012553661,0.0078809755,0.000077574085,0.0029986897,0.00044511785,0.0000058924006,0.004224892],"genre_scores_gemma":[0.9979452,0.00024783378,0.000097903634,0.0012166337,0.000050267576,0.00024793323,0.00006586887,0.000016723054,0.00011166057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985429,0.000115222465,0.0006119665,0.00028439524,0.00023460774,0.00021089955],"domain_scores_gemma":[0.9984138,0.00024527314,0.000567997,0.0003151992,0.00038985343,0.00006786618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011190685,0.00019204886,0.00063326705,0.000058371497,0.000059583057,0.0000026548994,0.00014969904,0.00006155605,0.0000237078],"category_scores_gemma":[0.000046304907,0.00009861294,0.00011437142,0.0003511859,0.00012936944,0.00004541908,0.00003433012,0.00009885698,6.6452094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09568713,0.08272744,0.3929923,0.000515542,0.0030453817,0.0002159048,0.27973825,0.0031102882,0.0012240056,0.00003079878,0.0042917593,0.1364212],"study_design_scores_gemma":[0.22198623,0.19512267,0.51767606,0.00055194384,0.0026694182,0.0000039998326,0.008773792,0.00044319982,0.039181586,0.000010993408,0.013273163,0.00030691206],"about_ca_topic_score_codex":0.0012349129,"about_ca_topic_score_gemma":0.0015305608,"teacher_disagreement_score":0.27096447,"about_ca_system_score_codex":0.00009907591,"about_ca_system_score_gemma":0.00046384655,"threshold_uncertainty_score":0.4021319},"labels":[],"label_agreement":null},{"id":"W3088293910","doi":"10.1016/j.annonc.2020.08.1672","title":"1358P Efficacy and toxicity of combined inhibition of EGFR and VEGFR in advanced non-small cell lung cancer patients harboring activating EGFR mutations: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Lung cancer; Meta-analysis; Bevacizumab; Epidermal growth factor receptor; Adverse effect; Gefitinib; Odds ratio; Cancer; Confidence interval; Chemotherapy","score_opus":0.08631305186697011,"score_gpt":0.4419172480569191,"score_spread":0.355604196189949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088293910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018180296,0.977445,0.000013822939,0.00036064806,0.000015107277,0.003731063,0.00015511662,0.000007280827,0.000091645044],"genre_scores_gemma":[0.05135095,0.94726604,0.0004009149,0.00019525421,0.0000056315175,0.0006299103,0.000107602515,0.000026102074,0.000017567883],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99763775,0.0002694086,0.0014269522,0.0003583144,0.00015572642,0.00015182445],"domain_scores_gemma":[0.99693465,0.000584458,0.0018639298,0.00019696621,0.00033058235,0.00008942315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030347428,0.0002872679,0.006054101,0.00034217237,0.000028519213,0.000004709188,0.000051151732,0.00014777569,0.000011526544],"category_scores_gemma":[0.00029106988,0.00021283819,0.00040267993,0.00072440587,0.00008116363,0.000079628095,0.00006287318,0.00016802872,1.2041085e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036877453,0.0006117847,0.00033986868,0.944188,0.03701193,0.000010222305,0.0007616046,0.0000067687865,0.000041775944,0.000015359352,0.000011983294,0.016963853],"study_design_scores_gemma":[0.0033481598,0.0020191176,0.0007170305,0.09019778,0.90173596,0.0000055850624,0.00012850246,0.000046421406,0.0003677766,0.000011409603,0.0011293348,0.00029290767],"about_ca_topic_score_codex":0.00011607199,"about_ca_topic_score_gemma":0.000039013223,"teacher_disagreement_score":0.86472404,"about_ca_system_score_codex":0.000102737606,"about_ca_system_score_gemma":0.00031397492,"threshold_uncertainty_score":0.8679289},"labels":[],"label_agreement":null},{"id":"W3088299032","doi":"10.1016/j.annonc.2020.08.1730","title":"1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"KRAS; Docetaxel; Medicine; Clinical endpoint; Oncology; Internal medicine; Phases of clinical research; Progression-free survival; Expanded access; Cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Progressive disease; Clinical trial","score_opus":0.03654458867401471,"score_gpt":0.38859521344056674,"score_spread":0.352050624766552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088299032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417853,0.0005816656,0.000033364788,0.00046475162,0.00020455456,0.0037355497,0.00008478612,0.000034796354,0.0006819936],"genre_scores_gemma":[0.9983299,0.00014480263,0.00032273165,0.0004062842,0.0000738562,0.0004845475,0.00012389732,0.00004736283,0.000066635934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792063,0.0001097678,0.00074836815,0.0004987791,0.00031014683,0.0004123084],"domain_scores_gemma":[0.9982125,0.00012434548,0.0005811247,0.00025572008,0.0005973021,0.00022901989],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010772323,0.0003217587,0.0009083492,0.00020073939,0.000056530836,0.000008510657,0.00011798399,0.00012810137,0.0000665235],"category_scores_gemma":[0.000064364074,0.00026273003,0.000100931924,0.0004592519,0.00007183244,0.0001925571,0.000046636345,0.00020828922,0.0000036471818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05306464,0.023563283,0.8588649,0.0007169213,0.0017590475,0.00026465353,0.037268903,0.0012613265,0.0030745664,0.0000027374147,0.0007242649,0.019434724],"study_design_scores_gemma":[0.41942608,0.07478611,0.47241354,0.001146426,0.003410951,0.0000023252137,0.006981441,0.0025381371,0.017222552,0.0000016456465,0.0014006337,0.0006701365],"about_ca_topic_score_codex":0.0020921351,"about_ca_topic_score_gemma":0.0009642085,"teacher_disagreement_score":0.3864514,"about_ca_system_score_codex":0.00026704711,"about_ca_system_score_gemma":0.00056655,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W3088316576","doi":"10.1016/j.annonc.2020.08.663","title":"549P Identification of RET rearrangement in 12888 Chinese lung cancer patients by next-generation sequencing (NGS)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Ipsen; Astex Pharmaceuticals; G1 Therapeutics; Pfizer; Astellas Pharma; Clovis Oncology; Merck KGaA; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Fusion gene; Cancer research; Cancer; Exon; Intron; Internal medicine; Oncology; Crizotinib; Genetics; Gene; Biology","score_opus":0.10871192538947436,"score_gpt":0.43354725046363013,"score_spread":0.3248353250741558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088316576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98922,0.0009845534,0.00006321269,0.008262619,0.00013027091,0.0004436366,0.000083897015,0.000008560758,0.00080325507],"genre_scores_gemma":[0.9973306,0.00063713157,0.00009792896,0.0013625784,0.00007815871,0.000070686765,0.00032397915,0.000009239362,0.00008968144],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991053,0.000045943932,0.00042489963,0.00016892901,0.0001455719,0.00010935943],"domain_scores_gemma":[0.9993268,0.000020549905,0.00025541597,0.00009938004,0.00023881382,0.0000589927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116730494,0.000077348144,0.00025273868,0.00006429816,0.000020762864,0.0000036540591,0.00004501612,0.00006368211,0.00007958657],"category_scores_gemma":[0.000099556,0.00006627399,0.00004343771,0.00020788386,0.000029966395,0.00010730919,0.000014795437,0.000059214566,0.0000020128289],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003088457,0.0007764396,0.3595986,0.00034366082,0.00029303605,0.000008331172,0.008375201,0.00035134878,0.556466,0.00007214747,0.03544727,0.037959106],"study_design_scores_gemma":[0.015110291,0.007604406,0.67286354,0.00043760004,0.00087199337,0.0000040642963,0.0011323001,0.019635772,0.2591016,0.00018484154,0.022545056,0.0005085108],"about_ca_topic_score_codex":0.00075624057,"about_ca_topic_score_gemma":0.00018939776,"teacher_disagreement_score":0.31326494,"about_ca_system_score_codex":0.00016231742,"about_ca_system_score_gemma":0.00022515655,"threshold_uncertainty_score":0.27025747},"labels":[],"label_agreement":null},{"id":"W3089025929","doi":"10.1016/j.annonc.2020.08.1716","title":"1402P Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; KRAS; Interquartile range; Cancer","score_opus":0.07062036124007424,"score_gpt":0.4127835892409054,"score_spread":0.34216322800083115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089025929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726066,0.0004671461,0.000056864636,0.01257689,0.00013267838,0.00076112815,0.000049460836,0.000034434866,0.013314783],"genre_scores_gemma":[0.9913758,0.00026576722,0.00518299,0.0026126055,0.00014325982,0.00016552291,0.000054483902,0.000027841328,0.00017174914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985553,0.000088130975,0.00055370195,0.000330999,0.00012081598,0.0003510732],"domain_scores_gemma":[0.99887925,0.00037052965,0.00028840656,0.00010156525,0.0002195751,0.00014066216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014954653,0.00016439523,0.0004886996,0.00021025895,0.000035473106,0.0000052511728,0.00007478777,0.00009886343,0.00009484906],"category_scores_gemma":[0.00033084446,0.0001573914,0.000065532324,0.0006302325,0.000035584526,0.00012811358,0.000032118864,0.00023626263,0.0000066911775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004643087,0.0005228798,0.8733978,0.0007402145,0.000104325445,0.00025148186,0.011756953,0.0013798587,0.027989348,0.000047744805,0.001405837,0.081939206],"study_design_scores_gemma":[0.009725286,0.0026307495,0.9372577,0.00086714345,0.00018058169,0.000008410856,0.0014774054,0.0056595798,0.03867953,0.00010090281,0.0030463855,0.00036634214],"about_ca_topic_score_codex":0.003495956,"about_ca_topic_score_gemma":0.0021154997,"teacher_disagreement_score":0.08157287,"about_ca_system_score_codex":0.00025241933,"about_ca_system_score_gemma":0.0007462678,"threshold_uncertainty_score":0.64182353},"labels":[],"label_agreement":null},{"id":"W3089046444","doi":"10.1016/j.annonc.2020.08.2279","title":"LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Oncology; Adjuvant; Internal medicine; Central nervous system; Adjuvant therapy; Disease; Chemotherapy; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.0504171646394417,"score_gpt":0.3656277545487134,"score_spread":0.3152105899092717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089046444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98840415,0.00095299666,0.000020662905,0.007540197,0.00015898702,0.00113821,0.00012064852,0.00006852919,0.0015955959],"genre_scores_gemma":[0.9971096,0.00025347286,0.00010015123,0.002033105,0.000071457944,0.00008681045,0.00027068277,0.000026903728,0.000047797097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983189,0.00015706032,0.00045398495,0.0003713454,0.0002764947,0.00042222437],"domain_scores_gemma":[0.99866146,0.000073580006,0.00023953832,0.00023278162,0.00036848764,0.00042413262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000075814365,0.00020067826,0.0005391005,0.00010023826,0.000050557897,0.000007717492,0.0001213756,0.00009090013,0.000067229485],"category_scores_gemma":[0.000111616675,0.00014520573,0.00008228255,0.0004553777,0.00011170361,0.00009319273,0.000026970436,0.0001803322,0.000015480455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032250512,0.004925882,0.5879958,0.00055879576,0.0010066632,0.0013671699,0.00702376,0.00033620777,0.0006614224,0.00021619542,0.009362174,0.35429537],"study_design_scores_gemma":[0.016179366,0.016153654,0.9544764,0.0005337052,0.0002174036,0.000009255262,0.0005602316,0.0006234786,0.0010126686,0.0000141411,0.009982773,0.00023690528],"about_ca_topic_score_codex":0.0003592197,"about_ca_topic_score_gemma":0.000053763095,"teacher_disagreement_score":0.3664806,"about_ca_system_score_codex":0.00016031104,"about_ca_system_score_gemma":0.00074948935,"threshold_uncertainty_score":0.5921318},"labels":[],"label_agreement":null},{"id":"W3089072541","doi":"10.1016/j.annonc.2020.08.1602","title":"1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Oncology; ROS1; Adenocarcinoma; Asymptomatic; Clinical trial; Cancer","score_opus":0.041363131630691455,"score_gpt":0.3780338126850281,"score_spread":0.3366706810543367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089072541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990559,0.00014284874,0.00006368885,0.006231447,0.00003155811,0.00066834944,0.00023467366,0.000013115671,0.0020553116],"genre_scores_gemma":[0.9962774,0.000056113255,0.0013880013,0.0018035733,0.000041485444,0.000022201171,0.00025985375,0.00001558877,0.00013579987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905854,0.000084102045,0.00028434867,0.00021599214,0.00018304044,0.00017396455],"domain_scores_gemma":[0.99891114,0.00031937784,0.00020817673,0.00012874906,0.00030543614,0.00012714526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007776508,0.00012726999,0.0004873803,0.00007926256,0.000028980294,0.0000016218739,0.000047130725,0.000050828592,0.00036950273],"category_scores_gemma":[0.00017430267,0.00007458473,0.00004842367,0.00029387116,0.000100228724,0.000043953572,0.000033069122,0.00007898489,0.000007129442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11107788,0.011701744,0.6662171,0.00031853444,0.0030874668,0.00064501015,0.012152635,0.0005332492,0.0015113174,0.000115517985,0.012783131,0.17985643],"study_design_scores_gemma":[0.042092323,0.059992336,0.8450542,0.00048601918,0.0012618095,0.000021564594,0.00085294235,0.000057696212,0.02613538,0.0000075629814,0.023782972,0.00025521332],"about_ca_topic_score_codex":0.00018378721,"about_ca_topic_score_gemma":0.00025262998,"teacher_disagreement_score":0.17960122,"about_ca_system_score_codex":0.00005552778,"about_ca_system_score_gemma":0.0003740688,"threshold_uncertainty_score":0.40457958},"labels":[],"label_agreement":null},{"id":"W3089166529","doi":"10.1016/j.annonc.2020.08.1616","title":"1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CMC Microsystems; Pfizer","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.04800706773866008,"score_gpt":0.4254812712738958,"score_spread":0.3774742035352357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089166529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716036,0.00014561169,0.0000060047455,0.012506539,0.00003679708,0.0006284248,0.00005615712,0.000022516406,0.014994356],"genre_scores_gemma":[0.99666995,0.000016604876,0.00022228104,0.0026619406,0.000055268327,0.000045724002,0.00027171857,0.00001259219,0.00004392248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928325,0.00003896155,0.0002045741,0.00017468752,0.0001437917,0.00015472995],"domain_scores_gemma":[0.99941164,0.000032122265,0.00010321177,0.00009730006,0.00014896374,0.00020677218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000303049,0.000094796065,0.00026077268,0.000061405284,0.000022519263,0.000002693283,0.00003606631,0.00005349826,0.00011183586],"category_scores_gemma":[0.000056629447,0.000065459346,0.000038459748,0.00018369517,0.000069643786,0.00006221944,0.000018239838,0.000076557146,0.000010955088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007112103,0.0020956467,0.83972824,0.00006911941,0.00016448686,0.00021837717,0.0010778367,0.0000128256515,0.000033419266,0.00009479641,0.002564403,0.14682877],"study_design_scores_gemma":[0.013036365,0.01245305,0.9612901,0.000147467,0.00021942657,0.0000012039872,0.000069837886,0.000050829924,0.0004963325,0.000086038795,0.012042584,0.000106717576],"about_ca_topic_score_codex":0.000026510104,"about_ca_topic_score_gemma":0.000011749816,"teacher_disagreement_score":0.14672205,"about_ca_system_score_codex":0.000030891137,"about_ca_system_score_gemma":0.0002949809,"threshold_uncertainty_score":0.26693547},"labels":[],"label_agreement":null},{"id":"W3090736401","doi":"10.1016/j.jmoldx.2020.09.006","title":"Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universitair Ziekenhuis Antwerpen; Vrije Universiteit Amsterdam; Clovis Oncology; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Bio-Rad Laboratories; Roche; Novartis; Meso Scale Diagnostics; Takeda Pharmaceutical Company; AbbVie; Merck; Bristol-Myers Squibb; AstraZeneca; Bayer; Pfizer; Boehringer Ingelheim","keywords":"Anaplastic lymphoma kinase; Immunohistochemistry; ROS1; Staining; Lung cancer; Pathology; Medicine; Cancer; Cancer research; Biology; Internal medicine; Adenocarcinoma","score_opus":0.004836796343790798,"score_gpt":0.2930180849642651,"score_spread":0.2881812886204743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090736401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330974,0.005530556,0.00044218454,0.00041802597,0.000025188185,0.00012068315,0.0000043585783,0.0000016331289,0.00014762484],"genre_scores_gemma":[0.99579626,0.00290176,0.0007950914,0.00046724905,0.000018644576,0.000005050384,0.0000019421789,0.0000084956955,0.0000054794914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994892,0.000009391944,0.00024003256,0.00007366295,0.00011823742,0.00006949332],"domain_scores_gemma":[0.9994793,0.00007687624,0.00018609033,0.000049307153,0.00013316593,0.00007529078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005115931,0.00007151976,0.00017178156,0.000047176007,0.000015038768,0.000008554851,0.000031560725,0.000033114673,0.000002767145],"category_scores_gemma":[0.00021674596,0.00006226119,0.000023891951,0.000072715266,0.000028890632,0.000049408434,0.000016451197,0.00014885905,1.0390025e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076294394,0.00023870467,0.6352948,0.001547295,0.00027728293,0.000479661,0.00880498,0.018339584,0.3197354,0.0000148283725,0.0001270707,0.0143774655],"study_design_scores_gemma":[0.011271592,0.004274517,0.55732703,0.0070299027,0.001730883,0.0001465627,0.0013045814,0.031888563,0.38448605,0.000027164031,0.00015470838,0.0003584665],"about_ca_topic_score_codex":0.000016350132,"about_ca_topic_score_gemma":7.2431783e-7,"teacher_disagreement_score":0.07796777,"about_ca_system_score_codex":0.000068567955,"about_ca_system_score_gemma":0.00013096728,"threshold_uncertainty_score":0.2538938},"labels":[],"label_agreement":null},{"id":"W3090996781","doi":"10.32388/xuinec","title":"National Cancer Institute of Canada","year":2020,"lang":"en","type":"article","venue":"Definitions","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Geography","score_opus":0.07323519649305321,"score_gpt":0.3285017538084827,"score_spread":0.25526655731542947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090996781","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19993684,0.0008244153,0.0005812498,0.12458909,0.000769957,0.0005055905,0.003114979,0.00008099908,0.6695969],"genre_scores_gemma":[0.9948588,0.000035025572,0.00066968915,0.003939102,0.000087254695,0.00004055253,0.0001468851,0.0000040057694,0.00021870226],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996664,0.000002185635,0.00008030293,0.000058988244,0.00013911456,0.000053026404],"domain_scores_gemma":[0.99974537,0.000010810619,0.000022299799,0.000032543732,0.00011742728,0.00007157771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000063794605,0.000033290613,0.00006705113,0.000014605812,0.000044973338,0.0000017463071,0.000015213083,0.0000106970765,0.00031859014],"category_scores_gemma":[0.00004022011,0.000029618588,0.000021568263,0.000115775176,0.000020604859,0.000029059245,0.0000046710857,0.00003119489,0.0000056173603],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097397926,0.00043253775,0.026332188,0.00028929656,0.0011492723,0.00010074823,0.0019251757,0.0019414455,0.0023627323,0.38852566,0.573903,0.0029404988],"study_design_scores_gemma":[0.0041648657,0.00021286975,0.120171785,0.00016319231,0.0006807269,0.00003426235,0.00039554323,0.0006075615,0.003057594,0.0034021975,0.86685944,0.00024997114],"about_ca_topic_score_codex":0.05874413,"about_ca_topic_score_gemma":0.11414661,"teacher_disagreement_score":0.79492193,"about_ca_system_score_codex":0.00009362275,"about_ca_system_score_gemma":0.0023247637,"threshold_uncertainty_score":0.9475238},"labels":[],"label_agreement":null},{"id":"W3091793382","doi":"10.1158/1078-0432.ccr-20-1835","title":"Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Microsemi (Canada)","funders":"Genentech","keywords":"KRAS; Adenocarcinoma; Cancer research; Biology; Druggability; Phenotype; Lung cancer; Population; Cancer; Medicine; Oncology; Genetics; Gene; Colorectal cancer","score_opus":0.20612529336943977,"score_gpt":0.5282688890374881,"score_spread":0.3221435956680484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091793382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96910536,0.0036915422,0.00005428901,0.025776079,0.000105919666,0.00083532656,0.000083924584,0.000026559908,0.00032100698],"genre_scores_gemma":[0.9961671,0.00029448405,0.00026408274,0.002288825,0.00043320525,0.00033510147,0.00003114023,0.000019633837,0.00016640621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790823,0.00028159385,0.0004540241,0.00052425225,0.00050023274,0.00033164897],"domain_scores_gemma":[0.9987421,0.00036109446,0.000028249675,0.00016512717,0.00024009407,0.0004633561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008765127,0.00010888887,0.00030605705,0.00012756836,0.00011895922,0.00004651983,0.000056852285,0.000074481955,0.00025883268],"category_scores_gemma":[0.00056493276,0.00009378224,0.00008769914,0.00040647903,0.00024681818,0.0001080333,0.00006637095,0.00054143585,0.00003141708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021992687,0.0003103355,0.9822314,0.00044980284,0.00012787129,0.00025002286,0.0022380087,0.000027702423,0.0031091343,0.00064744835,0.005726699,0.0026823487],"study_design_scores_gemma":[0.0028236855,0.00087990286,0.9897864,0.00018635401,0.00006313458,0.000009447502,0.0005410043,0.00022567005,0.0016451838,0.00037852742,0.0033500153,0.00011066973],"about_ca_topic_score_codex":0.0007956088,"about_ca_topic_score_gemma":0.0012048006,"teacher_disagreement_score":0.02706177,"about_ca_system_score_codex":0.000250173,"about_ca_system_score_gemma":0.00046373258,"threshold_uncertainty_score":0.38243288},"labels":[],"label_agreement":null},{"id":"W3091837880","doi":"10.1016/j.jtcvs.2020.09.120","title":"Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase–rearranged lung adenocarcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic and Cardiovascular Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Ono Pharmaceutical; Astellas Pharma; F. Hoffmann-La Roche; AstraZeneca; Taiho Pharmaceutical; Novartis; Chugai Pharmaceutical; Pfizer","keywords":"Anaplastic lymphoma kinase; Medicine; Lung cancer; Crizotinib; Hazard ratio; Adenocarcinoma; Internal medicine; ROS1; Oncology; Log-rank test; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer; Cancer research; Gastroenterology; Survival analysis; Confidence interval","score_opus":0.017764193328865863,"score_gpt":0.2977801466460907,"score_spread":0.28001595331722484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091837880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96739876,0.030926723,0.001030975,0.00020255039,0.000105462,0.00021194729,0.00004672037,0.000010756979,0.00006612182],"genre_scores_gemma":[0.9980993,0.0014226411,0.00014023116,0.0000397134,0.00024138817,0.00000465942,0.000021244894,0.000022598524,0.000008210475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850374,0.00017234651,0.00050536316,0.00019031715,0.0004435545,0.00018470032],"domain_scores_gemma":[0.9983988,0.00039940086,0.00028612232,0.00015334687,0.00039381208,0.00036855068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047818432,0.00017909976,0.0010466244,0.00014529492,0.00006491097,0.000029335148,0.0000400803,0.00007628178,0.000016161994],"category_scores_gemma":[0.00077093375,0.00012658001,0.0007561911,0.00026911622,0.00010357142,0.00011701108,0.000030378129,0.00013594796,4.1835705e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027241362,0.00015375149,0.86140573,0.0007937656,0.007852512,0.0023415748,0.00067772955,0.000013617982,0.00030495567,0.0000032161136,0.0002857498,0.12344327],"study_design_scores_gemma":[0.0009544425,0.00053052645,0.99130887,0.00043408998,0.0044852165,0.0013352936,0.00018158382,0.00020406868,0.00015571364,0.000007045492,0.0002813853,0.000121749086],"about_ca_topic_score_codex":0.000021849297,"about_ca_topic_score_gemma":6.158799e-7,"teacher_disagreement_score":0.12990317,"about_ca_system_score_codex":0.000063010804,"about_ca_system_score_gemma":0.0003469508,"threshold_uncertainty_score":0.5161783},"labels":[],"label_agreement":null},{"id":"W3093030175","doi":"10.1016/j.cllc.2020.09.013","title":"A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; National Institutes of Health; Clovis Oncology; Exelixis; Eli Lilly and Company; AstraZeneca; Shire; F. Hoffmann-La Roche; Takeda Pharmaceuticals U.S.A.; Neos Therapeutics; Foundation for the National Institutes of Health; Spectrum Pharmaceuticals; Novartis; National Cancer Institute; AbbVie; Merck; University of Colorado; Boehringer Ingelheim","keywords":"Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Oncology; Lung; Gastroenterology","score_opus":0.03232496123790799,"score_gpt":0.4204253364912456,"score_spread":0.38810037525333757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093030175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98730975,0.0022351933,0.000028669125,0.0005911804,0.0007892858,0.00805016,0.0006994648,0.00007534114,0.00022094302],"genre_scores_gemma":[0.9963714,0.00012731907,0.00007833023,0.00081374304,0.000359837,0.0013016864,0.00013536101,0.00009758574,0.0007147539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956341,0.00032097963,0.0014902551,0.0011573345,0.00082101685,0.00057633006],"domain_scores_gemma":[0.9973465,0.00037941913,0.0006283502,0.00057365466,0.0005320462,0.000539988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029358693,0.0005252517,0.0013443856,0.00015297373,0.0001817042,0.000029394258,0.00025286287,0.0001590327,0.00061382796],"category_scores_gemma":[0.00020105684,0.00036956504,0.00019869296,0.0007979174,0.00013782523,0.00017828422,0.00018770686,0.00073754945,0.000005739684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017271515,0.044330478,0.9134901,0.000503256,0.001190462,0.00017771019,0.010145084,0.00023867749,0.0000141300525,0.0000022930706,0.0058358735,0.006800402],"study_design_scores_gemma":[0.18385772,0.10622749,0.6924773,0.0009244016,0.007132109,6.107192e-7,0.004307491,0.002456891,0.00021761666,0.0000010009494,0.0015415892,0.0008557735],"about_ca_topic_score_codex":0.0014843275,"about_ca_topic_score_gemma":0.0025555259,"teacher_disagreement_score":0.22101282,"about_ca_system_score_codex":0.0009833346,"about_ca_system_score_gemma":0.0014263731,"threshold_uncertainty_score":0.9998756},"labels":[],"label_agreement":null},{"id":"W3093890556","doi":"10.1016/j.lungcan.2020.10.008","title":"Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Associazione Italiana per la Ricerca sul Cancro; MedImmune; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Eisai; Seattle Genetics; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Novartis; Ipsen; British Mycological Society; Daiichi-Sankyo; United Therapeutics Corporation; MSD Life Science Foundation, Public Interest Incorporated Foundation; Bayer; Celgene; AstraZeneca; Roche; Astellas Pharma US; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Clinical endpoint; Chemotherapy; Immunotherapy; Retrospective cohort study; Confidence interval; Gemcitabine; Hazard ratio; Cancer; Clinical trial","score_opus":0.007440933025061391,"score_gpt":0.3071473753137865,"score_spread":0.2997064422887251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093890556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867907,0.0037216893,0.000042863216,0.003988696,0.00043246182,0.0041674767,0.00009353767,0.000045342047,0.0007172263],"genre_scores_gemma":[0.98904914,0.00053247553,0.000081766055,0.0071524023,0.00030339477,0.0019974695,0.000013512653,0.00006736803,0.0008024879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984388,0.00005917315,0.00032334382,0.0005034401,0.00031369377,0.0003615734],"domain_scores_gemma":[0.9992293,0.000027432727,0.00012978156,0.00032445867,0.00016802823,0.00012096466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007707952,0.00028096457,0.00038388622,0.00005152036,0.00011452938,0.000043232998,0.00015444122,0.00008848199,0.00081036496],"category_scores_gemma":[0.000009305838,0.00018890334,0.00012337974,0.00033621376,0.000045119818,0.00010528935,0.00004493342,0.00038638926,0.000007821972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001095517,0.0010594643,0.96449727,0.000105808846,0.00054484134,0.000018032622,0.029253747,0.000030705658,0.00022687532,0.0000010495821,0.0012662577,0.0019004293],"study_design_scores_gemma":[0.013490081,0.00034288265,0.9813786,0.00014323245,0.0004506616,1.5395105e-7,0.0005607091,0.0015823324,0.00042038204,0.0000020309571,0.0014247717,0.0002041239],"about_ca_topic_score_codex":0.0032499097,"about_ca_topic_score_gemma":0.001738284,"teacher_disagreement_score":0.028693037,"about_ca_system_score_codex":0.001121484,"about_ca_system_score_gemma":0.00024248063,"threshold_uncertainty_score":0.8872928},"labels":[],"label_agreement":null},{"id":"W3094041802","doi":"10.1016/j.ijrobp.2020.07.2564","title":"Relating PIK3CA Mutation Status With Clinicopathologic Factors and Outcome in Patients With Cervical Cancer Treated With Primary Surgery With or Without Post-Operative Adjuvant Chemoradiotherapy","year":2020,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Translational Research in Oncology","funders":"","keywords":"Medicine; PTEN; Cervical cancer; Oncology; Internal medicine; Cancer; Chemoradiotherapy; Disease; CISH; PI3K/AKT/mTOR pathway; Gene; Genetics","score_opus":0.02809196796952891,"score_gpt":0.3605440806996842,"score_spread":0.3324521127301553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094041802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958557,0.00016576244,0.0011048552,0.0019652375,0.00011113729,0.000577202,0.00011128274,0.000032435735,0.000076388525],"genre_scores_gemma":[0.99391353,0.00015999927,0.0033495452,0.0018743839,0.00023492215,0.000034601813,0.00037009828,0.000045339944,0.000017560205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828583,0.00016103331,0.00063919974,0.00033286703,0.0003373515,0.00024374106],"domain_scores_gemma":[0.9974066,0.00039915706,0.0009981802,0.000088918605,0.0009094659,0.00019765581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014383784,0.0002961652,0.0009011928,0.00015046219,0.000073412295,0.00003136794,0.000088901164,0.00013639567,0.000040085753],"category_scores_gemma":[0.0000963901,0.00015162988,0.000059229125,0.00028920983,0.00021321379,0.00040551688,0.0000149040425,0.00042620793,0.0000011219871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011400721,0.0004736371,0.9661622,0.000022175349,0.00078586285,0.00016572214,0.0024644893,0.00065433804,0.00009733594,0.000031260286,0.000011983863,0.017730286],"study_design_scores_gemma":[0.01846306,0.009842277,0.96963423,0.00018308648,0.00037590766,0.00010038144,0.00047142818,0.00037379845,0.0001889389,0.00001242102,0.0001426592,0.000211823],"about_ca_topic_score_codex":0.00014209229,"about_ca_topic_score_gemma":0.000114175855,"teacher_disagreement_score":0.017518464,"about_ca_system_score_codex":0.00088983116,"about_ca_system_score_gemma":0.001297372,"threshold_uncertainty_score":0.6183287},"labels":[],"label_agreement":null},{"id":"W3094552190","doi":"10.1016/j.jtho.2020.10.007","title":"Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Merck Sharp and Dohme; Boehringer Ingelheim; Daiichi Sankyo Company; Clovis Oncology; F. Hoffmann-La Roche; Roche; Novartis; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Fluorescence in situ hybridization; Immunohistochemistry; In situ hybridization; In situ; Pathology; Internal medicine; Oncology; Gene; Genetics; Biology; Gene expression","score_opus":0.014438887838654395,"score_gpt":0.41802516681540647,"score_spread":0.4035862789767521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094552190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962497,0.00005983432,0.000089595706,0.002253662,0.00008446862,0.0010557871,0.000015806994,0.000004130517,0.00018703364],"genre_scores_gemma":[0.99833685,0.000010337995,0.00067953154,0.00083505944,0.000038315797,0.000032933964,0.000026838527,0.000012302715,0.00002780984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853826,0.00018795193,0.00055818626,0.00017353051,0.00027261474,0.00026947857],"domain_scores_gemma":[0.999161,0.0001637313,0.00030552276,0.000106303305,0.00012385681,0.00013960466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021190442,0.00014561317,0.0005051739,0.00014181292,0.00003579028,0.00001635152,0.00013029123,0.000049376566,0.0000144000705],"category_scores_gemma":[0.0002819435,0.00008550542,0.00004408253,0.0004105142,0.000026048312,0.00014109172,0.000026047215,0.00029682054,0.0000010215491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021331612,0.004598006,0.91002035,0.000025382533,0.00015564339,0.0012024761,0.015758092,0.0000825186,0.0072268643,2.0526986e-7,0.00018617374,0.039412696],"study_design_scores_gemma":[0.029889343,0.01178579,0.94341433,0.00022249552,0.00034307688,0.000045411314,0.012312234,0.00006553278,0.0016018207,0.0000017898099,0.00016915117,0.00014904642],"about_ca_topic_score_codex":0.00007242043,"about_ca_topic_score_gemma":0.000099179786,"teacher_disagreement_score":0.03926365,"about_ca_system_score_codex":0.00093160133,"about_ca_system_score_gemma":0.0005235555,"threshold_uncertainty_score":0.34868097},"labels":[],"label_agreement":null},{"id":"W3095097088","doi":"10.3747/co.27.5757","title":"Diagnostic Patterns of Non-Small-Cell Lung Cancer at Princess Margaret Cancer Centre","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Adenocarcinoma; Subtyping; Immunohistochemistry; Cancer; Bronchoscopy; Oncology; Biopsy; Internal medicine; Not Otherwise Specified; Pathology; Sampling (signal processing); Radiology","score_opus":0.04700107147173979,"score_gpt":0.4076436924188029,"score_spread":0.3606426209470631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095097088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97825605,0.011150936,0.0002697733,0.006229814,0.001383868,0.0009516481,0.0003479482,0.000035580637,0.0013743779],"genre_scores_gemma":[0.9924998,0.005280622,0.00006954142,0.0006574868,0.00047477643,0.00029830923,0.00014587348,0.000026851889,0.0005467188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989755,0.00003321955,0.00026973613,0.00030882092,0.00014302244,0.000269707],"domain_scores_gemma":[0.9991746,0.00013412806,0.00017206749,0.00015001616,0.00013246869,0.00023670288],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000026413281,0.00016265745,0.00038893265,0.000038880637,0.000049836177,0.000004072291,0.00009885634,0.00007851327,0.0015473265],"category_scores_gemma":[0.000039631963,0.00013318867,0.00009012776,0.00012110452,0.000040583134,0.000029437962,0.000095074494,0.00015564622,0.000019840072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008616277,0.0004518423,0.9557371,0.0010979915,0.00017673637,0.000047529807,0.003035616,0.000064524436,0.00034428126,0.00001436083,0.010153409,0.02879043],"study_design_scores_gemma":[0.009444357,0.0006595142,0.6139062,0.0009841247,0.0027259276,0.0000083998075,0.00054651767,0.001551331,0.0057881637,0.000005313096,0.36403826,0.00034189588],"about_ca_topic_score_codex":0.00042854747,"about_ca_topic_score_gemma":0.0007457651,"teacher_disagreement_score":0.35388485,"about_ca_system_score_codex":0.0006772028,"about_ca_system_score_gemma":0.00059055927,"threshold_uncertainty_score":0.9993654},"labels":[],"label_agreement":null},{"id":"W3096044474","doi":"10.1016/s1470-2045(20)30475-7","title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; AbbVie; Genentech; AstraZeneca; National Cancer Institute; National Institutes of Health; Pfizer; Amgen","keywords":"Biomarker; Medicine; Lung cancer; Oncology; Internal medicine; Clinical trial; Cancer","score_opus":0.06882650635968865,"score_gpt":0.39472622814967956,"score_spread":0.32589972178999094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096044474","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29851422,0.0042591076,0.0058123264,0.21006545,0.001268439,0.44673106,0.0011122625,0.0011441871,0.031092951],"genre_scores_gemma":[0.6396458,0.00018520054,0.0044061355,0.011306386,0.0018084357,0.33727315,0.000284639,0.00019142841,0.0048987875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977799,0.00021187025,0.0004918678,0.00058646273,0.00019376204,0.0007361465],"domain_scores_gemma":[0.998401,0.00029834046,0.00032392464,0.00052596733,0.00020646706,0.00024428556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002086272,0.00040845253,0.0009479783,0.00008507332,0.00024216618,0.000045764795,0.0003665538,0.00024231491,0.00043527514],"category_scores_gemma":[0.000040288192,0.00025511428,0.0002497643,0.00030820785,0.00017539565,0.00007955953,0.00010495818,0.0002468775,0.000046030575],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027323721,0.003169353,0.32342726,0.009141469,0.008710128,0.00052969536,0.0416483,0.00034493319,0.058459934,0.00031885377,0.4540918,0.07283457],"study_design_scores_gemma":[0.05075167,0.0047527784,0.029956473,0.00041937357,0.0038432677,0.00006065499,0.00074705627,0.03057449,0.0024206368,0.0000721294,0.87566537,0.0007360936],"about_ca_topic_score_codex":0.0002728982,"about_ca_topic_score_gemma":0.00026685421,"teacher_disagreement_score":0.42157358,"about_ca_system_score_codex":0.00052731484,"about_ca_system_score_gemma":0.0007171698,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W3096186999","doi":"10.7759/cureus.11224","title":"Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation","year":2020,"lang":"en","type":"article","venue":"Cureus","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; Research Institute in Oncology and Hematology; University of Winnipeg","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; GlaxoSmithKline; Manitoba Medical Service Foundation; Pfizer; AstraZeneca; Horizon 2020 Framework Programme; Eli Lilly and Company","keywords":"Medicine; Anaplastic lymphoma kinase; Nivolumab; Immunotherapy; Lung cancer; Oncology; Mutation; Epidermal growth factor receptor; Cancer research; Internal medicine; Chemotherapy; Targeted therapy; Cancer; Gene","score_opus":0.008914664854851305,"score_gpt":0.27211518262294765,"score_spread":0.26320051776809633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096186999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901252,0.0061350595,0.00013780185,0.0015892927,0.000034185818,0.0005582802,0.000019622874,0.000019402529,0.0013811662],"genre_scores_gemma":[0.9973352,0.00036570025,0.00069173233,0.0012285947,0.00003868029,0.00014256319,0.000030578074,0.000017091657,0.00014988337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956316,0.0000041741223,0.00009793999,0.00015803019,0.00007471357,0.000102005615],"domain_scores_gemma":[0.9997664,0.000010308104,0.0000394619,0.00007538948,0.00003828491,0.000070172944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000009230158,0.000086092485,0.00012422248,0.000021626927,0.000029234194,0.000012040491,0.000019768446,0.00002883923,0.00006952465],"category_scores_gemma":[0.0000023411662,0.000063677864,0.00001661537,0.000106913874,0.0000119417255,0.000049429207,0.0000074689483,0.00005809993,0.0000018495651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002008017,0.0010426871,0.67063254,0.0009748927,0.0009262611,0.0015474131,0.1633707,0.0018089507,0.012371019,0.0001759517,0.0022543662,0.14288719],"study_design_scores_gemma":[0.060748294,0.009319617,0.8581045,0.0019209114,0.0017023735,0.0002531155,0.011342172,0.017870238,0.017644145,0.00016069124,0.019624779,0.0013091263],"about_ca_topic_score_codex":0.00079922593,"about_ca_topic_score_gemma":0.00047958913,"teacher_disagreement_score":0.18747199,"about_ca_system_score_codex":0.00010270837,"about_ca_system_score_gemma":0.00010230091,"threshold_uncertainty_score":0.2596708},"labels":[],"label_agreement":null},{"id":"W3101089668","doi":"10.1056/nejmoa2027187","title":"First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1064,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK; Pfizer","keywords":"Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Cancer research; Medicine; Internal medicine; Oncology","score_opus":0.02574200789427179,"score_gpt":0.36193085816907555,"score_spread":0.3361888502748038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101089668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.606714,0.017571174,0.0037846228,0.36097646,0.0017027074,0.0011370205,0.00004599905,0.000049659,0.008018327],"genre_scores_gemma":[0.9842443,0.0023516344,0.0012951755,0.0064674686,0.0047085173,0.000008022499,0.000016305654,0.000028088758,0.0008804889],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985543,0.00003981164,0.00062582304,0.00017057531,0.0003949944,0.00021450041],"domain_scores_gemma":[0.99865824,0.00023834087,0.0003026045,0.000098925564,0.00021970052,0.00048220585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018818342,0.0001799682,0.00062282494,0.00013204214,0.000043475426,0.0000062132503,0.000086619715,0.000052541174,0.0008370893],"category_scores_gemma":[0.00046792507,0.00010379383,0.00007031879,0.00038378508,0.000052568437,0.00013021388,0.000015349939,0.00037262816,0.0000029654386],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028912676,0.00068249734,0.18198287,0.00077928894,0.0017102639,0.0072496813,0.043726366,0.0065895775,0.004853966,0.00023383391,0.065680616,0.6575984],"study_design_scores_gemma":[0.5287751,0.01937861,0.08511787,0.009748519,0.003743489,0.0020283188,0.0020290418,0.0033610428,0.0020992742,0.00031540258,0.34282365,0.0005797039],"about_ca_topic_score_codex":0.00023742052,"about_ca_topic_score_gemma":0.0003568133,"teacher_disagreement_score":0.65701866,"about_ca_system_score_codex":0.00015651698,"about_ca_system_score_gemma":0.0005429093,"threshold_uncertainty_score":0.9165541},"labels":[],"label_agreement":null},{"id":"W3101235024","doi":"10.1002/ijc.33405","title":"Hormonal factors in association with lung cancer among Asian women: A pooled analysis from the International Lung Cancer Consortium","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"Medical Research Council; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; Ministerio de Economía y Competitividad; National Medical Research Council; National Natural Science Foundation of China; Ministry of Health, Labour and Welfare; National Cancer Center","keywords":"Medicine; Lung cancer; Odds ratio; Menarche; Cancer; Internal medicine; Confidence interval; Adenocarcinoma; Gynecology; Menopause; Oncology; Obstetrics","score_opus":0.008419130887085265,"score_gpt":0.32478648572015434,"score_spread":0.31636735483306905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101235024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453823,0.0031033165,0.000361102,0.04872153,0.0010919712,0.0002492794,0.0005627374,0.000014711018,0.000513044],"genre_scores_gemma":[0.99365336,0.0009296609,0.00007312944,0.0034271455,0.0013607023,0.00013365623,0.00007644408,0.00002471135,0.00032118388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746037,0.000053504613,0.00061660504,0.0002572887,0.0013631992,0.0002490419],"domain_scores_gemma":[0.99767417,0.0001546511,0.00087608333,0.00009996248,0.0009850507,0.00021010278],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016713238,0.00021208725,0.0004534373,0.00026543412,0.00005737892,0.00012496074,0.00039046817,0.00008779985,0.002772043],"category_scores_gemma":[0.00011748706,0.00013563801,0.00024305587,0.00052164844,0.00005284319,0.00037069074,0.000045556553,0.00042911267,0.0000011494697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008067875,0.000098917495,0.95369494,0.000007041929,0.02804185,0.00008662548,0.0066226,0.005058744,0.0004155748,0.000019872423,0.0035469814,0.0016000468],"study_design_scores_gemma":[0.0039643515,0.00007354043,0.9802069,0.00025399047,0.0045722453,0.0000033768872,0.0010866695,0.0050939,0.00051886553,0.000016725468,0.0040518097,0.00015762392],"about_ca_topic_score_codex":0.0057726954,"about_ca_topic_score_gemma":0.0055232025,"teacher_disagreement_score":0.048271056,"about_ca_system_score_codex":0.004198017,"about_ca_system_score_gemma":0.0010914294,"threshold_uncertainty_score":0.99962467},"labels":[],"label_agreement":null},{"id":"W3103025422","doi":"10.1101/2020.11.13.381798","title":"Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada); Western University","funders":"","keywords":"Erlotinib; Lapatinib; Gefitinib; Sunitinib; Sorafenib; Pharmacogenomics; Tyrosine kinase; Tyrosine-kinase inhibitor; Precision medicine; Cancer; Personalized medicine; Drug; Medicine; Pharmacology; Computational biology; Bioinformatics; Biology; Cancer research; Epidermal growth factor receptor; Internal medicine; Breast cancer; Receptor; Genetics; Hepatocellular carcinoma","score_opus":0.015340415652752116,"score_gpt":0.25737560384040004,"score_spread":0.2420351881876479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103025422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98401576,0.0017194247,0.0035389205,0.0012589816,0.0021904442,0.0029567704,0.0038691738,0.0004302036,0.000020309875],"genre_scores_gemma":[0.9814051,0.00010813117,0.016882865,0.0003950319,0.00031751927,0.00072939787,0.0000075316757,0.00014320883,0.0000112475755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969485,0.0001099464,0.000704827,0.0011587528,0.00062751636,0.0004504482],"domain_scores_gemma":[0.9968789,0.000082203704,0.0005628337,0.0011528139,0.0006662637,0.000656964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019796967,0.0006451552,0.0007674597,0.0005290992,0.0001684335,0.00007867845,0.0002608913,0.00050207105,0.000030942447],"category_scores_gemma":[0.00046924496,0.0005583943,0.0003158212,0.0006174883,0.00012734163,0.0001194586,0.00044314883,0.00066546665,0.000012533684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000869529,0.000658501,0.0019273214,0.00039503892,0.0007003347,0.00010258722,0.00013786751,0.00007420635,0.9941193,0.000056928664,0.0009343944,0.000023989793],"study_design_scores_gemma":[0.0014198708,0.000654134,0.03750114,0.0014797043,0.00058964256,5.0830973e-8,0.00005603081,0.00012400665,0.9553571,0.0000019136933,0.0023416362,0.00047477926],"about_ca_topic_score_codex":0.00014369519,"about_ca_topic_score_gemma":0.0000028852871,"teacher_disagreement_score":0.03876221,"about_ca_system_score_codex":0.00060521305,"about_ca_system_score_gemma":0.0017774904,"threshold_uncertainty_score":0.9996868},"labels":[],"label_agreement":null},{"id":"W3107025032","doi":"10.1016/j.annonc.2020.10.394","title":"400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Afatinib; Osimertinib; Medicine; Oncology; Internal medicine; Erlotinib; Cancer; Epidermal growth factor receptor","score_opus":0.09305412879444001,"score_gpt":0.4502128618058295,"score_spread":0.35715873301138945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107025032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622435,0.000048649126,0.000008788075,0.006808915,0.000026557533,0.00071942975,0.000053210704,0.000004454216,0.0061056633],"genre_scores_gemma":[0.9985342,0.000041059713,0.00008295981,0.0010993656,0.000023004075,0.00004008418,0.00014885346,0.000006198066,0.000024248819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877465,0.00024276394,0.00045669702,0.00020467328,0.00018318115,0.00013800767],"domain_scores_gemma":[0.9992952,0.00015598966,0.00023101353,0.000110745495,0.00015483203,0.000052247793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021967864,0.000096859345,0.00046374174,0.0003364688,0.000024936098,0.0000043004084,0.00006211126,0.000048830465,0.000039332128],"category_scores_gemma":[0.00009637462,0.00007199694,0.00007691214,0.0010113925,0.00007496937,0.000057736586,0.000023306317,0.00010839079,0.000001076699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011069168,0.0027555216,0.9171501,0.000029414032,0.0013027091,0.00012153343,0.042564373,0.00012544236,0.000118416625,0.0001711573,0.00024118435,0.034313228],"study_design_scores_gemma":[0.0039378665,0.005067627,0.9853041,0.000025967593,0.0011686629,0.0000010364113,0.0038317402,0.00023546493,0.00020521197,0.000036998656,0.00013239023,0.000052919724],"about_ca_topic_score_codex":0.003133098,"about_ca_topic_score_gemma":0.0064555644,"teacher_disagreement_score":0.06815401,"about_ca_system_score_codex":0.00004904197,"about_ca_system_score_gemma":0.00015382355,"threshold_uncertainty_score":0.47363278},"labels":[],"label_agreement":null},{"id":"W3107432893","doi":"10.1002/1878-0261.12861","title":"Multiplex RNA‐based detection of clinically relevant <i>MET</i> alterations in advanced non‐small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eurostars; Instituto de Salud Carlos III; European Commission; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Oncolytics Biotech; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lung cancer; Multiplex; Medicine; Cancer research; RNA; Biology; Pathology; Bioinformatics; Gene; Genetics","score_opus":0.016278006275390916,"score_gpt":0.36432277458535794,"score_spread":0.348044768309967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107432893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95085204,0.00054358266,0.04206834,0.0032766343,0.00018351263,0.0009966192,0.000023611437,0.00003279485,0.0020228827],"genre_scores_gemma":[0.9825559,0.00006653877,0.013022958,0.0039195926,0.00004749924,0.00026118028,0.000038015587,0.000023350964,0.00006492193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886256,0.000076832606,0.00048699745,0.00028707113,0.00010621261,0.00018032413],"domain_scores_gemma":[0.9993128,0.00008875922,0.00017791652,0.00016926647,0.00012316719,0.00012808327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080173595,0.000121106044,0.00034427326,0.00007879718,0.000032922362,0.0000039568395,0.00005879778,0.00012025223,0.000043183554],"category_scores_gemma":[0.00012426771,0.000113034876,0.000109297696,0.00025565486,0.0000395761,0.000028408778,0.000020694857,0.00018815536,0.0000060578313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053475506,0.00045512404,0.008979667,0.0001248478,0.000081652426,0.00018597419,0.00090382586,0.008228488,0.9634435,0.0000106157895,0.00005021757,0.01700134],"study_design_scores_gemma":[0.024980014,0.0065454906,0.01416937,0.00021394897,0.0011407423,0.000012211502,0.00037513833,0.05831121,0.88235325,0.000028219447,0.011519526,0.00035086172],"about_ca_topic_score_codex":0.00023475356,"about_ca_topic_score_gemma":0.00031217432,"teacher_disagreement_score":0.08109023,"about_ca_system_score_codex":0.00024833303,"about_ca_system_score_gemma":0.00066128717,"threshold_uncertainty_score":0.46094283},"labels":[],"label_agreement":null},{"id":"W3108642522","doi":"10.1016/j.lungcan.2020.11.015","title":"A reply to “Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model”","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Saskatchewan Cancer Agency; Mount Sinai Hospital; McMaster University; Alberta Cancer Foundation; William Osler Health System; AstraZeneca (Canada)","funders":"AstraZeneca Canada","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.024112624666970464,"score_gpt":0.3370667255501405,"score_spread":0.31295410088317005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108642522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.526874,0.013362877,0.0020654963,0.4417519,0.00088044116,0.007681878,0.0059005907,0.00011259037,0.0013702203],"genre_scores_gemma":[0.73343664,0.0034409086,0.0036722443,0.22852558,0.0033803496,0.005200163,0.004596149,0.00029133688,0.01745662],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99764794,0.00007865847,0.00071228156,0.0008303256,0.00033601117,0.00039477393],"domain_scores_gemma":[0.99850535,0.00019804892,0.00043681238,0.00054075825,0.00017883074,0.0001402071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010797695,0.00046114114,0.0006309439,0.00018437872,0.00010839388,0.000042378928,0.00016084405,0.00025207648,0.000082250175],"category_scores_gemma":[0.000057093825,0.00030666933,0.00015650882,0.0004517896,0.00004115574,0.000105781626,0.00006593382,0.00047172603,0.000004721686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017616579,0.00011927392,0.07097944,0.0003700995,0.0013311248,0.00010905654,0.021695856,0.017945819,0.0012283083,9.4695747e-7,0.8821323,0.0023261448],"study_design_scores_gemma":[0.047064282,0.003371051,0.4555808,0.020600447,0.016133929,0.000028340108,0.0010464718,0.22007743,0.009154912,0.00024412428,0.22256534,0.004132859],"about_ca_topic_score_codex":0.06714196,"about_ca_topic_score_gemma":0.0019905732,"teacher_disagreement_score":0.65956694,"about_ca_system_score_codex":0.0062622502,"about_ca_system_score_gemma":0.0034169767,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W3109841362","doi":"10.1016/j.cllc.2020.11.005","title":"Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Chronic Disease Prevention and Health Promotion; Eurostars; University of California, San Francisco; Centers for Disease Control and Prevention; Comprehensive Cancer Center, University of California, Davis; Foundation Medicine; University of California; Cancer Registry of Greater California; University of Southern California; National Cancer Institute; Illinois Department of Public Health; Tempus; California Department of Public Health; Public Health Institute; Merck; Research and Development Corporation of Newfoundland and Labrador; Pfizer; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Race (biology); Ethnic group; Histology; Oncology; Internal medicine; Gerontology; Demography","score_opus":0.06266566209702124,"score_gpt":0.4391715871590069,"score_spread":0.37650592506198566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109841362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8430796,0.12977058,0.00014818874,0.019852214,0.0011767172,0.0011102569,0.0028270367,0.00008712326,0.001948232],"genre_scores_gemma":[0.9764524,0.018040786,0.00022722578,0.0029659949,0.00025785938,0.00050254643,0.00020656531,0.000052216175,0.0012943873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770755,0.00019572658,0.00087230565,0.0006006663,0.00027032942,0.00035341177],"domain_scores_gemma":[0.9984812,0.00052919384,0.0002744288,0.00024961718,0.00006618998,0.00039933517],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028214324,0.0002560462,0.0010047104,0.00008283073,0.000065072374,0.0000091183465,0.00011655037,0.00015698707,0.0016645011],"category_scores_gemma":[0.00017932155,0.00021014536,0.00019572431,0.00030764184,0.00031935988,0.000059476348,0.00012049244,0.00035167462,0.0000063790235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038541318,0.00030917508,0.84915155,0.000413485,0.0007598978,0.00008093506,0.00052767247,0.000046098954,0.00014018762,0.00003379657,0.13721822,0.010933587],"study_design_scores_gemma":[0.017209388,0.00076955266,0.82513887,0.0004802071,0.0063463952,0.000011157411,0.00016237937,0.005276512,0.00037308256,0.000053123138,0.14350596,0.00067340035],"about_ca_topic_score_codex":0.0024340781,"about_ca_topic_score_gemma":0.0036827212,"teacher_disagreement_score":0.13337277,"about_ca_system_score_codex":0.0005032038,"about_ca_system_score_gemma":0.00029333393,"threshold_uncertainty_score":0.9992481},"labels":[],"label_agreement":null},{"id":"W3110320999","doi":"10.3390/curroncol28010008","title":"Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Cohort; Internal medicine; Lung cancer; Population; Oncology; Cancer; Anaplastic lymphoma kinase","score_opus":0.05201036351907983,"score_gpt":0.40127606278073497,"score_spread":0.3492656992616551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110320999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738096,0.023112634,0.0002529598,0.00047579213,0.00055148656,0.000741125,0.000036098823,0.000015123262,0.0010051527],"genre_scores_gemma":[0.9970844,0.00234136,0.00015478766,0.00002294526,0.00010669908,0.00018529965,0.000024702209,0.000009668674,0.00007016079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993223,0.000031140855,0.00023156221,0.00020927271,0.000062424755,0.00014329967],"domain_scores_gemma":[0.99963474,0.000032890162,0.00009582317,0.00008090017,0.000054552478,0.00010107688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000033057062,0.00010633311,0.000345175,0.00005478038,0.000019438763,0.0000018152801,0.000026593982,0.000052954958,0.000022978875],"category_scores_gemma":[0.000010491717,0.00008525327,0.000040641604,0.00012571657,0.000027915066,0.000025783354,0.000015703634,0.00006942258,0.0000025711724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003122476,0.0007670918,0.9065812,0.0008856244,0.00010201192,0.0000252213,0.006107108,0.000278835,0.006664194,0.00010652511,0.00015534446,0.07801458],"study_design_scores_gemma":[0.041735873,0.006207457,0.89585185,0.0013757959,0.0022076387,0.00003734979,0.0069414508,0.01143549,0.0022076243,0.000029783847,0.03155673,0.00041297553],"about_ca_topic_score_codex":0.0002035132,"about_ca_topic_score_gemma":0.00019172038,"teacher_disagreement_score":0.077601604,"about_ca_system_score_codex":0.0010221617,"about_ca_system_score_gemma":0.0005614219,"threshold_uncertainty_score":0.34765273},"labels":[],"label_agreement":null},{"id":"W3111583901","doi":"10.1016/j.jtho.2020.11.013","title":"Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Boehringer Ingelheim; Takeda Oncology; National Cancer Institute; AbbVie Canada; National Institutes of Health; Cancer Center, University of Colorado; AbbVie","keywords":"Medicine; Observational study; Pulmonary function testing; Internal medicine","score_opus":0.09547113000828117,"score_gpt":0.4437106657822433,"score_spread":0.3482395357739621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111583901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672193,0.00011594646,0.0003457393,0.010503657,0.00018880701,0.00053639687,0.000008362969,0.000021589962,0.0015575481],"genre_scores_gemma":[0.99721557,0.000007696372,0.0007510969,0.0012735364,0.00052008807,0.000025458057,0.000029619403,0.000014728336,0.00016220941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901444,0.00013020688,0.00031130423,0.00012946386,0.00030431408,0.00011029983],"domain_scores_gemma":[0.99847156,0.00011345592,0.00058848027,0.0000535623,0.000659201,0.000113770686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002822741,0.00009562024,0.00032385124,0.00008184238,0.00008578979,0.000013770904,0.000038055157,0.000069782065,0.000050103834],"category_scores_gemma":[0.00023299294,0.00006915326,0.00004753031,0.00030281578,0.000026642192,0.00017969777,0.000011561768,0.0002609768,0.0000040430273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005503433,0.0018511066,0.9512306,0.00004221581,0.0015856369,0.0007227728,0.007829888,0.0001111582,0.0016477534,0.000044938475,0.00044921628,0.028981306],"study_design_scores_gemma":[0.0016829686,0.015051586,0.9786406,0.000116827745,0.0013772635,0.00012895699,0.0020101187,0.000104336876,0.00012861342,0.00013090105,0.000560275,0.000067544526],"about_ca_topic_score_codex":0.000010744892,"about_ca_topic_score_gemma":0.000028908082,"teacher_disagreement_score":0.02891376,"about_ca_system_score_codex":0.000437946,"about_ca_system_score_gemma":0.00049349444,"threshold_uncertainty_score":0.2819988},"labels":[],"label_agreement":null},{"id":"W3111766098","doi":"10.7150/jca.49391","title":"Genomic and clinical characteristics of <i>MET</i> exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib","year":2020,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China","keywords":"Crizotinib; Mechanism (biology); Cohort; Medicine; Cancer; Oncology; Cancer research; Internal medicine; Bioinformatics; Genetics; Biology; Lung cancer","score_opus":0.017153625379951604,"score_gpt":0.36380017035209483,"score_spread":0.3466465449721432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111766098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506295,0.0013712568,0.0006401665,0.0012250708,0.0001899132,0.0005024059,0.00096991484,0.000002109402,0.000036218542],"genre_scores_gemma":[0.9962144,0.0011494615,0.0017315621,0.0005129012,0.00023280917,0.00003557467,0.000017244553,0.000014822312,0.000091222515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886054,0.000021792952,0.0007154126,0.000136043,0.00015834461,0.00010786891],"domain_scores_gemma":[0.99864024,0.00010931035,0.00063691486,0.00006789207,0.0004244727,0.000121180885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015562783,0.000106224594,0.00055444136,0.000055718545,0.000032391436,0.000008215938,0.0000424097,0.00005152572,0.000013446092],"category_scores_gemma":[0.0002831124,0.000077198354,0.000088536064,0.000099278346,0.000044118362,0.00006579659,0.000018402656,0.0001322743,3.278966e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013565148,0.0002973676,0.99319357,0.00030851067,0.0003536212,0.000003936339,0.0006959376,0.0000011659897,0.0025778145,0.00024469523,0.00028856818,0.0006783147],"study_design_scores_gemma":[0.006962624,0.00056108733,0.9907299,0.0003702157,0.00059488235,0.000003953581,0.000035498273,0.000063016756,0.00014130585,0.00012586484,0.00034790678,0.00006370592],"about_ca_topic_score_codex":0.00005301697,"about_ca_topic_score_gemma":0.0005156676,"teacher_disagreement_score":0.0056061093,"about_ca_system_score_codex":0.0000707178,"about_ca_system_score_gemma":0.0002718468,"threshold_uncertainty_score":0.31480575},"labels":[],"label_agreement":null},{"id":"W3112394590","doi":"10.1002/mco2.46","title":"Pathway‐extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors","year":2020,"lang":"en","type":"article","venue":"MedComm","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada); London Health Sciences Centre; Western University","funders":"Compute Canada","keywords":"Erlotinib; Lapatinib; Sunitinib; Gefitinib; Sorafenib; Pharmacogenomics; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer; Precision medicine; Drug; Personalized medicine; Medicine; Computational biology; Pharmacology; Bioinformatics; Biology; Cancer research; Epidermal growth factor receptor; Internal medicine; Breast cancer; Receptor; Hepatocellular carcinoma","score_opus":0.018371061547999116,"score_gpt":0.28702201195815136,"score_spread":0.26865095041015224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112394590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986315,0.00075542624,0.0024168245,0.007264589,0.00055426307,0.0011533855,0.000630594,0.00013501669,0.00077487325],"genre_scores_gemma":[0.99336195,0.000019353241,0.0049778074,0.0011207986,0.00010003736,0.00013546507,0.00010176287,0.00002700431,0.00015580749],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889535,0.000047148587,0.00027503227,0.0002985169,0.0002962039,0.00018776076],"domain_scores_gemma":[0.9991085,0.0000682747,0.00011382443,0.00027584843,0.00011827261,0.00031526762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006327614,0.00017560332,0.0002520225,0.00013318742,0.00009051293,0.000012939841,0.00007944568,0.00008234726,0.000059988033],"category_scores_gemma":[0.00022491468,0.00012572562,0.000116223695,0.00027971403,0.00005374882,0.000072413066,0.000073710326,0.00014173955,0.000007986257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001303901,0.00048028407,0.0022167815,0.00006223916,0.00021640839,0.00003584374,0.004218131,0.00004846037,0.9725474,0.00003332501,0.006126004,0.012711227],"study_design_scores_gemma":[0.0019016755,0.001542986,0.008617595,0.0002435755,0.00018886573,0.0000055407463,0.0017975796,0.00019060046,0.9741647,0.000018960556,0.011183703,0.00014419518],"about_ca_topic_score_codex":0.00010024481,"about_ca_topic_score_gemma":0.000010073572,"teacher_disagreement_score":0.012567032,"about_ca_system_score_codex":0.000111170986,"about_ca_system_score_gemma":0.0002053142,"threshold_uncertainty_score":0.5126942},"labels":[],"label_agreement":null},{"id":"W3112691602","doi":"10.1111/cts.12943","title":"Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT‐1: Influence on <sup>18</sup>F‐FDG PET Uptake","year":2020,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Alberta Cancer Foundation","keywords":"Glucose uptake; Glucose transporter; Tyrosine kinase; Gefitinib; Chemistry; Medicine; Pharmacology; Cancer research; Internal medicine; Cancer; Insulin; Receptor","score_opus":0.05706567021462722,"score_gpt":0.38976688666796533,"score_spread":0.3327012164533381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112691602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828215,0.00006942631,0.000064740634,0.01534016,0.00012132216,0.0004438682,0.00023140067,0.000052825166,0.00085472135],"genre_scores_gemma":[0.9936812,0.000032827622,0.0011043905,0.0046256045,0.00031584126,0.000020609481,0.0000902869,0.000012440935,0.000116799114],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99783856,0.000032127384,0.0004796251,0.0007316294,0.0006247109,0.0002933229],"domain_scores_gemma":[0.9986456,0.00015204366,0.000063684114,0.00017105117,0.000119069344,0.0008485222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003644406,0.00018300432,0.0002498493,0.00008833524,0.00037601803,0.000077065335,0.00013709397,0.00005902208,0.0001178968],"category_scores_gemma":[0.00033197552,0.00014361592,0.00008097825,0.0006714914,0.0004650132,0.00031087038,0.000021915266,0.00023804071,0.000090952075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006889586,0.0057813697,0.3580146,0.00017239369,0.00023831165,0.0004409056,0.010623108,0.014392199,0.120416455,0.011801734,0.0069597764,0.46426955],"study_design_scores_gemma":[0.006154513,0.005240405,0.9346765,0.00031825138,0.00020763827,0.000024287143,0.00019019045,0.006833383,0.0044948873,0.00042265982,0.04089285,0.000544379],"about_ca_topic_score_codex":0.000028648727,"about_ca_topic_score_gemma":0.000007949215,"teacher_disagreement_score":0.57666194,"about_ca_system_score_codex":0.00003226304,"about_ca_system_score_gemma":0.00031759034,"threshold_uncertainty_score":0.5856488},"labels":[],"label_agreement":null},{"id":"W3112920278","doi":"","title":"Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Osimertinib; Lung cancer; Gefitinib; Medicine; Cancer research; In silico; Oncology; Mutation; Epidermal growth factor receptor; Cancer; Internal medicine; Biology; Erlotinib; Gene; Genetics","score_opus":0.023063001719618104,"score_gpt":0.29658115636865967,"score_spread":0.27351815464904156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112920278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98029757,0.0029375702,0.0007377437,0.012697028,0.0001383631,0.0022507985,0.0001338883,0.000033004744,0.0007740189],"genre_scores_gemma":[0.9958819,0.00008332165,0.0008307818,0.001337307,0.00003443972,0.0015319377,0.00003419389,0.000017342141,0.00024873405],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99896455,0.00002197954,0.0003019812,0.0002900823,0.00017425611,0.0002471317],"domain_scores_gemma":[0.99951035,0.000036097023,0.000070363196,0.00011552328,0.000057662142,0.00020999016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057170597,0.00012334128,0.0002655562,0.00008914205,0.000030908068,0.000010984588,0.000054123117,0.000041845407,0.000016837017],"category_scores_gemma":[0.00005336267,0.00011137749,0.000035332585,0.00040688523,0.00002526927,0.00008273947,0.000024758263,0.00006692341,8.287818e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027091745,0.0017560563,0.22418547,0.007139559,0.0021892213,0.0007802853,0.11227574,0.13389993,0.015586943,0.015643114,0.011895624,0.44755632],"study_design_scores_gemma":[0.042174693,0.00095853274,0.74198836,0.0022367835,0.0022656615,0.00003777485,0.0056733824,0.084376834,0.100949116,0.0101559535,0.0070326193,0.0021502825],"about_ca_topic_score_codex":0.00026688326,"about_ca_topic_score_gemma":0.00049640314,"teacher_disagreement_score":0.5178029,"about_ca_system_score_codex":0.00016338399,"about_ca_system_score_gemma":0.00010052674,"threshold_uncertainty_score":0.45418423},"labels":[],"label_agreement":null},{"id":"W3113469765","doi":"10.3747/co.27.5995","title":"Comprehensive Genomic Profiling for Non-Small-Cell Lung Cancer: Health and Budget Impact","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; Roche (Canada); William Osler Health System; Vancouver Coastal Health","funders":"","keywords":"Medicine; Hotspot (geology); Turnaround time; Oncology; Bioinformatics; Internal medicine; Operations management","score_opus":0.08430206606633102,"score_gpt":0.46455192016932384,"score_spread":0.38024985410299283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113469765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95354605,0.03433804,0.0011320986,0.0075959945,0.0005893073,0.0023135676,0.00019219569,0.000040016115,0.00025273248],"genre_scores_gemma":[0.9860508,0.004810287,0.003490315,0.003652698,0.0008351475,0.00058348937,0.00046473937,0.000042113206,0.00007045424],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99922806,0.000023063178,0.00019305656,0.000257142,0.000046139157,0.00025253344],"domain_scores_gemma":[0.99930686,0.000064298685,0.00011119182,0.00007926438,0.00009390217,0.00034449875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030471043,0.00012877776,0.00036807833,0.00003716309,0.000094152674,0.000007910495,0.000037340687,0.000045824658,0.000020929678],"category_scores_gemma":[0.000011593455,0.00010308172,0.00007252865,0.000066920475,0.000033309403,0.000022557631,0.000030161382,0.00012408406,0.0000038208264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015281392,0.0011512345,0.6196828,0.0075734565,0.0010184197,0.0000289953,0.022779785,0.00021815822,0.008050026,0.00014765987,0.058520053,0.2793013],"study_design_scores_gemma":[0.04124406,0.01633849,0.07535321,0.0005037105,0.0021264667,0.00008223795,0.0043031215,0.044426575,0.0018290081,0.00008628583,0.8129702,0.00073662825],"about_ca_topic_score_codex":0.00006755398,"about_ca_topic_score_gemma":0.000009687371,"teacher_disagreement_score":0.75445014,"about_ca_system_score_codex":0.0005437483,"about_ca_system_score_gemma":0.0015493773,"threshold_uncertainty_score":0.42035505},"labels":[],"label_agreement":null},{"id":"W3113726648","doi":"10.3747/co.27.7297","title":"Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC; BC Cancer Agency; Princess Margaret Cancer Centre; University of Manitoba; University Health Network; CancerCare Manitoba; Ottawa Hospital; Research Institute in Oncology and Hematology; University of Ottawa; Université Laval; BC Cancer Foundation; William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Biomarker; Lung cancer; Computational biology; Bioinformatics; Oncology; Cancer research; Biology; Genetics","score_opus":0.1711745368744772,"score_gpt":0.49338204193953483,"score_spread":0.32220750506505763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113726648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9256135,0.005348913,0.009722419,0.05005732,0.001549834,0.003963124,0.00037381478,0.00018125937,0.0031897754],"genre_scores_gemma":[0.9033092,0.0006456372,0.08925553,0.0030574577,0.0004390611,0.002136772,0.000546999,0.000091728856,0.00051761966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989398,0.000031936812,0.0002958932,0.0003893948,0.000060933813,0.00028201277],"domain_scores_gemma":[0.99891657,0.000315373,0.00011985046,0.00010800145,0.00023659885,0.00030361238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006609973,0.0001712542,0.0003305604,0.00009107146,0.00017003385,0.000020887488,0.000049558297,0.00006464245,0.000057634494],"category_scores_gemma":[0.00018313997,0.00015540888,0.000055803783,0.0002869017,0.000038292535,0.000038216713,0.000049929607,0.000113001704,0.000007426625],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008885658,0.0007953322,0.04814464,0.0011737945,0.00048819336,0.000056133096,0.0070056077,0.0005078757,0.057896957,0.000030502206,0.062082853,0.8209295],"study_design_scores_gemma":[0.06974212,0.0065989792,0.06627272,0.00232714,0.0094961915,0.00018660547,0.007921224,0.132419,0.013301277,0.000105587154,0.68984526,0.0017838671],"about_ca_topic_score_codex":0.000048431662,"about_ca_topic_score_gemma":0.00002607347,"teacher_disagreement_score":0.8191457,"about_ca_system_score_codex":0.00035454606,"about_ca_system_score_gemma":0.00037807328,"threshold_uncertainty_score":0.63373905},"labels":[],"label_agreement":null},{"id":"W3114402729","doi":"10.3747/co.27.6563","title":"Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Crizotinib; Medicine; Alectinib; Lung cancer; Internal medicine; Population; Oncology; Cohort; Prospective cohort study; Disease; Confidence interval; Ceritinib; Anaplastic lymphoma kinase","score_opus":0.03760398932381553,"score_gpt":0.40479088812428576,"score_spread":0.36718689880047023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114402729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048847,0.0024995196,0.000029826091,0.0033155417,0.0001273211,0.0019868552,0.00014212514,0.00006740601,0.0013429408],"genre_scores_gemma":[0.9982044,0.00029849313,0.0001806682,0.00025774838,0.00013927606,0.000538107,0.0002473773,0.000028357854,0.00010554409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862015,0.00007477698,0.0002863052,0.00044911407,0.00022961029,0.00034005594],"domain_scores_gemma":[0.9992485,0.000040299277,0.00015908573,0.00012561884,0.00016626324,0.0002602335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056232086,0.00024215276,0.0005566897,0.00014033233,0.00010161488,0.000018701885,0.00003653549,0.000044998542,0.000051895564],"category_scores_gemma":[0.000008646025,0.00016536129,0.000027074235,0.0004033194,0.00016807424,0.00010907824,0.000029089277,0.00025183146,6.855523e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013955678,0.0009929431,0.9793484,0.00029991838,0.00024179179,0.000029480272,0.0033370878,0.000008043573,0.0000041003987,0.0001464639,0.00082741585,0.01336876],"study_design_scores_gemma":[0.013348029,0.0059296316,0.97615737,0.00070017285,0.00031958646,0.0000032744988,0.00061060616,0.00016218606,0.000028647855,0.0000047986164,0.0025689956,0.00016670447],"about_ca_topic_score_codex":0.0022751386,"about_ca_topic_score_gemma":0.0032644502,"teacher_disagreement_score":0.013202055,"about_ca_system_score_codex":0.0018945822,"about_ca_system_score_gemma":0.0012460037,"threshold_uncertainty_score":0.67432374},"labels":[],"label_agreement":null},{"id":"W3118553886","doi":"10.1093/clinchem/hvaa307","title":"Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring","year":2020,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institute of General Medical Sciences; Merck; Pfizer; U.S. Department of Veterans Affairs","keywords":"Liquid biopsy; Epidermal growth factor receptor; COLD-PCR; Concordance; Medicine; T790M; Internal medicine; Digital polymerase chain reaction; Targeted therapy; Mutation; Molecular biology; Pathology; Oncology; Cancer research; Cancer; Biology; Polymerase chain reaction; Gefitinib; Gene; Genetics","score_opus":0.07922391559029132,"score_gpt":0.40228650558644624,"score_spread":0.3230625899961549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118553886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593973,0.0005273083,0.000060179595,0.0025836425,0.000054793956,0.00034909393,0.00040131653,0.00003471119,0.000049223585],"genre_scores_gemma":[0.9966841,0.00017346197,0.0022962522,0.00021621304,0.00026500053,0.0001389179,0.0001006759,0.00002035814,0.00010504102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873894,0.00005407033,0.0005580473,0.00035814827,0.00013676878,0.00015403602],"domain_scores_gemma":[0.99707043,0.0020926306,0.00022240895,0.0001494167,0.00021264983,0.00025244913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014697849,0.00014012381,0.00051349425,0.000033484088,0.00008228931,0.000013418717,0.00005206965,0.00008847095,0.00011931954],"category_scores_gemma":[0.003172513,0.00012000059,0.00031732398,0.0002975977,0.0001225965,0.00003968254,0.000019727431,0.00011953706,0.0000012763259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001866775,0.00032793797,0.88055474,0.00023750387,0.002687973,0.000026187283,0.0008475751,0.000010058413,0.107497744,0.000003810323,0.00020417532,0.005735521],"study_design_scores_gemma":[0.0032878174,0.00046679293,0.7571465,0.00010066917,0.0025789957,0.0000026152472,0.0006349609,0.00059746514,0.23441337,0.000012846144,0.000575059,0.00018295858],"about_ca_topic_score_codex":0.000010318805,"about_ca_topic_score_gemma":2.4375245e-7,"teacher_disagreement_score":0.12691562,"about_ca_system_score_codex":0.000047446312,"about_ca_system_score_gemma":0.00014604366,"threshold_uncertainty_score":0.4893482},"labels":[],"label_agreement":null},{"id":"W3119084223","doi":"10.1002/cac2.12128","title":"Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors","year":2021,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Ceritinib; Lung cancer; Medicine; ALK inhibitor; ROS1; Adenocarcinoma; Alectinib; Targeted therapy; Internal medicine; Oncology; Cancer research; Pathology; Cancer; Malignant pleural effusion","score_opus":0.04499332222414623,"score_gpt":0.37927840711824706,"score_spread":0.3342850848941008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119084223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688347,0.007175147,0.00084739795,0.01799539,0.00024524893,0.00089198735,0.0004515004,0.000068034584,0.0034905677],"genre_scores_gemma":[0.9903066,0.0011004157,0.0052766586,0.0017758486,0.00007820554,0.00022088227,0.00023865435,0.000028463945,0.0009742313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899554,0.000102496866,0.00030085625,0.0002946548,0.00013450222,0.00017197104],"domain_scores_gemma":[0.9977634,0.00027379303,0.00008660478,0.001241947,0.0004047912,0.00022944389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010661004,0.00014536334,0.000251337,0.00007452358,0.00031425996,0.000034355544,0.00016705987,0.00006813619,0.000066329594],"category_scores_gemma":[0.00013321091,0.0001078465,0.000054520035,0.0003427532,0.0001622911,0.0000936459,0.00026970106,0.00019446618,0.000006207174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027629055,0.00090382947,0.97142315,0.000027535678,0.00036257744,0.0000049750684,0.0019575544,0.000004440233,0.00050411857,0.00043338008,0.0028730556,0.02122909],"study_design_scores_gemma":[0.0031103129,0.00021784063,0.9517696,0.00030427327,0.00031446002,0.000012055837,0.00050239335,0.00010769797,0.00017509527,0.00002230136,0.04332166,0.00014231184],"about_ca_topic_score_codex":0.00016221816,"about_ca_topic_score_gemma":0.0003410239,"teacher_disagreement_score":0.040448606,"about_ca_system_score_codex":0.00016602632,"about_ca_system_score_gemma":0.0006166318,"threshold_uncertainty_score":0.43978524},"labels":[],"label_agreement":null},{"id":"W3119449300","doi":"10.1016/j.ccell.2020.12.017","title":"Lorlatinib in ALK-Rearranged Lung Cancer","year":2021,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer; Princess Margaret Cancer Foundation; Roche; Open Society Institute; Takeda Canada; Novartis","keywords":"Crizotinib; Lung cancer; Anaplastic lymphoma kinase; Medicine; Internal medicine; Oncology; ALK inhibitor; Interim analysis; Pemetrexed; Adenocarcinoma; Chemotherapy; Cancer; Clinical trial","score_opus":0.021502822140882824,"score_gpt":0.34632964989259796,"score_spread":0.3248268277517151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119449300","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037925292,0.1597887,0.000018399021,0.64669573,0.0035737695,0.0018020064,0.00073038845,0.000119369455,0.1834791],"genre_scores_gemma":[0.009447481,0.0133182015,0.00029786557,0.798906,0.009266733,0.0023650054,0.002371354,0.00024866764,0.16377866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980839,0.00005166629,0.0003580766,0.00063649355,0.0003621379,0.00050773495],"domain_scores_gemma":[0.9990361,0.000057518475,0.00015809399,0.00049059995,0.00015234873,0.00010538545],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000043975557,0.0003810123,0.00067916844,0.000115744704,0.00005665875,0.00003543602,0.00011812042,0.0005354704,0.0072487816],"category_scores_gemma":[0.0000085783295,0.00034127323,0.000206639,0.00028597531,0.000048076516,0.00007346479,0.000037825463,0.0011006913,0.000027517159],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025832222,0.00007107382,0.008542531,0.0010918048,0.00033253588,0.0013730922,0.0007101235,0.000028936476,0.00022940304,0.0000012949849,0.983625,0.0039683944],"study_design_scores_gemma":[0.0027002003,0.000036612117,0.0016634465,0.0012731394,0.0011067548,0.000009455142,0.00007854635,0.00006268666,0.0006322715,0.000006028731,0.9920834,0.00034747057],"about_ca_topic_score_codex":0.00911181,"about_ca_topic_score_gemma":0.0028240664,"teacher_disagreement_score":0.1522103,"about_ca_system_score_codex":0.0018979321,"about_ca_system_score_gemma":0.0016750131,"threshold_uncertainty_score":0.9999039},"labels":[],"label_agreement":null},{"id":"W3119533143","doi":"10.1016/j.jtho.2020.10.137","title":"MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"KRAS; Docetaxel; Medicine; Clinical endpoint; Oncology; Internal medicine; Cancer; Chemotherapy; Phases of clinical research; Progression-free survival; Clinical trial","score_opus":0.01519236063026138,"score_gpt":0.41002208929297873,"score_spread":0.39482972866271737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119533143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578214,0.0011953838,0.000100662146,0.00020898222,0.00073847076,0.0016366052,0.000034172837,0.000013276276,0.0002903004],"genre_scores_gemma":[0.997175,0.0001347272,0.0020273796,0.000088144545,0.00014524069,0.000120796525,0.000035862693,0.000045408215,0.00022748596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767756,0.0002232391,0.0009709364,0.00033905514,0.00042579926,0.00036339925],"domain_scores_gemma":[0.9972031,0.00015691588,0.0010630018,0.00025179808,0.0011029792,0.00022221853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002229672,0.00029814854,0.0009517042,0.00034116302,0.0000712767,0.000020062638,0.00011079331,0.00013698512,0.000080231395],"category_scores_gemma":[0.000090116126,0.00022636897,0.0001380222,0.00047635756,0.000046899266,0.00027748212,0.00004005661,0.00040389044,0.0000020991354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050426126,0.03381595,0.8432593,0.0006462893,0.002266467,0.0031988272,0.017141169,0.001968873,0.004410539,7.111313e-7,0.00022322887,0.04264252],"study_design_scores_gemma":[0.2704492,0.045563065,0.6311642,0.0033614754,0.011356482,0.00012343959,0.0134457685,0.0015637384,0.021270536,0.0000032741125,0.0010040698,0.0006947867],"about_ca_topic_score_codex":0.0003743235,"about_ca_topic_score_gemma":0.000907326,"teacher_disagreement_score":0.22002307,"about_ca_system_score_codex":0.0013979168,"about_ca_system_score_gemma":0.0013536165,"threshold_uncertainty_score":0.9231059},"labels":[],"label_agreement":null},{"id":"W3119781924","doi":"","title":"Relation entre la distribution intratumorale du Foscanâ et l'apoptose photoinduite dans un modèle de tumeur d'adénocarcinome colique (HT29) greffé chez la souris « nude ».","year":2007,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Medicine; Nuclear medicine; Physics","score_opus":0.012236344615742597,"score_gpt":0.25528281221629473,"score_spread":0.24304646760055212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119781924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63502187,0.0032276679,0.24875252,0.01817656,0.0008061069,0.0021710005,0.0010679078,0.00043249739,0.09034384],"genre_scores_gemma":[0.95543844,0.0036859605,0.0134532,0.00029928505,0.00015930881,0.00034066345,0.008646327,0.00014808118,0.017828759],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.98652464,0.009173874,0.0011825386,0.0013215258,0.0007734478,0.0010239893],"domain_scores_gemma":[0.9918809,0.0024312008,0.0010091667,0.0020034753,0.0019336182,0.0007416194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007254103,0.0008335304,0.000840279,0.0002855478,0.0007542261,0.00050189655,0.00084215234,0.0009899578,0.00046421465],"category_scores_gemma":[0.0016737068,0.000910535,0.00049387076,0.0008721722,0.00069271156,0.00037933938,0.0007018676,0.00181244,0.000121265766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034751868,0.007367895,0.2776513,0.0011035476,0.0016200416,0.0005007675,0.10688538,0.002157251,0.025587235,0.523318,0.004645132,0.048815947],"study_design_scores_gemma":[0.008133528,0.000015441805,0.6840107,0.008710223,0.0022253115,0.00058392965,0.0023740593,0.033853788,0.14549203,0.008687084,0.10402491,0.0018890059],"about_ca_topic_score_codex":0.0060902224,"about_ca_topic_score_gemma":0.0022371404,"teacher_disagreement_score":0.5146309,"about_ca_system_score_codex":0.0024028262,"about_ca_system_score_gemma":0.0020219802,"threshold_uncertainty_score":0.9993345},"labels":[],"label_agreement":null},{"id":"W3120136761","doi":"10.1183/13993003.03271-2020","title":"R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models","year":2021,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Crizotinib; Lung cancer; Medicine; Pulmonary hypertension; Internal medicine; Cardiology; Lung; Animal model; Oncology","score_opus":0.03801918031070295,"score_gpt":0.29742473485983006,"score_spread":0.2594055545491271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120136761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858395,0.001873274,0.000055018245,0.0007197877,0.00021688013,0.0001328383,0.000007963402,0.000021535338,0.0111332005],"genre_scores_gemma":[0.99669176,0.000082059734,0.0006713762,0.0015630773,0.0005611092,0.0000027174824,0.000005050609,0.000032251883,0.00039059957],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99896795,0.00017633036,0.00027305936,0.00022499781,0.00016866863,0.00018897117],"domain_scores_gemma":[0.99941134,0.000023205288,0.000050320996,0.00013734275,0.000121904784,0.0002558629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021147379,0.00011892902,0.00018414496,0.00011516223,0.00011228589,0.00007081258,0.00004198604,0.000023250414,0.00008022364],"category_scores_gemma":[0.00006488694,0.00009634606,0.000044743025,0.00012952222,0.000025155072,0.00016293781,0.000056640063,0.00018178835,0.000026032823],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002290998,0.0013483533,0.053911045,0.00010711557,0.0002637792,0.056514163,0.0028767164,0.00050101144,0.7907203,0.00025785313,0.008978285,0.082230404],"study_design_scores_gemma":[0.006602818,0.0015736104,0.90712625,0.0007971632,0.00025861128,0.007933881,0.0011488167,0.0004705136,0.0062039094,0.0001732447,0.06732984,0.00038133154],"about_ca_topic_score_codex":0.0000022612135,"about_ca_topic_score_gemma":0.0000035676874,"teacher_disagreement_score":0.8532152,"about_ca_system_score_codex":0.000060818136,"about_ca_system_score_gemma":0.00016827129,"threshold_uncertainty_score":0.39288783},"labels":[],"label_agreement":null},{"id":"W3120496075","doi":"10.1016/j.jtho.2020.10.090","title":"TT01.01 Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Bevacizumab; Pemetrexed; Oncology; Internal medicine; Carboplatin; Anaplastic lymphoma kinase; Chemotherapy; Progression-free survival; Paclitaxel; Lung cancer; Cisplatin","score_opus":0.01768990500250467,"score_gpt":0.41899168802046,"score_spread":0.4013017830179553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120496075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306464,0.00022143924,0.000038558654,0.0031893242,0.00013892377,0.00035684084,0.000011030907,0.000009073619,0.0029701455],"genre_scores_gemma":[0.9916768,0.00023703072,0.005156244,0.0006452224,0.00007842891,0.00001118981,0.000025033096,0.000032482465,0.0021375732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986989,0.00012254925,0.00051760295,0.00016577858,0.0002979531,0.00019724439],"domain_scores_gemma":[0.9985262,0.00019794547,0.0005232122,0.00016645277,0.00048231738,0.00010383407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015237258,0.00018378807,0.0008883609,0.0002705784,0.000040316718,0.000009734997,0.00007005418,0.00008507603,0.00010441282],"category_scores_gemma":[0.000034428103,0.00009580365,0.00014566486,0.0005160879,0.000057824047,0.00013177193,0.0000095890555,0.00020853781,8.8131117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015250435,0.002520517,0.90693706,0.00002543339,0.002038083,0.0011500504,0.0011918403,0.000022580583,0.00034431423,0.000007702022,0.00011050084,0.07040147],"study_design_scores_gemma":[0.01643826,0.009410031,0.9648921,0.00057420606,0.0007473025,0.00010112318,0.0005915833,0.000004777754,0.00553134,0.000021478865,0.001560177,0.00012763802],"about_ca_topic_score_codex":0.00013990719,"about_ca_topic_score_gemma":0.0006748299,"teacher_disagreement_score":0.07027383,"about_ca_system_score_codex":0.00045845244,"about_ca_system_score_gemma":0.0010222493,"threshold_uncertainty_score":0.39067593},"labels":[],"label_agreement":null},{"id":"W3126026051","doi":"10.1038/s41598-021-81639-0","title":"Loss of Parkinson’s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; University of Victoria; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Carcinogenesis; LRRK2; Carcinogen; Cancer research; Parkinson's disease; Gene; Bioinformatics; Biology; Medicine; Genetics; Pathology; Mutation; Disease","score_opus":0.0205244485402887,"score_gpt":0.31090069140748683,"score_spread":0.29037624286719815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126026051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368984,0.00088653166,0.0000418417,0.00029379106,0.0031818005,0.00050847715,0.000014065732,0.000047702593,0.0013359602],"genre_scores_gemma":[0.9934464,0.000009480327,0.0011877437,0.000024054907,0.000089749235,0.000038402715,0.00020998213,0.000017913348,0.004976243],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977669,0.000045668367,0.00055564404,0.00080659316,0.0005468898,0.00027827002],"domain_scores_gemma":[0.9976778,0.00002329916,0.00025000254,0.0011707378,0.0006950227,0.00018315943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005515977,0.00014593666,0.00033665667,0.000102699974,0.00019709919,0.000056394394,0.00005221702,0.000060289036,0.00039852885],"category_scores_gemma":[0.00020940385,0.00012106774,0.00018077239,0.0006116472,0.00014837932,0.00008641124,0.000053755964,0.000070408205,0.000008234772],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012831414,0.00041139254,0.56361896,0.00016037075,0.00013570026,0.0025340545,0.000731045,0.0000047331255,0.42966408,0.000014351298,0.0014654193,0.0012470904],"study_design_scores_gemma":[0.0003497081,0.000056634628,0.21866556,0.00006852925,0.00032700537,0.0008484777,0.00016682861,0.00002960935,0.7747964,0.00041224883,0.004164231,0.00011472665],"about_ca_topic_score_codex":0.0001974591,"about_ca_topic_score_gemma":0.00014514795,"teacher_disagreement_score":0.34513238,"about_ca_system_score_codex":0.00021071022,"about_ca_system_score_gemma":0.0013733353,"threshold_uncertainty_score":0.4936999},"labels":[],"label_agreement":null},{"id":"W3127294621","doi":"10.2217/cer-2020-0173","title":"Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Osimertinib; Lung cancer; Oncology; Internal medicine; Retrospective cohort study; Tyrosine-kinase inhibitor; Tyrosine kinase; Cohort; Cancer; Targeted therapy; Erlotinib; Epidermal growth factor receptor","score_opus":0.11775978284061421,"score_gpt":0.46844371141222735,"score_spread":0.3506839285716131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127294621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910594,0.005233133,0.0014562773,0.00023656945,0.00025841928,0.0016289677,0.000018992507,0.0000061844516,0.0001020518],"genre_scores_gemma":[0.9978713,0.0012267655,0.00017951107,0.000007597515,0.0003265926,0.00018496269,0.000016220272,0.000024101046,0.00016299385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812603,0.00057373056,0.0003234947,0.00027706724,0.00036809364,0.0003316033],"domain_scores_gemma":[0.9962236,0.002089983,0.00015341141,0.000097613854,0.0012733256,0.00016201052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007950289,0.00021603359,0.0007053835,0.00034646367,0.0002465526,0.00006510709,0.000046488683,0.00007786065,0.000026590998],"category_scores_gemma":[0.00008900695,0.00014811567,0.00015565324,0.00049407425,0.000050597824,0.00016050335,0.000023585353,0.00034327726,3.7035983e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058966754,0.004171815,0.85177493,0.0008542677,0.0013799712,0.0001487829,0.008075744,0.0047770827,0.116474904,0.000052477455,0.000106473235,0.006286884],"study_design_scores_gemma":[0.016727818,0.005332877,0.59361595,0.0008177549,0.0001446909,0.00001897774,0.0009025212,0.0018081676,0.38015565,0.00006546509,0.00027598153,0.00013413865],"about_ca_topic_score_codex":0.00036879137,"about_ca_topic_score_gemma":0.00092063996,"teacher_disagreement_score":0.26368076,"about_ca_system_score_codex":0.0015830329,"about_ca_system_score_gemma":0.0008158888,"threshold_uncertainty_score":0.6039982},"labels":[],"label_agreement":null},{"id":"W3127627036","doi":"10.3390/curroncol28010076","title":"Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Intensive care medicine; Cancer; Drug class; Concomitant; Pharmacology; Internal medicine","score_opus":0.20434215767772804,"score_gpt":0.564444830665835,"score_spread":0.36010267298810694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127627036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015830065,0.98037964,0.0000050412905,0.0026359407,0.0014315182,0.014734749,0.00020797073,0.00002425182,0.0005650501],"genre_scores_gemma":[0.0000037559475,0.99061555,0.00046192625,0.00021314071,0.00048378707,0.007041657,0.0007685094,0.00003500985,0.0003766512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975639,0.0005049092,0.0008611306,0.0005851679,0.00018989612,0.00029501613],"domain_scores_gemma":[0.9971751,0.0009915258,0.00085203326,0.0004965519,0.00033302876,0.00015177335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030248702,0.000457807,0.0029479957,0.0000925464,0.000101790356,0.000016700798,0.00010358218,0.00048646092,0.000042503994],"category_scores_gemma":[0.0010815546,0.00022476478,0.000959512,0.00043157316,0.00021308381,0.00003521659,0.000113024675,0.00047571262,0.0000038573994],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029127928,0.002120933,0.000028499728,0.14259979,0.00053636957,0.00004710936,0.00013610628,1.295364e-8,1.5372628e-7,0.00016477657,0.005415799,0.8489213],"study_design_scores_gemma":[0.001673927,0.0025519817,0.000013153927,0.16715164,0.010303233,0.0005235473,0.000015335398,3.970419e-7,0.0000033470149,0.000011774752,0.8176132,0.00013849205],"about_ca_topic_score_codex":0.0000027074886,"about_ca_topic_score_gemma":0.000004822567,"teacher_disagreement_score":0.84878284,"about_ca_system_score_codex":0.0017816646,"about_ca_system_score_gemma":0.0052921176,"threshold_uncertainty_score":0.93879896},"labels":[],"label_agreement":null},{"id":"W3128342266","doi":"10.1016/j.jtho.2021.01.1605","title":"A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Janssen Biotech; Foundation Medicine; Chugai Pharmaceutical; Genentech; Clinical Excellence Commission; Lunit; Relay Therapeutics; Northwell Health; Apollomics; Pfizer; Incyte; Siemens Medical Solutions USA; AstraZeneca; Novocure; Commission for Environmental Cooperation; MedStar Health Research Institute; Regeneron Pharmaceuticals; Array BioPharma; Agios Pharmaceuticals; Roche; Novartis; Heron Therapeutics; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Medtronic; Ariad Pharmaceuticals; Siemens Healthineers; Amgen; Boehringer Ingelheim; Exelixis; American Lung Association","keywords":"Medicine; Lung cancer; Cancer; Internal medicine; Oncology","score_opus":0.01810293350768457,"score_gpt":0.4496206825810844,"score_spread":0.43151774907339985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128342266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978598,0.00063154206,0.000023416998,0.00025196612,0.00013343032,0.000817827,0.000021393927,0.0000056949348,0.00025498224],"genre_scores_gemma":[0.99740154,0.00002923868,0.0020852722,0.00009401552,0.000096386095,0.00005470759,0.000016181331,0.000020849067,0.00020180045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984861,0.00022083774,0.0006091003,0.00017018076,0.00032832986,0.00018547397],"domain_scores_gemma":[0.9981677,0.00007167096,0.00070759776,0.00017218142,0.0007449794,0.00013589417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018653547,0.00015140524,0.00079555466,0.00022866821,0.000032152475,0.000008417671,0.000059427843,0.00006267406,0.0001095855],"category_scores_gemma":[0.00005187144,0.00009033859,0.00006021854,0.00044744727,0.0000390159,0.00012126031,0.000017840348,0.00023060295,4.3080556e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018102752,0.029671615,0.85672945,0.0002468567,0.0032210562,0.001694649,0.010870989,0.00014352245,0.000586988,0.0000020981881,0.00037576907,0.078354284],"study_design_scores_gemma":[0.18170471,0.21587922,0.5552194,0.0035833586,0.017873261,0.000813554,0.015313478,0.00012994939,0.0072241346,0.000012220476,0.0017696267,0.00047704397],"about_ca_topic_score_codex":0.00017962219,"about_ca_topic_score_gemma":0.00064164127,"teacher_disagreement_score":0.30150998,"about_ca_system_score_codex":0.0005960825,"about_ca_system_score_gemma":0.0013286226,"threshold_uncertainty_score":0.36839008},"labels":[],"label_agreement":null},{"id":"W3129029771","doi":"10.1001/jamaoncol.2020.6752","title":"Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got","year":2021,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; Neurology; MEDLINE; Psychiatry","score_opus":0.04064746612541352,"score_gpt":0.3827713780327475,"score_spread":0.342123911907334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129029771","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13546228,0.0014827934,0.000052620686,0.8314322,0.0054394533,0.0022035548,0.00004723659,0.0000677382,0.023812097],"genre_scores_gemma":[0.8293935,0.0017798735,0.00078659644,0.10348087,0.01565355,0.0015741893,0.00026544262,0.00008649894,0.046979465],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851507,0.00032607128,0.00034926986,0.0002757444,0.00024532923,0.00028849047],"domain_scores_gemma":[0.998339,0.00080071803,0.00014099105,0.00046563824,0.00015064531,0.00010301406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028388674,0.00015656516,0.000418481,0.0000433028,0.00023840724,0.00004211245,0.00015029688,0.00022258867,0.001128953],"category_scores_gemma":[0.00044353874,0.0000815793,0.0002234686,0.00026328999,0.00014316,0.0000535586,0.00006912429,0.0003790488,0.000114400544],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2618894,0.0011637125,0.00006970509,0.000029435978,0.0008001324,0.0005090541,0.0038912138,0.000008365832,0.000424839,0.0024853202,0.59548587,0.13324293],"study_design_scores_gemma":[0.23411997,0.0027404139,0.00029487506,0.000024844134,0.0006925922,0.00009812177,0.0015381061,0.00002906047,0.00023300799,0.00025071576,0.75990975,0.0000685359],"about_ca_topic_score_codex":0.00023468884,"about_ca_topic_score_gemma":0.0005489291,"teacher_disagreement_score":0.72795135,"about_ca_system_score_codex":0.00033560334,"about_ca_system_score_gemma":0.0013610993,"threshold_uncertainty_score":0.9997842},"labels":[],"label_agreement":null},{"id":"W3129514033","doi":"10.3389/fonc.2020.569715","title":"nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Docetaxel; Oncology; Clinical endpoint; Paclitaxel; Lung cancer; non-small cell lung cancer (NSCLC); Progression-free survival; Stage (stratigraphy); Chemotherapy; Adverse effect; Cancer; Nivolumab; Immunotherapy; Clinical trial","score_opus":0.006197421621776283,"score_gpt":0.3036336720379647,"score_spread":0.29743625041618843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129514033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331785,0.0038367023,0.00050877273,0.0004086652,0.00088527927,0.0016148466,0.00008212438,0.000035388162,0.0093103945],"genre_scores_gemma":[0.9566853,0.00096477306,0.017909735,0.00082632276,0.0000810022,0.00089007925,0.00048548676,0.000078500205,0.022078812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982757,0.00010913254,0.00038878006,0.00051949767,0.00018806959,0.00051880506],"domain_scores_gemma":[0.9991248,0.000042339154,0.00015623114,0.0003309088,0.00019440008,0.00015126615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000893521,0.00024797727,0.0006988373,0.00021747952,0.00006337072,0.000013810612,0.00009221499,0.00019108766,0.00014473712],"category_scores_gemma":[0.000038188882,0.00021188843,0.00006419828,0.00052255817,0.00008459364,0.00010959864,0.000040559516,0.00029077608,0.00000455998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013208572,0.0011286828,0.97514164,0.0002048498,0.00022080254,0.0005455751,0.0029700517,0.00075348676,0.000035429865,0.000007646646,0.0031577272,0.014513244],"study_design_scores_gemma":[0.06340278,0.0023969356,0.8819914,0.00055995473,0.00071979983,0.0000084556095,0.0029300367,0.0010922606,0.0004680593,0.000027147395,0.045926634,0.00047654906],"about_ca_topic_score_codex":0.0010890737,"about_ca_topic_score_gemma":0.0036399057,"teacher_disagreement_score":0.09315026,"about_ca_system_score_codex":0.0040214295,"about_ca_system_score_gemma":0.0021980766,"threshold_uncertainty_score":0.99980193},"labels":[],"label_agreement":null},{"id":"W3130089277","doi":"10.1016/j.lungcan.2021.02.030","title":"MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Roche; Merck; AstraZeneca","keywords":"Medicine; Discontinuation; Crizotinib; Internal medicine; Oncology; Lung cancer; Targeted therapy; Population; Chemotherapy; Cancer","score_opus":0.01069406291528424,"score_gpt":0.3345778876241834,"score_spread":0.32388382470889915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130089277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621422,0.029079473,0.0016088272,0.0024750293,0.0010629832,0.0016050155,0.00020034106,0.00009145179,0.0017346581],"genre_scores_gemma":[0.98323655,0.0016059225,0.0009789951,0.0026610524,0.00041746182,0.0012571283,0.000111599235,0.00007016514,0.009661112],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830663,0.00013731091,0.00032017299,0.00053853495,0.000307774,0.0003896022],"domain_scores_gemma":[0.9986948,0.00013623173,0.00013357901,0.0003609688,0.00044690585,0.00022754338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017058045,0.00025390205,0.00040092066,0.00015861235,0.00015671631,0.000059640457,0.00008574213,0.00010981319,0.00033723592],"category_scores_gemma":[0.00003352548,0.00023496101,0.00013857835,0.0005403137,0.00002017619,0.000113120775,0.00003432471,0.00017202202,0.000016738064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00884637,0.0008979917,0.1279715,0.0020147816,0.0050714863,0.0026479745,0.073571354,0.010150293,0.6741454,0.00013459177,0.024163539,0.07038471],"study_design_scores_gemma":[0.034320705,0.0019017432,0.45948452,0.013322861,0.0071064197,0.000495427,0.008414216,0.006959187,0.4401981,0.000041125986,0.025453713,0.0023020068],"about_ca_topic_score_codex":0.0017358592,"about_ca_topic_score_gemma":0.00037870213,"teacher_disagreement_score":0.331513,"about_ca_system_score_codex":0.0017704939,"about_ca_system_score_gemma":0.0014846198,"threshold_uncertainty_score":0.95814323},"labels":[],"label_agreement":null},{"id":"W3131136094","doi":"10.1097/md.0000000000023712","title":"Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment","year":2021,"lang":"en","type":"article","venue":"Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"National Natural Science Foundation of China","keywords":"Medicine; Epidermal growth factor receptor; Bevacizumab; Tyrosine kinase; Lung cancer; Erlotinib; Cancer research; Squamous cell cancer; EGFR inhibitors; Oncology; Internal medicine; Cancer; Receptor; Chemotherapy","score_opus":0.010596769908721672,"score_gpt":0.3039358038025027,"score_spread":0.293339033893781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131136094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99036413,0.0010451092,0.00020583058,0.003056552,0.00044401913,0.00428492,0.0002516992,0.000065779954,0.00028196533],"genre_scores_gemma":[0.9937672,0.00015038333,0.0016999594,0.0002728428,0.0003415325,0.00097581354,0.0017490595,0.00011066102,0.00093252707],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750245,0.00004756806,0.0005851,0.0007116824,0.0006359244,0.0005172771],"domain_scores_gemma":[0.9976957,0.00027239876,0.00041423814,0.00046880043,0.00077638536,0.0003724795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006309335,0.00055066537,0.0009894626,0.00019807527,0.00018929194,0.000011446667,0.00009352462,0.00011717446,0.00012785074],"category_scores_gemma":[0.0001047768,0.00031742488,0.00012957623,0.0004975201,0.00016755759,0.000100940626,0.000028095237,0.00017305194,0.0000033720246],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05661837,0.027368065,0.7648936,0.0042580194,0.0029194467,0.00052075036,0.013264299,0.00037299708,0.02937219,0.00010247759,0.008129914,0.09217987],"study_design_scores_gemma":[0.2829161,0.08454667,0.2671142,0.0093579,0.005199011,0.000019451361,0.0010126769,0.00031815618,0.34568813,0.000008903176,0.0027912115,0.0010276244],"about_ca_topic_score_codex":0.00025270056,"about_ca_topic_score_gemma":0.00011729109,"teacher_disagreement_score":0.49777943,"about_ca_system_score_codex":0.00079456886,"about_ca_system_score_gemma":0.00064650347,"threshold_uncertainty_score":0.99992776},"labels":[],"label_agreement":null},{"id":"W3131560519","doi":"","title":"Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu","year":2009,"lang":"en","type":"article","venue":"VUBIR (Vrije Universiteit Brussel)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Adenocarcinoma; Lung; Cancer research; Pharmacology; Internal medicine; Cancer","score_opus":0.012478037925891217,"score_gpt":0.30419200860016554,"score_spread":0.29171397067427435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131560519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972002,0.0002421439,0.000026442582,0.00080906734,0.000023957367,0.00048656433,0.000049543756,0.000005118045,0.0011569564],"genre_scores_gemma":[0.99908304,0.000037652655,0.00074644585,0.00005264925,0.000015485826,0.0000011584796,0.000009820014,0.0000069715093,0.00004674816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989997,0.00017164378,0.00029218028,0.00018651017,0.00022399581,0.00012596627],"domain_scores_gemma":[0.99906415,0.00020207651,0.00024841938,0.0003312469,0.0001016214,0.00005250659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023212245,0.00011184462,0.00034462998,0.00025541082,0.00004040044,0.0000030298334,0.00013612752,0.00007461711,0.000016595193],"category_scores_gemma":[0.000031887874,0.000070784474,0.00008241798,0.0008537951,0.0002779621,0.00017278253,0.000027824168,0.00015764976,1.8119228e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015104464,0.0027013794,0.96290946,0.00023128909,0.00017879832,0.00011056496,0.017187797,0.00016335277,0.007990815,0.0019346353,0.00016434459,0.00491714],"study_design_scores_gemma":[0.004902508,0.0010275928,0.980553,0.00029573787,0.00032353977,0.000015361871,0.008433466,0.00010008101,0.004080142,0.00013617778,0.000058292484,0.000074123716],"about_ca_topic_score_codex":0.0012577517,"about_ca_topic_score_gemma":0.00070084445,"teacher_disagreement_score":0.01764354,"about_ca_system_score_codex":0.00007893679,"about_ca_system_score_gemma":0.00025078026,"threshold_uncertainty_score":0.28865072},"labels":[],"label_agreement":null},{"id":"W3133838590","doi":"10.1016/j.jtho.2021.02.010","title":"Crizotinib in Patients With MET-Amplified NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Genentech; Exelixis; Revolution Medicines; Foundation Medicine; Sierra Oncology; Pfizer; Incyte; Astex Pharmaceuticals; Bayer Fund; AstraZeneca; Novocure; Merck KGaA; Jounce Therapeutics; Ariad Pharmaceuticals; Takeda Pharmaceutical Company; Amgen; Roche; Spectrum Pharmaceuticals; Merck; GlaxoSmithKline; Array BioPharma; G1 Therapeutics; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Fluorescence in situ hybridization; Internal medicine; ROS1; Retrospective cohort study; Gene duplication; Gastroenterology; Progression-free survival; Hazard ratio; Oncology; Confidence interval; Overall survival; Adenocarcinoma; Lung cancer; Gene; Cancer; Genetics","score_opus":0.019470229925141896,"score_gpt":0.4345962996276041,"score_spread":0.4151260697024622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133838590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873625,0.000312685,0.00017688112,0.0026231464,0.00035725473,0.00012716647,0.000004124761,0.000004667282,0.009031571],"genre_scores_gemma":[0.9891079,0.000020575399,0.009344929,0.00068251335,0.00011321037,0.0000034893956,0.000012149737,0.000010865772,0.0007043517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991839,0.00007846681,0.0003200283,0.00009531993,0.00018703828,0.0001352465],"domain_scores_gemma":[0.9990696,0.00006996074,0.00022886616,0.00010956604,0.00041797484,0.0001040815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014814673,0.00007507085,0.00035388992,0.00012884436,0.000024286888,0.000007454973,0.000041789168,0.00006645669,0.0001855218],"category_scores_gemma":[0.00009685757,0.000049732385,0.00006386461,0.00020626563,0.000028036122,0.000078230354,0.000014154876,0.00021264018,0.000008297559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00527274,0.0038533215,0.588481,0.00008129797,0.00081239984,0.0028413665,0.0013496089,0.000045378747,0.00044606742,0.0001931479,0.0022630412,0.3943606],"study_design_scores_gemma":[0.007749116,0.0055735717,0.94177186,0.0002807512,0.00090762007,0.00056915317,0.0007881198,0.0000034311224,0.0009840607,0.0002193579,0.041050237,0.000102714155],"about_ca_topic_score_codex":0.0000062392755,"about_ca_topic_score_gemma":0.0000257952,"teacher_disagreement_score":0.3942579,"about_ca_system_score_codex":0.00032844,"about_ca_system_score_gemma":0.0009325574,"threshold_uncertainty_score":0.20313336},"labels":[],"label_agreement":null},{"id":"W3134500232","doi":"10.3390/curroncol28020102","title":"Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cohort; Lung cancer; Internal medicine; Adverse effect; Oncology; Adenocarcinoma; Epidermal growth factor receptor; Retrospective cohort study; Cancer","score_opus":0.09222819135006739,"score_gpt":0.46588848023858614,"score_spread":0.37366028888851877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134500232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571127,0.0018755381,0.00014246309,0.00016152883,0.00016760446,0.00017145816,0.000016797605,0.0000052378173,0.0017480969],"genre_scores_gemma":[0.99946594,0.00012081583,0.00025359148,0.000043075128,0.000058850124,0.000016309625,0.00002708221,0.000004672393,0.000009639513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995536,0.000021516451,0.00017740921,0.000090392095,0.000071618975,0.00008544894],"domain_scores_gemma":[0.99942243,0.00016594156,0.00012689222,0.00008727206,0.0001640022,0.000033487962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007050549,0.00005392635,0.0001503135,0.00003267616,0.00003398879,0.0000027999567,0.000018538783,0.000028929036,0.00003995408],"category_scores_gemma":[0.00015326095,0.000034066412,0.000042593096,0.00012227568,0.00004556666,0.000028090084,0.000030253226,0.000069932794,5.324429e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000311872,0.0004395591,0.5707365,0.00013653845,0.00020821369,0.000007405075,0.0012602301,0.000028984925,0.023838349,0.00024405112,0.00026819273,0.40280077],"study_design_scores_gemma":[0.002714755,0.0013087791,0.98614585,0.0001676373,0.00050638703,0.00004305323,0.00057178386,0.00042373664,0.005751936,0.00022381672,0.0020882117,0.00005407712],"about_ca_topic_score_codex":0.00005243148,"about_ca_topic_score_gemma":0.00002389696,"teacher_disagreement_score":0.4154093,"about_ca_system_score_codex":0.00017753136,"about_ca_system_score_gemma":0.0004350687,"threshold_uncertainty_score":0.1389188},"labels":[],"label_agreement":null},{"id":"W3134581027","doi":"10.1016/j.annonc.2021.01.051","title":"36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Rash; Lung cancer; Internal medicine; Adverse effect; Oncology; Gastroenterology","score_opus":0.03507426874572082,"score_gpt":0.3850678834791013,"score_spread":0.3499936147333805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134581027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763226,0.0031479634,0.000023052828,0.0033708434,0.000060207305,0.0005589279,0.00006589633,0.00000826292,0.016442278],"genre_scores_gemma":[0.99752474,0.00095828605,0.000475133,0.0004309988,0.00004222253,0.00004070545,0.000047737165,0.000015517451,0.0004646408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879044,0.000089801615,0.00044208998,0.00032054298,0.00012266947,0.00023444963],"domain_scores_gemma":[0.9988918,0.00023079438,0.00020843388,0.00024998118,0.00031196585,0.00010702638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017681828,0.00014557844,0.0005833157,0.00007076467,0.00002903814,0.000003884878,0.000056970966,0.00012442563,0.0001472343],"category_scores_gemma":[0.00003569427,0.000116788,0.000056706485,0.00022093259,0.00013000137,0.000054057233,0.000045776815,0.00015542423,7.852892e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017996417,0.015589306,0.71562093,0.0037369237,0.0015718376,0.0020020187,0.015184547,0.004270976,0.05483886,0.00027894133,0.002546753,0.1663625],"study_design_scores_gemma":[0.011095085,0.010790554,0.9324401,0.00054289465,0.0005905822,0.0000879819,0.0017157351,0.0003537336,0.03872967,0.00004864577,0.0034130898,0.00019194954],"about_ca_topic_score_codex":0.0014899812,"about_ca_topic_score_gemma":0.0016800866,"teacher_disagreement_score":0.21681914,"about_ca_system_score_codex":0.00009981029,"about_ca_system_score_gemma":0.001432993,"threshold_uncertainty_score":0.47624764},"labels":[],"label_agreement":null},{"id":"W3134668651","doi":"10.21037/tlcr-20-927","title":"Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients","year":2021,"lang":"en","type":"article","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"","keywords":"KRAS; Medicine; Adenocarcinoma; Internal medicine; Oncology; Lung cancer; Stage (stratigraphy); Proportional hazards model; Concomitant; Cancer; Colorectal cancer; Gastroenterology; Biology","score_opus":0.016388278094672325,"score_gpt":0.387221100415381,"score_spread":0.3708328223207087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134668651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907737,0.0052735163,0.00014303395,0.0002270935,0.00006649657,0.0018680606,0.0008282139,0.000009936882,0.0008099796],"genre_scores_gemma":[0.99694985,0.0010639244,0.00032665697,0.000018666738,0.00005227008,0.0006833013,0.0003815901,0.000029085822,0.0004946438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998192,0.00017244963,0.00027096592,0.00038968283,0.0006186945,0.00035617923],"domain_scores_gemma":[0.9986885,0.00042780617,0.000057877023,0.00011094506,0.00054611993,0.0001687563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002445109,0.00015269687,0.00027622384,0.00016008668,0.00010436741,0.000029292158,0.00003551982,0.000084083906,0.00019517475],"category_scores_gemma":[0.00004106957,0.00013544605,0.000038204354,0.00044415338,0.00012081599,0.000143184,0.000022061482,0.0002673618,0.0000011538249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008071336,0.00019646279,0.99003047,0.0012018533,0.00022384133,0.000036699657,0.004011814,0.00038367073,0.0013091683,0.000029949611,0.000052664378,0.0017162467],"study_design_scores_gemma":[0.0071519315,0.00043182523,0.9763023,0.00044348426,0.00028857338,0.0000023091368,0.00007013079,0.0036818415,0.01141803,0.000029004832,0.000070363254,0.000110175904],"about_ca_topic_score_codex":0.0032799928,"about_ca_topic_score_gemma":0.00078648695,"teacher_disagreement_score":0.013728165,"about_ca_system_score_codex":0.00030319643,"about_ca_system_score_gemma":0.00099434,"threshold_uncertainty_score":0.55233294},"labels":[],"label_agreement":null},{"id":"W3135563856","doi":"10.1016/j.jtocrr.2021.100157","title":"Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Boehringer Ingelheim; Pfizer Canada; AbbVie; Merck; AstraZeneca; Novartis; Pfizer; Takeda Pharmaceutical Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Internal medicine; Alectinib; ALK inhibitor; Anaplastic lymphoma kinase; Oncology; Ceritinib; Lung cancer; Context (archaeology); Population; Hazard ratio; Brain metastasis; Gastroenterology; Cancer; Metastasis; Confidence interval; Biology","score_opus":0.052359026058187465,"score_gpt":0.4677355556769182,"score_spread":0.4153765296187307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135563856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98248845,0.00079771737,0.0000107288915,0.008169615,0.000806403,0.0017708252,0.000078096346,0.00005745519,0.0058206795],"genre_scores_gemma":[0.9752013,0.0011395715,0.0012833114,0.00023229777,0.000545539,0.00044844404,0.0001905496,0.000047900878,0.020911073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996966,0.00015585645,0.00071714714,0.0007580759,0.0009373874,0.0004655144],"domain_scores_gemma":[0.9962939,0.00053448166,0.00019709842,0.00043481318,0.0021058726,0.00043383168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013308615,0.00018528235,0.0005945061,0.00013429139,0.00035047033,0.00006708204,0.0000393064,0.00012807449,0.00019358832],"category_scores_gemma":[0.0028145157,0.00011699483,0.00016987626,0.00051255344,0.00029064956,0.00011772116,0.000087657645,0.00047656192,0.000002141898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041275457,0.00080233935,0.9658287,0.00013262374,0.0004701501,0.00032942832,0.00015986027,5.4143163e-7,0.000067352565,0.0000436326,0.021306861,0.010445742],"study_design_scores_gemma":[0.0034552887,0.0007013055,0.9591949,0.0005450843,0.0002520925,0.000008975235,0.00008625425,0.000012264565,0.0002613937,0.00015020107,0.035178017,0.00015421775],"about_ca_topic_score_codex":0.0010918466,"about_ca_topic_score_gemma":0.0015824466,"teacher_disagreement_score":0.015090395,"about_ca_system_score_codex":0.0003792646,"about_ca_system_score_gemma":0.0009225096,"threshold_uncertainty_score":0.47709107},"labels":[],"label_agreement":null},{"id":"W3135583340","doi":"10.1016/j.jtho.2020.11.027","title":"Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Takeda Canada; Merck Sharp and Dohme; Novartis Farmacéutica; Boehringer Ingelheim; Merck; GlaxoSmithKline; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Lung cancer; Placebo; Clinical endpoint; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Clinical trial; Adjuvant therapy; Chemotherapy; Cancer; Erlotinib; Epidermal growth factor receptor; Pathology","score_opus":0.03755095383676668,"score_gpt":0.48562114779050386,"score_spread":0.44807019395373715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135583340","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01346547,0.080666006,0.001695446,0.051843587,0.84110296,0.004438815,0.0051782583,0.00001845114,0.0015910174],"genre_scores_gemma":[0.14243102,0.023411186,0.0065093446,0.002942252,0.81860024,0.00038627425,0.00049237505,0.00029687033,0.0049304455],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99708354,0.00023634419,0.0011596436,0.00022854088,0.0010077034,0.00028422885],"domain_scores_gemma":[0.992363,0.0023866317,0.0016971817,0.00051130826,0.002897836,0.00014407616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010297615,0.00028776904,0.0016135676,0.00016794569,0.00015017364,0.000018113364,0.00042744985,0.0004988032,0.0001866671],"category_scores_gemma":[0.000975512,0.0001377425,0.0006643021,0.00023840414,0.00017030168,0.000046435074,0.0000738986,0.0008618307,5.461453e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019683791,0.00041766837,0.000054812164,0.0005131462,0.0035448405,0.00015542332,0.00893756,0.00011620953,0.001662858,0.000038062914,0.7465446,0.21833101],"study_design_scores_gemma":[0.0029537878,0.012201115,0.00010039282,0.0006639163,0.0026265702,0.00003619084,0.0070871157,0.0000035571913,0.005115151,0.000027969747,0.9690699,0.00011436529],"about_ca_topic_score_codex":0.00008661508,"about_ca_topic_score_gemma":0.00022383123,"teacher_disagreement_score":0.22252524,"about_ca_system_score_codex":0.00080377085,"about_ca_system_score_gemma":0.0062109814,"threshold_uncertainty_score":0.9994229},"labels":[],"label_agreement":null},{"id":"W3136918147","doi":"10.7150/jca.55322","title":"Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Medicine; Immunotherapy; Chemotherapy; Oncology; Cancer research; Internal medicine; Cancer","score_opus":0.010132802811150468,"score_gpt":0.3343565310179406,"score_spread":0.32422372820679013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136918147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683487,0.020505155,0.0009574372,0.008896788,0.00013032739,0.00036445245,0.000019177087,0.000007917683,0.00077006995],"genre_scores_gemma":[0.97740144,0.0074441493,0.009776634,0.0015280335,0.0004719828,0.00007684343,0.000007284409,0.000040632265,0.0032530057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994875,0.00000798295,0.00015144506,0.00009812783,0.00013668268,0.000118237345],"domain_scores_gemma":[0.9993876,0.00002198553,0.00014167627,0.00008775998,0.0002773478,0.000083626124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030167179,0.000111117064,0.00027426778,0.00003868416,0.000048780865,0.000025526835,0.000019323536,0.000023825918,0.000111930865],"category_scores_gemma":[0.0000016448671,0.000058859237,0.00005933309,0.00008391391,0.000038403203,0.000075710144,0.0000014208423,0.00005589077,1.9362716e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020398483,0.0014240441,0.12848395,0.00015546326,0.010223784,0.00078728294,0.005097611,0.00009165092,0.024896786,0.0003118588,0.0030514763,0.8050776],"study_design_scores_gemma":[0.119871534,0.03210862,0.18568344,0.0018147146,0.0040518357,0.0043210313,0.0019758584,0.000089692105,0.096380435,0.00027509403,0.5528664,0.0005613335],"about_ca_topic_score_codex":0.00004559548,"about_ca_topic_score_gemma":0.00014444749,"teacher_disagreement_score":0.80451626,"about_ca_system_score_codex":0.00023080286,"about_ca_system_score_gemma":0.00084265147,"threshold_uncertainty_score":0.240021},"labels":[],"label_agreement":null},{"id":"W3137057543","doi":"10.1016/j.jtho.2021.10.014","title":"Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Eli Lilly Japan; Merck Sharp and Dohme; Ono Pharmaceutical; Teijin Pharma; Daiichi-Sankyo; Taiho Pharmaceutical; Chugai Pharmaceutical; Roche; Novartis; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Boehringer Ingelheim; Amgen; Pfizer; Bayer; Shire; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Chemotherapy; Adjuvant; Adjuvant chemotherapy; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.04007172802736948,"score_gpt":0.45780914123256194,"score_spread":0.4177374132051925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137057543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666819,0.0037753154,0.00024379794,0.02814228,0.00041123346,0.00042779418,0.000050378814,0.0000143809575,0.00025293784],"genre_scores_gemma":[0.98046863,0.0013342984,0.009539153,0.0069982177,0.00018886544,0.000022724884,0.00005934626,0.00003174883,0.0013570223],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988251,0.00015613985,0.00046274194,0.00019552,0.00017348643,0.00018705371],"domain_scores_gemma":[0.9979735,0.0004960818,0.00033467243,0.00015326714,0.00087536185,0.00016714085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016450984,0.00016194898,0.00067370164,0.00010201412,0.00009676269,0.00003898476,0.00005758613,0.0001402084,0.00026887367],"category_scores_gemma":[0.0003628066,0.000106923,0.00016507092,0.00013944396,0.000067665525,0.00018537696,0.000015195688,0.00022202525,0.000003576818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027468434,0.0026580575,0.07702761,0.000041680123,0.0073269354,0.0023774258,0.010648885,0.000015017608,0.17175858,0.000076022916,0.008222668,0.6923787],"study_design_scores_gemma":[0.029053848,0.0135667445,0.73325574,0.0003996426,0.0018827094,0.0019992886,0.004020365,0.0001295599,0.10217078,0.0011222984,0.112022914,0.00037611063],"about_ca_topic_score_codex":0.00009072867,"about_ca_topic_score_gemma":0.000047903257,"teacher_disagreement_score":0.6920026,"about_ca_system_score_codex":0.00024944023,"about_ca_system_score_gemma":0.0010757108,"threshold_uncertainty_score":0.43601936},"labels":[],"label_agreement":null},{"id":"W3138307077","doi":"10.1016/j.jtho.2021.01.149","title":"FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Resistance (ecology); Multicenter study; Cancer; Epidermal growth factor receptor; Randomized controlled trial","score_opus":0.02324870945167406,"score_gpt":0.4558550673411255,"score_spread":0.43260635788945145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138307077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649686,0.00028617034,0.0009051058,0.0013842721,0.00016269452,0.00027494697,0.000023485252,0.000004516231,0.00046195704],"genre_scores_gemma":[0.99088126,0.000020960639,0.008188037,0.00024599023,0.000033530392,0.000007938984,0.000017974884,0.00001311049,0.0005911717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980786,0.0002985353,0.00097517733,0.00019714184,0.00028518637,0.0001653561],"domain_scores_gemma":[0.9979607,0.00012156501,0.00078918005,0.0003234088,0.000650172,0.0001549708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053232507,0.000116682764,0.0009502385,0.00057180866,0.00002295537,0.0000058504975,0.00012692135,0.000091947055,0.00012491446],"category_scores_gemma":[0.00022306161,0.00009552923,0.00020049704,0.0010715545,0.00003723062,0.00008684482,0.00003410567,0.00019740046,0.0000017796312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025505794,0.036601014,0.5179086,0.00055416994,0.027314782,0.010724301,0.036877368,0.0032787514,0.29530895,0.0002512984,0.0013061797,0.04436883],"study_design_scores_gemma":[0.010722678,0.0077787996,0.8527204,0.0007233181,0.025182916,0.0002075318,0.035934187,0.00071366644,0.06380137,0.0005033003,0.001416481,0.00029537268],"about_ca_topic_score_codex":0.00009137919,"about_ca_topic_score_gemma":0.0017635903,"teacher_disagreement_score":0.3348118,"about_ca_system_score_codex":0.00042730558,"about_ca_system_score_gemma":0.0006967596,"threshold_uncertainty_score":0.38955688},"labels":[],"label_agreement":null},{"id":"W3139044601","doi":"10.1016/j.jtho.2021.03.003","title":"The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institutes of Health; Association of Community Cancer Centers; Pfizer; Intuitive Surgical; Amgen; University of Colorado; National Cancer Institute; AbbVie; Gilead Sciences; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; International Association for the Study of Lung Cancer; American Cancer Society","keywords":"Medicine; Lung cancer; Association (psychology); Cancer; Database; Family medicine; Oncology; Internal medicine","score_opus":0.05223508326197522,"score_gpt":0.4841095428410118,"score_spread":0.4318744595790366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139044601","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006279726,0.20318736,0.00008185162,0.025252871,0.75981754,0.0025650016,0.00071975857,0.000008658747,0.0020872543],"genre_scores_gemma":[0.020092003,0.3407692,0.00055990054,0.00025148198,0.6275614,0.00087559805,0.00036788234,0.000092439834,0.0094300965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983884,0.00020868497,0.00048770328,0.00014718744,0.0006394101,0.00012858122],"domain_scores_gemma":[0.9943515,0.0023091459,0.0013429453,0.00016871377,0.0017852375,0.000042448595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012359313,0.0001348861,0.00047882771,0.00011120396,0.00012485993,0.000030147385,0.00018067904,0.00020817434,0.000007787984],"category_scores_gemma":[0.0011832317,0.00007380694,0.000120477656,0.000045660167,0.00004647206,0.00007452179,0.000074327705,0.00049616076,3.75373e-8],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016076767,0.0009419756,0.00015004343,0.00029752782,0.010101279,0.00020416762,0.005460296,0.0000071073127,0.00004988968,0.00008997791,0.8268163,0.15427376],"study_design_scores_gemma":[0.0018238348,0.0016207844,0.00029718713,0.0003076022,0.0054690847,0.0000318695,0.013332282,0.00003610571,0.000027314018,0.0000326747,0.9769544,0.00006688924],"about_ca_topic_score_codex":0.00013282266,"about_ca_topic_score_gemma":0.00053692615,"teacher_disagreement_score":0.15420687,"about_ca_system_score_codex":0.0011413862,"about_ca_system_score_gemma":0.0039448654,"threshold_uncertainty_score":0.6998022},"labels":[],"label_agreement":null},{"id":"W3140130406","doi":"10.3390/curroncol28020135","title":"Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lymphovascular invasion; Internal medicine; Adenocarcinoma; Oncology; Chemotherapy; Adjuvant therapy; Adjuvant; Lung cancer; Stage (stratigraphy); Cancer; Gastroenterology; Metastasis","score_opus":0.07003240408242814,"score_gpt":0.43034143034205646,"score_spread":0.36030902625962835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140130406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615779,0.026109796,0.00015588963,0.0029539368,0.0032313408,0.0006117537,0.00021267185,0.000069720714,0.0050769844],"genre_scores_gemma":[0.99400073,0.002309727,0.00048229672,0.0004723094,0.00050645834,0.00015608838,0.00078088156,0.00004350954,0.0012479997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831015,0.000057835343,0.00042044025,0.00055134646,0.00023344059,0.0004267826],"domain_scores_gemma":[0.9989384,0.00016965202,0.00013017001,0.00041861236,0.00013730394,0.00020590362],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000759892,0.00024830317,0.0006405301,0.00012811142,0.00007582086,0.000018713175,0.000111475456,0.00016972842,0.0019197693],"category_scores_gemma":[0.000044671535,0.00022460063,0.0001421775,0.00030597788,0.00007309145,0.00007586548,0.00007052293,0.0003354334,0.000060726557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071081,0.006174759,0.36381954,0.00036940046,0.0021082312,0.0044962326,0.020382643,0.00017130228,0.0047797053,0.0030899323,0.009682765,0.5778174],"study_design_scores_gemma":[0.08848618,0.0018230239,0.4109616,0.00047816895,0.0014111092,0.000080588434,0.004647181,0.0026360864,0.0048130914,0.00032940874,0.48364496,0.0006886011],"about_ca_topic_score_codex":0.0005310917,"about_ca_topic_score_gemma":0.0010904813,"teacher_disagreement_score":0.57712877,"about_ca_system_score_codex":0.0022220656,"about_ca_system_score_gemma":0.0011629256,"threshold_uncertainty_score":0.9989926},"labels":[],"label_agreement":null},{"id":"W3142040693","doi":"10.1002/ijc.33583","title":"The genomic landscape of young and old lung cancer patients highlights age‐dependent mutation frequencies and clinical actionability in young patients","year":2021,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"National Natural Science Foundation of China","keywords":"CDKN2A; KRAS; ROS1; Adenocarcinoma; Lung cancer; Medicine; Oncology; Internal medicine; Young adult; Exon; Cancer; Adenocarcinoma of the lung; Cancer research; Genetics; Biology; Gene; Colorectal cancer","score_opus":0.011092826581530211,"score_gpt":0.3585629371015031,"score_spread":0.3474701105199729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142040693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937228,0.002982113,0.000013589928,0.0011917497,0.0016559339,0.00016422797,0.000060703947,0.0000022963468,0.00020657844],"genre_scores_gemma":[0.9950851,0.0043212497,0.00006917879,0.000079763246,0.00020000096,0.000016374615,0.0000205123,0.000007826777,0.0001999449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987189,0.000054453427,0.0005648778,0.00013752573,0.00043332766,0.00009092435],"domain_scores_gemma":[0.9983255,0.000117509386,0.00037769385,0.000066582805,0.0010475683,0.00006512523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016287935,0.0000854446,0.0001996578,0.00007926447,0.00004866394,0.000038105394,0.00006859636,0.00004722466,0.00004898681],"category_scores_gemma":[0.00012183007,0.000057907997,0.00006756451,0.00006066145,0.00007305279,0.00016959256,0.00003350593,0.00014259588,1.7983697e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024310542,0.00022594679,0.9883925,0.000018428007,0.00059860275,0.00003148403,0.0006453699,0.000041046853,0.00013510887,0.0000848273,0.00010646408,0.009477149],"study_design_scores_gemma":[0.004030269,0.00011225843,0.99441975,0.00015819809,0.00025898067,0.00002353488,0.00015536798,0.00009705434,0.0002374485,0.00018330463,0.00027534764,0.00004850319],"about_ca_topic_score_codex":0.00076672144,"about_ca_topic_score_gemma":0.0037849948,"teacher_disagreement_score":0.0094286455,"about_ca_system_score_codex":0.00042653017,"about_ca_system_score_gemma":0.00033593347,"threshold_uncertainty_score":0.23614196},"labels":[],"label_agreement":null},{"id":"W3143019137","doi":"10.1007/s40273-021-01022-9","title":"Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Afatinib; Erlotinib; Gefitinib; Medicine; Lung cancer; Cost effectiveness; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer registry; Cancer; Risk analysis (engineering)","score_opus":0.025514685803821453,"score_gpt":0.36743199878691274,"score_spread":0.3419173129830913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143019137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450743,0.00066953525,0.00024441793,0.00035809964,0.00021405703,0.0017422829,0.0012196032,0.0000069654106,0.001037606],"genre_scores_gemma":[0.9958306,0.00032733957,0.00044288815,0.00046761628,0.000035297584,0.00094114,0.0010080027,0.000025863183,0.0009212574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989262,0.000030323734,0.00037120123,0.00037734953,0.000069948146,0.00022493348],"domain_scores_gemma":[0.9989504,0.00040285138,0.00018012094,0.00013441854,0.00019013387,0.00014206198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008545346,0.0001961259,0.00056129246,0.00015022545,0.00007878015,0.000016577742,0.00004148291,0.000046569035,0.0004195982],"category_scores_gemma":[0.00001523661,0.00020177667,0.00012303439,0.00022675945,0.00002324823,0.00007826841,0.000022642434,0.00009362863,6.0162614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009875201,0.0009461915,0.926221,0.00041467274,0.013412386,0.00017167728,0.0038845702,0.04401021,0.0014092554,0.000059593447,0.00022866295,0.00825422],"study_design_scores_gemma":[0.025166927,0.00028103383,0.82908046,0.00022098796,0.023113437,0.000018089848,0.0007068783,0.042917844,0.076682925,0.00003194599,0.0013658947,0.00041355556],"about_ca_topic_score_codex":0.8534752,"about_ca_topic_score_gemma":0.9741099,"teacher_disagreement_score":0.12063469,"about_ca_system_score_codex":0.0020320376,"about_ca_system_score_gemma":0.002681793,"threshold_uncertainty_score":0.8228214},"labels":[],"label_agreement":null},{"id":"W3145651314","doi":"10.1016/s1556-0864(21)01985-7","title":"143P Physician perceptions of barriers to epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Stage (stratigraphy); Mutation; Cancer research; Cancer; Genetics; Gene","score_opus":0.01918052090929674,"score_gpt":0.4075956766757863,"score_spread":0.38841515576648955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145651314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912161,0.00055061415,0.0014066707,0.0031168472,0.00067894475,0.0004386338,0.00009338439,0.000011654961,0.0024871514],"genre_scores_gemma":[0.9729635,0.000100927784,0.02477569,0.00093204825,0.00032439307,0.00004318195,0.000023785457,0.000032766267,0.0008036817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982756,0.00016569151,0.0007632801,0.00024016017,0.0002405174,0.0003147496],"domain_scores_gemma":[0.9977402,0.00022359366,0.0006257675,0.00015976945,0.0008833789,0.0003672618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022346037,0.00018729192,0.00066550565,0.000310908,0.000106616746,0.000012855431,0.00010495432,0.00012949633,0.00040857153],"category_scores_gemma":[0.0005252524,0.00016704931,0.00017605095,0.00060372066,0.000048635764,0.00021019884,0.00003759943,0.000386463,0.0000061463584],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016757594,0.0015602454,0.19702978,0.0010064751,0.00063173566,0.0012983797,0.025400005,0.007157452,0.5360091,0.000027417136,0.0016901676,0.2265135],"study_design_scores_gemma":[0.015072221,0.007911214,0.7178385,0.004736471,0.0035902655,0.0006019405,0.06849562,0.0026930268,0.16988775,0.00017844402,0.007891575,0.0011029548],"about_ca_topic_score_codex":0.00015370587,"about_ca_topic_score_gemma":0.0002471947,"teacher_disagreement_score":0.52080876,"about_ca_system_score_codex":0.0011467692,"about_ca_system_score_gemma":0.0028391005,"threshold_uncertainty_score":0.6812073},"labels":[],"label_agreement":null},{"id":"W3147842235","doi":"10.1016/s1556-0864(21)02027-x","title":"185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Carboplatin; Nivolumab; Trastuzumab; Phases of clinical research; Lapatinib; Immunotherapy; Chemotherapy; Cancer; Cisplatin; Breast cancer","score_opus":0.023105249282846383,"score_gpt":0.44140608400617776,"score_spread":0.41830083472333135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147842235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960877,0.0006546971,0.00026189716,0.0006287168,0.000063007246,0.0022100387,0.000010453917,0.000007481011,0.00007603499],"genre_scores_gemma":[0.9904099,0.00024164746,0.008823983,0.0000846552,0.000030612187,0.0001722864,0.00002639427,0.000034186407,0.00017629993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982607,0.0002612862,0.0005953033,0.00031847454,0.00033679328,0.00022747557],"domain_scores_gemma":[0.9985334,0.00021454607,0.00059083535,0.00014079969,0.00037630124,0.00014410146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032085777,0.00025029664,0.00069704093,0.00025821268,0.00010164692,0.0000276702,0.00004002275,0.00006855056,0.000044884462],"category_scores_gemma":[0.00006604617,0.00015825828,0.00003497866,0.00036060982,0.000045068555,0.00023670023,0.00001649554,0.00021900334,2.2355513e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039240554,0.022100378,0.3653404,0.00030160722,0.0005195119,0.0009925348,0.01245375,0.0024906301,0.0011478578,8.267267e-7,0.000005376042,0.5554066],"study_design_scores_gemma":[0.16522571,0.11616129,0.70147955,0.002143366,0.002438465,0.00045700304,0.0049285768,0.004942904,0.0018190318,0.000040109273,0.000053132633,0.00031087105],"about_ca_topic_score_codex":0.0003449473,"about_ca_topic_score_gemma":0.0034194984,"teacher_disagreement_score":0.55509573,"about_ca_system_score_codex":0.0013650211,"about_ca_system_score_gemma":0.0014501059,"threshold_uncertainty_score":0.64535856},"labels":[],"label_agreement":null},{"id":"W3148747298","doi":"10.1200/jco.2014.60.3555","title":"Reply to B. O'Sullivan et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"National Cancer Institute","keywords":"Medicine; Humanities; Philosophy","score_opus":0.15961020442785756,"score_gpt":0.5566031253860996,"score_spread":0.396992920958242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148747298","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033604202,0.00320082,0.00031409174,0.91951734,0.028012563,0.00046621962,0.000057679634,0.000011165359,0.045059696],"genre_scores_gemma":[0.0016770097,0.0019871881,0.0102245305,0.93518126,0.024657628,0.000011636715,0.00004828593,0.000068218935,0.026144223],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99147356,0.0014769087,0.0049826354,0.0004636331,0.0009886348,0.0006146133],"domain_scores_gemma":[0.9875321,0.0047457544,0.0037465328,0.000516899,0.0019006273,0.0015581236],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0073749027,0.0003952832,0.0035301633,0.0002880914,0.000055739893,0.000028491826,0.00041564967,0.001270801,0.0011882057],"category_scores_gemma":[0.011598353,0.00028035804,0.0012017956,0.00022544406,0.00030079632,0.00015441459,0.00012780479,0.0053123008,0.001118933],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015336087,0.0014901069,0.0035735387,0.000042639276,0.0022018084,0.009945843,0.00039586873,0.000043367898,0.000004526185,0.0001219629,0.85386026,0.12678647],"study_design_scores_gemma":[0.009201094,0.033466563,0.009639907,0.0007678203,0.0033577573,0.0015917663,0.0001521484,0.000009396717,0.0000021822093,0.00035469877,0.94123137,0.00022527973],"about_ca_topic_score_codex":0.00020401651,"about_ca_topic_score_gemma":0.000049635728,"teacher_disagreement_score":0.1265612,"about_ca_system_score_codex":0.0015902945,"about_ca_system_score_gemma":0.01698643,"threshold_uncertainty_score":0.99996483},"labels":[],"label_agreement":null},{"id":"W3151729207","doi":"10.1016/s1556-0864(21)01986-9","title":"144P Delays in epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/ IIIc/ IV) non-small cell lung cancer (NSCLC) patients and their impact on the use of first line tyrosine kinase inhibitor (TKIs) in a real-world setting","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Epidermal growth factor receptor; Internal medicine; Lung cancer; Stage (stratigraphy); Lung; Cancer; Pathology","score_opus":0.03451590880602718,"score_gpt":0.3889431964996445,"score_spread":0.3544272876936173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151729207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639803,0.00047169923,0.00005273556,0.0019530009,0.00023838125,0.0006155766,0.000110844536,0.000005601424,0.00015412224],"genre_scores_gemma":[0.996214,0.0003340844,0.0028471784,0.0002958226,0.00012778955,0.000035971287,0.00003173777,0.00003009299,0.000083351886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998011,0.0002808513,0.0009764386,0.00024046187,0.00017923696,0.00031201262],"domain_scores_gemma":[0.9969324,0.0014628138,0.00088085205,0.00014031676,0.00045826688,0.00012538712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042230528,0.00023821693,0.00067376613,0.00046822787,0.00006479885,0.00002006672,0.000072371644,0.00011792286,0.000045250483],"category_scores_gemma":[0.0008903224,0.00015012073,0.0001038259,0.0007295125,0.00004801352,0.0002619249,0.0000503269,0.0005531244,4.19158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020988865,0.0014691405,0.9315153,0.00032287557,0.000100939986,0.0004969184,0.0052017635,0.0055134683,0.010576338,0.000002962596,0.00012072626,0.042580724],"study_design_scores_gemma":[0.0076215556,0.0024777257,0.95431024,0.0033801752,0.00019310559,0.000046722642,0.0012252136,0.0064319973,0.023847371,0.000024033965,0.0002190891,0.00022275266],"about_ca_topic_score_codex":0.0012592995,"about_ca_topic_score_gemma":0.0050808648,"teacher_disagreement_score":0.042357974,"about_ca_system_score_codex":0.0014195505,"about_ca_system_score_gemma":0.0008403729,"threshold_uncertainty_score":0.6121746},"labels":[],"label_agreement":null},{"id":"W3152755738","doi":"10.46747/cfp.6704e99","title":"Diagnostic de cancer en première ligne","year":2021,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa; Employment and Social Development Canada","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.010626118813354646,"score_gpt":0.28694750209177955,"score_spread":0.2763213832784249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152755738","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09113653,0.3560999,0.00007799293,0.03611145,0.007527764,0.0008884577,0.0028258297,0.0000713244,0.50526077],"genre_scores_gemma":[0.67962605,0.009930135,0.00044988442,0.20472473,0.008711105,0.00042622688,0.00064909493,0.00018242035,0.09530035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798536,0.000110076304,0.00022147456,0.00043630574,0.00018313424,0.0010636692],"domain_scores_gemma":[0.9977111,0.00027205277,0.000055548502,0.0004303822,0.00020764179,0.0013232762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006501591,0.0002854777,0.0003595129,0.00010677037,0.00022189485,0.00006908649,0.00012497103,0.00019512793,0.00019002892],"category_scores_gemma":[0.00010265912,0.00032889223,0.00015867296,0.00050060754,0.000107897766,0.00013709729,0.00002279577,0.00028930558,0.0005865058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011599802,0.00043220664,0.014599027,0.0005811144,0.0017737182,0.0063630166,0.0029019637,0.0006066318,0.004016881,0.010784602,0.36293137,0.5949979],"study_design_scores_gemma":[0.0011919133,0.000098043885,0.09035836,0.0019367158,0.0017492904,0.00001333423,0.0031846205,0.00018834774,0.0015271165,0.0005952932,0.8987664,0.0003905475],"about_ca_topic_score_codex":0.16111244,"about_ca_topic_score_gemma":0.17813593,"teacher_disagreement_score":0.5946073,"about_ca_system_score_codex":0.004437973,"about_ca_system_score_gemma":0.0121892495,"threshold_uncertainty_score":0.9999163},"labels":[],"label_agreement":null},{"id":"W3156150685","doi":"10.2196/23161","title":"Data Integration to Improve Real-world Health Outcomes Research for Non–Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration","year":2021,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Medicine; Cohort; Descriptive statistics; Atezolizumab; Medical record; Nivolumab; Cancer; Internal medicine; Database; Statistics; Computer science","score_opus":0.23932604910049934,"score_gpt":0.5582879789472005,"score_spread":0.31896192984670113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156150685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7826239,0.00297457,0.010746032,0.17796808,0.0007533562,0.01634897,0.007254803,0.000067543115,0.0012627644],"genre_scores_gemma":[0.9443627,0.0052459496,0.004292051,0.009093429,0.0003568805,0.019673182,0.0057118563,0.00007717583,0.011186786],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9984647,0.00027638156,0.00027905457,0.00043057906,0.0002542012,0.00029507265],"domain_scores_gemma":[0.9984727,0.0003865166,0.00008634347,0.00040743392,0.00054143276,0.00010556769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074800965,0.00013431636,0.00024720805,0.00025277396,0.00017629897,0.000069387985,0.00010890571,0.000036216745,0.00002757833],"category_scores_gemma":[0.0000933178,0.00008969669,0.000025973044,0.00091043697,0.000042177453,0.00022556192,0.00006102462,0.00020387609,0.0000013293442],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008739728,0.00064759096,0.018679962,0.00092880183,0.00038523058,0.000017386204,0.84255725,0.0002520576,0.0018169975,0.0013523671,0.09409925,0.038389154],"study_design_scores_gemma":[0.010221517,0.0018090921,0.08767891,0.0020776524,0.00051544886,0.0000016727329,0.79969156,0.020962127,0.004152867,0.0015723935,0.070705034,0.00061173324],"about_ca_topic_score_codex":0.032343592,"about_ca_topic_score_gemma":0.1483656,"teacher_disagreement_score":0.16887465,"about_ca_system_score_codex":0.0010156275,"about_ca_system_score_gemma":0.001243065,"threshold_uncertainty_score":0.9741001},"labels":[],"label_agreement":null},{"id":"W3156170207","doi":"10.1016/j.ctarc.2021.100378","title":"RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis","year":2021,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Erlotinib; Ramucirumab; Internal medicine; Medicine; Placebo; Population; Oncology; Lung cancer; Subgroup analysis; Gastroenterology; Cancer; Epidermal growth factor receptor; Pathology; Confidence interval","score_opus":0.060560401384030245,"score_gpt":0.4003621795605682,"score_spread":0.33980177817653795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156170207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97269446,0.015581828,0.000036937567,0.004350194,0.000087882865,0.0034676527,0.0011505957,0.00008213746,0.0025483344],"genre_scores_gemma":[0.9350438,0.04428303,0.0013949351,0.00011406662,0.000032076612,0.002954257,0.01055301,0.00009225395,0.0055325506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967067,0.0006772063,0.00053984363,0.00073611474,0.000554487,0.00078561687],"domain_scores_gemma":[0.99535906,0.0008606362,0.00018416416,0.0017042598,0.0014484779,0.00044338722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029662525,0.00043644855,0.00080174033,0.001029586,0.0007776949,0.00016689088,0.00037144235,0.00010081933,0.0002476114],"category_scores_gemma":[0.00006837204,0.00032741396,0.00015120277,0.004814568,0.00041216073,0.0001707642,0.0002675245,0.0005507273,0.000016176802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011397669,0.005817514,0.9037652,0.0004904563,0.021052655,0.00042447855,0.02137161,0.02555294,0.00006184813,0.00017821169,0.002122553,0.0077648577],"study_design_scores_gemma":[0.2801751,0.006768083,0.52115095,0.0021124624,0.040831592,0.000024584451,0.019646911,0.08563576,0.0015312575,0.000038568294,0.03996219,0.0021225654],"about_ca_topic_score_codex":0.01952549,"about_ca_topic_score_gemma":0.029833019,"teacher_disagreement_score":0.38261428,"about_ca_system_score_codex":0.0030353605,"about_ca_system_score_gemma":0.0027582722,"threshold_uncertainty_score":0.9999178},"labels":[],"label_agreement":null},{"id":"W3156286581","doi":"10.1186/s40246-021-00320-9","title":"Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Human Genomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Park","funders":"Jiangxi Provincial Department of Science and Technology","keywords":"Oncology; Lung cancer; Internal medicine; Context (archaeology); Human genetics; Exome sequencing; Medicine; Carcinoma; Targeted therapy; Exome; Epidemiology; Incidence (geometry); Cohort; Bioinformatics; Biology; Cancer; Gene; Mutation; Genetics","score_opus":0.007989930306953521,"score_gpt":0.2499262124073366,"score_spread":0.24193628210038307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156286581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961778,0.00033666752,0.00005058089,0.000016935062,0.00007072909,0.00045073495,0.000072227755,0.000012545751,0.0028117814],"genre_scores_gemma":[0.9968554,0.000007730399,0.0009187698,0.00005868193,0.00004884449,0.000038887247,0.0013026316,0.00002735367,0.0007417156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991179,0.00001769355,0.0002846709,0.00024362018,0.00016813158,0.00016796339],"domain_scores_gemma":[0.99936014,0.000024470428,0.00011478157,0.00020206001,0.00023255084,0.00006601953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053187683,0.0001393112,0.00026627132,0.00012791739,0.00007062089,0.000018686462,0.000050291666,0.000045985173,0.00015405977],"category_scores_gemma":[0.000009548127,0.00011688226,0.000050074097,0.00018368968,0.000030726093,0.0000622878,0.00002903737,0.0000926073,0.000005629783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004885981,0.00020502284,0.98868823,0.00014948375,0.00011818063,0.000114962895,0.0035664106,0.00038736162,0.006614645,0.000018093906,0.00006129873,0.000027440767],"study_design_scores_gemma":[0.003913997,0.00009890852,0.9926173,0.00006596088,0.00020731402,0.000010206026,0.00058598514,0.0003281278,0.0019926578,0.000047713682,0.000014146375,0.00011765839],"about_ca_topic_score_codex":0.0002123376,"about_ca_topic_score_gemma":0.00044264924,"teacher_disagreement_score":0.004621987,"about_ca_system_score_codex":0.0002930597,"about_ca_system_score_gemma":0.00051661173,"threshold_uncertainty_score":0.476632},"labels":[],"label_agreement":null},{"id":"W3157820446","doi":"10.1371/journal.pone.0251080","title":"Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Pfizer Canada; Canadian Institutes of Health Research; Merck Canada; Roche; Pfizer; Boehringer Ingelheim","keywords":"Lung cancer; KRAS; Immunohistochemistry; PD-L1; ROS1; Cancer research; Cancer; Biology; Medicine; Oncology; Pathology; Internal medicine; Adenocarcinoma; Immunotherapy; Colorectal cancer","score_opus":0.025428027417779372,"score_gpt":0.2641626803961973,"score_spread":0.2387346529784179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157820446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884044,0.009947741,0.00004267262,0.00030996956,0.000021604974,0.00059658865,0.00004345515,0.000026172138,0.0006074135],"genre_scores_gemma":[0.992978,0.0019485747,0.0016411435,0.000111489826,0.000022016935,0.000082375256,0.00026247592,0.00003467696,0.0029192902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990148,0.000023366165,0.00020339324,0.00034228037,0.00025318615,0.0001629885],"domain_scores_gemma":[0.99888784,0.00006283275,0.0002091636,0.00028342928,0.00046966228,0.00008709332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091298556,0.00016520655,0.0003763847,0.000038424656,0.000103986065,0.000022786324,0.00003819427,0.00010138583,0.00004855398],"category_scores_gemma":[0.00005196726,0.00012813449,0.000027529382,0.00022940681,0.00007581885,0.00007464857,0.000024019624,0.00014999147,0.0000012070702],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018687882,0.00075383123,0.47005662,0.0010151293,0.0017208707,0.000017777738,0.0013872483,0.000010780931,0.5246694,0.000008435559,0.00011159977,0.00006139591],"study_design_scores_gemma":[0.0042361277,0.00040822485,0.18885008,0.0057303896,0.0058911354,0.000014473545,0.0010226684,0.0006816461,0.7928245,0.000013962834,0.00001968678,0.00030708066],"about_ca_topic_score_codex":0.0001607353,"about_ca_topic_score_gemma":0.00003451319,"teacher_disagreement_score":0.28120655,"about_ca_system_score_codex":0.00014594046,"about_ca_system_score_gemma":0.00035084604,"threshold_uncertainty_score":0.52251726},"labels":[],"label_agreement":null},{"id":"W3157973823","doi":"10.21037/tlcr-20-994","title":"Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review","year":2021,"lang":"en","type":"review","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Systemic therapy; Oncology; Randomized controlled trial; Ablative case; Radiation therapy; Narrative review; Lung cancer; Clinical trial; Radiofrequency ablation; Internal medicine; Radiosurgery; Cancer; Intensive care medicine; Ablation; Breast cancer","score_opus":0.1606018630053743,"score_gpt":0.5550271215563186,"score_spread":0.39442525855094435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157973823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027905294,0.98743945,0.0002843738,0.0031887614,0.00013574272,0.0050968532,0.0005325188,0.000031503107,0.0032879754],"genre_scores_gemma":[0.000056559402,0.9857276,0.0006193295,0.00024190005,0.00017505801,0.0040767267,0.0014657596,0.00009949034,0.007537571],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948466,0.0010490223,0.0010436897,0.00086466863,0.0015124456,0.00068361923],"domain_scores_gemma":[0.9972231,0.0011088469,0.0001845838,0.0004586434,0.000783767,0.00024107166],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001020062,0.00053855655,0.002510205,0.0006492208,0.00022050581,0.000052234,0.00023535562,0.00023435618,0.006130149],"category_scores_gemma":[0.00011507041,0.00035992797,0.0005397969,0.0022956668,0.00032840561,0.00017461495,0.000039646256,0.0013149111,0.00005657119],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015878232,0.00035517674,0.00003994598,0.073837884,0.003255185,0.000318185,0.005070534,0.00001869139,2.4636813e-7,0.00081765204,0.008285217,0.9078425],"study_design_scores_gemma":[0.0013940241,0.00016523832,0.00007451181,0.18557453,0.0020998411,0.00005160804,0.000553757,0.000049186827,6.161725e-7,0.000085196756,0.80961597,0.00033553495],"about_ca_topic_score_codex":0.0005681012,"about_ca_topic_score_gemma":0.0012090494,"teacher_disagreement_score":0.90750694,"about_ca_system_score_codex":0.0017168464,"about_ca_system_score_gemma":0.010322699,"threshold_uncertainty_score":0.99988526},"labels":[],"label_agreement":null},{"id":"W3159335234","doi":"10.2147/ott.s291801","title":"A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies","year":2021,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Merck Sharp and Dohme; EMD Serono; Genentech; Plexxikon; Bausch Health; STCube; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Silverback Therapeutics; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Aminex Therapeutics; Agios Pharmaceuticals; IFM Therapeutics; Symphogen; Pfizer; Incyte; Boston Pharmaceuticals; Five Prime Therapeutics; Loxo Oncology; Astex Pharmaceuticals; Eli Lilly and Company; National Comprehensive Cancer Network; Principia Biopharma; University of Texas MD Anderson Cancer Center; Puma Biotechnology; National Institutes of Health; BioMarin Pharmaceutical; Regeneron Pharmaceuticals; Baxalta; Immune Deficiency Foundation; Helsinn; Exelixis; Karyopharm Therapeutics; Bristol-Myers Squibb; American Society of Clinical Oncology; Sanofi; Amgen","keywords":"Crizotinib; Pazopanib; Medicine; ROS1; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Progressive disease; Gastroenterology; Pharmacology; Cancer; Sunitinib; Chemotherapy; Lung cancer; Adenocarcinoma","score_opus":0.00900558308648964,"score_gpt":0.2918006701008566,"score_spread":0.28279508701436695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159335234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955321,0.0010945733,0.000006831224,0.0014314721,0.00020881419,0.0013077601,0.000044568576,0.00001365049,0.0003602168],"genre_scores_gemma":[0.9984314,0.00022603993,0.0002418166,0.0005053365,0.000093436196,0.00012758172,0.000040424085,0.000026117503,0.0003078609],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989591,0.00006969245,0.00023247169,0.00024029397,0.00029914075,0.00019928986],"domain_scores_gemma":[0.9992362,0.0000582908,0.00014841814,0.00029477506,0.00020054239,0.000061756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008414033,0.00018359866,0.0003592825,0.00003418144,0.00013519885,0.000023614977,0.000060535756,0.000041269366,0.000031366097],"category_scores_gemma":[0.000017609087,0.000077974655,0.000064462336,0.00026557283,0.00014267697,0.00008182211,0.000022029488,0.00012302161,5.8265425e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5137051,0.04015978,0.21216844,0.00029864183,0.0031228478,0.00019832062,0.02345299,0.000059114376,0.045986637,0.0018653955,0.0019367383,0.15704605],"study_design_scores_gemma":[0.7699222,0.041535877,0.09554537,0.0007438713,0.00042052983,0.000012866726,0.0019785566,0.000017035762,0.06427233,0.0001806953,0.024957731,0.00041295087],"about_ca_topic_score_codex":0.000028069506,"about_ca_topic_score_gemma":0.00007838228,"teacher_disagreement_score":0.25621715,"about_ca_system_score_codex":0.000043632528,"about_ca_system_score_gemma":0.00028519408,"threshold_uncertainty_score":0.3179714},"labels":[],"label_agreement":null},{"id":"W3159441190","doi":"10.1200/jco.21.00688","title":"Reply to K. Yokoyama et al","year":2021,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Medicine","score_opus":0.1359303231355118,"score_gpt":0.5515343569202396,"score_spread":0.41560403378472777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159441190","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004843087,0.005798531,0.00042702287,0.93028843,0.030058151,0.00035563094,0.00004728179,0.000008611893,0.028173251],"genre_scores_gemma":[0.0014263839,0.0041491794,0.011184423,0.9298277,0.02301197,0.000013312279,0.00006505489,0.00006285209,0.030259134],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914085,0.0016648864,0.005010987,0.0005194003,0.0008005936,0.00059559854],"domain_scores_gemma":[0.98721975,0.0063967723,0.003326665,0.00052224385,0.0015012941,0.0010332527],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004433203,0.00037892524,0.0036415276,0.00023901917,0.00007032601,0.000039850816,0.00033813578,0.0012844735,0.0029442552],"category_scores_gemma":[0.009858678,0.00028189286,0.0016898433,0.0002762019,0.0002431216,0.00013408106,0.00014329565,0.0056498703,0.0005395288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008203026,0.0016590833,0.004719858,0.000065361,0.0030443922,0.026288863,0.00028739744,0.00003220462,0.000013783674,0.00014116209,0.83237374,0.13055389],"study_design_scores_gemma":[0.0075149494,0.018338086,0.022693412,0.0012803075,0.0037125943,0.002393843,0.00018333638,0.000007386642,0.000008042118,0.00014490788,0.9435049,0.00021821694],"about_ca_topic_score_codex":0.00014375857,"about_ca_topic_score_gemma":0.000052698826,"teacher_disagreement_score":0.13033566,"about_ca_system_score_codex":0.001151695,"about_ca_system_score_gemma":0.015094851,"threshold_uncertainty_score":0.99996334},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3159801410","doi":"10.1016/j.esmoop.2021.100113","title":"Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; National Cancer Institute; Bayer Yakuhin; Ignyta; Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; AstraZeneca; Genentech; Pfizer Japan; Bavarian Nordic; Ipsen; Exelixis; European Medicines Agency; PharmaMar; Celgene; Yakult Honsha; Bayer; Astellas Pharma; Eisai; Daiichi-Sankyo; AstraZeneca España; Ludwig Center at Harvard; Bristol-Myers Squibb; Teva Pharmaceutical Industries; Roche España; Nippon Kayaku; BeiGene; Les Laboratories Pierre Fabre; Helsinn; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Lung Cancer Research Foundation; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Ono Pharmaceutical; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; G1 Therapeutics; Roche; Merck Sharp and Dohme; Novartis; Kissei; Merck; Kyowa Hakko Kirin; Sanofi; Foundation Medicine; GlaxoSmithKline; Servier; Incyte; Pfizer; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Canadian Asian Studies Association; Boehringer Ingelheim España; Eli Lilly and Company; Society for Academic Continuing Medical Education","keywords":"Medicine; Quality of life (healthcare); Clinical trial; Oncology; Internal medicine; Cancer; Lung cancer; Phases of clinical research; ROS1; Adenocarcinoma","score_opus":0.018021475982970155,"score_gpt":0.36851374264837883,"score_spread":0.35049226666540867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159801410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888981,0.00034143272,0.000103499195,0.0009651577,0.00043124892,0.004870715,0.0025726806,0.000022423515,0.001794717],"genre_scores_gemma":[0.99579114,0.000054409327,0.0010644108,0.0005280038,0.00006488819,0.00062639243,0.0008843417,0.000031974258,0.0009544213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981608,0.0000756959,0.0005284661,0.00063539913,0.0002901413,0.0003094998],"domain_scores_gemma":[0.9983426,0.00020187136,0.00034566387,0.0003632604,0.0005181068,0.00022850439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009848941,0.0002938656,0.0007196508,0.000051123574,0.0003664659,0.000071360846,0.00011303741,0.0000769947,0.00046461736],"category_scores_gemma":[0.00008061124,0.00024056988,0.000119762524,0.00024091541,0.000040584015,0.00015635678,0.00039121605,0.00011190389,0.000001616864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033272489,0.015847137,0.9100898,0.000087099834,0.0045141866,0.0009025818,0.042029634,0.00003700926,0.0026311127,0.000020558382,0.004217078,0.01629654],"study_design_scores_gemma":[0.057750467,0.0055581448,0.87702817,0.0006808668,0.005996913,0.000031280142,0.025926847,0.00044527455,0.02558393,0.00007227799,0.00042523924,0.0005005869],"about_ca_topic_score_codex":0.020373086,"about_ca_topic_score_gemma":0.0051303776,"teacher_disagreement_score":0.054423217,"about_ca_system_score_codex":0.00028495002,"about_ca_system_score_gemma":0.00077313656,"threshold_uncertainty_score":0.9861503},"labels":[],"label_agreement":null},{"id":"W3163297753","doi":"10.1161/circ.142.suppl_3.15621","title":"Abstract 15621: Checkpoint Kinases Important Players in Lung Fibrogenesis and Pulmonary Vascular Remodeling: A Translational Study","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Bleomycin; Lung cancer; DNA damage; Idiopathic pulmonary fibrosis; Downregulation and upregulation; Cancer research; Lung; CHEK1; Kinase; Pulmonary hypertension; Fibrosis; Cell cycle; Cell cycle checkpoint; Internal medicine; Pathology; Cancer; Chemotherapy; Cell biology; Biology; DNA","score_opus":0.029674161334686287,"score_gpt":0.3055569952337339,"score_spread":0.2758828338990476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163297753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627334,0.0014464859,0.00042873697,0.00074780366,0.000024373887,0.000795486,0.000012014771,0.00003849723,0.0002332479],"genre_scores_gemma":[0.99938285,0.00004077171,0.00022662892,0.000109724286,0.00006515446,0.000036144203,0.000119190154,0.000016657179,0.0000028999316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990755,0.000016238639,0.00031237953,0.00027296634,0.00021288235,0.0001100472],"domain_scores_gemma":[0.99967134,0.000023610584,0.00006130665,0.00009993607,0.000041250743,0.00010252807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094169605,0.00010966404,0.00017238583,0.000075072705,0.000056943878,0.000015100906,0.00002078003,0.000045703033,0.000058915673],"category_scores_gemma":[0.000026426707,0.000103329985,0.000062395164,0.00017427262,0.000013536153,0.00012224702,0.0000062874183,0.00006773906,0.0000023866774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008884732,0.00024614276,0.98073095,0.00010345042,0.00012964506,0.0000801571,0.0021046097,0.004511255,0.007908792,0.000032557575,0.000005242879,0.00405835],"study_design_scores_gemma":[0.0014558879,0.000043197262,0.9235811,0.000043587643,0.00022181396,0.000010068225,0.00051565043,0.07384176,0.00010144401,0.00005971782,0.000034944067,0.0000907915],"about_ca_topic_score_codex":0.00011481726,"about_ca_topic_score_gemma":0.000017962744,"teacher_disagreement_score":0.0693305,"about_ca_system_score_codex":0.000071806084,"about_ca_system_score_gemma":0.000102256665,"threshold_uncertainty_score":0.42136744},"labels":[],"label_agreement":null},{"id":"W3163737568","doi":"10.21203/rs.3.rs-457070/v1","title":"Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy Outcomes","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Guangdong Provincial People's Hospital; National Natural Science Foundation of China","keywords":"Mutant; Stage (stratigraphy); Adjuvant therapy; Adjuvant; Oncology; Computational biology; Internal medicine; Biology; Medicine; Cancer research; Gene; Genetics; Cancer","score_opus":0.050219411204293456,"score_gpt":0.40230709692641864,"score_spread":0.3520876857221252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163737568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744295,0.017869147,0.00017228295,0.0017144075,0.00014413454,0.0025229256,0.00065322727,0.00007205997,0.002422324],"genre_scores_gemma":[0.9933836,0.0015297118,0.00068374263,0.000055504883,0.0001365963,0.00037949337,0.0011000781,0.00009077196,0.0026405123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653995,0.00016529582,0.0004656892,0.0007939997,0.0014066944,0.0006283869],"domain_scores_gemma":[0.9969469,0.000296833,0.00020438885,0.0012089659,0.0010829299,0.00026003894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005022819,0.00042630362,0.0010256612,0.00037792217,0.00028484047,0.00008308464,0.000322475,0.00028818854,0.00091407873],"category_scores_gemma":[0.00014679732,0.0002662971,0.0003042334,0.00038255655,0.0003043978,0.00005514211,0.0005822892,0.0012797386,0.0000067174783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004832327,0.0034346264,0.9274275,0.003793527,0.006773522,0.001999318,0.00720752,0.0007452426,0.012592655,0.0013205488,0.0012931247,0.028580118],"study_design_scores_gemma":[0.007255263,0.002581279,0.9768744,0.0026512514,0.00037980132,0.000018078763,0.0020739294,0.0001260207,0.0043879417,0.00035564622,0.002837146,0.00045924832],"about_ca_topic_score_codex":0.0028849377,"about_ca_topic_score_gemma":0.0027537104,"teacher_disagreement_score":0.04944692,"about_ca_system_score_codex":0.0005714658,"about_ca_system_score_gemma":0.0026067847,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W3165420531","doi":"10.1016/j.jtho.2021.05.003","title":"Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Chinook Therapeutics; Janssen Pharmaceuticals; Yuhan; Loxo Oncology; TG Therapeutics; Takeda Pharmaceutical Company; AbbVie; Roche; Novartis; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Celgene; Bayer; Aimmune Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Confidence interval; Stage (stratigraphy); Univariate analysis; Multivariate analysis; Proportional hazards model; Chemoradiotherapy; Performance status; Oncology; Cancer","score_opus":0.07614391861067087,"score_gpt":0.5020628422266695,"score_spread":0.42591892361599865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165420531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765104,0.000026915888,0.00000998874,0.0011570294,0.00021372765,0.0004328534,0.00008602404,0.0000031750471,0.0004192338],"genre_scores_gemma":[0.99621683,0.00008990864,0.0021880516,0.00014970124,0.00006604437,0.000008521266,0.000040339564,0.000010574577,0.0012300378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825084,0.00019543384,0.0009684223,0.00017415213,0.0002830537,0.00012809268],"domain_scores_gemma":[0.9981986,0.0004243217,0.00065992266,0.00016645115,0.00043835322,0.00011233055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033742058,0.00012248755,0.00073487195,0.00015980663,0.000028646426,0.000007373728,0.000041823576,0.00006509338,0.00002926841],"category_scores_gemma":[0.00013101063,0.000075948315,0.0000909234,0.00015527774,0.000048586237,0.00008846566,0.000024857201,0.00017489084,5.84919e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005596516,0.01003795,0.96327233,0.000020366519,0.0009930151,0.0005692572,0.0010004013,0.000016322105,0.0000027887822,0.000005364424,0.00003422274,0.018451465],"study_design_scores_gemma":[0.022748837,0.009206329,0.965091,0.00012137079,0.0008995381,0.00001612659,0.0011515906,0.000010996526,0.000018215134,0.0000053213666,0.0006730523,0.000057633104],"about_ca_topic_score_codex":0.0007242107,"about_ca_topic_score_gemma":0.006337776,"teacher_disagreement_score":0.018393833,"about_ca_system_score_codex":0.00047237572,"about_ca_system_score_gemma":0.00090718194,"threshold_uncertainty_score":0.35366276},"labels":[],"label_agreement":null},{"id":"W3165571064","doi":"10.1016/j.lungcan.2021.05.021","title":"A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; Trillium Health Centre; University Health Network; University of Toronto; St Joseph's Health Centre; Princess Margaret Cancer Centre; Markham Stouffville Hospital; Queen's University","funders":"Novartis Pharmaceuticals Canada; Princess Margaret Cancer Foundation; Array BioPharma","keywords":"Medicine; Pemetrexed; Carboplatin; KRAS; Internal medicine; Oncology; MEK inhibitor; Lung cancer; Neuroblastoma RAS viral oncogene homolog; Adverse effect; Rash; Trametinib; Chemotherapy; Cancer; Colorectal cancer; MAPK/ERK pathway; Kinase; Cisplatin","score_opus":0.012106317204449145,"score_gpt":0.34483031731766367,"score_spread":0.3327240001132145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165571064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969794,0.015517574,0.00005120791,0.000507157,0.00044345803,0.002098161,0.000116859956,0.000033729357,0.001533902],"genre_scores_gemma":[0.9943527,0.0010808754,0.00040215734,0.00042064526,0.00023877391,0.00092992955,0.000043070435,0.00007760711,0.0024542648],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99796146,0.000063786116,0.00055645185,0.00064292044,0.0003564654,0.00041888686],"domain_scores_gemma":[0.9988285,0.00011074499,0.00022758127,0.00040539607,0.0002287868,0.00019901259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013232711,0.00034653378,0.0007739692,0.00024263139,0.00008311241,0.000030452331,0.00008771785,0.00012076451,0.00037790716],"category_scores_gemma":[0.000024698116,0.00031073063,0.00010453746,0.0008072027,0.000054298263,0.00008611718,0.0000571278,0.0002641953,0.0000012011143],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030612927,0.012954227,0.7555379,0.0030393791,0.0025076051,0.00089979585,0.10167263,0.0009540032,0.07995285,0.000009284215,0.006820273,0.032590743],"study_design_scores_gemma":[0.38869253,0.0068129343,0.3434603,0.003996994,0.009121327,0.000063694904,0.027418341,0.03712397,0.17764743,0.00002107738,0.0033767885,0.0022646256],"about_ca_topic_score_codex":0.011574871,"about_ca_topic_score_gemma":0.0076195854,"teacher_disagreement_score":0.41207764,"about_ca_system_score_codex":0.0007308167,"about_ca_system_score_gemma":0.0011721896,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W3165955961","doi":"10.1200/jco.2021.39.15_suppl.6014","title":"TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novartis","keywords":"Medicine; Clinical endpoint; Interim analysis; Internal medicine; Randomized controlled trial; Hazard ratio; Radiation therapy; Stage (stratigraphy); Progression-free survival; Oncology; Surgery; Confidence interval; Chemotherapy","score_opus":0.14555708591810446,"score_gpt":0.5294386839519649,"score_spread":0.38388159803386046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165955961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881315,0.00031549492,0.005381503,0.002083851,0.0012379789,0.0022363546,0.000044902834,0.000007552355,0.00056081614],"genre_scores_gemma":[0.9924595,0.00038203588,0.0044886805,0.00048609107,0.00089906575,0.00010583859,0.00014481068,0.000022736773,0.0010112501],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99621904,0.00042423868,0.0025760792,0.00025826378,0.0003258179,0.0001965711],"domain_scores_gemma":[0.9933715,0.002600515,0.0026805548,0.00015348112,0.0009122884,0.0002816483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017455771,0.00019018361,0.0026064762,0.00011518905,0.00010742624,0.000022035745,0.00006348288,0.00024107138,0.00027599637],"category_scores_gemma":[0.002722904,0.00011573655,0.00037807733,0.00018056012,0.0001975951,0.0001836934,0.000024469882,0.00037047043,9.627113e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8551906,0.0032298113,0.0018378479,0.000087342516,0.0012543272,0.00012126685,0.00090100913,0.000026771231,0.00015906485,0.00007915613,0.000571177,0.13654163],"study_design_scores_gemma":[0.91771394,0.058716618,0.0023274415,0.00015518938,0.0029107688,0.00011173029,0.00029703698,0.0058053154,0.0003259395,0.00003412339,0.011486673,0.00011525349],"about_ca_topic_score_codex":0.00006624378,"about_ca_topic_score_gemma":0.00020266823,"teacher_disagreement_score":0.13642639,"about_ca_system_score_codex":0.00022511338,"about_ca_system_score_gemma":0.0057643163,"threshold_uncertainty_score":0.9998721},"labels":[],"label_agreement":null},{"id":"W3166078442","doi":"10.1200/jco.2021.39.15_suppl.e21127","title":"Impact of <i>KRAS</i> mutational variant on response to immunotherapy in metastatic NSCLC.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"KRAS; Medicine; Mutation; Internal medicine; Oncology; Cancer; Cancer research; Colorectal cancer; Genetics; Biology; Gene","score_opus":0.09607797808659894,"score_gpt":0.5561180739738766,"score_spread":0.4600400958872776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166078442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98619956,0.00030379408,0.0003719553,0.01082689,0.00041121454,0.00015128058,0.000017051752,0.0000021250034,0.0017161218],"genre_scores_gemma":[0.9884507,0.00012588469,0.008042006,0.0028824226,0.00015086126,0.000004542458,0.000004721795,0.000010570629,0.00032828847],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973596,0.0006119853,0.001518156,0.00011681785,0.00026700847,0.00012646326],"domain_scores_gemma":[0.9952746,0.003259427,0.000657342,0.00013851537,0.00047378443,0.00019631654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019695526,0.00008531698,0.0009060889,0.00017238507,0.000014336425,0.0000042308625,0.000060860184,0.00008921064,0.00037160265],"category_scores_gemma":[0.0036007059,0.000055691246,0.0004452866,0.00025336302,0.00004823211,0.00004918474,0.000011040255,0.00033443482,0.000012689385],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25923797,0.03572533,0.1287983,0.000059062553,0.009934398,0.032985512,0.0037035167,0.0058458527,0.026048318,0.0014487131,0.011797707,0.4844153],"study_design_scores_gemma":[0.016632836,0.02644106,0.94466555,0.00015485904,0.00030172343,0.000886333,0.00014556684,0.000026607564,0.00020720171,0.000528912,0.009950594,0.0000587557],"about_ca_topic_score_codex":0.000035211877,"about_ca_topic_score_gemma":0.000020603793,"teacher_disagreement_score":0.81586725,"about_ca_system_score_codex":0.00034818015,"about_ca_system_score_gemma":0.0065311943,"threshold_uncertainty_score":0.99910086},"labels":[],"label_agreement":null},{"id":"W3166697471","doi":"10.1200/jco.2021.39.15_suppl.tps6090","title":"The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Placebo; Internal medicine; Paclitaxel; Head and neck squamous-cell carcinoma; Hazard ratio; Chemotherapy; Oncology; Tolerability; Surgery; Head and neck cancer; Cancer; Adverse effect; Confidence interval; Pathology","score_opus":0.06951416991493115,"score_gpt":0.4445522497361714,"score_spread":0.37503807982124027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166697471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961208,0.00038453695,0.000013879746,0.0021634428,0.0002025237,0.00088393915,0.000008172377,0.0000019159081,0.00022075036],"genre_scores_gemma":[0.998312,0.000044476426,0.0012476358,0.00024051212,0.000028760329,0.00002240896,0.000008062431,0.000011655208,0.00008451735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971843,0.0005208349,0.0015320356,0.0001966332,0.00038400636,0.00018220782],"domain_scores_gemma":[0.9965487,0.001641814,0.00079415255,0.00018408583,0.00062745274,0.00020380806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000878084,0.0001301792,0.0010755892,0.00012888203,0.000042666168,0.000011853144,0.000076368095,0.000058966434,0.000010947487],"category_scores_gemma":[0.0007765884,0.000065068234,0.00006136644,0.00036340687,0.000087577486,0.000080209014,0.000032163192,0.0004055755,7.132406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016377512,0.017379072,0.95179695,0.00004707138,0.00016771973,0.00047996998,0.0020697217,0.00007536358,0.0000023127495,0.000014206892,0.0001656928,0.011424385],"study_design_scores_gemma":[0.062571235,0.060035925,0.8716798,0.00012820851,0.00046586408,0.000023427883,0.004469326,0.000035489848,0.0000058946057,0.000035938545,0.00048518073,0.00006372699],"about_ca_topic_score_codex":0.00026359898,"about_ca_topic_score_gemma":0.0076483856,"teacher_disagreement_score":0.080117196,"about_ca_system_score_codex":0.00020793833,"about_ca_system_score_gemma":0.0012031303,"threshold_uncertainty_score":0.42679787},"labels":[],"label_agreement":null},{"id":"W3167046238","doi":"10.1200/jco.2021.39.15_suppl.6074","title":"Efficacy of selpercatinib after prior systemic therapy in patients with <i>RET</i> mutant medullary thyroid cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Eli Lilly and Company","keywords":"Medicine; Medullary thyroid cancer; Cabozantinib; Vandetanib; Internal medicine; Oncology; Thyroid cancer; Cancer; Context (archaeology); Tyrosine kinase","score_opus":0.036999834271307944,"score_gpt":0.4385540106506166,"score_spread":0.4015541763793087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167046238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287,0.0034382772,0.000009216862,0.0022971076,0.00057005254,0.00033555066,0.000012979963,0.000003691374,0.00046316953],"genre_scores_gemma":[0.9948224,0.0022810285,0.0009667803,0.0015294258,0.00027840456,0.000016328115,0.0000060690945,0.000016592936,0.00008301135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974649,0.00025721744,0.001621599,0.00016385267,0.0003345028,0.00015791372],"domain_scores_gemma":[0.9971261,0.00072906946,0.0010324633,0.00018219526,0.00074928475,0.00018090542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056278484,0.00011580145,0.0011436961,0.00007281874,0.000016234582,0.000003925704,0.00007694891,0.0001788067,0.00014111945],"category_scores_gemma":[0.0004803533,0.00006828802,0.00022527485,0.0001977443,0.00009850643,0.000067303685,0.000018507853,0.00043966755,0.00000247167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012248818,0.0044784816,0.8818846,0.000055168373,0.0008028161,0.00065284973,0.00059086835,0.000033806435,0.00022037442,0.000007553046,0.00020658279,0.09881809],"study_design_scores_gemma":[0.034974825,0.011250059,0.94846314,0.0006270728,0.0004605341,0.00013354504,0.00015939523,0.000005580508,0.00025244855,0.000011441601,0.003591752,0.000070230155],"about_ca_topic_score_codex":0.000027584309,"about_ca_topic_score_gemma":0.000059196926,"teacher_disagreement_score":0.098747864,"about_ca_system_score_codex":0.00023583444,"about_ca_system_score_gemma":0.0038678395,"threshold_uncertainty_score":0.6861381},"labels":[],"label_agreement":null},{"id":"W3167482687","doi":"10.1200/jco.2021.39.15_suppl.12092","title":"Province-wide analysis of patient reported outcomes for stage IV non-small cell lung cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; University of Manitoba; Centre for Addiction and Mental Health; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Comorbidity; Lung cancer; Stage (stratigraphy); Depression (economics); Nausea; Anxiety; Cancer; Poisson regression; Internal medicine; Polypharmacy; Physical therapy; Population; Psychiatry","score_opus":0.07701379704352407,"score_gpt":0.4885437870052284,"score_spread":0.4115299899617043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167482687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989672,0.0007077289,0.0012820777,0.0050223605,0.00089090667,0.00037758524,0.000043157466,0.000004327784,0.0019998297],"genre_scores_gemma":[0.9831938,0.0005213107,0.009806312,0.00210704,0.00018824064,0.00002471626,0.000025324724,0.000014772314,0.004118451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967816,0.000108819986,0.0025193093,0.00018776188,0.00023852181,0.00016400186],"domain_scores_gemma":[0.99374634,0.0017868647,0.002893425,0.00022577344,0.0011180188,0.0002296056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072140025,0.000107763044,0.0017410949,0.0001566767,0.00003214746,0.000005072434,0.000067928195,0.00017713553,0.0001685563],"category_scores_gemma":[0.0020000595,0.000072142044,0.0010842681,0.00028278417,0.000056773693,0.000046210087,0.000028427492,0.00027172043,3.9096028e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080581725,0.0022199075,0.96489745,0.000112933434,0.010294305,0.0007571099,0.00024889526,0.00057327654,0.000117949916,0.000019599396,0.0021812315,0.017771514],"study_design_scores_gemma":[0.010032608,0.005125892,0.9056527,0.000088832385,0.029129276,0.000018570476,0.0005023511,0.0008826612,0.00080196786,0.000027122569,0.047640894,0.00009709826],"about_ca_topic_score_codex":0.00011289499,"about_ca_topic_score_gemma":0.0005418143,"teacher_disagreement_score":0.059244733,"about_ca_system_score_codex":0.00027706788,"about_ca_system_score_gemma":0.006112561,"threshold_uncertainty_score":0.99952185},"labels":[],"label_agreement":null},{"id":"W3167491954","doi":"10.1200/jco.2021.39.15_suppl.3126","title":"The value of defining molecular resistance in patients with progressive <i>EGFR</i> and <i>ALK</i>-driven lung cancer in a public system.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Osimertinib; T790M; Lung cancer; Internal medicine; Oncology; KRAS; Clinical trial; Cancer; Erlotinib; Epidermal growth factor receptor; Gefitinib","score_opus":0.022069826684956714,"score_gpt":0.42201902908191746,"score_spread":0.39994920239696075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167491954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814199,0.010606648,0.000022219381,0.0054006265,0.00022125321,0.00024344507,0.000008620093,0.0000021066458,0.0020751401],"genre_scores_gemma":[0.996852,0.00044332148,0.0022136595,0.00039032337,0.000041554154,0.000013899022,0.0000024535407,0.000009034753,0.000033764954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980611,0.00030981505,0.0010929746,0.00013074407,0.00025151065,0.00015382684],"domain_scores_gemma":[0.99760956,0.00070424884,0.0009250998,0.00011476963,0.00053215143,0.0001141993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006631232,0.00007595106,0.00067314855,0.000060105627,0.000030418343,0.000009907221,0.00006401726,0.000104295694,0.000004681216],"category_scores_gemma":[0.0007517822,0.00004325009,0.00008010506,0.00018691728,0.00013274541,0.000070525886,0.000028753933,0.00036873395,1.6425197e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012715334,0.0006419353,0.9872712,0.00010445917,0.00035850785,0.0008231809,0.00024594346,0.000051555144,0.000009980156,0.0017632334,0.00011428863,0.007344197],"study_design_scores_gemma":[0.014585226,0.0017801246,0.97719353,0.0015675928,0.0004117054,0.00004953092,0.00045993784,0.00009379514,0.00002173021,0.00006983407,0.003706935,0.000060037542],"about_ca_topic_score_codex":0.000020211486,"about_ca_topic_score_gemma":0.00055457396,"teacher_disagreement_score":0.015432049,"about_ca_system_score_codex":0.00027897305,"about_ca_system_score_gemma":0.0025194834,"threshold_uncertainty_score":0.44694555},"labels":[],"label_agreement":null},{"id":"W3167602226","doi":"10.1200/jco.2021.39.15_suppl.2032","title":"Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Feature selection; Receiver operating characteristic; Cohort; Cancer; Lung cancer; Logistic regression; Artificial intelligence","score_opus":0.0776540938749829,"score_gpt":0.5077409547707102,"score_spread":0.43008686089572734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167602226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205625,0.0038857954,0.00019680215,0.0019721556,0.0006975487,0.00030567264,0.000051618874,0.0000043289247,0.00082981173],"genre_scores_gemma":[0.9870753,0.0038262412,0.0064306958,0.0014733153,0.00079330197,0.000011321666,0.000023603117,0.000017900651,0.00034828013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953963,0.00085186533,0.002974816,0.00032222987,0.00023087267,0.00022388235],"domain_scores_gemma":[0.99561507,0.0018549506,0.0014877623,0.0002436927,0.00044212717,0.00035638033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029614922,0.00015390886,0.002150312,0.0002917807,0.000027581045,0.000009714741,0.000116903735,0.00030400345,0.00012245051],"category_scores_gemma":[0.0011866613,0.00011102718,0.0006947025,0.0004633573,0.00022212627,0.00010118614,0.000060793795,0.0006798634,7.893888e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010346163,0.0029313765,0.9688871,0.00007390771,0.0042704893,0.0007967136,0.0004033452,0.00014652083,0.0003127663,0.000010435652,0.001657342,0.019475376],"study_design_scores_gemma":[0.011984897,0.004867434,0.9625081,0.00009418084,0.011094315,0.0000715527,0.00044504812,0.0006366206,0.00011905186,0.000026568143,0.008050089,0.00010214515],"about_ca_topic_score_codex":0.0003084331,"about_ca_topic_score_gemma":0.0017623659,"teacher_disagreement_score":0.01937323,"about_ca_system_score_codex":0.00015548195,"about_ca_system_score_gemma":0.005961362,"threshold_uncertainty_score":0.9996739},"labels":[],"label_agreement":null},{"id":"W3167778461","doi":"10.1200/jco.2021.39.15_suppl.3003","title":"Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Lung cancer; Internal medicine; Pancreas; Oncology; Phases of clinical research; Clinical trial","score_opus":0.06311970170415009,"score_gpt":0.49937346485275863,"score_spread":0.43625376314860853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167778461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888607,0.0044943583,0.000019746796,0.0038148323,0.00032126237,0.00012558293,0.0000072150947,0.0000027482358,0.0023535304],"genre_scores_gemma":[0.9903023,0.0055624554,0.00263279,0.0010024654,0.00024441502,0.0000035945045,8.79591e-7,0.000011169272,0.00023988406],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983141,0.000110928115,0.0011842632,0.00013718478,0.00012996423,0.00012355225],"domain_scores_gemma":[0.9980924,0.0008182507,0.0006147907,0.000092909395,0.00019256829,0.00018908473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005530227,0.000079487356,0.000939806,0.00006604925,0.000025643436,0.0000033335925,0.00003300352,0.00011628179,0.0001109613],"category_scores_gemma":[0.0011006384,0.00005682193,0.00009441432,0.000105435574,0.00011442516,0.000055582826,0.000036727946,0.00033802286,5.649985e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006549186,0.0015544238,0.406411,0.00008894588,0.0006682566,0.0009938189,0.00071482034,0.00011212119,0.0020333205,0.000393421,0.00020004755,0.58028066],"study_design_scores_gemma":[0.021764612,0.0025673178,0.9281981,0.00063197897,0.0005010825,0.0003059557,0.00032914634,0.000042194428,0.00034179667,0.00016706265,0.045081727,0.00006903899],"about_ca_topic_score_codex":0.00008192895,"about_ca_topic_score_gemma":0.00014861743,"teacher_disagreement_score":0.5802116,"about_ca_system_score_codex":0.00012453896,"about_ca_system_score_gemma":0.0015202909,"threshold_uncertainty_score":0.26969308},"labels":[],"label_agreement":null},{"id":"W3168544199","doi":"10.1200/jco.2021.39.15_suppl.e21029","title":"Molecular characteristics of BRAF mutated non-small cell lung cancer and therapeutic outcomes: Multi-institution study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Trametinib; Vemurafenib; Dabrafenib; Oncology; Internal medicine; Lung cancer; KRAS; V600E; Cancer; Population; Adenocarcinoma; MEK inhibitor; Cancer research; Mutation; Kinase; Colorectal cancer; MAPK/ERK pathway; Metastatic melanoma","score_opus":0.0757969087840747,"score_gpt":0.48943926647804803,"score_spread":0.41364235769397334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168544199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460566,0.0013328983,0.0010865417,0.0015831791,0.0008065528,0.00028176224,0.000009335924,0.0000039299775,0.00029013012],"genre_scores_gemma":[0.9959507,0.00072149426,0.0017439482,0.0012281819,0.000117552816,0.000006741159,0.0000038648486,0.000010778487,0.0002167582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981536,0.00014951886,0.0012795312,0.00013817695,0.00016365868,0.00011549176],"domain_scores_gemma":[0.99783397,0.00035443297,0.00093633303,0.00012406976,0.0005838357,0.00016734321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048732,0.00010360431,0.001002378,0.00005958922,0.000029810239,0.0000060046623,0.0000507245,0.00014834083,0.00003749791],"category_scores_gemma":[0.00037508283,0.000070778595,0.00020694599,0.000098129894,0.00008640457,0.00003359344,0.00002663574,0.00034880845,0.0000010499704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041621496,0.0051467046,0.9406373,0.00008972369,0.0015893705,0.0018047973,0.00066091056,0.000034755027,0.002019926,0.000015342699,0.000028754743,0.047556195],"study_design_scores_gemma":[0.014027448,0.0031592024,0.9771573,0.00009571616,0.0029548772,0.0000902017,0.0004476618,0.00040036227,0.0006393889,0.000009631031,0.0009526575,0.000065581095],"about_ca_topic_score_codex":0.000052575928,"about_ca_topic_score_gemma":0.000053656997,"teacher_disagreement_score":0.047490615,"about_ca_system_score_codex":0.00011855039,"about_ca_system_score_gemma":0.0021894928,"threshold_uncertainty_score":0.3884066},"labels":[],"label_agreement":null},{"id":"W3169556370","doi":"10.1016/j.lungcan.2021.06.002","title":"The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; William Osler Health System; Humber Polytechnic; Dalhousie University; University of Toronto; Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa; McMaster University","funders":"","keywords":"Medicine; Lung cancer; Oncology; Intensive care medicine","score_opus":0.017649542354702362,"score_gpt":0.3591299504094271,"score_spread":0.34148040805472474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169556370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037501886,0.9935294,0.00006989514,0.00021382257,0.0011284123,0.0022760087,0.00030499193,0.000033973432,0.0020684826],"genre_scores_gemma":[0.00063921534,0.9907337,0.0005877428,0.000117998534,0.00035205655,0.002471549,0.00020554216,0.00012468855,0.0047675506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763244,0.00008073192,0.000834118,0.0005936616,0.00033486515,0.0005241652],"domain_scores_gemma":[0.99805754,0.000312295,0.00059037504,0.00063047546,0.00029252283,0.00011679414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018448371,0.00053939386,0.0018319862,0.00019748698,0.00015070567,0.000046859102,0.00026506078,0.00026104067,0.0004564782],"category_scores_gemma":[0.00003883509,0.00034029712,0.00052927516,0.0007948669,0.000065171596,0.00008627549,0.00007860466,0.00051077636,0.0000016634452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088591754,0.0005827879,0.010384829,0.047222935,0.005195775,0.000070520364,0.0036337834,0.00033852822,0.00013896957,0.00007026233,0.011316962,0.9209561],"study_design_scores_gemma":[0.004147048,0.00007821248,0.0010990965,0.05483792,0.00677981,0.000010474027,0.00048764568,0.00081752246,0.000056245535,0.0000018638957,0.9310977,0.00058648473],"about_ca_topic_score_codex":0.0010525004,"about_ca_topic_score_gemma":0.0013873931,"teacher_disagreement_score":0.92036957,"about_ca_system_score_codex":0.0009262536,"about_ca_system_score_gemma":0.003140051,"threshold_uncertainty_score":0.99990493},"labels":[],"label_agreement":null},{"id":"W3169642351","doi":"10.1200/jco.2021.39.15_suppl.3089","title":"Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University Health Network; University of Toronto; Princess Margaret Cancer Centre; McGill University Health Centre; McGill University","funders":"Conquer Cancer Foundation","keywords":"Medicine; Internal medicine; Oncology; Cancer; Logistic regression; Odds ratio; Clinical trial","score_opus":0.3203318339859995,"score_gpt":0.6138911154320323,"score_spread":0.2935592814460328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169642351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91623724,0.076879136,0.00019524158,0.0049856724,0.00016982792,0.0013769323,0.000014487611,0.00000381839,0.00013767678],"genre_scores_gemma":[0.9814211,0.010206578,0.0060224105,0.0020755692,0.00006629415,0.00009066309,0.0000071706595,0.000012646848,0.000097537406],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9942117,0.0015992951,0.003380771,0.00024616817,0.00042111354,0.00014099167],"domain_scores_gemma":[0.9912087,0.003714393,0.0034167175,0.0002114526,0.001282749,0.00016600377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044259,0.0001451123,0.005136498,0.00014354404,0.00003565885,0.0000087926155,0.00006919964,0.00015029991,0.00023339588],"category_scores_gemma":[0.0047098864,0.00008207757,0.00094073766,0.0005275235,0.00013677409,0.00013881418,0.000029239021,0.0004622377,0.0000010242384],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001671645,0.012374212,0.47020668,0.05682472,0.43529394,0.00046700996,0.0012844633,0.0005240933,0.000054489967,0.0000215819,0.00014227538,0.021134883],"study_design_scores_gemma":[0.010433777,0.007307634,0.30993766,0.013760006,0.6578331,0.00004514631,0.00020089882,0.0002511803,0.000032235617,0.000049453454,0.00001802114,0.00013085149],"about_ca_topic_score_codex":0.00006486455,"about_ca_topic_score_gemma":0.00053875666,"teacher_disagreement_score":0.22253919,"about_ca_system_score_codex":0.00013090236,"about_ca_system_score_gemma":0.0031298865,"threshold_uncertainty_score":0.5638514},"labels":[],"label_agreement":null},{"id":"W3171133605","doi":"10.1200/jco.2021.39.15_suppl.9120","title":"Population-based impacts of new therapies on outcomes for stage IV non-small cell lung cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Medicine; Systemic therapy; Internal medicine; Population; Cohort; Stage (stratigraphy); Proportional hazards model; Lung cancer; Retrospective cohort study; Hazard ratio; Comorbidity; Cancer; Oncology; Breast cancer","score_opus":0.09882337109539505,"score_gpt":0.5213115592388393,"score_spread":0.42248818814344424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171133605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809142,0.0009656067,0.00062008115,0.015334138,0.001067722,0.0002806552,0.000028157874,0.000004197715,0.000785245],"genre_scores_gemma":[0.9841435,0.00030877738,0.008542592,0.0038544873,0.0005269257,0.0000069103717,0.00001406719,0.000015549977,0.0025871694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983038,0.00007963508,0.0011876205,0.00011511583,0.0001756034,0.00013825361],"domain_scores_gemma":[0.99613714,0.0019073726,0.0011648174,0.00013684804,0.00041885837,0.00023498943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046405953,0.00009920864,0.0009960482,0.000068106034,0.000030257766,0.0000054752913,0.00006067359,0.00015946041,0.00019969269],"category_scores_gemma":[0.0008828158,0.000063870015,0.00049363816,0.00007743135,0.000025308442,0.0000386287,0.000007621574,0.00023498484,9.695282e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013766818,0.001270688,0.9717191,0.0001123332,0.00072307984,0.0000749496,0.000223107,0.00035055607,0.00015889415,0.0000594393,0.003092645,0.020838529],"study_design_scores_gemma":[0.015562707,0.005198722,0.9643825,0.00016421611,0.00097142946,0.000004691591,0.00014100914,0.00020010181,0.0006405124,0.000109822686,0.012563392,0.000060843176],"about_ca_topic_score_codex":0.0002919255,"about_ca_topic_score_gemma":0.00032304606,"teacher_disagreement_score":0.020777686,"about_ca_system_score_codex":0.00021219332,"about_ca_system_score_gemma":0.0054761255,"threshold_uncertainty_score":0.97144115},"labels":[],"label_agreement":null},{"id":"W3171453021","doi":"10.1200/jco.2021.39.15_suppl.e21123","title":"Sequencing of systemic therapies in advanced NSCLC with <i>MET</i> exon 14 skipping mutation: A multicenter experience.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Population; non-small cell lung cancer (NSCLC); Cancer; Adenocarcinoma","score_opus":0.07604376916599374,"score_gpt":0.47834963173901063,"score_spread":0.40230586257301687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171453021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948798,0.0020783227,0.0005398721,0.000852529,0.0004917771,0.00016608855,0.0000012734226,0.0000043843033,0.0009859824],"genre_scores_gemma":[0.98589635,0.00060314377,0.012487726,0.0007356847,0.0001741664,0.000010959806,0.0000019827644,0.000009554227,0.00008044378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787444,0.00020165456,0.0014265841,0.0001372575,0.00023070179,0.0001293584],"domain_scores_gemma":[0.99749106,0.00072197313,0.0010252617,0.00012067426,0.00053298956,0.00010805304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055848056,0.000084014784,0.00085358834,0.0000856404,0.000018575862,0.0000049922655,0.00005529148,0.000111492845,0.000049076654],"category_scores_gemma":[0.00071832753,0.000056294633,0.00016281336,0.00018789907,0.000099472054,0.0001749166,0.000013586654,0.0003072106,0.0000012908982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008900369,0.0032590486,0.54390246,0.00034815085,0.0019019404,0.014504836,0.052410424,0.0016444549,0.024348652,0.00026055978,0.00007406285,0.3484451],"study_design_scores_gemma":[0.10740755,0.030613156,0.6516635,0.011129445,0.0020478298,0.010367386,0.16920348,0.000385004,0.0066647166,0.00024880757,0.009805333,0.00046384125],"about_ca_topic_score_codex":0.000017672523,"about_ca_topic_score_gemma":0.000056529778,"teacher_disagreement_score":0.34798124,"about_ca_system_score_codex":0.00027940696,"about_ca_system_score_gemma":0.002014795,"threshold_uncertainty_score":0.357416},"labels":[],"label_agreement":null},{"id":"W3172081492","doi":"10.1056/nejmoa2103695","title":"Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1769,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Amgen","keywords":"KRAS; Medicine; Lung cancer; Mutation; Lung; Cancer research; Internal medicine; Oncology; Cancer; Biology; Genetics; Colorectal cancer; Gene","score_opus":0.013510520594671777,"score_gpt":0.33070006313670197,"score_spread":0.3171895425420302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172081492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76760805,0.024873314,0.08858533,0.10102145,0.0034256768,0.0014074835,0.00003675,0.000056576213,0.012985398],"genre_scores_gemma":[0.98193836,0.0004324677,0.007781825,0.0019548358,0.00449578,0.000010482047,0.00006235056,0.000026281312,0.0032976025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991041,0.000022812414,0.00030313994,0.000109238455,0.000319733,0.00014099214],"domain_scores_gemma":[0.9987437,0.00014194066,0.00021561283,0.00010276632,0.00055324065,0.00024273539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019084917,0.000110994224,0.0003544453,0.00008588367,0.000055015884,0.000008432898,0.000035505975,0.000034069657,0.0001707501],"category_scores_gemma":[0.00016826163,0.000063785476,0.0000607836,0.00016763419,0.00004230377,0.000085410094,0.0000035805804,0.00012986627,5.8024926e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009375643,0.00050256785,0.08799161,0.0009144127,0.00507677,0.006837981,0.015533214,0.0020699415,0.016301682,0.0014745502,0.2956988,0.55822283],"study_design_scores_gemma":[0.4241933,0.012876409,0.021486703,0.004045074,0.008745055,0.018480109,0.0039666314,0.0006838965,0.010749251,0.0011022442,0.49327385,0.00039747354],"about_ca_topic_score_codex":0.0001140697,"about_ca_topic_score_gemma":0.00014160504,"teacher_disagreement_score":0.5578253,"about_ca_system_score_codex":0.00022770581,"about_ca_system_score_gemma":0.0013880872,"threshold_uncertainty_score":0.26010963},"labels":[],"label_agreement":null},{"id":"W3172087835","doi":"10.1200/jco.2021.39.15_suppl.4147","title":"Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Immunohistochemistry; Cancer; Internal medicine; Oncology; Biomarker; Phases of clinical research; Colorectal cancer; Cancer research; Clinical trial; Biology","score_opus":0.27128782466024287,"score_gpt":0.5991039623348068,"score_spread":0.3278161376745639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172087835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893868,0.0013043728,0.0007432709,0.003749278,0.0010782382,0.0012465393,0.0003659591,0.0000059733093,0.0021195465],"genre_scores_gemma":[0.9916224,0.0008020793,0.0054535735,0.0005069074,0.00123113,0.000020460317,0.0001954918,0.000017425393,0.00015056597],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894334,0.00396342,0.005621373,0.00028267363,0.00046089117,0.00023823508],"domain_scores_gemma":[0.93561745,0.0575609,0.005134417,0.000444561,0.00084022625,0.00040245842],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0130964145,0.00020050329,0.008807442,0.00014808023,0.000019240986,0.00001428037,0.00019225155,0.00015121234,0.0011837515],"category_scores_gemma":[0.13032144,0.00010886507,0.0017290572,0.00012940353,0.00017658364,0.00012203081,0.000052065523,0.0007031121,0.000006236122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9122884,0.008512824,0.05056385,0.000023016733,0.0067943125,0.003339814,0.000098100165,0.0002598961,0.00042004234,0.00006361513,0.0034918487,0.014144247],"study_design_scores_gemma":[0.9329659,0.014409384,0.04271853,0.00094788783,0.005707914,0.00020939698,0.00010856238,0.0017086888,0.000020017125,0.00060735474,0.0005099404,0.000086464635],"about_ca_topic_score_codex":0.00063930434,"about_ca_topic_score_gemma":0.000277955,"teacher_disagreement_score":0.117225036,"about_ca_system_score_codex":0.0004924374,"about_ca_system_score_gemma":0.012877676,"threshold_uncertainty_score":0.9997293},"labels":[],"label_agreement":null},{"id":"W3172183878","doi":"10.1200/jco.2021.39.15_suppl.tps9129","title":"KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRAS<sup>G12C</sup> mutation.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"KRAS; Medicine; Docetaxel; Tolerability; Regimen; Oncology; Lung cancer; Internal medicine; Phases of clinical research; Clinical endpoint; Cancer; Cancer research; Chemotherapy; Pharmacology; Clinical trial; Adverse effect; Colorectal cancer","score_opus":0.04474401398625628,"score_gpt":0.44161075779425446,"score_spread":0.3968667438079982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172183878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416924,0.0008656167,0.00013945607,0.0005215026,0.00028077146,0.0022525787,0.00001754724,0.000009705334,0.0017435574],"genre_scores_gemma":[0.99678195,0.00052497676,0.0015746682,0.0002690234,0.00019674163,0.00013166368,0.000035081714,0.00003807912,0.00044780626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952507,0.0008372846,0.0026407135,0.00037184448,0.0005782739,0.0003211837],"domain_scores_gemma":[0.9936711,0.002013572,0.0022549808,0.00028682523,0.0014052059,0.00036829227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011999436,0.0002957328,0.0029470804,0.00022429423,0.000055305176,0.000015814152,0.0001338009,0.00021692505,0.0001680396],"category_scores_gemma":[0.0008966968,0.0001742586,0.00037560659,0.0004546072,0.00017988088,0.00016007468,0.000032642245,0.00066351047,0.0000019158117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51142496,0.04245688,0.4141764,0.0001713369,0.005724998,0.0030678236,0.004619851,0.0020111797,0.000013884899,0.0000041227413,0.00044237726,0.015886217],"study_design_scores_gemma":[0.86980057,0.0506417,0.065769754,0.00062122976,0.009362046,0.000068201894,0.0024180943,0.0007056305,0.000059047725,0.0000049689575,0.0003678143,0.00018096458],"about_ca_topic_score_codex":0.00048720985,"about_ca_topic_score_gemma":0.0013983264,"teacher_disagreement_score":0.3583756,"about_ca_system_score_codex":0.00048286936,"about_ca_system_score_gemma":0.0046922984,"threshold_uncertainty_score":0.8323936},"labels":[],"label_agreement":null},{"id":"W3172779990","doi":"10.1177/17588359211019675","title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Karl Landsteiner Privatuniversität für Gesundheitswissenschaften","keywords":"Medicine; Internal medicine; Brain metastasis; Lung cancer; Oncology; Adverse effect; Retrospective cohort study; Confidence interval; Population; Fusion gene; Cancer; Metastasis; Gene","score_opus":0.01930944574526549,"score_gpt":0.44439614040856573,"score_spread":0.42508669466330024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172779990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561686,0.0045487313,0.0003696743,0.00089958997,0.00020407204,0.0011720295,0.00007267502,0.000034370907,0.007081989],"genre_scores_gemma":[0.98858976,0.007589452,0.0012928932,0.0013102597,0.000054094085,0.0005891241,0.00046499382,0.000022662194,0.000086780536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977747,0.0002722831,0.00061154144,0.00053681585,0.00044250741,0.00036215453],"domain_scores_gemma":[0.9987292,0.00023869539,0.0002387978,0.00029173004,0.00034243928,0.00015913355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019799599,0.00021535487,0.0009827344,0.00024233959,0.000048970458,0.000008207877,0.0001854636,0.00025909618,0.00084450823],"category_scores_gemma":[0.00007903297,0.00016954103,0.00012303851,0.0021693995,0.000228457,0.000269951,0.00007014615,0.00037733707,8.736714e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044938482,0.005231598,0.7997174,0.00007438366,0.0008798231,0.00021256437,0.0054349094,0.00010141771,0.00006918192,0.00009568971,0.000006995213,0.1877266],"study_design_scores_gemma":[0.008995027,0.002088816,0.9754816,0.0003004055,0.0031560005,0.0000047939707,0.0010731074,0.0053454232,0.000876024,0.00029284006,0.0021648363,0.00022112469],"about_ca_topic_score_codex":0.00066421385,"about_ca_topic_score_gemma":0.0065281563,"teacher_disagreement_score":0.18750547,"about_ca_system_score_codex":0.0010749304,"about_ca_system_score_gemma":0.0011389958,"threshold_uncertainty_score":0.9246773},"labels":[],"label_agreement":null},{"id":"W3172780154","doi":"10.1016/j.jval.2021.04.1202","title":"RW3 Quantitative Bias Analysis (QBA) for Comparative Effectiveness of Alectinib versus Ceritinib in Non-Small Cell Lung Cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Alectinib; Ceritinib; Medicine; Lung cancer; Hazard ratio; Internal medicine; Oncology; Crizotinib; Confidence interval","score_opus":0.12709427324781572,"score_gpt":0.45329962642739347,"score_spread":0.3262053531795778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172780154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897991,0.004854258,0.0015134355,0.0003781533,0.0002870787,0.0017137241,0.00020755766,0.000011926047,0.0012347761],"genre_scores_gemma":[0.994621,0.00037176453,0.0041497285,0.00007394158,0.000029407789,0.00046187,0.00016655518,0.000017177348,0.000108572785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827355,0.000420493,0.00047376685,0.0003739984,0.00015473732,0.00030345464],"domain_scores_gemma":[0.9974142,0.0018296466,0.00021111872,0.00019266756,0.0002487696,0.00010361559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005454989,0.0001549968,0.00083046034,0.0003493382,0.000058808455,0.000008022866,0.00004845958,0.00006102291,0.000027192633],"category_scores_gemma":[0.00011673205,0.00014749709,0.00016486239,0.0015330007,0.000038564296,0.00004668074,0.000016414568,0.00014575453,0.0000011185195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006558414,0.002744309,0.8309806,0.009005711,0.00347524,0.00008377023,0.033412907,0.107732974,0.002285818,0.0022170816,0.00017285155,0.001330356],"study_design_scores_gemma":[0.03284573,0.002795131,0.86565477,0.0035784096,0.0021628914,0.0000030930698,0.009236042,0.057690267,0.02520165,0.0001375633,0.00029919742,0.0003952463],"about_ca_topic_score_codex":0.018885745,"about_ca_topic_score_gemma":0.0067613763,"teacher_disagreement_score":0.050042704,"about_ca_system_score_codex":0.00078592653,"about_ca_system_score_gemma":0.001726242,"threshold_uncertainty_score":0.9876476},"labels":[],"label_agreement":null},{"id":"W3173023813","doi":"10.1200/jco.2021.39.15_suppl.e21216","title":"Overall survival comparison in patients with and without brain metastases treated with osimertinib for metastatic EGFR mutation positive non-small cell lung cancer (NSCLC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Pediatric Oncology Group; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Brain metastasis; Osimertinib; Metastasis; Radiosurgery; Oncology; Internal medicine; Lung cancer; Population; non-small cell lung cancer (NSCLC); Radiation therapy; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.051671690123083786,"score_gpt":0.4544418732681256,"score_spread":0.40277018314504176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173023813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424076,0.0006234939,0.0019247663,0.001896307,0.00015768694,0.00074434665,0.00007090231,0.000004648671,0.00033711144],"genre_scores_gemma":[0.98506635,0.00006265632,0.013365321,0.0010235807,0.00009564495,0.00003643821,0.00009926172,0.000024951374,0.00022578379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978446,0.0003286586,0.0011394098,0.00023964731,0.00024055071,0.00020713508],"domain_scores_gemma":[0.99631023,0.0014529143,0.0010793181,0.000095524505,0.0008392526,0.0002227839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059879187,0.00017204415,0.0013158441,0.00010272857,0.00004614473,0.000016665328,0.00004206725,0.00009284788,0.00002878152],"category_scores_gemma":[0.00034957685,0.0001058924,0.00012822515,0.00015093731,0.00009170398,0.00012835364,0.0000137148345,0.00031865848,4.052266e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011434944,0.0031980304,0.9701275,0.00008701609,0.0017128907,0.00022043302,0.0004940851,0.00032592766,0.000037335576,0.000015824327,0.00035596397,0.011990017],"study_design_scores_gemma":[0.057967443,0.015937032,0.91908795,0.00036836963,0.0043301196,0.00003997528,0.00041340126,0.0007310929,0.00038206574,0.000016830401,0.0005929424,0.00013278084],"about_ca_topic_score_codex":0.00019166585,"about_ca_topic_score_gemma":0.0008589148,"teacher_disagreement_score":0.051039584,"about_ca_system_score_codex":0.00021918255,"about_ca_system_score_gemma":0.0019135618,"threshold_uncertainty_score":0.43181667},"labels":[],"label_agreement":null},{"id":"W3175516050","doi":"10.1016/j.eclinm.2021.100940","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial","year":2021,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Erlotinib; Afatinib; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Hazard ratio; Adverse effect; Surgery; Oncology; Cancer; Epidermal growth factor receptor; Confidence interval","score_opus":0.030983047934949163,"score_gpt":0.37449628892477677,"score_spread":0.3435132409898276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175516050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932497,0.0009376377,0.000023060713,0.00069309963,0.00067941943,0.002280128,0.00030301517,0.000009005172,0.0018248939],"genre_scores_gemma":[0.99738973,0.0000388513,0.00018886497,0.00013936832,0.0001428148,0.000090344874,0.00033388345,0.000022562683,0.0016536015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99736995,0.00019998924,0.0012219101,0.0003707222,0.00062286685,0.00021458394],"domain_scores_gemma":[0.9961414,0.0013262823,0.00094143016,0.0009404429,0.0005122777,0.00013819398],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020180926,0.00025024795,0.001308857,0.00010848681,0.00007650943,0.0000028949598,0.00015373032,0.00009373109,0.0010563855],"category_scores_gemma":[0.00076743367,0.00011868662,0.00070785376,0.0010306519,0.00029459866,0.000032658227,0.000042040832,0.00014564554,8.5691516e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66634256,0.024166858,0.28920248,0.0004091791,0.008718774,0.000056028915,0.002906529,0.00061107747,0.0010785009,0.000045794794,0.0008720262,0.00559019],"study_design_scores_gemma":[0.78985006,0.0140848225,0.15752459,0.00011951128,0.025300559,0.0000014451703,0.0003274869,0.00049861317,0.011669566,0.000004910543,0.00050264876,0.00011581908],"about_ca_topic_score_codex":0.00007823566,"about_ca_topic_score_gemma":0.0000843644,"teacher_disagreement_score":0.1316779,"about_ca_system_score_codex":0.00013256379,"about_ca_system_score_gemma":0.00086272426,"threshold_uncertainty_score":0.99985677},"labels":[],"label_agreement":null},{"id":"W3176900519","doi":"10.1158/1538-7445.am2021-2620","title":"Abstract 2620: Ignoring left truncation in overall survival within real-world genomic-phenomic data leads to inflated survival estimates","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Regimen; Oncology; Survival analysis; Pemetrexed; Internal medicine; KRAS; Colorectal cancer; FOLFOX; Cohort; Log-rank test; Cancer; Chemotherapy; Oxaliplatin","score_opus":0.16160553190674054,"score_gpt":0.48129034993289493,"score_spread":0.3196848180261544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176900519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98741007,0.0005923336,0.000017082972,0.0024507148,0.00047276096,0.00067339325,0.00016295155,0.000054622156,0.008166084],"genre_scores_gemma":[0.99323255,0.00048536778,0.0008008856,0.000092798706,0.00035850634,0.00010215324,0.00089679006,0.000060241215,0.003970699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975403,0.00011282558,0.00043522214,0.000724546,0.00060140446,0.00058572274],"domain_scores_gemma":[0.9980309,0.00027632964,0.00006355551,0.0009727605,0.00038155934,0.00027488355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001019464,0.00018864899,0.00037642758,0.00038203667,0.0001640976,0.00011873266,0.00027481388,0.00007617426,0.0006816203],"category_scores_gemma":[0.0002982091,0.00018132439,0.00003916491,0.00069726864,0.00007300577,0.00025138137,0.0003086602,0.000503227,0.00011810085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008988069,0.00043550198,0.647783,0.0004230326,0.00042779563,0.00057596085,0.0036145253,0.0061525838,0.3291056,0.0014459363,0.0024243162,0.0067129396],"study_design_scores_gemma":[0.0027532694,0.00009505494,0.97652656,0.00047083877,0.000085152235,0.000008237675,0.0004532918,0.00080486416,0.014757869,0.00028110915,0.0035005843,0.0002631407],"about_ca_topic_score_codex":0.019368306,"about_ca_topic_score_gemma":0.05391405,"teacher_disagreement_score":0.32874358,"about_ca_system_score_codex":0.0017180037,"about_ca_system_score_gemma":0.0023296848,"threshold_uncertainty_score":0.9871618},"labels":[],"label_agreement":null},{"id":"W3176990767","doi":"10.1016/j.athoracsur.2021.05.081","title":"The Case for Periadjuvant Therapy in Early-stage Lung Cancer","year":2021,"lang":"en","type":"letter","venue":"The Annals of Thoracic Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Cancer; Colorectal cancer; Lung; Melanoma; Breast cancer; Oncology; Internal medicine; Surgery","score_opus":0.12954310278707237,"score_gpt":0.4541874419956925,"score_spread":0.3246443392086201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176990767","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24532929,0.044507656,0.000009733735,0.7073021,0.0009332454,0.0012205177,0.00043364748,0.000021380833,0.00024240962],"genre_scores_gemma":[0.20995347,0.06644028,0.0000797589,0.66893804,0.0064976322,0.0036891787,0.0009799254,0.0003057551,0.043115955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825233,0.00024303068,0.0004921262,0.00029985557,0.0002625736,0.00045010296],"domain_scores_gemma":[0.9962056,0.002357785,0.00033253914,0.0007253249,0.00033216848,0.000046564994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089968543,0.00027034475,0.0006778625,0.00013293987,0.0002177379,0.000056104076,0.00014682466,0.00023116234,0.000103548206],"category_scores_gemma":[0.00016604581,0.0001397641,0.0005346067,0.0002612388,0.00013046854,0.000055152374,0.000035274374,0.00052889145,0.0000011339048],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000470798,0.000069722126,0.0022759333,0.0004919578,0.001154673,0.0037971535,0.0008770836,0.0000088831885,0.000019224657,0.000008512401,0.9257533,0.06507274],"study_design_scores_gemma":[0.00027545556,0.00007563953,0.0010929789,0.0009774816,0.000405685,0.00022337696,0.00038955276,0.0000799674,0.0019596596,0.000087969805,0.99418724,0.00024498964],"about_ca_topic_score_codex":0.0024181288,"about_ca_topic_score_gemma":0.0003281157,"teacher_disagreement_score":0.068433926,"about_ca_system_score_codex":0.00006838154,"about_ca_system_score_gemma":0.0007121054,"threshold_uncertainty_score":0.5699415},"labels":[],"label_agreement":null},{"id":"W3180315556","doi":"10.1093/noajnl/vdab070.008","title":"ECOA-8. Lung adenocarcinoma brain metastasis prediction using tumor DNA methylation profiling","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Brain metastasis; DNA methylation; Oncology; Lung cancer; Medicine; Methylation; Cohort; Metastasis; Internal medicine; Adenocarcinoma; Proportional hazards model; Cancer; Biology; Gene","score_opus":0.026771249438698137,"score_gpt":0.3661204175034585,"score_spread":0.33934916806476034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180315556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746575,0.0102837635,0.0053476333,0.0037189925,0.0016096495,0.0008580248,0.00009455613,0.00018939732,0.0032404799],"genre_scores_gemma":[0.97525346,0.00023616629,0.021199998,0.0022482043,0.00044898526,0.0001188064,0.00021711772,0.00004246799,0.00023480726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984993,0.00019911813,0.00034787797,0.00047188782,0.00020487575,0.0002769629],"domain_scores_gemma":[0.9989273,0.00034974297,0.00017927198,0.00023359213,0.0001930267,0.00011707252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014728587,0.00017849678,0.0003622115,0.000129635,0.00022963161,0.000019305378,0.000049174345,0.000080952675,0.00013704653],"category_scores_gemma":[0.00038012286,0.00016371993,0.000110043315,0.00029342633,0.00007262944,0.0003703565,0.000037930513,0.00021181218,0.000009606616],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033014463,0.0006220015,0.22285013,0.0003351,0.000645081,0.0016201016,0.00087273296,0.0027437655,0.72089326,0.00074802607,0.00085327163,0.047486395],"study_design_scores_gemma":[0.009626816,0.0021575359,0.08634979,0.00022157386,0.0048914896,0.0036186888,0.0026024422,0.016620455,0.75105757,0.0013897415,0.12084162,0.00062230084],"about_ca_topic_score_codex":0.000008901737,"about_ca_topic_score_gemma":0.00002977118,"teacher_disagreement_score":0.13650033,"about_ca_system_score_codex":0.00037196768,"about_ca_system_score_gemma":0.0006417589,"threshold_uncertainty_score":0.6676305},"labels":[],"label_agreement":null},{"id":"W3181684306","doi":"10.1016/j.jtocrr.2021.100212","title":"A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Kingston Health Sciences Centre; London Health Sciences Centre; University of Calgary; University Health Network; Ottawa Hospital; Université Laval; Centre Hospitalier de l’Université de Montréal; Hamilton Regional Laboratory Medicine Program; Queen Elizabeth II Health Sciences Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Trillium Health Centre; AstraZeneca (Canada); McMaster University; Dalhousie University; Hamilton Health Sciences; Western University; University of Toronto","funders":"Roche; AstraZeneca Canada; AstraZeneca; Pfizer","keywords":"T790M; Concordance; Digital polymerase chain reaction; Mutation; Medicine; Resistance mutation; Polymerase chain reaction; Oncology; Internal medicine; Biology; Genetics; Gene; KRAS; Reverse transcriptase","score_opus":0.17087415249630863,"score_gpt":0.5011210858427947,"score_spread":0.330246933346486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181684306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997197,0.00041446203,0.00041920305,0.00055016263,0.00020873852,0.0010576461,0.0000116708125,0.00000838011,0.00013275864],"genre_scores_gemma":[0.9989017,0.000022686358,0.00045668022,0.000046189944,0.0002814242,0.00008256475,0.000038943985,0.000011568435,0.00015819204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983892,0.000188576,0.0005268937,0.00029989044,0.00041806002,0.00017739777],"domain_scores_gemma":[0.9980266,0.0006615309,0.00013514717,0.00023028994,0.0007995882,0.0001468293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016126868,0.00006487477,0.00019813601,0.000062572566,0.00034215572,0.00005529723,0.000021393282,0.00005686022,0.000036613743],"category_scores_gemma":[0.0024765693,0.000043140313,0.000089741916,0.00021638586,0.0000950194,0.00006984855,0.000024176195,0.0001884731,3.8304546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020306063,0.001500793,0.8564054,0.00012890063,0.0013444732,0.00284358,0.002525195,0.00006921713,0.023676941,0.00002567535,0.000046595855,0.1112302],"study_design_scores_gemma":[0.0027137478,0.0010562214,0.97673786,0.00014270381,0.0009893589,0.00043975256,0.005164211,0.0039310367,0.0068080337,0.0011947834,0.0007216794,0.00010064308],"about_ca_topic_score_codex":0.029054593,"about_ca_topic_score_gemma":0.012440236,"teacher_disagreement_score":0.12033246,"about_ca_system_score_codex":0.00009677183,"about_ca_system_score_gemma":0.0010245522,"threshold_uncertainty_score":0.97741103},"labels":[],"label_agreement":null},{"id":"W3181817852","doi":"10.1016/j.ctro.2021.06.006","title":"Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study","year":2021,"lang":"en","type":"article","venue":"Clinical and Translational Radiation Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Epidermal growth factor receptor; Radiation therapy; Oncology; Lung cancer; Progressive disease; Response Evaluation Criteria in Solid Tumors; Retrospective cohort study; Clinical endpoint; Gefitinib; Cancer; Disease; Clinical trial","score_opus":0.05140204607555353,"score_gpt":0.49272009014468815,"score_spread":0.4413180440691346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181817852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95719504,0.0056388453,0.000675277,0.03465363,0.00061394006,0.00083792896,0.00018950914,0.0000389984,0.00015680068],"genre_scores_gemma":[0.9897778,0.0034173944,0.0033792434,0.0019782034,0.0005452114,0.00010772587,0.0001866657,0.000019198162,0.0005885692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761903,0.0007457114,0.00082109106,0.00046823558,0.00017640609,0.00016951829],"domain_scores_gemma":[0.9963673,0.0028115287,0.00014934689,0.0001150118,0.0002673231,0.0002895252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050834374,0.00014607781,0.0004783331,0.0000686378,0.00018088253,0.00002302315,0.000030077974,0.0002065394,0.00061242655],"category_scores_gemma":[0.00060508476,0.00012610192,0.00012027513,0.0001801693,0.00021834615,0.00012051319,0.0000099297495,0.00027359824,0.0000050469853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015307222,0.0015410515,0.8744296,0.000020887617,0.00075038045,0.00004738355,0.0015176284,0.000013202554,0.000046351317,0.00026396883,0.0005012675,0.1193376],"study_design_scores_gemma":[0.0143912025,0.0007979134,0.9540403,0.00001962666,0.0005592907,0.000029021328,0.00029133397,0.0021024775,0.000009101752,0.00008949362,0.027550988,0.00011928372],"about_ca_topic_score_codex":0.000030944702,"about_ca_topic_score_gemma":0.000087561464,"teacher_disagreement_score":0.11921832,"about_ca_system_score_codex":0.00006387844,"about_ca_system_score_gemma":0.0012603104,"threshold_uncertainty_score":0.6705641},"labels":[],"label_agreement":null},{"id":"W3182408948","doi":"10.1158/1078-0432.ccr-20-4607","title":"Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Medical Research Council; Canada Digital Adoption Program; National Research Foundation","keywords":"T790M; Transcriptome; Biology; Cancer research; Exome; EGFR inhibitors; Gene expression profiling; Exome sequencing; Genetics; Gene; Bioinformatics; KRAS; Epidermal growth factor receptor; Mutation; Cancer; Gene expression","score_opus":0.3480102590733958,"score_gpt":0.5620181373188999,"score_spread":0.21400787824550416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182408948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98038965,0.0057197046,0.0001802565,0.007729105,0.00012923502,0.00097120454,0.00022451629,0.000027757638,0.004628538],"genre_scores_gemma":[0.9899218,0.0054869154,0.00091295555,0.0006280105,0.00018928025,0.00022196132,0.00010939997,0.000024577286,0.0025050654],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997718,0.00061768235,0.00054496055,0.00039466014,0.00044680308,0.0002779076],"domain_scores_gemma":[0.9961543,0.0014358376,0.00010162797,0.00023381163,0.0018627768,0.00021163697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009254165,0.00013777905,0.0004935493,0.00011497906,0.00014341179,0.000025804347,0.00006305718,0.00013056763,0.0003682596],"category_scores_gemma":[0.00071802957,0.00010093704,0.00013678042,0.0003980626,0.00066870573,0.00007924881,0.000042649346,0.000610785,0.0000046786727],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015272921,0.007454317,0.13315332,0.004973712,0.012661318,0.0034177473,0.102674425,0.000072217124,0.093127735,0.019617941,0.006379935,0.6011944],"study_design_scores_gemma":[0.036394566,0.012772661,0.25202477,0.010125163,0.0035321517,0.00019687602,0.22554858,0.0028491232,0.4319576,0.018888263,0.004429622,0.0012806216],"about_ca_topic_score_codex":0.0002965266,"about_ca_topic_score_gemma":0.0001288503,"teacher_disagreement_score":0.5999138,"about_ca_system_score_codex":0.00017399655,"about_ca_system_score_gemma":0.0017902164,"threshold_uncertainty_score":0.4116093},"labels":[],"label_agreement":null},{"id":"W3183490659","doi":"10.1016/j.thorsurg.2021.04.010","title":"Can Biologic Aggressiveness and Metastatic Potential of Primary Lung Cancer Be Predicted from Clinical Staging Alone?","year":2021,"lang":"en","type":"review","venue":"Thoracic surgery clinics/Thorac. surg. clin.","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Lung cancer staging; Oncology; Lung; Cancer; Radiology; Internal medicine; Pathology","score_opus":0.1465580366192203,"score_gpt":0.4931692067074731,"score_spread":0.3466111700882528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183490659","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03170478,0.9521293,0.00012026094,0.00038688397,0.0040846784,0.0022026128,0.009058763,0.00019956125,0.000113130765],"genre_scores_gemma":[0.0040273485,0.97643644,0.0012675561,0.0004906957,0.0012781919,0.00050212425,0.0152767915,0.0002767054,0.00044415856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9865707,0.0036519126,0.0057526524,0.0021224276,0.0009211476,0.0009811734],"domain_scores_gemma":[0.9783853,0.0139096,0.004466041,0.0015720299,0.000881464,0.00078556366],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0042893626,0.0013395078,0.010970794,0.0007116503,0.00026447914,0.000109839624,0.00036712879,0.0011261426,0.0005705896],"category_scores_gemma":[0.0023108798,0.0010599294,0.002884566,0.0012530085,0.00072838255,0.00021081854,0.00042929617,0.001663621,0.000005990788],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004009697,0.0009527599,0.043415222,0.015135631,0.008097194,0.0017663386,0.00008713273,0.000006153446,0.0000017169616,0.000004733875,0.0016487957,0.92848337],"study_design_scores_gemma":[0.003729725,0.000597927,0.014172508,0.17069662,0.13788602,0.00040054464,0.0005589641,0.00036092027,0.000040900482,0.0001932884,0.66774726,0.003615348],"about_ca_topic_score_codex":0.0010287706,"about_ca_topic_score_gemma":0.00008539405,"teacher_disagreement_score":0.924868,"about_ca_system_score_codex":0.0004816729,"about_ca_system_score_gemma":0.009865069,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W3185315144","doi":"10.1158/1078-0432.ccr-21-1034","title":"FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Placebo; non-small cell lung cancer (NSCLC); Cancer; Surgery; Family medicine; Pathology; Adenocarcinoma; Alternative medicine; Environmental health","score_opus":0.20001285098560964,"score_gpt":0.5691318612122892,"score_spread":0.3691190102266796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185315144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3068692,0.6363301,0.00009581448,0.018303718,0.0009970064,0.021543028,0.0031195628,0.00010482378,0.012636727],"genre_scores_gemma":[0.106021784,0.8147887,0.0048055844,0.0012171821,0.0015700083,0.023086632,0.0012817706,0.00019245653,0.047035888],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957118,0.00068740686,0.0011722435,0.0009460575,0.00075299066,0.0007295092],"domain_scores_gemma":[0.99290055,0.0017730381,0.0002775469,0.0007205254,0.0039507854,0.00037755075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012672038,0.00029384412,0.0013910839,0.00014492356,0.00020935704,0.000032774868,0.0001913689,0.00020605036,0.0006160833],"category_scores_gemma":[0.0009780552,0.00020997346,0.00048132928,0.0017572466,0.0003201687,0.00006201161,0.00010107924,0.0004059671,0.0000067762835],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018725691,0.0179068,0.13969555,0.030522924,0.00777931,0.0012526877,0.0036097758,0.000029313518,0.004984134,0.00029496907,0.43733564,0.33786318],"study_design_scores_gemma":[0.043258067,0.014954532,0.015841728,0.01523431,0.0053965356,0.00002078091,0.001256627,0.001119194,0.031870324,0.000092861104,0.8701428,0.00081220345],"about_ca_topic_score_codex":0.0031228596,"about_ca_topic_score_gemma":0.0020014774,"teacher_disagreement_score":0.43280718,"about_ca_system_score_codex":0.0009133601,"about_ca_system_score_gemma":0.014619359,"threshold_uncertainty_score":0.99096686},"labels":[],"label_agreement":null},{"id":"W3186488369","doi":"10.1016/j.jtho.2021.07.008","title":"Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; G1 Therapeutics; Puma Biotechnology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Pfizer; Incyte; F. Hoffmann-La Roche; AbbVie; Daiichi-Sankyo; Teva Pharmaceutical Industries; Roche; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen","keywords":"Medicine; Alectinib; Internal medicine; Clinical endpoint; Oncology; Cohort; Asymptomatic; Confidence interval; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Clinical trial; Phases of clinical research; Crizotinib; Lung cancer","score_opus":0.043952505470356826,"score_gpt":0.4840153234446429,"score_spread":0.44006281797428604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186488369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583907,0.0007032095,0.00039516107,0.005448241,0.0009216933,0.0011489087,0.00020351936,0.0000070205706,0.005333182],"genre_scores_gemma":[0.9910618,0.00022009746,0.0068643335,0.0002382324,0.00032264777,0.00004141883,0.00004400214,0.000019127652,0.0011883227],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977604,0.00052505126,0.0009752289,0.00020206925,0.0003126698,0.00022458554],"domain_scores_gemma":[0.9973814,0.0008792846,0.0009436428,0.00022116773,0.00044716412,0.00012737837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056965504,0.00017655504,0.0008612625,0.00017171721,0.000091568894,0.0000112910675,0.00009969186,0.000094849776,0.000097332675],"category_scores_gemma":[0.00086982787,0.00010114487,0.0002897004,0.00040857785,0.00010822705,0.00013919531,0.000034546752,0.0002838162,0.0000018279611],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43161213,0.016170405,0.0026001765,0.00009632018,0.00722267,0.014061864,0.007522974,0.0005025195,0.0036866583,0.00004296231,0.0005162249,0.5159651],"study_design_scores_gemma":[0.74634683,0.07396015,0.017303526,0.0024432824,0.026237093,0.008856805,0.009116647,0.0002535576,0.088865444,0.00020811977,0.025965292,0.00044324392],"about_ca_topic_score_codex":0.00006528822,"about_ca_topic_score_gemma":0.00039872187,"teacher_disagreement_score":0.5155219,"about_ca_system_score_codex":0.00052749336,"about_ca_system_score_gemma":0.002184871,"threshold_uncertainty_score":0.4124568},"labels":[],"label_agreement":null},{"id":"W3187087408","doi":"10.1097/coc.0000000000000857","title":"A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non–Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Alberta Health Services","funders":"","keywords":"Medicine; Internal medicine; Anaplastic lymphoma kinase; Oncology; Lung cancer; Population; Chemotherapy; Targeted therapy; Cancer registry; Radiation therapy; Immunotherapy; Cancer; Cohort; Stage (stratigraphy)","score_opus":0.03589171005346983,"score_gpt":0.4420942888196092,"score_spread":0.4062025787661394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187087408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989661,0.00004757821,0.00017849184,0.00025042242,0.00013228813,0.00028144356,0.000045529476,0.0000019606437,0.0000961937],"genre_scores_gemma":[0.9980378,0.00009814863,0.00150765,0.00017979923,0.00006755692,0.000010827495,0.000012844189,0.000013188306,0.00007219286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984172,0.00024863638,0.0008848295,0.00014693697,0.00017526056,0.00012714283],"domain_scores_gemma":[0.9973725,0.00063294027,0.0012244518,0.0001373355,0.00045555527,0.00017722823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021113094,0.000106516876,0.0010219136,0.00006510707,0.000021243046,0.0000025053987,0.000041855557,0.00004149688,0.000060352166],"category_scores_gemma":[0.000074481075,0.00006968906,0.00010935168,0.00013181556,0.00008030533,0.00002374273,0.000012465738,0.00013104174,8.378598e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016469725,0.006179225,0.95594287,0.000043513337,0.00080102135,0.000112076385,0.00064539915,0.0004086097,0.000011044749,6.966549e-7,0.0000025822371,0.034206003],"study_design_scores_gemma":[0.016627723,0.038372148,0.9415433,0.00008122434,0.0016300365,0.000004377441,0.0014666539,0.00007680805,0.000046476005,5.599677e-7,0.00009760702,0.000053103937],"about_ca_topic_score_codex":0.002078257,"about_ca_topic_score_gemma":0.0017148787,"teacher_disagreement_score":0.0341529,"about_ca_system_score_codex":0.0002754896,"about_ca_system_score_gemma":0.0021231528,"threshold_uncertainty_score":0.3766382},"labels":[],"label_agreement":null},{"id":"W3191219220","doi":"10.1200/jco.21.00662","title":"Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":632,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Cedars-Sinai Medical Center","keywords":"Medicine; Rash; Lung cancer; Internal medicine; Population; Adverse effect; Epidermal growth factor receptor; Erlotinib; Oncology; Gastroenterology; Cancer","score_opus":0.10153645254976759,"score_gpt":0.5266134971143889,"score_spread":0.42507704456462125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191219220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757372,0.0006486306,0.000031126132,0.02009044,0.001153671,0.0006341472,0.00005683922,0.000011516686,0.0016363888],"genre_scores_gemma":[0.9924316,0.00037218383,0.00072638266,0.0045656115,0.0015416314,0.000027924312,0.00005241988,0.00002731685,0.00025493867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99649304,0.00055938447,0.0020702954,0.00029624728,0.00035202503,0.00022899867],"domain_scores_gemma":[0.9958752,0.0019827243,0.0012933225,0.0002498797,0.00040892104,0.00018994705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011832524,0.0001740695,0.0009824904,0.00007997068,0.000084778054,0.00003065366,0.00013453675,0.00022768602,0.00013788916],"category_scores_gemma":[0.0010342756,0.00010594197,0.0002358768,0.00027943356,0.0000903725,0.000095612195,0.000034720015,0.0009960374,0.000003962022],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055432174,0.055025037,0.36333737,0.00004865158,0.0033826586,0.0128737185,0.015529876,0.00046175593,0.0028388433,0.0000046130826,0.011547822,0.4795175],"study_design_scores_gemma":[0.24086122,0.024642048,0.70272815,0.001186406,0.0027736106,0.00013953038,0.0054616523,0.0018278458,0.0031085156,0.0000767053,0.016902996,0.00029132987],"about_ca_topic_score_codex":0.00044441468,"about_ca_topic_score_gemma":0.0012161798,"teacher_disagreement_score":0.47922614,"about_ca_system_score_codex":0.0004483917,"about_ca_system_score_gemma":0.003564687,"threshold_uncertainty_score":0.63236016},"labels":[],"label_agreement":null},{"id":"W3192563092","doi":"10.1016/j.lungcan.2021.08.003","title":"Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; University of Saskatchewan; Dalhousie University; Queen Elizabeth II Health Sciences Centre; McGill University Health Centre; University of Ottawa; Calgary Laboratory Services; University of Manitoba; University of Calgary; Spinal Cord Injury BC; Canada's Michael Smith Genome Sciences Centre; Sunnybrook Health Science Centre; Ottawa Hospital; University Health Network; McMaster University Medical Centre; Health Sciences Centre; London Health Sciences Centre; Health Sciences North; Institut Universitaire de Cardiologie et de Pneumologie de Québec; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Alberta; University of Toronto","funders":"Pfizer Canada","keywords":"ROS1; Immunohistochemistry; Medicine; Crizotinib; Lung cancer; Fluorescence in situ hybridization; Cancer research; Pathology; Cancer; Oncogene; Adenocarcinoma; Internal medicine; Biology; Gene; Cell cycle; Genetics","score_opus":0.03611358999379091,"score_gpt":0.40586751162549994,"score_spread":0.36975392163170906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192563092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623514,0.002594941,0.0009989415,0.00045310348,0.00048263816,0.007517115,0.0011231373,0.000023247703,0.00057174277],"genre_scores_gemma":[0.9868777,0.000055889726,0.004494937,0.0002790933,0.0001942491,0.0066882856,0.00023254521,0.00003574511,0.0011415788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863636,0.000023586272,0.00040361503,0.00037873548,0.00018591531,0.00037179305],"domain_scores_gemma":[0.9990263,0.000040083116,0.0001324989,0.00018808703,0.00043918213,0.00017384434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011094204,0.0001864582,0.00031484783,0.00014494952,0.00017594516,0.000023101376,0.00006518278,0.000060229322,0.00026574818],"category_scores_gemma":[0.00003097362,0.00017079122,0.00007362403,0.0004138016,0.000022424303,0.00008821404,0.000023295788,0.000103116436,8.3354587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053255808,0.0003532754,0.97725403,0.00051651656,0.00028266563,0.00005445787,0.0028681997,0.001818839,0.009285533,0.000013363117,0.00036356013,0.0071362783],"study_design_scores_gemma":[0.02177883,0.00033513777,0.90888983,0.0008040974,0.0016336098,0.000010786157,0.004075506,0.018105952,0.041793372,0.0000053031613,0.0021473723,0.00042020783],"about_ca_topic_score_codex":0.4392027,"about_ca_topic_score_gemma":0.81931096,"teacher_disagreement_score":0.38010827,"about_ca_system_score_codex":0.0025689865,"about_ca_system_score_gemma":0.0064952485,"threshold_uncertainty_score":0.999137},"labels":[],"label_agreement":null},{"id":"W3193808171","doi":"10.1016/j.jaad.2021.06.376","title":"26198 Evaluating patient outcomes in the BOLT 42-month trial using modified Response Evaluation Criteria in Solid Tumors methodology: Results from a preplanned analysis","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Vismodegib; Basal cell carcinoma; Solid tumor; Oncology; Clinical trial; Complete response; Radiology; Medical physics; Basal cell; Surgery; Internal medicine; Cancer; Chemotherapy","score_opus":0.15688400153559634,"score_gpt":0.5071435909954048,"score_spread":0.3502595894598085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193808171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778041,0.00030032417,0.00020941706,0.020962162,0.00014051098,0.0005060298,0.00003672879,0.0000027716303,0.00003790191],"genre_scores_gemma":[0.9907872,0.000016705155,0.00748277,0.0016368342,0.000037742728,0.000013828381,0.000010073408,0.000009167864,0.0000056609733],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99120975,0.00620252,0.0015352125,0.00021340809,0.00061735645,0.00022173405],"domain_scores_gemma":[0.99416435,0.0031577074,0.0021810075,0.00024488856,0.00019972202,0.000052349995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034886778,0.00014383583,0.0011563908,0.00053006696,0.00006005501,0.000010959849,0.00021218533,0.0000875881,0.000013863341],"category_scores_gemma":[0.006171417,0.000083671584,0.0003284144,0.0011271957,0.00017360758,0.000080535734,0.00005682442,0.00045428242,2.713651e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51989114,0.002637123,0.25175434,0.00004556737,0.010135884,0.0010785736,0.06084322,0.04804011,0.087216236,0.00004961272,0.0006292186,0.017678969],"study_design_scores_gemma":[0.059676614,0.0011182898,0.86548924,0.00025887665,0.0077331625,0.001250022,0.014305127,0.03908455,0.009600128,0.001261419,0.000037983216,0.00018456922],"about_ca_topic_score_codex":0.00044167397,"about_ca_topic_score_gemma":0.000076581775,"teacher_disagreement_score":0.6137349,"about_ca_system_score_codex":0.00023338452,"about_ca_system_score_gemma":0.0006173661,"threshold_uncertainty_score":0.73882085},"labels":[],"label_agreement":null},{"id":"W3195595411","doi":"10.2217/fon-2021-0608","title":"Brigatinib Versus Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3)","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Alectinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Internal medicine","score_opus":0.010820770635600545,"score_gpt":0.3412207235650259,"score_spread":0.33039995292942537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195595411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9163586,0.0064115524,0.00007601746,0.0048854994,0.003986602,0.0009586391,0.00017056371,0.00007457573,0.067077935],"genre_scores_gemma":[0.98957145,0.00059804285,0.003674101,0.001482462,0.001070269,0.00046406785,0.00036062463,0.000063453415,0.0027155227],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982292,0.00011133646,0.00037850311,0.0005810018,0.00018968507,0.0005102896],"domain_scores_gemma":[0.99873185,0.00032193869,0.00016198492,0.00029991276,0.00026327532,0.00022104756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007563888,0.00028007966,0.00057905057,0.00013150055,0.00013706047,0.000018147193,0.0000912416,0.00025002373,0.00046457408],"category_scores_gemma":[0.0000861867,0.000256496,0.00012967565,0.0005617532,0.00006616612,0.00007044878,0.000050526636,0.0002538025,0.000027186517],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051506534,0.013993863,0.05569296,0.0026333511,0.0051308065,0.034282003,0.029070463,0.0013210508,0.12174693,0.0032020465,0.033675548,0.6477445],"study_design_scores_gemma":[0.13944302,0.010280994,0.5171286,0.0015716112,0.0045548114,0.00037508033,0.015586161,0.0008899372,0.04966525,0.00008978023,0.25895023,0.001464483],"about_ca_topic_score_codex":0.0003903978,"about_ca_topic_score_gemma":0.006790307,"teacher_disagreement_score":0.64628,"about_ca_system_score_codex":0.0015806122,"about_ca_system_score_gemma":0.0029126524,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W3195897084","doi":"10.1016/j.jcpo.2021.100301","title":"Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer Policy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Merck","keywords":"Medicine; Value (mathematics); Economics; Intensive care medicine; Computer science","score_opus":0.0104108673269188,"score_gpt":0.3909021958075307,"score_spread":0.3804913284806119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195897084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9276714,0.058319427,0.00003916421,0.012137033,0.00018957103,0.00031608925,0.0000702961,0.000007922695,0.0012491376],"genre_scores_gemma":[0.9966314,0.0020375347,0.0005849486,0.000268827,0.0003310719,0.00003178249,0.0000052825258,0.000020558235,0.00008858405],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998755,0.000043136,0.0004664222,0.00015023633,0.00041522554,0.00017000498],"domain_scores_gemma":[0.9988047,0.0000317583,0.0004863334,0.0001809496,0.00026919425,0.000227057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004170697,0.00015235621,0.00037252702,0.00021575335,0.000047501533,0.000009530461,0.000040478462,0.000015765461,0.00006058307],"category_scores_gemma":[0.000044159293,0.00010433429,0.000268198,0.00019243774,0.000064289874,0.000086491455,0.0000152147,0.00007758525,3.244038e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004389732,0.008437164,0.06686049,0.00026601768,0.0027670416,0.0011068515,0.06930701,0.0015046543,0.043717276,0.0027461408,0.001669931,0.7972277],"study_design_scores_gemma":[0.032462627,0.008734299,0.24341054,0.00858671,0.005889121,0.00053850835,0.049178563,0.0017031326,0.6245705,0.0009514738,0.023273418,0.0007011058],"about_ca_topic_score_codex":0.00029614646,"about_ca_topic_score_gemma":0.000004723091,"teacher_disagreement_score":0.7965266,"about_ca_system_score_codex":0.0012118957,"about_ca_system_score_gemma":0.0020212093,"threshold_uncertainty_score":0.4254629},"labels":[],"label_agreement":null},{"id":"W3197633853","doi":"10.14740/jmc3743","title":"Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; ALK inhibitor; Internal medicine; Lymphoma; Progression-free survival; Chemotherapy","score_opus":0.013298503845811155,"score_gpt":0.3231392580916541,"score_spread":0.30984075424584295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197633853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925069,0.0042908327,0.00011830173,0.0020577107,0.00032143184,0.0002566335,0.000042806725,0.000009367253,0.00039599984],"genre_scores_gemma":[0.99842614,0.00041242747,0.00034132804,0.0003229067,0.00026406598,0.000027762075,0.00003501302,0.00002405328,0.00014627427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978806,0.00009292363,0.0004722632,0.00019599611,0.0010968908,0.00026133299],"domain_scores_gemma":[0.99832386,0.00036275678,0.00026144215,0.0001703284,0.00041053313,0.0004711058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014468443,0.00017954627,0.00045592233,0.00013591512,0.000059690574,0.000026670648,0.00010700363,0.00010940869,0.00043879426],"category_scores_gemma":[0.00038019498,0.00010987107,0.00010549405,0.0003020891,0.00007985844,0.00007414742,0.0000479974,0.00023890157,0.0000014297415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001880842,0.0029808257,0.7978711,0.000356782,0.00050703407,0.14094827,0.00089531724,0.00003208748,0.00016503215,0.000005838247,0.0016824446,0.05267441],"study_design_scores_gemma":[0.02653895,0.006130304,0.9315698,0.010820609,0.0019589458,0.0073713865,0.0012278423,0.00027686867,0.013606954,0.0000045211564,0.00019966348,0.000294165],"about_ca_topic_score_codex":0.00022434596,"about_ca_topic_score_gemma":0.0010008714,"teacher_disagreement_score":0.13369867,"about_ca_system_score_codex":0.00039184903,"about_ca_system_score_gemma":0.0022385768,"threshold_uncertainty_score":0.48044896},"labels":[],"label_agreement":null},{"id":"W3198449529","doi":"10.1016/j.lungcan.2021.08.014","title":"ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Population Health Research Institute; University of Toronto; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Crizotinib; Medicine; Alectinib; Bradycardia; Anaplastic lymphoma kinase; Internal medicine; Oncology; Adverse effect; Lung cancer; Heart rate","score_opus":0.07416902445756512,"score_gpt":0.44421100264302055,"score_spread":0.3700419781854554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198449529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.4883882e-7,0.9927166,0.000011950593,0.00061084493,0.0001695358,0.004822605,0.00040758075,0.000050236646,0.0012105095],"genre_scores_gemma":[0.0000061335663,0.9838793,0.00008654299,0.0012499145,0.0001583548,0.0061942744,0.00039506625,0.00007423064,0.007956167],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973113,0.00028412737,0.000985034,0.0007231985,0.0004098269,0.00028654825],"domain_scores_gemma":[0.99790627,0.00014992474,0.00055465073,0.00093531876,0.00022232394,0.00023153746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022932998,0.0006114439,0.012988111,0.00025077182,0.000087610424,0.00006608128,0.00010848474,0.0002358756,0.0010975956],"category_scores_gemma":[0.00007422857,0.0003647647,0.004578057,0.001269359,0.000026243739,0.00006593095,0.00007165325,0.0003087832,0.000017569837],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[2.7902337e-7,0.000022749535,0.0000010856553,0.55748117,0.43754378,0.00004819098,0.000025399777,8.555962e-8,2.1579297e-8,0.000025116227,0.0019300837,0.0029220707],"study_design_scores_gemma":[0.00012791,0.000013719392,5.624383e-7,0.075237125,0.7261137,0.00005466247,0.0000065739837,0.0000010216862,2.11049e-7,3.8119907e-7,0.19822466,0.00021951266],"about_ca_topic_score_codex":0.00021220582,"about_ca_topic_score_gemma":0.00007096872,"teacher_disagreement_score":0.482244,"about_ca_system_score_codex":0.0005207663,"about_ca_system_score_gemma":0.0009151846,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W3198698997","doi":"10.21203/rs.3.rs-268973/v1","title":"Predictors of Extra-Pulmonary Metastatic Disease in Patients with Recurrent Lung Cancer","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University","funders":"","keywords":"Medicine; Lung cancer; Disease; Oncology; Internal medicine; Pulmonary disease; Lung","score_opus":0.03601669326681954,"score_gpt":0.41909706450832146,"score_spread":0.3830803712415019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198698997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98187387,0.012925072,0.00001717328,0.00044082833,0.00022349824,0.0030092523,0.0010424921,0.000020689313,0.0004471436],"genre_scores_gemma":[0.9949817,0.0009463679,0.00018847153,0.000011210416,0.0000671791,0.0012482534,0.0021349033,0.0000447333,0.00037714836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997018,0.0002570003,0.00035378974,0.00055834185,0.0014015546,0.00041130488],"domain_scores_gemma":[0.99788153,0.000100898134,0.000108559594,0.00060459884,0.0009419698,0.00036242025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024371593,0.00022390354,0.0004807061,0.0004427565,0.000057148103,0.000030212213,0.00013137211,0.000064036256,0.0003558467],"category_scores_gemma":[0.00015578196,0.00016570977,0.000124248,0.000510048,0.00012837118,0.000071558876,0.0002560784,0.00076334033,0.0000014782083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095220894,0.0020459401,0.984299,0.0063740313,0.0006546728,0.00037934512,0.0009218408,0.00057268713,0.000003491447,0.000011006669,0.0003231477,0.003462648],"study_design_scores_gemma":[0.0019540808,0.0003273795,0.98660594,0.009207942,0.0005608238,5.4490795e-7,0.0003525299,0.00065837125,0.00001540667,0.000024947834,0.00014981898,0.00014223927],"about_ca_topic_score_codex":0.0010779094,"about_ca_topic_score_gemma":0.00021622928,"teacher_disagreement_score":0.013107882,"about_ca_system_score_codex":0.0009305052,"about_ca_system_score_gemma":0.0029914633,"threshold_uncertainty_score":0.6757449},"labels":[],"label_agreement":null},{"id":"W3199678110","doi":"10.1016/j.jtho.2021.06.026","title":"Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tyrosine-kinase inhibitor; Breather; Internal medicine; Oncology; Cancer","score_opus":0.026132655338786708,"score_gpt":0.4138631502951667,"score_spread":0.38773049495637996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199678110","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08153141,0.0074032485,0.00026471214,0.90130997,0.0022649618,0.0018117442,0.00013096801,0.000053384047,0.005229588],"genre_scores_gemma":[0.041818447,0.002253099,0.025340434,0.77395034,0.0199708,0.0003163247,0.00040095672,0.0005030004,0.13544658],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690527,0.00033863838,0.0010758712,0.00047548537,0.00057162903,0.0006331159],"domain_scores_gemma":[0.99757653,0.00025441006,0.0007375398,0.00043176525,0.00071316416,0.00028660242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049279135,0.00047939701,0.0017953119,0.0007964709,0.00008356256,0.00006214518,0.0002724571,0.0008355048,0.0009314138],"category_scores_gemma":[0.00025083133,0.00033729165,0.00038419335,0.00072623964,0.000040206538,0.0001865963,0.00007429927,0.0019382028,0.00009993598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008291343,0.0010265474,0.00017117092,0.00022077924,0.0009225387,0.049401935,0.0007707536,0.00013954187,0.008274257,6.137309e-7,0.5148249,0.4159556],"study_design_scores_gemma":[0.0062796604,0.009325358,0.00047744284,0.0031156612,0.00079126185,0.0063382853,0.00043170806,0.000020456433,0.0018305028,0.000030380726,0.9709616,0.00039773743],"about_ca_topic_score_codex":0.000058144553,"about_ca_topic_score_gemma":0.000056443238,"teacher_disagreement_score":0.45613664,"about_ca_system_score_codex":0.0021569955,"about_ca_system_score_gemma":0.0034610962,"threshold_uncertainty_score":0.9999819},"labels":[],"label_agreement":null},{"id":"W3202183889","doi":"10.1016/j.annonc.2021.08.1872","title":"1270P Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; Pathology","score_opus":0.05559042050641958,"score_gpt":0.4291765549029728,"score_spread":0.3735861343965532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202183889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97850364,0.0038113613,0.000029884513,0.00457144,0.00009659763,0.00031352957,0.00023737203,0.000006087806,0.0124300765],"genre_scores_gemma":[0.98843765,0.003454078,0.001515523,0.00095746474,0.0000306323,0.000066763365,0.00007672918,0.000012576266,0.0054485765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916357,0.000053380838,0.00037246876,0.00017948927,0.00007051149,0.00016058613],"domain_scores_gemma":[0.9992834,0.00014323714,0.00016461361,0.0001710326,0.000168331,0.00006939547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011523614,0.00009862792,0.00051013916,0.00016848704,0.000027727905,0.000004016467,0.000028765746,0.00004581222,0.00021918981],"category_scores_gemma":[0.00002614268,0.00008479231,0.000072593335,0.00016934087,0.00005936175,0.00004393266,0.00003570229,0.0000713095,0.0000011832542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001829639,0.0016106762,0.9429642,0.00057188503,0.0008011609,0.0003466528,0.003148804,0.0002569659,0.03418231,0.0012032303,0.0040392065,0.010691932],"study_design_scores_gemma":[0.0052950648,0.0007621173,0.93677485,0.00015324248,0.00070470653,0.000010838186,0.0007632621,0.00015072785,0.035374448,0.00008349851,0.019781303,0.00014594628],"about_ca_topic_score_codex":0.0036687213,"about_ca_topic_score_gemma":0.012233725,"teacher_disagreement_score":0.015742095,"about_ca_system_score_codex":0.00007144452,"about_ca_system_score_gemma":0.00082083023,"threshold_uncertainty_score":0.6826706},"labels":[],"label_agreement":null},{"id":"W3202260438","doi":"10.1016/j.annonc.2021.08.1951","title":"1350P Characteristics, treatment patterns and outcome of non-small cell lung cancer (NSCLC) patients presenting with brain-only metastatic disease","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Cohort; Brain metastasis; Oncology; Internal medicine; Disease; Lung cancer; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Metastasis; Cancer","score_opus":0.0440666885086134,"score_gpt":0.40140406024319986,"score_spread":0.35733737173458646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202260438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950487,0.0005283349,0.00007079705,0.0025571978,0.000092042246,0.00050501886,0.00045652624,0.000006796715,0.000734573],"genre_scores_gemma":[0.99686044,0.00044692022,0.0004074696,0.00075065636,0.000038757407,0.00007363033,0.0002143304,0.000019138737,0.0011886243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990443,0.00005087369,0.0003488821,0.00023127385,0.00012439993,0.0002002501],"domain_scores_gemma":[0.9988514,0.00013118444,0.00028362506,0.00019298306,0.0003711367,0.0001696787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045877667,0.00014588158,0.0005016265,0.00006274955,0.000037311445,0.000005974767,0.00003409319,0.000028288703,0.00008374082],"category_scores_gemma":[0.000048621227,0.00010593627,0.000080411286,0.000074956035,0.000056980924,0.000043050797,0.00003304002,0.000050015442,8.680033e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020527374,0.001555376,0.9801314,0.000601712,0.0006409161,0.0002223872,0.00094423216,0.0000045488696,0.00010448744,0.000010935413,0.00017708424,0.015401632],"study_design_scores_gemma":[0.004286482,0.0015924078,0.9888604,0.00013357284,0.0013876972,0.000007609479,0.00017477607,0.00007718821,0.00168613,0.0000060370753,0.0016944443,0.00009322678],"about_ca_topic_score_codex":0.00056466507,"about_ca_topic_score_gemma":0.0002619996,"teacher_disagreement_score":0.015308405,"about_ca_system_score_codex":0.000067601766,"about_ca_system_score_gemma":0.00066312833,"threshold_uncertainty_score":0.43199557},"labels":[],"label_agreement":null},{"id":"W3202394648","doi":"10.1016/j.annonc.2021.08.1956","title":"1356P Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oncology; Cumulative incidence; Incidence (geometry); Internal medicine; Brain metastasis; Histology; Pathology; Cancer; Metastasis","score_opus":0.025456983868278677,"score_gpt":0.41268124943199436,"score_spread":0.3872242655637157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202394648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98118824,0.008824155,0.00051578216,0.007579239,0.000046470224,0.0003172385,0.00024603488,0.0000043100986,0.0012785244],"genre_scores_gemma":[0.9942333,0.0016702065,0.0015271937,0.0022449554,0.000022678234,0.00003567709,0.00005808722,0.000010550984,0.00019736134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912375,0.00010734049,0.0002833491,0.00023903527,0.000082337974,0.00016416007],"domain_scores_gemma":[0.99887943,0.0004470634,0.00016878835,0.00010592909,0.00032397802,0.0000747921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018437464,0.00011173696,0.0004165864,0.000101843485,0.000024328305,0.0000033059368,0.00002771807,0.000040033083,0.0000497329],"category_scores_gemma":[0.00012357425,0.00010017936,0.00003892803,0.00012998862,0.00007574639,0.00009402959,0.000055431705,0.000087345536,1.9332852e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056189165,0.0008973051,0.7549698,0.0006027479,0.00044851482,0.00082736503,0.0096117435,0.00026067358,0.046264306,0.00015573628,0.00052811205,0.18487182],"study_design_scores_gemma":[0.010822749,0.001722212,0.7858733,0.0016269268,0.00076219183,0.000108740634,0.005198491,0.0024775858,0.18828663,0.00020732563,0.0026285823,0.0002852873],"about_ca_topic_score_codex":0.0018247855,"about_ca_topic_score_gemma":0.0013663128,"teacher_disagreement_score":0.18458654,"about_ca_system_score_codex":0.00005366418,"about_ca_system_score_gemma":0.0004441119,"threshold_uncertainty_score":0.40851957},"labels":[],"label_agreement":null},{"id":"W3202897019","doi":"10.1016/j.annonc.2021.08.1804","title":"1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CMC Microsystems; Pfizer","keywords":"Medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; A549 cell","score_opus":0.08885980664759292,"score_gpt":0.46728384066499595,"score_spread":0.37842403401740304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202897019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992544,0.0006235523,0.00013986831,0.0019505924,0.00008882863,0.0021953085,0.000032630585,0.000001864246,0.0024233775],"genre_scores_gemma":[0.9979888,0.00053778273,0.00019671115,0.00026072396,0.000019536896,0.00062635844,0.00002689784,0.000007022554,0.00033617608],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99911684,0.000073517134,0.0004081188,0.0001504567,0.00012295734,0.00012812603],"domain_scores_gemma":[0.99914145,0.00016170506,0.00023733405,0.0002687941,0.00017139896,0.000019333398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032341748,0.00007699039,0.00027233837,0.00007431216,0.000027067079,6.9942644e-7,0.000105721185,0.000040246956,0.000031525055],"category_scores_gemma":[0.000011462272,0.0000489156,0.00006666301,0.00025043785,0.000032673142,0.000028021806,0.00002839472,0.000064832755,3.401646e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013417513,0.12333864,0.24405752,0.004044213,0.0064317975,0.0003778762,0.22761919,0.018873218,0.010838088,0.0017751012,0.0054385494,0.3437883],"study_design_scores_gemma":[0.077478014,0.0062817726,0.8249103,0.00053359783,0.0023206375,0.0000043130344,0.073095866,0.003489423,0.007217033,0.00018239678,0.0043144496,0.00017220687],"about_ca_topic_score_codex":0.0009997505,"about_ca_topic_score_gemma":0.0012672174,"teacher_disagreement_score":0.58085275,"about_ca_system_score_codex":0.00005697785,"about_ca_system_score_gemma":0.00021726052,"threshold_uncertainty_score":0.19947203},"labels":[],"label_agreement":null},{"id":"W3202978375","doi":"10.21037/jtd-21-804","title":"Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Public Health Ontario; University Health Network; University of Toronto; Princess Margaret Cancer Centre; William Osler Health System","funders":"University of Toronto; Ontario Ministry of Health and Long-Term Care; Princess Margaret Cancer Foundation; Cancer Care Ontario","keywords":"Erlotinib; Medicine; Hazard ratio; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Cohort; Retrospective cohort study; Proportional hazards model; Oncology; Population; Cancer; Epidermal growth factor receptor; Confidence interval","score_opus":0.017346832669483312,"score_gpt":0.35597795721680303,"score_spread":0.3386311245473197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202978375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367464,0.0020503525,0.000007027265,0.0035346267,0.00015100568,0.00018239277,0.0001268374,0.0000020803336,0.00027104915],"genre_scores_gemma":[0.9954495,0.000989886,0.0003799218,0.0012170883,0.0000542365,0.000008015534,0.000012459593,0.000014804515,0.0018740926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990591,0.0000748708,0.0003682603,0.00015015672,0.00018351676,0.00016411679],"domain_scores_gemma":[0.99895144,0.00025240408,0.00020694095,0.00011526683,0.00012291732,0.000351064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012840822,0.00012049251,0.00031070574,0.00012831012,0.000023900799,0.000043274635,0.000032117743,0.000019308023,0.00012196085],"category_scores_gemma":[0.00013153772,0.00009583281,0.00003975922,0.00014083638,0.000011066926,0.00028827018,0.000030520077,0.00018874674,1.9350279e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056613045,0.00023822456,0.99065226,0.00040448643,0.00011785561,0.0053549996,0.00030482493,0.000102941354,0.000057465764,0.0000011886068,0.000293271,0.0019063744],"study_design_scores_gemma":[0.001980711,0.000037441827,0.99530137,0.00067473267,0.0006080374,0.000058167127,0.00038777298,0.0002945469,0.0001321509,0.0000061289684,0.00042724045,0.00009173107],"about_ca_topic_score_codex":0.18551718,"about_ca_topic_score_gemma":0.8267528,"teacher_disagreement_score":0.64123565,"about_ca_system_score_codex":0.00048780494,"about_ca_system_score_gemma":0.0022503051,"threshold_uncertainty_score":0.81990653},"labels":[],"label_agreement":null},{"id":"W3203211236","doi":"10.1016/j.annonc.2021.08.1768","title":"1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of Toronto; University Health Network; William Osler Health System","funders":"Roche; AstraZeneca","keywords":"Medicine; Osimertinib; Internal medicine; Oncology; Hazard ratio; Reimbursement; Overall survival; Placebo; Stage (stratigraphy); Cancer; Confidence interval; Adenocarcinoma; Pathology","score_opus":0.08022928519881459,"score_gpt":0.40717503482220657,"score_spread":0.32694574962339196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203211236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288386,0.0002537115,0.00022208154,0.004076322,0.0003554675,0.00060316175,0.00015339757,0.00001592012,0.0014360672],"genre_scores_gemma":[0.99716854,0.00009459162,0.00033298988,0.0012215971,0.00007747613,0.000024191384,0.00045812078,0.000019112014,0.0006033829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874157,0.00013996082,0.00037545254,0.0002530256,0.00024917247,0.00024081915],"domain_scores_gemma":[0.99873745,0.00033812693,0.0001747156,0.0002897513,0.00038578786,0.00007418765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013690455,0.00014556163,0.00053998054,0.000053028023,0.00005304927,0.000010668027,0.000086839114,0.00010002785,0.0001755292],"category_scores_gemma":[0.00008439505,0.00008890719,0.000092911934,0.0001840482,0.000075415235,0.00007549945,0.000038291957,0.00016302736,0.0000094679435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013576718,0.0022337139,0.9691063,0.000019085603,0.00092944846,0.00024150308,0.001423366,0.00072940387,0.000021008114,0.000067132314,0.00021694787,0.011435354],"study_design_scores_gemma":[0.078743264,0.0033720224,0.91499853,0.0001006282,0.00034168243,0.000001591626,0.00044247077,0.00013217115,0.00025106946,0.00010366592,0.0013690821,0.00014382278],"about_ca_topic_score_codex":0.00080696255,"about_ca_topic_score_gemma":0.0009484828,"teacher_disagreement_score":0.06516655,"about_ca_system_score_codex":0.000081944694,"about_ca_system_score_gemma":0.0005661778,"threshold_uncertainty_score":0.362553},"labels":[],"label_agreement":null},{"id":"W3203727420","doi":"10.1016/j.annonc.2021.08.2125","title":"LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Exon; Oncology; Multinational corporation; Internal medicine; Phases of clinical research; Phase (matter); Cancer research; Genetics; Gene; Chemotherapy","score_opus":0.07694720565537184,"score_gpt":0.47024311486773435,"score_spread":0.3932959092123625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203727420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914129,0.00093328225,0.000021761896,0.0031138458,0.00007658164,0.0007741582,0.00008559249,0.000012217332,0.003569662],"genre_scores_gemma":[0.9976999,0.0002690839,0.001035611,0.00015154426,0.00004644692,0.00008331304,0.00014673568,0.000012200684,0.0005551206],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988788,0.00010425068,0.00046260425,0.0002480599,0.00014250388,0.00016380558],"domain_scores_gemma":[0.9989461,0.0003141758,0.00017858812,0.00015804895,0.0003243599,0.00007874565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014816399,0.00012609575,0.00045750453,0.0001695734,0.000072680035,0.0000037952657,0.00003321032,0.0000694137,0.00012737724],"category_scores_gemma":[0.00021087455,0.0001108712,0.00006326175,0.00025834018,0.00007814251,0.000073276475,0.000034708148,0.00007351683,0.0000019760696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050414144,0.091627896,0.117846794,0.00017716276,0.0028450757,0.001242074,0.03693462,0.00024310606,0.015301741,0.0012209204,0.0003357552,0.72718346],"study_design_scores_gemma":[0.15702198,0.06958083,0.7117517,0.00048706305,0.001546489,0.00018755722,0.016132047,0.0006055448,0.019306216,0.00028356345,0.022703608,0.00039340826],"about_ca_topic_score_codex":0.00024946508,"about_ca_topic_score_gemma":0.00036854908,"teacher_disagreement_score":0.72679,"about_ca_system_score_codex":0.00011204806,"about_ca_system_score_gemma":0.0006074944,"threshold_uncertainty_score":0.45211965},"labels":[],"label_agreement":null},{"id":"W3203963820","doi":"10.1016/j.annonc.2021.08.1755","title":"1152P Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Brampton Civic Hospital; Princess Margaret Cancer Centre; University of Toronto; Canada Health Infoway; William Osler Health System; AstraZeneca (Canada); Western University","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Stage (stratigraphy); Overall survival; Tyrosine kinase; Erlotinib; Epidermal growth factor receptor; Receptor","score_opus":0.06894350956014282,"score_gpt":0.4350006015565685,"score_spread":0.36605709199642567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203963820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782165,0.00027818725,0.0000021600783,0.016461631,0.00010160446,0.00044763766,0.00015716538,0.000008343589,0.004326712],"genre_scores_gemma":[0.996375,0.00015205942,0.000054696262,0.0016579482,0.000019569563,0.000056365836,0.00022987412,0.000010131028,0.0014443592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983605,0.00033053273,0.00051383907,0.00028287125,0.00025087464,0.000261355],"domain_scores_gemma":[0.9986553,0.00048917625,0.00014877021,0.00039020384,0.00023632719,0.00008023195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023039934,0.00012547069,0.0007152418,0.00025059367,0.000037742175,0.0000055902015,0.000102995065,0.00004673382,0.0003249934],"category_scores_gemma":[0.00018231147,0.00008599742,0.000098122975,0.0015080567,0.00003886564,0.000031368218,0.000057078127,0.00018965779,0.0000023264663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019385444,0.0012124003,0.98640805,0.000005164562,0.002390731,0.0018028207,0.0020517863,0.00037266055,0.00010729878,0.000027301938,0.00081633625,0.0046115764],"study_design_scores_gemma":[0.003221876,0.00042131863,0.98711765,0.000019698675,0.0007023274,0.0000011299198,0.006472523,0.00009486544,0.00022668726,0.000040020226,0.0016138443,0.000068080335],"about_ca_topic_score_codex":0.97709507,"about_ca_topic_score_gemma":0.9989381,"teacher_disagreement_score":0.021843024,"about_ca_system_score_codex":0.0006980046,"about_ca_system_score_gemma":0.0034903302,"threshold_uncertainty_score":0.6191696},"labels":[],"label_agreement":null},{"id":"W3204109254","doi":"10.1016/j.annonc.2021.08.1797","title":"1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Oncology; Lung cancer; Epidermal growth factor receptor; Combination therapy; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Cancer; Erlotinib; Phases of clinical research","score_opus":0.03634859327166554,"score_gpt":0.399588596682932,"score_spread":0.36324000341126644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204109254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981704,0.0009174144,0.000016169706,0.01611883,0.000027931768,0.0004849214,0.000032505668,0.000008670422,0.000689561],"genre_scores_gemma":[0.99688554,0.00041093642,0.000118710195,0.002333186,0.000016821023,0.000060716404,0.00009974224,0.000010918408,0.00006341663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998958,0.00018637326,0.0003205045,0.0002443152,0.00014154219,0.00014928769],"domain_scores_gemma":[0.99913216,0.0002738173,0.00012615252,0.00022492808,0.00020124044,0.000041715044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020441462,0.00010496405,0.0004477765,0.00016103448,0.000030902167,0.0000087901035,0.000052576408,0.000060465827,0.00007233828],"category_scores_gemma":[0.0000650369,0.000067746674,0.0000515964,0.00069382304,0.00006400307,0.000055918932,0.000021363645,0.00011135713,0.0000010588368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001526489,0.004180926,0.93416107,0.0000069778257,0.0022862405,0.00033891163,0.013490292,0.00006591742,0.0025049015,0.000083602645,0.00007871126,0.041275937],"study_design_scores_gemma":[0.008753716,0.0028745034,0.977975,0.000033925186,0.000729043,0.000007809755,0.0059459694,0.0001521238,0.002133538,0.00009483225,0.0012265696,0.00007295648],"about_ca_topic_score_codex":0.0042707636,"about_ca_topic_score_gemma":0.017595552,"teacher_disagreement_score":0.04381392,"about_ca_system_score_codex":0.00005720682,"about_ca_system_score_gemma":0.00028918163,"threshold_uncertainty_score":0.98187304},"labels":[],"label_agreement":null},{"id":"W3204152960","doi":"10.1016/j.annonc.2021.08.1055","title":"533P Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Trk receptor; Medicine; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Fusion gene; Cancer research; Solid tumor; Cancer; Receptor; Gene; Neurotrophin; Biology; Genetics","score_opus":0.017311276759919565,"score_gpt":0.3733421316483758,"score_spread":0.35603085488845626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204152960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301827,0.000650822,0.000084469575,0.0018003624,0.000075301454,0.00052580005,0.00007065791,0.000006964274,0.003767326],"genre_scores_gemma":[0.9969255,0.00038363374,0.0017487698,0.0006322207,0.000013787522,0.000015744152,0.000109340384,0.000012264591,0.00015877592],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901307,0.000083110026,0.00034098676,0.00021617228,0.00015230566,0.00019436475],"domain_scores_gemma":[0.99885505,0.00026352267,0.00019413546,0.00014008222,0.000453717,0.00009349626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088410394,0.0001156345,0.00049391855,0.00009309027,0.000031678333,0.0000023795499,0.00003286219,0.000047349586,0.00007877016],"category_scores_gemma":[0.00014648959,0.00009011534,0.00004057815,0.00021893349,0.00012324358,0.000056293993,0.000033884655,0.00009672551,0.0000022836452],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011241765,0.009745721,0.38371834,0.00030855555,0.0013275743,0.0005957903,0.0063944594,0.00057420426,0.0011312071,0.00049515674,0.0008708375,0.58359635],"study_design_scores_gemma":[0.017893258,0.008862793,0.9643158,0.0005090322,0.00032654047,0.000030506131,0.00077612494,0.00001952115,0.0053361715,0.00012224633,0.0016919138,0.00011612669],"about_ca_topic_score_codex":0.000048045684,"about_ca_topic_score_gemma":0.00010359336,"teacher_disagreement_score":0.58348024,"about_ca_system_score_codex":0.000054605698,"about_ca_system_score_gemma":0.00051901786,"threshold_uncertainty_score":0.3674797},"labels":[],"label_agreement":null},{"id":"W3204840943","doi":"10.1016/j.annonc.2021.08.1848","title":"1243P Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Histology; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Incidence (geometry); Cumulative incidence; Lung cancer; Cohort","score_opus":0.03865106962071749,"score_gpt":0.3980041069635633,"score_spread":0.35935303734284585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204840943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914531,0.00472629,0.0004773702,0.0016939469,0.00007575129,0.00042187472,0.00040514593,0.000007807899,0.0007386841],"genre_scores_gemma":[0.989268,0.006263156,0.001182232,0.0014032522,0.000018907518,0.000092551825,0.000099092715,0.000017488854,0.0016553334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988591,0.00012857714,0.00036143902,0.00026935496,0.00009648918,0.00028504513],"domain_scores_gemma":[0.99883014,0.00026734176,0.0003122416,0.0001556364,0.00028170698,0.00015294013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014003064,0.00014293064,0.0006328313,0.00008113988,0.000039289338,0.000004058799,0.000040245628,0.00009395561,0.00017158793],"category_scores_gemma":[0.000056667537,0.00012906818,0.000047966685,0.00009266571,0.000132494,0.000067730834,0.00005307127,0.00012551919,5.662365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016826426,0.0012372773,0.79307306,0.0021095432,0.0013173815,0.0006491335,0.01137607,0.000015719466,0.158572,0.00011131479,0.00091389235,0.028941976],"study_design_scores_gemma":[0.02332541,0.007281799,0.80502677,0.00065859576,0.0025360822,0.00022602994,0.0023835506,0.0006560514,0.11797209,0.000105388186,0.03935727,0.00047094768],"about_ca_topic_score_codex":0.0013413223,"about_ca_topic_score_gemma":0.00036031957,"teacher_disagreement_score":0.04059991,"about_ca_system_score_codex":0.00012371156,"about_ca_system_score_gemma":0.0009543594,"threshold_uncertainty_score":0.52632475},"labels":[],"label_agreement":null},{"id":"W3205408622","doi":"10.1021/acs.jmedchem.1c00848","title":"Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites","year":2021,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Structural Genomics Consortium; National Cancer Institute; National Institutes of Health; National Institute of General Medical Sciences; Deutschen Konsortium für Translationale Krebsforschung; Deutsche Forschungsgemeinschaft; Wellcome Trust","keywords":"T790M; Chemistry; Allosteric regulation; Osimertinib; Epidermal growth factor receptor; Mutant; Cetuximab; EGFR inhibitors; Protein kinase domain; Pharmacology; Receptor; Cancer research; Biochemistry; Gefitinib; Erlotinib; Cancer; Biology; Genetics","score_opus":0.034222711396967385,"score_gpt":0.3040999913647356,"score_spread":0.2698772799677682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205408622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924942,0.0030255588,0.0004915528,0.0034520086,0.00010653618,0.00015020442,0.000011208785,0.000004416272,0.00026426857],"genre_scores_gemma":[0.9973488,0.00057669426,0.0012768001,0.000291881,0.00034086333,0.000005569368,0.0000070354354,0.000014660123,0.00013768468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875927,0.000071299975,0.0004322354,0.0001480696,0.00041096372,0.00017815705],"domain_scores_gemma":[0.9987257,0.00030393395,0.00036709313,0.00011804426,0.0003349214,0.00015031038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022087358,0.00014632156,0.00044468007,0.000037428457,0.000044342105,0.000012081708,0.00006965499,0.00006843359,0.00020854647],"category_scores_gemma":[0.00029702554,0.00009222588,0.00008691905,0.00022239986,0.00011900442,0.000091569345,0.000028313889,0.0003666837,7.6200087e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006216903,0.00032035654,0.06590125,0.00034689912,0.00046014594,0.00059118506,0.002927502,0.0000079607935,0.92566663,0.0000015649293,0.00029980988,0.0028549917],"study_design_scores_gemma":[0.006781691,0.0007912489,0.042394407,0.0014374387,0.0008823704,0.004445172,0.00348701,0.000061503415,0.9392644,0.000079859245,0.00021225019,0.0001626429],"about_ca_topic_score_codex":0.00001354496,"about_ca_topic_score_gemma":0.0000029664684,"teacher_disagreement_score":0.02350684,"about_ca_system_score_codex":0.00015060544,"about_ca_system_score_gemma":0.0005056544,"threshold_uncertainty_score":0.3760862},"labels":[],"label_agreement":null},{"id":"W3206007763","doi":"10.1016/j.jtho.2021.08.147","title":"MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Takeda (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Cohort; Oncology; Internal medicine","score_opus":0.020441402663337018,"score_gpt":0.4472418970218791,"score_spread":0.4268004943585421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206007763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97128433,0.00013984181,0.000029999128,0.0018298327,0.00042495748,0.0002322949,0.000035426176,0.0000043159935,0.026018996],"genre_scores_gemma":[0.9911176,0.00017704398,0.0021393988,0.0003777103,0.00006654496,0.000006921745,0.000019664965,0.000013902778,0.006081211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863684,0.00015081256,0.0006383494,0.0001275821,0.0002747213,0.00017171405],"domain_scores_gemma":[0.9984723,0.00017129231,0.00052765344,0.00014669623,0.0005628636,0.00011921694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025050354,0.0001094927,0.0006793263,0.00027303075,0.000025304944,0.000006615779,0.00006502215,0.00008362806,0.00015025814],"category_scores_gemma":[0.00012302061,0.00008276772,0.0001593065,0.0002895704,0.000053971915,0.00010821528,0.000031521016,0.00025454516,0.000005891146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007323964,0.0012781044,0.96891683,0.00003638207,0.0006441234,0.0011294081,0.0009964474,0.000009587823,0.00021132304,0.00010841336,0.0003631082,0.025573865],"study_design_scores_gemma":[0.0021726338,0.0016391706,0.99055886,0.00016955457,0.0006493591,0.00005683693,0.00032268887,0.0000033941262,0.0012993976,0.00008000159,0.002986468,0.000061628],"about_ca_topic_score_codex":0.00044321542,"about_ca_topic_score_gemma":0.0007874867,"teacher_disagreement_score":0.025512237,"about_ca_system_score_codex":0.0006523275,"about_ca_system_score_gemma":0.0009002079,"threshold_uncertainty_score":0.337517},"labels":[],"label_agreement":null},{"id":"W3206374629","doi":"10.1016/j.jmb.2021.167294","title":"Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells","year":2021,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Université de Montréal; Institute for Research in Immunology and Cancer; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Sunnybrook Hospital; Ontario Institute for Cancer Research","funders":"Genentech; Fondation Brain Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; Québec Consortium for Drug Discovery; Genome Canada","keywords":"Unfolded protein response; Epidermal growth factor receptor; Biology; Endoplasmic reticulum; Cancer research; Cell biology; Mutant; Receptor tyrosine kinase; Tyrosine kinase; Signal transduction; Lung cancer; Cancer; Biochemistry; Genetics; Medicine; Internal medicine","score_opus":0.014188029190766865,"score_gpt":0.34680914033973687,"score_spread":0.33262111114897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206374629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913988,0.0063300654,0.00040305438,0.0015451487,0.00017563281,0.00009552732,0.000021812233,0.0000025443328,0.000027401959],"genre_scores_gemma":[0.9979306,0.0005001708,0.0010935793,0.00032606174,0.000058987032,0.0000037229772,0.000025467663,0.000008788825,0.00005265022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992767,0.00012849605,0.00023987662,0.00012140611,0.0001072874,0.00012621995],"domain_scores_gemma":[0.9995075,0.00006471479,0.00013915684,0.000090214344,0.00013649002,0.000061949584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014622224,0.00008383084,0.00022280145,0.000103743005,0.000021974492,0.000018674955,0.000039918337,0.00009124671,0.000025605996],"category_scores_gemma":[0.00003851006,0.0000679199,0.000052953073,0.000086936394,0.00006741011,0.00003785353,0.000029455143,0.00012503832,2.7898707e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003825779,0.00007460882,0.065392196,0.000024970417,0.00023422048,0.00028607895,0.00022573944,0.0000837532,0.9320979,0.000017416136,0.00015532765,0.0010251964],"study_design_scores_gemma":[0.002163814,0.00012677173,0.16591288,0.00017573568,0.00027755456,0.0001825913,0.00018488424,0.000096157084,0.8305065,0.000084028616,0.00020746602,0.00008159231],"about_ca_topic_score_codex":0.000034107787,"about_ca_topic_score_gemma":0.000022779719,"teacher_disagreement_score":0.10159139,"about_ca_system_score_codex":0.00012124964,"about_ca_system_score_gemma":0.00024935516,"threshold_uncertainty_score":0.2769693},"labels":[],"label_agreement":null},{"id":"W3206782097","doi":"10.2139/ssrn.3792115","title":"Association Between EGFR Mutation Status and Immune Checkpoint Inhibitors and PD-L1 Expression in Non-Small-Cell Lung Cancer: A Meta-Analysis","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Meta-analysis; Oncology; Subgroup analysis; Medicine; Internal medicine; Lung cancer; Epidermal growth factor receptor; Immunotherapy; Mutation; Cancer; Biology; Genetics; Gene","score_opus":0.010919068117760838,"score_gpt":0.2999790786188448,"score_spread":0.289060010501084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206782097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9411883,0.05551787,0.00092816993,0.0018596253,0.00004697503,0.00025261435,0.000016669866,0.000010364817,0.00017944559],"genre_scores_gemma":[0.9860617,0.011382829,0.00028023188,0.000047037684,0.0001088589,0.000042678774,0.0000817095,0.000018447296,0.0019765222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803287,0.00011449474,0.00045319053,0.00026615633,0.00027241415,0.0008608689],"domain_scores_gemma":[0.9991752,0.00008087042,0.0003365616,0.00011315241,0.00016942227,0.00012480195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007416477,0.0001652405,0.00060361443,0.0002529941,0.00014846206,0.000062921616,0.000029767954,0.00010093918,0.000059834307],"category_scores_gemma":[0.0000514574,0.00013231205,0.00028461084,0.0004917553,0.000013250696,0.00016095997,0.000028003376,0.0007432362,8.132377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010741564,0.00027895797,0.8657054,0.00011047332,0.10948817,0.00005782696,0.003792879,0.0003057924,0.013393632,0.000111198955,0.000040339553,0.006607927],"study_design_scores_gemma":[0.009489256,0.00048463384,0.5838321,0.00010808414,0.36089802,0.00011321107,0.0066064815,0.0006767394,0.033076458,0.004027963,0.00021924857,0.00046784678],"about_ca_topic_score_codex":0.0010482557,"about_ca_topic_score_gemma":0.0033241615,"teacher_disagreement_score":0.28187332,"about_ca_system_score_codex":0.0024323196,"about_ca_system_score_gemma":0.0015660684,"threshold_uncertainty_score":0.63604313},"labels":[],"label_agreement":null},{"id":"W3206890460","doi":"10.1007/s40271-021-00552-w","title":"The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Patient","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Broadcom (Canada); Canadian Cancer Society","funders":"","keywords":"Lung cancer; Qualitative research; Disease; Medicine; Clinical endpoint; Cancer; Clinical trial; Oncology; Internal medicine; Gerontology; Intensive care medicine; Sociology","score_opus":0.04657380105503119,"score_gpt":0.4430560875118988,"score_spread":0.3964822864568676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206890460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405074,0.0010787192,0.0000028588347,0.0008358712,0.00085341017,0.0013193833,0.00038174263,0.0000066640123,0.0014706085],"genre_scores_gemma":[0.9990444,0.00008531379,0.000022074064,0.000085570064,0.00007268358,0.00023371412,0.000047323058,0.000013846608,0.0003950614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813354,0.00038805944,0.0006521477,0.00023653544,0.00039767774,0.00019206549],"domain_scores_gemma":[0.99807084,0.00050368457,0.00027119202,0.0004997857,0.00035607873,0.00029842296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004429445,0.0001090754,0.0003490391,0.000040008985,0.000095338684,0.000007736892,0.000089478934,0.000031184773,0.00014606939],"category_scores_gemma":[0.0009288677,0.00007333825,0.00016353448,0.00020874995,0.00012902975,0.000031239186,0.000043264696,0.00010059998,9.968646e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006297421,0.0012301614,0.9564463,0.000046881458,0.0010196932,0.00008506731,0.032452416,0.0000075059106,0.0000010844782,0.0005307697,0.00065277703,0.001229938],"study_design_scores_gemma":[0.028899489,0.0022203631,0.91039073,0.00013779745,0.0011956876,4.920541e-7,0.055478014,0.000054858876,0.00005472555,0.00028864265,0.0011345334,0.00014464119],"about_ca_topic_score_codex":0.16986029,"about_ca_topic_score_gemma":0.6926463,"teacher_disagreement_score":0.522786,"about_ca_system_score_codex":0.00019700143,"about_ca_system_score_gemma":0.0021912712,"threshold_uncertainty_score":0.83566767},"labels":[],"label_agreement":null},{"id":"W3207399235","doi":"10.1016/j.cllc.2021.10.001","title":"Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Genotyping; Internal medicine; Oncology; ROS1; Guideline; Prospective cohort study; Clinical trial; Biomarker; Cancer; Genotype; Pathology; Adenocarcinoma","score_opus":0.0745080612710012,"score_gpt":0.47380908286018025,"score_spread":0.3993010215891791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207399235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826998,0.00848364,0.00044944466,0.00066756696,0.0032280388,0.0029253073,0.0007170706,0.00006386767,0.0007652438],"genre_scores_gemma":[0.9421444,0.0007091617,0.053490162,0.0009072347,0.000616622,0.001186078,0.00025358965,0.00010788267,0.00058487646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966742,0.00012568673,0.0015514643,0.0008653491,0.00027206342,0.00051126495],"domain_scores_gemma":[0.9939755,0.0036491887,0.00049025804,0.00049917126,0.0011108795,0.00027497858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000272561,0.0003414969,0.0014018426,0.00008989882,0.000114877,0.00002219542,0.0001561221,0.00028792128,0.00010763036],"category_scores_gemma":[0.000859966,0.00030417333,0.00045745634,0.00033884824,0.00014951141,0.00006662534,0.00008173197,0.0005100318,0.0000027834758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044179275,0.0003659037,0.94392335,0.00164347,0.0005757279,0.00007348487,0.00022821185,0.004115177,0.00050092995,0.000014894889,0.00036917016,0.043771755],"study_design_scores_gemma":[0.11231679,0.005517935,0.8083883,0.004380707,0.0070105614,0.0000034065008,0.0021402976,0.03223603,0.0138607705,0.00002491811,0.01292106,0.0011992314],"about_ca_topic_score_codex":0.00015253769,"about_ca_topic_score_gemma":0.0012464804,"teacher_disagreement_score":0.13553505,"about_ca_system_score_codex":0.00084098906,"about_ca_system_score_gemma":0.00431724,"threshold_uncertainty_score":0.99994105},"labels":[],"label_agreement":null},{"id":"W3207551833","doi":"10.1016/j.jmoldx.2021.09.008","title":"Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection","year":2021,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Health Science Centre; University of Toronto; Queen Elizabeth II Health Sciences Centre","funders":"Merck Sharp and Dohme; EMD Serono; Roche; Hospices Civils de Lyon; Bayer Fund; F. Hoffmann-La Roche; Merck; Boehringer Ingelheim; Amgen; Pfizer; Genentech; Bayer; AstraZeneca","keywords":"Biology; Fusion gene; Receptor tyrosine kinase; Cancer research; Kinase; Computational biology; Oncology; Medicine; Gene; Genetics","score_opus":0.10073850831825157,"score_gpt":0.3779671981683163,"score_spread":0.27722868985006477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207551833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567647,0.0024462242,0.039801423,0.0003627547,0.00034905775,0.00021096582,0.000014398164,0.0000058117093,0.000044688044],"genre_scores_gemma":[0.97381014,0.00077531073,0.024827795,0.00025298752,0.00023887468,0.000011789419,0.000050920884,0.0000136809995,0.000018487452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917793,0.00006598092,0.0003016381,0.00010277676,0.00025659116,0.0000950846],"domain_scores_gemma":[0.99853367,0.0001461314,0.00022191321,0.000078984136,0.0009476585,0.00007163139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034061406,0.000077237644,0.00017844874,0.00005738016,0.00008912531,0.00005659815,0.000018488792,0.000060244103,0.000024144196],"category_scores_gemma":[0.0025588188,0.00006545481,0.000043416803,0.00007425539,0.000010427964,0.00008624331,0.000012524418,0.00007415457,6.7400146e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035307792,0.000036816164,0.00012267036,0.0000480534,0.000090885944,0.00012455751,0.00011500093,0.00024684568,0.98334825,0.00006880717,0.00009689315,0.01566591],"study_design_scores_gemma":[0.0015696473,0.0007050017,0.0012979972,0.00022268579,0.000776251,0.00037781446,0.00014302952,0.0016510913,0.99253,0.00036778467,0.0002895705,0.0000691523],"about_ca_topic_score_codex":0.000009739292,"about_ca_topic_score_gemma":0.00001020155,"teacher_disagreement_score":0.017045476,"about_ca_system_score_codex":0.0002063481,"about_ca_system_score_gemma":0.00037864494,"threshold_uncertainty_score":0.30633298},"labels":[],"label_agreement":null},{"id":"W3207592456","doi":"10.1016/j.jtho.2021.09.008","title":"Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; Compute Canada; Princess Margaret Cancer Foundation; Canadian Cancer Society; AstraZeneca","keywords":"Cancer research; Osimertinib; Gefitinib; Trametinib; Medicine; Gene knockdown; Crizotinib; Dabrafenib; Tyrosine kinase; Vemurafenib; Small interfering RNA; Kinase; Erlotinib; Lung cancer; Epidermal growth factor receptor; Mutation; Targeted therapy; Cancer; Biology; Cell culture; Oncology; MAPK/ERK pathway; Internal medicine; Gene; Melanoma; Transfection; Receptor","score_opus":0.010646522987556873,"score_gpt":0.4262906330278933,"score_spread":0.4156441100403364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207592456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9022856,0.041836716,0.0010357936,0.04655181,0.0023645484,0.0003475876,0.00017127671,0.000026090042,0.005380632],"genre_scores_gemma":[0.96987855,0.0016111173,0.004195781,0.004824934,0.00077739457,0.000029466064,0.00013106572,0.000040712148,0.018510988],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878925,0.00009742896,0.00046081343,0.00016813599,0.00026576448,0.0002186265],"domain_scores_gemma":[0.9986843,0.00006834815,0.0004339441,0.00012177791,0.0004829014,0.00020872822],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015321672,0.000129611,0.0004269661,0.00009440614,0.00009115976,0.000021704342,0.00006204275,0.0001416419,0.0010346401],"category_scores_gemma":[0.00006745689,0.000105693725,0.00014956162,0.00023530418,0.000045411944,0.00020000599,0.000022058872,0.00028212214,0.000010962243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004202682,0.0010819472,0.016350776,0.00014541009,0.001180794,0.0015074502,0.0015947148,0.00010588449,0.0652212,0.000012541316,0.804671,0.10770805],"study_design_scores_gemma":[0.003371245,0.0013163515,0.0025623601,0.0003338922,0.0029345858,0.0013230966,0.0010395856,0.00043642512,0.16262175,0.000116741176,0.8237191,0.00022489295],"about_ca_topic_score_codex":0.00009740039,"about_ca_topic_score_gemma":0.000030406154,"teacher_disagreement_score":0.107483156,"about_ca_system_score_codex":0.0009914334,"about_ca_system_score_gemma":0.0013476757,"threshold_uncertainty_score":0.9998785},"labels":[],"label_agreement":null},{"id":"W3208463219","doi":"10.1016/j.jmoldx.2021.07.027","title":"Comparison of RNA-Based Next-Generation Sequencing Assays for the Detection of NTRK Gene Fusions","year":2021,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pharmaceuticals Bayer; Bayer Canada; Bayer Corporation","keywords":"DNA sequencing; Computational biology; RNA; Gene; Biology; Genetics","score_opus":0.07400977865662105,"score_gpt":0.36373944882118203,"score_spread":0.28972967016456097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208463219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5152293,0.006205194,0.47711435,0.00084251486,0.00032628461,0.00021981917,0.000020926778,0.0000026120397,0.000039022067],"genre_scores_gemma":[0.9863263,0.0003894323,0.01291398,0.00017607678,0.00014208605,0.000008349828,0.000023440249,0.000011725283,0.0000086466825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912506,0.000044200868,0.00043111923,0.000064222455,0.00025675463,0.00007864714],"domain_scores_gemma":[0.9980239,0.0004741109,0.00042075195,0.0001402539,0.000889321,0.000051637635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015920069,0.000069033755,0.0002406598,0.00006613866,0.000069051515,0.000011078241,0.000042724478,0.000049034188,0.000010783967],"category_scores_gemma":[0.0011359033,0.00004893456,0.00017487725,0.00014661894,0.000027630227,0.00003274269,0.000008483164,0.00009864813,2.2744155e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003509761,0.00023265618,0.0019136197,0.0000512733,0.00026709025,0.000039979284,0.00018711007,0.017447291,0.9709783,0.000080762184,0.00021377497,0.008553051],"study_design_scores_gemma":[0.0013756427,0.0005570168,0.002082598,0.000145199,0.0015140267,0.000042655483,0.00029028454,0.015298943,0.9781258,0.00006331212,0.00046368293,0.00004085596],"about_ca_topic_score_codex":0.000014699105,"about_ca_topic_score_gemma":0.000025608699,"teacher_disagreement_score":0.471097,"about_ca_system_score_codex":0.00011948648,"about_ca_system_score_gemma":0.00055559474,"threshold_uncertainty_score":0.19954935},"labels":[],"label_agreement":null},{"id":"W3208688608","doi":"10.1016/j.thorsurg.2021.05.004","title":"Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment","year":2021,"lang":"en","type":"review","venue":"Thoracic surgery clinics/Thorac. surg. clin.","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Biopsy; Cancer; Systemic therapy; Intensive care medicine; Disease; Stage (stratigraphy); Selection (genetic algorithm); Oncology; Pathology; Internal medicine; Breast cancer","score_opus":0.05775955268263059,"score_gpt":0.43451561214889195,"score_spread":0.37675605946626134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208688608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057256855,0.9385233,0.000003050327,0.00006271137,0.0005351742,0.0029394021,0.00016087746,0.000028550414,0.0004900807],"genre_scores_gemma":[0.049351536,0.94873804,0.000080571896,0.000026479149,0.00015324284,0.000992862,0.00026372433,0.00011068772,0.00028285643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936199,0.0017274319,0.0030485487,0.00080305716,0.00033447542,0.00046656],"domain_scores_gemma":[0.9901768,0.006820346,0.0018863952,0.0006863399,0.0002880229,0.00014211355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003210345,0.0006778849,0.0052726343,0.00088662206,0.000063873114,0.000025004318,0.00013923363,0.0005767327,0.00009019889],"category_scores_gemma":[0.00025599686,0.00043536272,0.001275827,0.0016832397,0.00024135651,0.000090416055,0.000052293595,0.00048034528,0.0000029659816],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008255271,0.00072489027,0.08928411,0.007729984,0.0018525466,0.000050659684,0.0004281561,0.0000107341175,0.0000061714836,0.000012557763,0.000044246866,0.8990304],"study_design_scores_gemma":[0.016620725,0.0016773796,0.004630441,0.2576869,0.03378719,0.0005762942,0.0040446143,0.0017019112,0.0010738776,0.00012839795,0.6749181,0.0031541835],"about_ca_topic_score_codex":0.0028498897,"about_ca_topic_score_gemma":0.00050217845,"teacher_disagreement_score":0.8958762,"about_ca_system_score_codex":0.000894797,"about_ca_system_score_gemma":0.0039721373,"threshold_uncertainty_score":0.9998098},"labels":[],"label_agreement":null},{"id":"W3208834979","doi":"10.1016/j.jtho.2021.08.015","title":"EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Oncology; Protein kinase domain; Mutant; EGFR inhibitors; Internal medicine; Exon; Adenocarcinoma; Mutation; Epidermal growth factor receptor; Gene; Cancer; Receptor; Genetics; Biology","score_opus":0.023003212742827166,"score_gpt":0.44351515276307085,"score_spread":0.42051194002024367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208834979","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038061842,0.033043973,0.0004941595,0.06422516,0.85886014,0.0026965654,0.0008178818,0.000053617743,0.0017466675],"genre_scores_gemma":[0.023226772,0.03748612,0.006458298,0.0011596498,0.9213169,0.00031311993,0.0006012865,0.00027278377,0.009165074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962389,0.00038776742,0.001445997,0.00046029923,0.0009736218,0.0004934259],"domain_scores_gemma":[0.99567264,0.0012010838,0.0013272666,0.0005674687,0.0009585983,0.0002729628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008740107,0.000556324,0.0019611982,0.00040469613,0.00017005188,0.000055501587,0.00025746677,0.0009094626,0.0002265682],"category_scores_gemma":[0.0007002576,0.00029931896,0.0005597077,0.00045722837,0.00014697241,0.00013548326,0.000053703356,0.0014535674,0.0000070569763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022368213,0.0030675705,0.00021999473,0.00026481884,0.0020522014,0.009735954,0.0022240113,0.0004424532,0.001153869,0.00001548951,0.55433995,0.40411547],"study_design_scores_gemma":[0.009863692,0.01224958,0.00009631913,0.0014740863,0.0018767962,0.00029435378,0.00060639204,0.000015514295,0.0018160638,0.00013148293,0.97132015,0.0002555619],"about_ca_topic_score_codex":0.00012577741,"about_ca_topic_score_gemma":0.0015021438,"teacher_disagreement_score":0.41698018,"about_ca_system_score_codex":0.008046073,"about_ca_system_score_gemma":0.006578162,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3208878985","doi":"10.14309/01.ajg.0000776524.51669.ed","title":"S748 Early PRO-2 Symptom Remission Following Guselkumab Induction Treatment: Results Through Week 12 of the Phase 2 GALAXI 1 Study","year":2021,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Abdominal pain; Cohort; Interim analysis; Randomization; Corticosteroid; Randomized controlled trial; Surgery","score_opus":0.028776345253862762,"score_gpt":0.352085758854469,"score_spread":0.3233094136006063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208878985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935922,0.00011297238,0.00011057009,0.00525136,0.00040187972,0.00035365848,0.000012570081,0.000008047454,0.00015675391],"genre_scores_gemma":[0.9988038,0.000070182774,0.00039174868,0.00026074477,0.00017611438,0.000011221014,0.000005350901,0.000017850158,0.00026301466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982472,0.0004629886,0.0005847004,0.00017706973,0.00029683756,0.00023117241],"domain_scores_gemma":[0.9983265,0.00007462473,0.0009213204,0.00041084542,0.00018761177,0.000079121775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023541176,0.00015658798,0.00058425503,0.000062563144,0.00013639677,0.000011969676,0.00015026762,0.0000217828,0.000012233555],"category_scores_gemma":[0.000089208166,0.000077794255,0.00029941916,0.00022836076,0.0001871492,0.000102479906,0.000042825115,0.0002191617,0.0000012175964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063017584,0.01614861,0.8016536,0.000025342697,0.010031364,0.0009377355,0.051988848,0.00019172669,0.029352566,0.000016009324,0.0010976611,0.02553894],"study_design_scores_gemma":[0.052612446,0.19446282,0.70966464,0.00046238638,0.0063568917,0.003847865,0.02338205,0.000022564982,0.0072102174,0.00014120806,0.0016902951,0.00014658278],"about_ca_topic_score_codex":0.00017328918,"about_ca_topic_score_gemma":0.000038337803,"teacher_disagreement_score":0.17831422,"about_ca_system_score_codex":0.00020942485,"about_ca_system_score_gemma":0.0002357768,"threshold_uncertainty_score":0.31723577},"labels":[],"label_agreement":null},{"id":"W3209066466","doi":"10.1136/ijgc-2021-igcs.1","title":"O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Vinorelbine; Cervical cancer; Population; Adenocarcinoma; Chemotherapy; Oncology; Cancer; Cisplatin","score_opus":0.04412350336334246,"score_gpt":0.4121404875033292,"score_spread":0.36801698413998674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209066466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830687,0.001140191,0.00005075385,0.0123765925,0.0015033325,0.00038257326,0.000252553,0.0000082608085,0.0012170342],"genre_scores_gemma":[0.9960916,0.00060051365,0.0011306166,0.0013487826,0.00053108815,0.000037538146,0.000064868625,0.000018946186,0.00017603989],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99677604,0.00018766726,0.001538681,0.0003036076,0.0009445524,0.00024942672],"domain_scores_gemma":[0.9964317,0.0008125081,0.0009029168,0.00020086668,0.0013439076,0.00030808343],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042194346,0.00021987011,0.0008335264,0.00025430936,0.000026681842,0.00002088813,0.000306054,0.00014513798,0.0016210484],"category_scores_gemma":[0.0022096995,0.00016454727,0.000355332,0.0003662282,0.00017676014,0.0001487518,0.00007064631,0.0004640933,0.0000036066583],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48340616,0.055549357,0.22812022,0.0007406749,0.008329988,0.0060485117,0.005487861,0.00068358635,0.032368828,0.0021222555,0.018034108,0.15910845],"study_design_scores_gemma":[0.51971054,0.014120464,0.40429,0.001043712,0.001068267,0.000341856,0.00055861496,0.0005510823,0.020146085,0.0015238915,0.036182273,0.00046322568],"about_ca_topic_score_codex":0.00020083207,"about_ca_topic_score_gemma":0.00020740379,"teacher_disagreement_score":0.17616978,"about_ca_system_score_codex":0.00068799424,"about_ca_system_score_gemma":0.0018513873,"threshold_uncertainty_score":0.9992916},"labels":[],"label_agreement":null},{"id":"W3209738843","doi":"10.3390/curroncol28060376","title":"Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca France","keywords":"Genotyping; Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; EGFR inhibitors; Internal medicine; Bioinformatics; Genotype; Cancer; Genetics; Biology; Gene","score_opus":0.03199364249803129,"score_gpt":0.3708905361118632,"score_spread":0.3388968936138319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209738843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919096,0.0020610488,0.0037961153,0.00040598927,0.00037558583,0.0008769072,0.00011416149,0.000009087701,0.0004514837],"genre_scores_gemma":[0.9995,0.0000057587717,0.00028912182,0.00003540788,0.000028649376,0.00005054309,0.00007108936,0.000007818129,0.000011610001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999231,0.00009154816,0.00025982584,0.00012240508,0.00018399711,0.0001112705],"domain_scores_gemma":[0.99840796,0.000102686034,0.00024536886,0.0002310471,0.0009868585,0.000026095102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005047027,0.00007653357,0.00024626454,0.000024527317,0.00008231437,0.000002972248,0.00006648455,0.000039080605,0.000007597754],"category_scores_gemma":[0.000053348183,0.000040046853,0.0000743683,0.00026321286,0.00009274836,0.00003356394,0.00003593112,0.00008345594,6.2370333e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040953097,0.0007719371,0.8534809,0.000628631,0.0007101712,0.0000030978129,0.02322046,0.00029513644,0.0020175134,0.0063809985,0.000039104452,0.11204254],"study_design_scores_gemma":[0.0053766966,0.0014305974,0.96890855,0.00081621826,0.0017018034,0.000006968843,0.010628519,0.00008331924,0.00789882,0.000027199538,0.0030379624,0.00008332311],"about_ca_topic_score_codex":0.000100184276,"about_ca_topic_score_gemma":0.00005611912,"teacher_disagreement_score":0.115427695,"about_ca_system_score_codex":0.00020500617,"about_ca_system_score_gemma":0.0003944186,"threshold_uncertainty_score":0.16330633},"labels":[],"label_agreement":null},{"id":"W3209833176","doi":"10.1186/s12885-021-08746-z","title":"Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada","year":2021,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Grand River Hospital; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"Cancer Care Ontario","keywords":"Crizotinib; Medicine; Oncology; Lung cancer; ROS1; Internal medicine; ALK inhibitor; Quality-adjusted life year; Cost effectiveness; Cancer; Adenocarcinoma","score_opus":0.026309188689411765,"score_gpt":0.3413162003380924,"score_spread":0.3150070116486806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209833176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005175,0.006536641,0.00029708463,0.0002084717,0.00015592438,0.0014562154,0.00040082386,0.000010330712,0.0008827837],"genre_scores_gemma":[0.99503726,0.0012280685,0.00037976314,0.000098945515,0.00003774565,0.0023006643,0.00017047342,0.000033443222,0.000713667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854714,0.00006478948,0.00034447707,0.00046443965,0.00023914714,0.00033998908],"domain_scores_gemma":[0.99902,0.00016651282,0.00013873086,0.00033556312,0.00021125219,0.00012797659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006149639,0.0002491943,0.00080319954,0.00023553423,0.000040162464,0.000007975257,0.000055386223,0.000052756837,0.0003354728],"category_scores_gemma":[0.000012245755,0.00019611561,0.00012126493,0.0015561559,0.00002513632,0.00005421625,0.000016728955,0.00010270315,3.843017e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00069437036,0.00041562098,0.9058321,0.00033209717,0.0010827819,0.00015123762,0.0008183062,0.08358729,0.0007611858,0.0000015967428,0.000021047596,0.006302355],"study_design_scores_gemma":[0.014009204,0.00022469083,0.9576101,0.0008943932,0.0038957177,0.00000225068,0.00074569543,0.0063227923,0.015129908,9.272456e-7,0.0009242148,0.00024011763],"about_ca_topic_score_codex":0.92620116,"about_ca_topic_score_gemma":0.9986707,"teacher_disagreement_score":0.077264495,"about_ca_system_score_codex":0.0052900007,"about_ca_system_score_gemma":0.0071607134,"threshold_uncertainty_score":0.99852854},"labels":[],"label_agreement":null},{"id":"W3211033342","doi":"10.1016/j.jtho.2021.06.004","title":"EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"University of Ottawa","keywords":"Medicine; Oncology; Mutant; Internal medicine; Targeted therapy; EGFR inhibitors; Epidermal growth factor receptor; Cancer; Gene; Genetics","score_opus":0.02953205224597856,"score_gpt":0.4639302841023304,"score_spread":0.43439823185635185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211033342","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021153966,0.02253694,0.0005277183,0.09286638,0.8580896,0.002274277,0.00025245326,0.00003993488,0.0022587138],"genre_scores_gemma":[0.038549155,0.07403334,0.0038797583,0.0013196899,0.8603357,0.000222118,0.0009885615,0.00023943266,0.020432249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970392,0.00028846468,0.0011039062,0.00032772624,0.00088604464,0.00035463713],"domain_scores_gemma":[0.99620605,0.0011409343,0.0011875211,0.00039683346,0.0008402619,0.00022842138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063928566,0.00041077088,0.0015015107,0.00034875795,0.00013608737,0.000049413225,0.0002384471,0.0007166327,0.00028769916],"category_scores_gemma":[0.00044873683,0.0002182764,0.00043532037,0.00036729508,0.00007969271,0.00014192612,0.000038643757,0.0011586868,0.000006695046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076352833,0.0019003729,0.00020685134,0.00007787184,0.0014885089,0.0017721221,0.001862394,0.00020784381,0.00010862492,0.000024624585,0.42075467,0.5639608],"study_design_scores_gemma":[0.011509823,0.01314879,0.00035383398,0.00062148535,0.0012343839,0.00019095554,0.0004076722,0.00001179672,0.0003955597,0.00044974865,0.9714935,0.00018249438],"about_ca_topic_score_codex":0.00019014541,"about_ca_topic_score_gemma":0.0012506291,"teacher_disagreement_score":0.56377834,"about_ca_system_score_codex":0.00646783,"about_ca_system_score_gemma":0.008227518,"threshold_uncertainty_score":0.9973949},"labels":[],"label_agreement":null},{"id":"W3211285412","doi":"10.1093/eurheartj/ehab724.2848","title":"Bradycardia associated with ALK inhibitors in the treatment of non-small cell lung cancers: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University","funders":"","keywords":"Medicine; Crizotinib; Bradycardia; Anaplastic lymphoma kinase; Internal medicine; Adverse effect; Meta-analysis; Randomized controlled trial; Oncology; Clinical trial; Lung cancer; Heart rate; Blood pressure","score_opus":0.08011220958984257,"score_gpt":0.37501179476546653,"score_spread":0.294899585175624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211285412","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023487337,0.9956911,0.0000063239063,0.00017630865,0.00003170407,0.002457442,0.00006474816,0.000005428076,0.0015434643],"genre_scores_gemma":[0.00021900808,0.99794453,0.00010798388,0.00027140495,0.000066581066,0.00013554431,0.000088270215,0.000050208153,0.0011164539],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961111,0.002021885,0.0010195923,0.00028660204,0.00034735425,0.00021346392],"domain_scores_gemma":[0.9981025,0.00028745877,0.00088572566,0.0004428188,0.0001474088,0.00013409306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010323612,0.0003991873,0.0062643355,0.00026314877,0.00008860859,0.00006772229,0.00009828874,0.000046757123,0.00007021999],"category_scores_gemma":[0.000052472984,0.00017264279,0.002362082,0.0009757492,0.000032695003,0.000037798076,0.000014236017,0.0002971328,0.0000049663513],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000040964583,0.0006526876,0.00030813096,0.47261366,0.5176665,0.0019632871,0.0020191493,0.000010054784,8.757956e-8,0.0000011167316,0.0027127103,0.002048505],"study_design_scores_gemma":[0.0004692835,0.00033376535,0.00008915374,0.077881016,0.8665088,0.00056797185,0.00009682301,0.0000011258271,1.3173279e-7,5.619911e-8,0.053921707,0.00013018792],"about_ca_topic_score_codex":0.000040980605,"about_ca_topic_score_gemma":0.00004912657,"teacher_disagreement_score":0.39473265,"about_ca_system_score_codex":0.00055467454,"about_ca_system_score_gemma":0.0006240193,"threshold_uncertainty_score":0.70401686},"labels":[],"label_agreement":null},{"id":"W3211473910","doi":"10.1002/cam4.4427","title":"Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Oncology; Immunotherapy; Lung cancer; Targeted therapy; Systemic therapy; Chemotherapy; Progressive disease; Stage (stratigraphy); Cancer","score_opus":0.01172182587078692,"score_gpt":0.37394164764115956,"score_spread":0.36221982177037265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211473910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93421566,0.050411075,0.0000046732607,0.008846857,0.00038986394,0.00089122425,0.000026405412,0.000019552395,0.0051946575],"genre_scores_gemma":[0.96767366,0.025842894,0.00004574185,0.0031063855,0.00016124538,0.0005098901,0.000036058354,0.000028309318,0.0025958274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988147,0.00012752238,0.00028336007,0.00027276482,0.00028952878,0.00021210528],"domain_scores_gemma":[0.99899817,0.0004082501,0.000110925444,0.0003324302,0.00008563383,0.00006462458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021946381,0.0002107012,0.0005759873,0.00012678019,0.00005559311,0.0000050940052,0.000077339115,0.0000450338,0.00051063596],"category_scores_gemma":[0.000031201303,0.00010783981,0.00006676371,0.0004451227,0.00011573695,0.00003885463,0.000009229785,0.0001904173,6.665117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001878006,0.0003176361,0.8158627,0.0003613851,0.00058474706,0.00012207926,0.006142232,0.000054812932,0.029760841,0.00016909694,0.0017364906,0.14300998],"study_design_scores_gemma":[0.03292594,0.0025572057,0.9125519,0.0014173369,0.00052156457,0.0000072535895,0.0006623271,0.00008655864,0.03769483,0.00002579685,0.011327238,0.00022204731],"about_ca_topic_score_codex":0.0016994369,"about_ca_topic_score_gemma":0.0007756124,"teacher_disagreement_score":0.14278793,"about_ca_system_score_codex":0.00018612093,"about_ca_system_score_gemma":0.0002364477,"threshold_uncertainty_score":0.5591106},"labels":[],"label_agreement":null},{"id":"W3211577173","doi":"10.1016/j.jtho.2021.10.023","title":"CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; Centre Hospitalier de l’Université de Montréal; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Windsor Regional Hospital; Institut Universitaire de Cardiologie et de Pneumologie de Québec; Alberta Cancer Foundation; Sunnybrook Health Science Centre; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Canadian Cancer Society Research Institute; Takeda Canada; Merck Sharp and Dohme; Cancer Australia; Astellas Pharma Canada; AbbVie; Roche; Novartis; Sanofi; Merck; Boehringer Ingelheim; Amgen; Pfizer; Celgene; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Chemotherapy; Internal medicine; Randomized controlled trial; Platinum; Immunotherapy; Cancer; Nivolumab","score_opus":0.020163327168845627,"score_gpt":0.4295004179541777,"score_spread":0.4093370907853321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211577173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596083,0.0002469926,0.00095325924,0.0012597322,0.00010712869,0.001124191,0.000016608961,0.0000049446403,0.0003263044],"genre_scores_gemma":[0.9817136,0.000050277322,0.01766392,0.00027557192,0.000056799207,0.00003204162,0.000016915874,0.000023300598,0.00016760168],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981831,0.00036291505,0.0007144411,0.00015899984,0.00042103123,0.0001595148],"domain_scores_gemma":[0.9978828,0.00042049543,0.0008303018,0.0001455897,0.00060071814,0.00012012929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006499101,0.0001649838,0.0014791056,0.00022323952,0.000030274956,0.000010783177,0.00004529479,0.00006203692,0.00015295569],"category_scores_gemma":[0.0002547618,0.000086723274,0.00011087457,0.00027307754,0.00015699849,0.000094552655,0.0000069514144,0.00019497942,3.0341266e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9346077,0.0049844338,0.0031601188,0.000101484206,0.0011520612,0.00041240864,0.0009260682,0.000028322364,0.000098347,0.0000041434705,0.000037388603,0.054487515],"study_design_scores_gemma":[0.9690902,0.023665916,0.0018889894,0.00047968165,0.0026446502,0.00024235164,0.0004005231,0.00023632437,0.0008467377,0.000028828497,0.00037759962,0.00009817378],"about_ca_topic_score_codex":0.000020329337,"about_ca_topic_score_gemma":0.000088590605,"teacher_disagreement_score":0.054389343,"about_ca_system_score_codex":0.00026713684,"about_ca_system_score_gemma":0.0027011966,"threshold_uncertainty_score":0.47918066},"labels":[],"label_agreement":null},{"id":"W3211652415","doi":"10.1177/17588359211056306","title":"The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; William Osler Health System; McMaster University; Ottawa Hospital; University Health Network; Dalhousie University; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"AstraZeneca Canada; Pfizer","keywords":"Medicine; Lung cancer; Adjuvant; Oncology; Internal medicine; Cancer research; Pathology","score_opus":0.035450366814115994,"score_gpt":0.46102181578405454,"score_spread":0.42557144896993854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211652415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016593894,0.9922226,0.0002821173,0.0014074959,0.000760255,0.00157845,0.000016923825,0.00001602667,0.0035501742],"genre_scores_gemma":[0.000282933,0.9965313,0.00035669724,0.00063483085,0.00034089974,0.00068633124,0.00013601653,0.000047238067,0.0009837414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969339,0.00045015782,0.0011841375,0.00047435428,0.00048263144,0.0004748617],"domain_scores_gemma":[0.9975887,0.0012090157,0.00048638685,0.0003954066,0.00010141822,0.00021909225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055127876,0.00035193964,0.0021986582,0.00021717978,0.00005903522,0.00000725439,0.00020618772,0.0005915093,0.00047198884],"category_scores_gemma":[0.0001641624,0.00021336233,0.0002515706,0.00082618423,0.0002906442,0.00005683107,0.000088313725,0.001207289,0.0000055822543],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084751286,0.00040173117,0.000107433545,0.0036665183,0.00020279999,0.00049611466,0.00057859195,0.000007144216,0.0000020402804,0.00016131396,0.00023190274,0.9940597],"study_design_scores_gemma":[0.0035622914,0.00042969442,0.00007915027,0.019956922,0.0012802612,0.00008885591,0.00022353245,0.00006966002,0.000009148806,0.00020901351,0.9739121,0.00017932754],"about_ca_topic_score_codex":0.00041253673,"about_ca_topic_score_gemma":0.0037465286,"teacher_disagreement_score":0.99388033,"about_ca_system_score_codex":0.0014218445,"about_ca_system_score_gemma":0.009664581,"threshold_uncertainty_score":0.9959497},"labels":[],"label_agreement":null},{"id":"W3213091002","doi":"10.3390/curroncol28060386","title":"Canadian Consensus Recommendations on the Management of MET-Altered NSCLC","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; University of Manitoba; Juravinski Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; McMaster University; Alberta Health Services; Centre Hospitalier de l’Université de Montréal; Université Laval; William Osler Health System; Ottawa Hospital; CancerCare Manitoba; University Health Network; University of Toronto","funders":"EMD Serono","keywords":"Medicine; Targeted therapy; Consensus conference; non-small cell lung cancer (NSCLC); Oncology; Epidermal growth factor receptor; Lung cancer; Intensive care medicine; Internal medicine; Cancer","score_opus":0.12237288923556408,"score_gpt":0.4588427492843574,"score_spread":0.3364698600487933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213091002","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30546543,0.0035314593,0.00012509942,0.23810202,0.0062314817,0.0015987793,0.00036607622,0.000049073664,0.4445306],"genre_scores_gemma":[0.99391896,0.00049351976,0.0013867997,0.0011538899,0.000108739456,0.00011968953,0.00027015686,0.000010959547,0.0025372899],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99944943,0.000058953225,0.0001535908,0.00013029504,0.00006868833,0.00013902212],"domain_scores_gemma":[0.99943346,0.00009091583,0.00005094977,0.00021452332,0.00010854017,0.00010158524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000699036,0.00006360771,0.00013779615,0.000057880767,0.00008165257,0.0000039855427,0.00004021186,0.000027971799,0.0008277696],"category_scores_gemma":[0.000019876541,0.000044207718,0.00005127068,0.00014567206,0.000037339374,0.000005934216,0.000016646336,0.000093785486,0.000048302816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006675481,0.001162695,0.0042558196,0.00013454282,0.0013091126,0.00018981782,0.0010903582,0.0000072955463,0.00010014398,0.08364919,0.13478196,0.7732523],"study_design_scores_gemma":[0.0014665906,0.00024806042,0.008191893,0.00016337608,0.00049552316,0.00003001024,0.001623754,0.000021016203,0.00030621025,0.0004106731,0.98699015,0.000052759704],"about_ca_topic_score_codex":0.001027232,"about_ca_topic_score_gemma":0.006393571,"teacher_disagreement_score":0.8522082,"about_ca_system_score_codex":0.00047520883,"about_ca_system_score_gemma":0.000661485,"threshold_uncertainty_score":0.9063496},"labels":[],"label_agreement":null},{"id":"W3213168268","doi":"10.1002/cam4.4411","title":"The need for speed in advanced non‐small cell lung cancer: A population kinetics assessment","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Asymptomatic; Placebo; Lung cancer; Population; Radiation therapy; Oncology; Clinical trial; Internal medicine; Pathology","score_opus":0.016972362009273136,"score_gpt":0.3867362660368793,"score_spread":0.3697639040276061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213168268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142003,0.030818935,0.0021383644,0.04120621,0.002540664,0.002961624,0.00007833378,0.000059008882,0.0059965393],"genre_scores_gemma":[0.9850581,0.0037453594,0.0013111169,0.0016510555,0.0007452532,0.00083279,0.00028754974,0.00004278346,0.006325971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987139,0.000025692443,0.00038199002,0.00031457192,0.0002407352,0.00032308575],"domain_scores_gemma":[0.99898386,0.00015728908,0.00013919086,0.0003035412,0.00028345716,0.00013266678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012609555,0.00018037231,0.00036996222,0.00007227095,0.0001240339,0.000013663785,0.00007307299,0.00006419335,0.00014370191],"category_scores_gemma":[0.00006594817,0.00011958011,0.00006700098,0.0003786854,0.000046858473,0.000042711898,0.000021045165,0.00015374737,6.7994534e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070765556,0.0006724601,0.75331765,0.0015210437,0.0006403352,0.00014630999,0.003747073,0.004781041,0.07733021,0.0009468968,0.019509604,0.13667972],"study_design_scores_gemma":[0.03295531,0.000986665,0.85701287,0.00257049,0.0023278948,0.000018373024,0.0038279505,0.016847704,0.009079727,0.00039073755,0.07352715,0.00045513513],"about_ca_topic_score_codex":0.0012868599,"about_ca_topic_score_gemma":0.0025114042,"teacher_disagreement_score":0.13622458,"about_ca_system_score_codex":0.00093691243,"about_ca_system_score_gemma":0.0006029896,"threshold_uncertainty_score":0.48763353},"labels":[],"label_agreement":null},{"id":"W3214003785","doi":"10.1007/s00280-021-04369-0","title":"A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"Gilead Sciences","keywords":"Erlotinib; Medicine; Tyrosine-kinase inhibitor; Internal medicine; Lung cancer; Pharmacology; Clinical endpoint; Oncology; Epidermal growth factor receptor; Cancer; Clinical trial","score_opus":0.02987213903771854,"score_gpt":0.3992001376410065,"score_spread":0.36932799860328797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214003785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95586,0.039110232,0.000112336544,0.0016052313,0.00036795344,0.0025812075,0.00031306443,0.000010591334,0.000039370207],"genre_scores_gemma":[0.9741527,0.022327451,0.000242268,0.00081722665,0.00019807374,0.00152368,0.000031180633,0.000033789656,0.00067361863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990115,0.000048812253,0.00032062284,0.0003214323,0.00008719931,0.00021043782],"domain_scores_gemma":[0.9991039,0.00023610554,0.00019273433,0.00014018576,0.00022267232,0.00010439585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006222628,0.00021598965,0.0005406805,0.000059825496,0.000105978266,0.000007837556,0.000041994044,0.00004437623,0.00026396578],"category_scores_gemma":[0.0000029729165,0.00014492693,0.00008386523,0.00018730293,0.00012299973,0.000032613276,0.000011694621,0.00006383203,1.1622047e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009689208,0.04167982,0.029443007,0.0023072765,0.011848339,0.000143222,0.068413615,0.0002351487,0.68475336,0.000020100171,0.0044787447,0.14698817],"study_design_scores_gemma":[0.1389862,0.008379061,0.0022298484,0.00010423213,0.0074747833,0.000017170107,0.0039009184,0.0021342067,0.8261738,0.000014281164,0.010378456,0.00020707287],"about_ca_topic_score_codex":0.00066580484,"about_ca_topic_score_gemma":0.00017746552,"teacher_disagreement_score":0.1467811,"about_ca_system_score_codex":0.0001260572,"about_ca_system_score_gemma":0.00038421465,"threshold_uncertainty_score":0.59099483},"labels":[],"label_agreement":null},{"id":"W3214907506","doi":"10.1007/s40291-021-00563-1","title":"Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Molecular Diagnosis & Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer","keywords":"Lung cancer; Meta-analysis; Epidermal growth factor receptor; Human genetics; Oncology; Medicine; Molecular medicine; Internal medicine; Cancer; Biology; Bioinformatics; Genetics; Cell cycle; Gene","score_opus":0.0518443011907617,"score_gpt":0.3777282929214906,"score_spread":0.3258839917307289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214907506","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016485767,0.99342036,0.00031546148,0.00044935738,0.000097643555,0.0028807826,0.0010546285,0.00002654938,0.0001066463],"genre_scores_gemma":[0.0025133207,0.9854099,0.0014666982,0.00035913667,0.000042378797,0.008777399,0.0007179021,0.0001087258,0.0006045045],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966397,0.00048370825,0.0011394382,0.00088012445,0.00044558555,0.00041143718],"domain_scores_gemma":[0.9974693,0.0005151958,0.0006972202,0.000808847,0.00032047,0.00018898914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017815953,0.0006685202,0.004503619,0.00086128444,0.000060212435,0.00003848701,0.00029191165,0.0002568011,0.0026279439],"category_scores_gemma":[0.00006269317,0.0005104432,0.004517374,0.0024013463,0.00006328588,0.00006849532,0.00004869619,0.00036364677,0.000009105219],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029110312,0.0035697755,0.02081,0.03687213,0.59605384,0.0005585442,0.002073274,0.00028524722,0.00008374935,0.0000621019,0.0010664543,0.33853576],"study_design_scores_gemma":[0.001655772,0.00017973346,0.0018776531,0.0043149544,0.8506701,0.0000060899597,0.000039514976,0.000016832071,0.0018123261,0.000008144798,0.13863066,0.0007882077],"about_ca_topic_score_codex":0.0010551667,"about_ca_topic_score_gemma":0.00015565427,"teacher_disagreement_score":0.33774754,"about_ca_system_score_codex":0.00042813315,"about_ca_system_score_gemma":0.0009828057,"threshold_uncertainty_score":0.9997347},"labels":[],"label_agreement":null},{"id":"W3215921195","doi":"10.1016/j.jtho.2021.11.003","title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1481,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; BeiGene; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Grading (engineering); SMARCA4; Pathology; Immunohistochemistry; Lung; Adenoma; Internal medicine; Biology","score_opus":0.04722255255441719,"score_gpt":0.5551534797927689,"score_spread":0.5079309272383516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215921195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015748233,0.99658304,0.00007067555,0.00062732416,0.00052050204,0.00036467647,0.000043613763,0.0000017805648,0.0016309189],"genre_scores_gemma":[0.00080230605,0.9972743,0.0006130818,0.000009247232,0.0004068365,0.000014671846,0.000034098477,0.00002140248,0.00082406274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763167,0.00039612936,0.0013572571,0.00014341573,0.0003038589,0.00016766106],"domain_scores_gemma":[0.99452806,0.00060164864,0.0035641296,0.00031926954,0.0008745484,0.0001123237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006505621,0.00020526545,0.0022403381,0.00019471554,0.000055979082,0.00001051565,0.00020312775,0.0002014581,0.00008707104],"category_scores_gemma":[0.0003541228,0.00010539761,0.00097122655,0.00037316792,0.00015472568,0.00011156047,0.000033196106,0.00043645734,0.000002524531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012240419,0.00027044673,0.0001271839,0.0031695778,0.0015026117,0.0000952583,0.00010850383,0.000004301909,0.000010183959,0.00006990983,0.00396398,0.99055564],"study_design_scores_gemma":[0.0003062798,0.0014875182,0.0006056532,0.017186197,0.006332136,0.0011461776,0.00022472581,0.000008572837,0.000009682637,0.00003437225,0.97257644,0.000082273946],"about_ca_topic_score_codex":0.000012288312,"about_ca_topic_score_gemma":0.00000941654,"teacher_disagreement_score":0.9904734,"about_ca_system_score_codex":0.0010799457,"about_ca_system_score_gemma":0.00599609,"threshold_uncertainty_score":0.999639},"labels":[],"label_agreement":null},{"id":"W3217106497","doi":"10.1093/neuonc/noab196.288","title":"DDRE-04. EFFECTIVENESS AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH LEPTOMENINGEAL METASTASES FORM NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2021,"lang":"en","type":"review","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Medicine; Common Terminology Criteria for Adverse Events; Internal medicine; Oncology; Lung cancer; Adverse effect; Meta-analysis; Hazard ratio; Epidermal growth factor receptor; Cancer; Confidence interval; Erlotinib","score_opus":0.03459315506263771,"score_gpt":0.3857840444814286,"score_spread":0.3511908894187909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217106497","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000079215,0.9856811,0.00018011624,0.00006894599,0.00005667273,0.012656964,0.0011797633,0.000012863134,0.000084364765],"genre_scores_gemma":[0.00029974504,0.9905643,0.0005853906,0.00026951512,0.000017052926,0.0075469585,0.00060103595,0.0000623867,0.000053609707],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971375,0.0006301292,0.0010744353,0.00067700364,0.00020359627,0.00027737126],"domain_scores_gemma":[0.9957789,0.001978675,0.001244562,0.0004393161,0.00039361927,0.00016488279],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043041565,0.00052582327,0.011231128,0.00025583126,0.00009219973,0.000014034507,0.00009681397,0.00017167091,0.000052631425],"category_scores_gemma":[0.00015112477,0.00030401294,0.0012351271,0.0006014575,0.00007754924,0.000049574668,0.000075970835,0.00019814637,4.2004334e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066991124,0.00029808687,0.00016206985,0.83523834,0.15564387,0.000023288125,0.00009969747,0.0000012488013,0.0000010124201,0.0000064535657,0.000059199945,0.008399725],"study_design_scores_gemma":[0.0020494114,0.0013425952,0.000030376601,0.024264785,0.93701494,0.000034157383,0.000015839913,0.0000045205647,0.0000069161138,4.874243e-7,0.035027564,0.00020843103],"about_ca_topic_score_codex":0.000062016974,"about_ca_topic_score_gemma":0.00004374886,"teacher_disagreement_score":0.8109736,"about_ca_system_score_codex":0.00031075653,"about_ca_system_score_gemma":0.00086601154,"threshold_uncertainty_score":0.9999412},"labels":[],"label_agreement":null},{"id":"W4200071516","doi":"10.1016/j.critrevonc.2021.103566","title":"Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications","year":2021,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Radiation therapy; Breast cancer; Radioresistance; Systemic therapy; Oncology; Cancer; Disease; Internal medicine","score_opus":0.04894730476087189,"score_gpt":0.5086703591717768,"score_spread":0.45972305441090494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200071516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013072675,0.98994035,0.0007411673,0.00604829,0.00019894108,0.002656547,0.000046469228,0.000018834653,0.00033633038],"genre_scores_gemma":[0.000046164205,0.9920353,0.0041719675,0.0014216547,0.00013109737,0.0019570298,0.00016206576,0.000046324658,0.000028351666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961062,0.0010285082,0.0015735558,0.00082153693,0.00009313322,0.00037705124],"domain_scores_gemma":[0.99769676,0.0013497634,0.00022082674,0.00037510713,0.000102536906,0.0002549823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062564993,0.00038478913,0.0044771913,0.00025396107,0.000050180195,0.00001543111,0.000083479514,0.0007945291,0.00008894578],"category_scores_gemma":[0.00060102285,0.00031032457,0.00027138594,0.00046553972,0.0005164849,0.00004452723,0.00006502116,0.00070618244,0.000009532045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009844757,0.00045887486,0.0012727734,0.0082406,0.00015745079,0.00066151714,0.00003360561,4.428531e-8,4.9205585e-7,0.022980211,0.00043351756,0.96575105],"study_design_scores_gemma":[0.0012086876,0.000120892735,0.00023585033,0.016841898,0.0016412917,0.00516562,0.000018655217,0.000019149746,2.2446078e-7,0.00032068783,0.97418565,0.00024141841],"about_ca_topic_score_codex":0.0000233208,"about_ca_topic_score_gemma":0.00005990625,"teacher_disagreement_score":0.9737521,"about_ca_system_score_codex":0.0005864024,"about_ca_system_score_gemma":0.0009860796,"threshold_uncertainty_score":0.9999349},"labels":[],"label_agreement":null},{"id":"W4200244795","doi":"10.3390/curroncol28060434","title":"Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; T790M; Internal medicine; Lung cancer; Oncology; Clinical trial; Osimertinib; First line treatment; Chemotherapy; Retrospective cohort study; Cancer; Targeted therapy; Erlotinib; Epidermal growth factor receptor; Gefitinib","score_opus":0.07717024060493761,"score_gpt":0.4682755444734196,"score_spread":0.391105303868482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200244795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941929,0.002938825,0.000010836679,0.0010700687,0.00048697685,0.00047316012,0.000065946755,0.0000059100175,0.00075535284],"genre_scores_gemma":[0.9931562,0.0057601477,0.00007209048,0.000056055298,0.000055672976,0.00004663356,0.000042154392,0.000011998977,0.00079906004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869984,0.00010031351,0.00064858433,0.00027868437,0.00006752018,0.00020505264],"domain_scores_gemma":[0.99924535,0.00023414666,0.00020429112,0.000154538,0.00007116735,0.00009050532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087887885,0.00013718908,0.00069361035,0.00014301071,0.000010051577,0.000001971068,0.000039930157,0.00011512899,0.00008224592],"category_scores_gemma":[0.000024998277,0.00010695094,0.00009685346,0.00019241121,0.00007377659,0.000031016552,0.00004195006,0.00019849668,9.947154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006107246,0.0020463262,0.8908424,0.00017998253,0.00011424683,0.000051863903,0.0024054195,0.0000089967225,0.0006024944,0.000011654446,0.00005504064,0.103620544],"study_design_scores_gemma":[0.008857656,0.0004969585,0.98355716,0.0004791061,0.00055784197,0.0000028125685,0.0008497222,0.000211908,0.0015693596,0.000010676076,0.0033126855,0.00009410149],"about_ca_topic_score_codex":0.022263637,"about_ca_topic_score_gemma":0.26897562,"teacher_disagreement_score":0.24671198,"about_ca_system_score_codex":0.0013712673,"about_ca_system_score_gemma":0.0011826268,"threshold_uncertainty_score":0.9842472},"labels":[],"label_agreement":null},{"id":"W4200357671","doi":"10.3390/cells10123553","title":"Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer","year":2021,"lang":"en","type":"review","venue":"Cells","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Mutant; Lung cancer; Computational biology; Cancer; Cancer research; Biology; Mutation; Chemistry; Medicine; Genetics; Pathology; Gene","score_opus":0.020176981014175564,"score_gpt":0.3544534400173237,"score_spread":0.3342764590031481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200357671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034190324,0.9926315,0.00025512592,0.000023590866,0.000490304,0.0010621755,0.00014133555,0.000020919895,0.0050331424],"genre_scores_gemma":[0.0003025743,0.99444926,0.0008864262,0.00005625397,0.00012534818,0.00020789779,0.00020491939,0.00007871397,0.003688581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851316,0.000047012792,0.000500703,0.000412254,0.0002460933,0.00028076686],"domain_scores_gemma":[0.9988649,0.00005257264,0.0003271411,0.00046067403,0.00016028689,0.00013444193],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000052407187,0.00035161013,0.0015101493,0.00014597578,0.000056734956,0.000021645314,0.00014075471,0.00019753206,0.00046140028],"category_scores_gemma":[0.000007778972,0.0002759779,0.0006052214,0.00030176385,0.000042822387,0.000023919838,0.00007635396,0.00024949416,0.000022379114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008623716,0.00065179,0.00016429788,0.15977144,0.0050358674,0.002437778,0.0023697205,0.0002058968,0.005478624,0.00008195869,0.0038533306,0.8199407],"study_design_scores_gemma":[0.000634273,0.000057286114,0.0000031779048,0.02741446,0.012927335,0.000029193205,0.00014913525,0.00004169904,0.008087672,0.0000014012827,0.9503349,0.00031944105],"about_ca_topic_score_codex":0.00023620419,"about_ca_topic_score_gemma":0.000022873455,"teacher_disagreement_score":0.9464816,"about_ca_system_score_codex":0.00035715126,"about_ca_system_score_gemma":0.0019333693,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W4200374830","doi":"10.3390/curroncol29010007","title":"Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Targeted therapy; Internal medicine; Mutation; Gene mutation; Liquid biopsy; Tyrosine kinase; Cancer; Gefitinib; Incidence (geometry); Biopsy; Gene; Receptor; Biology","score_opus":0.04811144269615106,"score_gpt":0.4312516927352492,"score_spread":0.38314025003909813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200374830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09333527,0.9021181,0.000013958344,0.00004454182,0.0019148968,0.0019342587,0.00041441046,0.000015468997,0.00020909129],"genre_scores_gemma":[0.003934366,0.9927664,0.00030671043,0.000046776142,0.00013061971,0.0005734006,0.0021502338,0.000044798726,0.000046704692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977707,0.00033912942,0.00082532555,0.0005904444,0.00017879785,0.000295586],"domain_scores_gemma":[0.99852127,0.00021726984,0.0006619515,0.00019979967,0.00023926972,0.00016041839],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012720894,0.00038722574,0.0017279077,0.00032538627,0.000034911758,0.000008902573,0.00009789808,0.00045163723,0.000080676684],"category_scores_gemma":[0.00019582945,0.00030304055,0.00030335182,0.00032944453,0.00010381474,0.000040011717,0.000084705796,0.00040501144,0.000003815298],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005823839,0.00169708,0.082140274,0.020393226,0.000736184,0.00021788588,0.0007964806,9.506351e-7,0.000022050026,0.0000076301185,0.0015760359,0.89235395],"study_design_scores_gemma":[0.020946749,0.0061811884,0.09835279,0.04885246,0.026752995,0.00028465508,0.00038974782,0.000028844654,0.00068044855,0.000026705222,0.79562426,0.0018791591],"about_ca_topic_score_codex":0.00008029543,"about_ca_topic_score_gemma":0.000017784416,"teacher_disagreement_score":0.8904748,"about_ca_system_score_codex":0.0007463002,"about_ca_system_score_gemma":0.001446252,"threshold_uncertainty_score":0.9999422},"labels":[],"label_agreement":null},{"id":"W4200497550","doi":"10.3389/fonc.2021.739765","title":"Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Alectinib; Lung cancer; Oncology; Internal medicine; Osimertinib; Gefitinib; Erlotinib; Anaplastic lymphoma kinase; Meta-analysis; Regimen; Randomized controlled trial; Progression-free survival; Chemotherapy; Ceritinib; Cancer; Epidermal growth factor receptor; Malignant pleural effusion","score_opus":0.0901249450966908,"score_gpt":0.4410468439870257,"score_spread":0.35092189889033487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200497550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023845674,0.9805498,0.0061356137,0.000105303814,0.00018796686,0.011811865,0.0010737517,0.000012644699,0.00009922619],"genre_scores_gemma":[0.00006578534,0.9653114,0.021860937,0.0003308478,0.0000630462,0.0083382055,0.0033675737,0.00004893529,0.0006132381],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99605256,0.0012466698,0.001459802,0.0007206754,0.00021749892,0.0003028172],"domain_scores_gemma":[0.99652976,0.00086520636,0.0016014825,0.00058614917,0.0002702224,0.00014717338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006638052,0.00051480444,0.013836916,0.00035812083,0.00007069904,0.000019581037,0.00017279293,0.0002066328,0.00009708968],"category_scores_gemma":[0.0000721416,0.0003320947,0.0011678188,0.0010487422,0.00008096453,0.000059430004,0.00003751173,0.00019979442,7.2159315e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055979337,0.0003897121,0.00008557119,0.58830184,0.39795455,0.000096464355,0.0011613878,0.00031005972,7.129125e-8,0.000009573888,0.008925458,0.0027093126],"study_design_scores_gemma":[0.0020007847,0.00041336037,0.000007866955,0.091921486,0.8822103,0.000025894202,0.0006797315,0.00022042517,2.214083e-7,0.000002952388,0.022275321,0.00024162678],"about_ca_topic_score_codex":0.00038711808,"about_ca_topic_score_gemma":0.0004977867,"teacher_disagreement_score":0.49638036,"about_ca_system_score_codex":0.00080109807,"about_ca_system_score_gemma":0.0011447717,"threshold_uncertainty_score":0.9999131},"labels":[],"label_agreement":null},{"id":"W4200501854","doi":"10.1158/1535-7163.targ-21-p230","title":"Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"T790M; Osimertinib; Medicine; Epidermal growth factor receptor; Exon; Cancer research; EGFR inhibitors; Mutant; Lung cancer; Mutation; Gefitinib; Cancer; Oncology; Internal medicine; Erlotinib; Gene; Biology; Genetics","score_opus":0.010582206417046503,"score_gpt":0.289737410597893,"score_spread":0.2791552041808465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200501854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924399,0.0045287684,0.00023634442,0.00035007801,0.0001231472,0.0017241857,0.00046401913,0.0000166764,0.00011683436],"genre_scores_gemma":[0.9980251,0.00041235102,0.00068660796,0.0003290464,0.000032866632,0.00029706644,0.00008090747,0.00006291329,0.00007311724],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980736,0.00008656908,0.00056409545,0.00049700413,0.00046005342,0.00031870263],"domain_scores_gemma":[0.9983577,0.00005719268,0.00036502516,0.00030036873,0.00079639885,0.00012332789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006284359,0.0003134492,0.0005753165,0.00015378628,0.00007315182,0.000019500847,0.000081471255,0.00009524463,0.000030236873],"category_scores_gemma":[0.000011115987,0.00026381743,0.000080551414,0.0005737906,0.00008270802,0.00008938388,0.00003199301,0.00022964209,3.459436e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043654353,0.012872229,0.6411853,0.0013681882,0.0035509677,0.00027154453,0.022506693,0.00039841494,0.3062664,0.00002302438,0.00006236457,0.007129463],"study_design_scores_gemma":[0.03919671,0.0021323157,0.47595102,0.0011763354,0.002213709,0.000002384351,0.00224195,0.000117090734,0.47627744,0.000018899267,0.00016903001,0.00050311175],"about_ca_topic_score_codex":0.0010202178,"about_ca_topic_score_gemma":0.0010658094,"teacher_disagreement_score":0.17001104,"about_ca_system_score_codex":0.00050901074,"about_ca_system_score_gemma":0.00097618584,"threshold_uncertainty_score":0.9999814},"labels":[],"label_agreement":null},{"id":"W4200545467","doi":"10.1016/j.jtocrr.2021.100259","title":"Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Ethnic group; Confidence interval; Oncology; Subgroup analysis","score_opus":0.03152248506292136,"score_gpt":0.4202601434878151,"score_spread":0.3887376584248937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200545467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997484,0.00029758504,0.00000549819,0.0006381484,0.000049429207,0.0007309544,0.000014631351,0.000011249795,0.00076850166],"genre_scores_gemma":[0.9986555,0.00015305552,0.00013062921,0.00003041431,0.000043015214,0.00003412333,0.0000780271,0.000013670195,0.00086158374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978431,0.00028018022,0.0005063474,0.00039829058,0.0007896666,0.00018242106],"domain_scores_gemma":[0.9969231,0.0011980166,0.00018495486,0.00020179545,0.0012710072,0.00022114547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000619162,0.00012164263,0.0004681191,0.00011415274,0.000102382786,0.000013063316,0.000015355208,0.00011327017,0.000011611096],"category_scores_gemma":[0.0010669196,0.00006631089,0.00006459541,0.00036868686,0.00051960896,0.00006166936,0.00004011568,0.00030221973,3.882034e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031335524,0.0022165854,0.9820524,0.0002522378,0.00041163544,0.003546723,0.00015154603,0.000002449965,0.00011634597,0.000043593373,0.0000992209,0.007973743],"study_design_scores_gemma":[0.0057941577,0.0062913513,0.9737002,0.0005934587,0.00023214048,0.00007770272,0.000074846575,0.000005380655,0.012966149,0.000060089915,0.00013346228,0.000071061215],"about_ca_topic_score_codex":0.00043679544,"about_ca_topic_score_gemma":0.0000951633,"teacher_disagreement_score":0.012849803,"about_ca_system_score_codex":0.000057837737,"about_ca_system_score_gemma":0.00027165195,"threshold_uncertainty_score":0.27040794},"labels":[],"label_agreement":null},{"id":"W4205108145","doi":"10.1016/j.jtho.2021.12.011","title":"Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Foundation Medicine; Eli Lilly and Company; Ignyta; Takeda Pharmaceuticals U.S.A.; Merck Sharp and Dohme; Institut Gustave-Roussy; Genentech; BeiGene; Regeneron Pharmaceuticals; CMC Microsystems; Aptitude Health; AbbVie; Boehringer Ingelheim; Amgen; Ariad Pharmaceuticals; Chugai Pharmaceutical; Roche; EMD Serono; Novartis; Sanofi; Merck; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Continuation; Disease; Progressive disease; Atherosclerotic cardiovascular disease; MEDLINE","score_opus":0.014409973734452616,"score_gpt":0.4454697753667234,"score_spread":0.43105980163227076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205108145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816998,0.0019780414,0.00011961539,0.0076481206,0.00043397435,0.00048125177,0.00004735772,0.000004297303,0.0075874967],"genre_scores_gemma":[0.9978023,0.000017541925,0.0012486553,0.0003461491,0.00010640398,0.00003229006,0.000025316387,0.000008191177,0.00041312812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99896604,0.00017771703,0.00042334222,0.00008387656,0.00024319971,0.0001058222],"domain_scores_gemma":[0.9988396,0.000116804826,0.0006321869,0.0000776009,0.00023415122,0.00009965191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031221597,0.000065992266,0.00031976038,0.00021899832,0.000047537094,0.000003070363,0.000056905996,0.000029039551,0.00025819163],"category_scores_gemma":[0.00010774185,0.00005352407,0.00009528,0.00019699664,0.000053028143,0.00007880397,0.00003190997,0.00022642853,0.0000012643133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020788616,0.00645203,0.14419852,0.00018050511,0.0011018795,0.0067920256,0.014038173,0.0010731338,0.0038481178,0.0008982557,0.0045058485,0.7961229],"study_design_scores_gemma":[0.013803564,0.01824866,0.9068517,0.00065524643,0.0039433814,0.0019439557,0.010196107,0.00059903844,0.0034892468,0.004454042,0.035509966,0.00030507878],"about_ca_topic_score_codex":0.000010246801,"about_ca_topic_score_gemma":0.0000061275846,"teacher_disagreement_score":0.7958178,"about_ca_system_score_codex":0.0005205835,"about_ca_system_score_gemma":0.0009195824,"threshold_uncertainty_score":0.28270173},"labels":[],"label_agreement":null},{"id":"W4205109036","doi":"10.1038/labinvest.2013.36","title":"Quality Assurance","year":2013,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"University of Texas MD Anderson Cancer Center","keywords":"Quality assurance; Medicine; Pathology; External quality assessment","score_opus":0.020678680383676578,"score_gpt":0.3277490830816738,"score_spread":0.3070704026979972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205109036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902661,0.00016192166,0.00016160416,0.0037315707,0.00012344513,0.00035205195,0.000014286319,0.00009970074,0.005089339],"genre_scores_gemma":[0.9930034,0.000010717575,0.0029481174,0.0028851137,0.00009116227,0.00012787261,0.00006685672,0.000009524428,0.00085720466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947697,0.00003590369,0.00014257779,0.00012292029,0.00013173319,0.000089896435],"domain_scores_gemma":[0.9993869,0.000027671977,0.00005627481,0.00016517795,0.00024662135,0.000117323056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006410103,0.000064287255,0.000094661606,0.000029308885,0.00005557238,0.000021329002,0.000021570688,0.000040017774,0.00025062758],"category_scores_gemma":[0.00006985361,0.00005364637,0.000019366022,0.00021029763,0.000051225743,0.00021977551,0.0000028806971,0.00005330414,0.00043116973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010771221,0.00010623793,0.7808289,0.00015644006,0.00013183498,0.0000053269905,0.0012293285,0.000015054645,0.15521963,0.011714857,0.045285437,0.005296159],"study_design_scores_gemma":[0.0006633336,0.00004846695,0.97027004,0.00003601188,0.000040326915,0.0000014896259,0.00009557671,0.00004547473,0.014379493,0.003014507,0.011321252,0.000084037325],"about_ca_topic_score_codex":0.00012329864,"about_ca_topic_score_gemma":0.000013753617,"teacher_disagreement_score":0.18944111,"about_ca_system_score_codex":0.00006571257,"about_ca_system_score_gemma":0.00020200868,"threshold_uncertainty_score":0.5541958},"labels":[],"label_agreement":null},{"id":"W4205367336","doi":"10.1016/j.lungcan.2021.12.019","title":"Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Medicine; Anaplastic lymphoma kinase; Internal medicine; Cohort; Oncology; Clinical endpoint; Alectinib; Progressive disease; Lung cancer; Chemotherapy; Clinical trial","score_opus":0.016814873006195555,"score_gpt":0.3132456634977558,"score_spread":0.29643079049156024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205367336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978791,0.0012939267,0.000013532017,0.00010489512,0.00003541131,0.00054804294,0.00010721192,0.00000764266,0.000010271238],"genre_scores_gemma":[0.9990275,0.0000131118195,0.00007185177,0.000057747642,0.000022699101,0.0005719386,0.00021850344,0.000012264679,0.0000044126423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991635,0.00011131061,0.00019069602,0.00017364435,0.00027549695,0.000085339394],"domain_scores_gemma":[0.9993711,0.0000288218,0.00013975907,0.0002989861,0.000097684046,0.00006360905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008866602,0.000089872694,0.00019566774,0.00012432925,0.0001233219,0.000010765188,0.00004404811,0.000011867842,0.000039098373],"category_scores_gemma":[0.000011081878,0.00006247812,0.00003549116,0.00057654135,0.00007507948,0.00017454538,0.00004826871,0.00005596633,2.0268613e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006815458,0.00049630285,0.98258734,0.000063261105,0.0002981067,0.000005123975,0.0018518895,0.002239119,0.0007556445,0.0000076279966,0.000011046086,0.011002966],"study_design_scores_gemma":[0.001258066,0.00019140558,0.979507,0.00012810905,0.0015471259,2.5867462e-7,0.0002357627,0.016542427,0.0005139158,0.0000014778674,0.000008148955,0.000066273606],"about_ca_topic_score_codex":0.000172568,"about_ca_topic_score_gemma":0.0005158548,"teacher_disagreement_score":0.014303309,"about_ca_system_score_codex":0.00024333179,"about_ca_system_score_gemma":0.00017635853,"threshold_uncertainty_score":0.2547784},"labels":[],"label_agreement":null},{"id":"W4205646635","doi":"10.1158/1078-0432.ccr-21-3530","title":"Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; EMD Serono; Genentech; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Sanofi; Kyowa Hakko Kirin; Teijin Pharma; Daiichi-Sankyo; Halozyme; Mirati Therapeutics; National Center for Advancing Translational Sciences; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Pfizer; Symphogen; Bristol-Myers Squibb; AstraZeneca; Shire; Taiho Pharmaceutical; F. Hoffmann-La Roche; Novartis Pharma; AbbVie; Spectrum Pharmaceuticals; Medtronic Japan; Amgen; Bayer","keywords":"Osimertinib; Adjuvant; Lung cancer; Quality of life (healthcare); Clinical trial; Phases of clinical research; Epidermal growth factor receptor","score_opus":0.16964995954985748,"score_gpt":0.5233249970360567,"score_spread":0.3536750374861992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205646635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98154503,0.0012361897,0.000002439584,0.009573547,0.00044176518,0.00623273,0.00077379576,0.000026560447,0.0001679216],"genre_scores_gemma":[0.99528056,0.00044951492,0.000033783886,0.00086234923,0.00010056078,0.002279633,0.00036811488,0.000051171937,0.0005742842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98990345,0.0042752777,0.0025313632,0.0007751803,0.0016514377,0.00086327456],"domain_scores_gemma":[0.99492115,0.0026891653,0.0007027645,0.00061074615,0.0006823768,0.00039381257],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047357525,0.0002803436,0.0015601498,0.00039153302,0.00032380762,0.00002404678,0.00045307455,0.00015475976,0.0012589932],"category_scores_gemma":[0.0016253745,0.00018177158,0.0002148374,0.001795667,0.0003265549,0.0001050356,0.00018303833,0.002194719,0.0000032761939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1306965,0.005993937,0.8510994,0.00022075385,0.0003764029,0.000019826446,0.004129267,0.00007921787,0.000031652908,0.0000063960915,0.0033675819,0.003979079],"study_design_scores_gemma":[0.22094664,0.005539727,0.7715831,0.00021738808,0.0000734526,2.028966e-7,0.0009327356,0.0001971368,0.00005112932,0.000012510989,0.00026434925,0.00018164013],"about_ca_topic_score_codex":0.051515773,"about_ca_topic_score_gemma":0.005506632,"teacher_disagreement_score":0.090250134,"about_ca_system_score_codex":0.001286843,"about_ca_system_score_gemma":0.004790456,"threshold_uncertainty_score":0.999654},"labels":[],"label_agreement":null},{"id":"W4205958817","doi":"10.1016/j.jval.2021.11.594","title":"POSA193 Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Driver Mutations: Projections by Line of Therapy (LOT) in Western Europe (WE), 2021-2026","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lung cancer; Medicine; Incidence (geometry); Stage (stratigraphy); Oncology; Internal medicine; Epidemiology; Population; Cancer; Environmental health; Biology","score_opus":0.037267381836158894,"score_gpt":0.36435690747723504,"score_spread":0.32708952564107613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205958817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97336316,0.015726347,0.0003612497,0.006199787,0.0003457075,0.0031447746,0.00037557824,0.000029540344,0.00045386096],"genre_scores_gemma":[0.9853928,0.006741376,0.0016277517,0.0010308827,0.00006458898,0.0010406796,0.00023511959,0.000063345586,0.0038034404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981861,0.00030333354,0.00059559237,0.00033249368,0.00027756658,0.00030492895],"domain_scores_gemma":[0.99921006,0.00010410927,0.000248105,0.00024465818,0.00008765452,0.000105438594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033166105,0.00016831074,0.0004040697,0.0003349917,0.00014113291,0.000009843992,0.00009198518,0.000024046081,0.00021155027],"category_scores_gemma":[0.00001703357,0.00015127206,0.000058350357,0.0009846238,0.00003706475,0.00007069822,0.000035629473,0.0003062407,0.000004423192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004914684,0.0052813333,0.8418208,0.001532905,0.000422453,0.0001057903,0.056158118,0.0759197,0.0019883695,0.00011551306,0.003532931,0.012630667],"study_design_scores_gemma":[0.11791207,0.02073177,0.46476623,0.008044769,0.0021717576,0.00030210754,0.032396577,0.17324968,0.00643248,0.00064159196,0.17038769,0.002963279],"about_ca_topic_score_codex":0.02935912,"about_ca_topic_score_gemma":0.0013647408,"teacher_disagreement_score":0.3770545,"about_ca_system_score_codex":0.0006817697,"about_ca_system_score_gemma":0.0023472058,"threshold_uncertainty_score":0.9771045},"labels":[],"label_agreement":null},{"id":"W4206585470","doi":"10.1158/1055-9965.epi-21-0747","title":"Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data","year":2022,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto; University of Ottawa; Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; World Health Organization; Swiss Cancer Research Foundation; Financiadora de Estudos e Projetos; Princess Margaret Cancer Foundation; Hospital de Câncer de Barretos","keywords":"Oncology; Medicine; Lung cancer; Concordance; Internal medicine; Imputation (statistics); Missing data; Statistics","score_opus":0.1560184449681514,"score_gpt":0.459612541416953,"score_spread":0.30359409644880164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206585470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81026906,0.040695753,0.060231205,0.06553562,0.0047259247,0.010044058,0.0060984553,0.00015627733,0.0022436236],"genre_scores_gemma":[0.979671,0.00077598135,0.0057139155,0.0045823315,0.00020384297,0.0053949156,0.0032166399,0.00003764729,0.0004037157],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99678695,0.0007476467,0.0010577423,0.000771035,0.00019449182,0.0004421389],"domain_scores_gemma":[0.9942366,0.0038481632,0.0009884578,0.000676593,0.00017442953,0.000075782125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034838705,0.00026062343,0.00067856064,0.00031758455,0.00031811817,0.00000915313,0.0005422881,0.00011103149,0.0007466539],"category_scores_gemma":[0.001212144,0.0002005682,0.0002624198,0.00044670922,0.00019349219,0.00012649516,0.00018208608,0.00028236568,7.614824e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008184424,0.00033224648,0.89131445,0.00028857827,0.0015403029,0.0000051015713,0.00020434891,0.055554472,0.0032133337,0.00022050978,0.041546457,0.004961747],"study_design_scores_gemma":[0.0065128827,0.0004203348,0.2788772,0.000849855,0.0034151655,0.0000060880448,0.0016200509,0.69649565,0.0012647124,0.0013397321,0.00873535,0.00046296156],"about_ca_topic_score_codex":0.0070677293,"about_ca_topic_score_gemma":0.0018161092,"teacher_disagreement_score":0.6409412,"about_ca_system_score_codex":0.0015653527,"about_ca_system_score_gemma":0.0013739615,"threshold_uncertainty_score":0.99954426},"labels":[],"label_agreement":null},{"id":"W4206762718","doi":"10.3390/curroncol29010024","title":"Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute","keywords":"Afatinib; Osimertinib; Medicine; T790M; Lung cancer; Epidermal growth factor receptor; Oncology; Erlotinib; Tyrosine kinase; Internal medicine; Cancer research; Mutation; Incidence (geometry); Gefitinib; Cancer; Gene; Genetics; Biology; Receptor","score_opus":0.1932106472408075,"score_gpt":0.48916366595552113,"score_spread":0.29595301871471363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206762718","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000067443875,0.9854133,0.00001693449,0.00011099282,0.0012125404,0.008372667,0.00016082243,0.000023998291,0.0046819914],"genre_scores_gemma":[0.0000115240155,0.9891801,0.00010368077,0.000115655814,0.00008424511,0.008694229,0.0005886022,0.000051631516,0.0011703562],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9964995,0.0006271995,0.0016942318,0.0005185637,0.00032262373,0.00033789597],"domain_scores_gemma":[0.99659324,0.0011214266,0.0013374629,0.00064234185,0.0001705016,0.0001350452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006260608,0.00042396574,0.0041983603,0.0003766884,0.00008550606,0.000009809809,0.00031612845,0.00015825772,0.0016922889],"category_scores_gemma":[0.00026108432,0.00032836891,0.0005411535,0.0008989979,0.00007356295,0.00006467713,0.0001385534,0.00067851,0.00007284899],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000058358964,0.0006746508,0.000121217316,0.93874764,0.00031017905,0.00006180896,0.0002493577,0.0000014626058,1.2459863e-7,0.000012033391,0.0054838755,0.05433182],"study_design_scores_gemma":[0.00045854397,0.00015840938,0.0000029031855,0.540082,0.013166452,0.000046956055,0.000039389266,0.000019325313,1.3462316e-7,0.000001458984,0.44588542,0.00013905142],"about_ca_topic_score_codex":0.00026154425,"about_ca_topic_score_gemma":0.00013874957,"teacher_disagreement_score":0.44040155,"about_ca_system_score_codex":0.0037724676,"about_ca_system_score_gemma":0.0048769442,"threshold_uncertainty_score":0.99991685},"labels":[],"label_agreement":null},{"id":"W4210298556","doi":"10.2165/00128413-200615270-00041","title":"Cipher Pharmaceuticals has received final approval from Health Canada for CIP-Fenofibrate,","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fenofibrate; Pharmacy; Drug approval; Pharmacology; Family medicine; Drug","score_opus":0.07076342288765271,"score_gpt":0.37455700265032493,"score_spread":0.30379357976267224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210298556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80519307,0.0068377517,0.004443812,0.15054728,0.002918426,0.005166911,0.003267271,0.0003812599,0.021244207],"genre_scores_gemma":[0.97798854,0.000038034446,0.0044960594,0.007910917,0.0008029549,0.00011812921,0.0010278337,0.00005164637,0.007565867],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985582,0.000039871982,0.00036190107,0.00034408708,0.0002626963,0.00043323313],"domain_scores_gemma":[0.9992028,0.00011590299,0.000113439615,0.00019414963,0.00011567229,0.00025806835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088760025,0.00019911454,0.00033921923,0.0000436022,0.0002420945,0.000040848827,0.0000818378,0.000051364983,0.00061122206],"category_scores_gemma":[0.00001712833,0.00017219303,0.00008755745,0.00013959163,0.00005958828,0.00008296829,0.000017062139,0.00012900247,0.000022952856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007282111,0.00046878506,0.003759261,0.0001385472,0.0004317583,0.00008789112,0.00028525686,0.00012516942,0.0062069525,0.00015336464,0.96853155,0.019083224],"study_design_scores_gemma":[0.010399046,0.0003727965,0.019052234,0.000088826026,0.00044146058,0.0000262017,0.00022533096,0.001293208,0.0093027335,0.00045809138,0.9580482,0.00029185807],"about_ca_topic_score_codex":0.45028642,"about_ca_topic_score_gemma":0.114770845,"teacher_disagreement_score":0.3355156,"about_ca_system_score_codex":0.0005476658,"about_ca_system_score_gemma":0.0026594168,"threshold_uncertainty_score":0.90138227},"labels":[],"label_agreement":null},{"id":"W4210511187","doi":"10.1016/j.lungcan.2022.01.020","title":"Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Takeda (Canada); University Health Network","funders":"Swiss Cancer Research Foundation","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Nivolumab; Immunotherapy","score_opus":0.012730693498659464,"score_gpt":0.3251160578730218,"score_spread":0.3123853643743623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210511187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874824,0.0049581607,0.00002555721,0.0019057426,0.0004985491,0.0013939416,0.0006149768,0.00004827914,0.003072361],"genre_scores_gemma":[0.96961325,0.0012438514,0.00007794853,0.0006574339,0.00010715248,0.0030854235,0.00006420858,0.000051365336,0.025099367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986736,0.00004156468,0.00024178902,0.0004294146,0.00023666197,0.00037698037],"domain_scores_gemma":[0.99940664,0.000042340744,0.000090656446,0.00027773544,0.000032206026,0.00015043496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000049875962,0.00025417886,0.00041446695,0.00014495988,0.00018596044,0.000026615226,0.00007375099,0.000048869937,0.0011934614],"category_scores_gemma":[0.000002581958,0.00020678152,0.00010136228,0.00018149568,0.000023967847,0.0000669645,0.00006560946,0.00018482385,0.0000023528914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010513381,0.00030940337,0.98842573,0.00016577178,0.00040257446,0.00015176403,0.0059736436,0.00035187675,0.00024732045,0.000010973114,0.00048767604,0.003368144],"study_design_scores_gemma":[0.008610901,0.00034831013,0.97358805,0.00010305381,0.0009397719,0.000006528216,0.0007573093,0.0014138486,0.0005579993,0.0000030489707,0.01339,0.00028118808],"about_ca_topic_score_codex":0.054740973,"about_ca_topic_score_gemma":0.009691427,"teacher_disagreement_score":0.045049544,"about_ca_system_score_codex":0.0017818111,"about_ca_system_score_gemma":0.00036637118,"threshold_uncertainty_score":0.99971956},"labels":[],"label_agreement":null},{"id":"W4210665852","doi":"10.1016/j.lungcan.2022.01.023","title":"Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Afatinib; Medicine; Pembrolizumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Population; Carcinoma; Epidermal growth factor receptor; Surgery; Gastroenterology; Cancer; Gefitinib; Immunotherapy; Clinical trial","score_opus":0.0071702449301228755,"score_gpt":0.3156310337756659,"score_spread":0.30846078884554307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210665852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460095,0.0015279381,0.0000032803762,0.00013915599,0.00026482058,0.003226876,0.00008124062,0.00001898661,0.00013674935],"genre_scores_gemma":[0.99744064,0.0000067960086,0.000037078877,0.00007228192,0.000048007656,0.0014386108,0.00002404923,0.00005335897,0.0008791524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983096,0.000059826736,0.00040642053,0.00033775548,0.0006159849,0.00027037645],"domain_scores_gemma":[0.9991418,0.000028532326,0.00026818056,0.000413405,0.000084886306,0.00006320477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006732862,0.00021803107,0.00041424038,0.0001221024,0.0002525032,0.000006445708,0.00013897795,0.00003704992,0.00038982692],"category_scores_gemma":[0.000008041724,0.00013269001,0.00010453042,0.0004947203,0.000031527772,0.000079169105,0.0001265342,0.00019808116,1.02196736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011338295,0.0070526227,0.9597656,0.0004925965,0.0001978111,0.000056649216,0.018927783,0.0012806313,0.00010786167,4.4406056e-7,0.00013112892,0.00064856355],"study_design_scores_gemma":[0.12849575,0.007587841,0.857193,0.00044019998,0.0011115943,0.000003066068,0.0013065232,0.0015416874,0.0019945719,7.425653e-7,0.000092634415,0.00023236366],"about_ca_topic_score_codex":0.00067005004,"about_ca_topic_score_gemma":0.00049736805,"teacher_disagreement_score":0.11715746,"about_ca_system_score_codex":0.00092053914,"about_ca_system_score_gemma":0.00038181114,"threshold_uncertainty_score":0.5410941},"labels":[],"label_agreement":null},{"id":"W4210734941","doi":"10.1021/acs.jcim.1c01399","title":"Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation","year":2022,"lang":"en","type":"article","venue":"Journal of Chemical Information and Modeling","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"T790M; Chemistry; Selectivity; Stereochemistry; Mutant; Small molecule; Mechanism of action; Combinatorial chemistry; Biophysics; Epidermal growth factor receptor; Receptor; Biochemistry; Biology; In vitro; Gene","score_opus":0.022497302279967792,"score_gpt":0.28832725871823617,"score_spread":0.2658299564382684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210734941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9326356,0.00029971576,0.066144735,0.0005622348,0.00007709276,0.00014295564,0.000008554715,0.0000053062327,0.00012377628],"genre_scores_gemma":[0.9972518,0.000049950242,0.0025389274,0.00010753594,0.000023047198,0.000007661237,0.0000119847255,0.000004292785,0.00000480095],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989664,0.000018953695,0.0005485521,0.000039683986,0.00035308336,0.00007331941],"domain_scores_gemma":[0.9991101,0.000049564664,0.00048390008,0.00005706734,0.00025454417,0.00004479354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037902012,0.00006262879,0.00018222691,0.00010382712,0.00007103452,0.000010103007,0.00004401355,0.000025294026,0.000012206855],"category_scores_gemma":[0.00007792123,0.00004544024,0.000080924634,0.00014990164,0.000019865092,0.00026170432,0.00002167426,0.00016002006,9.966461e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043542674,0.0007928889,0.0015485851,0.0022357944,0.0010807023,0.000016326394,0.029210893,0.41435024,0.48115367,0.010863612,0.0004685423,0.05392449],"study_design_scores_gemma":[0.0047301436,0.00038056562,0.00008950428,0.0004219959,0.00045836103,0.00011289489,0.004501722,0.3512755,0.6359097,0.0016104496,0.00036707186,0.00014211376],"about_ca_topic_score_codex":0.000010862335,"about_ca_topic_score_gemma":3.683322e-7,"teacher_disagreement_score":0.15475602,"about_ca_system_score_codex":0.00016259786,"about_ca_system_score_gemma":0.00018574424,"threshold_uncertainty_score":0.18529992},"labels":[],"label_agreement":null},{"id":"W4211216207","doi":"10.1158/1078-0432.ccr-21-3597","title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Solid tumor; Cancer; Clinical trial; Disease; Chemotherapy","score_opus":0.042792781397966974,"score_gpt":0.4593572099433715,"score_spread":0.4165644285454045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211216207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733347,0.00013806604,0.0000021718972,0.00076730404,0.000056190314,0.00086350477,0.0003652992,0.0000048718434,0.00046913605],"genre_scores_gemma":[0.99928445,0.000075698845,0.000023335095,0.00011391353,0.000012222632,0.00007106156,0.00017057087,0.0000100794105,0.00023868177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997843,0.0005293255,0.0005187362,0.0002773313,0.00063323515,0.00019835019],"domain_scores_gemma":[0.9983334,0.00066981214,0.00015201236,0.00027978668,0.00047399887,0.00009101151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008031439,0.000080407546,0.0004670046,0.0002601886,0.00014100222,0.0000047597277,0.00012468967,0.000034659606,0.0006060767],"category_scores_gemma":[0.00027425616,0.00004686618,0.000094705545,0.0027107634,0.0003533479,0.000023573322,0.00018831047,0.0005432741,4.2902042e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061964206,0.0012664504,0.98159933,0.000015145285,0.0012135912,0.000005521855,0.00078155857,0.0003467422,0.00003662507,0.000030307512,0.0003293593,0.008178953],"study_design_scores_gemma":[0.0063465764,0.0012835396,0.99007773,0.0001067411,0.0006643334,3.0251414e-7,0.00058809086,0.00019470043,0.00020407168,0.000009451846,0.00047849806,0.000045975437],"about_ca_topic_score_codex":0.0020303822,"about_ca_topic_score_gemma":0.0005196754,"teacher_disagreement_score":0.008478395,"about_ca_system_score_codex":0.0002481633,"about_ca_system_score_gemma":0.00067448703,"threshold_uncertainty_score":0.6636115},"labels":[],"label_agreement":null},{"id":"W4213027978","doi":"10.21203/rs.3.rs-1132236/v1","title":"Cytoreductive Stereotactic Body Radiotherapy with Tyrosine Kinase Inhibitors for Intrathoracic Oligoprogressive EGFR-mutated Lung Cancer","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Oncology; Cancer research; Radiation therapy; Internal medicine; Cancer; Radiology; Receptor","score_opus":0.033393797484947654,"score_gpt":0.4601660223220043,"score_spread":0.4267722248370567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213027978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9287218,0.051269032,0.00063877273,0.006292687,0.00072730286,0.010865311,0.00095028133,0.00017869397,0.00035614634],"genre_scores_gemma":[0.9816874,0.0024007026,0.0024489479,0.00009310035,0.0014017487,0.008264096,0.0020524922,0.00020446218,0.0014470468],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99605477,0.00030307108,0.0004176749,0.001169948,0.001137958,0.0009166091],"domain_scores_gemma":[0.99533767,0.00022041624,0.00023428522,0.0008319863,0.0029044577,0.00047118968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038575527,0.0005166024,0.0008360062,0.0005285303,0.0003841675,0.00033417804,0.0001993031,0.00036568873,0.00027290193],"category_scores_gemma":[0.00017076179,0.00039032265,0.00025627695,0.0008039891,0.00034339496,0.0001876017,0.00018105883,0.0013706274,0.0000028551062],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053878024,0.021345494,0.25202447,0.08684515,0.08288773,0.022533957,0.11893982,0.0044887494,0.08799403,0.0012555569,0.059477,0.20833],"study_design_scores_gemma":[0.101051375,0.036451004,0.15613449,0.15372188,0.021583093,0.0016038337,0.06573011,0.027185429,0.40046346,0.000931593,0.025629723,0.009514005],"about_ca_topic_score_codex":0.0011433807,"about_ca_topic_score_gemma":0.00020139896,"teacher_disagreement_score":0.31246942,"about_ca_system_score_codex":0.0033611595,"about_ca_system_score_gemma":0.0051734257,"threshold_uncertainty_score":0.99985486},"labels":[],"label_agreement":null},{"id":"W4213132440","doi":"10.1016/j.ctarc.2022.100534","title":"Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system","year":2022,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"KRAS; Medicine; Reimbursement; Clinical trial; Lung cancer; Oncology; Internal medicine; Targeted therapy; Cancer; Bioinformatics; Health care; Biology; Colorectal cancer","score_opus":0.13422541032650281,"score_gpt":0.45275745784603594,"score_spread":0.3185320475195331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213132440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87692374,0.10481908,0.000048009362,0.012419014,0.00011361942,0.00225625,0.00029811307,0.000055314737,0.003066859],"genre_scores_gemma":[0.97926646,0.012548518,0.0019444603,0.00008176026,0.000049797916,0.0050218655,0.00020628105,0.000031235846,0.0008496371],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99834704,0.00039068834,0.00032928717,0.000299417,0.0002801802,0.00035336125],"domain_scores_gemma":[0.9978125,0.00027370473,0.00014105719,0.0009397976,0.0006168704,0.00021604578],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00024029438,0.0001650714,0.0003502368,0.000327087,0.0016941662,0.00003941051,0.00031310652,0.00004351995,0.00006362412],"category_scores_gemma":[0.000010353817,0.00013354036,0.000092153095,0.0005989173,0.00023562371,0.00006597516,0.00045834694,0.00040577503,0.0000014751769],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050699676,0.0028900101,0.53060645,0.0067752027,0.0059642913,0.00008293272,0.17431459,0.00080999645,0.09750562,0.015363082,0.0028408389,0.16234],"study_design_scores_gemma":[0.031279836,0.008905134,0.07637063,0.0052950727,0.005076615,0.00023793778,0.6072406,0.08982459,0.011084324,0.00044570872,0.16245466,0.0017849116],"about_ca_topic_score_codex":0.03807127,"about_ca_topic_score_gemma":0.0035940823,"teacher_disagreement_score":0.45423582,"about_ca_system_score_codex":0.0063319416,"about_ca_system_score_gemma":0.0030098974,"threshold_uncertainty_score":0.9996055},"labels":[],"label_agreement":null},{"id":"W4213133535","doi":"10.1016/j.annonc.2022.02.003","title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; European Society for Medical Oncology; Incyte; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Samsung; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Guideline; Voting; Consensus conference; Clinical trial; Multidisciplinary approach; Lung cancer; Family medicine; Panel discussion; MEDLINE; Oncology; Medical physics; Intensive care medicine; Pathology; Internal medicine","score_opus":0.07375977406662172,"score_gpt":0.45261268578839703,"score_spread":0.3788529117217753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213133535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9221946,0.0011833264,0.000013945801,0.01966065,0.00034652365,0.0009552035,0.0001163398,0.000010065354,0.055519365],"genre_scores_gemma":[0.99124867,0.001139658,0.00021508358,0.004395324,0.00002584554,0.00045498853,0.000021034424,0.00001367982,0.0024857225],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990947,0.00006705122,0.00028207197,0.00016332928,0.00020613393,0.00018668437],"domain_scores_gemma":[0.9993297,0.00008574999,0.00020254382,0.00023548507,0.00009881401,0.000047733007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018764855,0.000096008174,0.00024991413,0.00006502029,0.0000992444,0.0000017005638,0.00010081949,0.000025860041,0.00088884786],"category_scores_gemma":[0.0000034929776,0.000066545486,0.00007753936,0.00013023551,0.00006575608,0.000009757917,0.000083945655,0.00009582439,0.000003561506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007195833,0.021367256,0.027225815,0.002243495,0.020977682,0.0029182062,0.039430972,0.005106927,0.02526648,0.017619856,0.5554301,0.27521738],"study_design_scores_gemma":[0.017975703,0.01543396,0.024389438,0.000485073,0.002038315,0.000045642893,0.027199823,0.0009293566,0.07788647,0.000531059,0.8326451,0.0004400163],"about_ca_topic_score_codex":0.0006668187,"about_ca_topic_score_gemma":0.000023478677,"teacher_disagreement_score":0.27721506,"about_ca_system_score_codex":0.00016395397,"about_ca_system_score_gemma":0.00025885573,"threshold_uncertainty_score":0.9732261},"labels":[],"label_agreement":null},{"id":"W4213187594","doi":"10.3747/co.27.6577","title":"Erratum: Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020","year":2020,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Table (database); Column (typography); Oncology; Data mining; Computer science","score_opus":0.041788221589723826,"score_gpt":0.38705662514770167,"score_spread":0.34526840355797783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213187594","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045763157,0.6120574,0.000088621746,0.01599088,0.15028019,0.008184241,0.0017699469,0.000065044034,0.16580057],"genre_scores_gemma":[0.8162668,0.08825951,0.0004143747,0.0037816772,0.0042135017,0.0036835973,0.0071021584,0.0004269264,0.07585145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981722,0.00010717969,0.00063186476,0.00045046833,0.00024736903,0.0003909219],"domain_scores_gemma":[0.9990715,0.00009514546,0.0003306149,0.00023953889,0.00010129655,0.0001619374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007600798,0.00033003328,0.0011970103,0.00020591696,0.000019427913,0.0000049900636,0.00016887639,0.00018554807,0.00041968634],"category_scores_gemma":[0.00002220512,0.00027990201,0.00010335009,0.00051037414,0.00003651832,0.000024307348,0.000053684464,0.0011427642,0.000004369816],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012600725,0.0005801375,0.085505806,0.0026860368,0.000393046,0.0004668498,0.0014570417,0.00007621492,0.000017343542,0.0000064140067,0.8918886,0.016796494],"study_design_scores_gemma":[0.009797427,0.00068122003,0.059548378,0.0020793588,0.0030352953,0.000021526093,0.0012887157,0.00485295,0.000020642558,0.00004597609,0.9181144,0.0005140761],"about_ca_topic_score_codex":0.30642277,"about_ca_topic_score_gemma":0.9120859,"teacher_disagreement_score":0.77050364,"about_ca_system_score_codex":0.0027859195,"about_ca_system_score_gemma":0.025332512,"threshold_uncertainty_score":0.9999653},"labels":[],"label_agreement":null},{"id":"W4214510639","doi":"10.1016/j.jtocrr.2022.100304","title":"Trends of Molecular Testing for Lung Cancer at the King Faisal Hospital, Kigali: Therapeutic and Survival Implications","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Lung cancer; Cancer; Carboplatin; Internal medicine; Oncology; Stage (stratigraphy); Biomarker; Targeted therapy; Disease; Chemotherapy; Biology","score_opus":0.155052970415355,"score_gpt":0.5397272122547654,"score_spread":0.38467424183941035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214510639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97706395,0.0051265787,0.00006873153,0.015080325,0.00020313908,0.000716198,0.00004410016,0.000015433581,0.0016815688],"genre_scores_gemma":[0.99705863,0.00015628045,0.00013372966,0.00013796483,0.000089892565,0.00059109053,0.000022496153,0.000014079043,0.001795834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998597,0.00012198934,0.00038329285,0.00029456467,0.000398964,0.00020414285],"domain_scores_gemma":[0.99822253,0.0009806262,0.00012522575,0.000253442,0.0003061687,0.00011202472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016347958,0.00006739113,0.00019761526,0.00006194656,0.0005469717,0.000017969507,0.000041805783,0.000033933593,0.00005872772],"category_scores_gemma":[0.00061399664,0.00004118307,0.00007995666,0.0002870292,0.00036535828,0.000022539454,0.00017228935,0.00023098217,5.592456e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071655086,0.00025258216,0.9179337,0.00007280208,0.0003101322,0.000061926214,0.00026709354,0.000022728662,0.0017166265,0.0005116777,0.0017375131,0.07704154],"study_design_scores_gemma":[0.0014869471,0.0015327353,0.9623065,0.00006622642,0.00045988546,0.00014307255,0.0004455228,0.00064783456,0.00027428553,0.0015301952,0.030983152,0.00012362456],"about_ca_topic_score_codex":0.0004140252,"about_ca_topic_score_gemma":0.00004061411,"teacher_disagreement_score":0.07691791,"about_ca_system_score_codex":0.00007264202,"about_ca_system_score_gemma":0.00028203815,"threshold_uncertainty_score":0.4206919},"labels":[],"label_agreement":null},{"id":"W4214668206","doi":"10.3390/curroncol29020057","title":"ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Crizotinib; Cancer research; Medicine; Carcinogenesis; Lung cancer; Phenotype; Cancer; Oncology; Biology; Gene; Internal medicine; Genetics","score_opus":0.22134311375227061,"score_gpt":0.5415783904367565,"score_spread":0.32023527668448587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214668206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000121559184,0.9890331,0.00003247337,0.0004759835,0.0034567406,0.0034831744,0.00017182993,0.000038155697,0.0031869577],"genre_scores_gemma":[0.000019551402,0.9916282,0.00018415603,0.00019404513,0.00037492526,0.00561647,0.00045371338,0.000054939184,0.0014739505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784595,0.00018710153,0.0006409614,0.00067030214,0.00020833181,0.00044736572],"domain_scores_gemma":[0.99852747,0.00036426613,0.00027273767,0.0005014114,0.000056889832,0.00027722292],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022088816,0.00037519354,0.0016482269,0.00043874088,0.00012214521,0.000013112158,0.00029634882,0.00018011946,0.001790418],"category_scores_gemma":[0.000099219964,0.00030514668,0.00029731457,0.00077067927,0.000032444008,0.000041980307,0.00033848107,0.00079509296,0.00011296554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016432621,0.0005880454,0.0005941414,0.011358731,0.00011676512,0.00013383955,0.0005990256,0.000006811934,5.7571657e-7,0.000011856451,0.012992201,0.97358155],"study_design_scores_gemma":[0.00078877027,0.00036820312,0.00011142219,0.015709668,0.0035357377,0.00003613928,0.00006446044,0.00001904881,2.838397e-7,0.000001539393,0.9791213,0.00024342185],"about_ca_topic_score_codex":0.00029242795,"about_ca_topic_score_gemma":0.0003397988,"teacher_disagreement_score":0.9733381,"about_ca_system_score_codex":0.0027922317,"about_ca_system_score_gemma":0.004182017,"threshold_uncertainty_score":0.99994004},"labels":[],"label_agreement":null},{"id":"W4220683091","doi":"10.51731/cjht.2022.280","title":"Osimertinib (Tagrisso)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Reimbursement; Medicine; Oncology; Lung cancer; Exon; Drug; Adjuvant; Stage (stratigraphy); Internal medicine; Family medicine; Cancer; Pharmacology; Adenocarcinoma; Political science; Gene; Biology; Genetics","score_opus":0.025149900397469595,"score_gpt":0.3347979546627587,"score_spread":0.3096480542652891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220683091","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37436357,0.21766675,0.00022256061,0.40115836,0.0016774967,0.00081185007,0.00011562728,0.00023951486,0.0037442704],"genre_scores_gemma":[0.9978473,0.00010947831,0.00043533475,0.0012611265,0.000007927155,0.000013883369,0.000004761413,0.000008587117,0.00031157825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923307,0.000025538615,0.00029611983,0.0000692095,0.0001290601,0.00024698596],"domain_scores_gemma":[0.9994773,0.000016744205,0.00021373299,0.00013804766,0.00007117459,0.000082993385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023393602,0.000059762537,0.00020645937,0.00040836292,0.00041040272,0.000007856086,0.00012407245,0.000027985758,0.00019250016],"category_scores_gemma":[0.00010659805,0.00004886193,0.000058019938,0.00027066228,0.00006126,0.000035490153,0.000014331139,0.00032590234,0.0000038497437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031302032,0.00007254442,0.03537369,0.00006233713,0.0002010317,0.00072404277,0.0011090788,0.00007828526,0.000041900723,0.0020003282,0.057238955,0.9030665],"study_design_scores_gemma":[0.00085033017,0.0011640548,0.020976346,0.000050746214,0.000051975745,0.001237822,0.00845911,0.0000054051134,0.00014000389,0.0013438017,0.9656543,0.000066112596],"about_ca_topic_score_codex":0.0036988035,"about_ca_topic_score_gemma":0.00049470755,"teacher_disagreement_score":0.9084153,"about_ca_system_score_codex":0.00083797565,"about_ca_system_score_gemma":0.0043392545,"threshold_uncertainty_score":0.7697651},"labels":[],"label_agreement":null},{"id":"W4220831558","doi":"10.3390/cancers14071663","title":"In Silico Bioinformatics Followed by Molecular Validation Using Archival FFPE Tissue Biopsies Identifies a Panel of Transcripts Associated with Severe Asthma and Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Al Jalila Foundation","keywords":"Lung cancer; Medicine; Cancer; Periostin; Transcriptome; Cancer research; Pathology; Biology; Internal medicine; Gene expression; Extracellular matrix; Gene","score_opus":0.015554185652336067,"score_gpt":0.3037279770847644,"score_spread":0.28817379143242833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220831558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997031,0.001257203,0.00023148747,0.00023492862,0.00012306942,0.00047955188,0.00034985426,0.00001628973,0.0002766327],"genre_scores_gemma":[0.9989531,0.0000726248,0.00023893983,0.00014809314,0.000008129243,0.00010757538,0.00015933135,0.000017791448,0.0002944037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992169,0.000034310877,0.00020902655,0.00013941288,0.00024151667,0.0001588393],"domain_scores_gemma":[0.99966395,0.000021769863,0.00012225256,0.00009502701,0.00004572868,0.000051299034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006657049,0.00011310619,0.00022654883,0.00011717044,0.00009478883,0.0000144173155,0.000040216764,0.00002309821,0.00005522712],"category_scores_gemma":[0.000013449597,0.000103108025,0.000029782097,0.00031201154,0.000065620945,0.00013435994,0.000016177466,0.00009378445,8.087549e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014658862,0.0003473886,0.08700899,0.0016242389,0.0033598004,0.00023935799,0.06596101,0.115747385,0.71121097,0.00016873887,0.0057283803,0.007137839],"study_design_scores_gemma":[0.070565514,0.00506233,0.11940986,0.005115131,0.0094751455,0.00050456706,0.05157771,0.2106861,0.5177576,0.0003914653,0.006269046,0.0031855304],"about_ca_topic_score_codex":0.0026716564,"about_ca_topic_score_gemma":0.00018838367,"teacher_disagreement_score":0.19345337,"about_ca_system_score_codex":0.0011390257,"about_ca_system_score_gemma":0.0005508884,"threshold_uncertainty_score":0.42046234},"labels":[],"label_agreement":null},{"id":"W4220838234","doi":"10.1007/s10552-022-01566-x","title":"Lifestyle factors and lung cancer risk among never smokers in the Canadian Partnership for Tomorrow’s Health (CanPath)","year":2022,"lang":"en","type":"article","venue":"Cancer Causes & Control","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Canada Research Chairs; Institute of Cancer Research; Ontario Institute for Cancer Research; Dalhousie University; University of Alberta; Canadian Centre for Applied Research in Cancer Control; Alberta Health Services; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Lung cancer; Obesity; Risk factor; Logistic regression; Epidemiology; Environmental health; Body mass index; Passive smoking; Public health; Population; Demography; Gerontology; Internal medicine; Pathology","score_opus":0.023659074369504627,"score_gpt":0.3511968432467244,"score_spread":0.32753776887721975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220838234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96187335,0.015002738,0.000020463853,0.017947024,0.00042691332,0.002890952,0.0014256112,0.000034632456,0.00037833527],"genre_scores_gemma":[0.9831108,0.0003698839,0.0000072441635,0.0117436405,0.00018724486,0.0040151146,0.0000753899,0.00003423773,0.00045643485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851716,0.00014530274,0.00023915937,0.00032747167,0.00024194227,0.000528989],"domain_scores_gemma":[0.9990458,0.00018723562,0.00014475657,0.00023324961,0.00006193067,0.00032702283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003008759,0.00019526233,0.00034637403,0.00015338656,0.0007153599,0.000045936733,0.000107335174,0.0000455169,0.00022907516],"category_scores_gemma":[0.00005478406,0.00014040557,0.00009024569,0.00024596666,0.00007867824,0.00011124768,0.000013883496,0.0002869175,3.3107406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009637414,0.000038057835,0.9800124,0.000049852137,0.0002847665,0.000016961261,0.0049523846,0.0004502908,0.0000035471453,0.00017799564,0.012733704,0.0011836513],"study_design_scores_gemma":[0.005596369,0.00021583107,0.92956626,0.00006140923,0.00075155805,0.000004872033,0.0026247534,0.0010243437,0.000007978553,0.000032691616,0.05992297,0.00019092963],"about_ca_topic_score_codex":0.73631155,"about_ca_topic_score_gemma":0.85476273,"teacher_disagreement_score":0.11845117,"about_ca_system_score_codex":0.0023482705,"about_ca_system_score_gemma":0.0029013623,"threshold_uncertainty_score":0.6140646},"labels":[],"label_agreement":null},{"id":"W4220879423","doi":"10.1016/j.jtho.2022.02.011","title":"Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Sanofi Genzyme; Takeda Oncology; EMD Serono; Genentech; National Institutes of Health; Astellas Pharma; Daiichi-Sankyo; Damon Runyon Cancer Research Foundation; Revolution Medicines; American Cancer Society; Society for Immunotherapy of Cancer; Boehringer Ingelheim; AbbVie; Massachusetts Institute of Technology; Takeda Pharmaceutical Company; Broad Institute; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Merck; AstraZeneca; Canadian Asian Studies Association; Daiichi Sankyo Europe; National Cancer Institute; Foghorn Therapeutics; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; American Society of Clinical Oncology; Dana-Farber Cancer Institute; Pfizer; Conquer Cancer Foundation","keywords":"Medicine; Mutant; Adenocarcinoma; Mutation; Cancer research; Resistance (ecology); Lung; Oncology; Internal medicine; Genetics; Cancer; Gene; Biology; Ecology","score_opus":0.027668838212574216,"score_gpt":0.4252409717940304,"score_spread":0.3975721335814562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220879423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97227335,0.010351889,0.0011946112,0.010410568,0.0014645146,0.0004916187,0.000085902044,0.000016852633,0.0037106972],"genre_scores_gemma":[0.99701166,0.00005526298,0.0008106755,0.00021016448,0.00011308155,0.00005359422,0.00002323293,0.000011976061,0.0017103365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838495,0.0002737893,0.00062425254,0.00015739421,0.00033974065,0.0002198669],"domain_scores_gemma":[0.99893594,0.00017007676,0.00043372676,0.00013256034,0.00020314226,0.00012457138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005175885,0.00011000896,0.00039262426,0.00036975337,0.00016500508,0.000007843737,0.00010597662,0.000049927014,0.00029938619],"category_scores_gemma":[0.00013013322,0.000096671996,0.00013314639,0.00039366182,0.0000680942,0.000118133525,0.00004320744,0.0004857385,0.0000070450496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011721642,0.010861924,0.5520606,0.0012272497,0.0030839304,0.020250594,0.05331977,0.011264168,0.019340226,0.008381523,0.04299052,0.26549786],"study_design_scores_gemma":[0.009764201,0.0066870046,0.73459214,0.00039342057,0.0026430641,0.0053696134,0.019441554,0.0011330534,0.0005177859,0.0029298083,0.21608154,0.0004468276],"about_ca_topic_score_codex":0.000035835426,"about_ca_topic_score_gemma":0.000103872815,"teacher_disagreement_score":0.26505104,"about_ca_system_score_codex":0.0040229294,"about_ca_system_score_gemma":0.0013608013,"threshold_uncertainty_score":0.99980044},"labels":[],"label_agreement":null},{"id":"W4220880091","doi":"10.3390/curroncol29030160","title":"Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Pfizer Canada; Alberta Health Services; Pfizer","keywords":"Crizotinib; Medicine; ROS1; Oncology; Internal medicine; Cohort; Population; Retrospective cohort study; Pemetrexed; Anaplastic lymphoma kinase; Cancer; Lung cancer; Chemotherapy; Adenocarcinoma","score_opus":0.039168495117260616,"score_gpt":0.4042964550949553,"score_spread":0.3651279599776947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220880091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8711703,0.00071827765,0.000005368963,0.002079734,0.0008608709,0.0015379412,0.00026244164,0.000053001495,0.123312056],"genre_scores_gemma":[0.99491185,0.00022520023,0.00014894149,0.00013930399,0.000033560107,0.00037539232,0.0002108112,0.000016956572,0.0039379694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901426,0.00006637097,0.00022555522,0.00027378072,0.00017965292,0.0002403726],"domain_scores_gemma":[0.9994032,0.00003315455,0.00009616693,0.00020076892,0.000077566714,0.00018913882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012670289,0.00012501984,0.00039967848,0.0003207201,0.00017608452,0.000004707785,0.000058522393,0.000027193077,0.0004991294],"category_scores_gemma":[0.000015028262,0.00011051851,0.00006350132,0.0002997019,0.000078028286,0.000023562143,0.00006160141,0.00016948624,0.000005212532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075123666,0.00035294637,0.97881687,0.000037504382,0.0005338973,0.00008229739,0.0005799989,0.0000017499358,0.000015728652,0.002121464,0.004479191,0.012903209],"study_design_scores_gemma":[0.0024493823,0.00049484137,0.9026355,0.00001746833,0.0007296211,0.0000137907,0.00042657857,0.000017664057,0.000014017159,0.000108592045,0.09301194,0.00008059541],"about_ca_topic_score_codex":0.03436131,"about_ca_topic_score_gemma":0.046060074,"teacher_disagreement_score":0.12374156,"about_ca_system_score_codex":0.0016698359,"about_ca_system_score_gemma":0.00032349044,"threshold_uncertainty_score":0.97206897},"labels":[],"label_agreement":null},{"id":"W4220881379","doi":"10.1016/j.cllc.2022.03.002","title":"Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cilag; National Cancer Institute; Chugai Pharmaceutical; EMD Serono; Samsung; Genentech; Ipsen; Ono Pharmaceutical; Servier; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Yuhan; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Vomiting; Hypoalbuminemia; Internal medicine; Pleural effusion; Adverse effect; Discontinuation; Gastroenterology; Tolerability; Creatinine; Diarrhea","score_opus":0.027452091176557177,"score_gpt":0.41042706575234256,"score_spread":0.3829749745757854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220881379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813508,0.000976427,0.00080519967,0.0061239316,0.00092021085,0.0048630866,0.00069811643,0.000039199393,0.004223061],"genre_scores_gemma":[0.9920257,0.0002078171,0.0048242435,0.0008745496,0.000048708687,0.00085965724,0.0002509112,0.00001916553,0.00088930107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990591,0.00004275812,0.0004040885,0.00023148581,0.00013633631,0.00012626301],"domain_scores_gemma":[0.9994341,0.0001655031,0.00013461141,0.00014728328,0.000059975908,0.00005849179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024223271,0.00007460484,0.00024446854,0.000071046656,0.00008351249,0.000004030132,0.000041429423,0.000023262653,0.00019486278],"category_scores_gemma":[0.00002860894,0.00006256237,0.000052638363,0.0001623872,0.000038043054,0.000038542486,0.000056852692,0.00011314967,2.1114641e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013763596,0.0006844447,0.8613342,0.0001316188,0.0005433395,0.0000028265245,0.0002699771,0.00008500643,6.936784e-7,0.00061083236,0.0042434926,0.13071719],"study_design_scores_gemma":[0.014097735,0.0009836667,0.9413054,0.00024157108,0.0007142881,4.800605e-7,0.00028978576,0.00012435726,0.0000027480103,0.00006903679,0.042074498,0.0000964125],"about_ca_topic_score_codex":0.00003948902,"about_ca_topic_score_gemma":0.000040212904,"teacher_disagreement_score":0.13062078,"about_ca_system_score_codex":0.00019967319,"about_ca_system_score_gemma":0.00008468877,"threshold_uncertainty_score":0.25512195},"labels":[],"label_agreement":null},{"id":"W4220928355","doi":"10.1080/13696998.2022.2053403","title":"Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; KRAS; Internal medicine; Oncology; Personalized medicine; Polymerase chain reaction; Genetic testing; Cancer; Bioinformatics; Gene; Genetics; Colorectal cancer","score_opus":0.057040984885594635,"score_gpt":0.2991262615221178,"score_spread":0.24208527663652316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220928355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963695,0.00012268325,0.002164352,0.00021277624,0.0003163497,0.000597553,0.00009400896,0.0000068698687,0.00011591525],"genre_scores_gemma":[0.9957918,0.000012558356,0.003640558,0.000074706826,0.00019444313,0.00009515857,0.00013655634,0.000026826227,0.000027420709],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99882567,0.0000429135,0.0005501324,0.00014358084,0.0002636249,0.00017405026],"domain_scores_gemma":[0.99806535,0.00040484997,0.0009597606,0.000078225064,0.00032955056,0.0001622504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039883025,0.00012854669,0.00032550664,0.00012817369,0.0002310082,0.000043751075,0.0000675548,0.000036660414,0.000034961977],"category_scores_gemma":[0.00025978516,0.00010269411,0.00005628593,0.0001468179,0.000044262593,0.00027773035,0.000018039467,0.00025575625,7.687098e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025694736,0.0018434988,0.2801888,0.00042796016,0.004137951,0.00012140826,0.005260507,0.66172105,0.017064253,0.00012431697,0.00028795705,0.02625283],"study_design_scores_gemma":[0.038953066,0.009616062,0.08762837,0.00085675536,0.0038226936,0.0001269581,0.007948472,0.8490065,0.001542113,0.000019403153,0.000033901197,0.00044575025],"about_ca_topic_score_codex":0.0005310583,"about_ca_topic_score_gemma":0.00049191,"teacher_disagreement_score":0.19256043,"about_ca_system_score_codex":0.0013544831,"about_ca_system_score_gemma":0.0030489534,"threshold_uncertainty_score":0.54087126},"labels":[],"label_agreement":null},{"id":"W4220990951","doi":"10.1186/s12885-022-09342-5","title":"Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis","year":2022,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; Bristol-Myers Squibb (Canada); University of Calgary","funders":"Bristol-Myers Squibb","keywords":"Medicine; Reimbursement; Lung cancer; Surgical oncology; Population; Internal medicine; Oncology; Health care; Environmental health","score_opus":0.017964004879269368,"score_gpt":0.34392843500270304,"score_spread":0.3259644301234337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220990951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555725,0.0005468032,0.0000132535715,0.00091884093,0.00020233908,0.0005293964,0.00091664586,0.000018808068,0.0012966398],"genre_scores_gemma":[0.9911929,0.00015635445,0.0001388295,0.00026076587,0.000034744426,0.0019123127,0.0006345422,0.000027553095,0.0056420323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986889,0.00005885495,0.00029996084,0.00041215794,0.00018661849,0.00035350298],"domain_scores_gemma":[0.99937266,0.00006107566,0.00009308713,0.00024571182,0.000025018497,0.00020242305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006938622,0.00020949056,0.00052917504,0.0014517175,0.00012322323,0.00001575964,0.0000552003,0.00003189811,0.0011763449],"category_scores_gemma":[0.0000027289016,0.00018892605,0.00013899627,0.0013961636,0.00000936545,0.000042560485,0.000016094105,0.00010762542,3.6931894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007628219,0.00016396571,0.9506789,0.000034762772,0.0002630517,0.000041636788,0.0006719336,0.041510046,0.0000043274363,0.000006080553,0.000027160197,0.006521845],"study_design_scores_gemma":[0.004843181,0.000091005495,0.9856381,0.00003332644,0.0010994425,2.5854527e-7,0.0002907247,0.007314334,0.000015408472,0.0000017568851,0.0004962707,0.00017620742],"about_ca_topic_score_codex":0.9734597,"about_ca_topic_score_gemma":0.99836725,"teacher_disagreement_score":0.034959175,"about_ca_system_score_codex":0.0059192297,"about_ca_system_score_gemma":0.0010828172,"threshold_uncertainty_score":0.9997367},"labels":[],"label_agreement":null},{"id":"W4221033081","doi":"10.1038/s41571-022-00624-2","title":"Should the control arms of randomized trials have an expiry date?","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Randomized controlled trial; Chemotherapy; Clinical trial; Clinical equipoise; Lung cancer; MEDLINE; Intensive care medicine; Oncology; Surgery; Internal medicine","score_opus":0.46518099347242153,"score_gpt":0.64827772807525,"score_spread":0.18309673460282844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221033081","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.4583599e-7,0.97250855,0.000047157686,0.0026603458,0.0026673512,0.01629565,0.00023074482,0.00003044872,0.00555943],"genre_scores_gemma":[0.000005622357,0.98494875,0.0008156714,0.0060456116,0.0019319672,0.004354937,0.0009476562,0.000068380454,0.0008813692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9630847,0.027024856,0.008245968,0.0008160345,0.00048412816,0.00034429488],"domain_scores_gemma":[0.9404246,0.050017513,0.007372969,0.0016520338,0.00019799403,0.0003348602],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.03904313,0.0006178999,0.02929894,0.00015737345,0.000110922294,0.000013713596,0.00060058886,0.0021553405,0.0021883703],"category_scores_gemma":[0.045890488,0.00025592474,0.008436251,0.00032844846,0.00050839956,0.000049464197,0.00011316421,0.0045852917,0.000047262096],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048145205,0.000892039,0.000004480227,0.004338932,0.0038623067,0.000052014828,0.000053672644,9.110279e-8,2.7651481e-8,0.00047859864,0.010999156,0.9745042],"study_design_scores_gemma":[0.07230501,0.0011508209,0.0000020876619,0.003199987,0.061660096,0.00008252248,0.000024062765,0.0000023132213,3.0138647e-8,0.00007467686,0.8613202,0.00017818004],"about_ca_topic_score_codex":0.000018186065,"about_ca_topic_score_gemma":0.000018511015,"teacher_disagreement_score":0.97432595,"about_ca_system_score_codex":0.0002879062,"about_ca_system_score_gemma":0.0028356009,"threshold_uncertainty_score":0.9999893},"labels":[],"label_agreement":null},{"id":"W4221042784","doi":"10.6004/jnccn.2021.7278","title":"HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy","year":2022,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Osimertinib; Medicine; Discontinuation; Lung cancer; Chemotherapy; Oncology; Internal medicine; Intensive care medicine; Cancer; Adenocarcinoma","score_opus":0.0178787720146668,"score_gpt":0.3003399990160326,"score_spread":0.2824612270013658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221042784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361515,0.003053007,0.000054739627,0.0019558866,0.0002386191,0.0008922915,0.00017125513,0.000005500537,0.000013531309],"genre_scores_gemma":[0.9976725,0.0001610612,0.0002574133,0.0014652789,0.00016681351,0.00009189922,0.00006131333,0.000029199204,0.00009454493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985316,0.00012789562,0.00039967903,0.0001855055,0.0005824787,0.00017287956],"domain_scores_gemma":[0.99811625,0.00023828153,0.00075846125,0.000092603404,0.0006922041,0.000102181206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082491264,0.0001827907,0.0003657257,0.00008954914,0.00029025628,0.000029754832,0.000070185335,0.000035227942,0.000022213113],"category_scores_gemma":[0.00001124067,0.00011966005,0.00011620751,0.00023788495,0.000042102067,0.00010760052,0.000032958433,0.00019528974,2.2847118e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010211484,0.00019666458,0.9543753,0.00004801005,0.0006743208,0.0000052662576,0.0008458575,0.03963446,0.00009597665,0.0000021672752,0.0009479685,0.00215286],"study_design_scores_gemma":[0.011062439,0.00086033734,0.9821019,0.0007846203,0.00063371053,0.000005297772,0.0002685561,0.002867718,0.00026985136,0.0000062573563,0.0010136327,0.00012565855],"about_ca_topic_score_codex":0.00075438543,"about_ca_topic_score_gemma":0.0002933508,"teacher_disagreement_score":0.036766738,"about_ca_system_score_codex":0.0012721946,"about_ca_system_score_gemma":0.00046066786,"threshold_uncertainty_score":0.4879595},"labels":[],"label_agreement":null},{"id":"W4223430425","doi":"10.3390/curroncol29040215","title":"The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Vancouver Coastal Health Research Institute; Centre for Advancing Health Outcomes; Vancouver General Hospital; Vancouver Coastal Health","funders":"Vancouver Coastal Health Research Institute","keywords":"Medicine; Propensity score matching; Lung cancer; Stage (stratigraphy); Oncology; Internal medicine; Bioinformatics; Computational biology; Biology","score_opus":0.0789940274260995,"score_gpt":0.42211962173004935,"score_spread":0.34312559430394984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223430425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957271,0.0012532098,0.000082202925,0.0003507408,0.00052416965,0.00085396454,0.00015918729,0.000023037575,0.0010263566],"genre_scores_gemma":[0.9970246,0.00021035723,0.00030195157,0.00007304481,0.000052461288,0.0004605269,0.00031605962,0.00001521031,0.0015457826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876446,0.00018507737,0.0003163282,0.0002960446,0.00022045644,0.00021763751],"domain_scores_gemma":[0.99914974,0.00014591728,0.0002339224,0.00026020574,0.00009358671,0.00011660816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035173263,0.000119537064,0.00039812556,0.00009934032,0.00027749405,0.000017707336,0.00012465553,0.000055461365,0.00017160118],"category_scores_gemma":[0.000021109736,0.00008918988,0.00010900344,0.00034792663,0.00010069903,0.000042995183,0.00014814823,0.0002957402,0.0000011984562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033708445,0.004876847,0.8759675,0.0004413285,0.007491338,0.00039621632,0.013751548,0.00394708,0.0030826842,0.00017927095,0.00239847,0.08409686],"study_design_scores_gemma":[0.036231253,0.023354935,0.6336725,0.0000729525,0.034461245,0.000011563231,0.010751143,0.016872426,0.0028473127,0.00008220749,0.24071413,0.0009283461],"about_ca_topic_score_codex":0.0003191755,"about_ca_topic_score_gemma":0.00015533195,"teacher_disagreement_score":0.24229503,"about_ca_system_score_codex":0.0002630517,"about_ca_system_score_gemma":0.00066746556,"threshold_uncertainty_score":0.36370578},"labels":[],"label_agreement":null},{"id":"W4223537410","doi":"10.1093/neuonc/noac087","title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; F. Hoffmann-La Roche; Cancer Research Foundation","keywords":"ROS1; Medicine; Internal medicine; Oncology; Cancer; Adenocarcinoma","score_opus":0.009531803600998194,"score_gpt":0.2932586197177411,"score_spread":0.2837268161167429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223537410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861156,0.00029978057,0.00001906059,0.0029078883,0.00051408506,0.0018493019,0.00016475978,0.00014277057,0.007986779],"genre_scores_gemma":[0.99093795,0.00026435425,0.00083172315,0.0055378033,0.00021956458,0.00082155043,0.00028772771,0.00007102674,0.001028285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806094,0.00015787387,0.0004176745,0.0006010506,0.00029226215,0.00047018353],"domain_scores_gemma":[0.9990293,0.00021413865,0.00017809973,0.0003089318,0.00006281179,0.00020675668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012984002,0.00026544512,0.00052648666,0.0002121684,0.00038910488,0.000027630454,0.00011262386,0.000072441624,0.0003656389],"category_scores_gemma":[0.00007456028,0.00019749894,0.00005199666,0.0005293145,0.00011586646,0.00015287893,0.00014459029,0.0005433664,0.000008516683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018521685,0.0052442946,0.8448593,0.00022557734,0.0008644736,0.0067204195,0.024516955,0.000792407,0.03524299,0.0002119044,0.023683565,0.03911641],"study_design_scores_gemma":[0.066019535,0.029082421,0.61091673,0.00033120342,0.0020487425,0.023999505,0.0070267306,0.00044855397,0.0040828,0.000052575106,0.25459972,0.0013914516],"about_ca_topic_score_codex":0.0005082156,"about_ca_topic_score_gemma":0.0016545267,"teacher_disagreement_score":0.23394257,"about_ca_system_score_codex":0.0005760555,"about_ca_system_score_gemma":0.0013787049,"threshold_uncertainty_score":0.8053773},"labels":[],"label_agreement":null},{"id":"W4223965493","doi":"10.1200/edbk_351021","title":"Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer","year":2022,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Lung cancer; Cancer; Cancer survival; Radiation therapy; Global health; Quality (philosophy); Cause of death","score_opus":0.04305648339931472,"score_gpt":0.5496120036424352,"score_spread":0.5065555202431206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223965493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86148226,0.0015321763,0.00007135129,0.123936504,0.00049908075,0.0012962781,0.00020823469,0.0000148129775,0.0109593],"genre_scores_gemma":[0.9716597,0.0010740594,0.0054440037,0.018770551,0.00019234986,0.0017178756,0.00006407376,0.000009435381,0.0010679158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998051,0.00029201113,0.0008064694,0.00037926104,0.00020997503,0.0002612737],"domain_scores_gemma":[0.9979294,0.001236558,0.00033851774,0.00016742846,0.00008521611,0.00024285783],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087687577,0.00011277263,0.00059180375,0.00003483392,0.00010909761,0.000003795372,0.00012781576,0.000036228044,0.0027054287],"category_scores_gemma":[0.00038330685,0.00010409529,0.00022828371,0.00050605496,0.0002596515,0.00011113452,0.000106577325,0.00017373619,0.000001183528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018068937,0.001072492,0.8758059,0.000016234604,0.0001510782,0.0000013920077,0.0011564224,0.00051115593,0.000003444998,0.00033868125,0.004965103,0.115797386],"study_design_scores_gemma":[0.0020014218,0.00090280705,0.6877199,0.00001495532,0.00012412158,0.000001879487,0.0030532323,0.00017757645,0.0000030228846,0.00032008166,0.30560124,0.00007979351],"about_ca_topic_score_codex":0.003594369,"about_ca_topic_score_gemma":0.0008556665,"teacher_disagreement_score":0.30063614,"about_ca_system_score_codex":0.003942543,"about_ca_system_score_gemma":0.008676644,"threshold_uncertainty_score":0.99988115},"labels":[],"label_agreement":null},{"id":"W4224144883","doi":"10.21203/rs.3.rs-1523595/v1","title":"Efficacy and toxicity of combined inhibition of EGFR and VEGF in patients with advanced non-small-cell lung cancer harboring activating EGFR mutations: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Meta-analysis; Lung cancer; VEGF receptors; Toxicity; Oncology; Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cancer research; Internal medicine; Cancer","score_opus":0.07069963616731054,"score_gpt":0.43435065327598865,"score_spread":0.3636510171086781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224144883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025287246,0.9660798,0.0000077375225,0.00004716381,0.0000043553673,0.008293761,0.00022436601,0.000006837789,0.000048785252],"genre_scores_gemma":[0.05272606,0.94371307,0.00019959643,0.000012614484,0.0000036164813,0.0029583029,0.00029915437,0.00003406751,0.000053518637],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99737525,0.00051710726,0.0008264575,0.0004392205,0.0006127851,0.00022915695],"domain_scores_gemma":[0.99785906,0.00074035785,0.00060482905,0.00033841675,0.0003522267,0.00010510996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007303395,0.00026819392,0.0035136375,0.00071479956,0.0001200223,0.000020126417,0.00006026878,0.00006951256,0.000060836777],"category_scores_gemma":[0.00027025753,0.0001780447,0.00023992876,0.0017174084,0.00008564188,0.00010653606,0.0001089067,0.00036678198,1.1371982e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004328258,0.00036606527,0.001094314,0.9728571,0.021611512,0.0000070923033,0.0005470203,0.000008118352,0.000003363137,0.000006828509,0.0000019107201,0.003453363],"study_design_scores_gemma":[0.005147122,0.0013521872,0.0027210019,0.282464,0.70709383,0.0000032474522,0.0005745281,0.00005954903,0.000034226177,0.0000037417497,0.00019067584,0.0003558708],"about_ca_topic_score_codex":0.00020789244,"about_ca_topic_score_gemma":0.000047706082,"teacher_disagreement_score":0.69039315,"about_ca_system_score_codex":0.00037606308,"about_ca_system_score_gemma":0.00035820343,"threshold_uncertainty_score":0.72604525},"labels":[],"label_agreement":null},{"id":"W4224944657","doi":"10.7759/cureus.24513","title":"Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis","year":2022,"lang":"en","type":"article","venue":"Cureus","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Toxic epidermal necrolysis; Medicine; Osimertinib; Dermatology; Psoriasis; Epidermal growth factor receptor; Lung cancer; Internal medicine; Cancer; Erlotinib","score_opus":0.022438750213852467,"score_gpt":0.3209426453791461,"score_spread":0.29850389516529363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224944657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933231,0.0007156024,0.00015653194,0.002404358,0.00056369364,0.0004924596,0.00035792866,0.00007108103,0.0019152582],"genre_scores_gemma":[0.9961719,0.000026038226,0.0014281692,0.0009307012,0.00012281998,0.00021999454,0.00013147105,0.00003170892,0.00093721837],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99863714,0.000070332586,0.00033542834,0.000323043,0.00033710786,0.00029692336],"domain_scores_gemma":[0.99901736,0.0001174275,0.00012464041,0.0004011232,0.00007850037,0.00026095714],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012510168,0.00017564169,0.00043875846,0.000110369154,0.00024006507,0.000011644742,0.00013948859,0.000049172453,0.0014915346],"category_scores_gemma":[0.0001364977,0.000163587,0.00020022038,0.00044547833,0.000029778357,0.00007591354,0.00015003706,0.00015648399,0.000029585228],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061727718,0.01358982,0.16447319,0.0008454339,0.0613601,0.0065264576,0.07738803,0.019569553,0.057987828,0.0019747103,0.2897391,0.24481806],"study_design_scores_gemma":[0.123169735,0.03135114,0.45785916,0.00060727424,0.040069018,0.0034060306,0.026323033,0.0033993204,0.13306041,0.0008991639,0.17506441,0.0047913003],"about_ca_topic_score_codex":0.0004890694,"about_ca_topic_score_gemma":0.000092738104,"teacher_disagreement_score":0.29338595,"about_ca_system_score_codex":0.0003353617,"about_ca_system_score_gemma":0.00030204962,"threshold_uncertainty_score":0.99942124},"labels":[],"label_agreement":null},{"id":"W4225123144","doi":"10.1016/j.jtocrr.2022.100332","title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Janssen Pharmaceuticals; NIHR Leicester Clinical Research Facility; Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Merck Sharp and Dohme; EMD Serono; Genentech; Daiichi-Sankyo; National Institute for Health and Care Research; Exelixis; Kissei; Bristol-Myers Squibb; Society for Academic Continuing Medical Education; Comprehensive Cancer Center, City of Hope; Merck KGaA; Boehringer Ingelheim Japan; Taiho Pharmaceutical; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; Bayer; Gilead Sciences; Roche; Novartis; Kyowa Hakko Kirin; Sanofi; Manchester Biomedical Research Centre; Yuhan; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca; Ignyta; Ono Pharmaceutical; Eli Lilly and Company","keywords":"ROS1; Medicine; Term (time); Oncology; Internal medicine; Cancer; Adenocarcinoma; Physics","score_opus":0.07867063295629535,"score_gpt":0.49609754518857463,"score_spread":0.4174269122322793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225123144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992036,0.0010261765,0.000002655806,0.0019338084,0.0001382354,0.0007283598,0.000012163025,0.000009149564,0.0041134865],"genre_scores_gemma":[0.99663967,0.00084526796,0.00004839249,0.000074226205,0.00007360175,0.000047768917,0.00003354796,0.000008452903,0.0022290645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805117,0.00026141913,0.00057584856,0.00034657112,0.0005594965,0.0002055239],"domain_scores_gemma":[0.9985562,0.00078455516,0.00009812289,0.00020264661,0.00016421122,0.00019425835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021792825,0.00006949155,0.00029257868,0.00012337024,0.00019290356,0.000010426636,0.000028189936,0.00005200447,0.00023764512],"category_scores_gemma":[0.0008893579,0.000050164912,0.000056993817,0.0002494016,0.0002824579,0.000029896364,0.00023377984,0.00048521697,9.892992e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011665958,0.0011608002,0.9169242,0.000053857562,0.00010239604,0.0028073257,0.0005984996,0.0000018250262,0.0001403982,0.00005107087,0.00049449806,0.07649854],"study_design_scores_gemma":[0.002707997,0.0012019222,0.9925543,0.00012378024,0.00004730992,0.00034780713,0.00019747432,0.000009116972,0.00007668775,0.00015537196,0.002528021,0.0000502131],"about_ca_topic_score_codex":0.00025382199,"about_ca_topic_score_gemma":0.00006131611,"teacher_disagreement_score":0.07644833,"about_ca_system_score_codex":0.000070817776,"about_ca_system_score_gemma":0.0003262407,"threshold_uncertainty_score":0.26020473},"labels":[],"label_agreement":null},{"id":"W4225137529","doi":"10.7759/cureus.24605","title":"Pattern of Treatment Initiation and Outcomes for Patients With Metastatic Non-small Cell Lung Cancer in Ontario","year":2022,"lang":"en","type":"article","venue":"Cureus","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Windsor; Windsor Regional Hospital","funders":"","keywords":"Medicine; Docetaxel; Vinorelbine; Lung cancer; Gemcitabine; Hazard ratio; Chemotherapy; Internal medicine; Cancer; Oncology; Retrospective cohort study; Paclitaxel; Cisplatin; Confidence interval","score_opus":0.017803788174372264,"score_gpt":0.30275912831817114,"score_spread":0.28495534014379886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225137529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980489,0.00019793346,0.00012795065,0.00007958477,0.00006814838,0.0010708171,0.00017485827,0.000004010664,0.00022781767],"genre_scores_gemma":[0.99794394,0.000013861767,0.00040342822,0.00008588577,0.0000042219326,0.0007926545,0.00017162709,0.000010310511,0.000574051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999604,0.000008754295,0.000117067204,0.000113868446,0.000071589166,0.00008473537],"domain_scores_gemma":[0.9997587,0.0000310381,0.0000672582,0.000078498015,0.00003554152,0.00002896939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000018992976,0.00007602937,0.00016885586,0.00004104873,0.000039893705,0.0000031687737,0.000016511129,0.00000802633,0.00012779192],"category_scores_gemma":[0.0000017204758,0.00005318361,0.000025034546,0.000038793605,0.0000073377955,0.000030765343,0.000010464592,0.000030628467,1.1331097e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006844382,0.00053404854,0.99227506,0.000054460317,0.0001795921,0.0000025417455,0.0048948782,0.00012021652,0.000009781605,0.0000031034167,0.000027355416,0.001830507],"study_design_scores_gemma":[0.008387644,0.0015618143,0.98833925,0.00002486432,0.0006507535,5.1221497e-7,0.00035342263,0.0001704311,0.00005585506,0.000008947283,0.00038813555,0.00005838504],"about_ca_topic_score_codex":0.05123717,"about_ca_topic_score_gemma":0.12734884,"teacher_disagreement_score":0.076111674,"about_ca_system_score_codex":0.0008906445,"about_ca_system_score_gemma":0.00027160626,"threshold_uncertainty_score":0.95508075},"labels":[],"label_agreement":null},{"id":"W4225940599","doi":"10.3389/fphar.2022.846455","title":"Association of Risperidone With Gastric Cancer: Triangulation Method From Cell Study, Animal Study, and Cohort Study","year":2022,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Chiayi Chang Gung Memorial Hospital; Chang Gung Medical Foundation","keywords":"Risperidone; Medicine; Cancer; Apoptosis; Antipsychotic; Internal medicine; Population; Cell growth; Hazard ratio; Oncology; Pharmacology; Confidence interval; Gastroenterology; Cancer research; Schizophrenia (object-oriented programming); Biology; Psychiatry; Biochemistry","score_opus":0.008536208711589999,"score_gpt":0.34430346771294124,"score_spread":0.33576725900135124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225940599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935044,0.00057845144,0.00039673306,0.00023401371,0.0007247782,0.0043428694,0.00008053353,0.000019843525,0.00011835051],"genre_scores_gemma":[0.99605036,0.00003644657,0.0019860796,0.00006917845,0.00008095734,0.0012741935,0.0000349491,0.000018888359,0.00044897504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819976,0.0006187079,0.00031165048,0.0003568065,0.0003404001,0.00017265145],"domain_scores_gemma":[0.9994174,0.00008946279,0.00025785624,0.000109994566,0.000070738075,0.000054525448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005435045,0.00013182536,0.0004959097,0.00025209942,0.00011813208,0.000005892812,0.0000628593,0.000028197746,0.00030175905],"category_scores_gemma":[0.0000097111615,0.000119225886,0.000025262043,0.00046048829,0.000016538786,0.00005542483,0.000062444306,0.00021461268,2.825316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023428984,0.006676302,0.97229093,0.0000075063895,0.0020446342,0.000080127014,0.007781062,0.0004925007,0.00079417386,1.1785968e-7,0.0049660006,0.0025237151],"study_design_scores_gemma":[0.025666693,0.0063187005,0.937624,0.0000020819114,0.0041695116,0.0000020731538,0.024699591,0.000994357,0.0001640156,0.000004797108,0.0002634183,0.00009076713],"about_ca_topic_score_codex":0.0032549638,"about_ca_topic_score_gemma":0.00028861995,"teacher_disagreement_score":0.03466697,"about_ca_system_score_codex":0.00089903304,"about_ca_system_score_gemma":0.00017007027,"threshold_uncertainty_score":0.49205533},"labels":[],"label_agreement":null},{"id":"W4226017594","doi":"10.1016/j.annonc.2022.02.060","title":"51P Testing patterns and outcomes of different EGFR-positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Lung cancer","score_opus":0.036912437573272026,"score_gpt":0.3848027496706976,"score_spread":0.3478903120974256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226017594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927566,0.00013154242,0.0000028642257,0.0016494078,0.00009652418,0.0005898999,0.0004099468,0.000004632393,0.0043585957],"genre_scores_gemma":[0.99826425,0.00006729413,0.00021325024,0.000982078,0.000011160283,0.00015445132,0.00008120761,0.000015103603,0.00021117902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897176,0.00008755969,0.00034189233,0.00018570879,0.00012167617,0.0002914188],"domain_scores_gemma":[0.99911016,0.00027417383,0.00023086938,0.00010295791,0.0001381311,0.00014370086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013480311,0.000118799166,0.00044478453,0.0002969185,0.00007552773,0.0000028403476,0.000053768945,0.000022779086,0.00006585424],"category_scores_gemma":[0.000046320536,0.00010237528,0.000046877605,0.00018855683,0.000030458521,0.000027613445,0.00005711546,0.00013258205,1.8618366e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003736693,0.00042082698,0.983049,0.0001419533,0.00020246426,0.000053025826,0.0035721306,0.00005538235,0.000086345484,0.000017167053,0.00016258888,0.012201784],"study_design_scores_gemma":[0.002155772,0.0010948586,0.99460554,0.00011437223,0.00027437514,0.0000020836812,0.0007422152,0.0003018054,0.000493642,0.000019507526,0.00011699207,0.0000788104],"about_ca_topic_score_codex":0.52417,"about_ca_topic_score_gemma":0.4870063,"teacher_disagreement_score":0.03716368,"about_ca_system_score_codex":0.00042132442,"about_ca_system_score_gemma":0.000753184,"threshold_uncertainty_score":0.5223545},"labels":[],"label_agreement":null},{"id":"W4226065666","doi":"10.1016/j.annonc.2022.02.137","title":"110P Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Trk receptor; Internal medicine; Oncology; Receptor tyrosine kinase; Cohort; Fusion gene; Neurotrophin; Receptor; Gene","score_opus":0.018757779530853686,"score_gpt":0.3576391259504282,"score_spread":0.3388813464195745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226065666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879387,0.0001954867,0.0000057304323,0.0023948892,0.00008271067,0.0006116507,0.00012609769,0.000008827826,0.008635927],"genre_scores_gemma":[0.9986056,0.00009272111,0.00014001824,0.00067722186,0.000013844823,0.000030840623,0.00023674875,0.0000100633,0.0001929263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912107,0.00010476878,0.00027426987,0.00018127477,0.0001602035,0.00015840383],"domain_scores_gemma":[0.9993222,0.000137916,0.00018150211,0.00012256338,0.00017169278,0.00006412886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012199958,0.000091325455,0.00035138332,0.00013161452,0.00006565401,0.0000013107349,0.00004400136,0.000042699852,0.00032882445],"category_scores_gemma":[0.000039501894,0.000072924675,0.00003144574,0.00024391564,0.00008633929,0.000033722703,0.00006345857,0.000119697695,0.0000016908028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02216787,0.0118745435,0.5575875,0.00008726447,0.0013681189,0.00020127256,0.013034152,0.00031975738,0.00067769655,0.0008005872,0.00867034,0.3832109],"study_design_scores_gemma":[0.020663321,0.017947454,0.93405634,0.00008637174,0.00024513196,0.000023941522,0.000981792,0.000022577582,0.0011226573,0.000057451056,0.02468078,0.00011215492],"about_ca_topic_score_codex":0.00036491943,"about_ca_topic_score_gemma":0.00006346384,"teacher_disagreement_score":0.38309872,"about_ca_system_score_codex":0.000092387825,"about_ca_system_score_gemma":0.00025697393,"threshold_uncertainty_score":0.3600397},"labels":[],"label_agreement":null},{"id":"W4226117846","doi":"10.1016/j.annonc.2022.02.029","title":"20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Janssen Biotech; Sanofi Genzyme; EMD Serono; Nordic Pharma Group; Ono Pharmaceutical; Eisai; Merck KGaA; Yuhan; Puma Biotechnology; Teva Pharmaceutical Industries; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Chemotherapy; non-small cell lung cancer (NSCLC); Population; Cancer","score_opus":0.028155893834601615,"score_gpt":0.3790767388232577,"score_spread":0.3509208449886561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226117846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305946,0.0009294778,0.000031866046,0.0022578558,0.00026378373,0.0011487696,0.00019189615,0.000016277945,0.0021006297],"genre_scores_gemma":[0.99437714,0.003916945,0.00066492544,0.00036722762,0.0000410023,0.00030520212,0.000108631466,0.000020490159,0.0001984326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863833,0.00016270461,0.00044567138,0.00029067378,0.0002168031,0.00024580923],"domain_scores_gemma":[0.9992163,0.00007805865,0.0003706575,0.00013995304,0.00011114903,0.00008384595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021059274,0.00015332682,0.0004089947,0.00022130711,0.00008669489,0.000003395915,0.000074036616,0.0000833974,0.00024164707],"category_scores_gemma":[0.000015474585,0.00013276766,0.00006547509,0.00024642274,0.000060079135,0.00005910879,0.0000830323,0.00022561954,0.0000019092895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010652184,0.007885979,0.44515324,0.0019716946,0.0011019598,0.00053978444,0.0074672163,0.00058597425,0.030202035,0.00016711852,0.008148106,0.48612472],"study_design_scores_gemma":[0.018527182,0.013565471,0.91947657,0.00078969967,0.0007134358,0.000022787783,0.0016044358,0.0013284131,0.03359044,0.0000997547,0.009931693,0.00035009312],"about_ca_topic_score_codex":0.0009420373,"about_ca_topic_score_gemma":0.00013415638,"teacher_disagreement_score":0.4857746,"about_ca_system_score_codex":0.00024431606,"about_ca_system_score_gemma":0.00021497587,"threshold_uncertainty_score":0.5414108},"labels":[],"label_agreement":null},{"id":"W4226204497","doi":"10.1016/j.annonc.2022.02.086","title":"77TiP TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Solid tumor; Lung cancer; Cancer; Phase (matter); ROS1; Oncology; Internal medicine; Adenocarcinoma; Cancer research","score_opus":0.04924792611935426,"score_gpt":0.48957806313134566,"score_spread":0.4403301370119914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226204497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888114,0.0010712675,0.0000075706575,0.004689052,0.0001861001,0.0015119824,0.00066870026,0.000013369702,0.0030405743],"genre_scores_gemma":[0.9958414,0.000036448815,0.00008379512,0.0023036562,0.00007130022,0.0009173844,0.000028486647,0.000012607815,0.0007049091],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99911743,0.000059862294,0.00025656616,0.00023675516,0.00011718571,0.00021216855],"domain_scores_gemma":[0.99953467,0.000067241985,0.00013255971,0.000102257334,0.00009149646,0.00007178141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018738997,0.000106595486,0.00038125794,0.000087031105,0.00023494271,0.0000027824556,0.000048784666,0.000036197336,0.00026008647],"category_scores_gemma":[0.0000398696,0.00009435523,0.000058154867,0.00020369212,0.00005354461,0.000032623095,0.00010378894,0.00008743535,2.4337555e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014132698,0.0457447,0.3949521,0.00017724553,0.002834345,0.00064005743,0.059599876,0.0003514046,0.0019477915,0.0009508615,0.03513089,0.44353804],"study_design_scores_gemma":[0.13142549,0.2987804,0.2309319,0.00029829488,0.0026037244,0.0003976107,0.04039191,0.0026181058,0.0030598359,0.0010609282,0.2875783,0.00085348747],"about_ca_topic_score_codex":0.0016080172,"about_ca_topic_score_gemma":0.00086949905,"teacher_disagreement_score":0.44268456,"about_ca_system_score_codex":0.0002431907,"about_ca_system_score_gemma":0.00043072205,"threshold_uncertainty_score":0.38476944},"labels":[],"label_agreement":null},{"id":"W4229004609","doi":"10.1002/cam4.4789","title":"Association of anticoagulant use with clinical outcomes from crizotinib in <i>ALK</i><scp><i>‐</i></scp> and <i>ROS1</i>‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of <scp>PROFILE</scp> 1001","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Cancer Center, University of Colorado; Pfizer","keywords":"Crizotinib; ROS1; Medicine; Internal medicine; Retrospective cohort study; Surrogate endpoint; Gastroenterology; Oncology; Hazard ratio; Lung cancer; Clinical trial; Anaplastic lymphoma kinase; Confidence interval; Cancer; Adenocarcinoma","score_opus":0.02218792812441873,"score_gpt":0.33105121927717596,"score_spread":0.30886329115275724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229004609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921605,0.002788644,0.00014461778,0.0005150024,0.00046348732,0.0012200222,0.0010851849,0.00003916,0.0015834023],"genre_scores_gemma":[0.99302334,0.0016494144,0.0008521397,0.0008864326,0.00015334618,0.0003569652,0.0005055528,0.000056446926,0.002516357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655724,0.0002055082,0.0011035698,0.0007512744,0.000912921,0.00046949193],"domain_scores_gemma":[0.99587226,0.0017127494,0.0011679793,0.0005226136,0.00046856323,0.00025584068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006627289,0.0003676308,0.002012963,0.0005355783,0.00012637874,0.000011681687,0.00016196318,0.00013761241,0.00014281213],"category_scores_gemma":[0.0009950133,0.00028482924,0.00023260074,0.0018338835,0.0002245959,0.00014718912,0.000089270885,0.00054513314,6.157612e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013417985,0.00038071963,0.9795911,0.00013648678,0.0042930976,0.000052115607,0.0076292846,0.00056106376,0.0028753565,0.000009123122,0.0039014018,0.00043612672],"study_design_scores_gemma":[0.014150227,0.0012439738,0.9620594,0.00036290695,0.011121436,0.0000022523284,0.0064886403,0.0010843154,0.0012844831,0.000011975319,0.0021094223,0.00008098804],"about_ca_topic_score_codex":0.013279604,"about_ca_topic_score_gemma":0.0047425954,"teacher_disagreement_score":0.017531667,"about_ca_system_score_codex":0.0013143832,"about_ca_system_score_gemma":0.00073106907,"threshold_uncertainty_score":0.99996036},"labels":[],"label_agreement":null},{"id":"W4229072463","doi":"10.3390/curroncol29050258","title":"Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Government of Nunavut","keywords":"Lung cancer; Medicine; STK11; Adenocarcinoma; Population; Cancer; Internal medicine; Carcinoma; Pathology; Oncology; Environmental health","score_opus":0.04163273580281722,"score_gpt":0.3868027041280066,"score_spread":0.34516996832518937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229072463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957667,0.0011268567,0.000002451227,0.0021053855,0.00043814816,0.00040888082,0.0000584776,0.0000015971484,0.00009152665],"genre_scores_gemma":[0.99955755,0.00006110919,0.0000024394583,0.00014568021,0.00002255266,0.00010628293,0.000052986245,0.0000028521038,0.000048536167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956787,0.00009169491,0.00012808906,0.00007023194,0.00007221165,0.00006992444],"domain_scores_gemma":[0.9997482,0.000017635142,0.00010106044,0.00008411804,0.000030126872,0.000018869685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007396586,0.000037289155,0.00010391912,0.000066771936,0.000059481077,0.000001098148,0.000047790814,0.000017682232,0.0000889272],"category_scores_gemma":[0.000013917441,0.000022986314,0.000017820836,0.00013951301,0.000031298,0.000014442442,0.000018751869,0.000087450586,1.16376555e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001769469,0.00007881339,0.96766573,0.000059050846,0.000015178359,0.0000012324352,0.004766239,0.00001631516,0.00022165313,0.00027775,0.000015955382,0.026864389],"study_design_scores_gemma":[0.0004474118,0.000091363916,0.99406135,0.000024124012,0.000119363816,0.000009372198,0.00016747146,0.00047605712,0.0000044726103,0.000052093343,0.0045270696,0.000019859353],"about_ca_topic_score_codex":0.034570955,"about_ca_topic_score_gemma":0.09368862,"teacher_disagreement_score":0.059117667,"about_ca_system_score_codex":0.00081900955,"about_ca_system_score_gemma":0.0004030593,"threshold_uncertainty_score":0.9718579},"labels":[],"label_agreement":null},{"id":"W4229454790","doi":"10.1159/000523734","title":"Complex Germline K757N Mutation in Non-Small-Cell Lung Cancer: A Case Report","year":2022,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Germline mutation; Lung cancer; Germline; Oncology; Epidermal growth factor receptor; Mutation; Cancer research; Targeted therapy; Pembrolizumab; Carboplatin; Cancer; Internal medicine; Genetics; Biology; Chemotherapy; Immunotherapy; Gene","score_opus":0.027352073911410327,"score_gpt":0.3966273898230287,"score_spread":0.3692753159116184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229454790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862616,0.0008479316,0.00008070844,0.0010921648,0.0007957781,0.0014058986,0.000028903709,0.000041218962,0.009445781],"genre_scores_gemma":[0.994603,0.000037659822,0.0009988295,0.0005575326,0.00012677784,0.0014936534,0.00031637194,0.00003241039,0.0018337803],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99792457,0.00010893217,0.00094790227,0.00052369235,0.000173657,0.0003212661],"domain_scores_gemma":[0.9987501,0.00010996032,0.00048642015,0.00041910083,0.00010298855,0.00013145294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005853299,0.00017164671,0.00048575125,0.00034709513,0.00017233737,0.0000075622233,0.000025501584,0.00009684639,0.000726942],"category_scores_gemma":[0.000087949054,0.00017450981,0.00008117576,0.0004891888,0.000052371113,0.00004847285,0.00008692821,0.00037978144,0.0000013504041],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007692842,0.0008233244,0.04369171,0.00009756264,0.000061715706,0.9415984,0.0024539023,0.0023835273,0.00021547335,0.000008074082,0.0015890683,0.0070003252],"study_design_scores_gemma":[0.0028116622,0.0004047003,0.0067643817,0.000029931429,0.00029620767,0.96700704,0.002247174,0.002860443,0.00006736772,0.000034819386,0.017322514,0.00015372901],"about_ca_topic_score_codex":0.010303944,"about_ca_topic_score_gemma":0.007917891,"teacher_disagreement_score":0.036927328,"about_ca_system_score_codex":0.0030361407,"about_ca_system_score_gemma":0.0016544556,"threshold_uncertainty_score":0.9962865},"labels":[],"label_agreement":null},{"id":"W4229872115","doi":"10.21037/tcr.2016.09.11","title":"Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Crizotinib; Refractory (planetary science); Medicine; Lung cancer; Oncology; Internal medicine; Cancer research; Biology","score_opus":0.10416723740596698,"score_gpt":0.47039317201515723,"score_spread":0.3662259346091903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229872115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89985204,0.02863456,0.00876463,0.034972716,0.0006430871,0.0049065226,0.0012692302,0.00013818829,0.020819012],"genre_scores_gemma":[0.9831876,0.0017295693,0.001178742,0.0001664165,0.00069488684,0.0025131512,0.00005686515,0.000058635153,0.0104141],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981843,0.000061308885,0.00024153695,0.00039276638,0.00061581505,0.00050425756],"domain_scores_gemma":[0.9984948,0.00051944517,0.000048153393,0.00021051892,0.00055233506,0.00017473637],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039661114,0.00016297502,0.0002321608,0.00022434666,0.00033186533,0.000031153028,0.00011662335,0.00009423466,0.0016031367],"category_scores_gemma":[0.000022603834,0.00010698386,0.0001345665,0.000246628,0.00012348346,0.000155636,0.000010655077,0.0001861455,0.00001585791],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047468673,0.00090022903,0.19201137,0.0015549674,0.0017636509,0.00002641296,0.015053691,0.000085838714,0.52600807,0.001773939,0.02271846,0.23335649],"study_design_scores_gemma":[0.055456303,0.0019948692,0.37162772,0.0037573143,0.0014897119,0.000013389444,0.0016912634,0.0007562244,0.14321598,0.0041209683,0.41445667,0.0014195732],"about_ca_topic_score_codex":0.0008400534,"about_ca_topic_score_gemma":0.0005256155,"teacher_disagreement_score":0.3917382,"about_ca_system_score_codex":0.00042223005,"about_ca_system_score_gemma":0.0012314788,"threshold_uncertainty_score":0.99930954},"labels":[],"label_agreement":null},{"id":"W4230041933","doi":"10.21037/tcr.2016.11.58","title":"Biomarker guided treatment of advanced non-small cell lung cancer: does feasibility translate to improvements in patient care?","year":2016,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Biomarker; Medicine; Lung cancer; Oncology; Intensive care medicine; Internal medicine; Biology","score_opus":0.06364324924948517,"score_gpt":0.4534651701348904,"score_spread":0.38982192088540524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230041933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860106,0.003751547,0.0001441981,0.0037392774,0.00016047827,0.003911297,0.00096302025,0.000019056079,0.0013004914],"genre_scores_gemma":[0.9950771,0.0009822954,0.00092283386,0.000050447696,0.000052095023,0.0020456235,0.000052892585,0.00003506517,0.0007816501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755365,0.00009034848,0.0005215078,0.0005742245,0.0007392732,0.00052101916],"domain_scores_gemma":[0.9986193,0.00013718967,0.00006433638,0.00034838793,0.00058497797,0.00024580615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017427444,0.00022272706,0.0003763547,0.00036238908,0.00009767056,0.000010518812,0.00010825341,0.000080964055,0.00054616225],"category_scores_gemma":[0.000009454464,0.00013094289,0.00014374414,0.0005535305,0.00009140559,0.00010777765,0.00001327071,0.000083688996,0.000006254801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025856448,0.0010665096,0.4178775,0.0004977437,0.00028069856,0.000025773179,0.012359709,0.00035042167,0.18436316,0.00002683108,0.00011604872,0.38044995],"study_design_scores_gemma":[0.029262714,0.0030424553,0.67891324,0.0011966438,0.0003194325,0.0000018862141,0.00090757955,0.0001827779,0.27896443,0.00027135867,0.006486338,0.0004511246],"about_ca_topic_score_codex":0.006699374,"about_ca_topic_score_gemma":0.006849103,"teacher_disagreement_score":0.37999883,"about_ca_system_score_codex":0.0016643091,"about_ca_system_score_gemma":0.0013874548,"threshold_uncertainty_score":0.9999151},"labels":[],"label_agreement":null},{"id":"W4230501139","doi":"10.1200/jco.2004.22.14_suppl.7018","title":"A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Neutropenia; Febrile neutropenia; Internal medicine; Lung cancer; Regimen; Nausea; Vinorelbine; Surgery; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.05815052593919202,"score_gpt":0.4588959697301544,"score_spread":0.4007454437909624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230501139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334645,0.0010795044,0.00016985288,0.0018215048,0.00047349298,0.0013125096,0.00002075429,0.0000047123767,0.0017712327],"genre_scores_gemma":[0.99603724,0.001005863,0.0017747232,0.00026202743,0.0003703144,0.00003640759,0.0000045066004,0.000016031447,0.00049286307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972136,0.00020277356,0.0019529598,0.00022598935,0.00020854,0.00019612155],"domain_scores_gemma":[0.99684024,0.0011007008,0.0013616821,0.00011911233,0.00033584403,0.00024244706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012106617,0.00015752162,0.0016166356,0.00017866214,0.000045230114,0.0000072728703,0.00007465685,0.0002301119,0.00010129344],"category_scores_gemma":[0.0010626479,0.000107447944,0.00020513611,0.00014757446,0.00020519282,0.00008270228,0.00006309081,0.00062323327,5.100889e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88753074,0.008023661,0.06471552,0.00025714317,0.0011726052,0.0007856088,0.0034993626,0.000108480504,0.0032815584,0.000099672354,0.00050104095,0.030024601],"study_design_scores_gemma":[0.7518973,0.042219553,0.20217645,0.00053334696,0.000964164,0.000055130724,0.00024889444,0.0002884321,0.00038969063,0.0001802914,0.0009357546,0.000110999434],"about_ca_topic_score_codex":0.00044603398,"about_ca_topic_score_gemma":0.0011552607,"teacher_disagreement_score":0.13746093,"about_ca_system_score_codex":0.00035003686,"about_ca_system_score_gemma":0.0016837567,"threshold_uncertainty_score":0.43816},"labels":[],"label_agreement":null},{"id":"W4230554543","doi":"10.1200/jco.2004.22.14_suppl.7022","title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Erlotinib Hydrochloride; Regimen; Chemotherapy; Oncology; Chemotherapy regimen; Pemetrexed; Progression-free survival; Carboplatin; Placebo; Randomized controlled trial; Gastroenterology; Epidermal growth factor receptor; Cancer; Cisplatin; Pathology","score_opus":0.0520902160985434,"score_gpt":0.4512543726723138,"score_spread":0.39916415657377036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230554543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838412,0.00062289083,0.00038221007,0.0030237855,0.002516264,0.009243582,0.00015756475,0.000008217088,0.00020429921],"genre_scores_gemma":[0.98917866,0.0007391328,0.005961256,0.0008584893,0.0023913484,0.00052405015,0.000048729453,0.000057456837,0.000240867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98441225,0.0018985777,0.011313321,0.00050311023,0.0013955138,0.00047724225],"domain_scores_gemma":[0.9779771,0.010378094,0.009172579,0.0003022794,0.0016901628,0.0004797676],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013263103,0.00047327485,0.00976462,0.00037981503,0.000064212196,0.000009384715,0.00033355007,0.00067011465,0.00020640588],"category_scores_gemma":[0.01694616,0.00028304636,0.002164645,0.0005172906,0.00035768843,0.00023383838,0.000043651595,0.0011681177,2.8714894e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94185287,0.009386052,0.0054785777,0.00015338098,0.0059142946,0.00009509577,0.0005438735,0.02916705,0.00001501774,0.000015084484,0.00039538692,0.0069832886],"study_design_scores_gemma":[0.9635171,0.025429364,0.0013542911,0.0012232303,0.0049834717,0.000005418561,0.00014106379,0.0016688167,0.000046356283,0.000046523783,0.001354061,0.00023030085],"about_ca_topic_score_codex":0.0104246745,"about_ca_topic_score_gemma":0.044781245,"teacher_disagreement_score":0.04032827,"about_ca_system_score_codex":0.0011164735,"about_ca_system_score_gemma":0.041444745,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W4230807663","doi":"10.1503/cmaj.1041761","title":"Correction","year":2005,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Data science; World Wide Web; Information retrieval","score_opus":0.005473973358779392,"score_gpt":0.28176049984416063,"score_spread":0.2762865264853812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230807663","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20102356,0.00089603866,0.00054980104,0.4370331,0.008097663,0.0003375539,0.000019587009,0.00009469325,0.351948],"genre_scores_gemma":[0.94511086,0.00012234878,0.00033024387,0.026277063,0.00450473,0.0000062432177,0.000015635655,0.000012261766,0.02362063],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989148,0.000025840627,0.00017475199,0.000067205176,0.0005990091,0.00021841298],"domain_scores_gemma":[0.99845415,0.000039693095,0.000066671484,0.00004490705,0.00022566438,0.0011688996],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003087082,0.00005201099,0.000095577125,0.000108297936,0.00017427099,0.000032496377,0.000035211644,0.00014854551,0.007341954],"category_scores_gemma":[0.00054680434,0.000043775715,0.000060254442,0.00011775993,0.000009281962,0.00008379764,0.0000021024387,0.00039789174,0.0004957009],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000040092923,0.000031399308,0.050583985,0.0000012322871,0.00011631644,0.000115898816,0.00018215079,0.0000061400383,0.00000426601,0.00007217173,0.69196784,0.2569146],"study_design_scores_gemma":[0.0008942791,0.00004342187,0.058472633,0.000033790904,0.000061815175,0.0009182045,0.000120251665,0.00048173132,0.000018246465,0.000017338258,0.9388934,0.000044885448],"about_ca_topic_score_codex":0.0011923093,"about_ca_topic_score_gemma":0.021941466,"teacher_disagreement_score":0.7440873,"about_ca_system_score_codex":0.0022109093,"about_ca_system_score_gemma":0.003138474,"threshold_uncertainty_score":0.9959056},"labels":[],"label_agreement":null},{"id":"W4231355252","doi":"10.4212/cjhp.v71i2.1916","title":"Vinorelbine in advanced non-small-cell lung cancer: Has a survival benefit been achieved in clinical practice?","year":2018,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; London Health Sciences Centre","funders":"","keywords":"Vinorelbine; Medicine; Cisplatin; Oncology; Internal medicine; Lung cancer; Gynecology; Population; Regimen; Chemotherapy","score_opus":0.028784378919448666,"score_gpt":0.38706058870283594,"score_spread":0.35827620978338726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231355252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641921,0.0027165345,0.000011230581,0.027726226,0.001593602,0.0005912276,0.000028806438,0.0000045411502,0.0031357226],"genre_scores_gemma":[0.9964872,0.0004263763,0.0005182057,0.0012868362,0.0008731205,0.000018921502,0.0000066432167,0.000030820618,0.00035189057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998341,0.00008332943,0.000737058,0.00018603963,0.00022871455,0.00042384936],"domain_scores_gemma":[0.99824935,0.00017496296,0.0003789254,0.00020220006,0.00040240708,0.0005921819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007089047,0.00017645983,0.0004017318,0.00022577842,0.00016555595,0.000057595124,0.00025557983,0.000052474657,0.00018052234],"category_scores_gemma":[0.00021102147,0.00012723864,0.00013811245,0.00036571722,0.00019079483,0.00029347165,0.000020342117,0.0006509339,0.0000132252635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007239051,0.0005116713,0.96919245,0.000035815432,0.00039270037,0.001348784,0.005391916,0.00016259709,0.00011017473,0.00005484174,0.0029512427,0.019123934],"study_design_scores_gemma":[0.023736509,0.0024266962,0.9268503,0.0005529699,0.0010729512,0.00013830968,0.0013428113,0.00065373123,0.0005046865,0.00014589504,0.04222118,0.00035392935],"about_ca_topic_score_codex":0.072673626,"about_ca_topic_score_gemma":0.25234696,"teacher_disagreement_score":0.17967333,"about_ca_system_score_codex":0.00079995143,"about_ca_system_score_gemma":0.0043088333,"threshold_uncertainty_score":0.93350154},"labels":[],"label_agreement":null},{"id":"W4231610593","doi":"10.1385/1-59259-099-3:255","title":"The Laval University Screening Trial Results","year":2003,"lang":"en","type":"book-chapter","venue":"Humana Press eBooks","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychology","score_opus":0.07604962079116605,"score_gpt":0.30785272034442146,"score_spread":0.2318030995532554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231610593","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018242847,0.001998451,0.000026776828,0.00012629347,0.00033925992,0.0009984483,0.00010237069,0.00006537353,0.9963248],"genre_scores_gemma":[0.00047802625,0.0006133634,0.000121817066,0.00011702471,0.000378682,0.000006392547,0.00008786398,0.000040781095,0.9981561],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900657,0.000025142746,0.0002191381,0.0003010059,0.00026093223,0.00018720138],"domain_scores_gemma":[0.9990599,0.00008695626,0.00017896654,0.00048285667,0.000091534945,0.00009978234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001085568,0.0002161183,0.00026596233,0.00005415124,0.00042564806,0.000036901267,0.00012095424,0.00017155883,0.000026971755],"category_scores_gemma":[0.000015298769,0.00015710149,0.00018966071,0.0000033562453,0.00014450938,0.000018986395,0.00004847797,0.00029451976,0.000010240529],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03678639,0.000056696448,4.907081e-7,0.00007529026,0.0027712942,0.0006457596,0.0010206971,0.0000051048087,0.0000024304516,0.66809857,0.14488773,0.14564957],"study_design_scores_gemma":[0.026413238,0.00025988184,0.000005433987,0.0001463729,0.0010332484,0.000008161471,0.000023228524,0.000002671551,0.000014684107,0.00052192924,0.97142893,0.0001421989],"about_ca_topic_score_codex":0.00024073842,"about_ca_topic_score_gemma":0.00015327348,"teacher_disagreement_score":0.82654124,"about_ca_system_score_codex":0.00011940808,"about_ca_system_score_gemma":0.00013029297,"threshold_uncertainty_score":0.6406413},"labels":[],"label_agreement":null},{"id":"W4231998161","doi":"10.3747/co.v16i5.516","title":"The 4th Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Juravinski Cancer Centre; Mount Sinai Hospital; Western University; Ottawa Hospital; Princess Margaret Cancer Centre; Markham Stouffville Hospital; McMaster University; London Health Sciences Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Cancer; General surgery; Esophageal cancer; Oncology; Internal medicine","score_opus":0.09507281889842001,"score_gpt":0.46228741097530135,"score_spread":0.36721459207688134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231998161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7752052,0.0064838803,0.000069661444,0.08075251,0.0043468173,0.0016558283,0.00016293104,0.00010741926,0.13121575],"genre_scores_gemma":[0.9541555,0.0010592157,0.000036287514,0.002433078,0.0004786406,0.00026018114,0.00007225534,0.000013158486,0.041491687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991096,0.000059566122,0.0001746919,0.00021475615,0.00016488807,0.00027649768],"domain_scores_gemma":[0.9992526,0.00014715982,0.000088518354,0.0002668917,0.00014244393,0.00010238092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011110736,0.00013657592,0.00019669443,0.00002664328,0.0003454491,0.000015756457,0.00011879728,0.00006200205,0.0008153532],"category_scores_gemma":[0.000032931475,0.00006900545,0.0000692407,0.00008149938,0.0001321144,0.00003104826,0.000026217293,0.0002722252,0.00014286788],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005541544,0.0007924827,0.01795213,0.000013941731,0.00019095614,0.000042371485,0.006370615,0.000009936084,0.000034988934,0.0044574626,0.3534046,0.6161763],"study_design_scores_gemma":[0.0007645981,0.00077901105,0.04054472,0.00005833679,0.00019541648,0.000023080478,0.00009912036,0.000009492254,0.000088881985,0.00040986398,0.9569519,0.000075550546],"about_ca_topic_score_codex":0.00015415813,"about_ca_topic_score_gemma":0.059033066,"teacher_disagreement_score":0.6161008,"about_ca_system_score_codex":0.00095664035,"about_ca_system_score_gemma":0.00091345276,"threshold_uncertainty_score":0.95813715},"labels":[],"label_agreement":null},{"id":"W4232272905","doi":"10.1016/s1525-7304(11)70331-x","title":"2003 Highlights From: 10th World Conference on Lung Cancer Vancouver, British Columbia, Canada August 10-14, 2003","year":2003,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Family medicine; Gerontology; Oncology","score_opus":0.031852679934469046,"score_gpt":0.3582101110860964,"score_spread":0.32635743115162735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232272905","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35075775,0.06270716,0.00020982715,0.007789948,0.070291534,0.009582571,0.008924157,0.0006968972,0.48904017],"genre_scores_gemma":[0.2801837,0.004791544,0.00060017215,0.010162374,0.0013725939,0.0010093359,0.00025345891,0.00013141635,0.7014954],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962981,0.00018436815,0.0009858427,0.0010642181,0.0007026329,0.0007648704],"domain_scores_gemma":[0.99674326,0.0002597517,0.0003396997,0.00067859906,0.0011946214,0.00078409485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020492118,0.00036234112,0.0009534248,0.00005267592,0.00032591267,0.00016802622,0.0002233426,0.00024962018,0.043882288],"category_scores_gemma":[0.00049445656,0.00042350838,0.00016291007,0.0009327419,0.00019673292,0.00014496705,0.000036905578,0.0005984125,0.000032685308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104857856,0.00030365828,0.19413324,0.00006381626,0.00079342356,0.00021702066,0.000024352337,0.00002215658,0.0000032157282,0.0001460357,0.79973596,0.0044522677],"study_design_scores_gemma":[0.0062685614,0.00018916964,0.101699755,0.0013551022,0.0017672342,0.000004860776,0.00003600048,0.00035692877,0.000056013054,0.00007726663,0.8875843,0.0006047601],"about_ca_topic_score_codex":0.9035236,"about_ca_topic_score_gemma":0.9968689,"teacher_disagreement_score":0.21245526,"about_ca_system_score_codex":0.0022060224,"about_ca_system_score_gemma":0.011345504,"threshold_uncertainty_score":0.99982166},"labels":[],"label_agreement":null},{"id":"W4232532436","doi":"10.1200/jco.2004.22.14_suppl.6606","title":"RECIST (Response Evaluation Criteria in Solid Tumors) applied to response in lymphoma","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Solid tumor; Lymphoma; Oncology; Internal medicine; Cancer research; Cancer; Medical physics; Chemotherapy; Progressive disease","score_opus":0.12350108275360973,"score_gpt":0.5644260150150573,"score_spread":0.4409249322614476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232532436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748105,0.00010218473,0.0001029309,0.022052754,0.0006031067,0.0004825267,0.0000027370181,0.000004942762,0.001838331],"genre_scores_gemma":[0.9915555,0.00003362766,0.004192064,0.0037471247,0.00029217903,0.000034670305,0.000002422995,0.000013108725,0.00012931772],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9962514,0.00094629364,0.0020424172,0.00018676401,0.0003704001,0.0002026943],"domain_scores_gemma":[0.9967722,0.0018906977,0.0005827458,0.0001685743,0.0003043023,0.00028147173],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011386333,0.000105692205,0.0009342863,0.00041109096,0.000021579935,0.000008251398,0.000096443066,0.00020694887,0.00013674676],"category_scores_gemma":[0.010380013,0.00008198259,0.00014969031,0.00031668617,0.00006304244,0.00007263018,0.000025281397,0.00029169474,0.000050276587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5614309,0.007950568,0.012407437,0.000019374273,0.00023197236,0.004098847,0.0034805536,0.002790783,0.009061804,0.00015578353,0.0015516724,0.39682034],"study_design_scores_gemma":[0.03641744,0.011879881,0.9371287,0.00021941231,0.0001802095,0.0002696153,0.00037339146,0.000053515658,0.00024429618,0.0011238449,0.012026477,0.00008321314],"about_ca_topic_score_codex":0.00004875791,"about_ca_topic_score_gemma":0.0001608542,"teacher_disagreement_score":0.92472124,"about_ca_system_score_codex":0.0018789276,"about_ca_system_score_gemma":0.0069298623,"threshold_uncertainty_score":0.9986999},"labels":[],"label_agreement":null},{"id":"W4233112648","doi":"10.1200/jco.2005.01.6592","title":"In Reply:","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.11725802081902201,"score_gpt":0.5767194063668202,"score_spread":0.45946138554779814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233112648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79998016,0.00068388577,0.000052523534,0.14573003,0.0010109749,0.000098642,6.105373e-7,0.000003981042,0.05243919],"genre_scores_gemma":[0.96657616,0.00036145054,0.0084639555,0.020422714,0.0018278382,0.0000013588995,4.221837e-7,0.0000050034146,0.0023410725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985707,0.00006941183,0.0011104158,0.00006009842,0.00010784974,0.00008153913],"domain_scores_gemma":[0.9987975,0.0004169573,0.00045639317,0.000074018506,0.00011556139,0.00013958054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095176086,0.000037375863,0.0005072665,0.000067627676,0.000007952449,0.0000016392402,0.000037984315,0.00009395792,0.00027910894],"category_scores_gemma":[0.0010454071,0.000024026682,0.00016601292,0.000063770865,0.0000401435,0.000082223436,0.0000078800595,0.00034504305,0.000040413834],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017566594,0.003731246,0.1564184,0.00000940035,0.00033850793,0.001555155,0.00030693618,0.000048055634,0.000055071807,0.00057225395,0.07451944,0.7606889],"study_design_scores_gemma":[0.0061524366,0.003198375,0.18540074,0.000024943593,0.00014667524,0.00029607132,0.000040614806,0.000023163391,0.000023125807,0.00026856092,0.80440456,0.000020761243],"about_ca_topic_score_codex":0.000011740969,"about_ca_topic_score_gemma":0.000034242596,"teacher_disagreement_score":0.7606681,"about_ca_system_score_codex":0.0001679504,"about_ca_system_score_gemma":0.0010976468,"threshold_uncertainty_score":0.3056047},"labels":[],"label_agreement":null},{"id":"W4233507620","doi":"10.1158/1538-7445.sabcs18-ct200","title":"Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Atezolizumab; Carboplatin; Paclitaxel; Oncology; Nab-paclitaxel; Internal medicine; Medicine; Progression-free survival; Overall survival; Chemotherapy; Cancer; Cisplatin; Nivolumab; Immunotherapy","score_opus":0.07989084445208605,"score_gpt":0.4983019247232041,"score_spread":0.41841108027111806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233507620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883571,0.000833655,0.000069101974,0.00038254494,0.0003159314,0.009292285,0.00026645028,0.000043051266,0.0004398268],"genre_scores_gemma":[0.997099,0.00089989795,0.0008974012,0.000086126514,0.00018785865,0.0003807453,0.00016460069,0.000047997564,0.00023639466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938676,0.001183839,0.0031291002,0.00084194157,0.0006533253,0.00032424723],"domain_scores_gemma":[0.98381084,0.013200131,0.0014087466,0.0010373712,0.00024856787,0.0002943423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058402247,0.00041197275,0.0052261865,0.00024632958,0.00007597361,0.000034770976,0.00018852524,0.00023664985,0.000656328],"category_scores_gemma":[0.006725348,0.00022049359,0.00057469646,0.00066947157,0.00020272755,0.00012653906,0.00006381577,0.00035555926,0.000008751256],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72698045,0.0090779085,0.21653365,0.000050829007,0.0074520744,0.000116072704,0.0019945095,0.00011989397,0.00015844492,0.0000047783,0.00001597186,0.037495423],"study_design_scores_gemma":[0.87037724,0.01273611,0.108667694,0.00039557167,0.005189129,0.000002627285,0.0014161873,0.0005975004,0.00010809718,0.0001239984,0.000097138814,0.00028872062],"about_ca_topic_score_codex":0.0024141944,"about_ca_topic_score_gemma":0.0022895688,"teacher_disagreement_score":0.14339678,"about_ca_system_score_codex":0.000086941014,"about_ca_system_score_gemma":0.00048572765,"threshold_uncertainty_score":0.8991468},"labels":[],"label_agreement":null},{"id":"W4233808134","doi":"10.13175/swjpcc125-15","title":"September 2015 Tucson pulmonary journal club: genomic classifier for lung cancer","year":2015,"lang":"en","type":"article","venue":"Southwest Journal of Pulmonary and Critical Care","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Club; Lung cancer; Medicine; Internal medicine; Anatomy","score_opus":0.03370004922601362,"score_gpt":0.38622327718880717,"score_spread":0.35252322796279356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233808134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8490047,0.12800914,0.0026471475,0.008523789,0.0027821523,0.0007145384,0.00043346465,0.00003170888,0.007853368],"genre_scores_gemma":[0.99518585,0.00022111338,0.0012204723,0.00046208422,0.0017951658,0.000023381035,0.000026807817,0.000039016024,0.0010261086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852294,0.000049695594,0.00050581415,0.00019485565,0.00037318587,0.00035349373],"domain_scores_gemma":[0.99752533,0.000119100565,0.00015063895,0.00012640102,0.0012377211,0.00084078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026218538,0.00021150384,0.0004301805,0.00013680037,0.00021601065,0.00008732032,0.00009566578,0.00014258703,0.00010877454],"category_scores_gemma":[0.0001129673,0.00015552163,0.00025524094,0.000093473376,0.00014677446,0.00039577697,0.000032299802,0.00043042822,0.0000037731077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008044541,0.0018225407,0.85987294,0.002681575,0.0019372726,0.011146628,0.014046911,0.00036503843,0.004199773,0.0027425059,0.045178853,0.047961403],"study_design_scores_gemma":[0.03308747,0.011142774,0.3596422,0.0057439758,0.027156806,0.107578,0.20378375,0.005068279,0.0008655325,0.016626569,0.2262625,0.0030421386],"about_ca_topic_score_codex":0.00001677609,"about_ca_topic_score_gemma":0.0000074249347,"teacher_disagreement_score":0.5002307,"about_ca_system_score_codex":0.0003641098,"about_ca_system_score_gemma":0.0008235029,"threshold_uncertainty_score":0.6341988},"labels":[],"label_agreement":null},{"id":"W4235085491","doi":"10.1007/s10654-016-0209-8","title":"Erratum to: Bridging the etiologic and prognostic outlooks in individualized assessment of absolute risk of an illness: application in lung cancer","year":2016,"lang":"en","type":"erratum","venue":"European Journal of Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal; Western University","funders":"","keywords":"Medicine; Lung cancer; Bridging (networking); Epidemiology; Intensive care medicine; Risk assessment; Public health; Pathology","score_opus":0.030036492709305966,"score_gpt":0.3954736821328203,"score_spread":0.36543718942351433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235085491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90456265,0.034280397,0.013941384,0.012212523,0.008642259,0.0039909123,0.0005152612,0.000026996948,0.021827593],"genre_scores_gemma":[0.9806077,0.011059776,0.0047761197,0.0006754546,0.0010955906,0.00008323609,0.00010862426,0.00006801202,0.0015255066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945704,0.0029972736,0.0016955759,0.00029862256,0.00015729287,0.00028087248],"domain_scores_gemma":[0.9959272,0.0009567929,0.0024575007,0.00031221748,0.00022083073,0.00012542393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060262773,0.0002247889,0.0012010959,0.00040927425,0.00004231701,0.0000039057495,0.00023802687,0.00012762465,0.0000156401],"category_scores_gemma":[0.0022269152,0.00012418554,0.00012084171,0.0001825526,0.00018644941,0.00005582578,0.00007817223,0.0008555867,5.951361e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003154214,0.0003215555,0.8838565,0.00047157315,0.0009425822,0.0001349796,0.0021030721,0.00071005913,0.00024683552,0.0002457136,0.061758798,0.04889293],"study_design_scores_gemma":[0.0021327848,0.00079047505,0.9800195,0.002016139,0.0006771706,0.000065338376,0.00016602624,0.00071871484,0.0000021143242,0.00026146625,0.013022261,0.00012798462],"about_ca_topic_score_codex":0.00031623212,"about_ca_topic_score_gemma":0.00022093397,"teacher_disagreement_score":0.09616305,"about_ca_system_score_codex":0.00020344091,"about_ca_system_score_gemma":0.00047644085,"threshold_uncertainty_score":0.50641394},"labels":[],"label_agreement":null},{"id":"W4235340419","doi":"10.1016/s0169-5002(04)00142-4","title":"Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial*1","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Docetaxel; Medicine; Gemcitabine; Internal medicine; Regimen; Toxicity; Oncology; Phases of clinical research; Chemotherapy; Performance status; Progressive disease; Gastroenterology; Surgery","score_opus":0.0281149032536593,"score_gpt":0.36894898323737196,"score_spread":0.3408340799837127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235340419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867392,0.004866891,0.0008708942,0.0018395733,0.00039742058,0.003833067,0.00033976167,0.00003528716,0.0010779058],"genre_scores_gemma":[0.991754,0.00018913294,0.0028620884,0.0010627998,0.00022611528,0.0011573595,0.00009356141,0.000048509235,0.0026064184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987917,0.000015732841,0.00028692244,0.00043972037,0.00014411025,0.0003217963],"domain_scores_gemma":[0.99924445,0.000072783376,0.00011814792,0.00024492134,0.00008445664,0.00023525987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008101343,0.00025589726,0.0004096607,0.000104090286,0.00020063852,0.00003924285,0.00004807723,0.000054300366,0.000058574846],"category_scores_gemma":[0.000024766065,0.00020043532,0.00009331036,0.00009264968,0.000054850752,0.00008767408,0.000033753546,0.00010325001,0.0000016596659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45166454,0.049333997,0.073222175,0.029159186,0.016949218,0.0018729824,0.11844413,0.0007147642,0.06509186,0.003930245,0.045339745,0.14427716],"study_design_scores_gemma":[0.935697,0.014296389,0.008936347,0.0013128427,0.010355301,0.00004816298,0.0008011236,0.0055086496,0.011027482,0.0001289756,0.011064996,0.0008226946],"about_ca_topic_score_codex":0.00030298452,"about_ca_topic_score_gemma":0.00013388667,"teacher_disagreement_score":0.48403248,"about_ca_system_score_codex":0.00027662283,"about_ca_system_score_gemma":0.0003010906,"threshold_uncertainty_score":0.8173515},"labels":[],"label_agreement":null},{"id":"W4235603960","doi":"10.3747/co.19.1150","title":"Corrigendum: A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada","year":2012,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; University of British Columbia; University of Calgary; McGill University; Dalhousie University; Royal Victoria Hospital; Ottawa Hospital; BC Cancer Agency; Montreal General Hospital","funders":"","keywords":"Medicine; Tyrosine kinase; Lung cancer; Protein-Tyrosine Kinases; Personalized medicine; Cancer research; Bioinformatics; Cancer treatment; Cell; Tyrosine-kinase inhibitor; Oncology; Cancer; Internal medicine; Genetics; Receptor; Biology","score_opus":0.0968447443319824,"score_gpt":0.3901399568925661,"score_spread":0.29329521256058366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235603960","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18664798,0.58691347,0.000952381,0.002771731,0.15173465,0.041431963,0.019418983,0.000063806896,0.010065047],"genre_scores_gemma":[0.32384622,0.15803866,0.004490683,0.00075083424,0.013263012,0.055836946,0.01971562,0.0008273223,0.42323068],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800986,0.000071355855,0.0006606275,0.0004757775,0.00024535434,0.0005370485],"domain_scores_gemma":[0.99832195,0.00021557556,0.00049295457,0.00045762365,0.0002570189,0.00025490564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000623117,0.00050566887,0.001372152,0.00023395948,0.000075030934,0.0000069241178,0.00012677979,0.0002531069,0.00008601217],"category_scores_gemma":[0.000020839936,0.00031529562,0.0003228501,0.00030502304,0.00009622723,0.00003401478,0.000026066558,0.00019297314,9.277961e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0018644078,0.017418697,0.0654837,0.0028842816,0.0028970456,0.00003405079,0.016031565,0.00023880189,0.00016602283,0.000054620614,0.67837423,0.21455258],"study_design_scores_gemma":[0.009642435,0.0023316834,0.0054142363,0.00045349193,0.005317109,0.000006473665,0.0007584855,0.0011316852,0.00033769608,7.144177e-7,0.9743529,0.00025311828],"about_ca_topic_score_codex":0.5982038,"about_ca_topic_score_gemma":0.5774114,"teacher_disagreement_score":0.4288748,"about_ca_system_score_codex":0.01152647,"about_ca_system_score_gemma":0.011463118,"threshold_uncertainty_score":0.9999299},"labels":[],"label_agreement":null},{"id":"W4235822416","doi":"10.1093/annonc/mdv050.13","title":"Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (PTS) with Nsclc Harbouring EGFR Mutations (MUT): Subgroup Analyses by Race in Lux-Lung 3 (LL3) and Lux-Lung 6 (LL6)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Pemetrexed; Subgroup analysis; Lung cancer; Gemcitabine; Oncology; Gastroenterology; Chemotherapy; Cancer; Cisplatin; Gefitinib; Epidermal growth factor receptor; Confidence interval","score_opus":0.04781763379140514,"score_gpt":0.4072023918874924,"score_spread":0.3593847580960873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235822416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909556,0.0009274429,0.00010464557,0.0030336173,0.000068675334,0.00074781524,0.0000404407,0.000024818908,0.0040969574],"genre_scores_gemma":[0.9976531,0.00021108589,0.0007939191,0.0006921987,0.00004057102,0.00009102006,0.00018336302,0.00003862967,0.00029608965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983398,0.000130748,0.00043695248,0.00038792388,0.00032073155,0.000383845],"domain_scores_gemma":[0.9988924,0.00015688858,0.00021933067,0.0002343461,0.00029109453,0.00020591234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028385155,0.00024468006,0.00068016123,0.00028603277,0.000051803334,0.000017450435,0.000086753025,0.000091606744,0.000051462976],"category_scores_gemma":[0.000070690745,0.00018912865,0.00004626889,0.0003956809,0.00016023478,0.00025035234,0.000027346221,0.00020115638,0.0000023436905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027469678,0.0019034863,0.98241806,0.000089463974,0.00054067274,0.00012639946,0.0031766912,0.00050643075,0.00022651778,0.00012289843,0.0028606409,0.0052817767],"study_design_scores_gemma":[0.03925905,0.0067869094,0.9436228,0.00040344082,0.0004107529,0.000032526368,0.0013567442,0.0008436416,0.0014639564,0.00009529288,0.005324101,0.00040077427],"about_ca_topic_score_codex":0.0018274649,"about_ca_topic_score_gemma":0.0014895512,"teacher_disagreement_score":0.038795244,"about_ca_system_score_codex":0.00027129275,"about_ca_system_score_gemma":0.0004905568,"threshold_uncertainty_score":0.7712442},"labels":[],"label_agreement":null},{"id":"W4235863592","doi":"10.1002/9780471420194.tnmc66","title":"Essential <scp>TNM</scp>","year":2017,"lang":"en","type":"other","venue":"TNM Online","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Stage (stratigraphy); Coding (social sciences); Computational biology; Computer science; Biology; Mathematics; Statistics","score_opus":0.015258695884284315,"score_gpt":0.3620206315303994,"score_spread":0.34676193564611507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235863592","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024273714,0.0025102247,0.000060940056,0.00046905188,0.0009006023,0.0005042018,0.0042284955,0.00025595888,0.9908278],"genre_scores_gemma":[0.0003200868,0.00056348025,0.0017850413,0.00030777507,0.00311816,0.000032748216,0.007304398,0.0003231218,0.9862452],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991271,0.00000995003,0.00012919721,0.00029516977,0.00021266585,0.0002259279],"domain_scores_gemma":[0.9989523,0.00002743238,0.0002012863,0.00063352933,0.000043230775,0.00014216677],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000021685084,0.0002394919,0.00040173324,0.00014579813,0.00006606858,0.000022740214,0.00012724889,0.00022821623,0.0049930913],"category_scores_gemma":[0.00009000617,0.00018825251,0.00012915184,0.000044315126,0.00007606534,0.00002140275,0.00004005242,0.00018453354,0.0005954767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003536139,0.00029376076,0.00016177015,0.00010633318,0.00047763737,0.00013412125,0.0000549387,1.1843031e-7,0.000034897286,0.000045010638,0.9919936,0.006694294],"study_design_scores_gemma":[0.0014740912,0.000090621885,0.0009082645,0.00058069004,0.00080944947,0.000026319198,0.00002231708,0.000008235617,0.000035696878,0.000023733075,0.9959607,0.000059888065],"about_ca_topic_score_codex":0.00044589708,"about_ca_topic_score_gemma":0.0006446276,"teacher_disagreement_score":0.006634406,"about_ca_system_score_codex":0.00006862158,"about_ca_system_score_gemma":0.00029643084,"threshold_uncertainty_score":0.9959165},"labels":[],"label_agreement":null},{"id":"W4235870197","doi":"10.31525/ct1-nct04151342","title":"CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)","year":2019,"lang":"en","type":"article","venue":"Case Medical Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Medicine; Internal medicine","score_opus":0.11556634772438161,"score_gpt":0.47804548271932634,"score_spread":0.3624791349949447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235870197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96137315,0.00010963705,0.000022236965,0.010286983,0.00011633666,0.0017341275,0.000084386375,0.00002868264,0.026244452],"genre_scores_gemma":[0.9867871,0.000024277455,0.00019164334,0.001144834,0.00014586674,0.0003774152,0.00027683988,0.000030039771,0.011022008],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695903,0.00018494944,0.00021730055,0.00039580767,0.0017020464,0.00054088706],"domain_scores_gemma":[0.99708474,0.0002867415,0.000023503322,0.00043777117,0.0005806731,0.0015866018],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006450775,0.00013128309,0.00022563871,0.00039298076,0.00030470078,0.00005411897,0.000121439,0.00006890524,0.0069827302],"category_scores_gemma":[0.00041717562,0.0000970256,0.000042727217,0.0009182103,0.00012972788,0.00009169635,0.000039603165,0.00054845365,0.00015008716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042610528,0.0009923305,0.8042673,0.00022317222,0.0011648063,0.12017399,0.0034274177,0.0001986263,0.00019207981,0.0076345736,0.043271717,0.01802789],"study_design_scores_gemma":[0.031470817,0.0089415945,0.44228944,0.0016036805,0.0010074988,0.0055211782,0.02174275,0.011022575,0.0006547366,0.00048625265,0.4740156,0.0012438943],"about_ca_topic_score_codex":0.5364563,"about_ca_topic_score_gemma":0.7574411,"teacher_disagreement_score":0.43074387,"about_ca_system_score_codex":0.0019370903,"about_ca_system_score_gemma":0.013401246,"threshold_uncertainty_score":0.99392503},"labels":[],"label_agreement":null},{"id":"W4236537717","doi":"10.1093/annonc/mdw594.004","title":"440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"","keywords":"Afatinib; Medicine; Gefitinib; Oncology; Internal medicine; Lung cancer; Epidermal growth factor receptor; Cancer","score_opus":0.05931508410021057,"score_gpt":0.40550290188048754,"score_spread":0.34618781778027696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236537717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704181,0.00018272168,0.00022308342,0.0081240535,0.00027964255,0.00075148564,0.0016701188,0.000030881885,0.018319942],"genre_scores_gemma":[0.99476784,0.0001376895,0.0009457841,0.001464191,0.00014547232,0.000051200073,0.0018815757,0.000031638512,0.0005746058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821264,0.00014517098,0.00046609732,0.0005020044,0.00032593452,0.00034816551],"domain_scores_gemma":[0.9980032,0.0005780326,0.00030468026,0.00056635845,0.00040118507,0.00014658501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020845259,0.00020761613,0.00056119886,0.00014102888,0.000052918986,0.000009321603,0.0002113324,0.00014561714,0.00045878705],"category_scores_gemma":[0.00020448757,0.00013660324,0.00005656163,0.0001565391,0.00014643259,0.00031775548,0.00010260901,0.00012416352,0.00005741062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007525804,0.0048226723,0.7965995,0.00008279847,0.001979916,0.0004259579,0.0029881906,0.000021472666,0.0006393078,0.0014382447,0.026746143,0.15672997],"study_design_scores_gemma":[0.020597529,0.0050641396,0.95856434,0.0004895781,0.000381434,0.000008352681,0.00022661418,0.00006378687,0.0008895876,0.00040285772,0.013065051,0.00024674897],"about_ca_topic_score_codex":0.0013970516,"about_ca_topic_score_gemma":0.00091633055,"teacher_disagreement_score":0.1619648,"about_ca_system_score_codex":0.00017512815,"about_ca_system_score_gemma":0.0005544433,"threshold_uncertainty_score":0.55705184},"labels":[],"label_agreement":null},{"id":"W4236843498","doi":"10.1007/s40278-017-30139-7","title":"Health Canada: no link with crizotinib and GI perforations","year":2017,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crizotinib; Link (geometry); Medicine; Internal medicine; Computer science; Computer network; Lung cancer","score_opus":0.016911865814209632,"score_gpt":0.32804441181726307,"score_spread":0.31113254600305346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236843498","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2606433,0.0008897714,0.00081117137,0.49060115,0.0011699223,0.0018579761,0.00027307903,0.00020004873,0.24355358],"genre_scores_gemma":[0.9778135,0.00013632346,0.0014794214,0.00056778546,0.00022323364,0.000043026233,0.000061402556,0.000014837716,0.019660465],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994572,0.000008041066,0.00011661174,0.00015628451,0.000119607714,0.00014225932],"domain_scores_gemma":[0.99922174,0.000021510063,0.00010550421,0.00035922296,0.00012065418,0.00017139326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039144274,0.00008259419,0.00014476579,0.00003553452,0.0010910108,0.000054341876,0.00003489169,0.000024355984,0.0000473354],"category_scores_gemma":[0.000046986115,0.00006214412,0.000016999022,0.00003591804,0.00006109029,0.00013097709,0.000010779737,0.000108304506,0.000016297692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045303264,0.0011687427,0.3831536,0.000789395,0.0022040135,0.00025419067,0.001993972,0.00008000279,0.0011337262,0.018028103,0.37188092,0.2188603],"study_design_scores_gemma":[0.0012286389,0.00037585746,0.47774166,0.000117171316,0.00015628645,0.00015502157,0.00022048071,0.00013248276,0.000034854187,0.000021382199,0.51972395,0.00009221164],"about_ca_topic_score_codex":0.46091002,"about_ca_topic_score_gemma":0.5217114,"teacher_disagreement_score":0.7171702,"about_ca_system_score_codex":0.0002535079,"about_ca_system_score_gemma":0.0019769745,"threshold_uncertainty_score":0.83912826},"labels":[],"label_agreement":null},{"id":"W4237065704","doi":"10.1016/s0167-8140(03)80459-0","title":"83 Patterns of practice and outcome for patients with stage III non-small cell lung cancer in British Columbia 1991–2000","year":2003,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stage (stratigraphy); Lung cancer; Outcome (game theory); Oncology; Medicine; Cancer; Internal medicine; Biology; Mathematics","score_opus":0.007947434066234906,"score_gpt":0.3241844371439781,"score_spread":0.3162370030777432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237065704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525577,0.0023878065,0.00035593536,0.00016630781,0.000087221735,0.0011056862,0.00013113066,0.0000056605422,0.00050449127],"genre_scores_gemma":[0.9904518,0.0020721622,0.0035246138,0.00095879374,0.000028041823,0.00017921677,0.000025658499,0.000021076405,0.0027386192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938524,0.000035361554,0.00018800366,0.0001825456,0.000055152104,0.00015370751],"domain_scores_gemma":[0.999552,0.00013060149,0.00011480068,0.00007470144,0.00006374271,0.00006416593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008474219,0.00007144885,0.0003029546,0.00003064946,0.000048065333,0.000016292304,0.000018613851,0.000074870775,0.00010440842],"category_scores_gemma":[0.000011433802,0.00007828546,0.000020140198,0.000053588657,0.00003590692,0.00006002562,0.0000030791796,0.000067441375,4.6556455e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024033006,0.00057293137,0.98365134,0.00016828958,0.0001422134,0.000024509274,0.0018020979,0.000007067209,0.00003865105,0.000006472118,0.0001269088,0.013219205],"study_design_scores_gemma":[0.02606381,0.0025540516,0.90041065,0.000096726166,0.00028407204,0.000025398487,0.00050635537,0.00006488832,0.000020949095,0.0000037817374,0.069847,0.0001223321],"about_ca_topic_score_codex":0.017244576,"about_ca_topic_score_gemma":0.05755202,"teacher_disagreement_score":0.08324069,"about_ca_system_score_codex":0.00032241663,"about_ca_system_score_gemma":0.00021727463,"threshold_uncertainty_score":0.98929965},"labels":[],"label_agreement":null},{"id":"W4237645952","doi":"10.1093/annonc/mdw594.010","title":"446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Squamous-cell carcinoma of the lung; Oncology; Internal medicine; Lung; Basal cell; Second line; First line; Epidermal growth factor receptor; Cancer","score_opus":0.020458390560395893,"score_gpt":0.3443730455752647,"score_spread":0.3239146550148688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237645952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996162,0.00025980017,0.00002522445,0.0011695937,0.000057403595,0.00075223565,0.00046932828,0.000003216608,0.0011012015],"genre_scores_gemma":[0.99920326,0.000012945609,0.00024282899,0.00020383539,0.000011015698,0.00004528949,0.00002916783,0.000011703155,0.00023992127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990619,0.00005447194,0.00040488126,0.0001839843,0.000119781515,0.00017500178],"domain_scores_gemma":[0.99872726,0.00028749456,0.00040497392,0.00021762608,0.0003076402,0.00005499421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015516671,0.000107856205,0.0005309334,0.00023635842,0.00002320431,0.0000011631379,0.0000696601,0.00005903171,0.00008580999],"category_scores_gemma":[0.00006987737,0.000057397552,0.00012042123,0.0003678068,0.00015314721,0.000042874177,0.000028713383,0.00003534143,1.4042057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001179618,0.0007390302,0.9925627,0.00022196907,0.0007022514,0.0000032359949,0.0006516471,0.000010490993,0.00073420774,0.000031183015,0.0007246279,0.002439007],"study_design_scores_gemma":[0.0077852537,0.0036568756,0.977794,0.000059871556,0.0015538903,0.0000015051398,0.00018458409,0.00019767953,0.008331121,0.000014461784,0.00035654535,0.000064231455],"about_ca_topic_score_codex":0.00017527443,"about_ca_topic_score_gemma":0.0005751175,"teacher_disagreement_score":0.014768751,"about_ca_system_score_codex":0.000046068293,"about_ca_system_score_gemma":0.00023016908,"threshold_uncertainty_score":0.23406042},"labels":[],"label_agreement":null},{"id":"W4238034612","doi":"10.1038/modpathol.2013.25","title":"Quality Assurance","year":2013,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"University of Texas MD Anderson Cancer Center","keywords":"Quality assurance; Medical physics; Pathology; Medicine; External quality assessment","score_opus":0.02600844852043886,"score_gpt":0.3603041481797382,"score_spread":0.33429569965929934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238034612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95238835,0.00033343353,0.009569641,0.0034924366,0.00012724154,0.00027951517,0.000007347157,0.00006714649,0.033734918],"genre_scores_gemma":[0.99104214,0.000013396963,0.0026457333,0.0013481728,0.000046848803,0.00010688128,0.000019454019,0.000008455259,0.004768933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951655,0.000028836983,0.000109214576,0.00015228387,0.00006205686,0.00013107591],"domain_scores_gemma":[0.9996292,0.000026901345,0.000028215032,0.00020202291,0.00005909538,0.00005453855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043646978,0.000058037836,0.00013780943,0.000023028477,0.00003411207,0.0000054090738,0.000026043563,0.000048192815,0.000337087],"category_scores_gemma":[0.000030429197,0.00004436725,0.000036984457,0.00003341741,0.00003538502,0.000043232612,0.000010618125,0.000054236476,0.00045428603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007427695,0.0008436965,0.5711809,0.00014292456,0.00026392494,0.00039712465,0.003874155,0.000058277074,0.0964441,0.0048658634,0.018402485,0.30345228],"study_design_scores_gemma":[0.0012174638,0.00011275821,0.9866444,0.000008974719,0.00004590038,0.00013605252,0.000039969793,0.00031544222,0.00052781746,0.007581232,0.003291607,0.00007841841],"about_ca_topic_score_codex":0.000095722986,"about_ca_topic_score_gemma":0.00001684777,"teacher_disagreement_score":0.41546348,"about_ca_system_score_codex":0.000034608187,"about_ca_system_score_gemma":0.000045517252,"threshold_uncertainty_score":0.58390796},"labels":[],"label_agreement":null},{"id":"W4238045933","doi":"10.1007/s40278-017-26087-3","title":"Canadian Product Monograph update for trametinib (Mekinist)","year":2017,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trametinib; Product (mathematics); Business; Computer science; Biology; Genetics; Mathematics","score_opus":0.02492478443148356,"score_gpt":0.3537753122937217,"score_spread":0.3288505278622382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238045933","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31730977,0.0015449929,0.001929155,0.29093605,0.0043319995,0.006923318,0.0013018904,0.0004869331,0.37523592],"genre_scores_gemma":[0.97611547,0.000087380366,0.0042660153,0.00026775608,0.00030282742,0.00027404173,0.00016616391,0.000025258178,0.018495074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993248,0.000005924727,0.00013671526,0.00022479554,0.000074692914,0.00023309558],"domain_scores_gemma":[0.99892354,0.000019399942,0.00008620659,0.0006152237,0.00011085748,0.00024478883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071399605,0.000098436554,0.00014291167,0.00014430936,0.0009129764,0.00008808958,0.00008564094,0.00004307656,0.00008546662],"category_scores_gemma":[0.00011384701,0.000086046326,0.0001138724,0.00006116838,0.000054158736,0.00013306993,0.0000061398196,0.00008149752,0.00007290849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042460026,0.0019143224,0.08935712,0.0004075705,0.0030293374,0.00014096063,0.001135855,0.00002043936,0.0041166395,0.02473899,0.34411636,0.5305978],"study_design_scores_gemma":[0.0010179452,0.00012809732,0.061708286,0.000033749224,0.00034673157,0.00004388188,0.00009279552,0.000033587512,0.0005221389,0.00039676836,0.93557906,0.00009694967],"about_ca_topic_score_codex":0.06715575,"about_ca_topic_score_gemma":0.044372834,"teacher_disagreement_score":0.6588057,"about_ca_system_score_codex":0.00021672496,"about_ca_system_score_gemma":0.00056448596,"threshold_uncertainty_score":0.9730649},"labels":[],"label_agreement":null},{"id":"W4238219016","doi":"10.1200/jco.2004.22.14_suppl.3104","title":"The BC Cancer Agency experience with gefitinib in advanced non-small cell lung cancer (NSCLC)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gefitinib; Cancer; Lung cancer; Oncology; Internal medicine; Cancer research; Epidermal growth factor receptor","score_opus":0.053792637891429566,"score_gpt":0.4935900234301468,"score_spread":0.4397973855387172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238219016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864854,0.00453986,0.00021891609,0.009076192,0.0011737437,0.00038080002,0.00000353441,0.000005777221,0.0059526362],"genre_scores_gemma":[0.9861612,0.0078853145,0.002481149,0.0018468321,0.00060355186,0.000107522916,7.7709495e-7,0.000017739412,0.0008959457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997953,0.00007802843,0.0012479752,0.00018794132,0.00024601995,0.0002870129],"domain_scores_gemma":[0.9977627,0.00055449083,0.0009432343,0.00017209939,0.00031737852,0.00025009437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005390274,0.00013468096,0.00070045097,0.000056746154,0.0000896185,0.000010390274,0.00016355001,0.00014923624,0.00009825763],"category_scores_gemma":[0.00022969849,0.000070003516,0.00018265645,0.00018896304,0.00017560727,0.00010949605,0.000023352974,0.0006410636,0.0000037175573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049515194,0.0023355873,0.68592703,0.00006736479,0.0005251642,0.0016255305,0.0061735883,0.0036426946,0.00046560337,0.0001312249,0.00075279275,0.29340187],"study_design_scores_gemma":[0.03234413,0.0074889227,0.904401,0.00087519124,0.00079784537,0.00013146142,0.0017218133,0.00007222527,0.00061981566,0.00019503575,0.05115122,0.00020134862],"about_ca_topic_score_codex":0.0006678367,"about_ca_topic_score_gemma":0.0023887255,"teacher_disagreement_score":0.29320052,"about_ca_system_score_codex":0.0005908823,"about_ca_system_score_gemma":0.0057338667,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W4238221601","doi":"10.1136/jclinpath-2016-204244","title":"<i>ROS1-1</i>","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; University of Toronto; University Health Network","funders":"","keywords":"ROS1; Crizotinib; Cancer research; Fusion gene; Carcinoma; Tyrosine-kinase inhibitor; Immunohistochemistry; Cabozantinib; Fluorescence in situ hybridization; Adenocarcinoma; Receptor tyrosine kinase; Tyrosine kinase; Biology; Lung cancer; Medicine; Pathology; Cancer; Internal medicine; Gene; Receptor; Genetics","score_opus":0.41083355717530234,"score_gpt":0.6463043094909801,"score_spread":0.2354707523156777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238221601","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012901423,0.98755306,0.00003324954,0.00035406582,0.003005959,0.00024358982,0.000018752604,0.000006035004,0.008772411],"genre_scores_gemma":[0.00001229625,0.9926666,0.0012549205,0.00035789915,0.0025629394,0.0000059445283,0.000015061111,0.000030095056,0.0030942457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968765,0.00027047042,0.0023193911,0.00018692405,0.0001834157,0.00016329305],"domain_scores_gemma":[0.994993,0.0006071445,0.0034275795,0.0004800443,0.00024241707,0.00024984556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012081217,0.00020071206,0.004042708,0.0001308059,0.00005727286,0.000015914608,0.00023595865,0.00054811296,0.00009507976],"category_scores_gemma":[0.001945508,0.000114468516,0.0020817027,0.000042922667,0.0001884043,0.000050871342,0.000044950826,0.0011042843,0.000116992334],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030175204,0.00024941633,0.0001803922,0.0014349549,0.00063506054,0.0039021813,0.0000075237,1.8166892e-8,2.1580712e-8,0.00003447189,0.007096522,0.9864293],"study_design_scores_gemma":[0.0013396962,0.001098017,0.00037779068,0.006273939,0.007843821,0.007833489,0.0000022137226,6.306107e-8,2.6303816e-8,0.00010690882,0.9750424,0.000081651946],"about_ca_topic_score_codex":7.9445607e-7,"about_ca_topic_score_gemma":8.459757e-7,"teacher_disagreement_score":0.9863476,"about_ca_system_score_codex":0.00005520666,"about_ca_system_score_gemma":0.0018662021,"threshold_uncertainty_score":0.47976273},"labels":[],"label_agreement":null},{"id":"W4238789784","doi":"10.1002/0471463736.tnmp23.pub2","title":"Lung Cancer","year":2006,"lang":"en","type":"other","venue":"TNM Online","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Lung cancer; Medicine; Pathognomonic; Cancer; Disease; Population; Lung; Oncology; Internal medicine; Pathology","score_opus":0.010763501657981933,"score_gpt":0.3788176360334937,"score_spread":0.36805413437551177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238789784","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005526109,0.011562515,0.00003076462,0.0011638488,0.0003795696,0.0004436597,0.007602731,0.00024488752,0.97851676],"genre_scores_gemma":[0.00008689832,0.0004603592,0.0014993299,0.0005404425,0.0017934066,0.000067528046,0.0073091746,0.00030071687,0.98794216],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945694,0.0000044162057,0.00010139765,0.00017923111,0.00012280268,0.00013521801],"domain_scores_gemma":[0.9996347,0.0000062621966,0.00007072963,0.00020657353,0.000022646947,0.000059117858],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000006695653,0.0001510379,0.00024531333,0.00010502994,0.000015445563,0.0000045488164,0.00003471668,0.00012639961,0.018015005],"category_scores_gemma":[0.0000038541043,0.00011482006,0.00006612289,0.000080965656,0.000021701104,0.000006780904,0.000010286301,0.000099942066,0.000055588873],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000559438,0.00017450053,0.0009868785,0.00012311799,0.0002862132,0.000038970225,0.000011935885,8.638075e-7,0.0000054987436,0.00002127936,0.992718,0.0056271893],"study_design_scores_gemma":[0.0008766073,0.000026182133,0.0018212107,0.0005434751,0.00075961335,0.000005432389,0.000003909137,0.000035608777,0.000004040369,0.0000042305073,0.9958135,0.000106202846],"about_ca_topic_score_codex":0.003206632,"about_ca_topic_score_gemma":0.0033685847,"teacher_disagreement_score":0.017959414,"about_ca_system_score_codex":0.00013252976,"about_ca_system_score_gemma":0.00022138178,"threshold_uncertainty_score":0.9828827},"labels":[],"label_agreement":null},{"id":"W4239732381","doi":"10.3410/f.718121821.793519491","title":"Faculty Opinions recommendation of Emerging landscape of oncogenic signatures across human cancers.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Computational biology; Biology; Geography","score_opus":0.02911426030969623,"score_gpt":0.41848979908992134,"score_spread":0.38937553878022513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239732381","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000634928,0.003215577,0.000013012281,0.1023627,0.0007259667,0.0014227544,0.8920799,0.000028817054,0.00014490816],"genre_scores_gemma":[0.0001441467,0.0007055884,0.00024943586,0.002078946,0.00037805573,0.00025058095,0.99412876,0.00003350052,0.0020309566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958749,0.00020474337,0.001639484,0.0005992072,0.0013038303,0.00037782712],"domain_scores_gemma":[0.9910838,0.000108413304,0.0019277475,0.0013253723,0.005277093,0.00027756224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007356279,0.0004886065,0.0012141024,0.00031156756,0.0002584357,0.000043184005,0.00082153105,0.00061991886,0.00080675713],"category_scores_gemma":[0.0019444169,0.00027661517,0.0007939871,0.001437694,0.00035067846,0.00022714239,0.00028935858,0.000707827,0.000013305309],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027839063,0.00036889443,0.00003193072,0.008100218,0.0006349664,4.900614e-7,0.00030389792,1.6676053e-7,0.000022295499,0.00013443787,0.9870543,0.003320548],"study_design_scores_gemma":[0.0018158017,0.00026398583,0.0021333124,0.018885925,0.0007401733,0.000022642991,0.00008056117,0.000001771778,0.000089949055,0.000017925275,0.97570276,0.00024516182],"about_ca_topic_score_codex":0.00019454578,"about_ca_topic_score_gemma":0.000026498614,"teacher_disagreement_score":0.102048874,"about_ca_system_score_codex":0.0002834851,"about_ca_system_score_gemma":0.0010758811,"threshold_uncertainty_score":0.9999686},"labels":[],"label_agreement":null},{"id":"W4241222748","doi":"10.3747//co.19.949","title":"Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Oncology; Mutation; Lung cancer; EGFR inhibitors; Tyrosine-kinase inhibitor; Internal medicine; Cancer research; Biomarker; Tyrosine kinase; Erlotinib Hydrochloride; Gefitinib; Cancer; Gene; Receptor; Biology; Genetics","score_opus":0.04870029174905834,"score_gpt":0.4237004489221756,"score_spread":0.3750001571731173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241222748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921683,0.0007503018,0.0002551009,0.0012836831,0.0011424853,0.0018033527,0.0001547492,0.000042185206,0.0023998367],"genre_scores_gemma":[0.99370474,0.000042482294,0.002883936,0.00064462196,0.00027040206,0.0013636227,0.00017355259,0.00003379,0.0008828704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855924,0.00018142573,0.00033681933,0.00032102654,0.00016276077,0.00043875078],"domain_scores_gemma":[0.9987152,0.00021087195,0.0001443542,0.00024875428,0.00029541916,0.00038536236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020145903,0.00020747072,0.00034587382,0.0002513318,0.000097500706,0.000012150099,0.00007019129,0.000090978065,0.00059352064],"category_scores_gemma":[0.000066039174,0.00016689082,0.00004665012,0.0003228258,0.000052751944,0.00012631761,0.00003361208,0.00024833094,0.0000998197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009903726,0.012802889,0.7634504,0.00042134043,0.00040247958,0.0002346749,0.07523788,0.0014474232,0.0034982965,0.00010787575,0.006460525,0.12603249],"study_design_scores_gemma":[0.01798689,0.010923077,0.77358836,0.00056777464,0.001017846,0.00011418441,0.0044031437,0.0015434645,0.0024272918,0.000018034685,0.18675996,0.0006499486],"about_ca_topic_score_codex":0.00012536437,"about_ca_topic_score_gemma":0.0024819397,"teacher_disagreement_score":0.18029943,"about_ca_system_score_codex":0.0012404931,"about_ca_system_score_gemma":0.0008829994,"threshold_uncertainty_score":0.68056107},"labels":[],"label_agreement":null},{"id":"W4241950403","doi":"10.1007/978-1-4939-7131-2_101011","title":"RSiena","year":2018,"lang":"en","type":"book-chapter","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine","score_opus":0.02067861001149067,"score_gpt":0.32087543899107124,"score_spread":0.30019682897958055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241950403","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017039696,0.00028650637,0.000037839556,0.00047071,0.00017700819,0.00020096559,0.000014721107,0.00005916707,0.998736],"genre_scores_gemma":[0.0005563663,0.00007349635,0.0006451924,0.0008564368,0.0004283856,0.0000049313307,0.0001097146,0.000027393718,0.99729806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996095,5.024113e-7,0.0000821563,0.00013842876,0.00010000062,0.000069419526],"domain_scores_gemma":[0.999638,0.0000064953,0.0000288415,0.00019198083,0.00006625533,0.0000684178],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000010198373,0.000103371145,0.00014838892,0.00004671076,0.00002374208,0.000004979479,0.00002015342,0.00009865915,0.033450104],"category_scores_gemma":[0.0000021930787,0.000070911905,0.00007583136,0.000005081782,0.000039143404,0.00001147444,0.000011003034,0.00005930403,0.0032710868],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003370646,0.000040591483,0.000045289402,0.00006595673,0.0009143946,0.00011471036,0.00021840674,2.8751742e-8,0.000010018142,0.2064526,0.77366525,0.018439079],"study_design_scores_gemma":[0.0003996652,0.00017941267,0.000051793224,0.000100440026,0.00049859675,0.000027238582,0.0000051540105,8.3716446e-7,0.000023280178,0.005833441,0.99280685,0.00007330194],"about_ca_topic_score_codex":0.000009433961,"about_ca_topic_score_gemma":0.00001024187,"teacher_disagreement_score":0.2191416,"about_ca_system_score_codex":0.00008362522,"about_ca_system_score_gemma":0.000114379836,"threshold_uncertainty_score":0.997505},"labels":[],"label_agreement":null},{"id":"W4242349795","doi":"10.1159/000151874","title":"Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Progress in experimental tumor research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer; Lung cancer; Medicine; Lung; Pathology; Internal medicine","score_opus":0.15536649612209802,"score_gpt":0.58869860109657,"score_spread":0.433332104974472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242349795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021120286,0.99102324,8.77561e-8,0.00006195197,0.00021161196,0.0035834094,0.000035307938,0.00005214137,0.004821026],"genre_scores_gemma":[0.00066230283,0.9861885,0.00024306856,0.000019441291,0.00031279167,0.01076987,0.0001427067,0.000110546025,0.0015508172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969493,0.00022797532,0.00049685035,0.00065445766,0.0009213619,0.0007500415],"domain_scores_gemma":[0.9989908,0.00009482691,0.00009805186,0.00045912983,0.00011162421,0.00024560458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018911842,0.00036396433,0.0012245114,0.00066318247,0.00018832515,0.000048408703,0.00025647297,0.00013693879,0.0005377606],"category_scores_gemma":[0.00002117077,0.00027019955,0.00029786158,0.00092401763,0.00042998648,0.00007804751,0.0002206606,0.0009120722,0.00009408757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045375564,0.0011900669,0.0016505364,0.0075317873,0.00033266903,0.0023039088,0.0005523381,4.174628e-8,5.85375e-7,0.00010941218,0.003850344,0.98243296],"study_design_scores_gemma":[0.0010136904,0.0002255381,0.000040020575,0.014779339,0.00014279142,0.00033130829,0.00015884935,0.000011207479,0.000099138466,0.0000028114216,0.98295426,0.00024101898],"about_ca_topic_score_codex":0.00016528433,"about_ca_topic_score_gemma":0.0000065770055,"teacher_disagreement_score":0.9821919,"about_ca_system_score_codex":0.0025359006,"about_ca_system_score_gemma":0.0016155012,"threshold_uncertainty_score":0.999975},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4242460399","doi":"10.1200/jco.2017.74.6065","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Association for Molecular Pathology; American Society of Clinical Oncology; American Association for Cancer Research","keywords":"Medicine; Atezolizumab; Nivolumab; Pembrolizumab; Oncology; Internal medicine; Lung cancer; Guideline; Docetaxel; Pemetrexed; Chemotherapy; Clinical trial; Cancer; Intensive care medicine; Immunotherapy; Pathology; Cisplatin","score_opus":0.17173911777426318,"score_gpt":0.6087778275094344,"score_spread":0.4370387097351712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242460399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85728806,0.004488583,0.008674434,0.10948297,0.010235643,0.002482694,0.00016389028,0.000030643037,0.0071530924],"genre_scores_gemma":[0.6560702,0.09026978,0.20095018,0.0385616,0.011445527,0.00010668949,0.000034984554,0.00010468069,0.00245637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9870637,0.0011942862,0.010162549,0.0005719644,0.0005153668,0.0004921332],"domain_scores_gemma":[0.96408534,0.0105256615,0.020396052,0.00089106744,0.003268436,0.00083341816],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018309303,0.00032467092,0.0048509166,0.00006719801,0.0002403596,0.000030195415,0.0006985956,0.00095769425,0.00011529208],"category_scores_gemma":[0.0112593025,0.0002228826,0.0027284557,0.000109740795,0.0011607024,0.00028738874,0.00015022911,0.0019510392,0.00000936966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016327629,0.008300833,0.24586107,0.00017270133,0.005490426,0.00028100816,0.00021558104,0.00004878906,0.00009396282,0.000064309264,0.14029853,0.58284515],"study_design_scores_gemma":[0.042530786,0.03173495,0.08790016,0.00021719512,0.0042374013,0.00016792119,0.0009185782,0.0018002064,0.000031640117,0.000035440582,0.8302231,0.00020263813],"about_ca_topic_score_codex":0.0004892409,"about_ca_topic_score_gemma":0.0001279159,"teacher_disagreement_score":0.68992454,"about_ca_system_score_codex":0.0004431918,"about_ca_system_score_gemma":0.015044079,"threshold_uncertainty_score":0.9970693},"labels":[],"label_agreement":null},{"id":"W4242534568","doi":"10.3747//co.19.955","title":"EGFR tyrosine kinase inhibitors in lung cancer: make no assumptions","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Quality of life (healthcare); Protein-Tyrosine Kinases; Cancer; Cancer research; Tyrosine-kinase inhibitor; Lung; Kinase; Oncology; Bioinformatics; Internal medicine; Receptor; Biology","score_opus":0.058560057331227024,"score_gpt":0.455997478371914,"score_spread":0.39743742104068697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242534568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.901214,0.056233928,0.00010849434,0.00671063,0.01251747,0.0014157485,0.000113905924,0.00012895129,0.021556858],"genre_scores_gemma":[0.9942492,0.0015772978,0.0002879866,0.00027999107,0.0014592204,0.00045911927,0.00015389053,0.000021590202,0.0015116887],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907196,0.00004328979,0.00023638265,0.00017278356,0.000112516616,0.00036308673],"domain_scores_gemma":[0.99944746,0.000044103068,0.00007088877,0.00015794419,0.00008539387,0.00019420304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010119975,0.0001271696,0.0002528709,0.00014560972,0.00006026024,0.000005611146,0.00004180623,0.00009004967,0.00050652697],"category_scores_gemma":[0.000045641627,0.00009585107,0.00006357729,0.00020390931,0.000056957437,0.00008053246,0.000031812608,0.00021270044,0.0001321202],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000621544,0.0019678671,0.8063858,0.00013579907,0.00007243351,0.000016386839,0.00092024193,0.000007521532,0.00043381887,0.0004588324,0.024717687,0.16482143],"study_design_scores_gemma":[0.0028914972,0.00017593602,0.21906903,0.00017573762,0.00032973202,0.000016833545,0.00008618577,0.0001338169,0.00016301851,0.000012851734,0.77682865,0.000116706855],"about_ca_topic_score_codex":0.00015697844,"about_ca_topic_score_gemma":0.00022815926,"teacher_disagreement_score":0.75211096,"about_ca_system_score_codex":0.0012363695,"about_ca_system_score_gemma":0.00032063507,"threshold_uncertainty_score":0.5546115},"labels":[],"label_agreement":null},{"id":"W4242539800","doi":"10.1200/jco.2007.14.6407","title":"In Reply:","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.12408576901502229,"score_gpt":0.5903335612652479,"score_spread":0.46624779225022567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242539800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9064444,0.00041595343,0.00029841755,0.027743595,0.0017241377,0.00009420972,3.7023784e-7,0.0000034230372,0.063275546],"genre_scores_gemma":[0.9797853,0.00017237384,0.005385156,0.012200513,0.001082688,4.655052e-7,3.9213148e-7,0.0000048460115,0.0013682637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983768,0.000048425667,0.0012894208,0.000059727718,0.0001219194,0.00010369143],"domain_scores_gemma":[0.99828666,0.00080880156,0.0005182402,0.00007208814,0.00014302127,0.0001711647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025969006,0.00003706481,0.00050188863,0.00009279463,0.000008305072,0.000001307227,0.000036434336,0.00010978335,0.00013526395],"category_scores_gemma":[0.0015548797,0.000023909875,0.00016414937,0.000090191636,0.000047441572,0.000054712043,0.000007725796,0.00037451097,0.000016870565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038525467,0.0033492884,0.48128474,0.000013338359,0.00036460318,0.008106051,0.00031685355,0.000005498889,0.00011175104,0.00084762817,0.029015612,0.47273207],"study_design_scores_gemma":[0.0055256803,0.004094962,0.5041946,0.00002610061,0.00013205597,0.0003622789,0.000092420916,0.0000026014447,0.000040131432,0.0005430943,0.4849661,0.000019969015],"about_ca_topic_score_codex":0.000021311054,"about_ca_topic_score_gemma":0.000047458067,"teacher_disagreement_score":0.4727121,"about_ca_system_score_codex":0.00015375075,"about_ca_system_score_gemma":0.000950797,"threshold_uncertainty_score":0.18614486},"labels":[],"label_agreement":null},{"id":"W4242673250","doi":"10.3389/fonc.2017.00038","title":"Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Oncology; Immunotherapy; Internal medicine; Cancer; Lung; Cancer research; Algorithm; Computer science","score_opus":0.05532866719822796,"score_gpt":0.43866888631265805,"score_spread":0.38334021911443006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242673250","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046540867,0.98180556,0.0030014482,0.000055659184,0.0042755413,0.009115183,0.0008082451,0.000021617318,0.00087021233],"genre_scores_gemma":[0.000030143487,0.96400714,0.02127168,0.000036752368,0.00032477273,0.010455062,0.0016985052,0.00011872279,0.0020571956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977655,0.00007433822,0.00065180677,0.00073330494,0.00018032931,0.0005947301],"domain_scores_gemma":[0.99812883,0.00013862035,0.0007552185,0.0005932386,0.00016289453,0.00022116798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010030226,0.0006516773,0.0030973023,0.00040272332,0.00017168211,0.000026581676,0.00023149373,0.00026691318,0.00002391151],"category_scores_gemma":[0.000025045132,0.00042156005,0.0004479119,0.00014621274,0.000112254864,0.00006193291,0.000037829926,0.00029033318,0.000006749793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013231776,0.0019720423,0.0045599015,0.009419029,0.001190083,0.000071995324,0.00038452636,0.000005810206,4.9236815e-9,0.0000010181261,0.013894994,0.9683683],"study_design_scores_gemma":[0.011593512,0.0033777882,0.0003204516,0.0039726165,0.016456617,0.000007363233,0.000039545277,0.00017428718,3.011043e-7,0.0000066155776,0.96367544,0.000375445],"about_ca_topic_score_codex":0.000285563,"about_ca_topic_score_gemma":0.0001731966,"teacher_disagreement_score":0.96799284,"about_ca_system_score_codex":0.005477705,"about_ca_system_score_gemma":0.0040629883,"threshold_uncertainty_score":0.99982363},"labels":[],"label_agreement":null},{"id":"W4243933419","doi":"10.4161/cbt.5.9.3336","title":"Genomic Profiling of Lung Cancer Predicts Recurrence Suggesting Which Patients May in the Future Benefit From Aggressive Treatment","year":2006,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Regimen; Medicine; Chemotherapy; Oncology; Internal medicine; Disease; Stage (stratigraphy); Cancer; Precision medicine; Test (biology); Bioinformatics; Pathology; Biology","score_opus":0.014843396940465447,"score_gpt":0.3336417816624199,"score_spread":0.3187983847219545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243933419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9462596,0.05008745,0.0000055091496,0.0011148519,0.00054660573,0.0010782033,0.0006591612,0.000018824336,0.00022978442],"genre_scores_gemma":[0.9867434,0.010489483,0.00019985263,0.00029843225,0.00071463105,0.0008400877,0.00064265,0.00001914326,0.00005230724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892485,0.000066087465,0.00029742785,0.0003464764,0.00009959347,0.00026556198],"domain_scores_gemma":[0.99915874,0.000090188514,0.0003006418,0.00024819706,0.00016576768,0.00003644621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005503404,0.00020691985,0.00032788148,0.00006676108,0.00007858739,0.000007785569,0.00012340612,0.00012651933,0.00010052644],"category_scores_gemma":[0.000006235301,0.0001206468,0.00006528498,0.0002094779,0.000070306385,0.00003728435,0.000011749786,0.00012541498,0.0000011734165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002494804,0.000252857,0.9285816,0.000013403797,0.00024333732,0.000004276099,0.001445131,0.00013496117,0.0024092305,0.00007169444,0.00010715039,0.066486895],"study_design_scores_gemma":[0.005329783,0.00052579766,0.98510844,0.00026078522,0.00021511492,0.0000016450862,0.00018825397,0.0000896514,0.005525072,0.00022178909,0.0023972495,0.00013640149],"about_ca_topic_score_codex":0.008181706,"about_ca_topic_score_gemma":0.002902815,"teacher_disagreement_score":0.06635049,"about_ca_system_score_codex":0.0005398965,"about_ca_system_score_gemma":0.000343615,"threshold_uncertainty_score":0.9984229},"labels":[],"label_agreement":null},{"id":"W4244139576","doi":"10.1200/jco.2004.22.90140.5019","title":"Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Erlotinib; Rash; Internal medicine; Toxicity; Gastroenterology; Neutropenia; Chemotherapy; Erlotinib Hydrochloride; Oncology; Cancer; Surgery; Epidermal growth factor receptor","score_opus":0.1604161750413085,"score_gpt":0.5595969058124701,"score_spread":0.3991807307711616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244139576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950636,0.00049461046,0.000040467097,0.002169232,0.0010565929,0.00087573455,0.000014429973,0.0000052891705,0.00028006462],"genre_scores_gemma":[0.99652916,0.00055955554,0.0017620055,0.0004744798,0.00047864672,0.000070112896,0.00000177834,0.000016500859,0.0001077808],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99629676,0.00029509744,0.0024454491,0.00020150369,0.00047207327,0.00028908957],"domain_scores_gemma":[0.99617493,0.001098574,0.001850209,0.00016653155,0.0003606083,0.00034916744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020218666,0.00015608978,0.0018371231,0.0003741578,0.000045872086,0.0000050445833,0.00013094766,0.00010724194,0.00022889269],"category_scores_gemma":[0.0019098449,0.00008701285,0.00015177217,0.0005899451,0.00012277969,0.000107930224,0.00003825247,0.0006690797,0.0000022410475],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16961189,0.13283506,0.020355357,0.00008991615,0.004315925,0.00308094,0.009849773,0.00048485087,0.00007443563,0.00005135495,0.00039535717,0.65885514],"study_design_scores_gemma":[0.35684454,0.5732414,0.04867267,0.00041932755,0.002511318,0.00023620429,0.0051441523,0.000007309218,0.00005640679,0.00021326242,0.01251231,0.00014107408],"about_ca_topic_score_codex":0.00022229523,"about_ca_topic_score_gemma":0.0009778509,"teacher_disagreement_score":0.65871406,"about_ca_system_score_codex":0.00088717754,"about_ca_system_score_gemma":0.0058024204,"threshold_uncertainty_score":0.99983376},"labels":[],"label_agreement":null},{"id":"W4244148411","doi":"10.1007/s40274-013-0929-x","title":"Crizotinib effective but too costly in Canada and the US","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crizotinib; Quality of Life Research; Public health; Medicine; Lung cancer; Oncology","score_opus":0.00763180274617116,"score_gpt":0.316984452600487,"score_spread":0.3093526498543159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244148411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686945,0.0003231815,0.000003831562,0.024018165,0.00040016804,0.0015644967,0.000026976957,0.000012420644,0.004956248],"genre_scores_gemma":[0.96031576,0.00018936917,0.00007561147,0.037924223,0.000055663168,0.00038466367,0.000011473824,0.000016759037,0.0010264739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992618,0.000042757667,0.00024264745,0.00019083201,0.00005447946,0.00020751073],"domain_scores_gemma":[0.9992876,0.00033649092,0.00007148988,0.0001530348,0.000026710579,0.00012466226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007422872,0.00014302149,0.0003378394,0.000040451854,0.000055123837,0.000032931082,0.00006572875,0.000019345263,0.0002411792],"category_scores_gemma":[0.000026929723,0.00009066615,0.000056012606,0.000038833532,0.00004335195,0.000111077235,0.000034123725,0.00013564412,0.000052134128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012630761,0.00004306122,0.9556363,0.000023992185,0.00035651657,0.000014996944,0.0004198521,0.00006881504,0.000090138645,0.00026114914,0.015788779,0.02717006],"study_design_scores_gemma":[0.017583465,0.00003936471,0.9498948,0.000012597887,0.00031879748,0.00002374242,0.0004302047,0.0015227807,0.00050390814,0.00027156319,0.029217042,0.00018172449],"about_ca_topic_score_codex":0.95845467,"about_ca_topic_score_gemma":0.75927955,"teacher_disagreement_score":0.19917507,"about_ca_system_score_codex":0.00073132804,"about_ca_system_score_gemma":0.00048481493,"threshold_uncertainty_score":0.36972582},"labels":[],"label_agreement":null},{"id":"W4244361163","doi":"10.1016/j.jtho.2016.11.350","title":"OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Internal medicine; Lung cancer; Incidence (geometry); Retrospective cohort study; Cancer; Venous thromboembolism; Medical record; Chemotherapy; Oncology; Thrombosis","score_opus":0.020370648294505973,"score_gpt":0.4110875120792173,"score_spread":0.3907168637847113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244361163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847159,0.001031233,0.000075595715,0.0051247776,0.00071412965,0.00033501818,0.00004443455,0.00000796955,0.007950948],"genre_scores_gemma":[0.9955363,0.00039829029,0.0011592135,0.00061014673,0.00031605733,0.000015536712,0.0000066861094,0.000029599507,0.0019281331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988537,0.000095594245,0.0004410079,0.00015359728,0.00019963381,0.00025645515],"domain_scores_gemma":[0.9972406,0.00010342393,0.0015521157,0.00030855482,0.0006288225,0.00016650834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038937482,0.00016415691,0.0009496868,0.00012930566,0.00019342736,0.00002366387,0.00020597238,0.00017429198,0.00020258028],"category_scores_gemma":[0.00008727126,0.000111705784,0.00014842881,0.00008556933,0.00013107406,0.0001314181,0.000033719873,0.00033665664,0.0000042526076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017732494,0.020951793,0.35192856,0.002341266,0.033347905,0.012669226,0.055139817,0.00067934144,0.13618648,0.00012411429,0.074705936,0.29419306],"study_design_scores_gemma":[0.013696928,0.009998094,0.91441524,0.0020764903,0.013567221,0.0005064815,0.0008356444,0.00018557126,0.034076992,0.00028151725,0.009976845,0.00038296214],"about_ca_topic_score_codex":0.00070977636,"about_ca_topic_score_gemma":0.000299997,"teacher_disagreement_score":0.5624867,"about_ca_system_score_codex":0.0005466288,"about_ca_system_score_gemma":0.0015219408,"threshold_uncertainty_score":0.45552295},"labels":[],"label_agreement":null},{"id":"W4244950885","doi":"10.32388/0m0n96","title":"National Cancer Institute of Canada Clinical Trials Group","year":2020,"lang":"en","type":"reference-entry","venue":"Definitions","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Clinical trial; Cancer; Clinical Oncology; Medicine; Family medicine; Cancer therapy; Oncology; Internal medicine; Political science","score_opus":0.3023687019326833,"score_gpt":0.4664314527795563,"score_spread":0.164062750846873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244950885","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027023652,0.006941085,0.00013938322,0.009391655,0.006806385,0.0009873355,0.029313587,0.000052532727,0.9460978],"genre_scores_gemma":[0.11621907,0.50963616,0.010017458,0.02570037,0.02427674,0.0041653095,0.14012001,0.00036084937,0.16950399],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977007,0.0001334565,0.0010796696,0.00031007116,0.0006005023,0.00017563399],"domain_scores_gemma":[0.99816746,0.0005361297,0.00049391086,0.00017538891,0.00038512753,0.00024197361],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030271907,0.0002070217,0.0010426027,0.00010139718,0.0001106953,0.000011528021,0.00008359937,0.00023308053,0.0011215949],"category_scores_gemma":[0.0014520739,0.000169094,0.00034846467,0.00022878188,0.00009874722,0.00004600858,0.000029219857,0.00043577267,0.00002098432],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049345923,0.00022584414,0.0004633527,0.0002818584,0.0014992433,0.000039716037,0.00003262686,0.0000054898337,4.3238586e-7,0.012921348,0.97621095,0.008269764],"study_design_scores_gemma":[0.001894624,0.000110223926,0.003034082,0.0007727839,0.0019814721,0.00001203377,0.000031174615,0.00001051316,0.000002825513,0.0011682492,0.99083185,0.00015016466],"about_ca_topic_score_codex":0.093900844,"about_ca_topic_score_gemma":0.2716046,"teacher_disagreement_score":0.7765938,"about_ca_system_score_codex":0.0005318648,"about_ca_system_score_gemma":0.019827334,"threshold_uncertainty_score":0.9997915},"labels":[],"label_agreement":null},{"id":"W4245325188","doi":"10.1007/s40278-015-11694-6","title":"Health Canada reviews pazopanib-related pericardial effusion","year":2015,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pazopanib; Medicine; Pericardial effusion; Internal medicine; Cancer","score_opus":0.028787211363817775,"score_gpt":0.344699517841426,"score_spread":0.3159123064776082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245325188","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27566648,0.038462404,0.0009290292,0.24455048,0.00935079,0.006928163,0.00022627739,0.0007702629,0.42311612],"genre_scores_gemma":[0.9696423,0.001331493,0.0009245817,0.0018252142,0.0003029003,0.000101941434,0.00028225867,0.000030900712,0.0255584],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991019,0.00005671476,0.00028354468,0.00017260326,0.00020321869,0.00018201511],"domain_scores_gemma":[0.9991877,0.000020595227,0.00010615986,0.00024779435,0.00008749475,0.00035025468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014983414,0.00010385309,0.00028864905,0.000051898125,0.0001513511,0.000009724643,0.000030695537,0.000035073215,0.00007673878],"category_scores_gemma":[0.000089165376,0.000080877944,0.00007114786,0.00025555756,0.000018658267,0.00005620889,0.000011197134,0.00013013069,0.000114350114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053774933,0.0003101766,0.005146205,0.0000853455,0.00022762822,0.000048840542,0.00073938025,0.000041573992,0.0003117678,0.0004780109,0.91050667,0.08205063],"study_design_scores_gemma":[0.0010039469,0.00017708055,0.013426825,0.00009341973,0.00012993612,0.00014072855,0.00028221583,0.000041411487,0.000015997764,0.00002316655,0.9845901,0.000075162214],"about_ca_topic_score_codex":0.5088486,"about_ca_topic_score_gemma":0.11563981,"teacher_disagreement_score":0.69397587,"about_ca_system_score_codex":0.0012717373,"about_ca_system_score_gemma":0.0027263404,"threshold_uncertainty_score":0.90049744},"labels":[],"label_agreement":null},{"id":"W4245954238","doi":"10.1016/s0305-7372(04)00144-6","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆, ☆, ☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Oncology; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer research; Cancer; Cisplatin; Receptor","score_opus":0.013877398128715145,"score_gpt":0.32741736364032537,"score_spread":0.31353996551161023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245954238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94917995,0.027858445,0.000109905886,0.0028347683,0.000363783,0.018246653,0.0008835855,0.00007442847,0.00044848563],"genre_scores_gemma":[0.9181156,0.05876117,0.0040219342,0.0011993513,0.00016403185,0.015904557,0.000907512,0.00022695557,0.0006988614],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947036,0.0002620396,0.0016430101,0.0018340672,0.0005296123,0.0010276897],"domain_scores_gemma":[0.9968531,0.00033573454,0.0013050662,0.0007868326,0.00024596008,0.00047329962],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00048265106,0.0013876957,0.0029841794,0.000421349,0.00018681712,0.0001476004,0.00019343906,0.00029049572,0.000120170684],"category_scores_gemma":[0.000027018941,0.00091480534,0.00017302201,0.000848204,0.00017032867,0.0006777824,0.00005063995,0.00074513035,0.0000014283411],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17189841,0.016787529,0.6023797,0.003278898,0.0025592796,0.00072207616,0.033029847,0.003324839,0.017346302,0.000036163143,0.00020736316,0.1484296],"study_design_scores_gemma":[0.86543924,0.014981999,0.08783597,0.011025169,0.0026593017,0.000014443884,0.0026039705,0.0013360117,0.008946413,0.000023607108,0.0029708415,0.0021630211],"about_ca_topic_score_codex":0.06950875,"about_ca_topic_score_gemma":0.2054941,"teacher_disagreement_score":0.6935409,"about_ca_system_score_codex":0.0038726067,"about_ca_system_score_gemma":0.0024411252,"threshold_uncertainty_score":0.99995136},"labels":[],"label_agreement":null},{"id":"W4246278554","doi":"10.1158/1538-7445.sabcs18-ct012","title":"Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Tolerability; Medicine; Oncology; Open label; Internal medicine; Adverse effect","score_opus":0.1736007637037636,"score_gpt":0.544113882138634,"score_spread":0.3705131184348704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246278554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885508,0.00005554431,0.000017796781,0.00016638004,0.00026613206,0.010766967,0.000060816285,0.000017362778,0.00009823687],"genre_scores_gemma":[0.9986068,0.00004354857,0.0008225821,0.00026010675,0.000045763405,0.00010066916,0.000053239586,0.000025965257,0.000041339194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635327,0.0005241931,0.0020177842,0.0005982749,0.0003004611,0.00020599314],"domain_scores_gemma":[0.99622595,0.002224354,0.0005426595,0.0005625406,0.00020147342,0.00024299686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028960505,0.00020574368,0.0017732976,0.000071291885,0.000037559174,0.000029973957,0.00013823388,0.00007002651,0.00011842834],"category_scores_gemma":[0.0019570764,0.00013581713,0.00006955331,0.00016495118,0.000051021976,0.00018395105,0.00008058665,0.00017129262,0.000009357961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06348516,0.05010381,0.78573364,0.000049039576,0.00032087605,0.000010615952,0.00053708616,0.000029535924,0.0005589094,0.0000023381667,0.000023652228,0.099145345],"study_design_scores_gemma":[0.17590804,0.016887177,0.8058571,0.00045520216,0.0001873035,1.7276025e-7,0.00021398987,0.00001586599,0.00026190554,0.00000877116,0.000082723964,0.00012172667],"about_ca_topic_score_codex":0.00010852287,"about_ca_topic_score_gemma":0.000059684437,"teacher_disagreement_score":0.112422876,"about_ca_system_score_codex":0.000088485824,"about_ca_system_score_gemma":0.00019435442,"threshold_uncertainty_score":0.5538462},"labels":[],"label_agreement":null},{"id":"W4246327823","doi":"10.1016/j.jtho.2021.01.514","title":"P14.08 WITHDRAWN","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.021541697529334457,"score_gpt":0.4697760802409843,"score_spread":0.44823438271164984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246327823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8738322,0.004668528,0.00098587,0.034532215,0.001784765,0.00013076002,0.0000053241242,0.00001683507,0.0840435],"genre_scores_gemma":[0.9742138,0.00020960167,0.0144711,0.0018824498,0.0006080714,0.000002602292,0.000005662057,0.000012163909,0.008594554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993265,0.000058712718,0.00027721806,0.000074990356,0.0001481738,0.00011437826],"domain_scores_gemma":[0.9990983,0.00005760742,0.00021112752,0.0001106479,0.00039170615,0.00013061464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014413356,0.00006212688,0.00030267754,0.00007547389,0.000041449435,0.0000092290675,0.000040179755,0.000071769675,0.0005238129],"category_scores_gemma":[0.00010091264,0.000044440087,0.00011866773,0.00013741654,0.000037082526,0.000065293956,0.00001577751,0.00019294815,0.00003589811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016682101,0.0023624694,0.023070548,0.00015913641,0.001955849,0.019983057,0.0024177877,0.00005063174,0.017070249,0.0006774026,0.05410758,0.87647706],"study_design_scores_gemma":[0.0023556547,0.002740087,0.034300596,0.0001944975,0.0019476163,0.019818984,0.0013746779,0.000017991684,0.011356271,0.0009870458,0.9248024,0.0001041791],"about_ca_topic_score_codex":0.000003226496,"about_ca_topic_score_gemma":0.000009186067,"teacher_disagreement_score":0.8763729,"about_ca_system_score_codex":0.00028942886,"about_ca_system_score_gemma":0.0014934642,"threshold_uncertainty_score":0.5735384},"labels":[],"label_agreement":null},{"id":"W4247163431","doi":"10.1503/cmaj.050777","title":"News @ a glance","year":2005,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Data science; World Wide Web; Information retrieval","score_opus":0.006327735192643623,"score_gpt":0.2882770866463223,"score_spread":0.28194935145367866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247163431","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23292148,0.0013283934,0.00027061097,0.6269177,0.0012071684,0.00027042144,0.00003282343,0.00005498081,0.13699637],"genre_scores_gemma":[0.91166264,0.0002947038,0.0012110648,0.070657805,0.005532459,0.0000102750755,0.000018943425,0.000017205364,0.010594914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987445,0.000027743035,0.0002048994,0.00008126156,0.0006607702,0.0002808675],"domain_scores_gemma":[0.9981526,0.00003395518,0.00007830821,0.00006278606,0.0001946007,0.001477762],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002636182,0.0000626427,0.0001262488,0.00009263696,0.0001524056,0.000036984955,0.00005608824,0.00014668297,0.0060156654],"category_scores_gemma":[0.00044469984,0.000051332558,0.00006792984,0.00012415228,0.000011828735,0.00008504977,0.000003043514,0.0003875589,0.00047527615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000074900263,0.000051485356,0.1655735,0.000003787116,0.00021495928,0.00038915555,0.00035218423,0.0000045533893,0.000006871586,0.0003241142,0.5242272,0.30884475],"study_design_scores_gemma":[0.0013032263,0.000038402944,0.044289645,0.00003536778,0.0000544489,0.0006165921,0.00011664803,0.00010624486,0.0000075699204,0.000041527965,0.95333797,0.000052380678],"about_ca_topic_score_codex":0.0019448459,"about_ca_topic_score_gemma":0.047919907,"teacher_disagreement_score":0.67874116,"about_ca_system_score_codex":0.0018233112,"about_ca_system_score_gemma":0.0036820574,"threshold_uncertainty_score":0.99489295},"labels":[],"label_agreement":null},{"id":"W4247541485","doi":"10.1200/jco.2013.31.15_suppl.8028","title":"Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in <i>KRAS</i>-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Medicine; KRAS; Internal medicine; Tolerability; Oncology; Lung cancer; Docetaxel; Neutropenia; Mucositis; MEK inhibitor; Adverse effect; Cancer; Chemotherapy; Colorectal cancer; MAPK/ERK pathway","score_opus":0.04455802113006916,"score_gpt":0.4607209968679737,"score_spread":0.4161629757379045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247541485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890942,0.0011679766,0.00007368897,0.0060931128,0.0010045557,0.0015472135,0.000005246139,0.000007632161,0.0010063959],"genre_scores_gemma":[0.9925299,0.0015208753,0.0038270317,0.0013210548,0.000376318,0.0000966802,0.000007752361,0.000026021655,0.00029433877],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99687386,0.00029574477,0.0019476955,0.00029239786,0.00028658393,0.00030370094],"domain_scores_gemma":[0.9969673,0.0008827441,0.0012044704,0.00015079774,0.0004539848,0.00034065876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012375702,0.00020843526,0.001437067,0.00024337578,0.000035631492,0.000022782719,0.00009816888,0.00029245022,0.00012804529],"category_scores_gemma":[0.0006253854,0.00013836031,0.00015319884,0.00037401362,0.00013318095,0.00028371112,0.00002670276,0.0008587268,0.0000040152404],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18366648,0.039601065,0.26716256,0.00037278485,0.0011652501,0.002256102,0.002988757,0.00033796023,0.0063890703,0.0000720636,0.004443323,0.4915446],"study_design_scores_gemma":[0.7760377,0.06703756,0.13483341,0.0011850457,0.0016670933,0.00016471231,0.001052019,0.0014897732,0.0007934336,0.00024146301,0.0151097495,0.00038805127],"about_ca_topic_score_codex":0.00034193974,"about_ca_topic_score_gemma":0.00070690515,"teacher_disagreement_score":0.5923712,"about_ca_system_score_codex":0.00040583964,"about_ca_system_score_gemma":0.0025004204,"threshold_uncertainty_score":0.564217},"labels":[],"label_agreement":null},{"id":"W4249024289","doi":"10.1200/jco.2004.22.14_suppl.7135","title":"Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Pemetrexed; Medicine; Chemotherapy; Oncology; Internal medicine; Lung cancer; Discontinuation; Surgery; Cisplatin","score_opus":0.05604320246381494,"score_gpt":0.4716940325281952,"score_spread":0.41565083006438025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249024289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950417,0.00043488067,0.00033203798,0.00048909284,0.0015655726,0.0018936654,0.000058584814,0.0000052807145,0.00017913796],"genre_scores_gemma":[0.99777526,0.00024023437,0.0008909967,0.00025000048,0.00058508833,0.00015471921,0.000055953165,0.000018243894,0.000029516706],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948385,0.0008544083,0.0033294351,0.0003001399,0.000473826,0.00020369641],"domain_scores_gemma":[0.99457216,0.0014070914,0.002672621,0.00026349467,0.000788559,0.0002960669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002303358,0.0002038552,0.0031421618,0.00049520686,0.000030672953,0.000013733714,0.00014088764,0.00021331666,0.00016177785],"category_scores_gemma":[0.0012759864,0.00013803692,0.0009523917,0.00047252685,0.00011886312,0.00027641188,0.00003301632,0.00047475635,0.0000017440035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.856545,0.039532945,0.083723806,0.000009632407,0.005873699,0.00018230616,0.004867548,0.00022077977,0.000032283046,0.0000012373745,0.000019387417,0.0089914],"study_design_scores_gemma":[0.83784544,0.023509204,0.11662629,0.000071559945,0.020151947,2.7031024e-7,0.001464348,0.0001454108,0.000034189503,0.000017141956,0.000030573407,0.00010362368],"about_ca_topic_score_codex":0.001682729,"about_ca_topic_score_gemma":0.005986259,"teacher_disagreement_score":0.03290249,"about_ca_system_score_codex":0.0004458247,"about_ca_system_score_gemma":0.0019792682,"threshold_uncertainty_score":0.5628982},"labels":[],"label_agreement":null},{"id":"W4249928009","doi":"10.1515/iupac.79.0968","title":"Carcinogen","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glossary; Chemical nomenclature; Computer science; Toxicology; Library science; Chemistry; Philosophy; Biology; Linguistics; Organic chemistry","score_opus":0.015458000031924912,"score_gpt":0.4513197631540275,"score_spread":0.43586176312210256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249928009","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000120055374,0.0018513537,0.00002832588,0.0018049453,0.00058164,0.00048611156,0.9946977,0.000059175836,0.00037070725],"genre_scores_gemma":[0.00004975465,0.0009921815,0.00005666751,0.00066525117,0.0011715826,0.000034959183,0.9935284,0.00003823631,0.0034629535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827546,0.00002275248,0.00028937485,0.00038020004,0.00072848867,0.0003037047],"domain_scores_gemma":[0.99848884,0.00003506459,0.00012643232,0.0007134898,0.00040834316,0.00022780734],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010550602,0.00030832927,0.0005444847,0.00016561079,0.00007870195,0.000019613391,0.00011838931,0.00023767818,0.0048901066],"category_scores_gemma":[0.00013395608,0.00019572148,0.0001868734,0.00011589428,0.00007927753,0.000038476115,0.000055538258,0.00023170824,0.000008009551],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014275243,0.000243562,0.0001122504,0.00015529472,0.0004866547,0.00024951034,0.00001287848,9.867026e-8,0.000007857884,0.0000044019307,0.9938622,0.0047225356],"study_design_scores_gemma":[0.0024569589,0.0003943871,0.00036312203,0.00050406053,0.0013225096,0.00006603438,0.000015819674,3.5037834e-7,0.000022331105,0.000040615465,0.99460554,0.00020829741],"about_ca_topic_score_codex":0.00026344837,"about_ca_topic_score_gemma":0.00036448188,"teacher_disagreement_score":0.0048820972,"about_ca_system_score_codex":0.0008490562,"about_ca_system_score_gemma":0.0018862772,"threshold_uncertainty_score":0.99601954},"labels":[],"label_agreement":null},{"id":"W4250381459","doi":"10.1055/a-0751-1698","title":"Klinischer Nutzen des e-ASPECTS-Score","year":2019,"lang":"de","type":"article","venue":"Neuroradiologie Scan","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology; Thrombolysis; Stroke (engine); Internal medicine; Engineering","score_opus":0.03880895330414365,"score_gpt":0.3313926354217141,"score_spread":0.29258368211757046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250381459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85573095,0.027597545,0.000019853856,0.002151066,0.005570169,0.0012830672,0.00010753715,0.00024366734,0.10729614],"genre_scores_gemma":[0.98151445,0.0034287923,0.00032496714,0.0015542267,0.0012509013,0.000046445268,0.00013610059,0.00008495671,0.01165918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976772,0.00015500524,0.00039124727,0.00075824175,0.0002831697,0.0007351251],"domain_scores_gemma":[0.9983181,0.00020798267,0.00016380806,0.00086703687,0.00012455956,0.00031853982],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014958072,0.00040525253,0.0006214471,0.00013210095,0.00016509452,0.000064606655,0.00028219863,0.00023207227,0.0017908656],"category_scores_gemma":[0.00019972585,0.00032033928,0.00023061129,0.0003389479,0.0003001929,0.00013556864,0.00009405838,0.00046221638,0.0056924773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004022468,0.0006825496,0.9081682,0.00044897938,0.0018405147,0.00080207095,0.0015376743,0.00018066457,0.0047311042,0.0030558342,0.032007348,0.046142846],"study_design_scores_gemma":[0.006817833,0.0047214883,0.64621586,0.0005328122,0.0027904727,0.00008596045,0.0006750488,0.000317399,0.0019310061,0.0018138037,0.3333069,0.0007914173],"about_ca_topic_score_codex":0.00019366568,"about_ca_topic_score_gemma":0.000019579891,"teacher_disagreement_score":0.30129954,"about_ca_system_score_codex":0.00036743365,"about_ca_system_score_gemma":0.00064305466,"threshold_uncertainty_score":0.99992484},"labels":[],"label_agreement":null},{"id":"W4250591910","doi":"10.1093/annonc/mdw594.008","title":"444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ceritinib; Anaplastic lymphoma kinase; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; ALK inhibitor; Lung cancer","score_opus":0.021542957625337634,"score_gpt":0.36154001526130375,"score_spread":0.3399970576359661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250591910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941886,0.00020082812,0.0000070936762,0.0005937039,0.0000355565,0.0044142352,0.000044843015,0.000025818597,0.00048928877],"genre_scores_gemma":[0.9987059,0.00023288516,0.00018341297,0.00021275306,0.000007233501,0.0005095584,0.00003947577,0.00004038384,0.000068370406],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99769515,0.00026078598,0.00092546036,0.00046454428,0.0002934332,0.0003606535],"domain_scores_gemma":[0.9980989,0.00040595824,0.0006716361,0.0003361041,0.00034382567,0.0001435926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002547171,0.00030810683,0.0016087672,0.00034577862,0.00003356571,0.0000049468103,0.00006834509,0.000047422865,0.000046146546],"category_scores_gemma":[0.0002763693,0.00017172523,0.00007999568,0.0003625188,0.00024598028,0.00014225362,0.000019996547,0.000073833886,7.848427e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27938765,0.015090026,0.50075257,0.000072679046,0.0008833772,0.0005749166,0.0019882054,0.000005010565,0.00016973836,0.0000056176964,0.00003146041,0.20103876],"study_design_scores_gemma":[0.6471728,0.052639984,0.29690212,0.00056840584,0.00042451028,0.000045909404,0.0007587139,0.000007263605,0.0010561286,0.000010218525,0.00023455662,0.00017936816],"about_ca_topic_score_codex":0.00091152237,"about_ca_topic_score_gemma":0.0010996734,"teacher_disagreement_score":0.36778516,"about_ca_system_score_codex":0.00013618541,"about_ca_system_score_gemma":0.00031193875,"threshold_uncertainty_score":0.7002752},"labels":[],"label_agreement":null},{"id":"W4251053089","doi":"10.1057/978-1-349-95943-3_213","title":"Canadian Cancer Society Research Institute (CCSRI)","year":2019,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Global Affairs Canada; Canadian Breast Cancer Research Alliance; Camargo Foundation; Canada Council for the Arts; Killam Trusts; Government of Canada","keywords":"Cancer; Political science; Library science; Medicine; Computer science; Internal medicine","score_opus":0.05684334507515883,"score_gpt":0.36301031005692846,"score_spread":0.30616696498176965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251053089","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024750136,0.003317224,0.000005615709,0.0010227308,0.00089682924,0.0017248394,0.00073921395,0.000067054054,0.991979],"genre_scores_gemma":[0.67842096,0.0007033397,0.00018956342,0.00092936115,0.0006681332,0.00011067766,0.00040420383,0.00012488382,0.31844887],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974121,0.000018672545,0.0003558343,0.00071263977,0.00071112503,0.0007896663],"domain_scores_gemma":[0.99775386,0.00005416024,0.00011822126,0.0008586368,0.00050914654,0.0007059894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021006672,0.00047593203,0.0006351691,0.00038736546,0.0003395197,0.000058808786,0.00022367018,0.000552788,0.0017198423],"category_scores_gemma":[0.000013855939,0.00041189278,0.00042460265,0.000042896216,0.00029257894,9.726986e-7,0.000090668225,0.00085539493,0.0008621293],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051091436,0.000001412365,0.002011238,0.0004698194,0.0026527648,0.00044133456,0.0019230767,0.000004366392,0.00010156052,0.95291954,0.0058765914,0.03354719],"study_design_scores_gemma":[0.0027812172,0.0003840487,0.0019706541,0.0016621925,0.0013316079,0.00009663065,0.0001704782,0.000034575078,0.00011599147,0.31346914,0.6770122,0.0009712655],"about_ca_topic_score_codex":0.1722406,"about_ca_topic_score_gemma":0.28176293,"teacher_disagreement_score":0.6781735,"about_ca_system_score_codex":0.0026069738,"about_ca_system_score_gemma":0.0071593183,"threshold_uncertainty_score":0.99991584},"labels":[],"label_agreement":null},{"id":"W4252417430","doi":"10.3390/curroncol18120004","title":"The Significance of Progressionfree Survival as an Endpoint in Evaluating the Therapeutic Value of Antineoplastic Agents","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Value (mathematics); Intensive care medicine; Oncology; Internal medicine; Computer science","score_opus":0.22908647811029456,"score_gpt":0.5143444579374341,"score_spread":0.2852579798271395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252417430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389535,0.0015433047,0.000070210335,0.00027805654,0.0008069034,0.0008623427,0.0000067108404,0.000009280662,0.0025278477],"genre_scores_gemma":[0.999418,0.00012954368,0.0001740807,0.000024468172,0.000050609593,0.00013604862,0.0000090534995,0.000009071576,0.000049076538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99883133,0.00029134832,0.00033912153,0.00015318046,0.00021329222,0.00017169754],"domain_scores_gemma":[0.9989826,0.00033941987,0.00023895597,0.00026483453,0.00013147181,0.000042681717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054454454,0.00009117179,0.00022617288,0.000040619998,0.00007249189,0.0000028013364,0.00014514265,0.00003949933,0.00007697737],"category_scores_gemma":[0.0001671813,0.00004472275,0.00005116687,0.00014867392,0.0002194234,0.000028774393,0.000033538956,0.00013825104,0.0000039815754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013995398,0.0035253293,0.35935208,0.00018830244,0.00027980655,0.000014490058,0.01466659,0.000039241746,0.002695452,0.011021467,0.00006692052,0.6067508],"study_design_scores_gemma":[0.0035862592,0.00517761,0.9759889,0.00022907466,0.0005157803,0.000014477487,0.002542724,0.003077277,0.0021978412,0.0029550723,0.0036138603,0.000101073645],"about_ca_topic_score_codex":0.00010618615,"about_ca_topic_score_gemma":0.00007254245,"teacher_disagreement_score":0.6166369,"about_ca_system_score_codex":0.00008202185,"about_ca_system_score_gemma":0.00050768437,"threshold_uncertainty_score":0.18237408},"labels":[],"label_agreement":null},{"id":"W4252867417","doi":"10.1200/jco.20.03570","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Kingston General Hospital; University Health Network; Queen's University","funders":"","keywords":"Medicine; Guideline; Lung cancer; Oncology; Internal medicine; Targeted therapy; T790M; Osimertinib; Stage (stratigraphy); Cancer; Clinical endpoint; Clinical trial; Erlotinib; Epidermal growth factor receptor; Gefitinib; Pathology","score_opus":0.08343939901888191,"score_gpt":0.49462702697377,"score_spread":0.41118762795488806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252867417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93716264,0.006852761,0.013148462,0.039830413,0.00089850416,0.00072740763,0.00004655252,0.000008531597,0.001324727],"genre_scores_gemma":[0.68728006,0.038210645,0.2161298,0.042451005,0.0040869005,0.00016011675,0.0000994141,0.00008279059,0.011499283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811506,0.00009519063,0.0012905172,0.00018705787,0.00015421935,0.00015793834],"domain_scores_gemma":[0.99743897,0.00038556114,0.00080466864,0.0001399655,0.0010010896,0.0002297715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006919357,0.00011783236,0.0007924115,0.000044369513,0.00006934329,0.000018764531,0.000046162077,0.00013815415,0.0003179564],"category_scores_gemma":[0.00022704889,0.00007176162,0.0001978555,0.00007717266,0.00007425682,0.000095276024,0.000019138371,0.00030717463,0.0000015831268],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014387443,0.01086034,0.28244635,0.0004401522,0.010596854,0.0035944742,0.0021943885,0.001494617,0.010254439,0.000895647,0.14330518,0.5195301],"study_design_scores_gemma":[0.05894688,0.013964187,0.07932752,0.00029442954,0.0027935181,0.00034356213,0.0005153062,0.002203127,0.0028366647,0.00021636687,0.8383185,0.00023990787],"about_ca_topic_score_codex":0.000029935052,"about_ca_topic_score_gemma":0.00019492557,"teacher_disagreement_score":0.69501334,"about_ca_system_score_codex":0.00013053774,"about_ca_system_score_gemma":0.003299707,"threshold_uncertainty_score":0.58535385},"labels":[],"label_agreement":null},{"id":"W4253118244","doi":"10.1016/s0093-7754(01)90200-3","title":"Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Docetaxel; Vinorelbine; Medicine; Ifosfamide; Lung cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Phases of clinical research; Surgery; Cisplatin","score_opus":0.1612092728561817,"score_gpt":0.5138659854352491,"score_spread":0.3526567125790674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253118244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010652273,0.97962844,0.000005617977,0.00020931839,0.00028900598,0.005311103,0.0009977575,0.000004670133,0.0029018326],"genre_scores_gemma":[0.00040286416,0.99660677,0.00037465224,0.00017460808,0.00015517756,0.0011256166,0.00035497954,0.00003448572,0.0007708335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945167,0.0013650437,0.003100985,0.00046494912,0.00024123001,0.00031113473],"domain_scores_gemma":[0.99435663,0.002521326,0.0023279113,0.0005515564,0.00013368935,0.000108885586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026288503,0.00047258558,0.0074435687,0.00032979302,0.000024465156,0.0000032114376,0.00020468666,0.0003143983,0.0003556702],"category_scores_gemma":[0.0002620548,0.00028656458,0.00059399207,0.00059226155,0.00014414875,0.000028265898,0.000045620516,0.00025495,6.6565167e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003097288,0.002887952,0.0005823531,0.098383754,0.0006909946,0.00006356101,0.0010651674,0.000002067482,0.000010982287,0.000063963314,0.0002477603,0.8956917],"study_design_scores_gemma":[0.03336781,0.004263818,0.000050570652,0.13039687,0.010068374,0.00006500216,0.00037946342,0.000007892775,0.000053040956,0.000012820432,0.8210079,0.00032641328],"about_ca_topic_score_codex":0.0018330938,"about_ca_topic_score_gemma":0.0038940478,"teacher_disagreement_score":0.8953653,"about_ca_system_score_codex":0.0007367112,"about_ca_system_score_gemma":0.0023822207,"threshold_uncertainty_score":0.99995863},"labels":[],"label_agreement":null},{"id":"W4253465303","doi":"10.1200/jco.2012.30.18_suppl.lba7500","title":"LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Pemetrexed; Afatinib; Internal medicine; Rash; Lung cancer; Gastroenterology; Adverse effect; Erlotinib; Clinical endpoint; Adenocarcinoma; Oncology; Chemotherapy; Epidermal growth factor receptor; Cisplatin; Cancer; Randomized controlled trial","score_opus":0.1257192747879889,"score_gpt":0.5202801478412544,"score_spread":0.39456087305326554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253465303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417585,0.00077979325,0.00019478747,0.00045672586,0.0006232182,0.0034133017,0.00001744707,0.0000034982438,0.00033536422],"genre_scores_gemma":[0.99313563,0.00010779759,0.0062758066,0.00005503248,0.00017911958,0.0001560842,0.000009672982,0.000020640357,0.000060211296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971076,0.00029280307,0.0019289535,0.00017004556,0.00030283365,0.0001977235],"domain_scores_gemma":[0.9906925,0.0053310604,0.0029815405,0.00019772584,0.00059974415,0.00019743173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011709051,0.0001744088,0.0017281846,0.000098231365,0.00012962666,0.00000888671,0.00012357793,0.00009591366,0.000026518495],"category_scores_gemma":[0.0030843585,0.000092744616,0.00017985904,0.00018030233,0.00015221674,0.0002549251,0.000059281574,0.0002087004,1.5373313e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.510997,0.035624932,0.36433238,0.00009671506,0.00503364,0.000014275526,0.0048185177,0.00011415192,0.000042158,0.00009333482,0.000055284145,0.07877762],"study_design_scores_gemma":[0.844467,0.055713058,0.09202893,0.00023962828,0.0050472803,0.000010683287,0.0015600086,0.00046698368,0.00012465932,0.000016522199,0.00023687685,0.00008836195],"about_ca_topic_score_codex":0.000094164665,"about_ca_topic_score_gemma":0.000037038888,"teacher_disagreement_score":0.33347002,"about_ca_system_score_codex":0.00026201925,"about_ca_system_score_gemma":0.0006641988,"threshold_uncertainty_score":0.37820157},"labels":[],"label_agreement":null},{"id":"W4253822535","doi":"10.1515/iupac.79.1569","title":"Malignancy","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glossary; Chemical nomenclature; Computer science; Toxicology; Chemistry; Philosophy; Biology; Linguistics","score_opus":0.013936002324440196,"score_gpt":0.4512735390642447,"score_spread":0.4373375367398045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253822535","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047456462,0.0019920885,0.000049887803,0.0019812318,0.00067726773,0.0004837017,0.9942092,0.000067092085,0.00049208937],"genre_scores_gemma":[0.000021813803,0.0015821864,0.00008220642,0.0007083508,0.0010409425,0.00004106814,0.99140483,0.000039335526,0.0050792503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825394,0.000021685604,0.0003168553,0.0003895792,0.0007076437,0.00031028828],"domain_scores_gemma":[0.9985114,0.000034415738,0.00014627998,0.0007077928,0.00039092512,0.00020920754],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001022962,0.00031902824,0.00055141404,0.0001639237,0.000077350924,0.000021604696,0.00011668012,0.00024505504,0.0064734495],"category_scores_gemma":[0.00013805993,0.00020265019,0.00018618448,0.00012375963,0.00007545036,0.00004581642,0.00005146947,0.00022164229,0.000010161072],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001311929,0.00032174596,0.00003722252,0.00019149676,0.00041877644,0.00031578014,0.000008915583,6.642509e-8,0.0000055491464,0.000011403278,0.99189454,0.0066632912],"study_design_scores_gemma":[0.0025700557,0.0004241899,0.00015427895,0.001122419,0.0010855101,0.000072867806,0.000011887958,2.402747e-7,0.000017101544,0.00007751581,0.9942443,0.00021964729],"about_ca_topic_score_codex":0.000119421326,"about_ca_topic_score_gemma":0.00019758327,"teacher_disagreement_score":0.006463289,"about_ca_system_score_codex":0.00068779633,"about_ca_system_score_gemma":0.0016628777,"threshold_uncertainty_score":0.9944348},"labels":[],"label_agreement":null},{"id":"W4253981040","doi":"10.14740/jmc1985w","title":"A Case of Crizotinib-Resistant Lung Adenocarcinoma Harboring a KRAS Mutation and an EML4-ALK Fusion Gene","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Medicine; KRAS; Cancer research; Fusion gene; Adenocarcinoma; Lung cancer; Mutation; Gene; Oncology; Cancer; Internal medicine; Genetics; Biology; Colorectal cancer","score_opus":0.024952947876533103,"score_gpt":0.3611480030142384,"score_spread":0.33619505513770526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253981040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950661,0.0024548965,0.00085930707,0.0012113963,0.0001665273,0.000112061636,0.0000081731005,0.000007780599,0.00011376804],"genre_scores_gemma":[0.9977015,0.00012008068,0.0014582434,0.00019519778,0.00048285993,0.0000028277095,0.0000059789018,0.000012505193,0.000020766973],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99862367,0.00007988745,0.00046872653,0.0001138644,0.0005890631,0.0001247855],"domain_scores_gemma":[0.99875104,0.00022622774,0.00027792304,0.00011270299,0.00021104023,0.00042107282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005195938,0.00009732432,0.00030887208,0.00014255421,0.000074077034,0.000015343252,0.00004831127,0.00007895227,0.00013409444],"category_scores_gemma":[0.00083438103,0.00006694884,0.00007221492,0.000094183386,0.00007508378,0.00012078909,0.00002070491,0.00017017403,5.118197e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004978637,0.0037505713,0.09658306,0.0023933053,0.0016589307,0.46015468,0.014065103,0.00005450337,0.032376315,0.0021746592,0.0035462182,0.378264],"study_design_scores_gemma":[0.03204915,0.021095704,0.20243013,0.004073998,0.007037963,0.680999,0.008450784,0.013880003,0.025865056,0.0005333586,0.0029620768,0.0006228112],"about_ca_topic_score_codex":0.00026790798,"about_ca_topic_score_gemma":0.00006071477,"teacher_disagreement_score":0.3776412,"about_ca_system_score_codex":0.00006502541,"about_ca_system_score_gemma":0.0002738124,"threshold_uncertainty_score":0.27300945},"labels":[],"label_agreement":null},{"id":"W4254019757","doi":"10.3747//co.19.891","title":"Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Credit Valley Hospital","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Chemotherapy; Histology; Randomized controlled trial; Placebo; Subgroup analysis; Meta-analysis; Confidence interval; Pathology; Cisplatin","score_opus":0.07030190930661362,"score_gpt":0.43522296747926004,"score_spread":0.3649210581726464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254019757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76882213,0.2224923,0.0021114473,0.0003567931,0.000313803,0.0038005756,0.00012110833,0.000016036278,0.0019658066],"genre_scores_gemma":[0.9944725,0.0018619092,0.0010723325,0.000038757815,0.000042602656,0.002067033,0.00021231151,0.00001478097,0.00021777663],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959804,0.0012147439,0.0018816097,0.00032031085,0.00025508332,0.00034785527],"domain_scores_gemma":[0.9948073,0.0023573814,0.0019501278,0.00036767742,0.00037349368,0.00014404127],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026580303,0.00027628944,0.015063478,0.0018189739,0.000025975462,0.0000023201812,0.00010529887,0.0001295076,0.00095351966],"category_scores_gemma":[0.00049958884,0.00015715712,0.0040823133,0.0020503409,0.00015590903,0.00005812978,0.000024994273,0.00016482745,8.815873e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0896372,0.0031853302,0.19228865,0.00013927459,0.7059532,0.0000039780675,0.0024745115,0.0019541075,0.001065854,0.00019926959,0.000052197887,0.0030464537],"study_design_scores_gemma":[0.23186955,0.00022158185,0.010535111,0.000008880888,0.752914,7.7174934e-7,0.000318501,0.0033121365,0.0003140089,0.0000065744302,0.0003975598,0.00010129859],"about_ca_topic_score_codex":0.0009768914,"about_ca_topic_score_gemma":0.0021753972,"teacher_disagreement_score":0.22565037,"about_ca_system_score_codex":0.0004204691,"about_ca_system_score_gemma":0.00046257756,"threshold_uncertainty_score":0.99995977},"labels":[],"label_agreement":null},{"id":"W4255129493","doi":"10.1016/j.jtho.2018.08.1199","title":"P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Germline; Germline mutation; Lung cancer; Medicine; Mutation; Cancer; Genetics; T790M; Cancer research; Epidermal growth factor receptor; Oncology; Internal medicine; Biology; Gene; Gefitinib","score_opus":0.012173944046094998,"score_gpt":0.44192128446168666,"score_spread":0.42974734041559165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255129493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199265,0.0027010255,0.000045435943,0.004306941,0.0003110962,0.00039897521,0.00003271374,0.0000041205253,0.00020701053],"genre_scores_gemma":[0.99741346,0.00048345985,0.0010519245,0.0006176954,0.00027228086,0.000040630108,0.000004253727,0.00001260442,0.00010371304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989748,0.00009371114,0.00045590088,0.00018010433,0.00010586996,0.00018963424],"domain_scores_gemma":[0.99921024,0.00009318609,0.00020073265,0.000082433886,0.00024486746,0.0001685415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021674388,0.00013115029,0.0004123501,0.00027424982,0.00005046454,0.000011027961,0.00004874071,0.000085652006,0.00009239887],"category_scores_gemma":[0.0001045583,0.00008734485,0.00003695832,0.00023042731,0.000108643086,0.00009930901,0.00003597772,0.0001846807,0.0000010305585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055894465,0.00041498998,0.86685216,0.000050460396,0.00008403752,0.000031801752,0.0051775402,0.00006707656,0.0008821762,0.0000012294572,0.00015689836,0.12572269],"study_design_scores_gemma":[0.0019605553,0.0011916511,0.9944633,0.00018709544,0.000164962,0.00004963907,0.0003599555,0.00044953372,0.00015554104,0.00016261406,0.0007760405,0.00007906649],"about_ca_topic_score_codex":0.0006869194,"about_ca_topic_score_gemma":0.027349796,"teacher_disagreement_score":0.12761119,"about_ca_system_score_codex":0.00066725235,"about_ca_system_score_gemma":0.00044792544,"threshold_uncertainty_score":0.9903985},"labels":[],"label_agreement":null},{"id":"W4255131969","doi":"10.1016/j.cllc.2014.09.003","title":"Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment","year":2014,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Internal medicine; Carboplatin; Tolerability; Lung cancer; Renal function; Urology; Gastroenterology; Creatinine; Kidney disease; Population; Oncology; Chemotherapy; Adverse effect","score_opus":0.007468378888666048,"score_gpt":0.3285392792150845,"score_spread":0.3210709003264185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255131969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961505,0.00045098638,0.000084866835,0.00042382433,0.00006910235,0.0025247363,0.000079937105,0.000015004081,0.0002010305],"genre_scores_gemma":[0.99806,0.00057460426,0.00037937792,0.0002577883,0.000026312411,0.0002932064,0.00026444017,0.000040003695,0.00010425228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755573,0.00012139331,0.00090926234,0.0006229249,0.00044140496,0.00034929073],"domain_scores_gemma":[0.9983928,0.00031190005,0.0004626867,0.00036264438,0.00029598622,0.000173957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031544812,0.00031002954,0.0009966444,0.00037428638,0.00005250704,0.00001288892,0.00009262554,0.00012978754,0.000051188992],"category_scores_gemma":[0.000049142305,0.00020567172,0.00008197949,0.0011513551,0.00012681972,0.00012485878,0.000029279787,0.00031834547,3.151887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012215586,0.0039495374,0.95703334,0.00011669095,0.000918036,0.0000046061737,0.00078011357,0.010158837,0.0000017739202,0.0000069705343,0.000014649034,0.014799842],"study_design_scores_gemma":[0.06890602,0.0068964367,0.9163746,0.0010129338,0.0012421847,8.517887e-8,0.000040331608,0.0052187024,0.000016479014,0.0000029677572,0.00005646663,0.00023278146],"about_ca_topic_score_codex":0.0024734382,"about_ca_topic_score_gemma":0.011348729,"teacher_disagreement_score":0.056690432,"about_ca_system_score_codex":0.0006836432,"about_ca_system_score_gemma":0.00038731293,"threshold_uncertainty_score":0.83870494},"labels":[],"label_agreement":null},{"id":"W4255273450","doi":"10.1016/j.annonc.2020.10.349","title":"356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Chugai Pharmaceutical; Eli Lilly Japan; AstraZeneca; Eli Lilly and Company","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; Adjuvant; Hazard ratio; Discontinuation; Adenocarcinoma; Cancer; Confidence interval","score_opus":0.05058576355198821,"score_gpt":0.3667156560000392,"score_spread":0.316129892448051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255273450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825437,0.0010045391,0.000021228392,0.007559846,0.0001647587,0.0011652013,0.000121778794,0.00007145553,0.0016368476],"genre_scores_gemma":[0.9970327,0.00027475253,0.00010154163,0.002079052,0.000075472475,0.000088605564,0.00027167323,0.000028151222,0.00004807059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825764,0.00016145466,0.0004706221,0.0003842458,0.0002893243,0.00043670222],"domain_scores_gemma":[0.99860764,0.00007488051,0.00024917556,0.00024078488,0.0003889563,0.00043855587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007901529,0.00020837753,0.0005577463,0.00012567593,0.00005271159,0.0000081926,0.00012696178,0.000094184354,0.00006713693],"category_scores_gemma":[0.00011576542,0.00015091542,0.000085579704,0.000567492,0.00011254458,0.0000978509,0.000028589004,0.00018677021,0.000016657468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029871441,0.0044499757,0.6017961,0.0005290222,0.0009441378,0.0011397062,0.006197001,0.00031972834,0.0006310317,0.0002050397,0.009512015,0.34440482],"study_design_scores_gemma":[0.015475586,0.015223471,0.9560871,0.00053895864,0.00021706798,0.000008592,0.0005227877,0.00059332314,0.00097028964,0.000014383754,0.010109343,0.00023905902],"about_ca_topic_score_codex":0.00033479868,"about_ca_topic_score_gemma":0.00004997395,"teacher_disagreement_score":0.35429105,"about_ca_system_score_codex":0.00016924467,"about_ca_system_score_gemma":0.0007838293,"threshold_uncertainty_score":0.6154153},"labels":[],"label_agreement":null},{"id":"W4256062533","doi":"10.1200/jco.2002.20.5.1344","title":"Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non–Small-Cell Lung Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Docetaxel; Medicine; Lung cancer; Chemotherapy; Oncology; Cancer; Clinical trial; Internal medicine; Cost effectiveness; Palliative care; Randomized controlled trial; Radiation therapy; Intensive care medicine; Nursing","score_opus":0.09072873111643139,"score_gpt":0.495878979699561,"score_spread":0.40515024858312965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256062533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983821,0.004629405,0.0000075176067,0.0019899732,0.0020012248,0.00051601033,0.00009518183,0.0000023503444,0.0069373427],"genre_scores_gemma":[0.99152255,0.005274246,0.0003433767,0.00048090273,0.0004849842,0.00001835981,0.000006689755,0.000014872503,0.0018540391],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972035,0.00018058947,0.0020759183,0.00018098178,0.00019242552,0.00016657103],"domain_scores_gemma":[0.994811,0.0010444141,0.0031881807,0.00028299415,0.0004999399,0.00017345182],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004777795,0.00014245752,0.001685703,0.00016674412,0.000038298276,0.000003696631,0.00019485892,0.00021477352,0.0022871632],"category_scores_gemma":[0.00030615533,0.00008502595,0.0011641845,0.0002434047,0.00016666655,0.00007082032,0.000027198099,0.0004092214,0.0000048721904],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22853994,0.014112735,0.28061998,0.00028902784,0.06863781,0.0003136966,0.010085187,0.013114113,0.0017840957,0.00009325463,0.008980597,0.37342957],"study_design_scores_gemma":[0.5481724,0.08923743,0.21838073,0.00031815702,0.05189462,0.000033593195,0.006637331,0.0018384287,0.005318002,0.00005113817,0.077691816,0.00042631006],"about_ca_topic_score_codex":0.0002393948,"about_ca_topic_score_gemma":0.0011307858,"teacher_disagreement_score":0.37300324,"about_ca_system_score_codex":0.00038724896,"about_ca_system_score_gemma":0.0019157667,"threshold_uncertainty_score":0.99862486},"labels":[],"label_agreement":null},{"id":"W4280522194","doi":"10.3390/curroncol29050300","title":"HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"HRAS; Medicine; Lung cancer; Oncology; Mutation; Cancer research; Cancer; Internal medicine; KRAS; Gene; Biology; Genetics; Colorectal cancer","score_opus":0.06804205181276549,"score_gpt":0.47401629606604945,"score_spread":0.405974244253284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280522194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040494167,0.9916894,0.00002470189,0.0002055325,0.0012412868,0.004469365,0.0012329732,0.000019264691,0.001077014],"genre_scores_gemma":[0.0000027273227,0.99017125,0.0008093393,0.00011087627,0.00024806647,0.004149419,0.0033420546,0.00004462272,0.0011216456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852544,0.00012266586,0.00060155045,0.0004136654,0.00011451426,0.00022218312],"domain_scores_gemma":[0.99866426,0.00019470105,0.00058121927,0.00023594862,0.00020087247,0.00012301562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018494492,0.00032272507,0.0017140077,0.00017288965,0.00012217637,0.00001296288,0.0000732882,0.00018157047,0.00036928745],"category_scores_gemma":[0.00008184681,0.000246187,0.0003392614,0.00033919208,0.000052015388,0.000059589496,0.00005989675,0.00035484284,0.000001814081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026603262,0.00021191445,0.0000216365,0.36680114,0.00024364617,0.00048974785,0.00047305506,1.491053e-7,1.0108076e-7,0.000041374755,0.0061605764,0.62553006],"study_design_scores_gemma":[0.0010285103,0.0012074537,0.0000011663981,0.07287117,0.008247597,0.0047401846,0.00006650564,0.0000061055184,0.0000013284682,0.000023235292,0.91163903,0.00016768566],"about_ca_topic_score_codex":0.000026099902,"about_ca_topic_score_gemma":0.000019133662,"teacher_disagreement_score":0.9054785,"about_ca_system_score_codex":0.0006643008,"about_ca_system_score_gemma":0.0027992965,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W4280601706","doi":"10.3390/curroncol29050285","title":"Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Osimertinib; Medicine; Basal cell; Lung cancer; Mutation; Gene; Cancer research; Oncology; Lung; Gene mutation; Pathology; Bioinformatics; Internal medicine; Epidermal growth factor receptor; Cancer; Biology; Genetics; Erlotinib","score_opus":0.05409448897241014,"score_gpt":0.42873093835806386,"score_spread":0.3746364493856537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280601706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041767936,0.9911572,0.0000025727331,0.000038145994,0.00038459833,0.003612881,0.00017986428,0.000014116254,0.0004338335],"genre_scores_gemma":[0.0017528207,0.9924257,0.00013599379,0.000047837686,0.00006802417,0.0007821743,0.0046479376,0.00004323249,0.000096317744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787515,0.00023303316,0.0009360655,0.0005214997,0.000217253,0.00021699129],"domain_scores_gemma":[0.9982325,0.0002558317,0.0008434381,0.00039105868,0.00014878309,0.00012841866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001767157,0.0003377708,0.0017452815,0.0002661008,0.00005818142,0.0000067682427,0.00006968327,0.0001431588,0.00013000103],"category_scores_gemma":[0.00014349064,0.00023672928,0.00019585012,0.0005894329,0.000060649072,0.000040697974,0.00007060418,0.0005086455,0.0000017276619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000713755,0.0020772682,0.002551445,0.119875595,0.00012171549,0.0645515,0.0006008887,3.6146585e-7,1.68494e-8,0.000004002608,0.00095203484,0.8091938],"study_design_scores_gemma":[0.0048590126,0.0010838357,0.000726028,0.021267068,0.007046129,0.03268093,0.000019581097,0.000002039201,2.3646312e-7,8.7481146e-7,0.9320935,0.00022075263],"about_ca_topic_score_codex":0.00001677051,"about_ca_topic_score_gemma":0.00000640089,"teacher_disagreement_score":0.9311415,"about_ca_system_score_codex":0.00064368005,"about_ca_system_score_gemma":0.0010871674,"threshold_uncertainty_score":0.96535397},"labels":[],"label_agreement":null},{"id":"W4280616571","doi":"10.21203/rs.3.rs-1523595/v2","title":"Efficacy and toxicity of combined inhibition of EGFR and VEGF in patients with advanced non-small-cell lung cancer harboring activating EGFR mutations: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Amgen Canada; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Meta-analysis; Lung cancer; Epidermal growth factor receptor; Clinical endpoint; Adverse effect; Cochrane Library; Randomized controlled trial; Confidence interval; Cancer","score_opus":0.07069963616731054,"score_gpt":0.43435065327598865,"score_spread":0.3636510171086781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280616571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025287246,0.9660798,0.0000077375225,0.00004716381,0.0000043553673,0.008293761,0.00022436601,0.000006837789,0.000048785252],"genre_scores_gemma":[0.05272606,0.94371307,0.00019959643,0.000012614484,0.0000036164813,0.0029583029,0.00029915437,0.00003406751,0.000053518637],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99737525,0.00051710726,0.0008264575,0.0004392205,0.0006127851,0.00022915695],"domain_scores_gemma":[0.99785906,0.00074035785,0.00060482905,0.00033841675,0.0003522267,0.00010510996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007303395,0.00026819392,0.0035136375,0.00071479956,0.0001200223,0.000020126417,0.00006026878,0.00006951256,0.000060836777],"category_scores_gemma":[0.00027025753,0.0001780447,0.00023992876,0.0017174084,0.00008564188,0.00010653606,0.0001089067,0.00036678198,1.1371982e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004328258,0.00036606527,0.001094314,0.9728571,0.021611512,0.0000070923033,0.0005470203,0.000008118352,0.000003363137,0.000006828509,0.0000019107201,0.003453363],"study_design_scores_gemma":[0.005147122,0.0013521872,0.0027210019,0.282464,0.70709383,0.0000032474522,0.0005745281,0.00005954903,0.000034226177,0.0000037417497,0.00019067584,0.0003558708],"about_ca_topic_score_codex":0.00020789244,"about_ca_topic_score_gemma":0.000047706082,"teacher_disagreement_score":0.69039315,"about_ca_system_score_codex":0.00037606308,"about_ca_system_score_gemma":0.00035820343,"threshold_uncertainty_score":0.72604525},"labels":[],"label_agreement":null},{"id":"W4281289792","doi":"10.1200/jco.21.02278","title":"Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Post-hoc analysis; Internal medicine; Lung cancer; Adverse effect; Incidence (geometry); ALK inhibitor; Oncology","score_opus":0.020435421609981828,"score_gpt":0.43041616336475214,"score_spread":0.4099807417547703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281289792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965951,0.00038612165,0.00005334223,0.001312988,0.00029101997,0.0009184119,0.0002395309,0.0000023001871,0.00020122717],"genre_scores_gemma":[0.9981493,0.0001317649,0.00048125378,0.0009838106,0.00013446707,0.00002342943,0.000047211557,0.000011591528,0.000037215174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973621,0.00042060117,0.0015082068,0.0002132796,0.0003492219,0.00014663723],"domain_scores_gemma":[0.9958157,0.0020451127,0.001443524,0.00016340008,0.0003892374,0.0001430465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081843184,0.00012773964,0.0012782486,0.00014259813,0.00010740573,0.000005815101,0.0001229895,0.000065669316,0.00022479979],"category_scores_gemma":[0.00020180413,0.00007428055,0.00019346748,0.00045893792,0.00010930699,0.00006722573,0.00007255801,0.0006591969,1.6972625e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081173666,0.015240496,0.8005244,0.000005377357,0.005685895,0.0002199675,0.0046983995,0.0014819946,0.000037042864,0.0000014300037,0.000057165453,0.09087416],"study_design_scores_gemma":[0.10060565,0.032346934,0.85381156,0.00003553384,0.0106914835,0.0000029072248,0.001752552,0.00027842107,0.0000036596264,0.0000018238663,0.00040408634,0.00006537609],"about_ca_topic_score_codex":0.00051761395,"about_ca_topic_score_gemma":0.0010811137,"teacher_disagreement_score":0.09080878,"about_ca_system_score_codex":0.00026983832,"about_ca_system_score_gemma":0.0011165865,"threshold_uncertainty_score":0.3029073},"labels":[],"label_agreement":null},{"id":"W4281390999","doi":"10.1016/j.lungcan.2022.05.012","title":"Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Crizotinib; Lung cancer; Hazard ratio; Confidence interval; Clinical endpoint; Oncology; Population; ALK inhibitor; Adverse effect; Cancer; Gastroenterology; Clinical trial","score_opus":0.0043017809103495,"score_gpt":0.3100869242154153,"score_spread":0.3057851433050658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281390999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924351,0.0014499244,0.00011249186,0.00024769854,0.00013851223,0.00227842,0.0015026256,0.000009372957,0.0018258416],"genre_scores_gemma":[0.99861157,0.00016209442,0.00029908054,0.00007899583,0.000034985256,0.0004267851,0.00026812506,0.000020757672,0.00009758182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998546,0.00005148988,0.0004282151,0.00041500718,0.0003091975,0.00025011072],"domain_scores_gemma":[0.99916995,0.000046931353,0.00032136706,0.0002153406,0.00011073726,0.00013568813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007851393,0.00021359701,0.00069323234,0.00018159537,0.000103696606,0.000008274983,0.00006638013,0.00004699943,0.0001177393],"category_scores_gemma":[0.0000073755045,0.00018257236,0.00008795595,0.001025918,0.00008013693,0.0000811519,0.00005936286,0.00013937514,4.2936602e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050164927,0.0015850622,0.9173263,0.00026436776,0.0029320861,0.000022190297,0.0056516645,0.0018176892,0.00017404131,0.000021477828,0.000058420937,0.019981792],"study_design_scores_gemma":[0.16647786,0.002044858,0.8204494,0.00026485755,0.0072377245,9.0148706e-7,0.0006543531,0.0023825497,0.00015898646,0.0000018634034,0.00012399339,0.00020261071],"about_ca_topic_score_codex":0.0030317188,"about_ca_topic_score_gemma":0.003480371,"teacher_disagreement_score":0.116312936,"about_ca_system_score_codex":0.00075280946,"about_ca_system_score_gemma":0.00042755177,"threshold_uncertainty_score":0.74450845},"labels":[],"label_agreement":null},{"id":"W4281622178","doi":"10.2174/1381612828666220526125806","title":"Trabectedin in Cancers: Mechanisms and Clinical Applications","year":2022,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National College Students Innovation and Entrepreneurship Training Program; China Postdoctoral Science Foundation; National Natural Science Foundation of China; Harbin Medical University","keywords":"Trabectedin; Ifosfamide; Medicine; Soft tissue sarcoma; Cancer; Ovarian cancer; Sarcoma; Oncology; Cancer research; Pharmacology; Internal medicine; Chemotherapy; Bioinformatics; Biology; Pathology","score_opus":0.37002889141463713,"score_gpt":0.5688209869214935,"score_spread":0.1987920955068564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281622178","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.324825e-7,0.98239,0.012412094,0.00006720658,0.00056381925,0.0039654924,0.00009562836,0.00006532082,0.00044011767],"genre_scores_gemma":[0.00000950888,0.9944217,0.0012911501,0.00009801691,0.00023380666,0.0034911118,0.00028723912,0.000051168678,0.00011628212],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976526,0.00037752162,0.00076181424,0.0006270561,0.00025607317,0.00032494773],"domain_scores_gemma":[0.9985188,0.0006786255,0.00014793692,0.00025769448,0.000024398438,0.00037251666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044997747,0.00033524554,0.0012096151,0.00021094608,0.00009502534,0.000024026473,0.000132544,0.00015216644,0.00080158596],"category_scores_gemma":[0.000060650487,0.00027095946,0.00029845466,0.00050866226,0.00009812307,0.000044160217,0.00007422964,0.0010811308,0.000042653195],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021612654,0.0004627907,0.000012254933,0.0038325991,0.00021431645,0.000026069214,0.000018541765,5.815772e-7,1.14159526e-7,0.0008548865,0.0007681876,0.99378806],"study_design_scores_gemma":[0.001326089,0.00019350776,0.000011846197,0.0019416572,0.0049362713,0.000055223576,0.000010790141,0.00018820004,3.5298882e-7,0.00024647024,0.99086124,0.00022832604],"about_ca_topic_score_codex":0.0000057416382,"about_ca_topic_score_gemma":0.0000012981144,"teacher_disagreement_score":0.9935597,"about_ca_system_score_codex":0.0008353193,"about_ca_system_score_gemma":0.0012988271,"threshold_uncertainty_score":0.99997425},"labels":[],"label_agreement":null},{"id":"W4281633703","doi":"10.1200/jco.2022.40.16_suppl.3099","title":"Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (<i>NTRK</i>-fp) solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Cohort; Response Evaluation Criteria in Solid Tumors; Oncology; Progression-free survival; Trk receptor; Phases of clinical research; Clinical trial; Overall survival; Receptor","score_opus":0.0196159395241474,"score_gpt":0.403184964735448,"score_spread":0.3835690252113006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281633703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656475,0.00019616805,0.00008117904,0.0015589413,0.00025863346,0.0004962098,0.0000791705,0.000002669226,0.0007622903],"genre_scores_gemma":[0.9978424,0.0001440399,0.0009042657,0.00095681136,0.000031405885,0.0000070325987,0.000027669652,0.000011283577,0.00007510831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964142,0.0005970661,0.0021367252,0.00019059452,0.00049137394,0.0001700397],"domain_scores_gemma":[0.9951938,0.0015287122,0.0024425755,0.0001951612,0.00048673557,0.00015305605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010665503,0.00013016295,0.001643801,0.00025155535,0.00007668418,0.000002791037,0.00014215607,0.000058205635,0.00017658256],"category_scores_gemma":[0.00072864664,0.00007548024,0.00031205185,0.00094447524,0.00023903258,0.000065476415,0.00010631408,0.00058192195,3.6265573e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027471704,0.010567413,0.8277627,0.000037341426,0.006960444,0.00022083912,0.0014188713,0.011598733,0.000105077954,0.000068082765,0.0004385448,0.1133502],"study_design_scores_gemma":[0.026961239,0.016589016,0.947138,0.00014449014,0.006039965,0.000043978227,0.00060811307,0.0002535975,0.0000766362,0.000046514262,0.0020212098,0.00007723946],"about_ca_topic_score_codex":0.00005046032,"about_ca_topic_score_gemma":0.00010280266,"teacher_disagreement_score":0.11937525,"about_ca_system_score_codex":0.0002274586,"about_ca_system_score_gemma":0.0012910519,"threshold_uncertainty_score":0.30779946},"labels":[],"label_agreement":null},{"id":"W4281638918","doi":"10.1200/jco.2022.40.16_suppl.9091","title":"DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Population; Lung cancer; Internal medicine; Cancer","score_opus":0.1710566535487411,"score_gpt":0.5076650051780691,"score_spread":0.336608351629328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281638918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917574,0.00026930714,0.00007100456,0.005817679,0.0009166435,0.00055735203,0.00004644693,0.000011928519,0.00055222184],"genre_scores_gemma":[0.9944482,0.00021672835,0.0023409247,0.0021349795,0.00037277432,0.000010654357,0.000024829444,0.00002689748,0.0004240447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99469995,0.0011229719,0.0029936223,0.0003255253,0.00060809014,0.00024985525],"domain_scores_gemma":[0.99289733,0.0027272883,0.0029649034,0.0003222523,0.00080164825,0.0002865467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044982126,0.00020244705,0.0014561693,0.00020017517,0.0001717561,0.000016467246,0.0001824675,0.00020147167,0.00014583691],"category_scores_gemma":[0.0074056727,0.00011369049,0.00016588916,0.0004717947,0.00024386446,0.00013953808,0.00010493569,0.0013156707,0.0000018440135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13623738,0.012146655,0.81074524,0.00019790971,0.0017073537,0.00036854172,0.0028788948,0.004146579,0.00013746832,0.00029155778,0.002988115,0.02815431],"study_design_scores_gemma":[0.052469164,0.037588038,0.89280075,0.0006568393,0.00092540914,0.00015496704,0.0012470661,0.0016843848,0.000031665477,0.00021944675,0.011973201,0.0002490573],"about_ca_topic_score_codex":0.0003692523,"about_ca_topic_score_gemma":0.00079618755,"teacher_disagreement_score":0.08376822,"about_ca_system_score_codex":0.0004655176,"about_ca_system_score_gemma":0.0033696343,"threshold_uncertainty_score":0.8865817},"labels":[],"label_agreement":null},{"id":"W4281670642","doi":"10.1200/jco.2022.40.16_suppl.9016","title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Immunohistochemistry; Cohort; Interim analysis; Oncology; Stage (stratigraphy); Clinical endpoint; Cancer; Lung cancer; Interim; Chemotherapy; Clinical trial; Biology","score_opus":0.030104674396273245,"score_gpt":0.4231097895866135,"score_spread":0.39300511519034026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281670642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209857,0.0028834224,0.00009303816,0.0007382252,0.0006767169,0.00083962234,0.000018870103,0.000013488774,0.002638021],"genre_scores_gemma":[0.9917909,0.0011624126,0.0038714602,0.0021505468,0.00029743422,0.00010216259,0.000018540128,0.000050001167,0.0005565608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968156,0.00036648175,0.0017461076,0.0003185665,0.0003937461,0.0003594577],"domain_scores_gemma":[0.9968876,0.0005403623,0.0017235731,0.00023147059,0.00032712528,0.0002898439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076779944,0.00022299276,0.001295626,0.00021179131,0.00012212025,0.00001450027,0.00019404881,0.00015990443,0.00034666903],"category_scores_gemma":[0.00013716008,0.00015739475,0.00028993658,0.00031043845,0.00007698787,0.00015413211,0.0000562655,0.0010382526,0.0000026531027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012258976,0.0053140284,0.76830035,0.00006213078,0.0005346798,0.00035718095,0.0011505717,0.0028326537,0.00017674179,0.000002571908,0.001829886,0.20718025],"study_design_scores_gemma":[0.13946053,0.05423244,0.7064183,0.0009534655,0.0019431759,0.00008920941,0.0009823831,0.0007478973,0.00036288615,0.000035493453,0.09432333,0.00045089077],"about_ca_topic_score_codex":0.00025488384,"about_ca_topic_score_gemma":0.00011106329,"teacher_disagreement_score":0.20672935,"about_ca_system_score_codex":0.0013488911,"about_ca_system_score_gemma":0.003153681,"threshold_uncertainty_score":0.6418372},"labels":[],"label_agreement":null},{"id":"W4281676882","doi":"10.1200/jco.2022.40.16_suppl.102","title":"Largest evaluation of acquired resistance to sotorasib in <i>KRAS</i> p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Amgen","keywords":"KRAS; Medicine; Colorectal cancer; Internal medicine; Oncology; Clinical endpoint; Lung cancer; Progression-free survival; Cancer; Biomarker; Tumor progression; Overall survival; Clinical trial","score_opus":0.07079144942081898,"score_gpt":0.48157992749400935,"score_spread":0.41078847807319036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281676882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921862,0.0027604466,0.00003764144,0.0025485216,0.0006143541,0.00072565576,0.0002011671,0.0000038921544,0.0009221155],"genre_scores_gemma":[0.99757624,0.0006970625,0.0006971574,0.00052537426,0.00008693767,0.00014192874,0.000025643612,0.000017704993,0.00023195511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960577,0.0006544079,0.002109338,0.00027733578,0.0006796369,0.00022161215],"domain_scores_gemma":[0.99571794,0.00093602616,0.0019214916,0.00015561795,0.0010296106,0.00023930792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00329383,0.00015643943,0.0016284672,0.0005392437,0.000060161936,0.0000050176345,0.00014016613,0.0001643872,0.0004817119],"category_scores_gemma":[0.0005691829,0.00012710047,0.0003456679,0.0012204236,0.00012455611,0.000071837974,0.000073594194,0.0002519671,3.493057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010679631,0.0025065313,0.9430735,0.00011259949,0.00489675,0.00011746141,0.001444646,0.007831793,0.010154876,0.0000088858615,0.0033420278,0.01583131],"study_design_scores_gemma":[0.01612562,0.0026852265,0.95108986,0.0001700312,0.014844457,0.000012668971,0.00042568299,0.010400572,0.0015080749,0.000017537783,0.0025874393,0.00013285718],"about_ca_topic_score_codex":0.00094601774,"about_ca_topic_score_gemma":0.0079526445,"teacher_disagreement_score":0.015698453,"about_ca_system_score_codex":0.000944259,"about_ca_system_score_gemma":0.0043004146,"threshold_uncertainty_score":0.7628751},"labels":[],"label_agreement":null},{"id":"W4281680466","doi":"10.1200/jco.2022.40.16_suppl.tps8601","title":"TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"ROS1; Medicine; Crizotinib; Pemetrexed; Lung cancer; Internal medicine; Cohort; Oncology; Retrospective cohort study; Cancer; Chemotherapy; Adenocarcinoma; Cisplatin","score_opus":0.06680034650621461,"score_gpt":0.5470637216356914,"score_spread":0.4802633751294768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281680466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845977,0.0010222439,0.000028097651,0.006833416,0.0010339028,0.0009419562,0.00016173396,0.0000061359196,0.0015127741],"genre_scores_gemma":[0.99360996,0.00007359149,0.0004632998,0.0044765593,0.0006073919,0.00013963341,0.000004024936,0.000013525114,0.0006119918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978249,0.00021683049,0.0013148033,0.00020709833,0.00023792984,0.00019841117],"domain_scores_gemma":[0.9981752,0.0005143459,0.0008425303,0.000091034184,0.00016852972,0.00020835965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012988265,0.00011627231,0.0010139511,0.00008063046,0.00024558787,0.000005772992,0.00008075601,0.000079576974,0.00026016604],"category_scores_gemma":[0.00047728157,0.000086120606,0.00021133582,0.00018393755,0.0000796848,0.00005804986,0.000117699405,0.0004647122,2.794802e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02490642,0.04185051,0.6194662,0.000036093257,0.0020227386,0.0015464262,0.00560654,0.00013359963,0.00009614599,0.00015382646,0.012961415,0.29122007],"study_design_scores_gemma":[0.17402413,0.2835262,0.2914404,0.00019568311,0.0039048428,0.0011177728,0.0077342,0.001053528,0.000035435914,0.00045475215,0.23620266,0.00031036197],"about_ca_topic_score_codex":0.00021938862,"about_ca_topic_score_gemma":0.00037734755,"teacher_disagreement_score":0.32802582,"about_ca_system_score_codex":0.0006180133,"about_ca_system_score_gemma":0.0017245052,"threshold_uncertainty_score":0.35118964},"labels":[],"label_agreement":null},{"id":"W4281683594","doi":"10.1200/jco.2022.40.16_suppl.9069","title":"Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with <i>ALK</i>+ advanced non–small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Crizotinib; Medicine; Internal medicine; ALK inhibitor; Clinical endpoint; Progression-free survival; Lung cancer; Randomization; Oncology; Chemotherapy; Randomized controlled trial; Gastroenterology; Surgery","score_opus":0.05485920621376665,"score_gpt":0.46937578439565286,"score_spread":0.4145165781818862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281683594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930524,0.0012130102,0.00007172,0.0017029315,0.0010339075,0.0016372878,0.00022009344,0.0000075237144,0.0010611003],"genre_scores_gemma":[0.99332947,0.0008419742,0.004553661,0.00035753168,0.0004121206,0.00028623283,0.000047053767,0.00003631891,0.00013563213],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99661565,0.0004245007,0.0016690538,0.00031578995,0.00069242064,0.00028255736],"domain_scores_gemma":[0.9956581,0.0011040365,0.002253113,0.00030695793,0.0004336304,0.00024417945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006152464,0.00024159766,0.0016387183,0.00014449538,0.0000800413,0.000007397094,0.00019804429,0.000116274656,0.0003330457],"category_scores_gemma":[0.00016308969,0.00013747979,0.00027125812,0.0002708031,0.00019066603,0.00011317219,0.00005522827,0.00055655895,4.920061e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31955147,0.024563564,0.50915504,0.000033317046,0.0017610975,0.0005797815,0.0022543748,0.00033851422,0.0001506854,0.000007787146,0.00020276674,0.14140157],"study_design_scores_gemma":[0.7257165,0.16384265,0.09495802,0.00042746082,0.0026635332,0.00001549172,0.0014684991,0.0001290037,0.0003578159,0.000057131536,0.010134902,0.00022903166],"about_ca_topic_score_codex":0.0004995005,"about_ca_topic_score_gemma":0.00075794687,"teacher_disagreement_score":0.41419703,"about_ca_system_score_codex":0.0008516356,"about_ca_system_score_gemma":0.004690324,"threshold_uncertainty_score":0.8320433},"labels":[],"label_agreement":null},{"id":"W4281695484","doi":"10.1200/jco.2022.40.16_suppl.tps9159","title":"AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with <i>RET</i> fusion–positive advanced/metastatic NSCLC.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Pemetrexed; Internal medicine; Lung cancer; Oncology; Crizotinib; Response Evaluation Criteria in Solid Tumors; Population; Gemcitabine; Adverse effect; Phases of clinical research; Clinical trial; Cancer; Chemotherapy; Immunotherapy; Malignant pleural effusion","score_opus":0.0640521458669212,"score_gpt":0.4968587128532268,"score_spread":0.4328065669863056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281695484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956531,0.00016542974,0.00005165758,0.0017855612,0.00042358777,0.0010878412,0.0000530025,0.0000043611685,0.000775467],"genre_scores_gemma":[0.99765205,0.000054866385,0.0012469549,0.00075367675,0.00008894641,0.000045191184,0.000026298638,0.00001741271,0.00011456996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966762,0.00044892126,0.0019380335,0.0001990805,0.0005566192,0.00018114895],"domain_scores_gemma":[0.9961315,0.0011066999,0.0019171067,0.00017469932,0.00047118214,0.00019881006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067685,0.00013546739,0.0012561289,0.00018528817,0.00007735769,0.0000029838388,0.00012305785,0.000051575564,0.00031046546],"category_scores_gemma":[0.00064289797,0.00009007883,0.00016421321,0.00033682366,0.00007876661,0.00011251084,0.00008237859,0.00070389383,0.0000010213091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040655423,0.0827132,0.7616158,0.00004038589,0.0012273892,0.0010466008,0.0023118104,0.0008410152,0.0000057528946,0.000012193013,0.0011801715,0.10835025],"study_design_scores_gemma":[0.15995337,0.23158456,0.59516126,0.00015700639,0.0017892541,0.000066264045,0.0028121627,0.000115093564,0.000008320174,0.000052344214,0.008176698,0.00012368837],"about_ca_topic_score_codex":0.00002738128,"about_ca_topic_score_gemma":0.00007396415,"teacher_disagreement_score":0.16645457,"about_ca_system_score_codex":0.00029664254,"about_ca_system_score_gemma":0.001049121,"threshold_uncertainty_score":0.36733082},"labels":[],"label_agreement":null},{"id":"W4281750894","doi":"10.1200/jco.2022.40.16_suppl.e21139","title":"The impact of population-based EGFR testing in metastatic non-small cell lung cancer in Alberta.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Population; Lung cancer; Proportional hazards model; Epidermal growth factor receptor; Hazard ratio; Cancer; Confidence interval","score_opus":0.08172151486966567,"score_gpt":0.5107770710693393,"score_spread":0.42905555619967367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281750894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478126,0.0005370463,0.000018559542,0.0028870003,0.00034518878,0.00026772398,0.0000075130774,0.0000011519543,0.0011545831],"genre_scores_gemma":[0.9982442,0.00004799319,0.0011111188,0.00030111836,0.00009383856,0.00002576399,0.0000037594066,0.000009573484,0.00016263568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770117,0.00033863957,0.0015331209,0.000092064,0.00017946953,0.00015556625],"domain_scores_gemma":[0.9925433,0.00590129,0.0012156797,0.00010081255,0.00014173926,0.00009720271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016446133,0.00007578277,0.0006769222,0.00013218862,0.000051908493,0.0000034363568,0.000098868375,0.000045588025,0.00012472783],"category_scores_gemma":[0.0016955052,0.000044411416,0.00025155983,0.00031258288,0.00003352938,0.000033101005,0.000023104954,0.0005708906,4.0758084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069287285,0.0010746759,0.9282329,0.000021089352,0.00015696313,0.00012343729,0.00020205346,0.053181533,0.000035902383,0.000006730815,0.00020921013,0.016062653],"study_design_scores_gemma":[0.007589851,0.0037704082,0.97173834,0.00007534529,0.0003222548,0.00002124714,0.0001721628,0.015793737,0.000006110049,0.000108156026,0.00036142487,0.000040954903],"about_ca_topic_score_codex":0.015610557,"about_ca_topic_score_gemma":0.004803267,"teacher_disagreement_score":0.043505467,"about_ca_system_score_codex":0.0008996051,"about_ca_system_score_gemma":0.0041914205,"threshold_uncertainty_score":0.99094456},"labels":[],"label_agreement":null},{"id":"W4281763773","doi":"10.1200/jco.2022.40.16_suppl.e20504","title":"Real-world treatment patterns and clinical outcomes in early stage non-small cell lung cancer (eNSCLC) in Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Cohort; Proportional hazards model; Medical record; Retrospective cohort study; Cancer registry; Population; Hazard ratio; Lung cancer; Cancer; Surgery; Confidence interval","score_opus":0.07157574938865965,"score_gpt":0.4787463721276269,"score_spread":0.4071706227389672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281763773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104786,0.00020790595,0.0000038415333,0.005372363,0.0013317721,0.00041212255,0.00006891368,0.0000028269671,0.001552418],"genre_scores_gemma":[0.9920618,0.0028822639,0.00031481034,0.00169624,0.0002479688,0.000044005323,0.0000054687544,0.000017858103,0.0027295987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649507,0.00042366463,0.0022962375,0.00024318798,0.00027051265,0.00027131895],"domain_scores_gemma":[0.9967285,0.0017208424,0.00096975913,0.00015964518,0.00008078343,0.0003405042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011264365,0.00015222248,0.0014852727,0.00018765152,0.000044791217,0.0000059943636,0.000103570164,0.00009462151,0.00024623502],"category_scores_gemma":[0.00014520406,0.00010864799,0.00025008872,0.00015640314,0.00004489275,0.000047256104,0.00006585276,0.00088542333,6.0353767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083535025,0.001935552,0.97465175,0.000019148614,0.00038023456,0.0028377792,0.00034121325,0.00013818554,0.000001018235,0.000006514441,0.00046156085,0.018391676],"study_design_scores_gemma":[0.015986977,0.004941361,0.96545154,0.00004431606,0.00049253134,0.000017200186,0.0004982447,0.00016579562,0.0000025921152,0.000007920959,0.0123033775,0.00008813866],"about_ca_topic_score_codex":0.8679888,"about_ca_topic_score_gemma":0.9795154,"teacher_disagreement_score":0.11152652,"about_ca_system_score_codex":0.0035602974,"about_ca_system_score_gemma":0.012786205,"threshold_uncertainty_score":0.99281037},"labels":[],"label_agreement":null},{"id":"W4281773966","doi":"10.51731/cjht.2022.350","title":"Lorlatinib (Lorbrena)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Drug; Family medicine; Intensive care medicine; Political science; Pharmacology; Health care","score_opus":0.0271931516960458,"score_gpt":0.33553377938504764,"score_spread":0.30834062768900183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281773966","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3134336,0.1966852,0.00037194838,0.47881642,0.0020757122,0.0009375424,0.00015706349,0.0002749295,0.0072476054],"genre_scores_gemma":[0.99772704,0.00009014866,0.0006515424,0.0011856181,0.000009030313,0.000013486048,0.0000055858395,0.000008803999,0.00030874382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992628,0.000023864055,0.00027493678,0.00006823622,0.00013269552,0.00023747003],"domain_scores_gemma":[0.999483,0.00001766095,0.00020834077,0.00013959152,0.00007179467,0.00007965011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022310053,0.000059413524,0.00020505302,0.00044096762,0.0003959014,0.000008773957,0.000117970914,0.00002663308,0.00018408858],"category_scores_gemma":[0.0001000677,0.000049455735,0.00005610791,0.00027941444,0.00006619259,0.000038768,0.0000144555115,0.00032303727,0.0000035566438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026262083,0.000056350003,0.024295531,0.00006685965,0.0001641871,0.0007270913,0.0010736178,0.00010045731,0.000020195654,0.002919657,0.05148361,0.9190662],"study_design_scores_gemma":[0.0009099863,0.0012342971,0.01248816,0.0000559905,0.000043855944,0.00133602,0.008201354,0.0000070696474,0.0000684625,0.0019244079,0.9736664,0.000063976004],"about_ca_topic_score_codex":0.0023908322,"about_ca_topic_score_gemma":0.00075566495,"teacher_disagreement_score":0.9221828,"about_ca_system_score_codex":0.0008640417,"about_ca_system_score_gemma":0.004818508,"threshold_uncertainty_score":0.85478264},"labels":[],"label_agreement":null},{"id":"W4282000826","doi":"10.1200/jco.2022.40.16_suppl.9077","title":"Treatment patterns and outcomes in <i>ALK</i> or <i>ROS1</i> altered NSCLC: An ATOMIC Registry Study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Crizotinib; ROS1; Medicine; Alectinib; Internal medicine; Discontinuation; ALK inhibitor; Oncology; Ceritinib; Anaplastic lymphoma kinase; Cabozantinib; Lung cancer; Cancer; Adenocarcinoma","score_opus":0.11683352318446201,"score_gpt":0.5224911124055275,"score_spread":0.4056575892210655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282000826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216306,0.00013973845,0.000008010114,0.0056850594,0.0008836119,0.00044162694,0.00002768257,0.0000075715343,0.00064366683],"genre_scores_gemma":[0.99576724,0.00028230448,0.000359555,0.002152234,0.00034335657,0.000041773485,0.0000076027686,0.000015325846,0.0010306389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746966,0.00046146355,0.001434655,0.00021389117,0.00024869014,0.00017164489],"domain_scores_gemma":[0.99791443,0.00072693767,0.0008000581,0.00021903115,0.00006683927,0.0002726737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000820497,0.00013230917,0.0011886937,0.00010600222,0.00007603998,0.00000982722,0.00010283483,0.000086933185,0.00017402056],"category_scores_gemma":[0.00024198381,0.000079386366,0.00019217028,0.0000879917,0.000056239776,0.00008619558,0.000058182122,0.00049823016,0.0000017538708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003643284,0.010394709,0.90180105,0.0000067170668,0.00053011684,0.0027325859,0.0008756241,0.000008751159,0.000007977883,0.000011980088,0.00034657383,0.07964062],"study_design_scores_gemma":[0.03099097,0.058341246,0.86851335,0.000015972599,0.0007250608,0.000916222,0.0033175524,0.00002593801,0.0000034251025,0.00006687796,0.037003145,0.0000802691],"about_ca_topic_score_codex":0.0003572209,"about_ca_topic_score_gemma":0.0010020161,"teacher_disagreement_score":0.07956035,"about_ca_system_score_codex":0.00053201296,"about_ca_system_score_gemma":0.0015014876,"threshold_uncertainty_score":0.3237282},"labels":[],"label_agreement":null},{"id":"W4282926341","doi":"10.1158/1538-7445.am2022-ct223","title":"Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Crizotinib; Medicine; Internal medicine; ALK inhibitor; Lung cancer; Interim analysis; Oncology; Clinical endpoint; Progression-free survival; Anaplastic lymphoma kinase; Gastroenterology; Randomized controlled trial; Overall survival","score_opus":0.033986968074024,"score_gpt":0.4047510235122184,"score_spread":0.3707640554381944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282926341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888264,0.0036367578,0.000013266231,0.0014047436,0.00020545628,0.0037007413,0.0016564496,0.00002392037,0.000532269],"genre_scores_gemma":[0.99675685,0.0006668992,0.0000395761,0.00015695699,0.00015072024,0.0014849904,0.00031485016,0.000056412147,0.00037271573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972248,0.00023960716,0.0005413374,0.00067289633,0.0007572309,0.0005641408],"domain_scores_gemma":[0.99774045,0.0009972781,0.00017038826,0.0005318762,0.00034408012,0.00021592206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004768943,0.00026223937,0.0005168355,0.00024355146,0.0006250491,0.000038371007,0.00028494728,0.00005729304,0.001306863],"category_scores_gemma":[0.00010293016,0.00020197571,0.000062921245,0.0010241678,0.00017922114,0.00012505999,0.00026628425,0.0005825767,0.000003163225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1433046,0.040704362,0.4282618,0.0011948355,0.0036200187,0.0025563806,0.09811941,0.030928679,0.04298684,0.000047191385,0.009895535,0.19838038],"study_design_scores_gemma":[0.104782775,0.0060470724,0.86030364,0.0008156908,0.0006677303,0.0000056619488,0.012737824,0.0025455055,0.006995126,0.000015808153,0.004665401,0.00041778412],"about_ca_topic_score_codex":0.022806909,"about_ca_topic_score_gemma":0.008513739,"teacher_disagreement_score":0.43204185,"about_ca_system_score_codex":0.0011550917,"about_ca_system_score_gemma":0.0011091261,"threshold_uncertainty_score":0.9996061},"labels":[],"label_agreement":null},{"id":"W4282961610","doi":"10.1016/j.critrevonc.2022.103747","title":"Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: A systematic review","year":2022,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Lung cancer; Clinical trial; Inclusion and exclusion criteria; MEDLINE; Randomized controlled trial; Internal medicine; Systematic review; Oncology; Intensive care medicine; Physical therapy; Alternative medicine; Pathology","score_opus":0.7253479304992632,"score_gpt":0.6936135107392718,"score_spread":0.03173441975999136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282961610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002083969,0.9835829,0.0010318877,0.0020778594,0.0005041915,0.011587363,0.00008820453,0.000018472198,0.0010882538],"genre_scores_gemma":[0.00013609954,0.9829296,0.0037356976,0.0017103992,0.000080046986,0.0111976,0.000120208795,0.00005204773,0.000038292506],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.93804324,0.04639571,0.013391343,0.0009959062,0.0005065973,0.00066723506],"domain_scores_gemma":[0.8679545,0.12284306,0.0067510568,0.0017963365,0.00035005002,0.00030503265],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03849065,0.00079581636,0.03292875,0.00046920584,0.00011662989,0.000015714195,0.0007446681,0.0007988488,0.0010119383],"category_scores_gemma":[0.16994914,0.00042791673,0.0027419575,0.001688382,0.00059740344,0.00007658484,0.00032830925,0.0016529165,0.000010370965],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035443107,0.0011412528,0.00018298597,0.96196747,0.0006201087,0.00008490068,0.00014726058,0.0000011784296,0.0000011317519,0.0035114891,0.0002857256,0.03202108],"study_design_scores_gemma":[0.00191797,0.0003636368,0.00004729566,0.83049864,0.030023808,0.00016445472,0.0003931621,0.000021613258,0.0000023212333,0.00033645637,0.13572629,0.0005043384],"about_ca_topic_score_codex":0.00037580144,"about_ca_topic_score_gemma":0.0003223348,"teacher_disagreement_score":0.13544056,"about_ca_system_score_codex":0.0012229532,"about_ca_system_score_gemma":0.0033669746,"threshold_uncertainty_score":0.9999013},"labels":[],"label_agreement":null},{"id":"W4282974570","doi":"10.1016/j.jmoldx.2022.05.004","title":"Multicenter Evaluation of the Idylla GeneFusion in Non–Small-Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Janssen Pharmaceuticals; Invitae; Bio-Rad Laboratories; Roche; Novartis; Bayer; Universitair Medisch Centrum Groningen; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Universität zu Köln; Meso Scale Diagnostics; Merck; Abbott Laboratories","keywords":"Concordance; Medicine; Lung cancer; Oncology; Internal medicine; ROS1; Exon; Cancer; Multicenter study; Gene; Biology; Genetics; Adenocarcinoma; Randomized controlled trial","score_opus":0.012955769561754604,"score_gpt":0.33210704623277537,"score_spread":0.3191512766710208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282974570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114686,0.006446891,0.00027362234,0.0008632323,0.00045059354,0.0005110585,0.000014421981,0.0000011037331,0.00029219006],"genre_scores_gemma":[0.9984264,0.0005585105,0.0004451966,0.00042924896,0.000046010242,0.000039139082,0.0000040012105,0.00001217221,0.000039363316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987705,0.00012185159,0.00031052582,0.00006924785,0.0006367281,0.00009118424],"domain_scores_gemma":[0.99909616,0.00007248626,0.00030268327,0.00013596872,0.000350353,0.000042371026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038126955,0.00006675228,0.00014979899,0.0000965821,0.000049274928,0.0000046030596,0.00009112506,0.000022865845,0.00013784433],"category_scores_gemma":[0.00020034562,0.000046744746,0.000110167406,0.00018454016,0.000013782589,0.00002028479,0.00005905705,0.00018762237,3.0138222e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020931475,0.0021587878,0.7091498,0.00018948248,0.0004755279,0.00033631478,0.003617433,0.17673655,0.09042046,0.000029444353,0.003547876,0.013129022],"study_design_scores_gemma":[0.02456026,0.00092353916,0.800807,0.0010845021,0.0089302,0.00014862634,0.001414557,0.04093463,0.1181478,0.00017113707,0.0026229382,0.00025479367],"about_ca_topic_score_codex":0.00007291924,"about_ca_topic_score_gemma":0.000027304817,"teacher_disagreement_score":0.13580191,"about_ca_system_score_codex":0.0004347782,"about_ca_system_score_gemma":0.0005147551,"threshold_uncertainty_score":0.19061954},"labels":[],"label_agreement":null},{"id":"W4283333321","doi":"10.3390/curroncol29070352","title":"Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"KRAS; Neuroblastoma RAS viral oncogene homolog; Medicine; PDGFRA; Oncology; ROS1; Internal medicine; Lung cancer; Clinical trial; Targeted therapy; DNA sequencing; Cancer; Bioinformatics; Gene; Adenocarcinoma; Genetics; Biology","score_opus":0.13844159239084702,"score_gpt":0.43010600511863073,"score_spread":0.2916644127277837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283333321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98337626,0.008265913,0.00033725938,0.00083622645,0.0023691494,0.00066396414,0.000022507682,0.00002292996,0.004105769],"genre_scores_gemma":[0.9966569,0.00037382872,0.00032514922,0.00036759957,0.0003574616,0.00095434993,0.00018051655,0.000014156609,0.0007700165],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992397,0.000057440568,0.00018854463,0.00021662972,0.00010328387,0.00019441178],"domain_scores_gemma":[0.9996912,0.000018677916,0.00007057553,0.00011601173,0.000040365696,0.000063153595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009688075,0.000088801426,0.00018302359,0.00010909896,0.000115720206,0.000006769375,0.000049000322,0.000032581243,0.0006381012],"category_scores_gemma":[0.0000063726457,0.00008416692,0.00004189416,0.00015003477,0.000014434258,0.00004113423,0.00004966368,0.0002291367,0.0000073152237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021804856,0.0024439374,0.48117554,0.0005130159,0.00022449452,0.00041007556,0.02692168,0.019212602,0.06250702,0.00030520227,0.061259374,0.34480903],"study_design_scores_gemma":[0.017574346,0.0021208602,0.05120473,0.00016986002,0.0012952074,0.0001173813,0.005964979,0.22705562,0.0034065754,0.00007622372,0.69037604,0.0006381383],"about_ca_topic_score_codex":0.000579707,"about_ca_topic_score_gemma":0.00062861474,"teacher_disagreement_score":0.6291167,"about_ca_system_score_codex":0.004739349,"about_ca_system_score_gemma":0.0012523553,"threshold_uncertainty_score":0.99908125},"labels":[],"label_agreement":null},{"id":"W4284713731","doi":"10.3390/curroncol29070379","title":"Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"KRAS; ERCC1; Lung cancer; Medicine; Cancer research; Immunohistochemistry; Oncogene; Targeted therapy; Thymidylate synthase; Cancer; DNA repair; Oncology; Biology; Pathology; Colorectal cancer; Internal medicine; Gene; Cell cycle; Nucleotide excision repair","score_opus":0.039338051379760076,"score_gpt":0.40795000322129504,"score_spread":0.36861195184153495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284713731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98716074,0.0066359374,0.00019233538,0.00036319072,0.0011951856,0.0015993991,0.00015209323,0.000025867228,0.0026752732],"genre_scores_gemma":[0.99739385,0.0002539641,0.00029649216,0.00006633813,0.000110487534,0.0014550387,0.00016790578,0.00003106084,0.00022484332],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849117,0.00008254059,0.00042115533,0.00039999513,0.00019536332,0.00040978848],"domain_scores_gemma":[0.99923134,0.0000674863,0.0002059001,0.0003033539,0.000073979565,0.000117929616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112274254,0.00022739866,0.00052028743,0.00020997385,0.000103550214,0.0000061733203,0.000134239,0.00007008733,0.00020249042],"category_scores_gemma":[0.000010549,0.00015581548,0.00012085768,0.00025904027,0.00004851344,0.000029659133,0.000103964056,0.00025734238,0.0000024192248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001079508,0.010126841,0.8239785,0.0011645574,0.00058451504,0.0017249177,0.013405984,0.019006794,0.07051813,0.00017047998,0.00063039706,0.057609394],"study_design_scores_gemma":[0.118147515,0.04289079,0.15282911,0.002018882,0.010051368,0.00030484886,0.042208042,0.047257666,0.4955466,0.0006746989,0.085107446,0.0029630177],"about_ca_topic_score_codex":0.00052331487,"about_ca_topic_score_gemma":0.0001043145,"teacher_disagreement_score":0.6711494,"about_ca_system_score_codex":0.0018569771,"about_ca_system_score_gemma":0.0015726842,"threshold_uncertainty_score":0.6353971},"labels":[],"label_agreement":null},{"id":"W4284884980","doi":"10.1016/j.ejca.2022.05.023","title":"Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company; Ono Pharmaceutical; Ignyta; Chugai Pharmaceutical; EMD Serono; Genentech; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Eisai; Puma Biotechnology; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Mirati Therapeutics; National Medical Research Council; Kissei; GlaxoSmithKline; Novartis Institutes for BioMedical Research; Amgen; Dainippon Sumitomo Pharma; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Rash; Internal medicine; Adverse effect; Clinical endpoint; Maculopapular rash; Discontinuation; Brain metastasis; Lung cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Gastroenterology; Phases of clinical research; T790M; non-small cell lung cancer (NSCLC); Cancer; Surgery; Toxicity; Epidermal growth factor receptor; Metastasis; Gefitinib; Clinical trial","score_opus":0.06437095391339918,"score_gpt":0.3997258231664293,"score_spread":0.3353548692530301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284884980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806321,0.0057524303,0.00018713123,0.0015666354,0.0009133438,0.002568533,0.0011337484,0.000013799178,0.0072322697],"genre_scores_gemma":[0.9924605,0.00033879717,0.00082889805,0.00030814673,0.00043043445,0.00020858807,0.000026478074,0.00007750318,0.0053206924],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978147,0.00025324055,0.0009526648,0.00030101114,0.0003857731,0.00029261742],"domain_scores_gemma":[0.9977579,0.000093975825,0.0011404307,0.00029337086,0.0004933174,0.00022100013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006073763,0.00024073223,0.00063221826,0.00017266053,0.00024953013,0.000043543165,0.00032342694,0.0000132746245,0.00025400915],"category_scores_gemma":[0.000041696738,0.00018372796,0.00016492524,0.00027243924,0.0000390408,0.00012447489,0.000113277034,0.00015886979,0.0000016761592],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07966519,0.16688545,0.01783648,0.00057068,0.01416291,0.005959494,0.089434095,0.0040041916,0.15686654,0.00003848816,0.05429747,0.410279],"study_design_scores_gemma":[0.51761097,0.1425594,0.0032948917,0.00086655276,0.0128491465,0.00021887613,0.012763795,0.0009161202,0.03427135,0.000018880293,0.2739223,0.0007077518],"about_ca_topic_score_codex":0.00035914406,"about_ca_topic_score_gemma":0.00009911137,"teacher_disagreement_score":0.43794575,"about_ca_system_score_codex":0.0010764917,"about_ca_system_score_gemma":0.0010684828,"threshold_uncertainty_score":0.74922085},"labels":[],"label_agreement":null},{"id":"W4285403511","doi":"10.1016/j.lungcan.2022.07.008","title":"The changing landscape of pneumonitis in non-small cell lung cancer","year":2022,"lang":"en","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Lung cancer; Pneumonitis; Radiation Pneumonitis; Hypersensitivity pneumonitis; Lung; Oncology; Internal medicine","score_opus":0.005636140618514189,"score_gpt":0.3081479833239252,"score_spread":0.302511842705411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285403511","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0142932255,0.10332436,0.000013857065,0.001070166,0.8650495,0.0022980236,0.0019404334,0.00006236559,0.011948095],"genre_scores_gemma":[0.064199574,0.060715728,0.000083145314,0.00031995485,0.78454906,0.009899129,0.0015800034,0.00037344455,0.07827995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777377,0.000052584495,0.00045035876,0.00047887655,0.0006755492,0.0005688735],"domain_scores_gemma":[0.9985172,0.0003687417,0.00034981742,0.00046150808,0.00020182777,0.00010091078],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021354058,0.00034375524,0.00062165566,0.00028605564,0.00025648726,0.000035650643,0.00026313594,0.000280281,0.0009409041],"category_scores_gemma":[0.000041505526,0.0002585205,0.00019732345,0.00056501286,0.000048147063,0.00004908032,0.00014020044,0.00083668914,0.000001899623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014986517,0.00010196567,0.020965192,0.0013705489,0.0006268227,0.0000805932,0.00346493,0.00034164224,0.000062440056,0.0000074371683,0.9698923,0.0029362612],"study_design_scores_gemma":[0.0038963305,0.00014146723,0.002360262,0.0017305386,0.002341991,0.000002200827,0.0009898256,0.0011407717,0.00017977499,0.0000059270774,0.9868093,0.00040159846],"about_ca_topic_score_codex":0.006609898,"about_ca_topic_score_gemma":0.0037648287,"teacher_disagreement_score":0.080500394,"about_ca_system_score_codex":0.0014963895,"about_ca_system_score_gemma":0.0021556169,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4285597427","doi":"10.51731/cjht.2022.391","title":"Selpercatinib (Retevmo)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Drug; Political science; Health care; Pharmacology","score_opus":0.026523375509340825,"score_gpt":0.33789754651757126,"score_spread":0.31137417100823045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285597427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44237646,0.18757546,0.00018032087,0.36196962,0.0015300261,0.0008345792,0.0001398962,0.00024247592,0.0051511535],"genre_scores_gemma":[0.9974328,0.00012985301,0.0008067209,0.0013102719,0.0000076150313,0.00001658766,0.00000565297,0.000009103382,0.00028139498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992544,0.000027054097,0.0002821414,0.000070401235,0.00012894333,0.00023703124],"domain_scores_gemma":[0.99948883,0.000017241993,0.00018752796,0.00014765114,0.00007995744,0.00007880065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024525778,0.000059822152,0.00020340402,0.00040693968,0.00041033336,0.000008099625,0.00012856036,0.00002841307,0.00020394598],"category_scores_gemma":[0.000108921224,0.000049937848,0.000054899876,0.00027442005,0.0000648993,0.00003705276,0.000013862373,0.0003302372,0.0000036088625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023784753,0.000060067905,0.027227756,0.000079398465,0.00017769211,0.000614756,0.0019201316,0.00006520154,0.000036294223,0.0027770307,0.04952756,0.9174903],"study_design_scores_gemma":[0.0008783481,0.0012981733,0.014886521,0.00005670792,0.000048792666,0.0017016589,0.014040195,0.0000064354895,0.000083116014,0.0015419903,0.96538657,0.00007150755],"about_ca_topic_score_codex":0.002846508,"about_ca_topic_score_gemma":0.00062501465,"teacher_disagreement_score":0.91741884,"about_ca_system_score_codex":0.000986028,"about_ca_system_score_gemma":0.0055199214,"threshold_uncertainty_score":0.9792104},"labels":[],"label_agreement":null},{"id":"W4285733438","doi":"10.3390/curroncol29070396","title":"Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université Laval; Centre Hospitalier de l’Université de Montréal; William Osler Health System; Queen Elizabeth II Health Sciences Centre; University of Alberta; Institut universitaire de cardiologie et de pneumologie de Québec; University of Manitoba; University Health Network; CancerCare Manitoba; Dalhousie University; University of Toronto","funders":"Sanofi Genzyme; EMD Serono; Astellas Pharma; Puma Biotechnology; Helsinn; Merck KGaA; Janssen Canada; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Strong; GlaxoSmithKline","keywords":"Medicine; Lung cancer; Biomarker; Clinical trial; Targeted therapy; CLARITY; Oncology; Medical physics; Intensive care medicine; Cancer; Internal medicine","score_opus":0.24306722479949924,"score_gpt":0.512911178535237,"score_spread":0.2698439537357378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285733438","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010798242,0.98318577,0.0014182903,0.0016324639,0.003145188,0.0060030054,0.0007142547,0.00004327304,0.0038469878],"genre_scores_gemma":[0.0000017202418,0.9435923,0.038459092,0.00022312847,0.0006375428,0.010219727,0.002421503,0.000072072784,0.0043729274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811983,0.000108401284,0.00073045417,0.00052974594,0.00009239258,0.0004191736],"domain_scores_gemma":[0.99801594,0.0010096678,0.00032313305,0.00027313916,0.0001206419,0.00025749806],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018339118,0.00032542035,0.0013021237,0.0003879741,0.00021870002,0.000022952867,0.00013534134,0.00013925476,0.00089117343],"category_scores_gemma":[0.00024572396,0.00029702496,0.00024160692,0.00062821485,0.000017696146,0.000025419042,0.0000906844,0.0004586066,0.000016705984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016838707,0.0005120303,0.00016148905,0.0044863196,0.00016035227,0.0000108385175,0.00045006728,0.00027324678,5.7936614e-7,0.000025890404,0.08900916,0.9048932],"study_design_scores_gemma":[0.0019845532,0.00036864504,0.000009621325,0.003289001,0.003034983,0.000023607825,0.00008127937,0.0004889059,5.361637e-7,0.000011461682,0.99046636,0.00024102352],"about_ca_topic_score_codex":0.00037875044,"about_ca_topic_score_gemma":0.0003282637,"teacher_disagreement_score":0.9046522,"about_ca_system_score_codex":0.0025184609,"about_ca_system_score_gemma":0.0061086793,"threshold_uncertainty_score":0.9999482},"labels":[],"label_agreement":null},{"id":"W4286297054","doi":"10.1200/jco.2022.40.16_suppl.3006","title":"CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring <i>NRG1</i> fusions.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Cohort; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Internal medicine; Discontinuation; Cancer; Targeted therapy; Phases of clinical research; Clinical trial","score_opus":0.07209854940977523,"score_gpt":0.501764807270861,"score_spread":0.4296662578610858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092466,0.0005881119,0.000019816209,0.0041930443,0.0007638344,0.00019105342,0.000010617449,0.0000042226343,0.0033046522],"genre_scores_gemma":[0.9973232,0.00050633267,0.0008416429,0.00091785844,0.0003073485,0.000006000107,0.000003437881,0.000010267306,0.000083904895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99745,0.00028186452,0.0017459572,0.00012263635,0.00025602127,0.00014352218],"domain_scores_gemma":[0.997544,0.0010986702,0.00094087236,0.000105029816,0.0001281913,0.00018322002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014690867,0.0000802606,0.0009649133,0.00014401836,0.00006935114,0.0000026040536,0.000081985534,0.00008324356,0.000196826],"category_scores_gemma":[0.001053277,0.000062486644,0.00015771305,0.00016407737,0.00012854481,0.00006092598,0.00009953426,0.0007596737,0.0000010015673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048545487,0.016978152,0.3465996,0.00017916875,0.001613238,0.009538159,0.0034815543,0.0018001775,0.0022542975,0.0015866904,0.00456684,0.5628566],"study_design_scores_gemma":[0.03332085,0.01942233,0.88503796,0.00019363144,0.0005979894,0.0011343622,0.0008065416,0.000113557115,0.00013773462,0.00028782533,0.05883948,0.00010776637],"about_ca_topic_score_codex":0.000043491513,"about_ca_topic_score_gemma":0.000018053574,"teacher_disagreement_score":0.56274885,"about_ca_system_score_codex":0.0001949309,"about_ca_system_score_gemma":0.0018505445,"threshold_uncertainty_score":0.33004466},"labels":[],"label_agreement":null},{"id":"W4287970990","doi":"","title":"Cell-Free Circulating Tumour DNA Blood Testing to Detect <i>EGFR</i> T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liquid biopsy; Medicine; T790M; Biopsy; Oncology; Lung cancer; Intensive care medicine; Systematic review; Internal medicine; Osimertinib; Lung biopsy; Cancer; Epidermal growth factor receptor; MEDLINE","score_opus":0.013979574247629734,"score_gpt":0.28016332589809284,"score_spread":0.2661837516504631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287970990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805737,0.00076439965,0.0025311406,0.009812314,0.000072783645,0.00382919,0.000033187003,0.00021226428,0.0021710151],"genre_scores_gemma":[0.96960807,0.000024472187,0.023078589,0.0016346651,0.000085041196,0.0054172087,0.000030254736,0.000057628862,0.00006405631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998163,0.00003353871,0.0003914603,0.00053384824,0.0002415637,0.0006366221],"domain_scores_gemma":[0.99892807,0.00008545904,0.00024349305,0.00027165638,0.00012683838,0.0003445122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014435367,0.0002339979,0.00043351666,0.0002240421,0.0001374115,0.000030342995,0.0001474328,0.00006847774,0.0000059952004],"category_scores_gemma":[0.00014573638,0.00021307159,0.000039827304,0.0015105293,0.00001763999,0.00010166349,0.00007238918,0.00028112307,0.0000018039199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016521242,0.00048233915,0.8104255,0.0016786122,0.00020267273,0.00038938588,0.004536967,0.010498627,0.01362732,0.000016212594,0.0003587435,0.15761839],"study_design_scores_gemma":[0.016737806,0.0013105423,0.9553692,0.0004456821,0.00066588627,0.000084936364,0.002672606,0.0045817657,0.017422471,0.00003565924,0.00014281084,0.00053064077],"about_ca_topic_score_codex":0.0009384476,"about_ca_topic_score_gemma":0.0011719051,"teacher_disagreement_score":0.15708774,"about_ca_system_score_codex":0.00062007166,"about_ca_system_score_gemma":0.00077439577,"threshold_uncertainty_score":0.8688807},"labels":[],"label_agreement":null},{"id":"W4288969861","doi":"10.1016/j.jtocrr.2022.100385","title":"Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; EMD Serono; Otsuka America; Ribon Therapeutics; Takeda Oncology; Mirati Therapeutics; Bayer Fund; Abbott Laboratories; Clovis Oncology; National Center for Advancing Translational Sciences; Johnson and Johnson; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Ipsen Biopharmaceuticals; Novartis; Celgene; Unum Therapeutics; Merck KGaA; Servier; Gilead Sciences; Sanofi; Roche; Yuhan; Merck; GlaxoSmithKline; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Canadian Asian Studies Association; AstraZeneca; Aerie Pharmaceuticals; Pfizer; Ariad Pharmaceuticals; Boehringer Ingelheim; Amgen; Regeneron Pharmaceuticals","keywords":"Crizotinib; Refractory (planetary science); Medicine; Phase (matter); Term (time); Internal medicine; Oncology; Phases of clinical research; Clinical trial; Lung cancer; Materials science; Chemistry; Physics","score_opus":0.20621207331927188,"score_gpt":0.5581480541043659,"score_spread":0.35193598078509397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288969861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917271,0.0021568073,0.0000041024623,0.0022768218,0.00017931112,0.0024400917,0.00013912187,0.0000069601565,0.0010696496],"genre_scores_gemma":[0.9971562,0.0015180458,0.000057035017,0.00006410634,0.000101865386,0.000103712926,0.000058804908,0.000011254124,0.0009289485],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99409014,0.0021658305,0.002229062,0.00044448004,0.0008377285,0.00023277513],"domain_scores_gemma":[0.9913029,0.007097328,0.0007051457,0.00040204596,0.0002622636,0.0002303133],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01945681,0.00012352515,0.0012088354,0.00013879893,0.00020492777,0.000014971188,0.00006236815,0.00008200975,0.00009991904],"category_scores_gemma":[0.01956892,0.000069549176,0.00019681324,0.00027363168,0.001172527,0.000049409166,0.0002268377,0.0006072416,1.4302691e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6334086,0.01242419,0.06969211,0.00050686806,0.0010299952,0.0018976808,0.0020819644,0.0000041014337,0.0024117767,0.00014553501,0.0022835138,0.27411368],"study_design_scores_gemma":[0.7848662,0.004274228,0.20165081,0.000578321,0.0006014607,0.00033200515,0.00025190553,0.00007210505,0.0006171382,0.0005328652,0.006085119,0.0001378177],"about_ca_topic_score_codex":0.0002939198,"about_ca_topic_score_gemma":0.000029506014,"teacher_disagreement_score":0.27397588,"about_ca_system_score_codex":0.000036810492,"about_ca_system_score_gemma":0.0006927697,"threshold_uncertainty_score":0.98868966},"labels":[],"label_agreement":null},{"id":"W4289793990","doi":"10.1021/acs.molpharmaceut.2c00457","title":"Panitumumab-DOTA-<sup>111</sup>In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner–Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; University of Toronto; Canadian Institutes of Health Research; Amgen Canada; Terry Fox Foundation","keywords":"Radioimmunotherapy; Triple-negative breast cancer; DOTA; Cancer research; Nuclear medicine; Epidermal growth factor receptor; Medicine; Oncology; Breast cancer; Chemistry; Cancer; Internal medicine; Immunology; Chelation; Monoclonal antibody","score_opus":0.017494045284609034,"score_gpt":0.35041880639915457,"score_spread":0.33292476111454555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289793990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863864,0.0076935277,0.00054381014,0.0020842482,0.00020703879,0.0019165572,0.0010347689,0.000050855288,0.00008276029],"genre_scores_gemma":[0.9963955,0.00060803414,0.00061638205,0.0014019518,0.00007807073,0.00044673393,0.00020482215,0.000091030335,0.00015744107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822366,0.00021158106,0.00038278959,0.00041424058,0.00031539967,0.00045234742],"domain_scores_gemma":[0.9992278,0.000103097176,0.00016364621,0.000220458,0.00014440762,0.00014056652],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001609,0.00029160272,0.00045526706,0.00020443193,0.00019401981,0.000023701863,0.00011554146,0.00001729661,0.00053106854],"category_scores_gemma":[0.000027494418,0.00027322734,0.00014174056,0.00033536303,0.0000955694,0.00013289996,0.0000350794,0.0003022316,8.979482e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054278513,0.0019762071,0.051718492,0.0004136183,0.002577568,0.0005023711,0.009624167,0.0020565004,0.89128107,0.00050525443,0.0007144684,0.033202447],"study_design_scores_gemma":[0.050965928,0.0019056336,0.030065585,0.00018436539,0.0023616897,0.0008522267,0.0026129875,0.045711998,0.85184216,0.00073698116,0.011472765,0.0012876596],"about_ca_topic_score_codex":0.000322379,"about_ca_topic_score_gemma":0.000009262836,"teacher_disagreement_score":0.045538075,"about_ca_system_score_codex":0.0005182221,"about_ca_system_score_gemma":0.000319337,"threshold_uncertainty_score":0.999972},"labels":[],"label_agreement":null},{"id":"W4290719500","doi":"10.1200/po.22.00165","title":"Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Cancer; Breast cancer; Targeted therapy; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Gefitinib; Estrogen receptor; Epidermal growth factor receptor; Phases of clinical research; Clinical trial; Chemotherapy","score_opus":0.06288459229454123,"score_gpt":0.4389085319902534,"score_spread":0.3760239396957122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290719500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97815204,0.000015343998,0.00016334372,0.0006288624,0.00012243965,0.01963357,0.0010988619,0.000021663034,0.00016390248],"genre_scores_gemma":[0.97459906,0.0000019110225,0.0011036142,0.0002452222,0.00011454043,0.022684071,0.0011649334,0.000028236875,0.000058429105],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997366,0.00032210955,0.00081344787,0.0005437156,0.00073862384,0.00021608258],"domain_scores_gemma":[0.9973691,0.0009861643,0.00074479333,0.00025767443,0.0005702105,0.00007206623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038589217,0.00022098735,0.0006045207,0.00033205212,0.00054753316,0.000016281752,0.00018604782,0.000059581875,0.00037934518],"category_scores_gemma":[0.00048056818,0.0001396287,0.000109936394,0.0008610047,0.00008362003,0.00016859779,0.00007172349,0.00025453782,4.0849426e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39359757,0.05869985,0.40628874,0.00002755945,0.007869871,0.000033762695,0.030772036,0.013665593,0.00172313,0.00012899935,0.00053864194,0.08665425],"study_design_scores_gemma":[0.5274307,0.07624798,0.38624766,0.000067890156,0.00080554606,0.000001103831,0.0021344938,0.000269627,0.0009956914,0.00009426678,0.0054026535,0.0003024043],"about_ca_topic_score_codex":0.0029840951,"about_ca_topic_score_gemma":0.0019081637,"teacher_disagreement_score":0.13383313,"about_ca_system_score_codex":0.00072249543,"about_ca_system_score_gemma":0.0007241446,"threshold_uncertainty_score":0.56938934},"labels":[],"label_agreement":null},{"id":"W4291945697","doi":"","title":"Gemcitabine, pemetrexed, and novel agents in the treatment of thoracic cancer. Selected presentations from the 10th World Congress on Lung Cancer. Vancouver, Canada.","year":2004,"lang":"en","type":"other","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pemetrexed; Medicine; Gemcitabine; Cancer; Lung cancer; Oncology; Chemotherapy; Internal medicine; Intensive care medicine; Cisplatin","score_opus":0.027079354033805913,"score_gpt":0.3380264684549491,"score_spread":0.3109471144211432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291945697","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15667972,0.187613,0.000085760556,0.03694963,0.02573716,0.07515244,0.05433332,0.0004968678,0.4629521],"genre_scores_gemma":[0.24534832,0.007700067,0.00007736442,0.0011558671,0.0008259539,0.019309184,0.0008499465,0.00030869918,0.7244246],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99850994,0.000059781498,0.0002712035,0.00037524453,0.0004351216,0.00034870548],"domain_scores_gemma":[0.9989367,0.00021928504,0.00026261708,0.00039772573,0.00007628993,0.00010739145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044925906,0.0003226513,0.00045478344,0.00017759512,0.00009016783,0.000023731183,0.00015276254,0.00008180544,0.00028260975],"category_scores_gemma":[0.000028943776,0.00017787128,0.00005928254,0.0006927102,0.00008556928,0.000025939204,0.000012620909,0.0001489149,3.535813e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019286711,0.00085762754,0.1112996,0.00014415428,0.0022591855,0.00004223642,0.000781191,0.00015593138,0.0000017458743,0.000039864488,0.85770273,0.02652288],"study_design_scores_gemma":[0.004333256,0.000051544946,0.59016037,0.00045234108,0.0020777665,0.0000015228383,0.00026800748,0.00003955509,0.00007233618,0.000007804378,0.4023234,0.0002121136],"about_ca_topic_score_codex":0.88992125,"about_ca_topic_score_gemma":0.99379843,"teacher_disagreement_score":0.47886074,"about_ca_system_score_codex":0.0013003766,"about_ca_system_score_gemma":0.0012229914,"threshold_uncertainty_score":0.725338},"labels":[],"label_agreement":null},{"id":"W4291960217","doi":"","title":"Lung cancer.","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Lung cancer; Computer science; Data science; World Wide Web; Pathology","score_opus":0.015873333148464855,"score_gpt":0.31416156976530285,"score_spread":0.298288236616838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291960217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85143787,0.005543386,0.00032840355,0.02368103,0.00076931465,0.0021563338,0.00002628508,0.000210397,0.11584696],"genre_scores_gemma":[0.9925331,0.00007623852,0.0001584453,0.0007605733,0.00013999522,0.002215521,0.0000086535665,0.000007908029,0.0040995935],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996446,0.0000018181378,0.0000539866,0.000084451975,0.00007295014,0.0001422307],"domain_scores_gemma":[0.99978524,0.0000035562791,0.00001390503,0.00008442163,0.00002177757,0.00009110454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000019237661,0.000041944677,0.000066088876,0.000024564377,0.000031593336,0.00000634285,0.000017439372,0.000017302742,0.000044906872],"category_scores_gemma":[0.000009357057,0.000032043223,0.000028791203,0.000076705765,0.0000124494345,0.00003271586,0.000005187805,0.00003162408,0.000008062926],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001124806,0.000516239,0.19159003,0.00015108136,0.0009134599,0.00015536248,0.0010110787,0.00030055208,0.00008582303,0.005472805,0.011985461,0.78770566],"study_design_scores_gemma":[0.0025710217,0.00001311033,0.97408,0.000016821055,0.0002820683,0.000013706463,0.000022008639,0.0000042466636,0.0009083804,0.00023006604,0.021802401,0.00005614526],"about_ca_topic_score_codex":0.00028286036,"about_ca_topic_score_gemma":0.000034449688,"teacher_disagreement_score":0.7876495,"about_ca_system_score_codex":0.0002589476,"about_ca_system_score_gemma":0.00007846921,"threshold_uncertainty_score":0.13066848},"labels":[],"label_agreement":null},{"id":"W4292265575","doi":"10.3390/curroncol29080460","title":"Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Gefitinib; Erlotinib; Osimertinib; Afatinib; T790M; Lung cancer; Oncology; Internal medicine; Cohort; Erlotinib Hydrochloride; Cancer; Epidermal growth factor receptor","score_opus":0.09137764502172767,"score_gpt":0.4723196591562158,"score_spread":0.38094201413448814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292265575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121726,0.002448332,0.000004727407,0.00050800235,0.00073940976,0.004158343,0.00024307144,0.00004593208,0.0006348986],"genre_scores_gemma":[0.9919834,0.00560528,0.00021921597,0.00024541243,0.00009831171,0.0012106617,0.00034716484,0.000043421496,0.00024709606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756694,0.00042748894,0.0006355097,0.0007166445,0.00025949653,0.00039389823],"domain_scores_gemma":[0.9982205,0.000294572,0.0008062049,0.00028752149,0.00019482766,0.00019639416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017298786,0.00029929812,0.0009189794,0.000113147194,0.00014688981,0.000013167487,0.0000934659,0.000030011633,0.000119833974],"category_scores_gemma":[0.000117236945,0.0002208413,0.00006689802,0.00042223025,0.000035766087,0.00008491322,0.000121337354,0.0004392303,0.0000036463646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005253325,0.008967684,0.95566994,0.00015504425,0.0004364425,0.00019325549,0.0014946228,0.000008262184,0.0000016213867,6.6784804e-7,0.00007021071,0.032476928],"study_design_scores_gemma":[0.017583609,0.009693061,0.96677023,0.0005740955,0.0020838224,0.0000036227761,0.00049578724,0.00017549086,0.0000018973279,8.8506346e-7,0.0024264082,0.00019106409],"about_ca_topic_score_codex":0.0050684055,"about_ca_topic_score_gemma":0.009138734,"teacher_disagreement_score":0.032285865,"about_ca_system_score_codex":0.0024372195,"about_ca_system_score_gemma":0.0007486896,"threshold_uncertainty_score":0.90056473},"labels":[],"label_agreement":null},{"id":"W4292895541","doi":"10.1158/0008-5472.4287.72.17","title":"Highlights from Recent Cancer Literature","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Medicine; Internal medicine","score_opus":0.09094710602646557,"score_gpt":0.490147522526705,"score_spread":0.39920041650023946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292895541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7992725,0.14772077,0.000010173286,0.034181464,0.0014220525,0.0008477379,0.00037743195,0.00008177041,0.016086102],"genre_scores_gemma":[0.9335494,0.040767998,0.00031690046,0.00082468556,0.0034117473,0.001044368,0.00022463237,0.00004631421,0.019813966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843615,0.00007139826,0.0001293055,0.00024979014,0.0005397775,0.0005735619],"domain_scores_gemma":[0.9987628,0.00007083997,0.000024538185,0.00032155402,0.00043843122,0.0003818726],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017245427,0.0001165201,0.00017769182,0.0001321154,0.00017745662,0.000046766057,0.00009178015,0.000096652904,0.0042527225],"category_scores_gemma":[0.000034738347,0.00008141455,0.000050360897,0.00057643943,0.00007388817,0.00016986999,0.00004612469,0.00036547,0.000181364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010528462,0.0013269901,0.14592852,0.00032236375,0.0017478754,0.00016024079,0.020359956,0.000007355055,0.058763046,0.006164248,0.4979166,0.26624998],"study_design_scores_gemma":[0.0012402146,0.00006722508,0.043574635,0.00039685503,0.00011141391,0.0000036625552,0.0001310733,0.0000031029113,0.022014804,0.00028795193,0.93206066,0.00010840294],"about_ca_topic_score_codex":0.0025000141,"about_ca_topic_score_gemma":0.00019288219,"teacher_disagreement_score":0.43414405,"about_ca_system_score_codex":0.0008478501,"about_ca_system_score_gemma":0.0004942899,"threshold_uncertainty_score":0.99665755},"labels":[],"label_agreement":null},{"id":"W4292999575","doi":"10.54097/hset.v8i.1256","title":"Sotorasib and other drugs comparison in treating non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"KRAS; Medicine; Drug; Lung cancer; Drug resistance; Oncology; Targeted therapy; Pharmacology; Side effect (computer science); Internal medicine; Cancer; Colorectal cancer; Biology","score_opus":0.006842816938625655,"score_gpt":0.28348987852131835,"score_spread":0.2766470615826927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292999575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965902,0.0015569963,0.0000625085,0.0008022819,0.000120106815,0.00022132785,0.0000045090947,0.000060233982,0.00058181805],"genre_scores_gemma":[0.99796665,0.00006176669,0.0016112516,0.00002926937,0.000013111556,0.00017711244,7.0722683e-7,0.000009018891,0.00013109489],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9992737,0.000003973748,0.00013540189,0.00025989476,0.00010182231,0.00022519725],"domain_scores_gemma":[0.99978215,0.000022090611,0.000029168277,0.00011177152,0.0000132395335,0.000041602932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012093686,0.000087931665,0.00016864842,0.0006552352,0.00012014023,0.000012513185,0.00007682996,0.000038270944,0.000008043954],"category_scores_gemma":[0.0000098135,0.000075493845,0.000007449251,0.00094378163,0.00010337961,0.000040547242,0.000079772544,0.00016831164,6.634347e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013551918,0.00018674467,0.95315677,0.000100205405,0.000016295573,0.000055549197,0.0060722493,0.0052291057,0.022635961,0.008095267,0.00005703262,0.004381258],"study_design_scores_gemma":[0.016695485,0.001469605,0.3153039,0.0010943726,0.00031785673,0.00023829541,0.01483115,0.48236677,0.09277557,0.00039706397,0.0729468,0.0015631344],"about_ca_topic_score_codex":0.00034670133,"about_ca_topic_score_gemma":0.000058785954,"teacher_disagreement_score":0.63785285,"about_ca_system_score_codex":0.00022204088,"about_ca_system_score_gemma":0.000095199175,"threshold_uncertainty_score":0.30785495},"labels":[],"label_agreement":null},{"id":"W4293096174","doi":"10.1016/j.jtho.2022.07.006","title":"2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Disease; Molecular diagnostics; Biomarker; Molecular pathology; Classification scheme; Subject (documents); Bioinformatics; Pathology; Computational biology; Oncology; Data science; Computer science; Biology; Gene; Library science; Genetics","score_opus":0.025494064918205148,"score_gpt":0.4305638088209062,"score_spread":0.40506974390270106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293096174","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023235554,0.015614228,0.0014490006,0.9488561,0.0013018692,0.0011951479,0.00024088575,0.0000147881665,0.0080924],"genre_scores_gemma":[0.36483258,0.03975127,0.026401658,0.5280908,0.011007684,0.0018760413,0.0029002281,0.00061467587,0.024525115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768305,0.00025957476,0.0009095257,0.00031579452,0.00058557617,0.00024650892],"domain_scores_gemma":[0.99700624,0.0001326208,0.0018895736,0.00033065377,0.0005265028,0.00011440984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004656679,0.00023890893,0.0009397445,0.00037803504,0.00008895829,0.000021330508,0.00020679229,0.00050155324,0.0004796519],"category_scores_gemma":[0.00006553981,0.00019969733,0.00023408438,0.00034071968,0.00013289266,0.00008413451,0.00006361048,0.0010361534,0.0000018529317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009563731,0.00034390864,0.0018090045,0.00086743984,0.0019249683,0.000957668,0.0002387249,0.00001017845,0.012241037,0.000099477395,0.82110703,0.1594442],"study_design_scores_gemma":[0.0010015804,0.0011336092,0.008464734,0.00038434012,0.004338341,0.0008128774,0.00020215433,0.0005977781,0.00019875856,0.00015435825,0.9825464,0.00016508333],"about_ca_topic_score_codex":0.00008524131,"about_ca_topic_score_gemma":0.000009397012,"teacher_disagreement_score":0.42076537,"about_ca_system_score_codex":0.0017000604,"about_ca_system_score_gemma":0.0019475082,"threshold_uncertainty_score":0.8143421},"labels":[],"label_agreement":null},{"id":"W4294292647","doi":"10.51731/cjht.2022.433","title":"Cemiplimab (Libtayo)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Lung cancer; Oncology; Family medicine; Political science; Health care","score_opus":0.023578534964492186,"score_gpt":0.3292358113351322,"score_spread":0.30565727637064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294292647","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29590788,0.25779524,0.00042742817,0.43579778,0.0019295239,0.0009286968,0.00015885958,0.00030033148,0.0067542526],"genre_scores_gemma":[0.9978112,0.00013021451,0.0005474313,0.0011498246,0.000007663746,0.000014569857,0.0000052325877,0.000009382053,0.00032449485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992524,0.000021978014,0.00027346052,0.0000706707,0.00013006493,0.0002514292],"domain_scores_gemma":[0.99949527,0.000015479902,0.00019320521,0.0001469398,0.000070072085,0.000079025216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021221272,0.000060359107,0.00020757726,0.00043937628,0.000414592,0.000008868895,0.000127445,0.000028486018,0.00016626721],"category_scores_gemma":[0.000084606814,0.000050582094,0.000057127363,0.0002755543,0.00006483506,0.00003928058,0.000016517679,0.00033330248,0.0000036017484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035536952,0.00007839685,0.023096733,0.00008359095,0.00019333822,0.000990722,0.0011944585,0.00008252417,0.00003608756,0.0037134353,0.04893882,0.92155635],"study_design_scores_gemma":[0.0010923552,0.0012742599,0.010912551,0.00005490948,0.000051367548,0.0018374954,0.010492169,0.0000059239314,0.00010220543,0.002273587,0.9718326,0.00007060796],"about_ca_topic_score_codex":0.0024442675,"about_ca_topic_score_gemma":0.0005726,"teacher_disagreement_score":0.92289376,"about_ca_system_score_codex":0.0011194842,"about_ca_system_score_gemma":0.0052625486,"threshold_uncertainty_score":0.93355346},"labels":[],"label_agreement":null},{"id":"W4294934986","doi":"10.1016/j.jtho.2022.07.803","title":"EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; ROS1; Presentation (obstetrics); Internal medicine; Oncology; Cancer research; Radiology; Cancer; Adenocarcinoma","score_opus":0.020157280061994434,"score_gpt":0.4348659768479482,"score_spread":0.4147086967859538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294934986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211293,0.0005598414,0.00009167248,0.005116578,0.00039019441,0.00036223745,0.000047218535,0.000010017855,0.0013092946],"genre_scores_gemma":[0.99561775,0.00015048275,0.0030543786,0.00031611498,0.0000874108,0.000058377278,0.00006907252,0.00001562423,0.0006307744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887955,0.00018209573,0.0004301764,0.00014504959,0.00022117281,0.0001419588],"domain_scores_gemma":[0.999155,0.00017286613,0.00030423113,0.00009023863,0.0001466541,0.00013105356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002616311,0.00009208122,0.00026875985,0.000318214,0.00032385899,0.000017905077,0.000043850327,0.000044887784,0.0001338349],"category_scores_gemma":[0.000116505915,0.00008128351,0.00004717253,0.00022061638,0.000052967436,0.00018863953,0.00008925675,0.00025865683,0.0000016142518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027573796,0.003733345,0.68172693,0.00016933306,0.0008604453,0.0009897383,0.028638193,0.002391506,0.008611383,0.0007998071,0.008276637,0.26104534],"study_design_scores_gemma":[0.00934699,0.0065524206,0.9072351,0.00016180934,0.0017596903,0.0017790244,0.0058801305,0.0012466294,0.0007214313,0.0012075943,0.06383582,0.0002733769],"about_ca_topic_score_codex":0.00004718302,"about_ca_topic_score_gemma":0.00013663965,"teacher_disagreement_score":0.26077196,"about_ca_system_score_codex":0.00067988737,"about_ca_system_score_gemma":0.00026612185,"threshold_uncertainty_score":0.33146453},"labels":[],"label_agreement":null},{"id":"W4294935554","doi":"10.1016/j.jtho.2022.07.772","title":"EP08.02-089 Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Toxicity; Tyrosine kinase; Lung cancer; Cancer research; Tyrosine-kinase inhibitor; Immune system; Cancer; Kinase; Pharmacology; Oncology; Immunology; Internal medicine; Receptor; Cell biology; Biology","score_opus":0.011006900022209123,"score_gpt":0.3769497878806218,"score_spread":0.36594288785841267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294935554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874358,0.0069046556,0.000072866715,0.0021929245,0.0020180899,0.0005494149,0.000051775474,0.000008559574,0.00076586625],"genre_scores_gemma":[0.9964045,0.00025437187,0.0018529184,0.0002688365,0.00041096297,0.00013067936,0.00001314085,0.000033161123,0.0006314191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769855,0.00018933328,0.0011863866,0.00022743909,0.00037285252,0.00032544928],"domain_scores_gemma":[0.99827355,0.000066535686,0.0010238924,0.00021175227,0.0002559568,0.00016828845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061428075,0.0002094465,0.0007875882,0.00045037712,0.00008488988,0.000007749138,0.00014427766,0.00011987061,0.0006237167],"category_scores_gemma":[0.000044254677,0.00017914893,0.0003241612,0.0004564022,0.00008335612,0.00014114733,0.00014844531,0.00069154426,0.0000017335499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014505118,0.0065450547,0.12326265,0.0010402821,0.0008067895,0.0050399066,0.009651447,0.007508701,0.7339356,0.0000092036225,0.001922319,0.09577295],"study_design_scores_gemma":[0.015392164,0.010047843,0.094969705,0.0012658212,0.0027607197,0.0010875249,0.004843175,0.00048524453,0.84700805,0.000110108354,0.021432778,0.0005968861],"about_ca_topic_score_codex":0.0002705764,"about_ca_topic_score_gemma":0.00016843506,"teacher_disagreement_score":0.113072455,"about_ca_system_score_codex":0.0022441673,"about_ca_system_score_gemma":0.0015587617,"threshold_uncertainty_score":0.73054814},"labels":[],"label_agreement":null},{"id":"W4294938031","doi":"10.1016/j.jtho.2022.07.881","title":"EP10.01-004 Perspectives of Patients with Metastatic Lung Cancer on Symptom Screening and Patient-Reported Symptom Trajectory Data","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lung cancer; Trajectory; Oncology; Cancer; Internal medicine","score_opus":0.027068449417249642,"score_gpt":0.4198754109361209,"score_spread":0.3928069615188713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294938031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366325,0.0037891164,0.00023073149,0.0010519064,0.00026175828,0.0004382918,0.0001739796,0.000008926671,0.0003820189],"genre_scores_gemma":[0.99586076,0.00010701575,0.003542586,0.00024317125,0.000056555775,0.000025829942,0.000059229333,0.000023740597,0.000081116224],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99839044,0.0001901182,0.0005082218,0.00023753419,0.00049826765,0.00017540198],"domain_scores_gemma":[0.99812806,0.00017720315,0.0009836353,0.00027934014,0.00029748402,0.00013430309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002516113,0.00014581208,0.0005336466,0.0002691364,0.00014178453,0.000008004516,0.00013261405,0.00003124013,0.00026064768],"category_scores_gemma":[0.00008235509,0.00010306991,0.000066478104,0.00021417259,0.00009794553,0.00014324467,0.00009609021,0.00033429422,1.6080493e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017036129,0.006665532,0.45365834,0.00036161282,0.012462762,0.0013056637,0.03135661,0.0031944648,0.00036663073,0.00006432862,0.0033264416,0.4702015],"study_design_scores_gemma":[0.018137226,0.03284625,0.86001205,0.00087077275,0.017048731,0.0013213347,0.049436014,0.0015075267,0.0003180986,0.000056792298,0.017911555,0.00053366757],"about_ca_topic_score_codex":0.00008189509,"about_ca_topic_score_gemma":0.000029584875,"teacher_disagreement_score":0.46966782,"about_ca_system_score_codex":0.00058046903,"about_ca_system_score_gemma":0.00074836134,"threshold_uncertainty_score":0.4203069},"labels":[],"label_agreement":null},{"id":"W4294938234","doi":"10.1016/j.jtho.2022.07.872","title":"EP08.05-001 Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Radiation Pneumonitis; Lung cancer; Pneumonitis; Oncology; Internal medicine; Lung; Radiology; Cancer; Epidermal growth factor receptor","score_opus":0.022279197782759365,"score_gpt":0.42857966617410453,"score_spread":0.40630046839134515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294938234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935282,0.002798526,0.000024586912,0.000995887,0.00073264446,0.00067808863,0.000029671846,0.000005362899,0.0012070223],"genre_scores_gemma":[0.9985442,0.0004273548,0.00045041635,0.00017139383,0.000091496884,0.00009052128,0.000052459392,0.000020581325,0.00015155475],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99792784,0.0004948894,0.0007177383,0.00016981071,0.00049661833,0.0001931227],"domain_scores_gemma":[0.9980827,0.00014759645,0.00099006,0.000104114304,0.00057243864,0.000103096994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012693166,0.00012677773,0.00045226794,0.00043025814,0.000104858336,0.000010198598,0.000078410565,0.00008015817,0.00026766595],"category_scores_gemma":[0.00012154399,0.00011442827,0.00007114883,0.00038118003,0.000033413566,0.00014318118,0.00004672818,0.00035424638,8.073165e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011474489,0.0016729994,0.33449808,0.00020743124,0.00027241439,0.000100837555,0.004777884,0.0035338528,0.0044921893,0.0000013860644,0.0007273154,0.64856815],"study_design_scores_gemma":[0.011330389,0.0051987865,0.95323706,0.00045009228,0.0044580516,0.0003074794,0.0020953128,0.014768412,0.0048503415,0.00012296395,0.002924593,0.0002565194],"about_ca_topic_score_codex":0.00020199067,"about_ca_topic_score_gemma":0.000074308155,"teacher_disagreement_score":0.6483117,"about_ca_system_score_codex":0.0017810877,"about_ca_system_score_gemma":0.0011695557,"threshold_uncertainty_score":0.46662495},"labels":[],"label_agreement":null},{"id":"W4294939891","doi":"10.1016/j.jtho.2022.07.818","title":"EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; KRAS; non-small cell lung cancer (NSCLC); Lung cancer; Antibody; Cancer research; Oncology; Internal medicine; Cancer; Immunology; Colorectal cancer","score_opus":0.033409874385729114,"score_gpt":0.44283939244569553,"score_spread":0.4094295180599664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294939891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930054,0.0028694696,0.00016296859,0.0019021316,0.00057168497,0.000504629,0.0000655746,0.0000030680096,0.0009150971],"genre_scores_gemma":[0.99769205,0.0008462098,0.0009901138,0.00011771738,0.00013657458,0.00002950702,0.0000019016303,0.00001542442,0.00017048839],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983444,0.00030070342,0.0007175811,0.00017696549,0.00026962644,0.00019070564],"domain_scores_gemma":[0.9980239,0.00046769954,0.0010355876,0.00017298135,0.00021272908,0.00008708492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097597623,0.00013524093,0.0007821996,0.00020548244,0.00008078263,0.000005391965,0.00013796175,0.00009482108,0.000045523404],"category_scores_gemma":[0.00006594645,0.00008898989,0.00016981042,0.00022175179,0.00016855456,0.00011425515,0.00011659194,0.00055881334,1.2236026e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009011342,0.0075837057,0.29291698,0.0015715404,0.0025378645,0.0006460105,0.021698548,0.0116140535,0.39480865,0.00008069244,0.0023714064,0.2551592],"study_design_scores_gemma":[0.025027463,0.036632646,0.46333742,0.0018083777,0.014727149,0.0011626076,0.025136355,0.023769457,0.40053675,0.0018384608,0.004999609,0.0010236974],"about_ca_topic_score_codex":0.00038521242,"about_ca_topic_score_gemma":0.00009935698,"teacher_disagreement_score":0.2541355,"about_ca_system_score_codex":0.000318307,"about_ca_system_score_gemma":0.0013106264,"threshold_uncertainty_score":0.36289024},"labels":[],"label_agreement":null},{"id":"W4294940939","doi":"10.1016/j.jtho.2022.07.795","title":"EP08.02-112 Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.027287879768799372,"score_gpt":0.4541691762571138,"score_spread":0.4268812964883144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900867,0.001288389,0.000012445381,0.0048827976,0.0005165177,0.0010090672,0.000093631446,0.000003645464,0.0021068407],"genre_scores_gemma":[0.9961598,0.00010356268,0.0007459221,0.00022590617,0.00009694762,0.0001222234,0.000009706718,0.000020456195,0.0025155041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857044,0.00014281164,0.0005327,0.00016710383,0.00025910483,0.0003278233],"domain_scores_gemma":[0.99872947,0.00014666884,0.0005151301,0.00018342599,0.00012944256,0.0002958371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030677684,0.00017216102,0.00069239683,0.0005610703,0.000116078976,0.000010602031,0.000111930734,0.0000748699,0.00035330773],"category_scores_gemma":[0.000028792665,0.000111487716,0.0002263946,0.00022478291,0.000036372985,0.000061441475,0.000021165279,0.00024849368,0.0000020274372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0042552976,0.004962297,0.8357605,0.00013619462,0.0009090058,0.0027392835,0.0064904885,0.0044582607,0.000918421,0.000006949199,0.0021554467,0.1372079],"study_design_scores_gemma":[0.010756977,0.046029504,0.8766473,0.0003724675,0.0023009463,0.0008631294,0.0016878335,0.0012356538,0.0024829397,0.00006855427,0.057251815,0.00030288118],"about_ca_topic_score_codex":0.09027759,"about_ca_topic_score_gemma":0.11972503,"teacher_disagreement_score":0.13690501,"about_ca_system_score_codex":0.010591564,"about_ca_system_score_gemma":0.0112243015,"threshold_uncertainty_score":0.9943811},"labels":[],"label_agreement":null},{"id":"W4294941295","doi":"10.1016/j.jtho.2022.07.696","title":"EP08.02-014 Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cohort; Osimertinib; Line (geometry); East Asia; First line; Demography; Internal medicine; Geography; Archaeology; China","score_opus":0.03542274332694116,"score_gpt":0.47209933260513326,"score_spread":0.4366765892781921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294941295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520161,0.00013797403,0.000011426067,0.031919528,0.0005784387,0.00043745458,0.00015092673,0.000009389175,0.014738739],"genre_scores_gemma":[0.99535286,0.000026081294,0.0006263821,0.0010573793,0.00026097993,0.000033822795,0.000016510423,0.00002611321,0.002599867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982389,0.000295913,0.000613588,0.00017604411,0.00035396233,0.00032154238],"domain_scores_gemma":[0.9981943,0.00015188569,0.00050893245,0.00026745233,0.00022942777,0.00064804446],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009344673,0.00015573,0.0006200113,0.0008307637,0.00018441529,0.000007807151,0.00016763501,0.00006666543,0.00095243857],"category_scores_gemma":[0.00021932342,0.00012201653,0.000256823,0.00058582524,0.000049324444,0.000055638884,0.00003436085,0.00045757604,0.000013495083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10934977,0.0040779277,0.54174304,0.00013915691,0.0049823085,0.011260299,0.009153813,0.017047293,0.0037722448,0.00012710327,0.08315194,0.2151951],"study_design_scores_gemma":[0.002167541,0.025147628,0.8194852,0.00018963193,0.0011322389,0.0017356813,0.00094433984,0.00006085275,0.00023780414,0.0000679416,0.148663,0.00016813728],"about_ca_topic_score_codex":0.013626339,"about_ca_topic_score_gemma":0.030386062,"teacher_disagreement_score":0.27774218,"about_ca_system_score_codex":0.0036805654,"about_ca_system_score_gemma":0.0049887984,"threshold_uncertainty_score":0.99996084},"labels":[],"label_agreement":null},{"id":"W4294942902","doi":"10.1016/j.jtho.2022.07.786","title":"EP08.02-103 Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Internal medicine; Cancer research; Oncology","score_opus":0.02479497650447135,"score_gpt":0.4094396244081332,"score_spread":0.3846446479036618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435354,0.00012633912,0.00007324671,0.0021612663,0.0010502993,0.00078664307,0.00011088998,0.000012582511,0.011325179],"genre_scores_gemma":[0.9931774,0.00001106363,0.0023110714,0.0008474371,0.00049243536,0.0001745796,0.00018125233,0.000027715045,0.0027770149],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862415,0.00011566589,0.0004959524,0.00019633319,0.00028760062,0.00028028066],"domain_scores_gemma":[0.99849707,0.000074673604,0.00051440665,0.00015858182,0.00043687286,0.00031841008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002333012,0.00014731902,0.00037894206,0.00040441143,0.000325142,0.000019520925,0.00009804019,0.00006190843,0.0005720645],"category_scores_gemma":[0.00005126908,0.00011385908,0.00009881659,0.00033820144,0.000050738763,0.00017615671,0.000020311234,0.00025157913,0.0000022367853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009638155,0.0034946895,0.4166807,0.00020609474,0.0021642507,0.0015613004,0.026225206,0.0019049338,0.0047692126,0.00028678734,0.117252864,0.4158158],"study_design_scores_gemma":[0.01698571,0.038775995,0.11233384,0.00028915663,0.0026596612,0.0015004369,0.010088383,0.0011002532,0.008509756,0.00025830997,0.80674136,0.00075716904],"about_ca_topic_score_codex":0.0031589945,"about_ca_topic_score_gemma":0.05617013,"teacher_disagreement_score":0.6894885,"about_ca_system_score_codex":0.002233056,"about_ca_system_score_gemma":0.0019425771,"threshold_uncertainty_score":0.9610523},"labels":[],"label_agreement":null},{"id":"W4294942906","doi":"10.1016/j.jtho.2022.07.747","title":"EP08.02-065 Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Systemic therapy; Cancer; Oncology; Internal medicine; Cancer research; Breast cancer","score_opus":0.031064456675271628,"score_gpt":0.4757297295253387,"score_spread":0.4446652728500671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97461987,0.0019194116,0.0000732722,0.021214072,0.00086630863,0.00043949095,0.00003069672,0.000011808772,0.0008250994],"genre_scores_gemma":[0.9949601,0.00022384583,0.0008553201,0.001668843,0.00017128022,0.00012956515,0.000007174377,0.00002048428,0.0019633411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982749,0.0005448869,0.0005435471,0.00014138891,0.0002937166,0.0002015167],"domain_scores_gemma":[0.9989054,0.00024797602,0.00035256692,0.00016527122,0.00018121909,0.00014755057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096517784,0.00011092773,0.00047254874,0.0005539361,0.00013290496,0.000010266517,0.00013730505,0.000057394896,0.0004883545],"category_scores_gemma":[0.00008730869,0.00008903032,0.00012062781,0.0005306966,0.00002956119,0.00007978992,0.000041523715,0.0003956398,0.00001221286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05283193,0.005166604,0.12683056,0.0001560957,0.0016285138,0.0056078946,0.024640273,0.027669827,0.15370491,0.00012831196,0.020171637,0.58146346],"study_design_scores_gemma":[0.016235916,0.029738395,0.2953226,0.0006826579,0.0012213564,0.010763251,0.020771895,0.0002479813,0.006898109,0.00048850593,0.61706764,0.0005616788],"about_ca_topic_score_codex":0.00007987463,"about_ca_topic_score_gemma":0.000042752716,"teacher_disagreement_score":0.596896,"about_ca_system_score_codex":0.0021749495,"about_ca_system_score_gemma":0.0014570266,"threshold_uncertainty_score":0.56874174},"labels":[],"label_agreement":null},{"id":"W4294942918","doi":"10.1016/j.jtho.2022.07.632","title":"EP08.01-060 Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Term (time); Internal medicine; Cancer","score_opus":0.03262936974105671,"score_gpt":0.43071347476088573,"score_spread":0.39808410501982905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965808,0.0017749933,0.00009819339,0.00068612036,0.00028081538,0.00026836927,0.00023048287,0.0000043405453,0.00007592811],"genre_scores_gemma":[0.99811524,0.00043099318,0.0007451847,0.00025549644,0.000042214964,0.0000119539745,0.00024259542,0.000019009549,0.00013728773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983541,0.0002714157,0.0005444785,0.0002125057,0.0004483895,0.0001691074],"domain_scores_gemma":[0.9985662,0.00013266767,0.00065708644,0.00039510854,0.00016783363,0.00008109062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005652091,0.00014118667,0.00088976545,0.00043454795,0.000078491816,0.000015474554,0.00022764501,0.00004849455,0.00016149662],"category_scores_gemma":[0.00002630136,0.00009295467,0.00009912453,0.0005260317,0.00007951674,0.00037065224,0.00007391289,0.00026798705,1.02137506e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047761295,0.0016723259,0.9015667,0.000012392123,0.0042895493,0.00011839881,0.0016973051,0.00026728582,0.00013836137,0.0000036230776,0.00002060065,0.08543737],"study_design_scores_gemma":[0.0046851565,0.0037748043,0.98820066,0.000024468378,0.0017855426,0.000025378966,0.00078268105,0.000077228724,0.000024887968,0.000010288386,0.0005187386,0.000090175556],"about_ca_topic_score_codex":0.00050363975,"about_ca_topic_score_gemma":0.0015282197,"teacher_disagreement_score":0.08663399,"about_ca_system_score_codex":0.00060929864,"about_ca_system_score_gemma":0.00094796583,"threshold_uncertainty_score":0.37905815},"labels":[],"label_agreement":null},{"id":"W4295169256","doi":"10.1016/j.jtho.2022.07.695","title":"EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Internal medicine; ROS1; Cancer; Adenocarcinoma","score_opus":0.013159745558069796,"score_gpt":0.4129073631286669,"score_spread":0.39974761757059707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295169256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913142,0.0011178621,0.000047529134,0.0042525236,0.0003763988,0.00059017295,0.000031841075,0.0000057404313,0.002263734],"genre_scores_gemma":[0.9988485,0.000060717306,0.00041216955,0.00030709224,0.000045429602,0.00003093675,0.000006731781,0.000011634997,0.0002767939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853736,0.0003463661,0.00051929755,0.00014831228,0.00027559744,0.00017306465],"domain_scores_gemma":[0.99873775,0.00027622134,0.00053515646,0.00015044093,0.00021212897,0.000088287845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045309454,0.0001134245,0.0004485475,0.00016380378,0.00013593615,0.000005212691,0.00010920444,0.00006503001,0.00019059243],"category_scores_gemma":[0.00021314803,0.00007454885,0.000106085856,0.00035318767,0.00011982055,0.000080181104,0.00011849871,0.00044504335,3.9475327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052056783,0.0023505182,0.78582174,0.00014536934,0.00056399516,0.0007992239,0.0047856844,0.00028980445,0.0051318337,0.0000685154,0.0009934417,0.19384418],"study_design_scores_gemma":[0.0032431905,0.0024027033,0.9843613,0.00024267394,0.0008358162,0.0012941599,0.002340565,0.0006433369,0.0016806327,0.00032663535,0.0025391036,0.00008986465],"about_ca_topic_score_codex":0.00009626932,"about_ca_topic_score_gemma":0.00006142408,"teacher_disagreement_score":0.19853956,"about_ca_system_score_codex":0.00041000705,"about_ca_system_score_gemma":0.00062981545,"threshold_uncertainty_score":0.3040014},"labels":[],"label_agreement":null},{"id":"W4295297459","doi":"10.1016/j.jtho.2022.08.018","title":"Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; EMD Serono; Teijin Pharma; Daiichi-Sankyo; G1 Therapeutics; BeiGene; Mirati Therapeutics; Bristol-Myers Squibb; Society for Academic Continuing Medical Education; Johnson and Johnson; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Takeda Pharmaceutical Company; AbbVie; Merck; Yuhan; Merck KGaA; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Roche; Novartis; GlaxoSmithKline Japan; Sanofi; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Alectinib; Ceritinib; Medicine; Crizotinib; Internal medicine; ALK inhibitor; Anaplastic lymphoma kinase; Lung cancer; Gastroenterology; Oncology; Clinical endpoint; Adverse effect; Confidence interval; Clinical trial","score_opus":0.015249162801495204,"score_gpt":0.43815073301899576,"score_spread":0.4229015702175006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295297459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939231,0.00031066994,0.000007174632,0.0013259845,0.00047779756,0.0020952497,0.00010604241,0.000007066817,0.0017468686],"genre_scores_gemma":[0.9976459,0.00004803975,0.0014939634,0.00023887398,0.0001336979,0.00018869297,0.000034769364,0.000035835434,0.00018020015],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99713993,0.00043992107,0.0012061276,0.00026390218,0.00064151204,0.00030860325],"domain_scores_gemma":[0.99706936,0.0005301038,0.0016535511,0.00019618958,0.00042192364,0.0001288847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005263749,0.00021160248,0.0011301176,0.0004457893,0.00006875034,0.000005681228,0.00016652228,0.000097904194,0.00023443223],"category_scores_gemma":[0.00027805436,0.00015412977,0.00014840292,0.0007427731,0.00013072988,0.00012912495,0.000049316935,0.0006337778,3.3885252e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6091863,0.012103653,0.11186277,0.00026719272,0.0009052635,0.00049937796,0.005824666,0.001744802,0.00042433952,0.000022860184,0.00036061535,0.25679815],"study_design_scores_gemma":[0.28966555,0.0852356,0.6099833,0.003239154,0.0013855196,0.00013012026,0.0019452733,0.00010406802,0.0050288877,0.000038507664,0.0028970337,0.0003469479],"about_ca_topic_score_codex":0.00014881878,"about_ca_topic_score_gemma":0.00019031306,"teacher_disagreement_score":0.49812055,"about_ca_system_score_codex":0.0010593677,"about_ca_system_score_gemma":0.0020597735,"threshold_uncertainty_score":0.62852293},"labels":[],"label_agreement":null},{"id":"W4295817484","doi":"10.1016/j.annonc.2022.07.1070","title":"945P Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Stage (stratigraphy); Lung; Cancer; Respiratory system","score_opus":0.04894935660891992,"score_gpt":0.3957347785323185,"score_spread":0.34678542192339856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528694,0.034591205,0.000042302338,0.0052635176,0.0005504368,0.0004544101,0.0015930268,0.000017034276,0.0046186442],"genre_scores_gemma":[0.98895717,0.004519363,0.000043400352,0.0042741667,0.0002177145,0.00041780513,0.00011309872,0.000019051386,0.0014382156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986972,0.00016498032,0.00033297157,0.00031692302,0.00027212282,0.00021576087],"domain_scores_gemma":[0.9988658,0.00030204075,0.00027168455,0.00023821436,0.00022237883,0.000099881916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003429726,0.00015648859,0.0006057268,0.0002271918,0.00020213274,0.000020209975,0.00014164242,0.00005931418,0.00083990884],"category_scores_gemma":[0.000024260267,0.0001224908,0.00014318166,0.0003534311,0.00017743984,0.00005781721,0.00018497944,0.00019811113,3.2553808e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054926565,0.0002940244,0.95038366,0.000079094105,0.0146158375,0.00008220192,0.006922964,0.0008648189,0.0022160274,0.0002391267,0.014521525,0.009231451],"study_design_scores_gemma":[0.006436904,0.0005219529,0.75605047,0.000043730586,0.01184954,0.000005374879,0.0065368363,0.0020735273,0.001286389,0.000028508744,0.21489385,0.00027292178],"about_ca_topic_score_codex":0.022259941,"about_ca_topic_score_gemma":0.004095995,"teacher_disagreement_score":0.20037232,"about_ca_system_score_codex":0.00015788451,"about_ca_system_score_gemma":0.0007773134,"threshold_uncertainty_score":0.9842509},"labels":[],"label_agreement":null},{"id":"W4295817538","doi":"10.1016/j.annonc.2022.07.1065","title":"940P Programmed death-ligand 1 (PDL1) expression and real-world outcomes in resected, early-stage non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Brampton Civic Hospital; London Health Sciences Centre; AstraZeneca (Canada); William Osler Health System; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Lung cancer; Cancer; Lung; Ligand (biochemistry); Pathology; Internal medicine; Cancer research; Receptor","score_opus":0.05707741825648091,"score_gpt":0.42636990270218567,"score_spread":0.3692924844457047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801778,0.0011352656,0.0000052737632,0.0031111673,0.00016386838,0.0009904603,0.00007231337,0.000025242107,0.014318577],"genre_scores_gemma":[0.98935276,0.0008145876,0.0004608845,0.00065388536,0.000042280844,0.00070801476,0.00004449444,0.000024331215,0.0078987805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987517,0.00009661848,0.0003369974,0.00030120177,0.00018396569,0.00032953286],"domain_scores_gemma":[0.99923533,0.00013876474,0.00018195862,0.0002179132,0.000096867036,0.00012916708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021256867,0.00014814205,0.0004718483,0.00025829286,0.000112767324,0.00000802852,0.000087078086,0.00007125193,0.00015333801],"category_scores_gemma":[0.000022991406,0.00012264203,0.0000711803,0.00026496992,0.00005619733,0.000054676417,0.00012809047,0.0002307595,0.0000011331553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005810965,0.0009920646,0.97616553,0.00015354132,0.0001421986,0.00023950115,0.0032491374,0.000036004494,0.0066574295,0.00006652185,0.0023029337,0.009414043],"study_design_scores_gemma":[0.008009918,0.0030479997,0.9267463,0.00013342705,0.00022458144,0.000009385539,0.00084785564,0.00008585464,0.015494072,0.000068045556,0.04513259,0.00019996102],"about_ca_topic_score_codex":0.009790494,"about_ca_topic_score_gemma":0.0032821866,"teacher_disagreement_score":0.04941922,"about_ca_system_score_codex":0.00017971377,"about_ca_system_score_gemma":0.00048922346,"threshold_uncertainty_score":0.9968034},"labels":[],"label_agreement":null},{"id":"W4295827732","doi":"10.1016/j.annonc.2022.07.1268","title":"1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brain metastasis; Stage (stratigraphy); Oncology; Internal medicine; Metastasis; Cancer","score_opus":0.07787698650814676,"score_gpt":0.45925068328208735,"score_spread":0.3813736967739406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295827732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897946,0.0005605659,0.000011945652,0.004274023,0.0002549429,0.00060122495,0.0022809,0.000010315562,0.003026642],"genre_scores_gemma":[0.9960037,0.0003521388,0.00038027245,0.0005921757,0.000012597902,0.00011127573,0.0003047389,0.00001669938,0.0022264246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784344,0.00027144022,0.00095805107,0.00027240327,0.0004409355,0.00021371334],"domain_scores_gemma":[0.9957953,0.0023924583,0.0008677524,0.00036931655,0.0004640034,0.000111144174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041035388,0.00014080733,0.00087936217,0.00013629216,0.00007498167,0.0000014280752,0.00019904807,0.000079711725,0.0010132624],"category_scores_gemma":[0.0010386418,0.00012485556,0.000284222,0.00027270048,0.00038909056,0.000078459496,0.00018157724,0.00013602413,0.0000069500875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012338698,0.0055857943,0.88478786,0.00012669663,0.0018664568,0.000015417821,0.0016259609,0.00011669134,0.0003135975,0.0002850801,0.068907365,0.035135232],"study_design_scores_gemma":[0.013639887,0.019887028,0.8532104,0.00007770153,0.0009967491,0.0000038964204,0.0010190143,0.000057767433,0.0048320866,0.00008246392,0.105992004,0.00020101963],"about_ca_topic_score_codex":0.0005434686,"about_ca_topic_score_gemma":0.00008430668,"teacher_disagreement_score":0.037084643,"about_ca_system_score_codex":0.000097276774,"about_ca_system_score_gemma":0.0005074822,"threshold_uncertainty_score":0.9998999},"labels":[],"label_agreement":null},{"id":"W4295828333","doi":"10.1016/j.annonc.2022.07.1295","title":"1172P High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Exon; Lung cancer; Cancer research; Mutation; Cancer; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.042377125063117665,"score_gpt":0.40398834221574703,"score_spread":0.36161121715262934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872098,0.00046001226,0.000026004398,0.0049946923,0.00021658868,0.00063001446,0.00010329737,0.000009242695,0.006350378],"genre_scores_gemma":[0.99804854,0.00020619444,0.0002176593,0.00052842795,0.00003419598,0.00033282064,0.000076026205,0.000014668582,0.0005414371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998938,0.00013322968,0.00035387342,0.00021224572,0.00014952745,0.00021307846],"domain_scores_gemma":[0.9992998,0.00012376593,0.00024607166,0.00016168381,0.00011450332,0.000054138127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022606972,0.00010558622,0.0004105386,0.00030583618,0.00004696315,0.000001793316,0.00007473109,0.00007888392,0.000347179],"category_scores_gemma":[0.000027974167,0.000106890315,0.00007292202,0.0004430881,0.00005086432,0.00006885597,0.00005068441,0.00022225949,0.0000016312686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029675565,0.013804206,0.7218502,0.0008411385,0.00049423054,0.00034569408,0.018833993,0.01727656,0.0914737,0.00044497775,0.0059643434,0.1257034],"study_design_scores_gemma":[0.0073184483,0.003189122,0.9561826,0.00013177114,0.00020784252,0.000011262016,0.0013476813,0.0010848258,0.025232341,0.00020588099,0.0049253167,0.00016291327],"about_ca_topic_score_codex":0.011058672,"about_ca_topic_score_gemma":0.005000211,"teacher_disagreement_score":0.23433238,"about_ca_system_score_codex":0.00034259236,"about_ca_system_score_gemma":0.0008521634,"threshold_uncertainty_score":0.9955268},"labels":[],"label_agreement":null},{"id":"W4295828376","doi":"10.1016/j.annonc.2022.07.1237","title":"1112P Real-world treatment (tx) patterns and outcomes based on PD-L1 status in tx-naive patients (pts) with METex14 advanced non-small cell lung cancer (aNSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.02826066290229761,"score_gpt":0.3871112570587321,"score_spread":0.3588505941564345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98789716,0.00026677232,0.00001258151,0.0023782249,0.00016593319,0.0012752976,0.00053371396,0.000018130853,0.0074521783],"genre_scores_gemma":[0.99397606,0.00067966984,0.00035145835,0.0026652492,0.000018973766,0.00089649763,0.00024154784,0.000033647833,0.0011369154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985351,0.0001109921,0.00033425054,0.00039256498,0.00022997589,0.00039710102],"domain_scores_gemma":[0.99900126,0.000212338,0.0002420717,0.0002630035,0.0001246871,0.00015664437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085328815,0.0002406288,0.00063286547,0.0002529745,0.00009625618,0.0000049803125,0.00006322511,0.000046375666,0.0002534945],"category_scores_gemma":[0.000010546929,0.0001779511,0.00008748807,0.00022107438,0.00004788375,0.000049363607,0.000036908146,0.00014504009,0.0000014194482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013038731,0.0027297018,0.9578715,0.00007544963,0.0003016525,0.00010091337,0.0019935737,0.0019030053,0.000025871484,0.000015363068,0.0005981668,0.03308091],"study_design_scores_gemma":[0.016572786,0.015333127,0.9525955,0.00010072961,0.0004216528,0.0000010716176,0.0006022996,0.00031896096,0.0007233645,0.000007597796,0.013143812,0.00017914131],"about_ca_topic_score_codex":0.009557284,"about_ca_topic_score_gemma":0.00841847,"teacher_disagreement_score":0.032901768,"about_ca_system_score_codex":0.000857681,"about_ca_system_score_gemma":0.0006665376,"threshold_uncertainty_score":0.9970382},"labels":[],"label_agreement":null},{"id":"W4295828392","doi":"10.1016/j.annonc.2022.07.1236","title":"1111P Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Lung cancer; Oncology; Expanded access; Demographics; Demography","score_opus":0.05006063986485293,"score_gpt":0.4205134632515281,"score_spread":0.3704528233866752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97889936,0.00019214535,0.00007828696,0.0050188364,0.00014116828,0.0031915691,0.00011332287,0.000050829778,0.012314478],"genre_scores_gemma":[0.9940969,0.0002278015,0.00057734415,0.0006643351,0.000054014807,0.003398039,0.00052291213,0.000026994921,0.00043170812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983743,0.00015240887,0.0004523082,0.00037062835,0.00031059916,0.0003397577],"domain_scores_gemma":[0.9988196,0.00008010172,0.00044148296,0.00028441715,0.00029748416,0.00007694961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011437702,0.00022665925,0.0003974659,0.00011846335,0.00028846215,0.00002672243,0.00013879438,0.000057442143,0.0001124196],"category_scores_gemma":[0.000010948818,0.00014397677,0.00006974855,0.00083749346,0.000092567185,0.00024951543,0.000053894273,0.00015370065,0.00000112592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028247503,0.0051959576,0.93506,0.00007621587,0.00045812872,0.000036519774,0.005772516,0.006181236,0.00002808208,0.00006872104,0.0007325752,0.043565292],"study_design_scores_gemma":[0.01116482,0.011340933,0.96819466,0.00014285758,0.0006432597,0.000008024024,0.0012326903,0.0005357905,0.00062437734,0.000071092596,0.005840022,0.00020145353],"about_ca_topic_score_codex":0.012230718,"about_ca_topic_score_gemma":0.030583221,"teacher_disagreement_score":0.04336384,"about_ca_system_score_codex":0.0012710915,"about_ca_system_score_gemma":0.001155233,"threshold_uncertainty_score":0.9943469},"labels":[],"label_agreement":null},{"id":"W4295828460","doi":"10.1016/j.annonc.2022.07.1235","title":"1110P Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.15306855910501577,"score_gpt":0.52759099597619,"score_spread":0.3745224368711742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95288855,0.00026227516,0.00011517047,0.034903273,0.0007532602,0.0008187005,0.00010396553,0.000046194255,0.010108601],"genre_scores_gemma":[0.98744226,0.000084440595,0.0008299227,0.008430122,0.00008436432,0.00028664828,0.0002230786,0.000017065304,0.0026020785],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989386,0.000093996816,0.00044426706,0.00019768722,0.00013375995,0.00019168593],"domain_scores_gemma":[0.9989832,0.00036660247,0.00018602767,0.00018216467,0.00018845378,0.00009352592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034388274,0.00008970023,0.00042887012,0.00008623677,0.00011426064,0.0000030475665,0.0000765441,0.00007175607,0.00045622396],"category_scores_gemma":[0.00018341493,0.00007496858,0.00023578765,0.00012529836,0.00006945817,0.0000458518,0.000043858785,0.00013176975,0.000010288184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036848988,0.007749879,0.51817614,0.000110459754,0.0028447309,0.00017773933,0.0022022903,0.00014233547,0.0008106224,0.0013635637,0.17729726,0.2854401],"study_design_scores_gemma":[0.008107457,0.01367844,0.3256823,0.000014592342,0.00045707283,0.00003902075,0.0011759193,0.00010666515,0.00029023105,0.000675659,0.6496428,0.00012979325],"about_ca_topic_score_codex":0.00017445805,"about_ca_topic_score_gemma":0.00008032524,"teacher_disagreement_score":0.4723456,"about_ca_system_score_codex":0.00008462631,"about_ca_system_score_gemma":0.00051470473,"threshold_uncertainty_score":0.49953324},"labels":[],"label_agreement":null},{"id":"W4295828577","doi":"10.1016/j.annonc.2022.07.1303","title":"1180P Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"EMD Serono; Eisai; Merck KGaA; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Crizotinib; Nivolumab; Internal medicine; Oncology; Lung cancer; Progression-free survival; Pemetrexed; Real world data; Chemotherapy; Cancer; Immunotherapy","score_opus":0.08671700921615552,"score_gpt":0.5028440010374505,"score_spread":0.416126991821295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756716,0.0025517116,0.000013638961,0.0073349224,0.0006059859,0.001286254,0.00011169274,0.00001895826,0.012405221],"genre_scores_gemma":[0.98488474,0.00953135,0.002551387,0.0010718972,0.000118412274,0.0009580732,0.00007001726,0.000029544857,0.0007845855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978868,0.000406072,0.0006879372,0.00043795627,0.00023286352,0.00034836703],"domain_scores_gemma":[0.99819976,0.0008372071,0.0003823956,0.00032512782,0.00012309855,0.00013238563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079206814,0.00018440755,0.00069486396,0.0002671191,0.00007426816,0.0000061116866,0.00011351464,0.0000840734,0.00012622502],"category_scores_gemma":[0.00017002222,0.0001584704,0.00009715989,0.00032995568,0.000056195022,0.00010586415,0.0001487724,0.00029985578,7.965267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014365182,0.0038299004,0.79208475,0.00013902484,0.00028340053,0.00049650634,0.0023770034,0.00022627735,0.00012197936,0.00006651428,0.00069915445,0.198239],"study_design_scores_gemma":[0.020309491,0.012043848,0.870544,0.00034769464,0.0005214479,0.000029539671,0.0036750557,0.00032724856,0.00056399236,0.00008143663,0.091284096,0.0002721071],"about_ca_topic_score_codex":0.008038171,"about_ca_topic_score_gemma":0.013322317,"teacher_disagreement_score":0.19796689,"about_ca_system_score_codex":0.0004870223,"about_ca_system_score_gemma":0.00082864944,"threshold_uncertainty_score":0.9985674},"labels":[],"label_agreement":null},{"id":"W4295828587","doi":"10.1016/j.annonc.2022.07.1229","title":"1104P Health-related quality of life (HRQOL) in patients with ALK+ non-small cell lung cancer (NSCLC) in the phase III CROWN study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; non-small cell lung cancer (NSCLC); Quality of life (healthcare); Oncology; Internal medicine; Nursing; A549 cell","score_opus":0.06511884568022727,"score_gpt":0.44785721191884853,"score_spread":0.38273836623862123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295828587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143517,0.00092115026,0.0000022943125,0.0035956507,0.00009745836,0.0019554375,0.000087151566,0.0000055974897,0.0019000815],"genre_scores_gemma":[0.9970727,0.00005424287,0.000025023604,0.0022859185,0.000012323152,0.0003706373,0.00006476689,0.000011661296,0.000102705744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980898,0.00046414588,0.0007310497,0.00021390914,0.00026669767,0.00023443103],"domain_scores_gemma":[0.998907,0.00015149264,0.00048340502,0.00024787476,0.00013991861,0.00007026621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008266906,0.00011239513,0.00060574035,0.00015502263,0.0000711607,0.0000019120143,0.00012631301,0.00004136102,0.00016767261],"category_scores_gemma":[0.000030863655,0.00007748618,0.000051542953,0.00043180824,0.00005769962,0.000033597113,0.000047944795,0.00024100358,5.107272e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004572659,0.021543713,0.92686516,0.00012454607,0.00030388418,0.000030790856,0.036127694,0.00041244127,0.000027745129,0.000022549011,0.0024285375,0.0075402763],"study_design_scores_gemma":[0.038691185,0.015293302,0.93641293,0.000045684475,0.0001124845,8.669242e-7,0.008113743,0.000040753537,0.000033922894,0.000011507231,0.0011578847,0.00008572595],"about_ca_topic_score_codex":0.020223126,"about_ca_topic_score_gemma":0.004604088,"teacher_disagreement_score":0.034118526,"about_ca_system_score_codex":0.00020960851,"about_ca_system_score_gemma":0.0013880425,"threshold_uncertainty_score":0.9863013},"labels":[],"label_agreement":null},{"id":"W4296006125","doi":"10.1016/j.annonc.2022.07.687","title":"559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Oncology; EMD Serono; Genentech; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; Sociedad Española de Oncología Médica; Silverback Therapeutics; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; AstraZeneca; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences","keywords":"Medicine; Neratinib; Bevacizumab; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Population; Cancer; Gastroenterology; Chemotherapy; Phases of clinical research; Trastuzumab; Breast cancer","score_opus":0.10091057117074319,"score_gpt":0.4716622743300022,"score_spread":0.370751703159259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296006125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96074814,0.0010014612,0.0000059252566,0.034135036,0.0007923481,0.0009308395,0.0010195951,0.000018734385,0.0013479065],"genre_scores_gemma":[0.9925855,0.00027498204,0.000114013856,0.005223719,0.00019936413,0.0004958734,0.0007510087,0.000019214585,0.0003363433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835205,0.0003454193,0.00048988685,0.00027839444,0.000257649,0.00027658994],"domain_scores_gemma":[0.99902886,0.00037454788,0.0001774815,0.00023498294,0.00009320582,0.000090927795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036247727,0.00014271266,0.0004828344,0.00009641752,0.00013642444,0.000009026791,0.00015811593,0.000054788303,0.004055411],"category_scores_gemma":[0.0001367643,0.00010302517,0.00011884897,0.0003936889,0.00009112585,0.000051965926,0.0000788759,0.00033847947,0.000010825748],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121921055,0.043234006,0.029369928,0.000087911874,0.0028159407,0.0011205627,0.012634678,0.00017739837,0.0020816186,0.0012674935,0.47457966,0.31070974],"study_design_scores_gemma":[0.27519986,0.014326301,0.007914333,0.00007332436,0.00078967796,0.000020791635,0.0026345376,0.00061289273,0.0010588611,0.0007813437,0.69633955,0.00024853137],"about_ca_topic_score_codex":0.0025635827,"about_ca_topic_score_gemma":0.0015888094,"teacher_disagreement_score":0.31046122,"about_ca_system_score_codex":0.0001829493,"about_ca_system_score_gemma":0.0008282021,"threshold_uncertainty_score":0.996855},"labels":[],"label_agreement":null},{"id":"W4296011363","doi":"10.1016/j.annonc.2022.07.1055","title":"929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Durvalumab; Oncology; Pharmacodynamics; Stage (stratigraphy); Internal medicine; Lung cancer; Cancer; Pharmacokinetics; Immunotherapy","score_opus":0.04352965567501625,"score_gpt":0.369824625065871,"score_spread":0.3262949693908547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296011363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417615,0.00006745453,0.000009962464,0.00016136438,0.0000957318,0.004782754,0.00016596146,0.000009750124,0.0005308755],"genre_scores_gemma":[0.998896,0.000020547006,0.00004344793,0.0002242915,0.000009702875,0.00055900024,0.000072119605,0.000038571274,0.00013632906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980179,0.00016287065,0.0006045859,0.00038724454,0.00046345772,0.00036392067],"domain_scores_gemma":[0.99873155,0.00021346519,0.0005244469,0.0002744406,0.00018381319,0.00007225355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004712155,0.00024371865,0.00071296626,0.00028631257,0.00015427051,0.0000106367615,0.0001843585,0.0000400519,0.000041237956],"category_scores_gemma":[0.000018883778,0.00015761044,0.000032845055,0.0006673669,0.00007826929,0.00011014905,0.00014483849,0.00039345378,1.5974767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008127233,0.01760273,0.940663,0.00013411917,0.0005021962,0.0004776467,0.026483476,0.004719799,0.00008247901,0.0000057876728,0.00002671875,0.0011748067],"study_design_scores_gemma":[0.052254133,0.048090853,0.83162445,0.00015114393,0.00052389153,0.000022042377,0.046630006,0.020489272,0.000025908972,0.0000019086683,0.000011756461,0.000174609],"about_ca_topic_score_codex":0.011520683,"about_ca_topic_score_gemma":0.027012454,"teacher_disagreement_score":0.10903853,"about_ca_system_score_codex":0.000442678,"about_ca_system_score_gemma":0.00054072647,"threshold_uncertainty_score":0.9950617},"labels":[],"label_agreement":null},{"id":"W4296253011","doi":"10.3390/curroncol29090520","title":"Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"ROS1; Anaplastic lymphoma kinase; Medicine; Cancer research; Context (archaeology); Mutation; Tyrosine kinase; Lung cancer; Crizotinib; Tyrosine-kinase inhibitor; Targeted therapy; Internal medicine; Cancer; Gene; Adenocarcinoma; Receptor; Biology; Genetics","score_opus":0.05855500493016243,"score_gpt":0.41903275836317594,"score_spread":0.3604777534330135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296253011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916872,0.0015216225,0.00034017226,0.003059288,0.00051593815,0.0010125028,0.000034664536,0.00006443148,0.0017642018],"genre_scores_gemma":[0.99702245,0.00004652334,0.00087043224,0.00036017995,0.00007904444,0.00094042456,0.00015702026,0.000020608322,0.00050334324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902,0.000094925854,0.00021029857,0.00027727624,0.00018304358,0.0002144649],"domain_scores_gemma":[0.99951065,0.000054790115,0.000084884006,0.00017983581,0.000079792066,0.00009004129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009876676,0.000114909446,0.00022153588,0.00018668926,0.00011621066,0.0000059208146,0.000066600565,0.00003182589,0.00035792554],"category_scores_gemma":[0.00002642687,0.00009461831,0.000031413496,0.0005486222,0.000036605146,0.000038432605,0.000029648232,0.00012132685,0.000013681496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07101847,0.01330468,0.1140624,0.00034036272,0.0009367614,0.0024843467,0.062271856,0.0033059896,0.04456265,0.001842938,0.016161261,0.6697083],"study_design_scores_gemma":[0.022519179,0.015852705,0.22646803,0.00016062941,0.00020902947,0.00023054545,0.002791949,0.00021715164,0.0028592339,0.00017807553,0.7280563,0.0004571434],"about_ca_topic_score_codex":0.000028635277,"about_ca_topic_score_gemma":0.00021999149,"teacher_disagreement_score":0.71189505,"about_ca_system_score_codex":0.0007887785,"about_ca_system_score_gemma":0.00041922374,"threshold_uncertainty_score":0.39190337},"labels":[],"label_agreement":null},{"id":"W4296481633","doi":"10.3390/curroncol29100530","title":"STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; Beijing Xisike Clinical Oncology Research Foundation","keywords":"Medicine; Brain metastasis; Adenocarcinoma; Lung cancer; Metastasis; Lung; Fusion gene; Cancer research; Crizotinib; Pathology; Oncology; Internal medicine; Cancer; Gene; Biology; Genetics","score_opus":0.06532667119711873,"score_gpt":0.4425346738454791,"score_spread":0.3772080026483604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296481633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851225,0.0014270765,0.0001348035,0.007893678,0.00058768096,0.0012100474,0.00005642442,0.000049412385,0.0035183458],"genre_scores_gemma":[0.9956015,0.0000100832185,0.00082109094,0.00065947714,0.00009219232,0.0006615606,0.00017958178,0.000025923482,0.0019485942],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841464,0.00021622461,0.00037016463,0.00043848756,0.0002534011,0.00030708293],"domain_scores_gemma":[0.9991166,0.00012739025,0.00013783424,0.0003453138,0.00007732868,0.00019552677],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040839135,0.0001527918,0.00036138808,0.0003352914,0.00016908172,0.000007648865,0.00006493598,0.000038450464,0.00093653315],"category_scores_gemma":[0.000105332285,0.00012628072,0.00006186461,0.00055907265,0.000035422952,0.000040035527,0.0001284242,0.00030652146,0.00001829375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005757357,0.004686199,0.24948072,0.00021684721,0.00047230537,0.5379507,0.013787938,0.00041272945,0.000948427,0.0004915347,0.07174988,0.11404536],"study_design_scores_gemma":[0.008442395,0.004943793,0.03247046,0.00006571719,0.0006996119,0.08228459,0.004533105,0.0002762265,0.00022239618,0.000038071135,0.8657614,0.00026224332],"about_ca_topic_score_codex":0.00022390463,"about_ca_topic_score_gemma":0.00046975442,"teacher_disagreement_score":0.79401153,"about_ca_system_score_codex":0.001122963,"about_ca_system_score_gemma":0.0007688919,"threshold_uncertainty_score":0.99997675},"labels":[],"label_agreement":null},{"id":"W4296676807","doi":"10.1016/j.lungcan.2022.08.023","title":"EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; William Osler Health System; AstraZeneca (Canada); London Health Sciences Centre; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Centre; Canada Research Chairs; Western University","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Cohort; Adjuvant therapy; Oncology; Population; Lung cancer; Stage (stratigraphy); Retrospective cohort study; Disease; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.006545336997180896,"score_gpt":0.2823730039069236,"score_spread":0.2758276669097427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296676807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941906,0.00074010046,0.0000069116386,0.00029963237,0.00036110907,0.0020500608,0.001170718,0.000029059685,0.0011518137],"genre_scores_gemma":[0.9785897,0.0006918175,0.000046435583,0.00023996463,0.00004780107,0.0026935178,0.00018973314,0.000054210275,0.017446788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982462,0.00006126438,0.00031041654,0.0005043357,0.0004660209,0.00041174126],"domain_scores_gemma":[0.99919194,0.000057822923,0.00018848694,0.00028430257,0.00009949608,0.00017796518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004640286,0.00028917546,0.00037982222,0.00019413479,0.00021095973,0.000026599702,0.000083180516,0.000030800027,0.00075797964],"category_scores_gemma":[0.000003006881,0.00020689334,0.000044247092,0.00038425197,0.000028303082,0.00012335424,0.000051582636,0.00019588199,3.388131e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020420049,0.00018946333,0.9921605,0.0003944443,0.0003373944,0.00012747452,0.0016748258,0.0023849893,0.000003236648,0.0000029266942,0.00048063407,0.0020399261],"study_design_scores_gemma":[0.0063438592,0.00026846334,0.99013776,0.00025145878,0.000716727,8.42291e-7,0.00034453324,0.0011077798,0.0000848754,7.608197e-7,0.0004999154,0.00024301304],"about_ca_topic_score_codex":0.9829921,"about_ca_topic_score_gemma":0.98982865,"teacher_disagreement_score":0.016294973,"about_ca_system_score_codex":0.007578899,"about_ca_system_score_gemma":0.0020779413,"threshold_uncertainty_score":0.99623084},"labels":[],"label_agreement":null},{"id":"W4296767782","doi":"10.1016/j.jtho.2022.07.340","title":"EP02.01-013 Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; KRAS; Oncology; Internal medicine; Lung cancer; Cancer; Colorectal cancer","score_opus":0.013307281357276716,"score_gpt":0.3684444308555025,"score_spread":0.3551371494982258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296767782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761915,0.00022535554,0.000004744034,0.0008225935,0.00025594656,0.0006707281,0.000052386844,0.0000050895433,0.00034399188],"genre_scores_gemma":[0.99414366,0.00013195984,0.00027226834,0.00017332345,0.000030438865,0.00009870298,0.000018151275,0.000019165213,0.0051123034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872583,0.00012941167,0.00047914634,0.00020384956,0.000223312,0.00023846797],"domain_scores_gemma":[0.9991936,0.000073158626,0.00041789442,0.00012303602,0.00007207011,0.00012023304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016002398,0.00017489454,0.00055465597,0.00037006475,0.000056390705,0.0000108849135,0.0000759721,0.000045329536,0.00032221377],"category_scores_gemma":[0.0000037154605,0.0001203205,0.0000588553,0.00016966723,0.000020036292,0.00008531428,0.00004371302,0.0003414391,6.8286164e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001939315,0.0016956945,0.975422,0.000094239906,0.00021317646,0.0006528111,0.006533873,0.00041187947,0.000008829427,2.3589335e-7,0.000020886497,0.013007021],"study_design_scores_gemma":[0.007314171,0.0043695015,0.98639226,0.00019146009,0.0007279428,0.000035409448,0.00039298343,0.000032846725,0.000031011306,0.0000036709562,0.00040323002,0.00010551519],"about_ca_topic_score_codex":0.03960309,"about_ca_topic_score_gemma":0.35050142,"teacher_disagreement_score":0.31089833,"about_ca_system_score_codex":0.006534642,"about_ca_system_score_gemma":0.0010529216,"threshold_uncertainty_score":0.9972791},"labels":[],"label_agreement":null},{"id":"W4296768674","doi":"10.1016/j.jtho.2022.07.023","title":"OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; KRAS; Oncology; Mutation; Internal medicine; Lung cancer; Cancer; non-small cell lung cancer (NSCLC); Cancer research; Genetics; Colorectal cancer; Gene","score_opus":0.017092201985731224,"score_gpt":0.44098012343178916,"score_spread":0.4238879214460579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514496,0.00025859012,0.00053668563,0.0013992016,0.00030374495,0.0018879164,0.000022096157,0.000008698823,0.00043808878],"genre_scores_gemma":[0.99597317,0.000014249071,0.0022521468,0.0008477603,0.00010348553,0.00027202815,0.000013640882,0.000037563896,0.00048596182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982846,0.0002494961,0.00047600566,0.00023086435,0.0005122729,0.00024677214],"domain_scores_gemma":[0.99867535,0.000061038896,0.00052226026,0.00017155186,0.00039404084,0.00017573443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048184334,0.0001837432,0.0005260785,0.00040623284,0.00013013385,0.000014383918,0.00011929652,0.000034001514,0.00027559078],"category_scores_gemma":[0.00001176455,0.00012377708,0.000059067333,0.00047118214,0.000023499808,0.000110026194,0.000024180834,0.00036968445,0.0000026189816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057967555,0.026530785,0.6971195,0.000100171295,0.0016062756,0.0023964066,0.042624764,0.020752646,0.00053403823,0.0000012516393,0.000985055,0.14938155],"study_design_scores_gemma":[0.117951795,0.178939,0.67064553,0.0004289446,0.005686175,0.00038921105,0.019078858,0.0011898532,0.00089573424,0.000024797546,0.004205074,0.00056503754],"about_ca_topic_score_codex":0.00024622958,"about_ca_topic_score_gemma":0.00037200577,"teacher_disagreement_score":0.15240821,"about_ca_system_score_codex":0.0017736765,"about_ca_system_score_gemma":0.0015580276,"threshold_uncertainty_score":0.5047483},"labels":[],"label_agreement":null},{"id":"W4296770063","doi":"10.1016/j.jtho.2022.07.177","title":"P1.09-02 Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Oncology; Mutation; Internal medicine; Genetics; Gene","score_opus":0.0507382076439071,"score_gpt":0.4930215019475437,"score_spread":0.44228329430363655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296770063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969646,0.00031586885,0.00020090291,0.0011235754,0.0005886156,0.0003337219,0.000046243604,0.000005264388,0.00042122215],"genre_scores_gemma":[0.9943648,0.0008460306,0.0039382176,0.00017819545,0.000122025194,0.000031139123,0.00003327655,0.000015273172,0.00047105772],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812573,0.0003429569,0.0010099686,0.00015200763,0.00021471767,0.00015458801],"domain_scores_gemma":[0.9983045,0.00038802365,0.00095987663,0.0001225679,0.00011276849,0.000112251655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065476884,0.00011567198,0.00073181227,0.0003743668,0.000053028067,0.0000057354773,0.00005578391,0.000037044738,0.00010528207],"category_scores_gemma":[0.00009790046,0.000095092975,0.00012975033,0.00019672452,0.0000423321,0.00008818173,0.000035221085,0.0002741751,9.296606e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017059499,0.0015145218,0.20185399,0.00007085074,0.0004204159,0.001561983,0.0015973336,0.00010085278,0.0002275018,0.000034436423,0.000040311865,0.79087186],"study_design_scores_gemma":[0.0053060325,0.012305725,0.9694175,0.00021511235,0.0016085482,0.00090669317,0.0022162627,0.00021446006,0.00015310245,0.00019581147,0.0073499875,0.000110723784],"about_ca_topic_score_codex":0.000098688,"about_ca_topic_score_gemma":0.00019007965,"teacher_disagreement_score":0.7907611,"about_ca_system_score_codex":0.00087807036,"about_ca_system_score_gemma":0.00049768836,"threshold_uncertainty_score":0.3877779},"labels":[],"label_agreement":null},{"id":"W4296770892","doi":"10.1016/j.jtho.2022.07.861","title":"EP08.03-005 HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Radiation therapy; Disease; Lung; Targeted therapy; Lung disease; Oncology; Cancer research; Internal medicine; Radiology; Cancer","score_opus":0.021945224871566443,"score_gpt":0.4285558895482716,"score_spread":0.40661066467670515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296770892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787523,0.009625966,0.000059622966,0.009717895,0.00045320473,0.0010012662,0.00003887645,0.000024087012,0.00032675243],"genre_scores_gemma":[0.99284965,0.00075674127,0.0032441649,0.0020820855,0.0002659227,0.00017027793,0.000045657904,0.000054869844,0.0005306196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770623,0.00045823999,0.0006984987,0.00027972378,0.00046364334,0.00039365102],"domain_scores_gemma":[0.9983827,0.00014622904,0.0006872169,0.00023777854,0.00022340662,0.00032270025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046295737,0.00024781632,0.0009028846,0.00063741615,0.00011717815,0.000016572683,0.00018889362,0.00008410378,0.0008958394],"category_scores_gemma":[0.00007370758,0.00016044953,0.00013670673,0.0007406257,0.00011762674,0.00013887724,0.00003189803,0.00070415565,0.0000014532396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19477744,0.007623609,0.5940852,0.000112190704,0.0019455288,0.0496885,0.011138155,0.004277057,0.004998565,0.000029594225,0.0035931193,0.12773101],"study_design_scores_gemma":[0.072724804,0.039516207,0.7913717,0.0012864199,0.002163977,0.011779422,0.010243912,0.007771402,0.0020472608,0.00023732056,0.059810672,0.0010469223],"about_ca_topic_score_codex":0.00012969717,"about_ca_topic_score_gemma":0.0001688699,"teacher_disagreement_score":0.19728644,"about_ca_system_score_codex":0.0021057993,"about_ca_system_score_gemma":0.002959933,"threshold_uncertainty_score":0.98088133},"labels":[],"label_agreement":null},{"id":"W4296771556","doi":"10.1016/j.jtho.2022.07.388","title":"EP02.04-003 A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Retrospective cohort study; Overall survival; Epidermal growth factor receptor; Erlotinib; Cancer","score_opus":0.03243683485617222,"score_gpt":0.4700560418111188,"score_spread":0.4376192069549466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296771556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066526,0.0002518105,0.00003312954,0.004768166,0.0009773661,0.00038330886,0.00011354988,0.000008476844,0.0027989529],"genre_scores_gemma":[0.9982223,0.000009605178,0.0006826958,0.0006088562,0.000052580428,0.000021920898,0.00003519502,0.000019829436,0.0003470525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997601,0.00054088136,0.00089788873,0.00017468345,0.00056272023,0.00022283953],"domain_scores_gemma":[0.9980336,0.0004522483,0.0009921367,0.00016475045,0.00024286294,0.00011444516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069838366,0.00015804377,0.0011200426,0.00044192644,0.00008982367,0.0000056090907,0.0001342736,0.00006215421,0.00034412896],"category_scores_gemma":[0.00045263788,0.000120787285,0.00021868196,0.00038105703,0.00006796325,0.00007713393,0.00006223447,0.00055245357,0.000004441817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048643006,0.0073580346,0.9444988,0.00003582869,0.0009274525,0.00030941278,0.0029120503,0.00053667685,0.00034397998,0.00013810117,0.0034552235,0.034620162],"study_design_scores_gemma":[0.008389846,0.020433081,0.95355064,0.000099788216,0.0010368784,0.000098022625,0.004370186,0.00007345525,0.0011158589,0.00034392916,0.010324374,0.00016395596],"about_ca_topic_score_codex":0.00010346073,"about_ca_topic_score_gemma":0.00007590204,"teacher_disagreement_score":0.03445621,"about_ca_system_score_codex":0.0014240367,"about_ca_system_score_gemma":0.0005196678,"threshold_uncertainty_score":0.49255624},"labels":[],"label_agreement":null},{"id":"W4296773182","doi":"10.1016/j.jtho.2022.07.148","title":"MA12.09 Frequency and Detectability of Uncommon EGFR Mutations in NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer research","score_opus":0.020488858053774588,"score_gpt":0.4347767627322449,"score_spread":0.4142879046784703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296773182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121815,0.001251783,0.00007038065,0.003710606,0.0002485863,0.00017870391,0.000016544749,0.000003771333,0.0033014577],"genre_scores_gemma":[0.99605626,0.000030844916,0.003621295,0.00012503771,0.00004232948,0.000015309697,0.000004537649,0.0000065167023,0.00009786116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901867,0.00018326561,0.00044916428,0.00008524265,0.00016188201,0.000101800186],"domain_scores_gemma":[0.9992145,0.00016806433,0.0003260169,0.000101671925,0.00011789992,0.00007185923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046586295,0.000062237574,0.00033110744,0.00021942011,0.000061343184,0.0000025990219,0.00005804039,0.00004119685,0.00022433263],"category_scores_gemma":[0.00010313599,0.00005147075,0.00006832079,0.00022721614,0.00007125204,0.000065043314,0.00003262492,0.00029290302,6.580442e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019063171,0.0029323075,0.45694518,0.00022915997,0.00045522157,0.0010597516,0.0078277225,0.00045175958,0.014643552,0.00044101212,0.00045403524,0.512654],"study_design_scores_gemma":[0.0067044077,0.014084066,0.9301816,0.00017309401,0.0017036144,0.0047344407,0.011278723,0.00018657753,0.0029493987,0.015278518,0.012504678,0.00022083469],"about_ca_topic_score_codex":0.00013016231,"about_ca_topic_score_gemma":0.00016675149,"teacher_disagreement_score":0.5124332,"about_ca_system_score_codex":0.0006440592,"about_ca_system_score_gemma":0.00062791613,"threshold_uncertainty_score":0.2456285},"labels":[],"label_agreement":null},{"id":"W4296773600","doi":"10.1016/j.jtho.2022.07.753","title":"EP08.02-071 Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Medicine; Cohort; Oncology; Mutant; Radiation therapy; Internal medicine; Outcome (game theory); Epidermal growth factor receptor; Cancer; Gene; Erlotinib; Genetics","score_opus":0.035874043687401165,"score_gpt":0.4584005283914657,"score_spread":0.42252648470406456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296773600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766289,0.0008748054,0.000006909895,0.016742488,0.00045870437,0.0005667455,0.000059071677,0.0000050827866,0.004657279],"genre_scores_gemma":[0.9967762,0.00026239298,0.00041790135,0.0018592749,0.000084683394,0.000050170675,0.00003291745,0.000018117056,0.00049829006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978925,0.0004539029,0.0009498722,0.00014836795,0.00029265642,0.00026269618],"domain_scores_gemma":[0.9987044,0.0002596306,0.0005825682,0.00015985515,0.00010569037,0.0001878725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014267575,0.00012575058,0.00069524086,0.0012221384,0.00006305006,0.0000058229566,0.00012431885,0.00005735866,0.000537684],"category_scores_gemma":[0.00014941896,0.00010424482,0.00014038048,0.0007040609,0.000043679993,0.00009520808,0.00001966454,0.00041564734,0.0000020418477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016567166,0.0008651489,0.8394574,0.000026342643,0.00048165652,0.0014616007,0.0019588089,0.000649097,0.0010519786,0.0002617853,0.001623981,0.15050548],"study_design_scores_gemma":[0.0046897186,0.003409622,0.91465104,0.00006600426,0.00045174873,0.0005398348,0.0010423481,0.00009250653,0.0008623019,0.00033136422,0.07372528,0.00013821921],"about_ca_topic_score_codex":0.048040893,"about_ca_topic_score_gemma":0.10841448,"teacher_disagreement_score":0.15036726,"about_ca_system_score_codex":0.0026092748,"about_ca_system_score_gemma":0.0022680208,"threshold_uncertainty_score":0.95829827},"labels":[],"label_agreement":null},{"id":"W4296782686","doi":"10.1158/1055-9965.epi-22-0630","title":"Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers","year":2022,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Fondation Institut Universitaire de Cardiologie et de Pneumologie de Québec","keywords":"Oncology; Whole genome sequencing; Medicine; Internal medicine; Genome; Biology; Genetics; Computational biology; Gene","score_opus":0.04423567181439057,"score_gpt":0.3808961579138593,"score_spread":0.3366604860994687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296782686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97393876,0.012577094,0.00075479207,0.009645703,0.000555725,0.0012758343,0.00050423853,0.000057395322,0.0006904764],"genre_scores_gemma":[0.9926682,0.000091429596,0.0012492215,0.0009604336,0.00008110664,0.00085389864,0.0022195536,0.000027427048,0.0018487216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772614,0.0006236528,0.000697344,0.00042962728,0.00018679284,0.0003364336],"domain_scores_gemma":[0.9989243,0.00027637623,0.0003937708,0.00021922,0.0000896303,0.000096703516],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010637102,0.00016343762,0.00046451797,0.00026466785,0.00013451195,0.0000023581722,0.00010830822,0.00007512423,0.00092556316],"category_scores_gemma":[0.00022786157,0.00016250317,0.000161389,0.00046212276,0.00014361396,0.00012974923,0.00006162967,0.00022543539,0.0000050730646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005012818,0.0007909528,0.6054827,0.0006054839,0.0056905653,0.0002616202,0.0036088405,0.017849829,0.26077715,0.0013959756,0.0644461,0.03407797],"study_design_scores_gemma":[0.015737163,0.0018353992,0.90202993,0.0006944857,0.0014428144,0.00021662023,0.004761065,0.004901807,0.0012883038,0.010184997,0.056130633,0.0007768053],"about_ca_topic_score_codex":0.0028786345,"about_ca_topic_score_gemma":0.00012320095,"teacher_disagreement_score":0.29654723,"about_ca_system_score_codex":0.002181212,"about_ca_system_score_gemma":0.0008680527,"threshold_uncertainty_score":0.9999877},"labels":[],"label_agreement":null},{"id":"W4297178813","doi":"10.1016/j.cllc.2022.09.007","title":"Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Takeda (Canada); University Health Network","funders":"Takeda Canada; Swiss Cancer Research Foundation","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Crizotinib; Cancer","score_opus":0.03495241721016053,"score_gpt":0.40106089194501493,"score_spread":0.3661084747348544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297178813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854905,0.004063973,0.000006920794,0.0017997605,0.00096577394,0.0028253738,0.0008062192,0.00007792331,0.003963583],"genre_scores_gemma":[0.978321,0.0032379306,0.00041854347,0.0018418732,0.00015700464,0.0022231955,0.00029487116,0.00008423496,0.013421302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713534,0.00020902428,0.00083403004,0.0007574323,0.00045184052,0.0006123357],"domain_scores_gemma":[0.9984398,0.00029185612,0.0003269709,0.00045329967,0.00010814361,0.00037991893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003055302,0.00038656336,0.0011047,0.00017003379,0.0003160735,0.000023857849,0.00011395546,0.00007005214,0.00055241067],"category_scores_gemma":[0.000020755224,0.0002931014,0.00015245024,0.0003623497,0.00012917584,0.000100478515,0.00008871484,0.0004137071,9.793897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096340966,0.00074669666,0.98412067,0.00022067287,0.0005745097,0.000025867079,0.0016849384,0.00033916588,0.0000030622289,0.000030872077,0.0012456372,0.010044497],"study_design_scores_gemma":[0.020512199,0.0023793143,0.967801,0.00031136037,0.00065934676,9.0179407e-7,0.00095890684,0.0005422315,0.000013901642,0.000008964021,0.0064604706,0.00035143798],"about_ca_topic_score_codex":0.027750859,"about_ca_topic_score_gemma":0.034669165,"teacher_disagreement_score":0.019548789,"about_ca_system_score_codex":0.0064714057,"about_ca_system_score_gemma":0.0034023481,"threshold_uncertainty_score":0.99995214},"labels":[],"label_agreement":null},{"id":"W4298002020","doi":"10.3389/fcvm.2022.934214","title":"Overdrive pacing in the acute management of osimertinib-induced ventricular arrhythmias: A case report and literature review","year":2022,"lang":"en","type":"article","venue":"Frontiers in Cardiovascular Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Department of Science and Technology of Jilin Province; National Natural Science Foundation of China","keywords":"Medicine; QT interval; Osimertinib; Cardiology; Prolongation; Electrocardiography; Internal medicine; Anesthesia","score_opus":0.009628510220962654,"score_gpt":0.28698776743206844,"score_spread":0.27735925721110577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298002020","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08662311,0.9052237,0.00075347,0.002997386,0.0009259258,0.0022956834,0.000018746528,0.000015975302,0.0011459538],"genre_scores_gemma":[0.9586135,0.036783736,0.0019818833,0.0012260905,0.00017786212,0.0007959477,0.00021772312,0.000033569588,0.00016968638],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980559,0.00023595132,0.0004729339,0.0003580865,0.00067521527,0.00020195477],"domain_scores_gemma":[0.99904615,0.000029271887,0.0001251643,0.0006873033,0.00005195666,0.000060167633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014284514,0.00016888783,0.00079122145,0.00023260243,0.00008559611,0.000004624154,0.00007623018,0.00003745266,0.000013614619],"category_scores_gemma":[0.000059454454,0.00011159668,0.00027006245,0.0010529212,0.00005178961,0.000048054473,0.00006798663,0.0003233209,1.5072703e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056145716,0.000088463166,0.0044025537,0.0016627673,0.0041593197,0.96104217,0.0034202863,0.00006305848,0.00000642161,0.000030556537,0.006149137,0.018919155],"study_design_scores_gemma":[0.015650686,0.0009193132,0.0140623525,0.019174166,0.020527178,0.8293695,0.026737517,0.0001941689,0.00006484028,0.00017337594,0.07268423,0.000442683],"about_ca_topic_score_codex":0.000102113256,"about_ca_topic_score_gemma":0.0000018167332,"teacher_disagreement_score":0.8719904,"about_ca_system_score_codex":0.00022612416,"about_ca_system_score_gemma":0.00004765684,"threshold_uncertainty_score":0.45507807},"labels":[],"label_agreement":null},{"id":"W4298002983","doi":"10.3390/diagnostics12102360","title":"Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC","year":2022,"lang":"en","type":"article","venue":"Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"T790M; Medicine; Liquid biopsy; Epidermal growth factor receptor; Internal medicine; Lung cancer; Oncology; Biopsy; Pathology; Cancer; Cancer research; Gefitinib","score_opus":0.011675722041390163,"score_gpt":0.2929891324161918,"score_spread":0.2813134103748016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298002983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980871,0.00062570535,0.00023564542,0.000043090102,0.00008626285,0.00046790123,0.00028873913,0.000025191366,0.00014033928],"genre_scores_gemma":[0.99772954,0.000117640084,0.0014467032,0.00010184219,0.000008448938,0.00010111228,0.00045799246,0.000018046767,0.000018679628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989058,0.00007359771,0.0003662592,0.00021937139,0.00023500956,0.00019996897],"domain_scores_gemma":[0.99891686,0.00055918354,0.00018592204,0.00015596455,0.000086263775,0.00009580707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015716298,0.00011524884,0.0003111447,0.0009848588,0.00007802473,0.000010339511,0.000035734374,0.000027777312,0.00008054507],"category_scores_gemma":[0.0005059935,0.00011867185,0.00007226959,0.0021422326,0.000046311674,0.00004692681,0.00004542582,0.0001294986,0.0000014527935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025929316,0.0006931342,0.9588197,0.00012372869,0.0015510054,0.0008404694,0.0036088175,0.028448634,0.002861366,0.000061090905,0.00006048734,0.0026723053],"study_design_scores_gemma":[0.0027139836,0.0003391785,0.95093834,0.00005168964,0.00255252,0.000015043723,0.0025105604,0.039992277,0.00065745326,0.00000769721,0.00008205119,0.0001391801],"about_ca_topic_score_codex":0.0006300068,"about_ca_topic_score_gemma":0.000061030336,"teacher_disagreement_score":0.011543642,"about_ca_system_score_codex":0.0003070751,"about_ca_system_score_gemma":0.00018531963,"threshold_uncertainty_score":0.48392975},"labels":[],"label_agreement":null},{"id":"W4298400492","doi":"","title":"A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy","year":2017,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pulmonary disease; Disease; Retrospective cohort study; Physical therapy; Internal medicine; Intensive care medicine","score_opus":0.19175766769398295,"score_gpt":0.5460379996007253,"score_spread":0.35428033190674235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298400492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935342,0.00018475227,0.00008865499,0.00014568132,0.00025492487,0.0046721823,0.00013922845,0.000014616762,0.0009657672],"genre_scores_gemma":[0.9984527,0.0005733682,0.00011982074,0.0001494588,0.0001085719,0.00019706023,0.00007999245,0.000052455554,0.00026656612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976782,0.00024089545,0.0007215178,0.00052864506,0.0006097448,0.00022097581],"domain_scores_gemma":[0.9964612,0.00019804783,0.0014111217,0.0006111821,0.0009559672,0.00036249787],"candidate_categories":["scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.0006416818,0.00028161507,0.00086353684,0.0003611493,0.0004549598,0.0012065816,0.0008734045,0.000056818793,0.00074962806],"category_scores_gemma":[0.00065982726,0.00020059943,0.00006919668,0.0003824917,0.00010409399,0.002526985,0.00038443753,0.00024777048,0.0000030519568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008081112,0.0035953254,0.9422206,0.000023637876,0.0005595063,0.000042589672,0.00048653042,0.000010238188,0.00030381698,0.000006594999,0.00021850785,0.04445152],"study_design_scores_gemma":[0.0062580304,0.0011590213,0.990971,0.00054348167,0.00020373058,0.0000011039468,0.0000954877,0.000051013183,0.00029844418,0.00012413223,0.000068212335,0.00022633717],"about_ca_topic_score_codex":0.0007331002,"about_ca_topic_score_gemma":0.00007429484,"teacher_disagreement_score":0.048750386,"about_ca_system_score_codex":0.00037173837,"about_ca_system_score_gemma":0.0004034102,"threshold_uncertainty_score":0.99983025},"labels":[],"label_agreement":null},{"id":"W4299466851","doi":"10.17615/n3xz-w331","title":"Predicting Future Clinical Changes of MCI Patients Using Longitudinal and Multimodal Biomarkers","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Aging; National Key Research and Development Program of China; University of California, San Diego; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; University of California, Los Angeles; National Institutes of Health; Servier; National Natural Science Foundation of China; Eisai; Genentech; Northern California Institute for Research and Education; Pfizer; Biogen; BioClinica; Alzheimer's Association; Amorfix Life Sciences; Synarc; F. Hoffmann-La Roche; Medpace; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Novartis Pharmaceuticals Corporation; Foundation for the National Institutes of Health; Bayer HealthCare; Alzheimer's Disease Neuroimaging Initiative; Meso Scale Diagnostics; National Science Foundation","keywords":"Longitudinal data; Psychology; Computer science; Environmental science; Data mining","score_opus":0.048544506226151876,"score_gpt":0.3371740861302615,"score_spread":0.28862957990410965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299466851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548805,0.00074857584,0.00008293972,0.0027863465,0.00021717297,0.00022858108,0.00006148049,0.000040503073,0.00034635267],"genre_scores_gemma":[0.9853912,0.000021302656,0.013576259,0.0004337202,0.00047013455,0.0000035045082,0.00006960878,0.000013028533,0.000021251644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994159,0.000019697682,0.00018031416,0.00016996256,0.0001144396,0.000099718876],"domain_scores_gemma":[0.9996167,0.00005616182,0.00008514768,0.00007275285,0.000047439826,0.00012181409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028883382,0.00008536084,0.00019940874,0.000030502597,0.00006421812,0.0000180699,0.000027767746,0.000059351936,0.000036050038],"category_scores_gemma":[0.00007881054,0.00006457887,0.00003565379,0.00009995985,0.00011903074,0.00015386865,0.00004659585,0.00006729709,8.4039465e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002163038,0.000082714745,0.9904185,0.000102971855,0.00027065404,0.00000670977,0.0014232881,0.0000012364279,0.000057141817,0.0004459903,0.00040329652,0.006571193],"study_design_scores_gemma":[0.0037393854,0.0008938219,0.9887062,0.00011345028,0.0005162017,0.0000039722113,0.0013522499,0.0018913563,0.00068637077,0.00014649605,0.0018437752,0.00010675511],"about_ca_topic_score_codex":0.000044297274,"about_ca_topic_score_gemma":0.000005907262,"teacher_disagreement_score":0.013493319,"about_ca_system_score_codex":0.000009886589,"about_ca_system_score_gemma":0.000086873915,"threshold_uncertainty_score":0.26334497},"labels":[],"label_agreement":null},{"id":"W4299962243","doi":"","title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study","year":2017,"lang":"en","type":"preprint","venue":"Research Portal (Queen's University Belfast)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; European Commission","keywords":"Population; Medicine; Geography; Demography; Environmental health; Sociology","score_opus":0.03897309583147175,"score_gpt":0.35700798348860946,"score_spread":0.3180348876571377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299962243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899659,0.00007769748,0.0000022299569,0.0015270201,0.00006248599,0.0026016638,0.0012588761,0.000023593368,0.004480533],"genre_scores_gemma":[0.9937401,0.00026165842,0.00013903975,0.0000021986002,0.000059655307,0.000009421507,0.0015126505,0.000025906415,0.0042494154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974091,0.00038031803,0.00041725766,0.00064817484,0.0007704507,0.00037469016],"domain_scores_gemma":[0.9973991,0.00017336755,0.00038177692,0.00090577075,0.0008823175,0.00025769917],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003843391,0.00026914696,0.00072898716,0.00081119506,0.00017823189,0.00002854532,0.00027325904,0.00017094491,0.00005212974],"category_scores_gemma":[0.00025812275,0.0002502697,0.0001274444,0.00035292722,0.0001737951,0.00009638199,0.00033113992,0.00041822722,0.0000015696236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026893576,0.001954717,0.98335767,0.0005517752,0.0007589138,0.002939983,0.003780099,0.0010682915,0.0000384791,0.00011652668,0.0003928919,0.0023512684],"study_design_scores_gemma":[0.012479522,0.0018577588,0.97863454,0.0010286272,0.00050100154,0.0000018590223,0.003921627,0.00008902884,0.00025475788,0.000025483858,0.0010032806,0.00020249024],"about_ca_topic_score_codex":0.08187687,"about_ca_topic_score_gemma":0.0013440661,"teacher_disagreement_score":0.0805328,"about_ca_system_score_codex":0.00057636865,"about_ca_system_score_gemma":0.001894105,"threshold_uncertainty_score":0.99999493},"labels":[],"label_agreement":null},{"id":"W4299964292","doi":"","title":"Abstracts of the 10th World Conference on Lung Cancer. 10-14 August 2003, Vancouver, Canada.","year":2003,"lang":"en","type":"other","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Gerontology; General surgery; Oncology","score_opus":0.0213820476881532,"score_gpt":0.26900668434064245,"score_spread":0.24762463665248927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299964292","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005088387,0.0019685,0.0000012390356,0.00068077404,0.003658913,0.0018305953,0.0005012063,0.000032793258,0.9912751],"genre_scores_gemma":[0.014390519,0.00022481279,0.000023087343,0.0008319976,0.00020540289,0.0011561047,0.000037395017,0.00015036031,0.9829803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987385,0.000024868737,0.00022992185,0.00026729942,0.00040055142,0.00033883646],"domain_scores_gemma":[0.9989248,0.000020723626,0.0003149755,0.00043738852,0.00013530809,0.00016684175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004971902,0.00024040391,0.00037135193,0.000103362356,0.000042618252,0.000008701428,0.00013533828,0.00010517161,0.0048936564],"category_scores_gemma":[0.00006529187,0.00015722984,0.000058155205,0.000341429,0.000057446465,0.000014163851,0.000015199924,0.00019164478,0.0000036421732],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022174127,0.00007625879,0.0008195419,0.0001515448,0.0004063679,0.000013449191,0.0000149803545,0.00001072986,3.497299e-7,0.00011679267,0.99290025,0.005467564],"study_design_scores_gemma":[0.0010134828,0.000007909042,0.02554786,0.00036865537,0.00055625493,0.0000012623975,0.000015530777,0.0000018860317,0.00009586676,0.00000551486,0.9722398,0.00014597972],"about_ca_topic_score_codex":0.3612392,"about_ca_topic_score_gemma":0.96557343,"teacher_disagreement_score":0.60433424,"about_ca_system_score_codex":0.0007560419,"about_ca_system_score_gemma":0.0026098937,"threshold_uncertainty_score":0.996016},"labels":[],"label_agreement":null},{"id":"W4300007774","doi":"","title":"Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel","year":2013,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dasatinib; Docetaxel; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Tyrosine kinase; Receptor","score_opus":0.12923093846681985,"score_gpt":0.5050118134105867,"score_spread":0.3757808749437668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300007774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530965,0.0022887615,0.00002134522,0.00020781808,0.00007186776,0.0018634788,0.000110899826,0.000004942912,0.00012121633],"genre_scores_gemma":[0.99793327,0.001120402,0.0003843802,0.00008524899,0.000010927376,0.00026795716,0.000039979746,0.000026354865,0.00013146277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982001,0.00014130856,0.00074592105,0.00022885318,0.0005021265,0.00018166986],"domain_scores_gemma":[0.9978508,0.00024700604,0.00088877935,0.00027366861,0.00064067775,0.0000990636],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002917208,0.00019263968,0.0005303335,0.00032105972,0.000077875455,0.000245047,0.0002310807,0.0000327624,0.0012547453],"category_scores_gemma":[0.00012523055,0.00011937538,0.000051884017,0.00047861168,0.00015888666,0.0015851383,0.00009963135,0.00015274774,6.598941e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061822194,0.00054483983,0.983917,0.00027798474,0.0003779638,0.0000069805965,0.0012726482,0.00006307164,0.0040121353,0.000012030408,0.00023226858,0.008664829],"study_design_scores_gemma":[0.0030908498,0.00008700005,0.9924511,0.0013056016,0.00037036382,0.0000020772923,0.000105047926,0.00003226626,0.002255094,0.00016252737,0.000017328844,0.000120768906],"about_ca_topic_score_codex":0.00390642,"about_ca_topic_score_gemma":0.0007660967,"teacher_disagreement_score":0.0085440595,"about_ca_system_score_codex":0.000099529214,"about_ca_system_score_gemma":0.0002090789,"threshold_uncertainty_score":0.9996582},"labels":[],"label_agreement":null},{"id":"W4300338806","doi":"","title":"New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib","year":2017,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Afatinib; Focus (optics); Squamous cell cancer; Lung cancer; Medicine; Basal cell; Oncology; Internal medicine; Cancer; Gefitinib; Optics","score_opus":0.15783680967713204,"score_gpt":0.5705374081313067,"score_spread":0.41270059845417467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300338806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9468761,0.020346671,0.000033081906,0.0008337587,0.00048267853,0.0015872953,0.000055149223,0.000011677537,0.029773593],"genre_scores_gemma":[0.98367566,0.013774402,0.00054380845,0.00015328889,0.000118580596,0.00018837524,0.000012710645,0.00003302189,0.001500167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818575,0.00007926323,0.0005968452,0.00031775434,0.0005306866,0.0002897247],"domain_scores_gemma":[0.99792606,0.00019639591,0.00087291,0.0006810104,0.00014403179,0.00017961419],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022754724,0.00027283616,0.00066970364,0.0003179273,0.0002998459,0.0002972747,0.0011047361,0.00006566466,0.0013818936],"category_scores_gemma":[0.00007608126,0.00017496094,0.00015032996,0.0002552549,0.0000603473,0.0006144566,0.00010732263,0.00014767874,0.0000049858245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006745823,0.0014487386,0.7872791,0.00008988323,0.00030935174,0.00010390824,0.0024580488,0.00016664901,0.0058747157,0.00004466884,0.00743894,0.19411138],"study_design_scores_gemma":[0.0058050924,0.00013606023,0.9379273,0.00056693924,0.00037310598,0.0000054936613,0.00017539864,0.0000115116945,0.046484634,0.0003996876,0.007925375,0.00018941033],"about_ca_topic_score_codex":0.007032519,"about_ca_topic_score_gemma":0.00068927516,"teacher_disagreement_score":0.19392197,"about_ca_system_score_codex":0.0004512554,"about_ca_system_score_gemma":0.0006643594,"threshold_uncertainty_score":0.9995797},"labels":[],"label_agreement":null},{"id":"W4300664057","doi":"","title":"Antidepressant medication use and nasopharyngeal cancer risk: a nationwide population-based study","year":2018,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nasopharyngeal cancer; Antidepressant; Antidepressant medication; Cancer; Medicine; Psychiatry; Population; Oncology; Environmental health; Internal medicine; Nasopharyngeal carcinoma; Radiation therapy","score_opus":0.17490166699102636,"score_gpt":0.5685148660851816,"score_spread":0.39361319909415526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300664057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309534,0.0041795177,0.00024461016,0.00037402872,0.00040166618,0.0012167752,0.00010624145,0.00003701802,0.0003448003],"genre_scores_gemma":[0.9963433,0.0022303793,0.0003629642,0.00037943537,0.00028128613,0.00015142951,0.00006385974,0.000036329064,0.00015097768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797434,0.00017998747,0.00059261057,0.0003944001,0.00065033376,0.0002083225],"domain_scores_gemma":[0.9978075,0.00029338917,0.00068199274,0.00036272022,0.00060648617,0.00024789703],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005355539,0.00021284082,0.0004912225,0.00054313854,0.0003847107,0.00047440216,0.00037226378,0.00006491083,0.0030170153],"category_scores_gemma":[0.0004589035,0.00017059928,0.00007399915,0.0005526219,0.000092552546,0.0014512226,0.00014138997,0.00019193151,0.0000048197803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022912862,0.0005712547,0.9863224,0.00003746813,0.00049065566,0.000013642861,0.00036181527,0.000050779265,0.0017016779,0.000011204267,0.0036686389,0.0065413336],"study_design_scores_gemma":[0.002372807,0.000053686155,0.99346834,0.00029507783,0.0008002211,0.000003866292,0.00007459668,0.00036134268,0.0013533698,0.00026672802,0.0007839984,0.00016596755],"about_ca_topic_score_codex":0.016150974,"about_ca_topic_score_gemma":0.001628388,"teacher_disagreement_score":0.014522586,"about_ca_system_score_codex":0.00016373704,"about_ca_system_score_gemma":0.00031866314,"threshold_uncertainty_score":0.99789435},"labels":[],"label_agreement":null},{"id":"W4300981453","doi":"10.1007/s40291-022-00617-y","title":"Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Molecular Diagnosis & Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; Bayer (Canada)","funders":"Bayer Canada","keywords":"Human genetics; Molecular medicine; Medicine; Internal medicine; Oncology; Cancer; Cancer research; Biology; Genetics; Gene; Cell cycle","score_opus":0.009977446999398704,"score_gpt":0.31213043302820864,"score_spread":0.3021529860288099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300981453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188673,0.004506258,0.0000021670007,0.002048053,0.00013740973,0.00073795783,0.00025119973,0.000010888795,0.00041934015],"genre_scores_gemma":[0.9941303,0.0022471175,0.000044218217,0.0020053415,0.000013354151,0.0013509324,0.000052740124,0.00002301299,0.00013297886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903935,0.00006137132,0.00018427189,0.00020379861,0.00025013482,0.00026105336],"domain_scores_gemma":[0.9994985,0.00002355388,0.00006101291,0.00019004625,0.00006896204,0.00015793148],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006422088,0.00010547726,0.0001714023,0.00018915643,0.000107430555,0.0000051689003,0.00010179419,0.00002490835,0.0014880853],"category_scores_gemma":[0.000017966979,0.00009932478,0.00007704772,0.00030719896,0.000024252928,0.000027045928,0.000025199943,0.0001065682,0.0000031362192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040438408,0.00085379725,0.9848345,0.00002962,0.000119652286,0.00006873211,0.0013729942,0.000418623,0.0028137413,0.000072675204,0.0011341657,0.008241062],"study_design_scores_gemma":[0.0025798744,0.00051301654,0.9742186,0.00008319301,0.00009746925,0.000001920461,0.00009780378,0.000032646356,0.010839544,0.000063609274,0.011348719,0.00012358688],"about_ca_topic_score_codex":0.1641918,"about_ca_topic_score_gemma":0.026381316,"teacher_disagreement_score":0.13781048,"about_ca_system_score_codex":0.00051448226,"about_ca_system_score_gemma":0.0005880258,"threshold_uncertainty_score":0.9994247},"labels":[],"label_agreement":null},{"id":"W4301031710","doi":"10.17615/mp4q-6004","title":"ETV6-NTRK3 Fusion Oncogene Initiates Breast Cancer from Committed Mammary Progenitors via Activation of AP1 Complex","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; U.S. Department of Defense","keywords":"AP-1 transcription factor; Oncogene; Oncogene Proteins; Breast cancer; Cancer research; Progenitor cell; ETV6; Progenitor; Cancer; Biology; Medicine; Internal medicine; Cell biology; Genetics; Gene; Stem cell; Transcription factor; Regulation of gene expression; Chromosomal translocation","score_opus":0.034670743893022556,"score_gpt":0.2911552585540214,"score_spread":0.25648451466099886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301031710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9425928,0.0013069564,0.004112737,0.04535008,0.00031482414,0.0012017841,0.0013483693,0.00037470492,0.0033977546],"genre_scores_gemma":[0.98933107,0.00002719844,0.0062888516,0.0023267805,0.0003691633,0.000050575694,0.0014978946,0.000026820186,0.00008167268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991794,0.000033827895,0.00024149512,0.00020566482,0.00020479207,0.0001348133],"domain_scores_gemma":[0.99939394,0.00007706377,0.00012617672,0.00016478373,0.00010636687,0.00013169083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00001400013,0.0001486934,0.00027564584,0.00005266565,0.000093926225,0.000033586814,0.000085754116,0.000073118914,0.00075861113],"category_scores_gemma":[0.000017269425,0.00011944897,0.000059991104,0.00025905774,0.00008476431,0.0004135789,0.00006640984,0.000090600115,0.000011642649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028870017,0.0013176127,0.5190739,0.0006907398,0.0031240743,0.00008670304,0.016675558,0.00008389636,0.30448973,0.015097009,0.035840046,0.10063374],"study_design_scores_gemma":[0.0067501194,0.0005891054,0.62661624,0.00041239944,0.0010077883,0.000017373692,0.001271708,0.0023162253,0.33310255,0.009323284,0.018107599,0.0004855908],"about_ca_topic_score_codex":0.0009366057,"about_ca_topic_score_gemma":0.000017867755,"teacher_disagreement_score":0.107542366,"about_ca_system_score_codex":0.00005163069,"about_ca_system_score_gemma":0.00030369917,"threshold_uncertainty_score":0.830626},"labels":[],"label_agreement":null},{"id":"W4302233123","doi":"","title":"Extended abstracts of the 10th World Conference on Lung Cancer. 10-14 August 2003, Vancouver, Canada.","year":2003,"lang":"en","type":"other","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Library science; Family medicine; Demography; Oncology; Sociology","score_opus":0.021283499958690295,"score_gpt":0.2729955225722754,"score_spread":0.2517120226135851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302233123","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050496972,0.0021855433,0.0000017329975,0.00063099386,0.0037390967,0.0020916676,0.0005123634,0.00004018518,0.9907479],"genre_scores_gemma":[0.018514626,0.00024971817,0.000031533513,0.00078438956,0.0002024282,0.0013536809,0.00004177378,0.00016509565,0.97865677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985683,0.000030672007,0.00026153767,0.0003097843,0.0004492718,0.00038041707],"domain_scores_gemma":[0.99877965,0.000022635068,0.00035672498,0.00049799465,0.00015540641,0.00018759647],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000057318277,0.00027244297,0.000416869,0.000117998,0.00004827351,0.0000099284225,0.00015160492,0.00011646984,0.0050734207],"category_scores_gemma":[0.00007586868,0.00017959815,0.00006726421,0.00036923474,0.00006625459,0.000016576718,0.000017297432,0.00021212063,0.0000034878055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003193161,0.00010722909,0.00036367227,0.00015754736,0.00046735935,0.000018194363,0.00001622144,0.0000074784057,5.410771e-7,0.00015509884,0.9893312,0.009343512],"study_design_scores_gemma":[0.0012668822,0.000010340158,0.045002952,0.0003943987,0.00064850104,0.0000018018216,0.000020206113,0.0000025532624,0.00014134981,0.000010368238,0.9523275,0.0001731438],"about_ca_topic_score_codex":0.28582078,"about_ca_topic_score_gemma":0.9466048,"teacher_disagreement_score":0.660784,"about_ca_system_score_codex":0.0008076188,"about_ca_system_score_gemma":0.0027797346,"threshold_uncertainty_score":0.9958361},"labels":[],"label_agreement":null},{"id":"W4303628450","doi":"10.3390/curroncol29100582","title":"TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lung cancer; Medicine; Retrospective cohort study; Oncology; Adenocarcinoma; Exon; Targeted therapy; Internal medicine; Mutation; Cancer research; Gene; Cancer; Biology; Genetics","score_opus":0.03520972421015266,"score_gpt":0.41783411754914324,"score_spread":0.38262439333899056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303628450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97909856,0.001042895,0.000071262475,0.0003573868,0.0016660006,0.0032863491,0.000040628907,0.000053069958,0.014383857],"genre_scores_gemma":[0.9940903,0.00024899104,0.00017585514,0.00008121018,0.00012861167,0.0039902115,0.000118961565,0.00002412616,0.0011416922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855393,0.00012740423,0.00034190356,0.00045519494,0.00023518683,0.00028640602],"domain_scores_gemma":[0.9993623,0.000056902576,0.0001871849,0.0002108474,0.000099080025,0.00008367425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024016136,0.00015750776,0.00044288003,0.00033318505,0.0001833987,0.000006974452,0.00008308104,0.0000290193,0.0003196741],"category_scores_gemma":[0.000017307697,0.00015802874,0.00006153256,0.00066832674,0.000025175945,0.000046040288,0.00008843314,0.0004028297,0.000005426102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010420651,0.0022461887,0.976404,0.00006300902,0.00012035913,0.00015800851,0.008068239,0.00050839916,0.000114520786,0.00003779372,0.00062250544,0.011552738],"study_design_scores_gemma":[0.0063471803,0.0009701738,0.9743812,0.00004795684,0.000399779,0.000008422537,0.0050169043,0.0011006993,0.000022457754,0.000035615656,0.011529796,0.00013980061],"about_ca_topic_score_codex":0.0013952984,"about_ca_topic_score_gemma":0.0027168333,"teacher_disagreement_score":0.014991791,"about_ca_system_score_codex":0.005658964,"about_ca_system_score_gemma":0.00073165185,"threshold_uncertainty_score":0.99815816},"labels":[],"label_agreement":null},{"id":"W4303629062","doi":"10.3390/curroncol29100567","title":"Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; University of Calgary","funders":"","keywords":"Gefitinib; Medicine; Afatinib; Exon; Internal medicine; Oncology; Lung cancer; Targeted therapy; Mutation; T790M; Epidermal growth factor receptor; Cancer; Genetics; Gene; Biology","score_opus":0.03293858574738803,"score_gpt":0.3983722999513731,"score_spread":0.36543371420398507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303629062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939425,0.002530145,0.000040817413,0.0007800825,0.000131895,0.0015144368,0.0008631645,0.000007472317,0.00018945945],"genre_scores_gemma":[0.9979469,0.0005777388,0.00025649648,0.00005730638,0.000011595253,0.00063583266,0.00040649518,0.000014708095,0.000092904214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873364,0.00017280466,0.00039997703,0.00028616594,0.00017039335,0.000237036],"domain_scores_gemma":[0.9991505,0.00012166442,0.00033532493,0.00011030379,0.00009577101,0.00018644062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015938147,0.00017130084,0.000504322,0.000449078,0.00010680973,0.0000061228375,0.000038533584,0.00003317172,0.000044474025],"category_scores_gemma":[0.000012295037,0.00014208423,0.000034778855,0.00024476615,0.00007025593,0.000054995984,0.000024293124,0.00012747545,1.2406402e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001380118,0.0005774502,0.9690271,0.0005317093,0.00026626608,0.000022932372,0.017186541,0.00041219912,0.000063584856,0.000018480843,0.000080338075,0.01167538],"study_design_scores_gemma":[0.0054814094,0.0020834196,0.98369706,0.00022164287,0.0014771691,0.000014053173,0.0044514653,0.0013210052,0.00039133042,0.000009177377,0.00072946167,0.00012283544],"about_ca_topic_score_codex":0.18114716,"about_ca_topic_score_gemma":0.41717607,"teacher_disagreement_score":0.23602892,"about_ca_system_score_codex":0.0020332623,"about_ca_system_score_gemma":0.0012902754,"threshold_uncertainty_score":0.82430565},"labels":[],"label_agreement":null},{"id":"W4304789888","doi":"10.54097/hset.v14i.1845","title":"Lung Adenocarcinoma treatment: Traditional therapy and Immunotherapy","year":2022,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Lung cancer; Adenocarcinoma; Medicine; Immunotherapy; Oncology; Radiation therapy; Chemotherapy; Incidence (geometry); Internal medicine; Cancer","score_opus":0.015126094433139678,"score_gpt":0.26038004026302114,"score_spread":0.24525394582988147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304789888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888661,0.006886128,0.000025761692,0.003600916,0.000119166936,0.00019485322,0.000009293146,0.00009138368,0.00020642324],"genre_scores_gemma":[0.9977923,0.0010271583,0.0008531727,0.000036191992,0.00001852149,0.00015372153,0.0000042026904,0.000007527933,0.00010719245],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99940383,0.0000036919782,0.00008577348,0.00022585863,0.00011380429,0.00016702106],"domain_scores_gemma":[0.9997933,0.000019132369,0.00001568573,0.00011980938,0.000013440134,0.00003862479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006356758,0.00008470763,0.00012060904,0.0005339227,0.00021290257,0.000012584938,0.00005833043,0.000027937249,0.000019844545],"category_scores_gemma":[0.0000045693237,0.00006581485,0.000011414767,0.00063535053,0.00017552692,0.000060505758,0.000021931786,0.00008126926,0.000001006808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015459984,0.0009523212,0.11206554,0.000031825057,0.00024662958,0.0004199402,0.004539457,0.0007477221,0.106937,0.7032696,0.00016571784,0.07046964],"study_design_scores_gemma":[0.01974314,0.0064613214,0.7208015,0.000100038065,0.00011436543,0.0032030016,0.0014158452,0.024097089,0.03168655,0.0046634283,0.18680911,0.00090462924],"about_ca_topic_score_codex":0.00002092829,"about_ca_topic_score_gemma":0.000001045044,"teacher_disagreement_score":0.6986062,"about_ca_system_score_codex":0.00020360165,"about_ca_system_score_gemma":0.00009002525,"threshold_uncertainty_score":0.26838514},"labels":[],"label_agreement":null},{"id":"W4306377538","doi":"10.3390/curroncol29100618","title":"Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Anaplastic lymphoma kinase; Lung cancer; Cancer research; Fusion gene; Medicine; Crizotinib; Targeted therapy; Population; Fusion protein; Tyrosine kinase; Cancer; Oncology; Biology; Internal medicine; Gene; Genetics","score_opus":0.12937717125885242,"score_gpt":0.5041294039134623,"score_spread":0.3747522326546099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306377538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006715841,0.9885741,0.000014973973,0.00007367273,0.0021066556,0.0018551124,0.00020169224,0.000016467486,0.0070901588],"genre_scores_gemma":[0.0000811347,0.99642795,0.00006204194,0.00004607692,0.00017157977,0.0021394284,0.0004575918,0.000039020437,0.00057515275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850386,0.00014491053,0.00056645495,0.0003677807,0.00014815303,0.00026882588],"domain_scores_gemma":[0.998929,0.00023902817,0.00041106052,0.00028522738,0.000049089296,0.000086547196],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009485939,0.00028118945,0.0015533814,0.00028762766,0.000060817016,0.0000029538219,0.00016612008,0.0001550794,0.0015671679],"category_scores_gemma":[0.000013514183,0.00021011858,0.00032691995,0.00041860616,0.000056749257,0.000027920321,0.00009519498,0.00053532014,0.0000073781134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013147256,0.00080477266,0.0008907,0.018285384,0.00017101679,0.000033063832,0.00048064496,0.000003749338,3.6555252e-7,0.000020593316,0.0006208252,0.9786757],"study_design_scores_gemma":[0.0012748166,0.00027571066,0.00009899382,0.0049758945,0.003656242,0.000016054995,0.00015134795,0.00001109359,5.809809e-7,0.0000099975605,0.98937345,0.00015583167],"about_ca_topic_score_codex":0.00006744404,"about_ca_topic_score_gemma":0.00015989179,"teacher_disagreement_score":0.9887526,"about_ca_system_score_codex":0.0012426906,"about_ca_system_score_gemma":0.0024305172,"threshold_uncertainty_score":0.99934554},"labels":[],"label_agreement":null},{"id":"W4306742808","doi":"10.3390/curroncol29100624","title":"Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"AstraZeneca","keywords":"Medicine; Cohort; Concordance; Internal medicine; Oncology; Regimen; Biomarker; Lung cancer; Turnaround time","score_opus":0.10800472953245072,"score_gpt":0.4012493948112746,"score_spread":0.29324466527882387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306742808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872474,0.0017246256,0.0029132122,0.00028682433,0.0016004468,0.0039160256,0.00024480993,0.00008442389,0.0019822079],"genre_scores_gemma":[0.9357684,0.000020353162,0.056173492,0.00096772524,0.0009899916,0.0042677983,0.00042902958,0.00016531302,0.0012178846],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99813336,0.000043114924,0.00044678448,0.00053747336,0.00022116487,0.0006180796],"domain_scores_gemma":[0.9984424,0.000442019,0.0003607907,0.00028694182,0.0003292959,0.0001385154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012250729,0.00031390347,0.0004361219,0.00009176327,0.000861022,0.00003081105,0.00015581855,0.000058623795,0.000110551875],"category_scores_gemma":[0.00013103784,0.00023398359,0.000120379074,0.0003859064,0.00004215708,0.00011356479,0.0002130006,0.00021044604,0.000009793502],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051713723,0.0048790625,0.1229462,0.00053440087,0.0004249926,0.000031594904,0.010364387,0.017043304,0.0742846,0.000006529922,0.00096995424,0.76799786],"study_design_scores_gemma":[0.08342737,0.049405277,0.019079536,0.0018113193,0.012812584,0.00026986387,0.008527186,0.39219034,0.04317898,0.00018698537,0.3857326,0.0033779615],"about_ca_topic_score_codex":0.00036058156,"about_ca_topic_score_gemma":0.00004144099,"teacher_disagreement_score":0.7646199,"about_ca_system_score_codex":0.0047205156,"about_ca_system_score_gemma":0.0009137395,"threshold_uncertainty_score":0.9991002},"labels":[],"label_agreement":null},{"id":"W4306913474","doi":"10.1001/jamaoncol.2022.5068","title":"Methodologic Concerns in Secondary Analysis of KEYNOTE-048","year":2022,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; Neurology; MEDLINE; Psychiatry","score_opus":0.07565656600452525,"score_gpt":0.44372764315129026,"score_spread":0.368071077146765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306913474","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010289067,0.0017597405,0.00017417855,0.85292983,0.0009637071,0.00087214424,0.00090199814,0.000051078645,0.13205823],"genre_scores_gemma":[0.010264204,0.00042246087,0.005146768,0.9595993,0.0013176549,0.0004826892,0.006650987,0.000055111228,0.01606079],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978161,0.00062714814,0.00055363605,0.00045876263,0.0002449497,0.0002994142],"domain_scores_gemma":[0.99785894,0.00115454,0.00040242483,0.00044690576,0.00009024509,0.000046951503],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043114158,0.00021677266,0.0015373244,0.0010855105,0.000038724538,0.000007799812,0.00018112478,0.00083134865,0.009356834],"category_scores_gemma":[0.00020372709,0.00018467581,0.0004278977,0.0010358067,0.00012882175,0.00005973486,0.00010582864,0.0018538124,0.000009049632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003505746,0.0002949044,0.007205834,0.00022879151,0.009273388,0.005055371,0.0014236629,0.000112222966,0.00007757247,0.00016594386,0.9412599,0.03455184],"study_design_scores_gemma":[0.0024048758,0.0012134211,0.020284276,0.000018334362,0.00948042,0.000040339146,0.00026530505,0.000037633272,0.000018307832,0.0001344474,0.9659656,0.00013698303],"about_ca_topic_score_codex":0.0012216993,"about_ca_topic_score_gemma":0.00031768024,"teacher_disagreement_score":0.11599744,"about_ca_system_score_codex":0.0013401996,"about_ca_system_score_gemma":0.0013227087,"threshold_uncertainty_score":0.9915488},"labels":[],"label_agreement":null},{"id":"W4307550453","doi":"10.3390/curroncol29110636","title":"Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institut National d'Excellence en Santé et en Services Sociaux; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Afatinib; Osimertinib; Gefitinib; Medicine; Erlotinib; Lung cancer; Internal medicine; Oncology; Cohort; Cancer; Epidermal growth factor receptor","score_opus":0.055114064638240666,"score_gpt":0.3949324526849589,"score_spread":0.33981838804671827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307550453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98599416,0.0083253905,0.000005726535,0.0015262794,0.0029589694,0.0005785625,0.00049237395,0.000019100818,0.00009942617],"genre_scores_gemma":[0.99620265,0.0018055703,0.000095553805,0.0002208881,0.00012732971,0.00024880678,0.00036903645,0.000020443675,0.00090973603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877185,0.000106345644,0.00031641513,0.0003071018,0.00029156153,0.00020675037],"domain_scores_gemma":[0.9989998,0.00029134797,0.00021250088,0.00019442024,0.0001601449,0.00014182647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049933522,0.00014566726,0.00036740137,0.000082727376,0.00011387851,0.0000068043287,0.0000603228,0.000025625286,0.0003478372],"category_scores_gemma":[0.00008227365,0.0001328144,0.00004206538,0.00018975399,0.00006086109,0.00012369656,0.0001176763,0.00018871717,2.7202015e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003686055,0.0005252717,0.93199754,0.000102805156,0.0001319445,0.000024980194,0.00064465497,0.00019367824,0.00038891175,0.00006274575,0.030876037,0.03468285],"study_design_scores_gemma":[0.0035238825,0.00034220988,0.74712193,0.00028563166,0.00048696977,7.1000596e-7,0.00013235881,0.00020786647,0.0003016115,0.000010858899,0.24742693,0.000159066],"about_ca_topic_score_codex":0.88385975,"about_ca_topic_score_gemma":0.93953055,"teacher_disagreement_score":0.21655089,"about_ca_system_score_codex":0.0028879636,"about_ca_system_score_gemma":0.0020040446,"threshold_uncertainty_score":0.75519246},"labels":[],"label_agreement":null},{"id":"W4307910028","doi":"10.1016/s0959-8049(22)00827-9","title":"BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Exon; Cancer research; Mutant; EGFR inhibitors; Mutation; Lung cancer; Epidermal growth factor receptor; Molecular biology; Gene; Chemistry; Biology; Medicine; Cancer; Genetics; Internal medicine","score_opus":0.00955288568830906,"score_gpt":0.27470809078443814,"score_spread":0.2651552050961291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307910028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94966376,0.020832112,0.00021325247,0.021273108,0.00042942187,0.0005159645,0.00009138055,0.000014114256,0.006966894],"genre_scores_gemma":[0.9964058,0.00064374163,0.00035268476,0.00078722264,0.00025890587,0.000030152683,0.0000085661495,0.000028386581,0.0014845378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893546,0.00015051792,0.0003567003,0.00015870732,0.00023799427,0.00016060467],"domain_scores_gemma":[0.99932337,0.000066145214,0.00025056157,0.00009549622,0.00017082298,0.00009358892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004086385,0.00011735823,0.00018129822,0.00014204749,0.00046133777,0.000035130266,0.00006799458,0.00000980298,0.000058916983],"category_scores_gemma":[0.00006673932,0.00008540368,0.000051394272,0.0003367024,0.00007961179,0.00013075308,0.000051536925,0.00034017256,0.0000012383053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006710211,0.0026968683,0.5751934,0.00069986266,0.0027736023,0.0058254544,0.09699079,0.0119782295,0.03567338,0.0007902634,0.18577173,0.07489621],"study_design_scores_gemma":[0.008687648,0.0008666532,0.7375179,0.00067625724,0.00070265774,0.00027522352,0.003721808,0.00018860509,0.0009295023,0.000099731085,0.24607182,0.0002622022],"about_ca_topic_score_codex":0.000050295075,"about_ca_topic_score_gemma":0.00041413878,"teacher_disagreement_score":0.1623245,"about_ca_system_score_codex":0.00029913292,"about_ca_system_score_gemma":0.0001912621,"threshold_uncertainty_score":0.3548284},"labels":[],"label_agreement":null},{"id":"W4307994288","doi":"10.1007/s00520-022-07401-y","title":"Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review","year":2022,"lang":"en","type":"review","venue":"Supportive Care in Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Montréal","funders":"","keywords":"Medicine; Adverse effect; MEDLINE; Dysgeusia; Nausea; Intensive care medicine; Clinical trial; Internal medicine","score_opus":0.028689750749353326,"score_gpt":0.39269998643506876,"score_spread":0.36401023568571544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307994288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042348815,0.9898279,4.711319e-7,0.00029897012,0.00078814436,0.0067753242,0.0008500866,0.00001730577,0.0010183272],"genre_scores_gemma":[0.0004397862,0.98642653,0.00011268594,0.00018126838,0.000058929785,0.007877967,0.003896847,0.000059508828,0.0009464925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726415,0.00016327418,0.0012407781,0.00065025047,0.00040698887,0.0002745321],"domain_scores_gemma":[0.99873185,0.000035137266,0.00055287784,0.0003571425,0.00020405608,0.000118950185],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017815211,0.00040359478,0.0014934951,0.00041386782,0.00005294336,0.0000014832145,0.000115333314,0.00013404492,0.0025958673],"category_scores_gemma":[0.00005962818,0.00034422276,0.0003413364,0.0015161962,0.000029079383,0.00009246945,0.00009584747,0.00033847408,0.000019230338],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013860334,0.00037668014,0.0008764895,0.13878495,0.0007718405,0.00036874023,0.009754613,0.000036463116,3.145762e-7,0.00002423564,0.0071513555,0.84171575],"study_design_scores_gemma":[0.0013231672,0.00038001966,0.00015022943,0.24753207,0.0013131982,0.000003297158,0.0031299032,6.13374e-7,0.0000041134335,0.0000012672627,0.74591285,0.00024926517],"about_ca_topic_score_codex":0.00043367635,"about_ca_topic_score_gemma":0.0009312024,"teacher_disagreement_score":0.8414665,"about_ca_system_score_codex":0.0048257797,"about_ca_system_score_gemma":0.00085841084,"threshold_uncertainty_score":0.999901},"labels":[],"label_agreement":null},{"id":"W4308432482","doi":"10.1016/j.lungcan.2022.11.004","title":"Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Nausea; Internal medicine; Quality of life (healthcare); ALK inhibitor; Oncology; Nursing","score_opus":0.017987614608198272,"score_gpt":0.3551372383528579,"score_spread":0.3371496237446596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308432482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98343444,0.0049329037,0.000062423125,0.0012041385,0.0017147582,0.006446377,0.00077148486,0.000044468226,0.0013890006],"genre_scores_gemma":[0.9920279,0.00024603822,0.00012501597,0.0004910494,0.00011469552,0.0059405295,0.00024251886,0.000060127153,0.0007521538],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973383,0.00022796424,0.00091761426,0.0005744918,0.00056338555,0.00037824796],"domain_scores_gemma":[0.9975278,0.00095881574,0.0006335441,0.0005516968,0.00021437075,0.00011381302],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022812893,0.00035295478,0.0010732498,0.00012836276,0.00030268615,0.00001888894,0.00017484723,0.000053634154,0.0014885071],"category_scores_gemma":[0.000113203736,0.00024538525,0.0002552858,0.00051057566,0.00008051431,0.00009624384,0.0001421969,0.0003813469,9.055489e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22920753,0.0081852535,0.64187783,0.000177962,0.007702257,0.00033453273,0.07593995,0.02282652,0.0006264787,0.000009714109,0.0024510245,0.010660941],"study_design_scores_gemma":[0.90053695,0.0019152764,0.06575382,0.0003531648,0.008257173,0.0000022869049,0.011437334,0.008668427,0.0013691457,0.000011706965,0.0011917596,0.0005029679],"about_ca_topic_score_codex":0.026770907,"about_ca_topic_score_gemma":0.008638781,"teacher_disagreement_score":0.67132944,"about_ca_system_score_codex":0.0008898286,"about_ca_system_score_gemma":0.0005123926,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W4308607464","doi":"10.1038/s41598-022-21448-1","title":"Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; American Association for Cancer Research","keywords":"Metastasis; Stage (stratigraphy); Lung cancer; Distant metastasis; Oncology; Medicine; Internal medicine; Cancer; Biology","score_opus":0.01824512212737491,"score_gpt":0.35026792404362217,"score_spread":0.3320228019162473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308607464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559313,0.0010996532,0.00026958348,0.00019510122,0.0008766072,0.0009808321,0.0005316829,0.000017007758,0.00043640393],"genre_scores_gemma":[0.9890519,0.000005551087,0.0006497873,0.00002636084,0.000012157952,0.0009368109,0.0007229934,0.000013500318,0.008580972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835056,0.000036132962,0.0005507541,0.00048501068,0.00036841276,0.00020914256],"domain_scores_gemma":[0.9988897,0.00004054154,0.00034727776,0.00050209864,0.00014124862,0.00007913774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070845656,0.00009346455,0.00035644503,0.0006752698,0.00028529848,0.00003770113,0.000057497822,0.00001666925,0.00073539553],"category_scores_gemma":[0.000049382474,0.00008421609,0.00024320376,0.0018713606,0.00007093746,0.000065882086,0.000044620323,0.00006158459,3.9779113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001166818,0.0006493956,0.9087837,0.00015288356,0.00400045,0.0003582683,0.008998516,0.029903354,0.04130301,0.0003445951,0.0030159184,0.0023732297],"study_design_scores_gemma":[0.003042744,0.0003859016,0.84918135,0.00011784744,0.032249093,0.00007177472,0.0074168365,0.018742362,0.0076009645,0.0038212899,0.07674286,0.00062699633],"about_ca_topic_score_codex":0.0015516552,"about_ca_topic_score_gemma":0.0008187894,"teacher_disagreement_score":0.07372694,"about_ca_system_score_codex":0.0004797704,"about_ca_system_score_gemma":0.0004842307,"threshold_uncertainty_score":0.80520654},"labels":[],"label_agreement":null},{"id":"W4309029848","doi":"10.1016/j.ijrobp.2022.09.057","title":"Moving Away From Counting the Numbers: Leveraging a Sensible Clinical Trial Design for Oligometastatic Disease and Beyond","year":2022,"lang":"en","type":"editorial","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Medical physics; Disease; Internal medicine","score_opus":0.04584967574630065,"score_gpt":0.4119860364101202,"score_spread":0.36613636066381955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309029848","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034728196,0.0030990643,0.057064105,0.006971017,0.8936353,0.0023616094,0.0018509701,0.00005578576,0.00023399471],"genre_scores_gemma":[0.06622674,0.0026780667,0.016113337,0.001998779,0.90933937,0.0002469278,0.0030056431,0.00012762153,0.00026353585],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996933,0.0005770322,0.0012492569,0.00040315554,0.00059140165,0.00024617766],"domain_scores_gemma":[0.98738956,0.009091053,0.0021334488,0.00020207568,0.0010004514,0.00018343379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017809168,0.000289562,0.0008247072,0.00015133468,0.00026752893,0.000099640325,0.0003331445,0.00031020198,0.00007412185],"category_scores_gemma":[0.0035313135,0.00021981064,0.00044678265,0.00011620467,0.00019180209,0.00021053884,0.00010537371,0.0010751378,0.0000036639663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041423343,0.00146139,0.010553396,0.00006659991,0.01247436,0.00023074493,0.0021457013,0.0018039596,0.00006190714,0.001224227,0.827568,0.1009864],"study_design_scores_gemma":[0.07886763,0.0031594513,0.000608107,0.00015617917,0.0047620093,0.000034972283,0.00051525777,0.0047850288,0.000013057377,0.016287057,0.8904877,0.00032356346],"about_ca_topic_score_codex":0.00007457205,"about_ca_topic_score_gemma":0.0000044238977,"teacher_disagreement_score":0.100662835,"about_ca_system_score_codex":0.0011428046,"about_ca_system_score_gemma":0.0038795099,"threshold_uncertainty_score":0.89636177},"labels":[],"label_agreement":null},{"id":"W4309244403","doi":"10.1021/acs.jmedchem.2c01041","title":"Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19","year":2022,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill; Argonne National Laboratory; Ontario Genomics Institute; National Institute of General Medical Sciences; Genentech; Canada Foundation for Innovation; National Institutes of Health; Ontario Genomics; Wellcome Trust; Fundação de Amparo à Pesquisa do Estado de São Paulo; Genome Canada; Bayer; National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; AbbVie; Takeda Pharmaceutical Company; Janssen Pharmaceuticals; Merck KGaA; Innovative Medicines Initiative; Wellcome; Merck; Pfizer; McGill University; Boehringer Ingelheim","keywords":"Kinome; Gefitinib; Erlotinib; EGFR inhibitors; Quinazoline; Epidermal growth factor receptor; Chemistry; T790M; Erlotinib Hydrochloride; Mutant; Cancer research; Mutation; Kinase; Biology; Receptor; Biochemistry; Combinatorial chemistry; Gene","score_opus":0.009237360836169876,"score_gpt":0.31877437276026144,"score_spread":0.30953701192409155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309244403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236715,0.0006085354,0.002629554,0.0036339865,0.00015874431,0.0002709476,0.000041276173,0.0000069500215,0.00028284307],"genre_scores_gemma":[0.9979287,0.0000214527,0.0009592684,0.0004374511,0.00038788034,0.000025577361,0.00002547518,0.000016092663,0.00019813879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885494,0.000019351915,0.00040869683,0.00013567919,0.00043461626,0.0001467464],"domain_scores_gemma":[0.9989533,0.000116257615,0.00036628844,0.00009466349,0.00027425008,0.00019527598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002598396,0.00011509572,0.0003437777,0.000089282665,0.00011423893,0.000004903169,0.00006405329,0.000044387696,0.00008806188],"category_scores_gemma":[0.00020376123,0.000095055635,0.00009816828,0.00021595134,0.00004725093,0.000040360104,0.000028439721,0.00021183459,1.1953284e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027498442,0.0006144761,0.018969381,0.0007898178,0.00024915498,0.00014315615,0.0012078083,0.0010431871,0.96573144,0.000013924191,0.003072584,0.0054152105],"study_design_scores_gemma":[0.011717355,0.0034549944,0.004665647,0.0005461302,0.0013169278,0.0014245807,0.0025263454,0.00073999027,0.9661573,0.00014146601,0.007113383,0.00019588145],"about_ca_topic_score_codex":0.000012274965,"about_ca_topic_score_gemma":0.0000020157509,"teacher_disagreement_score":0.014303734,"about_ca_system_score_codex":0.00036523334,"about_ca_system_score_gemma":0.00054110173,"threshold_uncertainty_score":0.3876256},"labels":[],"label_agreement":null},{"id":"W4309342023","doi":"10.1016/j.lungcan.2022.11.009","title":"Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; AstraZeneca","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Observational study; Epidermal growth factor receptor; Chemotherapy; Medical record; Cancer","score_opus":0.05358302492849484,"score_gpt":0.38799351964314566,"score_spread":0.3344104947146508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309342023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668694,0.00024395861,0.000038042414,0.00027870666,0.00028210907,0.0012819465,0.0008978035,0.000020379875,0.00027010735],"genre_scores_gemma":[0.9978877,0.00006360546,0.0001780471,0.0001674826,0.00013714525,0.0010842264,0.00019452606,0.000026904017,0.00026038665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987825,0.000064350206,0.00030451763,0.00033883762,0.00031714325,0.00019264522],"domain_scores_gemma":[0.999328,0.00014441986,0.00017800703,0.00014303115,0.0001148123,0.000091685295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008289433,0.00019409393,0.00027202742,0.00018466687,0.00011423298,0.000019380153,0.00007590789,0.000026464668,0.0004671644],"category_scores_gemma":[0.000019059804,0.00015569667,0.000056744782,0.0002144472,0.00001430051,0.00015889328,0.000037194673,0.00012448704,2.5040248e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019795526,0.0011316137,0.9795763,0.000068583075,0.00032955818,0.00006110893,0.0052175806,0.007480046,0.00051739684,0.0000062164563,0.000029342407,0.0053842976],"study_design_scores_gemma":[0.004417781,0.0013296291,0.9743119,0.00009053687,0.00030022257,0.0000067546016,0.00067845976,0.018309692,0.0004110145,0.00000641978,0.000011257694,0.00012636198],"about_ca_topic_score_codex":0.027236069,"about_ca_topic_score_gemma":0.0016124661,"teacher_disagreement_score":0.025623603,"about_ca_system_score_codex":0.0021049867,"about_ca_system_score_gemma":0.00043650897,"threshold_uncertainty_score":0.97924167},"labels":[],"label_agreement":null},{"id":"W4309731105","doi":"10.1016/j.ctarc.2022.100662","title":"A reduced dosing strategy can work for Alectinib in ALK rearranged non small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Alectinib; Dosing; Lung cancer; Medicine; Cancer; Crizotinib; Oncology; Intensive care medicine; Internal medicine","score_opus":0.14559758084820454,"score_gpt":0.47367715177419567,"score_spread":0.32807957092599116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309731105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91815716,0.047204588,0.000012145089,0.018832035,0.00012749873,0.0046203607,0.0003753389,0.00004931776,0.01062154],"genre_scores_gemma":[0.9625299,0.011699175,0.0006596172,0.00008877488,0.00007043618,0.016815776,0.0003121132,0.000037889513,0.007786316],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985228,0.00023750094,0.0002371816,0.00034535246,0.0002071085,0.00045002036],"domain_scores_gemma":[0.99846715,0.00033220544,0.00006572972,0.0007714047,0.00019275416,0.00017074704],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00032323884,0.00016242774,0.00026878752,0.00030540433,0.0013022812,0.000054302756,0.00023284732,0.000050132894,0.00012674918],"category_scores_gemma":[0.000018141387,0.00013958155,0.00008045602,0.00082083675,0.00014268544,0.00004604876,0.00016390297,0.00037316393,6.675963e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034188926,0.009027021,0.47384533,0.0008368339,0.0029478967,0.00007405883,0.08274816,0.0023380003,0.03813153,0.0008413808,0.018476646,0.36731425],"study_design_scores_gemma":[0.0924567,0.01067004,0.34072798,0.002975422,0.005241143,0.00007130412,0.05535157,0.013439337,0.016306026,0.0014087289,0.45895478,0.0023969798],"about_ca_topic_score_codex":0.013374324,"about_ca_topic_score_gemma":0.008402599,"teacher_disagreement_score":0.44047812,"about_ca_system_score_codex":0.0023542948,"about_ca_system_score_gemma":0.00160853,"threshold_uncertainty_score":0.9999979},"labels":[],"label_agreement":null},{"id":"W4309942201","doi":"10.1016/j.lungcan.2022.11.017","title":"The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Population; Proportional hazards model; Epidermal growth factor receptor; Clinical trial; Cancer","score_opus":0.010252541598297648,"score_gpt":0.318615882465887,"score_spread":0.3083633408675894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309942201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993327,0.002670179,0.000015710055,0.0008647021,0.00034089384,0.001249809,0.00023080422,0.000008734254,0.0012921633],"genre_scores_gemma":[0.9970521,0.000023340897,0.000114283896,0.00025931146,0.000049359496,0.0011978677,0.000078087556,0.000040055907,0.001185645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848187,0.00006641443,0.00043803232,0.00028042006,0.00032399478,0.0004092913],"domain_scores_gemma":[0.99874896,0.00056253956,0.00022231646,0.00027930687,0.000087957924,0.000098941346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015139024,0.00020347425,0.00035888003,0.00013774107,0.00019483414,0.000013699123,0.00013545179,0.00002530551,0.0003325602],"category_scores_gemma":[0.00006374565,0.00015080874,0.00008990567,0.00076901325,0.00001942933,0.000045334575,0.00003581116,0.00026445228,2.5841342e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008058449,0.00010194427,0.7400124,0.00015828224,0.000105462575,0.000033151173,0.0006284652,0.2565457,0.00014989916,0.0000033895542,0.0010873349,0.0010933965],"study_design_scores_gemma":[0.0032870672,0.00011864558,0.8255101,0.00020315105,0.00034959085,0.0000028459517,0.00028991312,0.16977723,0.00014018302,0.000008416844,0.00013601332,0.00017686628],"about_ca_topic_score_codex":0.99356985,"about_ca_topic_score_gemma":0.9748308,"teacher_disagreement_score":0.08676847,"about_ca_system_score_codex":0.005729288,"about_ca_system_score_gemma":0.005110833,"threshold_uncertainty_score":0.9980875},"labels":[],"label_agreement":null},{"id":"W4310595717","doi":"10.1007/s11523-022-00931-9","title":"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Mirati Therapeutics","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; Adverse effect; Internal medicine; Gastroenterology; Cancer; Response Evaluation Criteria in Solid Tumors; Capsule; Pharmacology; Chemotherapy; Progressive disease","score_opus":0.017397823526277143,"score_gpt":0.3924252135381065,"score_spread":0.37502739001182933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310595717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715614,0.00041705885,0.000007213415,0.000046509762,0.000087504384,0.0018682799,0.00010824081,0.000014711096,0.00029433818],"genre_scores_gemma":[0.9970857,0.000004298767,0.0019697435,0.00021433894,0.00002744507,0.0005475041,0.00005633682,0.000028256025,0.000066392604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988573,0.0001369488,0.00030510843,0.00031132606,0.00018754613,0.00020177991],"domain_scores_gemma":[0.99940795,0.000056887544,0.0002087801,0.0001429384,0.00008762399,0.000095794625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020872496,0.00014200558,0.00042467206,0.00014163369,0.000105648964,0.00000405135,0.000042726075,0.000032452754,0.00013527705],"category_scores_gemma":[0.000018752035,0.00011564093,0.000015284622,0.00019577496,0.000052232925,0.000057818746,0.00007340485,0.00015918809,1.8117515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002602349,0.007667087,0.93456644,0.000089938345,0.0001890496,0.00003906879,0.019748015,0.0005206783,0.005130203,0.0000037416096,0.00003405384,0.029409386],"study_design_scores_gemma":[0.19241057,0.1402149,0.6292018,0.0001603555,0.0017771857,0.000013234905,0.028172385,0.004297727,0.0027591405,0.00003471213,0.00045502218,0.00050289894],"about_ca_topic_score_codex":0.00054882787,"about_ca_topic_score_gemma":0.00037069982,"teacher_disagreement_score":0.30536458,"about_ca_system_score_codex":0.00028241973,"about_ca_system_score_gemma":0.00040338846,"threshold_uncertainty_score":0.47157001},"labels":[],"label_agreement":null},{"id":"W4310753261","doi":"10.1016/j.annonc.2022.10.324","title":"296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Internal medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Chemotherapy; Stage (stratigraphy); Cancer; Epidermal growth factor receptor; Erlotinib; Gefitinib","score_opus":0.0326366005939003,"score_gpt":0.37178418750029063,"score_spread":0.33914758690639035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98667216,0.00095009315,0.000004311403,0.0025547224,0.00025337687,0.0015724266,0.0015691557,0.000049968436,0.006373767],"genre_scores_gemma":[0.991318,0.00054910197,0.00017395506,0.0026848004,0.000052247302,0.00036872574,0.0029353434,0.000056034958,0.0018618051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752444,0.00026175648,0.0007143327,0.00057817117,0.0004170401,0.0005042349],"domain_scores_gemma":[0.9982048,0.00016679762,0.0005150001,0.0004511115,0.00048335656,0.00017893138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002376772,0.00027952148,0.00068844255,0.0002831573,0.00014813781,0.000009786123,0.00021019639,0.0001322334,0.0012310453],"category_scores_gemma":[0.000045632114,0.00022427918,0.00009019858,0.00069707044,0.00009501887,0.00008769036,0.000101000034,0.00042088103,0.000010821042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13672523,0.020081809,0.5628384,0.0001756945,0.0046943245,0.0020571828,0.039721847,0.0044753817,0.020988321,0.000039784616,0.088597834,0.11960424],"study_design_scores_gemma":[0.11167951,0.038499124,0.7147939,0.00032083812,0.0005888586,0.000008690725,0.002605722,0.0011331545,0.029379783,0.00006144351,0.10019402,0.00073494576],"about_ca_topic_score_codex":0.018674908,"about_ca_topic_score_gemma":0.0015440992,"teacher_disagreement_score":0.15195554,"about_ca_system_score_codex":0.0004124221,"about_ca_system_score_gemma":0.0016086763,"threshold_uncertainty_score":0.99968195},"labels":[],"label_agreement":null},{"id":"W4310753897","doi":"10.1016/j.annonc.2022.10.500","title":"398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Medicine; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.02602173890808037,"score_gpt":0.3946457078920597,"score_spread":0.36862396898397937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996205,0.00090626074,0.00003049534,0.014202692,0.0001603146,0.0031405527,0.00006110041,0.000030767216,0.001505791],"genre_scores_gemma":[0.9926473,0.00042083117,0.000295364,0.0050674565,0.00006403755,0.0010007315,0.00006308638,0.00004597594,0.00039520275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99731886,0.0004251181,0.0010802022,0.0004057222,0.00039582048,0.00037429095],"domain_scores_gemma":[0.9984212,0.0003003521,0.0005440876,0.00043494787,0.0001873679,0.000112047885],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007925062,0.00026597237,0.0017606971,0.00033239674,0.00007187795,0.0000051276365,0.00017597541,0.00011004293,0.0018598359],"category_scores_gemma":[0.0000641382,0.0002195575,0.0002819035,0.00046547767,0.0001770722,0.00006844658,0.0000678352,0.00028873395,0.00000368132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.830016,0.032818325,0.005541618,0.00008161009,0.0029420767,0.00041283324,0.026155015,0.000050344268,0.008913657,0.000060676248,0.0030185124,0.089989305],"study_design_scores_gemma":[0.92778707,0.023339756,0.0052052927,0.00007421792,0.0006183409,0.00006312846,0.0046698796,0.00018123395,0.009405334,0.00018302212,0.028195497,0.00027722702],"about_ca_topic_score_codex":0.0008553668,"about_ca_topic_score_gemma":0.00018232457,"teacher_disagreement_score":0.09777104,"about_ca_system_score_codex":0.00014472767,"about_ca_system_score_gemma":0.00043822415,"threshold_uncertainty_score":0.9990526},"labels":[],"label_agreement":null},{"id":"W4310753899","doi":"10.1016/j.annonc.2022.10.356","title":"319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Crizotinib; Alectinib; Medicine; Refractory (planetary science); Randomized controlled trial; Internal medicine; Oncology; Lung cancer","score_opus":0.0517741438347148,"score_gpt":0.43679608422170196,"score_spread":0.38502194038698717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9289027,0.001263393,0.00002384758,0.007627596,0.0009742865,0.0031150584,0.00010576393,0.000038171456,0.057949204],"genre_scores_gemma":[0.99453837,0.0004303303,0.0006841319,0.0019005782,0.00013033701,0.00081808417,0.00012008971,0.00002994711,0.0013481162],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732006,0.0005944626,0.0010430054,0.0003354747,0.00036212846,0.00034486514],"domain_scores_gemma":[0.99750966,0.0011273262,0.0006915714,0.00032737083,0.00023046453,0.00011359476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010808051,0.0001913676,0.0015212577,0.00031613238,0.00008200016,0.000002945309,0.00014987076,0.000112276684,0.00093271065],"category_scores_gemma":[0.00083980535,0.0001691075,0.000382505,0.00041109594,0.00022669094,0.00008372545,0.0000851927,0.00033310716,0.0000063115904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90847546,0.00426005,0.00030406629,0.00008277361,0.000701784,0.00009654166,0.0029107204,0.00013670724,0.002347719,0.00070596824,0.005214191,0.07476403],"study_design_scores_gemma":[0.8470044,0.013859453,0.0006363248,0.000066265304,0.0003595411,0.000033478194,0.0007791538,0.000046733247,0.0022228584,0.0007599498,0.13408378,0.0001480431],"about_ca_topic_score_codex":0.0005404033,"about_ca_topic_score_gemma":0.00010109315,"teacher_disagreement_score":0.1288696,"about_ca_system_score_codex":0.00014095195,"about_ca_system_score_gemma":0.0011680818,"threshold_uncertainty_score":0.99998057},"labels":[],"label_agreement":null},{"id":"W4311117047","doi":"10.1038/s41467-022-32338-5","title":"Author Correction: Inferring structural variant cancer cell fraction","year":2022,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Prostate Cancer Canada; University of Ottawa; Simon Fraser University; McGill University; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Calgary; Genome Canada; Canada's Michael Smith Genome Sciences Centre; Vector Institute; McGill University and Génome Québec Innovation Centre; Toronto General Hospital; University Health Network; University of Toronto; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"Medical Research Council","keywords":"Computational biology; Fraction (chemistry); Computer science; Biology; Chemistry","score_opus":0.022503917592774793,"score_gpt":0.38492435158678195,"score_spread":0.36242043399400714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311117047","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019768551,0.18330114,0.000089391426,0.02494591,0.16032673,0.002100588,0.0010463338,0.00060265017,0.62738955],"genre_scores_gemma":[0.15361701,0.0135795465,0.0026082746,0.0019973035,0.0025217996,0.0014663488,0.01690611,0.00016434155,0.8071393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984432,0.00013245053,0.000359755,0.0003848733,0.000431171,0.00024853533],"domain_scores_gemma":[0.99681437,0.00014560859,0.0003583417,0.0022188646,0.00032283156,0.00013997231],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010091649,0.0003153868,0.0004219177,0.00017561881,0.0011217187,0.000063582986,0.00056457706,0.000814792,0.0035721296],"category_scores_gemma":[0.000093054805,0.0002947735,0.00021563141,0.00044163555,0.000071377544,0.00017243509,0.00036550133,0.005202452,0.0000201017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022404414,0.00014584517,0.0006871884,0.00006454501,0.0003707162,0.000011158945,0.0003976115,0.000028315815,0.000017354863,0.0004453656,0.9941894,0.0036201347],"study_design_scores_gemma":[0.0005065549,0.000081392274,0.010516441,0.00015360556,0.0013614511,0.000087092245,0.0003970975,0.0013733188,0.000011118532,0.000051917053,0.9852042,0.000255816],"about_ca_topic_score_codex":0.0025133768,"about_ca_topic_score_gemma":0.0046227076,"teacher_disagreement_score":0.17974968,"about_ca_system_score_codex":0.0024094079,"about_ca_system_score_gemma":0.0014690078,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W4311625660","doi":"10.3390/curroncol29120744","title":"A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pemetrexed; Medicine; Bosutinib; Oncology; Internal medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Progressive disease; Chemotherapy; Pharmacology; Dasatinib; Cisplatin","score_opus":0.029683974356000068,"score_gpt":0.3897604351764058,"score_spread":0.36007646082040573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311625660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967364,0.000053971562,0.0000066028188,0.00015533634,0.00028925433,0.002653915,0.00004166226,0.000010076561,0.00005274511],"genre_scores_gemma":[0.998972,0.0000013151835,0.00005573066,0.000026316384,0.000010862534,0.00070843357,0.00018508514,0.000014899234,0.000025373134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874073,0.00022408577,0.0003185255,0.00022067619,0.00031677075,0.00017918281],"domain_scores_gemma":[0.9993453,0.000055667613,0.00022154805,0.000164124,0.00016775922,0.0000456073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012851189,0.00012426691,0.00035788544,0.00024841775,0.00007360568,0.0000029565983,0.00007549904,0.000013632525,0.000072427385],"category_scores_gemma":[0.00004653321,0.00007758946,0.000021246158,0.0011792715,0.00005011728,0.000042580465,0.00004965047,0.0002508344,9.976418e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027286012,0.0802031,0.89308876,0.00006157149,0.00014499009,0.000024705812,0.009355279,0.00012419061,0.000102857935,0.000009352873,0.0002653761,0.013891242],"study_design_scores_gemma":[0.1139798,0.041247718,0.8375985,0.00012419074,0.00039677447,0.0000035640546,0.0053591034,0.00029110204,0.00020848944,0.000005868155,0.0006606057,0.00012427177],"about_ca_topic_score_codex":0.00011824143,"about_ca_topic_score_gemma":0.00039502306,"teacher_disagreement_score":0.1112512,"about_ca_system_score_codex":0.0007095452,"about_ca_system_score_gemma":0.0005693167,"threshold_uncertainty_score":0.31640065},"labels":[],"label_agreement":null},{"id":"W4311691578","doi":"10.1016/s2213-2600(22)00437-4","title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Interim analysis; Internal medicine; Progression-free survival; Lung cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Hazard ratio; Anaplastic lymphoma kinase; Cancer; Surgery; Phases of clinical research; Confidence interval; Randomized controlled trial; Clinical trial; Chemotherapy","score_opus":0.06995470582299267,"score_gpt":0.3998493722953477,"score_spread":0.32989466647235505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311691578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890739,0.00222271,0.00005049108,0.0012377271,0.00011570889,0.0045391573,0.0021896465,0.000011842859,0.0005588458],"genre_scores_gemma":[0.9970404,0.00015299769,0.000084939,0.0006049286,0.00011838489,0.0002604162,0.0016777012,0.000026120977,0.00003414427],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977196,0.00033734675,0.0006879974,0.00049466453,0.00052157935,0.00023881959],"domain_scores_gemma":[0.99683243,0.0010428862,0.0005462927,0.0013020544,0.00018990396,0.00008645768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009601251,0.00024103122,0.0012038625,0.00014986732,0.00025954348,0.000009342647,0.000724433,0.000028144592,0.0003891404],"category_scores_gemma":[0.00013448956,0.00012551749,0.000030258101,0.0012501157,0.0002325878,0.00011476817,0.00047757154,0.00031539702,2.4209368e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34263623,0.0072385278,0.6129161,0.00007912857,0.009834492,0.000045260407,0.011003915,0.0015180756,0.0002645155,0.0000066888488,0.0035030856,0.010953973],"study_design_scores_gemma":[0.5909519,0.0067405864,0.38125432,0.00024849005,0.013702018,2.7779583e-7,0.002458196,0.0023301474,0.00007558281,0.0000014553549,0.0020790605,0.00015795392],"about_ca_topic_score_codex":0.0023246673,"about_ca_topic_score_gemma":0.0023521117,"teacher_disagreement_score":0.24831569,"about_ca_system_score_codex":0.00013760552,"about_ca_system_score_gemma":0.00022542173,"threshold_uncertainty_score":0.5118454},"labels":[],"label_agreement":null},{"id":"W4311969069","doi":"10.51731/cjht.2022.522","title":"Tepotinib (Tepmetko)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Health care; Political science","score_opus":0.02609199232944256,"score_gpt":0.33716446812680095,"score_spread":0.3110724757973584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311969069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39249486,0.21269496,0.00041141993,0.38378313,0.0021435677,0.0010091863,0.00012156036,0.0002922085,0.007049102],"genre_scores_gemma":[0.99747175,0.00010339342,0.00092122436,0.001186296,0.000008376759,0.000014412208,0.000004760208,0.000009297523,0.00028048936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920976,0.0000270342,0.00030270463,0.00007191387,0.00013696098,0.000251626],"domain_scores_gemma":[0.9994565,0.000018299119,0.00021967245,0.00014596747,0.00007613504,0.00008342292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027071655,0.00006161003,0.00021676609,0.00049487123,0.00041573585,0.000009283467,0.00012937313,0.00002825617,0.00018567404],"category_scores_gemma":[0.00013156552,0.00005101306,0.000060522863,0.00030376925,0.00006800333,0.000035576315,0.000015450238,0.00034018586,0.0000036449806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019046733,0.00005394994,0.021675626,0.000052682004,0.00014665817,0.00069866277,0.00091032934,0.00004029312,0.000018885463,0.0017349032,0.034727734,0.93992126],"study_design_scores_gemma":[0.0009180619,0.0012423933,0.014527687,0.000052937976,0.00005049239,0.0018748834,0.012411166,0.0000039997467,0.000085856635,0.0021771656,0.9665883,0.00006704052],"about_ca_topic_score_codex":0.003067644,"about_ca_topic_score_gemma":0.00057590345,"teacher_disagreement_score":0.9398542,"about_ca_system_score_codex":0.00092654413,"about_ca_system_score_gemma":0.0053087426,"threshold_uncertainty_score":0.94174814},"labels":[],"label_agreement":null},{"id":"W4312019909","doi":"10.1200/jco.22.02121","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"Genentech; Pfizer; Bristol-Myers Squibb","keywords":"Guideline; Medicine; Clinical Practice; Family medicine; Schedule; Stage (stratigraphy); Medical physics; Pathology","score_opus":0.07129517158464499,"score_gpt":0.5037843898540751,"score_spread":0.43248921826943015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312019909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96676844,0.0039661564,0.0058161835,0.015315023,0.004142911,0.0012004258,0.00008612893,0.000016023876,0.002688674],"genre_scores_gemma":[0.93270284,0.005019115,0.024086995,0.01606928,0.0031426859,0.00025216653,0.000049538903,0.000057332643,0.01862003],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976119,0.00022212387,0.0014814327,0.00019303756,0.0002997518,0.00019180111],"domain_scores_gemma":[0.99682796,0.0010899402,0.0011875397,0.0001578708,0.00053362834,0.00020305334],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017495421,0.000119340504,0.0007264331,0.00011609101,0.00022970515,0.00001197467,0.0001361819,0.00011383677,0.0016948826],"category_scores_gemma":[0.0004335003,0.00008835009,0.00041063028,0.00011695615,0.000043850425,0.00010283205,0.000057337296,0.000566113,0.0000032890855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007034057,0.0067483746,0.44151345,0.00010605589,0.0026440732,0.00032005386,0.0021275722,0.0054677827,0.0017629208,0.0000969924,0.37819043,0.15398826],"study_design_scores_gemma":[0.020624913,0.013381545,0.0422577,0.000103097474,0.0012654755,0.000053832868,0.0009436435,0.0072556273,0.000098105294,0.000046116922,0.91381675,0.00015319602],"about_ca_topic_score_codex":0.00008457386,"about_ca_topic_score_gemma":0.000052734173,"teacher_disagreement_score":0.53562635,"about_ca_system_score_codex":0.0005239908,"about_ca_system_score_gemma":0.0034283672,"threshold_uncertainty_score":0.9992177},"labels":[],"label_agreement":null},{"id":"W4312100623","doi":"10.3390/curroncol30010012","title":"Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"Vancouver Coastal Health Research Institute","keywords":"Medicine; Lung cancer; Incidence (geometry); Stage (stratigraphy); Internal medicine; Oncology; Observational study; Targeted therapy; Disease; Epidemiology; Cohort; Demographics; Cancer; Retrospective cohort study; Demography; Biology","score_opus":0.021282045280777064,"score_gpt":0.36174118423036256,"score_spread":0.3404591389495855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312100623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994324,0.0019654837,0.00010800449,0.00025687172,0.00037098766,0.0022025516,0.000059392954,0.000012539104,0.000700137],"genre_scores_gemma":[0.9912089,0.0001316594,0.00014531109,0.000064009975,0.000033078675,0.0035166154,0.000062183295,0.000012857444,0.004825345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904406,0.00009174781,0.00025386823,0.00031155132,0.00013141213,0.00016738508],"domain_scores_gemma":[0.9995401,0.00004541788,0.00008717372,0.00013935933,0.00008079695,0.000107150656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097587115,0.00008257417,0.00034315902,0.00007444711,0.00014653069,0.000017163704,0.00004719625,0.000027295007,0.0005516633],"category_scores_gemma":[0.000013034267,0.00011236755,0.00003533437,0.0002451271,0.000020194215,0.000031404743,0.00007333388,0.00012481597,0.0000035955024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007094329,0.004920429,0.9826346,0.000040835246,0.00014993943,0.00013916423,0.0014613273,0.0008737332,0.00050186913,0.000001631615,0.003832626,0.005372914],"study_design_scores_gemma":[0.007274379,0.0052642524,0.92692286,0.000066544126,0.0013260128,0.00006551339,0.00056675303,0.0025445665,0.000052521744,0.000016228914,0.0556802,0.00022018314],"about_ca_topic_score_codex":0.031262722,"about_ca_topic_score_gemma":0.023970392,"teacher_disagreement_score":0.055711742,"about_ca_system_score_codex":0.0041201636,"about_ca_system_score_gemma":0.00072872307,"threshold_uncertainty_score":0.9997029},"labels":[],"label_agreement":null},{"id":"W4312114336","doi":"10.1200/jco.22.02124","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Guideline; Clinical Practice; Family medicine; Schedule; Stage (stratigraphy); Pathology","score_opus":0.06123616474840071,"score_gpt":0.48610858152854763,"score_spread":0.4248724167801469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96889895,0.0030708862,0.0065578776,0.015604748,0.0022389663,0.001119759,0.00007270224,0.000013335775,0.0024227775],"genre_scores_gemma":[0.928258,0.0043169013,0.03218013,0.016247397,0.002631197,0.00028601155,0.000052483712,0.000061724306,0.015966173],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980257,0.00016896705,0.0011681519,0.00017639737,0.00028735012,0.0001734347],"domain_scores_gemma":[0.9970464,0.0010596387,0.0010444138,0.00014144572,0.0005280881,0.00017998155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013036573,0.000110144625,0.0006299327,0.00010200148,0.00020733097,0.000010656547,0.000114303904,0.00008884597,0.0013802965],"category_scores_gemma":[0.00023134473,0.000073729614,0.00027776367,0.0001240161,0.000044484445,0.00009633382,0.000040541498,0.00050095486,0.000001945916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015098684,0.009205879,0.4088041,0.00013812885,0.0040333774,0.00074288977,0.0026957833,0.012147032,0.0014544037,0.00013372049,0.39962032,0.1459257],"study_design_scores_gemma":[0.025847033,0.026050366,0.042633396,0.0001313959,0.001459998,0.00008395616,0.0012522368,0.004849071,0.00009752608,0.000029577575,0.89740247,0.00016295427],"about_ca_topic_score_codex":0.000078552635,"about_ca_topic_score_gemma":0.00007101493,"teacher_disagreement_score":0.49778217,"about_ca_system_score_codex":0.00044835164,"about_ca_system_score_gemma":0.0035612949,"threshold_uncertainty_score":0.9995326},"labels":[],"label_agreement":null},{"id":"W4312114419","doi":"10.1016/j.jtho.2022.10.010","title":"Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Bevacizumab; Oncology; Internal medicine; Lung cancer; Progression-free survival; Randomized controlled trial; Pneumonitis; Epidermal growth factor receptor; Cancer; Lung; Overall survival; Chemotherapy; Erlotinib","score_opus":0.02327696652951689,"score_gpt":0.3954120527013132,"score_spread":0.3721350861717963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5087571,0.0059064645,0.0074868733,0.44968992,0.007420192,0.012048087,0.0023497974,0.00018713651,0.0061544008],"genre_scores_gemma":[0.69031763,0.0006714074,0.11852204,0.15685575,0.010272925,0.0021540592,0.007648685,0.0014549319,0.012102552],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972111,0.00021750938,0.001011455,0.00036885508,0.00072864705,0.00046244598],"domain_scores_gemma":[0.99556935,0.0007678097,0.002183249,0.00037829377,0.0009421265,0.00015919901],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024598715,0.00043578868,0.0014508188,0.00061431795,0.00021468921,0.000022198474,0.0002566783,0.00039153956,0.0004541797],"category_scores_gemma":[0.00009341762,0.00029990688,0.00032588307,0.00042935624,0.00019565318,0.00015388038,0.000027447326,0.0012487583,0.0000018717327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3455884,0.006355275,0.010700142,0.0024658032,0.038721975,0.007837002,0.010139352,0.0047412827,0.00038090293,0.00002691128,0.36344734,0.20959562],"study_design_scores_gemma":[0.056517612,0.07100003,0.003484534,0.0008581102,0.017332781,0.0006725139,0.00060268864,0.00015100079,0.00044790705,0.000016368183,0.84827906,0.0006374076],"about_ca_topic_score_codex":0.000071454575,"about_ca_topic_score_gemma":0.000023905099,"teacher_disagreement_score":0.48483172,"about_ca_system_score_codex":0.0024137206,"about_ca_system_score_gemma":0.0029787116,"threshold_uncertainty_score":0.9999453},"labels":[],"label_agreement":null},{"id":"W4312200106","doi":"10.1177/10781552221147500","title":"An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"review","venue":"Journal of Oncology Pharmacy Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Tolerability; Lung cancer; Internal medicine; Context (archaeology); Oncology; Adverse effect; Clinical trial; Neutropenia; non-small cell lung cancer (NSCLC); Intensive care medicine; Toxicity","score_opus":0.08405027830177551,"score_gpt":0.5071884258990789,"score_spread":0.42313814759730334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312200106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002825842,0.988203,0.000001351279,0.00094395084,0.0004607712,0.0013350635,0.000107064574,0.000002514549,0.0061204545],"genre_scores_gemma":[0.0017030666,0.9964257,0.000877602,0.0005404526,0.0001894244,0.00009554366,0.000016783388,0.000037688438,0.0001137618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966949,0.0012631642,0.0012761559,0.00022764242,0.00035147957,0.00018663569],"domain_scores_gemma":[0.9933073,0.0017871849,0.0041330275,0.0002537315,0.00038227622,0.00013648994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013012666,0.00025966938,0.0016496594,0.00023691033,0.00008251598,0.000008538052,0.0002779433,0.00012753693,0.00046782484],"category_scores_gemma":[0.0003005934,0.0001663156,0.00032940763,0.00044496468,0.00008456298,0.00029148575,0.0001233028,0.0012725128,5.973893e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008041282,0.0029208097,0.0019143051,0.008345407,0.0018126371,0.00027342315,0.004933645,0.0000160634,0.00027816955,0.00002584353,0.0008640487,0.9778115],"study_design_scores_gemma":[0.0037860766,0.0009453162,0.00031415006,0.0060808663,0.016073192,0.0013814061,0.0010661598,0.000030310677,0.000112529844,0.0000060967354,0.97007996,0.00012392088],"about_ca_topic_score_codex":0.00045291203,"about_ca_topic_score_gemma":0.000028076041,"teacher_disagreement_score":0.9776876,"about_ca_system_score_codex":0.00075597403,"about_ca_system_score_gemma":0.0059750564,"threshold_uncertainty_score":0.99966013},"labels":[],"label_agreement":null},{"id":"W4312996625","doi":"10.1057/978-1-349-96053-8_976","title":"Canadian Cancer Society Research Institute (CCSRI)","year":2022,"lang":"en","type":"book-chapter","venue":"The Grants Register 2023","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Political science; Medicine; Internal medicine","score_opus":0.1410468713612659,"score_gpt":0.4151819305607953,"score_spread":0.2741350591995294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312996625","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011878023,0.005647818,0.0000020255948,0.030165289,0.0012492305,0.0012354092,0.0009454041,0.000046195666,0.9605898],"genre_scores_gemma":[0.0020489036,0.0040971106,0.000027469578,0.0020670667,0.00058629387,0.00026693635,0.00041991868,0.0000926096,0.9903937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813104,0.000029996021,0.00023224094,0.00042432197,0.000707709,0.0004746757],"domain_scores_gemma":[0.9985934,0.00005067559,0.00008841672,0.00082911906,0.00016624758,0.00027214375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003463278,0.00025223664,0.00034497326,0.0001717979,0.00081278186,0.000045058696,0.00030212445,0.00017009885,0.0067962916],"category_scores_gemma":[0.00001187674,0.00017289865,0.00028669531,0.00013766247,0.0003391917,0.000058929247,0.0001308055,0.0009826995,0.00045716795],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057550988,0.00003228303,0.00017534074,0.00020385518,0.0021328072,0.00054543203,0.0028668833,0.000010887814,0.00000921217,0.039558712,0.9304973,0.023909777],"study_design_scores_gemma":[0.00059868704,0.00007099821,0.00030202043,0.00028962857,0.0004888734,0.000040714618,0.00011772143,0.000007783936,0.0000016446954,0.0025936132,0.99532,0.00016827181],"about_ca_topic_score_codex":0.4062054,"about_ca_topic_score_gemma":0.3737754,"teacher_disagreement_score":0.064822786,"about_ca_system_score_codex":0.00231533,"about_ca_system_score_gemma":0.0031905628,"threshold_uncertainty_score":0.99411166},"labels":[],"label_agreement":null},{"id":"W4313245421","doi":"10.3390/curroncol30010027","title":"LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Immunohistochemistry; Proportional hazards model; Adenocarcinoma; Biomarker; Population; Epidermal growth factor receptor; Cancer; Performance status; Progression-free survival; Cohort; Chemotherapy; non-small cell lung cancer (NSCLC)","score_opus":0.028832426764545,"score_gpt":0.4244811693461724,"score_spread":0.3956487425816274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313245421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97452575,0.017452909,0.00011076549,0.0023598995,0.0010347047,0.0018531671,0.00010561634,0.000039888157,0.0025172965],"genre_scores_gemma":[0.9890028,0.0014335214,0.00017446595,0.0008480146,0.00010735318,0.005811688,0.0003606652,0.000038447004,0.0022230186],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986813,0.000051358526,0.00030545908,0.00041472114,0.00018920926,0.00035793803],"domain_scores_gemma":[0.9992669,0.000112364796,0.00011906376,0.00025917744,0.000095280986,0.00014716088],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010983282,0.00020280632,0.00036468223,0.000096123586,0.00014845347,0.0000083539535,0.00014739821,0.000063695385,0.0012341517],"category_scores_gemma":[0.00004014618,0.00019000766,0.00007657592,0.00034726996,0.00003458629,0.000033496726,0.0000931071,0.00036343306,0.000013138714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033347623,0.013517974,0.69404876,0.00075489766,0.00047911715,0.00044345346,0.0055377204,0.0010845657,0.05790362,0.000014614733,0.053176608,0.16970387],"study_design_scores_gemma":[0.026346823,0.004219776,0.07076884,0.0003403797,0.00048497246,0.00008252455,0.0008957661,0.00089548394,0.004366923,0.000040717754,0.8909456,0.00061216],"about_ca_topic_score_codex":0.0001742627,"about_ca_topic_score_gemma":0.000037460497,"teacher_disagreement_score":0.83776903,"about_ca_system_score_codex":0.001964177,"about_ca_system_score_gemma":0.0010618134,"threshold_uncertainty_score":0.99967885},"labels":[],"label_agreement":null},{"id":"W4313362540","doi":"10.3390/curroncol30010037","title":"Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"KRAS; Medicine; Internal medicine; Atezolizumab; Oncology; Lung cancer; Nivolumab; Population; ROS1; Cancer; Immunotherapy; Colorectal cancer; Adenocarcinoma","score_opus":0.0553972814319021,"score_gpt":0.4255075984443378,"score_spread":0.3701103170124357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313362540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98625696,0.009461926,0.000044836703,0.00031420507,0.00052030466,0.001378624,0.0014019811,0.00001236111,0.0006087758],"genre_scores_gemma":[0.99390477,0.00123322,0.00062914385,0.00008428472,0.000055270168,0.00032576767,0.0036111122,0.000027995051,0.00012841486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987064,0.00012715942,0.00042964466,0.0003498801,0.00019721714,0.0001896765],"domain_scores_gemma":[0.9985554,0.00029250683,0.0004371772,0.0004974583,0.00015734663,0.000060094775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008166827,0.00016657094,0.0005123647,0.00013198744,0.000051464707,0.0000028152124,0.00016185331,0.000042083393,0.00085915637],"category_scores_gemma":[0.000020123805,0.00012949141,0.000047954803,0.00028316578,0.000053502754,0.000073933756,0.000074394084,0.00014643074,0.0000019137667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011605632,0.046776474,0.7594206,0.00020347173,0.0020602331,0.00008076056,0.012633817,0.00075822073,0.0019991782,0.0000075826033,0.0016690622,0.162785],"study_design_scores_gemma":[0.14865637,0.02025001,0.59964186,0.00032399516,0.0036736252,0.000011004007,0.0023234033,0.0021159865,0.0030779017,0.000010091208,0.21950583,0.00040991968],"about_ca_topic_score_codex":0.0017178596,"about_ca_topic_score_gemma":0.00044629723,"teacher_disagreement_score":0.21783677,"about_ca_system_score_codex":0.0009974847,"about_ca_system_score_gemma":0.0010634984,"threshold_uncertainty_score":0.94071597},"labels":[],"label_agreement":null},{"id":"W4313379654","doi":"10.1016/j.jmoldx.2022.12.004","title":"CANTRK","year":2022,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; William Osler Health System; Centre Hospitalier de l’Université de Montréal; Manitoba Health; Hôpital Maisonneuve-Rosemont; University Health Network; University of Alberta; Jewish General Hospital; Sunnybrook Health Science Centre; Hospital for Sick Children; Nova Scotia Health Authority; McMaster University; Hamilton Health Sciences; Ottawa Hospital; Calgary Laboratory Services; Health Sciences Centre; McGill University Health Centre; Kingston Health Sciences Centre; Queen's University; Institut universitaire de cardiologie et de pneumologie de Québec; University of Saskatchewan; Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Canada","keywords":"Computational biology; Biology","score_opus":0.006823315016619164,"score_gpt":0.30029387837687394,"score_spread":0.2934705633602548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313379654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741791,0.00940258,0.0025957155,0.0058109025,0.00090678566,0.00022034861,0.000032412187,0.000010977932,0.0068411822],"genre_scores_gemma":[0.9965596,0.00025036946,0.0014862439,0.0013111022,0.00008555636,0.0000061564165,0.0000066816697,0.000011572119,0.00028272034],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993942,0.000017999891,0.00017096079,0.000043064494,0.00029278905,0.000080988386],"domain_scores_gemma":[0.99953437,0.00006270362,0.00012123482,0.00008400679,0.00011013806,0.00008756064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007644068,0.000046767276,0.00012380617,0.000076319186,0.00006390469,0.0000061345013,0.000049865423,0.000010855973,0.00019702432],"category_scores_gemma":[0.0001548495,0.000039107126,0.000091924085,0.00010696867,0.000011953081,0.0000173857,0.000025325995,0.000154514,0.0000030448118],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012950847,0.009156038,0.32283482,0.00028073718,0.0077622156,0.1235939,0.005422652,0.03425262,0.06373125,0.038725052,0.32433546,0.06861017],"study_design_scores_gemma":[0.012904268,0.007706635,0.061427288,0.0002095057,0.0051498846,0.01287474,0.0019320025,0.0001828875,0.024149245,0.005503876,0.8675488,0.00041085616],"about_ca_topic_score_codex":0.000009175055,"about_ca_topic_score_gemma":6.296478e-7,"teacher_disagreement_score":0.54321337,"about_ca_system_score_codex":0.00015123477,"about_ca_system_score_gemma":0.0002419935,"threshold_uncertainty_score":0.21572782},"labels":[],"label_agreement":null},{"id":"W4313402076","doi":"10.3390/curroncol30010041","title":"Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma—A Case Series","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Alectinib; Medicine; Anaplastic lymphoma kinase; Adverse effect; Lung cancer; Anemia; Hemolytic anemia; Internal medicine; Oncology","score_opus":0.03503105194750395,"score_gpt":0.3708213236712511,"score_spread":0.33579027172374715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313402076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995937,0.0010779881,0.000009567729,0.0004506207,0.0003014417,0.0016581634,0.00009734817,0.000040709845,0.00042716405],"genre_scores_gemma":[0.9971112,0.000012839788,0.00033737288,0.000117935146,0.000042841137,0.0018454315,0.00027566287,0.000038162623,0.0002185473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984866,0.00014386483,0.0002936365,0.000441491,0.00026231777,0.00037211576],"domain_scores_gemma":[0.9992473,0.000070470815,0.00014490863,0.00028129545,0.0000974272,0.0001585736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006513251,0.00026704778,0.0004800008,0.00019399074,0.00018095667,0.000014840469,0.000056399374,0.000031357748,0.00047628896],"category_scores_gemma":[0.000008678434,0.00018464883,0.00005204286,0.00040716518,0.00007612361,0.000116020485,0.00004569002,0.0002524668,0.0000062837908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028538138,0.0030013607,0.9681749,0.000116824674,0.0002859811,0.0069621033,0.0037861527,0.000030777588,0.000004012085,0.000013353319,0.00010484829,0.014665925],"study_design_scores_gemma":[0.065301836,0.054181483,0.8412895,0.0002277869,0.004686777,0.013802462,0.0066219405,0.00019187719,0.00018099754,0.000039170023,0.012670436,0.00080571335],"about_ca_topic_score_codex":0.00026356286,"about_ca_topic_score_gemma":0.00085886853,"teacher_disagreement_score":0.12688532,"about_ca_system_score_codex":0.002061072,"about_ca_system_score_gemma":0.0008288803,"threshold_uncertainty_score":0.7529761},"labels":[],"label_agreement":null},{"id":"W4313506816","doi":"10.7554/elife.73288.sa2","title":"Author response: Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development","year":2022,"lang":"en","type":"peer-review","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Bayesian probability; Head and neck cancer; Regression; Oncology; Cancer; Head and neck; Regression analysis; Internal medicine; Statistics; Medicine; Mathematics; Surgery","score_opus":0.03340307429077256,"score_gpt":0.3981927096879559,"score_spread":0.36478963539718334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313506816","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28543293,0.6240239,0.00013948341,0.07947698,0.0015543856,0.0073540607,0.00063555007,0.00022068046,0.0011619965],"genre_scores_gemma":[0.13323316,0.14184435,0.0292044,0.004605824,0.00043920657,0.023739802,0.0018434684,0.00044464567,0.66464514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712414,0.00022312849,0.0006960728,0.00081155874,0.0007578769,0.0003872073],"domain_scores_gemma":[0.99866134,0.00014289448,0.0002794894,0.00053285266,0.00014503469,0.00023838106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007109735,0.0004887393,0.0009824182,0.00025232718,0.00021541853,0.0000322095,0.0001342762,0.00020596819,0.00036152327],"category_scores_gemma":[0.00014243562,0.00032808268,0.00007051305,0.00025741218,0.000048696405,0.00009916763,0.00023950289,0.00050530565,6.670117e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013217626,0.0006778176,0.09262236,0.019450234,0.0009757082,0.00055916386,0.0066817836,0.00012183668,0.00015117042,0.000017938986,0.15604407,0.7094803],"study_design_scores_gemma":[0.019068234,0.0015504283,0.05185907,0.16055863,0.00092254276,0.00031115007,0.00081496773,0.0028955198,0.00006766729,0.00006429146,0.7605103,0.0013771666],"about_ca_topic_score_codex":0.0002369174,"about_ca_topic_score_gemma":0.00063043134,"teacher_disagreement_score":0.7081031,"about_ca_system_score_codex":0.00082047743,"about_ca_system_score_gemma":0.0018105721,"threshold_uncertainty_score":0.99991715},"labels":[],"label_agreement":null},{"id":"W4313511988","doi":"10.3390/curroncol30010055","title":"Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Drug repositioning; Repurposing; Lung cancer; Drug; Chemotherapy; Cancer; Oncology; Drug resistance; Pharmacodynamics; Internal medicine; Pharmacology; Pharmacokinetics; Biology","score_opus":0.1861882306620551,"score_gpt":0.46329172325145623,"score_spread":0.27710349258940115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313511988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042410968,0.9885209,0.00034906468,0.00024556767,0.0026629644,0.0065245065,0.00012110163,0.00008303796,0.0014504252],"genre_scores_gemma":[0.000018095017,0.98483324,0.000549469,0.000026504767,0.00083016057,0.0028682344,0.0012736504,0.00009798736,0.0095026605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777365,0.000078459176,0.00078957214,0.00060556084,0.00011002809,0.00064274884],"domain_scores_gemma":[0.99864453,0.00030560416,0.00037018862,0.00037191014,0.0000913647,0.00021640732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026845076,0.00037788454,0.0016493022,0.0004393428,0.00013270648,0.000018129205,0.00015088309,0.0002851064,0.000021373427],"category_scores_gemma":[0.00005789953,0.0003119908,0.0004930301,0.00048453294,0.00004104288,0.000037031954,0.00010844678,0.00050664524,0.00006952568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010035307,0.0006587413,0.00032016737,0.04822236,0.00019838248,0.000043503904,0.0010945273,0.0000071442096,3.8369808e-7,0.00015379117,0.045194738,0.90409625],"study_design_scores_gemma":[0.0023742027,0.00021730295,0.000057622266,0.012949286,0.004634457,0.000036057427,0.000066356406,0.00011763952,2.8313005e-7,0.000073016934,0.9792341,0.00023964676],"about_ca_topic_score_codex":0.0002670742,"about_ca_topic_score_gemma":0.00044870496,"teacher_disagreement_score":0.9340394,"about_ca_system_score_codex":0.002111665,"about_ca_system_score_gemma":0.00371865,"threshold_uncertainty_score":0.99993324},"labels":[],"label_agreement":null},{"id":"W4313645062","doi":"10.2196/41640","title":"Lung Cancer Risk Prediction Nomogram in Nonsmoking Chinese Women: Retrospective Cross-sectional Cohort Study","year":2023,"lang":"en","type":"article","venue":"JMIR Public Health and Surveillance","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Natural Science Foundation of Henan Province","keywords":"Nomogram; Medicine; Lung cancer; Population; Retrospective cohort study; Cancer; Cohort; Breast cancer; Cross-sectional study; Internal medicine; Pathology; Environmental health","score_opus":0.0153244571830309,"score_gpt":0.38491480079952567,"score_spread":0.3695903436164948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313645062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947714,0.00043765552,0.000018694342,0.001150252,0.00050067384,0.0021808986,0.00024157572,0.00021391905,0.0004849141],"genre_scores_gemma":[0.99524295,0.0007349941,0.000010927531,0.0002908357,0.00026062518,0.0025142983,0.0001984387,0.000022553315,0.0007243737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979811,0.00014891686,0.00042356906,0.0005017403,0.0003736091,0.0005710948],"domain_scores_gemma":[0.9989573,0.00008316734,0.0001531284,0.00021303035,0.00016406813,0.00042931136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014288476,0.00016721521,0.0003804022,0.0003011244,0.00035433195,0.00008448623,0.000047056135,0.000073558884,0.000070602815],"category_scores_gemma":[0.00021823286,0.00013657147,0.000039847106,0.0012329498,0.000052926185,0.00017190436,0.000033767952,0.00029307732,0.000004402543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007769772,0.00031731697,0.99257,0.00008527219,0.00015109198,0.000011945171,0.0036203477,0.000027903954,5.83688e-7,0.000008740623,0.00044233102,0.0026867925],"study_design_scores_gemma":[0.0027394127,0.0004224379,0.99305785,0.000011537056,0.0000019209267,0.000008562457,0.0005318904,0.001897054,1.7663748e-8,0.000019526075,0.0012129558,0.000096829484],"about_ca_topic_score_codex":0.0022984757,"about_ca_topic_score_gemma":0.001899221,"teacher_disagreement_score":0.0030884575,"about_ca_system_score_codex":0.001429581,"about_ca_system_score_gemma":0.00084926764,"threshold_uncertainty_score":0.5569223},"labels":[],"label_agreement":null},{"id":"W4313649019","doi":"10.51731/cjht.2023.534","title":"Pralsetinib (Gavreto)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Political science; Health care","score_opus":0.0401246982092405,"score_gpt":0.37572661462384405,"score_spread":0.3356019164146036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313649019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47132552,0.057499133,0.00010396503,0.46435446,0.0012641368,0.00069640874,0.000060292823,0.0006056713,0.0040904153],"genre_scores_gemma":[0.997759,0.00057584635,0.00046756683,0.0005991287,0.0000129786495,0.0000065390004,0.0000071155373,0.00001014478,0.00056169],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99922764,0.000013204175,0.0002910401,0.00006946112,0.00009783232,0.00030080567],"domain_scores_gemma":[0.9994616,0.000025427633,0.00016436883,0.00014124604,0.00011040298,0.00009698545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025516262,0.00006406885,0.00021689908,0.00058447104,0.00015096828,0.0000127715575,0.00009349777,0.000066403554,0.000034591358],"category_scores_gemma":[0.0002997206,0.000048296435,0.000053334064,0.0004930357,0.00008469616,0.000048894704,0.000006267393,0.00019016567,0.000045624045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011288725,0.000016338321,0.031568285,0.00011467734,0.00013135973,0.0007295468,0.00068144675,0.000011080188,0.000026670183,0.001589168,0.10692095,0.8581992],"study_design_scores_gemma":[0.00097068184,0.00076010654,0.10038863,0.00034845524,0.00005175626,0.000568752,0.00571159,0.000008510044,0.00021028281,0.003443178,0.8874522,0.0000858728],"about_ca_topic_score_codex":0.0015251796,"about_ca_topic_score_gemma":0.0011098371,"teacher_disagreement_score":0.8581133,"about_ca_system_score_codex":0.00032472002,"about_ca_system_score_gemma":0.0037332133,"threshold_uncertainty_score":0.662256},"labels":[],"label_agreement":null},{"id":"W4316040798","doi":"10.1016/j.rmra.2022.11.184","title":"Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816","year":2023,"lang":"fr","type":"article","venue":"Revue des Maladies Respiratoires Actualités","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.0384736984404272,"score_gpt":0.33839564436678543,"score_spread":0.29992194592635824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316040798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965346,0.014449243,0.0043333042,0.007475035,0.0015836162,0.0024052404,0.0017902385,0.00047570324,0.002141648],"genre_scores_gemma":[0.92352724,0.060423084,0.004518241,0.0013350723,0.0017248224,0.0013627522,0.0014022423,0.0003012678,0.0054052877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99262893,0.0014549247,0.001525735,0.0013455001,0.00069747976,0.0023474565],"domain_scores_gemma":[0.9956918,0.0014206292,0.0007792023,0.000956664,0.00031147772,0.0008402287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002325695,0.0011860655,0.0013726611,0.00052615907,0.0009904535,0.00027503047,0.00052789476,0.00073869264,0.0018726081],"category_scores_gemma":[0.00079601834,0.0011385259,0.00053810305,0.00092063437,0.0004864013,0.00054845423,0.00034260677,0.0008883736,0.00009030915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070087267,0.0044851415,0.2656573,0.01594739,0.005180671,0.0050639194,0.23432867,0.110765636,0.22543003,0.007577741,0.0065956144,0.11195916],"study_design_scores_gemma":[0.037120815,0.005916925,0.62208974,0.030854441,0.0060260147,0.0006693338,0.020740699,0.10389811,0.09953045,0.0010367244,0.06816273,0.0039540017],"about_ca_topic_score_codex":0.006473125,"about_ca_topic_score_gemma":0.017149253,"teacher_disagreement_score":0.35643244,"about_ca_system_score_codex":0.006093022,"about_ca_system_score_gemma":0.0018462287,"threshold_uncertainty_score":0.99910647},"labels":[],"label_agreement":null},{"id":"W4317209129","doi":"10.1007/s11523-022-00941-7","title":"Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Pathology; Cancer; Cancer research; Internal medicine; Adenocarcinoma","score_opus":0.0675653515167773,"score_gpt":0.43998593053210705,"score_spread":0.37242057901532977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317209129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011626704,0.99070674,0.00017230476,0.00036645163,0.0019403342,0.005584418,0.000696,0.00016500284,0.0002524772],"genre_scores_gemma":[0.0010037448,0.9932168,0.00022579155,0.00006390811,0.0015086563,0.0033486101,0.0003128446,0.00011981959,0.00019980811],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741375,0.00023730946,0.00065079756,0.00083994376,0.00020717204,0.0006510506],"domain_scores_gemma":[0.9981022,0.000579492,0.00051615725,0.00036419358,0.000200798,0.0002371757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002055384,0.0006255333,0.0021246856,0.00025892176,0.00020579892,0.000054089607,0.0001722579,0.0003553014,0.000053624888],"category_scores_gemma":[0.000025211692,0.00042086997,0.0004663678,0.00036097917,0.00009817953,0.00008279788,0.000045063043,0.00051069155,0.000015486521],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027322373,0.0005525644,0.000022348859,0.081511445,0.003996351,0.0001729783,0.0048768395,0.000021728172,0.000013089466,0.002180678,0.001291752,0.905087],"study_design_scores_gemma":[0.0022015416,0.0019854414,0.00011263003,0.02219195,0.026445016,0.00009203528,0.014817723,0.00021184079,0.000007174259,0.000017814102,0.9313752,0.00054162194],"about_ca_topic_score_codex":0.0001803535,"about_ca_topic_score_gemma":0.000072461466,"teacher_disagreement_score":0.93008345,"about_ca_system_score_codex":0.0022830046,"about_ca_system_score_gemma":0.004120292,"threshold_uncertainty_score":0.9998243},"labels":[],"label_agreement":null},{"id":"W4317433563","doi":"10.2217/fon-2022-0919","title":"A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; BC Cancer Agency; University of Toronto","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; T790M; Oncology; Internal medicine; Second line; Real world data; First line; Epidermal growth factor receptor; Gefitinib; Cancer; Erlotinib; Data science","score_opus":0.0400914084856207,"score_gpt":0.3892553444016239,"score_spread":0.3491639359160032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317433563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920695,0.000023415389,0.0000017224721,0.0021587105,0.00022962457,0.0012720403,0.0003509463,0.000026903146,0.0038671752],"genre_scores_gemma":[0.99517304,0.000013936627,0.00014981462,0.00027256543,0.00022834969,0.000088849825,0.0010010601,0.000018243676,0.0030541627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899024,0.00009968861,0.00026252968,0.0002820297,0.00016882464,0.00019667755],"domain_scores_gemma":[0.9990974,0.00016050818,0.00013452237,0.00046166452,0.00009494154,0.000050936378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013828327,0.00012414422,0.00032914625,0.0001412811,0.000061322186,0.000005046601,0.000157222,0.000060985974,0.0002983654],"category_scores_gemma":[0.00002264454,0.00006327566,0.00001884191,0.00063112716,0.000051185478,0.000060125003,0.00010724646,0.00018938235,0.000017406244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008439122,0.0067433487,0.9031752,0.00006646458,0.0012182426,0.0004987099,0.014129826,0.000027838967,0.00003117073,0.00004478573,0.021228874,0.04439642],"study_design_scores_gemma":[0.013452689,0.0072335606,0.9583204,0.000054366305,0.00039342314,0.0000040952,0.002644375,0.00002419645,0.000024219462,0.0000063188863,0.017774018,0.00006838471],"about_ca_topic_score_codex":0.0004560123,"about_ca_topic_score_gemma":0.020346012,"teacher_disagreement_score":0.05514516,"about_ca_system_score_codex":0.00015084991,"about_ca_system_score_gemma":0.0003662703,"threshold_uncertainty_score":0.9975301},"labels":[],"label_agreement":null},{"id":"W4317568116","doi":"10.1097/coc.0000000000000976","title":"Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non–small Cell Lung Cancer Harboring Activating EGFR Mutations","year":2023,"lang":"en","type":"review","venue":"American Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Odds ratio; Epidermal growth factor receptor; Adverse effect; Clinical endpoint; Gefitinib; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.051375962068259506,"score_gpt":0.4729018708173301,"score_spread":0.4215259087490706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317568116","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90714914,0.09156993,0.000036088113,0.00012208961,0.0001480386,0.00081597676,0.000033452303,0.000005023702,0.00012023584],"genre_scores_gemma":[0.34618986,0.6507369,0.0028033804,0.0000618717,0.00008764788,0.00003800174,0.000026365762,0.0000396637,0.00001630694],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997241,0.00023970097,0.0019259872,0.00023009637,0.00019318162,0.00017003895],"domain_scores_gemma":[0.99360484,0.0020043855,0.0037877865,0.00012071485,0.00032057555,0.00016172351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042809904,0.00020502639,0.0028639366,0.00027485713,0.00002992718,0.0000039951174,0.00005920374,0.00013527273,0.0000048922398],"category_scores_gemma":[0.00038300635,0.00014466974,0.00017880135,0.00045924747,0.00036714485,0.00007343742,0.000042390027,0.00057200954,1.8840248e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008494488,0.0011117933,0.04603582,0.0027379636,0.00073881785,0.000034791567,0.00037443527,0.000025348008,0.000011102942,0.000003738933,0.0000057473167,0.948071],"study_design_scores_gemma":[0.07274852,0.07312724,0.7203393,0.09554882,0.020049402,0.000057294576,0.0014518052,0.0000851895,0.00011602928,0.00003197363,0.015610489,0.00083391264],"about_ca_topic_score_codex":0.00009234699,"about_ca_topic_score_gemma":0.00003253539,"teacher_disagreement_score":0.9472371,"about_ca_system_score_codex":0.00024917594,"about_ca_system_score_gemma":0.0015467933,"threshold_uncertainty_score":0.5899461},"labels":[],"label_agreement":null},{"id":"W4317863296","doi":"10.1200/jco.2023.41.4_suppl.106","title":"A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Tolerability; Adverse effect; Response Evaluation Criteria in Solid Tumors; Internal medicine; Colorectal cancer; Pharmacokinetics; Pharmacodynamics; Oncology; Cancer; Pharmacology; Phases of clinical research; Clinical trial","score_opus":0.08887203526624725,"score_gpt":0.5075697103502357,"score_spread":0.4186976750839884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715215,0.0000135046575,0.0000074474083,0.0005598716,0.0008111798,0.0012338823,0.0000100542065,0.000017522902,0.00019436116],"genre_scores_gemma":[0.99913543,0.000033516422,0.0002512582,0.000044678553,0.00028572,0.00009586032,0.000040122188,0.000023251578,0.00009018074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663025,0.00031323015,0.0021670414,0.00023755452,0.0004167664,0.00023517369],"domain_scores_gemma":[0.99660075,0.00035402976,0.002238207,0.00009444733,0.0005270982,0.00018545934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010195841,0.0001591993,0.0011339709,0.00041997488,0.00006634468,0.00000902803,0.00007993997,0.0001530077,0.000058602956],"category_scores_gemma":[0.00074220664,0.00011312989,0.0001335669,0.0006758278,0.000071111455,0.00030198236,0.00004591572,0.00063580385,0.0000071158374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040982172,0.029398022,0.79367226,0.00006499611,0.0011241891,0.00052179524,0.002969839,0.0010632256,0.0051609254,0.0000070986657,0.0005182911,0.124517195],"study_design_scores_gemma":[0.14972326,0.16149561,0.67533606,0.0015558002,0.0010638086,0.00004011911,0.0043323957,0.0011517579,0.0039542685,0.000032353528,0.0010626845,0.00025187037],"about_ca_topic_score_codex":0.00012556706,"about_ca_topic_score_gemma":0.0005466089,"teacher_disagreement_score":0.13209759,"about_ca_system_score_codex":0.00067822856,"about_ca_system_score_gemma":0.0011487982,"threshold_uncertainty_score":0.46133032},"labels":[],"label_agreement":null},{"id":"W4318067179","doi":"10.3389/fmed.2022.1051309","title":"Standardized classification schemes in reporting oncologic PET/CT","year":2023,"lang":"en","type":"review","venue":"Frontiers in Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Neuroendocrine tumors; Head and neck; Medical physics; Positron emission tomography; Cancer; Lymphoma; PET-CT; Oncology; Nuclear medicine; Radiology; Internal medicine; Surgery","score_opus":0.14108765561707645,"score_gpt":0.47732202941009316,"score_spread":0.3362343737930167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318067179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007811032,0.9904891,0.00034946992,0.0006948511,0.001713407,0.0019864063,0.000019116374,0.0001176305,0.004551877],"genre_scores_gemma":[0.00005197313,0.9891196,0.005788853,0.00008948273,0.00032806478,0.00059628725,0.0007919863,0.000071479764,0.0031622772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99617755,0.00014263466,0.0022763403,0.0005866444,0.0004536857,0.00036317005],"domain_scores_gemma":[0.99763685,0.00015739312,0.0015363289,0.00046915948,0.000077472854,0.00012276933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015097213,0.00036573218,0.0034051368,0.0010131107,0.000049466995,0.0000087641565,0.00012965164,0.000072168834,0.00006957851],"category_scores_gemma":[0.002640825,0.00024655715,0.00022115631,0.0013437162,0.00014148757,0.00005032,0.000032848624,0.0006433196,0.000018952042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039083632,0.00011959069,0.0050671333,0.012402717,0.0004941363,0.0072381073,0.00017240961,0.000001012791,3.6609418e-7,0.00007813976,0.040851146,0.9335362],"study_design_scores_gemma":[0.0023707494,0.00017709112,0.00059419544,0.039984852,0.0018866047,0.00037966843,0.0009417941,0.000051033032,1.9225006e-7,0.00021560071,0.9532035,0.00019473578],"about_ca_topic_score_codex":0.00011075738,"about_ca_topic_score_gemma":0.000040527706,"teacher_disagreement_score":0.93334144,"about_ca_system_score_codex":0.0020884362,"about_ca_system_score_gemma":0.0011343472,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W4318301860","doi":"10.1016/j.jtho.2022.09.125","title":"OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Internal medicine; Oncology; Lung cancer; Placebo; Cancer; Erlotinib; Epidermal growth factor receptor; Pathology; Gefitinib","score_opus":0.02533324856646252,"score_gpt":0.4374827494442849,"score_spread":0.4121495008778224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318301860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847977,0.0011644018,0.000040293915,0.0070175473,0.0011711656,0.00069184636,0.00015560347,0.00007069966,0.00489072],"genre_scores_gemma":[0.9875875,0.0010124467,0.0010388087,0.00046986126,0.00034751237,0.000044827786,0.00023987975,0.00005547827,0.009203655],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99715644,0.00026576323,0.0012876792,0.00033518474,0.0003789702,0.00057594985],"domain_scores_gemma":[0.99760354,0.0002465076,0.0009495892,0.00030665644,0.00056860613,0.00032507852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087082054,0.00026139748,0.0008951766,0.0008132909,0.000105208,0.000024088346,0.00022432153,0.00027334376,0.00025177465],"category_scores_gemma":[0.00020493453,0.00020366709,0.00017706788,0.0014428699,0.00007311822,0.00015677523,0.00007643483,0.0007851358,0.000053420375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06627414,0.0057459865,0.12100875,0.0016123406,0.0043720286,0.050098218,0.026403971,0.012740641,0.15518034,0.000027918148,0.2824728,0.27406287],"study_design_scores_gemma":[0.056828413,0.013046102,0.61894196,0.0031066064,0.0057020206,0.0012192269,0.008725133,0.01785284,0.05594395,0.00016187869,0.21719305,0.0012788124],"about_ca_topic_score_codex":0.0006318878,"about_ca_topic_score_gemma":0.0007141151,"teacher_disagreement_score":0.4979332,"about_ca_system_score_codex":0.0013747535,"about_ca_system_score_gemma":0.0023232088,"threshold_uncertainty_score":0.8305303},"labels":[],"label_agreement":null},{"id":"W4318693852","doi":"10.1200/jco.22.02186","title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Medicine; Afatinib; Clinical endpoint; Internal medicine; Oncology; Osimertinib; Lung cancer; Hazard ratio; Cancer; Clinical trial; Stage (stratigraphy); Adenocarcinoma; Confidence interval; Erlotinib; Epidermal growth factor receptor","score_opus":0.10840297314600988,"score_gpt":0.5189698770640995,"score_spread":0.4105669039180896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318693852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675907,0.0008045755,0.00048213528,0.020850962,0.0043654903,0.004163289,0.00073682924,0.00005984211,0.0009462112],"genre_scores_gemma":[0.9824337,0.0024509123,0.0013908022,0.0029769707,0.0039458754,0.00032229314,0.0009439206,0.00006423175,0.00547129],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930717,0.0010559765,0.00457662,0.00039159227,0.0004511279,0.00045297926],"domain_scores_gemma":[0.9798626,0.014922036,0.0034084932,0.0003795526,0.0009883463,0.0004390093],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061268313,0.00026259877,0.0029442688,0.00016008575,0.00019268245,0.000030104457,0.00030833494,0.00042151785,0.0002928297],"category_scores_gemma":[0.008428186,0.00014294544,0.001101028,0.00049565727,0.00026284638,0.00009924053,0.00006753308,0.0009711326,0.000016350648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89708036,0.0018015526,0.0001590921,0.000017978185,0.0031869712,0.0004542609,0.0009144054,0.00012817595,0.00054941815,0.000009812089,0.07624538,0.019452568],"study_design_scores_gemma":[0.91358954,0.008790943,0.0010347838,0.00016186395,0.00575361,0.0000103001485,0.00043026646,0.007671444,0.0003718648,0.00010365823,0.06194002,0.0001416835],"about_ca_topic_score_codex":0.00089573325,"about_ca_topic_score_gemma":0.0002996278,"teacher_disagreement_score":0.019310886,"about_ca_system_score_codex":0.00030248906,"about_ca_system_score_gemma":0.0049660453,"threshold_uncertainty_score":0.99992424},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4318925936","doi":"10.1158/1078-0432.ccr-22-3484","title":"Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in <i>EGFR</i> -Mutant Lung Adenocarcinomas","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Combination therapy; Oncology; Gefitinib; Acquired resistance; Internal medicine; Epidermal growth factor receptor; Regimen; Afatinib; Pharmacology; Cancer; Erlotinib","score_opus":0.10603535078340894,"score_gpt":0.498558414973884,"score_spread":0.39252306419047506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318925936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790759,0.003226942,0.0000064189253,0.013213621,0.00012546462,0.0011514828,0.000053476662,0.000035292738,0.003111415],"genre_scores_gemma":[0.9945504,0.0014462852,0.00017687157,0.0004632243,0.00009669319,0.0002709085,0.00006594753,0.000027206039,0.002902478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750435,0.00022248703,0.00077835703,0.00055527396,0.0005511369,0.00038836928],"domain_scores_gemma":[0.9980011,0.00089433836,0.00011570776,0.00035797185,0.00032233188,0.0003085606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021308432,0.00011760357,0.00045931686,0.00027413055,0.000103054175,0.000030063638,0.000089003195,0.00011062132,0.00003259354],"category_scores_gemma":[0.0009899162,0.000104667684,0.00005392378,0.0009629838,0.0003828166,0.00008499939,0.00017467457,0.00027228275,0.000005449115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024325885,0.0004755354,0.9506709,0.0010135554,0.00020630365,0.0012282002,0.0017229948,0.0000037379687,0.0062512713,0.0013734462,0.016631832,0.017989611],"study_design_scores_gemma":[0.0045095338,0.000427278,0.98446465,0.0006741598,0.0000736505,0.000015243171,0.00019242801,0.00011694517,0.0010836052,0.0006880119,0.007643887,0.000110616544],"about_ca_topic_score_codex":0.00042262455,"about_ca_topic_score_gemma":0.00035667903,"teacher_disagreement_score":0.033793718,"about_ca_system_score_codex":0.000214113,"about_ca_system_score_gemma":0.00055926957,"threshold_uncertainty_score":0.42682245},"labels":[],"label_agreement":null},{"id":"W4319240035","doi":"10.1016/j.lungcan.2023.02.002","title":"Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Instituto de Salud Carlos III; Institut Du Cancer de Montréal; Sociedad Española de Oncología Médica; Terry Fox Foundation","keywords":"Medicine; Taxane; Chemotherapy; Internal medicine; Immunotherapy; Oncology; Lung cancer; Progression-free survival; Cancer; Surgery; Gastroenterology; Breast cancer","score_opus":0.007287272378358274,"score_gpt":0.3189931669307253,"score_spread":0.311705894552367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319240035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876469,0.0062724403,0.00005566144,0.0015339312,0.00052348187,0.002979551,0.0005431631,0.00014629854,0.00029856994],"genre_scores_gemma":[0.98193145,0.0034953132,0.00069624436,0.0011075087,0.00020370194,0.0049491315,0.00057672936,0.00014286919,0.0068970565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980784,0.000022087555,0.00040005014,0.00062837754,0.00033787484,0.00053318904],"domain_scores_gemma":[0.9989992,0.00005749649,0.00018280899,0.00048042735,0.00012651188,0.00015357044],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003965137,0.00046713487,0.00066396315,0.00018734367,0.000107331485,0.00003071402,0.000106200474,0.0001313438,0.0016286209],"category_scores_gemma":[0.0000025142324,0.00030572733,0.00014138689,0.00047039587,0.000042013042,0.00014536943,0.000025962614,0.00016188232,0.000014668139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002888605,0.00069622346,0.95904785,0.0001669872,0.00082135573,0.00004891261,0.0034937558,0.0013601144,0.00015114759,5.7370113e-7,0.00046526603,0.030859178],"study_design_scores_gemma":[0.037764635,0.00078124803,0.9505459,0.00094580906,0.0004314715,2.9215872e-7,0.000070132075,0.0018334154,0.0018173209,0.0000060904345,0.005412092,0.00039161576],"about_ca_topic_score_codex":0.0020781711,"about_ca_topic_score_gemma":0.0056563932,"teacher_disagreement_score":0.03487603,"about_ca_system_score_codex":0.0019725547,"about_ca_system_score_gemma":0.00048366617,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W4319337483","doi":"10.1016/s0140-6736(23)00221-0","title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Five Prime Therapeutics; AstraZeneca; Amgen","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Lung cancer; Cancer; Taxane; Progressive disease; Chemotherapy; Breast cancer","score_opus":0.0813253911151174,"score_gpt":0.41939133726729505,"score_spread":0.33806594615217767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319337483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715325,0.0009001064,0.00047596343,0.0056913756,0.0006416482,0.013858143,0.00032890064,0.00020560533,0.006365745],"genre_scores_gemma":[0.9509923,0.0008340577,0.0017901846,0.0011822695,0.0032061022,0.018053982,0.001558257,0.00013385812,0.022249024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988057,0.0000497362,0.00024963755,0.00031405437,0.00018297935,0.0003978838],"domain_scores_gemma":[0.99883944,0.00029926363,0.00015455503,0.00045420765,0.00014141387,0.00011111942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029160097,0.00020864254,0.00060596067,0.00005818728,0.00024860862,0.0001026551,0.00025276552,0.00005587701,0.00011254941],"category_scores_gemma":[0.00005460923,0.00011890477,0.00006705392,0.0004053674,0.00005144598,0.00010041198,0.000037508817,0.00011003376,0.000029406978],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9052442,0.0011661542,0.0006401457,0.00040978502,0.0020311754,0.00012226161,0.0029114876,0.00014193436,0.00083237444,0.00009636719,0.08123653,0.0051676007],"study_design_scores_gemma":[0.9788359,0.0029622961,0.00016296358,0.00018525792,0.0027985224,0.000007764187,0.00021839417,0.0024059499,0.00092269666,0.000025713232,0.011294654,0.00017990253],"about_ca_topic_score_codex":0.000355505,"about_ca_topic_score_gemma":0.00020582745,"teacher_disagreement_score":0.0735917,"about_ca_system_score_codex":0.00016531786,"about_ca_system_score_gemma":0.0004876779,"threshold_uncertainty_score":0.48487958},"labels":[],"label_agreement":null},{"id":"W4319454669","doi":"10.21037/pcm-22-39","title":"The role of concurrent amplification of PD-L1, PD-L2 and JAK2 in metastatic lung adenocarcinoma as a biomarker of immune checkpoint inhibitor response: a case report","year":2023,"lang":"en","type":"article","venue":"Precision Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"PD-L1; Biomarker; Adenocarcinoma; Cancer research; Immune checkpoint; Immune system; Immunotherapy; Lung cancer; Medicine; Oncology; Immunology; Cancer; Internal medicine; Biology; Genetics","score_opus":0.03174351883292337,"score_gpt":0.3968917742011644,"score_spread":0.365148255368241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319454669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573046,0.038524885,0.00007870418,0.0024576038,0.00028949554,0.0010574434,0.00005745379,0.000016819524,0.00021300233],"genre_scores_gemma":[0.99727285,0.0018562346,0.000113523834,0.000019713738,0.000041886065,0.0002363674,0.00005102303,0.00002022828,0.0003881457],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975921,0.00015264202,0.0012502185,0.00030362484,0.0005128893,0.0001885564],"domain_scores_gemma":[0.99751484,0.0008923459,0.0006508357,0.00047124785,0.00036246123,0.00010826195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016635626,0.00016218005,0.00057821925,0.00035527276,0.00006092331,0.0000040201057,0.00007753015,0.00005184274,0.00011445669],"category_scores_gemma":[0.0013491672,0.000100140736,0.000082581566,0.0009041081,0.00030541726,0.00005591964,0.00006521603,0.00011633407,0.0000015343796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013360135,0.00068099325,0.0850617,0.0014174298,0.0013925661,0.0037813664,0.023275888,0.000038269383,0.5550524,0.00035393317,0.0026158565,0.31296948],"study_design_scores_gemma":[0.012552289,0.0018052368,0.8631744,0.0047752806,0.0017449424,0.004664574,0.013597942,0.0041690525,0.08754414,0.00085897924,0.004864977,0.0002481885],"about_ca_topic_score_codex":0.003066412,"about_ca_topic_score_gemma":0.00014497351,"teacher_disagreement_score":0.7781127,"about_ca_system_score_codex":0.00016623917,"about_ca_system_score_gemma":0.00043750598,"threshold_uncertainty_score":0.46355182},"labels":[],"label_agreement":null},{"id":"W4319460408","doi":"10.1007/s11523-023-00947-9","title":"Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"erratum","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Mutant; Cancer; Cancer research; Neuroscience; Internal medicine; Epidermal growth factor receptor; Erlotinib; Biology; Gene","score_opus":0.026562778920250763,"score_gpt":0.37817529279251416,"score_spread":0.3516125138722634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460408","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012273633,0.537187,0.004022492,0.011482408,0.39627492,0.021924715,0.0030229578,0.0012803426,0.012531544],"genre_scores_gemma":[0.61970097,0.1508675,0.0020783674,0.0027711333,0.057306632,0.023855463,0.006530271,0.001290509,0.13559915],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753165,0.00015047453,0.0004643577,0.00090662134,0.00027140902,0.0006755023],"domain_scores_gemma":[0.9982737,0.00036818287,0.00035862532,0.00033762676,0.00037526453,0.00028662937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001736527,0.0005435926,0.0010010058,0.00032041632,0.00027110815,0.00007038152,0.00014382905,0.0003979332,0.00006476051],"category_scores_gemma":[0.000056063483,0.00042323399,0.00023136534,0.00037378178,0.000073294716,0.00009210152,0.00004339095,0.0008041242,0.000015215674],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020778836,0.00088180247,0.00027154834,0.005109618,0.002800504,0.00017278233,0.02083995,0.00049240934,0.0007919188,0.0005805481,0.9035972,0.06238388],"study_design_scores_gemma":[0.0062486096,0.01052486,0.011598554,0.007958312,0.01535363,0.00012162727,0.10751449,0.008267138,0.0004027641,0.000037064223,0.8306818,0.0012911252],"about_ca_topic_score_codex":0.0008037427,"about_ca_topic_score_gemma":0.0007309281,"teacher_disagreement_score":0.6074273,"about_ca_system_score_codex":0.0030081512,"about_ca_system_score_gemma":0.0036881315,"threshold_uncertainty_score":0.99982196},"labels":[],"label_agreement":null},{"id":"W4319461436","doi":"10.1016/j.cllc.2023.01.009","title":"A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Helsinn; Eisai; National Comprehensive Cancer Network; Apollomics; BeiGene; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lung cancer; KRAS; Retrospective cohort study; Oncology; Internal medicine; Cancer","score_opus":0.03211703283370258,"score_gpt":0.439156164387392,"score_spread":0.4070391315536894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319461436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98362565,0.0057858373,0.000026067692,0.0017751835,0.002185875,0.003899262,0.0004917617,0.00013184686,0.0020784924],"genre_scores_gemma":[0.9515986,0.036255762,0.0002972353,0.004761337,0.00063759484,0.0011054474,0.00021127374,0.000113262104,0.0050194864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99597204,0.0001581136,0.0018613258,0.00086793146,0.00061277545,0.00052782166],"domain_scores_gemma":[0.9966675,0.00053540803,0.00085178594,0.0007045938,0.0007977286,0.00044297028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074338005,0.0003925786,0.0017536172,0.00010012938,0.00009907053,0.000015391823,0.00020349477,0.00023473136,0.00090101577],"category_scores_gemma":[0.00052642036,0.0002551094,0.0007026513,0.0005759014,0.0003028343,0.00012232804,0.00011629996,0.00061999355,0.00003972674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035731238,0.0008987728,0.97349465,0.0029917175,0.0015801905,0.00003797045,0.0001805618,0.0000064323012,0.0000021312965,0.0000049242535,0.01808108,0.0023642802],"study_design_scores_gemma":[0.009414587,0.00053037616,0.9729557,0.010060173,0.003909441,3.4852988e-7,0.000037281552,0.000564111,0.000023378592,0.0000028459503,0.0022243017,0.00027742214],"about_ca_topic_score_codex":0.0006364279,"about_ca_topic_score_gemma":0.0004974632,"teacher_disagreement_score":0.032027073,"about_ca_system_score_codex":0.00038608868,"about_ca_system_score_gemma":0.00082872156,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W4319758837","doi":"10.1016/j.cllc.2023.02.003","title":"Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Liquid biopsy; Precision medicine; ROS1; Targeted therapy; Genotyping; Oncology; Profiling (computer programming); Biopsy; Companion diagnostic; Internal medicine; Bioinformatics; Intensive care medicine; Pathology; Cancer; Gene; Adenocarcinoma; Genotype","score_opus":0.09745426049707119,"score_gpt":0.5102924480330977,"score_spread":0.4128381875360265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319758837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930951,0.00009866521,0.0008006407,0.0020566548,0.00044530557,0.0030748746,0.00007224786,0.0001343426,0.00022216693],"genre_scores_gemma":[0.9517958,0.00005290724,0.042984724,0.0038359214,0.0001411225,0.00047344013,0.0001604965,0.000094355586,0.00046119757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673414,0.00009843717,0.0013667904,0.00094640435,0.00038980652,0.00046442528],"domain_scores_gemma":[0.9966663,0.0015338312,0.0002591549,0.0005769897,0.00036577182,0.00059791416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041828802,0.00030645943,0.00083165086,0.00025445368,0.00012423248,0.00006239774,0.00012749134,0.0001465262,0.000013580997],"category_scores_gemma":[0.00396149,0.00022271722,0.0001253711,0.0011254521,0.00007263447,0.00012078382,0.00012605079,0.00020772534,0.000008339935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069122564,0.0004707661,0.8765866,0.000019356708,0.00023939152,0.00043565064,0.0000503073,0.0062255845,0.00004364884,0.0000022354752,0.00029201002,0.1149432],"study_design_scores_gemma":[0.009937861,0.001733913,0.9803079,0.00096002634,0.00063592853,0.0000045999113,0.000022743741,0.0033700864,0.00022001966,0.0000057864795,0.0025277059,0.00027345124],"about_ca_topic_score_codex":0.0006275775,"about_ca_topic_score_gemma":0.0003508568,"teacher_disagreement_score":0.11466975,"about_ca_system_score_codex":0.00055309193,"about_ca_system_score_gemma":0.0009346673,"threshold_uncertainty_score":0.90821445},"labels":[],"label_agreement":null},{"id":"W4319783108","doi":"10.1016/b978-0-12-822833-3.00002-4","title":"Historical development of EGFR-targeted therapy","year":2023,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Alberta; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Epidermal growth factor receptor; Tyrosine kinase; Lung cancer; Cancer research; Protein kinase domain; Targeted therapy; EGFR inhibitors; Drug development; Cancer; Oncology; Pharmacology; Drug; Internal medicine; Biology; Receptor","score_opus":0.03494992990411973,"score_gpt":0.30043776515267806,"score_spread":0.26548783524855835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319783108","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017505675,0.003429368,0.0000044524254,0.0001411183,0.0005134753,0.0006884004,0.000013925957,0.00010054595,0.99493366],"genre_scores_gemma":[0.0005558823,0.0002511171,0.0015292265,0.0001378313,0.00017655248,0.00007819728,0.00008336653,0.00010070446,0.9970871],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870324,0.000006470533,0.00048100672,0.00028746625,0.0003501837,0.0001716266],"domain_scores_gemma":[0.99918735,0.000031808093,0.00020071772,0.00032423157,0.00013653762,0.000119370845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079420905,0.0002692144,0.00058754365,0.00018253141,0.00006530358,0.00000468487,0.00007867178,0.00020397166,0.00023305503],"category_scores_gemma":[0.000007628444,0.00021134168,0.00021111601,0.000017109323,0.000038975984,0.0000097524835,0.00003105606,0.00019956238,0.00014923365],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047595637,0.000031123545,0.000039066665,0.0000989352,0.00076778466,0.00004530512,0.0009878551,7.4357914e-8,0.00009622234,0.00075337227,0.00095346384,0.9961792],"study_design_scores_gemma":[0.0009721941,0.00014000988,0.0004339164,0.00039742218,0.0002563852,0.0000067241517,0.0000074819013,2.6222853e-7,0.0003232561,0.0008329051,0.9964471,0.00018233949],"about_ca_topic_score_codex":0.0000016660227,"about_ca_topic_score_gemma":0.000010992,"teacher_disagreement_score":0.99599683,"about_ca_system_score_codex":0.0008937615,"about_ca_system_score_gemma":0.00074155006,"threshold_uncertainty_score":0.8618264},"labels":[],"label_agreement":null},{"id":"W4320075825","doi":"10.15173/sciential.vi8.2967","title":"Non-Small Cell Lung Carcinoma – A Brief Review and Discussion","year":2022,"lang":"en","type":"review","venue":"Sciential - McMaster Undergraduate Science Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Lung cancer; Radiation therapy; Medicine; Chemoradiotherapy; Lung; Small Cell Lung Carcinoma; Oncology; Stage (stratigraphy); Carcinoma; Cancer; Treatment of lung cancer; Chemotherapy; Radiology; Lung cancer screening; Intensive care medicine; Internal medicine; Small-cell carcinoma; Biology","score_opus":0.03217071137535256,"score_gpt":0.3453062727070355,"score_spread":0.31313556133168297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320075825","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032435448,0.9869748,0.00014712194,0.0020569721,0.0016081211,0.001676557,0.000033757267,0.00002386978,0.0074463845],"genre_scores_gemma":[0.0001297516,0.9824937,0.0006928917,0.0005267478,0.0002648249,0.000070425405,0.00003888117,0.000051721618,0.015731052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99566096,0.00011642352,0.00091136957,0.001039942,0.001426413,0.00084486936],"domain_scores_gemma":[0.99758875,0.000033700486,0.0007778564,0.000509536,0.00018916938,0.00090097403],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015778397,0.0005357286,0.0014927955,0.0007970171,0.0019244548,0.0006332056,0.00067804474,0.000087745095,0.0011117021],"category_scores_gemma":[0.00005752031,0.00029599032,0.0005761713,0.0022883439,0.0006663202,0.000552403,0.000570793,0.00097199704,0.000029886594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000099207955,0.0002601955,0.00014993525,0.027398251,0.00014938287,0.00026941887,0.00035191973,0.0000010246728,0.000016392281,0.000038739534,0.009689868,0.961665],"study_design_scores_gemma":[0.0009518233,0.00032047697,0.000068774156,0.014744653,0.007144946,0.0034481008,0.000092624134,0.0000394789,0.0000028775826,0.000068452784,0.97271776,0.00040003323],"about_ca_topic_score_codex":0.000021079586,"about_ca_topic_score_gemma":0.0000039653173,"teacher_disagreement_score":0.9630279,"about_ca_system_score_codex":0.0009537967,"about_ca_system_score_gemma":0.0047173966,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W4321254002","doi":"10.1016/j.jval.2023.02.007","title":"Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Merck KGaA","keywords":"Lung cancer; EQ-5D; Medicine; Quality of life (healthcare); Cancer; Baseline (sea); Internal medicine; Oncology; Health related quality of life; Political science","score_opus":0.031775053334926036,"score_gpt":0.3563054454033183,"score_spread":0.3245303920683923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321254002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997021,0.0006926905,0.00008444565,0.0007167996,0.00012377123,0.0010882561,0.000090503745,0.000033514985,0.00014897219],"genre_scores_gemma":[0.99819106,0.00035849304,0.0008499285,0.00026297732,0.000021369151,0.000092452305,0.00014519224,0.00002013141,0.000058372112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981821,0.00012289928,0.00062384683,0.00034791772,0.00028749817,0.00043569694],"domain_scores_gemma":[0.9990869,0.00009323084,0.0002884943,0.00028725967,0.00007406154,0.00017005025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062639435,0.00013497005,0.0006673956,0.000801285,0.000056299843,0.000005925158,0.00005942637,0.000042031308,0.000021040458],"category_scores_gemma":[0.000026507741,0.00011611141,0.000069094494,0.0027330134,0.000019843274,0.000051770134,0.000024566029,0.00017125605,0.0000012700515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007726496,0.00032186633,0.97267807,0.0009418111,0.0002197469,0.0000058504206,0.004231183,0.016626887,0.0000022567433,0.00000926693,0.00005091038,0.0048348894],"study_design_scores_gemma":[0.0028241228,0.00031849463,0.9761602,0.00080014643,0.00022992295,9.0964356e-8,0.00027895873,0.019232275,0.000017573271,0.000003801562,0.000057452533,0.00007695988],"about_ca_topic_score_codex":0.07517583,"about_ca_topic_score_gemma":0.004333124,"teacher_disagreement_score":0.070842706,"about_ca_system_score_codex":0.00091074454,"about_ca_system_score_gemma":0.0011964012,"threshold_uncertainty_score":0.93098265},"labels":[],"label_agreement":null},{"id":"W4321490951","doi":"10.1007/s41669-023-00396-0","title":"Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network; Hôpital Charles-Le Moyne; William Osler Health System","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Adjuvant; Lung cancer; Oncology; Internal medicine; Quality of life (healthcare); Disease; Cost effectiveness; Quality-adjusted life year; Cancer; Epidermal growth factor receptor","score_opus":0.040697525512166634,"score_gpt":0.4178555083762873,"score_spread":0.37715798286412067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321490951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908214,0.00011728427,0.000025671827,0.00006968183,0.00013546039,0.005958301,0.00033489586,0.000009507105,0.0025277743],"genre_scores_gemma":[0.99784106,0.000044701053,0.00009234561,0.000055871933,0.000015100706,0.0012260727,0.00062835956,0.000027653508,0.00006881492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988881,0.00016731882,0.000333683,0.0002591303,0.00019035743,0.00016142041],"domain_scores_gemma":[0.99874735,0.00016948581,0.00025216385,0.00015043738,0.0006147727,0.00006578083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007992501,0.00012642135,0.00035257367,0.00018464979,0.000035767407,0.0000133044705,0.00012393082,0.000033956603,0.00015967873],"category_scores_gemma":[0.000025674131,0.00011179106,0.000037191523,0.00030492202,0.000030399022,0.0001945671,0.000063580876,0.00007907526,0.000007847606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00394994,0.0011495892,0.9150576,0.0005506785,0.0013260365,0.0000081672615,0.0031444659,0.04968358,0.0063344226,0.000021523638,0.00038973114,0.01838427],"study_design_scores_gemma":[0.02452762,0.00027973307,0.8614466,0.00039509276,0.0013206784,3.0597516e-7,0.00014170891,0.032163594,0.07955601,0.000027119442,0.000019686557,0.00012183793],"about_ca_topic_score_codex":0.0023865816,"about_ca_topic_score_gemma":0.0002427065,"teacher_disagreement_score":0.07322159,"about_ca_system_score_codex":0.00066737086,"about_ca_system_score_gemma":0.0008628453,"threshold_uncertainty_score":0.4558707},"labels":[],"label_agreement":null},{"id":"W4322213257","doi":"10.14740/wjon1554","title":"Long-Term Responders to Erlotinib for Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor: Two Case Reports and a Single-Institutional Retrospective Study","year":2023,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Erlotinib; Epidermal growth factor receptor; Pulmonary adenocarcinoma; Oncology; Term (time); Internal medicine; Retrospective cohort study; Erlotinib Hydrochloride; Adenocarcinoma; Epidermal growth factor; Receptor; Cancer","score_opus":0.04206330271812381,"score_gpt":0.3784135378587796,"score_spread":0.3363502351406558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322213257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936211,0.00031672453,0.000103937804,0.0037188209,0.0006601105,0.0011097265,0.000022230352,0.00002745632,0.0004198913],"genre_scores_gemma":[0.99658793,0.00001717566,0.0015921479,0.0003021436,0.00040558894,0.000039687402,0.000019544477,0.0000251308,0.0010106326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862754,0.00008283398,0.0004973274,0.00028390277,0.0002502162,0.0002581678],"domain_scores_gemma":[0.9985106,0.00018465496,0.000362578,0.00014059353,0.0005206399,0.00028090848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003537877,0.00016310796,0.00048756704,0.0005467612,0.00020347083,0.000019034122,0.00003859269,0.00004478083,0.00005758637],"category_scores_gemma":[0.0002370807,0.000120210796,0.00007836087,0.000563566,0.00010342641,0.00014212298,0.000033657165,0.00021735304,0.000003697389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004733149,0.0009662377,0.8536339,0.000033349803,0.00075742323,0.12966084,0.0022500844,0.00002902122,0.00066761207,0.00006064417,0.001915009,0.005292753],"study_design_scores_gemma":[0.00527982,0.014465276,0.87179494,0.00013118403,0.00073407847,0.103574015,0.0011083641,0.000006720099,0.00009554276,0.00007538512,0.0025920083,0.00014269663],"about_ca_topic_score_codex":0.0000454661,"about_ca_topic_score_gemma":0.0006394371,"teacher_disagreement_score":0.026086837,"about_ca_system_score_codex":0.0008440973,"about_ca_system_score_gemma":0.0008309758,"threshold_uncertainty_score":0.4902054},"labels":[],"label_agreement":null},{"id":"W4322500492","doi":"10.1038/s41467-023-35962-x","title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":173,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; AstraZeneca","keywords":"Osimertinib; T790M; Lung cancer; Discontinuation; Medicine; Epidermal growth factor receptor; Oncology; Resistance mutation; Internal medicine; Tyrosine-kinase inhibitor; Cancer research; Chemotherapy; Cancer; Biology; Erlotinib; Gene; Gefitinib; Genetics; Polymerase chain reaction","score_opus":0.012054768902415264,"score_gpt":0.33082742314618996,"score_spread":0.3187726542437747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322500492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889215,0.0014422713,0.00014819166,0.0058072708,0.00013199521,0.0021156978,0.0006149476,0.000060347287,0.00075777946],"genre_scores_gemma":[0.9922981,0.00017701008,0.004208477,0.0005578359,0.000014257237,0.0005960743,0.0016996136,0.000023171584,0.00042544832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889517,0.00009014892,0.0003314521,0.00024288154,0.00025669995,0.00018367171],"domain_scores_gemma":[0.9975665,0.00038441026,0.00018260823,0.0014972293,0.00029632018,0.00007293358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116644376,0.00014109768,0.00035140122,0.00026360122,0.00016145344,0.000013464262,0.00048300019,0.000119211465,0.000034184395],"category_scores_gemma":[0.000085619686,0.00009478593,0.000099797486,0.0032236148,0.000044867094,0.000054059183,0.000115639894,0.00021360547,0.000004256007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03491687,0.0038432775,0.89232904,0.0001087634,0.011386863,0.000011420631,0.023668908,0.0077496488,0.0067647914,0.0012952107,0.012823042,0.0051021655],"study_design_scores_gemma":[0.026149696,0.00018944002,0.9641745,0.00023246255,0.004154035,2.2047297e-8,0.00061005517,0.0013200262,0.00078711065,0.000043661337,0.002166839,0.00017215325],"about_ca_topic_score_codex":0.0005408294,"about_ca_topic_score_gemma":0.014088389,"teacher_disagreement_score":0.07184546,"about_ca_system_score_codex":0.00020575424,"about_ca_system_score_gemma":0.00021591177,"threshold_uncertainty_score":0.7861652},"labels":[],"label_agreement":null},{"id":"W4323294773","doi":"10.2217/fon-2022-1059","title":"TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i> -positive non-small-cell lung cancer and other solid tumors","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Internal medicine; Oncology; Cancer; Brain metastasis; Clinical trial; Interim analysis; Clinical endpoint; Adverse effect; Adenocarcinoma; Metastasis","score_opus":0.012321025614561127,"score_gpt":0.38565660284578784,"score_spread":0.37333557723122673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323294773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856531,0.0006182887,0.0000026059595,0.0014038685,0.0004937877,0.0012234439,0.00019234717,0.000037797483,0.01037475],"genre_scores_gemma":[0.9969651,0.00007608483,0.00009014524,0.00071024173,0.0003652173,0.0002846941,0.00003039988,0.000019847283,0.0014582608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990245,0.000045403696,0.00026415268,0.00030005796,0.000108682725,0.00025716826],"domain_scores_gemma":[0.9995396,0.000037323156,0.00012061282,0.0001439854,0.000061850944,0.00009658729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009036444,0.0001585293,0.00045845925,0.00011214892,0.00011523836,0.000004043103,0.000053616397,0.000114914445,0.00008859535],"category_scores_gemma":[0.000009471501,0.00012814229,0.00004394662,0.0005052108,0.00005233266,0.000029854158,0.000075822274,0.00014441098,0.000003436623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038145124,0.024214752,0.74335486,0.0004183714,0.0017282311,0.002197044,0.12446934,0.00013373898,0.0059827105,0.00019027953,0.025196964,0.06829922],"study_design_scores_gemma":[0.16571291,0.0747557,0.56235194,0.00066178123,0.004105554,0.00030196234,0.0921715,0.0012095978,0.0037894044,0.00008254082,0.09392966,0.0009274471],"about_ca_topic_score_codex":0.0014958347,"about_ca_topic_score_gemma":0.00412924,"teacher_disagreement_score":0.18100289,"about_ca_system_score_codex":0.0003687603,"about_ca_system_score_gemma":0.00040052543,"threshold_uncertainty_score":0.5225491},"labels":[],"label_agreement":null},{"id":"W4327703589","doi":"10.1016/j.ctarc.2023.100696","title":"Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre","year":2023,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill Genome Centre; McGill University; McGill University Health Centre","funders":"","keywords":"KRAS; Lung cancer; Medicine; Cancer; Oncology; Internal medicine; Cohort; Clinical trial; Targeted therapy; Bioinformatics; Biology; Colorectal cancer","score_opus":0.1813665434080559,"score_gpt":0.46875777750188424,"score_spread":0.28739123409382833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327703589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8364461,0.13885057,0.000008448507,0.019921416,0.00014953934,0.0021788138,0.00057638553,0.00007955767,0.0017891374],"genre_scores_gemma":[0.8297531,0.15084688,0.00038583708,0.00012867738,0.0001506915,0.002179166,0.0008887784,0.000038813832,0.01562804],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836975,0.00018184389,0.00031783385,0.00035533408,0.00029166974,0.0004835613],"domain_scores_gemma":[0.9979862,0.00015330817,0.00012650152,0.0009108995,0.00054977706,0.00027332746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017382183,0.00019622063,0.00035280417,0.0002992042,0.0010017214,0.000046613102,0.0001950426,0.00008122659,0.00015261577],"category_scores_gemma":[0.000012227322,0.00015408262,0.00009668258,0.0007746599,0.00023029034,0.00010546515,0.00020706607,0.0001909083,0.000009744326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025942226,0.0010314399,0.38240916,0.002624905,0.0024380113,0.000026727266,0.17996767,0.0012490521,0.07028847,0.00048834604,0.05212499,0.30709183],"study_design_scores_gemma":[0.037047543,0.0033790495,0.22016408,0.008794902,0.005379732,0.000022864182,0.11833707,0.077562094,0.112853356,0.00007972495,0.41414934,0.0022302284],"about_ca_topic_score_codex":0.17844066,"about_ca_topic_score_gemma":0.28081518,"teacher_disagreement_score":0.36202437,"about_ca_system_score_codex":0.0062086927,"about_ca_system_score_gemma":0.004051687,"threshold_uncertainty_score":0.9976063},"labels":[],"label_agreement":null},{"id":"W4327935238","doi":"10.1055/s-0043-1760904","title":"Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA","year":2023,"lang":"en","type":"article","venue":"Pneumologie","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Internal medicine; Gynecology; Oncology; Adenocarcinoma; Cancer","score_opus":0.030512046612090157,"score_gpt":0.3286023584391381,"score_spread":0.2980903118270479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327935238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401504,0.00009557993,0.000002189525,0.0017479999,0.0001773356,0.00088006945,0.0005120607,0.00031601827,0.0022536952],"genre_scores_gemma":[0.99253947,0.00011998325,0.00011480859,0.00047491185,0.000040862,0.000092480564,0.004472791,0.000037376292,0.002107339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998378,0.000074125965,0.00034240278,0.0004730468,0.00033280277,0.00039965552],"domain_scores_gemma":[0.9989741,0.00017771307,0.000115172785,0.00047226707,0.00014422405,0.00011652781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011179838,0.00020559023,0.00031916573,0.00019083222,0.00007819614,0.000019621422,0.000121323385,0.000102324644,0.00020720653],"category_scores_gemma":[0.00022297635,0.00013678175,0.000044590266,0.0007355413,0.000064984786,0.000088755194,0.000048805872,0.00020387229,0.00024743716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013286009,0.001219636,0.93632174,0.000015510283,0.0006647061,0.0009901482,0.0024265263,0.00012818776,0.0035103557,0.000035060337,0.0060030827,0.035399016],"study_design_scores_gemma":[0.015246001,0.0017774866,0.9776438,0.00008902411,0.000058085327,0.0000010100867,0.00022815868,0.000052319912,0.001737496,0.000108255714,0.0028921927,0.00016616186],"about_ca_topic_score_codex":0.0022706063,"about_ca_topic_score_gemma":0.00019900357,"teacher_disagreement_score":0.041322045,"about_ca_system_score_codex":0.00016389176,"about_ca_system_score_gemma":0.00024789223,"threshold_uncertainty_score":0.5577798},"labels":[],"label_agreement":null},{"id":"W4328053701","doi":"10.1016/j.jtho.2023.03.016","title":"Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Ignyta; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; EMD Serono; Foundation Medicine; Galecto; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; Jazz Pharmaceuticals; Merck KGaA; Revolution Medicines; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Agenzia Italiana del Farmaco, Ministero della Salute; PharmaMar; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Open label; Exon; Cohort; Oncology; Internal medicine; Cancer research; Clinical trial; Gene; Genetics","score_opus":0.08658018113189056,"score_gpt":0.5278038491763837,"score_spread":0.4412236680444931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328053701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891481,0.00049153116,0.00010080724,0.003174956,0.0017972201,0.002562219,0.000049168368,0.000046351666,0.002629662],"genre_scores_gemma":[0.98852783,0.0006687183,0.0061691916,0.0002894841,0.0007700083,0.00030663848,0.00011980876,0.000057902696,0.0030904054],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975103,0.0002871289,0.0011117874,0.0003291994,0.0003242188,0.00043736753],"domain_scores_gemma":[0.99802786,0.0004064523,0.0007088704,0.00026911253,0.00028984682,0.00029787046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007164503,0.00026697095,0.00097536005,0.000679782,0.0001370038,0.000064617656,0.0002273093,0.00018086846,0.0001473541],"category_scores_gemma":[0.0003806358,0.00020708694,0.00016673461,0.00064818515,0.000081598766,0.00040195318,0.00007184137,0.0003609287,0.000079676494],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20799783,0.041067287,0.04335821,0.0001706984,0.0050417176,0.017365633,0.00889174,0.0003065861,0.01037385,0.00006218303,0.004407038,0.6609572],"study_design_scores_gemma":[0.80107516,0.05596287,0.034308784,0.0013624928,0.00824916,0.0015404418,0.0061975433,0.006356949,0.0031054618,0.00025979057,0.08082802,0.00075335946],"about_ca_topic_score_codex":0.00026818257,"about_ca_topic_score_gemma":0.00020454229,"teacher_disagreement_score":0.6602039,"about_ca_system_score_codex":0.0016647921,"about_ca_system_score_gemma":0.0012624821,"threshold_uncertainty_score":0.84447604},"labels":[],"label_agreement":null},{"id":"W4353095460","doi":"10.1016/j.lungcan.2023.107176","title":"Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Internazionale di Ricerca in Medicina Onlus","keywords":"Medicine; Presentation (obstetrics); Adenocarcinoma; Pooled analysis; Internal medicine; Lung; Oncology; General surgery; Meta-analysis; Surgery; Cancer","score_opus":0.06036838018464324,"score_gpt":0.45720151292088185,"score_spread":0.3968331327362386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353095460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049804248,0.947004,0.000007509674,0.000053002706,0.0003718627,0.0018179844,0.0008376549,0.000013124579,0.000090608824],"genre_scores_gemma":[0.10720677,0.8902658,0.00009123285,0.000041347826,0.00007407883,0.00020467464,0.0007862255,0.00005785104,0.0012719725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980644,0.000118029944,0.0010111702,0.00031199565,0.0003686699,0.00012576376],"domain_scores_gemma":[0.9976957,0.00026916506,0.0011068251,0.0004683632,0.00039304953,0.00006689772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012270332,0.00020526502,0.0018367837,0.00030129583,0.000025830626,0.000008924423,0.00011976814,0.00012138427,0.00009857339],"category_scores_gemma":[0.00017601035,0.0001092523,0.00047503476,0.001529994,0.00012355695,0.00006255057,0.00006998087,0.00013939796,2.6851941e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101285084,0.00016224492,0.9506719,0.01171441,0.016714234,0.0000035505082,0.00014341362,0.000004799861,5.54431e-8,0.000009886965,0.0006098651,0.01986435],"study_design_scores_gemma":[0.0013999509,0.00024987588,0.84040296,0.0051280544,0.14616436,0.0000014230802,0.000034354434,0.000060034046,6.9833703e-7,0.0000010927942,0.006445453,0.00011175808],"about_ca_topic_score_codex":0.0009585802,"about_ca_topic_score_gemma":0.000245412,"teacher_disagreement_score":0.12945011,"about_ca_system_score_codex":0.00014253045,"about_ca_system_score_gemma":0.00045588976,"threshold_uncertainty_score":0.44551796},"labels":[],"label_agreement":null},{"id":"W4360790490","doi":"10.3747/co.v17is1.615","title":"Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Royal Victoria Hospital","funders":"","keywords":"Medicine; Erlotinib; Bevacizumab; Targeted therapy; Oncology; Lung cancer; Maintenance therapy; Regimen; Disease; Chemotherapy; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.07191913498699157,"score_gpt":0.4479779822861797,"score_spread":0.37605884729918815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360790490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941595,0.001903951,0.00009430022,0.0010733753,0.0010818961,0.0013528534,0.00016668165,0.000018745875,0.00014868083],"genre_scores_gemma":[0.9975693,0.0007458517,0.00027067913,0.000035697492,0.00009342766,0.0009435674,0.0000939302,0.000014259524,0.00023325636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942064,0.00002762275,0.00015139229,0.00013896564,0.000098025856,0.00016334477],"domain_scores_gemma":[0.99922144,0.0003077054,0.00014575875,0.00011343221,0.0001620523,0.000049628572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005998175,0.00011611654,0.0003006793,0.000038960174,0.00008751979,0.0000014706206,0.000045192668,0.000038370537,0.00012170847],"category_scores_gemma":[0.0000319485,0.000057392546,0.000097002536,0.00009569677,0.000118077514,0.000024925428,0.000004574442,0.000067976594,0.000002107054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013556782,0.012118512,0.6153439,0.00010057673,0.007826702,0.000015903177,0.011104689,0.000065410044,0.0050526513,0.00060609187,0.0010827706,0.34532705],"study_design_scores_gemma":[0.023284236,0.010383052,0.7076688,0.000113845475,0.0069406466,0.000021797861,0.0013473079,0.00059992843,0.0033551995,0.00016108913,0.2459286,0.00019549885],"about_ca_topic_score_codex":0.000079981626,"about_ca_topic_score_gemma":0.000995719,"teacher_disagreement_score":0.34513158,"about_ca_system_score_codex":0.0002659135,"about_ca_system_score_gemma":0.00043740124,"threshold_uncertainty_score":0.23404},"labels":[],"label_agreement":null},{"id":"W4361187438","doi":"10.1158/1078-0432.c.6489322","title":"Data from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Confidence interval; Oncology; Hazard ratio; Head and neck cancer; Immunotherapy; Cancer; Nivolumab","score_opus":0.0908087730992378,"score_gpt":0.365827563669915,"score_spread":0.2750187905706772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361187438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859695,0.0013901363,0.00006489917,0.00071468815,0.00023187135,0.0025152618,0.008535896,0.000065667395,0.00051209744],"genre_scores_gemma":[0.9811604,0.0002539364,0.0054167635,0.00003428075,0.00012781439,0.00045145763,0.008338761,0.000071696835,0.004144885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974377,0.00011111327,0.00063408184,0.0010276038,0.00051055505,0.0002789197],"domain_scores_gemma":[0.9980372,0.0005193098,0.00026745212,0.0008235425,0.00012223322,0.00023022562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012805178,0.00046702632,0.0010184642,0.0002477903,0.000052679203,0.00004459178,0.00016305466,0.000086492706,0.00041459614],"category_scores_gemma":[0.0001043064,0.000273524,0.000059153488,0.00018457558,0.00011377387,0.00008698776,0.00033616717,0.00020726392,0.000010897689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10898112,0.02402451,0.6960548,0.01674391,0.014300547,0.02642252,0.06465273,0.0023519169,0.00037132093,0.00037853688,0.0050049694,0.04071308],"study_design_scores_gemma":[0.09415873,0.019887118,0.8329774,0.0023675014,0.011968928,0.00037791094,0.010988444,0.023567403,0.00037492168,0.00086092716,0.0012529396,0.0012177819],"about_ca_topic_score_codex":0.034858003,"about_ca_topic_score_gemma":0.02856628,"teacher_disagreement_score":0.13692255,"about_ca_system_score_codex":0.000386751,"about_ca_system_score_gemma":0.0023759361,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W4361216129","doi":"10.3390/curroncol30040283","title":"Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Concomitant; Medicine; Oral cavity; Basal cell; Head and neck cancer; Oral mucosa; Head and neck; Cancer; Carcinoma; Oncology; Pathology; Dermatology; Internal medicine; Surgery; Dentistry","score_opus":0.07864328662383319,"score_gpt":0.4359373814029732,"score_spread":0.35729409477914004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361216129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021539528,0.9937834,3.205178e-7,0.0008370367,0.001883932,0.0026323171,0.00022009226,0.000026532914,0.0005948121],"genre_scores_gemma":[0.000018159248,0.9977414,0.000027553951,0.00020287637,0.00024296495,0.0003646575,0.000476107,0.0000501145,0.0008761537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805164,0.00032647917,0.0007378735,0.00042338835,0.00020548316,0.00025510992],"domain_scores_gemma":[0.998314,0.00029943927,0.0005786075,0.00050997344,0.00016541203,0.00013252159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021903368,0.00038068643,0.0023489073,0.00012252756,0.00006340672,0.00002681138,0.00018550351,0.00024022213,0.00004777613],"category_scores_gemma":[0.00007705602,0.00020532074,0.000508649,0.00051895354,0.00015355612,0.00006480229,0.00018529696,0.00062439346,0.000023944742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000061223,0.00018279838,0.000041507545,0.2927242,0.00006538551,0.00006370059,0.00022538511,3.7573935e-9,1.0726818e-7,0.00004021661,0.011287002,0.6953636],"study_design_scores_gemma":[0.0006913633,0.00027039356,0.00003877814,0.29388532,0.0039474876,0.00021830031,0.000040119994,1.6914359e-7,2.4951703e-7,0.000016893553,0.70077765,0.000113288326],"about_ca_topic_score_codex":0.0000040517925,"about_ca_topic_score_gemma":0.0000032646467,"teacher_disagreement_score":0.6952503,"about_ca_system_score_codex":0.00058506354,"about_ca_system_score_gemma":0.0020029077,"threshold_uncertainty_score":0.8372737},"labels":[],"label_agreement":null},{"id":"W4361813749","doi":"10.1158/1078-0432.c.6531302.v1","title":"Data from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Medicine; Lung cancer; Internal medicine; Placebo; Population; Oncology; Confidence interval; Adjuvant; Cancer; Adenocarcinoma; Pathology; Alternative medicine; Environmental health","score_opus":0.11691099722231521,"score_gpt":0.43172597993785583,"score_spread":0.31481498271554065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361813749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045370173,0.55190635,0.0028205775,0.011541415,0.0032600649,0.09502391,0.2737596,0.0009202241,0.015397719],"genre_scores_gemma":[0.00898144,0.6156919,0.048105653,0.0007846948,0.0013506863,0.032356188,0.21599257,0.0004999671,0.07623693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964016,0.00014225674,0.0010744429,0.0015016262,0.0004301938,0.00044988087],"domain_scores_gemma":[0.9956119,0.0005079851,0.00071221666,0.0020316283,0.00094294245,0.00019329961],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025334617,0.0006430128,0.0020374013,0.0001834554,0.000095719624,0.000038044524,0.00046084536,0.00029551532,0.00027252384],"category_scores_gemma":[0.00015711426,0.00043807077,0.00034326367,0.00061725505,0.000076021635,0.000064608634,0.000503156,0.00022870161,0.000009638682],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005165613,0.0065379418,0.011661323,0.0451366,0.021919694,0.00042838918,0.004431565,0.0001183938,0.0012108901,0.000037493457,0.8755078,0.027844327],"study_design_scores_gemma":[0.063115984,0.009370889,0.010237747,0.08747882,0.097575106,0.000015621446,0.0026223422,0.03137957,0.013602489,0.00022094167,0.68078667,0.0035938297],"about_ca_topic_score_codex":0.031861093,"about_ca_topic_score_gemma":0.008461572,"teacher_disagreement_score":0.19472112,"about_ca_system_score_codex":0.00076820503,"about_ca_system_score_gemma":0.0070684412,"threshold_uncertainty_score":0.9998071},"labels":[],"label_agreement":null},{"id":"W4361813933","doi":"10.1158/1078-0432.c.6531302","title":"Data from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Lung cancer; Confidence interval; Oncology; Placebo; Population; Adjuvant; Cancer; Family medicine; Adenocarcinoma; Pathology; Alternative medicine; Environmental health","score_opus":0.11691099722231521,"score_gpt":0.43172597993785583,"score_spread":0.31481498271554065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361813933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045370173,0.55190635,0.0028205775,0.011541415,0.0032600649,0.09502391,0.2737596,0.0009202241,0.015397719],"genre_scores_gemma":[0.00898144,0.6156919,0.048105653,0.0007846948,0.0013506863,0.032356188,0.21599257,0.0004999671,0.07623693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964016,0.00014225674,0.0010744429,0.0015016262,0.0004301938,0.00044988087],"domain_scores_gemma":[0.9956119,0.0005079851,0.00071221666,0.0020316283,0.00094294245,0.00019329961],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025334617,0.0006430128,0.0020374013,0.0001834554,0.000095719624,0.000038044524,0.00046084536,0.00029551532,0.00027252384],"category_scores_gemma":[0.00015711426,0.00043807077,0.00034326367,0.00061725505,0.000076021635,0.000064608634,0.000503156,0.00022870161,0.000009638682],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005165613,0.0065379418,0.011661323,0.0451366,0.021919694,0.00042838918,0.004431565,0.0001183938,0.0012108901,0.000037493457,0.8755078,0.027844327],"study_design_scores_gemma":[0.063115984,0.009370889,0.010237747,0.08747882,0.097575106,0.000015621446,0.0026223422,0.03137957,0.013602489,0.00022094167,0.68078667,0.0035938297],"about_ca_topic_score_codex":0.031861093,"about_ca_topic_score_gemma":0.008461572,"teacher_disagreement_score":0.19472112,"about_ca_system_score_codex":0.00076820503,"about_ca_system_score_gemma":0.0070684412,"threshold_uncertainty_score":0.9998071},"labels":[],"label_agreement":null},{"id":"W4361823294","doi":"10.1158/0008-5472.c.6513130.v1","title":"Data from Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of British Columbia; Public Health Ontario; University of Toronto","funders":"National Center for Advancing Translational Sciences; Medical Research Council; Canadian Institutes of Health Research; Canadian Cancer Society Research Institute; National Institutes of Health; Medical Research and Materiel Command; Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología; Herlev Hospital; Princess Margaret Hospital Foundation; Universidad de Oviedo; Vanderbilt University; Moffitt Cancer Center; Norges Forskningsråd; Vanderbilt University Medical Center; Cancer Care Ontario; National Center for Research Resources; Georgia Clinical and Translational Science Alliance; National Cancer Institute; Sundhed og Sygdom, Det Frie Forskningsråd; Centre International de Recherche sur le Cancer; World Health Organization; Roy Castle Lung Cancer Foundation; U.S. Department of Defense","keywords":"Lung cancer; Medicine; Confidence interval; Context (archaeology); Decile; Internal medicine; Absolute risk reduction; National Lung Screening Trial; Oncology; Lung cancer screening; Demography; Statistics; Mathematics; Biology","score_opus":0.10274258615334463,"score_gpt":0.4278260905999775,"score_spread":0.32508350444663286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361823294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57299733,0.00909832,0.26282868,0.004271021,0.005448386,0.0047641923,0.118083715,0.0021948053,0.020313583],"genre_scores_gemma":[0.9353373,0.0032502385,0.032869708,0.0011152617,0.0010675765,0.00060614443,0.015625233,0.00026908264,0.009859466],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997315,0.00010063837,0.00043119577,0.001269484,0.00051480957,0.00036885662],"domain_scores_gemma":[0.9966748,0.00026760032,0.00036639214,0.002375556,0.00009111308,0.00022459048],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024211373,0.00043697344,0.0006005339,0.00023072788,0.00020739638,0.00012209314,0.000406734,0.00031840027,0.0007021104],"category_scores_gemma":[0.00011042515,0.000349649,0.0002264072,0.00014995683,0.000043994587,0.000117245545,0.0004185874,0.0010429854,0.00006935516],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043804376,0.0009654312,0.095284864,0.00058677467,0.007732361,0.0001597792,0.0009807798,0.7528866,0.00013878675,0.000017310207,0.123350196,0.017459072],"study_design_scores_gemma":[0.0019268747,0.000028756145,0.0956589,0.0008070415,0.005907833,3.5297884e-7,0.00006889831,0.89471334,0.000024718618,0.00028355687,0.00027047232,0.00030923384],"about_ca_topic_score_codex":0.05058293,"about_ca_topic_score_gemma":0.0064342865,"teacher_disagreement_score":0.36233997,"about_ca_system_score_codex":0.000828124,"about_ca_system_score_gemma":0.0028180436,"threshold_uncertainty_score":0.9998956},"labels":[],"label_agreement":null},{"id":"W4361840354","doi":"10.1158/0008-5472.22429852.v1","title":"Supplementary Data from Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Downregulation and upregulation; Resistance (ecology); EGFR inhibitors; Cancer research; Chemistry; Medicine; Internal medicine; Cancer; Biology; Epidermal growth factor receptor; Biochemistry; Gene","score_opus":0.048693557796176165,"score_gpt":0.36069795316215136,"score_spread":0.3120043953659752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361840354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93843263,0.0012485987,0.0013991835,0.004822717,0.0008396556,0.0034507534,0.048853062,0.00011604161,0.00083737855],"genre_scores_gemma":[0.87360585,0.00013987045,0.016835872,0.00004252501,0.00017058401,0.000093180715,0.10809638,0.000046196932,0.00096952316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773693,0.00006868705,0.000898858,0.0006527775,0.00045248243,0.00019025108],"domain_scores_gemma":[0.9977753,0.00023368176,0.00041909926,0.0013131404,0.00018119205,0.000077566874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002556613,0.00024820608,0.0006794262,0.0002527089,0.000019820462,0.000009363039,0.00029095224,0.00021092809,0.00090617104],"category_scores_gemma":[0.00012685967,0.0002129195,0.000084180814,0.00029123892,0.000086950735,0.00008728767,0.0006096017,0.00023546643,0.000009745538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042047463,0.0058893994,0.84279794,0.009022207,0.009053279,0.00038118585,0.011852764,0.00044271027,0.039143745,0.00073370116,0.07014887,0.0063294843],"study_design_scores_gemma":[0.023399057,0.0008701522,0.8376625,0.013432972,0.005684654,0.0000039428014,0.0020445152,0.0069937217,0.08034904,0.02035483,0.007826472,0.0013781427],"about_ca_topic_score_codex":0.018221706,"about_ca_topic_score_gemma":0.022120936,"teacher_disagreement_score":0.06482675,"about_ca_system_score_codex":0.00023151579,"about_ca_system_score_gemma":0.00048276936,"threshold_uncertainty_score":0.99572283},"labels":[],"label_agreement":null},{"id":"W4361840370","doi":"10.1158/0008-5472.22429852","title":"Supplementary Data from Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Downregulation and upregulation; Resistance (ecology); EGFR inhibitors; Business; Cancer research; Chemistry; Medicine; Internal medicine; Cancer; Epidermal growth factor receptor; Biology; Biochemistry; Gene","score_opus":0.048693557796176165,"score_gpt":0.36069795316215136,"score_spread":0.3120043953659752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361840370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93843263,0.0012485987,0.0013991835,0.004822717,0.0008396556,0.0034507534,0.048853062,0.00011604161,0.00083737855],"genre_scores_gemma":[0.87360585,0.00013987045,0.016835872,0.00004252501,0.00017058401,0.000093180715,0.10809638,0.000046196932,0.00096952316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773693,0.00006868705,0.000898858,0.0006527775,0.00045248243,0.00019025108],"domain_scores_gemma":[0.9977753,0.00023368176,0.00041909926,0.0013131404,0.00018119205,0.000077566874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002556613,0.00024820608,0.0006794262,0.0002527089,0.000019820462,0.000009363039,0.00029095224,0.00021092809,0.00090617104],"category_scores_gemma":[0.00012685967,0.0002129195,0.000084180814,0.00029123892,0.000086950735,0.00008728767,0.0006096017,0.00023546643,0.000009745538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042047463,0.0058893994,0.84279794,0.009022207,0.009053279,0.00038118585,0.011852764,0.00044271027,0.039143745,0.00073370116,0.07014887,0.0063294843],"study_design_scores_gemma":[0.023399057,0.0008701522,0.8376625,0.013432972,0.005684654,0.0000039428014,0.0020445152,0.0069937217,0.08034904,0.02035483,0.007826472,0.0013781427],"about_ca_topic_score_codex":0.018221706,"about_ca_topic_score_gemma":0.022120936,"teacher_disagreement_score":0.06482675,"about_ca_system_score_codex":0.00023151579,"about_ca_system_score_gemma":0.00048276936,"threshold_uncertainty_score":0.99572283},"labels":[],"label_agreement":null},{"id":"W4361884574","doi":"10.1158/1078-0432.22457748","title":"Supplemental Table 2 from Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Consortium canadien en neurodégénérescence associée au vieillissement","keywords":"Erlotinib; Stage (stratigraphy); Downregulation and upregulation; Lung cancer; Oncology; Medicine; Internal medicine; Cancer research; Cancer; Biology; Epidermal growth factor receptor; Gene","score_opus":0.021995124234254985,"score_gpt":0.32526549329099586,"score_spread":0.3032703690567409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361884574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780161,0.00034445737,0.0011133906,0.00011013829,0.0003674616,0.0030276852,0.016924651,0.00006290629,0.000033215503],"genre_scores_gemma":[0.98061705,0.000108196655,0.002923327,0.000066195455,0.0000351741,0.0007026557,0.01525396,0.00004642704,0.00024702167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984526,0.000065324064,0.0005076072,0.0004377087,0.00028567103,0.00025105715],"domain_scores_gemma":[0.99914265,0.0001478493,0.0002485215,0.00017324042,0.00020180673,0.00008593228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011748046,0.00022989635,0.00044174134,0.00022348134,0.0000869696,0.000026459667,0.00005662919,0.00013030201,0.00023056702],"category_scores_gemma":[0.000014070455,0.00020869325,0.00008291351,0.00012336647,0.000032297525,0.00007548949,0.00013347427,0.00016853976,7.4691616e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039067143,0.00087123836,0.98410046,0.00020853704,0.0005358367,0.0000023278005,0.0044437237,0.003114962,0.0010692223,0.000005953811,0.0015034068,0.00023760328],"study_design_scores_gemma":[0.01767489,0.00074022135,0.9569498,0.00026045987,0.00021153178,6.7970085e-8,0.0005715701,0.02028742,0.0027598226,0.00006998679,0.0003070378,0.00016721502],"about_ca_topic_score_codex":0.0072749094,"about_ca_topic_score_gemma":0.000536237,"teacher_disagreement_score":0.027150696,"about_ca_system_score_codex":0.00031236847,"about_ca_system_score_gemma":0.0003051663,"threshold_uncertainty_score":0.9993357},"labels":[],"label_agreement":null},{"id":"W4361884593","doi":"10.1158/1078-0432.22457751","title":"Supplemental Table 1 from Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Consortium canadien en neurodégénérescence associée au vieillissement","keywords":"Cetuximab; Stage (stratigraphy); Downregulation and upregulation; Lung cancer; Oncology; Medicine; Table (database); Table of contents; Cancer; Internal medicine; Computer science; Data mining; Biology; Colorectal cancer","score_opus":0.02276052364282938,"score_gpt":0.3258786945702772,"score_spread":0.3031181709274478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361884593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776317,0.000339068,0.0011368704,0.00011066363,0.00036527368,0.0030320294,0.01728905,0.00006290229,0.000032483567],"genre_scores_gemma":[0.98060524,0.00010548292,0.00298729,0.00006619341,0.000034673645,0.0007160683,0.015192303,0.00004649157,0.00024623427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845237,0.000065345674,0.00050738506,0.00043802903,0.00028574074,0.0002511474],"domain_scores_gemma":[0.99914014,0.00014991745,0.00024818178,0.0001735652,0.0002022451,0.00008594431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001181099,0.00022996773,0.00044163584,0.00022362423,0.00008696338,0.000026403726,0.000056659974,0.00013030127,0.00023488757],"category_scores_gemma":[0.000014238244,0.00020875987,0.00008292917,0.00012346015,0.00003229796,0.000075439035,0.00013349259,0.00016857764,7.5477817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039088936,0.0008673833,0.9841193,0.00020572862,0.0005332912,0.0000022564975,0.0044190204,0.0030857509,0.0011013624,0.0000058255305,0.0015210169,0.00023019894],"study_design_scores_gemma":[0.017497327,0.00073746796,0.9570716,0.0002626972,0.000211527,6.758191e-8,0.0005752671,0.02034622,0.0027667757,0.00006920008,0.0002948931,0.00016696227],"about_ca_topic_score_codex":0.0072045582,"about_ca_topic_score_gemma":0.0005331585,"teacher_disagreement_score":0.027047679,"about_ca_system_score_codex":0.00031228116,"about_ca_system_score_gemma":0.0003064975,"threshold_uncertainty_score":0.9994066},"labels":[],"label_agreement":null},{"id":"W4361885992","doi":"10.1158/1078-0432.22463994","title":"Sup. Figure 3: Foretinib and nintedanib inhibited the TRK-A in the kinase inhibition profile assay. from Foretinib Overcomes Entrectinib Resistance Associated with the &lt;i&gt;NTRK1&lt;/i&gt; G667C Mutation in &lt;i&gt;NTRK1&lt;/i&gt; Fusion–Positive Tumor Cells in a Brain Metastasis Model","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trk receptor; Kinase; IC50; Chemistry; Tropomyosin receptor kinase A; Nintedanib; Chromatography; Medicine; Biochemistry; Receptor; In vitro; Internal medicine","score_opus":0.015677769995890614,"score_gpt":0.2700662318363204,"score_spread":0.2543884618404298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361885992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475924,0.0022163864,0.0010418254,0.023378303,0.00029052838,0.012137873,0.006968523,0.00035064967,0.006023536],"genre_scores_gemma":[0.97609884,0.00045420075,0.0012125823,0.0021608463,0.00018474931,0.004197373,0.010053367,0.00026290215,0.0053751613],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99013513,0.0025029692,0.0019384056,0.0021779812,0.0018894791,0.0013560072],"domain_scores_gemma":[0.9908874,0.0053075836,0.0013551601,0.001443103,0.0007302821,0.00027649148],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003611522,0.0014789159,0.0018311092,0.0010058114,0.00063674944,0.00045030098,0.0006481463,0.0007868802,0.00030398622],"category_scores_gemma":[0.0018773444,0.00087553775,0.0004966685,0.0025137772,0.0006864114,0.00043508384,0.00053735194,0.0020552862,0.000033877724],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023663575,0.014939945,0.013140399,0.0030419372,0.011174129,0.00911969,0.3712704,0.05421651,0.13403808,0.04963477,0.3047319,0.011028683],"study_design_scores_gemma":[0.1023681,0.004252277,0.36790717,0.038563132,0.013762649,0.000301196,0.046415504,0.31096536,0.04033631,0.050606295,0.015031172,0.009490819],"about_ca_topic_score_codex":0.001011007,"about_ca_topic_score_gemma":0.060870312,"teacher_disagreement_score":0.3547668,"about_ca_system_score_codex":0.0017703656,"about_ca_system_score_gemma":0.0013217196,"threshold_uncertainty_score":0.99979603},"labels":[],"label_agreement":null},{"id":"W4361916408","doi":"10.1158/1078-0432.22457748.v1","title":"Supplemental Table 2 from Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Consortium canadien en neurodégénérescence associée au vieillissement","keywords":"Erlotinib; Downregulation and upregulation; Lung cancer; Stage (stratigraphy); Oncology; Medicine; Table (database); Internal medicine; Cancer research; Cancer; Computer science; Biology; Data mining; Epidermal growth factor receptor; Gene","score_opus":0.021995124234254985,"score_gpt":0.32526549329099586,"score_spread":0.3032703690567409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361916408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780161,0.00034445737,0.0011133906,0.00011013829,0.0003674616,0.0030276852,0.016924651,0.00006290629,0.000033215503],"genre_scores_gemma":[0.98061705,0.000108196655,0.002923327,0.000066195455,0.0000351741,0.0007026557,0.01525396,0.00004642704,0.00024702167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984526,0.000065324064,0.0005076072,0.0004377087,0.00028567103,0.00025105715],"domain_scores_gemma":[0.99914265,0.0001478493,0.0002485215,0.00017324042,0.00020180673,0.00008593228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011748046,0.00022989635,0.00044174134,0.00022348134,0.0000869696,0.000026459667,0.00005662919,0.00013030201,0.00023056702],"category_scores_gemma":[0.000014070455,0.00020869325,0.00008291351,0.00012336647,0.000032297525,0.00007548949,0.00013347427,0.00016853976,7.4691616e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039067143,0.00087123836,0.98410046,0.00020853704,0.0005358367,0.0000023278005,0.0044437237,0.003114962,0.0010692223,0.000005953811,0.0015034068,0.00023760328],"study_design_scores_gemma":[0.01767489,0.00074022135,0.9569498,0.00026045987,0.00021153178,6.7970085e-8,0.0005715701,0.02028742,0.0027598226,0.00006998679,0.0003070378,0.00016721502],"about_ca_topic_score_codex":0.0072749094,"about_ca_topic_score_gemma":0.000536237,"teacher_disagreement_score":0.027150696,"about_ca_system_score_codex":0.00031236847,"about_ca_system_score_gemma":0.0003051663,"threshold_uncertainty_score":0.9993357},"labels":[],"label_agreement":null},{"id":"W4361916461","doi":"10.1158/1078-0432.22457751.v1","title":"Supplemental Table 1 from Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Consortium canadien en neurodégénérescence associée au vieillissement","keywords":"Cetuximab; Downregulation and upregulation; Stage (stratigraphy); Lung cancer; Oncology; Medicine; Table (database); Internal medicine; Cancer research; Cancer; Computer science; Biology; Data mining; Colorectal cancer","score_opus":0.02276052364282938,"score_gpt":0.3258786945702772,"score_spread":0.3031181709274478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361916461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776317,0.000339068,0.0011368704,0.00011066363,0.00036527368,0.0030320294,0.01728905,0.00006290229,0.000032483567],"genre_scores_gemma":[0.98060524,0.00010548292,0.00298729,0.00006619341,0.000034673645,0.0007160683,0.015192303,0.00004649157,0.00024623427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845237,0.000065345674,0.00050738506,0.00043802903,0.00028574074,0.0002511474],"domain_scores_gemma":[0.99914014,0.00014991745,0.00024818178,0.0001735652,0.0002022451,0.00008594431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001181099,0.00022996773,0.00044163584,0.00022362423,0.00008696338,0.000026403726,0.000056659974,0.00013030127,0.00023488757],"category_scores_gemma":[0.000014238244,0.00020875987,0.00008292917,0.00012346015,0.00003229796,0.000075439035,0.00013349259,0.00016857764,7.5477817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039088936,0.0008673833,0.9841193,0.00020572862,0.0005332912,0.0000022564975,0.0044190204,0.0030857509,0.0011013624,0.0000058255305,0.0015210169,0.00023019894],"study_design_scores_gemma":[0.017497327,0.00073746796,0.9570716,0.0002626972,0.000211527,6.758191e-8,0.0005752671,0.02034622,0.0027667757,0.00006920008,0.0002948931,0.00016696227],"about_ca_topic_score_codex":0.0072045582,"about_ca_topic_score_gemma":0.0005331585,"teacher_disagreement_score":0.027047679,"about_ca_system_score_codex":0.00031228116,"about_ca_system_score_gemma":0.0003064975,"threshold_uncertainty_score":0.9994066},"labels":[],"label_agreement":null},{"id":"W4361922624","doi":"10.1158/1078-0432.22463994.v1","title":"Sup. Figure 3: Foretinib and nintedanib inhibited the TRK-A in the kinase inhibition profile assay. from Foretinib Overcomes Entrectinib Resistance Associated with the &lt;i&gt;NTRK1&lt;/i&gt; G667C Mutation in &lt;i&gt;NTRK1&lt;/i&gt; Fusion–Positive Tumor Cells in a Brain Metastasis Model","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trk receptor; Kinase; Chemistry; Tropomyosin receptor kinase A; IC50; Chromatography; Biochemistry; In vitro; Receptor","score_opus":0.015677769995890614,"score_gpt":0.2700662318363204,"score_spread":0.2543884618404298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361922624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475924,0.0022163864,0.0010418254,0.023378303,0.00029052838,0.012137873,0.006968523,0.00035064967,0.006023536],"genre_scores_gemma":[0.97609884,0.00045420075,0.0012125823,0.0021608463,0.00018474931,0.004197373,0.010053367,0.00026290215,0.0053751613],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99013513,0.0025029692,0.0019384056,0.0021779812,0.0018894791,0.0013560072],"domain_scores_gemma":[0.9908874,0.0053075836,0.0013551601,0.001443103,0.0007302821,0.00027649148],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003611522,0.0014789159,0.0018311092,0.0010058114,0.00063674944,0.00045030098,0.0006481463,0.0007868802,0.00030398622],"category_scores_gemma":[0.0018773444,0.00087553775,0.0004966685,0.0025137772,0.0006864114,0.00043508384,0.00053735194,0.0020552862,0.000033877724],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023663575,0.014939945,0.013140399,0.0030419372,0.011174129,0.00911969,0.3712704,0.05421651,0.13403808,0.04963477,0.3047319,0.011028683],"study_design_scores_gemma":[0.1023681,0.004252277,0.36790717,0.038563132,0.013762649,0.000301196,0.046415504,0.31096536,0.04033631,0.050606295,0.015031172,0.009490819],"about_ca_topic_score_codex":0.001011007,"about_ca_topic_score_gemma":0.060870312,"teacher_disagreement_score":0.3547668,"about_ca_system_score_codex":0.0017703656,"about_ca_system_score_gemma":0.0013217196,"threshold_uncertainty_score":0.99979603},"labels":[],"label_agreement":null},{"id":"W4361938797","doi":"10.1158/1078-0432.22479515.v1","title":"Supplementary Methods from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutant Cancers","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Memorial Sloan-Kettering Cancer Center","keywords":"Mutant; Gene isoform; PI3K/AKT/mTOR pathway; Cancer research; Chemistry; Internal medicine; Biology; Medicine; Apoptosis; Gene; Biochemistry","score_opus":0.02429356914993505,"score_gpt":0.3817978954849942,"score_spread":0.35750432633505913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361938797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978581,0.00012248721,0.00091957423,0.00017625884,0.00073250156,0.0061139613,0.012809954,0.00012116193,0.00042310974],"genre_scores_gemma":[0.9646784,0.00006547851,0.014907569,0.00018060219,0.0001898172,0.0012285452,0.018355982,0.00015126358,0.00024232714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99555814,0.00039626186,0.0011250703,0.0013734961,0.0009485458,0.0005984898],"domain_scores_gemma":[0.9973003,0.0002111125,0.00053023803,0.001105937,0.00050180755,0.00035060078],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004623813,0.00073020655,0.001391381,0.00068027,0.0001219814,0.00004189357,0.00029176325,0.00025295332,0.0011305653],"category_scores_gemma":[0.000057778663,0.00055992027,0.00016189853,0.00068993215,0.00012305289,0.0001923881,0.00035098015,0.0005899717,0.0000054691955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017278276,0.06362407,0.7504447,0.00086180656,0.019846858,0.0005522781,0.06958302,0.004010246,0.0088571515,0.00017084823,0.019396342,0.04537437],"study_design_scores_gemma":[0.15829515,0.047627512,0.7364401,0.002214381,0.011562606,0.0000046744744,0.017029589,0.0026018461,0.015451592,0.0014650889,0.0046313526,0.0026760777],"about_ca_topic_score_codex":0.034522455,"about_ca_topic_score_gemma":0.047457498,"teacher_disagreement_score":0.14101687,"about_ca_system_score_codex":0.002388164,"about_ca_system_score_gemma":0.001880999,"threshold_uncertainty_score":0.99978256},"labels":[],"label_agreement":null},{"id":"W4361956700","doi":"10.1158/1078-0432.c.6529943.v1","title":"Data from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Microsemi (Canada)","funders":"Genentech","keywords":"KRAS; Cancer research; Adenocarcinoma; Biology; Phenotype; Population; Druggability; Lung cancer; Cancer; Medicine; Oncology; Genetics; Colorectal cancer; Gene","score_opus":0.08816581398416727,"score_gpt":0.383100957652029,"score_spread":0.2949351436678617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361956700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98537475,0.0022918684,0.0010076817,0.0034227378,0.00046685364,0.0011577666,0.0058742897,0.00012227496,0.00028180602],"genre_scores_gemma":[0.98380536,0.00012236949,0.002817544,0.0004945836,0.0002503992,0.00027316387,0.011350385,0.00004216794,0.00084402296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980468,0.00006955049,0.00042340334,0.0009312972,0.00031183223,0.00021709212],"domain_scores_gemma":[0.9988109,0.00011670739,0.00006273877,0.00076849683,0.00008074795,0.00016044993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021965457,0.0002493489,0.00041899443,0.00024949454,0.00006885001,0.00008846778,0.000113917136,0.00013386035,0.00021297774],"category_scores_gemma":[0.00008276841,0.00022273074,0.00006872639,0.00012174343,0.00006094337,0.0001452118,0.00043348045,0.0003278587,0.00004094977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009878817,0.00075458793,0.9503496,0.0021514616,0.0016836334,0.0010072509,0.006425155,0.00054476626,0.0067400085,0.00095985143,0.027822103,0.00057367876],"study_design_scores_gemma":[0.0014240068,0.00007266229,0.9913265,0.0006519639,0.00051615876,0.000017827293,0.0007071612,0.0009770453,0.0009726524,0.002706749,0.00038627227,0.00024099073],"about_ca_topic_score_codex":0.008988029,"about_ca_topic_score_gemma":0.02085202,"teacher_disagreement_score":0.04097689,"about_ca_system_score_codex":0.0002849323,"about_ca_system_score_gemma":0.00028384864,"threshold_uncertainty_score":0.9976112},"labels":[],"label_agreement":null},{"id":"W4362459260","doi":"10.2217/fon-2022-1035","title":"Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called <i>MET</i> exon 14 skipping","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Lung cancer; Exon; Cancer; Targeted therapy; Oncology; Cancer research; Internal medicine; Mutation; Exon skipping; Genetics; Gene; Biology","score_opus":0.017210099592399008,"score_gpt":0.35186459170477435,"score_spread":0.33465449211237536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362459260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928282,0.001343538,0.00008969786,0.00060014444,0.0005526705,0.0014716088,0.00012919033,0.000020332898,0.0029646098],"genre_scores_gemma":[0.98682183,0.00020914924,0.008076736,0.00014289796,0.00026742008,0.0006367548,0.00015385746,0.00003151734,0.003659817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911267,0.000035386285,0.000373107,0.00017276888,0.00011254711,0.00019351943],"domain_scores_gemma":[0.9992211,0.00014802883,0.00027633962,0.00019959843,0.00010735115,0.000047568952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012841875,0.0001264353,0.00045035887,0.00009637374,0.000049192782,0.0000011573561,0.00008257796,0.00012019529,0.00003315499],"category_scores_gemma":[0.000018445277,0.00008057006,0.00013846689,0.0002643557,0.000040579103,0.00001192693,0.000036779435,0.00005990599,0.00000105628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003591282,0.0041402774,0.13869873,0.0052192006,0.0047547077,0.00013161627,0.22785406,0.0003654018,0.34416437,0.0002890464,0.02028648,0.25050482],"study_design_scores_gemma":[0.045916386,0.0063030636,0.30105144,0.0017390045,0.0050670025,0.000027365215,0.031615604,0.00058280217,0.4092046,0.00003101548,0.1978823,0.0005794164],"about_ca_topic_score_codex":0.00025921923,"about_ca_topic_score_gemma":0.0019362058,"teacher_disagreement_score":0.24992542,"about_ca_system_score_codex":0.00037011874,"about_ca_system_score_gemma":0.0014363324,"threshold_uncertainty_score":0.32855517},"labels":[],"label_agreement":null},{"id":"W4362473272","doi":"10.3390/cancers15072096","title":"Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"American Association for Cancer Research","keywords":"KRAS; STK11; Medicine; Stage (stratigraphy); Cancer; Database; Internal medicine; Oncology; Lung cancer; Biology; Colorectal cancer","score_opus":0.03947225731470985,"score_gpt":0.35680610025369,"score_spread":0.31733384293898015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362473272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977399,0.0011183745,0.000013325832,0.00024332176,0.00006754833,0.0002810316,0.0000701282,0.000009423751,0.00045691442],"genre_scores_gemma":[0.999308,0.0003482456,0.00012901587,0.00008920757,0.000013866134,0.000013023495,0.00006298416,0.0000035493713,0.000032114156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996468,0.0000137721045,0.000059355516,0.00011302774,0.000097228134,0.00006984701],"domain_scores_gemma":[0.9998092,0.000016039063,0.000024197374,0.00007327998,0.000039200164,0.000038079943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001364502,0.000039738115,0.00007716302,0.00006283629,0.000038888873,0.0000039413258,0.000013251517,0.000011369406,0.000014160097],"category_scores_gemma":[0.000026532533,0.00003582531,0.000009041752,0.00008614647,0.000039973896,0.0000642575,0.00005844535,0.00003522403,9.548472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012591352,0.000016546712,0.9746343,0.00013531723,0.000066745764,0.000012769798,0.0034208153,0.00015021865,0.0012561611,0.00003895032,0.00090799364,0.019234275],"study_design_scores_gemma":[0.0037306407,0.000013921038,0.96695447,0.00012043519,0.00030050467,0.0000020007171,0.0011127922,0.027193831,0.00019291679,0.00007646586,0.00025651316,0.000045499095],"about_ca_topic_score_codex":0.0017728647,"about_ca_topic_score_gemma":0.0004155395,"teacher_disagreement_score":0.027043613,"about_ca_system_score_codex":0.00047149384,"about_ca_system_score_gemma":0.00014517774,"threshold_uncertainty_score":0.2680053},"labels":[],"label_agreement":null},{"id":"W4362557395","doi":"10.3389/fonc.2023.1146053","title":"Is cancer stage data missing completely at random? A report from a large population-based cohort of non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Stage (stratigraphy); Cancer; Medicine; Lung cancer; Population; Oncology; Cohort; Internal medicine; Biology; Environmental health","score_opus":0.03756743624318103,"score_gpt":0.3961366286066293,"score_spread":0.35856919236344825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362557395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764695,0.0041012303,0.0068167727,0.0028005803,0.0022125863,0.0016356494,0.0038841674,0.000069035195,0.0020104507],"genre_scores_gemma":[0.96727717,0.0004493917,0.01459192,0.0014167939,0.00024001047,0.00047590642,0.008668977,0.00006290785,0.0068169343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832606,0.00006804065,0.0005361494,0.0005173016,0.00021565617,0.0003367736],"domain_scores_gemma":[0.99869746,0.00014403266,0.00033142965,0.0006308321,0.00008588636,0.00011037671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029845288,0.00016662019,0.00070286694,0.00021985911,0.00009619937,0.000007024116,0.00016626861,0.000151711,0.00055443344],"category_scores_gemma":[0.00006192977,0.00015326773,0.00007779298,0.00036427862,0.00004944178,0.000057465786,0.00009948596,0.00014607485,0.000003827656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046402833,0.00016884546,0.8836328,0.00014182307,0.00031483208,0.00041623798,0.0007380042,0.00038220745,0.00028425755,5.160896e-7,0.11103403,0.0024224548],"study_design_scores_gemma":[0.013262262,0.00008024631,0.8236844,0.00019496125,0.0010152677,0.0000039059905,0.00026023976,0.09090535,0.00033311086,0.000019504745,0.070069216,0.00017150889],"about_ca_topic_score_codex":0.025694434,"about_ca_topic_score_gemma":0.004694316,"teacher_disagreement_score":0.090523146,"about_ca_system_score_codex":0.0014044907,"about_ca_system_score_gemma":0.0012899492,"threshold_uncertainty_score":0.98079354},"labels":[],"label_agreement":null},{"id":"W4362566265","doi":"10.1007/174_2023_383","title":"Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation","year":2023,"lang":"en","type":"book-chapter","venue":"Medical radiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Randomized controlled trial; Interpretation (philosophy); Presentation (obstetrics); Medicine; Clinical trial; Medical physics; Drug development; Engineering ethics; Intensive care medicine; Computer science; Engineering; Drug; Pathology; Surgery; Pharmacology","score_opus":0.11707602682352904,"score_gpt":0.48573468478681153,"score_spread":0.3686586579632825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362566265","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004026608,0.03625854,0.5743947,0.050360627,0.008569397,0.02358969,0.00025807042,0.0008486278,0.3016937],"genre_scores_gemma":[0.1627238,0.07772647,0.0047889287,0.0076321405,0.003653966,0.0016472889,0.005964744,0.00030901493,0.7355536],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948902,0.0020673955,0.0019307819,0.0005339303,0.00037836144,0.00019933014],"domain_scores_gemma":[0.9838421,0.015064902,0.00046330207,0.00023409483,0.00009208438,0.0003035508],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011223688,0.00024887113,0.0032341497,0.00063031004,0.000028464494,0.000011114228,0.000086002896,0.0008213674,0.0009856017],"category_scores_gemma":[0.018026832,0.0001713176,0.0006025201,0.00012738082,0.00055848656,0.000027358436,0.000039235696,0.0005897361,0.000063400024],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23081274,0.0006398986,0.010863258,0.00054739625,0.091359325,0.003937916,0.0041052396,0.00023351233,0.0000058948035,0.12459877,0.04994117,0.48295486],"study_design_scores_gemma":[0.73435855,0.0015137222,0.009363548,0.0014828197,0.06560991,0.00032617582,0.00014580162,0.07168552,0.0000027796198,0.09062923,0.023921166,0.00096075126],"about_ca_topic_score_codex":0.00006798618,"about_ca_topic_score_gemma":0.00014008518,"teacher_disagreement_score":0.56960577,"about_ca_system_score_codex":0.00009629938,"about_ca_system_score_gemma":0.0005297899,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W4362579322","doi":"10.1016/s1556-0864(23)00346-5","title":"91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Osimertinib; Stage (stratigraphy); Internal medicine; Clinical endpoint; Regimen; Lung cancer; Oncology; Adjuvant; non-small cell lung cancer (NSCLC); Cancer; Surgery; Adenocarcinoma; Randomized controlled trial","score_opus":0.030936763858233893,"score_gpt":0.46906767792065146,"score_spread":0.43813091406241755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362579322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918979,0.00040277495,0.0000138778605,0.002391147,0.000534511,0.00088125333,0.000070590024,0.000021633794,0.0037863068],"genre_scores_gemma":[0.98806936,0.0010043253,0.00028522318,0.00016717601,0.00017851056,0.00009717841,0.000006646424,0.000022332672,0.0101692565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984337,0.00014755702,0.00057425007,0.0002436971,0.00023480988,0.00036598023],"domain_scores_gemma":[0.9989658,0.00014565072,0.00035038652,0.00019958623,0.00012365321,0.0002149043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036113625,0.00020822481,0.00076159654,0.00036110624,0.0000778361,0.000026797998,0.000097272,0.000089335306,0.00009975177],"category_scores_gemma":[0.000021174175,0.00014413515,0.00012560711,0.00045192515,0.000030260479,0.000102354774,0.000059100857,0.00021959232,0.000008255282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078009075,0.0015566366,0.9760897,0.000086160806,0.00057356304,0.0028069294,0.003644545,0.00008484698,0.00006738392,0.000003094896,0.0006291563,0.013677902],"study_design_scores_gemma":[0.00548495,0.004402437,0.98397785,0.00015960778,0.0010698049,0.000056190165,0.0030649211,0.00009853033,0.00011137715,0.000016963222,0.001444425,0.00011296555],"about_ca_topic_score_codex":0.009712506,"about_ca_topic_score_gemma":0.029664678,"teacher_disagreement_score":0.019952172,"about_ca_system_score_codex":0.0021318607,"about_ca_system_score_gemma":0.0008745867,"threshold_uncertainty_score":0.9968819},"labels":[],"label_agreement":null},{"id":"W4362585394","doi":"10.1016/s1556-0864(23)00273-3","title":"19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Afatinib; Erlotinib; Gefitinib; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer","score_opus":0.026347402457045813,"score_gpt":0.4532249383955534,"score_spread":0.4268775359385076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362585394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958191,0.0002289851,0.000093107206,0.0008729048,0.00046801224,0.00046474655,0.00010019729,0.000054889595,0.0018980738],"genre_scores_gemma":[0.995575,0.0004063312,0.0009133271,0.00020420195,0.00021932287,0.0000753708,0.00042007002,0.00002733332,0.0021590104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800247,0.0001918886,0.0008681314,0.0002627952,0.00034902993,0.00032570204],"domain_scores_gemma":[0.9981278,0.000120254525,0.000730999,0.00026565738,0.00048106356,0.00027418943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027286334,0.00022260888,0.0009151628,0.00091779017,0.00009381752,0.000017412964,0.00007843424,0.000130848,0.0002881831],"category_scores_gemma":[0.00007365037,0.00016303347,0.00050449965,0.001555483,0.00008378515,0.00022088499,0.000024363959,0.00019220673,0.000042519063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003300792,0.0015856671,0.9026138,0.000036735866,0.0056811,0.0012597181,0.00063152873,0.00048202966,0.000161049,0.0000017900987,0.0005677023,0.08367807],"study_design_scores_gemma":[0.0040832288,0.0025504427,0.9751445,0.00009412694,0.012843157,0.000017420418,0.00015039167,0.00041758045,0.00030630943,0.000050301984,0.0042140526,0.00012847701],"about_ca_topic_score_codex":0.00046457557,"about_ca_topic_score_gemma":0.0015270292,"teacher_disagreement_score":0.0835496,"about_ca_system_score_codex":0.0013745582,"about_ca_system_score_gemma":0.00032610595,"threshold_uncertainty_score":0.66483116},"labels":[],"label_agreement":null},{"id":"W4362585841","doi":"10.1016/s1556-0864(23)00351-9","title":"96P Characteristics of patients with resectable non-metastatic non-small cell lung cancer treated with or without neoadjuvant therapy in Europe and Canada: A real-world survey","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Vinorelbine; Carboplatin; Gemcitabine; Radiation therapy; Internal medicine; Oncology; Cisplatin; Lung cancer; Cancer; Chemotherapy; Surgery","score_opus":0.023797419697673516,"score_gpt":0.3826993075989642,"score_spread":0.3589018879012907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362585841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99831504,0.00009674641,0.000015848054,0.00026297243,0.0001167926,0.0006052109,0.00013817944,0.0000052766363,0.0004439257],"genre_scores_gemma":[0.99584085,0.0009533624,0.0006185967,0.00011835869,0.00004377677,0.000025638217,0.00006817257,0.000035720313,0.0022955062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864155,0.00015035919,0.0005157939,0.00016888879,0.0002590624,0.00026433505],"domain_scores_gemma":[0.99804145,0.00021909036,0.0006594063,0.00014304531,0.00077712175,0.00015987552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003576427,0.00017593954,0.00080904114,0.00031764226,0.000045729954,0.000010312148,0.000077867786,0.000038802922,0.000030298705],"category_scores_gemma":[0.00004379199,0.00009705592,0.000020892421,0.0008494082,0.00005898593,0.00006990365,0.000018700503,0.00023175855,4.019401e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010831081,0.000426638,0.9778795,0.00017289592,0.00037497535,0.0008503783,0.0006054007,0.00005263844,0.00015401884,1.479553e-7,0.00097451836,0.007677802],"study_design_scores_gemma":[0.005594131,0.0048857653,0.98705256,0.00047190845,0.00048794865,0.000032693446,0.00016477464,0.000248996,0.0002579761,3.6506688e-7,0.0006971705,0.00010572918],"about_ca_topic_score_codex":0.26370275,"about_ca_topic_score_gemma":0.70284027,"teacher_disagreement_score":0.43913752,"about_ca_system_score_codex":0.000550524,"about_ca_system_score_gemma":0.00497823,"threshold_uncertainty_score":0.88311666},"labels":[],"label_agreement":null},{"id":"W4362586002","doi":"10.1016/s1556-0864(23)00258-7","title":"40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Docetaxel; Medicine; Common Terminology Criteria for Adverse Events; Visual analogue scale; Quality of life (healthcare); Internal medicine; Clinical endpoint; Adverse effect; Physical therapy; Oncology; Clinical trial; Cancer","score_opus":0.08041390054959867,"score_gpt":0.48994981325527814,"score_spread":0.40953591270567946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362586002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98823977,0.00033570605,0.000047441692,0.005433025,0.0034656064,0.0007257244,0.000024392575,0.000039822018,0.0016885062],"genre_scores_gemma":[0.9983967,0.000071953145,0.0002806372,0.00040621468,0.00040545274,0.00003367316,0.00011160907,0.00002296636,0.00027081987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977759,0.00023051605,0.0010949688,0.00019517813,0.00039129477,0.00031213852],"domain_scores_gemma":[0.99762964,0.0008342844,0.00088015746,0.0002512931,0.00023288238,0.00017176878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053431944,0.00019352495,0.00089824386,0.00026242933,0.00011642703,0.000027245333,0.00015706864,0.0001429575,0.00019091909],"category_scores_gemma":[0.0004616864,0.000117416464,0.0002427199,0.0004989191,0.00008677929,0.0001352839,0.000051408857,0.00047350588,0.000036330206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6789397,0.0057050334,0.08393708,0.000036044235,0.0062322957,0.009359106,0.010345858,0.000612182,0.0019420371,0.000024646757,0.023599619,0.1792664],"study_design_scores_gemma":[0.6969844,0.014824064,0.2204336,0.00048018357,0.0067269485,0.0006114696,0.010560205,0.0019404752,0.0006606631,0.0003786344,0.0459117,0.00048766294],"about_ca_topic_score_codex":0.00052616367,"about_ca_topic_score_gemma":0.0003532126,"teacher_disagreement_score":0.17877872,"about_ca_system_score_codex":0.00064201985,"about_ca_system_score_gemma":0.0009211342,"threshold_uncertainty_score":0.47881043},"labels":[],"label_agreement":null},{"id":"W4362587522","doi":"10.1016/s1556-0864(23)00269-1","title":"15MO Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Loxo Oncology; Bavarian Nordic; Eli Lilly and Company; Bayer HealthCare; Incyte; Amgen","keywords":"Medicine; Trk receptor; Internal medicine; Lung cancer; Cancer; Oncology; Adverse effect; Cohort; Confidence interval; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Surgery; Clinical trial; Neurotrophin; Receptor; Phases of clinical research","score_opus":0.012531395940251905,"score_gpt":0.4192306762341641,"score_spread":0.4066992802939122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362587522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874383,0.00015729222,0.000019506648,0.00040553455,0.00005317369,0.0003805848,0.000023741191,0.000012871473,0.0002034528],"genre_scores_gemma":[0.9990159,0.00012083726,0.0004527073,0.00004513393,0.00003454347,0.000012852213,0.000113779286,0.000014695168,0.00018955053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989755,0.00011082228,0.00037571148,0.00015745481,0.00022367576,0.00015683498],"domain_scores_gemma":[0.9989033,0.000059711998,0.00042617923,0.00012300178,0.0003581289,0.00012972105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021165042,0.000116892035,0.000621931,0.00066111836,0.00004066856,0.0000068980657,0.000047656977,0.00008135063,0.00010944339],"category_scores_gemma":[0.000016297974,0.00006941585,0.000048873262,0.0013940453,0.00005935941,0.00011229784,0.000013018556,0.00016416417,5.4784516e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051254765,0.00073674094,0.9695843,0.000029780485,0.0021043688,0.00019009346,0.0007089929,0.00064216356,0.00016541792,6.4309296e-7,0.0001709187,0.020541117],"study_design_scores_gemma":[0.0045806826,0.0035538783,0.9836634,0.00013359576,0.0067725377,0.000022513901,0.00023185993,0.00041060886,0.00021895175,0.0000015068445,0.0003407962,0.00006969898],"about_ca_topic_score_codex":0.00023059527,"about_ca_topic_score_gemma":0.0006522706,"teacher_disagreement_score":0.020471416,"about_ca_system_score_codex":0.00026986442,"about_ca_system_score_gemma":0.00036795167,"threshold_uncertainty_score":0.2830696},"labels":[],"label_agreement":null},{"id":"W4362588616","doi":"10.1016/s1556-0864(23)00335-0","title":"81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Crizotinib; Cancer research; Lung cancer; Metastasis; Cancer; Oncology; Internal medicine","score_opus":0.010319327326104393,"score_gpt":0.4090416303925772,"score_spread":0.39872230306647277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362588616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959095,0.00011433334,0.000031326796,0.0014174539,0.00045751984,0.0012141413,0.00003194341,0.000024981173,0.00079881016],"genre_scores_gemma":[0.99877954,0.000018299224,0.00025522555,0.00031828147,0.00024238584,0.00007915343,0.000026988746,0.00003343815,0.00024669876],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99801725,0.00027400863,0.00062294357,0.00026347497,0.00044490345,0.00037740413],"domain_scores_gemma":[0.9981242,0.0003313921,0.00059331313,0.00019922048,0.00056782307,0.00018405021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000397101,0.00023321254,0.0006818581,0.0004411226,0.00021820041,0.000018485329,0.00013814459,0.00008306404,0.000021260437],"category_scores_gemma":[0.00023723797,0.00013785248,0.00010494409,0.0009707638,0.000108693755,0.00023372693,0.000066111934,0.0003053844,0.000011795951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07370186,0.045964215,0.14101668,0.0001033281,0.003582113,0.010075508,0.046855878,0.0014638951,0.0009591478,0.000024470191,0.0051773577,0.6710755],"study_design_scores_gemma":[0.05535603,0.16793343,0.75097036,0.0008309199,0.0023351319,0.000497849,0.01691598,0.00024013002,0.0016033,0.00016295208,0.0027958238,0.0003580949],"about_ca_topic_score_codex":0.00003743705,"about_ca_topic_score_gemma":0.00019824665,"teacher_disagreement_score":0.6707175,"about_ca_system_score_codex":0.001249474,"about_ca_system_score_gemma":0.0012513102,"threshold_uncertainty_score":0.56214607},"labels":[],"label_agreement":null},{"id":"W4362591319","doi":"10.1016/s1556-0864(23)00257-5","title":"30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Array BioPharma; Apollomics; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Rash; Chemotherapy; Lung cancer; Oncology; Population; Immunotherapy; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Progressive disease; Cancer","score_opus":0.008698202301313506,"score_gpt":0.37683261051435096,"score_spread":0.36813440821303745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362591319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966037,0.00008099024,0.00008125154,0.0017886432,0.00038192788,0.0006420872,0.00006426412,0.000030231615,0.0003268679],"genre_scores_gemma":[0.99821895,0.000058987483,0.0008404974,0.00016160781,0.00007474775,0.0000074734385,0.000052049698,0.000031428244,0.0005542707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983686,0.00017813951,0.00064362935,0.00018970743,0.00036453587,0.0002553695],"domain_scores_gemma":[0.99790657,0.00041594164,0.0005909023,0.00018358431,0.00060558703,0.0002974073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041018985,0.00017156354,0.00060733233,0.00044744485,0.00007557039,0.000009404089,0.00009732615,0.00011171457,0.00006374046],"category_scores_gemma":[0.00038476274,0.00011861336,0.000080694925,0.00044475612,0.00012665293,0.00014578587,0.00005700128,0.00022350217,0.000010600508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081662275,0.001012944,0.784532,0.00011908236,0.0009488854,0.0009983664,0.0036301126,0.00034669836,0.0041051274,0.000002328538,0.0004262513,0.122215934],"study_design_scores_gemma":[0.0071002594,0.012286757,0.9773059,0.00050148496,0.0007227095,0.00014272697,0.00040072264,0.000008231857,0.00061499444,0.000004029306,0.00080869696,0.000103495135],"about_ca_topic_score_codex":0.000010481265,"about_ca_topic_score_gemma":0.000026198519,"teacher_disagreement_score":0.1927739,"about_ca_system_score_codex":0.00037653552,"about_ca_system_score_gemma":0.0005291333,"threshold_uncertainty_score":0.48369125},"labels":[],"label_agreement":null},{"id":"W4362591364","doi":"10.1016/s1556-0864(23)00281-2","title":"27P Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Hazard ratio; Cohort; Proportional hazards model; Osimertinib; Epidermal growth factor receptor; Cancer; Confidence interval; Erlotinib","score_opus":0.020234847810806592,"score_gpt":0.39046488949458946,"score_spread":0.3702300416837829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362591364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955448,0.0002867109,0.00002425554,0.002567237,0.00034487137,0.0006414727,0.000048184873,0.000010163072,0.00053230283],"genre_scores_gemma":[0.9966991,0.0019276957,0.0006674244,0.000225263,0.000110977075,0.000084683845,0.00003276455,0.000026359929,0.00022574009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878037,0.0001895597,0.00036385204,0.00018818515,0.000244496,0.0002335138],"domain_scores_gemma":[0.9988167,0.00023136781,0.0004479319,0.00009889305,0.00033178608,0.000073307325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016921821,0.00016763384,0.00039108438,0.00038748284,0.00007712854,0.000018586601,0.000094069124,0.00004958967,0.00003762554],"category_scores_gemma":[0.000026707225,0.0000949748,0.000034685596,0.0006971858,0.00007949795,0.00024513388,0.000018189878,0.00032699268,0.0000020935063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065074395,0.00053958775,0.9665551,0.00009016803,0.00031940083,0.00017347856,0.0074957367,0.0014440024,0.00084560236,0.0000065181684,0.00017539387,0.015847558],"study_design_scores_gemma":[0.008661113,0.002554727,0.9850982,0.00034289522,0.0003235052,0.000007481844,0.0012074411,0.0001339807,0.000807838,0.000007217554,0.00073971524,0.00011588823],"about_ca_topic_score_codex":0.0005772518,"about_ca_topic_score_gemma":0.0035862874,"teacher_disagreement_score":0.018543083,"about_ca_system_score_codex":0.0005261616,"about_ca_system_score_gemma":0.0004910687,"threshold_uncertainty_score":0.387296},"labels":[],"label_agreement":null},{"id":"W4362601260","doi":"10.1002/cam4.5897","title":"Inequalities in survival and care across social determinants of health in a cohort of advanced lung cancer patients in Quebec (Canada): A high‐resolution population‐level analysis","year":2023,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut National d'Excellence en Santé et en Services Sociaux; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Gefitinib; Medicine; Osimertinib; Lung cancer; Internal medicine; Demography; Population; Cohort; Socioeconomic status; Oncology; Cancer; Erlotinib; Epidermal growth factor receptor; Environmental health","score_opus":0.031102502946708577,"score_gpt":0.4003195722600295,"score_spread":0.36921706931332093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362601260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502856,0.0024371715,0.000004304456,0.0010834805,0.00021798765,0.0006004666,0.00060174917,0.000007800939,0.0000184829],"genre_scores_gemma":[0.9981849,0.00077939633,0.000011998922,0.000078450226,0.00004291659,0.00018265452,0.00055916415,0.00001307625,0.00014743206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982846,0.00008329612,0.0007431953,0.00024725712,0.0003577431,0.00028390085],"domain_scores_gemma":[0.99932015,0.000061464954,0.00029058175,0.00010991107,0.00015785624,0.000060021423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023802463,0.00013599501,0.0008941716,0.00041072594,0.000044245884,0.0000017785953,0.00004411641,0.000055548317,0.000029408016],"category_scores_gemma":[0.00007280984,0.000117966556,0.00003192254,0.00155037,0.00008370767,0.00007015471,0.000025544006,0.00009094784,2.8042114e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001367753,0.000046060264,0.9634795,0.0005750209,0.00012528339,0.0000060287316,0.014636345,0.0008147956,0.000009973171,0.000015485699,0.000065148146,0.020089552],"study_design_scores_gemma":[0.0051891254,0.00007706236,0.98443836,0.0008736556,0.00020186134,7.7997434e-8,0.0085845,0.00050883845,0.000013073126,0.000008400238,0.000023213384,0.00008183693],"about_ca_topic_score_codex":0.9851145,"about_ca_topic_score_gemma":0.9974555,"teacher_disagreement_score":0.020958822,"about_ca_system_score_codex":0.0018581182,"about_ca_system_score_gemma":0.00093691907,"threshold_uncertainty_score":0.48589143},"labels":[],"label_agreement":null},{"id":"W4362676637","doi":"10.1200/jco.23.00281","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; Pathology","score_opus":0.08184180362781925,"score_gpt":0.507410448665457,"score_spread":0.4255686450376378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362676637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714732,0.0012230877,0.005069458,0.016442975,0.0019292003,0.0009722299,0.000044540226,0.000025673284,0.0028195991],"genre_scores_gemma":[0.87003285,0.01750085,0.046935495,0.014638364,0.0062215338,0.0002270021,0.00009903447,0.00010701842,0.04423785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814016,0.00009074641,0.0011762436,0.00017295647,0.00021837109,0.00020154043],"domain_scores_gemma":[0.99670386,0.0014202478,0.00082955393,0.00013800588,0.0007005304,0.00020777735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001157299,0.00011636535,0.0006553384,0.00013201556,0.00010032658,0.000013947039,0.00009243087,0.00016422861,0.0003723422],"category_scores_gemma":[0.00041450502,0.0000725256,0.00027178315,0.00019198243,0.000052924544,0.00011636675,0.000021787893,0.00031687494,0.000016547776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065354872,0.003065134,0.3278011,0.00017887824,0.0031216855,0.0006497558,0.001433286,0.004236935,0.0011588352,0.000070749025,0.5308414,0.12090675],"study_design_scores_gemma":[0.029763795,0.018674962,0.18905167,0.0005626334,0.0017773464,0.000041274216,0.00087991153,0.009319601,0.00019345108,0.00004822051,0.7494724,0.00021472595],"about_ca_topic_score_codex":0.00007330967,"about_ca_topic_score_gemma":0.00012136656,"teacher_disagreement_score":0.218631,"about_ca_system_score_codex":0.0002138087,"about_ca_system_score_gemma":0.0026676932,"threshold_uncertainty_score":0.47323734},"labels":[],"label_agreement":null},{"id":"W4362716531","doi":"10.1016/j.lungcan.2023.107191","title":"Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"Viropharma","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Oncology; Confidence interval; Vinorelbine; Discontinuation; Population; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Chemotherapy; Surgery; Phases of clinical research; Cisplatin","score_opus":0.024040701422515128,"score_gpt":0.3758878505984089,"score_spread":0.35184714917589377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362716531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906023,0.0038436297,0.00020887125,0.0009788059,0.00017446156,0.0020844177,0.00028629086,0.00014383612,0.0016773909],"genre_scores_gemma":[0.98775345,0.0010325814,0.0005549272,0.00010234246,0.00011778243,0.0022072096,0.0003679774,0.000057475376,0.0078062387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988483,0.00002352518,0.00031752183,0.00033672983,0.00018782676,0.000286093],"domain_scores_gemma":[0.9991468,0.00011422348,0.00021841512,0.00019740766,0.00021967005,0.00010345277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000672755,0.00021460261,0.00044059457,0.00024276422,0.00016601554,0.000023133658,0.00005466713,0.000072508934,0.00007746891],"category_scores_gemma":[0.000006739427,0.00016278954,0.00006689624,0.0006491437,0.000070025155,0.000100133744,0.000016717615,0.00009744491,0.0000011402192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064072694,0.00019049794,0.96830875,0.0010030692,0.0009412955,0.000004236842,0.009983368,0.0017814641,0.007322791,0.00002256448,0.005283659,0.004517606],"study_design_scores_gemma":[0.0062018586,0.0005101992,0.9286594,0.001088178,0.0030226542,0.0000016015342,0.0010645754,0.022617757,0.034311343,0.000024952978,0.0021865768,0.0003109205],"about_ca_topic_score_codex":0.008266066,"about_ca_topic_score_gemma":0.016156144,"teacher_disagreement_score":0.039649338,"about_ca_system_score_codex":0.0003296114,"about_ca_system_score_gemma":0.00035782444,"threshold_uncertainty_score":0.998338},"labels":[],"label_agreement":null},{"id":"W4362730611","doi":"10.21037/tlcr-22-723","title":"Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives","year":2023,"lang":"en","type":"review","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Foundation Medicine; Provincial Health Services Authority; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Sanofi; Chugai Pharmaceutical; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Cancer; Stage (stratigraphy); Chemotherapy; Disease","score_opus":0.10394915115969366,"score_gpt":0.5075621218298284,"score_spread":0.40361297067013474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362730611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009099007,0.98718345,0.00000941811,0.0046058623,0.00047222368,0.0037600866,0.0028162804,0.00010474086,0.0001380651],"genre_scores_gemma":[0.00089409004,0.99246967,0.00007867363,0.000015450754,0.0014412219,0.0030218218,0.0009713683,0.00014551927,0.00096216996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585545,0.0004515251,0.000724229,0.0009722677,0.0012224701,0.0007740612],"domain_scores_gemma":[0.9981168,0.00059255783,0.00016283005,0.00027528507,0.00057444023,0.0002781185],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046919097,0.00056143256,0.0015163628,0.0010227085,0.00031747343,0.00009176206,0.00021359506,0.0002947575,0.0010162381],"category_scores_gemma":[0.000028223138,0.0004251265,0.00031612563,0.0014778516,0.00027264823,0.00021999027,0.00004895474,0.0014870473,0.000010929631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027298875,0.00028603166,0.009296209,0.03757704,0.0031827642,0.00006249334,0.013812922,0.000010350302,0.0000074308546,0.0021405541,0.003349006,0.9300022],"study_design_scores_gemma":[0.0046828776,0.00015804678,0.022154326,0.033953905,0.0020838708,0.000017718006,0.0015227598,0.0002009002,0.0000053010904,0.00018674716,0.93410563,0.00092792074],"about_ca_topic_score_codex":0.002244249,"about_ca_topic_score_gemma":0.00091998396,"teacher_disagreement_score":0.9307566,"about_ca_system_score_codex":0.0016316946,"about_ca_system_score_gemma":0.0038438207,"threshold_uncertainty_score":0.99989694},"labels":[],"label_agreement":null},{"id":"W4365446409","doi":"10.1016/j.cell.2023.02.040","title":"Selpercatinib: First approved selective RET inhibitor","year":2023,"lang":"en","type":"article","venue":"Cell","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biology; Fusion protein; Cell biology; Small molecule; Cancer research; Kinase; Point mutation; Mutant; Biochemistry; Gene; Recombinant DNA","score_opus":0.014565872404500012,"score_gpt":0.2955862916170882,"score_spread":0.2810204192125882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365446409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80422163,0.00018308467,0.000039162787,0.003825512,0.0004404444,0.00074961944,0.000032857195,0.00043754347,0.19007017],"genre_scores_gemma":[0.9669548,0.00003742226,0.00032889927,0.00026359427,0.00019180572,0.000081689344,0.00011894752,0.000019874506,0.03200293],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995167,0.0000069713424,0.00008352558,0.0001592776,0.00008965434,0.00014383905],"domain_scores_gemma":[0.9996757,0.000036314683,0.000022677974,0.00013909618,0.00005416191,0.00007206014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000035319834,0.00007037743,0.00010125646,0.000051216797,0.000079462516,0.000008551462,0.000026083711,0.000039952232,0.00008824313],"category_scores_gemma":[0.000022239952,0.000056717046,0.00004098672,0.00029883735,0.000018067276,0.000028833123,0.000014200197,0.00006691878,0.00071945356],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001574444,0.00069630524,0.022229683,0.00042205016,0.00029218933,0.0001491762,0.0148274675,0.000050894494,0.031939697,0.00016234478,0.9248744,0.004198339],"study_design_scores_gemma":[0.008168537,0.0010248183,0.11151328,0.00017690135,0.00066498003,0.00002909918,0.0027983654,0.0012547362,0.16596954,0.00045409132,0.70750135,0.00044432175],"about_ca_topic_score_codex":0.00004272983,"about_ca_topic_score_gemma":0.00001845162,"teacher_disagreement_score":0.21737307,"about_ca_system_score_codex":0.00009041851,"about_ca_system_score_gemma":0.00009708297,"threshold_uncertainty_score":0.92473596},"labels":[],"label_agreement":null},{"id":"W4365512273","doi":"10.1158/1538-7445.am2023-ct206","title":"Abstract CT206: A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Niagara Health System; Windsor Regional Hospital; North York General Hospital; Grand River Hospital; St Joseph's Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Pembrolizumab; Internal medicine; KRAS; Response Evaluation Criteria in Solid Tumors; Oncology; Lung cancer; Adverse effect; MEK inhibitor; Gastroenterology; Cancer; Phases of clinical research; Clinical trial; Kinase; MAPK/ERK pathway; Immunotherapy; Colorectal cancer","score_opus":0.03269849598645779,"score_gpt":0.4195021822245747,"score_spread":0.3868036862381169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946167,0.00031185918,0.0000023881546,0.00018623336,0.00006840069,0.004017668,0.000061501174,0.000029590507,0.00070566585],"genre_scores_gemma":[0.99685913,0.00015582204,0.000041422463,0.000016473647,0.000030570118,0.0023857148,0.00007785797,0.000053678417,0.0003793318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764884,0.00008816317,0.00036719954,0.00047943162,0.0008860644,0.0005303322],"domain_scores_gemma":[0.9987197,0.00012491297,0.00011766578,0.00032162442,0.00057408964,0.00014201278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035117948,0.00019198662,0.00039699624,0.00090072124,0.00008205381,0.00002063825,0.00012624777,0.00006159314,0.00008511697],"category_scores_gemma":[0.00003021358,0.00014267908,0.000027677559,0.0023332383,0.000083873754,0.00015165942,0.000049895494,0.0004261441,0.0000059650743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008092614,0.008616394,0.9565638,0.0005982489,0.00017655162,0.00012650862,0.010807833,0.00084873085,0.0018087846,0.0000040878485,0.00031354924,0.012042945],"study_design_scores_gemma":[0.09132593,0.0063151694,0.89353514,0.0013324047,0.00009298296,3.4312075e-7,0.003589594,0.00019156885,0.0033657078,0.0000055807877,0.00007030843,0.00017529885],"about_ca_topic_score_codex":0.006644529,"about_ca_topic_score_gemma":0.0055407165,"teacher_disagreement_score":0.08323331,"about_ca_system_score_codex":0.00087763893,"about_ca_system_score_gemma":0.0014357502,"threshold_uncertainty_score":0.9999703},"labels":[],"label_agreement":null},{"id":"W4365512278","doi":"10.1158/1538-7445.am2023-ct202","title":"Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; Spinal Cord Injury BC; University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Avelumab; Response Evaluation Criteria in Solid Tumors; Oncology; Lung cancer; Clinical endpoint; Progressive disease; Adverse effect; Cohort; Cancer; Chemotherapy; Tolerability; Gastroenterology; Immunotherapy; Nivolumab; Clinical trial","score_opus":0.14204790365486764,"score_gpt":0.48933486052402336,"score_spread":0.3472869568691557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302566,0.0029043818,0.000015902742,0.00064421614,0.00016309168,0.0022270728,0.0004285974,0.00006278172,0.00052831403],"genre_scores_gemma":[0.99181616,0.0037821059,0.00027131377,0.000084765335,0.00006248177,0.001778906,0.0002861827,0.00007750459,0.0018405872],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969514,0.00012682063,0.00048588964,0.0007918241,0.00085781707,0.0007862455],"domain_scores_gemma":[0.9982084,0.0002796827,0.00013737884,0.00048246415,0.0005284604,0.0003635833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053926685,0.0003007849,0.0005234849,0.00079374533,0.00027503862,0.000064841115,0.00014724057,0.00007659522,0.00016278213],"category_scores_gemma":[0.00011855585,0.00020102317,0.000060927894,0.0019716588,0.00019756869,0.0002773332,0.00010517293,0.00040714297,0.000025499414],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12876794,0.013024025,0.077483885,0.010548143,0.0046110773,0.0062187556,0.04544787,0.0061456244,0.12429629,0.000013661376,0.047811497,0.53563124],"study_design_scores_gemma":[0.2764639,0.0075313533,0.64276505,0.00928518,0.0016934789,0.000010700189,0.015578997,0.008320208,0.03328934,0.000031105912,0.0035215765,0.0015091329],"about_ca_topic_score_codex":0.0029278887,"about_ca_topic_score_gemma":0.0024858667,"teacher_disagreement_score":0.56528115,"about_ca_system_score_codex":0.0012367906,"about_ca_system_score_gemma":0.0022716273,"threshold_uncertainty_score":0.8197487},"labels":[],"label_agreement":null},{"id":"W4366336901","doi":"10.46747/cfp.6904266","title":"Lung cancer crash course","year":2023,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Lung cancer; Medicine; Lung; Cancer; Crash; Survival rate; Mortality rate; Pathology; Oncology; Internal medicine; Computer science","score_opus":0.017127149296401706,"score_gpt":0.3274974886655304,"score_spread":0.3103703393691287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366336901","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4866385,0.0027517634,0.000007974759,0.0117854895,0.0012636008,0.0008986587,0.0006478026,0.0003354118,0.49567083],"genre_scores_gemma":[0.9057406,0.00012786119,0.000029549708,0.08285227,0.00057010906,0.00017446448,0.00029435894,0.00005114515,0.010159644],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.999158,0.000008103749,0.000094581046,0.00020314338,0.00013156302,0.00040458213],"domain_scores_gemma":[0.99919236,0.000012196656,0.000023963881,0.00022724197,0.00007074882,0.00047347264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000263749,0.00011797408,0.0001605589,0.00014260013,0.00015485482,0.000021277361,0.000060743525,0.000044952638,0.000018975037],"category_scores_gemma":[0.0000025788713,0.000111982285,0.000071259936,0.00052894786,0.00003870181,0.00006137288,0.0000073968545,0.000087583,0.00039070932],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007202635,0.000051704774,0.0138146095,0.00006126927,0.0004929216,0.00033520054,0.00035090183,0.00007564549,0.0016348241,0.0011156006,0.91252863,0.06953147],"study_design_scores_gemma":[0.0011597165,0.00005371342,0.5327713,0.00016225093,0.0005844866,9.4186606e-7,0.0007709362,0.00094914285,0.00011853008,0.00017145378,0.46301648,0.00024107311],"about_ca_topic_score_codex":0.031051168,"about_ca_topic_score_gemma":0.02388517,"teacher_disagreement_score":0.51895666,"about_ca_system_score_codex":0.00052003487,"about_ca_system_score_gemma":0.0016391533,"threshold_uncertainty_score":0.9939264},"labels":[],"label_agreement":null},{"id":"W4366351945","doi":"10.1007/s41669-023-00407-0","title":"Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Osimertinib; Medicine; Lung cancer; Health care; Population; Oncology; Disease; Internal medicine; Chemotherapy; Cancer; Intensive care medicine; Epidermal growth factor receptor; Erlotinib; Environmental health","score_opus":0.041307286050652516,"score_gpt":0.38080286673296865,"score_spread":0.3394955806823161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366351945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942242,0.0002026571,0.00004641763,0.0017856894,0.00003713007,0.0031313938,0.0004520225,0.000028897233,0.000091593065],"genre_scores_gemma":[0.99231577,0.0012299829,0.0001522159,0.0011879525,0.000013167258,0.0008379715,0.0041626017,0.000036343023,0.00006399913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986684,0.00014258333,0.00035340237,0.00045319053,0.00008896483,0.00029349205],"domain_scores_gemma":[0.99920774,0.00012824697,0.00018025233,0.00024622885,0.00010692485,0.00013060823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021625338,0.00022506708,0.00038832173,0.00047922437,0.00015444028,0.00008392028,0.00015864841,0.000042665037,0.000023204919],"category_scores_gemma":[0.000005799835,0.0001671505,0.00003359868,0.0014276326,0.000030985135,0.00025083066,0.000035046953,0.0001269125,0.0000018373498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012394422,0.00044709689,0.82892287,0.00005957716,0.00028995436,0.000019204628,0.008741718,0.15141639,0.000006100652,0.0000014931566,0.00004842103,0.008807746],"study_design_scores_gemma":[0.017015189,0.0005737666,0.7739607,0.00018848866,0.00060829986,3.1527568e-7,0.002416008,0.20396285,0.00022495344,0.0000042674537,0.00084300514,0.0002021343],"about_ca_topic_score_codex":0.01934001,"about_ca_topic_score_gemma":0.03413394,"teacher_disagreement_score":0.054962132,"about_ca_system_score_codex":0.0014814337,"about_ca_system_score_gemma":0.00026677817,"threshold_uncertainty_score":0.9871903},"labels":[],"label_agreement":null},{"id":"W4366412116","doi":"10.1186/s12885-023-10800-x","title":"Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults","year":2023,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ottawa Hospital; University of Alberta; BC Cancer Agency","funders":"BC Cancer Foundation; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Tolerability; Cohort; Anaplastic lymphoma kinase; Performance status; Surgical oncology; Progression-free survival; Cancer; Overall survival; Adverse effect","score_opus":0.023376643107598898,"score_gpt":0.3261138198742404,"score_spread":0.30273717676664147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366412116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878032,0.0058818324,0.0004735376,0.00019241901,0.0010319573,0.003449421,0.0006049379,0.00011725839,0.00044541864],"genre_scores_gemma":[0.9775623,0.0013051833,0.0013412868,0.00009289152,0.0002770637,0.0062298346,0.00024651157,0.00009796204,0.0128469635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873424,0.000016336897,0.00022584389,0.0004556433,0.00017608449,0.0003918742],"domain_scores_gemma":[0.99920964,0.000107799766,0.00011873897,0.00023995688,0.00015330366,0.00017054021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006561077,0.00026082367,0.0004007433,0.00009946933,0.00012756184,0.000030389047,0.00005250622,0.00005269741,0.00006213935],"category_scores_gemma":[0.000008608768,0.00018503472,0.00008859799,0.0002604951,0.000034111952,0.000090485926,0.0000194991,0.00006342579,0.000006228312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046072666,0.0021917159,0.7381371,0.02658371,0.026426602,0.00034902483,0.031895205,0.0019196941,0.011205293,0.00016949503,0.023010325,0.09203916],"study_design_scores_gemma":[0.29191554,0.004987541,0.5746088,0.0073449006,0.0450137,0.0000737453,0.01461204,0.048956163,0.0049518025,0.000012366015,0.0054164478,0.002106968],"about_ca_topic_score_codex":0.0033302736,"about_ca_topic_score_gemma":0.0037933215,"teacher_disagreement_score":0.24584289,"about_ca_system_score_codex":0.00047104698,"about_ca_system_score_gemma":0.00067174336,"threshold_uncertainty_score":0.7545497},"labels":[],"label_agreement":null},{"id":"W4366982411","doi":"10.1158/1078-0432.ccr-22-3413","title":"Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Canadian Institutes of Health Research; Chugai Pharmaceutical; EMD Serono; Genentech; Mirati Therapeutics; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; Conquer Cancer Foundation; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Prostate Cancer Foundation; American Society of Clinical Oncology; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; Takeda Oncology; Amgen","keywords":"KRAS; Cancer research; Lung cancer; STK11; Microsatellite instability; Biology; Adenocarcinoma; Missense mutation; Cancer; Medicine; Pathology; Mutation; Gene; Internal medicine; Colorectal cancer; Genetics","score_opus":0.12049070787620193,"score_gpt":0.5108255109347748,"score_spread":0.3903348030585729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366982411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985503,0.008598712,0.000007319344,0.0016261882,0.00029203048,0.0010460373,0.0001152504,0.000037433332,0.0027740241],"genre_scores_gemma":[0.9836703,0.012302297,0.00020758048,0.00025075316,0.00023178551,0.00068305514,0.000053248583,0.00003364554,0.0025673525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777895,0.00022422266,0.00073167484,0.0004852022,0.00030367746,0.00047624123],"domain_scores_gemma":[0.99799734,0.0010394064,0.000114929535,0.0003589659,0.00029490495,0.00019447655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017020733,0.00013536005,0.0004947104,0.00031274394,0.00012118791,0.000020384588,0.00015233588,0.00017203027,0.00032639512],"category_scores_gemma":[0.00025937194,0.00011040595,0.00011412083,0.00092906837,0.0003237068,0.00004937132,0.00017021404,0.00065538246,0.00004877197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003572923,0.00034700643,0.97565776,0.0003377355,0.000095042844,0.00009025845,0.0009000836,0.000101856305,0.0021760396,0.000044960336,0.0031705573,0.01672141],"study_design_scores_gemma":[0.004896228,0.0004656515,0.99018943,0.00023020306,0.00016230287,0.0000018140904,0.0006071632,0.00083722296,0.00034327118,0.0002582357,0.0018916455,0.00011683783],"about_ca_topic_score_codex":0.0012625556,"about_ca_topic_score_gemma":0.00074787793,"teacher_disagreement_score":0.016604573,"about_ca_system_score_codex":0.0001614584,"about_ca_system_score_gemma":0.001003755,"threshold_uncertainty_score":0.4502224},"labels":[],"label_agreement":null},{"id":"W4366997708","doi":"10.1200/jco.22.02524","title":"Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; European Society for Medical Oncology; Shanghai Jiao Tong University; Revolution Medicines; Jiangsu Hengrui Medicine; Calithera Biosciences; BeiGene; Mirati Therapeutics; McGill University; Moderna; Memorial Sloan-Kettering Cancer Center; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; KRAS; Clinical endpoint; Tolerability; Internal medicine; Clinical trial; Lung cancer; Oncology; Discontinuation; Phases of clinical research; Surrogate endpoint; Cancer; Adverse effect; Colorectal cancer","score_opus":0.03039771911843098,"score_gpt":0.43100504387916794,"score_spread":0.40060732476073696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366997708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984507,0.00028567275,0.000029289975,0.0003489014,0.00019941418,0.00045414656,0.000033056254,0.0000083492605,0.00019047891],"genre_scores_gemma":[0.9988849,0.0004804892,0.000256035,0.00014543837,0.000019569514,0.000007912951,0.000055928198,0.00001841552,0.00013131347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749076,0.00014942652,0.0016674658,0.00019912775,0.00030171665,0.00019147525],"domain_scores_gemma":[0.9966319,0.00093505596,0.0015088448,0.0001732868,0.00054964115,0.0002012561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049232517,0.0001605635,0.0018535316,0.0004971076,0.000019039053,0.000004637352,0.00009717089,0.0002160391,0.000056633267],"category_scores_gemma":[0.00033826957,0.00010231083,0.00033562473,0.0009958808,0.00015557713,0.000057311274,0.00003629472,0.00033198745,0.0000010181777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002733191,0.0025274868,0.9837051,0.000083328625,0.00614132,0.0002503576,0.00031108927,0.0009501102,0.00006800479,0.0000019813479,0.000104886516,0.0031231213],"study_design_scores_gemma":[0.021569755,0.0046287193,0.9619693,0.00022764012,0.010818429,0.0000031163972,0.000055262382,0.00047233127,0.00015809548,0.00000249705,0.000013740317,0.00008109702],"about_ca_topic_score_codex":0.00017847172,"about_ca_topic_score_gemma":0.00017407163,"teacher_disagreement_score":0.021735808,"about_ca_system_score_codex":0.00013444487,"about_ca_system_score_gemma":0.00081189,"threshold_uncertainty_score":0.41721144},"labels":[],"label_agreement":null},{"id":"W4367301161","doi":"10.21037/jtd-23-380","title":"A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Jiangsu Pharmaceutical Association","keywords":"Alectinib; Crizotinib; Ceritinib; Medicine; Anaplastic lymphoma kinase; Guideline; Lung cancer; Intensive care medicine; Oncology; Internal medicine; Pathology","score_opus":0.05279907099811555,"score_gpt":0.4804252321738786,"score_spread":0.4276261611757631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367301161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107707,0.0034314073,0.0009207907,0.002160293,0.0006035252,0.0012694328,0.00026336865,0.000012359403,0.00026176113],"genre_scores_gemma":[0.996602,0.00087805866,0.0011770345,0.00023674715,0.0003675773,0.00011325679,0.00008400417,0.000024519404,0.0005168077],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984966,0.00008221944,0.00061864295,0.00016010858,0.00047898048,0.00016343062],"domain_scores_gemma":[0.9967341,0.00032242291,0.0005798055,0.00016295425,0.001883911,0.00031684863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005171363,0.00012557738,0.00040321558,0.00015671205,0.00006845608,0.000009693581,0.00007449625,0.00004421359,0.000048272497],"category_scores_gemma":[0.00021494944,0.00009661217,0.00037188389,0.0002386949,0.000041957297,0.000110165725,0.000022049517,0.000118022486,0.000003635868],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02853179,0.006158346,0.25545684,0.009195657,0.005714784,0.0004501874,0.0074791093,0.054977752,0.0018650859,0.000026589743,0.027607394,0.60253644],"study_design_scores_gemma":[0.03497305,0.0032722831,0.7498679,0.0077363322,0.03956533,0.000019657899,0.0034544934,0.14976901,0.0042312527,0.0010447607,0.005505145,0.00056075637],"about_ca_topic_score_codex":0.000011368043,"about_ca_topic_score_gemma":0.0000058146993,"teacher_disagreement_score":0.6019757,"about_ca_system_score_codex":0.00020721098,"about_ca_system_score_gemma":0.0010347671,"threshold_uncertainty_score":0.39397302},"labels":[],"label_agreement":null},{"id":"W4367604408","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4730","title":"Recurrence-free Survival (RFS) in Surgically-resected Non-small Cell Lung Cancer Patients - A Systematic Literature Review and Meta-analysis","year":2023,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Meta-analysis; Lung cancer; Medicine; Oncology; Internal medicine","score_opus":0.02895363862483676,"score_gpt":0.33816519084052504,"score_spread":0.3092115522156883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367604408","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19635321,0.76715475,0.00007997424,0.008184773,0.00037237175,0.012860343,0.0012959652,0.00029477142,0.013403806],"genre_scores_gemma":[0.80717534,0.1317843,0.0006621363,0.002363449,0.00006976174,0.0048299045,0.0019193549,0.000085530686,0.051110234],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9983296,0.00015899944,0.00053385756,0.00039470565,0.00032683517,0.00025601007],"domain_scores_gemma":[0.9987847,0.00017516312,0.0001408327,0.00046885037,0.00028285492,0.00014760515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003369061,0.00022535688,0.0016048171,0.000351049,0.000049453323,0.000043790104,0.000114111186,0.00007522161,0.00054168614],"category_scores_gemma":[0.00012943851,0.00013149122,0.00041385743,0.0028400163,0.000016798418,0.000076357355,0.00006957195,0.00014868278,0.000012392285],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009658256,0.0013359451,0.26245722,0.4605057,0.24118374,0.0005094518,0.004355901,0.00007514209,0.000021396938,0.00016986483,0.02916735,0.00012169757],"study_design_scores_gemma":[0.0035637913,0.00015167486,0.07075388,0.0074518663,0.91644293,0.00000371123,0.00011613925,0.00091560837,0.000020112686,0.000020441037,0.00018784116,0.00037202853],"about_ca_topic_score_codex":0.000408164,"about_ca_topic_score_gemma":0.0013172354,"teacher_disagreement_score":0.6752592,"about_ca_system_score_codex":0.00010179674,"about_ca_system_score_gemma":0.0000907439,"threshold_uncertainty_score":0.5931083},"labels":[],"label_agreement":null},{"id":"W4367853457","doi":"10.7573/dic.2022-11-3","title":"Non-small-cell lung cancer: how to manage BRAF-mutated disease","year":2023,"lang":"en","type":"review","venue":"Drugs in Context","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Medicine; Oncology; Immunotherapy; Lung cancer; Disease; Retrospective cohort study; Adenocarcinoma; Clinical trial; Internal medicine; Targeted therapy; Cancer","score_opus":0.03356814065094145,"score_gpt":0.3770287535436488,"score_spread":0.34346061289270735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367853457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034520958,0.98979956,0.00001938226,0.0012795666,0.0007181135,0.0043471023,0.00052436785,0.00013882881,0.0028278655],"genre_scores_gemma":[0.0009589482,0.9409354,0.000044811146,0.00060950697,0.00026750387,0.0025392906,0.0007044058,0.00016094274,0.05377921],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980605,0.000055148124,0.0004690719,0.00069404574,0.00025571306,0.00046547898],"domain_scores_gemma":[0.9985069,0.0001535164,0.00019153574,0.0006044719,0.000083869476,0.0004597146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012061203,0.00049725716,0.0015013256,0.00048813815,0.00007102989,0.00006695347,0.00023678761,0.00016550138,0.0001210483],"category_scores_gemma":[0.00004610738,0.0004019413,0.0004114008,0.0009194004,0.00003069563,0.000053670068,0.000118736934,0.00035113693,0.00038975233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034084627,0.00017915064,0.00027573673,0.037655037,0.00075536204,0.00084334274,0.0017063376,0.0000048416246,2.2944775e-7,0.00003587737,0.018449368,0.9400606],"study_design_scores_gemma":[0.0015682892,0.00004329711,0.0001528517,0.03316066,0.004329769,0.0000036810502,0.0003214048,0.00004830846,0.0000010041654,0.000005632487,0.95997185,0.00039324263],"about_ca_topic_score_codex":0.00090635626,"about_ca_topic_score_gemma":0.0006094177,"teacher_disagreement_score":0.9415225,"about_ca_system_score_codex":0.0009894744,"about_ca_system_score_gemma":0.0009624506,"threshold_uncertainty_score":0.99984324},"labels":[],"label_agreement":null},{"id":"W4376143644","doi":"10.51731/cjht.2023.644","title":"Amivantamab (Rybrevant)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Epidermal growth factor receptor; Oncology; Drug; Chemotherapy; Disease; Lung cancer; Internal medicine; Intensive care medicine; Cancer; Pharmacology; Political science; Health care","score_opus":0.03132594971319125,"score_gpt":0.3619167096172947,"score_spread":0.33059075990410347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376143644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46833634,0.08237584,0.00021837675,0.44264787,0.0015020217,0.0007188691,0.000072027535,0.0007123052,0.0034163517],"genre_scores_gemma":[0.99772984,0.0009006958,0.00037621564,0.00051920966,0.000012379782,0.0000043932814,0.000006297071,0.000010717335,0.00044023854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921495,0.000012045113,0.00029236998,0.00007204694,0.00009912224,0.00030949403],"domain_scores_gemma":[0.99947685,0.00002532391,0.00015086925,0.00014880026,0.000102426595,0.000095725125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020492532,0.000068041314,0.00023384635,0.00067883695,0.00015611498,0.0000125473425,0.00009945988,0.000060996263,0.000025575104],"category_scores_gemma":[0.00021038135,0.000051128074,0.000058374422,0.00048993307,0.000085496824,0.00005187651,0.000007093049,0.00019023893,0.00005118346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010978093,0.000016927132,0.021569192,0.00013249215,0.00013954414,0.0010551623,0.0005398888,0.000011758999,0.000040454543,0.001190562,0.08359196,0.8917011],"study_design_scores_gemma":[0.0014553586,0.0009534367,0.10778712,0.0005089853,0.00008328041,0.0011186253,0.0077795205,0.000017393158,0.00035531286,0.0043520583,0.87547225,0.00011667656],"about_ca_topic_score_codex":0.001676602,"about_ca_topic_score_gemma":0.0012127052,"teacher_disagreement_score":0.8915844,"about_ca_system_score_codex":0.00042687153,"about_ca_system_score_gemma":0.0033871753,"threshold_uncertainty_score":0.6008704},"labels":[],"label_agreement":null},{"id":"W4376272496","doi":"10.1016/j.jtho.2023.05.007","title":"Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Marie-Josée and Henry R. Kravis Center for Molecular Oncology; Loxo Oncology; National Cancer Institute; National Institutes of Health; Royal College of Physicians and Surgeons of Canada; Helsinn; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Trametinib; Mdm2; Medicine; Cancer research; Adenocarcinoma; Lung cancer; Targeted therapy; MAPK/ERK pathway; MEK inhibitor; Cancer; Oncology; Internal medicine; Kinase; Gene; Biology; Genetics","score_opus":0.017626076959057865,"score_gpt":0.3820243639162987,"score_spread":0.3643982869572408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376272496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636817,0.0012160308,0.00032549922,0.0012439729,0.00009294138,0.00065806165,0.000008996893,0.000007551113,0.00007879532],"genre_scores_gemma":[0.99863416,0.00083243754,0.00036686208,0.00007743371,0.000021884425,0.000029515342,0.000011220153,0.0000125947545,0.000013912777],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991457,0.000106200685,0.00029628546,0.00014272884,0.0001923397,0.000116731426],"domain_scores_gemma":[0.99901426,0.00013347983,0.00043354733,0.00007171304,0.00026244586,0.00008455285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017454031,0.00010929768,0.00036049658,0.00030130573,0.000041927295,0.0000075408516,0.000029085095,0.00006892391,0.0000046501377],"category_scores_gemma":[0.000012943922,0.00007215533,0.000032496395,0.0002739087,0.0001225398,0.00016658287,0.000012790521,0.00015032267,2.9407798e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007896749,0.0014794694,0.33716428,0.00034871013,0.0016131393,0.00043163355,0.04515628,0.0005674477,0.02108082,0.0002867405,0.0005119704,0.5834628],"study_design_scores_gemma":[0.019497667,0.03060421,0.90473306,0.0010073618,0.0014759728,0.00097170303,0.009305412,0.0041334135,0.026763106,0.0007687153,0.00045351198,0.00028583806],"about_ca_topic_score_codex":0.000033660373,"about_ca_topic_score_gemma":0.000019433743,"teacher_disagreement_score":0.5831769,"about_ca_system_score_codex":0.00029796464,"about_ca_system_score_gemma":0.0002614887,"threshold_uncertainty_score":0.2942409},"labels":[],"label_agreement":null},{"id":"W4376619319","doi":"10.1016/j.lungcan.2023.107247","title":"Germline EGFR c.2527G &gt; A (p.V843I) variant and familial lung cancer","year":2023,"lang":"de","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Germline; Epidermal growth factor receptor; Lung cancer; Proband; Medicine; Germline mutation; Missense mutation; Adenocarcinoma; Exon; Gefitinib; Somatic cell; Oncology; Cancer research; Internal medicine; Cancer; Mutation; Genetics; Biology; Gene","score_opus":0.012307176042524784,"score_gpt":0.3530358392758478,"score_spread":0.340728663233323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376619319","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2950373,0.6384362,0.00034404884,0.027712423,0.022334456,0.0043060547,0.0042672623,0.00077698304,0.006785282],"genre_scores_gemma":[0.6978476,0.18474264,0.00029545865,0.0047804224,0.014175729,0.003124841,0.00088992034,0.0003922016,0.09375116],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963398,0.0000970713,0.00067484536,0.0010687361,0.00067327695,0.0011462921],"domain_scores_gemma":[0.998102,0.00017108898,0.00025803404,0.00063602114,0.00025656997,0.0005762657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025815345,0.0006375313,0.0008552378,0.00032802776,0.00046705006,0.00012974007,0.00020514529,0.00033279593,0.0022017206],"category_scores_gemma":[0.000065893044,0.00055909826,0.00022321506,0.0011108995,0.00021256387,0.00022861871,0.0001885456,0.00048041917,0.00021216217],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012741499,0.0007010022,0.2655368,0.004927031,0.01806991,0.0027285875,0.017499609,0.002082379,0.0026027344,0.0025857447,0.61786765,0.064124435],"study_design_scores_gemma":[0.020759901,0.0005447661,0.23852116,0.0059725796,0.030949833,0.000044772303,0.0008130495,0.11313703,0.0004683942,0.00023369354,0.5864835,0.0020713473],"about_ca_topic_score_codex":0.009397855,"about_ca_topic_score_gemma":0.0018449427,"teacher_disagreement_score":0.45369354,"about_ca_system_score_codex":0.001574729,"about_ca_system_score_gemma":0.0016987796,"threshold_uncertainty_score":0.99968606},"labels":[],"label_agreement":null},{"id":"W4376642196","doi":"10.1038/s41392-023-01403-w","title":"SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer","year":2023,"lang":"en","type":"article","venue":"Signal Transduction and Targeted Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Renji Hospital; Guangdong Provincial People's Hospital; National Natural Science Foundation of China","keywords":"Syk; Cancer research; Downregulation and upregulation; Population; In vivo; Targeted therapy; Medicine; Biology; Lung cancer; Cell; Oncology; Cancer; Internal medicine; Gene; Tyrosine kinase; Genetics; Receptor","score_opus":0.012581210938398363,"score_gpt":0.297163919530721,"score_spread":0.28458270859232265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376642196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594384,0.00077297876,0.00009167921,0.0016476538,0.00019843582,0.00078052713,0.00033413302,0.00015606171,0.00007470523],"genre_scores_gemma":[0.99688137,0.00073288474,0.00015345888,0.0006641552,0.000080198035,0.0001490371,0.00012540063,0.00004691209,0.0011666098],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986282,0.00014298799,0.00025477653,0.00035803355,0.00028671345,0.00032928787],"domain_scores_gemma":[0.9994126,0.00012712281,0.000069588,0.00010868992,0.00009953703,0.0001824506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025971237,0.00021106753,0.00028786086,0.00039052346,0.00013358555,0.000035419336,0.00003632908,0.00008536557,0.00045890512],"category_scores_gemma":[0.000016914379,0.0001631487,0.00005805701,0.001085375,0.00005043162,0.00013164198,0.0000045355605,0.00018199327,0.000010406184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0094217,0.00034222877,0.020104192,0.00004318885,0.0005243919,0.000101627054,0.0141415605,0.0009720112,0.94136864,0.0000020682917,0.00088143104,0.012096962],"study_design_scores_gemma":[0.04486332,0.0048328713,0.28882417,0.0014268793,0.00044946154,0.000020850466,0.0028304025,0.0019469179,0.6407017,0.00021425098,0.0127563495,0.0011327942],"about_ca_topic_score_codex":0.00034983907,"about_ca_topic_score_gemma":0.000053285454,"teacher_disagreement_score":0.3006669,"about_ca_system_score_codex":0.00018365598,"about_ca_system_score_gemma":0.0002303769,"threshold_uncertainty_score":0.6653011},"labels":[],"label_agreement":null},{"id":"W4376870566","doi":"10.1200/jco.22.02546","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Febrile neutropenia; Lung cancer; Chemotherapy; Regimen; Oncology; Phases of clinical research; Chemotherapy regimen; Dexamethasone; Gastroenterology; Surgery; Cisplatin","score_opus":0.057080918598974816,"score_gpt":0.4704023204420486,"score_spread":0.4133214018430738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376870566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947822,0.00018219383,0.00004271296,0.0012052445,0.00051605474,0.0019401923,0.00000780681,0.000010154086,0.0013134107],"genre_scores_gemma":[0.99685717,0.001198816,0.000741717,0.00026011167,0.0003076819,0.00007873897,0.000020058567,0.00002651644,0.0005091693],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99713564,0.0002776762,0.0018225887,0.0001856174,0.00035118763,0.0002273113],"domain_scores_gemma":[0.9956347,0.0016237281,0.0018798176,0.00015902102,0.0004917937,0.00021095094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014583751,0.00016719147,0.0023592962,0.000242531,0.000023697867,0.0000051444513,0.00009571631,0.00017924266,0.00010866353],"category_scores_gemma":[0.00043765808,0.0000892852,0.00034434436,0.00046806879,0.00016047854,0.00007011845,0.000011676192,0.0003819833,0.0000016910506],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9227839,0.0062357886,0.050320107,0.000044058426,0.0021926374,0.00013803241,0.00037731492,0.000059503498,0.000007641596,0.0000021016401,0.000682292,0.017156607],"study_design_scores_gemma":[0.93379754,0.038445476,0.023376584,0.00023261365,0.0030788777,0.0000027469025,0.00007669548,0.00018933564,0.000055822067,0.0000034066,0.00065669086,0.000084210566],"about_ca_topic_score_codex":0.00020793229,"about_ca_topic_score_gemma":0.00014264786,"teacher_disagreement_score":0.032209687,"about_ca_system_score_codex":0.00023487772,"about_ca_system_score_gemma":0.002174379,"threshold_uncertainty_score":0.3857255},"labels":[],"label_agreement":null},{"id":"W4377077924","doi":"10.1007/978-1-0716-3056-3_6","title":"Generation and Characterization of an Isogenic Cell Line Model of Radioresistant Esophageal Adenocarcinoma","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Radioresistance; Cancer research; Radiosensitivity; Adenocarcinoma; Cell cycle; Cancer; Esophageal cancer; Biology; DNA damage; Radiation therapy; DNA repair; Cell; Apoptosis; Cell culture; Medicine; Gene; DNA; Internal medicine; Genetics","score_opus":0.04422042892654888,"score_gpt":0.41340245913722146,"score_spread":0.3691820302106726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377077924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69958544,0.00032500515,0.29978544,0.000055538592,0.000030197598,0.00015610206,0.000030142397,0.0000078411595,0.000024291374],"genre_scores_gemma":[0.69114894,0.0001032652,0.3081617,0.00005199252,0.000016871732,0.000017297421,0.0004121713,0.000009650502,0.00007810373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992837,0.00020513154,0.00022100363,0.00016332114,0.000039167564,0.000087725515],"domain_scores_gemma":[0.9996817,0.00002007756,0.00007772604,0.0001435427,0.000044210592,0.00003271981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026590686,0.00006635664,0.0002075317,0.00016420976,0.000012580483,0.0000014550101,0.000028830114,0.00008135486,0.000005165802],"category_scores_gemma":[0.00002925429,0.000057621717,0.000029901912,0.00019143782,0.000047227863,0.000017729382,0.000017471213,0.000041666888,2.5947247e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003734039,0.0000590116,0.002906628,0.00003777454,0.00002677251,0.000008689188,0.00026501785,0.00026659673,0.9898988,0.00046621787,6.0704707e-7,0.006026521],"study_design_scores_gemma":[0.00093332405,0.00039392366,0.019728683,0.000008447547,0.00010296105,0.0000043707328,0.000015558322,0.1158359,0.8623956,0.0005292392,0.0000057070597,0.000046282137],"about_ca_topic_score_codex":0.000020317293,"about_ca_topic_score_gemma":0.0000026798523,"teacher_disagreement_score":0.12750322,"about_ca_system_score_codex":0.000020254973,"about_ca_system_score_gemma":0.000059403697,"threshold_uncertainty_score":0.23497455},"labels":[],"label_agreement":null},{"id":"W4377103003","doi":"10.3390/curroncol30050384","title":"Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Clinical trial; Oncology; Internal medicine; Chemotherapy; ALK inhibitor; Adenocarcinoma; Randomized controlled trial; Immunotherapy; non-small cell lung cancer (NSCLC); Cancer","score_opus":0.06432029119869255,"score_gpt":0.42426832604305653,"score_spread":0.359948034844364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377103003","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039288434,0.99139464,0.00008855808,0.00047358018,0.00073698926,0.0057452265,0.00009489381,0.000029055192,0.0010441849],"genre_scores_gemma":[0.00055075675,0.9945528,0.00010126426,0.000025387635,0.00014050498,0.0038529038,0.0003287101,0.00006084415,0.00038684582],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981263,0.000062578554,0.00068443146,0.00045292612,0.00031201338,0.00036170543],"domain_scores_gemma":[0.9987184,0.00006303431,0.00056656235,0.0004072388,0.0001710674,0.00007374507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017510983,0.00037718908,0.001169104,0.00023077297,0.000069661255,0.000013024954,0.00023826372,0.00014067507,0.000042188367],"category_scores_gemma":[0.0000016849307,0.00022763207,0.00019490733,0.00060959987,0.00004945738,0.000035058012,0.000071199065,0.00037108976,0.000005098966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051945903,0.0011824784,0.0033057078,0.090807095,0.0010346514,0.00006437633,0.0013537222,0.000008971184,4.2716444e-8,0.00004580958,0.0009898023,0.9011554],"study_design_scores_gemma":[0.0059134467,0.00058094773,0.0015901403,0.056237485,0.0083188815,0.000001405165,0.0018704564,0.000021265456,6.104767e-7,0.0000048939446,0.9251941,0.00026637563],"about_ca_topic_score_codex":0.000058507947,"about_ca_topic_score_gemma":0.00017306964,"teacher_disagreement_score":0.9242043,"about_ca_system_score_codex":0.0012259802,"about_ca_system_score_gemma":0.0009066301,"threshold_uncertainty_score":0.9282567},"labels":[],"label_agreement":null},{"id":"W4377940137","doi":"10.1158/1078-0432.ccr-23-0580","title":"The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; National Institutes of Health; Revolution Medicines; National Center for Advancing Translational Sciences; Seagen; Gilead Sciences; Sanofi; G1 Therapeutics; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research","keywords":"Medicine; Oncology; KRAS; Internal medicine; Cohort; Cancer; Lung cancer; Response Evaluation Criteria in Solid Tumors; Docetaxel; Confidence interval; Ramucirumab; Nivolumab; ROS1; Immunotherapy; Clinical trial; Adenocarcinoma; Phases of clinical research; Colorectal cancer","score_opus":0.1501539766493789,"score_gpt":0.5403167405984413,"score_spread":0.39016276394906235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377940137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98780733,0.0019461566,0.000057301964,0.0022883767,0.0008091949,0.004283261,0.0009110528,0.000076608936,0.0018207205],"genre_scores_gemma":[0.9514829,0.019109769,0.0017188092,0.0005445356,0.0029486485,0.004221893,0.001115194,0.00015297078,0.018705266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960296,0.00042401813,0.0010525964,0.0010421401,0.0007270302,0.00072458026],"domain_scores_gemma":[0.9929143,0.0043304954,0.0002366183,0.001113347,0.00095772435,0.00044750457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046247025,0.00022283375,0.00063272164,0.00010432792,0.00087256666,0.00015774071,0.0004744186,0.00015162093,0.000036126457],"category_scores_gemma":[0.00075864914,0.00012191183,0.00014822365,0.0005751927,0.00064948754,0.000098812234,0.0005037863,0.0009453287,0.0000070079095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029467945,0.00018867316,0.90839356,0.00014962873,0.0006919736,0.000023870036,0.00012559483,0.000003879627,0.000033328783,0.000020921429,0.041587297,0.045834493],"study_design_scores_gemma":[0.010507156,0.0009707449,0.937008,0.00044211157,0.0008707983,8.9382684e-7,0.0002586092,0.0025871017,0.000037338792,0.000045400335,0.047069304,0.00020249373],"about_ca_topic_score_codex":0.0038156796,"about_ca_topic_score_gemma":0.011430324,"teacher_disagreement_score":0.045631997,"about_ca_system_score_codex":0.00043291372,"about_ca_system_score_gemma":0.0028044672,"threshold_uncertainty_score":0.67111653},"labels":[],"label_agreement":null},{"id":"W4377944155","doi":"10.1016/j.jtho.2023.05.015","title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Astellas Pharma; Yuhan; BeiGene; G1 Therapeutics; Pfizer; Genentech; American Association for Cancer Research; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Osimertinib; Tolerability; Placebo; Internal medicine; Adverse effect; Oncology; Surgery; Cancer; Adenocarcinoma; Pathology","score_opus":0.05695210664319922,"score_gpt":0.4782207666485358,"score_spread":0.4212686600053366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377944155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884947,0.00014200971,0.00009163416,0.009538143,0.00018037621,0.0010994648,0.0004002841,0.000014557334,0.00003881589],"genre_scores_gemma":[0.998825,0.0000262103,0.00050493295,0.00027455686,0.00002894637,0.000009844276,0.00027694734,0.000015391643,0.000038144724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963289,0.0006067436,0.0020841153,0.0002315283,0.0005076257,0.00024107288],"domain_scores_gemma":[0.9965527,0.00063274003,0.001664766,0.000328319,0.0005799246,0.00024154622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018491326,0.00017027289,0.0017576177,0.00048784533,0.00006648204,0.000007841121,0.00014644559,0.00012225761,0.00018301414],"category_scores_gemma":[0.0006590938,0.0000977918,0.00018732635,0.0018320688,0.00012468733,0.000084903164,0.00006818272,0.00032533138,0.0000018658949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1406263,0.0022604184,0.8361096,0.00003891026,0.0042375736,0.000026913756,0.002326023,0.0003392834,0.000121828154,0.000007362071,0.0003565049,0.013549307],"study_design_scores_gemma":[0.05796281,0.007699741,0.9315937,0.000088156645,0.0014441026,0.000001024763,0.00080966123,0.00012969505,0.000043440108,0.000060402548,0.00008838951,0.00007886971],"about_ca_topic_score_codex":0.0036816527,"about_ca_topic_score_gemma":0.003964938,"teacher_disagreement_score":0.09548413,"about_ca_system_score_codex":0.0003587933,"about_ca_system_score_gemma":0.0010354916,"threshold_uncertainty_score":0.55655825},"labels":[],"label_agreement":null},{"id":"W4377982006","doi":"10.1016/j.jtocrr.2023.100530","title":"Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Québec Science (Canada); McGill University Health Centre","funders":"","keywords":"ROS1; Immunohistochemistry; Adenocarcinoma; Lung cancer; Carcinogenesis; Cancer research; Fluorescence in situ hybridization; Medicine; Biology; Internal medicine; Pathology; Cancer; Oncology; Gene; Genetics","score_opus":0.04095527057484923,"score_gpt":0.4228655320139387,"score_spread":0.3819102614390895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377982006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957019,0.0010769046,0.000008530085,0.0015353916,0.00004367091,0.000919448,0.000038166778,0.00013091946,0.0005450641],"genre_scores_gemma":[0.9960636,0.0002975045,0.00011711283,0.000057521924,0.00003417904,0.00018286331,0.0005131736,0.000040907882,0.00269316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662906,0.00031429523,0.0010599312,0.0007312681,0.0007985004,0.00046697079],"domain_scores_gemma":[0.9973853,0.00097073097,0.0002884931,0.00037854505,0.00052243506,0.00045445096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002318807,0.00020248063,0.00054579537,0.00016786656,0.0002919627,0.0000536853,0.00005757635,0.00032152823,0.00003117998],"category_scores_gemma":[0.002874308,0.00013144639,0.00007140737,0.0008882518,0.00064466853,0.00009916628,0.000059335223,0.0009726389,0.0000020752386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00111454,0.0006206935,0.9838305,0.00010554296,0.000259921,0.0039008558,0.00037333407,0.000004069862,0.0074632107,0.0000013882172,0.0018087139,0.0005172251],"study_design_scores_gemma":[0.0065898728,0.0011660329,0.9886419,0.0011886794,0.00021767679,0.00022743134,0.00052300195,0.00034117652,0.0007059748,0.000080500286,0.00013736542,0.00018035146],"about_ca_topic_score_codex":0.0003609606,"about_ca_topic_score_gemma":0.00010441283,"teacher_disagreement_score":0.006757236,"about_ca_system_score_codex":0.00015437626,"about_ca_system_score_gemma":0.0005762222,"threshold_uncertainty_score":0.53602284},"labels":[],"label_agreement":null},{"id":"W4378348142","doi":"10.3390/curroncol30050373","title":"The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Internal medicine; Oncology; Lung cancer; Fluorescence in situ hybridization; Epidermal growth factor receptor; Gene duplication; Cancer; Pathology; Gastroenterology; Gene; Biology","score_opus":0.06004930416990659,"score_gpt":0.43779557162726945,"score_spread":0.37774626745736284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378348142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934306,0.0033265506,0.000015347727,0.000825216,0.00075590785,0.00046283964,0.000014287015,0.000033503853,0.001135733],"genre_scores_gemma":[0.99829745,0.0014199346,0.00002372053,0.0000194645,0.00004149459,0.00010950142,0.00006611896,0.000006108336,0.000016190164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991801,0.000057483594,0.0002593512,0.00016919606,0.00010958792,0.00022427314],"domain_scores_gemma":[0.9994331,0.00016885306,0.000092618124,0.00018740496,0.00007770463,0.00004032811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017579847,0.00007751066,0.00020957059,0.00016294594,0.000051296007,0.0000044662925,0.000086756794,0.000056848956,0.000018243814],"category_scores_gemma":[0.00011531164,0.000057453817,0.000032823544,0.0007548419,0.00008401594,0.000034248642,0.000032570155,0.00013966007,0.00006590113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002351855,0.0015900452,0.33415878,0.000071547795,0.000060806462,0.000012274405,0.005370291,0.000113188384,0.0014347978,0.0017696792,0.00091308705,0.65427035],"study_design_scores_gemma":[0.0027812452,0.0019148537,0.79924184,0.00019829863,0.00015158209,0.000011265826,0.0032081732,0.0019977062,0.0007767316,0.002213737,0.18736471,0.00013983682],"about_ca_topic_score_codex":0.00006959428,"about_ca_topic_score_gemma":0.0006252755,"teacher_disagreement_score":0.65413046,"about_ca_system_score_codex":0.00033196513,"about_ca_system_score_gemma":0.0002698564,"threshold_uncertainty_score":0.23428987},"labels":[],"label_agreement":null},{"id":"W4378619207","doi":"10.3390/curroncol30060405","title":"Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Afatinib; Medicine; T790M; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Erlotinib; EGFR inhibitors; Cancer research; ERBB3; Cancer; Gefitinib","score_opus":0.28759267142771533,"score_gpt":0.5704480621714877,"score_spread":0.28285539074377236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378619207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000018356782,0.9884516,0.00009515371,0.0008806435,0.00066339265,0.008936693,0.00032190038,0.000041379153,0.0006073807],"genre_scores_gemma":[0.0000013788808,0.9849648,0.00024724315,0.000044172622,0.000247978,0.011909124,0.0016344131,0.000050501236,0.000900374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985151,0.00013365399,0.00065082056,0.00033340583,0.0001543907,0.0002125793],"domain_scores_gemma":[0.99731195,0.0013100882,0.0006399264,0.0004074386,0.00025380222,0.00007679712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013164167,0.00034666416,0.0020734144,0.00011581678,0.0001269716,0.0000055063965,0.00010711118,0.000115887946,0.000051751776],"category_scores_gemma":[0.00009110429,0.00015875498,0.0005410345,0.00045338,0.00014882266,0.000021387434,0.000013178711,0.00013612941,0.000029083709],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039745264,0.0008205454,0.000006117625,0.03788378,0.0018431289,0.000008786392,0.0012849163,4.6142426e-7,7.861053e-9,0.00014924769,0.0050252946,0.95293796],"study_design_scores_gemma":[0.0018580493,0.003928884,0.000006291416,0.056075487,0.020834815,0.000043947057,0.0003660184,0.0000038063204,1.4946666e-7,0.00002691587,0.9167361,0.00011950894],"about_ca_topic_score_codex":0.000018698172,"about_ca_topic_score_gemma":0.00008381438,"teacher_disagreement_score":0.95281845,"about_ca_system_score_codex":0.00093987986,"about_ca_system_score_gemma":0.0019911763,"threshold_uncertainty_score":0.647384},"labels":[],"label_agreement":null},{"id":"W4379014173","doi":"10.1158/1078-0432.c.6489322.v3","title":"Data from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AstraZeneca","keywords":"Tremelimumab; Durvalumab; Medicine; Head and neck squamous-cell carcinoma; Internal medicine; Confidence interval; Oncology; Head and neck cancer; Hazard ratio; Immunotherapy; Cancer; Nivolumab","score_opus":0.0908087730992378,"score_gpt":0.365827563669915,"score_spread":0.2750187905706772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379014173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859695,0.0013901363,0.00006489917,0.00071468815,0.00023187135,0.0025152618,0.008535896,0.000065667395,0.00051209744],"genre_scores_gemma":[0.9811604,0.0002539364,0.0054167635,0.00003428075,0.00012781439,0.00045145763,0.008338761,0.000071696835,0.004144885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974377,0.00011111327,0.00063408184,0.0010276038,0.00051055505,0.0002789197],"domain_scores_gemma":[0.9980372,0.0005193098,0.00026745212,0.0008235425,0.00012223322,0.00023022562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012805178,0.00046702632,0.0010184642,0.0002477903,0.000052679203,0.00004459178,0.00016305466,0.000086492706,0.00041459614],"category_scores_gemma":[0.0001043064,0.000273524,0.000059153488,0.00018457558,0.00011377387,0.00008698776,0.00033616717,0.00020726392,0.000010897689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10898112,0.02402451,0.6960548,0.01674391,0.014300547,0.02642252,0.06465273,0.0023519169,0.00037132093,0.00037853688,0.0050049694,0.04071308],"study_design_scores_gemma":[0.09415873,0.019887118,0.8329774,0.0023675014,0.011968928,0.00037791094,0.010988444,0.023567403,0.00037492168,0.00086092716,0.0012529396,0.0012177819],"about_ca_topic_score_codex":0.034858003,"about_ca_topic_score_gemma":0.02856628,"teacher_disagreement_score":0.13692255,"about_ca_system_score_codex":0.000386751,"about_ca_system_score_gemma":0.0023759361,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W4379197252","doi":"10.1007/s40273-023-01279-2","title":"A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Waterloo; Women's College Hospital; University of Toronto","funders":"","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Alectinib; ALK inhibitor; Lung cancer; Internal medicine; Systematic review; Oncology; Cochrane Library; Population; non-small cell lung cancer (NSCLC); Intensive care medicine; MEDLINE; Meta-analysis; Environmental health","score_opus":0.045303811579656184,"score_gpt":0.41740954539548386,"score_spread":0.3721057338158277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379197252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037411617,0.9784313,0.000037219124,0.0000080379505,0.00032067415,0.016701665,0.0006844092,0.000015580743,0.000059964575],"genre_scores_gemma":[0.0025231862,0.99270624,0.000074093514,0.00010173545,0.000022630065,0.0042155194,0.00016816604,0.00010819852,0.00008021411],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99715775,0.00032690456,0.0016024323,0.00043301552,0.000206396,0.00027347807],"domain_scores_gemma":[0.9965877,0.00077943655,0.0017972583,0.00048813978,0.00022826015,0.000119220014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003292267,0.00051279744,0.003796913,0.00029853414,0.000038419654,0.000010078283,0.0002614527,0.00006517595,0.00003369823],"category_scores_gemma":[0.00011852409,0.00027718418,0.0005172304,0.0008250058,0.00007033652,0.000086003914,0.00007709838,0.0001602999,0.000006572924],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022858233,0.00042263538,0.00035263557,0.9708501,0.0030134942,0.000015757709,0.000054176755,0.00034547283,0.0000013737867,0.000001106564,0.00003896276,0.024675692],"study_design_scores_gemma":[0.0064886217,0.00025584418,0.00020274984,0.9444293,0.04703252,0.0000046410532,0.00002916581,0.00021321097,0.000114908325,5.3500656e-7,0.0009271713,0.0003013239],"about_ca_topic_score_codex":0.0001932679,"about_ca_topic_score_gemma":0.000101814694,"teacher_disagreement_score":0.044019025,"about_ca_system_score_codex":0.0012207446,"about_ca_system_score_gemma":0.0023897258,"threshold_uncertainty_score":0.99996805},"labels":[],"label_agreement":null},{"id":"W4379280261","doi":"10.1056/nejmoa2304594","title":"Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Internal medicine; Hazard ratio; Placebo; Clinical endpoint; Lung cancer; Regimen; Population; Oncology; Surgery; Confidence interval; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology","score_opus":0.02339926590478572,"score_gpt":0.3316075296963627,"score_spread":0.30820826379157695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97073036,0.00062945974,0.00010733451,0.021764563,0.000511476,0.00022297027,0.0000033538474,0.000040741998,0.005989746],"genre_scores_gemma":[0.9952894,0.00033340734,0.00019521987,0.00056045543,0.0014595877,0.000002675306,0.000040143168,0.00002455078,0.0020945827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985622,0.00007046477,0.00046094926,0.00012874298,0.00053773314,0.00023990085],"domain_scores_gemma":[0.99895453,0.00021756734,0.00019318434,0.00013762238,0.00021203258,0.00028504385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050885114,0.00013963264,0.00047304961,0.00038997477,0.000033679822,0.000006767368,0.00007211368,0.000047171678,0.00019723327],"category_scores_gemma":[0.00025412827,0.000077809476,0.00004290621,0.0007093137,0.000059847567,0.000083973486,0.000010491431,0.00031578392,0.000011917082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026989842,0.0008614506,0.5117085,0.00028324936,0.0026139484,0.023102216,0.019673588,0.001464169,0.038091097,0.0005331751,0.15003197,0.22464679],"study_design_scores_gemma":[0.35358348,0.009009226,0.5580348,0.003032559,0.0010745053,0.002362594,0.0012472022,0.0002490365,0.0008428463,0.0007058778,0.06959198,0.0002659465],"about_ca_topic_score_codex":0.00047353553,"about_ca_topic_score_gemma":0.00024097224,"teacher_disagreement_score":0.32659364,"about_ca_system_score_codex":0.000107117885,"about_ca_system_score_gemma":0.0004363706,"threshold_uncertainty_score":0.31729785},"labels":[],"label_agreement":null},{"id":"W4379280591","doi":"10.1200/jco.2023.41.16_suppl.9072","title":"Outcomes of patients with advanced EGFR mutant lung cancer treated with first line (1L) osimertinib (osi) who would not have met eligibility criteria for the FLAURA trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Discontinuation; Performance status; Hazard ratio; Anemia; Proportional hazards model; Oncology; Creatinine; Clinical trial; Cancer; Confidence interval","score_opus":0.09955501633614276,"score_gpt":0.5343672649270595,"score_spread":0.4348122485909168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98357606,0.00020352623,0.00023487862,0.013104539,0.0007495295,0.0018216114,0.00017852815,0.000017854185,0.00011346525],"genre_scores_gemma":[0.99602574,0.00066072715,0.0009513788,0.0013932234,0.00035502698,0.00016681652,0.00003009933,0.000032349955,0.00038465098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968866,0.00015376229,0.0020015761,0.00026376938,0.00041702605,0.0002772837],"domain_scores_gemma":[0.99201626,0.0044315336,0.001881802,0.0003112083,0.0011385486,0.00022062837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012062677,0.00021218286,0.0017663377,0.00010472811,0.00010755009,0.000010330296,0.00015765456,0.00026340352,0.00009110248],"category_scores_gemma":[0.0021338842,0.00009360768,0.0004005484,0.0002550399,0.00024482483,0.00011412019,0.000029806246,0.0005167852,0.0000010658555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23166785,0.0025869042,0.71457064,0.00013278727,0.0047533293,0.00007006003,0.00041992418,0.0004452173,0.00003827903,0.000016075219,0.0027625759,0.04253633],"study_design_scores_gemma":[0.14703071,0.03380366,0.79772663,0.0002670591,0.0044831294,0.000006114685,0.00017307365,0.00044375547,0.0002425761,0.000026822681,0.015671454,0.00012499855],"about_ca_topic_score_codex":0.000103482365,"about_ca_topic_score_gemma":0.00042611395,"teacher_disagreement_score":0.084637135,"about_ca_system_score_codex":0.00030135986,"about_ca_system_score_gemma":0.0015063379,"threshold_uncertainty_score":0.38172105},"labels":[],"label_agreement":null},{"id":"W4379280905","doi":"10.1200/jco.2023.41.16_suppl.8567","title":"EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable <i>EGFR</i>-mutant non-small-cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Erlotinib; Durvalumab; non-small cell lung cancer (NSCLC); Lung cancer; Hazard ratio; Cancer; Nivolumab; Epidermal growth factor receptor; Confidence interval; Immunotherapy","score_opus":0.0736198032207939,"score_gpt":0.4727268993844826,"score_spread":0.39910709616368867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97832364,0.0022861704,0.000060613773,0.006758367,0.009268522,0.0005970349,0.000017592469,0.000032345957,0.002655733],"genre_scores_gemma":[0.9942041,0.0023055177,0.00031476555,0.00066414237,0.0017561006,0.000049883787,0.00003449854,0.000041904586,0.00062905793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99624354,0.0002475348,0.0021764885,0.00033936588,0.0005068731,0.00048617888],"domain_scores_gemma":[0.99635,0.001445957,0.0012110282,0.00021363817,0.00032679722,0.00045256288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020057927,0.00023992389,0.0013902836,0.00034158904,0.00009305028,0.000024852316,0.00016710756,0.00036374066,0.00011552122],"category_scores_gemma":[0.0013255745,0.00017468362,0.000599056,0.0007731588,0.00008230931,0.00021200419,0.000071645845,0.0009322083,0.000036593497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012158625,0.0085463775,0.65324855,0.0005998345,0.0032310383,0.00893086,0.0024645065,0.0035270185,0.010531759,0.00010842048,0.045662336,0.2509907],"study_design_scores_gemma":[0.2650151,0.02428702,0.5450773,0.0030596885,0.008131722,0.0001469745,0.0024286562,0.0148723805,0.008402169,0.0001233374,0.12733763,0.001117963],"about_ca_topic_score_codex":0.00037208642,"about_ca_topic_score_gemma":0.0004533224,"teacher_disagreement_score":0.2528565,"about_ca_system_score_codex":0.0015412034,"about_ca_system_score_gemma":0.004376651,"threshold_uncertainty_score":0.7763991},"labels":[],"label_agreement":null},{"id":"W4379280969","doi":"10.1200/jco.2023.41.16_suppl.9008","title":"Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Amgen","keywords":"Docetaxel; KRAS; Medicine; Clinical endpoint; Internal medicine; Oncology; Biomarker; Cancer; Lung cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Phases of clinical research; Randomized controlled trial; Clinical trial; Chemotherapy; Colorectal cancer","score_opus":0.1010531826313901,"score_gpt":0.5176842000167955,"score_spread":0.4166310173854054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379280969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577856,0.00035452246,0.000061363906,0.00036898884,0.0011667946,0.0010880886,0.000102980935,0.000013860823,0.0010648293],"genre_scores_gemma":[0.99776816,0.00083205826,0.0007153535,0.00012923121,0.00015638661,0.00004338942,0.00009127128,0.0000319217,0.00023220424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99590087,0.00029300156,0.0026959628,0.00029075428,0.0004910595,0.00032835794],"domain_scores_gemma":[0.99429834,0.0013701078,0.0027641219,0.0002483572,0.0010188553,0.0003002343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008959641,0.00024536558,0.0020666255,0.00043915227,0.000031412612,0.0000055679357,0.00016632873,0.0002982722,0.000112519505],"category_scores_gemma":[0.00077982066,0.00016022955,0.00044839492,0.0010322253,0.00020350376,0.00014377113,0.000036956426,0.00044003665,0.0000030053761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64276326,0.014858267,0.30855674,0.00019709702,0.0033184679,0.00045171977,0.0004234454,0.00051200984,0.0024139343,0.0000013485985,0.0023863688,0.024117323],"study_design_scores_gemma":[0.66954935,0.060685784,0.25996387,0.00061735837,0.0046878983,0.000007490271,0.00024227938,0.00091890007,0.0020539295,0.0000059384993,0.0010745374,0.00019268515],"about_ca_topic_score_codex":0.00046448206,"about_ca_topic_score_gemma":0.00033443107,"teacher_disagreement_score":0.04859287,"about_ca_system_score_codex":0.00035303002,"about_ca_system_score_gemma":0.0027922809,"threshold_uncertainty_score":0.6533972},"labels":[],"label_agreement":null},{"id":"W4379281203","doi":"10.1200/jco.2023.41.16_suppl.9116","title":"Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"LUNGevity Foundation","keywords":"Medicine; Internal medicine; Oncology; Proportional hazards model; Lung cancer; Osimertinib; Chemotherapy; Cancer; Medical record; Adenocarcinoma","score_opus":0.07240415758148412,"score_gpt":0.46693052407450025,"score_spread":0.39452636649301615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432456,0.00034795378,0.00046658996,0.0022028412,0.0012851354,0.00033059236,0.000040921706,0.000012345998,0.00098908],"genre_scores_gemma":[0.9938198,0.0027100078,0.0014328696,0.0005147932,0.00053831626,0.000015067635,0.000018927976,0.00003104452,0.00091921113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722654,0.00016124449,0.0018404481,0.00017814385,0.00033254214,0.00026110324],"domain_scores_gemma":[0.9958335,0.0011349239,0.001922848,0.00019441238,0.0005809664,0.00033331654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011307846,0.00016104171,0.0014889197,0.00017408167,0.000038944654,0.000007714569,0.00013579887,0.00014699608,0.00019251314],"category_scores_gemma":[0.00034488394,0.000099917466,0.00032599233,0.00030054865,0.00015490664,0.000068930836,0.000035140543,0.00051188207,0.000014293602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018575412,0.0017430539,0.9448481,0.0004346602,0.0018121846,0.0035926597,0.00060061,0.000053507774,0.0005008723,0.000014429031,0.00075350795,0.04378883],"study_design_scores_gemma":[0.008068462,0.0057407273,0.9789995,0.00041024847,0.0039788596,0.00017948278,0.00016235995,0.00019849143,0.00036523317,0.000015277488,0.0017700276,0.00011132589],"about_ca_topic_score_codex":0.00013297063,"about_ca_topic_score_gemma":0.00029811438,"teacher_disagreement_score":0.043677505,"about_ca_system_score_codex":0.00019040622,"about_ca_system_score_gemma":0.0029770692,"threshold_uncertainty_score":0.52811927},"labels":[],"label_agreement":null},{"id":"W4379281427","doi":"10.1200/jco.2023.41.16_suppl.9063","title":"Management of patients with <i>ALK</i>-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Pfizer","keywords":"Crizotinib; Medicine; ALK inhibitor; Lung cancer; Radiation therapy; Internal medicine; Brain metastasis; Randomization; Tyrosine-kinase inhibitor; Post-hoc analysis; Oncology; Surgery; Cancer; Gastroenterology; Randomized controlled trial; Metastasis","score_opus":0.04846021177409551,"score_gpt":0.49410377674524425,"score_spread":0.44564356497114876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900474,0.00014292912,0.0000470082,0.0043473244,0.0004890838,0.002348185,0.000016719483,0.0000047563353,0.0025565808],"genre_scores_gemma":[0.99538785,0.00087630627,0.0005273518,0.00211599,0.00023060889,0.000104749335,0.000009594903,0.000018802119,0.00072873227],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99759513,0.00043620603,0.0012408593,0.00018563568,0.00036430825,0.00017784782],"domain_scores_gemma":[0.99696875,0.0014259471,0.0010784623,0.00018699221,0.0002375525,0.000102306374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014793441,0.00013041242,0.0009184627,0.00014214483,0.000039774946,0.0000060820025,0.0001484494,0.00008796809,0.00003708163],"category_scores_gemma":[0.00010913338,0.00006903044,0.00018166845,0.0003509011,0.000065904336,0.000054066695,0.000015104578,0.00040720456,0.000001444704],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3707882,0.050998908,0.23390158,0.00011781734,0.0038908068,0.0020390989,0.007638687,0.0010828247,0.000034678513,0.000019051313,0.008574855,0.32091352],"study_design_scores_gemma":[0.31710202,0.07011937,0.60386384,0.00029821144,0.0008589604,0.0000015883486,0.0017245511,0.000057030917,0.00001813543,0.000008130501,0.0058786096,0.00006955445],"about_ca_topic_score_codex":0.000029414967,"about_ca_topic_score_gemma":0.000057613182,"teacher_disagreement_score":0.36996228,"about_ca_system_score_codex":0.0002505237,"about_ca_system_score_gemma":0.0005609635,"threshold_uncertainty_score":0.28149796},"labels":[],"label_agreement":null},{"id":"W4379281451","doi":"10.1200/jco.2023.41.16_suppl.9017","title":"Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; ROS1; Internal medicine; Oncology; Lung cancer; Cohort; Cancer; Adenocarcinoma","score_opus":0.037452175759279754,"score_gpt":0.4448131267924545,"score_spread":0.4073609510331747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225086,0.0039284783,0.00007629424,0.0013010661,0.0010063893,0.0010278627,0.00006648809,0.00001101483,0.00033154903],"genre_scores_gemma":[0.99577016,0.0030204745,0.00040944715,0.0002966603,0.0003812656,0.00004019352,0.00000988508,0.000019611842,0.000052291238],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960347,0.00069771585,0.002338355,0.00029252304,0.00030227812,0.00033442897],"domain_scores_gemma":[0.99432784,0.0035585612,0.001485142,0.00017525334,0.0002153444,0.0002378519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021638027,0.00019580733,0.0015496833,0.00026327206,0.00006161585,0.000016764372,0.00013080874,0.00019690793,0.000008172879],"category_scores_gemma":[0.0008888077,0.00012250325,0.0002446991,0.0004814488,0.00013715857,0.00011742865,0.000051001607,0.0006678938,9.2825985e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030739848,0.009640275,0.39314604,0.0021595436,0.0020651184,0.015147275,0.01454738,0.001886232,0.013986652,0.00011436661,0.0015824649,0.5149848],"study_design_scores_gemma":[0.09577339,0.010933294,0.8685023,0.0033263622,0.004103659,0.002723409,0.010042062,0.0026695684,0.00077527895,0.000019864216,0.00084709335,0.00028369922],"about_ca_topic_score_codex":0.00044294752,"about_ca_topic_score_gemma":0.00046478742,"teacher_disagreement_score":0.51470107,"about_ca_system_score_codex":0.00030717114,"about_ca_system_score_gemma":0.0013323069,"threshold_uncertainty_score":0.49955374},"labels":[],"label_agreement":null},{"id":"W4379282252","doi":"10.1200/jco.2023.41.16_suppl.e21118","title":"An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Afatinib; Osimertinib; Gefitinib; Erlotinib; Internal medicine; Oncology; Lung cancer; Epidermal growth factor receptor; Hazard ratio; Confidence interval; Proportional hazards model; Clinical endpoint; Performance status; Clinical trial; Cancer","score_opus":0.19225506038499515,"score_gpt":0.485844825525819,"score_spread":0.2935897651408238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957583,0.00067266735,0.00013081235,0.0016959645,0.00031700838,0.0003709279,0.0007991912,0.000020737974,0.00023441142],"genre_scores_gemma":[0.9933016,0.00029412206,0.0049550603,0.0006097787,0.00031388254,0.000043443808,0.00018533973,0.000031255597,0.00026554763],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957719,0.00053413934,0.0024291573,0.0003160544,0.00062851794,0.0003202441],"domain_scores_gemma":[0.9943091,0.0014106245,0.002580137,0.00023562311,0.0009524697,0.0005120191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011584994,0.00025443156,0.0033825007,0.00072259764,0.00006765787,0.000015237501,0.00017213174,0.00025342562,0.0008941578],"category_scores_gemma":[0.00039544096,0.00014648272,0.0016290344,0.0012259391,0.00016581843,0.00020269603,0.00004190138,0.00051706005,0.0000053149183],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002635869,0.004093866,0.5436153,0.000083052255,0.4176132,0.00055085705,0.0018218323,0.00090963294,0.00080419914,0.000009114284,0.0067648804,0.021098178],"study_design_scores_gemma":[0.008220284,0.01717557,0.38300517,0.00003249249,0.58497113,0.000024926938,0.00074568787,0.00034544192,0.003293834,0.000004886492,0.0019675693,0.00021298556],"about_ca_topic_score_codex":0.00047019363,"about_ca_topic_score_gemma":0.0002300065,"teacher_disagreement_score":0.16735794,"about_ca_system_score_codex":0.00017913544,"about_ca_system_score_gemma":0.0019150053,"threshold_uncertainty_score":0.9790401},"labels":[],"label_agreement":null},{"id":"W4379282849","doi":"10.1200/jco.2023.41.16_suppl.8521","title":"Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Surgery; Clinical endpoint; Oncology; Phases of clinical research; Neoadjuvant therapy; Chemotherapy; Randomized controlled trial; Gastroenterology; Cancer; Breast cancer","score_opus":0.11363242936900166,"score_gpt":0.4904432246227921,"score_spread":0.37681079525379046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779733,0.000107379754,0.000020766232,0.018702466,0.0010567495,0.00078906066,0.00016311588,0.000023987075,0.0011632113],"genre_scores_gemma":[0.9910575,0.0013889221,0.0005752028,0.0053078216,0.00068445643,0.00003254627,0.00017163092,0.00004594902,0.0007359819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99444664,0.0008163299,0.0033461666,0.00039726458,0.0006054051,0.00038822796],"domain_scores_gemma":[0.9807467,0.015633894,0.0023320839,0.00038502962,0.000563022,0.00033927488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004745242,0.00023334385,0.002201914,0.00013198749,0.00008661085,0.000023080447,0.0001891424,0.00032642297,0.00006752003],"category_scores_gemma":[0.00647848,0.000110945,0.00048355846,0.00044896573,0.0003245929,0.00015833102,0.000034469173,0.0010627359,0.000031922504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35405454,0.0066001066,0.50764215,0.0000047435333,0.0013526793,0.0004715615,0.00029368172,0.0000056719255,0.0000010072406,0.0000040090626,0.042938404,0.08663144],"study_design_scores_gemma":[0.34641674,0.031017162,0.5900144,0.00025824324,0.0005415053,0.000011088855,0.00023659588,0.000019366555,0.0000067185238,0.000065854634,0.031294145,0.00011818996],"about_ca_topic_score_codex":0.00042919288,"about_ca_topic_score_gemma":0.0003558395,"teacher_disagreement_score":0.08651324,"about_ca_system_score_codex":0.00023751167,"about_ca_system_score_gemma":0.0027525877,"threshold_uncertainty_score":0.7755814},"labels":[],"label_agreement":null},{"id":"W4379335761","doi":"10.1200/jco.2023.41.16_suppl.3053","title":"CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine; Colorectal cancer; Lung cancer; KRAS; Targeted therapy; Population; ROS1; Cancer; Adenocarcinoma","score_opus":0.06595717553733264,"score_gpt":0.4985419576020871,"score_spread":0.4325847820647544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938316,0.00012194732,0.00022382065,0.008597271,0.0005401521,0.00025915974,0.000017611108,0.000008149819,0.0008487394],"genre_scores_gemma":[0.99721485,0.00014161969,0.0013032875,0.0008788601,0.00019604222,0.000009136674,0.000005086634,0.000010482571,0.00024060413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972674,0.00029111843,0.0018175967,0.000120000055,0.00031472606,0.0001891206],"domain_scores_gemma":[0.9952867,0.0024769956,0.0015414117,0.00016582716,0.00043415552,0.00009490351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002903944,0.0000830606,0.00079468184,0.00010928929,0.00006773901,0.0000039283227,0.00013992193,0.00017428459,0.000024618505],"category_scores_gemma":[0.005166968,0.00005122369,0.00029989504,0.00035509208,0.000131947,0.00007247132,0.000041028856,0.00032001015,0.000007107363],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027969865,0.010853573,0.1081153,0.0006997805,0.0025851887,0.0044240365,0.042217273,0.00051869726,0.43570974,0.0024816212,0.0039655166,0.36045942],"study_design_scores_gemma":[0.013791592,0.011660279,0.9370766,0.00055596617,0.0005629405,0.00024364617,0.012970843,0.00026860074,0.011763612,0.0056682224,0.0053243623,0.00011333521],"about_ca_topic_score_codex":0.00009915784,"about_ca_topic_score_gemma":0.00087063,"teacher_disagreement_score":0.8289613,"about_ca_system_score_codex":0.00011027686,"about_ca_system_score_gemma":0.0007980248,"threshold_uncertainty_score":0.61857164},"labels":[],"label_agreement":null},{"id":"W4379337304","doi":"10.1200/jco.2023.41.16_suppl.e15144","title":"Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; ROS1; Immunohistochemistry; Lung cancer; Adenocarcinoma; Population; Pembrolizumab; Biomarker; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; Cancer; Pathology; Histology; Immunotherapy; Biology","score_opus":0.026041316998926454,"score_gpt":0.42986271819090716,"score_spread":0.4038214011919807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379337304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787104,0.00025915226,0.000026464415,0.0005278883,0.0001811853,0.00030138285,0.000009576154,0.0000053783174,0.0008179491],"genre_scores_gemma":[0.99869096,0.00027802394,0.00068993884,0.00006719554,0.00012615861,0.000018472674,0.000020471092,0.000013709744,0.00009507832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862814,0.000052124888,0.0008497675,0.00014363593,0.00019035855,0.00013596061],"domain_scores_gemma":[0.99815834,0.00024630668,0.0011340677,0.00009203774,0.00023876243,0.0001305161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037160423,0.00010961097,0.0005451543,0.00015510267,0.000028841678,0.0000045639363,0.000028730377,0.00014328201,0.00003249295],"category_scores_gemma":[0.00013836286,0.00006613191,0.00012263589,0.00022432495,0.00005540172,0.00008325057,0.000011546508,0.0002846163,6.78594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010390555,0.0014747987,0.9589416,0.0001332539,0.00091708597,0.00019871056,0.0005556981,0.002065658,0.007861056,0.0000024342983,0.0008290131,0.01663016],"study_design_scores_gemma":[0.0096724015,0.010573473,0.9767998,0.0004811235,0.00038198053,0.000045699886,0.00020322474,0.0005046964,0.001146067,0.000012735512,0.000105042134,0.00007378807],"about_ca_topic_score_codex":0.00075688615,"about_ca_topic_score_gemma":0.00007678763,"teacher_disagreement_score":0.017858192,"about_ca_system_score_codex":0.00072253164,"about_ca_system_score_gemma":0.0014591125,"threshold_uncertainty_score":0.26967812},"labels":[],"label_agreement":null},{"id":"W4379340511","doi":"10.1200/jco.2023.41.16_suppl.tps9160","title":"Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ottawa Hospital; BC Cancer Agency; William Osler Health System; Lions Gate Hospital; Grand River Hospital; McMaster University; University of Toronto; University Health Network; Western University","funders":"","keywords":"Osimertinib; Medicine; Pemetrexed; T790M; Oncology; Lung cancer; Docetaxel; Internal medicine; Chemotherapy; Erlotinib; Gefitinib; Epidermal growth factor receptor; Cancer; Cisplatin","score_opus":0.11977918865227226,"score_gpt":0.5251163492424061,"score_spread":0.40533716059013386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379340511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92612463,0.0020612762,0.00006394092,0.06570437,0.0009153784,0.0005175663,0.000008532519,0.00005732732,0.0045469906],"genre_scores_gemma":[0.9808234,0.009910587,0.0013569411,0.005131867,0.0009863755,0.000044309705,0.000012543976,0.000053564363,0.0016804375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968618,0.00024664635,0.001897536,0.00026356874,0.00037503033,0.00035540815],"domain_scores_gemma":[0.99681526,0.0011130418,0.0011543976,0.00021164988,0.0003908246,0.00031481162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018515898,0.00019400785,0.0013437546,0.00024521112,0.00004772329,0.000008645317,0.00015682254,0.00033152383,0.00030269087],"category_scores_gemma":[0.00057810405,0.00011844572,0.00027604876,0.0005451753,0.00013851315,0.000116650444,0.00002688222,0.0009165855,0.00002765665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02378889,0.0059937215,0.45897844,0.00018447831,0.0054859864,0.003728059,0.0044580353,0.001452851,0.0007883017,0.00016271586,0.040166147,0.45481238],"study_design_scores_gemma":[0.05036097,0.016674235,0.8428669,0.0008797604,0.00165634,0.0002620863,0.00098312,0.0016619012,0.0004978882,0.0003525532,0.08348652,0.0003177355],"about_ca_topic_score_codex":0.0001266626,"about_ca_topic_score_gemma":0.0001745511,"teacher_disagreement_score":0.45449463,"about_ca_system_score_codex":0.00034282877,"about_ca_system_score_gemma":0.0025591503,"threshold_uncertainty_score":0.48300764},"labels":[],"label_agreement":null},{"id":"W4379341221","doi":"10.1200/jco.2023.41.16_suppl.8523","title":"Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Oncology; KRAS; Lung cancer; Gemcitabine; Hazard ratio; Ipilimumab; Exact test; Cancer; Confidence interval; Immunotherapy; Colorectal cancer","score_opus":0.07769800303543296,"score_gpt":0.4769410763487024,"score_spread":0.39924307331326947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629655,0.0012316045,0.00009185404,0.03219971,0.0016693522,0.0007227955,0.000014215825,0.000021975784,0.001083027],"genre_scores_gemma":[0.9886258,0.0014564645,0.0029160662,0.003770491,0.00096274423,0.00008827712,0.000007260914,0.000045592853,0.0021272597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610746,0.00054913544,0.0022633332,0.00028605293,0.00036816663,0.00042584245],"domain_scores_gemma":[0.9960152,0.0018556495,0.0009138544,0.0002881141,0.00045611098,0.00047106124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037532677,0.000193163,0.0013352982,0.00047306833,0.000061322295,0.000013000492,0.00019902526,0.00032569276,0.00018722728],"category_scores_gemma":[0.0011711713,0.00013760576,0.0004999549,0.0006684432,0.000087796114,0.00007008047,0.00005609838,0.0007867043,0.000055527467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13875902,0.008973107,0.3381705,0.00019485867,0.0015387058,0.009109395,0.005364609,0.011813833,0.2799408,0.000008016447,0.037414603,0.16871254],"study_design_scores_gemma":[0.06190703,0.034834057,0.7138554,0.001262059,0.0005995665,0.00006355454,0.0009099695,0.0027428288,0.022136662,0.000037074693,0.1612966,0.00035520334],"about_ca_topic_score_codex":0.00035900756,"about_ca_topic_score_gemma":0.0003212182,"teacher_disagreement_score":0.3756849,"about_ca_system_score_codex":0.0008223631,"about_ca_system_score_gemma":0.0072952653,"threshold_uncertainty_score":0.99833244},"labels":[],"label_agreement":null},{"id":"W4379345526","doi":"10.1200/jco.2023.41.16_suppl.e21159","title":"Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Erlotinib; Oncology; Lung cancer; Meta-analysis; Cochrane Library; Epidermal growth factor receptor; Clinical trial; Cancer","score_opus":0.17527750369452477,"score_gpt":0.5179745255713109,"score_spread":0.3426970218767861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000275918,0.99059176,0.000010022431,0.0011086272,0.00024446254,0.0074764253,0.00006272843,0.0000095363175,0.00022053476],"genre_scores_gemma":[0.00016487349,0.9938234,0.00086283276,0.00179203,0.00017996231,0.0012501735,0.000040264375,0.0000671829,0.001819251],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99138856,0.0011024205,0.0061027873,0.0005386221,0.0005153121,0.00035230487],"domain_scores_gemma":[0.9908185,0.0018663151,0.005582502,0.00047390626,0.0006178065,0.0006409954],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002633757,0.00054439745,0.021247938,0.0005923456,0.00003813893,0.000021568507,0.00022017976,0.00045700304,0.00008648826],"category_scores_gemma":[0.0010442551,0.00026603337,0.0032620062,0.0011542266,0.000054669206,0.00006598636,0.00008197176,0.000890736,0.000020256977],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014509485,0.0022977097,0.0011238279,0.68938595,0.29338023,0.0009465941,0.0002393029,0.0000059036843,1.3209646e-8,0.000001923631,0.0021816033,0.010291868],"study_design_scores_gemma":[0.0028561158,0.0056271446,0.00023044407,0.0928457,0.8734711,0.000043329546,0.000022063612,0.0000016322473,6.829807e-8,0.0000014405589,0.02470092,0.00020004569],"about_ca_topic_score_codex":0.00008731958,"about_ca_topic_score_gemma":0.0005397617,"teacher_disagreement_score":0.5965402,"about_ca_system_score_codex":0.001371177,"about_ca_system_score_gemma":0.0037034396,"threshold_uncertainty_score":0.9999792},"labels":[],"label_agreement":null},{"id":"W4379346591","doi":"10.1200/jco.2023.41.16_suppl.9126","title":"Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Internal medicine; Pharmacokinetics; Cancer; Surgery","score_opus":0.04505073144794957,"score_gpt":0.4709536166532698,"score_spread":0.4259028852053202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379346591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931231,0.000045417753,0.0000137253965,0.005389738,0.00049412926,0.00071565347,0.000017682903,0.000006747352,0.00019381153],"genre_scores_gemma":[0.9988739,0.00033174196,0.00006690318,0.00043567774,0.000060340702,0.000008898171,0.000012601135,0.0000107738015,0.0001991524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973728,0.00037351268,0.0016809305,0.00014635318,0.00028356528,0.00014285938],"domain_scores_gemma":[0.9970464,0.00083257706,0.0014503229,0.00022865807,0.0003601328,0.00008191093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013032941,0.00009710426,0.0006566611,0.00007912803,0.00007532214,0.0000068585887,0.00013528648,0.000089239504,0.000017999479],"category_scores_gemma":[0.0007861506,0.00004469445,0.00010730331,0.0003657772,0.00013759473,0.000072261166,0.00004313343,0.0003513708,0.0000025383495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031947173,0.013111462,0.56131524,0.000043885637,0.0013842628,0.00053611776,0.0035537805,0.00023209454,0.0005862407,0.000059464714,0.0015427243,0.38568753],"study_design_scores_gemma":[0.03130881,0.01747079,0.9447099,0.00008766993,0.0005584264,0.000075816795,0.0019531643,0.0001011126,0.000065301174,0.00009258618,0.0035238916,0.000052541833],"about_ca_topic_score_codex":0.000015792175,"about_ca_topic_score_gemma":0.000117552874,"teacher_disagreement_score":0.385635,"about_ca_system_score_codex":0.0001411837,"about_ca_system_score_gemma":0.0005125014,"threshold_uncertainty_score":0.18225868},"labels":[],"label_agreement":null},{"id":"W4379646019","doi":"10.1200/jco.2023.41.17_suppl.lba9016","title":"Intracranial efficacy of sotorasib versus docetaxel in pretreated<i> KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Medicine; Docetaxel; Oncology; KRAS; Internal medicine; Randomized controlled trial; Lung cancer; Brain metastasis; Cancer; Chemotherapy; Metastasis","score_opus":0.08553337113873839,"score_gpt":0.5350344985612282,"score_spread":0.4495011274224898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379646019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788584,0.0022889597,0.00040752825,0.0034458858,0.0058920737,0.0051553594,0.00026279362,0.000032523654,0.0036564579],"genre_scores_gemma":[0.98455507,0.0066528795,0.005526846,0.0005470313,0.002009298,0.0001940166,0.00029696675,0.000039473933,0.00017842623],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99253917,0.00087611325,0.005128827,0.00042949762,0.00059840793,0.0004279642],"domain_scores_gemma":[0.974307,0.01893417,0.005091203,0.0005092594,0.00074121315,0.0004171521],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0049826102,0.00032605595,0.005121889,0.00022923046,0.000058498645,0.00002431364,0.00043277143,0.0004619562,0.00017529386],"category_scores_gemma":[0.021929193,0.00021885427,0.0009110252,0.0006064686,0.00022149792,0.00049336575,0.0001334032,0.0009233407,0.000014228042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9482684,0.0061184764,0.0013682834,0.00004450491,0.0044880635,0.0013807721,0.0003374807,0.00035009187,0.00014591233,0.0000062208373,0.0013585638,0.03613324],"study_design_scores_gemma":[0.967919,0.008601876,0.0010550792,0.00040209448,0.011112072,0.000032846176,0.00038993216,0.006686658,0.00004099749,0.000026325,0.003566124,0.00016697923],"about_ca_topic_score_codex":0.00077297166,"about_ca_topic_score_gemma":0.00036305902,"teacher_disagreement_score":0.035966262,"about_ca_system_score_codex":0.000563558,"about_ca_system_score_gemma":0.00714029,"threshold_uncertainty_score":0.9984883},"labels":[],"label_agreement":null},{"id":"W4379662232","doi":"10.1200/jco.2023.41.17_suppl.lba3","title":"Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; T790M; Hazard ratio; Adjuvant; Clinical endpoint; Placebo; Lung cancer; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Confidence interval; Clinical trial; Cancer; Adenocarcinoma; Pathology","score_opus":0.05934005480903422,"score_gpt":0.44847918798046527,"score_spread":0.38913913317143106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954206,0.00020943343,0.000050232797,0.0017580792,0.0010740284,0.00075515406,0.00014975276,0.000011524511,0.00057121634],"genre_scores_gemma":[0.99772775,0.00041331572,0.00028293414,0.0004700965,0.0004659115,0.00002233845,0.00012098773,0.000025314574,0.00047137847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957996,0.00060688466,0.0023953405,0.00027626762,0.00061249913,0.0003094036],"domain_scores_gemma":[0.9938004,0.0028193956,0.002115583,0.00031304045,0.00071202876,0.00023954353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015461823,0.00019140894,0.0018346442,0.00028545925,0.000051598123,0.000011240822,0.00022580363,0.00025832182,0.00029039418],"category_scores_gemma":[0.0008718159,0.000104412975,0.00052498665,0.0010911605,0.00013050898,0.00008533204,0.000060196227,0.0007888163,0.0000047939125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08851994,0.002414928,0.89566576,0.000021566197,0.004648251,0.00022416445,0.00070044975,0.0011711634,0.000055338056,0.000003058141,0.001434258,0.0051411074],"study_design_scores_gemma":[0.13707511,0.007400044,0.8480046,0.00012993933,0.0050608516,4.3642217e-7,0.00021214536,0.0008644851,0.00003449256,0.000013983511,0.0011093757,0.00009456164],"about_ca_topic_score_codex":0.0026676138,"about_ca_topic_score_gemma":0.0027554142,"teacher_disagreement_score":0.04855518,"about_ca_system_score_codex":0.00029651396,"about_ca_system_score_gemma":0.0026408301,"threshold_uncertainty_score":0.4684719},"labels":[],"label_agreement":null},{"id":"W4379879292","doi":"10.1182/bloodadvances.2023010722","title":"CNL and aCML are prognostically distinct: a large National Cancer Database analysis","year":2023,"lang":"en","type":"letter","venue":"Blood Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; MorphoSys; Astellas Pharma; Galecto; Incyte; Bristol-Myers Squibb; Constellation Pharmaceuticals; CTI Biopharma; Gilead Sciences; Karyopharm Therapeutics; Celgene","keywords":"Oncology; Medicine","score_opus":0.021608255773769108,"score_gpt":0.3620123949419686,"score_spread":0.34040413916819945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379879292","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052276994,0.039443873,0.00047759945,0.89852387,0.0009772162,0.00239588,0.046064567,0.0005883239,0.006300949],"genre_scores_gemma":[0.046238065,0.013296643,0.00886632,0.7540694,0.020361442,0.005129538,0.07846024,0.0004519051,0.07312645],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819696,0.000026795306,0.00026299123,0.00058644766,0.0005894898,0.00033730365],"domain_scores_gemma":[0.99894744,0.00025547837,0.00019247261,0.00024699027,0.00025532264,0.00010231227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076236494,0.0002757667,0.0005379234,0.00028144434,0.00014719255,0.00004543135,0.0000887339,0.00016749691,0.00022903147],"category_scores_gemma":[0.00027713538,0.00021142953,0.00014738613,0.0005010997,0.00008195918,0.00012751012,0.00007076083,0.0004336253,0.000026535858],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048115853,0.00047968776,0.3050797,0.001500871,0.011320091,0.0023362103,0.00016632736,0.000010425456,0.000011826951,0.00012451847,0.676855,0.002067221],"study_design_scores_gemma":[0.0016166805,0.00008405235,0.060772844,0.00047746388,0.017243033,0.000022962884,0.00004680537,0.000059225844,0.0000146166785,0.00019730357,0.919173,0.0002920008],"about_ca_topic_score_codex":0.00008005656,"about_ca_topic_score_gemma":0.0008311166,"teacher_disagreement_score":0.24430685,"about_ca_system_score_codex":0.00007430983,"about_ca_system_score_gemma":0.000292726,"threshold_uncertainty_score":0.86218464},"labels":[],"label_agreement":null},{"id":"W4380091268","doi":"10.1016/j.jval.2023.03.028","title":"P15 Indirect Treatment Comparisons of Time-to-Event Outcomes with Mis-Matched \"Time Zero\": Methodology and Application in Resectable Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Vancouver Coastal Health","funders":"","keywords":"Atezolizumab; Medicine; Nivolumab; Oncology; Adjuvant; Lung cancer; Internal medicine; Adjuvant chemotherapy; Cancer; Immunotherapy","score_opus":0.06422358985551754,"score_gpt":0.40355901932712707,"score_spread":0.33933542947160955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380091268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912149,0.0008947529,0.0007701127,0.0041871225,0.000034515877,0.002349569,0.000055158165,0.000041578238,0.0004523269],"genre_scores_gemma":[0.98178893,0.00044892577,0.012704305,0.00029772738,0.000023009447,0.0010674475,0.00011410903,0.00004011721,0.0035154528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867463,0.00019500667,0.00038331968,0.00030858748,0.00012628283,0.00031216381],"domain_scores_gemma":[0.99908924,0.00035870925,0.00014571442,0.00022472575,0.000035746485,0.00014588817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000478696,0.00014732823,0.0006503028,0.00033505904,0.00004603182,0.0000044575854,0.000045146466,0.000058659152,0.000026468295],"category_scores_gemma":[0.000020596992,0.00010986521,0.00003177809,0.0006108122,0.000025410813,0.000021802454,0.00001712904,0.00008738697,0.000025311816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032868443,0.0006264028,0.94530994,0.0006589149,0.00018936119,0.000015327534,0.009866303,0.035887275,0.0015740487,0.000015939395,0.0012296148,0.0042981682],"study_design_scores_gemma":[0.009500315,0.0020738526,0.931826,0.0007796476,0.00027507293,0.000008103209,0.0007565628,0.049528472,0.003186527,0.000066685294,0.0017484792,0.00025026494],"about_ca_topic_score_codex":0.04874762,"about_ca_topic_score_gemma":0.0019306133,"teacher_disagreement_score":0.04681701,"about_ca_system_score_codex":0.0007449177,"about_ca_system_score_gemma":0.0006419581,"threshold_uncertainty_score":0.9575868},"labels":[],"label_agreement":null},{"id":"W4380152124","doi":"10.1016/j.jval.2023.03.2433","title":"CO208 Recurrence Rates and Survival Among Patients with Early-Stage Cancers: A Systematic Literature Review","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Stage (stratigraphy); Medicine; Oncology; Internal medicine; Biology","score_opus":0.03182598772810142,"score_gpt":0.34936151797824433,"score_spread":0.3175355302501429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380152124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.907686,0.08700614,0.000005746648,0.0011880707,0.00022903462,0.0035023177,0.00011672521,0.000065533255,0.00020045333],"genre_scores_gemma":[0.9143781,0.08316681,0.00018339232,0.00069469074,0.000041944048,0.0004078871,0.00023582623,0.000029439634,0.0008619167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988621,0.000161551,0.00031006563,0.00022113818,0.00022254564,0.00022259311],"domain_scores_gemma":[0.9993298,0.00011423598,0.00014121577,0.00018932705,0.00008765514,0.00013774697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035566298,0.000117810305,0.00042507245,0.00010267748,0.00006443487,0.000022282724,0.000034923436,0.00003011986,0.0000065112717],"category_scores_gemma":[0.00010528297,0.000077143115,0.000021284624,0.00073032005,0.000031233147,0.00009010514,0.000012794798,0.00012861352,0.000007375431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003141159,0.00005282256,0.80046433,0.19587177,0.00005752057,0.000045781297,0.0025000656,0.000045987064,1.0519107e-7,0.00012997098,0.00049907935,0.00030112828],"study_design_scores_gemma":[0.0015026575,0.00047984035,0.6828806,0.31426165,0.00008084026,0.0000036456527,0.00014656989,0.00034625485,7.132147e-7,0.0000138748055,0.00018508687,0.00009828207],"about_ca_topic_score_codex":0.0026973241,"about_ca_topic_score_gemma":0.00018784669,"teacher_disagreement_score":0.118389875,"about_ca_system_score_codex":0.00026437404,"about_ca_system_score_gemma":0.00031561544,"threshold_uncertainty_score":0.4077565},"labels":[],"label_agreement":null},{"id":"W4380291366","doi":"10.2217/fon-2022-1289","title":"Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Comprehensive Cancer Network; Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Crown (dentistry); Oncology; Internal medicine; Dentistry","score_opus":0.010774628323068091,"score_gpt":0.32511510297901697,"score_spread":0.3143404746559489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380291366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883822,0.00033418657,0.000006239324,0.0034048294,0.00028539912,0.0016415662,0.00016287684,0.00004297503,0.005739713],"genre_scores_gemma":[0.99753976,0.000036840534,0.00025389186,0.00034439212,0.00021910551,0.00022475193,0.0002946317,0.000026995933,0.0010596282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988878,0.00013189027,0.00027050884,0.00029542757,0.00017854238,0.00023584501],"domain_scores_gemma":[0.9990064,0.00026919637,0.00019310908,0.0004129579,0.00007187635,0.000046496738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017630625,0.00016013897,0.00039192234,0.00005741944,0.00011015615,0.000007722334,0.0001655275,0.00007087425,0.000040849023],"category_scores_gemma":[0.000019312678,0.00007474435,0.000034187648,0.0006946066,0.00005805504,0.00003537801,0.000068522044,0.00029370192,0.0000033076167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041924664,0.00071706745,0.910751,0.00004527487,0.0004400449,0.00019578522,0.071166255,0.0021052083,0.00080348644,0.000009868207,0.007492782,0.0020807835],"study_design_scores_gemma":[0.01703934,0.00088096404,0.92977875,0.00020977532,0.0005205779,0.000005734929,0.046991184,0.00048930105,0.0003683748,0.0000012630034,0.003606205,0.000108502034],"about_ca_topic_score_codex":0.0058721662,"about_ca_topic_score_gemma":0.11946287,"teacher_disagreement_score":0.11359071,"about_ca_system_score_codex":0.00020043233,"about_ca_system_score_gemma":0.00056074676,"threshold_uncertainty_score":0.89660466},"labels":[],"label_agreement":null},{"id":"W4381848427","doi":"10.1016/j.esmoop.2023.101587","title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Reflex; Lung cancer; Intensive care medicine; Biomarker; Medical physics; Pathology; Internal medicine","score_opus":0.18011234910227428,"score_gpt":0.4606255245699017,"score_spread":0.28051317546762744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381848427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94688517,0.00013950377,0.00014767906,0.03603108,0.0001977903,0.011994488,0.00078551105,0.000060768685,0.0037580186],"genre_scores_gemma":[0.9806062,0.00003828937,0.0081893625,0.0023895463,0.000054718963,0.007627139,0.0005785552,0.000021859107,0.0004943197],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99936765,0.000032144962,0.00019242156,0.00020208686,0.000055892953,0.00014979529],"domain_scores_gemma":[0.99831355,0.0013573787,0.00007231754,0.00010558631,0.00011714075,0.00003404111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027105425,0.000086062435,0.00012549716,0.00006787813,0.00029081467,0.0000647178,0.000039020557,0.000030885316,0.00006653056],"category_scores_gemma":[0.0002533295,0.00006271009,0.000022717475,0.00015860941,0.000033925382,0.000040065133,0.000027239921,0.000035708184,0.000002200874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016280665,0.00067161873,0.2030379,0.00057402666,0.0016850674,0.00018791837,0.027108118,0.00056068646,0.032625753,0.00964771,0.6901975,0.032075617],"study_design_scores_gemma":[0.06320261,0.0033154807,0.78117746,0.0011207977,0.0013701045,0.00007317135,0.048910923,0.036658168,0.035515968,0.010492456,0.017051099,0.0011117416],"about_ca_topic_score_codex":0.0019173402,"about_ca_topic_score_gemma":0.0023430504,"teacher_disagreement_score":0.6731464,"about_ca_system_score_codex":0.000103125385,"about_ca_system_score_gemma":0.00030981385,"threshold_uncertainty_score":0.28984576},"labels":[],"label_agreement":null},{"id":"W4382363527","doi":"10.1158/1078-0432.ccr-22-3146","title":"Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Lung cancer; Erlotinib; Medicine; T790M; Gefitinib; Internal medicine; Oncology; Epidermal growth factor receptor; Tyrosine-kinase inhibitor; Confidence interval; Genotyping; Cancer; Genotype; Biology","score_opus":0.1159411974898816,"score_gpt":0.4822468623266429,"score_spread":0.3663056648367613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382363527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513924,0.00094264507,0.000012636777,0.0011901249,0.00025155075,0.001098671,0.0010165329,0.000042609994,0.000305976],"genre_scores_gemma":[0.99565005,0.0023210272,0.00022190163,0.00013002884,0.00014873466,0.00065598876,0.00011309213,0.000044537264,0.00071465387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644893,0.00034059767,0.0012340534,0.00069544563,0.0007732345,0.0005077632],"domain_scores_gemma":[0.99632347,0.0020034201,0.00030363022,0.00045666532,0.0005642827,0.00034851415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007296104,0.00021842914,0.000965529,0.0006733413,0.000102403064,0.000019119572,0.00021482055,0.00019233642,0.00033034856],"category_scores_gemma":[0.00075259095,0.00018743199,0.00026872498,0.0024068533,0.00037887858,0.00014883318,0.00010722721,0.0007296068,0.000029889494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019049877,0.00042861604,0.98623675,0.00029780003,0.00086891913,0.000029620125,0.002634131,0.00037635054,0.0022133782,0.00001909329,0.00046320522,0.004527135],"study_design_scores_gemma":[0.006259111,0.0009702265,0.9819222,0.00047649353,0.0006312671,1.4643983e-7,0.0008230351,0.0016776964,0.006773418,0.00006034795,0.0002374336,0.00016861151],"about_ca_topic_score_codex":0.0064177797,"about_ca_topic_score_gemma":0.0014086684,"teacher_disagreement_score":0.0050091115,"about_ca_system_score_codex":0.0002638791,"about_ca_system_score_gemma":0.00082799915,"threshold_uncertainty_score":0.97018063},"labels":[],"label_agreement":null},{"id":"W4383552633","doi":"10.3390/curroncol30070476","title":"Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Ottawa; Cancer Care Ontario; McMaster University; University of Manitoba; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Alberta; William Osler Health System; Ottawa Hospital; Health Sciences Centre; University Health Network; CancerCare Manitoba; Dalhousie University; University of Toronto","funders":"EMD Serono; Astellas Pharma; Incyte; Jazz Pharmaceuticals; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"KRAS; Medicine; Guideline; Targeted therapy; Oncology; Cancer; Internal medicine; Colorectal cancer; Pathology","score_opus":0.11958156781750422,"score_gpt":0.46184149178299755,"score_spread":0.3422599239654933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383552633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5861082,0.0005401746,0.000024857045,0.21502909,0.0038319745,0.002130147,0.00033949254,0.0001630243,0.19183302],"genre_scores_gemma":[0.99568754,0.00042652106,0.00014220289,0.0005471392,0.00006109356,0.000185304,0.00042011985,0.000013852394,0.002516232],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993568,0.00004772274,0.00017324107,0.00013706893,0.00008573024,0.00019942658],"domain_scores_gemma":[0.9994304,0.00012860175,0.00005810251,0.0001932612,0.00007465778,0.00011498436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011982943,0.000079530495,0.0001450424,0.00015887996,0.00011376121,0.0000038416006,0.000058093923,0.000035979723,0.0004171559],"category_scores_gemma":[0.000019752313,0.000053451524,0.000049281804,0.0003672364,0.000055843524,0.0000070180954,0.000018408538,0.00010461132,0.0003069192],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107297084,0.00068593916,0.0076041003,0.00015794313,0.0012463294,0.00023113878,0.0019273239,0.000043972905,0.000057047837,0.031520087,0.47959152,0.47682732],"study_design_scores_gemma":[0.0019004212,0.00039100842,0.031940114,0.0002078213,0.00047812687,0.0000149694715,0.0020114128,0.00020060857,0.00008596619,0.0005827921,0.96210515,0.000081602906],"about_ca_topic_score_codex":0.0022364436,"about_ca_topic_score_gemma":0.004920781,"teacher_disagreement_score":0.48251367,"about_ca_system_score_codex":0.00050156243,"about_ca_system_score_gemma":0.00040753605,"threshold_uncertainty_score":0.45675647},"labels":[],"label_agreement":null},{"id":"W4383895788","doi":"10.1200/jco.23.01055","title":"Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Guideline; Clinical Practice; Family medicine; Schedule; Clinical Oncology; Medical physics; Cancer; Pathology; Internal medicine","score_opus":0.08184180362781925,"score_gpt":0.507410448665457,"score_spread":0.4255686450376378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383895788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971317,0.0012377168,0.005186316,0.016498042,0.0019272423,0.0009583167,0.000044069726,0.000026113465,0.0028052016],"genre_scores_gemma":[0.87410736,0.016984474,0.044632636,0.013848945,0.0060242657,0.00021613736,0.00009541751,0.000103862,0.043986905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981405,0.00009200463,0.0011746287,0.00017313841,0.00021826821,0.00020145699],"domain_scores_gemma":[0.9966898,0.0014321617,0.0008289524,0.00013830689,0.0007028715,0.00020789841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011694962,0.000116244526,0.00065508846,0.00013206697,0.00010120024,0.000013935903,0.000091937305,0.00016418146,0.00036224927],"category_scores_gemma":[0.00042352846,0.00007246189,0.00027123638,0.00019200542,0.000052784926,0.00011449608,0.000021553984,0.0003188687,0.000016412243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006404683,0.003058146,0.32479095,0.00017793284,0.0031207975,0.00064536324,0.0014468101,0.004418344,0.001103208,0.00006920991,0.53143495,0.12332961],"study_design_scores_gemma":[0.030196566,0.018860925,0.1862356,0.00058033783,0.001807731,0.00004245405,0.00092968415,0.009782303,0.00019407089,0.00004834253,0.75110364,0.00021834606],"about_ca_topic_score_codex":0.00007444601,"about_ca_topic_score_gemma":0.00011970076,"teacher_disagreement_score":0.2196687,"about_ca_system_score_codex":0.00021384489,"about_ca_system_score_gemma":0.0026592293,"threshold_uncertainty_score":0.47173584},"labels":[],"label_agreement":null},{"id":"W4383982286","doi":"10.3390/curroncol30070481","title":"Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal; Pfizer (Canada); McMaster University; Spinal Cord Injury BC; Queen Elizabeth II Health Sciences Centre; Wilfrid Laurier University; University of Ottawa; Dalhousie University; University of Manitoba; Juravinski Cancer Centre; TransCanada (Canada)","funders":"Pfizer Canada; Pfizer","keywords":"Alectinib; Medicine; Discontinuation; ALK inhibitor; Anaplastic lymphoma kinase; Internal medicine; Quality of life (healthcare); Tyrosine-kinase inhibitor; Lung cancer; Population; Crizotinib; Oncology; Cancer","score_opus":0.06654338882178695,"score_gpt":0.42138742834013415,"score_spread":0.3548440395183472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383982286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955854,0.00013134752,0.0000126944815,0.00020468327,0.00047310232,0.0009597545,0.00008884651,0.000021521997,0.002522681],"genre_scores_gemma":[0.99893284,0.000033736695,0.00003546518,0.00007263662,0.00009346898,0.00025249377,0.00047139154,0.000014407952,0.00009354089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988079,0.00019224107,0.00031194897,0.0003009155,0.00014782633,0.00023915865],"domain_scores_gemma":[0.9991916,0.00017148851,0.00012834344,0.00013559533,0.00016122598,0.00021174212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017686655,0.00013800582,0.0003977119,0.00032952646,0.00008170065,0.0000095498135,0.0000356877,0.000066690496,0.000042757343],"category_scores_gemma":[0.000080802616,0.000113940405,0.000028013337,0.0004653922,0.00010905984,0.000110161105,0.000021051479,0.00012358255,0.000006280101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002553102,0.000223675,0.97588474,0.000101171536,0.0000627442,0.0000073442425,0.004728156,0.000012997883,0.00014549254,0.00027246974,0.00032014772,0.01798574],"study_design_scores_gemma":[0.005457281,0.00064504315,0.989546,0.00024599172,0.000048988266,3.6960768e-7,0.00039934134,0.00006436328,0.0003038836,0.0000112692105,0.0031629754,0.00011446823],"about_ca_topic_score_codex":0.018985998,"about_ca_topic_score_gemma":0.24942568,"teacher_disagreement_score":0.23043968,"about_ca_system_score_codex":0.00064089405,"about_ca_system_score_gemma":0.00072868465,"threshold_uncertainty_score":0.9875467},"labels":[],"label_agreement":null},{"id":"W4384338757","doi":"10.1158/1078-0432.c.6742700.v1","title":"Data from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; National Institutes of Health; Revolution Medicines; Seagen; Gilead Sciences; Sanofi; G1 Therapeutics; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research","keywords":"Medicine; KRAS; Internal medicine; Oncology; Cohort; Lung cancer; Cancer; Confidence interval; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Colorectal cancer","score_opus":0.07401438445914432,"score_gpt":0.404237008312921,"score_spread":0.33022262385377665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384338757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8947727,0.0021355012,0.0058443127,0.0013962159,0.0024017426,0.011154944,0.07850467,0.0002387955,0.0035511388],"genre_scores_gemma":[0.5283598,0.007199153,0.10400356,0.0022964512,0.006112794,0.0040900563,0.31988657,0.00056035334,0.027491326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966846,0.00010780473,0.0008760092,0.0016573601,0.0003568058,0.00031738283],"domain_scores_gemma":[0.9946677,0.0009514992,0.0005215772,0.003369281,0.0002919839,0.00019794387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006563409,0.00041643513,0.00086125964,0.000053101478,0.0002733843,0.00017710564,0.00089569483,0.00019585865,0.00005360805],"category_scores_gemma":[0.00012670593,0.00021923102,0.00010014695,0.00010117424,0.00012945857,0.0001048671,0.0025060521,0.00063323043,0.0000026548214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082534837,0.00017018225,0.92877156,0.00022338868,0.0031759096,0.000018782765,0.00027028815,0.0000146462935,0.00002145062,0.000004474518,0.06298283,0.0035211272],"study_design_scores_gemma":[0.009782947,0.00019885284,0.9509084,0.001513793,0.01329013,0.0000012951491,0.0003721928,0.0129676815,0.000022999357,0.00004576217,0.010422656,0.00047326522],"about_ca_topic_score_codex":0.03357036,"about_ca_topic_score_gemma":0.06009034,"teacher_disagreement_score":0.36641294,"about_ca_system_score_codex":0.00031736412,"about_ca_system_score_gemma":0.0018876259,"threshold_uncertainty_score":0.97286516},"labels":[],"label_agreement":null},{"id":"W4384338819","doi":"10.1158/1078-0432.c.6742700","title":"Data from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; National Institutes of Health; Revolution Medicines; Seagen; Gilead Sciences; Sanofi; G1 Therapeutics; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research","keywords":"Medicine; KRAS; Internal medicine; Cohort; Oncology; Cancer; ROS1; Lung cancer; Ramucirumab; Response Evaluation Criteria in Solid Tumors; Confidence interval; Clinical trial; Adenocarcinoma; Phases of clinical research; Colorectal cancer","score_opus":0.07401438445914432,"score_gpt":0.404237008312921,"score_spread":0.33022262385377665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384338819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8947727,0.0021355012,0.0058443127,0.0013962159,0.0024017426,0.011154944,0.07850467,0.0002387955,0.0035511388],"genre_scores_gemma":[0.5283598,0.007199153,0.10400356,0.0022964512,0.006112794,0.0040900563,0.31988657,0.00056035334,0.027491326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966846,0.00010780473,0.0008760092,0.0016573601,0.0003568058,0.00031738283],"domain_scores_gemma":[0.9946677,0.0009514992,0.0005215772,0.003369281,0.0002919839,0.00019794387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006563409,0.00041643513,0.00086125964,0.000053101478,0.0002733843,0.00017710564,0.00089569483,0.00019585865,0.00005360805],"category_scores_gemma":[0.00012670593,0.00021923102,0.00010014695,0.00010117424,0.00012945857,0.0001048671,0.0025060521,0.00063323043,0.0000026548214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082534837,0.00017018225,0.92877156,0.00022338868,0.0031759096,0.000018782765,0.00027028815,0.0000146462935,0.00002145062,0.000004474518,0.06298283,0.0035211272],"study_design_scores_gemma":[0.009782947,0.00019885284,0.9509084,0.001513793,0.01329013,0.0000012951491,0.0003721928,0.0129676815,0.000022999357,0.00004576217,0.010422656,0.00047326522],"about_ca_topic_score_codex":0.03357036,"about_ca_topic_score_gemma":0.06009034,"teacher_disagreement_score":0.36641294,"about_ca_system_score_codex":0.00031736412,"about_ca_system_score_gemma":0.0018876259,"threshold_uncertainty_score":0.97286516},"labels":[],"label_agreement":null},{"id":"W4385273525","doi":"10.3390/curroncol30080515","title":"Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Cohort; Lung cancer; Oncology; Targeted therapy; Cancer; Gastroenterology","score_opus":0.0836955566356466,"score_gpt":0.48041415866883386,"score_spread":0.39671860203318726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385273525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404263,0.00020430695,0.00006458858,0.0015341755,0.0014293479,0.0015380433,0.00010590425,0.00008674591,0.0009942709],"genre_scores_gemma":[0.9913559,0.0013789919,0.00058885425,0.00035856655,0.00027387723,0.0010837892,0.001018416,0.00004975059,0.0038918485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891824,0.000037426933,0.00033459408,0.0003297195,0.000108518674,0.00027147596],"domain_scores_gemma":[0.99907124,0.00027252844,0.00014082702,0.00015379631,0.00019590139,0.00016571372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010683817,0.00015605953,0.00040943106,0.00013336226,0.000099921075,0.000009515041,0.00004676131,0.00008095894,0.000043762295],"category_scores_gemma":[0.0000371401,0.00010898184,0.00007670676,0.0002493258,0.000070318616,0.00004604703,0.0000333701,0.000144115,0.000014034227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030241685,0.0008931164,0.9607371,0.00017360611,0.00022909751,0.000008401374,0.00033777714,0.0000076094834,0.000004919417,0.00001752183,0.011486588,0.025801847],"study_design_scores_gemma":[0.010958514,0.0010963258,0.9408662,0.00011081637,0.00078698667,6.6038734e-7,0.000088655135,0.0005990449,0.0000098583305,0.00002211541,0.045339487,0.0001213332],"about_ca_topic_score_codex":0.00023387306,"about_ca_topic_score_gemma":0.0013590682,"teacher_disagreement_score":0.0338529,"about_ca_system_score_codex":0.00031000582,"about_ca_system_score_gemma":0.00045163248,"threshold_uncertainty_score":0.44441506},"labels":[],"label_agreement":null},{"id":"W4385306292","doi":"10.21037/tlcr-23-81","title":"First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic","year":2023,"lang":"en","type":"article","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria; BC Children's Hospital; University of British Columbia","funders":"BC Cancer Foundation","keywords":"Osimertinib; Medicine; Internal medicine; Hazard ratio; Lung cancer; Oncology; Pneumonitis; Cohort; Epidermal growth factor receptor; Confidence interval; Cancer; Lung; Erlotinib","score_opus":0.0461746449445684,"score_gpt":0.42086440783338225,"score_spread":0.37468976288881384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385306292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978918,0.0029205712,0.0008011167,0.010370637,0.00011014947,0.00551582,0.0010194344,0.00013385265,0.00021039286],"genre_scores_gemma":[0.99189025,0.0022202188,0.0002753226,0.0002481216,0.0001757989,0.0025312877,0.00067152816,0.00007181982,0.0019156624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976789,0.00007159699,0.00034480452,0.0005445533,0.0007320859,0.0006280844],"domain_scores_gemma":[0.9978547,0.0010101898,0.00008152232,0.00025698965,0.0004697858,0.00032681428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041094495,0.00023158974,0.00029018527,0.00023386197,0.0010253243,0.00004191093,0.00014864583,0.00008730047,0.00018270453],"category_scores_gemma":[0.00006461689,0.00015700152,0.00007362026,0.0008970266,0.00017439666,0.000117070755,0.000032528824,0.00035132648,0.0000043664486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008725656,0.00028198084,0.9332351,0.002139388,0.0007111089,0.000013698885,0.0041555217,0.044533182,0.00063117384,0.00006479329,0.001029047,0.0044793254],"study_design_scores_gemma":[0.039106578,0.0005384563,0.9271274,0.00053641514,0.0006457127,0.0000054078932,0.00014969548,0.017032329,0.00025134083,0.00008588454,0.014166928,0.00035380266],"about_ca_topic_score_codex":0.0009614772,"about_ca_topic_score_gemma":0.0014604286,"teacher_disagreement_score":0.030380921,"about_ca_system_score_codex":0.0007388765,"about_ca_system_score_gemma":0.001396052,"threshold_uncertainty_score":0.78860694},"labels":[],"label_agreement":null},{"id":"W4385306306","doi":"10.21037/tlcr-23-222","title":"Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?","year":2023,"lang":"en","type":"letter","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lung cancer; Medicine; Mutation; Computational biology; Bioinformatics; Cancer research; Oncology; Genetics; Biology; Gene","score_opus":0.1073875751015785,"score_gpt":0.481054197274499,"score_spread":0.3736666221729205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385306306","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059257224,0.0225396,0.000099977085,0.9595825,0.0015685514,0.003634604,0.004219131,0.0004031506,0.0020267395],"genre_scores_gemma":[0.27330557,0.042980727,0.0025672112,0.25975958,0.06689811,0.034927834,0.049848378,0.0031249218,0.26658767],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99297035,0.0003181446,0.00061461725,0.0013311215,0.0033838095,0.0013819884],"domain_scores_gemma":[0.9971567,0.00049775076,0.00017853781,0.0007260015,0.0010283401,0.00041270533],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005301474,0.0006435618,0.0007679286,0.0011209019,0.00076348195,0.00020515818,0.000458927,0.0007938767,0.002659833],"category_scores_gemma":[0.000028821332,0.0005896965,0.00032775255,0.0013915454,0.00028133354,0.00039470196,0.00005136063,0.0035343806,0.00004790861],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032582475,0.00014658018,0.035109065,0.0035779222,0.0030038822,0.0014954987,0.004522664,0.0017240674,0.00010125032,0.0002764798,0.93835497,0.011361806],"study_design_scores_gemma":[0.006120178,0.00033571737,0.03677639,0.005451295,0.0032468857,0.00006510441,0.000466668,0.008911629,0.0003166089,0.0010263047,0.93580467,0.0014785683],"about_ca_topic_score_codex":0.013847088,"about_ca_topic_score_gemma":0.005500202,"teacher_disagreement_score":0.69982296,"about_ca_system_score_codex":0.002499693,"about_ca_system_score_gemma":0.005865475,"threshold_uncertainty_score":0.99977034},"labels":[],"label_agreement":null},{"id":"W4385481435","doi":"10.1016/j.jtho.2023.07.023","title":"Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Arena Pharmaceuticals; Da Volterra; GlaxoSmithKline; CMC Microsystems; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; ALK inhibitor; Internal medicine; Mutation; Cancer research; Progression-free survival; Oncology; Overall survival; Lung cancer; Biology; Genetics; Gene","score_opus":0.01836020434151036,"score_gpt":0.42185335904802235,"score_spread":0.403493154706512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385481435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610317,0.000058503512,0.00017520759,0.001222978,0.00010249058,0.00090195343,0.000018300656,0.000009326821,0.0014080782],"genre_scores_gemma":[0.9921376,0.000047870515,0.0072065736,0.000081700906,0.00003450856,0.000028284232,0.000053502983,0.000020517471,0.00038942177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988999,0.000105609004,0.00044708682,0.0001750937,0.00019499986,0.00017736209],"domain_scores_gemma":[0.99869967,0.00030264028,0.00038701104,0.000107037005,0.0003815453,0.00012211826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014507874,0.00014220449,0.0005144927,0.0004980338,0.00004135952,0.0000066470066,0.00003840624,0.0000770648,0.000017363356],"category_scores_gemma":[0.00015333078,0.000085490625,0.000028139644,0.00092774385,0.00005893129,0.00016125744,0.000013171259,0.00015004158,0.000004669767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058305275,0.002972081,0.66300726,0.0000713739,0.00090826076,0.0015987607,0.024757447,0.0067842086,0.00043374742,0.00005646256,0.00007661588,0.2410285],"study_design_scores_gemma":[0.01426226,0.02032559,0.9609737,0.0007011435,0.0007091675,0.0001765748,0.0017792053,0.00020354659,0.00016008249,0.00004116309,0.00055854156,0.000109073524],"about_ca_topic_score_codex":0.00008285988,"about_ca_topic_score_gemma":0.0005314522,"teacher_disagreement_score":0.2979664,"about_ca_system_score_codex":0.0005704893,"about_ca_system_score_gemma":0.00074495946,"threshold_uncertainty_score":0.34862062},"labels":[],"label_agreement":null},{"id":"W4385499877","doi":"10.18103/mra.v11i7.2.4130","title":"Assessing Access to And Outcomes of Medical Oncology and Radiation Oncology Consultation in Non-Small Cell Lung Cancer Patients: A Population-Based Study Using Administrative Data","year":2023,"lang":"en","type":"article","venue":"Medical Research Archives","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Essar Steel Algoma (Canada)","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Internal medicine; Lung cancer; Referral; Oncology; Interquartile range; Stage (stratigraphy); Population; Radiation therapy; Cancer; Family medicine","score_opus":0.1943920160566049,"score_gpt":0.5915192441900506,"score_spread":0.39712722813344575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385499877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098873,0.00013171945,0.00038232017,0.006567078,0.000073103816,0.0015825253,0.000057729994,0.000012389124,0.00020438519],"genre_scores_gemma":[0.9983701,0.00021603322,0.0006170854,0.00021058581,0.0000434693,0.00019035694,0.00032168624,0.000012301781,0.000018344306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971943,0.0005899393,0.00041658487,0.0003999057,0.0011007064,0.00029859247],"domain_scores_gemma":[0.9948549,0.004299823,0.00009332434,0.00018419012,0.000109385655,0.00045835198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014115389,0.000104053914,0.0003773954,0.0005835321,0.00012777332,0.00004406085,0.00021528293,0.00010317233,0.0000625839],"category_scores_gemma":[0.005277996,0.0000806188,0.000014519794,0.00057156966,0.00019251698,0.0001728591,0.00034479055,0.00036100388,6.301507e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015675843,0.0008854607,0.85262024,0.00013651294,0.00007085319,0.00008946021,0.00530992,0.000018043962,0.00003927741,0.000008328802,0.00007056011,0.1405946],"study_design_scores_gemma":[0.0056506167,0.00084781216,0.9365106,0.00027093387,0.000071020004,0.0000010490955,0.0036635476,0.052761152,0.000023464965,0.000032730943,0.00010664378,0.000060429466],"about_ca_topic_score_codex":0.0038672148,"about_ca_topic_score_gemma":0.0047131847,"teacher_disagreement_score":0.14053418,"about_ca_system_score_codex":0.00022383012,"about_ca_system_score_gemma":0.0033106436,"threshold_uncertainty_score":0.63186353},"labels":[],"label_agreement":null},{"id":"W4385757348","doi":"10.1016/j.ijrobp.2023.03.074","title":"Radiation Therapy in the Molecular Era of Lung Cancer: How Best to Integrate Targeted Therapeutics With Definitive Radiation Therapy for Epidermal Growth Factor Receptor–Mutant Unresectable Stage III Non-Small Cell Lung Cancer?","year":2023,"lang":"en","type":"letter","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Osimertinib; Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Radiation therapy; Targeted therapy; Internal medicine; Cancer research; Cancer; Erlotinib","score_opus":0.02571870403720141,"score_gpt":0.34753160015280254,"score_spread":0.32181289611560115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385757348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6775953,0.009609059,0.018858844,0.28001785,0.004164287,0.005389565,0.0041947123,0.00005760143,0.00011279938],"genre_scores_gemma":[0.83685,0.047323335,0.0017833018,0.10098984,0.0070327744,0.0016762678,0.0037643143,0.00028030179,0.0002998656],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968377,0.00050281384,0.0010251144,0.0005152529,0.00060236355,0.0005167845],"domain_scores_gemma":[0.99424917,0.001165391,0.0023050269,0.0002663251,0.0019076114,0.00010650799],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005207785,0.00057044224,0.0010690967,0.0004985596,0.00013423646,0.00008301228,0.0006109867,0.0006402983,0.000047873924],"category_scores_gemma":[0.00010327154,0.00039725465,0.0004008241,0.00062128226,0.00013380636,0.00029084075,0.00002944248,0.0015557715,0.0000023416083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009934642,0.0026007753,0.47635865,0.00051105616,0.020756373,0.00046178396,0.028361695,0.0099857235,0.03704409,0.0012930436,0.07921984,0.33347234],"study_design_scores_gemma":[0.14948659,0.035789944,0.098833404,0.0040625557,0.006540387,0.00017759699,0.0035199355,0.026481641,0.1796367,0.0024527146,0.4887665,0.004252039],"about_ca_topic_score_codex":0.0009819419,"about_ca_topic_score_gemma":0.00009636343,"teacher_disagreement_score":0.40954664,"about_ca_system_score_codex":0.0024817113,"about_ca_system_score_gemma":0.0030515261,"threshold_uncertainty_score":0.99984795},"labels":[],"label_agreement":null},{"id":"W4385779498","doi":"10.1007/s12325-023-02606-x","title":"Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Brain metastasis; Anaplastic lymphoma kinase; Internal medicine; Oncology; ALK inhibitor; Lung cancer; Interim analysis; Tyrosine-kinase inhibitor; Progression-free survival; Metastasis; Clinical trial; Cancer; Overall survival","score_opus":0.02005702054535472,"score_gpt":0.364229775795692,"score_spread":0.34417275525033725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385779498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688126,0.0011312315,0.00217736,0.0033361034,0.00012116834,0.0044074226,0.0003976797,0.000118611846,0.0014291842],"genre_scores_gemma":[0.9886986,0.0019318366,0.0051609417,0.00071249966,0.000048844264,0.0015296444,0.001001102,0.000057100435,0.00085945515],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989559,0.000033137236,0.00018593454,0.00033894743,0.00023141583,0.00025466704],"domain_scores_gemma":[0.9991869,0.0003315975,0.00010529638,0.00020142345,0.000102376966,0.000072425675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006210397,0.00023342611,0.0003241724,0.00017675945,0.00010744419,0.000015179115,0.00004012016,0.000022251485,0.000030631272],"category_scores_gemma":[0.00001970369,0.0001347509,0.00006281159,0.000424265,0.000051276616,0.00020362236,0.000004101358,0.00004897427,0.000019341984],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024741182,0.00433391,0.02971336,0.00008704748,0.0022050482,0.00012483059,0.0046483655,0.008850162,0.000039237853,0.0018872172,0.00010686111,0.9232628],"study_design_scores_gemma":[0.26704964,0.2927829,0.21787418,0.0027906997,0.0027549742,0.00006805299,0.0037963716,0.0022488383,0.007856101,0.008739949,0.19204189,0.0019963859],"about_ca_topic_score_codex":0.00006683231,"about_ca_topic_score_gemma":0.00030955698,"teacher_disagreement_score":0.9212664,"about_ca_system_score_codex":0.00024511013,"about_ca_system_score_gemma":0.000082860824,"threshold_uncertainty_score":0.5494982},"labels":[],"label_agreement":null},{"id":"W4385782360","doi":"10.1016/j.jtho.2023.08.010","title":"Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Alectinib; Crizotinib; Medicine; Ceritinib; Internal medicine; Hazard ratio; Clinical endpoint; ALK inhibitor; Confidence interval; Adverse effect; Oncology; Gastroenterology; Randomized controlled trial; Lung cancer","score_opus":0.045490594610487586,"score_gpt":0.5245308825252416,"score_spread":0.479040287914754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385782360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855985,0.00022447518,0.00000813355,0.006596902,0.0016991236,0.0007962623,0.00010345326,0.000018411885,0.004954743],"genre_scores_gemma":[0.9980113,0.00007260873,0.00055468216,0.00018364695,0.0005725571,0.000053613767,0.00005472758,0.000020533917,0.0004763425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980898,0.00025700047,0.00082983956,0.00020039234,0.0003785402,0.000244462],"domain_scores_gemma":[0.9980581,0.0005806326,0.0006770108,0.00017665407,0.00025613193,0.00025147153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065046,0.00014585834,0.0005416172,0.0004276168,0.000042332093,0.000008334276,0.00008262209,0.000114297014,0.0000519194],"category_scores_gemma":[0.0008626056,0.00010500461,0.00020222935,0.00045929156,0.0000897138,0.00009965925,0.000028115559,0.00033984578,0.000020014051],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7527484,0.0033611385,0.00041045496,0.00005383914,0.00027780927,0.0029080464,0.0014684545,0.000026689295,0.0004172985,0.000011582995,0.0029677458,0.2353485],"study_design_scores_gemma":[0.7281039,0.13964139,0.06729313,0.0042782817,0.003980848,0.00023473553,0.0019631784,0.0003146712,0.008914949,0.0004914619,0.04432395,0.00045950848],"about_ca_topic_score_codex":0.000013236124,"about_ca_topic_score_gemma":0.000019488698,"teacher_disagreement_score":0.23488899,"about_ca_system_score_codex":0.00036275043,"about_ca_system_score_gemma":0.0010526743,"threshold_uncertainty_score":0.42819637},"labels":[],"label_agreement":null},{"id":"W4385876725","doi":"10.3410/f.742667047.793600395","title":"Faculty Opinions recommendation of Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Oncology; Placebo; Internal medicine; Medicine; Biomarker; Chemotherapy; Randomized controlled trial; Double blind; Alternative medicine; Pathology; Biology","score_opus":0.11818341630541981,"score_gpt":0.4902618801276183,"score_spread":0.37207846382219845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385876725","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004129208,0.00081382063,0.00006612225,0.03649837,0.0007474646,0.009060256,0.95234656,0.000022369637,0.000032121254],"genre_scores_gemma":[0.001473712,0.00043028576,0.0006050694,0.00015864709,0.00006826255,0.001514225,0.995455,0.000032448228,0.00026230252],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956649,0.00043943737,0.0020512536,0.0005655568,0.0010452551,0.00023357516],"domain_scores_gemma":[0.9922092,0.0008437684,0.0021412184,0.0007361814,0.0039171255,0.00015251838],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001449281,0.0004415738,0.0018873797,0.0007502931,0.00011464956,0.000039779166,0.00038043503,0.00034176803,0.00004708134],"category_scores_gemma":[0.0041764965,0.00029456284,0.0005146509,0.0018594371,0.00032635435,0.00026305823,0.00010370143,0.00034748387,0.0000014308366],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05774594,0.005893741,0.00003936896,0.009707172,0.0023311547,3.8243476e-7,0.0008235808,0.0000019100892,0.000019486846,0.00015300783,0.9195173,0.003766958],"study_design_scores_gemma":[0.5273825,0.0012455428,0.0022494642,0.0061635156,0.0021175228,0.0000038708263,0.00032488175,0.00008681381,0.00003350799,0.000023948935,0.4601294,0.00023901352],"about_ca_topic_score_codex":0.00057862804,"about_ca_topic_score_gemma":0.00008445994,"teacher_disagreement_score":0.46963656,"about_ca_system_score_codex":0.00017511132,"about_ca_system_score_gemma":0.0005640567,"threshold_uncertainty_score":0.99995065},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"dataset","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4385973055","doi":"10.1016/j.jtocrr.2023.100562","title":"Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Kingston Health Sciences Centre; William Osler Health System; Queen's University; Brampton Civic Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research; EMD Serono; Genentech; Incyte; Canadian Cancer Society Research Institute; Helsinn; BeiGene; Merck KGaA; Princess Margaret Cancer Foundation; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Oncology; Toxicity; Targeted therapy; Cancer","score_opus":0.09678955994710657,"score_gpt":0.45914478222649396,"score_spread":0.3623552222793874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385973055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941149,0.001465659,0.0000073612377,0.0017608805,0.00005431168,0.0021985879,0.000004535681,0.000077492456,0.00031626807],"genre_scores_gemma":[0.9966195,0.00074939884,0.0011872285,0.000055747576,0.00011274469,0.00040953397,0.000048810438,0.000024039211,0.00079298014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975727,0.00031719077,0.0005584336,0.0005482719,0.00061858987,0.0003848187],"domain_scores_gemma":[0.99867415,0.00047994353,0.0001204913,0.00021021717,0.0002456553,0.0002695162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024626807,0.00015774713,0.00038098768,0.00026475533,0.00023681679,0.00011486455,0.000031596337,0.00013484176,0.000023688859],"category_scores_gemma":[0.00083687506,0.00009938568,0.00004831971,0.0005410954,0.00055710407,0.00012465066,0.00008249783,0.00042614073,0.0000021642409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024310453,0.0024604443,0.7601094,0.0006503581,0.0012625495,0.008664532,0.012509972,0.0000077825,0.020103117,0.00028675082,0.0003678222,0.19114622],"study_design_scores_gemma":[0.011774656,0.007954359,0.9517355,0.0010293472,0.00026932047,0.00037832715,0.0054108566,0.00011680278,0.007766501,0.0060724393,0.0070429514,0.00044891797],"about_ca_topic_score_codex":0.00060635176,"about_ca_topic_score_gemma":0.00011879655,"teacher_disagreement_score":0.19162613,"about_ca_system_score_codex":0.000042832526,"about_ca_system_score_gemma":0.00037371946,"threshold_uncertainty_score":0.40528303},"labels":[],"label_agreement":null},{"id":"W4386208573","doi":"10.21037/jtd-22-697","title":"Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Anaplastic lymphoma kinase; Internal medicine; Oncology; Asymptomatic; Specialty; Guideline; Radiation therapy; Clinical trial; Cancer; Family medicine; Pathology","score_opus":0.054462657608632226,"score_gpt":0.46032134625680005,"score_spread":0.4058586886481678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386208573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896734,0.00036399925,0.001789463,0.0050859,0.00056012423,0.0005103804,0.0016661066,0.000010024718,0.00034065443],"genre_scores_gemma":[0.99048436,0.0009553424,0.007569681,0.00042246218,0.00021325354,0.000015749769,0.00018549155,0.000021017091,0.00013263637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997999,0.00027203976,0.0009428388,0.00021139026,0.00043151606,0.0001432324],"domain_scores_gemma":[0.9967256,0.0012244581,0.0008897394,0.0001910637,0.0005747889,0.00039431138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012992542,0.00014488459,0.0005238869,0.0002175033,0.000053785938,0.000037446873,0.00014468034,0.00003157839,0.00008046137],"category_scores_gemma":[0.00084662414,0.00011530192,0.00013220045,0.00029877742,0.0000376849,0.0002748127,0.00008560085,0.00012421206,0.000001820136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022379449,0.0053516636,0.8203861,0.0020738046,0.012834077,0.003169728,0.00372814,0.0020273877,0.0006503333,0.00010491309,0.004351601,0.12294281],"study_design_scores_gemma":[0.0025687623,0.00069630065,0.9838353,0.0018765873,0.00504797,0.000009885008,0.0027918788,0.0018238694,0.00082324917,0.00012488698,0.000251084,0.00015026928],"about_ca_topic_score_codex":0.0005110612,"about_ca_topic_score_gemma":0.00012867998,"teacher_disagreement_score":0.16344917,"about_ca_system_score_codex":0.000112718924,"about_ca_system_score_gemma":0.00035395956,"threshold_uncertainty_score":0.47018757},"labels":[],"label_agreement":null},{"id":"W4386263853","doi":"10.21873/cgp.20394","title":"Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Genomics & Proteomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary; University of Lethbridge","funders":"","keywords":"ROS1; Fusion gene; Biology; Lung cancer; Cancer; Gene; Stage (stratigraphy); Computational biology; Cancer research; Disease; Oncology; Medicine; Adenocarcinoma; Genetics; Internal medicine","score_opus":0.014767197817478922,"score_gpt":0.28691213619568734,"score_spread":0.2721449383782084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386263853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919486,0.0022013288,0.0018665157,0.00025945285,0.00046975954,0.0024708412,0.0001952616,0.000069188936,0.00051907374],"genre_scores_gemma":[0.9907056,0.004496583,0.00091552356,0.00017665616,0.0001800355,0.0013845485,0.00005633292,0.00008913154,0.0019955658],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984873,0.000023579094,0.00046181917,0.00042626672,0.00015384071,0.00044720658],"domain_scores_gemma":[0.99919236,0.000024818704,0.00020062378,0.00033264438,0.0001054149,0.00014416398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013111182,0.00025186213,0.00043893524,0.000324809,0.00008683013,0.00001972206,0.00013984188,0.00013851265,0.000051184466],"category_scores_gemma":[0.000008713871,0.00025443602,0.00014562116,0.0007251668,0.00005933065,0.00008377847,0.000035288955,0.00025794923,0.000014766881],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038329998,0.00015033431,0.23293984,0.00080916804,0.00028832044,0.000035123878,0.008023718,0.008192601,0.74553806,0.0000071350855,0.000035840552,0.0035965494],"study_design_scores_gemma":[0.005064133,0.0002723043,0.6912076,0.00021715095,0.00056144263,0.0000029053876,0.0004601855,0.0046189744,0.29320186,0.00004473694,0.0039282786,0.0004204267],"about_ca_topic_score_codex":0.0040491126,"about_ca_topic_score_gemma":0.0015179361,"teacher_disagreement_score":0.45826775,"about_ca_system_score_codex":0.0011797571,"about_ca_system_score_gemma":0.00087963237,"threshold_uncertainty_score":0.99999076},"labels":[],"label_agreement":null},{"id":"W4386283660","doi":"10.3390/curroncol30090582","title":"Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Dalhousie University; Toronto General Hospital; University Health Network; University of Toronto; BC Cancer Agency; Mount Sinai Hospital","funders":"Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Trastuzumab; Context (archaeology); Discontinuation; Adverse effect; Pneumonitis; Intensive care medicine; Oncology; Internal medicine; Lung cancer; Toxicity; Cancer; Breast cancer; Lung","score_opus":0.09600679398990995,"score_gpt":0.4762684921125247,"score_spread":0.38026169812261473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386283660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000651052,0.99036074,0.00006404315,0.0005691904,0.0005721133,0.0020263854,0.00035341358,0.000042333286,0.005946697],"genre_scores_gemma":[0.00053980754,0.9982183,0.00005430889,0.000026823458,0.00023264693,0.00044970418,0.0001452713,0.00005481103,0.0002783579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850494,0.0002069127,0.0003625727,0.00038452828,0.00017351932,0.00036751872],"domain_scores_gemma":[0.9985961,0.00025637844,0.00037511825,0.00037084852,0.00018287517,0.00021872879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019551543,0.0003034988,0.001293543,0.00034073385,0.00018228273,0.000010254313,0.00017152248,0.00015244391,0.00006306602],"category_scores_gemma":[0.00008264891,0.00016531245,0.00030732775,0.0005624301,0.0001826677,0.000022698563,0.000035814246,0.0006079885,0.00002732139],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00001849845,0.00017788305,0.00034462922,0.0042535868,0.0024760866,0.00008968174,0.0020283388,0.000002391082,1.10632445e-8,0.0007684623,0.0016428584,0.98819757],"study_design_scores_gemma":[0.0007725196,0.00050388527,0.00033440068,0.006245484,0.014272571,0.00012471172,0.0016335469,0.000022860317,1.4466882e-7,0.00022043535,0.9756979,0.00017154012],"about_ca_topic_score_codex":0.035917178,"about_ca_topic_score_gemma":0.14288965,"teacher_disagreement_score":0.988026,"about_ca_system_score_codex":0.0046075075,"about_ca_system_score_gemma":0.00606176,"threshold_uncertainty_score":0.99957293},"labels":[],"label_agreement":null},{"id":"W4386350101","doi":"10.1158/1078-0432.c.6742700.v2","title":"Data from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Association for Cancer Research","keywords":"Medicine; KRAS; Internal medicine; Oncology; Cohort; Cancer; Lung cancer; ROS1; Confidence interval; Response Evaluation Criteria in Solid Tumors; Ramucirumab; Clinical trial; Adenocarcinoma; Phases of clinical research; Colorectal cancer","score_opus":0.07401438445914432,"score_gpt":0.404237008312921,"score_spread":0.33022262385377665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386350101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8947727,0.0021355012,0.0058443127,0.0013962159,0.0024017426,0.011154944,0.07850467,0.0002387955,0.0035511388],"genre_scores_gemma":[0.5283598,0.007199153,0.10400356,0.0022964512,0.006112794,0.0040900563,0.31988657,0.00056035334,0.027491326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966846,0.00010780473,0.0008760092,0.0016573601,0.0003568058,0.00031738283],"domain_scores_gemma":[0.9946677,0.0009514992,0.0005215772,0.003369281,0.0002919839,0.00019794387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006563409,0.00041643513,0.00086125964,0.000053101478,0.0002733843,0.00017710564,0.00089569483,0.00019585865,0.00005360805],"category_scores_gemma":[0.00012670593,0.00021923102,0.00010014695,0.00010117424,0.00012945857,0.0001048671,0.0025060521,0.00063323043,0.0000026548214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082534837,0.00017018225,0.92877156,0.00022338868,0.0031759096,0.000018782765,0.00027028815,0.0000146462935,0.00002145062,0.000004474518,0.06298283,0.0035211272],"study_design_scores_gemma":[0.009782947,0.00019885284,0.9509084,0.001513793,0.01329013,0.0000012951491,0.0003721928,0.0129676815,0.000022999357,0.00004576217,0.010422656,0.00047326522],"about_ca_topic_score_codex":0.03357036,"about_ca_topic_score_gemma":0.06009034,"teacher_disagreement_score":0.36641294,"about_ca_system_score_codex":0.00031736412,"about_ca_system_score_gemma":0.0018876259,"threshold_uncertainty_score":0.97286516},"labels":[],"label_agreement":null},{"id":"W4386759693","doi":"10.1016/j.jtho.2023.09.275","title":"Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; EMD Serono; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Invitae; Yale University; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pathology; Lung; Cell; Basal cell; Oncology; Internal medicine; Genetics; Biology","score_opus":0.0333078621977281,"score_gpt":0.4383378436677831,"score_spread":0.40502998147005503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386759693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948645,0.00071791565,0.00015781967,0.0019122084,0.00065125007,0.00032197678,0.000028274433,0.000007149681,0.0013389104],"genre_scores_gemma":[0.99764246,0.00008845264,0.001319528,0.00029096255,0.00008825567,0.0000054523175,0.0000043972695,0.0000137712,0.00054674415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998599,0.00016159726,0.00061325374,0.00012238525,0.000321627,0.00018217067],"domain_scores_gemma":[0.9982632,0.00021386215,0.00086307107,0.00021131747,0.00036452874,0.00008401586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029067323,0.000113880975,0.00052703114,0.00020456126,0.000057475263,0.0000039533993,0.00016191545,0.00010232485,0.000095862815],"category_scores_gemma":[0.000026271246,0.000070686656,0.000234155,0.00023733445,0.000109362096,0.000039451155,0.00010182822,0.00032940228,0.0000041078347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009056693,0.001757363,0.7022274,0.00090311386,0.0009601621,0.0011038473,0.0086035365,0.005347401,0.25051892,0.000046299785,0.006561226,0.021065054],"study_design_scores_gemma":[0.002589335,0.0017793367,0.9701118,0.00010521762,0.00137904,0.00039829232,0.0040617017,0.0012682043,0.015528181,0.000088180466,0.0026059996,0.0000846982],"about_ca_topic_score_codex":0.00007431605,"about_ca_topic_score_gemma":0.0000067954934,"teacher_disagreement_score":0.2678844,"about_ca_system_score_codex":0.00060108455,"about_ca_system_score_gemma":0.0008586316,"threshold_uncertainty_score":0.28825182},"labels":[],"label_agreement":null},{"id":"W4386837112","doi":"10.3390/curroncol30090616","title":"Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Zhejiang University","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Proportional hazards model; Adenocarcinoma; Population; Concordance; Epidermal growth factor receptor; Subgroup analysis; Univariate analysis; Log-rank test; Multivariate analysis; Confidence interval; Cancer","score_opus":0.050099587954701,"score_gpt":0.42981315133075554,"score_spread":0.37971356337605455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386837112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953698,0.0009423613,0.00060529227,0.00022617074,0.00014916765,0.0019697796,0.00050005806,0.000013442074,0.00022394635],"genre_scores_gemma":[0.99544394,0.0001541393,0.002277314,0.000029432229,0.000034753502,0.0010285794,0.0008561968,0.000022540915,0.00015309805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894464,0.00003192217,0.00034252185,0.00028123098,0.00018978956,0.00020992172],"domain_scores_gemma":[0.9988125,0.00042534957,0.00028184368,0.000108582804,0.0002928097,0.00007892822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006891486,0.00016900833,0.0004650071,0.00017216364,0.00004665713,0.0000038813687,0.00004330176,0.000033978806,0.000026172664],"category_scores_gemma":[0.000022851185,0.00011975823,0.000044940552,0.00028805077,0.00016798699,0.000054329106,0.000009848018,0.00006278559,0.0000014441706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019549218,0.0029686056,0.95886916,0.00097180455,0.0005619423,0.000024172017,0.0044115097,0.002062579,0.00010328667,0.0002543551,0.00030393366,0.02751374],"study_design_scores_gemma":[0.041107375,0.0045168283,0.9466517,0.00047844462,0.0011263326,0.000008298144,0.0005227936,0.0023791695,0.0007634064,0.00006793003,0.0022081556,0.00016954615],"about_ca_topic_score_codex":0.00013588421,"about_ca_topic_score_gemma":0.00031022707,"teacher_disagreement_score":0.039152455,"about_ca_system_score_codex":0.00045760217,"about_ca_system_score_gemma":0.0011593293,"threshold_uncertainty_score":0.4883599},"labels":[],"label_agreement":null},{"id":"W4386849885","doi":"10.7759/cureus.45517","title":"Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Cureus","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Crizotinib; Anaplastic lymphoma kinase; Adverse effect; Oncology; Lung cancer; Internal medicine; Discontinuation; Nausea","score_opus":0.027520064073618063,"score_gpt":0.36490512917515405,"score_spread":0.337385065101536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386849885","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026902708,0.9864973,0.000004090153,0.000019625251,0.00029680564,0.01232867,0.00016588558,0.000029017066,0.00038961982],"genre_scores_gemma":[0.00043219238,0.99366677,0.00003046193,0.000042793545,0.000054523698,0.004962764,0.00026055909,0.00007362125,0.0004763203],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9974917,0.00029956872,0.001253794,0.00036956705,0.00029788425,0.00028747786],"domain_scores_gemma":[0.99696124,0.0011253356,0.0009406648,0.0007722616,0.00010892722,0.00009154614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017276032,0.0005033138,0.0039055396,0.00018892765,0.000034780645,0.000005514197,0.00022163155,0.00015160527,0.000013677006],"category_scores_gemma":[0.00017337271,0.00026982254,0.00074838055,0.0008468863,0.00004534367,0.000025289339,0.000020898791,0.00008441615,0.000023980403],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010086317,0.0008192428,0.000013917991,0.98275536,0.0015859485,0.000395441,0.0007539052,0.000002585179,0.0000010308015,0.0000068351233,0.00018473569,0.013470911],"study_design_scores_gemma":[0.002322388,0.0011196834,0.000049425467,0.92246044,0.06527507,0.00003833614,0.00012471908,0.000022032531,0.000013479327,0.0000017749784,0.008363817,0.00020882691],"about_ca_topic_score_codex":0.0009190425,"about_ca_topic_score_gemma":0.00029740605,"teacher_disagreement_score":0.06368912,"about_ca_system_score_codex":0.0009918805,"about_ca_system_score_gemma":0.0011003775,"threshold_uncertainty_score":0.9999754},"labels":[],"label_agreement":null},{"id":"W4386878679","doi":"10.1158/2767-9764.crc-23-0084","title":"The Inherited <i>KRAS</i> -variant as a Biomarker of Cetuximab Response in NSCLC","year":2023,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"University of Texas MD Anderson Cancer Center; National Cancer Institute; NRG Oncology; Eli Lilly and Company","keywords":"Cetuximab; KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Proportional hazards model; Confidence interval; Log-rank test; Colorectal cancer; Cancer","score_opus":0.16787399247325435,"score_gpt":0.5265000442890272,"score_spread":0.35862605181577284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386878679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7620333,0.01501044,0.00001481587,0.18458685,0.00013569262,0.002343218,0.00017576263,0.00014279886,0.035557114],"genre_scores_gemma":[0.98426867,0.010013291,0.00015696108,0.00013842538,0.000014952709,0.0013795113,0.00006381054,0.00002280453,0.0039415844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798703,0.00075881695,0.00029541756,0.00016890149,0.0004356806,0.00035417557],"domain_scores_gemma":[0.9956376,0.0019072847,0.000054042957,0.001808569,0.0004860675,0.00010646109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020770764,0.00008082148,0.0001623554,0.00037256652,0.0004892959,0.0000344162,0.00058018346,0.000054801025,0.00007967016],"category_scores_gemma":[0.0010884114,0.00005770027,0.000060171515,0.0027382623,0.0005807463,0.0000641475,0.00036467257,0.00037447302,0.00009417798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026457684,0.0049044862,0.035535958,0.00050398515,0.002862396,0.0004951062,0.03894216,0.00010532828,0.25498655,0.053122047,0.2814494,0.3006349],"study_design_scores_gemma":[0.0058486313,0.00057004846,0.3942665,0.0008757737,0.00010835936,0.000030893014,0.0061543467,0.0026486507,0.0014890995,0.0028135679,0.5849967,0.00019744357],"about_ca_topic_score_codex":0.0026752558,"about_ca_topic_score_gemma":0.0013016325,"teacher_disagreement_score":0.35873052,"about_ca_system_score_codex":0.00041727335,"about_ca_system_score_gemma":0.0015117823,"threshold_uncertainty_score":0.40442044},"labels":[],"label_agreement":null},{"id":"W4386984616","doi":"10.1057/978-1-349-96073-6_966","title":"Canadian Cancer Society Research Institute (CCSRI)","year":2023,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Faculty of Education, Victoria University of Wellington; Research Committee, Aristotle University of Thessaloniki; Killam Trusts; Tel Aviv University; Camargo Foundation; University of Toronto; Hebrew University of Jerusalem; Canada Council for the Arts; Government of Canada","keywords":"Cancer; Political science; Library science; Medicine; Computer science; Internal medicine","score_opus":0.0828009747798583,"score_gpt":0.3785010300765693,"score_spread":0.295700055296711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386984616","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013346404,0.0015217614,0.000004177763,0.0014523683,0.0009808247,0.00137744,0.00095446693,0.00016193332,0.99341357],"genre_scores_gemma":[0.58494973,0.0011255494,0.00015801658,0.0007036349,0.00091773865,0.0002656404,0.0005551654,0.0001894047,0.4111351],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99731946,0.000018436023,0.00036808822,0.00070498826,0.00075220835,0.00083679945],"domain_scores_gemma":[0.9978113,0.00006940567,0.00010263948,0.00073448854,0.00048211205,0.0008000299],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002567086,0.0004576406,0.00058152,0.0004894244,0.00047093633,0.000060829152,0.00021633922,0.0005232684,0.0008833178],"category_scores_gemma":[0.000023823157,0.00040461804,0.00041687794,0.000073224306,0.00033717314,7.972658e-7,0.00010451866,0.00084012945,0.000941117],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036710102,0.0000010509675,0.00089271896,0.00038252102,0.00276691,0.0010981119,0.0022313625,0.000004011399,0.00006405727,0.9473663,0.008544598,0.036611635],"study_design_scores_gemma":[0.0020077883,0.00027234168,0.0019500947,0.0016036467,0.0012164444,0.00007004784,0.00022139524,0.00003277513,0.000079161655,0.6707774,0.32091588,0.0008530671],"about_ca_topic_score_codex":0.21653116,"about_ca_topic_score_gemma":0.44385993,"teacher_disagreement_score":0.5848163,"about_ca_system_score_codex":0.002247959,"about_ca_system_score_gemma":0.004664598,"threshold_uncertainty_score":0.99984056},"labels":[],"label_agreement":null},{"id":"W4387008412","doi":"10.2139/ssrn.4574067","title":"Presentation and Outcomes of KRAS&lt;sup&gt;G12C&lt;/sup&gt; Mutant Non-Small Cell Lung Cancer Patients with Stage IV Disease at Diagnosis (de novo)&amp;nbsp;Versus at Recurrence","year":2023,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Stage (stratigraphy); Medicine; Disease; Presentation (obstetrics); Cell; Cancer; Lung cancer; Internal medicine; Cancer research; Oncology; Biology; Surgery; Genetics; Colorectal cancer","score_opus":0.015696239524343188,"score_gpt":0.3154044142511861,"score_spread":0.2997081747268429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387008412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98796165,0.0071060234,0.00046396285,0.00090925966,0.00057702215,0.0018040241,0.0009815923,0.000052112733,0.0001443337],"genre_scores_gemma":[0.95793223,0.03436524,0.00022300132,0.000054461198,0.0002085617,0.00051973184,0.0007002663,0.00012444369,0.0058720666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995854,0.00012158668,0.0006944594,0.0007586088,0.0008481882,0.0017231378],"domain_scores_gemma":[0.9974753,0.00024961593,0.0008300073,0.00051586836,0.00042176194,0.0005074371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038961717,0.00060202944,0.0007985382,0.00031399954,0.00033316336,0.0000660669,0.00026684065,0.00020500047,0.00014012189],"category_scores_gemma":[0.00012208002,0.0004643505,0.00028206807,0.00025541976,0.00012839258,0.00016967472,0.00034965033,0.0013545491,0.000012572713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002264919,0.00063673547,0.98781526,0.00073884847,0.0024882727,0.000055842804,0.0017689425,0.0021652896,0.000081765094,0.00010153575,0.0003717481,0.0015108177],"study_design_scores_gemma":[0.022631468,0.0015937467,0.9600427,0.0018928765,0.0084107015,0.000036882197,0.000560322,0.0010811978,0.00036597787,0.00078232784,0.0015582151,0.0010435432],"about_ca_topic_score_codex":0.0009104136,"about_ca_topic_score_gemma":0.01005585,"teacher_disagreement_score":0.030029442,"about_ca_system_score_codex":0.006641754,"about_ca_system_score_gemma":0.005151601,"threshold_uncertainty_score":0.99978083},"labels":[],"label_agreement":null},{"id":"W4387105833","doi":"10.3390/curroncol30100635","title":"The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Crizotinib; Osimertinib; Cabozantinib; Medicine; Lung cancer; Acquired resistance; Adenocarcinoma; Oncology; Targeted therapy; Cancer research; Point mutation; Tyrosine-kinase inhibitor; Erlotinib; Internal medicine; Cancer; Mutation; Epidermal growth factor receptor; ROS1; Genetics; Biology; Gene","score_opus":0.05721777822825429,"score_gpt":0.4320573635367528,"score_spread":0.3748395853084985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387105833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98603016,0.009254455,0.000023407334,0.0031930343,0.00018343703,0.00085212896,0.000035139266,0.000026720772,0.00040148664],"genre_scores_gemma":[0.99316734,0.005932975,0.00014246914,0.00005061539,0.000018575734,0.0005153442,0.000065304106,0.000011234036,0.00009615656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992458,0.00006373257,0.0002416324,0.00018924671,0.000105756575,0.0001538073],"domain_scores_gemma":[0.9993177,0.00023814781,0.00014085835,0.00013378577,0.00011862163,0.000050860337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011260446,0.00009060868,0.00020283676,0.00009018317,0.00011472693,0.000009270197,0.00003227285,0.000034497698,0.000007762416],"category_scores_gemma":[0.0000444902,0.000056414003,0.000016869633,0.0003417525,0.00017963823,0.000037703863,0.000015798572,0.000059660917,6.035619e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030087032,0.0010915216,0.5934847,0.00031902123,0.0005066391,0.000028570581,0.022277715,0.00003051048,0.00260169,0.007114836,0.003036839,0.36649927],"study_design_scores_gemma":[0.011557297,0.0015614826,0.9161011,0.00038482036,0.00028380848,0.000011545299,0.0032928537,0.00072951213,0.0007119922,0.0005674816,0.06462425,0.0001738442],"about_ca_topic_score_codex":0.00006017379,"about_ca_topic_score_gemma":0.00036232301,"teacher_disagreement_score":0.36632544,"about_ca_system_score_codex":0.00006982449,"about_ca_system_score_gemma":0.00022529354,"threshold_uncertainty_score":0.23004963},"labels":[],"label_agreement":null},{"id":"W4387132514","doi":"10.3390/curroncol30100640","title":"Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Osimertinib; T790M; Medicine; Epidermal growth factor receptor; Oncology; Liquid biopsy; Lung cancer; Internal medicine; Circulating tumor DNA; Cancer research; EGFR inhibitors; Cancer; Gefitinib; Erlotinib","score_opus":0.10402288607630812,"score_gpt":0.45265034822490685,"score_spread":0.34862746214859874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387132514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950213,0.0021233808,0.00026941797,0.003066426,0.00021748227,0.00077364466,0.000031257012,0.000049117407,0.003967163],"genre_scores_gemma":[0.9978193,0.00022683179,0.0010577012,0.000014963925,0.000026869397,0.00020063414,0.00020586285,0.000011476224,0.00043633636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99918354,0.000050556035,0.00029843146,0.0002139445,0.000116112904,0.00013741932],"domain_scores_gemma":[0.9993605,0.00014839666,0.00014778266,0.0001625018,0.00011872686,0.00006208085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017173668,0.00008643002,0.00025652078,0.00020050042,0.00004561985,0.0000035016274,0.000018964085,0.000032640924,0.000027267828],"category_scores_gemma":[0.00012894072,0.000069042406,0.000023679355,0.0003826475,0.00010042993,0.00005822019,0.000014067119,0.000047537007,0.0000048025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034873816,0.007462207,0.08761906,0.0045464016,0.0022142879,0.3053664,0.11386804,0.00054470636,0.0017081382,0.0151713975,0.012484933,0.44552705],"study_design_scores_gemma":[0.09379731,0.013792858,0.46141133,0.0051083574,0.011367264,0.06794433,0.08125786,0.008471124,0.001280661,0.024354327,0.2291829,0.0020316811],"about_ca_topic_score_codex":0.00006297057,"about_ca_topic_score_gemma":0.0020207092,"teacher_disagreement_score":0.44349536,"about_ca_system_score_codex":0.0001772103,"about_ca_system_score_gemma":0.00033113218,"threshold_uncertainty_score":0.28154674},"labels":[],"label_agreement":null},{"id":"W4387208182","doi":"10.1016/j.ijrobp.2023.06.473","title":"Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy: Trial-Level Meta-Analysis and Individual-Level Analysis of NRG/RTOG 0617 and PROCLAIM","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Lung cancer; Meta-analysis; Randomized controlled trial; Chemoradiotherapy; Oncology; Surrogate endpoint; Progression-free survival; Subgroup analysis; Proportional hazards model; Confidence interval; Cancer; Overall survival","score_opus":0.038346035052038804,"score_gpt":0.3593833750066585,"score_spread":0.3210373399546197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387208182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951241,0.00046101827,0.0019233618,0.00056941074,0.00012930176,0.00081619585,0.0008989639,0.000013480238,0.00006414732],"genre_scores_gemma":[0.9953334,0.0004810192,0.0032940886,0.00009998376,0.00007973465,0.00008607248,0.0005315892,0.00002890283,0.00006526358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772537,0.00020620329,0.00090703025,0.00035190175,0.00058830186,0.0002211716],"domain_scores_gemma":[0.99638,0.00043533696,0.0016971988,0.00021295137,0.0011452575,0.00012929614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005999531,0.00028208928,0.0017431903,0.00089349196,0.000045138935,0.000020018531,0.0002217571,0.00015191313,0.00004738352],"category_scores_gemma":[0.000094136594,0.00018752132,0.0003772708,0.0012843801,0.00018182756,0.00019485014,0.000057010653,0.00023006662,2.6704237e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011281182,0.0008809847,0.8669571,0.000034628898,0.109573685,0.000022021968,0.0009959256,0.0037640557,0.0002478024,0.00009906236,0.00001332798,0.0061302055],"study_design_scores_gemma":[0.06626633,0.0028791209,0.85642207,0.00004939473,0.070870645,0.00000291999,0.00012836672,0.0018587991,0.0011715624,0.00013642045,0.0000267813,0.00018759308],"about_ca_topic_score_codex":0.00038883937,"about_ca_topic_score_gemma":0.00048568624,"teacher_disagreement_score":0.054985143,"about_ca_system_score_codex":0.00034067724,"about_ca_system_score_gemma":0.0007904684,"threshold_uncertainty_score":0.76468974},"labels":[],"label_agreement":null},{"id":"W4387296889","doi":"10.1111/ajco.14030","title":"Re‐re‐biopsy? How much tumor is enough in the era of precision oncology?","year":2023,"lang":"en","type":"editorial","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liquid biopsy; Erlotinib; Afatinib; Medicine; Precision medicine; Gefitinib; Cancer research; Lung cancer; Personalized medicine; Epidermal growth factor receptor; Targeted therapy; Oncology; Mutation; Biopsy; ROS1; Internal medicine; Cancer; Gene; Pathology; Bioinformatics; Adenocarcinoma; Biology; Genetics","score_opus":0.07119682710064731,"score_gpt":0.49022388508803566,"score_spread":0.4190270579873884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387296889","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009055743,0.0014629777,0.000027357557,0.09529772,0.86973727,0.0010644897,0.00024543647,0.00002601594,0.023082977],"genre_scores_gemma":[0.14368767,0.010608041,0.004300575,0.0012163079,0.8338247,0.000095224044,0.0002805791,0.00017765707,0.00580924],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99204654,0.0014869488,0.0038440465,0.0005719899,0.0015054155,0.00054508547],"domain_scores_gemma":[0.9683043,0.024659824,0.0045150006,0.0007532941,0.0014240753,0.0003435471],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007420599,0.00043892453,0.0034674008,0.00037652813,0.000093468276,0.00003288278,0.0007654589,0.0021481935,0.0002336413],"category_scores_gemma":[0.01611001,0.0002652579,0.0011752072,0.00063037477,0.00052419136,0.00014429871,0.00011400058,0.0057143853,0.00006605032],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027294941,0.0023674497,0.0008181467,0.00009787596,0.0009842895,0.003207302,0.0023028697,0.0000015789068,0.000011959557,0.000022255921,0.9241776,0.06327917],"study_design_scores_gemma":[0.009328029,0.01631545,0.0027146586,0.0008204682,0.0018807956,0.00021764237,0.009304082,0.0000059278523,0.000018207289,0.0006936307,0.9585101,0.00019101545],"about_ca_topic_score_codex":0.00008582091,"about_ca_topic_score_gemma":0.0002048225,"teacher_disagreement_score":0.13463193,"about_ca_system_score_codex":0.0008526237,"about_ca_system_score_gemma":0.010423885,"threshold_uncertainty_score":0.99998},"labels":[],"label_agreement":null},{"id":"W4387402365","doi":"10.1016/j.esmoop.2023.101683","title":"37P NET-mediated radio-resistance in early-stage non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre; McGill University","funders":"","keywords":"Stage (stratigraphy); Lung cancer; Resistance (ecology); Oncology; Medicine; Internal medicine; Biology; Ecology","score_opus":0.018454719119439796,"score_gpt":0.33735191911043033,"score_spread":0.31889719999099053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387402365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93297994,0.000589445,0.000021466472,0.0022003197,0.00033863308,0.0017052097,0.000118188604,0.000082725805,0.06196405],"genre_scores_gemma":[0.8678791,0.00037197047,0.00045441263,0.00050087355,0.00009765034,0.0005715112,0.00024033381,0.000041581294,0.12984255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998985,0.00002532889,0.00020902515,0.0003079047,0.00014820557,0.00032455754],"domain_scores_gemma":[0.9994068,0.00005844876,0.000064150605,0.00029516907,0.000043668955,0.000131754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013216904,0.00014201905,0.00026785373,0.000119135475,0.00007843887,0.000058456404,0.0002112574,0.00006696563,0.00055272406],"category_scores_gemma":[0.000019485165,0.00012304063,0.00004453074,0.00060078036,0.000025626017,0.00013215846,0.00009797207,0.00014439915,0.00025109007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027937925,0.00027623432,0.90750843,0.00029569914,0.00025645475,0.0009072963,0.0074986885,0.00023483286,0.00048671465,0.00017850855,0.08126337,0.0008143953],"study_design_scores_gemma":[0.004946075,0.000060616458,0.917249,0.00026880528,0.00012888739,8.020348e-7,0.00024529974,0.0005023815,0.0007158059,0.000025125639,0.07567422,0.00018297668],"about_ca_topic_score_codex":0.01680039,"about_ca_topic_score_gemma":0.014325787,"teacher_disagreement_score":0.06787851,"about_ca_system_score_codex":0.00026879777,"about_ca_system_score_gemma":0.0003897139,"threshold_uncertainty_score":0.9897468},"labels":[],"label_agreement":null},{"id":"W4387746099","doi":"10.1016/j.cllc.2023.10.006","title":"Clinical, Genomic, and Transcriptomic Featurses of Lung Adenocarcinoma With Uncommon EGFR Mutation","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Adenocarcinoma; Hazard ratio; Oncology; Transcriptome; Epidermal growth factor receptor; Lung cancer; Internal medicine; Mutation; Proportional hazards model; Cancer; Gene; Confidence interval; Biology; Genetics; Gene expression","score_opus":0.04045872465736925,"score_gpt":0.4408475566299222,"score_spread":0.4003888319725529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387746099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882811,0.006553261,0.00006469659,0.002317087,0.00067065493,0.00083418534,0.00008397381,0.00010789927,0.0010871702],"genre_scores_gemma":[0.9930765,0.0033728643,0.00050079514,0.00061517267,0.00037270912,0.00011156591,0.00010128954,0.000044448927,0.0018046635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982342,0.00009530461,0.0007593399,0.00045938854,0.00020315778,0.0002485818],"domain_scores_gemma":[0.9986486,0.00044935726,0.0002209454,0.0003161282,0.0001387201,0.00022627952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037279533,0.00018137126,0.00061840576,0.00009938469,0.00008250432,0.00001678802,0.00008042005,0.00016568122,0.00013228755],"category_scores_gemma":[0.00007327347,0.00013300251,0.0001861992,0.00030424423,0.00030967474,0.0000855265,0.000026955538,0.00028083223,0.000011110837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007044957,0.00017928521,0.96936196,0.00025879845,0.00085916906,0.000058891044,0.00032614902,0.000033285884,0.000111781585,0.000087978246,0.009750232,0.018267948],"study_design_scores_gemma":[0.005435837,0.00077509216,0.98737514,0.00034306064,0.0020295146,0.000015825004,0.00016965787,0.0014600625,0.00006443632,0.000047223697,0.0021343518,0.000149816],"about_ca_topic_score_codex":0.00020216993,"about_ca_topic_score_gemma":0.00022960723,"teacher_disagreement_score":0.018118132,"about_ca_system_score_codex":0.0001265703,"about_ca_system_score_gemma":0.00045666125,"threshold_uncertainty_score":0.54236853},"labels":[],"label_agreement":null},{"id":"W4387809545","doi":"10.1016/j.annonc.2023.10.060","title":"LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Lung cancer; Exon; Internal medicine; non-small cell lung cancer (NSCLC); Gene; A549 cell; Genetics","score_opus":0.029553060566340852,"score_gpt":0.41125183984126906,"score_spread":0.38169877927492823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97442853,0.0014537363,0.00004484741,0.01431656,0.00031595325,0.0058552097,0.00050660275,0.00012806548,0.0029504937],"genre_scores_gemma":[0.9779156,0.013734346,0.00030592666,0.0030179184,0.0001654564,0.0014193832,0.001334953,0.000060077746,0.0020463464],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997018,0.00021522475,0.0011737896,0.00073964085,0.00030317204,0.0005502024],"domain_scores_gemma":[0.9979333,0.00051415653,0.00056514994,0.00049759954,0.0002803484,0.00020943888],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004061477,0.00045793352,0.001932845,0.0002383586,0.00010608479,0.00001386182,0.00016408094,0.00022441219,0.0001736938],"category_scores_gemma":[0.00007007602,0.00035811673,0.00030256732,0.0007780659,0.0001240324,0.00010990389,0.00003852156,0.00015655362,0.000022334541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8051337,0.019242223,0.008530708,0.00012783885,0.004198407,0.0011056187,0.023443794,0.002451872,0.005239594,0.000005440712,0.004981996,0.12553883],"study_design_scores_gemma":[0.94649583,0.01305259,0.021337032,0.00029025105,0.0008803392,0.00000830623,0.0012888935,0.0022416967,0.0074588875,0.00013032476,0.006450239,0.00036560683],"about_ca_topic_score_codex":0.013467958,"about_ca_topic_score_gemma":0.005142903,"teacher_disagreement_score":0.14136216,"about_ca_system_score_codex":0.0013702207,"about_ca_system_score_gemma":0.0017056246,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W4387809564","doi":"10.1016/j.annonc.2023.10.063","title":"LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; Oncology; Chemotherapy; Internal medicine; Randomized controlled trial; Chemotherapy regimen; Adenocarcinoma; Cancer","score_opus":0.030231741122535478,"score_gpt":0.45074689493994546,"score_spread":0.42051515381741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692833,0.00044226774,0.000057511315,0.013811101,0.0003075937,0.011762841,0.000035030578,0.00016997592,0.0041304193],"genre_scores_gemma":[0.98676944,0.0012816531,0.00059673033,0.0054880944,0.00014912491,0.0039724815,0.00011883202,0.000061150226,0.0015625055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970492,0.0003228715,0.0010963506,0.0005362096,0.00042578316,0.0005695691],"domain_scores_gemma":[0.99800706,0.0005289756,0.0006338524,0.00037011932,0.0002682508,0.00019175798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076573883,0.00040933356,0.0029595913,0.00027863373,0.000062272586,0.000016677446,0.00012903307,0.00025482837,0.00035711282],"category_scores_gemma":[0.00022976511,0.00023193109,0.00036564106,0.0007400336,0.0002684426,0.00010023797,0.000022034183,0.00021201349,0.00002389639],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8948345,0.0034323807,0.00036941044,0.00004173238,0.0013242259,0.0003524398,0.0011489292,0.000032716693,0.00027743625,0.000022887036,0.0011003963,0.09706295],"study_design_scores_gemma":[0.9645757,0.024899254,0.0004960928,0.0004719857,0.0004373154,0.000028752864,0.00022769248,0.0008881226,0.001607771,0.000091976115,0.0060405354,0.00023476413],"about_ca_topic_score_codex":0.00010067277,"about_ca_topic_score_gemma":0.00010315759,"teacher_disagreement_score":0.09682819,"about_ca_system_score_codex":0.00024473004,"about_ca_system_score_gemma":0.0011617397,"threshold_uncertainty_score":0.94578755},"labels":[],"label_agreement":null},{"id":"W4387809567","doi":"10.1016/j.annonc.2023.10.069","title":"LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Oncology; Discontinuation; Chemotherapy; Cisplatin","score_opus":0.05048217222669842,"score_gpt":0.434699390876069,"score_spread":0.3842172186493706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9506625,0.000800731,0.000022029122,0.03936847,0.00014403548,0.0004932216,0.00004920342,0.000036058973,0.008423776],"genre_scores_gemma":[0.99167377,0.0049670367,0.00031472795,0.001430452,0.0000309088,0.000034630786,0.000049602168,0.000018480407,0.001480377],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990065,0.000029580926,0.00043310353,0.00019301953,0.00011420894,0.00022355025],"domain_scores_gemma":[0.99918556,0.0002565796,0.00017094226,0.00019169462,0.00012140241,0.00007382434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018921564,0.0001222194,0.00059204665,0.00017823692,0.000032011165,0.0000015713655,0.00005738644,0.000102279046,0.00010219504],"category_scores_gemma":[0.00012209012,0.00009714459,0.0000829101,0.0003069337,0.00011013102,0.000052675616,0.000028675558,0.000084920364,0.00000870912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037065274,0.0017612693,0.39401567,0.0003093472,0.00096178945,0.00011712129,0.0050228634,0.00022517648,0.004707197,0.0006998809,0.0041597052,0.58431345],"study_design_scores_gemma":[0.012056848,0.0039335117,0.86345935,0.00015795353,0.00013099503,0.000013180034,0.00055066997,0.00014691192,0.0070274295,0.0005698496,0.111810714,0.00014260362],"about_ca_topic_score_codex":0.00016663979,"about_ca_topic_score_gemma":0.0003158146,"teacher_disagreement_score":0.5841708,"about_ca_system_score_codex":0.00004254607,"about_ca_system_score_gemma":0.00013373847,"threshold_uncertainty_score":0.39614415},"labels":[],"label_agreement":null},{"id":"W4387810156","doi":"10.1016/j.annonc.2023.09.2830","title":"375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Oncology; De-escalation; Solid tumor; Internal medicine; Nuclear medicine; Cancer","score_opus":0.034195459923182535,"score_gpt":0.4102452826055652,"score_spread":0.3760498226823827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977046,0.00004583731,0.0000058203204,0.00035778532,0.00003777346,0.0015706873,0.00002125418,0.000022554545,0.00023367099],"genre_scores_gemma":[0.9994237,0.000048959126,0.00014588193,0.00007161732,0.000013347725,0.00012799384,0.00010625999,0.000021960557,0.000040282768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867666,0.000067071865,0.00046931702,0.00030168777,0.00022847699,0.00025680178],"domain_scores_gemma":[0.99919933,0.00008142611,0.00025729297,0.00019133954,0.00018188031,0.0000887547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001434341,0.00016122244,0.00054369477,0.00036055688,0.000054342676,0.0000036005438,0.00004931919,0.00006000878,0.0000149544385],"category_scores_gemma":[0.000031971354,0.000119529665,0.000026005675,0.00043692873,0.00009366148,0.00012135137,0.000024849182,0.00010775163,0.0000010479068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008284145,0.018754164,0.89540267,0.00018877481,0.00027483774,0.00017707968,0.014513235,0.0016405006,0.00048154383,0.000010149171,0.00009901067,0.060173903],"study_design_scores_gemma":[0.052490663,0.038411416,0.90436625,0.00036497344,0.00013220502,0.0000029153425,0.003208195,0.00026311047,0.00045515795,0.000017913304,0.00017644916,0.00011075134],"about_ca_topic_score_codex":0.00043015555,"about_ca_topic_score_gemma":0.00396944,"teacher_disagreement_score":0.06006315,"about_ca_system_score_codex":0.00009831567,"about_ca_system_score_gemma":0.00014214321,"threshold_uncertainty_score":0.4874278},"labels":[],"label_agreement":null},{"id":"W4387810689","doi":"10.1016/j.annonc.2023.09.2386","title":"1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Lung cancer; Cohort; Proportional hazards model; Demographics; Targeted therapy; Cancer; Progression-free survival; Exact test; Overall survival; Confidence interval; Demography","score_opus":0.026993990122922862,"score_gpt":0.42107418582286066,"score_spread":0.3940801956999378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676234,0.00024473236,0.000070079645,0.0014429447,0.000083231054,0.000726777,0.000047991598,0.00002160422,0.010600287],"genre_scores_gemma":[0.9982545,0.00022269782,0.0002181045,0.0002052636,0.000032797558,0.0002188044,0.00014749612,0.000016519176,0.00068386225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992122,0.00006162459,0.00024973793,0.0001647871,0.0001233774,0.00018829563],"domain_scores_gemma":[0.99920917,0.00026004823,0.00016710296,0.00012659564,0.00017875148,0.00005835756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016369823,0.000104070874,0.0003660899,0.00025749984,0.000029712504,0.0000021038431,0.000045597353,0.000083605,0.000070537986],"category_scores_gemma":[0.000029188168,0.00007913937,0.000061245715,0.00044104602,0.000083296625,0.000050624218,0.000011263416,0.00008566425,0.000015091273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017526759,0.0010714997,0.8839899,0.0015157263,0.0009884911,0.000625042,0.01333631,0.00593051,0.016597364,0.00012884638,0.011412349,0.062651336],"study_design_scores_gemma":[0.014819831,0.011733346,0.8672017,0.0005970413,0.0011221006,0.00002603807,0.001098527,0.0015956883,0.09832836,0.000073126146,0.0031778296,0.00022644427],"about_ca_topic_score_codex":0.0007560654,"about_ca_topic_score_gemma":0.0003514751,"teacher_disagreement_score":0.08173099,"about_ca_system_score_codex":0.00008152832,"about_ca_system_score_gemma":0.00045383256,"threshold_uncertainty_score":0.32272097},"labels":[],"label_agreement":null},{"id":"W4387810720","doi":"10.1016/j.annonc.2023.09.2393","title":"1360P Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Faculty of Medicine, Chulalongkorn University; Genentech; EMD Serono; Centre Léon Bérard; Centre Hospitalier Universitaire Vaudois; BeiGene; King Chulalongkorn Memorial Hospital; Amgen; Henry Ford Health System; F. Hoffmann-La Roche; Sanofi; Pfizer; Les Laboratories Pierre Fabre; Chulalongkorn University; National Cancer Centre of Singapore; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Post-hoc analysis; Neurocognitive; Clinical endpoint; Oncology; Cognition; Clinical trial; Psychiatry","score_opus":0.08028585454669245,"score_gpt":0.4161469821753147,"score_spread":0.33586112762862225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455285,0.0001600148,0.000012448974,0.0032160915,0.00010326533,0.0013729682,0.00047155243,0.000052097534,0.00005873278],"genre_scores_gemma":[0.99784744,0.000081270955,0.0001572825,0.000881684,0.000023979708,0.00008772727,0.00076878676,0.000024261197,0.00012756522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814385,0.00026088516,0.0006095064,0.00037759123,0.00028715536,0.00032101042],"domain_scores_gemma":[0.99852705,0.00043671537,0.00035286494,0.00030154124,0.0002325673,0.00014926617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002633514,0.0002341691,0.00074401643,0.00018212153,0.00010950303,0.0000069210178,0.00007101097,0.00007174223,0.000053533597],"category_scores_gemma":[0.0002992748,0.00012402389,0.000060447543,0.00047728402,0.00010458295,0.000101806254,0.00007904635,0.00010988631,0.0000028045692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021013494,0.0016583544,0.98073065,0.000040373117,0.001930019,0.00028656365,0.0022776853,0.00017130656,0.000011837282,0.0000027765434,0.0013568009,0.009432258],"study_design_scores_gemma":[0.011026925,0.0042657675,0.97636616,0.00012825959,0.001169014,0.000015152251,0.004771786,0.0002843094,0.00003807577,0.0000062243403,0.001803356,0.0001249764],"about_ca_topic_score_codex":0.0038973219,"about_ca_topic_score_gemma":0.004937561,"teacher_disagreement_score":0.009307282,"about_ca_system_score_codex":0.000063791886,"about_ca_system_score_gemma":0.00021104883,"threshold_uncertainty_score":0.5891611},"labels":[],"label_agreement":null},{"id":"W4387810740","doi":"10.1016/j.annonc.2023.09.2406","title":"1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Cilag; Chugai Pharmaceutical; BeiGene; Ipsen; Merck Sharp and Dohme; Eisai; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Daiichi-Sankyo; Amgen; Pfizer; Mesothelioma Applied Research Foundation","keywords":"ROS1; Medicine; Interim; Internal medicine; Interim analysis; Oncology; Lung cancer; Cancer; Clinical trial; Adenocarcinoma","score_opus":0.030367395179467675,"score_gpt":0.41128924309595116,"score_spread":0.3809218479164835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996041,0.000180135,0.000007124023,0.0003073643,0.00006802566,0.0007637591,0.0001717705,0.000009381882,0.002451453],"genre_scores_gemma":[0.9994669,0.000145155,0.00005850927,0.000075811164,0.000011995832,0.000043298132,0.000056352666,0.000009069496,0.00013294147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893296,0.000058114223,0.0004454385,0.00023210622,0.00015022942,0.00018117175],"domain_scores_gemma":[0.9991175,0.00008870894,0.00028851687,0.00018732931,0.00025151542,0.0000664257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001635225,0.00012116885,0.0007291336,0.00026094512,0.00002720572,0.0000016498711,0.00006638957,0.000067162255,0.00004716565],"category_scores_gemma":[0.00003398437,0.00009291204,0.00007831051,0.0012491136,0.00008438699,0.00003253013,0.000068329544,0.000066770575,5.229029e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001961264,0.0032992326,0.9678092,0.00009067587,0.0023997368,0.000016820039,0.0038719168,0.0003649403,0.000087812616,0.000004955576,0.0002665888,0.019826831],"study_design_scores_gemma":[0.009686226,0.010685641,0.9753434,0.00009903868,0.002275243,4.820134e-7,0.0011165966,0.00021286654,0.0003060894,0.0000018349705,0.00020449338,0.00006806412],"about_ca_topic_score_codex":0.002085226,"about_ca_topic_score_gemma":0.0033809815,"teacher_disagreement_score":0.019758767,"about_ca_system_score_codex":0.000109481065,"about_ca_system_score_gemma":0.00026982848,"threshold_uncertainty_score":0.37888432},"labels":[],"label_agreement":null},{"id":"W4387811483","doi":"10.1016/j.annonc.2023.09.1852","title":"666P Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; National Evidence-based Healthcare Collaborating Agency; Mirati Therapeutics; Yuhan; F. Hoffmann-La Roche; AstraZeneca; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.04426788104364964,"score_gpt":0.41592201133084694,"score_spread":0.3716541302871973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448526,0.00014548197,0.000035493347,0.0021753048,0.00007540284,0.00073891896,0.0003670971,0.000019916866,0.0019571264],"genre_scores_gemma":[0.997002,0.00044951303,0.00064417755,0.00037255013,0.000012242171,0.000014067583,0.0013508175,0.00001502802,0.00013961722],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989071,0.000075663644,0.00035890157,0.00027483053,0.00016308555,0.0002204128],"domain_scores_gemma":[0.99892884,0.00024343001,0.00020946363,0.00028063226,0.00024848565,0.00008915032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017853909,0.00011818684,0.00045832538,0.00017590066,0.000034734534,0.0000024173937,0.00009345401,0.00004582354,0.000047711037],"category_scores_gemma":[0.00014614145,0.0000896802,0.000021657477,0.00041326784,0.00013408622,0.000096211916,0.000101943115,0.0000944481,0.000008233266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016913448,0.0068567363,0.21052697,0.00029088138,0.0016830699,0.00048225283,0.005926442,0.00090668286,0.0009461251,0.00024806673,0.011587671,0.74363166],"study_design_scores_gemma":[0.018343447,0.010596556,0.96371025,0.0004204347,0.00037824467,0.000016842267,0.0008656133,0.00024297167,0.0013667447,0.00009816636,0.0038248042,0.00013589943],"about_ca_topic_score_codex":0.0001155187,"about_ca_topic_score_gemma":0.00013824632,"teacher_disagreement_score":0.7531833,"about_ca_system_score_codex":0.00004109778,"about_ca_system_score_gemma":0.0003277148,"threshold_uncertainty_score":0.36570522},"labels":[],"label_agreement":null},{"id":"W4387825294","doi":"10.1016/j.annonc.2023.09.2349","title":"1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Foundation Medicine; Takeda Pharmaceuticals International; Ignyta; Loxo Oncology; Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Pfizer Japan; Novartis Pharma; EMD Serono; Grifols; Ipsen; PharmaMar; Sociedad Española de Oncología Médica; Japanese Society of Medical Oncology; Amgen Astellas Biopharma; Otsuka Pharmaceutical; Daiichi-Sankyo; Les Laboratories Pierre Fabre; Bayer HealthCare; Springworks Therapeutics; Relay Therapeutics; Sysmex Corporation; Helsinn; Mylan; Mirati Therapeutics; Daiichi Sankyo Europe; Takeda Oncology; European Society for Medical Oncology; Agios Pharmaceuticals; Jazz Pharmaceuticals; Kissei; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Teva Pharmaceutical Industries; Bayer Yakuhin; Verastem Oncology; Amgen; Ariad Pharmaceuticals; Ono Pharmaceutical; Takeda Pharmaceutical Company; FibroGen; Puma Biotechnology; Medpace; OncoMed Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; Celgene; Yuhan; Mersana Therapeutics; Merck Sharp and Dohme; Spectrum Pharmaceuticals; Barbara Ann Karmanos Cancer Institute; Eli Lilly and Company; Novocure; Genentech; International Association for the Study of Lung Cancer; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Company; BeiGene; Astellas Pharma; Eisai; Pharmacyclics; Pfizer Pharmaceuticals; Exelixis; Sanofi; Servier; Incyte; Pfizer","keywords":"Medicine; non-small cell lung cancer (NSCLC); Lung cancer; Oncology; Cancer research; Internal medicine","score_opus":0.03218767099273469,"score_gpt":0.416854446127853,"score_spread":0.3846667751351183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631916,0.0021173994,0.00003575292,0.0037571033,0.00037266922,0.0010576397,0.00011374014,0.00004553864,0.029308554],"genre_scores_gemma":[0.9899048,0.0055917306,0.00043586423,0.0005446125,0.000099526806,0.00011947019,0.00016105273,0.000043231877,0.0030996893],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982503,0.000076719334,0.0005822784,0.0004037282,0.00021185272,0.00047510205],"domain_scores_gemma":[0.99854285,0.00030843986,0.00031740917,0.00033307014,0.0003584766,0.00013975453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022191812,0.00021876539,0.000760787,0.0003907119,0.000067927365,0.000005250766,0.0001429272,0.00018224535,0.00027152535],"category_scores_gemma":[0.000058967085,0.0001928092,0.00017575758,0.0008845218,0.000125273,0.000086468666,0.00008054574,0.00020273152,0.00003849604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007974088,0.0097557,0.16512845,0.0023874845,0.002245215,0.0023087556,0.027861202,0.0065755076,0.44324198,0.0007092567,0.054246813,0.27756554],"study_design_scores_gemma":[0.028426412,0.0087282965,0.76571244,0.0024499577,0.000819223,0.000045946927,0.0037874195,0.0014001984,0.13675807,0.00024719952,0.050940793,0.00068403245],"about_ca_topic_score_codex":0.001870462,"about_ca_topic_score_gemma":0.00050725683,"teacher_disagreement_score":0.600584,"about_ca_system_score_codex":0.00022675206,"about_ca_system_score_gemma":0.0010005526,"threshold_uncertainty_score":0.7862531},"labels":[],"label_agreement":null},{"id":"W4387825383","doi":"10.1016/j.annonc.2023.09.2360","title":"1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Grand River Hospital; William Osler Health System; Ottawa Hospital; University Health Network; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Lakeridge Health; Princess Margaret Cancer Centre; Hamilton Health Sciences; Brampton Civic Hospital; London Health Sciences Centre","funders":"","keywords":"Osimertinib; Medicine; Pemetrexed; Lung cancer; Internal medicine; Clinical endpoint; Oncology; T790M; Interim analysis; Cohort; Population; Epidermal growth factor receptor; Cancer; Chemotherapy; Clinical trial; Erlotinib; Gefitinib","score_opus":0.052830336301056734,"score_gpt":0.4452087737739607,"score_spread":0.39237843747290396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447733,0.00007972452,0.000033343218,0.0033231238,0.00006119447,0.0010240058,0.000064529384,0.00008097069,0.0008557568],"genre_scores_gemma":[0.9984834,0.00004699568,0.00008062175,0.00035702126,0.00002043984,0.00031595226,0.00042292598,0.00003201369,0.00024058174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987056,0.00007072453,0.00040465748,0.00030200498,0.00023856173,0.00027845433],"domain_scores_gemma":[0.9989004,0.000118164295,0.00021875057,0.00024574035,0.00041614028,0.00010079422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013939808,0.00016874261,0.0005884472,0.00059840776,0.000058161626,0.000006939522,0.000079140074,0.00006183449,0.00010363706],"category_scores_gemma":[0.000032812837,0.00011647242,0.000066557106,0.0021617692,0.0000861249,0.000084811065,0.000032171774,0.00012771951,0.0000058267883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014521176,0.0031830948,0.9734314,0.00004057091,0.0037959663,0.0001167216,0.004128275,0.007995226,0.000007149482,0.000007937168,0.00057801564,0.0052635246],"study_design_scores_gemma":[0.008844187,0.009673806,0.97574687,0.00009520219,0.0024693045,0.0000012727913,0.0012176593,0.001001731,0.00010586445,0.000009966661,0.0007084664,0.00012565461],"about_ca_topic_score_codex":0.0023876198,"about_ca_topic_score_gemma":0.014397234,"teacher_disagreement_score":0.012009614,"about_ca_system_score_codex":0.00015155645,"about_ca_system_score_gemma":0.00033590023,"threshold_uncertainty_score":0.80339944},"labels":[],"label_agreement":null},{"id":"W4387825407","doi":"10.1016/j.annonc.2023.09.2438","title":"1406P Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Osimertinib; Pneumonitis; Internal medicine; Toxicity; Discontinuation; Lung cancer; Rash; Population; Oncology; Cancer; Erlotinib; Surgery; Lung; Epidermal growth factor receptor","score_opus":0.09334028529714586,"score_gpt":0.45506616304249475,"score_spread":0.3617258777453489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197954,0.00034033402,0.000083445004,0.00544669,0.0000947849,0.0005565423,0.00029136086,0.000022092256,0.0011852399],"genre_scores_gemma":[0.99838966,0.0003793559,0.00045269,0.00018198774,0.000013511521,0.00011406312,0.00010807095,0.00001633619,0.00034434602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989882,0.000027857039,0.0004653016,0.00015352594,0.0001900227,0.00017507319],"domain_scores_gemma":[0.99865526,0.00019493698,0.00037403128,0.00023542144,0.00047369418,0.000066663095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011205115,0.00010417796,0.00050969847,0.0001787143,0.00003973737,0.0000013366638,0.00006831469,0.000040893192,0.00010262595],"category_scores_gemma":[0.00011063061,0.000072917996,0.0000846189,0.00038268778,0.00012352367,0.000056721372,0.000026378377,0.000055924724,0.000003276208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000849112,0.002998502,0.95319206,0.00081063964,0.0036813212,0.000025200308,0.004148008,0.00269561,0.0012751727,0.0006130637,0.0026485415,0.027062766],"study_design_scores_gemma":[0.006227428,0.0028015613,0.97673595,0.0002609463,0.001426148,0.0000015533467,0.00035626048,0.0008594794,0.006921612,0.00011729951,0.004171067,0.000120689125],"about_ca_topic_score_codex":0.00041803808,"about_ca_topic_score_gemma":0.00019350457,"teacher_disagreement_score":0.026942076,"about_ca_system_score_codex":0.000050321793,"about_ca_system_score_gemma":0.00027574287,"threshold_uncertainty_score":0.29735094},"labels":[],"label_agreement":null},{"id":"W4387825459","doi":"10.1016/j.annonc.2023.09.2414","title":"1381P TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Sanofi; AstraZeneca; Chugai Pharmaceutical; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Medicine; Internal medicine; Lung cancer; Oncology","score_opus":0.07791304895278989,"score_gpt":0.46156210773371886,"score_spread":0.383649058780929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387825459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918964,0.0013379317,0.000057132394,0.0020374504,0.000073192714,0.00043289867,0.00051317003,0.000029367153,0.0036224418],"genre_scores_gemma":[0.9959858,0.0007954329,0.0017162515,0.00025355423,0.000028527467,0.000017363396,0.0009892584,0.000019549288,0.0001942753],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988778,0.00007836202,0.0004776929,0.0002149335,0.00018184517,0.00016931456],"domain_scores_gemma":[0.99880475,0.00024112535,0.00040803532,0.00030932116,0.00017205064,0.00006474402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019567338,0.00012770631,0.00073012855,0.00019536994,0.00003346085,0.0000027471485,0.00006752475,0.00008425966,0.00010944342],"category_scores_gemma":[0.00003566092,0.00009527229,0.000058663038,0.00031117402,0.00015155767,0.00005784295,0.000038976446,0.00008859108,0.0000034305324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007819113,0.0028091837,0.14008884,0.00046100028,0.005642196,0.00010018672,0.010875492,0.0002230267,0.19248566,0.00041099574,0.0446718,0.5944125],"study_design_scores_gemma":[0.016134981,0.014099975,0.78255093,0.0010996745,0.0013728882,0.000014346879,0.003360124,0.0008962899,0.12504134,0.0003183741,0.054810986,0.0003000658],"about_ca_topic_score_codex":0.0038318897,"about_ca_topic_score_gemma":0.0011365447,"teacher_disagreement_score":0.64246213,"about_ca_system_score_codex":0.000039918123,"about_ca_system_score_gemma":0.00022750197,"threshold_uncertainty_score":0.57926965},"labels":[],"label_agreement":null},{"id":"W4387833512","doi":"10.1016/b978-0-12-822824-1.00023-7","title":"Molecular testing in lung cancer","year":2023,"lang":"en","type":"book-chapter","venue":"Diagnostic Molecular Pathology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; Royal Columbian Hospital","funders":"","keywords":"ROS1; Anaplastic lymphoma kinase; KRAS; Lung cancer; Cancer research; Tyrosine kinase; Receptor tyrosine kinase; Epidermal growth factor receptor; Medicine; Crizotinib; Cancer; Receptor Protein-Tyrosine Kinases; Personalized medicine; Bioinformatics; Biology; Oncology; Internal medicine; Colorectal cancer; Receptor; Adenocarcinoma","score_opus":0.019297764993146314,"score_gpt":0.3261873878034753,"score_spread":0.30688962281032894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387833512","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05414093,0.031938404,0.0018130558,0.0036638826,0.001967563,0.004781868,0.0005420725,0.00060533476,0.9005469],"genre_scores_gemma":[0.5009657,0.0080853915,0.006967839,0.014425577,0.0010903822,0.0054841787,0.003928699,0.0020990262,0.45695323],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99816054,0.000035387984,0.00042844593,0.000677805,0.0002693714,0.00042842035],"domain_scores_gemma":[0.99848115,0.000562895,0.00016314432,0.0004892817,0.00015174125,0.00015178122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010257541,0.0004098736,0.0006722404,0.00039615933,0.000041218835,0.0000133049725,0.00011199918,0.00044568485,0.00019323362],"category_scores_gemma":[0.0010745211,0.00041089772,0.00017479512,0.00014018815,0.00010475955,0.000019038176,0.00009621269,0.00048983225,0.00016183955],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106888976,0.00051877834,0.053244967,0.002159059,0.002797728,0.6577631,0.0010685592,0.0034387254,0.010741093,0.1925468,0.005237875,0.07037638],"study_design_scores_gemma":[0.06999207,0.009540868,0.32832828,0.07868741,0.06955182,0.015157364,0.00039894457,0.0077768457,0.014414022,0.2346992,0.15258288,0.018870303],"about_ca_topic_score_codex":0.0001395642,"about_ca_topic_score_gemma":0.00006720474,"teacher_disagreement_score":0.6426058,"about_ca_system_score_codex":0.0003149849,"about_ca_system_score_gemma":0.0004571648,"threshold_uncertainty_score":0.9998343},"labels":[],"label_agreement":null},{"id":"W4387882142","doi":"10.1016/j.annonc.2023.10.117","title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; American College of Radiology Imaging Network; Society for Immunotherapy of Cancer; Pfizer Japan; Genentech; Mirati Therapeutics; Jounce Therapeutics; Chugai Pharmaceutical; MSD K.K.; Jazz Pharmaceuticals; Eli Lilly Japan; ECOG-ACRIN Cancer Research Group; Janssen Biotech; Helsinn; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Janssen Research and Development; EMD Serono; International Association for the Study of Lung Cancer; Sanofi; Amgen; Pfizer","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Pemetrexed; Oncology; Chemotherapy regimen; Lung cancer; Hazard ratio; Osimertinib; Regimen; Progression-free survival; Phases of clinical research; Cancer; Cisplatin; Erlotinib; Epidermal growth factor receptor; Confidence interval","score_opus":0.036754216118626865,"score_gpt":0.4300967680827514,"score_spread":0.3933425519641245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387882142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98130935,0.00046890165,0.0000027363874,0.015169809,0.00006185504,0.0018540553,0.00014016399,0.000048158072,0.00094498665],"genre_scores_gemma":[0.99537,0.00038570308,0.0001225526,0.0032899,0.000059546663,0.00035194104,0.00017304177,0.00002744081,0.00021991775],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986279,0.000109951536,0.0003811656,0.00038809102,0.00024238865,0.00025048832],"domain_scores_gemma":[0.99899465,0.00022335503,0.00019249332,0.00035014426,0.00008245584,0.00015689459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023083981,0.00017829935,0.0004392857,0.00009283267,0.000061734885,0.000008793139,0.00007516012,0.000057764984,0.00002090695],"category_scores_gemma":[0.00008521603,0.00009916975,0.000041456125,0.00025764533,0.00011525795,0.00006507428,0.00004142772,0.00014816503,0.000005389209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27442074,0.007906552,0.14777093,0.000053321935,0.0007548148,0.001069532,0.015301056,0.000046078003,0.0017084065,0.000012205145,0.0014746821,0.5494817],"study_design_scores_gemma":[0.09542955,0.014806293,0.8767246,0.0005896676,0.00032657423,0.0000064463075,0.0016607655,0.0001631833,0.00092340587,0.00007549482,0.009115864,0.00017814373],"about_ca_topic_score_codex":0.00014791824,"about_ca_topic_score_gemma":0.0001470017,"teacher_disagreement_score":0.72895366,"about_ca_system_score_codex":0.00007736996,"about_ca_system_score_gemma":0.00045444033,"threshold_uncertainty_score":0.40440252},"labels":[],"label_agreement":null},{"id":"W4388045689","doi":"10.1016/j.jtho.2023.09.139","title":"MA04.06 Epigenomic Drug Effect on Osimertinib-Induced Drug Tolerant Persister in a Lung Cancer Patient-Derived Xenograft Model","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Medicine; Drug; Lung cancer; Epigenomics; Pharmacology; Cancer research; Oncology; Cancer; Internal medicine; Erlotinib; Genetics; Gene; Biology","score_opus":0.022681278175334493,"score_gpt":0.4259955665913915,"score_spread":0.403314288416057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915267,0.00075158174,0.000016053718,0.007862997,0.0007218806,0.0006019171,0.000019527013,0.000028369286,0.0008450246],"genre_scores_gemma":[0.99735945,0.00013533526,0.0002945564,0.00103995,0.00020161195,0.000079129015,0.000015465685,0.000038437764,0.0008360345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99822396,0.00023570651,0.0006343873,0.00023429227,0.00028674843,0.0003849307],"domain_scores_gemma":[0.9988346,0.00021151554,0.00042591468,0.00019155856,0.00013485622,0.00020155025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046046916,0.00021580195,0.00070982677,0.00051688997,0.00009025291,0.000015910287,0.00011910421,0.00011254342,0.00007497517],"category_scores_gemma":[0.000052999047,0.00015636218,0.00027037974,0.00033150142,0.000038184102,0.00010734828,0.000039594175,0.00046493163,0.000036178208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01854788,0.0031992237,0.058087375,0.0010625058,0.0037165065,0.0058087087,0.08299598,0.04462433,0.21626918,0.0000209799,0.042367518,0.5232998],"study_design_scores_gemma":[0.076485746,0.04648913,0.27732038,0.012280998,0.022348909,0.002627963,0.02266416,0.25626016,0.22753893,0.0007954843,0.05133664,0.0038514964],"about_ca_topic_score_codex":0.00012767663,"about_ca_topic_score_gemma":0.00012738418,"teacher_disagreement_score":0.51944834,"about_ca_system_score_codex":0.0013417779,"about_ca_system_score_gemma":0.0007758339,"threshold_uncertainty_score":0.63762647},"labels":[],"label_agreement":null},{"id":"W4388045801","doi":"10.1016/j.jtho.2023.09.463","title":"P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Oncology; Internal medicine; Lung cancer; Epidermal growth factor receptor; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Cancer research; Cancer; Gefitinib; Erlotinib","score_opus":0.0543660129831342,"score_gpt":0.48905417034100224,"score_spread":0.43468815735786803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447674,0.00031087047,0.000029543406,0.0022643565,0.00049623573,0.00083894166,0.00006526672,0.000038430964,0.0014795954],"genre_scores_gemma":[0.99704915,0.00006137915,0.00087591994,0.00014579177,0.00015947885,0.000026697535,0.000046729838,0.00003460684,0.001600251],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974065,0.0003393045,0.0011788335,0.00023515927,0.00046687239,0.0003733536],"domain_scores_gemma":[0.998033,0.00021112764,0.00083362067,0.00026280593,0.00044376546,0.00021570062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082981406,0.00019851685,0.0010178335,0.0008224398,0.00015279141,0.000007971474,0.00018529994,0.00013706574,0.00042598112],"category_scores_gemma":[0.0003008602,0.00015256264,0.0001524126,0.0011131691,0.00008854243,0.00012604914,0.00011540401,0.0005119654,0.000018823222],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074810885,0.103462085,0.07058539,0.0007958299,0.008608474,0.03193931,0.124270886,0.0026519909,0.17875132,0.0001636932,0.036178965,0.36778116],"study_design_scores_gemma":[0.14319105,0.3312059,0.32096985,0.0016430123,0.0051540285,0.0012484638,0.07216822,0.0032338935,0.012454872,0.0005781669,0.10719118,0.00096135575],"about_ca_topic_score_codex":0.00018244475,"about_ca_topic_score_gemma":0.00019189357,"teacher_disagreement_score":0.3668198,"about_ca_system_score_codex":0.0005044302,"about_ca_system_score_gemma":0.00088414544,"threshold_uncertainty_score":0.62213236},"labels":[],"label_agreement":null},{"id":"W4388074293","doi":"10.1016/j.jtho.2023.09.904","title":"EP06.03-12 Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Medicine; Exon; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.03609877914508521,"score_gpt":0.4449655504943838,"score_spread":0.4088667713492986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388074293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901326,0.00018923482,0.000013410549,0.0078492975,0.00031414366,0.00024340808,0.000055628214,0.00001211685,0.0011902137],"genre_scores_gemma":[0.9943837,0.0025009136,0.00039226923,0.0002022444,0.000116768286,0.00001679327,0.000026813474,0.000016237791,0.0023442819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888635,0.000087615765,0.0005737428,0.00013765391,0.00013346376,0.00018115132],"domain_scores_gemma":[0.9990678,0.00020136968,0.0003743597,0.000114835144,0.00009482124,0.0001468539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021523992,0.00013823435,0.00068541727,0.0004346964,0.00004509734,0.000009998355,0.000039472416,0.00008308768,0.000049396633],"category_scores_gemma":[0.000053720258,0.000097219134,0.00008292082,0.00018106875,0.00006835504,0.000090314505,0.000028300583,0.00014607534,0.0000049487608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004520851,0.0005757681,0.87058735,0.00008158533,0.000366531,0.00053789176,0.00153771,0.0000024544954,0.00041354317,0.000029084062,0.00026984402,0.12514614],"study_design_scores_gemma":[0.00204779,0.0019210189,0.9887124,0.00019047935,0.00057857414,0.00017886923,0.00066501996,0.000034325894,0.00019661392,0.00010817291,0.005295751,0.000071022725],"about_ca_topic_score_codex":0.000648778,"about_ca_topic_score_gemma":0.0031707543,"teacher_disagreement_score":0.12507512,"about_ca_system_score_codex":0.00043674058,"about_ca_system_score_gemma":0.00027323316,"threshold_uncertainty_score":0.39644814},"labels":[],"label_agreement":null},{"id":"W4388075765","doi":"10.1016/j.jtho.2023.09.1306","title":"EP12.03-01 Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Immunotherapy; Oncology; Lung cancer; Internal medicine; Targeted therapy; Tyrosine kinase; Cancer; Receptor","score_opus":0.010908201547530218,"score_gpt":0.3845963050386493,"score_spread":0.3736881034911191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388075765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723965,0.0003299187,0.000072470815,0.0012379437,0.00042656664,0.00046222255,0.000008517782,0.000016997283,0.00020573245],"genre_scores_gemma":[0.9970705,0.00021404772,0.001872642,0.00038158623,0.00004605727,0.00001559767,0.000030698848,0.000026960295,0.00034189125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987746,0.00014487037,0.00042365398,0.00015548343,0.0002830601,0.00021833443],"domain_scores_gemma":[0.99906677,0.00020500265,0.00036322387,0.000104434526,0.00016395333,0.00009658867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003117812,0.00015337457,0.00050295517,0.00037960266,0.00008705597,0.000006091699,0.00006444158,0.00009424392,0.000047161328],"category_scores_gemma":[0.000057329446,0.000103772356,0.0001404921,0.00035732845,0.000035514946,0.00023293006,0.000014978734,0.00022236984,0.000009648603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002499292,0.00054984755,0.8915658,0.00000940665,0.0013000531,0.00047517678,0.003805845,0.00006613626,0.0004618702,0.000002116827,0.00007105358,0.09919338],"study_design_scores_gemma":[0.009335152,0.0027482677,0.98589486,0.00018812272,0.00025167636,0.000047165573,0.00078075595,0.000025275613,0.00020758546,0.00008754694,0.00033174298,0.00010184576],"about_ca_topic_score_codex":0.000036625603,"about_ca_topic_score_gemma":0.000031006897,"teacher_disagreement_score":0.09909153,"about_ca_system_score_codex":0.00049041066,"about_ca_system_score_gemma":0.00035187425,"threshold_uncertainty_score":0.4231714},"labels":[],"label_agreement":null},{"id":"W4388080001","doi":"10.36401/jipo-23-22","title":"Treatment for Advanced Non–Small Lung Cancer (NSCLC) with Mutated <i>EGFR</i> in Low- and Middle-Income Countries (LMICs)","year":2023,"lang":"en","type":"article","venue":"Journal of Immunotherapy and Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Afatinib; Epidermal growth factor receptor; KRAS; Population; Oncology; Adenocarcinoma; Medicine; Cancer; Internal medicine; STK11; Erlotinib; Cancer research; Environmental health","score_opus":0.016584071986160815,"score_gpt":0.36556846930611114,"score_spread":0.34898439731995035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388080001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837215,0.012083493,0.0003807946,0.0025847394,0.00024476848,0.00082547584,0.000027896991,0.000011355722,0.00012000982],"genre_scores_gemma":[0.91478676,0.07892996,0.0039005796,0.0006955208,0.00013552424,0.00023260101,0.00001676812,0.000043863907,0.0012584517],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99910617,0.000040013696,0.00040347653,0.00015272341,0.00010447667,0.00019314805],"domain_scores_gemma":[0.99896085,0.00042625473,0.00026043432,0.00009309085,0.000179475,0.00007990776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021185547,0.00015082788,0.0004970128,0.00023408102,0.000088713015,0.000019298968,0.000042912478,0.00009424922,0.000024766145],"category_scores_gemma":[0.000016192107,0.000092742834,0.0000606173,0.00018194909,0.00006461893,0.00010363599,0.000008805069,0.00010415235,6.581007e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081172295,0.001141741,0.108844176,0.000746886,0.0033532,0.0010283715,0.024038225,0.0013655168,0.01137389,0.00009837488,0.00030082275,0.7665365],"study_design_scores_gemma":[0.32059342,0.08317115,0.3700377,0.019789038,0.002484166,0.0036222595,0.005175637,0.006342492,0.016403975,0.0009668581,0.17025885,0.001154449],"about_ca_topic_score_codex":0.00006203722,"about_ca_topic_score_gemma":0.00015425688,"teacher_disagreement_score":0.76538205,"about_ca_system_score_codex":0.0003890704,"about_ca_system_score_gemma":0.0005323411,"threshold_uncertainty_score":0.3781943},"labels":[],"label_agreement":null},{"id":"W4388084017","doi":"10.1016/j.jtho.2023.09.057","title":"OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Defence Medical Centre","funders":"","keywords":"Durvalumab; Medicine; Pemetrexed; Tremelimumab; Lung cancer; Epidermal growth factor receptor; Chemotherapy; Oncology; Tolerability; Internal medicine; Cisplatin; Pembrolizumab; Cancer; Immunotherapy; Adverse effect","score_opus":0.01720813783629397,"score_gpt":0.43329567382724554,"score_spread":0.41608753599095155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388084017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99115133,0.00081410474,0.000008535153,0.006537357,0.0004103677,0.00039008685,0.000003561571,0.000014658845,0.00066998054],"genre_scores_gemma":[0.9979206,0.00090055435,0.00069312577,0.00019434556,0.00013384793,0.0000065986374,0.000004931933,0.000021303405,0.00012473957],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99867815,0.00011333861,0.00057228503,0.00016998094,0.0002631891,0.00020304682],"domain_scores_gemma":[0.99905956,0.00023406102,0.0003760464,0.00011172846,0.000088560926,0.00013002005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006577648,0.00014017173,0.0005662134,0.00038414242,0.000064498294,0.000008450867,0.00005201525,0.00014036767,0.000017589196],"category_scores_gemma":[0.00014437866,0.00009905334,0.00009753616,0.0003419534,0.00009820825,0.00008933453,0.00003045427,0.00025915002,0.0000023458801],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070310505,0.00097274076,0.0277728,0.00017675046,0.000394335,0.0013169076,0.0059587,0.000029786599,0.013430433,0.000032720258,0.00030624907,0.94257754],"study_design_scores_gemma":[0.033025958,0.017934179,0.8912944,0.005443463,0.0012851058,0.0012830124,0.0056879446,0.00031444916,0.01697358,0.00042215656,0.02595336,0.00038235646],"about_ca_topic_score_codex":0.000015178902,"about_ca_topic_score_gemma":0.0000146774755,"teacher_disagreement_score":0.9421952,"about_ca_system_score_codex":0.00035973088,"about_ca_system_score_gemma":0.00030655568,"threshold_uncertainty_score":0.4039278},"labels":[],"label_agreement":null},{"id":"W4388084924","doi":"10.1016/j.jtho.2023.09.184","title":"MA10.06 CARMA-BROS: CAncers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Sunnybrook Health Science Centre","funders":"","keywords":"Observational study; Medicine; Real world data; Randomized controlled trial; Key (lock); Lung cancer; Intensive care medicine; Real world evidence; Data science; Oncology; Internal medicine; Computer science","score_opus":0.07094954310253289,"score_gpt":0.48963835149952933,"score_spread":0.41868880839699646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388084924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799213,0.00020762654,0.00018292373,0.01052315,0.0005138698,0.00062622386,0.00003594983,0.00004453026,0.00794445],"genre_scores_gemma":[0.9884008,0.000114293434,0.0028960195,0.0010053412,0.00039512102,0.00006645982,0.000084603766,0.00003269249,0.007004669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984741,0.0001485602,0.0005093146,0.00018803164,0.00043905553,0.00024091794],"domain_scores_gemma":[0.99850106,0.000140338,0.00038334407,0.00020350894,0.00053259725,0.00023917377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034255028,0.00015606536,0.00045495346,0.00038665262,0.0001503207,0.000024575445,0.00010989591,0.00006100247,0.00020347927],"category_scores_gemma":[0.00006439126,0.00011353678,0.00011358835,0.00077773863,0.00006092565,0.00014898238,0.000027489627,0.00029117338,0.000029156758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058217878,0.004377855,0.7011578,0.00041556184,0.008688606,0.023560937,0.013741901,0.030829139,0.008962777,0.0013832169,0.1457422,0.05531821],"study_design_scores_gemma":[0.00980791,0.013740484,0.7957339,0.0006004348,0.0060535264,0.0016980008,0.011426028,0.00090810034,0.0014214391,0.0005399953,0.15754138,0.0005287716],"about_ca_topic_score_codex":0.00028263207,"about_ca_topic_score_gemma":0.0008338927,"teacher_disagreement_score":0.09457612,"about_ca_system_score_codex":0.0011389853,"about_ca_system_score_gemma":0.002950382,"threshold_uncertainty_score":0.5233851},"labels":[],"label_agreement":null},{"id":"W4388085326","doi":"10.1016/j.jtho.2023.09.1414","title":"EP16.01-02 A Brief History of Lung Cancer in Canada: Care, Contributions and Challenges","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Family medicine; Intensive care medicine; Oncology","score_opus":0.02771504861242737,"score_gpt":0.42068840654527523,"score_spread":0.3929733579328479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388085326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77247494,0.19544475,0.00000917379,0.025125913,0.0015382401,0.00028388432,0.00010310874,0.000008976619,0.0050110295],"genre_scores_gemma":[0.9853679,0.01365642,0.00007196596,0.00019301978,0.00012072394,0.000014685012,0.000005030643,0.000008091328,0.00056216767],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99923575,0.000063809195,0.00032720508,0.00008230482,0.00014299803,0.00014794347],"domain_scores_gemma":[0.9991944,0.00012032907,0.0002561475,0.00007335982,0.00024445428,0.00011132027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017121683,0.00006832183,0.0003962547,0.00018593676,0.000018444118,0.0000010347451,0.000041155192,0.00006307836,0.000065098524],"category_scores_gemma":[0.00007269063,0.000055551543,0.000044589648,0.000109677705,0.000049886643,0.000044411616,0.000016956601,0.0001733132,3.8466123e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019237675,0.00054550165,0.11644778,0.0018802356,0.001936617,0.0043406473,0.02391595,0.00043670528,0.0016267872,0.00079053047,0.082795076,0.7633604],"study_design_scores_gemma":[0.0034127792,0.0009954105,0.52216184,0.0005872441,0.001310475,0.00044392742,0.00644839,0.0002155769,0.00022537363,0.000077328674,0.463994,0.00012765215],"about_ca_topic_score_codex":0.16518226,"about_ca_topic_score_gemma":0.57928514,"teacher_disagreement_score":0.76323277,"about_ca_system_score_codex":0.0069815773,"about_ca_system_score_gemma":0.0097889,"threshold_uncertainty_score":0.99683046},"labels":[],"label_agreement":null},{"id":"W4388087864","doi":"10.1016/j.jtho.2023.09.1258","title":"EP12.01-42 Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Tyrosine kinase; Cohort; Oncology; Lung cancer; Internal medicine; Term (time); Cohort study; Receptor","score_opus":0.010391728192855738,"score_gpt":0.3569277036322689,"score_spread":0.34653597543941317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388087864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942226,0.0005074694,0.000070736394,0.0047244984,0.00039467303,0.0009223438,0.00008382069,0.000034950113,0.0038392625],"genre_scores_gemma":[0.9948808,0.00021733828,0.00047201273,0.00050898985,0.00033242686,0.00007491953,0.00013609027,0.00006269426,0.00331471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834794,0.00011083425,0.00046101087,0.00027088093,0.00030162052,0.0005076987],"domain_scores_gemma":[0.99792445,0.0001087912,0.00047476793,0.00021181825,0.00062089745,0.0006592692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027410054,0.00028375583,0.0007404887,0.0005859379,0.00016537443,0.00003232219,0.000119360855,0.00017459532,0.000117688054],"category_scores_gemma":[0.000016327804,0.00018617707,0.000112182715,0.00079532544,0.00012325989,0.00013570872,0.000020223746,0.0004041482,0.000013775685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032447532,0.00049144117,0.9725373,0.00015574155,0.0013938725,0.011151754,0.0011182248,0.00018635236,0.0007712269,0.000003928638,0.0029357548,0.0060096825],"study_design_scores_gemma":[0.0060050273,0.008105918,0.971811,0.0012389893,0.004669427,0.001066324,0.0006456091,0.00016483424,0.0050545386,0.0000029586224,0.0009357487,0.00029965307],"about_ca_topic_score_codex":0.036829907,"about_ca_topic_score_gemma":0.16351907,"teacher_disagreement_score":0.12668917,"about_ca_system_score_codex":0.002178017,"about_ca_system_score_gemma":0.0035578911,"threshold_uncertainty_score":0.9695839},"labels":[],"label_agreement":null},{"id":"W4388092012","doi":"10.1016/j.jtho.2023.09.232","title":"MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Stage (stratigraphy); Internal medicine; Retrospective cohort study; Observational study; Overall survival; Population; Oncology; Cancer; Nivolumab","score_opus":0.03726675609655791,"score_gpt":0.4474466065650997,"score_spread":0.4101798504685418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388092012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464304,0.00019047176,0.00008484003,0.008196409,0.0007066072,0.001131621,0.000032928237,0.000014002863,0.005000053],"genre_scores_gemma":[0.98597205,0.00013616709,0.00045911002,0.0002574756,0.00026047134,0.000080323516,0.000010846015,0.0000272523,0.012796324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983551,0.00020348874,0.0005270313,0.00017091578,0.00040680828,0.00033664762],"domain_scores_gemma":[0.9981282,0.0008102238,0.00040935085,0.00023234809,0.0002988659,0.00012106194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010365006,0.00013919835,0.00056627794,0.00023032055,0.0001239207,0.000012892211,0.00016484108,0.000040401726,0.0000465748],"category_scores_gemma":[0.0001529945,0.00007930461,0.00006465107,0.00071632315,0.000046601188,0.00008670716,0.000031772794,0.0003463226,0.000003131794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023812354,0.0027565754,0.7831953,0.00035422677,0.0031390183,0.009891934,0.008266113,0.0059452197,0.00030484097,0.0005238518,0.055455077,0.10635546],"study_design_scores_gemma":[0.011357064,0.0068610576,0.8665654,0.0002719486,0.0012468911,0.00021213976,0.026385173,0.00038644086,0.00010255885,0.000159379,0.08624431,0.00020763482],"about_ca_topic_score_codex":0.25950354,"about_ca_topic_score_gemma":0.9455598,"teacher_disagreement_score":0.68605626,"about_ca_system_score_codex":0.0023515671,"about_ca_system_score_gemma":0.006887269,"threshold_uncertainty_score":0.99874276},"labels":[],"label_agreement":null},{"id":"W4388194702","doi":"10.1055/s-0041-1723302","title":"Patientenberichte aus ADAURA: HRQol Daten zu Osimertinib als adjuvante Therapie bei Patienten mit reseziertem EGFR-mutiertem (EGFRm) NSCLC","year":2021,"lang":"de","type":"article","venue":"Pneumologie","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.03802648954359052,"score_gpt":0.33190570222446714,"score_spread":0.29387921268087663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388194702","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3403651,0.5841696,0.000585946,0.031274594,0.017064692,0.0052826633,0.003093413,0.0009976972,0.017166251],"genre_scores_gemma":[0.96074754,0.014761942,0.00086286425,0.005689668,0.001230505,0.00060942094,0.0031624928,0.00027462534,0.012660942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928263,0.0005345593,0.0016810222,0.0018833475,0.0011632344,0.0019115671],"domain_scores_gemma":[0.9944858,0.0007248087,0.0007674886,0.002076571,0.0011561717,0.0007891561],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004124524,0.0011230994,0.0016486412,0.00030044332,0.000648365,0.00020047495,0.00067759206,0.0005864473,0.0012880664],"category_scores_gemma":[0.0010390055,0.00092733366,0.0006739101,0.001101717,0.00041386977,0.0004155153,0.0005430762,0.0009059087,0.0020109152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003753327,0.010711981,0.22544467,0.0013076499,0.044395484,0.018627679,0.012613292,0.00016497953,0.023850184,0.00092925876,0.11600249,0.542199],"study_design_scores_gemma":[0.030452708,0.00985705,0.12309464,0.0044283685,0.03202974,0.00030962162,0.006929394,0.0018958455,0.038045585,0.0017153941,0.746913,0.0043286183],"about_ca_topic_score_codex":0.00074342015,"about_ca_topic_score_gemma":0.0001043731,"teacher_disagreement_score":0.6309105,"about_ca_system_score_codex":0.0009832701,"about_ca_system_score_gemma":0.0015694825,"threshold_uncertainty_score":0.9996249},"labels":[],"label_agreement":null},{"id":"W4388195865","doi":"10.1055/s-0041-1723297","title":"Postoperativer Chemotherapie-Einsatz und Ergebnisse der ADAURA-Studie: Osimertinib als adjuvante Therapie beim resezierten EGFR-mutierten NSCLC","year":2021,"lang":"de","type":"article","venue":"Pneumologie","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Osimertinib; Gynecology; Internal medicine; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.03632839633121832,"score_gpt":0.365076771657707,"score_spread":0.3287483753264887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388195865","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16257489,0.7369473,0.00019478716,0.07782042,0.005144151,0.0026293956,0.0005697801,0.0004429049,0.013676385],"genre_scores_gemma":[0.918827,0.034011114,0.0011990367,0.014639979,0.0015503317,0.00042708975,0.0007418578,0.00027874668,0.028324828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947096,0.0005076016,0.0010249361,0.0015393487,0.0007743989,0.0014440892],"domain_scores_gemma":[0.9962044,0.00057699456,0.00035165614,0.001448188,0.00088677043,0.0005320038],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00039531954,0.0009784623,0.001446513,0.00020668322,0.0007200916,0.00017928374,0.00047544448,0.00052824436,0.0029578207],"category_scores_gemma":[0.00057196344,0.00077920535,0.0005289554,0.00082579197,0.00047374767,0.00030524877,0.00029288724,0.0007896966,0.001519407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044342843,0.013532145,0.11183349,0.0010643649,0.13395402,0.024478186,0.043940015,0.00021233219,0.12142157,0.0025833724,0.16451892,0.3780273],"study_design_scores_gemma":[0.027133219,0.00431344,0.096076615,0.0020829078,0.02530893,0.00032425195,0.008002148,0.00043582646,0.075109996,0.0020196033,0.75576615,0.0034268843],"about_ca_topic_score_codex":0.00042727473,"about_ca_topic_score_gemma":0.00020701767,"teacher_disagreement_score":0.7562521,"about_ca_system_score_codex":0.0007522322,"about_ca_system_score_gemma":0.0017509391,"threshold_uncertainty_score":0.9994659},"labels":[],"label_agreement":null},{"id":"W4388343130","doi":"10.1016/j.ctarc.2023.100774","title":"Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence","year":2023,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; Dalhousie University; University of Toronto; University Health Network","funders":"Amgen Canada","keywords":"Medicine; Hazard ratio; Internal medicine; Stage (stratigraphy); Oncology; Targeted therapy; Progressive disease; Lung cancer; Cancer; Disease; Gastroenterology; Confidence interval","score_opus":0.0782646992820013,"score_gpt":0.4428730312875759,"score_spread":0.3646083320055746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388343130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98576266,0.007239641,0.000001890853,0.003725465,0.000054952103,0.0016196702,0.0009819259,0.000030556002,0.00058325456],"genre_scores_gemma":[0.9256586,0.066423416,0.00014505537,0.000018746172,0.000016357324,0.0034214759,0.000540631,0.000024381492,0.0037513566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987766,0.000109707646,0.00019201996,0.00029555702,0.00029752147,0.00032858664],"domain_scores_gemma":[0.99800915,0.0006053781,0.00008893892,0.00068412453,0.00030548766,0.0003069132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001101761,0.00016741124,0.00024242571,0.00019336461,0.000605338,0.000026608774,0.00014326916,0.00004320259,0.00008021301],"category_scores_gemma":[0.000042157943,0.000115677976,0.000048481732,0.00044311746,0.00035071367,0.00010449039,0.00027976127,0.00011135041,0.000005311264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059487246,0.00062226347,0.99142045,0.00019363465,0.00044531422,0.000007425147,0.002825334,0.00003060269,0.00011840231,0.000041372637,0.00034423076,0.0033561077],"study_design_scores_gemma":[0.00778177,0.00052799797,0.9849575,0.00024405796,0.0006780381,2.9667186e-7,0.0003828248,0.0005852066,0.00081872486,0.0000082696815,0.0038927905,0.00012252395],"about_ca_topic_score_codex":0.0029891813,"about_ca_topic_score_gemma":0.0037870833,"teacher_disagreement_score":0.06010406,"about_ca_system_score_codex":0.0011973118,"about_ca_system_score_gemma":0.0004842426,"threshold_uncertainty_score":0.4717211},"labels":[],"label_agreement":null},{"id":"W4388452220","doi":"10.1021/acs.jmedchem.3c01669","title":"Discovery of a Hydroxylamine-Based Brain-Penetrant EGFR Inhibitor for Metastatic Non-Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Georgia Research Alliance; National Institute of General Medical Sciences; Natural Sciences and Engineering Research Council of Canada; University of Georgia","keywords":"Chemistry; Epidermal growth factor receptor; Pharmacology; Blood–brain barrier; In vivo; Efflux; Lung cancer; Cancer research; Receptor; Internal medicine; Medicine; Central nervous system; Biochemistry; Biology","score_opus":0.014950037300925709,"score_gpt":0.3317345154027068,"score_spread":0.3167844781017811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388452220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901769,0.002109259,0.0019512104,0.004362712,0.00031224004,0.0003571111,0.00008119128,0.000011953405,0.0006374343],"genre_scores_gemma":[0.9942582,0.00014177761,0.0009836743,0.0003636973,0.00067698775,0.000045373028,0.00004546443,0.000031125877,0.0034536717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852234,0.000011767562,0.0006206033,0.00014963832,0.00046048194,0.00023518513],"domain_scores_gemma":[0.9985837,0.0003179963,0.0004943597,0.00015807204,0.00027622213,0.00016968367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034145772,0.0001693722,0.00052780204,0.000111962465,0.000042521042,0.000010526983,0.00011048216,0.000057209487,0.000059392645],"category_scores_gemma":[0.00016740154,0.00012011486,0.0002743521,0.00026804238,0.000067334,0.000073566625,0.000012662218,0.00020445307,8.2652224e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010922932,0.00048455753,0.005173261,0.006132584,0.0009865224,0.0004898818,0.00061902916,0.0004966351,0.9593054,0.0000032960113,0.023577368,0.0016391743],"study_design_scores_gemma":[0.018692767,0.0010198893,0.002502254,0.0032929357,0.0039190147,0.00021258453,0.0011195744,0.0033115505,0.96364063,0.000053649557,0.002028557,0.000206575],"about_ca_topic_score_codex":0.000043022912,"about_ca_topic_score_gemma":0.0000049286728,"teacher_disagreement_score":0.021548811,"about_ca_system_score_codex":0.00022804012,"about_ca_system_score_gemma":0.0012717679,"threshold_uncertainty_score":0.4898142},"labels":[],"label_agreement":null},{"id":"W4388464484","doi":"10.1002/cncr.35094","title":"Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real‐world databases","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto; Roche (Canada); University of Calgary","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Lung cancer; Cancer; Retrospective cohort study; Internal medicine; Demography; Pediatrics","score_opus":0.023207582613293344,"score_gpt":0.33111463989103457,"score_spread":0.3079070572777412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388464484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640834,0.0002796578,0.0000031039415,0.00012314256,0.000061777464,0.0016947354,0.00138818,0.0000070007904,0.000034086905],"genre_scores_gemma":[0.9979138,0.0008582956,0.00004004722,0.000072482544,0.00002201855,0.0002590605,0.00039742317,0.00001912529,0.00041777059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989245,0.000067493296,0.00024153541,0.00027199867,0.00025905497,0.00023544907],"domain_scores_gemma":[0.99935853,0.00012713327,0.00019475158,0.00015031137,0.0001157475,0.00005353225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012122254,0.00016124101,0.00032150923,0.0001749804,0.00005975376,0.000011018286,0.000035855363,0.000013904826,0.000009810987],"category_scores_gemma":[0.000008285514,0.00010924309,0.000011659426,0.00046908864,0.000020850133,0.00009085176,0.000024789086,0.0000858551,8.4487674e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012012889,0.00023499958,0.9955478,0.000086396,0.00033864076,0.000016561497,0.0024820885,0.000564735,0.000022436567,0.000001538866,0.00007538783,0.0005093069],"study_design_scores_gemma":[0.007902335,0.00031807492,0.98915654,0.00015687432,0.0007138569,5.359181e-8,0.0008550585,0.000647648,0.000039679166,0.0000038510234,0.000102731276,0.00010326668],"about_ca_topic_score_codex":0.8628481,"about_ca_topic_score_gemma":0.91501117,"teacher_disagreement_score":0.052163053,"about_ca_system_score_codex":0.0026357998,"about_ca_system_score_gemma":0.0005336817,"threshold_uncertainty_score":0.6892525},"labels":[],"label_agreement":null},{"id":"W4388655064","doi":"10.1016/j.annonc.2023.09.134","title":"O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Antibody-drug conjugate; Epidermal growth factor receptor; Cohort; Cancer research; Cancer; Antibody; Monoclonal antibody; Immunology","score_opus":0.024903447188834357,"score_gpt":0.38965297613120514,"score_spread":0.3647495289423708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388655064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859763,0.0004665773,0.00003643768,0.0014754009,0.00014117004,0.00064422115,0.000039436633,0.000033847726,0.011186614],"genre_scores_gemma":[0.99630547,0.00047709874,0.0013501854,0.0007808314,0.000049320803,0.00016704085,0.00007731647,0.000033243035,0.00075946975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989946,0.000034344113,0.0002664184,0.00025134336,0.00014149558,0.00031180875],"domain_scores_gemma":[0.9993292,0.000060165,0.0001707159,0.00019048924,0.00016445895,0.00008493868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007808758,0.00014228307,0.00037907544,0.00020775045,0.000044125052,0.000005676781,0.00007235767,0.00009498637,0.00007689774],"category_scores_gemma":[0.000015307136,0.00011202333,0.000055699784,0.00037918097,0.000047740537,0.00008273153,0.000021625765,0.00011998052,0.000008740574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014732141,0.001349095,0.7123876,0.0002413707,0.00030648598,0.00011443971,0.0055836043,0.0015684662,0.0029007776,0.000025117253,0.004144706,0.26990512],"study_design_scores_gemma":[0.01954624,0.0046603032,0.9408583,0.00061985885,0.00017366509,0.000002124728,0.0009779999,0.00040736355,0.009127642,0.00006935099,0.023300128,0.00025703647],"about_ca_topic_score_codex":0.0004011551,"about_ca_topic_score_gemma":0.00026027075,"teacher_disagreement_score":0.26964808,"about_ca_system_score_codex":0.00015240666,"about_ca_system_score_gemma":0.000529317,"threshold_uncertainty_score":0.4568179},"labels":[],"label_agreement":null},{"id":"W4388688093","doi":"10.1056/nejme2311295","title":"Selective RET Kinase Inhibitors and Lung Cancer","year":2023,"lang":"en","type":"editorial","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Lung cancer; Cancer research; Medicine; Kinase; Cancer; Oncology; Internal medicine; Biology; Cell biology","score_opus":0.009524380589479523,"score_gpt":0.3484310154149687,"score_spread":0.33890663482548916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388688093","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004232362,0.025207419,0.000028064704,0.009976435,0.95918965,0.0003445455,0.00007365095,0.00003407603,0.0009138137],"genre_scores_gemma":[0.005270603,0.012386604,0.000091110174,0.00013281147,0.97601444,0.000009848005,0.000107950276,0.00006963038,0.005916981],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978672,0.00006225839,0.0006159453,0.00023457824,0.00097301806,0.00024695526],"domain_scores_gemma":[0.99714947,0.0009144913,0.00057525723,0.0001474261,0.00071689615,0.0004964667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005326863,0.00028912452,0.00094260793,0.00039166227,0.00007296702,0.000014762249,0.00008043798,0.00032202533,0.00010742833],"category_scores_gemma":[0.0019082933,0.00017940238,0.000099118566,0.00030257914,0.000102092075,0.00007643824,0.00002474345,0.0011099905,0.0000021176052],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006174761,0.000032856802,0.0011035376,0.00027223598,0.0011338629,0.0006356274,0.0015731959,0.0000044696494,0.00011455632,0.0000042382794,0.9619424,0.032565597],"study_design_scores_gemma":[0.047342654,0.0018747458,0.0007256575,0.004881765,0.004119547,0.0001279047,0.00014543385,0.000010911257,0.000057539903,0.00011254027,0.9404481,0.00015322145],"about_ca_topic_score_codex":0.0012218865,"about_ca_topic_score_gemma":0.0002485133,"teacher_disagreement_score":0.04672518,"about_ca_system_score_codex":0.0004240687,"about_ca_system_score_gemma":0.0020012816,"threshold_uncertainty_score":0.7315817},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4388829995","doi":"10.3390/curroncol30110729","title":"Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alectinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Crizotinib; Front line; Oncology; Internal medicine; Family medicine; Intensive care medicine","score_opus":0.1505248352377696,"score_gpt":0.48817386120664363,"score_spread":0.33764902596887403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388829995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004721858,0.99048316,0.000016525019,0.00017000943,0.0023841537,0.0018493282,0.00011407553,0.00014045606,0.00012040003],"genre_scores_gemma":[0.0023107638,0.9918771,0.00005985238,0.00003579022,0.000712988,0.0034469878,0.0009919495,0.00012527847,0.00043933216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972789,0.00011038159,0.00073953177,0.0009890898,0.00029933229,0.0005827595],"domain_scores_gemma":[0.9985653,0.00008405411,0.0003468022,0.00053206517,0.00007828974,0.00039347692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010208194,0.0005839867,0.0016911145,0.00050307176,0.00013789606,0.000038345144,0.00023695521,0.00028609615,0.00008922158],"category_scores_gemma":[0.00006011863,0.0003329185,0.00019402603,0.00087843806,0.00015579187,0.00017850332,0.00014695087,0.00032568857,0.000023093242],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000961344,0.001015698,0.002363579,0.0072570145,0.00014163644,0.0007342237,0.0028036823,0.0000051996217,0.0000017727745,0.000025316122,0.0005826704,0.9849731],"study_design_scores_gemma":[0.0030961973,0.0010714119,0.0006395831,0.051351465,0.0015252026,0.000115561255,0.0009964219,0.00022388669,0.0000039354013,0.0000048233687,0.94042844,0.0005430737],"about_ca_topic_score_codex":0.00047463417,"about_ca_topic_score_gemma":0.0009715273,"teacher_disagreement_score":0.98443,"about_ca_system_score_codex":0.0034290988,"about_ca_system_score_gemma":0.0017742773,"threshold_uncertainty_score":0.99991226},"labels":[],"label_agreement":null},{"id":"W4388830055","doi":"10.3390/curroncol30110728","title":"Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Servier","keywords":"V600E; Medicine; Lung cancer; Mutation; Concomitant; Oncology; Lung; Carcinoma; Internal medicine; Cancer research; Targeted therapy; Cancer; Gene; Biology; Genetics","score_opus":0.06493412070572355,"score_gpt":0.43306475197200517,"score_spread":0.36813063126628165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388830055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989636,0.00085409847,0.00024792677,0.0005124135,0.0005289776,0.0005018614,0.00002020007,0.000061039114,0.007377104],"genre_scores_gemma":[0.9980738,0.000116249124,0.00067390373,0.00007190398,0.00013385859,0.00008999179,0.0002216891,0.000012608218,0.00060599466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992472,0.00004223186,0.00020344746,0.00021715894,0.00010751553,0.00018246371],"domain_scores_gemma":[0.99942297,0.00011563002,0.0001158892,0.00014860867,0.00011617073,0.00008076122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010119038,0.00010318202,0.00027970978,0.000113565744,0.000043077194,0.0000035931064,0.000050000144,0.00008866202,0.000040442766],"category_scores_gemma":[0.00003022642,0.000069818016,0.000064310465,0.00024995964,0.00007964695,0.000022692315,0.000026938455,0.00015898168,0.000035643523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004458326,0.0014107953,0.86355925,0.00052725093,0.00007072124,0.000712833,0.00334689,0.000061212704,0.0011619002,0.00018260884,0.011750422,0.116770275],"study_design_scores_gemma":[0.004199929,0.00261992,0.98405755,0.00007299611,0.0004835867,0.00010804082,0.000594382,0.0002867274,0.001009253,0.000045366865,0.006433221,0.000089013396],"about_ca_topic_score_codex":0.000014860565,"about_ca_topic_score_gemma":0.000017741058,"teacher_disagreement_score":0.12049831,"about_ca_system_score_codex":0.00011420436,"about_ca_system_score_gemma":0.00033607913,"threshold_uncertainty_score":0.2847096},"labels":[],"label_agreement":null},{"id":"W4388899227","doi":"10.1200/go.23.00344","title":"Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities","year":2023,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Refining (metallurgy); Medicine; Intensive care medicine; Materials science; Metallurgy","score_opus":0.1621540335148205,"score_gpt":0.5802390929223848,"score_spread":0.41808505940756435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388899227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5936388,0.0033045406,0.0000053719564,0.16101976,0.0021350987,0.001220105,0.0010536292,0.00032247335,0.23730028],"genre_scores_gemma":[0.9862359,0.000689994,0.00063548307,0.0030233262,0.00067902374,0.0007460534,0.00015209617,0.000023082064,0.007815054],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979699,0.00015339379,0.00026379857,0.00052658265,0.00041323484,0.0006730405],"domain_scores_gemma":[0.9984709,0.00024060892,0.00015485393,0.0003423946,0.00047662188,0.00031460356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002679032,0.00018434726,0.00037535507,0.00009869146,0.00028285847,0.00004754858,0.00016057998,0.00022650402,0.00008695152],"category_scores_gemma":[0.0006587066,0.00015214314,0.00007551427,0.00085918646,0.00012737577,0.000094731804,0.00014499348,0.00031963966,0.00028708068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00501848,0.0007657337,0.12134589,0.00040536147,0.0009843518,0.0013800974,0.0048749433,0.0002739646,0.0012878838,0.010992078,0.4353716,0.41729963],"study_design_scores_gemma":[0.0031126041,0.004290877,0.09966132,0.00030771614,0.00034217464,0.00006290889,0.014498771,0.00008905736,0.00021504246,0.00045033105,0.87674403,0.00022519064],"about_ca_topic_score_codex":0.014629252,"about_ca_topic_score_gemma":0.014925234,"teacher_disagreement_score":0.4413724,"about_ca_system_score_codex":0.0050459607,"about_ca_system_score_gemma":0.0020116607,"threshold_uncertainty_score":0.9987735},"labels":[],"label_agreement":null},{"id":"W4389227554","doi":"10.1158/1535-7163.targ-23-b154","title":"Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Tolerability; ALK inhibitor; Crizotinib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Internal medicine; Pharmacodynamics; Lung cancer; Refractory (planetary science); Pharmacokinetics; Oncology; Pharmacology; Clinical trial; Phases of clinical research","score_opus":0.008498528870247834,"score_gpt":0.28725035057182013,"score_spread":0.2787518217015723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969156,0.00032086528,0.00004796583,0.00088779145,0.000086744454,0.0009831453,0.00010943702,0.000024755287,0.00062370923],"genre_scores_gemma":[0.99916375,0.00013854867,0.000040361876,0.0004059058,0.000023298966,0.00006676995,0.00002893422,0.000034014258,0.00009843611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898887,0.000048945923,0.0001825863,0.00025276744,0.00030585652,0.00022095533],"domain_scores_gemma":[0.99940085,0.0000482578,0.00013091984,0.00021813501,0.00014654949,0.0000553005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006363438,0.00017263199,0.0002604923,0.00008465532,0.00009414466,0.000008712988,0.000060457645,0.00006737513,0.000009667243],"category_scores_gemma":[0.0000074110835,0.00011337671,0.00005939919,0.00046572243,0.00010811694,0.000057548397,0.000050268573,0.00016974464,0.0000011049938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012710176,0.002212358,0.72188014,0.0003906761,0.0031514594,0.0001821034,0.014209928,0.002404875,0.09106564,0.000107105225,0.00016297387,0.15152258],"study_design_scores_gemma":[0.0033135107,0.000644607,0.9394347,0.00034221727,0.00030992905,0.0000023159462,0.00014319921,0.00014873555,0.0553107,0.00004453898,0.00018187855,0.00012365292],"about_ca_topic_score_codex":0.00027387377,"about_ca_topic_score_gemma":0.00009555698,"teacher_disagreement_score":0.2175546,"about_ca_system_score_codex":0.000253849,"about_ca_system_score_gemma":0.00028811756,"threshold_uncertainty_score":0.4623368},"labels":[],"label_agreement":null},{"id":"W4389241939","doi":"10.1158/1535-7163.targ-23-pr003","title":"Abstract PR003: Repotrectinib in patients with <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; ROS1; Cohort; Clinical endpoint; Lung cancer; Oncology; Cancer; Clinical trial; Adenocarcinoma","score_opus":0.013758122112712929,"score_gpt":0.317288329426474,"score_spread":0.30353020731376107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98922384,0.0027670565,0.00025220902,0.001823698,0.0010055065,0.003386633,0.0009020937,0.00010477693,0.0005341709],"genre_scores_gemma":[0.9925013,0.0007997597,0.0001227994,0.004077991,0.00030270295,0.0009484241,0.00072459294,0.00012637171,0.00039603657],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99746394,0.00009192005,0.0005394435,0.00067636097,0.00063585496,0.0005924685],"domain_scores_gemma":[0.9985315,0.00013827943,0.00031355117,0.0006135317,0.0002383712,0.00016477509],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015940882,0.00044058432,0.0005010698,0.0001344138,0.00023216766,0.0000937677,0.0002274863,0.00015276035,0.00016256775],"category_scores_gemma":[0.000012028811,0.00030074417,0.0001999826,0.00084749394,0.00009422133,0.00011011794,0.00006615929,0.00045482448,0.000023204353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16196886,0.012244031,0.5341155,0.00042324368,0.010283691,0.0023713927,0.02045759,0.003695308,0.07527974,0.00004173267,0.0097366115,0.16938227],"study_design_scores_gemma":[0.4743255,0.0033238565,0.4108251,0.0019579849,0.0069398936,0.000006183991,0.000922999,0.0017621673,0.08620693,0.00008414808,0.011934431,0.0017107886],"about_ca_topic_score_codex":0.0026221373,"about_ca_topic_score_gemma":0.0008254388,"teacher_disagreement_score":0.31235665,"about_ca_system_score_codex":0.0005099667,"about_ca_system_score_gemma":0.0008502539,"threshold_uncertainty_score":0.99994445},"labels":[],"label_agreement":null},{"id":"W4389275881","doi":"10.1200/jco.23.02219","title":"CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Chugai Pharmaceutical; GlaxoSmithKline; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Chemotherapy; Lung cancer; Epidermal growth factor receptor; Hazard ratio; Brain metastasis; Cancer; Metastasis; Erlotinib; Confidence interval","score_opus":0.06908951526366378,"score_gpt":0.48588338280253934,"score_spread":0.4167938675388756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389275881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205947,0.00024228518,0.00010354127,0.0056486498,0.00059634313,0.0005913162,0.000013682201,0.000019811392,0.0007248913],"genre_scores_gemma":[0.9916492,0.0018974508,0.0036220988,0.0011625517,0.0003628439,0.000026407168,0.000009140881,0.00004016064,0.0012301401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715865,0.00017767957,0.0018531423,0.00022914367,0.00027825622,0.0003031562],"domain_scores_gemma":[0.99611026,0.0014959436,0.001503123,0.00015717467,0.0004453533,0.00028814696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006651804,0.00018300825,0.0015678158,0.0002151125,0.000030048795,0.0000046037903,0.00013580215,0.00023661717,0.00035866883],"category_scores_gemma":[0.00070244196,0.00010688785,0.00025428107,0.00053931517,0.00013688256,0.00010061702,0.00002145584,0.00060470466,0.000009162595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024546485,0.0030988115,0.884462,0.00017561634,0.0012537729,0.00050145516,0.0017474977,0.00038935483,0.0028919645,0.000004537785,0.0022136131,0.07871487],"study_design_scores_gemma":[0.06821755,0.01524081,0.9025011,0.0007235263,0.00090524013,0.00006681545,0.00047102763,0.00070618314,0.0041232486,0.000012900199,0.006831056,0.00020054632],"about_ca_topic_score_codex":0.0001205464,"about_ca_topic_score_gemma":0.00015426968,"teacher_disagreement_score":0.07851432,"about_ca_system_score_codex":0.00024552643,"about_ca_system_score_gemma":0.0033164883,"threshold_uncertainty_score":0.5883308},"labels":[],"label_agreement":null},{"id":"W4389277047","doi":"10.1016/j.ijrobp.2023.10.056","title":"Efficacy and Safety of Immune Checkpoint Inhibitors (ICI) in Resectable Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Meta-analysis; Oncology; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC)","score_opus":0.048922972070889095,"score_gpt":0.4070350295211122,"score_spread":0.3581120574502231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389277047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032317484,0.99581474,0.00023846418,0.00067598175,0.0003275401,0.002206733,0.00027266308,0.000012049429,0.00012867882],"genre_scores_gemma":[0.001748886,0.99672574,0.00034353195,0.00015773658,0.00024697976,0.00025669232,0.00020778636,0.00004635987,0.000266291],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99580723,0.00048045124,0.0028665527,0.0003526912,0.00027812252,0.00021493131],"domain_scores_gemma":[0.9940323,0.00091470254,0.0040518395,0.00025230952,0.00062546314,0.000123361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00132999,0.00039453708,0.005879739,0.0006530929,0.000046748864,0.000020933818,0.00026764136,0.00030435104,0.000053568558],"category_scores_gemma":[0.00034590613,0.0002686995,0.0014849121,0.00079692894,0.000112617716,0.00012016246,0.000102433805,0.0005655117,0.000003892083],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024960775,0.0011529984,0.002663474,0.44240645,0.51716954,0.0001540885,0.0013120159,0.0002698776,0.000033706987,0.00051303377,0.00039495737,0.033680253],"study_design_scores_gemma":[0.0048382394,0.0005229482,0.0003731714,0.049827345,0.93478966,0.0001300943,0.00006258939,0.00017659439,0.000023589242,0.000113402806,0.008791413,0.0003509714],"about_ca_topic_score_codex":0.00019910536,"about_ca_topic_score_gemma":0.000037208647,"teacher_disagreement_score":0.4176201,"about_ca_system_score_codex":0.0010122479,"about_ca_system_score_gemma":0.0012492279,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W4389280186","doi":"10.1016/j.annonc.2023.10.663","title":"585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Exon; Oncology; Mutation; Internal medicine; Cancer research; Genetics; Gene","score_opus":0.04064274358285673,"score_gpt":0.39660253448124827,"score_spread":0.3559597908983915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98451346,0.00005670309,0.000024425035,0.0055329134,0.00010246045,0.00078189303,0.00003649825,0.000048223083,0.008903418],"genre_scores_gemma":[0.9953276,0.00020569004,0.00057802367,0.00058058975,0.000028423325,0.00021330365,0.00023261398,0.000029294668,0.0028044498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989628,0.000037085632,0.00029208604,0.00024739327,0.00017533357,0.00028529717],"domain_scores_gemma":[0.9991315,0.00011352088,0.00020653979,0.00018246562,0.00027562643,0.000090332316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107378466,0.00014394095,0.00039342025,0.000296968,0.00006835111,0.000006012506,0.000057651425,0.00007061691,0.00009393344],"category_scores_gemma":[0.000020437168,0.00010512832,0.00004468466,0.0005794457,0.000058959362,0.00009682069,0.000020412019,0.00012374426,0.000014231685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004161164,0.00064867473,0.9858519,0.00009958968,0.0001950596,0.000031838117,0.002271526,0.00093281345,0.00007800691,0.000009517113,0.0018253188,0.0076396754],"study_design_scores_gemma":[0.005227968,0.0018264488,0.9900575,0.00022180352,0.00022590587,7.5167986e-7,0.00034651722,0.0002340498,0.00034031933,0.000023120425,0.0013819413,0.000113673304],"about_ca_topic_score_codex":0.0031738165,"about_ca_topic_score_gemma":0.01993431,"teacher_disagreement_score":0.016760493,"about_ca_system_score_codex":0.00017046942,"about_ca_system_score_gemma":0.00049266627,"threshold_uncertainty_score":0.99794936},"labels":[],"label_agreement":null},{"id":"W4389280307","doi":"10.1016/j.annonc.2023.10.591","title":"512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Chemotherapy; Oncology; Internal medicine; Adenocarcinoma; Cancer","score_opus":0.05022058498647386,"score_gpt":0.43413890205650324,"score_spread":0.3839183170700294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531457,0.0007496664,0.000020179723,0.037763882,0.0001393456,0.00047754106,0.00004696396,0.000034439418,0.007622288],"genre_scores_gemma":[0.99173576,0.00493653,0.00029840175,0.0014118392,0.00003063455,0.00003564811,0.000048135862,0.000018243036,0.0014847842],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99900526,0.000029523375,0.0004324176,0.00019437072,0.00011405348,0.0002243859],"domain_scores_gemma":[0.99918264,0.00025851937,0.0001707932,0.00019288594,0.0001211024,0.0000740363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019010232,0.00012209373,0.0005906337,0.0001779165,0.00003196006,0.0000015705242,0.00005727775,0.00010213373,0.00009898641],"category_scores_gemma":[0.00012380481,0.00009705593,0.00008276785,0.00030616875,0.000109906374,0.000052603446,0.000028650367,0.00008465302,0.00000841667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037779834,0.0018090986,0.36032724,0.00032537009,0.0009971434,0.00011964405,0.0066342643,0.00023512638,0.0046777166,0.0006352039,0.0039898744,0.6164713],"study_design_scores_gemma":[0.012552273,0.0039524776,0.86026925,0.00016385363,0.00013744067,0.0000136462095,0.00074331806,0.00014693219,0.0083933165,0.0005923643,0.11288571,0.00014943513],"about_ca_topic_score_codex":0.00018386109,"about_ca_topic_score_gemma":0.00032261258,"teacher_disagreement_score":0.61632186,"about_ca_system_score_codex":0.000043024193,"about_ca_system_score_gemma":0.00013163626,"threshold_uncertainty_score":0.39578256},"labels":[],"label_agreement":null},{"id":"W4389286603","doi":"10.1016/j.annonc.2023.10.673","title":"595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Bispecific antibody; Antibody; Cancer research; Oncology; Immunology; Monoclonal antibody","score_opus":0.03239261749654995,"score_gpt":0.4176107955570832,"score_spread":0.38521817806053327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389286603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96496564,0.0021793928,0.000037610465,0.0036825424,0.00036974874,0.0010566665,0.000113140595,0.000045012333,0.027550243],"genre_scores_gemma":[0.99021184,0.0057145227,0.0004489723,0.00053551496,0.000096698925,0.00011922719,0.00016147726,0.000042812255,0.0026689256],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982736,0.00007609121,0.000574103,0.0003989053,0.00020841278,0.00046884795],"domain_scores_gemma":[0.9985556,0.0003111515,0.00031300462,0.0003286649,0.0003541186,0.00013746636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021659539,0.000215787,0.0007509434,0.00038508195,0.00006704285,0.000005115205,0.00014014362,0.00017768993,0.00026780317],"category_scores_gemma":[0.000058898164,0.00019011437,0.00017255815,0.000871858,0.0001231988,0.000086483225,0.00007929263,0.00019917695,0.000037391048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075065996,0.008985823,0.15253872,0.00223278,0.0020692039,0.002155613,0.025674809,0.0064414297,0.47839227,0.00066776015,0.04549248,0.2678425],"study_design_scores_gemma":[0.029422974,0.00890392,0.75766915,0.002486156,0.00083488174,0.000047558755,0.0039026632,0.0014127219,0.14170694,0.0002590155,0.05265504,0.000698953],"about_ca_topic_score_codex":0.0017808105,"about_ca_topic_score_gemma":0.0004979431,"teacher_disagreement_score":0.60513043,"about_ca_system_score_codex":0.00022415303,"about_ca_system_score_gemma":0.0009789789,"threshold_uncertainty_score":0.7752639},"labels":[],"label_agreement":null},{"id":"W4389430282","doi":"10.1016/j.cllc.2023.12.001","title":"Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Manchester Biomedical Research Centre; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Internal medicine; Lung cancer; Oncology; Adverse effect; Population; Cancer; Clinical trial; Gastroenterology; Adenocarcinoma","score_opus":0.03765262139459042,"score_gpt":0.44138423347119976,"score_spread":0.40373161207660935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389430282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884164,0.0029151377,0.0009100349,0.0009946162,0.0005788705,0.0015902995,0.0041075987,0.000100285564,0.00038676907],"genre_scores_gemma":[0.97173816,0.0059524695,0.001548802,0.0008407202,0.00017913179,0.00020271583,0.017707268,0.00007124753,0.0017594988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963719,0.0002106898,0.0014934029,0.0011948964,0.00033156353,0.0003975512],"domain_scores_gemma":[0.9967418,0.00090166344,0.0005525966,0.0011097094,0.0003446156,0.00034966768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062620733,0.00031775443,0.001234724,0.0003499846,0.00009402208,0.000030914212,0.00026179006,0.00016411355,0.00085761974],"category_scores_gemma":[0.00040024795,0.00026007133,0.00017041173,0.0023757648,0.00017855856,0.00020794403,0.00022529047,0.000439238,0.0000046727246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031450714,0.0014745335,0.90881026,0.00017036477,0.008799221,0.00089162635,0.001334331,0.0063503715,0.0006339531,0.0000058102078,0.0059405193,0.062443923],"study_design_scores_gemma":[0.009246849,0.00027000761,0.8439706,0.00082749315,0.014620098,0.000003963669,0.0004175582,0.12865984,0.00018661277,0.000008970454,0.0014909387,0.00029706344],"about_ca_topic_score_codex":0.008841691,"about_ca_topic_score_gemma":0.013629363,"teacher_disagreement_score":0.12230948,"about_ca_system_score_codex":0.00032814746,"about_ca_system_score_gemma":0.0011448016,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4389480834","doi":"10.1016/j.iotech.2023.100668","title":"157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Ipsen; Sanofi; Bayer HealthCare; F. Hoffmann-La Roche; Incyte; Natera; Amgen; ViiV Healthcare; Eisai; AstraZeneca; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; KRAS; Internal medicine; Lung; Cancer; Cisplatin; Colorectal cancer; Immunotherapy","score_opus":0.010848026459265988,"score_gpt":0.36124044456600973,"score_spread":0.35039241810674376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927504,0.0032583189,0.000059045527,0.0023606543,0.00029877646,0.0034855113,0.000082734725,0.00046352617,0.00071642204],"genre_scores_gemma":[0.9959431,0.00081540534,0.00057693425,0.00020618096,0.000032649896,0.0015527338,0.00012621614,0.00009118772,0.0006555333],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997312,0.00010318112,0.00082063826,0.0007935146,0.00021797567,0.00075267977],"domain_scores_gemma":[0.9982427,0.00025684742,0.00041743062,0.0007527781,0.00022049632,0.00010978797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020075469,0.000490348,0.0012656518,0.0016146121,0.00020864254,0.000008931451,0.00029553537,0.0005732311,0.00017204921],"category_scores_gemma":[0.00009090943,0.0004429165,0.000111754256,0.0022905516,0.00033011378,0.00008035707,0.00016098499,0.0005237858,0.0000068318204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071839904,0.0134157855,0.5997234,0.0004642439,0.0020451443,0.0011637299,0.009420363,0.00036619525,0.22453882,0.0000689581,0.0012086899,0.14040066],"study_design_scores_gemma":[0.49134013,0.03997913,0.29105905,0.001073586,0.0038817308,0.00021087179,0.015713984,0.013734581,0.13579914,0.00023560571,0.005312706,0.0016594729],"about_ca_topic_score_codex":0.0009707676,"about_ca_topic_score_gemma":0.0009864597,"teacher_disagreement_score":0.48415616,"about_ca_system_score_codex":0.00085242547,"about_ca_system_score_gemma":0.00095355505,"threshold_uncertainty_score":0.99980223},"labels":[],"label_agreement":null},{"id":"W4389487916","doi":"10.1016/j.iotech.2023.100553","title":"81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Sanofi","keywords":"Docetaxel; Medicine; Internal medicine; Discontinuation; Oncology; Lung cancer; Chemotherapy; Confidence interval; Progression-free survival; Retrospective cohort study; Response Evaluation Criteria in Solid Tumors; Performance status; Progressive disease","score_opus":0.010998413363552492,"score_gpt":0.31328312008101716,"score_spread":0.30228470671746466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389487916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385726,0.0004672282,0.000041564617,0.0018319513,0.000059123086,0.003176507,0.000032378655,0.00023306477,0.0003009436],"genre_scores_gemma":[0.99418366,0.0006808302,0.0010139622,0.00054244266,0.00001757502,0.0027627242,0.0004575495,0.000084153864,0.00025709637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750996,0.00012938087,0.000681187,0.0006848605,0.00022995574,0.00076467526],"domain_scores_gemma":[0.9983439,0.00023964538,0.00038924994,0.00073870894,0.000201645,0.00008684519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029541727,0.0004719746,0.0008412389,0.0014045164,0.00017703747,0.000025428282,0.00030583784,0.00024704344,0.00003032391],"category_scores_gemma":[0.00002797375,0.0003045802,0.0000493675,0.0032058498,0.00069713267,0.00012250445,0.000059455422,0.00054394774,0.0000039441866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027427725,0.0023244466,0.9517009,0.00022843055,0.00034966465,0.00079165894,0.028670257,0.0008972511,0.008926983,0.000028882288,0.00013289122,0.0032058293],"study_design_scores_gemma":[0.081556395,0.017474793,0.8104594,0.0014883867,0.0011886649,0.00012710893,0.029365513,0.009747943,0.04568284,0.000091732254,0.0016342286,0.001183018],"about_ca_topic_score_codex":0.011483026,"about_ca_topic_score_gemma":0.012321927,"teacher_disagreement_score":0.14124155,"about_ca_system_score_codex":0.00079240993,"about_ca_system_score_gemma":0.0006453821,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W4389677779","doi":"10.1080/14740338.2023.2294924","title":"Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Drug Safety","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Korea Health Industry Development Institute","keywords":"Medicine; Lung cancer; Cancer; Gefitinib; Lung; Internal medicine; Intensive care medicine; Oncology; Epidermal growth factor receptor","score_opus":0.009137389951940248,"score_gpt":0.31485448300877644,"score_spread":0.3057170930568362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389677779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947504,0.0013669933,0.0001600313,0.0008212918,0.0008432325,0.0012390547,0.00006233927,0.000088724984,0.0006679475],"genre_scores_gemma":[0.9962437,0.00081331056,0.00056156935,0.000577451,0.000100999845,0.0004010195,0.0002516111,0.000067556466,0.0009827444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985918,0.000031797354,0.00028106864,0.00043369245,0.00028627104,0.00037540344],"domain_scores_gemma":[0.9993369,0.00004610924,0.00008491278,0.0003109071,0.00008136086,0.00013984123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061136874,0.0002436217,0.0003058848,0.00021636343,0.000099187186,0.000017522403,0.00006916827,0.00006808282,0.000219967],"category_scores_gemma":[0.000006463495,0.0001876829,0.00006975026,0.0004862993,0.000028387009,0.00013997837,0.000040257335,0.00015116394,0.000035620033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016159035,0.0012218105,0.96279234,0.00030336255,0.00023276814,0.0005452828,0.012959174,0.004919391,0.000081686776,0.000011040643,0.002356431,0.0129608335],"study_design_scores_gemma":[0.009289672,0.0001987501,0.98133314,0.0018241215,0.00003072568,0.000008593243,0.000505005,0.001288975,0.00025150142,0.0000015927819,0.004950244,0.0003176927],"about_ca_topic_score_codex":0.00044698679,"about_ca_topic_score_gemma":0.00008124845,"teacher_disagreement_score":0.018540813,"about_ca_system_score_codex":0.00066409394,"about_ca_system_score_gemma":0.00019721026,"threshold_uncertainty_score":0.7653487},"labels":[],"label_agreement":null},{"id":"W4389837017","doi":"10.1093/jalm/jfad105","title":"Implementing Next-Generation Sequencing Process Changes to Increase Capacity and Improve Timeliness of Molecular Biomarker Profiling for Lung Cancer Patients","year":2023,"lang":"en","type":"article","venue":"The Journal of Applied Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Turnaround time; Biomarker; Profiling (computer programming); Medicine; Workflow; Lung cancer; Biomarker discovery; Statistical process control; Oncology; Psychological intervention; Internal medicine; Computer science; Operations management; Process (computing); Database; Biology; Engineering; Proteomics","score_opus":0.04268906032882494,"score_gpt":0.35131733907685714,"score_spread":0.3086282787480322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389837017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963541,0.00041496486,0.0005024803,0.001352784,0.0001553622,0.0010834127,0.000077581106,0.000012299627,0.000046990634],"genre_scores_gemma":[0.9981707,0.0000810289,0.00058802083,0.00064263126,0.00034574344,0.00009986952,0.00004026225,0.000022649087,0.00000911222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895185,0.000026226398,0.0003993544,0.00011692004,0.00030473818,0.00020090901],"domain_scores_gemma":[0.9983683,0.00007576467,0.00039564693,0.000105488885,0.00093220605,0.00012255138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010215745,0.00012462803,0.00030605914,0.00018289637,0.000118893986,0.000006804758,0.000063015854,0.000035471836,0.000010053301],"category_scores_gemma":[0.00015151605,0.00007458232,0.0000204719,0.00049348135,0.000052574687,0.00006363366,0.000023510509,0.00008557014,1.5806309e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037470396,0.000032758056,0.0024609,0.00050238747,0.00028780018,0.0000030014487,0.0033753484,0.00014927065,0.98816687,0.000048472397,0.00053871045,0.004059798],"study_design_scores_gemma":[0.008719018,0.0011429263,0.0030700671,0.0009487706,0.0031180845,0.000007637212,0.007311843,0.009424138,0.96539,0.000087614644,0.0005512614,0.00022864017],"about_ca_topic_score_codex":0.00007270536,"about_ca_topic_score_gemma":0.000035828154,"teacher_disagreement_score":0.02277685,"about_ca_system_score_codex":0.00012942268,"about_ca_system_score_gemma":0.00029708756,"threshold_uncertainty_score":0.3041379},"labels":[],"label_agreement":null},{"id":"W4389850548","doi":"10.1016/j.jtocrr.2023.100621","title":"Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Oncology; Adjuvant; Internal medicine; Subgroup analysis; Stage (stratigraphy); Epidermal growth factor receptor; Meta-analysis; Biology; Cancer; Erlotinib","score_opus":0.04608447736501201,"score_gpt":0.43569447291931473,"score_spread":0.3896099955543027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389850548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955035,0.00008659102,0.00003240484,0.0019214867,0.000116804826,0.0012805817,0.00007287435,0.00004477749,0.0009410064],"genre_scores_gemma":[0.9960591,0.000027658494,0.00016712896,0.00020011539,0.00010674291,0.00028798045,0.0002854227,0.000022640397,0.002843174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996648,0.00024821976,0.0008063248,0.00069679786,0.0011370662,0.00046358234],"domain_scores_gemma":[0.9979722,0.00037355337,0.00013172012,0.0004106664,0.0006495258,0.00046235643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017818299,0.00015771593,0.00051975955,0.00065258273,0.00020649316,0.000058913833,0.000048626844,0.00007575775,0.00017235577],"category_scores_gemma":[0.0007983295,0.00010333519,0.00013600376,0.0024697082,0.00022269171,0.00009589425,0.00011556666,0.00044782084,0.000040608127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023054625,0.0004662641,0.9870516,0.00004641959,0.0006481824,0.0046641645,0.00056851964,0.000051145413,0.0000065657196,0.000009371164,0.0006934108,0.0034889157],"study_design_scores_gemma":[0.002287881,0.0021713949,0.9928375,0.00017423341,0.0002835419,0.000016810802,0.0002115733,0.00019834125,0.000015203267,0.00008259268,0.0015947105,0.00012623175],"about_ca_topic_score_codex":0.0012753629,"about_ca_topic_score_gemma":0.0012840749,"teacher_disagreement_score":0.0057859067,"about_ca_system_score_codex":0.00014860318,"about_ca_system_score_gemma":0.00028214575,"threshold_uncertainty_score":0.42138866},"labels":[],"label_agreement":null},{"id":"W4390662775","doi":"10.1016/j.rmra.2023.11.548","title":"Données de vie réelle sur l’efficacité et la tolérance du mobocertinib chez des patients atteints de cancer bronchique non à petites cellules métastatiques avec insertion dans l’exon 20 de l’EGFR","year":2024,"lang":"fr","type":"article","venue":"Revue des Maladies Respiratoires Actualités","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Pharmaceutical Company","keywords":"Medicine; Gynecology","score_opus":0.025353295942411716,"score_gpt":0.32242815828032323,"score_spread":0.2970748623379115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390662775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92545134,0.061895035,0.0036859403,0.0025106554,0.0005987658,0.0009708351,0.00089684455,0.00027696614,0.0037136488],"genre_scores_gemma":[0.9313646,0.050775126,0.0025318046,0.0011563009,0.0010190022,0.00064578763,0.00027453876,0.00023141857,0.012001401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953397,0.00096897536,0.0009626305,0.00092622323,0.00038862452,0.0014138428],"domain_scores_gemma":[0.9971113,0.00113086,0.00028247948,0.0005186679,0.00039437535,0.0005622885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009059264,0.00080718804,0.00083896087,0.00030235655,0.0005387437,0.00041420877,0.00034268716,0.00047647217,0.0005446846],"category_scores_gemma":[0.0007619346,0.00076896837,0.00039913994,0.0005835382,0.00090538675,0.00074299925,0.00014968935,0.00067327695,0.0000691635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007125242,0.0018685152,0.41027465,0.01627793,0.0018162765,0.0011664557,0.17553674,0.005023674,0.031589594,0.0031759297,0.0023509199,0.3502068],"study_design_scores_gemma":[0.0045396183,0.0019732262,0.58728164,0.039783522,0.0023596084,0.0004708061,0.0041871406,0.018470054,0.057337504,0.0017414357,0.28020874,0.0016466709],"about_ca_topic_score_codex":0.0055477014,"about_ca_topic_score_gemma":0.01401152,"teacher_disagreement_score":0.34856012,"about_ca_system_score_codex":0.0035233642,"about_ca_system_score_gemma":0.0013509113,"threshold_uncertainty_score":0.99947613},"labels":[],"label_agreement":null},{"id":"W4390671980","doi":"10.1016/j.rmra.2023.11.553","title":"Efficacité intracrânienne du sotorasib versus docétaxel dans le cancer bronchique non à petites cellules (CBNPC) métastatique muté KRAS G12C données utiles à la pratique issues d’un essai randomisé contrôlé","year":2024,"lang":"fr","type":"article","venue":"Revue des Maladies Respiratoires Actualités","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02634388523035034,"score_gpt":0.32564985516182504,"score_spread":0.2993059699314747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390671980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66181624,0.3015293,0.004496385,0.014735144,0.004226599,0.0030996194,0.001927123,0.0005479046,0.0076216985],"genre_scores_gemma":[0.84816295,0.10939557,0.002550642,0.00060218654,0.0047724694,0.0020329463,0.0005699009,0.0004071837,0.031506117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931699,0.001491111,0.0016156209,0.0015567007,0.00056887424,0.0015977692],"domain_scores_gemma":[0.99293387,0.004386887,0.0004564257,0.0009823957,0.00052489,0.0007155469],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012486153,0.0013973515,0.0019012588,0.00046219653,0.0009965296,0.00090244436,0.0005563964,0.000820134,0.0015022294],"category_scores_gemma":[0.0013744109,0.001232201,0.0007512578,0.00079965504,0.0020411753,0.000980425,0.00023642488,0.0011438761,0.00018132139],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0131003475,0.004902828,0.009243231,0.03831715,0.01798233,0.011242677,0.16693251,0.003956853,0.04826608,0.23497713,0.012664382,0.43841448],"study_design_scores_gemma":[0.033479325,0.0026989498,0.007348475,0.027016755,0.00554203,0.0008066953,0.022234434,0.006765293,0.05603396,0.002129713,0.8333296,0.0026147738],"about_ca_topic_score_codex":0.0072247274,"about_ca_topic_score_gemma":0.010120418,"teacher_disagreement_score":0.82066524,"about_ca_system_score_codex":0.0015869334,"about_ca_system_score_gemma":0.0018606988,"threshold_uncertainty_score":0.9998777},"labels":[],"label_agreement":null},{"id":"W4390690905","doi":"10.1056/nejmoa2302299","title":"Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"National Cancer Institute; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"ROS1; Medicine; Internal medicine; Clinical endpoint; Lung cancer; Confidence interval; Oncology; Phases of clinical research; Clinical trial; Adenocarcinoma; Cancer; Gastroenterology","score_opus":0.011964946728081877,"score_gpt":0.3339295950752071,"score_spread":0.32196464834712524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390690905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89050287,0.052016437,0.0010580391,0.02977421,0.0032687525,0.00047824933,0.000010898938,0.000030031804,0.022860512],"genre_scores_gemma":[0.98405904,0.0025976335,0.00044181204,0.0009787881,0.004735199,0.000007760096,0.000010538412,0.000026524227,0.0071426877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987775,0.000039097344,0.0005060181,0.00016750791,0.00032071205,0.0001891387],"domain_scores_gemma":[0.9991406,0.00018698027,0.00014374708,0.00011372292,0.0001522303,0.00026270366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040187492,0.00015037078,0.0004213205,0.0003120221,0.000036399473,0.00001458189,0.00006006759,0.00005949969,0.00043292795],"category_scores_gemma":[0.00008202813,0.00009036271,0.000085082094,0.00037025716,0.00003725579,0.00008483212,0.00001257079,0.0004289529,0.0000043372115],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017758205,0.00046557392,0.10854025,0.00081899355,0.0011959098,0.014563951,0.030742038,0.0003122085,0.025773771,0.00013057863,0.14440094,0.67127997],"study_design_scores_gemma":[0.31980473,0.010636652,0.15826271,0.043176487,0.011803861,0.016060516,0.0038518335,0.0043610064,0.016756091,0.00106715,0.4132608,0.00095815456],"about_ca_topic_score_codex":0.00096027605,"about_ca_topic_score_gemma":0.00026190787,"teacher_disagreement_score":0.6703218,"about_ca_system_score_codex":0.00025657646,"about_ca_system_score_gemma":0.00081303273,"threshold_uncertainty_score":0.47402573},"labels":[],"label_agreement":null},{"id":"W4391139494","doi":"10.3389/fonc.2023.1330468","title":"Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Osimertinib; Adjuvant; Medicine; Lung cancer; Clinical decision making; Oncology; Delphi method; Consensus conference; Internal medicine; Intensive care medicine; Cancer; Adenocarcinoma; Computer science","score_opus":0.02124443453455981,"score_gpt":0.4032644460555802,"score_spread":0.3820200115210204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391139494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843609,0.005130078,0.0014020546,0.0013335998,0.0054415953,0.0012141905,0.00009208175,0.000034079603,0.0009914549],"genre_scores_gemma":[0.9654809,0.0013768788,0.028369443,0.00010328867,0.00028591434,0.0018694673,0.00010363316,0.000027083948,0.0023833485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876904,0.000026825217,0.00042523484,0.00043429367,0.00010089759,0.0002436899],"domain_scores_gemma":[0.99950606,0.00011692064,0.00007336714,0.00015665269,0.00006013551,0.00008688612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011349971,0.00015278066,0.00034384,0.0003218597,0.000031948563,0.000017928629,0.00006510566,0.00012221787,0.00009107362],"category_scores_gemma":[0.00004809631,0.00010928666,0.00007205,0.00015882793,0.000044602755,0.00006515798,0.000019271454,0.00010402643,0.000001953884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061414223,0.001052656,0.69484675,0.00020664273,0.00042409683,0.011338547,0.006835831,0.0003343979,0.00018937369,0.000007998012,0.00525237,0.27336988],"study_design_scores_gemma":[0.03908052,0.0073480937,0.5577774,0.0029229072,0.002126332,0.001629199,0.006837738,0.07896838,0.0024793644,0.0005639263,0.2992913,0.00097481697],"about_ca_topic_score_codex":0.00043804813,"about_ca_topic_score_gemma":0.0020193073,"teacher_disagreement_score":0.29403895,"about_ca_system_score_codex":0.0020595654,"about_ca_system_score_gemma":0.00096411275,"threshold_uncertainty_score":0.5385692},"labels":[],"label_agreement":null},{"id":"W4391180278","doi":"10.1016/j.jtho.2024.01.012","title":"Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute on Aging; University of California, Irvine; EMD Serono; Genentech; European Society for Medical Oncology; G1 Therapeutics; Seagen; Relay Therapeutics; University of California, San Francisco; NGM Biopharmaceuticals; Cancer Research Institute; AstraZeneca; Novocure; ViewRay; Celldex Therapeutics; Ipsen; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; International Association for the Study of Lung Cancer; Mirati Therapeutics; Association of American Medical Colleges; GlaxoSmithKline; Pfizer; American Association for Cancer Research; Amgen; American Society of Clinical Oncology; Eli Lilly and Company; Bristol-Myers Squibb; Hope Foundation; Sociedad Española de Oncología Médica; Society for Immunotherapy of Cancer; LUNGevity Foundation; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Conquer Cancer Foundation; Sanofi","keywords":"Durvalumab; Medicine; Osimertinib; Common Terminology Criteria for Adverse Events; Retrospective cohort study; Clinical endpoint; Internal medicine; Oncology; Proportional hazards model; Hazard ratio; Cohort; Adverse effect; Confidence interval; Adenocarcinoma; Cancer; Randomized controlled trial; Nivolumab","score_opus":0.035401231696182124,"score_gpt":0.45020228678219587,"score_spread":0.4148010550860137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391180278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990373,0.0009455103,0.00014562036,0.0015784227,0.004685189,0.0011034303,0.000016292286,0.00002511653,0.0011274106],"genre_scores_gemma":[0.99875826,0.00010732281,0.00034756938,0.000071859075,0.00039493464,0.000108785214,0.00003656073,0.000022848839,0.00015188458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998206,0.00020073466,0.00069126894,0.0002633377,0.00041468817,0.00022397874],"domain_scores_gemma":[0.9987245,0.00026428452,0.00032756533,0.00014914993,0.0004230742,0.000111421556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007103253,0.00016628492,0.00050818076,0.00034198753,0.00004794634,0.00004920541,0.00006735997,0.00012001476,0.00022982278],"category_scores_gemma":[0.00035714102,0.0001352965,0.000120925084,0.00043214083,0.000046861118,0.00037096895,0.000024728013,0.00041183687,0.000028696288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050125737,0.0043091783,0.83301276,0.00021064807,0.003185932,0.0021745185,0.009140204,0.00020934353,0.0019830689,0.000105750376,0.0010257355,0.0945171],"study_design_scores_gemma":[0.017598534,0.008300828,0.95982426,0.00037795314,0.002768449,0.00008570696,0.002243822,0.0031654078,0.0008895281,0.00003058633,0.0045367163,0.00017820689],"about_ca_topic_score_codex":0.0000891222,"about_ca_topic_score_gemma":0.00021928913,"teacher_disagreement_score":0.12681147,"about_ca_system_score_codex":0.0037535245,"about_ca_system_score_gemma":0.0008396634,"threshold_uncertainty_score":0.9815336},"labels":[],"label_agreement":null},{"id":"W4391534898","doi":"10.1016/j.jaci.2023.11.287","title":"Characterizing the HAE Patient Perspective on First-Line Prophylactic Treatment","year":2024,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Perspective (graphical); Medicine; Intensive care medicine; Computer science; Artificial intelligence","score_opus":0.03046258585216327,"score_gpt":0.3798598745887046,"score_spread":0.34939728873654136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391534898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93497604,0.012313456,0.000028776756,0.048555102,0.0013637092,0.0002091853,0.0000037143013,0.000014231437,0.0025358007],"genre_scores_gemma":[0.98845315,0.009945321,0.000066057226,0.00058874174,0.00034679874,0.0000061673713,0.0000019322595,0.000009812342,0.0005820486],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992139,0.0000653481,0.00039887024,0.00012956365,0.00008415765,0.00010821556],"domain_scores_gemma":[0.9992248,0.00035407004,0.0001401656,0.00011264158,0.00011174675,0.000056584155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101383506,0.000099124,0.00026140103,0.000058407193,0.000098195975,0.000021940261,0.00003733967,0.000077731565,0.0000836705],"category_scores_gemma":[0.00009509899,0.00004656642,0.00018934887,0.0000590084,0.00012695567,0.00005314381,0.000015040489,0.0003041702,0.000019528019],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013897473,0.0094763385,0.0030448262,0.000077063654,0.05846105,0.0047987276,0.020790922,0.000043056465,0.0016190386,0.02874758,0.0011339108,0.85791004],"study_design_scores_gemma":[0.011554506,0.117543794,0.22335762,0.001013752,0.0034460924,0.0037451794,0.007528766,0.0002362967,0.0010885822,0.0030662436,0.62707883,0.0003403168],"about_ca_topic_score_codex":0.000034302626,"about_ca_topic_score_gemma":0.000034438686,"teacher_disagreement_score":0.8575697,"about_ca_system_score_codex":0.00020755295,"about_ca_system_score_gemma":0.00015452868,"threshold_uncertainty_score":0.18989235},"labels":[],"label_agreement":null},{"id":"W4391611941","doi":"10.1002/cam4.6886","title":"Referred molecular testing as a barrier to optimal treatment decision making in metastatic non‐small cell lung cancer: Experience at a tertiary academic institution in Canada","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Osteoporosis Canada; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Guideline; Academic institution; Lung cancer; Internal medicine; Oncology; Cancer; Diagnostic test; Emergency medicine; Pathology","score_opus":0.029096597648333156,"score_gpt":0.384185755788805,"score_spread":0.3550891581404718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391611941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96678835,0.027887054,0.0006781128,0.0017598247,0.0006986549,0.001362873,0.00003685415,0.00003669009,0.00075160805],"genre_scores_gemma":[0.99372804,0.00077254715,0.0012935175,0.001863564,0.00014481998,0.0017546241,0.00002306244,0.000040081108,0.000379722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793315,0.00003361817,0.0005488113,0.0006174658,0.0004004668,0.00046647372],"domain_scores_gemma":[0.999155,0.00016869153,0.00007067952,0.00024829977,0.00006588368,0.00029144756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011815496,0.00030547436,0.00047976125,0.0003735584,0.0000713034,0.000011344596,0.00010822645,0.00006294054,0.00025518893],"category_scores_gemma":[0.00013889452,0.00022852793,0.000040725947,0.00095896097,0.000049107337,0.0001057706,0.000054085765,0.0002600815,0.000005058528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010429876,0.0001662425,0.54613084,0.0011888633,0.00040648607,0.012837153,0.055281572,0.054557376,0.079274654,0.00003675388,0.0021697073,0.24690738],"study_design_scores_gemma":[0.037571706,0.003319407,0.5007851,0.106213175,0.005530272,0.0009228017,0.020379428,0.23122193,0.05948899,0.0001508389,0.03170183,0.0027145082],"about_ca_topic_score_codex":0.6537012,"about_ca_topic_score_gemma":0.54110295,"teacher_disagreement_score":0.24419288,"about_ca_system_score_codex":0.01277779,"about_ca_system_score_gemma":0.005346637,"threshold_uncertainty_score":0.991012},"labels":[],"label_agreement":null},{"id":"W4391696625","doi":"10.2139/ssrn.4680814","title":"Osimertinib is Associated with Improved Outcomes Versus First- and Second-Generation Egfr Inhibitors in Pre-Treated But Not Untreated Nsclc Leptomeningeal Metastases: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Osimertinib; Meta-analysis; Medicine; Oncology; Internal medicine; EGFR inhibitors; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.037493344470089944,"score_gpt":0.35435663012399593,"score_spread":0.316863285653906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391696625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076361845,0.99471694,0.000010708492,0.0005113242,0.00004754468,0.0035189688,0.00035999628,0.000049078328,0.00002179529],"genre_scores_gemma":[0.008333028,0.9854563,0.000021499445,0.00016859254,0.00003746159,0.00074560504,0.00066711416,0.000094725845,0.004475713],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956428,0.00048763445,0.0015725465,0.0007158004,0.0004255445,0.0011556752],"domain_scores_gemma":[0.9978262,0.00027401996,0.0011306832,0.0003678597,0.00019930427,0.00020188674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014370492,0.0008583837,0.0071330853,0.00084326,0.00018484952,0.00016953697,0.0001176344,0.00025175087,0.00010359081],"category_scores_gemma":[0.00020548372,0.0004607034,0.0014012974,0.0015100973,0.00005698146,0.0001826423,0.00004208014,0.0014869395,0.00000598803],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082848506,0.00017657332,0.000053032745,0.12902726,0.8681389,0.000085654705,0.00028682887,0.0000010747548,0.0000012019889,0.000055819997,0.00009830674,0.0019924582],"study_design_scores_gemma":[0.0022383237,0.0008508225,0.000009776763,0.018022072,0.97733885,0.00035940643,0.00010040144,0.000039856688,0.000002953662,0.000011351735,0.00062895403,0.00039720917],"about_ca_topic_score_codex":0.00041767556,"about_ca_topic_score_gemma":0.008163462,"teacher_disagreement_score":0.111005194,"about_ca_system_score_codex":0.0026025516,"about_ca_system_score_gemma":0.0021763777,"threshold_uncertainty_score":0.99978447},"labels":[],"label_agreement":null},{"id":"W4391792531","doi":"10.1016/j.jtocrr.2024.100645","title":"Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; National Institutes of Health; Array BioPharma; Massachusetts General Hospital; Lunit; Amgen; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Alectinib; Medicine; Oncology; Crizotinib; Internal medicine; Lung cancer","score_opus":0.03893543307576351,"score_gpt":0.42166519799897556,"score_spread":0.38272976492321203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391792531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444896,0.0010216227,0.000008695916,0.0006354416,0.00016217446,0.0016503287,0.00004821874,0.000037053243,0.0019875222],"genre_scores_gemma":[0.998805,0.00035620955,0.00015664303,0.0000279463,0.00004945421,0.000033127148,0.000048016078,0.000025766403,0.0004978256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715024,0.00031887856,0.000800539,0.000607092,0.0007517738,0.00037147175],"domain_scores_gemma":[0.99777806,0.0011658006,0.00011376121,0.00023186716,0.00033491527,0.0003756046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014202519,0.000168826,0.00055428233,0.00021293851,0.00013298943,0.000056014134,0.000025305859,0.00010323941,0.000012170538],"category_scores_gemma":[0.0007619037,0.000101875776,0.000056644716,0.00043516664,0.0004206764,0.00008160734,0.00005894373,0.00059633626,0.0000010878483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026517546,0.0022830702,0.78638905,0.0016823433,0.0018653597,0.009260092,0.0025696568,0.000016625912,0.00004304105,0.0004312682,0.0010254367,0.16791649],"study_design_scores_gemma":[0.008083154,0.005798052,0.98152375,0.0025148487,0.00030332373,0.00022717007,0.00026440798,0.00010570863,0.000042394313,0.000069182905,0.00095309614,0.000114918075],"about_ca_topic_score_codex":0.00026985834,"about_ca_topic_score_gemma":0.00006324433,"teacher_disagreement_score":0.19513467,"about_ca_system_score_codex":0.00015600592,"about_ca_system_score_gemma":0.00048591368,"threshold_uncertainty_score":0.41543734},"labels":[],"label_agreement":null},{"id":"W4391823622","doi":"10.3390/curroncol31020074","title":"The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Osimertinib; Context (archaeology); Internal medicine; Population; Lung cancer; Adjuvant; Chemotherapy; Epidermal growth factor receptor; Cisplatin; Cancer; Erlotinib","score_opus":0.02972676126517259,"score_gpt":0.3924380459398545,"score_spread":0.3627112846746819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391823622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98154044,0.012990796,0.000009468306,0.0033410508,0.00047354758,0.00094851846,0.00010918046,0.000020237205,0.0005667307],"genre_scores_gemma":[0.9965947,0.0025661257,0.00019543753,0.00015150104,0.00007563897,0.00025645195,0.00006350076,0.000022782448,0.00007384085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990192,0.00006560059,0.00034872195,0.00021738681,0.00010667654,0.00024238514],"domain_scores_gemma":[0.9992703,0.00021381937,0.000090387985,0.0001967326,0.00012764687,0.00010110152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010721771,0.00013101152,0.00028182621,0.000074994445,0.00008159606,0.000012531368,0.00011272195,0.000066096225,0.00004832549],"category_scores_gemma":[0.000059054928,0.00008533051,0.00004719228,0.0002159963,0.00006549621,0.000033719134,0.00007550013,0.00023957559,0.0000037971188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020548253,0.0005411471,0.5425985,0.0002799182,0.00013506618,0.0000032300673,0.01823685,0.000002044237,0.0037600212,0.000048145583,0.0012670788,0.4329225],"study_design_scores_gemma":[0.0092762625,0.002512337,0.6551213,0.0023739946,0.00046463383,0.000006264276,0.0025287678,0.006219659,0.020361705,0.000144115,0.30061767,0.0003733001],"about_ca_topic_score_codex":0.00037661372,"about_ca_topic_score_gemma":0.0006448356,"teacher_disagreement_score":0.4325492,"about_ca_system_score_codex":0.00037418748,"about_ca_system_score_gemma":0.00031187385,"threshold_uncertainty_score":0.3479677},"labels":[],"label_agreement":null},{"id":"W4391888116","doi":"10.1016/j.prp.2024.155213","title":"Detection of EGFR T790M mutation using liquid biopsy for non-small cell lung cancer: Utility of droplet digital polymerase chain reaction vs. cobas real-time polymerase chain reaction","year":2024,"lang":"en","type":"article","venue":"Pathology - Research and Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Faculty of Medicine, Chulalongkorn University","keywords":"Osimertinib; T790M; Digital polymerase chain reaction; Lung cancer; Liquid biopsy; Mutation; Medicine; Polymerase chain reaction; Molecular biology; Internal medicine; Cancer research; Oncology; Epidermal growth factor receptor; Biology; Cancer; Gene; Gefitinib; Erlotinib; Genetics","score_opus":0.04015629574786065,"score_gpt":0.40758886102449843,"score_spread":0.36743256527663776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391888116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898686,0.0020219674,0.0028181328,0.0015964627,0.00030911659,0.0013713962,0.00045151467,0.0000543236,0.0015084881],"genre_scores_gemma":[0.99671435,0.0012619937,0.0006270273,0.00003074472,0.00020827107,0.00019995446,0.0002762799,0.000038071517,0.00064330566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980121,0.00034474902,0.0004338461,0.0005056657,0.0003263422,0.00037726108],"domain_scores_gemma":[0.99716645,0.0015493624,0.0002553363,0.00027170093,0.000589705,0.00016745934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014951873,0.00018024746,0.0003337835,0.00047794433,0.00023370278,0.00004813788,0.000050301573,0.00020294834,0.000027634707],"category_scores_gemma":[0.0008921469,0.00015562576,0.00008939284,0.0005434505,0.0002283958,0.00062045036,0.000038963346,0.00035451204,0.0000037816792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070191957,0.00055309205,0.00063828693,0.0010197404,0.00021896652,0.00020821369,0.0016586055,0.00000231177,0.96945447,0.00003963993,0.000068388166,0.019119093],"study_design_scores_gemma":[0.006789629,0.00848141,0.009399493,0.0009961566,0.0023605225,0.0028924067,0.005500465,0.03902244,0.9212196,0.00024037303,0.0025721097,0.0005254357],"about_ca_topic_score_codex":0.005205068,"about_ca_topic_score_gemma":0.00008774285,"teacher_disagreement_score":0.048234906,"about_ca_system_score_codex":0.00028063133,"about_ca_system_score_gemma":0.0006497525,"threshold_uncertainty_score":0.786854},"labels":[],"label_agreement":null},{"id":"W4391919142","doi":"10.1016/j.jtocrr.2024.100647","title":"Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cabozantinib; Medicine; Exon; Exon skipping; Mutation; Cancer research; Oncology; Targeted therapy; Internal medicine; Cancer; Genetics; Gene; Biology","score_opus":0.06866051547325637,"score_gpt":0.4670181337328081,"score_spread":0.39835761825955174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391919142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303937,0.0022227645,0.000020043854,0.0018476583,0.00022411169,0.00081028166,0.0000070872557,0.000051130304,0.0017775457],"genre_scores_gemma":[0.9973616,0.0002747717,0.00073063624,0.00008503124,0.00013472942,0.00012175324,0.000023199553,0.000023870412,0.0012444169],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997204,0.0003173308,0.0008472868,0.000696664,0.0006291589,0.00030554182],"domain_scores_gemma":[0.9981371,0.0008742958,0.00011050032,0.00032566697,0.00024021896,0.0003122059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00520333,0.00013033315,0.0003350651,0.00030984575,0.00016049873,0.000110993395,0.000016993976,0.00012368667,0.000043346263],"category_scores_gemma":[0.0018063604,0.00008720956,0.000058311107,0.000443949,0.0002500633,0.00015691984,0.000090941416,0.00069329375,0.0000014750636],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015137623,0.00017592238,0.01718039,0.00018512219,0.00011465375,0.90915644,0.0017351191,0.0000014686651,0.00010408315,0.000024195977,0.00046342603,0.06934539],"study_design_scores_gemma":[0.0030677028,0.005238123,0.21215664,0.002909462,0.00024423716,0.7179723,0.0028182156,0.00045344786,0.00016514512,0.00043172447,0.054247733,0.00029529975],"about_ca_topic_score_codex":0.0006195853,"about_ca_topic_score_gemma":0.00020425563,"teacher_disagreement_score":0.19497624,"about_ca_system_score_codex":0.000090082394,"about_ca_system_score_gemma":0.0011316685,"threshold_uncertainty_score":0.35563025},"labels":[],"label_agreement":null},{"id":"W4391960228","doi":"10.21203/rs.3.rs-3948986/v1","title":"Effective Survival Prediction and Evaluation for Cancer Patients","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Alberta Machine Intelligence Institute","keywords":"Cancer; Oncology; Medicine; Internal medicine","score_opus":0.07139961516236011,"score_gpt":0.5135459226389993,"score_spread":0.44214630747663924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391960228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96601385,0.007923893,0.000055662727,0.0018446032,0.0016208962,0.016052082,0.0027937382,0.000087221495,0.0036080452],"genre_scores_gemma":[0.98388904,0.00041954403,0.00006853728,0.000011124642,0.00058945967,0.012237195,0.0018419895,0.000040073704,0.00090301206],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997987,0.00018204137,0.000155106,0.0004978249,0.0009307439,0.00024728876],"domain_scores_gemma":[0.9977439,0.00021228778,0.00003557595,0.00020253455,0.001682217,0.00012349011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009263477,0.00014100903,0.00022082098,0.00026914064,0.00014229801,0.000073846495,0.00003796853,0.00017916916,0.00006194959],"category_scores_gemma":[0.0003266633,0.00011143818,0.00008716508,0.00016019764,0.000059806123,0.000030486506,0.00021949301,0.00052486814,0.000011091404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013885029,0.0011946117,0.2477255,0.022652287,0.0033555091,0.000012931245,0.0070068273,0.00042071426,0.00022486834,0.0009570751,0.023335937,0.69172525],"study_design_scores_gemma":[0.006941952,0.0027211236,0.9329612,0.006201525,0.0025730564,0.0000016102042,0.00062648824,0.020699942,0.0003990062,0.016425211,0.010180095,0.00026877382],"about_ca_topic_score_codex":0.0004904907,"about_ca_topic_score_gemma":0.00014841244,"teacher_disagreement_score":0.69145644,"about_ca_system_score_codex":0.0012916808,"about_ca_system_score_gemma":0.0008911983,"threshold_uncertainty_score":0.4544317},"labels":[],"label_agreement":null},{"id":"W4392012932","doi":"10.3389/bjbs.2024.11835","title":"Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta‐Analysis","year":2024,"lang":"en","type":"article","venue":"British Journal of Biomedical Science","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universiti Kebangsaan Malaysia","keywords":"Chemotherapy; Oncology; Lung cancer; Meta-analysis; Medicine; Cancer; Platinum; Internal medicine; Biology; Biochemistry","score_opus":0.008053114749823278,"score_gpt":0.29726173845369425,"score_spread":0.28920862370387096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392012932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177766,0.0022836467,0.0022821228,0.0032621822,0.000067503446,0.00023125176,0.000044814824,0.0000072551416,0.000043560693],"genre_scores_gemma":[0.9962253,0.000106588035,0.0023012743,0.0011869294,0.000021836177,0.000018327482,0.0000020929294,0.000007838029,0.0001298325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861467,0.000046017973,0.00029572882,0.0002343921,0.0005848936,0.00022427164],"domain_scores_gemma":[0.9990855,0.00023230679,0.00008844705,0.000067502275,0.00018645194,0.00033981405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063187216,0.0000902385,0.00037114846,0.00048888347,0.00007248003,0.00011261475,0.000110330766,0.000048336722,0.00023342107],"category_scores_gemma":[0.00021957826,0.00006607263,0.000106276966,0.0023460023,0.00013729249,0.00009270948,0.000015957905,0.0001512891,4.1209765e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006513193,0.009640954,0.5299645,0.0009557874,0.115271196,0.024162177,0.014387331,0.0018311198,0.028479083,0.0000057183875,0.010795282,0.25799364],"study_design_scores_gemma":[0.0034690714,0.0015343355,0.95852524,0.00060982874,0.030203665,0.00009315594,0.000054719898,0.0046938187,0.00046897624,0.0000072721177,0.00018892702,0.00015099208],"about_ca_topic_score_codex":0.00070709136,"about_ca_topic_score_gemma":0.00034711746,"teacher_disagreement_score":0.4285607,"about_ca_system_score_codex":0.00023531287,"about_ca_system_score_gemma":0.0008461504,"threshold_uncertainty_score":0.26943636},"labels":[],"label_agreement":null},{"id":"W4392382353","doi":"10.1016/j.lungcan.2024.107529","title":"Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Lung cancer; Population; T790M; Clinical trial; Oncology; Cohort; Cancer; Surgery; Epidermal growth factor receptor; Gefitinib; Erlotinib","score_opus":0.0368810711503858,"score_gpt":0.4325912659763442,"score_spread":0.3957101948259584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392382353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762674,0.0024937156,0.0005247763,0.0067966217,0.0016833595,0.006533071,0.0055415174,0.000099307494,0.00006023159],"genre_scores_gemma":[0.99311274,0.0009019828,0.0002906962,0.000822081,0.0006591063,0.0029311476,0.00017666913,0.00009106418,0.0010145061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747556,0.00009495615,0.0008096524,0.0006704695,0.0005259269,0.0004234271],"domain_scores_gemma":[0.9972558,0.0011518968,0.00030944176,0.0005837162,0.00055080367,0.00014831717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026585747,0.0004171921,0.00084568386,0.00006650031,0.00025121946,0.00006445659,0.00021025712,0.00018298574,0.0005156966],"category_scores_gemma":[0.00020905837,0.0001733203,0.00032230435,0.00031154483,0.0002868985,0.00017138026,0.000039371174,0.00042001743,0.000001483033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13294338,0.0009247332,0.81655383,0.0011003352,0.010810952,0.000010233176,0.0033693144,0.00020502304,0.00027366818,0.00011096426,0.0061483877,0.027549203],"study_design_scores_gemma":[0.17396401,0.009808813,0.735677,0.002881878,0.018761046,0.0000030397405,0.0004282691,0.008198888,0.011329702,0.000034636432,0.037804384,0.0011083555],"about_ca_topic_score_codex":0.0013918519,"about_ca_topic_score_gemma":0.0014345659,"teacher_disagreement_score":0.08087683,"about_ca_system_score_codex":0.00056431297,"about_ca_system_score_gemma":0.0008533167,"threshold_uncertainty_score":0.7067796},"labels":[],"label_agreement":null},{"id":"W4392617890","doi":"10.1093/neuonc/noae041","title":"Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Lung cancer; Oncology; Radiation therapy; Anaplastic lymphoma kinase; Internal medicine; Epidermal growth factor receptor; Precision medicine; Cancer; Pathology","score_opus":0.02122577001766642,"score_gpt":0.3476098907851175,"score_spread":0.3263841207674511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392617890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885623,0.00076659635,0.00025515282,0.0069269883,0.00066256104,0.0017735037,0.00085989444,0.00005023814,0.00014275957],"genre_scores_gemma":[0.9923806,0.00081918295,0.0023926883,0.003182006,0.0001469632,0.00046317672,0.00016934355,0.000067028996,0.00037900297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984922,0.00023581469,0.00036855915,0.00045702542,0.00011786866,0.00032854316],"domain_scores_gemma":[0.9984925,0.00094018294,0.00016645835,0.00016814312,0.00012367636,0.00010905373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001481372,0.00022893996,0.0005444827,0.00010427526,0.00008571269,0.00002561832,0.000085824155,0.000093574454,0.000031413427],"category_scores_gemma":[0.00012737156,0.00015638757,0.0001819605,0.0003781696,0.00024859855,0.00011536928,0.00008462761,0.00025400473,8.519564e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087969715,0.00042301556,0.013212413,0.0008151694,0.0004899952,0.00011550458,0.009589868,0.000034207216,0.9211351,0.000028634984,0.042826578,0.010449768],"study_design_scores_gemma":[0.021634478,0.0065591456,0.074592076,0.001269597,0.0042243977,0.00022101143,0.0050178804,0.027783053,0.71424353,0.00017028968,0.14320607,0.0010784952],"about_ca_topic_score_codex":0.0021098368,"about_ca_topic_score_gemma":0.00023811319,"teacher_disagreement_score":0.20689164,"about_ca_system_score_codex":0.0003613218,"about_ca_system_score_gemma":0.00072256796,"threshold_uncertainty_score":0.63773},"labels":[],"label_agreement":null},{"id":"W4392641667","doi":"10.1055/s-0044-1781403","title":"Pneumologische Onkologie Tumor Treating Fields (TTFields) therapy with standard systemic therapy in metastatic non-small cell lung cancer following progression on or after platinum-based therapy: global randomized, pivotal (phase 3) LUNAR study","year":2024,"lang":"en","type":"article","venue":"Pneumologie","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Systemic therapy; Lung cancer; Oncology; Cancer; Randomized controlled trial; Internal medicine; Breast cancer","score_opus":0.029584472651474705,"score_gpt":0.38852907401200865,"score_spread":0.35894460136053397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392641667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97652423,0.012835818,0.000806813,0.00082221424,0.0005407244,0.0076121064,0.00008461097,0.00031592732,0.00045752758],"genre_scores_gemma":[0.99123174,0.0007155758,0.000840457,0.00075599545,0.00010093961,0.0060639773,0.000038064063,0.000073373645,0.00017987452],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966328,0.0005022848,0.0007248004,0.00093582086,0.0005317674,0.000672541],"domain_scores_gemma":[0.9979046,0.0011474544,0.00020803601,0.0005034501,0.00009228163,0.00014416644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007320415,0.0006563829,0.0013421918,0.00023344996,0.00016013398,0.00014319642,0.00020844044,0.00016755158,0.00015854329],"category_scores_gemma":[0.000111744666,0.00033486367,0.0003601166,0.0006011952,0.000105984545,0.00013608988,0.000035783294,0.0005172275,0.00000608746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4093764,0.007147922,0.38880745,0.00071864075,0.0042375834,0.026585387,0.008111647,0.002383875,0.0019274942,0.000015667894,0.00014966431,0.15053825],"study_design_scores_gemma":[0.86500216,0.07277401,0.017463958,0.007503748,0.0029221042,0.00035243342,0.007689433,0.011646736,0.012301617,0.00013336631,0.00019286113,0.0020175988],"about_ca_topic_score_codex":0.00051247433,"about_ca_topic_score_gemma":0.00021398866,"teacher_disagreement_score":0.4556257,"about_ca_system_score_codex":0.00078539643,"about_ca_system_score_gemma":0.0013591986,"threshold_uncertainty_score":0.99991035},"labels":[],"label_agreement":null},{"id":"W4392654691","doi":"10.1007/s11523-024-01034-3","title":"Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","year":2024,"lang":"en","type":"letter","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; Placebo; Epidermal growth factor receptor; Stage (stratigraphy); Cancer; Pathology; Erlotinib; Biology","score_opus":0.05860293502871478,"score_gpt":0.41327494089060063,"score_spread":0.35467200586188585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392654691","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042618074,0.0059588943,0.000009655209,0.8336922,0.0016166068,0.0032733358,0.00057317514,0.00030632952,0.11195174],"genre_scores_gemma":[0.2660829,0.0018765817,0.0042901877,0.49373397,0.010449134,0.002637031,0.036995504,0.001313388,0.18262129],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963957,0.0006267311,0.00066644035,0.00072056893,0.0007770609,0.00081348734],"domain_scores_gemma":[0.99778867,0.0007966255,0.00018521766,0.0005498812,0.0005576245,0.00012200181],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005387332,0.0003630721,0.0011269216,0.0012362888,0.00005745647,0.000015701517,0.00020854881,0.0010975348,0.00058243674],"category_scores_gemma":[0.00019862609,0.00026967595,0.00013331098,0.0012282177,0.00043513585,0.0000548556,0.00010519852,0.0035606648,0.00011354051],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017435952,0.00036791002,0.0013220742,0.0008183856,0.0012152444,0.014326088,0.0009776804,0.000009627731,0.0010883181,0.000072322655,0.9772144,0.0008443289],"study_design_scores_gemma":[0.0066531133,0.004587006,0.00476775,0.0015479346,0.00080427434,0.00013896106,0.00021017152,0.000056316672,0.000421778,0.0006128612,0.979879,0.00032081906],"about_ca_topic_score_codex":0.0026088043,"about_ca_topic_score_gemma":0.00075138867,"teacher_disagreement_score":0.33995822,"about_ca_system_score_codex":0.0014347029,"about_ca_system_score_gemma":0.0033655555,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W4392859966","doi":"10.1016/j.lungcan.2024.107535","title":"A pragmatic guide for management of adverse events associated with lorlatinib","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Adverse effect; Clinical trial; Anaplastic lymphoma kinase; Concomitant; Tyrosine-kinase inhibitor; Intensive care medicine; Oncology; Internal medicine; Lung cancer; Cancer","score_opus":0.027980821829533785,"score_gpt":0.4324065033874051,"score_spread":0.40442568155787134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392859966","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006093679,0.98753595,0.00011677538,0.000068144276,0.00037154276,0.0045977985,0.0007091852,0.000054909542,0.006539574],"genre_scores_gemma":[0.000020867003,0.94982797,0.0012924062,0.00004215591,0.00009156249,0.0039205956,0.00077141303,0.00009468507,0.043938324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986625,0.000023211556,0.00049862236,0.00033385033,0.00026339316,0.00021846141],"domain_scores_gemma":[0.99911624,0.0000610642,0.00035603793,0.000286566,0.000108651555,0.0000714121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009800148,0.00030641974,0.0011228865,0.00012784581,0.00003439592,0.0000031648703,0.0000812529,0.000111042085,0.00011329664],"category_scores_gemma":[0.0000129693,0.00018865771,0.0003772709,0.00035469388,0.000022299957,0.000031826152,0.000030413872,0.0001229149,0.000010519616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066605426,0.000359321,0.00015008706,0.37374055,0.042542886,0.00012625514,0.000351934,0.000019687915,9.705187e-8,0.00074532186,0.034264788,0.54763246],"study_design_scores_gemma":[0.0013684055,0.00012723255,0.000047058034,0.15715244,0.06786069,0.000006172059,0.00003308222,0.000045222318,1.676656e-7,0.000021428941,0.7731697,0.00016841751],"about_ca_topic_score_codex":0.00004430204,"about_ca_topic_score_gemma":0.00004802627,"teacher_disagreement_score":0.7389049,"about_ca_system_score_codex":0.001023546,"about_ca_system_score_gemma":0.00067613815,"threshold_uncertainty_score":0.7693238},"labels":[],"label_agreement":null},{"id":"W4392908179","doi":"10.3390/curroncol31030115","title":"Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Grand River Hospital","funders":"","keywords":"Medicine; Turnaround time; Biomarker; Cohort; Lung cancer; Internal medicine; Oncology; Retrospective cohort study; Cancer; Carcinoma","score_opus":0.029767481017998955,"score_gpt":0.3721405988839503,"score_spread":0.3423731178659513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392908179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516195,0.0019060606,0.0000038238186,0.00052763306,0.00023553307,0.0011353103,0.000594381,0.000025637397,0.000409674],"genre_scores_gemma":[0.99797547,0.0002165796,0.000094446674,0.000063939595,0.000028938084,0.00012925954,0.0012152197,0.00003207375,0.00024410246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988786,0.000092332055,0.00016207802,0.0003269442,0.00013159424,0.00040845003],"domain_scores_gemma":[0.99901485,0.00013648612,0.00005445104,0.00024718232,0.00010569871,0.00044133642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050374183,0.0002725035,0.00032791283,0.00025353133,0.00020245711,0.000023544644,0.00005659581,0.000083307044,0.000103866485],"category_scores_gemma":[0.0000065847084,0.00015729021,0.000049000646,0.00024708686,0.00007001815,0.000091543625,0.000022346743,0.00022739211,0.000006170987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011429884,0.00266663,0.9716263,0.000039747098,0.00023829269,0.00014183526,0.0045351707,0.000045993984,0.000004533876,0.00000845719,0.0010549185,0.018495128],"study_design_scores_gemma":[0.010363682,0.007720927,0.9705564,0.00043203647,0.00042086584,0.00000952266,0.00063143217,0.0010605112,0.000010668099,0.000004883055,0.008601285,0.00018781361],"about_ca_topic_score_codex":0.030069618,"about_ca_topic_score_gemma":0.28930926,"teacher_disagreement_score":0.25923967,"about_ca_system_score_codex":0.004959317,"about_ca_system_score_gemma":0.0015729949,"threshold_uncertainty_score":0.9988605},"labels":[],"label_agreement":null},{"id":"W4393090887","doi":"10.1158/1538-7445.am2024-223","title":"Abstract 223: Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.0959895341810242,"score_gpt":0.4972038645440597,"score_spread":0.4012143303630355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393090887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9244088,0.035166357,0.00008679461,0.013774952,0.00046739765,0.002360637,0.00013848886,0.000057704554,0.023538882],"genre_scores_gemma":[0.98989797,0.0027700919,0.000118593125,0.00035002574,0.00042803507,0.0006121882,0.00001775688,0.000041571868,0.00576376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983619,0.000030285812,0.00026208488,0.000354839,0.0006655954,0.00032530626],"domain_scores_gemma":[0.9987987,0.00040662245,0.000029520774,0.00035934243,0.00019779756,0.0002079794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004094588,0.00015045806,0.00024203249,0.00027585027,0.00017438372,0.000034706012,0.00009768105,0.00006277684,0.00079418917],"category_scores_gemma":[0.000051405445,0.00007770874,0.00006460819,0.00052496,0.0002049705,0.000052251493,0.000024000377,0.00014996168,0.000018397084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018035581,0.00039833947,0.0066385292,0.0008957495,0.0008746428,0.00015151789,0.018734481,0.0003888392,0.042887177,0.0008423172,0.10814777,0.81823707],"study_design_scores_gemma":[0.005092325,0.0028573475,0.018393956,0.0039337627,0.00041600954,0.000011570517,0.002038063,0.0011113806,0.02193957,0.00025364867,0.9437525,0.00019985679],"about_ca_topic_score_codex":0.01486182,"about_ca_topic_score_gemma":0.0013701707,"teacher_disagreement_score":0.8356047,"about_ca_system_score_codex":0.0018411184,"about_ca_system_score_gemma":0.00121503,"threshold_uncertainty_score":0.9916983},"labels":[],"label_agreement":null},{"id":"W4393095518","doi":"10.1158/1538-7445.am2024-3012","title":"Abstract 3012: Characterizing the functional significance of \"variant of uncertain significance\" of the tumour suppressor <i>CDH1</i>","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Queen's University; McMaster University; University of Toronto","funders":"","keywords":"CDH1; Suppressor; Cancer; Medicine; Clinical significance; Cancer research; Computational biology; Biology; Genetics; Internal medicine; Cadherin; Cell","score_opus":0.07930126142558172,"score_gpt":0.4004470904916086,"score_spread":0.32114582906602684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393095518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97615784,0.005049313,0.000058611018,0.0110077225,0.0007481017,0.0017154106,0.00070211984,0.000026292433,0.004534587],"genre_scores_gemma":[0.99665546,0.0003635714,0.000035585264,0.000086909546,0.00028864088,0.00042339024,0.000020274489,0.000029565186,0.0020966255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997809,0.00013134103,0.00044306094,0.0003137183,0.0009664485,0.00033645742],"domain_scores_gemma":[0.9981649,0.00059913687,0.00014083293,0.00048284934,0.00053238304,0.000079913116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007967054,0.00013883285,0.00030653962,0.00012750119,0.0001456502,0.00002600492,0.00028762044,0.00006664515,0.00082476245],"category_scores_gemma":[0.0001316591,0.00007519167,0.00018377554,0.00080468395,0.0005911435,0.00009572982,0.00007826009,0.0004761051,0.000009356971],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003484888,0.00017954933,0.0017610249,0.0012480282,0.0004130825,0.000023146093,0.001355043,0.00015320496,0.98190176,0.0027269297,0.0064461175,0.003443614],"study_design_scores_gemma":[0.0010782504,0.00025574287,0.162856,0.0018632293,0.00028461538,0.000017515827,0.0011546466,0.00016530823,0.80779207,0.0006384451,0.023756238,0.0001379319],"about_ca_topic_score_codex":0.0021196338,"about_ca_topic_score_gemma":0.000079968064,"teacher_disagreement_score":0.17410968,"about_ca_system_score_codex":0.00027318374,"about_ca_system_score_gemma":0.0021397604,"threshold_uncertainty_score":0.90305704},"labels":[],"label_agreement":null},{"id":"W4393110029","doi":"10.1016/j.ccm.2024.02.006","title":"Drug-induced Lung Disease in the Oncology Patient","year":2024,"lang":"en","type":"article","venue":"Clinics in Chest Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Drug; Disease; Lung; Incidence (geometry); Lung cancer; Oncology; Internal medicine; Intensive care medicine; Lung disease; Pharmacology","score_opus":0.045966185383203496,"score_gpt":0.4498698050768412,"score_spread":0.4039036196936377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393110029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90283024,0.007719252,0.00001464773,0.07287399,0.0017527865,0.00088627636,0.000007896874,0.000048770158,0.013866155],"genre_scores_gemma":[0.99410504,0.0005630762,0.00005398051,0.004142903,0.00047050306,0.00016398246,0.00006527356,0.000017388627,0.00041784794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987414,0.000087528926,0.000456319,0.00027830215,0.00023938382,0.00019706288],"domain_scores_gemma":[0.99865854,0.000834052,0.00004404077,0.00030250128,0.000033527427,0.00012732447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005691794,0.00012338973,0.0002785333,0.0001704235,0.000029136261,0.0000074539826,0.00008789049,0.000065049244,0.0001043834],"category_scores_gemma":[0.00042743853,0.00006915316,0.000054258086,0.00044778732,0.00009142223,0.000038169375,0.000022050246,0.00042298064,0.00003130801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005535152,0.002934031,0.37197825,0.001402708,0.00031477847,0.013487832,0.0880452,0.00006028678,0.00015451347,0.00758254,0.051544365,0.461942],"study_design_scores_gemma":[0.010846197,0.0021108042,0.4161181,0.005028143,0.001533495,0.000096001495,0.0106767,0.009654337,0.00003863522,0.004951861,0.53857416,0.00037157236],"about_ca_topic_score_codex":0.00015484013,"about_ca_topic_score_gemma":0.00018724252,"teacher_disagreement_score":0.4870298,"about_ca_system_score_codex":0.00038261953,"about_ca_system_score_gemma":0.00053157005,"threshold_uncertainty_score":0.2819984},"labels":[],"label_agreement":null},{"id":"W4393165834","doi":"10.1016/j.esmoop.2024.102582","title":"3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University; Institute of Cancer Research; Montreal General Hospital; BC Cancer Agency","funders":"Janssen Biotech","keywords":"Osimertinib; Chemotherapy; Oncology; Medicine; Internal medicine; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.01046002646336001,"score_gpt":0.38087481027381986,"score_spread":0.37041478381045984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393165834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98353493,0.0013929894,0.00005969385,0.0075799203,0.0002217496,0.002561742,0.00007964582,0.00009733412,0.0044719693],"genre_scores_gemma":[0.9940458,0.0003687327,0.0018911159,0.0016112764,0.00005129336,0.0004793579,0.0002594376,0.000065283675,0.0012276879],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981631,0.0000571353,0.0004768493,0.0005916144,0.0003996659,0.00031161413],"domain_scores_gemma":[0.9990666,0.00007020382,0.00013213957,0.00050925155,0.000097429736,0.0001243545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020232695,0.00028377734,0.0006976119,0.00050594803,0.000055947712,0.000089431735,0.00022036326,0.00012826228,0.001140042],"category_scores_gemma":[0.000021529031,0.00019451685,0.0002313517,0.0012757462,0.00006527432,0.00022193324,0.00007785612,0.00020906063,0.000029896491],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027751062,0.0023321605,0.045248125,0.0003361658,0.005210171,0.00070782687,0.0078067076,0.00014429308,0.010708387,0.00023920629,0.000721304,0.8987946],"study_design_scores_gemma":[0.024880923,0.005159409,0.848433,0.0072396044,0.0036177218,0.00003212738,0.00072651904,0.008798874,0.06611458,0.00016715248,0.03401309,0.00081695936],"about_ca_topic_score_codex":0.0004730482,"about_ca_topic_score_gemma":0.00020345084,"teacher_disagreement_score":0.89797765,"about_ca_system_score_codex":0.00038395327,"about_ca_system_score_gemma":0.00033119408,"threshold_uncertainty_score":0.999773},"labels":[],"label_agreement":null},{"id":"W4393204492","doi":"10.1016/j.jtocrr.2024.100669","title":"Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Sanofi Genzyme; AstraZeneca Korea; EMD Serono; Genentech; Daiichi-Sankyo; G1 Therapeutics; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Sanofi; Amgen; American Association for Cancer Research; Eli Lilly and Company; Bristol-Myers Squibb; Seagen; LUNGevity Foundation; Pfizer","keywords":"Osimertinib; Oncology; Medicine; Retrospective cohort study; Cohort; Internal medicine; Mutant; Term (time); Cancer; Epidermal growth factor receptor; Biology; Genetics; Gene; Erlotinib","score_opus":0.10945630966295825,"score_gpt":0.5031910424772752,"score_spread":0.3937347328143169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393204492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942521,0.0011565253,0.00009033028,0.001530055,0.00026236978,0.0004901808,0.000017548238,0.000032310327,0.0021685797],"genre_scores_gemma":[0.9950751,0.0011016626,0.00020522256,0.000040256462,0.00015196315,0.00003344049,0.000038299127,0.000019103478,0.003334938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979899,0.00010665417,0.0006277846,0.00035318092,0.00068868254,0.00023378144],"domain_scores_gemma":[0.9984309,0.0005447527,0.00007907847,0.00028828267,0.00039303675,0.0002639262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018433224,0.00009712295,0.0003776141,0.00012078689,0.00006730251,0.0000460365,0.000030470217,0.00005611594,0.000116508],"category_scores_gemma":[0.0005513293,0.00005298409,0.00008951641,0.000275555,0.00045037514,0.00005682743,0.000048839553,0.00035888434,0.000009171876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028449297,0.0006269795,0.87991023,0.0010556272,0.0008261463,0.025044085,0.00026200165,1.4414587e-7,0.0001735409,0.00023890755,0.00053874194,0.091039084],"study_design_scores_gemma":[0.0006412545,0.0016578182,0.98875105,0.0010564029,0.0004798061,0.0013735825,0.000077152115,0.00004724607,0.00024174641,0.00031897597,0.005256878,0.00009808042],"about_ca_topic_score_codex":0.00017763268,"about_ca_topic_score_gemma":0.00007179462,"teacher_disagreement_score":0.10884081,"about_ca_system_score_codex":0.000038648002,"about_ca_system_score_gemma":0.00069276465,"threshold_uncertainty_score":0.21606286},"labels":[],"label_agreement":null},{"id":"W4393230429","doi":"10.37766/inplasy2024.3.0114","title":"Efficacy and Safety of neoadjuvant tislelizumab plus chemotherapy for the Treatment of non-small cell lung cancer: A Single-Arm Meta-Analysis Among Chinese Patients","year":2024,"lang":"en","type":"report","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Medicine; Chemotherapy; Oncology; Internal medicine; Lung cancer","score_opus":0.03333978379735843,"score_gpt":0.3540281697519227,"score_spread":0.3206883859545643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393230429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68749577,0.24753907,0.0031113257,0.001485215,0.0013262153,0.021841528,0.0064202263,0.00012197059,0.03065866],"genre_scores_gemma":[0.93347836,0.027336443,0.0011149099,0.00006499463,0.00017759185,0.0015522233,0.0011818855,0.00013748182,0.034956127],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99765563,0.00002200567,0.00092722004,0.0005920527,0.00055053266,0.00025257663],"domain_scores_gemma":[0.9976129,0.00034389086,0.0006592716,0.0006483334,0.00061670714,0.000118919466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013438112,0.0005506637,0.002621463,0.00030966164,0.00007410127,0.000023402863,0.00010372882,0.00019330558,0.0003880181],"category_scores_gemma":[0.000015686946,0.00025709928,0.0020609524,0.0004995322,0.000103496444,0.000027627075,0.000027242364,0.000100588935,5.2569175e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015070625,0.006501224,0.022233205,0.0032004125,0.9055432,0.000026361056,0.005275342,0.0010318845,0.000077773766,0.000006844374,0.0024795767,0.052117098],"study_design_scores_gemma":[0.013029989,0.0032618593,0.03193219,0.00014832149,0.9373564,0.0000035922285,0.00012237998,0.0018967192,0.00085460267,0.0000060686903,0.011061088,0.00032675546],"about_ca_topic_score_codex":0.009464331,"about_ca_topic_score_gemma":0.0017457815,"teacher_disagreement_score":0.24598256,"about_ca_system_score_codex":0.0010819297,"about_ca_system_score_gemma":0.001057244,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W4393654220","doi":"10.5281/zenodo.6929428","title":"HGG-oncohistones processed data","year":2022,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Computer science","score_opus":0.06497695503065935,"score_gpt":0.3431624862031819,"score_spread":0.27818553117252254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393654220","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038447804,0.00049271877,0.000041476076,0.00097537495,0.00022515909,0.0008538022,0.9791771,0.00043297812,0.017762927],"genre_scores_gemma":[0.0001724542,0.0005172419,0.000087045686,0.00035472534,0.00025221036,2.2579053e-7,0.9950569,0.0011645638,0.0023945987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785686,0.00016649361,0.0002937799,0.0007316588,0.0006251684,0.00032601654],"domain_scores_gemma":[0.9974758,0.0000210792,0.00018312056,0.0017044764,0.000400343,0.00021517705],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035663747,0.0002277315,0.0002973399,0.00031301673,0.002260745,0.0004372141,0.0015757056,0.00009838875,0.27176687],"category_scores_gemma":[0.0005502611,0.00022282514,0.000056441488,0.00055864174,0.00012833173,0.00023992904,0.0026556212,0.0005283491,0.004576111],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000896045,0.00038439393,3.511144e-7,0.0003913838,0.00023397716,0.00010677477,0.00014024736,0.0000021633803,0.00003455742,0.000033832654,0.9851582,0.013424486],"study_design_scores_gemma":[0.00097035547,0.0003921233,0.000039004724,0.00005206955,0.00035866883,0.000316873,0.00020879233,0.0000131427105,0.000007016232,0.000014791999,0.99742466,0.00020250298],"about_ca_topic_score_codex":0.000114090166,"about_ca_topic_score_gemma":0.0000016040439,"teacher_disagreement_score":0.26719075,"about_ca_system_score_codex":0.0004975102,"about_ca_system_score_gemma":0.00004706402,"threshold_uncertainty_score":0.99903816},"labels":[],"label_agreement":null},{"id":"W4393732101","doi":"10.5281/zenodo.6773261","title":"HGG-oncohistones processed data","year":2022,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Computer science","score_opus":0.06497695503065935,"score_gpt":0.3431624862031819,"score_spread":0.27818553117252254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393732101","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038447804,0.00049271877,0.000041476076,0.00097537495,0.00022515909,0.0008538022,0.9791771,0.00043297812,0.017762927],"genre_scores_gemma":[0.0001724542,0.0005172419,0.000087045686,0.00035472534,0.00025221036,2.2579053e-7,0.9950569,0.0011645638,0.0023945987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785686,0.00016649361,0.0002937799,0.0007316588,0.0006251684,0.00032601654],"domain_scores_gemma":[0.9974758,0.0000210792,0.00018312056,0.0017044764,0.000400343,0.00021517705],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035663747,0.0002277315,0.0002973399,0.00031301673,0.002260745,0.0004372141,0.0015757056,0.00009838875,0.27176687],"category_scores_gemma":[0.0005502611,0.00022282514,0.000056441488,0.00055864174,0.00012833173,0.00023992904,0.0026556212,0.0005283491,0.004576111],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000896045,0.00038439393,3.511144e-7,0.0003913838,0.00023397716,0.00010677477,0.00014024736,0.0000021633803,0.00003455742,0.000033832654,0.9851582,0.013424486],"study_design_scores_gemma":[0.00097035547,0.0003921233,0.000039004724,0.00005206955,0.00035866883,0.000316873,0.00020879233,0.0000131427105,0.000007016232,0.000014791999,0.99742466,0.00020250298],"about_ca_topic_score_codex":0.000114090166,"about_ca_topic_score_gemma":0.0000016040439,"teacher_disagreement_score":0.26719075,"about_ca_system_score_codex":0.0004975102,"about_ca_system_score_gemma":0.00004706402,"threshold_uncertainty_score":0.99903816},"labels":[],"label_agreement":null},{"id":"W4393853520","doi":"10.3390/curroncol31040146","title":"Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Janssen Canada; Princess Margaret Cancer Foundation","keywords":"Osimertinib; Medicine; Lung cancer; Discontinuation; Oncology; Internal medicine; Epidermal growth factor receptor; Cohort; Targeted therapy; Cancer; Erlotinib","score_opus":0.05602456726675455,"score_gpt":0.4146253927043479,"score_spread":0.35860082543759336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393853520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859807,0.001202937,0.0059350524,0.00018905211,0.00079626584,0.0008411269,0.004929462,0.000030282297,0.00009513255],"genre_scores_gemma":[0.9960393,0.000093773124,0.0011333037,0.0000586058,0.000033015487,0.0000628731,0.0025011655,0.00003299617,0.000044970366],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984669,0.000051973813,0.00046712157,0.00043911845,0.00021435565,0.00036050373],"domain_scores_gemma":[0.99912125,0.00014672399,0.0001602253,0.00029764257,0.00014716429,0.00012700263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006818154,0.00021568188,0.0004614415,0.00017209955,0.000039894043,0.000009186798,0.00015363056,0.00005553372,0.00014380866],"category_scores_gemma":[0.00003016816,0.00016740317,0.000034546087,0.00040688633,0.00003912127,0.0001225085,0.000052557043,0.00026475024,0.0000011687584],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043795898,0.001343449,0.9479795,0.0008601501,0.00023583866,0.000071874056,0.0014426308,0.005101222,0.0018711354,0.00002800376,0.0011631993,0.039465006],"study_design_scores_gemma":[0.0040638275,0.00035160076,0.14477275,0.0010239313,0.001038629,9.026402e-7,0.00079144724,0.83647096,0.009312212,0.000011964311,0.001573102,0.00058866176],"about_ca_topic_score_codex":0.19239052,"about_ca_topic_score_gemma":0.56683296,"teacher_disagreement_score":0.83136976,"about_ca_system_score_codex":0.0024845842,"about_ca_system_score_gemma":0.005739216,"threshold_uncertainty_score":0.9998973},"labels":[],"label_agreement":null},{"id":"W4393988317","doi":"10.1158/1538-7445.am2024-ct054","title":"Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chemotherapy; Medicine; Cancer; Oncology; Lung cancer; Cancer research; Disease; Internal medicine","score_opus":0.03345896056272359,"score_gpt":0.4453993473951861,"score_spread":0.41194038683246254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97636306,0.011637322,0.0000024312071,0.0077211917,0.0002451068,0.003122388,0.0005049156,0.00005488347,0.000348675],"genre_scores_gemma":[0.9938988,0.0026144716,0.000027978456,0.00022764223,0.00041003225,0.0019840044,0.00016182926,0.000064053966,0.0006111715],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99783254,0.00009619493,0.00032580606,0.00071874546,0.00060403376,0.00042269466],"domain_scores_gemma":[0.9988808,0.00022231245,0.000049117367,0.00043542183,0.0001712208,0.00024113555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042911552,0.00022512722,0.00024039827,0.00019090483,0.00014960267,0.00013416815,0.00009225432,0.00006864402,0.00019900709],"category_scores_gemma":[0.000047674028,0.00014189669,0.00005845206,0.0005843636,0.000112145295,0.00014983315,0.00006326938,0.000599047,0.000012824557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08335944,0.017394258,0.1419186,0.0025519447,0.0013376094,0.0066661844,0.07564011,0.00026022227,0.059856635,0.0000236625,0.02256058,0.58843076],"study_design_scores_gemma":[0.07373051,0.0034053675,0.8501734,0.015096773,0.00074247835,0.000005304202,0.0045144074,0.0019587257,0.037512638,0.00023460065,0.011852308,0.00077344844],"about_ca_topic_score_codex":0.0030697477,"about_ca_topic_score_gemma":0.0015510152,"teacher_disagreement_score":0.7082548,"about_ca_system_score_codex":0.0008241683,"about_ca_system_score_gemma":0.0008898981,"threshold_uncertainty_score":0.5786379},"labels":[],"label_agreement":null},{"id":"W4393988656","doi":"10.1158/1538-7445.am2024-ct282","title":"Abstract CT282: MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with <i>EGFR</i> mutations or other genomic alterations","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Chemotherapy; non-small cell lung cancer (NSCLC); Phases of clinical research; Internal medicine; Oncology; Lung cancer","score_opus":0.07977450229271568,"score_gpt":0.4745303498865178,"score_spread":0.3947558475938021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782679,0.005262081,0.0007859816,0.0009909662,0.000291221,0.01230589,0.0011875639,0.00013304314,0.00077537325],"genre_scores_gemma":[0.97034883,0.0010585802,0.0016279045,0.0001540525,0.0002736568,0.014319671,0.00019507165,0.00022743295,0.0117947785],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968525,0.00011143423,0.00065495766,0.00088687736,0.00066801725,0.00082620303],"domain_scores_gemma":[0.99723524,0.0008126131,0.00017086913,0.00064402336,0.00080486166,0.0003324213],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003937417,0.0004407985,0.00070832734,0.0005416739,0.00042564585,0.00015506118,0.0002549743,0.00008740051,0.0014549037],"category_scores_gemma":[0.000060575945,0.00029136796,0.00016655638,0.0013576213,0.00018658847,0.0002543704,0.000035791152,0.00042590126,0.000019594887],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19803211,0.0441854,0.008857709,0.021179583,0.036172263,0.0024761984,0.15252674,0.016779045,0.28394306,0.00020539177,0.029201925,0.20644058],"study_design_scores_gemma":[0.56109965,0.09761496,0.0074107,0.01371587,0.02262901,0.00015808381,0.0516485,0.022906905,0.15629555,0.000113135786,0.0622626,0.004145053],"about_ca_topic_score_codex":0.0044183107,"about_ca_topic_score_gemma":0.010486145,"teacher_disagreement_score":0.3630675,"about_ca_system_score_codex":0.0014944386,"about_ca_system_score_gemma":0.0046804273,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4393988822","doi":"10.1158/1538-7445.am2024-ct284","title":"Abstract CT284: A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring <i>HER2</i> tyrosine kinase domain mutations: Beamion LUNG-2","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Standard of care; Internal medicine; Oncology; Randomized controlled trial; Lung cancer; Cancer","score_opus":0.018943181692577412,"score_gpt":0.3876808565188834,"score_spread":0.368737674826306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685848,0.010582222,0.0009377999,0.00018815148,0.00021820406,0.018230082,0.0009058507,0.000039227423,0.00031370614],"genre_scores_gemma":[0.98832273,0.00050078327,0.0017578577,0.00002055259,0.000074697375,0.008767008,0.0002782504,0.00008979641,0.00018831065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99610215,0.00031157688,0.001119836,0.00059696665,0.0012885577,0.00058092776],"domain_scores_gemma":[0.995929,0.0012198297,0.000349051,0.00040488443,0.0018665625,0.00023069157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009562328,0.00037215985,0.0020964013,0.0006616124,0.00012195233,0.000060395625,0.00016166942,0.00007645872,0.00022794929],"category_scores_gemma":[0.00021741202,0.00022391957,0.00020788479,0.0013665288,0.0003723238,0.00019729362,0.00003566059,0.00047298914,0.0000012010444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97891146,0.0016053099,0.0011839244,0.003542138,0.0013294114,0.00019941234,0.0068484317,0.0019190658,0.0015162285,0.000025558455,0.00007070364,0.0028483474],"study_design_scores_gemma":[0.9783042,0.005055798,0.0004875374,0.0058525675,0.0018048723,0.0000011275888,0.001896211,0.0010428126,0.005214765,0.000012187674,0.00007726362,0.00025065642],"about_ca_topic_score_codex":0.0019035051,"about_ca_topic_score_gemma":0.002918147,"teacher_disagreement_score":0.019737989,"about_ca_system_score_codex":0.0014678843,"about_ca_system_score_gemma":0.0050257626,"threshold_uncertainty_score":0.9131175},"labels":[],"label_agreement":null},{"id":"W4393989833","doi":"10.1158/1538-7445.am2024-ct280","title":"Abstract CT280: FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Exon; Oncology; Chemotherapy; Internal medicine; Phases of clinical research; Biology; Genetics; Gene","score_opus":0.17402331634901724,"score_gpt":0.5215673596128443,"score_spread":0.34754404326382704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393989833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969908,0.0056248372,0.00022426718,0.012988578,0.00041718644,0.005631805,0.00038469562,0.00024600243,0.0045746267],"genre_scores_gemma":[0.97924596,0.0012605973,0.0010379392,0.0002024238,0.0012220782,0.007569552,0.0003488154,0.00011247906,0.009000147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975601,0.00004170805,0.00040428946,0.0007001922,0.0005821077,0.0007115911],"domain_scores_gemma":[0.9980373,0.00063121505,0.00007311237,0.00044205232,0.00047583657,0.00034051025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003529335,0.00030442968,0.0004212157,0.00031203995,0.0004658529,0.00013556393,0.00012527492,0.00010693864,0.0005988935],"category_scores_gemma":[0.00017614773,0.00021116651,0.00018027703,0.00086176523,0.00014503274,0.00019304136,0.00002081224,0.00031864955,0.00006357646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19169329,0.0055323155,0.00050481706,0.0010188916,0.002307311,0.00049114553,0.0034964974,0.0005776843,0.038275428,0.00032258115,0.008276612,0.7475034],"study_design_scores_gemma":[0.38583443,0.05131693,0.0020618786,0.0037688112,0.0010418269,0.00008370145,0.00085743645,0.0015517717,0.051306307,0.0007569127,0.50059843,0.00082158565],"about_ca_topic_score_codex":0.001212189,"about_ca_topic_score_gemma":0.0009012049,"teacher_disagreement_score":0.74668187,"about_ca_system_score_codex":0.0016188051,"about_ca_system_score_gemma":0.0020526615,"threshold_uncertainty_score":0.861112},"labels":[],"label_agreement":null},{"id":"W4394089302","doi":"10.6084/m9.figshare.20882171","title":"Additional file 8 of Strategies for understanding the role of cellular heterogeneity in the pathogenesis of lung cancer: a cell model for chronic exposure to cigarette smoke extract","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Food Inspection Agency","funders":"","keywords":"Cigarette smoke; Pathogenesis; Lung cancer; Cancer research; Medicine; Smoke; Bioinformatics; Biology; Pathology; Chemistry; Environmental health","score_opus":0.05424679838386833,"score_gpt":0.3227293049134099,"score_spread":0.2684825065295416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394089302","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025016492,0.002332645,0.000022541682,0.000028684439,0.000017584736,0.0019006555,0.9956287,0.0000037224268,0.00004044971],"genre_scores_gemma":[0.0053493534,0.000020702171,0.00004567746,0.000065209235,0.000074424934,0.014896027,0.9794958,0.000021075764,0.00003171848],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998958,0.000033138567,0.00031880365,0.00022489205,0.00029099392,0.00017417777],"domain_scores_gemma":[0.99819976,0.000922485,0.00035672396,0.00037167902,0.00011845364,0.00003092212],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005059684,0.0001751633,0.00033222706,0.000068552625,0.00009696486,0.00001081161,0.00025357038,0.00009990851,0.74583346],"category_scores_gemma":[0.000117154865,0.00011892025,0.00023768381,0.00012820185,0.000012478931,0.000047115635,0.00004985013,0.00011107022,4.548328e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006601736,0.00012077109,8.8765415e-7,0.0018095326,0.00018668576,0.0000018617619,0.00026624423,0.0029625087,0.00006814678,0.0000043568602,0.99442095,0.00009204053],"study_design_scores_gemma":[0.0008810033,0.000607552,0.00009330105,0.0028460629,0.0006760779,0.0000020437224,0.0022682103,0.004080891,0.00028524472,0.00011095406,0.98796946,0.00017922944],"about_ca_topic_score_codex":0.00013332213,"about_ca_topic_score_gemma":0.001115582,"teacher_disagreement_score":0.74583304,"about_ca_system_score_codex":0.00045596203,"about_ca_system_score_gemma":0.0014216235,"threshold_uncertainty_score":0.4849427},"labels":[],"label_agreement":null},{"id":"W4394089371","doi":"10.6084/m9.figshare.24038712","title":"Additional file 1 of A gene mutation-based risk model for prognostic prediction in liver metastases","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Mutation; Gene; Internal medicine; Oncology; Computational biology; Computer science; Bioinformatics; Medicine; Genetics; Biology","score_opus":0.0440460397261694,"score_gpt":0.31331501049014476,"score_spread":0.2692689707639754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394089371","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.3017853e-7,0.00006531701,0.000007756776,0.000008463359,0.000021194755,0.001329122,0.99851805,0.00003581684,0.000014071034],"genre_scores_gemma":[0.0000018667258,0.0000031253278,0.0015176372,0.000050972736,0.000104113955,0.021035768,0.9767606,0.000026373838,0.00049951253],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910235,0.000019804032,0.00025866588,0.00025642384,0.00022455955,0.00013816946],"domain_scores_gemma":[0.9972711,0.0019888654,0.0002478041,0.00018953216,0.0002449177,0.000057789355],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000016855565,0.00016002032,0.00025592875,0.00024094392,0.000046193094,0.000009137711,0.000058852303,0.0001324369,0.89759445],"category_scores_gemma":[0.005074243,0.00014614398,0.00013544637,0.00019836499,0.0000072472,0.000043686712,0.000012770739,0.00012406782,0.0014402989],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004039184,0.00020231736,6.5469715e-7,0.00097135507,0.00017052676,0.000038471746,0.000012185682,0.0029590668,7.224216e-8,3.3541077e-8,0.9953666,0.00023833271],"study_design_scores_gemma":[0.0009964125,0.00020881175,0.0006828807,0.0057255137,0.00056467415,0.000004500302,0.000008713597,0.07701376,0.000004942125,0.0000092551545,0.91467476,0.00010574824],"about_ca_topic_score_codex":0.00009166291,"about_ca_topic_score_gemma":0.00029907742,"teacher_disagreement_score":0.89615417,"about_ca_system_score_codex":0.00012879487,"about_ca_system_score_gemma":0.0010094985,"threshold_uncertainty_score":0.9993372},"labels":[],"label_agreement":null},{"id":"W4394094464","doi":"10.6084/m9.figshare.20882174","title":"Additional file 9 of Strategies for understanding the role of cellular heterogeneity in the pathogenesis of lung cancer: a cell model for chronic exposure to cigarette smoke extract","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Food Inspection Agency","funders":"","keywords":"Pathogenesis; Cigarette smoke; Lung cancer; Medicine; Cancer; Cancer research; Bioinformatics; Biology; Pathology; Environmental health; Internal medicine","score_opus":0.05425387557901887,"score_gpt":0.32274300455642785,"score_spread":0.26848912897740895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394094464","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024912506,0.0023323367,0.000022561437,0.000028685054,0.000017585236,0.0019001296,0.9956298,0.0000037460977,0.000040236766],"genre_scores_gemma":[0.005334305,0.000020941496,0.00004562818,0.00006521785,0.00007444799,0.014799768,0.9796071,0.000021093623,0.000031504704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998958,0.00003313735,0.00031880193,0.00022486772,0.00029102986,0.00017416352],"domain_scores_gemma":[0.9982,0.00092234986,0.00035668182,0.00037157608,0.00011844696,0.000030918258],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000050587074,0.00017514362,0.0003321774,0.00006856777,0.000096969925,0.000010809579,0.00025339855,0.00009989307,0.7450259],"category_scores_gemma":[0.00011714924,0.00011890705,0.00023767844,0.00012826754,0.000012478663,0.000047121397,0.00004983738,0.000111032816,4.5305032e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006602528,0.00012079283,8.942623e-7,0.0018096187,0.00018667658,0.0000018616488,0.00026627237,0.002962455,0.00006865785,0.0000043008267,0.99442255,0.00008987904],"study_design_scores_gemma":[0.00088011636,0.00060609414,0.00009392956,0.0028441688,0.00067557907,0.0000020423067,0.002267277,0.0040783677,0.00028151323,0.00011090477,0.9879809,0.00017908493],"about_ca_topic_score_codex":0.00013092837,"about_ca_topic_score_gemma":0.0011139658,"teacher_disagreement_score":0.74502546,"about_ca_system_score_codex":0.0004558737,"about_ca_system_score_gemma":0.0014208627,"threshold_uncertainty_score":0.48488888},"labels":[],"label_agreement":null},{"id":"W4394156934","doi":"10.6084/m9.figshare.24038715","title":"Additional file 2 of A gene mutation-based risk model for prognostic prediction in liver metastases","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gene; Mutation; Internal medicine; Computer science; Medicine; Computational biology; Oncology; Bioinformatics; Genetics; Biology","score_opus":0.04238411470020088,"score_gpt":0.31262650442352596,"score_spread":0.2702423897233251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394156934","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.284725e-7,0.00006643839,0.0000075758444,0.000008415035,0.000021325823,0.0013264058,0.9985194,0.00003580312,0.000014416195],"genre_scores_gemma":[0.0000018345647,0.0000032156424,0.001482132,0.000050991934,0.000105816216,0.020615676,0.97721255,0.000026342304,0.00050145376],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991026,0.000019796766,0.0002587912,0.00025621592,0.00022449876,0.00013811435],"domain_scores_gemma":[0.997302,0.0019585725,0.00024818332,0.0001891419,0.000244333,0.00005778119],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000016756061,0.0001599653,0.00025599654,0.00024077336,0.000046196754,0.000009159163,0.000058816877,0.00013243772,0.8956878],"category_scores_gemma":[0.005008366,0.00014609232,0.00013541806,0.00019819824,0.0000072470916,0.000043719094,0.000012768796,0.00012403693,0.0014237101],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040129915,0.00020212447,6.318923e-7,0.000980282,0.00017042602,0.000039587918,0.000012189473,0.0029726229,6.949878e-8,3.415936e-8,0.99533653,0.0002453964],"study_design_scores_gemma":[0.0010003687,0.00020813843,0.00066871796,0.005630259,0.00056054816,0.000004495741,0.000008588099,0.07622651,0.0000048921706,0.000009303087,0.915573,0.00010514893],"about_ca_topic_score_codex":0.000092662274,"about_ca_topic_score_gemma":0.00030099176,"teacher_disagreement_score":0.8942641,"about_ca_system_score_codex":0.00012883476,"about_ca_system_score_gemma":0.0010046453,"threshold_uncertainty_score":0.9993538},"labels":[],"label_agreement":null},{"id":"W4394183764","doi":"10.6084/m9.figshare.22616578","title":"Additional file 4 of Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer","year":2023,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Stage (stratigraphy); Medicine; Biopsy; Liquid biopsy; Lung cancer; Cancer; Lung; Oncology; Pathology; Radiology; Internal medicine; Biology","score_opus":0.04250284888631415,"score_gpt":0.3961725723217694,"score_spread":0.3536697234354552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394183764","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054703667,0.000036380232,6.998015e-7,0.000031463725,0.00024485108,0.00090592424,0.9921414,9.3263645e-7,0.0011679502],"genre_scores_gemma":[0.00015884265,0.00007673423,0.0011111276,0.000019249606,0.00015970442,0.00039642342,0.98950773,0.000017655697,0.008552516],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838936,0.00005346199,0.0007045569,0.0004204117,0.00024518798,0.00018700406],"domain_scores_gemma":[0.99847853,0.00040755025,0.00042792028,0.00044676542,0.00013173277,0.00010747445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015903545,0.00018300599,0.00063598744,0.00013200229,0.000026988968,0.0000141824285,0.00027980705,0.00027510268,0.73556125],"category_scores_gemma":[0.0001427709,0.00016196919,0.0001756359,0.00021779275,0.00011167631,0.000051746585,0.00021573578,0.00030688115,0.0004692592],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038292995,0.0006229337,0.0002111822,0.00022111858,0.00023480867,0.00013748553,0.00003949249,0.0000023759478,0.000004297786,2.0480071e-8,0.9974378,0.00070558314],"study_design_scores_gemma":[0.0016411054,0.00033564173,0.026357073,0.0012134736,0.00050118356,0.0000024089945,0.00006216072,0.00004009338,0.000057223784,4.7732726e-7,0.96965736,0.00013177906],"about_ca_topic_score_codex":0.007606057,"about_ca_topic_score_gemma":0.0022940098,"teacher_disagreement_score":0.73509204,"about_ca_system_score_codex":0.000069743146,"about_ca_system_score_gemma":0.0017188261,"threshold_uncertainty_score":0.9990024},"labels":[],"label_agreement":null},{"id":"W4394297992","doi":"10.6084/m9.figshare.20882159","title":"Additional file 5 of Strategies for understanding the role of cellular heterogeneity in the pathogenesis of lung cancer: a cell model for chronic exposure to cigarette smoke extract","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Food Inspection Agency","funders":"","keywords":"Pathogenesis; Cigarette smoke; Lung cancer; Medicine; Cancer; Cancer research; Bioinformatics; Biology; Pathology; Environmental health; Internal medicine","score_opus":0.054237072568887296,"score_gpt":0.32272710627270307,"score_spread":0.26849003370381574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394297992","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002492821,0.0023290142,0.00002249137,0.000028640154,0.000017584034,0.0019006215,0.9956328,0.0000037460907,0.000040159604],"genre_scores_gemma":[0.005340619,0.000020932812,0.00004566234,0.00006520228,0.000074446965,0.014896476,0.97950417,0.000021103333,0.000031401174],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895793,0.000033137847,0.0003188041,0.00022489787,0.0002910498,0.00017415667],"domain_scores_gemma":[0.99819994,0.0009222863,0.00035671558,0.00037167984,0.00011842766,0.00003092137],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000050596198,0.00017515618,0.00033222578,0.00006856667,0.000096967684,0.000010807676,0.00025357486,0.00009991234,0.7457342],"category_scores_gemma":[0.000117143485,0.000118914686,0.00023769823,0.00012827301,0.0000124782455,0.000047117515,0.00004985789,0.00011106423,4.5134072e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006602517,0.000120793855,8.9370786e-7,0.0018094108,0.00018666968,0.0000018616585,0.00026596768,0.0029571292,0.000068697766,0.0000043827627,0.9944274,0.000090792215],"study_design_scores_gemma":[0.00088338996,0.0006080226,0.00009516769,0.0028524918,0.0006778302,0.0000020488608,0.002274955,0.004062575,0.00028228137,0.00011069596,0.9879709,0.00017967555],"about_ca_topic_score_codex":0.00013348223,"about_ca_topic_score_gemma":0.0011163293,"teacher_disagreement_score":0.7457338,"about_ca_system_score_codex":0.0004559085,"about_ca_system_score_gemma":0.001421045,"threshold_uncertainty_score":0.48492002},"labels":[],"label_agreement":null},{"id":"W4394306511","doi":"10.6084/m9.figshare.21062529","title":"DNA repair in lung cancer: a large-scale quantitative analysis for polymorphisms in DNA repairing pathway genes and lung cancer susceptibility","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Waterloo","funders":"","keywords":"Lung cancer; Gene; DNA repair; Genetics; Biology; DNA; Lung cancer susceptibility; Cancer; Cancer research; Medicine; Oncology; Single-nucleotide polymorphism; Genotype","score_opus":0.031744491755595544,"score_gpt":0.36397842928458735,"score_spread":0.3322339375289918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394306511","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004948961,0.0260158,0.0000010209911,0.00021143608,0.00012240192,0.0021415174,0.9664744,0.00007004138,0.000014414652],"genre_scores_gemma":[0.0010359635,0.00060182874,0.00013046304,0.0002570296,0.00011022327,0.009142828,0.9883539,0.00004494644,0.0003228175],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973566,0.000117820935,0.00060440175,0.0010639685,0.00033604325,0.0005212013],"domain_scores_gemma":[0.99843574,0.00026770993,0.00032827206,0.00066197774,0.00014967863,0.00015664584],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020668977,0.00041583745,0.0010033724,0.0006973252,0.00018257782,0.000027677508,0.0001585944,0.000232824,0.13897032],"category_scores_gemma":[0.0003467587,0.0003963156,0.000406091,0.0011502379,0.000017542397,0.0001324452,0.00019928886,0.00039582502,0.0000033723995],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000193857,0.00026965034,0.033968236,0.0024550108,0.0017765065,0.00014279463,0.00093504833,0.00026127687,0.000015986116,7.775767e-7,0.9597795,0.00020137796],"study_design_scores_gemma":[0.0039687846,0.00026445033,0.0587035,0.0044036475,0.0045497557,0.0000059338663,0.00074265373,0.008486075,0.000069045665,0.0000042700913,0.91805357,0.0007483198],"about_ca_topic_score_codex":0.009472685,"about_ca_topic_score_gemma":0.15848309,"teacher_disagreement_score":0.1490104,"about_ca_system_score_codex":0.001705238,"about_ca_system_score_gemma":0.000987394,"threshold_uncertainty_score":0.9998489},"labels":[],"label_agreement":null},{"id":"W4394338685","doi":"10.6084/m9.figshare.20882168","title":"Additional file 7 of Strategies for understanding the role of cellular heterogeneity in the pathogenesis of lung cancer: a cell model for chronic exposure to cigarette smoke extract","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Food Inspection Agency","funders":"","keywords":"Cigarette smoke; Lung cancer; Pathogenesis; Biology; Cancer research; Computational biology; Bioinformatics; Medicine; Pathology; Immunology; Toxicology","score_opus":0.05428461012460663,"score_gpt":0.322763690183485,"score_spread":0.2684790800588784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394338685","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002492078,0.0023307614,0.000022520631,0.00002865007,0.000017587066,0.001900413,0.9956312,0.0000037461964,0.000040161136],"genre_scores_gemma":[0.005322377,0.000020970603,0.000045652978,0.00006520383,0.000074456795,0.014883916,0.9795349,0.0000211064,0.000031407184],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989579,0.000033130378,0.0003188093,0.0002249205,0.00029105358,0.00017418692],"domain_scores_gemma":[0.99820054,0.0009216995,0.000356704,0.0003716965,0.00011844505,0.00003092431],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005059528,0.00017516817,0.00033222945,0.00006857117,0.00009696985,0.000010813015,0.00025360144,0.00009990992,0.74316025],"category_scores_gemma":[0.00011597843,0.00011892579,0.00023768573,0.00012827394,0.000012480019,0.00004712309,0.00004986157,0.0001110734,4.5224454e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006601548,0.000120797835,8.9295065e-7,0.0018245203,0.00018669455,0.0000018618498,0.00026631178,0.0029616237,0.00006886351,0.000004371952,0.99440676,0.000091272654],"study_design_scores_gemma":[0.0008800317,0.0006066399,0.000092966504,0.002867945,0.0006752512,0.000002040618,0.0022647963,0.004072795,0.0002823377,0.00011078356,0.9879654,0.00017901653],"about_ca_topic_score_codex":0.00013356088,"about_ca_topic_score_gemma":0.0011168086,"teacher_disagreement_score":0.7431598,"about_ca_system_score_codex":0.00045598365,"about_ca_system_score_gemma":0.0014214801,"threshold_uncertainty_score":0.4849653},"labels":[],"label_agreement":null},{"id":"W4394384460","doi":"10.6084/m9.figshare.20013097","title":"Additional file 3 of Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Immunotherapy; Signature (topology); Identification (biology); Gene signature; Cancer research; Transforming growth factor; Adenocarcinoma; Computational biology; Lung; Gene; Biology; Medicine; Oncology; Internal medicine; Cancer; Gene expression; Genetics; Mathematics","score_opus":0.01704100870408829,"score_gpt":0.2847756540904457,"score_spread":0.2677346453863574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394384460","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014184656,0.0055041937,0.0000026773196,0.000016705626,0.00005200098,0.0021739572,0.99222094,0.000012003979,0.0000033504457],"genre_scores_gemma":[0.0000679957,0.00007664762,0.00021018405,0.000029635192,0.00006607857,0.007508613,0.9916891,0.000029630359,0.00032213805],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988713,0.000024283425,0.00051201,0.0002598652,0.00022812399,0.00010436936],"domain_scores_gemma":[0.9977349,0.00069107185,0.00082417106,0.00024968307,0.00046754573,0.000032605072],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000036669982,0.00016722373,0.00037796752,0.00017686922,0.00007307177,0.0000056244676,0.00008988785,0.00022180103,0.96029645],"category_scores_gemma":[0.0004170701,0.00015442846,0.00019865729,0.00015964404,0.000017306518,0.000047774905,0.00001675419,0.00012366663,0.0000017218764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038931755,0.00021327309,0.0000015171026,0.0012168497,0.0009149731,7.859221e-7,0.00007096168,0.000018731367,0.0016820373,3.0031984e-7,0.995005,0.00048626077],"study_design_scores_gemma":[0.002746154,0.0008941367,0.0014238324,0.0017194861,0.00029444185,0.000006240816,0.000036045007,0.00016241206,0.003103335,0.000018929006,0.98948956,0.000105451516],"about_ca_topic_score_codex":0.000010618144,"about_ca_topic_score_gemma":0.0000014621803,"teacher_disagreement_score":0.9602947,"about_ca_system_score_codex":0.00007753415,"about_ca_system_score_gemma":0.00038081527,"threshold_uncertainty_score":0.629741},"labels":[],"label_agreement":null},{"id":"W4394400215","doi":"10.6084/m9.figshare.21339104","title":"Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies","year":2022,"lang":"en","type":"review","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Osimertinib; Meta-analysis; Randomized controlled trial; Oncology; Medicine; Internal medicine; Psychology; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.1024580156076927,"score_gpt":0.4091141145047187,"score_spread":0.306656098897026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394400215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.4185292e-7,0.83328193,4.1393633e-7,0.000022347498,0.0000048198353,0.028531166,0.13810925,0.000009198061,0.00004062999],"genre_scores_gemma":[0.00002167483,0.88785285,0.00004316885,0.000063472784,0.0000028716765,0.024640948,0.08712411,0.000029418088,0.00022151873],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969602,0.0005047171,0.0017969446,0.00032091822,0.0002985763,0.00011862657],"domain_scores_gemma":[0.9913817,0.005262284,0.0024392647,0.00034158002,0.0005118413,0.000063317886],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039585202,0.000383175,0.02668493,0.00026748006,0.00006219145,0.0000072558228,0.00006914207,0.00005692197,0.007942009],"category_scores_gemma":[0.006269624,0.0001734089,0.0027055712,0.00053733145,0.000027906079,0.000026857106,0.000051886072,0.00008181723,0.0000012565815],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031215793,0.00007913102,8.611607e-8,0.5367212,0.45925105,9.034426e-7,0.00006631082,2.8423744e-7,6.09689e-10,0.0000011394483,0.000390482,0.00036779448],"study_design_scores_gemma":[0.09530948,0.00017018664,8.9268184e-7,0.16131337,0.73602116,0.0000015978428,0.000014920005,0.0000028941884,1.4059596e-8,3.3688985e-7,0.007065642,0.000099521334],"about_ca_topic_score_codex":0.0000030851654,"about_ca_topic_score_gemma":0.000001598412,"teacher_disagreement_score":0.37540787,"about_ca_system_score_codex":0.000063962776,"about_ca_system_score_gemma":0.00016414681,"threshold_uncertainty_score":0.99296486},"labels":[],"label_agreement":null},{"id":"W4394421035","doi":"10.6084/m9.figshare.20882165","title":"Additional file 6 of Strategies for understanding the role of cellular heterogeneity in the pathogenesis of lung cancer: a cell model for chronic exposure to cigarette smoke extract","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Food Inspection Agency","funders":"","keywords":"Cigarette smoke; Lung cancer; Pathogenesis; Medicine; Biology; Cancer research; Bioinformatics; Pathology; Environmental health","score_opus":0.054231708386889434,"score_gpt":0.32269319048531064,"score_spread":0.2684614820984212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394421035","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024769022,0.0023358916,0.000022542199,0.000028663499,0.00001758555,0.0019031337,0.995623,0.0000037457128,0.000040648658],"genre_scores_gemma":[0.0053442623,0.000020903026,0.00004564755,0.000065199834,0.00007444854,0.014912591,0.97948426,0.000021103337,0.00003159022],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895793,0.00003313923,0.00031881078,0.00022490171,0.00029105096,0.00017417363],"domain_scores_gemma":[0.9981998,0.0009224256,0.00035672323,0.00037168467,0.00011845233,0.000030922918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000050597926,0.0001751581,0.0003322223,0.00006856536,0.00009695176,0.000010812682,0.00025359594,0.00009990755,0.7442244],"category_scores_gemma":[0.000117148484,0.00011891979,0.00023768138,0.00012827983,0.000012478964,0.000047121437,0.000049860042,0.00011107229,4.5228572e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000663385,0.00012134366,8.916311e-7,0.0018095988,0.0001866931,0.0000018610334,0.0002667392,0.0029178252,0.00006860283,0.000004419321,0.99446493,0.000090734284],"study_design_scores_gemma":[0.00087805954,0.00060404354,0.000093921444,0.002832375,0.0006733998,0.0000020339423,0.0022634354,0.0040127393,0.00027853673,0.00011052293,0.9880724,0.00017851968],"about_ca_topic_score_codex":0.00013479631,"about_ca_topic_score_gemma":0.0011348164,"teacher_disagreement_score":0.74422395,"about_ca_system_score_codex":0.0004553514,"about_ca_system_score_gemma":0.0014212715,"threshold_uncertainty_score":0.48494083},"labels":[],"label_agreement":null},{"id":"W4394433419","doi":"10.6084/m9.figshare.20013100","title":"Additional file 4 of Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Immunotherapy; Gene signature; Signature (topology); Identification (biology); Adenocarcinoma; Cancer research; Transforming growth factor; Medicine; Oncology; Lung; Computational biology; Gene; Internal medicine; Biology; Cancer; Gene expression; Genetics","score_opus":0.017171427475958657,"score_gpt":0.28518402014205485,"score_spread":0.26801259266609617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394433419","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014121785,0.0055230972,0.0000026933506,0.00001667631,0.00005155857,0.0021756818,0.9922008,0.000012019111,0.0000033420995],"genre_scores_gemma":[0.00006965082,0.00007666565,0.00021044903,0.0000296728,0.00006546501,0.007510905,0.99169594,0.00002963037,0.00031162694],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887115,0.000024280413,0.00051218417,0.00025989,0.00022811042,0.00010438064],"domain_scores_gemma":[0.99774164,0.0006923386,0.0008243067,0.00024980944,0.0004592982,0.000032606822],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000036697955,0.00016723479,0.00037805227,0.00017694736,0.00007310632,0.0000056273107,0.00008995067,0.00022181885,0.95968056],"category_scores_gemma":[0.00041153154,0.00015445633,0.00019867189,0.00015962466,0.000017309472,0.00004778154,0.000016760257,0.00012366299,0.0000016884654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039347497,0.00021354518,0.0000015215339,0.0012087625,0.00091571687,7.891466e-7,0.00007108631,0.000018497838,0.0016589013,3.10951e-7,0.9950311,0.0004862888],"study_design_scores_gemma":[0.0027511157,0.00091366883,0.0014382768,0.0017329993,0.000298201,0.000006337523,0.00003635083,0.00016385669,0.0030598603,0.00001921818,0.98947406,0.00010606199],"about_ca_topic_score_codex":0.0000105285735,"about_ca_topic_score_gemma":0.0000014678781,"teacher_disagreement_score":0.9596788,"about_ca_system_score_codex":0.000077250734,"about_ca_system_score_gemma":0.00037945985,"threshold_uncertainty_score":0.6298546},"labels":[],"label_agreement":null},{"id":"W4394518810","doi":"10.6084/m9.figshare.23498186","title":"Additional file 6 of Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort","year":2023,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Profiling (computer programming); Lung cancer; Cohort; Oncology; Molecular biomarkers; Internal medicine; Medicine; Computational biology; Biology; Computer science; Operating system","score_opus":0.011583293340298695,"score_gpt":0.32920468191778113,"score_spread":0.31762138857748246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394518810","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004856233,0.00020116204,2.7465575e-7,0.0000305468,0.00006365941,0.0021736396,0.99171627,0.0000011062265,0.0009571412],"genre_scores_gemma":[0.000045465258,0.00006691019,0.0020634288,0.000022938386,0.0000406651,0.0025101304,0.99404484,0.00002186329,0.001183769],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990437,0.000018200448,0.00025250352,0.00036363702,0.0001621043,0.00015982626],"domain_scores_gemma":[0.9991928,0.00029289853,0.00015521397,0.00021192993,0.00006550386,0.00008169781],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005803989,0.00018684335,0.000363301,0.00016046206,0.000030536165,0.000028688915,0.00012378482,0.00012016578,0.18896596],"category_scores_gemma":[0.00016672364,0.00015373886,0.000045202563,0.00026626798,0.000043561573,0.00004152656,0.00012411241,0.00013967692,0.00012320497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037079255,0.00013815239,0.003112001,0.00033978882,0.0004643038,0.000230893,0.000026751408,0.000004655044,0.000028063434,1.255518e-8,0.9949409,0.0006774215],"study_design_scores_gemma":[0.0020584837,0.00015503677,0.038294982,0.0041234693,0.0013527839,0.000016494823,0.00008509951,0.00017865741,0.00013308674,0.0000028358813,0.9532821,0.00031696315],"about_ca_topic_score_codex":0.0015546132,"about_ca_topic_score_gemma":0.0009986518,"teacher_disagreement_score":0.18884274,"about_ca_system_score_codex":0.000104631355,"about_ca_system_score_gemma":0.0009047971,"threshold_uncertainty_score":0.81177545},"labels":[],"label_agreement":null},{"id":"W4394609958","doi":"10.3390/curroncol31040159","title":"Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Immunotherapy; Adenocarcinoma; Pathological; Internal medicine; Medical diagnosis; Oncology; Cancer; Epidemiology; Chemotherapy; Pathology","score_opus":0.049690140935690484,"score_gpt":0.4436744220795795,"score_spread":0.39398428114388906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394609958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96402735,0.032496244,0.0001525447,0.0006141052,0.0011020034,0.0010039405,0.00023847609,0.0000138849855,0.000351444],"genre_scores_gemma":[0.99474424,0.00414698,0.00013932027,0.000015628946,0.00016169432,0.0005315724,0.00013562034,0.000012477496,0.0001124884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909484,0.000042879507,0.00029336207,0.0002483509,0.00014324862,0.00017731791],"domain_scores_gemma":[0.9992525,0.0004182135,0.00006554777,0.00009587218,0.000057614376,0.00011022977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013897414,0.00011422015,0.00040295624,0.00011802006,0.000015711339,0.000003198634,0.000043339267,0.00014799865,0.00011095065],"category_scores_gemma":[0.000053594104,0.0000862682,0.00007153667,0.00014414673,0.00011019891,0.000027561322,0.000029180961,0.00010429503,0.0000014279735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042837672,0.003935514,0.7277894,0.0009619656,0.00034997307,0.00014846405,0.0014330344,0.000016599166,0.0006528522,0.0013568971,0.0060830587,0.25684386],"study_design_scores_gemma":[0.024645882,0.0076434,0.81716377,0.0023669954,0.0025713455,0.00004121167,0.0005542956,0.008486167,0.00086565875,0.00014924406,0.13517343,0.00033859868],"about_ca_topic_score_codex":0.001219994,"about_ca_topic_score_gemma":0.003735946,"teacher_disagreement_score":0.25650528,"about_ca_system_score_codex":0.0017509209,"about_ca_system_score_gemma":0.0015360062,"threshold_uncertainty_score":0.45785972},"labels":[],"label_agreement":null},{"id":"W4394843319","doi":"10.1007/s40487-024-00276-5","title":"Correction: Real-World Treatment Patterns and Survival Among Patients with Stage I–III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment","year":2024,"lang":"en","type":"erratum","venue":"Oncology and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; AstraZeneca (Canada); Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Primary treatment; Medicine; Stage (stratigraphy); Squamous cell cancer; Lung cancer; Cancer treatment; Oncology; Surgery; Internal medicine; Cancer; Biology","score_opus":0.012918693792509484,"score_gpt":0.3077022416866206,"score_spread":0.2947835478941111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394843319","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88110065,0.008740097,0.000012580669,0.00046091102,0.021843107,0.0030046506,0.00044559964,0.00012664289,0.08426575],"genre_scores_gemma":[0.18211082,0.14970829,0.000035578338,0.0003783191,0.001493783,0.0015251271,0.0030507783,0.00018134252,0.66151595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978107,0.00011028568,0.00043290685,0.0009249499,0.00023977864,0.00048134633],"domain_scores_gemma":[0.9984948,0.00040017327,0.0003286864,0.00036993934,0.00012535145,0.0002810751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000116536896,0.000734517,0.0013500854,0.00033742478,0.00029611588,0.00006955852,0.00005333732,0.00048228767,0.00029635156],"category_scores_gemma":[0.000002981499,0.00048497718,0.00018710177,0.00021101674,0.00014601705,0.00008998477,0.000030794996,0.00046497272,0.000005772717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012906067,0.0015748058,0.84456176,0.0003811558,0.0026758958,0.0005023631,0.0025445821,0.000003314163,0.000003605804,0.000002034571,0.06784842,0.07861146],"study_design_scores_gemma":[0.009102915,0.005455773,0.74094224,0.0010113223,0.0023719962,0.000016055445,0.00024332516,0.00005481945,0.000055441815,0.0000035660617,0.24022682,0.0005157308],"about_ca_topic_score_codex":0.03270289,"about_ca_topic_score_gemma":0.037474543,"teacher_disagreement_score":0.69898987,"about_ca_system_score_codex":0.0024733057,"about_ca_system_score_gemma":0.0023152707,"threshold_uncertainty_score":0.9997602},"labels":[],"label_agreement":null},{"id":"W4394894139","doi":"10.1016/j.heliyon.2024.e29668","title":"Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Heliyon","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University Health Centre; Université de Montréal; McGill University","funders":"","keywords":"Osimertinib; Medicine; Lung cancer; Epidermal growth factor receptor; Meta-analysis; Oncology; Internal medicine; Complication; Metastasis; Cancer; Pathology; Erlotinib","score_opus":0.0401148284260839,"score_gpt":0.38566563334830667,"score_spread":0.3455508049222228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394894139","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004637244,0.9891242,0.000008592374,0.00019093574,0.00003057533,0.008937077,0.0014724279,0.000075693664,0.00011414284],"genre_scores_gemma":[0.00009763957,0.97677237,0.00008876928,0.0005388199,0.000011150535,0.00782594,0.00072151254,0.000113034665,0.013830755],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99663657,0.00031220468,0.0014283465,0.00086885196,0.00034475597,0.00040925934],"domain_scores_gemma":[0.9978787,0.00022687235,0.0008854633,0.0006504296,0.00016939307,0.00018915725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042495722,0.0008828278,0.011771616,0.00065879733,0.000057751822,0.00007784713,0.00013549688,0.00022785674,0.00030369466],"category_scores_gemma":[0.000067753805,0.00044114294,0.0020661498,0.001970617,0.000032093765,0.00006679127,0.00006142007,0.00041304543,0.00001664326],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003819864,0.00012325679,0.00015132013,0.6724472,0.32674164,0.000072761315,0.00023257901,3.6542818e-7,1.4399143e-7,3.0940595e-7,0.00009598933,0.00013065133],"study_design_scores_gemma":[0.0005162824,0.00011618327,0.00002272402,0.18444912,0.8132102,0.0000106762345,0.000015703936,0.000023807786,0.0000016823469,1.2462282e-7,0.0013161802,0.00031731036],"about_ca_topic_score_codex":0.0007309111,"about_ca_topic_score_gemma":0.0007049255,"teacher_disagreement_score":0.48799807,"about_ca_system_score_codex":0.0006569336,"about_ca_system_score_gemma":0.00054497796,"threshold_uncertainty_score":0.999804},"labels":[],"label_agreement":null},{"id":"W4396228145","doi":"10.1503/cmaj.231562","title":"Oral targeted therapy for the treatment of non–small cell lung carcinoma","year":2024,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Carcinoma; Oncology; Lung; Disease; Internal medicine; Targeted therapy; Cancer","score_opus":0.025865202778131417,"score_gpt":0.34699443732497776,"score_spread":0.32112923454684633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396228145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012549962,0.99280727,0.000043214477,0.002986248,0.0014488474,0.0016418766,0.0003881751,0.000009453527,0.0005494194],"genre_scores_gemma":[0.00023166521,0.9920981,0.00011232945,0.0006096496,0.001845936,0.00027377522,0.00019938953,0.000055459048,0.004573685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808484,0.00008870664,0.00064923265,0.00020254756,0.0005729184,0.00040177358],"domain_scores_gemma":[0.99792594,0.000344934,0.00038976804,0.00016902854,0.00031102606,0.000859314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044365012,0.00028593623,0.0010310506,0.00024172563,0.00020563923,0.00005906052,0.00015453968,0.00048352985,0.00069412077],"category_scores_gemma":[0.0001055721,0.00014720512,0.0009068458,0.00027287303,0.000028817838,0.000022345377,0.0000042457045,0.00047024182,0.00003374395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000070781402,0.00011524589,0.00046891405,0.0010584136,0.002385519,0.00018178747,0.0004992542,2.3510405e-7,7.3865365e-8,0.000011310636,0.07340015,0.921872],"study_design_scores_gemma":[0.0017485615,0.00047664903,0.00021854942,0.0013725584,0.0064666257,0.00013689118,0.00010360046,0.00008093322,9.969169e-7,0.000007688232,0.9892686,0.000118374315],"about_ca_topic_score_codex":0.0026708562,"about_ca_topic_score_gemma":0.0046706446,"teacher_disagreement_score":0.92175364,"about_ca_system_score_codex":0.0039240336,"about_ca_system_score_gemma":0.015707983,"threshold_uncertainty_score":0.99989974},"labels":[],"label_agreement":null},{"id":"W4396228167","doi":"10.1503/cmaj.240465","title":"The journey of a patient with lung cancer from symptoms to treatment","year":2024,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lung cancer; Medicine; Family medicine; Physical therapy; Internal medicine","score_opus":0.004867878710585129,"score_gpt":0.2903265628751923,"score_spread":0.2854586841646072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396228167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85442185,0.00849268,0.00009806111,0.13191772,0.0014232093,0.0004372758,0.00021260367,0.00002145823,0.0029751628],"genre_scores_gemma":[0.99339783,0.0007287549,0.00009180604,0.0032176627,0.00092623517,0.00006369927,0.000014134882,0.000019099267,0.0015407728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859357,0.00004138166,0.00025278158,0.000109309156,0.0007490244,0.0002539256],"domain_scores_gemma":[0.99835825,0.0001583148,0.000077021665,0.0000804098,0.00022735383,0.0010986625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016366213,0.00009094091,0.00015962528,0.00009687265,0.00019888191,0.000083556966,0.0000566262,0.00008417954,0.0011698514],"category_scores_gemma":[0.00012216641,0.00004693765,0.00007664295,0.00021279014,0.000019501607,0.000043831405,0.000004076232,0.00022760693,0.000018962835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008730707,0.00010214968,0.14040409,0.000019888867,0.0052573816,0.0017497849,0.008119692,0.00007291222,0.000023381393,0.00044977485,0.13482575,0.7088879],"study_design_scores_gemma":[0.0014482107,0.0006781534,0.028066231,0.0008652075,0.0008058622,0.00025830258,0.00095761614,0.0006064066,0.0000869521,0.00005674824,0.96606004,0.00011027103],"about_ca_topic_score_codex":0.0181973,"about_ca_topic_score_gemma":0.07620215,"teacher_disagreement_score":0.8312343,"about_ca_system_score_codex":0.003485422,"about_ca_system_score_gemma":0.0065762307,"threshold_uncertainty_score":0.9997432},"labels":[],"label_agreement":null},{"id":"W4396616739","doi":"10.3390/curroncol31050182","title":"Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; Disease; Lung cancer; Cancer; Adenocarcinoma","score_opus":0.04158427184206845,"score_gpt":0.4435635217311858,"score_spread":0.4019792498891174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396616739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525464,0.00057608995,0.00032630126,0.001083392,0.00020061292,0.0012354635,0.0010200621,0.000049894345,0.0002535203],"genre_scores_gemma":[0.9946611,0.00037671084,0.00028280178,0.000035563426,0.000035318157,0.00041546187,0.0038608934,0.00001962087,0.00031254097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907446,0.000029286812,0.00029336973,0.0003179802,0.00012002526,0.00016489631],"domain_scores_gemma":[0.9990433,0.00034652988,0.000119876204,0.00013104742,0.00026084337,0.00009843733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034672044,0.00018088905,0.0005198656,0.00042828996,0.00007078691,0.00001213413,0.000024429684,0.000048051566,0.000051592033],"category_scores_gemma":[0.000021273283,0.000107214226,0.00014991156,0.00041268792,0.000057002373,0.000053580694,0.000012285058,0.000046605175,0.0000017984008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046246964,0.001402281,0.83687687,0.00017038756,0.004096441,0.00002296733,0.0013482876,0.00002220378,0.000008907354,0.00007777121,0.00006471846,0.15544668],"study_design_scores_gemma":[0.005269355,0.007011332,0.9663595,0.00031264554,0.015604323,0.0000028379884,0.00012312114,0.0018101505,0.00035384728,0.000010472489,0.0030283546,0.000114091155],"about_ca_topic_score_codex":0.00051568326,"about_ca_topic_score_gemma":0.0024638046,"teacher_disagreement_score":0.1553326,"about_ca_system_score_codex":0.0004668542,"about_ca_system_score_gemma":0.00017183064,"threshold_uncertainty_score":0.43720692},"labels":[],"label_agreement":null},{"id":"W4396774318","doi":"10.1016/j.lungcan.2024.107816","title":"Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Crizotinib; Medicine; ROS1; Meta-analysis; Oncology; Lung cancer; Fusion gene; Internal medicine; Cancer; Gene; Adenocarcinoma; Genetics","score_opus":0.04719019416161372,"score_gpt":0.4142573196791078,"score_spread":0.36706712551749404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396774318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022324748,0.99004436,0.000005473642,0.00025396605,0.00005319474,0.008352465,0.0009008709,0.000008968914,0.00015743621],"genre_scores_gemma":[0.0007154772,0.99312913,0.00027816513,0.00008524995,0.000029634206,0.003812855,0.00012093921,0.00004863228,0.0017798934],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971217,0.00025907645,0.0013885131,0.00063065655,0.0003829606,0.00021711757],"domain_scores_gemma":[0.9972314,0.00050347147,0.0011168101,0.0008108412,0.0002479337,0.00008953658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031755565,0.00059022405,0.0069305208,0.0004670296,0.00003955528,0.000021096881,0.0001529122,0.000117249925,0.00008375243],"category_scores_gemma":[0.00001920619,0.00026055114,0.0009789137,0.0025346726,0.000084687446,0.000063582906,0.000035280143,0.00019643601,1.833608e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009336191,0.00021935077,0.00016346996,0.8865599,0.104878716,0.000047629488,0.0026813422,0.0000472315,0.0000042736997,0.000015847329,0.00009779046,0.005191075],"study_design_scores_gemma":[0.00069141365,0.00024143612,0.00018933893,0.27715728,0.7177125,0.000011306581,0.000032812834,0.00002817871,0.0000066445423,2.7424113e-7,0.0037714583,0.0001573214],"about_ca_topic_score_codex":0.0009034814,"about_ca_topic_score_gemma":0.0020609968,"teacher_disagreement_score":0.6128338,"about_ca_system_score_codex":0.00046778613,"about_ca_system_score_gemma":0.00068493705,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W4396830479","doi":"10.7759/cureus.60061","title":"KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Cureus","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"KRAS; Medicine; Oncology; Internal medicine; Lung; Carcinoma; Pathology; Cancer; Colorectal cancer","score_opus":0.025523738517258816,"score_gpt":0.35661628222133507,"score_spread":0.33109254370407626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396830479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018521967,0.9831388,0.000015865355,0.000057031455,0.00019835694,0.01378272,0.00014779934,0.000038664333,0.0026022524],"genre_scores_gemma":[0.00034240982,0.99033797,0.0001447293,0.0001213806,0.00005625598,0.0056196414,0.00029326938,0.000093231145,0.002991141],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9978505,0.0001522344,0.00089657004,0.0005739663,0.00023270155,0.00029406982],"domain_scores_gemma":[0.9987033,0.00026352203,0.0002922833,0.0004789233,0.00007844828,0.00018354898],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003014298,0.000531098,0.0030520144,0.00019457321,0.00003449543,0.0000426571,0.00011302695,0.00012689509,0.000052427422],"category_scores_gemma":[0.0002121659,0.00032679038,0.00037199195,0.00045932297,0.00003785861,0.000052367217,0.000061816725,0.00038514016,0.00014880906],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000032345824,0.00013672722,0.000056180437,0.9950076,0.0010401716,0.0008384105,0.00035751014,3.0940445e-8,2.6043141e-8,0.000022876928,0.0011931964,0.0013440313],"study_design_scores_gemma":[0.00047223605,0.00022589536,0.00003176501,0.8400354,0.13961284,0.00062379276,0.000078353514,0.00004367578,4.503018e-8,0.00003200591,0.01859657,0.00024744164],"about_ca_topic_score_codex":0.00007776918,"about_ca_topic_score_gemma":0.000025703606,"teacher_disagreement_score":0.15497223,"about_ca_system_score_codex":0.00052861136,"about_ca_system_score_gemma":0.0012030822,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W4396951348","doi":"10.3390/curroncol31050205","title":"Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; KRAS; Oncology; Internal medicine; Bioinformatics; Family medicine; Cancer research; Cancer; Colorectal cancer; Biology","score_opus":0.08340987674810557,"score_gpt":0.4720470574185583,"score_spread":0.3886371806704527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396951348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513954,0.0012109706,0.000010270187,0.00021398907,0.0005170237,0.0008933218,0.000012429567,0.000025609777,0.001976827],"genre_scores_gemma":[0.99931264,0.00013352983,0.00004478171,0.000012254616,0.00003996041,0.00010640272,0.000039328603,0.000011046505,0.00030002694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920905,0.000053802065,0.00023018771,0.00022221771,0.00014955505,0.00013516417],"domain_scores_gemma":[0.999518,0.00014461808,0.00005015363,0.0001382142,0.0000950732,0.000053938937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007459222,0.00009405385,0.00025374914,0.0002149001,0.000017829767,0.0000058129226,0.000041213236,0.000026444235,0.000098839],"category_scores_gemma":[0.000028937218,0.000062709114,0.000022459228,0.0004420746,0.000038666472,0.0000641839,0.00002058279,0.0001370689,0.000019560357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000334912,0.002725303,0.9521608,0.00015094872,0.00011995299,0.00007450323,0.0030332005,0.000011847455,0.000008252391,0.00003538458,0.000782447,0.040562447],"study_design_scores_gemma":[0.0041936645,0.003478615,0.98359185,0.00077513274,0.00039354234,0.0000018104644,0.00032449464,0.000095741605,0.0000117183545,0.000021187421,0.0070460215,0.000066242814],"about_ca_topic_score_codex":0.00027626727,"about_ca_topic_score_gemma":0.0012811357,"teacher_disagreement_score":0.040496204,"about_ca_system_score_codex":0.000361406,"about_ca_system_score_gemma":0.00037482902,"threshold_uncertainty_score":0.25572035},"labels":[],"label_agreement":null},{"id":"W4396979010","doi":"10.1016/j.jtocrr.2024.100691","title":"EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Shionogi; Astellas Pharma; Kyowa Hakko Kirin; Eisai; Chugai Pharmaceutical; Celltrion; Kissei; Taiho Pharmaceutical; Genomic Health; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Li–Fraumeni syndrome; Germline; Family history; Genetic testing; Medicine; Germline mutation; Oncology; Lung cancer; Adenocarcinoma; Internal medicine; Cancer research; Mutation; Genetics; Cancer; Biology; Gene","score_opus":0.08971594190306834,"score_gpt":0.44677033427935625,"score_spread":0.3570543923762879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396979010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278605,0.002122993,0.000046101748,0.0016543018,0.00017533376,0.002484832,0.000013848525,0.000053902437,0.0006626126],"genre_scores_gemma":[0.9948347,0.000023646055,0.00076851336,0.00011296342,0.00011141132,0.00051248,0.00006732303,0.000039106017,0.0035298609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973093,0.00013436035,0.00078459096,0.0007024743,0.00067266414,0.00039658055],"domain_scores_gemma":[0.9971493,0.0011458183,0.00013342287,0.00039973904,0.0009130102,0.00025873864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00229922,0.00017464154,0.00039600182,0.00016913882,0.0002116054,0.00006655481,0.00003913278,0.00010215172,0.000018405866],"category_scores_gemma":[0.0014527595,0.00007591354,0.00007099567,0.00047009115,0.0004579265,0.00011530121,0.000056792775,0.00063774735,0.0000013397913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054524216,0.0004145209,0.56299806,0.00021709947,0.00036411354,0.4277586,0.00057643076,0.0000043315763,0.00000530959,0.000011484648,0.0031007528,0.0040040337],"study_design_scores_gemma":[0.0036137246,0.0057030693,0.88148266,0.0010345989,0.00043299876,0.09824274,0.00050860905,0.0014313546,0.000004506733,0.000107304244,0.0072383555,0.00020005245],"about_ca_topic_score_codex":0.0009772067,"about_ca_topic_score_gemma":0.00018182381,"teacher_disagreement_score":0.32951587,"about_ca_system_score_codex":0.0004487188,"about_ca_system_score_gemma":0.0018005058,"threshold_uncertainty_score":0.319402},"labels":[],"label_agreement":null},{"id":"W4397006962","doi":"10.1016/j.esmoop.2024.103273","title":"252P Impact of informative censoring on the interpretation of progression-free survival (PFS) estimates in phase III randomized trials (RCT) in metastatic breast cancer (MBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Censoring (clinical trials); Randomized controlled trial; Oncology; Metastatic breast cancer; Medicine; Internal medicine; Breast cancer; Progression-free survival; Overall survival; Cancer; Pathology","score_opus":0.05797926994222724,"score_gpt":0.4893996818491113,"score_spread":0.43142041190688407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397006962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863132,0.0006240523,0.00032582457,0.0018041338,0.0002500649,0.005983555,0.00045248523,0.000019251132,0.0042274054],"genre_scores_gemma":[0.9986363,0.00009484929,0.00041239502,0.000028325481,0.000016408094,0.0006738264,0.000057969486,0.000012687812,0.00006724232],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99835414,0.0003393192,0.00082141184,0.00013208503,0.00022113525,0.00013191298],"domain_scores_gemma":[0.9971677,0.0022209827,0.00028948806,0.00020131808,0.000081721606,0.000038794424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022696801,0.0001406464,0.0010652076,0.00021372677,0.000023227512,0.00004429004,0.00016165774,0.00002672262,0.0003906433],"category_scores_gemma":[0.0011188746,0.0000684129,0.0001817076,0.00034994693,0.000076631004,0.00029664463,0.000066740664,0.00012483879,0.0000027826406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49257302,0.003717815,0.015869875,0.0016370314,0.011186319,0.00015382475,0.13134733,0.011006372,0.0010589146,0.00767253,0.001955494,0.32182148],"study_design_scores_gemma":[0.76372594,0.0018021871,0.055049524,0.022129009,0.0033167133,0.000032221873,0.006093946,0.13273454,0.01011769,0.004521584,0.000047767455,0.00042891235],"about_ca_topic_score_codex":0.00978981,"about_ca_topic_score_gemma":0.0005235954,"teacher_disagreement_score":0.32139257,"about_ca_system_score_codex":0.00025603652,"about_ca_system_score_gemma":0.00046025089,"threshold_uncertainty_score":0.99680406},"labels":[],"label_agreement":null},{"id":"W4397007490","doi":"10.1016/j.esmoop.2024.103097","title":"109O Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): Results from SOFT and TEXT phase III studies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Invasive lobular carcinoma; Endocrine system; Adjuvant therapy; Medicine; Adjuvant; Oncology; Gynecology; Internal medicine; Breast cancer; Cancer; Hormone; Invasive ductal carcinoma","score_opus":0.06478760111655238,"score_gpt":0.4140119191026694,"score_spread":0.34922431798611697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96051687,0.02401203,0.00010964596,0.0067931744,0.0004943372,0.0039981934,0.0011806733,0.000078787976,0.0028162692],"genre_scores_gemma":[0.99025667,0.0012711991,0.0010340572,0.0005506072,0.00027324236,0.00051784306,0.000649368,0.00003299226,0.005414047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894446,0.000022253162,0.00026204775,0.00044291755,0.00012840958,0.0001999077],"domain_scores_gemma":[0.9991689,0.00031774363,0.000050277624,0.00025843023,0.0001046181,0.000100031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010969262,0.00017751307,0.00036486197,0.00005439563,0.00013814498,0.000106865475,0.00010784748,0.00003086386,0.0001042921],"category_scores_gemma":[0.000098427845,0.00012279295,0.000042672516,0.0000876483,0.000064903346,0.00018473672,0.00011168255,0.00007737088,0.000018599232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02557436,0.002934544,0.0080399765,0.00082199776,0.018115569,0.0036992577,0.060599957,0.000021068221,0.018054368,0.0034375584,0.29819062,0.56051075],"study_design_scores_gemma":[0.15375286,0.011157478,0.030701337,0.0017568992,0.003357509,0.00013894588,0.0055500153,0.0006068185,0.044870626,0.0050963117,0.7421718,0.0008394038],"about_ca_topic_score_codex":0.003169012,"about_ca_topic_score_gemma":0.00051324815,"teacher_disagreement_score":0.55967134,"about_ca_system_score_codex":0.000108630455,"about_ca_system_score_gemma":0.00027862738,"threshold_uncertainty_score":0.5007351},"labels":[],"label_agreement":null},{"id":"W4397024997","doi":"10.1681/asn.20203110s136a","title":"Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Semaglutide; Post-hoc analysis; Placebo; Urology; Internal medicine; Medicine; Pooled analysis; Post hoc; Endocrinology; Meta-analysis; Diabetes mellitus; Alternative medicine; Pathology; Type 2 diabetes","score_opus":0.009341531240679572,"score_gpt":0.29358536532938734,"score_spread":0.2842438340887078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397024997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9157808,0.00024867835,0.00016647803,0.08362559,0.000009196089,0.00014214577,0.000010706158,0.0000013568667,0.000015066274],"genre_scores_gemma":[0.9902249,0.00027795657,0.0018357747,0.007587033,0.000045401008,0.0000018742036,0.0000027384574,0.0000058327496,0.000018469533],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991327,0.00016202265,0.00036914655,0.00007923886,0.00016268832,0.00009420403],"domain_scores_gemma":[0.9984775,0.0001530378,0.0009450667,0.00012550235,0.0002579625,0.000040912004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003290696,0.00007600569,0.0005691209,0.000071186165,0.000026893524,0.0000022590614,0.0001003698,0.000025478084,0.000010160983],"category_scores_gemma":[0.000049368686,0.000038412185,0.00025560372,0.00087478175,0.0005026863,0.000029830544,0.000027291364,0.00015834419,5.0535476e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040219877,0.001707027,0.17610122,0.0004355254,0.04638587,0.00006254642,0.09703912,0.015000234,0.5846931,0.00021109435,0.028512923,0.009631496],"study_design_scores_gemma":[0.0061823027,0.0071473704,0.92766494,0.000066126944,0.013084213,0.00022373753,0.040864132,0.001824519,0.0011688804,0.00008061482,0.0016081991,0.000084971696],"about_ca_topic_score_codex":0.00042402663,"about_ca_topic_score_gemma":0.00004405586,"teacher_disagreement_score":0.7515637,"about_ca_system_score_codex":0.000046839414,"about_ca_system_score_gemma":0.00019501155,"threshold_uncertainty_score":0.18521686},"labels":[],"label_agreement":null},{"id":"W4399070680","doi":"10.1016/j.critrevonc.2024.104401","title":"Rediscovering immunohistochemistry in lung cancer","year":2024,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lung cancer; Immunohistochemistry; Medicine; Pathology; Oncology","score_opus":0.0617392239826426,"score_gpt":0.5304947154319777,"score_spread":0.4687554914493351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399070680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000071565637,0.9826637,0.000015344433,0.001256164,0.0013795398,0.0020861472,0.000046270816,0.000047286405,0.012498393],"genre_scores_gemma":[0.00003954877,0.99265635,0.0005404965,0.00035077005,0.00023362848,0.0049924357,0.0001282115,0.00008286756,0.0009756756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960382,0.00030098777,0.001932009,0.00090132374,0.00014491788,0.0006825658],"domain_scores_gemma":[0.99821424,0.00076072157,0.00019727487,0.0005866856,0.00005228969,0.00018876488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005054801,0.00060497096,0.0053751944,0.00039392617,0.00004022789,0.000017985281,0.00024839994,0.0010185136,0.0004651357],"category_scores_gemma":[0.0015902247,0.00044269473,0.000668116,0.00068710773,0.0003279546,0.00005977846,0.00017897354,0.0016665288,0.00023460151],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019362671,0.00045042517,0.00008751378,0.1885002,0.00027966715,0.003915978,0.0001596935,8.628387e-8,0.0000028715406,0.010422638,0.012709454,0.7834521],"study_design_scores_gemma":[0.00045398725,0.00007488687,0.0000022212048,0.14574637,0.0038723757,0.00144207,0.000021826858,0.000009085537,0.0000012308441,0.00022935023,0.8478646,0.0002819644],"about_ca_topic_score_codex":0.0000615371,"about_ca_topic_score_gemma":0.00004949097,"teacher_disagreement_score":0.8351552,"about_ca_system_score_codex":0.0036575126,"about_ca_system_score_gemma":0.0024673268,"threshold_uncertainty_score":0.9998025},"labels":[],"label_agreement":null},{"id":"W4399153733","doi":"10.1200/jco.24.00762","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Guideline; Medicine; Clinical Practice; Family medicine; Schedule; Stage (stratigraphy); Clinical Oncology; Cancer; Pathology; Internal medicine","score_opus":0.06257167324106218,"score_gpt":0.5001184062087508,"score_spread":0.43754673296768865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399153733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8977576,0.015695494,0.030553294,0.03763621,0.0074643395,0.0016905488,0.000085070504,0.00004136259,0.009076064],"genre_scores_gemma":[0.8618705,0.012310134,0.060918793,0.00972618,0.0061784363,0.00012975733,0.00003316147,0.000089165085,0.04874383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998261,0.0000758967,0.0011229053,0.00018688093,0.00018863691,0.00016472745],"domain_scores_gemma":[0.9973354,0.0013707457,0.00045805812,0.00011625742,0.0005279193,0.00019164725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088980224,0.000119352255,0.00059291295,0.000111762376,0.0000794662,0.00002774222,0.00007632398,0.00015715428,0.0007690882],"category_scores_gemma":[0.00021411631,0.000070624534,0.00030453596,0.00013720106,0.000050179682,0.00014299554,0.000015412685,0.0004052837,0.000008933849],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00596013,0.0035241353,0.1370521,0.0005043941,0.00487105,0.0012250545,0.0023455129,0.0023215988,0.0011142286,0.00024702842,0.5874888,0.253346],"study_design_scores_gemma":[0.009052144,0.011327902,0.021521261,0.0007483049,0.0016809682,0.000053274893,0.00030277163,0.007717442,0.00012869963,0.000037637878,0.94730425,0.00012532233],"about_ca_topic_score_codex":0.000050735438,"about_ca_topic_score_gemma":0.00008248048,"teacher_disagreement_score":0.3598155,"about_ca_system_score_codex":0.0002816678,"about_ca_system_score_gemma":0.003518484,"threshold_uncertainty_score":0.84209764},"labels":[],"label_agreement":null},{"id":"W4399218247","doi":"10.1200/jco.24.00581","title":"Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i> -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Grifols; Lunit; Sociedad Española de Oncología Médica; BeiGene; Taiho Pharmaceutical; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Lung cancer; Internal medicine; Oncology; ALK inhibitor","score_opus":0.04732648856136055,"score_gpt":0.475723419983027,"score_spread":0.4283969314216664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399218247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895454,0.00072063215,0.00005155528,0.003145871,0.0026305236,0.0010475133,0.0000730552,0.000012099628,0.002773357],"genre_scores_gemma":[0.99722207,0.00015922067,0.0007424542,0.0010584369,0.00050437014,0.00003575871,0.000018532275,0.000026953507,0.00023223675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750155,0.00023023758,0.0014157932,0.00027332315,0.00035383532,0.00022523286],"domain_scores_gemma":[0.9954353,0.0031844145,0.00065538916,0.00019996571,0.0003196508,0.00020525765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063360657,0.00018705694,0.0010828136,0.0000811808,0.00006090284,0.000024949011,0.0001540306,0.00013495878,0.00015809196],"category_scores_gemma":[0.000328907,0.000095863565,0.00025657922,0.00021162332,0.000101103986,0.00014002105,0.000042578184,0.0008930327,0.000008185379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025969837,0.0079272,0.877073,0.000017559609,0.0020864888,0.00066443614,0.0028581088,0.00008209845,0.000005852109,0.00000824,0.001694543,0.08161263],"study_design_scores_gemma":[0.12595417,0.027688636,0.83566004,0.00027078527,0.0029955865,0.0000019760741,0.0015710535,0.00007681934,0.000013900649,0.000010359805,0.0056423545,0.000114306014],"about_ca_topic_score_codex":0.00026217956,"about_ca_topic_score_gemma":0.000561389,"teacher_disagreement_score":0.09998433,"about_ca_system_score_codex":0.00035854033,"about_ca_system_score_gemma":0.0019079689,"threshold_uncertainty_score":0.39092028},"labels":[],"label_agreement":null},{"id":"W4399218268","doi":"10.1200/jco.24.00733","title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Centro de Investigación Biomédica en Red de Cáncer; European Commission; National Institute on Minority Health and Health Disparities; Comunidad de Madrid; Instituto de Salud Carlos III; Gilead Sciences","keywords":"Medicine; Docetaxel; Open label; Lung cancer; Oncology; Randomized controlled trial; Internal medicine; Phases of clinical research; Cancer; Chemotherapy","score_opus":0.15434764482793675,"score_gpt":0.5628618517731004,"score_spread":0.4085142069451637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399218268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950586,0.014282485,0.0029340521,0.009357557,0.0055756965,0.013735237,0.000103416096,0.00004424276,0.0033812777],"genre_scores_gemma":[0.98028404,0.0035723476,0.00558533,0.0011472544,0.0009310402,0.0012917545,0.000019059591,0.000064599306,0.0071046036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99545515,0.0006683721,0.0027777927,0.00039240374,0.0003276486,0.00037861918],"domain_scores_gemma":[0.9879049,0.009480164,0.0014136032,0.00032432482,0.00049294607,0.00038407618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041144216,0.0002946598,0.0029197996,0.00013823307,0.00016295527,0.00009175643,0.00040791614,0.00014739491,0.00024200472],"category_scores_gemma":[0.0019673132,0.00013984974,0.0006260956,0.00033671045,0.00019690093,0.00022859048,0.00008188832,0.0007275683,0.0000068217073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70615757,0.013350011,0.0002081066,0.00025232788,0.0110168895,0.0013581138,0.00178969,0.00009424976,0.000060510985,0.00007820011,0.008171345,0.257463],"study_design_scores_gemma":[0.8772753,0.0464113,0.0001037456,0.0003576764,0.029377574,0.00011498966,0.0013323227,0.0038898082,0.000046196634,0.00009065014,0.040830906,0.00016956904],"about_ca_topic_score_codex":0.0002915636,"about_ca_topic_score_gemma":0.00074702495,"teacher_disagreement_score":0.25729346,"about_ca_system_score_codex":0.0007097402,"about_ca_system_score_gemma":0.0063082865,"threshold_uncertainty_score":0.99932504},"labels":[],"label_agreement":null},{"id":"W4399281115","doi":"10.1200/jco.2024.42.16_suppl.12092","title":"Novel genome-wide significant germline genetic variants associated with venous thrombo-embolism (VTE) and arterial embolism (ATE) risk in patients with <i>ALK</i> and <i>ROS1</i> fusion non-small cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Pulmonary embolism; Venous thromboembolism; Germline; Internal medicine; Oncology; Cardiology; Thrombosis; Genetics; Gene","score_opus":0.017677674896626368,"score_gpt":0.3451939423154888,"score_spread":0.3275162674188624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944507,0.002005434,0.0005236373,0.0008542841,0.0009769828,0.00068755343,0.00011184094,0.000014430558,0.00037512535],"genre_scores_gemma":[0.99398196,0.0023445748,0.0019220641,0.00095337274,0.000610897,0.00001947459,0.000024298857,0.00004994558,0.000093410206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973704,0.00017939815,0.0013511449,0.0004051098,0.00033693534,0.00035701552],"domain_scores_gemma":[0.9973646,0.0008117568,0.0009450026,0.00015462379,0.00033511923,0.0003889269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076117297,0.00026605392,0.0013467768,0.00016593594,0.000084262676,0.000046494744,0.000088672605,0.00031550968,0.00003847988],"category_scores_gemma":[0.00021212253,0.00016593907,0.000109472356,0.00022137706,0.00018067192,0.00012323339,0.000049935716,0.0008129329,0.0000015770382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005709029,0.0066081,0.9505357,0.00019837948,0.0019257966,0.0013237483,0.002478336,0.00024250893,0.0010700357,0.000005591533,0.0005058298,0.029396908],"study_design_scores_gemma":[0.025585117,0.007673313,0.9614444,0.00064102135,0.002623447,0.000052769054,0.000054838285,0.00045319216,0.000017104612,0.000037889404,0.0012275344,0.00018939965],"about_ca_topic_score_codex":0.00032515227,"about_ca_topic_score_gemma":0.00033299995,"teacher_disagreement_score":0.029207509,"about_ca_system_score_codex":0.00028701447,"about_ca_system_score_gemma":0.0019957596,"threshold_uncertainty_score":0.67667985},"labels":[],"label_agreement":null},{"id":"W4399304614","doi":"10.1200/jco.2024.42.16_suppl.10022","title":"Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Solid tumor; Oncology; Internal medicine; Cancer","score_opus":0.040032194962885834,"score_gpt":0.43847416982381215,"score_spread":0.3984419748609263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372566,0.00058336597,0.000022429207,0.0033257764,0.00059833983,0.0002446535,0.00009177394,0.000010054401,0.0013979448],"genre_scores_gemma":[0.996025,0.0006262722,0.0020930034,0.0003073755,0.00074120116,0.0000014084903,0.000083418716,0.000016071905,0.000106218286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970068,0.00018694355,0.0022241191,0.00021418999,0.0002279079,0.00014006082],"domain_scores_gemma":[0.99645734,0.0020863358,0.0008532784,0.00014301829,0.00024812555,0.00021192344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007705812,0.000113153976,0.0009925492,0.00016635502,0.000017239456,0.000009014453,0.00007259302,0.0001775745,0.000049294737],"category_scores_gemma":[0.0013789458,0.00006897956,0.00012494865,0.00025417472,0.00009687985,0.00012072513,0.000028423166,0.0005714179,0.0000048931274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04606782,0.005211708,0.78655577,0.00011557709,0.0012765119,0.0009991134,0.002270346,0.000065837055,0.000024220133,0.000055929588,0.006623111,0.15073408],"study_design_scores_gemma":[0.027041372,0.008871844,0.95544255,0.00032249306,0.0008641079,0.000022078271,0.00006277694,0.00010030567,0.00001072103,0.00008016043,0.007114415,0.00006720117],"about_ca_topic_score_codex":0.000044507764,"about_ca_topic_score_gemma":0.00002922488,"teacher_disagreement_score":0.16888678,"about_ca_system_score_codex":0.00011737171,"about_ca_system_score_gemma":0.0015035908,"threshold_uncertainty_score":0.2812905},"labels":[],"label_agreement":null},{"id":"W4399395212","doi":"10.1200/jco.24.00720","title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Hôpital Charles-Le Moyne","funders":"Aptitude Health","keywords":"Medicine; Internal medicine; Oncology; Clinical endpoint; Population; Lung cancer; Phases of clinical research; non-small cell lung cancer (NSCLC); Chemotherapy; Gastroenterology; Clinical trial","score_opus":0.033745585985306394,"score_gpt":0.44297073263212905,"score_spread":0.40922514664682264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256575,0.00199096,0.0000642675,0.0012807089,0.00058982096,0.002589173,0.000018899002,0.000012897766,0.00088752276],"genre_scores_gemma":[0.99666446,0.00034585258,0.0013613648,0.0007348515,0.00048655333,0.00013809,0.00001177266,0.000030755153,0.0002262994],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705267,0.0004047277,0.0015989288,0.00029753213,0.0003409581,0.00030521266],"domain_scores_gemma":[0.9980318,0.0006335204,0.0007667051,0.0002116709,0.0001968816,0.00015943573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011384037,0.00021420464,0.0010650335,0.00018096858,0.00007158919,0.000029997986,0.00017677477,0.00024067136,0.00005755156],"category_scores_gemma":[0.00019549383,0.00011746287,0.00024971415,0.00036025807,0.00009525743,0.00018454879,0.000024162786,0.0010113552,0.000001973699],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27806288,0.02915448,0.20687482,0.00027887122,0.0008191992,0.0018569808,0.004239378,0.00057140214,0.0006150464,0.000011204567,0.0012565983,0.47625914],"study_design_scores_gemma":[0.7172253,0.13985035,0.11065747,0.002976482,0.002224663,0.000044924236,0.00033070528,0.0010290239,0.00057577476,0.00005503544,0.024621578,0.00040868745],"about_ca_topic_score_codex":0.00022344202,"about_ca_topic_score_gemma":0.0003132065,"teacher_disagreement_score":0.47585046,"about_ca_system_score_codex":0.00065099704,"about_ca_system_score_gemma":0.0027846473,"threshold_uncertainty_score":0.4939845},"labels":[],"label_agreement":null},{"id":"W4399428100","doi":"10.3390/curroncol31060251","title":"Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Alberta","funders":"F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Medicine; Adjuvant; Internal medicine; Lung cancer; Oncology; Population; Adjuvant therapy; Stage (stratigraphy); Cancer; Immunotherapy","score_opus":0.031863476342999845,"score_gpt":0.3983236514301238,"score_spread":0.366460175087124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399428100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203676,0.004016925,0.000010226729,0.00013865798,0.0006478391,0.0018502767,0.0009679441,0.0000098451455,0.0003215047],"genre_scores_gemma":[0.9979653,0.000966656,0.00004812689,0.000015156485,0.000045979014,0.00055310206,0.0002014306,0.000017361788,0.00018689687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990667,0.00002080689,0.0002366141,0.00030160815,0.00011254619,0.00026171972],"domain_scores_gemma":[0.9994413,0.00013232342,0.000096200376,0.00011124309,0.00009531138,0.00012359422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003333547,0.00019024592,0.0003958461,0.000117092146,0.00005373579,0.000007354347,0.00003773631,0.000041721014,0.000052227137],"category_scores_gemma":[0.000009942004,0.00011761542,0.0000559837,0.00013649109,0.00003884642,0.000037309113,0.00001628326,0.00010007569,5.0088147e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007445411,0.0010710504,0.7450626,0.0003966491,0.00026940298,0.000024794173,0.002162857,0.0001232806,0.000019878722,0.000017863124,0.0009479681,0.24915913],"study_design_scores_gemma":[0.017501995,0.015655063,0.9316004,0.0015905842,0.0010402042,0.000003587966,0.00037948648,0.0027548063,0.00025027536,0.000012204982,0.028929092,0.0002823374],"about_ca_topic_score_codex":0.31350267,"about_ca_topic_score_gemma":0.57050735,"teacher_disagreement_score":0.25700468,"about_ca_system_score_codex":0.0048604147,"about_ca_system_score_gemma":0.00523485,"threshold_uncertainty_score":0.9989597},"labels":[],"label_agreement":null},{"id":"W4399451380","doi":"10.1200/jco.2024.42.17_suppl.lba8505","title":"Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Biotech","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Lung cancer; Pharmacokinetics; Osimertinib; Urology; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Epidermal growth factor receptor; Erlotinib","score_opus":0.03199664137692556,"score_gpt":0.42768336129724355,"score_spread":0.395686719920318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399451380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697098,0.0069617545,0.00046727934,0.011819164,0.003021962,0.0038321153,0.00014783134,0.000035453468,0.004004647],"genre_scores_gemma":[0.9869083,0.009222846,0.0007636634,0.0017439171,0.0008604988,0.00015724644,0.00007317731,0.000047744375,0.00022259426],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9918704,0.0018898845,0.004614167,0.00052452734,0.00062696007,0.0004740704],"domain_scores_gemma":[0.98065704,0.016052986,0.0023804575,0.00029954326,0.00033639575,0.00027355694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00525837,0.00039327773,0.004351421,0.00020815578,0.00008222216,0.00006014691,0.00027069266,0.0004061201,0.000047628],"category_scores_gemma":[0.0024086456,0.00020526572,0.00070131314,0.00037992626,0.00025681916,0.00023713494,0.000061865045,0.0013610645,0.0000038626185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94869405,0.0052935057,0.003002015,0.00007514579,0.0017809718,0.006484754,0.0008183377,0.00018759842,0.00040489124,0.000052017116,0.000657414,0.03254927],"study_design_scores_gemma":[0.96961594,0.013210777,0.006667303,0.0017828515,0.0027995491,0.00014559021,0.0002468482,0.0011576477,0.000032202282,0.0003162488,0.0037868146,0.00023823975],"about_ca_topic_score_codex":0.0008842259,"about_ca_topic_score_gemma":0.0013587225,"teacher_disagreement_score":0.03231103,"about_ca_system_score_codex":0.0022821033,"about_ca_system_score_gemma":0.0057464154,"threshold_uncertainty_score":0.9998901},"labels":[],"label_agreement":null},{"id":"W4399452280","doi":"10.1200/jco.2024.42.17_suppl.lba8503","title":"Lorlatinib vs crizotinib in treatment-naïve patients with advanced <i>ALK</i>+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Internal medicine; Progression-free survival; Overall survival; Cancer research","score_opus":0.033117509232032535,"score_gpt":0.4386722818950109,"score_spread":0.40555477266297835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874476,0.0024222273,0.000026725045,0.0051238067,0.0014035522,0.0012873752,0.00008739306,0.000014061459,0.0021872658],"genre_scores_gemma":[0.995019,0.0014619424,0.0021090147,0.00037739618,0.0006779043,0.000058349444,0.000018482695,0.000032776647,0.00024509963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973896,0.000304164,0.0013651716,0.00032898408,0.0003687408,0.00024330152],"domain_scores_gemma":[0.9959579,0.0026535646,0.0006148287,0.00027675502,0.0002498052,0.000247151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075290026,0.00021628644,0.0010811081,0.00007529894,0.000082478226,0.000031562453,0.00015932224,0.00016147287,0.00009406885],"category_scores_gemma":[0.00035397738,0.000103631966,0.00018409881,0.0001994018,0.00013857646,0.00013109673,0.00006732276,0.0006268998,0.000003282123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008097011,0.0032857193,0.8423119,0.000028678327,0.00080885267,0.00041270518,0.0014678114,0.000029044322,0.000003960461,0.000008879079,0.0007357975,0.14280964],"study_design_scores_gemma":[0.038098663,0.021277701,0.91912085,0.0005302947,0.0017152794,0.00000773788,0.0010771555,0.00008742122,0.000009039787,0.000040613788,0.017923571,0.00011167826],"about_ca_topic_score_codex":0.00031808685,"about_ca_topic_score_gemma":0.0015024157,"teacher_disagreement_score":0.14269796,"about_ca_system_score_codex":0.0003632913,"about_ca_system_score_gemma":0.0019957728,"threshold_uncertainty_score":0.4225989},"labels":[],"label_agreement":null},{"id":"W4399452667","doi":"10.1200/jco.2024.42.17_suppl.lba8500","title":"Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Clinical endpoint; Lung cancer; Adverse effect; Neutropenia; Chemotherapy; Phases of clinical research; Toxicity; Progression-free survival; Oncology; Gastroenterology; Randomized controlled trial","score_opus":0.032692144126641835,"score_gpt":0.40939710860556705,"score_spread":0.3767049644789252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924216,0.0013861763,0.00012772955,0.0031101245,0.00032943225,0.0019461972,0.0001484306,0.00002371185,0.0005065998],"genre_scores_gemma":[0.9949681,0.00034758155,0.0021760012,0.0016093118,0.00043238685,0.00007555562,0.000066903835,0.00006185032,0.0002622903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621546,0.00038780214,0.001972884,0.00052329985,0.0005394637,0.0003610982],"domain_scores_gemma":[0.9955429,0.002270304,0.0012020558,0.0003310945,0.000315263,0.00033839268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011679704,0.00036717797,0.001624505,0.00017039587,0.000084902334,0.00005852711,0.0001693419,0.00017286143,0.00006475775],"category_scores_gemma":[0.00021388134,0.00018384116,0.00021059607,0.0004216528,0.00021188913,0.00016695153,0.00002734642,0.0009835081,0.0000023911377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07031552,0.015222062,0.81682104,0.00025436337,0.0039348733,0.0019317371,0.0045854817,0.00029523173,0.00010437436,0.0000013810229,0.0038295467,0.0827044],"study_design_scores_gemma":[0.21394718,0.046732467,0.72337157,0.0017762937,0.0065617342,0.000047345195,0.00070374506,0.00126591,0.0002052617,0.0000147424535,0.0050346837,0.00033909248],"about_ca_topic_score_codex":0.0012107592,"about_ca_topic_score_gemma":0.0013346152,"teacher_disagreement_score":0.14363165,"about_ca_system_score_codex":0.0009382554,"about_ca_system_score_gemma":0.0038660627,"threshold_uncertainty_score":0.7496825},"labels":[],"label_agreement":null},{"id":"W4399480368","doi":"10.1200/jco.24.01001","title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Ono Pharmaceutical; Chugai Pharmaceutical; Seagen; MacroGenics; Astex Pharmaceuticals; Novocure; Regeneron Pharmaceuticals; Yuhan; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Chemotherapy; Biology","score_opus":0.049807727072665654,"score_gpt":0.43392178263423586,"score_spread":0.3841140555615702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886831,0.0012885984,0.000052691536,0.0058983937,0.0019512802,0.0010023236,0.000119660705,0.000021133663,0.00098282],"genre_scores_gemma":[0.99681556,0.0014874729,0.00028909778,0.00053101033,0.0005971023,0.000028605227,0.00005366707,0.00003419923,0.00016328091],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99597037,0.0006323373,0.002337443,0.00037314667,0.0003805854,0.000306108],"domain_scores_gemma":[0.99210256,0.006255532,0.0009880915,0.00020760932,0.00023534897,0.00021083112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012689692,0.00022351692,0.0011652128,0.00019002019,0.000052099007,0.00002630334,0.00018411977,0.0002492488,0.00007083625],"category_scores_gemma":[0.00070749375,0.00012376739,0.00016935023,0.00032673808,0.0001271613,0.00015656781,0.00003667355,0.0012589361,0.0000057206357],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24942696,0.03614108,0.2411817,0.0001646232,0.003567251,0.03635366,0.022141429,0.000120042954,0.0016137512,0.000021982292,0.0040293797,0.40523815],"study_design_scores_gemma":[0.2643289,0.07871974,0.64192927,0.0013312855,0.0023537516,0.0002036815,0.0028603172,0.00056904525,0.00017795489,0.00006956042,0.007092542,0.00036398513],"about_ca_topic_score_codex":0.0015536502,"about_ca_topic_score_gemma":0.0024591186,"teacher_disagreement_score":0.40487418,"about_ca_system_score_codex":0.0012861221,"about_ca_system_score_gemma":0.0035633205,"threshold_uncertainty_score":0.63211775},"labels":[],"label_agreement":null},{"id":"W4399507469","doi":"10.1503/cmaj.231562-f","title":"Traitement ciblé oral contre le cancer du poumon non à petites cellules","year":2024,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Montfort Hospital","funders":"","keywords":"Gynecology; Medicine","score_opus":0.007086006544935529,"score_gpt":0.28373053163769385,"score_spread":0.27664452509275833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399507469","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047931746,0.14627518,0.0006355304,0.7622235,0.024009561,0.00055482634,0.00083797966,0.00006175927,0.017469905],"genre_scores_gemma":[0.8850805,0.018631753,0.00012435384,0.013102859,0.018033193,0.000064480875,0.00013366247,0.00007801041,0.06475117],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967515,0.00017383932,0.0006051636,0.00029278395,0.0012797253,0.00089699327],"domain_scores_gemma":[0.9964256,0.00023840272,0.00015813972,0.000099916615,0.0004187118,0.0026592135],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011066627,0.00025460895,0.00039867673,0.0003084611,0.00044054602,0.00035605737,0.00015142278,0.00048462037,0.024478989],"category_scores_gemma":[0.00029815894,0.00022798518,0.00025027883,0.00039101313,0.00008762415,0.00026944888,0.000009800352,0.001086357,0.00060960534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011396704,0.00014908727,0.033430673,0.00018723942,0.001870258,0.0045084613,0.0024901584,0.00005538362,0.000033936278,0.0029522362,0.66065484,0.29365632],"study_design_scores_gemma":[0.0021784557,0.00014417099,0.019736273,0.0022361632,0.0008385335,0.00039444788,0.001562554,0.0047106487,0.000029860355,0.00021671808,0.9677259,0.00022628388],"about_ca_topic_score_codex":0.076301344,"about_ca_topic_score_gemma":0.19435553,"teacher_disagreement_score":0.8371488,"about_ca_system_score_codex":0.006017827,"about_ca_system_score_gemma":0.01870336,"threshold_uncertainty_score":0.9977979},"labels":[],"label_agreement":null},{"id":"W4399570686","doi":"10.1200/jco.2024.42.16_suppl.tps8651","title":"Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated <i>KRAS G12C+</i>advanced non-small cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Pemetrexed; Medicine; Pembrolizumab; Chemotherapy; Lung cancer; Oncology; KRAS; Lung; Internal medicine; non-small cell lung cancer (NSCLC); Phases of clinical research; Cancer; Cancer research; Cisplatin; Colorectal cancer; Immunotherapy","score_opus":0.04445174887146803,"score_gpt":0.48963043435992293,"score_spread":0.4451786854884549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399570686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889397,0.00523501,0.0001547716,0.0025065728,0.00085390935,0.001186204,0.00003489464,0.000022574888,0.0010663369],"genre_scores_gemma":[0.99591255,0.0013683895,0.0010921379,0.00069307606,0.00036241318,0.000052361276,0.0000103091,0.00004660684,0.00046217072],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99638593,0.00025497147,0.0022743747,0.00039618375,0.00036540598,0.00032313238],"domain_scores_gemma":[0.9966476,0.0014144917,0.0010151255,0.00023599948,0.0003456147,0.00034118755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008798539,0.000290673,0.0018261906,0.000390571,0.000060386195,0.000016108655,0.00014382404,0.0002731347,0.0002061864],"category_scores_gemma":[0.00029946954,0.00020440647,0.00033838107,0.00050553307,0.00012264345,0.00012703202,0.000038572143,0.000829578,0.0000013010549],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030435089,0.040013637,0.5690543,0.0009020128,0.0041723005,0.0040616095,0.0074038706,0.000827032,0.005806672,0.000019913754,0.00384326,0.33346027],"study_design_scores_gemma":[0.42802498,0.09649748,0.42610654,0.0026454676,0.008441161,0.00021696294,0.0019673735,0.02039724,0.0030183818,0.00007435181,0.011966985,0.0006430664],"about_ca_topic_score_codex":0.0002906007,"about_ca_topic_score_gemma":0.00034314988,"teacher_disagreement_score":0.3975899,"about_ca_system_score_codex":0.0004723713,"about_ca_system_score_gemma":0.0031765578,"threshold_uncertainty_score":0.8335454},"labels":[],"label_agreement":null},{"id":"W4399571391","doi":"10.1200/jco.2024.42.16_suppl.tps8668","title":"FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Exon; Oncology; Chemotherapy; Internal medicine; Mutation; Cancer research; Gene; Genetics; Biology","score_opus":0.1094437706771043,"score_gpt":0.5412324112596139,"score_spread":0.43178864058250954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399571391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662364,0.0013335537,0.0030369961,0.024932241,0.0015216407,0.0015835697,0.00005509462,0.00002754544,0.0012729757],"genre_scores_gemma":[0.989196,0.001683717,0.0056461655,0.0006425073,0.00134462,0.00013924656,0.00008151954,0.00003700066,0.001229242],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99727815,0.00010950686,0.0019099489,0.00023543295,0.00027371405,0.00019322635],"domain_scores_gemma":[0.9965158,0.0015777056,0.0010414683,0.0001737571,0.00043730764,0.0002539239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007105225,0.00018389017,0.0011824892,0.00017055665,0.000063024454,0.000012430902,0.00007155292,0.00021445274,0.00014234385],"category_scores_gemma":[0.00057349534,0.000111291505,0.000641434,0.0002028191,0.00012817231,0.00015012099,0.0000066530874,0.0002518017,0.000008323197],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3823233,0.013385524,0.0002852282,0.000103778075,0.002545971,0.00028414515,0.0007379581,0.0003122973,0.0005277154,0.00022558674,0.000831956,0.59843653],"study_design_scores_gemma":[0.45308873,0.28952295,0.0017877895,0.0004984185,0.0034019423,0.00023099202,0.00024363062,0.00066138204,0.0014158307,0.0009091011,0.24808899,0.00015024673],"about_ca_topic_score_codex":0.00002657888,"about_ca_topic_score_gemma":0.00011311019,"teacher_disagreement_score":0.5982863,"about_ca_system_score_codex":0.0004186064,"about_ca_system_score_gemma":0.0024220715,"threshold_uncertainty_score":0.45383358},"labels":[],"label_agreement":null},{"id":"W4399571397","doi":"10.1200/jco.2024.42.16_suppl.tps8654","title":"Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring <i>HER2</i> tyrosine kinase domain (TKD) mutations.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; non-small cell lung cancer (NSCLC); Oncology; Standard of care; Lung cancer; Lung; Internal medicine; Clinical endpoint; Randomized controlled trial; A549 cell","score_opus":0.018421592337278008,"score_gpt":0.41105150654300915,"score_spread":0.3926299142057311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399571397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807824,0.005544805,0.0042766174,0.00051125884,0.0026729968,0.0053842533,0.00012012838,0.000012691042,0.0006948688],"genre_scores_gemma":[0.9925665,0.00072417257,0.005806343,0.00011807163,0.00033413744,0.00030146792,0.000045412788,0.000048030557,0.00005584276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936223,0.00057465263,0.0044347006,0.000342878,0.0006967564,0.00032871292],"domain_scores_gemma":[0.9896579,0.0056629935,0.0028128708,0.00023374261,0.0013339019,0.00029860952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002265327,0.0003219456,0.0048785005,0.0003955498,0.0000494434,0.00001717709,0.00014532053,0.00021897799,0.00006994162],"category_scores_gemma":[0.0016667149,0.00020637621,0.0009706031,0.00041707206,0.0002997941,0.00018167097,0.000032235203,0.0007119068,7.757591e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9703918,0.0046562073,0.0018045167,0.00060565205,0.0020626413,0.00040399117,0.0019449805,0.00083865447,0.00008868754,0.000028658704,0.00012117232,0.017053034],"study_design_scores_gemma":[0.94855917,0.038998354,0.00083210785,0.0018074343,0.007642903,0.0000041844423,0.0006371888,0.00091545074,0.00018327143,0.00003199554,0.0002200016,0.00016797087],"about_ca_topic_score_codex":0.00009698048,"about_ca_topic_score_gemma":0.00022081152,"teacher_disagreement_score":0.034342147,"about_ca_system_score_codex":0.00073718233,"about_ca_system_score_gemma":0.005477289,"threshold_uncertainty_score":0.9716476},"labels":[],"label_agreement":null},{"id":"W4399705963","doi":"10.1016/j.jtocrr.2024.100697","title":"Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Cancer Research Society; Cancer Research Foundation","keywords":"Medicine; Oncology; Lung cancer; Internal medicine","score_opus":0.0655007970993161,"score_gpt":0.487848837616346,"score_spread":0.4223480405170299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399705963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936469,0.00033218483,0.000008345058,0.0014343258,0.00039319185,0.0024688072,0.0000739047,0.000060952305,0.0015813533],"genre_scores_gemma":[0.979966,0.0024292145,0.0005081569,0.00010438789,0.00019575347,0.00041551344,0.00021430098,0.000041138228,0.01612554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965703,0.00015217651,0.0012813263,0.00097018015,0.00059806206,0.0004279588],"domain_scores_gemma":[0.9971964,0.001416107,0.00013595613,0.00040527855,0.00039281498,0.00045346364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019567893,0.0001469673,0.00070431916,0.00010765647,0.00016893701,0.0002592442,0.000033115663,0.00014576007,0.000049478967],"category_scores_gemma":[0.0012637306,0.00012195807,0.00019576003,0.0002453737,0.00036377113,0.00012019046,0.000059366706,0.000384172,0.0000013205021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017437553,0.0010928498,0.79190785,0.00010948517,0.0003544719,0.008063645,0.000044680055,8.9255664e-8,2.1183139e-7,0.000003835989,0.0017127851,0.19653572],"study_design_scores_gemma":[0.0049538435,0.0030547432,0.9447161,0.0006802463,0.00022484601,0.00023665093,0.00005573835,0.000016935257,5.177454e-7,0.000236035,0.04569308,0.0001312713],"about_ca_topic_score_codex":0.038549975,"about_ca_topic_score_gemma":0.22937283,"teacher_disagreement_score":0.19640446,"about_ca_system_score_codex":0.00016496753,"about_ca_system_score_gemma":0.00059684936,"threshold_uncertainty_score":0.9678524},"labels":[],"label_agreement":null},{"id":"W4399764893","doi":"10.1038/s41416-024-02755-y","title":"Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response","year":2024,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Government of Canada; Terry Fox Research Institute; Lung Cancer Research Foundation","keywords":"Biology; Adenocarcinoma; Lung cancer; Cancer research; DNA repair; Transcriptome; Gene; Genomics; Copy-number variation; Genetics; Cancer; Gene expression; Oncology; Medicine; Genome","score_opus":0.01157266906522251,"score_gpt":0.3248591430253017,"score_spread":0.3132864739600792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399764893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8941036,0.10285655,0.000027379483,0.0016162513,0.0006455681,0.00026918133,0.000115440715,0.00001844967,0.0003475744],"genre_scores_gemma":[0.9918265,0.0026405146,0.0002950946,0.0002841107,0.00032210402,0.00004104447,0.000011815354,0.00004049117,0.0045383526],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987303,0.000100416684,0.00042187146,0.00021253825,0.00030048654,0.00023441229],"domain_scores_gemma":[0.9992556,0.00013450143,0.00014770169,0.0001213625,0.00019711367,0.00014374033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003355318,0.00015150971,0.00037088667,0.00026674083,0.000066467954,0.00022622912,0.00011631956,0.0000564202,0.00046482263],"category_scores_gemma":[0.00012747996,0.00013626892,0.00017617803,0.00023258549,0.000089886424,0.0003663995,0.000031592765,0.00034735564,0.000007795639],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018727748,0.0011643237,0.077106945,0.0017950885,0.0084619885,0.19433638,0.044399243,0.00067111617,0.47346294,0.0003675349,0.115617834,0.06388887],"study_design_scores_gemma":[0.005031757,0.0005963075,0.7711518,0.008739851,0.0015454263,0.015873373,0.0036469924,0.0004557944,0.17317143,0.0010078002,0.018398741,0.00038072374],"about_ca_topic_score_codex":0.000955488,"about_ca_topic_score_gemma":0.0010649909,"teacher_disagreement_score":0.6940448,"about_ca_system_score_codex":0.00083158654,"about_ca_system_score_gemma":0.0010775988,"threshold_uncertainty_score":0.5556885},"labels":[],"label_agreement":null},{"id":"W4399872066","doi":"10.1002/ijc.35031","title":"Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer","year":2024,"lang":"en","type":"review","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen Elizabeth II Health Sciences Centre; McGill University; McGill University Health Centre; Dalhousie University; Western University; University of Toronto; William Osler Health System; University of Alberta; Juravinski Cancer Centre; Trillium Health Centre; Vancouver Coastal Health Research Institute; Vancouver Coastal Health; University of British Columbia","funders":"Merck Canada; AstraZeneca Canada; Roche Canada","keywords":"Systemic therapy; Medicine; Lung cancer; Cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.01947924567008963,"score_gpt":0.4235454941580283,"score_spread":0.40406624848793865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399872066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013672342,0.98335433,0.00016020014,0.00017004393,0.0016319572,0.0005932502,0.00019465644,0.0000067643614,0.0002164574],"genre_scores_gemma":[0.08399118,0.91463536,0.0001335132,0.000058076654,0.0005225257,0.00013546679,0.0000112124035,0.000051629377,0.00046105855],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9981303,0.00003806313,0.0009591121,0.00023569964,0.00047305727,0.00016377046],"domain_scores_gemma":[0.99831647,0.00008309915,0.0008704513,0.00010874661,0.0005220648,0.00009916344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012055153,0.00029263558,0.0011753223,0.00046282855,0.000016721258,0.000044118926,0.00021853692,0.00014908142,0.000063987965],"category_scores_gemma":[0.000010457259,0.00020032849,0.00033876082,0.00016393427,0.000049092207,0.00016623567,0.000042267024,0.00050584844,0.0000013694564],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021553991,0.000117376556,0.002262881,0.015544291,0.005435382,0.000341084,0.0057011023,0.00044874445,0.00011569361,0.00007788301,0.00026516116,0.96947485],"study_design_scores_gemma":[0.012519126,0.00058583776,0.0012283657,0.68430865,0.01897176,0.0010422587,0.0009044722,0.0005683479,0.00008509644,0.0001619575,0.27873853,0.0008856135],"about_ca_topic_score_codex":0.00026420297,"about_ca_topic_score_gemma":0.0000947733,"teacher_disagreement_score":0.96858925,"about_ca_system_score_codex":0.0011306291,"about_ca_system_score_gemma":0.001963598,"threshold_uncertainty_score":0.81691587},"labels":[],"label_agreement":null},{"id":"W4400029468","doi":"10.1016/j.annonc.2024.05.541","title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; McGill University","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Genentech; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; MacroGenics; Plexxikon; BeiGene; Mirati Therapeutics; Yuhan; Mersana Therapeutics; PharmaMar; LAM Therapeutics; Astex Pharmaceuticals; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; LG Chem; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Osimertinib; Oncology; Lung cancer; Internal medicine; Mutant; Disease; Cancer research; Cancer; Epidermal growth factor receptor; Genetics; Gene","score_opus":0.020748794662583826,"score_gpt":0.36457837862506415,"score_spread":0.3438295839624803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400029468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790969,0.013127016,0.00026276734,0.0036684533,0.0003427613,0.00067143486,0.0014179401,0.00003589046,0.001376827],"genre_scores_gemma":[0.99381846,0.0040777707,0.00093793025,0.00023698689,0.00006785315,0.00017570992,0.000474117,0.00003465063,0.00017653254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982751,0.00007074852,0.0006057326,0.00049878657,0.00021880034,0.0003308485],"domain_scores_gemma":[0.99849886,0.00043846678,0.0003095436,0.00037110335,0.00018151429,0.00020049798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014203285,0.00024659952,0.00087938,0.00046565125,0.000043752072,0.000008926477,0.00012051692,0.00012625082,0.0005577916],"category_scores_gemma":[0.000046715228,0.00019043036,0.0002409027,0.0010521022,0.00013723124,0.000095065734,0.000051878647,0.0002168428,0.0000040430064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079843365,0.004727245,0.4889849,0.0029922833,0.066840656,0.004617609,0.009016537,0.028280687,0.0054892446,0.0001366936,0.004780819,0.30428994],"study_design_scores_gemma":[0.062363643,0.010827235,0.8057357,0.002110243,0.04532471,0.000009846237,0.0019495962,0.03401275,0.021038521,0.00023833306,0.015449554,0.0009398815],"about_ca_topic_score_codex":0.011281971,"about_ca_topic_score_gemma":0.009625205,"teacher_disagreement_score":0.31675076,"about_ca_system_score_codex":0.00028986606,"about_ca_system_score_gemma":0.0017393086,"threshold_uncertainty_score":0.99530196},"labels":[],"label_agreement":null},{"id":"W4400036644","doi":"10.1200/jco.2024.42.16_suppl.8577","title":"A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alethia Biotherapeutics (Canada); McGill University; Institute for Research in Immunology and Cancer; Institut universitaire de cardiologie et de pneumologie de Québec; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Chemoimmunotherapy; Oncology; Cancer; Internal medicine; Clinical trial; Phases of clinical research; Lung cancer; Chemotherapy; Immunotherapy","score_opus":0.03577434989442194,"score_gpt":0.43372774922604534,"score_spread":0.3979533993316234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872445,0.00057039096,0.00028762003,0.008303762,0.0011651753,0.0021427325,0.000025471645,0.000007913078,0.00025242448],"genre_scores_gemma":[0.9923628,0.000054962216,0.005108482,0.001514934,0.00040983656,0.00011198078,0.000008206111,0.000039616694,0.00038918733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969395,0.00025599,0.0016821194,0.00026427623,0.0005831616,0.0002749521],"domain_scores_gemma":[0.9976594,0.00089820346,0.0005773826,0.00022419028,0.00039572967,0.00024513583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017242327,0.00022176206,0.001508137,0.0002221094,0.00006476219,0.000019919798,0.00016997408,0.00011770644,0.000058359004],"category_scores_gemma":[0.00026022954,0.000107614986,0.00037624937,0.00047731362,0.00007920349,0.000117096126,0.00004788733,0.000648266,0.0000031762738],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71586245,0.03985434,0.042443044,0.0006117029,0.011546331,0.001391602,0.011523393,0.0010474226,0.0036791628,0.00002675022,0.0050228927,0.16699089],"study_design_scores_gemma":[0.68449026,0.25466123,0.03788732,0.002167303,0.00775717,0.00002665447,0.000436361,0.00032963385,0.00077587296,0.000034436744,0.011126081,0.0003076991],"about_ca_topic_score_codex":0.00006975919,"about_ca_topic_score_gemma":0.00012060808,"teacher_disagreement_score":0.21480688,"about_ca_system_score_codex":0.00046852094,"about_ca_system_score_gemma":0.0049135713,"threshold_uncertainty_score":0.8716464},"labels":[],"label_agreement":null},{"id":"W4400036770","doi":"10.1200/jco.2024.42.16_suppl.8013","title":"Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Durvalumab; Tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Internal medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Anaplastic lymphoma kinase; Pathology; Cancer; Nivolumab; Receptor; Immunotherapy","score_opus":0.05820676860958907,"score_gpt":0.45930521840007354,"score_spread":0.4010984497904845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400036770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915464,0.001286308,0.0009911774,0.0030499038,0.0024336397,0.0014576283,0.000021484448,0.000028195478,0.0015770148],"genre_scores_gemma":[0.9951315,0.0002677704,0.0021190476,0.00087452895,0.0010003551,0.00014302341,0.000018053835,0.00003046273,0.0004152914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965188,0.00024718407,0.0020107473,0.00043924098,0.00045539506,0.00032865079],"domain_scores_gemma":[0.9976579,0.0004180286,0.0007113811,0.0002044444,0.000670824,0.00033742998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014138542,0.00023837929,0.0012120804,0.0002354189,0.00006132706,0.00005764309,0.00012030814,0.00025162118,0.00011771461],"category_scores_gemma":[0.0009328991,0.00018129418,0.00021547428,0.00087151973,0.000057660083,0.0003844572,0.00006192162,0.0006141655,0.000013514859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007944162,0.002905991,0.95249444,0.00014786085,0.00045138827,0.0010129727,0.0010107793,0.0031682176,0.0003138195,0.000029191395,0.0018437714,0.02867739],"study_design_scores_gemma":[0.017062511,0.0077087795,0.96336544,0.00083466736,0.0010105054,0.000037716985,0.0006356536,0.0059018363,0.00023547048,0.000068618596,0.0029418434,0.00019695965],"about_ca_topic_score_codex":0.00058930024,"about_ca_topic_score_gemma":0.004650475,"teacher_disagreement_score":0.028480431,"about_ca_system_score_codex":0.00329694,"about_ca_system_score_gemma":0.0034052057,"threshold_uncertainty_score":0.8621383},"labels":[],"label_agreement":null},{"id":"W4400038187","doi":"10.1200/jco.2024.42.16_suppl.8642","title":"Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral <i>EGFR</i> mutations: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Meta-analysis; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.13364122823626895,"score_gpt":0.5163258210502982,"score_spread":0.3826845928140293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400038187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000164906,0.9968498,0.000006144387,0.00088842044,0.000058738227,0.0018356211,0.00005217892,0.0000031201416,0.00014109035],"genre_scores_gemma":[0.0014228486,0.9972865,0.00051051745,0.0005427132,0.00003161412,0.000039794686,0.00003667378,0.000021397858,0.00010794107],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9937046,0.0008748493,0.0047346395,0.0002762267,0.0002845395,0.00012511782],"domain_scores_gemma":[0.99297804,0.0026373267,0.0036553196,0.00021848266,0.00028477973,0.00022607988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002263011,0.00028684572,0.014580443,0.00034834284,0.000021794389,0.00001211232,0.000076008495,0.00022428641,0.000022114307],"category_scores_gemma":[0.0014203353,0.00013322242,0.0012617352,0.0005367713,0.00019132323,0.0000687306,0.000048763264,0.0006848191,0.0000013646123],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046324654,0.001488669,0.0013690665,0.6266003,0.3099972,0.00023426421,0.00011302872,0.0000012349133,2.2393167e-9,0.00006146339,0.00015977849,0.05951169],"study_design_scores_gemma":[0.0033050773,0.0032481337,0.0021706752,0.049634162,0.9264764,0.0001291039,0.000014867019,0.0000015444831,3.347431e-9,0.000014584126,0.014905003,0.000100444144],"about_ca_topic_score_codex":0.000014625029,"about_ca_topic_score_gemma":0.00003018895,"teacher_disagreement_score":0.61647916,"about_ca_system_score_codex":0.00011375052,"about_ca_system_score_gemma":0.00097157405,"threshold_uncertainty_score":0.99668986},"labels":[],"label_agreement":null},{"id":"W4400108728","doi":"10.1200/jco.2024.42.16_suppl.8559","title":"Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with <i>KRAS</i>G12C mutation: A phase 1b study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Panitumumab; KRAS; Mutation; Lung cancer; Internal medicine; Oncology; Cancer; Cancer research; Colorectal cancer; Genetics; Biology; Gene","score_opus":0.07031068528454834,"score_gpt":0.5278725660293183,"score_spread":0.45756188074477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98507476,0.0025431109,0.0036224457,0.0033208542,0.0016491791,0.002011533,0.000045993824,0.000037102684,0.0016950362],"genre_scores_gemma":[0.9911286,0.0002777738,0.0029787184,0.0008153324,0.0016570833,0.00023232956,0.000018830733,0.000043821143,0.002847477],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975514,0.00013121426,0.0014837917,0.00029558048,0.0002856532,0.00025240207],"domain_scores_gemma":[0.9968717,0.0012404042,0.00072536425,0.0001649778,0.00065515534,0.0003423878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082135975,0.00020513144,0.001170406,0.00014339128,0.0000806965,0.000038379196,0.00011032818,0.0002014775,0.00012023363],"category_scores_gemma":[0.0002021652,0.00012245605,0.00037497506,0.00023195955,0.00008591566,0.0001432958,0.000018870127,0.0005447214,0.0000066294383],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07045387,0.07597279,0.23256116,0.0025026628,0.02528944,0.028336378,0.01726121,0.0012191079,0.00069476105,0.00012652106,0.0768698,0.4687123],"study_design_scores_gemma":[0.3529087,0.25014597,0.10130533,0.002303255,0.04439506,0.0016888045,0.0047188173,0.014298868,0.00085641595,0.00019970624,0.22638024,0.0007988276],"about_ca_topic_score_codex":0.00013701722,"about_ca_topic_score_gemma":0.00028732297,"teacher_disagreement_score":0.46791348,"about_ca_system_score_codex":0.0005939128,"about_ca_system_score_gemma":0.0060811834,"threshold_uncertainty_score":0.99955344},"labels":[],"label_agreement":null},{"id":"W4400108744","doi":"10.1200/jco.2024.42.16_suppl.8549","title":"Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Lung cancer; Cancer; Internal medicine; Cancer research","score_opus":0.10922058810761197,"score_gpt":0.48642766543260335,"score_spread":0.37720707732499137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400108744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987218,0.0051054335,0.00004445419,0.0049760207,0.0017809605,0.0005539746,0.000018390287,0.00000748825,0.00029526796],"genre_scores_gemma":[0.9953776,0.0017293642,0.0020221479,0.0003634527,0.0002987799,0.0000137331135,0.0000030887516,0.000023066994,0.00016874544],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99712515,0.0003896215,0.001885709,0.0002312328,0.00017324906,0.00019503295],"domain_scores_gemma":[0.9945389,0.00428773,0.00055720925,0.00013022403,0.00016705139,0.00031889646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021711567,0.00014730205,0.0010105566,0.00030387533,0.000019982475,0.0000129442005,0.00006482512,0.00014800087,0.00006905807],"category_scores_gemma":[0.0010993324,0.000102032696,0.0002685626,0.0002849552,0.00011086318,0.00004996056,0.00003268209,0.0003641732,0.000005279412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31358,0.009298576,0.025162859,0.0003891877,0.007307124,0.005225782,0.0051815705,0.000396277,0.08075975,0.000010889391,0.00308561,0.5496023],"study_design_scores_gemma":[0.19145022,0.17590886,0.54101986,0.0027837497,0.007467354,0.0002740677,0.0018924469,0.001599512,0.0158221,0.000050536757,0.061171137,0.00056016754],"about_ca_topic_score_codex":0.0001220867,"about_ca_topic_score_gemma":0.00010288591,"teacher_disagreement_score":0.54904217,"about_ca_system_score_codex":0.00049986853,"about_ca_system_score_gemma":0.002783,"threshold_uncertainty_score":0.49369228},"labels":[],"label_agreement":null},{"id":"W4400109132","doi":"10.1200/jco.2024.42.16_suppl.8052","title":"Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Stage (stratigraphy); Oncology; Internal medicine; Hazard ratio; Adenocarcinoma; ROS1; Cohort; Chemotherapy; Lung cancer; Proportional hazards model; Cancer; Confidence interval; Colorectal cancer","score_opus":0.04536788095441011,"score_gpt":0.46609689625186485,"score_spread":0.4207290152974547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218243,0.0015138079,0.00048430727,0.002106762,0.0004440128,0.00025128416,0.000040888295,0.00000820058,0.0029683055],"genre_scores_gemma":[0.9924673,0.00044181081,0.0026995465,0.0003038001,0.00012920394,0.000015767888,0.000014784762,0.000015954574,0.003911863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978135,0.00013817589,0.0014228761,0.00018475417,0.00026492338,0.00017574178],"domain_scores_gemma":[0.99748737,0.0011149856,0.00065065315,0.00014656757,0.00042520955,0.0001752191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006623458,0.00011726744,0.0013494404,0.0005845004,0.00002359037,0.000012052242,0.00009121908,0.00017625852,0.00044177432],"category_scores_gemma":[0.00024808038,0.00007116639,0.0004520111,0.00092198414,0.00009621932,0.00012582155,0.000019228382,0.0005493107,0.000003157082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073728536,0.00091334234,0.9835679,0.00010145063,0.006184614,0.0010629215,0.0010395373,0.0023128185,0.00009332022,0.00002388101,0.00049676344,0.0034661745],"study_design_scores_gemma":[0.0053703687,0.0023938064,0.9745674,0.00022131833,0.009925585,0.000008230449,0.0002837773,0.0028002542,0.000102742204,0.000014116337,0.0042368528,0.000075516175],"about_ca_topic_score_codex":0.0007522993,"about_ca_topic_score_gemma":0.0014824799,"teacher_disagreement_score":0.00900046,"about_ca_system_score_codex":0.00027879816,"about_ca_system_score_gemma":0.0028808669,"threshold_uncertainty_score":0.5110534},"labels":[],"label_agreement":null},{"id":"W4400151466","doi":"10.1016/j.annonc.2024.05.375","title":"463P A real-world study to evaluate biomarker testing and treatment management in patients with locally advanced unresectable or metastatic G/GEJ adenocarcinoma in France, Germany, Italy, Spain, UK and Canada: Adelphi Real World G/GEJ cancer disease specific programme","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Toronto Public Health","funders":"","keywords":"Medicine; Biomarker; Oncology; Adenocarcinoma; Internal medicine; Cancer","score_opus":0.08284073563039081,"score_gpt":0.4049356520725289,"score_spread":0.3220949164421381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899418,0.0021952845,0.0000033259576,0.0019847981,0.00009716917,0.00422654,0.00009904498,0.000024188577,0.001427886],"genre_scores_gemma":[0.99460864,0.0006674865,0.0009129795,0.00028532645,0.00002479427,0.0013418128,0.000041513144,0.00003815029,0.0020792764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978663,0.00011978,0.00051689625,0.0006300333,0.0003463075,0.00052072405],"domain_scores_gemma":[0.9988806,0.00023489915,0.00011323106,0.00025599657,0.00018370048,0.0003315276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025941728,0.00029746533,0.00062615436,0.00060442224,0.00005765116,0.000027270113,0.00006714182,0.00002128612,0.000048038077],"category_scores_gemma":[0.000026486752,0.00020588584,0.000028507618,0.0011470411,0.000081356186,0.00009585332,0.00007101971,0.000101401754,0.0000011547058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031304276,0.001835481,0.8107734,0.00025408642,0.0009107383,0.0026578426,0.00087166,0.00020841447,0.000003342743,0.000031535765,0.00033222637,0.17899087],"study_design_scores_gemma":[0.008977074,0.005730737,0.97946936,0.00066364027,0.00067930954,0.0000031328748,0.00067202747,0.00031129972,0.000004587197,0.000028478595,0.0032615087,0.00019886371],"about_ca_topic_score_codex":0.320851,"about_ca_topic_score_gemma":0.86041445,"teacher_disagreement_score":0.5395635,"about_ca_system_score_codex":0.00090842665,"about_ca_system_score_gemma":0.001404761,"threshold_uncertainty_score":0.8395781},"labels":[],"label_agreement":null},{"id":"W4400244096","doi":"10.2196/51381","title":"Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Gefitinib; Lung cancer; Population; Cancer registry; Internal medicine; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Cancer; Environmental health","score_opus":0.09334291967005612,"score_gpt":0.5398483479697775,"score_spread":0.4465054282997214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400244096","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14146349,0.0000028668353,0.000057078578,0.00038212453,0.000011245792,0.856708,0.0012652437,0.000035709178,0.0000742757],"genre_scores_gemma":[0.15357196,2.3305675e-7,0.001639569,0.000004939183,0.00009910715,0.8423842,0.00029599288,0.0000390046,0.0019649488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970188,0.00023316847,0.0009125643,0.00061574363,0.0008809114,0.00033877583],"domain_scores_gemma":[0.9969321,0.0009550734,0.0003201181,0.00015421721,0.0015209016,0.00011760895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009535895,0.00020428766,0.000466704,0.00049214216,0.00013654491,0.000065188586,0.00007064106,0.0000932272,0.000055583776],"category_scores_gemma":[0.0012657793,0.00015663583,0.00008411856,0.00073368615,0.000060867944,0.0003819256,0.00003638466,0.00021723022,6.1065487e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051558975,0.0044142357,0.86035043,0.0056942566,0.0009906302,0.000017962058,0.036931355,0.00013543005,0.005844978,0.000311071,0.0054956954,0.028254958],"study_design_scores_gemma":[0.04506151,0.017070075,0.9042098,0.008998377,0.00008727149,0.0000064821675,0.0012813951,0.002535311,0.017105162,0.001319095,0.0020120027,0.00031352547],"about_ca_topic_score_codex":0.00083850324,"about_ca_topic_score_gemma":0.00041175366,"teacher_disagreement_score":0.04385934,"about_ca_system_score_codex":0.0008707966,"about_ca_system_score_gemma":0.0010606996,"threshold_uncertainty_score":0.6387424},"labels":[],"label_agreement":null},{"id":"W4400265274","doi":"10.1200/jco.2024.42.16_suppl.tps2689","title":"A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tolerability; Medicine; Open label; Open label study; Maximum tolerated dose; Oncology; Internal medicine; Adverse effect","score_opus":0.15761621244561821,"score_gpt":0.5822574384733649,"score_spread":0.4246412260277467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400265274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851962,0.00033921638,0.00004425581,0.010968313,0.00039610028,0.00071965536,0.000007076975,0.0000037307723,0.0023254824],"genre_scores_gemma":[0.9986445,0.00017289667,0.00035639518,0.0005615218,0.00014100617,0.000009945619,0.0000016041456,0.0000068097766,0.0001053514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99752617,0.00036597598,0.0016842699,0.00015562773,0.00017437754,0.00009359826],"domain_scores_gemma":[0.9968831,0.0022116455,0.000505645,0.0001457325,0.00014633704,0.00010752866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002897111,0.0000792073,0.0008863581,0.00007144976,0.000030368019,0.00001253613,0.00009203891,0.00008137327,0.000055182096],"category_scores_gemma":[0.0015454027,0.000041920026,0.00007422688,0.00016179883,0.000106715,0.00012038796,0.00004467513,0.00048748447,0.000002204956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025328796,0.05022072,0.073230356,0.000072368915,0.00082911266,0.00090079015,0.0027647654,0.00008394407,0.0003979319,0.0009913596,0.0005775384,0.8446023],"study_design_scores_gemma":[0.06578619,0.10423784,0.8127251,0.0005501018,0.00077457674,0.00010813547,0.0016339126,0.0010896358,0.00005952708,0.0015857898,0.01135861,0.000090552036],"about_ca_topic_score_codex":0.000021171456,"about_ca_topic_score_gemma":0.000055176908,"teacher_disagreement_score":0.84451175,"about_ca_system_score_codex":0.00016150632,"about_ca_system_score_gemma":0.0009812581,"threshold_uncertainty_score":0.21179046},"labels":[],"label_agreement":null},{"id":"W4400270477","doi":"10.1200/jco.2024.42.16_suppl.e20530","title":"What is a bad ALK? A scoping review of molecular markers of poor prognosis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; University Health Network; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Crizotinib; Internal medicine; Oncology; Lung cancer","score_opus":0.16078240076422504,"score_gpt":0.5981349064903068,"score_spread":0.43735250572608175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400270477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011966017,0.9897918,0.000009714473,0.0052444106,0.0018075667,0.0015718634,0.000020905856,0.0000045507636,0.0015372062],"genre_scores_gemma":[0.000011705243,0.99458164,0.0017924077,0.0028936288,0.00036504783,0.000048969043,0.000012902261,0.000040279803,0.00025340696],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99262613,0.0005557174,0.005903068,0.00026196984,0.00047252164,0.00018058799],"domain_scores_gemma":[0.9920668,0.0012637902,0.0054917824,0.00025102485,0.00065877265,0.00026780608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002764451,0.0002724538,0.0076314183,0.00023637795,0.000011254578,0.0000092871815,0.00020674498,0.0005220973,0.00024355069],"category_scores_gemma":[0.0018788526,0.00015904331,0.0033601315,0.00036311685,0.0001833871,0.00010217778,0.000073749776,0.00094964524,0.000017642504],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000905786,0.0005330167,0.000010182319,0.2624512,0.0035344963,0.0004892277,0.000016525806,2.692825e-8,2.4190987e-7,0.000015454068,0.006956243,0.7259028],"study_design_scores_gemma":[0.0007295083,0.003445351,0.000004813211,0.50798726,0.024778573,0.0003052122,0.000012514691,2.9323311e-7,0.0000012898596,0.00001947697,0.46265733,0.000058356094],"about_ca_topic_score_codex":0.0000056246695,"about_ca_topic_score_gemma":0.0000020542868,"teacher_disagreement_score":0.72584444,"about_ca_system_score_codex":0.00021785586,"about_ca_system_score_gemma":0.01081694,"threshold_uncertainty_score":0.9947908},"labels":[],"label_agreement":null},{"id":"W4400391734","doi":"10.1016/j.ejca.2024.114204","title":"Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Amgen","keywords":"KRAS; Medicine; Pharmacokinetics; Lung cancer; Oncology; Internal medicine; Pharmacology; Cancer; Colorectal cancer","score_opus":0.010072802012246071,"score_gpt":0.3122388276896341,"score_spread":0.30216602567738804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400391734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864761,0.0054837866,0.00009415214,0.00075995526,0.00048884057,0.00055731664,0.000032831722,0.00005529328,0.0060516726],"genre_scores_gemma":[0.9934055,0.0004915317,0.000588751,0.000312,0.00024142064,0.000013376571,0.000022815077,0.000088665045,0.0048358995],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998355,0.00013776701,0.0005461966,0.00025058433,0.00041882138,0.0002916773],"domain_scores_gemma":[0.99896884,0.00004556355,0.00023856903,0.00018205808,0.0003506494,0.00021430946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020679194,0.00023581844,0.00039176462,0.00023196833,0.000053426735,0.000062081665,0.00011999119,0.000023963265,0.00033854877],"category_scores_gemma":[0.000048519018,0.00013849812,0.00009828163,0.0005285431,0.000055814457,0.00031528162,0.000018572335,0.0003180081,0.00003893009],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016553728,0.0013504328,0.37092602,0.0005804857,0.0029435798,0.013068457,0.0081205685,0.0016234198,0.002451081,0.00003002596,0.011307571,0.5710446],"study_design_scores_gemma":[0.030823126,0.0067120185,0.8521573,0.009191791,0.0018485417,0.00019929314,0.00038288947,0.0001257685,0.0010366461,0.000010072566,0.097008295,0.0005042757],"about_ca_topic_score_codex":0.000041109808,"about_ca_topic_score_gemma":0.00007371128,"teacher_disagreement_score":0.57054037,"about_ca_system_score_codex":0.0005337668,"about_ca_system_score_gemma":0.00062460423,"threshold_uncertainty_score":0.5647789},"labels":[],"label_agreement":null},{"id":"W4400408056","doi":"10.1200/jco.2024.42.16_suppl.tps6122","title":"Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Oncology; Basal cell; Internal medicine; Head and neck; Minimal residual disease; Head and neck cancer; Cancer research; Radiation therapy; Surgery; Leukemia","score_opus":0.04711227416459132,"score_gpt":0.4684984377249661,"score_spread":0.4213861635603747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400408056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743,0.0028220373,0.00006577564,0.0071771606,0.00054702855,0.00035342723,0.000005648764,0.000009788608,0.0015891587],"genre_scores_gemma":[0.997765,0.00019982795,0.0006689986,0.0007786052,0.00033240474,0.000014225778,0.0000062695954,0.000018434524,0.00021620933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802446,0.00029907568,0.0010783355,0.00022298982,0.00022637645,0.00014873994],"domain_scores_gemma":[0.99844944,0.00066697586,0.00026446613,0.00012078247,0.0001223408,0.00037597684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006918319,0.00012042495,0.0006095369,0.00017893569,0.00002200268,0.000017324954,0.000063937965,0.00012157729,0.000042285115],"category_scores_gemma":[0.0004736552,0.00008738236,0.00019066977,0.00012680165,0.00011060934,0.00011372638,0.00003284667,0.00056149083,0.0000081496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01343861,0.00960734,0.6520515,0.00029377075,0.00040222114,0.04341616,0.002689852,0.00025697958,0.0007090415,0.00033229036,0.0025742503,0.27422798],"study_design_scores_gemma":[0.013795906,0.0136799775,0.95581836,0.00016850086,0.0007794201,0.0001974076,0.0007146386,0.00013965795,0.00001409897,0.00036583937,0.014234965,0.00009120682],"about_ca_topic_score_codex":0.00003976544,"about_ca_topic_score_gemma":0.00012722249,"teacher_disagreement_score":0.30376688,"about_ca_system_score_codex":0.00020969922,"about_ca_system_score_gemma":0.0016804357,"threshold_uncertainty_score":0.3563349},"labels":[],"label_agreement":null},{"id":"W4400452669","doi":"10.1016/j.jtho.2024.05.270","title":"PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Exon; Oncology; Chemotherapy; Internal medicine; Genetics; Gene","score_opus":0.06063335095721781,"score_gpt":0.4938462651588927,"score_spread":0.43321291420167485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9544617,0.0042315493,0.0032682996,0.030599955,0.001992885,0.0022624012,0.00008025992,0.00010146573,0.0030015146],"genre_scores_gemma":[0.9703709,0.00056966575,0.021624692,0.000781001,0.0019806097,0.00036367858,0.000081808095,0.00007615708,0.0041515236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982668,0.000070307564,0.0007742027,0.0002951928,0.00025645902,0.0003370407],"domain_scores_gemma":[0.9981224,0.0005675432,0.00046843203,0.00020961632,0.00036871375,0.00026328614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032633758,0.00027737502,0.0007496613,0.0002909879,0.00018849071,0.000044163047,0.000094631934,0.0001471899,0.00014127702],"category_scores_gemma":[0.00019598818,0.00017586522,0.00032101994,0.00038671365,0.00007228967,0.00020232043,0.000011228801,0.00025704238,0.000015484438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21111329,0.0054487325,0.00012539921,0.00019157905,0.0018470623,0.0010455054,0.0018476808,0.00042729705,0.0035329172,0.000053638167,0.001890392,0.7724765],"study_design_scores_gemma":[0.20368542,0.19213313,0.00031420158,0.0015311155,0.0054539153,0.0033619252,0.0007436148,0.0014494384,0.006972439,0.0007132327,0.5832508,0.00039073426],"about_ca_topic_score_codex":0.00002825982,"about_ca_topic_score_gemma":0.00009780921,"teacher_disagreement_score":0.7720858,"about_ca_system_score_codex":0.0012889489,"about_ca_system_score_gemma":0.0016387862,"threshold_uncertainty_score":0.7171576},"labels":[],"label_agreement":null},{"id":"W4400452973","doi":"10.1016/j.jtho.2024.05.150","title":"PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; ROS1; Trident; Oncology; Internal medicine; Phase (matter); Adenocarcinoma; Cancer","score_opus":0.014774741149493426,"score_gpt":0.4350643118021281,"score_spread":0.4202895706526347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987688,0.0012996081,0.00018819624,0.0061931736,0.0026437037,0.0007624583,0.0000973438,0.000017782173,0.0011097073],"genre_scores_gemma":[0.99709713,0.00007606756,0.0006911602,0.0006050919,0.0009689339,0.000023331104,0.000078535544,0.000025950454,0.00043380895],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99828684,0.00023547927,0.0006594231,0.00022458995,0.00037735444,0.00021632912],"domain_scores_gemma":[0.99855185,0.0005060825,0.00039008856,0.00018338342,0.00023099702,0.0001375736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043554784,0.00016858801,0.0005085758,0.00019039416,0.0000928436,0.000052771255,0.00011321818,0.00011831123,0.00027375575],"category_scores_gemma":[0.00019323397,0.000090024354,0.00017417317,0.00033166746,0.00008024546,0.00019819921,0.000033212596,0.0005609815,0.000025556918],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25817335,0.0058839903,0.012983539,0.000034522152,0.0020519095,0.004688821,0.0048663253,0.000029325287,0.0003704784,0.00004404194,0.016785843,0.69408786],"study_design_scores_gemma":[0.4980418,0.10528941,0.21733908,0.005178199,0.01493413,0.0023121287,0.0047398526,0.00052223547,0.0035468312,0.0013876782,0.14570044,0.0010082133],"about_ca_topic_score_codex":0.00009953106,"about_ca_topic_score_gemma":0.00009779981,"teacher_disagreement_score":0.69307965,"about_ca_system_score_codex":0.0006719622,"about_ca_system_score_gemma":0.0010116214,"threshold_uncertainty_score":0.36710867},"labels":[],"label_agreement":null},{"id":"W4400833855","doi":"10.1002/mco2.644","title":"Development of a genome atlas for discriminating benign, preinvasive, and invasive lung nodules","year":2024,"lang":"en","type":"article","venue":"MedComm","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"Guangzhou Medical University; National Science Foundation","keywords":"Atlas (anatomy); Lung; Medicine; Pathology; Biology; Anatomy; Internal medicine","score_opus":0.02416500924613048,"score_gpt":0.33116557228044013,"score_spread":0.30700056303430967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400833855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868523,0.00443473,0.0041429996,0.0009907677,0.00012478873,0.0008530358,0.000049652717,0.000047722566,0.002504042],"genre_scores_gemma":[0.96485627,0.00005737975,0.033751715,0.00006123174,0.000056490226,0.00018469653,0.00011032087,0.00001837053,0.0009035362],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994322,0.0000067025426,0.00018195323,0.00016436372,0.00009617434,0.00011859226],"domain_scores_gemma":[0.9996232,0.00013747883,0.00003207775,0.00009079243,0.00005719085,0.00005925328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006793488,0.00008847198,0.00016181564,0.000074729855,0.00007589167,0.000017239781,0.0000306919,0.000027513655,0.000023327138],"category_scores_gemma":[0.000058453115,0.000065942,0.00004103002,0.00007010797,0.000031871034,0.000052111503,0.000031890908,0.000042140204,0.000002431014],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036817152,0.0010017033,0.033036828,0.027645042,0.0064918417,0.0002683405,0.2634517,0.00005412221,0.2577587,0.028229311,0.004389631,0.3773046],"study_design_scores_gemma":[0.01505285,0.0020971342,0.29503706,0.011583849,0.007920582,0.00035237512,0.027714448,0.005054277,0.37911087,0.004847085,0.24950059,0.0017289037],"about_ca_topic_score_codex":0.000015477764,"about_ca_topic_score_gemma":0.00008449315,"teacher_disagreement_score":0.37557572,"about_ca_system_score_codex":0.00008987785,"about_ca_system_score_gemma":0.00023596358,"threshold_uncertainty_score":0.26890367},"labels":[],"label_agreement":null},{"id":"W4400873244","doi":"10.3390/cancers16142611","title":"Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Cancers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Neurocognitive; Meta-analysis; Lung cancer; Medicine; Internal medicine; Cochrane Library; Adverse effect; Mood; Cognition; Clinical psychology; Psychiatry","score_opus":0.04527651436493039,"score_gpt":0.3998928138437337,"score_spread":0.3546162994788033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400873244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007149706,0.9861688,0.0000070508645,0.00019459637,0.00013764232,0.011615388,0.000632065,0.00003875613,0.0011985342],"genre_scores_gemma":[0.000078446625,0.97847724,0.000061233615,0.001010913,0.000018219991,0.009921762,0.00021840614,0.0000886491,0.010125155],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971659,0.0001950605,0.0011975118,0.0008538879,0.0002552224,0.00033242546],"domain_scores_gemma":[0.99849385,0.000120194985,0.0004723849,0.00050254597,0.00012601455,0.0002850287],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002460396,0.0006335025,0.0074283076,0.00070170057,0.000044572374,0.000013376117,0.00013548926,0.00016709889,0.00029191017],"category_scores_gemma":[0.000060533373,0.00040899913,0.0019430952,0.0025910044,0.00002406786,0.00005055739,0.0000692226,0.00043400767,0.00008052822],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000029563857,0.000014851048,0.000007539484,0.847621,0.15041947,0.00013533152,0.00037466208,0.000033713306,1.7754548e-8,0.0000023667535,0.0005067373,0.0008813104],"study_design_scores_gemma":[0.00027311305,0.000045794,0.0000039105735,0.16035144,0.8293237,0.000014824956,0.000053494514,0.000034662487,7.273561e-8,0.0000016655084,0.009627858,0.00026945604],"about_ca_topic_score_codex":0.0006954026,"about_ca_topic_score_gemma":0.00034720075,"teacher_disagreement_score":0.6872696,"about_ca_system_score_codex":0.002768787,"about_ca_system_score_gemma":0.001704444,"threshold_uncertainty_score":0.9998362},"labels":[],"label_agreement":null},{"id":"W4401113520","doi":"10.1007/s40487-024-00292-5","title":"Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC","year":2024,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Osimertinib; Medicine; Discontinuation; Oncology; Internal medicine; Lung cancer; Tolerability; Erlotinib; Regimen; Epidermal growth factor receptor; Cancer; Adverse effect","score_opus":0.016297307568909986,"score_gpt":0.3246357236851056,"score_spread":0.3083384161161956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401113520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964259,0.0015669091,0.000033267723,0.0012046334,0.0000341119,0.00046501379,0.000022297856,0.000015643414,0.0002322114],"genre_scores_gemma":[0.9981723,0.0005302234,0.00014678041,0.00032730316,0.000017969482,0.00014997655,0.00006687166,0.00001098536,0.00057762396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995641,0.00004025274,0.00009165311,0.00016558394,0.000047128597,0.00009126844],"domain_scores_gemma":[0.99978554,0.0000774019,0.000017971113,0.0000656331,0.000012059534,0.00004136528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029515892,0.000088504145,0.00014661092,0.000062413426,0.000026381014,0.000021598114,0.000007277794,0.000030210807,0.000041141087],"category_scores_gemma":[0.0000023194932,0.000050479022,0.00001516656,0.000050805527,0.00003733835,0.00008441574,0.0000037092814,0.00004375207,0.0000019408992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011108299,0.0004665446,0.6796559,0.000009793305,0.0003174231,0.000082983475,0.0024796817,4.2348722e-7,0.000007476777,0.00007240528,0.00001825247,0.31577826],"study_design_scores_gemma":[0.006883655,0.003745751,0.9650106,0.00008385627,0.00022484957,0.000010224185,0.00010678814,0.000034947763,0.00003200518,0.000035244855,0.023771575,0.000060527098],"about_ca_topic_score_codex":0.00015753036,"about_ca_topic_score_gemma":0.00019327555,"teacher_disagreement_score":0.31571773,"about_ca_system_score_codex":0.000083891544,"about_ca_system_score_gemma":0.00004867039,"threshold_uncertainty_score":0.20584749},"labels":[],"label_agreement":null},{"id":"W4401246140","doi":"10.22141/2663-3272.7.1.2024.97","title":"Молекулярні біомаркери в менеджменті пацієнтів з недрібноклітинним раком легень","year":2024,"lang":"uk","type":"article","venue":"Practical oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Geography","score_opus":0.05376135599322803,"score_gpt":0.5215471573161271,"score_spread":0.4677858013228991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401246140","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054454594,0.035293832,0.002735713,0.2449549,0.014790983,0.0019018521,0.00022556166,0.000703147,0.69394857],"genre_scores_gemma":[0.8934855,0.0072996104,0.007982748,0.008429899,0.0067010894,0.00042168392,0.0003191921,0.00024799185,0.07511232],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99533796,0.0004826697,0.0010290642,0.0012362612,0.0006811772,0.0012328407],"domain_scores_gemma":[0.9945979,0.003284045,0.0002150355,0.00073812745,0.00027354574,0.00089134515],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008347867,0.0006175077,0.001109476,0.00035639977,0.00030182643,0.00023461803,0.00021607727,0.00089931005,0.010714998],"category_scores_gemma":[0.0016281216,0.0005117872,0.00044550406,0.00080239034,0.0005169707,0.000592359,0.00022485627,0.0018088061,0.016976623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011968103,0.004917216,0.0012350045,0.0014392425,0.005656676,0.020731855,0.0043066624,0.0000135060645,0.0012845001,0.29920503,0.29170138,0.36831215],"study_design_scores_gemma":[0.0027696856,0.003909367,0.00153795,0.00048486644,0.006071588,0.0016284605,0.0009026089,0.0018679069,0.00022585658,0.0035318204,0.97658664,0.0004832426],"about_ca_topic_score_codex":0.00054341985,"about_ca_topic_score_gemma":0.00017282157,"teacher_disagreement_score":0.88804,"about_ca_system_score_codex":0.0024228864,"about_ca_system_score_gemma":0.009262086,"threshold_uncertainty_score":0.9997334},"labels":[],"label_agreement":null},{"id":"W4401281322","doi":"10.1016/j.lungcan.2024.107919","title":"Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute; EMD Serono; International Society for Pharmacoepidemiology; Gilead Sciences; Sanofi; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Ceritinib; Oncology; Internal medicine; Cancer; Receptor","score_opus":0.01174501105919376,"score_gpt":0.329370564327469,"score_spread":0.31762555326827524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401281322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96276575,0.031218609,0.0004183728,0.0002343944,0.0007152627,0.0025498695,0.000550588,0.00005538755,0.0014917479],"genre_scores_gemma":[0.9909567,0.0029758008,0.0007743773,0.00008096417,0.00038082257,0.0018690563,0.00017532591,0.00005704203,0.0027298995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883586,0.000040287807,0.00025588373,0.00050106854,0.000118848206,0.00024802357],"domain_scores_gemma":[0.9992997,0.0001801057,0.00009094273,0.00015394554,0.00014833186,0.00012698324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010945043,0.00026943814,0.00041595596,0.00015687595,0.00012856018,0.000042333206,0.000025524663,0.00007669001,0.00003264681],"category_scores_gemma":[0.0000059059525,0.0002136152,0.00008979639,0.00022274631,0.000057134166,0.00016564244,0.000019635841,0.00008474037,2.9461242e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009280513,0.0001882197,0.058537364,0.009327388,0.0020753772,0.00008076459,0.0076976297,0.0017995227,0.8895034,0.0005846127,0.0014761045,0.027801564],"study_design_scores_gemma":[0.008726851,0.0011110273,0.048268072,0.0052528116,0.004600759,0.000012796791,0.00029308294,0.027300386,0.9017388,0.000052030904,0.0021487859,0.00049456407],"about_ca_topic_score_codex":0.0052821217,"about_ca_topic_score_gemma":0.005854609,"teacher_disagreement_score":0.028242808,"about_ca_system_score_codex":0.002100112,"about_ca_system_score_gemma":0.00075320655,"threshold_uncertainty_score":0.8710975},"labels":[],"label_agreement":null},{"id":"W4401351374","doi":"10.1016/j.lungcan.2024.107921","title":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"UCLH Biomedical Research Centre; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; University College London; Amgen","keywords":"Docetaxel; Medicine; KRAS; Oncology; Internal medicine; Mutation; Chemotherapy; Cancer; Genetics","score_opus":0.013747274052184733,"score_gpt":0.36173386110479955,"score_spread":0.3479865870526148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401351374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831912,0.006761623,0.00072009326,0.0013893481,0.0010410883,0.0039731064,0.0001769933,0.00028471995,0.0024618558],"genre_scores_gemma":[0.99162924,0.00015323557,0.0009307707,0.00021817788,0.00008408601,0.0027774754,0.00046915634,0.000070295675,0.0036675767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858415,0.000017321807,0.00035273822,0.0004545936,0.00024826883,0.0003429374],"domain_scores_gemma":[0.99925005,0.00012366749,0.000104772625,0.00023799122,0.00016787896,0.000115633695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044476317,0.00025534784,0.00038789798,0.00017187143,0.000068136906,0.00004465166,0.000040658422,0.000080357415,0.000120711346],"category_scores_gemma":[0.000044043245,0.00017845775,0.00010938246,0.000397667,0.000038514037,0.00021230716,0.000009301528,0.00011651535,0.000006641142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025955796,0.0018291242,0.6684627,0.0032235517,0.012459179,0.0021175756,0.015722597,0.004693426,0.0025642335,0.00097248086,0.011830345,0.25016898],"study_design_scores_gemma":[0.19570786,0.013221861,0.5707992,0.013136951,0.027240165,0.0003565217,0.0044201887,0.03541197,0.011817966,0.00037006923,0.12388917,0.0036281247],"about_ca_topic_score_codex":0.001097048,"about_ca_topic_score_gemma":0.0017072336,"teacher_disagreement_score":0.24654084,"about_ca_system_score_codex":0.0009245301,"about_ca_system_score_gemma":0.0005641909,"threshold_uncertainty_score":0.72772956},"labels":[],"label_agreement":null},{"id":"W4401352393","doi":"10.3390/curroncol31080327","title":"Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Osimertinib; Medicine; Lung cancer; Attrition; Population; Health care; Clinical trial; Oncology; Cohort; Intensive care medicine; Cancer; Internal medicine; Adenocarcinoma; Environmental health","score_opus":0.03808895447084735,"score_gpt":0.4177917083479862,"score_spread":0.3797027538771388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401352393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98821616,0.0037430942,0.0000035888245,0.004684777,0.00025184196,0.0024153504,0.00026492224,0.000039162893,0.00038111574],"genre_scores_gemma":[0.99368674,0.0030203238,0.00006394574,0.0004524825,0.00003645064,0.000739623,0.0010039619,0.000048576836,0.0009478994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814695,0.0001709336,0.0004909999,0.0005879721,0.00012982811,0.00047329435],"domain_scores_gemma":[0.9990475,0.00029103918,0.00014108414,0.00021700098,0.000054741744,0.00024860058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006547068,0.00031990546,0.00073611893,0.00035704524,0.000068208254,0.000022782031,0.000047947156,0.00008218287,0.00001384847],"category_scores_gemma":[0.000006543393,0.00022751141,0.00005394255,0.00038234267,0.000043151256,0.000093624105,0.000032020846,0.00027840634,0.000002612465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046324646,0.0014918189,0.9186549,0.00046623568,0.00011483518,0.00010285635,0.0047341273,0.000022047701,0.000002319583,0.000019039273,0.0002226645,0.07370589],"study_design_scores_gemma":[0.009891414,0.003069932,0.9741235,0.0019799646,0.00024381229,0.000004272298,0.0002314994,0.00040521641,0.00005155509,0.0000020127907,0.009805545,0.0001913253],"about_ca_topic_score_codex":0.12571484,"about_ca_topic_score_gemma":0.3854426,"teacher_disagreement_score":0.25972778,"about_ca_system_score_codex":0.0041618547,"about_ca_system_score_gemma":0.00074717135,"threshold_uncertainty_score":0.99966097},"labels":[],"label_agreement":null},{"id":"W4401352524","doi":"10.3390/curroncol31080334","title":"Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer—A Single-Center Experience","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Lung cancer; DNA sequencing; Gene; Center (category theory); Computational biology; Oncology; Medical physics; Pathology; Internal medicine; Bioinformatics; Genetics; Biology","score_opus":0.1499229713963053,"score_gpt":0.4040749898841506,"score_spread":0.2541520184878453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401352524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483892,0.045666654,0.0014940383,0.00053740526,0.002048829,0.00081022707,0.000025476751,0.00007266932,0.00095555146],"genre_scores_gemma":[0.99463475,0.0030470695,0.000733893,0.00016674785,0.00049088866,0.00045696407,0.00019458342,0.000030561056,0.00024456857],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99860275,0.0000624518,0.00034840088,0.0005314515,0.00012168309,0.00033328842],"domain_scores_gemma":[0.99946845,0.000054941294,0.00006682594,0.00019978543,0.00006650748,0.00014348491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010275326,0.00021201406,0.00034673736,0.00018162682,0.00009533148,0.000067330155,0.000062835454,0.00011038353,0.00010766051],"category_scores_gemma":[0.000015259442,0.00018188168,0.00006057207,0.0002125239,0.00008602623,0.00017718252,0.000051635452,0.00023158008,0.000010188264],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016375704,0.0026630422,0.09651711,0.002294031,0.0005162218,0.0013723777,0.04598834,0.00062678376,0.38124922,0.00017834161,0.004153488,0.4642773],"study_design_scores_gemma":[0.029351162,0.008098922,0.01571199,0.0060278913,0.0065667634,0.0028041594,0.013210777,0.4151267,0.118665814,0.00010825314,0.38131806,0.0030095174],"about_ca_topic_score_codex":0.0003213302,"about_ca_topic_score_gemma":0.0005936138,"teacher_disagreement_score":0.46126777,"about_ca_system_score_codex":0.0025757167,"about_ca_system_score_gemma":0.000965438,"threshold_uncertainty_score":0.741692},"labels":[],"label_agreement":null},{"id":"W4401358118","doi":"10.3390/curroncol31080326","title":"Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; ROS1; Lung cancer; Cancer; Cancer research; Oncology; Internal medicine; Pathology; Computational biology; Adenocarcinoma; Biology","score_opus":0.10107801015452265,"score_gpt":0.447185383841595,"score_spread":0.34610737368707234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401358118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904067,0.0017840634,0.000020389667,0.00026961343,0.002264952,0.0017815089,0.00015982421,0.00011137796,0.0032015673],"genre_scores_gemma":[0.99469566,0.0022185186,0.00017847131,0.00003888229,0.0007510681,0.000821643,0.00021699646,0.000048281567,0.0010304612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984864,0.000053329164,0.00038008543,0.0005412194,0.00018135174,0.00035761585],"domain_scores_gemma":[0.9990131,0.00017698665,0.00026466415,0.00020226509,0.00014622949,0.0001967063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001124016,0.00027407045,0.00040572273,0.00019710572,0.00015178812,0.000083099556,0.000057712336,0.00005803345,0.000090131834],"category_scores_gemma":[0.000037281345,0.00021766839,0.00005598191,0.00024571593,0.00003181088,0.00011252459,0.00007005518,0.00023422921,0.000014817517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006767594,0.002496198,0.8173851,0.0003981662,0.00033380865,0.00013964175,0.0030597358,9.4935683e-7,0.00009302754,0.000007290039,0.00030214945,0.17571627],"study_design_scores_gemma":[0.0046102176,0.0023725694,0.94793034,0.0006236469,0.0029942153,0.000006570629,0.00038491908,0.0014063605,0.000049880327,0.0000019379768,0.039396625,0.0002226927],"about_ca_topic_score_codex":0.0019612669,"about_ca_topic_score_gemma":0.0013623454,"teacher_disagreement_score":0.17549357,"about_ca_system_score_codex":0.0014366272,"about_ca_system_score_gemma":0.0005149755,"threshold_uncertainty_score":0.887626},"labels":[],"label_agreement":null},{"id":"W4401481084","doi":"10.1016/j.lungcan.2024.107927","title":"Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"Association of Pathology Chairs; Mayo Foundation for Medical Education and Research; Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison; Mayo Clinic","keywords":"Immunotherapy; Medicine; Immunohistochemistry; Oncology; Predictive value; Lung cancer; Lung; Internal medicine; Copy-number variation; Value (mathematics); Cancer research; Cancer; Gene; Biology; Genome","score_opus":0.0033432570704485676,"score_gpt":0.28164715645814914,"score_spread":0.27830389938770056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401481084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943583,0.050827272,0.0002394327,0.00009765376,0.000060817132,0.0006076221,0.000060999944,0.00003062322,0.0044925846],"genre_scores_gemma":[0.9966337,0.0012689554,0.00025064204,0.00006090888,0.000023381564,0.00020501885,0.000039400038,0.000040137453,0.0014778222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992352,0.00001571794,0.00017795549,0.00029282382,0.00011016164,0.00016811129],"domain_scores_gemma":[0.99963456,0.000042112333,0.000048822298,0.0001573882,0.000054948527,0.000062192245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042112384,0.00017810919,0.00026875196,0.00005956066,0.000032309195,0.000018046834,0.000031686308,0.00008521441,0.00006492924],"category_scores_gemma":[0.0000023080047,0.00013825066,0.000037065638,0.0001864219,0.000096241165,0.000050880946,0.00001463736,0.00015429284,6.026469e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005159117,0.00011500462,0.92306936,0.0010370038,0.0008356988,0.000207698,0.0046529323,0.00019863989,0.06837048,0.00006676247,0.0003009729,0.0006295354],"study_design_scores_gemma":[0.02349299,0.0013608042,0.5804187,0.00908418,0.00565766,0.00032094077,0.002080863,0.04956746,0.32623857,0.0001450107,0.0005387694,0.0010940753],"about_ca_topic_score_codex":0.0018190627,"about_ca_topic_score_gemma":0.000016007263,"teacher_disagreement_score":0.34265068,"about_ca_system_score_codex":0.00032474255,"about_ca_system_score_gemma":0.00024060954,"threshold_uncertainty_score":0.5637698},"labels":[],"label_agreement":null},{"id":"W4401498430","doi":"10.1007/s00432-024-05909-w","title":"The HUNT lung-SNP model: genetic variants plus clinical variables improve lung cancer risk assessment over clinical models","year":2024,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"St. Olavs Hospital Universitetssykehuset i Trondheim; Norges Forskningsråd; Universitetet i Oslo; Helse Midt-Norge; Norges Teknisk-Naturvitenskapelige Universitet","keywords":"Medicine; Single-nucleotide polymorphism; Lung cancer; Internal medicine; SNP; Prospective cohort study; Receiver operating characteristic; Oncology; Genotype; Biology; Genetics","score_opus":0.1492986237302806,"score_gpt":0.619794960385542,"score_spread":0.47049633665526147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401498430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7599191,0.14456931,0.019608563,0.050844338,0.013775478,0.0029946635,0.00039160092,0.000075730815,0.007821232],"genre_scores_gemma":[0.6183412,0.36856627,0.0036089376,0.0011122323,0.0050676204,0.00019466663,0.000004693703,0.000064916654,0.0030394737],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9925139,0.0016036585,0.003197837,0.0007042401,0.0011653388,0.0008150516],"domain_scores_gemma":[0.98827034,0.0080702035,0.0007469922,0.00048120585,0.0013408207,0.0010904203],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012142394,0.00027152037,0.0013563182,0.00017868869,0.00043943909,0.00021705696,0.00039757084,0.00061341294,0.0002251199],"category_scores_gemma":[0.001151395,0.0001545584,0.0006909596,0.00035241037,0.0010851246,0.00028964836,0.00026624074,0.004177907,0.000004523164],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075339107,0.0026809464,0.25210178,0.00030428031,0.012137558,0.0011636701,0.00028148133,0.004048465,0.000029256402,0.0044609876,0.10708708,0.60817057],"study_design_scores_gemma":[0.012944825,0.0102511905,0.15922037,0.00073034567,0.0043216506,0.00009061069,0.0001771993,0.73473394,0.0000028511881,0.015251428,0.062013477,0.00026213954],"about_ca_topic_score_codex":0.00084771594,"about_ca_topic_score_gemma":0.0007962775,"teacher_disagreement_score":0.7306855,"about_ca_system_score_codex":0.0015826687,"about_ca_system_score_gemma":0.019888224,"threshold_uncertainty_score":0.9981195},"labels":[],"label_agreement":null},{"id":"W4401527030","doi":"10.1200/jco.2024.42.23_suppl.215","title":"Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Richard Tam Foundation","keywords":"Medicine; Lung cancer; Oncology; Precision medicine; Crizotinib; Internal medicine; Cancer research; Pathology","score_opus":0.0898393799532811,"score_gpt":0.5290685278054648,"score_spread":0.43922914785218364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401527030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465582,0.0026062748,0.00012935848,0.025376905,0.0010425831,0.00061847916,0.000013207208,0.000010179029,0.02364481],"genre_scores_gemma":[0.9900756,0.0024278273,0.0024342153,0.0020645624,0.0010794486,0.00002207654,0.000003335674,0.000022752212,0.0018701949],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998154,0.000093181494,0.0012592468,0.000141431,0.00022678796,0.0001253427],"domain_scores_gemma":[0.99710673,0.002133208,0.00032848853,0.00013197657,0.00011338424,0.00018619357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008880339,0.000101161146,0.0007687809,0.00015434812,0.000021921638,0.0000049373334,0.000066873945,0.00013149325,0.00015085509],"category_scores_gemma":[0.0003662268,0.000047403722,0.00016799386,0.00015846713,0.00013992049,0.00004000051,0.000009765067,0.00017956004,0.0000055216756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055421875,0.0013979978,0.07067122,0.00007201468,0.0014340853,0.000808455,0.0052600913,0.0008099732,0.0006052364,0.00030328706,0.032771025,0.8803244],"study_design_scores_gemma":[0.019870447,0.051283043,0.14114076,0.0017356353,0.002244576,0.00015223224,0.0006996721,0.0046561253,0.00013591153,0.00038669433,0.7775685,0.00012640656],"about_ca_topic_score_codex":0.0007047576,"about_ca_topic_score_gemma":0.00047354572,"teacher_disagreement_score":0.880198,"about_ca_system_score_codex":0.00083033164,"about_ca_system_score_gemma":0.0020459623,"threshold_uncertainty_score":0.3629449},"labels":[],"label_agreement":null},{"id":"W4401560936","doi":"10.1056/nejme2406495","title":"Osimertinib in Stage III <i>EGFR</i> -Mutated NSCLC — Game, Set, Match","year":2024,"lang":"en","type":"editorial","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Osimertinib; ROS1; Epidermal growth factor receptor; Tyrosine kinase; Lung cancer; Cancer research; Medicine; Oncology; Internal medicine; Personalized medicine; Erlotinib; Cancer; Biology; Bioinformatics; Receptor; Adenocarcinoma; Colorectal cancer","score_opus":0.013460676894426198,"score_gpt":0.3453272976438109,"score_spread":0.3318666207493847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401560936","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0087808035,0.025180018,0.00013949859,0.012966835,0.942409,0.0007368996,0.00016641057,0.00006912677,0.009551414],"genre_scores_gemma":[0.026620468,0.004533943,0.00015864563,0.0005093503,0.9346798,0.000010542532,0.0005295433,0.00012906568,0.032828633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960951,0.00010556844,0.0014700645,0.00036311612,0.0015505396,0.0004155945],"domain_scores_gemma":[0.9971753,0.0007289768,0.0006989676,0.00032199654,0.0005124234,0.0005623731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010059973,0.00048191875,0.001583802,0.0007598664,0.000035135035,0.00003155235,0.00021967277,0.00048418707,0.0007482547],"category_scores_gemma":[0.00083159376,0.00030183545,0.00021485862,0.00054753444,0.00011170899,0.000111284746,0.000039997107,0.0022535133,0.000036219182],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016936274,0.00011784512,0.00021221938,0.00040195833,0.000870425,0.0050552753,0.0032588067,0.000023358294,0.00020276837,0.000012086054,0.9706078,0.01754382],"study_design_scores_gemma":[0.08599938,0.0021698503,0.00013377226,0.0065639205,0.002442038,0.00042235566,0.00040328104,0.000018991026,0.000043015563,0.00020097612,0.90139014,0.00021226388],"about_ca_topic_score_codex":0.001511274,"about_ca_topic_score_gemma":0.0002819666,"teacher_disagreement_score":0.084305756,"about_ca_system_score_codex":0.0005729498,"about_ca_system_score_gemma":0.0027056995,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W4401805547","doi":"10.1057/978-1-349-96110-8_956","title":"Canadian Cancer Society Research Institute (CCSRI)","year":2024,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Cancer; Library science; Medicine; Computer science; Internal medicine","score_opus":0.05754273411356199,"score_gpt":0.37262532311670127,"score_spread":0.3150825890031393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401805547","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103524704,0.009346149,0.0000031694117,0.0018036156,0.0011256045,0.0012521079,0.00095902575,0.000116651456,0.98529017],"genre_scores_gemma":[0.60667026,0.00092212594,0.00013994372,0.00062867365,0.00095406175,0.00019163585,0.0003312605,0.0001407205,0.39002135],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9974601,0.00001147924,0.00035586374,0.0007524804,0.00067706045,0.00074298744],"domain_scores_gemma":[0.9980569,0.000042046497,0.00007004758,0.0006747445,0.00039243605,0.000763822],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020136178,0.00047945915,0.0005484557,0.00047390442,0.00034292115,0.00009358673,0.00019196815,0.0005089404,0.0014318515],"category_scores_gemma":[0.000010365798,0.00040352793,0.00046059006,0.00005895575,0.00033864425,7.904922e-7,0.000103259816,0.0010157841,0.00093524286],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019540694,6.516779e-7,0.00019779107,0.0004471815,0.0021859317,0.00091014995,0.0015923496,0.0000014442668,0.000046060926,0.97137827,0.0048998534,0.01832078],"study_design_scores_gemma":[0.0006669787,0.0001376381,0.00017287284,0.0012856325,0.0010322162,0.0000730977,0.00009469704,0.000021094667,0.000050035458,0.5519074,0.44413546,0.00042285124],"about_ca_topic_score_codex":0.16743883,"about_ca_topic_score_gemma":0.32626492,"teacher_disagreement_score":0.6065667,"about_ca_system_score_codex":0.002820952,"about_ca_system_score_gemma":0.004538307,"threshold_uncertainty_score":0.99984264},"labels":[],"label_agreement":null},{"id":"W4401844652","doi":"10.1002/mco2.694","title":"Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies","year":2024,"lang":"en","type":"review","venue":"MedComm","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Targeted therapy; Medicine; Tyrosine-kinase inhibitor; Drug resistance; Acquired resistance; Mechanism (biology); Tumor microenvironment; Cancer; Cancer research; Biology; Internal medicine","score_opus":0.04239765128279061,"score_gpt":0.3760929962378824,"score_spread":0.3336953449550918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401844652","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008586031,0.9965952,0.00016969183,0.00027278683,0.00028665655,0.0009837244,0.00013662223,0.00005209153,0.0014173592],"genre_scores_gemma":[0.0012856859,0.99382937,0.0020924292,0.00009937236,0.00009719743,0.00016133327,0.00012252532,0.000059708986,0.0022524055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989177,0.000042098014,0.0003744177,0.0003096953,0.00019221767,0.00016389186],"domain_scores_gemma":[0.99934316,0.000058888214,0.00010716816,0.00032108757,0.0000558308,0.0001138663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105459316,0.000290264,0.0010582363,0.00019346405,0.00004467488,0.000041130523,0.00006976917,0.00012374409,0.000043218333],"category_scores_gemma":[0.00001944174,0.00019047922,0.00017567964,0.00031730684,0.000034578003,0.000047989743,0.000044704993,0.00018190726,0.000015151183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056546352,0.00017714396,0.0000033943409,0.032600135,0.0011384414,0.00012839262,0.0009606925,2.3182967e-7,0.00021953696,0.011456389,0.0076600336,0.9455991],"study_design_scores_gemma":[0.00049225986,0.00021568761,0.00001616364,0.023125894,0.0018427285,0.000015118326,0.00016943805,8.251182e-7,0.00013656005,0.0009505494,0.9728531,0.00018163388],"about_ca_topic_score_codex":0.000040441744,"about_ca_topic_score_gemma":0.00004414616,"teacher_disagreement_score":0.9651931,"about_ca_system_score_codex":0.00013088452,"about_ca_system_score_gemma":0.00037143473,"threshold_uncertainty_score":0.7767517},"labels":[],"label_agreement":null},{"id":"W4402013812","doi":"10.1016/j.heliyon.2024.e37082","title":"Outcomes with non-small cell lung cancer and brain-only metastasis","year":2024,"lang":"en","type":"article","venue":"Heliyon","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Swiss Cancer Research Foundation","keywords":"Brain metastasis; Lung cancer; Oncology; Medicine; Internal medicine; Disease; Cancer; Metastasis; Lung","score_opus":0.011526318326761743,"score_gpt":0.31971849858115875,"score_spread":0.308192180254397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402013812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9395652,0.04021544,0.0003943175,0.009111502,0.00022040123,0.0004784628,0.00006723765,0.00009964486,0.00984779],"genre_scores_gemma":[0.9614872,0.0021077925,0.0016908086,0.0018087346,0.000116411924,0.00012111105,0.000027974434,0.000042870175,0.03259715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945146,0.0000061897017,0.00008750873,0.00020755321,0.000104187355,0.00014307634],"domain_scores_gemma":[0.99969137,0.000050769268,0.000015896716,0.0001202375,0.0000314618,0.00009025213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000033240707,0.00011472866,0.00016675812,0.000070777634,0.000047631096,0.000038345224,0.000020401003,0.000029178882,0.00014063722],"category_scores_gemma":[0.000003966019,0.00007012592,0.000039944116,0.00012007736,0.000021853977,0.00005315573,0.000012735147,0.000078158024,0.000018855093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012321718,0.00023635145,0.9061545,0.006979631,0.0021854215,0.000632898,0.0053005,0.000025737952,0.0019570913,0.00058689644,0.011410176,0.06440757],"study_design_scores_gemma":[0.008251213,0.0010290444,0.71760505,0.004502516,0.008051786,0.0002653048,0.0011737476,0.00059452915,0.008326189,0.000037363512,0.24947381,0.0006894153],"about_ca_topic_score_codex":0.00017871158,"about_ca_topic_score_gemma":0.00027472415,"teacher_disagreement_score":0.23806365,"about_ca_system_score_codex":0.00008068459,"about_ca_system_score_gemma":0.00023477133,"threshold_uncertainty_score":0.2859652},"labels":[],"label_agreement":null},{"id":"W4402049169","doi":"10.3390/curroncol31090379","title":"Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute","keywords":"Medicine; Lung cancer; Cancer research; Gene; Bioinformatics; Oncology; Internal medicine; Biology; Genetics","score_opus":0.07484700401369274,"score_gpt":0.4602603801157329,"score_spread":0.3854133761020402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402049169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021638282,0.9906413,0.0013618686,0.00004542721,0.0016389985,0.0032810273,0.00017760278,0.000037683523,0.0025997218],"genre_scores_gemma":[0.00019351236,0.98911524,0.005930037,0.000025565072,0.00032543665,0.0017920913,0.00089811767,0.00008857138,0.0016314595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802566,0.00008023397,0.00067492406,0.00063899375,0.00023222809,0.0003479737],"domain_scores_gemma":[0.9986743,0.000049953447,0.000396697,0.0004770871,0.00021638449,0.00018559952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001194033,0.000474009,0.001539237,0.00034736595,0.000084555344,0.000034844543,0.00017266351,0.00012429013,0.00019898024],"category_scores_gemma":[0.0000029762448,0.0003175202,0.0002811575,0.00041832885,0.000082068385,0.000086457905,0.00009313507,0.00041092728,0.00005027366],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021148513,0.0011691565,0.00017505173,0.08615546,0.002674513,0.00040035654,0.0010121117,0.0000231156,0.0000018795712,0.000041638075,0.0032283643,0.9050972],"study_design_scores_gemma":[0.0021411013,0.00094315055,0.00011164321,0.051604565,0.053766295,0.00007780683,0.00016670101,0.00082789146,0.0000040312834,0.0000067174783,0.8899616,0.0003884875],"about_ca_topic_score_codex":0.00007043448,"about_ca_topic_score_gemma":0.00008183292,"teacher_disagreement_score":0.90470874,"about_ca_system_score_codex":0.0013528789,"about_ca_system_score_gemma":0.0022754543,"threshold_uncertainty_score":0.9999277},"labels":[],"label_agreement":null},{"id":"W4402104157","doi":"10.1016/j.jaad.2024.07.641","title":"53844 Clusters with Luster: Application of Unsupervised Machine Learning Pipeline and Subgroup Analysis for CTCL Patients Prior to Diagnosis","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Pipeline (software); Artificial intelligence; Machine learning; Dermatology; Computer science; Programming language","score_opus":0.00886400238795033,"score_gpt":0.3173145537476634,"score_spread":0.30845055135971305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96578246,0.0006495623,0.0115326205,0.02156494,0.000025283143,0.00040159147,0.000023741162,0.000006248236,0.0000135603705],"genre_scores_gemma":[0.9954976,0.00017426664,0.003499253,0.0007246247,0.000023983475,0.000027816182,0.00000819914,0.000013754815,0.000030494046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999103,0.0000575631,0.00043756037,0.000121193145,0.00016969969,0.00011095389],"domain_scores_gemma":[0.99901116,0.00020992922,0.00052323664,0.00007223229,0.00010228502,0.00008113204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080186204,0.00009715175,0.00054585235,0.00032547856,0.000040398136,0.0000054056513,0.000098411016,0.000033558008,0.000004332696],"category_scores_gemma":[0.000052703825,0.000056322122,0.00015924865,0.00062306377,0.00013573216,0.000053815707,0.000030328747,0.00016430161,4.0970784e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007250428,0.00015640796,0.9585353,0.00024526217,0.002068897,0.0000034219722,0.0010308969,0.0006599301,0.00056502875,0.00003503696,0.00028203943,0.035692696],"study_design_scores_gemma":[0.0067670415,0.002423641,0.919179,0.00055444986,0.017816804,0.00065655244,0.0012037286,0.029672392,0.006663798,0.00008184372,0.014712636,0.0002680978],"about_ca_topic_score_codex":0.000067808316,"about_ca_topic_score_gemma":0.000009842796,"teacher_disagreement_score":0.03935633,"about_ca_system_score_codex":0.000050184055,"about_ca_system_score_gemma":0.000045824952,"threshold_uncertainty_score":0.22967495},"labels":[],"label_agreement":null},{"id":"W4402266752","doi":"10.1158/1538-7445.pediatric24-pr011","title":"Abstract PR011: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Updated data from the iMATRIX Alectinib phase I/II open-label, multi-center study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alectinib; Medicine; Center (category theory); Solid tumor; Oncology; Internal medicine; Cancer; Crizotinib; Chemistry; Lung cancer","score_opus":0.1832606208784122,"score_gpt":0.5303666304707177,"score_spread":0.34710600959230553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901754,0.002495073,0.0000074545896,0.0013300027,0.0001308905,0.0045190654,0.0011666459,0.000061578816,0.00011387243],"genre_scores_gemma":[0.9967436,0.0007803804,0.00013752512,0.00013370281,0.00023521675,0.0005759757,0.0005902714,0.00006922359,0.0007340819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744576,0.00015210613,0.00034109465,0.0009221986,0.0005798995,0.00055891287],"domain_scores_gemma":[0.9985619,0.00012999424,0.000051571034,0.00088528416,0.00015675265,0.00021450546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006857128,0.00023671938,0.00033470857,0.00021846463,0.0005159978,0.0003665023,0.0006591192,0.000055245186,0.00037706265],"category_scores_gemma":[0.00011941685,0.00013401333,0.00001616999,0.0009343238,0.00014978676,0.0004655976,0.0008896571,0.0008751064,0.000027104441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009386298,0.032552686,0.8378552,0.00030193914,0.0032148287,0.0019372558,0.0133487815,0.000011542868,0.0072301854,0.0000068705044,0.0405132,0.05364121],"study_design_scores_gemma":[0.09845792,0.0048213326,0.8753809,0.007594151,0.00070572423,0.00011585651,0.0043343105,0.0014416716,0.0009872768,0.000013996874,0.005594043,0.0005528714],"about_ca_topic_score_codex":0.015279467,"about_ca_topic_score_gemma":0.009275423,"teacher_disagreement_score":0.089071624,"about_ca_system_score_codex":0.00035292492,"about_ca_system_score_gemma":0.0013116499,"threshold_uncertainty_score":0.9912779},"labels":[],"label_agreement":null},{"id":"W4402396951","doi":"10.1016/j.jtho.2024.09.1379","title":"Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Durvalumab; Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; Stage (stratigraphy); Oncology; Internal medicine; Lung cancer; Cancer; Immunotherapy; Nivolumab","score_opus":0.03071190997090472,"score_gpt":0.4315908156606996,"score_spread":0.4008789056897949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402396951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860831,0.0020638555,0.00035819982,0.0060221558,0.0020514552,0.00046027475,0.000032050048,0.000024810837,0.0029040969],"genre_scores_gemma":[0.99493545,0.000210223,0.0014202001,0.00027493786,0.00056262943,0.000037677102,0.00008179199,0.000022824945,0.002454269],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986549,0.00012452435,0.0005731821,0.00018245567,0.00026534955,0.00019959071],"domain_scores_gemma":[0.9988854,0.00032208374,0.00027502602,0.00011175664,0.00029213753,0.00011358357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044320693,0.00014199749,0.00037413125,0.00040008934,0.000047658486,0.00004556589,0.000049363203,0.00015679224,0.00030106225],"category_scores_gemma":[0.00025042973,0.00010702981,0.00009817786,0.0005113352,0.000049397106,0.0004954912,0.000019056333,0.00031505674,0.000017322878],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11778024,0.0034195995,0.02017554,0.0011793515,0.0023190724,0.014274218,0.01543605,0.0013371594,0.03409814,0.0006986505,0.013718523,0.7755635],"study_design_scores_gemma":[0.06863309,0.037663117,0.38337472,0.008031466,0.009376838,0.0027389391,0.011467185,0.013533496,0.11376972,0.00075489323,0.34911883,0.0015377111],"about_ca_topic_score_codex":0.000115878174,"about_ca_topic_score_gemma":0.00023827927,"teacher_disagreement_score":0.77402574,"about_ca_system_score_codex":0.0018391167,"about_ca_system_score_gemma":0.0013600877,"threshold_uncertainty_score":0.4809226},"labels":[],"label_agreement":null},{"id":"W4402501807","doi":"10.11159/icbb24.128","title":"An Investigation into EGFR Tyrosine Kinase Inhibitors: Adverse Events, Cost and Prescribing Trends","year":2024,"lang":"en","type":"article","venue":"Proceedings of the World Congress on New Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Tyrosine kinase; Adverse effect; Medicine; Computer science; Pharmacology; Internal medicine; Receptor","score_opus":0.01617566747137884,"score_gpt":0.301927394778965,"score_spread":0.2857517273075862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402501807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96722037,0.0025779644,0.0000019022373,0.026809828,0.00048436888,0.00058445614,0.0000112478665,0.00095964334,0.001350248],"genre_scores_gemma":[0.99193364,0.00011063896,0.001004999,0.0000925041,0.00005023407,0.00007604406,0.0000070596307,0.000022033073,0.0067028464],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991279,0.0000029083062,0.00020329223,0.0003080964,0.00020086998,0.00015688951],"domain_scores_gemma":[0.9995837,0.00002718109,0.00009989333,0.00016376034,0.00007262201,0.000052828007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076996694,0.0001670044,0.00018623116,0.0004486845,0.00010391075,0.00003939036,0.00016889647,0.000079354984,0.0000067592787],"category_scores_gemma":[0.00009609895,0.00010855026,0.000056456724,0.0007607787,0.00022100827,0.00033167793,0.00010185145,0.00020819317,0.000001916995],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025856515,0.00024132164,0.10013818,0.000796754,0.0004081345,0.000012660409,0.0019181527,0.000013115223,0.10450992,0.037867855,0.032079816,0.7217555],"study_design_scores_gemma":[0.002405472,0.0008548746,0.017627485,0.006734597,0.0008748371,0.000033473465,0.003984299,0.000871248,0.9147608,0.015650585,0.035797745,0.00040453943],"about_ca_topic_score_codex":0.00009876741,"about_ca_topic_score_gemma":0.00004843979,"teacher_disagreement_score":0.81025094,"about_ca_system_score_codex":0.00014878587,"about_ca_system_score_gemma":0.00006640857,"threshold_uncertainty_score":0.44265512},"labels":[],"label_agreement":null},{"id":"W4402558343","doi":"10.1016/j.annonc.2024.08.1361","title":"1304P Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation; AstraZeneca; EMD Serono; Pfizer; Amgen","keywords":"Crizotinib; Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine","score_opus":0.04988997537621109,"score_gpt":0.40813072264665934,"score_spread":0.35824074727044825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539065,0.00031726633,0.0000015734647,0.0003991413,0.00013639721,0.0011991153,0.00013293017,0.00001870074,0.0024042395],"genre_scores_gemma":[0.99882364,0.00005371246,0.00015880266,0.00046926664,0.000012469887,0.00023299347,0.000053689313,0.00002317394,0.0001722248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888307,0.00006268893,0.0003410392,0.0002791923,0.00015259284,0.00028142869],"domain_scores_gemma":[0.9990669,0.00007190579,0.00012836435,0.00019019666,0.00027495282,0.00026767314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007973816,0.0001477992,0.00042316687,0.0003260633,0.000031915377,0.000005444584,0.00007151541,0.000077263256,0.000095076786],"category_scores_gemma":[0.000048593192,0.00011695203,0.000032602144,0.0005511554,0.00007770827,0.00010585681,0.000018675884,0.00014481644,0.0000011860102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068475713,0.0023340136,0.95086753,0.00035647783,0.00055283215,0.0003397978,0.0333797,0.00028085074,0.0027548794,0.00002679596,0.00060735096,0.007815034],"study_design_scores_gemma":[0.016385088,0.023711221,0.90043795,0.0009660577,0.00053439656,0.000003052318,0.015023699,0.00021261215,0.03542725,0.000010993522,0.0069348454,0.00035281215],"about_ca_topic_score_codex":0.08804655,"about_ca_topic_score_gemma":0.07381097,"teacher_disagreement_score":0.050429538,"about_ca_system_score_codex":0.00024152816,"about_ca_system_score_gemma":0.0027682032,"threshold_uncertainty_score":0.94308954},"labels":[],"label_agreement":null},{"id":"W4402558380","doi":"10.1016/j.annonc.2024.08.1347","title":"1290P Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; ROS1; Oncology; Internal medicine; Cancer; Adenocarcinoma","score_opus":0.017995656564135962,"score_gpt":0.37439781244780723,"score_spread":0.35640215588367125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98901576,0.0009992291,0.00011740547,0.0017993944,0.00010858881,0.00075331976,0.00009856028,0.000018586174,0.007089186],"genre_scores_gemma":[0.9981086,0.00037496877,0.00075902004,0.00034691495,0.000011748099,0.000019096542,0.00014658173,0.000014134239,0.0002188928],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991213,0.000055671033,0.00031471855,0.00021424054,0.00013080526,0.00016323222],"domain_scores_gemma":[0.9993015,0.0002034541,0.00010072477,0.000109720946,0.00021124733,0.0000733614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009891733,0.000112683374,0.00037651023,0.00015522484,0.000021963335,0.0000035006215,0.000032915632,0.00004990312,0.00008128435],"category_scores_gemma":[0.00005123163,0.0000809415,0.00003540113,0.00027487802,0.00011373346,0.00007006943,0.000024924182,0.000102577695,0.000005240837],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008870186,0.003380299,0.027906153,0.00030176886,0.0011279025,0.00026321603,0.004558742,0.0002878683,0.00066486566,0.0005684309,0.0016752884,0.9503953],"study_design_scores_gemma":[0.038277067,0.04284525,0.877072,0.0028762317,0.0011526078,0.00007320918,0.0011666922,0.00031962636,0.005970002,0.00051194924,0.029378774,0.00035659358],"about_ca_topic_score_codex":0.00008517095,"about_ca_topic_score_gemma":0.000066791115,"teacher_disagreement_score":0.9500387,"about_ca_system_score_codex":0.00006315856,"about_ca_system_score_gemma":0.0003238849,"threshold_uncertainty_score":0.33006987},"labels":[],"label_agreement":null},{"id":"W4402558405","doi":"10.1016/j.annonc.2024.08.1346","title":"1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ROS1; Oncology; Internal medicine; Lung cancer; Phases of clinical research; Clinical trial; Safety profile; Cancer; Adenocarcinoma; Adverse effect","score_opus":0.0491402154988023,"score_gpt":0.4385308151696402,"score_spread":0.3893905996708379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100906,0.004282392,0.00008306612,0.0009193808,0.00023987038,0.0014242104,0.0006711985,0.000017523605,0.0013532944],"genre_scores_gemma":[0.9966431,0.001020588,0.0013012983,0.00025173704,0.000051372557,0.00012276515,0.0001723641,0.000026399928,0.00041035248],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984576,0.00012802362,0.0007237696,0.00031948014,0.00015156093,0.00021957215],"domain_scores_gemma":[0.9985141,0.0007432486,0.0003082603,0.0001604931,0.00016665377,0.000107198655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030213513,0.00018365133,0.0010143728,0.00019129258,0.000037509406,0.0000059295644,0.000053806714,0.000073723815,0.0001862414],"category_scores_gemma":[0.00018062639,0.000119285054,0.00009248152,0.0002840874,0.00008666946,0.00008662883,0.000033867203,0.00013211597,0.0000011590122],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04085677,0.012655729,0.014981925,0.0011205744,0.00420848,0.00035712332,0.011124109,0.00025201138,0.009761407,0.000037009035,0.0025432534,0.90210164],"study_design_scores_gemma":[0.4462995,0.18678981,0.19342732,0.008452809,0.017449029,0.00003877186,0.0029919252,0.0019247216,0.08698326,0.00018485574,0.054152098,0.0013059037],"about_ca_topic_score_codex":0.0007740202,"about_ca_topic_score_gemma":0.0005431766,"teacher_disagreement_score":0.9007957,"about_ca_system_score_codex":0.00009860963,"about_ca_system_score_gemma":0.0008008653,"threshold_uncertainty_score":0.48643032},"labels":[],"label_agreement":null},{"id":"W4402558442","doi":"10.1016/j.annonc.2024.08.1369","title":"1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Docetaxel; Oncology; Lung cancer; Internal medicine; Chemotherapy; Cancer research","score_opus":0.019711067759654484,"score_gpt":0.3586001921693946,"score_spread":0.3388891244097401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97935945,0.00415443,0.00031323274,0.0072274073,0.00029868304,0.001623932,0.0021633878,0.00008050557,0.004778969],"genre_scores_gemma":[0.9909611,0.00067925546,0.0041176416,0.0016826278,0.00011821868,0.000327761,0.0011195396,0.00008054199,0.0009133643],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973553,0.00014419314,0.000703598,0.0008325998,0.00037602437,0.00058828184],"domain_scores_gemma":[0.9980368,0.0004863129,0.00031598276,0.0005591985,0.00035111158,0.00025059227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019593416,0.00041438948,0.00092551677,0.00037621128,0.00008376831,0.000031174728,0.00019718843,0.000172914,0.00014357403],"category_scores_gemma":[0.00008126629,0.00029156808,0.0001253322,0.0006443021,0.00017424978,0.00024464747,0.00006741135,0.00036101663,0.000017920105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06428229,0.016248588,0.22565599,0.0024289482,0.008634941,0.0057176086,0.02003425,0.0038713326,0.0033341858,0.0004462256,0.08965514,0.5596905],"study_design_scores_gemma":[0.16566709,0.06691023,0.36336026,0.00777092,0.008538558,0.00015430912,0.0035428014,0.0028767348,0.035669897,0.00033189802,0.3424292,0.0027481336],"about_ca_topic_score_codex":0.004337881,"about_ca_topic_score_gemma":0.0052030836,"teacher_disagreement_score":0.55694234,"about_ca_system_score_codex":0.00034218814,"about_ca_system_score_gemma":0.0017816391,"threshold_uncertainty_score":0.9999536},"labels":[],"label_agreement":null},{"id":"W4402558452","doi":"10.1016/j.annonc.2024.08.1351","title":"1294P Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adenocarcinoma; Histology; Lung cancer; Oncology; Pathology; Internal medicine; Cancer","score_opus":0.020745352884882304,"score_gpt":0.3733605415073323,"score_spread":0.35261518862244995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9359457,0.0050418396,0.0000076675,0.05662244,0.0006712332,0.0005623546,0.00013500718,0.000021080574,0.0009927041],"genre_scores_gemma":[0.99678296,0.00015751195,0.00016523144,0.0016290625,0.00016719184,0.00009032422,0.000058308513,0.000024383662,0.000925056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987035,0.00017490839,0.00030882366,0.00037659227,0.00017802951,0.00025816238],"domain_scores_gemma":[0.9988113,0.0004992392,0.00009869966,0.00032598127,0.0001453393,0.00011944176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030604683,0.00015234278,0.00041788907,0.00012408044,0.00006004515,0.000010415033,0.000094521805,0.00015496311,0.000060097515],"category_scores_gemma":[0.00013486088,0.000100307734,0.00004760572,0.00023292848,0.00017586641,0.000057280104,0.000054819477,0.00022524416,0.0000055953224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007438569,0.00021817174,0.9001566,0.00009059393,0.0004081948,0.00034457323,0.004662482,0.00000810085,0.00023741605,0.00009235929,0.07585804,0.01048487],"study_design_scores_gemma":[0.0025566004,0.0031805658,0.90134764,0.00040548918,0.000256879,0.000008939142,0.00038545864,0.000026422427,0.00023963761,0.00006951251,0.09140408,0.000118798205],"about_ca_topic_score_codex":0.0030095587,"about_ca_topic_score_gemma":0.0013603502,"teacher_disagreement_score":0.060837258,"about_ca_system_score_codex":0.00028123683,"about_ca_system_score_gemma":0.00079474185,"threshold_uncertainty_score":0.45495725},"labels":[],"label_agreement":null},{"id":"W4402558483","doi":"10.1016/j.annonc.2024.08.1344","title":"1287P Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Predictive value; Lung cancer; Toxicity; Oncology; Internal medicine","score_opus":0.025320002150827758,"score_gpt":0.40755104750283544,"score_spread":0.3822310453520077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820071,0.005673166,0.000043045828,0.0015904276,0.00015366526,0.00030734093,0.00002794799,0.0000095652385,0.010187766],"genre_scores_gemma":[0.9977722,0.0014527771,0.00028889556,0.00014419132,0.00006164017,0.000053321506,0.000005937672,0.000011434958,0.0002095912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999239,0.00004374586,0.00027463885,0.00019492664,0.00007766516,0.00016997142],"domain_scores_gemma":[0.9996127,0.00011563873,0.00007572243,0.0000835286,0.00006251003,0.000049892704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015006437,0.00008853543,0.000329131,0.00021746088,0.000016424123,0.0000050639496,0.000033752767,0.00009958587,0.0000300591],"category_scores_gemma":[0.000020457352,0.00007563779,0.000041245454,0.00021145743,0.000060819584,0.00009339605,0.000031823412,0.00014114965,4.6420234e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042301754,0.0014006669,0.8622366,0.003157942,0.0005858794,0.00071513886,0.017851353,0.0008694104,0.072374314,0.0002831646,0.000880796,0.039221678],"study_design_scores_gemma":[0.0026497243,0.00085236295,0.93020886,0.0013919804,0.00024889,0.00001684436,0.00063080125,0.004039824,0.0587464,0.00017459708,0.0009382692,0.0001014524],"about_ca_topic_score_codex":0.0011990679,"about_ca_topic_score_gemma":0.00047401866,"teacher_disagreement_score":0.06797222,"about_ca_system_score_codex":0.00016633555,"about_ca_system_score_gemma":0.00046719713,"threshold_uncertainty_score":0.30844197},"labels":[],"label_agreement":null},{"id":"W4402559918","doi":"10.1016/j.annonc.2024.08.1310","title":"1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Cancer research; Internal medicine; Lung cancer","score_opus":0.06455710799785216,"score_gpt":0.508165654786099,"score_spread":0.4436085467882468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589912,0.0014671576,0.00001042511,0.0054281345,0.00025740516,0.00066711224,0.000068180496,0.00002289402,0.033087455],"genre_scores_gemma":[0.9979154,0.00018373827,0.00007262489,0.0005622867,0.000085422624,0.000066716486,0.00003965678,0.00001682886,0.0010573468],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989203,0.00007199729,0.00039969975,0.00024255579,0.00015418864,0.0002112331],"domain_scores_gemma":[0.9993341,0.00014133604,0.00010076107,0.0001765913,0.00016637583,0.00008083374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019909423,0.0001219339,0.00049064984,0.00025538856,0.00003229035,0.00000385764,0.00006579431,0.000080212405,0.00012075035],"category_scores_gemma":[0.000051089417,0.000099900026,0.00008930957,0.00027923763,0.000084435014,0.000075415424,0.000043460226,0.00012543167,0.000010435126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042547453,0.08374812,0.027063169,0.0006274965,0.0052775843,0.006049567,0.1194248,0.00022818656,0.023740636,0.0037343185,0.06667547,0.65917593],"study_design_scores_gemma":[0.07633879,0.38011563,0.14698206,0.002262362,0.005082285,0.00048544662,0.041359298,0.0011410597,0.09226747,0.003494182,0.24944784,0.0010235789],"about_ca_topic_score_codex":0.00059818395,"about_ca_topic_score_gemma":0.0004124091,"teacher_disagreement_score":0.65815234,"about_ca_system_score_codex":0.00008746887,"about_ca_system_score_gemma":0.0004660502,"threshold_uncertainty_score":0.4073805},"labels":[],"label_agreement":null},{"id":"W4402560836","doi":"10.1016/j.annonc.2024.08.1269","title":"1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Adjuvant; Placebo; Stage (stratigraphy); Oncology; Internal medicine; Cancer; Alternative medicine; Pathology; Immunotherapy","score_opus":0.13863269686914514,"score_gpt":0.5114329727693283,"score_spread":0.37280027590018316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756623,0.0028715574,0.00035838078,0.003906371,0.00038763808,0.0030997891,0.00030832982,0.000058759866,0.0014429174],"genre_scores_gemma":[0.9882923,0.00081741123,0.0003475731,0.0008493319,0.00016601346,0.00029907812,0.00003710505,0.00005691288,0.009134281],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978697,0.00014008272,0.0007444039,0.00050611387,0.00032509986,0.00041462085],"domain_scores_gemma":[0.998059,0.00065351627,0.00031383318,0.0004946225,0.00031366062,0.0001654159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039536724,0.00032016353,0.0010946261,0.00023974397,0.00013720541,0.000028939998,0.00020254165,0.00016621679,0.00036627933],"category_scores_gemma":[0.000152508,0.00017494963,0.0002801151,0.00043135646,0.00026108185,0.00013724992,0.00007534895,0.00020192402,0.000003637143],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2516502,0.018946903,0.0068479627,0.002809021,0.01846179,0.0014937103,0.06439251,0.00021024093,0.04350756,0.0012672553,0.032875832,0.557537],"study_design_scores_gemma":[0.39601755,0.18244067,0.08466302,0.0018968297,0.012089624,0.0005714066,0.024828227,0.006213494,0.053858016,0.00061441143,0.23526506,0.001541695],"about_ca_topic_score_codex":0.0013140348,"about_ca_topic_score_gemma":0.00078215636,"teacher_disagreement_score":0.5559953,"about_ca_system_score_codex":0.00014561252,"about_ca_system_score_gemma":0.0014928152,"threshold_uncertainty_score":0.7134239},"labels":[],"label_agreement":null},{"id":"W4402561075","doi":"10.1016/j.annonc.2024.08.1046","title":"986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; OncoMed Pharmaceutical; European Society for Medical Oncology; AstraZeneca; Novocure; Institut National Du Cancer; FibroGen; Astellas Pharma; Eisai; Sociedad Española de Oncología Médica; BeiGene; Sierra Oncology; Fondation ARC pour la Recherche sur le Cancer; Pharmacyclics; Agios Pharmaceuticals; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; Celgene","keywords":"Medicine; Lenvatinib; Hepatocellular carcinoma; Oncology; Internal medicine; Immunotherapy; Phases of clinical research; Sorafenib; Chemotherapy; Cancer","score_opus":0.071613809024952,"score_gpt":0.4218901432045754,"score_spread":0.3502763341796234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918346,0.00111699,0.00015453923,0.0016890098,0.00017997182,0.0039736433,0.0007403262,0.0000612014,0.00024971698],"genre_scores_gemma":[0.9955822,0.000082034196,0.0016496206,0.00043177503,0.00002365665,0.00055445667,0.001122194,0.000055824537,0.0004982142],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99767697,0.00020110518,0.00077806896,0.00056551665,0.00038407007,0.00039428327],"domain_scores_gemma":[0.9984488,0.00035521618,0.00024563647,0.00043295592,0.00040138062,0.00011600057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002479067,0.0003045829,0.00077184185,0.0003504536,0.000070582166,0.00002810574,0.00013879147,0.00007991786,0.000075237804],"category_scores_gemma":[0.00014772489,0.00020961784,0.0000917741,0.00052748696,0.00011311475,0.00021074079,0.00003569251,0.00025193483,0.0000136451745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14585595,0.1666912,0.4374848,0.0004974416,0.005780411,0.0032359455,0.019399408,0.00038378694,0.00093375746,0.0001558666,0.0018207717,0.21776065],"study_design_scores_gemma":[0.51445913,0.16365618,0.29532298,0.0016931385,0.0007834023,0.000011843458,0.002805656,0.007182658,0.002603386,0.00013089046,0.01073469,0.00061601924],"about_ca_topic_score_codex":0.0005362987,"about_ca_topic_score_gemma":0.00031873802,"teacher_disagreement_score":0.3686032,"about_ca_system_score_codex":0.00028356162,"about_ca_system_score_gemma":0.00084624236,"threshold_uncertainty_score":0.85479677},"labels":[],"label_agreement":null},{"id":"W4402565617","doi":"10.1016/j.annonc.2024.08.2297","title":"LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Chugai Pharmaceutical; Amgen; Pfizer; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Mesothelioma Applied Research Foundation","keywords":"Osimertinib; Medicine; Mutant; Acquired resistance; Lung cancer; Oncology; Cancer research; Internal medicine; Cancer; Epidermal growth factor receptor; Genetics; Biology; Gene","score_opus":0.028635943468299348,"score_gpt":0.3866559773268554,"score_spread":0.3580200338585561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936391,0.00078202033,0.0005902972,0.001966842,0.0002590364,0.0019303946,0.0004832345,0.000028249995,0.00032083257],"genre_scores_gemma":[0.9979967,0.00011729375,0.00076710375,0.00039036723,0.000043091924,0.0002752094,0.00018721687,0.00003267388,0.00019034525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980338,0.00010683682,0.00066694885,0.0005279638,0.0003322865,0.00033211746],"domain_scores_gemma":[0.99838793,0.00030147965,0.0002805158,0.0005243673,0.00032816164,0.0001775324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021169557,0.00024439083,0.0008559793,0.00026531308,0.000072605704,0.000014734553,0.00021903738,0.00009318193,0.000110112276],"category_scores_gemma":[0.000044208246,0.00016527898,0.0001334077,0.0011129393,0.000054546857,0.000115310286,0.00006231427,0.000107243024,0.0000021710282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2523636,0.03844775,0.44013077,0.00071591133,0.033799566,0.0012034577,0.10415795,0.013247845,0.0129549,0.00030367097,0.0018097119,0.10086487],"study_design_scores_gemma":[0.17023127,0.08848688,0.66800785,0.0012495983,0.022519896,8.2969217e-7,0.00856956,0.004142228,0.03228617,0.00016986203,0.0033790467,0.0009568182],"about_ca_topic_score_codex":0.004046182,"about_ca_topic_score_gemma":0.02121077,"teacher_disagreement_score":0.22787708,"about_ca_system_score_codex":0.00025787274,"about_ca_system_score_gemma":0.0006358757,"threshold_uncertainty_score":0.99664956},"labels":[],"label_agreement":null},{"id":"W4402565676","doi":"10.1016/j.annonc.2024.08.2289","title":"LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Ottawa Hospital; Dalhousie University; University of Ottawa","funders":"","keywords":"Durvalumab; Medicine; Placebo; Internal medicine; Oncology; Lung cancer; Adjuvant; Double blind; non-small cell lung cancer (NSCLC); Cancer; Pathology; Immunotherapy; A549 cell","score_opus":0.0812384853944997,"score_gpt":0.4632508735200075,"score_spread":0.3820123881255078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578059,0.009965737,0.00007926732,0.0020132207,0.0005020166,0.008271647,0.0001318669,0.000043187876,0.02118721],"genre_scores_gemma":[0.9958414,0.00086743274,0.000119724784,0.00026028385,0.00012248415,0.0016052081,0.00006867413,0.000028704257,0.0010861123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99720526,0.0003319033,0.0012364606,0.00047920636,0.00032103338,0.00042613343],"domain_scores_gemma":[0.9979615,0.0006779556,0.00039701612,0.00034519687,0.00045855812,0.00015972625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009576083,0.00029274178,0.0023766048,0.0003728532,0.000055967623,0.000016991036,0.00016595745,0.0001801772,0.00022584164],"category_scores_gemma":[0.00009335075,0.00021878618,0.00034528086,0.0006453344,0.00016190135,0.00008124642,0.00006746032,0.0002592088,0.000007493104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96171415,0.009866374,0.0009678161,0.00046260792,0.003936528,0.00057349465,0.006897008,0.00027623048,0.0013696837,0.00013356256,0.0061572692,0.007645289],"study_design_scores_gemma":[0.98224527,0.0064717657,0.00049534,0.00045717158,0.0027763085,0.000020484094,0.0013430155,0.0036666351,0.00067078444,0.000054862023,0.0016229649,0.00017538601],"about_ca_topic_score_codex":0.010028277,"about_ca_topic_score_gemma":0.004781913,"teacher_disagreement_score":0.03803553,"about_ca_system_score_codex":0.0003267081,"about_ca_system_score_gemma":0.0021185493,"threshold_uncertainty_score":0.99656403},"labels":[],"label_agreement":null},{"id":"W4402565677","doi":"10.1016/j.annonc.2024.08.2296","title":"LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; Chemotherapy; Oncology; Interim; Lung cancer; Internal medicine; Chemotherapy regimen; Cancer research; Cancer; Adenocarcinoma; ROS1","score_opus":0.022275084750157815,"score_gpt":0.4032019958116301,"score_spread":0.38092691106147225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776355,0.007067244,0.00004158212,0.009319155,0.00078532426,0.0011508747,0.00026393146,0.000068508234,0.003667868],"genre_scores_gemma":[0.98825616,0.0026447726,0.00041065997,0.006019105,0.00022859382,0.00046538992,0.00018345953,0.0000811404,0.0017106979],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982282,0.000075448406,0.00048770447,0.0005806892,0.00021330734,0.00041467178],"domain_scores_gemma":[0.99904317,0.00014460881,0.00015652458,0.00032229835,0.00010952446,0.0002238655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000119064964,0.00032106953,0.0006545366,0.00020212673,0.000032433596,0.000024356828,0.0001262493,0.00018008387,0.0015658487],"category_scores_gemma":[0.00001188027,0.00025625777,0.00019387815,0.00019732764,0.00008574884,0.00012315331,0.000038670973,0.0002954404,0.000021184174],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09851261,0.008180784,0.14236675,0.0027713657,0.0033096245,0.0039508766,0.01907595,0.00043644715,0.04859354,0.00010989686,0.021340642,0.6513515],"study_design_scores_gemma":[0.043941546,0.010140504,0.67062545,0.0055039576,0.0008316693,0.000013576975,0.0005058696,0.005646319,0.089655906,0.0006394715,0.17138584,0.001109908],"about_ca_topic_score_codex":0.00041340635,"about_ca_topic_score_gemma":0.00032077354,"teacher_disagreement_score":0.6502416,"about_ca_system_score_codex":0.0004278431,"about_ca_system_score_gemma":0.0009514288,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4402565779","doi":"10.1016/j.annonc.2024.08.1971","title":"1877P Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Lakeridge Health; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Trastuzumab; Adverse effect; Oncology; Meta-analysis; Internal medicine; Cancer; Breast cancer","score_opus":0.09088546132920396,"score_gpt":0.47424189706307723,"score_spread":0.3833564357338733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95442843,0.018646913,0.00034575348,0.011366304,0.00023626142,0.0009296626,0.00010264245,0.000090223475,0.0138538005],"genre_scores_gemma":[0.99810696,0.00021694957,0.0005227156,0.0005251641,0.000029928482,0.00009309584,0.000029457886,0.000018003233,0.00045772883],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99886674,0.000101913574,0.00041923634,0.00024180533,0.00016412325,0.00020618134],"domain_scores_gemma":[0.9991682,0.00028344957,0.00011587523,0.00021977843,0.00013015402,0.00008255099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027031425,0.00013175151,0.0011843916,0.0005810377,0.00001252935,0.0000028808713,0.000066795285,0.00009689798,0.00022384367],"category_scores_gemma":[0.00007847973,0.00009663323,0.00080520415,0.00081287895,0.00009166257,0.000060183538,0.000020541656,0.00011656269,0.000011232743],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011714625,0.0074715377,0.017236955,0.0024927729,0.79176545,0.003909914,0.016967468,0.0023113908,0.009331616,0.0060332036,0.012095655,0.12921256],"study_design_scores_gemma":[0.0062072114,0.014816276,0.0961884,0.00022675697,0.78019404,0.000120244375,0.0017843063,0.0012162233,0.05653009,0.0031140887,0.039120525,0.00048180323],"about_ca_topic_score_codex":0.00050768605,"about_ca_topic_score_gemma":0.0006138658,"teacher_disagreement_score":0.12873076,"about_ca_system_score_codex":0.000082885446,"about_ca_system_score_gemma":0.00046616822,"threshold_uncertainty_score":0.39405888},"labels":[],"label_agreement":null},{"id":"W4402666045","doi":"10.1016/j.cllc.2024.09.003","title":"A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol","year":2024,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Institut universitaire de cardiologie et de pneumologie de Québec; Ottawa Hospital; Princess Margaret Cancer Centre; Kingston Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; McGill University Health Centre","funders":"Canadian Cancer Society Research Institute; Novartis Pharmaceuticals Canada; Novartis","keywords":"Medicine; Lung cancer; Master regulator; Internal medicine; Phases of clinical research; Oncology; KRAS; Cancer; Chemotherapy","score_opus":0.033905800890108716,"score_gpt":0.4154961196874887,"score_spread":0.38159031879738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402666045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9273911,0.00042707022,0.000008079756,0.00021135646,0.00060695794,0.070353225,0.00018569324,0.000034823966,0.00078168215],"genre_scores_gemma":[0.94814694,0.000026453847,0.000054493135,0.00013807455,0.00022791067,0.049757034,0.00002020656,0.00007525611,0.0015536281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962053,0.00012538383,0.0015905873,0.00078467204,0.0007795793,0.0005145141],"domain_scores_gemma":[0.9978731,0.00028534932,0.0004764544,0.0007018905,0.00043070273,0.00023245298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005096785,0.00041291266,0.0010493017,0.00020001014,0.00012977293,0.000037275855,0.000296451,0.00021873007,0.00037295348],"category_scores_gemma":[0.000060065373,0.00023450688,0.00024970586,0.0009674041,0.00019253186,0.00019801338,0.00023740146,0.0007710889,0.0000019694528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005641335,0.01642537,0.964915,0.0011093325,0.0009877982,0.000057955644,0.004422175,0.00009977065,0.000052270705,0.0000072390353,0.0018427381,0.0044390494],"study_design_scores_gemma":[0.106421374,0.021762902,0.85590947,0.0067305486,0.0028370086,0.0000022840152,0.0010592663,0.0012870323,0.0010610486,0.000015105659,0.0023610257,0.00055291306],"about_ca_topic_score_codex":0.0018081075,"about_ca_topic_score_gemma":0.0037037951,"teacher_disagreement_score":0.10900547,"about_ca_system_score_codex":0.0005747322,"about_ca_system_score_gemma":0.0020059245,"threshold_uncertainty_score":0.9562913},"labels":[],"label_agreement":null},{"id":"W4402866999","doi":"10.1016/j.cancergen.2024.08.054","title":"52. A ClinGen Somatic curation effort focused on EGFR variants","year":2024,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Somatic cell; Computational biology; Biology; Evolutionary biology; Computer science; Genetics","score_opus":0.029104279748229853,"score_gpt":0.37836881114119003,"score_spread":0.34926453139296015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402866999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94700474,0.020503381,0.004347405,0.004650351,0.004936644,0.0015365827,0.00013169834,0.00035062362,0.016538566],"genre_scores_gemma":[0.9910183,0.0012285147,0.0014039829,0.0006555492,0.0005974238,0.00018092118,0.000057764024,0.000040783718,0.0048167757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924517,0.000008835872,0.00017934413,0.00022540675,0.00018076501,0.0001604776],"domain_scores_gemma":[0.9995893,0.000026322447,0.000028735058,0.00021245389,0.000051843024,0.0000913067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040657018,0.00011799123,0.00014146467,0.000073900934,0.00005690934,0.000046171746,0.000040087405,0.00005871031,0.0002576885],"category_scores_gemma":[0.000009074339,0.00009329092,0.000061767845,0.00016985412,0.00001974031,0.00004523809,0.000009979854,0.000084420906,0.00013856504],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034537795,0.00077016087,0.056732133,0.0021807991,0.00331526,0.00052410265,0.010502377,0.00315939,0.0130866775,0.006425037,0.052344605,0.8506141],"study_design_scores_gemma":[0.009714157,0.0033545494,0.2676842,0.004628009,0.007130097,0.00010549495,0.00033421972,0.08222411,0.05171453,0.007295856,0.56456745,0.0012473372],"about_ca_topic_score_codex":0.000045858214,"about_ca_topic_score_gemma":0.00005096989,"teacher_disagreement_score":0.8493667,"about_ca_system_score_codex":0.00033069061,"about_ca_system_score_gemma":0.0003895345,"threshold_uncertainty_score":0.38042933},"labels":[],"label_agreement":null},{"id":"W4402895492","doi":"10.3389/fonc.2024.1398414","title":"Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Electricity Association; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Alectinib; Medicine; Anaplastic lymphoma kinase; Adverse effect; Lung cancer; Crizotinib; Radiology; Gastroenterology; Internal medicine; Surgery","score_opus":0.013578547959699816,"score_gpt":0.3626423671664212,"score_spread":0.34906381920672136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402895492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8935786,0.014422376,0.013464042,0.0021490406,0.010850501,0.003821765,0.00029651262,0.000102965474,0.06131418],"genre_scores_gemma":[0.9800775,0.0002528128,0.013438921,0.00031280733,0.0002547946,0.0007763143,0.00007961427,0.000035104586,0.0047721094],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990614,0.000021056281,0.00030759315,0.0003126197,0.00007110288,0.0002262321],"domain_scores_gemma":[0.99952006,0.00009078249,0.00009496582,0.00017369053,0.000046811194,0.000073708565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001265145,0.0001165152,0.00037366312,0.00023558977,0.000042563533,0.000006361907,0.000026970616,0.00009897242,0.000085155865],"category_scores_gemma":[0.000020256235,0.00010328976,0.00009636965,0.00019788997,0.000050643648,0.000030302748,0.000013832423,0.00013782375,0.0000016543415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000680485,0.0013239098,0.12155761,0.00203865,0.0010755757,0.0858345,0.009461465,0.0005684541,0.0009588905,0.00021136533,0.63834643,0.13794266],"study_design_scores_gemma":[0.022464182,0.0101567665,0.003285923,0.0023918976,0.0048599117,0.020904679,0.0056050704,0.025501812,0.016628854,0.0019093849,0.8854609,0.0008306371],"about_ca_topic_score_codex":0.0010163588,"about_ca_topic_score_gemma":0.00066039036,"teacher_disagreement_score":0.24711445,"about_ca_system_score_codex":0.00077551714,"about_ca_system_score_gemma":0.0007824678,"threshold_uncertainty_score":0.4212034},"labels":[],"label_agreement":null},{"id":"W4402985672","doi":"10.1200/op.2024.20.10_suppl.133","title":"The time toxicity efficacy-effectiveness gap: A population-based study of stage III/IV non-small cell lung cancer (NSCLC) in Ontario, Canada.","year":2024,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Toxicity; Stage (stratigraphy); Oncology; Medicine; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); Population; Environmental health; Biology","score_opus":0.016826033273149976,"score_gpt":0.3632909559385401,"score_spread":0.34646492266539014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402985672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869422,0.000561479,0.00004657463,0.0020234357,0.0005439272,0.0022810856,0.000020945836,0.000027497897,0.007552866],"genre_scores_gemma":[0.99528956,0.000011881969,0.00011888825,0.00041419375,0.000048488266,0.00039266355,0.000030836596,0.00002199187,0.0036715076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843514,0.0003958923,0.0003485004,0.00032531415,0.00025131804,0.00024380612],"domain_scores_gemma":[0.99524105,0.004047673,0.00019249774,0.0002843376,0.00015146246,0.00008299841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062039634,0.00016393611,0.0003651484,0.000089349276,0.00015229499,0.00002409129,0.00010152766,0.000094699084,0.00018659001],"category_scores_gemma":[0.00021977101,0.000117423195,0.000049311308,0.0003038563,0.00002401207,0.00011205387,0.000033697328,0.0004528284,0.0000043503956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0056039775,0.009982902,0.94115144,0.00054949755,0.002188011,0.0021097662,0.011042624,0.012713269,0.0015954728,0.00012268356,0.004005018,0.008935344],"study_design_scores_gemma":[0.008466884,0.0013685437,0.95402336,0.00022866203,0.0017958201,0.000010063105,0.0016521737,0.0036139216,0.0002845667,0.0000033339845,0.028379746,0.00017292265],"about_ca_topic_score_codex":0.9746211,"about_ca_topic_score_gemma":0.9926605,"teacher_disagreement_score":0.024374727,"about_ca_system_score_codex":0.0048486255,"about_ca_system_score_gemma":0.009570372,"threshold_uncertainty_score":0.9989716},"labels":[],"label_agreement":null},{"id":"W4403012554","doi":"10.1016/s1470-2045(24)00492-3","title":"Precision medicine with MET exon 14: a partial success","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Exon; Precision medicine; Computational biology; Genetics; Psychology; Biology; Gene","score_opus":0.04578434813325103,"score_gpt":0.43022742791886226,"score_spread":0.3844430797856112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57628196,0.008526538,0.002670581,0.19782938,0.0022462318,0.0014824091,0.000036186717,0.00046891434,0.2104578],"genre_scores_gemma":[0.99201286,0.00029239515,0.00060241297,0.0018271466,0.0017248724,0.00012538709,0.00003735532,0.000017399609,0.0033601806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992335,0.000073154966,0.00013655635,0.00019071695,0.00016531536,0.00020079219],"domain_scores_gemma":[0.99936926,0.00023274656,0.0000324511,0.00025604275,0.000047213387,0.00006227588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003023294,0.00009727022,0.000332121,0.00004935861,0.00006743785,0.000012104273,0.00008639001,0.00005641982,0.0005159141],"category_scores_gemma":[0.00003701321,0.00004168327,0.000029201072,0.00019513065,0.00014763643,0.00004501949,0.000022956183,0.00017525516,0.00008378041],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067332867,0.0006772505,0.017392615,0.00063775043,0.0028223074,0.002836992,0.019721085,0.0001351434,0.0039855894,0.04622365,0.32047534,0.578359],"study_design_scores_gemma":[0.0042750263,0.0036229673,0.0078934245,0.00032382313,0.0010726982,0.0004594386,0.00028995587,0.00032053737,0.00041537403,0.0010031856,0.9802402,0.00008333465],"about_ca_topic_score_codex":0.00013145445,"about_ca_topic_score_gemma":0.00011100767,"teacher_disagreement_score":0.6597649,"about_ca_system_score_codex":0.00015550732,"about_ca_system_score_gemma":0.0002394911,"threshold_uncertainty_score":0.5648898},"labels":[],"label_agreement":null},{"id":"W4403089919","doi":"10.1200/jco-24-01689","title":"Reply to H.O. Al-Shamsi et al","year":2024,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine","score_opus":0.12282141675795488,"score_gpt":0.5830338120229609,"score_spread":0.460212395265006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089919","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021205634,0.041060362,0.0010314635,0.86159605,0.041379403,0.0002487599,0.000036305224,0.000019589428,0.03342241],"genre_scores_gemma":[0.13363415,0.017017089,0.012325305,0.7582551,0.008746349,0.000012138336,0.000008192992,0.00006495342,0.06993668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580127,0.00052934815,0.0025896293,0.00030357647,0.00040708008,0.0003690715],"domain_scores_gemma":[0.99413985,0.0036902258,0.0005991966,0.00022792535,0.00041655163,0.0009262488],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004474815,0.0001772552,0.0012283302,0.00018269262,0.000040730836,0.000040748302,0.00015551248,0.00027953667,0.0017121293],"category_scores_gemma":[0.004066569,0.00012716555,0.0007561072,0.0002744315,0.00017714806,0.00021462857,0.00006417598,0.0015224313,0.0010933069],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057981175,0.0010253364,0.0019665463,0.000050639544,0.0012595523,0.00519473,0.00040452628,0.0000399329,0.000025788346,0.0021853615,0.6237963,0.3634715],"study_design_scores_gemma":[0.003324931,0.018213274,0.019129673,0.0011242877,0.0018921355,0.0013581956,0.00018989659,0.00015123117,0.000011771685,0.00074378686,0.9537548,0.00010601438],"about_ca_topic_score_codex":0.00012468042,"about_ca_topic_score_gemma":0.000035136218,"teacher_disagreement_score":0.3633655,"about_ca_system_score_codex":0.000670871,"about_ca_system_score_gemma":0.0077173477,"threshold_uncertainty_score":0.99968445},"labels":[],"label_agreement":null},{"id":"W4403099656","doi":"10.1080/14796694.2024.2406117","title":"Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"BeiGene; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Lung cancer; Crown (dentistry); Internal medicine; Oncology; Dentistry","score_opus":0.01162281737132365,"score_gpt":0.35224840993712775,"score_spread":0.3406255925658041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403099656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658991,0.004527532,0.0000063025345,0.0064391647,0.001326642,0.0012247605,0.00044636798,0.00004330327,0.02008683],"genre_scores_gemma":[0.9945935,0.00018722976,0.0002631483,0.0005332704,0.0012849885,0.0001676816,0.00020370739,0.000028042756,0.0027384066],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.998856,0.00012549268,0.00034150787,0.00033202316,0.0001426915,0.00020225103],"domain_scores_gemma":[0.9990596,0.00044348542,0.000084044266,0.00031082405,0.000044600176,0.00005740128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022977493,0.00014655676,0.00034374834,0.00008639206,0.000048533275,0.000013863781,0.00011677008,0.00013652086,0.00025024472],"category_scores_gemma":[0.000038976963,0.00009095071,0.000061260966,0.00029548563,0.00003728726,0.00003392105,0.000048282676,0.0003328385,0.000015662454],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007637171,0.005212973,0.19459134,0.0005434081,0.0022178565,0.003324785,0.433663,0.00022872128,0.0040292186,0.00034187135,0.29907352,0.049136125],"study_design_scores_gemma":[0.040924046,0.0051433425,0.5072634,0.0010995464,0.0031151106,0.000021946327,0.14074986,0.0011090749,0.0010374862,0.000042471103,0.29902005,0.00047362436],"about_ca_topic_score_codex":0.0077355094,"about_ca_topic_score_gemma":0.018383827,"teacher_disagreement_score":0.3126721,"about_ca_system_score_codex":0.00027813384,"about_ca_system_score_gemma":0.0005053267,"threshold_uncertainty_score":0.9995281},"labels":[],"label_agreement":null},{"id":"W4403226923","doi":"10.1016/j.cjca.2024.08.097","title":"THE IMPACT OF COVID-19 PANDEMIC ON TRAINEES' DIAGNOSTIC PERFORMANCE IN ECG INTERPRETATION","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Interpretation (philosophy); Coronavirus Infections; Virology; Internal medicine; Outbreak; Linguistics","score_opus":0.020315751059540234,"score_gpt":0.3534323322162323,"score_spread":0.33311658115669207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403226923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908949,0.0034576263,0.0006589865,0.001376656,0.00045681326,0.00014766827,0.000028123855,0.0000035743753,0.0029756287],"genre_scores_gemma":[0.9991544,0.00049713656,0.000008242703,0.00009855356,0.00016787012,0.0000055223836,0.0000057920015,0.000006533873,0.00005596299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994745,0.000058116428,0.00021892323,0.00005824303,0.000051643892,0.00013855737],"domain_scores_gemma":[0.999008,0.00056222867,0.00005219888,0.00007396148,0.00005428542,0.00024935155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025244209,0.000060661554,0.00020234242,0.00024571802,0.000035882393,0.0000089825035,0.000052575724,0.000044482087,0.000013817135],"category_scores_gemma":[0.0006161597,0.000034686786,0.00013987222,0.00012566795,0.00008290475,0.000037487145,0.0000015272583,0.00017534663,0.0000032166265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025392813,0.000004925066,0.82286304,0.00008876054,0.00093614677,0.0007089397,0.004960165,0.088401735,0.000071346854,0.00025031768,0.007046219,0.07441445],"study_design_scores_gemma":[0.0020431953,0.0032192133,0.94616777,0.0006008653,0.00039307604,0.0029899948,0.0009278987,0.0032863815,0.000014341288,0.00069231796,0.03955187,0.000113089736],"about_ca_topic_score_codex":0.0012864826,"about_ca_topic_score_gemma":0.0019097956,"teacher_disagreement_score":0.12330469,"about_ca_system_score_codex":0.0008844679,"about_ca_system_score_gemma":0.0036166715,"threshold_uncertainty_score":0.641582},"labels":[],"label_agreement":null},{"id":"W4403245149","doi":"10.1038/s41698-024-00726-3","title":"Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway","year":2024,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Chinese Society of Clinical Oncology; Peking Union Medical College Hospital; Beijing Xisike Clinical Oncology Research Foundation","keywords":"Cancer research; Medicine; MAPK/ERK pathway; Lung cancer; Oncology; Internal medicine; Lung; Biology; Kinase; Genetics","score_opus":0.01327931864195656,"score_gpt":0.33231253703911107,"score_spread":0.3190332183971545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403245149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612699,0.009123708,0.00046670483,0.009115705,0.0012731267,0.0015962005,0.00017724719,0.00012594702,0.016851446],"genre_scores_gemma":[0.99268353,0.0005772924,0.0034561474,0.0016439821,0.00020492918,0.00048502797,0.00017983593,0.00003295787,0.00073628896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998427,0.00015200334,0.0003922071,0.00045732438,0.0002680467,0.00030341742],"domain_scores_gemma":[0.9983976,0.0010143128,0.00005059264,0.00033418243,0.00009022921,0.00011308696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032021024,0.00019261654,0.0003268873,0.00023941757,0.00014027425,0.000053159427,0.00013381141,0.00018646212,0.00036539274],"category_scores_gemma":[0.00020824726,0.00012701425,0.00007732859,0.00041810915,0.0001385396,0.00021792289,0.000041602045,0.00035048331,0.00005667974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006735101,0.002722359,0.13964595,0.0015233133,0.0013748902,0.007112635,0.058291182,0.00033780496,0.09008016,0.043712415,0.035147548,0.6193782],"study_design_scores_gemma":[0.017591614,0.0030594536,0.8337143,0.0018363352,0.0016066999,0.0009666558,0.0042097494,0.004098123,0.001805348,0.017024925,0.11305478,0.0010319848],"about_ca_topic_score_codex":0.0014771869,"about_ca_topic_score_gemma":0.00090500107,"teacher_disagreement_score":0.6940684,"about_ca_system_score_codex":0.0014421598,"about_ca_system_score_gemma":0.0015363006,"threshold_uncertainty_score":0.51794904},"labels":[],"label_agreement":null},{"id":"W4403410249","doi":"10.1016/j.jtho.2024.09.441","title":"P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Cancer research","score_opus":0.021139339467213112,"score_gpt":0.4677583966244069,"score_spread":0.44661905715719374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797312,0.0026104404,0.0052558235,0.0082284035,0.00046368103,0.002194874,0.00005126884,0.00006741683,0.001396895],"genre_scores_gemma":[0.98232824,0.00019748206,0.009912035,0.0010612287,0.000711199,0.00020561527,0.00003168041,0.00008585572,0.0054666437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986028,0.00009458513,0.0005762796,0.00025889245,0.00018961761,0.00027781306],"domain_scores_gemma":[0.998835,0.00017061172,0.00031151532,0.00022289054,0.00027850037,0.0001814499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030518242,0.00022403199,0.0006564323,0.0002746005,0.00012070097,0.00005196223,0.00010847541,0.00009762003,0.00022347433],"category_scores_gemma":[0.000029799843,0.00014526876,0.000202427,0.00024197433,0.000057767542,0.00019488894,0.000009078701,0.00024805707,0.000018546121],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045439858,0.015227165,0.0058822474,0.00055749196,0.011391356,0.0020615472,0.020989519,0.0006006161,0.033863164,0.00019466762,0.025819913,0.83797246],"study_design_scores_gemma":[0.058941107,0.09743243,0.0075536217,0.0012146599,0.012014073,0.003210847,0.003791549,0.0011237564,0.0054517104,0.00043726657,0.80819607,0.00063292694],"about_ca_topic_score_codex":0.000018882021,"about_ca_topic_score_gemma":0.000083771294,"teacher_disagreement_score":0.8373395,"about_ca_system_score_codex":0.000914674,"about_ca_system_score_gemma":0.0011080452,"threshold_uncertainty_score":0.5923888},"labels":[],"label_agreement":null},{"id":"W4403410272","doi":"10.1016/j.jtho.2024.09.462","title":"P2.11A.12 Machine Learning-Based Clinicogenomic Prediction of Response to PD-(L)1 Inhibition in KRAS Altered Non-Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; KRAS; Lung cancer; Oncology; Cancer research; Internal medicine; Cancer; Colorectal cancer","score_opus":0.023557788308013142,"score_gpt":0.43049473602326505,"score_spread":0.4069369477152519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829055,0.0022862088,0.0020823292,0.005087685,0.0013458285,0.00044963867,0.00006836321,0.000017665132,0.000371711],"genre_scores_gemma":[0.99640656,0.0002222722,0.0016259574,0.0003715436,0.0004761292,0.00003381586,0.000024981862,0.00002824291,0.0008105148],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983742,0.0002980333,0.0007756547,0.00018680237,0.0001772888,0.00018799285],"domain_scores_gemma":[0.9988701,0.00030990638,0.00036928977,0.000115603274,0.00018091411,0.00015419828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010684502,0.0001337632,0.00046003523,0.000646116,0.000036652615,0.000012414363,0.00004986858,0.00014987012,0.00015029966],"category_scores_gemma":[0.00012576232,0.00010907219,0.00016244286,0.00029147216,0.000034133147,0.00008232682,0.0000206338,0.0004973403,0.000009234086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07505622,0.0036907457,0.23019414,0.0026781752,0.0013695378,0.0039560464,0.0127886,0.06988199,0.44884905,0.000008491428,0.009750061,0.14177695],"study_design_scores_gemma":[0.024723368,0.045325894,0.5134597,0.010483453,0.009126638,0.0013408855,0.0018972862,0.09173274,0.12511316,0.00016695853,0.17586777,0.00076216855],"about_ca_topic_score_codex":0.00014101321,"about_ca_topic_score_gemma":0.00021668147,"teacher_disagreement_score":0.3237359,"about_ca_system_score_codex":0.001305743,"about_ca_system_score_gemma":0.0019104938,"threshold_uncertainty_score":0.44478348},"labels":[],"label_agreement":null},{"id":"W4403410304","doi":"10.1016/j.jtho.2024.09.054","title":"OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Pooled analysis; Meta-analysis; Adenocarcinoma; Cancer","score_opus":0.03214442016209941,"score_gpt":0.48421321979866294,"score_spread":0.45206879963656355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96465564,0.004197576,0.015553229,0.012833355,0.0006342062,0.00065343647,0.00037574026,0.00003327397,0.0010635626],"genre_scores_gemma":[0.96738464,0.0000510037,0.030010981,0.00078245415,0.00030215658,0.000025904199,0.00007919775,0.000028159757,0.0013355248],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9985652,0.00013571675,0.0006370648,0.00020256592,0.0002638085,0.00019566208],"domain_scores_gemma":[0.99791956,0.0008943901,0.0004872758,0.00018538667,0.00034524742,0.00016814198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005025001,0.00016494136,0.0010837724,0.0006016284,0.000046100464,0.00002236306,0.000100237296,0.00007888457,0.00041050045],"category_scores_gemma":[0.00018600194,0.00009160459,0.00038149318,0.0007314112,0.0000861948,0.00013185556,0.00001649303,0.00018596047,0.000003753466],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0394494,0.0032468475,0.035243757,0.0006976203,0.1740151,0.0033536502,0.008040608,0.0019665626,0.020945124,0.0005167214,0.019168487,0.6933561],"study_design_scores_gemma":[0.023919707,0.03792103,0.036010884,0.0031404924,0.6288041,0.002007104,0.007242199,0.013002408,0.030916505,0.0017356796,0.21440123,0.00089867803],"about_ca_topic_score_codex":0.00017846405,"about_ca_topic_score_gemma":0.0005670862,"teacher_disagreement_score":0.69245744,"about_ca_system_score_codex":0.00029042488,"about_ca_system_score_gemma":0.001423196,"threshold_uncertainty_score":0.44946918},"labels":[],"label_agreement":null},{"id":"W4403410406","doi":"10.1016/j.jtho.2024.09.026","title":"OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Samsung; Université de Versailles Saint-Quentin-en-Yvelines; Sir Run Run Shaw Hospital; Faculty of Medicine, Prince of Songkla University; Deutsches Zentrum für Lungenforschung; College of Medicine, Seoul National University; Seoul National University Bundang Hospital; Prince of Songkla University; Institut Gustave-Roussy; Yonsei University College of Medicine; McGill University; Baskent Üniversitesi; Shanghai Jiao Tong University; Royal Marsden NHS Foundation Trust; Kindai University; Zhejiang University; Sungkyunkwan University; Yonsei University; Deutsches Krebsforschungszentrum; Capital Medical University; Seoul National University; Zhengzhou University; City of Hope; Kanazawa University; Nationales Centrum für Tumorerkrankungen Heidelberg; Universitätsklinikum Heidelberg; Hospital de Câncer de Barretos; Shanghai Chest Hospital","keywords":"Osimertinib; Medicine; Oncology; Mutant; First line; Second line; Internal medicine; Line (geometry); Epidermal growth factor receptor; Genetics; Cancer; Biology","score_opus":0.022268470418228156,"score_gpt":0.42492215481743734,"score_spread":0.4026536843992092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808855,0.0028019345,0.00009022108,0.010191701,0.002956963,0.0009148204,0.000018967872,0.0000207299,0.0021191475],"genre_scores_gemma":[0.99662024,0.00022232221,0.0005590139,0.0003944878,0.00027611706,0.000030108955,0.000004271637,0.00003491359,0.0018585471],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99770594,0.00021684945,0.0011020823,0.00024859337,0.0004279756,0.00029856194],"domain_scores_gemma":[0.99842715,0.0003442467,0.0005154811,0.00032745057,0.000251695,0.00013398484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066702964,0.00021669354,0.0008439189,0.00030664698,0.00007469327,0.000019229303,0.00023594528,0.00014224894,0.00021356219],"category_scores_gemma":[0.0002712511,0.00012803431,0.00031436345,0.0005827325,0.00009825044,0.00015866179,0.00009035594,0.00060795475,0.000021115939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04037343,0.010600518,0.10488137,0.001244019,0.0060397033,0.010484193,0.039374925,0.002529644,0.014906808,0.00020977615,0.0057193814,0.76363623],"study_design_scores_gemma":[0.07460857,0.058830157,0.53361714,0.009439331,0.019791842,0.0077190516,0.025270889,0.0036577217,0.0219933,0.0021460073,0.24156629,0.0013596811],"about_ca_topic_score_codex":0.00006359917,"about_ca_topic_score_gemma":0.00052481546,"teacher_disagreement_score":0.76227653,"about_ca_system_score_codex":0.0009584733,"about_ca_system_score_gemma":0.0013456651,"threshold_uncertainty_score":0.52210873},"labels":[],"label_agreement":null},{"id":"W4403410433","doi":"10.1016/j.jtho.2024.09.019","title":"PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of California, Davis; University of Texas MD Anderson Cancer Center; Institut Gustave-Roussy; Chinese Academy of Medical Sciences; Comprehensive Cancer Center, University of California, Davis; Zhengzhou University; Kanazawa University; Kindai University; Harbin Medical University","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.025264826565226155,"score_gpt":0.4676684770420523,"score_spread":0.4424036504768261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876873,0.0030221986,0.00027683785,0.003582708,0.0004523442,0.0012299012,0.000028653909,0.000021884878,0.003698173],"genre_scores_gemma":[0.9958338,0.00009831799,0.0031493814,0.00014851235,0.00011198001,0.000078705576,0.000007004547,0.000022645963,0.0005496086],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979341,0.00035542226,0.0009262807,0.00021419453,0.00034554183,0.00022446761],"domain_scores_gemma":[0.9983032,0.00052371324,0.0005299352,0.00018559366,0.0003123082,0.00014528802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067103066,0.00018943996,0.0011125705,0.00027369,0.000053168093,0.000015965796,0.000102335354,0.000082210034,0.000179446],"category_scores_gemma":[0.00015932352,0.00011825624,0.00019908462,0.0005113693,0.00013144755,0.00017352193,0.00003419514,0.0002760607,0.000015079366],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42717686,0.011538518,0.032679886,0.0005070232,0.008491397,0.011463542,0.062154137,0.0053558038,0.0030092048,0.00035793008,0.0012100884,0.4360556],"study_design_scores_gemma":[0.7707937,0.028524233,0.120125584,0.0030764956,0.015271045,0.0063485815,0.04012526,0.0012817783,0.0009390873,0.0031090905,0.009719647,0.0006855376],"about_ca_topic_score_codex":0.00013579556,"about_ca_topic_score_gemma":0.0005970713,"teacher_disagreement_score":0.43537006,"about_ca_system_score_codex":0.0010890369,"about_ca_system_score_gemma":0.0010337859,"threshold_uncertainty_score":0.48223495},"labels":[],"label_agreement":null},{"id":"W4403419530","doi":"10.1016/j.jtho.2024.09.770","title":"P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"NOSM University; Thunder Bay Regional Health Sciences Centre; Université Laval; Ottawa Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Western University","funders":"","keywords":"Medicine; Observational study; Lung cancer; Database; Environmental health; Internal medicine","score_opus":0.08874857220178278,"score_gpt":0.5242819123374549,"score_spread":0.43553334013567213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97205824,0.0030032468,0.00004295646,0.01865164,0.0014369972,0.0029141922,0.00017705881,0.000044385895,0.0016713138],"genre_scores_gemma":[0.9969463,0.00012552044,0.000641421,0.0005171017,0.0004974887,0.00019382237,0.000043327407,0.00003420987,0.001000826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715114,0.00051792385,0.0010051104,0.00038439178,0.0004849629,0.00045648846],"domain_scores_gemma":[0.9980927,0.0002545935,0.0004326949,0.00026863575,0.00043684925,0.0005145229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013184793,0.00022418443,0.0008034199,0.0011859101,0.00015523286,0.00008014826,0.0001625006,0.00007206388,0.0001325034],"category_scores_gemma":[0.000087794484,0.00017587142,0.0001223553,0.0011432313,0.000035401976,0.00037317377,0.00004140536,0.00063872983,0.000011866303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00071732036,0.0033232197,0.95048606,0.00037928953,0.0017653838,0.005259786,0.012755385,0.00006371663,0.000012258366,0.00019430059,0.005183022,0.019860232],"study_design_scores_gemma":[0.0037255134,0.002347756,0.95142025,0.0009964319,0.0013664932,0.00025930873,0.031808045,0.0013980098,0.0000028177715,0.0000115511,0.0065131932,0.00015064015],"about_ca_topic_score_codex":0.26743752,"about_ca_topic_score_gemma":0.8895696,"teacher_disagreement_score":0.62213206,"about_ca_system_score_codex":0.010567092,"about_ca_system_score_gemma":0.007867995,"threshold_uncertainty_score":0.9977565},"labels":[],"label_agreement":null},{"id":"W4403419630","doi":"10.1016/j.jtho.2024.09.585","title":"P3.06D.10 Concordance of Liquid Biopsy and Tissue Biopsy for the Detection of EGFR Mutation in Stage III NSCLC in the United States","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Concordance; Medicine; Stage (stratigraphy); Biopsy; Liquid biopsy; Oncology; Pathology; Internal medicine; Cancer","score_opus":0.02240898837132275,"score_gpt":0.43630960504835115,"score_spread":0.4139006166770284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98740065,0.0034022022,0.0043764496,0.0039563454,0.00027591386,0.00044019235,0.000026746155,0.0000038718767,0.000117639225],"genre_scores_gemma":[0.99836206,0.00043036664,0.0007748963,0.00009646382,0.00007451678,0.000024621768,0.000011943469,0.000008492856,0.00021663474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991111,0.000119602344,0.00046959965,0.00008246793,0.00011905376,0.00009814488],"domain_scores_gemma":[0.99867845,0.00072647474,0.00030310472,0.00008434139,0.00018196851,0.000025659667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007246343,0.0000745729,0.00026502123,0.00032016038,0.000029787147,0.000008688107,0.00006399822,0.000067765715,0.000020007077],"category_scores_gemma":[0.00010491347,0.000040601353,0.000047830406,0.00045078283,0.00010984057,0.00007969173,0.000009345502,0.0001716301,4.3518526e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024715299,0.0013963312,0.0028285747,0.0019119648,0.0011677286,0.001199798,0.04639503,0.0025998575,0.20085001,0.00086648227,0.00042053897,0.7156484],"study_design_scores_gemma":[0.029528024,0.08770543,0.15855232,0.0062323846,0.0076832506,0.012272338,0.14856368,0.046058066,0.22928584,0.005145915,0.26814163,0.0008311073],"about_ca_topic_score_codex":0.00037655723,"about_ca_topic_score_gemma":0.00022902199,"teacher_disagreement_score":0.7148173,"about_ca_system_score_codex":0.00017545246,"about_ca_system_score_gemma":0.0002467034,"threshold_uncertainty_score":0.16556752},"labels":[],"label_agreement":null},{"id":"W4403419632","doi":"10.1016/j.jtho.2024.09.517","title":"P2.16F.03 Development of a Patient-Friendly Lung Cancer Lexicon","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Lexicon; Lung cancer; Radiology; Oncology; Natural language processing","score_opus":0.017917203542575238,"score_gpt":0.46574949764445367,"score_spread":0.4478322941018784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97121924,0.014245219,0.00071844045,0.0044758082,0.002054307,0.00024950507,0.000012120348,0.000018052311,0.007007334],"genre_scores_gemma":[0.9833118,0.00021405009,0.014908749,0.00022247552,0.0002498915,0.000019916033,0.000004782791,0.000017533162,0.001050817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998873,0.000043492288,0.0005792476,0.00011390859,0.0002321407,0.00015818584],"domain_scores_gemma":[0.9991912,0.000071010894,0.00028672733,0.000090439935,0.00023821654,0.00012235233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019726442,0.00010296198,0.00037760325,0.00023059666,0.000042721495,0.000010093646,0.00006331068,0.00008714309,0.0003570598],"category_scores_gemma":[0.00003430809,0.000070961214,0.00012526123,0.00019305915,0.000043910306,0.0001017893,0.00002472704,0.00021594287,0.000010345143],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007804838,0.00056475337,0.004068215,0.00061085937,0.0017893671,0.00081637566,0.010013198,0.000057531157,0.0052360627,0.00023457572,0.011179151,0.96464944],"study_design_scores_gemma":[0.0020122773,0.0047836616,0.012199932,0.0028632202,0.0038418823,0.00178618,0.0027528224,0.00037470084,0.035923593,0.00038120092,0.93281436,0.0002661794],"about_ca_topic_score_codex":0.000017715267,"about_ca_topic_score_gemma":0.000031936772,"teacher_disagreement_score":0.96438324,"about_ca_system_score_codex":0.0008752075,"about_ca_system_score_gemma":0.0034154535,"threshold_uncertainty_score":0.60588676},"labels":[],"label_agreement":null},{"id":"W4403419783","doi":"10.1016/j.jtho.2024.09.445","title":"P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lions Gate Hospital; Grand River Hospital; Lakeridge Health; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Osimertinib; Medicine; Pemetrexed; Lung cancer; Oncology; Prospective cohort study; Internal medicine; Cohort; Cancer; Chemotherapy; Epidermal growth factor receptor; Cisplatin; Erlotinib","score_opus":0.008008396597811867,"score_gpt":0.4372606523799116,"score_spread":0.4292522557820997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951262,0.0011277695,0.000010657363,0.00036245215,0.0004494157,0.0022937327,0.000017573971,0.000017844475,0.00059436937],"genre_scores_gemma":[0.9987485,0.00002658303,0.000647853,0.00005544031,0.00008617202,0.00021007788,0.000010859315,0.000030843625,0.00018371789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983448,0.00012901647,0.0006101346,0.00025768872,0.00045101176,0.00020734346],"domain_scores_gemma":[0.9988352,0.00014857251,0.00041640393,0.00014569725,0.0003486257,0.00010550901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027155058,0.00018344312,0.0006359069,0.0004013816,0.000031216972,0.000010674599,0.00006564479,0.00008290841,0.00013803778],"category_scores_gemma":[0.00008419692,0.000110261804,0.000088376655,0.00053251325,0.000058909023,0.00014004836,0.000022059221,0.00040129904,0.000003208532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019646833,0.004583713,0.8732061,0.00012183902,0.0011429192,0.0006377484,0.0029889555,0.00018833311,0.000089087705,0.0000015450169,0.00010025155,0.0972927],"study_design_scores_gemma":[0.0076048058,0.013947976,0.97378385,0.001813345,0.0015702271,0.000023211953,0.00034900816,0.000099181016,0.00052855443,0.000007975698,0.00017045299,0.00010138832],"about_ca_topic_score_codex":0.00003261948,"about_ca_topic_score_gemma":0.000067267756,"teacher_disagreement_score":0.100577794,"about_ca_system_score_codex":0.0011735152,"about_ca_system_score_gemma":0.0006929976,"threshold_uncertainty_score":0.4496346},"labels":[],"label_agreement":null},{"id":"W4403419979","doi":"10.1016/j.jtho.2024.09.143","title":"MA07.06 Eradicating Drug Tolerant Persisters (DTPs) In EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) By Targeting TROP2","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Drug; Cancer research; Oncology; Internal medicine; Pharmacology","score_opus":0.0115437669861495,"score_gpt":0.3983043843750104,"score_spread":0.3867606173888609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96127677,0.02096066,0.00052221766,0.0101148905,0.0009048775,0.0003834181,0.000023457796,0.000026486177,0.005787212],"genre_scores_gemma":[0.99213415,0.0005025242,0.004375813,0.0009841819,0.00043909688,0.000030536066,0.00003427164,0.00003675698,0.0014626619],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982732,0.00017934668,0.00070198084,0.00024457855,0.00025583987,0.0003450485],"domain_scores_gemma":[0.9990463,0.00019111726,0.0003437828,0.00011323644,0.00013316858,0.0001723956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006610589,0.00019198793,0.00053660246,0.0003445343,0.00007756849,0.000047250604,0.00014276402,0.00012307591,0.00015937652],"category_scores_gemma":[0.000037301954,0.00014773595,0.00020639162,0.00035346785,0.000041929194,0.00014751221,0.00001976352,0.00064233603,0.000010568621],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026756304,0.0036855936,0.06273706,0.0045777922,0.0028540532,0.01800919,0.11472597,0.0025949108,0.1612436,0.000030810064,0.3408706,0.2859948],"study_design_scores_gemma":[0.029549304,0.011260258,0.039731957,0.020214925,0.02528601,0.0093237525,0.09682438,0.09296944,0.037826553,0.0002573552,0.63386524,0.002890809],"about_ca_topic_score_codex":0.0002048743,"about_ca_topic_score_gemma":0.000037145026,"teacher_disagreement_score":0.29299468,"about_ca_system_score_codex":0.0015002695,"about_ca_system_score_gemma":0.001083493,"threshold_uncertainty_score":0.6024497},"labels":[],"label_agreement":null},{"id":"W4403420001","doi":"10.1016/j.jtho.2024.09.065","title":"OA12.03 Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Stage (stratigraphy); Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.03484657134441829,"score_gpt":0.47502015657193275,"score_spread":0.4401735852275145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063076,0.0034104188,0.00014986451,0.00890375,0.0012102113,0.00074439886,0.0001489064,0.000026597305,0.0047751158],"genre_scores_gemma":[0.99621713,0.0001278046,0.00036853465,0.0011784113,0.00026775466,0.000053197284,0.00002638261,0.000029956835,0.0017308494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979246,0.00038542453,0.00083089294,0.00023595875,0.00033168888,0.00029143185],"domain_scores_gemma":[0.99811596,0.0010547509,0.00026180406,0.00022233803,0.0002031226,0.00014202524],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007897239,0.0002059701,0.00069481804,0.00023766958,0.000087498396,0.000052051513,0.00014750536,0.00012294161,0.0012927578],"category_scores_gemma":[0.00020398242,0.000114661365,0.00019941732,0.0004063301,0.00008290984,0.00021198491,0.00005497261,0.0007222477,0.000060495695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05438434,0.018469727,0.43923667,0.00017464058,0.012181261,0.048996657,0.07077058,0.0002135593,0.0017052228,0.00016377679,0.010618526,0.34308502],"study_design_scores_gemma":[0.035998438,0.016574735,0.7872416,0.0013653652,0.0077554644,0.0007234162,0.047006257,0.00042435387,0.00074631127,0.0007143372,0.100920156,0.00052956474],"about_ca_topic_score_codex":0.0004832693,"about_ca_topic_score_gemma":0.00069051195,"teacher_disagreement_score":0.34800494,"about_ca_system_score_codex":0.000823725,"about_ca_system_score_gemma":0.001067438,"threshold_uncertainty_score":0.9996202},"labels":[],"label_agreement":null},{"id":"W4403420029","doi":"10.1016/j.jtho.2024.09.131","title":"MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ROS1; Internal medicine; Lung cancer; Oncology; Cancer; Safety profile; Intensive care medicine; Adenocarcinoma; Adverse effect","score_opus":0.009353308013044336,"score_gpt":0.39624856093847466,"score_spread":0.3868952529254303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930538,0.0022225878,0.00002395933,0.0013886768,0.00050338375,0.00075714913,0.000026278998,0.000005801603,0.0020183402],"genre_scores_gemma":[0.99900013,0.00013410386,0.0003658228,0.000089994064,0.000120518,0.000013187968,0.0000027456986,0.000011888998,0.00026160007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898523,0.00009336041,0.00042823673,0.00014300388,0.00019743993,0.00015272337],"domain_scores_gemma":[0.99927133,0.000121192745,0.00024970894,0.00011688404,0.00015640327,0.000084487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030049778,0.0001202389,0.00041231455,0.00010586131,0.000063394546,0.000012185678,0.00008138786,0.00006266221,0.000039002844],"category_scores_gemma":[0.000024178787,0.000064176274,0.000055984994,0.0003122982,0.00006112708,0.00006495226,0.000041098494,0.00026797855,8.3613133e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038461655,0.0020862648,0.9089877,0.00014550891,0.0006084965,0.00022920746,0.0039423904,0.00012529091,0.000015377966,0.0000057981497,0.00038352708,0.07962428],"study_design_scores_gemma":[0.0064592725,0.009841637,0.97609234,0.00041397582,0.0018961397,0.00008742926,0.0014190739,0.00008459761,0.00005148127,0.000012365699,0.0035686463,0.00007305514],"about_ca_topic_score_codex":0.00013041626,"about_ca_topic_score_gemma":0.00030264448,"teacher_disagreement_score":0.07955123,"about_ca_system_score_codex":0.0006392596,"about_ca_system_score_gemma":0.0007184067,"threshold_uncertainty_score":0.26170325},"labels":[],"label_agreement":null},{"id":"W4403420106","doi":"10.1016/j.jtho.2024.09.186","title":"MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Mutation; Cancer research; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.00967764361359079,"score_gpt":0.39723011494927507,"score_spread":0.38755247133568427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932751,0.0029238334,0.0002166821,0.0014012187,0.00022431006,0.0003327574,0.000028368047,0.000024547657,0.0015731561],"genre_scores_gemma":[0.9956092,0.00029833752,0.0032430561,0.0001766581,0.00008215501,0.000011953787,0.000058606583,0.000022381244,0.0004976202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987391,0.00008236104,0.0005462823,0.00017212726,0.00029582667,0.00016427506],"domain_scores_gemma":[0.99866736,0.00013681165,0.00040153853,0.00011741671,0.00053499034,0.00014188634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020000675,0.00014475547,0.00044530779,0.00025717684,0.000072624156,0.000020670186,0.000057933852,0.00010494912,0.00006636243],"category_scores_gemma":[0.000080239835,0.00009941442,0.00007806747,0.00030165806,0.00017938082,0.00032834866,0.000013137497,0.0002654634,0.000007882741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060597644,0.0014918367,0.5891847,0.0008256599,0.0018650953,0.00080357934,0.0041419277,0.0003196139,0.0051629776,0.00015304498,0.003312506,0.38667932],"study_design_scores_gemma":[0.0036929306,0.0051989458,0.9688086,0.0011253688,0.0014426336,0.00033923305,0.0008305078,0.00016307762,0.0020637785,0.00027821297,0.015893713,0.00016298446],"about_ca_topic_score_codex":0.000016542974,"about_ca_topic_score_gemma":0.000023061375,"teacher_disagreement_score":0.38651633,"about_ca_system_score_codex":0.0002711036,"about_ca_system_score_gemma":0.00046786305,"threshold_uncertainty_score":0.40540022},"labels":[],"label_agreement":null},{"id":"W4403432450","doi":"10.1016/j.annonc.2024.10.006","title":"Lung cancer research and treatment: global perspectives and strategic calls to action","year":2024,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Action (physics); Call to action; Cancer; Intensive care medicine; Oncology; Internal medicine; Marketing","score_opus":0.4288030712226979,"score_gpt":0.6514425563294657,"score_spread":0.2226394851067678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403432450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022958084,0.9821031,3.2377437e-7,0.002647002,0.0001275082,0.0010664087,0.00025225125,0.000014785866,0.011492776],"genre_scores_gemma":[0.001695988,0.9956611,0.000044977984,0.000046461828,0.0002196503,0.0003530551,0.00003378309,0.000017737557,0.0019272594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894017,0.00009381701,0.00022463643,0.00038787417,0.00012537182,0.00022815734],"domain_scores_gemma":[0.99931276,0.00009515853,0.00006927897,0.00013635548,0.00021545206,0.00017096825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013039215,0.00019202329,0.00093603466,0.00020107004,0.000058546153,0.00001986407,0.000034504552,0.00020972779,0.00004491595],"category_scores_gemma":[0.000016629263,0.00012506818,0.00010313026,0.00032803998,0.00014053105,0.000029042867,0.000040838335,0.00016046259,0.000009510659],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063834195,0.00026436843,0.000032230757,0.0046411282,0.0017082515,0.0000950206,0.00085035287,9.9547464e-8,0.0000012916075,0.0030283274,0.0024110968,0.986904],"study_design_scores_gemma":[0.000463161,0.0048852814,0.0000779643,0.0036918307,0.00305585,0.00013380978,0.0011163753,0.0000016211994,0.0000016080734,0.00053815154,0.9859337,0.00010063763],"about_ca_topic_score_codex":0.0012214202,"about_ca_topic_score_gemma":0.0005874445,"teacher_disagreement_score":0.98680335,"about_ca_system_score_codex":0.00078845135,"about_ca_system_score_gemma":0.0015955655,"threshold_uncertainty_score":0.5100132},"labels":[],"label_agreement":null},{"id":"W4403464744","doi":"10.1016/j.jtho.2024.09.1234","title":"EP.12E.02 Landscape, Management &amp; Outcome of Real-World Fusion-positive Non-Small Cell Lung Cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Outcome (game theory); Oncology; Lung cancer; Internal medicine","score_opus":0.021849918105674923,"score_gpt":0.44467539721926386,"score_spread":0.4228254791135889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403464744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74127656,0.008880914,0.0021989378,0.009292815,0.0038791043,0.0010216909,0.00009353734,0.000043208238,0.23331322],"genre_scores_gemma":[0.94536304,0.002342913,0.008019535,0.0005173566,0.00061223796,0.00003627643,0.000022164068,0.00003913292,0.043047357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985296,0.000072162264,0.00070304505,0.00019257618,0.0002672881,0.00023529993],"domain_scores_gemma":[0.9988391,0.00016095396,0.00039556777,0.00018242137,0.00025279418,0.0001691671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003441299,0.00017106769,0.00059672375,0.00050284824,0.000056075594,0.000018554698,0.00012166371,0.000097586155,0.0006499654],"category_scores_gemma":[0.000010487365,0.0001210063,0.00025580882,0.00038047708,0.00004401135,0.00008775588,0.0000615358,0.00033889237,0.000026489557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043167467,0.003658209,0.38938922,0.0073567294,0.010865773,0.008187047,0.011318914,0.0009035837,0.006375661,0.0010490586,0.15364835,0.4029307],"study_design_scores_gemma":[0.009466814,0.0055088354,0.5227906,0.008438385,0.035144053,0.0013797879,0.0031196112,0.0014499296,0.00693844,0.00061208615,0.40422964,0.00092179363],"about_ca_topic_score_codex":0.00019740021,"about_ca_topic_score_gemma":0.00039632502,"teacher_disagreement_score":0.40200892,"about_ca_system_score_codex":0.00070122746,"about_ca_system_score_gemma":0.0005236734,"threshold_uncertainty_score":0.7116666},"labels":[],"label_agreement":null},{"id":"W4403469663","doi":"10.1016/j.jtho.2024.09.1416","title":"MA19.12 Identification of Novel Therapeutic Targets for SOX2 Driven Lung Squamous Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Identification (biology); Basal cell; SOX2; Lung; Cancer research; Squamous-cell carcinoma of the lung; Oncology; Internal medicine; Gene; Genetics","score_opus":0.029353119897125114,"score_gpt":0.43755416756908666,"score_spread":0.4082010476719615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403469663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88811046,0.022316836,0.07156822,0.009464259,0.00396292,0.0012671624,0.00011605763,0.000035919045,0.0031581735],"genre_scores_gemma":[0.99323004,0.000047548692,0.004388524,0.00014963714,0.00035339105,0.00002112066,0.000018591318,0.000022109398,0.0017690283],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898344,0.00003566799,0.0005495135,0.0001253463,0.00016170404,0.00014435496],"domain_scores_gemma":[0.9989404,0.0001969418,0.00037929983,0.00012401293,0.00027953365,0.00007977435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030873698,0.00009649882,0.00033065947,0.00021658312,0.00004331522,0.000014542827,0.00008268093,0.0001018377,0.00005550013],"category_scores_gemma":[0.00003755222,0.00007138986,0.0002064577,0.00011084391,0.000044127613,0.00010384473,0.000011522543,0.00015661145,0.0000040524324],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038721452,0.005517162,0.011042913,0.004747026,0.001976634,0.00062563084,0.0139056705,0.0010482561,0.61631936,0.0016520662,0.024299894,0.31499326],"study_design_scores_gemma":[0.022602223,0.028097762,0.16521005,0.001097766,0.035610646,0.006286879,0.007887256,0.08394806,0.29542154,0.0042115157,0.3485481,0.0010781683],"about_ca_topic_score_codex":0.000007922019,"about_ca_topic_score_gemma":0.000006392893,"teacher_disagreement_score":0.32424822,"about_ca_system_score_codex":0.0004145682,"about_ca_system_score_gemma":0.0007128447,"threshold_uncertainty_score":0.2911194},"labels":[],"label_agreement":null},{"id":"W4403470104","doi":"10.1016/j.jtho.2024.09.1014","title":"EP.07D.01 Regional Longitudinal Evaluation of Treatment Patterns in Early-Stage Non-Small Cell Lung Cancer (ELEVATE)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine","score_opus":0.06135978248095595,"score_gpt":0.4795673355762905,"score_spread":0.4182075530953345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403470104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014527,0.004859784,0.0002960407,0.0020396246,0.00075614924,0.00048682277,0.000032786615,0.000007263546,0.001376275],"genre_scores_gemma":[0.9960899,0.0010548286,0.00060963636,0.00007178167,0.00038164714,0.00006150031,0.00001547936,0.000020850995,0.0016944027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851036,0.00014390022,0.00058757665,0.00018917467,0.00036676062,0.00020223967],"domain_scores_gemma":[0.9989319,0.00012051733,0.00034226466,0.00013359768,0.00035540454,0.000116313815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062107574,0.00015378905,0.00047238538,0.00037921238,0.000029013614,0.000014441213,0.00007080828,0.000121602636,0.00043456696],"category_scores_gemma":[0.000018215811,0.00011015989,0.00019482375,0.00022243339,0.000037719514,0.00011687047,0.000015287702,0.00023068792,0.0000056711933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016718742,0.0020909484,0.7801673,0.00095793355,0.001847143,0.0017961364,0.009578423,0.0035612555,0.0035393282,0.000042537587,0.0016840028,0.19306314],"study_design_scores_gemma":[0.006836905,0.00737038,0.9438848,0.002180225,0.008457158,0.000588371,0.0012007923,0.009897434,0.0059190933,0.00014293003,0.013270399,0.0002515473],"about_ca_topic_score_codex":0.001007684,"about_ca_topic_score_gemma":0.00086267054,"teacher_disagreement_score":0.1928116,"about_ca_system_score_codex":0.0032566625,"about_ca_system_score_gemma":0.002930892,"threshold_uncertainty_score":0.8516059},"labels":[],"label_agreement":null},{"id":"W4403474065","doi":"10.1016/j.jtho.2024.09.1241","title":"EP.12G.02 Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Biomarker; Cancer; Lung cancer; Oncology; Internal medicine","score_opus":0.030085991116694237,"score_gpt":0.42683102300074255,"score_spread":0.3967450318840483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403474065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989264,0.0056015146,0.00050257903,0.0027200473,0.00048628266,0.0006240665,0.00008068063,0.000006002878,0.0007148316],"genre_scores_gemma":[0.9896126,0.001332657,0.0077439295,0.0002080444,0.000097327335,0.00008561468,0.000004970241,0.000022522145,0.00089234335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999069,0.000042205167,0.00040573883,0.0001756188,0.000094918265,0.0002125558],"domain_scores_gemma":[0.9989284,0.0005511585,0.00018005997,0.00006811449,0.0001115418,0.00016070915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016205257,0.00014478921,0.00044498735,0.00020669351,0.00004222737,0.00001818126,0.000032260723,0.00003122966,0.000025122441],"category_scores_gemma":[0.0000314933,0.00010065636,0.000046882586,0.00016979285,0.000021985317,0.00007152932,0.000014297375,0.000117292664,1.5850735e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006058788,0.00017786455,0.18004069,0.00084501324,0.00064473104,0.001919579,0.0007594554,0.0002554048,0.0013243279,0.0000054554903,0.0004400264,0.8129816],"study_design_scores_gemma":[0.0137849,0.008274815,0.8871831,0.0056329127,0.010240376,0.0018213277,0.0034591907,0.04494574,0.0030289243,0.00026726673,0.020744674,0.0006167557],"about_ca_topic_score_codex":0.18692315,"about_ca_topic_score_gemma":0.7568886,"teacher_disagreement_score":0.8123648,"about_ca_system_score_codex":0.002453821,"about_ca_system_score_gemma":0.004191842,"threshold_uncertainty_score":0.8184912},"labels":[],"label_agreement":null},{"id":"W4403476460","doi":"10.1016/j.jtho.2024.09.812","title":"EP.02G.01 Differentiation and Metabolic Phenotypes of Lung Squamous Cell Carcinoma Organoids are Modified by the Tumor Microenvironments","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto","funders":"","keywords":"Organoid; Medicine; Phenotype; Basal cell; Lung; Cancer research; Carcinoma; Pathology; Oncology; Internal medicine; Cell biology; Biology; Biochemistry; Gene","score_opus":0.01035010994945471,"score_gpt":0.3426637841896223,"score_spread":0.33231367424016756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738859,0.022476686,0.0003356448,0.0020975,0.0004024232,0.00020452666,0.000031212665,0.0000064561623,0.00055968034],"genre_scores_gemma":[0.9979343,0.00024329287,0.00025165887,0.00019600836,0.00015925708,0.0000064731794,0.0000100218185,0.000018440089,0.0011805646],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99910945,0.0000989624,0.0003625037,0.00012097024,0.00017511174,0.00013302904],"domain_scores_gemma":[0.9993203,0.00011201737,0.00031402506,0.0001132709,0.000057778034,0.00008258351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015392496,0.00011527555,0.00036374983,0.000109328575,0.00005895547,0.000016918457,0.00007166571,0.000062065694,0.00009922808],"category_scores_gemma":[0.0000240625,0.00006834816,0.00009298794,0.00010514745,0.00007714304,0.00007744511,0.000028109538,0.00020938419,0.000003906545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00378197,0.0046540205,0.2223088,0.0027565616,0.0029401965,0.0014532546,0.015451533,0.00017146493,0.54562545,0.00037125516,0.049284294,0.15120119],"study_design_scores_gemma":[0.0060091172,0.0036575494,0.7507049,0.00032093926,0.0152289625,0.002369775,0.003180632,0.0021187507,0.17477056,0.0006205473,0.040639848,0.00037841615],"about_ca_topic_score_codex":0.000025204987,"about_ca_topic_score_gemma":0.000004960605,"teacher_disagreement_score":0.52839607,"about_ca_system_score_codex":0.00018448039,"about_ca_system_score_gemma":0.00016478918,"threshold_uncertainty_score":0.27871573},"labels":[],"label_agreement":null},{"id":"W4403476484","doi":"10.1016/j.jtho.2024.09.1025","title":"EP.07E.03 TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Adenocarcinoma; Internal medicine; Lung; Cancer research; Gastroenterology; Cancer; Biology","score_opus":0.02168329886991565,"score_gpt":0.46473034816603187,"score_spread":0.4430470492961162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836643,0.008306645,0.00037259088,0.0017565897,0.0006511781,0.0003446941,0.00015748193,0.000020626452,0.0047258995],"genre_scores_gemma":[0.9955592,0.0006391663,0.0024892516,0.0001002403,0.00016297359,0.00001532424,0.00004152073,0.000021320908,0.0009709898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820495,0.00029427136,0.0008215423,0.00018646127,0.0002705893,0.00022221763],"domain_scores_gemma":[0.9982703,0.00057565846,0.0004984596,0.00016861822,0.0002930264,0.00019397496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070329045,0.00015009932,0.0005522708,0.0006285759,0.00005317532,0.000018871133,0.00011413226,0.00013739336,0.00036627523],"category_scores_gemma":[0.00044734898,0.00011626274,0.00017807625,0.0005709715,0.00012404576,0.0002099001,0.000023003477,0.0005845883,0.000028461878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004300725,0.0023598778,0.68845737,0.0016044823,0.003014726,0.013709269,0.012637291,0.00103121,0.0045397403,0.00071233633,0.012081289,0.25555167],"study_design_scores_gemma":[0.006463268,0.007948389,0.9133765,0.0030880633,0.008322814,0.004654747,0.0057518855,0.0056701936,0.0053674695,0.0019036768,0.03696097,0.0004919906],"about_ca_topic_score_codex":0.00023288546,"about_ca_topic_score_gemma":0.00008121026,"teacher_disagreement_score":0.2550597,"about_ca_system_score_codex":0.0008830814,"about_ca_system_score_gemma":0.0019530138,"threshold_uncertainty_score":0.4741057},"labels":[],"label_agreement":null},{"id":"W4403537638","doi":"10.1016/j.esmoop.2024.103754","title":"8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Precision medicine; Drug; Lung; Oncology; Medical physics; Internal medicine; Pharmacology; Pathology","score_opus":0.04747564389814995,"score_gpt":0.4132002471207954,"score_spread":0.36572460322264544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5940246,0.006681041,0.00039105542,0.037428007,0.002069887,0.0073375,0.00009132573,0.00017864797,0.35179794],"genre_scores_gemma":[0.9494019,0.0005358772,0.002893325,0.000896203,0.00047270788,0.0004044817,0.00009654153,0.00004448157,0.045254473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989672,0.000015853399,0.000305883,0.00027615394,0.00026040876,0.00017450225],"domain_scores_gemma":[0.9991,0.0002851695,0.00005446222,0.00035096644,0.00009212153,0.000117276766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020976507,0.00014916385,0.00027759193,0.0000897604,0.00014797944,0.00004193344,0.00017194387,0.00003049317,0.0004463203],"category_scores_gemma":[0.00008795699,0.00007434798,0.000053205516,0.00040357726,0.000042367126,0.000114816714,0.00007728076,0.000057642053,0.000034526256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034090775,0.0002755559,0.007953586,0.00016053983,0.0007863356,0.00017350691,0.034636937,0.00043927864,0.0014030308,0.0007351352,0.20177332,0.75132185],"study_design_scores_gemma":[0.003694351,0.0024911086,0.028595569,0.0032368863,0.0013426928,0.000059301958,0.0029028335,0.0032130803,0.0043379785,0.0003509712,0.94956845,0.0002067791],"about_ca_topic_score_codex":0.029988883,"about_ca_topic_score_gemma":0.0015173609,"teacher_disagreement_score":0.7511151,"about_ca_system_score_codex":0.00094477955,"about_ca_system_score_gemma":0.0004545253,"threshold_uncertainty_score":0.97647053},"labels":[],"label_agreement":null},{"id":"W4403646523","doi":"10.3390/curroncol31100471","title":"Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; McGill University","funders":"","keywords":"Medicine; Lung cancer; Central nervous system; Disease; Cancer; Drug; Antibody-drug conjugate; Antibody; Cancer research; Oncology; Immunology; Monoclonal antibody; Internal medicine; Pharmacology","score_opus":0.0771929828441595,"score_gpt":0.47313183176248164,"score_spread":0.39593884891832215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403646523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012400531,0.98851985,0.0002924325,0.00010412874,0.0027206675,0.005925062,0.0019506805,0.000045498615,0.00031769992],"genre_scores_gemma":[0.0002671489,0.9927368,0.00018199201,0.00000918755,0.00066578574,0.0037370436,0.0015045935,0.0000738861,0.0008235341],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835813,0.00007937766,0.0005659893,0.0004576819,0.00013628924,0.0004025292],"domain_scores_gemma":[0.9985494,0.0003915845,0.00042393562,0.00034926587,0.00015137195,0.00013446277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007528532,0.0004941005,0.002087498,0.00013464442,0.00009549409,0.000020238796,0.00012900209,0.000113948685,0.000027934224],"category_scores_gemma":[0.0000041134685,0.00021794283,0.00067393336,0.00020882915,0.00010943325,0.00001880982,0.000021752085,0.00016276896,0.00000845391],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009277029,0.0011869768,0.00020004674,0.10776348,0.0054704305,0.00008237998,0.0010355981,0.000011704056,0.0000011663367,0.00009907473,0.0031571302,0.88089925],"study_design_scores_gemma":[0.0017987498,0.001359678,0.000015197306,0.015525847,0.086263016,0.00007544541,0.00030514676,0.00016442472,0.000010818364,6.4126874e-7,0.8943105,0.00017058024],"about_ca_topic_score_codex":0.00026377605,"about_ca_topic_score_gemma":0.00014452834,"teacher_disagreement_score":0.89115334,"about_ca_system_score_codex":0.001668109,"about_ca_system_score_gemma":0.0027122921,"threshold_uncertainty_score":0.88874507},"labels":[],"label_agreement":null},{"id":"W4403647807","doi":"10.1097/ede.0000000000001807","title":"Socioeconomic Status, Smoking, and Lung Cancer: Mediation and Bias Analysis in the SYNERGY Study","year":2023,"lang":"en","type":"article","venue":"Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Public Health Ontario; University of Toronto; Institut National de la Recherche Scientifique; Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Compagnia di San Paolo; Regione Lombardia; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Fondation de France; Ministry of Labour and Social Protection of the Russian Federation; Istituto Nazionale per l'Assicurazione Contro Gli Infortuni sul Lavoro; Universidad de Oviedo; Deutsche Gesetzliche Unfallversicherung; Ministerstvo Zdravotnictví Ceské Republiky; European Commission; World Health Organization","keywords":"Socioeconomic status; Lung cancer; Mediation; Environmental health; Medicine; Demography; Oncology; Political science; Sociology; Population","score_opus":0.04933080651086719,"score_gpt":0.4162160092736204,"score_spread":0.3668852027627532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403647807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98729974,0.002950632,0.00001831363,0.009171893,0.000079605095,0.00030122572,0.000015780888,0.000022097527,0.00014068928],"genre_scores_gemma":[0.9956475,0.002665487,0.000027292625,0.001202784,0.000069073634,0.00016760615,0.00008839422,0.000005676305,0.00012618986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898136,0.0003211056,0.00024465867,0.0002192055,0.000038096667,0.00019559766],"domain_scores_gemma":[0.9984169,0.0013068708,0.00008810936,0.00012685587,0.000013225733,0.00004802055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010306695,0.00007521326,0.00034692735,0.00021013897,0.00006851616,0.0000045262527,0.00002699025,0.000050199666,0.000047608588],"category_scores_gemma":[0.0003224063,0.000048223123,0.000034396046,0.00025982448,0.000052435615,0.000030741325,0.000020577343,0.00008945403,0.0000024257588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010355856,0.00003011574,0.99005,0.000009295805,0.0008729577,0.000008209377,0.0036654712,0.0003327379,0.0000018390826,0.00030215716,0.001483636,0.0032332046],"study_design_scores_gemma":[0.00080867147,0.00009150081,0.98995113,0.0000041577605,0.0011481505,0.0000018779735,0.002043702,0.0047335625,4.2009918e-7,0.00032489895,0.0008506583,0.000041237014],"about_ca_topic_score_codex":0.004829621,"about_ca_topic_score_gemma":0.0044669667,"teacher_disagreement_score":0.008347733,"about_ca_system_score_codex":0.0001030096,"about_ca_system_score_gemma":0.0000546935,"threshold_uncertainty_score":0.7300975},"labels":[],"label_agreement":null},{"id":"W4403687222","doi":"10.51731/cjht.2024.1006","title":"Osimertinib (Tagrisso)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Chemistry","score_opus":0.025332631547092532,"score_gpt":0.3596782912347435,"score_spread":0.33434565968765095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403687222","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077723585,0.6168531,0.00059955736,0.29900876,0.0016596199,0.00039525257,0.000036811616,0.00036093517,0.0033623697],"genre_scores_gemma":[0.99786496,0.00058479985,0.00059316726,0.0005090282,0.00001925568,0.0000040325726,0.000002645391,0.000010672527,0.000411453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930465,0.00000984881,0.00028881477,0.00007789435,0.00008263166,0.0002361491],"domain_scores_gemma":[0.9996207,0.000024729863,0.00007394285,0.000113764356,0.0000757196,0.00009119464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016995157,0.000067847075,0.00019422264,0.00048289972,0.0001016061,0.000029037861,0.00007655713,0.00006501302,0.00005604148],"category_scores_gemma":[0.000118232114,0.00004738287,0.0000664644,0.00027480777,0.000077269906,0.000066734065,0.0000040525088,0.0002517004,0.000023154891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004734663,0.000011075705,0.0032321052,0.00016392913,0.0001538533,0.0007194038,0.00043771425,0.0000029144462,0.000026758846,0.0027083987,0.031726763,0.96081233],"study_design_scores_gemma":[0.00032221037,0.0005262138,0.009125555,0.00075960276,0.000085624015,0.0010683165,0.0018607258,0.00001653087,0.0003683336,0.002521093,0.98328084,0.000064953674],"about_ca_topic_score_codex":0.0023036583,"about_ca_topic_score_gemma":0.00066594966,"teacher_disagreement_score":0.9607474,"about_ca_system_score_codex":0.00047242607,"about_ca_system_score_gemma":0.004707914,"threshold_uncertainty_score":0.83516365},"labels":[],"label_agreement":null},{"id":"W4403714283","doi":"10.1007/s00428-024-03886-6","title":"Exploratory evidence maps for the WHO Classification of Tumours 5th edition for lung and thymus tumors","year":2024,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care","funders":"Horizon 2020; European Commission; World Health Organization","keywords":"Pathology; Lung; Medicine; Internal medicine","score_opus":0.07309691345631665,"score_gpt":0.4303522087427664,"score_spread":0.3572552952864498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403714283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61425894,0.17001306,0.16345277,0.031951874,0.0033935606,0.011815297,0.0016266854,0.0007462586,0.0027415657],"genre_scores_gemma":[0.98784196,0.0050309575,0.0037767168,0.0007099937,0.00073468796,0.001093653,0.0004655538,0.00005356928,0.00029287848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977867,0.00016181097,0.0006089453,0.0007128901,0.00028600096,0.00044366246],"domain_scores_gemma":[0.99511,0.0037306147,0.00024541674,0.00055574824,0.00020074309,0.00015749341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010418127,0.00034185348,0.0006004391,0.00020852084,0.00029671355,0.00004280039,0.00025106792,0.00015748887,0.000012095665],"category_scores_gemma":[0.0012855917,0.00020438239,0.00025911292,0.00031197953,0.00084757555,0.00024008592,0.00008736103,0.0003814244,0.000004450018],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006134222,0.0015835654,0.015776848,0.010472715,0.0055843056,0.00026061508,0.020407032,0.00054623245,0.24707961,0.19313513,0.1377065,0.36131322],"study_design_scores_gemma":[0.021177819,0.019315556,0.41094568,0.017245304,0.027232483,0.0002211205,0.03394311,0.18933229,0.058392543,0.1284678,0.09063694,0.0030893623],"about_ca_topic_score_codex":0.000039690884,"about_ca_topic_score_gemma":0.000013245134,"teacher_disagreement_score":0.3951688,"about_ca_system_score_codex":0.00008653662,"about_ca_system_score_gemma":0.0005564662,"threshold_uncertainty_score":0.8334472},"labels":[],"label_agreement":null},{"id":"W4403726996","doi":"10.14309/01.ajg.0001031884.07198.ef","title":"S629 It Is Good to Know if You Glow: A Scoping Review of ALDH2 Mutations and Guidelines for Esophageal Cancer","year":2024,"lang":"en","type":"review","venue":"The American Journal of Gastroenterology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Esophageal cancer; ALDH2; Intensive care medicine; Cancer; Internal medicine; Genetics; Allele; Gene","score_opus":0.058709613863005494,"score_gpt":0.47415322366427215,"score_spread":0.41544360980126666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403726996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014345271,0.96473706,0.00047705046,0.032703564,0.00027737208,0.0013599194,0.00027631034,0.0000059626927,0.000019293833],"genre_scores_gemma":[0.000032986944,0.98420924,0.0033258465,0.011469939,0.0004319362,0.00022096859,0.000021840146,0.000044444303,0.00024279332],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99785995,0.00014471971,0.0013113917,0.00022751404,0.00019396452,0.00026242604],"domain_scores_gemma":[0.9973949,0.00014380597,0.0013986678,0.00024508167,0.00065173476,0.00016578636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004130986,0.00028660943,0.0025780913,0.0002396465,0.00005148011,0.000012486021,0.00019653032,0.00003486432,0.000047715246],"category_scores_gemma":[0.00016984377,0.0001586472,0.0005956896,0.0002805286,0.0002102379,0.000034637967,0.00006186005,0.00024035384,0.0000040343743],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053675304,0.00011052438,0.00016584298,0.10389217,0.0045316266,0.00006152456,0.0005164709,0.000005837611,0.0000014137987,0.000013146861,0.06671915,0.82344556],"study_design_scores_gemma":[0.0007458062,0.007838456,0.000018764353,0.56677246,0.022609567,0.0020445932,0.00015641615,0.0000046304704,6.477849e-7,0.000016533624,0.3996981,0.00009399492],"about_ca_topic_score_codex":0.000041109524,"about_ca_topic_score_gemma":0.000030104986,"teacher_disagreement_score":0.82335156,"about_ca_system_score_codex":0.00013899883,"about_ca_system_score_gemma":0.0007538268,"threshold_uncertainty_score":0.6469446},"labels":[],"label_agreement":null},{"id":"W4403729779","doi":"10.3390/curroncol31110489","title":"A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer research; Adenocarcinoma; Drug; Bioinformatics; Computational biology; Cancer; Internal medicine; Pharmacology; Biology","score_opus":0.04764835217381774,"score_gpt":0.423176046897272,"score_spread":0.37552769472345426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403729779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95261586,0.03606895,0.00039621093,0.0051346454,0.0017764359,0.0006734751,0.000039058614,0.00007701195,0.0032183363],"genre_scores_gemma":[0.99790907,0.0007571043,0.00026303236,0.00016087492,0.00025128186,0.00006727682,0.000073508105,0.000016527792,0.0005013531],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991687,0.000032794705,0.00018669374,0.00031291545,0.00009399479,0.00020493672],"domain_scores_gemma":[0.99961466,0.000103339175,0.000027432243,0.00010301465,0.000044989512,0.000106578496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009794656,0.00012180016,0.00024368074,0.00018979824,0.00004078861,0.000013980871,0.000025637019,0.0000694017,0.000042379314],"category_scores_gemma":[0.000027623488,0.00009883273,0.000053556832,0.00020819617,0.00005741606,0.000055072444,0.000047921865,0.00022550164,0.000032523425],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051882194,0.0024177074,0.13325939,0.0013108084,0.0005825049,0.0019080017,0.023824405,0.000008869751,0.013678221,0.004584272,0.021322189,0.79658484],"study_design_scores_gemma":[0.01376012,0.001480196,0.57649195,0.0019692807,0.002180262,0.001847826,0.0036108238,0.011208816,0.0012360534,0.00043345348,0.385215,0.0005662092],"about_ca_topic_score_codex":0.00008485538,"about_ca_topic_score_gemma":0.00011746102,"teacher_disagreement_score":0.7960186,"about_ca_system_score_codex":0.0006045006,"about_ca_system_score_gemma":0.0004246765,"threshold_uncertainty_score":0.4030282},"labels":[],"label_agreement":null},{"id":"W4403824763","doi":"10.1016/j.cllc.2024.10.009","title":"A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer","year":2024,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Phenotype; Crizotinib; Oncology; Pathology; Internal medicine; Cancer research; Gene; Genetics; Biology","score_opus":0.04387556233235692,"score_gpt":0.4588760357133568,"score_spread":0.4150004733809999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403824763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000109554676,0.9832599,0.000006132007,0.0011968842,0.0009639875,0.009215771,0.0007932377,0.00005753441,0.00439699],"genre_scores_gemma":[0.0006688101,0.98967177,0.00051044533,0.0008441875,0.0003209793,0.006009551,0.00029395724,0.0002012607,0.0014790521],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99413776,0.00044694575,0.0030611854,0.0011371927,0.00064975617,0.0005671714],"domain_scores_gemma":[0.99671257,0.000616239,0.0012521697,0.000651646,0.00043234738,0.0003350428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092657376,0.0007531871,0.004597361,0.00032636346,0.000031489788,0.000017072984,0.00036367757,0.0005787327,0.000722487],"category_scores_gemma":[0.00059826014,0.0005405397,0.001819126,0.0013681384,0.00024171018,0.00006035033,0.00015278888,0.0010671166,0.000019054369],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016277716,0.000804074,0.00334392,0.58102864,0.0039625526,0.00022465478,0.000057547797,0.0000010596607,0.000005385693,0.000020368487,0.028129194,0.38225982],"study_design_scores_gemma":[0.0016374604,0.00041175904,0.00024616052,0.5318953,0.059736997,0.000011364459,0.000010794065,0.000066243374,0.000008590436,0.0000054438233,0.40551463,0.000455291],"about_ca_topic_score_codex":0.00063370453,"about_ca_topic_score_gemma":0.00018384872,"teacher_disagreement_score":0.38180453,"about_ca_system_score_codex":0.00082522613,"about_ca_system_score_gemma":0.0051452927,"threshold_uncertainty_score":0.9997046},"labels":[],"label_agreement":null},{"id":"W4403847447","doi":"10.21037/actr-24-101","title":"A new ALK inhibitor is not a game changer, but an older one is!","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Computer science","score_opus":0.40507471595213795,"score_gpt":0.5887407088941433,"score_spread":0.18366599294200536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403847447","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005523388,0.8387895,0.00049383927,0.14348118,0.002997406,0.0055466713,0.00031170476,0.00033874597,0.0025175572],"genre_scores_gemma":[0.011989566,0.81003684,0.0029993847,0.12527403,0.009834619,0.00038623382,0.0001802146,0.00010687973,0.03919225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962633,0.0005598634,0.0018740799,0.0006568376,0.0003733982,0.0002725125],"domain_scores_gemma":[0.99708796,0.0013375734,0.00026314668,0.000640004,0.000109988985,0.00056135975],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00323862,0.00024839968,0.0019385116,0.00006418297,0.000034482022,0.000063922314,0.00011161219,0.00018062233,0.006530978],"category_scores_gemma":[0.00258642,0.00016521498,0.0009566606,0.00033317637,0.000059168826,0.00013274663,0.000044542227,0.0003349968,0.0018875676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094209696,0.0003897602,0.00005006174,0.0025769297,0.00079303887,0.00005544688,0.00018256846,7.6282145e-9,0.00011083851,0.00014120502,0.276196,0.71940994],"study_design_scores_gemma":[0.0032189975,0.00093360717,0.00027329286,0.01708712,0.004580345,0.00002269191,0.000011358872,0.000013177469,0.0003660777,0.0002077465,0.97308505,0.00020052669],"about_ca_topic_score_codex":0.00014151311,"about_ca_topic_score_gemma":0.0000061947067,"teacher_disagreement_score":0.7192094,"about_ca_system_score_codex":0.00007371424,"about_ca_system_score_gemma":0.0007020316,"threshold_uncertainty_score":0.99888957},"labels":[],"label_agreement":null},{"id":"W4403992066","doi":"10.1016/j.lungcan.2024.108000","title":"Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]","year":2024,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Cancer; Lung; Anaplastic lymphoma kinase; Oncology; Internal medicine; Receptor","score_opus":0.014557669215704791,"score_gpt":0.32902184021540215,"score_spread":0.31446417099969737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403992066","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.402049,0.42062667,0.00085405685,0.0017763696,0.10417074,0.027975773,0.021186015,0.00035026425,0.021011101],"genre_scores_gemma":[0.33153507,0.04423705,0.0012476874,0.00089207443,0.008502805,0.027489614,0.004428338,0.00073742465,0.58092993],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99627197,0.00010939321,0.0007807102,0.001612282,0.00042688867,0.0007987284],"domain_scores_gemma":[0.99777424,0.00016924345,0.00048312653,0.00050114555,0.00058378006,0.0004884751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021332197,0.0010793534,0.0016403642,0.00059287,0.00033730187,0.00012290668,0.00012620859,0.0004606668,0.00018422151],"category_scores_gemma":[0.00001905427,0.00092438655,0.0003034964,0.0006668433,0.00011903758,0.00022170825,0.00011178396,0.00054924726,0.0000013195917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025323508,0.00045696762,0.029330745,0.044589397,0.009610688,0.00029507236,0.011928797,0.0033912768,0.101586565,0.00018837483,0.77923715,0.01685264],"study_design_scores_gemma":[0.038808487,0.0067449026,0.049274936,0.091769956,0.07295882,0.00006930694,0.0016093722,0.065573774,0.36731124,0.00010789883,0.29902643,0.006744885],"about_ca_topic_score_codex":0.03897498,"about_ca_topic_score_gemma":0.07812919,"teacher_disagreement_score":0.5599188,"about_ca_system_score_codex":0.010006388,"about_ca_system_score_gemma":0.004557934,"threshold_uncertainty_score":0.9993207},"labels":[],"label_agreement":null},{"id":"W4404046467","doi":"10.1136/thorax-2024-btsabstracts.11","title":"S5 Real-world evidence on the journey of lung cancer patients in England: delays in diagnosis and treatment","year":2024,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lung cancer; Medicine; Real world evidence; Cancer; Computer science; Intensive care medicine; Oncology; Internal medicine","score_opus":0.040478470224077134,"score_gpt":0.3827903585579534,"score_spread":0.34231188833387627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404046467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977494,0.0025078005,0.0000010198956,0.004058984,0.00008945275,0.0005647294,0.000018508434,0.000010851164,0.0029736853],"genre_scores_gemma":[0.9847841,0.013428532,0.000020992251,0.00016921818,0.000029623125,0.00038719663,0.000005779314,0.000008298165,0.0011662199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994362,0.000028686865,0.00016944106,0.000150505,0.00011105375,0.00010410733],"domain_scores_gemma":[0.9994394,0.00037500716,0.000022260518,0.0001005335,0.000023034854,0.000039721395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007117685,0.00008533881,0.0001441432,0.0001465439,0.000018935767,0.000012749541,0.00002302364,0.00001988074,0.00019214058],"category_scores_gemma":[0.000030117337,0.00004302528,0.000027987915,0.0002443478,0.000019055014,0.000057766967,0.000009700098,0.000059843824,0.0000019647118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053828993,0.00025088285,0.9756292,0.00004854538,0.00008910506,0.000024040097,0.0030392422,0.00001671672,0.000007869364,0.00036870677,0.00067697006,0.0197949],"study_design_scores_gemma":[0.0015533104,0.00047826237,0.99247485,0.0020433187,0.00018970734,7.159944e-7,0.00009027462,0.00053647044,0.00066986936,0.00003990836,0.0018681866,0.000055105058],"about_ca_topic_score_codex":0.023846418,"about_ca_topic_score_gemma":0.04907587,"teacher_disagreement_score":0.025229454,"about_ca_system_score_codex":0.0005084615,"about_ca_system_score_gemma":0.00012015155,"threshold_uncertainty_score":0.98265386},"labels":[],"label_agreement":null},{"id":"W4404059736","doi":"10.3390/curroncol31110497","title":"Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Western University; AstraZeneca (Canada); William Osler Health System; Princess Margaret Cancer Centre; Canada Research Chairs; Lawson Health Research Institute; University Health Network; University of Toronto","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Expression (computer science); Cell; Cancer; Oncology; Ligand (biochemistry); Bioinformatics; Pathology; Internal medicine; Receptor; Biology; Genetics","score_opus":0.056623169681209264,"score_gpt":0.45057567968763923,"score_spread":0.39395251000642995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404059736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924198,0.0010389602,0.000034715056,0.00008934586,0.0012341803,0.0031871148,0.00005171502,0.0001145905,0.0018295879],"genre_scores_gemma":[0.9952727,0.00053060084,0.00028754285,0.000025718009,0.00016708305,0.0006990435,0.0000969091,0.00004581594,0.00287461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998179,0.00012078374,0.00045760538,0.0006251868,0.00024617746,0.00037123193],"domain_scores_gemma":[0.99888873,0.00023270791,0.00014380884,0.00028563617,0.00015146096,0.0002976308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017444824,0.00026351682,0.00054652966,0.0001835733,0.00012084212,0.000055883294,0.000084859086,0.00010921833,0.000038912847],"category_scores_gemma":[0.000018116898,0.00016839735,0.00009545537,0.00025220093,0.000104891325,0.00009242632,0.00009781338,0.00044802215,0.000006483145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029588852,0.0039217393,0.9791307,0.00035491135,0.000253408,0.00013367656,0.0024827903,0.0000014181622,0.00001239703,0.000002900186,0.0008811754,0.012528993],"study_design_scores_gemma":[0.00965119,0.0031566008,0.9762436,0.00036568055,0.0014501443,6.9816946e-7,0.0003375136,0.00015448689,0.000070185735,0.0000024145406,0.008389553,0.0001778897],"about_ca_topic_score_codex":0.0013399998,"about_ca_topic_score_gemma":0.002944574,"teacher_disagreement_score":0.012351103,"about_ca_system_score_codex":0.0003676363,"about_ca_system_score_gemma":0.00049171515,"threshold_uncertainty_score":0.6867045},"labels":[],"label_agreement":null},{"id":"W4404258995","doi":"10.1200/jco-24-02133","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Stage (stratigraphy); Oncology; Cancer; Lung cancer; Internal medicine; Gynecology; Pathology","score_opus":0.06257167324106218,"score_gpt":0.5001184062087508,"score_spread":0.43754673296768865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404258995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8956547,0.016089743,0.03177612,0.037797164,0.0075654113,0.0016897393,0.000086274194,0.000042613116,0.009298263],"genre_scores_gemma":[0.8646019,0.011944838,0.05918992,0.009434631,0.0060752975,0.00012714848,0.000032404812,0.000087476496,0.048506375],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982605,0.0000770285,0.0011219006,0.00018714897,0.00018865448,0.00016477013],"domain_scores_gemma":[0.9973213,0.0013838945,0.00045794077,0.000116575226,0.00052836724,0.00019188876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092106767,0.00011925546,0.0005929141,0.00011181813,0.000079969584,0.000027729206,0.00007596854,0.00016031128,0.00074703066],"category_scores_gemma":[0.00021824904,0.00007057546,0.00030404952,0.000137205,0.000050052815,0.00014073953,0.000015255787,0.00040806856,0.000008897684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058497055,0.0034825872,0.13037428,0.0004973137,0.004820985,0.0011802518,0.0023649798,0.0023783052,0.0010617025,0.00023986258,0.590022,0.257728],"study_design_scores_gemma":[0.009086162,0.011508877,0.020318445,0.0007626927,0.0016865467,0.000053492215,0.00031394928,0.007963251,0.00012730855,0.0000372481,0.9480162,0.00012580582],"about_ca_topic_score_codex":0.000051526476,"about_ca_topic_score_gemma":0.00008234428,"teacher_disagreement_score":0.3579942,"about_ca_system_score_codex":0.00028187843,"about_ca_system_score_gemma":0.0035079254,"threshold_uncertainty_score":0.8179462},"labels":[],"label_agreement":null},{"id":"W4404290023","doi":"10.1016/j.jtocrr.2024.100765","title":"Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; LUNGevity Foundation","keywords":"Oncology; Medicine; Internal medicine; Disease; Lung cancer; Cancer; Cancer research; Lung; Pathology","score_opus":0.09377657879051397,"score_gpt":0.5098656703436437,"score_spread":0.41608909155312973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404290023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423563,0.001427257,0.00002723976,0.0033545326,0.00007462412,0.000719362,0.000040061248,0.000048646732,0.00007264616],"genre_scores_gemma":[0.9978197,0.0007876929,0.0000728013,0.0002113704,0.00009090981,0.00013511555,0.00025269357,0.000022023942,0.0006076459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685663,0.0003439124,0.0007019513,0.000736093,0.0009536248,0.00040780383],"domain_scores_gemma":[0.99731666,0.0004288705,0.000085129206,0.0003529325,0.00017932485,0.0016370632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020077478,0.00017490679,0.0004898227,0.0005461131,0.00012049888,0.00007232315,0.00004226042,0.00010601547,0.00008110829],"category_scores_gemma":[0.0013829658,0.00010116313,0.00009358221,0.00091804884,0.000532476,0.00014182118,0.00006594052,0.00059764495,0.0000022035472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027960516,0.00050452433,0.96971685,0.00019084693,0.0010221055,0.008598195,0.00036841634,0.000003151308,0.0000010321886,0.000016340011,0.00006693312,0.019231986],"study_design_scores_gemma":[0.0015011239,0.0010288265,0.9917137,0.00076593866,0.0019498479,0.00008608502,0.000342363,0.001562848,0.000008171787,0.00023148455,0.0006700803,0.00013950035],"about_ca_topic_score_codex":0.000343216,"about_ca_topic_score_gemma":0.00018938414,"teacher_disagreement_score":0.021996867,"about_ca_system_score_codex":0.00014374012,"about_ca_system_score_gemma":0.0013352395,"threshold_uncertainty_score":0.4125313},"labels":[],"label_agreement":null},{"id":"W4404298048","doi":"10.1093/ejcts/ezae406","title":"Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"European Journal of Cardio-Thoracic Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Adenocarcinoma; Internal medicine; Stage (stratigraphy); Oncology; Cohort; Lymphadenectomy; Lung; Proportional hazards model; Retrospective cohort study; Lung cancer; Lymph node; Gastroenterology; Cancer","score_opus":0.012910904531323748,"score_gpt":0.26386731010819975,"score_spread":0.250956405576876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404298048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363446,0.004398039,0.00025208172,0.000054669414,0.00043828133,0.0003050144,0.0000480472,0.00003600475,0.00083340926],"genre_scores_gemma":[0.99938,0.00009353825,0.000086860266,0.000020204612,0.00017775716,0.0000037635027,0.000027397458,0.000066230736,0.0001442367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811995,0.00046859382,0.0004599775,0.00024208109,0.0004459808,0.00026342378],"domain_scores_gemma":[0.99882716,0.00041024794,0.00015978544,0.000154834,0.0001776605,0.0002702871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076454127,0.00021440929,0.00048049478,0.0005213605,0.0000591931,0.000079358855,0.000048328562,0.000028581919,0.0000137601355],"category_scores_gemma":[0.00022204638,0.00014581805,0.00017318134,0.0003856351,0.00007713139,0.00028175663,0.000022227725,0.00020777254,0.0000034483676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011512779,0.00010893744,0.9755453,0.00019875301,0.00070364075,0.006351559,0.0013885825,0.00003666403,0.000008130191,0.0000013165643,0.00030046937,0.014205358],"study_design_scores_gemma":[0.0010576973,0.0008597858,0.9944995,0.0015783791,0.0008567108,0.00015993394,0.00027888332,0.000030863506,0.000042421616,0.0000012214355,0.00049807946,0.00013654534],"about_ca_topic_score_codex":0.000011074018,"about_ca_topic_score_gemma":0.0000023590515,"teacher_disagreement_score":0.018954167,"about_ca_system_score_codex":0.00024895257,"about_ca_system_score_gemma":0.00029856685,"threshold_uncertainty_score":0.59462875},"labels":[],"label_agreement":null},{"id":"W4404353135","doi":"10.1016/j.fander.2024.09.160","title":"Décollement séreux de la rétine sous binimétinib non récidivant sous tramétinib","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Tine; Medicine; Engineering","score_opus":0.03152175790992463,"score_gpt":0.40489060558248763,"score_spread":0.373368847672563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404353135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5947067,0.16571647,0.017981447,0.14129315,0.0071325875,0.0031381287,0.0012501352,0.0024059187,0.06637545],"genre_scores_gemma":[0.94034535,0.03285743,0.008434459,0.008023494,0.0008293497,0.00059886574,0.00033035045,0.00018678617,0.008393942],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935424,0.0011346268,0.001134634,0.0011369481,0.0005078752,0.002543526],"domain_scores_gemma":[0.99497724,0.002981489,0.00026189888,0.0008724674,0.00017498463,0.0007319093],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018721101,0.00092067814,0.001146072,0.00051396183,0.0003632542,0.0004504105,0.0006300431,0.0011079896,0.0006891995],"category_scores_gemma":[0.0012996445,0.00082336453,0.00066702254,0.0006510643,0.0008267768,0.00030423419,0.000311459,0.0014916528,0.0010154502],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006524888,0.003317772,0.09893283,0.00489453,0.005039206,0.066179164,0.013752836,0.0030720735,0.0038366078,0.023981651,0.6901229,0.08621795],"study_design_scores_gemma":[0.0063227653,0.0019993705,0.047421604,0.0035639724,0.004431769,0.018184021,0.008075242,0.014765473,0.01165232,0.012645757,0.8691845,0.001753214],"about_ca_topic_score_codex":0.0005096102,"about_ca_topic_score_gemma":0.000107492,"teacher_disagreement_score":0.34563863,"about_ca_system_score_codex":0.0019024312,"about_ca_system_score_gemma":0.0063702846,"threshold_uncertainty_score":0.99976236},"labels":[],"label_agreement":null},{"id":"W4404393548","doi":"10.51731/cjht.2024.1025","title":"Overview of Systematic Reviews of ICIs in NSCLC With EGFR, ALK, ROS1, and RET Actionable Driver Mutations","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada","keywords":"ROS1; Medicine; Cancer research; Oncology; Internal medicine; Cancer; Adenocarcinoma","score_opus":0.07018628142857407,"score_gpt":0.38070954589236666,"score_spread":0.3105232644637926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404393548","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10063212,0.87535924,0.00024646503,0.021274608,0.00018152551,0.001672248,0.000052062078,0.00003566971,0.0005460435],"genre_scores_gemma":[0.9863936,0.0122927055,0.001098731,0.000082722305,0.0000031632399,0.000026994721,0.0000034470236,0.0000083838895,0.00009027653],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9989732,0.000043156142,0.00066011207,0.00008070184,0.000102207094,0.00014061198],"domain_scores_gemma":[0.9992596,0.00008126342,0.00034509244,0.00014123513,0.00012087124,0.00005193249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039793504,0.00007813195,0.0005831356,0.00058909977,0.000043521384,0.000009623353,0.00005947962,0.000053148953,0.000018915853],"category_scores_gemma":[0.0002657421,0.000049877555,0.00004838339,0.0004637161,0.00011756681,0.00010073186,0.000004615022,0.00016105198,9.351172e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114539944,0.0002853091,0.049886435,0.47458574,0.001821572,0.0013272106,0.013768486,0.00016237567,0.00033147977,0.028224474,0.013620465,0.41587192],"study_design_scores_gemma":[0.0074773915,0.007790999,0.09451245,0.61458135,0.0031676602,0.0059960517,0.05438775,0.0003494744,0.0016428445,0.01299292,0.19633697,0.00076414144],"about_ca_topic_score_codex":0.0037712548,"about_ca_topic_score_gemma":0.0061823223,"teacher_disagreement_score":0.88576144,"about_ca_system_score_codex":0.00038353947,"about_ca_system_score_gemma":0.0020353564,"threshold_uncertainty_score":0.5701034},"labels":[],"label_agreement":null},{"id":"W4404404889","doi":"10.1016/j.lana.2024.100936","title":"Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study","year":2024,"lang":"en","type":"article","venue":"The Lancet Regional Health - Americas","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Queen's University; University of British Columbia","funders":"Ipsen; Servier; Astellas Pharma; Genome British Columbia; Genome Canada; Incyte; Terry Fox Research Institute; Eisai; Sanofi; AstraZeneca Canada; AstraZeneca; Pfizer; Amgen","keywords":"Lung cancer; Population; Panel discussion; Oncology; Medicine; Business; Environmental health","score_opus":0.18006433103031935,"score_gpt":0.4806961889388904,"score_spread":0.30063185790857105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404404889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95698816,0.0026124294,0.020531539,0.0078109214,0.00038591318,0.01108983,0.00030615856,0.00013452077,0.00014053583],"genre_scores_gemma":[0.987307,0.000314187,0.0060588853,0.0024712177,0.00016896159,0.0030929002,0.00017993916,0.000046115307,0.00036078054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984515,0.000107142594,0.00041786092,0.0003439607,0.00028455362,0.00039501122],"domain_scores_gemma":[0.9976996,0.0013456085,0.00017621646,0.00041194324,0.000184915,0.00018172187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049188285,0.00020772469,0.00062616856,0.00019138915,0.00026213244,0.000018887695,0.00014237672,0.000029522023,0.00000930831],"category_scores_gemma":[0.00003077468,0.00013663292,0.00013054757,0.0008473817,0.00003548715,0.00005323136,0.000022481388,0.00015901815,0.0000039402853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00967755,0.0028198003,0.4879965,0.008215067,0.002314481,0.00007083408,0.028541544,0.13250946,0.005530731,0.0014827438,0.00270998,0.31813133],"study_design_scores_gemma":[0.011202734,0.0028979343,0.92889833,0.0035396165,0.0009485664,0.0000124038515,0.0021359157,0.042206343,0.0008186279,0.00019882816,0.0066925534,0.0004481415],"about_ca_topic_score_codex":0.010263361,"about_ca_topic_score_gemma":0.0018155456,"teacher_disagreement_score":0.44090185,"about_ca_system_score_codex":0.0014782085,"about_ca_system_score_gemma":0.0017821138,"threshold_uncertainty_score":0.9963274},"labels":[],"label_agreement":null},{"id":"W4404512668","doi":"10.1016/j.lungcan.2024.108034","title":"Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Weight gain; Intensive care medicine; Internal medicine; Body weight","score_opus":0.005804123158632089,"score_gpt":0.3434996721612806,"score_spread":0.3376955490026485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404512668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7583408,0.18079658,0.005841244,0.038432777,0.0011815807,0.0032909263,0.0042070914,0.00046032618,0.0074487342],"genre_scores_gemma":[0.99561757,0.0010399595,0.00043908472,0.00021072038,0.00042801257,0.0005526487,0.00027778494,0.000022513615,0.0014117187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932647,0.000011508987,0.0001201614,0.00032050474,0.00007039825,0.00015097386],"domain_scores_gemma":[0.9995619,0.000050657494,0.000034937842,0.00012601829,0.00013966706,0.00008679269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042258005,0.000115558345,0.00023427913,0.00013646159,0.00014263773,0.00004735663,0.00001981715,0.000082339655,0.000050596504],"category_scores_gemma":[0.0000145569065,0.00009102985,0.00008967977,0.0005481767,0.000031430445,0.000064805274,0.000012899922,0.00009553887,4.5411127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002739738,0.000033183474,0.95175546,0.00037991008,0.006091923,0.0000050556164,0.0068962537,0.000010387427,0.00033418956,0.003093353,0.006801504,0.024571365],"study_design_scores_gemma":[0.0010769204,0.00009064695,0.9771663,0.00015519133,0.0109415455,0.000003863821,0.0006977128,0.0015007799,0.00008979707,0.00032429682,0.007813239,0.0001397009],"about_ca_topic_score_codex":0.0001816622,"about_ca_topic_score_gemma":0.0010931077,"teacher_disagreement_score":0.2372768,"about_ca_system_score_codex":0.00054092176,"about_ca_system_score_gemma":0.00014908866,"threshold_uncertainty_score":0.37120894},"labels":[],"label_agreement":null},{"id":"W4404580924","doi":"10.1016/j.jlb.2024.100213","title":"Discover: Plasma testing in patients with advanced undergenotyped NSCLC and in targeted therapy resistance","year":2024,"lang":"en","type":"article","venue":"The Journal of Liquid Biopsy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.010644848470623391,"score_gpt":0.27844660586675474,"score_spread":0.2678017573961313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404580924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995092,0.003250128,0.000026782813,0.001067254,0.0000749246,0.00019124105,0.0000053507824,0.000006552744,0.0002858019],"genre_scores_gemma":[0.99846697,0.00032907593,0.0009881391,0.00006246271,0.00003492149,0.0000024963074,0.0000030373603,0.000012416376,0.00010048936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994245,0.000033347114,0.00021351996,0.000072002236,0.00015019733,0.0001063956],"domain_scores_gemma":[0.99963945,0.00010745784,0.000081155544,0.00007352519,0.00006180986,0.000036628866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014990938,0.000079478465,0.00014343912,0.000114468225,0.000027862012,0.000012841618,0.00004027731,0.000020976671,0.0000073459523],"category_scores_gemma":[0.000035629204,0.000039158727,0.000016711823,0.00033611926,0.000035107652,0.000119573306,0.00000724141,0.00014561081,7.1378685e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0781411,0.0014161201,0.8377818,0.00034314208,0.0010589815,0.00078323676,0.012729922,0.0010108266,0.037111625,0.00026712436,0.00042036094,0.028935747],"study_design_scores_gemma":[0.008963932,0.0028380996,0.9830919,0.0017376898,0.00013904311,0.000059407063,0.0005540038,0.00008946275,0.0015059982,0.00014456558,0.0007442239,0.00013170502],"about_ca_topic_score_codex":0.000023881315,"about_ca_topic_score_gemma":0.00010281693,"teacher_disagreement_score":0.14531006,"about_ca_system_score_codex":0.00010267976,"about_ca_system_score_gemma":0.00016077046,"threshold_uncertainty_score":0.15968466},"labels":[],"label_agreement":null},{"id":"W4404581054","doi":"10.1016/j.jlb.2024.100206","title":"Expanding the Impact of Liquid Biopsies in patients with newly diagnosed advanced lung cancer (Expandinglung)","year":2024,"lang":"en","type":"article","venue":"The Journal of Liquid Biopsy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; TD Bank Group; Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Medicine; Liquid biopsy; Cancer; Oncology; Internal medicine","score_opus":0.010220362704933105,"score_gpt":0.3408422893939555,"score_spread":0.3306219266890224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404581054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99136734,0.0066893655,0.00008270389,0.000972042,0.00029557227,0.00041924202,0.00003477141,0.000012977648,0.0001259961],"genre_scores_gemma":[0.99880755,0.0007059981,0.0001289102,0.000056436096,0.00015284476,0.000015616906,0.000005512521,0.000026954429,0.00010019288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988272,0.000065503395,0.00043662274,0.00010520302,0.0003391133,0.00022636034],"domain_scores_gemma":[0.9989833,0.00026628756,0.00027459007,0.00019258384,0.00020022958,0.00008296955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003066615,0.00017558309,0.0003335558,0.00021390873,0.000083035105,0.000026378899,0.00015222852,0.000043543085,0.00009408595],"category_scores_gemma":[0.000056195182,0.00006923461,0.00016381261,0.0005091442,0.00010878242,0.00021383741,0.000026106816,0.00025953524,0.0000010896873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091255695,0.002640498,0.6651568,0.0009859975,0.011598994,0.0007568481,0.07927124,0.022211047,0.11111957,0.0003052021,0.005195433,0.009502726],"study_design_scores_gemma":[0.02618199,0.030041441,0.8947992,0.0130818235,0.0046490408,0.00054308644,0.0050489553,0.00069774775,0.023890909,0.00012244644,0.0002905005,0.00065287127],"about_ca_topic_score_codex":0.00037181805,"about_ca_topic_score_gemma":0.000026612113,"teacher_disagreement_score":0.22964244,"about_ca_system_score_codex":0.00043642806,"about_ca_system_score_gemma":0.00045572387,"threshold_uncertainty_score":0.28233054},"labels":[],"label_agreement":null},{"id":"W4404625463","doi":"10.1200/po.24.00331","title":"Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Internal medicine; Meta-analysis; Epidermal growth factor receptor; Oncology; Cochrane Library; Adverse effect; Gastroenterology; Cancer; Gefitinib; Erlotinib","score_opus":0.05529877687620812,"score_gpt":0.39678806373164016,"score_spread":0.34148928685543206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404625463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010320988,0.99135697,0.000026945774,0.00025932144,0.00007022358,0.0066774357,0.00044330498,0.000016848137,0.00011683821],"genre_scores_gemma":[0.0020350718,0.9951584,0.0008159221,0.00015020247,0.00001719955,0.0010200288,0.00039183622,0.00005361824,0.00035776006],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996588,0.0004995061,0.0017066676,0.00070124853,0.00027131903,0.00023329027],"domain_scores_gemma":[0.9969286,0.0012587655,0.0010335197,0.00036093398,0.00023740402,0.00018079387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042670892,0.0005145421,0.0072118007,0.000602854,0.00005788235,0.000026983429,0.000094661875,0.00024019102,0.0001350745],"category_scores_gemma":[0.00027298118,0.0002837198,0.0005499975,0.00090995216,0.00010476009,0.00007955532,0.0001143603,0.00033138096,0.0000034395302],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001910166,0.0013361523,0.0013959173,0.85881674,0.0767877,0.00003501929,0.00073278433,0.0000025882655,2.7163114e-7,0.000009593149,0.00016916885,0.060523055],"study_design_scores_gemma":[0.0026515936,0.0013667104,0.0008098004,0.0842971,0.9043266,0.00002148469,0.000029867388,0.000022869794,7.572009e-7,0.000003842663,0.0061707683,0.00029859963],"about_ca_topic_score_codex":0.00015267612,"about_ca_topic_score_gemma":0.00013141904,"teacher_disagreement_score":0.8275389,"about_ca_system_score_codex":0.00048450413,"about_ca_system_score_gemma":0.00047115464,"threshold_uncertainty_score":0.9999615},"labels":[],"label_agreement":null},{"id":"W4404685471","doi":"10.1002/pds.70049","title":"Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; AstraZeneca; LUNGevity Foundation","keywords":"Medicine; Real world data; Lung cancer; Oncology; Intensive care medicine; Internal medicine; Data science","score_opus":0.06315954439058842,"score_gpt":0.4433597664851399,"score_spread":0.3802002220945515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404685471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95231515,0.03661251,0.00070548063,0.005931868,0.0005412085,0.0004945208,0.000610899,0.000052214313,0.0027361335],"genre_scores_gemma":[0.9579305,0.037948422,0.0015034818,0.0011790245,0.00027620635,0.000045378667,0.00039599443,0.000018677847,0.0007023317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873096,0.00017454106,0.0004274043,0.00041530942,0.000046889712,0.00020489396],"domain_scores_gemma":[0.9981849,0.0013451776,0.00008940283,0.00026994845,0.000022505208,0.000088026405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070980657,0.00014640443,0.0004578787,0.00012285094,0.00004023745,0.0000038281264,0.000106414984,0.00004339953,0.00017341327],"category_scores_gemma":[0.000041592648,0.000108699496,0.000044054617,0.00018524803,0.00008555665,0.00008417539,0.00007703979,0.000240917,0.0000030500032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004551502,0.00013011716,0.87966484,0.0002498801,0.00043543254,0.00008651022,0.0015328492,0.00012119957,0.003171003,0.000063219755,0.004915636,0.109174155],"study_design_scores_gemma":[0.009722043,0.0001597872,0.7657114,0.0012541583,0.0017597622,0.00001213563,0.00028020356,0.16917951,0.00792945,0.00036693734,0.043174583,0.0004500184],"about_ca_topic_score_codex":0.0075612343,"about_ca_topic_score_gemma":0.001909875,"teacher_disagreement_score":0.16905832,"about_ca_system_score_codex":0.00006163636,"about_ca_system_score_gemma":0.00016962462,"threshold_uncertainty_score":0.9990475},"labels":[],"label_agreement":null},{"id":"W4404704376","doi":"10.1016/j.lungcan.2024.108040","title":"The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; Cancer Center, University of Colorado; National Institutes of Health; National Cancer Institute; Georgia Clinical and Translational Science Alliance","keywords":"Medicine; Osimertinib; Pemetrexed; Lung cancer; Oncology; Chemotherapy; Internal medicine; Cancer research; Cancer; Epidermal growth factor receptor; Cisplatin; Erlotinib","score_opus":0.0069943952562110025,"score_gpt":0.3123541077166042,"score_spread":0.30535971246039323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404704376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985326,0.0065167984,0.0003511497,0.00050957303,0.00025699587,0.0019960243,0.000044760018,0.00006739563,0.00040403238],"genre_scores_gemma":[0.99689525,0.00018915015,0.0016611033,0.00006573309,0.00008916827,0.00051399844,0.000049289774,0.00007975576,0.00045652094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846274,0.00003932388,0.0003681848,0.00038455767,0.00037479008,0.00037042075],"domain_scores_gemma":[0.9990391,0.0002393678,0.00019146352,0.00024024861,0.00019904802,0.00009073704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012707608,0.00025867595,0.00035915483,0.00016154203,0.00013851417,0.00007063542,0.000071508504,0.000043013653,0.0000453321],"category_scores_gemma":[0.000014634218,0.00014989499,0.000069227906,0.00063501776,0.000064436026,0.00013618196,0.000018166045,0.00023302059,9.338193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024275598,0.0006419562,0.87200284,0.0020027321,0.0023662965,0.00012128675,0.03165256,0.0056434865,0.0033864037,0.000048265392,0.000341217,0.07936541],"study_design_scores_gemma":[0.033922907,0.0011575401,0.8430605,0.024019066,0.005971591,0.000009765603,0.0026571897,0.057284664,0.0296991,0.000008873176,0.0013294355,0.00087939965],"about_ca_topic_score_codex":0.0006480073,"about_ca_topic_score_gemma":0.0006745646,"teacher_disagreement_score":0.07848601,"about_ca_system_score_codex":0.0005080671,"about_ca_system_score_gemma":0.00042870568,"threshold_uncertainty_score":0.611254},"labels":[],"label_agreement":null},{"id":"W4404867964","doi":"10.21037/tlcr-24-913","title":"Correlations between 14-gene RNA-level assay and clinical and molecular features in resectable non-squamous non-small cell lung cancer: a cross-sectional study","year":2024,"lang":"en","type":"article","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Peking Union Medical College; Chinese Society of Clinical Oncology; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences","keywords":"Medicine; Lung cancer; Cross-sectional study; Cancer; Gene; Oncology; RNA; Cancer research; Bioinformatics; Internal medicine; Pathology; Biology; Genetics","score_opus":0.06929900856981809,"score_gpt":0.47666833867248687,"score_spread":0.4073693301026688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404867964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97207975,0.019121114,0.0011125919,0.0019203501,0.00032378914,0.0025904134,0.000767589,0.000047168127,0.0020372428],"genre_scores_gemma":[0.99358666,0.0006985691,0.0005483208,0.000051138093,0.0005009643,0.0008055065,0.0002225279,0.000062629784,0.003523676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967183,0.00024620292,0.00061931,0.00086470303,0.0010148522,0.0005366296],"domain_scores_gemma":[0.99792343,0.0010655433,0.000046758698,0.00024292752,0.0004147935,0.0003065717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016059554,0.00025524688,0.00040148784,0.0005646489,0.0003939743,0.00024064022,0.00012794737,0.00023857634,0.00018779824],"category_scores_gemma":[0.00005950363,0.0002306391,0.00011476312,0.00087823294,0.0002662332,0.00022113018,0.000060487106,0.0012026719,0.0000051706356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003213009,0.00032607387,0.99214286,0.0004165251,0.0005785553,0.00013122064,0.0016754979,0.0008008962,0.00069081713,0.00014460312,0.0007588132,0.0020128577],"study_design_scores_gemma":[0.004803419,0.000301645,0.98508793,0.00025623752,0.0004226258,0.000012786084,0.00009199077,0.008032247,0.00027508673,0.00019988362,0.00030415284,0.0002119809],"about_ca_topic_score_codex":0.007033383,"about_ca_topic_score_gemma":0.0038032066,"teacher_disagreement_score":0.021506926,"about_ca_system_score_codex":0.00043653813,"about_ca_system_score_gemma":0.0020473532,"threshold_uncertainty_score":0.9995789},"labels":[],"label_agreement":null},{"id":"W4404998198","doi":"10.1177/12034754241302821","title":"Evaluating the Implementation and Impact of BRAF Reflex Mutation Testing in Melanoma, Lung, and Colorectal Cancers","year":2024,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Oncology; Colorectal cancer; Melanoma; Targeted therapy; Cancer; Retrospective cohort study; Lung cancer","score_opus":0.056870790483537575,"score_gpt":0.45458281915059645,"score_spread":0.3977120286670589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404998198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98494786,0.01330273,0.00001112157,0.0012641771,0.00012342058,0.00016588144,0.000004500351,0.000004510105,0.0001758009],"genre_scores_gemma":[0.9987071,0.00090695656,0.0001344557,0.00008164847,0.00012904337,0.0000033787237,0.000006183556,0.000008707862,0.00002252128],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990871,0.000054930137,0.00044632025,0.00009147716,0.00021716705,0.000103025675],"domain_scores_gemma":[0.99826413,0.0013118503,0.00020085757,0.000036914924,0.0001246215,0.000061622464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006701069,0.00008662674,0.00030131658,0.00023503906,0.000047238216,0.00001583236,0.0000127973335,0.000026945465,0.000024459106],"category_scores_gemma":[0.00030600955,0.000046764224,0.000041887022,0.00020943787,0.000084787636,0.00009025637,0.000006763637,0.0001236658,3.829429e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006036151,0.000031527543,0.4107827,0.00049573014,0.00068944285,0.0017358965,0.013134019,0.00011537371,0.013452193,0.000028294282,0.0015650447,0.55736613],"study_design_scores_gemma":[0.005493597,0.012931456,0.8504876,0.0072713518,0.0037118038,0.07239349,0.021004753,0.02435274,0.00064781203,0.001087101,0.0003004925,0.00031778056],"about_ca_topic_score_codex":0.0009715603,"about_ca_topic_score_gemma":0.00008505445,"teacher_disagreement_score":0.5570484,"about_ca_system_score_codex":0.0001705598,"about_ca_system_score_gemma":0.00053802284,"threshold_uncertainty_score":0.19069897},"labels":[],"label_agreement":null},{"id":"W4405035130","doi":"10.1182/blood-2024-200769","title":"Transcriptomic Analysis of Clonal Hematopoiesis in Non-Small Cell Lung Carcinoma Unveils a Tumorigenic and Dysregulated Immune Profile","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immune system; Small Cell Lung Carcinoma; Transcriptome; Cancer research; Biology; Haematopoiesis; Lung; Carcinoma; Stem cell; Immunology; Medicine; Small-cell carcinoma; Internal medicine; Genetics; Gene; Gene expression","score_opus":0.005720436749283372,"score_gpt":0.2531410656925709,"score_spread":0.2474206289432875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405035130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844314,0.009810489,0.000035118115,0.00011610329,0.00005211491,0.00043432647,0.00008520829,0.000030434714,0.0009930908],"genre_scores_gemma":[0.99854094,0.000058344984,0.00037379353,0.000015338539,0.000019030766,0.000064684595,0.00012630767,0.000018279272,0.0007832641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991579,0.000017230734,0.00029861403,0.00024664795,0.000112611975,0.00016700303],"domain_scores_gemma":[0.99965584,0.000032525815,0.000037354817,0.00017493549,0.00003574939,0.00006358808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074228345,0.00012662419,0.00039766674,0.00043784032,0.000024332781,0.000015020649,0.000040217587,0.000055018503,0.00013787678],"category_scores_gemma":[0.0000032321263,0.00010458539,0.00016418801,0.0009056824,0.00003413078,0.00004086855,0.000011303814,0.00008431847,0.000003309642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017161242,0.0022975923,0.6396328,0.003095728,0.01047559,0.0007537409,0.0130744865,0.000049434395,0.3292089,0.00030720021,0.00015468385,0.000778172],"study_design_scores_gemma":[0.004504574,0.00019991522,0.86296624,0.00025691174,0.018360244,0.000041614396,0.00043170527,0.006041653,0.10697663,0.000025568275,0.000036777103,0.00015813735],"about_ca_topic_score_codex":0.0005103621,"about_ca_topic_score_gemma":0.00012518508,"teacher_disagreement_score":0.22333342,"about_ca_system_score_codex":0.000056461693,"about_ca_system_score_gemma":0.0001818064,"threshold_uncertainty_score":0.42648685},"labels":[],"label_agreement":null},{"id":"W4405126086","doi":"10.1182/blood-2024-203888","title":"SUVR (SUVmax Lymphoma/SUVmax Liver) Vs Deauville Score for Predicting Relapse in Hodgkin Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Hodgkin lymphoma; Oncology; Nuclear medicine","score_opus":0.015505536817918024,"score_gpt":0.29043364945214545,"score_spread":0.27492811263422745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405126086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812342,0.0091790315,0.00026631576,0.00069495826,0.000558849,0.0011849641,0.00012981793,0.00030560186,0.006446269],"genre_scores_gemma":[0.99330926,0.00031087274,0.0023122416,0.0002661058,0.00043907302,0.00038204275,0.00015257587,0.0000721447,0.002755702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99861753,0.00002368914,0.00031965855,0.00044647563,0.00021367255,0.00037898208],"domain_scores_gemma":[0.99928635,0.00017508534,0.000048927468,0.00027891225,0.00006792592,0.00014281573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015755554,0.00020889021,0.00029567603,0.00021606666,0.000112988375,0.000059811027,0.00008611719,0.00012819137,0.00006798135],"category_scores_gemma":[0.00011378758,0.00017786051,0.00015313775,0.00035108638,0.000042531425,0.00013782264,0.000040211053,0.00006732082,0.00006367562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016742114,0.010598917,0.4118795,0.0051019713,0.0045775883,0.007502471,0.01951514,0.00010079277,0.0044105905,0.0106620295,0.024798788,0.499178],"study_design_scores_gemma":[0.121910535,0.0076922,0.48590258,0.010637106,0.012161718,0.0034579495,0.003771852,0.015051926,0.02762837,0.0029647804,0.30662486,0.0021961206],"about_ca_topic_score_codex":0.0004608234,"about_ca_topic_score_gemma":0.0002142824,"teacher_disagreement_score":0.4969819,"about_ca_system_score_codex":0.0002895609,"about_ca_system_score_gemma":0.00053173094,"threshold_uncertainty_score":0.7252941},"labels":[],"label_agreement":null},{"id":"W4405165478","doi":"10.1016/j.annonc.2024.10.645","title":"615P Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of a global real-world (rw) study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Chemoradiotherapy; Oncology; Internal medicine; Overall survival","score_opus":0.0729573448425896,"score_gpt":0.4939715026471867,"score_spread":0.4210141578045971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405165478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943794,0.00044984944,0.00005366349,0.0018427558,0.00004766121,0.0009379573,0.00026627007,0.000026251095,0.0019961766],"genre_scores_gemma":[0.998047,0.0007069701,0.00017312072,0.00021817423,0.000031112904,0.00006337093,0.00016453743,0.000015291065,0.00058042014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835086,0.00017619453,0.0006285953,0.00041868474,0.0001953508,0.00023033505],"domain_scores_gemma":[0.99893355,0.00036411354,0.00019439496,0.00022032092,0.00018113789,0.00010646186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023251909,0.00021394978,0.0012146153,0.00038197622,0.00003245854,0.000012841393,0.00005102005,0.00009507887,0.000079130805],"category_scores_gemma":[0.000018384775,0.00014416272,0.00021147927,0.0010588735,0.000115904004,0.00008287956,0.000015691763,0.00009184036,0.0000011294026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021653492,0.0046225996,0.9372675,0.00002937576,0.013065465,0.00059147837,0.00178014,0.000066218294,0.000016350341,0.000098159355,0.00006447471,0.04023288],"study_design_scores_gemma":[0.009046068,0.021144234,0.9623777,0.00009541443,0.0054126256,0.000015439433,0.0010572795,0.00046298606,0.00015365898,0.000026753607,0.000100720645,0.00010708229],"about_ca_topic_score_codex":0.021789392,"about_ca_topic_score_gemma":0.041108232,"teacher_disagreement_score":0.040125795,"about_ca_system_score_codex":0.00045527256,"about_ca_system_score_gemma":0.00047221463,"threshold_uncertainty_score":0.9847246},"labels":[],"label_agreement":null},{"id":"W4405165483","doi":"10.1016/j.annonc.2024.10.670","title":"637P Taletrectinib vs repotrectinib in ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ROS1; Lung cancer; Matching (statistics); Internal medicine; Oncology; Cancer; Adenocarcinoma; Pathology","score_opus":0.05405829193496321,"score_gpt":0.4310774231623228,"score_spread":0.3770191312273596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405165483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9210202,0.009631273,0.00015527608,0.0057027405,0.0012054663,0.0011706225,0.00013540812,0.00012805895,0.060850915],"genre_scores_gemma":[0.9926172,0.00067933305,0.00055720535,0.0011517355,0.00023822168,0.0002760411,0.00010978313,0.000055654582,0.004314814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979246,0.00014593558,0.0006836631,0.0005532982,0.00021129723,0.00048115972],"domain_scores_gemma":[0.9986888,0.00040263167,0.0002584457,0.00026763757,0.0002171118,0.00016536859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034608465,0.00028169178,0.00093612936,0.00045714734,0.000078731246,0.00002750296,0.00011386366,0.00026764398,0.00024275483],"category_scores_gemma":[0.000061875944,0.00024792505,0.000213745,0.0007024082,0.000098996585,0.000105715124,0.000058901063,0.0005062,0.000029653249],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004593017,0.007584261,0.33660498,0.0032449951,0.004536679,0.004783165,0.08673579,0.0010248075,0.021994026,0.00039629283,0.12557773,0.40292427],"study_design_scores_gemma":[0.021119349,0.018677903,0.58872944,0.008424272,0.005255525,0.00075092557,0.008976592,0.009610936,0.18949665,0.00063730363,0.146427,0.0018941023],"about_ca_topic_score_codex":0.004556725,"about_ca_topic_score_gemma":0.0030336995,"teacher_disagreement_score":0.40103015,"about_ca_system_score_codex":0.00041323432,"about_ca_system_score_gemma":0.0012134648,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W4405181601","doi":"10.1158/1538-8514.cancerchem24-pr004","title":"Abstract PR004: Brain penetrant allosteric EGFR inhibitors for NSCLC","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; T790M; Osimertinib; Gefitinib; Cancer research; Pharmacology; Epidermal growth factor receptor; EGFR inhibitors; In vivo; Kinome; Mutant; Medicine; Chemistry; Allosteric regulation; Kinase; Cancer; Biology; Internal medicine; Receptor; Biochemistry; Gene; Genetics","score_opus":0.026207182971794737,"score_gpt":0.35854694130504794,"score_spread":0.3323397583332532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71602833,0.14505854,0.026565587,0.091168806,0.0043584257,0.005375678,0.0005498531,0.00078753056,0.010107271],"genre_scores_gemma":[0.9902189,0.00038124766,0.0008157105,0.00621955,0.0002796032,0.00038117912,0.0000919392,0.000086978056,0.0015248983],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989594,0.00001204085,0.00021336938,0.00031912717,0.00021590872,0.0002801073],"domain_scores_gemma":[0.99951494,0.000052690448,0.000034483477,0.00022619618,0.000075801836,0.000095866206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007371015,0.0001957594,0.00019769218,0.00009409958,0.00006636452,0.0000711329,0.000066638015,0.00009080942,0.0001261724],"category_scores_gemma":[0.0000046979562,0.00015842612,0.00020737463,0.00019996558,0.000042756954,0.00005795686,0.000012025987,0.00012768542,0.000021478469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003221907,0.0003253291,0.00065215304,0.0010553162,0.0034392616,0.0003956962,0.0024879181,0.00015673235,0.5513841,0.0018696774,0.00620839,0.4317032],"study_design_scores_gemma":[0.003550632,0.0006868606,0.0045257634,0.0009109594,0.0021984223,0.000057073543,0.000229831,0.0011898589,0.104456365,0.0009784721,0.880703,0.0005127944],"about_ca_topic_score_codex":0.00008600699,"about_ca_topic_score_gemma":0.000027578655,"teacher_disagreement_score":0.87449455,"about_ca_system_score_codex":0.0002868677,"about_ca_system_score_gemma":0.00040042368,"threshold_uncertainty_score":0.64604294},"labels":[],"label_agreement":null},{"id":"W4405363665","doi":"10.1101/2024.02.22.24302979","title":"Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Genzyme; Genentech; Shionogi; Regeneron Pharmaceuticals; Natera; MacroGenics; Pfizer; Incyte; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; Eisai; Jazz Pharmaceuticals; Puma Biotechnology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Seagen; LUNGevity Foundation; Amgen; Johns Hopkins University; Mesothelioma Applied Research Foundation","keywords":"Lung cancer; Line (geometry); Medicine; Oncology; Mathematics; Geometry","score_opus":0.05815704656506881,"score_gpt":0.393274180367731,"score_spread":0.33511713380266217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405363665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849855,0.0074488292,0.00005142264,0.0006721429,0.00089459214,0.00080626877,0.0010368831,0.000046123347,0.0040582386],"genre_scores_gemma":[0.98736256,0.006344914,0.002014756,0.00014934273,0.0004892265,0.00020172962,0.001110604,0.00006911016,0.0022577266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984159,0.000033096218,0.00046328455,0.0006790486,0.00020386903,0.00020478872],"domain_scores_gemma":[0.99829733,0.00010089425,0.000207414,0.0012480387,0.000060828348,0.00008550019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016800126,0.00026046293,0.0006041098,0.00026301935,0.000017569928,0.00002236065,0.00034087844,0.00011012174,0.00015260105],"category_scores_gemma":[0.000014176143,0.00020598687,0.00009037021,0.00023940507,0.000042601307,0.000025033236,0.0006119218,0.00052924984,0.000008649218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009176011,0.00024577847,0.97035974,0.0009474879,0.0006314839,0.00024493109,0.0025365972,0.00017236559,0.0024391692,0.0000056984636,0.0007344543,0.021590527],"study_design_scores_gemma":[0.004065057,0.00016817717,0.9484415,0.0070618116,0.0021645578,0.0000017988059,0.00018429426,0.020438049,0.013130857,0.0004241878,0.003395513,0.00052418315],"about_ca_topic_score_codex":0.02372057,"about_ca_topic_score_gemma":0.015326526,"teacher_disagreement_score":0.021918232,"about_ca_system_score_codex":0.00019929539,"about_ca_system_score_gemma":0.00070436375,"threshold_uncertainty_score":0.9827806},"labels":[],"label_agreement":null},{"id":"W4405364924","doi":"10.1016/j.msard.2024.106115","title":"154. Efficacy and Safety of Tolebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase 3 GEMINI 1 and 2 Trials","year":2024,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); University of Toronto; St. Michael's Hospital","funders":"","keywords":"Teriflunomide; Multiple sclerosis; Medicine; Phase (matter); Internal medicine; Oncology; Fingolimod; Immunology","score_opus":0.06294736156404931,"score_gpt":0.3237788504028992,"score_spread":0.2608314888388499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405364924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699559,0.024446841,0.000017079032,0.0027919004,0.0004675685,0.0010627831,0.00058102753,0.0000624461,0.0006144569],"genre_scores_gemma":[0.9816458,0.017540181,0.00032654955,0.000055635883,0.000043518266,0.000038156515,0.00024020928,0.000033368855,0.00007653919],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980625,0.00015475311,0.0008435201,0.0005326459,0.00016126261,0.00024535618],"domain_scores_gemma":[0.9969381,0.0024824871,0.00016551724,0.00025751587,0.000029353665,0.00012702966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006177825,0.00024448577,0.00055763556,0.000121640514,0.00019787264,0.00007931483,0.000056854544,0.00018635324,0.000025018619],"category_scores_gemma":[0.0012124556,0.00015969016,0.00010581098,0.0002957285,0.0002702287,0.00013367711,0.00006442597,0.00026959006,0.0000025748377],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03234661,0.0013679196,0.05162851,0.00022482827,0.0024694533,0.000023180972,0.02907837,0.00025774367,0.037827343,0.00013963849,0.0016589666,0.84297746],"study_design_scores_gemma":[0.2144304,0.0011799535,0.7472004,0.00653977,0.0023621735,0.000007803375,0.006078707,0.012451281,0.0011048476,0.00014873946,0.007963703,0.00053216197],"about_ca_topic_score_codex":0.0020074078,"about_ca_topic_score_gemma":0.00046532752,"teacher_disagreement_score":0.84244525,"about_ca_system_score_codex":0.0000596522,"about_ca_system_score_gemma":0.00007834289,"threshold_uncertainty_score":0.65119755},"labels":[],"label_agreement":null},{"id":"W4405365084","doi":"10.1016/j.msard.2024.106138","title":"177. Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Results from the FENopta Trial Open-label Extension","year":2024,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Multiple sclerosis; Medicine; Open label; Disease; Extension (predicate logic); Relapsing remitting; Clinical trial; Physical medicine and rehabilitation; Internal medicine; Immunology","score_opus":0.06102225189578062,"score_gpt":0.3068371326029154,"score_spread":0.24581488070713478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405365084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97617245,0.008733718,0.00006295758,0.009949019,0.0011787479,0.0027514594,0.000524502,0.00017080129,0.00045633502],"genre_scores_gemma":[0.9919276,0.0062202383,0.000253438,0.00029931724,0.00009928068,0.0002148719,0.0004378813,0.00007408611,0.00047328166],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99745345,0.00020209012,0.00057523634,0.00097575266,0.00032717147,0.00046630285],"domain_scores_gemma":[0.99818605,0.00072481175,0.00013176823,0.00060833263,0.000051955947,0.00029705005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045056612,0.00036462196,0.00043905788,0.00014226531,0.00054454984,0.00033424975,0.00020039933,0.00022796758,0.0000376579],"category_scores_gemma":[0.0006508696,0.00024473248,0.0001430554,0.00061174145,0.00020924093,0.00038232404,0.0002076601,0.0005567919,0.00002886859],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2085454,0.012412597,0.031353917,0.0003139451,0.0029888146,0.00026586282,0.015225444,0.002173127,0.042469155,0.000371016,0.015768243,0.66811246],"study_design_scores_gemma":[0.32213795,0.00090944994,0.5749069,0.0073845633,0.0014393177,0.0000040691466,0.0020494624,0.08547664,0.00021955055,0.0008109752,0.0038750174,0.0007861578],"about_ca_topic_score_codex":0.0057729273,"about_ca_topic_score_gemma":0.0017440196,"teacher_disagreement_score":0.66732633,"about_ca_system_score_codex":0.00024174865,"about_ca_system_score_gemma":0.0002672253,"threshold_uncertainty_score":0.9979901},"labels":[],"label_agreement":null},{"id":"W4405612427","doi":"10.1016/j.kint.2024.11.028","title":"International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study","year":2024,"lang":"en","type":"article","venue":"Kidney International","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Science Foundation of Sri Lanka; European Research Council; National Institute for Occupational Safety and Health; University of Illinois at Chicago; Universitat Oberta de Catalunya; National Institutes of Health; Bureau of Policy and Strategy, Ministry of Public Health; Medical Research Council; Indian Council of Medical Research; Colt Foundation; Universidad de Chile; Eli Lilly and Company; Ministry of Public Health; National University of Singapore; World Health Organization; University College London; National Science Foundation; Horizon 2020 Framework Programme; Duke-NUS Medical School; H2020 European Research Council; Ministry Of Health, Nutrition and Indigenous Medicine; Thai Health Promotion Foundation; European Commission; Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias; Johns Hopkins University; Agencia Nacional de Investigación y Desarrollo; Public Health Foundation of India; Johns Hopkins Bloomberg School of Public Health; Styrelsen för Internationellt Utvecklingssamarbete; Universitat Pompeu Fabra; Fondo Nacional de Desarrollo Científico y Tecnológico; Harvard University; London School of Hygiene and Tropical Medicine","keywords":"Cross-sectional study; Epidemiology; Medicine; Disadvantaged; Population; Environmental health; Demography; Degree (music); Gerontology; Internal medicine; Pathology","score_opus":0.0724967040022304,"score_gpt":0.4054425120163454,"score_spread":0.332945808014115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405612427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97887075,0.000078053745,0.002641351,0.0010127935,0.0036413947,0.00092402054,0.01187623,0.00012423881,0.0008311674],"genre_scores_gemma":[0.98058635,0.000036702415,0.0016842665,0.000240728,0.0006195977,0.0002302174,0.015839232,0.000046599303,0.00071632606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966626,0.00023195149,0.0012066746,0.0008093795,0.0008041438,0.000285243],"domain_scores_gemma":[0.9979611,0.00083073543,0.0003699206,0.0003137758,0.00026263762,0.00026183735],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000407852,0.00034215098,0.0004525569,0.000653278,0.00013712491,0.00007184038,0.00031779736,0.00016458209,0.004846272],"category_scores_gemma":[0.0014134749,0.00030540445,0.00030992983,0.00024480867,0.0000935384,0.00046119254,0.000052343104,0.0004950705,0.00002892235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047068854,0.0014824965,0.9925552,0.0001248475,0.0007905204,0.000047527155,0.0007469964,0.0024215567,0.000074335854,0.0005841178,0.00034821543,0.00035352405],"study_design_scores_gemma":[0.0044293734,0.00022827787,0.9744446,0.00079060526,0.00017754665,0.000013002417,0.00017941215,0.018228563,0.000029891895,0.001064155,0.00018020494,0.0002343373],"about_ca_topic_score_codex":0.006433391,"about_ca_topic_score_gemma":0.0007417319,"teacher_disagreement_score":0.018110543,"about_ca_system_score_codex":0.001069674,"about_ca_system_score_gemma":0.00046937683,"threshold_uncertainty_score":0.9999398},"labels":[],"label_agreement":null},{"id":"W4405617673","doi":"","title":"Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.","year":2024,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Profiling (computer programming); Computational biology; DNA profiling; DNA; Medicine; Biology; Oncology; Computer science; Genetics","score_opus":0.02630963885794012,"score_gpt":0.3397459053348001,"score_spread":0.31343626647685996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405617673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9238337,0.011276415,0.013256557,0.028664453,0.0019493971,0.015511465,0.0006544991,0.00077019224,0.0040833196],"genre_scores_gemma":[0.96814334,0.00014184508,0.009692311,0.0008788697,0.000207143,0.019377718,0.00022090117,0.000062734995,0.0012751066],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986529,0.000017094073,0.0002691482,0.00041454026,0.000118813434,0.000527525],"domain_scores_gemma":[0.9993107,0.000111176516,0.000086152424,0.00021830527,0.000105703504,0.00016799525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001206631,0.00018338561,0.00033641764,0.00028423034,0.00013594399,0.000042950636,0.000079784004,0.00009919616,0.0000122433075],"category_scores_gemma":[0.000009650611,0.00015735369,0.000110975496,0.00029495094,0.000040067654,0.000041022002,0.000024434032,0.0001933043,0.0000042327374],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061469834,0.0016824333,0.14994194,0.019783791,0.0042434977,0.0003237914,0.001531111,0.0020371205,0.014861875,0.0054049166,0.038049534,0.7615253],"study_design_scores_gemma":[0.041559923,0.0021004765,0.3288919,0.0019381803,0.006441012,0.00012605489,0.0032942866,0.2612289,0.07831786,0.00075092906,0.27333748,0.0020130004],"about_ca_topic_score_codex":0.00011772445,"about_ca_topic_score_gemma":0.000057263944,"teacher_disagreement_score":0.7595123,"about_ca_system_score_codex":0.0011920051,"about_ca_system_score_gemma":0.0015240121,"threshold_uncertainty_score":0.64166975},"labels":[],"label_agreement":null},{"id":"W4405748806","doi":"10.1016/j.jval.2024.10.002","title":"P1 Indirect Treatment Comparison of Larotrectinib vs Entrectinib in NTRK-Fusion Solid Tumors: Demonstration of a Novel Bayesian Hierarchical Modelling Approach for Basket Trials","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Bayesian probability; Medicine; Bayesian network; Bayesian inference; Oncology; Internal medicine; Computer science; Cancer research; Artificial intelligence","score_opus":0.16389463171589036,"score_gpt":0.44161497162682145,"score_spread":0.2777203399109311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80954087,0.0035762358,0.17778893,0.0015152972,0.00033441006,0.0062092654,0.00029101523,0.00007196031,0.000672044],"genre_scores_gemma":[0.96005666,0.00025380575,0.03895039,0.00002648314,0.00010889731,0.0003121286,0.00022251999,0.000025830115,0.00004328347],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99740607,0.0002914781,0.0014076896,0.00036967476,0.00023403471,0.00029104282],"domain_scores_gemma":[0.9984704,0.0009025034,0.00030123332,0.00016904753,0.00004390241,0.00011290794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013981299,0.00018265253,0.0011432082,0.00049928075,0.000050321883,0.0000128961465,0.000045146295,0.00010680034,0.0000098586415],"category_scores_gemma":[0.0001308645,0.00014279984,0.00017842161,0.00047893758,0.000035280907,0.000060365997,0.0000093226245,0.00017328595,3.2404364e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052414243,0.0152795585,0.065773025,0.0075112027,0.0007386235,0.000019069194,0.056067828,0.68623394,0.002416197,0.00470267,0.00018748466,0.15582898],"study_design_scores_gemma":[0.0061916723,0.0024793176,0.0013284856,0.0019565532,0.00016508698,0.000013384062,0.00084422337,0.98145473,0.005025358,0.00025909985,0.00017162474,0.00011044688],"about_ca_topic_score_codex":0.0046450193,"about_ca_topic_score_gemma":0.00020799784,"teacher_disagreement_score":0.29522082,"about_ca_system_score_codex":0.0006142739,"about_ca_system_score_gemma":0.0012540824,"threshold_uncertainty_score":0.70219105},"labels":[],"label_agreement":null},{"id":"W4405749371","doi":"10.1016/j.jval.2024.10.1283","title":"EPH155 The Impact of Adjuvant Alectinib in Reducing Recurrences and Recurrence-Related Treatment Costs in Resected Early-Stage ALK+ Non-Small Cell Lung Cancer Across Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Alectinib; Medicine; Lung cancer; Stage (stratigraphy); Oncology; Adjuvant; Internal medicine; Crizotinib; Biology","score_opus":0.030710343570659878,"score_gpt":0.39518242157878847,"score_spread":0.3644720780081286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405749371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679972,0.028493183,7.552613e-7,0.0011046614,0.00037039613,0.0014525069,0.0002647089,0.000013097277,0.00030351456],"genre_scores_gemma":[0.9931769,0.006258243,0.000035574343,0.00002614491,0.00003049182,0.00017017807,0.000037052967,0.000018580153,0.00024682868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817955,0.0001962369,0.0005875396,0.00038180244,0.00017822727,0.00047661221],"domain_scores_gemma":[0.9991554,0.00032305002,0.00013329457,0.00020386829,0.000043095784,0.00014130813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044593902,0.00019328481,0.00042159067,0.00014589749,0.00007514563,0.000023597724,0.00006787559,0.000067838475,0.000024920615],"category_scores_gemma":[0.000049842514,0.00012267227,0.00004887178,0.0009899697,0.000051673138,0.00006146875,0.000020862135,0.00033555104,4.2576752e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020404223,0.0003199089,0.87745064,0.00084538286,0.00015457273,0.00023684389,0.056445915,0.009742849,0.00012981596,0.0000132634195,0.00043290202,0.054023862],"study_design_scores_gemma":[0.0039135544,0.0014863545,0.94580317,0.007261244,0.000059486727,0.000019006391,0.0026793412,0.037891854,0.0004456448,0.000022891652,0.00021815296,0.00019928513],"about_ca_topic_score_codex":0.99132025,"about_ca_topic_score_gemma":0.8692616,"teacher_disagreement_score":0.12205866,"about_ca_system_score_codex":0.00471028,"about_ca_system_score_gemma":0.006034057,"threshold_uncertainty_score":0.9996008},"labels":[],"label_agreement":null},{"id":"W4405749999","doi":"10.1016/j.jval.2024.10.3140","title":"SA59 Evaluating the Optimal TKI for Patients With ALK Positive Advanced Non-Small-Cell Lung Cancer (aNSCLC) in the First Line (1L) Setting: An Updated Systematic Literature Review (SLR) and Network Meta-Analysis (NMA)","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Luminex (Canada)","funders":"","keywords":"Medicine; Meta-analysis; Lung cancer; Systematic review; Oncology; Internal medicine; MEDLINE; Chemistry","score_opus":0.04057041200427511,"score_gpt":0.39568381005014447,"score_spread":0.3551133980458694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405749999","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15062448,0.8117029,0.00069995335,0.018818442,0.00016821743,0.017424589,0.00043030904,0.000045446963,0.000085671934],"genre_scores_gemma":[0.9583025,0.016945824,0.008556792,0.009180207,0.00019973316,0.005022588,0.0014719974,0.00008098397,0.00023939059],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976376,0.00053510675,0.000695245,0.00044938957,0.00033264753,0.00034995546],"domain_scores_gemma":[0.9984298,0.0006190553,0.00027693436,0.00038554534,0.00020248296,0.00008622418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019476293,0.0002510956,0.001017367,0.00012754399,0.00022473146,0.00008820696,0.000114633425,0.00005218804,0.000013016103],"category_scores_gemma":[0.000056315243,0.00011575785,0.00020671169,0.0014888515,0.000022902086,0.00012154638,0.000018854924,0.00028117027,4.194808e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080465415,0.0013120471,0.032065168,0.38285437,0.062061697,0.00010521537,0.06963205,0.4449362,0.0000042745,0.00040805837,0.0022825974,0.0035336614],"study_design_scores_gemma":[0.0052490653,0.004169159,0.014297776,0.12437395,0.24568194,0.00002625126,0.0011527276,0.6039931,0.0000043533655,0.00006698888,0.00046964377,0.0005150161],"about_ca_topic_score_codex":0.0005698547,"about_ca_topic_score_gemma":0.0005346702,"teacher_disagreement_score":0.807678,"about_ca_system_score_codex":0.00029214425,"about_ca_system_score_gemma":0.0003852401,"threshold_uncertainty_score":0.47204682},"labels":[],"label_agreement":null},{"id":"W4405750198","doi":"10.1016/j.jval.2024.10.2422","title":"MSR188 A Predictive Patient-Level Surrogacy Model Between Progression-Free Survival (PFS) and Overall Survival (OS) in Patients With Pre-Treated Advanced or Metastatic (A/M) Non-Small-Cell Lung Cancer (NSCLC) With a KRASG12C Mutation","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Oncology; Medicine; non-small cell lung cancer (NSCLC); Overall survival; Internal medicine; Progression-free survival; Lung cancer","score_opus":0.027523443073903427,"score_gpt":0.338721106796708,"score_spread":0.3111976637228046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405750198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897114,0.0014299848,0.0018457341,0.0005044371,0.0001423818,0.0051776622,0.0009496966,0.00010177199,0.00013694871],"genre_scores_gemma":[0.9911706,0.00023811928,0.006784807,0.00008961343,0.000039549403,0.0009256198,0.00046481256,0.000096369666,0.00019050943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700624,0.00023392451,0.0006651019,0.00077671226,0.00071057316,0.0006074594],"domain_scores_gemma":[0.9985173,0.00035713965,0.00024340153,0.00035415837,0.00021129666,0.00031674432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032427345,0.00041700518,0.00072293537,0.00039412227,0.00011650429,0.00005541637,0.000100739955,0.000085383464,0.000013878103],"category_scores_gemma":[0.000056405246,0.00027108585,0.000044266293,0.000764376,0.00007465983,0.00037358733,0.00005782354,0.0003540347,0.0000010914033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049759257,0.0011154956,0.9242349,0.0027733021,0.00050651317,0.00015660019,0.012521912,0.038037296,0.0000070778888,0.000041379193,0.00005482106,0.015574775],"study_design_scores_gemma":[0.027215509,0.005976703,0.7934511,0.008542561,0.0007168468,0.000007034248,0.00074217946,0.16267647,0.00005945021,0.00012252756,0.000024717385,0.0004649558],"about_ca_topic_score_codex":0.00904726,"about_ca_topic_score_gemma":0.0026189783,"teacher_disagreement_score":0.13078386,"about_ca_system_score_codex":0.0010952211,"about_ca_system_score_gemma":0.0024822266,"threshold_uncertainty_score":0.99997413},"labels":[],"label_agreement":null},{"id":"W4405764199","doi":"10.1177/17588359241308466","title":"Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Oncology; Internal medicine; Epidermal growth factor receptor; Lung cancer; Cancer research; ROS1; Crizotinib; Stage (stratigraphy); Targeted therapy; Cancer; Adenocarcinoma; Biology","score_opus":0.015666433802951872,"score_gpt":0.41040352604992875,"score_spread":0.3947370922469769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405764199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067923,0.015689418,0.005390422,0.005055819,0.00030252358,0.00072646904,0.00004999762,0.00008606884,0.012020031],"genre_scores_gemma":[0.99626464,0.0009225866,0.0010272379,0.0005011527,0.000021765656,0.00011176364,0.00007556049,0.000014929953,0.0010603596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864143,0.00010339824,0.00038119397,0.00026309208,0.00037331358,0.00023759456],"domain_scores_gemma":[0.9990463,0.0005607221,0.000060691298,0.00017377158,0.000056912493,0.000101560465],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021689717,0.00012415215,0.0006229831,0.00060280185,0.000023409233,0.0000050015983,0.00009153807,0.00012637353,0.0012077455],"category_scores_gemma":[0.00007362752,0.000080261605,0.000083619845,0.0016831845,0.0002711948,0.00013671053,0.000017788063,0.00029488743,0.0000072719276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059519085,0.0011207297,0.7863328,0.00016135856,0.0034991927,0.0016475937,0.005754695,0.0017307897,0.0000997919,0.004358573,0.000011605413,0.1946877],"study_design_scores_gemma":[0.008428088,0.0023411906,0.8820061,0.00053239084,0.004471281,0.0000312827,0.0023380038,0.012790122,0.00013950355,0.0016517409,0.084976844,0.00029342118],"about_ca_topic_score_codex":0.00025427545,"about_ca_topic_score_gemma":0.0026257986,"teacher_disagreement_score":0.19439428,"about_ca_system_score_codex":0.00029143938,"about_ca_system_score_gemma":0.00065366674,"threshold_uncertainty_score":0.9997053},"labels":[],"label_agreement":null},{"id":"W4405834584","doi":"10.3390/curroncol32010013","title":"Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Waterloo; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Government of Ontario","keywords":"Anaplastic lymphoma kinase; Medicine; Lung cancer; Tyrosine kinase; Crizotinib; Oncology; Internal medicine; Receptor Protein-Tyrosine Kinases; Cancer research; Tyrosine-kinase inhibitor; Alectinib; Protein-Tyrosine Kinases; Cancer; Receptor","score_opus":0.046244530630114994,"score_gpt":0.40030091955048674,"score_spread":0.3540563889203717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405834584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940341,0.0005727183,0.0000030837643,0.0003141355,0.0019805913,0.0017191132,0.0001141707,0.000030729527,0.0012313317],"genre_scores_gemma":[0.9974812,0.00011776892,0.00009255823,0.00007001464,0.00010056762,0.0005264321,0.0003047127,0.000047826612,0.0012588943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972744,0.00015216798,0.0010206401,0.00068485877,0.00041302046,0.0004549356],"domain_scores_gemma":[0.9986378,0.00038846247,0.00023502101,0.0003432292,0.00015635941,0.00023915283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028526256,0.00034140545,0.0011096055,0.0006562735,0.000050397364,0.000014706629,0.00011575634,0.00011187848,0.0002845208],"category_scores_gemma":[0.000065878405,0.00024817162,0.00009986919,0.0010191213,0.00009476115,0.00008076871,0.00006801754,0.00044512708,0.0000011366266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014776927,0.006314617,0.9469978,0.00021994663,0.00042816615,0.0006196512,0.0022458446,0.00004178668,0.000003382532,0.0000017999237,0.0018757057,0.039773557],"study_design_scores_gemma":[0.014225057,0.0021005832,0.9774114,0.0010355368,0.0012410842,0.0000015336553,0.00039203174,0.00017568025,0.000011286737,5.859383e-7,0.003170688,0.00023455468],"about_ca_topic_score_codex":0.887405,"about_ca_topic_score_gemma":0.99840367,"teacher_disagreement_score":0.11099871,"about_ca_system_score_codex":0.0058593457,"about_ca_system_score_gemma":0.0062994305,"threshold_uncertainty_score":0.9999971},"labels":[],"label_agreement":null},{"id":"W4405856849","doi":"10.3399/bjgp25x740493","title":"Achieving earlier diagnosis of symptomatic lung cancer","year":2024,"lang":"en","type":"article","venue":"British Journal of General Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Lung cancer; Lung; Cancer; Intensive care medicine; Data science; General surgery; Pathology; Computer science; Internal medicine","score_opus":0.011497066927215516,"score_gpt":0.36628381384316705,"score_spread":0.3547867469159515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405856849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8535896,0.13336055,0.00037698128,0.0068097296,0.00092950877,0.00020290988,0.000030055076,0.000018840166,0.004681848],"genre_scores_gemma":[0.9716484,0.01898364,0.006064114,0.0006683702,0.00080228003,0.00002181651,0.0000041354733,0.000028447495,0.0017788059],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989964,0.00006840059,0.00039818994,0.00009934411,0.0003132995,0.00012441479],"domain_scores_gemma":[0.9990093,0.00026424864,0.00023753129,0.00007244227,0.00031117813,0.000105278785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029019805,0.00007653166,0.00023836958,0.00009413664,0.000054514625,0.00009244772,0.000055351815,0.000039708153,0.00036188343],"category_scores_gemma":[0.00040847875,0.000070841175,0.00014173919,0.0001885531,0.000027235328,0.0005914674,0.000015670224,0.0002470195,0.0000042268184],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032036053,0.0013325406,0.05189846,0.002240142,0.0082400795,0.011602628,0.0024707331,0.00093415385,0.0057613584,0.00055985915,0.20664643,0.70799327],"study_design_scores_gemma":[0.010083493,0.0025983846,0.27969766,0.04142833,0.035841327,0.10765039,0.0019588459,0.0049540238,0.007895764,0.00022933735,0.5067123,0.0009501118],"about_ca_topic_score_codex":0.0007457674,"about_ca_topic_score_gemma":0.00002002865,"teacher_disagreement_score":0.7070432,"about_ca_system_score_codex":0.00016385016,"about_ca_system_score_gemma":0.0004063905,"threshold_uncertainty_score":0.396237},"labels":[],"label_agreement":null},{"id":"W4405861407","doi":"10.1016/j.lungcan.2024.108066","title":"FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Exon; Oncology; Internal medicine; Chemotherapy; Mutation; Cancer research; Gene; Genetics; Biology","score_opus":0.04779677523494436,"score_gpt":0.46264716297713754,"score_spread":0.4148503877421932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405861407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009969791,0.983407,0.00028799448,0.0010970759,0.00094238424,0.01082733,0.0016425746,0.00012621346,0.000672416],"genre_scores_gemma":[0.0010154418,0.97066647,0.0005464706,0.000113954906,0.00082855514,0.013981346,0.0035592145,0.00019860636,0.009089946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976166,0.000043141663,0.0009092269,0.00071666547,0.00034226774,0.00037209474],"domain_scores_gemma":[0.99833995,0.0001572209,0.0005901653,0.000518619,0.00021098102,0.00018307474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008655113,0.0006698259,0.0019226485,0.00028195654,0.00013794142,0.00003351109,0.00010826564,0.00025449673,0.0002647304],"category_scores_gemma":[0.000028394108,0.00042717744,0.0008361348,0.00054272666,0.00007341672,0.000103119695,0.000013823108,0.00018471536,0.000016359158],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028388096,0.002093132,0.0000033423219,0.015504558,0.0053706993,0.000033725675,0.0007427498,0.00007079105,0.000007155865,0.00007087733,0.0015198237,0.94619507],"study_design_scores_gemma":[0.10721159,0.0087474035,0.0000020165703,0.01846473,0.02341985,0.000024407193,0.00003366571,0.00013676981,0.00007429755,0.000035495224,0.8414756,0.0003741567],"about_ca_topic_score_codex":0.0003700403,"about_ca_topic_score_gemma":0.00047166998,"teacher_disagreement_score":0.94582087,"about_ca_system_score_codex":0.0018009127,"about_ca_system_score_gemma":0.0018802829,"threshold_uncertainty_score":0.999818},"labels":[],"label_agreement":null},{"id":"W4405915233","doi":"10.21037/tlcr-24-844","title":"Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer","year":2024,"lang":"en","type":"letter","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Lung cancer; Lymphoma; Cancer research; Anaplastic large-cell lymphoma; Oncology; Pathology","score_opus":0.028413118537557853,"score_gpt":0.39281326944864364,"score_spread":0.3644001509110858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405915233","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023354035,0.11908385,0.0004163066,0.8284277,0.0018407911,0.006758807,0.005205228,0.0001884502,0.0147248795],"genre_scores_gemma":[0.53121275,0.018098067,0.0033275369,0.2132192,0.038429055,0.025797829,0.02584606,0.001982684,0.14208683],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950415,0.0002184645,0.000636129,0.0011876491,0.0017131767,0.0012030638],"domain_scores_gemma":[0.9980659,0.0006424912,0.00010333718,0.0003480252,0.00063044013,0.00020982377],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043480124,0.0005624332,0.0007008826,0.0011587562,0.00028129105,0.00014924935,0.0002885335,0.0007234439,0.001244536],"category_scores_gemma":[0.000021467937,0.0005072408,0.00027491632,0.0013639835,0.00018226966,0.00014582375,0.0000572305,0.0027821683,0.00006611151],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050916016,0.00022987268,0.012983722,0.0074413503,0.0012862465,0.002884959,0.0035761436,0.001845202,0.0004356112,0.000071866234,0.96631825,0.0024176277],"study_design_scores_gemma":[0.015969632,0.00077173597,0.030026294,0.02586171,0.005478535,0.000067995235,0.0003845917,0.069902815,0.0010150336,0.00062000327,0.84749496,0.0024067243],"about_ca_topic_score_codex":0.006937899,"about_ca_topic_score_gemma":0.0014237748,"teacher_disagreement_score":0.61520845,"about_ca_system_score_codex":0.0029794816,"about_ca_system_score_gemma":0.0060870755,"threshold_uncertainty_score":0.9997379},"labels":[],"label_agreement":null},{"id":"W4406124968","doi":"10.1177/17588359241308784","title":"The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; William Osler Health System; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Dalhousie University; University of Toronto; University of Manitoba; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital; CancerCare Manitoba; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Eli Lilly Canada; Bayer Canada; Pfizer Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; EMD Serono; Astellas Pharma; Genentech; AstraZeneca Canada; Amgen Canada; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Epidermal growth factor receptor; KRAS; Anaplastic lymphoma kinase; Medicine; Crizotinib; Cancer research; Lung cancer; ROS1; Erlotinib; Clinical trial; Biomarker; EGFR inhibitors; Cancer; Targeted therapy; Oncology; Internal medicine; Biology; Adenocarcinoma; Colorectal cancer","score_opus":0.022030025022744974,"score_gpt":0.4331020654722201,"score_spread":0.4110720404494751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406124968","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012760414,0.9870696,0.00064180803,0.00074195646,0.0009057218,0.0022471584,0.000036951475,0.00002529083,0.008203927],"genre_scores_gemma":[0.000706977,0.9948339,0.0011923623,0.0005596105,0.00017051624,0.0014773794,0.000047513764,0.00005115859,0.0009605878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675965,0.000284564,0.0013695331,0.0005435854,0.00046830627,0.0005743804],"domain_scores_gemma":[0.995671,0.0029188162,0.0006614895,0.00045823748,0.00014865134,0.00014184194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006466199,0.00047967996,0.0025912724,0.0003221767,0.000088517205,0.000009965563,0.00055575126,0.0005876872,0.00019116505],"category_scores_gemma":[0.00020292857,0.00028798435,0.00032416277,0.00075315783,0.00035668528,0.000080594386,0.00012120424,0.0009448369,0.000002231163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012408168,0.00064552116,0.0010082256,0.006917362,0.0004604179,0.00007067544,0.0007249557,0.000039153234,0.000004556072,0.00016077791,0.000041235922,0.989803],"study_design_scores_gemma":[0.006372998,0.0004346048,0.00013524407,0.025299331,0.0015897452,0.00002679136,0.00059260003,0.00047871587,0.0000031529096,0.000061033938,0.9647338,0.0002720091],"about_ca_topic_score_codex":0.00006495784,"about_ca_topic_score_gemma":0.0017272831,"teacher_disagreement_score":0.98953104,"about_ca_system_score_codex":0.00083044183,"about_ca_system_score_gemma":0.006057138,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W4406147178","doi":"10.1017/s0266462324001673","title":"OD38 Real-World Analysis Of First-Line Maintenance Treatment For Patients With Nonsquamous Advanced/Metastatic Non-Small-Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oncology; Medicine; Lung cancer; Internal medicine; Cancer; Intensive care medicine; Lung","score_opus":0.011728120257827311,"score_gpt":0.40628282144314226,"score_spread":0.39455470118531494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406147178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553717,0.007549961,0.012559513,0.01946056,0.0011727313,0.0022147074,0.0010380226,0.00005275416,0.0005800716],"genre_scores_gemma":[0.9823085,0.002590172,0.014136026,0.00012943038,0.0000457138,0.00024090332,0.00020485053,0.000024380883,0.00032003885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983759,0.000017061646,0.0008045217,0.0002397491,0.0003372735,0.00022547293],"domain_scores_gemma":[0.9980289,0.00013961758,0.0005702677,0.00016733207,0.0010156861,0.00007821744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115120005,0.00017784483,0.00060216547,0.002025631,0.000045787438,0.000014412705,0.00016866297,0.000053886095,0.00003620304],"category_scores_gemma":[0.000018131746,0.00012453066,0.00020377427,0.00090620166,0.000048661073,0.00009492971,0.000023124132,0.00020903007,2.5591567e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069465634,0.0013267825,0.91168505,0.00092063576,0.0062929336,0.00019657682,0.0008517181,0.01207121,0.000012727449,0.0007265366,0.00025216548,0.06496902],"study_design_scores_gemma":[0.056806844,0.025159527,0.8012978,0.016526515,0.018727764,0.00009927098,0.009062804,0.041260555,0.0009836195,0.00056253705,0.028588677,0.0009241034],"about_ca_topic_score_codex":0.0004068678,"about_ca_topic_score_gemma":0.0031949773,"teacher_disagreement_score":0.11038726,"about_ca_system_score_codex":0.0034001062,"about_ca_system_score_gemma":0.0012788661,"threshold_uncertainty_score":0.8891159},"labels":[],"label_agreement":null},{"id":"W4406150859","doi":"10.3390/curroncol32010032","title":"Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Chemotherapy; Cancer; Disease; Cohort; Retrospective cohort study; Internal medicine; Stage (stratigraphy); Oncology; Lung","score_opus":0.030863362943480292,"score_gpt":0.4227936493556759,"score_spread":0.3919302864121956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406150859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872476,0.0027379403,0.000016157735,0.0009213239,0.0006945146,0.001096976,0.00005857259,0.00002213221,0.0072048185],"genre_scores_gemma":[0.9974987,0.00046367102,0.00007412469,0.0002538034,0.000069234884,0.0009465161,0.0002238099,0.000010882141,0.00045928397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915075,0.00004912978,0.00023174341,0.00023634486,0.000097508324,0.00023449466],"domain_scores_gemma":[0.9996226,0.00007906918,0.00005144182,0.00013280344,0.0000591107,0.000055017874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003111977,0.00014482792,0.0003551148,0.00024323334,0.000031294596,0.0000063158714,0.000039489383,0.000066228706,0.00007752101],"category_scores_gemma":[0.000013216839,0.00010579441,0.00003503591,0.00023972342,0.000058965245,0.00005853539,0.000020195414,0.000116253024,0.0000022527252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046427175,0.0020713136,0.78206825,0.00008383354,0.00009900274,0.000022045651,0.0014495786,0.0000613099,0.0000013523696,0.00014946841,0.0003280414,0.21320152],"study_design_scores_gemma":[0.023253907,0.0009231727,0.9601745,0.0003688406,0.00025530678,5.4950914e-7,0.00022159777,0.00008538941,0.000013231797,0.000038769325,0.014574223,0.00009049795],"about_ca_topic_score_codex":0.00092211575,"about_ca_topic_score_gemma":0.0020087461,"teacher_disagreement_score":0.21311103,"about_ca_system_score_codex":0.0030502826,"about_ca_system_score_gemma":0.0012135985,"threshold_uncertainty_score":0.7976383},"labels":[],"label_agreement":null},{"id":"W4406187066","doi":"10.1016/j.ajt.2024.12.231","title":"Missed opportunities for cure in patients with non-metastatic hepatocellular carcinoma in Canada","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; University of Alberta; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Dalhousie University; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Oncology; Internal medicine; Carcinoma; Intensive care medicine; General surgery","score_opus":0.013385922803610933,"score_gpt":0.2577090277659245,"score_spread":0.2443231049623136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406187066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969088,0.00004757088,0.0015052737,0.0010243524,0.000053664873,0.00031519574,0.000044885663,0.0000011390439,0.000099136116],"genre_scores_gemma":[0.99826664,0.00004906692,0.0011808185,0.00036834856,0.0000062251106,0.000015612984,0.00007880511,0.0000068035347,0.000027695047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939513,0.000021283355,0.00027561883,0.000066102024,0.00013810753,0.00010374167],"domain_scores_gemma":[0.9995765,0.00006235489,0.00014511932,0.000045731587,0.000121863384,0.000048448797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051878542,0.00007421356,0.00023834039,0.00020528179,0.000016999555,0.000005211501,0.00003191366,0.0000069602934,0.0000037356483],"category_scores_gemma":[0.0000042425804,0.00005670136,0.000027490292,0.00019406661,0.000024218416,0.00006847845,6.4784416e-7,0.00006628531,4.1809667e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013395083,0.000113290414,0.9889624,0.00015555217,0.00009859132,0.00023550144,0.0007120297,0.00027202384,0.000024293438,0.000012794762,0.000076664415,0.007997322],"study_design_scores_gemma":[0.00819221,0.0009239179,0.98580766,0.0004980426,0.000424503,0.000016380824,0.0032980922,0.00040073722,0.00023726218,0.000015467882,0.000120568955,0.00006515622],"about_ca_topic_score_codex":0.15201819,"about_ca_topic_score_gemma":0.115695365,"teacher_disagreement_score":0.036322825,"about_ca_system_score_codex":0.0003433361,"about_ca_system_score_gemma":0.0019961805,"threshold_uncertainty_score":0.9004409},"labels":[],"label_agreement":null},{"id":"W4406226708","doi":"10.54254/2753-8818/2024.19975","title":"Can SDH1 in Chinese Medicine Target ALK for NSCLC Remission?","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer research","score_opus":0.003603667013049308,"score_gpt":0.34602530774366747,"score_spread":0.34242164073061815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406226708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86098266,0.0021623436,0.0002790698,0.092081755,0.0004701611,0.000714365,0.000009246831,0.000038134902,0.043262266],"genre_scores_gemma":[0.9966808,0.00003314153,0.0008435231,0.0012848937,0.000046697467,0.000015956954,0.0000066806188,0.0000022571871,0.0010860241],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9993357,0.000008712698,0.000111905065,0.00021022152,0.00014474739,0.00018868438],"domain_scores_gemma":[0.9995713,0.00014143741,0.000013189456,0.000095095005,0.000063645755,0.000115308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025691057,0.00007402294,0.00014787332,0.00010098811,0.00012206975,0.000008937641,0.000073138086,0.000026674665,0.00007854122],"category_scores_gemma":[0.00058158435,0.000037007474,0.000018390034,0.0005371529,0.0011530715,0.000042099364,0.00003314455,0.00008734738,4.770563e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025262506,0.000065673405,0.011300687,0.000045378427,0.000011682403,0.000009116009,0.00044439553,6.402964e-7,0.011436959,0.9542211,0.0004229891,0.021788752],"study_design_scores_gemma":[0.005693836,0.0005296463,0.22721726,0.00063788035,0.000121268306,0.000030277555,0.00027859517,0.005586516,0.0034300995,0.7520111,0.0042745443,0.00018893425],"about_ca_topic_score_codex":0.000053632677,"about_ca_topic_score_gemma":0.000009944157,"teacher_disagreement_score":0.21591657,"about_ca_system_score_codex":0.00006320439,"about_ca_system_score_gemma":0.0001762184,"threshold_uncertainty_score":0.424854},"labels":[],"label_agreement":null},{"id":"W4406242645","doi":"10.3390/curroncol32010036","title":"Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Taiwan University; National Taiwan University Hospital Yunlin Branch; National Taiwan University Hospital","keywords":"Afatinib; Osimertinib; Medicine; Lung cancer; Exon; Oncology; Cancer research; Internal medicine; Epidermal growth factor receptor; Pathology; Erlotinib; Cancer; Genetics; Gene; Biology","score_opus":0.03632840727836727,"score_gpt":0.42257790405982154,"score_spread":0.38624949678145426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406242645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893643,0.0019463034,0.00026528275,0.0015635388,0.0012759842,0.0023559844,0.000013564301,0.000030562387,0.0031844717],"genre_scores_gemma":[0.99771154,0.00026260404,0.00023734951,0.00016024195,0.00009498928,0.0010502446,0.000061099665,0.000016056336,0.00040584986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984545,0.00015528088,0.00043644468,0.00046111218,0.00014732064,0.0003453598],"domain_scores_gemma":[0.9993626,0.0000832646,0.00014442274,0.00021579323,0.000105462736,0.0000884448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021729484,0.00020847995,0.0004894372,0.00029987106,0.000056869347,0.000012870324,0.00009898361,0.00008926035,0.00006783588],"category_scores_gemma":[0.00003327413,0.00016479027,0.00004514137,0.00047340352,0.00005729831,0.00005985211,0.000046376794,0.00030253016,0.000006102685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011042688,0.0045275744,0.966766,0.00027551118,0.00009868926,0.00007304718,0.008098715,0.00006667791,0.00033103843,0.00001139139,0.00040263942,0.01824444],"study_design_scores_gemma":[0.028726565,0.0021398552,0.94328314,0.0009513907,0.0007029638,0.0000026010978,0.008208851,0.0015180811,0.0007328288,0.000008076333,0.013464562,0.00026108322],"about_ca_topic_score_codex":0.0013254129,"about_ca_topic_score_gemma":0.018367415,"teacher_disagreement_score":0.027622296,"about_ca_system_score_codex":0.0011239966,"about_ca_system_score_gemma":0.0008869131,"threshold_uncertainty_score":0.9995448},"labels":[],"label_agreement":null},{"id":"W4406246319","doi":"10.1016/j.yonc.2013.07.026","title":"10.1016/j.yonc.2013.07.026","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Gefitinib; Head and neck cancer; Oncology; Placebo; Internal medicine; Randomized controlled trial; Head and neck; Cancer; Surgery; Alternative medicine; Pathology","score_opus":0.006505302705838934,"score_gpt":0.2385647032122836,"score_spread":0.23205940050644466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406246319","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011302205,0.00017674304,6.7431097e-7,0.0018115065,0.0000018419445,0.00028236787,0.000019771314,0.000101538775,0.99647534],"genre_scores_gemma":[0.0006451756,9.884789e-7,0.00022777152,0.00017339368,0.00015042584,0.000039443097,0.000056758312,0.000020976287,0.99868506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99941975,0.000009764625,0.00010980007,0.00016036484,0.00012683924,0.00017345847],"domain_scores_gemma":[0.99954104,0.000016830256,0.00001431453,0.0002220436,0.000038634265,0.00016710332],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000030859115,0.00009606473,0.00014165805,0.000045262703,0.00005705995,0.000013829465,0.000047568847,0.000036984453,0.9978047],"category_scores_gemma":[0.000009331359,0.0000780479,0.00005093756,0.00011112519,0.00001801746,0.00004509882,0.0000094920915,0.00005460676,0.99528253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007494883,0.00009744517,9.357072e-7,0.000006273671,0.00006918753,0.000016026588,0.000042789634,0.000015023304,0.000025066956,8.4344475e-7,0.48278984,0.5168616],"study_design_scores_gemma":[0.000830296,0.0002936486,0.00023593107,0.000030979387,0.00015294222,0.000022387176,0.0000018748605,0.000039648326,0.00006900469,0.000004193319,0.9982349,0.00008419425],"about_ca_topic_score_codex":0.000094529634,"about_ca_topic_score_gemma":3.8159703e-7,"teacher_disagreement_score":0.5167774,"about_ca_system_score_codex":0.00007777582,"about_ca_system_score_gemma":0.00006206819,"threshold_uncertainty_score":0.31827012},"labels":[],"label_agreement":null},{"id":"W4406269790","doi":"10.1101/2025.01.07.631497","title":"Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using In Silico Modelling","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; University College London; Cancer Research UK","keywords":"In silico; Lung cancer; Computational biology; Cancer; Computer science; Biology; Medicine; Oncology; Internal medicine; Genetics","score_opus":0.022561795550973703,"score_gpt":0.29012857812237886,"score_spread":0.26756678257140515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406269790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874837,0.005261851,0.0038363999,0.00031064698,0.0006523719,0.0020110947,0.00023593965,0.00012683739,0.00008118918],"genre_scores_gemma":[0.9947742,0.0004666616,0.0035718272,0.00025223944,0.00014486017,0.00067221245,0.0000016749465,0.00008227733,0.00003399502],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99764514,0.00008876956,0.00061084563,0.00083972554,0.00028710064,0.00052843435],"domain_scores_gemma":[0.9985336,0.00008903714,0.0002718025,0.00061099883,0.00033807702,0.00015650125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029975595,0.00046909458,0.00066324417,0.0007585922,0.00014031712,0.00008927268,0.0002168492,0.0004093119,0.000024599725],"category_scores_gemma":[0.00002745667,0.00050891464,0.00015043085,0.00090946,0.00004861356,0.000109156594,0.00015419199,0.0008946074,0.0000017468167],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071772454,0.0011518184,0.82407635,0.0027117084,0.00047569268,0.000117824165,0.0006377283,0.118954055,0.05159532,0.00018643303,0.000015807114,0.000005475844],"study_design_scores_gemma":[0.0051127435,0.00004034119,0.17382067,0.0056450106,0.001204314,2.0846537e-8,0.000060455168,0.80060345,0.012790958,0.0000039172924,0.00006861676,0.000649506],"about_ca_topic_score_codex":0.0033560172,"about_ca_topic_score_gemma":0.000117908916,"teacher_disagreement_score":0.6816494,"about_ca_system_score_codex":0.0020134347,"about_ca_system_score_gemma":0.002560936,"threshold_uncertainty_score":0.99973625},"labels":[],"label_agreement":null},{"id":"W4406300138","doi":"10.1503/cmaj.241820","title":"Correction to “Screening for lung cancer”","year":2025,"lang":"en","type":"erratum","venue":"Canadian Medical Association Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Data science; Lung cancer; World Wide Web; Information retrieval; Text mining; Medicine; Pathology; Data mining","score_opus":0.008998456006819993,"score_gpt":0.33347310027888744,"score_spread":0.32447464427206746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406300138","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000097046744,0.00848389,0.017092958,0.33638746,0.40874627,0.0028569307,0.0015315294,0.00011792295,0.22468598],"genre_scores_gemma":[0.0002113511,0.00091427105,0.0007417589,0.0345041,0.019415312,0.0002909056,0.0007221309,0.000050381703,0.9431498],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975988,0.000052630596,0.00046391375,0.0002626259,0.001062195,0.0005597914],"domain_scores_gemma":[0.99628675,0.0001993957,0.00027181962,0.000118257056,0.0010722816,0.0020514817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005690148,0.00021372849,0.00046822248,0.00053766003,0.00046498515,0.00010865054,0.0001414773,0.0007908086,0.0022955486],"category_scores_gemma":[0.0031757783,0.0001999796,0.00026516695,0.00036185113,0.000010659694,0.00005737184,0.0000120809855,0.0016939974,0.000012131724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000017452629,0.000015381891,0.0034570715,0.00006824395,0.0008367307,0.00007471346,0.00013533256,0.000013154632,2.21858e-7,0.000013818596,0.90552056,0.089847304],"study_design_scores_gemma":[0.0012016097,0.000093456554,0.003841854,0.0022758513,0.0009174747,0.00008279586,0.00011273319,0.0021264183,0.000001196569,0.000009272045,0.98917264,0.00016471557],"about_ca_topic_score_codex":0.016035765,"about_ca_topic_score_gemma":0.14708327,"teacher_disagreement_score":0.7184638,"about_ca_system_score_codex":0.0073451144,"about_ca_system_score_gemma":0.027435828,"threshold_uncertainty_score":0.9986165},"labels":[],"label_agreement":null},{"id":"W4406447669","doi":"10.1016/j.yonc.2013.04.012","title":"10.1016/j.yonc.2013.04.012","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Genotype; Oncology; Lung; Internal medicine; Resistance (ecology); Lung cancer; Cancer research; Pathology; Genetics; Gene; Biology; Ecology","score_opus":0.007003438079141223,"score_gpt":0.24056978958287673,"score_spread":0.2335663515037355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406447669","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016132208,0.00019267408,6.2026646e-7,0.0017095138,0.0000019222684,0.00029149928,0.000019161944,0.00010895082,0.99606246],"genre_scores_gemma":[0.00076705037,9.876379e-7,0.00019858105,0.00017026615,0.0001632612,0.000041190026,0.00005721358,0.000022174485,0.99857926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994206,0.000009716091,0.00010955466,0.00015559941,0.00012649417,0.0001780503],"domain_scores_gemma":[0.9995372,0.000021992222,0.000014280454,0.00021805888,0.00003703251,0.00017142574],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000030508594,0.000096138996,0.0001409365,0.00004743038,0.000053389405,0.000013189126,0.000046688056,0.000036986985,0.99681294],"category_scores_gemma":[0.000011748395,0.00007811519,0.000050800365,0.000122007965,0.000017555396,0.000049922848,0.000009424326,0.000054088483,0.9902643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008216942,0.00011152111,0.0000012351989,0.000006983023,0.00007680854,0.000021115744,0.000047595884,0.000013968009,0.00003137261,8.452685e-7,0.44470698,0.5548994],"study_design_scores_gemma":[0.0008182131,0.00027428425,0.00034348055,0.00002888865,0.00015926019,0.000027294487,0.0000019340068,0.000033967182,0.00007295939,0.0000041606063,0.9981513,0.00008426879],"about_ca_topic_score_codex":0.00009186729,"about_ca_topic_score_gemma":4.649875e-7,"teacher_disagreement_score":0.5548151,"about_ca_system_score_codex":0.00007764144,"about_ca_system_score_gemma":0.000060537477,"threshold_uncertainty_score":0.3185445},"labels":[],"label_agreement":null},{"id":"W4406447729","doi":"10.1016/j.yonc.2013.04.016","title":"10.1016/j.yonc.2013.04.016","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Erlotinib; Open label; Oncology; Internal medicine; Chemotherapy; Lung cancer; Cancer; Randomized controlled trial; Epidermal growth factor receptor","score_opus":0.006657984889861931,"score_gpt":0.2388944018324282,"score_spread":0.23223641694256625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406447729","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010795613,0.00015348308,7.6294265e-7,0.0025758927,0.0000018679707,0.00029115134,0.000020656349,0.00011129382,0.9957653],"genre_scores_gemma":[0.0006032726,8.806712e-7,0.00021989395,0.00017784887,0.00014776753,0.000041603213,0.000052498723,0.000022354086,0.9987339],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994118,0.000009819749,0.00011125132,0.000163487,0.00012745893,0.00017614469],"domain_scores_gemma":[0.99953634,0.000017596481,0.000014500982,0.00022444029,0.000039087987,0.00016801582],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000031039504,0.000097074015,0.00014222329,0.000048334205,0.00005360241,0.000013412509,0.000047997484,0.000037052807,0.9968949],"category_scores_gemma":[0.0000093545195,0.000076947166,0.000051616873,0.00012105523,0.000018491217,0.00004696948,0.000009556826,0.00005225837,0.9903393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007799587,0.00009519003,8.3008e-7,0.0000061815085,0.0000690191,0.000016235912,0.00004101067,0.00001062279,0.000030271345,0.0000013089126,0.47942197,0.5202294],"study_design_scores_gemma":[0.0008726995,0.00029133883,0.00021933591,0.000028432674,0.00014888523,0.000021507582,0.0000016273085,0.00003178726,0.000075479526,0.000004652637,0.99821925,0.00008501258],"about_ca_topic_score_codex":0.00007771268,"about_ca_topic_score_gemma":4.6123498e-7,"teacher_disagreement_score":0.52014434,"about_ca_system_score_codex":0.000080839294,"about_ca_system_score_gemma":0.00006682212,"threshold_uncertainty_score":0.31378144},"labels":[],"label_agreement":null},{"id":"W4406448479","doi":"10.1016/j.ypat.2013.12.028","title":"10.1016/j.ypat.2013.12.028","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chromosomal translocation; Genetic testing; Lung; Computational biology; Oncology; Genetics; Internal medicine; Gene; Biology","score_opus":0.006826405754475754,"score_gpt":0.23463772256104368,"score_spread":0.2278113168065679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406448479","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011175934,0.00012220758,7.5885765e-7,0.0016658007,0.0000018798095,0.0002982275,0.000019924415,0.00009889057,0.9966747],"genre_scores_gemma":[0.0006687869,8.0296184e-7,0.00022403282,0.00016620992,0.00014587732,0.00004327022,0.000058945898,0.000020533722,0.99867153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994201,0.000009620481,0.000110508874,0.00015985616,0.0001266258,0.00017326225],"domain_scores_gemma":[0.99954844,0.000016343922,0.000014383407,0.00022219952,0.000033196502,0.00016543428],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000029082563,0.00009617051,0.00014043317,0.00004821306,0.00005435995,0.000013372782,0.00004697209,0.000036668316,0.9969078],"category_scores_gemma":[0.000008800228,0.000078180776,0.000051201925,0.00009740883,0.000016997583,0.00004479039,0.000009273624,0.000053186246,0.99072546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008889433,0.000107133834,0.000001580492,0.0000066415896,0.00007075906,0.000017738505,0.000047923095,0.00001764959,0.000024987894,7.925457e-7,0.44046974,0.55914617],"study_design_scores_gemma":[0.00083888153,0.00030443724,0.00034380556,0.000030533265,0.00015299903,0.000020985844,0.0000017927733,0.000050589373,0.000060888775,0.0000044841804,0.9981063,0.00008427799],"about_ca_topic_score_codex":0.00010328058,"about_ca_topic_score_gemma":8.6823826e-7,"teacher_disagreement_score":0.5590619,"about_ca_system_score_codex":0.000074346695,"about_ca_system_score_gemma":0.00006116077,"threshold_uncertainty_score":0.31881195},"labels":[],"label_agreement":null},{"id":"W4406519712","doi":"10.1016/s0765-2046(98)80112-3","title":"10.1016/s0765-2046(98)80112-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.0075182572900998,"score_gpt":0.24226430916685282,"score_spread":0.23474605187675301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406519712","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001057478,0.00013252585,6.4858915e-7,0.0012052692,0.0000018268701,0.0002975523,0.000018919493,0.00008936622,0.99719644],"genre_scores_gemma":[0.00061315397,5.892171e-7,0.00024683354,0.00017892511,0.00017156685,0.000044057124,0.00005310284,0.00002157586,0.9986702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993901,0.000009871677,0.00011540688,0.00016969901,0.00013369475,0.00018120435],"domain_scores_gemma":[0.9995281,0.000016907488,0.000014704659,0.00022994743,0.000039708728,0.00017061815],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000031821604,0.00010125091,0.00015306797,0.000052420677,0.000058250447,0.00001457404,0.00005037546,0.00003865807,0.99842525],"category_scores_gemma":[0.000010152965,0.00008330538,0.0000546704,0.00014198938,0.000017870252,0.000045826233,0.000009857935,0.000057739533,0.99469626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009946107,0.00012540483,0.0000013969907,0.0000084092135,0.0000899561,0.000022500357,0.00005118174,0.00001235525,0.00003297614,0.0000013282516,0.49131158,0.50824344],"study_design_scores_gemma":[0.00086003024,0.00028903133,0.00040709565,0.00003231315,0.00017050393,0.000020474714,0.000002073217,0.00003073589,0.00008947187,0.0000063320526,0.9980028,0.00008909777],"about_ca_topic_score_codex":0.00005833169,"about_ca_topic_score_gemma":3.7899304e-7,"teacher_disagreement_score":0.50815433,"about_ca_system_score_codex":0.00008539037,"about_ca_system_score_gemma":0.000071282884,"threshold_uncertainty_score":0.33970946},"labels":[],"label_agreement":null},{"id":"W4406537836","doi":"10.1016/s1155-195x(20)30149-3","title":"10.1016/s1155-195x(20)30149-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Carcinogen; Biology; Genetics","score_opus":0.005706873641995155,"score_gpt":0.2359564617106534,"score_spread":0.23024958806865825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406537836","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011145581,0.00013927583,8.387276e-7,0.0013678109,0.0000018917419,0.00030643705,0.00002718525,0.00011200009,0.99693],"genre_scores_gemma":[0.00061658834,5.2784105e-7,0.00021919156,0.00018466658,0.00016049528,0.00004571189,0.00007911439,0.000022690321,0.998671],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936694,0.000010511854,0.00011993886,0.00017669062,0.00013702748,0.00018891532],"domain_scores_gemma":[0.9995078,0.000018811992,0.0000151719405,0.00024077187,0.000040721934,0.00017672885],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003494946,0.00010399455,0.00015467337,0.000054185668,0.00006175454,0.00001502046,0.000052066775,0.000039656697,0.9971571],"category_scores_gemma":[0.000011383412,0.00008618807,0.00005811961,0.00014777381,0.000019139938,0.00004694489,0.0000102705435,0.000059868744,0.9911861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010541309,0.00012249054,0.0000012161304,0.000008298937,0.000087585,0.000023456603,0.00005018875,0.000020111509,0.000049160168,9.898903e-7,0.41823792,0.58129317],"study_design_scores_gemma":[0.00091331376,0.000300676,0.00022198292,0.000032923355,0.00017458081,0.000026540678,0.0000020720906,0.000035638568,0.00009866495,0.0000052329906,0.99809617,0.000092183276],"about_ca_topic_score_codex":0.00004246558,"about_ca_topic_score_gemma":4.2628824e-7,"teacher_disagreement_score":0.58120096,"about_ca_system_score_codex":0.00008837014,"about_ca_system_score_gemma":0.0000767264,"threshold_uncertainty_score":0.35146475},"labels":[],"label_agreement":null},{"id":"W4406554218","doi":"10.1016/s1558-0164(12)70147-5","title":"10.1016/s1558-0164(12)70147-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Link (geometry); Oncology; Computer network; Computer science","score_opus":0.006279285825704807,"score_gpt":0.2340355489832528,"score_spread":0.227756263157548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406554218","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007782207,0.00011070923,0.0000011278219,0.0011202765,0.0000018621298,0.00030430817,0.000021084956,0.00011005858,0.99755234],"genre_scores_gemma":[0.0007554628,6.829725e-7,0.00024169151,0.00018208203,0.00015896827,0.000044754823,0.0000622101,0.000022952598,0.9985312],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936575,0.000010391824,0.00012006566,0.00017615684,0.0001402845,0.00018737414],"domain_scores_gemma":[0.9995179,0.000018191296,0.00001562537,0.00023741358,0.000034742417,0.00017609932],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003431688,0.00010528958,0.00015312537,0.0000512493,0.00006201082,0.000015172981,0.00005169144,0.000039230556,0.99734455],"category_scores_gemma":[0.000011931307,0.00008611853,0.000058534373,0.000113758375,0.000019087984,0.000046352558,0.0000103693565,0.000059963248,0.9971299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013556628,0.00014758042,4.3714542e-7,0.000009941697,0.00010442585,0.000026265576,0.000063121006,0.000022205726,0.000046718,0.0000012410095,0.7772318,0.22221069],"study_design_scores_gemma":[0.00089134893,0.00033578664,0.00035677737,0.00003309028,0.00016861572,0.00002503426,0.0000021110068,0.000036610283,0.00007788991,0.0000054424354,0.9979745,0.000092766415],"about_ca_topic_score_codex":0.000051947012,"about_ca_topic_score_gemma":4.7560502e-7,"teacher_disagreement_score":0.22211793,"about_ca_system_score_codex":0.00008786305,"about_ca_system_score_gemma":0.00007115976,"threshold_uncertainty_score":0.35118118},"labels":[],"label_agreement":null},{"id":"W4406557148","doi":"10.1016/s1876-1143(12)70055-1","title":"10.1016/s1876-1143(12)70055-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Malignancy; Medicine; Internal medicine","score_opus":0.006328050280784669,"score_gpt":0.23452162856520578,"score_spread":0.2281935782844211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406557148","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010199507,0.00011621591,8.571772e-7,0.0011856937,0.0000018810883,0.00030806565,0.000021759575,0.00011043199,0.9972351],"genre_scores_gemma":[0.00069514685,6.776203e-7,0.00024482,0.00018912212,0.0001606294,0.00004563985,0.00006358532,0.000022659433,0.9985777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936527,0.000010622085,0.00012018172,0.0001749061,0.00013952213,0.00018947924],"domain_scores_gemma":[0.99951756,0.000018773113,0.0000148320305,0.00023684755,0.00003427405,0.0001776944],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003476809,0.00010474442,0.00015230947,0.000053068485,0.00006138386,0.000015322115,0.00005159395,0.000039786082,0.9971986],"category_scores_gemma":[0.000012330172,0.00008617609,0.000057085814,0.00011502155,0.000018783374,0.000048699145,0.000010395061,0.000059340895,0.99053776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105568935,0.00011730397,0.000001431314,0.000007319861,0.00008217041,0.000022179142,0.00005060472,0.000014537758,0.000037067617,0.000001002944,0.32745582,0.672105],"study_design_scores_gemma":[0.000908,0.00031499838,0.00037089625,0.000033017157,0.00016981216,0.000024749063,0.0000020742768,0.00003056348,0.00009455432,0.0000046756545,0.9979546,0.00009206481],"about_ca_topic_score_codex":0.000051757754,"about_ca_topic_score_gemma":4.926997e-7,"teacher_disagreement_score":0.6720129,"about_ca_system_score_codex":0.000088381035,"about_ca_system_score_gemma":0.000073394294,"threshold_uncertainty_score":0.3514159},"labels":[],"label_agreement":null},{"id":"W4406564757","doi":"10.1016/j.ypdi.2016.02.010","title":"10.1016/j.ypdi.2016.02.010","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; EGFR inhibitors; Cancer research; Oncology; Cancer; Internal medicine; Epidermal growth factor receptor","score_opus":0.005498137929811186,"score_gpt":0.23447861916153348,"score_spread":0.2289804812317223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406564757","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010785529,0.00014418799,8.3516875e-7,0.0013753894,0.0000020029747,0.00028614717,0.000020812955,0.00010447577,0.9969876],"genre_scores_gemma":[0.00064375275,7.703487e-7,0.00022872673,0.00017386967,0.00015864495,0.000039270177,0.000056711397,0.00002147863,0.9986768],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994171,0.000009414392,0.00011219809,0.00016232612,0.00012314488,0.00017578222],"domain_scores_gemma":[0.99953675,0.000017489896,0.0000145884105,0.00022664711,0.000038642178,0.00016586295],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003164448,0.00009711474,0.00014212847,0.00004973996,0.00005680324,0.000013904456,0.000048793845,0.00003925763,0.9968551],"category_scores_gemma":[0.000011556921,0.00007784449,0.000052368738,0.0001263112,0.000018884692,0.0000455016,0.000009625936,0.000058144473,0.99177665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083084014,0.000104972736,8.714421e-7,0.00000606385,0.00006780029,0.000015695741,0.000041511827,0.000007839194,0.000042315653,8.907306e-7,0.385679,0.61394995],"study_design_scores_gemma":[0.0008467522,0.00032203688,0.0002362279,0.000036442896,0.00015060662,0.000020846679,0.0000018956381,0.00002750648,0.00010526428,0.0000056164877,0.9981615,0.00008528586],"about_ca_topic_score_codex":0.000047188492,"about_ca_topic_score_gemma":2.7978345e-7,"teacher_disagreement_score":0.61386466,"about_ca_system_score_codex":0.000073043506,"about_ca_system_score_gemma":0.000082732266,"threshold_uncertainty_score":0.31744063},"labels":[],"label_agreement":null},{"id":"W4406564883","doi":"10.1016/j.ypdi.2015.02.014","title":"10.1016/j.ypdi.2015.02.014","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Tyrosine kinase; Epidermal growth factor receptor; Lung cancer; Clinical Oncology; Internal medicine; Oncology; Receptor Protein-Tyrosine Kinases; Tyrosine-kinase inhibitor; Cancer research; Cancer; Receptor","score_opus":0.005633256645288417,"score_gpt":0.24617966287333243,"score_spread":0.24054640622804402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406564883","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00091930485,0.00014902792,0.000001050824,0.0015365636,0.0000018798225,0.00027940306,0.000018617871,0.00010257216,0.9969916],"genre_scores_gemma":[0.0007966092,5.493641e-7,0.0002590802,0.00018276008,0.00016161172,0.00003829593,0.0000575553,0.000021025553,0.9984825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942315,0.000009946178,0.00010915528,0.00015897358,0.0001278858,0.00017088332],"domain_scores_gemma":[0.9995451,0.000014299607,0.000014378408,0.00022317887,0.000038962502,0.00016405732],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003286469,0.000095409516,0.000142806,0.000047445323,0.000053584547,0.000013706022,0.00004713512,0.000035421977,0.9962938],"category_scores_gemma":[0.000011037336,0.00007778833,0.00005055741,0.00012706585,0.000017897264,0.000044272612,0.0000094166035,0.000053260334,0.99112535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008213238,0.00010618857,0.0000011531735,0.000006263412,0.000073619,0.000015622252,0.00004471676,0.000011833979,0.000025166395,0.0000013925072,0.48040166,0.51923025],"study_design_scores_gemma":[0.0008290839,0.0003207747,0.00025457915,0.000029064382,0.00016124378,0.00001986563,0.0000019490888,0.00004320429,0.00008494671,0.000005075999,0.99816644,0.00008376377],"about_ca_topic_score_codex":0.00004995037,"about_ca_topic_score_gemma":3.0386954e-7,"teacher_disagreement_score":0.51914644,"about_ca_system_score_codex":0.00007463935,"about_ca_system_score_gemma":0.00006510158,"threshold_uncertainty_score":0.31721163},"labels":[],"label_agreement":null},{"id":"W4406565032","doi":"10.1016/j.ypdi.2014.01.046","title":"10.1016/j.ypdi.2014.01.046","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunosurveillance; Medicine; Mechanism (biology); Mechanism of action; Pharmacology; Action (physics); Cancer; Internal medicine; Biology","score_opus":0.005733475179611426,"score_gpt":0.23752903334721814,"score_spread":0.23179555816760672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406565032","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009028592,0.00017574649,8.385339e-7,0.0012797898,0.0000019163924,0.0002755094,0.000019430914,0.00011005001,0.99723387],"genre_scores_gemma":[0.00062432396,9.386869e-7,0.00022590147,0.00016937291,0.00015278069,0.00003860206,0.00006113487,0.0000220446,0.9987049],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994192,0.000009862532,0.00010961295,0.00016296482,0.00012579393,0.00017254315],"domain_scores_gemma":[0.9995471,0.000017224504,0.000014421234,0.00022685251,0.000032017215,0.00016235132],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0000319587,0.0000958648,0.00014153113,0.000048336817,0.000054271975,0.0000140057755,0.000047783557,0.000036665155,0.99737734],"category_scores_gemma":[0.000009881208,0.00007797013,0.000051691022,0.00010691296,0.00001791069,0.000044484223,0.000009423709,0.00005357669,0.9931978],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007866191,0.000093374525,0.0000011569642,0.000005779578,0.00006149398,0.00001412264,0.00003438835,0.000011095735,0.000028365399,0.0000010245282,0.5098252,0.48984528],"study_design_scores_gemma":[0.00083500706,0.00029400055,0.00032085503,0.000026195421,0.00015046047,0.000021084226,0.0000018728599,0.000028775541,0.00008055498,0.0000055829246,0.9981518,0.00008383627],"about_ca_topic_score_codex":0.00006611536,"about_ca_topic_score_gemma":3.4132802e-7,"teacher_disagreement_score":0.48976144,"about_ca_system_score_codex":0.00007340304,"about_ca_system_score_gemma":0.00006498295,"threshold_uncertainty_score":0.31795296},"labels":[],"label_agreement":null},{"id":"W4406565189","doi":"10.1016/j.ypdi.2013.01.033","title":"10.1016/j.ypdi.2013.01.033","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Class (philosophy); ROS1; Lung cancer; Lung; Oncology; Computational biology; Internal medicine; Cancer; Adenocarcinoma; Artificial intelligence; Biology; Computer science","score_opus":0.006515690751570662,"score_gpt":0.23741628264232525,"score_spread":0.2309005918907546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406565189","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011697162,0.00016738145,7.27702e-7,0.0018131511,0.000001919592,0.00029231186,0.0000198482,0.000102443366,0.9964325],"genre_scores_gemma":[0.00063820026,0.0000010399796,0.00021027493,0.00016247849,0.00015273734,0.000041092386,0.00006134845,0.000021103551,0.9987117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942106,0.000009321561,0.00011081449,0.00015954032,0.00012550375,0.00017376307],"domain_scores_gemma":[0.9995516,0.00001627869,0.000014329308,0.0002209181,0.000032934884,0.00016394531],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000030113995,0.00009595092,0.00014105342,0.000048408794,0.000055653596,0.000013995985,0.000047321693,0.000036923946,0.99701095],"category_scores_gemma":[0.000009076089,0.00007811031,0.000050303785,0.00012844228,0.000017817598,0.000046669433,0.000009386342,0.000054059332,0.99136055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007971981,0.00010424256,0.0000010421754,0.0000062141225,0.00006889835,0.000014940127,0.000041371783,0.000013270858,0.000028818724,8.0763465e-7,0.48411977,0.51552093],"study_design_scores_gemma":[0.000831415,0.0002873916,0.0002845092,0.000029459801,0.00014690563,0.000020563692,0.0000020089087,0.000040476978,0.00006324293,0.0000051398806,0.99820465,0.0000842297],"about_ca_topic_score_codex":0.00009667782,"about_ca_topic_score_gemma":5.9210976e-7,"teacher_disagreement_score":0.51543665,"about_ca_system_score_codex":0.00007216535,"about_ca_system_score_gemma":0.00005934792,"threshold_uncertainty_score":0.3185246},"labels":[],"label_agreement":null},{"id":"W4406578735","doi":"10.1016/s1541-9800(11)70745-1","title":"10.1016/s1541-9800(11)70745-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.0058911606311220326,"score_gpt":0.23644299812864805,"score_spread":0.23055183749752603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578735","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017350317,0.00011510527,8.029821e-7,0.0014175138,0.0000020023144,0.0003075158,0.000022079768,0.000109849294,0.9962901],"genre_scores_gemma":[0.00081915775,5.3629947e-7,0.00025890858,0.00018115056,0.00016127343,0.000046459823,0.00006297441,0.00002273744,0.9984468],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993655,0.000010718702,0.00012041422,0.00017600317,0.00014000584,0.00018736008],"domain_scores_gemma":[0.99950916,0.000020042307,0.000015320082,0.00024069991,0.000040663446,0.00017412072],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003510526,0.00010462278,0.00015260621,0.000051865758,0.00006178202,0.000015209575,0.000053079297,0.000039790328,0.9974569],"category_scores_gemma":[0.000012722709,0.00008601733,0.000056610887,0.00014516454,0.000019724002,0.00004616888,0.000010581044,0.000051673836,0.99027616],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008347575,0.00013641703,0.0000028154047,0.000009236663,0.00007489836,0.000025344762,0.000058544603,0.00001758253,0.00003308423,0.0000014654368,0.53079253,0.4687646],"study_design_scores_gemma":[0.0008943678,0.00025163018,0.00037412348,0.000033760607,0.00016791275,0.000024457862,0.0000023277576,0.00003295445,0.00009474124,0.000005498762,0.99802625,0.00009194837],"about_ca_topic_score_codex":0.00008169129,"about_ca_topic_score_gemma":7.1356175e-7,"teacher_disagreement_score":0.46867266,"about_ca_system_score_codex":0.00008693024,"about_ca_system_score_gemma":0.00007151928,"threshold_uncertainty_score":0.35076848},"labels":[],"label_agreement":null},{"id":"W4406579938","doi":"10.1016/s1541-9800(07)70298-3","title":"10.1016/s1541-9800(07)70298-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Link (geometry); Lymphoma; Medicine; Internal medicine; Computer science","score_opus":0.0061172081256513295,"score_gpt":0.23803883296694608,"score_spread":0.23192162484129475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579938","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011320976,0.00014102052,8.035157e-7,0.0012173782,0.0000017963615,0.00031155362,0.000022118871,0.00011015053,0.9970631],"genre_scores_gemma":[0.00066130434,6.5080206e-7,0.00023449323,0.00018607525,0.00015738756,0.000046835677,0.000062968815,0.000022736322,0.99862754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993645,0.000010607966,0.00012063551,0.00017610949,0.00013973413,0.00018843784],"domain_scores_gemma":[0.9995099,0.000018494276,0.000015341826,0.00023780613,0.00004110366,0.0001773795],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000034183122,0.000105123385,0.00015364967,0.000050845618,0.00006176657,0.000015354366,0.00005207792,0.000039687722,0.99834496],"category_scores_gemma":[0.000012337466,0.00008637801,0.000057236983,0.00013188024,0.00001934008,0.00004815276,0.000010416845,0.000060105667,0.9957572],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014792036,0.00013353344,0.00000115849,0.000008711725,0.00009041208,0.000026955082,0.000053196207,0.000014878188,0.000031745683,0.0000012389503,0.4622659,0.53722435],"study_design_scores_gemma":[0.00091398536,0.00038663912,0.00026322246,0.000033848242,0.00016990528,0.000027054062,0.0000020591826,0.0000333596,0.000089555426,0.000006190857,0.9979818,0.00009236698],"about_ca_topic_score_codex":0.000049310023,"about_ca_topic_score_gemma":2.6171273e-7,"teacher_disagreement_score":0.53713197,"about_ca_system_score_codex":0.000089946116,"about_ca_system_score_gemma":0.000076047254,"threshold_uncertainty_score":0.3522393},"labels":[],"label_agreement":null},{"id":"W4406583745","doi":"10.1016/s1155-195x(21)42933-6","title":"10.1016/s1155-195x(21)42933-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.005882704580894502,"score_gpt":0.23699197650790874,"score_spread":0.23110927192701425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406583745","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013606667,0.00013168382,8.3409265e-7,0.0017111471,0.0000019093295,0.00031062745,0.000023032062,0.00011245404,0.99634767],"genre_scores_gemma":[0.00065388356,6.0569835e-7,0.00023343922,0.00023978368,0.00015862712,0.000046049332,0.00006426378,0.000022771486,0.9985806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936706,0.000010353915,0.00012060753,0.0001764514,0.00013684526,0.00018868537],"domain_scores_gemma":[0.9995091,0.00001899937,0.000015338326,0.00023858788,0.00004050589,0.00017747706],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000034277182,0.00010444061,0.00015382293,0.000054427062,0.000061480394,0.000015132112,0.000052126936,0.000039764494,0.99704075],"category_scores_gemma":[0.000012713977,0.00008648004,0.000057363704,0.00015037111,0.000019318632,0.000046892477,0.000010433621,0.000060202023,0.9913043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011244664,0.00013151659,0.0000011892203,0.000008758443,0.000087719854,0.000024137582,0.00005656382,0.000016146847,0.00005131148,0.0000014237697,0.39692014,0.60258865],"study_design_scores_gemma":[0.0008972097,0.00030620614,0.00033711604,0.000034130524,0.00016782536,0.000025813193,0.0000021637543,0.00003272279,0.00010404995,0.000006306994,0.9979939,0.00009258047],"about_ca_topic_score_codex":0.000053635238,"about_ca_topic_score_gemma":2.6883558e-7,"teacher_disagreement_score":0.602496,"about_ca_system_score_codex":0.00008984457,"about_ca_system_score_gemma":0.00007617825,"threshold_uncertainty_score":0.35265535},"labels":[],"label_agreement":null},{"id":"W4406584012","doi":"10.1016/j.yonc.2013.05.003","title":"10.1016/j.yonc.2013.05.003","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Crizotinib; Medicine; Acquired resistance; Oncology; Internal medicine; Lung cancer; Cancer","score_opus":0.006421922914557348,"score_gpt":0.23765955921994153,"score_spread":0.2312376363053842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584012","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00088699843,0.00018134991,7.1869385e-7,0.0017273417,0.0000021469234,0.00029763495,0.000018064278,0.00009231109,0.99679345],"genre_scores_gemma":[0.0003975408,0.0000011098042,0.00022061619,0.0001850816,0.0001362363,0.000040275903,0.00005270394,0.000020283394,0.99894613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994296,0.000009639433,0.00010774252,0.0001563797,0.00012591033,0.00017072957],"domain_scores_gemma":[0.99955493,0.000015820946,0.000014165634,0.0002159774,0.00003326487,0.0001658651],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000029800942,0.00009496672,0.00014147034,0.000046383517,0.000054014752,0.000013493993,0.000045385543,0.00003691788,0.9961032],"category_scores_gemma":[0.000009250514,0.00007610946,0.00005087562,0.00012674635,0.000017760198,0.00004338597,0.000008839271,0.000053172273,0.989253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006275944,0.000085988766,6.717539e-7,0.0000059732997,0.00006385942,0.000018631677,0.00003302965,0.000011651855,0.000025574067,8.568548e-7,0.4915541,0.50813687],"study_design_scores_gemma":[0.0008309456,0.00031912042,0.00018048998,0.000029846537,0.00014786767,0.000029463801,0.0000016807944,0.000033597713,0.00007834311,0.000004048939,0.99826276,0.00008185065],"about_ca_topic_score_codex":0.00008420246,"about_ca_topic_score_gemma":3.7973675e-7,"teacher_disagreement_score":0.50805503,"about_ca_system_score_codex":0.00007633928,"about_ca_system_score_gemma":0.00006393783,"threshold_uncertainty_score":0.31036538},"labels":[],"label_agreement":null},{"id":"W4406637225","doi":"10.1016/b978-0-7295-3929-6.50041-0","title":"10.1016/b978-0-7295-3929-6.50041-0","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.009350089104992907,"score_gpt":0.23112523807677274,"score_spread":0.22177514897177983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406637225","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010083248,0.0007921746,4.6663962e-7,0.0005258882,0.000006227954,0.0007833543,0.00021720653,0.00017686545,0.9974968],"genre_scores_gemma":[0.0000029186124,0.0000028508825,0.00013402589,0.00019398158,0.00052700535,0.000055597862,0.00062716776,0.00013172698,0.99832475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866027,0.0000067431392,0.00029722948,0.00043554712,0.00032153222,0.00027869825],"domain_scores_gemma":[0.99892324,0.00003474968,0.00008552688,0.00054322503,0.00010115043,0.00031211623],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000041546726,0.00038518454,0.00052616827,0.00021387608,0.000082884835,0.000027010075,0.00011655769,0.00026001834,0.9978733],"category_scores_gemma":[0.000010155527,0.00033841416,0.0002214439,0.00004388845,0.0000493943,0.00004262222,0.00003913204,0.0002557339,0.9941985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016373958,0.00006392331,4.6354035e-8,0.000038410457,0.0005086061,0.00012653526,0.00003143512,0.0000046090445,0.0000032442304,0.00008512186,0.36408907,0.63488525],"study_design_scores_gemma":[0.0008881982,0.00048729838,0.0000072947582,0.0003386268,0.0010551884,0.000060812206,5.535291e-7,0.000003834505,0.0000074814952,0.00016441452,0.9966722,0.00031406712],"about_ca_topic_score_codex":0.00003087371,"about_ca_topic_score_gemma":7.3773765e-7,"teacher_disagreement_score":0.6345712,"about_ca_system_score_codex":0.0002750361,"about_ca_system_score_gemma":0.00025561263,"threshold_uncertainty_score":0.9999068},"labels":[],"label_agreement":null},{"id":"W4406698363","doi":"10.51731/cjht.25.1064","title":"Ivosidenib (Tibsovo)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.016761126834953326,"score_gpt":0.35869270102917783,"score_spread":0.3419315741942245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406698363","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13155214,0.2970532,0.0015839633,0.54877144,0.0016522687,0.0007324274,0.000027314127,0.00023332356,0.018393915],"genre_scores_gemma":[0.9962605,0.00035870075,0.00091866666,0.0015271415,0.0000060216967,0.000004418155,0.0000015993577,0.000004898229,0.0009180342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993271,0.000011702855,0.00030375988,0.00006740553,0.000064022,0.00022598928],"domain_scores_gemma":[0.9994877,0.000022811251,0.00013190215,0.0001519893,0.0001431205,0.00006245096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014298227,0.00006453164,0.00023311545,0.00062059675,0.0001506293,0.000014763714,0.00010332817,0.00006967377,0.000025286534],"category_scores_gemma":[0.00024148145,0.000049209695,0.00005615226,0.00031097987,0.000094780786,0.00004652984,0.0000061793057,0.00020707668,0.0000052479436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014903659,0.000028875365,0.0336228,0.00015100208,0.0002151714,0.00026796525,0.00025629162,0.000005207262,0.000030019468,0.0097383205,0.05341934,0.9022501],"study_design_scores_gemma":[0.0014693264,0.00056508294,0.06296181,0.0009488822,0.0001310616,0.0004032195,0.0044222814,0.000004253272,0.00083467003,0.011086875,0.9170872,0.00008536381],"about_ca_topic_score_codex":0.0037815822,"about_ca_topic_score_gemma":0.002877908,"teacher_disagreement_score":0.90216476,"about_ca_system_score_codex":0.0006168979,"about_ca_system_score_gemma":0.0066630305,"threshold_uncertainty_score":0.99896824},"labels":[],"label_agreement":null},{"id":"W4406760478","doi":"10.1093/oncolo/oyae356","title":"Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Amgen","keywords":"KRAS; Medicine; Oncology; Lung cancer; Cancer; Adverse effect; Internal medicine; Pooled analysis; Cancer research; Colorectal cancer; Meta-analysis","score_opus":0.00639325103339201,"score_gpt":0.32502417040903736,"score_spread":0.31863091937564536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406760478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777562,0.0012578521,0.00039147897,0.0013285722,0.00015142439,0.0015305887,0.000045661352,0.000030078918,0.017508129],"genre_scores_gemma":[0.9897297,0.0017829083,0.00055371795,0.00026399057,0.00000591647,0.00019858031,0.0000722368,0.000009345615,0.007383593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989875,0.00005995837,0.00038448116,0.0002550836,0.000115463714,0.00019754402],"domain_scores_gemma":[0.999376,0.00007240099,0.00016093378,0.00027664204,0.000065899425,0.000048110887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018860283,0.00015253857,0.00041748935,0.00018689144,0.00008362441,0.0000023595255,0.000103825674,0.00006912451,0.000085969485],"category_scores_gemma":[0.00000833854,0.00010219893,0.0001117569,0.001149059,0.00009021755,0.000035100424,0.00007384651,0.00012073217,0.0000018125434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012773604,0.0011261529,0.9595804,0.00082351256,0.009128089,0.0001267377,0.0014374201,0.012452913,0.0019616291,0.00029398096,0.00038258894,0.011409215],"study_design_scores_gemma":[0.008873747,0.00013518048,0.9742987,0.00039523107,0.011059318,9.918024e-7,0.0010784564,0.002093166,0.001279148,0.00007116074,0.000591815,0.00012308681],"about_ca_topic_score_codex":0.001409639,"about_ca_topic_score_gemma":0.0012750251,"teacher_disagreement_score":0.014718299,"about_ca_system_score_codex":0.0004983275,"about_ca_system_score_gemma":0.0001736291,"threshold_uncertainty_score":0.41675514},"labels":[],"label_agreement":null},{"id":"W4406788256","doi":"10.1016/j.critrevonc.2025.104631","title":"Future directions in the evaluation and management of newly diagnosed metastatic cancer","year":2025,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health; Siemens Healthineers; Society of Nuclear Medicine and Molecular Imaging","keywords":"Cancer; Medicine; Oncology; Intensive care medicine; General surgery; Internal medicine","score_opus":0.10333730852043564,"score_gpt":0.5364956610348124,"score_spread":0.43315835251437673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406788256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069275593,0.98546743,0.000024634304,0.0038406947,0.00054943335,0.0053951177,0.000029135506,0.000008065541,0.00467853],"genre_scores_gemma":[0.000029449911,0.9874638,0.0013968188,0.00053328107,0.00005643532,0.010331977,0.00007923698,0.0000139981885,0.00009502921],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644834,0.0014711967,0.001186474,0.00043724893,0.0001825755,0.0002741628],"domain_scores_gemma":[0.99687755,0.002355449,0.00021435822,0.00038937666,0.00010343711,0.00005982552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012772945,0.0002952909,0.0028251961,0.0003347444,0.000050113766,0.000006998722,0.00015017464,0.00026283323,0.00014819317],"category_scores_gemma":[0.001056578,0.00017603538,0.00025465264,0.00081683096,0.00022268407,0.00003434972,0.000059451155,0.00044398295,0.000009705612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000071543723,0.00044711254,0.000053592343,0.052641507,0.00019902755,0.00019897395,0.00019619142,8.267309e-8,9.266913e-9,0.027215695,0.0014238666,0.9176168],"study_design_scores_gemma":[0.0010946806,0.00012406374,0.00018083438,0.05139132,0.009346345,0.00019983697,0.00027383034,0.000005429967,5.9313283e-8,0.00074925786,0.93652505,0.00010928824],"about_ca_topic_score_codex":0.00004960257,"about_ca_topic_score_gemma":0.0004848978,"teacher_disagreement_score":0.9351012,"about_ca_system_score_codex":0.00052309927,"about_ca_system_score_gemma":0.00081279833,"threshold_uncertainty_score":0.71785146},"labels":[],"label_agreement":null},{"id":"W4406815113","doi":"10.1002/cam4.70369","title":"Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With <scp><i>EGFR</i></scp> Exon 20 Insertion Mutations Receiving Mobocertinib: The <scp>EXTRACT</scp> Study","year":2025,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; University of Toronto; Princess Margaret Cancer Centre","funders":"Takeda Development Center Americas","keywords":"Medicine; Internal medicine; Lung cancer; Cohort; Demographics; Adverse effect; Oncology; Demography","score_opus":0.013910075759684861,"score_gpt":0.31511208801140655,"score_spread":0.3012020122517217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406815113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096566,0.0018705757,0.00017789006,0.00078605546,0.00025961484,0.0029162646,0.00017613874,0.000041082443,0.0028067247],"genre_scores_gemma":[0.9899954,0.0009877927,0.000099299905,0.0003708542,0.00009224866,0.0010915244,0.00013876734,0.00004962698,0.007174455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980629,0.000073388794,0.0006319813,0.00048544435,0.0003988344,0.00034745914],"domain_scores_gemma":[0.9976822,0.0006260567,0.0005332623,0.0004954502,0.0005000306,0.0001629648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014880292,0.000396939,0.0008314569,0.00031926608,0.00018077371,0.00001319928,0.00012439954,0.000063980486,0.00003330174],"category_scores_gemma":[0.000076277545,0.000207965,0.00006555229,0.00067838107,0.00017058755,0.00011215266,0.000034063385,0.00018007892,4.0976573e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069520844,0.00097599963,0.9776859,0.00041857696,0.0014463214,0.000008380045,0.014594,0.00028868805,0.00040449807,0.000010065847,0.00064753863,0.0034504735],"study_design_scores_gemma":[0.0126583595,0.0024352006,0.96705383,0.0014443323,0.005007571,0.0000010287825,0.008721668,0.00009908311,0.0015355032,0.0000057640405,0.0009871303,0.00005055647],"about_ca_topic_score_codex":0.015321588,"about_ca_topic_score_gemma":0.019272156,"teacher_disagreement_score":0.012588838,"about_ca_system_score_codex":0.00064659235,"about_ca_system_score_gemma":0.00070724613,"threshold_uncertainty_score":0.99862355},"labels":[],"label_agreement":null},{"id":"W4406907125","doi":"10.51731/cjht.2025.1065","title":"Osimertinib (Tagrisso)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Receptor","score_opus":0.01814201831550905,"score_gpt":0.3576238266743232,"score_spread":0.33948180835881414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406907125","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14767139,0.28625324,0.00135293,0.5477888,0.0015582574,0.0007328761,0.00002798599,0.00023229863,0.014382207],"genre_scores_gemma":[0.9966142,0.00031398097,0.0007528948,0.001556934,0.0000057427005,0.000004463884,0.00000184101,0.000004640918,0.00074527966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931765,0.000011987698,0.00031594533,0.00006665374,0.000060904473,0.0002268805],"domain_scores_gemma":[0.9994958,0.000022276192,0.00014336355,0.00014436967,0.00013158661,0.000062586165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015051341,0.00006382156,0.00023081018,0.00053791626,0.0001512012,0.000011746095,0.000098066615,0.00006923903,0.000024539002],"category_scores_gemma":[0.00023544283,0.00004751668,0.000054887678,0.00031286283,0.00008687081,0.00003953772,0.00000573927,0.00020212683,0.0000050165236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013414335,0.000027317745,0.03618459,0.000104165134,0.00018439708,0.00013731977,0.0002030037,0.0000044242506,0.000025575842,0.0044950563,0.038123697,0.92049706],"study_design_scores_gemma":[0.001207336,0.0004598329,0.08380111,0.00067045284,0.00011427583,0.000203355,0.0031785995,0.00000484857,0.0008758899,0.004906878,0.90450543,0.000071994036],"about_ca_topic_score_codex":0.0031275954,"about_ca_topic_score_gemma":0.0011803573,"teacher_disagreement_score":0.92042506,"about_ca_system_score_codex":0.0004743897,"about_ca_system_score_gemma":0.0054113334,"threshold_uncertainty_score":0.9599473},"labels":[],"label_agreement":null},{"id":"W4406912930","doi":"10.1515/tjb-2024-0181","title":"Investigation into drug resistance to cisplatin in cancer stem cell-enriched population in non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Turkish Journal of Biochemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Consortium canadien en neurodégénérescence associée au vieillissement","keywords":"Cisplatin; Lung cancer; Drug resistance; Cancer; Cancer stem cell; Drug; Cell; Oncology; Population; Cancer research; Medicine; Internal medicine; Biology; Pharmacology; Chemotherapy; Microbiology; Genetics; Environmental health","score_opus":0.007841319651661195,"score_gpt":0.30146393089296997,"score_spread":0.2936226112413088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406912930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98726887,0.007935467,0.00007276245,0.003205498,0.00021468711,0.0003087475,0.0000088137,0.0000073075635,0.0009778797],"genre_scores_gemma":[0.9914299,0.00030143146,0.0009953667,0.00051639194,0.00011464294,0.000057264704,0.000020801654,0.000014559009,0.006549588],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879056,0.000025060068,0.0005793078,0.00021363582,0.00020765376,0.00018377413],"domain_scores_gemma":[0.99921364,0.000031539843,0.00028874303,0.00015254739,0.00017996863,0.00013355112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001904816,0.00015478217,0.00031034488,0.00023839084,0.000039976552,0.000023475468,0.00010630569,0.00010049523,0.000021079533],"category_scores_gemma":[0.000020539906,0.00014375868,0.000064382264,0.0006842209,0.000021039938,0.000081146805,0.000023661234,0.00028329215,6.121215e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037919186,0.000181609,0.6589583,0.0015588538,0.00006774271,0.000081964805,0.004397928,0.0014884226,0.3193014,0.0000060054153,0.010444247,0.003134339],"study_design_scores_gemma":[0.006219932,0.000045614895,0.37452173,0.0056735906,0.00042907844,0.000006395551,0.0015132425,0.00042239093,0.6101193,0.0001998868,0.00053366966,0.00031518086],"about_ca_topic_score_codex":0.0014239748,"about_ca_topic_score_gemma":0.001422705,"teacher_disagreement_score":0.29081792,"about_ca_system_score_codex":0.001444712,"about_ca_system_score_gemma":0.0006934066,"threshold_uncertainty_score":0.5862309},"labels":[],"label_agreement":null},{"id":"W4406932867","doi":"10.3390/curroncol32020075","title":"Oligometastatic NSCLC: Current Perspectives and Future Challenges","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Disease; Clinical trial; Intensive care medicine; Multidisciplinary approach; Medical physics; Oncology; Internal medicine","score_opus":0.13971459430012853,"score_gpt":0.5199513401859603,"score_spread":0.3802367458858318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406932867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014106249,0.9863284,0.000013333686,0.0013570284,0.0031671165,0.0014620763,0.00011247338,0.000058477344,0.0074996767],"genre_scores_gemma":[0.0000023611467,0.9972738,0.00012814786,0.000013989291,0.0013640459,0.0006000136,0.00026131936,0.000028505234,0.0003278438],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838406,0.00017347046,0.00040415346,0.0006060098,0.00014495102,0.00028734474],"domain_scores_gemma":[0.9989216,0.00023308813,0.0002239519,0.00031859253,0.00013050942,0.00017228407],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010302683,0.00042420297,0.0018920717,0.00039980464,0.00008635723,0.000014342983,0.00009789844,0.00020925164,0.00009319462],"category_scores_gemma":[0.000058352452,0.00029598418,0.00033478823,0.00024310424,0.00013324176,0.000037338385,0.00008731071,0.00058063585,0.00003571938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008344231,0.0006389263,0.000003462904,0.04401919,0.0005280547,0.000017857086,0.0012405863,4.9672564e-9,4.7109756e-9,0.0037600643,0.0017647421,0.9480188],"study_design_scores_gemma":[0.00093893433,0.000323225,0.00004159756,0.013736775,0.0077267857,0.00010001569,0.0010513295,4.0994703e-7,1.476017e-8,0.0001118828,0.9757693,0.0001997465],"about_ca_topic_score_codex":0.0000015234838,"about_ca_topic_score_gemma":0.0000055851933,"teacher_disagreement_score":0.97400457,"about_ca_system_score_codex":0.00069805543,"about_ca_system_score_gemma":0.0017253748,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W4407001040","doi":"10.1016/j.lungcan.2025.108412","title":"EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Health records; Electronic database; Retrospective cohort study; Electronic health record; Real world evidence; Medical record; Database; Internal medicine; Health care","score_opus":0.0344460277777888,"score_gpt":0.48366972175411665,"score_spread":0.44922369397632783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407001040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883146,0.0027365366,0.000062284445,0.0051543573,0.00011647268,0.0013857757,0.0001622871,0.00003995448,0.0015108504],"genre_scores_gemma":[0.9933328,0.0015561858,0.002382532,0.0009363362,0.00003102175,0.00039771188,0.00013020403,0.000017602966,0.0012156058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980854,0.00015173183,0.0006852026,0.0005442632,0.00016434243,0.0003690955],"domain_scores_gemma":[0.99785405,0.000978006,0.0006066616,0.00036046814,0.0001052956,0.00009552369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004246942,0.00019553398,0.00089811924,0.00073373463,0.00005620385,0.000012227215,0.00005271518,0.000051337665,0.000031186762],"category_scores_gemma":[0.0007515946,0.00014799455,0.00012403034,0.0025061176,0.00004668802,0.00011480842,0.000023269566,0.00025233225,2.2343214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002918675,0.0006962586,0.9739769,0.00012976672,0.0019508782,0.000011397226,0.00018413707,0.00029383152,0.000019929244,0.000076137796,0.000052705156,0.022316195],"study_design_scores_gemma":[0.0066400864,0.000547927,0.9778215,0.0006658723,0.0029771968,3.5345042e-7,0.00008424412,0.010249475,0.000017539964,0.000013142721,0.00087789673,0.00010473625],"about_ca_topic_score_codex":0.111749396,"about_ca_topic_score_gemma":0.4696345,"teacher_disagreement_score":0.3578851,"about_ca_system_score_codex":0.0041824295,"about_ca_system_score_gemma":0.0027732507,"threshold_uncertainty_score":0.99964035},"labels":[],"label_agreement":null},{"id":"W4407019124","doi":"10.2139/ssrn.5115348","title":"Characteristics and Outcomes of Hispanic Patients with Ret-Rearrangement Non-Small Lung Cancer (Nsclc) Treated in Real-World Practice","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Lung cancer; Medicine; Internal medicine; Oncology; Real world evidence","score_opus":0.008668458469439803,"score_gpt":0.32041413326995327,"score_spread":0.31174567480051346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407019124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127555,0.002966205,0.00019376053,0.0016593975,0.00025791046,0.0013660918,0.00015242773,0.000019315241,0.002109357],"genre_scores_gemma":[0.96380204,0.030418484,0.00030959316,0.00017440568,0.00008505339,0.00012776504,0.00020672435,0.00003900499,0.00483691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772835,0.00007877932,0.0005751781,0.0003627352,0.0003243095,0.0009306223],"domain_scores_gemma":[0.9984064,0.00009024412,0.0006830377,0.00029323882,0.00042611937,0.000100953905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040827043,0.00033232407,0.0007470972,0.00040280554,0.000073233095,0.000031229232,0.00011835235,0.00013181247,0.0000237293],"category_scores_gemma":[0.00006332863,0.00024306895,0.000098753764,0.00023390831,0.000041456333,0.00008294491,0.00009296495,0.0017994338,4.337575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008443797,0.000570085,0.9818176,0.00029600295,0.003206695,0.000019596444,0.00053742697,0.000019710946,0.000008285849,0.00058634573,0.000051636445,0.01204221],"study_design_scores_gemma":[0.0063743936,0.0006255518,0.9857692,0.0017950826,0.0041384604,0.000014607451,0.000262129,0.000086830674,0.000016105161,0.00027556377,0.0004027547,0.00023932492],"about_ca_topic_score_codex":0.0072302395,"about_ca_topic_score_gemma":0.015237796,"teacher_disagreement_score":0.027473474,"about_ca_system_score_codex":0.003709292,"about_ca_system_score_gemma":0.0052794735,"threshold_uncertainty_score":0.9993807},"labels":[],"label_agreement":null},{"id":"W4407340976","doi":"10.1016/j.jaci.2024.12.1054","title":"Pharmacokinetics and Pharmacodynamics of Twice-Yearly Depemokimab in the Randomized, Double-Blind, Placebo-Controlled Parallel Phase III ANCHOR-1/2 Trials","year":2025,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacodynamics; Placebo; Pharmacokinetics; Double blind; Medicine; Phase (matter); Pharmacology; Chemistry; Alternative medicine; Pathology","score_opus":0.0483485386380931,"score_gpt":0.45094516659706685,"score_spread":0.4025966279589738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407340976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716822,0.019215599,0.00095025415,0.004971279,0.000640323,0.0012883601,0.0000048940733,0.0000045797274,0.0012425312],"genre_scores_gemma":[0.94935143,0.048843537,0.00047411746,0.00083103863,0.00015295732,0.000043761007,0.0000062327254,0.000007935914,0.00028899516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964271,0.000920408,0.0021825717,0.00015427839,0.00014696254,0.00016867249],"domain_scores_gemma":[0.9948359,0.0037827669,0.00096380844,0.00013870477,0.00021359674,0.000065223365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037922848,0.00016065821,0.001986916,0.00021522692,0.000055091077,0.000019427962,0.00013356494,0.0001823778,0.000050429535],"category_scores_gemma":[0.00069312827,0.00008853411,0.00042229798,0.00015394078,0.00038880704,0.00007686277,0.000036182133,0.0005777687,4.654125e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9646156,0.001568628,0.00034685218,0.000017985616,0.012765539,0.000077378834,0.00037355575,0.000022888256,0.00046200296,0.0012627629,0.00022195026,0.018264888],"study_design_scores_gemma":[0.9897904,0.0013600306,0.0008024725,0.00011474724,0.004032674,0.000113346476,0.0005115789,0.0006929257,0.000057804697,0.0006168682,0.0018370966,0.00007006518],"about_ca_topic_score_codex":0.00003349181,"about_ca_topic_score_gemma":0.000022239396,"teacher_disagreement_score":0.029627938,"about_ca_system_score_codex":0.00002697626,"about_ca_system_score_gemma":0.0002909077,"threshold_uncertainty_score":0.36103162},"labels":[],"label_agreement":null},{"id":"W4407406090","doi":"10.3390/curroncol32020105","title":"Abstracts of the 2024 Canadian Association of Medical Oncologists Annual Scientific Meeting","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Medical Association","funders":"EMD Serono; Merck Canada; Amgen; Siemens Healthineers; Bristol-Myers Squibb Canada; Eisai; Pfizer; Incyte; Eli Lilly Canada; Varian Medical Systems; Ipsen Biopharmaceuticals; Bayer Canada; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Illumina; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; Novocure; AstraZeneca; Pfizer Canada; Amgen Canada; Ipsen; AbbVie Canada; Provincial Health Services Authority; BeiGene; GlaxoSmithKline; Apotex","keywords":"Medicine; Family medicine; Library science","score_opus":0.03937231224790707,"score_gpt":0.4424284691026565,"score_spread":0.40305615685474944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87416357,0.0015662297,0.000009132306,0.024641413,0.010165977,0.00055213016,0.00014753573,0.0000133818385,0.08874063],"genre_scores_gemma":[0.99637383,0.00004444182,0.000035423644,0.00013502501,0.0000683193,0.000016928296,0.000024649406,0.0000029316484,0.0032984512],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900335,0.000066771994,0.0003029124,0.0001332516,0.00032522014,0.00016847755],"domain_scores_gemma":[0.9990929,0.00017134991,0.00019798875,0.0001419186,0.00029504125,0.00010079512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006632843,0.000056636592,0.0002037355,0.00013771054,0.00009059728,0.000004917443,0.00012347789,0.00014409267,0.0001463974],"category_scores_gemma":[0.001079187,0.00003869296,0.00006985716,0.00033686758,0.00015341312,0.000021025404,0.000040859035,0.00018319275,0.0000047702065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037972313,0.001038726,0.64186317,0.000317772,0.00036179376,0.000014355745,0.0022966126,0.000033800676,0.00024188992,0.0032165246,0.21150261,0.13907477],"study_design_scores_gemma":[0.0013704596,0.00011953199,0.3333487,0.00034716236,0.00034074165,0.0000036646422,0.000557026,0.00006727492,0.00048472598,0.0001742572,0.6631479,0.000038503727],"about_ca_topic_score_codex":0.00712978,"about_ca_topic_score_gemma":0.08594514,"teacher_disagreement_score":0.45164534,"about_ca_system_score_codex":0.0012706205,"about_ca_system_score_gemma":0.0059843897,"threshold_uncertainty_score":0.9996508},"labels":[],"label_agreement":null},{"id":"W4407607529","doi":"10.1016/j.lungcan.2025.108452","title":"Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mutation; Lung cancer; Oncology; Internal medicine; Lung; Cancer; Cancer research; Genetics; Gene; Biology","score_opus":0.002382273752439514,"score_gpt":0.26599251725522083,"score_spread":0.26361024350278134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407607529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912849,0.002405786,0.0009878257,0.00012437314,0.00010281221,0.003009709,0.00020693969,0.000026025204,0.0018516169],"genre_scores_gemma":[0.9961599,0.000114612056,0.00040867488,0.0001080973,0.000023096374,0.0015649594,0.00025560838,0.000026611877,0.0013384374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904287,0.000025381349,0.00019114366,0.0003268328,0.00019222382,0.00022152154],"domain_scores_gemma":[0.9992811,0.000115080926,0.00012108214,0.00015755858,0.00024849633,0.00007664586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023386598,0.00019452457,0.00031071887,0.000194558,0.00008311821,0.000015860165,0.000039721417,0.000062621315,0.000029609158],"category_scores_gemma":[0.000013217922,0.00013999858,0.000025648775,0.00044217586,0.00008217433,0.00014959632,0.000013491878,0.00011426424,3.9380947e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005852144,0.0003554725,0.99050623,0.001629436,0.00057026424,0.000023738601,0.0027809201,0.0017678157,0.00006849393,0.000014536607,0.0003992913,0.0012986062],"study_design_scores_gemma":[0.011591042,0.00061717763,0.9770827,0.0027879043,0.0029422902,9.145903e-7,0.00019871184,0.0022765594,0.002308786,0.000007650928,0.00004554845,0.00014067255],"about_ca_topic_score_codex":0.00137191,"about_ca_topic_score_gemma":0.0008656167,"teacher_disagreement_score":0.013423469,"about_ca_system_score_codex":0.00048198132,"about_ca_system_score_gemma":0.0006700148,"threshold_uncertainty_score":0.57089764},"labels":[],"label_agreement":null},{"id":"W4407621799","doi":"10.1016/j.ijgc.2024.100497","title":"TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Open label; Second line treatment; Surgery; Randomized controlled trial; Overall survival","score_opus":0.10189097653742804,"score_gpt":0.4888273389316147,"score_spread":0.3869363623941866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407621799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98379636,0.0025211195,0.00052188744,0.0039629512,0.0013656436,0.006874861,0.0004805764,0.000021378584,0.0004552338],"genre_scores_gemma":[0.99091405,0.0014838638,0.0008084716,0.00097250775,0.00046096425,0.002814406,0.00004745916,0.00003252311,0.002465737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972238,0.00019457637,0.0012754624,0.00044899064,0.0005076094,0.00034954245],"domain_scores_gemma":[0.9961181,0.0014123471,0.0010241899,0.00022046625,0.0010014476,0.00022342501],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018993675,0.00044738484,0.0019113503,0.0002814158,0.00014032588,0.00009085212,0.0004179686,0.00008450554,0.0021846853],"category_scores_gemma":[0.00023761558,0.0002594362,0.00047629976,0.0002136893,0.000079985155,0.00020965048,0.0000523709,0.00017496709,0.0000037021148],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4785421,0.052420966,0.0042031906,0.00007250157,0.028761815,0.00024885195,0.0021308518,0.0007823716,0.0015087632,0.00013366448,0.0004971169,0.43069783],"study_design_scores_gemma":[0.90060383,0.048998337,0.008032453,0.0004894707,0.0074877604,0.000028183198,0.0013270015,0.0047388813,0.0060174423,0.00023139072,0.021698143,0.00034709644],"about_ca_topic_score_codex":0.0010191917,"about_ca_topic_score_gemma":0.0050041485,"teacher_disagreement_score":0.43035072,"about_ca_system_score_codex":0.0042416607,"about_ca_system_score_gemma":0.0016171698,"threshold_uncertainty_score":0.9999858},"labels":[],"label_agreement":null},{"id":"W4407722585","doi":"10.1089/derm.2025.0041","title":"Osimertinib-Induced Lichenoid Drug Eruption: A Case Report","year":2025,"lang":"en","type":"letter","venue":"Dermatitis","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dermatology; Osimertinib; Drug eruption; Drug; Pharmacology; Internal medicine; Receptor","score_opus":0.018014421738830718,"score_gpt":0.3249485541040475,"score_spread":0.30693413236521677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407722585","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027362888,0.00048516737,0.00007700118,0.9397339,0.0010963542,0.00086632674,0.00018661025,0.00020080851,0.054617506],"genre_scores_gemma":[0.016511744,0.000048813235,0.00059774343,0.885476,0.0024987198,0.00036149018,0.0033419086,0.000052944302,0.09111067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983922,0.000050671333,0.0005192153,0.0004212455,0.0003195522,0.00029707377],"domain_scores_gemma":[0.99869454,0.00007936804,0.000233267,0.00071093335,0.00019254615,0.00008933378],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000057686604,0.0003083579,0.00050150126,0.00021816963,0.00016521978,0.000055403474,0.00007291975,0.00038297995,0.0006730412],"category_scores_gemma":[0.0000636466,0.00027638543,0.00022345148,0.00022201023,0.00003217717,0.00008189322,0.000040277853,0.00081342534,0.00018691726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[9.981983e-7,0.000027223447,0.00010610446,0.00031875342,0.00033836134,0.33450076,0.0003059384,1.4868647e-7,0.0000025918132,0.000005309486,0.6627151,0.0016787564],"study_design_scores_gemma":[0.00077623385,0.00003136833,0.00047408362,0.0004198489,0.0012456169,0.12355259,0.000047182926,0.000011449406,0.0001787457,0.000041441213,0.8730158,0.00020560897],"about_ca_topic_score_codex":0.0012893593,"about_ca_topic_score_gemma":0.00007303713,"teacher_disagreement_score":0.21094817,"about_ca_system_score_codex":0.00028491757,"about_ca_system_score_gemma":0.0005839925,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W4407728170","doi":"10.1136/bmjoq-2024-003001","title":"Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) Project","year":2025,"lang":"en","type":"article","venue":"BMJ Open Quality","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"AstraZeneca Canada","keywords":"Biomarker; Medicine; Turnaround time; Lung cancer; Cancer; Oncology; Internal medicine; Operations management","score_opus":0.09445107519890134,"score_gpt":0.4728844058171065,"score_spread":0.37843333061820517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407728170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98764515,0.001785595,0.0018475082,0.0006159114,0.000026448573,0.0068064686,0.00012900069,0.000030990188,0.0011129153],"genre_scores_gemma":[0.96541446,0.00002922095,0.03272953,0.00032742386,0.000010704353,0.0010758603,0.0001426224,0.000025124174,0.0002450689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866754,0.00016617752,0.00038305274,0.00035742152,0.00016682701,0.00025897386],"domain_scores_gemma":[0.99825495,0.0004516961,0.00037433163,0.00036177912,0.000494366,0.00006285377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042854494,0.00018009733,0.00036697404,0.00003840651,0.0005445443,0.00021607701,0.00011452333,0.000049023234,0.000004095097],"category_scores_gemma":[0.0005762816,0.00012250489,0.000027930331,0.00026565997,0.00014415331,0.00030254593,0.00015680325,0.00010645319,3.4485584e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011155885,0.0002280852,0.67335236,0.000755508,0.00045253115,0.0000034596394,0.0023126022,0.0000808689,0.000661277,0.0002032706,0.00014703262,0.32068744],"study_design_scores_gemma":[0.009309139,0.00015628854,0.9750178,0.0024185062,0.0009586312,0.0000060299108,0.0024219973,0.008343311,0.0004013672,0.0003085156,0.00035366206,0.0003047443],"about_ca_topic_score_codex":0.0062276684,"about_ca_topic_score_gemma":0.0009068849,"teacher_disagreement_score":0.32038268,"about_ca_system_score_codex":0.00017057023,"about_ca_system_score_gemma":0.0009687118,"threshold_uncertainty_score":0.9414413},"labels":[],"label_agreement":null},{"id":"W4407781655","doi":"10.1016/j.canep.2025.102774","title":"Age-specific lung cancer incidence trends in Canada from 1992 to 2022","year":2025,"lang":"en","type":"article","venue":"Cancer Epidemiology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Alberta Cancer Foundation; University of Calgary","funders":"Canadian Cancer Society","keywords":"Medicine; Incidence (geometry); Lung cancer; Cancer; Demography; Oncology; Internal medicine","score_opus":0.039081336767464205,"score_gpt":0.4121209593337929,"score_spread":0.37303962256632867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407781655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7303843,0.120573714,0.0011257526,0.13351096,0.0055026063,0.0009380491,0.00092909345,0.00007469203,0.0069608437],"genre_scores_gemma":[0.96105295,0.0027715017,0.0006577929,0.027110958,0.00036683455,0.0011414789,0.00020944282,0.000022772103,0.006666247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818677,0.00014391799,0.00051317393,0.00056787493,0.00010255752,0.00048573784],"domain_scores_gemma":[0.99874836,0.0005216518,0.000095833195,0.0003873413,0.000045320023,0.00020148355],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018366284,0.0001997831,0.0007174139,0.00024725843,0.00006636974,0.000003842347,0.00015417777,0.0000965311,0.0021204872],"category_scores_gemma":[0.0001381786,0.00017382085,0.00006982578,0.00067698193,0.000051720617,0.00003973854,0.000062813604,0.0002627273,0.0000060713733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010160363,0.000019812156,0.6548277,0.000024155457,0.00016770208,0.00009892425,0.00018863214,0.0015141289,0.00018977065,0.0003599149,0.2894725,0.053035174],"study_design_scores_gemma":[0.0010436876,0.000027642516,0.7322657,0.00027593112,0.00012935634,0.0000012940353,0.00010121052,0.00044879946,0.000109220346,0.00034699228,0.2651059,0.00014423812],"about_ca_topic_score_codex":0.9823954,"about_ca_topic_score_gemma":0.9882084,"teacher_disagreement_score":0.2306687,"about_ca_system_score_codex":0.005261858,"about_ca_system_score_gemma":0.0025676782,"threshold_uncertainty_score":0.9987917},"labels":[],"label_agreement":null},{"id":"W4407856069","doi":"10.1016/j.lungcan.2025.108441","title":"Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]","year":2025,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Anaplastic lymphoma kinase; Cancer research; ALK inhibitor; Tyrosine kinase; Tyrosine-kinase inhibitor; Kinase; Oncology; Internal medicine; Cancer; Genetics; Biology","score_opus":0.01313441767526678,"score_gpt":0.32763194866333406,"score_spread":0.31449753098806726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407856069","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42077702,0.36238635,0.0021136033,0.002272842,0.10700576,0.040471096,0.02663476,0.0003622592,0.03797633],"genre_scores_gemma":[0.23577559,0.043189697,0.00156484,0.0011941901,0.0056987307,0.027543664,0.004816278,0.00046949016,0.6797475],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964253,0.00012782919,0.0007825213,0.0015014806,0.0003853336,0.00077753514],"domain_scores_gemma":[0.997541,0.00021076058,0.00057279255,0.00053045363,0.00071392674,0.00043105616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020224533,0.0010322982,0.0017104881,0.000600359,0.00040452092,0.000089730165,0.00013627483,0.00046379925,0.00015491244],"category_scores_gemma":[0.00002658094,0.00091293216,0.00028007242,0.0006747323,0.00011305279,0.0002125474,0.00010939251,0.00046599726,4.6756975e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003551069,0.000604429,0.06378875,0.04004525,0.009526702,0.00016607327,0.009018812,0.004426174,0.084048524,0.0001956722,0.7616221,0.023006493],"study_design_scores_gemma":[0.053509682,0.005766353,0.09487419,0.08587744,0.061655227,0.000033135057,0.0014137436,0.047485884,0.41324964,0.00007154066,0.22980317,0.0062599783],"about_ca_topic_score_codex":0.046810348,"about_ca_topic_score_gemma":0.08569126,"teacher_disagreement_score":0.6417712,"about_ca_system_score_codex":0.009830162,"about_ca_system_score_gemma":0.005527881,"threshold_uncertainty_score":0.99933213},"labels":[],"label_agreement":null},{"id":"W4408014791","doi":"10.1200/jco-24-02786","title":"Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Lung cancer; Clinical Practice; Family medicine; Clinical Oncology; Medical physics; Cancer; Oncology; Pathology; Internal medicine","score_opus":0.06068914633941983,"score_gpt":0.5161611105901931,"score_spread":0.45547196425077324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408014791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8880065,0.0070239417,0.034987632,0.040011637,0.008898166,0.0019245024,0.00005584371,0.000024870898,0.019066906],"genre_scores_gemma":[0.80429137,0.010531954,0.062339164,0.024351198,0.0034519928,0.00013855739,0.00002705986,0.000050425624,0.09481827],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787176,0.00011500388,0.0015025123,0.00018010744,0.00015603878,0.00017457081],"domain_scores_gemma":[0.9967517,0.0013118772,0.000831295,0.00015217144,0.00079019764,0.00016272494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010924515,0.00012178251,0.0007672414,0.00013591316,0.000116974814,0.000015905498,0.00010654242,0.00021233156,0.000500592],"category_scores_gemma":[0.00066209125,0.00008351452,0.00038717536,0.0001399432,0.000052787043,0.000104320054,0.000027302383,0.00038401465,0.000004739671],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003483023,0.0029488977,0.46986756,0.00016524162,0.0021377641,0.00009347569,0.0006337386,0.0008288147,0.0007306793,0.00015267248,0.38122365,0.13773447],"study_design_scores_gemma":[0.017350782,0.0049057323,0.09776105,0.0004977024,0.001633835,0.000009472075,0.00029986037,0.0045052357,0.00021482035,0.00008487898,0.8726202,0.00011641562],"about_ca_topic_score_codex":0.00006746773,"about_ca_topic_score_gemma":0.00009059136,"teacher_disagreement_score":0.49139658,"about_ca_system_score_codex":0.00032518012,"about_ca_system_score_gemma":0.003772428,"threshold_uncertainty_score":0.6692125},"labels":[],"label_agreement":null},{"id":"W4408039612","doi":"10.21037/tcr-24-1633","title":"The TROP2 paradox: enhancing precision in immunotherapy for advanced non-small cell lung cancer patients—a commentary","year":2025,"lang":"en","type":"letter","venue":"Translational Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Oncology; Cancer; Cancer research; Intensive care medicine; Internal medicine","score_opus":0.030881961521577385,"score_gpt":0.4214709577133293,"score_spread":0.3905889961917519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408039612","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023464624,0.028127719,0.0010967948,0.9301538,0.00096299074,0.011822813,0.0021866765,0.000036521764,0.0021480736],"genre_scores_gemma":[0.094402336,0.03505514,0.00534215,0.73723227,0.008525843,0.067064725,0.01932462,0.00053122634,0.032521717],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640846,0.00023991273,0.00062452356,0.0006420318,0.0012873912,0.0007976716],"domain_scores_gemma":[0.99674565,0.0019724758,0.00012325896,0.00042982656,0.0006658741,0.00006289841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063631823,0.00034985563,0.00048021204,0.00043636854,0.0005679766,0.0000888569,0.00039956742,0.00034772334,0.00018014872],"category_scores_gemma":[0.000022074966,0.0002584744,0.00025329032,0.00056794443,0.00009681316,0.000112691574,0.000022239592,0.0016696918,0.0000030550043],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021511929,0.0004185402,0.010193038,0.0015109774,0.00049151067,0.000026106489,0.0024920513,0.000232105,0.00036798418,0.000022364587,0.9354,0.04669411],"study_design_scores_gemma":[0.012297586,0.0005179977,0.010949639,0.0017672817,0.00029427418,7.4614843e-7,0.00014005387,0.00037812503,0.0009857792,0.00048167218,0.97183615,0.00035067077],"about_ca_topic_score_codex":0.0020541174,"about_ca_topic_score_gemma":0.0020654607,"teacher_disagreement_score":0.19292153,"about_ca_system_score_codex":0.0012304616,"about_ca_system_score_gemma":0.0018756692,"threshold_uncertainty_score":0.99998677},"labels":[],"label_agreement":null},{"id":"W4408051654","doi":"10.1016/j.jtocrr.2025.100816","title":"Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; Winship Cancer Institute; International Association for the Study of Lung Cancer","keywords":"Oncology; Medicine; Biomarker discovery; Biomarker; Internal medicine; Medical physics; Biology; Proteomics","score_opus":0.2424729015559155,"score_gpt":0.6030156848792918,"score_spread":0.3605427833233763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408051654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807763,0.00008517012,0.000034199602,0.0004373445,0.000076619304,0.0009838474,0.00025527383,0.0000014891518,0.000048438982],"genre_scores_gemma":[0.99882764,0.0005669421,0.00023337221,0.000020651118,0.000028666856,0.00008151238,0.00008983356,0.000004092933,0.00014731023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978473,0.00020673746,0.0011169427,0.0003241394,0.00039761758,0.00010725976],"domain_scores_gemma":[0.9945949,0.0033436841,0.0008139013,0.00034943462,0.0008500821,0.000048049023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027940094,0.00006471761,0.0006624176,0.00012148855,0.00003725152,0.0000061440437,0.00007231515,0.00005603252,0.0000029937305],"category_scores_gemma":[0.0015517907,0.000034496043,0.0000891309,0.000478815,0.00025822764,0.00007693419,0.000107001564,0.00011397996,1.7903525e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077255006,0.0032768762,0.90114343,0.000057193116,0.0062496457,0.000002517215,0.0002992372,0.000026224072,0.000004781686,0.000002101761,0.000051844552,0.08811362],"study_design_scores_gemma":[0.003518759,0.003349532,0.9852848,0.0001117549,0.0021811344,1.4240237e-7,0.00089531246,0.004501976,0.0000041864782,0.000005410823,0.000120409066,0.000026573642],"about_ca_topic_score_codex":0.026733106,"about_ca_topic_score_gemma":0.010175383,"teacher_disagreement_score":0.088087045,"about_ca_system_score_codex":0.00018258719,"about_ca_system_score_gemma":0.0009839657,"threshold_uncertainty_score":0.97974795},"labels":[],"label_agreement":null},{"id":"W4408064743","doi":"10.1016/j.lungcan.2025.108309","title":"200 Stage shift in lung cancers found during a screening study: Early detection is only half the battle","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Stage (stratigraphy); Battle; Oncology; Internal medicine; Ancient history; History","score_opus":0.011095965016378002,"score_gpt":0.34747468509005724,"score_spread":0.33637872007367925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408064743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895851,0.0032116259,0.0006553667,0.0018570325,0.000848154,0.00128322,0.000032246324,0.000066803026,0.0024604602],"genre_scores_gemma":[0.9897301,0.000084695486,0.000041656986,0.00043409906,0.0001692053,0.00052043557,0.0000045440447,0.0000273154,0.008987954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987522,0.000045531397,0.00025638053,0.00036602747,0.00025015356,0.0003297564],"domain_scores_gemma":[0.99938226,0.00008285979,0.00007658073,0.00033389594,0.00005959126,0.00006478775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011461338,0.00018244423,0.00024199618,0.00018263947,0.00028251536,0.00006436435,0.00010155354,0.000061741885,0.00030054693],"category_scores_gemma":[0.00002668811,0.00013874428,0.000076459764,0.00059290254,0.00004339479,0.000150519,0.000045242177,0.00026778982,0.0000040555947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038640917,0.00012989405,0.9798746,0.00021792679,0.0009494249,0.000053571446,0.009433311,0.0010183166,0.00027065448,0.00006625286,0.0007269929,0.0068726134],"study_design_scores_gemma":[0.004226248,0.00010074035,0.9869807,0.0004675665,0.000686984,0.0000024876808,0.0017925045,0.0015137086,0.000501676,0.00001297014,0.0035588183,0.00015560427],"about_ca_topic_score_codex":0.05295892,"about_ca_topic_score_gemma":0.050911024,"teacher_disagreement_score":0.007640807,"about_ca_system_score_codex":0.0017507955,"about_ca_system_score_gemma":0.0005897158,"threshold_uncertainty_score":0.96640736},"labels":[],"label_agreement":null},{"id":"W4408085490","doi":"10.18103/mra.v13i2.6109","title":"Burkitt Lymphoma – A Model of Cancer Chemotherapy","year":2025,"lang":"en","type":"article","venue":"Medical Research Archives","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"","keywords":"Lymphoma; Medicine; Cancer; Chemotherapy; Cancer chemotherapy; Oncology; Internal medicine; Cancer research","score_opus":0.04038776920883182,"score_gpt":0.47577480293146407,"score_spread":0.43538703372263227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408085490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6755921,0.0094884625,0.0102483,0.0677399,0.00014819381,0.0011747055,0.00005711311,0.00007504329,0.23547614],"genre_scores_gemma":[0.96928227,0.0051183165,0.001417425,0.00095484615,0.000079133926,0.0002185675,0.000012914137,0.000013200715,0.022903306],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99841094,0.00006725485,0.0001837712,0.00020090185,0.00082821527,0.00030891356],"domain_scores_gemma":[0.99899566,0.0004043322,0.000018651654,0.00023504764,0.0000871896,0.00025913373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000260616,0.00007458827,0.00021177476,0.00026602997,0.000085454194,0.000006825043,0.00015498235,0.00005095918,0.00045760855],"category_scores_gemma":[0.000482054,0.000051990708,0.00007660439,0.00031998576,0.0005223636,0.000021210479,0.00007216359,0.0001760299,0.0000057274265],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048673953,0.00065077096,0.0100338245,0.0002489699,0.00039049832,0.000024656763,0.0012521278,0.00001803671,0.004946206,0.008615166,0.0057619223,0.9675711],"study_design_scores_gemma":[0.036538046,0.0016748311,0.20185924,0.0069673727,0.00044680116,0.000018379147,0.0015344538,0.29659843,0.07130218,0.111442275,0.27112755,0.0004904134],"about_ca_topic_score_codex":0.00044477353,"about_ca_topic_score_gemma":0.0000652066,"teacher_disagreement_score":0.96708065,"about_ca_system_score_codex":0.00007268156,"about_ca_system_score_gemma":0.0026799454,"threshold_uncertainty_score":0.5010493},"labels":[],"label_agreement":null},{"id":"W4408091797","doi":"10.2196/65118","title":"Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gefitinib; Erlotinib; Aotearoa; Epidermal growth factor receptor; Medicine; Oncology; Lung cancer; Internal medicine; Population; Cancer; Environmental health; Political science","score_opus":0.009103397577824251,"score_gpt":0.32255082608513996,"score_spread":0.3134474285073157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408091797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98947763,0.00062665483,0.000011734739,0.001997973,0.00059468136,0.0057847355,0.0013338559,0.000038902544,0.00013381471],"genre_scores_gemma":[0.99120176,0.00018455836,0.0005336198,0.00020315558,0.000083718456,0.0021701383,0.00042821403,0.000037385365,0.005157424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979689,0.0000762108,0.00064690114,0.0007130621,0.00028086774,0.00031405917],"domain_scores_gemma":[0.9990029,0.00016353205,0.00023313938,0.00027644282,0.0001558333,0.000168162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000044182332,0.00034649507,0.0008232817,0.00030734934,0.000058301615,0.000026169533,0.00007357633,0.00012549532,0.00031998448],"category_scores_gemma":[0.000053272994,0.00029401213,0.000080208716,0.000572531,0.000023339473,0.00015337841,0.00004389285,0.00019273833,0.0000046384507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059743784,0.00071478286,0.9788693,0.000024543077,0.0004117839,0.000018941675,0.010219691,0.00063286326,0.0009650972,0.0000011583932,0.00077292847,0.0067714746],"study_design_scores_gemma":[0.011365316,0.00042845035,0.98505616,0.00030257544,0.00037885134,2.309262e-7,0.00061770726,0.00024377283,0.0011356648,0.00006007952,0.00017965186,0.00023152052],"about_ca_topic_score_codex":0.23678002,"about_ca_topic_score_gemma":0.06837569,"teacher_disagreement_score":0.16840433,"about_ca_system_score_codex":0.0018456678,"about_ca_system_score_gemma":0.000468926,"threshold_uncertainty_score":0.9999512},"labels":[],"label_agreement":null},{"id":"W4408098673","doi":"10.2139/ssrn.5159364","title":"Progress in Cancer Therapeutics: Is There an Upper Limit on the Maximum Effect that Can Be Detected in Randomized Trials","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Randomized controlled trial; Limit (mathematics); Cancer; Medicine; Internal medicine; Mathematics; Mathematical analysis","score_opus":0.042124412377576075,"score_gpt":0.38763034371939287,"score_spread":0.3455059313418168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408098673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88564897,0.0665924,0.000048182595,0.039925564,0.00077008695,0.006200739,0.00010422099,0.000049211445,0.00066060055],"genre_scores_gemma":[0.9615131,0.03373979,0.000022074672,0.0014804933,0.00028657028,0.0016434927,0.00004550719,0.00005210082,0.0012168767],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99414825,0.0025504855,0.0008232908,0.0004859355,0.00048708072,0.0015049481],"domain_scores_gemma":[0.9975632,0.0011500999,0.00056715915,0.0005108438,0.000120514014,0.000088186294],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0068947156,0.00050239294,0.0019136422,0.0004561048,0.00013968447,0.000111101144,0.00035440008,0.00036340184,0.00015624125],"category_scores_gemma":[0.0002257349,0.00026229394,0.0006152281,0.00028968317,0.00011026125,0.000048725127,0.00006670972,0.0045126653,0.0000017486294],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.19405529,0.0020565959,0.10843607,0.0005134034,0.024796434,0.00014989177,0.0127475755,0.00030356777,0.00009342678,0.0068619708,0.0002291694,0.6497566],"study_design_scores_gemma":[0.73749804,0.0055581112,0.025715388,0.011447901,0.017715776,0.00026000838,0.0064294077,0.0017076001,0.0055702,0.18289058,0.0033895078,0.0018174641],"about_ca_topic_score_codex":0.0020731797,"about_ca_topic_score_gemma":0.014850483,"teacher_disagreement_score":0.64793915,"about_ca_system_score_codex":0.003931143,"about_ca_system_score_gemma":0.009228734,"threshold_uncertainty_score":0.99998295},"labels":[],"label_agreement":null},{"id":"W4408120720","doi":"10.3390/curroncol32030146","title":"Lung Cancer: Targeted Therapy in 2025","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Santé Montérégie; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; KRAS; Lung cancer; Targeted therapy; ROS1; Cancer research; Mutation; Cancer; Oncology; Lung; Colorectal cancer; Internal medicine; Bioinformatics; Adenocarcinoma; Gene; Biology; Genetics","score_opus":0.12248327390680631,"score_gpt":0.554714250862028,"score_spread":0.43223097695522167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408120720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000065077743,0.9881935,0.000008871444,0.0003096587,0.0032168871,0.002118927,0.00011672558,0.000040387262,0.0059884936],"genre_scores_gemma":[0.0000033430888,0.9942286,0.00004134994,0.00010283045,0.00032538635,0.0020341496,0.0006846089,0.000023038683,0.0025566798],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986076,0.00013431197,0.0004800871,0.0003936785,0.00010254356,0.00028179103],"domain_scores_gemma":[0.99923056,0.00016694218,0.00018210619,0.00026274432,0.000073397096,0.00008423031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008211507,0.0003003476,0.0017129262,0.0003938352,0.000037933693,0.0000067712235,0.000118224125,0.00028822996,0.00048420194],"category_scores_gemma":[0.000038641454,0.0002156559,0.00030790182,0.000540242,0.000040721763,0.000021946094,0.000039744467,0.0004888924,0.000023425733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001626831,0.00045308075,0.0006721066,0.012595195,0.00038507156,0.000034202923,0.00009636603,2.659864e-7,3.5338257e-8,0.00006871267,0.019642046,0.9660367],"study_design_scores_gemma":[0.0016908064,0.0001608913,0.000118984084,0.018525153,0.0018342042,0.000007441535,0.000008689137,0.000005581657,1.6859936e-7,0.000012014856,0.9774939,0.00014216463],"about_ca_topic_score_codex":0.000084218926,"about_ca_topic_score_gemma":0.00007177257,"teacher_disagreement_score":0.96589446,"about_ca_system_score_codex":0.0018973668,"about_ca_system_score_gemma":0.0053725103,"threshold_uncertainty_score":0.95306027},"labels":[],"label_agreement":null},{"id":"W4408140353","doi":"10.1093/oncolo/oyae347","title":"Real-world characteristics and outcomes of <i>ERBB2-</i> mutant NSCLC in Latin American patients (CLICaP)","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Latin Americans; Mutant; Oncology; Internal medicine; Medicine; Biology; Political science; Genetics; Gene","score_opus":0.019686864164362487,"score_gpt":0.3584937315319411,"score_spread":0.3388068673675786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408140353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845872,0.000058880436,0.000004612013,0.0031161453,0.0001451606,0.00033821937,0.000077674595,0.000034257795,0.011637852],"genre_scores_gemma":[0.99761087,0.00020062827,0.00019229882,0.0003634379,0.000034128698,0.000034376444,0.000036406,0.000011521018,0.0015163488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938744,0.000029035993,0.0002255346,0.00013442225,0.00010363315,0.000119959936],"domain_scores_gemma":[0.9995013,0.00020171753,0.000074333584,0.00015430435,0.000028298551,0.000040076116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009084872,0.000087830165,0.0002743273,0.000068866975,0.0000311583,0.000012553989,0.000045125387,0.000019434721,0.0000276621],"category_scores_gemma":[0.00005644792,0.000048473954,0.000036212834,0.00023864798,0.00024083117,0.000021938316,0.00003165414,0.00010181898,0.0000059061576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067087225,0.00023566841,0.9468202,0.00004745992,0.0000976361,0.000033462085,0.00084801443,5.7803607e-7,0.00022266166,0.0010759651,0.0004005106,0.05015078],"study_design_scores_gemma":[0.00064911065,0.00034205,0.9924736,0.00007421027,0.00016394444,0.0000012630406,0.00015600077,0.000066804954,0.00007767688,0.000082196995,0.005863009,0.000050110408],"about_ca_topic_score_codex":0.0018143251,"about_ca_topic_score_gemma":0.0008004475,"teacher_disagreement_score":0.05010067,"about_ca_system_score_codex":0.0001438028,"about_ca_system_score_gemma":0.00009139609,"threshold_uncertainty_score":0.2742729},"labels":[],"label_agreement":null},{"id":"W4408156064","doi":"10.3390/curroncol32030148","title":"First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Internal medicine; Oncology; Cohort; Retrospective cohort study; Missense mutation; Targeted therapy; Combination therapy; Mutation; Cancer; Gene; Genetics","score_opus":0.03635438079926965,"score_gpt":0.4495554314770668,"score_spread":0.4132010506777971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408156064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91611534,0.004841524,0.042499263,0.012933385,0.0028817388,0.006993465,0.00018999002,0.00027895084,0.013266338],"genre_scores_gemma":[0.9942871,0.0009857087,0.0005659968,0.00028945415,0.000071823946,0.0011990275,0.00096912024,0.000013613288,0.0016181989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899644,0.000037337708,0.0002863482,0.00035416926,0.000119516255,0.00020616407],"domain_scores_gemma":[0.99897087,0.00013843412,0.00013307387,0.00021436765,0.0004796197,0.000063632324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013728363,0.00014819638,0.0005160463,0.0003046248,0.00014229472,0.000010047633,0.000060758062,0.00009162218,0.000105614476],"category_scores_gemma":[0.00012190704,0.00012321261,0.0002089026,0.0008732402,0.00006391879,0.000048278314,0.000015673446,0.00012376215,0.000006433817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016067935,0.004077485,0.74849844,0.0001011893,0.0058053834,0.000007088628,0.00066674646,0.0002726633,0.00013149844,0.0062093274,0.003766845,0.22885656],"study_design_scores_gemma":[0.016843451,0.0022266414,0.7987287,0.00008230894,0.004065264,0.0000020390282,0.00010748666,0.0040530916,0.00042057206,0.002316369,0.17100294,0.00015113957],"about_ca_topic_score_codex":0.000031344694,"about_ca_topic_score_gemma":0.00011936668,"teacher_disagreement_score":0.22870544,"about_ca_system_score_codex":0.00092326844,"about_ca_system_score_gemma":0.00030438253,"threshold_uncertainty_score":0.5024464},"labels":[],"label_agreement":null},{"id":"W4408219747","doi":"10.3390/curroncol32030151","title":"Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Amgen","keywords":"Medicine; Health care; Lung cancer; Intensive care medicine; Resource (disambiguation); Cancer; Cancer treatment; Oncology; Internal medicine; Computer science; Economic growth","score_opus":0.09417792613514225,"score_gpt":0.4704176026045945,"score_spread":0.3762396764694522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408219747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91172236,0.038513035,0.000039140654,0.043876227,0.00034510024,0.0039866096,0.00026840132,0.000014557922,0.0012345627],"genre_scores_gemma":[0.96825355,0.028789653,0.000032868058,0.00094956724,0.00006426377,0.0014378673,0.00026125117,0.0000124217795,0.00019858105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984757,0.00031070903,0.00047564044,0.00032065605,0.00013456718,0.00028277506],"domain_scores_gemma":[0.99902874,0.00032894223,0.00016056218,0.00033642663,0.00008478229,0.000060562208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017277287,0.00021512796,0.00049715536,0.00024570702,0.00010948369,0.000010669238,0.000097036216,0.00005490281,0.00001440766],"category_scores_gemma":[0.00000974878,0.00011778041,0.00006811029,0.00051294686,0.000059439913,0.000021937485,0.0000178625,0.00012329317,6.052739e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017218126,0.0022430182,0.81459004,0.00071187556,0.00010049493,0.000049792136,0.013885164,0.00005657007,0.0000013605318,0.0002663143,0.00041101963,0.16751216],"study_design_scores_gemma":[0.010916475,0.0030617276,0.85943997,0.0008841135,0.0009799305,0.000012313321,0.004285778,0.00092887966,0.00009125346,0.000062389634,0.119204976,0.00013218129],"about_ca_topic_score_codex":0.024682844,"about_ca_topic_score_gemma":0.18318994,"teacher_disagreement_score":0.16737998,"about_ca_system_score_codex":0.0022429319,"about_ca_system_score_gemma":0.000786321,"threshold_uncertainty_score":0.9818119},"labels":[],"label_agreement":null},{"id":"W4408236824","doi":"10.1080/14796694.2025.2463318","title":"A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.004826428086192625,"score_gpt":0.321617607089152,"score_spread":0.3167911790029594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408236824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626304,0.0006248028,0.000018495397,0.007436786,0.0003548859,0.003042553,0.00018040431,0.0000149739235,0.0020640602],"genre_scores_gemma":[0.99630046,0.000058330977,0.00009249114,0.0026113666,0.00014898836,0.00028511885,0.00020541875,0.000020902757,0.00027693223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988009,0.0002064058,0.00036046238,0.0002751569,0.00016710105,0.00019001489],"domain_scores_gemma":[0.99781907,0.0014363457,0.0002502253,0.00035844778,0.000101566824,0.000034329936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016595141,0.0001857828,0.00045854846,0.00008314799,0.000065277134,0.000003815758,0.00015018292,0.000115562994,0.000025173982],"category_scores_gemma":[0.00010082446,0.00009458338,0.00005507966,0.0003631726,0.00007085109,0.000022280821,0.000031034644,0.00026308995,7.495493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11599864,0.0151146585,0.44727114,0.0010277131,0.005163094,0.00046605064,0.24461485,0.0020956814,0.005102632,0.00010491642,0.031198801,0.13184181],"study_design_scores_gemma":[0.104035005,0.007035037,0.86323214,0.0012261489,0.00089655846,5.2011245e-7,0.0082169585,0.00022338369,0.010731311,0.000014314608,0.0041859117,0.0002027013],"about_ca_topic_score_codex":0.0020371827,"about_ca_topic_score_gemma":0.005960903,"teacher_disagreement_score":0.415961,"about_ca_system_score_codex":0.00033564842,"about_ca_system_score_gemma":0.0005448405,"threshold_uncertainty_score":0.38569984},"labels":[],"label_agreement":null},{"id":"W4408272010","doi":"10.21203/rs.3.rs-5984691/v1","title":"Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: Results of a first-in-human Phase 1 trial","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Solid tumor; Conjugate; Medicine; Drug; Antibody-drug conjugate; Oncology; Phase (matter); Pharmacology; Internal medicine; Cancer; Immunology; Physics; Mathematics; Antibody; Monoclonal antibody","score_opus":0.03341631292622424,"score_gpt":0.4399543575598095,"score_spread":0.4065380446335852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408272010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853607,0.0002600641,0.00000824074,0.0008264551,0.00018089422,0.0076544243,0.0014773527,0.000039659164,0.004192236],"genre_scores_gemma":[0.99439293,0.00008932225,0.00021094872,0.000019847173,0.00009879658,0.0012491845,0.0024331165,0.000040531962,0.0014653475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583024,0.0003684062,0.0010736566,0.00092807936,0.0011096277,0.00069000636],"domain_scores_gemma":[0.9973748,0.00030544266,0.000308173,0.000995776,0.0008065091,0.00020935174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086644606,0.00036889574,0.0011056322,0.0013025948,0.000103108694,0.000044195833,0.00032804933,0.000207801,0.000054342614],"category_scores_gemma":[0.00062294217,0.0002971587,0.0001614057,0.00065256644,0.00022972797,0.00010494279,0.000412353,0.001347098,0.0000041727762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76276886,0.02983888,0.1378757,0.010788226,0.0014718779,0.0012367589,0.025852546,0.0019406175,0.00012879937,0.00025599432,0.0065387953,0.021302907],"study_design_scores_gemma":[0.8522963,0.016888507,0.07856411,0.04210231,0.0002832361,0.00000190784,0.002312447,0.0006698793,0.002052189,0.00089120294,0.0031974781,0.00074044673],"about_ca_topic_score_codex":0.0023820982,"about_ca_topic_score_gemma":0.00573048,"teacher_disagreement_score":0.089527406,"about_ca_system_score_codex":0.001356044,"about_ca_system_score_gemma":0.0013172358,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W4408272642","doi":"10.51199/vjsel.2024.4.5","title":"Ung thư phổi không tế bào nhỏ giai đoạn sớm kết quả điều trị phẫu thuật nội soi hỗ trợ (VATS) ở người cao tuổi và theo dõi trung hạn tại Bệnh viện Thống Nhất","year":2025,"lang":"vi","type":"article","venue":"Vietnam Journal of Endolaparoscopic Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stage (stratigraphy); Medicine; Term (time); Lung cancer; Oncology; Biology; Physics","score_opus":0.01645161403852595,"score_gpt":0.3390061821013813,"score_spread":0.3225545680628553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408272642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85273606,0.09524128,0.00075340737,0.005987303,0.02578007,0.0018170875,0.0002357692,0.00018888888,0.017260164],"genre_scores_gemma":[0.96728164,0.015479028,0.00040523888,0.0028518534,0.0036209254,0.00011361719,0.00009586838,0.00022510334,0.009926735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98948747,0.0010578102,0.004060411,0.0012778345,0.0019051475,0.0022113037],"domain_scores_gemma":[0.990403,0.0033595157,0.0025523761,0.001523577,0.0010428142,0.0011187281],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00295255,0.0015416496,0.0037820977,0.0018461263,0.0012835573,0.0005024901,0.0008863038,0.00074303016,0.0016113565],"category_scores_gemma":[0.0018567423,0.0012655193,0.0021506862,0.0019796344,0.00050690904,0.0012563126,0.00026133796,0.0021983413,0.00013790284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061518447,0.00882035,0.53397024,0.006317618,0.027162204,0.008652699,0.018969562,0.0008111791,0.05973278,0.0034753208,0.17565271,0.15028352],"study_design_scores_gemma":[0.058305312,0.0045694658,0.44238743,0.07136257,0.03739821,0.0035491947,0.027995069,0.0023622452,0.071303494,0.0047565936,0.2689621,0.0070483284],"about_ca_topic_score_codex":0.0004565866,"about_ca_topic_score_gemma":0.00016637197,"teacher_disagreement_score":0.14323519,"about_ca_system_score_codex":0.0016601153,"about_ca_system_score_gemma":0.005271257,"threshold_uncertainty_score":0.9997332},"labels":[],"label_agreement":null},{"id":"W4408457164","doi":"10.1080/14796694.2025.2475728","title":"The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Medicine; Real world evidence; Value (mathematics); Oncology; Internal medicine; Intensive care medicine","score_opus":0.024923823832679836,"score_gpt":0.41306330247154305,"score_spread":0.3881394786388632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408457164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005101315,0.9929569,0.0000041552403,0.00079048163,0.00052649894,0.003867035,0.00009470418,0.000014448374,0.0012356582],"genre_scores_gemma":[0.0007049539,0.99607056,0.000786667,0.00008251172,0.00015341376,0.00087604835,0.00036146736,0.000026840324,0.00093755824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839264,0.00019243333,0.0006652211,0.00031615084,0.00014657338,0.00028699863],"domain_scores_gemma":[0.9977563,0.0012093887,0.00056244084,0.00028057588,0.00014889208,0.000042393523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026067748,0.00024783183,0.0013224392,0.00030907473,0.00006902919,0.0000059008908,0.00016349794,0.00022763197,0.000021545384],"category_scores_gemma":[0.00016651112,0.00013451446,0.00021154877,0.0006456319,0.00007943953,0.000044448607,0.00003377417,0.00029070023,0.0000011024438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030244485,0.0002750803,0.012210861,0.0077401823,0.0005862633,0.000030910593,0.001014048,0.000002066697,2.434408e-7,0.0006343298,0.0009974582,0.9762061],"study_design_scores_gemma":[0.0025098156,0.00090864213,0.009112644,0.016396994,0.0016176593,0.0000027522103,0.0004711545,0.0000014047333,5.7343357e-7,0.000044576584,0.96880174,0.00013204754],"about_ca_topic_score_codex":0.00021155072,"about_ca_topic_score_gemma":0.0035394288,"teacher_disagreement_score":0.97607404,"about_ca_system_score_codex":0.0010800718,"about_ca_system_score_gemma":0.0032030956,"threshold_uncertainty_score":0.56821537},"labels":[],"label_agreement":null},{"id":"W4408459343","doi":"10.1177/17588359251323985","title":"Immunotherapy in advanced, <i>KRAS</i> G12C-mutant non-small-cell lung cancer: current strategies and future directions","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; Cancer research; Blockade; Lung cancer; Cancer; Mutation; Immunotherapy; Mutant; Selumetinib; Oncology; Internal medicine; Biology; Colorectal cancer; Receptor","score_opus":0.016739884954371346,"score_gpt":0.4375702361328022,"score_spread":0.4208303511784309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408459343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059139038,0.988282,0.00028424733,0.0010537454,0.0026240963,0.002461515,0.000046955698,0.000058794525,0.0051294775],"genre_scores_gemma":[0.000059294493,0.99555004,0.00037087052,0.0006590605,0.0005822223,0.0024170605,0.00009667712,0.000057164478,0.00020762082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968831,0.0003047944,0.0010774019,0.0007657463,0.00036662823,0.0006023603],"domain_scores_gemma":[0.9982765,0.000687314,0.00036369634,0.00038701558,0.00006951808,0.00021600879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033638856,0.00063998817,0.0026841841,0.0004814749,0.00010758287,0.000024496847,0.00028769713,0.0006567,0.00025144502],"category_scores_gemma":[0.00002274081,0.00045896013,0.0002562008,0.0009276437,0.0002957831,0.00020175628,0.00007595059,0.0015373591,0.0000037776758],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009261035,0.00069229916,0.00017672566,0.011896993,0.00023788254,0.00014709293,0.000547697,0.000004985942,9.0363244e-7,0.00042477302,0.000018944243,0.9857591],"study_design_scores_gemma":[0.0039822296,0.00032020343,0.000077071716,0.016786505,0.0011810038,0.000080521815,0.0006537507,0.000032376563,7.8416554e-7,0.0003095963,0.97623086,0.0003450794],"about_ca_topic_score_codex":0.000087087865,"about_ca_topic_score_gemma":0.00090606854,"teacher_disagreement_score":0.985414,"about_ca_system_score_codex":0.0013980039,"about_ca_system_score_gemma":0.006854212,"threshold_uncertainty_score":0.9997862},"labels":[],"label_agreement":null},{"id":"W4408551261","doi":"10.3390/curroncol32030174","title":"Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Exon; Lung cancer; Oncology; Cancer; Bioinformatics; Cancer research; Internal medicine; Computational biology; Genetics; Gene; Biology","score_opus":0.024756178992961914,"score_gpt":0.39438976761126765,"score_spread":0.36963358861830575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408551261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360764,0.0009812033,0.0006067686,0.0003039969,0.00087118894,0.0010869311,0.000029831404,0.00002731533,0.0024851144],"genre_scores_gemma":[0.99805534,0.00019365334,0.0005321304,0.00012673662,0.000044793567,0.0004413499,0.00007919583,0.000019645928,0.0005071624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989677,0.000034789744,0.00024465067,0.0003244471,0.000127528,0.0003008704],"domain_scores_gemma":[0.9993632,0.000053672647,0.0001038413,0.00019453806,0.00019639415,0.000088398396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048368074,0.00017829236,0.00035637242,0.00019094751,0.00008959281,0.0000081818935,0.00006930928,0.00007199777,0.00003218922],"category_scores_gemma":[0.000012292988,0.00012743555,0.000031715914,0.00037273826,0.000051640953,0.00006796211,0.000031522013,0.00021070438,0.000003853384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005764549,0.001247852,0.94424087,0.00019381025,0.00007797574,0.000021808562,0.00057040964,0.00020368026,0.000034682686,0.000011635407,0.00013743201,0.052683376],"study_design_scores_gemma":[0.019732349,0.0012616131,0.9648949,0.001263204,0.00068334764,0.0000020064317,0.0003428552,0.0007071837,0.000343117,0.000008074716,0.010553174,0.00020816093],"about_ca_topic_score_codex":0.00014532924,"about_ca_topic_score_gemma":0.0028767423,"teacher_disagreement_score":0.052475218,"about_ca_system_score_codex":0.00080696447,"about_ca_system_score_gemma":0.0010707679,"threshold_uncertainty_score":0.519667},"labels":[],"label_agreement":null},{"id":"W4408555214","doi":"10.1055/s-0045-1804649","title":"Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study","year":2025,"lang":"en","type":"article","venue":"Pneumologie","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre; McGill University Health Centre; Montreal General Hospital","funders":"","keywords":"Osimertinib; Mutant; Medicine; Internal medicine; Oncology; Line (geometry); Cancer research; Biology; Genetics; Epidermal growth factor receptor; Cancer; Gene; Erlotinib; Mathematics","score_opus":0.022415700022272934,"score_gpt":0.3398477815802626,"score_spread":0.31743208155798963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408555214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867163,0.00058667205,0.000053231153,0.005527795,0.00089133385,0.0018348878,0.00002685587,0.00006843579,0.0042945254],"genre_scores_gemma":[0.995543,0.00008885236,0.00010449857,0.0006539036,0.000027412098,0.0002218991,0.000017261757,0.000018888864,0.0033242754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984244,0.000083273706,0.00053166755,0.0003870941,0.00024314468,0.00033041232],"domain_scores_gemma":[0.99879676,0.00025032047,0.00014916503,0.0006410857,0.00010819555,0.000054488894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017713424,0.00021957845,0.0005125884,0.00014139006,0.00010512628,0.000010733488,0.00023628997,0.00008985071,0.00006906837],"category_scores_gemma":[0.0004629181,0.00013867869,0.00014993983,0.00060485915,0.00009575799,0.000059718426,0.00017121212,0.000230771,0.000012523009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038228245,0.0033896014,0.9390373,0.00026242566,0.00097321445,0.00032276375,0.0039383667,0.00084075844,0.0077159186,0.0003801805,0.00068775594,0.038628872],"study_design_scores_gemma":[0.023066262,0.001527695,0.95747703,0.00052846357,0.0009769343,0.000017191001,0.0021025685,0.00027621887,0.010391279,0.00059321785,0.002788373,0.00025473407],"about_ca_topic_score_codex":0.00032701658,"about_ca_topic_score_gemma":0.00091840595,"teacher_disagreement_score":0.038374137,"about_ca_system_score_codex":0.0003460023,"about_ca_system_score_gemma":0.00041489597,"threshold_uncertainty_score":0.5655153},"labels":[],"label_agreement":null},{"id":"W4408555253","doi":"10.1055/s-0045-1804661","title":"Früherkennung und Screening des Lungenkarzinoms – Empfehlungen der IASLC-Expertengruppe","year":2025,"lang":"de","type":"article","venue":"Pneumologie","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of British Columbia","funders":"","keywords":"Medicine; Gynecology","score_opus":0.038921949361546096,"score_gpt":0.3878085890414232,"score_spread":0.3488866396798771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408555253","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13090648,0.7931968,0.0058401767,0.008759457,0.00600384,0.0019965814,0.00017293013,0.0005682085,0.05255554],"genre_scores_gemma":[0.9643192,0.008907308,0.0045709475,0.0032242287,0.0008900598,0.00027883888,0.00028668178,0.00009639321,0.017426316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968875,0.00017930925,0.0006401511,0.0008841872,0.00033497403,0.0010738812],"domain_scores_gemma":[0.9979231,0.0004482742,0.00016933799,0.0008402313,0.00030785566,0.0003112488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027635385,0.00057939545,0.000743865,0.00035139982,0.00065328024,0.00014039091,0.00038270414,0.00039669866,0.0007070534],"category_scores_gemma":[0.00047177338,0.00049820484,0.00032483053,0.00073365925,0.00044570497,0.00020866346,0.00026805417,0.0004690667,0.0005799611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051079545,0.0015332383,0.56782293,0.0009845792,0.026294956,0.0015484258,0.004951492,0.00037258994,0.0017154515,0.0032986111,0.027228003,0.36373892],"study_design_scores_gemma":[0.00982886,0.0015332352,0.5093968,0.002913063,0.037151843,0.000043102664,0.00369518,0.0024056488,0.005943561,0.0054766717,0.4198508,0.001761278],"about_ca_topic_score_codex":0.0006828461,"about_ca_topic_score_gemma":0.00012068056,"teacher_disagreement_score":0.83341277,"about_ca_system_score_codex":0.00071912433,"about_ca_system_score_gemma":0.0007908429,"threshold_uncertainty_score":0.999747},"labels":[],"label_agreement":null},{"id":"W4408599782","doi":"10.1016/j.jtho.2025.02.016","title":"Corrigendum to ‘OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs’ [Journal of Thoracic Oncology Vol. 19 No. 10S (2024) S28]","year":2025,"lang":"en","type":"erratum","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Pooled analysis; Cancer; Meta-analysis; Adenocarcinoma","score_opus":0.03426890095538612,"score_gpt":0.46778001545292425,"score_spread":0.4335111144975381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408599782","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12062914,0.07410341,0.13796724,0.11150594,0.43938726,0.020250643,0.021454565,0.00027392348,0.074427895],"genre_scores_gemma":[0.05710537,0.0021938535,0.18222569,0.017122809,0.015180846,0.0003834954,0.0026824358,0.00046316348,0.72264236],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99270993,0.0011048878,0.0035417422,0.00070850353,0.0011476082,0.0007873444],"domain_scores_gemma":[0.9828743,0.001799179,0.007405128,0.000777651,0.006242334,0.000901463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00244522,0.00087375974,0.0066431197,0.0037133396,0.00019275436,0.000052502255,0.00082257367,0.0009511861,0.0016512455],"category_scores_gemma":[0.0033092354,0.0005639675,0.001717075,0.0022283609,0.00032611287,0.00026521125,0.00015199263,0.001999455,0.000012268839],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041161627,0.0023660115,0.0020191018,0.0006546699,0.06086968,0.0017647913,0.0014421559,0.00034233677,0.00051774766,0.000014739403,0.81049436,0.078352794],"study_design_scores_gemma":[0.006195892,0.027709045,0.0015457663,0.002309648,0.16989262,0.0008549496,0.001986873,0.0003392245,0.0005962972,0.00012479324,0.7879248,0.00052007806],"about_ca_topic_score_codex":0.0006355085,"about_ca_topic_score_gemma":0.0036430443,"teacher_disagreement_score":0.64821446,"about_ca_system_score_codex":0.0026974136,"about_ca_system_score_gemma":0.020548236,"threshold_uncertainty_score":0.9996812},"labels":[],"label_agreement":null},{"id":"W4408605892","doi":"10.1016/j.cllc.2025.03.003","title":"Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer","year":2025,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Western University; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.05301872819949766,"score_gpt":0.4923063349317381,"score_spread":0.43928760673224043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408605892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002855222,0.97266537,0.000071958486,0.000359381,0.0010284114,0.023739286,0.0016644913,0.00003816975,0.0004300908],"genre_scores_gemma":[0.00001324101,0.9686528,0.000056847693,0.00075303944,0.00020814793,0.019353375,0.00046599936,0.00006609806,0.01043044],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9961081,0.00028435673,0.0022320098,0.0006416211,0.00040499336,0.00032888327],"domain_scores_gemma":[0.9934883,0.0029329932,0.0016770429,0.0008500983,0.0008988682,0.00015267615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043939243,0.000571706,0.0051955925,0.00009183167,0.00013795584,0.000018769993,0.00031442483,0.00027882945,0.00018304691],"category_scores_gemma":[0.00091139856,0.00025890963,0.0014852918,0.00064552657,0.0001545026,0.00006033879,0.00005317407,0.00038797862,0.0000027783205],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111972106,0.00019787876,0.0017021844,0.8980549,0.011506597,0.0000019876409,0.000029110604,5.1225385e-7,2.045751e-9,0.0000434642,0.023270337,0.06508105],"study_design_scores_gemma":[0.0027367123,0.00021887117,0.00017452784,0.7433583,0.14989431,8.7269206e-7,0.0000054399034,0.000019590667,8.0538875e-8,0.0000012261883,0.10337488,0.00021514873],"about_ca_topic_score_codex":0.00013777796,"about_ca_topic_score_gemma":0.000122413,"teacher_disagreement_score":0.15469657,"about_ca_system_score_codex":0.0006728818,"about_ca_system_score_gemma":0.003005492,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W4408796178","doi":"10.1016/j.labinv.2024.103947","title":"1702 The Clinical, Pathological, and Molecular Features of Tumor Mutational Burden-High Non-Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Pathological; Lung cancer; Pathology; Medicine; Cancer; Cancer research; Biology; Oncology; Internal medicine","score_opus":0.011914733168870312,"score_gpt":0.32917403235350196,"score_spread":0.31725929918463164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408796178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097186,0.002862302,0.00021002765,0.004505496,0.0001983285,0.00054207456,0.00008112274,0.000024517314,0.0006042466],"genre_scores_gemma":[0.9926602,0.00016121852,0.0021143223,0.004455069,0.000085017215,0.00014538312,0.00006856603,0.000009604844,0.00030062313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991657,0.00009289674,0.00028542525,0.00021763534,0.00013729968,0.00010103289],"domain_scores_gemma":[0.99916595,0.00012438338,0.00014971396,0.0001850172,0.0003015136,0.00007340114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017601905,0.00011029135,0.00019155207,0.00005564299,0.00010557138,0.000021791688,0.000056617504,0.000075543496,0.00002492697],"category_scores_gemma":[0.000101767946,0.00007337762,0.000040095463,0.00032843737,0.0002621541,0.000050334347,0.000018486744,0.00015259821,0.000001474516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023355236,0.00052268273,0.70182306,0.0015713194,0.0010415398,0.00021305896,0.005080129,0.0012121267,0.2152249,0.031344473,0.036682907,0.0050502187],"study_design_scores_gemma":[0.0029571776,0.00023517992,0.9236527,0.0004073996,0.0012735305,0.0000051693373,0.0006341489,0.00045330488,0.06390688,0.0037194344,0.00257699,0.00017805265],"about_ca_topic_score_codex":0.00012344841,"about_ca_topic_score_gemma":0.000019259676,"teacher_disagreement_score":0.22182965,"about_ca_system_score_codex":0.00004398916,"about_ca_system_score_gemma":0.00065423903,"threshold_uncertainty_score":0.29922524},"labels":[],"label_agreement":null},{"id":"W4408805972","doi":"10.14740/wjon2531","title":"Actionable Mutations and Survival Rates in Non-Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.013546489093965839,"score_gpt":0.3790145321565497,"score_spread":0.36546804306258385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408805972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9071041,0.005137816,0.00037092133,0.0138457455,0.0011448502,0.00028499504,0.000005597736,0.0000054322772,0.07210056],"genre_scores_gemma":[0.98319787,0.0006145723,0.001298241,0.0004902523,0.000104794926,0.00002005334,0.0000029088535,0.0000054730713,0.014265832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949574,0.000030509056,0.00024016289,0.000072295814,0.00005484143,0.00010645451],"domain_scores_gemma":[0.9995086,0.00014440554,0.00011933315,0.00004392517,0.00012936033,0.000054379336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012523818,0.00005925801,0.0002308122,0.00033885703,0.000047940048,0.000007926388,0.000029409552,0.000034684235,0.00012087408],"category_scores_gemma":[0.000018704231,0.000047554684,0.000036641428,0.00027614008,0.000032432785,0.00005461264,0.0000111687,0.00017271713,0.0000010188668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003281636,0.0006534888,0.95451856,0.00015681087,0.00042348652,0.00027857677,0.0012040688,0.000785061,0.0023377142,0.00070059055,0.009623525,0.028989982],"study_design_scores_gemma":[0.010264065,0.00045762985,0.8634975,0.0003474697,0.0009637427,0.00008780179,0.0012576855,0.00041205253,0.0013024537,0.000583582,0.12072824,0.000097783435],"about_ca_topic_score_codex":0.00021992082,"about_ca_topic_score_gemma":0.0020192182,"teacher_disagreement_score":0.11110471,"about_ca_system_score_codex":0.0004232292,"about_ca_system_score_gemma":0.0009327519,"threshold_uncertainty_score":0.19392237},"labels":[],"label_agreement":null},{"id":"W4408838099","doi":"10.1080/14796694.2025.2474789","title":"Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Medicine; Docetaxel; KRAS; Oncology; Internal medicine; Lung cancer; Cancer; Cancer research; Colorectal cancer","score_opus":0.00967252552037447,"score_gpt":0.36812172813231336,"score_spread":0.3584492026119389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408838099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8200203,0.032748446,0.0008297219,0.01558929,0.005784713,0.008528978,0.00063523167,0.0004651439,0.11539813],"genre_scores_gemma":[0.82945293,0.0032359527,0.007902115,0.0071569984,0.004313339,0.007824829,0.0057651536,0.00021175241,0.13413692],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863887,0.000060443115,0.00030876236,0.00043331296,0.00010104569,0.0004575916],"domain_scores_gemma":[0.9990267,0.00021820836,0.00013367666,0.00030537753,0.00016283445,0.00015321148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010726607,0.00027543984,0.00058184,0.00018474452,0.00016622129,0.000018589095,0.00012678636,0.00032099962,0.00018427998],"category_scores_gemma":[0.000040806157,0.00022089487,0.000179988,0.00035696352,0.00005357226,0.000049474755,0.00003668874,0.0002276473,0.000012661285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025709117,0.004644473,0.059111685,0.004562752,0.009440602,0.0019627274,0.020764934,0.00015216014,0.033215657,0.0018638038,0.67080075,0.16777135],"study_design_scores_gemma":[0.068781264,0.0040286137,0.009986225,0.000564148,0.00891437,0.0000390011,0.004894629,0.0011320987,0.008564052,0.000041624393,0.89246553,0.0005884162],"about_ca_topic_score_codex":0.0008376307,"about_ca_topic_score_gemma":0.0019704888,"teacher_disagreement_score":0.22166483,"about_ca_system_score_codex":0.0011756596,"about_ca_system_score_gemma":0.0015748473,"threshold_uncertainty_score":0.9007831},"labels":[],"label_agreement":null},{"id":"W4408850276","doi":"10.3390/curroncol32040191","title":"Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Johnson and Johnson","keywords":"Osimertinib; T790M; Medicine; Oncology; Lung cancer; Internal medicine; Resistance mutation; Mutation; Epidermal growth factor receptor; Cancer research; Cancer; Erlotinib; Gefitinib; Genetics; Gene; Biology; Polymerase chain reaction","score_opus":0.06329768972517265,"score_gpt":0.44544967815056435,"score_spread":0.3821519884253917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408850276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000067225126,0.9701681,0.00013608443,0.00040571063,0.0008665612,0.024791537,0.0034093943,0.00006196456,0.00009340997],"genre_scores_gemma":[0.000015275153,0.9423721,0.00008642208,0.00017170157,0.000107833075,0.028803809,0.02768992,0.000067484296,0.0006854664],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99568534,0.0011921474,0.0014308267,0.00077182165,0.00034987408,0.0005700022],"domain_scores_gemma":[0.9955029,0.0015829687,0.0014751046,0.00045640196,0.000852158,0.00013048197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004429823,0.0008241667,0.0033269525,0.0005795122,0.00017165218,0.00005817428,0.0003000946,0.0003308288,0.000024588713],"category_scores_gemma":[0.00046221848,0.0004474097,0.00048074272,0.0022382706,0.000066896886,0.00008630808,0.00003326932,0.000746614,0.0000051135275],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007972333,0.0014291904,0.00015224676,0.93025124,0.0017082558,0.000071760485,0.001846211,0.0000020675548,5.9273997e-8,0.0000228124,0.00912218,0.055314273],"study_design_scores_gemma":[0.0032889217,0.00037440355,0.000044173717,0.7727051,0.022052465,0.000017294322,0.000109893896,0.000055538854,6.020928e-7,0.0000068514287,0.2010052,0.0003395931],"about_ca_topic_score_codex":0.000021533637,"about_ca_topic_score_gemma":0.00013150266,"teacher_disagreement_score":0.19188303,"about_ca_system_score_codex":0.0033205545,"about_ca_system_score_gemma":0.0028692102,"threshold_uncertainty_score":0.99979776},"labels":[],"label_agreement":null},{"id":"W4408919769","doi":"10.21037/jtd-2024-2100","title":"When to initiate durvalumab after concurrent chemoradiation in unresectable stage III non-small cell lung cancer?—A commentary on the phase II TORG 1937 (DATE) study","year":2025,"lang":"en","type":"letter","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Occupational Cancer Research Centre; Western University","funders":"","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Lung cancer; Oncology; Cancer; Internal medicine; Biology; Immunotherapy","score_opus":0.021662807752842187,"score_gpt":0.38507067342519297,"score_spread":0.3634078656723508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408919769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5323647,0.0024615359,0.00010555097,0.4575766,0.0016330696,0.0037583674,0.0014788558,0.000016866548,0.0006044107],"genre_scores_gemma":[0.6470818,0.00017546462,0.000028602088,0.34501386,0.0019370306,0.00055352336,0.0003578523,0.00005369173,0.0047981725],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973177,0.0002809367,0.0008395941,0.00038461178,0.00076618016,0.00041102627],"domain_scores_gemma":[0.9980694,0.00017909624,0.00058952573,0.0005194658,0.00028544277,0.00035708584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042031353,0.00043815034,0.00075114943,0.00052769174,0.00016593702,0.000097886084,0.00031908634,0.00012647675,0.00072142703],"category_scores_gemma":[0.0000631412,0.00029807515,0.0002834473,0.00031273704,0.000030369501,0.0001692019,0.0001351269,0.0012803331,0.000007352015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041509815,0.004563399,0.011062022,0.0012952016,0.00095883297,0.0048915,0.003355757,0.00022475337,0.000010859864,6.12802e-7,0.9665465,0.0029395863],"study_design_scores_gemma":[0.06480342,0.012893303,0.024546446,0.025631595,0.030804085,0.000023097477,0.0038365507,0.001188384,0.00093620195,0.000093469745,0.8330505,0.002192969],"about_ca_topic_score_codex":0.0006385596,"about_ca_topic_score_gemma":0.00012528626,"teacher_disagreement_score":0.13349602,"about_ca_system_score_codex":0.0013050174,"about_ca_system_score_gemma":0.0014107462,"threshold_uncertainty_score":0.99994713},"labels":[],"label_agreement":null},{"id":"W4408956663","doi":"10.1080/14796694.2025.2481022","title":"Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Cochrane Library; Internal medicine; MEDLINE; Oncology; Checklist; Meta-analysis; Incidence (geometry); Systematic review","score_opus":0.02311140128761007,"score_gpt":0.41173944101363935,"score_spread":0.3886280397260293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408956663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025925974,0.98899764,0.0000032912044,0.0026751563,0.001337213,0.0049836016,0.00069823716,0.000017276465,0.0012849667],"genre_scores_gemma":[0.0000034696775,0.9931729,0.00038413648,0.0030545837,0.00055036886,0.0006440343,0.00077408814,0.000033152926,0.0013832734],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99555796,0.0019222148,0.0016904612,0.00042073432,0.00014969999,0.00025891108],"domain_scores_gemma":[0.9950862,0.001517481,0.0020111594,0.00081964035,0.0004785214,0.00008698198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049288245,0.00044049282,0.0059886654,0.0002025197,0.000059078568,0.0000019786844,0.00029210886,0.00046277329,0.00009525089],"category_scores_gemma":[0.0020759315,0.00021920785,0.0011587961,0.00090606534,0.00016468768,0.000023658657,0.00011263171,0.0006379829,0.000011984547],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024305544,0.0002101965,0.000012891193,0.97268766,0.0009663633,0.000060563383,0.00008128188,7.57434e-8,0.0000041047797,0.0011039138,0.008765647,0.01608301],"study_design_scores_gemma":[0.0003299097,0.00054338906,0.000033090346,0.7320343,0.01086811,0.00036832667,0.000014136332,2.3700888e-7,0.0000028347633,0.000015184483,0.25569305,0.00009742666],"about_ca_topic_score_codex":0.0000045941647,"about_ca_topic_score_gemma":0.000002563049,"teacher_disagreement_score":0.2469274,"about_ca_system_score_codex":0.00036864015,"about_ca_system_score_gemma":0.0017466396,"threshold_uncertainty_score":0.8939037},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4408978958","doi":"10.1016/s1556-0864(25)00197-2","title":"2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Oncology; Disease; Adenocarcinoma; Cancer","score_opus":0.016857338226273035,"score_gpt":0.4293698245302836,"score_spread":0.41251248630401055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408978958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934731,0.0012993467,0.00019272587,0.0025947257,0.00029468167,0.00085039146,0.000018716111,0.000014401264,0.0012619174],"genre_scores_gemma":[0.99463797,0.00012732277,0.0036997658,0.00078425364,0.00006712776,0.0000647754,0.000031665913,0.00001980412,0.00056733517],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984884,0.00015153167,0.000533514,0.00029262475,0.00028820534,0.00024571235],"domain_scores_gemma":[0.9985347,0.00027539473,0.00052013155,0.00019924989,0.00021918479,0.00025133768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022308798,0.00020352738,0.0005351012,0.0003179448,0.00011725316,0.000027525073,0.00007526573,0.000107948756,0.000025334606],"category_scores_gemma":[0.0003917635,0.00012989982,0.00008335502,0.0002410521,0.00007966992,0.00025287998,0.000041478037,0.00029114794,0.0000019044875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061881687,0.0038190149,0.21949874,0.00041970174,0.00080425147,0.00051195716,0.0022009134,0.000058659065,0.0013463775,0.00031981326,0.0009994878,0.7081394],"study_design_scores_gemma":[0.02223082,0.009121317,0.93188834,0.006516011,0.0023100325,0.000078249024,0.0015496023,0.0000662531,0.0014501418,0.0009822245,0.02345152,0.00035550262],"about_ca_topic_score_codex":0.000009350913,"about_ca_topic_score_gemma":0.000012621967,"teacher_disagreement_score":0.7123896,"about_ca_system_score_codex":0.00048758608,"about_ca_system_score_gemma":0.0005919962,"threshold_uncertainty_score":0.5297161},"labels":[],"label_agreement":null},{"id":"W4408978961","doi":"10.1016/s1556-0864(25)00195-9","title":"LBA2: Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Crizotinib; Medicine; ROS1; Lung cancer; Oncology; Internal medicine; Matching (statistics); Cancer; Adenocarcinoma; Pathology","score_opus":0.01945353136888187,"score_gpt":0.43611796631393235,"score_spread":0.41666443494505045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408978961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629497,0.0040560034,0.0011678822,0.00588948,0.0020342157,0.00080764625,0.000036151796,0.000029127928,0.023029823],"genre_scores_gemma":[0.99037385,0.00031478732,0.0039081355,0.0013270002,0.00031886643,0.00005936344,0.000018668263,0.00003287929,0.0036464364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977599,0.00027425817,0.0009856158,0.00030032205,0.00025589898,0.00042401717],"domain_scores_gemma":[0.99799293,0.0004125115,0.00080477155,0.00020889258,0.0003843756,0.00019650457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005421437,0.00027596796,0.0012098243,0.0007385958,0.00012683148,0.000034547847,0.00019648358,0.00027957195,0.00014792576],"category_scores_gemma":[0.00009185329,0.0002268916,0.00024887527,0.0006915016,0.00008131638,0.0001343233,0.00007074918,0.00093425123,0.00000916748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015361095,0.007403069,0.6582764,0.0014808205,0.0032900998,0.00356692,0.025906282,0.0016234831,0.012552999,0.000090940965,0.030608933,0.23983897],"study_design_scores_gemma":[0.020103151,0.007521042,0.87323534,0.006842923,0.008907567,0.001030898,0.010148505,0.0018893564,0.041308828,0.00035655615,0.027836075,0.0008197807],"about_ca_topic_score_codex":0.0006405796,"about_ca_topic_score_gemma":0.0012718564,"teacher_disagreement_score":0.23901919,"about_ca_system_score_codex":0.0019241864,"about_ca_system_score_gemma":0.0023191548,"threshold_uncertainty_score":0.9252371},"labels":[],"label_agreement":null},{"id":"W4408979288","doi":"10.1016/s1556-0864(25)00277-1","title":"82P: A retrospective real-world evidence study of MTAP status and clinical outcomes in patients with advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retrospective cohort study; Real world evidence; Lung cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.021060984740557398,"score_gpt":0.48835200343156415,"score_spread":0.46729101869100675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967059,0.00063110836,0.00002602136,0.00048257725,0.0003826919,0.00084803085,0.000006856714,0.000003678572,0.00091315864],"genre_scores_gemma":[0.9967889,0.0008135932,0.0015448772,0.00014138928,0.00003152178,0.00002216001,9.06605e-7,0.00000949638,0.0006471247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853426,0.00015377536,0.0007400786,0.00019166006,0.00020232187,0.00017789377],"domain_scores_gemma":[0.9982189,0.00035916784,0.0006745275,0.00015553836,0.00048412516,0.00010775814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035547817,0.00012415355,0.00083028834,0.00031246463,0.000033212542,0.00000579765,0.000070225404,0.00006458124,0.000014676414],"category_scores_gemma":[0.00014759135,0.00008082131,0.00006883292,0.00033903346,0.00006476402,0.00011728487,0.000041199157,0.00035232224,1.8422736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040107872,0.0031769613,0.9746334,0.00010809249,0.0005927072,0.00006618421,0.0013397823,0.000039189523,0.000008705229,0.0000035345245,0.00006864287,0.015952023],"study_design_scores_gemma":[0.0076727113,0.009405972,0.9792799,0.00076605397,0.001538769,0.0000014684823,0.0011514255,0.000013115537,0.000023022678,0.000017222157,0.00007041897,0.000059971946],"about_ca_topic_score_codex":0.0006272853,"about_ca_topic_score_gemma":0.0048380382,"teacher_disagreement_score":0.015892051,"about_ca_system_score_codex":0.00095757894,"about_ca_system_score_gemma":0.0011232729,"threshold_uncertainty_score":0.32957974},"labels":[],"label_agreement":null},{"id":"W4408979331","doi":"10.1016/s1556-0864(25)00290-4","title":"95P: Adagrasib (ADA) plus cetuximab (CETUX) in patients (pts) with advanced KRASG12C-mutated non-small cell lung cancer (NSCLC) from KRYSTAL-1","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Basilea Pharmaceutica; Astellas Pharma; Eisai; Castle Biosciences; Pfizer; Moderna; Boston Pharmaceuticals; Agios Pharmaceuticals; Eisai Canada; BeiGene; Mirati Therapeutics; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; Servier; Gilead Sciences; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Internal medicine; Cancer; Colorectal cancer","score_opus":0.008133498182003375,"score_gpt":0.38217835053725147,"score_spread":0.3740448523552481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98411,0.002389658,0.0011958649,0.0019422007,0.0009993914,0.0008244565,0.000059696322,0.000020764775,0.008457987],"genre_scores_gemma":[0.99063694,0.0003151489,0.0063212155,0.0009195941,0.00014847533,0.000055867145,0.00005321197,0.000036878468,0.0015126448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980371,0.00012270537,0.00077817915,0.00032136595,0.00034031726,0.00040034685],"domain_scores_gemma":[0.9981342,0.00016508852,0.00067772553,0.0002617096,0.0005568088,0.0002044758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001819182,0.00028119422,0.00093989266,0.00044931672,0.00008888084,0.000022114942,0.00019455333,0.00021087435,0.00014927887],"category_scores_gemma":[0.000047981855,0.0002059148,0.00014345154,0.00055420946,0.00006519333,0.00019360133,0.00005303396,0.0005936827,0.000005269019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030401295,0.0070760637,0.63023716,0.00077072025,0.0030283006,0.0024684665,0.0060262606,0.0041581574,0.004808361,0.000026897462,0.00934228,0.30165604],"study_design_scores_gemma":[0.08294789,0.012655345,0.8437296,0.005621847,0.008187992,0.00012310842,0.004168954,0.0018659442,0.010258674,0.00030843634,0.029235113,0.0008970981],"about_ca_topic_score_codex":0.0004283602,"about_ca_topic_score_gemma":0.00074772263,"teacher_disagreement_score":0.30075893,"about_ca_system_score_codex":0.0025404934,"about_ca_system_score_gemma":0.0030933511,"threshold_uncertainty_score":0.83969617},"labels":[],"label_agreement":null},{"id":"W4408979333","doi":"10.1016/s1556-0864(25)00287-4","title":"92P: Real-world treatment sequencing and outcomes in ALK-positive metastatic non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.023817211696568166,"score_gpt":0.45924516566625434,"score_spread":0.4354279539696862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706835,0.002276294,0.00022454147,0.005475434,0.00044495508,0.00050909683,0.000016536522,0.000006695081,0.020362915],"genre_scores_gemma":[0.9822006,0.0014350777,0.0058329664,0.00072471215,0.00006689434,0.000047831134,0.0000044775634,0.000012525466,0.009674883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998977,0.00010233476,0.00047347666,0.00015082503,0.00009862825,0.00019773442],"domain_scores_gemma":[0.9990868,0.0002676216,0.00029889937,0.000102444115,0.00013607099,0.000108193555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021063114,0.00015278524,0.0006924576,0.000460746,0.000054121534,0.000012946101,0.000048527938,0.0000535225,0.000034355715],"category_scores_gemma":[0.000022418417,0.00010301318,0.00011053228,0.00024279168,0.000042550844,0.00007769895,0.000020769821,0.0001850578,0.0000010578534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014040946,0.0013526299,0.7945377,0.00048386672,0.0033064983,0.0033693002,0.0086926045,0.00060359994,0.0034062678,0.00015099162,0.0010043907,0.18168806],"study_design_scores_gemma":[0.014690473,0.0055719875,0.9288105,0.002085985,0.015320765,0.0004674127,0.0057948604,0.0015547612,0.014870685,0.00065841945,0.009780001,0.00039418656],"about_ca_topic_score_codex":0.0021369073,"about_ca_topic_score_gemma":0.0040329047,"teacher_disagreement_score":0.18129387,"about_ca_system_score_codex":0.00404541,"about_ca_system_score_gemma":0.0021593433,"threshold_uncertainty_score":0.99977785},"labels":[],"label_agreement":null},{"id":"W4408979470","doi":"10.1016/s1556-0864(25)00319-3","title":"124TiP: TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Osimertinib; non-small cell lung cancer (NSCLC); Chemotherapy; Platinum; Oncology; Internal medicine; Cancer research; Lung cancer; Cancer; Adenocarcinoma; A549 cell","score_opus":0.012009612388934202,"score_gpt":0.4170762565770559,"score_spread":0.40506664418812166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356574,0.00083098724,0.00047112835,0.0014091452,0.00022021605,0.0033338198,0.000039757088,0.000015276039,0.000113928734],"genre_scores_gemma":[0.99609894,0.0001445823,0.0027029456,0.0005154762,0.000036113943,0.00019393516,0.000031047257,0.0000412153,0.00023573832],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975147,0.00021160864,0.001110146,0.0004011796,0.0004154119,0.00034691763],"domain_scores_gemma":[0.9975584,0.00020804761,0.0011412959,0.00029884963,0.0004505317,0.0003428407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024461412,0.00033886314,0.0010920144,0.00048099877,0.000108665874,0.000021198535,0.00016103212,0.00008921926,0.000071683746],"category_scores_gemma":[0.00008515168,0.00021009146,0.000086272215,0.000565668,0.000096205775,0.00017101143,0.000047401205,0.0004006585,5.2990987e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30159456,0.029286264,0.2639589,0.0008298361,0.0017673629,0.0008675062,0.0045910147,0.00055882015,0.0008028904,0.0000024421406,0.00037055387,0.39536986],"study_design_scores_gemma":[0.40891948,0.09304943,0.4605335,0.009484367,0.010583143,0.00005823691,0.0048007183,0.0036373558,0.006242974,0.000047845835,0.0018425297,0.000800414],"about_ca_topic_score_codex":0.00004699328,"about_ca_topic_score_gemma":0.00013041236,"teacher_disagreement_score":0.39456943,"about_ca_system_score_codex":0.00056452275,"about_ca_system_score_gemma":0.0025021816,"threshold_uncertainty_score":0.8567281},"labels":[],"label_agreement":null},{"id":"W4408979494","doi":"10.1016/s1556-0864(25)00299-0","title":"104P: MOMENT disease registry: Patient characteristics and treatment patterns from interim enrollment analysis of patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring METexon 14 (METex14) skipping treated with systemic therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Interim analysis; Interim; Oncology; Internal medicine; Lung cancer; Systemic therapy; Disease; Cancer; Clinical trial","score_opus":0.01092587723108532,"score_gpt":0.35502823836852576,"score_spread":0.3441023611374404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440664,0.0020527462,0.0016815037,0.00025632532,0.00021075236,0.0009484365,0.00033410877,0.000010304176,0.00009915586],"genre_scores_gemma":[0.99621356,0.0021438978,0.0010023145,0.00012511197,0.000046280587,0.00015970189,0.00013280369,0.000025114598,0.0001512396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826086,0.00012307735,0.000765745,0.00033028077,0.00027828073,0.00024176048],"domain_scores_gemma":[0.9975856,0.00010082501,0.0012717067,0.0003081105,0.00049749477,0.00023625331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008988929,0.00031343996,0.0011715284,0.0004957949,0.00007440682,0.000026052685,0.00009118008,0.00007662803,0.00003867022],"category_scores_gemma":[0.000010414571,0.00019184113,0.0001797098,0.0003638615,0.00004867515,0.00009328319,0.000030665513,0.00014768868,1.601752e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010738495,0.0021378794,0.8136059,0.00026269807,0.011645548,0.00024298133,0.0022102874,0.0004637388,0.001719525,9.047937e-7,0.000017039401,0.15695497],"study_design_scores_gemma":[0.00993587,0.0098919775,0.9421528,0.0030250615,0.026975283,0.000008799188,0.0010743224,0.0011238066,0.0047897277,0.0000012650514,0.0007730964,0.00024801935],"about_ca_topic_score_codex":0.00039706702,"about_ca_topic_score_gemma":0.000081796345,"teacher_disagreement_score":0.15670696,"about_ca_system_score_codex":0.001957784,"about_ca_system_score_gemma":0.0006778269,"threshold_uncertainty_score":0.7823054},"labels":[],"label_agreement":null},{"id":"W4408979538","doi":"10.1016/s1556-0864(25)00317-x","title":"122TiP: TROPION-Lung10: Phase III study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig in non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); BC Cancer Agency","funders":"Innovent Biologics; Novocure; Regeneron Pharmaceuticals; Yuhan; Gilead Sciences; EQRx; BeiGene; Mirati Therapeutics; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Cancer research; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); A549 cell","score_opus":0.011069265108833071,"score_gpt":0.4012138063917119,"score_spread":0.39014454128287884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907887,0.0017359096,0.0039915796,0.00070093665,0.00046015217,0.0016216896,0.00003443916,0.000011639583,0.00065498316],"genre_scores_gemma":[0.9892105,0.0003859232,0.008730245,0.00018839585,0.00011099841,0.00018323779,0.00002142071,0.000032921398,0.0011363627],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978946,0.0001816491,0.0009678425,0.0003646009,0.00026730943,0.00032401955],"domain_scores_gemma":[0.9980222,0.00020037376,0.0008834532,0.00032042692,0.0003790657,0.00019447775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027023157,0.00028985325,0.0010139918,0.0006550223,0.00018994336,0.000028207976,0.00015791577,0.00010596122,0.000069234295],"category_scores_gemma":[0.000034733457,0.0002160353,0.00008444925,0.0004229223,0.00009141909,0.00030211452,0.000068616886,0.0004716712,0.0000011243592],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07537432,0.046778522,0.31904933,0.0030862878,0.0048286603,0.0028607186,0.03274366,0.029945286,0.3396533,0.00008094017,0.005275613,0.14032334],"study_design_scores_gemma":[0.35945436,0.05815271,0.3542678,0.009067258,0.028249633,0.0025099628,0.060198035,0.010234532,0.10564773,0.00054029207,0.00961711,0.002060581],"about_ca_topic_score_codex":0.00045679274,"about_ca_topic_score_gemma":0.0009981456,"teacher_disagreement_score":0.28408003,"about_ca_system_score_codex":0.0009316374,"about_ca_system_score_gemma":0.0019084946,"threshold_uncertainty_score":0.88096637},"labels":[],"label_agreement":null},{"id":"W4408979741","doi":"10.1016/s1556-0864(25)00329-6","title":"134TiP: Evaluation of an additional cohort of patients with non-small cell lung cancer (NSCLC) in the phase I/II duravelo-1 study of zelenectide pevedotin (BT8009), a bicycle toxin conjugate","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Sierra Oncology; Ipsen; Daiichi Sankyo Europe; Servier; Genentech; Institut Gustave-Roussy; European Society for Medical Oncology; Basilea Pharmaceutica; Eisai; Incyte; Boston Pharmaceuticals; Seagen; Agios Pharmaceuticals; Eisai Canada; Cholangiocarcinoma Foundation; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Celldex Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; Bayer HealthCare; Sanofi; Exelixis; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Merck KGaA; Celgene; Amgen","keywords":"Medicine; Conjugate; Oncology; Lung cancer; Cohort; Internal medicine; Toxin; Microbiology","score_opus":0.017534328091956403,"score_gpt":0.43620637209627355,"score_spread":0.4186720440043171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664766,0.00018475782,0.000034690165,0.00031719246,0.00016730723,0.0013925701,0.00021004412,0.0000019354932,0.0010438173],"genre_scores_gemma":[0.99884635,0.00001697942,0.000719554,0.00011281046,0.0000499078,0.000100394456,0.00007556004,0.0000095595315,0.00006889087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979647,0.00037745354,0.0007992187,0.00014765916,0.00057773275,0.00013327101],"domain_scores_gemma":[0.9971662,0.0002335919,0.0010416798,0.00018662577,0.0013194233,0.000052453554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010406094,0.0001253357,0.0005635692,0.0003301813,0.000055229568,0.0000037418527,0.00013645148,0.000069856134,0.00033019012],"category_scores_gemma":[0.000113725575,0.0000797145,0.00007464671,0.0003856002,0.00006820705,0.000102403064,0.000023653705,0.00020434438,1.9952375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01286025,0.04752024,0.82045233,0.00044535863,0.0024471402,0.000082478844,0.014730532,0.0032246935,0.004508078,0.000010356405,0.0021993914,0.09151917],"study_design_scores_gemma":[0.018183738,0.013943134,0.9527505,0.00051332475,0.004254401,0.000016195036,0.004135336,0.0008699913,0.0050489204,0.000046149282,0.00015987098,0.00007844735],"about_ca_topic_score_codex":0.00026012864,"about_ca_topic_score_gemma":0.0008103778,"teacher_disagreement_score":0.13229819,"about_ca_system_score_codex":0.00042497957,"about_ca_system_score_gemma":0.0021781176,"threshold_uncertainty_score":0.38638872},"labels":[],"label_agreement":null},{"id":"W4408979751","doi":"10.1016/s1556-0864(25)00328-4","title":"133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; Sumitomo Dainippon Pharma Oncology; Sun Pharma; Chinese Society of Clinical Oncology; PharmaMar; European Society for Medical Oncology; Coherus Biosciences; Seagen; Pfizer; Biogen; Incyte; International Association for the Study of Lung Cancer; BeiGene; Mirati Therapeutics; Les Laboratories Pierre Fabre; AstraZeneca; Associazione Italiana di Oncologia Medica; Novocure; Ipsen; Jazz Pharmaceuticals; Revolution Medicines; Regeneron Pharmaceuticals; G1 Therapeutics; Jounce Therapeutics; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Cilag; Cardinal Health; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; First line treatment; Internal medicine; Lung; Cancer; Chemotherapy; Immunotherapy","score_opus":0.026725202347766104,"score_gpt":0.41932747852948,"score_spread":0.3926022761817139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730908,0.016399099,0.0011897469,0.0013098634,0.0010786231,0.0060023586,0.00022766025,0.000018853449,0.00068296917],"genre_scores_gemma":[0.98403084,0.0059310654,0.005448578,0.00008638275,0.00019562924,0.0014987789,0.0000515358,0.00008214826,0.0026750658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949289,0.0005245951,0.0025915918,0.0006399095,0.0007075425,0.00060744665],"domain_scores_gemma":[0.99280685,0.001454759,0.0035128077,0.00068391656,0.001145489,0.0003961956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004983169,0.000821956,0.0047671264,0.0008244903,0.00021065115,0.000022640106,0.00030873253,0.00013805478,0.00055661285],"category_scores_gemma":[0.000080585356,0.0005114185,0.00089951913,0.0007315046,0.0002513189,0.00016401078,0.00007204422,0.00028377405,0.0000023631771],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81719124,0.080395274,0.0031871507,0.0037050904,0.029092124,0.003839752,0.023737092,0.01814141,0.0060300874,0.0000091424545,0.00051058736,0.0141610745],"study_design_scores_gemma":[0.7437079,0.07086215,0.00055032584,0.0020618285,0.08426051,0.0001957267,0.005329756,0.0031422793,0.088549845,0.00003135153,0.0008621511,0.00044619082],"about_ca_topic_score_codex":0.008093057,"about_ca_topic_score_gemma":0.0025448012,"teacher_disagreement_score":0.08251976,"about_ca_system_score_codex":0.0027974735,"about_ca_system_score_gemma":0.004700488,"threshold_uncertainty_score":0.99973375},"labels":[],"label_agreement":null},{"id":"W4408980253","doi":"10.1016/s1556-0864(25)00379-x","title":"LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Chemoradiotherapy; Oncology; Internal medicine; Stage (stratigraphy); non-small cell lung cancer (NSCLC); Lung cancer; Overall survival; Cancer; Epidermal growth factor receptor; A549 cell; Erlotinib","score_opus":0.010945723136319701,"score_gpt":0.37819552117808153,"score_spread":0.36724979804176183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993258,0.0012598003,0.0003486367,0.0014119506,0.00047298378,0.001263444,0.00014781751,0.000015787575,0.001821569],"genre_scores_gemma":[0.9958096,0.00020512422,0.0004847526,0.0014784975,0.00012832884,0.00012458452,0.000104755556,0.000038078066,0.0016262581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728394,0.00048025057,0.0009131719,0.0004094113,0.00047078764,0.00044245852],"domain_scores_gemma":[0.99763465,0.00036834076,0.0007684326,0.000384622,0.00068059005,0.00016338316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005664866,0.00034578424,0.001283345,0.00053070654,0.00013320253,0.000062987674,0.00029081333,0.00018326608,0.0007914493],"category_scores_gemma":[0.000036016485,0.00021265421,0.00024166108,0.0014397486,0.000089778136,0.00018014082,0.00006409305,0.00070040545,0.000003690403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017311154,0.003937513,0.9591684,0.000036508656,0.008419543,0.00049216603,0.004943537,0.00096145464,0.00022903235,0.0000023251118,0.0010358582,0.003462514],"study_design_scores_gemma":[0.020985663,0.0028307566,0.9598367,0.0002703848,0.010144627,0.000004014489,0.0030180113,0.00061014766,0.00057936384,0.000012057189,0.0014720986,0.0002361429],"about_ca_topic_score_codex":0.0043157204,"about_ca_topic_score_gemma":0.00709317,"teacher_disagreement_score":0.0036745078,"about_ca_system_score_codex":0.0016030449,"about_ca_system_score_gemma":0.0016106234,"threshold_uncertainty_score":0.8671787},"labels":[],"label_agreement":null},{"id":"W4408980259","doi":"10.1016/s1556-0864(25)00357-0","title":"163P: Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.021169923163706268,"score_gpt":0.43500369100691866,"score_spread":0.4138337678432124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364985,0.00042725928,0.00036515217,0.008539924,0.0008616557,0.0009516346,0.000015626669,0.0000029735436,0.005185914],"genre_scores_gemma":[0.99766666,0.000036148576,0.00096089527,0.0004559677,0.00012562209,0.00003198595,0.0000095278765,0.000006992478,0.00070618663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864244,0.00025023427,0.0007109804,0.00010852534,0.00017054525,0.00011727028],"domain_scores_gemma":[0.99905705,0.00016052918,0.00034791956,0.00014452972,0.00023357062,0.00005642617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007592454,0.00008284173,0.0003820977,0.00018976057,0.000044976878,0.0000053554295,0.00008757468,0.000049065697,0.000057754194],"category_scores_gemma":[0.00010550267,0.000050594113,0.00012568921,0.00025995684,0.000020303234,0.00005329221,0.000014233129,0.00018749599,8.6453935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022279283,0.0019576962,0.87172276,0.00028129702,0.000370408,0.00008478039,0.0055211713,0.0057728672,0.00086110336,0.000045038607,0.0029303683,0.08817324],"study_design_scores_gemma":[0.01093028,0.0013452675,0.97875506,0.00020096535,0.0006817265,0.0000064446835,0.0005495826,0.000079353784,0.00067135243,0.00008190234,0.0066417805,0.000056293822],"about_ca_topic_score_codex":0.00046500732,"about_ca_topic_score_gemma":0.0015654004,"teacher_disagreement_score":0.10703231,"about_ca_system_score_codex":0.0005375566,"about_ca_system_score_gemma":0.0006931155,"threshold_uncertainty_score":0.20631681},"labels":[],"label_agreement":null},{"id":"W4408980301","doi":"10.1016/s1556-0864(25)00353-3","title":"159P: Patient and clinician preferences for adjuvant treatment in early-stage non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Adjuvant; Oncology; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Lung","score_opus":0.028447219294535725,"score_gpt":0.45288004761676903,"score_spread":0.4244328283222333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987935,0.004721149,0.00020314594,0.0020436996,0.00067802373,0.0008494206,0.00003272375,0.0000045687375,0.0035322658],"genre_scores_gemma":[0.99235696,0.0015105058,0.002902703,0.00043768735,0.00011791539,0.00012892245,0.000004586512,0.00000954205,0.0025311892],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99899197,0.000059487975,0.00051829644,0.00015937496,0.00008039876,0.00019049946],"domain_scores_gemma":[0.99910086,0.00019643393,0.00034606998,0.00009818044,0.00015639838,0.00010205428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001679946,0.00012903236,0.00052220613,0.00022482107,0.000052113475,0.000012049175,0.000051911327,0.00010989857,0.000024522617],"category_scores_gemma":[0.000027592614,0.00008666536,0.000111287365,0.00011329901,0.000037627615,0.00005481755,0.000019204634,0.0001421435,6.1836084e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022943192,0.0013235772,0.35157505,0.00029505807,0.0005363178,0.00017118368,0.0052002664,0.00007041069,0.0003129467,0.000019406723,0.00080574665,0.63739574],"study_design_scores_gemma":[0.01793903,0.026788102,0.81136864,0.0021569498,0.005910406,0.00007362936,0.0065760026,0.0010610886,0.008072057,0.00050622347,0.11918342,0.00036442958],"about_ca_topic_score_codex":0.00038376116,"about_ca_topic_score_gemma":0.00096333394,"teacher_disagreement_score":0.6370313,"about_ca_system_score_codex":0.00074256235,"about_ca_system_score_gemma":0.0013676897,"threshold_uncertainty_score":0.35341105},"labels":[],"label_agreement":null},{"id":"W4408980795","doi":"10.1016/s1556-0864(25)00395-8","title":"201P: Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Osimertinib; Chemoradiotherapy; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer; Radiology; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.011183346550844117,"score_gpt":0.3971920526254999,"score_spread":0.38600870607465576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240834,0.001787643,0.00011374862,0.0015406541,0.0006481631,0.0026634363,0.00005536375,0.000020116207,0.000762522],"genre_scores_gemma":[0.99608237,0.000092787064,0.0010807101,0.0013371109,0.00007968795,0.000344203,0.00003506941,0.00004523845,0.0009028476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974055,0.00028602095,0.0010086836,0.00037515975,0.00051143323,0.0004131812],"domain_scores_gemma":[0.99738514,0.00026247045,0.0011518965,0.00035960178,0.0006879946,0.00015292133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003788969,0.00034492696,0.0010390581,0.00027211514,0.00014654544,0.000050975523,0.00020333429,0.00018163444,0.00020473886],"category_scores_gemma":[0.00006232809,0.00018746943,0.00014194984,0.000528342,0.00010239139,0.00019144508,0.00006753822,0.00065748976,0.0000021462547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014739204,0.003945145,0.9534156,0.00005644832,0.0016335957,0.00043023334,0.0060233013,0.000058165748,0.00016968168,5.147927e-7,0.00058833364,0.018939817],"study_design_scores_gemma":[0.019756433,0.004041005,0.9681073,0.000977625,0.00202472,0.000008775201,0.002690619,0.000084839,0.0011145457,0.000009559553,0.0009843094,0.0002002566],"about_ca_topic_score_codex":0.001011861,"about_ca_topic_score_gemma":0.00096115103,"teacher_disagreement_score":0.01873956,"about_ca_system_score_codex":0.0011240375,"about_ca_system_score_gemma":0.0017540255,"threshold_uncertainty_score":0.76447815},"labels":[],"label_agreement":null},{"id":"W4408981050","doi":"10.1016/s1556-0864(25)00423-x","title":"230P: A retrospective analysis on patterns of surveillance after curative intent treatment for unresectable stage III non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; BC Cancer Agency","funders":"Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Stage (stratigraphy); Oncology; Retrospective cohort study; Internal medicine; Lung cancer; Lung; Radiology","score_opus":0.016564479674886976,"score_gpt":0.4334877923987314,"score_spread":0.4169233127238444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408981050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98012805,0.0014133311,0.011682747,0.0019582047,0.0005382571,0.0009379991,0.00036468092,0.0000066941575,0.002970044],"genre_scores_gemma":[0.9887913,0.00049754995,0.0008930436,0.00028648713,0.00011458646,0.00019771881,0.000019565854,0.000013782205,0.009185989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868166,0.00010039764,0.0005798094,0.00023356671,0.00017054772,0.00023403755],"domain_scores_gemma":[0.99802107,0.00024248312,0.0006660299,0.00021262164,0.0007549702,0.000102844766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025217969,0.0001906031,0.0009974192,0.00050609134,0.000057814705,0.000011039218,0.000087570435,0.00010511979,0.00017103058],"category_scores_gemma":[0.000043908112,0.00012890421,0.00047077643,0.00044214443,0.000038619197,0.000058059824,0.000022869976,0.00017469093,6.259439e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012409318,0.0024375662,0.9490239,0.00034828015,0.012921869,0.00021823494,0.004244841,0.0010714557,0.0010710414,0.00004885207,0.0009545133,0.015250141],"study_design_scores_gemma":[0.012026532,0.015209236,0.9205903,0.00096265535,0.016522694,0.000017936642,0.0031803274,0.0014796493,0.021374112,0.000075840435,0.008284933,0.00027579968],"about_ca_topic_score_codex":0.00043871233,"about_ca_topic_score_gemma":0.0018735698,"teacher_disagreement_score":0.028433604,"about_ca_system_score_codex":0.0027046078,"about_ca_system_score_gemma":0.0010715077,"threshold_uncertainty_score":0.7072455},"labels":[],"label_agreement":null},{"id":"W4408999963","doi":"10.3390/curroncol32040201","title":"Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Osimertinib; Gefitinib; Medicine; T790M; Bevacizumab; Lung cancer; Epidermal growth factor receptor; Oncology; Cancer research; Targeted therapy; Internal medicine; Cancer; Erlotinib; Chemotherapy","score_opus":0.04802578443562181,"score_gpt":0.44813008596809084,"score_spread":0.400104301532469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408999963","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017139059,0.9770846,0.00001749338,0.00018472371,0.00023520424,0.004698264,0.00051452086,0.000021336378,0.000104796796],"genre_scores_gemma":[0.0015279106,0.9930278,0.0007957373,0.000109620785,0.000045740828,0.0030550135,0.00089612626,0.00004637297,0.0004956573],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9976123,0.00017195389,0.0009951058,0.0007602878,0.00013534942,0.0003249962],"domain_scores_gemma":[0.99801254,0.00033211682,0.00072335545,0.0004118094,0.00031749145,0.00020265687],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001647345,0.0005392454,0.0025079784,0.00034194085,0.00007564713,0.000031549553,0.00005238252,0.00027343762,0.00002703093],"category_scores_gemma":[0.00012034389,0.00037125358,0.00015199896,0.00056764635,0.00018417214,0.00013625273,0.000108842134,0.0003840489,3.390796e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000382259,0.0006837192,0.015925907,0.2315436,0.0007703553,0.019749945,0.0012687785,9.955887e-7,7.002545e-7,0.000008815906,0.00045416685,0.72921073],"study_design_scores_gemma":[0.012045234,0.0015739732,0.002609605,0.5087387,0.026432272,0.031927366,0.000115222574,0.000056167824,0.0000016571985,0.000007003889,0.4157157,0.000777065],"about_ca_topic_score_codex":0.00008588673,"about_ca_topic_score_gemma":0.0002779196,"teacher_disagreement_score":0.72843367,"about_ca_system_score_codex":0.0003689333,"about_ca_system_score_gemma":0.0017610465,"threshold_uncertainty_score":0.99987394},"labels":[],"label_agreement":null},{"id":"W4409001910","doi":"10.1016/s1556-0864(25)00537-4","title":"345TiP: A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homologue 3 (B7-H3) protein-targeted antibody-drug conjugate (ADC), in combination with standard of care (SoC), in patients with advanced solid tumours, including lung cancers","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Merck Sharp and Dohme; Gilead Sciences","keywords":"Medicine; Conjugate; Standard of care; Antibody-drug conjugate; Antibody; Drug; Cancer research; Pharmacology; Oncology; Internal medicine; Monoclonal antibody; Immunology; Mathematical analysis","score_opus":0.008450471555992288,"score_gpt":0.4182881550432056,"score_spread":0.40983768348721333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409001910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584526,0.00057042536,0.00025214622,0.0004219231,0.00020353906,0.0025045164,0.000050245482,0.000010734216,0.00014122513],"genre_scores_gemma":[0.9979545,0.000044297616,0.0017277736,0.00004531489,0.00001916123,0.00006513349,0.00008621371,0.000023838384,0.000033757267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997537,0.000319684,0.0010900942,0.00027045322,0.00051507517,0.00026769485],"domain_scores_gemma":[0.9969837,0.00010979665,0.0013524636,0.00020831879,0.001246356,0.00009935326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004342404,0.00023702555,0.0011322257,0.0008286055,0.00008298352,0.000008928599,0.00012357786,0.00011210118,0.000011901189],"category_scores_gemma":[0.00011381621,0.00017334495,0.00007027175,0.00085550075,0.0001206407,0.0002882798,0.000045889905,0.00039440495,1.2735096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06431705,0.008159057,0.861156,0.0008073746,0.0007654082,0.0004983461,0.022776516,0.0059019304,0.0040523256,0.00002581695,0.00005766656,0.031482525],"study_design_scores_gemma":[0.10142998,0.06623428,0.78389573,0.007031682,0.001793951,0.000033840035,0.028350953,0.00054637494,0.010130611,0.00009847859,0.00010830552,0.0003457833],"about_ca_topic_score_codex":0.0004370985,"about_ca_topic_score_gemma":0.0022541792,"teacher_disagreement_score":0.077260226,"about_ca_system_score_codex":0.0027546145,"about_ca_system_score_gemma":0.0019060689,"threshold_uncertainty_score":0.7203221},"labels":[],"label_agreement":null},{"id":"W4409076608","doi":"10.1016/b978-0-443-30219-0.00007-8","title":"Lung cancer: Advances in clinical research","year":2025,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Lung cancer; Medicine; Cancer; Lung; Intensive care medicine; Oncology; Internal medicine","score_opus":0.04687157753717242,"score_gpt":0.4725293198912035,"score_spread":0.4256577423540311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409076608","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043234628,0.06748174,8.090082e-7,0.00066051976,0.00062654744,0.0012830358,0.00006106449,0.000036346337,0.9298067],"genre_scores_gemma":[0.0005560748,0.018739475,0.00017445428,0.00048303584,0.0005597701,0.00028727404,0.000050932777,0.0000467969,0.9791022],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979346,0.00005829634,0.0006506606,0.0005642374,0.00044950444,0.0003427177],"domain_scores_gemma":[0.9987054,0.0002619109,0.00011624846,0.00050990295,0.0002536965,0.0001528578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053147104,0.00025651968,0.0006983639,0.00039233826,0.00009455994,0.000019061912,0.000141898,0.00034305707,0.00039076604],"category_scores_gemma":[0.000063117535,0.00021310913,0.00023366473,0.000042671152,0.00021571646,0.000038862257,0.00009620334,0.0011273558,0.000048063906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083538085,0.000034324432,0.0019183982,0.00038907348,0.00024431662,0.0001492591,0.00011153834,4.2005775e-7,4.8974266e-7,0.006102288,0.0023738006,0.98859257],"study_design_scores_gemma":[0.0013114657,0.00012774304,0.0005536511,0.0038155094,0.00041507647,0.000004358976,0.000012869625,0.0000089831765,0.0000034198579,0.003100209,0.99048436,0.00016236339],"about_ca_topic_score_codex":0.000009930578,"about_ca_topic_score_gemma":0.00050140586,"teacher_disagreement_score":0.9884302,"about_ca_system_score_codex":0.00059842895,"about_ca_system_score_gemma":0.0016264137,"threshold_uncertainty_score":0.8690338},"labels":[],"label_agreement":null},{"id":"W4409100763","doi":"10.1016/j.jtho.2025.03.022","title":"PP01.15 Transcriptional Changes Associated with Tolerance to EGFR Tyrosine Kinase Inhibitors in Mutant EGFR Lung Cancer PDX Models","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Mutant; Lung cancer; Tyrosine kinase; Cancer research; Receptor tyrosine kinase; Oncology; Internal medicine; Receptor; Genetics; Gene; Biology","score_opus":0.020283172524426497,"score_gpt":0.4167645258222943,"score_spread":0.39648135329786777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409100763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402911,0.006763137,0.001286787,0.047666468,0.0010548844,0.0005888272,0.00005803551,0.000018997405,0.0022717356],"genre_scores_gemma":[0.9936757,0.00030558626,0.0011664546,0.0029512213,0.0002603175,0.00007645282,0.000012196028,0.00001808138,0.0015339939],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986747,0.000097752505,0.00046362917,0.00019474416,0.00028751732,0.0002816837],"domain_scores_gemma":[0.9989538,0.00008734067,0.00026676463,0.000110844936,0.00041584158,0.00016540241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003174101,0.00017122655,0.0005920375,0.00044625654,0.00006856383,0.000015132286,0.00009545843,0.00014248332,0.00008490483],"category_scores_gemma":[0.00005695589,0.00012529551,0.000088808454,0.0006251683,0.00005522339,0.00014590134,0.000015381578,0.00034529195,0.0000011913942],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033592008,0.011828762,0.13578536,0.0012659762,0.0068260687,0.007938228,0.023991596,0.092372246,0.11901222,0.0027669258,0.041209456,0.52341115],"study_design_scores_gemma":[0.057616316,0.025123766,0.5961383,0.03451465,0.015710201,0.001822016,0.006872982,0.026331704,0.05371657,0.0036155514,0.17629534,0.0022425917],"about_ca_topic_score_codex":0.0001540313,"about_ca_topic_score_gemma":0.002366994,"teacher_disagreement_score":0.52116853,"about_ca_system_score_codex":0.0022163775,"about_ca_system_score_gemma":0.0013807964,"threshold_uncertainty_score":0.579575},"labels":[],"label_agreement":null},{"id":"W4409119243","doi":"10.1002/cncr.35786","title":"Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment","year":2025,"lang":"en","type":"review","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Lung cancer; Cancer; Anaplastic large-cell lymphoma; Oncology; Lymphoma; Clinical trial; Cancer research; Internal medicine","score_opus":0.01404914865503118,"score_gpt":0.3725995719649833,"score_spread":0.3585504233099521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409119243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008481513,0.98581624,0.000043137064,0.0001052392,0.0010639933,0.0029491636,0.0013752931,0.000046167566,0.008515977],"genre_scores_gemma":[0.00011063374,0.9790266,0.00011494663,0.00024051775,0.00036568643,0.006640693,0.0006373103,0.00007547819,0.012788131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787927,0.000064216154,0.00056536763,0.0007965436,0.00018031218,0.0005143166],"domain_scores_gemma":[0.99882936,0.00016643527,0.00028786346,0.0004180826,0.00010610717,0.0001921558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00003633735,0.000695232,0.0019615781,0.00039958948,0.00009734992,0.000031254764,0.00014388372,0.00025551431,0.00036847097],"category_scores_gemma":[0.000010972267,0.0005028586,0.00045145524,0.0007040544,0.000058056514,0.0001031382,0.000045928926,0.00016460007,0.00003233197],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000621558,0.00031083135,0.00040714123,0.020363105,0.0007684586,0.00023557497,0.00017890253,0.00005089304,3.2704915e-7,0.000023393022,0.0009395823,0.97665966],"study_design_scores_gemma":[0.0031369908,0.00021392906,0.00020898269,0.05257453,0.010987778,0.000008635967,0.00003535949,0.00003288225,0.000025302172,0.000005350368,0.93235046,0.0004197769],"about_ca_topic_score_codex":0.0012231077,"about_ca_topic_score_gemma":0.002606034,"teacher_disagreement_score":0.97623986,"about_ca_system_score_codex":0.0059168283,"about_ca_system_score_gemma":0.00517523,"threshold_uncertainty_score":0.9997423},"labels":[],"label_agreement":null},{"id":"W4409129984","doi":"10.1200/jco-25-00275","title":"Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Dysgeusia; Adverse effect; Clinical endpoint; Population; Clinical trial; Lung cancer; ROS1; Gastroenterology; Phases of clinical research; Surgery; Cancer; Adenocarcinoma","score_opus":0.04814570984505929,"score_gpt":0.49935750184501054,"score_spread":0.45121179199995126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409129984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88967586,0.0029428906,0.0001807018,0.014225226,0.0030812242,0.00030819472,0.0000051315574,0.000007604003,0.08957319],"genre_scores_gemma":[0.98006696,0.0023361365,0.0022010962,0.0063312505,0.0007240861,0.00001785609,0.0000021784638,0.000011376534,0.008309088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978418,0.000121644924,0.0015607021,0.00015400839,0.00013283701,0.00018902349],"domain_scores_gemma":[0.9978814,0.00086345576,0.0007084535,0.0001308479,0.00023472286,0.00018108843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009295019,0.00010354168,0.0010008228,0.00018475878,0.00003068271,0.000006927673,0.00010805971,0.00025117517,0.0001454771],"category_scores_gemma":[0.00057952205,0.00007415335,0.00031951276,0.00026965633,0.000072592295,0.00005429531,0.000029188463,0.0007529323,0.0000059571244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012326905,0.0021824585,0.83436066,0.00009283154,0.0004167541,0.0006372142,0.00020534734,0.00006800406,0.00013372065,0.000058893052,0.022853468,0.13775797],"study_design_scores_gemma":[0.02342643,0.0038102756,0.6471534,0.0004619027,0.001654403,0.00007068658,0.0003251829,0.00028803793,0.00035352336,0.00017202935,0.3221772,0.0001069565],"about_ca_topic_score_codex":0.00017114387,"about_ca_topic_score_gemma":0.0003523764,"teacher_disagreement_score":0.29932374,"about_ca_system_score_codex":0.0004152771,"about_ca_system_score_gemma":0.0042522615,"threshold_uncertainty_score":0.75433296},"labels":[],"label_agreement":null},{"id":"W4409349079","doi":"10.1016/j.bioorg.2025.108467","title":"Synthesis and evaluation of novel amino pyrimidine derivatives containing sulfonamide and their application as EGFR inhibitors","year":2025,"lang":"en","type":"article","venue":"Bioorganic Chemistry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ste. Anne's Hospital","funders":"National Natural Science Foundation of China","keywords":"Sulfonamide; Chemistry; Pyrimidine; Combinatorial chemistry; Stereochemistry","score_opus":0.01844347112196556,"score_gpt":0.3127335055272453,"score_spread":0.2942900344052798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409349079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941193,0.0014101007,0.00024962344,0.0006402477,0.000013975165,0.00027209087,0.000014224107,0.000021424225,0.0032590525],"genre_scores_gemma":[0.99944806,0.0000736037,0.00013492988,0.000052194042,0.000032892476,0.000060935945,0.00003557896,0.000008369507,0.00015342362],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994676,0.0000076601455,0.00015864264,0.00019077901,0.00010375162,0.00007157189],"domain_scores_gemma":[0.99950755,0.00010065203,0.0000807684,0.00013577899,0.0001360073,0.000039218692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013197043,0.000096679934,0.00015959927,0.000026227526,0.000049796883,0.000008247269,0.00002449624,0.00006326509,0.00002910166],"category_scores_gemma":[0.00023592249,0.00007934149,0.000020032649,0.00012405943,0.000078389996,0.00003229847,0.000027953825,0.000042178086,3.6562926e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034361423,0.00009812822,0.0071905297,0.00017594422,0.00014716343,1.8139079e-7,0.00038656822,8.6778465e-7,0.9721702,0.000114803166,0.00003462693,0.019646665],"study_design_scores_gemma":[0.0014050045,0.000024011788,0.025742028,0.00019874409,0.00039226876,0.000010648703,0.0016551287,0.0006455322,0.9695014,0.00012932558,0.00023251462,0.00006340757],"about_ca_topic_score_codex":0.00005761055,"about_ca_topic_score_gemma":0.0000027969397,"teacher_disagreement_score":0.019583257,"about_ca_system_score_codex":0.00012965572,"about_ca_system_score_gemma":0.0002153906,"threshold_uncertainty_score":0.3235452},"labels":[],"label_agreement":null},{"id":"W4409595460","doi":"10.1016/j.lungcan.2025.108551","title":"Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Takeda Pharmaceutical Company; Takeda Pharmaceuticals U.S.A.; AstraZeneca; LUNGevity Foundation","keywords":"Medicine; Afatinib; Osimertinib; Oncology; Lung cancer; Internal medicine; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.021994936969514413,"score_gpt":0.38232338040072067,"score_spread":0.36032844343120624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409595460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97545165,0.010216524,0.004194464,0.0016683458,0.00088752835,0.0022944012,0.00025542095,0.0001001901,0.004931472],"genre_scores_gemma":[0.9878675,0.0036553657,0.0014406447,0.0005389342,0.000079699115,0.0009371788,0.00017074248,0.000038013364,0.0052719507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976521,0.0001241807,0.00080814125,0.0006040891,0.00033971644,0.0004717536],"domain_scores_gemma":[0.99860066,0.00014756378,0.00028189676,0.0004783938,0.00033349867,0.00015800071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022676801,0.000358125,0.0010093268,0.00077306875,0.00011830413,0.000025853731,0.00017355595,0.00010353411,0.0005491671],"category_scores_gemma":[0.000031014893,0.00029524317,0.00033075467,0.0030952862,0.00012989934,0.00010679854,0.000042358057,0.00028240157,0.000002994864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013411188,0.0012689362,0.9741476,0.00054050575,0.006350388,0.00004537794,0.0019974858,0.0073646866,0.0023871155,0.00027688438,0.0011634298,0.003116464],"study_design_scores_gemma":[0.016228411,0.00012091406,0.9255587,0.00085089775,0.008285303,6.641388e-7,0.00023482284,0.037850477,0.008631467,0.000016819913,0.0018386033,0.0003829436],"about_ca_topic_score_codex":0.03468835,"about_ca_topic_score_gemma":0.048068352,"teacher_disagreement_score":0.04858893,"about_ca_system_score_codex":0.0010476633,"about_ca_system_score_gemma":0.001640715,"threshold_uncertainty_score":0.99995},"labels":[],"label_agreement":null},{"id":"W4409625073","doi":"10.1158/1538-7445.am2025-550","title":"Abstract 550: Patient-derived organoids as a screening platform to identify mechanisms of osimertinib resistance in non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Organoid; Osimertinib; Lung cancer; Medicine; Cancer; Computational biology; Biology; Cancer research; Oncology; Internal medicine; Cell biology; Adenocarcinoma","score_opus":0.04241366480294725,"score_gpt":0.43045650748326825,"score_spread":0.388042842680321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409625073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838423,0.0031927854,0.00076597655,0.0015491402,0.00021337435,0.0018688007,0.00008018863,0.000027363205,0.008460036],"genre_scores_gemma":[0.9928197,0.00031141326,0.0014509215,0.0003657171,0.00004945992,0.0011550767,0.000021705058,0.000039860504,0.003786103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773717,0.000038129496,0.0004712225,0.0005011638,0.0006265423,0.0006257831],"domain_scores_gemma":[0.998561,0.00014316723,0.00009488879,0.00042753466,0.00055480923,0.00021860086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036596242,0.00019061835,0.00038608882,0.00062340347,0.0001659474,0.000042276646,0.00023190622,0.00012247595,0.000735197],"category_scores_gemma":[0.000108465894,0.00017412352,0.00008283809,0.0014211512,0.000072714145,0.000115412586,0.0001465958,0.0004464301,0.000018010547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015490849,0.00036012192,0.015441734,0.0014603275,0.00034093586,0.00012208434,0.005830887,0.00018387486,0.9565095,0.0005417828,0.0061840466,0.011475672],"study_design_scores_gemma":[0.0041583767,0.00021611723,0.119088866,0.0038238848,0.0001580581,7.724347e-7,0.0024691403,0.000055108343,0.86739993,0.0007688021,0.0016244678,0.00023647345],"about_ca_topic_score_codex":0.008057313,"about_ca_topic_score_gemma":0.005101503,"teacher_disagreement_score":0.103647135,"about_ca_system_score_codex":0.00096939254,"about_ca_system_score_gemma":0.001583528,"threshold_uncertainty_score":0.9985481},"labels":[],"label_agreement":null},{"id":"W4409629189","doi":"10.1158/1538-7445.am2025-4289","title":"Abstract 4289: Discovery of potent RAD51 inhibitors with anticancer activity in preclinical models of non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University Health Network","funders":"","keywords":"Cancer; Medicine; Lung cancer; Pharmacology; Cancer research; Computational biology; Oncology; Biology; Internal medicine","score_opus":0.06628005333678891,"score_gpt":0.4632152967950916,"score_spread":0.39693524345830267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409629189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869801,0.0034606555,0.00030503428,0.0010505469,0.00015649085,0.0013045626,0.000114631,0.000009300268,0.006618723],"genre_scores_gemma":[0.99510825,0.002164579,0.00017137399,0.000042645235,0.000081176186,0.0005043691,0.0000074857508,0.000024672447,0.0018954506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809474,0.000067652334,0.0004034528,0.00043343054,0.00057640247,0.00042432864],"domain_scores_gemma":[0.9986927,0.00026144754,0.00012482132,0.000410306,0.00040414146,0.00010660554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043122983,0.00016259728,0.00051310565,0.00035501822,0.000056070123,0.000017539382,0.00015231203,0.000115677416,0.000057102447],"category_scores_gemma":[0.000035224515,0.00011996589,0.00010313572,0.0008280561,0.00029798402,0.00020780577,0.00008975675,0.0005184605,6.412985e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072352383,0.0036764485,0.78145593,0.007406972,0.0013038197,0.00009578228,0.002635642,0.013551362,0.13665892,0.00039703836,0.0032961646,0.04228668],"study_design_scores_gemma":[0.008579739,0.0005718266,0.5808366,0.0057914555,0.00041761197,0.0000010014661,0.00053442596,0.0028067448,0.39979652,0.00023364472,0.0001868838,0.00024353425],"about_ca_topic_score_codex":0.015156484,"about_ca_topic_score_gemma":0.0028449534,"teacher_disagreement_score":0.26313758,"about_ca_system_score_codex":0.00080492976,"about_ca_system_score_gemma":0.0037453135,"threshold_uncertainty_score":0.9914017},"labels":[],"label_agreement":null},{"id":"W4409630656","doi":"10.1158/1538-7445.am2025-4623","title":"Abstract 4623: The relationship of KRAS mutation and clinical outcomes in patients treated with consolidation durvalumab for locally advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Durvalumab; Medicine; Lung cancer; Oncology; Internal medicine; KRAS; Cancer; Immunotherapy","score_opus":0.059412391343784274,"score_gpt":0.4702794653159846,"score_spread":0.4108670739722003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409630656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467516,0.00048048128,0.00015415784,0.0010043685,0.000070423936,0.0027961773,0.00007557886,0.000010200631,0.0007334568],"genre_scores_gemma":[0.99694717,0.00020322487,0.00021188974,0.00008695711,0.000020151374,0.001083832,0.00008496295,0.000016243395,0.0013455768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987819,0.00008140697,0.00038319323,0.00027554506,0.00025273563,0.00022521403],"domain_scores_gemma":[0.997844,0.0011147604,0.0001123019,0.00020543959,0.00066189666,0.00006159177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043918283,0.00010774674,0.00025944036,0.00019758282,0.00014561905,0.000020129564,0.00006991047,0.000082621926,0.000029247269],"category_scores_gemma":[0.000265629,0.00006887665,0.000048215974,0.0004245153,0.00017028378,0.00008537282,0.000020790849,0.00025260454,9.0721795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010351905,0.00027846615,0.98677164,0.00029359013,0.0001735415,0.0000022433956,0.00037909922,0.00017224772,0.000063941865,0.0000997774,0.00025952922,0.010470717],"study_design_scores_gemma":[0.009665919,0.0003756559,0.98767185,0.0005291275,0.00020202348,1.7278286e-7,0.00030523603,0.00027022735,0.0007613957,0.000070213704,0.00008585825,0.00006231241],"about_ca_topic_score_codex":0.0015113393,"about_ca_topic_score_gemma":0.0020207362,"teacher_disagreement_score":0.010408404,"about_ca_system_score_codex":0.00038776133,"about_ca_system_score_gemma":0.0010750392,"threshold_uncertainty_score":0.28087083},"labels":[],"label_agreement":null},{"id":"W4409633951","doi":"10.1158/1538-7445.am2025-7410","title":"Abstract 7410: Make it better and faster: a retrospective study examining the introduction of an agnostic, reflexive, and expanded pathological protocol for lung cancer patients in Saskatchewan, Canada","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Pathological; Protocol (science); Lung cancer; Medicine; Cancer; Reflexivity; Retrospective cohort study; Oncology; Pathology; Internal medicine; Alternative medicine; Sociology; Social science","score_opus":0.05625772534206818,"score_gpt":0.4658112349045153,"score_spread":0.4095535095624471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409633951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943906,0.000058064034,0.0000037506568,0.0022554765,0.00005637179,0.053504143,0.0000697771,0.000005631665,0.00014077166],"genre_scores_gemma":[0.8561253,0.0000093407025,0.000056937017,0.00014843259,0.00010706717,0.14316055,0.000012053292,0.000009835936,0.00037046752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998667,0.00010625536,0.00024617556,0.00039698358,0.00032669757,0.0002568862],"domain_scores_gemma":[0.9991578,0.00014180077,0.0000618968,0.00019609502,0.00037686148,0.00006555638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040854226,0.00011193722,0.00023755162,0.00011627211,0.0001589067,0.000028081191,0.0000661233,0.00004910756,0.000048195518],"category_scores_gemma":[0.00014725073,0.0000726514,0.000012673216,0.00026036164,0.00013388711,0.00006387824,0.00006165638,0.00026493176,3.0979734e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012110692,0.0004788078,0.9570295,0.00033833296,0.00014556253,0.00001680101,0.0052367705,0.000009993809,0.0011611292,0.000009408518,0.0028213384,0.031541258],"study_design_scores_gemma":[0.0051149908,0.0008761354,0.9835129,0.00022809542,0.00006324254,8.3468984e-7,0.008719586,0.000038313425,0.00085806905,0.00005208655,0.00047099165,0.000064797285],"about_ca_topic_score_codex":0.15870409,"about_ca_topic_score_gemma":0.7030176,"teacher_disagreement_score":0.5443135,"about_ca_system_score_codex":0.00076535356,"about_ca_system_score_gemma":0.0009529422,"threshold_uncertainty_score":0.8468982},"labels":[],"label_agreement":null},{"id":"W4409652571","doi":"10.1158/1538-7445.am2025-813","title":"Abstract 813: <i>In vitro</i> and <i>in vivo</i> modelling of drug tolerance and minimal residual disease to discover effective therapeutic combination strategies for EGFR-mutated lung cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Drug; Medicine; In vivo; Lung cancer; Disease; Cancer; In vitro; Pharmacology; Oncology; Cancer research; Internal medicine; Biology; Biotechnology; Genetics","score_opus":0.030131876624509356,"score_gpt":0.4141105124048923,"score_spread":0.38397863578038294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409652571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98285764,0.011226042,0.00033952066,0.002327345,0.00006712871,0.0025734056,0.00028296933,0.000009762851,0.00031616326],"genre_scores_gemma":[0.9964602,0.00073612126,0.00009178461,0.00017222458,0.00003273354,0.002020208,0.000017163979,0.000018110119,0.0004514363],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99875516,0.000064561806,0.00023104073,0.00037651544,0.0002509774,0.00032174514],"domain_scores_gemma":[0.9991628,0.00034260238,0.000037368987,0.00013575159,0.00021218369,0.00010932473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031303297,0.00013388047,0.0002818977,0.0003087302,0.00009013647,0.000050106068,0.00005872253,0.00004282166,0.00001172151],"category_scores_gemma":[0.000023088765,0.000116121504,0.000029761375,0.0004499436,0.00012573568,0.00018652737,0.000033329638,0.00018264414,1.3745301e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061929703,0.0022891916,0.1922056,0.013803423,0.0012517526,0.0001323353,0.024234716,0.090288505,0.5573148,0.0070422045,0.0043392773,0.045168504],"study_design_scores_gemma":[0.03771441,0.0007328489,0.6060942,0.009096038,0.0008212004,0.000002000644,0.00708636,0.08208949,0.24354558,0.010729548,0.001232889,0.000855473],"about_ca_topic_score_codex":0.0034711123,"about_ca_topic_score_gemma":0.0012409101,"teacher_disagreement_score":0.41388857,"about_ca_system_score_codex":0.00043834065,"about_ca_system_score_gemma":0.0008827762,"threshold_uncertainty_score":0.5247307},"labels":[],"label_agreement":null},{"id":"W4409686990","doi":"10.1016/j.jtocrr.2025.100837","title":"Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; McGill University Health Centre; Institut universitaire de cardiologie et de pneumologie de Québec; William Osler Health System; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer Canada; Amgen Canada; AstraZeneca; Pfizer; Amgen","keywords":"Lung cancer; Biomarker; Medicine; Cancer; Oncology; Intensive care medicine; Internal medicine; Biology; Genetics","score_opus":0.24735867700694428,"score_gpt":0.5728935209881609,"score_spread":0.3255348439812167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409686990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74302775,0.0009835692,0.016739296,0.07474465,0.0007212993,0.007896632,0.000018498456,0.00007308359,0.15579522],"genre_scores_gemma":[0.97582996,0.000069788795,0.019220598,0.00063903583,0.000053859658,0.00096701976,0.000003323736,0.000008133126,0.00320827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973538,0.00019555826,0.00081536634,0.0006469789,0.0005658212,0.0004224626],"domain_scores_gemma":[0.9969274,0.0020290983,0.000055908888,0.0002586963,0.0004610779,0.00026783833],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004458625,0.000105273226,0.0003275411,0.00049260206,0.00015279218,0.00007198365,0.00006655905,0.00008180166,0.000009337458],"category_scores_gemma":[0.015578457,0.00007595462,0.000034616285,0.0016527504,0.00012286124,0.00009136729,0.0001721132,0.00036956958,0.0000018646149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001532354,0.0025335273,0.97009605,0.0004985617,0.00011591617,0.00061318144,0.00053554354,0.0000219606,0.000608484,0.0045026913,0.0018409352,0.01847991],"study_design_scores_gemma":[0.00061820453,0.00017669964,0.993796,0.0010771394,0.00010335132,0.00002412359,0.0007717375,0.001648795,0.000009034155,0.00051461067,0.0011619427,0.000098379634],"about_ca_topic_score_codex":0.0013134758,"about_ca_topic_score_gemma":0.00006489662,"teacher_disagreement_score":0.23280221,"about_ca_system_score_codex":0.0002513467,"about_ca_system_score_gemma":0.0004888546,"threshold_uncertainty_score":0.99271375},"labels":[],"label_agreement":null},{"id":"W4409721270","doi":"10.1200/po-24-00500","title":"Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada); Bayer (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Trk receptor; Oncology; Cancer; Hazard ratio; Progression-free survival; Lung cancer; Receptor; Confidence interval; Neurotrophin; Chemotherapy","score_opus":0.011398444702965325,"score_gpt":0.34334784540911234,"score_spread":0.33194940070614704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409721270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984308,0.0004220115,0.00010105544,0.0040617716,0.00093736843,0.0027406993,0.00011421045,0.000113604474,0.007201297],"genre_scores_gemma":[0.9775199,0.00048337007,0.008148278,0.0009982008,0.00023993052,0.0010559185,0.0004459905,0.00007734208,0.011031041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973257,0.0002533541,0.00064261083,0.000793839,0.00046759695,0.00051688054],"domain_scores_gemma":[0.99814373,0.00030092587,0.00030362443,0.0005540168,0.00047774817,0.00021995112],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018983555,0.00043203693,0.0009065876,0.0006850162,0.00025536967,0.000041390187,0.00017002062,0.00023067326,0.0010587543],"category_scores_gemma":[0.00006177688,0.00028685492,0.00009567926,0.001212684,0.00020409582,0.0001877384,0.00009057676,0.00043935032,0.000049298887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028485512,0.0057504307,0.7220641,0.00011832614,0.0006037072,0.00007073635,0.003318912,0.00011024009,0.0055349637,0.00022397997,0.045804333,0.18791477],"study_design_scores_gemma":[0.037128285,0.0064459224,0.6524257,0.0020931184,0.00047790218,0.000002854607,0.0010533913,0.000058384412,0.0062549305,0.0000596176,0.29349902,0.0005008923],"about_ca_topic_score_codex":0.003258975,"about_ca_topic_score_gemma":0.008631778,"teacher_disagreement_score":0.24769467,"about_ca_system_score_codex":0.0022196355,"about_ca_system_score_gemma":0.0012134173,"threshold_uncertainty_score":0.99995834},"labels":[],"label_agreement":null},{"id":"W4409722550","doi":"10.1007/s40273-025-01488-x","title":"Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Lung cancer; Quality of Life Research; Oncology; Chemotherapy; Health economics; Adjuvant chemotherapy; Internal medicine; Pharmacoeconomics; Cisplatin; Intensive care medicine; Public health; Cancer; Crizotinib; Pathology","score_opus":0.013683453788698027,"score_gpt":0.3488611628773168,"score_spread":0.33517770908861877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409722550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920625,0.0003758615,0.0002530657,0.00015699577,0.000544234,0.0031085133,0.0005149217,0.0000059645977,0.00297793],"genre_scores_gemma":[0.99810106,0.00019611773,0.00021192161,0.00032468393,0.000026619045,0.00081231917,0.000115033006,0.000022909442,0.00018936401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929446,0.000021281017,0.00019438507,0.00023159086,0.000047623635,0.0002106606],"domain_scores_gemma":[0.99928933,0.00030065232,0.00009638818,0.00010784531,0.00014341896,0.00006234956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000673582,0.00013808598,0.00031465775,0.000082833685,0.00004021021,0.000005776393,0.000060215327,0.000026310212,0.00003795725],"category_scores_gemma":[0.00000570616,0.00012427523,0.0000390927,0.00012271389,0.000017045802,0.0000531025,0.000012152451,0.00008213956,2.309604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019214313,0.0006070229,0.9544552,0.0010357784,0.0014188059,0.0000055527253,0.00051849626,0.0052958075,0.0011031799,0.000024930352,0.0016228894,0.014698016],"study_design_scores_gemma":[0.13069686,0.00074919104,0.65098625,0.00082662015,0.0014721969,4.9278094e-7,0.00032190955,0.010450912,0.19995932,0.000014085319,0.0041127726,0.00040941604],"about_ca_topic_score_codex":0.32951698,"about_ca_topic_score_gemma":0.3314595,"teacher_disagreement_score":0.30346897,"about_ca_system_score_codex":0.0023646774,"about_ca_system_score_gemma":0.0029091602,"threshold_uncertainty_score":0.68073964},"labels":[],"label_agreement":null},{"id":"W4409761185","doi":"10.1016/j.eprac.2025.03.016","title":"A Real-World Pharmacovigilance Analysis of Lorlatinib-Associated Metabolic Effects Using the FDA Adverse Events Reporting System (FAERS) Database From 2013 to 2024","year":2025,"lang":"en","type":"article","venue":"Endocrine Practice","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacovigilance; Adverse Event Reporting System; Medicine; Adverse effect; Database; Pharmacology","score_opus":0.027317995963639288,"score_gpt":0.4321755279743372,"score_spread":0.40485753201069796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409761185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795567,0.0012564257,0.0017275435,0.0032465977,0.0010834003,0.0016401612,0.00025115788,0.00012078965,0.011117258],"genre_scores_gemma":[0.9901756,0.00018811249,0.0052216644,0.00072616845,0.00010378024,0.00011166634,0.00024858062,0.000021829765,0.0032026174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775285,0.00029627298,0.00088482106,0.0004034119,0.00038769058,0.00027493486],"domain_scores_gemma":[0.99621636,0.0013527571,0.0013809375,0.0006161107,0.00031855947,0.0001152737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055167923,0.00019963656,0.00067868683,0.00041902714,0.0001734621,0.000014387447,0.00012008176,0.00002049304,0.00010686957],"category_scores_gemma":[0.0029284635,0.00014700198,0.00021283337,0.0027923794,0.000019004357,0.00029950452,0.00011541041,0.00022669767,0.000018512379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026962229,0.0026462565,0.7635993,0.0013991287,0.11611879,0.0029641318,0.004027228,0.020340016,0.061670672,0.0015940019,0.01632045,0.0066238088],"study_design_scores_gemma":[0.013106209,0.00020539844,0.48375136,0.003685453,0.30151433,0.000080558995,0.0072022085,0.06309582,0.033049937,0.00002356359,0.093465365,0.00081978814],"about_ca_topic_score_codex":0.029494736,"about_ca_topic_score_gemma":0.00086023356,"teacher_disagreement_score":0.27984795,"about_ca_system_score_codex":0.00033621362,"about_ca_system_score_gemma":0.0002722629,"threshold_uncertainty_score":0.97696793},"labels":[],"label_agreement":null},{"id":"W4409774343","doi":"10.1080/14796694.2025.2489319","title":"Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; EMD Serono; Jazz Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Sanofi; G1 Therapeutics; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Plain language; Oncology; Order (exchange); Intensive care medicine; Internal medicine; Linguistics","score_opus":0.003513448381446309,"score_gpt":0.33379465714999235,"score_spread":0.33028120876854605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409774343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569722,0.0025291636,0.0000012629257,0.005215929,0.00012128871,0.0010643059,0.000027243621,0.000013131346,0.034055486],"genre_scores_gemma":[0.995643,0.0003209409,0.0000632675,0.00051070197,0.00015835204,0.00045345604,0.000038466536,0.000009988073,0.0028017932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945575,0.00008086779,0.00009585396,0.00016512786,0.00007517623,0.0001272487],"domain_scores_gemma":[0.999608,0.00016927917,0.00004644807,0.00011971151,0.000028176792,0.000028395141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006218969,0.000120715275,0.00028282675,0.00013549124,0.000040301147,0.00000353542,0.000028534303,0.000055686483,0.00002729073],"category_scores_gemma":[0.000003969788,0.00005424314,0.000018389204,0.00040996756,0.00002901812,0.000017793847,0.0000072935895,0.000097753815,4.0039652e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009449599,0.0014745168,0.826901,0.00064137636,0.0018305419,0.0007773258,0.038567085,0.00013179421,0.001028542,0.0023105992,0.006911206,0.10997637],"study_design_scores_gemma":[0.049329564,0.044998437,0.76342154,0.0021626062,0.0044304235,0.00009977063,0.011937871,0.00024549098,0.0031145737,0.000011847682,0.11984578,0.000402107],"about_ca_topic_score_codex":0.0020824706,"about_ca_topic_score_gemma":0.0627933,"teacher_disagreement_score":0.112934574,"about_ca_system_score_codex":0.00044467856,"about_ca_system_score_gemma":0.000513531,"threshold_uncertainty_score":0.9543083},"labels":[],"label_agreement":null},{"id":"W4409805543","doi":"10.1016/j.healun.2025.02.198","title":"Trifecta-Lung Study: First Results Showing Correlation Between dd-cfDNA and Molecular Injury in Transbronchial Lung Biopsies","year":2025,"lang":"en","type":"article","venue":"The Journal of Heart and Lung Transplantation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lung; Medicine; Correlation; Pathology; Radiology; Internal medicine; Mathematics","score_opus":0.008979958202856969,"score_gpt":0.31603203675420477,"score_spread":0.3070520785513478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409805543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920631,0.0018360747,0.0020168978,0.003215687,0.0001244908,0.00056331005,0.000022607108,0.000008900083,0.00014894553],"genre_scores_gemma":[0.99892414,0.0007139523,0.0001382905,0.00008694333,0.000059405607,0.0000052866535,0.000025506497,0.000007973832,0.000038523696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990543,0.000118102325,0.0004295137,0.00010651195,0.00017493423,0.000116617724],"domain_scores_gemma":[0.9995182,0.00022039397,0.00008959473,0.00007159449,0.000051384864,0.000048828733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005295889,0.00011178428,0.00025775324,0.00023328597,0.00015896239,0.000025255298,0.000028875265,0.00005481999,0.000002577854],"category_scores_gemma":[0.000017687842,0.00007726301,0.00004701099,0.00020282276,0.000037714686,0.00016977702,0.0000035870687,0.0002110202,1.5084393e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005932918,0.00025260804,0.9496996,0.0006219668,0.00081855623,0.0000951635,0.032026187,0.00064782356,0.0062617394,0.00006946759,0.0004096382,0.0031643237],"study_design_scores_gemma":[0.008310253,0.00057675247,0.9831091,0.0008126214,0.0032610071,0.000115634946,0.00092097686,0.001454722,0.0011733603,0.00005318883,0.00012067668,0.00009168805],"about_ca_topic_score_codex":0.00015691407,"about_ca_topic_score_gemma":0.00008837442,"teacher_disagreement_score":0.03340951,"about_ca_system_score_codex":0.00006869191,"about_ca_system_score_gemma":0.000087193745,"threshold_uncertainty_score":0.3150694},"labels":[],"label_agreement":null},{"id":"W4409821093","doi":"10.1158/1538-7445.am2025-lb416","title":"Abstract LB416: SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Cancer; Adenocarcinoma","score_opus":0.0415253501626779,"score_gpt":0.39136179555278156,"score_spread":0.34983644539010367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409821093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829263,0.0005203668,0.000010195037,0.00056745304,0.000051076324,0.002084872,0.00037374647,0.000048342146,0.008051318],"genre_scores_gemma":[0.9945915,0.00019696966,0.00032030276,0.00021337753,0.00004351951,0.00052164483,0.00017608271,0.00006219079,0.00387446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700373,0.000112944734,0.0005037215,0.000728182,0.00088636857,0.000765033],"domain_scores_gemma":[0.99755704,0.00040470585,0.00015603726,0.0006241444,0.0009946994,0.0002633426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002830758,0.000338274,0.00066318596,0.0005363188,0.00018461517,0.00005717859,0.00021375532,0.00015913192,0.00046873186],"category_scores_gemma":[0.00018748608,0.00022518152,0.00006343858,0.0011420385,0.00041397972,0.00022953392,0.000083671446,0.0005626245,0.000012424652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08669073,0.003170166,0.84609485,0.0019172803,0.0019209855,0.00011250656,0.0034153166,0.00011651372,0.016349932,0.0011151868,0.0027120411,0.03638452],"study_design_scores_gemma":[0.024102047,0.002553335,0.94194883,0.0032911564,0.00023752257,0.0000031653287,0.0006622627,0.00002112363,0.020930214,0.00004396272,0.005891674,0.00031469084],"about_ca_topic_score_codex":0.00462616,"about_ca_topic_score_gemma":0.0011817702,"teacher_disagreement_score":0.09585403,"about_ca_system_score_codex":0.00056883064,"about_ca_system_score_gemma":0.0013614269,"threshold_uncertainty_score":0.9182636},"labels":[],"label_agreement":null},{"id":"W4409822141","doi":"10.1158/1538-7445.am2025-ct073","title":"Abstract CT073: A first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) in adult patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Solid tumor; Medicine; Cancer; Internal medicine; Gerontology; Oncology","score_opus":0.021826099649434647,"score_gpt":0.41343379946459047,"score_spread":0.3916076998151558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604774,0.00011978911,0.0000012658342,0.0004588527,0.000016487826,0.0027723538,0.000010474203,0.000008808736,0.00056421827],"genre_scores_gemma":[0.998605,0.000037027992,0.000052119758,0.00002180126,0.0000039553042,0.0010782856,0.000023808527,0.000015980264,0.00016201641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985195,0.000058385092,0.00031725553,0.00033924426,0.0004509002,0.00031476165],"domain_scores_gemma":[0.9991925,0.00006461044,0.000066552115,0.00021144886,0.00039969332,0.00006518983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024084022,0.00012262109,0.00034198494,0.00055708503,0.00007348391,0.00001608342,0.00007265593,0.00003843394,0.000026875869],"category_scores_gemma":[0.000052710013,0.00009104431,0.000010657899,0.0009849106,0.00011219119,0.00013600483,0.00003775324,0.00030482397,6.226843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002096606,0.003106992,0.9863106,0.0002839323,0.000060902945,0.00006674182,0.0029468825,0.00033125014,0.00018399063,0.000055789857,0.000025400133,0.004530928],"study_design_scores_gemma":[0.026617689,0.0021583757,0.9663341,0.0015237989,0.000022765256,4.366587e-7,0.0023638569,0.000056102144,0.00075473107,0.00006333591,0.00002298719,0.000081813516],"about_ca_topic_score_codex":0.008081001,"about_ca_topic_score_gemma":0.0630185,"teacher_disagreement_score":0.0549375,"about_ca_system_score_codex":0.00050442194,"about_ca_system_score_gemma":0.00035836012,"threshold_uncertainty_score":0.99852425},"labels":[],"label_agreement":null},{"id":"W4409822415","doi":"10.1158/1538-7445.am2025-ct022","title":"Abstract CT022: Divarasib plus migoprotafib combination treatment in patients with <i>KRAS G12C</i>-positive non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; KRAS; Cancer; Internal medicine; Lung cancer; Oncology; Colorectal cancer","score_opus":0.02211388574136848,"score_gpt":0.39293627723895913,"score_spread":0.37082239149759066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976071,0.0019289843,0.000034425735,0.0015074358,0.00019409013,0.0046623806,0.00016356308,0.00003250584,0.0154056],"genre_scores_gemma":[0.9872829,0.000514381,0.000080984035,0.00017990425,0.00007224333,0.003720083,0.0002030237,0.000040399136,0.007906132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978544,0.000076801254,0.00028925296,0.00057014107,0.00058862177,0.0006207544],"domain_scores_gemma":[0.9985926,0.00011643532,0.00007556894,0.00036931553,0.0006666691,0.00017939183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018063353,0.00026730966,0.000394107,0.0004606988,0.00024985598,0.000063338906,0.00013940818,0.000113817805,0.00023002067],"category_scores_gemma":[0.000016616566,0.00019730153,0.00007445358,0.0009040054,0.00012509334,0.00013567631,0.000054745375,0.00037687522,0.000017047465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023417994,0.0026117254,0.9641811,0.00056674524,0.00067026337,0.000087401575,0.0032018973,0.00025605733,0.0011276021,0.00014086062,0.002531871,0.022282677],"study_design_scores_gemma":[0.019768989,0.00091274176,0.9650243,0.0014594871,0.0002719447,3.879787e-7,0.00031409925,0.00012343579,0.0106268935,0.00004062891,0.0012497788,0.00020734718],"about_ca_topic_score_codex":0.016160818,"about_ca_topic_score_gemma":0.002901155,"teacher_disagreement_score":0.022075329,"about_ca_system_score_codex":0.0055855988,"about_ca_system_score_gemma":0.002869029,"threshold_uncertainty_score":0.99823177},"labels":[],"label_agreement":null},{"id":"W4409841664","doi":"10.1016/j.adro.2025.101797","title":"Efficacy and Safety of Metastatic Directed Treatment of Oligometastatic Disease: Results of a Meta-analysis","year":2025,"lang":"en","type":"review","venue":"Advances in Radiation Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Clinical trial; Oncology; Disease; Intensive care medicine; MEDLINE; Internal medicine","score_opus":0.05567259004361238,"score_gpt":0.4747112815380677,"score_spread":0.41903869149445533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409841664","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002774954,0.99536324,0.00010416807,0.00008453595,0.00005932316,0.0017428938,0.001832146,0.00000985014,0.00077608775],"genre_scores_gemma":[0.0010602106,0.99383616,0.0029843443,0.000008755345,0.000008241449,0.0003833883,0.001326768,0.000011600056,0.00038052668],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99736875,0.00042024732,0.00154574,0.00035890538,0.00017454488,0.00013178185],"domain_scores_gemma":[0.99506116,0.002584547,0.0017703144,0.00037697403,0.00012676853,0.00008023505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019099566,0.0002695963,0.005113562,0.0010716304,0.000017251265,0.0000015284013,0.00006208313,0.00007561016,0.000050582406],"category_scores_gemma":[0.0005363959,0.0001796456,0.00093061663,0.0016491783,0.00013463099,0.000061446306,0.000015029844,0.000058022233,4.663973e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005810118,0.0013251994,0.000071682516,0.010881185,0.10902525,0.00001949906,0.00032181636,0.00063332106,1.6556383e-7,0.00026375678,0.000007917258,0.8768692],"study_design_scores_gemma":[0.0042891833,0.00084916217,0.00060352864,0.0005522216,0.5984782,0.0000024172018,0.000024144996,0.00003839472,0.0000026692003,0.000052184914,0.3950185,0.00008938237],"about_ca_topic_score_codex":0.000086055894,"about_ca_topic_score_gemma":0.0001106741,"teacher_disagreement_score":0.8767798,"about_ca_system_score_codex":0.00039183744,"about_ca_system_score_gemma":0.0010533882,"threshold_uncertainty_score":0.7325735},"labels":[],"label_agreement":null},{"id":"W4410069277","doi":"10.3390/therapeutics2020007","title":"The Impact of Leptomeningeal Metastasis in Patients with Non-Small Cell Lung Cancer with EGFR Mutation: Survival Analysis of a Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; London Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Retrospective cohort study; Oncology; Lung cancer; Internal medicine; Mutation; Cohort; Metastasis; Survival analysis; Cancer; Biology; Genetics; Gene","score_opus":0.00984477797708888,"score_gpt":0.34180978481870233,"score_spread":0.33196500684161345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410069277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731195,0.00022464046,0.00022821758,0.00003935146,0.000026038613,0.0011861142,0.000071346,0.000006757813,0.00090559636],"genre_scores_gemma":[0.99953264,0.000037041522,0.000105076746,0.000014415634,0.0000050242065,0.00009095305,0.000033559587,0.000012006223,0.00016930295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910516,0.000055984634,0.00024288728,0.00017400611,0.0002800416,0.00014192244],"domain_scores_gemma":[0.9990394,0.0000790988,0.00018275513,0.00026926302,0.00040289815,0.000026557234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015474383,0.00013440139,0.00047843438,0.00022671708,0.000057367073,0.000009389909,0.00006665932,0.000024355293,0.000019667606],"category_scores_gemma":[0.0000027192082,0.000069543166,0.000088152774,0.0015025042,0.000066597524,0.00003015162,0.000012359506,0.000088201225,8.4660975e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096954184,0.0009808801,0.9692084,0.000018739556,0.022291891,0.0000023869718,0.0035469236,0.002276582,0.000016566804,0.000009312674,0.0000030442395,0.0006757093],"study_design_scores_gemma":[0.004565566,0.0014565611,0.9759112,0.00003991002,0.015751176,6.853975e-8,0.0012630883,0.0007502078,0.00019513589,0.0000039578936,0.0000016317525,0.00006151183],"about_ca_topic_score_codex":0.0032320048,"about_ca_topic_score_gemma":0.0024163395,"teacher_disagreement_score":0.0067027626,"about_ca_system_score_codex":0.00045548764,"about_ca_system_score_gemma":0.0003670759,"threshold_uncertainty_score":0.4885846},"labels":[],"label_agreement":null},{"id":"W4410170034","doi":"10.3390/curroncol32050270","title":"Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Osimertinib; T790M; Medicine; Anaplastic lymphoma kinase; Lung cancer; Epidermal growth factor receptor; Adenocarcinoma; Oncology; Cancer research; Internal medicine; Gefitinib; Cancer; Erlotinib","score_opus":0.05754058701564763,"score_gpt":0.4557590945605607,"score_spread":0.39821850754491306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410170034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792523,0.0075768176,0.00004383463,0.0012882653,0.00031453857,0.0009811209,0.000015916687,0.000008032485,0.0018462713],"genre_scores_gemma":[0.99924856,0.00023375652,0.00006571882,0.00003094229,0.000015406786,0.00014010222,0.00009347827,0.000003987649,0.00016801404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917316,0.00008678143,0.00040614457,0.00015791123,0.00007658601,0.0000994002],"domain_scores_gemma":[0.9993526,0.00016650224,0.00017920986,0.00017155589,0.000103088736,0.000027091317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001331804,0.000087023356,0.0003152908,0.0001398147,0.000033624918,0.0000029333858,0.000027525073,0.000051173152,0.000012621422],"category_scores_gemma":[0.00006162874,0.00005706703,0.00005119871,0.00026540385,0.0001004413,0.000021535086,0.000008808773,0.00005854696,3.080123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005612795,0.010364336,0.77787244,0.0005057641,0.00052393734,0.007741729,0.016988348,0.0000054810234,0.00032379018,0.002874735,0.0014154435,0.1808227],"study_design_scores_gemma":[0.049789708,0.008772944,0.87143373,0.00055783254,0.0043899324,0.013386157,0.006944575,0.002288388,0.004074359,0.0010184523,0.037115775,0.00022816336],"about_ca_topic_score_codex":0.00029283398,"about_ca_topic_score_gemma":0.00008353946,"teacher_disagreement_score":0.18059453,"about_ca_system_score_codex":0.0002558741,"about_ca_system_score_gemma":0.00031112137,"threshold_uncertainty_score":0.23271261},"labels":[],"label_agreement":null},{"id":"W4410231412","doi":"10.3390/curroncol32050274","title":"Molecular Profiling in Non-Small-Cell Lung Cancer: A Single-Center Study on Prevalence and Prognosis","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; KRAS; Lung cancer; Internal medicine; Single Center; Targeted therapy; Oncology; Overall survival; Cancer; Colorectal cancer","score_opus":0.04784863247506222,"score_gpt":0.42550229505138204,"score_spread":0.3776536625763198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410231412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884558,0.004451741,0.00006334215,0.0006763498,0.00048203662,0.0027658497,0.000009618127,0.000021883205,0.0030734097],"genre_scores_gemma":[0.9979184,0.0002683585,0.00012382113,0.00016881141,0.000031252996,0.0013114765,0.00000971786,0.000009438436,0.00015868478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991448,0.000056145414,0.00019858702,0.00032591756,0.00008150715,0.00019307602],"domain_scores_gemma":[0.99965626,0.000044226093,0.0000536294,0.00012970665,0.000060548555,0.000055655455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007660322,0.0001238085,0.00023742479,0.00015548136,0.00003940895,0.000010243842,0.00004965771,0.000050232964,0.000009449619],"category_scores_gemma":[0.00002084414,0.00010427121,0.000030891657,0.00019320266,0.000030769108,0.000023030607,0.000047858848,0.00016638252,0.0000016679911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103167324,0.006087154,0.9665559,0.000655694,0.00008898061,0.000050315422,0.0011940609,0.000009369385,0.0007630084,0.000028153147,0.00013505241,0.024329169],"study_design_scores_gemma":[0.03306916,0.0065143607,0.9333492,0.0037185643,0.002632073,0.000015076367,0.001954614,0.0019981398,0.008197292,0.000041610194,0.008086762,0.00042317063],"about_ca_topic_score_codex":0.000025078716,"about_ca_topic_score_gemma":0.000046601574,"teacher_disagreement_score":0.033206698,"about_ca_system_score_codex":0.00049976347,"about_ca_system_score_gemma":0.0002793019,"threshold_uncertainty_score":0.42520565},"labels":[],"label_agreement":null},{"id":"W4410243556","doi":"10.3390/ijms26104519","title":"Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; St. Boniface Hospital; CancerCare Manitoba; University of Manitoba; The Metabolomics Innovation Centre; Université Laval; University of Alberta","funders":"Fonds de Recherche du Québec - Santé; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval","keywords":"Medicine; Cohort; Receiver operating characteristic; Oncology; Lung cancer; Internal medicine; Stage (stratigraphy); Logistic regression; Metabolomics; Area under the curve; Bioinformatics; Biology","score_opus":0.018744387463206436,"score_gpt":0.4306853983898046,"score_spread":0.41194101092659813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410243556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95904297,0.00078383886,0.035995055,0.0015831783,0.0016089329,0.00015520275,0.00000996285,0.000003171545,0.00081771886],"genre_scores_gemma":[0.9951892,0.00014428695,0.004245226,0.00017874573,0.00009243374,0.000009274707,0.0000018548201,0.0000026921682,0.00013630622],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990553,0.00003119219,0.00039209146,0.000094491435,0.00036230983,0.000064615946],"domain_scores_gemma":[0.99881774,0.00009135113,0.00029779493,0.000042963195,0.0007146682,0.000035457208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046860677,0.000049026523,0.00014330311,0.00024637723,0.00003636002,0.00003296569,0.00014089631,0.000029861736,0.000012967855],"category_scores_gemma":[0.00017230018,0.000036822526,0.00017116785,0.00016545056,0.00009079597,0.00017053656,0.000013474008,0.000056297686,1.9732703e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024100372,0.0006819237,0.37840185,0.00011610862,0.006320803,0.000059312297,0.0005906311,0.0038303956,0.11979574,0.0052877073,0.00060620345,0.4818993],"study_design_scores_gemma":[0.008784778,0.0014203057,0.27054137,0.0008453174,0.002221691,0.000081255435,0.0004346083,0.0073849517,0.69954306,0.0026624892,0.00590903,0.00017116258],"about_ca_topic_score_codex":0.00004615232,"about_ca_topic_score_gemma":0.000003966262,"teacher_disagreement_score":0.5797473,"about_ca_system_score_codex":0.00007583927,"about_ca_system_score_gemma":0.00041059434,"threshold_uncertainty_score":0.15015791},"labels":[],"label_agreement":null},{"id":"W4410255805","doi":"10.1016/j.lungcan.2025.108579","title":"Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Exon; Lung cancer; Cancer research; Oncology; Epidermal growth factor; Receptor; Mutation; Internal medicine; Gene; Genetics; Biology","score_opus":0.006628700707250518,"score_gpt":0.31542100738779666,"score_spread":0.30879230668054614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410255805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874089,0.00648165,0.00010267242,0.0010069428,0.0008112155,0.0025323085,0.00021857991,0.00013013244,0.0013076151],"genre_scores_gemma":[0.99413127,0.0015118775,0.0003231056,0.00037554774,0.00016177475,0.0012379872,0.00016808348,0.000054526598,0.0020358237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980571,0.00007387275,0.00051605026,0.0006393761,0.00024405764,0.00046951335],"domain_scores_gemma":[0.9990871,0.000111734684,0.00020303708,0.00024560423,0.0001853852,0.00016715951],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000662616,0.00038375746,0.0005623733,0.00030492878,0.00015874425,0.000039988994,0.0000928151,0.00020898956,0.00018980158],"category_scores_gemma":[0.000033851065,0.00031073892,0.00007758379,0.0005682771,0.00005164682,0.00017379051,0.00004150543,0.0003477458,0.000005359302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001880495,0.00038803185,0.9155286,0.001902998,0.00039997132,0.00008911682,0.0016595728,0.00043231246,0.055321217,0.000028063527,0.0014287336,0.02094088],"study_design_scores_gemma":[0.030804802,0.00075680885,0.8564128,0.020050233,0.0016848805,0.00002953485,0.0006150527,0.01974231,0.06805807,0.00002336712,0.0007909039,0.0010312079],"about_ca_topic_score_codex":0.0024463376,"about_ca_topic_score_gemma":0.0013263648,"teacher_disagreement_score":0.059115782,"about_ca_system_score_codex":0.0015410201,"about_ca_system_score_gemma":0.0006142019,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W4410271452","doi":"10.1164/ajrccm.2025.211.abstracts.a3241","title":"Integrating Interstitial Lung Abnormality Detection Into Lung Cancer Screening: A Mixed Methods Approach for Care Pathway Development","year":2025,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Lung; Lung cancer screening; Intensive care medicine; Abnormality; Pathology; Radiology; Internal medicine","score_opus":0.021609002254480723,"score_gpt":0.42195690992788015,"score_spread":0.40034790767339945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410271452","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15488191,0.023238044,0.81935143,0.0008387274,0.000550617,0.00041982444,0.000009298037,0.00002196142,0.00068820285],"genre_scores_gemma":[0.90907186,0.000022734823,0.08916702,0.0012461477,0.00035864598,0.00009531088,0.000010679201,0.000014485948,0.00001312171],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99847203,0.0002099447,0.00060063665,0.00024454447,0.00024583616,0.00022700446],"domain_scores_gemma":[0.998008,0.00037828795,0.000182674,0.0001202147,0.00105766,0.00025317704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005336043,0.00019755792,0.00059981016,0.0002543551,0.00026870603,0.000020509742,0.000078620695,0.00006075965,0.00001256898],"category_scores_gemma":[0.00076519203,0.0001379282,0.000116347845,0.00029961165,0.00047245322,0.00010290203,0.00003334409,0.00032919968,3.01552e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007418003,0.00005039949,0.011264858,0.0013192251,0.00039964958,0.000030835767,0.011653774,0.000008476494,0.001649737,0.00031386147,0.00012474538,0.9724426],"study_design_scores_gemma":[0.0208521,0.02038084,0.043056592,0.01068827,0.010555614,0.0004035778,0.7600407,0.0026860316,0.05720144,0.00017062467,0.072809406,0.0011547912],"about_ca_topic_score_codex":0.00013204468,"about_ca_topic_score_gemma":0.000049949194,"teacher_disagreement_score":0.97128785,"about_ca_system_score_codex":0.0004729605,"about_ca_system_score_gemma":0.0006331451,"threshold_uncertainty_score":0.5624549},"labels":[],"label_agreement":null},{"id":"W4410273312","doi":"10.1164/ajrccm.2025.211.abstracts.a4630","title":"Since Cell Transcriptomic Profiling of Cytochrome P450 Expression in the Lung in COPD","year":2025,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Transcriptome; COPD; Profiling (computer programming); Gene expression profiling; Lung; Cytochrome P450; Computational biology; Bioinformatics; Intensive care medicine; Gene expression; Internal medicine; Genetics; Gene; Metabolism; Biology","score_opus":0.01207576115260226,"score_gpt":0.3541009580353244,"score_spread":0.3420251968827221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410273312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97616863,0.018539682,0.0004679592,0.0030721196,0.00006603831,0.00020567937,0.0000039926313,0.0000026349844,0.0014732666],"genre_scores_gemma":[0.99754786,0.000082117454,0.00033448564,0.0019490458,0.00006475369,0.000008320576,0.0000012789582,0.000005248018,0.0000068871996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891084,0.00015173474,0.00045735628,0.00011098201,0.0002343764,0.00013471687],"domain_scores_gemma":[0.9992146,0.00034213506,0.00009063617,0.000112452086,0.0001651754,0.00007501872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003322626,0.00009416941,0.00041628964,0.00023339267,0.000033158387,0.0000040401555,0.00007767324,0.000029873434,0.000011220267],"category_scores_gemma":[0.00019201428,0.00005418246,0.000047380938,0.00036958806,0.0004886574,0.00005845625,0.000007805079,0.0002795662,9.0716036e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002693592,0.001022715,0.47575536,0.0033725516,0.000118424985,0.0016675132,0.03255739,0.00003338718,0.43110228,0.003669517,0.0011726026,0.04683467],"study_design_scores_gemma":[0.020918654,0.016291907,0.6717564,0.012691082,0.0016694731,0.00024191123,0.22008397,0.00006744275,0.050192524,0.0004889037,0.005257314,0.00034045125],"about_ca_topic_score_codex":0.00002512638,"about_ca_topic_score_gemma":0.000009099646,"teacher_disagreement_score":0.38090974,"about_ca_system_score_codex":0.000083998704,"about_ca_system_score_gemma":0.00024357815,"threshold_uncertainty_score":0.22094965},"labels":[],"label_agreement":null},{"id":"W4410276658","doi":"10.1164/ajrccm.2025.211.abstracts.a7746","title":"ING-006, A Novel Oral GPR40/GPR84 Fatty Acid Receptor Modulator: A Comparative Study With Nintedanib and Nerandomilast (BI-1015550) in Bleomycin-induced Lung Fibrosis and CAM-IPF Xenograft Models","year":2025,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Bausch Health (Canada)","funders":"","keywords":"Nintedanib; Medicine; Free fatty acid receptor 1; Idiopathic pulmonary fibrosis; Bleomycin; Receptor; Cancer research; Lung; Internal medicine; Agonist; Chemotherapy","score_opus":0.02810877872120137,"score_gpt":0.36412144691431997,"score_spread":0.3360126681931186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410276658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890012,0.0061126784,0.0017573886,0.0021766447,0.00008702428,0.00059530966,0.000018430213,0.0000138990135,0.00023741675],"genre_scores_gemma":[0.9971244,0.000057766585,0.0012773881,0.0013690192,0.00010514173,0.000034479945,0.0000038969274,0.000018137438,0.000009792602],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9981736,0.00018932449,0.000611623,0.00036022626,0.00037835274,0.00028687256],"domain_scores_gemma":[0.998276,0.00031723184,0.00016785414,0.00020662935,0.0006310803,0.0004011889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034542102,0.0003002575,0.0011783651,0.00039064442,0.00015710978,0.00003470996,0.00008298625,0.000056168967,0.000012616194],"category_scores_gemma":[0.00024457052,0.00019553346,0.000051664258,0.0005173182,0.0010145231,0.0002181102,0.00005583687,0.00046680472,1.4343183e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025612004,0.0023890065,0.7677909,0.0012012944,0.0027411021,0.00072373246,0.10071183,0.0001269647,0.038799133,0.0014850724,0.0011646248,0.057254296],"study_design_scores_gemma":[0.12340503,0.09959079,0.26071897,0.008704423,0.007979014,0.000809679,0.4902433,0.0017698837,0.003728027,0.00023677401,0.0016477938,0.0011663234],"about_ca_topic_score_codex":0.00022949069,"about_ca_topic_score_gemma":0.00013683933,"teacher_disagreement_score":0.507072,"about_ca_system_score_codex":0.00015778968,"about_ca_system_score_gemma":0.00030638403,"threshold_uncertainty_score":0.7973623},"labels":[],"label_agreement":null},{"id":"W4410397042","doi":"10.1016/j.jtocrr.2025.100843","title":"Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010–2023): A Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Hôpital Charles-Le Moyne; Lakeridge Health; Cancer Care South East; Queen's University","funders":"","keywords":"Medicine; Meta-analysis; Lung cancer; Oncology; Internal medicine","score_opus":0.1783990665376195,"score_gpt":0.5371745444105063,"score_spread":0.35877547787288677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410397042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93507665,0.035504963,0.002519644,0.01589876,0.00095934846,0.0051790224,0.00017883425,0.000102546794,0.004580214],"genre_scores_gemma":[0.9606212,0.0012466328,0.00028425318,0.0001887713,0.00010680316,0.0009167593,0.00015492251,0.000012807534,0.036467873],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99764687,0.00022702871,0.00061496824,0.00058581756,0.00050130766,0.00042403594],"domain_scores_gemma":[0.9970888,0.0017357472,0.00010693254,0.00044065464,0.0003541474,0.0002737418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009802952,0.00016787462,0.0010215442,0.0002462923,0.00028784134,0.00007943438,0.00003617156,0.00013518854,0.00021198836],"category_scores_gemma":[0.00072701625,0.00009023721,0.0010432635,0.00043516146,0.00023274566,0.000038910413,0.000052331434,0.00020576725,0.0000015848284],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009860041,0.0036230877,0.23970596,0.00035174008,0.5782896,0.00066409266,0.00044845202,0.0000022487734,0.0004398791,0.00037483248,0.03768243,0.13743164],"study_design_scores_gemma":[0.0084679695,0.0047052014,0.27001074,0.00006660485,0.43649724,0.000024488902,0.00029432037,0.00023946006,0.0015892667,0.0046099005,0.27315113,0.0003436975],"about_ca_topic_score_codex":0.0009113777,"about_ca_topic_score_gemma":0.00014225443,"teacher_disagreement_score":0.23546869,"about_ca_system_score_codex":0.00012016063,"about_ca_system_score_gemma":0.0003443955,"threshold_uncertainty_score":0.36797667},"labels":[],"label_agreement":null},{"id":"W4410406044","doi":"10.1080/14796694.2025.2489339","title":"Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Gilead Sciences","keywords":"Docetaxel; Medicine; Lung cancer; Oncology; Internal medicine; Cancer","score_opus":0.0034647502534123713,"score_gpt":0.296094019994754,"score_spread":0.2926292697413416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410406044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583823,0.000687267,0.0000067810843,0.00061974523,0.00037705692,0.0014019437,0.00006260543,0.0000076202937,0.010998775],"genre_scores_gemma":[0.99782574,0.000019000345,0.000111576875,0.00031792367,0.00005895179,0.0001308249,0.000025222595,0.000011270742,0.0014995171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991999,0.00007894143,0.00024382783,0.0001876896,0.0001359786,0.00015366128],"domain_scores_gemma":[0.9993846,0.000055777793,0.00015573206,0.0002860109,0.00008580524,0.00003209228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007258106,0.00012050331,0.00037636227,0.00011535167,0.000036418525,0.0000019755505,0.000110916655,0.0000942321,0.0000467596],"category_scores_gemma":[0.000008217507,0.000070790105,0.000043172655,0.0003603781,0.000045638888,0.000021483673,0.000047523714,0.00017384603,3.7530117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010467408,0.002743291,0.97795457,0.00024021162,0.00030268825,0.000019273226,0.0101719,0.00005818598,0.00014101161,0.00003590197,0.002466319,0.0048199333],"study_design_scores_gemma":[0.015798548,0.001716894,0.971646,0.00022984255,0.00067240663,8.3066584e-7,0.0068314876,0.000017151147,0.0004352428,0.0000031670133,0.0025787621,0.000069683134],"about_ca_topic_score_codex":0.0021223577,"about_ca_topic_score_gemma":0.0108153345,"teacher_disagreement_score":0.014751808,"about_ca_system_score_codex":0.00045147698,"about_ca_system_score_gemma":0.0006907286,"threshold_uncertainty_score":0.60352105},"labels":[],"label_agreement":null},{"id":"W4410421568","doi":"10.1016/j.jtho.2025.05.012","title":"Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Chugai Pharmaceutical; Janssen Research and Development; EMD Serono; Manchester Clinical Research Facility; Genentech; LG Chem; Grifols; Pfizer Japan; Sociedad Española de Oncología Médica; Otsuka Pharmaceutical; Astellas Pharma; Eisai; Curtin University of Technology; Clovis Oncology; National Institute for Health and Care Research; BeiGene; Mirati Therapeutics; Revolution Medicines; Kissei; Johnson and Johnson; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Array BioPharma; Manchester Biomedical Research Centre; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Sanofi; Amgen; G1 Therapeutics; Jounce Therapeutics; Bayer Yakuhin; Celgene; AstraZeneca; Ignyta; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Exon; Lung cancer; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Mutation; Cancer research; Genetics; Gene; Biology","score_opus":0.0415045479709282,"score_gpt":0.47087504440988687,"score_spread":0.42937049643895864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410421568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915254,0.0010379516,0.00014401037,0.005867472,0.00021387341,0.00045507945,0.000017576596,0.0000072058233,0.00073139224],"genre_scores_gemma":[0.99615777,0.000106224106,0.0029642251,0.00048037473,0.00007609645,0.000026094822,0.000008996757,0.00000740339,0.00017282972],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99880934,0.00020122515,0.00050660863,0.0001534299,0.00016443591,0.00016497848],"domain_scores_gemma":[0.9987056,0.00061319635,0.00031201055,0.00015283393,0.00015224675,0.000064105065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050574593,0.00009840945,0.00038229697,0.00015255401,0.000073339426,0.000018446193,0.00007634125,0.000049505663,0.00000863936],"category_scores_gemma":[0.00038518925,0.00005745057,0.000036053072,0.00028548008,0.00006989283,0.00012069443,0.000026447715,0.00026131925,9.009999e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025254142,0.0034354443,0.1953306,0.00004483812,0.002124017,0.0028825426,0.03277503,0.00086803327,0.0009012679,0.00006755955,0.00088818715,0.73542833],"study_design_scores_gemma":[0.014104483,0.005082078,0.9505758,0.0007217841,0.0020328474,0.00015829434,0.022673,0.000091370035,0.00022307022,0.00040042424,0.0038492377,0.000087585286],"about_ca_topic_score_codex":0.00017012536,"about_ca_topic_score_gemma":0.00089487224,"teacher_disagreement_score":0.7552452,"about_ca_system_score_codex":0.00026272997,"about_ca_system_score_gemma":0.0005840788,"threshold_uncertainty_score":0.23427661},"labels":[],"label_agreement":null},{"id":"W4410522286","doi":"10.1080/14796694.2025.2500915","title":"A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; University College London; Cancer Research UK; F. Hoffmann-La Roche; CRUK Lung Cancer Centre of Excellence; University College London Hospitals NHS Foundation Trust; Pfizer","keywords":"Atezolizumab; Medicine; Chemotherapy; Oncology; Lung cancer; Internal medicine; Cancer; Intensive care medicine; Immunotherapy; Pembrolizumab","score_opus":0.02306044395468954,"score_gpt":0.35097972535087146,"score_spread":0.3279192813961819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410522286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984612,0.0006874633,0.00015936827,0.0077603296,0.00015225976,0.0026759773,0.000033888085,0.000035529672,0.0038832123],"genre_scores_gemma":[0.99308676,0.00005516212,0.00081079226,0.0038746023,0.00014123743,0.0006723295,0.000045146662,0.000040452363,0.0012735219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985504,0.00011774962,0.00035346017,0.00037973156,0.00021800106,0.00038062892],"domain_scores_gemma":[0.99903965,0.00015753224,0.00021664883,0.00038760397,0.00011545211,0.00008314033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014838856,0.00027477706,0.0007025717,0.00015623613,0.000082725026,0.000011056981,0.0001444887,0.00014058256,0.00012544749],"category_scores_gemma":[0.00000585511,0.00016169158,0.000060424227,0.00050605845,0.00011398304,0.000030371477,0.00001626458,0.00028387047,0.0000011143379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04463618,0.014855202,0.7230503,0.0010108618,0.004020006,0.00097032404,0.13363883,0.004051392,0.01432126,0.00004175279,0.010746498,0.04865741],"study_design_scores_gemma":[0.170793,0.016128192,0.625249,0.0025395881,0.0035846126,0.000025160529,0.055132385,0.005360615,0.09382129,0.000007239445,0.026423233,0.00093568367],"about_ca_topic_score_codex":0.001219687,"about_ca_topic_score_gemma":0.012752078,"teacher_disagreement_score":0.12615682,"about_ca_system_score_codex":0.0007478063,"about_ca_system_score_gemma":0.0011830434,"threshold_uncertainty_score":0.7115959},"labels":[],"label_agreement":null},{"id":"W4410586982","doi":"10.1007/s12325-025-03195-7","title":"Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"EMD Serono","keywords":"Medicine; Rheumatology; Internal medicine; Oncology; Family medicine; General surgery; Intensive care medicine","score_opus":0.020835090550126657,"score_gpt":0.40953198234919574,"score_spread":0.3886968917990691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410586982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90156376,0.020313183,0.016434526,0.034688357,0.00092359853,0.010686021,0.000084596526,0.00012522866,0.015180735],"genre_scores_gemma":[0.97616124,0.009350012,0.006279567,0.00062009064,0.00011170263,0.0016260723,0.00011601298,0.000025504507,0.005709801],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993486,0.000025538571,0.00013843692,0.00020495562,0.00013115737,0.00015130162],"domain_scores_gemma":[0.99933463,0.00016759666,0.00016545893,0.0001980857,0.0001067154,0.000027520822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004194382,0.00013473612,0.00015327029,0.000061023347,0.00028542895,0.0000463916,0.00004763965,0.000022470156,0.000016105469],"category_scores_gemma":[0.000021521559,0.000050359347,0.00003293439,0.00021347025,0.00004917683,0.0005360517,0.0000038152675,0.0000602253,0.0000013644145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034396045,0.0040945024,0.46441042,0.000042384312,0.0006845769,0.0000052142786,0.0035790235,0.000993747,0.00006102453,0.0012717133,0.00014372855,0.52127403],"study_design_scores_gemma":[0.026093906,0.008977651,0.063909136,0.0010107355,0.0004979125,0.000009519959,0.0045703673,0.00024191453,0.0009083524,0.0012951078,0.89222187,0.0002635098],"about_ca_topic_score_codex":0.00007462674,"about_ca_topic_score_gemma":0.0006482648,"teacher_disagreement_score":0.89207816,"about_ca_system_score_codex":0.00023131802,"about_ca_system_score_gemma":0.00017875158,"threshold_uncertainty_score":0.21953174},"labels":[],"label_agreement":null},{"id":"W4410611436","doi":"10.1016/j.esmoop.2025.105110","title":"Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"National Cancer Institute; Loxo Oncology; Bayer HealthCare; Bayer Corporation; Bayer","keywords":"Trk receptor; Cancer; Line (geometry); Fusion; Medicine; Internal medicine; Neurotrophin","score_opus":0.01762276124513903,"score_gpt":0.3755784067848174,"score_spread":0.3579556455396784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410611436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98101205,0.00021513704,0.000074507174,0.0026537608,0.000114456096,0.004296499,0.00013661398,0.00001375305,0.011483245],"genre_scores_gemma":[0.98849136,0.00028990195,0.00079720863,0.00020778748,0.000022390628,0.00050823955,0.00018456481,0.000011284797,0.009487287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995363,0.000007757365,0.00012918867,0.00017373127,0.000062803476,0.00009024688],"domain_scores_gemma":[0.99959826,0.00007534536,0.00005346215,0.00014227818,0.000085742875,0.000044898086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028225506,0.000091865986,0.00021930938,0.000037285623,0.000107007145,0.000011835202,0.000042634078,0.000028668343,0.0001257846],"category_scores_gemma":[0.000020577963,0.00005669785,0.000024958958,0.00009700385,0.000022727361,0.000044930184,0.000033858614,0.00002091176,0.0000014115908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016599065,0.0037023677,0.6008496,0.0002161857,0.0018548988,0.000005577612,0.0020254203,0.00008494666,0.000019286781,0.0007883887,0.0024522748,0.37140197],"study_design_scores_gemma":[0.046781935,0.0041528614,0.80628484,0.0006804101,0.0010693854,9.677403e-7,0.00007544488,0.000026866206,0.0013287264,0.00009513212,0.13940218,0.00010124207],"about_ca_topic_score_codex":0.004260333,"about_ca_topic_score_gemma":0.0016598487,"teacher_disagreement_score":0.3713007,"about_ca_system_score_codex":0.00013248691,"about_ca_system_score_gemma":0.0001926506,"threshold_uncertainty_score":0.64403766},"labels":[],"label_agreement":null},{"id":"W4410764962","doi":"10.1016/j.lungcan.2025.108596","title":"Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Fondation Institut Universitaire de Cardiologie et de Pneumologie de Québec","keywords":"KRAS; Medicine; Mutant; Adenocarcinoma; Mutation; Cancer research; Lung cancer; Oncology; Internal medicine; Cancer; Genetics; Gene; Biology; Colorectal cancer","score_opus":0.01598881384185044,"score_gpt":0.38761122630906397,"score_spread":0.3716224124672135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410764962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099165,0.0051001376,0.00016328155,0.0013692483,0.00042646079,0.00081796333,0.00015755896,0.000041882482,0.00093182514],"genre_scores_gemma":[0.9981805,0.00041061745,0.0001994822,0.00044997095,0.000043497243,0.00011546967,0.00012398208,0.000018877961,0.00045756475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985943,0.00006660252,0.0005374304,0.0003856913,0.00017091038,0.00024510437],"domain_scores_gemma":[0.99922204,0.00018265906,0.0001623021,0.0001955611,0.0001273054,0.000110107845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018908652,0.00021338984,0.0007298754,0.00025931303,0.00006738735,0.000027394039,0.000058233105,0.00010878831,0.000062040395],"category_scores_gemma":[0.000110307876,0.00017361724,0.00004757827,0.00031246117,0.000076906144,0.00007278121,0.00004345627,0.00015686445,0.0000021394133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031118563,0.00013913577,0.99324167,0.00032886778,0.00024625132,0.000053135354,0.0014594396,0.000024922374,0.00072265783,0.00017510688,0.00037324513,0.0029243957],"study_design_scores_gemma":[0.0030919816,0.00017865398,0.99217105,0.00032045977,0.0006560639,0.000007653091,0.0005492815,0.0019361671,0.00073466665,0.0000321565,0.0001720619,0.00014978115],"about_ca_topic_score_codex":0.0005495171,"about_ca_topic_score_gemma":0.00049299095,"teacher_disagreement_score":0.007188896,"about_ca_system_score_codex":0.00019012454,"about_ca_system_score_gemma":0.0002132897,"threshold_uncertainty_score":0.7079906},"labels":[],"label_agreement":null},{"id":"W4410773123","doi":"10.1016/j.jtho.2025.05.017","title":"Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor–Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"West China Hospital, Sichuan University; Sichuan University","keywords":"Medicine; Milestone; Refractory (planetary science); Pregnancy; Fetus; Pharmacokinetics; Obstetrics; Pediatrics; Oncology; Internal medicine","score_opus":0.010454245963589662,"score_gpt":0.3527189224648989,"score_spread":0.3422646765013092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410773123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928123,0.0041396823,0.0004360348,0.001188136,0.00008976176,0.000758614,0.00003336598,0.000012913205,0.0005292052],"genre_scores_gemma":[0.993846,0.00021966625,0.005571755,0.00017386365,0.000031219897,0.00003469595,0.000020118763,0.000019851263,0.00008280154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986216,0.00011872222,0.00057194364,0.00023047617,0.000206521,0.00025075482],"domain_scores_gemma":[0.9989071,0.000087676824,0.00047299635,0.00008547399,0.00021779073,0.00022895132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008925607,0.00023178392,0.0006124253,0.0003263075,0.0001387942,0.000027829497,0.000033457243,0.00007524266,0.000004842951],"category_scores_gemma":[0.00000917657,0.00014086695,0.000022398435,0.00026043082,0.00014142018,0.00015412312,0.000028088503,0.0003007854,1.9950157e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011820164,0.0011506033,0.82559305,0.00085300993,0.00131291,0.0037621656,0.0032812601,0.00020026547,0.00012139829,0.000035468045,0.000022504033,0.15184717],"study_design_scores_gemma":[0.011154246,0.0087381955,0.9590023,0.007812562,0.0025533424,0.0065417537,0.0018987543,0.00017349969,0.0012252071,0.0000017029955,0.00067737594,0.00022102037],"about_ca_topic_score_codex":0.00011579242,"about_ca_topic_score_gemma":0.00025568475,"teacher_disagreement_score":0.15162615,"about_ca_system_score_codex":0.0005698872,"about_ca_system_score_gemma":0.00053694024,"threshold_uncertainty_score":0.57443875},"labels":[],"label_agreement":null},{"id":"W4410802745","doi":"10.1200/jco.2025.43.16_suppl.8641","title":"Dermatologic prophylaxis and impact on patient-reported outcomes in first-line <i>EGFR</i> -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; Dermatology","score_opus":0.05556107731935047,"score_gpt":0.4735049464103127,"score_spread":0.41794386909096226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980275,0.00037796015,0.000025315338,0.016520845,0.0004133767,0.0012676811,0.00005704968,0.000015858885,0.0010469548],"genre_scores_gemma":[0.9960922,0.0004317425,0.00038099076,0.002830226,0.000096392876,0.000029928298,0.00003061175,0.000012690288,0.00009519138],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962987,0.00034988896,0.002569308,0.00028695393,0.00026996524,0.00022519332],"domain_scores_gemma":[0.992229,0.0051306756,0.0018307053,0.00029218948,0.00032689548,0.00019057121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007150551,0.00022412394,0.0016515454,0.00013074632,0.00007735521,0.000015241325,0.0001035134,0.00024459968,0.000013591809],"category_scores_gemma":[0.004852337,0.00009526499,0.00025014376,0.00033391253,0.00018195935,0.00008219812,0.000028915716,0.0007032904,0.0000017085908],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64614415,0.0084048435,0.13470949,0.000016462871,0.0020810931,0.0032400442,0.00042450542,0.0002518183,0.0000569001,0.000012196124,0.0008213542,0.20383716],"study_design_scores_gemma":[0.60831743,0.09592484,0.28268215,0.000648164,0.0015795631,0.00019392274,0.00038572977,0.00019854185,0.00026095728,0.00015725622,0.00949954,0.00015191603],"about_ca_topic_score_codex":0.0002629104,"about_ca_topic_score_gemma":0.00028224615,"teacher_disagreement_score":0.20368524,"about_ca_system_score_codex":0.00037565472,"about_ca_system_score_gemma":0.001861959,"threshold_uncertainty_score":0.5809051},"labels":[],"label_agreement":null},{"id":"W4410802748","doi":"10.1200/jco.2025.43.16_suppl.8541","title":"Biomarker testing of lung cancer in North America versus globally.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Biomarker; Oncology; Cancer; Internal medicine","score_opus":0.1102041036443382,"score_gpt":0.5515508042231393,"score_spread":0.4413467005788011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95900536,0.0019285879,0.00010528116,0.0073378473,0.002004619,0.00016016507,0.000010056677,0.000004659467,0.02944342],"genre_scores_gemma":[0.9944745,0.0005573339,0.0034977805,0.0010501835,0.0001802643,0.000004423204,0.0000014838872,0.00000458221,0.00022947264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982283,0.00009911577,0.0013083414,0.00009479923,0.00014897539,0.000120433564],"domain_scores_gemma":[0.9969955,0.0016335828,0.00082550716,0.00008974183,0.0003552201,0.00010042148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004419666,0.00006592025,0.00075064297,0.00012179247,0.000015242848,0.0000023717052,0.000084108004,0.00010661435,0.00007533114],"category_scores_gemma":[0.002749096,0.00004593829,0.0001724585,0.00046581426,0.000108456195,0.00004211595,0.000028063258,0.00028139312,0.0000011500435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021809647,0.0006184302,0.6525065,0.000029886738,0.0005960358,0.000140896,0.000043809487,0.000097728676,0.000022837265,0.000021692498,0.002084623,0.34165666],"study_design_scores_gemma":[0.010724297,0.002309865,0.944828,0.00020867598,0.0008445427,0.000009546906,0.00008411875,0.0004794296,0.0000064745254,0.00002869688,0.040441133,0.000035242378],"about_ca_topic_score_codex":0.00025964077,"about_ca_topic_score_gemma":0.0006164961,"teacher_disagreement_score":0.3416214,"about_ca_system_score_codex":0.00032107506,"about_ca_system_score_gemma":0.0033248772,"threshold_uncertainty_score":0.58981895},"labels":[],"label_agreement":null},{"id":"W4410802805","doi":"10.1200/jco.2025.43.16_suppl.8643","title":"Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; ROS1; Cancer; Lung cancer; Oncology; Internal medicine; Adenocarcinoma","score_opus":0.1026324238354544,"score_gpt":0.5523450391033218,"score_spread":0.4497126152678674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667229,0.025172343,0.00025076477,0.0062052864,0.00045647108,0.0005146951,0.000024140401,0.000004281364,0.0006490991],"genre_scores_gemma":[0.98253757,0.010196896,0.004653558,0.00040532186,0.00024080556,0.000017370012,0.000002141996,0.000008180637,0.001938171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983973,0.00007500513,0.0011092739,0.00017723562,0.000080791135,0.00016037436],"domain_scores_gemma":[0.99444485,0.0041902815,0.00080890075,0.00007999291,0.00033087132,0.00014509488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007784903,0.00011440308,0.0013158489,0.000080256934,0.00011398149,0.000007773362,0.00004386645,0.00010546458,0.0000028718634],"category_scores_gemma":[0.0006272805,0.000078804296,0.000111785295,0.0001193023,0.00033126798,0.00006975888,0.000055614393,0.00028155724,6.480558e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064423964,0.00067486987,0.7930266,0.0007852024,0.0025673136,0.00002967756,0.0013927502,0.000047244186,0.00017755677,0.00009579925,0.0032616116,0.19149897],"study_design_scores_gemma":[0.039210215,0.005210014,0.9044306,0.001147284,0.0032297228,0.000026338852,0.0016525453,0.000068503745,0.00036870042,0.00033535672,0.044204563,0.00011610502],"about_ca_topic_score_codex":0.0000300086,"about_ca_topic_score_gemma":0.00031575595,"teacher_disagreement_score":0.19138286,"about_ca_system_score_codex":0.00008643948,"about_ca_system_score_gemma":0.0005505843,"threshold_uncertainty_score":0.32135457},"labels":[],"label_agreement":null},{"id":"W4410802840","doi":"10.1200/jco.2025.43.16_suppl.8519","title":"Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with <i>KRAS</i> G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Eli Lilly and Company","keywords":"Medicine; KRAS; Immunotherapy; Oncology; Internal medicine; Mutant; Clinical trial; Cancer; Genetics","score_opus":0.03074186538294071,"score_gpt":0.4333939144166533,"score_spread":0.4026520490337126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98862535,0.0021934712,0.00013544086,0.0070166085,0.00053971366,0.0009122251,0.00006595306,0.0000032822077,0.0005079733],"genre_scores_gemma":[0.98737407,0.010314651,0.0012225391,0.00082121824,0.00013587647,0.000010454662,0.000026307083,0.0000117198315,0.00008315447],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971891,0.00023261097,0.0020554264,0.00017199373,0.00020831607,0.0001425442],"domain_scores_gemma":[0.99489194,0.0030386685,0.0014547923,0.0002439144,0.00028078048,0.000089931746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005186909,0.0001549102,0.0015136058,0.00008278568,0.000037654496,0.0000035279904,0.000104117484,0.0001550857,0.000062081395],"category_scores_gemma":[0.0004922135,0.00007568724,0.0002405514,0.0002024017,0.00022747675,0.000059925696,0.000017787723,0.00023339126,7.533611e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32376358,0.012372859,0.21738662,0.000015671778,0.0020327677,0.00005401361,0.00046704223,0.00011668609,0.00005387316,0.00006264354,0.00012489497,0.44354934],"study_design_scores_gemma":[0.30922285,0.028436186,0.6109791,0.00029340264,0.00093907135,0.0000035356666,0.00009315717,0.000011571157,0.00013594888,0.00015037363,0.049676374,0.000058440364],"about_ca_topic_score_codex":0.00013376944,"about_ca_topic_score_gemma":0.00024989844,"teacher_disagreement_score":0.4434909,"about_ca_system_score_codex":0.00023271171,"about_ca_system_score_gemma":0.0011190713,"threshold_uncertainty_score":0.3086436},"labels":[],"label_agreement":null},{"id":"W4410802869","doi":"10.1200/jco.2025.43.16_suppl.8513","title":"Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Placebo; Internal medicine; Pathology; Alternative medicine","score_opus":0.08479915726876193,"score_gpt":0.49022092613509843,"score_spread":0.4054217688663365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863714,0.00034434686,0.00014622361,0.006702792,0.0006488923,0.0015015292,0.00002696262,0.000009139108,0.004248692],"genre_scores_gemma":[0.99806,0.00010888973,0.00055941916,0.00069254515,0.00016668651,0.00001706412,0.000015701205,0.000010434251,0.0003692444],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956538,0.0010837413,0.0025406664,0.00022758498,0.0003343544,0.00015982709],"domain_scores_gemma":[0.9881056,0.008877637,0.0020987743,0.00027433917,0.0004720161,0.00017161378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00263363,0.00015700223,0.0020772102,0.00012051392,0.000092919734,0.000014331776,0.00014875575,0.000147764,0.000021127353],"category_scores_gemma":[0.006221377,0.00008274124,0.0002843397,0.00019989023,0.00040486167,0.00007585683,0.000060056944,0.0005965327,0.0000013163993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85645163,0.018896483,0.08313708,0.000035430883,0.0053506424,0.00012445298,0.002628587,0.000065868444,0.0001091002,0.00034799596,0.002999901,0.029852804],"study_design_scores_gemma":[0.74383765,0.008458584,0.23764338,0.0003773772,0.0046969866,0.000022717888,0.0008974693,0.0003413733,0.00009924358,0.0003127472,0.003242895,0.00006953971],"about_ca_topic_score_codex":0.00019617878,"about_ca_topic_score_gemma":0.00016382539,"teacher_disagreement_score":0.1545063,"about_ca_system_score_codex":0.000117683776,"about_ca_system_score_gemma":0.0013884308,"threshold_uncertainty_score":0.7448019},"labels":[],"label_agreement":null},{"id":"W4410802901","doi":"10.1200/jco.2025.43.16_suppl.10013","title":"CCDI-COG molecular characterization initiative: The expanding data on childhood cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; CancerCare Manitoba","funders":"","keywords":"Medicine; Cog; Childhood cancer; Cancer; Family medicine; Gerontology; Oncology; Internal medicine","score_opus":0.13516708324912505,"score_gpt":0.5607126190603696,"score_spread":0.42554553581124455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83052605,0.0012191148,0.0029463952,0.14163688,0.0036472857,0.00050890876,0.000067353256,0.000015468297,0.019432548],"genre_scores_gemma":[0.98109704,0.0011736245,0.0003269708,0.016377706,0.00068232446,0.000008364151,0.00004910184,0.000007947712,0.00027691823],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984507,0.00020834232,0.0009120135,0.00014298697,0.00017771804,0.00010826545],"domain_scores_gemma":[0.9979378,0.00075450994,0.0007456277,0.00027728587,0.00019627066,0.000088494824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087882846,0.00007972118,0.0005189325,0.0000769291,0.00007239091,0.000011811832,0.00020606205,0.00012301723,0.0000722347],"category_scores_gemma":[0.0015155271,0.00004414902,0.00013254226,0.00016149456,0.00007772822,0.000107948836,0.000060906663,0.000483056,0.0000055235587],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018400615,0.0037335663,0.05057323,0.00003735425,0.0036844395,0.00046543952,0.00061958266,0.000037733356,0.0015871633,0.0023795883,0.009945861,0.925096],"study_design_scores_gemma":[0.0073990813,0.0031604108,0.79894775,0.0003929772,0.0019036329,0.000047404294,0.00018786063,0.00012879565,0.0003886896,0.0004529574,0.1869244,0.00006603692],"about_ca_topic_score_codex":0.000007874372,"about_ca_topic_score_gemma":0.000006213151,"teacher_disagreement_score":0.92502993,"about_ca_system_score_codex":0.00012824674,"about_ca_system_score_gemma":0.0021544946,"threshold_uncertainty_score":0.3821981},"labels":[],"label_agreement":null},{"id":"W4410803003","doi":"10.1200/jco.2025.43.16_suppl.8646","title":"Rechallenge with first-generation RET inhibitors in <i>RET</i> -rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Proto-Oncogene Proteins c-ret; Oncology; Cancer research; Internal medicine; Receptor","score_opus":0.09299969860512383,"score_gpt":0.4516467348935483,"score_spread":0.3586470362884244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8348046,0.00066847785,0.000065959495,0.15390638,0.0007171426,0.000978668,0.00008683835,0.000028894898,0.008743046],"genre_scores_gemma":[0.9844244,0.0010693087,0.0061459676,0.0030348345,0.0013096931,0.000049750142,0.00016777076,0.00002758558,0.0037706492],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653363,0.0005560511,0.0019590396,0.00035841748,0.0003658778,0.00022696321],"domain_scores_gemma":[0.9941414,0.0032081113,0.0015282511,0.00044228998,0.00050353695,0.00017641122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019433658,0.0002067434,0.0010267089,0.00009433661,0.00011104521,0.000025046611,0.00017933555,0.00040377508,0.00004891251],"category_scores_gemma":[0.0033744639,0.00009616737,0.00014777575,0.00035995888,0.00021640028,0.0001292868,0.000029140127,0.0009820658,0.0000048349875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16299288,0.0060707293,0.30753595,0.00013868177,0.003765525,0.0034120742,0.006332589,0.00034365244,0.00025268673,0.000119928176,0.41531476,0.09372055],"study_design_scores_gemma":[0.07152057,0.030289037,0.35056475,0.004129843,0.0028040588,0.00032495172,0.0021556937,0.00020076944,0.00043962713,0.00014483357,0.5370976,0.00032829065],"about_ca_topic_score_codex":0.00055097515,"about_ca_topic_score_gemma":0.011862212,"teacher_disagreement_score":0.15087155,"about_ca_system_score_codex":0.0003340543,"about_ca_system_score_gemma":0.0035484398,"threshold_uncertainty_score":0.66193926},"labels":[],"label_agreement":null},{"id":"W4410803025","doi":"10.1200/jco.2025.43.16_suppl.10019","title":"Second malignant neoplasm risk after mediastinal radiotherapy for pediatric Hodgkin lymphoma on Children’s Oncology Group AHOD1331.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; University Health Network; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Radiation therapy; Pediatric oncology; Hodgkin lymphoma; Lymphoma; Oncology; Internal medicine; Cancer","score_opus":0.030939594430976953,"score_gpt":0.4525656285661679,"score_spread":0.42162603413519095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772964,0.0033033686,0.002666827,0.00833626,0.004692543,0.00083395344,0.00010442561,0.000019038685,0.0027471646],"genre_scores_gemma":[0.9586229,0.0040481105,0.018738985,0.011320345,0.0055928202,0.000108580636,0.000023620109,0.00003975821,0.0015049088],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965187,0.0004506854,0.0020949221,0.00032761763,0.00025691022,0.0003512106],"domain_scores_gemma":[0.9928994,0.0045793345,0.0016003057,0.00022926663,0.0003229621,0.00036873415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018304625,0.00022840081,0.00165355,0.00035210935,0.00009056008,0.000012884891,0.0001753844,0.00055145996,0.0003546276],"category_scores_gemma":[0.0015100301,0.00015446769,0.00077911763,0.0001994498,0.00014986629,0.0000785401,0.000028092256,0.0005986125,0.000011957996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017111309,0.005085169,0.23358007,0.000053784046,0.002505031,0.0006104736,0.0003932937,0.000020989954,0.000017125376,0.00041592127,0.036868665,0.70333815],"study_design_scores_gemma":[0.030245144,0.03025627,0.71508074,0.00007049058,0.0024425115,0.0004025229,0.00006125566,0.000048922087,0.000024840592,0.0005833828,0.22066122,0.0001226846],"about_ca_topic_score_codex":0.000019224874,"about_ca_topic_score_gemma":0.00008020764,"teacher_disagreement_score":0.7032155,"about_ca_system_score_codex":0.00077443774,"about_ca_system_score_gemma":0.003610323,"threshold_uncertainty_score":0.6404558},"labels":[],"label_agreement":null},{"id":"W4410803029","doi":"10.1200/jco.2025.43.16_suppl.8622","title":"Novel potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Targeted therapy; Cancer research; Erlotinib; Gefitinib; Oncology; Pharmacology; Epidermal growth factor receptor; Internal medicine; Cancer","score_opus":0.09480371908270102,"score_gpt":0.49798839209019147,"score_spread":0.40318467300749045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88752156,0.004285575,0.044698507,0.053050164,0.004258968,0.0010346917,0.0000100498155,0.000015196237,0.0051253107],"genre_scores_gemma":[0.9718233,0.0006918278,0.022016805,0.0033575278,0.0015657531,0.000013132809,0.000005931913,0.000007773536,0.000517975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987316,0.00006379135,0.0008925366,0.00011459675,0.00009463536,0.00010281038],"domain_scores_gemma":[0.99810064,0.00074519904,0.000524146,0.000046276273,0.00048308712,0.00010065907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009547565,0.00007045819,0.0005011286,0.00008034116,0.000069747715,0.000008593615,0.000028593688,0.00015765397,0.000006142414],"category_scores_gemma":[0.0013019625,0.000046683577,0.00019321172,0.00008054586,0.000043953412,0.00006221718,0.000010465917,0.00024457512,4.5268993e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023972583,0.0017204082,0.016907327,0.00002254977,0.0013534585,0.000025545938,0.00032828058,0.0000713795,0.0069672777,0.0005464988,0.02478628,0.94487375],"study_design_scores_gemma":[0.091054045,0.04483283,0.23621744,0.00041367728,0.0032934558,0.00035878594,0.0011864314,0.0041708993,0.008294332,0.0027036627,0.6071479,0.00032657367],"about_ca_topic_score_codex":0.000014440178,"about_ca_topic_score_gemma":0.000014668449,"teacher_disagreement_score":0.9445472,"about_ca_system_score_codex":0.00015665505,"about_ca_system_score_gemma":0.0012960648,"threshold_uncertainty_score":0.22991633},"labels":[],"label_agreement":null},{"id":"W4410803224","doi":"10.1200/jco.2025.43.16_suppl.8612","title":"Exploring decisional needs of patients considering first line treatment of advanced EGFR+ lung cancer: An interpretive descriptive study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Descriptive research; Oncology; Descriptive statistics; Internal medicine","score_opus":0.184280585907974,"score_gpt":0.5239373958316611,"score_spread":0.3396568099236871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954507,0.00085408473,0.0003492728,0.0006427215,0.0015611432,0.0005219902,0.000025929898,0.0000047813583,0.0005893806],"genre_scores_gemma":[0.9957275,0.0017599395,0.0020769802,0.00012840492,0.00015896739,0.000045250163,0.0000034769826,0.000010429875,0.00008905455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972911,0.00016177127,0.0020220438,0.00014117113,0.00024487075,0.00013903399],"domain_scores_gemma":[0.995528,0.0018246725,0.001302264,0.00016393705,0.0010046138,0.0001765533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039250756,0.00014223362,0.0013966799,0.00028659758,0.000042052052,0.0000032717783,0.00009161499,0.00009516368,0.000057747493],"category_scores_gemma":[0.0013034927,0.00009683305,0.00032000066,0.00023048175,0.00013323656,0.00020463247,0.000040550836,0.0002065532,3.44119e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008989002,0.012906991,0.6786745,0.000040711588,0.002735366,0.00007001262,0.012027451,0.0007583756,0.00005027831,0.000056675446,0.000065201064,0.28362542],"study_design_scores_gemma":[0.028713426,0.070119664,0.8750269,0.001228509,0.003171739,0.000008554126,0.01678312,0.0002021252,0.00062247977,0.00012341236,0.0038920601,0.00010801725],"about_ca_topic_score_codex":0.0001494286,"about_ca_topic_score_gemma":0.00021707534,"teacher_disagreement_score":0.2835174,"about_ca_system_score_codex":0.0010596996,"about_ca_system_score_gemma":0.0021094412,"threshold_uncertainty_score":0.3948737},"labels":[],"label_agreement":null},{"id":"W4410803745","doi":"10.1200/jco.2025.43.16_suppl.8605","title":"MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Hamilton Health Sciences; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; KRAS; Lung cancer; Cancer; Cancer research; Internal medicine; Oncology; Pathology; Colorectal cancer","score_opus":0.08510264118710671,"score_gpt":0.5179413332001931,"score_spread":0.4328386920130864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9258007,0.006563811,0.004646112,0.036340397,0.0065728673,0.0018320588,0.0006219058,0.00003853118,0.017583657],"genre_scores_gemma":[0.9484977,0.0026530265,0.025521627,0.0081344545,0.0019355824,0.00011900897,0.00024082772,0.000049117174,0.012848649],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596006,0.00024057881,0.0028750813,0.00034099963,0.00025171821,0.00033158078],"domain_scores_gemma":[0.9921338,0.004680052,0.0016671123,0.00027386378,0.00087497116,0.00037019944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015565282,0.00022295972,0.0017170211,0.00018589757,0.0000970124,0.000021021155,0.0001963235,0.00029326678,0.00024134715],"category_scores_gemma":[0.002313131,0.00015218562,0.00062787917,0.00023729843,0.00012308075,0.000093733826,0.00004442125,0.0006863008,0.000015988668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0525203,0.01741162,0.054989446,0.0007974554,0.023561597,0.0022450825,0.002243189,0.001053323,0.0020325312,0.0004148771,0.39669102,0.44603953],"study_design_scores_gemma":[0.18563025,0.012121409,0.10073109,0.0014395093,0.030062169,0.00008131844,0.0008356487,0.004270948,0.0012735246,0.0027639095,0.6603111,0.00047914826],"about_ca_topic_score_codex":0.0005723424,"about_ca_topic_score_gemma":0.00037735442,"teacher_disagreement_score":0.4455604,"about_ca_system_score_codex":0.00048576834,"about_ca_system_score_gemma":0.005370809,"threshold_uncertainty_score":0.95275843},"labels":[],"label_agreement":null},{"id":"W4410804753","doi":"10.1200/jco.2025.43.16_suppl.tps8666","title":"Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Alectinib; Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Crizotinib; Cancer research; Lung cancer; Kinase; Lymphoma; Cancer; Oncology; Pathology; Internal medicine; Biology","score_opus":0.024372276477032263,"score_gpt":0.4274987139296226,"score_spread":0.4031264374525903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921969,0.00059517083,0.00026438807,0.0024673685,0.00090859504,0.0025707132,0.00007579357,0.000008311029,0.0009127147],"genre_scores_gemma":[0.9975056,0.00027342685,0.00082464766,0.00066476176,0.0002517234,0.00018643377,0.000018578725,0.000022989509,0.00025183617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967793,0.0003183069,0.0018812069,0.000365885,0.00032996244,0.00032532986],"domain_scores_gemma":[0.99502105,0.0022023257,0.0012573167,0.00024723698,0.0009749515,0.00029714432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038261688,0.00029372753,0.0017106759,0.00029978142,0.00012737734,0.000010435068,0.00015693669,0.00015299699,0.000017261154],"category_scores_gemma":[0.0003639259,0.00017012197,0.0002677761,0.000723465,0.00012035653,0.00008758427,0.000042087624,0.00027767415,0.0000013009317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06636005,0.06578793,0.72630936,0.00007769882,0.0032950332,0.0007020747,0.006243766,0.00425413,0.00006139427,0.0000062377835,0.0011318097,0.1257705],"study_design_scores_gemma":[0.14373758,0.110899426,0.7325449,0.00055511185,0.003528235,0.000010239944,0.0012422963,0.00047137815,0.0007662838,0.000014903654,0.0060572354,0.00017241885],"about_ca_topic_score_codex":0.0006358136,"about_ca_topic_score_gemma":0.0063926782,"teacher_disagreement_score":0.12559809,"about_ca_system_score_codex":0.0017121838,"about_ca_system_score_gemma":0.003672307,"threshold_uncertainty_score":0.69373727},"labels":[],"label_agreement":null},{"id":"W4410804997","doi":"10.1200/jco.2025.43.16_suppl.10004","title":"Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Open label; Solid tumor; Crizotinib; ALK inhibitor; Oncology; Internal medicine; Clinical trial; Cancer","score_opus":0.15231239893266446,"score_gpt":0.5570303500313922,"score_spread":0.40471795109872777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045086,0.00057080336,0.000111871705,0.0067995037,0.0005022586,0.001344139,0.00008315104,0.00000875084,0.00012866159],"genre_scores_gemma":[0.9918982,0.00088376075,0.0031034097,0.0035151124,0.00033081477,0.000019922198,0.000036896978,0.000018547751,0.00019333795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971333,0.000405427,0.0015901048,0.0004010617,0.00022434873,0.00024576308],"domain_scores_gemma":[0.9975332,0.00071025884,0.0008719463,0.0004954767,0.0001816211,0.0002075132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015270922,0.00018385192,0.0011203092,0.00012093457,0.00019340031,0.000049403392,0.00058888266,0.00012184766,0.000043942757],"category_scores_gemma":[0.0016448232,0.000093596216,0.000055806362,0.00030279663,0.00013954222,0.00026993113,0.000648303,0.0009375312,0.0000031212294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012604701,0.0395457,0.87957436,0.00000988433,0.0015609991,0.0005919108,0.00047127405,0.000002453889,0.000020172914,0.0000033437773,0.0038337235,0.061781455],"study_design_scores_gemma":[0.1914591,0.0141549315,0.78343374,0.0011301221,0.0016716985,0.00023224577,0.00060173037,0.0002213758,0.0000065072895,0.000020472527,0.006956571,0.00011148582],"about_ca_topic_score_codex":0.00047512556,"about_ca_topic_score_gemma":0.0019729468,"teacher_disagreement_score":0.1788544,"about_ca_system_score_codex":0.00013007535,"about_ca_system_score_gemma":0.0021987928,"threshold_uncertainty_score":0.40731585},"labels":[],"label_agreement":null},{"id":"W4410805321","doi":"10.1200/jco.2025.43.16_suppl.6045","title":"Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Immune checkpoint; Blockade; Squamous cell cancer; Oncology; Head and neck; Cancer; Transcriptome; Immune system; Head and neck squamous-cell carcinoma; Head and neck cancer; Internal medicine; Cancer research; Immunology; Receptor; Gene expression; Biology; Gene; Surgery","score_opus":0.06671949807138279,"score_gpt":0.4877176401056447,"score_spread":0.42099814203426195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604526,0.0016390296,0.0013911126,0.03456929,0.0009954998,0.00059903495,0.000039632054,0.0000073692772,0.00030642466],"genre_scores_gemma":[0.9907099,0.0005811578,0.004968101,0.0023847518,0.00019710255,0.00004641729,0.000004364635,0.0000130028875,0.0010951746],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996267,0.00049233454,0.002428317,0.00028271668,0.0002614428,0.00026816592],"domain_scores_gemma":[0.9969967,0.001491435,0.00054774515,0.00020812865,0.00027722318,0.00047879698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021312656,0.00017526915,0.0017022317,0.0006942585,0.000042471955,0.000014223792,0.00012944957,0.0001624087,0.00014896433],"category_scores_gemma":[0.0021611832,0.00011895551,0.0004549606,0.0008611858,0.00006704187,0.000052215168,0.000042001957,0.0005839655,0.0000035055546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32613763,0.013243386,0.21019322,0.0003150077,0.009586865,0.0025217037,0.0058070216,0.0035075713,0.007985239,0.000016609787,0.002846799,0.41783896],"study_design_scores_gemma":[0.03008998,0.026041405,0.8657232,0.00032719687,0.012430065,0.000052394647,0.0004881199,0.0010023849,0.00078705244,0.00006471382,0.0628137,0.00017976925],"about_ca_topic_score_codex":0.00083832536,"about_ca_topic_score_gemma":0.0052029984,"teacher_disagreement_score":0.65553,"about_ca_system_score_codex":0.0006176482,"about_ca_system_score_gemma":0.0033948715,"threshold_uncertainty_score":0.6022356},"labels":[],"label_agreement":null},{"id":"W4410805349","doi":"10.1200/jco.2025.43.16_suppl.8590","title":"Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Adverse effect; Phase (matter); Event (particle physics); Internal medicine; Intensive care medicine","score_opus":0.14913641320519486,"score_gpt":0.6175495238850138,"score_spread":0.46841311067981894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859594,0.000057505396,0.00005690564,0.007646262,0.00036850508,0.00048517744,0.000009279199,0.0000023346815,0.0054146308],"genre_scores_gemma":[0.9983486,0.00004998157,0.00019705763,0.0008643548,0.00009128157,0.00001348579,0.0000020152966,0.000003798954,0.00042944754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764216,0.0003300291,0.0016249226,0.000097681266,0.00020632191,0.000098860364],"domain_scores_gemma":[0.99653494,0.0021176918,0.0008190321,0.00023076644,0.00021500446,0.000082537874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014925647,0.00008170827,0.000774677,0.00017384443,0.000030348921,0.000002785155,0.00012753077,0.0000897469,0.00007449958],"category_scores_gemma":[0.0019794544,0.00003915703,0.0005103498,0.00020911677,0.00007966964,0.000043133827,0.0000134109205,0.0004304087,0.0000048351308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052942988,0.05560545,0.8424527,0.000011103933,0.001910123,0.00025490022,0.0015725511,0.00061360345,0.000028020688,0.00043388098,0.0033810632,0.08844228],"study_design_scores_gemma":[0.022376323,0.020852413,0.95245343,0.000047243193,0.00073704123,0.00001101571,0.0009530643,0.00005660027,0.000002553628,0.00020824614,0.0022753614,0.000026677295],"about_ca_topic_score_codex":0.000078437384,"about_ca_topic_score_gemma":0.000058773625,"teacher_disagreement_score":0.11000073,"about_ca_system_score_codex":0.00022011957,"about_ca_system_score_gemma":0.0019485472,"threshold_uncertainty_score":0.3456639},"labels":[],"label_agreement":null},{"id":"W4410809316","doi":"10.1200/jco.2025.43.16_suppl.e20695","title":"Clinical prognostic factors associated with progression-free survival in pts with metastatic EGFR-mutant non-small cell lung cancer treated with gefitinib first-line therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Gefitinib; Medicine; Oncology; Lung cancer; Internal medicine; Mutant; Progression-free survival; Cancer research; Epidermal growth factor receptor; Cancer; Overall survival; Gene","score_opus":0.08928770459103813,"score_gpt":0.47621264863229523,"score_spread":0.3869249440412571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909772,0.0010042068,0.00027643764,0.0043271165,0.00048006725,0.0015260866,0.00003715121,0.000027641781,0.001344043],"genre_scores_gemma":[0.99525285,0.0011299856,0.0019718534,0.000753313,0.00020966462,0.00010329389,0.00003414436,0.000048423604,0.0004964806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953415,0.0006230694,0.0025380058,0.00044767358,0.0005794787,0.00047031877],"domain_scores_gemma":[0.98987794,0.0061616157,0.0022342247,0.0003393628,0.000960934,0.000425922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020026432,0.0003769783,0.0024569326,0.00024968397,0.000098669465,0.0000253716,0.0002628331,0.0003436271,0.000077763674],"category_scores_gemma":[0.0018682302,0.00018057287,0.00030382862,0.0007156668,0.00030967218,0.000121013865,0.000045049906,0.001322678,9.626424e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010936858,0.00832255,0.95736057,0.00008628968,0.0036925497,0.001677079,0.00023080199,0.00020278769,0.000007117405,0.000008402931,0.00030034047,0.01717465],"study_design_scores_gemma":[0.060640678,0.033780716,0.89648205,0.002646782,0.004079007,0.00003553143,0.0003010939,0.00034525376,0.000066166576,0.000029533556,0.0013805288,0.00021266051],"about_ca_topic_score_codex":0.00017447949,"about_ca_topic_score_gemma":0.0036996917,"teacher_disagreement_score":0.060878523,"about_ca_system_score_codex":0.0005202069,"about_ca_system_score_gemma":0.0065770764,"threshold_uncertainty_score":0.99905473},"labels":[],"label_agreement":null},{"id":"W4410811046","doi":"10.1200/jco.2025.43.16_suppl.e23226","title":"Identifying barriers and effective strategies to improve biomarker testing rates in non-small cell lung cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Biomarker; Lung cancer; Cancer; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.05129701276020442,"score_gpt":0.5035954622646207,"score_spread":0.4522984495044163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865897,0.0012943131,0.0007811695,0.002524897,0.0013267733,0.00050774036,0.0000032099965,0.0000050575213,0.0069670854],"genre_scores_gemma":[0.9944404,0.00019748283,0.0037550682,0.0010796362,0.0001815763,0.000036046997,4.898034e-7,0.000007720739,0.0003016159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849796,0.0001375591,0.0009387497,0.00017107076,0.0000860393,0.0001686172],"domain_scores_gemma":[0.9970117,0.0019801026,0.0004333865,0.00007306241,0.0002684021,0.00023334655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010788898,0.00010090344,0.0006994874,0.0001879822,0.00004852596,0.000025381105,0.00006080419,0.00015078577,0.00001711985],"category_scores_gemma":[0.001720483,0.00007284769,0.00010483715,0.00026440775,0.00006824542,0.00010464696,0.000042393774,0.00039898162,0.0000010392523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011118364,0.0002921739,0.7941611,0.00024460413,0.0005831354,0.00035737126,0.00073086465,0.00009701296,0.0056877127,0.000036212314,0.00089527474,0.19580272],"study_design_scores_gemma":[0.008060839,0.0027581132,0.982739,0.0006604729,0.00084427436,0.000015469173,0.002021924,0.00063057576,0.0005740727,0.00031865132,0.0012976646,0.00007896083],"about_ca_topic_score_codex":0.00027903877,"about_ca_topic_score_gemma":0.00018896653,"teacher_disagreement_score":0.19572376,"about_ca_system_score_codex":0.0002961041,"about_ca_system_score_gemma":0.002658654,"threshold_uncertainty_score":0.4716338},"labels":[],"label_agreement":null},{"id":"W4410814329","doi":"10.1200/jco.2025.43.16_suppl.5004","title":"Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Quality of life (healthcare); Health related quality of life; Oncology; Gerontology; Internal medicine; Physical therapy; Disease; Nursing","score_opus":0.185211030578615,"score_gpt":0.6027982367111153,"score_spread":0.41758720613250033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410814329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8894833,0.0007669874,0.00015622436,0.105013594,0.0006310412,0.00048654404,0.0000053988147,0.000003711702,0.003453221],"genre_scores_gemma":[0.98894113,0.00021639907,0.00072287145,0.009630205,0.00010635952,0.0000074184686,0.0000028701124,0.0000046918863,0.00036802993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951337,0.00098707,0.0033631248,0.00010903017,0.00026930083,0.0001378011],"domain_scores_gemma":[0.9934253,0.0039071576,0.0021205354,0.00019904926,0.00021050104,0.00013746085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053674174,0.000087414875,0.0017950061,0.00012459629,0.000032254906,0.0000036880726,0.00012559252,0.00015328887,0.000031711308],"category_scores_gemma":[0.004643598,0.000041314244,0.00032232943,0.00025238525,0.00016427634,0.000047928577,0.000012299296,0.00061948027,0.0000016584424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29415512,0.02377739,0.44562978,0.00017489599,0.0038098258,0.00033556722,0.0015383977,0.00008553124,0.000016230144,0.0030157103,0.006976253,0.22048531],"study_design_scores_gemma":[0.29442233,0.021418916,0.6673114,0.0001594053,0.0005599438,0.000026071928,0.00048480928,0.00001533177,0.0000027468027,0.00088755164,0.014666136,0.000045373716],"about_ca_topic_score_codex":0.0003354951,"about_ca_topic_score_gemma":0.00035758244,"teacher_disagreement_score":0.2216816,"about_ca_system_score_codex":0.0001479585,"about_ca_system_score_gemma":0.0055249142,"threshold_uncertainty_score":0.98009604},"labels":[],"label_agreement":null},{"id":"W4410815858","doi":"10.1200/jco.2025.43.16_suppl.tps8115","title":"KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II–IIIB (N2) non–small-cell lung cancer (NSCLC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Chemotherapy; Lung cancer; Stage (stratigraphy); Phases of clinical research; Oncology; non-small cell lung cancer (NSCLC); Cancer; Internal medicine; Surgery; Immunotherapy","score_opus":0.10847958062044266,"score_gpt":0.5293499109900792,"score_spread":0.42087033036963656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410815858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676145,0.0006227932,0.004670602,0.003368806,0.00038606435,0.0022923362,0.00003878787,0.000011842339,0.0018473448],"genre_scores_gemma":[0.97130924,0.0003788462,0.015414378,0.0019625642,0.00042144643,0.00017262954,0.000011705745,0.00004232466,0.010286867],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970255,0.00015210312,0.0017317879,0.00033663952,0.00044475184,0.0003092225],"domain_scores_gemma":[0.9957792,0.00088283204,0.0017288416,0.0002588493,0.0010346489,0.00031561495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010695076,0.00024671532,0.0016892677,0.00021193695,0.00015028166,0.000016828713,0.00018811214,0.00020325903,0.00018776333],"category_scores_gemma":[0.00029003626,0.00014155707,0.0002353739,0.00037713413,0.0002085036,0.00011391247,0.000034591518,0.00056055025,4.4935408e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29438132,0.031137703,0.6118727,0.0012780986,0.013812014,0.0007601009,0.0069372025,0.005434817,0.0007919698,0.00008068201,0.010061155,0.023452261],"study_design_scores_gemma":[0.6435116,0.2011716,0.06028955,0.0035065534,0.014183204,0.00019841535,0.005562705,0.0265873,0.00199132,0.00013653607,0.042248156,0.0006130778],"about_ca_topic_score_codex":0.0002136369,"about_ca_topic_score_gemma":0.000627303,"teacher_disagreement_score":0.5515831,"about_ca_system_score_codex":0.00049959007,"about_ca_system_score_gemma":0.014006177,"threshold_uncertainty_score":0.99158347},"labels":[],"label_agreement":null},{"id":"W4410820423","doi":"10.1200/jco.2025.43.16_suppl.8046","title":"Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Chemotherapy; Adjuvant; Oncology; Adjuvant chemotherapy; Cisplatin; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Breast cancer; Nivolumab","score_opus":0.08332271275839634,"score_gpt":0.48218000100747865,"score_spread":0.3988572882490823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774581,0.002186632,0.000977813,0.0127824275,0.0020900483,0.00077187637,0.00006817466,0.000013394146,0.0036514986],"genre_scores_gemma":[0.97928226,0.0034712183,0.0044887546,0.009583608,0.00037426932,0.00003705177,0.000024721887,0.000037613157,0.002700503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643725,0.00012196054,0.0022221413,0.00043390054,0.0003625082,0.00042223276],"domain_scores_gemma":[0.9970483,0.00082431175,0.0011157276,0.0003002039,0.0003630261,0.000348399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009843196,0.0002898125,0.0019725487,0.00027763806,0.00007806301,0.000028178776,0.00023041607,0.000278363,0.0005087939],"category_scores_gemma":[0.00041651566,0.00020839491,0.00034313736,0.0003430589,0.00015324875,0.00015958183,0.00010515278,0.00089260464,0.0000046278296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002815815,0.0047591296,0.92423934,0.00006881011,0.002062998,0.00046465948,0.0004110168,0.00016166127,0.0011350136,0.000030324254,0.012058229,0.051793016],"study_design_scores_gemma":[0.053205293,0.0011332683,0.9074036,0.00062217214,0.0013020649,0.000030788262,0.00021319004,0.0028125169,0.0002443058,0.00006061188,0.032797463,0.00017472675],"about_ca_topic_score_codex":0.002585917,"about_ca_topic_score_gemma":0.0010527975,"teacher_disagreement_score":0.05161829,"about_ca_system_score_codex":0.00062246463,"about_ca_system_score_gemma":0.0034269565,"threshold_uncertainty_score":0.84980977},"labels":[],"label_agreement":null},{"id":"W4410822585","doi":"10.1200/jco.2025.43.16_suppl.e20031","title":"The HALP score as a prognostic biomarker in non-small cell lung cancer: A comprehensive meta-analysis of over 7,000 patients.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Meta-analysis; Biomarker; Oncology; Internal medicine; Cancer","score_opus":0.10909629497560241,"score_gpt":0.495622854527877,"score_spread":0.3865265595522746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837205,0.006459496,0.000047012552,0.004668683,0.0005590799,0.00058735564,0.00002487359,0.0000025219424,0.0039304947],"genre_scores_gemma":[0.99575907,0.0009851082,0.0003135538,0.0020221767,0.000045201337,0.00004234918,0.000007002311,0.0000076289357,0.00081788935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705595,0.00031527827,0.002018818,0.00017333512,0.00025802545,0.00017857799],"domain_scores_gemma":[0.9937172,0.0036490622,0.0014683316,0.00020635275,0.0008280768,0.00013099996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077608676,0.00013030018,0.0020766489,0.00032821638,0.00004594129,0.000008609628,0.00014830986,0.0001781166,0.00018419337],"category_scores_gemma":[0.0008465181,0.00006773122,0.0014686349,0.0007291649,0.00015749053,0.000041752908,0.000048567865,0.0004140778,0.0000013466142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013949148,0.002190654,0.85972995,0.00006192816,0.11862694,0.00011644186,0.00019806986,0.00018229787,0.000019406652,0.00005344335,0.002926168,0.0144998],"study_design_scores_gemma":[0.004770636,0.0014096391,0.77636564,0.000045409834,0.20683101,0.000002213325,0.0000939684,0.0004498899,0.000010475518,0.00005824399,0.009920484,0.000042382555],"about_ca_topic_score_codex":0.0005552924,"about_ca_topic_score_gemma":0.000832309,"teacher_disagreement_score":0.08820407,"about_ca_system_score_codex":0.0002203412,"about_ca_system_score_gemma":0.0018722313,"threshold_uncertainty_score":0.33212578},"labels":[],"label_agreement":null},{"id":"W4410823208","doi":"10.1200/jco.2025.43.16_suppl.e20003","title":"Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive non-small cell lung cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Osimertinib; Adjuvant; Oncology; Lung cancer; Internal medicine; Adverse effect; Mutation; Cancer; Lung; Epidermal growth factor receptor; Gene; Erlotinib; Genetics; Biology","score_opus":0.039176949167436644,"score_gpt":0.4746904172840064,"score_spread":0.43551346811656977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806414,0.00031313638,0.00013388474,0.006475741,0.0008124216,0.00045906982,0.000012359487,0.0000067107794,0.011145277],"genre_scores_gemma":[0.99273664,0.0006851071,0.0020505174,0.0010435651,0.00014178522,0.00002205704,0.00000863635,0.000012917319,0.0032987983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977945,0.00025198015,0.0013460893,0.00020422775,0.0002043222,0.00019886399],"domain_scores_gemma":[0.99676263,0.0016847588,0.00082575943,0.00011685643,0.00040661567,0.00020337645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007730731,0.00014139446,0.0011406996,0.00026020402,0.000048138765,0.0000036828653,0.00007664967,0.0001474778,0.00004146699],"category_scores_gemma":[0.0004007579,0.00009137422,0.00015395123,0.00031896454,0.00009356702,0.000086662454,0.00003165721,0.0005618906,0.0000013944725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034255222,0.0010374563,0.98289275,0.00005923378,0.00079353136,0.00076257647,0.00036730262,0.00012754816,0.000035261975,0.00005055983,0.000394592,0.010053687],"study_design_scores_gemma":[0.02009744,0.0026748662,0.9738911,0.00048231313,0.0013111321,0.000016427482,0.00038328982,0.00024351595,0.00007880948,0.00006384285,0.00067901134,0.000078294885],"about_ca_topic_score_codex":0.0013175522,"about_ca_topic_score_gemma":0.0063535487,"teacher_disagreement_score":0.016671918,"about_ca_system_score_codex":0.00044264598,"about_ca_system_score_gemma":0.0031929298,"threshold_uncertainty_score":0.56641203},"labels":[],"label_agreement":null},{"id":"W4410830901","doi":"10.1038/s41591-025-03732-5","title":"Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Amgen","keywords":"Lung cancer; Medicine; Cancer research; Clinical efficacy; Oncology; Internal medicine","score_opus":0.01136452044854152,"score_gpt":0.4237356422214463,"score_spread":0.41237112177290475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410830901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97716475,0.012865242,0.00008718116,0.0024210494,0.0009690905,0.001025614,0.000011684764,0.000029582145,0.0054258313],"genre_scores_gemma":[0.9956214,0.0005324488,0.00027119592,0.0020312322,0.00015427741,0.000053101732,0.000042904827,0.000022427552,0.0012710476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983648,0.000056519664,0.00067883247,0.00037123662,0.00026763155,0.00026096968],"domain_scores_gemma":[0.998917,0.00020865758,0.00016589981,0.00036264316,0.00021494481,0.00013084288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028332285,0.00020791373,0.0007327201,0.0003111724,0.000030687308,0.000003123906,0.00013197317,0.0003786384,0.00009826076],"category_scores_gemma":[0.0003132998,0.00014718992,0.00011172136,0.00072806835,0.00013465149,0.000026992171,0.000037344755,0.0007030344,0.000002459282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035182328,0.0009716406,0.967775,0.000711993,0.0002980198,0.0005054512,0.0005544606,0.000028924014,0.008177173,0.00006598808,0.0041477615,0.016411752],"study_design_scores_gemma":[0.023527382,0.0005959594,0.92985576,0.004100844,0.001903467,0.000011051732,0.00019518423,0.0012442131,0.03540348,0.00004004129,0.0029302607,0.0001923318],"about_ca_topic_score_codex":0.00043314192,"about_ca_topic_score_gemma":0.00019282266,"teacher_disagreement_score":0.037919227,"about_ca_system_score_codex":0.0001739684,"about_ca_system_score_gemma":0.00061516376,"threshold_uncertainty_score":0.60022306},"labels":[],"label_agreement":null},{"id":"W4410845417","doi":"10.1016/j.cllc.2025.05.006","title":"KRAS ctDNA Detection in Patients With Resectable Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fondation de l'Hôpital Général de Montréal; Fonds de Recherche du Québec - Santé; American Society on Aging; American Surgical Association Foundation","keywords":"Medicine; KRAS; Adenocarcinoma; Internal medicine; Stage (stratigraphy); Liquid biopsy; Oncology; Clinical trial; Biopsy; Gastroenterology; Cancer; Colorectal cancer","score_opus":0.013075088355639933,"score_gpt":0.3976272195076861,"score_spread":0.3845521311520462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410845417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744714,0.0027121995,0.00025404306,0.0009556132,0.00077831064,0.001094862,0.000017578319,0.000056769233,0.006683503],"genre_scores_gemma":[0.9937891,0.00013744473,0.00014225258,0.0009006296,0.00014420247,0.00023884584,0.00002872308,0.000019149165,0.00459965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872863,0.000053055483,0.00040298823,0.00038093774,0.00018364089,0.00025074003],"domain_scores_gemma":[0.99924004,0.0001290912,0.00007984874,0.00029128022,0.00015443128,0.00010531692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014427517,0.00013448659,0.00032148094,0.00012735307,0.00007737754,0.000016865048,0.00006370709,0.00012480372,0.00015911396],"category_scores_gemma":[0.00008520332,0.00010001217,0.00007916276,0.00045810064,0.000064836684,0.00009130607,0.000023526727,0.00029340337,0.000007179375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009532124,0.00034600883,0.9800365,0.00010323224,0.0002915447,0.000009074407,0.0000600235,0.000022649576,0.000005543518,0.000058710826,0.0031263262,0.014987161],"study_design_scores_gemma":[0.0075194673,0.0003591461,0.9879816,0.00045973263,0.00058368803,4.220767e-7,0.000022050952,0.0004883747,0.00010345424,0.000056310844,0.0023241516,0.00010157089],"about_ca_topic_score_codex":0.00036724002,"about_ca_topic_score_gemma":0.0010951667,"teacher_disagreement_score":0.01488559,"about_ca_system_score_codex":0.00053234457,"about_ca_system_score_gemma":0.0005014392,"threshold_uncertainty_score":0.40783778},"labels":[],"label_agreement":null},{"id":"W4410864457","doi":"10.21037/jtd-2025-91","title":"Perioperative toripalimab and chemotherapy in resectable non-small cell lung cancer: another weapon in the armamentarium","year":2025,"lang":"en","type":"letter","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Perioperative; Chemotherapy; Lung cancer; Intensive care medicine; General surgery; Surgery; Oncology","score_opus":0.011628345246167623,"score_gpt":0.35444695290167655,"score_spread":0.3428186076555089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410864457","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1857122,0.0170696,0.00003062401,0.7912711,0.00063369254,0.0014954798,0.00015786271,0.0000062853896,0.0036231717],"genre_scores_gemma":[0.17788179,0.0075667184,0.00046968274,0.78745764,0.0031625235,0.00031926963,0.00011948068,0.00009265571,0.022930203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986211,0.00014719806,0.0004196759,0.0002219342,0.000334177,0.00025592704],"domain_scores_gemma":[0.99922955,0.000089723406,0.00025605853,0.0002275367,0.00011503462,0.000082118815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023490607,0.00024703637,0.00048302865,0.00032164497,0.000055356435,0.00008429121,0.00016683948,0.00013552842,0.00015179117],"category_scores_gemma":[0.000019818335,0.00015436231,0.00014188724,0.0002520143,0.000041091,0.00011324436,0.0000215962,0.0010036961,7.43368e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027549856,0.00098266,0.1143586,0.0036032102,0.0006422259,0.0062827333,0.009505611,0.000077574594,0.00014587228,0.0000027858923,0.858286,0.0033577308],"study_design_scores_gemma":[0.014291801,0.00079870655,0.0905522,0.012629038,0.0047741686,0.00009800784,0.0030576477,0.00039347526,0.0005200366,0.000084408806,0.872055,0.00074550556],"about_ca_topic_score_codex":0.0005365455,"about_ca_topic_score_gemma":0.000118244716,"teacher_disagreement_score":0.023806395,"about_ca_system_score_codex":0.0006322705,"about_ca_system_score_gemma":0.0012724812,"threshold_uncertainty_score":0.62947124},"labels":[],"label_agreement":null},{"id":"W4410872297","doi":"10.1007/s12325-025-03239-y","title":"Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Referral; Stage (stratigraphy); Chemoradiotherapy; Internal medicine; Rheumatology; Oncology; Family medicine; Overall survival","score_opus":0.007839728466091026,"score_gpt":0.31028360856865783,"score_spread":0.3024438801025668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410872297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949162,0.0022122096,0.000081725244,0.00083746214,0.000074168376,0.0010483946,0.00002384622,0.000026974165,0.00077900523],"genre_scores_gemma":[0.9919342,0.0062668594,0.00012814009,0.0007034604,0.000028191258,0.00018412377,0.00020222629,0.00002101916,0.0005317884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990899,0.00006778897,0.00022318064,0.0002719731,0.00011210404,0.00023508025],"domain_scores_gemma":[0.9995022,0.00012455361,0.00008031829,0.00022351043,0.00003773083,0.000031696516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012367904,0.00016834537,0.00025191717,0.00020933498,0.000071734845,0.000046564597,0.000103746934,0.00004170939,0.00005556503],"category_scores_gemma":[0.0000066693965,0.00010329496,0.000019287756,0.00032611765,0.000081091595,0.0003171911,0.000010809466,0.00015329443,5.551169e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085493206,0.00011855467,0.9658357,0.000042847107,0.00010818326,0.000011288676,0.004511377,0.0020012169,0.000019740544,0.000060837792,0.00002528945,0.026410013],"study_design_scores_gemma":[0.019824574,0.0006216664,0.95928943,0.00048875157,0.00003254925,0.0000016849763,0.003570194,0.001068337,0.00026648087,0.00033886987,0.014284804,0.00021265616],"about_ca_topic_score_codex":0.003925533,"about_ca_topic_score_gemma":0.0029195272,"teacher_disagreement_score":0.026197357,"about_ca_system_score_codex":0.0002623611,"about_ca_system_score_gemma":0.00008523544,"threshold_uncertainty_score":0.59342575},"labels":[],"label_agreement":null},{"id":"W4410941170","doi":"10.1101/2025.05.30.25328679","title":"Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations A case Study using Lung-MAP S1400I","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Health Sciences Centre; Sunnybrook Health Science Centre; Public Health Ontario; University of Toronto; Toronto Public Health","funders":"University of North Carolina at Chapel Hill; National Institute for Health and Care Research","keywords":"Lung cancer; Lung; Clinical trial; Medicine; Oncology; Internal medicine","score_opus":0.1699983745339169,"score_gpt":0.5563305253244444,"score_spread":0.3863321507905275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410941170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843902,0.00023700591,0.00044335474,0.0011681976,0.0044943825,0.0070801442,0.0014956797,0.0000897092,0.00060133456],"genre_scores_gemma":[0.9951505,0.0000172107,0.00191835,0.00014857958,0.0003929247,0.00064657297,0.000119916134,0.000024329156,0.0015816097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606115,0.0002700962,0.0019507806,0.00092080043,0.0004880659,0.0003090882],"domain_scores_gemma":[0.9975024,0.00018001057,0.0004755127,0.001151721,0.00036597357,0.00032438463],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007329713,0.00041052228,0.0016782797,0.00022757554,0.0001342791,0.00002172717,0.00018677216,0.00020661065,0.00017827287],"category_scores_gemma":[0.00021808111,0.00033704183,0.0006876277,0.00055359286,0.00007623432,0.000045494995,0.00016391471,0.00041708138,8.573756e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028721471,0.0023730083,0.9884848,0.0005388433,0.0016495775,0.0006408498,0.0011168949,0.0014621348,5.1879994e-7,0.00005895735,0.00023049048,0.0005717838],"study_design_scores_gemma":[0.022158954,0.00025383852,0.96698236,0.00043742915,0.008569228,0.000009403714,0.0003435715,0.000787119,0.0000014412836,0.00008483833,0.00012942076,0.00024240333],"about_ca_topic_score_codex":0.09568912,"about_ca_topic_score_gemma":0.15792356,"teacher_disagreement_score":0.062234443,"about_ca_system_score_codex":0.00088288443,"about_ca_system_score_gemma":0.0023647118,"threshold_uncertainty_score":0.99990815},"labels":[],"label_agreement":null},{"id":"W4410958726","doi":"10.1016/j.annonc.2025.04.003","title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre","funders":"Genentech; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Daiichi-Sankyo; Gilead Sciences; Servier; Pfizer; Yonsei University; Regeneron Pharmaceuticals; Natera; Seagen; Sanofi; Apollomics; International Association for the Study of Lung Cancer; BeiGene; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Samsung; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Yuhan; Amgen; Celgene","keywords":"Osimertinib; Medicine; Epidermal growth factor receptor; Cancer research; Lung cancer; Oncology; Internal medicine; Receptor; Erlotinib","score_opus":0.04496678258221625,"score_gpt":0.4243055604986285,"score_spread":0.37933877791641224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410958726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881331,0.001629742,0.000052189935,0.005457716,0.00018953694,0.0033606358,0.0005277329,0.000047519763,0.0006018249],"genre_scores_gemma":[0.9953723,0.00031692258,0.00063472555,0.0018878672,0.0000680754,0.0007424158,0.0005757858,0.00003250972,0.00036937377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763596,0.00028926297,0.00074408617,0.0006667193,0.0002868417,0.00037714074],"domain_scores_gemma":[0.9978505,0.00081721693,0.00047660206,0.00042973537,0.00022337191,0.0002025713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002725101,0.00030763182,0.00066402496,0.00016918949,0.00023972943,0.00001625114,0.00015239265,0.00012011244,0.000033901528],"category_scores_gemma":[0.00034413298,0.00018087163,0.00009766794,0.00037970417,0.00008960264,0.00015808335,0.0001000781,0.00026705556,0.0000014020903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24124634,0.029778231,0.3273267,0.00075374136,0.002517474,0.00042700223,0.036850713,0.0005158929,0.054603074,0.00004346551,0.010923474,0.29501393],"study_design_scores_gemma":[0.11465489,0.028077764,0.79019284,0.00655434,0.0019980436,0.0000019648526,0.0048451177,0.0009357276,0.04655576,0.00006968313,0.005467989,0.0006458831],"about_ca_topic_score_codex":0.00071413093,"about_ca_topic_score_gemma":0.00009583117,"teacher_disagreement_score":0.46286616,"about_ca_system_score_codex":0.0002695215,"about_ca_system_score_gemma":0.0013579198,"threshold_uncertainty_score":0.73757315},"labels":[],"label_agreement":null},{"id":"W4411011492","doi":"10.1016/j.cllc.2025.05.009","title":"Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Crizotinib; Timeline; Lung cancer; Internal medicine; Oncology; Intensive care medicine","score_opus":0.052301883469510736,"score_gpt":0.5085346421026976,"score_spread":0.45623275863318685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411011492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96575266,0.008437083,0.00050280883,0.00863316,0.0015631898,0.0034316108,0.005862908,0.0000838296,0.0057327566],"genre_scores_gemma":[0.9823592,0.0014875508,0.0046478445,0.0028403758,0.00096321787,0.001215731,0.0015629756,0.000024282728,0.0048988746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984923,0.000058112888,0.0005817103,0.0005351998,0.00013292488,0.00019976524],"domain_scores_gemma":[0.9964874,0.0026332184,0.00016531414,0.00028059212,0.0002953083,0.00013817327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001430599,0.00017780422,0.00040253787,0.000021793232,0.00012431925,0.000026898317,0.000048353206,0.00012336783,0.000022870909],"category_scores_gemma":[0.0027457767,0.00013193207,0.00015191302,0.00011849146,0.000097873926,0.00004625277,0.000033560256,0.00007473155,0.0000032938622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029617888,0.0008544636,0.53881556,0.00005266206,0.0017557318,0.000009511283,0.00019011486,0.0000308296,0.0000059121303,0.00012853285,0.020865204,0.43432972],"study_design_scores_gemma":[0.036767572,0.0020589288,0.9363987,0.0017437582,0.0062309355,8.0962343e-7,0.00008589015,0.003797732,0.00005844995,0.00068171875,0.0119484095,0.0002271259],"about_ca_topic_score_codex":0.0009713514,"about_ca_topic_score_gemma":0.00029461953,"teacher_disagreement_score":0.4341026,"about_ca_system_score_codex":0.00060779596,"about_ca_system_score_gemma":0.0005886851,"threshold_uncertainty_score":0.5380034},"labels":[],"label_agreement":null},{"id":"W4411212746","doi":"10.2196/64399","title":"Next-Generation Sequencing–Based Testing Among Patients With Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States: Predictive Modeling Using Machine Learning Methods","year":2025,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lung cancer; Oncology; DNA sequencing; Medicine; Internal medicine; Cancer; Artificial intelligence; Medical physics; Machine learning; Computer science; Biology; DNA","score_opus":0.06987583562322436,"score_gpt":0.39188032337793427,"score_spread":0.3220044877547099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411212746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8843305,0.00076946686,0.11162527,0.00011814281,0.00012394202,0.0027535048,0.00008144553,0.00006170641,0.00013602668],"genre_scores_gemma":[0.9585373,0.000058551916,0.037961155,0.0007798278,0.000053336917,0.0020355906,0.00032815826,0.00005279935,0.00019327922],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982433,0.00025735266,0.00040530588,0.00043901397,0.0002787213,0.00037633482],"domain_scores_gemma":[0.9987273,0.00027515524,0.00022634746,0.00023526022,0.0004585626,0.00007735035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027004618,0.000302805,0.00037089438,0.00036504967,0.00031569737,0.00006951083,0.00010368993,0.00006044557,0.000040338084],"category_scores_gemma":[0.000092567985,0.00018804194,0.000052873937,0.0015262988,0.00004972598,0.00022224995,0.000025036183,0.00040871714,2.2840827e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035404414,0.00014574334,0.17275059,0.00026506136,0.00016852772,0.00001642755,0.0030832142,0.8178843,0.0015746466,9.548922e-7,0.000009004362,0.0037474842],"study_design_scores_gemma":[0.005065742,0.00032980836,0.0068411035,0.0011188713,0.0011520756,9.867957e-7,0.0015414633,0.9829144,0.00078373647,0.000004492385,0.000046987134,0.00020036158],"about_ca_topic_score_codex":0.015251398,"about_ca_topic_score_gemma":0.004110535,"teacher_disagreement_score":0.16590948,"about_ca_system_score_codex":0.0015397614,"about_ca_system_score_gemma":0.0015326309,"threshold_uncertainty_score":0.9913061},"labels":[],"label_agreement":null},{"id":"W4411312400","doi":"10.1016/j.jtho.2025.06.005","title":"Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Capital Commission; Japan Science and Technology Agency; Japan Society for the Promotion of Science; Università degli Studi del Piemonte Orientale; World Education Services; Japan Agency for Medical Research and Development; National Cancer Center; Japan Society for the Promotion of Science London; Core Research for Evolutional Science and Technology; National Cancer Coalition","keywords":"Penetrance; Medicine; Germline; Adenocarcinoma; Germline mutation; Genetics; Oncology; Internal medicine; Gene; Mutation; Cancer; Biology; Phenotype","score_opus":0.01195021980601712,"score_gpt":0.37216109097231664,"score_spread":0.3602108711662995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411312400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993432,0.0046729804,0.0005579086,0.00048658604,0.0001237149,0.00028302532,0.00009927173,0.0000045098327,0.00034002162],"genre_scores_gemma":[0.9965134,0.00042847783,0.0026059025,0.00007706477,0.000035826557,0.0000062913387,0.000008513018,0.000011305977,0.0003132203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886805,0.00017418546,0.0005469754,0.00012576341,0.00014390907,0.0001411461],"domain_scores_gemma":[0.99830675,0.00022293224,0.00086734403,0.00012945285,0.0003995963,0.000073907504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039437704,0.00011343176,0.0006466252,0.00020761705,0.00004773219,0.000005288659,0.00007184112,0.00011682987,0.000020839912],"category_scores_gemma":[0.00014757874,0.00007940921,0.00008444314,0.00020462344,0.00011082738,0.00006432294,0.000020518322,0.00022540278,2.989931e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004719783,0.00064278464,0.968828,0.00020082945,0.002478319,0.00020281629,0.0009493658,0.00015024094,0.0070496867,0.000025105763,0.00023527822,0.014517767],"study_design_scores_gemma":[0.0026144008,0.0024653825,0.9880062,0.00043954895,0.003031597,0.00022954257,0.00012306329,0.00045903912,0.0022956152,0.0002432059,0.00003318965,0.00005926747],"about_ca_topic_score_codex":0.000058580452,"about_ca_topic_score_gemma":0.000037643225,"teacher_disagreement_score":0.019178124,"about_ca_system_score_codex":0.00021951702,"about_ca_system_score_gemma":0.0010714894,"threshold_uncertainty_score":0.32382137},"labels":[],"label_agreement":null},{"id":"W4411372338","doi":"10.1016/j.jaccao.2025.05.003","title":"Lung Cancer and Cardiovascular Disease","year":2025,"lang":"fi","type":"review","venue":"JACC CardioOncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Toronto General Hospital; Centre Integre de Sante et de Services Sociaux de Laval","funders":"National Cancer Institute","keywords":"Disease; Lung cancer; Medicine; Cancer; Lung; Internal medicine; Cardiology; Intensive care medicine; Oncology","score_opus":0.022213307078135135,"score_gpt":0.38366007277202696,"score_spread":0.36144676569389184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411372338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042113752,0.9598001,0.00012523169,0.0012678584,0.0043332656,0.0038248168,0.0011635276,0.000078079436,0.02936498],"genre_scores_gemma":[0.00043677003,0.9658158,0.000080957565,0.00055024214,0.0022563094,0.0031515122,0.0004682991,0.00008730625,0.02715285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962035,0.00049801863,0.0006823963,0.0013898655,0.0004634683,0.00076275313],"domain_scores_gemma":[0.99695694,0.00050230115,0.00022151845,0.0013642372,0.0002695913,0.0006854282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004095824,0.0008392488,0.004569704,0.00038992826,0.0002997821,0.00005528277,0.00021686095,0.0006633773,0.00038032283],"category_scores_gemma":[0.0002537658,0.0007009461,0.0026980795,0.0005788969,0.00026278003,0.00008292611,0.00029852623,0.0006353843,0.000059989045],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068031564,0.00010583095,0.002609632,0.03886957,0.040781096,0.0012229682,0.00014454081,0.00007813893,1.01495154e-7,0.0002923586,0.01536026,0.90046746],"study_design_scores_gemma":[0.002327037,0.00009237199,0.0015839105,0.01069116,0.14037256,0.000088959925,0.00006734481,0.000032864184,1.6820007e-7,0.000011378557,0.84428287,0.0004493552],"about_ca_topic_score_codex":0.0006658093,"about_ca_topic_score_gemma":0.000036024103,"teacher_disagreement_score":0.9000181,"about_ca_system_score_codex":0.001648578,"about_ca_system_score_gemma":0.006493648,"threshold_uncertainty_score":0.99954414},"labels":[],"label_agreement":null},{"id":"W4411417714","doi":"10.51731/cjht.2025.1147","title":"Durvalumab (Imfinzi) and Tremelimumab (Imjudo)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Durvalumab; Gemcitabine; Internal medicine; Lung cancer; Regimen; Immunotherapy; Cancer; Pembrolizumab","score_opus":0.015955109993478225,"score_gpt":0.33904363239080565,"score_spread":0.32308852239732744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411417714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38070846,0.30846608,0.0004880688,0.3022242,0.00080195384,0.0006264474,0.000030870575,0.0001587728,0.0064951614],"genre_scores_gemma":[0.9965995,0.0010910791,0.00070097,0.0010838937,0.0000060758707,0.00000489994,0.0000018690683,0.0000060642055,0.0005056685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992576,0.00001628824,0.00032110346,0.000092344686,0.000071130715,0.00024153607],"domain_scores_gemma":[0.9994833,0.000028106653,0.00013679177,0.00014960585,0.00012369333,0.00007852869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017940805,0.00008173263,0.00028104967,0.00060239376,0.00019618725,0.000020414878,0.00008122255,0.00008034786,0.000014640366],"category_scores_gemma":[0.00022471778,0.00006337218,0.000043246226,0.00026763492,0.0001410973,0.00005411592,0.000009134859,0.00021002791,0.000001871797],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020529367,0.000022299651,0.023067247,0.0001518476,0.00016168701,0.00014003176,0.00028783604,0.0000019780432,0.000018117084,0.004542911,0.011459013,0.9601265],"study_design_scores_gemma":[0.0047821514,0.0013824584,0.20426531,0.001508823,0.0002891979,0.0008889512,0.0089435065,0.000021177955,0.000528243,0.014201609,0.7630059,0.00018267226],"about_ca_topic_score_codex":0.0031101578,"about_ca_topic_score_gemma":0.003158012,"teacher_disagreement_score":0.95994383,"about_ca_system_score_codex":0.00048987725,"about_ca_system_score_gemma":0.0044488953,"threshold_uncertainty_score":0.7892149},"labels":[],"label_agreement":null},{"id":"W4411709014","doi":"10.21037/tlcr-2024-1034","title":"Response of non-small cell lung cancer harboring different epidermal growth factor receptor mutations to ablative radiotherapy","year":2025,"lang":"en","type":"article","venue":"Translational Lung Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; McGill University Health Centre; McGill University","funders":"","keywords":"Ablative case; Epidermal growth factor receptor; Medicine; Lung cancer; Cancer research; Radiation therapy; Lung; Oncology; Receptor; Bioinformatics; Internal medicine; Biology","score_opus":0.03893809645269872,"score_gpt":0.4328416493779434,"score_spread":0.3939035529252447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411709014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961348,0.0059121177,0.009087644,0.018154124,0.0003221983,0.0027243863,0.00089789246,0.00004656155,0.0015070632],"genre_scores_gemma":[0.9883534,0.0005908938,0.002755636,0.0002916139,0.0001715092,0.0015547653,0.00008817804,0.00004766588,0.006146394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746937,0.00027258534,0.0004734603,0.0005005981,0.00077014155,0.0005138658],"domain_scores_gemma":[0.99757,0.00094137056,0.00007591394,0.00027100008,0.00089187094,0.00024984076],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003919196,0.00024430527,0.0004266321,0.00074601936,0.00030210035,0.00003640429,0.00018125628,0.00011023601,0.0012266281],"category_scores_gemma":[0.0000663808,0.0002120974,0.0001642129,0.0010756224,0.00012902966,0.00012853785,0.000025597988,0.0003894148,0.000004712009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011360402,0.0010302782,0.6022741,0.0018338342,0.003059744,0.000019494511,0.021694321,0.0046846713,0.33608663,0.0021162184,0.008225979,0.007614307],"study_design_scores_gemma":[0.006775614,0.00036522263,0.8704189,0.0014158924,0.00044438348,0.000001053059,0.00029412966,0.006483276,0.10996238,0.00012360698,0.0033770732,0.00033844143],"about_ca_topic_score_codex":0.0018004227,"about_ca_topic_score_gemma":0.00027177203,"teacher_disagreement_score":0.26814482,"about_ca_system_score_codex":0.0011902765,"about_ca_system_score_gemma":0.0023742812,"threshold_uncertainty_score":0.99968636},"labels":[],"label_agreement":null},{"id":"W4411744409","doi":"10.1101/2025.06.26.659534","title":"EGFR Mutation Subtypes Modulate Distinct Metabolic Profiles and Clinical Outcomes in Lung Cancer: A Retrospective Analysis","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Lung cancer; Medicine; Oncology; Retrospective cohort study; Mutation; Internal medicine; Cancer; Lung; Bioinformatics; Biology; Genetics; Gene","score_opus":0.01299323485168026,"score_gpt":0.32587826581618956,"score_spread":0.3128850309645093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411744409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920393,0.003711004,0.00042557198,0.00068070035,0.00056654046,0.0014760287,0.00091237924,0.00016694801,0.000021484597],"genre_scores_gemma":[0.9955542,0.0015350187,0.0019006314,0.00013001297,0.00016002933,0.00059924094,0.0000049223704,0.000043270673,0.00007265545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997371,0.00014647626,0.0007573208,0.0010683732,0.0003076056,0.0003492101],"domain_scores_gemma":[0.9981027,0.00011695531,0.0004077458,0.0007185671,0.00045147134,0.00020255007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003991232,0.00045479694,0.0014134176,0.000716651,0.00010812178,0.00009419557,0.00013941756,0.0003741072,0.000035806446],"category_scores_gemma":[0.00032775683,0.00036628864,0.00034996896,0.0011733323,0.000119752556,0.00010465901,0.00018746917,0.0006028432,0.0000025192624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005702883,0.00027683843,0.9920647,0.00031948322,0.0064346762,0.000070489295,0.00003294051,0.000105462386,0.0002968429,0.00030361974,0.000024221203,0.000013682698],"study_design_scores_gemma":[0.0014771089,0.000041314775,0.98306936,0.00035281674,0.010458325,7.610851e-9,0.000004595442,0.0031328269,0.0010119618,0.000004458405,0.00011643573,0.00033078014],"about_ca_topic_score_codex":0.0018560081,"about_ca_topic_score_gemma":0.00032350337,"teacher_disagreement_score":0.008995346,"about_ca_system_score_codex":0.00067296776,"about_ca_system_score_gemma":0.001039772,"threshold_uncertainty_score":0.9998789},"labels":[],"label_agreement":null},{"id":"W4411857643","doi":"10.1093/oncolo/oyaf194","title":"Mitigation and management of adverse events associated with amivantamab therapy","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Johnson and Johnson","keywords":"Medicine; Erlotinib; Adverse effect; Rash; Oncology; Internal medicine; Epidermal growth factor receptor; Hypoalbuminemia; Chemotherapy; Paronychia; Gefitinib; Targeted therapy; Cancer; Dermatology","score_opus":0.036916925977640534,"score_gpt":0.40258748234630176,"score_spread":0.36567055636866125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411857643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026981757,0.9834701,0.000011572232,0.00017096897,0.0000708427,0.0020384893,0.000054118616,0.000023580089,0.013890527],"genre_scores_gemma":[0.00051988947,0.99282616,0.00016779114,0.00006260178,0.000014405158,0.00022458262,0.00023762057,0.000011057635,0.00593588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993563,0.00007761645,0.00020387187,0.00014843454,0.00012353396,0.00009019872],"domain_scores_gemma":[0.9993545,0.00013340682,0.00024792066,0.00019922122,0.000042146334,0.000022832799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011385427,0.0001489208,0.0005976561,0.00004823863,0.00006116831,0.000001619987,0.00006666674,0.000078962315,0.000018540464],"category_scores_gemma":[0.000011533416,0.000070419286,0.00009531339,0.00019823555,0.00009782716,0.0000143336665,0.000026989566,0.00008816962,0.0000016437419],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005155989,0.00028123028,0.0002544947,0.0063886144,0.0031470768,0.000032005286,0.000071258975,7.6073604e-7,7.0409996e-8,0.0003618098,0.00033563207,0.9890755],"study_design_scores_gemma":[0.0048527233,0.0010730589,0.0113348365,0.058000106,0.015630616,0.000021174688,0.00024244528,0.000002028922,0.0000017634935,0.000107263404,0.90853065,0.00020332032],"about_ca_topic_score_codex":0.000024793937,"about_ca_topic_score_gemma":0.000015245404,"teacher_disagreement_score":0.9888722,"about_ca_system_score_codex":0.00026557982,"about_ca_system_score_gemma":0.0002372257,"threshold_uncertainty_score":0.28716153},"labels":[],"label_agreement":null},{"id":"W4411992242","doi":"10.1016/j.jtocrr.2025.100876","title":"Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; Takeda Pharmaceutical Company; LUNGevity Foundation","keywords":"Medicine; Lung cancer; Oncology; ROS1; Internal medicine; Term (time); Cancer; Adenocarcinoma","score_opus":0.13808751252396867,"score_gpt":0.5202878453184,"score_spread":0.38220033279443133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411992242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915086,0.0002541916,0.000102561185,0.0013571793,0.00024276944,0.0007067667,0.000017403338,0.000020023765,0.0057904916],"genre_scores_gemma":[0.9873538,0.0005974407,0.00054224423,0.000095375115,0.00009626837,0.00005490721,0.000039126728,0.000011755277,0.011209105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979478,0.00013872456,0.000766866,0.00034804468,0.0005501459,0.0002484349],"domain_scores_gemma":[0.9980636,0.0006297564,0.00010599113,0.00038741663,0.0005946125,0.00021857084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016176086,0.00010481745,0.00049687555,0.00013468089,0.000100883866,0.000027005775,0.000043399345,0.000068612586,0.00008308218],"category_scores_gemma":[0.0012180906,0.000055444983,0.0000783344,0.0003168358,0.00046626487,0.00004453873,0.00007145967,0.00032477113,0.0000017607052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001088453,0.0008945291,0.93855387,0.00046500625,0.00067390205,0.0025409088,0.00012987987,1.6587775e-7,0.0001298942,0.00012527978,0.0016044439,0.053793695],"study_design_scores_gemma":[0.0011835861,0.0014690567,0.98294544,0.00057354337,0.00040596488,0.00020098884,0.00014974609,0.000026994774,0.00018969562,0.0002683029,0.012505666,0.0000810226],"about_ca_topic_score_codex":0.00023990888,"about_ca_topic_score_gemma":0.00019926036,"teacher_disagreement_score":0.053712673,"about_ca_system_score_codex":0.000034448858,"about_ca_system_score_gemma":0.00092787505,"threshold_uncertainty_score":0.22609809},"labels":[],"label_agreement":null},{"id":"W4412076815","doi":"10.1016/j.jtho.2025.07.009","title":"Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer","year":2025,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"Foundation Medicine; Loxo Oncology; Novartis Pharma; EMD Serono; Genentech; PharmaMar; European Society for Medical Oncology; Eisai; Bayer HealthCare; Relay Therapeutics; Boston Pharmaceuticals; Janssen Scientific Affairs; Takeda Oncology; Mirati Therapeutics; Teva Pharmaceutical Industries; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Associazione Italiana per la Ricerca sul Cancro; Eli Lilly and Company; National Comprehensive Cancer Network; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Celgene; BeiGene; International Association for the Study of Lung Cancer; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; American Society of Clinical Oncology; Bristol-Myers Squibb; Ariad Pharmaceuticals; Amgen; Incyte; Pfizer; LUNGevity Foundation","keywords":"Medicine; Statement (logic); Lung cancer; Association (psychology); Cancer; Family medicine; Oncology; Internal medicine; Epistemology","score_opus":0.03954637161951112,"score_gpt":0.5335992569666205,"score_spread":0.49405288534710934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412076815","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012632709,0.98622423,0.00010234424,0.006845171,0.0023748006,0.0024410835,0.00041018956,0.0000035697856,0.00033533768],"genre_scores_gemma":[0.0014672137,0.99543446,0.0003649857,0.0005554413,0.0006038516,0.0004570413,0.000041535466,0.00002077663,0.0010547093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803513,0.00029533013,0.0010036189,0.0001358296,0.00040599535,0.00012408767],"domain_scores_gemma":[0.9941553,0.0024629468,0.0024471907,0.00018682377,0.0007092086,0.00003852624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008700335,0.00016315687,0.0011238146,0.000111932946,0.0000728478,0.000018508645,0.00027148132,0.00009851238,0.000053946314],"category_scores_gemma":[0.0005346956,0.000077302306,0.0004383718,0.00014146097,0.000026009675,0.000018328294,0.00005333867,0.0003422611,5.222608e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046143244,0.0010347402,0.0007027738,0.001806641,0.021019895,0.0001266548,0.0010431188,0.00006116567,0.000002722503,0.000022550237,0.035314877,0.9384034],"study_design_scores_gemma":[0.0013875671,0.0007860432,0.00020775096,0.0044538197,0.033486754,0.000033020722,0.0011424847,0.000033854703,0.0000039402657,0.000032393546,0.95837075,0.00006161312],"about_ca_topic_score_codex":0.00023389861,"about_ca_topic_score_gemma":0.0001607796,"teacher_disagreement_score":0.9383418,"about_ca_system_score_codex":0.002424587,"about_ca_system_score_gemma":0.003580912,"threshold_uncertainty_score":0.6352384},"labels":[],"label_agreement":null},{"id":"W4412125702","doi":"10.1200/jco-25-00040","title":"Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Jewish General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Genentech; National Institute for Health and Care Research","keywords":"Medicine; KRAS; Cancer; Term (time); Lung cancer; Oncology; Internal medicine; Colorectal cancer","score_opus":0.04610129798774334,"score_gpt":0.4679623443631901,"score_spread":0.4218610463754468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412125702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441004,0.000430069,0.00023452926,0.00075201015,0.0011476853,0.0011204036,0.00001863915,0.0000040603577,0.0018825766],"genre_scores_gemma":[0.9979837,0.000110075154,0.0003890048,0.00079031364,0.0001419477,0.000025563786,0.000008902178,0.000013847649,0.0005366628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972866,0.00022929632,0.0017588927,0.00022097069,0.00029482532,0.00020937315],"domain_scores_gemma":[0.9970625,0.0006421645,0.0012845377,0.00017848884,0.0006328223,0.00019948704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059054483,0.00016656911,0.0013608449,0.00020093673,0.0000361173,0.0000072015478,0.00013008522,0.00015528985,0.000042424927],"category_scores_gemma":[0.00023384916,0.000108499524,0.0002615491,0.00027197052,0.00009677963,0.00007839527,0.00004686154,0.00048996386,0.0000011095714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010419373,0.03234326,0.90662473,0.00007451094,0.0014235816,0.00045143883,0.00088028744,0.000018397655,0.000056948687,0.000002651157,0.00031996387,0.047384832],"study_design_scores_gemma":[0.09176245,0.035427306,0.86826044,0.000547393,0.003229745,0.000004582625,0.0002253703,0.000013169745,0.00021790856,0.000005689321,0.00022794007,0.00007801369],"about_ca_topic_score_codex":0.00012453785,"about_ca_topic_score_gemma":0.00047888153,"teacher_disagreement_score":0.081343085,"about_ca_system_score_codex":0.0005508109,"about_ca_system_score_gemma":0.002285906,"threshold_uncertainty_score":0.44244823},"labels":[],"label_agreement":null},{"id":"W4412163802","doi":"10.1158/1557-3265.aimachine-a014","title":"Abstract A014: Machine Learning-Guided Discovery of Drug Combinations Targeting PI3K and mTOR Pathways Using Cell Line and PDX Data","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PI3K/AKT/mTOR pathway; Drug discovery; Computational biology; Medicine; Bioinformatics; Biology; Signal transduction; Cell biology","score_opus":0.26484641605504405,"score_gpt":0.5520178040006288,"score_spread":0.2871713879455848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412163802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854707,0.009429027,0.00011674083,0.0024811227,0.0001642107,0.00051527517,0.00028377664,0.000020083464,0.001519056],"genre_scores_gemma":[0.99266785,0.0034712253,0.0006735073,0.000107277425,0.00013060677,0.000022978547,0.00024520876,0.000017910703,0.002663405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821407,0.00017701805,0.0005579341,0.00046024186,0.0003322145,0.00025851058],"domain_scores_gemma":[0.9977965,0.0012400721,0.000116021,0.0003934911,0.00031385777,0.00014008208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017795123,0.000112235924,0.00035667434,0.00015559263,0.00026120208,0.000057341855,0.00015363628,0.000080347614,0.00006241229],"category_scores_gemma":[0.001182424,0.00008973488,0.000047187554,0.00030577148,0.00037636652,0.0001855299,0.0004119818,0.0006691735,0.0000018203586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011246175,0.003607699,0.89792705,0.0031625137,0.0009476626,0.000101650985,0.001290557,0.00022357656,0.01855058,0.0015672602,0.019087194,0.052409664],"study_design_scores_gemma":[0.04912856,0.0026747459,0.76630974,0.0048779277,0.0025485682,0.000023641684,0.0046170494,0.08119461,0.018803291,0.0047379932,0.063981034,0.0011028544],"about_ca_topic_score_codex":0.0023079328,"about_ca_topic_score_gemma":0.00018547934,"teacher_disagreement_score":0.13161731,"about_ca_system_score_codex":0.0001041874,"about_ca_system_score_gemma":0.00084021385,"threshold_uncertainty_score":0.36592823},"labels":[],"label_agreement":null},{"id":"W4412213112","doi":"","title":"lydelig – lyksom:36 kc, 2 helsideskort, 1 spaltekort","year":2024,"lang":"da","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Environmental science","score_opus":0.016699868086984482,"score_gpt":0.3597965605084581,"score_spread":0.3430966924214736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412213112","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039707813,0.093661934,0.0025493952,0.024253432,0.012695168,0.0019192498,0.00040751795,0.0011218513,0.8236836],"genre_scores_gemma":[0.70746285,0.0024040067,0.0005905756,0.0017595039,0.0018238464,0.00007927821,0.00021326466,0.00007908264,0.28558758],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977235,0.00003311473,0.00049718475,0.00069661345,0.00045835713,0.0005912386],"domain_scores_gemma":[0.99873394,0.00014208745,0.000044997974,0.0005581187,0.00011518748,0.0004056963],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016296668,0.00038687536,0.0004313551,0.00024113491,0.00015954969,0.0002125512,0.00012266495,0.000175559,0.012951599],"category_scores_gemma":[0.000043067903,0.00029044523,0.00028756712,0.00052628556,0.00009834692,0.00022864192,0.00006878513,0.00029833123,0.00929025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017261664,0.0009118875,0.008056324,0.002032801,0.005547812,0.0046392446,0.0037692336,0.000049527636,0.0012130169,0.060326606,0.7265318,0.18674915],"study_design_scores_gemma":[0.0016439384,0.00059028715,0.005568185,0.0014058244,0.0033874353,0.0002084011,0.0010014555,0.002106382,0.0014936848,0.00091305573,0.9812128,0.00046858535],"about_ca_topic_score_codex":0.0011326929,"about_ca_topic_score_gemma":0.00021007613,"teacher_disagreement_score":0.66775507,"about_ca_system_score_codex":0.0005442601,"about_ca_system_score_gemma":0.0011653729,"threshold_uncertainty_score":0.99995476},"labels":[],"label_agreement":null},{"id":"W4412263960","doi":"","title":"C4.4A IS A PROGNOSTIC INDICATOR IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ADENOCARCINOMAS","year":2011,"lang":"","type":"article","venue":"Research at the University of Copenhagen (University of Copenhagen)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Glycomics Centre","funders":"","keywords":"Lung cancer; Medicine; Oncology; Internal medicine; Lung; Cancer; Cell; Pathology; Cancer research; Biology; Genetics","score_opus":0.027141671253469547,"score_gpt":0.27440948514894753,"score_spread":0.24726781389547797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412263960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8951017,0.010754059,0.00017968909,0.0004119834,0.000085287975,0.0047320146,0.0005304245,0.000018831046,0.08818598],"genre_scores_gemma":[0.79344016,0.0010158326,0.00040870564,0.00003705409,0.000019260406,0.0000018985095,0.000079811914,0.00004631418,0.20495094],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9952821,0.00069932337,0.0003880096,0.0009961149,0.0014471249,0.0011872993],"domain_scores_gemma":[0.9961152,0.0003527185,0.00060999405,0.001058335,0.0011879486,0.000675801],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008774756,0.00048626759,0.00097125466,0.00069582945,0.0013251049,0.000026886059,0.001628902,0.0003250227,0.40417942],"category_scores_gemma":[0.00003977078,0.00047473176,0.0002972823,0.0018903061,0.0016427031,0.00059684936,0.0011437737,0.00086144975,0.014956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009379886,0.0044582677,0.1046649,0.0022192812,0.0026858468,0.001332412,0.16628169,0.000035796882,0.0005220156,0.000030407244,0.7062542,0.0021353436],"study_design_scores_gemma":[0.014927809,0.0026546759,0.90376633,0.0013868677,0.0026246754,0.0000039141078,0.036569957,0.0003237216,0.0024765227,0.0000019887575,0.034714945,0.0005485894],"about_ca_topic_score_codex":0.019842168,"about_ca_topic_score_gemma":0.0045766663,"teacher_disagreement_score":0.7991014,"about_ca_system_score_codex":0.0016970212,"about_ca_system_score_gemma":0.002959973,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W4412408955","doi":"10.1080/08998280.2025.2524792","title":"Racial disparities in non–small cell lung cancer survival outcomes: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Baylor University Medical Center Proceedings","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Lung cancer; Medicine; Cancer; Oncology; Gerontology; Internal medicine","score_opus":0.04357059714521711,"score_gpt":0.3585309345267064,"score_spread":0.3149603373814893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412408955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010540859,0.99190813,0.000037448714,0.0012851412,0.00008954298,0.0038603812,0.00034320174,0.000039042316,0.0024265975],"genre_scores_gemma":[0.00006835428,0.98523223,0.00005249148,0.0008648896,0.000025361538,0.00017589731,0.0001583911,0.000023002418,0.013399365],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975207,0.00008915725,0.00075677346,0.0006601491,0.0006008127,0.00037240193],"domain_scores_gemma":[0.9985972,0.00021376241,0.0004056639,0.00021063443,0.00019103846,0.00038167337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045232289,0.00054192607,0.007918454,0.00069591566,0.00010420075,0.000036411722,0.00032321786,0.0003320253,0.00045534867],"category_scores_gemma":[0.00023039416,0.00036420077,0.0019183842,0.0012442704,0.00009527815,0.000115855175,0.00023783206,0.00053415727,0.000004403194],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006763736,0.00019188896,0.0019411572,0.92151207,0.07508124,0.00010264549,0.0001879397,1.0641172e-8,1.8184163e-9,0.00006581076,0.00057774264,0.00033270952],"study_design_scores_gemma":[0.00094966235,0.000026199643,0.00007102524,0.08794338,0.89139104,0.000008517745,0.0001477864,0.000007173177,1.715251e-8,7.482964e-7,0.019193027,0.00026140726],"about_ca_topic_score_codex":0.0004952825,"about_ca_topic_score_gemma":0.0003567899,"teacher_disagreement_score":0.8335687,"about_ca_system_score_codex":0.00060199224,"about_ca_system_score_gemma":0.00063851295,"threshold_uncertainty_score":0.99988097},"labels":[],"label_agreement":null},{"id":"W4412431011","doi":"10.1016/j.ejca.2025.115624","title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Research and Development; Johnson and Johnson; Cilag; Novocure","keywords":"Refractory (planetary science); Medicine; Oncology; Lung cancer; Internal medicine; Lung; Cancer; Cancer research; Biology","score_opus":0.013184561142536626,"score_gpt":0.29179966001687424,"score_spread":0.2786150988743376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412431011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314344,0.0028633224,0.000070185684,0.0010017543,0.00030109787,0.00067366206,0.0000394374,0.000009928822,0.0018971906],"genre_scores_gemma":[0.99847233,0.0010829322,0.000046993046,0.00014998234,0.00006678254,0.000012502179,0.000012676842,0.000024070583,0.00013170141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985247,0.00031899274,0.00055232027,0.0002096451,0.00024304524,0.00015126496],"domain_scores_gemma":[0.9990156,0.00020261672,0.00041115342,0.00015374403,0.00015974639,0.00005710228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027434586,0.00014617795,0.00023675797,0.00016867937,0.00007621156,0.00003232826,0.000057793208,0.000024506042,0.000012531732],"category_scores_gemma":[0.000052713585,0.00009202146,0.000026126685,0.0003018679,0.000037647256,0.000084580686,0.000020762178,0.00025772952,4.8248063e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021934764,0.00094471447,0.6109515,0.000053236396,0.0005434079,0.0015404073,0.029062482,0.002198737,0.001410043,0.000005305385,0.00076474814,0.33059067],"study_design_scores_gemma":[0.024701703,0.0024344155,0.96525633,0.0010749316,0.00044348062,0.000012486424,0.0038386357,0.00019115343,0.00031234196,0.0000046694977,0.0016260741,0.00010377842],"about_ca_topic_score_codex":0.002147418,"about_ca_topic_score_gemma":0.0061991047,"teacher_disagreement_score":0.35430485,"about_ca_system_score_codex":0.0006568235,"about_ca_system_score_gemma":0.000310132,"threshold_uncertainty_score":0.37525263},"labels":[],"label_agreement":null},{"id":"W4412431079","doi":"10.1016/j.ejca.2025.115622","title":"TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Hazard ratio; Oncology; Internal medicine; Stage (stratigraphy); Cohort; Proportional hazards model; Adenocarcinoma; Confidence interval; Cancer; Biology","score_opus":0.012496538016717088,"score_gpt":0.3558904715178846,"score_spread":0.34339393350116754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412431079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96319604,0.012076782,0.00062210934,0.0007628278,0.0003004292,0.00025011747,0.0001334495,0.000010185503,0.02264803],"genre_scores_gemma":[0.9962016,0.0010450786,0.00052904495,0.00016941044,0.00007693651,0.000004834128,0.000013206823,0.000017018512,0.0019428739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986251,0.000273653,0.0006028032,0.00012685088,0.0002254613,0.00014613495],"domain_scores_gemma":[0.9988104,0.00009019967,0.0004659758,0.00016028703,0.0003613229,0.00011179276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004524993,0.000115490264,0.00029458434,0.00034585636,0.000051282943,0.00001380107,0.00011259408,0.000017764934,0.00022327107],"category_scores_gemma":[0.00021124133,0.00009259997,0.00010658572,0.00044242342,0.000075290525,0.00011545973,0.000018534918,0.0002797066,0.0000057595753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060786126,0.00023929495,0.9591118,0.00015883465,0.0007508976,0.0006838951,0.0019226292,0.0011327012,0.00094280567,0.0001524056,0.0047474355,0.02954943],"study_design_scores_gemma":[0.005013428,0.00028147522,0.98407334,0.0010524638,0.0009133827,0.000025760279,0.0004915545,0.00019617252,0.0014294651,0.000040307477,0.0063948045,0.00008782517],"about_ca_topic_score_codex":0.000270026,"about_ca_topic_score_gemma":0.000058593978,"teacher_disagreement_score":0.03300553,"about_ca_system_score_codex":0.0002855026,"about_ca_system_score_gemma":0.0007288268,"threshold_uncertainty_score":0.37761173},"labels":[],"label_agreement":null},{"id":"W4412434154","doi":"10.1016/j.lungcan.2025.108662","title":"Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Canadian Patient Safety Institute; Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Internal medicine; Oncology; Intensive care medicine","score_opus":0.029684763254258697,"score_gpt":0.4571309382903152,"score_spread":0.42744617503605653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412434154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004568209,0.99227494,0.00009895675,0.0006953597,0.00043492267,0.0029954868,0.0007552777,0.000034650493,0.00266471],"genre_scores_gemma":[0.000024827556,0.99249154,0.0005476961,0.0015766345,0.00016842052,0.001477535,0.0017271262,0.000064652224,0.0019215451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979582,0.00010514814,0.00052591664,0.0006642041,0.0004216007,0.00032492162],"domain_scores_gemma":[0.9985701,0.00040555163,0.00023676586,0.00024948054,0.00018896557,0.0003491417],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011858398,0.00040676945,0.0011000953,0.00010329461,0.000135974,0.000050641607,0.000066734916,0.00029353958,0.00016764211],"category_scores_gemma":[0.00023274454,0.00030754448,0.00015663107,0.00013903744,0.00008022988,0.00016268299,0.000096467855,0.00020032484,9.4075915e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048635884,0.00031217176,0.001182112,0.013455893,0.0008494007,0.000010731451,0.0002769981,2.0432207e-8,2.7305369e-8,0.00009704554,0.050972607,0.93279433],"study_design_scores_gemma":[0.0028407539,0.00034581302,0.00021110973,0.030938625,0.0053354893,0.000008871776,0.00002995219,0.000042224838,4.88017e-7,0.00002113172,0.9599227,0.0003028479],"about_ca_topic_score_codex":0.00022496167,"about_ca_topic_score_gemma":0.00006086049,"teacher_disagreement_score":0.9324915,"about_ca_system_score_codex":0.00042223014,"about_ca_system_score_gemma":0.0007843774,"threshold_uncertainty_score":0.99993765},"labels":[],"label_agreement":null},{"id":"W4412442574","doi":"10.1016/j.jval.2025.04.1023","title":"HTA12 Navigating Uncertainty in Overall Survival Data: Insights from Positive Canadian HTAs on Lung Cancer Therapies","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Oncology; Medicine; Internal medicine; Data science; Computer science","score_opus":0.03571097321427342,"score_gpt":0.3928041791517588,"score_spread":0.3570932059374854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412442574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687165,0.008747521,0.000008707952,0.018030701,0.00064276904,0.0008899961,0.00072201225,0.000021817053,0.002219949],"genre_scores_gemma":[0.9929377,0.0005868157,0.0001456932,0.0051801368,0.00012736965,0.000062247884,0.00081245555,0.000014260717,0.00013330893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986688,0.00017331833,0.00031133625,0.00037287356,0.00015784151,0.0003158113],"domain_scores_gemma":[0.99913764,0.00024972938,0.00006720943,0.0003463363,0.00003908866,0.00015999241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016317055,0.00013944467,0.00030506664,0.00017075025,0.00012161031,0.000019879344,0.000108964865,0.00006505631,0.000029839095],"category_scores_gemma":[0.000048395996,0.0001180641,0.000022968008,0.00032861458,0.000026658478,0.00008997288,0.000026331165,0.00031803775,0.0000026432067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073956454,0.0006283627,0.86120886,0.00051909016,0.0008617879,0.0003152408,0.044985246,0.031476993,0.000077922305,0.020350207,0.0053344257,0.033502318],"study_design_scores_gemma":[0.009057483,0.0002681659,0.93445617,0.00960862,0.00011765592,0.0000013532762,0.0025366761,0.033676226,0.000053012503,0.0022742553,0.007630661,0.00031973235],"about_ca_topic_score_codex":0.9748042,"about_ca_topic_score_gemma":0.7461914,"teacher_disagreement_score":0.22861287,"about_ca_system_score_codex":0.0028745926,"about_ca_system_score_gemma":0.003455835,"threshold_uncertainty_score":0.75169593},"labels":[],"label_agreement":null},{"id":"W4412443185","doi":"10.1016/j.jval.2025.04.1898","title":"EE299 Cost Per PFS-Based Responder for TKI-Naive Patients Receiving Repotrectinib or Entrectinib in ROS1 Fusion Positive Non-Small Cell Lung Cancer (NSCLC) in the United States (US)","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; ROS1; Oncology; Internal medicine; Lung cancer; Cancer; Adenocarcinoma","score_opus":0.026787791570512417,"score_gpt":0.37073762019562845,"score_spread":0.343949828625116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412443185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986372,0.00062679325,0.00023857263,0.005853273,0.0004578456,0.005515298,0.000168868,0.00002678248,0.00074057275],"genre_scores_gemma":[0.98911667,0.00043599276,0.00072399277,0.007060217,0.00005035952,0.0011540406,0.00056825066,0.000036537815,0.0008539647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765074,0.0004885661,0.00065691845,0.00046615323,0.00022954411,0.0005080845],"domain_scores_gemma":[0.9976538,0.0015243981,0.00022873431,0.0002777996,0.00022120909,0.00009406645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084704027,0.0002247753,0.00038995294,0.0007194984,0.00017628478,0.000029012936,0.000106769265,0.000107976215,0.000037438218],"category_scores_gemma":[0.00032983188,0.00015817986,0.000066243345,0.001315463,0.00003072154,0.000060218546,0.000025390935,0.00035604564,0.0000016730937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039628884,0.0015777443,0.92139274,0.00096413825,0.00006031852,0.000041177565,0.042034186,0.01957127,0.000052815114,0.000026021113,0.0024758924,0.007840781],"study_design_scores_gemma":[0.021783242,0.0013649502,0.9102147,0.0063686,0.00015635775,0.0000027681472,0.0069397716,0.04688559,0.00073661096,0.00008049787,0.005162913,0.00030394775],"about_ca_topic_score_codex":0.06782783,"about_ca_topic_score_gemma":0.012231468,"teacher_disagreement_score":0.055596363,"about_ca_system_score_codex":0.0020455145,"about_ca_system_score_gemma":0.0020571507,"threshold_uncertainty_score":0.9383796},"labels":[],"label_agreement":null},{"id":"W4412491393","doi":"10.1200/jco-25-01061","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital; London Health Sciences Centre","funders":"","keywords":"Guideline; Medicine; Clinical Practice; Family medicine; Clinical Oncology; Schedule; Stage (stratigraphy); Cancer; Pathology; Internal medicine","score_opus":0.05752244483960633,"score_gpt":0.5041533275611548,"score_spread":0.4466308827215485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412491393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9073891,0.0049052965,0.03972351,0.02951052,0.0032494904,0.0016041175,0.00003821988,0.00001936508,0.01356039],"genre_scores_gemma":[0.83762497,0.009623974,0.08026374,0.025087625,0.0026748981,0.00014191378,0.000030447829,0.000047561378,0.044504847],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982315,0.0000911565,0.001199957,0.00016622686,0.0001512813,0.00015988138],"domain_scores_gemma":[0.9968205,0.0013344716,0.00075245625,0.00013939275,0.0008093885,0.00014375543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008433128,0.00011359449,0.00067261065,0.00011849231,0.00009332726,0.000013974377,0.00009321928,0.00016792085,0.00028582988],"category_scores_gemma":[0.0003684357,0.000070667484,0.00026314933,0.00012008851,0.00005507349,0.00009815896,0.000019463272,0.0003311033,0.0000028645936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00863152,0.0045737787,0.47982097,0.00022516976,0.0034913335,0.00022414624,0.00085906504,0.0020403948,0.0007473423,0.00023242843,0.34089732,0.1582565],"study_design_scores_gemma":[0.028087908,0.011844169,0.13205242,0.00082129636,0.0022385505,0.000014378639,0.0004749391,0.003627332,0.00032929605,0.00006611818,0.82029176,0.00015183902],"about_ca_topic_score_codex":0.0000751708,"about_ca_topic_score_gemma":0.00012374147,"teacher_disagreement_score":0.4793944,"about_ca_system_score_codex":0.00028425173,"about_ca_system_score_gemma":0.004223894,"threshold_uncertainty_score":0.74930066},"labels":[],"label_agreement":null},{"id":"W4412530407","doi":"10.1093/ejcts/ezaf239","title":"Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status","year":2025,"lang":"en","type":"article","venue":"European Journal of Cardio-Thoracic Surgery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Mutation; Medicine; Platinum; Adjuvant; Epidermal growth factor; Cancer; Cancer research; Biology; Receptor; Genetics; Gene; Biochemistry","score_opus":0.016490245819473,"score_gpt":0.32398100408975655,"score_spread":0.30749075827028355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412530407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934227,0.0030771494,0.00009490622,0.00017746692,0.000599058,0.00023796908,0.00019873129,0.0000059454956,0.002186102],"genre_scores_gemma":[0.9989567,0.00051601895,0.0002522036,0.00004246804,0.00008268349,0.0000051018687,0.000039520975,0.000027308924,0.000078024714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974241,0.00056496373,0.0011854164,0.000178104,0.00039007602,0.00025729404],"domain_scores_gemma":[0.99810517,0.00045283374,0.0007280657,0.00013656002,0.0004661079,0.00011128571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086950674,0.00017446297,0.0008328584,0.00093091343,0.000024469178,0.000007880417,0.00006422672,0.000036143374,0.000048630798],"category_scores_gemma":[0.00050411676,0.00014735945,0.0003015433,0.00063560344,0.000051707437,0.00019618303,0.000024749193,0.00023423927,5.75817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010891997,0.00030892715,0.9267107,0.0002650759,0.000588665,0.00030165145,0.0026286207,0.00082053686,0.00045891028,0.000008261911,0.0007487376,0.0660707],"study_design_scores_gemma":[0.0018450036,0.0001676578,0.9903971,0.0018157205,0.00030407502,0.000009585222,0.0005522232,0.000034735986,0.004422695,0.000020381849,0.0003225979,0.00010820267],"about_ca_topic_score_codex":0.000103456405,"about_ca_topic_score_gemma":0.00006530491,"teacher_disagreement_score":0.06596249,"about_ca_system_score_codex":0.00053755776,"about_ca_system_score_gemma":0.0004419194,"threshold_uncertainty_score":0.60091436},"labels":[],"label_agreement":null},{"id":"W4412603757","doi":"10.1042/bcj20240731","title":"Comparison of Classical P81 and SVI-P Cation-Exchange Papers in Radiometric Protein Kinase Assays","year":2025,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Department of Health and Aged Care, Australian Government; Jack Brockhoff Foundation; Bethlehem Griffiths Research Foundation","keywords":"Kinase; Protein kinase A; Chemistry; MAPK/ERK pathway; Biochemistry","score_opus":0.0179410245975307,"score_gpt":0.36858646426397534,"score_spread":0.3506454396664446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412603757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98802096,0.0036601776,0.00010726782,0.0028121183,0.000067190085,0.00024502608,0.0000036673916,0.0000075459925,0.00507608],"genre_scores_gemma":[0.9981947,0.00007699317,0.0010032647,0.00008822693,0.00006352199,0.000016602746,0.000010185052,0.0000047367025,0.00054179394],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993312,0.000022491684,0.0002601858,0.00011109187,0.00015389774,0.00012115647],"domain_scores_gemma":[0.9996373,0.00004579455,0.000074952586,0.000077115,0.000055830977,0.00010897519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009407826,0.00007415629,0.000219604,0.00031385745,0.00003497264,0.000012019941,0.000039204348,0.00007527762,0.000053411128],"category_scores_gemma":[0.00015792294,0.000057115663,0.000046011533,0.0005183947,0.00006397699,0.000022648763,0.00001708415,0.00019748807,0.0000012085077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033280716,0.0015933599,0.33840695,0.00033733697,0.00027068323,0.00005118723,0.0006794154,0.0000015487424,0.568829,0.0007315797,0.009871401,0.078894734],"study_design_scores_gemma":[0.012597239,0.00083014317,0.6889499,0.0014882924,0.00064791506,0.00012536618,0.0008700508,0.00064096105,0.2735795,0.00051073876,0.019461315,0.00029857332],"about_ca_topic_score_codex":0.00002043759,"about_ca_topic_score_gemma":0.0000033699096,"teacher_disagreement_score":0.35054296,"about_ca_system_score_codex":0.00018705188,"about_ca_system_score_gemma":0.00016391296,"threshold_uncertainty_score":0.23291092},"labels":[],"label_agreement":null},{"id":"W4412640741","doi":"10.3390/curroncol32080414","title":"Characterization of the Population, Treatment Patterns, and Outcomes of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor Mutation (EGFRm): A Retrospective Cohort Study from IPO Porto","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Cohort; Retrospective cohort study; Population; Progressive disease; Progression-free survival; Performance status; Chemotherapy; Palliative care","score_opus":0.01806836788747555,"score_gpt":0.3560763343324271,"score_spread":0.3380079664449515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412640741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940042,0.00009542747,0.0005110216,0.00019691834,0.00033254357,0.004068985,0.000757976,0.000012648859,0.000020273868],"genre_scores_gemma":[0.99808425,0.00009623824,0.0002099771,0.000033584623,0.000015711774,0.0006219828,0.0008242716,0.000016617376,0.000097362135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886096,0.00009103283,0.00039408664,0.00031767454,0.00020509926,0.00013112862],"domain_scores_gemma":[0.99879783,0.00007893536,0.0004995575,0.00019559417,0.00038029483,0.00004777283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000037425652,0.00020242177,0.0006115288,0.00009946141,0.00007092978,0.0000060387465,0.00004712506,0.00003584622,0.000055989258],"category_scores_gemma":[0.000026843773,0.00010425399,0.00004366164,0.00022146234,0.000046977362,0.00009389021,0.000022255372,0.00007169366,1.7636019e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008621052,0.0024150256,0.9860431,0.00013607122,0.0011470742,0.0000024261014,0.0021486308,0.0000059046743,0.00011948104,0.000005311517,0.0000046972573,0.0071101533],"study_design_scores_gemma":[0.01007479,0.0021130207,0.98373145,0.00022748676,0.002511307,3.9931047e-7,0.0003569248,0.000038837326,0.0008291288,0.000004322764,0.000019834437,0.000092488866],"about_ca_topic_score_codex":0.0013093074,"about_ca_topic_score_gemma":0.0012648441,"teacher_disagreement_score":0.009212685,"about_ca_system_score_codex":0.0006587164,"about_ca_system_score_gemma":0.00036206536,"threshold_uncertainty_score":0.42513543},"labels":[],"label_agreement":null},{"id":"W4412653243","doi":"10.1016/j.lungcan.2025.108672","title":"Adjuvant therapy in pStage IA1–IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study)","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Society of Thoracic Surgeons","keywords":"Medicine; Oncology; Adenocarcinoma; Internal medicine; Adjuvant; Lung; Multicenter study; Cancer; Randomized controlled trial","score_opus":0.018883263490755635,"score_gpt":0.3849086370658569,"score_spread":0.36602537357510123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412653243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872111,0.0056790086,0.00016848378,0.0013014231,0.0005681218,0.0041430737,0.00007896609,0.000064954846,0.00078486686],"genre_scores_gemma":[0.9963694,0.0004102552,0.00007550837,0.00071464473,0.000109342276,0.0011328282,0.000029781431,0.000037217305,0.0011209884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808997,0.0001321955,0.00042409112,0.0006593075,0.0003121547,0.000382283],"domain_scores_gemma":[0.99909955,0.00012566069,0.00011307301,0.00043277952,0.000109992376,0.0001189449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015008799,0.0003136531,0.00044824253,0.0003474446,0.000216712,0.00007498389,0.000115312614,0.00006716444,0.00015672337],"category_scores_gemma":[0.000032127624,0.00025654677,0.0000705136,0.00046264246,0.00004954375,0.00015741424,0.0000626442,0.0003014008,0.0000034501154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042565973,0.002066486,0.9620071,0.00011649362,0.00061409286,0.00016247202,0.015227911,0.00006733338,0.00007743072,0.000031071504,0.00031271414,0.018891258],"study_design_scores_gemma":[0.012400305,0.00084375,0.97639203,0.0009044941,0.0007031412,0.0000023744033,0.0069299424,0.0012056358,0.00011935371,0.000014594081,0.00026248998,0.00022187515],"about_ca_topic_score_codex":0.004473607,"about_ca_topic_score_gemma":0.005314496,"teacher_disagreement_score":0.018669384,"about_ca_system_score_codex":0.0008542875,"about_ca_system_score_gemma":0.00028967008,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W4412750736","doi":"10.3390/cancers17152522","title":"Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Kingston Health Sciences Centre; University of Ottawa; Queen's University","funders":"","keywords":"Medicine; Pneumonitis; Lung cancer; Cancer; Intensive care medicine; Hypersensitivity pneumonitis; Disease; Lung; Pathology; Internal medicine","score_opus":0.02221243422884437,"score_gpt":0.3670415026560334,"score_spread":0.344829068427189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412750736","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061910045,0.9885414,0.00011323338,0.00005178025,0.0006275411,0.002730955,0.00067164295,0.00002597182,0.0010464656],"genre_scores_gemma":[0.0027512591,0.99387765,0.00016455544,0.000055533674,0.00005717721,0.0010086114,0.0004364014,0.000033931134,0.0016148603],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9982629,0.000032049178,0.0007873452,0.00047890822,0.00022164875,0.00021717326],"domain_scores_gemma":[0.99908495,0.000032625514,0.0004451537,0.00018111595,0.00020025544,0.000055928456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012132607,0.00029237315,0.0009373678,0.0005024367,0.00008475491,0.000018001727,0.00005855226,0.00014341151,0.000036186877],"category_scores_gemma":[0.000020670983,0.00026926157,0.00007518687,0.0010550508,0.00005393054,0.00012429024,0.00006915361,0.00016781481,1.8570474e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023600003,0.00006922823,0.07617723,0.08084273,0.0014864142,0.0000042688794,0.00025973486,0.000058470767,0.0000017125121,0.00011715647,0.0006495474,0.8403099],"study_design_scores_gemma":[0.008718262,0.00019050516,0.23405278,0.41450128,0.010952897,0.0000074807413,0.00021054313,0.00031613495,0.000009671666,0.000020864094,0.3303524,0.00066720176],"about_ca_topic_score_codex":0.00042359217,"about_ca_topic_score_gemma":0.00008710138,"teacher_disagreement_score":0.8396427,"about_ca_system_score_codex":0.002812098,"about_ca_system_score_gemma":0.0011148562,"threshold_uncertainty_score":0.999976},"labels":[],"label_agreement":null},{"id":"W4412769522","doi":"10.2139/ssrn.5369804","title":"Beyond Single-Run Metrics with Cp-Fuse: A Rigorous Multi-Cohort Evaluation of Clinico-Pathological Fusion for Improved Survival Prediction in Tcga","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; McGill University","funders":"","keywords":"Fuse (electrical); Fusion; Cohort; Computer science; Statistics; Mathematics; Engineering","score_opus":0.0433698196743959,"score_gpt":0.3741292647284404,"score_spread":0.3307594450540445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412769522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92238843,0.0063734893,0.062243666,0.0006242185,0.001364028,0.005387159,0.0002953245,0.00006215675,0.0012614978],"genre_scores_gemma":[0.9882732,0.0033355744,0.0054700375,0.000053540243,0.00034315055,0.0004319566,0.0006347151,0.000042292722,0.0014155151],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963988,0.0002775338,0.0009405189,0.00058059895,0.00073046825,0.0010720502],"domain_scores_gemma":[0.99737626,0.0001928542,0.0007316646,0.00036282823,0.0012378739,0.000098535515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0052087028,0.00034167912,0.0007976422,0.00065948453,0.00012967273,0.000033828725,0.00017022603,0.00047135813,0.000020534328],"category_scores_gemma":[0.0007049218,0.0002547157,0.0002810447,0.00046521815,0.000065778935,0.000088597764,0.00008845055,0.0022791615,7.412688e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009964523,0.012445817,0.44642815,0.0009927907,0.008667969,0.000038643368,0.0016889732,0.00817549,0.0052484763,0.005165158,0.000141413,0.5010426],"study_design_scores_gemma":[0.15147433,0.036913734,0.4657855,0.004360386,0.05043798,0.001251428,0.0067065703,0.13700122,0.0023106413,0.14088373,0.0006659668,0.0022085167],"about_ca_topic_score_codex":0.00024500053,"about_ca_topic_score_gemma":0.0019893572,"teacher_disagreement_score":0.49883407,"about_ca_system_score_codex":0.00538354,"about_ca_system_score_gemma":0.010924211,"threshold_uncertainty_score":0.9999905},"labels":[],"label_agreement":null},{"id":"W4412855756","doi":"10.1016/s1470-2045(25)00364-x","title":"Cancer clinical trials should capture tobacco smoking status","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"World Health Organization","keywords":"Cancer; Medicine; Clinical trial; Tobacco use; Environmental health; Oncology; Internal medicine","score_opus":0.247731422496764,"score_gpt":0.5755754296091893,"score_spread":0.3278440071124253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412855756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40956455,0.015710395,0.00049837946,0.27546877,0.0070090084,0.0021393935,0.00019271908,0.0002398698,0.28917694],"genre_scores_gemma":[0.9456189,0.0034350466,0.0005134689,0.038137946,0.0022051677,0.0002953522,0.000044338976,0.000016180093,0.009733545],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983385,0.0005479689,0.0004761635,0.0002116652,0.000105667976,0.00032000034],"domain_scores_gemma":[0.9981939,0.0011377268,0.0001604614,0.00035123946,0.000081033875,0.00007559296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018359283,0.000110512316,0.0008725747,0.00004487516,0.00010569481,0.000013627958,0.000113805996,0.0001890749,0.0003898824],"category_scores_gemma":[0.00074679824,0.000059746977,0.00015388301,0.00017510261,0.00011443721,0.00002432148,0.000047507976,0.0004045594,0.000015484413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012295465,0.00029072468,0.41312245,0.00004583235,0.0017507066,0.000057609526,0.000899806,0.000035668396,0.00011587933,0.0076968935,0.23660634,0.33814856],"study_design_scores_gemma":[0.005946516,0.0001812376,0.14196189,0.00007111413,0.0013071375,0.000007209901,0.00035585725,0.000024986877,0.000050877134,0.0007080567,0.8493254,0.000059705115],"about_ca_topic_score_codex":0.0007515554,"about_ca_topic_score_gemma":0.00066528236,"teacher_disagreement_score":0.61271906,"about_ca_system_score_codex":0.0003878259,"about_ca_system_score_gemma":0.0011346958,"threshold_uncertainty_score":0.42689386},"labels":[],"label_agreement":null},{"id":"W4412862175","doi":"10.1021/acs.jproteome.5c00385","title":"Myeloid-Derived Growth Factor-Regulated Oncogenesis in Lung Adenocarcinoma Is Associated with EGFR Status and Cancer Aggressiveness","year":2025,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Science and Technology Council; Chang Gung University; Chang Gung Memorial Hospital","keywords":"Carcinogenesis; Lung cancer; Cancer research; Adenocarcinoma; Oncology; Cancer; Epidermal growth factor receptor; Biology; Internal medicine; Medicine","score_opus":0.037400490873098456,"score_gpt":0.4029774575763373,"score_spread":0.36557696670323886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412862175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843069,0.010602223,0.000032123604,0.0038836363,0.000051608335,0.0009006304,0.000030602,0.000008236004,0.00018404069],"genre_scores_gemma":[0.99673975,0.0017783467,0.00017697364,0.000071525494,0.000048921676,0.00009266613,0.0000055140085,0.000021181791,0.0010651242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980089,0.00022126187,0.00037011364,0.0002156379,0.0007283139,0.00045574913],"domain_scores_gemma":[0.9978702,0.0001813576,0.00020800532,0.00013612038,0.0013864479,0.00021785202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047068487,0.00014486018,0.0004387857,0.00082741585,0.00014512331,0.00005634021,0.0001024522,0.00011445646,0.0001053841],"category_scores_gemma":[0.00029530298,0.00009810916,0.000057873083,0.0011503168,0.00014529223,0.00016628616,0.000053209522,0.000511535,8.148852e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012879092,0.00030808256,0.96194047,0.0003431845,0.0012062715,0.00058780645,0.0017297656,0.000009103359,0.026374917,0.00002360377,0.0002848485,0.005904012],"study_design_scores_gemma":[0.0061639063,0.0006031476,0.96522784,0.0026940086,0.0001911347,0.00003067725,0.00043992943,0.00008989861,0.024192644,0.00013972059,0.00013199956,0.000095083284],"about_ca_topic_score_codex":0.0011362404,"about_ca_topic_score_gemma":0.00017361723,"teacher_disagreement_score":0.012432846,"about_ca_system_score_codex":0.0014699918,"about_ca_system_score_gemma":0.0023247055,"threshold_uncertainty_score":0.41239277},"labels":[],"label_agreement":null},{"id":"W4413050186","doi":"10.1016/j.lungcan.2025.108683","title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; KRAS; Chemotherapy; Adverse effect; Cancer; Population; Confidence interval","score_opus":0.006267195991771177,"score_gpt":0.3542312934856155,"score_spread":0.3479640974938443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413050186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96724975,0.009852195,0.000986988,0.0008555818,0.001914177,0.014784785,0.0007743996,0.00009946793,0.0034826614],"genre_scores_gemma":[0.988706,0.0013513432,0.00040274186,0.0002645946,0.00026111925,0.0070017725,0.00012805783,0.000040093302,0.0018442764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970307,0.0002826393,0.0010664605,0.00071250316,0.00037862276,0.00052909076],"domain_scores_gemma":[0.99788946,0.0005190673,0.0006113665,0.00045392077,0.00034101182,0.00018517526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029946544,0.00052614044,0.0030211,0.00023930229,0.000099027224,0.00004025102,0.00017913793,0.0002670662,0.000666043],"category_scores_gemma":[0.00021329953,0.00040270793,0.00058785133,0.00087690627,0.00014663067,0.00018176917,0.000048981463,0.00032840183,0.0000018911592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9617789,0.002308038,0.016360091,0.00036605264,0.0040923283,0.00006560143,0.00069949747,0.0006461077,0.00830628,0.00002110174,0.00075491256,0.0046011163],"study_design_scores_gemma":[0.9567437,0.00032852514,0.0033504532,0.0011804583,0.007927964,9.2623446e-7,0.00005493306,0.022388745,0.007568545,0.000050763145,0.00010176238,0.00030322297],"about_ca_topic_score_codex":0.019331817,"about_ca_topic_score_gemma":0.0040467368,"teacher_disagreement_score":0.021742638,"about_ca_system_score_codex":0.0017435695,"about_ca_system_score_gemma":0.002512169,"threshold_uncertainty_score":0.99984246},"labels":[],"label_agreement":null},{"id":"W4413105938","doi":"10.1093/noajnl/vdaf123.137","title":"TRLS-14 CLINICOPATHOLOGIC CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH KRAS G12C MUTANT NSCLC WITH BRAIN METASTASES","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; KRAS; Internal medicine; Oncology; Cohort; STK11; Population; Retrospective cohort study; Cancer; Lung cancer; Gastroenterology; Colorectal cancer","score_opus":0.0099296812370401,"score_gpt":0.34007192561209215,"score_spread":0.3301422443750521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413105938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945146,0.00051832537,0.0002445814,0.002318381,0.00025497412,0.0006711209,0.00016587751,0.000041732685,0.0012704126],"genre_scores_gemma":[0.99416715,0.00023487312,0.0022045376,0.0029997395,0.000017482713,0.00007748893,0.00007427347,0.00001406742,0.00021036173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894875,0.00009361809,0.00031411703,0.00032064266,0.00013644743,0.000186432],"domain_scores_gemma":[0.9985913,0.0007346201,0.00024194576,0.00020633586,0.00015927323,0.000066516746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008611217,0.00018998662,0.0006289179,0.00011231055,0.000085126325,0.000006803147,0.000058100853,0.00006199634,0.000023456776],"category_scores_gemma":[0.00030277204,0.00010917,0.00004017566,0.00015107663,0.0003310011,0.00010803638,0.00003152831,0.00014075593,0.0000016663861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011673314,0.00065132347,0.9594445,0.00008621376,0.00021658224,0.00013400763,0.00015423936,0.000004057083,0.00042937874,0.00022849227,0.00009264051,0.0373912],"study_design_scores_gemma":[0.006575231,0.004557324,0.9589548,0.00007742988,0.0009131267,0.00002380188,0.00015477082,0.0000037665882,0.0006284613,0.00009609726,0.027906578,0.00010857291],"about_ca_topic_score_codex":0.000005004471,"about_ca_topic_score_gemma":0.000045617602,"teacher_disagreement_score":0.037282627,"about_ca_system_score_codex":0.00004371328,"about_ca_system_score_gemma":0.0002274356,"threshold_uncertainty_score":0.44518235},"labels":[],"label_agreement":null},{"id":"W4413118800","doi":"10.51731/cjht.2025.1187","title":"Crovalimab (Piasky)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01764724544898367,"score_gpt":0.36121228104006936,"score_spread":0.3435650355910857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413118800","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14540508,0.2765523,0.0018442735,0.5525817,0.001685103,0.0007277357,0.000032025288,0.00024289846,0.02092883],"genre_scores_gemma":[0.99602395,0.00033936376,0.0011078047,0.0016431175,0.000005531096,0.000004295769,0.0000017598126,0.0000049348196,0.0008692205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933785,0.000011548541,0.00029477544,0.000066828885,0.00006203756,0.00022693406],"domain_scores_gemma":[0.99949807,0.000019434521,0.00012960748,0.00015256906,0.00014336767,0.000056955363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014953101,0.00006347889,0.00023233371,0.00060552947,0.00015647872,0.000015134464,0.000099895486,0.000066994915,0.00002078087],"category_scores_gemma":[0.00020456218,0.000048302238,0.000056713216,0.00032485818,0.00009709374,0.00004318711,0.000006032568,0.00019438493,0.000004252675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014384912,0.00003027348,0.021057643,0.00014465126,0.00019683469,0.0002163537,0.0002209378,0.0000046074456,0.00001993401,0.008198774,0.036233764,0.9336618],"study_design_scores_gemma":[0.0014514107,0.00049784756,0.044159763,0.0006735635,0.00011446065,0.00030572538,0.0034668187,0.00000418775,0.0005866521,0.006694408,0.9419739,0.00007125323],"about_ca_topic_score_codex":0.003025308,"about_ca_topic_score_gemma":0.0017604375,"teacher_disagreement_score":0.9335906,"about_ca_system_score_codex":0.0006145155,"about_ca_system_score_gemma":0.0067581176,"threshold_uncertainty_score":0.99887264},"labels":[],"label_agreement":null},{"id":"W4413182431","doi":"10.3390/curroncol32080451","title":"Experiences of Advanced Non-Small Cell Lung Cancer Patients with Targeted Therapy Using Journey Mapping: A Qualitative Study","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Anhui Medical University; National Natural Science Foundation of China","keywords":"Medicine; Lung cancer; Quality of life (healthcare); Anxiety; Psychological intervention; Disease; Patient experience; Qualitative research; Targeted therapy; Cancer; Intensive care medicine; Oncology; Internal medicine; Health care; Nursing; Psychiatry","score_opus":0.07399336612741549,"score_gpt":0.4823931383254396,"score_spread":0.40839977219802415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413182431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227285,0.003999625,0.0006017669,0.00006617171,0.00083477044,0.0016333708,0.00001349891,0.000014941889,0.00056300766],"genre_scores_gemma":[0.99842495,0.00013623596,0.0007040272,0.000055831486,0.00003099777,0.0004927742,0.000022499056,0.000010407533,0.00012229118],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9990065,0.000113773356,0.00029521488,0.0002495153,0.00014566799,0.00018933837],"domain_scores_gemma":[0.9991468,0.00007494366,0.00022487006,0.00013575556,0.00035508367,0.0000625241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008458254,0.00014811908,0.00039473962,0.00015949325,0.00008902666,0.0000055866003,0.00007238663,0.000040389714,0.00006557713],"category_scores_gemma":[0.000015833108,0.0001012612,0.000047646776,0.0003511015,0.00008117277,0.000056361536,0.000023742323,0.0001175601,4.2229937e-7],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047898994,0.0047354433,0.26631385,0.00012055124,0.00042269364,0.000004041345,0.71692705,0.00006394314,0.00037743515,0.000006591691,0.00019464156,0.010354788],"study_design_scores_gemma":[0.022128932,0.00387762,0.099269934,0.00051220914,0.00056382373,5.742186e-7,0.8686707,0.0003653859,0.0012135453,0.0000150332935,0.0031809544,0.00020127022],"about_ca_topic_score_codex":0.00008566482,"about_ca_topic_score_gemma":0.000029013048,"teacher_disagreement_score":0.16704391,"about_ca_system_score_codex":0.0003775133,"about_ca_system_score_gemma":0.00088571967,"threshold_uncertainty_score":0.41293117},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"qualitative","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"qualitative","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4413223210","doi":"10.3390/curroncol32080448","title":"Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer—A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University; Western University; Princess Margaret Cancer Centre; NOSM University; McGill University; Health Sciences North","funders":"","keywords":"Medicine; Osimertinib; Oncology; Lung cancer; Regimen; Bevacizumab; Clinical trial; Internal medicine; Epidermal growth factor receptor; Cancer; Erlotinib; Chemotherapy","score_opus":0.06341274929620676,"score_gpt":0.5037685852525103,"score_spread":0.44035583595630357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413223210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000052615915,0.97295743,0.000028087557,0.00054413103,0.0014725373,0.007236677,0.000100609344,0.000017998378,0.017637279],"genre_scores_gemma":[0.0000019561385,0.99327487,0.00022606576,0.00022651473,0.00006669735,0.0050188084,0.0005991067,0.000023051742,0.0005629043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975914,0.00031206827,0.0010075525,0.0005303251,0.00022256165,0.00033613385],"domain_scores_gemma":[0.9982947,0.00022066827,0.00073491334,0.00047760748,0.00020358624,0.000068501955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028230442,0.00043978775,0.0022834192,0.0002109685,0.00006438349,0.000005041712,0.00032498894,0.00014425481,0.00012398897],"category_scores_gemma":[0.000023830195,0.00026786112,0.0003474777,0.001075054,0.0000737727,0.000051662148,0.00008967901,0.0005025581,0.000007035135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001710571,0.000537835,0.000017642576,0.23699465,0.00029970656,0.00004456525,0.0005555972,0.0000029016005,2.537616e-8,0.00004026262,0.0030066678,0.75848305],"study_design_scores_gemma":[0.0012644737,0.00019898842,0.0000138931855,0.20740563,0.007319914,0.000007983972,0.00045637277,0.0000022577956,4.1290934e-7,0.0000084783915,0.7831705,0.00015110588],"about_ca_topic_score_codex":0.000006336562,"about_ca_topic_score_gemma":0.00005113603,"teacher_disagreement_score":0.7801638,"about_ca_system_score_codex":0.001364897,"about_ca_system_score_gemma":0.0017552979,"threshold_uncertainty_score":0.99997735},"labels":[],"label_agreement":null},{"id":"W4413225934","doi":"10.21203/rs.3.rs-7029929/v1","title":"Genes associated with genetic and rare lung diseases and the risk of lung cancer","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of British Columbia; Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Lung cancer; Lung; Medicine; Cancer; Bioinformatics; Genetics; Pathology; Biology; Internal medicine","score_opus":0.021106687220349703,"score_gpt":0.41317332882392466,"score_spread":0.39206664160357496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413225934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7847083,0.20751001,0.00003107144,0.0017737737,0.00007542242,0.0028140608,0.0023589092,0.000027966325,0.0007004645],"genre_scores_gemma":[0.95905125,0.037540216,0.00006118425,0.00002617833,0.00010278916,0.00085626,0.00015133814,0.000019134766,0.0021916581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983394,0.00035864027,0.00017485413,0.00035543184,0.0005237673,0.0002478978],"domain_scores_gemma":[0.9982597,0.00057553145,0.00010614562,0.00035794204,0.00057038805,0.00013027563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026539172,0.00016340382,0.00040570405,0.00016373798,0.00023190219,0.00005095946,0.00008873969,0.00010959514,0.000043349708],"category_scores_gemma":[0.00027548912,0.00008910404,0.00007037956,0.00023431459,0.00043730138,0.000020511288,0.00031002835,0.00044886261,1.4839058e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004618735,0.00009957254,0.98557365,0.00269704,0.002339935,0.000028252982,0.0012705805,0.00014387636,0.0000034056739,0.000059843336,0.0011854946,0.0061364924],"study_design_scores_gemma":[0.0040416066,0.00011414097,0.9835634,0.004334441,0.0028202392,0.0000022367462,0.00049382803,0.0039655794,0.000022519795,0.0002701789,0.00026566043,0.0001061221],"about_ca_topic_score_codex":0.003094941,"about_ca_topic_score_gemma":0.00051467126,"teacher_disagreement_score":0.17434292,"about_ca_system_score_codex":0.00023574207,"about_ca_system_score_gemma":0.0011139768,"threshold_uncertainty_score":0.46786454},"labels":[],"label_agreement":null},{"id":"W4413330771","doi":"10.21203/rs.3.rs-7292685/v1","title":"Molecular Determinants of Lung Function Decline: A Multi- Level Analysis of Gene Expression","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lung function; Function (biology); Gene; Expression (computer science); Gene expression; Computational biology; Biology; Lung; Internal medicine; Genetics; Medicine; Computer science","score_opus":0.09639354950758285,"score_gpt":0.4939423482794228,"score_spread":0.39754879877183996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413330771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971817,0.0037496611,0.020310363,0.0001339556,0.0001467495,0.0017162944,0.0014460563,0.00002712926,0.00065277104],"genre_scores_gemma":[0.9926014,0.00027635516,0.004836637,0.000015105977,0.00002882142,0.00023113021,0.00077171886,0.000016866064,0.0012219984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765915,0.00020033612,0.0004952251,0.0004620996,0.00092086714,0.000262342],"domain_scores_gemma":[0.99739635,0.00013567747,0.0001996636,0.00082032545,0.0013271812,0.0001208018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004833635,0.0001740966,0.00071587856,0.0014992021,0.00006726041,0.00001288117,0.00017116553,0.00025762522,0.00010403738],"category_scores_gemma":[0.0003301599,0.00014238237,0.0004349346,0.0011488735,0.00008702309,0.000028849694,0.00045345727,0.0004153136,0.0000016050802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00149799,0.0028018325,0.8187347,0.013123675,0.012199884,0.000212304,0.002066332,0.008681277,0.11104641,0.000067097884,0.00076531287,0.028803155],"study_design_scores_gemma":[0.003074183,0.00046438692,0.7331106,0.005045725,0.009569838,0.000001711546,0.0004936053,0.036051616,0.21170998,0.00008693243,0.00016621884,0.00022518932],"about_ca_topic_score_codex":0.00087357394,"about_ca_topic_score_gemma":0.00015820036,"teacher_disagreement_score":0.10066356,"about_ca_system_score_codex":0.00026872245,"about_ca_system_score_gemma":0.00095486786,"threshold_uncertainty_score":0.58061844},"labels":[],"label_agreement":null},{"id":"W4413344950","doi":"10.1371/journal.pone.0330630","title":"A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Crizotinib; Alectinib; Anaplastic lymphoma kinase; Pharmacovigilance; Ceritinib; Internal medicine; Database; Pleural effusion; Pericardial effusion; Adverse effect; Oncology; Malignant pleural effusion","score_opus":0.04621825421014673,"score_gpt":0.3559656280137427,"score_spread":0.30974737380359596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413344950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779147,0.00017336138,0.000053127023,0.00040022456,0.00014049045,0.00057364604,0.0002527919,0.000036170484,0.00057873747],"genre_scores_gemma":[0.9976233,0.00007616927,0.00091687526,0.00012386132,0.00009793221,0.000039348495,0.0002508099,0.000011078825,0.00086062466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868697,0.00006970745,0.00053526706,0.00028145552,0.00027404987,0.00015254828],"domain_scores_gemma":[0.9989536,0.00010364904,0.00042893412,0.00028393694,0.00014573084,0.000084159066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002192587,0.00011999072,0.00051435607,0.00022003775,0.00013215744,0.000008110915,0.000049076443,0.000028556391,0.000040766205],"category_scores_gemma":[0.00016339197,0.00008797294,0.00011052845,0.0010824038,0.000021858552,0.00006447654,0.000086335465,0.00009954996,0.000002502567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029676687,0.00066611636,0.8407631,0.0002535863,0.01416675,0.000052813146,0.0010994659,0.00042549425,0.14136258,0.0000087923645,0.0006542045,0.00025036218],"study_design_scores_gemma":[0.006470656,0.00017038296,0.7452612,0.007157096,0.09977896,0.0000027040576,0.0031846121,0.11164402,0.025681004,0.0000070310434,0.00023810862,0.00040422095],"about_ca_topic_score_codex":0.008369888,"about_ca_topic_score_gemma":0.00053640065,"teacher_disagreement_score":0.11568157,"about_ca_system_score_codex":0.00034208407,"about_ca_system_score_gemma":0.00011278519,"threshold_uncertainty_score":0.99823344},"labels":[],"label_agreement":null},{"id":"W4413365072","doi":"10.1016/j.lungcan.2025.108717","title":"Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Mount Sinai Hospital; Public Health Ontario; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Dalhousie University; Juravinski Cancer Centre; William Osler Health System; University of Alberta; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Intensive care medicine","score_opus":0.023430912474930395,"score_gpt":0.39245221475810704,"score_spread":0.36902130228317664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413365072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002367231,0.8271001,0.0000011415124,0.0025633997,0.00022531294,0.0022039025,0.00044866864,0.0000197133,0.1674354],"genre_scores_gemma":[0.00012811787,0.97234005,0.00007397777,0.00034184277,0.00012462225,0.00071208004,0.0000922506,0.000033894456,0.026153138],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987692,0.00007391269,0.00031252275,0.00036832105,0.00021720822,0.00025878206],"domain_scores_gemma":[0.99887466,0.00014159856,0.00016558729,0.0005692893,0.000121130615,0.0001277047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009794714,0.00029607804,0.0009236956,0.00024314407,0.00012025484,0.000015850552,0.0001436387,0.00012377911,0.00065098895],"category_scores_gemma":[0.000017706823,0.00017582855,0.00036026843,0.00048082133,0.0000619316,0.000008672018,0.000023793456,0.00024689143,0.000017072463],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002707828,0.0000727904,0.000030043691,0.041762177,0.008491536,0.00012530344,0.00056405715,0.0000014788914,7.1699e-8,0.012723124,0.07013288,0.86606944],"study_design_scores_gemma":[0.00039128162,0.00003417,0.00004807767,0.07258315,0.010712874,0.000005869561,0.00038362388,0.0000015444908,3.6552035e-7,0.000010740172,0.91569275,0.0001355412],"about_ca_topic_score_codex":0.028370904,"about_ca_topic_score_gemma":0.0074837045,"teacher_disagreement_score":0.8659339,"about_ca_system_score_codex":0.0020107594,"about_ca_system_score_gemma":0.0019648548,"threshold_uncertainty_score":0.9780993},"labels":[],"label_agreement":null},{"id":"W4413607291","doi":"10.64628/aap.fywsn9p3n","title":"Lung cancer: Predicting which patients are at high risk of recurrence to improve outcomes","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Lung cancer; Cancer; Medicine; Oncology; Internal medicine","score_opus":0.009869681459001817,"score_gpt":0.33506830974266627,"score_spread":0.32519862828366447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413607291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828276,0.0012148607,0.00005321451,0.0018154941,0.0037432855,0.0020251204,0.0042044627,0.00013558821,0.003980379],"genre_scores_gemma":[0.988538,0.0004736509,0.00096700515,0.00015819714,0.00016977206,0.0006175468,0.0002802481,0.000045811874,0.008749768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981858,0.000026380074,0.0004798852,0.0006532513,0.0004065329,0.00024811373],"domain_scores_gemma":[0.9983017,0.00009664263,0.00034895743,0.00054178084,0.00052406255,0.0001868485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084207364,0.0003068244,0.0006169305,0.00015639681,0.000070496,0.000023542081,0.00012616857,0.0001751093,0.00022528562],"category_scores_gemma":[0.00028434503,0.00021679282,0.00016489513,0.00019967805,0.00001942773,0.00002464444,0.00082743587,0.0004500048,0.000024170804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005804966,0.00014677407,0.9815753,0.0017193182,0.0014647082,0.000004210978,0.0009908258,0.00024274632,0.000011147939,0.00002892137,0.004934552,0.008823409],"study_design_scores_gemma":[0.0018461238,0.00029549314,0.98536605,0.0039362074,0.005069104,7.0259955e-7,0.0001642855,0.0007943253,0.0014123499,0.00028399902,0.0004933408,0.00033803767],"about_ca_topic_score_codex":0.01005353,"about_ca_topic_score_gemma":0.0036971988,"teacher_disagreement_score":0.008485371,"about_ca_system_score_codex":0.00097345834,"about_ca_system_score_gemma":0.0005421801,"threshold_uncertainty_score":0.9965386},"labels":[],"label_agreement":null},{"id":"W4413635208","doi":"10.2196/66342","title":"Efficacy of Fuzheng Quxie Formula Against Postoperative Metastasis of Lung Cancer in Stage IIA-IIIA With Negative Driver Genes: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial","year":2025,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Preprint; Randomized controlled trial; Lung cancer; Oncology; Stage (stratigraphy); Internal medicine; Surgery","score_opus":0.12515388482719278,"score_gpt":0.5725628012877209,"score_spread":0.44740891646052805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413635208","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019036602,0.000014667403,0.0002767887,0.0003630627,0.000009491094,0.9788952,0.00011715981,0.000020278592,0.0012667653],"genre_scores_gemma":[0.017793087,0.0000034856048,0.0011015645,0.000035744288,0.000043644544,0.97861654,0.00002472291,0.00003540585,0.0023457916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961981,0.00080426806,0.0011875883,0.0004944831,0.0007818624,0.0005336801],"domain_scores_gemma":[0.99522287,0.0018919513,0.00047358454,0.00042730643,0.0018484642,0.00013579942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018213745,0.0003119786,0.0020267523,0.0007343406,0.00015741539,0.000048383736,0.0002115853,0.00012589525,0.00013430571],"category_scores_gemma":[0.00056856783,0.00018480864,0.00042265,0.0008536845,0.0004064641,0.0002106595,0.00008959016,0.0003587373,6.658389e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98174804,0.004299449,0.0007133959,0.0022582053,0.002588071,0.000011464371,0.0027451254,0.000117489566,0.0020172326,0.000525758,0.0001134214,0.0028623163],"study_design_scores_gemma":[0.96496,0.0029795903,0.00013983161,0.006080317,0.00021952661,1.843536e-7,0.00044205436,0.0011466001,0.02139828,0.00002235235,0.002469951,0.00014133242],"about_ca_topic_score_codex":0.00043940175,"about_ca_topic_score_gemma":0.0003137989,"teacher_disagreement_score":0.019381048,"about_ca_system_score_codex":0.00051143375,"about_ca_system_score_gemma":0.0027454374,"threshold_uncertainty_score":0.7536277},"labels":[],"label_agreement":null},{"id":"W4413680467","doi":"10.36401/jipo-24-35","title":"Prevalence of Molecular Mutations in Non–Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion","year":2025,"lang":"en","type":"review","venue":"Journal of Immunotherapy and Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer; Microsoft","keywords":"Expert opinion; Lung cancer; Cancer; Medicine; Current (fluid); Systematic review; Oncology; Political science; MEDLINE; Intensive care medicine; Internal medicine; Engineering","score_opus":0.06732499684879138,"score_gpt":0.4350480169799695,"score_spread":0.3677230201311781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413680467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002470513,0.9956902,0.00010164321,0.00049359514,0.00012447612,0.0032506739,0.000010545199,0.0000011604762,0.000080601705],"genre_scores_gemma":[0.00021576874,0.9987316,0.0002576404,0.000120509336,0.00002307253,0.00056183053,0.000006113559,0.000010199975,0.00007325758],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99798584,0.00053906685,0.0010670058,0.00018282083,0.0001231634,0.00010212039],"domain_scores_gemma":[0.99814296,0.00068972446,0.00086365035,0.00019433381,0.00007170056,0.000037645004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005824057,0.00022241361,0.0018355425,0.0002761296,0.00003542656,0.00001172411,0.00009985099,0.00012420796,0.0000056548256],"category_scores_gemma":[0.000045750658,0.00011366739,0.00016664584,0.00020971427,0.000055907472,0.000047524354,0.000018388668,0.00022402953,5.6106504e-8],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050856015,0.00032238307,0.00006247573,0.34305778,0.00029870585,0.000022620692,0.0023019414,0.0000012316331,0.0000014498653,0.000010504145,0.000041580544,0.65382844],"study_design_scores_gemma":[0.0041250875,0.0018653056,0.00023503433,0.9280739,0.006496912,0.0008257107,0.00038337195,0.000016960996,0.0000042623014,0.00004578843,0.05775329,0.00017440671],"about_ca_topic_score_codex":0.00002528075,"about_ca_topic_score_gemma":0.000005576919,"teacher_disagreement_score":0.65365404,"about_ca_system_score_codex":0.00030106495,"about_ca_system_score_gemma":0.00066086923,"threshold_uncertainty_score":0.46352217},"labels":[],"label_agreement":null},{"id":"W4413824545","doi":"10.36469/001c.142771","title":"Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Immunotherapy; Chemotherapy; Health care; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.0543748553438399,"score_gpt":0.444466954937541,"score_spread":0.3900920995937011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413824545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636091,0.007940429,0.000041431238,0.02543094,0.00018574584,0.0024552708,0.00026828353,0.000007776293,0.000061009785],"genre_scores_gemma":[0.9698193,0.022285646,0.0016244289,0.0033326389,0.00004409583,0.0001631077,0.00009481082,0.000046605597,0.002589348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771357,0.00021330707,0.0010214284,0.0002770778,0.00017323709,0.0006013666],"domain_scores_gemma":[0.99720776,0.00081643846,0.0004817938,0.00020134402,0.0007531637,0.0005395149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010057307,0.0002090921,0.0009160109,0.00082257745,0.0004625801,0.00009682182,0.000098816876,0.00008632054,0.000007247378],"category_scores_gemma":[0.00015082947,0.00014948875,0.00010624477,0.00037810334,0.0000878298,0.00019017539,0.000058663758,0.000432992,2.6305113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013783014,0.00021360566,0.94332194,0.0022806316,0.00045177553,0.000010702571,0.0013828564,0.000045448814,0.0000022531801,0.00015876468,0.0017766119,0.04897709],"study_design_scores_gemma":[0.01991586,0.003696891,0.9471334,0.0013198488,0.00031445888,0.000015470276,0.004738612,0.0017501336,0.00006197722,0.00010481474,0.02072418,0.00022432584],"about_ca_topic_score_codex":0.003672031,"about_ca_topic_score_gemma":0.0024091736,"teacher_disagreement_score":0.048752762,"about_ca_system_score_codex":0.0016718649,"about_ca_system_score_gemma":0.002518912,"threshold_uncertainty_score":0.60959744},"labels":[],"label_agreement":null},{"id":"W4413908691","doi":"10.3390/curroncol32090489","title":"The Clinical Characteristics, Treatment, and Prognosis of Lung Cancer in Young Patients in the New Era of Cancer Treatment: A Retrospective and Comprehensive Analysis","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Natural Science Foundation of Beijing Municipality","keywords":"Medicine; Lung cancer; Cancer; Cancer treatment; Retrospective cohort study; Oncology; Internal medicine; Intensive care medicine","score_opus":0.05155691512651745,"score_gpt":0.4847655050773518,"score_spread":0.43320858995083433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413908691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844639,0.012383777,0.000003644061,0.001526104,0.00028843273,0.00101419,0.00015965394,0.0000030040856,0.00015731515],"genre_scores_gemma":[0.9626456,0.03685055,0.000014900141,0.000031760268,0.00003861687,0.00031140292,0.00003812625,0.000004068881,0.00006500962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990015,0.00013538293,0.00042957725,0.00022707638,0.000069175134,0.00013730388],"domain_scores_gemma":[0.9991687,0.0003076443,0.00021410655,0.0001383514,0.00013178607,0.000039416806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007004487,0.000124721,0.0005901704,0.00011901836,0.00004966159,0.000006823341,0.000042365376,0.000059773203,0.000009790368],"category_scores_gemma":[0.000041730753,0.000065998254,0.0000886887,0.00043470153,0.00018398128,0.000023330147,0.000021149559,0.00011246037,6.399913e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021055131,0.0009573583,0.8097632,0.000029600407,0.0012631709,0.000001593099,0.0026658436,0.0000011774628,0.0000030683616,0.0000782462,0.00006514508,0.18496104],"study_design_scores_gemma":[0.005461046,0.00089117,0.9872907,0.00013748705,0.0035654206,3.7494414e-7,0.00032718902,0.00022574184,0.00001474692,0.000031837135,0.0020146947,0.000039619874],"about_ca_topic_score_codex":0.0065754666,"about_ca_topic_score_gemma":0.025700934,"teacher_disagreement_score":0.18492141,"about_ca_system_score_codex":0.0006397283,"about_ca_system_score_gemma":0.00046801785,"threshold_uncertainty_score":0.99401826},"labels":[],"label_agreement":null},{"id":"W4414047779","doi":"10.1056/nejmoa2503001","title":"Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Janssen Research and Development","keywords":"Overall survival; Osimertinib; Adverse effect; Survival analysis; Survival rate","score_opus":0.009100186127946447,"score_gpt":0.31867890706951074,"score_spread":0.3095787209415643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414047779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9295469,0.002707576,0.0013213925,0.02826252,0.0009302313,0.00036014998,0.0000031040042,0.000023582013,0.036844548],"genre_scores_gemma":[0.9933239,0.00043322457,0.0011008919,0.001569379,0.0006557852,0.000002938449,0.000015209992,0.000015831827,0.0028828226],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986825,0.000054703505,0.0005310412,0.00014487085,0.00037548324,0.00021143034],"domain_scores_gemma":[0.9990217,0.00018853214,0.00021491662,0.00015452913,0.00021615012,0.0002041403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032720406,0.00016507923,0.00057901576,0.00031786732,0.00003447999,0.0000070608953,0.000082609666,0.000047851925,0.00010922096],"category_scores_gemma":[0.00018297805,0.0000941992,0.000050744675,0.00038601508,0.00007063914,0.000104664665,0.000010792864,0.00032648025,0.0000019587676],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023112414,0.0008760008,0.26090536,0.00025859944,0.0016683707,0.004281796,0.0049632243,0.00088425115,0.015154568,0.0017883333,0.017811883,0.6682952],"study_design_scores_gemma":[0.52160496,0.006916792,0.27521184,0.0070468546,0.0017371684,0.0014557329,0.0014216937,0.00009520352,0.0016559851,0.0015844657,0.18097562,0.00029369842],"about_ca_topic_score_codex":0.0002477619,"about_ca_topic_score_gemma":0.0002409903,"teacher_disagreement_score":0.6680015,"about_ca_system_score_codex":0.00017365602,"about_ca_system_score_gemma":0.0006370309,"threshold_uncertainty_score":0.3841332},"labels":[],"label_agreement":null},{"id":"W4414056345","doi":"10.1016/j.jtho.2025.06.025","title":"The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; AIO-Studien; International Association for the Study of Lung Cancer; AstraZeneca","keywords":"Lung cancer staging; Lung cancer; Stage (stratigraphy); Overall survival; Ninth; Neoplasm staging; Cancer staging; Tumor stage","score_opus":0.049976963296787524,"score_gpt":0.5594834934295361,"score_spread":0.5095065301327486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414056345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910281,0.00026966634,0.00039218485,0.006132491,0.0006780254,0.0009590126,0.000111425405,0.0000013732074,0.00042774135],"genre_scores_gemma":[0.99952483,0.00010107632,0.00004040446,0.0000971624,0.00011134597,0.000061599516,0.000012932752,0.000005666806,0.000044985096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984444,0.00040346396,0.00062287296,0.000081169856,0.00033801043,0.0001101268],"domain_scores_gemma":[0.99710786,0.0013664638,0.0009294601,0.00017426287,0.00040943455,0.000012488769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013271912,0.0000826891,0.00029570516,0.00021563431,0.0001041529,0.000016039656,0.00021105168,0.000036724952,0.0000071039217],"category_scores_gemma":[0.00047098225,0.000036647445,0.00014551039,0.0003228573,0.000047920304,0.00009734509,0.00004797231,0.00028036957,1.8239485e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059515466,0.005069377,0.8535335,0.00012383699,0.0064474423,0.0000264814,0.015154412,0.06933848,0.012734617,0.0009972344,0.003167739,0.027455334],"study_design_scores_gemma":[0.0071617463,0.0021790026,0.9446378,0.0010268269,0.0022700452,0.0000073622487,0.01516394,0.018636895,0.008023905,0.00048750325,0.00030824935,0.00009677115],"about_ca_topic_score_codex":0.0027033812,"about_ca_topic_score_gemma":0.002467782,"teacher_disagreement_score":0.091104254,"about_ca_system_score_codex":0.0011331846,"about_ca_system_score_gemma":0.0011238365,"threshold_uncertainty_score":0.40867218},"labels":[],"label_agreement":null},{"id":"W4414062917","doi":"10.1016/j.lungcan.2025.108748","title":"Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world study","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Lung cancer; Stage (stratigraphy); Mutation; Cancer; Lung","score_opus":0.010605903276625087,"score_gpt":0.32990914063305166,"score_spread":0.3193032373564266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414062917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952923,0.00051078515,0.000106540785,0.00009454697,0.00004015697,0.0025492953,0.0004892411,0.00004346729,0.0008736482],"genre_scores_gemma":[0.9944931,0.00009499975,0.00022274432,0.00009238436,0.000012027108,0.00084642257,0.00020100911,0.000028009876,0.0040092818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840915,0.0000464178,0.00039003737,0.00053468015,0.00029582452,0.00032388416],"domain_scores_gemma":[0.99901354,0.00006471721,0.00025322454,0.0003056463,0.00026364703,0.00009921104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054988006,0.00035095564,0.00090175756,0.00038820013,0.000087772,0.00003554847,0.00006902531,0.00005176337,0.000095596304],"category_scores_gemma":[0.000004297473,0.00023180792,0.00006541789,0.0023137948,0.000043666627,0.0000935011,0.000017867158,0.00008447353,9.8984586e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016543977,0.0018340184,0.98049617,0.0002350039,0.007819653,0.000058027606,0.0014719095,0.0044335034,0.000019280676,0.000002621906,0.000025258716,0.0019501424],"study_design_scores_gemma":[0.025207996,0.0012791307,0.95605874,0.0004063235,0.011023182,2.5888687e-7,0.00039718507,0.0051806527,0.00023774986,4.1052814e-7,0.000008207172,0.00020019071],"about_ca_topic_score_codex":0.17742558,"about_ca_topic_score_gemma":0.18124385,"teacher_disagreement_score":0.024437472,"about_ca_system_score_codex":0.0024230226,"about_ca_system_score_gemma":0.0006699832,"threshold_uncertainty_score":0.94528526},"labels":[],"label_agreement":null},{"id":"W4414082275","doi":"10.1200/jco-25-00788","title":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epidermal growth factor receptor; Lung cancer; Exon; Tyrosine kinase; Adverse effect; Mutation; Gefitinib; Tyrosine-kinase inhibitor; Kinase","score_opus":0.057831053484738014,"score_gpt":0.47379767761173325,"score_spread":0.41596662412699525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414082275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922672,0.0003776957,0.0002872639,0.0026518432,0.00068810116,0.0017572216,0.00002860551,0.000012243732,0.0019298184],"genre_scores_gemma":[0.99673307,0.00026482347,0.0014863003,0.00041085435,0.00018553062,0.0001171342,0.000023512792,0.000019450961,0.00075932365],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954337,0.0007175658,0.0030477622,0.00027145824,0.0002900382,0.00023950233],"domain_scores_gemma":[0.9942073,0.002549601,0.0020544145,0.00017996728,0.000792105,0.00021656723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012619005,0.00021641923,0.002253136,0.00040018148,0.00008354566,0.000008501705,0.00012615613,0.00026693815,0.00020933812],"category_scores_gemma":[0.0015825758,0.00013888697,0.00033774838,0.000499124,0.00016187181,0.00015441736,0.00003622922,0.00070123735,0.0000015803364],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26151314,0.0520737,0.64317304,0.00024181342,0.004012281,0.00045251494,0.007721468,0.0006047872,0.0021291175,0.000030340783,0.0013312199,0.026716558],"study_design_scores_gemma":[0.7463025,0.033416264,0.20986325,0.0006768558,0.004732898,0.000018650475,0.0018477066,0.0013129313,0.0011389941,0.000054381322,0.0004571337,0.00017847236],"about_ca_topic_score_codex":0.0008149643,"about_ca_topic_score_gemma":0.001377232,"teacher_disagreement_score":0.48478934,"about_ca_system_score_codex":0.0003791288,"about_ca_system_score_gemma":0.0030826293,"threshold_uncertainty_score":0.56636465},"labels":[],"label_agreement":null},{"id":"W4414082877","doi":"10.1016/j.jtho.2025.07.117","title":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Chugai Pharmaceutical; Johnson and Johnson; University of California, Irvine; Daiichi Sankyo Europe; Gilead Sciences; LEO Pharma; Genentech; Grifols; GlaxoSmithKline; Orient Europharma; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; G1 Therapeutics; Revolution Medicines; Merck KGaA; BeiGene; Mirati Therapeutics; Sanofi; Amgen; Pfizer; AstraZeneca; Bristol-Myers Squibb","keywords":"Randomized controlled trial; Incidence (geometry); Regimen; MEDLINE; Clinical trial","score_opus":0.010068541213104881,"score_gpt":0.43336797958588713,"score_spread":0.4232994383727823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414082877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8958225,0.0021726117,0.00578358,0.016093533,0.0026409097,0.008161096,0.0000069802927,0.00003517094,0.06928358],"genre_scores_gemma":[0.99466985,0.00041634266,0.0030767086,0.00082208205,0.000073777715,0.00037523,0.0000060535194,0.000009589264,0.0005503346],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973804,0.0006610421,0.0011299427,0.00019294221,0.0003439846,0.00029172195],"domain_scores_gemma":[0.9975048,0.0009386699,0.0008707588,0.00020347616,0.00039570327,0.000086643886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011009038,0.00021851009,0.0020433995,0.0002088451,0.0000963912,0.000024365048,0.00016850552,0.00012083209,0.00004592101],"category_scores_gemma":[0.00044996457,0.000106738706,0.00030946382,0.00055998814,0.00020091729,0.0000897363,0.00003557627,0.00031243076,0.0000034873767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9396294,0.00051480596,0.000053576117,0.00005132631,0.0027058749,0.00068761123,0.00020087985,0.00023959299,0.00004163514,0.00063186506,0.00032311733,0.05492032],"study_design_scores_gemma":[0.9844423,0.0045593185,0.00030646005,0.00042004124,0.0044040815,0.00013529847,0.0014008336,0.00007450932,0.000325383,0.0005212384,0.0033159088,0.00009460624],"about_ca_topic_score_codex":0.000008628261,"about_ca_topic_score_gemma":0.00008771149,"teacher_disagreement_score":0.098847345,"about_ca_system_score_codex":0.0012452278,"about_ca_system_score_gemma":0.0011296116,"threshold_uncertainty_score":0.4352678},"labels":[],"label_agreement":null},{"id":"W4414239951","doi":"10.51731/cjht.2025.1224","title":"Osimertinib (Tagrisso)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Osimertinib; Exon; Disease; Cancer; Drug; T790M","score_opus":0.01814201831550905,"score_gpt":0.3576238266743232,"score_spread":0.33948180835881414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414239951","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14767139,0.28625324,0.00135293,0.5477888,0.0015582574,0.0007328761,0.00002798599,0.00023229863,0.014382207],"genre_scores_gemma":[0.9966142,0.00031398097,0.0007528948,0.001556934,0.0000057427005,0.000004463884,0.00000184101,0.000004640918,0.00074527966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931765,0.000011987698,0.00031594533,0.00006665374,0.000060904473,0.0002268805],"domain_scores_gemma":[0.9994958,0.000022276192,0.00014336355,0.00014436967,0.00013158661,0.000062586165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015051341,0.00006382156,0.00023081018,0.00053791626,0.0001512012,0.000011746095,0.000098066615,0.00006923903,0.000024539002],"category_scores_gemma":[0.00023544283,0.00004751668,0.000054887678,0.00031286283,0.00008687081,0.00003953772,0.00000573927,0.00020212683,0.0000050165236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013414335,0.000027317745,0.03618459,0.000104165134,0.00018439708,0.00013731977,0.0002030037,0.0000044242506,0.000025575842,0.0044950563,0.038123697,0.92049706],"study_design_scores_gemma":[0.001207336,0.0004598329,0.08380111,0.00067045284,0.00011427583,0.000203355,0.0031785995,0.00000484857,0.0008758899,0.004906878,0.90450543,0.000071994036],"about_ca_topic_score_codex":0.0031275954,"about_ca_topic_score_gemma":0.0011803573,"teacher_disagreement_score":0.92042506,"about_ca_system_score_codex":0.0004743897,"about_ca_system_score_gemma":0.0054113334,"threshold_uncertainty_score":0.9599473},"labels":[],"label_agreement":null},{"id":"W4414283050","doi":"10.51731/cjht.2025.1225","title":"Amivantamab (Rybrevant)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Exon; Lung cancer; Pemetrexed; Carboplatin; Drug; Disease; Mutation; Epidermal growth factor receptor","score_opus":0.014489350832959812,"score_gpt":0.3545799191784978,"score_spread":0.34009056834553797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414283050","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12785241,0.30414283,0.0017891343,0.5482637,0.0016681826,0.000776892,0.000038100537,0.0002384648,0.015230263],"genre_scores_gemma":[0.99637985,0.0005739397,0.0009184953,0.0014174469,0.000005728756,0.0000037145032,0.0000019967931,0.0000051075217,0.000693738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931115,0.000012285025,0.00031101817,0.00006982679,0.00006396816,0.00023173493],"domain_scores_gemma":[0.99949664,0.0000228254,0.0001366163,0.00015550245,0.00012897988,0.000059459533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001427348,0.000067357614,0.00024835736,0.00060566596,0.00014998567,0.00001339147,0.00010424254,0.00006524356,0.000019924422],"category_scores_gemma":[0.00020235743,0.000050709816,0.00005675093,0.00030438375,0.000096159405,0.000044333945,0.000006487149,0.0002058683,0.0000052416963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014044346,0.00002645069,0.02375067,0.00015309785,0.00017719845,0.00023113529,0.00017751881,0.0000034324191,0.000022877888,0.0052051228,0.040594306,0.92964417],"study_design_scores_gemma":[0.0014713855,0.0005208782,0.054498825,0.0008915771,0.00012275006,0.0003971545,0.0037379314,0.0000051326433,0.00054804777,0.0067270286,0.93100303,0.00007625271],"about_ca_topic_score_codex":0.0021817603,"about_ca_topic_score_gemma":0.0017467036,"teacher_disagreement_score":0.9295679,"about_ca_system_score_codex":0.0006417844,"about_ca_system_score_gemma":0.0061325193,"threshold_uncertainty_score":0.99950176},"labels":[],"label_agreement":null},{"id":"W4414307001","doi":"10.1101/2025.09.09.25335109","title":"Panorama of Chromosomal Instability in Lung Cancer","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Chromosome instability; Genome instability; Lung cancer; Carcinogenesis; Mutation; Somatic cell; Disease; Genome","score_opus":0.017951923856813223,"score_gpt":0.3608732951840917,"score_spread":0.3429213713272785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414307001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848442,0.0031676895,0.000035408884,0.0010306238,0.0005712596,0.00084934686,0.00022633235,0.000031037158,0.009244104],"genre_scores_gemma":[0.9973524,0.00033180867,0.00031382887,0.000098723416,0.00007468917,0.00033273583,0.00007890117,0.000010524458,0.0014063739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988995,0.000042636824,0.0003667324,0.0003537172,0.00017786215,0.00015954062],"domain_scores_gemma":[0.999177,0.00004424736,0.00011880277,0.0004764663,0.00012517057,0.000058344318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010839495,0.00016815226,0.0004887155,0.0001501539,0.000017287257,0.000006227452,0.00010302645,0.00017337117,0.0003157392],"category_scores_gemma":[0.00006858442,0.0001414441,0.0001232593,0.0002032911,0.000060727874,0.000021242873,0.00016580649,0.0003230058,0.0000014986708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000558096,0.0002968932,0.9934724,0.002042724,0.0002453359,0.000023194192,0.00076711725,0.00018295404,0.00023824773,0.0001226954,0.00013175148,0.0024208697],"study_design_scores_gemma":[0.0015300163,0.000043159776,0.99105406,0.0018347028,0.00057162455,0.000001143691,0.000054145414,0.0007831035,0.0023103033,0.00023946792,0.0014451285,0.00013312823],"about_ca_topic_score_codex":0.0026820765,"about_ca_topic_score_gemma":0.0006545738,"teacher_disagreement_score":0.012508216,"about_ca_system_score_codex":0.000460596,"about_ca_system_score_gemma":0.0013159261,"threshold_uncertainty_score":0.57679236},"labels":[],"label_agreement":null},{"id":"W4414399627","doi":"10.1186/s43045-025-00574-2","title":"Is there an association between antipsychotic use and breast cancer risk? A retrospective observational case series","year":2025,"lang":"en","type":"article","venue":"Middle East Current Psychiatry","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Breast cancer; Retrospective cohort study; Antipsychotic; Medical record; Observational study; Tertiary referral hospital","score_opus":0.052914846232231375,"score_gpt":0.348160206082836,"score_spread":0.2952453598506046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414399627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851967,0.003956133,0.00013872732,0.0059793014,0.0015774571,0.00046353182,0.002422779,0.000070430004,0.00019495407],"genre_scores_gemma":[0.99632776,0.0004356701,0.0005845197,0.00030676686,0.00054842443,0.00007755931,0.00019588825,0.000021274942,0.0015021675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988163,0.00006130643,0.00026210852,0.00040514753,0.00023002995,0.00022507411],"domain_scores_gemma":[0.99912196,0.000029529006,0.00019059007,0.00024704344,0.00028099568,0.00012988635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010002891,0.00020057395,0.00026778513,0.00011258683,0.00030892759,0.00009803798,0.000046278514,0.00009685553,0.00012035394],"category_scores_gemma":[0.00002748476,0.00017518696,0.000086080676,0.00035546967,0.000042244545,0.0004740168,0.000020316082,0.00025701014,0.0000073816273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001087296,0.00034460527,0.9900426,0.00013494375,0.0006631426,0.000007265494,0.0006949816,0.0000023327896,0.0000029190467,0.00076405646,0.002589933,0.004644447],"study_design_scores_gemma":[0.0019649274,0.00008975127,0.9923635,0.0004803628,0.0012025846,0.00010722329,0.00056237384,0.0000788144,0.0000033442573,0.0012050722,0.0017913289,0.00015068697],"about_ca_topic_score_codex":0.000425215,"about_ca_topic_score_gemma":0.00086665753,"teacher_disagreement_score":0.011131043,"about_ca_system_score_codex":0.00038521396,"about_ca_system_score_gemma":0.00035461833,"threshold_uncertainty_score":0.71439165},"labels":[],"label_agreement":null},{"id":"W4414501656","doi":"10.1158/1538-7445.pediatric25-a017-pr013","title":"Abstract A017-PR013: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: An update from the iMATRIX alectinib phase I/II open-label, multi-center study","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Alectinib; Anaplastic lymphoma kinase; Phases of clinical research; Pleomorphic xanthoastrocytoma; Lymphoma; Hematopathology; Crizotinib","score_opus":0.09833172118076185,"score_gpt":0.5130758411045395,"score_spread":0.4147441199237777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414501656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925005,0.0011017598,0.0000096698295,0.0013994294,0.000112316346,0.004442284,0.00021259075,0.000037595502,0.00018386067],"genre_scores_gemma":[0.99683136,0.00067475147,0.00019110196,0.00039085041,0.00013975738,0.0009170708,0.00009537764,0.00004498638,0.0007147282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764436,0.00019408026,0.00035423975,0.00073508377,0.0004790244,0.00059318607],"domain_scores_gemma":[0.99874026,0.00010464146,0.000076952114,0.00061524706,0.00023949763,0.00022342247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005563478,0.00024540108,0.00038892127,0.00025551298,0.0007646455,0.00023114284,0.00045294172,0.000062419946,0.00017869183],"category_scores_gemma":[0.00011659817,0.00014707945,0.000022473896,0.0008612861,0.00016758185,0.0003090269,0.000419698,0.0007532903,0.000009340898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005982412,0.019817693,0.9362654,0.00007495915,0.00083348696,0.00024156016,0.0046275174,0.00001050633,0.0029031988,0.000010162572,0.0023057826,0.02692733],"study_design_scores_gemma":[0.075616,0.0023361985,0.91440153,0.0024218208,0.00023855195,0.000015477817,0.0026573187,0.00012754125,0.0010225243,0.00001902065,0.00090589456,0.00023813926],"about_ca_topic_score_codex":0.01719411,"about_ca_topic_score_gemma":0.0138028,"teacher_disagreement_score":0.06963359,"about_ca_system_score_codex":0.00041385798,"about_ca_system_score_gemma":0.0011740191,"threshold_uncertainty_score":0.9893505},"labels":[],"label_agreement":null},{"id":"W4414509893","doi":"10.1158/1538-7445.pediatric25-a021","title":"Abstract A021: Standardized Oncogenic Classification Guidance of Critical Diagnostic and Therapeutic markers in pediatric cancers: NTRK fusions","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Hamilton Health Sciences","funders":"","keywords":"Fusion gene; Trk receptor; Clinical significance; Cancer; Receptor tyrosine kinase; Hematopathology","score_opus":0.06779333936634896,"score_gpt":0.4845084661941785,"score_spread":0.4167151268278295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414509893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9511228,0.03486184,0.00007793895,0.005452789,0.00022126827,0.0010060297,0.0001015102,0.00002076333,0.007135019],"genre_scores_gemma":[0.9898207,0.008895354,0.00013069632,0.00011113518,0.000094912866,0.0005411305,0.000010123768,0.00001424582,0.00038165742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984992,0.00010734022,0.00031247234,0.0003220969,0.00041715556,0.0003417289],"domain_scores_gemma":[0.99770033,0.0014639735,0.000039882685,0.00027000453,0.00040606144,0.00011972554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005390856,0.00010677797,0.00025736788,0.0003946166,0.00012604483,0.000022149388,0.00009251016,0.00008470795,0.00023056725],"category_scores_gemma":[0.00094368274,0.00009170112,0.000049617665,0.00092414895,0.00029467404,0.00005517681,0.000041935393,0.00031193768,0.000003820492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027269316,0.001075427,0.77808034,0.004037315,0.00054602313,0.00013074657,0.0021183968,0.00008437654,0.036079578,0.011594652,0.00807146,0.15545474],"study_design_scores_gemma":[0.0027286818,0.00016126908,0.99143624,0.00053010986,0.00022891052,0.0000017295383,0.0006197695,0.00009886012,0.0012260963,0.001103984,0.0017732519,0.00009110675],"about_ca_topic_score_codex":0.0016875028,"about_ca_topic_score_gemma":0.0006438815,"teacher_disagreement_score":0.21335588,"about_ca_system_score_codex":0.001055134,"about_ca_system_score_gemma":0.0025252867,"threshold_uncertainty_score":0.44797504},"labels":[],"label_agreement":null},{"id":"W4414558145","doi":"10.1016/j.ijrobp.2025.06.3745","title":"Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; London Health Sciences Centre; University of Toronto; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Radiation therapy; Clinical trial; Lung cancer; Clinical endpoint; Cancer; Randomized controlled trial; Systemic therapy","score_opus":0.03558672304077824,"score_gpt":0.43802050584468016,"score_spread":0.4024337828039019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414558145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5996542,0.01489435,0.22904849,0.012752122,0.009606154,0.13032806,0.0005949124,0.00010594131,0.0030157731],"genre_scores_gemma":[0.93564314,0.0034060213,0.011472297,0.0028597065,0.0027941582,0.042836994,0.00010151753,0.00006608806,0.0008200904],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99799407,0.00027863076,0.0011179389,0.00024262653,0.00016136232,0.00020537993],"domain_scores_gemma":[0.99683464,0.0008228775,0.0012417195,0.00012644337,0.0009063563,0.00006798366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096721185,0.00021152414,0.0008913339,0.00031741982,0.000059169684,0.000028878461,0.00023190996,0.00014710322,0.000050705785],"category_scores_gemma":[0.00021223858,0.00015903081,0.0003431425,0.0002325414,0.00006531553,0.00015031283,0.000014571619,0.00026370387,0.000001575699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005535861,0.0020798615,0.63509595,0.00018732666,0.006052347,0.00003805665,0.0026633767,0.0031484815,0.015447739,0.0056893607,0.003951852,0.32010978],"study_design_scores_gemma":[0.43523997,0.012533571,0.17269231,0.0033030568,0.004410784,0.0003328701,0.0016221507,0.040969223,0.058130298,0.03626474,0.23307578,0.0014252412],"about_ca_topic_score_codex":0.000059500475,"about_ca_topic_score_gemma":0.000014427322,"teacher_disagreement_score":0.46240363,"about_ca_system_score_codex":0.0023620434,"about_ca_system_score_gemma":0.0022513228,"threshold_uncertainty_score":0.6485088},"labels":[],"label_agreement":null},{"id":"W4414578957","doi":"10.1016/j.labinv.2025.104245","title":"Ultrarapid EGFR Testing in Non–Small Cell Lung Carcinoma Patients: Findings From a Canadian Clinical Testing Workflow","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health Research Institute; Vancouver Coastal Health; BC Cancer Agency; Simon Fraser University; Vancouver General Hospital; Canadian Centre for Applied Research in Cancer Control; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Lung cancer; Turnaround time; Logistic regression; Genetic testing; Carcinoma; Cancer; Multivariate analysis","score_opus":0.021789214878438243,"score_gpt":0.2906748463020358,"score_spread":0.26888563142359756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414578957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901929,0.00019361105,0.00003570409,0.000440632,0.00030115337,0.0007157642,0.00008190601,0.00005942526,0.007978923],"genre_scores_gemma":[0.9857729,0.0000028297698,0.01036828,0.0028798515,0.00009330642,0.00007969952,0.00029542032,0.000024224417,0.00048346622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852794,0.00007684933,0.0005553962,0.0004018439,0.0001401973,0.00029773978],"domain_scores_gemma":[0.99843,0.0004286991,0.00012815758,0.00025392766,0.00043521688,0.00032396778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021807081,0.0001883501,0.00027241133,0.00028584356,0.00015517406,0.000049197733,0.00008500952,0.00017281454,0.000019773053],"category_scores_gemma":[0.0009787091,0.00019227358,0.000036487676,0.0012819911,0.000075808326,0.0001590254,0.0000125813485,0.0003047558,0.000021267619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009476202,0.0000689264,0.99490595,0.00006562597,0.00003089622,0.00002428499,0.0007755783,0.000030559615,0.00085691095,0.00004598673,0.0009634306,0.0022223578],"study_design_scores_gemma":[0.0023639684,0.00010052486,0.99237597,0.00064258167,0.0002051977,2.483603e-7,0.00011618996,0.0020687184,0.0011716385,0.0005205322,0.00027823,0.00015622408],"about_ca_topic_score_codex":0.029748848,"about_ca_topic_score_gemma":0.02310033,"teacher_disagreement_score":0.010332576,"about_ca_system_score_codex":0.0007842965,"about_ca_system_score_gemma":0.002683902,"threshold_uncertainty_score":0.9947255},"labels":[],"label_agreement":null},{"id":"W4414608766","doi":"10.3390/curroncol32100542","title":"Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic impact analysis; Health care; Clinical Practice; MEDLINE; Health economics; Resource (disambiguation); Healthcare system; Standard of care","score_opus":0.023909653244370256,"score_gpt":0.40941640313812333,"score_spread":0.38550674989375305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414608766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844372,0.0133414725,0.000041723055,0.0002944318,0.00016668568,0.00056608714,0.00037017255,0.000010426702,0.000771774],"genre_scores_gemma":[0.97438425,0.024709025,0.00011678681,0.000020082725,0.00003738736,0.00018381407,0.00015693998,0.0000068244094,0.00038492086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991886,0.00005358868,0.00028210718,0.00028992697,0.000040320436,0.0001454723],"domain_scores_gemma":[0.9994583,0.00014370473,0.0001423988,0.00015170006,0.000040331157,0.00006353974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005233034,0.0001502603,0.0004899948,0.00045867445,0.000033558328,0.000008724612,0.00003893988,0.000052324165,0.00012570895],"category_scores_gemma":[0.000004125378,0.00011355858,0.00010005902,0.00023311941,0.00004797106,0.000041466836,0.000023480157,0.000065211665,5.127321e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010837668,0.00028896678,0.95549846,0.00014527072,0.0016965765,0.000004111444,0.001692299,0.00012761797,0.000111995556,0.000013914628,0.00010562184,0.040206812],"study_design_scores_gemma":[0.0038073272,0.00032359335,0.98728657,0.0001419086,0.0031245116,3.965487e-7,0.00013547493,0.0042778836,0.00019157534,0.000037814683,0.000596015,0.0000769117],"about_ca_topic_score_codex":0.03563151,"about_ca_topic_score_gemma":0.039754294,"teacher_disagreement_score":0.0401299,"about_ca_system_score_codex":0.001496282,"about_ca_system_score_gemma":0.0005946075,"threshold_uncertainty_score":0.9777677},"labels":[],"label_agreement":null},{"id":"W4414634804","doi":"10.1109/iccv51701.2025.01422","title":"From Reflection to Perfection: Scaling Inference-Time Optimization for Text-to-Image Diffusion Models via Reflection Tuning","year":2025,"lang":"en","type":"article","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kootenay Association for Science & Technology","funders":"Centre for Perceptual and Interactive Intelligence","keywords":"Scaling; Reflection (computer programming); Scalability; Construct (python library); Diffusion; Quality (philosophy)","score_opus":0.024142518841439746,"score_gpt":0.37296886738528084,"score_spread":0.3488263485438411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414634804","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05748347,0.000020952346,0.91967666,0.0022789806,0.00042128444,0.0012054797,0.000010418386,0.00023788301,0.018664872],"genre_scores_gemma":[0.78445345,0.000016376087,0.1987971,0.0011898858,0.0003517437,0.0004342389,0.00038194345,0.00003285207,0.014342371],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989745,0.000026057569,0.00026082393,0.00040209657,0.00014715453,0.00018936352],"domain_scores_gemma":[0.99923295,0.00008089406,0.000048171394,0.0002040195,0.00030946516,0.00012448963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009047688,0.00015674884,0.0002170659,0.0003657113,0.0003525827,0.000072110175,0.00003982953,0.00010310518,0.00027424167],"category_scores_gemma":[0.00009045693,0.00013885788,0.00007530446,0.0006503731,0.0000108675185,0.00025256546,0.00003267324,0.00008300229,0.000038079404],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016258887,0.00062130525,0.00080785796,0.00012879494,0.00045529823,0.0000028358336,0.004017692,0.45746425,0.38862336,0.00066624593,0.0057857432,0.13980073],"study_design_scores_gemma":[0.0021484115,0.0005813626,0.0007978091,0.00036429326,0.0004967024,0.0000035641667,0.00031762256,0.977333,0.013549955,0.00210136,0.002096933,0.00020896488],"about_ca_topic_score_codex":0.00080866594,"about_ca_topic_score_gemma":0.0000697523,"teacher_disagreement_score":0.72697,"about_ca_system_score_codex":0.0005673698,"about_ca_system_score_gemma":0.00011538474,"threshold_uncertainty_score":0.56624603},"labels":[],"label_agreement":null},{"id":"W4414710065","doi":"10.1016/j.esmoop.2025.105690","title":"113P Evaluating molecular diagnostic tools for detecting ALK and ROS1 mutations in non-small cell lung cancer: A real-world analysis","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"ROS1; Lung; Mutation; Cell; Lung cancer","score_opus":0.027228960125445022,"score_gpt":0.4147688840025716,"score_spread":0.3875399238771266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414710065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97492844,0.00048865343,0.005183099,0.0010678503,0.00008168428,0.003287595,0.00005832486,0.00002163673,0.014882721],"genre_scores_gemma":[0.98697096,0.00008760544,0.008167382,0.0003469407,0.000020991589,0.002188023,0.0001422394,0.00001661793,0.0020592157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990488,0.000040982377,0.0002786879,0.00033020548,0.00009378661,0.00020752627],"domain_scores_gemma":[0.9985158,0.0010063427,0.00009205476,0.00021143556,0.00010976322,0.000064601576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027575434,0.00012553122,0.00033105598,0.00031642025,0.00016924454,0.00014770743,0.00010212313,0.000038038837,0.000045821966],"category_scores_gemma":[0.0005411646,0.00011817368,0.0000795889,0.0009669505,0.000017665703,0.00013255495,0.0000853898,0.00009042601,7.7173763e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013581217,0.0002932732,0.87423635,0.0005060905,0.002690085,0.00008122334,0.0037022466,0.01714008,0.0015980607,0.00043910384,0.0003149233,0.09886278],"study_design_scores_gemma":[0.008792895,0.000232941,0.88315284,0.00096232595,0.0145973675,0.0000018088456,0.0014248508,0.08125741,0.008141186,0.00049838505,0.0006049393,0.00033302995],"about_ca_topic_score_codex":0.022617271,"about_ca_topic_score_gemma":0.03246793,"teacher_disagreement_score":0.098529756,"about_ca_system_score_codex":0.0002824848,"about_ca_system_score_gemma":0.0003778602,"threshold_uncertainty_score":0.985187},"labels":[],"label_agreement":null},{"id":"W4414795299","doi":"10.3390/curroncol32100554","title":"Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Tyrosine kinase; Germline; Somatic cell; Mutation; Germline mutation; Transformation (genetics); Kinase; Tyrosine-kinase inhibitor; Cell","score_opus":0.0397401604240349,"score_gpt":0.3678151553657346,"score_spread":0.3280749949416997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414795299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96673673,0.0011620778,0.0033416157,0.0012476731,0.00021908304,0.0007431869,0.000040831885,0.000045351113,0.026463425],"genre_scores_gemma":[0.99876904,0.00018719427,0.00023739628,0.000084706175,0.000028827655,0.00008091572,0.00033946257,0.000007155563,0.00026526797],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993997,0.000028957156,0.00023464665,0.0001372149,0.000072955285,0.00012652916],"domain_scores_gemma":[0.9995691,0.000027825032,0.00008461698,0.00011411545,0.00015455266,0.000049758226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047106172,0.0001020975,0.00023547695,0.00015344289,0.000042185864,0.0000037364327,0.00002210269,0.00006362836,0.000046402783],"category_scores_gemma":[0.0000070158335,0.00007368229,0.000047635713,0.00026419671,0.000058597583,0.00004549242,0.0000059846275,0.000091652175,0.0000070615774],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00484272,0.012939278,0.06751627,0.0032749206,0.0006763974,0.0001356229,0.0069249524,0.000117151234,0.116234906,0.010788401,0.0034466903,0.7731027],"study_design_scores_gemma":[0.05976344,0.010594811,0.073198535,0.002860439,0.0058378675,0.00009829142,0.0022581534,0.001142396,0.61165977,0.0005313203,0.23152727,0.0005277064],"about_ca_topic_score_codex":0.000040388273,"about_ca_topic_score_gemma":0.000047343594,"teacher_disagreement_score":0.77257496,"about_ca_system_score_codex":0.00030573556,"about_ca_system_score_gemma":0.0003474631,"threshold_uncertainty_score":0.30046767},"labels":[],"label_agreement":null},{"id":"W4414800137","doi":"10.1093/neuonc/noaf193.011","title":"JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Placebo; Confidence interval; Glioma; Exploratory analysis; Astrocytoma; Brain tumor; Phases of clinical research","score_opus":0.032921942262096396,"score_gpt":0.39499049717856516,"score_spread":0.3620685549164688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414800137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884587,0.00039657057,0.005375811,0.0021664,0.00074393395,0.0019076185,0.00017059184,0.00008746245,0.0006929023],"genre_scores_gemma":[0.99778765,0.00005344755,0.00045824778,0.0006868002,0.00019597891,0.00039088188,0.0001316353,0.000030565086,0.00026480338],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983418,0.00025608085,0.0004152734,0.0005177976,0.00022948644,0.00023954445],"domain_scores_gemma":[0.99892735,0.00010418896,0.00025844845,0.00040592923,0.00020914956,0.00009493637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000602012,0.00026547833,0.0007488831,0.00018475401,0.00014057531,0.000015711892,0.000078289944,0.00010647659,0.00015770253],"category_scores_gemma":[0.000021452726,0.00019405554,0.000120689125,0.00031926268,0.000116489806,0.00014057869,0.00002308729,0.00016377808,0.000013175661],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0137976585,0.034919187,0.012748107,0.00008038056,0.015313608,0.0045908866,0.013837993,0.0012078983,0.8858549,0.000885158,0.002940859,0.01382337],"study_design_scores_gemma":[0.3401969,0.15587243,0.020217154,0.0003137761,0.06577363,0.0009403654,0.09783529,0.0013783459,0.28356984,0.004104402,0.028547354,0.0012505209],"about_ca_topic_score_codex":0.0012071773,"about_ca_topic_score_gemma":0.00028325772,"teacher_disagreement_score":0.6022851,"about_ca_system_score_codex":0.000632552,"about_ca_system_score_gemma":0.0012697979,"threshold_uncertainty_score":0.7913355},"labels":[],"label_agreement":null},{"id":"W4414801326","doi":"10.1016/j.ejca.2025.116037","title":"Response to Letter Re: TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma","year":2025,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Adenocarcinoma; Lung; Stage (stratigraphy); Adenocarcinoma of the lung","score_opus":0.017281973019050885,"score_gpt":0.3447939960168734,"score_spread":0.3275120229978225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414801326","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24141817,0.009343467,0.00054436346,0.734003,0.0015443785,0.0014314372,0.002323425,0.000036738977,0.009354994],"genre_scores_gemma":[0.37613922,0.001653552,0.0026522905,0.5753041,0.004060749,0.00008234882,0.0004294867,0.00027730974,0.039400965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99572957,0.0016105054,0.0012487465,0.00036453098,0.00068412925,0.00036253085],"domain_scores_gemma":[0.9970285,0.00045002208,0.0011474439,0.00047276597,0.0006979392,0.00020328845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001240853,0.00036157545,0.0007979087,0.0011027122,0.00007749592,0.00004045571,0.00032636992,0.0001206532,0.0005085273],"category_scores_gemma":[0.00072879484,0.00030197663,0.00028442717,0.0006873578,0.00010435283,0.00013315523,0.00005657295,0.0017837803,0.000024780627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027778174,0.00008425219,0.029545723,0.00028382093,0.00091693,0.008400666,0.0017759438,0.0003557656,0.0003143686,0.0000011746029,0.9519615,0.0035820245],"study_design_scores_gemma":[0.0047864933,0.0007459738,0.16971147,0.0037678406,0.0019692343,0.00007452885,0.00013638473,0.00001900489,0.00037397654,0.000006567878,0.81810975,0.00029879907],"about_ca_topic_score_codex":0.00031662223,"about_ca_topic_score_gemma":0.00004417035,"teacher_disagreement_score":0.15869893,"about_ca_system_score_codex":0.00091601355,"about_ca_system_score_gemma":0.001698885,"threshold_uncertainty_score":0.99994326},"labels":[],"label_agreement":null},{"id":"W4414804117","doi":"10.1016/j.jtho.2025.07.003","title":"A Response to the Letter to the Editor: “Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups”","year":2025,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Research and Development","keywords":"MEDLINE; Complete response; Clinical trial; Text mining","score_opus":0.012445314026864236,"score_gpt":0.39968048449831395,"score_spread":0.38723517047144973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414804117","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05174716,0.0006930015,0.00016938621,0.9352707,0.009398422,0.0013238754,0.00006688059,0.0000195218,0.001311036],"genre_scores_gemma":[0.028513987,0.00004864233,0.0018683888,0.9156153,0.028563801,0.00015254001,0.000025156989,0.000083757,0.025128417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946039,0.0021857482,0.001275699,0.00047166832,0.00077911967,0.0006838919],"domain_scores_gemma":[0.99159145,0.0060962853,0.0007674849,0.00088972633,0.00046997677,0.0001850782],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0049770437,0.00044401447,0.0011902452,0.0010746516,0.00024533234,0.000100601974,0.00085907185,0.0007328033,0.00013743936],"category_scores_gemma":[0.0030418064,0.00024488062,0.00046695877,0.000831595,0.00009190946,0.00009837991,0.00023885998,0.0036107525,0.00009661362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036004648,0.00017574494,0.00004665989,0.000058147205,0.0005690112,0.0028061375,0.0032261787,0.00022194153,0.00084286917,0.0000021787037,0.9375693,0.01847716],"study_design_scores_gemma":[0.0014272269,0.0030681638,0.0023295903,0.001432081,0.001265271,0.0008067745,0.00036932802,0.000011043924,0.00020038574,0.000030270954,0.9888465,0.00021337271],"about_ca_topic_score_codex":0.00008105758,"about_ca_topic_score_gemma":0.00015342605,"teacher_disagreement_score":0.051277168,"about_ca_system_score_codex":0.0026832293,"about_ca_system_score_gemma":0.001986067,"threshold_uncertainty_score":0.998688},"labels":[],"label_agreement":null},{"id":"W4415016947","doi":"10.1016/j.jtocrr.2025.100918","title":"Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Tyrosine kinase; Alectinib; Tyrosine-kinase inhibitor; Kinase; Drug; Clinical trial","score_opus":0.07263741346254414,"score_gpt":0.4980557138905667,"score_spread":0.42541830042802253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415016947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98546565,0.002187116,0.000050822753,0.00609084,0.00027030398,0.0011436947,0.000012926557,0.000022586666,0.0047560576],"genre_scores_gemma":[0.99270654,0.00064736255,0.00046000493,0.00015149287,0.00017055783,0.00006191403,0.000030172236,0.000010201937,0.0057617663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827814,0.00007849391,0.0006781615,0.00038250297,0.00034512978,0.00023757809],"domain_scores_gemma":[0.997903,0.0009687767,0.000098045675,0.00025621158,0.00054380175,0.0002301651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015737707,0.00009564062,0.00037383643,0.0001562027,0.00014605228,0.000022314132,0.000029223547,0.0001284592,0.000018107992],"category_scores_gemma":[0.0025802783,0.00006321204,0.0001058422,0.00028269817,0.00048864074,0.00004020961,0.00010170812,0.00023282287,8.3686524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027204892,0.0054389616,0.60950834,0.0013117507,0.0011995394,0.0013628533,0.0003472514,0.0000014678715,0.0062062135,0.0019920547,0.07869359,0.29121748],"study_design_scores_gemma":[0.019521208,0.00469947,0.7656822,0.0018464086,0.00085308217,0.00019066558,0.00024082883,0.00022613532,0.021841746,0.009332901,0.17527288,0.00029242944],"about_ca_topic_score_codex":0.00015546437,"about_ca_topic_score_gemma":0.000027940721,"teacher_disagreement_score":0.29092506,"about_ca_system_score_codex":0.000035314584,"about_ca_system_score_gemma":0.00045452744,"threshold_uncertainty_score":0.30890206},"labels":[],"label_agreement":null},{"id":"W4415295624","doi":"10.1016/j.annonc.2025.09.018","title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Foundation Medicine; Genentech; Ipsen; BeiGene; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Incyte; F. Hoffmann-La Roche; Roche; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alectinib; Crizotinib; Overall survival; Lung; Phases of clinical research; Standard of care","score_opus":0.04998713965319557,"score_gpt":0.4563106273006205,"score_spread":0.40632348764742493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415295624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97819036,0.0009322868,0.000029463632,0.0013311631,0.00034177833,0.0015611544,0.00010569706,0.000011578398,0.017496502],"genre_scores_gemma":[0.9973122,0.00039991058,0.00006754874,0.0003369825,0.000022879436,0.00016701664,0.00006506559,0.000010950596,0.0016174699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984469,0.00019696078,0.0005606976,0.0003364179,0.00016834417,0.00029071007],"domain_scores_gemma":[0.9984781,0.00038906618,0.00034224615,0.0003387162,0.0003890233,0.00006282025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022826555,0.00018516801,0.00091219303,0.0003713678,0.000065695116,0.000004286461,0.00015582025,0.00009848309,0.00009908253],"category_scores_gemma":[0.000076764765,0.0001394067,0.00025246784,0.0013054903,0.00008813187,0.000045846646,0.000065702916,0.00017238646,5.2213704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021983711,0.02168931,0.8380963,0.00030865349,0.024146508,0.00016974617,0.019458687,0.00627343,0.004069437,0.00018298846,0.0024878462,0.06113335],"study_design_scores_gemma":[0.10205259,0.013887615,0.84358716,0.00035700286,0.020399032,0.0000016103846,0.0036979998,0.0017750775,0.011988669,0.000022848071,0.001963522,0.00026689703],"about_ca_topic_score_codex":0.005199294,"about_ca_topic_score_gemma":0.009635893,"teacher_disagreement_score":0.08006889,"about_ca_system_score_codex":0.00022948267,"about_ca_system_score_gemma":0.0010983294,"threshold_uncertainty_score":0.7859812},"labels":[],"label_agreement":null},{"id":"W4415295904","doi":"10.1056/nejmoa2510308","title":"Survival with Osimertinib plus Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AstraZeneca","keywords":"Osimertinib; Chemotherapy; Adverse effect; Overall survival; Survival analysis","score_opus":0.009634318483463232,"score_gpt":0.3230936744721828,"score_spread":0.31345935598871955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415295904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9041329,0.004778093,0.0029177603,0.06033344,0.000992239,0.0005193401,0.0000023999423,0.000029420644,0.026294395],"genre_scores_gemma":[0.9928304,0.000558259,0.0009250937,0.002312167,0.00065084803,0.000003538082,0.000010442734,0.000016718423,0.0026925553],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988782,0.00004172648,0.00045204264,0.00012760214,0.0003194692,0.00018099813],"domain_scores_gemma":[0.9991672,0.0001441312,0.00018872228,0.00013773981,0.00018903715,0.00017317501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030373823,0.00014866395,0.0005476325,0.00026894629,0.000030558516,0.0000054907036,0.00007437397,0.000044132215,0.00012852477],"category_scores_gemma":[0.00010338334,0.00008396031,0.00004437735,0.0004594845,0.00006807478,0.00007502989,0.000005949159,0.00026887326,0.0000014328145],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026738534,0.000557197,0.0934961,0.00016458571,0.0015471769,0.001712252,0.00625672,0.0008565106,0.0105189765,0.00056471495,0.012595143,0.8449921],"study_design_scores_gemma":[0.67970604,0.006383686,0.12938905,0.0052377647,0.0012444716,0.0009359101,0.001794403,0.00015637123,0.0028146426,0.0007190336,0.17136474,0.00025386256],"about_ca_topic_score_codex":0.00018249323,"about_ca_topic_score_gemma":0.00013526916,"teacher_disagreement_score":0.84473825,"about_ca_system_score_codex":0.00019595116,"about_ca_system_score_gemma":0.00077083224,"threshold_uncertainty_score":0.3423802},"labels":[],"label_agreement":null},{"id":"W4415371933","doi":"10.22146/inajbcs.v57i3.supplement.24251","title":"Effectiveness and safety of camrelizumab combined with pemetrexed-carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC): a systematic review and meta-analysis","year":2025,"lang":"","type":"review","venue":"Indonesian Journal of Biomedicine and Clinical Sciences","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Pemetrexed; Adverse effect; Jadad scale; Hazard ratio; Chemotherapy; Survival rate; Immunotherapy","score_opus":0.027789815321777635,"score_gpt":0.4037758252972134,"score_spread":0.37598600997543574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415371933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011715122,0.9810372,0.00037110542,0.0011218458,0.00018608119,0.0053615496,0.000092023125,0.000003406605,0.00011163891],"genre_scores_gemma":[0.16136281,0.8378497,0.00030772982,0.00019793079,0.000039917617,0.0001560694,0.0000072925122,0.00001602591,0.00006250991],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9910968,0.0015809342,0.0051024877,0.0008860069,0.00088588666,0.00044788202],"domain_scores_gemma":[0.98810726,0.005552992,0.0047942116,0.0003925656,0.00059617567,0.0005567799],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007662433,0.00075712526,0.014522912,0.0014419939,0.00021390159,0.00004981194,0.0003766902,0.0002763096,0.000057203928],"category_scores_gemma":[0.000709543,0.00037687866,0.0012687215,0.004804142,0.0015385144,0.00019730137,0.00011334776,0.00072378636,2.009183e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071905047,0.000673262,0.02081408,0.8728898,0.08890867,0.00024387713,0.0002618287,0.000009317992,0.0000019405725,0.000008867456,0.000009020116,0.015460292],"study_design_scores_gemma":[0.0068985866,0.00520093,0.009414525,0.26566425,0.7118861,0.00010444352,0.00046698799,0.000053382315,0.000001928831,0.0000056317704,0.00002068897,0.00028252468],"about_ca_topic_score_codex":0.00033373976,"about_ca_topic_score_gemma":0.0002549094,"teacher_disagreement_score":0.62297744,"about_ca_system_score_codex":0.00015817846,"about_ca_system_score_gemma":0.0024964423,"threshold_uncertainty_score":0.99986833},"labels":[],"label_agreement":null},{"id":"W4415451466","doi":"10.1210/jendso/bvaf149.1746","title":"OR28-05 Selpercatinib in Pediatric and Adolescent Patients with RET-Altered Solid Tumors: Safety and Efficacy Results from the Phase 1/2 LIBRETTO-121 Study","year":2025,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Dosing; Adverse effect; Clinical trial; Phases of clinical research; Maximum tolerated dose; Clinical efficacy","score_opus":0.0095854848950007,"score_gpt":0.3216386794391016,"score_spread":0.3120531945441009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415451466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904456,0.00064288493,0.000012018562,0.0077345083,0.00021582734,0.00078797695,0.00007059436,0.0000071083987,0.00008346284],"genre_scores_gemma":[0.9977384,0.00053925783,0.0002658782,0.0009229917,0.00026771278,0.0000046046466,0.000011896805,0.000011829647,0.00023742803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875796,0.000104024264,0.00051899033,0.00017831822,0.00027811655,0.00016258664],"domain_scores_gemma":[0.998955,0.00026117984,0.0003139752,0.00025249462,0.00014027861,0.00007705978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002070383,0.00014751307,0.00031942333,0.000032912816,0.00016581886,0.00003507109,0.00012276445,0.000020882344,0.0000046302503],"category_scores_gemma":[0.0001792903,0.00006862931,0.00010249736,0.00028768307,0.000061451094,0.00008968564,0.00009401815,0.00039095292,2.2895853e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036743649,0.0037697076,0.9517458,0.000057926467,0.0007217885,0.000036476784,0.010766096,0.00004077558,0.000026847321,0.000004618564,0.02295086,0.0062047117],"study_design_scores_gemma":[0.04355492,0.00082119624,0.95056057,0.00033444658,0.0008568247,0.000019702016,0.0022187356,0.000047282112,0.000036711524,0.000019606005,0.0014620811,0.00006790894],"about_ca_topic_score_codex":0.00005264841,"about_ca_topic_score_gemma":0.000018406648,"teacher_disagreement_score":0.039880555,"about_ca_system_score_codex":0.00013748984,"about_ca_system_score_gemma":0.00022322472,"threshold_uncertainty_score":0.27986223},"labels":[],"label_agreement":null},{"id":"W4415451907","doi":"10.1016/j.cllc.2025.10.018","title":"Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Lung cancer; Epidermal growth factor receptor; Placebo; Biomarker; Epidermal growth factor","score_opus":0.034201739119460645,"score_gpt":0.4352266216902665,"score_spread":0.4010248825708058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415451907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95348024,0.017385129,0.0012021151,0.00446932,0.006057872,0.011345398,0.0006174467,0.000224311,0.005218141],"genre_scores_gemma":[0.9701954,0.005066997,0.0014559124,0.0038251816,0.0012056124,0.006776501,0.0003323937,0.00010542603,0.011036588],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943456,0.00053980097,0.0025483812,0.001228614,0.0004015615,0.0009360438],"domain_scores_gemma":[0.9954295,0.0023500782,0.00066786027,0.0006312433,0.0004060878,0.00051521655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009865458,0.0006261774,0.0027277938,0.0003266732,0.00027211063,0.000051119958,0.00031182193,0.00046113497,0.0013115149],"category_scores_gemma":[0.0013057056,0.0005058021,0.00095862965,0.00080453313,0.00030884932,0.00019081244,0.00015589136,0.0009464483,0.00001594407],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90206075,0.0047104987,0.02794349,0.0011232445,0.0037783433,0.00010529149,0.0018713529,0.0003116752,0.0007132998,0.00039712666,0.020531632,0.036453288],"study_design_scores_gemma":[0.9794508,0.0011834613,0.001602479,0.0014154476,0.0036602602,0.0000015051523,0.00016273142,0.0043233735,0.002080235,0.00011645205,0.005434125,0.00056910684],"about_ca_topic_score_codex":0.0018424495,"about_ca_topic_score_gemma":0.00031309755,"teacher_disagreement_score":0.07739007,"about_ca_system_score_codex":0.0013895486,"about_ca_system_score_gemma":0.0038561362,"threshold_uncertainty_score":0.99973935},"labels":[],"label_agreement":null},{"id":"W4415475011","doi":"10.1681/asn.2025w0yhj3mx","title":"REN p.L16del Mutation Is Associated with a Milder In Vitro and Clinical Phenotype Compared with Other Signal Peptide Mutations","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"In vitro; Mutation; Phenotype; Signal peptide; Peptide","score_opus":0.017527583604803554,"score_gpt":0.34148961442628806,"score_spread":0.3239620308214845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415475011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98592955,0.00012554677,0.0010308597,0.0124758165,0.000019301753,0.00022911669,0.000013199722,0.000004538405,0.00017206554],"genre_scores_gemma":[0.981346,0.000035555815,0.007553402,0.01076393,0.00003422726,0.0000057286643,0.0000042836773,0.00000967576,0.00024719877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991304,0.00011420566,0.0003719118,0.00010768865,0.00015633732,0.00011942496],"domain_scores_gemma":[0.99867517,0.00027037214,0.00067368645,0.00010248971,0.00023473678,0.000043539545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001882536,0.00009060199,0.00045687275,0.000054904216,0.000056360353,0.0000056264407,0.0000668849,0.000041103474,0.00001226294],"category_scores_gemma":[0.00002556588,0.000052202293,0.00013999168,0.0003758539,0.00064170844,0.00004449921,0.000015351265,0.00023151592,2.2558761e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01389953,0.0031099836,0.85032356,0.00009655411,0.01807365,0.00006993278,0.017229488,0.0015467093,0.030522106,0.000072044066,0.047020387,0.01803603],"study_design_scores_gemma":[0.0074982964,0.0016560657,0.9822471,0.00017772785,0.0015016727,0.00009272862,0.0032291175,0.0012393896,0.00024031065,0.00021641793,0.0018258222,0.00007533095],"about_ca_topic_score_codex":0.0002572224,"about_ca_topic_score_gemma":0.00010534927,"teacher_disagreement_score":0.13192354,"about_ca_system_score_codex":0.00010904981,"about_ca_system_score_gemma":0.00040534028,"threshold_uncertainty_score":0.23644015},"labels":[],"label_agreement":null},{"id":"W4415502772","doi":"10.1093/oncolo/oyaf287","title":"Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Discontinuation; Adverse effect; Crown (dentistry); Post-hoc analysis; Term (time)","score_opus":0.018162467902239843,"score_gpt":0.34178945367326324,"score_spread":0.3236269857710234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415502772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933541,0.00007287519,0.0000069531475,0.00043618926,0.000038288203,0.00083216536,0.0000075419157,0.0000037921857,0.0052481405],"genre_scores_gemma":[0.99785364,0.000025158404,0.000070652175,0.00012099411,0.0000030099557,0.000079058605,0.0000041379267,0.000002879043,0.0018404688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958277,0.000052990024,0.00012415125,0.00006948492,0.000109778484,0.000060821167],"domain_scores_gemma":[0.99966955,0.00008246319,0.00006197585,0.00015147286,0.000026906355,0.0000076264064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014965606,0.000045982528,0.00012587648,0.00002891383,0.000015685506,0.0000010137429,0.000055070923,0.000014457268,0.000011137698],"category_scores_gemma":[0.00001829033,0.000022988215,0.000018300485,0.0001813709,0.00008130949,0.00000901401,0.00002969767,0.00004237553,3.4012268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010979413,0.0024482459,0.98386765,0.00008244369,0.0011224733,0.00012356344,0.0060157785,0.000058056066,0.000020713927,0.0002592762,0.00030418125,0.0045996676],"study_design_scores_gemma":[0.0042425375,0.0007865699,0.989251,0.00014104403,0.00068709155,5.734593e-7,0.004595679,0.0000056741537,0.000011938637,0.0000525155,0.00020499267,0.000020378195],"about_ca_topic_score_codex":0.00013563356,"about_ca_topic_score_gemma":0.00065510866,"teacher_disagreement_score":0.005383346,"about_ca_system_score_codex":0.000060818864,"about_ca_system_score_gemma":0.000024895486,"threshold_uncertainty_score":0.09374322},"labels":[],"label_agreement":null},{"id":"W4415519187","doi":"10.1016/j.jtho.2025.09.1320","title":"EP.06.26 Resectable Lung Cancer With KRAS Mutation May Have Less Lymphatic Metastasis","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lung cancer; KRAS; Mutation; Metastasis; Lymphatic system","score_opus":0.024917900625227966,"score_gpt":0.4756826160250965,"score_spread":0.4507647153998685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9252872,0.014583023,0.006998407,0.029380962,0.0011341848,0.00081449765,0.000025065434,0.000044464938,0.02173222],"genre_scores_gemma":[0.97987145,0.00042037255,0.0067118597,0.0010450579,0.00021454348,0.000055711935,0.000009245838,0.000025225469,0.011646508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876267,0.00014221869,0.00045190795,0.00015688551,0.00026062533,0.00022567238],"domain_scores_gemma":[0.9985892,0.00016992113,0.00044174585,0.00015677403,0.00051955925,0.00012281121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034935505,0.00014158181,0.0005393615,0.0003550009,0.00011497676,0.000024728255,0.00009258469,0.00009849893,0.00016836813],"category_scores_gemma":[0.000079888414,0.00009447485,0.00011155227,0.00033532784,0.000070468246,0.00018046853,0.000020419102,0.00019636628,0.000004829903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009103347,0.002374295,0.15909266,0.0019792276,0.012346561,0.0046884203,0.0057523553,0.0038614993,0.0021162643,0.0007271063,0.05504669,0.7429116],"study_design_scores_gemma":[0.04471359,0.017248778,0.2316785,0.010357054,0.08689322,0.013409665,0.038315084,0.00644144,0.0497508,0.0037718972,0.4958821,0.0015378819],"about_ca_topic_score_codex":0.00022848134,"about_ca_topic_score_gemma":0.00041717765,"teacher_disagreement_score":0.7413737,"about_ca_system_score_codex":0.0013861213,"about_ca_system_score_gemma":0.0023545858,"threshold_uncertainty_score":0.4176934},"labels":[],"label_agreement":null},{"id":"W4415519239","doi":"10.1016/j.jtho.2025.09.079","title":"OA14.03 Functional Characterization of Osimertinib-Induced Drug Tolerant Persisters in Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Adenocarcinoma; Lung; Epidermal growth factor receptor; Drug resistance; Tyrosine kinase; Drug; Tyrosine-kinase inhibitor; Population; Gefitinib","score_opus":0.02178682906306032,"score_gpt":0.4020771405004481,"score_spread":0.3802903114373878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925763,0.00042947673,0.00021745315,0.007045395,0.00094091083,0.00020149731,0.000005851205,0.0000049295713,0.001896831],"genre_scores_gemma":[0.997984,0.0000346259,0.00033022492,0.00061196,0.00012650713,0.0000075512075,0.000021075646,0.000007414323,0.0008766554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893963,0.000095420786,0.00057105726,0.000107942156,0.00016083271,0.00012509528],"domain_scores_gemma":[0.99909776,0.00009097056,0.0004063942,0.000098025164,0.00024412975,0.00006270062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026236248,0.000090681904,0.0004107767,0.00040580556,0.0000347858,0.000005601969,0.000059267804,0.00008552786,0.00011188081],"category_scores_gemma":[0.00006273303,0.000072773706,0.0001319358,0.0002706319,0.00003344709,0.000109526634,0.000016885637,0.00020704311,0.000002828031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076387455,0.0024351436,0.50902885,0.00066349865,0.0016525912,0.000518507,0.006327286,0.00012568441,0.34198084,0.0002702147,0.0025078114,0.1268508],"study_design_scores_gemma":[0.002365118,0.0007068784,0.9809892,0.00043480098,0.00094079063,0.00021226658,0.0009397355,0.00030296238,0.009883502,0.00003925542,0.0031161525,0.00006932949],"about_ca_topic_score_codex":0.00002015042,"about_ca_topic_score_gemma":0.000010484364,"teacher_disagreement_score":0.47196034,"about_ca_system_score_codex":0.000541935,"about_ca_system_score_gemma":0.00088346074,"threshold_uncertainty_score":0.29676256},"labels":[],"label_agreement":null},{"id":"W4415519671","doi":"10.1016/j.jtho.2025.09.466","title":"P1.17.81 Unveiling the Natural History of Lung Cancer by Sex, Histology, and Nodule Type Using Mathematical Modeling","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Natural history; Lung cancer; Nodule (geology); Solitary pulmonary nodule; Lung","score_opus":0.027339318885115416,"score_gpt":0.4543247194899735,"score_spread":0.42698540060485807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.914356,0.06977553,0.0036334395,0.0048273923,0.0015946246,0.00024173978,0.000004449562,0.000009130682,0.0055577066],"genre_scores_gemma":[0.9873053,0.00029516342,0.00409766,0.0006344058,0.00011648219,0.0000032244366,0.0000018238119,0.0000103017965,0.0075356616],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991985,0.00007078571,0.00039948756,0.00009445466,0.00011170233,0.00012505127],"domain_scores_gemma":[0.999225,0.00014075602,0.0002724193,0.00010333139,0.00020868608,0.000049780516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029160862,0.00008807488,0.00041126835,0.000113618844,0.00005446824,0.000003392495,0.00007032331,0.00009596259,0.00009255763],"category_scores_gemma":[0.00008830002,0.0000555661,0.00007153827,0.000089835354,0.00013247029,0.000056052293,0.000030476429,0.00030028308,3.5931967e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011728013,0.0043287515,0.028454626,0.005270405,0.0140970005,0.001097305,0.03341799,0.020295253,0.1253249,0.0034014652,0.30084783,0.45173648],"study_design_scores_gemma":[0.005515024,0.0021459972,0.00070408505,0.0024050174,0.014794316,0.0032458776,0.0033002864,0.78788155,0.0019208663,0.0024985976,0.17515977,0.00042860452],"about_ca_topic_score_codex":0.000052660922,"about_ca_topic_score_gemma":0.000010016126,"teacher_disagreement_score":0.7675863,"about_ca_system_score_codex":0.0015609945,"about_ca_system_score_gemma":0.0013633744,"threshold_uncertainty_score":0.40819466},"labels":[],"label_agreement":null},{"id":"W4415519672","doi":"10.1016/j.jtho.2025.09.1188","title":"EP.01.04 Features, Demographics and Treatment Profiles of Primary Lung Cancer Cases in Nigeria: The Largest Single Centre Report in West Africa","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Lung cancer; Incidence (geometry); Demographics; Cancer; Cancer registry; Cancer incidence","score_opus":0.019567081256498742,"score_gpt":0.4042042607077438,"score_spread":0.38463717945124504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95619136,0.02392516,0.000007985443,0.015691927,0.0003729412,0.00049901486,0.000024034598,0.0000047318417,0.0032828392],"genre_scores_gemma":[0.99539804,0.0020809933,0.0006845627,0.00018506893,0.00008829213,0.00002814164,0.000011619733,0.000008837411,0.001514432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891615,0.00013048349,0.0005182736,0.0001336197,0.00012970093,0.00017175051],"domain_scores_gemma":[0.99899524,0.00027924322,0.00040257422,0.00013645957,0.00012915155,0.00005730388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028260518,0.000119200406,0.0005139515,0.00029548476,0.000046627083,0.000008619518,0.000054831104,0.00011770384,0.000020832238],"category_scores_gemma":[0.00011721888,0.00007029067,0.00008368314,0.00036713967,0.00009901779,0.00005880869,0.000024693203,0.00021654867,9.056055e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012501918,0.0018821891,0.9270807,0.00019710859,0.0005583642,0.0057483856,0.0021902414,0.00004422585,0.000981701,0.000052065625,0.0025503377,0.05746448],"study_design_scores_gemma":[0.0031334888,0.0015890746,0.93956786,0.0011441817,0.0014716248,0.0027550848,0.002307559,0.000014236346,0.0009863443,0.000103838735,0.046816815,0.000109892026],"about_ca_topic_score_codex":0.00033142616,"about_ca_topic_score_gemma":0.0064629107,"teacher_disagreement_score":0.057354588,"about_ca_system_score_codex":0.0010058957,"about_ca_system_score_gemma":0.001283692,"threshold_uncertainty_score":0.3606456},"labels":[],"label_agreement":null},{"id":"W4415519733","doi":"10.1016/j.jtho.2025.09.1459","title":"EP.08.22 Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Cohort; Hazard ratio; Stage (stratigraphy); Osimertinib; Overall survival; Cohort study","score_opus":0.02482755089397919,"score_gpt":0.45152699523988427,"score_spread":0.42669944434590507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938704,0.00016976934,0.0003727625,0.0016519021,0.0003879481,0.00040098687,0.000023446464,0.000008951657,0.0031138533],"genre_scores_gemma":[0.99416375,0.00014302251,0.0010461432,0.00048086554,0.00006765799,0.000010447638,0.000013268374,0.000014024202,0.0040608025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985728,0.00014481833,0.00066252565,0.00019569989,0.00019269595,0.00023142218],"domain_scores_gemma":[0.99871635,0.00042206133,0.00039301167,0.00016329995,0.00015174446,0.00015351926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000293793,0.00016588267,0.0007369691,0.0002929579,0.00006951355,0.00002120899,0.000070275135,0.000120718956,0.00007236491],"category_scores_gemma":[0.00010381093,0.00010041707,0.00012425239,0.00015112403,0.00006871169,0.00010785095,0.000037476868,0.00025849874,0.0000022129693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019677002,0.0016947709,0.9522445,0.00004690243,0.00093083305,0.00029165347,0.0007805146,0.000017067023,0.0000024608153,0.000031103842,0.00008650555,0.041905988],"study_design_scores_gemma":[0.012548679,0.0069995695,0.975249,0.00035215498,0.001129617,0.00002602172,0.0015566727,0.000015169736,0.000038351904,0.000056420264,0.0019405746,0.000087788816],"about_ca_topic_score_codex":0.00017910103,"about_ca_topic_score_gemma":0.0010990263,"teacher_disagreement_score":0.0418182,"about_ca_system_score_codex":0.00086328696,"about_ca_system_score_gemma":0.0010629344,"threshold_uncertainty_score":0.40948895},"labels":[],"label_agreement":null},{"id":"W4415519791","doi":"10.1016/j.jtho.2025.09.032","title":"OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Osimertinib; Chemotherapy; Pathological; Disease; Stage (stratigraphy); Neoadjuvant therapy","score_opus":0.01204574346857208,"score_gpt":0.4340913452839231,"score_spread":0.42204560181535106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492192,0.0075528235,0.0014137704,0.03537227,0.0004221072,0.00033375964,0.000029865836,0.000016733542,0.005639453],"genre_scores_gemma":[0.9909682,0.00036820996,0.0034980362,0.003088552,0.00017823587,0.000018507799,0.000043452263,0.00001865123,0.0018181234],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981725,0.00021767606,0.00074978214,0.00026130202,0.00030759015,0.00029113755],"domain_scores_gemma":[0.99856293,0.00020718163,0.000396123,0.00033335725,0.00025208376,0.00024833396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038531073,0.00018087517,0.0008412478,0.0008211449,0.00006422585,0.000024727178,0.00017421995,0.00014618404,0.00038516268],"category_scores_gemma":[0.00020301018,0.00014107779,0.00033285542,0.0011062757,0.00007118503,0.00011360723,0.000038602062,0.0003973881,0.000007916099],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037575796,0.006083879,0.293057,0.00018344366,0.021527968,0.014593881,0.0030772146,0.003781289,0.026172196,0.00045738535,0.025663855,0.5678261],"study_design_scores_gemma":[0.01696862,0.0029446052,0.8319701,0.0010739934,0.02637309,0.00010394401,0.0018337547,0.0015361226,0.014773601,0.0060162684,0.09589239,0.000513523],"about_ca_topic_score_codex":0.00043583583,"about_ca_topic_score_gemma":0.00020119877,"teacher_disagreement_score":0.5673126,"about_ca_system_score_codex":0.00071743364,"about_ca_system_score_gemma":0.001684116,"threshold_uncertainty_score":0.57529855},"labels":[],"label_agreement":null},{"id":"W4415520086","doi":"10.1016/j.jtho.2025.09.1000","title":"P3.16.07 Canadian Action Plan for Lung Cancer - Patient Perspective","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Lung cancer; Action (physics); Plan (archaeology); Action plan; MEDLINE","score_opus":0.02601026845966635,"score_gpt":0.4957272293236868,"score_spread":0.4697169608640204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7666584,0.009942938,0.004238382,0.1259585,0.008445738,0.001958082,0.00019833275,0.000028421031,0.08257118],"genre_scores_gemma":[0.9931064,0.00016930613,0.0015448357,0.0020436044,0.00036862263,0.00005586352,0.000009420779,0.00000951928,0.002692383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937576,0.000034486606,0.00023793854,0.00009667459,0.000085542015,0.00016957236],"domain_scores_gemma":[0.99900216,0.00007200758,0.00020030014,0.0000712776,0.00049125333,0.00016297725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010546726,0.00007750047,0.00025954974,0.0002879009,0.00010789594,0.000009025765,0.000043146167,0.00009501177,0.00016177577],"category_scores_gemma":[0.00007073163,0.000059197093,0.00010974444,0.00011963222,0.0000254588,0.000067277906,0.000006166715,0.00016748522,0.0000015687018],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053805215,0.0007441994,0.018197622,0.0002821379,0.00361335,0.00033068805,0.0066647646,0.00033802536,0.00092831836,0.0020102554,0.21863581,0.7428743],"study_design_scores_gemma":[0.00396547,0.0054761395,0.026984936,0.00065377454,0.00541424,0.00056015793,0.017389424,0.0005648206,0.0021848062,0.0017631612,0.93483335,0.00020971682],"about_ca_topic_score_codex":0.016204912,"about_ca_topic_score_gemma":0.050620247,"teacher_disagreement_score":0.7426646,"about_ca_system_score_codex":0.006381906,"about_ca_system_score_gemma":0.0039076377,"threshold_uncertainty_score":0.9974324},"labels":[],"label_agreement":null},{"id":"W4415520210","doi":"10.1016/j.jtho.2025.09.927","title":"P3.12.65 First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; MEDLINE; Disease; Neoplasm staging","score_opus":0.03006908009901295,"score_gpt":0.49352239960862987,"score_spread":0.46345331950961693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9471732,0.0029257615,0.0006649531,0.034584682,0.0026342906,0.00070466724,0.000027290685,0.000045874676,0.0112393005],"genre_scores_gemma":[0.983191,0.00084096607,0.0048375023,0.00310779,0.00017904473,0.000023642146,0.00004961086,0.000030998846,0.0077394494],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99702424,0.000245635,0.0017598972,0.00029661818,0.00029417462,0.00037943033],"domain_scores_gemma":[0.9971673,0.0010682517,0.0008914231,0.00028353525,0.0003538028,0.00023572032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008813826,0.00025811308,0.001279957,0.00041330757,0.00013168517,0.000025563215,0.00020422363,0.00031623343,0.00021692186],"category_scores_gemma":[0.00113212,0.00018965846,0.00035319795,0.00055592484,0.00012399908,0.0001682795,0.000056539153,0.0007899331,0.000027782711],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008998849,0.0028298306,0.3485351,0.00010257212,0.0014699035,0.0008837566,0.00037011912,0.00017813306,0.00084761134,0.000029440707,0.027717974,0.6080367],"study_design_scores_gemma":[0.029876703,0.010825004,0.5979483,0.0011546215,0.0035398917,0.00043833183,0.001087985,0.00057723676,0.0019748649,0.0009816671,0.35109282,0.0005025809],"about_ca_topic_score_codex":0.000073626325,"about_ca_topic_score_gemma":0.00047792934,"teacher_disagreement_score":0.6075341,"about_ca_system_score_codex":0.00077344227,"about_ca_system_score_gemma":0.0011334877,"threshold_uncertainty_score":0.7734048},"labels":[],"label_agreement":null},{"id":"W4415520288","doi":"10.1016/j.jtho.2025.09.1118","title":"PT1.03.06 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Acquired resistance; Osimertinib; Tyrosine-kinase inhibitor; Tyrosine kinase; Kinase","score_opus":0.016036992200530342,"score_gpt":0.40690262097484164,"score_spread":0.3908656287743113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86622995,0.0020616737,0.06498224,0.056498203,0.0014284456,0.0009405448,0.00028949467,0.00006127927,0.007508156],"genre_scores_gemma":[0.96755266,0.00011160933,0.02433314,0.0019800093,0.00013439314,0.000015220071,0.00011135363,0.000019137167,0.0057425],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977711,0.00016256282,0.001172814,0.00027800532,0.00034507117,0.0002704667],"domain_scores_gemma":[0.9976197,0.00026801368,0.00086785114,0.00039848132,0.000626556,0.0002194208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042740945,0.00020744062,0.0012807901,0.0007554634,0.00009577432,0.000015859952,0.00024568956,0.00020152067,0.00044241213],"category_scores_gemma":[0.00025095633,0.00016251109,0.00038424323,0.0013934774,0.000063940664,0.0000959827,0.00007704179,0.00016574681,0.00001985977],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18154654,0.013501353,0.0677263,0.0013591362,0.12767752,0.0062160953,0.013562548,0.012282688,0.16716811,0.004717683,0.20805681,0.19618522],"study_design_scores_gemma":[0.026382726,0.011586629,0.25400087,0.0025851193,0.11353005,0.00019106673,0.0035171479,0.0028213968,0.17541666,0.016044173,0.39281604,0.0011081106],"about_ca_topic_score_codex":0.00015714661,"about_ca_topic_score_gemma":0.00080459646,"teacher_disagreement_score":0.1950771,"about_ca_system_score_codex":0.00076008606,"about_ca_system_score_gemma":0.00096229557,"threshold_uncertainty_score":0.662701},"labels":[],"label_agreement":null},{"id":"W4415520426","doi":"10.1016/j.jtho.2025.09.015","title":"PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Overall survival; Chemotherapy; Progression-free survival; Survival rate","score_opus":0.033442603702206385,"score_gpt":0.4544711842950624,"score_spread":0.421028580592856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9342776,0.004225814,0.0012482689,0.042726796,0.0029047607,0.0007013897,0.000012156834,0.000039218725,0.013864014],"genre_scores_gemma":[0.9832964,0.0023954066,0.0051669343,0.002889113,0.0005628765,0.00003975516,0.000021790049,0.00004558887,0.0055821515],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979452,0.00013948181,0.00095750997,0.00027232172,0.00029756827,0.00038793526],"domain_scores_gemma":[0.99827987,0.00044134047,0.00056187925,0.0002727813,0.00028088174,0.00016323211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004655164,0.00026712962,0.0009019919,0.0004312029,0.00009488698,0.000019665316,0.00020439002,0.00022936917,0.00027668377],"category_scores_gemma":[0.00016004166,0.00021384985,0.00028076392,0.000421568,0.00008881345,0.00017977107,0.000027576109,0.00054223504,0.000014768479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086054765,0.0035891572,0.017380876,0.00016890599,0.0021313925,0.00077595323,0.0020846666,0.0014790619,0.005437076,0.0003039041,0.008335848,0.87225837],"study_design_scores_gemma":[0.09086288,0.013874043,0.1223162,0.0013541674,0.0016897827,0.0003025165,0.0010396258,0.00093817763,0.008895185,0.0016600873,0.75644654,0.000620792],"about_ca_topic_score_codex":0.000053230946,"about_ca_topic_score_gemma":0.00015511135,"teacher_disagreement_score":0.8716376,"about_ca_system_score_codex":0.0009727272,"about_ca_system_score_gemma":0.001123316,"threshold_uncertainty_score":0.8720544},"labels":[],"label_agreement":null},{"id":"W4415520472","doi":"10.1016/j.jtho.2025.09.355","title":"P1.11.55 Identifying Patients Cured From Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Anti-PD-(L)1 Therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Lung cancer; Cancer; Respiratory disease; Chemotherapy; Cell","score_opus":0.022508638690742617,"score_gpt":0.4370143230663238,"score_spread":0.4145056843755812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675823,0.0055438904,0.0018580488,0.0022501347,0.0012752429,0.0005477422,0.000037045542,0.0000137980305,0.0017158587],"genre_scores_gemma":[0.9876168,0.0010655968,0.008728981,0.0010196602,0.00020125485,0.000036069654,0.000028273966,0.000028113822,0.0012752905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857277,0.00012074419,0.00056472054,0.00021382424,0.00026623477,0.00026168575],"domain_scores_gemma":[0.9984017,0.00015635288,0.00064324745,0.00019952476,0.00045214704,0.00014705064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016162016,0.00020394292,0.0007003745,0.00029184335,0.000114950424,0.000034428747,0.00015509035,0.00009495204,0.00021062848],"category_scores_gemma":[0.000024649578,0.00013479716,0.00016540963,0.00030839175,0.000047837053,0.00015885851,0.000029066907,0.00031497626,0.00000592923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041645532,0.0040868795,0.7950952,0.00054229045,0.005902944,0.0010802853,0.0076010185,0.0003482952,0.007597581,0.000023196255,0.01744446,0.15611328],"study_design_scores_gemma":[0.029379098,0.0033791363,0.8618703,0.0029477212,0.014943526,0.00014068867,0.0039907577,0.0005845647,0.022639344,0.00048285743,0.05904566,0.000596376],"about_ca_topic_score_codex":0.000351783,"about_ca_topic_score_gemma":0.00018964957,"teacher_disagreement_score":0.15551691,"about_ca_system_score_codex":0.0006183385,"about_ca_system_score_gemma":0.0014419138,"threshold_uncertainty_score":0.54968685},"labels":[],"label_agreement":null},{"id":"W4415520663","doi":"10.1016/j.jtho.2025.09.924","title":"P3.12.62 First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Cohort; Chemotherapy; Cohort study; MEDLINE","score_opus":0.01191241342935816,"score_gpt":0.4269445142671295,"score_spread":0.4150321008377713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.815547,0.0039067646,0.029646521,0.0756457,0.0062306197,0.005256948,0.00015787904,0.00015413787,0.06345442],"genre_scores_gemma":[0.9691461,0.0005916236,0.018109286,0.004053972,0.00061336055,0.00012533253,0.000119196746,0.000058267073,0.00718287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980417,0.000057615744,0.00096998113,0.0002733773,0.00027433582,0.0003830037],"domain_scores_gemma":[0.99782985,0.0003413271,0.00075703766,0.00026895275,0.00059790234,0.00020493237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048364073,0.00026729165,0.0009769456,0.00036286472,0.00018556682,0.000023596747,0.0001773825,0.00025274965,0.00016958486],"category_scores_gemma":[0.00023890274,0.00020655761,0.00028346968,0.00042420675,0.000095841904,0.0001573307,0.000022455119,0.00037774706,0.000007572486],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023909463,0.002220759,0.025042007,0.000492068,0.0047347755,0.000405187,0.0014089273,0.00038085965,0.008894159,0.0001132183,0.028587807,0.9038108],"study_design_scores_gemma":[0.039387304,0.014750937,0.11073937,0.0018734284,0.007105077,0.0010361341,0.0015897236,0.0024957592,0.017082093,0.0013391653,0.8019657,0.0006353074],"about_ca_topic_score_codex":0.00002010919,"about_ca_topic_score_gemma":0.00010344721,"teacher_disagreement_score":0.9031755,"about_ca_system_score_codex":0.0009914336,"about_ca_system_score_gemma":0.0013035217,"threshold_uncertainty_score":0.8423175},"labels":[],"label_agreement":null},{"id":"W4415703654","doi":"10.1158/2159-8290.cd-25-0581","title":"A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked","year":2025,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Cancer Institute; Moffitt Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Transcriptome; Adenocarcinoma; Lung; Stage (stratigraphy); Signature (topology); Lung cancer","score_opus":0.008720699792768776,"score_gpt":0.3163689174485795,"score_spread":0.3076482176558107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415703654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98300254,0.00797082,0.0006808176,0.0019853262,0.00054236565,0.0025399455,0.0003129893,0.000026568994,0.0029386189],"genre_scores_gemma":[0.9772773,0.000059118676,0.00006597393,0.0019072223,0.000088278575,0.0010300061,0.00023200964,0.00001987283,0.01932024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915063,0.000011714028,0.00018205454,0.0002975622,0.00012066649,0.00023736904],"domain_scores_gemma":[0.9995629,0.000060077946,0.000046929563,0.00018530976,0.00009446683,0.000050283532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028140477,0.00014309854,0.00024313742,0.0001249858,0.00005398545,0.0000337834,0.000054429565,0.00008526631,0.00003988951],"category_scores_gemma":[0.00005210289,0.00011605115,0.00009144195,0.00019703874,0.000034011624,0.00026713355,0.000025152476,0.000114187744,0.000001075267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037261393,0.00021172735,0.9735002,0.00028772923,0.00021789267,0.0000064010787,0.000265011,0.00007466066,0.00001949094,0.0003549228,0.02173051,0.0029588477],"study_design_scores_gemma":[0.0059502693,0.00014196502,0.9883806,0.0007612513,0.0005049632,2.6297639e-7,0.00011194427,0.00033441163,0.0003046786,0.00016745484,0.003223669,0.00011850369],"about_ca_topic_score_codex":0.0002123929,"about_ca_topic_score_gemma":0.00016312354,"teacher_disagreement_score":0.018506842,"about_ca_system_score_codex":0.0005806783,"about_ca_system_score_gemma":0.0005282118,"threshold_uncertainty_score":0.47324285},"labels":[],"label_agreement":null},{"id":"W4415711778","doi":"10.1016/j.jtocrr.2025.100929","title":"Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"Gilead UK and Ireland Corporate Contributions; Gilead Sciences","keywords":"Docetaxel; Quality of life (healthcare); Randomized controlled trial; Phases of clinical research; Chemotherapy; Exploratory analysis","score_opus":0.15520455605900418,"score_gpt":0.5380789188335684,"score_spread":0.3828743627745642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415711778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022144,0.0014202795,0.000041853014,0.0022730317,0.00025285844,0.0030940175,0.0000087311055,0.000014313787,0.002673481],"genre_scores_gemma":[0.99837893,0.00035907762,0.00011997304,0.000112887225,0.000051169587,0.0003033233,0.00001907922,0.000008870346,0.0006466811],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99565345,0.0010657262,0.0017403937,0.00044690803,0.0008252267,0.00026830652],"domain_scores_gemma":[0.9937918,0.0046169,0.0004328411,0.00047736938,0.00043591656,0.00024516112],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0076674917,0.00014028237,0.0010587139,0.00017096149,0.00013310423,0.000036941223,0.000041484098,0.00008249737,0.000029981837],"category_scores_gemma":[0.013319556,0.000067622794,0.00016250672,0.00047027686,0.0012258254,0.00006126732,0.00007752921,0.00044355667,3.5587865e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92956626,0.0024433,0.029273435,0.00022092175,0.0023177364,0.00054807233,0.0004456147,0.0000019033266,0.000028803624,0.00067086995,0.00041770446,0.034065396],"study_design_scores_gemma":[0.96903265,0.0038233544,0.022087654,0.00031905493,0.0008998064,0.00003376646,0.0007055301,0.00009313401,0.000047209916,0.0011325337,0.0017134016,0.00011190898],"about_ca_topic_score_codex":0.0018167109,"about_ca_topic_score_gemma":0.00034026595,"teacher_disagreement_score":0.039466403,"about_ca_system_score_codex":0.00006374375,"about_ca_system_score_gemma":0.0015233306,"threshold_uncertainty_score":0.99499166},"labels":[],"label_agreement":null},{"id":"W4415731870","doi":"10.21037/jtd-2025-761","title":"Strategies for improving biomarker testing rates in non-small cell lung cancer in north America: a scoping review","year":2025,"lang":"en","type":"review","venue":"Journal of Thoracic Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biomarker; Multidisciplinary approach; Lung cancer; MEDLINE; Cancer; Multidisciplinary team","score_opus":0.04784484187489856,"score_gpt":0.4556918683824409,"score_spread":0.40784702650754234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415731870","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013335783,0.99524325,0.00031042026,0.00011575206,0.00025142162,0.003588513,0.00014505924,0.000008075956,0.00020417817],"genre_scores_gemma":[0.00018009184,0.9970083,0.001536311,0.00018237109,0.00014352567,0.00068902026,0.000059869693,0.000039723596,0.00016075678],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9978096,0.00011214991,0.0012945855,0.0002882005,0.00018994228,0.00030554552],"domain_scores_gemma":[0.99758404,0.00044756287,0.0012405614,0.0002158635,0.00027990178,0.00023205818],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031359398,0.000355657,0.0019092396,0.0005511573,0.000050066865,0.000064052096,0.00016961858,0.0000675936,0.00002324926],"category_scores_gemma":[0.00045036865,0.00025411457,0.00051717355,0.0010929417,0.00002624137,0.00019597924,0.000044578588,0.00032690202,9.850012e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042746993,0.00012629981,0.0015132554,0.48086697,0.0001059476,0.00022350425,0.000028335731,0.000028749393,2.85093e-7,2.008104e-7,0.00009514727,0.51696855],"study_design_scores_gemma":[0.0006123775,0.00007851816,0.00067509274,0.98408234,0.010090921,0.000010159182,0.00009429384,0.00018671523,2.068504e-7,0.0000045958877,0.003926919,0.00023784071],"about_ca_topic_score_codex":0.00008842179,"about_ca_topic_score_gemma":0.00014208343,"teacher_disagreement_score":0.5167307,"about_ca_system_score_codex":0.00059020723,"about_ca_system_score_gemma":0.010378874,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W4415733338","doi":"10.1177/17588359251387393","title":"Antibody–drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Docetaxel; Randomized controlled trial; Overall survival; Lung; Lung cancer; Subgroup analysis; Clinical trial","score_opus":0.055942934672215214,"score_gpt":0.5015752000993928,"score_spread":0.4456322654271776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415733338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014914095,0.949631,0.0013006815,0.0007457958,0.00027372254,0.047058184,0.00026501121,0.000032593784,0.00069155294],"genre_scores_gemma":[0.000026847409,0.9546282,0.0006079012,0.0010432989,0.00004115477,0.041808866,0.0005624666,0.000046520327,0.0012347422],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9869496,0.004784275,0.006392715,0.0008219756,0.0005500673,0.00050135714],"domain_scores_gemma":[0.9489049,0.044937633,0.0048694876,0.00061767147,0.0004151051,0.000255241],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009872596,0.0009148201,0.08222096,0.00085876806,0.00006938723,0.000013307501,0.00036612415,0.00048762903,0.0004755913],"category_scores_gemma":[0.0072746384,0.00045199096,0.008807047,0.0012479352,0.0003996525,0.00007546073,0.000058664733,0.00045169747,9.554967e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013143885,0.0003328979,8.829272e-7,0.57395494,0.38005397,0.000020026719,0.0001107643,0.0000053262243,1.8149294e-7,0.00009925977,0.000008394162,0.032269496],"study_design_scores_gemma":[0.17614855,0.00028337288,3.823416e-8,0.07705599,0.7319925,0.0000063705174,0.00004001245,0.00018993419,5.3859077e-7,0.000030395784,0.014025902,0.00022642942],"about_ca_topic_score_codex":0.000055488148,"about_ca_topic_score_gemma":0.00013812628,"teacher_disagreement_score":0.49689892,"about_ca_system_score_codex":0.00047992542,"about_ca_system_score_gemma":0.002984886,"threshold_uncertainty_score":0.9997932},"labels":[],"label_agreement":null},{"id":"W4415768344","doi":"10.1016/j.jtho.2025.10.006","title":"Corrigendum to “The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423–1440]”","year":2025,"lang":"en","type":"erratum","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lung cancer; Overall survival; Lung cancer staging; Ninth; Association (psychology); Neoplasm staging; Staging system","score_opus":0.062171978940883284,"score_gpt":0.5373235145508077,"score_spread":0.47515153560992446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415768344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8415262,0.003855564,0.0031498477,0.030364448,0.098992504,0.010118639,0.004565501,0.000012633995,0.0074146274],"genre_scores_gemma":[0.99103904,0.0004788264,0.0002293271,0.0004244483,0.0028791123,0.00016114813,0.00024826603,0.00004358702,0.004496271],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9950096,0.0013943884,0.002009246,0.00023140294,0.0010569972,0.0002983902],"domain_scores_gemma":[0.98997474,0.0014455607,0.004935709,0.0004114896,0.003173004,0.000059524726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033589648,0.0003036337,0.0013084149,0.0009747197,0.00014739018,0.000033991266,0.0007595919,0.0002561038,0.00008667301],"category_scores_gemma":[0.0020216245,0.00015305358,0.00053146126,0.0007518531,0.00010257694,0.00018970123,0.00016179317,0.0015626258,2.6958628e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016522564,0.009074511,0.06575578,0.0006157588,0.014776902,0.00018913054,0.018007204,0.046106406,0.002937343,0.00006731145,0.80160826,0.0243388],"study_design_scores_gemma":[0.038042597,0.0658179,0.52936244,0.027311748,0.049098544,0.0004047383,0.067633554,0.05015266,0.009041101,0.00077448145,0.16051972,0.0018404986],"about_ca_topic_score_codex":0.0034464072,"about_ca_topic_score_gemma":0.006796782,"teacher_disagreement_score":0.64108855,"about_ca_system_score_codex":0.0043204604,"about_ca_system_score_gemma":0.0072688274,"threshold_uncertainty_score":0.99950176},"labels":[],"label_agreement":null},{"id":"W4415817417","doi":"10.1007/s11523-025-01182-0","title":"Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Grifols; Casen Recordati; Japanese Society of Medical Oncology; Pfizer Japan; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; Seagen; Lunit; Johnson and Johnson; Les Laboratories Pierre Fabre; Verily Life Sciences; BeiGene; Mirati Therapeutics; Ipsen; Five Prime Therapeutics; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Puma Biotechnology; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Pfizer; Innovent Biologics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Amgen; Mesothelioma Applied Research Foundation","keywords":"Lung cancer; Exon; Phases of clinical research; Epidermal growth factor receptor; Cell; Cancer","score_opus":0.013197917408025058,"score_gpt":0.38700755247232627,"score_spread":0.3738096350643012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415817417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929682,0.0022589117,0.00005383039,0.00053388113,0.0000794918,0.002014905,0.00016273452,0.0000173053,0.0019107457],"genre_scores_gemma":[0.9973316,0.00034677892,0.00018938759,0.0007062371,0.000040762778,0.00038873844,0.000044719534,0.000020532238,0.0009312399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907935,0.000075987744,0.00027696847,0.0002833158,0.00007425441,0.00021009905],"domain_scores_gemma":[0.99934393,0.0001527449,0.00012749172,0.00026008495,0.00005760997,0.00005815984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065495515,0.0001995221,0.000460088,0.000100963305,0.000076158554,0.000009723445,0.000059054113,0.00008640447,0.00031522554],"category_scores_gemma":[0.0000061332316,0.00010843734,0.000065169785,0.00023328495,0.00008844287,0.00003627344,0.000016451866,0.000108296845,0.0000013511919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063977833,0.006063522,0.9454127,0.000023107637,0.0019371483,0.00005918042,0.018435562,0.00013946477,0.012394455,0.000007494974,0.0006873462,0.008442235],"study_design_scores_gemma":[0.14063759,0.013515141,0.8271316,0.00023544456,0.0019208987,0.0000064421815,0.0043309308,0.0009089683,0.007311663,0.00007797311,0.003694794,0.00022849799],"about_ca_topic_score_codex":0.031915493,"about_ca_topic_score_gemma":0.011428546,"teacher_disagreement_score":0.13423981,"about_ca_system_score_codex":0.0011989038,"about_ca_system_score_gemma":0.00084057375,"threshold_uncertainty_score":0.97453105},"labels":[],"label_agreement":null},{"id":"W4415934922","doi":"10.58931/cot.2025.2342","title":"Original Research: Biomarker Testing in a Canadian Centre for Patients with Non‑small Cell Lung Cancer: Assessing Residual Risks","year":2025,"lang":"","type":"article","venue":"Canadian oncology today.","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Manitoba Health; Lunenfeld-Tanenbaum Research Institute; Occupational Cancer Research Centre; Public Health Ontario; University of Toronto; Toronto Public Health","funders":"","keywords":"ROS1; Erlotinib; Guideline; Biomarker; Lung cancer; Crizotinib; Epidermal growth factor receptor; Genetic testing; Cancer","score_opus":0.07447973931669052,"score_gpt":0.4308980292734839,"score_spread":0.35641828995679337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415934922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85087276,0.004305928,0.00003067566,0.023313476,0.0022807524,0.007182126,0.0019489679,0.000029608233,0.110035725],"genre_scores_gemma":[0.98466796,0.0001094712,0.00212483,0.0017672487,0.00033198416,0.0008010332,0.00044231818,0.00009674557,0.009658396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402463,0.00041259185,0.0007416886,0.0011435959,0.0003312804,0.003346225],"domain_scores_gemma":[0.9936405,0.0012668767,0.00022305244,0.00054926483,0.0016090714,0.0027112644],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0011015893,0.0005311355,0.0008231639,0.002950195,0.0014741002,0.00019682886,0.00038384908,0.00069520983,0.00043513702],"category_scores_gemma":[0.0007980825,0.00052238506,0.00008867,0.0025403048,0.0004184423,0.00022005546,0.000050606417,0.0010483017,0.000019631923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00024197822,0.00033215052,0.9086581,0.0004933279,0.00045587955,0.0008261606,0.0017229666,0.00010557488,0.000013462167,0.00014040842,0.04385665,0.04315336],"study_design_scores_gemma":[0.012950567,0.00093343784,0.67971885,0.0032192578,0.0013754007,0.000005918501,0.0025293822,0.00280167,0.000032132393,0.000057045214,0.29584518,0.0005311425],"about_ca_topic_score_codex":0.9907039,"about_ca_topic_score_gemma":0.99915123,"teacher_disagreement_score":0.25198853,"about_ca_system_score_codex":0.036539108,"about_ca_system_score_gemma":0.16275531,"threshold_uncertainty_score":0.99982584},"labels":[],"label_agreement":null},{"id":"W4415939652","doi":"10.1016/j.annonc.2025.08.2684","title":"2063eP Real-world treatment patterns and outcomes in stage IV NSCLC: A retrospective study from Southwestern Ontario","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"MD Precision (Canada); London Health Sciences Centre; Western University","funders":"","keywords":"Retrospective cohort study; Stage (stratigraphy); MEDLINE; Medical record","score_opus":0.05379844394685784,"score_gpt":0.4340419835925989,"score_spread":0.38024353964574104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98098075,0.000075017175,0.000006107893,0.0022630321,0.00012558392,0.0008462012,0.00013906023,0.000015763235,0.0155484555],"genre_scores_gemma":[0.98178464,0.000114949435,0.00006213698,0.00051475124,0.000018679788,0.00011695436,0.00004192457,0.000008535621,0.017337443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990583,0.000059337952,0.00031150997,0.00030039047,0.000094146424,0.0001763215],"domain_scores_gemma":[0.99941677,0.00010143126,0.000104869425,0.0002419863,0.00007414302,0.000060772483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007819859,0.00015002512,0.00062940276,0.00022285769,0.00003320544,0.0000072976145,0.000042458036,0.000060281433,0.00012932452],"category_scores_gemma":[0.000014635535,0.00011261579,0.00006615785,0.00012304039,0.000041995536,0.000043835378,0.000038099122,0.00009527505,0.000003439121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030151499,0.0026789946,0.97404563,0.000008803643,0.0009381791,0.00018364722,0.012597974,0.0000013732898,0.000011649806,0.00011364033,0.00007121775,0.009047346],"study_design_scores_gemma":[0.0068252487,0.004104638,0.9832832,0.000054322703,0.000321716,7.528631e-7,0.0025787938,0.000002174085,0.000061833816,0.0001998511,0.002500005,0.0000674505],"about_ca_topic_score_codex":0.48930392,"about_ca_topic_score_gemma":0.8929393,"teacher_disagreement_score":0.40363538,"about_ca_system_score_codex":0.0006450926,"about_ca_system_score_gemma":0.0004777203,"threshold_uncertainty_score":0.51409686},"labels":[],"label_agreement":null},{"id":"W4415939780","doi":"10.1016/j.annonc.2025.08.2506","title":"1882P Glans-look lung cancer research study (GLR): A population-level real-world evidence database","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Lung cancer; Clinical trial; Real world evidence; Clinical research; MEDLINE; Cancer; Evidence-based medicine; Personalization; Evidence-based practice","score_opus":0.31764986044598575,"score_gpt":0.6132934011239383,"score_spread":0.2956435406779525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94113725,0.0035754372,0.00004731688,0.023088465,0.0004126304,0.0019390481,0.00013761334,0.000041854863,0.02962036],"genre_scores_gemma":[0.981895,0.0015210524,0.0003474031,0.0010655671,0.00012998689,0.00039215767,0.000074491196,0.000012826162,0.01456149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983123,0.0002503945,0.00040577812,0.000353113,0.00035324116,0.00032517329],"domain_scores_gemma":[0.9979975,0.0006023638,0.0001092817,0.00047764342,0.0007045744,0.000108603774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008754349,0.0001177897,0.0004057723,0.00047506051,0.00015834226,0.000010723224,0.000148915,0.00006648932,0.00028737434],"category_scores_gemma":[0.00037369502,0.00009883159,0.00006444318,0.00083871215,0.0001060166,0.00014093037,0.00011056423,0.00023520853,0.000010942606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007193188,0.001819738,0.8797644,0.00025537956,0.00078216015,0.00013029158,0.0012811964,0.000025579626,0.00047778993,0.0022923213,0.07977366,0.032678198],"study_design_scores_gemma":[0.0025059765,0.001663124,0.9745672,0.0008520898,0.00052674196,0.0000035764551,0.00092097966,0.00011134298,0.00051548437,0.00030452418,0.017924415,0.00010456176],"about_ca_topic_score_codex":0.044539012,"about_ca_topic_score_gemma":0.024575008,"teacher_disagreement_score":0.09480282,"about_ca_system_score_codex":0.00034835425,"about_ca_system_score_gemma":0.00163175,"threshold_uncertainty_score":0.99322397},"labels":[],"label_agreement":null},{"id":"W4415939861","doi":"10.1016/j.annonc.2025.08.2637","title":"2013P Repotrectinib in adult and pediatric patients with NTRK+ advanced solid tumors: Updated results from the TRIDENT-1 and CARE trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Micropalaeontological Society; Bamfield Marine Sciences Centre","keywords":"Standard of care; Clinical trial; Solid tumor; MEDLINE; Tyrosine kinase","score_opus":0.030687893561948426,"score_gpt":0.40925444022155,"score_spread":0.37856654665960154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98943996,0.00219598,0.0000023793398,0.0054550106,0.00011922881,0.0008022507,0.0002469985,0.00001131132,0.0017269001],"genre_scores_gemma":[0.9973863,0.0009888374,0.00018150317,0.00088472373,0.00005768449,0.000047964724,0.0002728911,0.000006934966,0.00017318576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988338,0.00015191938,0.0005277026,0.0002491318,0.000095914584,0.0001415264],"domain_scores_gemma":[0.99848926,0.00061526854,0.0003089058,0.00018016444,0.0003564628,0.000049908467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022753028,0.00010640154,0.00052736286,0.00011085046,0.000050904844,0.000007663151,0.000041511663,0.00007492914,0.000008762496],"category_scores_gemma":[0.0010180922,0.000062581974,0.00003279518,0.00022499567,0.00006272886,0.000057560846,0.000028706514,0.00010047347,7.999927e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01582088,0.0008712097,0.70071125,0.00010211949,0.000636792,0.00008356868,0.00945639,0.000028545146,0.00008376504,0.00007769105,0.02158957,0.25053823],"study_design_scores_gemma":[0.032892395,0.002975301,0.953732,0.00021856681,0.0006603357,0.0000030975395,0.0028446694,0.000009562052,0.0007083845,0.00017205182,0.0056785676,0.00010507178],"about_ca_topic_score_codex":0.0008511769,"about_ca_topic_score_gemma":0.00066658854,"teacher_disagreement_score":0.25302073,"about_ca_system_score_codex":0.00003861996,"about_ca_system_score_gemma":0.00031548968,"threshold_uncertainty_score":0.25520188},"labels":[],"label_agreement":null},{"id":"W4415940101","doi":"10.1016/j.annonc.2025.08.2627","title":"2003P Real-world (RW) characteristics and outcomes of ERBB2-altered (HER2+) metastatic non-small cell lung cancer (mNSCLC) in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Lung cancer; MEDLINE; Clinical trial; Cancer; Expanded access","score_opus":0.029002719480758256,"score_gpt":0.3957886970125683,"score_spread":0.36678597753181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662552,0.00067637465,0.000010011739,0.0082219215,0.00029666218,0.00049889134,0.00013782314,0.0000037379516,0.0238994],"genre_scores_gemma":[0.98812795,0.0011981814,0.00035008055,0.0019290976,0.00001860248,0.00007034503,0.000043641616,0.000011353965,0.008250775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989859,0.000045345405,0.0004723624,0.00018430728,0.00009177107,0.0002203534],"domain_scores_gemma":[0.99905276,0.0002985441,0.00022641385,0.00017889592,0.00016356051,0.00007981227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000989847,0.00013509148,0.00069872366,0.00017707066,0.000023604121,0.0000027123458,0.00006270218,0.00004802561,0.0000824591],"category_scores_gemma":[0.00005501001,0.000113029084,0.000048246227,0.00022531938,0.000059940667,0.00002668538,0.000030632465,0.00010024147,4.085739e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016709308,0.00047931162,0.97515684,0.0006881061,0.0007048721,0.000057400463,0.00084445206,0.000013767779,0.0003329459,0.0003168103,0.010318766,0.010919651],"study_design_scores_gemma":[0.002591988,0.00027763215,0.9760286,0.00019379158,0.0006069752,0.0000018493224,0.00020269629,0.00016237548,0.0016354449,0.00005364395,0.018150428,0.0000945352],"about_ca_topic_score_codex":0.8275289,"about_ca_topic_score_gemma":0.9207377,"teacher_disagreement_score":0.09320878,"about_ca_system_score_codex":0.00018607036,"about_ca_system_score_gemma":0.0025815682,"threshold_uncertainty_score":0.46091923},"labels":[],"label_agreement":null},{"id":"W4415940472","doi":"10.1016/j.annonc.2025.08.2443","title":"1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Stage (stratigraphy); Disease; Minimal residual disease; Residual","score_opus":0.0398736530682345,"score_gpt":0.4313741866833378,"score_spread":0.39150053361510334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399836,0.0019921495,0.00006448805,0.007776936,0.00006986147,0.00083508494,0.00016150005,0.000016278478,0.005085329],"genre_scores_gemma":[0.99698627,0.00012256061,0.00005796709,0.0016173947,0.000018331979,0.0000986361,0.00017961356,0.0000113779515,0.0009078444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982905,0.00029755518,0.0005878995,0.000321615,0.00024924116,0.00025322358],"domain_scores_gemma":[0.9984598,0.0003987648,0.00023351681,0.0005327056,0.00027553272,0.00009967059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030794772,0.00015312861,0.0006824728,0.00035154048,0.00006080683,0.000008018929,0.00018306458,0.00008141704,0.00024322537],"category_scores_gemma":[0.00022556706,0.00010934096,0.00016010001,0.0013749019,0.000114215,0.000051408722,0.00008563709,0.00016045508,0.000003012628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008371688,0.015108533,0.90045774,0.00012028681,0.021462707,0.0011692009,0.01055113,0.006467642,0.006845988,0.0012622023,0.012534358,0.01564852],"study_design_scores_gemma":[0.014405158,0.0031898415,0.9521344,0.00015900334,0.0078087235,6.209557e-7,0.009182588,0.0006666206,0.0049206577,0.0005715291,0.006776887,0.00018400027],"about_ca_topic_score_codex":0.011089688,"about_ca_topic_score_gemma":0.0034455885,"teacher_disagreement_score":0.051676624,"about_ca_system_score_codex":0.00007909349,"about_ca_system_score_gemma":0.00070393627,"threshold_uncertainty_score":0.99549556},"labels":[],"label_agreement":null},{"id":"W4415940566","doi":"10.1016/j.annonc.2025.08.2579","title":"1955P SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"AstraZeneca","keywords":"Osimertinib; Tolerability; Disease; Safety profile; Adverse effect","score_opus":0.045052076973173046,"score_gpt":0.44228154625093946,"score_spread":0.3972294692777664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935044,0.0010610252,0.0001482342,0.0038540657,0.00006780327,0.0011636189,0.000065052234,0.000022112758,0.004267629],"genre_scores_gemma":[0.9967699,0.00037911636,0.0017033998,0.000632347,0.000015811325,0.00009600599,0.00009450594,0.000012584147,0.00029632088],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985415,0.00012706578,0.0005217964,0.00039993945,0.00018985543,0.00021985306],"domain_scores_gemma":[0.998744,0.00037366105,0.00026611236,0.00032321308,0.0001476085,0.00014539789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002722002,0.00017425549,0.0005746322,0.00016499491,0.00007394231,0.0000057604893,0.000055925047,0.00010554881,0.000025079864],"category_scores_gemma":[0.0003572723,0.00011894769,0.00006939536,0.00023232154,0.00015026476,0.00012761616,0.000049489256,0.00012806866,5.9081174e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07059606,0.0049311817,0.24006845,0.0012604229,0.0005075296,0.000047770227,0.0026968182,0.00012105462,0.01993131,0.0043168114,0.0005289512,0.65499365],"study_design_scores_gemma":[0.016462633,0.008777857,0.9215578,0.005806466,0.0004992427,0.0000067477727,0.0009823263,0.00011384095,0.015363772,0.0014632114,0.028680697,0.0002854242],"about_ca_topic_score_codex":0.00007174815,"about_ca_topic_score_gemma":0.000049405946,"teacher_disagreement_score":0.68148935,"about_ca_system_score_codex":0.000091480506,"about_ca_system_score_gemma":0.0005159441,"threshold_uncertainty_score":0.4850546},"labels":[],"label_agreement":null},{"id":"W4415940700","doi":"10.1016/j.annonc.2025.08.2608","title":"1984P Real-world efficacy and outcomes in older adults with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A Canadian multicenter experience","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Brampton Civic Hospital; Queen Elizabeth II Health Sciences Centre; Hôpital du Sacré-Cœur de Montréal; McGill University; BC Cancer Agency; Northeast Cancer Centre; Institute of Cancer Research; Juravinski Cancer Centre; Western University; University Health Network; Ottawa Regional Cancer Foundation; Hôpital Fleurimont; Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Anaplastic lymphoma kinase; Clinical trial; Lymphoma; MEDLINE; Multicenter study","score_opus":0.013906956313904331,"score_gpt":0.3705956109970542,"score_spread":0.35668865468314986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98385423,0.00093758106,0.00001163287,0.0027129848,0.00015664949,0.0010917721,0.00004151813,0.000014120834,0.0111795105],"genre_scores_gemma":[0.9956365,0.00056505325,0.00042382604,0.001856909,0.000016617018,0.00033738103,0.000021508808,0.000016449738,0.0011257328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886644,0.00003559656,0.00028828718,0.0003388444,0.000090933245,0.00037990787],"domain_scores_gemma":[0.9991313,0.00016870532,0.00010414358,0.00021329512,0.00015669563,0.00022586406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052908017,0.00018548481,0.00047809433,0.0003889793,0.000064112966,0.0000075394796,0.00007585472,0.0000817114,0.00005037284],"category_scores_gemma":[0.000040076808,0.00014445251,0.00004193508,0.0003337833,0.00011105118,0.00006834986,0.000022937946,0.00008525608,0.0000014308016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024827681,0.001250172,0.8961671,0.0003657169,0.00027870908,0.00039218002,0.012094259,0.00007798329,0.00032841155,0.0000370421,0.0007068257,0.08581881],"study_design_scores_gemma":[0.020077446,0.00092148467,0.971362,0.0009977013,0.00019998587,0.0000031063933,0.0013675438,0.00032057022,0.0011631049,0.0000018051106,0.003440222,0.00014500535],"about_ca_topic_score_codex":0.14301257,"about_ca_topic_score_gemma":0.55169725,"teacher_disagreement_score":0.40868467,"about_ca_system_score_codex":0.00029643628,"about_ca_system_score_gemma":0.0012683786,"threshold_uncertainty_score":0.8626942},"labels":[],"label_agreement":null},{"id":"W4415940751","doi":"10.1016/j.annonc.2025.08.1252","title":"677P EGFR-BPI: A novel prognostic tool for EGFR-mutated NSCLC with brain metastases","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hellenic Society of Medical Oncology; Sjöbergstiftelsen; European Society for Medical Oncology; University of Crete; Cancerfonden; Canadian Cancer Society","keywords":"Brain metastasis; Metastasis; MEDLINE; Cancer; Neoplasm staging","score_opus":0.05569170123665718,"score_gpt":0.44329145867720104,"score_spread":0.38759975744054387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79973984,0.0022265406,0.021124551,0.13498612,0.00045609847,0.005712363,0.0007809688,0.00017594206,0.03479757],"genre_scores_gemma":[0.9782898,0.00004170894,0.008571862,0.00843453,0.000058238154,0.0005424882,0.00026880216,0.00002140041,0.003771191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990706,0.000031881973,0.0002886805,0.00024158199,0.00010485659,0.0002623903],"domain_scores_gemma":[0.9986105,0.0005743952,0.00012960813,0.00019561638,0.00042386944,0.000065987144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017975268,0.00014082705,0.00044806916,0.00016321757,0.00006467062,0.000007640993,0.00006721268,0.00008425899,0.0000512358],"category_scores_gemma":[0.00041997558,0.000101255515,0.00010363282,0.00028817775,0.00011798445,0.000059049347,0.000021349411,0.000073560645,0.0000053064073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013828867,0.014725537,0.04359234,0.0020339505,0.015283954,0.00040769385,0.0030497452,0.0003309314,0.025547685,0.04831697,0.33788088,0.49500144],"study_design_scores_gemma":[0.034309145,0.027555728,0.077192985,0.00094751903,0.0045250864,0.00018530429,0.0010874806,0.00035522765,0.020978145,0.0021376342,0.8302569,0.0004688523],"about_ca_topic_score_codex":0.00010047031,"about_ca_topic_score_gemma":0.00008812446,"teacher_disagreement_score":0.4945326,"about_ca_system_score_codex":0.000057540426,"about_ca_system_score_gemma":0.0010826039,"threshold_uncertainty_score":0.412908},"labels":[],"label_agreement":null},{"id":"W4415940823","doi":"10.1016/j.annonc.2025.08.2612","title":"1988P Real-world treatment patterns and survival in patients (pts) with ROS1-positive (ROS1+) locally advanced or metastatic (LAM) non-small cell lung cancer (NSCLC) in Canada and Europe","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Bristol-Myers Squibb","keywords":"Lung cancer; Respiratory disease; Chemotherapy; Cancer; Overall survival; MEDLINE","score_opus":0.02030350977072649,"score_gpt":0.35482434904905485,"score_spread":0.3345208392783284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275887,0.0003859667,0.000025071175,0.0011676839,0.00009919021,0.0010075385,0.00017163676,0.00000465271,0.0043794187],"genre_scores_gemma":[0.99514335,0.0020161609,0.00022390552,0.0008187269,0.000008954862,0.00016715116,0.00005992769,0.000016714923,0.0015451248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988861,0.000088580084,0.0003248354,0.00031400527,0.000110210116,0.0002762644],"domain_scores_gemma":[0.9992641,0.00019011604,0.00013306814,0.0001337843,0.0001758762,0.00010303947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006758009,0.00019166312,0.0005686016,0.00017564846,0.000032241118,0.000005748098,0.000041273026,0.000031448424,0.000022130664],"category_scores_gemma":[0.000013597635,0.00013350515,0.000019258214,0.00029896857,0.00005450285,0.00005018954,0.000031822317,0.00009146571,2.2100068e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017670792,0.00072325655,0.9513495,0.00018735572,0.0002980266,0.00030191077,0.0008880215,0.00014671835,0.000029552575,0.000022628737,0.00013094817,0.044154983],"study_design_scores_gemma":[0.013187018,0.003540638,0.98000157,0.0005125408,0.0003266395,0.0000019393708,0.00040361713,0.00012225946,0.00092498446,0.0000050375907,0.0008502694,0.0001234573],"about_ca_topic_score_codex":0.81928754,"about_ca_topic_score_gemma":0.990479,"teacher_disagreement_score":0.17119151,"about_ca_system_score_codex":0.0007105991,"about_ca_system_score_gemma":0.0032653068,"threshold_uncertainty_score":0.5792514},"labels":[],"label_agreement":null},{"id":"W4415940937","doi":"10.1016/j.annonc.2025.08.2610","title":"1986P TRUST-II global study: Efficacy and safety of taletrectinib after prior entrectinib exposure in patients with advanced ROS1+ non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"ROS1; Lung cancer; Tyrosine kinase; Tyrosine-kinase inhibitor; Clinical trial; Cancer; Cell; Clinical Practice","score_opus":0.010248784556993082,"score_gpt":0.3588284323872693,"score_spread":0.34857964783027623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921119,0.001261815,0.000007466458,0.0006759454,0.00017674752,0.0017213126,0.00008687647,0.000010642504,0.003947292],"genre_scores_gemma":[0.9985015,0.00019253661,0.00030094667,0.00031809774,0.00001812088,0.0001589573,0.000017324748,0.000010113186,0.00048243362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989002,0.000058434933,0.00039694418,0.00029434438,0.00012581001,0.00022431952],"domain_scores_gemma":[0.9992024,0.000086391534,0.0001938781,0.00019411078,0.0002536264,0.00006963112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010081447,0.00016104124,0.0005426463,0.000111225374,0.00004431879,0.0000028247202,0.0000579066,0.000093047616,0.00004765079],"category_scores_gemma":[0.000037836893,0.00012422535,0.00004614233,0.00033698624,0.000071914794,0.000050044262,0.00006012561,0.00010675948,3.7274228e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065592085,0.003949302,0.9043683,0.00014218298,0.00035251325,0.000017997883,0.0023727904,0.000049730475,0.00002387694,0.0000048874736,0.0001697404,0.0819895],"study_design_scores_gemma":[0.02383362,0.0074363425,0.9645601,0.0002660092,0.00039408996,8.5976484e-7,0.0005611544,0.0000067813226,0.0004058,0.000004808732,0.0024407993,0.00008963824],"about_ca_topic_score_codex":0.00038858497,"about_ca_topic_score_gemma":0.0013561369,"teacher_disagreement_score":0.08189986,"about_ca_system_score_codex":0.00014654914,"about_ca_system_score_gemma":0.0004974576,"threshold_uncertainty_score":0.5065763},"labels":[],"label_agreement":null},{"id":"W4415941164","doi":"10.1016/j.annonc.2025.08.687","title":"258eP Effective biomarker testing rates in advanced non-small cell lung cancer (NSCLC) patients in U.S. community oncology practices","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Biomarker; Lung cancer; Precision oncology; Profiling (computer programming); Standard of care; Cancer","score_opus":0.05814192484491954,"score_gpt":0.4745007925859957,"score_spread":0.41635886774107617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92637295,0.0010646561,0.000013450417,0.0029151947,0.00026769683,0.0012593188,0.000017444643,0.000013426758,0.068075866],"genre_scores_gemma":[0.99552554,0.0004947598,0.00095357577,0.0022745517,0.000012664758,0.0004928201,0.00003970011,0.000012504176,0.0001938781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840677,0.0006045366,0.00041860715,0.00021540294,0.00007452987,0.0002801398],"domain_scores_gemma":[0.99647766,0.0023808167,0.00049735844,0.00020079283,0.00038875762,0.00005461777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061694265,0.00015233959,0.0005359356,0.00032914834,0.00006657944,0.0000049997666,0.00010758285,0.0001688326,0.000020632737],"category_scores_gemma":[0.0010684669,0.00013494407,0.000051314673,0.00059900526,0.00008693158,0.00012904305,0.00009006184,0.0004259383,0.0000026581336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007293879,0.0032738906,0.8179293,0.0003169823,0.00015802869,0.00003507106,0.0024490792,0.00011739429,0.001984483,0.000017137783,0.0005972693,0.17239197],"study_design_scores_gemma":[0.007993889,0.002770313,0.97785026,0.00061334734,0.00015949609,0.0000013660488,0.0010017775,0.0003274848,0.0032628386,0.00010642283,0.0058121197,0.000100667574],"about_ca_topic_score_codex":0.012200952,"about_ca_topic_score_gemma":0.009623404,"teacher_disagreement_score":0.1722913,"about_ca_system_score_codex":0.0004723305,"about_ca_system_score_gemma":0.001341239,"threshold_uncertainty_score":0.9943769},"labels":[],"label_agreement":null},{"id":"W4415941235","doi":"10.1016/j.annonc.2025.08.2591","title":"1967P MET testing and treatment (tx) sequencing after progression on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real-world (rw) study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Interim analysis; Interim; C-Met; Clinical trial","score_opus":0.07704972867911013,"score_gpt":0.4562838769249002,"score_spread":0.37923414824579005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975068,0.00020987174,0.00002258785,0.00028391217,0.000023976145,0.0012486789,0.00007438441,0.0000150035285,0.0006147813],"genre_scores_gemma":[0.99684006,0.00016174224,0.002460804,0.00013561617,0.000008221853,0.00025493835,0.00006529803,0.000009398395,0.000063945845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986288,0.00010506559,0.00049442466,0.00042265886,0.0001661061,0.00018292536],"domain_scores_gemma":[0.9988352,0.00028211536,0.0003511266,0.00024021037,0.00020903736,0.000082331135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015178492,0.00020367219,0.0006900464,0.0003213236,0.00006570833,0.000009598961,0.00003843854,0.000069736205,0.00001181299],"category_scores_gemma":[0.00014509153,0.00013053679,0.000043074666,0.0007678134,0.00009400752,0.00009627643,0.000059337122,0.000047090612,1.6330084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010198101,0.0026944084,0.8104249,0.000085258725,0.0011733873,0.000014693615,0.0016879467,0.00007340682,0.0007585858,0.000024648734,0.000010353425,0.1728543],"study_design_scores_gemma":[0.009541975,0.024179788,0.960825,0.0012198138,0.0018239155,0.000001871216,0.000782529,0.00021247304,0.0011200293,0.000036318394,0.00014243943,0.00011380377],"about_ca_topic_score_codex":0.001144208,"about_ca_topic_score_gemma":0.0035774051,"teacher_disagreement_score":0.17274049,"about_ca_system_score_codex":0.000338691,"about_ca_system_score_gemma":0.000160388,"threshold_uncertainty_score":0.5323136},"labels":[],"label_agreement":null},{"id":"W4415941435","doi":"10.1016/j.annonc.2025.08.2433","title":"1808eP Bronchoalveolar lavage (BAL) to accelerate time to molecular (AToM-001) diagnosis in early-stage lung cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Bronchoalveolar lavage; Liquid biopsy; Lung cancer; Concordance; Genotyping; Biopsy; Lung tumor","score_opus":0.027671680429813814,"score_gpt":0.4355999144893546,"score_spread":0.40792823405954076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93223596,0.0016994585,0.00008036041,0.03653723,0.00015466717,0.0010769564,0.00011799769,0.00003135026,0.028065996],"genre_scores_gemma":[0.9558404,0.0004748926,0.00068422663,0.02684255,0.00005551857,0.000916167,0.000042074967,0.0000269097,0.015117258],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878037,0.00006723023,0.00033870374,0.00032291425,0.00014019341,0.00035060203],"domain_scores_gemma":[0.99915653,0.00009549615,0.00007082401,0.0002778414,0.00021267564,0.00018664436],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015847052,0.00015785798,0.0004844817,0.00035442412,0.000039579947,0.000011804806,0.00013291086,0.00012674491,0.0011292706],"category_scores_gemma":[0.00007984528,0.00014774123,0.000085547974,0.00049108925,0.000032660806,0.00006602815,0.00008860295,0.00013154904,0.00013869438],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013655685,0.003636763,0.3329174,0.00049418694,0.0022005485,0.001236636,0.005201872,0.001823919,0.022579286,0.0020186496,0.4403389,0.18618625],"study_design_scores_gemma":[0.0031162654,0.00164179,0.14835617,0.00035925134,0.00028147709,0.000001944083,0.00007100059,0.0000607227,0.036016073,0.000073878604,0.8098196,0.00020187492],"about_ca_topic_score_codex":0.0033705698,"about_ca_topic_score_gemma":0.000607629,"teacher_disagreement_score":0.36948064,"about_ca_system_score_codex":0.00025009352,"about_ca_system_score_gemma":0.0005211869,"threshold_uncertainty_score":0.9997838},"labels":[],"label_agreement":null},{"id":"W4415941460","doi":"10.1016/j.annonc.2025.08.2581","title":"1957P Day-7 ctDNA response as a prognostic marker in EGFR-mutant NSCLC under osimertinib: The MELROSE study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Osimertinib; Circulating tumor DNA; Prospective cohort study; Multicenter study; Chemotherapy","score_opus":0.05093655239407268,"score_gpt":0.4587565328063985,"score_spread":0.4078199804123258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9311739,0.000828911,0.000014354148,0.047784597,0.00019270611,0.0015067759,0.000008976193,0.000022784268,0.018466972],"genre_scores_gemma":[0.99031764,0.000078240904,0.00003734604,0.0060309027,0.000026758453,0.00026304022,0.000007179199,0.000012843481,0.003226062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837714,0.0005365596,0.00040787456,0.00025305012,0.00016469497,0.0002606938],"domain_scores_gemma":[0.9981132,0.0011966832,0.00011359472,0.00035326113,0.00016115484,0.00006209794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001026336,0.00013522503,0.00038008098,0.00019961769,0.00007291286,0.000008374667,0.00012255421,0.00009309425,0.0001296909],"category_scores_gemma":[0.00083044404,0.00008683531,0.000081671,0.00044767538,0.00013524441,0.000039343344,0.0000683865,0.00017723114,0.000029841132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04482508,0.030799609,0.5732049,0.00020167035,0.0059297187,0.0024195428,0.030286262,0.0001583042,0.011784971,0.0072921207,0.0362145,0.25688332],"study_design_scores_gemma":[0.0060974737,0.0056610866,0.9248423,0.0001642258,0.000558479,0.000028839308,0.0055557764,0.00003683399,0.0009948062,0.0012467812,0.054707833,0.00010555598],"about_ca_topic_score_codex":0.00036887344,"about_ca_topic_score_gemma":0.00029901203,"teacher_disagreement_score":0.35163742,"about_ca_system_score_codex":0.00011809365,"about_ca_system_score_gemma":0.0011996819,"threshold_uncertainty_score":0.3541041},"labels":[],"label_agreement":null},{"id":"W4415962648","doi":"10.1158/0008-5472.can-25-3502","title":"Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada)","funders":"","keywords":"Kinome; Exon; EGFR inhibitors; Lung; Epidermal growth factor receptor; Erlotinib; Cell","score_opus":0.030792000093462793,"score_gpt":0.4108915992425694,"score_spread":0.3800995991491066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415962648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751475,0.0027718619,0.0013610137,0.009715824,0.000106602114,0.0030969372,0.00018243365,0.00004776179,0.0075700874],"genre_scores_gemma":[0.97716326,0.00019287845,0.002109267,0.0007374597,0.00020486303,0.0026818432,0.000066146225,0.000044198798,0.016800098],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825245,0.000058579382,0.00024353889,0.0005535841,0.00031814,0.00057369575],"domain_scores_gemma":[0.9984327,0.0004842004,0.0000518454,0.00023049898,0.00058326666,0.00021747507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002385731,0.00019171565,0.00030423937,0.00030147278,0.0005066535,0.00007266975,0.00008834865,0.000095340016,0.00009029868],"category_scores_gemma":[0.000088324305,0.0001505367,0.00006612181,0.00077272643,0.00019200948,0.00008528419,0.00003838528,0.00034203078,0.0000033158738],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023189463,0.001756205,0.30354026,0.008124831,0.0045485543,0.00025556385,0.047340564,0.0008674182,0.21847658,0.0018871371,0.2698608,0.12015264],"study_design_scores_gemma":[0.071745835,0.008534757,0.15168071,0.007179296,0.0036970917,0.0000756968,0.015272689,0.0139317615,0.5732019,0.0013475876,0.15161692,0.0017157715],"about_ca_topic_score_codex":0.0019720362,"about_ca_topic_score_gemma":0.0025083565,"teacher_disagreement_score":0.3547253,"about_ca_system_score_codex":0.0014984917,"about_ca_system_score_gemma":0.0029683325,"threshold_uncertainty_score":0.6138708},"labels":[],"label_agreement":null},{"id":"W4415991569","doi":"10.3390/curroncol32110626","title":"Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Crizotinib; ROS1; Lung cancer; Targeted therapy; Tyrosine kinase; Ceritinib; Protein-Tyrosine Kinases; Anaplastic lymphoma kinase; Disease","score_opus":0.03439287116426077,"score_gpt":0.4319434604115565,"score_spread":0.39755058924729575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415991569","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23357196,0.7092854,0.001366159,0.004392653,0.0024941948,0.0029005592,0.00013992976,0.00009109052,0.04575805],"genre_scores_gemma":[0.9660504,0.030341739,0.00026194451,0.0014230801,0.000120861434,0.00025561242,0.00050825026,0.000018419436,0.0010196972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919367,0.00006693679,0.00026042445,0.00022513549,0.00007493165,0.00017888666],"domain_scores_gemma":[0.9993053,0.000043657186,0.00012765615,0.00020903826,0.00024294724,0.000071417395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009143145,0.00012541143,0.00042042497,0.00009264979,0.000053258518,0.0000046372143,0.00008065455,0.00006413714,0.0003724849],"category_scores_gemma":[0.000008735795,0.00009843327,0.00007851755,0.00026088092,0.000038832164,0.00004402929,0.000028435074,0.00014692223,0.0000046409086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002392473,0.00350225,0.47344294,0.0068154307,0.0011646085,0.000034104814,0.0022328298,0.000020706606,0.0030788246,0.00040797007,0.07207781,0.4369833],"study_design_scores_gemma":[0.019340541,0.0035073855,0.4832596,0.018509835,0.02019031,0.000034980912,0.0010462642,0.007737091,0.0075902464,0.000184897,0.43784168,0.00075718726],"about_ca_topic_score_codex":0.00007028407,"about_ca_topic_score_gemma":0.000052884086,"teacher_disagreement_score":0.73247844,"about_ca_system_score_codex":0.00029037966,"about_ca_system_score_gemma":0.0008565173,"threshold_uncertainty_score":0.40784487},"labels":[],"label_agreement":null},{"id":"W4416088305","doi":"10.3390/curroncol32110629","title":"A Narrative Review of the Strengths and Limitations of Real-World Evidence in Comparison to Randomized Clinical Trials: What Are the Opportunities in Thoracic Oncology for Real-World Evidence to Shine?","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Randomized controlled trial; Narrative review; Psychological intervention; Clinical trial; Alternative medicine; MEDLINE; Medical literature","score_opus":0.705300470599139,"score_gpt":0.6747941548787231,"score_spread":0.030506315720415955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416088305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009860721,0.9556326,0.000044602864,0.024196194,0.0016519875,0.017710222,0.00010179754,0.000010369374,0.0005536173],"genre_scores_gemma":[0.0003637432,0.98997676,0.00040370657,0.00069245277,0.00015673316,0.0077228006,0.000086995125,0.000019977982,0.00057684426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98228115,0.011806155,0.004691007,0.00062195933,0.0002928325,0.0003068919],"domain_scores_gemma":[0.8338162,0.16120236,0.0033254393,0.0007661948,0.00070019736,0.000189645],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014162865,0.00042211174,0.008536383,0.0006836741,0.00008490784,0.000021245567,0.00043979098,0.00022149342,0.000021414187],"category_scores_gemma":[0.08267597,0.0002230919,0.00094437023,0.0015079034,0.00047787628,0.00014876382,0.00023481628,0.0007216519,0.0000013100031],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004390489,0.0005792932,0.00032459985,0.046618972,0.00036760015,0.0000046251157,0.0035682481,0.0000031388238,5.0182173e-8,0.0005939323,0.007909702,0.9356393],"study_design_scores_gemma":[0.0067224707,0.0005795479,0.00021909107,0.42405155,0.0059672976,0.0000026025903,0.003215013,0.000014569017,3.0776226e-7,0.000069109854,0.55903184,0.00012658554],"about_ca_topic_score_codex":0.000298558,"about_ca_topic_score_gemma":0.027076686,"teacher_disagreement_score":0.9355128,"about_ca_system_score_codex":0.0010822285,"about_ca_system_score_gemma":0.0063946894,"threshold_uncertainty_score":0.99923813},"labels":[],"label_agreement":null},{"id":"W4416141003","doi":"10.1093/neuonc/noaf201.0122","title":"BIOM-34. GENOMIC ANALYSIS OF CSF CTDNA IN LUNG CANCER-RELATED LEPTOMENINGEAL METASTASES","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Aneuploidy; Lung cancer; Chemotherapy; Allele; Mutation; Lung","score_opus":0.013977656757288275,"score_gpt":0.3812545465734455,"score_spread":0.3672768898161572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848391,0.001970074,0.000040111896,0.0029316463,0.000406395,0.0004527875,0.00008779641,0.000048272632,0.009223852],"genre_scores_gemma":[0.9979423,0.00037980778,0.00031837734,0.0008278038,0.000021003765,0.00011066565,0.000099943165,0.000011992305,0.0002881067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884343,0.0001104852,0.0004262838,0.00029922667,0.000098214514,0.00022237899],"domain_scores_gemma":[0.9992525,0.0002285536,0.0001473532,0.00022612992,0.00007961276,0.00006583136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107123094,0.0001313424,0.0006502697,0.0009835771,0.000040832918,0.0000050436124,0.00008132131,0.000108446904,0.00032017057],"category_scores_gemma":[0.00005517761,0.000115135816,0.00016030666,0.0016908782,0.00007054365,0.000038642283,0.000044313896,0.00015444841,0.0000040712807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058753183,0.0017514793,0.5303958,0.00025162412,0.016971081,0.0005119878,0.0037291602,0.0026492996,0.39796698,0.00133179,0.0048120255,0.0390412],"study_design_scores_gemma":[0.020596096,0.0021763456,0.7044829,0.00019823751,0.07224838,0.000042440523,0.0012360653,0.018307526,0.027116148,0.00015803786,0.15294698,0.00049081934],"about_ca_topic_score_codex":0.0012788951,"about_ca_topic_score_gemma":0.0008421611,"teacher_disagreement_score":0.37085083,"about_ca_system_score_codex":0.0008855779,"about_ca_system_score_gemma":0.0008642429,"threshold_uncertainty_score":0.46951023},"labels":[],"label_agreement":null},{"id":"W4416357241","doi":"10.3390/curroncol32110646","title":"Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Dabrafenib; Somatic evolution in cancer; Trametinib; Lung cancer; Vinorelbine; Osimertinib; Comparative genomic hybridization; Targeted therapy; Precision medicine","score_opus":0.09184051403745307,"score_gpt":0.44234619666758646,"score_spread":0.3505056826301334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416357241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905802,0.0017360728,0.001851931,0.0007401515,0.001095249,0.00035663618,0.000025861784,0.000019611587,0.0035942595],"genre_scores_gemma":[0.9987001,0.000087096356,0.00047064148,0.00004336385,0.000111610236,0.00006568811,0.00013293712,0.0000062302383,0.0003823312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993245,0.000064503714,0.00016594928,0.00020794767,0.00009115855,0.00014593557],"domain_scores_gemma":[0.99968845,0.000067890374,0.000048172536,0.00007930913,0.00006471419,0.00005146939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009389518,0.00009672455,0.00024648433,0.00018768877,0.000052928106,0.0000070623782,0.000022327653,0.00003535578,0.000087753004],"category_scores_gemma":[0.000025820735,0.00007340708,0.000031430896,0.00016965323,0.00010536339,0.000044620363,0.00002204307,0.00011381609,0.000007656732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005567473,0.0022584822,0.8968529,0.00034701833,0.0013924978,0.00010806689,0.001038109,0.0004360545,0.0038048788,0.014281829,0.0020394227,0.07187328],"study_design_scores_gemma":[0.008009414,0.0005598163,0.9745748,0.00007878876,0.00083114405,0.000023350283,0.0006512419,0.00030127398,0.000028517636,0.00048205175,0.014374557,0.00008502721],"about_ca_topic_score_codex":0.00009191279,"about_ca_topic_score_gemma":0.00048454574,"teacher_disagreement_score":0.07772192,"about_ca_system_score_codex":0.00051036495,"about_ca_system_score_gemma":0.00068757246,"threshold_uncertainty_score":0.29934537},"labels":[],"label_agreement":null},{"id":"W4416391857","doi":"10.1016/j.annonc.2025.09.087","title":"LBA73 Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Foundation Medicine; Genentech; PharmaMar; AstraZeneca Korea; Ipsen; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; LG Chem; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Pfizer; Incyte; F. Hoffmann-La Roche; Chugai Pharmaceutical; Celltrion; Roche; Relay Therapeutics; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alectinib; Crizotinib; Overall survival; Lung cancer; Phases of clinical research; Survival analysis","score_opus":0.019633282549771185,"score_gpt":0.3854270002300882,"score_spread":0.365793717680317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915202,0.00044968413,0.000032566804,0.00045340462,0.00008157683,0.0018226231,0.00020583505,0.0000055239575,0.0054285624],"genre_scores_gemma":[0.99868643,0.00028009442,0.00008774414,0.00026378944,0.000009261975,0.00008712535,0.00007427386,0.000011515874,0.0004997463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848,0.00016795496,0.00058847165,0.00032840497,0.00019771872,0.00023741958],"domain_scores_gemma":[0.9984257,0.00023430049,0.00046157526,0.0002899438,0.00052760576,0.000060835424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017531188,0.00018967415,0.00097355817,0.0003053017,0.000059706865,0.0000030691174,0.00010763444,0.00008367604,0.00005007161],"category_scores_gemma":[0.000036146106,0.00012885657,0.000119735865,0.0008424445,0.000120808145,0.00005839582,0.000063068146,0.0001385264,9.4637954e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011328869,0.007828656,0.95558697,0.00015753435,0.0047230115,0.000011491726,0.0061980532,0.0010717417,0.00018352916,0.000026933443,0.00015266283,0.012730551],"study_design_scores_gemma":[0.044926345,0.008704051,0.9377503,0.00030924418,0.0056987717,4.4857165e-7,0.00085929036,0.00018225008,0.0012363946,0.000005425012,0.0002240829,0.0001034075],"about_ca_topic_score_codex":0.0038183955,"about_ca_topic_score_gemma":0.0065920656,"teacher_disagreement_score":0.033597477,"about_ca_system_score_codex":0.00012338636,"about_ca_system_score_gemma":0.000602639,"threshold_uncertainty_score":0.57722974},"labels":[],"label_agreement":null},{"id":"W4416507772","doi":"10.1016/j.lungcan.2025.108850","title":"Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Activation Laboratories","funders":"Pfizer","keywords":"Lung cancer; Tyrosine-kinase inhibitor; Tyrosine kinase; MEDLINE; Personalized medicine; Cancer","score_opus":0.01354000152627287,"score_gpt":0.35769011416939617,"score_spread":0.3441501126431233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416507772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677285,0.02342905,0.00017873509,0.0029573508,0.0004417566,0.0037730176,0.00036046453,0.00003566626,0.0010954379],"genre_scores_gemma":[0.98158807,0.0032455462,0.0005947505,0.0019645295,0.00010466377,0.010061788,0.00035173204,0.00002530232,0.0020636362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987094,0.000046752066,0.00031206667,0.00042800224,0.00015858466,0.00034521404],"domain_scores_gemma":[0.99921805,0.00019637785,0.00012555868,0.00025064143,0.00012386504,0.00008553201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058242487,0.0002707088,0.00033021648,0.00014742803,0.00017720343,0.00004998514,0.00008694493,0.00007341614,0.000040189665],"category_scores_gemma":[0.00002040853,0.0001686621,0.00006727936,0.0003899931,0.00007861583,0.00008930631,0.00004200625,0.000119845834,3.238359e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037379367,0.0039177956,0.80249673,0.00362066,0.0029260092,0.00008499719,0.05590619,0.006765471,0.010483074,0.00034438237,0.039665636,0.070051104],"study_design_scores_gemma":[0.088875584,0.0075841844,0.40939438,0.0113803875,0.012713664,0.000008069036,0.036985833,0.03391338,0.10454542,0.00034298646,0.2919716,0.002284515],"about_ca_topic_score_codex":0.009746783,"about_ca_topic_score_gemma":0.0036074936,"teacher_disagreement_score":0.39310235,"about_ca_system_score_codex":0.0009926945,"about_ca_system_score_gemma":0.00040433666,"threshold_uncertainty_score":0.9968474},"labels":[],"label_agreement":null},{"id":"W4416630733","doi":"10.1016/j.jlb.2025.100373","title":"Liquid Biopsies of Lung Cancer and Next Generation Sequencing at Sub-Saharan Africa Sites (LUNGS@AFRICA)","year":2025,"lang":"en","type":"article","venue":"The Journal of Liquid Biopsy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Sinai Health System; Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Liquid biopsy; Biopsy; Cancer; Cohort; Lung biopsy; Lung; DNA sequencing","score_opus":0.044976309237278515,"score_gpt":0.32353854819721917,"score_spread":0.27856223895994064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416630733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9485885,0.04561915,0.00011338453,0.004365604,0.0002276797,0.00021674325,0.000018184228,0.000010234138,0.0008405471],"genre_scores_gemma":[0.9925654,0.005370642,0.00035355965,0.00015017789,0.00024465224,0.000007940013,0.0000053854174,0.000012217837,0.0012900266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990068,0.000055204633,0.0004368397,0.000104807725,0.00022800689,0.00016831797],"domain_scores_gemma":[0.9990216,0.000100613484,0.0003251679,0.00016514295,0.00030972174,0.00007776924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003127053,0.00013743619,0.00030871027,0.0001819649,0.00016439683,0.000019312905,0.000092719354,0.00006178513,0.000046645666],"category_scores_gemma":[0.000057791076,0.00008163818,0.00009355261,0.0002961384,0.00011720949,0.0001463837,0.000047701214,0.00012867345,9.640331e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012493118,0.0000543376,0.0012994376,0.000115435745,0.00054706354,0.000017273405,0.0036828455,0.000081152735,0.98833627,0.000057539663,0.004255506,0.0003038013],"study_design_scores_gemma":[0.0040257974,0.002939382,0.007690992,0.001642021,0.005380956,0.0006005731,0.0013173046,0.0023194244,0.9622806,0.000052156156,0.011448586,0.00030226252],"about_ca_topic_score_codex":0.000078735386,"about_ca_topic_score_gemma":0.000027433784,"teacher_disagreement_score":0.04397692,"about_ca_system_score_codex":0.00035089045,"about_ca_system_score_gemma":0.00034492736,"threshold_uncertainty_score":0.33291084},"labels":[],"label_agreement":null},{"id":"W4416771546","doi":"10.1007/s12254-025-01087-8","title":"EGFR-mutated advanced non-small cell lung cancer: new era of systemic therapy towards new standards of care","year":2025,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CARE Canada","funders":"","keywords":"Osimertinib; Clinical trial; Lung cancer; Chemotherapy; Standard of care; Systemic therapy","score_opus":0.009708134768383999,"score_gpt":0.3524578201357958,"score_spread":0.3427496853674118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416771546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68502873,0.051855784,0.005464928,0.00936779,0.0019154515,0.002375841,0.00029757048,0.000111088455,0.24358284],"genre_scores_gemma":[0.97583133,0.009492285,0.003043023,0.0009505056,0.00031050915,0.000020771231,0.000113067115,0.00006395237,0.010174578],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975507,0.00020635997,0.0009739257,0.0003586369,0.00060906063,0.0003013077],"domain_scores_gemma":[0.9979523,0.000110874775,0.0004427801,0.00041470156,0.0006983718,0.00038097482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038790732,0.0002546452,0.0011217756,0.00017582279,0.000033013093,0.0000035635178,0.0002977957,0.0001520065,0.0008653345],"category_scores_gemma":[0.00026438318,0.0001802579,0.00020051774,0.00046531955,0.00018856283,0.000037228216,0.00010107306,0.0003556894,0.0000063542866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023396816,0.00073762133,0.0058307545,0.0031319256,0.0010650044,0.0003850972,0.006698867,0.0002288564,0.036544546,0.00009036106,0.049380492,0.8935668],"study_design_scores_gemma":[0.12615216,0.02004417,0.07354902,0.019892782,0.0054985406,0.00017234034,0.004905095,0.00065557286,0.115177296,0.00007803946,0.63287604,0.0009989713],"about_ca_topic_score_codex":0.0005897826,"about_ca_topic_score_gemma":0.00015456324,"teacher_disagreement_score":0.8925678,"about_ca_system_score_codex":0.0005741454,"about_ca_system_score_gemma":0.011110868,"threshold_uncertainty_score":0.9944952},"labels":[],"label_agreement":null},{"id":"W4416795272","doi":"10.1016/j.lungcan.2025.108858","title":"Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Lung cancer; Brain metastasis; Anaplastic lymphoma kinase; Tyrosine kinase; Tyrosine-kinase inhibitor; ALK inhibitor; ROS1","score_opus":0.009281889041171434,"score_gpt":0.3533143530854521,"score_spread":0.3440324640442807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416795272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909982,0.0037866482,0.00007524427,0.00048666302,0.000100979814,0.0025589007,0.00093084347,0.00003330329,0.0010292177],"genre_scores_gemma":[0.993652,0.001654621,0.00074924197,0.0002467893,0.000054810364,0.00048133172,0.00021700324,0.000048974856,0.0028952197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781615,0.00012150017,0.00068720325,0.00062992127,0.000331679,0.0004135564],"domain_scores_gemma":[0.9982135,0.00039922463,0.00037225292,0.00035919066,0.0004495874,0.00020621603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019259161,0.00042050116,0.00088618614,0.00044881538,0.00009708373,0.000027839282,0.00009675618,0.00007397971,0.00011154207],"category_scores_gemma":[0.000054400367,0.0002706899,0.00012690057,0.0013536885,0.00022573011,0.00020725919,0.00005453395,0.00025391785,4.6725293e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025710603,0.0010455097,0.98814905,0.001261717,0.0019952455,0.00006296432,0.0003641594,0.0008418554,0.000048959824,0.000011579145,0.002184727,0.0014631624],"study_design_scores_gemma":[0.014065578,0.0017541979,0.9707719,0.004846461,0.00592207,0.0000014790405,0.000036213438,0.0010325222,0.0012104898,0.0000037991038,0.00007881303,0.0002764701],"about_ca_topic_score_codex":0.029064799,"about_ca_topic_score_gemma":0.027046047,"teacher_disagreement_score":0.017377153,"about_ca_system_score_codex":0.0009423572,"about_ca_system_score_gemma":0.001523672,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W4417056537","doi":"10.2139/ssrn.5830306","title":"Exploring decisional needs of adults considering first line treatment for advanced EGFR+ lung cancer: An interpretive descriptive study","year":2025,"lang":"","type":"preprint","venue":"SSRN Electronic Journal","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Thematic analysis; Feeling; Qualitative research; Inclusion (mineral); Quality of life (healthcare); Descriptive statistics; First line treatment; Lung cancer","score_opus":0.055109495612682295,"score_gpt":0.38100897585134275,"score_spread":0.32589948023866044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417056537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.913354,0.034631923,0.039639257,0.0005931862,0.0033712166,0.0074108345,0.0007615989,0.00005389188,0.00018411122],"genre_scores_gemma":[0.8948613,0.0982478,0.00097205624,0.000036138023,0.0008656245,0.0036588665,0.00010420452,0.00010788052,0.0011461466],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99261534,0.00025506062,0.0020827465,0.0010841012,0.0007329222,0.0032298544],"domain_scores_gemma":[0.9946432,0.00091485964,0.0014735993,0.0007980053,0.0016911158,0.00047921683],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011196566,0.0012162128,0.002116369,0.0011750823,0.0008485539,0.0001046769,0.0005548751,0.00026870254,0.000096398544],"category_scores_gemma":[0.00041079134,0.001041171,0.0009278481,0.00059889565,0.00015909119,0.0006910987,0.00029172376,0.0026311404,0.0000016388885],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.033762123,0.011991991,0.027881395,0.00095331407,0.047507882,0.00007113778,0.30917504,0.043915287,0.00022054664,0.0047239154,0.000016507234,0.5197809],"study_design_scores_gemma":[0.061714835,0.059085518,0.002693342,0.029602403,0.024331287,0.00030786963,0.7970245,0.010283555,0.0023170293,0.010151812,0.00061606534,0.0018718031],"about_ca_topic_score_codex":0.003394877,"about_ca_topic_score_gemma":0.017452145,"teacher_disagreement_score":0.51790905,"about_ca_system_score_codex":0.037236154,"about_ca_system_score_gemma":0.032061774,"threshold_uncertainty_score":0.99966985},"labels":[],"label_agreement":null},{"id":"W4417259921","doi":"10.1016/j.jtho.2025.12.004","title":"High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer Consortium","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre","funders":"National Institute of Environmental Health Sciences; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; Texas A and M University Health Science Center; World Health Organization","keywords":"Lung cancer; Genetic epidemiology; Genetic variants; Epidemiology; Glycosylation; Personalized medicine; Genetic testing; Genetic predisposition","score_opus":0.032396372872059334,"score_gpt":0.4625969334342655,"score_spread":0.4302005605622062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417259921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92747045,0.058532733,0.0061163614,0.0030245772,0.003722012,0.00043246362,0.00014737267,0.00001401056,0.0005400516],"genre_scores_gemma":[0.98171467,0.007082379,0.009006143,0.0011118879,0.00050602265,0.000050253246,0.000013006407,0.00002169923,0.00049393275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973896,0.00053353555,0.0012486803,0.00030767178,0.00019637638,0.00032413873],"domain_scores_gemma":[0.9967422,0.0009154838,0.0014039823,0.00026864544,0.00049360964,0.00017608619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030574616,0.00022970875,0.0013036388,0.0003154192,0.00013176842,0.000005186665,0.00020270997,0.00030533815,0.00030899406],"category_scores_gemma":[0.0003368613,0.00017595272,0.00022548404,0.0003259039,0.00018262427,0.00011288773,0.00004612307,0.00055143266,0.0000014513329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002977822,0.0005573755,0.87290406,0.00044323778,0.005438441,0.00042238555,0.0012015725,0.007833626,0.0043624225,0.0003876128,0.004775927,0.09869549],"study_design_scores_gemma":[0.0036532762,0.0005738937,0.97997886,0.001188009,0.0063609034,0.000051694777,0.00022817015,0.0026041525,0.0009967949,0.0017095738,0.0024890304,0.00016565026],"about_ca_topic_score_codex":0.0040629352,"about_ca_topic_score_gemma":0.0010611474,"teacher_disagreement_score":0.10707476,"about_ca_system_score_codex":0.0011322876,"about_ca_system_score_gemma":0.0028677653,"threshold_uncertainty_score":0.71751434},"labels":[],"label_agreement":null},{"id":"W4417434215","doi":"10.51731/cjht.2025.1307","title":"Lazertinib and Amivantamab (Lazcluze and Rybrevant)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Lung cancer; Drug; Clinical Practice; Cancer","score_opus":0.012612102283990068,"score_gpt":0.3396914984257826,"score_spread":0.32707939614179254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417434215","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10196356,0.691217,0.00015971875,0.20403813,0.0008933566,0.0005171434,0.000057514877,0.000042865926,0.0011107197],"genre_scores_gemma":[0.9688008,0.028422162,0.00050700735,0.0015259848,0.000016777733,0.000006134326,0.0000022344582,0.000014660601,0.0007042496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808985,0.00006201532,0.0008698427,0.0002427406,0.00012443248,0.0006111405],"domain_scores_gemma":[0.9986716,0.00013249984,0.00047073816,0.00026051397,0.00022386976,0.00024078652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004753458,0.00023493638,0.00072223286,0.0011494913,0.00056401757,0.00008573056,0.00016935283,0.00023303229,0.000024137027],"category_scores_gemma":[0.00066784886,0.00019389567,0.00006339276,0.00045782077,0.00068518537,0.00013839501,0.00004216507,0.0006026844,0.0000023284433],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041894033,0.00003230905,0.033413608,0.000774727,0.00040219803,0.00029324566,0.00087697647,0.000001104219,0.000014643444,0.0038589472,0.008188566,0.95210177],"study_design_scores_gemma":[0.0061303554,0.0029218774,0.14556426,0.007510296,0.0010008215,0.0014374322,0.031158974,0.000046952566,0.00033032132,0.013152837,0.790383,0.00036292002],"about_ca_topic_score_codex":0.0065718587,"about_ca_topic_score_gemma":0.006257247,"teacher_disagreement_score":0.95173883,"about_ca_system_score_codex":0.00074658793,"about_ca_system_score_gemma":0.009426466,"threshold_uncertainty_score":0.9961892},"labels":[],"label_agreement":null},{"id":"W4417480349","doi":"10.1016/j.jval.2025.09.147","title":"CO45 Clinical Efficacy and Safety of Targeted Therapies for HER2 Mutant Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Literature Review","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Clinical efficacy; Systematic review; Clinical trial; Mutant; Lung; Cell","score_opus":0.03639967329631678,"score_gpt":0.41791284638852894,"score_spread":0.38151317309221217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417480349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05604073,0.923364,0.0009531924,0.0060031917,0.00035522744,0.012961945,0.00022555166,0.000028384131,0.00006781383],"genre_scores_gemma":[0.2744832,0.6998873,0.017722799,0.005138434,0.000055314813,0.0014815166,0.000117176285,0.000043484084,0.0010708122],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9980024,0.00027134767,0.0011276021,0.00027201796,0.00011063672,0.00021600531],"domain_scores_gemma":[0.9981582,0.0009845624,0.00035384073,0.00026138301,0.00013978507,0.00010223456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085071364,0.00016016925,0.0011572388,0.00010350959,0.0000631566,0.000008687386,0.000058966016,0.00004775154,0.000009248613],"category_scores_gemma":[0.0003093159,0.00010009616,0.00010057501,0.00044621792,0.00003376478,0.00003465705,0.000014150833,0.00014422354,2.7785777e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010873065,0.00065697735,0.0037158818,0.98287976,0.00066643517,0.000022870061,0.0032384864,0.00027551976,0.00004673493,0.00035612372,0.0005886367,0.0064652846],"study_design_scores_gemma":[0.024025368,0.0024853447,0.010793125,0.9465068,0.002834961,0.000021215012,0.00081533036,0.009151607,0.000121060926,0.00011441748,0.0028572446,0.0002735012],"about_ca_topic_score_codex":0.00024061646,"about_ca_topic_score_gemma":0.00006192613,"teacher_disagreement_score":0.22347671,"about_ca_system_score_codex":0.00020150853,"about_ca_system_score_gemma":0.0011773405,"threshold_uncertainty_score":0.40818027},"labels":[],"label_agreement":null},{"id":"W4417481350","doi":"10.1016/j.jval.2025.09.3481","title":"MSR205 Transportability of Overall Survival Estimates From the United States to Germany in eGFR+ Advanced NSCLC Patients Post-Tyrosine Kinase Inhibitor (TKI) Treatment","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Overall survival; German; Lung cancer; Medical record; MEDLINE; Health records","score_opus":0.01765356673892164,"score_gpt":0.33530550878238613,"score_spread":0.3176519420434645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417481350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871426,0.0007863283,0.00002672596,0.009141342,0.00024231715,0.0018113939,0.00075576047,0.000026650849,0.000066886154],"genre_scores_gemma":[0.99583554,0.0002605602,0.0008338125,0.0015494251,0.000019526158,0.0001227163,0.0013155312,0.00001542246,0.000047472735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984406,0.00012952871,0.00063220976,0.000314615,0.00019513976,0.0002879094],"domain_scores_gemma":[0.9988549,0.00041836544,0.000107782835,0.0003394439,0.00015716426,0.00012237082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018034175,0.0001870063,0.00044650113,0.00019714586,0.000059411734,0.0000073679375,0.00007050355,0.000047796562,0.000023992212],"category_scores_gemma":[0.00012179079,0.00012749727,0.00006342922,0.000553033,0.000043406322,0.000054652628,0.000014473138,0.00010324371,0.0000022547247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015125013,0.0029927376,0.96548694,0.00028831867,0.00010911037,0.00001384992,0.009120177,0.012188136,0.00022943727,0.0004269912,0.00011590373,0.0075158803],"study_design_scores_gemma":[0.0074920533,0.001184054,0.98625886,0.000874428,0.00006954408,1.4672645e-7,0.0005566497,0.00083328504,0.000994781,0.00033183282,0.0013095625,0.00009480003],"about_ca_topic_score_codex":0.1451441,"about_ca_topic_score_gemma":0.0051925653,"teacher_disagreement_score":0.13995154,"about_ca_system_score_codex":0.0011493947,"about_ca_system_score_gemma":0.0005847907,"threshold_uncertainty_score":0.86054844},"labels":[],"label_agreement":null},{"id":"W4417526956","doi":"10.1016/j.cllc.2025.12.005","title":"Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib","year":2025,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Chemotherapy; Lung cancer; Osimertinib; Phases of clinical research; Pemetrexed; Disease; Adenocarcinoma","score_opus":0.025086633603350963,"score_gpt":0.4423766151278952,"score_spread":0.4172899815245443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417526956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621586,0.00964982,0.00008064175,0.015078091,0.005678899,0.0061594504,0.00020272154,0.00011786662,0.0008738908],"genre_scores_gemma":[0.97888786,0.004407803,0.0003180017,0.011951086,0.0004650042,0.0025532446,0.00015185564,0.00010103347,0.0011641297],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963021,0.00018767905,0.0013409696,0.0010308808,0.0005179916,0.0006203494],"domain_scores_gemma":[0.99666756,0.0014733189,0.00043918128,0.00090290693,0.000112066205,0.00040493952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003127819,0.0005431957,0.0010913954,0.00011739713,0.00025221088,0.00006467797,0.0002966022,0.0002337037,0.0004283606],"category_scores_gemma":[0.00028236973,0.00034372573,0.00070992217,0.00048035756,0.00011160397,0.00012299573,0.00007726947,0.0006449127,0.0000060561483],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23989655,0.006312909,0.3987968,0.00016513486,0.0033293278,0.00016204735,0.0012327154,0.00014888366,0.00066012796,0.00003350301,0.0071869995,0.342075],"study_design_scores_gemma":[0.8092586,0.002945868,0.14603455,0.0060420325,0.0053561516,2.4293996e-7,0.0005252308,0.007118514,0.0027077517,0.00012381174,0.018924113,0.00096313097],"about_ca_topic_score_codex":0.0006885766,"about_ca_topic_score_gemma":0.0002834872,"teacher_disagreement_score":0.56936204,"about_ca_system_score_codex":0.001013817,"about_ca_system_score_gemma":0.0016831895,"threshold_uncertainty_score":0.9999015},"labels":[],"label_agreement":null},{"id":"W4417539105","doi":"10.1136/jitc-2025-012205","title":"Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; Canadian Institutes of Health Research; Foundation Medicine; EMD Serono; Genentech; National Institutes of Health; Mirati Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lung cancer; Selection (genetic algorithm); Tumor microenvironment; Smoking history; Cancer; Differential (mechanical device)","score_opus":0.013308753787749896,"score_gpt":0.3321649297811176,"score_spread":0.31885617599336774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417539105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9268314,0.059976924,0.010106307,0.00046110264,0.0010382656,0.0012913037,0.0001238748,0.000014642174,0.00015614685],"genre_scores_gemma":[0.9745899,0.015983125,0.0047744126,0.0014995387,0.000096729826,0.00042460053,0.000028621258,0.00007758702,0.0025254767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979497,0.00005702555,0.0009971955,0.00032581374,0.00031165002,0.00035857328],"domain_scores_gemma":[0.99807715,0.00015540732,0.0008565893,0.0004104467,0.00043345694,0.000066926026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025483486,0.00033534213,0.0010929252,0.0010131231,0.00010353087,0.00001589858,0.00023037208,0.00016625982,0.00048492468],"category_scores_gemma":[0.0000124798935,0.0002822207,0.00078429794,0.00059227546,0.000066418404,0.000086527485,0.000008602122,0.00030226342,1.088077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011651395,0.0019599928,0.47300074,0.0006112032,0.010059772,0.0000032960293,0.0026509308,0.055538557,0.34377623,0.000024889796,0.0005678294,0.100155175],"study_design_scores_gemma":[0.06979379,0.0010682131,0.8155796,0.0033300046,0.0042217565,0.0000014839962,0.00022599555,0.024967369,0.074344195,0.000040609935,0.0058605354,0.0005664404],"about_ca_topic_score_codex":0.0006241251,"about_ca_topic_score_gemma":0.00043859045,"teacher_disagreement_score":0.34257886,"about_ca_system_score_codex":0.0020953573,"about_ca_system_score_gemma":0.0010677681,"threshold_uncertainty_score":0.999963},"labels":[],"label_agreement":null},{"id":"W648132389","doi":"10.1200/jco.2007.25.18_suppl.21047","title":"Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Gastroenterology; Histology; Esophageal cancer; Adenocarcinoma; Cancer; Single-nucleotide polymorphism; Carcinoma; Lung cancer; Genotype; Esophagus; Oncology; Biology; Gene","score_opus":0.12390230898249707,"score_gpt":0.501151456860917,"score_spread":0.3772491478784199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W648132389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97854906,0.0028746661,0.00008553814,0.017219217,0.0003091998,0.00017274452,0.000007483843,0.000004411252,0.000777696],"genre_scores_gemma":[0.99575585,0.00047117044,0.0006623856,0.001550169,0.0005520264,0.0000024520152,0.0000014192864,0.000008457125,0.0009960391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847555,0.00015837603,0.0009083461,0.00014466283,0.00015062609,0.00016244921],"domain_scores_gemma":[0.995083,0.00382395,0.00060933403,0.0000924138,0.00013082226,0.00026049043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018567353,0.00009407152,0.00059185916,0.000055975703,0.00009641087,0.000009523066,0.000048444348,0.00022050757,0.000021762531],"category_scores_gemma":[0.0012779812,0.000055179164,0.00006483893,0.00005095647,0.0004245761,0.00010670094,0.000038150618,0.0005942966,9.634721e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004551992,0.00009263351,0.96896756,0.00001711298,0.0001893256,0.00019680602,0.00034989108,0.000001026047,0.000017443506,0.0010490849,0.0001577557,0.028506143],"study_design_scores_gemma":[0.004482283,0.001913392,0.97765803,0.000034062024,0.00052635325,0.00022239033,0.00005785206,0.0000031771963,0.0000049920477,0.001102907,0.013946637,0.00004791103],"about_ca_topic_score_codex":0.00016068442,"about_ca_topic_score_gemma":0.00017158182,"teacher_disagreement_score":0.028458232,"about_ca_system_score_codex":0.0001032507,"about_ca_system_score_gemma":0.00054721604,"threshold_uncertainty_score":0.2581956},"labels":[],"label_agreement":null},{"id":"W6884303944","doi":"10.1016/j.jlb.2025.100302","title":"Corrigendum to “PP01.28 Expanding the Impact of Liquid Biopsies in patients with newly diagnosed advanced lung cancer (Expandinglung)” [J Liq Biopsy 5 (2024) e1–e32 100206]","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Pediatric Oncology Group; Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Biopsy; Lung biopsy; Liquid biopsy; MEDLINE; Cancer","score_opus":0.07986181896657975,"score_gpt":0.5351509989987554,"score_spread":0.45528918003217567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6884303944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841972,0.010342386,0.00021599808,0.0003212722,0.0011332362,0.00203098,0.00018248307,0.000027482425,0.0015489459],"genre_scores_gemma":[0.9953191,0.0024835803,0.00020619098,0.00027000354,0.00007118696,0.00033854778,0.00003763789,0.000055204287,0.0012184973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974206,0.00012167991,0.000869303,0.00048833096,0.00058914156,0.00051096117],"domain_scores_gemma":[0.9977154,0.00027963982,0.00065919576,0.00055244216,0.0005170431,0.00027628205],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003575201,0.00042176968,0.0010090717,0.0012057949,0.00025764006,0.00029613494,0.00090330926,0.00009762446,0.0029974838],"category_scores_gemma":[0.00028482822,0.00026111366,0.00022651987,0.0023447247,0.00012919377,0.0009706731,0.00034393146,0.00034109148,0.000002471318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034894224,0.0007032959,0.95779264,0.00015357367,0.0011922774,0.000040595678,0.0012896339,0.0016841487,0.011755402,0.000019591866,0.016206713,0.0056727016],"study_design_scores_gemma":[0.0051639336,0.0002252216,0.9800538,0.0031042057,0.00049321016,0.0000033296085,0.00034892952,0.000050617065,0.009825606,0.00010146053,0.0003336103,0.00029606678],"about_ca_topic_score_codex":0.0072075524,"about_ca_topic_score_gemma":0.00033723944,"teacher_disagreement_score":0.022261167,"about_ca_system_score_codex":0.0009122354,"about_ca_system_score_gemma":0.00083396654,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W6894229614","doi":"10.5683/sp/dsgeji","title":"Quon Sang Lung Laundry Shop--Fort MacLeod--Laser Scanning--Metadata--2016","year":2018,"lang":"en","type":"dataset","venue":"Borealis","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Laundry; Lung; Lung cancer; Patient privacy; MEDLINE","score_opus":0.015530692950221532,"score_gpt":0.33645262251043545,"score_spread":0.3209219295602139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6894229614","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000075913464,0.0012304729,0.000028625194,0.000511229,0.0005925222,0.0008456169,0.99257135,0.00011390505,0.0040303646],"genre_scores_gemma":[0.0000413346,0.00064992986,0.0003852429,0.001357803,0.0017779365,0.00019495795,0.98827815,0.000080949496,0.007233723],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761474,0.000049179147,0.00049798144,0.00070097967,0.0005880756,0.00054904795],"domain_scores_gemma":[0.99758273,0.00006436153,0.00027507026,0.0014986088,0.00021038747,0.00036882813],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018322439,0.00052169326,0.00074237643,0.00030623292,0.00020690102,0.00012888164,0.00030909388,0.00040579267,0.0010214052],"category_scores_gemma":[0.00009835924,0.0004040606,0.00026276076,0.0002235097,0.00016468766,0.0002716717,0.00013557171,0.00035345744,0.00012210636],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009643575,0.0001845333,0.0003984345,0.00029623433,0.0009975409,0.00029593325,0.000044911885,7.468725e-7,0.000003676617,0.000015031713,0.99678236,0.0008841372],"study_design_scores_gemma":[0.0014467158,0.00023990365,0.002692705,0.0006608716,0.0034382213,0.00008066782,0.000038750302,0.000009698561,0.00004732138,0.000021566391,0.9909264,0.00039721746],"about_ca_topic_score_codex":0.0482894,"about_ca_topic_score_gemma":0.011855433,"teacher_disagreement_score":0.03643397,"about_ca_system_score_codex":0.00047143336,"about_ca_system_score_gemma":0.00080464745,"threshold_uncertainty_score":0.9998918},"labels":[],"label_agreement":null},{"id":"W6901515577","doi":"10.60692/04jt1-1sy42","title":"Additional file 6 of Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lung cancer; Cohort; Profiling (computer programming); Gene; Gene expression profiling; Genotype","score_opus":0.00960215321998506,"score_gpt":0.2442866188772596,"score_spread":0.23468446565727455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901515577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8703647,0.0000055452806,0.00012882534,0.000026495294,0.000076964905,0.0059779575,0.117091954,0.00009924294,0.006228263],"genre_scores_gemma":[0.9705581,1.8285678e-7,0.00056283234,0.00003389594,0.00002038043,0.013205472,0.01542017,0.000009722411,0.00018922205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992539,0.000012802182,0.00033750312,0.00010189243,0.00016055137,0.00013330599],"domain_scores_gemma":[0.9995368,0.000035318197,0.00015291474,0.0001083384,0.00010847285,0.000058121757],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006175857,0.0001060103,0.00017642508,0.00028320707,0.000035074965,0.000018650233,0.00002842666,0.00005037576,0.004856628],"category_scores_gemma":[0.000038708044,0.000080253005,0.000037410664,0.00038740426,0.000017595225,0.00013689641,0.000020939104,0.00004240522,0.00006233303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046683894,0.0000055471287,0.96721417,0.0021425684,0.00019593324,0.00001816689,0.006741792,0.00012556695,0.0000094165725,0.000002416032,0.023346974,0.00015079773],"study_design_scores_gemma":[0.0018682221,0.00004344294,0.97971696,0.0013274781,0.00011912885,0.00001717378,0.0027036585,0.013413471,0.00021593271,3.5393546e-7,0.0004564331,0.0001177546],"about_ca_topic_score_codex":0.000025652265,"about_ca_topic_score_gemma":7.4858343e-7,"teacher_disagreement_score":0.101671785,"about_ca_system_score_codex":0.0001004107,"about_ca_system_score_gemma":0.00014526001,"threshold_uncertainty_score":0.99605304},"labels":[],"label_agreement":null},{"id":"W6901766222","doi":"10.60692/rjtzv-38y81","title":"Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"DNA sequencing; Lung cancer; Identification (biology); Clinical Practice; Precision medicine; Best practice; Disease; Molecular diagnostics","score_opus":0.10087921866151457,"score_gpt":0.3248418855452931,"score_spread":0.22396266688377853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901766222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97848594,0.00008466045,0.01625731,0.00064200745,0.00060488214,0.0015410135,0.00020448945,0.00014873937,0.00203098],"genre_scores_gemma":[0.99627995,0.000001896243,0.0021245277,0.00010596158,0.00022181908,0.00051407807,0.0003536969,0.000018420513,0.00037966904],"study_design_codex":"qualitative","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99818015,0.000021188003,0.0012552841,0.00021925905,0.00012358672,0.0002005366],"domain_scores_gemma":[0.9990893,0.000019827681,0.0005225803,0.00015024949,0.00014399369,0.0000740275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000505799,0.00014950873,0.0002286913,0.00029499512,0.00017007768,0.00025957724,0.000028304856,0.00005136592,0.0000061440196],"category_scores_gemma":[0.00006233023,0.00012810955,0.0000475967,0.00021221105,0.000007685781,0.00063661847,0.000016887767,0.00009221985,0.000009775523],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018023659,0.000020216376,0.2027872,0.021302313,0.000599312,0.0002147184,0.70872,0.007115571,0.009207306,0.00041113154,0.003221312,0.046220627],"study_design_scores_gemma":[0.006501402,0.00017533504,0.02548554,0.0074373246,0.00087174936,0.0005970111,0.042464364,0.890097,0.023758577,0.000003965289,0.0019687125,0.00063900696],"about_ca_topic_score_codex":0.00024737202,"about_ca_topic_score_gemma":0.000012563532,"teacher_disagreement_score":0.8829814,"about_ca_system_score_codex":0.0007274695,"about_ca_system_score_gemma":0.00023502452,"threshold_uncertainty_score":0.5224156},"labels":[],"label_agreement":null},{"id":"W6901881358","doi":"10.6084/m9.figshare.19135855","title":"Additional file 1 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto","funders":"","keywords":"Trametinib; Pharmacokinetics; Hepatic dysfunction; Cancer; Phases of clinical research; Drug","score_opus":0.02123129135647916,"score_gpt":0.30874819727061736,"score_spread":0.2875169059141382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901881358","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34526134,0.00003125559,2.4631923e-8,0.000005221744,0.000008496169,0.000485961,0.65407455,0.000004334572,0.00012879347],"genre_scores_gemma":[0.56539017,2.7676163e-7,0.00003076653,0.000022378044,0.000005611427,0.0022097738,0.43223202,0.000006225399,0.000102753074],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9994692,0.000017865377,0.00013321605,0.00011910534,0.0001967916,0.00006379141],"domain_scores_gemma":[0.99960345,0.00011464808,0.00010947562,0.00006501114,0.00007717862,0.000030228057],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000005507186,0.000061117214,0.0001284841,0.0000678457,0.000031617397,0.0000015999494,0.000019620587,0.0000074348914,0.9316989],"category_scores_gemma":[0.000080867416,0.000051621286,0.000014573282,0.00016986408,0.0000043689333,0.000034053213,0.000018759865,0.000049303002,0.000003276482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081393705,0.010149699,0.0030907812,0.000221389,0.00018020079,0.000012199486,0.0010408872,0.0005059284,0.00005269052,5.9566858e-8,0.9450283,0.038903892],"study_design_scores_gemma":[0.05536138,0.023802998,0.6693149,0.00325998,0.00047502996,0.000004503516,0.0020915486,0.0005641346,0.00027850128,0.0000027668643,0.24457438,0.0002698482],"about_ca_topic_score_codex":0.000021101172,"about_ca_topic_score_gemma":0.000024122937,"teacher_disagreement_score":0.93169564,"about_ca_system_score_codex":0.00009578418,"about_ca_system_score_gemma":0.00007325954,"threshold_uncertainty_score":0.21050549},"labels":[],"label_agreement":null},{"id":"W6901981926","doi":"10.60692/znqeq-kvq57","title":"The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers","year":2016,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"","keywords":"Crizotinib; Gene knockdown; Transfection; HEK 293 cells; Plasma protein binding; Binding site; Ligand binding assay; Cell","score_opus":0.05703986711915195,"score_gpt":0.2900129381269129,"score_spread":0.23297307100776096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901981926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934172,0.000009142688,0.0029001238,0.0002361645,0.0001527467,0.0010980638,0.00006016999,0.000049007827,0.0020773567],"genre_scores_gemma":[0.99904734,9.930908e-8,0.00018855707,0.000075027274,0.00003692008,0.00016067986,0.000004995989,0.000011231002,0.00047512425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986739,0.000099880956,0.000587795,0.00012431145,0.0003091234,0.00020494664],"domain_scores_gemma":[0.9991076,0.00003176483,0.00024332346,0.00041133323,0.0001278953,0.00007806878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032509022,0.00013013792,0.00022013923,0.00014487651,0.00019505969,0.000077789875,0.00009686086,0.000041623804,0.000012100552],"category_scores_gemma":[0.00003386786,0.00006759425,0.00004787131,0.00017292933,0.00003405882,0.0004137535,0.00003142978,0.000047950565,0.000040286748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043138134,0.000023688954,0.7587301,0.00021211806,0.00024455867,0.000016410013,0.2371765,0.00011447387,0.0004064465,0.00028405062,0.0002243601,0.0021359157],"study_design_scores_gemma":[0.006818463,0.0003016286,0.9586449,0.0015269893,0.00020290002,0.0000031466777,0.024095856,0.000048582842,0.0047808667,0.0000018283087,0.0033337486,0.00024108353],"about_ca_topic_score_codex":0.00011454772,"about_ca_topic_score_gemma":0.000031600368,"teacher_disagreement_score":0.21308064,"about_ca_system_score_codex":0.00037206293,"about_ca_system_score_gemma":0.00008463225,"threshold_uncertainty_score":0.27564135},"labels":[],"label_agreement":null},{"id":"W6902047749","doi":"10.6084/m9.figshare.19336230.v1","title":"Additional file 1 of Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Population; Survival analysis; MEDLINE; Lung cancer; Incidence (geometry); Lung","score_opus":0.017844524608299554,"score_gpt":0.3100614382239239,"score_spread":0.29221691361562435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902047749","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04604973,0.00002519471,3.6613557e-8,0.00013408394,0.00001272263,0.00023391459,0.9518693,0.000007670582,0.0016673224],"genre_scores_gemma":[0.4285923,8.754252e-7,0.000043126838,0.000049104674,0.0000071794166,0.002265678,0.56689036,0.000007688093,0.0021437071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992509,0.00002730804,0.00019915901,0.00021641758,0.00013385175,0.00017237106],"domain_scores_gemma":[0.99940115,0.00023334255,0.00009028096,0.0001357776,0.000030166266,0.00010925126],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000010160807,0.00011852453,0.00031595136,0.0009094181,0.00006174199,0.0000057296716,0.000038210765,0.000022057935,0.9494478],"category_scores_gemma":[0.000023515051,0.000111066845,0.0000964422,0.0008383444,0.00000196768,0.000028991839,0.000013261025,0.00006660087,0.000003122926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001783247,0.00016074475,0.85008246,0.000044838507,0.00017213968,0.000051746825,0.000179148,0.0039708354,2.2256592e-7,2.964444e-7,0.14277323,0.0025465328],"study_design_scores_gemma":[0.0013720117,0.00007896919,0.97364634,0.000191702,0.00016020972,2.3676026e-7,0.000097740376,0.0026666366,0.000003032115,4.5900998e-7,0.021692649,0.00009002989],"about_ca_topic_score_codex":0.43235135,"about_ca_topic_score_gemma":0.94097525,"teacher_disagreement_score":0.94944465,"about_ca_system_score_codex":0.0013771008,"about_ca_system_score_gemma":0.0005352702,"threshold_uncertainty_score":0.57142866},"labels":[],"label_agreement":null},{"id":"W6902120313","doi":"10.6084/m9.figshare.26745791.v1","title":"Additional file 1 of Uncovering molecular features driving lung adenocarcinoma heterogeneity in patients who formerly smoked","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adenocarcinoma; Lung; Lung cancer; Population","score_opus":0.009467441800864024,"score_gpt":0.2759722824915076,"score_spread":0.2665048406906436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902120313","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02246499,0.00047150347,3.5220356e-7,0.000021809732,0.000024508776,0.0002446964,0.9745224,0.000029705132,0.0022199934],"genre_scores_gemma":[0.36303908,4.1735188e-7,0.00010384802,0.00005148148,0.000027143984,0.0003766108,0.6360749,0.000014176312,0.0003123299],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993801,0.000008633715,0.000118779455,0.00017729666,0.00018010924,0.00013505587],"domain_scores_gemma":[0.99957824,0.00015719525,0.000034712564,0.000112334725,0.000064511805,0.00005303416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000005635417,0.00009656595,0.0001330162,0.000097258715,0.000024681829,0.000019969575,0.00004217265,0.000051281975,0.8336833],"category_scores_gemma":[0.0003117144,0.00008585816,0.00008755856,0.00016618223,0.0000039393735,0.00010486599,0.000032155687,0.00009489213,0.000109934874],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007948616,0.00004245097,0.0029111442,0.0003060812,0.00009088142,0.000052985568,0.0000817753,0.000015316979,0.000008095757,0.0000021894075,0.99487823,0.001602893],"study_design_scores_gemma":[0.0005361463,0.00014630846,0.8580492,0.010920887,0.000048819125,0.000007681117,0.00001757599,0.0002354389,0.00052244373,0.000012229763,0.12939024,0.00011302596],"about_ca_topic_score_codex":0.000010230079,"about_ca_topic_score_gemma":0.000021744576,"teacher_disagreement_score":0.865488,"about_ca_system_score_codex":0.0001611732,"about_ca_system_score_gemma":0.00014414766,"threshold_uncertainty_score":0.35011944},"labels":[],"label_agreement":null},{"id":"W6902132127","doi":"10.6084/m9.figshare.24465060","title":"Additional file 1 of First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis","year":2023,"lang":"en","type":"article","venue":"Open MIND","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Table (database); Whole brain radiotherapy; Radiation therapy; Brain metastasis; Retrospective cohort study","score_opus":0.04725204976302719,"score_gpt":0.3586239669788937,"score_spread":0.31137191721586654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902132127","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012040424,0.062788285,0.00018719058,0.015194832,0.000037851085,0.02532967,0.8800285,0.000028726556,0.004364524],"genre_scores_gemma":[0.05851832,0.010635832,0.076545,0.0050073876,0.00015470797,0.091678634,0.5462509,0.00048217835,0.21072708],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99848646,0.00012093828,0.00047079037,0.00044529323,0.0002531593,0.00022334218],"domain_scores_gemma":[0.99776596,0.0012754846,0.0003302947,0.00038238455,0.000118318174,0.00012756098],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000200522,0.0002920496,0.002062125,0.00024967606,0.0000673426,0.000039170078,0.0001097661,0.000043112228,0.23716564],"category_scores_gemma":[0.000060190858,0.00016592417,0.00022781054,0.001357397,0.000055494664,0.00010318296,0.000025589237,0.00006761097,0.00002090692],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023700967,0.0015310963,0.00022483562,0.039459284,0.5582489,0.0010434878,0.005152329,0.0035780556,0.000024744586,0.0000030869267,0.387655,0.00070910814],"study_design_scores_gemma":[0.024707504,0.0036779987,0.00029161858,0.01041545,0.93004346,0.000048784033,0.001122309,0.0042866995,0.0001643768,0.0000016740797,0.02466595,0.00057415775],"about_ca_topic_score_codex":0.0014835837,"about_ca_topic_score_gemma":0.012030951,"teacher_disagreement_score":0.37179458,"about_ca_system_score_codex":0.00039784508,"about_ca_system_score_gemma":0.00053092244,"threshold_uncertainty_score":0.7635317},"labels":[],"label_agreement":null},{"id":"W6902163011","doi":"10.6084/m9.figshare.14767246.v1","title":"Additional file 1 of Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Odds ratio; Hormone; Sex steroid; Lung cancer; Confidence interval; Sex hormone receptor; Steroid hormone; Testosterone (patch); Epidemiology","score_opus":0.13831644236194723,"score_gpt":0.35755061186095916,"score_spread":0.21923416949901192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902163011","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012801631,0.1459306,7.564383e-7,0.0002730358,0.000002595026,0.0009223232,0.8514925,0.000009240356,0.00008877275],"genre_scores_gemma":[0.34127596,0.008141707,0.000497979,0.0020238294,0.00008171513,0.008295285,0.63588065,0.00004693722,0.003755933],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99833447,0.0003820781,0.000551712,0.00031724095,0.0002641425,0.00015033632],"domain_scores_gemma":[0.9931289,0.0055842767,0.00063909794,0.00033107962,0.00022485048,0.00009177768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015008265,0.00018437792,0.0016849615,0.000071573544,0.0001520997,0.000017187114,0.00007321596,0.000068995614,0.22444631],"category_scores_gemma":[0.004997135,0.0001074967,0.00035684282,0.0004077569,0.000029825498,0.00006698117,0.00008728618,0.00012626433,0.0000042526035],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016680797,0.0002981865,0.012083859,0.07978027,0.18719454,0.000046500227,0.0020376132,0.000040441133,0.000051264033,0.00000389619,0.7179802,0.00046651307],"study_design_scores_gemma":[0.0005122437,0.00028162895,0.2265416,0.03782682,0.732284,0.000052483145,0.00039777148,0.00011613386,0.00015309059,0.0000206083,0.0014881272,0.00032550367],"about_ca_topic_score_codex":0.00007139829,"about_ca_topic_score_gemma":0.00010456404,"teacher_disagreement_score":0.7164921,"about_ca_system_score_codex":0.000081984654,"about_ca_system_score_gemma":0.00014331075,"threshold_uncertainty_score":0.77626264},"labels":[],"label_agreement":null},{"id":"W6902182663","doi":"10.6084/m9.figshare.19135861","title":"Additional file 3 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto","funders":"","keywords":"Trametinib; Pharmacokinetics; Hepatic dysfunction; Cancer; Phases of clinical research; Drug","score_opus":0.020838075923909124,"score_gpt":0.3082590588344491,"score_spread":0.28742098291053997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902182663","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3462304,0.000031395288,2.4754257e-8,0.000005192721,0.0000085718175,0.00048556927,0.6531051,0.0000043255486,0.00012946459],"genre_scores_gemma":[0.5674647,2.811873e-7,0.000030443942,0.000022392536,0.000005685159,0.0021712387,0.43019408,0.0000062338963,0.00010494499],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9994692,0.000017847922,0.00013327617,0.000119052616,0.00019683219,0.000063786414],"domain_scores_gemma":[0.99960387,0.00011361878,0.00010949307,0.000064912194,0.000077869154,0.00003022543],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000005504655,0.00006110848,0.00012849741,0.00006782272,0.000031614636,0.0000016032836,0.000019608067,0.00000743425,0.93007284],"category_scores_gemma":[0.00008084539,0.000051607938,0.000014572338,0.00016980017,0.0000043692485,0.000034079792,0.00001874611,0.00004929278,0.000003312829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008395743,0.010401029,0.0031731997,0.00023090882,0.00018459607,0.000012660601,0.0010672294,0.00051887217,0.00005415828,6.0683725e-8,0.94304436,0.040473368],"study_design_scores_gemma":[0.05603376,0.023727695,0.66453046,0.0032472652,0.00046987325,0.000004453051,0.0020778354,0.00056405657,0.00028413505,0.000002770204,0.24878828,0.00026940505],"about_ca_topic_score_codex":0.000021344149,"about_ca_topic_score_gemma":0.000024289222,"teacher_disagreement_score":0.9300695,"about_ca_system_score_codex":0.00009616964,"about_ca_system_score_gemma":0.00007330064,"threshold_uncertainty_score":0.21045107},"labels":[],"label_agreement":null},{"id":"W6902191558","doi":"10.6084/m9.figshare.25210472","title":"Additional file 1 of Risk prediction models for lung cancer in people who have never smoked: a protocol of a systematic review","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Health Services Authority; Brock University; University of British Columbia","funders":"","keywords":"Protocol (science); Table (database); Predictive modelling; Lung cancer; Risk assessment","score_opus":0.032166521491750304,"score_gpt":0.392405871864972,"score_spread":0.3602393503732217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902191558","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007250791,0.001658533,0.00020492882,0.00014328356,0.000026457814,0.19742021,0.79544574,0.0000024033934,0.0050259307],"genre_scores_gemma":[0.0009229431,0.00011284918,0.0032562953,0.000043327993,0.00004227101,0.97419435,0.0127523625,0.000019625058,0.008655966],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9992302,0.0000263206,0.00037988945,0.00015451928,0.00013561698,0.00007346501],"domain_scores_gemma":[0.9992709,0.0003040057,0.00014754345,0.0001366518,0.00011166509,0.000029238588],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010523307,0.000072260584,0.00039834628,0.000058691374,0.000017711323,0.0000124705,0.00005514814,0.000031232976,0.23417021],"category_scores_gemma":[0.00016671795,0.000052077263,0.000076143,0.00014357764,0.000012267934,0.00019262815,0.00001916891,0.00004651142,0.000005041467],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007866121,0.00016042971,0.00007773975,0.19178335,0.00035911443,0.0000030399408,0.001331407,0.00018761006,0.0000024195658,0.000016405542,0.8037299,0.0022699214],"study_design_scores_gemma":[0.002093382,0.00025904138,0.0009630745,0.8163932,0.0026522,0.0000122852,0.00031502757,0.13623975,0.00006578158,0.00010925017,0.04077695,0.00012005524],"about_ca_topic_score_codex":0.00026246853,"about_ca_topic_score_gemma":0.00029982027,"teacher_disagreement_score":0.7826934,"about_ca_system_score_codex":0.0001429591,"about_ca_system_score_gemma":0.0005046536,"threshold_uncertainty_score":0.76652986},"labels":[],"label_agreement":null},{"id":"W6902209036","doi":"10.6084/m9.figshare.25150611","title":"Additional file 1 of Impact of individual level uncertainty of lung cancer polygenic risk score (PRS) on risk stratification","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Lung cancer; Table (database); Cancer; Risk stratification; Single-nucleotide polymorphism","score_opus":0.0559594393280274,"score_gpt":0.365121106404165,"score_spread":0.3091616670761376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902209036","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011477777,0.0005330816,5.889358e-7,0.00001472167,0.000022963755,0.0003123093,0.98668796,0.000018554687,0.0009320732],"genre_scores_gemma":[0.4114699,0.000011170106,0.000060975977,0.000005943333,0.000057462577,0.00035166234,0.58771604,0.000010336851,0.00031646847],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99916685,0.000024527906,0.00024510923,0.00017219887,0.00028737876,0.00010396174],"domain_scores_gemma":[0.9987623,0.00055971235,0.000246838,0.00017998595,0.00019403537,0.000057147252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000021731323,0.000110047964,0.00019000795,0.00011874306,0.000032982378,0.000008449356,0.00006742373,0.00006516627,0.95268226],"category_scores_gemma":[0.00058781076,0.00008213129,0.00018860737,0.00024415855,0.000015470085,0.0000619161,0.000015028997,0.00013134159,0.000067576344],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000443878,0.00010856936,0.0006171982,0.00032985208,0.0007686991,0.0000020802374,0.00032385066,0.00042305927,0.000035946246,0.0000065215563,0.98836195,0.008977876],"study_design_scores_gemma":[0.0008841106,0.0007767403,0.96191597,0.014415136,0.00085819216,0.0000053361987,0.00013345692,0.0024735616,0.0010961309,0.00007369424,0.0171988,0.000168874],"about_ca_topic_score_codex":0.0005115881,"about_ca_topic_score_gemma":0.00009568191,"teacher_disagreement_score":0.97116315,"about_ca_system_score_codex":0.00016860726,"about_ca_system_score_gemma":0.0010940082,"threshold_uncertainty_score":0.3349217},"labels":[],"label_agreement":null},{"id":"W6902218777","doi":"10.6084/m9.figshare.22616572.v1","title":"Additional file 2 of Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Liquid biopsy; Concordance; Lung cancer; Pathological","score_opus":0.041573035474742136,"score_gpt":0.3589488563716697,"score_spread":0.31737582089692756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902218777","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041323025,0.00004280016,2.3233464e-7,0.000035593017,0.000042071042,0.00028212066,0.9551805,0.000021104008,0.003072527],"genre_scores_gemma":[0.19206601,0.0000056252647,0.00015471001,0.00003535145,0.00010304838,0.0006382874,0.8033778,0.0000124848975,0.0036066726],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991953,0.00001971245,0.00031092332,0.00018061484,0.00015187584,0.00014160121],"domain_scores_gemma":[0.99917644,0.00032252958,0.0001325219,0.00016325674,0.00013505385,0.00007017494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002716262,0.0000800181,0.00021667371,0.0000812914,0.000019056752,0.000002890568,0.00006133802,0.000088004934,0.9731282],"category_scores_gemma":[0.0003607378,0.000071522634,0.00012722972,0.00026354825,0.000014185535,0.000034898967,0.000047495058,0.00011205092,0.0003209519],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008141435,0.00016735266,0.0017330637,0.00036708722,0.00004927382,0.000047580168,0.000091630005,0.000010624474,0.000023326424,1.8215697e-7,0.9971454,0.00028304636],"study_design_scores_gemma":[0.0013819031,0.00023647712,0.84148544,0.0032117544,0.00006514338,0.0000017410268,0.00007578564,0.0015085205,0.00048347912,0.0000018892789,0.15145151,0.000096329146],"about_ca_topic_score_codex":0.00015174187,"about_ca_topic_score_gemma":0.000053037147,"teacher_disagreement_score":0.9728072,"about_ca_system_score_codex":0.000031303956,"about_ca_system_score_gemma":0.0004561398,"threshold_uncertainty_score":0.4125294},"labels":[],"label_agreement":null},{"id":"W6902228857","doi":"10.6084/m9.figshare.26745794.v1","title":"Additional file 2 of Uncovering molecular features driving lung adenocarcinoma heterogeneity in patients who formerly smoked","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adenocarcinoma; Lung; Lung cancer; Population","score_opus":0.00913796915458877,"score_gpt":0.2754079863947583,"score_spread":0.2662700172401695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902228857","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022325953,0.00047989885,3.4445537e-7,0.000021707736,0.000024680729,0.0002444335,0.9745978,0.000029721776,0.0022754774],"genre_scores_gemma":[0.36079174,4.3023414e-7,0.00010170375,0.0000516253,0.000027646662,0.00036995753,0.63832843,0.000014193969,0.00031428173],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993803,0.000008630603,0.00011883598,0.00017715544,0.00018006134,0.00013500296],"domain_scores_gemma":[0.9995809,0.0001548362,0.000034764107,0.00011210544,0.00006435932,0.000053025822],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00000560274,0.00009653333,0.00013305081,0.00009719108,0.00002468375,0.000020015617,0.000042147716,0.00005128229,0.8308626],"category_scores_gemma":[0.00030772045,0.00008582835,0.000087540575,0.00016604502,0.0000039393153,0.00010494232,0.00003215088,0.00009486892,0.000108689506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007906599,0.000042457454,0.0028148496,0.00030918236,0.0000909277,0.00005455442,0.00008188947,0.000015402875,0.000007802201,0.00000223147,0.9949215,0.0016512766],"study_design_scores_gemma":[0.0005415808,0.00014675038,0.8529636,0.010809292,0.000048769543,0.000007721099,0.000017434886,0.00023443197,0.00052046805,0.000012368264,0.13458446,0.000113094444],"about_ca_topic_score_codex":0.000010339623,"about_ca_topic_score_gemma":0.000021881306,"teacher_disagreement_score":0.8603371,"about_ca_system_score_codex":0.00016122224,"about_ca_system_score_gemma":0.0001434664,"threshold_uncertainty_score":0.34999785},"labels":[],"label_agreement":null},{"id":"W6920293694","doi":"10.60692/4xck9-epy89","title":"Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Osimertinib; Adverse effect; Docetaxel; Randomized controlled trial; Incidence (geometry); Lung cancer; Hazard ratio","score_opus":0.034174864216582654,"score_gpt":0.29604648097238795,"score_spread":0.2618716167558053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920293694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7955683,0.04578068,0.008034275,0.0011100033,0.00019036044,0.14236967,0.0058226525,0.00021985477,0.0009041993],"genre_scores_gemma":[0.99567294,0.000015877085,0.0001410273,0.00015412402,0.0000013566352,0.0037982927,0.00012440709,0.0000066052,0.00008536332],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976202,0.0002561446,0.0016012391,0.000112206195,0.0003192087,0.00009100285],"domain_scores_gemma":[0.99738914,0.0002202163,0.0014976318,0.00021598277,0.0006326011,0.00004444445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010210412,0.00016380197,0.005270904,0.00031996993,0.000107029744,0.000011250139,0.000035595403,0.0000187362,0.00001752719],"category_scores_gemma":[0.00022620232,0.00008133003,0.0005154656,0.00035936173,0.000052924217,0.000109338194,0.000027707832,0.00003068048,4.944453e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06532892,0.00003474214,0.002711497,0.1939645,0.6938079,5.052976e-7,0.04387054,0.00015408247,1.2236521e-7,0.00010814693,0.00001381614,0.0000052608216],"study_design_scores_gemma":[0.21356143,0.00023747892,0.00087825244,0.0013906084,0.7787918,0.000003543583,0.0046016276,0.00046039768,0.0000024899007,1.993179e-7,0.0000011605571,0.00007102334],"about_ca_topic_score_codex":0.0000051035154,"about_ca_topic_score_gemma":1.16541806e-7,"teacher_disagreement_score":0.20010464,"about_ca_system_score_codex":0.000064447384,"about_ca_system_score_gemma":0.000035080342,"threshold_uncertainty_score":0.36030844},"labels":[],"label_agreement":null},{"id":"W6920596186","doi":"10.6084/m9.figshare.16907365","title":"Additional file 1 of Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Grand River Hospital; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Crizotinib; Docetaxel; Pemetrexed; Lung cancer; Table (database); Chemotherapy; Survival analysis; ROS1","score_opus":0.021211982091586524,"score_gpt":0.3273349454131584,"score_spread":0.30612296332157185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920596186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7794942,0.00021051428,0.000011313276,0.000083056395,0.000023762987,0.001303747,0.21296509,5.1907324e-7,0.005907804],"genre_scores_gemma":[0.95204824,0.00004492349,0.002484123,0.000021038692,0.000011086235,0.0020650318,0.04152565,0.000015414142,0.0017844794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991205,0.000040726663,0.00025635542,0.00027718258,0.00015183246,0.0001534547],"domain_scores_gemma":[0.99893993,0.0004950382,0.0001341869,0.0001983712,0.00016479299,0.000067649926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000033855536,0.0001303932,0.0005416213,0.00013018963,0.00002343374,0.0000064921915,0.0000605748,0.000029680592,0.22993164],"category_scores_gemma":[0.000029721265,0.00010383456,0.000060359536,0.0008329041,0.000019947558,0.000053854434,0.000022944978,0.000053900923,0.0000014444296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030709833,0.0049471552,0.7452695,0.00046019658,0.0069421977,0.0012421217,0.0034568252,0.058715153,0.0017849942,0.000001081199,0.015931914,0.1581779],"study_design_scores_gemma":[0.01603771,0.0006846299,0.9009412,0.0025829847,0.0032445774,0.000005512058,0.0017225852,0.004526465,0.02344562,8.8473e-7,0.04651789,0.0002899706],"about_ca_topic_score_codex":0.5416908,"about_ca_topic_score_gemma":0.9848809,"teacher_disagreement_score":0.4431901,"about_ca_system_score_codex":0.0011705196,"about_ca_system_score_gemma":0.0041268975,"threshold_uncertainty_score":0.7707723},"labels":[],"label_agreement":null},{"id":"W6920630887","doi":"10.6084/m9.figshare.22616572","title":"Additional file 2 of Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Liquid biopsy; Concordance; Lung cancer; Pathological","score_opus":0.041573035474742136,"score_gpt":0.3589488563716697,"score_spread":0.31737582089692756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920630887","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041323025,0.00004280016,2.3233464e-7,0.000035593017,0.000042071042,0.00028212066,0.9551805,0.000021104008,0.003072527],"genre_scores_gemma":[0.19206601,0.0000056252647,0.00015471001,0.00003535145,0.00010304838,0.0006382874,0.8033778,0.0000124848975,0.0036066726],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991953,0.00001971245,0.00031092332,0.00018061484,0.00015187584,0.00014160121],"domain_scores_gemma":[0.99917644,0.00032252958,0.0001325219,0.00016325674,0.00013505385,0.00007017494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002716262,0.0000800181,0.00021667371,0.0000812914,0.000019056752,0.000002890568,0.00006133802,0.000088004934,0.9731282],"category_scores_gemma":[0.0003607378,0.000071522634,0.00012722972,0.00026354825,0.000014185535,0.000034898967,0.000047495058,0.00011205092,0.0003209519],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008141435,0.00016735266,0.0017330637,0.00036708722,0.00004927382,0.000047580168,0.000091630005,0.000010624474,0.000023326424,1.8215697e-7,0.9971454,0.00028304636],"study_design_scores_gemma":[0.0013819031,0.00023647712,0.84148544,0.0032117544,0.00006514338,0.0000017410268,0.00007578564,0.0015085205,0.00048347912,0.0000018892789,0.15145151,0.000096329146],"about_ca_topic_score_codex":0.00015174187,"about_ca_topic_score_gemma":0.000053037147,"teacher_disagreement_score":0.9728072,"about_ca_system_score_codex":0.000031303956,"about_ca_system_score_gemma":0.0004561398,"threshold_uncertainty_score":0.4125294},"labels":[],"label_agreement":null},{"id":"W6920714080","doi":"10.6084/m9.figshare.12866737.v2","title":"Pricing methods in outcome-based contracting: δ3: reference-based pricing","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pooling; Inflation (cosmology); Dimension (graph theory); Markov chain Monte Carlo; Foreign exchange; Set (abstract data type); Value (mathematics)","score_opus":0.18867596407295836,"score_gpt":0.45604649429281635,"score_spread":0.267370530219858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920714080","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.137839,0.007284437,0.026548706,0.10730328,0.0014114161,0.025809947,0.22014253,0.005863991,0.46779668],"genre_scores_gemma":[0.9450435,8.8685385e-7,0.023000512,0.006774766,0.000117781536,0.00026997554,0.024619991,0.000041268224,0.00013131456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892926,0.000064831,0.00030873873,0.00028609982,0.00017115752,0.00023990913],"domain_scores_gemma":[0.99892217,0.00051967433,0.00013003225,0.00017861566,0.000078187986,0.00017130413],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007048689,0.00015539455,0.00031005646,0.00009179642,0.000060630337,0.000029150355,0.000075406875,0.00008330542,0.019480592],"category_scores_gemma":[0.0024631086,0.000129644,0.00007885859,0.0003487939,0.000004085424,0.00006766873,0.000018264578,0.00026512414,0.00022492511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020907088,0.0031074993,0.3997358,0.012193117,0.0010177731,0.002893431,0.008515405,0.011462025,0.021806445,0.00022069892,0.115771115,0.42118597],"study_design_scores_gemma":[0.026905755,0.0018026689,0.19484092,0.011238065,0.0007552729,0.000019143037,0.0014649528,0.08128913,0.058177106,0.000027248492,0.62214124,0.0013385038],"about_ca_topic_score_codex":0.000059447764,"about_ca_topic_score_gemma":0.00001536799,"teacher_disagreement_score":0.8072045,"about_ca_system_score_codex":0.000204228,"about_ca_system_score_gemma":0.00038252302,"threshold_uncertainty_score":0.98141575},"labels":[],"label_agreement":null},{"id":"W6920772230","doi":"10.6084/m9.figshare.12601276.v1","title":"Costs of in-house genomic profiling and implications for economic evaluation: A case example of non-small cell lung cancer (NSCLC)","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profiling (computer programming); Activity-based costing; Cost–benefit analysis; Cost estimate; Economic evaluation; Health economics; Medical costs; Cost driver","score_opus":0.07764295015092962,"score_gpt":0.3691843685213458,"score_spread":0.29154141837041614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920772230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85295194,0.0024159222,0.000022178167,0.00046271205,0.000019827883,0.0030863725,0.14056267,0.000018594508,0.00045980216],"genre_scores_gemma":[0.99017584,0.000016074762,0.00075200363,0.00009451222,0.000053550113,0.0015066649,0.007367252,0.000021464373,0.000012651291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995131,0.00000819942,0.00019377521,0.00016925459,0.00003115087,0.00008453683],"domain_scores_gemma":[0.9995255,0.000077386125,0.000112180736,0.000116832016,0.00010353709,0.00006459066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000029720271,0.00006805754,0.00016120239,0.00003857625,0.00002692972,0.000004824083,0.00003104153,0.000031974065,0.002085817],"category_scores_gemma":[0.000045241202,0.00006604232,0.00003611325,0.000049816448,0.000004482259,0.000034900717,0.000020232277,0.00003242487,0.0000059700224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012399893,0.0014168007,0.5363374,0.027717901,0.0019989558,0.00014747836,0.04077321,0.017326633,0.1024293,0.0004170942,0.15915363,0.111041665],"study_design_scores_gemma":[0.046878174,0.0019173096,0.589909,0.007133726,0.0042153304,0.0002557179,0.002734799,0.24072206,0.09442452,0.00009697951,0.010545972,0.0011664148],"about_ca_topic_score_codex":0.00036364506,"about_ca_topic_score_gemma":0.00028986292,"teacher_disagreement_score":0.22339542,"about_ca_system_score_codex":0.00018632736,"about_ca_system_score_gemma":0.0005415995,"threshold_uncertainty_score":0.9988264},"labels":[],"label_agreement":null},{"id":"W6920864355","doi":"10.6084/m9.figshare.26757034.v1","title":"Additional file 1 of Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Drug; Cancer; Clinical trial; Lung","score_opus":0.027344402079996766,"score_gpt":0.3372725535397265,"score_spread":0.30992815145972974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920864355","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020922922,0.0011856308,0.00018742695,0.00008487733,0.000014454049,0.0009515133,0.9764672,0.000010424972,0.00017556625],"genre_scores_gemma":[0.6312072,0.0000033894626,0.0010163748,0.000009497916,0.000012636586,0.0009826528,0.36672047,0.000011868168,0.000035870726],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9992398,0.000010373679,0.0002635539,0.00018175358,0.00020539014,0.00009911411],"domain_scores_gemma":[0.99859196,0.0008291562,0.000088285095,0.00008537347,0.00037954142,0.000025700865],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000020474947,0.00009581021,0.00022560869,0.00016711677,0.000015336247,0.000005400967,0.00004713251,0.00005108615,0.25622016],"category_scores_gemma":[0.00014813717,0.00008339362,0.000072388204,0.00027969532,0.00000937305,0.00008403394,0.0000050748613,0.00007138991,0.0000028279992],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004388864,0.0015596856,0.0009637629,0.041001882,0.00046723385,0.00002755591,0.014351098,0.17494996,0.0033110497,0.000041962063,0.74573725,0.013199709],"study_design_scores_gemma":[0.026445208,0.0023624583,0.032000225,0.3606093,0.0005941006,0.000002867055,0.0010185648,0.49511346,0.07151905,0.00005330055,0.009643289,0.0006381887],"about_ca_topic_score_codex":0.000029284018,"about_ca_topic_score_gemma":0.0001500153,"teacher_disagreement_score":0.73609394,"about_ca_system_score_codex":0.00014876561,"about_ca_system_score_gemma":0.0013214999,"threshold_uncertainty_score":0.74445975},"labels":[],"label_agreement":null},{"id":"W6921078895","doi":"10.6084/m9.figshare.29162452.v1","title":"Additional file 1 of Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany","year":2025,"lang":"en","type":"article","venue":"Open MIND","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Retrospective cohort study; Lung; MEDLINE; Lung cancer","score_opus":0.014780627611221469,"score_gpt":0.3316293945948206,"score_spread":0.31684876698359915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921078895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7628469,0.000020056052,0.000004924585,0.00006972785,0.000017013374,0.0011435931,0.23366459,3.5685636e-7,0.0022328752],"genre_scores_gemma":[0.97463506,0.00003149714,0.002915245,0.000050205566,0.000009146856,0.0011578776,0.014214467,0.000009870052,0.0069766045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994081,0.000009015586,0.00016725496,0.00021628116,0.00008191281,0.00011739021],"domain_scores_gemma":[0.9993549,0.00031753368,0.000094817704,0.00009836402,0.00007952119,0.000054845787],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000013284687,0.000118869815,0.00033069868,0.00009574572,0.000045882232,0.000015782982,0.000033863183,0.000012231534,0.019952217],"category_scores_gemma":[0.000012270403,0.00008124604,0.000020921752,0.00011308266,0.000017799552,0.000048034795,0.000022016764,0.00002973253,3.3772673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000126194,0.00021087984,0.9756817,0.0000637286,0.00043689288,0.000010155064,0.0004733026,0.000006601134,0.0000018022338,4.2212807e-7,0.015903981,0.0070843385],"study_design_scores_gemma":[0.005831718,0.000262896,0.98685986,0.00037274667,0.0005473598,2.9639517e-7,0.00022637793,0.00017942119,0.00008893064,0.0000024395856,0.0055539273,0.000074011514],"about_ca_topic_score_codex":0.59593785,"about_ca_topic_score_gemma":0.9524366,"teacher_disagreement_score":0.35649878,"about_ca_system_score_codex":0.00060140016,"about_ca_system_score_gemma":0.0011454007,"threshold_uncertainty_score":0.9809437},"labels":[],"label_agreement":null},{"id":"W6929244373","doi":"10.5061/dryad.sj3tx96fp","title":"Agriculture land-use change seasonally rewires stream food webs: A case study from headwater streams in the Lake Erie watershed","year":2025,"lang":"en","type":"dataset","venue":"DRYAD","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Canada First Research Excellence Fund","keywords":"Riparian zone; Agriculture; Trophic level; STREAMS; Food web; Watershed; Ecosystem; Biomass (ecology)","score_opus":0.030512372528198602,"score_gpt":0.31908669668918194,"score_spread":0.28857432416098333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929244373","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22359134,0.00043528725,1.513908e-7,0.0010186449,0.00021287061,0.0020227362,0.77263564,0.000034115208,0.000049199592],"genre_scores_gemma":[0.04176277,0.0001617762,0.000019677302,0.0012649033,0.00053706503,0.0010465528,0.9544524,0.000015944133,0.00073889905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981964,0.0001745301,0.00032830337,0.0005650697,0.00039284833,0.00034280278],"domain_scores_gemma":[0.998721,0.00014800274,0.00010918947,0.000825525,0.00008840754,0.000107887055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097978154,0.0004448624,0.000591691,0.00013459029,0.00013404367,0.00014546794,0.00022502561,0.00025486492,0.00025685987],"category_scores_gemma":[0.00003682325,0.00022730895,0.00013996131,0.00027377513,0.0000351582,0.00012550286,0.00009545482,0.00047509666,0.00001681281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117016396,0.0018514042,0.024138369,0.00011213759,0.0009997607,0.012180879,0.003788913,7.4560086e-7,5.662767e-7,6.695264e-7,0.9561697,0.0006398107],"study_design_scores_gemma":[0.003867003,0.0010211425,0.014551744,0.00042662548,0.0022945006,0.00022979117,0.004620407,0.0000012027017,0.0000044434146,0.000006880917,0.9727016,0.00027465817],"about_ca_topic_score_codex":0.016480131,"about_ca_topic_score_gemma":0.5718031,"teacher_disagreement_score":0.55532295,"about_ca_system_score_codex":0.00014187758,"about_ca_system_score_gemma":0.00017162268,"threshold_uncertainty_score":0.9900692},"labels":[],"label_agreement":null},{"id":"W6930400274","doi":"10.5281/zenodo.12409745","title":"Vw id4 brochure pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Notice; Event (particle physics); Signage; Bottle; Train; Electric cars; Electric motor; Buzzer","score_opus":0.02232629375739874,"score_gpt":0.2961637198573504,"score_spread":0.27383742609995165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930400274","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000147316905,0.0015868895,0.00020138462,0.0010196429,0.00024252561,0.0006563235,0.0004321934,0.0013654556,0.99448085],"genre_scores_gemma":[0.001348075,0.00032931086,0.00022143945,0.00023186616,0.000606912,9.380954e-8,0.004505201,0.009371549,0.98338556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987043,0.00006553198,0.00016809463,0.0004596996,0.00033065586,0.00027171272],"domain_scores_gemma":[0.99907845,0.0000048995607,0.00007577943,0.0004674009,0.00017437448,0.00019907937],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000106629595,0.00020209246,0.00023380335,0.00038591845,0.00037695246,0.00033933128,0.00029675342,0.00015163637,0.24409671],"category_scores_gemma":[0.00010055533,0.00018302698,0.0000932887,0.00038339564,0.00009694671,0.000042593085,0.0003484302,0.00032280767,0.23563178],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019813337,0.00009868971,5.883116e-7,0.0003635825,0.00033222925,0.000092335424,0.00028213923,3.2236102e-7,0.00011484875,0.0013138355,0.97710305,0.020278538],"study_design_scores_gemma":[0.0005998761,0.00021297729,0.000026401816,0.0003906716,0.00028199394,0.00019708762,0.00010976581,0.000010431602,0.000024051065,0.00014142232,0.99784344,0.00016189727],"about_ca_topic_score_codex":0.000038062353,"about_ca_topic_score_gemma":8.5579234e-7,"teacher_disagreement_score":0.020740345,"about_ca_system_score_codex":0.00022374303,"about_ca_system_score_gemma":0.000011303701,"threshold_uncertainty_score":0.7649634},"labels":[],"label_agreement":null},{"id":"W6930400583","doi":"10.5281/zenodo.12251550","title":"global biodiversity pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biodiversity; Convention on Biological Diversity; Measurement of biodiversity; Agricultural biodiversity; Food security; Ecosystem services; Global biodiversity; Agriculture","score_opus":0.024222120597600313,"score_gpt":0.2866081478150699,"score_spread":0.26238602721746956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930400583","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042450196,0.0007670653,0.00013789524,0.00090945495,0.00022491212,0.0004739401,0.0024034618,0.0011652594,0.99387556],"genre_scores_gemma":[0.0013922488,0.00027997,0.00021785704,0.00030223207,0.00031456578,3.4125783e-8,0.009614549,0.0026397433,0.9852388],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998969,0.00005196821,0.00010987718,0.00038578932,0.0002664336,0.00021693858],"domain_scores_gemma":[0.99928683,0.0000023080033,0.00005735236,0.00033848078,0.00014068707,0.00017436992],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008275009,0.00015526781,0.00017482217,0.00020486224,0.0003898732,0.0002572758,0.00025668283,0.0001169275,0.18261987],"category_scores_gemma":[0.00006006971,0.00014568894,0.00008165426,0.00039337753,0.00010279062,0.000035141475,0.00042385803,0.00015501394,0.2954928],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021252032,0.000091834576,0.0000066502976,0.00019871771,0.00031763242,0.000094321156,0.00011408073,2.7057501e-7,0.0000075318158,0.00048272096,0.9840996,0.014565343],"study_design_scores_gemma":[0.00054636947,0.00016255323,0.00013418973,0.00014246337,0.00029275534,0.00013911485,0.000088990455,0.0000030140932,0.0000038765784,0.00006419866,0.998298,0.00012450152],"about_ca_topic_score_codex":0.00010011249,"about_ca_topic_score_gemma":0.0000013608562,"teacher_disagreement_score":0.11287293,"about_ca_system_score_codex":0.0003663832,"about_ca_system_score_gemma":0.000009090085,"threshold_uncertainty_score":0.81812733},"labels":[],"label_agreement":null},{"id":"W6930874250","doi":"10.5281/zenodo.15625993","title":"Cleaned spawner survey data","year":2025,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Escapement; Code (set theory); Survey data collection; Aerial survey; Fish <Actinopterygii>; Survey methodology","score_opus":0.07932023619355667,"score_gpt":0.35472097100661265,"score_spread":0.275400734813056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930874250","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023704002,0.00022013256,0.000108508706,0.0005695856,0.00024509963,0.00072427135,0.97428447,0.0003168868,0.023507325],"genre_scores_gemma":[0.00018526388,0.000574332,0.0001030436,0.00043342513,0.00022365135,5.484111e-8,0.99251944,0.0006019086,0.00535888],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977621,0.0003525681,0.00032174925,0.0007571233,0.00045355168,0.0003529024],"domain_scores_gemma":[0.99666184,0.00005608846,0.00014035615,0.0022523801,0.0006702829,0.0002190648],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00065315585,0.00024503493,0.00034382974,0.00034615488,0.0012628275,0.00048760933,0.0015119845,0.00017058633,0.01753449],"category_scores_gemma":[0.0014621622,0.00022570789,0.00005793995,0.0006175507,0.00012721203,0.00014845192,0.0025086596,0.00047555633,0.0038414223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011919283,0.0002731398,0.000002302475,0.0002416033,0.00035122078,0.000055085173,0.000040030165,0.0000013448122,0.000006994117,0.00002869606,0.98041946,0.018460924],"study_design_scores_gemma":[0.0010256111,0.00021347908,0.00060079887,0.00015136106,0.00037284676,0.00008053571,0.00003985617,0.000021616943,0.0000060438624,0.000009042738,0.997289,0.00018979525],"about_ca_topic_score_codex":0.0005189043,"about_ca_topic_score_gemma":0.000013494169,"teacher_disagreement_score":0.018271128,"about_ca_system_score_codex":0.00028546204,"about_ca_system_score_gemma":0.000044856053,"threshold_uncertainty_score":0.9969342},"labels":[],"label_agreement":null},{"id":"W6931091892","doi":"10.5281/zenodo.15777507","title":"ExCANFAR: Expansion du Canadian Astronomy Network for Advanced Research - 2025 DRI Connect poster","year":2025,"lang":"fr","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Dementia Research Alliance","funders":"","keywords":"Research program; Basic research","score_opus":0.02887548987622739,"score_gpt":0.31808282656743714,"score_spread":0.28920733669120974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931091892","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025590733,0.019894257,0.019232994,0.092059724,0.007890435,0.011631478,0.004235311,0.00095728977,0.8185078],"genre_scores_gemma":[0.738231,0.0022468301,0.004952001,0.003026242,0.0040062563,0.000006851397,0.017275205,0.0036081935,0.22664739],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635553,0.00061772234,0.00044627962,0.0007536888,0.00041096008,0.0014158179],"domain_scores_gemma":[0.99636257,0.00021530439,0.00009322233,0.00069815735,0.0019494245,0.0006813082],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013798223,0.00027676264,0.00034200132,0.00063455635,0.004908235,0.0006613418,0.0006739744,0.00018466167,0.014461203],"category_scores_gemma":[0.0010256402,0.0003006958,0.00013045831,0.0013228366,0.00036613352,0.0003178601,0.0005549463,0.00053901965,0.004041389],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028616734,0.00018011886,0.000075492455,0.0002477434,0.00031023243,0.000033756798,0.0009099879,0.00029158918,0.00022483274,0.016935878,0.6073113,0.37319288],"study_design_scores_gemma":[0.0030318287,0.0008672173,0.0014788767,0.00076998485,0.00020890018,0.00003554315,0.0013641835,0.00039459066,0.0001916342,0.0006137745,0.9908123,0.00023117382],"about_ca_topic_score_codex":0.005670198,"about_ca_topic_score_gemma":0.00065195654,"teacher_disagreement_score":0.7126403,"about_ca_system_score_codex":0.0022419286,"about_ca_system_score_gemma":0.00029771012,"threshold_uncertainty_score":0.9999445},"labels":[],"label_agreement":null},{"id":"W6931132721","doi":"10.5281/zenodo.4527654","title":"In-silico investigation of curcumin drug-likeness, gene-targets and prognostic relevance of the targets in panels of human cancer cohorts","year":2021,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Development Research Centre","funders":"","keywords":"Curcumin; Druggability; Cancer; Drug; Cancer drugs; Drug resistance; Temozolomide; Drug discovery; Pharmacogenomics","score_opus":0.024428510956763873,"score_gpt":0.29056137432278506,"score_spread":0.2661328633660212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931132721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959295,0.0010913794,0.000020445988,0.0006503914,0.000041261075,0.0004875015,0.00008903939,0.000018255818,0.0016722265],"genre_scores_gemma":[0.99892294,0.00025576144,0.000111807356,0.000049016617,0.000017821529,3.0107856e-7,0.00019866432,0.00015129446,0.00029237295],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99899805,0.00015050001,0.000302709,0.00020137585,0.00021876291,0.00012861354],"domain_scores_gemma":[0.9991285,0.000027867809,0.00015115178,0.00022471132,0.00041701214,0.000050728664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019982854,0.00007561438,0.00019607793,0.00011231503,0.00014711836,0.000016113207,0.00012366263,0.000031406642,0.00046590733],"category_scores_gemma":[0.00034839413,0.00006474645,0.000026243015,0.0005306275,0.00018797776,0.000094369636,0.00018632114,0.00010143048,0.000006144458],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015379062,0.00083209056,0.15039392,0.0019118519,0.00022480967,0.00006628221,0.021411352,0.0003270816,0.7985368,0.0027268662,0.0055181035,0.017897075],"study_design_scores_gemma":[0.001852807,0.00016343595,0.6701974,0.000639268,0.000094578485,0.000035109497,0.00056160724,0.00011798948,0.31232575,0.0005515504,0.013349201,0.000111295594],"about_ca_topic_score_codex":0.00021124909,"about_ca_topic_score_gemma":0.000016837796,"teacher_disagreement_score":0.51980346,"about_ca_system_score_codex":0.000094857634,"about_ca_system_score_gemma":0.00003054267,"threshold_uncertainty_score":0.5101359},"labels":[],"label_agreement":null},{"id":"W6931184974","doi":"10.5281/zenodo.4077729","title":"[FILMS VOIR] Le club Vinland (2020) FILMS STREAMING VF EN GRATUIT ET VOSTFR knc","year":2020,"lang":"fr","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Club; Table (database); Key (lock)","score_opus":0.024888791917212105,"score_gpt":0.2873036565466946,"score_spread":0.2624148646294825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931184974","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05633875,0.017555201,0.014834309,0.13873261,0.0026390296,0.0046679317,0.006564489,0.003124953,0.7555427],"genre_scores_gemma":[0.9262674,0.003562611,0.0029230453,0.0040183207,0.0018125825,5.0639676e-7,0.011097113,0.004269835,0.04604862],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970488,0.000583562,0.0004328563,0.0007197485,0.0005217341,0.00069328706],"domain_scores_gemma":[0.9980712,0.000084197614,0.00016119806,0.00048109583,0.0005163289,0.0006859793],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004763511,0.00032112456,0.0003556947,0.0001413253,0.0016635299,0.0007209843,0.0006154621,0.00016114568,0.032860365],"category_scores_gemma":[0.0010138345,0.0003343412,0.00012938172,0.0008258572,0.0002276229,0.00044540752,0.00086820434,0.00061141164,0.015595149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021403715,0.00061265164,0.00007863489,0.0005168048,0.0005849916,0.00038333767,0.012515153,0.00035882537,0.004876408,0.009666539,0.8048452,0.16534738],"study_design_scores_gemma":[0.0025890626,0.0010415001,0.0013591636,0.00025640245,0.0002853782,0.00021528327,0.003822145,0.002183583,0.0006347749,0.000078402234,0.9872187,0.00031564862],"about_ca_topic_score_codex":0.00026878976,"about_ca_topic_score_gemma":0.0000036303743,"teacher_disagreement_score":0.8699286,"about_ca_system_score_codex":0.00029200304,"about_ca_system_score_gemma":0.00007014918,"threshold_uncertainty_score":0.9999109},"labels":[],"label_agreement":null},{"id":"W6931480808","doi":"10.5281/zenodo.6132501","title":"Cliona lobata Hancock 1849","year":2014,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Shore; Lobata; Sieve (category theory); Smooth surface","score_opus":0.027730124825908566,"score_gpt":0.29523143601535984,"score_spread":0.26750131118945125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931480808","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044547647,0.00018505873,0.008919626,0.0045511224,0.0002425858,0.0008096565,0.00017398146,0.0012832831,0.93928707],"genre_scores_gemma":[0.9875856,0.0000651421,0.0008169868,0.0007156997,0.00031837536,6.541441e-8,0.002259224,0.00096013263,0.007278741],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895686,0.00010171657,0.00015999106,0.000281317,0.0002600466,0.00024005225],"domain_scores_gemma":[0.9990026,0.000015840975,0.000052756484,0.00039281015,0.0003444667,0.00019152982],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024036704,0.000099746736,0.00012955577,0.00013141827,0.0010515691,0.00020198057,0.0002482171,0.000042403582,0.009305496],"category_scores_gemma":[0.00033025703,0.00009131084,0.000049673505,0.000307881,0.000080913946,0.00011864202,0.00026042652,0.00013484298,0.01043318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014960667,0.0004639237,0.00008920285,0.00012506754,0.00019936965,0.000025957386,0.0010513589,0.000025008256,0.0028624232,0.020571813,0.58563006,0.3888062],"study_design_scores_gemma":[0.001128066,0.00034881418,0.0032262441,0.000036619185,0.00006121148,0.00012291787,0.0000993718,0.00024074456,0.00031108793,0.00026076435,0.99407065,0.00009353249],"about_ca_topic_score_codex":0.000015815283,"about_ca_topic_score_gemma":2.84369e-7,"teacher_disagreement_score":0.943038,"about_ca_system_score_codex":0.00014911777,"about_ca_system_score_gemma":0.0000056210365,"threshold_uncertainty_score":0.99160016},"labels":[],"label_agreement":null},{"id":"W6939122846","doi":"10.60692/ppne9-nk764","title":"Additional file 6 of Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lung cancer; Cohort; Profiling (computer programming); Gene; Gene expression profiling; Genotype","score_opus":0.00960215321998506,"score_gpt":0.2442866188772596,"score_spread":0.23468446565727455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939122846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8703647,0.0000055452806,0.00012882534,0.000026495294,0.000076964905,0.0059779575,0.117091954,0.00009924294,0.006228263],"genre_scores_gemma":[0.9705581,1.8285678e-7,0.00056283234,0.00003389594,0.00002038043,0.013205472,0.01542017,0.000009722411,0.00018922205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992539,0.000012802182,0.00033750312,0.00010189243,0.00016055137,0.00013330599],"domain_scores_gemma":[0.9995368,0.000035318197,0.00015291474,0.0001083384,0.00010847285,0.000058121757],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006175857,0.0001060103,0.00017642508,0.00028320707,0.000035074965,0.000018650233,0.00002842666,0.00005037576,0.004856628],"category_scores_gemma":[0.000038708044,0.000080253005,0.000037410664,0.00038740426,0.000017595225,0.00013689641,0.000020939104,0.00004240522,0.00006233303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046683894,0.0000055471287,0.96721417,0.0021425684,0.00019593324,0.00001816689,0.006741792,0.00012556695,0.0000094165725,0.000002416032,0.023346974,0.00015079773],"study_design_scores_gemma":[0.0018682221,0.00004344294,0.97971696,0.0013274781,0.00011912885,0.00001717378,0.0027036585,0.013413471,0.00021593271,3.5393546e-7,0.0004564331,0.0001177546],"about_ca_topic_score_codex":0.000025652265,"about_ca_topic_score_gemma":7.4858343e-7,"teacher_disagreement_score":0.101671785,"about_ca_system_score_codex":0.0001004107,"about_ca_system_score_gemma":0.00014526001,"threshold_uncertainty_score":0.99605304},"labels":[],"label_agreement":null},{"id":"W6939721098","doi":"10.6084/m9.figshare.19336230","title":"Additional file 1 of Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Population; Survival analysis; MEDLINE; Lung cancer; Incidence (geometry); Lung","score_opus":0.017844524608299554,"score_gpt":0.3100614382239239,"score_spread":0.29221691361562435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939721098","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04604973,0.00002519471,3.6613557e-8,0.00013408394,0.00001272263,0.00023391459,0.9518693,0.000007670582,0.0016673224],"genre_scores_gemma":[0.4285923,8.754252e-7,0.000043126838,0.000049104674,0.0000071794166,0.002265678,0.56689036,0.000007688093,0.0021437071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992509,0.00002730804,0.00019915901,0.00021641758,0.00013385175,0.00017237106],"domain_scores_gemma":[0.99940115,0.00023334255,0.00009028096,0.0001357776,0.000030166266,0.00010925126],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000010160807,0.00011852453,0.00031595136,0.0009094181,0.00006174199,0.0000057296716,0.000038210765,0.000022057935,0.9494478],"category_scores_gemma":[0.000023515051,0.000111066845,0.0000964422,0.0008383444,0.00000196768,0.000028991839,0.000013261025,0.00006660087,0.000003122926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001783247,0.00016074475,0.85008246,0.000044838507,0.00017213968,0.000051746825,0.000179148,0.0039708354,2.2256592e-7,2.964444e-7,0.14277323,0.0025465328],"study_design_scores_gemma":[0.0013720117,0.00007896919,0.97364634,0.000191702,0.00016020972,2.3676026e-7,0.000097740376,0.0026666366,0.000003032115,4.5900998e-7,0.021692649,0.00009002989],"about_ca_topic_score_codex":0.43235135,"about_ca_topic_score_gemma":0.94097525,"teacher_disagreement_score":0.94944465,"about_ca_system_score_codex":0.0013771008,"about_ca_system_score_gemma":0.0005352702,"threshold_uncertainty_score":0.57142866},"labels":[],"label_agreement":null},{"id":"W6939853024","doi":"10.6084/m9.figshare.c.3801409_d1.v1","title":"Additional file 1: Table S1. of Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC","year":2017,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Scale (ratio); Clinical trial; Safety profile; MEDLINE","score_opus":0.039852374685745054,"score_gpt":0.3598488638166962,"score_spread":0.31999648913095113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939853024","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002483544,0.00009421637,2.0650333e-7,0.00011167231,0.000016351038,0.0002232545,0.9499734,0.000008086723,0.04932443],"genre_scores_gemma":[0.1910897,0.000002187797,0.00025190652,0.00005973514,0.00008908625,0.00023617953,0.8058351,0.000010534105,0.0024255128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935085,0.000012827647,0.00020811644,0.00014522845,0.0001660843,0.000116899],"domain_scores_gemma":[0.99897903,0.00025277236,0.00023611916,0.00025676924,0.00021980285,0.000055505745],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000011434648,0.00008912567,0.00024363238,0.00007540718,0.000078002595,0.0000101045425,0.00008090197,0.000055637287,0.89749116],"category_scores_gemma":[0.001194917,0.00007500371,0.000081896775,0.00008707097,0.000018882467,0.00012569706,0.000044890763,0.00006736976,0.00035994753],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063534506,0.00015293654,0.00010797928,0.00008716682,0.00016186616,0.000021819702,0.00009020684,0.000009055214,0.00025622649,0.000004444164,0.99730253,0.001742203],"study_design_scores_gemma":[0.0041954853,0.0004003035,0.26704603,0.016386086,0.0003305672,0.000013981005,0.00017325227,0.00019906706,0.020712841,0.0000633107,0.6902481,0.00023098213],"about_ca_topic_score_codex":0.00021392081,"about_ca_topic_score_gemma":0.00009494589,"teacher_disagreement_score":0.8971312,"about_ca_system_score_codex":0.00007780973,"about_ca_system_score_gemma":0.000332256,"threshold_uncertainty_score":0.46265173},"labels":[],"label_agreement":null},{"id":"W6940415662","doi":"10.6084/m9.figshare.c.3801409_d1","title":"Additional file 1: Table S1. of Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC","year":2017,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Scale (ratio); Clinical trial; Safety profile; MEDLINE","score_opus":0.039852374685745054,"score_gpt":0.3598488638166962,"score_spread":0.31999648913095113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6940415662","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002483544,0.00009421637,2.0650333e-7,0.00011167231,0.000016351038,0.0002232545,0.9499734,0.000008086723,0.04932443],"genre_scores_gemma":[0.1910897,0.000002187797,0.00025190652,0.00005973514,0.00008908625,0.00023617953,0.8058351,0.000010534105,0.0024255128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935085,0.000012827647,0.00020811644,0.00014522845,0.0001660843,0.000116899],"domain_scores_gemma":[0.99897903,0.00025277236,0.00023611916,0.00025676924,0.00021980285,0.000055505745],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000011434648,0.00008912567,0.00024363238,0.00007540718,0.000078002595,0.0000101045425,0.00008090197,0.000055637287,0.89749116],"category_scores_gemma":[0.001194917,0.00007500371,0.000081896775,0.00008707097,0.000018882467,0.00012569706,0.000044890763,0.00006736976,0.00035994753],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063534506,0.00015293654,0.00010797928,0.00008716682,0.00016186616,0.000021819702,0.00009020684,0.000009055214,0.00025622649,0.000004444164,0.99730253,0.001742203],"study_design_scores_gemma":[0.0041954853,0.0004003035,0.26704603,0.016386086,0.0003305672,0.000013981005,0.00017325227,0.00019906706,0.020712841,0.0000633107,0.6902481,0.00023098213],"about_ca_topic_score_codex":0.00021392081,"about_ca_topic_score_gemma":0.00009494589,"teacher_disagreement_score":0.8971312,"about_ca_system_score_codex":0.00007780973,"about_ca_system_score_gemma":0.000332256,"threshold_uncertainty_score":0.46265173},"labels":[],"label_agreement":null},{"id":"W6957748378","doi":"10.6084/m9.figshare.10279136","title":"MOESM1 of Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Mutation; Lung cancer; Funnel plot; Germline mutation; Somatic cell; Family history","score_opus":0.03218064549066371,"score_gpt":0.3631912127461981,"score_spread":0.33101056725553435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957748378","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032695107,0.79568017,0.00007982619,0.0015933779,0.000051854775,0.005540166,0.16404189,0.000029979286,0.000287611],"genre_scores_gemma":[0.8972337,0.0021161635,0.0012968217,0.0007057445,0.00003514449,0.0022793321,0.095237195,0.000024291232,0.0010716096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99940926,0.000018595565,0.00020513631,0.00016777667,0.00010826875,0.00009093556],"domain_scores_gemma":[0.9995433,0.000031278112,0.00011106643,0.00014928177,0.00012535306,0.00003971901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000024479772,0.00009036564,0.0004997539,0.00012655927,0.000015059645,0.000011239914,0.000030409301,0.00004232799,0.012092537],"category_scores_gemma":[0.000055593722,0.00006539894,0.0002907675,0.00036179292,0.000002470309,0.000058701884,0.000009264696,0.000042250616,0.0000060840525],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040423175,0.0009905038,0.01475935,0.3076742,0.48612416,0.0005063909,0.01071787,0.01720413,0.0013131136,0.00007364595,0.1318764,0.028355993],"study_design_scores_gemma":[0.0074395295,0.00050092925,0.082365476,0.041846156,0.7904072,0.00008251844,0.00020071615,0.0728728,0.00080601504,0.00015565017,0.0026878272,0.0006351729],"about_ca_topic_score_codex":0.000034152497,"about_ca_topic_score_gemma":0.000029573968,"teacher_disagreement_score":0.8645386,"about_ca_system_score_codex":0.000047562404,"about_ca_system_score_gemma":0.00007182138,"threshold_uncertainty_score":0.98881054},"labels":[],"label_agreement":null},{"id":"W6957829327","doi":"10.60692/nhgp8-rxj80","title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Osimertinib; Discontinuation; Placebo; Adjuvant; Adverse effect; Quality of life (healthcare)","score_opus":0.05680745313068906,"score_gpt":0.33430588451211957,"score_spread":0.2774984313814305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957829327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937835,0.000004928107,0.00044271766,0.0005253883,0.0000862663,0.0025362826,0.002470267,0.0000882272,0.00006242961],"genre_scores_gemma":[0.9977386,2.4812815e-7,0.00006708862,0.00011375213,0.000007714293,0.00006983542,0.001970017,0.000010809078,0.000021945709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690443,0.0001843553,0.0019428876,0.00020643673,0.00054434116,0.0002175303],"domain_scores_gemma":[0.9980026,0.00006280933,0.0008840705,0.00049576606,0.00039681816,0.00015791744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008127937,0.00018906899,0.0010075149,0.00046515794,0.000088275825,0.000027182185,0.00009681127,0.00008091515,0.000052869887],"category_scores_gemma":[0.00011344636,0.000110764515,0.00010504707,0.0018740678,0.000049424354,0.00020797996,0.000057080168,0.00010185075,0.0000181996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018359255,0.00005789898,0.9482533,0.00013153804,0.001409967,6.6045595e-7,0.031162538,0.0002956631,9.27863e-7,0.000011813964,0.000037427853,0.0002790619],"study_design_scores_gemma":[0.070307314,0.00066790683,0.9217303,0.00013863436,0.00038140523,1.00879184e-7,0.0057633347,0.0008907633,0.00001847385,7.402601e-7,0.0000052964256,0.00009577417],"about_ca_topic_score_codex":0.0038783154,"about_ca_topic_score_gemma":0.00018525562,"teacher_disagreement_score":0.051948056,"about_ca_system_score_codex":0.00019155773,"about_ca_system_score_gemma":0.00021176784,"threshold_uncertainty_score":0.58628786},"labels":[],"label_agreement":null},{"id":"W6958120550","doi":"10.60692/0bd00-7zf73","title":"The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers","year":2016,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"","keywords":"Crizotinib; Gene knockdown; Transfection; HEK 293 cells; Plasma protein binding; Binding site; Ligand binding assay; Cell","score_opus":0.05703986711915195,"score_gpt":0.2900129381269129,"score_spread":0.23297307100776096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958120550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934172,0.000009142688,0.0029001238,0.0002361645,0.0001527467,0.0010980638,0.00006016999,0.000049007827,0.0020773567],"genre_scores_gemma":[0.99904734,9.930908e-8,0.00018855707,0.000075027274,0.00003692008,0.00016067986,0.000004995989,0.000011231002,0.00047512425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986739,0.000099880956,0.000587795,0.00012431145,0.0003091234,0.00020494664],"domain_scores_gemma":[0.9991076,0.00003176483,0.00024332346,0.00041133323,0.0001278953,0.00007806878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032509022,0.00013013792,0.00022013923,0.00014487651,0.00019505969,0.000077789875,0.00009686086,0.000041623804,0.000012100552],"category_scores_gemma":[0.00003386786,0.00006759425,0.00004787131,0.00017292933,0.00003405882,0.0004137535,0.00003142978,0.000047950565,0.000040286748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043138134,0.000023688954,0.7587301,0.00021211806,0.00024455867,0.000016410013,0.2371765,0.00011447387,0.0004064465,0.00028405062,0.0002243601,0.0021359157],"study_design_scores_gemma":[0.006818463,0.0003016286,0.9586449,0.0015269893,0.00020290002,0.0000031466777,0.024095856,0.000048582842,0.0047808667,0.0000018283087,0.0033337486,0.00024108353],"about_ca_topic_score_codex":0.00011454772,"about_ca_topic_score_gemma":0.000031600368,"teacher_disagreement_score":0.21308064,"about_ca_system_score_codex":0.00037206293,"about_ca_system_score_gemma":0.00008463225,"threshold_uncertainty_score":0.27564135},"labels":[],"label_agreement":null},{"id":"W6958148548","doi":"10.6084/m9.figshare.10279136.v1","title":"MOESM1 of Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Mutation; Lung cancer; Funnel plot; Germline mutation; Somatic cell; Family history","score_opus":0.03218064549066371,"score_gpt":0.3631912127461981,"score_spread":0.33101056725553435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958148548","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032695107,0.79568017,0.00007982619,0.0015933779,0.000051854775,0.005540166,0.16404189,0.000029979286,0.000287611],"genre_scores_gemma":[0.8972337,0.0021161635,0.0012968217,0.0007057445,0.00003514449,0.0022793321,0.095237195,0.000024291232,0.0010716096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99940926,0.000018595565,0.00020513631,0.00016777667,0.00010826875,0.00009093556],"domain_scores_gemma":[0.9995433,0.000031278112,0.00011106643,0.00014928177,0.00012535306,0.00003971901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000024479772,0.00009036564,0.0004997539,0.00012655927,0.000015059645,0.000011239914,0.000030409301,0.00004232799,0.012092537],"category_scores_gemma":[0.000055593722,0.00006539894,0.0002907675,0.00036179292,0.000002470309,0.000058701884,0.000009264696,0.000042250616,0.0000060840525],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040423175,0.0009905038,0.01475935,0.3076742,0.48612416,0.0005063909,0.01071787,0.01720413,0.0013131136,0.00007364595,0.1318764,0.028355993],"study_design_scores_gemma":[0.0074395295,0.00050092925,0.082365476,0.041846156,0.7904072,0.00008251844,0.00020071615,0.0728728,0.00080601504,0.00015565017,0.0026878272,0.0006351729],"about_ca_topic_score_codex":0.000034152497,"about_ca_topic_score_gemma":0.000029573968,"teacher_disagreement_score":0.8645386,"about_ca_system_score_codex":0.000047562404,"about_ca_system_score_gemma":0.00007182138,"threshold_uncertainty_score":0.98881054},"labels":[],"label_agreement":null},{"id":"W6958320171","doi":"10.6084/m9.figshare.24465060.v1","title":"Additional file 1 of First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Table (database); Whole brain radiotherapy; Radiation therapy; Brain metastasis; Retrospective cohort study","score_opus":0.0450125221258772,"score_gpt":0.33085958800895415,"score_spread":0.28584706588307696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958320171","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005879678,0.021052144,0.0000031393283,0.0013520186,0.0000036256006,0.0027895356,0.97448933,0.000042842872,0.00020859273],"genre_scores_gemma":[0.0017080099,0.0004112821,0.0006748659,0.00082403695,0.00002051119,0.021875381,0.96756107,0.000052897267,0.0068719713],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99857545,0.00009159183,0.00041333915,0.0003968824,0.00028312943,0.00023962301],"domain_scores_gemma":[0.99727833,0.0017352242,0.00032378838,0.00035583068,0.00017616113,0.00013067374],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000060122387,0.0003138218,0.0018145349,0.000284795,0.000061682455,0.000019051187,0.00007168801,0.000052263946,0.7732238],"category_scores_gemma":[0.0002236916,0.000182459,0.00031349354,0.0014764721,0.000016263653,0.000072664276,0.000016186223,0.00007969407,0.000044578326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018677667,0.00017732805,0.000010370505,0.048019424,0.082446195,0.00020587372,0.0004242077,0.00075150485,9.612006e-7,3.490147e-7,0.86775964,0.000017380758],"study_design_scores_gemma":[0.024608182,0.0042401026,0.00065998523,0.07883899,0.80970997,0.00006729923,0.0005934227,0.008817703,0.00008577163,0.0000018631645,0.0714447,0.0009320429],"about_ca_topic_score_codex":0.00036616522,"about_ca_topic_score_gemma":0.0037623588,"teacher_disagreement_score":0.79631495,"about_ca_system_score_codex":0.00041959714,"about_ca_system_score_gemma":0.00042940406,"threshold_uncertainty_score":0.7440462},"labels":[],"label_agreement":null},{"id":"W6958371911","doi":"10.6084/m9.figshare.19135861.v1","title":"Additional file 3 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto","funders":"","keywords":"Trametinib; Pharmacokinetics; Hepatic dysfunction; Cancer; Phases of clinical research; Drug","score_opus":0.020838075923909124,"score_gpt":0.3082590588344491,"score_spread":0.28742098291053997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958371911","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3462304,0.000031395288,2.4754257e-8,0.000005192721,0.0000085718175,0.00048556927,0.6531051,0.0000043255486,0.00012946459],"genre_scores_gemma":[0.5674647,2.811873e-7,0.000030443942,0.000022392536,0.000005685159,0.0021712387,0.43019408,0.0000062338963,0.00010494499],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9994692,0.000017847922,0.00013327617,0.000119052616,0.00019683219,0.000063786414],"domain_scores_gemma":[0.99960387,0.00011361878,0.00010949307,0.000064912194,0.000077869154,0.00003022543],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000005504655,0.00006110848,0.00012849741,0.00006782272,0.000031614636,0.0000016032836,0.000019608067,0.00000743425,0.93007284],"category_scores_gemma":[0.00008084539,0.000051607938,0.000014572338,0.00016980017,0.0000043692485,0.000034079792,0.00001874611,0.00004929278,0.000003312829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008395743,0.010401029,0.0031731997,0.00023090882,0.00018459607,0.000012660601,0.0010672294,0.00051887217,0.00005415828,6.0683725e-8,0.94304436,0.040473368],"study_design_scores_gemma":[0.05603376,0.023727695,0.66453046,0.0032472652,0.00046987325,0.000004453051,0.0020778354,0.00056405657,0.00028413505,0.000002770204,0.24878828,0.00026940505],"about_ca_topic_score_codex":0.000021344149,"about_ca_topic_score_gemma":0.000024289222,"teacher_disagreement_score":0.9300695,"about_ca_system_score_codex":0.00009616964,"about_ca_system_score_gemma":0.00007330064,"threshold_uncertainty_score":0.21045107},"labels":[],"label_agreement":null},{"id":"W6958401563","doi":"10.6084/m9.figshare.19135858","title":"Additional file 2 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto","funders":"","keywords":"Pharmacokinetics; Trametinib; Hepatic dysfunction; Cancer; Phases of clinical research; Drug","score_opus":0.02047443436435042,"score_gpt":0.30811407221058584,"score_spread":0.2876396378462354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958401563","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34468338,0.000031809115,2.4139117e-8,0.000005203018,0.0000085597985,0.00048587724,0.65464884,0.000004340533,0.00013195538],"genre_scores_gemma":[0.5643479,2.8434982e-7,0.000030112937,0.000022398573,0.0000056999024,0.0021691823,0.433315,0.000006222005,0.00010318282],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99946934,0.000017859284,0.00013327606,0.000119015545,0.00019674205,0.00006376776],"domain_scores_gemma":[0.99960524,0.00011301897,0.00010962948,0.00006488555,0.00007700598,0.000030223564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000005476958,0.00006109767,0.00012851572,0.00006780104,0.000031619726,0.0000016034406,0.000019609608,0.0000074349346,0.9304718],"category_scores_gemma":[0.000079886195,0.00005160432,0.000014570448,0.00016973134,0.0000043688724,0.00003407667,0.000018757211,0.00004929159,0.000003241338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008167375,0.010237333,0.0030191839,0.00022540828,0.00018181739,0.000012647519,0.001051106,0.0005129285,0.000051312203,6.116403e-8,0.94355273,0.040338714],"study_design_scores_gemma":[0.055761248,0.023816714,0.65983737,0.0032208967,0.00047349682,0.0000045154334,0.0020709503,0.00056057615,0.00027687452,0.0000027901688,0.2537052,0.00026939047],"about_ca_topic_score_codex":0.000021314963,"about_ca_topic_score_gemma":0.000024266476,"teacher_disagreement_score":0.93046856,"about_ca_system_score_codex":0.00009581176,"about_ca_system_score_gemma":0.00007293178,"threshold_uncertainty_score":0.2104363},"labels":[],"label_agreement":null},{"id":"W6958547845","doi":"10.6084/m9.figshare.24329838","title":"Additional file 1 of Hybrid delivery of cluster-set resistance training for individuals previously treated for lung cancer: the results of a single-arm feasibility trial","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lung; Table (database); Protocol (science); Resistance training; Clinical trial; MEDLINE","score_opus":0.11418028955256318,"score_gpt":0.3672631942841686,"score_spread":0.25308290473160544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958547845","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007307194,0.00015603796,9.3525995e-7,0.0001695144,0.000027884458,0.0034618427,0.9884011,0.000027605667,0.00044789357],"genre_scores_gemma":[0.06430768,0.000003488587,0.0004972207,0.000039079107,0.00012587591,0.0074717384,0.925991,0.000018942093,0.0015449715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988959,0.00003515662,0.0004665703,0.00021911353,0.00020698446,0.000176262],"domain_scores_gemma":[0.99510455,0.0037418269,0.00045212838,0.00023098753,0.00042625776,0.0000442317],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010019721,0.00010984681,0.00034018006,0.000067881854,0.00007141696,0.000005824999,0.00009636476,0.000042177035,0.17996214],"category_scores_gemma":[0.004301801,0.00008037827,0.00021044878,0.00022818892,0.000024560411,0.000049350383,0.000023726785,0.000042911826,0.0000023769085],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00752603,0.00018287229,0.000007714053,0.00086425163,0.00026116997,0.0000010180603,0.0006976815,0.000027617747,0.000018054352,0.0000010198436,0.9893001,0.0011124748],"study_design_scores_gemma":[0.1086577,0.0042353617,0.0039343685,0.024359098,0.0012153648,0.000005499982,0.0008622,0.0017514024,0.0042527593,0.0001469038,0.8502557,0.00032362697],"about_ca_topic_score_codex":0.000020967753,"about_ca_topic_score_gemma":0.00010887096,"teacher_disagreement_score":0.17995976,"about_ca_system_score_codex":0.000111589594,"about_ca_system_score_gemma":0.00057426805,"threshold_uncertainty_score":0.8207875},"labels":[],"label_agreement":null},{"id":"W6958652944","doi":"10.6084/m9.figshare.25150611.v1","title":"Additional file 1 of Impact of individual level uncertainty of lung cancer polygenic risk score (PRS) on risk stratification","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Lung cancer; Table (database); Cancer; Risk stratification; Single-nucleotide polymorphism","score_opus":0.0559594393280274,"score_gpt":0.365121106404165,"score_spread":0.3091616670761376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958652944","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011477777,0.0005330816,5.889358e-7,0.00001472167,0.000022963755,0.0003123093,0.98668796,0.000018554687,0.0009320732],"genre_scores_gemma":[0.4114699,0.000011170106,0.000060975977,0.000005943333,0.000057462577,0.00035166234,0.58771604,0.000010336851,0.00031646847],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99916685,0.000024527906,0.00024510923,0.00017219887,0.00028737876,0.00010396174],"domain_scores_gemma":[0.9987623,0.00055971235,0.000246838,0.00017998595,0.00019403537,0.000057147252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000021731323,0.000110047964,0.00019000795,0.00011874306,0.000032982378,0.000008449356,0.00006742373,0.00006516627,0.95268226],"category_scores_gemma":[0.00058781076,0.00008213129,0.00018860737,0.00024415855,0.000015470085,0.0000619161,0.000015028997,0.00013134159,0.000067576344],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000443878,0.00010856936,0.0006171982,0.00032985208,0.0007686991,0.0000020802374,0.00032385066,0.00042305927,0.000035946246,0.0000065215563,0.98836195,0.008977876],"study_design_scores_gemma":[0.0008841106,0.0007767403,0.96191597,0.014415136,0.00085819216,0.0000053361987,0.00013345692,0.0024735616,0.0010961309,0.00007369424,0.0171988,0.000168874],"about_ca_topic_score_codex":0.0005115881,"about_ca_topic_score_gemma":0.00009568191,"teacher_disagreement_score":0.97116315,"about_ca_system_score_codex":0.00016860726,"about_ca_system_score_gemma":0.0010940082,"threshold_uncertainty_score":0.3349217},"labels":[],"label_agreement":null},{"id":"W6967704917","doi":"10.5281/zenodo.1208124","title":"Development Of A Viability Assay For The Hsjd-Dipg-007 Cell Line","year":2018,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"","keywords":"Viability assay; Cell culture; Drug development; Line (geometry); Cell; Drug discovery","score_opus":0.04229990061078775,"score_gpt":0.3132785537962225,"score_spread":0.27097865318543474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6967704917","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38207778,0.0005473046,0.19466019,0.008434164,0.00069667806,0.0082294885,0.0008995672,0.0013033404,0.40315148],"genre_scores_gemma":[0.98875695,0.00001615868,0.0068069235,0.00017889998,0.00019765194,3.490275e-7,0.0006353108,0.00045332292,0.0029544414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904114,0.00006935532,0.00023528861,0.00022617354,0.0002291603,0.00019889907],"domain_scores_gemma":[0.9985728,0.000054751523,0.000087051965,0.0003534019,0.0008367422,0.000095255295],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066894473,0.00008858483,0.00012348335,0.0000726765,0.0012346618,0.000071983966,0.00026262843,0.000035718494,0.00467395],"category_scores_gemma":[0.0003803997,0.000063605585,0.000049175585,0.0002581498,0.00016997434,0.000058638067,0.00022705685,0.000085315165,0.0008811336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010702616,0.0021608528,0.00013431074,0.0007642618,0.0007532783,0.000006570757,0.020417681,0.000023848914,0.055638585,0.0033599467,0.21169746,0.70397294],"study_design_scores_gemma":[0.0011146286,0.00039658992,0.0019541166,0.000024231776,0.00008738459,0.000011397076,0.00042895591,0.0003329954,0.011270924,0.00005775466,0.9842523,0.0000687235],"about_ca_topic_score_codex":0.000010194773,"about_ca_topic_score_gemma":0.0000011296343,"teacher_disagreement_score":0.7725548,"about_ca_system_score_codex":0.00015941013,"about_ca_system_score_gemma":0.000024009394,"threshold_uncertainty_score":0.9998968},"labels":[],"label_agreement":null},{"id":"W6968970764","doi":"10.5281/zenodo.4172306","title":"123-[HD]-Watch! Baikal: The Heart of the World 3D (2020) Online Full For Free PutlockeR'S wic","year":2020,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"EPIC; Action (physics); Ideal (ethics); Eternity; The Internet","score_opus":0.033887851463222686,"score_gpt":0.29121407143071826,"score_spread":0.25732621996749555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968970764","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20686948,0.0015674662,0.006745938,0.6645371,0.00094874087,0.01047676,0.0060065407,0.001973969,0.100874014],"genre_scores_gemma":[0.9763422,0.00010194053,0.0030568496,0.00652985,0.00097582705,7.773491e-7,0.002043647,0.001657984,0.009290916],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869865,0.00013255318,0.00026589606,0.0002898512,0.0003552544,0.00025777696],"domain_scores_gemma":[0.9986276,0.00005334506,0.000109031105,0.0005874099,0.00045510294,0.00016748175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022690541,0.00012923256,0.00019070014,0.000047254485,0.0009780512,0.000119387056,0.00064331444,0.00003699743,0.0033169847],"category_scores_gemma":[0.0006931489,0.00008222902,0.000117661984,0.0006840999,0.00017485293,0.00008189714,0.00059573655,0.00022911356,0.00052113074],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033582214,0.00031662403,0.00007750499,0.00017981172,0.00026176142,0.00000625861,0.0023600336,0.00007784488,0.0048622675,0.0019247864,0.9689473,0.020649984],"study_design_scores_gemma":[0.0014940461,0.00047263876,0.0023292291,0.0000486147,0.00016045493,0.0000412246,0.00031849317,0.00050083344,0.0007354352,0.0002032753,0.99361116,0.00008456899],"about_ca_topic_score_codex":0.000023874183,"about_ca_topic_score_gemma":0.0000074523523,"teacher_disagreement_score":0.7694727,"about_ca_system_score_codex":0.000102014325,"about_ca_system_score_gemma":0.000020392183,"threshold_uncertainty_score":0.9975941},"labels":[],"label_agreement":null},{"id":"W6976439795","doi":"10.6084/m9.figshare.12601276.v2","title":"Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profiling (computer programming); Activity-based costing; Cost estimate; Cost–benefit analysis; Health economics; Economic evaluation; Medical costs; Cost driver","score_opus":0.07764295015092962,"score_gpt":0.3691843685213458,"score_spread":0.29154141837041614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976439795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85295194,0.0024159222,0.000022178167,0.00046271205,0.000019827883,0.0030863725,0.14056267,0.000018594508,0.00045980216],"genre_scores_gemma":[0.99017584,0.000016074762,0.00075200363,0.00009451222,0.000053550113,0.0015066649,0.007367252,0.000021464373,0.000012651291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995131,0.00000819942,0.00019377521,0.00016925459,0.00003115087,0.00008453683],"domain_scores_gemma":[0.9995255,0.000077386125,0.000112180736,0.000116832016,0.00010353709,0.00006459066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000029720271,0.00006805754,0.00016120239,0.00003857625,0.00002692972,0.000004824083,0.00003104153,0.000031974065,0.002085817],"category_scores_gemma":[0.000045241202,0.00006604232,0.00003611325,0.000049816448,0.000004482259,0.000034900717,0.000020232277,0.00003242487,0.0000059700224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012399893,0.0014168007,0.5363374,0.027717901,0.0019989558,0.00014747836,0.04077321,0.017326633,0.1024293,0.0004170942,0.15915363,0.111041665],"study_design_scores_gemma":[0.046878174,0.0019173096,0.589909,0.007133726,0.0042153304,0.0002557179,0.002734799,0.24072206,0.09442452,0.00009697951,0.010545972,0.0011664148],"about_ca_topic_score_codex":0.00036364506,"about_ca_topic_score_gemma":0.00028986292,"teacher_disagreement_score":0.22339542,"about_ca_system_score_codex":0.00018632736,"about_ca_system_score_gemma":0.0005415995,"threshold_uncertainty_score":0.9988264},"labels":[],"label_agreement":null},{"id":"W6976467341","doi":"10.60692/7314n-bgd71","title":"Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Osimertinib; Adverse effect; Docetaxel; Randomized controlled trial; Incidence (geometry); Lung cancer; Hazard ratio","score_opus":0.034174864216582654,"score_gpt":0.29604648097238795,"score_spread":0.2618716167558053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976467341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7955683,0.04578068,0.008034275,0.0011100033,0.00019036044,0.14236967,0.0058226525,0.00021985477,0.0009041993],"genre_scores_gemma":[0.99567294,0.000015877085,0.0001410273,0.00015412402,0.0000013566352,0.0037982927,0.00012440709,0.0000066052,0.00008536332],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976202,0.0002561446,0.0016012391,0.000112206195,0.0003192087,0.00009100285],"domain_scores_gemma":[0.99738914,0.0002202163,0.0014976318,0.00021598277,0.0006326011,0.00004444445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010210412,0.00016380197,0.005270904,0.00031996993,0.000107029744,0.000011250139,0.000035595403,0.0000187362,0.00001752719],"category_scores_gemma":[0.00022620232,0.00008133003,0.0005154656,0.00035936173,0.000052924217,0.000109338194,0.000027707832,0.00003068048,4.944453e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06532892,0.00003474214,0.002711497,0.1939645,0.6938079,5.052976e-7,0.04387054,0.00015408247,1.2236521e-7,0.00010814693,0.00001381614,0.0000052608216],"study_design_scores_gemma":[0.21356143,0.00023747892,0.00087825244,0.0013906084,0.7787918,0.000003543583,0.0046016276,0.00046039768,0.0000024899007,1.993179e-7,0.0000011605571,0.00007102334],"about_ca_topic_score_codex":0.0000051035154,"about_ca_topic_score_gemma":1.16541806e-7,"teacher_disagreement_score":0.20010464,"about_ca_system_score_codex":0.000064447384,"about_ca_system_score_gemma":0.000035080342,"threshold_uncertainty_score":0.36030844},"labels":[],"label_agreement":null},{"id":"W6976544593","doi":"10.60692/wxhp0-nvk51","title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Osimertinib; Discontinuation; Placebo; Adjuvant; Adverse effect; Quality of life (healthcare)","score_opus":0.05680745313068906,"score_gpt":0.33430588451211957,"score_spread":0.2774984313814305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976544593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937835,0.000004928107,0.00044271766,0.0005253883,0.0000862663,0.0025362826,0.002470267,0.0000882272,0.00006242961],"genre_scores_gemma":[0.9977386,2.4812815e-7,0.00006708862,0.00011375213,0.000007714293,0.00006983542,0.001970017,0.000010809078,0.000021945709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690443,0.0001843553,0.0019428876,0.00020643673,0.00054434116,0.0002175303],"domain_scores_gemma":[0.9980026,0.00006280933,0.0008840705,0.00049576606,0.00039681816,0.00015791744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008127937,0.00018906899,0.0010075149,0.00046515794,0.000088275825,0.000027182185,0.00009681127,0.00008091515,0.000052869887],"category_scores_gemma":[0.00011344636,0.000110764515,0.00010504707,0.0018740678,0.000049424354,0.00020797996,0.000057080168,0.00010185075,0.0000181996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018359255,0.00005789898,0.9482533,0.00013153804,0.001409967,6.6045595e-7,0.031162538,0.0002956631,9.27863e-7,0.000011813964,0.000037427853,0.0002790619],"study_design_scores_gemma":[0.070307314,0.00066790683,0.9217303,0.00013863436,0.00038140523,1.00879184e-7,0.0057633347,0.0008907633,0.00001847385,7.402601e-7,0.0000052964256,0.00009577417],"about_ca_topic_score_codex":0.0038783154,"about_ca_topic_score_gemma":0.00018525562,"teacher_disagreement_score":0.051948056,"about_ca_system_score_codex":0.00019155773,"about_ca_system_score_gemma":0.00021176784,"threshold_uncertainty_score":0.58628786},"labels":[],"label_agreement":null},{"id":"W6976737113","doi":"10.6084/m9.figshare.19126247.v1","title":"Additional file 7 of How do changes in flow magnitude due to hydropower operations affect fish abundance and biomass in temperate regions? A systematic review","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Hydro (Canada); Fisheries and Oceans Canada; Carleton University","funders":"","keywords":"Biomass (ecology); Temperate climate; Abundance (ecology); Hydropower; Magnitude (astronomy); Fish <Actinopterygii>; Flow (mathematics); Production (economics)","score_opus":0.022914944725021064,"score_gpt":0.30017365268623036,"score_spread":0.2772587079612093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976737113","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025866868,0.0026053216,1.5264474e-7,0.0027944238,0.000010754914,0.0017589305,0.9923784,0.000013411272,0.0001799043],"genre_scores_gemma":[0.025442775,0.000045001845,0.00028245978,0.0017629495,0.00002581223,0.02329058,0.94753623,0.000018514429,0.0015956804],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.99928313,0.00008789036,0.00016015234,0.00018971127,0.00016508695,0.000114011294],"domain_scores_gemma":[0.99943197,0.00021528409,0.000052670202,0.00017256815,0.00007032846,0.000057165056],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000042120417,0.00009871208,0.00033699675,0.00014542701,0.00007039995,0.000019456273,0.000056852583,0.000020799935,0.7518048],"category_scores_gemma":[0.0010663293,0.00008516733,0.00003484212,0.000440315,0.0000054453,0.00005981137,0.000056023666,0.000081288745,0.000056446355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000497223,0.000082091785,0.0000056667614,0.025138006,0.000027279082,0.00007822461,0.00020069323,0.000014355478,0.000011295665,0.0000013366175,0.97440374,0.000032350286],"study_design_scores_gemma":[0.0014604029,0.00064821803,0.007120707,0.8106911,0.00018289921,0.00035108262,0.0004752321,0.00069382857,0.000060859726,0.0000074255145,0.17796452,0.0003436808],"about_ca_topic_score_codex":0.000019660403,"about_ca_topic_score_gemma":0.0010133504,"teacher_disagreement_score":0.79643923,"about_ca_system_score_codex":0.00015011423,"about_ca_system_score_gemma":0.00013209824,"threshold_uncertainty_score":0.3473023},"labels":[],"label_agreement":null},{"id":"W6976759968","doi":"10.6084/m9.figshare.12601276","title":"Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profiling (computer programming); Activity-based costing; Cost estimate; Cost–benefit analysis; Health economics; Economic evaluation; Medical costs; Cost driver","score_opus":0.07764295015092962,"score_gpt":0.3691843685213458,"score_spread":0.29154141837041614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976759968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85295194,0.0024159222,0.000022178167,0.00046271205,0.000019827883,0.0030863725,0.14056267,0.000018594508,0.00045980216],"genre_scores_gemma":[0.99017584,0.000016074762,0.00075200363,0.00009451222,0.000053550113,0.0015066649,0.007367252,0.000021464373,0.000012651291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995131,0.00000819942,0.00019377521,0.00016925459,0.00003115087,0.00008453683],"domain_scores_gemma":[0.9995255,0.000077386125,0.000112180736,0.000116832016,0.00010353709,0.00006459066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000029720271,0.00006805754,0.00016120239,0.00003857625,0.00002692972,0.000004824083,0.00003104153,0.000031974065,0.002085817],"category_scores_gemma":[0.000045241202,0.00006604232,0.00003611325,0.000049816448,0.000004482259,0.000034900717,0.000020232277,0.00003242487,0.0000059700224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012399893,0.0014168007,0.5363374,0.027717901,0.0019989558,0.00014747836,0.04077321,0.017326633,0.1024293,0.0004170942,0.15915363,0.111041665],"study_design_scores_gemma":[0.046878174,0.0019173096,0.589909,0.007133726,0.0042153304,0.0002557179,0.002734799,0.24072206,0.09442452,0.00009697951,0.010545972,0.0011664148],"about_ca_topic_score_codex":0.00036364506,"about_ca_topic_score_gemma":0.00028986292,"teacher_disagreement_score":0.22339542,"about_ca_system_score_codex":0.00018632736,"about_ca_system_score_gemma":0.0005415995,"threshold_uncertainty_score":0.9988264},"labels":[],"label_agreement":null},{"id":"W6976953797","doi":"10.6084/m9.figshare.19135858.v1","title":"Additional file 2 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto","funders":"","keywords":"Pharmacokinetics; Trametinib; Hepatic dysfunction; Cancer; Phases of clinical research; Drug","score_opus":0.02047443436435042,"score_gpt":0.30811407221058584,"score_spread":0.2876396378462354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976953797","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34468338,0.000031809115,2.4139117e-8,0.000005203018,0.0000085597985,0.00048587724,0.65464884,0.000004340533,0.00013195538],"genre_scores_gemma":[0.5643479,2.8434982e-7,0.000030112937,0.000022398573,0.0000056999024,0.0021691823,0.433315,0.000006222005,0.00010318282],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99946934,0.000017859284,0.00013327606,0.000119015545,0.00019674205,0.00006376776],"domain_scores_gemma":[0.99960524,0.00011301897,0.00010962948,0.00006488555,0.00007700598,0.000030223564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000005476958,0.00006109767,0.00012851572,0.00006780104,0.000031619726,0.0000016034406,0.000019609608,0.0000074349346,0.9304718],"category_scores_gemma":[0.000079886195,0.00005160432,0.000014570448,0.00016973134,0.0000043688724,0.00003407667,0.000018757211,0.00004929159,0.000003241338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008167375,0.010237333,0.0030191839,0.00022540828,0.00018181739,0.000012647519,0.001051106,0.0005129285,0.000051312203,6.116403e-8,0.94355273,0.040338714],"study_design_scores_gemma":[0.055761248,0.023816714,0.65983737,0.0032208967,0.00047349682,0.0000045154334,0.0020709503,0.00056057615,0.00027687452,0.0000027901688,0.2537052,0.00026939047],"about_ca_topic_score_codex":0.000021314963,"about_ca_topic_score_gemma":0.000024266476,"teacher_disagreement_score":0.93046856,"about_ca_system_score_codex":0.00009581176,"about_ca_system_score_gemma":0.00007293178,"threshold_uncertainty_score":0.2104363},"labels":[],"label_agreement":null},{"id":"W6977203721","doi":"10.6084/m9.figshare.19135855.v1","title":"Additional file 1 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto","funders":"","keywords":"Trametinib; Pharmacokinetics; Hepatic dysfunction; Cancer; Phases of clinical research; Drug","score_opus":0.02123129135647916,"score_gpt":0.30874819727061736,"score_spread":0.2875169059141382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977203721","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34526134,0.00003125559,2.4631923e-8,0.000005221744,0.000008496169,0.000485961,0.65407455,0.000004334572,0.00012879347],"genre_scores_gemma":[0.56539017,2.7676163e-7,0.00003076653,0.000022378044,0.000005611427,0.0022097738,0.43223202,0.000006225399,0.000102753074],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9994692,0.000017865377,0.00013321605,0.00011910534,0.0001967916,0.00006379141],"domain_scores_gemma":[0.99960345,0.00011464808,0.00010947562,0.00006501114,0.00007717862,0.000030228057],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000005507186,0.000061117214,0.0001284841,0.0000678457,0.000031617397,0.0000015999494,0.000019620587,0.0000074348914,0.9316989],"category_scores_gemma":[0.000080867416,0.000051621286,0.000014573282,0.00016986408,0.0000043689333,0.000034053213,0.000018759865,0.000049303002,0.000003276482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081393705,0.010149699,0.0030907812,0.000221389,0.00018020079,0.000012199486,0.0010408872,0.0005059284,0.00005269052,5.9566858e-8,0.9450283,0.038903892],"study_design_scores_gemma":[0.05536138,0.023802998,0.6693149,0.00325998,0.00047502996,0.000004503516,0.0020915486,0.0005641346,0.00027850128,0.0000027668643,0.24457438,0.0002698482],"about_ca_topic_score_codex":0.000021101172,"about_ca_topic_score_gemma":0.000024122937,"teacher_disagreement_score":0.93169564,"about_ca_system_score_codex":0.00009578418,"about_ca_system_score_gemma":0.00007325954,"threshold_uncertainty_score":0.21050549},"labels":[],"label_agreement":null},{"id":"W6977340065","doi":"10.6084/m9.figshare.c.7942780","title":"Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI","year":2025,"lang":"en","type":"other","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Heart failure; Proportional hazards model; Creatinine; Risk factor; Biomarker; Vascular endothelial growth factor; Cluster (spacecraft); Disease","score_opus":0.019446713248926394,"score_gpt":0.3283150735944205,"score_spread":0.30886836034549414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977340065","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024511172,0.005881333,0.000088433175,0.0007116691,0.00036970025,0.015977504,0.8313261,0.00049211533,0.12064197],"genre_scores_gemma":[0.107693985,0.00011439644,0.0510821,0.0026113647,0.000659776,0.004179804,0.62803054,0.0024324807,0.20319553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914056,0.000029640973,0.0001227574,0.00033591015,0.00020286773,0.00016823423],"domain_scores_gemma":[0.99946886,0.000012027099,0.00008942557,0.000248699,0.000071581155,0.00010943296],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000016666767,0.0002191485,0.00035240926,0.00025399303,0.000032849508,0.000025198011,0.000042574553,0.00013772064,0.02179411],"category_scores_gemma":[0.00010235511,0.00016560128,0.000055325614,0.00021877016,0.0000052610794,0.000027768583,0.00004177802,0.00010532466,0.000050673443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049480343,0.00014697856,0.2180304,0.000523571,0.00093703956,0.000010690913,0.0000821973,0.000009376596,8.359135e-7,6.37328e-7,0.77968735,0.0005214769],"study_design_scores_gemma":[0.0045118197,0.00017304545,0.22870296,0.020177606,0.0004870768,0.0000014152025,0.0000382925,0.000020783513,0.000005676958,0.0000020466407,0.7456117,0.00026757343],"about_ca_topic_score_codex":0.0006417588,"about_ca_topic_score_gemma":0.0003732129,"teacher_disagreement_score":0.20329554,"about_ca_system_score_codex":0.0001568551,"about_ca_system_score_gemma":0.00024847142,"threshold_uncertainty_score":0.9791001},"labels":[],"label_agreement":null},{"id":"W6977365153","doi":"10.6084/m9.figshare.14767246","title":"Additional file 1 of Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Odds ratio; Hormone; Sex steroid; Lung cancer; Confidence interval; Sex hormone receptor; Steroid hormone; Testosterone (patch); Epidemiology","score_opus":0.13831644236194723,"score_gpt":0.35755061186095916,"score_spread":0.21923416949901192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977365153","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012801631,0.1459306,7.564383e-7,0.0002730358,0.000002595026,0.0009223232,0.8514925,0.000009240356,0.00008877275],"genre_scores_gemma":[0.34127596,0.008141707,0.000497979,0.0020238294,0.00008171513,0.008295285,0.63588065,0.00004693722,0.003755933],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99833447,0.0003820781,0.000551712,0.00031724095,0.0002641425,0.00015033632],"domain_scores_gemma":[0.9931289,0.0055842767,0.00063909794,0.00033107962,0.00022485048,0.00009177768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015008265,0.00018437792,0.0016849615,0.000071573544,0.0001520997,0.000017187114,0.00007321596,0.000068995614,0.22444631],"category_scores_gemma":[0.004997135,0.0001074967,0.00035684282,0.0004077569,0.000029825498,0.00006698117,0.00008728618,0.00012626433,0.0000042526035],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016680797,0.0002981865,0.012083859,0.07978027,0.18719454,0.000046500227,0.0020376132,0.000040441133,0.000051264033,0.00000389619,0.7179802,0.00046651307],"study_design_scores_gemma":[0.0005122437,0.00028162895,0.2265416,0.03782682,0.732284,0.000052483145,0.00039777148,0.00011613386,0.00015309059,0.0000206083,0.0014881272,0.00032550367],"about_ca_topic_score_codex":0.00007139829,"about_ca_topic_score_gemma":0.00010456404,"teacher_disagreement_score":0.7164921,"about_ca_system_score_codex":0.000081984654,"about_ca_system_score_gemma":0.00014331075,"threshold_uncertainty_score":0.77626264},"labels":[],"label_agreement":null},{"id":"W6984965354","doi":"","title":"Sicko","year":2007,"lang":"en","type":"other","venue":"CDU eSpace Institutional Repository (Charles Darwin University)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bureaucracy; Public health; Government (linguistics); Pretext","score_opus":0.009967460708930584,"score_gpt":0.2564750348329132,"score_spread":0.24650757412398258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6984965354","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005581137,0.0015750369,0.0012792884,0.00018484295,0.0010281226,0.00047427218,0.00010897758,0.0003574025,0.99443394],"genre_scores_gemma":[0.010696307,0.00024864872,0.0012268454,0.00013888268,0.00079280173,0.0000022262598,0.00025918364,0.00014186358,0.98649323],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986989,0.000026177944,0.00014614666,0.000465064,0.00039895743,0.00026477964],"domain_scores_gemma":[0.9990153,0.000029139317,0.00017473189,0.00039563244,0.00011613172,0.000269116],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000040281655,0.0003086351,0.00035347597,0.0010358203,0.00031702348,0.00002657894,0.00015977448,0.00036293804,0.0010273841],"category_scores_gemma":[0.000019165202,0.00031107196,0.0002141136,0.00041609787,0.00037944198,0.00009889937,0.00006792395,0.00028160165,0.00027980845],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008824457,0.0012254277,0.006731885,0.00070957723,0.0036647434,0.025824154,0.0004873157,0.000106693486,0.0011418711,0.11242368,0.84154165,0.005260552],"study_design_scores_gemma":[0.0013417363,0.00009150338,0.000787565,0.000565144,0.0007433074,0.00027113262,0.00023143242,0.0000063758307,0.00020782555,0.0000052605533,0.9954712,0.0002775554],"about_ca_topic_score_codex":0.0003217526,"about_ca_topic_score_gemma":0.0000710083,"teacher_disagreement_score":0.1539295,"about_ca_system_score_codex":0.00094380096,"about_ca_system_score_gemma":0.001295161,"threshold_uncertainty_score":0.99993414},"labels":[],"label_agreement":null},{"id":"W6994846875","doi":"","title":"Brampton, Laura","year":2012,"lang":"en","type":"other","venue":"Research Portal (King's College London)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"","score_opus":0.04136312669749068,"score_gpt":0.40462525166084035,"score_spread":0.36326212496334964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6994846875","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032288462,0.009703069,0.000010794225,0.00092528056,0.00063612155,0.0022175785,0.00061069353,0.00029342427,0.98528016],"genre_scores_gemma":[0.035231482,0.0009138725,0.00055454107,0.00023091755,0.0020507693,0.00038013692,0.0007362155,0.0007081341,0.95919394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996195,0.00013119732,0.00037794161,0.00061813474,0.0015055449,0.0011721678],"domain_scores_gemma":[0.9978516,0.00013992433,0.00016773024,0.000881308,0.00029152093,0.0006678835],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00053266773,0.00040990277,0.0006963502,0.0009806916,0.0002218032,0.000057400113,0.000260487,0.00049595407,0.034972772],"category_scores_gemma":[0.00014957765,0.00033780228,0.00024412155,0.00088105444,0.0002836143,0.00009960951,0.00015564551,0.00096121326,0.0020041678],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007455204,0.00047642383,0.0043204837,0.00037959148,0.00083606393,0.0012422878,0.00009643189,1.1107537e-7,0.00006123707,0.0060776966,0.9834462,0.002988929],"study_design_scores_gemma":[0.0020849444,0.00028040417,0.0013871924,0.0008629652,0.00027941487,0.00019454323,0.00022078487,0.0000039954566,0.00010637678,0.00009554991,0.9941786,0.0003052089],"about_ca_topic_score_codex":0.0015490239,"about_ca_topic_score_gemma":0.0008840088,"teacher_disagreement_score":0.034908596,"about_ca_system_score_codex":0.0002792318,"about_ca_system_score_gemma":0.0012451782,"threshold_uncertainty_score":0.9999074},"labels":[],"label_agreement":null},{"id":"W6995525562","doi":"","title":"Pathogenesis, antibiotherapy, and anti-inflammatory therapy of pneumococcal pneumonia","year":2001,"lang":"en","type":"other","venue":"Library and Archives Canada (Government of Canada)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pneumococcal pneumonia; Pneumonia; Pneumococcal vaccine; Streptococcus pneumoniae; Pneumococcal disease; Antibiotics; Pneumococcal infections; Pneumococcal conjugate vaccine; Antibiotic therapy","score_opus":0.0035123414774872568,"score_gpt":0.1867305850383765,"score_spread":0.18321824356088925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995525562","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15770553,0.015903655,0.000017533272,0.0019344919,0.0002587844,0.0008733565,0.0009386003,0.00003439663,0.82233363],"genre_scores_gemma":[0.57812744,0.041385747,0.000842111,0.0010528065,0.00023022824,0.000016849155,0.00006710056,0.00034743894,0.37793028],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984407,0.000032729044,0.00026158476,0.00027197337,0.00078478176,0.00020825675],"domain_scores_gemma":[0.999255,0.00005680671,0.00024167041,0.0002330002,6.634436e-7,0.00021284478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000005625965,0.00026362285,0.00049913756,0.000054055436,0.000053455973,0.0000075355906,0.00008228879,0.0000663678,0.00021257627],"category_scores_gemma":[7.1205903e-7,0.00021955224,0.000040930616,0.000058843372,0.000117426855,0.000056820074,0.00003771995,0.00009050564,2.2195488e-9],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062813726,0.00024712543,0.5248581,0.00142172,0.0018937882,0.0006444082,0.00016639681,0.0000032698547,0.3902006,0.006441138,0.010272965,0.06322237],"study_design_scores_gemma":[0.0020266164,0.0002382109,0.3953669,0.0008190609,0.00014878501,0.000047619917,0.0005875891,0.000025955114,0.034224268,0.000054973065,0.56608516,0.00037482646],"about_ca_topic_score_codex":0.0053500477,"about_ca_topic_score_gemma":0.010408065,"teacher_disagreement_score":0.5558122,"about_ca_system_score_codex":0.0000066868233,"about_ca_system_score_gemma":0.0015452091,"threshold_uncertainty_score":0.895308},"labels":[],"label_agreement":null},{"id":"W6995598351","doi":"","title":"Origin and evolution of Avalonia: evidence from U-Pb and Lu-Hf isotopes in zircon from the Mira terrane, Canada, and the Stavelot-Venn Massif, Belguim","year":2014,"lang":"en","type":"other","venue":"SUNScholar (Stellenbosch University)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Zircon; Isotope; Sample (material); Geochronology","score_opus":0.01025228477288118,"score_gpt":0.22619559439699422,"score_spread":0.21594330962411304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995598351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84523505,0.084374115,0.0008442179,0.0060031163,0.00070079963,0.0034954094,0.0015348603,0.00008783512,0.057724603],"genre_scores_gemma":[0.8007467,0.01672177,0.0013229501,0.00037119468,0.0003076731,0.000008302918,0.00016925974,0.00018244896,0.1801697],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867845,0.00025012865,0.0001881657,0.00043369693,0.00026036176,0.00018922894],"domain_scores_gemma":[0.9987851,0.00044573075,0.00019862504,0.00040273988,0.000056599692,0.00011124374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016973677,0.0002576059,0.0004910283,0.00018790392,0.00015388193,0.000035144563,0.00017480591,0.00019613908,0.0001742547],"category_scores_gemma":[0.00008603536,0.00017191049,0.00004667632,0.00020637282,0.00030534298,0.00013814341,0.000111044705,0.00037702374,0.0000026014145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025894034,0.00024734923,0.87384397,0.0008181217,0.0036722412,0.00049017806,0.009288819,0.000008802773,0.0020510254,0.003445275,0.0911311,0.01241372],"study_design_scores_gemma":[0.010300745,0.0001735799,0.2330358,0.0029686487,0.0021785111,0.000013294289,0.004489711,0.00007546746,0.00011276753,0.00017536833,0.74604434,0.00043179517],"about_ca_topic_score_codex":0.8315584,"about_ca_topic_score_gemma":0.76670516,"teacher_disagreement_score":0.6549132,"about_ca_system_score_codex":0.0003075985,"about_ca_system_score_gemma":0.00052422285,"threshold_uncertainty_score":0.7010307},"labels":[],"label_agreement":null},{"id":"W6996999879","doi":"","title":"Thomas Mallon — The Very Heart of It: New York Diaries, 1983-1994 - with Lisa Page","year":2025,"lang":"en","type":"other","venue":"Internet Archive (Internet Archive)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Romance; Biography; Performance art; Aside; Quarter (Canadian coin); Publishing; Poetry; Penny","score_opus":0.014250977524534855,"score_gpt":0.2738857565461588,"score_spread":0.25963477902162396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996999879","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020123225,0.0021396,0.0094879735,0.0019335999,0.0006790512,0.0017561665,0.0010912069,0.00019399017,0.9825172],"genre_scores_gemma":[0.011899289,0.00024472107,0.0043970435,0.0016397287,0.00063434197,0.00013087821,0.0011121673,0.000355789,0.97958606],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973195,0.00019345598,0.00059889065,0.00082333427,0.0005135406,0.0005512309],"domain_scores_gemma":[0.9977647,0.0004940079,0.00039538316,0.001018776,0.000032608517,0.00029448993],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000102145386,0.00072076614,0.0010279431,0.00048286267,0.000041131338,0.000078472105,0.00063406205,0.00016329947,0.007307983],"category_scores_gemma":[0.000048799822,0.00045300397,0.00045635845,0.00016465613,0.0006330149,0.000046442463,0.00036740492,0.00073854934,0.00026161302],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009852799,0.0002828582,0.0025124298,0.000350883,0.0027345044,0.00014221233,0.0042752633,0.0000034067941,0.00011457643,0.003713569,0.9840145,0.00087052566],"study_design_scores_gemma":[0.0023291223,0.0010653295,0.0017102327,0.0049163694,0.0012622299,0.0000962546,0.0002337976,0.000086471744,0.00035717888,0.0004730282,0.9870756,0.00039433903],"about_ca_topic_score_codex":0.07389049,"about_ca_topic_score_gemma":0.040831223,"teacher_disagreement_score":0.033059265,"about_ca_system_score_codex":0.000098643584,"about_ca_system_score_gemma":0.0009343802,"threshold_uncertainty_score":0.99979216},"labels":[],"label_agreement":null},{"id":"W6998440911","doi":"","title":"Address at the convocation of the University of Toronto, June 19th, 1890.","year":2014,"lang":"en","type":"article","venue":"QSpace (Queen's University Library)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Exposition (narrative); Work (physics); Government (linguistics)","score_opus":0.005750750167368707,"score_gpt":0.20716437071625723,"score_spread":0.20141362054888853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998440911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6521167,0.00023284755,0.00037426225,0.1591279,0.0004480288,0.001125751,0.00016049405,0.00012932175,0.1862847],"genre_scores_gemma":[0.78736395,0.00016863935,0.00017853573,0.0001042317,0.000021563867,1.0764551e-7,0.000028410148,0.000008042489,0.21212654],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99941134,0.00009603068,0.00006874747,0.00014980295,0.0001621568,0.0001119276],"domain_scores_gemma":[0.99923193,0.00008407015,0.00014165486,0.00041507106,0.00006144548,0.0000658332],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003041193,0.00008989586,0.00016509279,0.000025057157,0.00020750149,0.000003894459,0.00021102269,0.000059351813,0.0009993357],"category_scores_gemma":[0.000012143344,0.000063811065,0.00011578681,0.00015274646,0.00023737278,0.00031354922,0.0001633879,0.00006917622,0.000012350288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011166426,0.0005706898,0.1961207,0.00031983093,0.00090876076,0.000025152314,0.008742157,0.00017024606,0.00049201516,0.028898938,0.75933105,0.0033038354],"study_design_scores_gemma":[0.0023143052,0.00017396602,0.26878145,0.00013080641,0.0006649431,8.6940463e-7,0.0038511546,0.000025051888,0.007444213,0.000058661106,0.7164299,0.00012468174],"about_ca_topic_score_codex":0.015220597,"about_ca_topic_score_gemma":0.0012066114,"teacher_disagreement_score":0.15902367,"about_ca_system_score_codex":0.00017017697,"about_ca_system_score_gemma":0.0001699222,"threshold_uncertainty_score":0.9999139},"labels":[],"label_agreement":null},{"id":"W7009235793","doi":"","title":"Differential response of non-small cell lung cancer (NSCLC) harboring different epidermal growth factor receptor (EGFR) mutations to ablative radiation therapy","year":2020,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine, McGill University; McGill University","keywords":"Epidermal growth factor receptor; Lung cancer; Ablative case; Radiation therapy; Mutation; Cancer; Epidermal growth factor","score_opus":0.017062402332806648,"score_gpt":0.29657965094145233,"score_spread":0.2795172486086457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7009235793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985722,0.0006209095,0.000011334302,0.00020618491,0.0017006275,0.0034138667,0.004600417,0.00017157827,0.0035530776],"genre_scores_gemma":[0.9885577,0.0009379343,0.00057201023,0.0002967358,0.00019235768,0.0012298581,0.0033125265,0.00028647034,0.004614418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955737,0.00043378325,0.0012117341,0.0012173878,0.0008703251,0.00069307705],"domain_scores_gemma":[0.9964893,0.000512318,0.0009016374,0.0005551147,0.0008087073,0.0007329314],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016427883,0.0009951779,0.001335037,0.0006840455,0.00067138294,0.000068604786,0.00034447978,0.000562321,0.00093363674],"category_scores_gemma":[0.00044675803,0.00091240346,0.0005980874,0.0007273608,0.000045663684,0.00036492455,0.00006767468,0.001022764,0.000060793867],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103756,0.0013142896,0.00397982,0.0013897569,0.002895904,0.00005905996,0.0015953231,0.000063903375,0.9204203,0.0011870689,0.000041330655,0.056677666],"study_design_scores_gemma":[0.0066401586,0.0011073729,0.18097873,0.0012859695,0.0017253623,0.0000030128574,0.0005565845,0.0001200392,0.80406153,0.00012989,0.0023409717,0.0010504051],"about_ca_topic_score_codex":0.0006275236,"about_ca_topic_score_gemma":0.00024248217,"teacher_disagreement_score":0.17699891,"about_ca_system_score_codex":0.0019959647,"about_ca_system_score_gemma":0.00046210174,"threshold_uncertainty_score":0.9999797},"labels":[],"label_agreement":null},{"id":"W7027404113","doi":"","title":"Comparative Clinical and Cost-Effectiveness Analysis of First- and Second-Line Therapies for the Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer in Ontario, Canada","year":2021,"lang":"en","type":"dissertation","venue":"UWSpace (University of Waterloo)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Cancer; Clinical trial; Disease; Nivolumab; Population","score_opus":0.03127938020887663,"score_gpt":0.33007073244156315,"score_spread":0.29879135223268655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027404113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944784,0.0030951146,0.000014727852,0.00013553715,0.0000806987,0.0016911752,0.00048116807,0.0000017037152,0.00002149642],"genre_scores_gemma":[0.94589907,0.0024917899,0.0005775076,0.0000069088996,0.0000048965067,0.000035073797,0.00073346344,0.0000100964335,0.050241183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993051,0.000052417246,0.00019114719,0.00024502617,0.00010127392,0.0001049902],"domain_scores_gemma":[0.9987684,0.00052357954,0.00027456263,0.00015060735,0.00023226542,0.000050573322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000707884,0.00016614291,0.0010467772,0.00014413308,0.00007208037,0.0000035160904,0.00004631452,0.000060807088,0.0001725939],"category_scores_gemma":[0.000004104511,0.000116737596,0.00014833311,0.00020909098,0.000081991166,0.000036967554,0.00000883871,0.00006994951,1.3657368e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008515677,0.0014196713,0.4840402,0.0029742606,0.035630967,0.00007144746,0.45655024,0.0029106578,0.0006196095,0.000009921478,0.00008375035,0.007173592],"study_design_scores_gemma":[0.008235927,0.0010682506,0.7673064,0.00039880918,0.019250376,5.5428984e-7,0.19984156,0.0018552,0.0015565343,0.000002029807,0.0003530843,0.0001312999],"about_ca_topic_score_codex":0.9727784,"about_ca_topic_score_gemma":0.9998741,"teacher_disagreement_score":0.2832662,"about_ca_system_score_codex":0.000321583,"about_ca_system_score_gemma":0.0010190991,"threshold_uncertainty_score":0.4760421},"labels":[],"label_agreement":null},{"id":"W7029184713","doi":"","title":"It's all about me: Understanding recreational vehicle useage (caravanning) on the Alaska Highway","year":2008,"lang":"en","type":"article","venue":"eCite Digital Repository (University of Tasmania)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Recreation; Focus group; Tourism; Focus (optics); Qualitative research","score_opus":0.04486235986605848,"score_gpt":0.2535881925604909,"score_spread":0.20872583269443246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7029184713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80290675,0.000066941466,0.0002636171,0.0015464238,0.00013464966,0.00023713057,0.000055115088,0.000056951736,0.19473243],"genre_scores_gemma":[0.9792012,0.00002925482,0.00010248017,0.00027288968,0.000062552484,7.08634e-7,0.000059813596,0.000013281214,0.020257846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911284,0.000021601682,0.00011942829,0.00022871316,0.00035736206,0.00016005652],"domain_scores_gemma":[0.9992776,0.0001416204,0.00012137512,0.00025659736,0.00008833969,0.00011449571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000036837115,0.00012052481,0.00017236958,0.000075483265,0.00046559898,0.00003510406,0.00012223731,0.000058748476,0.00006786617],"category_scores_gemma":[0.000023883482,0.00010677155,0.0001427312,0.00013736136,0.00021338335,0.0003467555,0.000042663276,0.000115529554,0.00004115927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028432903,0.0030984588,0.51314133,0.00024176454,0.0055787256,0.0060964413,0.040186625,0.0007806213,0.016958142,0.030879151,0.378485,0.0017104761],"study_design_scores_gemma":[0.008606673,0.0021999513,0.83254945,0.0010035252,0.0012072971,0.0006368286,0.022099223,0.0008849909,0.005668958,0.00069890096,0.123569995,0.00087419525],"about_ca_topic_score_codex":0.000041183877,"about_ca_topic_score_gemma":0.000005521809,"teacher_disagreement_score":0.31940815,"about_ca_system_score_codex":0.00040218676,"about_ca_system_score_gemma":0.0001412953,"threshold_uncertainty_score":0.43540174},"labels":[],"label_agreement":null},{"id":"W7034860524","doi":"","title":"The valedictory address, delivered before the athenaeum of Toronto, at the close of their annual session, on Thursday, April 30, 1846.","year":2014,"lang":"en","type":"article","venue":"QSpace (Queen's University Library)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Period (music); MEDLINE; George (robot)","score_opus":0.0050114821491435875,"score_gpt":0.21507453809002083,"score_spread":0.21006305594087724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7034860524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67206764,0.0011366341,0.000062154555,0.13624364,0.000554473,0.0018209273,0.00085247424,0.000300275,0.18696176],"genre_scores_gemma":[0.8871205,0.0006521576,0.000060586393,0.0003610144,0.00011718173,0.0000028112229,0.000049203576,0.000039138267,0.11159742],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988412,0.00021537524,0.00014810446,0.00023046407,0.00033189877,0.00023294188],"domain_scores_gemma":[0.99849457,0.0003155196,0.00023187052,0.0007594084,0.00008787155,0.000110784335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010126611,0.00019370366,0.00025095715,0.000033120676,0.0004602427,0.000012434445,0.000433369,0.00009297991,0.0004979141],"category_scores_gemma":[0.000029900264,0.00009029281,0.00018433746,0.00013591826,0.00047404855,0.00027062063,0.0002564827,0.00015456477,0.000011384724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008680098,0.00038295295,0.024725113,0.00008296585,0.00083966233,0.000018524219,0.010285054,0.000023265415,0.000044071054,0.02204357,0.93399173,0.006695099],"study_design_scores_gemma":[0.002719341,0.00103231,0.09207362,0.00028577764,0.0005786632,0.0000013684444,0.012343323,0.000028978982,0.0032598495,0.0003702414,0.88712424,0.00018226301],"about_ca_topic_score_codex":0.006280416,"about_ca_topic_score_gemma":0.000745372,"teacher_disagreement_score":0.21505284,"about_ca_system_score_codex":0.00014127562,"about_ca_system_score_gemma":0.00019038486,"threshold_uncertainty_score":0.94941527},"labels":[],"label_agreement":null},{"id":"W7044092825","doi":"","title":"Using next generation sequencing to detect clinically relevant oncogene mutations in lung cancer","year":2017,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Winnipeg; University of Manitoba","funders":"","keywords":"KRAS; Lung cancer; DNA sequencing; Concordance; Fusion gene; Mutation; Gene; Cancer; Digital polymerase chain reaction","score_opus":0.08336095904535124,"score_gpt":0.3589254410887889,"score_spread":0.27556448204343764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7044092825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934947,0.00051436154,0.00084483845,0.00060845976,0.0005565679,0.0008994632,0.00006448906,0.000029652763,0.0029875073],"genre_scores_gemma":[0.9775415,0.00066369487,0.01605698,0.00007804648,0.00025149772,0.0000070992073,0.0007615212,0.000049674472,0.004589983],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988396,0.000046093857,0.00022296689,0.00039537527,0.00028083075,0.00021514123],"domain_scores_gemma":[0.99875003,0.00003841981,0.00040676506,0.00035775336,0.0003120583,0.00013494963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013384073,0.00020126298,0.0004472361,0.00037200254,0.00034476072,0.000032698452,0.00015553356,0.00023798343,0.000032435444],"category_scores_gemma":[0.00008442242,0.00024606078,0.00015025315,0.00019330451,0.00003727516,0.00021590274,0.000024967303,0.00023566918,0.000011094627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028136729,0.00062583317,0.17865758,0.003445689,0.0035603868,0.0020045885,0.02434791,0.023853038,0.6249379,0.00017530154,0.005870387,0.12970774],"study_design_scores_gemma":[0.011657072,0.0014161564,0.79610574,0.009555381,0.012107182,0.000054870638,0.085209735,0.06578992,0.009814774,0.00014013366,0.0061534303,0.0019955854],"about_ca_topic_score_codex":0.02507402,"about_ca_topic_score_gemma":0.69944745,"teacher_disagreement_score":0.67437345,"about_ca_system_score_codex":0.001620556,"about_ca_system_score_gemma":0.0013894765,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W7071215893","doi":"","title":"Smoking, sex, and nonâSmall cell lung cancer: Steroid hormone receptors in tumor tissue (S0424)","year":2018,"lang":"en","type":"article","venue":"eScholarship (California Digital Library)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation","keywords":"Receptor; Immunohistochemistry; Estrogen receptor; Quartile; Steroid hormone receptor; Hormone receptor; Lung cancer; Hazard ratio; Progesterone receptor","score_opus":0.008891004012788032,"score_gpt":0.2603714389043114,"score_spread":0.2514804348915234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7071215893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657967,0.0032992463,0.000023306417,0.00083446194,0.00020892489,0.0006803551,0.00092233584,0.00018107619,0.028053567],"genre_scores_gemma":[0.9898421,0.00018051588,0.0005370446,0.0011096487,0.00035388186,0.00009048385,0.00040802872,0.00009514934,0.007383152],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998297,0.000039925086,0.00039507102,0.0005211084,0.0002744654,0.00047243477],"domain_scores_gemma":[0.9990949,0.00005747462,0.00011376469,0.00030556938,0.000041476713,0.00038681127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000087930865,0.00031203157,0.00037364176,0.00021713278,0.00012145329,0.00039906416,0.00014532852,0.00011621995,0.0005874301],"category_scores_gemma":[0.000043151984,0.0002685593,0.00006314244,0.00040206147,0.00014134668,0.001488952,0.00013415903,0.00033370475,0.00021540951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002776487,0.0003731488,0.97062236,0.0001666734,0.00011432569,0.00015827408,0.00033983932,0.0000011780262,0.00077749323,0.00005525025,0.009385735,0.017728094],"study_design_scores_gemma":[0.009043311,0.0016061474,0.13310708,0.0007339252,0.0004002125,0.00009538549,0.0002968529,0.00018756722,0.0390704,0.00061594736,0.8138231,0.0010200813],"about_ca_topic_score_codex":0.00005329262,"about_ca_topic_score_gemma":0.000013735409,"teacher_disagreement_score":0.83751523,"about_ca_system_score_codex":0.0001487354,"about_ca_system_score_gemma":0.00022815347,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W7072048555","doi":"","title":"The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine","year":2015,"lang":"en","type":"book","venue":"Directory of Open access Books (OAPEN Foundation)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Precision medicine; Targeted therapy; Disease; Cancer; Radiation therapy; Personalized medicine; Stage (stratigraphy); Malignant disease; Patient care","score_opus":0.08689291256766876,"score_gpt":0.4384536766463737,"score_spread":0.35156076407870496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7072048555","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01447986,0.014542592,0.000067605266,0.0012726727,0.00089871744,0.007824965,0.0000685293,0.000023342693,0.9608217],"genre_scores_gemma":[0.021854037,0.00584248,0.0006170284,0.00016321924,0.00028488098,0.0005880514,0.0012441764,0.00012857992,0.96927756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974008,0.000098246455,0.0011310414,0.0004702606,0.00064109976,0.00025853675],"domain_scores_gemma":[0.9966667,0.00043667053,0.0013725825,0.0006722674,0.00064777315,0.00020398281],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035643426,0.0004525606,0.0015114989,0.00028576583,0.00009728607,0.00009402458,0.00086514896,0.00008232163,0.0029030966],"category_scores_gemma":[0.000051996867,0.0003011438,0.00021620242,0.00022559636,0.00032495917,0.0004139821,0.00014723091,0.00019388777,0.000017443772],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048422925,0.0036440927,0.03958997,0.0051249913,0.012427051,0.00013105012,0.026014866,0.0002189531,0.0012356949,0.009222408,0.079219714,0.8183289],"study_design_scores_gemma":[0.033566523,0.0023024946,0.030772015,0.008387079,0.010557437,0.000009019322,0.0008402766,0.0003006053,0.0035229027,0.0021724827,0.90664023,0.00092893734],"about_ca_topic_score_codex":0.017393466,"about_ca_topic_score_gemma":0.0053235744,"teacher_disagreement_score":0.82742053,"about_ca_system_score_codex":0.0014160757,"about_ca_system_score_gemma":0.010590083,"threshold_uncertainty_score":0.9999441},"labels":[],"label_agreement":null},{"id":"W7084075736","doi":"10.6084/m9.figshare.30038713.v1","title":"Appendix 5. Outcomes by Intervention Program Type.pdf","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Psychological intervention; Supervisor; Transfer of training; Intervention (counseling); Transfer of learning; Work (physics); Organizational culture; Organizational learning","score_opus":0.020851435747238824,"score_gpt":0.38983812179498994,"score_spread":0.36898668604775114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084075736","genre_codex":"other","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025965968,0.010278247,0.00003367082,0.013662531,0.0015257706,0.009201057,0.26322976,0.0019038528,0.67419916],"genre_scores_gemma":[0.22415273,0.0000062977456,0.00031941623,0.0013856544,0.000040402843,0.0010061132,0.55794877,0.000018552353,0.21512204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964345,0.000006073925,0.00008971804,0.00010805054,0.000063499174,0.00008919038],"domain_scores_gemma":[0.9997554,0.00001575392,0.00002509931,0.00011346528,0.00005607303,0.000034249595],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000007642189,0.00006290673,0.00009494024,0.000037693506,0.000035192694,0.00001979647,0.00003528753,0.000035558292,0.19153658],"category_scores_gemma":[0.000106423955,0.000048485414,0.00006791433,0.00012005369,0.0000023340403,0.000037187474,0.00002146943,0.000050017046,0.007244773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009445222,0.00021391151,0.0030789832,0.00013060488,0.00012575596,0.000005278513,0.000020062256,1.3647762e-7,0.00000901251,0.000013089777,0.9188841,0.077509634],"study_design_scores_gemma":[0.00097321934,0.00013679665,0.02647898,0.0011854172,0.0000835833,0.0000019190788,0.000034697856,0.00001823482,0.0003445392,0.00002489359,0.9706719,0.000045807592],"about_ca_topic_score_codex":0.00002220389,"about_ca_topic_score_gemma":0.000010151373,"teacher_disagreement_score":0.45907712,"about_ca_system_score_codex":0.00006666596,"about_ca_system_score_gemma":0.000048758095,"threshold_uncertainty_score":0.9935282},"labels":[],"label_agreement":null},{"id":"W7084140186","doi":"10.4000/14nio","title":"Introduction","year":2021,"lang":"fr","type":"book-chapter","venue":"Presses universitaires de Rouen et du Havre eBooks","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Urban environment; Power (physics); Quarter (Canadian coin); Context (archaeology)","score_opus":0.01106491705763696,"score_gpt":0.253946130646149,"score_spread":0.24288121358851206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084140186","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013307427,0.008698909,0.0015387429,0.025193268,0.0023280345,0.00079765095,0.00022675935,0.00018988899,0.959696],"genre_scores_gemma":[0.38753965,0.0033606722,0.0015186194,0.00076554174,0.0049306713,0.000021543307,0.0010999696,0.00017333127,0.60059],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978306,0.00011629879,0.0003449367,0.000787048,0.00037521787,0.00054588413],"domain_scores_gemma":[0.99808526,0.00018841606,0.0002580459,0.0006770178,0.00042863915,0.00036263614],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001376993,0.0005723454,0.00062644243,0.00025658877,0.0003660573,0.00009920656,0.00023079597,0.0004700789,0.0055071316],"category_scores_gemma":[0.00007243768,0.0006244436,0.00037246017,0.000042399333,0.0003325746,0.00023529242,0.00023389654,0.0005760289,0.0002603095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024589404,0.00019974112,0.00106912,0.0006885015,0.003572972,0.0031699871,0.001771023,0.00048005072,0.00063424086,0.87456405,0.027116084,0.08648835],"study_design_scores_gemma":[0.0019180924,0.00032790797,0.0007192819,0.0013436408,0.0052821725,0.00048422138,0.0010417006,0.0000952821,0.0007466109,0.0032695022,0.98420465,0.0005669454],"about_ca_topic_score_codex":0.00049360323,"about_ca_topic_score_gemma":0.00024117142,"teacher_disagreement_score":0.95708853,"about_ca_system_score_codex":0.0013991718,"about_ca_system_score_gemma":0.0011282349,"threshold_uncertainty_score":0.9996207},"labels":[],"label_agreement":null},{"id":"W7086889519","doi":"10.5281/zenodo.17308686","title":"Culture and Uncertainty Study: Interview Questionnaire and Codebook updated with survey questions","year":2025,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Codebook; Set (abstract data type); Data set; Interview; Survey data collection","score_opus":0.026403782018187057,"score_gpt":0.3159159468774912,"score_spread":0.28951216485930414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7086889519","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076024747,0.0015602328,0.00019246369,0.0006879648,0.00007809195,0.002062511,0.99154794,0.0003601045,0.0027504128],"genre_scores_gemma":[0.005141703,0.0012938519,0.000047484948,0.00023248083,0.000046783185,4.761136e-7,0.9902974,0.00026521846,0.0026746364],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982506,0.0005525722,0.00023148717,0.0005142028,0.0002489922,0.0002021372],"domain_scores_gemma":[0.9984245,0.000019507104,0.00010833039,0.00047486988,0.0007804938,0.00019233419],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042087448,0.00023880746,0.00032256078,0.00022248257,0.0012189554,0.0004169669,0.00023423422,0.000110343964,0.0010104794],"category_scores_gemma":[0.00031645873,0.00018694361,0.000024387773,0.00039013813,0.00019190482,0.00009631073,0.00050567236,0.00038536833,0.00009158755],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012303684,0.0003358759,0.000045047593,0.00030100287,0.0004066017,0.000042607033,0.00038680888,0.000002678843,0.000002111958,0.00005201857,0.98703545,0.011266735],"study_design_scores_gemma":[0.0014716096,0.001070137,0.005138391,0.0006205036,0.00055047846,0.0001623621,0.0002623902,0.00001585551,8.0709094e-7,0.000009056492,0.9905263,0.00017208929],"about_ca_topic_score_codex":0.0007806044,"about_ca_topic_score_gemma":0.00012443356,"teacher_disagreement_score":0.011094646,"about_ca_system_score_codex":0.00020555433,"about_ca_system_score_gemma":0.000031863026,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W7104177074","doi":"10.1016/j.annonc.2025.08.2675","title":"2053eP ESMO treatment (tx) guideline adherence in patients (pts) with lung cancer (LC) with EGFR or ALK (EGFR/ALK) alterations: A WAYFIND-R registry-based study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Lung cancer; Guideline; MEDLINE; Erlotinib; Chemotherapy","score_opus":0.05267926010928427,"score_gpt":0.4611828682689936,"score_spread":0.4085036081597093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104177074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97583246,0.0006839403,0.00032695415,0.012585594,0.00016595001,0.0033153137,0.00012280123,0.000041707,0.006925265],"genre_scores_gemma":[0.990389,0.0001461566,0.0018110852,0.0025012533,0.000045201963,0.0012618649,0.00020234945,0.00002201171,0.003621086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831104,0.000099875164,0.00059296214,0.00044274752,0.0002398192,0.0003135393],"domain_scores_gemma":[0.9984101,0.00014026587,0.00027958507,0.00044255354,0.00062389334,0.00010358356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012808111,0.00026198677,0.00062195875,0.00023838916,0.00009162808,0.0000134526945,0.00010661541,0.00009926978,0.00022422252],"category_scores_gemma":[0.00006845273,0.00015865013,0.000057170844,0.00048622375,0.00010106499,0.000086260414,0.000021362503,0.00011538146,0.0000032761604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008414524,0.0142281,0.8853627,0.00015737955,0.0019366714,0.0003992071,0.0023824554,0.0018199963,0.000024191211,0.000107697,0.014252036,0.070915066],"study_design_scores_gemma":[0.11949886,0.13716526,0.6105903,0.0025062265,0.0040531447,0.000016499629,0.0033265164,0.0016183346,0.0017887327,0.00006578169,0.11860685,0.0007634892],"about_ca_topic_score_codex":0.0059184455,"about_ca_topic_score_gemma":0.026814217,"teacher_disagreement_score":0.27477238,"about_ca_system_score_codex":0.0006381506,"about_ca_system_score_gemma":0.003430415,"threshold_uncertainty_score":0.9909439},"labels":[],"label_agreement":null},{"id":"W7104180020","doi":"10.1016/j.annonc.2025.08.2580","title":"1956P Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT-cohort A interim analysis)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Lakeridge Health; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Western University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Brampton Civic Hospital; Lions Gate Hospital; London Health Sciences Centre","funders":"","keywords":"Osimertinib; Interim; Lung cancer; Chemotherapy; Interim analysis","score_opus":0.051855382793633435,"score_gpt":0.4608945026276346,"score_spread":0.40903911983400115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104180020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93153346,0.005237057,0.0003368301,0.03831933,0.00015299961,0.0011447808,0.000030747466,0.00010541103,0.023139378],"genre_scores_gemma":[0.98840714,0.003680401,0.0004159176,0.005571532,0.00004790745,0.00031277674,0.0000704805,0.000032750395,0.0014610857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983454,0.00010372658,0.0005928714,0.00042662775,0.00017548271,0.00035593827],"domain_scores_gemma":[0.9988164,0.00013306577,0.00025811276,0.00037126878,0.0003255497,0.00009563419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033155386,0.00023076896,0.0009372587,0.0005541611,0.000039420243,0.0000075212165,0.00014019017,0.00018396117,0.00023582268],"category_scores_gemma":[0.000045237284,0.00017006209,0.0001795303,0.001214396,0.00012932913,0.000070956485,0.00003445378,0.00023335156,0.0000028801646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009052542,0.005235326,0.7755989,0.00041770536,0.034991477,0.00022839653,0.009111616,0.0014057204,0.004766519,0.0007537993,0.011832336,0.1466057],"study_design_scores_gemma":[0.019110061,0.006616126,0.87651956,0.0010589598,0.009151843,0.00002056189,0.0015244369,0.003247327,0.028076066,0.00031577193,0.053785574,0.00057368644],"about_ca_topic_score_codex":0.0017011372,"about_ca_topic_score_gemma":0.0014117057,"teacher_disagreement_score":0.14603202,"about_ca_system_score_codex":0.00022203139,"about_ca_system_score_gemma":0.0008481059,"threshold_uncertainty_score":0.6934931},"labels":[],"label_agreement":null},{"id":"W7112335456","doi":"","title":"Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach","year":2010,"lang":"en","type":"article","venue":"PubMed Central","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Bevacizumab; Targeted therapy; Lung cancer; Maintenance therapy; Regimen; Disease; Chemotherapy","score_opus":0.012732913915334624,"score_gpt":0.26352061160192247,"score_spread":0.2507876976865879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112335456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194,0.0018250187,0.00036669342,0.0016095478,0.00037188787,0.0021209621,0.000043665685,0.000035220506,0.0016870042],"genre_scores_gemma":[0.99478066,0.00017385125,0.0008810044,0.00052893144,0.00022453663,0.00258307,0.00007715428,0.000030668627,0.00072014966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986067,0.00005050432,0.00019601,0.00025771855,0.00026367843,0.0006254031],"domain_scores_gemma":[0.99939084,0.00007298884,0.00008448899,0.0002457438,0.000050567327,0.00015537957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019141649,0.00019050753,0.0002290846,0.00008045162,0.00011361171,0.00004556107,0.000105494335,0.00004440615,0.00010201711],"category_scores_gemma":[0.0000125495,0.000100057274,0.00006355687,0.00023134136,0.00007087752,0.00008611082,0.000007721352,0.0002596949,0.0000026568607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010673021,0.002146872,0.9110732,0.00050960615,0.0029723998,0.000063266736,0.0554616,0.002557168,0.004028473,0.0017318118,0.0013736256,0.017014684],"study_design_scores_gemma":[0.00799461,0.00013888627,0.9805144,0.00011446745,0.0007720036,0.00006163928,0.0044550775,0.002082237,0.0013676586,0.000025638094,0.0021922213,0.0002811458],"about_ca_topic_score_codex":0.0003524397,"about_ca_topic_score_gemma":0.00047679376,"teacher_disagreement_score":0.06944122,"about_ca_system_score_codex":0.0002688778,"about_ca_system_score_gemma":0.0004775085,"threshold_uncertainty_score":0.40802172},"labels":[],"label_agreement":null},{"id":"W7112769154","doi":"","title":"Amplificación Oncogénica Como Marcador Tumoral en un Grupo dePacientes con Cáncer Pulmonar","year":2009,"lang":"en","type":"article","venue":"TSpace","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Universidad Nacional de Colombia","keywords":"Lung cancer; Gene; Lung; Primary tumor; Correlation; Lung tumor","score_opus":0.01646920387376501,"score_gpt":0.37541813624609494,"score_spread":0.35894893237232994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112769154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9219113,0.0016628202,0.00049075467,0.02821635,0.0002519561,0.0008506992,0.00003382154,0.00026425734,0.046318047],"genre_scores_gemma":[0.9833452,0.00012222763,0.0024237134,0.0013854313,0.00015275295,0.00002442555,0.00008592902,0.000019379371,0.012440905],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989932,0.00003360484,0.0001633506,0.0002769513,0.00023375425,0.0002990948],"domain_scores_gemma":[0.9993087,0.000053907053,0.000061032068,0.00030685536,0.00007229647,0.00019723008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007775463,0.00016488404,0.00024903685,0.00006658171,0.00010660102,0.000025721096,0.000083132436,0.00006337659,0.00081106846],"category_scores_gemma":[0.00003929046,0.00013184373,0.00009199192,0.00018745921,0.00005670516,0.00006329914,0.000018469966,0.00014523871,0.00027913027],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002945715,0.00856695,0.14718902,0.00041203242,0.0018752352,0.0041604764,0.04135559,0.00012945218,0.11892118,0.037664607,0.112827234,0.5239525],"study_design_scores_gemma":[0.009780689,0.002796303,0.6651783,0.00047024322,0.0012559108,0.0006401212,0.0046972563,0.0004942543,0.015231122,0.001961222,0.29670048,0.0007941186],"about_ca_topic_score_codex":0.00013662897,"about_ca_topic_score_gemma":0.000014837689,"teacher_disagreement_score":0.5231584,"about_ca_system_score_codex":0.00018963743,"about_ca_system_score_gemma":0.00011655983,"threshold_uncertainty_score":0.8880631},"labels":[],"label_agreement":null},{"id":"W7114800430","doi":"10.1016/j.jtocrr.2025.100944","title":"Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC","funders":"International Association for the Study of Lung Cancer","keywords":"Targeted therapy; Lung; Cell; Cell therapy; Acquired resistance; Immunotherapy","score_opus":0.07505819556033028,"score_gpt":0.5350332632889704,"score_spread":0.4599750677286401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114800430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97014254,0.009904338,0.000017197735,0.00909277,0.000102609316,0.00057172717,0.0000020170664,0.000015365375,0.010151439],"genre_scores_gemma":[0.9898711,0.004076525,0.0004564276,0.0004271684,0.00005651595,0.00006368293,0.0000029019495,0.0000056638582,0.0050400193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864966,0.00009985018,0.00039852405,0.00038664538,0.00024886584,0.00021646055],"domain_scores_gemma":[0.9991355,0.0002897535,0.00003624153,0.00017554751,0.00019343532,0.0001695429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001193198,0.000079121724,0.0002596237,0.00011584494,0.00012471496,0.00005760574,0.000021526592,0.00007067468,0.000014061381],"category_scores_gemma":[0.00052685494,0.00005499003,0.000023266553,0.00028628382,0.0002948637,0.000071469454,0.000050278315,0.00025468247,4.9477825e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008944595,0.00028970267,0.89364624,0.00019318603,0.00013210493,0.0013353463,0.0013757262,0.0000023116693,0.0007650233,0.002414049,0.006671623,0.09228021],"study_design_scores_gemma":[0.0016917808,0.00034507754,0.93850404,0.0004580415,0.000013597071,0.000018738572,0.0009628786,0.000018707358,0.000117071446,0.00560541,0.052189127,0.000075516626],"about_ca_topic_score_codex":0.00020654526,"about_ca_topic_score_gemma":0.0003751043,"teacher_disagreement_score":0.09220469,"about_ca_system_score_codex":0.000025509327,"about_ca_system_score_gemma":0.000355413,"threshold_uncertainty_score":0.22424284},"labels":[],"label_agreement":null},{"id":"W7114902100","doi":"10.53366/jimki.vi.953","title":"Associations Between Genetic Variants and Adverse Effects of Gefitinib in Non-small Cell Lung Cancer: A Systematic Review","year":2025,"lang":"","type":"article","venue":"JIMKI Jurnal Ilmiah Mahasiswa Kedokteran Indonesia","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gefitinib; Adverse effect; Lung cancer; Pharmacogenomics; Erlotinib; Pharmacogenetics; Genetic testing; CYP2D6; Meta-analysis","score_opus":0.007255484987686441,"score_gpt":0.297768045910995,"score_spread":0.2905125609233085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114902100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7461399,0.23974651,0.00047048368,0.0010846462,0.0009331723,0.010016371,0.00044860216,0.00003541715,0.0011249352],"genre_scores_gemma":[0.94937366,0.04694785,0.00034150606,0.0009942736,0.00021777312,0.0010512462,0.000089825815,0.00007751765,0.0009063477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99394304,0.00067565625,0.0029687968,0.0008932405,0.00064868806,0.00087060826],"domain_scores_gemma":[0.99547607,0.0011974233,0.0016443536,0.000821439,0.00045687603,0.0004038406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006868552,0.0008045348,0.0035662444,0.00093289674,0.0002998642,0.0000804977,0.00039234775,0.00041946853,0.000051984534],"category_scores_gemma":[0.0002784107,0.0007388284,0.00049347925,0.0017025052,0.00014439161,0.00024046485,0.00015565395,0.0007473627,0.00001264583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062523846,0.00064875314,0.5268948,0.4658919,0.0025032535,0.0002593034,0.0020535165,0.00002480731,0.00024157033,0.000037599075,0.00031365588,0.0010683159],"study_design_scores_gemma":[0.008124134,0.00022963855,0.65551037,0.30856434,0.02643251,0.000015549838,0.00011910113,0.0003186087,0.00025249814,0.00002680824,0.000010779091,0.00039566556],"about_ca_topic_score_codex":0.0012240589,"about_ca_topic_score_gemma":0.00017484702,"teacher_disagreement_score":0.2032338,"about_ca_system_score_codex":0.0011238224,"about_ca_system_score_gemma":0.0015529852,"threshold_uncertainty_score":0.9995063},"labels":[],"label_agreement":null},{"id":"W7116844250","doi":"10.1177/17588359251385410","title":"TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i> -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; Pfizer Japan; EMD Serono; Daiichi-Sankyo; Eli Lilly and Company; Ono Pharmaceutical; Sanofi; Apollomics; Yuhan; Taiho Pharmaceutical; Boehringer Ingelheim Japan; BeiGene; Chugai Pharmaceutical; Nihon Medi-Physics; Astellas Pharma; AstraZeneca; Novocure; Genomic Health; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Chemotherapy; Disease; Randomized controlled trial; Phases of clinical research; Clinical trial; Lung disease","score_opus":0.012525595294375842,"score_gpt":0.3687785906845456,"score_spread":0.35625299539016975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116844250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832274,0.0038063014,0.00047069506,0.002265842,0.00026569614,0.009619294,0.0000406595,0.000063085456,0.00024107058],"genre_scores_gemma":[0.993389,0.001427055,0.0008478981,0.0014177539,0.000030449415,0.0025206064,0.00018237959,0.00006853649,0.000116334886],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99622595,0.00038379466,0.0011642124,0.0008942178,0.0007143797,0.0006174349],"domain_scores_gemma":[0.9970844,0.0011800881,0.00059162424,0.0005477243,0.00020876038,0.00038742364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038566033,0.00056880375,0.002041032,0.00034004214,0.00014692213,0.000020766423,0.00028654502,0.00018673991,0.00017491539],"category_scores_gemma":[0.00013206048,0.0003490441,0.00007180706,0.00091515086,0.0007590257,0.00019870233,0.000068867645,0.0005567907,8.2308094e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75386465,0.018611448,0.048356835,0.00032768576,0.0011362841,0.00031138194,0.003116145,0.00017608733,0.000036287314,0.000023304336,0.000015867357,0.17402405],"study_design_scores_gemma":[0.95850927,0.019907001,0.011015511,0.0016043815,0.002026305,0.000003200504,0.0014353523,0.00287384,0.00041899175,0.000032561733,0.0017557709,0.00041781517],"about_ca_topic_score_codex":0.00016076097,"about_ca_topic_score_gemma":0.0010907096,"teacher_disagreement_score":0.20464464,"about_ca_system_score_codex":0.00048254617,"about_ca_system_score_gemma":0.0023068148,"threshold_uncertainty_score":0.99989617},"labels":[],"label_agreement":null},{"id":"W7116917451","doi":"10.1016/j.annonc.2025.10.716","title":"1005P MET testing and treatment (tx) sequencing after progression of disease (PD) on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Final analysis of a global real-world (rw) study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Disease; C-Met; MEDLINE; Respiratory disease","score_opus":0.07739625107389356,"score_gpt":0.44608546161368484,"score_spread":0.3686892105397913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116917451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978136,0.00025285312,0.00001850262,0.00026397253,0.000015401241,0.0012231577,0.00014578729,0.000009936543,0.00025679893],"genre_scores_gemma":[0.9974478,0.00015981535,0.0019494997,0.00007946431,0.0000068197264,0.00021576893,0.00008003684,0.000008101623,0.000052724907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986375,0.00010344922,0.0005083818,0.00038478267,0.0001982599,0.0001676208],"domain_scores_gemma":[0.99869514,0.00030434987,0.0004087692,0.00024450687,0.00023903437,0.00010820666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013894746,0.00018868256,0.00066985696,0.00029958342,0.000057270474,0.0000055992,0.00003682406,0.00005372237,0.000010882959],"category_scores_gemma":[0.00018272926,0.00012274797,0.000049345155,0.00073501957,0.00010863901,0.000088966,0.00004850819,0.000038481343,8.4240284e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020074574,0.0034254347,0.86945224,0.00014717256,0.00095483055,0.000015663796,0.0009186278,0.00019777234,0.00043677105,0.000030680363,0.000007763123,0.10433846],"study_design_scores_gemma":[0.00923401,0.017267153,0.9687986,0.0011123209,0.002289559,6.74991e-7,0.0003572907,0.00023596344,0.00051578006,0.000048196882,0.000049693528,0.00009080509],"about_ca_topic_score_codex":0.0008159456,"about_ca_topic_score_gemma":0.0017170578,"teacher_disagreement_score":0.10424765,"about_ca_system_score_codex":0.00023896321,"about_ca_system_score_gemma":0.000247738,"threshold_uncertainty_score":0.5005517},"labels":[],"label_agreement":null},{"id":"W7116961433","doi":"10.1016/j.annonc.2025.10.694","title":"981P Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with HER2 Exon 20 mutant NSCLC: Randomized dose optimization","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi-Sankyo","keywords":"Penetrant (biochemical); Mutant; Exon; Mutation; Randomized controlled trial","score_opus":0.01277304934096056,"score_gpt":0.3394166619055724,"score_spread":0.32664361256461183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116961433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710496,0.000671844,0.0006532977,0.011579381,0.00018564978,0.0022508241,0.000028522232,0.000034530425,0.01354634],"genre_scores_gemma":[0.99555355,0.0002629068,0.0015379477,0.0017834252,0.00003168979,0.00016000516,0.000103836304,0.000017613509,0.000549042],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99859124,0.0002110702,0.00047513086,0.00030880445,0.00016406579,0.00024971305],"domain_scores_gemma":[0.99887294,0.00035408608,0.00020407345,0.0001518964,0.00033346814,0.00008353183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003183631,0.00017939623,0.0007694178,0.00028934557,0.00005504422,0.000009598277,0.00004844379,0.00014553174,0.000034671048],"category_scores_gemma":[0.00021209155,0.00013094337,0.0000702862,0.00039732183,0.0001414343,0.000102757826,0.000025218178,0.00013632147,0.0000013669378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5349455,0.016686127,0.22401972,0.00079280254,0.0049590394,0.00030789446,0.013625036,0.006263866,0.0020123534,0.0030638613,0.01321378,0.18011002],"study_design_scores_gemma":[0.77492404,0.013177587,0.18992737,0.0009524092,0.0012388078,0.000020150264,0.00032879354,0.002026346,0.0043050298,0.0007805992,0.0118275285,0.0004913306],"about_ca_topic_score_codex":0.0005616368,"about_ca_topic_score_gemma":0.00031354115,"teacher_disagreement_score":0.23997857,"about_ca_system_score_codex":0.00014046022,"about_ca_system_score_gemma":0.0005732442,"threshold_uncertainty_score":0.53397155},"labels":[],"label_agreement":null},{"id":"W7116981447","doi":"10.1016/j.annonc.2025.10.609","title":"903MO Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in patients (pts) with resectable epidermal growth factor receptor-mutated (EGFRm) stage II–IIIB non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from NeoADAURA","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Lung cancer; Chemotherapy; Neoadjuvant therapy; Stage (stratigraphy); Epidermal growth factor receptor","score_opus":0.021858885541620753,"score_gpt":0.34920376093870376,"score_spread":0.327344875397083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116981447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894716,0.0010642274,0.00004821675,0.003734772,0.00050148304,0.0025908884,0.0005976779,0.00007892469,0.0019122075],"genre_scores_gemma":[0.99007696,0.00069525035,0.0007854731,0.0042084395,0.00004490415,0.00041860028,0.0006693168,0.00007907144,0.0030219923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642164,0.00016802186,0.0012970113,0.0008464341,0.0004386996,0.00082820916],"domain_scores_gemma":[0.9971697,0.0003377925,0.00085689203,0.00060049625,0.0007770432,0.000258079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016555733,0.00054805074,0.0015128588,0.0004202138,0.00019137353,0.000029064362,0.00022261462,0.00017794456,0.0007178056],"category_scores_gemma":[0.00014278603,0.00042570097,0.00021526772,0.0007146569,0.000163679,0.00027816746,0.00011713777,0.00043986505,0.000007738158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004262905,0.0035856331,0.9544038,0.00018904518,0.0017491756,0.00029954562,0.0018898936,0.00011565571,0.0029877122,0.000012115863,0.009297775,0.021206697],"study_design_scores_gemma":[0.040267635,0.0070372103,0.8480694,0.00089888705,0.0007524779,0.0000073918495,0.00038046172,0.00026136683,0.08054921,0.00003536072,0.021074664,0.00066589925],"about_ca_topic_score_codex":0.024459423,"about_ca_topic_score_gemma":0.0012146283,"teacher_disagreement_score":0.10633441,"about_ca_system_score_codex":0.00051792536,"about_ca_system_score_gemma":0.001510011,"threshold_uncertainty_score":0.99981946},"labels":[],"label_agreement":null},{"id":"W7117002553","doi":"10.1016/j.annonc.2025.10.681","title":"LBA13 Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in EGFR Exon 20 mutant NSCLC: Randomized dose optimization and CNS activity","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi-Sankyo","keywords":"Penetrant (biochemical); Mutant; Exon; Mutation; Dose dependence","score_opus":0.022452845484421897,"score_gpt":0.37923110418426537,"score_spread":0.3567782586998435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117002553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95595837,0.0018752438,0.0010249136,0.028443301,0.00018932813,0.0016058092,0.000025920092,0.00003372589,0.010843405],"genre_scores_gemma":[0.99525905,0.0015083319,0.0010243958,0.0013544193,0.00004426128,0.00014727475,0.000027264381,0.0000138774785,0.00062111084],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985955,0.00029410844,0.0004018049,0.00033992724,0.000118224016,0.00025048474],"domain_scores_gemma":[0.99870706,0.0006994781,0.0001798494,0.00014122609,0.00017595942,0.00009645634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052083604,0.00017945218,0.00083562935,0.0003014244,0.0000698489,0.000012804602,0.00004074494,0.00018650747,0.000025752717],"category_scores_gemma":[0.0003526738,0.00014675714,0.00007984904,0.00033319424,0.00019082357,0.00012754985,0.00003982672,0.00016973919,8.200385e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29076728,0.011582132,0.02678058,0.0013723022,0.004696504,0.00064967957,0.021557396,0.0029529957,0.10812764,0.0063791205,0.013270881,0.51186347],"study_design_scores_gemma":[0.7676778,0.0108131,0.10134304,0.0012571707,0.0022035989,0.00020658593,0.0009800775,0.015452285,0.063102655,0.003379274,0.03268072,0.00090373185],"about_ca_topic_score_codex":0.00090922945,"about_ca_topic_score_gemma":0.00051485276,"teacher_disagreement_score":0.51095974,"about_ca_system_score_codex":0.00013745844,"about_ca_system_score_gemma":0.0005808911,"threshold_uncertainty_score":0.59845823},"labels":[],"label_agreement":null},{"id":"W7117253610","doi":"10.1620/tjem.2025.j157","title":"&lt;i&gt;KRAS&lt;/i&gt; and &lt;i&gt;MET&lt;/i&gt; Co-Mutation in One Lesion and &lt;i&gt;EGFR&lt;/i&gt; Mutation in Another Lesion of Early-Stage Synchronous Multiple Lung Adenocarcinomas: A Case Report","year":2025,"lang":"en","type":"article","venue":"The Tohoku Journal of Experimental Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lesion; Lung; Mutation; Computed tomography; Order (exchange)","score_opus":0.025100146791934383,"score_gpt":0.33008802703583334,"score_spread":0.30498788024389895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117253610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9295608,0.06269568,0.0008540278,0.0014493627,0.00063613645,0.002208283,0.000054630313,0.000055663677,0.0024854068],"genre_scores_gemma":[0.9940405,0.0016316456,0.00140671,0.00037282245,0.0004488805,0.0001427741,0.00015183614,0.00012222774,0.0016826035],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99391776,0.0004985252,0.0025783186,0.0008229568,0.0013680212,0.0008144035],"domain_scores_gemma":[0.99598783,0.0007478068,0.0015970035,0.00074618496,0.00043737938,0.00048376893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019812344,0.0007998082,0.0016982682,0.0014257097,0.00040568988,0.00006527358,0.00029141398,0.0003697006,0.00024091559],"category_scores_gemma":[0.0006062278,0.0006085765,0.00024269147,0.000995209,0.0007814432,0.00074995746,0.00016653055,0.0005750856,0.0000070091423],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029866893,0.0020225039,0.010534597,0.00045072607,0.0007897739,0.012256345,0.02221015,0.0001901138,0.9402794,0.0010439099,0.0018254726,0.0054103015],"study_design_scores_gemma":[0.11690425,0.02159421,0.4668127,0.019286703,0.0066375397,0.056676585,0.018614259,0.008156878,0.27026647,0.000647535,0.011544089,0.0028587761],"about_ca_topic_score_codex":0.00032288537,"about_ca_topic_score_gemma":0.0005959843,"teacher_disagreement_score":0.67001295,"about_ca_system_score_codex":0.001538177,"about_ca_system_score_gemma":0.00060684053,"threshold_uncertainty_score":0.99963653},"labels":[],"label_agreement":null},{"id":"W7117298964","doi":"10.1016/j.iotech.2025.101461","title":"262P EGFR mutations (EGFR+) or ALK rearrangements (ALK+) in the BR31 trial of adjuvant durvalumab (D) v placebo (P)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Dalhousie University; University of Ottawa","funders":"","keywords":"Durvalumab; Placebo; Adjuvant; Mutation; Clinical trial","score_opus":0.01786102216622019,"score_gpt":0.3937564791857949,"score_spread":0.3758954570195747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117298964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86061466,0.0026628054,0.0003075606,0.05210539,0.0020517237,0.0050070784,0.00006607618,0.00028447952,0.076900244],"genre_scores_gemma":[0.99261355,0.00038104897,0.0016006653,0.00080316165,0.00005316673,0.0013675722,0.0000981218,0.000021970542,0.0030607327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981196,0.00019127897,0.00072197046,0.00037075928,0.00019614148,0.0004002683],"domain_scores_gemma":[0.9982532,0.00055267406,0.00024147735,0.0007608936,0.00016254588,0.000029200357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044340227,0.00022223388,0.00067255256,0.0008481463,0.00016517325,0.0000095098385,0.0004070332,0.0004916962,0.00023027314],"category_scores_gemma":[0.0006489678,0.00015066341,0.000121593126,0.0012883049,0.0005704977,0.00006714294,0.00011647215,0.00044466447,0.000035942394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12961422,0.015132591,0.021789888,0.00046412862,0.0060474677,0.0018254538,0.012567137,0.00006977289,0.037641566,0.04771216,0.0333566,0.693779],"study_design_scores_gemma":[0.36428583,0.012657359,0.015449628,0.0005170032,0.0028668423,0.00053787674,0.023939086,0.000103529346,0.0073483004,0.009187351,0.56261384,0.000493369],"about_ca_topic_score_codex":0.00035972786,"about_ca_topic_score_gemma":0.0008505776,"teacher_disagreement_score":0.69328564,"about_ca_system_score_codex":0.0006202758,"about_ca_system_score_gemma":0.0011329245,"threshold_uncertainty_score":0.6143876},"labels":[],"label_agreement":null},{"id":"W7117725501","doi":"10.1039/d5cp03925h","title":"Lung cancer targeting by trimethoxy flavans: a molecular simulation study","year":2025,"lang":"en","type":"article","venue":"Physical Chemistry Chemical Physics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Imam Mohammed Ibn Saud Islamic University","keywords":"Molecular dynamics; Lung cancer; Density functional theory; Virtual screening; Principal component analysis; Docking (animal); Molecular model; Reactivity (psychology)","score_opus":0.008029343097354546,"score_gpt":0.3742071771352433,"score_spread":0.3661778340378888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117725501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880535,0.0005316017,0.0042932443,0.00036009788,0.00003800928,0.00058812666,0.000043139993,0.00012754866,0.0052128728],"genre_scores_gemma":[0.9980825,0.000004506421,0.00018344956,0.00023939794,0.00033720714,0.00018940159,0.00021763914,0.000029493636,0.000716366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987574,0.000016942995,0.00022826172,0.00045121336,0.00027851117,0.00026762355],"domain_scores_gemma":[0.9992456,0.00012702568,0.00007359645,0.0002827599,0.00014242098,0.00012863785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000034191064,0.00024564395,0.00038706604,0.00000945711,0.000069243324,0.000024599409,0.00010090646,0.00007009717,0.000028108401],"category_scores_gemma":[0.00007666583,0.00022296738,0.00017870506,0.0003639392,0.0000567216,0.0000706391,0.000059577706,0.00027856056,0.000003835185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084713094,0.0025104294,0.00091785914,0.0002505592,0.00052758,0.0000066703824,0.00027042825,0.0013485543,0.9887827,0.000027975762,0.002416459,0.0028560697],"study_design_scores_gemma":[0.0023049572,0.00002839447,0.000047512112,0.000089348316,0.0010980535,2.0514071e-7,0.000102118196,0.03265253,0.9620869,0.0007500785,0.00063258916,0.00020726548],"about_ca_topic_score_codex":0.00004081805,"about_ca_topic_score_gemma":4.0849265e-8,"teacher_disagreement_score":0.03130398,"about_ca_system_score_codex":0.00031326094,"about_ca_system_score_gemma":0.00015832308,"threshold_uncertainty_score":0.90923464},"labels":[],"label_agreement":null},{"id":"W7123483602","doi":"10.1016/j.cancergen.2025.10.085","title":"81. The journey to the first full approval of a ClinGen somatic cancer variant curation expert panel - NTRK fusions","year":2025,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; McMaster University","funders":"","keywords":"Fusion gene; Cancer; Genome; Precision medicine; Gene; Trk receptor; Gene nomenclature","score_opus":0.05440799410959532,"score_gpt":0.38402323653093395,"score_spread":0.32961524242133866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7123483602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6463146,0.08334191,0.022579247,0.23050019,0.0050702207,0.005889274,0.00037308587,0.00010645029,0.005824986],"genre_scores_gemma":[0.9811904,0.0072322735,0.0011425087,0.0063749393,0.0006687785,0.0011760768,0.000018534198,0.000026900367,0.0021696286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990587,0.000030381276,0.00030834685,0.00019483376,0.00021186867,0.00019584554],"domain_scores_gemma":[0.9991027,0.000076973265,0.000106799685,0.00044752014,0.00019306231,0.000072914234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097341464,0.00013554965,0.00020012981,0.000055204382,0.00029479244,0.00002914822,0.00017441084,0.000055265406,0.00015850551],"category_scores_gemma":[0.00004327131,0.00007320637,0.00008370232,0.00035341718,0.000062532476,0.000025775456,0.000060779694,0.00010971207,0.000007252641],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010374062,0.001475186,0.038253944,0.0012165229,0.005589413,0.000047365,0.12500891,0.05112777,0.021076998,0.0040926095,0.33375707,0.4173168],"study_design_scores_gemma":[0.00411761,0.0005367503,0.08901707,0.0015585612,0.0033096871,0.00003100832,0.0052449317,0.01977889,0.009454748,0.0007399122,0.8657915,0.00041934766],"about_ca_topic_score_codex":0.0011648607,"about_ca_topic_score_gemma":0.003141685,"teacher_disagreement_score":0.5320344,"about_ca_system_score_codex":0.0002547904,"about_ca_system_score_gemma":0.0007721491,"threshold_uncertainty_score":0.2985269},"labels":[],"label_agreement":null},{"id":"W7123703764","doi":"10.1016/j.cancergen.2025.10.053","title":"49. Evidence-based curation of EGFR fusions in solid tumors reveals a complex molecular mechanism","year":2025,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Fusion gene; Epidermal growth factor receptor; Gene; Fusion protein; Somatic cell; Cancer; Mutation; Targeted therapy","score_opus":0.049240848562005175,"score_gpt":0.40750093252781244,"score_spread":0.3582600839658073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7123703764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97406274,0.007080127,0.011155533,0.00471105,0.00023775354,0.0010450805,0.0000583011,0.000028487686,0.0016208981],"genre_scores_gemma":[0.9948904,0.00073235715,0.0023990688,0.001408608,0.000026857377,0.0001596091,0.000032442134,0.000011778649,0.00033885892],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917424,0.000034390487,0.00029990642,0.00018663912,0.0001576096,0.00014724482],"domain_scores_gemma":[0.9993875,0.00004327639,0.000087745175,0.00024974448,0.000175433,0.00005627269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064282955,0.000104101186,0.00024199579,0.00015632165,0.000038022,0.0000073006963,0.00006564207,0.000051637908,0.000104486084],"category_scores_gemma":[0.00005174966,0.00009608849,0.00005973347,0.0003752372,0.000039607607,0.00003191924,0.000021610424,0.000066789755,0.0000028879858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017589415,0.0003810625,0.039299175,0.0006736308,0.00022619193,0.000057612404,0.00082654407,0.009352665,0.9276851,0.0073591014,0.0016534518,0.012309588],"study_design_scores_gemma":[0.0064260787,0.00077654084,0.27463278,0.0072124884,0.0013548678,0.0000058990713,0.00045068804,0.018289052,0.6784756,0.009003288,0.00296089,0.00041179635],"about_ca_topic_score_codex":0.00027952227,"about_ca_topic_score_gemma":0.00018082917,"teacher_disagreement_score":0.24920946,"about_ca_system_score_codex":0.00031706237,"about_ca_system_score_gemma":0.0007707292,"threshold_uncertainty_score":0.3918375},"labels":[],"label_agreement":null},{"id":"W7132891376","doi":"","title":"DCAF1 as a Novel Therapeutic Target for Lung Cancer","year":2023,"lang":"","type":"dissertation","venue":"TSpace","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Toronto","keywords":"Gene knockdown; Ubiquitin ligase; RNA interference; Cell cycle; Lung cancer; Cell growth; Downregulation and upregulation","score_opus":0.034293413007827574,"score_gpt":0.4634215391464925,"score_spread":0.4291281261386649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132891376","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46167874,0.24044414,0.02858929,0.0452976,0.060440034,0.049772345,0.0041652275,0.0020875486,0.10752507],"genre_scores_gemma":[0.19755578,0.0039359354,0.0014279325,0.0012821773,0.001834687,0.00727292,0.006482237,0.00048001704,0.7797283],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973452,0.00002730613,0.000504049,0.00084024057,0.0005036412,0.0007795302],"domain_scores_gemma":[0.99795616,0.0002935165,0.00042336053,0.00050454575,0.000528367,0.0002940676],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015260551,0.00066352315,0.00082691124,0.00028650617,0.0004412509,0.000083606385,0.0001963446,0.00045698532,0.002171279],"category_scores_gemma":[0.00010920994,0.00059734506,0.00043880843,0.0005642582,0.000053936972,0.00008752232,0.000021097898,0.00035943018,0.00020957932],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010403471,0.005178617,0.010121394,0.026143327,0.056276977,0.00022803087,0.5667826,0.0038323146,0.06268168,0.0146769555,0.12825218,0.11542247],"study_design_scores_gemma":[0.061129175,0.006709724,0.036212914,0.017227272,0.07546461,0.000058637415,0.24608937,0.05398577,0.026630512,0.0023209841,0.4681617,0.006009335],"about_ca_topic_score_codex":0.0057417764,"about_ca_topic_score_gemma":0.00089714373,"teacher_disagreement_score":0.67220324,"about_ca_system_score_codex":0.000876853,"about_ca_system_score_gemma":0.0027422206,"threshold_uncertainty_score":0.9996478},"labels":[],"label_agreement":null},{"id":"W7136041386","doi":"10.6084/m9.figshare.5103625.v1","title":"Additional file 1: Table S1. of Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC","year":2017,"lang":"","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Scale (ratio); Clinical trial; Safety profile; MEDLINE","score_opus":0.041844148771836245,"score_gpt":0.36070240910909873,"score_spread":0.3188582603372625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136041386","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010850451,0.0008050454,3.5514103e-7,0.00018548248,0.00008607059,0.0006441909,0.9365332,0.000009869137,0.06162729],"genre_scores_gemma":[0.20748141,0.00001998742,0.00016899561,0.000073603056,0.00029848836,0.0004902043,0.78688866,0.00002869809,0.004549951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979978,0.0000609786,0.0007089665,0.0004225132,0.00044707317,0.00036264796],"domain_scores_gemma":[0.99649423,0.0009738239,0.0010000091,0.00067612645,0.00068114663,0.00017465862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003615477,0.00029382028,0.00071907963,0.0002065995,0.00027432898,0.00004162202,0.00027232716,0.00019629295,0.98184335],"category_scores_gemma":[0.0041101505,0.00027162995,0.00025247678,0.0002537402,0.00007603612,0.0003729378,0.00016956938,0.00022201694,0.001471223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022393304,0.0005905104,0.000099569384,0.00041694948,0.0007861403,0.00007065553,0.0003767752,0.00004020709,0.00024750264,0.000007487253,0.9921852,0.004955074],"study_design_scores_gemma":[0.007926078,0.0009740763,0.14269167,0.07059436,0.0012979951,0.000016652872,0.0005819003,0.0006548938,0.017524539,0.00007358542,0.7571009,0.00056337035],"about_ca_topic_score_codex":0.0006103723,"about_ca_topic_score_gemma":0.0002382836,"teacher_disagreement_score":0.98037213,"about_ca_system_score_codex":0.00028033997,"about_ca_system_score_gemma":0.0014619845,"threshold_uncertainty_score":0.9999736},"labels":[],"label_agreement":null},{"id":"W7136059292","doi":"10.6084/m9.figshare.5103625","title":"Additional file 1: Table S1. of Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC","year":2017,"lang":"","type":"article","venue":"Figshare","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Scale (ratio); Clinical trial; Safety profile; MEDLINE","score_opus":0.041844148771836245,"score_gpt":0.36070240910909873,"score_spread":0.3188582603372625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136059292","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010850451,0.0008050454,3.5514103e-7,0.00018548248,0.00008607059,0.0006441909,0.9365332,0.000009869137,0.06162729],"genre_scores_gemma":[0.20748141,0.00001998742,0.00016899561,0.000073603056,0.00029848836,0.0004902043,0.78688866,0.00002869809,0.004549951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979978,0.0000609786,0.0007089665,0.0004225132,0.00044707317,0.00036264796],"domain_scores_gemma":[0.99649423,0.0009738239,0.0010000091,0.00067612645,0.00068114663,0.00017465862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003615477,0.00029382028,0.00071907963,0.0002065995,0.00027432898,0.00004162202,0.00027232716,0.00019629295,0.98184335],"category_scores_gemma":[0.0041101505,0.00027162995,0.00025247678,0.0002537402,0.00007603612,0.0003729378,0.00016956938,0.00022201694,0.001471223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022393304,0.0005905104,0.000099569384,0.00041694948,0.0007861403,0.00007065553,0.0003767752,0.00004020709,0.00024750264,0.000007487253,0.9921852,0.004955074],"study_design_scores_gemma":[0.007926078,0.0009740763,0.14269167,0.07059436,0.0012979951,0.000016652872,0.0005819003,0.0006548938,0.017524539,0.00007358542,0.7571009,0.00056337035],"about_ca_topic_score_codex":0.0006103723,"about_ca_topic_score_gemma":0.0002382836,"teacher_disagreement_score":0.98037213,"about_ca_system_score_codex":0.00028033997,"about_ca_system_score_gemma":0.0014619845,"threshold_uncertainty_score":0.9999736},"labels":[],"label_agreement":null},{"id":"W7161221734","doi":"","title":"Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results from a Global Registry for Consideration in the Journal of Clinical Lung Cancer","year":2025,"lang":"","type":"article","venue":"NSUWorks (Nova Southeastern University)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Observational study; Timeline; Cancer registry; Psychological intervention; Medical record; Stage (stratigraphy); Disease; MEDLINE","score_opus":0.06794278091198555,"score_gpt":0.4324746104362483,"score_spread":0.3645318295242628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161221734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657225,0.0037196274,0.013551934,0.0038612133,0.0015619907,0.0043590823,0.0062724613,0.000009456588,0.00094172393],"genre_scores_gemma":[0.99604005,0.00065291306,0.0012428493,0.00027068797,0.0004736996,0.000015106681,0.00027966505,0.000013560969,0.0010114695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976411,0.00040979724,0.0009938206,0.00042795393,0.00024073636,0.00028662934],"domain_scores_gemma":[0.99171156,0.006046633,0.00085472804,0.0002742204,0.0010024017,0.00011047204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006627605,0.0002823484,0.00063708937,0.0001682189,0.00026923997,0.00006480518,0.00015665089,0.00024139696,0.00001004766],"category_scores_gemma":[0.002048338,0.00021494218,0.00024040771,0.00036129044,0.00016570034,0.0001615853,0.000044871573,0.00019573067,5.4530005e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027250217,0.0020960062,0.71488804,0.00016767308,0.0038805301,0.00006739335,0.013942198,0.001459724,0.0000052470064,0.0004332668,0.0009748853,0.2348348],"study_design_scores_gemma":[0.25586817,0.010779563,0.55020255,0.016391214,0.04339348,0.000016434524,0.060939632,0.056253593,0.000043716103,0.0009318374,0.0042995163,0.00088033173],"about_ca_topic_score_codex":0.001112578,"about_ca_topic_score_gemma":0.0021123188,"teacher_disagreement_score":0.23395447,"about_ca_system_score_codex":0.00059874385,"about_ca_system_score_gemma":0.0015106483,"threshold_uncertainty_score":0.8765088},"labels":[],"label_agreement":null},{"id":"W7161936342","doi":"10.82308/9424","title":"Differential response of non-small cell lung cancer (NSCLC) harboring different epidermal growth factor receptor (EGFR) mutations to ablative radiation therapy","year":2020,"lang":"en","type":"dissertation","venue":"","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Cancer; Transfection; Epidermal growth factor receptor; Mutation","score_opus":0.015896647849789145,"score_gpt":0.32394388038823924,"score_spread":0.30804723253845007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161936342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989956,0.00067533035,0.0015467295,0.0009963532,0.0012455125,0.0030181534,0.0006091105,0.00010056414,0.0018522136],"genre_scores_gemma":[0.9831335,0.0007988998,0.00068643846,0.00024490393,0.00039357212,0.0009730343,0.0034988911,0.00013095737,0.010139821],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99759233,0.00014218035,0.00073931844,0.00067005545,0.00048196485,0.00037417203],"domain_scores_gemma":[0.99808127,0.0002974524,0.00047028382,0.00029404127,0.00047344,0.00038351724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000047550635,0.0005768705,0.0008837696,0.00042726533,0.00016430354,0.000047622896,0.00015317854,0.0002782752,0.0019372707],"category_scores_gemma":[0.00010197248,0.00046287308,0.00034437265,0.00038573542,0.000024839132,0.000116708,0.000021674554,0.00034494634,0.00002494836],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02221328,0.0020428547,0.05551265,0.002234121,0.0051122126,0.000034886725,0.081788324,0.00009435057,0.80095315,0.00022846038,0.004942202,0.02484349],"study_design_scores_gemma":[0.0050376803,0.0008515386,0.53515244,0.00062051427,0.0011734166,6.095041e-7,0.0013624011,0.0004675562,0.45434934,0.000008511575,0.00045364958,0.00052233913],"about_ca_topic_score_codex":0.00076587475,"about_ca_topic_score_gemma":0.00016170758,"teacher_disagreement_score":0.4796398,"about_ca_system_score_codex":0.0006797043,"about_ca_system_score_gemma":0.000938449,"threshold_uncertainty_score":0.9997823},"labels":[],"label_agreement":null},{"id":"W88170961","doi":"10.1023/a:1019504210176","title":"A case–control study of lung cancer in Casablanca, Morocco","year":2002,"lang":"en","type":"article","venue":"Cancer Causes & Control","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"International Development Research Centre","keywords":"Medicine; Chronic bronchitis; Lung cancer; Odds ratio; Snuff; Confidence interval; Case-control study; Internal medicine; Epidemiology; Logistic regression; Passive smoking; Cancer; Bronchitis; Environmental health; Pathology","score_opus":0.022387381094597435,"score_gpt":0.3461246374696292,"score_spread":0.32373725637503176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W88170961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727187,0.021501996,0.000068575464,0.00090484874,0.0004082154,0.0027963412,0.00056325895,0.000054951295,0.0009831049],"genre_scores_gemma":[0.9955854,0.00042972653,0.000010016653,0.0008503045,0.00027562876,0.0017082933,0.0000023228006,0.000042314467,0.001095985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983583,0.000079796475,0.0004878084,0.0003973425,0.00027187107,0.00040486877],"domain_scores_gemma":[0.99894035,0.00012544676,0.00017827578,0.00039388548,0.00019884457,0.00016322626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008942811,0.00025823514,0.00072905916,0.00019423969,0.00007860195,0.000016445523,0.0000821446,0.00008158348,0.0022906852],"category_scores_gemma":[0.0000387832,0.00021367347,0.00011206227,0.00034163566,0.00005301193,0.0001219049,0.000012682028,0.00019077992,0.000007933643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005002824,0.00151512,0.96374226,0.00016231416,0.0024243922,0.0046746274,0.005734042,0.0017249085,0.0007365072,0.000025652505,0.0020815956,0.016678298],"study_design_scores_gemma":[0.17197004,0.0027119853,0.75664234,0.0009566676,0.014662384,0.0012074753,0.00469163,0.042162683,0.00038203722,0.000021081103,0.0034907237,0.0011009487],"about_ca_topic_score_codex":0.011543865,"about_ca_topic_score_gemma":0.01470614,"teacher_disagreement_score":0.20709991,"about_ca_system_score_codex":0.00059973355,"about_ca_system_score_gemma":0.00020041985,"threshold_uncertainty_score":0.99862134},"labels":[],"label_agreement":null},{"id":"W98997307","doi":"10.5306/wjco.v2.i6.262","title":"Review of the treatment of metastatic non small cell lung carcinoma: A practical approach","year":2011,"lang":"en","type":"article","venue":"World Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Concomitant; Oncology; Internal medicine; Lung; Basal cell; Carcinoma; Targeted therapy; Intensive care medicine; Cancer","score_opus":0.19098098851533368,"score_gpt":0.488099751398657,"score_spread":0.29711876288332334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W98997307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59248376,0.13857262,0.0015975793,0.014199798,0.0028173611,0.003886317,0.000030429692,0.000011867821,0.24640028],"genre_scores_gemma":[0.92894834,0.021407215,0.0460053,0.0015579178,0.00024141851,0.000022210885,0.0000030330373,0.00001741259,0.0017971197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741554,0.0003887689,0.0017518917,0.00012336593,0.00018481277,0.00013563862],"domain_scores_gemma":[0.9965436,0.000818474,0.0018561129,0.000266288,0.0003481062,0.0001674295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091634406,0.00011576372,0.0012900232,0.00007752981,0.00002171527,0.0000010952563,0.00010481943,0.000059351885,0.00016793232],"category_scores_gemma":[0.00036635034,0.00005733969,0.0006867043,0.00020603806,0.00017864196,0.000034713325,0.00001978158,0.00026510883,0.0000023449893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007212873,0.10521243,0.62260574,0.013320183,0.008258131,0.0012309937,0.0062425,0.000009876764,0.00022577312,0.001991584,0.030640764,0.20304912],"study_design_scores_gemma":[0.0403058,0.049998794,0.45080593,0.006181051,0.047870718,0.0015270694,0.00083428057,0.00017858163,0.001998441,0.00042281876,0.3995704,0.000306121],"about_ca_topic_score_codex":0.00005371178,"about_ca_topic_score_gemma":0.00002721213,"teacher_disagreement_score":0.36892962,"about_ca_system_score_codex":0.00015428282,"about_ca_system_score_gemma":0.001764302,"threshold_uncertainty_score":0.3129796},"labels":[],"label_agreement":null}]}